Gene "Gene synonym" Ensembl "Gene description" Uniprot Chromosome Position "Protein class" "Biological process" "Molecular function" "Disease involvement" Evidence "HPA evidence" "UniProt evidence" "NeXtProt evidence" "MS evidence" "RNA tissue specificity" "RNA tissue distribution" "RNA tissue specificity score" "RNA tissue specific NX" "RNA cell line specificity" "RNA cell line distribution" "RNA cell line specificity score" "RNA cell line specific NX" "RNA cancer specificity" "RNA cancer distribution" "RNA cancer specificity score" "RNA cancer specific FPKM" "RNA brain regional specificity" "RNA brain regional distribution" "RNA brain regional specificity score" "RNA brain regional specific NX" "RNA blood cell specificity" "RNA blood cell distribution" "RNA blood cell specificity score" "RNA blood cell specific NX" "RNA blood lineage specificity" "RNA blood lineage distribution" "RNA blood lineage specificity score" "RNA blood lineage specific NX" "RNA mouse brain regional specificity" "RNA mouse brain regional distribution" "RNA mouse brain regional specificity score" "RNA mouse brain regional specific pTPM" "RNA pig brain regional specificity" "RNA pig brain regional distribution" "RNA pig brain regional specificity score" "RNA pig brain regional specific pTPM" Antibody "Reliability (IH)" "Reliability (Mouse Brain)" "Reliability (IF)" "Subcellular location" "Secretome location" "Blood concentration - Conc. blood IM [pg/L]" "Blood concentration - Conc. blood MS [pg/L]" "Subcellular main location" "Subcellular additional location" "Antibody RRID" "Pathology prognostics - Breast cancer" "Pathology prognostics - Cervical cancer" "Pathology prognostics - Colorectal cancer" "Pathology prognostics - Endometrial cancer" "Pathology prognostics - Glioma" "Pathology prognostics - Head and neck cancer" "Pathology prognostics - Liver cancer" "Pathology prognostics - Lung cancer" "Pathology prognostics - Melanoma" "Pathology prognostics - Ovarian cancer" "Pathology prognostics - Pancreatic cancer" "Pathology prognostics - Prostate cancer" "Pathology prognostics - Renal cancer" "Pathology prognostics - Stomach cancer" "Pathology prognostics - Testis cancer" "Pathology prognostics - Thyroid cancer" "Pathology prognostics - Urothelial cancer" "Tissue RNA - adipose tissue [NX]" "Tissue RNA - adrenal gland [NX]" "Tissue RNA - amygdala [NX]" "Tissue RNA - appendix [NX]" "Tissue RNA - basal ganglia [NX]" "Tissue RNA - bone marrow [NX]" "Tissue RNA - breast [NX]" "Tissue RNA - cerebellum [NX]" "Tissue RNA - cerebral cortex [NX]" "Tissue RNA - cervix, uterine [NX]" "Tissue RNA - colon [NX]" "Tissue RNA - corpus callosum [NX]" "Tissue RNA - ductus deferens [NX]" "Tissue RNA - duodenum [NX]" "Tissue RNA - endometrium 1 [NX]" "Tissue RNA - epididymis [NX]" "Tissue RNA - esophagus [NX]" "Tissue RNA - fallopian tube [NX]" "Tissue RNA - gallbladder [NX]" "Tissue RNA - heart muscle [NX]" "Tissue RNA - hippocampal formation [NX]" "Tissue RNA - hypothalamus [NX]" "Tissue RNA - kidney [NX]" "Tissue RNA - liver [NX]" "Tissue RNA - lung [NX]" "Tissue RNA - lymph node [NX]" "Tissue RNA - midbrain [NX]" "Tissue RNA - olfactory region [NX]" "Tissue RNA - ovary [NX]" "Tissue RNA - pancreas [NX]" "Tissue RNA - parathyroid gland [NX]" "Tissue RNA - pituitary gland [NX]" "Tissue RNA - placenta [NX]" "Tissue RNA - pons and medulla [NX]" "Tissue RNA - prostate [NX]" "Tissue RNA - rectum [NX]" "Tissue RNA - retina [NX]" "Tissue RNA - salivary gland [NX]" "Tissue RNA - seminal vesicle [NX]" "Tissue RNA - skeletal muscle [NX]" "Tissue RNA - skin 1 [NX]" "Tissue RNA - small intestine [NX]" "Tissue RNA - smooth muscle [NX]" "Tissue RNA - spinal cord [NX]" "Tissue RNA - spleen [NX]" "Tissue RNA - stomach 1 [NX]" "Tissue RNA - testis [NX]" "Tissue RNA - thalamus [NX]" "Tissue RNA - thymus [NX]" "Tissue RNA - thyroid gland [NX]" "Tissue RNA - tongue [NX]" "Tissue RNA - tonsil [NX]" "Tissue RNA - urinary bladder [NX]" "Tissue RNA - vagina [NX]" "Tissue RNA - B-cells [NX]" "Tissue RNA - dendritic cells [NX]" "Tissue RNA - granulocytes [NX]" "Tissue RNA - monocytes [NX]" "Tissue RNA - NK-cells [NX]" "Tissue RNA - T-cells [NX]" "Tissue RNA - total PBMC [NX]" "Cell RNA - A-431 [NX]" "Cell RNA - A549 [NX]" "Cell RNA - AF22 [NX]" "Cell RNA - AN3-CA [NX]" "Cell RNA - ASC diff [NX]" "Cell RNA - ASC TERT1 [NX]" "Cell RNA - BEWO [NX]" "Cell RNA - BJ [NX]" "Cell RNA - BJ hTERT+ [NX]" "Cell RNA - BJ hTERT+ SV40 Large T+ [NX]" "Cell RNA - BJ hTERT+ SV40 Large T+ RasG12V [NX]" "Cell RNA - CACO-2 [NX]" "Cell RNA - CAPAN-2 [NX]" "Cell RNA - Daudi [NX]" "Cell RNA - EFO-21 [NX]" "Cell RNA - fHDF/TERT166 [NX]" "Cell RNA - HaCaT [NX]" "Cell RNA - HAP1 [NX]" "Cell RNA - HBEC3-KT [NX]" "Cell RNA - HBF TERT88 [NX]" "Cell RNA - HDLM-2 [NX]" "Cell RNA - HEK 293 [NX]" "Cell RNA - HEL [NX]" "Cell RNA - HeLa [NX]" "Cell RNA - Hep G2 [NX]" "Cell RNA - HHSteC [NX]" "Cell RNA - HL-60 [NX]" "Cell RNA - HMC-1 [NX]" "Cell RNA - HSkMC [NX]" "Cell RNA - hTCEpi [NX]" "Cell RNA - hTEC/SVTERT24-B [NX]" "Cell RNA - hTERT-HME1 [NX]" "Cell RNA - HUVEC TERT2 [NX]" "Cell RNA - K-562 [NX]" "Cell RNA - Karpas-707 [NX]" "Cell RNA - LHCN-M2 [NX]" "Cell RNA - MCF7 [NX]" "Cell RNA - MOLT-4 [NX]" "Cell RNA - NB-4 [NX]" "Cell RNA - NTERA-2 [NX]" "Cell RNA - PC-3 [NX]" "Cell RNA - REH [NX]" "Cell RNA - RH-30 [NX]" "Cell RNA - RPMI-8226 [NX]" "Cell RNA - RPTEC TERT1 [NX]" "Cell RNA - RT4 [NX]" "Cell RNA - SCLC-21H [NX]" "Cell RNA - SH-SY5Y [NX]" "Cell RNA - SiHa [NX]" "Cell RNA - SK-BR-3 [NX]" "Cell RNA - SK-MEL-30 [NX]" "Cell RNA - T-47d [NX]" "Cell RNA - THP-1 [NX]" "Cell RNA - TIME [NX]" "Cell RNA - U-138 MG [NX]" "Cell RNA - U-2 OS [NX]" "Cell RNA - U-2197 [NX]" "Cell RNA - U-251 MG [NX]" "Cell RNA - U-266/70 [NX]" "Cell RNA - U-266/84 [NX]" "Cell RNA - U-698 [NX]" "Cell RNA - U-87 MG [NX]" "Cell RNA - U-937 [NX]" "Cell RNA - WM-115 [NX]" "Blood RNA - basophil [NX]" "Blood RNA - classical monocyte [NX]" "Blood RNA - eosinophil [NX]" "Blood RNA - gdT-cell [NX]" "Blood RNA - intermediate monocyte [NX]" "Blood RNA - MAIT T-cell [NX]" "Blood RNA - memory B-cell [NX]" "Blood RNA - memory CD4 T-cell [NX]" "Blood RNA - memory CD8 T-cell [NX]" "Blood RNA - myeloid DC [NX]" "Blood RNA - naive B-cell [NX]" "Blood RNA - naive CD4 T-cell [NX]" "Blood RNA - naive CD8 T-cell [NX]" "Blood RNA - neutrophil [NX]" "Blood RNA - NK-cell [NX]" "Blood RNA - non-classical monocyte [NX]" "Blood RNA - plasmacytoid DC [NX]" "Blood RNA - T-reg [NX]" "Blood RNA - total PBMC [NX]" "Brain RNA - amygdala [NX]" "Brain RNA - basal ganglia [NX]" "Brain RNA - cerebellum [NX]" "Brain RNA - cerebral cortex [NX]" "Brain RNA - hippocampal formation [NX]" "Brain RNA - hypothalamus [NX]" "Brain RNA - midbrain [NX]" "Brain RNA - olfactory region [NX]" "Brain RNA - pons and medulla [NX]" "Brain RNA - thalamus [NX]" A2M "CPAMD5, FWP007, S863-7" ENSG00000175899 Alpha-2-macroglobulin P01023 12 9067664-9116229 "Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins" "Protease inhibitor, Serine protease inhibitor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 231.0;lung: 227.4" "Group enriched" "Detected in some" 5 "AF22: 111.0;ASC diff: 33.0;Hep G2: 89.4;SK-MEL-30: 32.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "gdT-cell: 4.4" "Group enriched" "Detected in many" 7 "dendritic cells: 1.4;T-cells: 4.4" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA002265, CAB017621" Supported "Secreted to blood" 2900000000000 220000000000 "CAB017621: AB_1118894, HPA002265: AB_1078142" "unprognostic (1.73e-2)" "unprognostic (1.05e-3)" "unprognostic (1.72e-1)" "unprognostic (2.29e-2)" "unprognostic (7.36e-2)" "unprognostic (3.91e-2)" "unprognostic (7.95e-2)" "unprognostic (3.65e-2)" "unprognostic (2.38e-1)" "unprognostic (7.19e-2)" "unprognostic (4.71e-2)" "unprognostic (2.06e-2)" "unprognostic (1.28e-2)" "unprognostic (8.04e-3)" "unprognostic (2.32e-2)" "unprognostic (8.58e-2)" "unprognostic (9.03e-3)" 77.4 20.5 12.5 14.7 16.8 0.3 39.6 6.1 16.1 41.8 27.3 25.3 10.5 15.0 54.6 28.2 39.5 30.6 49.7 68.0 12.4 10.2 50.0 231.0 227.4 14.9 16.9 8.0 40.8 13.0 20.9 20.4 48.0 20.5 77.3 35.9 47.5 20.5 26.3 26.0 10.2 23.1 57.7 20.9 42.3 25.8 26.2 13.0 4.0 29.5 17.0 8.6 68.9 59.0 0.2 1.4 0.0 0.4 0.0 4.4 0.3 0.0 0.0 111.0 0.0 33.0 2.4 0.3 13.2 3.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 89.4 0.0 0.1 0.1 5.5 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.2 0.5 0.0 0.2 0.1 0.1 0.0 0.0 0.0 0.1 0.2 0.0 32.1 0.0 0.0 0.0 0.0 0.9 0.2 0.0 0.1 0.0 0.1 0.0 0.0 2.1 0.0 0.4 0.0 4.4 0.2 2.6 0.2 0.5 1.2 0.3 0.0 0.1 0.7 0.0 0.0 0.0 1.4 0.0 0.3 12.5 16.8 6.1 16.1 12.4 10.2 16.9 8.0 20.5 13.0 AARS2 "AARSL, bA444E17.1, KIAA1270" ENSG00000124608 "Alanyl-tRNA synthetase 2, mitochondrial" Q5JTZ9 6 44299654-44313326 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Protein biosynthesis" "Aminoacyl-tRNA synthetase, Ligase, RNA-binding, tRNA-binding" "Cancer-related genes, Cardiomyopathy, Disease mutation, Premature ovarian failure, Primary mitochondrial disease" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA035636, HPA061396" Approved Enhanced Mitochondria Mitochondria "HPA035636: AB_10670837, HPA061396: " "unprognostic (1.56e-1)" "unprognostic (3.24e-2)" "unprognostic (2.58e-2)" "unprognostic (2.04e-3)" "unprognostic (2.83e-1)" "unprognostic (1.69e-1)" "unprognostic (8.83e-3)" "unprognostic (5.12e-2)" "unprognostic (3.64e-2)" "unprognostic (1.38e-1)" "unprognostic (2.19e-2)" "unprognostic (1.37e-2)" "unprognostic (1.74e-1)" "unprognostic (1.84e-1)" "unprognostic (1.48e-1)" "unprognostic (1.08e-1)" "unprognostic (2.02e-1)" 8.6 10.7 15.9 16.2 11.8 11.4 9.9 23.5 19.8 11.4 14.5 11.4 13.0 15.3 14.1 10.4 17.2 13.4 15.9 10.4 13.2 8.9 10.3 12.6 10.9 13.4 12.4 14.3 17.1 13.8 16.2 14.2 10.1 11.1 13.2 9.8 11.2 14.4 14.6 10.2 16.8 18.3 12.1 8.8 14.1 12.3 12.9 14.1 14.7 12.3 10.4 13.4 10.2 13.9 7.1 3.2 3.7 3.4 3.7 5.5 2.8 10.4 7.9 10.3 19.0 6.1 5.7 13.7 8.7 4.5 9.2 8.9 8.5 5.7 11.5 13.9 3.7 7.9 11.4 12.4 3.6 8.1 18.3 13.4 7.7 10.0 4.0 12.4 11.9 4.8 7.9 7.4 7.9 7.8 15.8 11.3 4.9 11.7 10.4 10.7 7.7 7.7 12.4 6.3 7.9 4.8 9.5 24.6 8.9 7.5 8.4 11.6 7.8 16.2 6.6 10.0 10.0 6.1 10.8 6.7 6.2 11.9 5.6 11.0 17.1 3.7 2.4 0.0 3.4 3.3 5.5 3.6 4.8 4.4 2.6 7.1 4.7 4.3 0.7 3.7 3.4 3.2 3.0 2.8 15.9 11.8 23.5 19.8 13.2 8.9 12.4 14.3 11.1 14.1 ABCB1 "ABC20, CD243, CLCS, GP170, MDR1, P-gp, PGY1" ENSG00000085563 "ATP binding cassette subfamily B member 1" P08183 7 87503633-87713323 "Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" Transport "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "adrenal gland: 57.8;intestine: 49.6" "Cell line enhanced" "Detected in some" "CACO-2: 29.4;HEK 293: 9.0;HEL: 16.3;Hep G2: 8.1;RPTEC TERT1: 11.3;SH-SY5Y: 36.0" "Cancer enhanced" "Detected in many" "renal cancer: 14.2" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "MAIT T-cell: 19.2" "Group enriched" "Detected in many" 8 "NK-cells: 11.4;T-cells: 19.2" "CAB001716, HPA002199" Enhanced Approved "Nucleoplasm,Focal adhesion sites,Cytosol" "Nucleoplasm, Focal adhesion sites, Cytosol" "CAB001716: , HPA002199: AB_1844428" "unprognostic (5.38e-3)" "unprognostic (2.45e-2)" "unprognostic (1.42e-1)" "unprognostic (1.06e-1)" "unprognostic (2.25e-2)" "unprognostic (9.99e-5)" "unprognostic (2.23e-3)" "unprognostic (5.65e-3)" "unprognostic (1.14e-1)" "unprognostic (5.17e-2)" "prognostic favourable (3.33e-4)" "unprognostic (5.19e-1)" "prognostic favourable (2.95e-4)" "unprognostic (2.06e-1)" "unprognostic (1.50e-1)" "unprognostic (3.83e-1)" "unprognostic (6.12e-2)" 2.6 57.8 9.4 3.2 11.5 1.2 3.4 5.1 10.5 5.5 22.7 3.8 2.0 14.4 9.4 3.5 2.0 3.2 9.0 1.8 9.2 6.6 19.1 15.6 3.8 2.2 9.4 5.7 2.2 1.5 1.7 1.3 3.1 11.1 2.7 10.7 7.6 1.5 2.1 1.1 1.3 49.6 5.7 9.0 2.4 1.7 1.3 8.6 0.1 2.4 1.4 2.2 2.6 5.9 1.9 0.0 0.1 0.0 11.4 19.2 1.5 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.0 29.4 0.0 0.0 0.0 0.0 0.0 2.1 0.0 0.0 0.0 9.0 16.3 1.9 8.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 1.4 0.0 0.0 0.1 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 11.3 0.0 0.4 36.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 1.8 0.0 0.4 3.2 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 7.8 0.0 19.2 0.4 2.0 4.7 0.0 1.9 1.2 4.8 0.1 11.4 0.0 0.0 0.0 1.5 9.4 11.5 5.1 10.5 9.2 6.6 9.4 5.7 11.1 8.6 ABCC1 "GS-X, MRP, MRP1" ENSG00000103222 "ATP binding cassette subfamily C member 1" P33527 16 15949577-16143074 "Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters" Transport Hydrolase "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "EFO-21: 38.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 6 "basophil: 7.5;eosinophil: 3.1;T-reg: 2.1" "Group enriched" "Detected in many" 7 "granulocytes: 7.5;T-cells: 2.1" "Low region specificity" "Detected in all" HPA002380 Uncertain Supported "Plasma membrane" "Plasma membrane" "HPA002380: AB_1844432" "unprognostic (9.97e-2)" "unprognostic (2.06e-1)" "unprognostic (2.05e-2)" "unprognostic (2.94e-1)" "unprognostic (4.89e-2)" "unprognostic (1.15e-1)" "prognostic unfavourable (5.42e-5)" "unprognostic (3.42e-1)" "unprognostic (3.31e-1)" "unprognostic (4.07e-2)" "unprognostic (9.78e-3)" "unprognostic (7.19e-2)" "prognostic unfavourable (1.55e-6)" "unprognostic (1.84e-1)" "unprognostic (1.15e-1)" "unprognostic (1.43e-2)" "unprognostic (1.80e-2)" 8.9 8.2 2.4 8.3 3.1 8.4 9.6 4.4 5.0 8.3 10.7 2.6 15.5 3.5 10.5 12.7 14.7 5.6 9.6 8.0 2.1 2.4 4.5 1.6 10.9 12.2 3.0 2.1 6.8 5.8 18.4 4.2 5.2 4.1 9.6 4.1 12.0 16.9 10.9 20.8 6.6 8.2 16.4 4.0 9.2 10.9 15.1 2.3 26.8 15.7 12.6 15.6 15.3 11.8 0.7 0.5 7.5 0.5 0.4 2.1 0.2 2.2 24.2 0.1 6.3 5.6 3.5 1.3 7.1 8.7 6.2 6.4 3.8 17.5 6.6 38.2 13.7 6.5 2.0 7.0 4.7 11.5 2.2 8.1 14.2 14.0 16.7 2.9 21.1 7.3 4.7 1.8 1.0 6.8 8.2 3.4 1.9 4.5 5.2 2.7 3.8 3.6 18.5 3.6 3.2 2.3 8.2 3.5 5.8 9.0 9.8 2.4 3.4 1.5 0.6 0.4 1.4 5.1 5.7 6.3 3.2 2.2 3.2 3.0 0.7 7.5 0.1 3.1 0.6 0.4 0.6 0.7 0.5 0.6 0.5 0.3 0.6 0.6 0.0 0.4 0.5 0.3 2.1 0.2 2.4 3.1 4.4 5.0 2.1 2.4 3.0 2.1 4.1 2.3 ABCC2 "CMOAT, cMRP, DJS, MRP2" ENSG00000023839 "ATP binding cassette subfamily C member 2" Q92887 10 99782732-99852192 "Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters" Transport "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "intestine: 28.4;kidney: 25.6;liver: 74.3" "Group enriched" "Detected in some" 5 "A549: 59.0;Hep G2: 58.8" "Cancer enhanced" "Detected in many" "liver cancer: 24.0" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "basophil: 4.1" "Lineage enriched" "Detected in single" 6 "granulocytes: 4.1" "Not detected" "Not detected" "Not detected" "Not detected" "HPA004860, CAB037271" Enhanced "CAB037271: AB_2221326, HPA004860: AB_1844433" "unprognostic (1.49e-3)" "unprognostic (5.92e-2)" "unprognostic (1.59e-1)" "unprognostic (3.67e-1)" "unprognostic (1.93e-2)" "unprognostic (2.33e-1)" "unprognostic (2.51e-1)" "unprognostic (7.15e-3)" "unprognostic (5.68e-2)" "unprognostic (2.01e-1)" "unprognostic (4.30e-1)" "unprognostic (1.40e-3)" "prognostic unfavourable (1.93e-5)" "unprognostic (1.31e-1)" "unprognostic (3.22e-2)" "unprognostic (2.95e-1)" "unprognostic (1.26e-2)" 0.8 0.3 0.1 0.1 0.1 0.1 1.1 0.3 0.1 0.2 13.4 0.1 0.1 16.1 0.3 0.5 0.2 0.4 13.7 0.2 0.1 0.1 25.6 74.3 0.3 0.1 0.1 0.1 0.2 0.6 0.0 0.1 1.2 0.1 0.3 0.0 0.1 0.3 0.1 0.6 0.6 28.4 0.1 0.2 0.8 0.4 0.4 0.1 0.1 0.3 0.4 0.1 0.7 0.3 0.3 0.7 4.1 0.2 0.1 0.5 0.0 0.0 59.0 0.9 2.9 4.5 3.5 1.0 0.1 0.3 0.1 0.2 12.6 0.1 0.1 0.1 0.2 0.3 0.1 0.1 0.2 0.1 0.1 0.0 0.2 58.8 0.1 0.0 0.2 0.5 4.1 0.4 0.4 0.1 0.0 0.1 0.0 0.2 0.0 0.4 0.1 0.0 0.1 0.0 0.1 0.4 0.0 0.0 0.0 0.1 0.9 7.3 0.0 0.1 0.1 0.1 0.1 0.3 0.1 0.2 0.0 0.0 4.8 0.9 0.3 4.1 0.2 0.3 0.3 0.0 0.4 0.2 0.3 0.1 0.3 0.3 0.3 0.1 1.3 0.1 0.1 0.7 0.5 0.0 0.1 0.1 0.3 0.1 0.1 0.1 0.1 0.1 0.1 0.1 ABCC3 "cMOAT2, EST90757, MLP2, MOAT-D, MRP3" ENSG00000108846 "ATP binding cassette subfamily C member 3" O15438 17 50634777-50692252 "Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters" Transport "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "gallbladder: 53.5;liver: 66.2" "Cell line enhanced" "Detected in many" "A549: 33.9;CAPAN-2: 25.9;HeLa: 14.3;RPTEC TERT1: 14.8;RT4: 14.7" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in single" "Cell type enhanced" "Detected in some" "intermediate monocyte: 6.2;non-classical monocyte: 7.6" "Lineage enriched" "Detected in many" 5 "monocytes: 7.6" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB037136, HPA048483" Enhanced Supported "Plasma membrane" "Plasma membrane" "CAB037136: AB_477165, HPA048483: " "unprognostic (1.57e-2)" "unprognostic (1.60e-1)" "unprognostic (1.53e-1)" "unprognostic (1.65e-2)" "unprognostic (9.67e-3)" "unprognostic (6.19e-3)" "unprognostic (7.44e-3)" "unprognostic (8.20e-2)" "unprognostic (3.18e-1)" "unprognostic (5.13e-2)" "prognostic unfavourable (9.57e-4)" "unprognostic (1.60e-3)" "prognostic unfavourable (4.68e-6)" "unprognostic (3.42e-1)" "unprognostic (4.77e-2)" "unprognostic (4.44e-2)" "unprognostic (1.57e-3)" 3.5 36.0 0.4 17.0 0.4 0.5 7.7 0.3 0.4 1.9 23.9 0.8 14.1 10.3 1.6 4.6 5.3 1.0 53.5 0.8 0.4 0.4 13.5 66.2 9.0 10.3 0.6 0.0 1.0 22.2 1.7 0.8 3.5 1.5 5.4 7.7 0.8 4.7 23.6 0.4 4.8 37.0 2.5 4.6 4.9 12.8 1.0 0.0 0.8 4.5 7.0 7.9 7.1 3.5 0.0 1.6 1.3 7.6 0.3 0.5 7.4 2.4 33.9 0.0 0.1 1.9 3.0 0.0 4.5 5.7 0.3 0.3 1.8 25.9 0.0 3.5 8.8 6.2 0.0 0.4 0.4 0.0 0.0 0.7 14.3 10.3 7.7 0.0 0.0 3.4 2.5 1.3 2.8 0.6 0.0 0.0 3.5 7.9 0.0 0.0 0.0 4.5 0.0 0.0 0.1 14.8 14.7 0.0 0.3 8.2 1.4 0.0 1.1 0.0 7.5 0.2 1.5 0.1 3.6 0.0 0.0 0.0 3.7 0.0 0.3 0.3 2.8 0.0 0.0 6.2 0.0 0.0 0.1 0.0 1.6 0.0 0.0 0.0 1.3 0.3 7.6 0.2 0.5 7.4 0.4 0.4 0.3 0.4 0.4 0.4 0.6 0.0 1.5 0.0 ABCC5 "EST277145, MOAT-C, MRP5, SMRP" ENSG00000114770 "ATP binding cassette subfamily C member 5" O15440 3 183919934-184018015 "Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters" Transport "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "RT4: 47.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA044067, HPA052295" Uncertain Approved "Nucleoplasm,Plasma membrane,Cell Junctions" "Plasma membrane, Cell Junctions" Nucleoplasm "HPA044067: , HPA052295: " "unprognostic (9.39e-2)" "unprognostic (6.23e-3)" "unprognostic (3.83e-2)" "unprognostic (1.10e-3)" "unprognostic (2.28e-2)" "unprognostic (2.07e-1)" "prognostic unfavourable (6.78e-8)" "unprognostic (4.46e-2)" "unprognostic (6.07e-3)" "unprognostic (1.02e-1)" "unprognostic (5.91e-3)" "prognostic unfavourable (3.40e-4)" "unprognostic (1.10e-1)" "unprognostic (9.05e-3)" "unprognostic (1.64e-1)" "unprognostic (3.33e-2)" "unprognostic (1.24e-2)" 7.9 11.2 24.7 9.6 26.2 12.0 6.7 42.8 28.6 7.7 11.4 12.0 13.4 6.8 14.1 7.0 17.1 6.1 11.6 16.0 19.1 13.7 12.8 3.6 9.4 7.3 20.5 18.5 11.8 4.9 22.4 20.5 10.8 21.7 10.6 14.4 31.1 7.4 9.3 41.0 14.5 8.5 10.5 12.9 16.3 48.5 9.4 20.9 9.3 5.5 7.3 7.4 18.1 12.7 4.2 3.5 15.8 4.5 5.0 7.0 4.5 7.3 4.0 9.3 11.1 9.3 10.6 14.4 5.9 4.7 5.3 5.8 6.3 5.6 7.9 14.0 5.6 29.5 11.4 6.5 7.0 8.6 11.1 16.7 10.1 5.7 3.8 5.1 13.1 16.9 6.6 5.7 3.8 6.2 15.5 11.0 9.1 19.3 13.9 5.8 9.6 7.8 9.7 3.1 4.7 19.4 47.5 17.0 10.1 6.1 33.6 10.0 20.2 1.6 7.1 6.2 6.1 7.9 8.1 4.2 8.2 7.3 4.6 10.2 6.3 10.7 4.5 7.7 7.0 2.1 4.5 3.2 4.0 3.1 3.5 4.2 4.6 6.3 15.8 5.0 3.5 1.3 5.0 4.5 24.7 26.2 42.8 28.6 19.1 13.7 20.5 18.5 21.7 20.9 ABCC6 "ARA, EST349056, MLP1, MRP6, PXE, URG7" ENSG00000091262 "ATP binding cassette subfamily C member 6" O95255 16 16148928-16223522 "Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters" "Sensory transduction, Transport, Vision" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 27.4" "Cell line enriched" "Detected in some" 8 "Hep G2: 37.7" "Cancer enhanced" "Detected in many" "liver cancer: 16.7" "Cell type enriched" "Detected in some" 5 "classical monocyte: 7.3" "Lineage enriched" "Detected in many" 5 "monocytes: 7.3" "Low region specificity" "Detected in many" "Not detected" "Not detected" HPA038105 Supported "Plasma membrane" "Plasma membrane" "HPA038105: " "unprognostic (1.32e-1)" "unprognostic (1.11e-1)" "unprognostic (5.98e-2)" "unprognostic (3.15e-2)" "unprognostic (1.59e-1)" "unprognostic (3.09e-1)" "prognostic favourable (3.82e-4)" "unprognostic (6.54e-3)" "unprognostic (3.64e-1)" "unprognostic (9.10e-2)" "unprognostic (1.30e-1)" "unprognostic (1.65e-1)" "unprognostic (1.12e-3)" "unprognostic (3.42e-1)" "unprognostic (2.00e-1)" "unprognostic (4.91e-2)" "unprognostic (1.41e-1)" 2.3 1.4 0.2 0.0 0.2 0.0 1.1 0.0 0.0 0.1 1.5 7.0 0.0 0.0 0.0 0.3 1.2 0.8 0.1 0.1 9.0 27.4 2.8 0.0 0.2 0.1 6.7 0.5 0.1 0.0 0.7 1.2 6.7 0.2 1.7 0.0 3.7 0.0 0.2 0.1 2.2 0.0 2.2 0.0 0.0 0.0 0.2 0.9 1.3 7.3 0.6 0.1 1.2 0.0 0.9 0.4 0.0 0.0 0.5 1.1 0.0 0.2 0.5 0.9 3.7 1.4 0.0 0.5 0.0 0.0 0.4 0.0 0.3 0.0 0.4 1.1 0.1 37.7 0.2 0.0 0.2 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.9 0.2 0.0 0.0 0.0 0.0 1.3 0.0 0.1 0.6 0.0 0.4 0.1 4.8 3.1 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 1.0 7.3 0.3 0.0 1.0 0.0 0.0 0.1 0.0 0.9 0.2 0.1 0.1 1.3 0.6 0.1 0.1 0.0 1.2 ABCG2 "ABCP, BCRP, CD338, EST157481, MXR" ENSG00000118777 "ATP binding cassette subfamily G member 2 (Junior blood group)" Q9UNQ0 4 88090264-88231322 "Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins" Transport "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "ductus deferens: 49.6;intestine: 56.6;seminal vesicle: 61.0" "Cell line enhanced" "Detected in many" "A549: 19.9;BEWO: 34.7;MCF7: 11.5;RPMI-8226: 17.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "MAIT T-cell: 5.7" "Low lineage specificity" "Detected in many" "CAB037299, HPA054719" Enhanced Supported "Nucleoplasm,Plasma membrane" "Plasma membrane" Nucleoplasm "CAB037299: AB_476804, HPA054719: " "unprognostic (5.04e-1)" "unprognostic (3.05e-2)" "unprognostic (2.01e-1)" "unprognostic (1.10e-1)" "unprognostic (1.01e-3)" "unprognostic (9.19e-2)" "unprognostic (1.09e-1)" "unprognostic (1.30e-1)" "unprognostic (9.14e-2)" "unprognostic (1.37e-1)" "unprognostic (3.01e-3)" "unprognostic (4.52e-2)" "unprognostic (1.67e-3)" "unprognostic (8.82e-3)" "unprognostic (7.04e-2)" "unprognostic (1.30e-1)" "unprognostic (1.92e-1)" 2.8 2.5 11.6 0.8 14.8 1.2 2.4 4.3 9.7 13.6 12.5 8.4 49.6 24.9 14.4 4.2 1.5 6.1 3.3 2.0 16.0 12.2 2.3 19.7 3.0 0.8 17.6 5.6 5.6 0.6 3.2 7.0 12.3 17.0 5.5 8.1 6.9 2.9 61.0 0.4 0.6 56.6 11.8 15.7 0.9 1.2 1.9 5.5 0.0 3.8 0.8 1.3 2.0 3.1 1.2 0.5 0.0 0.2 2.4 5.7 0.7 0.7 19.9 5.9 0.0 0.2 0.0 34.7 0.7 0.6 1.0 1.7 4.4 0.2 0.0 0.2 0.1 5.8 0.2 0.6 1.5 5.6 0.9 0.2 0.1 5.9 0.0 0.3 0.0 0.1 2.4 2.3 0.1 1.8 0.4 0.0 0.6 11.5 2.7 0.1 2.0 0.0 1.3 0.0 17.4 0.0 4.2 0.1 0.2 4.1 0.4 0.5 0.1 0.0 0.0 0.8 0.7 0.2 0.0 5.5 2.1 0.0 1.5 0.0 0.8 0.0 0.0 0.0 1.9 0.0 5.7 0.1 0.7 0.6 0.0 1.2 0.7 0.3 0.0 2.4 0.2 0.5 1.7 0.7 11.6 14.8 4.3 9.7 16.0 12.2 17.6 5.6 17.0 5.5 ABI1 "ABI-1, E3B1, SSH3BP1" ENSG00000136754 "Abl interactor 1" Q8IZP0 10 26746593-26861087 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Host-virus interaction" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB008375, HPA029973, HPA068407" Approved Enhanced "Plasma membrane,Cell Junctions,Cytosol" 400000 "Plasma membrane, Cell Junctions" Cytosol "CAB008375: AB_592744, HPA029973: , HPA068407: " "unprognostic (2.83e-3)" "unprognostic (8.69e-2)" "unprognostic (1.12e-1)" "unprognostic (3.96e-1)" "unprognostic (2.51e-2)" "unprognostic (9.24e-3)" "unprognostic (1.88e-3)" "unprognostic (2.03e-1)" "unprognostic (6.04e-2)" "unprognostic (4.38e-1)" "unprognostic (2.40e-2)" "unprognostic (5.48e-2)" "unprognostic (1.98e-1)" "unprognostic (1.07e-1)" "unprognostic (1.79e-1)" "unprognostic (1.37e-1)" "unprognostic (1.18e-1)" 24.0 14.0 32.0 28.1 32.6 54.1 21.4 28.2 35.5 22.5 22.7 19.8 14.8 24.8 23.9 15.4 45.1 20.3 21.6 14.1 47.3 23.1 21.9 17.8 22.5 32.1 25.0 26.4 25.3 17.0 19.1 14.4 22.7 20.9 19.1 24.8 26.7 30.9 17.0 16.6 33.0 26.0 21.6 27.5 25.5 23.9 12.4 20.5 43.5 18.8 27.3 40.9 25.2 30.3 36.1 26.8 51.5 28.0 20.5 44.5 31.5 23.2 13.1 10.7 10.5 16.2 20.0 16.0 23.6 16.1 17.5 20.4 15.3 27.6 42.8 12.1 25.0 26.1 12.9 15.3 19.5 28.5 11.5 18.8 8.9 10.8 11.1 9.1 19.0 13.6 19.5 17.1 10.2 21.1 13.8 27.4 17.8 10.0 21.3 8.7 8.8 6.3 23.1 19.9 27.5 18.6 10.8 8.9 9.5 19.6 19.2 19.7 12.4 14.5 26.2 13.4 16.5 16.9 12.0 6.1 9.8 50.9 19.3 23.3 9.6 35.5 23.8 51.5 27.0 28.0 25.8 36.1 25.9 30.0 26.8 28.6 24.4 26.5 37.9 20.5 26.7 22.3 44.5 31.5 32.0 32.6 28.2 31.9 47.3 23.1 25.0 26.4 20.9 20.5 ABL1 "ABL, c-ABL, JTK7, p150" ENSG00000097007 "ABL proto-oncogene 1, non-receptor tyrosine kinase" P00519 9 130713946-130887675 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins" "Apoptosis, Autophagy, Cell adhesion, DNA damage, DNA repair, Endocytosis" "DNA-binding, Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002686, HPA027251, HPA027280, HPA028409" Supported Enhanced "Nucleoplasm,Nuclear bodies" Nucleoplasm "Nuclear bodies" "CAB002686: , HPA027251: AB_1844453, HPA027280: AB_1844454, HPA028409: AB_10601011" "unprognostic (4.82e-2)" "unprognostic (3.99e-2)" "unprognostic (5.55e-2)" "unprognostic (4.72e-2)" "unprognostic (1.16e-1)" "unprognostic (1.46e-1)" "unprognostic (3.75e-3)" "unprognostic (1.89e-3)" "unprognostic (2.34e-1)" "unprognostic (2.54e-2)" "unprognostic (1.09e-2)" "unprognostic (1.48e-1)" "unprognostic (3.96e-3)" "unprognostic (1.10e-2)" "unprognostic (1.47e-1)" "unprognostic (1.22e-1)" "unprognostic (1.06e-1)" 20.1 11.6 12.4 15.0 18.1 10.7 22.0 6.7 16.0 28.9 34.3 29.1 12.1 11.9 26.6 16.9 21.4 20.8 30.9 14.2 10.3 8.4 9.9 6.7 13.8 8.7 24.1 9.4 24.2 12.2 27.7 14.5 13.6 17.1 27.3 15.8 19.4 14.6 18.0 10.8 14.2 17.0 66.6 14.3 10.8 21.9 9.8 21.2 5.8 19.5 11.4 9.1 35.8 31.9 3.1 3.1 1.1 5.0 2.4 2.6 1.6 7.0 15.7 16.9 20.4 24.8 30.3 6.2 12.4 19.5 14.6 12.4 12.3 9.2 11.6 7.2 16.5 13.7 8.5 11.5 10.8 7.3 5.3 7.6 26.9 10.5 16.9 11.7 10.7 22.1 12.7 26.1 16.2 20.2 42.6 9.3 17.8 13.4 14.8 9.6 18.7 11.6 17.2 21.9 12.6 14.7 8.3 15.8 19.7 20.8 8.1 10.0 15.9 10.8 23.1 56.0 14.5 21.4 19.5 2.8 6.6 15.6 23.1 9.7 17.7 0.2 2.1 1.1 2.0 1.2 2.6 3.1 2.0 1.9 2.0 1.4 1.9 1.7 0.2 2.4 5.0 3.1 0.9 1.6 12.4 18.1 6.7 16.0 10.3 8.4 24.1 9.4 17.1 21.2 ABL2 "ABLL, ARG" ENSG00000143322 "ABL proto-oncogene 2, non-receptor tyrosine kinase" P42684 1 179099327-179229684 "Cancer-related genes, Enzymes, Predicted intracellular proteins, RAS pathway related proteins" "Cell adhesion" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "hTERT-HME1: 31.7;TIME: 29.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001866, CAB017106, HPA072754" Uncertain Supported Nucleoplasm Nucleoplasm "CAB017106: , HPA001866: AB_1078082, HPA072754: " "unprognostic (3.05e-1)" "prognostic unfavourable (3.50e-4)" "unprognostic (1.07e-1)" "unprognostic (4.71e-2)" "unprognostic (9.45e-2)" "unprognostic (8.23e-3)" "unprognostic (1.91e-2)" "unprognostic (4.81e-3)" "unprognostic (1.26e-1)" "unprognostic (6.98e-2)" "unprognostic (1.12e-1)" "unprognostic (3.73e-1)" "prognostic unfavourable (1.78e-7)" "unprognostic (4.76e-2)" "unprognostic (4.14e-2)" "unprognostic (6.08e-2)" "prognostic unfavourable (8.40e-4)" 14.3 5.2 8.6 7.4 13.7 3.7 8.3 14.9 10.6 9.2 6.6 5.8 4.5 4.0 5.4 4.7 3.9 4.3 18.8 6.8 9.7 3.9 4.9 4.3 11.5 3.7 6.5 6.1 5.6 8.4 9.2 8.4 6.1 8.1 5.1 5.2 5.8 4.5 4.4 5.2 6.6 3.7 6.9 6.2 3.9 4.7 9.2 8.6 3.6 5.8 3.1 3.6 6.7 11.2 2.8 2.0 3.8 1.2 1.8 2.2 0.6 10.0 5.5 3.7 2.5 3.2 7.3 2.3 11.1 9.1 13.7 9.9 4.0 3.1 5.8 8.2 7.9 5.0 5.2 3.7 19.4 3.6 4.8 2.8 5.0 2.0 5.8 3.1 0.9 6.7 4.9 19.4 31.7 15.1 6.6 1.7 17.7 2.6 2.4 1.6 3.6 1.8 3.7 6.2 2.8 4.6 1.6 2.3 5.1 9.2 2.9 22.8 2.6 2.6 29.5 14.2 10.6 6.8 17.8 3.1 3.8 6.0 6.7 1.7 13.7 3.8 1.2 0.4 2.2 0.4 1.0 1.8 1.4 1.4 0.9 2.8 1.9 2.0 2.6 1.8 0.5 2.0 0.8 0.6 8.6 13.7 14.9 10.6 9.7 3.9 6.5 6.1 8.1 8.6 ACAP1 "CENTB1, KIAA0050" ENSG00000072818 "ArfGAP with coiled-coil, ankyrin repeat and PH domains 1" Q15027 17 7336529-7351478 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Protein transport, Transport" "GTPase activation" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 29.4;bone marrow: 30.3;lymphoid tissue: 51.5" "Cell line enhanced" "Detected in some" "Daudi: 18.5;HDLM-2: 24.4;Karpas-707: 24.1;NB-4: 29.8;REH: 11.9;U-937: 19.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA075570 Approved Approved "Golgi apparatus" "Golgi apparatus" "HPA075570: " "unprognostic (1.20e-2)" "prognostic favourable (3.66e-4)" "unprognostic (2.49e-1)" "prognostic favourable (2.97e-5)" "unprognostic (4.43e-4)" "prognostic favourable (4.17e-5)" "unprognostic (5.66e-3)" "unprognostic (1.11e-2)" "unprognostic (4.67e-2)" "unprognostic (2.48e-2)" "unprognostic (1.42e-2)" "unprognostic (1.91e-1)" "prognostic unfavourable (1.65e-10)" "unprognostic (1.14e-1)" "unprognostic (5.58e-2)" "unprognostic (2.90e-1)" "unprognostic (8.61e-3)" 2.6 0.6 0.6 31.4 1.3 30.3 1.1 1.0 1.2 1.4 4.5 0.4 0.4 3.2 0.9 1.5 3.3 2.0 3.1 1.4 0.6 0.6 2.9 2.3 7.3 29.3 2.7 0.1 1.0 0.7 0.0 0.8 0.5 1.2 1.8 1.5 1.7 9.6 1.3 0.5 1.2 19.2 0.8 1.3 44.9 3.7 1.4 0.9 51.5 2.5 1.0 33.9 3.7 1.8 17.8 13.3 22.4 5.9 23.7 29.4 16.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.1 0.1 0.0 18.5 0.1 0.0 0.0 0.0 0.0 0.0 24.4 0.0 7.0 0.1 0.0 0.0 9.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 24.1 0.0 0.0 11.2 29.8 0.3 0.0 11.9 0.1 2.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.1 0.0 0.0 0.1 0.0 0.0 7.5 6.3 8.4 0.1 19.7 0.0 17.0 5.9 22.4 24.6 1.8 27.5 16.6 25.8 26.1 10.5 17.8 22.7 22.4 17.7 23.7 0.2 13.3 29.4 16.1 0.6 1.3 1.0 1.2 0.6 0.6 2.7 0.1 1.2 0.9 ACKR3 "CMKOR1, CXCR7, GPR159, RDC1" ENSG00000144476 "Atypical chemokine receptor 3" P25106 2 236567787-236582358 "Cancer-related genes, G-protein coupled receptors, Predicted membrane proteins" "Cell adhesion, Host-virus interaction" "Developmental protein, G-protein coupled receptor, Receptor, Transducer" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in some" "HeLa: 22.8;MCF7: 16.8;RT4: 66.7;SiHa: 20.4;U-2197: 70.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Group enriched" "Detected in many" 6 "NK-cells: 6.1;T-cells: 6.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA032003, HPA049718" Approved Supported "Vesicles,Plasma membrane" "Vesicles, Plasma membrane" "HPA032003: , HPA049718: " "unprognostic (1.65e-2)" "prognostic unfavourable (4.64e-4)" "unprognostic (2.50e-1)" "unprognostic (1.92e-3)" "unprognostic (2.10e-1)" "unprognostic (1.23e-1)" "unprognostic (7.34e-3)" "unprognostic (1.55e-2)" "unprognostic (1.85e-2)" "unprognostic (1.35e-1)" "unprognostic (9.70e-3)" "unprognostic (6.69e-2)" "prognostic unfavourable (1.76e-6)" "prognostic unfavourable (2.01e-4)" "unprognostic (9.71e-2)" "unprognostic (8.57e-3)" "prognostic unfavourable (2.93e-4)" 56.1 2.9 5.4 6.9 5.6 1.7 28.5 2.2 6.4 10.7 15.2 8.9 9.1 5.7 9.9 20.4 23.6 14.6 15.3 30.2 8.4 3.0 3.8 29.6 10.9 7.2 3.8 6.5 19.3 25.7 2.2 10.7 59.6 8.4 14.2 12.8 25.2 8.9 8.9 36.4 16.0 15.7 32.6 7.2 70.9 12.6 9.4 5.5 0.2 34.3 22.3 8.6 59.2 17.8 1.0 0.2 0.1 0.5 6.1 6.1 0.6 0.0 0.0 1.3 0.0 2.3 0.0 9.8 0.5 0.3 0.4 1.0 0.1 0.0 0.0 1.1 0.0 14.3 0.0 5.1 0.0 0.0 0.0 0.0 22.8 0.0 0.0 0.0 0.0 0.6 13.1 0.0 0.0 2.3 0.2 0.0 0.0 16.8 0.0 0.0 2.3 0.1 0.0 1.6 0.1 0.0 66.7 0.0 0.0 20.4 0.1 0.0 0.0 0.0 0.0 0.1 5.3 70.1 0.0 0.2 0.0 0.0 0.2 1.4 0.1 0.0 0.1 0.0 4.1 0.3 6.1 0.6 2.1 5.0 0.2 1.0 1.8 2.3 0.1 6.1 0.5 0.0 3.1 0.6 5.4 5.6 2.2 6.4 8.4 3.0 3.8 6.5 8.4 5.5 ACLY "ACL, ATPCL, CLATP" ENSG00000131473 "ATP citrate lyase" P53396 17 41866908-41930542 "Cancer-related genes, Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins" "Lipid biosynthesis, Lipid metabolism" Transferase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB007783, HPA022434, HPA022953, HPA022959, HPA028758" Enhanced Supported "Nucleoplasm,Plasma membrane,Cytosol" 2100000 "Plasma membrane, Cytosol" Nucleoplasm "CAB007783: AB_562242, HPA022434: AB_1844513, HPA022953: AB_1844514, HPA022959: AB_1844515, HPA028758: AB_10603575" "unprognostic (2.21e-2)" "prognostic unfavourable (1.79e-4)" "unprognostic (1.41e-1)" "unprognostic (1.21e-2)" "unprognostic (2.83e-1)" "unprognostic (8.94e-3)" "prognostic unfavourable (3.66e-4)" "unprognostic (3.38e-3)" "unprognostic (4.11e-2)" "unprognostic (5.94e-3)" "unprognostic (2.13e-2)" "unprognostic (3.01e-2)" "unprognostic (3.88e-3)" "unprognostic (1.66e-1)" "unprognostic (9.36e-2)" "unprognostic (3.90e-2)" "unprognostic (4.67e-3)" 38.3 24.0 16.7 26.2 22.9 19.1 35.7 21.5 29.1 22.9 22.2 25.1 18.0 30.7 27.0 24.9 23.2 23.7 28.2 18.4 18.3 33.7 37.8 22.2 23.3 27.4 23.1 17.9 19.0 30.6 27.1 19.5 26.7 49.0 41.3 23.2 15.6 25.4 19.6 10.9 19.6 29.6 27.2 26.2 24.5 24.6 20.7 21.4 32.0 21.3 18.2 24.6 20.3 21.3 16.1 23.9 25.2 26.3 16.0 23.9 21.4 23.2 79.1 37.4 32.2 57.8 54.3 34.4 32.7 35.8 41.2 51.8 40.1 26.8 37.8 21.0 45.8 37.0 48.2 56.0 34.5 34.0 46.1 21.6 45.6 41.7 26.9 34.9 28.3 43.1 16.9 72.4 14.6 43.4 26.6 30.2 34.1 23.7 57.4 19.6 24.3 14.4 37.7 45.2 48.4 42.2 41.4 70.4 38.7 23.3 73.0 25.0 43.5 33.4 46.6 32.2 26.5 32.3 53.6 17.7 22.5 35.9 54.4 27.1 26.1 18.9 20.7 25.2 23.8 22.1 22.5 16.1 19.0 21.3 23.9 13.8 14.6 16.1 10.7 16.0 26.3 13.9 23.9 21.4 16.7 22.9 21.5 27.7 18.3 33.7 23.1 17.9 49.0 21.4 ACO1 "IREB1, IREBP, IRP1" ENSG00000122729 "Aconitase 1" P21399 9 32384603-32454769 "Cancer-related genes, Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins" "Tricarboxylic acid cycle" "Lyase, RNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 80.9" "Cell line enhanced" "Detected in many" "ASC diff: 52.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019371, HPA024157" Enhanced Supported Mitochondria,Cytosol 8000000 "Mitochondria, Cytosol" "HPA019371: AB_1844519, HPA024157: AB_1844520" "unprognostic (2.11e-1)" "unprognostic (5.61e-2)" "unprognostic (8.38e-2)" "unprognostic (9.12e-2)" "unprognostic (2.63e-1)" "unprognostic (3.12e-2)" "unprognostic (4.25e-3)" "unprognostic (2.61e-2)" "unprognostic (1.37e-1)" "unprognostic (1.19e-1)" "unprognostic (2.55e-1)" "unprognostic (3.08e-1)" "prognostic favourable (5.73e-5)" "unprognostic (2.54e-1)" "unprognostic (6.58e-2)" "unprognostic (1.65e-1)" "unprognostic (3.23e-2)" 41.4 27.2 9.6 7.1 9.4 1.5 30.1 8.9 8.1 9.3 19.7 6.2 6.4 21.9 12.8 14.6 12.8 7.2 8.9 15.1 6.5 7.6 40.5 80.9 9.2 9.4 6.1 6.2 14.1 27.9 8.9 8.7 11.3 7.7 10.7 9.8 11.7 11.7 9.5 11.2 5.5 28.4 14.5 6.0 6.4 13.5 11.4 5.9 6.0 18.4 7.2 5.1 13.9 11.7 4.7 7.1 21.4 8.8 4.7 7.4 6.2 9.4 8.7 6.7 10.6 52.5 28.5 3.0 17.9 44.1 8.2 6.5 9.1 2.9 1.9 5.7 18.7 1.3 13.3 17.1 16.6 6.0 3.6 13.8 9.4 9.9 26.4 1.3 5.6 24.8 5.3 21.2 15.0 21.3 4.9 4.1 23.4 2.4 7.3 6.6 7.0 9.2 5.7 10.0 1.9 31.4 8.7 0.8 2.8 18.6 0.7 1.9 4.3 3.4 23.0 30.1 10.2 10.0 4.6 2.0 3.8 3.7 21.0 4.6 2.6 21.4 8.7 2.4 7.4 8.8 6.4 4.7 5.2 5.7 7.1 4.2 6.8 7.0 1.0 4.7 7.2 3.4 2.8 6.2 9.6 9.4 8.9 8.1 6.5 7.6 6.1 6.2 7.7 5.9 ACPP "ACP-3, ACP3, PAP" ENSG00000014257 "Acid phosphatase, prostate" P15309 3 132317367-132368298 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" Hydrolase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 8 "prostate: 345.2" "Cell line enhanced" "Detected in some" "BJ hTERT+: 10.2;NB-4: 7.7;RPMI-8226: 32.3;U-698: 9.4;U-87 MG: 9.0" "Cancer enriched" "Detected in many" 275 "prostate cancer: 1227.2" "Low region specificity" "Detected in single" "Cell type enhanced" "Detected in many" "eosinophil: 43.1" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in some" "CAB000071, HPA004335, HPA063916" Enhanced "Secreted to blood" 9200 "CAB000071: , HPA004335: AB_1079684, HPA063916: " "unprognostic (6.67e-2)" "unprognostic (4.70e-2)" "unprognostic (1.76e-1)" "unprognostic (7.77e-2)" "unprognostic (1.74e-1)" "unprognostic (2.58e-2)" "unprognostic (2.46e-1)" "unprognostic (7.41e-2)" "unprognostic (1.81e-1)" "unprognostic (3.78e-3)" "unprognostic (2.14e-1)" "unprognostic (5.95e-2)" "unprognostic (9.38e-2)" "unprognostic (1.35e-1)" "unprognostic (1.18e-1)" "unprognostic (3.91e-2)" "unprognostic (1.71e-1)" 0.4 0.6 0.4 0.7 1.6 1.4 0.8 0.3 0.7 3.9 0.4 0.2 0.0 0.4 0.3 2.5 14.7 0.6 0.2 0.9 0.3 0.3 6.2 0.3 2.0 2.7 0.6 0.8 0.4 0.8 0.5 0.3 5.3 0.7 345.2 0.7 0.8 9.1 0.2 0.3 2.5 0.4 0.4 2.2 1.0 0.5 1.0 0.6 0.2 1.3 6.6 6.8 0.5 1.5 0.2 11.2 43.1 9.7 0.9 0.0 2.9 0.2 0.0 0.0 0.0 0.1 0.6 7.0 0.1 10.2 0.0 0.0 0.2 0.2 5.7 0.4 0.0 2.9 0.0 0.0 0.0 0.0 0.3 1.1 0.2 0.1 0.1 4.1 0.1 0.6 0.8 0.0 0.0 0.0 0.1 1.6 0.1 0.1 0.0 7.7 0.4 1.2 0.0 0.0 32.3 3.1 3.8 0.0 2.5 0.0 1.2 0.3 0.2 3.7 0.0 0.0 0.1 1.5 0.0 0.4 0.2 9.4 9.0 7.3 0.1 0.0 9.7 43.1 0.0 8.6 0.0 0.2 0.0 0.0 11.2 0.0 0.0 0.0 8.5 0.9 7.7 0.8 0.0 2.9 0.4 1.6 0.3 0.7 0.3 0.3 0.6 0.8 0.7 0.6 ACSL3 "ACS3, FACL3, PRO2194" ENSG00000123983 "Acyl-CoA synthetase long chain family member 3" O95573 2 222860934-222944639 "Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins" "Fatty acid metabolism, Lipid metabolism" Ligase "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in all" 4 "parathyroid gland: 206.1" "Cell line enhanced" "Detected in all" "SK-MEL-30: 92.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA011315, HPA071021" Approved Approved "Nucleoli,Lipid droplets" Nucleoli "Lipid droplets" "HPA011315: AB_1848344, HPA071021: " "unprognostic (1.87e-1)" "unprognostic (5.64e-2)" "unprognostic (2.36e-1)" "unprognostic (9.35e-3)" "unprognostic (7.53e-2)" "unprognostic (2.07e-2)" "prognostic unfavourable (2.75e-4)" "prognostic unfavourable (8.78e-4)" "unprognostic (3.90e-2)" "unprognostic (2.50e-1)" "unprognostic (2.64e-1)" "unprognostic (4.26e-2)" "unprognostic (1.17e-3)" "unprognostic (1.36e-1)" "unprognostic (2.72e-1)" "unprognostic (2.65e-1)" "unprognostic (1.60e-1)" 14.7 17.0 22.8 9.9 26.0 16.3 51.5 19.4 45.9 15.3 16.5 16.1 11.6 12.7 10.9 18.4 28.3 9.0 11.8 22.7 20.9 22.8 17.9 22.3 15.6 10.5 19.6 21.2 11.7 10.3 206.1 8.8 19.1 24.4 44.4 16.7 14.4 34.2 15.5 19.1 11.4 12.7 12.2 22.2 9.7 28.3 13.7 14.2 13.5 17.3 11.2 8.7 14.6 15.4 15.0 22.5 21.8 16.8 16.6 20.1 16.5 9.9 17.6 27.0 29.3 11.8 29.3 7.5 12.7 33.0 15.2 32.2 15.8 25.7 4.8 7.4 12.1 29.4 5.8 28.3 19.8 8.6 11.1 11.2 14.3 17.7 26.0 7.4 5.5 15.1 40.1 25.2 44.0 16.6 21.2 18.3 21.5 21.2 14.4 8.7 13.7 9.2 7.9 22.9 8.1 21.9 40.9 14.2 10.6 7.5 20.3 92.7 10.2 18.1 11.4 10.2 16.3 8.8 9.3 6.5 3.1 16.5 11.0 6.9 30.9 16.6 14.6 21.8 20.1 16.8 19.3 11.6 12.8 14.6 15.7 15.0 18.7 16.7 21.8 16.6 15.9 22.5 9.5 16.5 22.8 26.0 19.4 45.9 20.9 22.8 19.6 21.2 24.4 14.2 ACVR1 "ACVR1A, ACVRLK2, ALK2, SKR1" ENSG00000115170 "Activin A receptor type 1" Q04771 2 157736444-157875862 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Kinase, Receptor, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA007505, HPA046514" Approved Approved Nucleoli,Cytosol Nucleoli Cytosol "HPA007505: AB_1844752, HPA046514: " "unprognostic (6.99e-2)" "unprognostic (3.32e-2)" "unprognostic (3.02e-1)" "unprognostic (1.19e-2)" "unprognostic (2.73e-1)" "unprognostic (6.09e-2)" "unprognostic (3.66e-3)" "unprognostic (1.08e-1)" "unprognostic (3.99e-1)" "unprognostic (3.20e-1)" "unprognostic (2.65e-2)" "unprognostic (4.29e-2)" "unprognostic (2.42e-1)" "unprognostic (3.43e-3)" "unprognostic (3.17e-1)" "unprognostic (1.76e-2)" "prognostic unfavourable (5.17e-4)" 18.9 9.2 18.0 10.0 12.7 1.6 38.7 15.3 12.2 25.2 14.4 7.4 8.4 8.9 24.8 26.8 11.0 16.6 20.5 18.8 18.7 8.6 21.7 18.9 22.5 15.1 10.4 7.9 18.5 12.3 11.3 17.0 14.2 12.3 16.8 10.5 14.3 18.1 13.6 15.6 12.8 11.5 29.2 12.3 9.2 11.8 8.8 10.9 7.5 34.0 14.6 6.9 16.1 32.5 1.4 2.4 3.8 2.6 1.9 10.0 1.6 2.1 4.2 4.9 6.4 25.0 26.1 6.9 15.1 25.2 12.1 13.0 3.3 4.7 0.0 7.0 16.4 5.9 3.5 8.2 13.1 14.5 3.0 8.6 2.5 4.8 19.8 0.6 10.2 32.6 15.6 24.9 31.8 13.2 3.1 2.4 15.3 3.7 0.1 0.2 7.4 7.7 1.4 6.6 1.8 15.8 7.9 4.4 5.4 5.8 3.3 20.7 1.7 2.3 19.0 18.5 6.1 9.1 5.7 1.6 1.2 0.1 19.0 0.5 19.9 3.8 2.6 0.2 1.1 1.7 1.2 1.4 7.8 2.5 1.8 0.8 3.1 1.5 0.8 1.9 2.3 2.4 10.0 1.6 18.0 12.7 15.3 12.2 18.7 8.6 10.4 7.9 12.3 10.9 ACVR1B "ActRIB, ACVRLK4, ALK4, SKR2" ENSG00000135503 "Activin A receptor type 1B" P36896 12 51951667-51997078 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Kinase, Receptor, Serine/threonine-protein kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB026126, HPA063761" Approved Approved Cytosol Cytosol "CAB026126: , HPA063761: " "unprognostic (8.66e-2)" "unprognostic (5.72e-2)" "unprognostic (1.16e-1)" "unprognostic (3.23e-3)" "unprognostic (2.34e-1)" "unprognostic (2.54e-1)" "unprognostic (1.21e-3)" "unprognostic (1.00e-1)" "unprognostic (7.68e-2)" "unprognostic (5.29e-2)" "unprognostic (2.56e-1)" "unprognostic (2.37e-1)" "unprognostic (4.52e-2)" "unprognostic (9.02e-2)" "unprognostic (6.60e-2)" "unprognostic (8.96e-2)" "unprognostic (4.79e-2)" 11.1 7.4 12.0 6.4 14.6 7.9 14.3 14.2 24.4 8.6 16.7 5.1 28.0 19.2 6.7 13.1 14.4 10.9 11.1 7.6 11.2 10.5 24.6 21.0 10.3 7.1 8.1 14.7 7.1 35.1 24.9 10.9 7.5 7.3 10.0 17.1 8.7 21.7 34.3 11.7 30.6 19.8 8.2 5.8 6.7 17.2 10.6 4.8 3.9 9.9 5.8 8.4 10.1 12.1 0.5 1.3 6.8 4.0 0.1 1.6 0.6 6.2 13.8 10.7 5.9 12.3 9.7 6.1 7.1 8.1 7.6 5.8 27.8 9.7 2.7 10.0 7.7 11.1 10.2 8.6 7.9 4.0 12.0 6.8 3.5 8.6 14.1 10.9 25.5 18.9 11.2 8.6 10.9 10.7 7.2 8.6 6.7 12.8 10.4 9.5 10.4 4.8 5.6 8.3 3.5 21.5 9.6 13.7 11.4 7.7 11.0 5.0 12.1 7.1 6.7 5.2 8.0 5.9 3.4 5.2 3.7 3.8 5.6 5.3 6.7 4.5 2.2 6.8 0.7 3.3 1.0 0.1 0.6 0.7 1.3 0.5 1.6 0.9 1.9 0.1 4.0 0.7 1.0 0.6 12.0 14.6 14.2 24.4 11.2 10.5 8.1 14.7 7.3 4.8 ACVR2A "ACTRII, ACVR2" ENSG00000121989 "Activin A receptor type 2A" P27037 2 147844517-147930826 "Cancer-related genes, Enzymes, Predicted membrane proteins" "Kinase, Receptor, Serine/threonine-protein kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HHSteC: 20.5;RH-30: 17.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA046997 Approved Approved Cytosol Cytosol "HPA046997: AB_10970077" "unprognostic (4.55e-2)" "unprognostic (2.26e-2)" "unprognostic (2.09e-1)" "unprognostic (7.34e-3)" "unprognostic (2.75e-1)" "unprognostic (1.17e-1)" "unprognostic (4.41e-3)" "unprognostic (8.73e-3)" "unprognostic (1.30e-2)" "unprognostic (3.61e-1)" "unprognostic (1.34e-2)" "unprognostic (1.52e-1)" "prognostic favourable (1.62e-4)" "unprognostic (1.16e-1)" "unprognostic (1.40e-1)" "unprognostic (3.95e-1)" "unprognostic (3.99e-2)" 12.0 6.0 13.6 8.2 9.9 3.8 10.7 14.5 14.2 10.2 14.1 4.7 9.7 10.4 9.3 9.9 13.6 7.6 17.7 5.6 10.0 9.0 9.0 10.3 7.5 4.7 5.9 10.6 7.6 9.8 8.6 15.9 10.6 7.3 12.2 9.1 7.6 12.2 12.0 19.6 29.5 17.8 13.8 5.4 6.5 9.3 11.0 6.4 1.5 9.5 6.9 6.8 13.5 11.8 0.7 3.0 0.5 3.6 7.7 4.6 1.4 1.3 1.5 9.8 3.6 5.8 3.7 4.0 3.0 3.6 5.2 9.1 4.2 5.9 0.0 2.7 4.8 4.6 8.9 4.4 6.7 1.0 5.4 0.6 2.7 7.3 20.5 0.6 0.7 6.2 5.6 3.3 6.7 3.9 1.4 2.5 3.5 3.4 0.3 0.5 11.0 2.6 0.1 17.1 0.9 4.2 8.3 9.7 5.5 2.5 3.1 3.7 1.9 1.0 3.0 4.8 5.7 4.5 2.1 0.7 0.2 1.8 3.0 0.3 3.8 0.4 3.0 0.5 1.2 3.6 0.5 0.3 4.6 2.1 2.3 0.7 3.0 0.7 0.1 7.7 3.1 3.0 0.4 1.4 13.6 9.9 14.5 14.2 10.0 9.0 5.9 10.6 7.3 6.4 ACVR2B ActR-IIB ENSG00000114739 "Activin A receptor type 2B" Q13705 3 38453851-38493142 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins" "Kinase, Receptor, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, Heterotaxy" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "AF22: 16.6;NTERA-2: 20.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA007398, CAB025115, HPA040384" Approved Approved "Nucleoplasm,Nuclear bodies,Cytosol" "Nucleoplasm, Cytosol" "Nuclear bodies" "CAB025115: , HPA007398: , HPA040384: " "unprognostic (5.11e-2)" "unprognostic (1.54e-1)" "unprognostic (3.47e-1)" "unprognostic (8.73e-2)" "unprognostic (9.24e-2)" "unprognostic (2.21e-1)" "unprognostic (1.32e-2)" "unprognostic (1.25e-2)" "unprognostic (1.88e-1)" "unprognostic (1.53e-2)" "unprognostic (5.14e-2)" "unprognostic (1.30e-1)" "unprognostic (4.08e-3)" "unprognostic (1.64e-1)" "unprognostic (1.98e-1)" "unprognostic (1.83e-1)" "unprognostic (4.75e-1)" 2.8 7.4 5.5 4.6 7.9 1.1 5.5 13.2 7.5 5.2 3.4 7.2 4.5 2.8 4.7 5.1 2.5 5.6 3.3 3.9 5.9 5.4 5.3 5.4 6.9 2.2 5.9 5.4 8.3 6.1 11.3 5.1 16.0 6.5 3.9 3.6 5.0 4.6 4.2 15.9 2.4 2.8 4.6 4.7 3.1 4.0 9.1 9.1 12.8 4.8 1.7 2.2 4.2 10.3 0.3 0.3 0.5 0.2 0.5 1.6 0.3 0.8 1.4 16.6 1.4 0.6 0.4 8.9 0.3 0.5 0.3 0.7 2.4 1.1 0.1 1.3 0.4 1.0 6.3 1.0 0.9 2.4 4.1 4.2 2.6 3.5 0.8 3.0 1.6 0.7 0.9 0.5 1.8 1.1 7.0 1.4 0.3 1.3 5.1 1.9 20.5 0.7 1.7 5.5 1.0 1.1 2.0 3.9 6.8 0.5 2.5 2.2 1.4 4.0 0.9 0.6 2.7 0.4 1.4 4.0 5.4 0.9 0.6 2.5 1.1 0.5 0.1 0.1 0.4 0.2 0.6 0.2 1.0 0.5 0.0 0.3 1.6 1.5 0.3 0.5 0.2 0.3 0.7 0.3 5.5 7.9 13.2 7.0 5.9 5.4 5.9 5.4 6.5 9.1 ADAM10 "CD156c, HsT18717, kuz, MADM" ENSG00000137845 "ADAM metallopeptidase domain 10" O14672 15 58588807-58749978 "Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Notch signaling pathway" "Hydrolase, Metalloprotease, Protease" "Alzheimer disease, Amyloidosis, Cancer-related genes, Disease mutation, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "U-2197: 76.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB001709, HPA050670" Approved Supported "Nucleoplasm,Vesicles,Plasma membrane" "Intracellular and membrane" 8200000 "Plasma membrane" "Nucleoplasm, Vesicles" "CAB001709: , HPA050670: " "unprognostic (1.43e-1)" "unprognostic (1.38e-1)" "unprognostic (2.77e-1)" "unprognostic (5.04e-2)" "unprognostic (3.09e-1)" "unprognostic (2.70e-3)" "unprognostic (7.48e-2)" "prognostic unfavourable (8.46e-5)" "unprognostic (3.99e-2)" "unprognostic (1.19e-1)" "prognostic unfavourable (1.90e-4)" "unprognostic (6.69e-2)" "unprognostic (2.57e-2)" "unprognostic (2.57e-3)" "unprognostic (9.14e-2)" "unprognostic (2.09e-2)" "unprognostic (1.60e-2)" 25.9 11.1 15.5 17.1 17.7 15.6 20.0 25.2 17.6 18.6 20.1 15.7 12.7 13.9 19.9 11.8 17.1 13.8 18.0 18.8 17.6 13.7 20.8 14.8 25.0 26.1 23.1 12.4 13.9 13.1 10.9 11.6 36.1 14.5 23.6 16.7 14.6 12.4 19.1 8.9 15.4 15.6 12.8 30.4 40.4 18.4 8.5 18.9 38.5 27.3 9.2 14.9 30.0 19.1 6.2 12.7 26.9 23.7 9.8 12.2 12.8 11.8 26.9 7.3 8.0 9.4 13.6 18.5 10.2 30.4 7.5 10.5 12.4 15.7 5.5 31.6 9.1 24.3 4.4 10.8 10.0 8.2 5.6 9.4 9.8 11.5 10.5 6.6 27.2 11.9 8.0 5.2 7.7 14.6 5.9 15.0 13.2 4.4 21.9 7.6 10.0 3.8 9.1 24.0 14.1 17.5 32.1 8.0 5.2 11.1 12.9 17.6 7.7 13.3 10.3 9.9 11.0 76.0 9.8 8.4 18.1 6.0 13.8 12.9 17.3 12.9 18.8 10.4 8.1 21.5 12.2 5.3 8.0 7.1 12.7 6.2 8.4 7.0 26.9 9.8 23.7 5.8 10.3 12.8 15.5 17.7 25.2 16.9 17.6 13.7 23.1 12.4 14.5 18.9 ADAM9 "CORD9, KIAA0021, MCMP, MDC9, Mltng" ENSG00000168615 "ADAM metallopeptidase domain 9" Q13443 8 38996869-39105144 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins" "Hydrolase, Metalloprotease, Protease" "Cancer-related genes, Cone-rod dystrophy" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "classical monocyte: 11.4" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA004000 Approved "Endoplasmic reticulum,Vesicles" "Secreted - unknown location" 640000 Vesicles "Endoplasmic reticulum" "HPA004000: AB_1844584" "prognostic unfavourable (1.14e-4)" "prognostic unfavourable (2.25e-4)" "unprognostic (1.32e-3)" "unprognostic (1.27e-1)" "unprognostic (2.86e-1)" "unprognostic (1.40e-1)" "prognostic unfavourable (7.21e-6)" "unprognostic (5.77e-2)" "unprognostic (1.55e-1)" "unprognostic (1.48e-2)" "prognostic unfavourable (2.52e-5)" "unprognostic (5.83e-2)" "prognostic unfavourable (3.99e-4)" "unprognostic (2.80e-1)" "unprognostic (5.76e-2)" "unprognostic (2.27e-1)" "unprognostic (1.23e-2)" 36.7 25.0 14.7 21.7 13.6 10.4 17.1 20.9 14.4 21.8 24.4 13.2 21.8 19.4 24.9 19.8 24.1 15.5 31.7 28.5 12.5 10.1 29.4 11.6 39.2 20.3 19.2 12.9 17.6 11.1 37.5 10.4 30.1 15.8 23.8 23.8 15.4 44.5 21.4 18.3 12.8 25.4 32.8 22.0 25.7 33.2 13.7 12.7 2.4 24.0 14.9 11.7 34.8 19.2 0.6 8.1 3.4 11.4 3.1 0.8 2.8 41.1 29.8 11.8 7.2 19.1 61.6 15.3 55.9 61.1 31.4 29.4 14.1 29.9 2.1 21.1 38.4 17.6 5.0 39.5 60.9 2.0 5.1 2.2 20.7 12.2 38.7 1.6 4.8 47.4 23.5 30.9 35.2 42.7 4.3 14.0 65.3 4.0 1.6 1.0 1.7 9.6 1.4 21.3 7.1 51.0 11.8 1.6 2.4 14.9 17.9 13.6 14.5 3.0 73.4 24.0 23.1 45.3 25.6 4.5 6.9 2.3 39.8 2.7 16.3 1.4 11.4 2.2 0.6 6.1 0.3 0.1 0.3 0.8 8.1 0.6 0.1 0.6 3.4 3.1 2.6 2.7 0.4 2.8 14.7 13.6 20.9 14.4 12.5 10.1 19.2 12.9 15.8 12.7 ADAMTS1 "C3-C5, KIAA1346, METH1" ENSG00000154734 "ADAM metallopeptidase with thrombospondin type 1 motif 1" Q9UHI8 21 26835747-26845409 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters" "Heparin-binding, Hydrolase, Metalloprotease, Protease" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "ovary: 112.8" "Cell line enhanced" "Detected in many" "ASC diff: 60.9;BJ: 71.0;hTEC/SVTERT24-B: 49.0;hTERT-HME1: 44.6;RPTEC TERT1: 41.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 6 "gdT-cell: 8.0;NK-cell: 9.0" "Group enriched" "Detected in many" 85 "NK-cells: 9.0;T-cells: 8.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in some" "CAB016394, HPA031498" Uncertain Approved "Plasma membrane" "Secreted to extracellular matrix" 1900000 "Plasma membrane" "CAB016394: AB_626637, HPA031498: " "unprognostic (6.82e-2)" "unprognostic (1.35e-1)" "unprognostic (1.21e-1)" "unprognostic (1.64e-1)" "unprognostic (1.18e-2)" "prognostic unfavourable (5.13e-4)" "unprognostic (1.03e-1)" "unprognostic (3.28e-1)" "unprognostic (2.37e-2)" "unprognostic (5.39e-2)" "unprognostic (1.75e-1)" "unprognostic (4.55e-2)" "unprognostic (9.70e-3)" "unprognostic (8.27e-3)" "unprognostic (1.12e-1)" "unprognostic (6.76e-2)" "unprognostic (1.57e-1)" 70.6 13.4 8.2 18.7 14.0 0.7 29.0 6.3 9.2 22.0 18.2 9.5 4.8 3.3 27.7 25.8 30.0 45.8 62.3 40.9 7.6 4.8 15.4 22.8 25.0 10.9 12.7 3.7 112.8 9.3 6.3 7.6 56.8 13.2 23.3 16.5 7.8 5.8 8.1 25.7 6.1 16.2 46.4 10.2 7.2 16.8 12.8 11.4 0.0 14.3 18.1 2.7 32.7 45.3 0.0 0.0 0.0 0.0 9.0 8.0 1.4 0.0 0.0 1.1 0.0 60.9 15.1 3.7 71.0 24.8 12.3 8.1 0.0 0.0 0.0 4.9 22.5 1.3 0.8 3.6 21.7 0.0 22.6 0.0 7.4 0.0 11.7 2.8 0.0 16.9 0.0 49.0 44.6 5.0 1.2 0.0 36.4 0.0 0.3 0.0 4.0 2.8 0.0 28.1 0.2 41.6 4.0 0.0 5.5 3.3 0.0 0.3 0.1 0.7 5.1 17.5 0.9 27.2 10.5 0.1 0.0 0.0 14.4 0.0 5.3 0.0 0.0 0.0 8.0 0.0 0.8 0.0 0.3 0.6 0.0 0.0 0.0 1.5 0.0 9.0 0.0 0.0 0.0 1.4 8.2 14.0 6.3 9.2 7.6 4.8 12.7 3.7 13.2 11.4 ADAMTS18 ADAMTS21 ENSG00000140873 "ADAM metallopeptidase with thrombospondin type 1 motif 18" Q8TE60 16 77247813-77435114 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins" "Hydrolase, Metalloprotease, Protease" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 8 "adipose tissue: 16.1;brain: 31.9;placenta: 27.6" "Group enriched" "Detected in some" 8 "HUVEC TERT2: 12.1;TIME: 3.7;U-87 MG: 7.4" "Low cancer specificity" "Detected in single" "Region enriched" "Detected in all" 5 "cerebellum: 31.9" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in single" 5 "cerebellum: 3.7" "Not detected" "Not detected" HPA044326 Uncertain Approved "Midbody,Mitotic spindle" "Secreted to extracellular matrix" "Midbody, Mitotic spindle" "HPA044326: AB_10961006" "unprognostic (1.10e-2)" "unprognostic (2.78e-1)" "unprognostic (1.38e-1)" "unprognostic (2.50e-1)" "unprognostic (8.13e-2)" "unprognostic (2.05e-2)" "unprognostic (1.09e-1)" "unprognostic (6.27e-2)" "unprognostic (2.46e-2)" "unprognostic (2.98e-1)" "unprognostic (4.11e-2)" "unprognostic (2.20e-2)" "unprognostic (8.17e-4)" "unprognostic (1.77e-5)" "unprognostic (2.17e-1)" "unprognostic (3.41e-1)" "unprognostic (2.47e-4)" 16.1 0.6 1.1 0.8 5.1 0.4 3.2 31.9 3.3 2.2 0.4 8.2 0.0 0.5 1.6 0.4 0.5 0.7 1.1 0.4 2.0 1.3 0.5 0.3 0.5 0.5 1.8 1.4 0.5 0.8 0.4 1.4 27.6 6.4 1.0 0.4 0.2 2.1 0.5 1.0 0.4 0.4 1.2 3.7 0.3 0.3 0.7 2.4 0.0 0.4 0.0 0.3 0.8 0.4 0.0 0.9 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.5 0.4 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 12.1 0.0 0.0 0.0 0.0 0.0 0.8 0.9 0.0 0.1 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.7 3.7 0.1 0.0 0.0 0.0 0.0 0.0 0.3 7.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 1.1 5.1 31.9 3.3 2.0 1.3 1.8 1.4 6.4 2.4 ADAMTS20 GON-1 ENSG00000173157 "ADAM metallopeptidase with thrombospondin type 1 motif 20" P59510 12 43353866-43551921 "Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins" "Hydrolase, Metalloprotease, Protease" "Cancer-related genes" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Group enriched" "Detected in some" 8 "brain: 5.1;placenta: 3.6;retina: 1.5;testis: 2.3" "Cell line enhanced" "Detected in some" "EFO-21: 2.4;Karpas-707: 6.6;NB-4: 2.9;NTERA-2: 5.2;U-266/70: 7.5;U-266/84: 3.8" "Not detected" "Not detected" "Region enhanced" "Detected in many" "pons and medulla: 5.1" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA027608, HPA027609" Uncertain "Secreted to extracellular matrix" "HPA027608: AB_10600098, HPA027609: AB_10599024" "unprognostic (3.18e-2)" "unprognostic (1.19e-1)" "unprognostic (1.91e-2)" "unprognostic (2.04e-1)" "unprognostic (9.61e-2)" "unprognostic (3.29e-1)" "unprognostic (6.67e-2)" "unprognostic (2.26e-1)" "unprognostic (1.05e-4)" "unprognostic (7.42e-2)" "unprognostic (2.02e-1)" "unprognostic (9.81e-3)" "unprognostic (2.57e-1)" 0.2 0.0 0.7 0.1 1.4 0.1 0.0 0.0 1.2 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.3 0.7 0.0 0.0 0.1 0.0 0.6 0.0 0.3 0.0 0.2 0.0 3.6 5.1 0.0 0.0 1.5 0.2 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.1 2.3 1.1 0.0 0.1 0.0 0.2 0.1 0.3 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 2.4 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 6.6 0.2 0.0 0.0 2.9 5.2 0.1 0.0 0.0 1.6 0.0 0.0 0.0 0.7 0.0 0.0 0.1 1.4 0.0 0.0 0.0 0.7 0.0 0.0 7.5 3.8 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 1.4 0.0 1.2 0.3 0.7 0.6 0.0 5.1 1.1 ADAMTS3 "ADAMTS-4, KIAA0366" ENSG00000156140 "ADAM metallopeptidase with thrombospondin type 1 motif 3" O15072 4 72280969-72569386 "Cancer-related genes, Predicted secreted proteins" "Heparin-binding, Hydrolase, Metalloprotease, Protease" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in some" "AF22: 12.3;AN3-CA: 7.1;HEL: 12.7;K-562: 10.8;SH-SY5Y: 6.5;U-2 OS: 7.9" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA021368, HPA021369" Uncertain Approved "Intermediate filaments" "Secreted to extracellular matrix" "Intermediate filaments" "HPA021368: , HPA021369: " "unprognostic (1.93e-1)" "unprognostic (3.47e-3)" "unprognostic (1.41e-1)" "unprognostic (1.05e-3)" "unprognostic (6.11e-2)" "unprognostic (2.60e-1)" "unprognostic (3.26e-3)" "unprognostic (1.60e-3)" "unprognostic (5.92e-4)" "unprognostic (3.11e-2)" "unprognostic (1.93e-1)" "unprognostic (2.60e-1)" "unprognostic (8.63e-3)" "unprognostic (1.65e-3)" "unprognostic (1.17e-1)" "unprognostic (2.72e-1)" "unprognostic (1.50e-4)" 5.3 2.6 3.3 4.4 5.6 2.1 7.8 0.3 4.6 4.4 2.3 1.1 1.9 0.5 9.6 14.4 1.0 7.5 1.9 2.8 1.3 0.9 4.7 2.7 3.1 2.0 0.7 2.2 7.5 1.0 12.4 1.1 8.2 2.2 2.6 1.1 3.9 1.4 3.4 0.8 1.5 0.9 4.6 1.8 1.9 1.6 5.6 1.3 0.6 4.4 0.8 1.0 2.1 2.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 12.3 7.1 0.1 0.3 0.1 0.6 2.0 1.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 4.5 0.0 1.7 0.0 1.6 12.7 0.9 0.0 0.2 0.0 0.0 1.6 0.1 0.6 0.1 0.0 10.8 0.0 0.0 0.0 1.1 0.0 2.0 3.7 0.0 2.5 0.0 4.2 0.0 0.5 6.5 0.0 0.5 0.1 0.1 0.1 0.1 5.3 7.9 0.0 0.6 0.0 0.0 0.0 1.1 0.0 2.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.3 5.6 0.3 4.6 1.3 0.9 0.7 2.2 2.2 1.3 ADAMTS4 "ADAMTS-2, ADMP-1, KIAA0688" ENSG00000158859 "ADAM metallopeptidase with thrombospondin type 1 motif 4" O75173 1 161184308-161199056 "Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters" "Hydrolase, Metalloprotease, Protease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adipose tissue: 58.0" "Cell line enhanced" "Detected in some" "hTEC/SVTERT24-B: 10.7;HUVEC TERT2: 12.9;SH-SY5Y: 7.2;TIME: 10.8;U-251 MG: 9.6" "Low cancer specificity" "Detected in all" "Group enriched" "Detected in all" 5 "basal ganglia: 20.7;cerebral cortex: 10.0;midbrain: 28.6;pons and medulla: 20.5;thalamus: 15.7" "Cell type enriched" "Detected in some" 8 "plasmacytoid DC: 8.0" "Lineage enriched" "Detected in many" 8 "dendritic cells: 8.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB025876, HPA051296, HPA068374" Uncertain Supported "Nuclear speckles" "Secreted to extracellular matrix" "Nuclear speckles" "CAB025876: , HPA051296: , HPA068374: " "unprognostic (2.70e-2)" "unprognostic (8.10e-3)" "unprognostic (3.00e-3)" "unprognostic (2.75e-1)" "unprognostic (9.95e-3)" "unprognostic (1.19e-1)" "unprognostic (1.07e-1)" "prognostic unfavourable (5.00e-4)" "unprognostic (1.20e-2)" "unprognostic (9.59e-3)" "unprognostic (2.48e-2)" "unprognostic (1.59e-1)" "prognostic unfavourable (7.27e-7)" "unprognostic (1.10e-2)" "unprognostic (1.04e-1)" "unprognostic (1.44e-3)" "unprognostic (3.13e-2)" 58.0 9.7 2.6 18.1 20.7 1.8 14.6 1.5 10.7 7.8 6.3 33.4 0.0 1.9 5.8 2.0 7.7 14.2 16.4 19.5 3.4 2.3 3.1 11.0 15.7 2.7 28.6 3.5 35.7 10.6 4.7 4.9 4.4 20.5 5.8 3.4 0.0 1.7 1.7 7.7 1.7 3.0 12.0 15.5 1.9 8.1 1.7 15.7 0.0 7.5 1.2 1.4 8.7 4.0 0.5 8.0 1.0 0.2 0.4 0.6 0.2 0.0 0.0 0.2 0.1 6.0 3.8 0.5 4.8 0.2 0.4 2.8 0.1 0.1 0.2 4.1 1.5 0.1 0.0 0.0 1.7 0.1 0.3 0.1 0.4 1.2 0.6 0.0 0.1 4.2 0.0 10.7 0.1 12.9 0.1 0.3 0.3 0.1 0.0 0.2 4.8 0.0 0.1 4.7 0.1 0.0 0.1 0.1 7.2 0.0 0.1 0.1 0.2 0.5 10.8 6.8 0.1 0.3 9.6 0.2 0.1 0.1 2.1 0.1 0.1 0.7 0.2 0.2 0.6 0.1 0.3 0.3 0.3 0.3 0.1 0.5 0.4 0.4 1.0 0.4 0.1 8.0 0.3 0.2 2.6 20.7 1.5 10.0 3.4 2.3 28.6 3.5 20.5 15.7 ADAMTS5 "ADAMTS11, ADMP-2" ENSG00000154736 "ADAM metallopeptidase with thrombospondin type 1 motif 5" Q9UNA0 21 26917912-26966513 "Cancer-related genes, Predicted secreted proteins" "Hydrolase, Metalloprotease, Protease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "breast: 21.2;placenta: 20.9" "Cell line enhanced" "Detected in some" "ASC diff: 23.3;ASC TERT1: 9.9;fHDF/TERT166: 9.3;RH-30: 24.7;U-87 MG: 8.9" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 6 "classical monocyte: 1.5" "Lineage enriched" "Detected in single" 6 "monocytes: 1.5" "Low region specificity" "Detected in some" "Low region specificity" "Detected in single" "HPA005661, CAB025996, HPA030906, HPA030908" Approved Supported Nucleoplasm "Secreted to extracellular matrix" 18000 Nucleoplasm "CAB025996: , HPA005661: AB_1078101, HPA030906: , HPA030908: " "unprognostic (1.97e-1)" "unprognostic (2.88e-3)" "unprognostic (2.69e-2)" "unprognostic (4.01e-2)" "unprognostic (4.67e-1)" "unprognostic (2.10e-2)" "unprognostic (4.38e-8)" "unprognostic (1.11e-3)" "unprognostic (7.66e-2)" "unprognostic (6.17e-2)" "unprognostic (8.13e-2)" "unprognostic (7.76e-2)" "prognostic unfavourable (2.46e-4)" "unprognostic (6.69e-3)" "unprognostic (3.01e-1)" "prognostic unfavourable (8.54e-4)" "unprognostic (1.15e-1)" 14.1 0.4 1.0 1.6 0.6 0.0 21.2 2.5 0.9 5.5 2.3 0.4 7.2 0.3 10.7 8.2 1.2 3.3 1.0 6.9 1.0 0.0 1.6 0.8 1.2 0.4 1.1 0.4 14.9 0.4 0.1 0.4 20.9 1.5 2.2 0.8 2.3 1.8 9.7 11.0 3.3 2.4 6.2 1.1 6.4 1.8 2.3 0.4 0.6 5.3 1.5 0.6 2.8 3.1 0.0 0.2 0.0 1.5 0.0 0.0 0.3 0.0 0.0 0.0 0.0 23.3 9.9 0.0 1.2 0.2 1.4 0.5 0.0 0.0 0.0 0.0 9.3 0.0 0.0 0.0 2.0 0.0 0.9 0.0 0.3 0.0 2.4 0.0 0.0 5.4 0.0 0.9 0.1 0.0 0.0 0.0 5.8 0.0 0.0 0.0 0.1 0.0 0.0 24.7 0.0 2.2 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 6.3 0.3 1.3 0.5 0.0 0.0 0.0 8.9 0.1 1.1 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 1.0 0.6 2.5 0.9 1.0 0.0 1.1 0.4 1.5 0.4 ADAMTS6 ADAM-TS6 ENSG00000049192 "ADAM metallopeptidase with thrombospondin type 1 motif 6" Q9UKP5 5 65148736-65481920 "Cancer-related genes, Predicted secreted proteins" "Hydrolase, Metalloprotease, Protease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "placenta: 32.4" "Cell line enhanced" "Detected in many" "BJ: 9.8;HBF TERT88: 10.8;hTEC/SVTERT24-B: 10.0;hTERT-HME1: 11.9;TIME: 11.2;U-2197: 12.8" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in some" "Cell type enhanced" "Detected in many" "memory B-cell: 4.8;naive B-cell: 3.6" "Group enriched" "Detected in many" 13 "B-cells: 4.8;T-cells: 1.4" "Low region specificity" "Detected in some" "Low region specificity" "Detected in all" HPA043441 Enhanced "Secreted to extracellular matrix" "HPA043441: " "unprognostic (1.53e-1)" "unprognostic (1.40e-1)" "unprognostic (2.70e-3)" "unprognostic (4.33e-2)" "unprognostic (1.03e-2)" "unprognostic (2.39e-2)" "unprognostic (8.24e-2)" "unprognostic (1.65e-2)" "unprognostic (4.77e-2)" "unprognostic (8.04e-2)" "unprognostic (1.56e-1)" "unprognostic (2.13e-1)" "unprognostic (1.13e-6)" "unprognostic (3.23e-5)" "unprognostic (2.09e-1)" "unprognostic (3.02e-4)" "unprognostic (4.18e-3)" 2.2 0.7 0.9 2.0 0.8 0.3 1.8 0.2 1.8 2.9 1.4 0.8 1.6 0.6 5.1 3.0 1.0 2.7 6.3 2.3 0.8 0.9 1.5 0.5 2.3 1.7 0.8 1.4 1.8 0.5 0.4 2.0 32.4 2.9 2.3 0.9 1.4 0.6 0.9 0.4 0.8 2.4 5.4 3.2 3.4 1.8 1.9 0.7 3.3 0.9 1.2 1.9 3.6 1.7 4.8 0.2 0.0 0.0 0.0 1.4 0.1 2.0 0.0 0.5 0.5 0.0 1.6 0.0 9.8 5.8 6.1 7.2 0.0 0.2 0.0 0.0 3.7 0.4 0.1 1.9 10.8 1.5 0.0 0.1 3.6 0.2 0.3 0.0 0.5 0.7 0.0 10.0 11.9 5.4 0.0 0.0 3.7 0.0 0.5 0.0 0.0 0.0 0.3 2.1 0.0 0.0 0.0 0.3 0.4 0.2 0.0 0.0 0.0 0.0 11.2 2.4 3.6 12.8 7.8 0.0 0.0 0.0 2.7 0.5 0.0 0.0 0.0 0.0 1.3 0.0 1.0 4.8 0.3 0.5 0.0 3.6 1.3 1.4 0.0 0.0 0.0 0.2 0.0 0.1 0.9 0.8 0.2 1.4 0.8 0.9 0.8 1.4 2.9 0.7 ADAMTS8 "ADAM-TS8, FLJ41712, METH2" ENSG00000134917 "ADAM metallopeptidase with thrombospondin type 1 motif 8" Q9UP79 11 130404925-130428993 "Cancer-related genes, Plasma proteins, Predicted secreted proteins" "Heparin-binding, Hydrolase, Metalloprotease, Protease" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "gallbladder: 13.0;lung: 21.0" "Cell line enhanced" "Detected in some" "HEK 293: 1.9;HMC-1: 5.7;NTERA-2: 2.8;U-2 OS: 12.9" "Cancer enhanced" "Detected in many" "endometrial cancer: 5.7" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Group enriched" "Detected in many" 4 "amygdala: 6.4;cerebral cortex: 7.6;hippocampal formation: 7.3;olfactory region: 5.2" HPA066349 Approved "Secreted to extracellular matrix" 2200000 "HPA066349: " "unprognostic (4.76e-6)" "unprognostic (3.92e-2)" "unprognostic (6.13e-2)" "prognostic favourable (1.38e-4)" "unprognostic (2.41e-1)" "unprognostic (7.81e-2)" "unprognostic (3.09e-2)" "unprognostic (9.83e-2)" "unprognostic (1.09e-4)" "unprognostic (3.05e-1)" "unprognostic (1.50e-1)" "unprognostic (2.40e-1)" "unprognostic (4.66e-3)" "unprognostic (4.03e-3)" "unprognostic (5.23e-1)" "unprognostic (1.05e-1)" "unprognostic (2.41e-1)" 2.1 0.1 1.5 10.2 2.5 0.0 0.5 0.6 4.4 1.3 5.3 0.5 0.2 1.1 2.6 1.5 3.1 1.7 13.0 3.9 1.6 0.6 2.1 0.2 21.0 0.2 0.7 0.2 1.0 0.7 0.0 0.8 2.7 0.9 2.9 0.5 0.7 0.3 5.7 0.4 0.1 1.6 7.4 0.8 0.9 5.6 0.2 0.4 0.2 0.4 0.2 0.4 3.8 3.4 0.0 0.0 0.2 0.0 0.1 0.6 0.0 0.0 0.3 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 1.9 0.0 1.8 0.0 0.0 0.0 5.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.8 0.0 0.0 0.0 0.1 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 12.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 1.5 2.5 0.6 3.2 1.6 0.6 0.7 0.2 0.9 0.4 ADAMTS9 KIAA1312 ENSG00000163638 "ADAM metallopeptidase with thrombospondin type 1 motif 9" Q9P2N4 3 64515654-64688000 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "ER-Golgi transport, Protein transport, Transport" "Hydrolase, Metalloprotease, Protease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adipose tissue: 51.4" "Cell line enriched" "Detected in some" 5 "SH-SY5Y: 52.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA028567, HPA028577, HPA028601" Approved Approved "Endoplasmic reticulum,Vesicles" "Secreted to extracellular matrix" Vesicles "Endoplasmic reticulum" "HPA028567: AB_10599275, HPA028577: AB_10600330, HPA028601: " "unprognostic (2.21e-1)" "unprognostic (1.06e-1)" "unprognostic (1.41e-1)" "unprognostic (4.83e-2)" "unprognostic (3.08e-1)" "unprognostic (1.37e-2)" "unprognostic (7.80e-3)" "unprognostic (5.85e-2)" "unprognostic (2.77e-1)" "unprognostic (2.64e-1)" "unprognostic (1.11e-1)" "unprognostic (7.67e-2)" "unprognostic (3.16e-3)" "unprognostic (1.46e-2)" "unprognostic (3.01e-1)" "unprognostic (1.98e-3)" "unprognostic (5.00e-3)" 51.4 4.7 5.6 12.0 11.5 0.5 15.2 3.9 8.0 10.4 10.4 2.8 7.2 1.6 13.9 5.6 6.8 7.7 8.2 29.6 5.7 2.7 9.0 3.1 11.5 7.7 6.8 0.3 17.4 9.9 17.2 2.4 30.5 12.4 7.4 3.2 0.7 3.5 4.3 10.8 2.6 3.2 12.2 12.6 4.4 4.6 3.1 5.9 0.0 6.4 3.7 1.6 19.6 29.2 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.5 5.6 0.0 0.2 0.0 0.5 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.9 0.1 0.0 0.6 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.7 0.0 3.5 1.0 0.0 0.0 0.2 9.4 0.2 0.0 0.1 0.0 0.0 0.0 3.0 0.0 0.0 0.9 0.0 11.2 0.1 0.0 52.2 0.0 0.0 0.0 0.0 0.2 2.1 0.3 0.1 0.0 0.3 0.0 0.0 0.0 0.2 0.0 11.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 5.6 11.5 3.9 8.0 5.7 2.7 6.8 0.3 12.4 5.9 ADCY1 "AC1, DFNB44" ENSG00000164742 "Adenylate cyclase 1" Q08828 7 45574140-45723116 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Biological rhythms, cAMP biosynthesis" "Calmodulin-binding, Lyase" "Cancer-related genes, Deafness, Non-syndromic deafness" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 29.0" "Cell line enhanced" "Detected in many" "hTERT-HME1: 15.0;SCLC-21H: 9.1;SH-SY5Y: 17.3;SK-MEL-30: 19.9;WM-115: 11.3" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB018364, HPA068274" Uncertain Approved Mitochondria Mitochondria "CAB018364: AB_2223098, HPA068274: " "unprognostic (9.41e-3)" "unprognostic (7.30e-4)" "unprognostic (9.31e-2)" "unprognostic (2.98e-1)" "unprognostic (4.18e-2)" "unprognostic (3.07e-3)" "unprognostic (1.32e-1)" "unprognostic (7.31e-2)" "unprognostic (1.64e-3)" "unprognostic (2.89e-1)" "unprognostic (7.73e-3)" "unprognostic (1.54e-1)" "unprognostic (4.74e-6)" "unprognostic (2.49e-1)" "unprognostic (7.65e-3)" "unprognostic (2.87e-1)" "unprognostic (2.23e-1)" 2.8 2.8 11.5 0.7 11.7 0.4 6.8 22.7 29.0 7.8 0.9 2.0 0.0 0.7 2.7 1.1 1.2 2.4 1.2 4.0 11.6 4.0 1.8 9.6 1.0 0.8 5.8 13.4 1.2 3.6 1.0 1.5 0.9 6.2 4.1 1.0 5.0 0.8 2.1 9.2 0.6 0.7 1.6 2.2 1.0 1.8 3.9 1.2 0.0 3.0 0.2 0.8 1.0 1.5 0.5 0.4 0.6 0.1 0.0 0.2 0.0 0.5 3.8 1.4 2.2 2.8 0.0 2.7 0.1 0.0 0.5 0.2 0.4 0.0 0.0 0.2 0.1 1.2 2.5 0.1 0.0 6.9 1.8 0.0 0.0 0.3 0.0 0.1 0.0 3.4 1.9 0.3 15.0 0.1 0.2 4.6 0.2 4.6 0.0 0.0 5.6 0.0 0.0 0.0 7.5 0.0 3.7 9.1 17.3 1.4 0.0 19.9 1.3 2.3 0.0 0.4 2.9 0.3 2.3 0.0 0.0 0.0 0.0 0.0 11.3 0.4 0.1 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.4 0.2 0.2 0.0 0.6 0.0 0.0 0.0 0.0 0.0 11.5 11.7 22.7 29.0 11.6 4.0 5.8 13.4 6.2 1.2 ADM AM ENSG00000148926 Adrenomedullin P35318 11 10304680-10307397 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" Hormone "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "placenta: 133.1" "Cell line enhanced" "Detected in many" "ASC diff: 107.9;fHDF/TERT166: 53.9;HSkMC: 65.9;U-138 MG: 56.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in some" 19 "neutrophil: 62.3" "Lineage enriched" "Detected in many" 19 "granulocytes: 62.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in single" CAB016075 Approved "Secreted to blood" 31000 46000 "CAB016075: AB_628693" "unprognostic (1.67e-1)" "unprognostic (2.89e-2)" "unprognostic (1.78e-1)" "unprognostic (5.22e-2)" "unprognostic (1.55e-2)" "unprognostic (5.27e-3)" "prognostic unfavourable (7.56e-4)" "unprognostic (1.78e-3)" "unprognostic (1.06e-1)" "unprognostic (2.83e-1)" "unprognostic (8.13e-3)" "unprognostic (3.12e-1)" "prognostic unfavourable (6.33e-4)" "unprognostic (9.70e-3)" "unprognostic (2.01e-1)" "unprognostic (2.02e-2)" "unprognostic (1.62e-2)" 65.2 18.3 6.8 18.3 12.4 21.1 52.1 2.5 15.0 28.3 23.3 5.9 1.6 4.8 11.6 8.0 26.5 7.9 18.7 28.3 4.7 3.5 17.3 26.1 34.3 15.2 8.0 2.0 19.0 16.0 10.8 8.4 133.1 14.2 13.8 7.0 23.5 9.6 2.1 92.3 28.7 8.0 11.8 12.7 14.6 10.7 11.6 9.9 0.3 15.9 13.3 10.1 76.1 32.4 0.1 0.6 62.3 3.2 0.0 0.0 0.4 5.3 4.2 5.1 1.4 107.9 46.3 8.0 40.8 38.2 38.6 26.6 21.4 6.5 0.0 1.8 53.9 7.6 1.4 6.3 32.5 0.1 1.6 0.1 2.0 2.5 13.7 0.2 0.1 65.9 5.1 4.4 7.1 8.7 0.0 0.0 9.6 0.1 0.0 1.2 9.6 1.6 0.1 0.1 7.6 2.3 7.3 0.1 0.4 15.5 3.4 0.0 4.7 0.0 2.5 56.8 0.8 35.5 5.9 0.4 4.3 1.4 17.0 0.0 16.9 0.0 1.7 0.0 0.0 1.9 0.0 0.1 0.0 0.0 0.6 0.0 0.0 0.0 62.3 0.0 3.2 0.0 0.0 0.4 6.8 12.4 2.5 15.0 4.7 3.5 8.0 2.0 14.2 9.9 ADNP "ADNP1, KIAA0784" ENSG00000101126 "Activity dependent neuroprotector homeobox" Q9H2P0 20 50888916-50931421 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Autism spectrum disorder, Cancer-related genes, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA006371 Supported Approved Nucleoplasm Nucleoplasm "HPA006371: AB_1078105" "unprognostic (3.40e-2)" "unprognostic (6.81e-2)" "unprognostic (1.21e-1)" "unprognostic (1.06e-2)" "unprognostic (1.68e-1)" "unprognostic (6.68e-2)" "prognostic unfavourable (1.65e-5)" "unprognostic (1.73e-1)" "unprognostic (1.80e-1)" "unprognostic (4.38e-2)" "unprognostic (3.11e-1)" "unprognostic (1.39e-2)" "unprognostic (1.29e-1)" "unprognostic (4.91e-2)" "unprognostic (3.63e-1)" "unprognostic (1.90e-2)" "unprognostic (1.08e-1)" 23.7 26.5 32.2 28.1 29.3 21.3 32.4 46.0 35.4 26.3 24.2 23.0 34.2 18.4 32.6 38.7 27.8 28.4 25.5 19.9 27.2 21.1 23.7 22.7 27.9 29.0 29.0 28.5 38.8 21.7 49.2 32.4 23.5 25.6 27.4 22.4 26.1 25.3 30.6 31.8 28.6 25.6 28.6 23.9 28.6 24.9 33.4 28.2 50.2 28.4 17.4 31.1 32.1 33.1 16.4 28.7 15.0 24.6 15.1 30.9 8.1 20.5 19.5 37.0 19.4 18.4 18.2 15.9 15.4 17.4 30.3 22.3 27.9 16.3 26.9 20.2 18.4 23.7 31.1 29.4 35.8 12.9 11.1 19.2 21.8 21.5 17.9 30.6 16.7 17.2 36.6 18.5 33.5 20.1 25.4 19.1 19.0 20.8 30.1 20.3 18.5 15.6 28.1 20.5 19.7 17.7 27.8 30.8 23.2 35.2 50.7 25.9 24.1 28.7 17.1 27.0 29.1 20.4 16.6 13.9 16.1 45.8 15.2 18.0 18.4 15.0 12.3 10.6 20.8 18.5 22.5 13.6 23.4 19.0 13.9 16.4 23.4 30.9 6.3 15.1 24.6 28.7 15.4 8.1 32.2 29.3 46.0 35.4 27.2 21.1 29.0 28.5 25.6 28.2 ADORA2A "ADORA2, RDC8" ENSG00000128271 "Adenosine A2a receptor" P29274 22 24417879-24442360 "Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 7 "blood: 22.8;bone marrow: 28.1;brain: 43.9;lymphoid tissue: 59.0" "Cell line enhanced" "Detected in many" "Daudi: 15.0;Karpas-707: 20.7;RPMI-8226: 14.6;SK-BR-3: 29.7;U-266/70: 20.8;U-266/84: 27.1;U-698: 21.2" "Not detected" "Not detected" "Region enriched" "Detected in all" 8 "basal ganglia: 43.9" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Region enriched" "Detected in some" 10 "basal ganglia: 357.5" "Region enriched" "Detected in single" 95 "basal ganglia: 166.0" "CAB001943, HPA065566, HPA075997" Enhanced Supported "CAB001943: , HPA065566: , HPA075997: " "unprognostic (7.30e-2)" "unprognostic (2.42e-2)" "unprognostic (3.30e-2)" "unprognostic (2.04e-1)" "unprognostic (7.44e-2)" "unprognostic (1.88e-3)" "unprognostic (9.85e-2)" "unprognostic (3.63e-1)" "unprognostic (2.88e-2)" "unprognostic (4.57e-3)" "unprognostic (2.15e-3)" "unprognostic (1.87e-3)" "unprognostic (6.81e-4)" "unprognostic (1.50e-1)" "unprognostic (9.78e-3)" "unprognostic (1.30e-1)" "unprognostic (7.10e-3)" 1.0 2.4 1.9 10.4 43.9 28.1 1.5 3.4 3.8 0.8 2.0 1.7 0.3 5.4 1.4 1.4 1.0 0.9 2.4 3.5 2.4 1.8 3.5 4.3 5.1 14.8 2.6 1.6 1.2 0.8 0.0 2.1 1.4 2.3 1.6 0.8 3.3 2.7 1.5 1.2 0.9 2.6 0.7 1.3 7.5 2.8 2.0 5.7 59.0 1.3 0.9 8.6 3.8 1.3 17.7 1.1 13.7 9.0 2.2 22.8 11.2 0.2 0.3 0.4 0.1 0.2 0.1 0.4 0.2 9.3 0.5 0.9 1.7 0.1 15.0 1.0 0.2 0.3 0.9 0.0 0.0 1.8 2.6 0.2 0.0 2.1 0.1 0.3 7.5 0.1 0.0 2.8 0.0 3.3 0.1 20.7 0.0 0.2 5.2 1.6 0.6 0.0 0.1 0.7 14.6 0.0 0.1 1.5 8.7 0.4 29.7 0.1 0.3 1.4 0.2 0.9 1.4 0.2 0.1 20.8 27.1 21.2 4.7 5.1 0.1 3.0 0.8 4.8 8.6 2.6 20.1 9.6 16.1 16.9 1.1 17.7 22.8 18.3 13.7 2.2 9.0 1.1 21.4 11.2 1.9 43.9 3.4 3.8 2.4 1.8 2.6 1.6 2.3 5.7 ADRA1B ENSG00000170214 "Adrenoceptor alpha 1B" P35368 5 159865080-159972544 "Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 21.6;liver: 20.3;lymphoid tissue: 17.4" "Cell line enhanced" "Detected in some" "EFO-21: 13.0;HaCaT: 6.6;TIME: 11.0;U-2 OS: 9.2;U-251 MG: 7.0" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA074416 Supported "Plasma membrane" "Plasma membrane" "HPA074416: " "unprognostic (4.93e-3)" "unprognostic (2.94e-2)" "unprognostic (1.79e-1)" "prognostic unfavourable (6.00e-5)" "prognostic unfavourable (6.98e-4)" "unprognostic (4.08e-3)" "unprognostic (1.67e-3)" "unprognostic (1.68e-1)" "unprognostic (6.12e-2)" "prognostic favourable (2.67e-4)" "unprognostic (2.28e-1)" "unprognostic (1.37e-1)" "prognostic unfavourable (1.40e-6)" "unprognostic (5.24e-4)" "unprognostic (2.54e-1)" "prognostic favourable (3.19e-5)" "unprognostic (1.59e-2)" 5.3 2.9 5.3 0.9 9.0 0.4 2.3 1.3 21.6 0.9 1.2 0.7 0.8 1.2 1.5 3.6 1.1 3.6 1.3 3.3 6.2 5.8 7.4 20.3 4.7 2.3 1.2 13.9 6.2 0.8 1.0 0.8 1.1 5.2 1.6 1.1 0.9 1.0 1.9 1.6 1.3 1.7 1.2 0.9 17.4 0.9 0.8 0.5 0.0 2.0 0.0 1.1 0.8 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 4.7 0.3 0.0 2.4 0.9 0.1 0.5 0.2 0.6 0.3 0.0 4.2 0.0 13.0 3.8 6.6 0.0 0.5 0.3 0.0 0.3 0.0 1.6 0.0 5.0 0.0 0.0 2.8 0.0 0.0 0.2 0.0 0.0 0.0 2.5 0.0 0.0 0.0 0.1 0.6 0.0 0.7 0.0 4.5 0.0 0.4 0.0 0.0 0.3 0.4 0.1 0.0 11.0 0.1 9.2 0.0 7.0 0.0 0.0 0.0 3.3 0.0 4.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.3 9.0 1.3 21.6 6.2 5.8 1.2 13.9 5.2 0.5 AFDN "AF-6, AF6, MLLT4" ENSG00000130396 "Afadin, adherens junction formation factor" P55196 6 167826922-167972023 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins" "Cell adhesion" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB013496, HPA030212, HPA030213, HPA030214, HPA030215, HPA049868" Approved Enhanced "Nucleoplasm,Plasma membrane,Cell Junctions" "Plasma membrane, Cell Junctions" Nucleoplasm "CAB013496: , HPA030212: AB_10599291, HPA030213: AB_10601340, HPA030214: AB_10601005, HPA030215: AB_10601556, HPA049868: " "prognostic unfavourable (7.43e-5)" "unprognostic (2.66e-3)" "unprognostic (2.07e-2)" "unprognostic (2.61e-1)" "unprognostic (1.13e-1)" "unprognostic (9.06e-2)" "unprognostic (4.12e-1)" "unprognostic (3.12e-2)" "unprognostic (4.12e-1)" "unprognostic (1.09e-3)" "unprognostic (1.75e-1)" "unprognostic (1.73e-2)" "unprognostic (5.56e-2)" "unprognostic (5.43e-3)" "unprognostic (1.59e-1)" "unprognostic (4.72e-2)" "unprognostic (5.68e-2)" 17.0 7.4 14.9 13.0 17.2 1.8 23.5 17.8 19.3 19.6 26.3 16.1 25.5 22.2 15.8 17.7 59.5 27.9 18.2 13.9 15.6 7.2 20.6 29.3 26.3 5.1 17.1 12.5 16.2 29.7 16.4 27.4 18.7 16.1 20.9 27.2 15.3 38.6 18.6 12.7 24.8 42.3 17.4 13.0 13.5 21.1 16.3 15.2 2.1 25.7 13.7 24.5 16.3 27.9 3.5 0.6 2.9 0.5 0.0 1.2 0.0 19.4 6.1 42.4 15.1 4.1 3.5 31.6 7.9 4.0 6.8 8.5 25.9 12.1 3.4 14.7 4.7 9.4 17.6 16.2 12.3 21.9 18.2 0.1 2.6 19.6 6.2 2.1 9.3 2.4 10.9 11.5 27.1 12.6 38.9 13.6 4.4 8.3 0.2 0.1 10.4 2.8 12.5 11.1 14.7 12.5 9.5 19.7 12.0 8.0 30.5 12.0 3.6 0.8 18.5 3.2 15.4 13.7 13.0 0.2 16.5 7.1 9.5 4.5 27.8 0.0 0.5 0.0 1.0 0.5 0.6 3.5 1.2 0.4 0.6 2.7 0.0 0.5 2.9 0.0 0.3 0.0 0.6 0.0 14.9 17.2 17.8 19.3 15.6 7.2 17.1 12.5 16.1 15.2 AFF1 "AF-4, AF4, MLLT2, PBM1" ENSG00000172493 "AF4/FMR2 family member 1" P51825 4 86935002-87141054 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "placenta: 121.7" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA069947 Approved Nucleoplasm,Mitochondria "Nucleoplasm, Mitochondria" "HPA069947: " "unprognostic (1.01e-1)" "unprognostic (7.56e-2)" "unprognostic (2.57e-3)" "unprognostic (1.53e-1)" "unprognostic (1.33e-1)" "unprognostic (1.55e-2)" "unprognostic (1.79e-1)" "unprognostic (6.23e-2)" "unprognostic (6.09e-2)" "unprognostic (7.13e-2)" "unprognostic (1.24e-1)" "unprognostic (8.32e-3)" "unprognostic (5.86e-2)" "unprognostic (1.33e-2)" "unprognostic (4.41e-1)" "unprognostic (2.55e-1)" "unprognostic (2.71e-2)" 33.7 16.6 8.0 11.8 9.5 19.5 26.5 6.5 12.2 20.2 21.0 10.5 18.9 11.1 27.4 16.6 15.8 18.6 15.3 22.4 10.3 5.3 27.6 15.5 18.4 12.9 9.3 5.5 24.7 19.0 28.6 18.5 121.7 9.5 16.8 14.3 27.0 16.0 25.6 58.8 18.6 16.2 20.3 11.5 13.9 15.0 6.7 10.3 17.0 38.8 21.1 13.9 19.5 26.5 11.3 14.6 21.1 5.4 5.1 8.8 2.8 7.8 7.2 6.0 6.3 9.9 11.8 8.5 7.9 11.6 6.0 9.0 7.6 14.5 8.9 10.8 9.6 3.6 9.4 11.9 8.4 15.1 3.7 18.4 18.7 6.3 7.7 17.6 14.6 9.6 8.6 10.3 9.1 22.1 11.3 25.1 2.5 2.1 15.9 5.1 7.9 2.5 12.6 3.5 11.3 17.7 7.5 13.6 2.5 12.0 7.9 3.8 4.7 14.8 11.0 11.2 10.2 6.8 4.3 21.8 12.1 15.3 9.2 20.4 4.0 3.5 5.4 11.7 6.7 4.1 7.4 8.0 8.8 6.6 6.0 11.3 4.7 4.4 21.1 5.1 2.2 14.6 7.5 2.8 8.0 9.5 6.5 12.2 10.3 5.3 9.3 5.5 9.5 10.3 AFF3 "LAF4, MLLT2-like" ENSG00000144218 "AF4/FMR2 family member 3" P51826 2 99545419-100142739 "Cancer-related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 43.6" "Cell line enhanced" "Detected in many" "Daudi: 23.3;T-47d: 11.7;U-698: 34.5" "Cancer enhanced" "Detected in many" "breast cancer: 11.4" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 6 "memory B-cell: 16.2;naive B-cell: 27.5;plasmacytoid DC: 12.8" "Group enriched" "Detected in many" 16 "B-cells: 27.5;dendritic cells: 12.8" "Low region specificity" "Detected in all" "HPA044512, HPA053379" Approved Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "HPA044512: AB_10795984, HPA053379: " "unprognostic (1.05e-2)" "unprognostic (3.01e-2)" "unprognostic (2.30e-1)" "unprognostic (4.88e-3)" "unprognostic (1.02e-1)" "unprognostic (4.98e-5)" "unprognostic (1.11e-3)" "unprognostic (3.04e-2)" "unprognostic (8.75e-2)" "unprognostic (3.07e-1)" "unprognostic (1.95e-3)" "unprognostic (7.57e-2)" "prognostic unfavourable (5.64e-4)" "unprognostic (6.40e-3)" "unprognostic (6.79e-2)" "unprognostic (3.69e-2)" "unprognostic (7.87e-3)" 3.2 2.4 6.0 40.2 6.1 10.3 16.6 20.5 9.9 4.2 4.2 1.8 0.8 1.2 8.9 1.7 4.1 4.1 2.3 4.9 6.3 6.2 1.8 2.4 7.6 23.3 5.4 6.8 7.5 1.1 0.3 5.2 6.9 4.4 18.9 2.3 5.5 6.6 3.3 1.0 1.0 5.9 8.6 6.6 43.6 4.8 6.0 2.5 34.7 1.7 0.7 42.0 7.4 2.7 27.5 12.8 0.2 0.2 0.9 1.2 0.4 0.1 0.0 9.8 3.4 0.0 0.4 0.0 1.3 0.3 2.9 1.0 0.0 0.0 23.3 0.1 1.5 0.1 0.2 0.0 1.7 5.9 2.8 0.0 0.1 0.0 0.2 0.1 6.7 0.6 0.0 6.1 0.1 0.0 0.1 0.0 0.0 0.1 1.9 0.3 1.3 1.6 3.2 0.0 0.1 0.0 0.0 9.7 3.4 0.1 0.1 6.3 11.7 10.7 3.9 9.3 2.5 0.3 1.5 0.2 0.0 34.5 8.7 0.8 0.7 0.2 0.2 0.0 0.0 0.2 0.2 16.2 0.1 0.0 2.9 27.5 1.2 0.0 0.1 0.9 0.2 12.8 0.0 0.4 6.0 6.1 20.5 9.9 6.3 6.2 5.4 6.8 4.4 2.5 AFF4 "AF5Q31, MCEF" ENSG00000072364 "AF4/FMR2 family member 4" Q9UHB7 5 132875379-132963634 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Cancer-related genes, Disease mutation, Dwarfism, Obesity, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA023690, HPA029634" Approved Supported "Nucleoplasm,Nucleoli fibrillar center" "Nucleoplasm, Nucleoli fibrillar center" "HPA023690: AB_1844633, HPA029634: " "unprognostic (3.24e-2)" "unprognostic (1.86e-2)" "unprognostic (6.17e-3)" "unprognostic (1.45e-1)" "unprognostic (1.99e-1)" "unprognostic (1.10e-1)" "unprognostic (2.56e-2)" "unprognostic (7.37e-2)" "unprognostic (1.18e-1)" "unprognostic (6.13e-2)" "unprognostic (4.94e-2)" "unprognostic (3.52e-1)" "unprognostic (1.16e-2)" "unprognostic (2.77e-2)" "unprognostic (3.25e-2)" "prognostic unfavourable (6.44e-4)" "unprognostic (1.69e-1)" 22.9 29.6 22.8 19.1 38.7 38.3 23.6 37.8 25.6 26.2 21.8 25.2 22.1 14.6 27.6 19.5 29.8 20.8 26.8 21.3 18.7 18.7 25.7 24.2 24.8 19.6 19.0 19.7 34.0 24.9 48.8 40.1 20.4 18.3 26.7 18.5 27.5 25.2 25.1 32.1 22.2 17.8 24.4 18.8 17.3 24.8 17.6 24.4 26.6 33.9 15.7 19.2 26.3 24.7 8.7 5.2 12.2 4.9 3.8 5.5 1.5 16.8 13.6 18.8 20.8 14.5 17.5 14.7 18.3 19.7 16.9 21.6 20.1 11.1 8.6 21.8 23.9 8.5 15.1 22.6 28.3 6.1 9.7 10.6 18.6 7.1 18.6 3.7 11.1 20.5 15.1 29.2 29.8 16.1 7.6 7.3 21.0 6.4 10.2 4.0 7.2 5.6 6.9 18.3 3.2 14.7 23.8 14.7 15.5 20.8 5.1 20.7 10.8 6.0 22.7 20.3 17.3 17.8 19.4 10.1 17.2 7.8 19.1 6.9 13.8 12.2 2.4 3.8 5.5 2.0 4.1 7.7 5.1 3.7 2.9 8.7 5.3 4.6 5.2 3.8 4.9 5.2 2.5 1.5 22.8 38.7 37.8 25.6 18.7 18.7 19.0 19.7 18.3 24.4 AFP "FETA, HPAFP" ENSG00000081051 "Alpha fetoprotein" P02771 4 73431138-73456174 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "heart muscle: 4.3;liver: 9.6;lung: 2.9" "Cell line enriched" "Detected in some" 190 "Hep G2: 214.4" "Group enriched" "Detected in some" 14 "liver cancer: 208.8;testis cancer: 49.4" "Region enhanced" "Detected in single" "basal ganglia: 1.0" "Not detected" "Not detected" "Not detected" "Not detected" "Region enhanced" "Detected in single" "cerebellum: 0.8" "Not detected" "Not detected" "HPA010607, HPA023600, CAB024283, CAB025339" Approved Approved "Golgi apparatus,Cytosol" "Secreted to blood" 6000000 930000 "Golgi apparatus" Cytosol "CAB024283: AB_2650473, CAB025339: , HPA010607: AB_1078141, HPA023600: AB_1844769" "unprognostic (4.69e-1)" "unprognostic (1.87e-1)" "unprognostic (3.34e-3)" "unprognostic (1.48e-1)" "unprognostic (1.48e-3)" "unprognostic (2.95e-2)" "unprognostic (3.35e-1)" "unprognostic (1.54e-1)" "unprognostic (3.81e-2)" "unprognostic (1.01e-1)" "unprognostic (1.25e-1)" "unprognostic (1.63e-6)" "unprognostic (1.98e-2)" "unprognostic (5.80e-2)" "unprognostic (1.14e-1)" 0.0 0.4 0.1 0.0 1.0 0.0 1.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 4.3 0.3 0.0 0.0 9.6 2.9 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 214.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 1.0 0.0 0.4 0.3 0.0 0.0 0.0 0.0 0.0 AGER "RAGE, SCARJ1" ENSG00000204305 "Advanced glycosylation end-product specific receptor" Q15109 6 32180968-32184324 "Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins" "Inflammatory response" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 8 "lung: 178.6" "Cell line enhanced" "Detected in some" "HEK 293: 5.3;MCF7: 4.5;RPTEC TERT1: 5.5;U-266/70: 6.6" "Cancer enhanced" "Detected in all" "lung cancer: 27.2" "Not detected" "Not detected" "Low cell type specificity" "Detected in single" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in single" "Low region specificity" "Detected in many" "CAB011682, HPA064436, HPA069474" Enhanced Approved "Nucleoli fibrillar center,Plasma membrane,Cell Junctions" "Secreted in other tissues" 140000 "Plasma membrane, Cell Junctions" "Nucleoli fibrillar center" "CAB011682: AB_2258049, HPA064436: , HPA069474: " "unprognostic (9.37e-2)" "unprognostic (3.70e-1)" "unprognostic (2.37e-2)" "unprognostic (1.14e-1)" "unprognostic (4.55e-2)" "unprognostic (1.59e-3)" "unprognostic (4.36e-2)" "unprognostic (1.00e-1)" "unprognostic (4.38e-2)" "unprognostic (1.27e-1)" "prognostic favourable (3.41e-4)" "unprognostic (1.24e-1)" "prognostic unfavourable (9.01e-7)" "unprognostic (3.57e-1)" "unprognostic (3.70e-2)" "unprognostic (4.44e-2)" "prognostic favourable (2.74e-6)" 0.2 0.3 0.2 0.3 0.2 0.2 0.2 0.9 0.2 0.3 0.3 0.2 0.2 0.2 0.3 0.6 0.4 0.4 0.2 0.2 0.2 0.0 0.5 0.2 178.6 0.2 0.2 0.2 0.5 0.3 0.1 0.7 0.4 0.4 0.5 0.3 0.2 0.2 0.2 0.3 0.2 0.2 0.2 0.2 1.0 0.2 0.2 0.2 0.2 22.6 0.2 0.2 0.2 0.3 0.7 0.7 1.0 0.3 0.1 0.5 0.1 0.2 0.2 0.0 0.6 0.3 2.1 2.9 0.1 0.3 0.1 0.2 0.1 0.5 0.2 2.3 0.5 2.3 0.2 1.2 0.4 0.4 5.3 1.4 0.1 0.0 0.0 0.6 2.4 0.3 0.3 0.1 0.2 0.4 0.0 0.8 0.3 4.5 0.3 1.7 0.0 0.0 0.1 0.3 0.3 5.5 0.1 0.1 0.5 0.1 0.0 2.0 1.3 0.1 0.3 0.0 1.6 1.6 0.2 6.6 3.4 2.4 2.3 0.5 0.6 0.0 0.3 0.0 0.5 0.0 0.1 0.0 0.3 0.2 0.0 0.7 0.4 0.3 1.0 0.1 0.2 0.7 0.0 0.1 0.2 0.2 0.9 0.2 0.2 0.0 0.2 0.2 0.4 0.2 AHNAK2 C14orf78 ENSG00000185567 "AHNAK nucleoprotein 2" Q8IVF2 14 104937244-104978357 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "skin 1: 131.1" "Cell line enhanced" "Detected in many" "ASC diff: 28.1;ASC TERT1: 32.0;HBEC3-KT: 28.1;hTCEpi: 70.8;hTERT-HME1: 30.2;TIME: 31.7" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 12 "plasmacytoid DC: 1.6" "Lineage enriched" "Detected in single" 17 "dendritic cells: 1.6" "HPA000878, HPA002940, HPA004145, HPA020111" Enhanced Enhanced "Plasma membrane,Cytosol" Cytosol "Plasma membrane" "HPA000878: , HPA002940: AB_1859547, HPA004145: AB_1859546, HPA020111: " "unprognostic (3.56e-1)" "unprognostic (6.04e-2)" "unprognostic (6.19e-3)" "unprognostic (1.31e-3)" "unprognostic (9.55e-4)" "unprognostic (1.76e-1)" "unprognostic (1.36e-1)" "prognostic unfavourable (2.79e-5)" "unprognostic (3.43e-1)" "unprognostic (3.06e-3)" "prognostic unfavourable (4.05e-6)" "unprognostic (1.48e-1)" "unprognostic (1.17e-2)" "unprognostic (1.39e-2)" "unprognostic (6.97e-2)" "unprognostic (2.05e-1)" "prognostic unfavourable (2.23e-5)" 6.9 1.8 2.9 2.0 5.6 1.0 8.5 3.0 13.7 17.2 23.0 2.9 5.7 1.7 16.3 2.9 25.8 7.1 3.2 1.5 2.4 3.1 1.1 10.8 2.3 1.0 2.7 11.6 1.8 1.2 1.2 0.7 1.8 23.3 5.7 5.1 10.1 6.0 14.6 1.6 131.1 4.8 19.9 4.8 1.1 7.1 3.2 0.8 0.0 1.2 14.4 3.0 10.0 19.5 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.6 19.7 0.0 1.3 28.1 32.0 0.0 2.4 5.0 0.8 0.4 0.0 8.8 0.0 3.3 18.5 14.2 0.0 28.1 0.4 0.0 0.1 0.0 13.0 0.1 2.6 0.0 0.9 4.1 70.8 2.8 30.2 12.3 0.0 0.0 14.2 1.6 0.0 0.0 0.0 9.7 0.0 1.3 0.0 19.2 0.0 0.1 0.1 10.4 0.0 0.4 1.3 0.0 31.7 6.8 4.2 7.7 2.1 0.0 0.0 0.0 20.7 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 2.9 5.6 3.0 13.7 2.4 3.1 2.7 11.6 23.3 0.8 AHR bHLHe76 ENSG00000106546 "Aryl hydrocarbon receptor" P35869 7 16916359-17346152 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Cell cycle, Transcription, Transcription regulation" "Activator, DNA-binding, Receptor, Repressor" "Cancer-related genes, Retinitis pigmentosa" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "placenta: 69.6" "Cell line enhanced" "Detected in many" "hTCEpi: 28.3;hTERT-HME1: 29.5;RT4: 24.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "CAB005072, HPA029722, HPA029723" Enhanced Supported Nucleoplasm,Cytosol Cytosol Nucleoplasm "CAB005072: AB_633731, HPA029722: AB_10599189, HPA029723: AB_10599025" "unprognostic (1.29e-2)" "unprognostic (1.21e-2)" "unprognostic (2.13e-1)" "unprognostic (1.39e-2)" "unprognostic (7.28e-2)" "unprognostic (1.22e-1)" "unprognostic (1.44e-1)" "unprognostic (3.39e-1)" "unprognostic (4.32e-2)" "unprognostic (9.98e-2)" "unprognostic (1.24e-3)" "unprognostic (2.89e-1)" "unprognostic (7.53e-3)" "unprognostic (2.00e-1)" "unprognostic (2.82e-3)" "unprognostic (3.25e-2)" "unprognostic (9.45e-2)" 23.1 12.2 2.5 13.2 3.5 19.8 19.1 1.6 3.5 14.6 14.0 5.7 8.7 8.5 11.9 10.1 14.2 11.2 22.2 14.8 3.2 2.2 7.3 23.9 26.4 20.0 6.5 2.5 21.3 6.8 4.5 3.8 69.6 3.7 21.4 8.9 10.9 11.1 8.5 5.2 16.6 13.7 12.1 4.8 15.6 13.3 6.8 4.0 7.1 12.4 7.9 12.3 26.7 26.6 1.1 9.3 5.6 7.6 3.1 2.9 2.0 3.0 2.5 1.0 0.0 7.7 5.3 0.4 6.3 9.2 2.9 4.3 3.1 6.8 0.0 1.9 9.3 8.5 0.6 5.8 7.8 0.1 1.4 1.8 3.2 2.7 14.5 3.0 4.5 7.2 28.3 11.2 29.5 9.8 0.2 0.0 13.3 1.6 0.0 4.8 0.8 4.0 0.0 0.0 0.1 9.4 24.3 0.9 0.0 4.7 5.2 4.6 3.6 1.0 1.6 1.2 0.0 16.1 0.0 1.3 0.0 0.0 20.6 11.9 20.2 0.7 7.6 5.6 0.7 3.6 1.1 0.8 2.6 1.4 9.3 1.1 1.5 1.1 0.8 3.1 1.3 2.2 2.9 2.0 2.5 3.5 1.6 3.5 3.2 2.2 6.5 2.5 3.7 4.0 AHSG "A2HS, FETUA, HSGA" ENSG00000145192 "Alpha 2-HS glycoprotein" P02765 3 186612923-186621318 "Cancer-related genes, Plasma proteins, Predicted secreted proteins" "Mineral balance" "Cancer-related genes, Disease mutation, Hypotrichosis, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 269 "liver: 402.0" "Cell line enriched" "Detected in some" 77 "Hep G2: 210.3" "Cancer enriched" "Detected in some" 284 "liver cancer: 1231.6" "Not detected" "Not detected" "Cell type enhanced" "Detected in single" "NK-cell: 1.4" "Lineage enhanced" "Detected in single" "NK-cells: 1.4" "Not detected" "Not detected" "Not detected" "Not detected" "HPA001524, HPA001525, CAB026209" Enhanced Enhanced "Golgi apparatus" "Secreted to blood" 225100000000 140000000000 "Golgi apparatus" "CAB026209: , HPA001524: AB_1078851, HPA001525: AB_1078849" "unprognostic (6.40e-2)" "unprognostic (1.31e-1)" "unprognostic (2.03e-2)" "unprognostic (3.20e-2)" "unprognostic (1.07e-2)" "unprognostic (1.16e-2)" "unprognostic (7.47e-3)" "unprognostic (3.05e-1)" "unprognostic (5.27e-2)" "unprognostic (8.64e-2)" "unprognostic (3.99e-7)" "unprognostic (5.21e-2)" "unprognostic (5.21e-2)" "unprognostic (1.04e-1)" 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 402.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 210.3 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 AJUBA "JUB, MGC15563" ENSG00000129474 "Ajuba LIM protein" Q96IF1 14 22971174-22982642 "Cancer-related genes, Predicted intracellular proteins" "Cell adhesion, Cell cycle, RNA-mediated gene silencing, Transcription, Transcription regulation" Repressor "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 55.0" "Cell line enhanced" "Detected in many" "HBEC3-KT: 49.0;hTCEpi: 51.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in some" "Low region specificity" "Detected in many" HPA006171 Approved Approved "Nucleoplasm,Golgi apparatus" "Nucleoplasm, Golgi apparatus" "HPA006171: AB_1852044" "unprognostic (1.15e-1)" "unprognostic (2.99e-2)" "unprognostic (2.39e-1)" "unprognostic (1.24e-3)" "unprognostic (9.81e-2)" "unprognostic (1.49e-1)" "unprognostic (1.80e-3)" "unprognostic (2.73e-1)" "unprognostic (1.39e-1)" "unprognostic (1.86e-1)" "prognostic unfavourable (5.67e-4)" "unprognostic (1.47e-1)" "unprognostic (3.19e-3)" "unprognostic (2.94e-1)" "unprognostic (2.68e-1)" "unprognostic (9.35e-3)" "unprognostic (2.07e-1)" 2.9 2.0 1.1 2.4 1.8 0.0 4.1 1.1 1.6 11.1 2.0 1.6 4.9 0.5 8.8 4.4 12.3 4.7 7.9 3.2 2.3 0.6 15.6 55.0 8.5 2.2 1.5 1.3 8.2 5.6 5.5 1.4 12.5 2.6 9.2 1.1 7.1 5.5 11.0 1.5 31.3 1.7 4.3 0.5 2.9 2.6 4.1 1.3 7.1 15.4 5.3 6.6 3.7 10.0 1.3 1.0 2.6 1.2 2.9 2.5 0.6 10.2 12.2 16.3 6.2 1.6 2.9 13.1 10.1 13.4 23.7 21.3 26.0 10.7 0.2 10.6 20.8 33.4 12.4 49.0 29.0 0.9 1.1 0.7 19.8 29.2 18.6 1.0 0.7 9.1 51.3 9.9 38.3 9.1 0.4 0.6 21.9 8.2 1.0 1.2 1.0 16.8 2.8 13.6 0.2 23.8 16.0 0.0 1.4 30.5 9.0 1.9 12.6 1.0 8.1 10.3 20.8 1.6 9.6 0.1 0.3 0.1 1.6 0.9 4.6 2.2 1.2 0.5 1.4 0.5 0.5 0.4 1.2 2.5 0.4 1.3 1.5 0.9 2.6 2.9 0.8 1.0 0.2 0.6 1.1 1.8 1.1 1.6 2.3 0.6 1.5 1.3 2.6 1.3 AK9 "AKD1, AKD2, C6orf199, C6orf224, dJ70A9.1, FLJ25791, FLJ42177, MGC26954" ENSG00000155085 "Adenylate kinase 9" Q5TCS8 6 109492856-109691217 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Nucleotide metabolism" "Kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in single" "HPA030804, HPA030805, HPA031779, HPA031781, HPA036324, HPA036711" Enhanced Enhanced "Nucleoplasm,Nuclear membrane" "Nucleoplasm, Nuclear membrane" "HPA030804: , HPA030805: , HPA031779: AB_10603674, HPA031781: , HPA036324: , HPA036711: " "unprognostic (9.68e-3)" "unprognostic (2.15e-1)" "unprognostic (1.66e-2)" "unprognostic (2.36e-2)" "unprognostic (3.42e-1)" "unprognostic (7.28e-2)" "unprognostic (1.41e-3)" "unprognostic (6.76e-3)" "unprognostic (1.89e-1)" "unprognostic (3.50e-2)" "unprognostic (1.67e-4)" "unprognostic (2.58e-1)" "unprognostic (2.98e-2)" "unprognostic (1.24e-1)" "unprognostic (1.30e-1)" "unprognostic (8.39e-2)" "unprognostic (5.56e-2)" 4.6 4.7 7.7 5.6 8.4 4.7 8.3 13.5 8.7 5.0 6.5 8.5 4.1 5.0 6.3 11.1 6.2 11.3 5.2 6.9 9.1 10.3 7.6 4.5 6.7 5.5 9.4 4.9 6.7 4.6 15.4 33.3 4.4 11.5 5.9 6.7 3.7 7.0 6.3 6.1 5.5 6.2 5.7 11.7 6.5 6.1 22.0 7.7 20.5 11.4 4.1 5.0 5.9 4.4 11.2 2.9 15.1 4.1 4.9 6.4 1.6 2.6 1.8 7.7 13.7 7.2 4.5 5.7 4.0 5.0 4.2 5.8 2.9 5.3 5.6 2.1 3.8 4.6 2.2 4.4 9.0 11.9 4.8 4.2 4.5 2.9 5.9 5.3 2.6 3.6 8.5 7.8 10.2 5.5 4.0 4.7 3.1 5.3 4.6 3.6 1.7 2.9 6.1 4.3 5.2 6.2 5.1 9.4 8.0 4.9 4.7 6.7 6.0 6.5 5.9 4.1 2.7 5.9 2.6 2.5 2.1 3.3 8.2 6.7 2.2 15.1 2.8 6.5 5.1 1.5 4.4 10.5 5.1 6.1 2.0 11.2 6.4 5.5 5.4 4.9 4.1 2.9 3.6 1.6 7.7 8.4 13.5 8.7 9.1 10.3 9.4 4.9 11.5 7.7 AKAP12 "AKAP250, SSeCKS" ENSG00000131016 "A-kinase anchoring protein 12" Q02952 6 151239999-151358557 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" Calmodulin-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "REH: 43.1;TIME: 42.9;U-251 MG: 45.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 184 "basophil: 20.4" "Lineage enriched" "Detected in single" 184 "granulocytes: 20.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA006344, CAB026379, HPA056230" Enhanced Enhanced "Plasma membrane,Cytosol" 6400000 "Plasma membrane, Cytosol" "CAB026379: , HPA006344: AB_1078118, HPA056230: AB_2683073" "unprognostic (6.66e-2)" "unprognostic (1.51e-1)" "unprognostic (9.90e-3)" "prognostic unfavourable (7.08e-4)" "unprognostic (2.61e-2)" "unprognostic (8.88e-2)" "unprognostic (5.05e-2)" "prognostic unfavourable (6.34e-5)" "unprognostic (1.34e-1)" "unprognostic (8.26e-3)" "unprognostic (2.59e-1)" "unprognostic (4.72e-2)" "unprognostic (4.51e-3)" "unprognostic (1.10e-3)" "unprognostic (3.51e-1)" "unprognostic (7.03e-3)" "unprognostic (2.34e-2)" 52.5 11.2 11.5 11.0 18.1 2.0 38.5 31.3 21.2 11.5 23.4 1.9 5.9 6.1 20.5 13.6 12.8 15.6 32.3 22.8 9.8 17.4 14.9 20.6 18.2 6.9 11.4 9.9 49.0 7.6 2.0 11.1 24.1 28.7 13.5 9.4 26.6 3.3 14.7 11.3 4.1 10.6 27.9 14.1 8.1 12.4 62.0 6.6 0.3 11.4 6.6 2.8 34.5 24.7 0.0 0.0 20.4 0.0 0.0 0.1 0.0 1.7 8.6 12.4 0.0 23.4 35.1 4.3 10.0 5.4 4.5 4.5 0.2 32.5 0.0 4.0 7.5 0.2 23.5 7.4 4.0 11.1 8.6 0.1 9.6 7.9 2.6 0.0 2.2 24.8 0.0 19.1 1.0 29.4 2.1 0.2 16.3 0.1 0.0 0.0 7.7 10.1 43.1 0.5 0.0 26.1 1.4 8.8 5.1 3.2 0.1 5.7 0.6 0.1 42.9 0.6 8.0 25.6 45.9 0.0 0.0 0.0 14.9 0.0 8.6 20.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 11.5 18.1 31.3 19.1 9.8 17.4 11.4 9.9 28.7 6.6 AKAP9 "AKAP350, AKAP450, CG-NAP, HYPERION, KIAA0803, LQT11, MU-RMS-40.16A, PPP1R45, PRKA9, YOTIAO" ENSG00000127914 "A-kinase anchoring protein 9" Q99996 7 91940867-92110673 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cancer-related genes, Disease mutation, Long QT syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008548, CAB012909, HPA026109" Supported Enhanced "Golgi apparatus,Vesicles,Centrosome" "Golgi apparatus" "Vesicles, Centrosome" "CAB012909: AB_2533235, HPA008548: AB_1078121, HPA026109: AB_1844688" "unprognostic (9.57e-2)" "unprognostic (1.66e-1)" "unprognostic (2.13e-1)" "unprognostic (5.97e-3)" "unprognostic (1.20e-1)" "unprognostic (1.47e-1)" "unprognostic (4.75e-2)" "unprognostic (1.31e-2)" "unprognostic (1.28e-1)" "unprognostic (6.59e-2)" "unprognostic (7.59e-2)" "unprognostic (6.32e-2)" "prognostic favourable (2.10e-6)" "unprognostic (8.89e-2)" "unprognostic (1.73e-1)" "unprognostic (7.77e-2)" "unprognostic (3.96e-2)" 13.7 15.9 18.0 22.6 17.1 14.9 15.6 35.8 17.5 14.4 24.5 4.7 17.2 25.5 13.0 17.1 15.3 12.4 15.0 14.8 13.3 7.0 19.5 25.1 19.9 13.2 12.4 12.3 22.3 21.3 22.1 40.5 12.9 14.0 11.9 25.3 11.1 20.1 25.9 29.6 16.1 29.1 12.0 11.1 10.4 15.0 6.9 14.4 10.3 14.9 15.7 8.6 14.0 14.2 34.4 39.5 31.9 16.6 10.6 20.3 3.4 11.2 7.0 10.4 6.6 14.9 11.0 7.4 8.4 5.7 4.3 5.5 11.9 9.8 10.2 12.2 7.4 10.4 10.0 5.5 8.1 9.2 8.5 11.2 12.2 7.8 6.1 18.5 11.9 6.9 8.8 8.9 10.2 9.3 16.6 16.7 7.3 16.3 12.6 7.3 8.0 8.7 7.7 17.4 8.2 5.9 12.4 17.0 11.9 17.8 20.0 8.6 5.2 9.0 17.1 8.7 11.2 15.2 11.4 12.0 13.2 13.7 7.7 9.4 9.8 31.9 16.6 21.4 18.4 9.3 15.4 31.4 18.7 16.7 7.2 34.4 20.3 19.3 23.2 10.6 16.3 39.5 14.9 3.4 18.0 17.1 35.8 17.5 13.3 7.0 12.4 12.3 14.0 14.4 AKR1B1 "ALDR1, AR" ENSG00000085662 "Aldo-keto reductase family 1 member B" P15121 7 134442350-134459284 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" Oxidoreductase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in all" 4 "adrenal gland: 302.2;seminal vesicle: 109.3" "Cell line enhanced" "Detected in many" "A549: 121.0;BJ hTERT+: 222.0;RPTEC TERT1: 105.0;U-87 MG: 99.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA026425, CAB027391, CAB047353, HPA052751" Enhanced Supported Nucleoplasm,Cytosol 1700000 Cytosol Nucleoplasm "CAB027391: , CAB047353: , HPA026425: AB_10601563, HPA052751: " "unprognostic (2.76e-2)" "unprognostic (2.84e-2)" "unprognostic (2.02e-2)" "unprognostic (1.37e-2)" "unprognostic (6.81e-2)" "unprognostic (2.26e-1)" "unprognostic (4.18e-2)" "unprognostic (5.09e-2)" "unprognostic (2.51e-3)" "unprognostic (2.47e-1)" "unprognostic (2.98e-2)" "unprognostic (8.78e-2)" "unprognostic (2.81e-2)" "prognostic unfavourable (2.44e-5)" "unprognostic (2.03e-1)" "unprognostic (1.39e-1)" "prognostic unfavourable (7.00e-4)" 5.9 302.2 7.5 4.7 13.7 2.5 9.5 6.9 10.9 4.4 3.9 8.2 50.4 2.7 4.6 6.1 4.2 4.6 5.2 24.2 7.3 8.4 17.7 2.5 6.9 10.0 9.5 9.0 8.2 7.2 9.4 8.0 24.8 11.9 5.5 4.1 5.8 4.4 109.3 37.6 2.8 4.8 5.6 7.9 6.7 5.0 5.2 5.9 7.3 6.0 10.3 7.6 7.1 3.7 31.4 34.8 22.5 26.0 26.3 42.7 47.2 13.3 121.0 13.6 19.3 58.9 16.0 36.3 13.0 222.0 19.1 24.8 5.6 12.3 0.0 6.0 21.7 5.7 14.8 12.9 15.2 4.8 13.6 6.8 18.2 16.4 84.4 0.0 0.0 14.9 9.7 27.3 7.3 26.9 0.0 4.5 21.1 0.2 20.0 9.2 22.7 0.1 20.9 8.7 10.1 105.0 65.4 10.2 22.7 90.9 0.1 9.5 0.0 10.2 21.2 18.9 8.8 1.7 14.1 12.5 13.7 33.8 99.9 0.0 11.3 22.5 26.0 1.2 37.9 17.0 34.0 31.4 32.4 36.7 34.8 28.5 42.7 41.1 2.1 26.3 8.9 4.9 22.0 47.2 7.5 13.7 6.9 10.9 7.3 8.4 9.5 9.0 11.9 5.9 AKT1 "AKT, PKB, PRKBA, RAC" ENSG00000142208 "AKT serine/threonine kinase 1" P31749 14 104769349-104795751 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins" "Apoptosis, Carbohydrate metabolism, Glucose metabolism, Glycogen biosynthesis, Glycogen metabolism, Neurogenesis, Sugar transport, Translation regulation, Transport" "Developmental protein, Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "MCF7: 113.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "eosinophil: 30.7" "Lineage enriched" "Detected in all" 5 "granulocytes: 30.7" "Low region specificity" "Detected in all" "HPA002891, CAB003765" Supported Supported Nucleoplasm,Microtubules Nucleoplasm Microtubules "CAB003765: AB_562035, HPA002891: AB_1078123" "unprognostic (3.30e-2)" "unprognostic (4.27e-2)" "unprognostic (1.98e-1)" "unprognostic (1.84e-1)" "unprognostic (3.70e-1)" "unprognostic (9.17e-3)" "unprognostic (1.55e-3)" "unprognostic (1.21e-1)" "unprognostic (1.47e-1)" "prognostic favourable (4.83e-4)" "unprognostic (3.58e-2)" "unprognostic (1.90e-2)" "prognostic favourable (2.12e-4)" "unprognostic (7.14e-2)" "unprognostic (1.28e-1)" "unprognostic (1.06e-1)" "unprognostic (2.41e-1)" 31.7 45.4 22.9 24.2 23.6 20.3 40.0 20.9 29.5 24.7 32.6 20.0 30.8 22.5 27.0 21.5 33.0 25.5 30.3 47.7 22.9 19.1 26.3 49.2 31.3 21.0 22.1 14.7 25.9 43.0 20.3 16.7 28.4 21.5 31.1 18.2 25.3 30.4 36.1 23.8 20.4 24.0 40.5 17.5 35.4 32.6 16.2 18.8 26.3 32.7 22.4 29.3 36.7 35.9 3.2 5.2 30.7 5.8 5.7 6.2 3.0 15.1 30.3 25.0 37.2 19.4 20.1 28.0 27.9 34.0 41.3 33.1 19.8 18.3 18.3 21.5 38.2 19.7 17.7 26.0 18.0 41.8 7.2 13.9 18.1 21.3 21.5 22.6 36.3 28.8 21.9 20.7 13.8 30.8 12.1 20.4 26.4 113.2 28.4 28.9 6.5 21.7 26.8 23.2 12.5 19.1 37.7 28.7 23.9 23.3 30.5 17.5 39.9 33.7 24.6 27.7 13.3 39.4 28.0 22.2 10.7 15.8 23.3 19.1 33.3 3.3 5.3 30.7 5.4 5.2 4.0 2.9 4.8 6.2 3.6 3.2 2.5 5.7 11.8 5.7 5.8 5.2 4.7 3.0 22.9 23.6 20.9 29.5 22.9 19.1 22.1 14.7 21.5 18.8 AKT2 ENSG00000105221 "AKT serine/threonine kinase 2" P31751 19 40230317-40285536 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins" "Apoptosis, Carbohydrate metabolism, Glucose metabolism, Glycogen biosynthesis, Glycogen metabolism, Sugar transport, Translation regulation, Transport" "Developmental protein, Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Diabetes mellitus, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004204, HPA064521" Uncertain Supported Nucleoplasm,Vesicles,Cytosol "Nucleoplasm, Vesicles, Cytosol" "CAB004204: AB_626659, HPA064521: " "unprognostic (6.13e-2)" "unprognostic (2.21e-1)" "unprognostic (1.56e-1)" "prognostic unfavourable (1.05e-6)" "unprognostic (2.85e-1)" "unprognostic (6.40e-3)" "unprognostic (9.59e-2)" "unprognostic (1.22e-2)" "unprognostic (2.98e-2)" "unprognostic (2.49e-2)" "unprognostic (3.02e-1)" "prognostic unfavourable (4.74e-4)" "unprognostic (1.30e-2)" "unprognostic (1.89e-1)" "unprognostic (3.28e-1)" "unprognostic (6.16e-2)" "unprognostic (2.00e-1)" 31.1 20.3 15.4 17.6 15.2 21.3 18.2 46.3 18.2 23.3 18.2 23.4 21.2 12.3 22.8 28.0 22.1 22.7 14.0 23.1 15.4 10.0 23.0 62.5 14.6 17.8 17.9 13.3 27.8 24.5 21.1 24.0 17.5 14.7 19.7 12.3 26.8 18.5 24.3 48.5 18.3 17.1 20.0 16.8 18.7 15.5 21.3 15.7 26.6 52.6 29.5 23.6 19.6 19.9 6.3 8.8 7.7 4.4 3.2 4.9 2.4 22.4 55.4 21.1 21.7 26.3 32.2 11.7 15.0 22.2 31.1 27.8 24.3 20.9 22.9 13.4 33.1 9.8 23.4 31.3 20.1 21.9 26.7 15.0 35.1 15.3 16.5 17.2 18.1 29.7 18.8 21.1 20.1 6.7 19.3 24.0 17.3 18.7 27.3 8.4 11.4 14.9 18.2 11.5 16.5 24.2 36.8 29.1 17.8 15.4 26.4 12.5 20.8 22.2 6.7 19.0 18.8 17.0 23.5 22.4 19.2 18.8 18.6 20.4 15.5 7.6 4.4 3.6 4.5 2.0 4.5 3.9 3.6 3.0 3.0 6.3 3.5 4.9 7.7 3.2 2.6 8.8 2.7 2.4 15.4 15.2 46.3 18.2 15.4 10.0 17.9 13.3 14.7 15.7 AKT3 "PKBG, PRKBG, RAC-gamma" ENSG00000117020 "AKT serine/threonine kinase 3" Q9Y243 1 243488233-243851079 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB013090, HPA026441" Approved Supported Cytosol Cytosol "CAB013090: AB_2533692, HPA026441: AB_1844711" "unprognostic (1.33e-1)" "unprognostic (1.27e-1)" "unprognostic (2.40e-2)" "unprognostic (8.45e-2)" "unprognostic (1.89e-1)" "unprognostic (1.75e-1)" "unprognostic (1.96e-1)" "unprognostic (3.77e-1)" "unprognostic (2.32e-1)" "unprognostic (2.28e-1)" "unprognostic (5.47e-3)" "unprognostic (1.37e-1)" "unprognostic (6.71e-2)" "unprognostic (3.64e-3)" "unprognostic (1.29e-1)" "unprognostic (8.14e-2)" "prognostic unfavourable (9.27e-4)" 15.4 17.0 16.0 7.8 15.2 2.2 11.0 39.9 33.4 16.9 16.1 12.4 17.4 4.1 19.7 12.3 10.0 11.8 12.1 9.8 15.5 13.6 12.8 4.0 11.3 7.9 14.2 15.8 29.8 4.4 15.1 14.6 17.0 18.4 19.4 6.6 8.9 4.1 23.9 4.8 4.7 8.1 20.4 12.1 9.9 8.7 10.4 14.8 2.9 17.7 5.0 6.2 17.2 18.6 1.9 0.8 1.2 0.9 3.8 3.6 0.6 23.5 2.4 14.9 0.0 11.0 12.6 7.9 13.3 12.2 8.6 7.6 0.1 9.7 0.0 0.0 16.8 0.3 8.2 5.3 11.4 5.9 6.4 0.3 0.0 0.0 5.7 0.1 2.6 6.5 0.0 10.7 9.7 17.6 0.0 0.1 3.9 0.0 5.0 1.1 6.3 3.7 2.7 9.1 0.1 2.9 0.8 19.1 25.3 0.1 0.0 23.8 0.0 8.0 13.8 15.3 11.8 0.1 11.0 1.3 0.4 2.8 11.2 1.2 12.8 1.2 0.9 0.5 2.3 0.3 3.6 1.0 2.2 2.5 0.8 1.9 1.9 1.7 0.2 3.8 0.7 0.6 0.7 0.6 16.0 15.2 39.9 22.9 15.5 13.6 14.2 15.8 18.4 14.8 ALB ENSG00000163631 Albumin P02768 4 73397114-73421412 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 81 "liver: 3075.8" "Cell line enriched" "Detected in some" 39 "Hep G2: 308.4" "Cancer enriched" "Detected in many" 384 "liver cancer: 14213.7" "Not detected" "Not detected" "Cell type enriched" "Detected in single" 13 "naive CD4 T-cell: 1.3" "Lineage enriched" "Detected in single" 13 "T-cells: 1.3" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB006262, HPA031024, HPA031025" Enhanced Enhanced "Endoplasmic reticulum,Golgi apparatus" "Secreted to blood" 40000000000000 "Golgi apparatus" "Endoplasmic reticulum" "CAB006262: AB_425297, HPA031024: AB_2673703, HPA031025: AB_2673704" "unprognostic (1.38e-1)" "unprognostic (8.72e-2)" "unprognostic (1.73e-1)" "unprognostic (2.60e-1)" "unprognostic (4.44e-1)" "unprognostic (2.46e-1)" "unprognostic (9.53e-3)" "unprognostic (2.16e-2)" "unprognostic (2.40e-1)" "unprognostic (6.43e-2)" "unprognostic (3.84e-2)" "unprognostic (5.37e-2)" "unprognostic (1.25e-1)" "prognostic unfavourable (7.87e-4)" "unprognostic (7.23e-2)" "unprognostic (1.05e-3)" "unprognostic (1.02e-2)" 0.1 0.0 0.1 0.2 0.1 0.0 0.1 0.1 0.3 0.1 0.1 0.1 0.1 0.0 0.1 0.8 0.1 0.0 0.1 0.1 0.1 0.0 4.9 3075.8 0.1 0.1 0.1 0.1 0.1 38.0 0.0 0.1 0.1 0.2 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 1.0 0.0 0.3 0.1 0.1 0.3 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 1.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 2.1 0.1 308.4 0.0 7.9 0.2 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.1 6.8 0.0 0.0 0.2 0.0 0.0 3.6 0.0 0.0 0.0 0.0 0.9 0.0 0.1 0.0 0.0 0.5 0.0 2.5 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.3 0.1 0.0 0.1 0.1 0.2 0.1 ALCAM "CD166, MEMD" ENSG00000170017 "Activated leukocyte cell adhesion molecule" Q13740 3 105366909-105576900 "Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins, Transporters" "Adaptive immunity, Cell adhesion, Immunity" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "parathyroid gland: 122.5" "Cell line enhanced" "Detected in many" "hTERT-HME1: 64.6;U-138 MG: 77.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "myeloid DC: 20.7" "Lineage enriched" "Detected in many" 6 "dendritic cells: 20.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002148, HPA010926" Enhanced "Intracellular and membrane" 1800000000 "CAB002148: AB_442053, HPA010926: AB_1078449" "unprognostic (6.82e-2)" "unprognostic (2.66e-1)" "unprognostic (2.13e-1)" "unprognostic (2.19e-1)" "unprognostic (9.48e-3)" "unprognostic (2.08e-2)" "unprognostic (1.63e-3)" "unprognostic (3.89e-2)" "unprognostic (1.75e-1)" "unprognostic (4.01e-2)" "unprognostic (1.09e-1)" "unprognostic (1.07e-1)" "prognostic favourable (3.15e-4)" "unprognostic (3.15e-1)" "unprognostic (4.47e-2)" "unprognostic (9.57e-2)" "unprognostic (7.76e-2)" 16.6 14.1 23.6 5.2 31.1 4.2 34.2 4.2 25.3 12.9 8.2 25.0 13.9 7.2 7.0 15.4 4.0 20.6 9.9 4.7 23.2 24.3 9.6 19.4 29.6 4.2 45.1 19.7 24.6 15.3 122.5 11.9 5.3 31.5 14.0 6.6 3.0 17.9 17.5 0.9 5.9 7.3 10.8 35.3 3.0 14.2 2.3 43.8 2.2 25.6 2.7 6.2 9.9 5.5 3.5 20.7 3.7 3.2 0.4 1.6 2.0 38.4 14.8 10.7 5.4 16.2 7.1 0.1 31.5 18.4 20.3 28.6 0.1 8.0 2.7 13.1 44.3 29.8 1.7 25.0 60.2 2.5 2.6 0.3 11.4 0.7 18.2 15.6 0.1 12.6 18.7 26.0 64.6 22.3 0.0 4.6 26.6 2.6 2.2 5.7 2.2 16.8 1.4 0.9 0.1 30.8 4.3 7.7 21.5 3.2 3.1 2.0 6.0 10.3 46.2 77.9 26.6 3.4 37.2 0.0 0.0 0.2 17.7 3.3 33.2 0.0 3.2 2.4 0.4 1.5 1.4 3.5 1.1 0.7 20.7 2.2 0.2 0.2 3.7 0.4 0.8 7.4 1.6 2.0 23.6 31.1 4.2 24.6 23.2 24.3 45.1 19.7 31.5 43.8 ALDOA ENSG00000149925 "Aldolase, fructose-bisphosphate A" P04075 16 30064164-30070457 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" Glycolysis Lyase "Cancer-related genes, Disease mutation, Glycogen storage disease, Hereditary hemolytic anemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in all" 6 "skeletal muscle: 1296.2" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "HPA004177, CAB006252" Enhanced Supported Cytosol 1200000000 Cytosol "CAB006252: AB_437007, HPA004177: AB_1078128" "unprognostic (2.63e-2)" "unprognostic (3.22e-2)" "unprognostic (6.80e-2)" "unprognostic (1.33e-1)" "unprognostic (6.74e-3)" "unprognostic (4.28e-3)" "prognostic unfavourable (5.79e-5)" "prognostic unfavourable (7.32e-5)" "unprognostic (1.68e-1)" "unprognostic (1.81e-1)" "unprognostic (2.30e-2)" "unprognostic (1.57e-1)" "unprognostic (1.81e-1)" "unprognostic (1.28e-1)" "unprognostic (1.22e-1)" "unprognostic (2.19e-3)" "unprognostic (4.48e-2)" 27.9 30.9 34.7 24.2 42.3 36.0 25.3 31.2 59.7 21.0 32.8 16.3 25.9 29.4 21.9 33.9 73.5 22.1 24.4 109.3 31.6 33.4 28.2 11.1 17.9 34.0 35.0 49.6 23.4 19.4 51.0 25.2 19.9 38.0 23.6 23.5 24.6 37.9 36.9 1296.2 28.4 21.5 30.1 22.7 17.4 24.4 9.2 18.9 18.5 26.6 189.8 29.0 36.8 27.7 61.1 142.9 165.7 166.3 50.5 93.2 217.0 138.7 104.6 31.5 101.2 48.3 55.1 100.7 84.0 87.6 85.7 107.2 73.9 107.0 94.6 137.8 84.8 106.0 63.1 183.2 62.9 41.6 83.0 77.4 83.9 163.2 75.4 112.5 83.1 75.5 64.7 96.2 64.7 63.1 66.6 62.5 90.8 197.9 68.4 93.0 78.3 88.2 102.1 50.6 211.5 106.7 79.0 63.1 44.4 52.4 221.1 78.4 94.0 76.3 75.0 126.6 50.5 69.0 90.8 123.5 84.3 86.6 235.6 109.3 99.9 106.7 164.0 130.3 70.2 156.8 79.1 61.1 76.8 72.5 142.9 55.5 73.8 70.3 165.7 50.5 166.3 53.8 93.2 217.0 34.7 42.3 31.2 59.7 31.6 33.4 35.0 49.6 38.0 18.9 ALDOA ENSG00000285043 "Aldolase, fructose-bisphosphate A" P04075 16 30053090-30070420 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" Glycolysis Lyase "Cancer-related genes, Disease mutation, Glycogen storage disease, Hereditary hemolytic anemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" HPA004177 Uncertain Supported Cytosol 1200000000 Cytosol "HPA004177: AB_1078128" 1.8 0.9 2.7 1.1 5.0 2.1 7.2 0.7 7.7 4.9 1.5 2.0 2.4 0.0 2.5 3.9 0.9 3.6 1.6 5.3 2.3 1.3 0.0 2.3 2.0 0.8 4.4 2.2 0.8 0.8 3.0 1.4 4.0 2.4 0.5 2.8 1.6 7.5 10.6 0.6 0.1 1.9 0.4 1.7 1.3 11.6 0.8 1.2 4.7 0.2 2.7 1.2 1.0 7.0 6.6 0.9 6.2 4.2 8.5 12.5 3.7 8.8 1.9 6.2 1.5 5.2 1.5 4.0 6.9 5.4 21.6 3.6 5.0 24.5 5.9 6.8 6.3 14.0 10.9 3.8 4.3 7.9 6.0 8.2 5.9 11.5 10.5 2.3 5.1 0.5 10.7 12.2 7.7 1.2 7.1 13.4 3.9 4.9 8.0 2.1 5.5 7.6 4.0 22.4 15.1 0.7 6.1 5.0 1.0 1.6 1.5 5.1 4.0 1.7 8.0 2.4 3.7 5.3 7.3 5.5 8.0 7.6 11.4 3.5 0.1 6.2 0.1 5.3 2.6 7.4 7.0 7.0 5.7 6.6 6.2 8.5 6.6 0.9 4.2 2.3 5.6 5.4 12.5 ALDOB ENSG00000136872 "Aldolase, fructose-bisphosphate B" P05062 9 101420578-101435823 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" Glycolysis Lyase "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 30 "intestine: 804.1;kidney: 253.1;liver: 598.8" "Cell line enhanced" "Detected in some" "BEWO: 14.1;NB-4: 13.2;RPMI-8226: 15.2;SH-SY5Y: 13.2" "Cancer enriched" "Detected in many" 31 "liver cancer: 1414.0" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in single" "HPA002198, CAB020827" Enhanced 930000000 "CAB020827: , HPA002198: AB_1078129" "unprognostic (6.58e-3)" "unprognostic (2.83e-1)" "unprognostic (1.43e-3)" "unprognostic (1.03e-1)" "unprognostic (8.10e-2)" "unprognostic (1.96e-2)" "unprognostic (1.44e-3)" "unprognostic (4.34e-2)" "unprognostic (4.57e-2)" "unprognostic (2.66e-1)" "unprognostic (5.79e-2)" "unprognostic (7.48e-2)" "unprognostic (1.66e-2)" "unprognostic (2.02e-1)" "unprognostic (2.58e-1)" "unprognostic (5.19e-2)" "unprognostic (1.96e-2)" 0.1 0.1 0.1 0.6 0.1 0.0 0.1 0.1 0.2 0.1 334.5 0.2 0.2 145.9 0.2 0.6 0.1 0.1 5.7 0.1 0.1 0.1 253.1 598.8 0.1 0.1 0.1 0.1 0.1 18.3 0.0 0.4 0.1 0.4 0.1 0.0 0.2 0.2 0.1 0.1 0.1 804.1 0.1 0.1 0.2 1.5 0.3 0.1 0.2 0.2 0.2 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.2 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 14.1 0.0 0.0 0.0 0.0 0.3 0.0 2.9 1.4 0.0 0.4 0.0 0.0 0.0 0.3 0.0 1.3 0.0 0.4 0.0 3.5 0.3 0.0 0.0 0.0 0.0 0.0 0.7 0.1 0.0 0.0 0.2 13.2 0.2 0.0 0.2 3.1 15.2 0.0 0.0 2.5 13.2 1.5 0.0 0.0 0.0 0.1 0.7 0.0 0.7 5.3 0.2 0.4 0.2 1.6 0.0 1.1 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.4 0.1 ALDOC ENSG00000109107 "Aldolase, fructose-bisphosphate C" P09972 17 28573115-28577264 "Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins" Glycolysis Lyase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "brain: 166.7;heart muscle: 56.9" "Cell line enhanced" "Detected in many" "RPMI-8226: 62.2;U-266/70: 42.9" "Cancer enriched" "Detected in all" 6 "glioma: 128.9" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003282, CAB020828, HPA067442" Enhanced Supported Approved "Nucleoplasm,Nucleoli fibrillar center,Vesicles,Cytosol" 280000000 "Nucleoplasm, Nucleoli fibrillar center" "Vesicles, Cytosol" "CAB020828: , HPA003282: AB_1078130, HPA067442: " "unprognostic (2.90e-1)" "unprognostic (4.45e-3)" "unprognostic (5.69e-3)" "unprognostic (1.43e-1)" "unprognostic (3.56e-1)" "prognostic unfavourable (9.80e-4)" "unprognostic (1.03e-1)" "unprognostic (1.70e-1)" "unprognostic (1.30e-1)" "unprognostic (6.03e-3)" "unprognostic (3.90e-1)" "unprognostic (3.24e-2)" "prognostic unfavourable (1.29e-7)" "unprognostic (1.28e-1)" "unprognostic (2.00e-1)" "unprognostic (2.74e-2)" "unprognostic (1.23e-1)" 26.0 9.4 86.7 4.8 78.9 7.5 9.8 100.1 166.7 3.8 5.3 17.4 0.3 7.0 4.4 4.6 7.1 3.9 4.4 56.9 64.6 54.3 3.3 26.2 4.6 6.5 69.9 51.4 12.8 1.6 4.7 2.3 2.1 98.1 6.0 5.6 16.5 4.2 6.1 1.7 12.5 15.0 4.6 34.4 6.7 8.7 4.6 23.4 0.0 2.1 0.5 10.0 3.4 3.5 12.2 4.6 8.8 4.1 13.7 20.5 8.8 7.4 0.5 3.5 14.4 7.2 7.4 0.7 3.8 8.6 2.9 18.1 4.3 0.7 3.5 4.6 3.4 9.7 2.3 23.6 5.5 3.0 2.2 6.7 2.7 7.4 6.8 2.4 7.8 6.8 3.3 0.3 5.9 1.3 4.6 18.8 2.5 3.5 2.8 8.1 5.4 3.9 2.4 0.4 62.2 0.4 1.0 9.2 16.4 2.2 17.7 0.1 9.6 5.5 0.9 0.3 1.4 0.5 0.6 42.9 12.3 2.6 28.1 7.0 0.5 0.1 3.5 1.4 11.4 4.1 16.2 12.2 15.6 9.2 4.6 11.5 20.5 15.1 8.8 13.7 2.3 2.2 19.5 8.8 86.7 78.9 100.1 78.5 64.6 54.3 69.9 51.4 98.1 23.4 ALK CD246 ENSG00000171094 "ALK receptor tyrosine kinase" Q9UM73 2 29192774-29921566 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 8.1;pituitary gland: 17.9" "Cell line enriched" "Detected in some" 6 "SH-SY5Y: 26.4" "Group enriched" "Detected in some" 5 "glioma: 1.0;melanoma: 1.5;ovarian cancer: 0.7;thyroid cancer: 1.3" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA010694 Approved Supported "Plasma membrane" "Plasma membrane" "HPA010694: AB_1078133" "unprognostic (4.96e-2)" "unprognostic (1.11e-2)" "unprognostic (1.45e-1)" "unprognostic (4.56e-7)" "unprognostic (7.17e-2)" "unprognostic (1.71e-1)" "unprognostic (9.07e-3)" "unprognostic (6.29e-3)" "unprognostic (1.18e-1)" "unprognostic (1.01e-1)" "unprognostic (2.67e-4)" "unprognostic (3.70e-2)" "unprognostic (2.06e-2)" "unprognostic (7.15e-2)" "unprognostic (1.98e-1)" "unprognostic (1.38e-1)" "unprognostic (3.61e-2)" 1.8 3.1 3.6 1.2 4.4 0.3 1.1 0.5 8.1 0.7 2.1 2.0 0.0 0.7 0.5 0.5 0.6 0.5 1.2 0.4 3.4 4.9 0.4 0.5 1.1 0.5 2.7 4.2 0.6 0.4 0.4 17.9 0.5 5.5 0.5 1.2 2.4 0.9 0.8 0.3 0.9 1.5 0.9 2.1 0.5 0.8 4.9 0.9 0.0 1.6 0.0 0.3 0.6 1.2 0.0 0.0 0.0 0.2 0.0 0.7 0.0 0.0 0.0 0.4 0.0 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.5 0.0 3.5 0.0 0.0 0.1 0.3 26.4 0.0 0.0 0.6 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 3.1 0.0 4.0 0.0 0.1 0.0 0.7 0.0 0.2 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 3.6 4.4 0.5 5.9 3.4 4.9 2.7 4.2 5.5 0.9 ALKBH6 MGC15677 ENSG00000239382 "AlkB homolog 6" Q3KRA9 19 36009120-36014239 "Cancer-related genes, Predicted intracellular proteins" "Dioxygenase, Oxidoreductase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA073835, HPA074340" Approved Supported "Nucleoplasm,Focal adhesion sites" Nucleoplasm "Focal adhesion sites" "HPA073835: , HPA074340: " "unprognostic (1.90e-3)" "unprognostic (1.82e-1)" "unprognostic (5.16e-3)" "unprognostic (1.12e-2)" "unprognostic (1.24e-1)" "unprognostic (5.86e-5)" "unprognostic (6.21e-2)" "unprognostic (4.53e-2)" "unprognostic (3.95e-1)" "unprognostic (3.56e-2)" "unprognostic (8.78e-4)" "unprognostic (1.77e-2)" "unprognostic (2.31e-5)" "unprognostic (9.34e-2)" "unprognostic (2.15e-1)" "unprognostic (3.82e-1)" "unprognostic (1.05e-3)" 8.4 7.0 14.1 6.4 15.2 6.8 6.3 7.8 18.9 5.8 8.2 7.8 2.5 6.6 6.5 6.6 6.5 8.2 7.7 9.2 13.0 14.9 5.7 12.6 6.8 8.7 14.8 12.5 5.4 3.4 8.2 8.5 6.2 19.5 9.7 4.6 6.5 8.7 9.9 6.3 5.8 6.4 8.5 10.5 8.9 9.6 4.2 4.9 5.7 6.2 3.7 8.4 7.2 4.7 18.1 13.5 29.5 15.0 15.7 19.5 9.4 10.3 11.1 4.2 6.2 6.6 4.0 7.1 10.3 6.9 12.1 12.3 4.6 5.5 9.1 16.5 5.7 4.1 4.4 11.9 6.4 14.3 8.0 5.2 4.2 4.9 7.5 4.5 16.0 6.0 8.6 10.0 3.4 8.2 8.1 6.9 6.5 10.8 10.8 5.9 3.3 7.2 6.9 5.8 6.5 8.7 4.6 5.1 5.3 7.0 8.4 8.6 6.7 10.2 3.5 6.3 9.3 14.3 10.0 13.0 7.7 6.4 13.7 5.1 6.7 29.5 11.4 27.3 17.1 15.0 13.0 18.1 15.5 16.1 9.6 14.6 13.2 12.8 9.6 15.7 11.7 13.5 19.5 9.4 14.1 15.2 7.8 18.9 13.0 14.9 14.8 12.5 19.5 4.9 ALPK2 HAK ENSG00000198796 "Alpha kinase 2" Q86TB3 18 58481247-58628957 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "heart muscle: 35.3;skeletal muscle: 35.3;tongue: 12.4" "Cell line enhanced" "Detected in many" "BJ: 26.0;BJ hTERT+: 15.8;fHDF/TERT166: 23.5;U-138 MG: 13.3" "Cancer enriched" "Detected in some" 6 "renal cancer: 7.3" "Not detected" "Not detected" "Cell type enhanced" "Detected in single" "non-classical monocyte: 1.8" "Low lineage specificity" "Detected in single" "Region enhanced" "Detected in single" "cerebellum: 1.1" "Low region specificity" "Detected in many" "HPA027377, HPA027976, HPA028084, HPA029801" Uncertain Approved Cytosol Cytosol "HPA027377: AB_10600635, HPA027976: AB_10611246, HPA028084: AB_10601996, HPA029801: AB_10602006" "unprognostic (7.35e-2)" "unprognostic (4.91e-2)" "unprognostic (1.64e-1)" "unprognostic (4.60e-3)" "unprognostic (2.64e-1)" "unprognostic (8.27e-2)" "unprognostic (1.22e-1)" "unprognostic (1.41e-1)" "unprognostic (3.44e-1)" "unprognostic (1.06e-1)" "unprognostic (5.13e-2)" "unprognostic (1.33e-2)" "prognostic unfavourable (8.20e-5)" "unprognostic (5.27e-3)" "unprognostic (2.50e-1)" "unprognostic (4.73e-2)" "unprognostic (3.20e-2)" 0.8 0.0 0.1 2.8 0.1 0.0 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.0 0.1 0.9 0.8 0.0 0.4 35.3 0.1 0.0 5.2 2.8 0.1 3.3 0.1 0.1 0.1 0.1 0.0 0.1 0.5 0.1 0.1 0.0 0.2 0.4 0.1 35.3 0.3 0.6 0.1 0.1 0.2 1.2 0.6 0.1 5.5 0.3 12.4 7.9 0.5 0.1 0.0 0.5 0.0 1.8 0.0 0.3 0.0 0.0 6.9 0.5 0.0 0.2 1.8 0.1 26.0 15.8 11.0 9.5 1.6 0.0 0.0 2.7 23.5 0.0 0.0 0.0 11.3 5.6 0.0 0.0 2.1 0.9 1.4 0.0 0.0 1.6 0.0 3.3 0.1 0.0 0.0 0.2 7.0 0.0 0.0 0.0 0.1 0.0 0.0 5.7 0.0 0.2 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 13.3 5.8 1.8 4.4 10.7 9.2 0.0 2.6 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.3 0.1 0.0 0.0 0.0 0.1 0.0 0.0 1.8 0.5 0.1 0.0 0.1 0.1 0.1 0.2 0.1 0.0 0.1 0.1 0.1 0.1 ALPL "HOPS, TNSALP" ENSG00000162551 "Alkaline phosphatase, liver/bone/kidney" P05186 1 21509372-21578412 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" Biomineralization Hydrolase "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 73.3;liver: 52.7;lung: 45.1" "Cell line enhanced" "Detected in some" "HSkMC: 52.2;hTEC/SVTERT24-B: 40.8;LHCN-M2: 29.7;SCLC-21H: 26.0" "Cancer enhanced" "Detected in all" "testis cancer: 199.6" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 91 "neutrophil: 73.3" "Lineage enriched" "Detected in single" 127 "granulocytes: 73.3" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA007105, HPA008765, CAB020829" Enhanced Approved Cytosol "Intracellular and membrane" 7300000 Cytosol "CAB020829: , HPA007105: AB_1078137, HPA008765: AB_1078138" "unprognostic (3.89e-2)" "unprognostic (1.27e-1)" "unprognostic (5.57e-2)" "unprognostic (1.19e-1)" "prognostic unfavourable (7.57e-4)" "unprognostic (3.05e-3)" "unprognostic (6.50e-3)" "unprognostic (1.01e-1)" "prognostic unfavourable (7.08e-4)" "unprognostic (1.17e-2)" "unprognostic (2.48e-3)" "unprognostic (1.74e-1)" "unprognostic (7.28e-2)" "unprognostic (1.73e-2)" "unprognostic (2.27e-1)" "unprognostic (9.70e-3)" "unprognostic (2.58e-1)" 15.9 22.7 4.5 17.6 6.0 2.6 10.6 2.2 7.8 2.2 2.1 4.1 0.7 1.9 3.7 1.1 2.0 5.7 2.8 10.9 5.7 4.2 29.7 52.7 45.1 28.1 5.3 4.8 1.2 4.3 2.4 4.1 2.2 7.7 2.6 1.3 18.3 3.1 6.6 0.9 1.8 2.7 2.5 3.8 19.6 1.8 2.9 2.7 0.5 3.7 1.7 3.9 7.1 8.4 0.5 0.0 73.3 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.2 1.9 3.3 0.1 0.7 0.2 0.4 0.2 0.0 0.6 2.2 0.0 0.0 8.9 0.0 0.1 0.0 0.6 0.0 1.1 1.0 0.5 0.0 0.2 52.2 0.0 40.8 0.1 0.0 0.0 0.0 29.7 0.0 0.0 0.0 11.9 0.0 0.0 1.1 0.0 0.0 0.0 26.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 1.5 1.2 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.0 0.0 0.8 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.1 0.0 0.0 73.3 0.0 0.0 0.0 0.0 0.0 4.5 6.0 2.2 7.8 5.7 4.2 5.3 4.8 7.7 2.7 ALPP ENSG00000163283 "Alkaline phosphatase, placental" P05187 2 232378534-232382889 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" Hydrolase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 17 "placenta: 240.2" "Group enriched" "Detected in some" 6 "HaCaT: 86.1;SiHa: 23.7" "Cancer enhanced" "Detected in many" "endometrial cancer: 15.3" "Not detected" "Not detected" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "CAB026327, HPA038764, HPA038765, HPA051699" Enhanced Approved "Plasma membrane" "Intracellular and membrane" "Plasma membrane" "CAB026327: , HPA038764: , HPA038765: , HPA051699: " "unprognostic (4.86e-2)" "unprognostic (5.19e-3)" "unprognostic (6.67e-3)" "unprognostic (2.60e-1)" "unprognostic (2.44e-3)" "unprognostic (1.26e-2)" "prognostic unfavourable (4.33e-4)" "unprognostic (1.44e-1)" "unprognostic (4.09e-1)" "unprognostic (2.12e-1)" "unprognostic (1.27e-2)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 14.5 0.1 0.0 0.0 0.0 0.1 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 9.2 0.0 0.0 0.0 0.2 0.0 0.0 0.0 240.2 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 1.0 0.5 1.6 0.5 1.1 0.5 0.3 0.4 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.1 9.7 0.0 0.0 0.0 86.1 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 23.7 8.4 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.4 0.7 0.5 0.2 0.5 0.3 0.3 0.3 0.1 1.0 0.4 0.4 1.6 1.1 0.5 0.5 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 AMER1 "FAM123B, FLJ39827, RP11-403E24.2, WTX" ENSG00000184675 "APC membrane recruitment protein 1" Q5JTC6 X 64185117-64205744 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Wnt signaling pathway" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "NTERA-2: 15.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "NK-cell: 2.0" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA065214, HPA065265" Approved Supported "Nuclear bodies,Vesicles,Plasma membrane" "Nuclear bodies" "Vesicles, Plasma membrane" "HPA065214: , HPA065265: " "unprognostic (1.56e-2)" "unprognostic (8.85e-2)" "unprognostic (6.86e-2)" "unprognostic (2.74e-1)" "unprognostic (2.12e-2)" "unprognostic (1.86e-1)" "unprognostic (3.57e-2)" "unprognostic (1.48e-1)" "unprognostic (8.02e-2)" "unprognostic (1.75e-1)" "unprognostic (6.31e-2)" "unprognostic (3.43e-1)" "unprognostic (4.69e-4)" "unprognostic (1.26e-1)" "unprognostic (1.13e-1)" "unprognostic (6.19e-2)" "unprognostic (2.89e-1)" 3.0 3.4 3.0 2.8 5.6 2.3 3.0 8.8 4.9 6.8 4.7 3.1 7.8 3.3 9.8 11.3 6.9 5.2 2.4 3.5 3.0 3.4 4.2 7.1 2.8 2.6 4.5 1.6 15.5 8.1 5.1 3.9 2.0 6.3 4.5 3.2 6.8 7.0 5.3 9.0 4.8 3.7 6.6 2.9 3.7 5.1 1.4 4.3 2.4 3.4 6.5 3.4 4.3 5.7 0.4 0.2 0.0 0.3 2.0 1.0 0.1 2.9 2.2 5.6 4.5 2.2 2.1 4.5 1.4 1.2 2.0 1.3 7.1 1.0 5.6 1.8 2.9 4.1 12.0 3.9 2.0 2.6 2.4 3.4 4.4 4.5 1.6 7.2 0.9 3.0 5.2 1.5 3.1 1.2 5.2 5.7 1.1 3.4 4.7 3.9 15.1 4.3 11.3 9.2 4.1 0.9 0.9 2.5 3.8 3.5 4.8 1.9 1.5 2.1 0.7 2.5 5.8 6.5 1.8 2.9 2.0 4.3 1.1 8.2 0.0 0.0 0.3 0.0 0.4 0.1 0.0 0.4 0.0 0.4 0.0 0.3 1.0 0.0 0.0 2.0 0.0 0.2 0.9 0.1 3.0 5.6 8.8 4.9 3.0 3.4 4.5 1.6 6.3 4.3 AMPH ENSG00000078053 Amphiphysin P49418 7 38383704-38631567 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "brain: 57.2" "Cell line enhanced" "Detected in some" "ASC diff: 31.8;ASC TERT1: 18.8;BJ hTERT+ SV40 Large T+: 12.3;BJ hTERT+ SV40 Large T+ RasG12V: 14.6;HBF TERT88: 11.3;HSkMC: 11.0;U-138 MG: 12.1;WM-115: 10.8" "Cancer enhanced" "Detected in many" "glioma: 3.8" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB008559, HPA019828, HPA019829" Enhanced Supported "Plasma membrane,Cytosol" Cytosol "Plasma membrane" "CAB008559: AB_1611845, HPA019828: AB_1844801, HPA019829: AB_1844802" "unprognostic (1.76e-2)" "unprognostic (1.59e-1)" "unprognostic (5.94e-2)" "unprognostic (7.36e-2)" "unprognostic (3.24e-3)" "unprognostic (2.92e-1)" "unprognostic (4.90e-2)" "unprognostic (2.55e-2)" "unprognostic (4.37e-1)" "unprognostic (1.08e-1)" "prognostic favourable (9.96e-4)" "unprognostic (5.06e-2)" "unprognostic (5.81e-5)" "unprognostic (1.23e-2)" "unprognostic (5.63e-2)" "unprognostic (8.03e-2)" "unprognostic (1.68e-3)" 3.8 2.4 17.4 2.5 17.7 1.0 2.8 29.7 57.2 7.7 2.2 1.8 0.0 1.4 5.1 4.7 4.5 5.7 4.2 6.5 13.5 16.0 3.7 1.4 1.6 1.3 10.4 20.4 1.7 2.9 1.2 12.6 1.0 26.5 2.4 2.5 4.8 1.5 4.2 2.9 1.3 1.9 5.0 4.9 1.9 2.0 3.5 1.5 0.0 1.2 0.2 1.1 2.9 1.7 0.2 1.6 0.0 0.8 0.7 2.9 0.2 0.0 0.0 8.0 0.0 31.8 18.8 0.0 1.1 0.0 12.3 14.6 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.0 11.3 0.0 0.9 0.1 0.0 0.0 0.0 0.1 0.0 11.0 0.0 0.0 0.0 0.9 0.0 0.2 0.0 0.1 0.0 0.1 4.0 0.0 0.0 0.0 0.9 0.0 0.0 2.3 0.0 0.0 0.0 0.3 0.0 0.0 0.0 12.1 8.5 4.2 4.5 0.0 0.1 0.0 8.2 0.1 10.8 0.0 0.8 0.0 2.9 0.2 1.7 0.0 1.0 1.5 0.2 0.2 0.4 2.0 0.0 0.7 0.2 1.6 0.2 0.2 17.4 17.7 29.7 32.9 13.5 16.0 10.4 20.4 26.5 1.5 ANAPC1 "APC1, MCPR, TSG24" ENSG00000153107 "Anaphase promoting complex subunit 1" Q9H1A4 2 111611639-111884690 "Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins" "Cell cycle, Cell division, Mitosis, Ubl conjugation pathway" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA036329, HPA036330, HPA042998" Approved Approved Vesicles Vesicles "HPA036329: AB_10670714, HPA036330: , HPA042998: " "unprognostic (1.74e-1)" "unprognostic (5.04e-2)" "unprognostic (1.10e-2)" "prognostic unfavourable (1.34e-4)" "unprognostic (3.49e-1)" "unprognostic (2.15e-1)" "unprognostic (2.16e-4)" "unprognostic (1.23e-1)" "unprognostic (3.94e-2)" "unprognostic (2.59e-1)" "unprognostic (3.65e-2)" "unprognostic (1.23e-1)" "unprognostic (2.13e-2)" "unprognostic (1.94e-1)" "unprognostic (1.98e-1)" "unprognostic (1.15e-2)" "unprognostic (1.92e-1)" 4.9 4.4 3.2 6.1 4.4 4.3 5.8 6.0 4.6 4.9 6.0 5.6 5.6 2.5 6.5 5.2 3.4 4.5 3.5 3.2 3.8 4.0 4.1 7.5 3.0 6.7 5.3 8.7 4.1 4.8 4.1 7.3 4.7 3.7 7.5 5.2 5.5 4.8 2.9 6.0 4.5 6.5 3.9 8.4 5.4 4.9 6.3 5.6 0.7 3.0 6.4 8.7 4.5 18.1 12.9 14.5 10.1 6.1 8.1 14.3 11.0 7.9 13.6 11.9 25.8 11.7 30.9 9.0 9.8 15.6 21.9 12.0 17.3 13.8 12.4 33.1 12.4 13.9 6.3 35.9 11.9 5.6 5.7 20.0 18.8 12.3 31.0 13.6 9.2 7.6 20.8 9.1 22.0 11.1 21.8 16.9 17.6 7.4 17.4 11.9 6.9 11.2 9.9 9.5 6.4 12.3 8.6 11.3 12.8 9.6 11.4 10.5 21.0 28.3 9.5 15.2 9.6 0.0 2.7 0.7 5.9 3.0 8.7 6.3 5.3 5.0 5.6 4.2 8.6 7.3 0.5 6.4 2.4 2.2 2.3 4.5 ANG "RAA1, RNASE5" ENSG00000214274 Angiogenin P03950 14 20684177-20698971 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins" "Angiogenesis, Differentiation, Stress response" "Developmental protein, DNA-binding, Endonuclease, Hydrolase, Nuclease, Protein synthesis inhibitor" "Amyotrophic lateral sclerosis, Cancer-related genes, Disease mutation, Neurodegeneration" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 18 "liver: 371.4" "Cell line enriched" "Detected in many" 5 "Hep G2: 56.6" "Cancer enriched" "Detected in all" 17 "liver cancer: 279.2" "Low region specificity" "Detected in single" "Cell type enhanced" "Detected in many" "classical monocyte: 18.1;myeloid DC: 10.4" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" HPA055896 Approved "Nucleoli,Actin filaments" "Secreted to blood" 307535000 230000000 Nucleoli "Actin filaments" "HPA055896: " "unprognostic (2.50e-2)" "unprognostic (1.82e-1)" "unprognostic (9.77e-2)" "prognostic favourable (6.85e-4)" "unprognostic (5.71e-3)" "unprognostic (6.99e-2)" "prognostic favourable (7.83e-5)" "unprognostic (1.16e-1)" "unprognostic (3.20e-3)" "unprognostic (9.19e-3)" "unprognostic (1.31e-1)" "unprognostic (3.69e-1)" "unprognostic (6.65e-2)" "unprognostic (1.03e-1)" "unprognostic (3.39e-1)" "unprognostic (2.00e-1)" "unprognostic (3.09e-1)" 17.0 0.9 0.7 2.6 0.7 0.7 16.4 0.5 0.7 14.4 9.0 0.7 6.6 3.5 10.7 10.3 8.0 3.8 13.3 3.8 0.8 0.7 10.6 371.4 6.9 2.3 1.0 0.1 17.7 9.0 1.3 1.1 1.9 0.8 17.5 6.5 5.5 20.2 7.7 3.5 4.0 7.4 9.7 1.5 1.5 7.9 7.1 0.4 0.0 4.2 5.5 3.6 14.3 15.0 4.5 10.4 0.3 18.1 0.0 0.9 4.8 1.4 3.7 0.9 0.0 9.3 11.2 0.1 1.6 3.2 0.4 1.5 2.2 1.9 0.1 0.4 4.5 1.4 1.0 1.1 0.5 6.2 1.4 0.3 2.0 56.6 2.0 1.4 0.2 9.0 0.9 0.5 1.9 2.1 0.0 10.4 1.3 0.2 0.3 0.4 0.2 4.1 0.2 1.5 4.2 0.9 1.1 0.0 0.1 1.6 0.6 2.5 1.5 0.2 1.8 0.6 1.1 0.5 0.2 2.2 1.7 0.2 1.1 0.7 1.8 0.0 18.1 0.0 0.3 2.1 0.2 4.5 0.9 0.8 10.4 2.4 0.2 0.2 0.3 0.0 0.1 1.6 0.4 4.8 0.7 0.7 0.5 0.6 0.8 0.7 1.0 0.1 0.8 0.4 ANGPT1 "Ang1, KIAA0003" ENSG00000154188 "Angiopoietin 1" Q15389 8 107249482-107498055 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins" "Angiogenesis, Differentiation" "Developmental protein" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "ASC diff: 30.2;HEL: 16.9;HSkMC: 50.2;U-138 MG: 24.2;WM-115: 15.8" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in some" 4 "neutrophil: 9.3" "Lineage enriched" "Detected in many" 4 "granulocytes: 9.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB017815, HPA018793, HPA018816" Approved "Secreted to blood" 32019377 "CAB017815: , HPA018793: AB_1844820, HPA018816: AB_1844821" "unprognostic (7.71e-2)" "unprognostic (2.13e-1)" "unprognostic (6.37e-2)" "unprognostic (4.11e-3)" "unprognostic (7.36e-2)" "unprognostic (3.80e-2)" "unprognostic (2.22e-3)" "unprognostic (3.29e-2)" "unprognostic (1.07e-2)" "unprognostic (5.54e-2)" "unprognostic (2.62e-1)" "unprognostic (1.44e-1)" "prognostic favourable (4.40e-4)" "unprognostic (4.56e-3)" "unprognostic (1.69e-1)" "unprognostic (3.24e-1)" "unprognostic (1.76e-1)" 23.3 3.9 3.4 5.4 2.3 0.4 5.9 14.2 2.6 9.1 3.8 5.1 22.3 1.4 2.9 8.0 7.3 3.2 11.2 5.8 8.5 2.1 8.0 1.4 25.1 0.8 2.4 4.3 7.3 1.5 1.2 35.0 14.2 6.2 23.8 2.3 13.0 7.6 28.5 14.1 1.9 2.6 5.2 4.7 7.4 5.2 2.3 4.7 0.7 5.2 3.1 0.7 5.8 5.6 0.3 0.5 9.3 2.2 0.3 0.4 1.1 0.0 0.8 3.1 1.8 30.2 10.5 2.3 10.0 8.5 2.7 4.0 2.0 0.0 0.0 0.0 5.2 0.0 1.3 0.0 3.5 0.0 0.4 16.9 0.2 0.0 8.6 0.2 0.0 50.2 0.0 1.7 0.2 0.2 9.0 1.8 3.5 0.0 0.3 2.5 3.2 0.3 0.0 0.0 1.0 0.0 0.0 0.0 1.4 0.3 0.2 0.0 0.7 0.0 0.1 24.2 0.3 0.8 0.2 0.1 1.0 0.0 3.4 0.3 15.8 0.3 2.0 0.0 0.3 2.2 0.4 0.1 0.3 0.3 0.5 0.3 0.1 0.1 9.3 0.3 0.9 0.5 0.1 1.1 3.4 2.3 14.2 2.6 8.5 2.1 2.4 4.3 6.2 4.7 ANGPT2 Ang2 ENSG00000091879 "Angiopoietin 2" O15123 8 6499651-6563409 "Cancer-related genes, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins" "Angiogenesis, Differentiation" "Developmental protein" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Group enriched" "Detected in some" 8 "HMC-1: 9.9;HSkMC: 23.6;HUVEC TERT2: 36.5;WM-115: 11.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "basophil: 5.4" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in some" "Low region specificity" "Detected in all" "CAB011437, CAB017626" Approved "Secreted to blood" 4244467 31000 "CAB011437: , CAB017626: AB_1118956" "unprognostic (1.28e-1)" "prognostic unfavourable (7.99e-5)" "unprognostic (1.93e-2)" "unprognostic (1.23e-1)" "unprognostic (4.85e-1)" "unprognostic (4.86e-2)" "prognostic unfavourable (6.36e-5)" "unprognostic (1.66e-3)" "prognostic unfavourable (4.48e-4)" "unprognostic (2.94e-3)" "unprognostic (6.19e-3)" "unprognostic (1.38e-1)" "prognostic unfavourable (1.52e-7)" "prognostic unfavourable (3.87e-4)" "unprognostic (1.12e-1)" "unprognostic (1.46e-2)" "unprognostic (6.44e-2)" 15.8 0.8 5.3 5.0 20.6 0.6 17.9 10.4 19.5 9.3 3.5 0.5 2.2 1.6 6.2 2.8 3.8 5.8 7.2 10.1 6.1 5.9 3.0 4.1 4.6 8.3 13.1 1.0 3.0 1.2 1.9 1.1 20.0 20.8 4.3 2.7 0.5 2.8 4.4 17.7 3.3 2.6 9.9 9.4 2.3 2.3 1.4 12.4 2.9 10.5 2.2 3.9 14.8 8.1 1.9 1.1 5.4 0.7 0.8 1.2 0.2 0.0 0.1 0.1 0.1 0.2 0.2 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 2.5 0.2 0.0 0.5 0.0 9.9 23.6 0.0 0.0 0.0 36.5 0.0 0.2 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.4 0.0 0.0 0.0 0.0 0.0 0.6 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 11.9 5.4 0.7 0.6 0.9 0.4 0.9 0.7 0.8 0.8 0.1 1.9 0.9 1.2 0.8 0.8 0.4 1.1 0.2 0.2 5.3 20.6 10.4 19.5 6.1 5.9 13.1 1.0 20.8 12.4 ANK3 ENSG00000151150 "Ankyrin 3" Q12955 10 60026298-60733490 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Autism spectrum disorder, Cancer-related genes, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 95.4;parathyroid gland: 74.4" "Cell line enhanced" "Detected in many" "RT4: 24.3;SK-BR-3: 24.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "CAB013249, CAB015179, HPA038455" Enhanced Supported "Plasma membrane" "Plasma membrane" "CAB013249: AB_2533145, CAB015179: AB_633909, HPA038455: " "unprognostic (1.91e-1)" "unprognostic (5.33e-3)" "unprognostic (6.76e-3)" "unprognostic (1.94e-1)" "unprognostic (1.13e-1)" "unprognostic (3.70e-3)" "unprognostic (3.47e-1)" "unprognostic (1.62e-1)" "unprognostic (1.89e-1)" "unprognostic (1.21e-2)" "unprognostic (3.83e-1)" "unprognostic (2.28e-2)" "prognostic favourable (8.88e-16)" "unprognostic (5.75e-2)" "unprognostic (2.59e-1)" "unprognostic (1.00e-1)" "unprognostic (2.83e-2)" 2.7 3.1 21.1 3.1 24.8 1.1 9.1 95.4 29.1 5.5 10.5 21.5 19.4 15.7 9.7 52.9 7.1 8.2 8.9 31.2 24.4 16.4 38.9 6.6 10.1 2.5 26.8 19.8 5.2 5.0 74.4 10.5 31.9 31.9 8.6 8.8 6.5 16.1 19.4 29.2 16.0 10.6 5.9 16.5 5.9 6.3 3.4 30.0 0.6 17.2 4.6 3.4 5.6 6.6 6.2 3.5 1.7 0.4 2.1 7.7 1.3 4.1 2.4 15.0 0.2 0.0 0.9 11.6 0.3 0.2 0.0 0.3 10.7 8.1 0.2 4.9 0.3 5.9 8.0 7.2 0.2 0.2 5.4 0.1 4.6 0.0 3.1 0.0 0.2 7.4 4.6 3.8 0.2 1.7 2.0 10.1 3.4 13.8 0.0 0.4 6.8 13.0 0.0 10.8 2.0 2.7 24.3 7.8 1.4 0.3 24.4 0.0 14.2 0.0 4.9 0.4 1.5 6.6 0.7 0.4 0.0 0.0 2.7 0.1 9.3 1.7 0.4 0.6 4.1 0.3 3.7 6.2 7.0 2.2 0.2 1.9 7.7 1.9 1.1 2.1 0.4 3.5 1.0 1.3 21.1 24.8 95.4 29.1 24.4 16.4 26.8 19.8 31.9 30.0 ANKRD12 "FLJ20053, GAC-1, KIAA0874" ENSG00000101745 "Ankyrin repeat domain 12" Q6UB98 18 9136228-9285985 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "Karpas-707: 45.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA040705 Approved Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "HPA040705: AB_10673301" "unprognostic (2.20e-1)" "unprognostic (1.14e-1)" "unprognostic (3.59e-1)" "unprognostic (1.37e-1)" "unprognostic (1.46e-1)" "unprognostic (3.41e-3)" "unprognostic (7.25e-2)" "unprognostic (6.17e-2)" "prognostic unfavourable (6.71e-4)" "unprognostic (1.24e-2)" "unprognostic (1.55e-1)" "unprognostic (3.38e-1)" "unprognostic (2.39e-2)" "unprognostic (4.62e-1)" "unprognostic (1.56e-1)" "unprognostic (3.03e-1)" "unprognostic (1.03e-2)" 17.0 10.9 22.2 23.1 26.1 19.6 15.4 48.1 25.4 17.8 18.8 10.1 18.2 13.7 14.6 15.4 16.1 12.1 16.1 12.3 19.9 13.5 14.7 16.5 14.6 22.1 20.2 18.3 16.3 16.7 15.5 16.4 19.2 17.4 15.9 13.6 9.5 15.7 20.6 25.8 21.8 18.1 17.2 21.3 20.3 15.3 29.3 23.8 11.4 18.2 13.0 19.5 24.2 22.6 18.7 19.2 51.2 10.7 8.8 19.0 5.2 4.1 2.8 3.9 2.6 6.3 6.5 3.2 6.5 6.1 2.3 3.2 2.5 3.2 5.8 3.8 4.5 3.9 2.9 2.5 6.3 6.1 3.5 2.6 2.0 3.7 4.6 6.1 8.5 3.4 5.7 3.3 5.4 3.9 6.0 45.8 5.7 2.3 4.1 4.2 1.4 2.9 3.7 5.5 21.1 3.0 6.6 9.1 3.3 6.4 3.2 4.6 3.9 5.2 8.4 17.3 8.0 13.8 6.0 13.4 20.6 10.8 8.5 3.3 6.5 27.4 8.7 25.5 14.5 7.7 16.1 18.7 18.7 13.9 5.9 17.3 19.0 14.8 51.2 8.8 10.7 19.2 13.0 5.2 22.2 26.1 48.1 25.4 19.9 13.5 20.2 18.3 17.4 23.8 ANXA1 "ANX1, LPC1" ENSG00000135046 "Annexin A1" P04083 9 73151757-73170393 "Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transporters" "Adaptive immunity, Immunity, Inflammatory response, Innate immunity" "Phospholipase A2 inhibitor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "esophagus: 432.6;tongue: 235.4" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA011271, HPA011272, CAB013023, CAB035987, CAB058693" Enhanced Enhanced "Nucleoplasm,Plasma membrane,Cytosol" "Secreted to blood" 77000000 "Plasma membrane, Cytosol" Nucleoplasm "CAB013023: AB_2533983, CAB035987: , CAB058693: , HPA011271: AB_1844883, HPA011272: AB_1844884" "unprognostic (2.53e-2)" "unprognostic (1.31e-1)" "unprognostic (9.08e-2)" "prognostic favourable (5.71e-5)" "unprognostic (1.53e-2)" "unprognostic (4.28e-2)" "unprognostic (1.82e-2)" "unprognostic (1.30e-2)" "unprognostic (1.30e-1)" "unprognostic (1.14e-1)" "unprognostic (2.54e-3)" "unprognostic (1.47e-1)" "unprognostic (9.82e-3)" "unprognostic (1.13e-1)" "unprognostic (8.55e-2)" "prognostic favourable (4.57e-5)" "prognostic unfavourable (6.19e-6)" 52.7 3.5 2.7 11.5 3.3 81.4 45.9 0.9 2.5 61.5 8.5 3.6 5.5 2.4 6.9 11.2 432.6 11.9 14.9 8.9 3.2 2.5 9.1 2.1 37.3 7.6 4.3 1.9 11.7 2.4 0.5 6.3 149.5 13.5 12.9 4.4 6.4 93.0 7.2 7.9 11.6 6.4 12.3 6.5 5.9 5.9 5.6 3.1 3.9 21.7 235.4 153.3 18.0 83.1 0.7 98.9 146.2 79.1 27.3 52.5 102.8 65.9 104.2 4.7 4.9 66.5 63.3 0.3 114.3 71.4 47.3 32.1 3.0 59.7 0.1 37.8 99.7 81.2 10.1 69.2 37.5 37.3 0.7 5.0 31.0 0.1 53.1 11.0 2.5 36.4 57.4 47.8 94.0 67.0 20.9 2.8 58.3 0.2 19.4 6.0 5.9 42.4 0.0 26.6 0.2 106.4 14.0 0.0 0.0 39.3 1.0 26.4 0.2 1.7 82.7 55.5 34.9 76.2 58.6 0.4 0.1 0.2 128.1 10.2 83.4 146.2 79.1 141.1 52.2 21.5 52.5 0.7 47.0 45.9 98.9 0.2 13.7 25.4 8.6 27.3 19.3 3.5 8.3 102.8 2.7 3.3 0.9 2.5 3.2 2.5 4.3 1.9 13.5 3.1 ANXA11 ANX11 ENSG00000122359 "Annexin A11" P50995 10 80150889-80205572 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters" "Cell cycle, Cell division" "Amyotrophic lateral sclerosis, Cancer-related genes, Disease mutation, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004851, HPA027545" Supported Supported Nucleoplasm,Cytosol 530000 Nucleoplasm Cytosol "CAB004851: AB_626682, HPA027545: AB_1844851" "unprognostic (1.85e-2)" "unprognostic (2.85e-2)" "unprognostic (5.35e-3)" "unprognostic (5.06e-2)" "unprognostic (8.18e-3)" "unprognostic (1.99e-1)" "unprognostic (4.01e-3)" "unprognostic (6.28e-2)" "unprognostic (2.32e-2)" "unprognostic (4.88e-2)" "unprognostic (3.46e-2)" "unprognostic (2.56e-2)" "prognostic favourable (6.69e-8)" "unprognostic (2.69e-3)" "unprognostic (1.84e-1)" "unprognostic (6.79e-2)" "unprognostic (2.02e-1)" 44.1 7.3 19.4 27.8 23.8 37.0 61.1 22.8 24.4 26.4 34.4 8.6 18.4 28.6 20.2 36.4 49.5 23.9 47.5 57.1 17.2 8.3 39.1 21.9 35.1 38.1 10.8 14.2 27.3 24.0 26.2 9.7 35.0 7.5 28.9 27.6 16.7 20.2 27.8 39.5 18.6 44.1 28.1 11.2 22.9 29.3 15.1 6.6 45.7 18.9 39.2 31.8 34.9 39.6 12.7 14.4 77.9 12.1 11.6 21.9 13.0 34.7 30.5 1.8 9.0 39.1 38.6 19.5 26.0 67.0 16.2 16.8 27.6 54.4 2.3 18.8 38.9 45.5 7.8 21.7 9.8 59.1 13.9 14.2 18.1 21.4 22.9 15.6 35.3 40.7 13.2 9.0 6.9 23.0 13.9 26.4 12.8 20.7 19.0 34.5 3.3 64.7 14.5 2.7 52.6 27.4 32.3 0.8 6.3 11.2 45.0 25.4 13.3 19.2 27.7 11.4 17.1 26.0 13.6 16.1 21.9 15.1 11.9 26.1 7.5 22.6 12.1 77.9 14.5 9.6 15.3 12.7 18.3 20.3 9.1 10.9 17.3 14.9 43.8 11.6 10.7 14.4 21.9 13.0 19.4 23.8 22.8 24.4 17.2 8.3 10.8 14.2 7.5 6.6 ANXA2 "ANX2, ANX2L4, CAL1H, LIP2, LPC2D" ENSG00000182718 "Annexin A2" P07355 15 60347134-60402883 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transporters" "Host-virus interaction" RNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB004311, HPA046964, HPA061798" Enhanced Approved "Plasma membrane,Cytosol" "Secreted to blood" 16000000 "Plasma membrane" Cytosol "CAB004311: AB_626677, HPA046964: AB_2732537, HPA061798: AB_2732671" "unprognostic (1.61e-1)" "unprognostic (1.31e-3)" "unprognostic (1.84e-1)" "prognostic favourable (6.88e-5)" "unprognostic (4.06e-3)" "unprognostic (5.42e-3)" "prognostic unfavourable (2.54e-5)" "prognostic unfavourable (7.51e-4)" "unprognostic (2.94e-1)" "unprognostic (4.10e-3)" "prognostic unfavourable (8.47e-6)" "unprognostic (5.16e-2)" "prognostic unfavourable (2.11e-6)" "unprognostic (7.74e-2)" "unprognostic (2.55e-1)" "unprognostic (7.41e-2)" "prognostic unfavourable (6.59e-5)" 91.7 29.8 4.9 23.5 7.1 6.6 50.1 4.5 5.6 65.1 39.1 8.6 38.2 26.4 38.3 40.3 158.8 26.2 54.9 29.9 4.7 5.5 36.7 28.5 62.0 46.6 10.8 5.7 23.3 94.3 29.7 12.8 84.1 25.7 29.5 35.2 31.7 74.7 27.9 22.7 77.3 71.9 37.1 15.1 32.6 25.6 18.7 7.1 14.6 31.0 122.7 81.4 34.0 87.4 35.5 209.6 183.3 138.0 15.2 83.9 150.8 142.1 158.7 8.4 3.7 114.7 184.1 36.5 169.9 109.6 108.0 94.8 75.2 68.6 0.3 139.9 219.8 152.1 37.3 319.1 118.4 30.3 3.9 2.8 76.4 29.2 69.2 0.1 2.1 89.8 87.1 76.7 165.4 201.2 11.3 16.6 230.6 16.5 0.6 8.4 18.2 123.6 1.6 46.1 7.9 191.4 86.7 11.0 6.2 67.2 15.3 66.7 32.8 5.9 229.5 92.1 125.5 308.8 166.8 6.2 20.3 2.7 86.8 1.6 183.2 183.3 138.0 17.7 33.4 122.6 36.5 35.5 38.5 38.5 209.6 16.9 4.5 18.1 3.9 15.2 129.1 32.0 83.9 150.8 4.9 7.1 4.5 5.6 4.7 5.5 10.8 5.7 25.7 7.1 ANXA4 ANX4 ENSG00000196975 "Annexin A4" P09525 2 69644425-69827100 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "gallbladder: 212.1;pancreas: 160.1" "Cell line enhanced" "Detected in many" "EFO-21: 67.4;Hep G2: 70.3;RPTEC TERT1: 98.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB005076, HPA007393, CAB017560" Enhanced Approved Cytosol 580000 Cytosol "CAB005076: AB_630869, CAB017560: AB_2227370, HPA007393: AB_1078168" "prognostic unfavourable (8.55e-4)" "unprognostic (3.37e-2)" "unprognostic (4.82e-2)" "unprognostic (9.03e-2)" "unprognostic (1.62e-3)" "unprognostic (1.66e-1)" "unprognostic (3.57e-1)" "unprognostic (3.21e-1)" "unprognostic (4.52e-2)" "prognostic unfavourable (2.38e-4)" "unprognostic (7.23e-3)" "unprognostic (1.29e-1)" "prognostic unfavourable (6.05e-4)" "unprognostic (1.79e-1)" "unprognostic (8.85e-2)" "unprognostic (3.60e-2)" "unprognostic (3.97e-2)" 18.7 5.9 4.2 12.2 4.3 4.1 9.7 1.3 3.0 16.9 32.7 5.3 12.9 43.2 22.8 11.5 16.1 11.9 212.1 6.8 4.3 3.1 36.2 30.9 19.2 5.9 5.1 2.4 12.3 160.1 5.8 3.3 50.9 11.8 18.1 14.9 10.3 11.7 11.4 6.9 12.9 85.7 12.3 6.5 7.2 16.9 5.6 3.6 4.0 24.7 12.9 8.3 11.0 13.2 17.6 21.3 27.6 23.7 3.6 10.3 8.9 10.7 39.0 0.5 4.8 30.0 25.9 1.8 10.4 15.7 4.2 6.1 5.8 19.4 3.5 67.4 16.9 16.6 3.7 16.7 4.5 9.9 3.1 5.3 3.5 70.3 21.3 1.8 6.9 15.4 16.6 5.8 14.1 11.0 0.3 3.2 11.7 9.7 2.7 3.4 0.9 5.4 2.9 1.0 4.3 98.6 15.6 0.8 3.6 11.5 16.0 15.7 5.3 24.3 15.9 7.9 3.8 10.5 5.8 1.3 1.4 0.1 12.3 9.2 5.3 27.6 14.8 11.9 10.3 17.4 7.8 17.6 5.3 7.7 21.3 15.9 0.9 5.8 2.0 3.6 23.7 6.4 5.9 8.9 4.2 4.3 1.3 3.0 4.3 3.1 5.1 2.4 11.8 3.6 ANXA7 ANX7 ENSG00000138279 "Annexin A7" P20073 10 73375101-73414076 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "PC-3: 122.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004312, HPA064290" Approved Approved Nucleoplasm,Cytosol 540000 Nucleoplasm Cytosol "CAB004312: AB_626681, HPA064290: " "unprognostic (1.48e-1)" "unprognostic (4.70e-2)" "unprognostic (1.90e-1)" "unprognostic (2.23e-1)" "unprognostic (1.48e-1)" "unprognostic (1.66e-1)" "unprognostic (1.54e-1)" "unprognostic (2.08e-1)" "unprognostic (2.06e-2)" "unprognostic (1.17e-1)" "unprognostic (1.47e-1)" "unprognostic (2.67e-1)" "prognostic favourable (1.98e-4)" "unprognostic (1.63e-1)" "unprognostic (8.37e-2)" "unprognostic (6.93e-2)" "unprognostic (3.06e-2)" 27.4 27.1 28.0 18.5 28.7 24.1 29.3 23.5 33.1 25.2 21.1 25.0 15.5 13.0 25.1 28.2 24.7 19.7 20.7 36.6 27.2 26.8 39.4 40.8 21.5 33.0 26.0 28.8 26.2 24.2 103.3 28.1 23.3 24.9 24.1 25.4 22.8 26.0 25.3 75.4 21.5 17.3 32.3 25.4 21.3 18.0 11.7 15.5 17.1 30.2 28.2 26.7 27.6 20.5 35.3 36.4 53.0 34.9 33.0 44.4 42.5 24.2 17.6 6.9 16.8 27.0 26.6 15.0 16.2 42.9 21.3 18.0 25.6 28.8 9.7 16.5 30.6 20.4 12.8 19.2 21.2 23.9 9.5 13.7 8.8 22.8 23.8 19.5 6.3 16.5 18.7 26.6 47.7 18.9 17.8 27.6 27.0 19.4 11.0 12.6 7.7 122.1 9.1 19.6 17.6 36.9 14.9 5.5 7.6 18.3 42.3 15.3 26.4 10.4 17.6 8.7 15.8 26.3 20.9 17.9 25.4 13.7 20.6 25.3 6.7 53.0 34.9 45.1 22.2 26.2 30.1 35.3 34.4 27.7 36.4 24.0 31.5 27.7 35.4 33.0 25.6 15.6 44.4 42.5 28.0 28.7 23.5 33.1 27.2 26.8 26.0 28.8 24.9 15.5 AOC3 "HPAO, VAP-1, VAP1" ENSG00000131471 "Amine oxidase, copper containing 3" Q16853 17 42851184-42858130 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Cell adhesion" Oxidoreductase "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enriched" "Detected in some" 18 "ASC diff: 83.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 13 "neutrophil: 1.2" "Lineage enriched" "Detected in single" 13 "granulocytes: 1.2" "Low region specificity" "Detected in many" "HPA000980, CAB025797" Enhanced Approved "Golgi apparatus,Cytosol" "Secreted - unknown location" 240000000 Cytosol "Golgi apparatus" "CAB025797: , HPA000980: AB_1078170" "unprognostic (2.20e-1)" "unprognostic (4.49e-2)" "prognostic unfavourable (3.68e-4)" "unprognostic (2.97e-2)" "unprognostic (1.17e-1)" "unprognostic (2.64e-1)" "unprognostic (2.22e-1)" "unprognostic (2.15e-2)" "unprognostic (1.48e-1)" "unprognostic (4.00e-2)" "unprognostic (2.95e-1)" "unprognostic (9.02e-2)" "prognostic unfavourable (1.79e-5)" "unprognostic (5.61e-2)" "unprognostic (1.67e-1)" "unprognostic (8.39e-2)" "prognostic unfavourable (6.98e-4)" 97.0 11.5 0.4 18.7 1.0 0.0 67.7 0.5 1.3 26.9 44.3 1.0 16.3 3.6 44.7 34.8 36.1 18.5 50.9 12.1 0.4 0.4 5.8 8.3 48.0 7.9 0.5 1.2 23.8 2.4 2.2 1.3 10.8 2.0 36.5 9.4 32.1 8.0 24.7 7.7 5.5 15.0 79.2 0.6 7.5 17.7 16.2 0.3 1.0 6.6 11.6 2.6 75.9 20.9 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.2 83.5 0.1 1.3 0.0 0.0 0.0 0.2 0.2 0.0 0.1 0.2 0.0 0.1 0.2 0.0 0.2 0.3 1.4 0.1 0.1 4.6 0.2 0.0 0.2 0.9 0.2 0.1 0.2 0.0 0.0 0.4 0.1 0.0 0.0 0.3 0.1 0.1 0.2 0.2 0.7 0.0 0.5 0.0 0.1 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.7 0.3 0.1 1.2 1.3 0.1 0.1 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.4 1.0 0.5 1.3 0.4 0.4 0.5 1.2 2.0 0.3 AP2B1 "ADTB2, CLAPB1" ENSG00000006125 "Adaptor related protein complex 2 beta 1 subunit" P63010 17 35578046-35726409 "Cancer-related genes, Predicted intracellular proteins" "Endocytosis, Protein transport, Transport" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB017631, HPA056733, HPA067983" Approved Supported Vesicles 680000 Vesicles "CAB017631: AB_2058201, HPA056733: , HPA067983: " "unprognostic (1.49e-2)" "unprognostic (4.04e-3)" "unprognostic (2.15e-3)" "unprognostic (1.48e-1)" "unprognostic (1.16e-1)" "unprognostic (3.01e-2)" "unprognostic (1.51e-3)" "unprognostic (2.64e-2)" "unprognostic (1.06e-1)" "unprognostic (4.73e-2)" "unprognostic (2.58e-2)" "unprognostic (2.50e-1)" "prognostic favourable (2.62e-4)" "unprognostic (1.70e-1)" "unprognostic (1.10e-1)" "unprognostic (3.25e-2)" "unprognostic (1.57e-2)" 20.1 19.9 36.6 16.3 51.3 18.6 27.6 32.8 59.0 27.8 29.8 35.2 17.0 15.1 20.0 33.1 13.1 22.9 20.2 30.3 36.8 36.1 32.9 16.0 23.6 16.0 35.5 39.9 28.7 15.4 75.6 30.0 30.6 40.7 20.0 39.0 21.8 18.7 25.3 23.3 13.1 16.7 26.1 37.0 18.4 21.6 45.3 27.4 18.5 31.5 10.6 20.1 19.6 21.5 12.6 10.7 15.8 15.4 9.5 19.4 10.3 42.4 54.5 28.1 32.9 46.4 51.0 12.0 21.9 33.5 32.3 34.9 30.5 37.2 20.7 19.5 40.8 40.6 38.4 62.8 46.2 24.7 35.5 28.0 39.9 16.6 26.6 26.9 19.8 32.5 24.9 32.7 49.7 50.8 42.4 30.0 50.5 8.6 26.1 13.1 22.6 39.3 22.0 40.1 15.1 40.7 24.6 23.1 28.4 27.2 9.6 29.9 39.2 18.2 50.4 24.6 22.7 26.5 32.7 12.7 23.0 19.5 31.5 20.1 26.0 15.0 11.3 15.8 16.6 15.4 17.8 12.6 14.9 14.9 10.6 11.5 6.9 8.7 13.3 9.5 15.1 10.7 19.4 10.3 36.6 51.3 32.8 59.0 36.8 36.1 35.5 39.9 40.7 27.4 APAF1 "APAF-1, CED4" ENSG00000120868 "Apoptotic peptidase activating factor 1" O14727 12 98645141-98735433 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" Apoptosis "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 33.0" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA031373, CAB069399" Enhanced Supported "Nucleoplasm,Golgi apparatus,Cytosol" "Nucleoplasm, Cytosol" "Golgi apparatus" "CAB069399: AB_1611908, HPA031373: AB_10602230" "unprognostic (1.32e-1)" "unprognostic (5.12e-2)" "prognostic favourable (5.90e-4)" "unprognostic (2.21e-1)" "unprognostic (3.94e-1)" "unprognostic (8.21e-3)" "unprognostic (2.03e-3)" "unprognostic (1.35e-1)" "unprognostic (2.26e-2)" "unprognostic (5.92e-3)" "unprognostic (5.63e-2)" "unprognostic (6.04e-2)" "unprognostic (9.93e-3)" "unprognostic (3.47e-2)" "unprognostic (2.53e-1)" "unprognostic (3.53e-2)" "unprognostic (3.07e-2)" 10.5 4.7 10.3 11.0 11.0 36.1 8.8 13.4 11.5 10.8 11.6 8.2 5.5 7.0 10.6 7.5 6.2 6.3 11.6 5.8 10.2 8.6 5.8 6.8 11.8 11.2 8.8 6.7 10.8 7.4 5.7 6.2 10.1 8.2 9.1 12.9 8.5 8.2 6.4 6.0 7.5 14.9 7.2 10.9 15.9 8.6 6.1 9.3 15.7 7.0 3.9 14.2 9.5 9.0 2.8 6.3 33.0 8.7 1.1 1.9 1.5 4.3 6.6 20.2 7.7 6.9 12.2 5.6 11.0 8.3 8.4 8.5 4.2 3.2 6.6 3.1 9.2 7.3 14.1 8.0 10.6 4.6 5.7 12.0 6.3 5.2 2.4 11.7 15.5 5.0 2.5 8.5 4.4 14.4 5.6 3.4 12.3 1.2 6.2 12.3 5.5 3.8 7.8 16.1 2.1 4.9 7.8 2.9 5.0 8.6 3.6 3.2 6.3 17.6 11.1 5.7 4.5 6.5 3.5 2.3 4.3 7.3 2.2 16.5 7.5 6.2 8.7 7.2 1.9 3.6 1.5 2.4 1.4 1.1 6.3 2.8 1.4 0.9 33.0 1.1 3.6 4.6 0.9 1.5 10.3 11.0 13.4 11.5 10.2 8.6 8.8 6.7 8.2 9.3 APC "DP2, DP2.5, DP3, PPP1R46" ENSG00000134982 "APC, WNT signaling pathway regulator" P25054 5 112707498-112846239 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Wnt signaling pathway" "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 40.9" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA013349 Supported "HPA013349: AB_1844913" "unprognostic (4.80e-2)" "unprognostic (1.19e-1)" "unprognostic (3.72e-2)" "unprognostic (1.14e-1)" "unprognostic (1.10e-1)" "unprognostic (7.09e-3)" "unprognostic (1.62e-1)" "unprognostic (8.10e-3)" "unprognostic (2.35e-1)" "unprognostic (4.85e-3)" "unprognostic (1.27e-1)" "unprognostic (4.18e-2)" "unprognostic (1.02e-2)" "unprognostic (1.07e-1)" "unprognostic (3.35e-1)" "unprognostic (2.23e-2)" "unprognostic (1.96e-1)" 7.2 5.4 40.9 6.4 21.7 8.5 6.3 19.1 39.7 6.8 7.1 10.3 2.0 6.6 6.3 3.9 8.4 5.0 5.5 7.4 37.9 12.9 6.9 6.2 6.7 5.6 23.6 20.7 7.6 4.6 13.8 7.2 5.5 39.1 5.9 6.9 4.0 4.0 4.9 7.0 6.1 8.8 8.1 19.1 6.2 5.4 5.3 20.6 3.6 6.5 2.7 6.2 6.2 3.9 3.8 3.0 12.9 2.9 3.0 3.4 1.1 8.3 7.7 12.8 9.3 10.6 8.8 5.2 13.5 6.4 7.5 8.9 6.1 6.8 16.1 13.1 17.2 6.8 13.1 11.0 12.4 9.6 8.9 12.2 11.1 4.6 5.2 6.1 6.7 7.4 7.6 12.7 8.4 10.4 15.0 5.6 10.9 5.8 7.0 3.1 4.6 2.7 6.0 15.9 7.8 6.9 10.6 13.0 7.8 12.8 5.0 5.5 6.9 5.0 16.6 15.3 7.4 15.0 10.2 4.4 6.6 6.3 8.5 11.4 8.5 10.4 2.9 5.0 3.4 1.4 2.9 3.1 1.8 2.1 2.3 3.8 2.9 2.8 12.9 3.0 2.5 3.0 1.6 1.1 40.9 21.7 19.1 31.4 37.9 12.9 23.6 20.7 39.1 20.6 APEX1 "APE, APE-1, APEN, APEX, APX, HAP1, REF-1, REF1" ENSG00000100823 "Apurinic/apyrimidinic endodeoxyribonuclease 1" P27695 14 20455191-20457772 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA recombination, DNA repair, Transcription, Transcription regulation" "Activator, DNA-binding, Endonuclease, Exonuclease, Hydrolase, Lyase, Nuclease, Repressor, RNA-binding" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA000956, HPA002564, CAB004294, CAB047307" Supported Supported Nucleoplasm 98000 Nucleoplasm "CAB004294: AB_626685, CAB047307: , HPA000956: , HPA002564: AB_1078174" "unprognostic (2.80e-3)" "unprognostic (1.39e-1)" "unprognostic (1.55e-2)" "unprognostic (4.74e-3)" "unprognostic (1.97e-2)" "unprognostic (5.88e-2)" "prognostic unfavourable (7.82e-5)" "unprognostic (4.21e-2)" "unprognostic (3.14e-2)" "unprognostic (2.46e-2)" "unprognostic (2.42e-2)" "unprognostic (1.68e-1)" "unprognostic (1.38e-1)" "unprognostic (1.22e-1)" "unprognostic (1.83e-2)" "unprognostic (2.54e-1)" "unprognostic (7.08e-2)" 43.9 52.8 30.6 33.2 32.5 55.6 43.6 24.1 44.9 38.5 41.9 37.3 28.4 44.1 53.2 30.1 40.7 42.9 46.4 34.4 28.0 27.4 44.4 61.3 31.8 44.5 30.2 31.1 64.7 48.4 31.8 21.7 29.4 34.4 36.1 39.8 36.0 35.5 38.9 53.2 41.2 37.6 40.9 30.1 51.0 41.7 20.9 28.3 73.2 51.2 38.5 48.4 41.8 32.7 35.0 53.0 1.5 23.7 20.6 32.5 38.4 43.9 54.1 48.5 44.7 34.1 49.3 41.8 41.3 44.5 61.6 53.5 39.4 43.7 84.9 36.9 31.5 47.2 57.7 43.7 57.2 37.9 24.6 34.4 32.0 65.6 35.9 109.2 35.8 50.9 48.3 40.1 39.8 51.4 39.9 28.0 49.3 42.8 69.9 46.0 47.8 48.9 77.8 54.5 35.6 51.7 59.3 58.5 37.3 44.8 55.9 44.4 34.0 49.4 33.1 32.5 54.5 32.7 38.5 37.6 65.1 57.3 14.5 69.4 41.0 0.1 23.7 1.5 19.0 20.5 25.9 35.0 23.8 22.6 46.8 31.4 32.5 28.3 1.5 20.6 12.4 53.0 14.1 38.4 30.6 32.5 24.1 44.9 28.0 27.4 30.2 31.1 34.4 28.3 APOA1 ENSG00000118137 "Apolipoprotein A1" P02647 11 116835751-116837950 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Cholesterol metabolism, Lipid metabolism, Lipid transport, Steroid metabolism, Sterol metabolism, Transport" "Amyloidosis, Atherosclerosis, Cancer-related genes, Disease mutation, Neuropathy" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 4 "liver: 573.5" "Cell line enriched" "Detected in some" 18 "Hep G2: 247.4" "Cancer enriched" "Detected in many" 48 "liver cancer: 4515.8" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "plasmacytoid DC: 3.6" "Group enriched" "Detected in many" 4 "dendritic cells: 3.6;T-cells: 2.4" "Low region specificity" "Detected in some" "Low region specificity" "Detected in all" "CAB016778, HPA046715" Supported Approved Vesicles,Cytosol "Secreted to blood" 2185000000000 220000000000 Vesicles Cytosol "CAB016778: , HPA046715: " "unprognostic (1.88e-3)" "unprognostic (4.53e-2)" "unprognostic (7.46e-2)" "unprognostic (4.00e-3)" "unprognostic (3.70e-2)" "unprognostic (1.41e-1)" "prognostic favourable (5.05e-4)" "unprognostic (5.40e-2)" "unprognostic (1.89e-1)" "unprognostic (9.60e-3)" "unprognostic (1.59e-3)" "unprognostic (7.02e-2)" "prognostic unfavourable (1.67e-8)" "unprognostic (3.46e-3)" "unprognostic (1.15e-1)" "unprognostic (6.24e-2)" "unprognostic (9.54e-2)" 0.2 0.0 0.2 0.2 0.2 0.0 0.2 0.2 0.2 0.2 24.6 0.2 0.2 55.6 0.2 0.3 0.2 0.1 0.3 1.3 0.2 0.0 0.2 573.5 0.2 0.2 0.2 0.2 0.7 0.2 0.0 0.2 0.2 0.2 0.2 0.0 0.2 0.3 0.2 0.2 0.0 127.9 0.2 0.2 0.4 0.3 11.8 0.2 0.2 0.2 0.3 0.2 0.2 0.2 0.5 3.6 0.0 0.7 0.7 2.4 0.5 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 13.8 0.0 0.2 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.1 247.4 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 1.2 0.1 0.0 0.0 1.2 1.5 0.0 0.2 0.4 1.7 0.7 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.1 0.0 0.4 0.0 0.4 0.0 0.0 0.2 0.0 2.4 0.7 0.3 0.0 0.2 1.8 0.8 0.5 0.8 1.7 0.0 0.7 0.0 3.6 2.1 0.5 0.2 0.2 0.2 0.2 0.2 0.0 0.2 0.2 0.2 0.2 APOA2 ENSG00000158874 "Apolipoprotein A2" P02652 1 161222292-161223631 "Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Host-virus interaction, Lipid transport, Transport" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 321 "liver: 932.2" "Cell line enriched" "Detected in some" 9 "Hep G2: 596.2" "Cancer enriched" "Detected in many" 329 "liver cancer: 11230.1" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "intermediate monocyte: 2.1;neutrophil: 2.9" "Group enriched" "Detected in many" 20 "dendritic cells: 1.0;granulocytes: 2.9;monocytes: 2.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" CAB025885 Supported "Secreted to blood" 229315000000 210000000000 "CAB025885: " "unprognostic (2.05e-1)" "unprognostic (4.70e-2)" "unprognostic (1.12e-1)" "unprognostic (2.99e-1)" "unprognostic (9.82e-2)" "unprognostic (1.92e-1)" "unprognostic (3.16e-1)" "unprognostic (2.79e-1)" "unprognostic (1.57e-2)" "unprognostic (4.40e-3)" "unprognostic (3.16e-2)" "unprognostic (2.22e-1)" "unprognostic (1.60e-1)" "unprognostic (6.09e-2)" 0.1 0.0 0.1 0.1 0.1 0.5 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.2 0.1 0.0 0.1 0.1 0.1 0.0 0.2 932.2 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.2 0.0 0.1 0.1 0.1 0.3 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 1.0 2.9 2.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 65.6 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.3 596.2 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.4 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.2 0.0 0.0 1.1 0.0 0.0 2.1 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 2.9 0.0 0.8 0.7 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 APOBEC3B "FLJ21201, PHRBNL" ENSG00000179750 "Apolipoprotein B mRNA editing enzyme catalytic subunit 3B" Q9UH17 22 38982347-38992804 "Cancer-related genes, Predicted intracellular proteins" "Antiviral defense, Immunity, Innate immunity" "Hydrolase, RNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 20.1" "Cell line enhanced" "Detected in many" "A-431: 59.6;Karpas-707: 67.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in some" "Cell type enhanced" "Detected in many" "memory B-cell: 10.2" "Low lineage specificity" "Detected in many" "HPA056980, HPA066719" Approved Nucleoplasm Nucleoplasm "HPA056980: , HPA066719: " "unprognostic (2.92e-2)" "prognostic favourable (2.58e-5)" "unprognostic (4.29e-2)" "unprognostic (1.19e-1)" "unprognostic (2.50e-1)" "unprognostic (1.35e-1)" "unprognostic (1.69e-2)" "unprognostic (2.18e-1)" "unprognostic (1.35e-1)" "unprognostic (6.36e-2)" "unprognostic (1.08e-2)" "unprognostic (5.88e-2)" "prognostic unfavourable (2.78e-4)" "unprognostic (8.47e-2)" "unprognostic (2.98e-2)" "unprognostic (2.70e-1)" "unprognostic (1.04e-1)" 1.6 2.3 0.3 4.4 2.2 20.1 1.4 0.3 1.2 2.3 9.9 0.7 0.3 5.8 2.0 2.4 4.6 1.2 2.2 1.6 0.6 0.2 3.6 0.9 2.5 4.3 0.3 0.3 1.7 5.7 0.4 0.3 6.4 0.8 2.1 10.0 1.3 4.8 0.3 4.1 1.9 8.8 1.0 0.7 10.4 3.8 2.0 0.3 5.9 3.3 0.3 12.0 2.0 2.4 10.2 0.8 1.7 5.8 2.2 3.8 5.9 59.6 6.7 2.6 16.1 0.3 1.5 4.5 5.5 4.8 10.6 13.9 12.8 10.9 0.6 5.0 5.5 25.6 0.3 1.1 10.7 21.6 0.6 17.2 1.4 3.3 0.1 14.2 10.4 0.5 0.1 11.0 0.5 4.1 9.6 67.6 16.4 1.6 0.0 8.0 0.0 6.0 0.4 25.8 21.5 2.1 10.1 0.4 0.0 0.0 0.0 3.7 7.9 4.1 2.5 11.7 20.4 1.8 0.1 15.0 4.1 0.0 8.3 15.9 23.7 0.5 1.3 0.0 0.3 5.8 0.0 10.2 0.8 0.5 0.8 3.2 0.0 0.4 1.7 2.2 1.8 0.1 3.8 5.9 0.3 2.2 0.3 1.2 0.6 0.2 0.3 0.3 0.8 0.3 APOC1 ENSG00000130208 "Apolipoprotein C1" P02654 19 44914247-44919349 "Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins" "Lipid transport, Transport" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 12 "liver: 702.7" "Cell line enhanced" "Detected in many" "Hep G2: 98.0;HSkMC: 60.7;K-562: 25.5;SK-MEL-30: 45.2" "Cancer enriched" "Detected in all" 21 "liver cancer: 3253.7" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in some" 8 "myeloid DC: 8.9" "Lineage enriched" "Detected in single" 13 "dendritic cells: 8.9" "Low region specificity" "Detected in many" HPA051518 Supported "Secreted to blood" 60000000000 26000000000 "HPA051518: " "unprognostic (3.51e-2)" "unprognostic (3.31e-3)" "unprognostic (1.14e-1)" "unprognostic (2.59e-2)" "unprognostic (2.06e-1)" "unprognostic (1.47e-1)" "prognostic favourable (1.15e-7)" "unprognostic (9.51e-3)" "unprognostic (1.30e-1)" "unprognostic (4.18e-2)" "unprognostic (1.11e-1)" "unprognostic (2.52e-1)" "unprognostic (7.13e-3)" "unprognostic (3.48e-3)" "unprognostic (1.65e-1)" "unprognostic (2.01e-3)" "unprognostic (1.65e-1)" 1.5 58.9 6.6 1.6 30.0 2.4 3.6 0.6 4.4 1.5 1.8 4.9 0.3 0.9 0.6 2.5 0.4 0.8 1.8 0.4 4.1 7.8 0.6 702.7 12.6 6.1 20.2 1.0 4.1 1.1 0.4 2.6 2.3 6.6 0.6 1.1 1.3 2.0 0.4 1.2 1.4 1.0 0.5 11.7 9.6 1.3 1.0 5.2 1.0 0.7 0.5 1.9 1.2 0.3 0.2 8.9 0.0 0.6 0.2 0.0 0.6 0.4 4.6 2.1 0.8 6.7 7.0 19.8 0.2 0.3 0.8 1.3 9.7 8.7 1.4 1.7 0.1 0.3 2.7 0.3 0.4 0.0 11.2 6.2 0.6 98.0 6.0 4.6 3.2 60.7 0.5 0.8 0.3 0.2 25.5 0.1 0.3 0.6 0.2 0.3 20.0 0.9 1.0 2.8 0.1 1.2 0.3 0.9 0.5 3.3 0.0 45.2 0.4 17.0 0.7 0.0 0.3 0.0 0.2 0.8 0.8 1.5 0.1 1.3 0.5 0.0 0.1 0.0 0.0 0.6 0.0 0.0 0.0 0.0 8.9 0.2 0.0 0.0 0.0 0.2 0.0 1.0 0.0 0.6 6.6 30.0 0.6 3.1 4.1 7.8 20.2 1.0 6.6 5.2 APOC3 ENSG00000110245 "Apolipoprotein C3" P02656 11 116829706-116833072 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins" "Lipid degradation, Lipid metabolism, Lipid transport, Transport" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 8 "liver: 714.1" "Group enriched" "Detected in some" 19 "CACO-2: 27.8;Hep G2: 75.2" "Cancer enriched" "Detected in many" 643 "liver cancer: 4021.9" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "HPA065365, HPA073918" Supported Approved "Nucleoplasm,Nucleoli,Cell Junctions" "Secreted to blood" 88520000000 97000000000 Nucleoplasm "Nucleoli, Cell Junctions" "HPA065365: , HPA073918: " "prognostic favourable (3.77e-4)" "unprognostic (2.33e-1)" "prognostic unfavourable (6.87e-5)" "unprognostic (1.60e-2)" "unprognostic (5.21e-2)" 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.2 0.1 38.7 0.1 0.1 31.7 0.1 0.2 0.1 0.0 0.1 0.1 0.1 0.0 0.4 714.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.2 0.1 0.0 0.1 0.1 0.1 0.1 0.0 91.3 0.1 0.1 0.3 0.0 0.3 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 27.8 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 75.2 0.0 2.6 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 1.6 0.9 0.0 0.0 0.3 1.0 1.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.8 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.2 0.1 0.0 0.1 0.1 0.2 0.1 APOD ENSG00000189058 "Apolipoprotein D" P05090 3 195568702-195584205 "Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins" Transport "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in all" 6 "breast: 840.7" "Group enriched" "Detected in some" 7 "ASC diff: 233.9;ASC TERT1: 126.0" "Cancer enhanced" "Detected in all" "melanoma: 925.2" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 10 "memory B-cell: 6.7" "Lineage enriched" "Detected in single" 10 "B-cells: 6.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA040520 Enhanced Approved "Plasma membrane" "Secreted to blood" 27730000 220000000000 "Plasma membrane" "HPA040520: " "prognostic favourable (5.51e-4)" "unprognostic (7.62e-3)" "unprognostic (7.85e-3)" "unprognostic (3.34e-3)" "unprognostic (2.20e-1)" "unprognostic (1.02e-2)" "unprognostic (3.09e-2)" "unprognostic (2.06e-3)" "unprognostic (1.26e-1)" "unprognostic (3.45e-1)" "unprognostic (3.38e-1)" "unprognostic (3.19e-1)" "unprognostic (6.90e-3)" "prognostic unfavourable (6.02e-4)" "unprognostic (1.38e-1)" "prognostic unfavourable (4.12e-4)" "unprognostic (1.71e-3)" 134.4 15.2 39.7 5.7 39.9 3.4 840.7 14.7 66.1 75.0 16.4 79.7 10.9 12.9 36.6 30.0 46.1 42.9 36.4 124.7 45.5 29.2 8.5 3.5 11.8 6.5 96.9 28.2 19.4 28.3 9.0 14.3 59.6 50.9 39.7 13.1 99.1 152.5 35.1 110.4 66.0 7.2 30.4 81.6 3.6 28.7 32.0 56.5 0.0 87.7 42.2 6.6 62.1 95.7 6.7 0.1 0.4 0.6 0.0 0.1 0.1 0.0 0.1 0.0 0.0 233.9 126.0 0.3 2.0 0.5 0.0 0.0 12.9 0.0 0.0 0.0 0.1 0.0 0.0 0.7 0.0 0.0 0.1 0.0 0.0 0.0 0.9 0.0 0.0 6.4 1.4 0.0 1.1 0.2 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 2.3 2.0 4.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 25.3 0.4 0.1 0.0 0.1 0.1 0.0 6.7 0.0 0.0 0.0 0.6 0.0 0.0 0.3 0.0 0.6 0.1 0.0 0.1 39.7 39.9 14.7 39.5 45.5 29.2 96.9 28.2 50.9 56.5 APOE AD2 ENSG00000130203 "Apolipoprotein E" P02649 19 44905754-44909393 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins" "Cholesterol metabolism, Lipid metabolism, Lipid transport, Steroid metabolism, Sterol metabolism, Transport" Heparin-binding "Alzheimer disease, Amyloidosis, Cancer-related genes, Disease mutation, Hyperlipidemia, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adrenal gland: 226.8;liver: 508.1" "Cell line enhanced" "Detected in some" "ASC diff: 163.3;Hep G2: 75.9;HSkMC: 119.7;SK-MEL-30: 151.8" "Cancer enhanced" "Detected in all" "liver cancer: 3183.8" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB008363, HPA065539, HPA068768, CAB069921" Enhanced Approved Vesicles "Secreted to blood" 37650000000 63000000000 Vesicles "CAB008363: AB_590560, CAB069921: AB_920623, HPA065539: AB_2685509, HPA068768: AB_2686029" "unprognostic (8.98e-2)" "unprognostic (2.32e-2)" "unprognostic (2.49e-2)" "unprognostic (5.28e-2)" "unprognostic (3.77e-2)" "unprognostic (7.25e-2)" "unprognostic (5.22e-3)" "unprognostic (6.13e-2)" "unprognostic (5.06e-2)" "unprognostic (4.13e-1)" "unprognostic (5.78e-2)" "unprognostic (1.38e-1)" "unprognostic (1.74e-1)" "unprognostic (7.76e-2)" "unprognostic (1.64e-1)" "unprognostic (1.12e-3)" "unprognostic (4.13e-2)" 76.8 226.8 78.4 14.6 106.8 9.7 12.8 26.6 109.8 13.6 15.1 40.3 0.8 7.7 9.4 10.9 2.6 4.3 17.1 6.9 41.4 57.9 121.8 508.1 21.5 46.0 104.0 34.5 23.5 5.2 2.7 4.9 17.2 54.1 6.6 5.2 11.2 8.5 3.4 5.7 33.0 10.2 3.6 35.1 89.2 13.4 12.6 33.9 4.9 6.0 1.3 8.6 11.8 6.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.4 0.8 0.2 163.3 6.7 5.9 0.1 0.3 0.7 0.1 38.7 0.2 0.1 0.8 0.0 0.5 1.0 0.1 0.0 0.1 0.3 0.2 0.1 75.9 16.8 0.5 0.1 119.7 0.2 1.2 0.1 0.0 9.9 0.2 0.1 0.2 0.1 0.2 20.4 0.1 0.2 0.6 0.1 0.2 0.0 0.4 0.2 0.3 0.1 151.8 14.0 4.3 0.2 1.1 0.2 0.1 0.1 0.4 0.6 0.3 0.5 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 78.4 106.8 26.6 53.4 41.4 57.9 104.0 34.5 54.1 33.9 APOL2 APOL-II ENSG00000128335 "Apolipoprotein L2" Q9BQE5 22 36226203-36239954 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Lipid transport, Transport" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" HPA001078 Uncertain Approved "Nucleoplasm,Nuclear bodies,Cytosol" 10000000 "Nucleoplasm, Cytosol" "Nuclear bodies" "HPA001078: AB_10602432" "unprognostic (4.19e-2)" "unprognostic (1.58e-1)" "unprognostic (1.50e-2)" "unprognostic (4.26e-3)" "unprognostic (2.62e-1)" "unprognostic (1.62e-1)" "unprognostic (3.95e-2)" "unprognostic (2.38e-2)" "unprognostic (7.39e-2)" "unprognostic (2.14e-2)" "unprognostic (1.70e-2)" "unprognostic (1.14e-1)" "prognostic unfavourable (1.22e-7)" "unprognostic (1.80e-1)" "unprognostic (6.79e-2)" "unprognostic (2.66e-2)" "prognostic favourable (5.06e-6)" 21.5 14.2 17.4 25.3 12.0 6.9 20.3 26.5 30.1 16.7 15.6 11.1 11.1 25.0 20.3 17.9 10.2 15.3 25.6 17.3 15.1 19.3 18.2 39.7 23.6 22.0 20.2 11.9 12.6 10.1 11.2 57.1 14.6 28.7 19.0 16.1 15.9 15.2 18.8 16.5 9.6 21.7 22.2 16.2 26.2 22.7 7.2 12.0 14.9 23.0 12.7 17.0 25.8 19.4 6.2 6.0 43.0 17.0 9.9 15.5 4.6 7.4 5.5 5.4 4.1 21.2 16.5 10.3 10.1 23.7 27.6 37.5 2.2 6.1 9.0 17.2 18.2 3.5 5.9 8.1 13.7 30.4 6.7 4.2 11.7 10.4 35.8 9.0 8.2 20.8 5.5 19.3 5.1 17.9 7.5 25.6 17.2 2.7 9.1 4.0 2.0 5.1 9.4 7.0 5.3 27.8 19.7 9.8 2.8 6.9 13.2 5.4 4.1 1.3 17.3 16.7 8.3 3.4 5.6 15.5 7.7 2.8 14.4 4.7 6.3 8.9 8.6 5.8 15.5 17.0 14.1 6.2 11.2 12.7 6.0 4.1 6.5 10.9 43.0 9.9 11.4 3.7 10.5 4.6 17.4 12.0 26.5 30.1 15.1 19.3 20.2 11.9 28.7 12.0 APPBP2 "Hs.84084, KIAA0228, PAT1" ENSG00000062725 "Amyloid beta precursor protein binding protein 2" Q92624 17 60443149-60526219 "Cancer-related genes, Predicted intracellular proteins" "Protein transport, Transport" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "MCF7: 47.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA066777 Uncertain "Centriolar satellite" "Centriolar satellite" "HPA066777: " "unprognostic (1.43e-1)" "unprognostic (1.89e-1)" "unprognostic (1.40e-3)" "unprognostic (2.97e-2)" "unprognostic (2.93e-2)" "unprognostic (4.53e-2)" "prognostic unfavourable (3.65e-4)" "unprognostic (7.67e-2)" "unprognostic (9.24e-2)" "unprognostic (2.39e-1)" "unprognostic (2.90e-3)" "unprognostic (6.87e-2)" "unprognostic (5.07e-2)" "unprognostic (1.03e-1)" "unprognostic (3.84e-1)" "unprognostic (1.31e-1)" "unprognostic (9.36e-2)" 18.8 16.0 16.1 13.2 22.6 5.3 15.9 28.1 27.3 17.5 13.9 25.4 12.9 10.1 18.5 13.8 14.5 14.5 16.1 10.1 16.6 16.0 18.4 15.0 16.4 10.9 20.8 15.4 27.9 17.1 23.4 20.4 24.3 25.1 19.4 12.8 13.4 13.0 15.0 14.5 12.6 10.8 16.7 18.5 15.4 14.5 30.8 21.2 17.9 17.8 7.2 11.0 15.8 15.3 12.7 12.0 15.7 14.2 15.6 16.7 9.3 6.9 9.5 10.0 8.3 10.7 11.3 5.6 11.0 7.6 6.1 7.9 4.6 6.1 7.3 18.6 9.2 6.0 7.0 3.8 10.9 6.4 5.4 9.2 8.9 9.4 11.4 7.5 10.2 11.0 5.1 6.4 6.3 9.5 6.8 8.5 8.9 47.1 10.6 3.8 2.2 4.2 7.1 16.7 8.4 9.5 11.5 10.9 9.3 9.5 1.6 7.9 13.3 5.2 12.3 13.9 17.0 9.5 8.3 9.1 28.6 6.0 9.2 4.5 9.8 13.5 12.0 15.0 10.2 8.7 11.7 9.7 12.0 11.2 12.0 12.7 16.7 12.2 15.7 15.6 14.2 7.2 11.5 9.3 16.1 22.6 28.1 24.1 16.6 16.0 20.8 15.4 25.1 21.2 AR "AIS, DHTR, HUMARA, NR3C4, SBMA, SMAX1" ENSG00000169083 "Androgen receptor" P10275 X 67544032-67730619 "Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Receptor" "Cancer-related genes, Disease mutation, FDA approved drug targets, Neurodegeneration, Pseudohermaphroditism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 49.0" "Cell line enhanced" "Detected in some" "AF22: 11.0;BJ hTERT+: 9.6;HAP1: 14.1;LHCN-M2: 12.4;RH-30: 20.5;T-47d: 8.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 16 "plasmacytoid DC: 5.4" "Lineage enriched" "Detected in single" 16 "dendritic cells: 5.4" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB000001, HPA065701, CAB065764" Enhanced Approved Mitochondria Mitochondria "CAB000001: AB_2060174, CAB065764: AB_10620739, HPA065701: " "unprognostic (1.34e-1)" "unprognostic (8.10e-3)" "unprognostic (2.49e-2)" "unprognostic (5.95e-2)" "unprognostic (1.04e-2)" "unprognostic (3.35e-2)" "prognostic favourable (8.77e-4)" "unprognostic (4.99e-2)" "unprognostic (1.72e-1)" "unprognostic (7.79e-2)" "unprognostic (2.30e-1)" "unprognostic (2.29e-1)" "prognostic favourable (1.03e-8)" "unprognostic (8.23e-3)" "unprognostic (8.90e-2)" "unprognostic (4.23e-2)" "unprognostic (7.97e-2)" 10.1 1.2 0.9 1.6 0.9 0.1 10.7 0.4 1.6 34.4 1.9 2.4 25.4 0.2 20.5 20.5 2.2 17.5 4.3 5.7 0.9 1.5 6.3 49.0 1.5 0.2 1.2 0.7 14.4 1.0 0.1 2.3 0.3 1.9 28.0 0.5 3.8 1.6 36.1 8.1 3.9 1.1 7.6 1.9 0.9 1.6 9.3 1.2 5.4 3.1 2.0 1.2 6.3 13.1 0.0 5.4 0.3 0.0 0.1 0.0 0.1 0.0 4.6 11.0 0.0 0.0 0.1 0.0 5.8 9.6 0.4 0.1 0.2 0.0 0.0 0.0 0.7 0.0 14.1 0.0 0.1 0.0 1.8 0.0 1.1 0.0 0.6 0.0 0.0 4.5 0.0 1.6 0.0 3.4 4.0 1.8 12.4 1.2 0.0 0.0 4.4 0.0 0.0 20.5 0.0 0.3 0.0 0.0 0.0 0.0 0.2 0.0 8.6 5.2 0.2 0.2 2.0 0.1 2.9 0.0 0.0 0.0 4.2 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.3 0.1 0.0 5.4 0.0 0.1 0.9 0.9 0.4 1.6 0.9 1.5 1.2 0.7 1.9 1.2 AREG "AREGB, SDGF" ENSG00000109321 Amphiregulin P15514 4 74445134-74455009 "Cancer-related genes, Predicted membrane proteins" "Cytokine, Growth factor" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "placenta: 83.5" "Cell line enhanced" "Detected in some" "CACO-2: 41.8;HBEC3-KT: 72.5;hTCEpi: 73.7;hTERT-HME1: 157.7;MCF7: 45.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in some" "Group enriched" "Detected in some" 9 "basophil: 8.2;eosinophil: 11.6;NK-cell: 3.3" "Group enriched" "Detected in many" 9 "granulocytes: 11.6;NK-cells: 3.3" "Region enriched" "Detected in single" 4 "olfactory region: 1.5" "Low region specificity" "Detected in all" "HPA008720, CAB023519" Approved Approved Mitochondria Mitochondria "CAB023519: AB_2060673, HPA008720: AB_1844978" "unprognostic (1.44e-2)" "unprognostic (1.84e-3)" "unprognostic (3.36e-2)" "unprognostic (2.26e-1)" "unprognostic (3.54e-3)" "prognostic unfavourable (2.61e-5)" "unprognostic (1.02e-2)" "prognostic unfavourable (1.05e-5)" "unprognostic (2.90e-1)" "unprognostic (8.06e-2)" "prognostic unfavourable (8.32e-5)" "unprognostic (2.56e-2)" "unprognostic (2.49e-3)" "unprognostic (2.40e-2)" "unprognostic (1.69e-1)" "unprognostic (1.23e-1)" "unprognostic (6.83e-3)" 19.5 1.1 0.4 9.2 2.1 28.9 20.3 0.3 0.4 5.7 6.7 0.2 0.2 0.7 1.7 1.6 22.3 6.0 34.8 13.6 0.5 0.4 2.5 1.7 14.4 13.3 0.4 0.0 5.8 1.0 0.0 7.8 83.5 1.3 1.9 5.0 1.4 3.9 0.9 9.9 3.4 10.0 1.5 1.0 11.3 5.3 4.6 0.0 1.6 1.2 13.4 13.6 8.7 4.6 0.4 0.8 11.6 0.0 3.3 0.4 0.1 1.7 11.9 0.0 0.0 0.1 0.1 0.0 0.3 0.5 0.0 0.3 41.8 6.7 0.0 0.9 0.0 1.9 0.0 72.5 0.7 0.0 0.0 0.0 0.3 1.9 22.5 0.2 0.0 0.6 73.7 4.3 157.7 0.0 0.1 0.0 1.6 45.5 0.0 0.0 0.0 4.8 0.0 0.0 0.0 4.1 0.3 0.0 0.0 2.4 0.1 0.0 1.3 0.0 0.1 0.0 1.7 0.6 0.0 0.1 0.0 0.0 0.0 0.0 0.1 8.2 0.0 11.6 0.0 0.0 0.0 0.3 0.4 0.0 0.8 0.4 0.2 0.0 0.1 3.3 0.0 0.1 0.0 0.1 0.4 2.1 0.3 0.4 0.5 0.4 0.4 0.0 1.3 0.0 ARG2 ENSG00000081181 "Arginase 2" P78540 14 67619798-67651720 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Adaptive immunity, Arginine metabolism, Immunity, Innate immunity, Urea cycle" Hydrolase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "prostate: 53.7;thyroid gland: 75.4" "Cell line enhanced" "Detected in many" "HAP1: 25.0" "Cancer enhanced" "Detected in all" "prostate cancer: 49.9" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA000663, CAB009435" Enhanced Supported Mitochondria Mitochondria "CAB009435: AB_2059089, HPA000663: AB_1078192" "unprognostic (8.74e-3)" "unprognostic (3.06e-2)" "unprognostic (1.35e-2)" "unprognostic (2.29e-1)" "unprognostic (2.30e-1)" "unprognostic (9.13e-2)" "unprognostic (1.10e-2)" "unprognostic (3.43e-3)" "unprognostic (4.62e-3)" "unprognostic (5.37e-2)" "unprognostic (4.66e-3)" "unprognostic (1.72e-1)" "unprognostic (9.39e-2)" "unprognostic (4.26e-1)" "unprognostic (2.31e-1)" "unprognostic (4.34e-1)" "unprognostic (1.26e-1)" 1.5 3.9 2.4 1.7 6.4 0.6 2.7 8.3 5.3 9.3 5.4 0.5 2.0 2.1 3.7 2.3 7.3 0.8 4.9 2.1 3.3 5.5 41.4 2.0 1.7 0.6 3.2 1.7 8.8 2.6 32.1 22.5 4.4 4.6 53.7 1.1 3.4 26.6 3.8 17.2 0.8 10.4 2.2 3.9 0.7 1.4 1.9 2.1 0.1 75.4 13.6 2.2 5.3 4.1 2.5 1.7 2.0 1.4 0.3 2.9 3.4 3.5 0.5 6.2 4.0 0.9 0.0 8.4 2.8 7.5 9.1 15.4 15.3 1.8 6.0 0.7 1.8 0.8 25.0 11.3 11.0 0.2 6.2 2.7 1.1 17.5 2.7 0.6 16.4 0.4 14.8 4.4 21.6 15.3 7.9 0.0 0.6 1.7 0.9 0.6 11.8 0.2 0.2 0.8 6.9 7.4 6.0 13.8 5.2 1.7 1.7 2.6 6.4 0.2 3.1 2.7 6.9 0.2 2.0 0.5 0.9 2.0 5.5 3.1 4.6 0.3 1.4 2.0 1.1 0.5 0.5 0.7 0.3 0.9 1.7 2.5 0.6 0.6 1.7 0.3 1.2 0.1 2.9 3.4 2.4 6.4 8.3 5.3 3.3 5.5 3.2 1.7 4.6 2.1 ARHGAP26 "GRAF, KIAA0621, OPHN1L, OPHN1L1" ENSG00000145819 "Rho GTPase activating protein 26" Q9UNA1 5 142770377-143229011 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "GTPase activation" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Karpas-707: 39.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 4 "neutrophil: 19.6;NK-cell: 5.8" "Group enriched" "Detected in many" 4 "granulocytes: 19.6;NK-cells: 5.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA035106, HPA035107" Enhanced Approved Cytosol Cytosol "HPA035106: , HPA035107: AB_10669855" "prognostic favourable (2.05e-4)" "prognostic favourable (1.36e-4)" "prognostic favourable (6.95e-4)" "prognostic favourable (5.93e-6)" "unprognostic (1.19e-1)" "unprognostic (1.93e-2)" "unprognostic (4.19e-3)" "unprognostic (5.93e-2)" "unprognostic (2.22e-1)" "unprognostic (9.43e-3)" "unprognostic (7.19e-3)" "unprognostic (8.65e-2)" "unprognostic (3.21e-3)" "unprognostic (5.67e-2)" "unprognostic (2.70e-2)" "unprognostic (2.95e-2)" "prognostic favourable (2.88e-6)" 13.3 5.7 18.4 18.6 22.7 33.9 13.0 29.2 23.9 15.9 14.2 7.5 9.9 13.2 9.4 10.9 7.6 18.5 16.4 17.0 12.8 10.5 8.0 7.7 20.0 8.8 12.9 15.4 4.8 5.5 4.8 15.1 22.4 11.9 8.5 14.8 8.8 14.6 11.2 14.0 8.5 12.6 11.1 12.6 18.9 17.0 16.1 12.2 10.3 10.0 5.4 13.6 9.4 10.6 0.3 2.0 19.6 2.8 5.8 3.0 1.0 6.8 13.7 3.8 3.5 5.7 6.3 5.9 0.8 1.1 3.3 5.8 18.8 15.5 0.9 6.8 2.2 3.3 1.9 6.4 4.1 14.1 2.2 0.0 1.7 11.9 3.6 10.1 1.3 2.3 11.4 6.1 14.1 4.9 0.2 39.0 1.0 1.0 5.7 4.2 1.8 3.5 2.2 5.7 16.3 9.7 10.5 1.5 2.4 1.7 1.9 3.2 1.0 3.1 9.4 1.8 2.6 0.2 3.6 1.7 5.5 0.2 4.7 9.5 2.5 2.9 2.8 1.6 3.0 1.7 1.3 0.2 0.6 1.8 2.0 0.3 0.2 0.8 19.6 5.8 1.0 0.5 0.2 1.0 18.4 22.7 29.2 23.9 12.8 10.5 12.9 15.4 11.9 12.2 ARHGAP32 "GC-GAP, GRIT, KIAA0712, MGC1892, RICS" ENSG00000134909 "Rho GTPase activating protein 32" A7KAX9 11 128965060-129279324 "Cancer-related genes, Predicted intracellular proteins" "GTPase activation" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 46.9" "Cell line enhanced" "Detected in many" "RT4: 21.4;SK-BR-3: 23.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA038382, HPA038389, HPA061505" Approved Approved "Nucleoplasm,Nucleoli fibrillar center,Golgi apparatus" "Golgi apparatus" "Nucleoplasm, Nucleoli fibrillar center" "HPA038382: , HPA038389: AB_10670972, HPA061505: " "unprognostic (1.17e-1)" "unprognostic (3.58e-2)" "unprognostic (2.54e-2)" "unprognostic (1.82e-1)" "unprognostic (3.89e-2)" "unprognostic (5.64e-2)" "unprognostic (1.52e-1)" "unprognostic (5.97e-2)" "unprognostic (7.32e-2)" "unprognostic (1.34e-1)" "prognostic unfavourable (6.64e-4)" "unprognostic (1.47e-1)" "unprognostic (6.17e-3)" "unprognostic (1.17e-1)" "unprognostic (4.01e-1)" "unprognostic (5.80e-2)" "unprognostic (1.64e-2)" 4.0 5.9 22.1 3.4 32.8 1.7 9.4 4.7 46.9 8.2 12.3 5.1 1.5 18.4 7.3 8.4 21.9 12.2 6.8 3.8 9.9 6.8 6.5 4.5 5.2 1.5 6.4 21.7 10.2 13.3 14.9 5.3 7.5 5.4 6.0 14.3 4.5 13.4 4.1 6.2 16.0 19.0 5.5 4.3 2.6 10.8 9.2 8.4 5.8 3.6 12.8 12.9 8.0 13.1 1.3 1.6 0.7 2.1 3.0 1.2 0.6 6.5 3.5 10.9 0.0 3.6 3.6 7.9 2.4 3.4 1.6 1.9 8.0 13.5 0.0 3.8 4.7 14.9 5.0 6.2 3.0 0.0 1.7 0.1 1.7 3.0 1.7 0.0 0.0 3.5 8.1 1.5 9.2 1.9 0.3 0.1 2.7 5.0 5.3 0.1 2.9 3.7 13.2 3.3 1.3 1.7 21.4 10.8 4.4 3.7 23.4 4.5 12.1 2.1 3.6 5.6 2.9 3.3 4.7 0.1 0.0 0.0 2.4 14.9 3.5 0.0 0.4 0.0 0.3 2.1 1.2 0.0 0.4 0.6 1.0 1.3 0.8 0.2 0.7 3.0 0.7 1.6 0.4 0.6 22.1 32.8 4.7 46.9 9.9 6.8 6.4 21.7 5.4 8.4 ARHGAP35 "GRF-1, GRLF1, KIAA1722, P190A, p190ARhoGAP, p190RhoGAP" ENSG00000160007 "Rho GTPase activating protein 35" Q9NRY4 19 46918676-47005077 "Cancer-related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "DNA-binding, GTPase activation, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB037311, HPA055184, HPA056470" Approved Supported "Nuclear bodies,Aggresome" "Nuclear bodies" Aggresome "CAB037311: AB_477435, HPA055184: , HPA056470: " "unprognostic (5.47e-3)" "unprognostic (1.38e-1)" "unprognostic (1.80e-1)" "unprognostic (2.40e-2)" "unprognostic (2.01e-2)" "unprognostic (7.78e-3)" "unprognostic (9.82e-3)" "unprognostic (4.41e-2)" "unprognostic (2.71e-1)" "unprognostic (2.73e-2)" "unprognostic (3.25e-2)" "unprognostic (1.92e-1)" "prognostic favourable (5.55e-8)" "unprognostic (2.78e-1)" "unprognostic (1.45e-1)" "unprognostic (1.04e-1)" "unprognostic (1.16e-1)" 4.0 3.1 11.9 1.9 9.0 0.8 5.4 6.1 11.7 4.5 4.4 3.9 3.9 3.3 5.3 4.3 2.6 8.7 10.7 9.9 6.7 7.7 4.8 2.1 8.4 6.2 4.2 17.3 4.4 2.0 4.4 3.9 4.8 5.6 9.0 3.4 5.1 4.2 4.6 2.2 3.1 13.8 7.0 2.4 4.5 2.2 1.1 1.4 0.9 1.2 1.0 3.1 1.1 20.0 22.8 15.4 13.6 14.1 11.8 2.6 10.9 15.7 11.1 12.8 12.2 7.2 10.8 7.8 44.7 12.3 14.2 14.2 15.4 7.4 5.9 14.6 16.0 9.4 13.2 8.6 12.4 11.9 14.3 12.6 13.5 10.0 9.7 3.9 12.7 11.8 8.3 13.5 8.0 8.4 9.3 10.5 3.3 9.3 40.2 15.5 14.7 20.2 19.0 8.1 17.9 10.5 12.5 9.8 7.8 10.6 12.9 4.1 7.4 8.8 22.0 9.0 23.9 0.9 1.0 0.9 2.8 0.8 2.9 0.8 2.6 3.1 1.3 1.1 1.0 1.2 0.4 1.0 1.2 1.4 0.8 1.1 ARHGEF12 "KIAA0382, LARG" ENSG00000196914 "Rho guanine nucleotide exchange factor 12" Q9NZN5 11 120336914-120489936 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "GTPase activation, Guanine-nucleotide releasing factor" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "basophil: 2.2" "Group enriched" "Detected in many" 5 "granulocytes: 2.2;NK-cells: 1.5;T-cells: 1.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA018911, CAB025581" Approved Approved "Nucleoplasm,Plasma membrane,Cytosol" "Plasma membrane, Cytosol" Nucleoplasm "CAB025581: , HPA018911: AB_1845003" "unprognostic (1.55e-1)" "unprognostic (1.29e-1)" "unprognostic (6.91e-3)" "unprognostic (1.28e-1)" "unprognostic (7.28e-2)" "unprognostic (5.39e-2)" "unprognostic (1.56e-1)" "unprognostic (5.55e-2)" "unprognostic (4.79e-2)" "unprognostic (7.77e-2)" "unprognostic (4.34e-3)" "unprognostic (4.78e-2)" "prognostic favourable (5.43e-6)" "unprognostic (1.29e-1)" "unprognostic (4.38e-2)" "unprognostic (2.13e-1)" "unprognostic (1.48e-1)" 17.6 19.2 27.6 8.3 32.5 5.9 19.6 40.4 41.5 21.7 16.4 12.4 15.7 14.9 17.5 15.9 17.8 18.6 17.3 23.4 21.8 17.7 41.2 38.8 24.1 6.5 15.8 26.3 16.3 16.9 55.8 17.2 25.4 21.1 16.8 17.8 20.7 16.7 20.0 24.1 29.0 14.8 18.6 10.8 12.4 19.0 6.7 13.0 3.0 31.3 15.0 10.9 19.4 22.9 0.3 0.3 2.2 0.1 1.5 1.0 0.4 12.9 10.9 14.7 14.0 19.9 19.9 6.1 15.3 17.3 9.3 11.9 12.7 9.5 1.1 18.8 27.3 9.8 18.8 19.4 18.2 10.7 9.2 21.1 11.7 9.8 17.8 0.0 15.7 18.9 14.1 20.4 22.7 28.2 17.8 43.3 23.5 9.0 0.0 0.0 4.0 9.4 4.6 16.8 4.1 22.9 22.6 10.8 13.3 21.4 18.0 5.6 15.3 1.7 27.8 20.7 8.9 13.4 11.1 12.7 5.1 7.2 8.5 2.7 15.6 2.2 0.0 0.0 1.0 0.1 0.2 0.3 0.6 0.6 0.0 0.3 0.0 0.5 0.0 1.5 0.1 0.3 0.7 0.4 27.6 32.5 40.4 41.5 21.8 17.7 15.8 26.3 21.1 13.0 ARHGEF6 "alpha-PIX, alphaPIX, Cool-2, Cool2, KIAA0006, MRX46" ENSG00000129675 "Rac/Cdc42 guanine nucleotide exchange factor 6" Q15052 X 136665547-136782088 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Guanine-nucleotide releasing factor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HEL: 21.7;HL-60: 27.0;HMC-1: 103.2;U-937: 29.0" "Cancer enhanced" "Detected in all" "glioma: 24.7" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA003578 Approved Approved Cytosol Cytosol "HPA003578: AB_1078203" "unprognostic (9.64e-2)" "unprognostic (3.47e-2)" "unprognostic (3.32e-2)" "unprognostic (1.29e-2)" "unprognostic (7.28e-2)" "unprognostic (2.06e-3)" "unprognostic (9.08e-2)" "unprognostic (7.87e-3)" "unprognostic (4.21e-1)" "unprognostic (2.56e-1)" "unprognostic (1.15e-1)" "unprognostic (1.10e-1)" "unprognostic (4.69e-3)" "unprognostic (5.29e-2)" "unprognostic (1.35e-2)" "unprognostic (2.64e-1)" "unprognostic (1.28e-3)" 22.0 10.4 16.9 15.3 15.4 14.8 13.9 6.4 14.6 6.4 8.3 12.8 3.7 4.0 8.4 6.1 4.4 4.5 9.5 27.0 21.7 13.6 5.0 4.5 13.8 20.6 20.7 10.2 9.5 2.7 8.8 4.8 24.4 15.1 6.4 6.3 8.4 6.2 5.1 37.5 4.3 9.6 9.3 14.6 20.2 6.4 3.2 14.6 2.6 4.1 8.6 20.5 8.8 7.9 3.1 8.8 31.5 8.8 5.5 9.9 6.2 0.2 0.0 1.0 0.0 2.2 5.8 0.0 0.3 1.8 0.3 1.6 0.0 0.0 1.0 0.4 1.5 0.1 1.2 0.0 0.3 5.0 0.3 21.7 0.0 0.0 0.8 27.0 103.2 6.2 0.0 1.0 0.0 0.5 0.1 4.3 3.9 0.0 12.7 16.6 0.9 0.4 4.8 7.3 0.0 0.3 5.4 0.0 1.3 0.0 0.2 0.7 0.6 11.3 0.1 1.5 0.2 1.8 1.3 0.7 0.0 10.4 6.9 29.0 2.0 20.2 7.2 31.5 6.8 8.8 8.0 3.1 7.6 5.5 8.8 2.6 7.0 6.1 4.2 5.5 6.8 2.8 9.9 6.2 16.9 15.4 6.4 14.0 21.7 13.6 20.7 10.2 15.1 14.6 ARID1A "B120, BAF250, BAF250a, C10rf4, C1orf4, P270, SMARCF1" ENSG00000117713 "AT-rich interaction domain 1A" O14497 1 26693236-26782110 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Neurogenesis, Transcription, Transcription regulation" "Chromatin regulator, DNA-binding" "Cancer-related genes, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA005456, CAB016334" Supported Enhanced Nucleoplasm Nucleoplasm "CAB016334: AB_673396, HPA005456: AB_1078205" "unprognostic (2.83e-1)" "unprognostic (1.81e-1)" "unprognostic (7.48e-2)" "unprognostic (1.41e-1)" "unprognostic (2.44e-1)" "unprognostic (1.89e-2)" "prognostic unfavourable (4.18e-4)" "unprognostic (3.02e-1)" "unprognostic (3.66e-2)" "unprognostic (1.34e-1)" "unprognostic (9.69e-2)" "unprognostic (7.76e-2)" "unprognostic (1.01e-2)" "unprognostic (1.62e-2)" "unprognostic (6.05e-2)" "unprognostic (2.66e-1)" "unprognostic (6.54e-2)" 18.6 18.4 17.4 24.9 17.0 33.8 27.8 23.6 19.1 20.3 23.7 21.7 23.9 15.8 24.1 17.3 23.2 20.6 21.9 15.5 14.8 12.8 13.7 15.9 18.8 35.6 20.3 19.2 24.1 23.9 27.5 15.8 19.3 17.2 16.5 16.4 18.9 21.4 23.1 22.6 20.6 20.7 18.4 15.4 25.9 19.5 16.5 19.8 57.3 24.8 14.2 24.5 24.4 20.4 4.3 5.3 7.4 3.3 4.7 5.1 3.5 18.9 18.0 25.6 26.6 7.4 7.1 12.0 8.9 7.7 12.2 8.7 13.2 12.8 26.8 7.8 11.5 11.5 22.2 9.8 14.3 33.2 8.7 22.8 11.7 8.8 6.1 33.7 7.3 8.2 7.0 14.4 10.3 10.5 27.2 30.0 7.9 9.0 28.4 13.1 27.0 8.4 29.7 16.9 15.2 7.6 12.8 23.9 19.7 15.6 13.2 10.7 3.9 19.2 18.4 13.1 12.7 12.2 14.4 14.3 18.8 12.3 8.0 21.6 11.6 0.4 3.3 2.9 4.0 2.9 5.1 4.3 3.2 4.9 3.1 4.3 4.0 4.4 7.4 4.7 2.8 5.3 1.5 3.5 17.4 17.0 23.6 19.1 14.8 12.8 20.3 19.2 17.2 19.8 ARID1B "6A3-5, BAF250b, DAN15, ELD/OSA1, KIAA1235, p250R" ENSG00000049618 "AT-rich interaction domain 1B" Q8NFD5 6 156777374-157210779 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Neurogenesis, Transcription, Transcription regulation" "Chromatin regulator, DNA-binding" "Cancer-related genes, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA016511, HPA075291" Approved Supported Nucleoplasm Nucleoplasm "HPA016511: AB_1845008, HPA075291: " "prognostic unfavourable (1.04e-4)" "unprognostic (9.82e-2)" "unprognostic (1.73e-1)" "unprognostic (5.42e-2)" "unprognostic (7.47e-2)" "unprognostic (1.40e-2)" "unprognostic (2.73e-2)" "unprognostic (2.89e-1)" "unprognostic (1.18e-1)" "prognostic unfavourable (4.16e-4)" "unprognostic (2.53e-1)" "unprognostic (5.33e-2)" "unprognostic (1.07e-3)" "unprognostic (2.46e-1)" "unprognostic (1.80e-1)" "unprognostic (3.53e-1)" "unprognostic (1.16e-1)" 18.3 15.0 20.2 18.8 20.9 25.8 19.3 42.1 32.8 20.0 17.4 26.3 21.7 15.3 23.0 14.2 18.6 20.7 15.9 16.8 20.4 11.3 14.2 10.6 17.0 18.3 19.4 16.7 30.2 18.5 47.4 29.2 12.2 17.7 17.7 13.3 24.0 20.0 20.2 30.6 27.3 17.8 21.7 14.9 21.1 15.0 10.7 24.6 24.0 23.8 13.3 26.3 23.5 21.0 9.5 11.9 5.6 3.0 2.7 5.6 1.6 7.0 10.9 16.1 21.9 13.2 12.2 11.0 7.5 9.9 9.8 9.8 9.6 10.3 22.4 4.7 12.8 9.0 13.7 12.3 9.7 22.5 9.7 16.2 11.0 11.4 9.3 13.5 11.9 13.8 9.9 14.9 13.3 13.6 19.0 17.5 7.0 8.3 15.6 15.2 8.1 5.8 35.6 6.9 12.1 6.7 13.2 14.8 18.9 15.1 15.9 8.8 10.7 21.2 13.9 12.4 13.2 11.4 14.7 12.1 10.8 28.7 10.8 16.2 16.6 5.6 3.0 2.5 5.4 2.4 5.0 6.8 4.7 3.8 2.3 9.5 4.0 5.6 5.5 2.7 2.6 11.9 4.6 1.6 20.2 20.9 42.1 32.8 20.4 11.3 19.4 16.7 17.7 24.6 ARID2 "BAF200, DKFZp686G052, FLJ30619, KIAA1557" ENSG00000189079 "AT-rich interaction domain 2" Q68CP9 12 45729665-45908040 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Chromatin regulator, DNA-binding" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA063044 Supported "Nucleoplasm,Plasma membrane" Nucleoplasm "Plasma membrane" "HPA063044: " "unprognostic (8.41e-2)" "unprognostic (1.03e-1)" "unprognostic (4.02e-2)" "unprognostic (3.94e-2)" "unprognostic (4.15e-2)" "prognostic favourable (5.75e-4)" "unprognostic (1.26e-2)" "unprognostic (9.71e-2)" "unprognostic (9.04e-2)" "unprognostic (5.57e-2)" "unprognostic (1.34e-1)" "unprognostic (2.47e-1)" "unprognostic (1.12e-2)" "unprognostic (9.21e-2)" "unprognostic (3.02e-1)" "unprognostic (2.00e-1)" "unprognostic (6.53e-2)" 9.0 7.9 7.1 14.6 7.2 14.0 11.8 15.7 8.8 10.2 11.4 8.2 17.9 6.4 12.2 10.7 11.5 8.8 10.6 8.2 7.4 5.8 8.7 6.9 10.2 13.0 9.6 3.8 12.2 10.7 18.4 15.1 10.3 7.5 9.9 8.1 10.1 9.7 20.6 8.6 13.5 12.6 12.5 7.3 10.2 9.0 30.9 11.0 33.3 11.5 8.2 11.2 10.0 10.0 2.1 5.3 10.5 4.9 3.1 4.4 1.3 5.4 7.8 14.0 6.1 6.0 4.2 7.6 3.8 5.4 5.3 5.0 11.1 5.6 10.5 7.0 5.2 6.6 11.3 6.4 7.7 4.6 5.4 13.9 8.6 5.4 4.1 10.9 6.4 3.4 4.9 6.7 10.7 5.4 11.7 10.9 4.7 7.1 15.6 7.8 8.3 4.2 12.1 10.0 10.1 5.1 9.0 7.6 9.7 6.2 7.2 6.0 10.9 21.9 6.4 5.7 6.9 3.8 4.9 7.3 6.0 29.3 4.4 28.7 4.0 10.5 1.7 4.2 4.1 2.2 4.3 1.7 3.7 4.4 2.4 2.1 3.6 3.3 2.4 3.1 4.9 5.3 3.1 1.3 7.1 7.2 15.7 8.8 7.4 5.8 9.6 3.8 7.5 11.0 ARID5B "FLJ21150, MRF2" ENSG00000150347 "AT-rich interaction domain 5B" Q14865 10 61901300-62096944 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 88.6" "Cell line enhanced" "Detected in many" "BJ hTERT+: 44.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA015037 Uncertain Approved "Nucleoplasm,Endoplasmic reticulum,Plasma membrane,Cytosol" "Endoplasmic reticulum" "Nucleoplasm, Plasma membrane, Cytosol" "HPA015037: AB_1845015" "unprognostic (3.31e-1)" "unprognostic (1.99e-2)" "unprognostic (2.94e-2)" "unprognostic (1.86e-1)" "unprognostic (1.17e-1)" "unprognostic (5.60e-2)" "unprognostic (1.50e-2)" "unprognostic (4.90e-2)" "unprognostic (3.90e-1)" "unprognostic (6.03e-2)" "unprognostic (1.97e-1)" "unprognostic (5.75e-1)" "unprognostic (1.20e-2)" "unprognostic (1.15e-1)" "unprognostic (2.58e-1)" "unprognostic (1.94e-1)" "unprognostic (3.93e-2)" 43.3 5.6 7.8 13.8 9.9 4.2 22.6 3.3 11.5 27.5 14.0 9.5 4.4 6.8 29.4 10.4 14.0 15.6 27.2 16.0 5.9 5.1 14.6 5.7 14.6 14.4 11.8 6.5 18.6 4.3 14.7 11.4 22.4 9.4 16.6 8.2 6.9 14.5 7.3 88.6 15.0 12.1 29.4 10.4 12.7 9.4 7.7 10.5 8.6 7.5 11.7 18.0 22.5 17.1 21.2 1.0 4.3 3.6 5.7 14.7 2.6 0.8 0.3 2.3 5.7 5.1 13.7 0.4 16.6 44.8 11.8 9.3 20.1 0.9 1.4 4.0 15.9 5.5 8.0 2.5 14.3 5.2 2.4 0.7 4.1 5.0 9.5 0.2 9.9 17.3 1.3 7.0 8.0 1.4 0.7 2.2 3.8 2.8 5.4 0.4 0.4 5.2 6.6 3.8 0.4 7.8 9.0 1.3 1.7 7.4 4.1 4.8 3.4 0.2 1.2 6.6 8.9 9.9 4.2 0.1 0.0 4.3 5.7 0.3 2.1 4.3 0.6 0.4 7.3 1.4 0.9 19.0 10.5 6.3 1.0 21.2 6.9 4.5 1.2 5.7 3.6 0.5 14.7 2.6 7.8 9.9 3.3 11.5 5.9 5.1 11.8 6.5 9.4 10.5 ARNT "bHLHe2, HIF-1beta" ENSG00000143437 "Aryl hydrocarbon receptor nuclear translocator" P27540 1 150809705-150876768 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enriched" "Detected in many" 7 "U-698: 94.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001759, CAB004318" Supported Supported "Nucleoplasm,Nuclear bodies" "Nucleoplasm, Nuclear bodies" "CAB004318: AB_626698, HPA001759: AB_1078213" "unprognostic (1.81e-1)" "unprognostic (8.14e-2)" "unprognostic (6.87e-2)" "unprognostic (5.76e-2)" "unprognostic (1.86e-1)" "unprognostic (4.10e-2)" "unprognostic (9.43e-2)" "unprognostic (5.27e-3)" "unprognostic (5.05e-1)" "unprognostic (3.42e-2)" "unprognostic (1.22e-1)" "unprognostic (9.52e-2)" "unprognostic (1.85e-3)" "unprognostic (2.68e-1)" "unprognostic (4.67e-1)" "unprognostic (6.45e-2)" "unprognostic (6.92e-2)" 23.5 20.8 12.1 14.5 12.6 11.3 25.1 25.4 14.4 28.0 17.2 18.7 12.8 10.9 26.1 14.4 16.6 20.4 17.9 20.0 10.2 8.2 14.4 32.2 21.6 12.0 11.6 9.5 31.8 22.4 16.5 22.9 31.7 12.3 18.2 16.4 28.3 15.2 16.3 25.5 21.9 15.2 22.6 14.0 19.2 16.5 14.9 12.3 18.8 16.1 13.9 18.0 23.0 24.4 6.6 12.7 23.9 15.6 8.0 8.8 9.7 4.0 4.1 6.2 4.7 13.4 12.9 8.4 4.5 9.0 6.2 5.7 3.5 4.1 4.2 4.1 8.1 4.6 5.6 5.1 5.4 6.7 3.4 5.0 7.0 4.1 7.7 6.0 5.9 10.0 4.8 7.5 6.7 7.6 6.5 8.5 6.4 7.8 4.8 3.3 5.1 3.2 6.0 7.5 6.0 4.9 4.1 4.1 6.1 8.8 6.0 3.5 7.7 13.1 5.4 5.2 4.6 4.1 3.9 9.7 7.0 94.7 6.3 0.2 3.5 23.9 15.6 13.9 8.8 14.7 7.9 6.2 7.2 8.4 12.7 6.6 7.0 7.1 8.1 8.0 14.7 5.2 7.2 9.7 12.1 12.6 25.4 14.4 10.2 8.2 11.6 9.5 12.3 12.3 ASPH "BAH, CASQ2BP1, HAAH, JCTN" ENSG00000198363 "Aspartate beta-hydroxylase" Q12797 8 61500556-61714640 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Dioxygenase, Oxidoreductase" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "U-87 MG: 102.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "plasmacytoid DC: 21.0" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA055161, HPA059303" Uncertain Enhanced "Endoplasmic reticulum" 900000 "Endoplasmic reticulum" "HPA055161: , HPA059303: " "unprognostic (8.07e-2)" "prognostic unfavourable (8.07e-5)" "unprognostic (1.73e-2)" "unprognostic (4.48e-2)" "unprognostic (2.32e-1)" "unprognostic (1.85e-2)" "unprognostic (2.82e-2)" "prognostic unfavourable (3.61e-4)" "unprognostic (6.39e-2)" "unprognostic (3.64e-1)" "prognostic unfavourable (1.75e-4)" "unprognostic (9.50e-2)" "prognostic unfavourable (1.57e-5)" "unprognostic (8.96e-2)" "unprognostic (1.65e-1)" "prognostic unfavourable (4.24e-4)" "unprognostic (2.74e-2)" 104.6 60.4 27.3 15.0 29.5 4.8 84.3 35.2 31.3 22.3 23.8 10.6 18.3 14.0 16.8 17.8 22.4 16.5 19.1 33.9 26.1 22.4 19.0 23.0 22.5 10.9 21.1 22.2 20.5 13.8 12.5 15.7 14.7 20.5 17.3 26.8 23.6 28.8 23.4 103.1 12.0 13.9 26.1 16.7 12.8 30.5 6.4 19.6 2.9 31.7 36.0 13.7 30.0 25.4 3.3 21.0 15.9 5.2 4.9 3.4 2.3 50.0 72.7 10.2 6.2 45.8 43.5 3.5 89.8 83.5 38.5 40.4 12.4 66.7 3.8 6.2 52.6 18.7 6.3 31.3 65.8 1.4 6.4 8.9 44.2 34.0 29.4 1.3 1.4 35.7 7.1 21.4 27.3 16.2 2.4 3.6 33.8 10.6 0.3 1.8 5.8 42.9 2.4 11.0 0.8 23.5 41.5 10.6 3.7 27.9 13.2 11.1 5.4 2.4 50.8 39.0 20.0 35.6 31.6 2.3 2.9 0.1 102.6 0.8 26.0 1.1 5.2 0.1 1.6 1.9 3.1 3.3 2.3 1.6 6.1 3.3 3.4 1.6 15.9 4.9 1.0 21.0 2.3 2.3 27.3 29.5 35.2 31.3 26.1 22.4 21.1 22.2 20.5 19.6 ASPM "ASP, Calmbp1, FLJ10517, FLJ10549, MCPH5" ENSG00000066279 "Abnormal spindle microtubule assembly" Q8IZT6 1 197084128-197146694 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division, Mitosis" Calmodulin-binding "Cancer-related genes, Disease mutation, Mental retardation, Primary microcephaly" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "lymphoid tissue: 62.8" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in some" 5 "plasmacytoid DC: 1.5;T-reg: 2.4" "Group enriched" "Detected in many" 5 "dendritic cells: 1.5;T-cells: 2.4" "Not detected" "Not detected" "Low region specificity" "Detected in many" CAB017816 Approved "Plasma membrane,Cytosol" "Plasma membrane, Cytosol" "CAB017816: " "unprognostic (3.24e-1)" "unprognostic (1.56e-1)" "unprognostic (2.81e-2)" "prognostic unfavourable (1.97e-4)" "unprognostic (3.67e-1)" "unprognostic (3.47e-2)" "prognostic unfavourable (1.25e-4)" "prognostic unfavourable (2.41e-4)" "unprognostic (4.67e-3)" "unprognostic (9.29e-2)" "prognostic unfavourable (2.40e-4)" "unprognostic (1.03e-1)" "unprognostic (0.00e+0)" "unprognostic (7.31e-3)" "unprognostic (1.23e-1)" "unprognostic (4.94e-2)" "unprognostic (3.66e-2)" 0.7 0.7 0.2 12.4 0.4 13.8 1.5 0.2 0.4 1.2 2.8 0.2 0.2 2.8 0.3 1.5 8.7 0.2 0.4 0.6 0.2 0.2 0.5 1.3 1.9 7.0 0.3 0.2 0.5 0.3 0.0 0.2 1.8 0.5 0.4 2.8 0.3 1.5 0.2 0.5 4.6 3.1 0.8 0.5 4.3 1.7 6.3 0.2 62.8 0.3 5.0 6.9 1.2 2.3 0.0 1.5 0.0 0.0 0.3 2.4 0.0 19.8 11.1 18.1 11.0 1.0 2.5 6.8 15.9 11.2 15.8 12.5 7.7 15.5 20.3 5.7 12.4 20.1 15.5 6.3 19.7 18.2 11.8 14.2 26.2 7.4 0.2 21.2 10.1 0.2 0.6 12.7 8.9 16.6 17.8 24.1 16.2 7.8 17.0 9.9 8.2 3.0 13.0 24.8 14.9 5.7 5.5 9.5 13.5 22.6 11.7 5.1 13.0 8.8 12.6 9.8 9.5 16.8 28.9 6.9 9.4 11.7 7.7 5.8 19.8 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.4 0.2 0.0 0.0 0.0 0.0 0.0 0.3 0.0 1.5 2.4 0.0 0.2 0.4 0.2 0.4 0.2 0.2 0.3 0.2 0.5 0.2 ASPSCR1 "ASPL, ASPS, TUG, UBXD9, UBXN9" ENSG00000169696 "ASPSCR1, UBX domain containing tether for SLC2A4" Q9BZE9 17 81976807-82017406 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enriched" "Detected in all" 5 "Hep G2: 80.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA026749 Approved Supported "Nucleoplasm,Vesicles,Plasma membrane" Nucleoplasm "Vesicles, Plasma membrane" "HPA026749: AB_1845114" "unprognostic (5.01e-2)" "unprognostic (1.19e-3)" "unprognostic (7.61e-2)" "unprognostic (1.34e-1)" "unprognostic (1.36e-1)" "prognostic favourable (8.55e-4)" "unprognostic (2.02e-1)" "unprognostic (2.07e-2)" "unprognostic (3.43e-1)" "unprognostic (1.71e-3)" "prognostic favourable (2.67e-4)" "unprognostic (1.13e-1)" "prognostic unfavourable (1.26e-4)" "unprognostic (3.16e-2)" "unprognostic (1.13e-1)" "unprognostic (2.27e-1)" "unprognostic (1.01e-2)" 10.3 12.6 14.3 12.6 14.5 16.8 10.6 16.5 20.8 9.9 12.9 16.7 11.8 17.5 10.1 15.8 11.9 9.3 15.1 11.5 13.1 12.6 15.8 31.9 14.1 14.8 18.9 12.9 8.8 17.8 17.0 19.7 21.8 14.8 13.2 7.1 14.4 22.6 9.9 25.1 15.5 14.4 9.1 12.6 13.2 13.0 16.9 14.6 9.8 16.4 12.9 13.0 9.7 8.3 8.1 14.6 15.7 11.3 7.2 10.5 5.2 4.9 8.8 3.4 5.0 2.2 2.7 14.9 4.7 3.6 5.7 5.6 5.1 5.8 5.1 4.9 3.4 2.4 3.7 3.6 1.8 3.5 11.2 5.7 7.2 80.8 7.1 5.0 8.3 3.1 3.9 2.9 2.0 5.5 5.7 7.3 3.2 17.0 4.6 10.9 4.3 6.4 5.1 5.0 10.4 5.6 4.6 9.2 9.4 3.9 12.3 8.8 7.4 12.0 4.5 9.9 6.8 7.2 5.9 5.3 3.2 5.7 5.3 5.1 5.9 15.7 11.3 8.0 6.7 7.6 4.0 7.9 10.5 9.0 14.6 8.1 8.0 6.0 2.9 7.2 9.3 9.1 4.9 5.2 14.3 14.5 16.5 20.8 13.1 12.6 18.9 12.9 14.8 14.6 ASXL1 KIAA0978 ENSG00000171456 "Additional sex combs like 1, transcriptional regulator" Q8IXJ9 20 32358330-32439319 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation, Ubl conjugation pathway" "Chromatin regulator, Repressor" "Cancer-related genes, Craniosynostosis" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA064156 Approved Nucleoplasm,Nucleoli "Nucleoplasm, Nucleoli" "HPA064156: " "unprognostic (1.49e-1)" "unprognostic (5.97e-2)" "unprognostic (8.36e-2)" "prognostic unfavourable (2.86e-4)" "unprognostic (6.69e-2)" "prognostic favourable (9.16e-4)" "unprognostic (2.01e-3)" "unprognostic (2.89e-1)" "unprognostic (1.49e-1)" "unprognostic (1.38e-1)" "unprognostic (4.32e-2)" "unprognostic (3.21e-2)" "unprognostic (1.84e-3)" "unprognostic (5.47e-2)" "unprognostic (1.90e-1)" "unprognostic (4.82e-2)" "unprognostic (1.06e-1)" 24.3 19.6 19.0 35.0 18.2 39.0 24.7 28.3 23.8 32.4 22.7 17.7 16.9 15.6 32.4 22.2 14.3 20.5 21.6 17.9 19.7 10.7 21.2 25.2 27.3 26.7 20.3 14.7 28.1 27.1 21.2 16.3 19.8 18.2 20.6 16.4 16.6 17.4 23.3 25.5 18.2 21.8 21.8 12.2 28.2 19.7 32.1 23.0 47.4 26.8 15.8 29.0 23.2 35.3 9.8 3.1 1.3 0.8 1.7 14.6 1.9 22.6 13.2 20.7 11.4 9.5 11.8 18.0 15.2 13.0 26.6 19.7 39.1 14.6 21.4 9.8 18.7 15.8 17.4 14.6 21.7 32.0 9.4 34.2 20.9 21.4 8.5 14.2 14.2 13.1 9.8 18.5 13.9 14.6 16.5 11.6 12.3 6.9 19.4 11.5 5.0 15.2 11.3 24.7 9.2 10.9 10.9 9.5 14.9 27.6 9.2 12.1 13.1 10.1 15.1 28.3 24.7 13.0 16.9 13.6 14.5 15.8 14.3 37.9 10.8 0.0 0.8 1.3 4.4 0.7 3.5 9.8 5.2 5.6 0.7 5.8 5.8 5.9 0.9 1.7 0.7 3.1 14.6 1.9 19.0 18.2 28.3 23.8 19.7 10.7 20.3 14.7 18.2 23.0 ASXL2 "ASXH2, FLJ10898, KIAA1685" ENSG00000143970 "Additional sex combs like 2, transcriptional regulator" Q76L83 2 25733753-25878516 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" Repressor "Cancer-related genes, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA034646, HPA058040" Enhanced Nucleoplasm Nucleoplasm "HPA034646: , HPA058040: " "unprognostic (4.78e-2)" "unprognostic (3.41e-2)" "unprognostic (2.23e-2)" "unprognostic (1.09e-2)" "unprognostic (1.01e-1)" "unprognostic (2.88e-2)" "unprognostic (2.98e-2)" "unprognostic (2.80e-1)" "unprognostic (2.68e-3)" "unprognostic (3.17e-2)" "unprognostic (1.39e-2)" "unprognostic (1.29e-1)" "unprognostic (1.33e-3)" "unprognostic (1.82e-1)" "unprognostic (1.58e-1)" "unprognostic (2.31e-1)" "unprognostic (3.75e-2)" 15.0 14.9 14.5 14.1 16.5 10.4 13.1 23.0 16.1 14.4 13.9 15.7 13.0 9.8 14.7 9.9 17.5 12.1 10.0 14.2 15.2 8.9 14.7 10.2 13.1 15.3 14.3 8.5 11.4 12.1 28.0 17.4 17.4 13.9 10.5 14.2 12.6 15.3 14.1 20.5 14.2 12.9 13.3 12.3 15.4 12.1 20.7 18.0 26.2 16.5 10.7 17.0 16.7 13.5 3.0 3.7 4.7 2.7 1.8 4.5 1.3 15.4 9.3 7.2 5.1 7.2 10.1 9.3 8.6 13.4 8.4 7.6 10.3 8.4 9.7 5.0 9.7 9.7 14.2 10.5 12.2 9.6 6.5 17.1 8.4 11.4 6.1 18.9 17.1 5.0 10.9 12.8 10.2 10.7 14.9 7.8 8.9 6.3 8.9 6.3 10.2 6.7 10.0 24.7 7.8 7.7 10.6 7.9 8.9 10.4 9.8 8.7 5.5 8.1 14.2 11.9 13.6 10.3 12.3 15.9 15.6 20.2 11.1 16.0 8.5 2.1 2.4 3.7 4.5 2.7 3.6 2.7 3.5 3.9 2.3 3.0 3.0 3.6 4.7 1.8 2.4 3.7 2.5 1.3 14.5 16.5 23.0 16.1 15.2 8.9 14.3 8.5 13.9 18.0 ATF1 TREB36 ENSG00000123268 "Activating transcription factor 1" P18846 12 50763710-50821122 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB016222, HPA055069, HPA055406" Supported Enhanced Nucleoplasm Nucleoplasm "CAB016222: AB_2290030, HPA055069: , HPA055406: " "unprognostic (1.71e-1)" "unprognostic (1.50e-3)" "unprognostic (1.50e-1)" "unprognostic (9.05e-2)" "unprognostic (6.68e-2)" "unprognostic (1.58e-1)" "prognostic unfavourable (1.53e-5)" "unprognostic (3.65e-1)" "unprognostic (8.17e-3)" "unprognostic (5.94e-2)" "unprognostic (4.31e-3)" "unprognostic (5.52e-2)" "unprognostic (1.73e-1)" "unprognostic (2.74e-2)" "unprognostic (2.46e-1)" "unprognostic (2.27e-1)" "unprognostic (8.75e-2)" 24.4 20.7 9.8 13.7 9.5 10.2 16.2 28.1 10.6 22.4 19.7 8.1 14.6 12.3 19.2 14.2 16.2 15.5 13.4 20.0 10.8 8.0 17.7 19.8 15.1 15.8 12.2 6.0 24.7 11.8 18.1 15.2 36.1 11.9 20.7 15.1 12.5 16.3 14.2 37.9 12.9 18.8 13.4 12.3 22.9 12.7 9.3 13.9 34.4 30.8 16.3 16.2 21.6 20.0 13.3 13.6 26.3 12.3 12.2 18.8 11.6 13.4 9.7 10.3 10.5 14.9 15.8 25.6 14.3 24.6 22.6 17.8 19.9 21.3 18.5 23.6 16.5 11.2 12.1 14.7 24.2 18.2 12.6 20.4 22.0 10.6 28.5 29.3 19.6 16.9 23.3 16.1 26.6 10.9 24.8 17.9 16.7 19.9 18.4 18.6 15.0 15.6 17.7 16.0 21.9 17.2 9.3 13.9 7.5 30.2 13.2 21.5 18.3 17.9 7.5 15.9 19.3 13.4 11.3 9.9 11.7 29.7 15.4 16.5 7.5 4.2 11.5 26.3 13.9 12.3 15.8 13.0 15.1 16.4 13.6 13.3 18.8 14.3 7.3 12.2 7.7 6.2 17.9 11.6 9.8 9.5 28.1 10.6 10.8 8.0 12.2 6.0 11.9 13.9 ATG13 KIAA0652 ENSG00000175224 "Autophagy related 13" O75143 11 46617527-46674818 "Cancer-related genes, Predicted intracellular proteins, Transporters" Autophagy "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA039350 Approved "Nucleoplasm,Plasma membrane,Cytosol" Cytosol "Nucleoplasm, Plasma membrane" "HPA039350: AB_10673142" "unprognostic (3.66e-1)" "unprognostic (1.14e-1)" "unprognostic (1.51e-1)" "unprognostic (1.65e-1)" "unprognostic (5.36e-2)" "unprognostic (2.31e-1)" "prognostic unfavourable (8.59e-5)" "unprognostic (1.05e-1)" "unprognostic (1.10e-1)" "unprognostic (1.27e-1)" "unprognostic (1.35e-1)" "unprognostic (7.57e-2)" "unprognostic (2.44e-2)" "unprognostic (2.41e-1)" "unprognostic (2.14e-1)" "unprognostic (7.68e-2)" "unprognostic (3.47e-1)" 13.8 15.8 20.2 11.9 27.3 25.8 12.5 32.8 37.0 13.2 12.6 39.5 9.2 14.3 12.9 16.8 14.9 16.6 14.5 17.8 19.5 16.3 14.3 21.1 11.5 13.6 31.8 18.2 15.6 19.7 24.4 23.1 13.5 27.2 12.8 12.0 21.3 17.0 13.5 20.9 16.3 12.4 12.3 15.7 16.2 16.5 60.6 34.9 14.8 18.6 8.8 15.8 12.5 13.0 15.8 20.0 38.9 24.0 17.0 24.7 20.3 13.7 25.2 19.4 11.4 27.1 31.8 19.6 16.0 28.4 19.8 25.4 17.2 13.7 12.9 11.4 24.1 16.8 18.6 21.7 20.1 24.4 35.5 13.8 17.6 30.0 30.4 18.4 24.1 38.2 25.9 13.6 30.2 19.5 24.1 29.5 17.7 20.6 18.3 27.3 24.2 21.9 17.5 25.1 22.5 13.3 15.1 18.5 18.6 22.1 17.8 23.6 25.4 38.1 19.1 24.4 15.0 22.5 17.5 26.9 29.8 16.3 30.3 16.7 17.9 21.2 20.7 26.9 21.3 24.0 17.2 15.8 19.2 16.8 20.0 12.7 16.6 18.3 38.9 17.0 18.7 14.9 24.7 20.3 20.2 27.3 32.8 37.0 19.5 16.3 31.8 18.2 27.2 34.9 ATIC "AICARFT, IMPCHASE, PURH" ENSG00000138363 "5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase" P31939 2 215311817-215349773 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Purine biosynthesis" "Hydrolase, Multifunctional enzyme, Transferase" "Cancer-related genes, Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB013462, HPA021012" Supported Enhanced "Plasma membrane,Cytosol" 3400000 "Plasma membrane, Cytosol" "CAB013462: , HPA021012: AB_1845169" "unprognostic (1.41e-2)" "unprognostic (2.18e-1)" "unprognostic (1.13e-2)" "unprognostic (8.46e-2)" "unprognostic (2.90e-1)" "unprognostic (3.81e-2)" "prognostic unfavourable (1.99e-7)" "unprognostic (1.86e-2)" "unprognostic (5.07e-2)" "unprognostic (1.83e-1)" "unprognostic (6.31e-3)" "unprognostic (9.21e-2)" "prognostic unfavourable (8.77e-4)" "unprognostic (1.00e-1)" "unprognostic (1.30e-1)" "unprognostic (4.18e-2)" "unprognostic (4.39e-3)" 19.4 27.4 21.1 23.0 28.4 16.9 24.8 12.1 32.3 20.6 26.7 29.1 18.1 23.4 27.9 15.6 19.1 21.9 19.1 18.2 20.3 21.1 23.1 35.6 17.3 36.1 29.7 19.9 23.4 32.9 25.1 21.1 31.1 24.4 21.9 35.9 19.5 14.4 29.4 35.5 17.0 20.6 26.7 21.7 29.0 20.4 15.0 28.0 46.3 16.1 13.5 35.3 27.6 18.0 21.7 13.4 2.9 8.9 19.6 22.8 10.0 20.2 30.7 17.1 29.1 23.0 23.3 8.6 20.7 18.0 23.7 27.2 59.1 31.8 29.5 25.7 21.6 21.3 37.6 31.2 34.0 21.9 36.4 35.9 26.3 53.0 29.8 44.9 18.4 19.7 24.0 31.6 38.2 15.8 46.3 24.6 32.5 29.9 39.1 21.8 65.9 17.2 36.4 24.7 26.4 25.1 32.7 26.9 18.6 16.6 20.5 23.4 33.6 16.0 13.9 20.1 20.8 25.9 13.0 31.1 40.6 61.2 17.5 25.1 29.0 2.9 6.0 0.1 13.2 8.9 22.8 21.7 18.6 20.0 13.4 13.2 18.9 17.5 0.7 19.6 7.4 11.7 17.7 10.0 21.1 28.4 12.1 32.3 20.3 21.1 29.7 19.9 24.4 28.0 ATM "ATA, ATC, ATD, ATDC, TEL1, TELO1" ENSG00000149311 "ATM serine/threonine kinase" Q13315 11 108222484-108369102 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Cell cycle, DNA damage" "DNA-binding, Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, Neurodegeneration, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "U-698: 47.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000102, HPA067142" Supported Enhanced Nucleoplasm,Vesicles "Nucleoplasm, Vesicles" "CAB000102: , HPA067142: " "unprognostic (9.77e-2)" "unprognostic (1.47e-1)" "unprognostic (3.04e-1)" "unprognostic (2.36e-1)" "unprognostic (5.70e-2)" "unprognostic (2.86e-2)" "unprognostic (6.32e-3)" "unprognostic (1.05e-1)" "unprognostic (8.19e-2)" "unprognostic (1.63e-1)" "unprognostic (7.68e-2)" "unprognostic (6.16e-2)" "unprognostic (2.17e-3)" "unprognostic (3.10e-1)" "unprognostic (7.87e-2)" "unprognostic (1.21e-1)" "unprognostic (2.81e-1)" 8.3 10.9 12.7 26.5 19.3 16.8 9.4 17.7 14.4 10.9 8.5 10.9 8.8 6.0 11.2 11.4 6.9 9.5 9.2 9.6 12.4 8.5 7.7 9.5 10.1 33.4 19.6 6.7 20.5 20.7 15.7 29.2 8.8 14.5 9.1 7.9 7.2 15.1 9.8 6.2 8.4 16.5 10.6 23.4 22.6 8.9 6.1 17.9 19.5 10.7 5.1 26.9 10.7 10.7 13.7 6.1 13.5 12.5 7.6 18.5 4.4 2.6 3.8 7.5 4.0 9.8 14.3 1.9 6.0 6.7 3.5 5.8 4.7 6.3 9.4 8.9 4.8 4.0 5.7 5.0 5.4 7.5 3.3 8.5 4.7 4.7 5.1 10.2 9.2 9.2 3.1 5.2 10.2 7.2 8.2 6.4 6.8 1.9 7.0 9.4 6.1 3.8 5.5 5.2 14.8 3.9 5.4 5.1 6.3 6.9 3.2 10.3 4.9 5.8 11.3 8.6 4.8 4.9 5.6 4.3 4.5 47.4 5.7 11.3 9.6 13.5 5.7 3.8 14.9 5.3 10.4 11.1 10.5 11.3 2.7 13.7 18.5 17.9 10.8 7.6 12.5 6.1 5.3 4.4 12.7 19.3 17.7 14.4 12.4 8.5 19.6 6.7 14.5 17.9 ATP1A1 ENSG00000163399 "ATPase Na+/K+ transporting subunit alpha 1" P05023 1 116372668-116410261 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters" "Ion transport, Potassium transport, Sodium transport, Sodium/potassium transport, Transport" "Cancer-related genes, Charcot-Marie-Tooth disease, Epilepsy, FDA approved drug targets, Mental retardation, Neurodegeneration, Neuropathy, Primary hypomagnesemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "intestine: 195.4;parathyroid gland: 194.4" "Cell line enhanced" "Detected in all" "SK-MEL-30: 248.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB018702, CAB069993" Enhanced 380000 "CAB018702: AB_626713, CAB069993: AB_2060979" "unprognostic (6.18e-2)" "unprognostic (2.18e-1)" "unprognostic (6.91e-2)" "unprognostic (1.42e-2)" "unprognostic (6.80e-2)" "unprognostic (2.15e-1)" "prognostic unfavourable (1.42e-4)" "unprognostic (1.80e-1)" "unprognostic (1.21e-2)" "unprognostic (6.32e-2)" "unprognostic (1.61e-2)" "unprognostic (1.65e-1)" "prognostic favourable (8.98e-8)" "unprognostic (4.75e-2)" "unprognostic (1.17e-1)" "unprognostic (3.11e-2)" "prognostic unfavourable (4.01e-4)" 17.4 25.6 22.4 16.2 40.3 10.5 26.9 74.2 67.4 17.8 121.9 14.2 56.1 92.3 13.1 38.3 34.9 17.7 65.8 41.1 26.1 18.7 162.7 34.6 35.1 9.6 19.2 27.6 17.4 78.6 194.4 25.0 19.2 34.1 22.1 65.7 24.1 84.4 53.7 19.0 40.5 195.4 17.7 20.7 13.7 25.0 17.0 13.9 9.1 101.2 13.7 16.2 14.2 23.1 10.3 22.0 6.4 29.7 10.4 30.2 17.2 32.9 12.2 12.7 6.3 25.5 24.7 65.2 19.8 39.4 24.4 34.7 48.7 23.7 26.1 28.0 23.4 43.1 25.0 41.7 35.5 9.6 27.7 15.2 23.0 41.1 19.5 38.1 21.4 27.5 69.9 28.4 37.5 29.9 25.0 25.3 21.6 65.6 15.4 13.8 29.8 24.5 14.9 29.6 23.1 88.1 34.0 12.5 11.0 30.7 58.4 248.8 15.3 22.1 26.3 13.9 19.5 35.9 40.0 12.2 9.5 20.1 42.7 22.0 81.6 6.4 13.3 6.1 23.2 20.9 24.8 10.3 26.4 24.9 22.0 5.3 30.2 22.0 1.6 10.4 29.7 11.1 20.3 17.2 22.4 40.3 74.2 67.4 26.1 18.7 19.2 27.6 34.1 13.9 ATP2B3 "CFAP39, CLA2, PMCA3, SCAX1" ENSG00000067842 "ATPase plasma membrane Ca2+ transporting 3" Q16720 X 153517676-153582939 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins" "Calcium transport, Ion transport, Transport" Calmodulin-binding "Cancer-related genes, Disease mutation, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 7 "adrenal gland: 18.6;brain: 23.2" "Cell line enhanced" "Detected in some" "SCLC-21H: 14.3;SH-SY5Y: 4.2;THP-1: 3.5;U-937: 3.3" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA001583 Enhanced "HPA001583: AB_1079641" "unprognostic (1.35e-1)" "unprognostic (3.07e-2)" "unprognostic (3.28e-1)" "unprognostic (6.82e-2)" "unprognostic (1.30e-1)" "unprognostic (4.32e-2)" "unprognostic (2.67e-1)" "unprognostic (6.34e-2)" "unprognostic (2.68e-2)" "unprognostic (8.58e-2)" "unprognostic (1.38e-3)" "unprognostic (3.44e-1)" "unprognostic (2.71e-12)" "unprognostic (1.44e-3)" "unprognostic (2.04e-1)" "unprognostic (2.42e-2)" 0.8 18.6 5.4 0.9 11.3 0.8 0.8 16.1 23.2 0.8 0.9 3.9 0.0 0.9 0.9 2.6 0.8 3.1 0.8 0.8 7.8 5.5 1.0 0.8 0.8 0.8 4.3 11.5 0.8 0.9 0.8 1.2 1.7 13.6 0.8 0.8 1.4 1.3 1.3 0.8 0.9 0.9 0.9 1.4 0.8 0.8 1.1 0.9 0.0 0.8 0.0 0.8 0.8 0.1 0.0 0.5 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 14.3 4.2 0.0 0.0 0.0 0.0 3.5 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 3.3 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 5.4 11.3 16.1 20.7 7.8 5.5 4.3 11.5 13.6 0.9 ATP7B WND ENSG00000123191 "ATPase copper transporting beta" P35670 13 51930436-52012125 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters" "Copper transport, Ion transport, Transport" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "gallbladder: 18.5;liver: 13.5" "Cell line enhanced" "Detected in many" "BEWO: 18.8;CACO-2: 10.8;HEL: 28.6;Hep G2: 9.9;RPTEC TERT1: 16.7" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "neutrophil: 1.0" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in many" "HPA009137, HPA013187" Supported Supported "Golgi apparatus" "Golgi apparatus" "HPA009137: , HPA013187: AB_1845206" "unprognostic (1.13e-2)" "unprognostic (1.61e-1)" "unprognostic (2.15e-1)" "prognostic unfavourable (5.01e-4)" "unprognostic (3.49e-1)" "unprognostic (5.51e-2)" "unprognostic (1.55e-2)" "unprognostic (1.18e-1)" "unprognostic (2.24e-1)" "unprognostic (5.77e-2)" "unprognostic (8.29e-2)" "unprognostic (1.17e-1)" "unprognostic (3.26e-3)" "unprognostic (4.66e-2)" "unprognostic (3.54e-1)" "unprognostic (6.21e-3)" "unprognostic (1.40e-1)" 3.4 0.7 1.8 2.4 2.9 1.8 1.6 7.0 2.8 1.4 6.8 1.1 1.1 10.5 1.6 1.9 1.1 1.9 18.5 1.8 2.1 2.1 2.1 13.5 1.2 1.1 1.6 1.1 2.0 1.7 7.7 1.2 7.1 3.5 1.9 2.6 1.4 3.0 1.1 1.1 0.7 9.6 1.5 1.1 1.6 4.5 7.1 1.6 1.1 1.1 1.1 1.1 2.1 1.1 0.0 0.0 1.0 0.3 0.0 0.5 0.1 0.4 1.6 2.9 2.6 0.6 0.5 18.8 0.8 0.2 0.9 0.6 10.8 0.1 0.0 0.3 1.4 0.2 2.0 2.4 0.6 0.2 4.0 28.6 0.3 9.9 0.9 0.3 6.7 1.2 2.8 0.1 1.1 2.0 7.6 0.0 0.8 0.5 0.1 0.7 0.9 0.9 1.0 0.8 0.0 16.7 1.8 2.2 1.2 1.0 1.6 1.1 4.5 0.2 1.1 0.1 1.0 1.6 0.3 0.3 0.4 0.1 0.0 0.1 0.4 0.0 0.3 0.0 0.0 0.0 0.5 0.0 0.3 0.1 0.0 0.0 0.1 0.0 1.0 0.0 0.0 0.0 0.0 0.1 1.8 2.9 7.0 2.8 2.1 2.1 1.6 1.1 3.5 1.6 ATR "FRP1, MEC1, SCKL, SCKL1" ENSG00000175054 "ATR serine/threonine kinase" Q13535 3 142449235-142578826 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" "DNA damage, DNA repair" "DNA-binding, Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, Dwarfism, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA054320 Supported "Nucleoplasm,Golgi apparatus" Nucleoplasm "Golgi apparatus" "HPA054320: " "unprognostic (1.47e-1)" "unprognostic (8.90e-2)" "unprognostic (2.90e-1)" "unprognostic (4.23e-2)" "unprognostic (2.25e-2)" "unprognostic (6.42e-2)" "prognostic unfavourable (8.39e-5)" "unprognostic (3.44e-1)" "unprognostic (1.67e-1)" "unprognostic (3.02e-1)" "prognostic unfavourable (1.23e-5)" "unprognostic (1.94e-1)" "unprognostic (5.61e-2)" "unprognostic (1.06e-1)" "unprognostic (3.55e-1)" "unprognostic (1.69e-2)" "unprognostic (1.43e-1)" 10.5 24.3 7.7 11.4 15.9 10.1 14.8 11.3 14.6 10.1 8.5 10.0 10.4 6.0 14.7 16.8 9.4 12.1 9.3 8.8 9.8 7.1 9.6 12.0 10.3 16.0 10.0 8.1 12.3 13.6 18.0 22.5 8.8 12.5 11.0 11.2 9.5 12.5 10.8 7.7 11.2 10.9 9.8 8.8 14.2 9.0 15.3 9.7 19.0 13.8 7.7 15.1 10.9 10.6 5.8 2.8 2.2 4.0 6.7 6.0 0.8 22.5 11.1 7.4 8.4 10.6 11.6 8.8 12.4 7.0 9.3 9.6 5.2 7.2 18.4 12.9 8.8 14.6 10.9 11.5 14.1 5.9 7.2 10.1 8.4 5.0 4.7 16.9 5.7 9.1 6.4 8.8 10.5 9.6 7.0 8.3 9.5 9.9 12.7 7.0 7.1 7.9 10.6 10.8 13.3 9.4 10.5 5.3 5.3 22.9 8.3 8.1 12.1 6.9 12.4 9.5 4.8 12.3 13.3 10.8 6.4 17.1 12.3 6.6 7.5 0.7 2.7 2.2 4.4 4.0 6.0 3.1 3.2 4.2 2.8 5.8 4.1 4.0 1.7 6.7 2.5 2.5 2.4 0.8 7.7 15.9 11.3 14.6 9.8 7.1 10.0 8.1 12.5 9.7 ATRX "JMS, MRX52, RAD54, XH2, XNP" ENSG00000085224 "ATRX, chromatin remodeler" P46100 X 77504878-77786269 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors" "DNA damage, DNA repair, Transcription, Transcription regulation" "Chromatin regulator, DNA-binding, Helicase, Hydrolase" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001906, CAB009372, HPA064684, CAB068176" Supported Supported "Nuclear bodies" "Nuclear bodies" "CAB009372: AB_2061023, CAB068176: , HPA001906: AB_1078249, HPA064684: " "unprognostic (1.77e-2)" "unprognostic (1.55e-1)" "unprognostic (6.65e-2)" "unprognostic (4.37e-2)" "unprognostic (1.67e-1)" "unprognostic (9.69e-2)" "unprognostic (8.11e-2)" "unprognostic (1.15e-2)" "unprognostic (6.04e-2)" "unprognostic (2.35e-2)" "unprognostic (1.09e-1)" "unprognostic (5.80e-2)" "unprognostic (5.14e-3)" "unprognostic (1.50e-1)" "unprognostic (6.19e-2)" "unprognostic (1.76e-2)" "unprognostic (2.24e-1)" 16.4 16.6 24.5 18.9 29.3 24.3 16.3 48.2 26.4 20.6 15.4 7.1 18.9 10.2 20.2 17.1 13.5 13.8 13.4 15.1 22.9 15.8 16.6 12.2 15.9 18.6 21.1 21.3 25.4 18.3 35.7 28.1 15.9 20.2 18.4 12.6 7.1 15.8 16.5 20.1 14.1 13.5 22.3 15.3 20.1 15.6 6.5 22.4 23.7 19.8 12.7 16.5 19.9 21.1 21.9 12.8 21.5 11.5 14.6 17.7 5.7 15.1 24.4 25.1 16.8 12.5 16.8 8.9 13.1 12.1 9.7 11.5 8.3 13.3 21.0 13.5 13.9 13.5 20.0 7.8 16.6 11.8 13.1 12.7 29.0 6.1 6.8 16.5 4.4 11.1 7.7 14.3 13.7 17.1 14.9 24.2 12.1 11.9 12.7 8.6 18.1 18.9 20.6 34.6 10.8 9.5 20.3 14.3 24.7 26.4 10.4 8.7 8.3 8.4 23.6 13.7 21.3 15.4 9.2 7.2 22.3 18.9 10.1 13.1 12.1 21.3 6.9 13.8 17.7 8.7 17.1 19.2 16.3 13.7 5.1 21.9 16.8 13.5 21.5 14.6 11.5 12.8 12.8 5.7 24.5 29.3 48.2 26.4 22.9 15.8 21.1 21.3 20.2 22.4 AURKA "AIK, ARK1, AurA, BTAK, PPP1R47, STK15, STK6, STK7" ENSG00000087586 "Aurora kinase A" O14965 20 56369389-56392337 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division, Cilium biogenesis/degradation, Mitosis" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "lymphoid tissue: 32.3;testis: 41.1" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB001454, HPA002636" Enhanced Approved Nucleoplasm,Centrosome,Cytosol "Nucleoplasm, Centrosome, Cytosol" "CAB001454: AB_563420, HPA002636: AB_1845217" "unprognostic (7.73e-2)" "unprognostic (2.46e-2)" "unprognostic (2.76e-2)" "prognostic unfavourable (9.40e-5)" "unprognostic (1.92e-1)" "unprognostic (2.11e-2)" "prognostic unfavourable (1.49e-4)" "unprognostic (4.69e-3)" "unprognostic (2.42e-1)" "unprognostic (6.88e-2)" "prognostic unfavourable (6.13e-4)" "unprognostic (1.40e-1)" "prognostic unfavourable (1.47e-8)" "unprognostic (1.67e-1)" "unprognostic (6.83e-2)" "unprognostic (9.00e-2)" "unprognostic (5.14e-2)" 3.7 2.3 1.5 12.7 1.3 8.3 3.0 1.3 1.8 1.4 6.7 1.3 0.8 7.3 1.8 1.2 7.7 1.1 3.7 4.1 1.1 1.1 2.4 5.1 2.9 12.3 1.6 0.9 8.3 1.4 0.3 0.7 6.1 1.5 1.0 8.3 1.5 2.7 0.5 6.9 2.1 7.2 2.7 1.3 7.4 4.3 41.1 1.1 32.3 1.2 5.9 13.3 2.4 2.4 3.9 5.2 6.0 8.7 2.0 6.6 2.6 32.5 24.0 16.1 11.3 0.9 2.1 20.4 26.7 12.5 64.7 27.3 67.2 22.8 10.7 18.4 10.9 26.3 28.5 17.9 69.0 9.6 10.9 19.0 24.6 41.8 0.5 25.4 26.8 1.0 1.9 22.4 20.1 15.1 21.5 8.5 27.5 33.2 15.2 19.7 14.7 24.8 11.6 31.1 11.8 10.3 8.6 13.9 7.5 37.3 43.0 17.9 25.5 15.9 8.6 28.1 27.9 15.5 37.6 11.9 13.8 18.5 15.2 14.8 23.2 0.2 5.3 6.0 1.9 8.7 2.9 3.9 3.3 1.9 5.2 1.4 1.5 1.5 3.7 2.0 4.8 1.2 6.6 2.6 1.5 1.3 1.3 1.8 1.1 1.1 1.6 0.9 1.5 1.1 AURKB "Aik2, AIM-1, ARK2, AurB, IPL1, PPP1R48, STK12, STK5" ENSG00000178999 "Aurora kinase B" Q96GD4 17 8204733-8210600 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Cell cycle, Cell division, Mitosis" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 19.7;lymphoid tissue: 59.9" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Cell type enhanced" "Detected in many" "T-reg: 10.9" "Lineage enriched" "Detected in many" 5 "T-cells: 10.9" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" "CAB005862, HPA037708" Enhanced Supported Nucleoplasm,Midbody "Nucleoplasm, Midbody" "CAB005862: AB_449204, HPA037708: " "unprognostic (4.76e-2)" "unprognostic (3.61e-3)" "unprognostic (2.25e-1)" "unprognostic (3.14e-2)" "unprognostic (2.27e-1)" "unprognostic (6.05e-2)" "prognostic unfavourable (1.24e-4)" "unprognostic (1.99e-3)" "unprognostic (9.41e-3)" "unprognostic (3.47e-2)" "unprognostic (4.61e-3)" "unprognostic (1.01e-2)" "prognostic unfavourable (0.00e+0)" "unprognostic (7.77e-2)" "unprognostic (2.93e-1)" "unprognostic (6.76e-2)" "unprognostic (3.77e-1)" 1.2 1.3 0.4 22.1 0.6 19.7 2.0 0.6 0.6 2.6 5.8 0.5 0.9 5.9 0.9 1.3 17.1 0.3 2.2 1.0 0.4 0.2 1.4 1.8 2.4 17.8 0.4 0.4 0.8 0.6 0.0 0.4 3.8 0.8 0.9 5.5 0.7 2.7 0.4 2.1 5.0 8.1 1.3 0.7 11.2 4.2 1.2 0.4 59.9 0.5 8.0 19.1 2.1 5.0 2.3 0.8 1.2 0.6 0.5 10.9 1.4 41.0 28.2 42.0 20.2 0.9 1.4 16.1 19.7 10.6 40.8 37.7 36.5 12.4 41.0 10.2 7.8 30.2 30.5 13.5 33.8 18.0 50.1 24.4 16.1 30.8 0.1 12.9 24.0 0.7 0.6 23.9 15.0 18.8 15.2 15.9 17.9 19.5 46.8 18.3 26.1 12.6 31.7 38.7 17.0 8.9 8.1 9.1 13.0 17.5 7.9 13.4 13.8 8.7 7.3 16.4 16.9 14.7 51.2 11.6 7.7 30.8 7.9 19.6 33.1 0.0 0.6 0.9 0.6 0.4 0.2 1.6 1.9 3.1 0.8 2.3 0.2 1.0 1.2 0.5 0.3 0.2 10.9 1.4 0.4 0.6 0.6 0.6 0.4 0.2 0.4 0.4 0.8 0.4 AXIN1 PPP1R49 ENSG00000103126 "Axin 1" O15169 16 287440-352673 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Apoptosis, Wnt signaling pathway" "Developmental protein" "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB012987 Approved Supported Nucleoli,Vesicles "Nucleoli, Vesicles" "CAB012987: AB_2533178" "unprognostic (3.81e-2)" "unprognostic (1.56e-1)" "unprognostic (1.90e-1)" "unprognostic (7.64e-2)" "unprognostic (1.90e-1)" "unprognostic (1.06e-1)" "prognostic unfavourable (3.38e-5)" "unprognostic (1.23e-1)" "unprognostic (3.58e-1)" "unprognostic (1.56e-1)" "unprognostic (4.58e-2)" "unprognostic (2.02e-2)" "unprognostic (1.57e-1)" "unprognostic (4.41e-2)" "unprognostic (1.94e-1)" "unprognostic (1.23e-2)" "unprognostic (1.03e-1)" 10.8 8.3 13.7 18.9 17.1 28.1 21.0 26.4 13.6 10.4 15.8 12.7 9.4 17.3 12.6 8.5 14.1 10.7 12.7 11.0 11.5 7.7 9.8 9.6 13.6 13.4 15.6 10.6 13.3 17.7 11.1 11.9 8.4 13.9 11.4 10.2 9.6 13.9 9.5 17.7 16.9 17.6 18.9 9.6 15.1 15.2 9.6 14.6 17.5 12.7 7.5 14.5 11.9 22.9 1.8 1.4 5.5 1.1 3.6 10.4 2.4 9.4 13.8 7.3 12.9 5.5 5.1 15.5 6.4 5.9 8.9 7.7 20.2 11.1 14.7 9.9 6.6 13.7 11.5 10.0 4.0 14.4 18.8 9.5 11.5 14.7 9.4 10.9 10.6 5.0 17.5 9.2 11.3 5.8 23.7 8.1 4.0 25.4 11.7 7.6 16.8 8.4 22.2 6.7 20.4 6.7 5.6 16.8 10.3 12.2 13.7 20.1 9.0 13.9 6.6 8.9 9.5 10.2 9.2 9.4 9.2 18.0 4.2 7.3 8.7 1.4 1.1 5.5 10.4 0.9 9.5 1.8 3.0 7.0 0.8 1.6 3.2 4.3 3.2 3.6 0.7 1.4 3.0 2.4 13.7 17.1 26.4 13.6 11.5 7.7 15.6 10.6 13.9 14.6 AXIN2 "DKFZp781B0869, MGC126582" ENSG00000168646 "Axin 2" Q9Y2T1 17 65528563-65561647 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Wnt signaling pathway" "Developmental protein" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "AF22: 13.3;CACO-2: 24.7;Hep G2: 36.9" "Cancer enhanced" "Detected in all" "colorectal cancer: 33.4" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "naive CD4 T-cell: 5.1" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB012283, CAB017783" Approved Uncertain "Nucleoplasm,Plasma membrane,Cytosol" "Nucleoplasm, Plasma membrane" Cytosol "CAB012283: AB_2290204, CAB017783: " "unprognostic (1.31e-2)" "unprognostic (1.29e-1)" "unprognostic (1.05e-2)" "unprognostic (3.45e-3)" "unprognostic (4.48e-1)" "unprognostic (9.81e-2)" "unprognostic (1.12e-2)" "unprognostic (1.82e-1)" "unprognostic (4.57e-2)" "unprognostic (8.84e-3)" "prognostic favourable (6.58e-4)" "unprognostic (1.98e-1)" "unprognostic (1.42e-1)" "unprognostic (3.45e-2)" "unprognostic (2.10e-1)" "unprognostic (2.74e-1)" "unprognostic (1.25e-1)" 7.4 10.1 9.0 7.0 8.9 0.9 5.2 8.2 13.1 16.5 12.2 8.7 10.5 7.2 29.0 7.7 6.5 18.6 6.9 7.3 7.9 5.7 3.5 2.5 15.2 3.4 5.3 10.3 14.7 3.9 3.2 5.8 18.2 10.6 14.8 15.2 7.8 4.6 9.8 12.4 14.9 7.5 18.0 4.8 6.9 14.6 6.8 9.0 27.6 11.3 3.6 3.8 11.8 8.7 4.1 0.0 4.4 0.0 1.9 5.1 0.8 0.0 6.6 13.3 0.2 4.8 2.0 5.9 0.2 0.6 0.4 0.8 24.7 2.4 0.4 0.8 3.8 0.2 2.7 0.0 0.9 1.1 1.5 0.0 1.1 36.9 0.5 0.0 0.0 1.2 1.0 1.0 0.3 1.1 0.1 0.6 0.6 0.1 6.4 0.0 2.6 0.3 4.6 0.7 0.0 1.2 0.1 4.1 2.7 0.2 0.1 2.3 0.4 0.1 3.0 2.6 4.8 3.7 0.8 0.0 1.3 1.7 1.2 0.3 1.2 4.4 0.0 0.0 0.3 0.0 0.8 1.0 2.3 0.4 0.0 4.1 5.1 0.8 0.0 1.9 0.0 0.0 0.0 0.8 9.0 8.9 8.2 13.1 7.9 5.7 5.3 10.3 10.6 9.0 AZGP1 "ZA2G, ZAG" ENSG00000160862 "Alpha-2-glycoprotein 1, zinc-binding" P25311 7 99966720-99976157 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 158.8;salivary gland: 270.5" "Cell line enhanced" "Detected in some" "Hep G2: 19.8;Karpas-707: 11.3;RPMI-8226: 45.9;SK-BR-3: 9.3;T-47d: 15.4" "Group enriched" "Detected in many" 12 "breast cancer: 412.6;liver cancer: 273.6;prostate cancer: 469.5" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in single" 4 "olfactory region: 0.9" "HPA012582, CAB016087, CAB032276" Enhanced "Secreted to blood" 55210000000 160000000000 "CAB016087: AB_667849, CAB032276: AB_2062580, HPA012582: AB_1845226" "unprognostic (8.14e-2)" "unprognostic (1.50e-1)" "unprognostic (3.41e-1)" "unprognostic (5.42e-3)" "unprognostic (4.98e-2)" "unprognostic (5.74e-3)" "prognostic favourable (2.90e-4)" "unprognostic (1.50e-1)" "unprognostic (1.85e-1)" "unprognostic (2.19e-1)" "unprognostic (2.35e-2)" "unprognostic (1.79e-1)" "prognostic favourable (1.53e-4)" "unprognostic (2.18e-1)" "unprognostic (2.08e-2)" "unprognostic (9.80e-2)" "unprognostic (3.51e-3)" 6.4 0.0 1.1 1.3 1.7 0.0 64.1 1.1 1.4 1.1 1.4 1.5 0.9 1.4 0.9 1.2 1.3 0.0 2.2 9.0 1.2 0.4 18.0 158.8 3.0 0.9 2.7 1.2 1.0 55.3 0.0 0.9 1.0 1.3 62.4 0.0 1.6 270.5 2.5 1.0 11.5 1.5 0.9 1.1 0.9 14.4 1.2 1.7 0.9 1.0 3.0 3.2 1.0 1.6 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.3 0.0 2.0 0.0 0.0 0.0 0.0 0.0 1.4 5.1 0.2 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 19.8 1.9 0.5 0.0 0.2 0.0 0.0 0.0 0.0 0.1 11.3 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.6 45.9 0.0 0.0 0.0 0.7 0.3 9.3 4.5 15.4 0.0 0.0 0.1 0.0 0.7 0.3 0.7 0.3 0.1 0.0 0.1 5.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 1.1 1.7 1.1 1.4 1.2 0.4 2.7 1.2 1.3 1.7 B2M ENSG00000166710 Beta-2-microglobulin P61769 15 44711477-44718877 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" Immunity "Amyloidosis, Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "THP-1: 175.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002572, HPA006361" Enhanced Enhanced "Golgi apparatus,Plasma membrane,Cytosol" "Intracellular and membrane" 3200000000 "Golgi apparatus, Plasma membrane" Cytosol "CAB002572: AB_563434, HPA006361: AB_1078278" "unprognostic (9.45e-2)" "unprognostic (5.63e-2)" "unprognostic (3.02e-1)" "unprognostic (8.14e-2)" "unprognostic (1.18e-1)" "unprognostic (4.82e-2)" "unprognostic (1.81e-2)" "unprognostic (1.25e-1)" "unprognostic (2.69e-2)" "unprognostic (1.12e-1)" "unprognostic (2.44e-3)" "unprognostic (2.02e-2)" "unprognostic (4.77e-2)" "unprognostic (2.39e-1)" "unprognostic (5.25e-2)" "unprognostic (1.97e-2)" "unprognostic (2.17e-2)" 127.2 50.9 24.2 109.2 29.8 131.1 85.2 11.8 23.1 70.5 111.4 29.1 43.3 79.1 72.7 74.7 80.5 36.8 112.8 73.6 26.0 23.1 109.7 140.3 191.2 172.1 42.2 18.8 54.8 42.7 7.8 40.5 91.9 33.1 78.7 128.9 53.5 121.5 40.9 45.7 94.1 178.5 55.1 56.7 272.8 52.5 30.0 29.5 108.0 97.7 71.5 131.6 135.9 73.5 138.9 74.9 341.3 132.8 128.8 215.8 323.7 33.1 14.7 1.4 8.3 54.6 73.6 52.1 22.0 44.9 35.8 60.9 19.1 77.4 15.8 31.1 21.4 29.3 5.5 9.8 17.2 110.7 13.0 60.2 89.2 22.1 41.6 33.7 36.1 37.2 9.1 11.0 11.8 24.4 15.3 2.2 39.6 17.7 13.8 89.0 2.4 31.4 16.8 36.0 100.3 31.2 137.5 5.8 2.1 23.0 18.7 25.9 6.2 175.3 48.5 70.3 7.8 92.6 42.9 41.0 93.8 29.5 68.5 111.3 33.6 221.2 90.4 210.9 126.8 132.8 125.9 138.9 171.7 141.1 58.9 109.4 137.0 167.5 341.3 128.8 106.5 74.9 215.8 323.7 24.2 29.8 11.8 23.1 26.0 23.1 42.2 18.8 33.1 29.5 BAD "BBC2, BCL2L8" ENSG00000002330 "BCL2 associated agonist of cell death" Q92934 11 64269830-64284704 "Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins" Apoptosis "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004205, HPA028185, HPA062105" Approved Enhanced Mitochondria Mitochondria "CAB004205: AB_626717, HPA028185: AB_10603445, HPA062105: " "unprognostic (1.47e-1)" "unprognostic (3.08e-2)" "unprognostic (1.17e-1)" "unprognostic (8.24e-3)" "unprognostic (2.60e-1)" "unprognostic (6.73e-2)" "unprognostic (1.24e-3)" "unprognostic (1.07e-1)" "unprognostic (1.99e-1)" "unprognostic (1.10e-1)" "unprognostic (1.36e-1)" "unprognostic (1.14e-1)" "unprognostic (8.26e-2)" "unprognostic (9.04e-2)" "unprognostic (2.17e-1)" "unprognostic (1.48e-1)" "unprognostic (7.95e-2)" 23.1 23.2 35.3 12.6 30.7 17.7 20.6 15.9 43.9 21.2 25.7 22.7 20.1 24.0 18.3 19.7 18.8 23.2 22.5 30.3 32.7 23.8 21.4 22.3 17.7 14.3 29.6 20.2 18.8 26.9 19.4 15.2 24.9 18.4 22.9 13.6 23.1 39.9 27.0 23.9 20.4 21.1 17.2 22.9 14.9 37.8 18.6 14.8 19.3 29.2 15.8 14.1 18.2 14.4 26.5 42.0 43.5 32.3 24.0 30.7 23.1 31.9 30.1 8.8 13.2 10.7 13.1 12.9 13.6 15.9 21.0 16.7 18.3 18.4 6.9 24.5 12.7 17.0 5.7 21.4 4.2 26.7 21.0 8.5 27.2 8.7 16.5 7.4 16.0 12.6 18.5 16.1 9.9 13.2 3.2 14.9 9.1 31.8 16.5 16.7 3.4 38.5 15.7 5.2 19.3 12.7 15.1 18.2 24.4 13.7 16.3 16.6 24.5 11.1 10.9 25.7 17.4 39.8 14.9 28.3 21.0 7.0 21.0 5.3 14.0 32.5 32.3 43.5 25.3 24.0 25.8 26.0 26.9 24.6 22.5 26.5 19.4 20.0 41.7 24.0 22.6 42.0 30.7 23.1 35.3 30.7 15.9 43.9 32.7 23.8 29.6 20.2 18.4 14.8 BAG1 ENSG00000107262 "BCL2 associated athanogene 1" Q99933 9 33247820-33264720 "Cancer-related genes, Predicted intracellular proteins" Apoptosis Chaperone "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HeLa: 81.3;NB-4: 77.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002486, HPA018121" Supported Supported Nucleoplasm Nucleoplasm "CAB002486: AB_563422, HPA018121: AB_1845255" "unprognostic (4.49e-3)" "unprognostic (4.52e-2)" "unprognostic (2.33e-2)" "unprognostic (1.32e-3)" "unprognostic (5.46e-2)" "unprognostic (3.67e-3)" "unprognostic (2.10e-1)" "unprognostic (1.34e-2)" "unprognostic (4.62e-2)" "unprognostic (7.21e-2)" "unprognostic (4.24e-1)" "unprognostic (2.23e-1)" "prognostic favourable (2.22e-16)" "unprognostic (4.45e-2)" "unprognostic (4.03e-1)" "unprognostic (7.64e-3)" "unprognostic (1.07e-2)" 21.5 22.1 30.0 14.6 34.3 25.2 28.6 21.2 25.0 21.4 32.0 18.3 19.5 20.8 15.5 20.4 26.9 17.4 34.8 48.6 25.0 24.3 41.9 34.5 21.2 14.1 33.8 20.1 14.4 43.2 40.9 24.9 16.6 20.0 24.7 27.7 18.2 38.5 26.4 93.2 26.7 27.2 22.2 27.7 21.4 32.5 46.0 20.5 14.9 29.7 41.9 21.2 30.8 27.3 10.2 18.8 29.4 11.6 8.2 9.0 5.1 10.4 10.4 8.9 19.5 13.6 8.0 12.4 8.5 12.2 13.1 13.5 7.3 10.1 34.7 6.4 8.6 13.2 10.3 7.0 8.7 17.5 9.7 17.3 81.3 11.4 11.5 39.5 21.1 8.1 39.3 6.1 14.8 15.5 19.9 17.4 10.8 16.4 27.0 77.7 17.2 15.3 14.2 12.7 22.3 16.6 30.6 28.5 17.1 38.0 33.5 8.5 15.2 48.2 8.2 5.9 7.5 17.2 14.8 13.9 21.5 18.8 4.9 21.4 3.3 12.2 11.5 29.4 5.8 11.6 5.2 6.8 6.6 6.9 14.0 10.2 9.0 5.4 7.0 8.2 11.2 18.8 7.8 5.1 30.0 34.3 21.2 25.0 25.0 24.3 33.8 20.1 20.0 20.5 BAP1 "hucep-6, KIAA0272, UCHL2" ENSG00000163930 "BRCA1 associated protein 1" Q92560 3 52401013-52410350 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Ubl conjugation pathway" "Chromatin regulator, Hydrolase, Protease, Thiol protease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004322, HPA028814, HPA028815, HPA055560" Approved Enhanced Nucleoplasm,Cytosol Nucleoplasm Cytosol "CAB004322: AB_626723, HPA028814: AB_10602393, HPA028815: , HPA055560: " "unprognostic (1.52e-1)" "unprognostic (7.96e-2)" "unprognostic (1.96e-2)" "unprognostic (6.04e-2)" "unprognostic (1.74e-1)" "unprognostic (2.55e-2)" "unprognostic (9.41e-3)" "unprognostic (8.53e-3)" "unprognostic (1.33e-1)" "unprognostic (3.15e-1)" "unprognostic (4.64e-3)" "unprognostic (3.30e-3)" "prognostic favourable (3.29e-7)" "unprognostic (6.37e-2)" "unprognostic (1.91e-1)" "unprognostic (5.54e-2)" "unprognostic (2.92e-1)" 13.8 17.6 35.6 14.7 33.3 37.3 13.5 21.8 50.4 12.5 17.0 16.3 11.5 12.4 14.7 14.6 21.2 12.1 15.7 16.4 41.5 15.5 16.6 19.0 14.9 15.2 19.4 27.6 16.9 16.3 30.0 11.1 14.8 19.6 14.4 14.9 15.6 17.9 14.6 24.8 40.5 13.9 14.5 10.0 16.1 13.3 37.3 14.7 18.6 15.3 12.9 16.0 14.1 11.7 5.5 8.4 11.3 5.0 3.0 8.5 3.9 15.3 17.5 21.2 18.0 20.5 13.2 23.9 15.2 19.7 24.7 19.2 21.1 14.4 22.0 7.6 21.2 12.5 22.3 24.5 15.8 21.8 21.1 27.3 37.0 21.8 19.1 25.6 24.3 19.7 32.9 27.3 14.7 19.7 23.3 19.5 18.6 13.3 30.3 35.1 23.9 21.3 13.1 17.2 21.7 15.2 24.9 8.1 26.1 18.7 5.4 22.2 15.3 35.4 21.1 22.4 20.6 26.8 28.2 29.6 38.9 31.5 24.4 27.0 26.4 3.4 5.0 7.4 8.5 3.9 4.0 5.0 6.8 6.9 3.3 5.5 4.9 6.4 11.3 3.0 3.1 8.4 6.0 3.9 35.6 33.3 21.8 50.4 41.5 15.5 19.4 27.6 19.6 14.7 BARD1 ENSG00000138376 "BRCA1 associated RING domain 1" Q99728 2 214725646-214809711 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA repair, Ubl conjugation pathway" Transferase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" "CAB034106, HPA035354, HPA044864" Enhanced Supported "Nuclear speckles,Cytoplasmic bodies" "Nuclear speckles" "Cytoplasmic bodies" "CAB034106: AB_2061237, HPA035354: , HPA044864: " "unprognostic (4.85e-2)" "unprognostic (1.87e-2)" "unprognostic (1.74e-2)" "unprognostic (8.37e-3)" "unprognostic (2.57e-2)" "unprognostic (1.03e-2)" "unprognostic (6.25e-4)" "unprognostic (1.99e-1)" "unprognostic (2.16e-2)" "unprognostic (3.92e-3)" "unprognostic (2.80e-2)" "unprognostic (7.41e-2)" "unprognostic (1.94e-8)" "unprognostic (3.94e-2)" "unprognostic (2.28e-1)" "unprognostic (1.57e-1)" "unprognostic (1.08e-1)" 4.4 1.9 3.2 11.8 4.8 16.1 4.9 1.2 5.8 7.3 5.4 5.4 3.6 3.7 6.8 5.0 10.0 4.1 3.9 3.6 3.4 2.8 2.2 2.1 5.3 8.2 5.1 1.9 5.8 3.7 3.6 6.3 3.8 4.5 5.7 6.1 1.9 4.7 6.5 12.4 16.3 4.5 7.5 5.3 4.7 3.8 9.5 3.9 25.8 4.0 8.0 9.9 8.3 7.8 9.7 6.6 6.0 3.4 6.1 16.0 2.0 7.7 4.3 11.7 6.0 1.6 2.0 8.0 9.4 5.5 9.3 10.7 5.4 7.7 8.3 4.5 3.9 8.5 8.4 5.5 13.3 6.6 4.4 8.3 7.9 5.7 0.6 9.2 8.4 2.7 0.8 8.2 4.5 3.1 4.6 23.5 8.9 6.4 16.5 9.6 9.2 2.2 14.3 11.8 7.5 2.7 6.5 3.7 5.9 8.6 9.9 3.4 10.2 9.2 2.7 12.0 8.4 7.0 8.5 7.1 7.9 16.9 4.8 7.0 8.0 2.9 1.7 6.0 4.8 3.4 3.1 8.9 5.3 5.2 3.0 9.7 2.5 3.6 0.5 6.1 2.9 6.6 16.0 2.0 3.2 4.8 1.2 5.8 3.4 2.8 5.1 1.9 4.5 3.9 BAX BCL2L4 ENSG00000087088 "BCL2 associated X, apoptosis regulator" Q07812 19 48954815-48961798 "Cancer-related genes, Predicted intracellular proteins, Transporters" "Apoptosis, Host-virus interaction" "Cancer-related genes, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004206, HPA027878" Approved 1300000 "CAB004206: AB_626729, HPA027878: AB_10601687" "unprognostic (4.11e-2)" "unprognostic (4.70e-2)" "unprognostic (1.50e-1)" "unprognostic (6.23e-2)" "unprognostic (1.70e-1)" "unprognostic (2.82e-1)" "prognostic unfavourable (1.63e-5)" "unprognostic (4.92e-2)" "unprognostic (1.09e-1)" "unprognostic (4.71e-2)" "unprognostic (3.66e-2)" "unprognostic (8.10e-2)" "unprognostic (1.19e-2)" "unprognostic (7.83e-2)" "unprognostic (1.08e-1)" "unprognostic (4.47e-3)" "unprognostic (6.22e-2)" 15.2 20.0 12.3 26.0 13.2 25.3 20.2 7.6 13.6 14.9 33.3 15.1 13.5 30.7 19.3 11.2 21.4 15.5 40.4 14.9 11.3 10.2 19.5 26.1 26.6 25.9 18.7 12.5 16.4 16.2 8.8 10.0 21.5 14.9 16.6 27.8 10.3 16.5 13.3 11.6 17.1 28.7 16.3 15.1 37.8 19.6 10.7 13.2 37.8 17.7 16.3 26.5 19.1 19.5 6.6 10.6 11.1 16.5 9.1 6.4 6.6 34.0 56.6 34.3 30.0 34.2 33.6 56.5 23.3 46.7 30.6 43.0 15.0 33.4 41.6 10.9 35.5 18.5 15.5 45.3 25.5 32.1 35.8 17.7 11.5 55.4 55.0 18.4 56.9 45.9 32.5 25.4 15.3 70.5 17.3 17.1 52.6 24.1 29.8 28.9 26.5 16.2 21.0 22.7 16.0 32.2 33.1 19.7 23.3 19.5 14.0 10.7 11.2 33.3 41.3 39.6 43.0 24.1 31.8 19.7 25.1 27.0 24.0 25.1 54.6 4.3 10.4 10.5 6.0 15.3 4.3 6.6 3.4 6.4 10.4 5.8 2.3 5.3 11.1 9.1 16.5 10.6 6.3 6.6 12.3 13.2 7.6 13.6 11.3 10.2 18.7 12.5 14.9 13.2 BCL10 "c-E10, CARMEN, CIPER, CLAP, mE10" ENSG00000142867 "B cell CLL/lymphoma 10" O95999 1 85266248-85277090 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Apoptosis, Immunity" "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HUVEC TERT2: 40.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB001944, HPA017925" Approved Approved Nucleoplasm Nucleoplasm "CAB001944: , HPA017925: AB_1845312" "unprognostic (3.78e-3)" "unprognostic (2.53e-1)" "prognostic favourable (2.51e-4)" "unprognostic (1.61e-1)" "unprognostic (3.47e-1)" "unprognostic (2.61e-2)" "prognostic unfavourable (7.21e-7)" "unprognostic (7.06e-2)" "unprognostic (2.36e-1)" "unprognostic (9.46e-2)" "unprognostic (1.27e-2)" "unprognostic (1.73e-1)" "unprognostic (4.92e-3)" "unprognostic (3.18e-2)" "unprognostic (1.06e-1)" "unprognostic (1.63e-1)" "unprognostic (1.07e-1)" 17.2 10.7 5.8 16.4 6.0 19.6 20.7 5.8 8.6 14.7 21.5 7.5 9.5 12.2 14.8 10.0 29.0 8.5 16.7 7.5 5.9 5.4 11.9 11.4 20.4 21.5 6.5 5.2 11.6 9.1 5.4 6.3 11.8 5.9 11.6 20.4 6.4 11.8 12.4 5.0 14.6 27.6 9.9 6.1 18.5 13.0 8.5 5.1 18.3 11.3 12.7 22.1 14.3 17.6 22.4 14.2 37.5 18.2 10.4 13.3 9.0 15.7 3.3 4.6 4.9 6.6 9.8 7.8 12.1 11.0 8.8 12.2 4.0 6.4 7.1 8.6 9.5 8.6 5.2 12.9 12.8 6.0 4.0 7.4 3.3 5.5 10.3 7.3 7.0 7.8 14.3 13.1 11.7 40.0 5.3 6.4 14.7 3.0 7.0 6.0 8.0 11.2 5.0 10.5 4.5 30.6 12.2 3.1 4.1 3.7 12.5 11.5 4.2 5.0 19.9 9.1 6.4 11.1 12.0 5.2 2.8 6.9 4.5 6.4 6.2 25.2 15.1 20.1 10.0 18.2 11.1 22.4 13.1 11.3 14.2 20.3 12.4 11.4 37.5 10.4 13.5 12.0 13.3 9.0 5.8 6.0 5.8 8.6 5.9 5.4 6.5 5.2 5.9 5.1 BCL11A "BCL11A-L, BCL11A-S, BCL11A-XL, CTIP1, EVI9, HBFQTL5, ZNF856" ENSG00000119866 "B cell CLL/lymphoma 11A" Q9H165 2 60450520-60555154 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" Repressor "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 107.1" "Cell line enhanced" "Detected in some" "Daudi: 20.3;MOLT-4: 18.7;REH: 19.1;U-698: 41.8;U-937: 13.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 6 "memory B-cell: 39.6;naive B-cell: 53.7;plasmacytoid DC: 107.1" "Group enriched" "Detected in many" 16 "B-cells: 53.7;dendritic cells: 107.1" "Group enriched" "Detected in all" 5 "amygdala: 42.3;basal ganglia: 57.1;cerebral cortex: 62.7;hippocampal formation: 65.3;olfactory region: 101.8" "Group enriched" "Detected in all" 4 "basal ganglia: 58.3;cerebral cortex: 93.2;hippocampal formation: 97.2;olfactory region: 128.9" "CAB014891, HPA029003" Enhanced Supported "Nucleoplasm,Nuclear bodies" Nucleoplasm "Nuclear bodies" "CAB014891: , HPA029003: " "unprognostic (4.10e-3)" "unprognostic (6.72e-2)" "unprognostic (4.50e-2)" "unprognostic (9.41e-3)" "unprognostic (2.37e-1)" "unprognostic (4.47e-3)" "unprognostic (2.53e-2)" "unprognostic (1.68e-2)" "unprognostic (1.02e-1)" "unprognostic (2.45e-1)" "unprognostic (4.27e-4)" "unprognostic (1.23e-2)" "unprognostic (2.35e-2)" "unprognostic (3.59e-2)" "unprognostic (2.26e-1)" "unprognostic (4.40e-2)" "unprognostic (2.99e-2)" 1.5 2.4 6.6 13.9 14.6 17.0 5.5 1.8 34.5 3.9 8.6 0.2 0.1 7.6 1.8 1.4 13.6 4.8 2.2 4.7 14.5 3.4 1.7 1.5 3.0 21.2 3.5 14.4 1.6 11.3 1.2 3.9 0.9 9.6 4.8 5.1 0.0 11.4 2.0 1.4 24.9 11.4 2.9 2.0 13.5 3.3 2.0 2.6 20.9 2.4 4.0 30.4 3.6 7.8 53.7 107.1 1.3 5.1 1.0 0.1 1.2 0.2 0.0 1.7 0.0 0.3 0.3 0.1 0.6 0.0 0.0 0.0 0.0 0.0 20.3 0.1 0.0 4.1 6.3 3.0 0.0 0.3 6.0 0.0 0.2 0.1 0.0 7.3 0.0 0.7 1.6 0.0 1.0 1.0 0.3 0.1 0.0 0.0 18.7 7.4 11.5 0.1 19.1 0.5 7.7 0.0 0.3 8.2 2.0 0.1 0.1 0.1 0.1 3.5 0.5 0.1 4.8 0.1 0.0 0.3 0.0 41.8 0.0 13.4 0.6 0.4 2.9 0.5 0.0 5.1 0.1 39.6 0.0 0.0 10.7 53.7 0.1 0.1 1.3 1.0 3.7 107.1 0.1 1.2 6.6 14.6 1.8 34.5 14.5 3.4 3.5 14.4 9.6 2.6 BCL11B "CTIP-2, CTIP2, hRIT1-alpha, ZNF856B" ENSG00000127152 "B cell CLL/lymphoma 11B" Q9C0K0 14 99169287-99271524 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" Repressor "Cancer-related genes, Disease mutation, Mental retardation, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 13.7;lymphoid tissue: 25.4;skin 1: 17.6" "Cell line enriched" "Detected in some" 6 "MOLT-4: 32.6" "Low cancer specificity" "Detected in many" "Region enhanced" "Detected in many" "basal ganglia: 13.7" "Group enriched" "Detected in many" 8 "gdT-cell: 3.3;MAIT T-cell: 3.0;memory CD4 T-cell: 4.5;memory CD8 T-cell: 3.7;naive CD4 T-cell: 7.4;naive CD8 T-cell: 4.9;T-reg: 3.0" "Lineage enriched" "Detected in single" 14 "T-cells: 7.4" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA049117 Enhanced Supported Approved "Nucleoplasm,Nucleoli fibrillar center" Nucleoplasm "Nucleoli fibrillar center" "HPA049117: AB_2680639" "unprognostic (1.64e-5)" "unprognostic (4.66e-2)" "unprognostic (2.35e-2)" "unprognostic (1.87e-2)" "unprognostic (9.37e-2)" "unprognostic (5.97e-2)" "unprognostic (4.75e-2)" "unprognostic (6.07e-2)" "unprognostic (1.74e-1)" "unprognostic (1.40e-2)" "unprognostic (1.90e-1)" "unprognostic (1.12e-1)" "unprognostic (1.60e-6)" "unprognostic (1.07e-3)" "unprognostic (1.61e-1)" "unprognostic (3.31e-3)" "prognostic favourable (7.48e-4)" 0.3 0.4 4.4 6.6 13.7 5.2 1.3 0.3 3.8 0.8 1.3 0.1 0.0 2.3 1.9 0.8 3.9 0.3 3.0 0.8 4.8 1.0 0.3 0.5 1.1 10.8 0.8 2.6 0.2 0.1 0.0 0.1 0.0 0.6 0.6 1.7 0.3 5.0 0.7 0.1 17.6 3.0 0.2 0.7 4.9 2.1 0.4 1.6 25.4 0.9 1.5 8.8 2.0 2.3 0.0 0.0 0.1 0.0 0.5 7.4 1.1 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.3 1.2 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 1.3 0.0 0.1 0.0 0.0 3.0 0.0 1.8 32.6 0.5 0.3 0.0 5.1 0.0 0.0 0.0 1.8 2.6 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.1 0.0 2.0 0.0 0.0 1.4 0.4 0.0 0.0 0.0 0.1 3.3 0.0 3.0 0.0 4.5 3.7 0.0 0.0 7.4 4.9 0.0 0.5 0.0 0.0 3.0 1.1 4.4 13.7 0.3 3.8 4.8 1.0 0.8 2.6 0.6 1.6 BCL2 "Bcl-2, PPP1R50" ENSG00000171791 "BCL2, apoptosis regulator" P10415 18 63123346-63320128 "Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" Apoptosis "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Karpas-707: 22.3;U-266/70: 77.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 6 "gdT-cell: 2.3;MAIT T-cell: 7.6;memory B-cell: 5.2;memory CD4 T-cell: 6.3;memory CD8 T-cell: 3.8;naive B-cell: 4.1;naive CD4 T-cell: 5.1;naive CD8 T-cell: 4.5;T-reg: 6.7" "Group enriched" "Detected in many" 8 "B-cells: 5.2;T-cells: 7.6" "Low region specificity" "Detected in all" "CAB000003, HPA055295" Enhanced Supported "Nucleoplasm,Nuclear membrane" "Nuclear membrane" Nucleoplasm "CAB000003: AB_2064429, HPA055295: " "unprognostic (1.11e-3)" "prognostic favourable (5.13e-5)" "unprognostic (5.49e-2)" "unprognostic (1.19e-1)" "unprognostic (1.89e-1)" "unprognostic (3.05e-3)" "unprognostic (2.88e-1)" "unprognostic (1.93e-3)" "unprognostic (4.78e-2)" "unprognostic (2.08e-1)" "unprognostic (2.23e-2)" "unprognostic (8.51e-2)" "prognostic favourable (1.29e-8)" "unprognostic (6.67e-2)" "unprognostic (1.19e-1)" "prognostic unfavourable (2.47e-4)" "unprognostic (2.63e-1)" 12.9 3.0 10.1 15.7 9.4 5.3 24.6 4.7 8.4 14.8 7.8 7.4 9.1 5.0 17.1 9.3 4.7 12.2 9.2 6.5 10.0 8.1 8.5 2.3 5.0 14.6 10.8 5.6 18.2 2.9 19.6 7.0 22.4 9.2 8.4 5.9 10.8 5.4 15.7 20.0 6.3 10.5 8.6 9.3 17.8 5.4 3.5 10.5 21.0 35.6 2.9 13.4 7.9 16.4 5.2 0.3 0.7 0.2 0.7 7.6 1.9 0.4 0.1 2.3 1.8 2.7 0.4 0.8 0.2 0.2 0.7 0.5 1.1 0.1 0.0 0.4 0.2 0.1 2.0 0.3 0.4 13.3 0.4 0.0 0.6 0.2 0.5 12.1 1.8 0.5 0.2 0.9 1.9 0.2 0.2 22.3 0.4 0.4 2.5 5.2 0.5 0.4 11.4 0.5 8.6 3.8 1.8 1.9 1.8 0.0 0.0 2.7 0.1 10.2 0.1 3.0 1.0 0.3 1.5 77.6 10.2 0.8 0.5 8.6 1.7 0.7 0.0 0.0 2.3 0.0 7.6 5.2 6.3 3.8 0.1 4.1 5.1 4.5 0.1 0.7 0.2 0.3 6.7 1.9 10.1 9.4 4.7 8.4 10.0 8.1 10.8 5.6 9.2 10.5 BCL2L1 "Bcl-X, bcl-xL, bcl-xS, BCL2L, BCLX, PPP1R52" ENSG00000171552 "BCL2 like 1" Q07817 20 31664452-31723989 "Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters" "Apoptosis, Endocytosis" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA035734, CAB072801" Approved Approved Mitochondria Mitochondria "CAB072801: , HPA035734: " "unprognostic (2.29e-1)" "unprognostic (5.40e-3)" "unprognostic (1.78e-2)" "prognostic unfavourable (9.10e-4)" "unprognostic (1.37e-1)" "unprognostic (1.09e-1)" "unprognostic (5.04e-2)" "unprognostic (7.82e-3)" "prognostic favourable (9.57e-4)" "unprognostic (1.67e-1)" "prognostic unfavourable (5.87e-4)" "unprognostic (1.06e-1)" "prognostic favourable (8.89e-5)" "unprognostic (9.67e-2)" "unprognostic (3.03e-2)" "unprognostic (2.02e-2)" "unprognostic (3.32e-2)" 30.8 21.4 25.1 16.4 34.3 57.0 40.7 27.7 40.7 28.2 22.6 37.0 13.0 31.3 18.7 12.2 36.9 31.5 35.9 26.9 27.0 23.7 42.6 39.3 40.6 17.8 43.4 24.3 11.5 28.5 17.5 22.8 29.0 33.4 24.8 21.4 31.5 33.8 21.5 21.9 26.1 30.4 19.2 28.8 26.6 28.0 30.2 38.4 56.4 25.8 15.4 20.7 24.5 22.4 3.9 7.8 17.0 8.9 12.5 27.2 16.5 62.7 37.4 6.9 6.6 37.3 27.0 22.1 15.0 24.6 15.7 15.1 88.2 30.5 10.3 38.4 21.7 21.2 9.2 42.5 11.1 10.8 2.4 47.0 8.0 43.9 27.9 4.7 27.9 19.3 17.7 19.9 43.3 22.5 29.1 7.9 53.2 17.9 13.8 4.5 9.5 33.4 8.7 20.8 32.6 64.5 17.5 18.0 8.4 18.4 18.2 8.6 36.2 5.4 31.1 19.9 23.0 7.9 27.0 5.2 29.1 8.5 29.3 20.7 12.5 17.0 8.1 15.4 27.2 8.2 21.0 3.9 12.4 18.1 7.8 3.7 5.7 13.0 9.8 12.5 8.9 4.7 13.8 16.5 25.1 34.3 27.7 40.7 27.0 23.7 43.4 24.3 33.4 38.4 BCL2L2 "BCL-W, KIAA0271, PPP1R51" ENSG00000129473 "BCL2 like 2" Q92843 14 23298790-23311759 "Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters" Apoptosis "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB040539, HPA048740" Approved Uncertain Nucleoplasm Nucleoplasm "CAB040539: , HPA048740: " "unprognostic (8.23e-3)" "unprognostic (9.85e-2)" "unprognostic (1.71e-2)" "unprognostic (6.08e-2)" "unprognostic (2.04e-1)" "unprognostic (1.64e-1)" "unprognostic (3.47e-3)" "unprognostic (1.53e-2)" "unprognostic (1.78e-1)" "unprognostic (2.91e-3)" "unprognostic (1.50e-3)" "unprognostic (2.60e-1)" "prognostic favourable (1.99e-6)" "unprognostic (2.44e-1)" "unprognostic (2.00e-1)" "unprognostic (6.60e-2)" "unprognostic (5.38e-2)" 29.9 22.8 38.2 15.6 33.6 7.4 25.1 27.3 44.8 13.7 32.3 27.4 21.9 19.4 19.0 20.6 32.8 16.6 17.6 23.8 36.2 32.9 22.3 9.0 18.6 8.6 43.3 39.5 17.5 30.6 34.1 16.5 15.1 32.8 31.8 20.4 15.0 36.5 31.9 10.6 29.2 19.0 34.8 40.9 11.3 22.3 14.9 28.1 1.2 25.6 11.8 10.1 23.0 23.2 1.3 1.8 0.6 1.8 0.1 0.3 1.3 11.8 12.7 11.6 8.4 22.3 19.5 10.5 21.4 13.1 10.7 11.7 7.8 18.8 7.7 7.7 11.7 21.9 7.2 13.4 13.4 3.9 6.8 8.4 17.0 15.3 13.9 9.2 15.1 15.1 26.5 8.0 12.9 9.0 8.3 7.5 12.6 8.9 0.7 6.2 4.4 24.9 5.5 14.2 3.4 9.3 20.1 15.3 9.2 9.6 15.4 17.4 9.7 7.4 17.4 19.0 11.9 12.9 11.0 9.7 5.8 1.1 12.0 7.6 21.5 0.0 1.8 0.4 0.3 1.8 0.2 1.3 0.0 0.2 1.8 1.0 0.3 0.0 0.6 0.1 1.0 0.9 0.1 1.3 38.2 33.6 27.3 44.8 36.2 32.9 43.3 39.5 32.8 28.1 BCL2L2-PABPN1 ENSG00000258643 "BCL2L2-PABPN1 readthrough" Q92843 14 23306835-23325369 "Cancer-related genes, Predicted intracellular proteins, Transporters" Apoptosis "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "BJ hTERT+ SV40 Large T+: 21.2;BJ hTERT+ SV40 Large T+ RasG12V: 23.1" "Low cancer specificity" "Detected in single" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "Low region specificity" "Detected in all" "HPA000637, HPA048740" Approved Uncertain "Nucleoplasm,Nuclear speckles" Nucleoplasm "Nuclear speckles" "HPA000637: AB_1079553, HPA048740: " "unprognostic (1.32e-2)" "unprognostic (8.74e-2)" "unprognostic (1.21e-1)" "unprognostic (1.32e-3)" "unprognostic (9.82e-3)" "unprognostic (2.85e-2)" "unprognostic (1.05e-6)" "unprognostic (4.39e-2)" "unprognostic (1.67e-1)" "unprognostic (1.84e-3)" "unprognostic (7.61e-2)" "unprognostic (3.47e-2)" "unprognostic (1.72e-7)" "unprognostic (3.13e-2)" "unprognostic (8.77e-2)" "unprognostic (3.46e-3)" "unprognostic (4.95e-2)" 11.4 5.3 14.2 5.8 17.7 12.0 17.7 16.4 24.2 17.9 21.0 14.4 11.4 4.5 13.7 6.9 14.4 16.1 16.0 11.2 17.8 9.5 7.1 6.9 10.3 6.4 13.1 21.2 8.0 21.4 29.1 11.4 18.0 17.5 16.3 5.6 7.5 22.1 37.7 7.0 14.5 7.7 18.6 20.2 9.7 13.0 15.0 14.8 0.0 14.4 5.7 5.4 16.6 12.1 1.9 1.1 2.1 4.4 3.5 0.3 1.1 5.1 6.5 4.2 3.4 0.3 9.5 3.3 1.4 13.6 21.2 23.1 5.3 16.7 1.7 1.2 7.1 7.2 4.8 6.5 5.5 3.5 5.3 0.4 0.9 8.6 2.9 1.8 10.3 8.6 12.0 7.8 1.4 5.0 1.5 5.0 6.5 7.8 0.2 1.0 5.2 4.2 3.1 0.1 1.1 3.7 2.1 7.0 2.8 2.1 7.1 1.9 3.7 2.7 1.8 5.5 4.4 5.4 3.6 2.8 2.6 0.5 2.3 3.8 8.5 2.1 4.4 0.3 0.2 1.6 0.2 1.4 0.0 0.0 0.6 1.9 0.3 0.1 0.8 3.5 2.6 1.1 0.0 1.1 14.2 17.7 16.4 24.2 17.8 9.5 13.1 21.2 17.5 14.8 BCL3 "BCL4, D19S37" ENSG00000069399 "B cell CLL/lymphoma 3" P20749 19 44747705-44760044 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" Activator "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HDLM-2: 26.5;Karpas-707: 22.0;SiHa: 28.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "neutrophil: 16.5" "Lineage enriched" "Detected in all" 6 "granulocytes: 16.5" "Not detected" "Not detected" "Low region specificity" "Detected in many" "CAB002051, HPA047514" Approved Supported Nucleoplasm,Vesicles,Midbody Nucleoplasm "Vesicles, Midbody" "CAB002051: AB_563428, HPA047514: " "prognostic favourable (9.67e-4)" "unprognostic (8.82e-2)" "unprognostic (2.81e-1)" "unprognostic (7.54e-2)" "prognostic unfavourable (4.01e-4)" "unprognostic (3.49e-2)" "unprognostic (2.34e-3)" "unprognostic (2.79e-1)" "prognostic favourable (3.74e-4)" "unprognostic (2.09e-2)" "unprognostic (9.23e-2)" "unprognostic (1.81e-1)" "prognostic unfavourable (3.13e-14)" "unprognostic (8.24e-2)" "unprognostic (1.36e-1)" "unprognostic (3.77e-2)" "unprognostic (3.04e-2)" 17.7 13.0 4.0 21.1 5.6 35.2 18.7 1.4 4.7 11.7 14.9 2.4 5.9 24.5 10.4 9.7 27.1 12.5 22.7 20.1 3.9 2.0 17.8 52.1 36.4 20.5 4.3 0.5 26.5 13.2 2.4 9.2 9.5 5.6 16.0 8.0 8.8 13.7 13.7 20.2 9.0 35.5 11.5 6.5 41.6 15.0 8.3 4.0 6.5 13.9 22.9 37.0 18.7 11.9 1.3 2.6 16.5 2.4 1.8 1.5 0.7 3.8 13.4 0.3 7.1 2.6 5.4 0.6 2.4 2.6 1.5 2.2 2.8 7.1 3.8 5.5 4.7 4.3 0.9 4.0 0.9 26.5 0.2 0.4 7.0 3.6 6.2 0.3 11.4 9.4 3.2 3.3 4.2 4.0 0.5 22.0 0.9 3.2 0.0 2.9 0.3 5.6 1.7 2.7 1.4 6.8 8.1 0.0 0.4 28.2 14.4 0.7 5.0 2.9 6.7 4.8 5.0 7.5 0.9 20.9 8.2 3.9 8.9 0.5 3.6 0.2 2.4 4.2 0.7 1.6 1.0 1.3 0.9 1.1 2.1 1.1 0.5 0.6 16.5 1.8 0.9 2.6 1.5 0.7 4.0 5.6 1.4 4.7 3.9 2.0 4.3 0.5 5.6 4.0 BCL6 "BCL5, BCL6A, LAZ3, ZBTB27, ZNF51" ENSG00000113916 "B cell CLL/lymphoma 6" P41182 3 187721377-187745727 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Immunity, Inflammatory response, Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 114.3" "Cell line enhanced" "Detected in many" "ASC diff: 26.8;Daudi: 42.1;HSkMC: 30.6;U-698: 58.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in many" 4 "neutrophil: 63.4" "Lineage enriched" "Detected in many" 4 "granulocytes: 63.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000307, HPA004899, HPA050645" Enhanced Supported "Nucleoplasm,Golgi apparatus" Nucleoplasm "Golgi apparatus" "CAB000307: AB_2063451, HPA004899: AB_1078273, HPA050645: " "unprognostic (5.36e-2)" "unprognostic (3.29e-2)" "unprognostic (1.63e-3)" "unprognostic (2.49e-1)" "unprognostic (2.85e-1)" "unprognostic (6.34e-3)" "unprognostic (2.62e-2)" "unprognostic (3.33e-3)" "unprognostic (8.75e-2)" "unprognostic (2.04e-2)" "unprognostic (1.63e-3)" "unprognostic (1.29e-1)" "prognostic unfavourable (1.27e-9)" "unprognostic (5.22e-2)" "unprognostic (7.82e-2)" "unprognostic (5.67e-2)" "unprognostic (2.58e-2)" 47.1 14.3 21.8 23.2 25.9 50.6 48.0 58.7 23.7 21.2 21.2 19.2 11.5 4.1 17.7 8.8 20.9 28.3 22.3 18.6 21.5 8.0 10.1 20.1 26.3 24.5 31.6 9.3 20.2 15.6 9.1 23.3 7.5 28.5 17.3 5.8 15.9 19.1 11.8 114.3 36.4 8.1 24.4 50.1 27.2 16.1 10.2 26.6 18.9 14.8 10.4 22.4 24.9 20.0 3.9 5.6 63.4 15.4 0.9 1.3 5.2 1.2 3.6 3.5 0.8 26.8 21.4 3.9 4.2 10.4 4.9 5.2 2.5 2.0 42.1 3.1 5.3 2.0 1.1 2.8 4.2 8.9 1.4 0.0 1.7 6.0 13.9 0.5 0.2 30.6 17.9 6.0 9.2 2.7 0.4 7.3 4.7 1.4 1.4 0.3 0.3 2.7 11.7 1.8 0.2 3.4 6.2 0.8 0.0 4.9 2.1 2.7 9.2 1.5 5.5 11.9 1.9 4.3 1.9 5.4 1.7 58.5 6.5 1.5 8.4 1.6 6.9 4.1 1.3 8.7 1.3 1.4 0.8 1.2 5.6 3.9 0.5 0.6 63.4 0.9 15.4 0.9 0.6 5.2 21.8 25.9 58.7 23.7 21.5 8.0 31.6 9.3 28.5 26.6 BCL7A BCL7 ENSG00000110987 "BCL tumor suppressor 7A" Q4VC05 12 122019422-122062044 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Daudi: 25.9;MOLT-4: 19.0;U-698: 29.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "naive B-cell: 8.4;plasmacytoid DC: 9.7" "Group enriched" "Detected in many" 10 "B-cells: 8.4;dendritic cells: 9.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA019762 Approved Approved Nucleoplasm,Vesicles "Nucleoplasm, Vesicles" "HPA019762: AB_10962489" "unprognostic (3.27e-1)" "unprognostic (2.97e-2)" "prognostic unfavourable (6.81e-4)" "unprognostic (1.35e-1)" "unprognostic (1.46e-1)" "unprognostic (1.23e-1)" "prognostic unfavourable (2.04e-4)" "unprognostic (5.18e-1)" "unprognostic (5.13e-2)" "unprognostic (1.06e-2)" "unprognostic (3.13e-1)" "unprognostic (3.11e-1)" "prognostic favourable (1.54e-6)" "unprognostic (4.86e-2)" "unprognostic (8.56e-2)" "unprognostic (6.16e-3)" "unprognostic (1.51e-2)" 3.8 3.7 13.0 9.8 14.5 9.9 6.5 19.8 18.2 6.7 4.2 6.8 3.3 3.6 6.0 7.4 3.3 10.3 4.3 9.4 9.5 7.5 10.7 5.3 5.1 19.4 6.6 15.9 4.9 11.7 8.3 6.1 2.8 6.8 6.3 3.8 3.8 8.2 7.2 12.8 8.2 3.4 4.1 5.1 6.5 4.4 3.1 7.9 26.4 11.1 3.5 15.8 6.9 5.4 8.4 9.7 0.1 0.1 0.5 0.9 0.6 1.7 2.4 7.9 5.6 0.5 0.3 1.7 1.0 1.0 1.7 1.5 1.0 0.7 25.9 2.9 0.8 2.3 5.7 5.5 1.4 0.0 9.4 1.3 0.2 1.4 1.7 4.0 2.3 1.2 5.2 1.2 7.1 2.1 5.8 0.0 1.0 3.6 19.0 0.3 2.8 4.0 10.5 2.7 0.3 3.1 4.4 7.9 8.9 1.3 0.3 3.3 5.3 3.3 1.9 0.3 1.7 2.9 1.7 2.7 1.8 29.9 0.5 2.5 1.8 0.1 0.0 0.0 0.1 0.0 0.0 2.9 0.2 0.2 2.2 8.4 0.9 0.6 0.1 0.5 0.1 9.7 0.0 0.6 13.0 14.5 19.8 18.0 9.5 7.5 6.6 15.9 6.8 7.9 BCL9 ENSG00000116128 "B cell CLL/lymphoma 9" O00512 1 147541412-147626216 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Wnt signaling pathway" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "NTERA-2: 24.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA020274 Approved Approved "Nucleoplasm,Nuclear bodies" "Nucleoplasm, Nuclear bodies" "HPA020274: " "unprognostic (2.31e-1)" "unprognostic (1.52e-2)" "unprognostic (5.32e-2)" "unprognostic (1.38e-1)" "unprognostic (1.04e-1)" "unprognostic (1.65e-1)" "prognostic unfavourable (6.74e-4)" "unprognostic (1.03e-1)" "unprognostic (2.78e-1)" "unprognostic (2.29e-1)" "unprognostic (4.78e-3)" "unprognostic (3.92e-2)" "unprognostic (1.64e-3)" "unprognostic (2.58e-1)" "unprognostic (2.20e-1)" "unprognostic (1.37e-1)" "unprognostic (1.60e-2)" 4.5 7.8 10.2 5.9 9.2 3.1 4.8 22.3 12.6 18.2 9.4 8.1 10.9 5.3 23.9 15.9 6.8 18.9 5.2 8.3 8.0 7.4 9.6 4.3 5.0 4.0 5.9 8.7 17.0 6.1 14.6 10.6 4.5 6.8 10.5 7.9 11.8 8.1 13.2 7.9 7.8 5.5 15.7 5.4 3.8 7.6 6.1 6.5 22.4 7.8 8.0 6.0 9.6 8.0 0.4 0.0 0.6 0.3 0.1 2.6 1.0 3.0 2.9 20.9 15.5 2.4 2.8 4.1 2.5 3.9 2.7 2.6 3.8 4.5 2.9 5.5 2.3 2.4 13.2 4.5 2.6 6.8 3.7 1.4 3.2 2.5 2.0 0.8 4.1 2.8 3.8 3.2 2.3 4.2 2.7 4.7 2.4 6.8 7.1 0.7 24.6 6.5 7.6 5.2 5.5 10.6 3.4 5.7 12.3 2.8 5.1 4.8 6.5 1.4 3.0 1.9 9.1 5.4 3.9 21.1 5.3 5.4 4.8 0.8 9.2 0.0 0.3 0.6 1.0 0.0 0.9 0.2 1.2 1.2 0.0 0.4 2.6 1.6 0.2 0.1 0.1 0.0 0.9 1.0 10.2 9.2 22.3 12.6 8.0 7.4 5.9 8.7 6.8 6.5 BCL9L DLNB11 ENSG00000186174 "B cell CLL/lymphoma 9 like" Q86UU0 11 118893875-118925608 "Cancer-related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" Activator "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA049370, HPA053421" Uncertain Enhanced Nucleoplasm Nucleoplasm "HPA049370: , HPA053421: " "unprognostic (1.67e-2)" "unprognostic (1.48e-2)" "unprognostic (1.20e-1)" "unprognostic (2.71e-1)" "unprognostic (2.87e-1)" "unprognostic (1.90e-1)" "unprognostic (6.61e-3)" "unprognostic (1.17e-3)" "unprognostic (1.03e-1)" "unprognostic (4.61e-2)" "unprognostic (4.66e-3)" "unprognostic (1.39e-1)" "unprognostic (2.83e-3)" "unprognostic (4.85e-3)" "unprognostic (2.24e-2)" "unprognostic (2.14e-1)" "unprognostic (2.90e-3)" 18.4 18.9 10.2 17.2 10.0 13.3 23.8 31.7 9.9 27.4 16.4 6.7 15.8 13.2 22.3 12.8 18.9 22.2 21.2 15.6 9.0 4.1 10.9 9.0 17.1 13.8 9.5 7.7 22.2 16.4 9.0 6.5 31.9 9.1 16.1 4.1 14.5 21.5 14.7 19.1 19.9 14.6 22.8 7.9 13.9 14.0 9.0 8.6 13.0 12.2 11.9 16.7 21.9 25.6 0.6 0.6 1.1 0.5 0.7 2.2 0.8 12.2 22.2 3.2 5.8 10.4 10.1 20.4 16.9 13.1 5.4 3.1 23.6 24.4 3.3 22.6 17.7 23.7 1.5 31.0 1.4 4.0 0.8 3.3 12.4 8.1 11.7 1.1 3.2 12.7 19.4 6.4 13.0 4.7 4.2 3.9 3.7 20.5 2.4 0.9 3.8 12.8 5.2 1.3 2.2 5.6 8.5 1.7 2.5 23.8 36.2 3.4 28.4 1.4 15.8 17.2 13.2 5.2 14.3 0.8 0.0 0.9 9.3 3.8 9.8 0.0 0.5 0.0 2.2 0.0 1.5 0.3 1.2 1.3 0.1 0.6 1.9 1.5 1.1 0.7 0.0 0.6 0.2 0.8 10.2 10.0 31.7 9.9 9.0 4.1 9.5 7.7 9.1 8.6 BCLAF1 "BTF, KIAA0164" ENSG00000029363 "BCL2 associated transcription factor 1" Q9NYF8 6 136256627-136289851 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Transcription, Transcription regulation" "DNA-binding, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA006484, HPA006669, HPA027770" Enhanced Enhanced "Nuclear speckles" 190000 "Nuclear speckles" "HPA006484: , HPA006669: AB_1078302, HPA027770: AB_1845484" "prognostic unfavourable (1.64e-4)" "unprognostic (1.60e-1)" "prognostic favourable (3.44e-4)" "unprognostic (1.45e-1)" "unprognostic (9.46e-3)" "unprognostic (2.29e-1)" "unprognostic (2.13e-3)" "unprognostic (1.63e-1)" "unprognostic (5.07e-2)" "unprognostic (1.14e-1)" "unprognostic (2.69e-1)" "unprognostic (1.40e-1)" "unprognostic (7.20e-2)" "unprognostic (1.08e-1)" "unprognostic (1.56e-1)" "unprognostic (7.93e-2)" "unprognostic (4.19e-3)" 22.6 20.9 19.3 20.6 33.6 93.9 26.8 56.9 31.0 27.6 23.2 13.3 18.1 15.2 25.8 21.3 22.7 22.9 12.4 17.0 20.4 19.0 19.3 22.0 19.9 22.7 24.4 19.5 33.5 20.5 34.8 50.2 25.5 27.8 21.4 23.7 14.2 23.5 18.2 26.8 22.2 20.8 23.1 22.4 22.7 22.2 16.7 27.2 38.6 24.7 21.5 25.4 24.0 23.2 22.2 25.2 35.7 20.4 29.1 24.9 13.4 18.2 15.9 37.7 31.4 12.0 10.2 19.2 34.9 21.7 23.5 25.1 22.6 12.4 38.5 21.8 26.7 17.8 42.2 23.0 29.6 21.2 26.2 47.9 22.9 24.5 13.9 80.1 30.5 13.9 11.5 33.2 20.8 20.8 42.5 19.1 24.6 21.8 31.9 9.1 27.7 16.6 29.0 47.4 17.1 17.6 35.1 32.1 22.2 34.2 16.5 13.3 15.4 16.2 28.6 18.7 27.4 22.3 34.0 16.2 29.2 53.1 11.1 25.8 21.6 15.4 16.4 24.2 21.1 20.4 21.0 22.2 19.4 17.6 25.2 19.8 24.9 22.3 35.7 29.1 19.7 14.9 14.7 13.4 19.3 33.6 56.9 31.0 20.4 19.0 24.4 19.5 27.8 27.2 BCOR "FLJ20285, KIAA1575" ENSG00000183337 "BCL6 corepressor" Q6W2J9 X 40049815-40177329 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Chromatin regulator, Repressor" "Cancer-related genes, Disease mutation, Microphthalmia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA056308, HPA073591" Enhanced Nucleoplasm Nucleoplasm "HPA056308: , HPA073591: " "unprognostic (2.75e-2)" "unprognostic (2.83e-1)" "unprognostic (2.45e-1)" "unprognostic (9.26e-2)" "unprognostic (1.55e-1)" "unprognostic (9.80e-3)" "prognostic unfavourable (1.30e-5)" "unprognostic (3.82e-3)" "unprognostic (6.86e-2)" "unprognostic (1.86e-1)" "unprognostic (4.08e-2)" "unprognostic (1.18e-1)" "unprognostic (3.91e-3)" "unprognostic (6.83e-2)" "unprognostic (9.57e-2)" "unprognostic (2.63e-1)" "unprognostic (1.55e-1)" 9.1 12.8 8.7 8.7 10.5 20.6 13.3 11.5 12.0 10.0 12.6 22.7 11.9 7.8 11.1 13.9 13.6 10.4 8.6 13.0 7.1 5.4 11.2 13.3 11.4 15.2 12.9 8.4 19.8 13.6 19.7 11.9 12.5 10.7 13.2 8.2 13.7 11.1 16.5 28.8 13.6 10.3 12.9 8.6 11.4 11.5 9.8 15.8 18.4 16.0 11.4 13.5 13.8 25.5 6.5 7.3 7.6 7.1 8.2 6.8 11.8 12.9 8.6 17.5 21.4 2.0 1.5 3.0 4.4 7.0 5.6 4.6 3.6 5.2 11.8 5.2 8.2 12.1 28.5 3.7 5.0 20.6 25.9 13.1 13.2 14.1 3.4 10.6 7.6 2.6 5.5 6.2 3.6 7.6 33.7 28.5 6.9 8.3 24.0 22.2 17.2 13.4 11.7 18.1 13.3 10.3 8.2 12.5 22.7 9.2 8.2 6.9 8.8 23.4 6.2 6.1 7.7 8.9 4.9 16.9 13.1 12.3 5.3 9.7 9.3 7.6 5.0 4.5 6.8 6.1 4.3 6.5 4.7 3.9 7.3 5.5 4.7 4.8 1.1 8.2 7.1 3.1 5.5 11.8 8.7 10.5 11.5 12.0 7.1 5.4 12.9 8.4 10.7 15.8 BCORL1 "CXorf10, FLJ11362" ENSG00000085185 "BCL6 corepressor like 1" Q5H9F3 X 129981107-130058083 "Cancer-related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Chromatin regulator, Repressor" "Autism spectrum disorder, Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "AN3-CA: 20.0;HAP1: 30.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA031775, HPA031777, HPA068568" Uncertain Approved "Nucleoplasm,Plasma membrane" Nucleoplasm "Plasma membrane" "HPA031775: AB_10602332, HPA031777: AB_10671578, HPA068568: " "unprognostic (8.07e-2)" "unprognostic (2.78e-2)" "unprognostic (7.09e-2)" "prognostic unfavourable (2.20e-5)" "unprognostic (4.58e-1)" "unprognostic (1.68e-3)" "unprognostic (1.96e-3)" "unprognostic (5.56e-3)" "unprognostic (2.39e-1)" "unprognostic (8.02e-2)" "unprognostic (4.46e-2)" "unprognostic (2.04e-1)" "prognostic unfavourable (5.00e-4)" "unprognostic (9.18e-2)" "unprognostic (2.60e-2)" "unprognostic (3.09e-1)" "unprognostic (1.41e-2)" 7.5 7.9 7.7 5.2 9.1 9.8 9.1 19.8 10.5 8.7 8.3 10.7 8.1 5.4 9.2 5.4 5.8 9.3 4.2 6.9 8.4 4.5 7.5 4.7 6.7 5.3 7.6 5.9 11.4 8.9 13.4 15.0 28.9 7.5 8.1 4.5 6.0 6.5 8.4 6.0 6.5 6.0 8.8 5.3 7.7 6.6 26.1 8.1 6.8 10.3 2.2 5.1 6.7 8.5 1.2 1.6 3.5 1.3 0.8 1.3 0.7 2.2 5.4 12.7 20.0 7.5 5.4 3.5 2.9 3.5 3.8 4.4 6.5 1.4 1.0 6.6 5.9 1.3 30.1 1.2 3.6 2.2 4.4 10.3 2.6 2.2 3.7 2.5 3.0 3.3 2.5 7.5 0.4 4.6 4.9 10.6 2.5 1.3 3.8 7.8 3.5 3.8 8.1 5.1 1.4 2.1 0.3 2.1 7.2 1.6 0.4 1.9 4.4 3.9 3.8 3.1 4.0 3.8 2.8 3.4 6.2 1.6 2.1 5.3 1.4 0.1 1.3 2.8 1.3 0.2 1.0 1.2 0.9 0.8 1.6 1.0 0.6 0.7 3.5 0.8 0.5 0.7 0.2 0.7 7.7 9.1 19.8 10.5 8.4 4.5 7.6 5.9 7.5 8.1 BCR "ALL, BCR1, CML, D22S11, D22S662, PHL" ENSG00000186716 "BCR, RhoGEF and GTPase activating protein" P11274 22 23179704-23318037 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "GTPase activation, Guanine-nucleotide releasing factor, Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "K-562: 43.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010421, CAB018545, HPA038337" Approved Approved Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "CAB010421: AB_2274682, CAB018545: AB_2063918, HPA038337: AB_10675795" "unprognostic (7.46e-3)" "unprognostic (2.43e-2)" "unprognostic (2.15e-3)" "unprognostic (1.16e-1)" "unprognostic (5.35e-2)" "unprognostic (1.45e-1)" "unprognostic (5.08e-2)" "unprognostic (1.44e-1)" "unprognostic (7.55e-2)" "unprognostic (1.81e-1)" "unprognostic (9.46e-2)" "unprognostic (2.39e-2)" "prognostic favourable (9.15e-10)" "unprognostic (1.47e-1)" "unprognostic (7.10e-2)" "unprognostic (4.10e-2)" "unprognostic (7.43e-2)" 14.5 8.4 24.0 9.1 41.2 26.7 10.5 14.2 26.5 13.6 9.7 10.3 10.6 8.7 9.2 13.9 19.3 10.8 8.3 7.8 20.9 13.0 16.3 8.3 11.3 10.9 16.0 15.6 8.8 12.9 14.5 14.9 15.7 14.2 7.0 6.8 8.3 15.5 9.7 3.4 12.8 8.7 9.0 9.5 9.1 14.0 9.6 15.4 11.8 16.6 5.5 9.2 9.2 8.8 1.5 0.8 1.2 1.0 2.8 6.6 2.5 18.6 8.1 12.4 12.7 7.4 5.1 18.8 6.8 6.3 6.3 5.1 14.1 7.5 13.0 12.6 5.7 19.2 1.3 18.8 1.8 24.9 12.9 11.4 11.1 11.2 9.7 10.5 6.0 4.3 12.7 9.4 8.2 21.8 43.5 6.1 2.8 12.3 9.8 8.2 10.5 7.9 12.9 5.0 8.6 9.7 11.8 11.4 10.8 12.4 10.7 5.1 6.7 8.6 24.6 3.8 0.4 6.1 5.5 1.4 5.6 4.6 9.7 8.0 5.8 0.0 1.0 0.0 6.6 0.4 2.3 1.4 3.3 3.3 0.8 1.5 2.6 3.6 1.2 2.8 1.0 0.8 1.6 2.5 24.0 41.2 14.2 24.9 20.9 13.0 16.0 15.6 14.2 15.4 BDNF ENSG00000176697 "Brain derived neurotrophic factor" P23560 11 27654893-27722058 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins" "Growth factor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 14.5;smooth muscle: 10.5" "Cell line enhanced" "Detected in many" "BJ: 22.4;BJ hTERT+ SV40 Large T+: 17.2;BJ hTERT+ SV40 Large T+ RasG12V: 13.1;HBF TERT88: 16.5;U-138 MG: 24.1" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in single" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009564, HPA031440, HPA056104" Enhanced Supported "Nuclear speckles,Mitochondria" "Secreted to blood" 19244000 "Nuclear speckles, Mitochondria" "CAB009564: AB_2064213, HPA031440: , HPA056104: " "unprognostic (1.25e-2)" "unprognostic (2.84e-1)" "unprognostic (4.35e-2)" "unprognostic (2.54e-2)" "unprognostic (1.01e-2)" "unprognostic (6.82e-2)" "unprognostic (2.39e-2)" "unprognostic (2.21e-1)" "unprognostic (3.20e-1)" "unprognostic (1.78e-1)" "unprognostic (1.22e-2)" "unprognostic (2.65e-1)" "unprognostic (3.22e-2)" "unprognostic (3.88e-2)" "unprognostic (5.88e-2)" "unprognostic (1.40e-1)" "unprognostic (2.84e-3)" 0.9 1.3 5.0 0.6 4.5 0.5 0.6 9.4 14.5 1.6 0.8 0.6 0.7 0.8 0.7 8.2 1.4 0.5 2.1 5.8 8.5 5.7 0.9 0.5 4.1 0.4 2.5 4.7 1.2 1.0 0.2 2.3 3.7 12.7 4.9 0.4 3.0 0.9 4.2 1.3 2.1 0.5 10.5 1.0 0.6 0.9 1.3 0.0 0.0 2.3 0.0 0.4 3.2 1.2 0.1 0.4 0.0 0.2 0.1 1.0 0.1 1.6 6.6 0.2 0.0 2.3 1.9 0.0 22.4 4.3 17.2 13.1 0.0 2.6 0.0 2.1 8.1 1.0 0.1 0.2 16.5 0.1 0.1 0.0 2.2 0.0 10.0 0.1 0.1 5.8 2.2 3.8 2.2 0.7 0.0 0.0 2.7 0.0 0.0 0.0 2.1 1.8 0.0 1.3 0.0 2.5 0.0 0.1 0.6 4.3 0.0 0.0 0.1 0.0 7.4 24.1 4.0 9.3 5.0 0.3 0.0 0.0 9.3 0.6 1.3 0.0 0.0 0.0 0.1 0.2 0.2 0.1 0.0 0.6 0.2 0.1 0.7 0.4 0.0 0.1 0.0 0.4 1.0 0.1 5.0 4.5 9.4 9.4 8.5 5.7 2.5 4.7 12.7 0.0 BHMT2 ENSG00000132840 "Betaine--homocysteine S-methyltransferase 2" Q9H2M3 5 79069717-79089466 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Methyltransferase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 10 "kidney: 87.9;liver: 122.9" "Cell line enhanced" "Detected in some" "BJ hTERT+: 8.9;Hep G2: 37.2;hTEC/SVTERT24-B: 22.8;U-87 MG: 9.6" "Group enriched" "Detected in many" 14 "liver cancer: 79.6;renal cancer: 52.9" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "Low region specificity" "Detected in some" HPA044573 Enhanced 1400000 "HPA044573: AB_10795044" "unprognostic (5.03e-2)" "unprognostic (4.42e-2)" "unprognostic (2.60e-2)" "unprognostic (3.76e-2)" "unprognostic (4.40e-2)" "unprognostic (2.90e-3)" "unprognostic (1.56e-2)" "unprognostic (1.95e-1)" "unprognostic (1.87e-2)" "unprognostic (2.45e-3)" "unprognostic (1.41e-2)" "unprognostic (1.02e-1)" "unprognostic (1.76e-2)" "unprognostic (5.05e-2)" "unprognostic (1.49e-1)" "unprognostic (1.60e-1)" "unprognostic (1.06e-3)" 9.3 4.4 1.7 0.9 2.0 0.2 8.2 1.1 1.0 1.7 3.4 1.1 2.9 0.6 3.2 10.5 3.5 1.4 2.9 3.3 1.5 1.5 87.9 122.9 0.6 0.4 1.6 1.0 1.9 0.5 0.5 3.2 0.3 3.5 3.0 0.8 8.2 0.8 4.0 2.2 0.4 1.3 10.5 2.2 0.3 2.4 1.4 0.9 0.0 4.6 1.9 0.4 6.4 4.4 0.9 0.5 3.2 0.4 2.4 0.7 0.3 0.0 0.0 0.0 0.0 4.3 3.1 1.4 3.7 8.9 2.1 4.1 0.0 0.0 0.0 0.0 4.7 0.0 0.0 0.0 3.0 0.0 0.0 0.1 0.1 37.2 3.4 0.2 0.0 3.8 0.0 22.8 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 1.1 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 9.6 0.2 0.0 2.5 0.4 0.7 0.4 0.3 0.5 0.5 0.6 0.4 0.2 0.9 0.6 0.7 3.2 2.4 0.2 0.5 0.4 0.3 1.7 2.0 1.1 1.0 1.5 1.5 1.6 1.0 3.5 0.9 BIRC2 "API1, c-IAP1, cIAP1, hiap-2, MIHB, RNF48" ENSG00000110330 "Baculoviral IAP repeat containing 2" Q13490 11 102347211-102378670 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Apoptosis, Transcription, Transcription regulation, Ubl conjugation pathway" "Activator, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA005513, CAB020661" Supported Supported "Nucleoplasm,Nucleoli fibrillar center,Cytosol" "Nucleoli fibrillar center, Cytosol" Nucleoplasm "CAB020661: , HPA005513: AB_1846746" "unprognostic (1.36e-1)" "unprognostic (3.29e-1)" "unprognostic (9.52e-3)" "unprognostic (1.62e-1)" "unprognostic (1.37e-1)" "unprognostic (7.02e-2)" "unprognostic (2.72e-2)" "unprognostic (1.04e-2)" "unprognostic (1.17e-2)" "unprognostic (9.59e-2)" "unprognostic (1.05e-2)" "unprognostic (3.02e-2)" "unprognostic (1.84e-2)" "unprognostic (1.07e-1)" "unprognostic (9.20e-2)" "unprognostic (5.00e-2)" "unprognostic (1.64e-2)" 20.9 25.8 19.1 23.3 24.1 25.9 57.0 20.5 28.5 25.1 22.2 18.4 18.7 19.3 24.6 31.1 18.6 17.0 21.1 39.2 19.1 18.3 24.3 36.8 34.0 47.2 23.3 15.8 21.5 40.8 22.0 27.3 24.3 22.3 19.6 22.2 14.3 21.9 22.1 38.8 17.3 24.4 23.8 26.3 27.6 19.0 19.7 15.5 51.2 18.9 17.3 21.9 22.2 20.2 5.8 12.6 37.5 16.6 12.2 12.0 9.8 9.6 7.2 11.1 8.7 14.1 19.5 7.1 37.5 14.4 21.5 13.1 8.9 24.1 10.6 37.2 17.2 10.7 7.2 9.9 25.9 14.2 3.7 10.7 5.3 10.8 14.4 6.4 6.9 12.4 19.3 12.3 15.8 14.7 9.6 0.0 38.7 3.1 6.8 5.7 5.3 7.0 3.4 14.4 7.1 16.6 11.2 4.6 6.1 13.1 8.0 11.2 12.6 7.8 24.1 45.6 10.3 13.7 24.2 4.4 6.0 7.3 9.8 8.2 33.2 31.7 16.6 37.5 9.1 15.2 7.5 5.8 8.7 8.4 12.6 5.6 11.3 11.3 25.5 12.2 16.3 7.6 12.0 9.8 19.1 24.1 20.5 28.5 19.1 18.3 23.3 15.8 22.3 15.5 BIRC3 "API2, c-IAP2, cIAP2, hiap-1, MALT2, MIHC, RNF49" ENSG00000023445 "Baculoviral IAP repeat containing 3" Q13489 11 102317450-102339403 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Apoptosis, Ubl conjugation pathway" Transferase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 46.0;lymphoid tissue: 46.3" "Cell line enhanced" "Detected in many" "CAPAN-2: 37.5;Daudi: 33.0;HDLM-2: 31.2;hTERT-HME1: 32.8;U-266/70: 22.0;U-266/84: 18.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "memory B-cell: 32.9;naive B-cell: 32.9" "Group enriched" "Detected in many" 10 "B-cells: 32.9;T-cells: 17.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA002317 Enhanced Approved Supported Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "HPA002317: AB_1846748" "prognostic favourable (3.60e-4)" "unprognostic (2.89e-1)" "prognostic favourable (9.35e-4)" "unprognostic (3.28e-2)" "prognostic unfavourable (7.28e-4)" "unprognostic (5.83e-3)" "unprognostic (2.23e-1)" "unprognostic (3.88e-3)" "unprognostic (9.62e-2)" "unprognostic (1.29e-1)" "prognostic unfavourable (3.03e-4)" "unprognostic (3.21e-1)" "prognostic unfavourable (6.66e-6)" "unprognostic (6.42e-2)" "unprognostic (6.23e-3)" "unprognostic (1.00e-1)" "unprognostic (3.85e-2)" 6.9 3.3 1.4 43.9 2.3 5.1 5.4 0.5 2.0 5.3 13.1 0.5 2.8 6.8 2.9 3.7 8.4 3.9 13.9 6.0 2.2 1.3 10.8 12.5 21.8 46.3 2.8 1.2 3.4 7.0 1.1 14.5 0.9 2.2 8.7 6.2 1.1 9.2 4.7 2.2 5.5 46.0 7.3 3.0 34.9 15.9 3.2 2.7 34.2 3.0 4.1 34.0 12.6 6.2 32.9 0.8 2.0 2.6 2.5 17.1 2.8 6.3 5.1 0.0 0.1 0.1 0.7 0.6 0.5 4.3 0.6 0.7 0.9 37.5 33.0 17.0 0.3 3.6 0.0 0.9 2.1 31.2 0.1 0.1 1.5 0.2 6.5 0.5 0.7 0.7 4.6 2.1 32.8 0.1 0.1 0.0 0.8 0.0 2.2 0.3 0.1 0.2 0.0 0.3 1.6 8.5 3.3 0.0 0.1 0.5 0.5 0.3 1.6 0.3 1.7 7.2 0.7 0.4 6.5 22.0 18.8 11.6 1.3 1.8 0.8 2.0 0.9 0.4 1.4 2.2 2.5 32.9 10.7 3.5 0.8 32.9 7.5 2.2 0.5 2.5 2.6 0.3 17.1 2.8 1.4 2.3 0.5 2.0 2.2 1.3 2.8 1.2 2.2 2.7 BIRC5 "API4, EPR-1, survivin" ENSG00000089685 "Baculoviral IAP repeat containing 5" O15392 17 78214186-78225636 "Cancer-related genes, Predicted intracellular proteins" "Apoptosis, Cell cycle, Cell division, Chromosome partition, Mitosis, Transcription, Transcription regulation" "Protease inhibitor, Repressor, Thiol protease inhibitor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 61.6;testis: 51.4" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "T-reg: 14.0" "Lineage enriched" "Detected in many" 6 "T-cells: 14.0" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" "HPA002830, CAB004270" Enhanced Supported "Cytokinetic bridge" "Cytokinetic bridge" "CAB004270: AB_628302, HPA002830: AB_1857672" "unprognostic (8.04e-2)" "unprognostic (3.51e-2)" "unprognostic (4.48e-3)" "unprognostic (2.72e-3)" "unprognostic (3.37e-1)" "unprognostic (3.84e-2)" "prognostic unfavourable (5.28e-6)" "prognostic unfavourable (4.49e-4)" "unprognostic (3.56e-3)" "unprognostic (4.53e-3)" "unprognostic (2.87e-3)" "unprognostic (6.67e-2)" "prognostic unfavourable (0.00e+0)" "unprognostic (3.77e-2)" "unprognostic (4.70e-2)" "unprognostic (1.59e-1)" "unprognostic (1.16e-1)" 2.3 1.5 0.4 14.1 0.7 20.8 5.3 0.7 0.6 1.9 4.8 0.3 0.2 4.6 0.9 1.4 13.4 0.4 2.2 2.4 0.5 0.4 1.3 2.2 2.4 9.7 0.6 0.2 0.9 0.8 0.0 0.4 6.1 0.5 0.9 5.2 0.2 2.1 0.2 0.6 3.5 4.7 2.4 0.7 6.3 3.2 51.4 0.3 61.6 0.5 14.4 11.7 2.0 3.2 2.5 0.8 0.5 0.0 2.2 14.0 3.0 31.6 29.6 26.7 28.9 1.7 2.8 9.8 24.4 13.7 34.8 22.9 24.2 12.5 32.6 9.9 14.1 16.9 27.0 15.6 30.5 11.0 37.5 21.5 17.5 28.4 0.2 20.7 16.2 0.9 1.1 19.3 14.3 24.6 26.9 27.6 26.7 18.3 44.0 19.8 19.9 52.1 23.0 43.4 25.2 8.2 11.7 33.0 22.8 18.7 21.2 16.6 28.0 19.6 9.2 42.2 37.4 18.2 34.6 20.0 16.1 37.7 15.4 8.7 36.6 0.0 0.0 0.0 0.7 0.0 0.2 2.5 4.3 2.8 0.8 0.3 0.0 0.4 0.5 2.2 0.0 0.3 14.0 3.0 0.4 0.7 0.7 0.6 0.5 0.4 0.6 0.2 0.5 0.3 BIRC6 BRUCE ENSG00000115760 "Baculoviral IAP repeat containing 6" Q9NR09 2 32357028-32618899 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Apoptosis, Cell cycle, Cell division, Mitosis, Ubl conjugation pathway" "Protease inhibitor, Thiol protease inhibitor, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA074409, HPA074738" Supported "Golgi apparatus,Vesicles,Mitotic spindle" "Golgi apparatus, Vesicles" "Mitotic spindle" "HPA074409: , HPA074738: " "unprognostic (3.38e-2)" "unprognostic (8.13e-3)" "unprognostic (8.88e-2)" "unprognostic (7.06e-3)" "unprognostic (6.69e-3)" "unprognostic (9.01e-2)" "unprognostic (4.51e-2)" "unprognostic (2.07e-1)" "unprognostic (1.32e-1)" "unprognostic (1.86e-1)" "unprognostic (4.49e-2)" "unprognostic (4.00e-2)" "unprognostic (2.07e-2)" "unprognostic (1.30e-1)" "unprognostic (4.61e-1)" "unprognostic (7.32e-2)" "unprognostic (3.37e-1)" 15.0 16.7 10.3 20.7 14.4 18.4 16.1 21.9 13.7 16.2 13.0 15.3 15.6 8.7 17.2 13.9 13.2 13.1 11.7 11.4 9.8 7.3 14.1 14.8 12.5 16.1 13.9 11.8 23.6 24.8 32.5 17.4 14.1 14.8 11.3 13.6 11.5 14.7 17.1 20.9 14.9 16.0 12.5 13.3 16.1 13.9 13.0 14.4 23.1 21.5 9.2 17.2 16.2 12.0 3.8 2.8 10.6 2.4 2.3 3.4 0.7 15.1 12.7 11.8 5.1 9.3 13.2 7.1 6.7 9.5 8.3 7.9 8.7 3.6 16.3 5.4 12.6 7.0 16.5 10.0 10.3 13.0 7.5 22.0 8.0 7.2 5.1 20.4 7.8 8.8 4.9 13.0 11.6 12.3 17.8 7.0 7.7 5.8 10.2 4.7 7.9 7.5 10.4 19.0 5.5 6.0 15.6 8.8 13.5 13.3 6.9 6.1 4.6 7.3 19.2 8.7 9.8 5.9 10.2 9.4 13.1 21.8 6.3 10.1 5.7 10.6 1.6 0.9 2.7 1.2 3.4 1.7 2.1 2.3 1.3 3.8 2.3 2.6 2.7 2.3 2.4 2.8 1.6 0.7 10.3 14.4 21.9 13.7 9.8 7.3 13.9 11.8 14.8 14.4 BLK MGC10442 ENSG00000136573 "BLK proto-oncogene, Src family tyrosine kinase" P51451 8 11486894-11564604 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Diabetes mellitus" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 15 "blood: 47.8;intestine: 23.5;lymphoid tissue: 39.8" "Cell line enhanced" "Detected in some" "Daudi: 43.0;REH: 11.6;RPMI-8226: 14.2;U-698: 21.0;U-87 MG: 8.9" "Low cancer specificity" "Detected in some" "Not detected" "Not detected" "Group enriched" "Detected in some" 4 "memory B-cell: 47.8;naive B-cell: 33.9" "Lineage enriched" "Detected in many" 5 "B-cells: 47.8" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB005093, HPA069571" Approved Approved Nucleoplasm Nucleoplasm "CAB005093: AB_2274756, HPA069571: " "unprognostic (6.50e-5)" "unprognostic (4.22e-3)" "unprognostic (5.64e-2)" "unprognostic (1.42e-1)" "unprognostic (3.45e-1)" "unprognostic (5.98e-6)" "unprognostic (1.59e-2)" "unprognostic (8.94e-4)" "unprognostic (1.02e-3)" "unprognostic (9.83e-3)" "unprognostic (1.22e-2)" "unprognostic (4.66e-2)" "unprognostic (9.05e-6)" "unprognostic (5.62e-2)" "unprognostic (5.43e-2)" "unprognostic (2.19e-1)" "unprognostic (1.16e-1)" 0.5 0.2 0.1 32.3 0.1 1.7 0.2 0.1 0.1 0.1 1.2 0.0 0.0 0.3 0.1 0.0 1.9 0.2 0.4 0.3 0.1 0.1 1.3 0.5 0.6 27.6 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.4 0.4 0.3 2.4 0.0 0.1 0.1 23.5 0.0 0.1 31.9 1.4 0.2 0.0 3.9 0.7 0.4 39.8 2.5 0.4 47.8 4.3 0.1 0.0 0.0 9.8 1.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 43.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 11.6 0.0 14.2 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 2.2 3.7 21.0 8.9 0.0 0.0 0.0 0.0 0.0 0.5 0.0 9.8 47.8 0.3 1.1 0.0 33.9 0.2 0.1 0.1 0.0 0.0 4.3 0.4 1.9 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 BLM "BS, RECQ2, RECQL3" ENSG00000197299 "Bloom syndrome RecQ like helicase" P54132 15 90717327-90816165 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "DNA damage, DNA repair, DNA replication" "DNA-binding, Helicase, Hydrolase" "Cancer-related genes, Disease mutation, Dwarfism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "lymphoid tissue: 36.7" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA005689 Approved Supported Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "HPA005689: AB_1845372" "unprognostic (2.77e-1)" "unprognostic (3.82e-3)" "unprognostic (4.03e-2)" "unprognostic (2.98e-2)" "unprognostic (4.75e-2)" "unprognostic (9.89e-2)" "unprognostic (6.12e-5)" "unprognostic (2.82e-2)" "unprognostic (4.55e-3)" "unprognostic (5.24e-3)" "unprognostic (1.80e-3)" "unprognostic (9.12e-2)" "unprognostic (1.55e-15)" "unprognostic (6.53e-3)" "unprognostic (6.55e-2)" "unprognostic (2.43e-1)" "unprognostic (1.83e-2)" 1.8 0.4 3.1 11.4 1.5 5.5 0.6 4.7 2.6 0.7 1.9 0.9 0.5 1.4 1.2 1.1 2.9 0.4 1.3 1.0 2.3 2.4 0.9 0.5 2.0 7.7 2.8 0.2 0.9 0.4 0.0 1.2 3.6 0.5 0.7 2.5 0.7 7.8 0.0 1.7 0.6 2.8 0.5 1.9 6.7 1.4 4.9 0.5 36.7 0.6 3.1 9.3 1.4 0.7 7.4 1.2 4.3 1.6 4.6 5.0 1.6 5.4 7.8 8.7 5.1 0.0 0.4 5.5 4.1 1.2 4.7 5.1 6.8 3.8 14.1 2.6 1.1 9.1 13.4 3.7 6.1 8.5 9.9 14.7 8.4 2.2 0.0 14.1 7.3 0.0 0.0 4.7 2.4 3.3 12.7 4.4 4.9 3.4 10.6 7.8 9.3 1.7 10.8 16.4 5.4 1.1 9.8 6.5 6.1 3.3 4.4 2.6 3.1 11.6 1.8 3.4 6.3 3.5 8.7 3.2 13.1 14.7 1.9 10.0 5.8 2.5 1.0 4.3 3.1 1.2 4.8 7.4 2.8 3.8 1.2 4.3 2.0 2.2 0.8 4.6 1.6 1.2 5.0 1.6 3.1 1.5 4.7 1.7 2.3 2.4 2.8 0.2 0.5 0.5 BLMH BH ENSG00000108578 "Bleomycin hydrolase" Q13867 17 30248195-30292056 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Hydrolase, Protease, Thiol protease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skin 1: 67.5" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA039548, HPA064307" Enhanced Supported "Nucleoplasm,Nuclear bodies,Cytosol" 59000000 "Nucleoplasm, Nuclear bodies, Cytosol" "HPA039548: AB_10805479, HPA064307: AB_2685241" "unprognostic (6.85e-2)" "unprognostic (2.79e-1)" "unprognostic (1.48e-1)" "unprognostic (2.46e-1)" "unprognostic (1.76e-1)" "unprognostic (2.54e-2)" "unprognostic (3.91e-3)" "unprognostic (2.07e-1)" "unprognostic (2.05e-3)" "unprognostic (6.69e-3)" "unprognostic (1.95e-3)" "unprognostic (2.14e-2)" "unprognostic (2.14e-2)" "unprognostic (1.22e-3)" "unprognostic (1.05e-1)" "unprognostic (1.34e-1)" "unprognostic (1.44e-1)" 11.2 8.3 9.0 17.1 10.2 8.5 14.2 12.1 14.5 10.5 9.8 8.5 9.6 6.7 13.1 12.2 15.7 8.4 10.1 9.7 7.5 7.2 13.6 7.5 13.6 20.3 9.5 8.5 8.8 15.3 15.0 8.3 14.6 9.2 8.4 8.5 7.3 12.8 9.5 15.0 67.5 10.0 15.7 11.1 13.2 9.2 12.4 8.6 24.7 9.3 15.5 13.6 10.8 11.7 4.6 6.6 0.9 5.7 9.8 17.3 6.3 10.1 16.1 15.6 10.8 10.7 11.5 7.5 9.5 5.9 15.0 13.0 23.6 3.0 30.3 17.0 7.6 7.1 33.7 13.0 12.7 8.0 26.5 18.6 14.5 20.0 15.6 33.8 11.5 13.5 0.9 11.7 6.8 22.0 39.6 12.4 6.2 7.7 41.8 24.7 14.9 7.5 36.3 40.5 20.0 12.0 9.1 36.0 12.9 8.4 16.4 10.3 11.2 17.5 14.0 9.3 18.7 4.1 16.8 15.0 30.8 40.9 7.1 0.0 12.4 0.0 5.7 0.9 10.5 3.9 17.3 4.6 12.6 13.7 6.5 4.2 11.6 12.3 0.7 9.8 1.9 6.6 12.4 6.3 9.0 10.2 12.1 14.5 7.5 7.2 9.5 8.5 9.2 8.6 BMI1 "PCGF4, RNF51" ENSG00000168283 "BMI1 proto-oncogene, polycomb ring finger" P35226 10 22321211-22331484 "Cancer-related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Chromatin regulator, Repressor" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HDLM-2: 87.1;U-937: 102.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "CAB011120, HPA030471, HPA030472" Supported Approved "Nucleoplasm,Nucleoli,Nuclear bodies,Cytosol" "Nucleoplasm, Nuclear bodies" "Nucleoli, Cytosol" "CAB011120: , HPA030471: , HPA030472: AB_10601090" "unprognostic (5.44e-1)" "unprognostic (2.98e-1)" "unprognostic (4.24e-2)" "unprognostic (4.37e-2)" "unprognostic (2.76e-3)" "unprognostic (6.93e-2)" "prognostic unfavourable (2.60e-8)" "unprognostic (9.43e-2)" "unprognostic (7.95e-2)" "unprognostic (7.84e-2)" "unprognostic (8.23e-2)" "unprognostic (1.56e-1)" "unprognostic (7.44e-2)" "unprognostic (9.73e-2)" "unprognostic (8.56e-2)" "unprognostic (7.91e-3)" "unprognostic (3.41e-2)" 19.7 23.5 28.0 17.0 35.0 13.3 26.5 26.1 33.7 21.6 22.3 26.3 11.6 14.1 23.9 22.8 16.0 17.0 17.4 15.1 28.3 24.2 19.2 25.5 16.7 17.9 42.3 27.7 18.8 18.6 40.0 37.6 20.6 24.8 25.5 16.0 16.5 15.7 20.3 28.5 10.3 14.6 26.3 34.8 24.6 16.5 24.3 40.7 12.9 17.6 10.6 18.8 21.5 25.9 5.0 1.8 13.0 3.4 6.2 8.4 2.4 12.7 6.2 7.1 2.2 12.5 10.1 7.2 8.6 3.9 6.6 7.8 6.5 16.0 6.5 5.9 7.8 4.5 10.3 6.1 8.2 87.1 12.8 18.0 5.3 7.3 7.5 6.6 10.0 6.5 10.6 7.2 8.0 4.6 17.8 11.1 8.7 5.1 17.8 1.9 1.6 14.8 13.3 10.2 6.2 6.2 4.2 6.0 11.9 5.7 7.5 9.6 6.7 26.7 9.8 7.4 22.2 17.7 11.6 13.7 17.8 14.4 10.5 102.3 4.8 13.0 1.5 2.5 6.1 3.4 8.4 5.0 6.4 5.8 1.0 2.6 5.5 5.2 0.6 6.2 2.1 1.8 4.3 2.4 28.0 35.0 26.1 33.7 28.3 24.2 42.3 27.7 24.8 40.7 BMP2 BMP2A ENSG00000125845 "Bone morphogenetic protein 2" P12643 20 6767664-6780280 "Cancer-related genes, Predicted secreted proteins" "Chondrogenesis, Differentiation, Osteogenesis" "Cytokine, Developmental protein, Growth factor" "Cancer-related genes, Disease mutation, Dwarfism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "CACO-2: 20.7;HeLa: 13.5;hTERT-HME1: 12.2;RT4: 16.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 7 "NK-cell: 2.2" "Lineage enriched" "Detected in single" 7 "NK-cells: 2.2" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA058610, CAB078457" Enhanced Vesicles "Secreted to blood" 24353 Vesicles "CAB078457: AB_2532532, HPA058610: " "unprognostic (2.22e-2)" "unprognostic (9.32e-2)" "unprognostic (6.12e-2)" "unprognostic (3.56e-2)" "unprognostic (1.94e-2)" "unprognostic (2.48e-1)" "unprognostic (3.70e-3)" "unprognostic (3.12e-3)" "unprognostic (8.51e-2)" "unprognostic (8.46e-2)" "unprognostic (2.53e-3)" "unprognostic (5.39e-3)" "unprognostic (7.81e-2)" "unprognostic (3.76e-1)" "unprognostic (2.77e-1)" "unprognostic (3.01e-2)" "unprognostic (7.49e-2)" 11.1 1.1 1.6 10.5 3.1 0.6 5.3 1.8 7.5 3.7 13.1 2.6 1.9 4.2 3.4 6.7 3.7 3.7 15.6 3.9 2.4 1.6 3.6 3.8 12.8 1.3 2.9 1.3 3.1 9.2 4.7 2.3 7.6 2.7 8.8 9.5 18.3 2.0 1.2 2.6 9.1 13.4 3.4 1.4 8.0 13.8 1.1 2.7 0.3 13.2 6.2 3.1 14.1 9.1 0.0 0.0 0.3 0.0 2.2 0.0 0.0 0.0 0.2 0.0 0.0 0.3 0.1 0.0 0.5 2.3 0.0 0.0 20.7 0.0 0.0 0.3 0.7 6.9 4.1 1.8 0.0 0.0 3.7 0.0 13.5 0.0 1.0 0.0 0.5 0.1 6.3 0.0 12.2 4.2 0.0 0.0 0.1 0.0 0.0 3.9 0.5 0.5 4.0 0.0 0.3 1.5 16.5 0.7 1.0 4.9 0.0 0.0 0.0 4.3 1.0 1.2 1.8 0.0 0.5 0.2 0.5 0.0 2.1 1.1 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 2.2 0.0 0.0 0.0 0.0 1.6 3.1 1.8 3.3 2.4 1.6 2.9 1.3 2.7 2.7 BMP4 BMP2B ENSG00000125378 "Bone morphogenetic protein 4" P12644 14 53949736-53958761 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins" "Chondrogenesis, Differentiation, Osteogenesis" "Cytokine, Developmental protein, Growth factor" "Cancer-related genes, Disease mutation, Microphthalmia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "retina: 72.4" "Cell line enhanced" "Detected in many" "CACO-2: 26.0;CAPAN-2: 65.2;EFO-21: 21.7;Hep G2: 69.4;U-2 OS: 20.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Group enriched" "Detected in many" 5 "classical monocyte: 1.8;intermediate monocyte: 2.9;memory CD4 T-cell: 2.5;naive CD4 T-cell: 3.3;naive CD8 T-cell: 1.1;non-classical monocyte: 4.3" "Group enriched" "Detected in many" 12 "monocytes: 4.3;T-cells: 3.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB006863, HPA066235" Enhanced "Secreted to blood" 161800000 "CAB006863: , HPA066235: " "unprognostic (1.30e-1)" "unprognostic (3.27e-2)" "unprognostic (1.29e-1)" "unprognostic (5.20e-3)" "unprognostic (3.39e-2)" "unprognostic (3.32e-1)" "unprognostic (2.78e-2)" "unprognostic (3.11e-1)" "unprognostic (3.45e-3)" "unprognostic (7.67e-2)" "unprognostic (2.45e-3)" "unprognostic (7.06e-2)" "unprognostic (1.58e-2)" "unprognostic (2.93e-3)" "unprognostic (1.37e-1)" "unprognostic (3.22e-1)" "unprognostic (1.24e-1)" 7.9 7.8 1.2 3.6 2.0 0.0 10.3 8.1 3.1 8.6 11.7 3.6 3.5 7.8 5.9 2.7 6.0 5.4 9.9 8.3 2.1 0.8 6.1 2.8 8.2 3.4 2.4 2.6 12.0 2.1 0.0 4.1 21.4 11.9 18.0 14.5 72.4 6.4 9.4 7.3 9.4 11.0 11.0 3.7 2.7 11.9 2.4 2.6 1.6 7.3 4.5 4.0 13.0 22.5 0.0 0.3 0.0 4.3 0.0 3.3 0.9 3.3 8.7 0.4 0.4 0.1 0.0 0.1 1.7 7.4 4.4 3.4 26.0 65.2 0.0 21.7 0.0 15.9 1.8 0.2 2.4 0.8 1.3 0.0 1.7 69.4 4.4 0.0 0.2 0.0 0.6 2.1 0.1 13.0 0.0 0.0 2.1 1.5 1.1 0.0 3.0 0.7 0.0 2.3 0.0 6.2 0.2 0.0 0.0 0.0 0.2 0.2 8.5 0.3 0.6 0.1 20.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.9 0.0 1.8 0.0 0.3 2.9 0.0 0.0 2.5 0.5 0.3 0.0 3.3 1.1 0.0 0.0 4.3 0.1 0.0 0.9 1.2 2.0 8.1 3.1 2.1 0.8 2.4 2.6 11.9 2.6 BMPR1A "ACVRLK3, ALK3, CD292" ENSG00000107779 "Bone morphogenetic protein receptor type 1A" P36894 10 86756601-86932838 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Kinase, Receptor, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB019398 Approved Approved Cytosol Cytosol "CAB019398: " "unprognostic (1.36e-1)" "unprognostic (2.46e-1)" "unprognostic (3.34e-1)" "unprognostic (9.61e-2)" "unprognostic (1.05e-3)" "unprognostic (9.34e-2)" "prognostic unfavourable (8.93e-4)" "unprognostic (3.64e-1)" "unprognostic (2.38e-2)" "unprognostic (1.53e-1)" "unprognostic (9.24e-2)" "unprognostic (9.42e-2)" "unprognostic (4.32e-2)" "unprognostic (1.80e-1)" "unprognostic (1.47e-1)" "unprognostic (1.01e-2)" "unprognostic (1.07e-1)" 8.9 7.0 9.4 7.9 12.4 0.9 10.7 14.1 9.2 19.4 20.6 10.9 7.7 6.2 16.3 12.3 8.4 10.9 10.8 11.0 7.7 6.1 8.2 4.6 7.4 2.9 7.3 7.6 16.1 10.6 10.0 14.0 7.4 8.5 12.8 9.3 10.9 12.6 14.2 8.4 11.3 9.8 16.5 12.2 3.4 12.1 7.8 9.2 0.3 19.4 7.8 5.7 16.0 11.4 1.8 1.1 3.6 0.8 0.9 1.4 0.3 7.5 3.8 14.7 12.5 7.7 5.0 2.6 7.6 8.0 4.5 5.2 6.5 6.7 2.3 3.5 9.7 8.1 6.5 8.3 6.6 2.5 3.7 2.9 3.6 10.7 4.1 4.0 20.4 4.4 3.5 6.0 4.4 0.0 4.5 1.6 5.2 3.2 2.6 3.2 8.0 1.8 0.0 5.8 0.0 9.2 7.2 1.5 4.8 8.5 4.3 5.1 7.3 2.0 3.8 3.2 5.2 6.6 7.0 0.4 7.0 2.9 2.8 2.7 2.6 2.0 0.8 0.6 1.4 0.5 0.9 1.8 1.4 1.2 0.3 1.5 1.0 1.1 3.6 0.9 0.6 1.1 0.7 0.3 9.4 12.4 14.1 9.2 7.7 6.1 7.3 7.6 8.5 9.2 BNIP3 Nip3 ENSG00000176171 "BCL2 interacting protein 3" Q12983 10 131966455-131982013 "Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Apoptosis, Host-virus interaction" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "pancreas: 122.7" "Cell line enhanced" "Detected in many" "A-431: 73.3;HBF TERT88: 51.0;U-87 MG: 69.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003015, CAB011676" Supported Uncertain Cytosol Cytosol "CAB011676: , HPA003015: AB_1078290" "unprognostic (1.01e-3)" "unprognostic (1.42e-3)" "unprognostic (1.46e-1)" "unprognostic (8.04e-2)" "unprognostic (1.58e-2)" "unprognostic (1.62e-3)" "unprognostic (6.57e-3)" "unprognostic (1.12e-1)" "unprognostic (2.71e-2)" "unprognostic (1.46e-1)" "unprognostic (1.10e-1)" "unprognostic (2.64e-2)" "prognostic unfavourable (4.55e-4)" "unprognostic (2.37e-3)" "unprognostic (1.04e-1)" "unprognostic (3.29e-2)" "unprognostic (2.98e-1)" 19.3 12.0 18.3 4.0 18.6 3.0 8.7 13.5 28.3 7.7 4.6 13.0 5.1 4.0 6.0 11.4 8.1 6.0 7.9 43.3 16.9 14.6 27.6 53.4 6.7 4.6 16.5 14.2 19.3 122.7 6.0 7.3 13.0 22.6 18.2 2.9 5.2 19.2 6.6 48.0 9.0 4.5 6.0 13.3 4.9 6.4 6.0 11.1 3.3 10.8 6.2 4.0 9.2 7.3 6.1 3.0 5.1 3.5 2.2 23.4 8.9 73.3 5.9 4.2 11.9 11.4 12.1 21.9 17.9 16.6 13.5 38.7 1.2 1.6 0.1 29.1 10.3 4.5 9.0 25.4 51.0 3.9 6.8 2.6 3.8 17.0 15.3 3.3 2.1 8.4 6.4 13.1 13.3 9.4 6.7 0.2 22.0 5.8 1.7 18.7 3.6 17.8 4.1 2.1 6.2 14.8 1.2 5.6 13.2 3.6 7.6 10.1 4.6 4.7 10.7 19.2 6.4 7.2 14.1 12.6 10.7 10.2 69.4 0.1 3.2 2.2 3.5 5.1 9.8 2.3 10.4 5.7 13.9 10.3 3.0 6.1 23.4 15.4 0.9 2.2 3.1 2.3 13.2 8.9 18.3 18.6 13.5 28.3 16.9 14.6 16.5 14.2 22.6 11.1 BNIP3L "BNIP3a, Nix" ENSG00000104765 "BCL2 interacting protein 3 like" O60238 8 26382898-26505636 "Cancer-related genes, Predicted membrane proteins, Transporters" "Apoptosis, Host-virus interaction" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA015652, CAB025371" Enhanced Supported "Nuclear speckles,Mitochondria" Mitochondria "Nuclear speckles" "CAB025371: , HPA015652: AB_1845406" "unprognostic (1.02e-1)" "unprognostic (2.90e-1)" "unprognostic (2.00e-1)" "unprognostic (8.36e-2)" "unprognostic (6.24e-2)" "unprognostic (1.63e-1)" "unprognostic (1.64e-3)" "unprognostic (1.46e-2)" "unprognostic (5.04e-2)" "unprognostic (2.02e-1)" "unprognostic (2.06e-2)" "unprognostic (2.97e-2)" "prognostic unfavourable (5.92e-5)" "unprognostic (8.72e-3)" "unprognostic (5.16e-2)" "prognostic unfavourable (3.95e-4)" "unprognostic (7.59e-3)" 61.7 27.8 32.7 18.2 39.1 79.4 40.1 26.1 39.0 35.0 19.9 32.3 30.7 11.5 27.3 34.0 26.7 26.4 28.0 36.0 36.0 27.4 39.9 22.9 31.3 20.7 43.1 31.9 63.4 10.4 26.8 16.0 51.2 41.0 23.7 14.9 20.9 22.1 39.2 21.0 38.1 14.5 26.5 47.9 19.5 16.7 33.0 43.9 17.8 21.5 12.4 25.2 48.3 30.8 14.2 30.4 68.7 53.9 7.8 17.6 36.3 18.1 6.9 16.6 11.2 46.3 29.2 14.0 18.4 54.1 17.3 38.3 3.1 8.8 5.6 17.4 34.6 9.3 8.2 23.6 57.6 3.6 4.5 23.2 7.2 5.4 25.8 2.0 40.3 35.0 18.6 19.6 11.8 22.1 10.4 13.6 36.2 7.9 14.3 7.6 5.3 7.6 7.7 21.1 11.0 17.9 11.8 17.7 15.8 8.9 1.8 13.9 9.1 4.4 28.9 32.5 14.1 20.3 4.1 20.0 9.0 7.5 49.4 4.2 7.3 49.9 53.9 32.1 7.6 27.8 6.7 12.4 11.4 8.3 30.4 14.2 17.6 12.8 68.7 7.8 17.4 6.9 15.0 36.3 32.7 39.1 26.1 39.0 36.0 27.4 43.1 31.9 41.0 43.9 BRAF BRAF1 ENSG00000157764 "B-Raf proto-oncogene, serine/threonine kinase" P15056 7 140719327-140924928 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Allosteric enzyme, Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Cardiomyopathy, Deafness, Disease mutation, Ectodermal dysplasia, FDA approved drug targets, Mental retardation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001328, CAB004552, HPA071048" Approved Approved Vesicles,Cytosol Vesicles Cytosol "CAB004552: AB_626760, HPA001328: AB_1078296, HPA071048: " "unprognostic (2.98e-3)" "unprognostic (5.66e-2)" "unprognostic (2.20e-2)" "unprognostic (2.66e-3)" "unprognostic (2.44e-1)" "unprognostic (1.48e-2)" "unprognostic (2.07e-2)" "unprognostic (4.23e-2)" "unprognostic (4.07e-2)" "unprognostic (1.58e-2)" "unprognostic (6.53e-2)" "unprognostic (1.91e-2)" "unprognostic (3.79e-3)" "unprognostic (2.08e-1)" "unprognostic (1.76e-1)" "unprognostic (8.01e-2)" "unprognostic (5.46e-2)" 13.1 12.1 20.1 16.5 20.4 27.8 14.2 29.9 21.5 12.4 12.3 9.5 12.5 9.3 15.3 17.0 11.8 11.5 12.0 13.6 13.2 12.2 13.7 12.8 15.9 13.3 9.9 17.8 16.8 13.2 28.9 24.8 13.7 15.3 14.5 11.0 10.7 11.6 16.6 12.9 15.6 10.5 13.0 10.9 12.3 12.0 24.9 12.2 13.5 16.6 7.5 12.1 18.6 18.1 2.6 1.9 7.5 2.4 7.0 5.6 1.1 5.4 4.6 6.8 8.1 8.3 10.7 10.9 6.1 6.5 4.9 7.1 5.0 5.9 9.3 4.7 6.2 3.0 6.0 4.8 9.0 8.6 4.9 6.0 4.5 4.6 7.0 9.8 6.1 7.1 5.4 5.2 10.8 5.7 9.5 16.7 8.7 2.9 13.0 10.3 6.3 2.9 8.5 5.8 7.6 4.8 10.4 7.9 6.6 7.0 4.3 6.3 4.0 6.7 8.4 5.3 4.1 11.5 4.9 19.4 11.0 14.8 8.7 9.9 5.7 3.3 2.0 7.5 3.1 1.7 2.1 2.6 3.0 2.4 1.6 2.6 5.6 2.8 4.1 7.0 2.4 1.9 2.7 1.1 20.1 20.4 29.9 21.5 13.2 12.2 9.9 17.8 15.3 12.2 BRCA1 "BRCC1, FANCS, PPP1R53, RNF53" ENSG00000012048 "BRCA1, DNA repair associated" P38398 17 43044295-43170245 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Cell cycle, DNA damage, DNA recombination, DNA repair, Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism, Transcription, Transcription regulation, Ubl conjugation pathway" "Activator, DNA-binding, Transferase" "Cancer-related genes, Disease mutation, Fanconi anemia, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Group enriched" "Detected in all" 5 "dendritic cells: 9.1;granulocytes: 9.7;monocytes: 12.7" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB001946, HPA004840, HPA034966, HPA057371" Approved Supported "Nucleoplasm,Nuclear bodies" "Nucleoplasm, Nuclear bodies" "CAB001946: , HPA004840: , HPA034966: AB_10795287, HPA057371: " "unprognostic (7.87e-3)" "unprognostic (6.97e-2)" "unprognostic (3.53e-3)" "unprognostic (2.39e-1)" "unprognostic (5.42e-2)" "unprognostic (7.07e-3)" "unprognostic (1.56e-3)" "unprognostic (4.14e-3)" "unprognostic (9.62e-3)" "unprognostic (2.47e-1)" "unprognostic (5.53e-3)" "unprognostic (1.28e-1)" "unprognostic (1.08e-4)" "unprognostic (1.08e-3)" "unprognostic (1.48e-1)" "unprognostic (2.12e-1)" "unprognostic (8.31e-2)" 4.8 4.3 6.0 9.6 11.3 15.3 5.1 12.9 10.6 5.4 9.2 3.4 6.8 4.3 5.4 5.5 9.1 5.5 3.3 6.5 6.6 5.3 4.2 7.7 4.9 13.0 7.5 5.9 5.1 4.7 4.2 11.0 5.3 10.5 4.1 10.4 3.7 5.4 7.4 7.3 8.3 6.7 5.5 9.2 5.9 5.1 17.6 7.0 10.9 15.6 7.3 14.6 5.5 5.6 2.0 9.1 9.7 12.7 1.4 1.3 10.7 15.5 25.2 13.9 11.1 2.3 5.2 13.6 18.3 7.9 15.4 14.7 15.3 12.1 35.9 3.4 7.0 18.0 18.9 10.2 25.9 16.4 13.8 16.9 19.8 13.2 0.5 30.1 14.7 1.4 1.7 23.2 7.4 7.9 25.4 15.4 14.5 10.3 25.2 9.9 7.6 6.7 17.4 29.3 14.7 5.7 15.1 9.6 10.3 14.1 4.7 6.9 12.4 13.9 5.2 13.8 11.2 17.8 19.1 7.2 17.6 27.6 11.1 17.9 14.4 4.6 12.7 1.8 1.3 4.0 1.3 1.1 1.3 1.0 9.1 2.0 1.2 1.3 9.7 1.4 1.5 1.4 0.4 10.7 6.0 11.3 12.9 10.6 6.6 5.3 7.5 5.9 10.5 7.0 BRCA2 "BRCC2, FACD, FAD, FAD1, FANCD, FANCD1, XRCC11" ENSG00000139618 "BRCA2, DNA repair associated" P51587 13 32315474-32400266 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cell cycle, DNA damage, DNA recombination, DNA repair" DNA-binding "Cancer-related genes, Disease mutation, Fanconi anemia, Tumor suppressor" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 23.2;testis: 16.9" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA026815 Uncertain Approved Nucleoplasm,Cytosol Nucleoplasm Cytosol "HPA026815: AB_10602692" "unprognostic (9.36e-2)" "unprognostic (2.50e-1)" "unprognostic (4.50e-3)" "unprognostic (1.06e-2)" "unprognostic (5.40e-2)" "unprognostic (2.26e-2)" "unprognostic (1.37e-2)" "unprognostic (1.15e-1)" "unprognostic (1.60e-2)" "unprognostic (2.01e-1)" "unprognostic (6.97e-3)" "unprognostic (4.06e-2)" "unprognostic (3.07e-9)" "unprognostic (2.36e-2)" "unprognostic (1.18e-1)" "unprognostic (1.88e-1)" "unprognostic (1.32e-1)" 2.4 1.0 0.6 13.8 0.6 11.6 3.2 0.6 0.6 1.8 4.0 0.2 0.2 1.4 1.5 2.7 3.0 1.0 0.7 2.1 0.6 0.7 1.0 1.4 3.5 5.3 0.7 0.5 1.4 3.3 0.4 0.7 7.0 0.8 0.9 2.0 0.1 1.8 0.3 3.3 1.8 3.2 0.8 2.1 6.6 1.5 16.9 0.1 23.2 0.9 4.8 4.2 1.3 1.7 1.3 1.9 0.4 0.2 1.5 0.8 0.0 3.9 3.5 6.0 4.5 0.6 1.6 6.2 4.3 2.7 5.0 4.6 8.2 5.3 14.0 2.8 2.1 5.4 4.9 2.5 9.6 9.1 2.6 8.9 2.2 3.2 0.2 12.7 4.4 0.3 0.3 9.1 6.3 4.0 5.8 4.9 5.7 4.5 10.1 7.5 7.2 1.9 10.0 15.5 2.7 1.3 4.3 2.3 4.3 5.2 2.2 2.1 2.6 6.3 3.1 5.7 6.1 6.3 5.9 1.9 2.9 7.2 2.9 5.1 5.4 0.1 0.2 0.2 0.3 0.2 0.1 0.9 0.4 0.2 0.2 1.3 0.6 0.8 0.4 1.5 0.2 1.9 0.4 0.0 0.6 0.6 0.6 0.6 0.6 0.7 0.7 0.5 0.8 0.1 BRD3 "KIAA0043, ORFX, RING3L" ENSG00000169925 "Bromodomain containing 3" Q15059 9 134030305-134068535 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Chromatin regulator" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA051830 Approved Approved "Nuclear bodies" "Nuclear bodies" "HPA051830: " "unprognostic (3.53e-2)" "unprognostic (2.17e-1)" "unprognostic (1.55e-2)" "unprognostic (1.90e-1)" "unprognostic (6.20e-2)" "unprognostic (2.60e-2)" "unprognostic (2.98e-2)" "unprognostic (3.48e-2)" "unprognostic (1.11e-2)" "unprognostic (6.75e-2)" "unprognostic (2.79e-1)" "unprognostic (1.98e-1)" "prognostic favourable (2.71e-7)" "unprognostic (1.00e-1)" "unprognostic (4.71e-2)" "unprognostic (2.57e-2)" "unprognostic (1.42e-1)" 16.3 15.7 18.0 12.0 20.0 12.3 14.2 21.8 21.8 21.0 20.3 26.7 17.3 13.8 21.7 17.4 14.6 17.7 12.6 17.1 19.9 14.8 11.3 14.5 14.6 11.9 15.8 15.8 19.1 18.7 21.8 15.8 15.7 15.6 19.9 10.3 16.6 16.5 22.5 29.2 19.6 12.9 16.3 17.8 20.1 14.8 17.8 18.2 35.4 18.7 9.2 10.3 17.9 14.1 7.3 16.6 14.6 12.9 15.4 11.9 7.8 4.0 12.4 15.8 12.3 8.8 7.2 14.5 4.2 4.7 4.6 4.7 10.3 6.8 1.5 4.4 3.8 14.2 14.6 5.7 3.7 9.6 8.2 8.8 14.0 11.6 7.9 11.5 7.9 7.6 7.1 5.3 6.1 7.5 7.9 4.6 4.7 13.7 21.3 15.5 21.1 9.6 15.8 22.8 7.7 6.5 4.3 23.2 21.4 18.6 7.0 4.9 10.1 19.2 9.6 11.3 6.3 7.3 3.7 2.5 2.6 1.4 5.7 8.0 7.5 5.9 12.9 14.5 11.9 9.8 10.0 7.1 9.6 10.6 12.5 7.3 9.1 9.7 14.6 15.4 7.9 16.6 4.4 7.8 18.0 20.0 21.8 21.8 19.9 14.8 15.8 15.8 15.6 18.2 BRD4 "CAP, HUNK1, HUNKI, MCAP" ENSG00000141867 "Bromodomain containing 4" O60885 19 15235519-15332545 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "DNA damage, Host-virus interaction, Transcription, Transcription regulation" "Chromatin regulator" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA015055, HPA061646, CAB068177, CAB068178" Supported Enhanced Nucleoplasm Nucleoplasm "CAB068177: , CAB068178: , HPA015055: AB_1845435, HPA061646: " "unprognostic (2.83e-3)" "unprognostic (2.39e-2)" "unprognostic (6.37e-3)" "unprognostic (3.38e-2)" "unprognostic (2.15e-1)" "unprognostic (9.53e-3)" "unprognostic (3.03e-3)" "unprognostic (6.13e-2)" "unprognostic (7.63e-2)" "unprognostic (2.72e-2)" "unprognostic (3.98e-2)" "unprognostic (5.26e-2)" "unprognostic (1.83e-3)" "unprognostic (2.43e-1)" "unprognostic (2.73e-1)" "unprognostic (1.28e-1)" "unprognostic (1.22e-1)" 23.0 20.7 27.8 25.6 30.1 25.2 20.4 32.1 29.9 20.8 19.6 17.2 18.9 17.6 23.4 12.5 22.9 18.6 15.8 21.3 20.3 12.4 18.1 25.3 22.5 22.7 14.8 17.6 27.3 31.3 19.1 18.8 34.0 17.6 20.8 10.7 18.9 22.0 19.3 47.7 27.3 21.0 20.3 13.9 26.8 20.2 20.1 16.8 34.2 21.5 11.6 23.7 20.9 24.8 6.9 4.3 11.6 4.4 4.9 3.5 2.0 20.5 20.7 12.9 24.4 12.4 8.8 15.6 15.1 12.4 12.0 12.6 21.9 31.0 25.8 25.1 16.5 20.6 15.0 14.3 10.4 25.8 9.9 24.4 18.2 19.0 18.9 24.0 27.2 12.9 14.8 14.8 29.3 11.6 41.3 26.2 7.6 26.6 22.6 17.4 26.4 24.4 28.4 13.6 16.1 9.5 22.2 15.6 14.2 20.0 14.7 17.1 14.7 16.5 18.4 31.3 15.0 27.8 23.8 21.4 18.8 13.1 17.3 19.6 24.2 5.2 3.6 3.9 3.5 4.4 2.7 5.4 3.1 2.9 2.1 6.9 3.1 2.9 11.6 4.9 3.9 4.3 2.2 2.0 27.8 30.1 32.1 29.9 20.3 12.4 14.8 17.6 17.6 16.8 BRIP1 "BACH1, FANCJ, OF" ENSG00000136492 "BRCA1 interacting protein C-terminal helicase 1" Q9BX63 17 61681266-61863521 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "DNA damage, DNA repair" "Helicase, Hydrolase" "Cancer-related genes, Disease mutation, Fanconi anemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 30.1" "Cell line enhanced" "Detected in many" "MCF7: 41.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in some" "Low cell type specificity" "Detected in many" "Group enriched" "Detected in many" 4 "B-cells: 2.2;granulocytes: 2.1;T-cells: 3.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA005474 Approved Supported "Nucleoplasm,Nuclear membrane" "Nucleoplasm, Nuclear membrane" "HPA005474: AB_2667333" "unprognostic (1.88e-1)" "unprognostic (1.55e-2)" "prognostic favourable (3.45e-5)" "unprognostic (6.85e-4)" "unprognostic (3.09e-1)" "prognostic favourable (3.62e-4)" "unprognostic (2.60e-3)" "unprognostic (5.60e-2)" "unprognostic (5.66e-3)" "unprognostic (6.71e-2)" "unprognostic (1.50e-3)" "unprognostic (2.75e-2)" "unprognostic (3.41e-12)" "unprognostic (1.19e-2)" "unprognostic (2.25e-1)" "unprognostic (3.96e-2)" "unprognostic (3.62e-3)" 1.0 0.9 0.7 6.3 3.5 9.1 1.1 0.6 1.4 1.4 2.6 0.2 0.6 2.8 1.5 1.2 3.7 0.8 1.8 0.4 0.5 0.5 0.6 2.3 1.3 4.0 0.5 0.9 2.1 1.3 0.1 0.4 1.7 0.7 1.0 2.8 0.4 1.4 0.0 0.4 2.7 5.5 1.0 0.5 2.3 1.3 10.8 0.4 30.1 0.4 2.0 6.6 1.3 1.7 2.2 0.5 2.1 0.3 0.6 3.7 0.5 12.3 4.2 12.2 6.9 0.4 1.1 2.7 11.4 6.7 12.2 15.8 4.3 3.9 7.3 2.6 2.4 4.5 6.3 2.3 16.4 1.8 7.7 7.5 6.7 5.3 0.1 9.6 4.4 0.2 0.1 9.7 2.6 2.6 5.2 5.0 7.6 41.4 15.2 3.3 2.6 3.6 9.5 23.4 3.5 1.6 5.6 4.9 12.7 4.4 1.5 1.8 4.1 3.7 2.2 18.0 13.1 6.6 13.1 3.1 6.0 7.9 3.7 4.6 4.5 2.1 0.3 1.5 0.5 0.2 0.6 2.2 1.2 0.6 0.4 1.8 1.8 0.9 1.0 0.6 0.2 0.5 3.7 0.5 0.7 3.5 0.6 1.4 0.5 0.5 0.5 0.9 0.7 0.4 BRMS1 DKFZP564A063 ENSG00000174744 "Breast cancer metastasis suppressor 1" Q9HCU9 11 66337333-66345125 "Cancer-related genes, Predicted intracellular proteins" "Apoptosis, Transcription, Transcription regulation" Repressor "Cancer-related genes, Tumor suppressor" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010824, HPA019637" Approved Approved Centrosome Centrosome "CAB010824: , HPA019637: AB_1845448" "unprognostic (1.75e-1)" "unprognostic (2.64e-2)" "unprognostic (2.01e-1)" "unprognostic (4.31e-2)" "unprognostic (1.72e-2)" "unprognostic (5.50e-2)" "prognostic unfavourable (6.74e-4)" "unprognostic (2.99e-1)" "unprognostic (2.62e-1)" "unprognostic (4.48e-1)" "unprognostic (2.24e-1)" "unprognostic (2.39e-1)" "unprognostic (1.27e-1)" "unprognostic (5.67e-3)" "unprognostic (2.54e-1)" "unprognostic (6.32e-2)" "unprognostic (1.61e-1)" 17.2 18.9 16.7 23.4 24.5 37.0 20.5 9.1 18.7 13.7 19.7 14.5 24.7 21.0 14.6 21.0 24.1 16.1 26.0 13.7 16.6 10.7 23.4 22.2 16.7 25.8 20.1 16.1 14.0 37.6 17.6 12.6 24.1 17.6 22.3 16.0 12.8 23.9 29.8 24.2 26.1 22.6 13.0 16.2 26.3 19.6 37.4 20.9 25.3 20.8 29.3 21.4 16.2 17.5 38.5 32.1 50.7 38.0 22.2 37.2 28.9 24.2 31.8 10.7 17.9 11.4 11.9 15.2 16.7 18.6 30.7 20.6 25.9 16.0 16.4 25.3 16.6 28.6 20.4 30.9 14.5 19.4 17.0 14.9 17.0 18.8 21.3 21.5 17.5 13.4 33.3 30.9 23.2 18.8 17.7 7.7 18.2 39.1 26.2 51.4 23.2 30.0 22.3 19.7 30.7 19.0 14.1 22.7 18.2 21.0 21.7 54.5 26.4 13.4 18.1 23.1 21.9 37.1 21.0 16.0 15.8 25.9 29.9 14.1 24.7 19.0 38.0 36.7 31.1 36.2 33.2 38.5 33.5 29.6 29.8 36.1 29.7 28.0 50.7 22.2 31.0 32.1 37.2 28.9 16.7 24.5 9.1 18.7 16.6 10.7 20.1 16.1 17.6 20.9 BTG1 APRO2 ENSG00000133639 "BTG anti-proliferation factor 1" P62324 12 92140278-92145897 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 190.7" "Cell line enhanced" "Detected in all" "ASC TERT1: 49.6" "Low cancer specificity" "Detected in all" "Region enriched" "Detected in all" 5 "cerebellum: 66.8" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA005972 Approved Nucleoplasm,Cytosol Nucleoplasm Cytosol "HPA005972: AB_1078303" "prognostic favourable (4.36e-5)" "unprognostic (1.43e-1)" "unprognostic (2.32e-1)" "unprognostic (1.37e-2)" "unprognostic (1.07e-1)" "unprognostic (3.61e-3)" "unprognostic (1.10e-1)" "unprognostic (5.51e-2)" "unprognostic (1.46e-1)" "unprognostic (1.34e-2)" "unprognostic (2.50e-1)" "unprognostic (4.94e-2)" "prognostic unfavourable (1.95e-7)" "unprognostic (1.14e-1)" "unprognostic (1.56e-1)" "unprognostic (5.79e-2)" "unprognostic (9.81e-2)" 52.0 22.1 11.5 58.3 13.4 126.9 114.4 66.8 10.4 41.7 40.1 5.5 21.9 15.5 30.1 22.0 28.7 27.9 39.9 49.2 11.9 8.1 22.2 58.1 85.6 190.7 10.4 8.2 29.1 64.2 17.6 17.1 23.4 13.3 28.7 18.1 21.0 19.0 25.9 31.6 70.6 34.3 26.0 24.6 77.1 26.4 19.0 8.9 148.9 15.7 14.3 58.2 54.2 35.2 58.3 6.6 94.3 14.0 47.1 95.2 26.1 6.8 8.6 9.5 1.1 35.7 49.6 4.1 7.7 17.1 5.2 5.2 5.1 2.4 7.4 1.6 8.2 4.7 3.1 8.7 9.7 8.9 6.7 1.4 6.0 2.6 36.2 5.4 2.5 42.3 26.2 11.9 36.9 10.4 5.1 9.8 5.9 7.1 3.8 17.4 2.3 9.9 13.1 5.3 2.3 16.0 14.3 5.3 10.6 9.7 7.5 25.0 31.4 12.6 3.3 5.9 1.8 4.5 4.7 13.6 7.2 12.3 4.6 4.3 6.6 22.3 13.6 94.3 17.0 10.6 20.1 44.5 34.3 29.8 6.6 58.3 95.2 39.1 52.3 47.1 14.0 6.2 39.2 26.1 11.5 13.4 66.8 10.4 11.9 8.1 10.4 8.2 13.3 8.9 BTG2 "APRO1, MGC126063, MGC126064, PC3, TIS21" ENSG00000159388 "BTG anti-proliferation factor 2" P78543 1 203305491-203309602 "Cancer-related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Daudi: 36.9;HMC-1: 38.6;U-266/70: 59.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA002355 Uncertain Approved Nucleoplasm,Vesicles Vesicles Nucleoplasm "HPA002355: AB_1078304" "prognostic favourable (8.53e-4)" "unprognostic (1.54e-1)" "unprognostic (4.63e-2)" "unprognostic (4.81e-3)" "unprognostic (5.91e-2)" "unprognostic (1.46e-1)" "unprognostic (2.47e-1)" "unprognostic (7.87e-3)" "unprognostic (4.72e-1)" "unprognostic (1.71e-1)" "unprognostic (1.61e-1)" "unprognostic (1.18e-2)" "unprognostic (4.46e-2)" "unprognostic (6.22e-2)" "unprognostic (4.34e-1)" "unprognostic (1.17e-1)" "unprognostic (2.86e-3)" 61.6 45.9 10.1 61.4 20.6 46.9 27.8 13.0 10.4 23.0 53.3 27.8 27.0 15.2 27.1 24.6 55.7 103.7 76.1 65.3 10.4 10.0 22.3 4.3 40.7 20.0 12.2 5.5 102.0 117.6 7.0 52.2 42.7 28.3 61.0 38.5 30.4 18.1 104.1 98.9 30.5 36.6 50.8 22.7 32.7 67.1 11.5 9.9 82.9 36.7 45.2 49.0 64.7 21.5 14.1 17.3 34.5 14.2 5.7 8.5 7.1 0.9 1.4 2.6 1.0 3.3 2.4 21.7 2.5 5.0 0.6 2.5 1.9 0.4 36.9 1.8 0.8 16.2 9.4 9.9 1.2 2.4 4.6 19.3 2.7 4.2 7.2 0.1 38.6 2.4 18.4 2.4 4.5 13.5 8.9 25.6 6.7 0.8 4.0 1.2 1.1 0.2 2.5 8.7 18.5 1.2 30.1 0.4 2.7 2.0 0.8 0.3 2.1 2.3 3.3 0.0 4.3 0.6 0.1 59.8 30.2 23.6 0.5 0.9 1.5 3.2 8.1 9.9 4.7 12.1 7.1 14.1 5.3 4.8 5.1 13.1 8.5 5.9 34.5 5.7 14.2 17.3 4.9 7.1 10.1 20.6 13.0 10.4 10.4 10.0 12.2 5.5 28.3 9.9 BTK "AGMX1, ATK, IMD1, PSCTK1, XLA" ENSG00000010671 "Bruton tyrosine kinase" Q06187 X 101349447-101390796 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Adaptive immunity, Apoptosis, Immunity, Innate immunity, Transcription, Transcription regulation" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, Dwarfism, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "blood: 77.5;lymphoid tissue: 37.0" "Cell line enhanced" "Detected in some" "Daudi: 28.8;HEL: 40.0;HMC-1: 144.1;U-937: 20.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "basophil: 77.5" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA001198, HPA002028, CAB016689" Enhanced Supported "Plasma membrane,Cytosol" 610000 "Plasma membrane, Cytosol" "CAB016689: AB_1611894, HPA001198: AB_1078305, HPA002028: AB_1078306" "unprognostic (3.19e-2)" "unprognostic (2.51e-3)" "unprognostic (1.06e-2)" "unprognostic (3.66e-2)" "unprognostic (5.69e-2)" "unprognostic (3.76e-3)" "unprognostic (6.55e-2)" "unprognostic (3.58e-3)" "unprognostic (6.02e-2)" "unprognostic (3.12e-1)" "unprognostic (1.02e-1)" "unprognostic (1.41e-1)" "unprognostic (2.08e-3)" "unprognostic (7.80e-2)" "unprognostic (1.29e-2)" "unprognostic (1.56e-2)" "unprognostic (8.14e-2)" 7.3 2.4 3.3 23.5 5.6 14.0 2.6 0.8 3.6 2.3 3.0 4.7 0.3 2.2 1.9 2.6 2.4 2.0 3.7 3.3 3.3 2.5 2.2 2.5 10.7 25.1 5.4 1.2 1.2 1.5 0.2 1.4 3.2 4.1 2.5 4.5 1.5 3.2 1.0 1.0 2.5 12.9 3.3 10.8 37.0 3.1 1.3 6.3 4.0 1.7 1.8 36.7 5.8 2.0 13.7 13.2 77.5 20.7 0.0 0.0 6.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 28.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 40.0 0.0 0.0 0.0 16.0 144.1 0.0 0.0 0.0 0.0 0.0 8.4 0.3 0.0 0.0 0.0 11.2 0.2 0.0 12.1 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 9.5 0.0 0.0 0.0 0.0 0.0 0.3 0.1 13.7 0.0 20.9 0.0 77.5 11.3 19.3 0.0 18.1 0.0 13.7 0.0 0.0 13.2 13.7 0.0 0.0 4.5 0.0 20.7 6.0 0.0 6.1 3.3 5.6 0.8 3.6 3.3 2.5 5.4 1.2 4.1 6.3 BUB1B "Bub1A, BUBR1, MAD3L, SSK1" ENSG00000156970 "BUB1 mitotic checkpoint serine/threonine kinase B" O60566 15 40161023-40221136 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Apoptosis, Cell cycle, Cell division, Mitosis" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 49.5;testis: 25.6" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "naive B-cell: 2.8;plasmacytoid DC: 2.8" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "Low region specificity" "Detected in some" HPA008419 Supported Cytosol Cytosol "HPA008419: AB_1078308" "unprognostic (4.40e-2)" "unprognostic (2.23e-1)" "unprognostic (4.65e-2)" "unprognostic (2.44e-3)" "unprognostic (9.66e-2)" "unprognostic (3.52e-2)" "prognostic unfavourable (7.43e-6)" "prognostic unfavourable (3.56e-4)" "unprognostic (3.69e-3)" "unprognostic (2.32e-1)" "prognostic unfavourable (1.79e-4)" "unprognostic (1.76e-2)" "unprognostic (0.00e+0)" "unprognostic (3.75e-2)" "unprognostic (4.66e-2)" "unprognostic (2.20e-1)" "unprognostic (3.94e-2)" 1.0 0.9 0.3 18.4 0.6 11.4 1.5 0.4 0.5 1.3 4.0 0.4 0.1 3.3 1.1 0.8 6.5 0.5 1.1 0.6 0.4 0.4 0.8 0.7 1.8 8.7 0.4 0.3 0.6 0.5 0.0 0.4 3.4 0.5 0.6 4.4 0.3 1.6 0.1 0.7 2.3 2.9 1.2 0.6 5.4 1.7 25.6 0.1 49.5 0.5 3.1 10.6 1.1 2.0 2.8 2.8 0.0 0.2 0.7 0.7 0.5 21.6 11.0 35.1 13.9 0.8 2.5 11.3 20.5 11.5 22.0 19.1 16.0 8.3 19.6 11.5 7.4 24.4 33.1 11.1 24.0 16.8 17.8 28.6 28.4 14.9 0.0 25.7 15.7 0.5 0.6 13.4 12.7 15.9 24.6 20.9 21.9 7.3 20.2 15.7 23.7 12.5 21.7 28.8 14.8 6.7 11.0 22.9 14.1 12.7 12.1 4.5 14.1 13.4 9.2 16.9 17.9 16.8 18.2 10.9 18.5 32.0 9.0 29.0 21.9 0.0 0.0 0.0 0.2 0.2 0.3 2.4 0.7 0.6 0.7 2.8 0.1 0.4 0.0 0.7 0.1 2.8 0.0 0.5 0.3 0.6 0.4 0.5 0.4 0.4 0.4 0.3 0.5 0.1 C1QBP "gC1Q-R, gC1qR, HABP1, p32, SF2p32" ENSG00000108561 "Complement C1q binding protein" Q07021 17 5432777-5448830 "Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters" "Adaptive immunity, Apoptosis, Complement pathway, Host-virus interaction, Immunity, Innate immunity, mRNA processing, mRNA splicing, Ribosome biogenesis, Transcription, Transcription regulation" "Cancer-related genes, Disease mutation, Primary mitochondrial disease" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" HPA026483 Supported Approved "Plasma membrane,Mitochondria" "Intracellular and membrane" 930000 "Plasma membrane" Mitochondria "HPA026483: AB_1847108" "unprognostic (2.18e-1)" "unprognostic (1.74e-1)" "unprognostic (3.80e-2)" "unprognostic (6.40e-2)" "unprognostic (2.60e-1)" "unprognostic (6.76e-2)" "unprognostic (7.47e-2)" "unprognostic (4.62e-2)" "unprognostic (2.40e-3)" "unprognostic (6.03e-2)" "unprognostic (4.60e-3)" "unprognostic (3.08e-2)" "unprognostic (7.80e-3)" "unprognostic (1.20e-1)" "unprognostic (3.13e-1)" "unprognostic (3.28e-1)" "unprognostic (3.97e-1)" 24.1 51.6 34.0 51.0 31.4 36.3 42.3 25.8 46.2 22.0 48.8 21.1 22.5 33.9 25.8 25.7 51.1 27.1 33.0 47.1 34.8 35.4 48.4 69.0 26.6 81.1 35.4 25.1 25.2 51.9 32.7 31.2 26.7 36.6 23.8 52.2 24.9 25.1 28.0 55.0 27.3 30.0 29.2 27.8 43.8 26.4 21.3 17.2 55.4 28.1 71.9 46.0 25.5 25.4 59.5 68.1 9.9 35.8 39.0 55.6 65.7 48.8 76.0 26.9 43.4 20.1 24.8 36.4 37.5 30.7 87.4 53.8 72.7 16.4 105.0 37.1 28.3 43.8 86.4 50.9 80.9 24.0 148.7 48.3 39.5 84.5 32.1 58.9 38.5 27.4 46.8 48.0 69.5 44.5 57.4 26.9 33.9 34.1 83.6 42.6 60.6 45.5 66.7 38.1 57.3 50.4 37.0 21.6 40.5 30.8 39.6 52.2 25.0 29.8 26.1 28.1 25.6 31.9 81.4 14.1 21.5 46.2 26.8 56.7 43.0 9.9 34.7 8.3 40.1 35.8 52.5 59.5 45.0 39.9 68.1 49.4 55.6 46.3 2.8 39.0 26.9 56.9 34.3 65.7 34.0 31.4 25.8 46.2 34.8 35.4 35.4 25.1 36.6 17.2 C3orf70 ENSG00000187068 "Chromosome 3 open reading frame 70" A6NLC5 3 185078050-185153014 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "smooth muscle: 26.6" "Cell line enhanced" "Detected in some" "SCLC-21H: 19.0;SK-BR-3: 8.3;WM-115: 10.2" "Cancer enhanced" "Detected in many" "glioma: 10.5" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA041861 Uncertain Approved Cytosol Cytosol "HPA041861: AB_10804119" "unprognostic (1.45e-1)" "unprognostic (2.17e-3)" "unprognostic (3.92e-3)" "unprognostic (2.77e-1)" "unprognostic (2.31e-1)" "unprognostic (6.62e-4)" "unprognostic (5.56e-2)" "unprognostic (1.05e-1)" "unprognostic (1.11e-1)" "unprognostic (1.32e-1)" "unprognostic (5.98e-3)" "unprognostic (9.91e-2)" "prognostic unfavourable (6.40e-6)" "unprognostic (1.06e-1)" "unprognostic (8.48e-2)" "unprognostic (6.57e-2)" "unprognostic (7.84e-2)" 4.6 2.3 14.4 4.7 13.8 0.9 2.0 7.9 18.2 7.2 12.1 11.1 7.9 5.3 12.1 6.1 10.1 6.8 6.1 3.3 11.1 10.2 1.6 1.3 2.4 1.3 11.4 7.1 5.9 1.1 4.0 1.4 2.9 10.5 10.2 8.2 5.2 5.5 16.4 1.5 2.9 6.5 26.6 11.1 4.2 4.4 7.5 7.0 0.0 2.4 1.0 1.7 13.2 3.3 1.2 1.2 3.4 1.6 1.7 1.1 0.5 0.0 0.1 2.2 0.0 0.0 0.1 0.1 2.9 0.1 0.5 0.0 1.3 0.0 0.0 0.0 0.3 0.1 1.0 0.0 0.2 0.0 0.7 2.5 0.1 0.7 0.0 0.4 4.2 0.3 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.1 0.0 0.1 1.0 0.2 0.1 4.6 0.1 0.0 0.4 19.0 0.2 0.9 8.3 0.5 0.6 2.1 0.8 0.0 2.2 0.1 1.4 0.0 0.0 0.0 0.0 0.0 10.2 3.4 1.2 1.7 0.8 1.0 1.0 1.0 0.8 0.8 0.6 1.2 1.0 1.1 3.3 1.7 1.6 1.2 0.7 0.5 14.4 13.8 7.9 9.6 11.1 10.2 11.4 7.1 10.5 7.0 C6 ENSG00000039537 "Complement C6" P13671 5 41142234-41261438 "Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted secreted proteins, Transporters" "Complement pathway, Cytolysis, Immunity, Innate immunity" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 7 "liver: 176.1" "Group enriched" "Detected in some" 13 "ASC diff: 5.1;ASC TERT1: 7.1;HSkMC: 18.8" "Group enriched" "Detected in many" 7 "liver cancer: 49.0;pancreatic cancer: 12.5" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in single" "HPA043823, CAB069427" Enhanced "Secreted to blood" 7600000000 "CAB069427: AB_1614336, HPA043823: AB_10960262" "unprognostic (9.79e-2)" "unprognostic (1.96e-2)" "unprognostic (5.94e-3)" "unprognostic (3.02e-2)" "unprognostic (1.67e-1)" "unprognostic (1.18e-1)" "unprognostic (1.12e-3)" "unprognostic (4.66e-2)" "unprognostic (3.72e-2)" "unprognostic (1.53e-1)" "unprognostic (2.34e-1)" "unprognostic (3.04e-3)" "prognostic favourable (4.31e-4)" "unprognostic (2.69e-4)" "unprognostic (1.61e-1)" "unprognostic (1.40e-2)" "unprognostic (3.51e-2)" 2.3 0.1 0.2 0.1 0.2 0.0 1.0 0.1 0.2 0.3 0.5 0.5 0.1 0.1 0.2 2.7 0.3 8.8 2.4 24.1 0.2 0.0 5.2 176.1 0.9 0.8 0.1 0.1 3.2 10.1 0.0 0.4 0.4 0.6 0.2 0.0 0.2 0.1 0.1 0.2 0.0 0.8 0.1 0.2 0.1 0.4 1.7 0.1 0.1 0.4 0.7 0.2 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.1 7.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.7 0.2 0.0 18.8 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.1 0.2 0.2 0.0 0.1 0.1 0.6 0.1 C7 ENSG00000112936 "Complement C7" P10643 5 40909252-40982939 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins" "Complement alternate pathway, Complement pathway, Cytolysis, Immunity, Innate immunity" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "ovary: 199.9" "Group enriched" "Detected in some" 9 "ASC diff: 37.6;HHSteC: 49.7;HSkMC: 68.4;SH-SY5Y: 46.4" "Cancer enhanced" "Detected in all" "pancreatic cancer: 73.8" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in some" "Low region specificity" "Detected in some" HPA001465 Approved "Secreted to blood" 67000000000 "HPA001465: AB_1078554" "unprognostic (5.01e-2)" "unprognostic (3.74e-2)" "unprognostic (7.40e-2)" "unprognostic (4.68e-3)" "unprognostic (5.35e-2)" "unprognostic (1.43e-3)" "prognostic favourable (5.89e-4)" "unprognostic (6.67e-2)" "unprognostic (3.45e-1)" "unprognostic (2.21e-2)" "unprognostic (1.33e-1)" "unprognostic (1.93e-3)" "unprognostic (2.24e-2)" "unprognostic (6.10e-3)" "unprognostic (1.12e-1)" "unprognostic (2.14e-1)" "unprognostic (2.06e-3)" 54.4 99.5 0.8 7.4 1.6 0.0 10.5 1.1 1.0 30.2 34.7 3.1 14.8 2.5 36.8 48.6 55.3 47.7 48.2 79.7 0.9 0.3 81.3 41.0 29.1 69.0 3.9 1.5 199.9 32.4 3.0 5.2 55.4 3.7 52.5 4.8 1.4 5.1 17.5 1.9 1.8 17.0 43.3 3.2 33.6 17.9 44.6 0.7 3.1 32.4 1.1 7.2 39.9 29.6 0.7 0.4 1.6 0.3 1.5 0.4 0.0 0.0 0.0 0.0 0.0 37.6 5.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 49.7 0.0 0.0 68.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 46.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.3 0.4 0.2 0.3 0.1 0.2 0.2 0.2 0.0 0.7 0.3 0.4 1.1 1.5 0.3 0.4 0.0 0.0 0.8 1.6 1.1 1.0 0.9 0.3 3.9 1.5 3.7 0.7 CA8 "CALS, CARP" ENSG00000178538 "Carbonic anhydrase 8" P35219 8 60187347-60281412 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 41.0;brain: 26.8;parathyroid gland: 56.8" "Cell line enhanced" "Detected in some" "HEK 293: 12.6;K-562: 22.7;NB-4: 13.1;WM-115: 6.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in some" 20 "basophil: 41.0" "Lineage enriched" "Detected in many" 20 "granulocytes: 41.0" "Region enriched" "Detected in some" 37 "cerebellum: 1413.4" "Region enriched" "Detected in all" 9 "cerebellum: 163.0" "HPA024748, CAB025545, CAB047309" Enhanced "CAB025545: , CAB047309: , HPA024748: AB_1846003" "unprognostic (1.55e-1)" "unprognostic (2.89e-2)" "unprognostic (4.43e-2)" "unprognostic (3.46e-3)" "unprognostic (6.67e-2)" "unprognostic (3.19e-1)" "unprognostic (3.85e-2)" "unprognostic (3.54e-2)" "unprognostic (1.28e-1)" "unprognostic (1.19e-1)" "prognostic favourable (5.79e-5)" "unprognostic (3.23e-2)" "unprognostic (1.68e-2)" "unprognostic (2.12e-1)" "unprognostic (1.71e-2)" "unprognostic (1.95e-1)" "unprognostic (1.41e-1)" 2.3 1.5 9.2 1.1 11.6 1.1 6.5 26.8 6.9 6.3 2.2 3.6 0.6 1.8 2.8 12.8 0.9 2.5 1.0 3.8 7.8 6.0 7.4 0.6 1.6 1.0 4.2 5.3 0.7 3.0 56.8 9.8 8.1 3.4 3.3 3.1 1.5 6.6 0.9 2.0 0.9 1.7 1.3 1.9 1.3 5.9 9.3 6.2 1.7 0.7 1.3 1.0 1.3 2.1 0.1 2.0 41.0 0.0 0.0 0.0 0.0 0.0 2.9 3.9 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.8 0.0 0.0 1.3 0.0 0.1 0.0 12.6 5.2 0.0 0.0 4.2 2.1 1.4 0.0 0.0 0.0 0.0 0.0 22.7 0.2 0.0 0.0 3.6 13.1 0.2 0.0 0.0 0.0 0.3 0.5 1.0 5.8 0.0 0.0 1.2 0.0 5.3 0.8 0.0 0.0 0.4 0.0 0.0 0.2 0.0 0.0 0.0 0.0 6.6 41.0 0.0 0.3 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 9.2 11.6 26.8 6.9 7.8 6.0 4.2 5.3 3.4 6.2 CACNA1D "CACH3, CACN4, CACNL1A2, Cav1.3, CCHL1A2" ENSG00000157388 "Calcium voltage-gated channel subunit alpha1 D" Q01668 3 53328963-53813733 "Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "Cancer-related genes, Deafness, Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in some" "HMC-1: 14.1;RPMI-8226: 32.8;SK-BR-3: 6.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 9 "basophil: 7.2" "Lineage enriched" "Detected in single" 20 "granulocytes: 7.2" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA020215 Uncertain Approved "Nuclear membrane" "Nuclear membrane" "HPA020215: AB_1845860" "unprognostic (5.85e-2)" "unprognostic (4.90e-3)" "unprognostic (5.09e-2)" "unprognostic (2.24e-2)" "unprognostic (7.55e-2)" "unprognostic (1.77e-2)" "unprognostic (1.92e-1)" "unprognostic (2.32e-2)" "unprognostic (2.95e-1)" "unprognostic (4.42e-2)" "unprognostic (3.90e-3)" "unprognostic (1.53e-1)" "prognostic favourable (8.34e-8)" "unprognostic (1.14e-1)" "unprognostic (3.05e-2)" "unprognostic (8.09e-3)" "unprognostic (6.70e-3)" 0.6 13.4 10.0 0.8 12.6 1.4 3.6 12.2 16.5 11.2 2.8 3.7 0.1 3.3 6.8 13.2 1.2 14.9 6.2 1.8 5.3 3.5 4.2 3.0 9.0 0.5 2.5 9.6 1.2 5.3 3.0 13.6 1.4 8.7 5.7 3.1 10.1 1.1 3.5 0.6 1.5 4.2 1.7 2.2 4.4 1.8 3.0 1.6 0.0 5.2 0.0 0.6 2.3 0.6 0.1 0.3 7.2 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.8 0.0 0.1 0.0 0.0 1.5 1.4 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.2 0.2 0.0 0.0 0.0 0.0 14.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.2 0.0 0.0 0.1 32.8 0.3 2.2 3.0 1.3 0.2 6.2 0.7 1.8 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 7.2 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 10.0 12.6 12.2 16.5 5.3 3.5 2.5 9.6 8.7 1.6 CAD GATD4 ENSG00000084774 "Carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase" P27708 2 27217390-27243943 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Pyrimidine biosynthesis" "Allosteric enzyme, Hydrolase, Ligase, Multifunctional enzyme, Transferase" "Cancer-related genes, Congenital disorder of glycosylation, Disease mutation, Epilepsy" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB007781, HPA057266, HPA069341" Supported Supported Nucleoplasm 26000 Nucleoplasm "CAB007781: AB_562057, HPA057266: AB_2683387, HPA069341: AB_2686125" "unprognostic (1.69e-1)" "unprognostic (7.34e-2)" "unprognostic (1.49e-1)" "unprognostic (4.71e-3)" "unprognostic (2.55e-1)" "unprognostic (1.92e-1)" "prognostic unfavourable (1.72e-11)" "unprognostic (1.25e-1)" "unprognostic (2.22e-1)" "unprognostic (2.37e-1)" "unprognostic (1.01e-1)" "unprognostic (6.11e-2)" "prognostic unfavourable (1.82e-4)" "unprognostic (6.94e-2)" "unprognostic (1.75e-1)" "unprognostic (1.14e-1)" "unprognostic (5.93e-3)" 12.0 11.9 10.1 23.1 12.4 11.1 18.9 13.3 13.1 14.6 12.4 10.9 9.7 12.1 21.0 18.0 16.3 16.6 15.8 9.8 8.6 8.8 13.1 22.9 13.0 27.9 11.8 9.5 24.4 18.1 10.7 16.4 10.6 10.1 12.5 11.6 12.9 11.7 18.3 12.3 26.0 13.2 17.3 12.5 18.7 11.4 21.3 10.8 35.2 13.8 14.1 18.5 12.7 13.1 5.1 4.9 0.8 2.3 3.7 7.9 2.6 25.2 22.9 10.2 20.4 16.6 13.7 8.1 10.7 7.5 13.6 9.7 25.9 10.1 22.6 9.7 9.8 14.3 30.0 14.2 10.2 14.8 24.2 32.3 17.4 13.5 8.3 25.4 16.3 10.4 11.7 19.7 22.5 14.5 22.7 12.6 11.9 25.4 16.2 37.8 24.5 17.4 28.4 30.6 23.5 10.0 12.9 20.5 10.3 15.0 10.7 12.5 8.3 10.7 13.0 20.6 17.0 16.0 21.5 26.2 16.9 46.2 8.3 24.5 17.7 0.0 1.2 0.5 4.7 2.3 4.0 5.1 6.5 7.7 2.7 5.0 4.3 4.3 0.8 3.7 1.2 4.9 7.9 2.6 10.1 12.4 13.3 13.1 8.6 8.8 11.8 9.5 10.1 10.8 CALCA CALC1 ENSG00000110680 "Calcitonin related polypeptide alpha" "P01258, P06881" 11 14966668-14972354 "Cancer-related genes, Plasma proteins, Predicted secreted proteins, Transporters" Hormone "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 4 "parathyroid gland: 122.2;thyroid gland: 55.3" "Cell line enhanced" "Detected in some" "EFO-21: 2.8;hTERT-HME1: 1.7;Karpas-707: 1.8;SCLC-21H: 3.4" "Cancer enriched" "Detected in many" 7 "lung cancer: 64.7" "Region enriched" "Detected in single" 48 "pons and medulla: 19.8" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in many" 5 "pons and medulla: 60.6" HPA059886 Supported "Secreted to blood" 96005 "HPA059886: " "unprognostic (1.97e-1)" "prognostic unfavourable (4.49e-5)" "unprognostic (5.99e-2)" "unprognostic (2.42e-1)" "unprognostic (1.17e-1)" "unprognostic (6.45e-2)" "unprognostic (1.28e-1)" "unprognostic (7.66e-2)" "unprognostic (3.33e-2)" "unprognostic (7.49e-2)" "unprognostic (6.74e-2)" "unprognostic (2.53e-3)" "unprognostic (1.02e-2)" 0.2 0.0 0.1 0.3 0.4 0.0 0.8 0.1 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.0 0.2 6.2 16.8 0.6 0.0 0.1 0.0 0.0 0.1 122.2 0.2 0.0 19.8 1.2 0.0 0.3 0.4 0.0 0.3 0.0 0.0 0.3 1.5 4.6 0.0 0.0 0.0 0.6 55.3 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.6 0.0 0.0 2.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 1.8 0.0 0.0 0.0 0.5 0.0 0.0 0.2 0.0 0.0 0.0 0.0 3.4 0.1 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.2 0.1 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.1 0.4 0.1 0.2 0.0 0.2 0.1 0.0 19.8 0.0 CALR "cC1qR, CRT, FLJ26680, RO, SSA" ENSG00000179218 Calreticulin P27797 19 12938578-12944489 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" Chaperone "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB001513, HPA002242, CAB019952, CAB079775" Enhanced Supported "Endoplasmic reticulum" "Intracellular and membrane" 450000000 "Endoplasmic reticulum" "CAB001513: , CAB019952: AB_2069792, CAB079775: AB_303403, HPA002242: AB_1078384" "unprognostic (1.49e-1)" "unprognostic (1.57e-1)" "unprognostic (8.46e-2)" "unprognostic (4.25e-2)" "unprognostic (9.44e-3)" "unprognostic (6.93e-2)" "unprognostic (2.47e-2)" "unprognostic (4.60e-2)" "unprognostic (2.61e-1)" "prognostic favourable (1.10e-4)" "unprognostic (2.07e-1)" "unprognostic (3.76e-1)" "prognostic unfavourable (1.11e-16)" "unprognostic (2.37e-1)" "unprognostic (1.96e-1)" "unprognostic (1.37e-1)" "unprognostic (5.27e-2)" 67.5 55.5 31.9 58.9 36.1 86.4 64.6 20.9 38.9 50.2 52.3 42.5 65.7 44.1 61.6 108.4 65.2 49.1 67.5 62.5 31.6 35.2 81.9 302.6 61.8 83.6 33.5 33.4 59.6 124.3 56.4 60.3 98.0 35.7 53.1 60.0 43.2 121.0 68.6 25.1 34.2 53.8 56.9 42.1 66.6 49.7 65.0 32.7 61.6 250.6 55.0 65.2 39.4 68.0 25.1 57.2 16.1 38.6 26.3 48.4 16.2 116.3 46.0 63.2 137.7 79.9 72.1 57.9 155.6 127.8 93.8 136.6 70.3 93.7 74.7 143.7 180.5 46.4 69.1 99.2 95.0 55.5 39.4 62.2 56.0 106.9 188.8 249.7 84.4 66.8 46.0 86.9 73.6 112.8 53.2 37.9 76.1 80.4 69.3 163.3 56.2 65.3 53.6 53.6 90.4 82.4 66.7 24.0 51.4 96.5 53.1 31.8 71.0 103.6 97.6 78.4 49.4 111.4 69.5 47.3 42.2 75.1 110.4 109.0 86.1 16.1 19.5 10.1 48.4 38.6 34.3 25.1 29.2 36.7 20.4 22.4 21.6 39.2 6.6 26.3 30.8 57.2 21.5 16.2 31.9 36.1 20.9 38.9 31.6 35.2 33.5 33.4 35.7 32.7 CAMTA1 KIAA0833 ENSG00000171735 "Calmodulin binding transcription activator 1" Q9Y6Y1 1 6785324-7769706 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" Activator "Cancer-related genes, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA036342, HPA036343" Approved Supported Cytosol Cytosol "HPA036342: , HPA036343: AB_10671839" "unprognostic (1.11e-1)" "unprognostic (6.31e-2)" "unprognostic (5.80e-2)" "unprognostic (4.14e-3)" "unprognostic (3.10e-2)" "unprognostic (1.47e-2)" "prognostic unfavourable (5.25e-4)" "unprognostic (1.08e-2)" "unprognostic (3.59e-1)" "prognostic favourable (4.10e-4)" "unprognostic (3.90e-3)" "unprognostic (8.84e-2)" "unprognostic (1.35e-3)" "unprognostic (2.17e-2)" "unprognostic (9.19e-3)" "unprognostic (1.42e-1)" "unprognostic (9.03e-3)" 18.4 24.3 31.6 12.2 30.7 12.1 21.7 24.4 37.1 16.5 30.2 19.9 13.2 28.3 20.0 46.7 22.7 16.8 17.7 58.1 26.4 27.6 36.7 37.2 16.5 13.3 31.2 26.5 17.1 18.6 22.0 17.6 14.3 47.5 22.2 27.1 25.0 27.1 29.6 48.0 12.9 30.4 38.4 23.9 15.7 21.5 23.0 19.4 14.7 30.8 20.5 17.5 31.3 18.7 19.8 32.3 28.3 32.4 10.3 18.1 18.9 21.5 12.2 33.9 17.2 17.5 26.8 9.5 23.5 18.1 25.3 21.4 14.7 27.5 18.0 18.5 24.5 13.4 17.7 24.2 36.2 13.4 19.2 20.2 28.8 28.7 28.5 15.3 14.7 18.0 16.9 18.2 28.1 28.1 14.2 24.4 29.1 20.9 20.3 42.0 23.4 14.3 13.6 30.2 39.7 34.1 12.6 35.1 28.3 16.6 24.7 36.0 13.4 19.2 16.4 18.0 15.2 18.5 14.6 18.7 23.0 48.2 26.9 34.5 10.1 27.5 32.4 28.3 11.5 19.4 12.5 19.8 18.0 14.2 30.6 16.2 14.7 12.8 6.6 10.3 14.7 32.3 18.1 18.9 31.6 30.7 24.4 37.1 26.4 27.6 31.2 26.5 47.5 19.4 CANT1 "SCAN-1, SHAPY" ENSG00000171302 "Calcium activated nucleotidase 1" Q8WVQ1 17 78991717-79009867 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" Hydrolase "Cancer-related genes, Disease mutation, Dwarfism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "T-47d: 71.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019627, HPA019639, HPA022818" Enhanced 2300000 "HPA019627: AB_1845969, HPA019639: AB_1845970, HPA022818: AB_1845971" "unprognostic (1.98e-2)" "unprognostic (2.49e-2)" "unprognostic (1.50e-2)" "unprognostic (5.36e-2)" "unprognostic (2.13e-2)" "unprognostic (2.21e-2)" "prognostic unfavourable (1.41e-4)" "prognostic unfavourable (2.90e-4)" "unprognostic (1.76e-1)" "unprognostic (9.00e-2)" "unprognostic (3.30e-1)" "unprognostic (2.49e-1)" "prognostic unfavourable (6.21e-4)" "unprognostic (7.04e-2)" "unprognostic (5.06e-2)" "unprognostic (1.16e-1)" "unprognostic (7.23e-2)" 13.8 15.3 9.6 13.1 10.2 8.1 13.0 12.2 10.8 17.7 43.8 12.3 25.4 25.5 12.0 14.3 27.5 10.0 19.5 10.8 9.0 6.9 10.3 17.7 11.1 11.5 12.5 7.7 10.4 14.7 13.1 11.8 33.0 12.0 36.7 41.5 7.9 30.3 41.4 9.0 8.9 27.2 8.0 12.4 18.1 25.8 19.0 10.3 14.1 12.4 8.9 14.4 10.3 13.7 4.1 3.8 17.5 4.4 3.1 6.2 4.4 26.4 29.0 8.1 11.7 7.7 9.2 10.4 16.3 14.3 17.6 14.9 13.7 25.0 6.4 9.6 11.4 13.4 6.9 12.9 17.6 10.6 12.6 8.3 8.8 11.4 6.6 7.9 13.1 9.5 8.3 16.2 8.8 30.3 10.4 10.9 11.7 14.3 12.0 4.7 5.5 30.9 6.7 13.3 7.2 7.7 13.3 11.7 11.7 8.7 57.8 12.3 71.4 9.5 15.1 26.3 23.8 11.8 20.4 12.9 10.7 6.2 16.8 6.1 16.4 6.1 3.8 8.1 6.2 4.4 6.1 4.1 4.6 5.2 3.8 2.9 4.5 4.4 17.5 3.1 2.9 2.7 3.8 4.4 9.6 10.2 12.2 10.8 9.0 6.9 12.5 7.7 12.0 10.3 CANX "CNX, IP90, P90" ENSG00000127022 Calnexin P27824 5 179678628-179730925 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" Chaperone "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "SK-MEL-30: 107.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004738, HPA009433, HPA009696" Enhanced Enhanced "Endoplasmic reticulum" 82000000 "Endoplasmic reticulum" "CAB004738: AB_626784, HPA009433: AB_1078380, HPA009696: AB_1078379" "unprognostic (6.56e-2)" "unprognostic (9.34e-3)" "prognostic favourable (1.38e-4)" "unprognostic (1.19e-1)" "unprognostic (7.86e-2)" "unprognostic (1.41e-2)" "unprognostic (4.66e-3)" "unprognostic (8.57e-2)" "unprognostic (4.34e-2)" "unprognostic (1.25e-2)" "unprognostic (2.17e-3)" "unprognostic (4.48e-2)" "unprognostic (2.28e-1)" "unprognostic (1.87e-1)" "unprognostic (7.12e-2)" "prognostic unfavourable (3.17e-4)" "unprognostic (2.15e-1)" 49.3 35.4 40.0 35.8 40.9 57.6 37.8 27.3 49.1 93.0 33.6 37.1 48.3 44.0 42.7 115.4 31.6 31.7 30.0 51.3 36.9 50.9 61.6 120.8 34.7 30.1 47.5 27.9 41.0 78.2 13.7 33.0 70.5 44.9 33.5 55.1 32.2 121.5 48.5 28.5 23.4 68.5 60.5 48.8 38.2 31.7 34.3 30.0 31.0 113.4 25.9 29.9 41.4 47.6 10.1 26.3 25.9 28.9 18.7 22.6 30.0 8.2 23.4 19.9 12.1 42.8 31.8 10.1 42.8 47.0 49.4 42.0 20.3 19.2 62.9 60.1 34.3 5.7 31.2 23.3 56.5 16.1 9.5 10.1 58.4 13.2 58.3 19.3 9.6 6.2 42.9 26.5 77.2 20.4 7.9 24.5 5.4 7.7 9.7 0.3 4.0 1.4 10.1 14.4 6.8 36.4 24.5 10.0 2.4 12.0 5.2 107.2 40.5 8.5 38.0 11.3 18.9 12.8 33.2 7.4 25.8 15.9 17.1 12.6 11.0 25.9 28.9 8.8 17.7 21.2 22.6 10.1 13.9 16.3 26.3 7.7 9.5 10.6 6.1 18.7 18.0 25.3 10.1 30.0 40.0 40.9 27.3 33.3 36.9 50.9 47.5 27.9 44.9 30.0 CAP2 ENSG00000112186 "Cyclase associated actin cytoskeleton regulatory protein 2" P40123 6 17393216-17557792 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "skeletal muscle: 165.7" "Cell line enhanced" "Detected in many" "LHCN-M2: 33.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 4 "MAIT T-cell: 2.9" "Lineage enriched" "Detected in single" 29 "T-cells: 2.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA050530, HPA054147" Enhanced Approved "Nucleoplasm,Plasma membrane,Cytosol" "Nucleoplasm, Cytosol" "Plasma membrane" "HPA050530: AB_2681159, HPA054147: AB_2682400" "unprognostic (7.27e-2)" "unprognostic (5.71e-3)" "unprognostic (1.63e-2)" "unprognostic (1.55e-1)" "unprognostic (4.86e-1)" "unprognostic (2.23e-2)" "unprognostic (9.94e-2)" "unprognostic (3.58e-2)" "unprognostic (7.72e-2)" "unprognostic (1.65e-1)" "unprognostic (6.43e-2)" "unprognostic (2.30e-1)" "unprognostic (1.59e-1)" "unprognostic (1.06e-2)" "unprognostic (1.47e-1)" "unprognostic (8.05e-2)" "unprognostic (1.75e-3)" 5.8 4.1 13.8 3.0 20.1 0.7 3.9 7.5 26.4 5.6 7.7 1.9 2.0 1.9 9.2 5.9 7.0 5.8 3.8 31.2 19.9 8.7 3.3 2.0 2.1 1.1 5.3 17.3 2.1 1.6 3.2 1.7 6.2 8.6 8.4 3.6 2.9 2.5 10.1 165.7 0.9 2.6 13.1 2.0 1.6 3.3 1.1 1.3 0.0 2.3 14.5 1.3 4.6 6.4 0.0 0.0 0.0 0.0 0.0 2.9 0.1 5.4 8.4 16.3 19.6 0.1 0.0 3.5 19.3 14.1 15.9 14.5 2.8 2.4 0.0 18.2 20.7 2.8 7.2 7.2 23.0 0.0 2.7 0.0 5.4 9.2 1.5 0.0 0.0 1.2 3.5 8.0 3.5 0.7 0.0 0.0 33.5 8.7 0.0 0.0 6.2 4.8 1.8 21.7 0.3 8.3 2.2 2.1 4.1 6.5 21.0 11.4 23.2 3.9 0.0 12.9 12.3 0.3 16.9 0.0 0.0 0.0 4.2 0.0 17.5 0.0 0.0 0.0 0.1 0.0 2.9 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 13.8 20.1 7.5 26.4 19.9 8.7 5.3 17.3 8.6 1.3 CAPN6 "CalpM, CANPX, CAPNX" ENSG00000077274 "Calpain 6" Q9Y6Q1 X 111245103-111270523 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "epididymis: 62.9;placenta: 173.5" "Cell line enhanced" "Detected in some" "HAP1: 3.5;HDLM-2: 11.0;NTERA-2: 17.3" "Cancer enhanced" "Detected in many" "endometrial cancer: 25.9" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "NK-cell: 1.2;plasmacytoid DC: 2.0" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" HPA040259 Approved Vesicles Vesicles "HPA040259: " "unprognostic (1.27e-3)" "unprognostic (2.04e-1)" "unprognostic (2.69e-2)" "unprognostic (5.77e-3)" "unprognostic (2.07e-1)" "unprognostic (9.93e-2)" "unprognostic (8.39e-3)" "unprognostic (1.06e-1)" "unprognostic (2.08e-1)" "unprognostic (9.45e-3)" "unprognostic (5.12e-1)" "unprognostic (6.25e-2)" "unprognostic (7.67e-2)" "unprognostic (6.50e-2)" "unprognostic (5.02e-3)" "unprognostic (2.66e-1)" "unprognostic (6.30e-2)" 1.7 0.0 0.2 1.7 0.2 0.0 6.0 0.3 0.3 3.9 4.2 0.2 23.4 0.2 18.2 62.9 2.4 2.9 2.6 0.4 0.2 0.0 5.1 0.4 0.3 1.1 0.2 0.4 1.9 4.1 0.0 0.2 173.5 0.3 3.6 2.2 2.1 5.6 21.7 1.7 1.0 1.3 2.0 0.3 1.0 7.2 2.8 0.2 0.5 1.7 4.7 2.9 1.4 2.6 0.1 2.0 0.8 0.0 1.2 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 3.5 0.0 0.0 11.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 17.3 0.0 0.0 0.0 0.1 1.5 0.0 0.1 0.4 0.4 0.4 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.8 0.0 0.0 0.0 0.0 0.6 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 2.0 0.1 0.0 0.2 0.2 0.3 0.3 0.2 0.0 0.2 0.4 0.3 0.2 CARD11 "BIMP3, CARMA1" ENSG00000198286 "Caspase recruitment domain family member 11" Q9BXL7 7 2906141-3043945 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 21.4;lymphoid tissue: 44.7" "Cell line enhanced" "Detected in some" "Daudi: 39.7;K-562: 15.8;RT4: 29.9;U-698: 35.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "plasmacytoid DC: 21.4" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "Low region specificity" "Detected in many" HPA052984 Approved "HPA052984: AB_2682005" "unprognostic (3.12e-2)" "unprognostic (1.75e-1)" "unprognostic (2.17e-1)" "unprognostic (8.46e-3)" "unprognostic (4.81e-1)" "unprognostic (3.44e-2)" "unprognostic (1.71e-1)" "unprognostic (2.31e-1)" "unprognostic (5.65e-2)" "unprognostic (5.11e-2)" "unprognostic (2.09e-2)" "unprognostic (3.09e-1)" "prognostic unfavourable (6.68e-8)" "unprognostic (3.74e-2)" "unprognostic (4.75e-2)" "unprognostic (1.31e-1)" "prognostic favourable (1.10e-4)" 1.2 1.7 1.4 44.7 1.0 9.0 0.9 0.7 1.4 1.7 1.4 1.2 0.6 1.9 0.8 0.5 2.7 1.2 11.4 0.8 1.4 2.3 1.9 1.4 3.8 25.0 2.1 0.5 0.9 1.4 0.1 1.0 0.5 1.1 2.8 1.2 1.2 6.7 1.0 0.3 0.5 14.2 1.4 2.9 27.4 3.9 1.4 1.5 22.8 1.3 1.7 28.6 9.4 5.2 4.6 21.4 0.3 0.0 3.3 5.5 1.8 5.3 0.8 0.0 0.0 0.0 0.0 4.1 0.0 0.0 0.2 0.0 10.5 11.7 39.7 9.9 0.0 8.9 0.0 0.1 0.1 13.5 0.3 0.0 1.0 0.1 0.2 0.1 0.0 0.0 0.0 0.0 0.0 7.6 15.8 0.0 0.0 0.1 1.5 0.0 15.0 0.0 1.9 0.0 9.9 3.8 29.9 0.1 0.5 0.0 0.0 0.0 0.0 0.8 5.0 0.0 4.0 0.0 0.0 4.1 0.0 35.4 0.0 0.0 0.0 0.3 0.0 0.0 5.5 0.0 5.2 3.8 3.2 3.6 0.6 4.6 2.1 3.8 0.1 3.3 0.0 21.4 2.2 1.8 1.4 1.0 0.7 1.4 1.4 2.3 2.1 0.5 1.1 1.5 CARM1 PRMT4 ENSG00000142453 "Coactivator associated arginine methyltransferase 1" Q86X55 19 10871513-10923070 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Host-virus interaction, Transcription, Transcription regulation" "Chromatin regulator, Methyltransferase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 64.3" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB032961, HPA043561, HPA048073" Supported Enhanced Nucleoplasm "Intracellular and membrane" Nucleoplasm "CAB032961: AB_2068446, HPA043561: , HPA048073: " "unprognostic (9.46e-2)" "unprognostic (3.61e-1)" "unprognostic (2.94e-2)" "unprognostic (2.23e-1)" "unprognostic (2.69e-2)" "unprognostic (3.13e-2)" "unprognostic (1.66e-3)" "unprognostic (3.76e-2)" "unprognostic (7.81e-2)" "unprognostic (6.18e-2)" "unprognostic (9.31e-2)" "unprognostic (7.25e-2)" "prognostic unfavourable (7.88e-6)" "unprognostic (1.71e-2)" "unprognostic (6.26e-2)" "unprognostic (1.00e-1)" "prognostic unfavourable (8.37e-4)" 12.2 8.8 12.3 12.6 16.1 13.2 9.6 12.5 17.7 15.8 14.0 9.3 9.0 11.5 19.6 9.1 20.5 14.8 12.4 14.7 11.2 7.2 9.3 14.5 8.9 12.4 7.8 10.2 13.0 16.9 8.2 6.9 15.3 9.5 12.6 10.2 12.0 11.4 13.2 64.3 12.5 12.0 15.6 6.6 9.8 11.1 17.5 8.6 9.4 10.0 12.7 15.6 15.8 15.9 1.3 1.6 0.3 1.4 0.1 2.6 0.4 22.4 16.7 24.1 32.6 20.1 27.5 23.1 16.2 28.1 24.1 23.2 25.8 8.3 31.0 19.4 28.2 21.5 24.5 24.3 15.2 34.7 20.0 9.5 10.9 31.3 17.2 14.3 12.4 18.8 15.9 16.4 19.8 30.4 22.8 27.9 14.1 40.7 24.9 12.3 29.7 27.9 34.9 12.3 36.0 14.5 11.7 17.5 16.8 11.6 14.0 15.6 14.0 12.3 18.2 29.0 16.4 27.5 18.9 27.2 21.4 27.1 19.1 23.0 12.6 0.0 1.4 0.2 1.2 1.4 0.5 1.3 0.9 2.6 1.3 1.3 1.0 0.9 0.3 0.1 0.7 1.6 0.8 0.4 12.3 16.1 12.5 17.7 11.2 7.2 7.8 10.2 9.5 8.6 CARS CARS1 ENSG00000110619 "Cysteinyl-tRNA synthetase" P49589 11 3000922-3057613 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Protein biosynthesis" "Aminoacyl-tRNA synthetase, Ligase" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002383, HPA002384, CAB075734, CAB075735, CAB075736, CAB075737" Enhanced Enhanced Cytosol 110000 Cytosol "CAB075734: , CAB075735: , CAB075736: , CAB075737: , HPA002383: AB_1078399, HPA002384: AB_1846033" "unprognostic (9.10e-3)" "unprognostic (1.83e-1)" "unprognostic (4.16e-3)" "unprognostic (1.43e-1)" "unprognostic (1.00e-2)" "unprognostic (7.97e-2)" "prognostic unfavourable (5.16e-4)" "unprognostic (1.41e-2)" "unprognostic (1.05e-1)" "unprognostic (8.00e-2)" "unprognostic (5.51e-2)" "unprognostic (2.45e-1)" "prognostic unfavourable (0.00e+0)" "unprognostic (5.37e-2)" "unprognostic (1.71e-1)" "unprognostic (1.48e-1)" "unprognostic (3.46e-1)" 24.9 15.9 15.8 15.8 17.7 9.0 15.9 9.5 29.1 13.4 16.3 19.1 11.1 15.9 14.0 10.7 16.0 10.8 14.2 12.5 15.3 18.7 10.7 22.1 15.1 17.2 23.3 15.9 14.5 42.5 14.9 15.9 14.0 23.0 10.8 17.6 7.4 20.3 14.8 24.6 18.8 17.8 21.0 16.1 14.8 22.8 13.4 17.3 9.8 23.0 14.5 22.7 14.4 19.4 8.3 13.3 18.0 23.9 16.4 18.1 11.6 7.5 3.8 5.0 15.0 19.5 18.0 4.5 19.3 22.0 13.3 24.1 9.4 18.0 11.7 5.7 24.3 19.4 16.3 21.9 18.4 34.1 3.7 6.6 6.6 7.2 46.8 13.7 14.5 29.6 17.3 11.5 12.9 17.5 11.0 41.5 13.1 11.5 9.6 0.0 18.7 6.9 4.6 8.3 14.6 0.0 12.6 10.7 14.2 4.7 13.6 21.1 0.0 0.0 6.0 5.5 5.1 13.6 0.2 30.9 28.1 7.4 0.0 7.2 10.8 7.7 12.0 8.8 15.2 10.5 13.0 8.3 13.6 13.6 13.3 6.0 7.5 12.1 18.0 16.4 23.9 5.2 18.1 11.6 15.8 17.7 9.5 29.1 15.3 18.7 23.3 15.9 23.0 17.3 CASC3 "BTZ, MLN51" ENSG00000108349 "Cancer susceptibility 3" O15234 17 40140318-40172183 "Cancer-related genes, Predicted intracellular proteins, Transporters" "mRNA processing, mRNA splicing, mRNA transport, Nonsense-mediated mRNA decay, Stress response, Translation regulation, Transport" RNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA024592, HPA050262" Approved Approved "Nuclear membrane" "Nuclear membrane" "HPA024592: AB_1846034, HPA050262: " "unprognostic (3.76e-2)" "unprognostic (3.18e-1)" "unprognostic (2.00e-1)" "unprognostic (1.00e-1)" "unprognostic (1.98e-1)" "unprognostic (1.77e-2)" "unprognostic (1.48e-3)" "unprognostic (3.40e-3)" "unprognostic (3.38e-1)" "unprognostic (1.16e-2)" "unprognostic (3.29e-3)" "unprognostic (2.87e-1)" "unprognostic (1.66e-2)" "unprognostic (1.15e-1)" "unprognostic (3.41e-1)" "unprognostic (1.27e-1)" "unprognostic (1.48e-2)" 27.4 21.0 37.8 20.4 34.8 22.6 26.8 30.0 36.5 30.1 27.3 40.7 19.3 16.4 35.9 26.8 22.2 35.1 21.7 17.8 36.6 32.7 21.6 14.7 23.2 21.8 39.9 27.7 42.1 22.7 31.8 32.6 21.4 29.4 27.4 23.4 25.7 22.5 36.6 50.9 23.0 19.6 35.0 40.7 23.2 22.7 59.7 31.0 19.6 29.4 18.1 25.5 34.1 29.7 6.5 7.2 26.1 11.5 6.8 9.2 5.6 13.3 13.7 17.7 19.8 14.3 15.1 11.3 13.6 12.2 18.7 16.2 14.9 11.7 25.0 21.8 17.1 24.1 21.5 14.4 25.7 17.0 19.0 18.0 17.1 14.9 13.1 22.0 12.2 15.6 13.3 18.3 28.8 23.2 19.4 18.8 15.3 7.7 32.2 12.4 13.9 8.4 20.2 23.6 25.7 9.7 11.8 27.7 15.9 20.3 73.3 17.9 24.1 17.4 15.4 16.3 17.1 15.4 21.4 18.0 16.6 25.3 15.6 12.0 17.7 5.8 5.9 8.6 9.2 8.0 8.3 6.5 6.9 8.3 7.2 6.5 7.9 7.4 26.1 6.8 11.5 3.9 6.4 5.6 37.8 34.8 30.0 36.5 36.6 32.7 39.9 27.7 29.4 31.0 CASP1 "ICE, IL1BC" ENSG00000137752 "Caspase 1" P29466 11 105025443-105035250 "Cancer-related genes, Enzymes, Predicted intracellular proteins" Apoptosis "Hydrolase, Protease, Thiol protease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 64.2;lymphoid tissue: 40.7" "Cell line enhanced" "Detected in many" "BJ hTERT+: 37.8;HBEC3-KT: 17.9;HHSteC: 20.3;U-937: 44.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Region enhanced" "Detected in many" "olfactory region: 22.8" "Low region specificity" "Detected in all" "CAB002685, HPA003056" Approved Supported Nucleoplasm,Cytosol Cytosol Nucleoplasm "CAB002685: , HPA003056: AB_1846037" "unprognostic (1.21e-3)" "unprognostic (3.02e-1)" "unprognostic (9.47e-3)" "unprognostic (1.43e-1)" "unprognostic (1.47e-1)" "unprognostic (1.21e-1)" "unprognostic (5.24e-2)" "unprognostic (1.97e-1)" "unprognostic (1.66e-1)" "unprognostic (6.67e-2)" "unprognostic (2.75e-2)" "unprognostic (1.35e-1)" "prognostic unfavourable (3.11e-4)" "unprognostic (9.03e-2)" "unprognostic (2.30e-2)" "unprognostic (3.18e-1)" "unprognostic (5.19e-2)" 7.4 3.9 6.6 15.1 17.0 8.2 6.9 3.5 7.0 4.1 12.8 2.2 2.9 34.0 3.0 4.2 10.6 4.3 7.3 4.9 9.3 3.0 6.4 5.8 20.5 16.2 16.7 2.6 4.4 3.4 0.2 3.7 8.7 13.3 6.1 13.9 3.7 7.0 3.2 1.6 9.9 37.2 5.2 17.4 40.7 5.6 1.5 11.0 4.1 3.7 5.6 9.0 9.7 13.2 7.3 39.6 40.5 64.2 11.1 34.3 31.2 0.4 0.1 0.0 1.8 2.0 4.2 0.3 1.9 37.8 4.8 13.2 0.0 0.2 6.1 0.7 2.1 2.7 0.0 17.9 1.1 4.0 0.0 0.3 0.2 0.4 20.3 7.1 0.0 7.2 12.7 3.9 10.4 2.0 0.0 0.0 1.1 0.0 0.2 9.9 0.0 0.1 5.9 0.1 4.8 0.1 2.9 0.1 0.1 5.6 0.3 8.3 0.4 16.4 2.4 4.4 0.2 0.4 0.5 0.0 1.7 0.0 2.7 44.7 0.9 12.3 42.8 23.2 25.4 64.2 34.3 7.3 18.1 22.0 39.6 6.0 9.9 16.4 40.5 11.1 64.0 1.4 22.2 31.2 6.6 17.0 3.5 7.0 9.3 3.0 16.7 2.6 13.3 11.0 CASP10 MCH4 ENSG00000003400 "Caspase 10" Q92851 2 201182881-201229406 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" Apoptosis "Hydrolase, Protease, Thiol protease" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "intestine: 42.4" "Cell line enhanced" "Detected in many" "HUVEC TERT2: 17.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003780, HPA017059" Approved Approved "Golgi apparatus,Vesicles" "Golgi apparatus" Vesicles "CAB003780: AB_289592, HPA017059: AB_1846040" "unprognostic (4.01e-2)" "unprognostic (8.24e-2)" "unprognostic (4.80e-1)" "unprognostic (1.28e-3)" "unprognostic (4.74e-2)" "unprognostic (2.25e-1)" "prognostic unfavourable (8.54e-4)" "unprognostic (1.73e-2)" "unprognostic (1.48e-2)" "unprognostic (3.68e-2)" "unprognostic (1.91e-1)" "unprognostic (1.04e-1)" "prognostic unfavourable (6.05e-7)" "unprognostic (3.23e-2)" "unprognostic (2.19e-2)" "unprognostic (4.49e-2)" "unprognostic (1.38e-2)" 16.0 3.3 3.4 10.1 3.4 14.9 7.6 1.9 3.3 7.0 17.7 4.4 4.3 18.6 8.3 8.2 10.4 4.9 7.2 4.8 3.6 3.0 10.3 7.8 14.2 10.4 4.1 1.4 3.4 6.1 1.4 2.1 8.5 4.7 5.0 11.9 4.1 6.9 6.9 3.6 5.4 42.4 4.8 5.6 26.1 8.7 2.1 2.5 17.1 6.8 8.2 17.9 9.4 6.1 7.8 6.0 4.7 15.4 7.1 7.1 5.8 2.9 2.3 0.1 0.2 0.1 0.2 5.1 0.5 3.4 0.3 1.3 3.1 6.8 0.2 4.9 1.7 1.9 0.1 1.6 0.9 1.4 3.3 8.2 2.4 10.2 1.1 5.4 8.9 0.3 1.4 3.7 0.3 17.7 9.8 12.1 0.3 0.1 10.5 5.1 0.3 1.5 5.7 0.3 12.1 6.2 4.1 0.1 0.1 2.8 0.1 1.3 0.0 5.2 7.1 0.2 0.5 2.3 0.1 13.2 7.8 0.3 3.3 4.2 0.1 4.7 9.6 0.6 6.2 13.5 5.2 7.8 5.2 3.4 5.3 5.0 7.1 6.0 1.9 7.1 15.4 6.0 1.0 5.8 3.4 3.4 1.9 3.3 3.6 3.0 4.1 1.4 4.7 2.5 CASP2 "ICH1, MGC2181, NEDD2, PPP1R57" ENSG00000106144 "Caspase 2" P42575 7 143288215-143307696 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" Apoptosis "Hydrolase, Protease, Thiol protease" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 45.7" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB012175, HPA050678" Approved Approved Nucleoplasm Nucleoplasm "CAB012175: , HPA050678: " "unprognostic (6.96e-2)" "prognostic favourable (7.38e-4)" "unprognostic (2.74e-2)" "unprognostic (7.51e-2)" "unprognostic (4.24e-2)" "unprognostic (2.39e-2)" "prognostic unfavourable (2.34e-4)" "unprognostic (1.74e-2)" "unprognostic (1.34e-2)" "prognostic favourable (2.89e-4)" "unprognostic (1.91e-2)" "unprognostic (1.64e-1)" "prognostic unfavourable (5.01e-6)" "unprognostic (2.66e-3)" "unprognostic (9.48e-2)" "unprognostic (1.19e-1)" "unprognostic (1.64e-1)" 10.5 6.5 6.6 10.7 6.7 26.8 10.2 9.6 10.9 9.6 8.5 9.0 8.2 8.2 10.8 7.8 14.1 8.4 5.7 6.1 5.7 4.1 7.3 5.8 9.8 15.8 6.9 6.1 8.7 8.1 12.1 6.6 11.3 7.3 7.6 10.2 10.1 11.6 5.8 4.3 14.2 14.0 7.4 6.3 18.6 7.5 8.6 6.9 45.7 8.9 8.0 23.0 7.4 10.2 18.5 11.8 33.2 17.7 13.4 21.4 7.6 10.7 10.1 11.4 20.2 6.4 7.6 6.1 11.1 5.0 10.2 11.2 10.1 12.3 20.5 10.5 7.0 10.6 11.4 8.7 13.6 17.9 8.8 12.1 16.0 6.9 3.4 23.6 15.2 5.2 7.2 12.3 4.4 8.7 10.1 13.1 10.8 10.6 41.0 24.9 14.3 10.3 30.2 5.9 12.5 6.0 9.2 12.5 14.1 22.0 9.6 7.0 10.5 9.0 9.7 9.0 6.3 16.2 11.0 10.9 10.7 23.8 10.2 28.1 16.4 33.2 10.8 9.3 14.9 11.9 14.6 15.8 20.6 15.4 9.8 18.5 15.4 17.8 12.3 13.4 17.7 11.8 21.4 7.6 6.6 6.7 9.6 10.9 5.7 4.1 6.9 6.1 7.3 6.9 CASP3 "apopain, CPP32, CPP32B, Yama" ENSG00000164305 "Caspase 3" P42574 4 184627696-184649509 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" Apoptosis "Hydrolase, Protease, Thiol protease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 76.7" "Cell line enhanced" "Detected in all" "Karpas-707: 72.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in all" 7 "basophil: 76.7;eosinophil: 62.8" "Lineage enriched" "Detected in all" 7 "granulocytes: 76.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000091, HPA002643, CAB008381" Enhanced Supported Nucleoplasm,Mitochondria 310000 "Nucleoplasm, Mitochondria" "CAB000091: , CAB008381: AB_590737, HPA002643: AB_1846048" "unprognostic (1.38e-1)" "unprognostic (1.06e-1)" "unprognostic (2.21e-2)" "prognostic favourable (2.24e-4)" "unprognostic (2.29e-3)" "unprognostic (3.58e-2)" "unprognostic (9.57e-3)" "unprognostic (5.86e-2)" "unprognostic (3.56e-2)" "unprognostic (1.12e-2)" "unprognostic (1.70e-2)" "unprognostic (2.41e-1)" "prognostic unfavourable (2.30e-5)" "unprognostic (1.41e-2)" "unprognostic (5.74e-3)" "unprognostic (1.30e-1)" "unprognostic (4.05e-3)" 20.7 11.6 10.8 16.9 10.5 16.7 10.0 22.3 9.2 10.4 25.4 12.8 12.5 32.3 13.9 11.5 22.8 8.9 12.0 8.8 10.0 8.8 10.6 18.7 12.4 23.6 10.2 8.5 8.3 10.0 4.6 13.6 29.4 9.7 8.8 20.9 8.2 13.0 10.0 12.6 9.5 49.7 9.3 12.6 26.5 18.7 6.4 10.9 44.7 7.8 13.5 24.3 16.2 11.0 4.2 5.2 76.7 10.6 9.2 9.9 7.0 8.2 4.6 18.3 8.7 11.4 15.2 10.6 24.8 18.8 17.4 10.1 8.3 6.9 11.5 3.9 12.1 7.0 14.5 8.8 19.9 29.4 7.9 18.3 3.6 19.3 13.6 14.9 17.5 20.7 10.8 11.0 9.0 21.5 15.1 72.7 17.9 3.5 23.5 13.9 18.1 5.8 17.0 8.6 11.0 15.0 13.5 10.5 11.4 10.7 9.8 13.9 5.3 9.7 14.6 8.0 7.3 5.9 11.4 33.8 31.7 7.9 9.7 10.4 11.3 76.7 4.2 62.8 5.5 6.8 5.7 4.2 5.1 7.8 5.2 3.1 3.9 5.8 5.8 9.2 10.6 4.1 9.9 7.0 10.8 10.5 22.3 9.2 10.0 8.8 10.2 8.5 9.7 10.9 CASP4 "ICE(rel)II, ICH-2, TX" ENSG00000196954 "Caspase 4" P49662 11 104942866-104969436 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Immunity, Inflammatory response, Innate immunity, Necrosis" "Hydrolase, Protease, Thiol protease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "blood: 82.8" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "HPA027588, CAB037167" Approved Approved "Plasma membrane,Cytosol" "Intracellular and membrane" Cytosol "Plasma membrane" "CAB037167: AB_258864, HPA027588: AB_10603781" "unprognostic (1.19e-2)" "unprognostic (3.73e-1)" "unprognostic (3.44e-1)" "unprognostic (1.99e-2)" "unprognostic (7.19e-3)" "unprognostic (2.63e-2)" "unprognostic (1.26e-2)" "unprognostic (1.56e-2)" "unprognostic (5.31e-2)" "unprognostic (2.71e-1)" "unprognostic (2.38e-3)" "unprognostic (8.39e-3)" "prognostic unfavourable (3.27e-11)" "unprognostic (6.75e-2)" "unprognostic (1.34e-1)" "unprognostic (1.79e-2)" "unprognostic (4.08e-3)" 10.6 6.3 0.5 9.7 0.5 6.1 9.4 0.0 0.0 4.7 3.5 8.9 3.5 5.9 14.1 5.8 7.3 4.9 0.5 0.5 6.7 16.5 14.0 10.5 1.0 7.5 16.8 0.0 3.0 10.7 5.8 4.0 11.2 1.9 1.6 10.4 8.8 4.3 2.0 19.0 8.2 0.2 4.2 11.3 8.2 8.0 20.5 29.3 82.8 43.2 29.6 35.7 46.8 6.3 2.1 0.0 2.8 13.7 31.2 5.3 11.0 21.5 17.7 24.8 5.3 29.0 3.3 23.7 14.2 10.6 0.0 19.0 16.9 3.7 0.1 8.6 1.6 13.8 33.6 8.6 4.2 28.3 28.5 21.1 29.5 30.7 0.2 0.0 13.5 0.6 5.0 10.2 0.0 6.3 3.8 4.1 2.9 14.8 10.1 0.1 0.0 10.1 7.2 10.0 2.9 12.6 15.9 18.7 6.5 16.4 7.7 0.0 0.0 0.0 9.5 19.7 13.0 14.9 39.1 7.0 31.5 43.2 34.6 20.5 24.2 30.1 29.3 20.0 14.8 22.0 82.8 29.6 33.5 4.9 35.7 46.8 CASP6 MCH2 ENSG00000138794 "Caspase 6" P55212 4 109688622-109703583 "Cancer-related genes, Enzymes, Predicted intracellular proteins" Apoptosis "Hydrolase, Protease, Thiol protease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "intestine: 42.8" "Cell line enhanced" "Detected in all" "Karpas-707: 38.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003775, HPA011337, HPA024303" Enhanced Supported Nucleoplasm,Cytosol Cytosol Nucleoplasm "CAB003775: AB_562064, HPA011337: AB_1846053, HPA024303: AB_1846052" "unprognostic (1.07e-1)" "unprognostic (1.91e-1)" "prognostic favourable (2.64e-5)" "unprognostic (1.45e-2)" "unprognostic (1.90e-1)" "unprognostic (1.46e-1)" "unprognostic (3.03e-3)" "unprognostic (9.87e-2)" "unprognostic (2.73e-2)" "unprognostic (2.59e-3)" "unprognostic (1.15e-2)" "unprognostic (6.78e-2)" "unprognostic (2.44e-1)" "unprognostic (8.74e-3)" "unprognostic (2.18e-1)" "unprognostic (2.41e-1)" "prognostic favourable (9.93e-4)" 8.1 6.1 3.6 6.7 4.3 5.3 14.3 2.8 3.8 6.9 25.5 2.8 4.5 23.4 5.9 4.3 8.7 5.3 11.7 4.9 4.0 2.0 11.0 14.3 5.6 8.5 5.0 1.6 7.0 13.0 2.3 6.4 4.3 4.5 8.1 19.5 3.4 8.0 10.3 3.4 6.5 42.8 14.0 6.6 9.1 9.2 2.7 4.3 14.5 11.2 3.3 8.4 8.2 12.7 4.4 8.0 8.5 7.0 5.6 21.3 8.0 12.4 4.0 8.3 7.5 6.1 6.0 12.3 7.0 4.8 6.2 6.8 6.7 25.6 1.3 8.1 7.1 5.8 9.9 11.0 5.0 19.7 6.5 10.9 3.6 5.9 4.9 10.9 7.7 6.6 8.2 6.0 1.5 11.8 14.1 38.8 10.1 7.0 28.1 6.9 6.3 7.3 9.8 5.3 6.8 20.6 11.8 8.8 6.6 7.4 13.3 4.1 5.7 4.0 10.0 6.9 7.4 3.3 7.9 5.7 10.3 1.4 9.0 13.1 3.5 8.5 5.3 6.3 4.9 4.8 5.3 4.1 17.8 9.3 6.0 4.4 21.3 11.8 1.1 5.6 7.0 8.0 16.4 8.0 3.6 4.3 2.8 3.8 4.0 2.0 5.0 1.6 4.5 4.3 CASP7 "CMH-1, ICE-LAP3, MCH3" ENSG00000165806 "Caspase 7" P55210 10 113679162-113730907 "Cancer-related genes, Enzymes, Predicted intracellular proteins" Apoptosis "Hydrolase, Protease, Thiol protease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "intestine: 64.8" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in some" CAB025563 Approved "CAB025563: " "prognostic favourable (2.11e-4)" "unprognostic (3.18e-2)" "unprognostic (2.82e-2)" "unprognostic (2.18e-1)" "unprognostic (2.85e-1)" "unprognostic (1.33e-1)" "unprognostic (2.63e-3)" "unprognostic (3.96e-1)" "unprognostic (2.04e-1)" "unprognostic (1.22e-2)" "unprognostic (1.07e-1)" "unprognostic (2.35e-2)" "prognostic unfavourable (5.90e-4)" "unprognostic (5.45e-3)" "unprognostic (2.62e-1)" "unprognostic (2.86e-1)" "unprognostic (4.33e-3)" 16.5 7.8 8.6 12.3 8.7 3.4 22.1 4.7 11.3 13.3 35.5 5.9 9.8 30.8 12.6 6.1 12.0 9.5 7.8 9.0 7.6 3.9 14.1 15.7 16.2 12.2 7.3 2.7 11.0 18.4 5.7 9.6 10.2 9.1 11.9 28.5 5.8 21.8 10.5 9.7 10.9 64.8 9.3 12.4 12.3 21.0 4.3 8.0 12.0 8.4 8.1 11.3 10.6 36.6 9.6 8.6 14.6 17.1 5.4 12.2 7.4 10.8 11.7 9.6 5.1 17.6 15.5 6.7 12.6 19.7 22.5 28.3 8.7 18.8 11.5 7.5 11.4 9.6 11.8 9.5 16.0 17.8 15.9 7.4 8.7 14.5 11.8 7.9 9.8 10.0 6.4 12.8 5.3 29.7 1.9 15.7 8.3 14.6 18.7 6.2 1.7 7.2 19.1 39.1 6.9 17.8 8.0 0.7 5.7 9.7 14.1 6.6 16.7 7.0 14.2 5.0 9.6 5.2 10.3 11.6 7.3 0.3 5.1 14.9 5.6 14.6 12.5 9.4 9.6 17.1 8.4 9.6 8.3 12.2 8.6 7.3 6.5 8.7 2.1 5.4 14.0 1.1 11.1 7.4 8.6 8.7 4.7 11.3 7.6 3.9 7.3 2.7 9.1 8.0 CASP8 "Casp-8, FLICE, MACH, MCH5" ENSG00000064012 "Caspase 8" Q14790 2 201233443-201287711 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Apoptosis, Host-virus interaction" "Hydrolase, Protease, Thiol protease" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 52.5" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001302, CAB002047, HPA005688, HPA006191" Approved Supported Nucleoplasm,Cytosol Cytosol Nucleoplasm "CAB002047: AB_563465, HPA001302: AB_1846057, HPA005688: AB_1846056, HPA006191: " "unprognostic (5.21e-3)" "unprognostic (2.10e-1)" "unprognostic (1.83e-2)" "unprognostic (9.69e-3)" "unprognostic (2.09e-1)" "unprognostic (5.60e-2)" "prognostic unfavourable (3.02e-4)" "unprognostic (2.10e-1)" "unprognostic (4.79e-2)" "prognostic favourable (1.25e-4)" "unprognostic (7.75e-2)" "unprognostic (5.11e-2)" "prognostic unfavourable (1.27e-6)" "unprognostic (7.67e-3)" "unprognostic (2.43e-1)" "unprognostic (2.53e-1)" "unprognostic (4.53e-3)" 14.1 10.6 2.0 31.6 2.6 27.1 10.2 1.4 1.8 7.9 18.5 3.9 7.0 9.6 9.6 12.0 11.7 9.1 12.1 4.4 2.1 2.3 16.4 14.8 17.1 28.3 3.9 1.1 8.2 7.6 1.8 5.9 12.3 3.2 9.8 8.7 4.4 9.6 8.4 2.7 7.4 34.7 5.1 5.0 37.7 7.4 3.8 2.7 43.7 6.7 10.7 43.4 9.6 7.3 13.8 13.7 52.5 17.0 22.2 26.4 12.0 14.3 12.2 3.6 9.9 10.0 14.6 5.5 6.3 6.2 7.5 12.4 16.4 25.0 1.6 13.9 4.9 7.3 7.8 7.5 14.8 9.3 7.1 14.0 9.9 15.6 8.1 10.8 15.2 12.7 18.5 14.2 11.1 7.1 12.5 31.2 6.8 5.9 14.1 11.5 5.8 10.9 10.6 7.4 25.5 14.1 16.0 1.0 0.5 8.2 13.6 8.1 3.6 8.5 8.8 8.1 8.4 4.2 4.9 28.3 12.6 9.7 12.2 14.6 7.6 20.7 13.0 24.9 25.0 17.0 23.1 13.8 20.5 26.4 13.7 7.8 13.3 16.9 52.5 22.2 15.6 6.1 24.0 12.0 2.0 2.6 1.4 1.8 2.1 2.3 3.9 1.1 3.2 2.7 CASP9 "APAF-3, ICE-LAP6, MCH6, PPP1R56" ENSG00000132906 "Caspase 9" P55211 1 15490832-15526534 "Cancer-related genes, Enzymes, Predicted intracellular proteins" Apoptosis "Hydrolase, Protease, Thiol protease" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001473, CAB004348, HPA046488" Approved Approved Mitochondria Mitochondria "CAB004348: AB_673489, HPA001473: AB_1078401, HPA046488: " "prognostic favourable (5.91e-4)" "unprognostic (2.42e-1)" "unprognostic (8.94e-3)" "unprognostic (7.84e-2)" "unprognostic (1.93e-2)" "unprognostic (8.54e-3)" "unprognostic (1.90e-3)" "unprognostic (6.75e-2)" "unprognostic (2.58e-1)" "unprognostic (1.29e-1)" "unprognostic (9.09e-2)" "unprognostic (1.98e-1)" "unprognostic (1.39e-2)" "unprognostic (2.35e-1)" "unprognostic (3.21e-2)" "unprognostic (5.48e-2)" "prognostic favourable (1.67e-5)" 7.4 24.1 7.8 8.2 9.3 8.9 5.5 11.1 8.7 8.3 9.3 10.2 18.9 5.2 11.9 16.5 7.5 13.4 29.1 10.2 8.3 7.2 11.6 9.4 10.8 12.6 10.7 4.3 33.4 29.0 15.6 18.5 14.7 8.8 10.2 6.4 8.7 6.6 19.0 8.2 2.8 13.3 7.8 9.0 11.0 6.7 14.4 7.1 6.2 14.8 7.2 14.6 7.3 8.1 11.2 11.7 23.3 11.2 13.0 5.1 6.1 7.1 10.4 4.1 7.1 9.3 4.6 3.7 5.2 6.9 7.8 10.0 7.3 8.6 10.4 12.3 7.1 2.5 6.8 5.5 9.0 3.6 8.5 7.4 23.2 7.3 8.7 7.2 8.7 6.3 10.2 11.9 3.6 8.3 16.7 9.7 4.6 3.6 2.4 8.2 4.0 5.8 4.8 10.2 12.1 9.6 4.1 3.5 6.8 7.4 1.8 12.3 4.4 5.2 3.3 10.4 4.8 11.2 3.4 9.4 14.1 11.7 7.9 7.8 3.4 22.7 11.2 23.3 5.1 8.2 3.7 9.6 3.0 3.6 11.7 11.2 1.7 2.6 16.0 13.0 7.9 5.2 2.8 6.1 7.8 9.3 11.1 8.7 8.3 7.2 10.7 4.3 8.8 7.1 CAST ENSG00000153113 Calpastatin P20810 5 96525267-96779595 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Protease inhibitor, Thiol protease inhibitor" "Cancer-related genes, Palmoplantar keratoderma" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 201.9" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009491, HPA036881, HPA036882" Approved Enhanced "Endoplasmic reticulum,Cytosol" 18000000 "Endoplasmic reticulum, Cytosol" "CAB009491: AB_2259755, HPA036881: , HPA036882: " "unprognostic (2.17e-1)" "unprognostic (1.39e-1)" "unprognostic (2.44e-2)" "unprognostic (1.91e-2)" "unprognostic (4.68e-2)" "unprognostic (1.45e-1)" "unprognostic (3.79e-1)" "unprognostic (4.53e-3)" "unprognostic (1.94e-2)" "unprognostic (6.11e-3)" "prognostic unfavourable (9.27e-5)" "unprognostic (2.66e-2)" "unprognostic (1.69e-2)" "prognostic unfavourable (1.20e-5)" "unprognostic (1.16e-1)" "unprognostic (2.79e-1)" "prognostic unfavourable (4.98e-4)" 38.3 20.7 10.4 25.0 16.3 22.1 32.0 8.7 21.7 38.0 44.6 10.5 18.6 25.6 24.8 25.9 87.4 19.5 25.5 98.5 11.9 10.6 27.2 38.2 29.5 21.1 14.3 12.5 26.9 14.8 22.3 25.3 52.6 24.8 30.0 34.5 12.7 38.7 23.2 201.9 40.7 56.3 36.2 18.7 21.7 22.2 21.2 15.6 10.1 25.6 51.2 34.1 42.2 57.0 24.5 32.7 12.4 48.0 18.3 26.6 27.2 47.9 39.6 6.7 17.5 40.6 75.7 23.7 34.2 48.4 27.4 35.7 9.7 29.3 6.9 32.4 46.3 81.7 12.7 46.5 33.2 44.6 12.0 8.9 41.9 11.6 31.2 5.8 15.5 34.2 43.1 39.3 64.1 30.6 7.5 22.4 33.3 15.1 2.8 0.2 5.2 14.7 2.7 22.7 11.8 54.4 20.3 28.4 6.8 34.9 19.2 22.3 11.7 6.3 40.6 37.4 15.9 24.9 34.5 7.5 20.0 3.2 42.4 3.1 10.3 2.5 48.0 7.0 26.6 29.0 25.2 24.5 23.9 26.5 32.7 22.7 12.2 16.3 12.4 18.3 32.2 9.0 24.2 27.2 10.4 16.3 8.7 21.7 11.9 10.6 14.3 12.5 24.8 15.6 CAT ENSG00000121691 Catalase P04040 11 34438925-34472062 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Hydrogen peroxide" "Mitogen, Oxidoreductase, Peroxidase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 258.3;liver: 184.8" "Cell line enhanced" "Detected in many" "HL-60: 75.2;THP-1: 62.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in all" 13 "eosinophil: 258.3" "Lineage enriched" "Detected in all" 13 "granulocytes: 258.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB001515, HPA051282, HPA055838" Enhanced Enhanced Vesicles 960000000 Vesicles "CAB001515: AB_384710, HPA051282: AB_2681419, HPA055838: AB_2682937" "unprognostic (3.62e-2)" "unprognostic (2.72e-1)" "unprognostic (3.59e-3)" "unprognostic (5.43e-2)" "unprognostic (4.44e-2)" "unprognostic (5.80e-3)" "prognostic favourable (9.67e-4)" "unprognostic (9.95e-3)" "unprognostic (3.22e-1)" "unprognostic (7.23e-2)" "unprognostic (3.34e-2)" "unprognostic (9.77e-2)" "prognostic favourable (1.96e-8)" "unprognostic (1.01e-1)" "unprognostic (7.31e-2)" "unprognostic (4.77e-2)" "unprognostic (6.59e-3)" 70.0 33.0 9.4 10.1 9.6 54.2 36.1 3.1 7.7 15.3 26.6 18.6 15.7 22.2 13.5 9.5 14.8 14.2 19.0 22.4 10.7 5.2 50.4 184.8 26.1 21.3 14.5 6.0 11.0 24.7 7.1 5.0 16.4 10.2 23.2 11.3 11.4 14.5 13.2 27.8 19.7 29.2 11.6 11.3 17.9 15.9 6.2 11.6 23.4 41.7 14.9 11.5 20.4 24.9 7.6 19.9 258.3 17.5 5.5 5.0 17.8 6.1 6.8 5.0 7.8 48.4 21.1 10.6 7.8 9.9 8.8 9.7 3.8 6.2 15.2 7.6 15.5 14.7 8.4 8.5 9.8 13.2 7.7 12.8 7.3 21.9 5.7 75.2 6.4 11.3 5.9 2.6 1.0 10.6 26.5 6.3 11.1 5.8 15.4 13.4 0.0 16.6 10.9 23.8 12.4 24.1 23.3 2.6 4.0 8.8 14.2 11.6 20.3 62.8 7.5 5.3 5.2 13.2 4.6 5.1 2.9 3.2 10.4 51.8 3.8 12.5 17.5 258.3 3.2 14.7 3.8 7.6 3.8 3.6 19.9 6.8 3.8 4.0 17.1 5.5 15.5 13.4 5.0 17.8 9.4 9.6 3.1 7.7 10.7 5.2 14.5 6.0 10.2 11.6 CAV1 CAV ENSG00000105974 "Caveolin 1" Q03135 7 116524785-116561184 "Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters" "Host-virus interaction" "Cancer-related genes, Congenital generalized lipodystrophy, Diabetes mellitus, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "ASC TERT1: 142.2;BJ hTERT+: 149.8;HBEC3-KT: 145.9;LHCN-M2: 152.1;U-138 MG: 121.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 6 "basophil: 10.6;memory B-cell: 6.0" "Group enriched" "Detected in many" 37 "B-cells: 6.0;granulocytes: 10.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003791, HPA049326" Enhanced Supported "Golgi apparatus" "Golgi apparatus" "CAB003791: AB_562068, HPA049326: " "unprognostic (5.98e-2)" "unprognostic (1.35e-3)" "unprognostic (3.35e-1)" "unprognostic (5.37e-2)" "unprognostic (4.62e-3)" "unprognostic (2.35e-3)" "unprognostic (8.07e-2)" "prognostic unfavourable (7.17e-5)" "unprognostic (1.31e-1)" "unprognostic (2.25e-1)" "unprognostic (1.79e-3)" "unprognostic (7.92e-2)" "prognostic unfavourable (1.29e-4)" "unprognostic (1.65e-3)" "unprognostic (2.72e-1)" "unprognostic (7.40e-2)" "unprognostic (6.14e-3)" 143.9 2.3 2.4 27.5 5.9 0.0 70.5 1.0 3.8 73.8 57.4 2.6 32.3 4.3 84.6 40.9 51.1 31.4 42.0 60.2 2.7 2.3 5.7 4.2 132.7 8.6 7.9 4.5 26.6 3.8 2.0 1.9 92.0 4.2 42.3 13.7 13.6 12.8 26.5 33.3 21.7 18.6 104.0 5.5 28.6 30.1 21.5 5.2 2.8 92.1 34.7 6.6 85.9 33.7 6.0 0.1 10.6 0.0 0.0 0.2 1.1 27.4 22.4 0.6 0.2 92.9 142.2 1.3 65.5 149.8 36.2 38.2 0.1 40.9 0.0 23.2 77.0 51.8 0.1 145.9 55.1 1.8 1.2 0.0 8.9 0.0 12.8 0.0 0.1 48.5 31.0 52.8 35.0 109.0 0.0 1.5 152.1 2.8 0.0 0.0 2.1 10.8 0.3 1.5 15.6 20.5 0.1 0.0 0.0 20.1 1.3 3.2 0.1 0.2 83.7 121.4 13.9 46.3 18.0 6.1 0.9 0.1 48.9 0.0 43.8 10.6 0.0 0.0 0.0 0.0 0.0 6.0 0.2 0.1 0.0 1.3 0.1 0.0 0.0 0.0 0.0 0.1 0.0 1.1 2.4 5.9 1.0 3.8 2.7 2.3 7.9 4.5 4.2 5.2 CBFA2T3 "ETO2, MTG16, MTGR2, RUNX1T3, ZMYND4" ENSG00000129993 "CBFA2/RUNX1 translocation partner 3" O75081 16 88874858-88977204 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Differentiation, Transcription, Transcription regulation" Repressor "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 75.9" "Cell line enhanced" "Detected in some" "HEL: 21.0;K-562: 36.7;MCF7: 17.0;MOLT-4: 18.6;NB-4: 22.7;REH: 36.9;T-47d: 16.8" "Low cancer specificity" "Detected in many" "Region enhanced" "Detected in all" "cerebellum: 26.0" "Cell type enhanced" "Detected in many" "plasmacytoid DC: 11.6" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA059931, HPA062423, HPA065890" Approved Enhanced Nucleoplasm Nucleoplasm "HPA059931: , HPA062423: , HPA065890: " "unprognostic (2.47e-1)" "unprognostic (2.03e-2)" "unprognostic (9.24e-3)" "unprognostic (2.62e-1)" "unprognostic (1.98e-1)" "prognostic favourable (3.95e-4)" "unprognostic (1.13e-3)" "unprognostic (1.69e-2)" "unprognostic (1.25e-1)" "unprognostic (2.10e-1)" "unprognostic (7.30e-3)" "unprognostic (2.38e-1)" "unprognostic (7.04e-5)" "unprognostic (2.18e-1)" "unprognostic (4.08e-2)" "unprognostic (4.62e-2)" "unprognostic (9.35e-3)" 10.0 1.7 3.6 11.3 7.4 8.2 6.1 26.0 5.4 2.3 3.9 1.3 1.4 3.9 3.2 2.1 2.1 1.9 2.5 6.2 3.0 3.0 0.7 2.0 6.4 9.5 2.0 3.8 0.9 24.9 0.7 2.7 3.8 2.3 3.7 1.5 3.1 4.5 2.9 14.2 2.6 5.5 1.5 1.2 14.7 3.5 3.2 2.2 75.9 2.4 2.0 10.3 3.6 4.8 3.7 11.6 3.6 4.9 0.1 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 1.0 0.4 0.0 0.0 0.0 0.0 0.0 0.1 0.0 21.0 0.0 0.0 0.0 5.5 10.4 0.0 0.0 0.0 0.0 0.0 36.7 0.1 0.0 17.0 18.6 22.7 0.4 0.0 36.9 0.2 3.7 0.0 0.0 7.2 1.6 0.8 0.1 0.1 16.8 5.8 0.1 0.0 0.1 0.1 0.0 0.1 0.1 12.2 0.0 6.4 0.0 1.1 2.7 2.7 0.0 3.2 0.0 3.7 0.0 0.0 7.1 2.1 0.0 0.0 3.6 0.1 4.9 11.6 0.0 1.7 3.6 7.4 26.0 5.4 3.0 3.0 2.0 3.8 2.3 2.2 CBFB PEBP2B ENSG00000067955 "Core-binding factor beta subunit" Q13951 16 67029116-67101058 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "U-698: 99.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA038852 Uncertain Approved Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "HPA038852: AB_10795358" "unprognostic (1.05e-1)" "unprognostic (1.18e-2)" "unprognostic (1.30e-1)" "unprognostic (3.22e-2)" "unprognostic (4.66e-2)" "unprognostic (3.80e-3)" "prognostic unfavourable (2.83e-4)" "unprognostic (1.63e-2)" "unprognostic (1.47e-1)" "unprognostic (1.11e-1)" "unprognostic (4.46e-3)" "unprognostic (1.88e-2)" "prognostic unfavourable (2.89e-8)" "unprognostic (1.03e-1)" "unprognostic (4.31e-2)" "unprognostic (1.37e-1)" "unprognostic (1.20e-1)" 15.9 10.9 15.9 26.4 25.1 20.5 15.0 9.5 14.3 15.4 10.6 23.3 11.8 8.8 15.3 10.2 20.5 14.3 16.3 21.5 16.2 13.2 12.1 14.4 16.1 32.6 23.6 12.4 17.3 13.6 40.4 18.8 13.2 17.5 14.6 11.1 13.7 19.6 10.3 33.3 14.8 12.2 11.7 22.4 18.2 17.1 7.3 24.2 42.2 17.0 14.8 31.0 15.9 18.8 6.5 9.1 20.5 9.2 14.8 7.0 5.1 15.4 10.3 9.0 14.7 6.6 8.5 14.5 17.9 10.7 16.9 15.0 20.7 17.7 34.2 17.1 15.2 15.4 16.1 10.1 22.8 11.7 9.2 23.7 8.8 16.4 9.4 30.9 51.1 8.5 6.9 18.9 14.6 13.7 25.2 12.2 17.5 11.7 31.8 16.6 8.8 14.6 64.5 39.1 29.0 11.9 13.8 13.3 11.9 45.9 7.0 18.3 6.3 22.2 18.9 26.3 18.0 14.9 24.0 16.7 29.7 99.9 20.0 21.2 23.6 20.5 7.4 7.4 6.7 9.2 7.0 6.5 6.6 7.0 9.1 6.4 6.3 5.3 4.6 14.8 6.1 3.3 7.0 5.1 15.9 25.1 9.5 14.3 16.2 13.2 23.6 12.4 17.5 24.2 CBL "c-Cbl, CBL2, RNF55" ENSG00000110395 "Cbl proto-oncogene" P22681 11 119206276-119313926 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Ubl conjugation pathway" Transferase "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 40.9" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 11.8" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004350, HPA027956" Enhanced Supported Cytosol Cytosol "CAB004350: AB_2244054, HPA027956: AB_10601094" "unprognostic (2.52e-1)" "unprognostic (1.32e-3)" "unprognostic (1.60e-1)" "unprognostic (1.15e-1)" "unprognostic (1.50e-2)" "unprognostic (2.92e-1)" "unprognostic (4.10e-3)" "unprognostic (9.75e-2)" "unprognostic (1.72e-1)" "unprognostic (1.52e-1)" "unprognostic (1.03e-2)" "unprognostic (5.23e-2)" "unprognostic (5.21e-2)" "unprognostic (5.27e-2)" "unprognostic (1.52e-1)" "unprognostic (1.12e-1)" "unprognostic (5.85e-2)" 9.9 5.5 9.1 17.0 11.1 11.1 8.8 10.7 12.0 6.2 7.5 8.7 3.0 5.7 9.9 5.3 7.5 7.4 6.3 5.9 8.0 9.6 5.5 4.0 10.3 16.3 8.1 6.9 6.3 5.6 16.6 4.1 9.1 9.3 5.3 7.5 6.4 5.4 7.1 3.9 7.4 8.6 10.6 8.9 13.3 7.3 32.3 5.1 40.9 6.0 5.5 15.6 7.6 7.7 1.8 3.3 11.8 3.7 0.6 1.9 1.0 6.3 4.8 16.8 10.5 5.0 6.0 9.9 6.8 7.1 6.6 6.6 10.2 7.8 15.0 6.2 8.6 9.3 11.5 5.8 14.5 8.5 2.7 15.4 3.6 3.1 6.2 17.9 17.6 5.2 6.5 16.9 18.2 16.3 12.4 6.3 11.9 6.8 9.5 10.0 8.7 5.3 10.3 8.4 2.8 5.9 5.1 2.3 7.0 12.7 5.5 4.5 5.8 15.1 13.6 10.3 7.3 7.2 8.9 2.1 3.1 12.2 4.2 15.5 7.3 0.8 3.2 2.4 1.3 3.7 1.1 1.8 1.6 1.3 3.3 1.8 1.8 1.9 11.8 0.6 3.1 1.8 1.4 1.0 9.1 11.1 10.7 12.0 8.0 9.6 8.1 6.9 9.3 5.1 CBLB "Cbl-b, RNF56" ENSG00000114423 "Cbl proto-oncogene B" Q13191 3 105655461-105869552 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Ubl conjugation pathway" Transferase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "U-138 MG: 23.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA018327, HPA019880" Approved Supported Nucleoplasm,Cytosol Cytosol Nucleoplasm "HPA018327: AB_1846097, HPA019880: AB_1846099" "unprognostic (2.65e-1)" "unprognostic (9.42e-2)" "unprognostic (1.72e-2)" "unprognostic (2.38e-1)" "unprognostic (5.89e-3)" "unprognostic (2.80e-2)" "unprognostic (8.18e-2)" "unprognostic (1.10e-1)" "unprognostic (7.05e-2)" "unprognostic (1.66e-1)" "unprognostic (9.29e-2)" "unprognostic (1.50e-2)" "unprognostic (1.43e-2)" "unprognostic (8.21e-2)" "unprognostic (2.83e-1)" "unprognostic (1.20e-2)" "unprognostic (3.09e-2)" 38.4 9.0 3.7 19.5 4.9 15.5 16.3 24.4 3.8 13.7 18.7 5.9 7.7 9.3 13.8 12.2 8.3 12.5 13.4 27.5 3.8 4.8 7.4 6.7 16.3 19.1 4.4 1.9 17.7 6.8 3.4 13.5 25.4 7.9 12.9 8.0 11.6 9.1 6.3 10.3 8.5 13.8 25.6 5.7 16.4 12.4 9.2 5.2 11.6 13.5 7.0 18.0 24.9 24.1 5.1 3.1 2.8 2.1 10.3 9.9 1.6 1.6 2.2 7.6 3.7 8.7 8.8 4.9 5.6 2.8 1.6 2.7 2.9 1.9 3.6 4.0 3.0 2.8 1.0 1.0 2.0 2.7 2.9 1.9 11.7 1.8 12.8 1.3 1.4 8.4 3.0 4.4 12.0 5.5 2.0 11.5 3.5 2.0 1.9 0.9 2.7 3.2 4.1 2.3 0.6 4.0 7.2 5.8 6.4 6.7 0.8 8.8 1.6 2.9 3.1 23.4 2.0 3.2 1.3 6.5 0.5 5.6 6.2 1.2 1.5 0.7 1.5 2.8 9.9 0.9 8.8 2.2 5.1 5.6 1.3 5.1 4.4 8.0 1.0 10.3 2.1 3.1 5.6 1.6 3.7 4.9 24.4 3.8 3.8 4.8 4.4 1.9 7.9 5.2 CBLC "CBL-3, CBL-SL, RNF57" ENSG00000142273 "Cbl proto-oncogene C" Q9ULV8 19 44777869-44800634 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Ubl conjugation pathway" Transferase "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 66.8" "Cell line enhanced" "Detected in some" "A-431: 19.0;BEWO: 13.1;CACO-2: 12.8;CAPAN-2: 26.3;HaCaT: 18.4;HBEC3-KT: 16.0;hTCEpi: 12.2;RT4: 16.0;SK-BR-3: 14.6;T-47d: 10.5" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB008087, HPA035266" Approved Approved Nucleoplasm Nucleoplasm "CAB008087: AB_2228531, HPA035266: " "unprognostic (1.58e-1)" "unprognostic (2.25e-1)" "unprognostic (8.21e-3)" "unprognostic (1.55e-1)" "unprognostic (3.04e-2)" "unprognostic (3.91e-2)" "unprognostic (1.67e-1)" "unprognostic (2.13e-2)" "unprognostic (3.82e-1)" "unprognostic (7.39e-2)" "unprognostic (1.06e-2)" "unprognostic (1.85e-1)" "prognostic favourable (3.11e-6)" "unprognostic (3.50e-1)" "unprognostic (8.25e-3)" "unprognostic (2.90e-2)" "unprognostic (2.21e-3)" 0.1 0.0 0.5 8.5 0.2 0.0 4.8 0.1 0.4 4.4 39.5 0.1 3.2 29.5 1.7 1.7 22.0 1.4 18.8 0.1 0.6 0.0 4.9 15.1 1.3 0.1 0.1 0.3 0.8 18.1 0.9 0.7 4.1 0.2 6.9 6.9 0.5 11.4 5.2 0.1 20.8 66.8 0.4 0.1 0.1 10.2 1.6 0.1 0.5 1.9 13.2 15.7 7.6 8.9 0.0 0.0 0.0 0.0 0.0 0.8 0.0 19.0 0.0 0.0 0.0 0.0 0.0 13.1 0.0 0.0 0.0 0.0 12.8 26.3 0.0 0.0 0.0 18.4 0.0 16.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 12.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 16.0 0.1 0.0 0.0 14.6 0.0 10.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.2 0.1 0.4 0.6 0.0 0.1 0.3 0.2 0.1 CCAR1 "CARP-1, CARP1, FLJ10590" ENSG00000060339 "Cell division cycle and apoptosis regulator 1" Q8IX12 10 68721012-68792377 "Cancer-related genes, Predicted intracellular proteins" "Apoptosis, Cell cycle, Transcription, Transcription regulation" "Activator, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA007856, HPA048513" Supported Supported "Nucleoplasm,Golgi apparatus" Nucleoplasm "Golgi apparatus" "HPA007856: AB_1078415, HPA048513: " "unprognostic (1.71e-1)" "unprognostic (1.22e-1)" "unprognostic (2.34e-2)" "unprognostic (1.86e-1)" "unprognostic (5.15e-3)" "unprognostic (1.71e-2)" "prognostic unfavourable (1.41e-5)" "unprognostic (1.10e-1)" "unprognostic (3.25e-2)" "prognostic favourable (4.05e-5)" "unprognostic (2.89e-2)" "unprognostic (3.21e-3)" "prognostic unfavourable (1.37e-4)" "unprognostic (1.67e-1)" "unprognostic (2.36e-1)" "unprognostic (2.24e-1)" "unprognostic (1.41e-2)" 24.2 28.0 22.6 38.7 27.9 27.8 24.6 36.9 31.7 26.0 28.7 21.5 24.7 22.7 23.9 23.7 26.5 19.7 23.2 21.6 21.3 20.5 27.4 22.3 23.4 37.5 31.7 17.9 32.1 22.9 28.6 44.3 29.2 23.6 25.0 31.1 26.0 26.7 37.9 47.0 32.3 25.4 24.5 30.4 28.6 23.5 18.9 29.9 42.1 28.5 20.6 37.4 28.8 25.0 12.4 18.6 12.3 12.8 8.8 16.0 9.1 26.4 27.7 32.0 21.4 13.9 13.4 24.9 23.7 20.4 25.9 17.8 36.5 21.6 31.2 13.1 16.3 20.9 33.4 18.8 28.4 21.3 21.0 25.0 19.1 22.6 15.8 39.4 29.4 13.4 23.4 21.8 26.9 20.7 34.0 20.2 24.9 19.1 26.2 25.0 31.9 25.9 30.7 19.1 18.6 22.6 20.2 18.5 16.1 23.3 38.4 23.3 26.0 24.2 20.2 16.1 20.3 17.3 25.5 14.0 18.4 33.5 13.5 26.6 15.2 4.9 12.8 12.3 15.5 11.5 13.8 12.3 11.0 14.9 18.6 12.4 13.3 14.0 3.1 8.8 12.8 11.8 16.0 9.1 22.6 27.9 36.9 31.7 21.3 20.5 31.7 17.9 23.6 29.9 CCDC120 JM11 ENSG00000147144 "Coiled-coil domain containing 120" Q96HB5 X 49053572-49069857 "Cancer-related genes, Predicted intracellular proteins" "Developmental protein" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "A-431: 14.1;BEWO: 20.3;HaCaT: 13.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA000561 Uncertain Mitochondria Mitochondria "HPA000561: AB_2244190" "unprognostic (1.65e-1)" "unprognostic (1.79e-1)" "unprognostic (1.19e-1)" "unprognostic (7.59e-3)" "unprognostic (1.80e-3)" "unprognostic (1.08e-2)" "unprognostic (2.59e-3)" "unprognostic (1.23e-1)" "unprognostic (1.04e-1)" "unprognostic (1.72e-1)" "unprognostic (1.43e-1)" "unprognostic (1.66e-2)" "unprognostic (4.85e-2)" "unprognostic (2.64e-2)" "unprognostic (3.82e-3)" "unprognostic (4.54e-3)" "unprognostic (2.34e-3)" 3.3 3.1 5.8 3.1 4.7 2.9 5.0 17.3 5.8 8.4 6.8 1.6 10.4 12.0 5.5 9.9 27.6 5.1 4.1 2.1 4.0 1.6 7.0 4.8 4.4 2.6 1.5 3.3 6.5 7.0 6.1 12.2 13.3 4.0 6.0 3.3 4.7 11.4 10.2 1.5 26.1 12.5 2.5 1.8 3.8 7.7 5.8 1.5 6.0 5.6 8.8 15.1 7.4 12.2 2.5 2.2 3.9 0.8 1.6 1.5 0.4 14.1 1.9 3.1 0.1 0.0 0.0 20.3 0.5 0.7 1.1 1.7 4.7 6.1 0.5 2.2 0.8 13.7 2.4 8.0 0.1 3.6 4.6 1.3 3.3 1.6 1.0 0.0 2.4 1.8 6.4 1.3 0.4 1.7 1.9 0.2 0.0 11.9 4.9 0.3 3.6 0.1 4.4 2.3 1.3 6.1 7.6 4.3 3.3 2.5 5.1 1.4 12.4 1.9 0.8 0.1 3.7 0.1 0.1 4.6 3.1 0.1 0.1 0.0 0.6 2.9 0.8 1.5 1.4 0.2 0.9 0.8 1.5 1.3 0.3 2.5 1.5 1.4 3.9 1.6 0.4 2.2 0.5 0.4 5.8 4.7 17.3 5.8 4.0 1.6 1.5 3.3 4.0 1.5 CCDC6 "D10S170, H4, PTC, TPC, TST1" ENSG00000108091 "Coiled-coil domain containing 6" Q16204 10 59788763-59906656 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019049, HPA019051" Enhanced Supported Cytosol Cytosol "HPA019049: AB_1846163, HPA019051: AB_1846164" "unprognostic (1.88e-2)" "unprognostic (1.72e-2)" "unprognostic (4.41e-2)" "unprognostic (1.25e-3)" "unprognostic (5.98e-3)" "prognostic favourable (5.48e-4)" "prognostic unfavourable (1.11e-4)" "unprognostic (7.39e-2)" "unprognostic (2.45e-1)" "unprognostic (2.28e-1)" "prognostic unfavourable (3.95e-4)" "unprognostic (4.08e-1)" "unprognostic (4.69e-2)" "unprognostic (2.23e-1)" "unprognostic (2.56e-1)" "unprognostic (9.95e-2)" "unprognostic (4.19e-2)" 13.7 13.3 22.8 11.7 41.8 12.8 20.7 13.8 27.1 23.0 23.9 11.3 10.7 20.4 28.4 16.6 33.2 23.6 16.2 11.2 17.0 18.1 19.4 10.9 15.5 18.7 13.8 17.6 19.8 22.5 16.8 13.7 13.3 14.5 18.7 18.4 9.6 25.5 14.0 18.2 26.0 20.4 28.1 11.8 14.5 16.6 12.6 12.3 10.6 19.1 14.8 20.7 21.7 23.8 7.1 7.3 0.2 3.4 1.2 2.3 1.4 15.8 14.3 7.2 16.1 11.0 16.6 14.7 7.8 10.4 7.8 9.2 27.8 31.1 13.6 11.8 13.0 23.5 14.4 14.2 11.7 20.3 7.2 11.1 11.6 16.9 13.3 12.6 10.4 12.0 18.9 13.0 32.0 11.5 8.3 8.7 10.1 21.3 5.2 7.3 11.5 9.8 7.1 11.8 8.5 13.1 13.6 7.4 6.4 9.8 41.5 8.7 26.3 6.8 11.7 7.3 13.4 11.3 13.0 4.6 5.3 6.2 11.6 24.2 4.5 0.0 2.9 0.0 1.5 3.4 1.8 6.7 2.3 2.1 7.3 7.1 2.2 1.6 0.2 1.2 1.9 1.9 2.1 1.4 22.8 41.8 13.8 27.1 17.0 18.1 13.8 17.6 14.5 12.3 CCL14 "CKb1, HCC-1, HCC-3, MCIF, NCC-2, SCYA14, SCYL2" ENSG00000276409 "C-C motif chemokine ligand 14" Q16627 17 35983291-35987004 "Cancer-related genes, Plasma proteins, Predicted secreted proteins" Cytokine "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "breast: 80.7;lymphoid tissue: 98.4" "Cell line enriched" "Detected in single" 52 "HUVEC TERT2: 35.0" "Low cancer specificity" "Detected in some" "Not detected" "Not detected" "Not detected" "Not detected" "CAB004423, HPA030268" Uncertain "Secreted to blood" 5200000 19000000 "CAB004423: AB_627716, HPA030268: AB_10603782" "unprognostic (4.13e-2)" "unprognostic (5.85e-2)" "unprognostic (4.86e-2)" "unprognostic (3.55e-3)" "unprognostic (2.50e-1)" "unprognostic (1.99e-2)" "unprognostic (8.79e-5)" "unprognostic (1.44e-1)" "unprognostic (1.53e-1)" "unprognostic (8.10e-2)" "unprognostic (6.33e-3)" "unprognostic (3.00e-2)" "unprognostic (7.27e-3)" "unprognostic (1.36e-2)" "unprognostic (3.95e-1)" "unprognostic (3.52e-1)" "unprognostic (1.14e-1)" 56.3 5.1 0.0 5.9 0.0 0.0 80.7 0.0 0.0 37.6 8.4 0.0 16.6 0.0 37.6 11.1 20.9 9.1 17.3 27.5 0.0 8.7 34.2 26.4 39.1 0.0 0.0 12.4 0.8 2.0 6.5 0.0 0.0 23.5 0.7 4.1 6.5 11.4 21.9 7.5 3.9 19.1 0.0 98.4 0.2 15.0 0.0 1.3 17.6 16.7 6.2 25.3 45.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 35.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.2 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 CCL19 "CKb11, ELC, exodus-3, MIP-3b, SCYA19" ENSG00000172724 "C-C motif chemokine ligand 19" Q99731 9 34689567-34691277 "Cancer-related genes, Predicted secreted proteins" "Chemotaxis, Inflammatory response" Cytokine "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 10 "lymphoid tissue: 418.9" "Cell line enhanced" "Detected in some" "ASC TERT1: 1.9;Daudi: 2.5;HDLM-2: 7.5;HL-60: 1.9;TIME: 3.7" "Cancer enhanced" "Detected in all" "testis cancer: 118.4" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 4 "intermediate monocyte: 2.3" "Lineage enriched" "Detected in single" 6 "monocytes: 2.3" "Low region specificity" "Detected in many" HPA067758 Enhanced "Secreted to blood" 195000 "HPA067758: " "prognostic favourable (2.88e-5)" "prognostic favourable (9.91e-6)" "unprognostic (8.25e-3)" "unprognostic (1.16e-1)" "unprognostic (1.65e-1)" "unprognostic (1.67e-2)" "unprognostic (1.30e-2)" "unprognostic (1.48e-1)" "unprognostic (1.17e-2)" "unprognostic (8.36e-3)" "unprognostic (8.31e-2)" "unprognostic (2.43e-1)" "prognostic unfavourable (8.63e-7)" "unprognostic (7.98e-2)" "unprognostic (1.68e-2)" "unprognostic (2.03e-1)" "unprognostic (1.87e-1)" 22.5 0.6 1.2 82.3 1.1 0.0 10.2 0.8 1.3 5.8 4.7 1.5 1.5 1.0 1.5 5.9 16.3 3.4 10.4 16.5 0.8 0.7 11.8 12.8 13.6 418.9 2.1 1.0 3.4 1.7 0.0 2.0 0.6 1.5 7.0 11.0 7.4 23.1 1.0 0.7 8.7 40.2 4.5 2.2 8.2 9.0 2.8 0.6 73.1 14.9 9.9 90.9 13.4 2.3 0.0 0.0 0.3 2.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 1.9 0.4 0.0 0.0 0.0 0.0 0.0 0.0 2.5 0.0 0.0 0.4 0.0 0.0 0.0 7.5 0.0 0.6 0.0 0.0 0.0 1.9 0.0 0.0 0.0 0.0 0.9 0.0 1.6 0.4 0.0 0.0 0.3 0.0 0.4 0.0 0.7 0.7 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 3.7 0.0 0.0 0.1 0.3 0.4 0.0 0.0 0.0 0.9 0.0 0.0 0.5 0.0 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.1 1.2 1.1 0.8 1.3 0.8 0.7 2.1 1.0 1.5 0.6 CCL2 "GDCF-2, HC11, MCAF, MCP-1, MCP1, MGC9434, SCYA2, SMC-CF" ENSG00000108691 "C-C motif chemokine ligand 2" P13500 17 34255218-34257203 "Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins" "Chemotaxis, Inflammatory response" Cytokine "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Group enriched" "Detected in many" 4 "BJ hTERT+: 159.2;HMC-1: 207.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 6 "classical monocyte: 10.3;eosinophil: 3.9" "Group enriched" "Detected in many" 6 "granulocytes: 3.9;monocytes: 10.3" "Low region specificity" "Detected in many" "CAB013676, HPA019163" Approved Approved "Golgi apparatus,Vesicles" "Secreted to blood" 342420 "Golgi apparatus" Vesicles "CAB013676: , HPA019163: AB_1846179" "unprognostic (6.43e-2)" "unprognostic (4.14e-2)" "unprognostic (4.78e-2)" "unprognostic (5.57e-2)" "unprognostic (2.37e-3)" "unprognostic (8.64e-2)" "unprognostic (2.78e-2)" "unprognostic (7.53e-2)" "unprognostic (2.90e-1)" "unprognostic (1.19e-1)" "unprognostic (9.33e-2)" "unprognostic (2.65e-1)" "prognostic unfavourable (4.51e-4)" "unprognostic (1.33e-1)" "unprognostic (2.50e-2)" "unprognostic (1.81e-1)" "unprognostic (4.92e-2)" 78.1 31.2 10.3 52.3 50.6 19.1 19.0 1.5 23.3 9.7 41.9 28.6 3.0 9.4 7.2 7.6 14.4 25.8 62.0 76.9 45.1 6.7 32.5 38.4 105.2 16.9 16.0 2.0 28.6 32.8 15.2 17.3 22.8 63.6 42.0 25.3 22.3 13.5 13.4 17.8 10.5 16.7 34.6 85.4 16.1 30.2 4.6 8.6 4.8 20.8 21.6 19.1 27.2 9.0 0.0 1.1 3.9 10.3 0.0 0.1 2.3 0.0 1.2 3.4 0.0 9.6 8.2 0.0 9.7 159.2 20.7 44.4 0.5 0.0 0.0 7.7 2.2 5.3 0.3 0.0 10.5 0.0 0.0 0.0 1.1 0.0 0.3 0.0 207.5 9.1 0.0 4.3 0.2 9.4 0.5 1.7 0.0 0.0 0.0 1.5 0.4 0.0 0.0 0.2 1.7 29.6 0.0 0.0 0.6 0.0 0.5 0.2 0.3 0.2 0.5 11.1 0.4 0.3 0.0 0.1 0.0 0.0 6.5 3.0 7.0 0.0 10.3 3.9 0.0 0.3 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.1 0.7 0.0 0.0 0.3 0.0 2.3 10.3 50.6 1.5 23.3 45.1 6.7 16.0 2.0 63.6 8.6 CCL21 "6Ckine, CKb9, ECL, exodus-2, SCYA21, SLC, TCA4" ENSG00000137077 "C-C motif chemokine ligand 21" O00585 9 34709005-34710124 "Cancer-related genes, Plasma proteins, Predicted secreted proteins" "Chemotaxis, Inflammatory response" Cytokine "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "lymphoid tissue: 430.9" "Cell line enhanced" "Detected in some" "Daudi: 3.6;HL-60: 2.3;K-562: 3.8;RH-30: 2.4;U-937: 1.9" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB005067, HPA051210" Enhanced "Secreted to blood" 197877 770000 "CAB005067: AB_2071925, HPA051210: " "unprognostic (3.06e-3)" "unprognostic (7.19e-3)" "unprognostic (9.89e-2)" "unprognostic (5.50e-2)" "unprognostic (4.51e-3)" "unprognostic (1.21e-2)" "unprognostic (1.04e-2)" "unprognostic (8.07e-2)" "unprognostic (4.15e-2)" "unprognostic (2.49e-2)" "unprognostic (3.70e-1)" "unprognostic (8.99e-3)" "unprognostic (3.50e-3)" "unprognostic (1.58e-1)" "unprognostic (2.66e-2)" "unprognostic (8.91e-2)" 24.4 6.5 0.3 83.5 0.4 0.0 18.0 0.3 0.4 13.6 25.5 0.4 5.9 3.7 26.8 23.7 80.1 23.0 23.2 18.8 0.3 0.0 19.6 11.0 30.5 430.9 0.3 0.3 13.8 3.3 0.0 0.4 7.4 0.5 9.4 11.9 0.7 96.9 4.1 4.7 7.6 71.2 10.6 0.3 35.9 10.7 5.5 0.3 2.3 91.0 44.8 181.2 15.7 9.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 3.6 0.3 0.0 0.4 0.0 0.0 0.0 0.3 0.0 1.3 0.0 0.0 0.7 2.3 0.3 0.0 0.0 0.0 0.0 0.0 3.8 0.0 0.0 0.0 0.0 1.2 0.8 0.0 0.9 2.4 0.6 0.0 0.0 0.3 0.5 1.0 0.0 0.0 0.0 0.0 1.5 0.0 0.2 0.5 0.0 0.8 0.0 0.8 0.0 1.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.4 0.3 0.4 0.3 0.0 0.3 0.3 0.5 0.3 CCL23 "Ckb-8, CKb8, MIP-3, MPIF-1, SCYA23" ENSG00000274736 "C-C motif chemokine ligand 23" P55773 17 36013056-36017968 "Cancer-related genes, Plasma proteins, Predicted secreted proteins" "Chemotaxis, Inflammatory response" "Cytokine, Heparin-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 50.3" "Group enriched" "Detected in some" 4 "HEL: 12.6;THP-1: 26.9" "Low cancer specificity" "Detected in some" "Cell type enriched" "Detected in single" 173 "eosinophil: 50.3" "Lineage enriched" "Detected in single" 173 "granulocytes: 50.3" HPA042015 Uncertain "Secreted to blood" 91400 57000 "HPA042015: AB_10794039" "unprognostic (1.65e-3)" "unprognostic (1.43e-2)" "unprognostic (1.04e-1)" "unprognostic (9.50e-2)" "unprognostic (3.59e-2)" "unprognostic (2.39e-1)" "unprognostic (1.20e-4)" "unprognostic (2.17e-1)" "unprognostic (6.49e-2)" "unprognostic (1.08e-2)" "unprognostic (7.05e-2)" "unprognostic (6.93e-2)" "unprognostic (1.35e-3)" "unprognostic (2.18e-1)" "unprognostic (2.76e-1)" "unprognostic (1.20e-2)" "unprognostic (1.95e-1)" 5.8 0.5 0.0 13.1 0.0 2.1 3.7 0.0 0.5 2.1 2.0 0.0 1.0 0.0 1.8 3.0 1.3 1.5 2.2 4.6 0.0 3.0 5.9 7.9 8.0 0.3 0.0 1.2 0.0 0.0 0.5 1.5 0.2 1.7 7.2 0.7 0.0 1.1 0.5 0.4 1.0 8.4 0.0 2.0 0.0 0.1 0.0 0.4 1.1 0.6 0.5 3.0 0.0 0.2 0.1 50.3 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 12.6 0.0 0.0 0.0 1.6 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 26.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.6 0.0 0.2 0.2 50.3 0.0 0.2 0.0 0.2 0.0 0.1 0.1 0.0 0.0 0.1 0.2 0.0 0.2 0.0 0.0 0.0 CCL4 "Act-2, AT744.1, LAG1, MIP-1-beta, SCYA4" ENSG00000275302 "C-C motif chemokine ligand 4" P13236 17 36103590-36105621 "Cancer-related genes, Predicted secreted proteins" "Chemotaxis, Inflammatory response" Cytokine "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "blood: 69.3;lung: 23.1;lymphoid tissue: 20.8" "Group enriched" "Detected in some" 23 "Karpas-707: 5.1;U-266/70: 11.2;U-266/84: 5.4" "Low cancer specificity" "Detected in all" "Group enriched" "Detected in many" 5 "gdT-cell: 69.3;MAIT T-cell: 21.8;memory CD8 T-cell: 40.6;naive CD8 T-cell: 30.5" "Lineage enriched" "Detected in many" 17 "T-cells: 69.3" CAB007805 Approved "Secreted to blood" 131867 "CAB007805: AB_598177" "unprognostic (6.03e-2)" "unprognostic (2.48e-2)" "prognostic favourable (3.54e-4)" "prognostic favourable (1.97e-5)" "unprognostic (2.06e-1)" "unprognostic (7.02e-2)" "unprognostic (9.08e-2)" "unprognostic (2.69e-1)" "prognostic favourable (3.97e-4)" "unprognostic (3.45e-1)" "unprognostic (8.57e-2)" "unprognostic (1.61e-1)" "prognostic unfavourable (1.68e-4)" "unprognostic (3.71e-1)" "unprognostic (1.30e-1)" "unprognostic (1.18e-1)" "unprognostic (1.18e-2)" 2.3 2.6 0.0 3.7 0.4 9.3 5.7 0.1 3.6 0.9 2.9 1.4 0.5 0.2 1.6 0.8 1.7 1.6 4.4 3.8 0.0 1.3 5.7 23.1 20.8 1.1 0.0 3.4 0.9 0.0 0.2 4.3 0.9 1.1 1.0 3.9 1.6 1.6 0.5 0.0 0.9 1.4 1.5 10.4 2.3 0.3 0.0 1.0 1.6 2.0 4.3 1.9 0.8 1.8 0.4 4.0 0.6 3.0 69.3 11.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 5.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 11.2 5.4 0.3 0.0 0.0 0.0 1.7 0.2 4.0 69.3 0.0 21.8 0.9 7.7 40.6 0.1 1.8 2.3 30.5 1.6 3.0 0.6 0.4 0.0 11.6 CCNA1 CT146 ENSG00000133101 "Cyclin A1" P78396 13 36431520-36442882 "Cancer-related genes, Predicted intracellular proteins" "Cell cycle, Cell division, Mitosis" Cyclin "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 24.5;parathyroid gland: 24.2;testis: 50.4" "Cell line enriched" "Detected in some" 4 "HMC-1: 85.1" "Cancer enhanced" "Detected in many" "endometrial cancer: 20.7;ovarian cancer: 18.6" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 108 "basophil: 24.5" "Lineage enriched" "Detected in single" 233 "granulocytes: 24.5" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA060646, HPA077614" Enhanced Approved "Nucleoplasm,Nuclear bodies" "Nucleoplasm, Nuclear bodies" "HPA060646: , HPA077614: " "unprognostic (1.92e-3)" "unprognostic (1.21e-1)" "unprognostic (4.69e-3)" "unprognostic (1.89e-3)" "unprognostic (5.46e-2)" "prognostic unfavourable (1.70e-4)" "unprognostic (1.51e-1)" "unprognostic (3.40e-1)" "unprognostic (1.24e-1)" "unprognostic (4.01e-3)" "unprognostic (1.64e-1)" "unprognostic (4.04e-6)" "unprognostic (7.04e-3)" "unprognostic (2.45e-1)" "unprognostic (1.42e-1)" "unprognostic (2.63e-2)" 0.4 0.8 7.3 0.4 6.2 1.3 0.6 0.2 4.7 4.0 0.3 1.6 0.0 0.4 2.6 4.7 0.3 11.1 0.6 0.3 4.5 5.9 0.3 0.2 1.0 1.0 1.9 5.5 1.2 0.5 24.2 4.8 0.2 3.1 0.3 0.3 0.1 0.4 0.2 1.3 0.2 0.3 5.1 1.0 0.3 0.4 50.4 0.4 0.2 0.4 0.0 0.5 0.4 0.6 0.1 0.0 24.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.7 0.0 0.2 3.0 0.3 0.0 0.0 0.1 0.0 0.1 0.0 0.1 1.7 85.1 0.0 8.3 0.1 0.7 0.2 0.0 0.1 0.0 1.0 0.1 16.6 0.5 2.1 0.0 2.0 0.0 0.5 0.0 0.6 1.4 0.0 2.0 0.0 0.0 16.6 1.0 0.0 0.0 0.0 0.6 0.2 0.0 0.0 0.0 21.0 0.1 24.5 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.3 6.2 0.2 4.7 4.5 5.9 1.9 5.5 3.1 0.4 CCNA2 "CCN1, CCNA" ENSG00000145386 "Cyclin A2" P20248 4 121816444-121823933 "Cancer-related genes, Predicted intracellular proteins" "Cell cycle, Cell division, Host-virus interaction, Mitosis" Cyclin "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "lymphoid tissue: 122.3" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in some" "T-reg: 6.8" "Group enriched" "Detected in many" 5 "NK-cells: 1.7;T-cells: 6.8" "Low region specificity" "Detected in single" "CAB000114, HPA020626" Enhanced Enhanced Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "CAB000114: AB_563675, HPA020626: AB_1847376" "unprognostic (4.02e-2)" "unprognostic (1.93e-1)" "unprognostic (7.66e-3)" "prognostic unfavourable (8.78e-4)" "unprognostic (1.25e-1)" "unprognostic (1.67e-2)" "prognostic unfavourable (9.17e-5)" "prognostic unfavourable (4.27e-4)" "unprognostic (3.92e-3)" "unprognostic (2.65e-2)" "prognostic unfavourable (4.43e-6)" "unprognostic (8.38e-3)" "prognostic unfavourable (0.00e+0)" "unprognostic (1.65e-1)" "unprognostic (1.82e-1)" "unprognostic (6.07e-2)" "unprognostic (1.59e-1)" 3.2 1.5 1.3 18.6 1.7 21.6 1.8 5.1 1.2 2.5 6.3 1.0 0.8 6.6 2.2 2.1 11.7 1.7 2.4 3.2 1.8 1.8 1.7 1.6 3.4 15.6 1.6 0.8 4.5 0.9 0.5 3.2 12.0 1.3 2.2 7.8 1.0 2.1 0.8 1.1 4.2 7.4 2.4 1.8 8.9 2.9 8.4 0.8 122.3 1.4 18.8 18.4 2.5 5.1 0.3 0.9 0.6 0.3 1.7 6.8 1.9 38.1 9.9 27.3 11.6 1.4 3.8 22.3 26.6 11.7 35.5 26.4 21.6 23.7 35.1 7.2 14.0 12.9 34.3 15.7 29.2 16.8 15.8 28.2 13.2 21.0 0.3 42.4 20.0 0.9 1.2 14.6 8.8 21.2 40.0 35.3 28.1 13.7 54.0 24.6 21.5 11.1 24.8 52.8 17.1 10.0 7.6 11.6 12.3 14.0 17.1 7.4 14.3 18.0 12.4 16.6 25.2 17.5 25.4 22.4 23.7 40.2 9.5 43.2 18.4 0.0 0.3 0.6 0.2 0.1 0.1 0.3 2.0 1.4 0.9 0.1 0.0 0.5 0.3 1.7 0.3 0.1 6.8 1.9 1.3 1.7 5.1 1.2 1.8 1.8 1.6 0.8 1.3 0.8 CCNB1 CCNB ENSG00000134057 "Cyclin B1" P14635 5 69167010-69178245 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters" "Cell cycle, Cell division, Mitosis" Cyclin "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 71.4" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" "CAB000115, CAB003804, HPA030741, HPA061448" Enhanced Enhanced Cytosol Cytosol "CAB000115: , CAB003804: AB_562272, HPA030741: , HPA061448: " "unprognostic (4.12e-2)" "unprognostic (2.75e-2)" "unprognostic (1.91e-3)" "unprognostic (4.08e-3)" "unprognostic (2.78e-1)" "unprognostic (1.39e-1)" "prognostic unfavourable (1.54e-7)" "prognostic unfavourable (3.38e-4)" "unprognostic (1.43e-2)" "unprognostic (1.63e-2)" "unprognostic (2.49e-3)" "unprognostic (1.40e-1)" "prognostic unfavourable (1.11e-16)" "unprognostic (2.44e-1)" "unprognostic (3.73e-1)" "unprognostic (1.44e-1)" "unprognostic (5.15e-3)" 3.2 4.6 2.7 23.9 4.8 20.5 4.6 6.5 5.6 4.4 9.9 1.6 1.6 9.3 3.5 2.8 28.8 3.3 3.5 1.9 3.5 4.2 4.6 2.9 3.4 23.6 4.0 4.2 3.7 4.0 1.6 2.6 12.1 11.5 2.6 14.2 1.7 5.3 1.7 2.0 6.4 8.7 6.4 2.5 9.1 7.1 21.7 1.3 71.4 6.3 23.3 30.1 5.3 7.5 13.2 5.1 2.4 4.1 6.5 14.7 5.5 58.7 40.7 55.8 49.6 2.9 5.0 131.9 26.0 19.5 68.7 58.1 60.1 55.4 36.1 31.7 24.0 37.1 56.1 56.9 77.1 35.4 27.8 22.9 33.9 41.4 0.9 19.9 26.2 2.2 3.6 39.4 27.5 36.6 27.7 28.7 55.9 55.9 27.3 23.8 31.1 25.8 28.7 40.3 37.0 25.1 21.7 28.4 17.9 44.8 21.1 19.3 40.3 20.9 15.4 15.3 49.8 27.6 65.0 14.4 26.6 50.4 21.2 35.0 47.0 2.4 1.8 1.2 2.8 4.1 4.0 13.2 7.6 6.7 5.1 8.6 2.5 2.4 1.0 6.5 1.9 4.2 14.7 5.5 2.7 4.8 6.5 5.6 3.5 4.2 4.0 4.2 11.5 1.3 CCNB2 HsT17299 ENSG00000157456 "Cyclin B2" O95067 15 59105078-59125045 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters" "Cell cycle, Cell division, Mitosis" Cyclin "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 70.2;testis: 73.9" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Cell type enriched" "Detected in many" 4 "T-reg: 17.8" "Lineage enriched" "Detected in many" 6 "T-cells: 17.8" "Not detected" "Not detected" "Not detected" "Not detected" "HPA008873, CAB009575" Enhanced Enhanced "Golgi apparatus,Cytosol" Cytosol "Golgi apparatus" "CAB009575: AB_2072392, HPA008873: AB_1078604" "unprognostic (2.69e-2)" "unprognostic (2.25e-1)" "unprognostic (4.43e-2)" "unprognostic (1.96e-2)" "unprognostic (1.77e-1)" "unprognostic (4.65e-2)" "prognostic unfavourable (2.83e-4)" "prognostic unfavourable (4.63e-4)" "prognostic unfavourable (3.21e-5)" "unprognostic (1.09e-1)" "prognostic unfavourable (1.74e-5)" "unprognostic (4.48e-2)" "prognostic unfavourable (0.00e+0)" "unprognostic (1.96e-1)" "unprognostic (1.41e-1)" "unprognostic (3.98e-2)" "unprognostic (4.44e-1)" 2.0 1.1 0.4 21.0 0.4 24.7 2.5 0.3 0.6 1.8 5.5 0.5 0.2 5.2 1.0 1.5 11.3 0.5 1.6 1.2 0.4 0.4 1.0 1.0 1.9 12.0 0.4 0.3 0.8 0.7 0.0 0.4 6.7 0.4 1.1 6.3 0.4 2.1 0.6 0.4 3.6 5.1 2.0 1.3 5.2 3.0 73.9 0.2 70.2 0.8 10.3 16.0 1.8 3.4 1.8 2.3 0.7 0.1 3.0 17.8 1.8 28.4 25.1 41.3 10.2 1.8 3.8 21.9 23.6 15.2 36.6 30.1 40.6 17.6 26.5 17.1 15.2 35.2 39.0 20.1 34.6 27.5 20.9 34.3 29.4 23.0 0.5 25.5 22.1 1.4 2.7 15.7 20.1 24.8 34.6 42.6 27.6 20.7 29.1 37.2 30.5 14.9 34.0 58.4 26.9 11.5 20.2 25.7 17.4 32.4 17.6 21.3 30.5 25.5 12.9 18.2 31.0 20.1 44.9 19.0 28.4 47.1 11.9 58.4 25.7 0.0 0.1 0.6 0.1 0.0 0.2 1.8 3.9 4.1 2.3 0.9 0.0 0.1 0.7 3.0 0.0 0.1 17.8 1.8 0.4 0.4 0.3 0.6 0.4 0.4 0.4 0.3 0.4 0.2 CCND1 "BCL1, D11S287E, PRAD1, U21B31" ENSG00000110092 "Cyclin D1" P24385 11 69641087-69654474 "Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted intracellular proteins" "Cell cycle, Cell division, DNA damage, Transcription, Transcription regulation" "Cyclin, Repressor" "Cancer-related genes, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "U-266/70: 94.3;WM-115: 131.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "memory B-cell: 3.0;myeloid DC: 3.4" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000024, HPA027802" Uncertain Supported Nucleoplasm Nucleoplasm "CAB000024: AB_563678, HPA027802: " "unprognostic (4.90e-2)" "unprognostic (1.54e-1)" "unprognostic (7.62e-2)" "unprognostic (1.39e-2)" "unprognostic (2.18e-1)" "prognostic unfavourable (5.51e-4)" "unprognostic (1.38e-1)" "unprognostic (2.53e-2)" "unprognostic (9.46e-2)" "unprognostic (4.84e-3)" "prognostic unfavourable (1.96e-4)" "unprognostic (4.39e-2)" "unprognostic (2.61e-3)" "unprognostic (4.38e-3)" "unprognostic (1.16e-1)" "unprognostic (6.40e-3)" "unprognostic (2.57e-1)" 52.0 11.6 9.7 6.0 9.7 0.7 22.8 3.4 7.7 15.4 8.9 15.4 19.9 8.4 18.8 23.1 37.7 11.8 31.0 23.9 10.8 8.8 14.5 68.1 22.2 3.7 12.4 5.6 6.5 31.5 83.2 16.6 38.1 10.0 30.7 6.8 24.8 25.6 21.7 2.0 43.6 10.4 16.5 12.6 12.9 19.2 4.0 7.5 9.0 17.1 23.1 23.6 21.4 22.1 3.0 3.4 0.8 0.0 0.0 0.9 0.3 47.6 19.1 6.3 0.1 19.6 20.7 13.7 75.6 28.1 8.8 5.2 21.4 37.0 0.0 34.3 39.3 34.9 0.6 20.5 15.9 0.1 3.8 0.0 4.7 21.7 4.7 0.3 0.7 11.7 4.0 12.4 4.8 15.1 0.0 0.1 69.5 20.2 0.0 2.7 11.6 21.1 0.1 20.2 1.1 41.0 29.5 1.0 25.0 0.9 17.9 47.0 10.9 0.9 63.0 43.4 12.1 18.8 51.3 94.3 56.3 0.1 37.1 0.6 131.3 0.8 0.0 0.0 0.9 0.0 0.1 3.0 0.4 0.2 3.4 2.5 0.8 0.2 0.2 0.0 0.0 0.0 0.0 0.3 9.7 9.7 3.4 7.7 10.8 8.8 12.4 5.6 10.0 7.5 CCND2 ENSG00000118971 "Cyclin D2" P30279 12 4273772-4305350 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cell cycle, Cell division" Cyclin "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "AF22: 32.3;HBEC3-KT: 29.5;HDLM-2: 49.7;Karpas-707: 71.7;RH-30: 46.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA049138, HPA054196" Approved Enhanced Nucleoplasm Nucleoplasm "HPA049138: , HPA054196: " "unprognostic (2.98e-3)" "unprognostic (1.15e-1)" "unprognostic (7.21e-2)" "unprognostic (1.65e-2)" "unprognostic (1.70e-2)" "unprognostic (4.82e-2)" "unprognostic (4.94e-2)" "unprognostic (2.01e-3)" "unprognostic (3.16e-2)" "unprognostic (1.66e-2)" "prognostic favourable (2.52e-4)" "unprognostic (1.75e-1)" "unprognostic (1.25e-1)" "unprognostic (8.23e-2)" "unprognostic (4.52e-1)" "prognostic favourable (9.76e-5)" "unprognostic (7.06e-2)" 13.7 39.3 20.8 12.0 15.9 23.6 10.4 6.1 22.3 14.4 28.3 8.1 24.3 18.5 21.9 41.9 12.2 16.5 9.1 36.9 17.5 7.3 6.0 5.7 12.8 24.5 7.9 17.0 11.6 18.4 8.3 19.2 23.5 9.3 16.4 24.2 14.1 8.3 22.4 2.0 9.2 19.6 45.5 14.0 16.5 11.1 5.2 8.6 6.2 18.5 6.9 13.6 22.3 16.3 3.9 2.1 4.6 1.0 9.1 14.8 5.4 0.0 0.0 32.3 0.0 5.6 0.8 0.0 0.0 0.0 0.0 0.0 13.8 0.0 0.0 0.2 0.0 4.1 0.9 29.5 0.0 49.7 0.8 0.3 0.0 0.2 0.1 12.6 2.7 10.8 4.9 0.0 22.3 0.0 3.4 71.7 6.2 0.0 0.0 16.6 13.3 0.0 0.0 46.9 23.4 0.0 2.8 0.0 0.0 0.0 0.0 0.0 0.0 0.1 2.3 0.0 9.4 0.0 0.0 1.2 12.1 0.0 0.1 9.1 0.0 4.1 1.0 4.6 9.1 0.2 13.7 3.9 13.0 11.0 2.1 1.5 8.2 9.8 1.5 9.1 0.1 1.0 14.8 5.4 20.8 15.9 6.1 22.3 17.5 7.3 7.9 17.0 9.3 8.6 CCND3 ENSG00000112576 "Cyclin D3" P30281 6 41934933-42050357 "Cancer-related genes, Predicted intracellular proteins" "Cell cycle, Cell division" Cyclin "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 129.2;lymphoid tissue: 142.5" "Cell line enhanced" "Detected in all" "MOLT-4: 92.5;REH: 87.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000116, HPA071369" Approved Supported "Nucleoplasm,Nuclear bodies,Cytosol" "Nucleoplasm, Nuclear bodies" Cytosol "CAB000116: , HPA071369: " "unprognostic (4.53e-2)" "unprognostic (4.45e-2)" "unprognostic (2.45e-1)" "unprognostic (4.40e-3)" "unprognostic (1.01e-1)" "unprognostic (9.80e-2)" "unprognostic (3.40e-2)" "unprognostic (5.25e-2)" "unprognostic (7.76e-2)" "unprognostic (3.45e-1)" "unprognostic (9.17e-2)" "unprognostic (6.39e-2)" "unprognostic (2.45e-3)" "unprognostic (9.12e-2)" "unprognostic (1.71e-1)" "prognostic favourable (8.08e-6)" "unprognostic (2.11e-1)" 20.2 39.8 16.1 28.9 17.5 74.7 36.0 13.3 19.8 13.3 17.3 11.3 14.1 16.0 10.8 10.4 13.5 13.4 19.0 16.3 15.4 14.5 13.7 8.0 32.1 83.8 14.1 15.5 11.1 10.9 5.0 10.1 21.9 9.3 14.2 11.4 10.2 18.1 14.4 6.5 14.6 22.0 11.7 11.5 51.2 18.0 7.4 10.0 142.5 26.8 9.3 32.8 13.0 16.6 24.1 42.4 129.2 45.8 39.0 52.8 66.2 9.0 33.1 3.5 7.7 6.3 12.9 40.2 10.6 6.1 11.0 8.1 6.2 4.1 39.0 18.0 7.1 5.6 9.2 13.0 5.7 6.6 6.0 61.8 14.8 5.0 13.9 10.1 54.6 12.3 8.5 10.6 4.0 13.5 31.1 3.8 15.7 12.2 92.5 48.5 1.5 7.1 87.9 13.5 4.3 25.4 6.1 11.8 3.1 9.0 11.6 5.2 7.1 39.5 22.5 12.2 6.7 10.6 11.9 2.5 1.9 60.9 7.1 21.3 7.4 129.2 30.5 87.7 52.8 35.1 37.0 16.4 36.4 42.5 42.4 24.1 42.8 45.0 42.8 39.0 45.8 27.8 23.2 66.2 16.1 17.5 13.3 19.8 15.4 14.5 14.1 15.5 9.3 10.0 CCNE1 CCNE ENSG00000105173 "Cyclin E1" P24864 19 29811898-29824308 "Cancer-related genes, Predicted intracellular proteins" "Cell cycle, Cell division" Cyclin "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 23.3;placenta: 46.7" "Cell line enhanced" "Detected in many" "BEWO: 79.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB000308, CAB016682, HPA018169" Approved Enhanced Nucleoplasm Nucleoplasm "CAB000308: , CAB016682: AB_1614564, HPA018169: AB_1847384" "unprognostic (2.90e-3)" "unprognostic (1.33e-2)" "unprognostic (1.47e-3)" "prognostic unfavourable (6.35e-6)" "unprognostic (5.78e-2)" "unprognostic (4.77e-2)" "prognostic unfavourable (3.89e-5)" "unprognostic (1.26e-3)" "unprognostic (3.14e-3)" "prognostic unfavourable (2.97e-4)" "unprognostic (3.29e-2)" "unprognostic (7.07e-2)" "unprognostic (1.11e-16)" "unprognostic (5.61e-2)" "unprognostic (1.92e-1)" "unprognostic (6.63e-2)" "unprognostic (1.46e-1)" 1.6 6.8 2.4 4.5 2.9 23.3 0.6 6.3 3.3 0.8 3.0 1.7 1.1 2.3 1.2 0.6 4.7 0.7 2.2 4.4 2.3 2.8 1.2 0.7 1.1 4.6 1.9 1.9 0.9 1.4 1.7 1.0 46.7 2.8 1.1 3.8 1.5 3.2 1.2 2.2 4.4 2.5 3.0 1.7 4.6 2.0 12.3 1.6 4.1 1.6 2.1 5.9 2.7 2.5 2.7 1.6 1.6 1.9 0.0 1.4 0.5 4.0 8.4 6.5 9.2 1.4 1.6 79.9 6.5 1.4 2.9 3.5 8.5 8.2 3.4 15.3 2.8 1.2 7.6 3.3 4.1 10.8 4.7 2.9 8.2 8.9 1.1 11.3 7.7 1.6 1.8 3.9 0.5 3.5 11.6 1.5 4.3 6.0 6.2 3.2 10.8 2.0 9.3 7.6 2.6 2.2 6.5 5.5 4.6 9.3 11.5 1.0 2.5 8.4 2.0 6.7 25.4 4.0 4.3 6.5 4.5 23.4 3.8 1.4 3.6 0.0 0.1 0.0 0.6 1.9 1.1 2.7 0.5 0.4 1.6 0.2 0.1 0.9 1.6 0.0 1.9 0.0 1.4 0.5 2.4 2.9 6.3 3.3 2.3 2.8 1.9 1.9 2.8 1.6 CCNE2 CYCE2 ENSG00000175305 "Cyclin E2" O96020 8 94879770-94896678 "Cancer-related genes, Predicted intracellular proteins" "Cell cycle, Cell division" Cyclin "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 24.2;brain: 22.2;testis: 18.9" "Cell line enhanced" "Detected in many" "Karpas-707: 39.3" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "T-reg: 8.8" "Group enriched" "Detected in many" 4 "NK-cells: 2.2;T-cells: 8.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB007825, CAB019374" Enhanced "CAB007825: AB_598148, CAB019374: " "unprognostic (1.80e-2)" "unprognostic (4.81e-2)" "unprognostic (7.49e-2)" "unprognostic (2.08e-2)" "unprognostic (2.36e-1)" "prognostic favourable (5.87e-4)" "unprognostic (8.37e-4)" "prognostic unfavourable (8.77e-4)" "unprognostic (3.18e-2)" "unprognostic (2.19e-2)" "unprognostic (3.64e-2)" "unprognostic (1.04e-2)" "unprognostic (7.01e-12)" "unprognostic (1.81e-2)" "unprognostic (1.50e-1)" "unprognostic (1.06e-2)" "unprognostic (3.03e-1)" 1.3 0.9 3.1 4.9 11.3 24.2 1.5 3.3 6.3 1.7 4.0 10.4 0.0 2.6 1.3 0.1 3.6 1.0 1.7 0.9 5.7 3.5 0.9 1.6 1.7 7.9 8.0 6.5 1.4 2.3 0.5 1.1 3.1 11.8 1.3 4.3 0.6 1.5 0.0 0.8 4.4 3.1 1.4 22.2 1.9 2.9 18.9 4.9 12.7 1.1 2.4 7.0 1.9 1.9 1.1 1.3 1.1 0.3 2.2 8.8 1.1 17.7 2.4 9.5 5.9 1.1 2.1 6.5 18.3 6.4 11.5 11.3 4.2 8.0 9.3 12.5 7.7 9.4 7.3 6.7 15.6 6.5 6.8 18.8 10.0 1.6 0.1 7.5 11.5 0.6 0.4 8.3 0.8 5.9 8.0 39.3 16.3 5.1 28.7 3.5 3.2 5.5 20.5 16.4 4.4 3.2 10.0 13.8 5.8 12.3 3.3 2.3 16.5 8.0 5.0 12.2 8.0 9.0 16.3 7.5 7.8 22.7 9.9 13.8 8.9 0.0 0.3 0.2 1.6 0.3 0.5 0.7 2.0 2.3 1.3 1.1 0.6 1.3 1.1 2.2 0.3 0.1 8.8 1.1 3.1 11.3 3.3 5.7 5.7 3.5 8.0 6.5 11.8 4.9 CCNG1 CCNG ENSG00000113328 "Cyclin G1" P51959 5 163437569-163446151 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division, Mitosis" Cyclin "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB000350 Supported Supported Nucleoplasm Nucleoplasm "CAB000350: " "unprognostic (2.49e-2)" "unprognostic (1.64e-1)" "prognostic favourable (7.00e-4)" "unprognostic (2.92e-2)" "unprognostic (9.04e-2)" "unprognostic (2.26e-1)" "unprognostic (6.25e-2)" "unprognostic (1.58e-1)" "unprognostic (6.15e-2)" "unprognostic (1.45e-2)" "unprognostic (1.29e-2)" "unprognostic (1.20e-1)" "unprognostic (1.38e-3)" "unprognostic (1.46e-1)" "unprognostic (1.38e-1)" "unprognostic (1.19e-1)" "unprognostic (7.89e-2)" 32.3 24.8 11.1 16.0 14.6 9.6 20.5 9.0 9.7 27.9 43.5 11.0 14.1 41.4 22.3 23.6 24.7 19.4 25.8 29.8 11.5 10.3 40.4 46.6 20.7 26.0 22.5 9.1 44.1 42.5 13.5 12.6 17.9 17.0 39.3 26.9 12.6 25.6 18.1 51.7 10.2 68.7 35.8 27.1 22.7 24.6 17.0 15.8 26.5 38.3 29.7 15.6 48.1 21.4 23.2 23.3 15.9 14.0 15.4 36.5 22.8 9.5 10.7 44.6 25.0 38.6 74.4 47.0 13.2 32.4 13.5 30.5 23.1 19.5 23.4 13.5 17.6 3.9 24.6 33.0 19.9 11.2 31.1 18.5 14.2 40.1 42.2 8.5 12.5 80.7 19.1 13.3 13.7 43.2 15.8 16.7 45.6 5.9 14.9 11.5 20.4 9.7 13.0 21.9 12.9 32.7 37.0 10.6 12.0 0.0 5.5 26.9 20.9 27.4 25.1 8.7 18.8 7.3 11.5 14.9 5.8 15.8 15.5 14.4 14.5 15.9 10.3 11.8 15.1 14.0 22.3 23.2 26.6 20.6 23.3 14.5 36.5 29.8 4.2 15.4 13.0 8.9 31.3 22.8 11.1 14.6 9.0 9.7 11.5 10.3 22.5 9.1 17.0 15.8 CCNG2 ENSG00000138764 "Cyclin G2" Q16589 4 77157151-77433388 "Cancer-related genes, Predicted intracellular proteins" "Cell cycle, Cell division, Mitosis" Cyclin "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "eosinophil: 16.0" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Region enhanced" "Detected in all" "cerebellum: 99.1" HPA034684 Approved Approved Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "HPA034684: AB_10669894" "unprognostic (2.58e-1)" "unprognostic (3.00e-1)" "unprognostic (1.46e-2)" "unprognostic (2.29e-1)" "unprognostic (5.73e-2)" "unprognostic (8.15e-2)" "unprognostic (8.40e-3)" "unprognostic (1.72e-2)" "unprognostic (1.20e-2)" "unprognostic (3.06e-1)" "prognostic unfavourable (8.57e-4)" "unprognostic (2.04e-1)" "prognostic favourable (2.47e-5)" "unprognostic (7.98e-2)" "unprognostic (2.20e-1)" "unprognostic (2.28e-1)" "unprognostic (1.05e-3)" 18.4 8.1 11.3 13.5 15.1 25.9 26.7 53.0 17.2 15.1 12.3 8.9 9.6 8.6 16.4 10.7 45.2 8.0 10.4 6.3 9.6 5.4 23.0 3.4 12.8 21.4 7.3 10.6 12.5 7.2 8.8 7.7 20.0 7.3 26.1 11.0 12.2 18.4 10.5 7.5 12.8 9.8 13.5 7.4 14.2 7.7 8.0 7.8 25.3 17.3 7.2 22.6 20.3 18.6 4.8 2.2 16.0 2.3 1.6 4.6 0.6 10.2 1.3 23.1 12.2 15.3 19.7 15.7 8.6 24.9 6.7 12.6 1.5 14.9 20.7 14.0 8.0 7.4 6.0 28.5 13.1 14.3 4.0 1.7 6.0 3.0 8.0 3.0 21.6 16.6 14.2 3.1 7.0 10.1 0.9 12.7 12.4 4.0 14.0 6.5 2.3 1.4 8.1 22.5 1.3 42.5 28.5 6.1 19.6 10.2 16.2 6.0 12.0 4.6 9.3 9.2 9.4 6.6 1.4 9.3 7.1 14.6 6.4 4.8 4.6 11.4 1.5 16.0 0.8 2.0 1.9 2.7 1.2 0.8 1.5 4.8 0.9 0.5 6.5 1.6 2.3 2.2 4.6 0.6 11.3 15.1 53.0 17.2 9.6 5.4 7.3 10.6 7.3 7.8 CCNH "CycH, p34, p37" ENSG00000134480 "Cyclin H" P51946 5 87318416-87413019 "Cancer-related genes, Predicted intracellular proteins" "Cell cycle, Transcription, Transcription regulation" Cyclin "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB019416, HPA044138" Approved Supported Nucleoplasm Nucleoplasm "CAB019416: AB_2259936, HPA044138: " "unprognostic (5.65e-2)" "unprognostic (3.94e-3)" "unprognostic (4.01e-3)" "unprognostic (4.12e-1)" "unprognostic (1.10e-1)" "unprognostic (9.30e-2)" "unprognostic (3.93e-2)" "unprognostic (6.43e-2)" "unprognostic (8.79e-2)" "prognostic unfavourable (4.35e-4)" "unprognostic (4.16e-2)" "unprognostic (2.27e-2)" "prognostic unfavourable (3.92e-5)" "unprognostic (1.48e-1)" "unprognostic (2.35e-1)" "unprognostic (1.61e-1)" "unprognostic (9.62e-2)" 32.4 25.8 18.7 16.1 25.2 28.9 25.5 40.9 29.9 16.3 14.7 19.2 16.9 16.0 15.5 23.7 17.4 14.9 23.2 20.3 23.4 19.4 22.6 33.8 21.7 19.6 20.8 21.4 24.3 21.0 24.3 32.5 14.8 27.3 25.3 19.0 16.6 17.9 20.5 24.4 13.7 18.8 15.7 22.1 17.2 16.3 46.9 22.3 28.4 25.7 13.9 23.6 19.7 16.4 19.9 23.1 33.5 25.7 16.7 22.8 19.0 19.4 9.3 9.2 6.1 13.4 9.5 9.4 14.1 18.4 25.0 34.8 15.7 11.0 13.2 4.9 21.9 9.9 11.5 22.9 23.6 14.5 14.6 23.5 16.7 15.2 24.2 18.8 19.1 13.2 8.6 13.1 31.8 21.9 15.5 22.5 20.7 11.6 13.2 15.6 3.7 36.3 11.0 21.4 19.4 21.0 10.5 9.2 5.8 7.8 7.0 17.0 17.1 14.8 15.0 24.4 9.4 14.1 12.4 7.2 6.8 19.7 15.7 17.8 10.8 20.1 21.8 33.5 15.3 24.9 22.7 19.9 20.3 20.6 23.1 16.6 21.0 20.1 18.2 16.7 25.7 13.7 22.8 19.0 18.7 25.2 40.9 29.9 23.4 19.4 20.8 21.4 27.3 22.3 CCR10 GPR2 ENSG00000184451 "C-C motif chemokine receptor 10" P46092 17 42678889-42683917 "Cancer-related genes, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 31.1" "Cell line enhanced" "Detected in some" "Karpas-707: 8.6;RPMI-8226: 6.2;U-266/70: 17.7;U-266/84: 8.0" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "T-reg: 31.1" "Group enriched" "Detected in many" 9 "dendritic cells: 10.9;T-cells: 31.1" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB011684, HPA048007, HPA069188" Uncertain Supported "Endoplasmic reticulum" "Endoplasmic reticulum" "CAB011684: AB_731502, HPA048007: , HPA069188: " "unprognostic (3.25e-2)" "unprognostic (2.71e-2)" "unprognostic (5.70e-2)" "unprognostic (2.41e-2)" "unprognostic (5.25e-2)" "unprognostic (2.23e-3)" "unprognostic (5.18e-4)" "unprognostic (1.15e-1)" "unprognostic (9.55e-2)" "unprognostic (1.56e-1)" "unprognostic (1.21e-3)" "unprognostic (1.01e-2)" "unprognostic (2.32e-11)" "unprognostic (2.84e-2)" "unprognostic (1.53e-1)" "unprognostic (1.88e-2)" "unprognostic (1.87e-1)" 10.0 5.4 5.7 4.8 5.3 0.7 3.0 7.3 7.3 3.9 9.7 0.9 1.5 5.1 5.8 1.4 1.5 4.5 1.5 2.5 3.5 5.0 1.6 0.5 2.2 12.5 1.9 5.0 5.2 2.6 0.4 14.0 2.3 4.1 2.1 1.0 1.1 4.0 2.0 9.1 1.1 8.7 1.8 4.4 4.3 5.0 2.2 1.2 0.5 1.5 0.3 3.6 1.0 2.0 2.3 10.9 0.1 0.3 0.0 31.1 0.7 0.5 0.8 1.1 4.9 0.3 0.8 1.1 2.4 0.5 0.2 0.4 0.7 0.3 0.1 0.3 0.3 0.9 0.0 0.1 0.1 2.3 1.2 0.0 3.1 0.4 0.7 0.0 0.3 0.8 0.0 0.4 0.0 0.1 2.6 8.6 0.0 0.3 0.1 2.3 0.6 1.2 0.6 0.2 6.2 1.1 0.0 0.8 1.1 0.7 0.0 0.2 0.8 0.9 2.4 2.9 0.6 0.9 0.3 17.7 8.0 2.5 1.4 0.7 0.9 0.0 0.3 0.1 0.2 0.0 0.1 2.3 5.2 2.6 0.2 2.1 0.6 0.8 0.0 0.0 0.1 10.9 31.1 0.7 5.7 5.3 7.3 7.3 3.5 5.0 1.9 5.0 4.1 1.2 CCR7 "BLR2, CD197, CDw197, CMKBR7, EBI1" ENSG00000126353 "C-C motif chemokine receptor 7" P32248 17 40553769-40565472 "Cancer-related genes, CD markers, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 11 "blood: 252.3;lymphoid tissue: 110.6" "Cell line enriched" "Detected in some" 79 "HDLM-2: 171.5" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Cell type enhanced" "Detected in many" "naive CD4 T-cell: 252.3" "Lineage enriched" "Detected in many" 4 "T-cells: 252.3" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB003796, HPA031383, HPA074467" Enhanced Approved Mitochondria Mitochondria "CAB003796: AB_562261, HPA031383: , HPA074467: " "prognostic favourable (3.84e-4)" "prognostic favourable (8.03e-6)" "unprognostic (2.26e-3)" "unprognostic (1.32e-3)" "unprognostic (2.35e-3)" "prognostic favourable (7.61e-7)" "unprognostic (2.71e-4)" "unprognostic (2.58e-2)" "unprognostic (4.48e-2)" "unprognostic (4.68e-4)" "unprognostic (1.10e-2)" "unprognostic (3.11e-1)" "unprognostic (1.08e-3)" "unprognostic (3.12e-1)" "prognostic unfavourable (7.72e-4)" "unprognostic (1.02e-1)" "unprognostic (7.95e-2)" 2.8 0.4 0.2 26.0 0.2 5.2 1.7 0.2 0.3 2.2 1.2 0.3 0.8 0.3 1.2 0.5 1.4 2.3 2.0 1.9 0.2 0.2 1.5 1.7 3.4 110.6 0.3 0.2 1.5 0.3 0.0 1.0 1.0 0.4 1.3 2.1 0.7 8.4 0.2 0.2 1.1 16.2 0.2 0.4 20.3 1.8 1.2 0.3 57.1 2.0 1.2 53.8 4.2 1.3 58.8 2.9 2.3 0.3 44.1 252.3 109.3 0.0 0.1 0.0 0.0 0.0 0.0 2.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 171.5 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.3 0.0 0.0 0.5 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.2 0.0 0.9 0.1 1.1 0.2 0.0 0.0 1.1 0.3 0.2 3.1 0.1 3.6 37.2 53.3 15.3 0.2 58.8 252.3 133.9 2.3 44.1 0.2 2.9 30.3 109.3 0.2 0.2 0.2 0.3 0.2 0.2 0.3 0.2 0.4 0.3 CD14 ENSG00000170458 "CD14 molecule" P08571 5 140631728-140633701 "Cancer-related genes, CD markers, Plasma proteins, Predicted secreted proteins" "Immunity, Inflammatory response, Innate immunity" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in all" 4 "blood: 189.4;liver: 165.8" "Cell line enhanced" "Detected in many" "A549: 8.9;CACO-2: 13.6;SiHa: 16.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "classical monocyte: 189.4" "Group enriched" "Detected in many" 5 "granulocytes: 52.3;monocytes: 189.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001887, HPA002127, CAB033631, CAB072865, CAB072866" Enhanced Supported Vesicles "Secreted to blood" 2752500000 15000000000 Vesicles "CAB033631: AB_781932, CAB072865: , CAB072866: , HPA001887: AB_1078442, HPA002127: AB_1078440" "unprognostic (1.92e-1)" "unprognostic (1.68e-1)" "unprognostic (3.42e-3)" "unprognostic (3.89e-2)" "unprognostic (3.29e-2)" "unprognostic (1.54e-1)" "unprognostic (4.71e-3)" "unprognostic (4.88e-2)" "unprognostic (2.16e-1)" "unprognostic (1.06e-1)" "unprognostic (1.83e-1)" "unprognostic (2.43e-1)" "prognostic unfavourable (6.80e-5)" "unprognostic (1.20e-2)" "unprognostic (6.87e-3)" "unprognostic (8.12e-2)" "unprognostic (6.92e-2)" 27.9 44.1 9.0 42.7 25.2 9.8 11.7 3.5 8.9 5.6 10.0 6.0 1.8 5.4 5.6 24.0 4.5 12.0 14.6 18.9 11.7 7.4 12.7 165.8 23.8 34.7 21.6 2.9 14.2 5.3 4.3 10.1 37.3 18.9 8.5 9.2 14.6 28.5 5.8 10.2 3.5 12.1 21.4 18.2 35.5 6.6 6.5 17.3 2.2 7.9 5.8 6.6 15.9 3.8 0.5 23.6 52.3 189.4 0.2 0.4 124.2 0.1 8.9 0.1 0.5 1.2 0.3 0.4 0.8 4.1 1.3 1.6 13.6 2.1 0.4 0.6 4.9 3.8 0.0 1.6 0.2 0.1 0.9 0.3 0.5 1.8 4.8 1.0 0.4 3.9 0.2 0.2 1.3 0.0 0.2 0.2 1.2 0.3 0.0 0.5 0.2 0.3 0.3 0.4 1.1 0.2 0.0 2.4 1.0 16.3 0.4 0.5 0.3 1.7 0.6 0.2 0.3 1.5 1.2 0.7 0.9 0.5 0.4 0.4 0.1 0.4 189.4 1.0 0.3 36.6 0.4 0.5 0.2 0.2 23.6 0.1 0.3 0.2 52.3 0.2 4.8 1.3 0.1 124.2 9.0 25.2 3.5 8.9 11.7 7.4 21.6 2.9 18.9 17.3 CD1D ENSG00000158473 "CD1d molecule" P15813 1 158179947-158184896 "Cancer-related genes, CD markers, Predicted membrane proteins" "Immunity, Innate immunity" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 49.5;lymphoid tissue: 17.8" "Cell line enhanced" "Detected in some" "HBEC3-KT: 9.1;HHSteC: 14.1;MOLT-4: 18.6;THP-1: 11.4" "Low cancer specificity" "Detected in many" "Group enriched" "Detected in many" 6 "classical monocyte: 49.5;intermediate monocyte: 22.4;myeloid DC: 49.5" "Group enriched" "Detected in many" 8 "dendritic cells: 49.5;monocytes: 49.5" "Low region specificity" "Detected in all" "CAB016107, HPA072662" Enhanced Supported "Endoplasmic reticulum" 720000 "Endoplasmic reticulum" "CAB016107: AB_626960, HPA072662: " "unprognostic (8.67e-2)" "unprognostic (6.99e-2)" "unprognostic (2.48e-1)" "unprognostic (1.48e-2)" "unprognostic (1.05e-1)" "unprognostic (1.42e-1)" "unprognostic (3.85e-1)" "unprognostic (9.67e-3)" "unprognostic (2.37e-1)" "unprognostic (3.52e-1)" "unprognostic (2.23e-2)" "unprognostic (4.46e-2)" "prognostic unfavourable (2.12e-5)" "unprognostic (9.31e-3)" "unprognostic (2.35e-1)" "unprognostic (2.32e-2)" "unprognostic (3.38e-1)" 1.5 1.2 0.0 8.6 0.0 2.6 1.2 0.0 0.0 0.8 2.5 9.5 1.5 0.0 0.4 1.4 2.0 1.4 0.0 0.1 1.6 10.5 2.3 5.5 0.2 0.3 0.7 0.0 0.6 0.0 1.4 3.7 0.7 0.3 0.6 0.0 12.2 2.2 0.4 17.8 1.4 1.4 1.8 3.4 1.6 0.5 6.3 49.5 2.5 49.5 0.1 0.1 23.5 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 3.2 0.0 4.8 0.0 9.1 0.0 0.0 0.1 0.2 0.0 0.0 14.1 0.1 0.0 5.3 0.7 0.0 1.1 0.0 0.0 0.0 0.0 0.0 18.6 1.8 0.8 0.0 0.0 0.0 0.0 0.9 0.0 1.8 0.0 0.0 0.0 0.0 0.0 11.4 0.0 0.0 2.9 0.0 0.0 0.5 0.0 0.5 0.0 5.2 0.7 0.0 49.5 0.1 0.0 22.4 0.1 6.3 0.0 0.0 49.5 4.7 0.0 0.0 2.5 0.1 3.6 0.5 0.0 23.5 CD27 "S152, TNFRSF7, Tp55" ENSG00000139193 "CD27 molecule" P26842 12 6444867-6451718 "Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins" Apoptosis Receptor "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 82.3;lymphoid tissue: 60.4" "Group enriched" "Detected in some" 141 "Daudi: 63.7;U-698: 35.3" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Cell type enhanced" "Detected in many" "T-reg: 82.3" "Group enriched" "Detected in many" 7 "B-cells: 41.8;T-cells: 82.3" "Not detected" "Not detected" "Low region specificity" "Detected in many" "CAB002420, HPA038936" Enhanced 28000 "CAB002420: AB_563539, HPA038936: " "unprognostic (2.75e-3)" "prognostic favourable (3.77e-5)" "unprognostic (8.87e-3)" "prognostic favourable (2.90e-4)" "unprognostic (2.35e-1)" "prognostic favourable (6.65e-7)" "unprognostic (3.56e-2)" "unprognostic (9.37e-2)" "prognostic favourable (5.50e-4)" "unprognostic (1.31e-3)" "unprognostic (4.32e-2)" "unprognostic (2.74e-1)" "prognostic unfavourable (1.19e-6)" "unprognostic (2.80e-1)" "unprognostic (3.15e-1)" "unprognostic (1.28e-1)" "unprognostic (7.35e-2)" 1.1 0.6 0.4 40.8 0.5 2.0 1.2 0.4 0.4 1.7 10.0 0.2 0.5 5.3 0.8 0.6 4.9 1.6 3.7 0.9 0.4 0.4 1.7 1.0 2.9 49.5 0.4 0.1 1.0 0.5 0.0 0.6 0.4 0.2 1.3 2.9 1.2 10.7 1.4 0.4 0.6 19.4 0.2 0.6 45.7 3.7 0.5 0.1 33.5 3.1 2.3 60.4 9.1 1.2 41.8 0.3 0.8 0.1 8.3 82.3 22.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 63.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.3 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 35.3 0.0 0.0 0.0 0.8 0.1 0.1 16.7 0.1 28.7 41.8 40.1 37.5 0.1 10.5 55.6 39.1 0.8 8.3 0.1 0.3 82.3 22.1 0.4 0.5 0.4 0.4 0.4 0.4 0.4 0.1 0.2 0.1 CD274 "B7-H, B7-H1, B7H1, PD-L1, PDCD1LG1, PDL1" ENSG00000120217 "CD274 molecule" Q9NZQ7 9 5450503-5470566 "Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins" "Adaptive immunity, Immunity" Receptor "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lung: 23.9;placenta: 56.0" "Cell line enhanced" "Detected in many" "HDLM-2: 33.4;HHSteC: 22.3;U-251 MG: 37.0" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "basophil: 8.4" "Group enriched" "Detected in many" 6 "granulocytes: 8.4;T-cells: 2.4" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" CAB076385 Enhanced "CAB076385: AB_2687655" "prognostic favourable (8.89e-4)" "unprognostic (4.54e-2)" "prognostic favourable (1.64e-5)" "unprognostic (1.27e-2)" "unprognostic (2.96e-2)" "unprognostic (1.08e-1)" "unprognostic (4.61e-2)" "unprognostic (1.44e-1)" "unprognostic (1.68e-2)" "unprognostic (5.67e-4)" "unprognostic (7.39e-3)" "unprognostic (1.69e-2)" "unprognostic (1.24e-2)" "unprognostic (1.35e-1)" "unprognostic (1.49e-2)" "unprognostic (2.67e-1)" "unprognostic (9.02e-2)" 3.4 2.1 1.7 10.8 3.2 1.4 2.2 2.5 3.3 2.0 2.3 2.5 2.8 2.6 1.7 2.4 3.0 1.9 4.3 9.5 1.4 3.7 3.0 3.6 23.9 6.4 2.3 0.7 1.7 2.7 3.8 7.4 56.0 3.2 2.9 2.2 3.3 1.7 1.6 4.3 1.3 2.7 2.3 2.4 12.8 1.9 1.2 1.0 11.6 3.7 2.1 5.8 3.1 1.9 0.9 0.0 8.4 0.1 0.4 2.4 0.7 5.8 0.1 0.0 0.2 0.0 0.0 0.0 11.7 9.9 3.0 4.1 0.0 1.9 0.0 0.2 0.3 0.2 0.0 5.0 9.7 33.4 0.0 3.3 0.1 0.0 22.3 0.0 0.0 0.2 0.0 6.1 9.1 5.7 0.0 1.1 9.0 0.0 0.1 0.0 0.0 0.1 0.0 1.6 0.3 0.6 0.1 0.0 0.1 0.1 0.9 0.7 0.0 0.1 10.7 6.3 2.0 0.1 37.0 0.2 0.1 0.1 2.1 0.1 0.0 8.4 0.1 0.3 1.2 0.1 2.1 0.9 2.4 1.8 0.0 0.2 1.3 0.7 5.7 0.4 0.0 0.0 1.1 0.7 1.7 3.2 2.5 3.3 1.4 3.7 2.3 0.7 3.2 1.0 CD36 "FAT, GP3B, GP4, GPIV, SCARB3" ENSG00000135218 "CD36 molecule" P16671 7 80369575-80679277 "Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters" "Cell adhesion, Transport" Receptor "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adipose tissue: 464.3;breast: 156.1" "Group enriched" "Detected in some" 5 "ASC diff: 80.8;HEL: 38.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Group enriched" "Detected in many" 4 "classical monocyte: 104.4;intermediate monocyte: 30.4;myeloid DC: 56.9" "Group enriched" "Detected in many" 45 "dendritic cells: 56.9;monocytes: 104.4" "Low region specificity" "Detected in many" "HPA002018, CAB025866, HPA071026" Enhanced Enhanced "Golgi apparatus" 92000000 "Golgi apparatus" "CAB025866: , HPA002018: AB_1078464, HPA071026: " "unprognostic (7.16e-2)" "unprognostic (1.80e-2)" "unprognostic (1.06e-3)" "unprognostic (6.52e-2)" "unprognostic (2.05e-1)" "unprognostic (1.28e-1)" "unprognostic (2.63e-1)" "unprognostic (9.35e-2)" "unprognostic (2.64e-2)" "unprognostic (1.97e-1)" "unprognostic (1.23e-3)" "unprognostic (1.18e-1)" "unprognostic (1.84e-3)" "prognostic unfavourable (4.47e-4)" "unprognostic (7.05e-3)" "unprognostic (4.87e-2)" "unprognostic (2.73e-3)" 464.3 3.6 1.2 8.9 1.3 10.9 156.1 0.5 0.5 1.8 31.8 0.6 3.3 9.8 1.8 7.5 7.5 3.3 7.2 76.8 1.8 1.9 2.2 13.3 11.5 4.8 0.6 0.3 2.5 3.9 3.1 0.8 37.9 2.9 9.2 3.5 0.8 4.6 2.3 23.6 5.4 23.4 4.7 0.8 42.8 5.0 6.0 0.5 2.7 13.6 15.3 1.4 9.4 19.2 0.3 56.9 1.8 104.4 0.7 0.2 60.2 0.0 0.0 0.2 0.1 80.8 0.8 0.1 0.2 2.7 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.0 1.0 0.1 0.0 0.1 0.1 38.4 0.1 6.1 0.0 0.0 0.0 7.8 3.1 0.0 0.0 0.2 1.3 0.0 0.4 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.2 0.3 0.2 0.1 0.0 2.7 4.4 0.0 0.1 0.5 0.1 0.0 0.0 0.1 0.1 0.0 13.2 10.2 0.9 104.4 0.3 0.2 30.4 0.2 0.3 0.0 0.0 56.9 0.0 0.1 0.0 1.8 0.7 7.5 14.3 0.1 60.2 1.2 1.3 0.5 0.5 1.8 1.9 0.6 0.3 2.9 0.5 CD38 ENSG00000004468 "CD38 molecule" P28907 4 15778275-15853230 "Cancer-related genes, CD markers, Enzymes, Predicted intracellular proteins" "Hydrolase, Receptor, Transferase" "Cancer-related genes, Diabetes mellitus" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "lymphoid tissue: 94.9;seminal vesicle: 104.1" "Cell line enhanced" "Detected in some" "Daudi: 49.8;Karpas-707: 13.9;MOLT-4: 12.6;REH: 10.0;U-266/70: 10.8;U-698: 9.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "NK-cell: 15.3" "Group enriched" "Detected in all" 4 "B-cells: 9.0;dendritic cells: 5.1;NK-cells: 15.3" "Low region specificity" "Detected in all" "CAB002493, HPA022132, CAB025255, HPA052381" Enhanced Supported "Plasma membrane" "Plasma membrane" "CAB002493: AB_563556, CAB025255: , HPA022132: AB_1846300, HPA052381: AB_2681807" "unprognostic (1.27e-2)" "unprognostic (8.06e-3)" "unprognostic (1.06e-2)" "prognostic favourable (9.68e-4)" "unprognostic (1.13e-1)" "unprognostic (1.82e-3)" "unprognostic (2.74e-1)" "unprognostic (8.51e-2)" "unprognostic (5.87e-2)" "unprognostic (6.15e-6)" "unprognostic (5.23e-1)" "unprognostic (4.34e-1)" "unprognostic (6.63e-6)" "unprognostic (1.79e-1)" "unprognostic (5.74e-2)" "unprognostic (2.12e-2)" "unprognostic (2.13e-1)" 4.1 3.3 3.8 17.6 8.5 9.3 2.6 0.7 12.0 1.0 3.2 10.4 14.6 4.3 0.7 0.9 2.3 2.4 1.5 5.0 4.0 4.2 1.2 5.4 4.7 16.1 4.9 3.1 0.6 0.7 0.0 2.5 0.6 3.1 10.8 2.7 4.4 2.8 104.1 14.2 0.5 6.2 0.9 1.8 20.6 2.0 0.7 2.5 94.9 2.8 2.0 13.2 7.6 0.9 9.0 5.1 1.3 2.2 15.3 2.3 3.7 0.0 4.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 49.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 13.9 0.0 0.0 12.6 3.0 0.0 0.0 10.0 0.0 7.8 0.0 0.0 0.0 0.6 0.0 0.0 0.2 0.0 2.2 0.2 0.0 0.0 0.0 0.0 10.8 0.1 9.4 0.1 2.4 0.1 0.0 1.7 0.0 1.1 2.2 0.3 9.0 1.4 1.2 4.1 6.6 2.3 1.8 1.3 15.3 1.4 5.1 2.1 3.7 3.8 8.5 0.7 6.2 4.0 4.2 4.9 3.1 3.1 2.5 CD40 "Bp50, p50, TNFRSF5" ENSG00000101017 "CD40 molecule" P25942 20 46118272-46129863 "Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins" Immunity Receptor "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "CAPAN-2: 26.7;EFO-21: 46.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "memory B-cell: 36.1;naive B-cell: 41.3" "Group enriched" "Detected in many" 6 "B-cells: 41.3;monocytes: 10.8" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB002495, HPA031567, HPA031568, CAB072868" Enhanced "Secreted to blood" 16000 "CAB002495: AB_563562, CAB072868: , HPA031567: AB_2673936, HPA031568: AB_2673937" "unprognostic (6.41e-2)" "unprognostic (1.55e-2)" "unprognostic (7.08e-3)" "unprognostic (6.21e-2)" "unprognostic (4.23e-3)" "unprognostic (1.25e-1)" "unprognostic (7.64e-3)" "unprognostic (1.34e-1)" "unprognostic (4.15e-2)" "unprognostic (7.16e-2)" "unprognostic (2.48e-2)" "unprognostic (7.04e-2)" "prognostic unfavourable (4.48e-4)" "unprognostic (1.22e-1)" "unprognostic (4.95e-2)" "unprognostic (1.60e-2)" "unprognostic (2.28e-2)" 13.0 4.6 3.6 38.6 4.7 1.1 11.6 9.7 4.4 11.3 9.2 3.6 7.8 6.5 9.6 8.6 9.9 9.7 8.6 9.5 4.5 2.6 10.0 10.0 18.8 34.7 3.3 3.2 14.8 14.0 12.1 5.9 6.5 5.4 14.7 5.2 13.7 13.0 11.6 7.5 9.0 11.8 10.0 4.6 30.1 8.4 4.4 4.4 11.5 16.5 6.7 46.0 12.5 13.8 41.3 4.1 1.0 10.8 0.6 1.4 4.8 9.0 1.4 0.0 4.5 1.7 0.9 1.8 1.6 0.5 1.3 1.3 0.0 26.7 14.5 46.9 0.3 1.1 0.8 5.7 1.4 9.7 0.0 3.4 0.0 2.5 13.4 0.0 4.6 6.0 2.2 5.5 0.0 10.1 1.1 0.0 0.2 0.0 0.0 0.0 0.6 0.0 0.3 0.3 1.5 11.8 0.1 0.0 0.0 7.9 4.5 0.0 0.9 4.8 0.0 0.0 15.0 0.0 0.0 0.0 0.0 9.9 3.4 1.7 0.0 1.0 7.7 0.1 1.3 10.8 0.9 36.1 0.7 0.5 4.1 41.3 1.4 1.0 0.7 0.6 7.5 2.1 1.0 4.8 3.6 4.7 9.7 4.4 4.5 2.6 3.3 3.2 5.4 4.4 CD40LG "CD154, CD40L, gp39, hCD40L, HIGM1, IMD3, TNFSF5, TRAP" ENSG00000102245 "CD40 ligand" P29965 X 136648193-136660390 "Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins" Cytokine "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "blood: 29.2;intestine: 8.7;lymphoid tissue: 33.7" "Cell line enriched" "Detected in single" 72 "MOLT-4: 22.4" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in many" 5 "gdT-cell: 9.4;MAIT T-cell: 22.9;memory CD4 T-cell: 29.2;naive CD4 T-cell: 28.1" "Lineage enriched" "Detected in single" 58 "T-cells: 29.2" "Not detected" "Not detected" "Low region specificity" "Detected in many" HPA045827 Enhanced "Secreted to blood" 433000 "HPA045827: AB_10959606" "unprognostic (1.94e-5)" "unprognostic (1.24e-2)" "unprognostic (3.26e-1)" "unprognostic (1.27e-3)" "unprognostic (4.71e-2)" "unprognostic (3.56e-5)" "unprognostic (3.66e-2)" "unprognostic (5.48e-3)" "unprognostic (2.77e-1)" "unprognostic (2.14e-4)" "unprognostic (1.87e-1)" "unprognostic (1.55e-1)" "unprognostic (6.70e-4)" "unprognostic (2.15e-1)" "unprognostic (5.19e-2)" "unprognostic (2.36e-3)" "unprognostic (2.92e-2)" 2.0 0.5 0.3 22.4 0.3 1.4 1.2 0.3 0.3 2.0 3.3 0.1 0.0 1.7 1.5 1.3 1.6 1.6 2.6 1.1 0.4 0.4 1.6 1.1 4.0 14.6 0.4 0.0 0.7 0.6 0.0 0.4 0.2 0.3 1.0 3.1 1.0 4.9 1.3 0.4 1.1 8.7 0.5 0.6 9.9 1.7 0.6 0.1 33.7 1.4 2.0 26.1 3.0 1.4 0.0 0.0 0.5 0.0 0.2 29.2 4.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 22.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.1 9.4 0.0 22.9 0.0 29.2 4.1 0.0 0.0 28.1 0.2 0.5 0.2 0.0 0.0 3.3 4.7 0.3 0.3 0.3 0.3 0.4 0.4 0.4 0.0 0.3 0.1 CD44 "CD44R, CSPG8, HCELL, IN, MC56, MDU2, MDU3, MIC4, Pgp1" ENSG00000026508 "CD44 molecule (Indian blood group)" P16070 11 35138870-35232402 "Blood group antigen proteins, Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" "Cell adhesion" "Blood group antigen, Receptor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB000112, CAB000316, HPA005785" Enhanced Enhanced "Golgi apparatus,Plasma membrane" "Secreted - unknown location" 2400000000 "Plasma membrane" "Golgi apparatus" "CAB000112: , CAB000316: AB_2076596, HPA005785: AB_1078467" "unprognostic (5.33e-2)" "unprognostic (1.85e-1)" "unprognostic (4.97e-2)" "unprognostic (9.90e-3)" "unprognostic (3.50e-3)" "unprognostic (1.46e-2)" "unprognostic (1.56e-2)" "unprognostic (8.12e-2)" "unprognostic (1.57e-1)" "unprognostic (4.18e-2)" "unprognostic (1.51e-3)" "unprognostic (4.63e-2)" "prognostic unfavourable (1.78e-8)" "unprognostic (6.41e-2)" "unprognostic (4.14e-2)" "unprognostic (3.93e-2)" "unprognostic (7.98e-2)" 45.5 9.0 10.5 42.5 21.7 53.0 35.6 4.7 13.4 43.2 19.5 26.3 8.3 10.6 80.5 20.3 66.5 18.6 48.0 11.7 14.9 9.3 12.4 9.1 43.4 48.4 31.5 6.1 12.8 83.9 0.8 3.8 19.4 40.7 30.1 24.5 30.2 148.2 22.4 15.9 107.7 18.9 44.5 100.5 30.9 19.9 7.2 20.3 17.9 20.6 53.9 53.7 55.0 54.2 22.7 41.0 19.1 65.2 54.6 53.1 59.9 41.5 37.6 0.3 0.1 22.7 62.8 0.1 81.5 63.8 45.4 25.3 2.5 13.1 0.0 10.9 115.5 71.7 0.8 88.6 62.4 8.9 0.4 1.5 18.5 0.0 22.4 21.1 97.8 28.3 70.0 61.1 49.6 15.9 0.3 13.6 43.5 0.2 1.9 13.9 0.8 11.1 0.1 7.7 0.6 66.5 12.0 0.1 0.1 15.4 0.4 36.9 2.2 1.2 45.6 56.6 10.2 69.4 83.7 23.6 25.4 0.2 85.9 11.9 82.2 19.1 65.2 6.0 26.2 45.7 37.0 22.7 39.8 34.9 41.0 16.2 34.5 28.7 16.4 54.6 59.3 14.2 53.1 59.9 10.5 21.7 4.7 13.4 14.9 9.3 31.5 6.1 40.7 20.3 CD46 "MCP, MGC26544, MIC10, TLX, TRA2.10" ENSG00000117335 "CD46 molecule" P15529 1 207752057-207795513 "Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins" "Complement pathway, Fertilization, Host-virus interaction, Immunity, Innate immunity" "Host cell receptor for virus entry, Receptor" "Cancer-related genes, Disease mutation, Hemolytic uremic syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in all" 4 "basophil: 41.7;eosinophil: 63.7;neutrophil: 69.8" "Lineage enriched" "Detected in all" 5 "granulocytes: 69.8" "CAB010401, HPA016903" Enhanced Uncertain "Plasma membrane" 1000000 "Plasma membrane" "CAB010401: AB_2291289, HPA016903: AB_1846309" "unprognostic (1.42e-2)" "prognostic unfavourable (8.54e-5)" "unprognostic (3.94e-2)" "unprognostic (2.14e-2)" "unprognostic (3.28e-2)" "unprognostic (6.30e-2)" "unprognostic (1.91e-2)" "unprognostic (1.82e-1)" "unprognostic (1.25e-1)" "unprognostic (2.74e-1)" "unprognostic (8.79e-2)" "unprognostic (2.50e-1)" "unprognostic (6.78e-3)" "prognostic favourable (2.38e-4)" "unprognostic (1.76e-1)" "unprognostic (8.23e-2)" "unprognostic (1.49e-2)" 38.0 78.0 13.0 22.9 20.5 18.5 57.0 12.9 17.8 27.5 35.4 25.3 64.3 32.9 39.7 32.6 43.2 30.4 25.2 20.6 16.1 15.5 50.8 57.8 43.6 25.0 21.4 13.2 27.6 47.9 86.6 32.7 119.6 29.1 47.0 28.5 26.7 68.4 60.5 18.8 18.4 39.8 25.0 21.8 26.9 33.9 16.5 20.7 20.3 25.3 21.8 30.3 37.2 27.0 7.7 8.1 69.8 14.1 7.5 13.5 14.9 26.2 14.8 13.9 6.4 44.0 43.5 21.2 19.7 28.7 13.0 17.7 14.6 69.9 4.0 20.1 19.6 35.6 10.4 27.0 19.9 20.2 14.8 8.7 16.3 26.1 28.0 19.0 30.4 37.4 40.3 19.6 15.5 36.4 18.3 17.5 20.0 12.3 9.0 16.7 15.9 14.8 6.1 22.1 24.7 53.3 52.0 14.1 9.6 24.9 56.1 32.3 44.1 16.3 31.2 14.0 12.5 29.4 22.4 23.6 28.5 12.1 20.5 12.5 13.1 41.7 13.5 63.7 9.2 14.0 12.5 7.7 11.7 10.1 8.1 6.0 13.5 11.2 69.8 7.5 14.1 4.2 10.1 14.9 13.0 20.5 12.9 17.8 16.1 15.5 21.4 13.2 29.1 20.7 CD59 "16.3A5, EJ16, EJ30, EL32, G344, MIC11, MIN1, MIN2, MIN3, MSK21, p18-20" ENSG00000085063 "CD59 molecule (CD59 blood group)" P13987 11 33703010-33736491 "Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cancer-related genes, Disease mutation, Hereditary hemolytic anemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "placenta: 285.5" "Cell line enhanced" "Detected in many" "TIME: 213.3;U-2197: 176.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "CAB001448, HPA026494" Supported Uncertain "Golgi apparatus,Vesicles" "Intracellular and membrane" 98000000 "Golgi apparatus, Vesicles" "CAB001448: AB_563604, HPA026494: AB_1846321" "unprognostic (2.07e-2)" "prognostic unfavourable (3.81e-5)" "unprognostic (7.40e-2)" "unprognostic (1.14e-2)" "unprognostic (2.11e-2)" "prognostic unfavourable (3.10e-5)" "unprognostic (5.65e-2)" "unprognostic (1.46e-1)" "unprognostic (4.47e-2)" "unprognostic (2.98e-1)" "prognostic unfavourable (2.92e-5)" "unprognostic (1.66e-2)" "prognostic favourable (1.39e-10)" "prognostic unfavourable (9.03e-4)" "unprognostic (1.31e-1)" "unprognostic (1.03e-2)" "unprognostic (3.09e-1)" 96.7 41.0 36.7 26.3 44.3 23.8 76.0 25.9 32.7 44.8 36.9 24.0 57.9 16.5 45.4 132.8 68.4 53.2 67.6 90.5 35.6 38.4 100.0 61.0 86.4 39.8 39.7 25.8 39.3 52.3 60.6 48.0 285.5 68.7 47.4 37.7 51.4 114.8 62.6 70.6 43.4 25.0 52.4 32.9 26.2 54.7 28.1 23.1 16.1 85.9 57.7 40.0 51.2 63.4 13.5 20.5 42.8 4.8 17.7 60.4 11.1 16.5 15.5 4.6 13.5 107.8 84.5 2.7 94.2 105.1 23.6 27.7 7.2 49.8 1.2 16.8 101.4 18.7 8.5 93.9 33.2 26.3 12.9 1.7 54.9 10.8 29.4 9.9 5.7 39.2 23.8 20.0 96.4 144.0 11.6 38.3 148.6 15.1 4.6 4.1 2.5 80.9 1.7 14.4 13.3 71.3 28.3 3.2 4.3 32.8 15.2 17.3 11.6 1.0 213.3 54.3 13.0 176.7 32.6 17.0 33.2 1.6 46.7 0.0 94.3 30.5 4.8 42.8 11.3 1.6 14.4 13.5 24.0 12.7 20.5 10.6 15.7 9.3 28.4 17.7 0.9 10.5 60.4 11.1 36.7 44.3 25.9 32.7 35.6 38.4 39.7 25.8 68.7 23.1 CD70 "CD27L, CD27LG, TNFSF7" ENSG00000125726 "CD70 molecule" P32970 19 6583183-6604103 "Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins" Cytokine "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 23.3;lymphoid tissue: 12.7" "Cell line enhanced" "Detected in many" "SiHa: 36.0;THP-1: 29.6;U-251 MG: 43.8;U-266/70: 78.0;U-266/84: 56.4" "Cancer enhanced" "Detected in many" "renal cancer: 24.7" "Not detected" "Not detected" "Cell type enhanced" "Detected in many" "memory B-cell: 13.9;T-reg: 23.3" "Group enriched" "Detected in many" 38 "B-cells: 13.9;T-cells: 23.3" HPA046582 Uncertain Nucleoplasm Nucleoplasm "HPA046582: " "unprognostic (8.71e-2)" "unprognostic (9.91e-2)" "unprognostic (1.61e-1)" "unprognostic (2.33e-4)" "unprognostic (1.73e-2)" "unprognostic (1.51e-2)" "unprognostic (1.61e-1)" "prognostic unfavourable (6.29e-4)" "unprognostic (1.36e-2)" "unprognostic (1.25e-1)" "unprognostic (1.92e-1)" "unprognostic (1.72e-1)" "prognostic unfavourable (3.22e-4)" "unprognostic (2.57e-2)" "unprognostic (1.40e-1)" "unprognostic (2.27e-1)" "unprognostic (2.08e-1)" 5.3 0.2 0.2 9.3 0.2 1.4 2.2 0.9 0.9 1.4 4.1 0.2 0.1 1.0 0.4 1.8 4.0 0.7 0.8 0.4 0.2 0.2 1.7 0.4 1.9 6.1 0.4 0.1 0.3 0.4 0.0 0.3 0.3 0.2 0.9 3.1 0.2 3.1 1.2 1.2 3.3 5.2 0.7 0.5 11.8 1.7 1.9 0.1 3.2 0.8 1.8 12.7 3.1 1.1 13.9 0.1 0.2 0.0 0.4 23.3 0.9 0.2 7.4 0.0 14.5 0.3 0.2 0.0 0.0 0.0 0.0 0.5 0.0 0.1 13.9 0.8 0.0 10.1 8.9 0.7 0.0 0.0 0.3 0.0 11.0 0.0 0.0 0.0 0.4 0.1 0.0 8.5 6.1 0.0 0.2 0.4 0.2 0.0 0.2 17.5 0.1 13.4 3.7 0.0 3.0 4.7 0.0 0.0 0.0 36.0 0.0 0.1 0.1 29.6 0.2 0.1 6.5 0.0 43.8 78.0 56.4 25.1 8.0 4.4 2.8 0.2 0.0 0.0 1.9 0.0 4.8 13.9 3.2 5.0 0.0 4.0 0.4 1.3 0.1 0.4 0.0 0.1 23.3 0.9 0.2 0.2 0.9 0.9 0.2 0.2 0.4 0.1 0.2 0.1 CD74 DHLAG ENSG00000019582 "CD74 molecule" P04233 5 150401637-150412929 "Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins" "Adaptive immunity, Immunity" Chaperone "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 504.7" "Cell line enhanced" "Detected in many" "CAPAN-2: 115.7;Daudi: 178.0;HDLM-2: 255.6;REH: 154.1;RPMI-8226: 104.9;U-266/70: 85.9;U-698: 98.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in all" 4 "classical monocyte: 191.6;intermediate monocyte: 303.5;memory B-cell: 467.7;myeloid DC: 437.9;naive B-cell: 504.7;non-classical monocyte: 140.0;plasmacytoid DC: 303.2" "Group enriched" "Detected in all" 5 "B-cells: 504.7;dendritic cells: 437.9;monocytes: 303.5" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB002506, HPA010592" Enhanced Supported "Golgi apparatus" 90000 "Golgi apparatus" "CAB002506: AB_563630, HPA010592: AB_1078482" "prognostic favourable (1.06e-4)" "unprognostic (1.48e-2)" "unprognostic (4.80e-3)" "prognostic favourable (6.53e-6)" "unprognostic (1.41e-1)" "unprognostic (4.53e-2)" "unprognostic (2.05e-1)" "unprognostic (3.69e-3)" "unprognostic (1.54e-2)" "unprognostic (3.48e-2)" "unprognostic (2.20e-2)" "unprognostic (2.64e-1)" "unprognostic (5.44e-3)" "unprognostic (1.73e-1)" "unprognostic (4.95e-2)" "unprognostic (2.05e-1)" "unprognostic (4.24e-2)" 137.8 95.7 53.2 177.0 81.4 40.7 104.2 8.4 43.5 89.6 68.2 79.0 30.0 98.3 60.0 73.9 43.6 68.1 81.3 104.1 46.9 43.5 168.3 60.1 222.5 310.1 78.3 23.1 53.4 34.1 15.1 51.0 27.9 79.8 72.6 63.6 72.9 123.0 55.4 40.5 56.6 182.8 55.1 123.1 372.1 77.3 23.7 68.1 201.1 83.4 45.6 288.2 91.7 47.0 504.7 437.9 76.1 303.5 42.2 41.2 238.1 1.9 0.0 0.0 0.1 0.1 0.1 0.6 0.0 0.0 0.0 0.0 23.1 115.7 178.0 7.2 0.0 0.5 0.0 0.0 0.0 255.6 0.0 5.8 0.1 14.1 0.3 0.4 0.3 1.4 0.0 0.0 0.0 0.0 0.4 70.9 0.0 0.0 0.2 0.8 0.3 0.0 154.1 0.2 104.9 0.5 7.5 0.2 0.5 0.3 0.2 5.1 4.7 21.3 0.2 0.6 0.5 0.5 0.2 85.9 9.2 98.6 41.3 8.0 37.7 6.3 191.6 76.1 16.8 303.5 18.7 467.7 14.8 24.8 437.9 504.7 7.8 13.5 16.8 42.2 140.0 303.2 41.2 238.1 53.2 81.4 8.4 43.5 46.9 43.5 78.3 23.1 79.8 68.1 CD79A "IGA, MB-1" ENSG00000105369 "CD79a molecule" P11912 19 41877120-41881372 "Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Immunity" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 7 "blood: 125.3;intestine: 43.5;lymphoid tissue: 119.2" "Group enriched" "Detected in some" 24 "Daudi: 155.5;REH: 48.3;U-698: 135.4" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in some" 38 "memory B-cell: 106.4;naive B-cell: 125.3" "Lineage enriched" "Detected in many" 41 "B-cells: 125.3" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" CAB000019 Enhanced "CAB000019: AB_2244527" "prognostic favourable (8.45e-5)" "unprognostic (1.63e-3)" "unprognostic (4.13e-3)" "unprognostic (1.31e-3)" "unprognostic (2.02e-1)" "prognostic favourable (1.18e-5)" "unprognostic (1.23e-2)" "unprognostic (8.11e-3)" "unprognostic (9.41e-3)" "unprognostic (1.12e-2)" "unprognostic (2.53e-1)" "unprognostic (2.32e-1)" "prognostic unfavourable (2.15e-5)" "unprognostic (6.08e-2)" "unprognostic (3.39e-1)" "unprognostic (1.17e-1)" "unprognostic (1.46e-1)" 1.3 0.6 0.5 103.8 0.5 5.4 1.3 0.5 0.5 1.8 6.3 0.1 0.1 4.9 0.6 0.2 4.4 1.0 2.3 0.8 0.5 0.5 2.3 0.9 4.3 114.9 0.5 0.1 0.6 0.6 0.0 0.5 0.5 0.1 1.0 3.4 1.8 13.6 1.2 0.5 0.5 43.5 0.2 0.5 108.1 9.7 0.8 0.1 32.0 2.4 1.9 119.2 6.8 1.0 125.3 3.0 0.7 0.3 0.2 2.3 4.5 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 155.5 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.1 0.9 0.0 0.0 48.3 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.4 0.1 0.0 0.4 0.0 0.0 0.7 0.1 135.4 0.0 4.6 0.0 0.7 0.1 0.5 0.1 0.1 0.0 106.4 0.3 0.1 0.2 125.3 0.4 2.3 0.4 0.2 0.3 3.0 0.8 4.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.1 0.1 0.1 CD79B "B29, IGB" ENSG00000007312 "CD79b molecule" P40259 17 63928740-63932354 "Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins" "Adaptive immunity, Immunity" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "blood: 138.8;lymphoid tissue: 56.6" "Cell line enhanced" "Detected in some" "Daudi: 114.9;REH: 37.8;U-698: 157.4" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Group enriched" "Detected in many" 5 "memory B-cell: 100.6;naive B-cell: 138.8" "Lineage enriched" "Detected in many" 6 "B-cells: 138.8" "Not detected" "Not detected" "Not detected" "Not detected" "HPA009178, CAB009751" Enhanced "CAB009751: AB_2275844, HPA009178: AB_1078483" "unprognostic (3.90e-3)" "unprognostic (1.61e-3)" "unprognostic (5.21e-2)" "unprognostic (3.45e-3)" "unprognostic (4.22e-3)" "prognostic favourable (2.35e-4)" "unprognostic (1.82e-1)" "unprognostic (9.25e-3)" "unprognostic (3.89e-2)" "unprognostic (1.48e-1)" "unprognostic (1.04e-1)" "unprognostic (2.87e-2)" "unprognostic (2.50e-3)" "unprognostic (1.89e-1)" "unprognostic (1.44e-1)" "unprognostic (4.28e-2)" "unprognostic (2.75e-1)" 1.7 0.7 0.4 50.6 0.4 11.1 1.2 0.3 0.4 0.6 1.7 0.3 0.3 0.7 0.6 0.5 2.6 0.6 1.4 3.4 0.4 0.2 2.3 1.7 1.3 56.6 0.4 0.3 0.6 1.6 0.0 9.0 0.5 0.3 1.0 1.3 0.8 8.9 0.9 1.2 0.9 22.4 0.5 0.4 56.0 1.8 0.6 0.3 3.7 1.4 1.7 46.6 4.5 0.9 138.8 4.2 0.5 25.0 3.4 9.2 9.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 114.9 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 6.3 0.0 0.0 0.0 2.4 0.0 0.0 37.8 0.1 0.5 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 1.7 0.1 0.0 0.4 0.0 0.0 5.8 5.6 157.4 0.0 0.2 0.0 0.5 1.1 0.0 4.2 16.5 4.8 100.6 5.4 2.8 4.2 138.8 3.7 2.2 0.5 3.4 25.0 0.6 9.2 9.0 0.4 0.4 0.3 0.4 0.4 0.2 0.4 0.3 0.3 0.3 CD82 "IA4, KAI1, R2, ST6, TSPAN27" ENSG00000085117 "CD82 molecule" P27701 11 44564427-44620363 "Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HMC-1: 77.3;LHCN-M2: 45.7;U-87 MG: 54.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "neutrophil: 80.5" "Group enriched" "Detected in all" 6 "B-cells: 51.1;granulocytes: 80.5;T-cells: 25.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002508, HPA028900, HPA061418" Supported Approved Vesicles Vesicles "CAB002508: AB_563640, HPA028900: AB_10603558, HPA061418: " "unprognostic (5.31e-2)" "unprognostic (4.62e-1)" "unprognostic (2.38e-2)" "unprognostic (1.33e-1)" "unprognostic (2.79e-1)" "unprognostic (1.37e-2)" "unprognostic (1.78e-1)" "unprognostic (7.29e-2)" "unprognostic (3.48e-1)" "unprognostic (2.97e-1)" "unprognostic (2.58e-2)" "unprognostic (1.58e-1)" "unprognostic (3.48e-3)" "unprognostic (1.86e-3)" "unprognostic (2.33e-2)" "unprognostic (2.88e-2)" "unprognostic (6.30e-2)" 14.7 4.9 16.3 21.6 23.1 43.6 13.8 6.3 13.6 17.5 20.7 23.0 53.0 25.9 4.8 13.5 58.3 19.8 21.7 12.7 16.9 13.3 10.2 18.8 38.8 22.8 17.9 9.2 9.0 11.6 2.8 3.9 20.7 14.0 14.3 6.8 18.6 29.8 55.2 10.5 34.6 36.0 8.9 10.2 21.9 22.5 4.5 12.6 23.9 8.3 23.5 33.5 16.3 28.1 51.1 6.7 80.5 9.1 7.2 25.6 9.5 5.0 0.7 6.6 1.3 4.5 17.2 0.2 2.9 23.6 5.1 13.0 0.3 3.4 5.2 3.5 1.4 19.2 0.9 15.0 11.8 23.2 0.4 32.5 1.5 0.1 3.3 8.9 77.3 23.7 17.6 21.4 11.4 9.0 0.2 1.6 45.7 3.6 8.6 16.7 0.2 0.3 0.2 27.6 7.3 3.0 4.9 0.2 0.3 1.8 27.6 3.8 26.3 8.8 5.0 16.2 2.1 0.3 27.5 0.6 0.0 0.1 54.7 4.9 8.6 48.4 9.1 16.0 4.9 4.8 8.5 51.1 24.9 11.6 2.2 30.9 8.6 3.8 80.5 7.2 3.4 6.7 25.6 9.5 16.3 23.1 6.3 13.6 16.9 13.3 17.9 9.2 14.0 12.6 CD9 "BA2, MIC3, MRP-1, P24, TSPAN29" ENSG00000010278 "CD9 molecule" P21926 12 6199715-6238271 "Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins, Transporters" "Cell adhesion, Fertilization" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "CAPAN-2: 127.8;HUVEC TERT2: 82.6;RT4: 94.7;TIME: 188.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 21 "basophil: 137.8;eosinophil: 98.3" "Lineage enriched" "Detected in many" 24 "granulocytes: 137.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB002490 Supported Supported "Plasma membrane" 68000000 "Plasma membrane" "CAB002490: AB_563643" "unprognostic (1.38e-1)" "unprognostic (6.36e-3)" "unprognostic (8.27e-3)" "unprognostic (6.98e-3)" "unprognostic (3.89e-1)" "unprognostic (2.81e-1)" "unprognostic (1.32e-1)" "unprognostic (2.08e-2)" "unprognostic (2.90e-1)" "unprognostic (2.60e-2)" "prognostic unfavourable (1.59e-4)" "unprognostic (2.30e-1)" "prognostic favourable (6.49e-5)" "unprognostic (6.10e-2)" "unprognostic (1.77e-1)" "prognostic favourable (8.93e-5)" "unprognostic (9.26e-2)" 38.1 44.5 20.0 24.1 36.2 3.1 48.2 6.8 29.6 55.0 68.3 63.1 151.6 19.5 36.2 43.4 139.8 38.4 23.2 39.2 30.3 15.6 39.9 12.2 61.1 8.2 43.3 23.3 14.1 23.3 89.5 15.2 13.0 28.7 77.9 73.5 25.5 91.6 180.4 11.3 60.1 29.6 62.2 48.9 12.2 27.7 10.4 47.7 6.0 63.6 112.3 85.8 54.5 76.0 1.9 0.9 137.8 5.6 0.2 1.1 5.6 33.9 14.9 0.3 9.2 14.7 15.1 12.9 20.1 40.2 6.9 10.6 10.9 127.8 0.1 5.0 4.3 74.5 7.8 40.2 5.3 1.7 5.5 0.1 11.3 2.3 6.3 0.1 42.8 0.0 29.9 12.6 10.9 82.6 1.5 0.1 4.3 48.6 0.1 3.7 11.6 15.0 0.3 24.6 43.2 67.6 94.7 0.0 2.9 20.0 16.6 17.2 7.7 3.5 188.9 0.7 18.9 0.7 2.4 0.1 0.1 5.1 11.8 0.0 18.6 137.8 5.6 98.3 0.1 1.8 0.2 0.5 0.1 0.1 0.9 1.9 0.4 1.1 2.6 0.2 0.0 0.3 0.0 5.6 20.0 36.2 6.8 29.6 30.3 15.6 43.3 23.3 28.7 47.7 CDC16 "ANAPC6, APC6, CUT9" ENSG00000130177 "Cell division cycle 16" Q13042 13 114234887-114272723 "Cancer-related genes, Predicted intracellular proteins" "Cell cycle, Cell division, Mitosis, Ubl conjugation pathway" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA042826 Approved "HPA042826: AB_10793987" "unprognostic (7.32e-2)" "unprognostic (1.43e-2)" "unprognostic (2.05e-1)" "unprognostic (1.18e-3)" "unprognostic (1.50e-1)" "unprognostic (7.19e-3)" "unprognostic (6.82e-3)" "unprognostic (9.86e-2)" "unprognostic (7.64e-2)" "unprognostic (4.07e-1)" "unprognostic (1.27e-2)" "unprognostic (1.08e-2)" "unprognostic (1.99e-3)" "unprognostic (2.48e-1)" "unprognostic (1.42e-1)" "unprognostic (1.11e-3)" "unprognostic (1.51e-2)" 27.0 28.2 29.2 24.7 38.0 19.1 33.8 27.2 31.7 30.2 30.7 37.1 29.7 22.5 34.1 44.9 24.6 39.6 27.9 27.4 27.4 26.2 29.4 41.6 25.3 28.5 37.9 28.2 33.8 47.4 22.1 30.6 29.4 32.4 28.4 33.0 27.5 23.8 36.1 30.0 35.0 29.5 33.7 33.0 33.0 27.1 34.5 30.0 27.9 30.1 22.8 31.8 25.2 26.5 9.2 7.5 4.1 3.8 13.3 5.6 2.6 29.1 14.2 22.2 22.6 28.5 36.3 12.8 26.8 21.9 27.4 26.8 13.7 20.9 23.5 10.2 35.9 14.4 19.3 25.2 36.5 14.1 22.7 19.9 18.9 13.1 29.9 35.5 26.9 25.9 27.2 19.0 24.2 26.1 16.1 9.1 37.7 11.5 15.4 16.4 25.1 13.3 8.0 11.3 17.0 32.8 17.9 23.2 20.6 14.4 26.4 42.3 18.6 42.5 21.4 12.3 21.7 10.0 16.1 13.5 10.8 25.0 29.0 21.2 16.6 2.7 3.8 4.1 4.4 3.6 4.1 9.2 2.9 5.6 5.4 7.2 3.2 3.5 0.9 13.3 3.1 7.5 5.3 2.6 29.2 38.0 27.2 31.7 27.4 26.2 37.9 28.2 32.4 30.0 CDC20 "CDC20A, p55CDC" ENSG00000117399 "Cell division cycle 20" Q12834 1 43358955-43363203 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division, Differentiation, Mitosis, Neurogenesis, Ubl conjugation pathway" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 42.0;testis: 73.2" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Group enriched" "Detected in some" 7 "memory B-cell: 4.5;memory CD4 T-cell: 3.3;memory CD8 T-cell: 3.6;NK-cell: 9.8;T-reg: 11.2" "Group enriched" "Detected in many" 9 "B-cells: 4.5;NK-cells: 9.8;T-cells: 11.2" "Low region specificity" "Detected in some" "Low region specificity" "Detected in many" "CAB004525, HPA045842, HPA055288" Enhanced Enhanced Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "CAB004525: AB_628089, HPA045842: , HPA055288: " "unprognostic (1.66e-2)" "unprognostic (1.09e-1)" "unprognostic (1.73e-2)" "unprognostic (2.14e-3)" "unprognostic (1.58e-1)" "unprognostic (1.09e-1)" "prognostic unfavourable (4.00e-8)" "unprognostic (9.06e-3)" "unprognostic (1.17e-2)" "unprognostic (1.23e-2)" "prognostic unfavourable (1.32e-4)" "unprognostic (8.55e-2)" "prognostic unfavourable (0.00e+0)" "unprognostic (2.84e-2)" "unprognostic (2.28e-1)" "unprognostic (2.01e-1)" "unprognostic (1.29e-2)" 1.3 1.2 0.6 16.6 1.1 20.2 1.8 0.8 1.3 2.1 6.2 2.8 0.4 5.8 1.1 1.6 17.8 0.4 1.9 1.2 0.9 0.5 2.2 1.2 1.8 13.4 1.1 0.7 0.9 0.5 0.0 0.4 3.9 1.2 0.8 7.0 0.4 2.9 0.4 0.6 4.6 6.4 2.8 1.2 7.8 4.4 73.2 0.7 42.0 1.2 11.7 21.7 1.9 4.2 4.5 0.9 0.8 0.1 9.8 11.2 2.7 51.7 25.3 35.3 23.0 1.2 3.1 33.9 24.0 21.6 70.1 37.4 39.6 43.2 30.0 14.1 22.0 36.5 38.6 45.8 58.5 23.5 28.5 43.9 25.0 24.5 0.3 30.6 16.0 1.0 2.1 48.6 44.1 29.7 19.8 20.6 31.7 20.0 29.4 18.8 44.7 34.1 42.8 48.5 19.0 17.1 13.8 20.9 10.3 42.5 28.7 13.3 20.1 38.8 15.4 21.0 49.2 23.3 74.5 15.9 14.0 31.1 15.0 38.2 31.2 0.0 0.1 0.0 0.4 0.0 0.0 4.5 3.3 3.6 0.9 0.9 0.1 0.3 0.8 9.8 0.0 0.2 11.2 2.7 0.6 1.1 0.8 1.3 0.9 0.5 1.1 0.7 1.2 0.7 CDC25A ENSG00000164045 "Cell division cycle 25A" P30304 3 48157146-48188402 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division, Mitosis" "Hydrolase, Protein phosphatase" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 13.0;lymphoid tissue: 23.0;testis: 19.4" "Low cell line specificity" "Detected in many" "Cancer enhanced" "Detected in many" "testis cancer: 19.0" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in some" "memory B-cell: 1.7" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA005855 Approved "Nucleoplasm,Golgi apparatus,Vesicles" "Golgi apparatus" "Nucleoplasm, Vesicles" "HPA005855: AB_1846364" "unprognostic (1.49e-1)" "unprognostic (8.13e-2)" "unprognostic (1.20e-2)" "unprognostic (1.43e-3)" "unprognostic (2.14e-1)" "unprognostic (9.51e-2)" "unprognostic (7.05e-7)" "unprognostic (1.35e-2)" "unprognostic (4.32e-3)" "unprognostic (8.92e-3)" "unprognostic (4.41e-2)" "unprognostic (9.09e-2)" "unprognostic (4.41e-3)" "unprognostic (1.57e-3)" "unprognostic (1.07e-1)" "unprognostic (1.29e-1)" "unprognostic (2.72e-1)" 0.8 1.2 1.1 5.5 1.1 13.0 0.8 0.7 1.2 1.1 3.3 0.6 1.0 1.8 0.6 0.9 3.9 0.4 2.2 0.7 1.3 2.4 1.2 0.9 0.7 4.1 1.4 0.2 2.1 3.6 0.4 2.3 4.2 1.2 1.0 4.0 1.5 1.8 0.5 0.7 0.8 2.1 0.8 0.7 3.6 1.3 19.4 0.2 23.0 1.6 8.8 7.4 0.8 1.3 1.7 0.9 0.5 0.1 0.0 1.0 0.1 7.5 3.7 17.8 9.6 0.6 1.2 12.3 10.5 4.0 13.2 10.7 16.1 3.9 22.4 4.1 2.7 5.7 30.5 7.2 13.9 7.3 16.0 28.7 6.8 7.9 0.6 20.2 8.3 0.6 1.1 16.4 7.1 5.0 22.8 11.9 7.1 4.0 25.2 15.7 26.0 8.5 11.3 11.7 12.2 3.3 7.1 8.4 10.4 6.5 7.6 3.3 4.0 14.3 2.5 6.5 10.0 7.2 14.2 6.0 17.9 35.2 4.8 22.5 5.4 0.0 0.0 0.5 0.4 0.0 0.0 1.7 0.6 0.2 0.9 0.0 0.0 1.0 0.0 0.0 0.1 0.5 0.0 0.1 1.1 1.1 0.7 1.2 1.3 2.4 1.4 0.2 1.2 0.2 CDC25B ENSG00000101224 "Cell division cycle 25B" P30305 20 3786772-3806121 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division, Mitosis" "Hydrolase, Protein phosphatase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Group enriched" "Detected in all" 5 "B-cells: 4.5;NK-cells: 9.3;T-cells: 15.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA038892, HPA038893, HPA075215" Enhanced Supported "Vesicles,Mitotic spindle" Vesicles "Mitotic spindle" "HPA038892: , HPA038893: , HPA075215: " "unprognostic (4.69e-2)" "unprognostic (5.74e-2)" "unprognostic (2.93e-2)" "prognostic unfavourable (4.76e-4)" "unprognostic (1.13e-1)" "unprognostic (4.23e-1)" "prognostic unfavourable (1.19e-4)" "unprognostic (1.31e-2)" "unprognostic (4.92e-2)" "unprognostic (2.74e-1)" "unprognostic (1.67e-1)" "unprognostic (6.03e-2)" "prognostic unfavourable (2.94e-13)" "unprognostic (1.15e-1)" "unprognostic (2.38e-1)" "unprognostic (3.94e-1)" "unprognostic (9.46e-2)" 12.1 8.7 15.1 27.7 23.3 26.0 28.8 49.6 21.1 13.0 14.7 12.8 4.6 14.9 17.0 10.3 11.7 13.0 18.6 7.5 15.7 12.5 13.3 11.0 33.0 42.8 21.9 12.5 17.3 5.7 7.5 21.0 30.3 13.8 11.0 12.0 7.7 7.4 10.2 6.2 19.8 16.8 14.8 14.7 24.5 14.1 6.3 22.3 33.3 18.7 20.8 31.6 15.3 16.3 4.5 1.3 1.5 1.8 9.3 15.5 5.9 29.8 64.5 8.6 14.3 10.6 10.4 4.3 14.8 22.2 24.8 18.5 11.2 43.3 20.8 6.4 15.1 43.7 11.7 24.6 11.7 8.0 12.6 11.2 20.7 13.5 42.3 8.7 5.8 10.2 19.8 23.0 27.2 13.7 7.2 55.1 14.6 24.0 27.1 12.7 6.4 27.6 14.2 24.4 14.9 16.9 2.8 6.2 13.5 35.1 33.5 17.2 11.3 4.5 11.3 13.3 16.1 24.1 19.6 13.4 21.2 8.4 6.8 8.6 12.8 1.5 1.4 0.0 13.6 1.8 12.7 3.5 13.6 13.7 1.3 4.5 11.4 13.2 0.1 9.3 0.9 0.7 15.5 5.9 15.1 23.3 49.6 21.1 15.7 12.5 21.9 12.5 13.8 22.3 CDC25C "CDC25, PPP1R60" ENSG00000158402 "Cell division cycle 25C" P30307 5 138285265-138338355 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Cell cycle, Cell division, Host-virus interaction, Mitosis" "Hydrolase, Protein phosphatase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "lymphoid tissue: 23.3;testis: 22.3" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "NK-cell: 2.1;T-reg: 2.7" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in some" "Low region specificity" "Detected in all" "CAB003800, HPA066991" Approved Supported "Nuclear speckles" "Nuclear speckles" "CAB003800: AB_562081, HPA066991: " "unprognostic (2.45e-3)" "unprognostic (5.89e-3)" "prognostic favourable (2.49e-4)" "unprognostic (9.72e-3)" "unprognostic (2.17e-1)" "unprognostic (1.53e-1)" "prognostic unfavourable (3.03e-6)" "prognostic unfavourable (4.38e-4)" "unprognostic (5.56e-2)" "unprognostic (2.08e-1)" "unprognostic (1.70e-3)" "unprognostic (1.00e-1)" "unprognostic (0.00e+0)" "unprognostic (5.04e-2)" "unprognostic (1.43e-1)" "unprognostic (2.59e-1)" "unprognostic (3.06e-1)" 1.1 0.6 0.3 6.7 0.4 5.2 1.1 0.4 0.6 0.6 3.3 0.1 0.7 3.0 0.3 0.6 2.5 0.2 0.4 0.7 0.4 0.4 0.4 0.6 0.7 2.6 0.4 0.3 0.3 0.3 0.0 0.4 1.9 0.3 0.4 4.0 0.0 1.2 0.7 0.2 1.1 3.7 0.5 0.3 1.7 1.2 22.3 0.2 23.3 0.3 1.8 5.0 0.6 0.9 1.0 0.1 0.7 0.0 2.1 2.7 0.5 13.5 5.6 19.0 14.6 0.4 1.9 4.8 8.1 8.8 18.6 25.7 13.6 26.3 6.3 6.9 4.9 7.3 15.6 12.5 18.0 5.2 10.7 4.8 7.7 10.1 0.1 3.2 4.9 0.4 0.5 11.0 9.0 11.9 7.0 12.4 11.3 7.4 8.8 8.1 4.9 6.2 5.8 17.3 7.3 3.2 4.1 9.6 5.9 18.3 5.6 8.7 9.3 6.7 3.6 10.3 8.7 7.1 13.0 7.6 6.2 6.2 4.1 6.9 7.8 0.0 0.0 0.1 0.6 0.0 0.0 1.0 0.5 0.3 0.0 0.2 0.0 0.0 0.7 2.1 0.0 0.1 2.7 0.5 0.3 0.4 0.4 0.6 0.4 0.4 0.4 0.3 0.3 0.2 CDC27 "ANAPC3, APC3, D0S1430E, D17S978E, NUC2" ENSG00000004897 "Cell division cycle 27" P30260 17 47117703-47189422 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Ubl conjugation pathway" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB016315, HPA028129, HPA052399, HPA065835" Supported Enhanced Nucleoplasm Nucleoplasm "CAB016315: AB_627228, HPA028129: AB_10603559, HPA052399: , HPA065835: " "unprognostic (2.34e-2)" "unprognostic (8.83e-3)" "prognostic favourable (1.77e-4)" "unprognostic (4.26e-2)" "unprognostic (7.99e-2)" "unprognostic (8.93e-3)" "prognostic unfavourable (4.38e-4)" "prognostic unfavourable (8.15e-4)" "unprognostic (1.98e-1)" "unprognostic (1.45e-1)" "unprognostic (4.05e-3)" "unprognostic (6.17e-2)" "prognostic unfavourable (6.39e-5)" "unprognostic (2.64e-1)" "unprognostic (1.58e-1)" "unprognostic (7.95e-2)" "unprognostic (3.66e-2)" 29.2 18.9 19.4 18.7 25.2 23.0 23.3 26.0 33.0 23.7 17.2 14.8 13.8 14.4 23.2 19.6 17.6 17.6 18.6 22.8 18.3 22.6 16.8 23.8 20.4 21.3 19.4 23.9 19.5 14.3 27.8 26.8 25.0 31.5 17.6 18.2 14.6 15.7 16.5 31.6 15.5 15.3 24.4 17.7 24.2 16.1 23.5 17.4 25.2 42.8 15.5 22.9 23.6 17.3 9.0 7.7 9.6 10.3 12.8 11.6 5.4 23.2 24.9 20.9 16.9 14.1 22.5 12.4 32.9 29.7 31.5 32.3 15.9 12.3 31.3 22.2 27.6 11.2 22.5 18.6 43.4 45.0 23.1 36.4 26.4 14.1 15.3 21.4 16.6 16.3 9.2 28.3 22.4 32.5 29.0 17.5 25.6 19.8 26.2 9.7 9.9 20.4 14.1 53.8 13.9 18.9 14.7 13.9 17.0 16.5 5.8 18.3 17.6 15.1 34.5 32.9 28.6 20.8 24.3 17.9 31.0 28.5 18.2 12.8 22.7 9.6 4.4 6.2 8.1 10.3 7.8 6.0 6.8 8.5 6.0 9.0 6.7 7.6 5.7 12.8 7.4 7.7 11.6 5.4 19.4 25.2 26.0 33.0 18.3 22.6 19.4 23.9 31.5 17.4 CDC34 "E2-CDC34, UBC3, UBE2R1" ENSG00000099804 "Cell division cycle 34" P49427 19 531712-542092 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Cell cycle, Ubl conjugation pathway" Transferase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002382, CAB005109, CAB047311" Approved Supported "Nuclear speckles,Cytosol" "Nuclear speckles" Cytosol "CAB005109: AB_2276050, CAB047311: , HPA002382: AB_1846370" "unprognostic (4.65e-2)" "unprognostic (2.02e-1)" "unprognostic (1.41e-1)" "unprognostic (8.72e-2)" "unprognostic (2.84e-1)" "unprognostic (5.73e-2)" "prognostic unfavourable (7.57e-4)" "unprognostic (2.20e-1)" "unprognostic (3.11e-1)" "unprognostic (3.83e-2)" "unprognostic (2.09e-2)" "unprognostic (3.06e-2)" "unprognostic (3.02e-2)" "unprognostic (8.87e-3)" "unprognostic (9.68e-2)" "unprognostic (7.82e-3)" "unprognostic (3.33e-2)" 16.5 15.9 21.3 11.3 19.1 24.7 20.4 25.7 30.9 16.0 20.5 19.5 10.5 15.4 13.3 13.4 15.6 14.5 13.6 35.6 21.1 18.2 12.1 36.0 13.0 9.9 18.5 19.8 17.0 37.4 11.3 17.0 24.9 16.2 17.2 10.6 15.3 26.4 18.5 63.9 19.0 13.2 18.6 14.3 12.7 15.7 43.6 15.0 12.2 13.1 17.0 8.7 19.2 16.4 2.9 2.8 11.5 4.5 1.5 4.1 1.3 18.4 18.4 23.7 19.5 10.8 10.3 23.7 16.6 12.7 17.9 18.7 28.6 11.3 10.2 17.4 11.8 12.8 18.6 14.0 9.2 16.6 50.0 9.4 12.2 30.9 26.9 13.2 11.4 13.3 21.0 15.1 15.8 21.3 40.2 20.4 11.8 26.4 18.0 17.6 29.9 17.9 16.7 12.2 17.1 13.5 11.0 30.9 22.9 14.4 15.0 27.6 12.0 19.4 17.4 13.1 15.6 30.4 22.1 20.4 15.6 13.6 17.9 18.7 13.5 4.5 3.5 6.2 2.3 3.4 1.7 2.9 3.2 4.1 2.8 1.7 2.5 2.4 11.5 1.5 4.5 2.3 3.1 1.3 21.3 19.1 25.7 30.9 21.1 18.2 18.5 19.8 16.2 15.0 CDC37 P50CDC37 ENSG00000105401 "Cell division cycle 37" Q16543 19 10391134-10420121 "Cancer-related genes, Predicted intracellular proteins" Chaperone "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003928, CAB004214" Supported Supported Cytosol 260000 Cytosol "CAB004214: AB_627232, HPA003928: AB_1846373" "unprognostic (2.40e-1)" "unprognostic (1.06e-1)" "unprognostic (1.27e-1)" "unprognostic (2.33e-2)" "unprognostic (2.46e-3)" "unprognostic (6.21e-2)" "unprognostic (1.37e-1)" "unprognostic (7.90e-2)" "unprognostic (1.25e-1)" "unprognostic (7.61e-3)" "unprognostic (1.96e-2)" "unprognostic (1.82e-2)" "unprognostic (1.84e-2)" "prognostic favourable (2.33e-4)" "unprognostic (5.80e-2)" "unprognostic (1.23e-1)" "unprognostic (3.02e-2)" 47.3 29.7 33.0 41.6 33.0 41.8 42.0 35.8 46.8 31.9 35.5 17.8 32.7 31.8 36.3 34.8 37.9 30.1 42.8 49.5 28.1 31.3 33.6 35.6 38.2 33.4 26.6 36.4 34.4 34.2 26.8 24.2 34.3 32.9 31.5 27.7 21.6 37.0 34.4 148.6 29.3 31.3 28.7 23.0 43.5 34.0 23.4 29.8 32.6 33.5 50.7 34.6 33.0 48.0 33.2 45.2 40.0 46.0 40.2 52.3 53.0 52.9 35.2 19.0 27.1 26.2 22.9 24.5 62.9 28.6 39.7 34.1 40.2 20.9 31.6 51.1 38.4 33.1 25.7 40.8 27.5 25.4 75.8 60.0 28.5 56.9 41.4 34.7 27.5 27.9 22.4 46.3 20.9 50.8 46.5 38.3 30.6 50.4 34.6 85.5 46.5 62.5 34.5 25.5 36.2 36.3 34.6 22.2 32.4 29.5 31.2 26.9 21.4 37.5 56.4 46.5 26.7 63.7 50.2 52.2 51.3 39.1 36.5 56.5 37.5 29.2 46.0 40.0 52.3 45.8 47.3 33.2 42.3 46.9 45.2 29.1 33.0 38.1 26.6 40.2 44.1 38.4 44.0 53.0 33.0 33.0 35.8 46.8 28.1 31.3 26.6 36.4 32.9 29.8 CDC6 CDC18L ENSG00000094804 "Cell division cycle 6" Q99741 17 40287633-40304657 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division, DNA replication, Mitosis" "Cancer-related genes, Disease mutation, Dwarfism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 30.0" "Cell line enhanced" "Detected in many" "SK-BR-3: 85.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "plasmacytoid DC: 6.2" "Group enriched" "Detected in many" 5 "dendritic cells: 6.2;NK-cells: 2.2;T-cells: 3.4" "Not detected" "Not detected" "Low region specificity" "Detected in all" "HPA050114, HPA065070" Approved Supported "Nucleoplasm,Cytokinetic bridge,Mitotic spindle,Cytosol" "Nucleoplasm, Cytosol" "Cytokinetic bridge, Mitotic spindle" "HPA050114: , HPA065070: " "unprognostic (1.29e-1)" "unprognostic (7.22e-2)" "unprognostic (1.23e-3)" "unprognostic (7.97e-2)" "unprognostic (7.12e-2)" "unprognostic (2.89e-2)" "prognostic unfavourable (5.96e-8)" "unprognostic (2.31e-3)" "unprognostic (1.46e-3)" "unprognostic (1.41e-1)" "prognostic unfavourable (2.90e-4)" "unprognostic (5.47e-2)" "unprognostic (3.00e-15)" "unprognostic (1.86e-2)" "unprognostic (1.35e-1)" "unprognostic (3.95e-3)" "unprognostic (3.88e-2)" 1.8 2.9 3.1 10.8 2.6 16.8 1.5 2.3 6.0 2.7 5.8 0.8 2.7 5.3 1.9 1.6 9.0 1.3 5.4 1.6 1.9 1.4 1.8 5.1 2.8 10.6 1.0 1.5 1.5 3.6 1.1 1.2 9.4 0.8 1.4 5.6 0.2 3.2 4.1 0.9 2.3 7.9 2.4 1.6 7.7 2.7 14.8 1.2 30.0 1.3 5.0 10.1 4.1 3.0 0.7 6.2 0.2 0.3 2.2 3.4 1.2 25.0 17.3 21.0 14.9 1.1 2.3 19.1 27.3 8.2 23.9 29.0 19.6 11.2 20.2 17.1 5.8 36.4 18.1 12.4 23.8 10.7 14.2 16.4 20.7 17.6 0.7 22.4 10.1 0.5 0.9 27.7 16.7 7.2 29.9 19.0 11.6 13.1 32.5 5.4 17.2 6.4 24.0 51.0 19.1 4.0 28.2 14.4 12.9 24.8 85.2 8.4 17.3 19.4 6.0 17.3 24.7 28.3 32.3 7.9 17.2 39.0 15.0 14.8 18.9 0.1 0.3 0.0 1.3 0.0 0.9 0.7 1.2 2.1 1.4 0.7 0.9 2.1 0.2 2.2 0.0 6.2 3.4 1.2 3.1 2.6 2.3 6.0 1.9 1.4 1.0 1.5 0.8 1.2 CDC73 "C1orf28, FIHP, HRPT1, HRPT2, parafibromin" ENSG00000134371 "Cell division cycle 73" Q6P1J9 1 193121997-193253901 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cell cycle, Transcription, Transcription regulation, Wnt signaling pathway" "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB016359, HPA030772" Supported Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "CAB016359: AB_628102, HPA030772: " "unprognostic (4.41e-2)" "unprognostic (6.22e-2)" "unprognostic (1.90e-2)" "unprognostic (5.30e-2)" "unprognostic (2.88e-3)" "unprognostic (3.53e-2)" "unprognostic (2.48e-3)" "unprognostic (5.74e-2)" "unprognostic (1.25e-1)" "unprognostic (1.40e-1)" "unprognostic (7.23e-3)" "unprognostic (2.17e-1)" "unprognostic (5.44e-3)" "unprognostic (3.47e-1)" "unprognostic (2.49e-1)" "unprognostic (6.73e-3)" "unprognostic (2.98e-3)" 23.4 20.0 18.1 16.8 22.9 21.0 20.1 25.6 22.6 20.4 20.1 14.5 16.3 12.0 26.8 15.2 20.6 14.9 16.4 21.4 18.4 15.0 18.8 17.1 17.2 16.6 19.7 15.9 23.3 14.5 27.1 24.8 17.3 19.4 26.9 16.2 13.6 17.3 19.0 44.5 15.0 14.5 25.6 23.9 16.0 15.7 16.3 22.1 20.6 27.1 14.1 15.8 26.8 35.0 6.6 6.7 10.2 7.0 9.0 12.5 5.2 13.3 12.0 15.9 10.2 14.9 14.5 12.2 14.4 14.0 17.4 15.3 8.2 15.9 17.4 10.2 17.7 13.1 14.4 13.6 21.3 11.0 6.8 12.6 10.9 8.0 14.0 17.1 12.6 11.8 13.2 16.3 15.6 14.8 19.1 14.1 23.3 12.3 13.9 8.5 15.3 4.5 12.5 9.6 16.6 20.4 9.3 4.8 13.1 18.0 22.2 20.5 19.1 12.4 16.5 17.0 3.9 14.4 14.7 13.2 9.8 14.3 10.2 10.5 29.6 6.6 7.0 10.2 9.3 6.8 12.5 6.6 9.2 9.2 6.7 5.4 8.4 8.7 7.4 9.0 5.7 4.9 9.3 5.2 18.1 22.9 25.6 22.6 18.4 15.0 19.7 15.9 19.4 22.1 CDH1 "CD324, UVO, uvomorulin" ENSG00000039068 "Cadherin 1" P12830 16 68737225-68835548 "Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Cancer-related genes, Disease mutation, Ectodermal dysplasia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 125.5" "Cell line enhanced" "Detected in some" "BEWO: 105.6;CACO-2: 35.5;CAPAN-2: 49.6;HaCaT: 47.9;hTCEpi: 33.8;MCF7: 29.3;RT4: 36.5;T-47d: 31.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Group enriched" "Detected in some" 12 "myeloid DC: 2.8;plasmacytoid DC: 8.5" "Lineage enriched" "Detected in single" 18 "dendritic cells: 8.5" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB000087, HPA004812, CAB028364, CAB072855, CAB072856, CAB072857" Enhanced Supported "Golgi apparatus,Plasma membrane,Cell Junctions" 22000000 "Plasma membrane, Cell Junctions" "Golgi apparatus" "CAB000087: AB_2533003, CAB028364: AB_2076812, CAB072855: , CAB072856: , CAB072857: , HPA004812: AB_1078369" "unprognostic (3.95e-2)" "unprognostic (1.91e-1)" "unprognostic (1.12e-3)" "unprognostic (1.13e-1)" "unprognostic (1.42e-1)" "unprognostic (2.78e-1)" "unprognostic (5.04e-3)" "unprognostic (1.63e-1)" "unprognostic (5.47e-2)" "unprognostic (2.85e-1)" "unprognostic (1.19e-2)" "unprognostic (3.61e-1)" "prognostic favourable (2.06e-4)" "unprognostic (1.21e-1)" "unprognostic (2.62e-1)" "unprognostic (2.51e-1)" "unprognostic (5.92e-2)" 1.1 0.7 1.3 14.8 1.5 0.5 15.3 0.8 1.1 14.4 63.8 1.8 42.4 25.5 4.7 18.6 48.5 9.7 48.9 0.8 1.5 1.0 24.2 64.9 24.4 0.5 1.8 0.9 5.6 71.5 62.2 13.2 55.2 2.8 28.9 25.9 11.8 66.6 43.7 0.8 30.5 125.5 1.5 1.1 3.5 21.6 2.1 1.8 11.7 83.0 26.2 32.6 16.8 21.7 0.0 8.5 0.0 0.0 0.3 0.4 0.1 21.3 2.2 0.0 0.0 0.0 0.0 105.6 0.0 0.0 0.0 0.0 35.5 49.6 0.0 0.4 0.0 47.9 0.0 23.8 0.0 4.1 0.6 0.0 0.1 7.6 0.0 0.0 0.2 0.0 33.8 0.0 0.0 0.0 0.0 0.0 0.0 29.3 0.0 0.1 0.8 0.1 0.0 0.0 0.3 8.7 36.5 1.3 0.1 0.2 0.0 9.0 31.5 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.4 2.8 0.0 0.0 0.0 0.0 0.3 0.0 8.5 0.1 0.1 1.3 1.5 0.8 1.1 1.5 1.0 1.8 0.9 2.8 1.8 CDH11 "CAD11, OB" ENSG00000140937 "Cadherin 11" P55287 16 64943753-65126112 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Cancer-related genes, Deafness, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "ovary: 71.0" "Cell line enhanced" "Detected in many" "BJ: 47.1;fHDF/TERT166: 64.3;HSkMC: 44.3;PC-3: 55.3;U-2197: 37.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB013072 Enhanced 70000 "CAB013072: AB_2533068" "unprognostic (1.77e-1)" "unprognostic (1.51e-1)" "unprognostic (1.50e-1)" "unprognostic (6.93e-2)" "unprognostic (6.00e-2)" "unprognostic (1.02e-1)" "unprognostic (6.96e-2)" "unprognostic (1.28e-1)" "unprognostic (2.09e-1)" "unprognostic (2.30e-2)" "unprognostic (3.74e-2)" "unprognostic (6.75e-2)" "prognostic unfavourable (2.48e-9)" "unprognostic (1.43e-3)" "unprognostic (3.20e-2)" "unprognostic (1.26e-1)" "unprognostic (5.07e-3)" 8.1 3.6 5.5 9.2 12.1 0.3 6.1 5.5 8.8 24.1 4.3 7.5 2.4 2.7 25.9 5.9 3.0 6.8 22.4 4.6 7.3 5.1 4.8 1.0 20.8 5.9 7.8 8.5 71.0 1.7 1.2 6.0 44.2 8.3 8.0 4.9 22.2 7.3 9.7 2.5 5.7 3.4 20.5 10.6 35.1 5.1 4.0 5.4 0.1 4.8 1.9 4.9 18.4 11.7 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 10.2 0.0 7.3 15.9 0.0 47.1 27.3 12.1 6.9 0.8 0.0 0.0 0.0 64.3 0.0 0.0 0.3 8.7 0.0 0.4 0.0 0.2 0.0 6.0 0.0 2.8 44.3 0.0 14.8 3.0 3.4 0.0 0.0 6.4 0.0 0.0 0.0 3.7 55.3 0.1 7.3 0.0 0.0 0.0 0.1 7.0 0.0 0.0 0.0 0.0 0.0 0.0 25.0 3.4 37.8 13.3 0.0 0.0 0.0 4.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.5 12.1 5.5 8.8 7.3 5.1 7.8 8.5 8.3 5.4 CDH17 "cadherin, HPT-1" ENSG00000079112 "Cadherin 17" Q12864 8 94127171-94217303 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion, Transport" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 10 "intestine: 184.4" "Group enriched" "Detected in some" 7 "CACO-2: 33.3;U-266/70: 55.3" "Group enriched" "Detected in many" 6 "colorectal cancer: 156.4;stomach cancer: 54.9" "Not detected" "Not detected" "Cell type enriched" "Detected in many" 5 "neutrophil: 12.1" "Lineage enriched" "Detected in many" 8 "granulocytes: 12.1" "Not detected" "Not detected" "Low region specificity" "Detected in all" "HPA023614, HPA023616, CAB025143, HPA026556" Enhanced Enhanced "Nucleoplasm,Cell Junctions" 3400000 "Cell Junctions" Nucleoplasm "CAB025143: , HPA023614: AB_1845896, HPA023616: AB_1845895, HPA026556: AB_1845897" "unprognostic (2.08e-1)" "unprognostic (5.00e-2)" "unprognostic (1.05e-1)" "unprognostic (1.09e-1)" "unprognostic (3.02e-1)" "unprognostic (3.06e-2)" "unprognostic (5.60e-2)" "unprognostic (3.38e-3)" "unprognostic (2.11e-1)" "unprognostic (1.74e-1)" "unprognostic (5.47e-2)" "unprognostic (3.74e-2)" "unprognostic (2.36e-1)" "unprognostic (1.29e-1)" "unprognostic (1.31e-1)" "unprognostic (7.33e-2)" "unprognostic (1.46e-2)" 0.3 0.2 0.2 17.6 0.3 0.3 0.3 0.2 0.2 0.3 88.9 0.2 0.2 54.5 0.4 0.3 0.4 0.4 7.0 0.6 0.2 0.3 0.3 0.3 0.3 0.5 0.2 0.2 0.3 0.4 0.0 0.3 0.2 0.2 0.4 44.0 0.2 0.3 0.2 0.3 0.2 184.4 1.4 0.2 0.6 0.3 0.3 0.2 0.3 0.2 0.2 0.5 0.4 0.3 1.5 0.8 12.1 1.0 1.4 0.6 0.1 0.1 6.1 0.3 0.4 0.0 0.1 0.5 0.1 0.1 0.0 0.1 33.3 1.5 0.2 0.1 0.0 0.4 0.1 0.1 0.1 0.1 0.5 0.1 0.6 0.2 0.1 0.1 1.7 0.0 0.0 0.1 0.0 0.0 0.2 0.7 0.0 0.4 0.2 0.5 0.2 0.2 0.4 0.1 1.0 0.1 0.1 0.6 0.4 0.2 0.2 0.2 0.3 0.3 0.2 0.3 0.3 0.5 0.2 55.3 0.1 0.1 0.1 0.2 0.3 2.5 1.0 1.2 0.5 0.8 0.3 0.6 0.5 0.4 0.8 1.5 0.5 0.6 12.1 1.4 0.5 0.7 0.5 0.1 0.2 0.3 0.2 0.2 0.2 0.3 0.2 0.2 0.2 0.2 CDH5 "7B4, CD144" ENSG00000179776 "Cadherin 5" P33151 16 66366622-66404786 "Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "placenta: 96.6" "Group enriched" "Detected in some" 6 "HUVEC TERT2: 111.2;TIME: 95.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB028366, HPA075875" Approved Supported "Nucleoplasm,Nuclear membrane,Plasma membrane" 1000000000 "Plasma membrane" "Nucleoplasm, Nuclear membrane" "CAB028366: AB_2276033, HPA075875: " "unprognostic (1.05e-1)" "unprognostic (8.13e-2)" "unprognostic (6.11e-2)" "unprognostic (4.89e-2)" "unprognostic (4.96e-2)" "unprognostic (5.50e-3)" "unprognostic (9.38e-2)" "unprognostic (5.28e-2)" "unprognostic (1.32e-1)" "unprognostic (1.46e-1)" "unprognostic (2.33e-2)" "unprognostic (2.32e-1)" "prognostic unfavourable (5.14e-4)" "unprognostic (9.49e-3)" "unprognostic (3.01e-2)" "unprognostic (2.22e-1)" "unprognostic (3.15e-2)" 48.7 5.6 4.0 6.2 5.8 0.6 28.1 2.6 4.8 11.1 6.6 3.4 5.5 3.7 18.7 11.2 8.4 7.2 12.6 21.7 4.5 4.3 7.8 12.7 43.7 9.7 6.5 2.8 7.7 3.6 5.0 3.5 96.6 7.6 9.0 4.8 8.5 5.2 4.4 19.0 7.0 6.8 12.1 5.4 10.8 5.7 6.7 3.3 1.2 16.6 15.7 4.5 11.7 11.3 0.0 0.6 0.4 0.8 0.1 0.1 1.1 0.0 0.0 0.6 0.0 0.0 0.0 7.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 17.9 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 111.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 2.3 0.0 0.0 0.0 95.3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.8 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.4 0.0 0.1 0.0 0.4 0.1 0.0 0.6 0.1 1.1 4.0 5.8 2.6 4.8 4.5 4.3 6.5 2.8 7.6 3.3 CDK1 "CDC2, CDC28A" ENSG00000170312 "Cyclin dependent kinase 1" P06493 10 60778331-60794852 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Transporters" "Apoptosis, Biological rhythms, Cell cycle, Cell division, Host-virus interaction, Mitosis" "Host cell receptor for virus entry, Kinase, Receptor, Serine/threonine-protein kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "lymphoid tissue: 88.4" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "NK-cell: 6.1;T-reg: 5.7" "Group enriched" "Detected in many" 5 "dendritic cells: 1.7;NK-cells: 6.1;T-cells: 5.7" "Low region specificity" "Detected in single" "HPA003387, CAB003799" Enhanced Supported Nucleoplasm,Cytosol Cytosol Nucleoplasm "CAB003799: AB_344898, HPA003387: AB_1846356" "unprognostic (6.34e-2)" "prognostic favourable (8.81e-4)" "unprognostic (1.90e-1)" "unprognostic (6.82e-2)" "unprognostic (6.67e-2)" "unprognostic (3.83e-2)" "prognostic unfavourable (1.10e-6)" "prognostic unfavourable (7.88e-4)" "unprognostic (1.30e-2)" "unprognostic (1.30e-1)" "prognostic unfavourable (4.15e-6)" "unprognostic (1.80e-2)" "prognostic unfavourable (0.00e+0)" "unprognostic (2.27e-1)" "unprognostic (2.75e-1)" "unprognostic (2.13e-1)" "unprognostic (1.60e-1)" 4.1 2.2 0.8 17.8 2.4 17.8 4.4 0.7 1.6 4.2 6.5 1.1 3.4 6.1 2.9 4.8 19.0 1.5 2.4 2.3 0.9 0.7 3.1 1.7 5.7 15.1 1.7 0.6 2.2 1.0 0.5 4.4 13.3 1.2 1.5 8.3 1.0 3.8 2.9 1.0 4.9 8.3 2.7 2.5 8.3 5.0 13.8 1.2 88.4 1.8 16.7 20.1 3.2 6.9 0.9 1.7 0.0 0.2 6.1 5.7 1.8 48.2 18.4 48.9 19.3 3.2 4.9 20.1 36.5 26.6 44.5 42.9 43.0 42.7 44.2 14.2 10.0 30.0 33.2 21.2 46.4 31.4 24.2 23.2 18.1 24.9 0.5 35.5 24.0 0.9 2.1 28.8 28.1 26.7 35.3 54.5 49.5 12.8 44.6 25.5 21.5 38.7 38.8 45.5 21.7 17.0 16.0 22.9 20.1 24.5 37.3 18.9 40.2 21.8 11.0 19.0 40.6 20.0 49.8 21.4 34.3 39.9 16.4 39.8 23.6 0.0 0.0 0.0 0.5 0.2 0.5 0.9 1.5 2.7 0.5 0.5 0.5 1.5 0.0 6.1 0.2 1.7 5.7 1.8 0.8 2.4 0.7 1.6 0.9 0.7 1.7 0.6 1.2 1.2 CDK12 "CRK7, CRKR, CRKRS, KIAA0904" ENSG00000167258 "Cyclin dependent kinase 12" Q9NYV4 17 39461511-39564907 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "mRNA processing, mRNA splicing" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "SK-BR-3: 85.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008038, HPA073305" Supported Enhanced "Nucleoplasm,Nuclear speckles" "Nucleoplasm, Nuclear speckles" "HPA008038: AB_1078570, HPA073305: " "unprognostic (2.02e-1)" "unprognostic (1.80e-1)" "unprognostic (2.61e-2)" "unprognostic (7.56e-2)" "unprognostic (1.05e-1)" "unprognostic (3.19e-1)" "unprognostic (2.56e-3)" "unprognostic (2.37e-2)" "unprognostic (3.86e-2)" "unprognostic (3.00e-3)" "unprognostic (6.87e-3)" "unprognostic (1.86e-1)" "unprognostic (3.06e-2)" "unprognostic (9.10e-2)" "unprognostic (1.24e-1)" "unprognostic (2.22e-2)" "unprognostic (5.32e-1)" 16.0 13.1 12.4 17.4 9.2 32.4 14.0 23.4 17.8 18.2 17.6 9.6 15.7 11.1 15.7 12.0 16.9 12.2 12.5 11.0 10.1 6.7 10.2 18.5 13.5 15.2 10.9 14.3 17.4 11.3 19.0 12.2 18.4 9.5 12.7 11.7 10.4 15.6 11.1 11.1 17.0 16.5 11.0 10.6 16.3 11.8 18.9 8.3 29.0 15.0 5.4 17.3 16.3 20.5 5.1 4.0 10.4 2.9 6.6 4.0 0.9 8.7 10.8 6.5 6.1 4.8 5.4 6.1 7.9 6.7 10.9 8.1 13.3 5.4 12.4 7.0 8.3 14.2 13.0 10.0 10.5 8.1 11.2 13.4 7.4 10.3 4.7 18.3 9.4 5.8 6.9 13.2 10.5 6.6 22.7 8.2 6.2 4.1 14.9 4.7 6.8 4.9 9.9 14.1 7.0 4.1 10.5 7.0 4.5 10.1 85.6 6.9 11.0 7.9 7.1 9.9 7.9 6.9 10.2 6.7 4.8 17.5 7.0 7.8 6.4 10.4 2.9 4.1 4.0 2.2 3.0 2.9 2.5 2.7 1.8 5.1 2.9 2.7 9.7 6.6 1.8 4.0 2.0 0.9 12.4 9.2 23.4 17.8 10.1 6.7 10.9 14.3 9.5 8.3 CDK2 ENSG00000123374 "Cyclin dependent kinase 2" P24941 12 55966769-55972784 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division, DNA damage, DNA repair, Meiosis, Mitosis" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "SK-MEL-30: 105.5" "Cancer enhanced" "Detected in all" "melanoma: 88.3" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB013115, HPA066915" Enhanced Enhanced Nucleoplasm,Centrosome,Cytosol Nucleoplasm "Centrosome, Cytosol" "CAB013115: AB_2536375, HPA066915: " "unprognostic (2.36e-2)" "unprognostic (2.60e-1)" "unprognostic (3.71e-2)" "unprognostic (1.83e-2)" "unprognostic (1.75e-1)" "prognostic unfavourable (9.94e-4)" "prognostic unfavourable (8.61e-5)" "unprognostic (3.48e-2)" "unprognostic (1.31e-1)" "unprognostic (4.67e-2)" "unprognostic (5.38e-3)" "unprognostic (4.69e-3)" "prognostic unfavourable (1.46e-10)" "unprognostic (1.05e-1)" "unprognostic (1.76e-1)" "unprognostic (6.16e-2)" "unprognostic (6.75e-2)" 10.7 7.6 4.5 20.8 6.5 18.7 11.5 4.2 4.3 12.6 11.6 3.5 6.0 6.1 10.7 6.4 13.6 10.8 12.6 10.1 5.4 2.2 8.3 16.7 19.5 12.2 6.0 2.0 14.2 8.3 5.2 4.2 49.0 7.3 10.8 9.1 51.2 9.3 9.9 10.8 14.6 9.3 11.8 5.0 12.5 10.1 7.8 5.1 39.3 9.5 10.7 14.7 16.7 10.1 9.3 10.8 5.2 3.9 4.5 7.6 4.3 16.5 8.9 19.6 10.9 4.0 5.2 36.2 20.6 10.8 25.6 24.0 18.7 15.9 15.7 15.5 7.6 10.6 14.9 9.0 26.1 18.5 14.6 18.1 14.8 7.1 1.3 14.3 13.1 2.7 2.3 17.3 6.0 12.9 17.2 14.3 17.8 12.7 29.6 12.1 7.8 13.3 29.0 18.9 11.8 7.4 16.2 8.1 10.5 23.5 8.6 105.5 18.6 10.5 7.2 17.7 17.2 13.6 15.0 8.2 9.4 19.6 10.0 10.5 15.2 5.2 3.6 3.1 7.0 3.9 7.0 9.3 3.2 5.0 2.7 6.1 3.0 5.3 1.7 4.5 1.6 10.8 7.6 4.3 4.5 6.5 4.2 4.3 5.4 2.2 6.0 2.0 7.3 5.1 CDK4 PSK-J3 ENSG00000135446 "Cyclin dependent kinase 4" P11802 12 57747727-57756013 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Group enriched" "Detected in all" 10 "HBEC3-KT: 125.1;LHCN-M2: 138.1;RH-30: 434.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA006024, CAB013116, CAB069405" Supported Supported "Nucleoplasm,Nuclear membrane,Nucleoli,Cytosol" Cytosol "Nucleoplasm, Nuclear membrane, Nucleoli" "CAB013116: AB_2536376, CAB069405: AB_1613464, HPA006024: " "unprognostic (8.88e-2)" "unprognostic (2.53e-1)" "unprognostic (5.27e-2)" "unprognostic (9.01e-2)" "unprognostic (2.21e-1)" "unprognostic (1.10e-1)" "prognostic unfavourable (2.09e-7)" "unprognostic (7.39e-2)" "unprognostic (3.23e-3)" "unprognostic (2.93e-2)" "unprognostic (3.19e-2)" "unprognostic (9.10e-2)" "prognostic unfavourable (3.15e-5)" "unprognostic (3.32e-1)" "unprognostic (1.67e-1)" "unprognostic (3.64e-1)" "unprognostic (1.57e-2)" 32.2 43.1 13.8 22.2 15.7 24.0 45.0 13.1 17.9 36.3 28.2 20.1 22.8 15.2 51.4 28.1 29.9 31.0 32.3 27.4 14.5 12.1 24.0 36.9 26.8 26.4 18.3 13.7 61.4 54.4 18.9 34.2 25.0 16.0 37.2 26.9 26.2 29.3 24.1 27.8 25.6 20.7 34.1 13.5 27.2 23.9 24.6 17.5 29.2 54.3 32.1 27.5 33.6 30.9 29.6 25.5 2.6 19.9 15.8 32.1 22.2 9.3 10.8 14.3 12.7 13.1 11.5 9.5 5.4 17.6 23.8 19.8 15.4 8.9 13.6 9.7 8.4 7.2 19.7 125.1 18.1 6.7 9.1 12.7 7.3 10.8 15.4 14.4 8.8 11.3 9.2 14.6 16.8 15.3 13.5 11.7 138.1 13.5 13.7 11.7 16.8 11.0 12.4 434.6 12.6 7.4 14.7 12.9 12.1 9.5 7.2 14.4 9.6 17.5 6.9 11.2 10.5 12.6 10.9 5.8 9.5 20.9 10.3 13.3 13.4 1.7 14.3 2.6 26.2 19.9 27.0 29.6 23.1 23.7 21.0 28.1 32.1 28.5 1.2 15.8 12.0 25.5 16.6 22.2 13.8 15.7 13.1 17.9 14.5 12.1 18.3 13.7 16.0 17.5 CDK6 PLSTIRE ENSG00000105810 "Cyclin dependent kinase 6" Q00534 7 92604921-92836594 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division, Differentiation" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Primary microcephaly" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 74.6" "Cell line enhanced" "Detected in many" "MOLT-4: 91.7;REH: 44.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002637, CAB004363" Enhanced Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "CAB004363: AB_627242, HPA002637: AB_1846432" "unprognostic (1.29e-1)" "unprognostic (5.98e-3)" "unprognostic (9.07e-2)" "unprognostic (2.78e-3)" "unprognostic (2.56e-2)" "unprognostic (3.24e-2)" "unprognostic (3.39e-1)" "unprognostic (2.42e-3)" "unprognostic (7.19e-2)" "unprognostic (7.78e-3)" "prognostic unfavourable (3.86e-6)" "unprognostic (4.06e-2)" "unprognostic (4.09e-3)" "unprognostic (1.09e-1)" "unprognostic (7.88e-2)" "unprognostic (1.93e-1)" "prognostic unfavourable (2.33e-5)" 6.6 11.3 6.0 9.1 7.5 22.5 5.9 2.4 6.0 7.8 10.0 9.6 5.7 7.5 6.0 5.9 8.5 4.6 7.8 6.6 6.9 4.2 6.5 7.5 7.3 7.4 7.0 5.2 5.0 10.0 25.7 4.2 20.5 7.5 6.1 9.2 4.4 10.9 6.1 2.0 11.6 9.4 9.8 7.5 6.3 10.8 5.4 8.0 74.6 4.3 9.2 10.3 6.7 9.0 3.6 5.6 6.5 4.8 3.9 7.1 2.3 6.0 2.8 7.8 5.0 2.3 2.6 1.6 6.3 3.9 3.1 3.0 7.7 4.7 4.7 3.6 4.2 3.8 4.3 9.0 7.4 10.3 3.0 11.8 5.4 7.4 1.4 7.3 0.5 2.5 4.9 4.2 20.0 1.2 11.2 13.0 5.6 1.2 91.7 0.7 2.4 2.6 44.8 27.6 7.9 4.3 0.1 4.1 26.8 0.7 2.1 3.7 0.1 12.0 4.6 10.3 16.1 4.0 12.6 7.0 0.1 6.3 1.5 25.0 13.6 4.9 1.9 6.5 5.2 3.9 5.9 2.0 5.5 5.6 4.0 3.6 7.1 4.0 1.1 3.9 4.8 5.6 2.8 2.3 6.0 7.5 2.4 6.0 6.9 4.2 7.0 5.2 7.5 8.0 CDK7 "CAK, CAK1, CDKN7, MO15, STK1" ENSG00000134058 "Cyclin dependent kinase 7" P50613 5 69234795-69277430 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division, DNA damage, DNA repair, Transcription, Transcription regulation" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004364, HPA007932" Enhanced "CAB004364: AB_627243, HPA007932: AB_1078492" "unprognostic (3.12e-2)" "unprognostic (1.23e-1)" "unprognostic (4.87e-2)" "unprognostic (4.53e-2)" "unprognostic (3.29e-2)" "unprognostic (4.64e-2)" "unprognostic (2.49e-3)" "unprognostic (1.64e-2)" "unprognostic (7.77e-3)" "unprognostic (1.81e-2)" "prognostic unfavourable (3.09e-4)" "unprognostic (3.40e-2)" "prognostic unfavourable (9.42e-7)" "unprognostic (2.61e-1)" "unprognostic (2.38e-1)" "unprognostic (3.86e-2)" "unprognostic (1.55e-2)" 7.9 12.9 10.9 6.2 15.2 44.1 14.0 10.8 14.7 9.4 12.7 6.0 6.3 15.8 9.4 8.6 23.4 18.5 16.5 8.1 11.5 9.3 13.8 10.6 10.1 8.8 7.6 9.7 7.7 9.1 3.3 16.2 22.9 11.2 11.2 14.8 6.6 13.2 6.5 15.9 15.4 9.8 12.1 9.2 7.9 13.9 29.0 7.8 12.1 20.0 15.6 15.5 10.7 11.7 15.6 15.0 22.4 11.3 12.4 15.3 7.8 3.7 7.8 1.8 0.5 2.4 11.6 14.7 6.5 7.7 10.8 17.5 16.7 1.9 2.8 10.2 1.7 2.5 1.4 2.8 5.9 1.3 7.0 0.4 8.2 7.9 0.4 6.7 3.2 14.3 13.9 9.0 2.8 13.6 10.4 4.5 4.9 0.7 4.1 14.8 1.7 7.5 6.7 0.4 1.1 1.6 1.0 0.6 6.5 1.5 5.8 3.4 11.6 0.6 2.6 0.1 3.2 0.9 5.1 4.8 8.4 3.7 0.8 4.0 0.8 7.3 10.9 22.4 8.6 11.3 14.8 12.4 12.9 15.3 15.0 15.6 11.1 13.2 10.0 12.4 8.0 11.2 12.8 7.8 10.9 15.2 10.8 12.7 11.5 9.3 7.6 9.7 11.2 7.8 CDKN1A "CAP20, CDKN1, CIP1, P21, p21CIP1, p21Cip1/Waf1, SDI1, WAF1" ENSG00000124762 "Cyclin dependent kinase inhibitor 1A" P38936 6 36676460-36687339 "Cancer-related genes, Predicted intracellular proteins" "Cell cycle" "Protein kinase inhibitor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HHSteC: 97.4;HSkMC: 71.6;hTCEpi: 92.6;LHCN-M2: 72.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "intermediate monocyte: 21.0;non-classical monocyte: 27.7" "Group enriched" "Detected in many" 8 "B-cells: 8.8;dendritic cells: 8.5;monocytes: 27.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000064, HPA005946, CAB069401" Supported Supported "Nucleoplasm,Nuclear bodies" "Nucleoplasm, Nuclear bodies" "CAB000064: , CAB069401: AB_1620493, HPA005946: " "unprognostic (7.99e-3)" "unprognostic (4.01e-2)" "unprognostic (1.58e-1)" "prognostic favourable (3.14e-5)" "unprognostic (1.57e-2)" "unprognostic (2.19e-2)" "unprognostic (1.39e-2)" "prognostic unfavourable (7.05e-4)" "unprognostic (1.30e-1)" "unprognostic (7.27e-2)" "unprognostic (2.79e-2)" "unprognostic (7.55e-3)" "prognostic favourable (4.95e-5)" "unprognostic (8.32e-2)" "unprognostic (6.52e-2)" "unprognostic (1.12e-1)" "unprognostic (3.21e-2)" 81.2 27.0 8.2 21.9 29.8 22.0 38.0 4.8 13.7 25.2 60.8 13.9 10.2 39.8 17.5 17.7 63.5 49.4 47.3 35.9 22.2 8.4 29.1 102.2 55.8 6.3 16.6 4.9 59.1 45.5 12.8 22.8 38.6 44.1 42.0 40.7 8.8 18.0 11.4 98.6 43.5 144.9 40.2 29.6 13.6 25.2 25.3 10.3 6.6 22.7 42.2 27.4 50.5 44.4 8.8 8.5 1.8 27.7 0.2 1.1 13.3 3.0 12.4 9.6 0.2 33.8 60.5 17.6 50.3 40.8 6.2 24.5 1.1 2.9 2.0 1.8 31.5 6.9 0.4 55.5 10.1 4.0 2.5 0.3 10.3 15.4 97.4 0.0 15.1 71.6 92.6 57.1 18.0 32.4 0.5 14.2 72.2 6.4 0.4 1.2 1.2 1.8 6.1 7.9 3.5 11.0 23.1 4.3 4.2 11.6 1.0 2.3 3.8 12.6 17.9 10.9 10.3 0.7 4.1 23.9 4.6 6.1 14.1 1.1 30.3 0.0 9.3 0.2 0.2 21.0 0.3 8.8 0.4 0.3 8.0 5.7 0.1 0.1 1.8 0.2 27.7 8.5 1.1 13.3 8.2 29.8 4.8 13.7 22.2 8.4 16.6 4.9 44.1 10.3 CDKN1B "KIP1, P27KIP1" ENSG00000111276 "Cyclin dependent kinase inhibitor 1B" P46527 12 12715058-12722371 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cell cycle" "Protein kinase inhibitor" "Cancer-related genes, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003691, CAB021888, HPA059086" Approved Supported Nucleoplasm,Vesicles Nucleoplasm Vesicles "CAB003691: AB_425362, CAB021888: , HPA059086: " "unprognostic (5.67e-2)" "unprognostic (9.76e-2)" "prognostic favourable (5.15e-4)" "unprognostic (6.90e-3)" "unprognostic (5.84e-3)" "unprognostic (1.03e-2)" "prognostic unfavourable (3.25e-4)" "unprognostic (4.04e-2)" "unprognostic (1.11e-1)" "unprognostic (2.85e-3)" "unprognostic (9.23e-3)" "unprognostic (2.96e-1)" "prognostic unfavourable (8.39e-4)" "unprognostic (1.23e-1)" "unprognostic (8.68e-2)" "unprognostic (2.88e-1)" "unprognostic (1.15e-1)" 29.8 30.9 30.2 25.0 30.0 40.2 45.3 64.5 50.6 31.6 34.4 35.6 19.9 29.2 33.1 19.8 26.0 24.3 24.3 21.2 33.0 29.5 20.8 23.3 29.2 38.5 42.9 25.1 46.2 15.1 22.2 15.9 26.8 26.3 25.1 22.2 31.4 23.5 24.2 48.8 26.1 26.4 19.4 46.0 34.3 19.4 19.2 39.0 43.0 29.4 21.4 25.5 34.1 29.1 6.2 3.3 19.2 4.5 6.2 10.6 2.9 12.8 6.4 34.3 5.9 11.8 6.7 16.8 12.1 19.2 16.7 20.6 18.3 14.6 0.1 4.6 6.9 12.3 16.0 5.9 15.0 21.8 11.3 10.0 17.6 18.4 15.8 8.5 7.1 7.4 12.8 5.5 16.1 9.9 10.7 36.7 5.9 16.5 11.9 12.2 13.7 6.0 8.8 11.2 21.5 8.0 13.9 13.0 21.4 17.3 12.5 22.6 6.6 19.1 6.7 8.3 13.2 7.5 11.7 31.8 21.0 11.6 10.3 12.8 8.0 4.5 3.1 6.8 5.4 3.1 5.6 6.2 6.9 6.5 3.2 4.8 7.4 5.2 19.2 6.2 4.5 3.3 10.6 2.9 30.2 30.0 64.5 50.6 33.0 29.5 42.9 25.1 26.3 39.0 CDKN1C "BWCR, BWS, KIP2, P57" ENSG00000129757 "Cyclin dependent kinase inhibitor 1C" P49918 11 2883213-2885773 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cell cycle" "Protein kinase inhibitor" "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 60.3;placenta: 105.6" "Cell line enhanced" "Detected in many" "EFO-21: 8.3;HeLa: 8.5;RPMI-8226: 11.2;SH-SY5Y: 22.8;SiHa: 15.9;SK-MEL-30: 8.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Group enriched" "Detected in some" 9 "intermediate monocyte: 26.1;non-classical monocyte: 60.3" "Lineage enriched" "Detected in many" 12 "monocytes: 60.3" HPA002924 Enhanced Approved "Nucleoplasm,Nuclear bodies,Cytosol" "Nucleoplasm, Nuclear bodies, Cytosol" "HPA002924: AB_1079548" "unprognostic (5.49e-3)" "unprognostic (2.62e-1)" "unprognostic (9.82e-3)" "unprognostic (5.79e-3)" "unprognostic (4.15e-1)" "unprognostic (2.84e-2)" "unprognostic (1.95e-2)" "unprognostic (1.85e-1)" "unprognostic (3.13e-1)" "unprognostic (3.15e-1)" "unprognostic (2.95e-1)" "unprognostic (3.39e-2)" "unprognostic (2.15e-1)" "unprognostic (3.31e-2)" "unprognostic (8.53e-2)" "unprognostic (1.93e-1)" "unprognostic (2.94e-1)" 53.6 20.7 3.3 5.4 11.9 3.4 13.0 0.9 9.2 10.6 6.9 18.4 3.9 3.3 8.3 5.2 9.9 8.5 7.7 6.9 8.5 5.4 22.7 3.0 5.1 1.8 28.7 4.9 30.9 7.9 1.5 4.0 105.6 11.5 7.2 1.9 8.3 3.1 5.9 27.6 3.0 7.9 6.3 27.9 7.1 7.4 4.3 14.5 0.3 2.0 7.6 2.1 11.2 9.8 0.0 5.0 1.4 60.3 0.0 0.3 2.5 0.1 0.0 1.1 0.0 0.3 0.3 1.2 0.2 0.4 0.2 0.0 2.2 0.2 0.0 8.3 0.1 0.3 0.2 0.2 0.1 3.7 0.8 0.1 8.5 0.0 2.3 0.0 1.0 1.7 1.1 0.0 0.1 0.2 1.8 0.6 0.3 0.0 0.0 3.9 7.4 2.7 1.4 0.0 11.2 0.4 0.0 2.4 22.8 15.9 0.2 8.7 0.1 1.8 0.3 0.0 1.5 0.0 0.0 4.8 0.0 0.0 0.0 1.2 4.5 1.4 0.2 0.2 0.1 26.1 0.3 0.0 0.1 0.1 5.0 0.0 0.2 0.0 0.3 0.0 60.3 0.0 0.1 2.5 3.3 11.9 0.9 5.6 8.5 5.4 28.7 4.9 11.5 14.5 CDKN2A "ARF, CDK4I, CDKN2, CMM2, INK4, INK4a, MLM, MTS1, p14, p14ARF, p16, p16INK4a, p19, p19Arf" ENSG00000147889 "Cyclin dependent kinase inhibitor 2A" "P42771, Q8N726" 9 21967753-21995301 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Apoptosis, Cell cycle, rRNA processing, Transcription, Transcription regulation, Ubl conjugation pathway" DNA-binding "Cancer-related genes, Disease mutation, Li-Fraumeni syndrome, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 22.6;pituitary gland: 39.3" "Cell line enhanced" "Detected in many" "CAPAN-2: 50.0;HEK 293: 56.7;HeLa: 53.1;SK-MEL-30: 53.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "T-reg: 22.6" "Group enriched" "Detected in many" 8 "B-cells: 7.2;T-cells: 22.6" "Low region specificity" "Detected in many" "CAB000093, CAB000445, CAB018232, HPA047838" Enhanced Supported Nucleoli Nucleoli "CAB000093: AB_442119, CAB000445: , CAB018232: AB_785018, HPA047838: " "unprognostic (3.41e-2)" "unprognostic (4.51e-2)" "unprognostic (3.00e-3)" "prognostic unfavourable (1.82e-7)" "unprognostic (5.22e-2)" "prognostic favourable (5.19e-4)" "prognostic unfavourable (2.17e-4)" "unprognostic (1.25e-2)" "unprognostic (1.05e-1)" "unprognostic (1.04e-1)" "unprognostic (1.71e-1)" "unprognostic (1.56e-2)" "prognostic unfavourable (5.76e-7)" "unprognostic (9.41e-2)" "unprognostic (1.22e-2)" "unprognostic (3.05e-2)" "unprognostic (3.55e-1)" 5.4 8.6 2.9 4.5 3.9 1.8 5.3 1.7 3.1 1.2 2.5 4.4 0.1 1.2 1.2 1.9 6.3 3.0 2.6 0.7 1.7 1.0 0.9 1.2 3.0 3.0 3.6 1.6 1.5 1.5 8.5 39.3 6.7 5.0 1.9 1.1 1.2 2.4 2.9 0.9 1.3 3.7 1.0 3.0 8.9 6.0 13.0 1.9 3.9 1.4 3.0 14.0 2.7 1.5 7.2 0.2 0.8 1.8 0.4 22.6 2.2 2.1 0.0 0.3 14.1 0.1 0.1 6.1 2.3 0.0 19.6 34.9 3.5 50.0 7.2 32.2 1.6 6.0 5.9 36.4 15.8 30.9 56.7 0.0 53.1 2.3 1.5 3.5 3.0 3.8 0.0 19.8 11.0 2.0 0.0 32.9 17.9 0.1 0.3 0.0 0.4 29.2 0.0 13.3 26.4 4.0 0.0 33.0 2.3 38.0 6.3 53.0 7.5 0.1 6.5 0.1 0.4 0.0 0.1 14.7 8.3 29.4 0.0 9.4 0.1 0.8 1.3 0.2 6.2 0.6 9.7 7.2 8.0 11.0 0.2 7.0 0.5 4.7 0.4 0.4 1.8 0.0 22.6 2.2 2.9 3.9 1.7 3.1 1.7 1.0 3.6 1.6 5.0 1.9 CDKN2C "INK4C, p18" ENSG00000123080 "Cyclin dependent kinase inhibitor 2C" P42773 1 50960745-50974633 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "U-937: 52.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB005303, CAB018398, HPA019057, HPA019764" Approved Approved Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "CAB005303: AB_2078729, CAB018398: AB_2078731, HPA019057: AB_1854865, HPA019764: AB_1854866" "unprognostic (4.07e-2)" "unprognostic (1.47e-3)" "unprognostic (2.89e-1)" "unprognostic (4.86e-2)" "unprognostic (6.70e-2)" "unprognostic (4.76e-3)" "prognostic unfavourable (1.58e-4)" "unprognostic (1.59e-2)" "unprognostic (1.59e-1)" "unprognostic (1.71e-1)" "unprognostic (2.28e-1)" "unprognostic (2.38e-1)" "prognostic unfavourable (1.70e-10)" "unprognostic (2.55e-2)" "unprognostic (2.12e-1)" "unprognostic (6.45e-2)" "unprognostic (1.24e-1)" 42.1 12.6 5.9 10.7 7.9 14.9 31.7 4.3 5.7 13.1 13.0 8.7 7.7 6.6 17.1 13.9 11.5 8.4 13.7 20.1 5.7 3.1 7.4 3.3 7.9 11.0 13.7 5.3 22.5 9.4 23.1 5.7 3.1 3.9 10.3 5.7 6.0 5.4 12.2 9.2 8.5 7.9 15.1 7.5 8.5 5.3 5.3 8.9 54.2 8.0 4.9 9.8 17.4 21.7 3.4 7.4 12.2 2.5 6.0 14.1 3.8 13.8 5.7 1.0 19.1 19.7 2.8 0.2 13.2 13.4 22.2 19.5 0.3 4.7 27.2 11.9 11.2 1.7 12.9 1.7 10.9 16.4 17.3 20.6 43.6 3.5 1.0 14.3 9.4 1.0 0.3 6.0 2.6 5.8 9.2 0.0 12.9 3.4 18.4 6.9 0.0 14.0 22.0 18.0 0.0 7.0 5.8 9.7 22.7 18.0 12.7 4.2 6.3 48.6 4.6 25.5 9.8 15.4 0.2 27.9 26.5 22.4 0.0 52.3 22.4 12.2 2.5 11.0 5.2 1.4 6.0 3.4 7.7 6.8 6.1 1.9 4.3 4.1 0.2 6.0 0.6 7.4 14.1 3.8 5.9 7.9 4.3 5.7 5.7 3.1 13.7 5.3 3.9 8.9 CDX2 CDX3 ENSG00000165556 "Caudal type homeobox 2" Q99626 13 27962137-27971139 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 12 "intestine: 21.2" "Group enriched" "Detected in some" 6 "CACO-2: 14.4;CAPAN-2: 4.8;HEK 293: 8.0" "Cancer enriched" "Detected in many" 6 "colorectal cancer: 63.7" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "CAB002221, HPA045669, HPA049580" Enhanced Enhanced Nucleoplasm Nucleoplasm "CAB002221: AB_563649, HPA045669: , HPA049580: " "unprognostic (1.42e-1)" "unprognostic (2.41e-1)" "unprognostic (2.92e-1)" "unprognostic (8.11e-3)" "unprognostic (4.19e-6)" "unprognostic (1.73e-4)" "unprognostic (1.71e-1)" "unprognostic (1.58e-1)" "unprognostic (5.51e-2)" "unprognostic (6.07e-3)" "unprognostic (1.13e-1)" "unprognostic (1.09e-1)" 0.0 0.0 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.0 21.2 13.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.1 14.3 0.0 0.0 0.0 0.0 16.3 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 14.4 4.8 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 8.0 0.0 0.2 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 CEACAM5 "CD66e, CEA" ENSG00000105388 "Carcinoembryonic antigen related cell adhesion molecule 5" P06731 19 41708585-41729798 "Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins" "Apoptosis, Cell adhesion" "Cancer-related genes, Oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "esophagus: 103.5;intestine: 118.2;lymphoid tissue: 100.6" "Cell line enriched" "Detected in some" 6 "HaCaT: 17.0" "Cancer enhanced" "Detected in many" "colorectal cancer: 1007.1" "Not detected" "Not detected" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in single" "CAB000021, CAB000022, HPA011041, HPA019758" Enhanced Supported "Plasma membrane" "Intracellular and membrane" 19000000 "Plasma membrane" "CAB000021: , CAB000022: AB_2335697, HPA011041: AB_1078481, HPA019758: AB_1846326" "unprognostic (1.54e-2)" "unprognostic (7.59e-2)" "unprognostic (5.49e-3)" "unprognostic (1.80e-1)" "unprognostic (1.38e-2)" "unprognostic (2.22e-1)" "unprognostic (3.49e-1)" "unprognostic (2.11e-1)" "unprognostic (2.19e-2)" "unprognostic (2.89e-1)" "unprognostic (8.67e-9)" "unprognostic (2.92e-1)" "unprognostic (2.71e-2)" "unprognostic (6.31e-2)" "unprognostic (1.85e-1)" 0.1 0.1 0.1 78.8 0.1 0.0 0.1 0.1 0.2 12.5 117.1 0.2 0.1 2.5 0.9 0.1 103.5 0.3 1.2 0.1 0.1 0.1 0.1 0.1 3.3 0.1 0.1 0.1 0.2 0.2 0.0 0.2 0.5 0.1 0.3 118.2 0.2 6.8 0.1 0.1 0.6 12.8 3.3 0.1 0.1 20.1 0.2 0.1 0.6 0.2 29.4 100.6 2.0 14.1 0.6 0.6 1.8 0.7 0.6 0.5 0.3 0.0 0.2 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.7 2.6 0.0 0.1 0.0 17.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 1.2 0.2 0.0 0.4 1.4 0.3 0.0 0.1 0.0 0.5 0.9 0.2 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.4 0.0 0.4 0.4 0.0 0.0 0.1 0.1 0.2 1.2 0.3 0.8 0.3 0.2 0.1 0.5 0.2 0.3 0.6 0.6 0.4 0.5 1.8 0.6 0.7 0.5 0.3 0.3 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 CEACAM6 "CD66c, NCA" ENSG00000086548 "Carcinoembryonic antigen related cell adhesion molecule 6" P40199 19 41750977-41772208 "Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Apoptosis, Cell adhesion" "Cancer-related genes, Oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "esophagus: 81.4;gallbladder: 75.7;lung: 129.1" "Cell line enriched" "Detected in some" 8 "A549: 57.9" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "neutrophil: 2.6" "Group enriched" "Detected in many" 6 "granulocytes: 2.6;monocytes: 1.3" "CAB008370, HPA011041" Enhanced 79000000 "CAB008370: AB_592067, HPA011041: AB_1078481" "unprognostic (1.00e-2)" "unprognostic (2.05e-1)" "unprognostic (2.62e-2)" "unprognostic (8.22e-2)" "unprognostic (1.39e-1)" "unprognostic (9.06e-3)" "unprognostic (2.32e-2)" "unprognostic (1.37e-1)" "unprognostic (2.49e-1)" "unprognostic (5.22e-2)" "unprognostic (3.70e-3)" "unprognostic (1.93e-1)" "unprognostic (2.42e-4)" "unprognostic (4.08e-1)" "unprognostic (8.71e-3)" "unprognostic (2.85e-1)" "unprognostic (7.68e-2)" 0.3 0.3 0.3 7.4 0.3 29.7 0.3 0.3 0.3 16.8 35.3 0.2 0.1 5.8 0.9 0.2 81.4 1.1 75.7 2.3 0.3 0.3 0.3 0.8 129.1 0.1 0.3 0.1 0.3 1.7 0.0 0.3 32.1 0.2 0.9 43.1 0.2 50.1 0.1 0.3 2.1 12.8 0.9 0.3 0.8 2.6 0.3 0.1 1.0 0.3 25.3 58.1 2.3 21.0 0.1 0.3 2.6 1.3 0.1 0.3 5.2 0.0 57.9 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 1.9 1.6 0.0 0.0 0.0 6.9 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.3 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 3.9 0.0 0.0 0.1 1.6 0.0 0.0 0.0 0.3 0.2 0.6 0.0 0.0 1.5 0.0 0.2 0.6 0.1 0.0 0.1 0.2 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.3 0.1 0.3 1.3 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 2.6 0.1 0.5 0.3 0.0 5.2 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.1 0.2 0.1 CEBPA "C/EBP-alpha, CEBP" ENSG00000245848 "CCAAT/enhancer binding protein alpha" P49715 19 33299934-33302564 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Host-virus interaction, Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "breast: 52.3;liver: 44.3" "Cell line enhanced" "Detected in some" "BEWO: 42.6;Hep G2: 22.8;NB-4: 23.5;THP-1: 85.0;U-937: 27.2" "Cancer enhanced" "Detected in all" "liver cancer: 70.6" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "basophil: 11.0;non-classical monocyte: 11.8" "Group enriched" "Detected in many" 13 "dendritic cells: 4.1;granulocytes: 11.0;monocytes: 11.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA052734, HPA065037, HPA067937" Approved Approved Nucleoplasm,Vesicles Nucleoplasm Vesicles "HPA052734: , HPA065037: , HPA067937: " "unprognostic (1.80e-1)" "unprognostic (7.62e-3)" "unprognostic (2.09e-3)" "unprognostic (2.21e-2)" "unprognostic (3.38e-1)" "unprognostic (3.99e-2)" "unprognostic (1.94e-1)" "unprognostic (2.43e-3)" "unprognostic (5.95e-2)" "unprognostic (3.96e-2)" "unprognostic (3.09e-1)" "unprognostic (9.45e-2)" "unprognostic (8.02e-3)" "unprognostic (2.19e-1)" "unprognostic (1.98e-1)" "unprognostic (2.49e-2)" "unprognostic (2.72e-2)" 40.7 1.5 2.3 7.6 4.6 8.4 52.3 2.1 4.0 3.5 9.0 5.2 1.1 9.0 2.2 2.1 6.1 2.4 6.4 6.6 3.9 2.4 2.0 44.3 39.9 10.3 4.1 3.1 1.3 9.0 4.5 1.7 17.4 2.7 3.8 5.1 1.9 5.6 1.6 15.4 23.7 12.7 2.9 6.6 3.0 3.5 1.2 2.6 2.2 2.5 10.7 3.5 5.4 7.9 0.1 4.1 11.0 11.8 0.0 0.6 1.5 0.5 1.0 0.0 1.5 12.3 0.0 42.6 0.0 0.3 0.0 0.0 5.1 0.0 0.0 0.6 0.0 1.9 1.2 0.1 0.0 7.3 1.5 0.0 0.0 22.8 0.2 7.5 9.1 0.4 5.5 0.0 0.0 0.0 0.4 0.0 0.0 2.6 0.0 23.5 1.0 0.5 0.0 0.0 0.2 0.0 3.7 0.0 0.3 0.1 0.1 0.1 2.9 85.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 27.2 0.0 11.0 6.0 0.0 0.6 9.4 0.6 0.0 0.1 0.4 4.1 0.1 0.2 0.4 2.1 0.0 11.8 0.2 0.0 1.5 2.3 4.6 2.1 4.0 3.9 2.4 4.1 3.1 2.7 2.6 CENPF hcp-1 ENSG00000117724 "Centromere protein F" P49454 1 214603195-214664588 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division, Differentiation, DNA synthesis, Mitosis, Myogenesis" "Developmental protein" "Cancer-related genes, Ciliopathy, Primary ciliary dyskinesia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "bone marrow: 19.5;lymphoid tissue: 67.5" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in some" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in single" "Not detected" "Not detected" "Low region specificity" "Detected in single" "HPA052382, HPA064308, CAB070134" Enhanced Supported Nucleoplasm Nucleoplasm "CAB070134: AB_2229328, HPA052382: , HPA064308: " "unprognostic (2.80e-1)" "unprognostic (2.16e-1)" "unprognostic (2.65e-1)" "unprognostic (5.30e-2)" "unprognostic (1.73e-1)" "unprognostic (2.40e-2)" "prognostic unfavourable (2.29e-5)" "unprognostic (1.13e-2)" "unprognostic (2.58e-3)" "unprognostic (1.11e-1)" "prognostic unfavourable (1.39e-4)" "unprognostic (1.58e-1)" "prognostic unfavourable (0.00e+0)" "unprognostic (3.92e-2)" "unprognostic (1.71e-1)" "unprognostic (1.89e-2)" "unprognostic (4.12e-1)" 1.6 1.5 1.0 10.7 1.3 19.5 1.1 0.4 0.9 2.1 5.6 0.3 0.0 4.6 1.2 1.7 9.4 0.8 0.4 1.7 0.6 0.6 1.0 0.8 3.2 6.2 0.6 0.5 1.4 0.6 0.0 0.4 6.4 0.8 0.7 4.5 0.4 1.9 0.0 0.5 4.7 6.4 1.6 1.5 3.8 2.3 9.4 0.6 67.5 0.6 7.6 7.6 1.4 2.9 0.3 0.3 0.0 0.0 0.7 1.9 0.2 32.2 18.3 39.5 20.6 1.5 2.0 15.4 20.0 8.2 12.0 11.9 14.5 20.0 30.8 11.9 11.1 20.1 24.3 13.1 20.5 26.8 15.3 25.3 28.1 20.7 0.2 35.7 13.8 0.7 1.0 17.3 20.0 12.6 22.7 18.4 21.5 12.3 21.1 14.3 35.0 8.1 22.5 55.8 10.1 11.8 8.0 18.5 25.2 27.0 18.0 10.4 21.5 13.7 16.5 21.9 25.8 18.1 41.3 14.2 15.3 29.6 9.5 25.8 19.3 0.0 0.0 0.0 0.4 0.0 0.1 0.2 1.4 0.4 0.3 0.3 1.9 0.8 0.0 0.7 0.0 0.3 1.7 0.2 1.0 1.3 0.4 0.9 0.6 0.6 0.6 0.5 0.8 0.6 CEP76 "C18orf9, FLJ12542, HsT1705" ENSG00000101624 "Centrosomal protein 76" Q8TAP6 18 12661833-12702777 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Region enriched" "Detected in many" 11 "cerebellum: 70.6" HPA039395 Approved "HPA039395: AB_10673357" "unprognostic (3.39e-1)" "unprognostic (2.99e-2)" "unprognostic (2.26e-1)" "unprognostic (9.31e-3)" "unprognostic (1.65e-1)" "unprognostic (1.37e-1)" "unprognostic (2.57e-4)" "unprognostic (2.99e-1)" "unprognostic (4.00e-4)" "unprognostic (7.88e-3)" "unprognostic (2.45e-1)" "unprognostic (8.70e-2)" "unprognostic (1.67e-2)" "unprognostic (4.39e-2)" "unprognostic (2.37e-1)" "unprognostic (5.70e-2)" "unprognostic (8.21e-2)" 6.1 7.5 6.2 6.8 9.9 10.4 7.9 18.6 10.2 7.8 5.9 4.4 5.2 5.3 7.0 11.0 12.0 5.9 5.4 5.4 5.4 6.3 6.5 9.6 5.6 7.1 5.3 9.1 7.9 6.7 6.5 9.9 6.9 8.8 6.0 8.3 5.0 8.2 7.9 11.4 10.3 6.4 7.1 5.3 6.1 6.8 18.4 5.9 15.7 7.6 6.0 9.3 7.0 7.4 4.4 3.6 3.5 7.1 6.0 6.6 3.7 5.8 6.1 10.4 5.0 6.1 3.3 10.1 6.9 8.0 13.8 10.7 13.8 7.2 8.0 6.3 4.5 4.8 10.0 4.5 11.9 4.9 8.3 7.2 7.4 11.8 4.7 16.0 8.3 2.6 4.5 8.1 5.3 7.2 11.7 12.2 8.9 4.5 14.1 11.6 7.6 4.1 10.0 9.0 8.6 7.2 6.0 7.8 7.0 8.8 5.7 5.6 4.1 9.1 6.7 9.4 19.0 9.0 8.3 6.9 11.8 9.4 4.7 8.1 6.1 0.8 3.9 3.5 4.9 7.1 6.6 3.4 5.3 5.8 3.6 4.4 5.3 6.0 1.4 6.0 2.9 2.0 5.8 3.7 6.2 9.9 18.6 10.2 5.4 6.3 5.3 9.1 8.8 5.9 CFH "ARMD4, ARMS1, FHL1, HF, HF1, HF2, HUS" ENSG00000000971 "Complement factor H" P08603 1 196651878-196747504 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins" "Complement alternate pathway, Host-virus interaction, Immunity, Innate immunity" "Age-related macular degeneration, Cancer-related genes, Disease mutation, Hemolytic uremic syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "liver: 295.2" "Cell line enhanced" "Detected in many" "ASC diff: 25.2;HHSteC: 31.8;HSkMC: 31.0;RH-30: 23.2;RT4: 56.3" "Cancer enriched" "Detected in all" 9 "liver cancer: 151.1" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "MAIT T-cell: 16.5" "Lineage enriched" "Detected in single" 27 "T-cells: 16.5" "CAB016385, CAB016769, HPA038922, HPA049176, HPA053326" Supported Approved Vesicles "Secreted to blood" 395836666667 110000000000 Vesicles "CAB016385: AB_627572, CAB016769: , HPA038922: , HPA049176: , HPA053326: " "unprognostic (2.40e-1)" "unprognostic (9.86e-2)" "unprognostic (1.22e-1)" "unprognostic (8.39e-2)" "unprognostic (5.40e-3)" "unprognostic (1.80e-1)" "unprognostic (3.75e-3)" "unprognostic (7.40e-2)" "unprognostic (1.06e-1)" "unprognostic (1.04e-1)" "unprognostic (9.08e-2)" "unprognostic (2.08e-1)" "prognostic unfavourable (1.92e-6)" "unprognostic (6.50e-3)" "unprognostic (4.49e-3)" "unprognostic (1.73e-1)" "unprognostic (1.37e-1)" 28.6 5.5 1.6 3.7 3.8 0.1 8.8 2.6 2.7 10.4 9.1 1.0 3.9 3.7 2.5 8.7 15.2 3.4 17.0 47.3 2.0 1.2 7.0 295.2 11.0 10.3 5.3 1.7 40.9 1.9 1.7 4.3 5.1 5.3 10.3 10.4 6.3 19.0 3.3 10.0 11.5 8.1 12.6 4.2 3.3 5.8 6.4 2.9 0.7 22.0 22.8 5.8 17.2 16.8 0.0 0.1 0.6 0.1 0.0 16.5 1.0 0.0 16.1 0.0 0.0 25.2 14.3 0.0 6.5 15.9 0.9 3.5 0.0 3.0 0.0 2.4 0.0 0.5 0.0 5.9 0.6 0.3 0.0 4.8 19.1 0.0 31.8 0.2 0.0 31.0 0.1 4.7 2.0 19.8 18.1 0.6 22.5 0.0 0.1 0.0 0.1 0.0 0.0 23.2 5.1 0.0 56.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 1.4 19.2 0.2 0.2 0.2 0.2 0.0 0.0 3.4 0.0 1.4 0.0 0.1 0.0 1.8 0.0 16.5 0.0 6.0 3.5 0.1 0.0 0.4 1.4 0.6 0.0 0.0 0.0 0.0 1.0 1.6 3.8 2.6 2.7 2.0 1.2 5.3 1.7 5.3 2.9 CFHR1 "CFHL, CFHL1, CFHL1P, CFHR1P, FHR1, H36-1, H36-2, HFL1, HFL2" ENSG00000244414 "Complement factor H related 1" Q03591 1 196819757-196832189 "Cancer-related genes, Plasma proteins, Predicted secreted proteins" "Cancer-related genes, Hemolytic uremic syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 174 "liver: 218.9" "Cell line enhanced" "Detected in some" "ASC diff: 2.6;HeLa: 3.1;HL-60: 4.7;U-266/70: 6.2" "Cancer enriched" "Detected in single" 798 "liver cancer: 182.4" "Not detected" "Not detected" "Not detected" "Not detected" "HPA038915, HPA038922, HPA040726" Supported Approved Vesicles "Secreted to blood" 15000000000 Vesicles "HPA038915: , HPA038922: , HPA040726: " "unprognostic (2.28e-1)" "unprognostic (3.18e-1)" "unprognostic (3.50e-2)" "unprognostic (1.88e-2)" "prognostic favourable (8.71e-6)" "unprognostic (3.02e-1)" "unprognostic (3.70e-1)" "unprognostic (2.50e-1)" "unprognostic (8.48e-2)" "unprognostic (7.21e-4)" "unprognostic (7.01e-4)" "unprognostic (1.13e-1)" "unprognostic (6.41e-2)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 218.9 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.7 0.1 0.0 0.0 0.3 0.2 2.6 1.0 0.0 0.0 0.1 0.0 0.4 0.0 0.1 0.2 0.0 0.6 0.5 0.0 0.0 0.0 0.0 0.0 1.6 3.1 0.2 0.2 4.7 0.8 0.1 0.0 0.0 0.0 0.1 0.3 2.3 0.8 0.0 1.4 0.0 0.8 0.0 0.8 2.0 0.0 0.0 0.3 0.0 0.1 0.9 0.0 0.2 0.4 0.0 1.4 0.9 0.4 0.2 0.2 6.2 0.0 1.1 0.0 0.4 0.9 0.0 0.0 0.0 0.1 0.0 0.7 0.0 0.3 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.1 CFLAR "c-FLIP, CASH, CASP8AP1, Casper, CLARP, FLAME, FLIP, I-FLICE, MRIT" ENSG00000003402 "CASP8 and FADD like apoptosis regulator" O15519 2 201116104-201176687 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Apoptosis, Host-virus interaction" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "U-266/70: 54.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in all" 5 "neutrophil: 79.2" "Lineage enriched" "Detected in all" 6 "granulocytes: 79.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019044, CAB022157, CAB025216" Uncertain Supported "Nucleoplasm,Nuclear bodies,Plasma membrane,Cytosol" "Nucleoplasm, Plasma membrane, Cytosol" "Nuclear bodies" "CAB022157: , CAB025216: , HPA019044: AB_10696204" "unprognostic (4.61e-2)" "unprognostic (5.32e-2)" "unprognostic (2.49e-1)" "unprognostic (1.44e-1)" "unprognostic (2.95e-2)" "prognostic favourable (2.79e-4)" "unprognostic (7.46e-2)" "unprognostic (9.01e-2)" "unprognostic (1.76e-1)" "unprognostic (6.12e-2)" "unprognostic (3.08e-2)" "unprognostic (4.91e-2)" "unprognostic (2.90e-2)" "unprognostic (7.83e-2)" "unprognostic (9.13e-2)" "unprognostic (6.84e-2)" "unprognostic (2.24e-2)" 35.4 17.6 13.7 29.8 17.4 66.8 31.6 26.9 12.6 20.5 25.7 13.5 31.3 17.5 24.7 27.6 21.0 19.2 22.1 58.1 14.7 7.7 24.9 18.9 58.5 34.3 16.8 8.9 14.6 14.3 9.1 18.7 28.3 12.6 23.2 17.7 20.9 21.8 27.4 113.7 16.7 26.8 30.5 13.8 35.7 19.4 10.9 14.8 17.2 31.2 26.2 31.4 24.1 33.7 5.3 6.6 79.2 12.6 8.7 11.8 7.8 5.1 10.6 7.6 4.5 23.6 18.1 9.4 13.1 22.9 8.7 10.6 12.2 19.4 1.4 12.5 15.2 3.8 2.4 9.9 13.9 38.8 7.4 7.8 9.1 19.8 16.5 5.8 25.9 19.7 9.8 14.6 12.9 44.0 26.3 32.7 15.7 4.3 2.7 23.2 2.6 8.0 2.8 1.8 11.1 10.8 10.7 1.7 3.0 8.8 7.8 10.3 5.5 10.9 47.7 18.2 7.6 6.7 6.4 54.5 17.9 8.7 12.9 4.7 9.0 16.3 12.1 13.5 11.7 12.3 10.3 5.3 10.1 11.0 6.6 4.0 6.4 8.3 79.2 8.7 12.6 4.6 11.8 7.8 13.7 17.4 26.9 12.6 14.7 7.7 16.8 8.9 12.6 14.8 CFTR "ABC35, ABCC7, CF, CFTR/MRP, dJ760C5.1, MRP7, TNR-CFTR" ENSG00000001626 "Cystic fibrosis transmembrane conductance regulator" P13569 7 117465784-117715971 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Ion channel, Isomerase" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 4 "pancreas: 103.0" "Group enriched" "Detected in some" 22 "CACO-2: 12.5;MOLT-4: 47.0;U-266/70: 25.7" "Cancer enhanced" "Detected in many" "colorectal cancer: 23.9;pancreatic cancer: 28.0" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in some" "Region enriched" "Detected in many" 5 "olfactory region: 6.3" "CAB001951, HPA021939" Enhanced "CAB001951: , HPA021939: AB_1846578" "unprognostic (6.38e-3)" "unprognostic (9.55e-2)" "unprognostic (1.77e-2)" "unprognostic (1.44e-2)" "unprognostic (8.74e-2)" "unprognostic (8.57e-2)" "prognostic unfavourable (9.44e-4)" "unprognostic (3.20e-3)" "unprognostic (1.13e-1)" "unprognostic (8.89e-2)" "unprognostic (1.55e-2)" "unprognostic (2.14e-2)" "unprognostic (4.78e-3)" "unprognostic (1.24e-1)" "unprognostic (2.58e-1)" "unprognostic (9.08e-2)" "unprognostic (6.64e-2)" 0.4 0.2 0.4 10.5 0.4 0.0 0.3 0.3 0.3 2.5 19.8 0.1 0.8 10.5 0.6 2.1 0.4 0.4 15.8 0.3 0.4 0.3 1.1 1.4 5.7 0.1 0.5 0.1 0.3 103.0 0.0 0.3 0.1 0.1 1.5 12.5 0.1 22.4 0.1 0.3 1.1 24.2 0.3 0.7 0.3 0.6 0.9 0.1 0.1 0.3 0.2 0.3 0.4 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 12.5 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 47.0 0.0 0.8 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 25.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.4 0.3 0.3 0.4 0.3 0.5 0.1 0.1 0.1 CGA "FSHA, GPHa, GPHA1, HCG, LHA, TSHA" ENSG00000135346 "Glycoprotein hormones, alpha polypeptide" P01215 6 87085498-87095406 "Cancer-related genes, Plasma proteins, Predicted secreted proteins" Hormone "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 62 "pituitary gland: 398.8;placenta: 489.3" "Cell line enriched" "Detected in some" 19 "BEWO: 105.3" "Cancer enhanced" "Detected in many" "testis cancer: 13.0" "Not detected" "Not detected" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Not detected" "Not detected" "Region enriched" "Detected in single" 11 "hypothalamus: 69.2" "CAB023350, HPA029698" Enhanced "Secreted to blood" "CAB023350: AB_617281, HPA029698: " "unprognostic (1.66e-1)" "unprognostic (2.10e-1)" "unprognostic (3.22e-5)" "unprognostic (1.46e-2)" "unprognostic (1.51e-1)" "unprognostic (2.69e-2)" "unprognostic (3.17e-1)" "unprognostic (7.04e-3)" "unprognostic (1.51e-1)" "unprognostic (2.85e-1)" "unprognostic (4.32e-2)" "unprognostic (8.32e-2)" "unprognostic (9.15e-3)" 0.1 0.1 0.0 0.1 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.1 3.1 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.0 398.8 489.3 0.2 0.1 0.0 0.0 0.1 0.1 0.2 0.2 0.0 0.6 0.0 0.1 7.1 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 2.2 1.9 3.5 1.5 1.1 2.1 0.2 0.0 0.2 0.0 0.0 0.0 0.0 105.3 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.5 0.2 0.0 5.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 3.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.5 0.0 0.1 0.0 0.0 0.0 2.3 1.1 1.0 1.7 0.5 0.7 1.3 0.8 1.4 0.6 2.2 1.2 2.1 3.5 1.1 1.5 1.9 0.6 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 CHCHD7 "COX23, MGC2217" ENSG00000170791 "Coiled-coil-helix-coiled-coil-helix domain containing 7" Q9BUK0 8 56211686-56218798 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" HPA050783 Approved Approved "Cell Junctions,Aggresome" "Cell Junctions" Aggresome "HPA050783: " "unprognostic (1.64e-2)" "unprognostic (3.23e-2)" "unprognostic (3.18e-2)" "prognostic unfavourable (1.39e-6)" "unprognostic (4.46e-2)" "unprognostic (2.43e-1)" "unprognostic (5.04e-2)" "unprognostic (8.38e-3)" "unprognostic (1.62e-1)" "unprognostic (9.03e-2)" "unprognostic (2.24e-1)" "unprognostic (1.15e-1)" "prognostic favourable (9.47e-5)" "unprognostic (1.94e-1)" "unprognostic (5.07e-1)" "unprognostic (1.77e-2)" "unprognostic (2.50e-1)" 16.6 14.8 24.1 19.6 29.4 17.6 18.9 27.1 23.3 17.6 20.7 18.3 22.8 22.5 13.1 34.3 15.7 17.6 12.3 27.0 21.0 19.5 23.4 18.0 19.4 24.4 27.0 16.0 36.3 20.0 22.5 48.3 13.3 26.7 19.2 21.3 19.2 34.5 18.0 23.2 14.6 26.2 14.8 32.0 33.0 17.7 7.6 24.8 27.4 19.8 18.3 24.9 15.5 16.4 31.0 33.6 26.2 20.6 24.2 31.1 17.3 18.8 6.0 13.5 4.4 36.0 25.6 14.0 13.5 12.7 10.8 8.1 15.4 23.1 17.8 11.9 7.9 10.6 14.0 20.7 13.4 7.7 26.9 27.2 14.4 21.3 18.3 23.2 17.5 30.5 19.1 7.6 34.2 11.2 13.3 11.7 25.3 9.4 23.1 34.4 11.9 8.7 26.6 4.1 14.8 19.8 20.4 3.5 2.3 7.1 11.0 10.0 11.5 13.0 16.2 5.7 12.1 18.3 12.6 12.4 12.6 29.7 16.0 34.5 9.7 21.5 20.6 26.2 23.2 19.0 22.5 31.0 26.0 23.6 22.8 26.4 31.1 27.8 7.9 24.2 16.6 33.6 29.7 17.3 24.1 29.4 27.1 23.3 21.0 19.5 27.0 16.0 26.7 24.8 CHD4 "Mi-2b, Mi2-BETA" ENSG00000111642 "Chromodomain helicase DNA binding protein 4" Q14839 12 6570082-6614524 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Transcription, Transcription regulation" "Chromatin regulator, DNA-binding, Helicase, Hydrolase" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA012008 Supported Enhanced Nucleoplasm Nucleoplasm "HPA012008: AB_1846633" "unprognostic (6.11e-2)" "unprognostic (2.26e-2)" "unprognostic (1.71e-2)" "unprognostic (6.40e-3)" "unprognostic (8.99e-2)" "unprognostic (3.36e-3)" "prognostic unfavourable (6.03e-6)" "unprognostic (2.66e-2)" "unprognostic (1.05e-1)" "unprognostic (6.85e-2)" "unprognostic (3.15e-1)" "unprognostic (3.94e-1)" "unprognostic (2.06e-1)" "unprognostic (3.33e-1)" "unprognostic (1.82e-1)" "unprognostic (9.84e-2)" "unprognostic (1.66e-1)" 23.5 34.9 21.9 50.0 33.5 27.2 25.9 29.4 25.1 28.1 29.5 29.3 38.5 18.6 37.2 35.4 29.1 28.0 40.3 52.8 23.5 19.2 29.5 25.0 25.5 30.9 33.6 19.4 34.6 27.4 58.4 25.3 29.5 27.2 21.5 26.0 26.5 24.8 46.2 33.7 31.1 24.4 36.6 30.3 29.4 27.2 29.7 28.9 75.7 38.4 33.7 38.4 34.7 24.3 12.6 16.8 12.8 9.1 13.5 16.7 5.8 20.5 18.7 46.5 17.4 19.1 21.5 27.3 22.8 22.2 25.2 23.2 31.2 16.0 44.2 9.1 25.7 18.4 43.6 25.1 34.0 33.0 22.4 61.7 29.1 19.5 16.6 48.4 29.6 20.7 12.5 24.3 17.1 29.3 48.5 22.1 23.9 25.7 45.9 15.8 44.5 17.7 39.4 28.6 24.1 15.9 24.3 22.0 28.3 29.3 32.6 22.6 14.9 27.6 27.2 25.7 54.8 18.8 26.6 35.8 21.3 56.4 17.0 29.6 18.8 9.0 7.7 9.2 12.2 9.1 12.0 10.5 10.3 11.1 7.9 12.6 13.0 12.3 12.8 13.5 8.1 16.8 16.7 5.8 21.9 33.5 29.4 25.1 23.5 19.2 33.6 19.4 27.2 28.9 CHD7 "CRG, FLJ20357, FLJ20361, KIAA1416" ENSG00000171316 "Chromodomain helicase DNA binding protein 7" Q9P2D1 8 60678778-60868028 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "rRNA processing, Transcription, Transcription regulation" "Chromatin regulator, DNA-binding, Helicase, Hydrolase" "Cancer-related genes, Disease mutation, Hypogonadotropic hypogonadism, Kallmann syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 47.1" "Cell line enhanced" "Detected in many" "AF22: 25.8;SCLC-21H: 23.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Group enriched" "Detected in many" 15 "B-cells: 12.2;granulocytes: 12.6;T-cells: 5.5" "Low region specificity" "Detected in many" "Region enriched" "Detected in all" 4 "cerebellum: 110.3" HPA053075 Supported Nucleoplasm,Nucleoli Nucleoplasm Nucleoli "HPA053075: " "unprognostic (3.77e-2)" "unprognostic (3.28e-3)" "unprognostic (3.17e-2)" "prognostic unfavourable (5.34e-5)" "unprognostic (9.59e-2)" "unprognostic (1.14e-1)" "unprognostic (1.86e-3)" "unprognostic (3.41e-2)" "unprognostic (3.06e-1)" "unprognostic (2.73e-1)" "unprognostic (2.46e-1)" "unprognostic (1.33e-1)" "unprognostic (9.09e-2)" "unprognostic (9.21e-2)" "unprognostic (1.75e-1)" "unprognostic (8.20e-2)" "unprognostic (2.17e-1)" 3.9 2.2 7.0 7.9 11.2 25.1 4.1 47.1 9.0 2.3 5.7 13.4 3.1 5.9 2.6 3.2 5.1 3.2 3.1 4.1 8.1 4.3 3.6 3.6 4.7 7.0 8.1 3.3 1.4 6.4 12.4 9.9 5.6 9.9 2.9 5.5 6.4 5.7 2.8 10.3 5.7 6.6 2.4 7.5 6.1 4.5 4.3 12.2 1.6 5.4 2.2 7.3 2.9 5.9 12.2 0.6 12.6 0.6 0.0 5.5 0.4 3.8 1.9 25.8 4.5 0.0 0.0 8.1 0.2 0.0 0.9 0.8 4.8 3.6 7.5 0.4 0.0 2.3 13.2 3.8 0.8 2.8 7.1 17.6 3.2 6.3 1.1 5.3 3.3 0.5 2.9 0.0 4.3 3.8 1.3 6.7 0.6 3.9 8.3 6.0 17.7 0.9 17.3 6.1 2.4 2.0 4.4 23.6 11.7 0.7 2.9 7.2 5.2 5.0 4.4 0.2 4.2 0.2 2.1 7.1 4.1 11.7 1.5 0.6 6.6 10.4 0.3 12.6 2.6 0.1 3.3 8.0 2.9 0.9 0.1 12.2 5.5 2.0 7.1 0.0 0.6 0.6 0.2 0.4 7.0 11.2 47.1 6.5 8.1 4.3 8.1 3.3 9.9 12.2 CHD8 "DUPLIN, HELSNF1, KIAA1564" ENSG00000100888 "Chromodomain helicase DNA binding protein 8" Q9HCK8 14 21385194-21456126 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Transcription, Transcription regulation, Wnt signaling pathway" "Activator, Chromatin regulator, DNA-binding, Helicase, Hydrolase, Repressor" "Autism, Autism spectrum disorder, Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA052186, HPA076133" Enhanced "Nucleoplasm,Plasma membrane" Nucleoplasm "Plasma membrane" "HPA052186: , HPA076133: " "unprognostic (3.45e-1)" "unprognostic (9.71e-2)" "unprognostic (3.31e-1)" "unprognostic (2.67e-1)" "unprognostic (1.14e-1)" "unprognostic (3.43e-1)" "prognostic unfavourable (4.94e-4)" "unprognostic (7.31e-2)" "unprognostic (9.22e-2)" "prognostic favourable (8.35e-4)" "unprognostic (1.64e-1)" "unprognostic (2.63e-2)" "unprognostic (2.54e-3)" "unprognostic (2.88e-1)" "unprognostic (9.24e-2)" "unprognostic (2.51e-1)" "unprognostic (8.07e-3)" 13.9 14.5 13.0 14.8 21.5 34.8 17.0 28.9 25.7 15.8 14.4 26.6 14.1 11.1 18.3 13.4 17.4 15.9 11.7 12.3 13.5 13.3 14.0 11.2 15.5 18.5 15.4 15.2 20.7 19.0 34.7 25.3 15.2 20.3 16.3 14.6 19.3 15.7 14.9 16.9 24.5 16.4 17.2 13.1 19.2 16.1 15.2 18.1 29.9 17.4 10.4 24.8 16.6 14.5 12.3 7.8 12.8 7.4 8.7 8.6 3.0 16.2 21.3 23.6 11.0 15.1 13.1 13.4 12.9 14.9 19.7 19.7 18.5 14.1 26.9 8.2 17.3 20.0 28.9 18.2 25.0 20.6 13.2 23.6 14.3 22.4 14.0 32.6 22.5 17.6 14.8 22.1 15.9 17.5 16.4 14.4 14.9 17.5 23.4 13.3 18.0 18.1 22.0 17.9 9.1 14.6 30.1 17.3 16.6 20.3 15.8 11.2 11.1 15.8 20.5 16.4 12.6 9.6 15.3 16.4 19.5 26.9 6.6 12.1 16.3 12.8 4.8 12.1 7.7 5.0 8.6 5.8 6.8 7.5 3.3 12.3 7.4 6.4 11.0 8.7 7.4 7.8 5.7 3.0 13.0 21.5 28.9 25.7 13.5 13.3 15.4 15.2 20.3 18.1 CHEK1 CHK1 ENSG00000149554 "Checkpoint kinase 1" O14757 11 125625136-125676255 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, DNA damage, DNA repair" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "ductus deferens: 80.0;seminal vesicle: 66.8" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "T-reg: 11.7" "Lineage enriched" "Detected in many" 6 "T-cells: 11.7" "Low region specificity" "Detected in single" HPA044364 Supported Nucleoplasm,Vesicles Nucleoplasm Vesicles "HPA044364: " "unprognostic (6.74e-2)" "unprognostic (3.63e-1)" "prognostic favourable (3.62e-4)" "unprognostic (5.54e-2)" "unprognostic (2.17e-1)" "unprognostic (1.03e-1)" "prognostic unfavourable (3.70e-6)" "unprognostic (3.95e-3)" "unprognostic (1.26e-3)" "unprognostic (2.54e-2)" "prognostic unfavourable (3.10e-6)" "unprognostic (1.75e-1)" "prognostic unfavourable (1.04e-8)" "unprognostic (2.89e-2)" "unprognostic (2.64e-1)" "unprognostic (8.16e-2)" "unprognostic (1.33e-1)" 3.0 2.5 2.5 9.0 2.8 14.9 2.1 1.1 2.2 2.5 5.2 1.3 80.0 5.0 1.9 10.2 6.5 1.7 3.6 1.5 2.4 2.4 3.7 2.0 1.8 9.6 3.0 1.2 3.8 4.0 25.5 3.5 3.8 1.5 2.9 6.3 1.6 2.6 66.8 1.2 2.9 5.2 2.3 3.0 3.6 2.8 7.2 1.5 22.4 1.8 4.5 8.8 3.8 3.3 1.9 1.8 1.9 0.7 1.2 11.7 1.0 12.7 10.4 23.4 14.2 4.8 10.3 10.2 17.9 8.6 11.5 12.4 25.4 28.3 33.4 18.5 7.0 15.4 14.3 9.4 14.2 20.9 6.6 61.9 8.7 13.0 1.5 31.6 11.8 5.3 2.0 14.5 10.3 13.6 31.3 29.4 15.1 6.6 46.9 15.5 23.7 9.4 28.6 21.9 17.5 10.6 17.0 14.8 15.7 14.7 10.2 4.3 27.5 10.3 9.1 16.6 14.1 8.0 16.4 6.6 11.8 47.6 6.1 23.8 19.4 1.9 0.5 0.3 1.3 0.7 1.2 1.9 3.5 1.6 1.1 1.5 3.3 2.0 0.4 1.2 0.4 1.8 11.7 1.0 2.5 2.8 1.1 2.2 2.4 2.4 3.0 1.2 1.5 1.5 CHEK2 "bA444G7, CDS1, CHK2, HuCds1, PP1425, RAD53" ENSG00000183765 "Checkpoint kinase 2" O96017 22 28687743-28742422 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Apoptosis, Cell cycle, Cell division, DNA damage, DNA repair, Mitosis, Transcription, Transcription regulation" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, Li-Fraumeni syndrome, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA001878, CAB002030" Enhanced Supported "Nucleoplasm,Golgi apparatus" Nucleoplasm "Golgi apparatus" "CAB002030: AB_563660, HPA001878: AB_1078514" "unprognostic (1.54e-1)" "unprognostic (2.20e-1)" "unprognostic (5.83e-2)" "unprognostic (2.93e-2)" "unprognostic (2.42e-1)" "unprognostic (3.83e-2)" "unprognostic (1.49e-3)" "unprognostic (5.08e-3)" "unprognostic (3.33e-3)" "unprognostic (9.62e-3)" "unprognostic (1.28e-2)" "unprognostic (3.13e-1)" "prognostic unfavourable (7.80e-9)" "unprognostic (2.38e-2)" "unprognostic (1.78e-1)" "unprognostic (7.27e-2)" "unprognostic (6.79e-3)" 5.6 8.3 2.5 13.0 7.0 13.7 5.6 0.7 5.6 6.6 9.8 2.5 4.8 6.8 4.8 10.9 10.0 4.3 6.0 6.0 4.1 2.3 5.3 6.5 7.9 10.1 6.7 1.6 12.9 6.7 1.2 4.2 10.1 5.1 8.3 10.6 8.7 7.0 5.8 2.2 6.3 8.5 5.4 5.0 9.8 5.8 9.7 3.6 13.1 7.5 4.8 13.7 6.2 6.7 11.8 8.7 6.5 8.4 2.9 4.4 3.7 14.7 4.7 13.5 16.7 3.8 19.2 8.7 7.3 8.6 9.7 14.2 12.0 10.1 17.4 6.2 5.1 14.2 20.5 13.4 11.3 12.4 15.7 22.9 9.0 19.8 3.8 14.5 16.8 8.1 6.2 12.4 11.0 10.7 13.8 15.2 9.0 20.7 11.6 23.3 19.0 12.0 25.3 9.2 20.3 6.0 6.1 7.9 4.5 8.1 14.5 8.0 9.9 13.4 3.7 7.8 9.3 6.8 3.8 9.2 16.2 34.0 7.4 15.2 9.9 6.5 3.7 1.2 1.1 8.4 2.3 11.8 2.2 2.1 8.7 8.4 4.4 2.8 0.3 2.9 4.1 7.0 2.8 3.7 2.5 7.0 0.7 5.6 4.1 2.3 6.7 1.6 5.1 3.6 CHFR "FLJ10796, RNF196" ENSG00000072609 "Checkpoint with forkhead and ring finger domains" Q96EP1 12 132822187-132956304 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division, Mitosis, Ubl conjugation pathway" Transferase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA045768, HPA073826" Approved Uncertain "Nuclear bodies,Microtubules" "Nuclear bodies, Microtubules" "HPA045768: , HPA073826: " "unprognostic (1.46e-1)" "unprognostic (2.11e-2)" "unprognostic (1.41e-1)" "unprognostic (3.86e-2)" "unprognostic (2.08e-1)" "unprognostic (2.14e-3)" "unprognostic (6.56e-4)" "unprognostic (1.94e-2)" "unprognostic (2.36e-2)" "unprognostic (1.25e-1)" "unprognostic (1.00e-2)" "unprognostic (3.98e-3)" "prognostic unfavourable (4.21e-9)" "unprognostic (5.03e-1)" "unprognostic (8.46e-2)" "unprognostic (6.71e-2)" "unprognostic (1.11e-2)" 13.7 11.4 14.1 19.0 15.0 25.8 12.5 20.0 16.9 12.1 15.2 16.5 13.4 19.0 15.6 16.7 21.6 12.6 14.3 13.7 12.5 9.8 12.8 13.4 17.0 21.7 15.1 12.6 9.6 16.8 9.6 20.6 22.9 13.0 14.3 12.8 15.5 13.9 14.7 21.0 16.7 18.7 17.8 15.1 24.9 16.8 19.2 14.2 22.3 13.5 12.7 18.4 18.6 14.2 6.6 12.1 19.7 17.0 12.3 12.5 10.1 4.4 10.8 9.1 0.8 8.0 10.7 17.0 9.1 7.6 9.7 10.1 8.5 3.8 0.1 8.8 10.6 7.1 1.1 9.2 5.6 0.6 9.6 14.4 7.4 8.6 17.5 0.6 25.0 14.4 8.4 8.8 6.6 11.8 6.1 0.0 6.7 14.8 10.4 11.2 10.9 8.6 1.4 1.3 4.4 6.4 20.9 8.9 11.4 7.5 7.7 7.0 13.8 14.9 13.2 0.6 2.2 5.0 3.3 15.9 0.0 2.1 0.0 3.0 8.7 17.6 14.2 19.7 10.8 16.9 10.0 6.6 8.7 11.6 12.1 4.5 8.3 9.1 18.9 12.3 17.0 6.6 12.5 10.1 14.1 15.0 20.0 16.9 12.5 9.8 15.1 12.6 13.0 14.2 CHGA ENSG00000100604 "Chromogranin A" P10645 14 92923080-92935293 "Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins" "Antibiotic, Antimicrobial, Fungicide" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "parathyroid gland: 577.6" "Group enriched" "Detected in some" 134 "SCLC-21H: 43.3;SH-SY5Y: 117.9" "Cancer enhanced" "Detected in many" "pancreatic cancer: 114.8" "Region enhanced" "Detected in many" "cerebral cortex: 97.9" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB000023, HPA017369, CAB040544, CAB055506, CAB058688" Enhanced Supported Vesicles "Intracellular and membrane" 78000000 Vesicles "CAB000023: , CAB040544: , CAB055506: AB_2081135, CAB058688: , HPA017369: AB_1846698" "prognostic favourable (7.85e-5)" "unprognostic (4.89e-2)" "unprognostic (5.96e-2)" "unprognostic (1.17e-1)" "unprognostic (1.43e-2)" "unprognostic (5.95e-2)" "prognostic unfavourable (2.40e-4)" "unprognostic (1.74e-1)" "unprognostic (2.23e-1)" "unprognostic (4.56e-2)" "prognostic favourable (4.07e-4)" "unprognostic (1.85e-1)" "unprognostic (8.81e-13)" "unprognostic (1.07e-2)" "unprognostic (1.77e-1)" "unprognostic (9.17e-2)" "prognostic unfavourable (3.99e-4)" 2.0 81.9 6.6 3.1 18.7 1.3 1.3 0.5 97.9 1.9 36.1 4.0 0.0 15.8 1.3 1.3 1.2 1.3 1.3 1.2 11.2 14.0 1.3 1.2 1.4 1.2 8.0 36.1 1.2 15.9 577.6 81.1 1.2 17.1 2.0 7.9 0.4 1.3 1.3 1.2 1.3 38.8 1.3 2.5 1.3 51.9 32.5 0.7 0.0 5.9 0.0 1.2 1.3 0.2 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 43.3 117.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 6.6 18.7 0.5 97.9 11.2 14.0 8.0 36.1 17.1 0.7 CHI3L1 "GP39, YKL40" ENSG00000133048 "Chitinase 3 like 1" P36222 1 203178931-203186749 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Apoptosis, Inflammatory response" Antimicrobial "Asthma, Cancer-related genes, Schizophrenia" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "liver: 336.4" "Cell line enhanced" "Detected in some" "ASC diff: 39.8;ASC TERT1: 88.7;HSkMC: 78.7;THP-1: 125.5;U-138 MG: 37.2;U-87 MG: 37.1" "Cancer enriched" "Detected in all" 8 "glioma: 1313.7" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 490 "neutrophil: 81.3" "Lineage enriched" "Detected in single" 490 "granulocytes: 81.3" "Low region specificity" "Detected in all" "Region enriched" "Detected in single" 13 "olfactory region: 10.7" HPA077365 Approved "Golgi apparatus" "Secreted to blood" 25100000 230000000 "Golgi apparatus" "HPA077365: " "unprognostic (2.11e-3)" "unprognostic (1.21e-1)" "unprognostic (1.29e-1)" "unprognostic (1.07e-1)" "unprognostic (6.01e-3)" "unprognostic (8.81e-2)" "unprognostic (2.09e-1)" "unprognostic (1.48e-1)" "unprognostic (4.46e-2)" "unprognostic (1.30e-1)" "unprognostic (7.98e-2)" "unprognostic (1.43e-1)" "unprognostic (1.20e-2)" "unprognostic (1.98e-2)" "unprognostic (3.43e-2)" "unprognostic (1.14e-2)" "unprognostic (9.39e-3)" 19.0 0.8 20.3 53.4 58.0 81.6 23.9 1.2 69.4 4.3 2.1 5.0 0.0 0.9 4.3 25.5 3.5 10.2 1.9 2.6 9.1 17.8 11.9 336.4 10.0 12.4 32.3 3.6 4.5 2.5 0.8 22.9 4.7 66.4 1.5 1.6 9.1 19.3 1.1 10.5 10.0 2.2 3.3 23.5 2.9 1.7 3.4 6.5 0.9 2.0 1.7 14.6 61.5 4.0 0.0 0.0 81.3 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 39.8 88.7 0.0 0.0 0.0 0.0 0.0 8.8 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 1.0 0.0 0.0 78.7 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.6 0.3 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 125.5 0.0 37.2 0.1 0.0 0.0 0.2 4.7 0.0 37.1 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 81.3 0.0 0.1 0.0 0.0 0.1 20.3 58.0 1.2 28.9 9.1 17.8 32.3 3.6 66.4 6.5 CHP2 ENSG00000166869 "Calcineurin like EF-hand protein 2" O43745 16 23754627-23758951 "Cancer-related genes, Predicted intracellular proteins" "Protein transport, Transport" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 8 "intestine: 105.8;skin 1: 36.8" "Cell line enhanced" "Detected in many" "hTERT-HME1: 9.2;NB-4: 10.6" "Cancer enhanced" "Detected in many" "colorectal cancer: 10.4" "Low region specificity" "Detected in single" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" CAB072806 Approved "CAB072806: " "unprognostic (4.82e-1)" "unprognostic (3.40e-1)" "unprognostic (4.93e-2)" "unprognostic (1.01e-2)" "unprognostic (8.85e-2)" "unprognostic (3.54e-1)" "unprognostic (4.54e-2)" "unprognostic (1.47e-1)" "unprognostic (1.38e-1)" "unprognostic (5.31e-2)" "unprognostic (4.70e-2)" "unprognostic (1.44e-5)" "unprognostic (2.21e-1)" "unprognostic (5.97e-2)" "unprognostic (7.84e-2)" "unprognostic (9.01e-2)" 0.3 0.0 0.3 8.8 0.5 0.0 0.5 0.4 0.7 2.3 37.4 0.7 0.8 54.8 0.4 0.6 0.4 0.1 0.3 0.3 0.3 0.1 0.5 0.3 0.5 0.3 1.2 0.3 0.3 0.3 0.0 0.3 0.8 0.8 1.4 26.2 0.4 0.6 0.5 0.3 36.8 105.8 0.9 0.9 0.3 0.0 2.9 0.6 0.5 0.3 0.5 0.4 6.2 1.4 1.5 1.3 2.5 0.9 0.4 0.9 0.1 1.2 2.7 0.9 0.8 1.7 1.7 1.6 3.6 1.4 0.6 1.3 0.8 2.9 0.6 1.2 3.1 1.8 0.6 3.5 0.8 0.8 0.3 0.6 5.1 2.1 2.1 0.5 0.9 1.2 1.1 3.2 9.2 1.5 1.5 1.3 1.6 0.2 0.1 10.6 0.5 2.6 0.3 0.2 1.7 1.4 1.5 0.8 1.0 1.1 0.3 0.1 0.3 0.2 1.6 0.7 1.0 1.0 0.2 0.6 0.2 0.3 0.0 0.7 0.7 1.2 0.9 0.2 0.9 0.5 0.5 0.7 0.6 0.7 0.4 1.5 0.9 0.8 2.5 0.4 0.5 1.3 0.3 0.1 0.3 0.5 0.4 0.7 0.3 0.1 1.2 0.3 0.8 0.6 CIB2 "DFNB48, KIP2, USH1J" ENSG00000136425 "Calcium and integrin binding family member 2" O75838 15 78104606-78131544 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Deafness, Disease mutation, Non-syndromic deafness, Retinitis pigmentosa, Usher syndrome" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "heart muscle: 45.5;intestine: 48.5" "Cell line enhanced" "Detected in many" "AN3-CA: 21.0;HAP1: 18.4;NTERA-2: 15.3;SCLC-21H: 19.0;SH-SY5Y: 20.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 51 "plasmacytoid DC: 16.1" "Lineage enriched" "Detected in single" 51 "dendritic cells: 16.1" "Low region specificity" "Detected in all" HPA036697 Approved "HPA036697: AB_10672475" "unprognostic (5.77e-2)" "unprognostic (1.83e-2)" "unprognostic (2.81e-2)" "prognostic unfavourable (7.05e-4)" "unprognostic (1.46e-1)" "unprognostic (2.57e-1)" "unprognostic (1.11e-2)" "unprognostic (6.73e-3)" "unprognostic (1.66e-1)" "unprognostic (9.94e-3)" "unprognostic (3.18e-1)" "unprognostic (7.49e-2)" "prognostic favourable (6.16e-4)" "unprognostic (9.78e-2)" "unprognostic (1.01e-1)" "unprognostic (1.68e-1)" "unprognostic (7.64e-3)" 5.8 8.8 9.7 3.4 6.7 1.2 6.0 5.1 8.2 9.6 11.0 3.5 2.8 16.0 6.1 3.2 4.2 4.3 3.2 45.5 7.2 6.8 7.0 0.8 1.9 3.3 6.9 4.9 6.9 13.0 9.2 7.1 4.8 9.1 7.9 6.3 4.2 6.8 8.2 6.3 4.2 48.5 7.5 4.1 3.7 2.7 13.4 2.0 35.0 3.0 1.9 5.4 6.0 7.9 0.0 16.1 0.1 0.0 0.0 0.3 0.1 1.8 4.1 11.8 21.0 0.5 0.7 9.0 1.2 0.4 1.0 2.1 0.0 4.6 0.2 2.4 5.4 1.0 18.4 3.6 0.3 10.4 13.2 1.2 0.7 0.6 2.1 0.0 1.7 1.1 1.6 1.7 1.0 2.1 4.2 0.1 1.9 0.3 0.5 0.2 15.3 0.1 7.8 0.0 0.5 1.3 0.4 19.0 20.0 3.1 1.5 1.6 0.3 1.2 0.1 0.0 10.2 1.1 0.1 0.2 0.2 3.4 0.5 0.0 2.6 0.0 0.0 0.0 0.3 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.1 0.2 0.1 0.0 0.0 16.1 0.0 0.1 9.7 6.7 5.1 8.2 7.2 6.8 6.9 4.9 9.1 2.0 CIC KIAA0306 ENSG00000079432 "Capicua transcriptional repressor" Q96RK0 19 42268537-42295797 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Repressor" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB026388, HPA044341, HPA064725" Approved Supported Nucleoplasm,Vesicles Nucleoplasm Vesicles "CAB026388: , HPA044341: , HPA064725: " "unprognostic (2.02e-2)" "unprognostic (4.08e-1)" "unprognostic (1.41e-2)" "unprognostic (3.54e-3)" "unprognostic (3.67e-1)" "unprognostic (4.17e-3)" "unprognostic (1.49e-1)" "unprognostic (2.06e-1)" "unprognostic (4.87e-1)" "unprognostic (1.85e-2)" "unprognostic (1.72e-3)" "unprognostic (3.10e-1)" "unprognostic (4.23e-2)" "unprognostic (1.00e-1)" "unprognostic (2.38e-1)" "unprognostic (1.88e-2)" "unprognostic (1.56e-1)" 18.6 15.7 30.5 22.8 29.9 28.1 20.3 46.8 31.6 17.5 14.7 24.7 13.0 16.5 28.6 12.3 12.3 22.1 17.4 12.1 25.5 15.2 14.9 15.1 15.8 21.5 25.2 20.1 31.5 22.6 16.6 22.6 13.2 20.4 14.4 6.2 19.0 23.8 20.8 21.0 34.1 16.1 16.3 16.5 24.7 14.5 31.5 25.6 13.6 16.8 10.6 13.4 13.6 17.4 2.3 2.0 5.0 2.6 0.6 2.5 1.6 17.6 32.0 12.3 16.9 8.0 15.1 6.0 13.5 11.3 11.4 10.6 9.0 10.9 12.3 12.9 10.6 8.6 6.8 20.4 3.7 29.8 9.2 10.3 20.2 10.7 10.1 5.8 29.4 18.0 12.0 12.9 7.6 10.4 10.1 25.9 6.4 16.8 11.4 11.1 7.7 18.2 9.8 10.5 7.3 9.5 16.6 15.9 13.1 12.8 8.0 10.1 9.5 12.5 19.9 27.3 22.2 9.3 16.4 21.5 14.8 8.4 21.2 9.2 16.1 3.4 1.8 1.0 2.5 2.6 1.9 1.7 1.3 1.6 1.7 2.3 0.9 1.5 5.0 0.6 1.9 2.0 0.5 1.6 30.5 29.9 46.8 31.6 25.5 15.2 25.2 20.1 20.4 25.6 CIITA "C2TA, MHC2TA, NLRA" ENSG00000179583 "Class II major histocompatibility complex transactivator" P33076 16 10866222-10943021 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Transcription, Transcription regulation" "Activator, Acyltransferase, Kinase, Transferase" "Cancer-related genes, Disease mutation, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 67.2" "Cell line enhanced" "Detected in some" "HDLM-2: 22.8;REH: 40.0;U-698: 11.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB016084, HPA054757" Enhanced Supported Nucleoplasm Nucleoplasm "CAB016084: AB_627261, HPA054757: " "unprognostic (1.45e-3)" "unprognostic (1.38e-2)" "unprognostic (8.22e-3)" "unprognostic (1.12e-2)" "unprognostic (5.66e-2)" "unprognostic (2.88e-3)" "unprognostic (2.92e-2)" "unprognostic (1.55e-2)" "unprognostic (1.15e-2)" "unprognostic (1.85e-1)" "unprognostic (1.23e-1)" "unprognostic (3.72e-1)" "unprognostic (1.64e-2)" "unprognostic (2.72e-2)" "unprognostic (6.33e-3)" "unprognostic (2.74e-1)" "unprognostic (1.05e-2)" 8.0 5.9 4.6 47.7 7.1 4.3 6.8 1.5 5.5 6.3 3.7 10.6 4.2 10.4 8.1 10.4 4.8 5.2 8.1 4.9 4.7 3.5 8.8 2.9 15.0 27.0 9.4 1.1 2.5 3.5 1.9 4.0 1.2 6.6 5.5 4.3 5.5 13.3 4.3 2.9 4.4 17.4 3.7 15.6 25.9 6.2 1.5 7.4 12.6 6.1 5.2 67.2 6.3 6.8 27.3 19.0 6.5 11.9 0.7 0.5 1.7 0.1 0.2 0.3 0.3 0.1 0.0 0.2 0.1 0.0 0.1 0.1 0.3 5.5 5.0 0.8 0.0 0.9 0.0 0.0 0.1 22.8 0.2 2.9 1.0 0.6 0.0 0.4 0.4 1.0 0.0 0.1 0.0 0.0 0.3 2.0 0.1 0.3 0.2 0.4 0.1 0.1 40.0 0.3 3.5 0.0 1.6 0.9 0.1 0.9 0.3 0.9 0.5 1.6 0.3 2.1 0.3 0.6 0.2 8.4 0.6 11.8 7.5 0.5 6.8 0.2 11.9 6.5 0.3 9.5 0.1 17.9 0.1 0.5 17.7 27.3 0.1 0.2 2.8 0.7 10.0 19.0 0.4 1.7 4.6 7.1 1.5 5.5 4.7 3.5 9.4 1.1 6.6 7.4 CKB CKBB ENSG00000166165 "Creatine kinase B" P12277 14 103519659-103523111 "Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Kinase, Transferase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 158.5" "Cell line enhanced" "Detected in many" "CACO-2: 53.1;HEK 293: 135.1;SCLC-21H: 76.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in some" 10 "non-classical monocyte: 50.0" "Lineage enriched" "Detected in many" 17 "monocytes: 50.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001254, CAB047313" Enhanced Supported Cytosol 50000000 Cytosol "CAB047313: , HPA001254: AB_1078528" "unprognostic (9.97e-2)" "unprognostic (1.33e-3)" "unprognostic (4.25e-3)" "unprognostic (1.10e-1)" "unprognostic (7.63e-2)" "unprognostic (3.62e-2)" "unprognostic (1.64e-1)" "unprognostic (1.30e-1)" "unprognostic (4.24e-1)" "unprognostic (4.60e-2)" "unprognostic (2.68e-3)" "unprognostic (9.89e-3)" "prognostic favourable (4.02e-8)" "unprognostic (2.62e-1)" "unprognostic (1.10e-1)" "unprognostic (1.67e-2)" "unprognostic (2.13e-1)" 32.4 27.3 75.4 10.4 114.6 3.1 5.3 94.3 158.5 29.1 121.5 51.4 23.8 17.6 37.3 8.9 28.6 35.7 17.8 36.4 60.7 43.2 26.7 3.4 12.8 3.6 63.4 93.3 15.8 10.2 20.3 9.7 3.7 63.3 107.5 55.0 43.9 18.3 92.1 19.1 14.4 17.5 53.2 31.9 3.6 66.7 22.1 50.9 0.0 19.8 7.8 3.9 43.0 13.0 0.0 2.9 1.4 50.0 0.0 0.1 0.9 0.3 6.7 26.9 1.4 0.2 0.2 0.5 2.9 0.0 0.3 0.1 53.1 0.8 0.0 3.2 2.0 5.9 7.8 0.1 0.0 1.2 135.1 10.0 29.7 18.2 1.1 0.0 8.2 1.0 0.0 0.2 0.1 0.0 17.4 0.4 0.4 2.2 0.2 0.3 10.5 21.0 1.7 0.5 27.6 4.9 0.2 76.9 31.6 5.7 0.9 2.1 2.5 4.1 0.1 0.1 5.2 0.5 12.6 1.3 0.3 0.9 0.7 0.2 0.9 0.3 0.1 1.4 0.0 5.1 0.0 0.0 0.0 0.0 2.9 0.0 0.0 0.1 0.1 0.0 50.0 0.0 0.1 0.9 75.4 114.6 94.3 152.7 60.7 43.2 63.4 93.3 63.3 50.9 CKS1B "CKS1, ckshs1" ENSG00000173207 "CDC28 protein kinase regulatory subunit 1B" P61024 1 154974653-154979249 "Cancer-related genes, Predicted intracellular proteins" "Cell cycle, Cell division" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "HPA003424, HPA030762" Approved Approved Nucleoplasm,Vesicles,Mitochondria,Cytosol "Mitochondria, Cytosol" "Nucleoplasm, Vesicles" "HPA003424: , HPA030762: AB_10670044" "unprognostic (1.06e-2)" "unprognostic (1.62e-1)" "unprognostic (2.84e-1)" "prognostic unfavourable (7.89e-4)" "unprognostic (1.34e-1)" "unprognostic (2.59e-2)" "prognostic unfavourable (2.94e-5)" "unprognostic (2.01e-3)" "prognostic unfavourable (3.12e-5)" "unprognostic (3.63e-2)" "prognostic unfavourable (6.13e-4)" "unprognostic (3.19e-1)" "prognostic unfavourable (6.03e-7)" "unprognostic (3.12e-2)" "unprognostic (1.44e-1)" "prognostic favourable (4.87e-4)" "unprognostic (1.37e-1)" 25.3 14.5 13.5 13.4 19.0 36.4 24.8 4.2 14.6 15.6 17.4 12.4 19.8 14.7 14.7 13.8 28.2 15.2 14.1 16.5 15.3 8.0 16.6 29.5 12.9 23.8 29.5 8.8 14.2 12.8 8.3 9.4 35.6 15.9 11.7 18.8 7.5 12.8 13.1 5.9 22.6 22.9 12.5 19.8 18.0 14.7 22.8 21.5 30.2 15.5 19.3 25.5 11.1 23.3 23.9 30.4 2.2 32.8 9.0 12.2 8.7 59.4 82.1 61.5 33.3 8.9 9.1 49.2 27.7 21.5 60.1 48.2 79.3 88.0 56.7 47.4 18.3 55.2 61.0 39.7 56.5 50.9 39.5 38.3 36.5 55.7 2.7 46.1 35.3 5.3 17.2 51.4 71.3 30.1 62.2 77.1 45.2 59.2 43.2 35.6 78.0 74.1 43.5 50.7 72.6 21.4 21.8 25.1 63.4 41.9 39.7 45.8 53.1 64.6 16.8 39.1 40.5 32.2 65.9 47.6 92.3 80.0 24.8 39.3 53.9 0.7 4.4 2.2 7.0 26.0 8.4 23.9 9.9 9.5 7.2 22.6 12.2 11.5 0.6 9.0 32.8 30.4 10.6 8.7 13.5 19.0 4.2 14.6 15.3 8.0 29.5 8.8 15.9 21.5 CKS2 ENSG00000123975 "CDC28 protein kinase regulatory subunit 2" P33552 9 89311198-89316703 "Cancer-related genes, Predicted intracellular proteins" "Cell cycle, Cell division" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 54.6;testis: 103.2" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "plasmacytoid DC: 54.6" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA003424, HPA030762" Approved Approved Nucleoplasm,Vesicles,Mitochondria,Cytosol "Mitochondria, Cytosol" "Nucleoplasm, Vesicles" "HPA003424: , HPA030762: AB_10670044" "unprognostic (8.30e-2)" "unprognostic (3.00e-1)" "unprognostic (1.50e-2)" "unprognostic (2.80e-2)" "unprognostic (2.96e-1)" "unprognostic (1.35e-1)" "prognostic unfavourable (2.51e-6)" "unprognostic (3.57e-3)" "unprognostic (7.04e-2)" "unprognostic (1.34e-2)" "prognostic unfavourable (6.85e-4)" "unprognostic (1.24e-2)" "prognostic unfavourable (1.78e-5)" "unprognostic (2.13e-3)" "unprognostic (1.44e-1)" "unprognostic (2.84e-1)" "unprognostic (1.84e-1)" 4.8 22.4 4.2 22.7 6.1 38.1 10.7 4.0 7.5 3.6 10.8 3.0 16.7 10.8 4.6 4.4 20.4 2.8 4.7 3.3 6.1 3.2 11.0 10.2 9.5 24.6 5.2 4.3 3.9 2.6 7.0 2.2 12.4 5.0 4.8 10.7 3.2 4.4 7.6 3.6 6.1 9.3 4.1 5.4 12.6 6.8 103.2 3.6 41.6 4.6 13.5 20.8 8.1 16.7 18.3 54.6 12.4 7.5 11.6 17.9 6.5 86.6 74.3 45.5 30.4 13.4 12.2 33.2 51.6 27.9 57.2 45.8 30.5 43.0 64.9 30.6 19.3 61.0 54.5 39.7 65.8 50.6 44.1 32.9 54.4 80.9 5.8 67.0 37.5 4.4 9.2 40.9 36.2 52.9 39.2 56.9 73.2 65.0 52.6 118.1 66.4 68.6 45.6 50.0 38.7 44.9 19.9 38.5 22.9 42.8 41.6 41.6 50.1 39.0 30.0 24.7 47.0 59.7 75.0 46.1 93.5 52.4 36.5 38.8 35.2 10.5 5.9 12.4 7.0 7.5 7.9 18.3 9.6 6.7 6.5 13.5 5.2 6.8 4.2 11.6 4.1 54.6 17.9 6.5 4.2 6.1 4.0 7.5 6.1 3.2 5.2 4.3 5.0 3.6 CLDN3 "C7orf1, CPE-R2, CPETR2, HRVP1, RVP1" ENSG00000165215 "Claudin 3" O15551 7 73768997-73770270 "Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters" "Cancer-related genes, Williams-Beuren syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 100.4;thyroid gland: 91.6" "Cell line enhanced" "Detected in some" "MCF7: 65.0;PC-3: 13.9;RPMI-8226: 11.1;SCLC-21H: 17.2;T-47d: 30.9" "Low cancer specificity" "Detected in many" "Group enriched" "Detected in some" 7 "cerebellum: 3.1;pons and medulla: 3.0" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA014361 Enhanced Supported "Cell Junctions" 15000 "Cell Junctions" "HPA014361: " "unprognostic (1.84e-1)" "unprognostic (4.83e-2)" "unprognostic (2.05e-1)" "unprognostic (5.27e-2)" "unprognostic (2.61e-1)" "unprognostic (1.31e-1)" "unprognostic (2.79e-2)" "unprognostic (8.26e-2)" "unprognostic (3.11e-1)" "unprognostic (1.46e-1)" "unprognostic (2.28e-3)" "unprognostic (1.42e-1)" "prognostic favourable (3.39e-5)" "unprognostic (1.46e-2)" "unprognostic (1.87e-1)" "unprognostic (5.18e-2)" "unprognostic (6.72e-2)" 0.3 0.1 0.1 11.5 0.1 0.2 7.1 3.1 0.2 3.8 77.9 1.6 21.8 24.3 2.8 8.8 0.3 9.4 11.3 0.1 0.2 0.4 20.7 16.0 6.0 0.2 0.0 0.0 4.3 38.0 0.2 7.4 3.1 3.0 14.6 8.0 1.9 31.1 32.1 0.1 2.1 100.4 0.5 0.0 0.1 0.7 1.2 0.0 2.2 91.6 0.9 3.6 0.8 0.4 0.2 0.0 0.1 0.0 0.0 0.1 0.5 0.7 1.0 0.0 0.1 0.0 0.0 5.2 0.0 0.0 0.0 0.0 1.2 10.3 0.0 2.9 0.0 0.3 0.1 0.0 0.0 0.0 1.4 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 65.0 0.1 0.3 0.6 13.9 0.0 0.0 11.1 0.6 0.0 17.2 0.2 0.0 9.9 0.0 30.9 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.5 0.1 0.1 3.1 0.2 0.2 0.4 0.0 0.0 3.0 0.0 CLDN4 "CPE-R, CPETR, CPETR1, hCPE-R, WBSCR8" ENSG00000189143 "Claudin 4" O14493 7 73799542-73832693 "Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Ion channel" "Cancer-related genes, Williams-Beuren syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "thyroid gland: 141.0" "Cell line enhanced" "Detected in some" "A-431: 43.1;BEWO: 50.7;CAPAN-2: 94.7;MCF7: 48.3;PC-3: 61.7;RT4: 41.7;SK-BR-3: 80.3" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in single" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" CAB002610 Enhanced Supported "Plasma membrane" "Plasma membrane" "CAB002610: " "unprognostic (1.14e-1)" "unprognostic (2.79e-2)" "unprognostic (2.25e-1)" "unprognostic (1.23e-2)" "unprognostic (1.56e-2)" "unprognostic (1.84e-1)" "unprognostic (1.60e-2)" "unprognostic (7.09e-2)" "unprognostic (3.07e-1)" "prognostic unfavourable (3.28e-4)" "unprognostic (2.16e-3)" "unprognostic (5.11e-1)" "prognostic favourable (3.46e-10)" "unprognostic (5.77e-2)" "unprognostic (1.37e-1)" "unprognostic (9.38e-2)" "unprognostic (4.63e-2)" 0.7 0.2 0.4 17.1 0.4 0.0 17.1 0.4 0.5 17.5 53.7 0.7 23.2 25.0 5.1 15.9 62.3 15.4 15.4 0.5 0.4 0.3 30.2 2.0 28.8 0.4 0.4 0.4 5.5 32.4 2.7 3.5 78.1 1.3 31.8 24.7 0.7 52.0 25.7 0.6 35.3 93.3 2.7 0.4 0.4 2.7 2.5 0.4 3.8 141.0 60.9 55.7 38.5 21.0 0.1 0.1 0.2 0.1 0.1 0.6 0.0 43.1 0.5 0.0 0.2 0.0 0.0 50.7 0.4 0.0 0.0 0.0 22.5 94.7 0.0 3.5 0.0 23.8 0.0 0.0 0.0 0.0 0.0 0.0 2.6 15.2 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 48.3 0.0 0.2 0.0 61.7 0.0 0.8 1.0 11.6 41.7 10.1 0.2 0.0 80.3 0.1 31.4 0.1 0.0 0.1 1.8 0.4 0.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.1 0.1 0.0 0.1 0.0 0.2 0.0 0.1 0.0 0.6 0.2 0.1 0.0 0.1 0.0 0.0 0.4 0.4 0.4 0.5 0.4 0.3 0.4 0.4 1.3 0.4 CLDN7 "CEPTRL2, CPETRL2, Hs.84359" ENSG00000181885 "Claudin 7" O95471 17 7259903-7263983 "Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 166.7" "Cell line enhanced" "Detected in some" "BEWO: 26.6;CACO-2: 27.7;CAPAN-2: 53.9;HaCaT: 113.3;MCF7: 39.4;SK-BR-3: 47.2" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "CAB013063, HPA014703, HPA073662" Enhanced Approved "Vesicles,Cell Junctions" Vesicles "Cell Junctions" "CAB013063: , HPA014703: AB_1846873, HPA073662: " "unprognostic (5.47e-2)" "unprognostic (2.22e-1)" "unprognostic (4.12e-2)" "unprognostic (2.90e-1)" "unprognostic (1.05e-1)" "unprognostic (8.67e-2)" "unprognostic (3.41e-2)" "unprognostic (1.98e-2)" "unprognostic (5.64e-3)" "unprognostic (8.34e-2)" "unprognostic (4.89e-3)" "unprognostic (1.62e-2)" "prognostic favourable (8.96e-11)" "prognostic favourable (4.09e-4)" "unprognostic (1.87e-1)" "prognostic favourable (1.85e-4)" "unprognostic (1.62e-1)" 1.6 2.0 0.4 28.0 0.4 0.0 9.5 0.4 0.4 9.9 71.4 0.4 47.6 47.2 2.4 49.3 73.4 13.4 47.2 0.7 0.4 0.3 30.0 12.1 32.3 0.8 0.4 0.4 3.4 70.9 12.3 7.3 25.0 0.4 9.8 42.5 0.7 40.9 42.2 0.9 2.9 166.7 1.8 0.5 1.4 1.2 1.8 0.4 1.5 40.5 28.3 45.6 12.2 19.3 3.8 1.6 0.0 3.0 2.2 6.7 2.3 3.2 0.3 0.0 0.0 0.0 0.2 26.6 0.0 0.0 0.0 0.0 27.7 53.9 0.0 1.0 0.1 113.3 0.0 3.4 0.0 0.0 0.6 0.0 0.7 0.0 2.1 0.0 0.2 0.5 5.4 0.0 0.2 2.5 0.3 0.1 0.0 39.4 0.0 0.3 0.1 1.0 0.0 0.0 0.7 0.0 0.0 6.5 0.1 0.3 47.2 0.0 17.2 0.4 5.2 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 1.0 0.0 2.2 3.0 4.8 0.5 1.5 3.3 1.6 3.8 3.7 6.7 0.0 2.2 0.1 0.2 0.9 2.3 0.4 0.4 0.4 0.4 0.4 0.3 0.4 0.4 0.4 0.4 CLEC3B "TN, TNA" ENSG00000163815 "C-type lectin domain family 3 member B" P05452 3 45001548-45036071 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "breast: 185.2;lung: 216.5" "Cell line enhanced" "Detected in some" "ASC diff: 50.0;ASC TERT1: 99.6;U-2197: 20.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002582, HPA034794" Approved "Secreted to blood" 6540000000 46000000000 "CAB002582: AB_564027, HPA034794: " "unprognostic (2.04e-1)" "unprognostic (1.80e-3)" "unprognostic (2.58e-1)" "unprognostic (4.57e-2)" "unprognostic (7.75e-2)" "prognostic favourable (1.53e-4)" "prognostic favourable (9.99e-9)" "unprognostic (1.75e-2)" "unprognostic (2.25e-1)" "unprognostic (4.02e-1)" "prognostic favourable (5.68e-4)" "unprognostic (9.33e-2)" "unprognostic (2.39e-2)" "unprognostic (7.46e-2)" "unprognostic (1.39e-1)" "unprognostic (5.54e-2)" "unprognostic (4.21e-2)" 70.8 11.5 6.6 16.9 8.9 0.5 185.2 5.9 10.2 17.4 20.3 4.8 39.0 8.4 15.7 54.2 17.2 6.9 38.8 72.8 8.1 6.8 20.6 7.0 216.5 8.3 8.8 7.4 5.1 6.1 2.1 5.0 37.7 13.2 7.4 10.1 17.7 9.7 19.2 26.5 27.6 16.3 90.3 10.0 65.5 8.3 24.9 1.5 2.3 15.8 40.8 5.4 28.0 24.0 0.0 0.0 0.0 0.0 0.0 0.7 0.2 0.0 0.0 0.0 0.0 50.0 99.6 0.0 6.5 10.3 0.2 1.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 7.9 0.0 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.0 0.3 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.7 0.0 20.1 0.0 0.2 0.2 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 6.6 8.9 5.9 10.2 8.1 6.8 8.8 7.4 13.2 1.5 CLIC1 "G6, NCC27, p64CLCP" ENSG00000213719 "Chloride intracellular channel 1" O00299 6 31730581-31739763 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters" "Ion transport, Transport" "Chloride channel, Ion channel, Voltage-gated channel" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB020825, CAB040557" Enhanced Supported Cytosol 78000000 Cytosol "CAB020825: , CAB040557: " "unprognostic (7.26e-2)" "unprognostic (9.32e-2)" "unprognostic (2.78e-3)" "unprognostic (7.29e-2)" "unprognostic (6.93e-2)" "unprognostic (2.73e-2)" "prognostic unfavourable (8.90e-7)" "unprognostic (2.58e-2)" "unprognostic (8.51e-2)" "unprognostic (8.71e-3)" "unprognostic (1.19e-3)" "unprognostic (1.34e-1)" "prognostic unfavourable (8.11e-5)" "unprognostic (4.51e-2)" "unprognostic (2.89e-1)" "unprognostic (1.35e-2)" "unprognostic (7.31e-2)" 64.5 22.9 7.4 33.7 11.3 35.3 41.1 2.5 8.3 38.7 50.3 9.0 27.1 24.5 30.0 29.2 59.0 26.3 60.8 35.5 7.9 7.7 70.8 28.3 58.6 59.6 13.9 3.7 34.8 30.3 11.1 17.0 72.3 12.1 42.2 43.5 20.0 37.7 33.6 18.3 45.0 54.9 31.5 13.6 79.9 34.8 16.7 9.2 52.9 46.1 37.4 58.5 49.2 40.0 39.0 30.5 70.9 39.4 33.5 37.2 67.9 26.7 12.4 20.4 10.6 13.6 28.8 10.2 11.9 24.5 21.9 18.4 28.5 20.1 11.0 17.4 42.5 16.2 15.2 35.7 29.6 8.7 8.0 21.0 10.7 24.6 17.6 36.6 29.7 17.8 18.9 36.9 35.3 36.6 24.2 34.9 42.0 17.8 17.0 47.7 1.8 18.2 3.0 11.2 25.9 49.2 16.7 3.9 4.6 9.9 11.4 16.6 7.8 51.9 24.2 30.5 21.5 9.5 37.6 11.4 21.3 14.8 14.7 27.6 31.3 45.8 36.5 48.1 37.2 39.4 30.3 39.0 22.5 34.5 30.5 30.4 7.0 21.9 70.9 33.5 33.8 17.2 31.0 67.9 7.4 11.3 2.5 8.3 7.9 7.7 13.9 3.7 12.1 9.2 CLIP1 "CLIP, CLIP-170, CLIP170, CYLN1, RSN" ENSG00000130779 "CAP-Gly domain containing linker protein 1" P30622 12 122271432-122422632 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" Transport "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 96.5" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004399, HPA026678" Approved Supported "Microtubule ends,Cytosol" 7700 "Microtubule ends, Cytosol" "CAB004399: AB_671001, HPA026678: AB_1846954" "unprognostic (1.18e-1)" "unprognostic (2.01e-1)" "unprognostic (1.72e-1)" "unprognostic (4.91e-2)" "unprognostic (6.28e-2)" "unprognostic (2.28e-1)" "unprognostic (1.20e-1)" "unprognostic (4.73e-2)" "unprognostic (2.51e-1)" "unprognostic (7.62e-2)" "unprognostic (2.31e-2)" "unprognostic (8.97e-2)" "unprognostic (3.26e-2)" "unprognostic (5.50e-2)" "unprognostic (2.63e-1)" "unprognostic (3.37e-1)" "unprognostic (2.52e-3)" 14.4 12.6 9.8 9.1 10.9 6.4 11.7 44.5 11.5 11.6 19.5 4.3 13.9 5.7 14.3 10.1 24.8 7.5 7.7 11.8 9.3 7.5 10.0 15.2 10.0 5.8 6.5 9.5 6.3 9.1 37.8 10.9 36.5 8.7 13.2 7.1 6.7 11.8 15.1 96.5 16.8 9.1 31.1 7.2 5.9 9.6 6.1 6.9 3.7 24.1 25.9 10.1 22.2 16.6 5.3 5.4 18.2 10.6 3.9 7.2 3.7 15.3 19.4 12.0 12.1 10.3 15.9 20.9 21.9 20.9 14.9 9.3 9.0 7.6 6.9 14.8 28.4 19.7 7.6 9.0 16.9 28.9 5.5 2.3 12.9 9.5 20.5 7.9 12.7 10.5 31.0 17.1 25.9 14.9 8.6 4.7 14.9 8.9 4.9 2.8 4.5 17.2 4.6 9.3 3.4 13.4 17.6 4.6 2.9 47.0 11.5 19.2 9.9 4.7 28.8 11.3 12.2 26.5 14.3 5.3 4.1 4.1 19.4 4.0 7.8 3.6 6.5 5.2 7.2 10.6 5.4 5.3 6.7 6.5 5.4 3.6 5.0 3.7 18.2 3.9 8.6 3.5 5.8 3.7 9.8 10.9 44.5 11.5 9.3 7.5 6.5 9.5 8.7 6.9 CLSTN1 "CDHR12, CSTN1, KIAA0911" ENSG00000171603 "Calsyntenin 1" O94985 1 9729026-9824526 "Cancer-related genes, Plasma proteins, Predicted membrane proteins" "Cell adhesion" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 102.0" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA012412 Enhanced 70000000 "HPA012412: AB_1846981" "unprognostic (4.63e-2)" "unprognostic (2.89e-1)" "unprognostic (9.76e-2)" "unprognostic (1.43e-1)" "unprognostic (9.79e-2)" "unprognostic (1.63e-1)" "unprognostic (2.44e-3)" "unprognostic (3.07e-2)" "unprognostic (2.54e-1)" "unprognostic (3.24e-2)" "unprognostic (1.34e-1)" "unprognostic (1.25e-1)" "prognostic favourable (4.10e-7)" "unprognostic (1.12e-1)" "unprognostic (2.65e-1)" "unprognostic (4.05e-2)" "unprognostic (4.72e-2)" 13.6 20.1 38.2 15.0 51.2 5.2 15.4 90.5 102.0 24.2 28.6 25.1 11.7 16.7 35.9 14.2 21.0 35.1 25.6 16.3 32.1 31.2 23.3 4.7 16.0 16.4 25.8 53.8 33.6 31.1 27.8 21.0 22.8 32.3 33.6 26.1 29.8 30.0 24.9 10.3 45.6 18.6 28.8 22.0 14.4 15.1 8.1 21.6 15.3 20.9 12.9 16.1 18.0 23.6 2.5 2.7 8.5 1.7 0.9 6.3 2.5 27.2 16.2 23.4 21.8 25.0 16.6 7.7 17.4 19.5 22.3 20.4 11.4 65.8 21.5 45.6 34.3 39.0 13.7 61.5 17.9 24.4 16.7 6.4 20.4 12.0 34.7 12.0 10.4 16.9 42.4 28.8 19.6 31.1 2.9 16.8 10.9 12.7 13.3 6.2 9.8 13.0 20.1 8.6 10.3 27.6 7.9 25.0 15.8 25.1 48.4 19.4 9.8 20.6 46.3 26.4 21.0 17.6 28.8 17.1 15.8 31.1 22.6 19.3 29.8 8.5 1.4 4.3 6.3 1.7 3.3 2.3 4.0 4.7 2.7 2.5 2.9 2.6 0.8 0.9 1.7 1.7 3.6 2.5 38.2 51.2 90.5 99.9 32.1 31.2 25.8 53.8 32.3 21.6 CLTC "CLTCL2, Hc" ENSG00000141367 "Clathrin heavy chain" Q00610 17 59619689-59696956 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Autophagy, Cell cycle, Cell division, Mitosis" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "CAB010389, CAB011571, CAB017155, HPA059143" Approved Enhanced "Vesicles,Endosomes,Lysosomes,Mitotic spindle,Cytosol" 51000000 "Vesicles, Endosomes, Lysosomes" "Mitotic spindle, Cytosol" "CAB010389: AB_2083184, CAB011571: AB_2083165, CAB017155: , HPA059143: " "unprognostic (1.56e-1)" "prognostic unfavourable (7.35e-4)" "prognostic favourable (7.65e-4)" "unprognostic (1.03e-1)" "unprognostic (2.62e-1)" "unprognostic (5.23e-3)" "prognostic unfavourable (5.54e-4)" "unprognostic (1.11e-1)" "unprognostic (6.43e-2)" "unprognostic (1.09e-1)" "unprognostic (3.34e-2)" "unprognostic (2.69e-1)" "unprognostic (1.49e-1)" "unprognostic (1.18e-1)" "unprognostic (9.22e-2)" "unprognostic (1.10e-1)" "prognostic unfavourable (2.02e-4)" 39.5 45.7 47.4 35.1 57.6 30.7 57.9 59.1 83.6 38.1 45.0 25.1 47.7 27.9 38.7 52.3 32.1 30.9 34.1 39.9 47.1 53.7 48.6 46.0 46.5 60.7 53.9 59.3 29.8 23.3 96.1 30.0 51.5 57.0 38.9 48.9 22.7 28.6 54.4 44.2 30.5 27.7 45.8 47.8 28.0 34.2 29.4 28.8 28.0 43.7 26.6 31.2 37.1 40.6 10.0 24.6 13.9 24.6 12.3 15.6 13.1 46.9 71.1 35.1 34.7 59.3 48.3 40.1 50.5 53.3 45.3 47.3 43.5 28.9 32.7 58.0 71.7 31.0 52.2 42.0 60.5 35.1 28.1 53.6 45.0 67.5 45.2 36.6 31.0 45.7 25.7 68.8 44.4 50.0 53.3 46.3 70.5 83.7 21.7 10.9 30.2 41.5 19.3 58.8 39.6 50.7 66.7 31.5 37.5 31.3 20.5 29.9 48.7 23.1 63.9 83.1 49.6 39.6 51.7 36.5 51.2 30.2 60.9 24.8 50.7 10.5 20.9 13.9 12.7 24.6 15.6 10.0 11.7 13.7 24.6 9.1 10.0 11.0 13.4 12.3 20.7 16.1 14.5 13.1 47.4 57.6 59.1 83.6 47.1 53.7 53.9 59.3 57.0 28.8 CLTCL1 "CHC22, CLH22, CLTCL, CLTD" ENSG00000070371 "Clathrin heavy chain like 1" P53675 22 19179473-19291716 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "skeletal muscle: 53.0" "Cell line enhanced" "Detected in many" "HMC-1: 34.3;K-562: 16.0" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 8 "classical monocyte: 3.3;neutrophil: 8.4" "Group enriched" "Detected in many" 15 "granulocytes: 8.4;monocytes: 3.3" "HPA075327, HPA075795" Enhanced Approved Vesicles Vesicles "HPA075327: , HPA075795: " "unprognostic (1.29e-2)" "unprognostic (3.13e-2)" "unprognostic (1.93e-2)" "unprognostic (3.16e-3)" "unprognostic (8.20e-2)" "unprognostic (6.93e-3)" "unprognostic (1.60e-1)" "unprognostic (3.28e-1)" "unprognostic (4.42e-2)" "unprognostic (2.93e-3)" "unprognostic (3.14e-1)" "unprognostic (1.02e-1)" "unprognostic (1.20e-1)" "unprognostic (8.71e-4)" "unprognostic (1.61e-1)" "unprognostic (2.10e-2)" "unprognostic (1.06e-1)" 2.9 3.3 1.1 0.9 2.0 9.7 1.6 3.4 1.8 1.3 1.0 3.7 1.2 0.4 2.3 3.1 2.2 1.4 0.9 5.6 1.3 1.7 1.0 1.7 1.2 0.6 2.7 1.4 1.4 0.9 2.1 14.9 1.1 4.1 1.8 0.8 4.2 1.5 1.1 53.0 2.1 0.9 2.4 3.6 0.9 1.0 17.2 1.2 1.3 2.7 10.4 0.7 1.2 1.3 0.2 0.3 8.4 3.3 0.0 0.3 0.6 2.2 2.3 1.5 2.5 5.8 3.2 0.7 1.6 1.7 2.3 3.4 0.8 0.7 0.9 0.2 3.6 0.8 2.4 4.5 1.8 0.1 2.4 0.1 2.2 2.7 2.9 3.2 34.3 13.7 3.7 4.1 5.8 1.4 16.0 0.9 5.2 1.8 0.4 11.4 2.0 1.9 1.2 13.1 0.0 1.7 0.9 3.7 0.6 3.4 2.1 0.2 4.6 13.8 0.4 4.0 8.6 2.2 2.6 1.8 4.2 0.4 2.4 8.8 0.8 0.0 3.3 0.3 0.1 0.7 0.0 0.0 0.1 0.3 0.3 0.2 0.3 0.0 8.4 0.0 0.0 0.1 0.0 0.6 1.1 2.0 3.4 1.8 1.3 1.7 2.7 1.4 4.1 1.2 CLU "APOJ, CLI, CLU1, CLU2, KUB1, SGP-2, SP-40, TRPM-2" ENSG00000120885 Clusterin P10909 8 27596917-27615031 "Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Apoptosis, Complement pathway, Immunity, Innate immunity" Chaperone "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "epididymis: 580.4;liver: 590.5" "Cell line enhanced" "Detected in many" "HeLa: 233.1;SK-BR-3: 203.8;T-47d: 148.7;U-2 OS: 133.0" "Cancer enhanced" "Detected in all" "glioma: 1485.6" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in many" 7 "basophil: 69.2" "Lineage enriched" "Detected in many" 25 "granulocytes: 69.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA000572, CAB016253" Enhanced "Secreted to blood" 131033333333 36000000000 "CAB016253: AB_673562, HPA000572: AB_1078539" "unprognostic (1.10e-2)" "unprognostic (1.81e-2)" "unprognostic (1.14e-3)" "unprognostic (2.74e-2)" "unprognostic (5.59e-2)" "unprognostic (4.13e-2)" "unprognostic (1.76e-2)" "unprognostic (2.37e-1)" "unprognostic (1.46e-1)" "unprognostic (1.05e-1)" "unprognostic (2.87e-2)" "unprognostic (1.41e-1)" "unprognostic (1.80e-2)" "unprognostic (2.33e-2)" "unprognostic (1.72e-1)" "prognostic favourable (7.66e-5)" "unprognostic (5.29e-2)" 82.5 217.4 233.5 50.2 280.3 3.4 90.4 141.2 414.7 78.3 47.9 139.5 184.6 19.9 55.4 580.4 48.3 217.2 172.7 24.6 176.2 154.7 69.8 590.5 30.5 127.3 209.0 173.1 49.6 134.8 220.4 34.3 8.5 189.0 63.4 18.0 125.4 62.2 359.2 7.7 12.8 24.0 87.9 255.2 17.2 56.6 161.5 113.5 5.3 106.6 11.8 134.8 72.2 54.7 0.1 1.3 69.2 2.1 0.9 2.7 110.6 0.7 96.0 4.2 4.9 23.8 32.8 13.4 17.0 33.6 4.5 2.3 18.4 15.2 0.3 68.3 15.1 32.2 18.2 2.7 2.9 70.8 17.6 41.6 233.1 22.6 20.8 1.0 111.1 54.9 11.0 19.4 5.6 59.1 0.5 49.0 1.5 16.1 0.3 3.1 35.0 11.4 0.3 16.1 13.3 44.4 69.3 3.9 2.4 23.6 203.8 1.0 148.7 0.6 8.7 1.3 133.0 7.6 5.7 6.3 22.4 0.7 107.0 6.9 0.6 69.2 2.1 0.9 2.3 0.6 0.8 0.0 2.7 2.5 0.7 0.1 0.3 0.8 9.6 0.9 0.1 1.3 0.7 110.6 233.5 280.3 141.2 223.1 176.2 154.7 209.0 173.1 189.0 113.5 CNBD1 FLJ35802 ENSG00000176571 "Cyclic nucleotide binding domain containing 1" Q8NA66 8 86866442-87615219 "Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 14 "testis: 16.9" "Group enriched" "Detected in some" 11 "Karpas-707: 9.1;U-266/70: 5.4" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "HPA025037, HPA027469, HPA027786" Uncertain "Secreted in male reproductive system" "HPA025037: AB_10794318, HPA027469: AB_10599492, HPA027786: AB_10600231" "unprognostic (1.89e-1)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.2 16.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 9.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.6 0.4 0.0 0.0 0.0 0.0 0.0 0.0 5.4 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 CNBP "CNBP1, DM2, RNF163, ZCCHC22, ZNF9" ENSG00000169714 "CCHC-type zinc finger nucleic acid binding protein" P62633 3 129169484-129183922 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Transcription, Transcription regulation" "DNA-binding, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA063097 Supported Nucleoplasm,Cytosol 43000 "Nucleoplasm, Cytosol" "HPA063097: " "unprognostic (1.74e-1)" "unprognostic (3.11e-2)" "unprognostic (4.84e-1)" "unprognostic (3.35e-2)" "unprognostic (6.28e-2)" "unprognostic (7.38e-2)" "unprognostic (7.02e-3)" "unprognostic (1.23e-1)" "unprognostic (1.06e-3)" "unprognostic (6.39e-2)" "prognostic unfavourable (3.51e-4)" "unprognostic (4.72e-3)" "unprognostic (4.62e-3)" "unprognostic (1.89e-1)" "unprognostic (2.03e-1)" "unprognostic (2.51e-1)" "unprognostic (1.58e-1)" 54.2 52.8 36.4 33.6 33.7 35.9 46.6 43.5 35.6 58.1 47.1 34.5 40.5 32.4 54.5 49.4 55.6 40.9 48.5 78.2 33.0 32.0 38.0 71.6 47.5 40.6 39.7 30.3 67.4 65.4 39.3 33.5 41.5 33.3 62.3 37.1 41.3 48.9 50.9 182.1 46.7 40.6 71.9 38.0 43.2 43.1 32.1 33.1 39.0 67.3 81.1 41.2 76.1 63.5 74.3 60.3 120.1 84.1 61.7 83.4 172.9 61.2 36.3 53.0 42.0 53.0 45.5 41.8 48.2 76.5 52.6 60.5 53.2 43.2 81.5 41.4 44.8 46.1 69.2 55.9 71.3 54.7 50.4 78.7 37.5 57.2 52.8 84.4 45.3 43.9 65.6 36.8 133.0 46.4 58.9 56.1 55.0 73.3 78.2 62.1 64.6 61.4 68.8 49.2 97.1 54.4 59.1 72.2 57.8 38.0 37.6 102.2 43.3 58.1 48.8 39.0 38.4 53.5 48.7 52.8 48.0 128.2 40.1 57.9 51.4 93.4 84.1 96.8 64.1 63.8 80.6 74.3 77.4 68.9 60.3 62.7 83.4 72.0 120.1 61.7 48.9 35.1 73.9 172.9 36.4 33.7 43.5 35.6 33.0 32.0 39.7 30.3 33.3 33.1 CNKSR1 "CNK, CNK1, KSR" ENSG00000142675 "Connector enhancer of kinase suppressor of Ras 1" Q969H4 1 26177403-26189886 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "A-431: 11.6;BEWO: 10.1;CAPAN-2: 17.9;HaCaT: 13.2;hTCEpi: 11.4;SK-BR-3: 11.6;T-47d: 10.9" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Group enriched" "Detected in some" 7 "memory B-cell: 2.1;memory CD4 T-cell: 2.4;naive CD4 T-cell: 1.4;T-reg: 2.6" "Group enriched" "Detected in many" 8 "B-cells: 2.1;T-cells: 2.6" "Not detected" "Not detected" "Not detected" "Not detected" HPA030847 Uncertain Approved Cytosol Cytosol "HPA030847: AB_10601100" "unprognostic (2.73e-3)" "unprognostic (1.27e-1)" "unprognostic (1.10e-1)" "unprognostic (1.19e-2)" "unprognostic (5.07e-2)" "unprognostic (1.03e-1)" "unprognostic (3.15e-1)" "unprognostic (1.61e-2)" "unprognostic (5.26e-2)" "unprognostic (1.37e-1)" "unprognostic (3.68e-1)" "unprognostic (2.49e-3)" "unprognostic (1.69e-3)" "unprognostic (1.90e-2)" "unprognostic (3.27e-2)" "unprognostic (2.91e-1)" "prognostic favourable (5.91e-4)" 0.7 0.0 1.0 3.5 1.4 0.0 4.5 5.4 1.1 4.4 19.1 0.8 12.8 8.6 1.9 11.9 15.4 6.1 13.3 0.7 1.4 1.2 10.0 2.9 10.2 0.7 0.9 0.7 2.5 27.6 10.2 12.6 32.4 1.2 10.3 5.4 0.7 15.7 18.9 17.7 11.9 22.6 1.0 1.3 1.3 7.3 1.5 0.7 1.9 20.6 11.9 15.9 6.1 5.3 2.1 0.0 0.0 0.0 0.2 2.6 0.5 11.6 0.0 0.2 0.1 0.2 0.0 10.1 0.3 0.0 0.4 0.0 1.8 17.9 1.9 6.0 0.0 13.2 0.3 8.4 0.3 0.4 0.6 0.2 4.3 5.0 0.1 0.1 0.2 0.0 11.4 0.0 3.2 0.0 1.5 0.1 0.0 5.4 0.1 0.6 5.2 1.1 0.1 0.1 0.0 1.0 6.8 2.5 0.6 0.0 11.6 0.2 10.9 0.0 0.0 0.0 1.8 0.7 0.1 4.1 0.7 0.5 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 2.1 2.4 0.0 0.0 0.3 1.4 0.1 0.0 0.2 0.0 0.0 2.6 0.5 1.0 1.4 5.4 1.1 1.4 1.2 0.9 0.7 1.2 0.7 CNN1 "Sm-Calp, SMCC" ENSG00000130176 "Calponin 1" P51911 19 11538717-11550323 "Cancer-related genes, Predicted intracellular proteins" "Actin-binding, Calmodulin-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "smooth muscle: 489.2;urinary bladder: 357.9" "Cell line enhanced" "Detected in some" "BJ: 34.6;BJ hTERT+: 13.3;BJ hTERT+ SV40 Large T+: 18.1;BJ hTERT+ SV40 Large T+ RasG12V: 25.1;HBF TERT88: 28.0;K-562: 12.9;U-2 OS: 13.0" "Cancer enhanced" "Detected in all" "prostate cancer: 142.1" "Low region specificity" "Detected in some" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB000007, HPA014263" Enhanced Approved "Actin filaments" "Actin filaments" "CAB000007: AB_2082148, HPA014263: AB_1847039" "unprognostic (4.98e-3)" "unprognostic (1.01e-1)" "unprognostic (3.04e-3)" "unprognostic (1.95e-1)" "unprognostic (2.47e-1)" "unprognostic (4.20e-1)" "unprognostic (5.10e-3)" "unprognostic (1.76e-1)" "unprognostic (1.35e-1)" "unprognostic (7.06e-2)" "unprognostic (2.19e-1)" "unprognostic (2.01e-1)" "prognostic unfavourable (5.43e-6)" "unprognostic (1.70e-2)" "unprognostic (1.07e-1)" "unprognostic (2.78e-3)" "unprognostic (6.11e-3)" 9.3 4.1 0.5 34.9 0.9 0.0 7.9 0.5 1.2 90.5 193.4 1.3 78.1 9.4 182.6 50.6 140.5 52.2 105.7 22.2 0.6 0.6 6.2 1.0 9.5 2.2 0.7 1.8 36.5 1.3 0.0 0.7 4.0 2.2 120.1 26.4 8.8 9.1 125.2 4.8 4.5 37.1 489.2 1.0 1.2 66.5 16.4 0.5 0.4 3.2 4.5 3.3 357.9 26.8 0.0 0.4 0.0 0.1 0.0 0.0 5.2 0.0 0.5 2.2 0.4 0.2 0.0 1.4 34.6 13.3 18.1 25.1 9.8 0.0 0.1 1.0 9.8 0.1 0.0 0.0 28.0 0.0 0.0 0.0 0.0 0.8 0.9 0.0 0.1 1.2 0.0 11.1 0.0 0.0 12.9 0.0 0.0 0.0 0.1 1.7 1.1 0.2 0.1 0.4 1.3 0.0 0.0 0.0 0.5 0.0 0.0 0.1 0.0 0.0 0.1 0.1 13.0 0.5 0.4 0.0 0.1 0.0 1.2 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.2 0.5 0.9 0.5 1.2 0.6 0.6 0.7 1.8 2.2 0.5 CNOT3 "KIAA0691, LENG2, NOT3, NOT3H" ENSG00000088038 "CCR4-NOT transcription complex subunit 3" O75175 19 54137717-54155708 "Cancer-related genes, Predicted intracellular proteins" "RNA-mediated gene silencing, Transcription, Transcription regulation, Translation regulation" "Developmental protein, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HEK 293: 71.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA006408 Approved Approved Cytosol Cytosol "HPA006408: AB_1078543" "unprognostic (1.23e-1)" "unprognostic (2.54e-1)" "unprognostic (1.75e-2)" "unprognostic (1.40e-1)" "unprognostic (4.86e-2)" "unprognostic (1.90e-1)" "prognostic unfavourable (2.22e-4)" "unprognostic (9.06e-2)" "unprognostic (1.43e-2)" "unprognostic (2.65e-2)" "unprognostic (9.30e-3)" "unprognostic (4.08e-3)" "prognostic unfavourable (2.77e-4)" "unprognostic (2.18e-1)" "unprognostic (1.73e-1)" "unprognostic (2.11e-1)" "unprognostic (2.66e-2)" 18.1 25.2 25.5 23.6 26.4 21.4 20.2 46.8 27.9 22.1 20.7 24.5 27.7 21.3 25.0 26.5 22.1 23.6 19.7 16.2 21.9 15.6 21.3 20.2 17.9 23.9 25.5 20.8 28.0 22.7 27.6 30.2 24.2 20.3 23.3 17.5 20.7 22.4 31.4 20.2 25.2 21.4 22.0 16.7 26.3 21.9 34.4 26.9 33.6 26.3 14.3 23.3 23.8 29.9 3.2 6.7 8.4 3.1 1.6 3.6 2.9 13.6 22.0 22.8 13.1 8.5 8.6 16.0 12.8 22.2 17.2 15.4 14.1 11.8 16.8 8.2 14.8 14.4 25.3 12.5 17.8 17.4 71.4 26.1 14.3 12.5 14.8 14.9 18.3 10.9 12.0 15.3 25.9 13.6 19.2 15.8 12.6 16.9 18.4 8.8 13.9 17.7 18.4 17.5 10.9 11.5 27.7 14.7 12.5 24.7 17.8 8.1 10.2 16.0 12.1 14.6 16.9 7.7 17.3 14.8 16.2 23.2 12.7 11.4 15.4 1.4 3.1 5.2 3.6 2.2 2.5 2.9 2.4 3.2 2.8 3.2 2.7 2.6 8.4 1.6 2.6 6.7 2.5 2.9 25.5 26.4 46.8 27.9 21.9 15.6 25.5 20.8 20.3 26.9 CNTF HCNTF ENSG00000242689 "Ciliary neurotrophic factor" P26441 11 58622673-58625733 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Differentiation, Neurogenesis" "Developmental protein, Growth factor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "brain: 47.5" "Cell line enhanced" "Detected in many" "U-2197: 12.7" "Low cancer specificity" "Detected in some" "Region enriched" "Detected in many" 5 "midbrain: 47.5" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" HPA019654 Approved Approved Vesicles Vesicles "HPA019654: AB_1859050" "unprognostic (1.88e-1)" "unprognostic (2.64e-3)" "unprognostic (1.01e-2)" "unprognostic (4.37e-2)" "unprognostic (1.52e-1)" "unprognostic (5.91e-2)" "unprognostic (1.63e-1)" "unprognostic (9.24e-2)" "unprognostic (5.87e-2)" "unprognostic (1.63e-1)" "unprognostic (8.25e-4)" "unprognostic (5.42e-2)" "unprognostic (8.50e-2)" "unprognostic (1.02e-1)" "unprognostic (1.91e-1)" "unprognostic (9.50e-2)" "unprognostic (9.67e-2)" 2.0 0.7 1.4 0.9 4.8 10.0 0.8 1.2 1.6 0.3 0.9 2.5 1.1 1.4 0.3 1.4 0.9 8.3 0.8 2.5 1.8 1.6 0.9 0.9 0.8 0.6 47.5 0.9 0.3 0.5 1.2 0.5 0.6 9.3 0.6 1.3 3.1 1.3 0.4 3.7 0.9 0.9 0.6 22.8 0.6 0.5 0.7 1.2 0.2 1.0 3.7 0.6 0.6 0.3 0.4 0.0 0.0 0.3 0.0 0.7 0.2 2.1 0.8 3.4 3.5 1.0 0.3 1.7 1.6 2.2 1.6 1.2 2.9 2.9 4.3 1.2 2.2 3.8 3.6 3.9 3.2 3.0 2.1 2.3 4.3 1.6 0.4 3.3 4.2 1.0 1.3 5.3 1.7 1.7 3.4 1.0 2.0 0.9 3.2 3.1 2.1 1.5 2.2 2.4 3.0 1.9 2.5 1.5 4.2 2.2 2.3 5.8 2.9 2.4 1.2 2.5 1.9 12.7 4.0 2.4 4.9 3.7 6.6 1.7 2.9 0.0 0.3 0.0 0.3 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.2 1.4 4.8 1.2 1.4 1.8 1.6 47.5 0.9 9.3 1.2 CNTRL "CEP1, CEP110" ENSG00000119397 Centriolin Q7Z7A1 9 121074863-121177610 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HL-60: 34.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA020468, HPA020480, HPA051583" Approved Supported Centrosome,Cytosol Centrosome Cytosol "HPA020468: , HPA020480: , HPA051583: " "unprognostic (4.33e-3)" "unprognostic (2.89e-3)" "unprognostic (2.09e-2)" "unprognostic (7.97e-2)" "unprognostic (1.17e-2)" "prognostic favourable (9.21e-5)" "unprognostic (1.05e-2)" "unprognostic (3.22e-3)" "unprognostic (3.74e-3)" "unprognostic (2.02e-1)" "unprognostic (1.78e-2)" "unprognostic (5.47e-2)" "unprognostic (3.60e-3)" "unprognostic (9.83e-3)" "unprognostic (2.43e-1)" "unprognostic (3.57e-2)" "unprognostic (1.13e-2)" 7.7 4.7 5.5 22.2 11.7 24.0 6.8 10.9 8.7 8.4 5.5 4.9 5.9 3.8 7.3 6.4 5.6 8.4 5.1 4.4 6.6 4.3 4.0 3.8 9.3 20.3 8.1 4.1 10.6 5.2 4.0 17.3 5.8 7.0 7.2 5.5 4.4 6.3 8.6 2.8 5.2 8.8 5.7 9.7 14.8 7.1 30.2 9.8 26.7 6.2 4.2 19.2 8.6 7.1 12.7 10.5 15.0 6.9 4.8 10.4 2.5 5.3 3.6 10.0 7.2 1.5 2.3 1.7 3.7 2.8 2.9 2.5 2.1 5.9 24.6 1.4 2.7 11.3 3.3 2.2 4.8 14.9 2.6 12.8 6.5 2.5 2.1 34.8 15.6 1.4 1.7 3.1 7.5 6.4 8.3 14.1 2.8 3.4 13.6 11.9 3.4 2.9 12.9 15.1 7.0 1.4 2.5 3.8 5.7 12.7 2.3 2.9 4.9 16.7 4.7 3.1 5.4 4.8 6.8 9.8 10.7 16.7 2.6 14.4 7.1 12.2 6.9 15.0 7.5 4.5 5.7 10.8 7.7 5.5 3.4 12.7 9.3 6.6 2.7 4.8 5.8 10.5 10.4 2.5 5.5 11.7 10.9 8.7 6.6 4.3 8.1 4.1 7.0 9.8 COL11A1 "CO11A1, COLL6, STL2" ENSG00000060718 "Collagen type XI alpha 1 chain" P12107 1 102876467-103108872 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Cancer-related genes, Cataract, Deafness, Disease mutation, Dwarfism, Ectodermal dysplasia, Stickler syndrome" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "placenta: 33.3" "Cell line enhanced" "Detected in some" "AF22: 38.3;BJ: 13.5;BJ hTERT+ SV40 Large T+ RasG12V: 28.6;HBF TERT88: 16.2;HSkMC: 48.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in some" "Low region specificity" "Detected in many" HPA058335 Approved "Endoplasmic reticulum" "Secreted to extracellular matrix" 270000 "Endoplasmic reticulum" "HPA058335: " "unprognostic (2.60e-3)" "unprognostic (6.61e-4)" "unprognostic (9.58e-2)" "unprognostic (5.06e-5)" "unprognostic (2.83e-1)" "unprognostic (2.85e-2)" "unprognostic (6.03e-3)" "unprognostic (2.23e-3)" "unprognostic (9.08e-2)" "unprognostic (1.21e-1)" "unprognostic (1.12e-2)" "unprognostic (1.94e-2)" "unprognostic (3.01e-12)" "unprognostic (1.27e-2)" "unprognostic (3.53e-1)" "unprognostic (3.54e-2)" "unprognostic (2.32e-2)" 1.2 1.8 8.6 1.3 9.1 0.8 1.5 2.0 7.9 2.3 1.1 4.1 0.0 1.0 1.8 1.0 0.8 0.8 5.9 0.8 8.3 8.6 1.0 0.8 1.2 0.9 8.1 5.9 1.2 1.9 1.0 5.5 33.3 11.1 1.1 1.4 5.9 3.3 2.2 0.9 2.4 0.9 1.3 9.0 2.2 0.9 4.7 5.8 0.0 0.9 0.6 0.8 1.1 0.4 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.2 38.3 0.0 1.5 2.0 0.0 13.5 5.1 7.7 28.6 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 16.2 0.0 0.0 0.0 0.0 0.0 4.1 0.0 0.0 48.2 0.0 0.3 0.0 0.0 0.0 0.0 10.3 0.0 0.0 0.0 2.7 0.0 0.0 2.3 0.0 5.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 8.9 0.0 1.4 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 8.6 9.1 2.0 7.9 8.3 8.6 8.1 5.9 11.1 5.8 COL17A1 "BP180, BPAG2" ENSG00000065618 "Collagen type XVII alpha 1 chain" Q9UMD9 10 104031286-104086002 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" "Cancer-related genes, Disease mutation, Epidermolysis bullosa" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "placenta: 85.8;skin 1: 123.2;tongue: 64.0" "Cell line enhanced" "Detected in some" "HaCaT: 55.3;HBEC3-KT: 88.6;hTCEpi: 115.1;hTERT-HME1: 98.0" "Cancer enhanced" "Detected in many" "head and neck cancer: 227.4" "Region enriched" "Detected in single" 4 "basal ganglia: 1.2" "Cell type enriched" "Detected in single" 15 "neutrophil: 3.7" "Lineage enriched" "Detected in single" 15 "granulocytes: 3.7" "Region enriched" "Detected in single" 4 "cerebellum: 1.1" "Not detected" "Not detected" "HPA043673, HPA052963" Enhanced Supported "Golgi apparatus,Plasma membrane" "Secreted to extracellular matrix" "Plasma membrane" "Golgi apparatus" "HPA043673: AB_10960893, HPA052963: " "prognostic favourable (1.38e-4)" "unprognostic (1.33e-1)" "unprognostic (4.01e-1)" "unprognostic (1.01e-1)" "unprognostic (9.65e-2)" "unprognostic (3.75e-1)" "unprognostic (2.13e-1)" "unprognostic (6.82e-3)" "unprognostic (1.63e-1)" "unprognostic (7.85e-3)" "prognostic unfavourable (1.86e-4)" "unprognostic (2.12e-1)" "unprognostic (1.71e-1)" "unprognostic (1.14e-1)" "unprognostic (1.23e-1)" "unprognostic (3.75e-2)" "unprognostic (8.35e-2)" 0.2 0.0 0.2 4.4 1.2 7.5 8.1 0.2 0.2 15.2 9.3 0.2 0.9 2.0 0.6 2.6 31.5 0.1 1.2 0.2 0.2 0.1 0.4 0.2 0.7 0.2 0.2 0.2 0.2 0.2 0.0 0.6 85.8 0.2 5.0 5.4 0.2 15.5 7.3 0.5 123.2 23.2 0.8 0.2 0.3 3.9 4.0 0.2 18.1 2.0 64.0 24.7 3.0 17.3 0.0 0.0 3.7 0.2 0.0 0.0 0.8 3.1 0.0 0.1 0.0 0.0 0.0 9.8 0.0 0.0 0.0 0.0 0.0 24.3 0.0 0.7 0.0 55.3 0.0 88.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 115.1 0.0 98.0 0.4 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.3 0.0 0.0 0.0 5.0 3.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.6 0.0 0.7 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.7 0.0 0.2 0.0 0.0 0.8 0.2 1.2 0.2 0.2 0.2 0.1 0.2 0.2 0.2 0.2 COL18A1 "KNO, KNO1, KS" ENSG00000182871 "Collagen type XVIII alpha 1 chain" P39060 21 45405137-45513720 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Cell adhesion" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 273.2" "Cell line enhanced" "Detected in many" "BJ hTERT+: 31.2;EFO-21: 70.3;NTERA-2: 39.1;TIME: 41.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in some" 5 "neutrophil: 7.3" "Lineage enriched" "Detected in many" 6 "granulocytes: 7.3" "Region enriched" "Detected in many" 6 "cerebellum: 24.8" "Low region specificity" "Detected in all" "CAB001961, HPA011025, HPA036104" Approved Approved "Golgi apparatus" "Secreted to extracellular matrix" 250000000 "Golgi apparatus" "CAB001961: , HPA011025: AB_1078551, HPA036104: " "unprognostic (4.32e-2)" "unprognostic (1.20e-1)" "unprognostic (1.76e-2)" "unprognostic (3.47e-2)" "unprognostic (3.25e-2)" "unprognostic (5.55e-2)" "prognostic favourable (6.16e-4)" "unprognostic (4.23e-3)" "unprognostic (9.93e-2)" "unprognostic (3.48e-1)" "unprognostic (2.77e-1)" "unprognostic (5.50e-2)" "unprognostic (1.70e-1)" "unprognostic (1.83e-2)" "unprognostic (9.44e-2)" "unprognostic (9.10e-3)" "unprognostic (2.25e-3)" 25.5 14.4 2.2 12.7 13.0 5.6 17.7 3.4 8.5 40.4 12.7 26.0 19.6 12.6 22.2 72.5 12.0 18.8 25.3 18.5 3.5 5.3 36.2 273.2 11.9 7.6 35.5 3.5 43.3 21.8 2.6 17.8 16.5 20.8 13.9 2.3 17.3 8.8 20.2 8.1 23.1 10.6 33.4 31.9 14.5 7.1 11.0 23.6 2.3 16.0 12.0 6.7 28.7 18.2 0.4 0.4 7.3 0.4 0.0 1.2 0.2 2.5 19.1 4.8 4.3 8.9 7.4 1.0 18.4 31.2 8.8 2.4 11.9 6.8 0.5 70.3 18.2 8.6 1.0 1.1 1.7 0.2 5.3 11.0 0.3 16.2 8.6 0.4 1.1 8.7 0.7 0.8 1.0 27.1 11.1 0.1 3.2 4.4 0.4 1.1 39.1 7.1 0.5 3.0 1.1 29.7 0.4 5.4 4.1 1.8 2.0 5.8 1.8 3.0 41.3 0.2 2.8 0.1 4.3 0.1 0.2 0.3 0.0 0.9 7.6 1.0 0.4 1.5 0.1 0.4 0.2 0.4 0.4 0.0 0.1 0.1 1.2 0.6 7.3 0.0 0.3 0.4 0.0 0.2 2.2 13.0 3.4 8.5 3.5 5.3 35.5 3.5 20.8 23.6 COL1A1 OI4 ENSG00000108821 "Collagen type I alpha 1 chain" P02452 17 50183289-50201632 "Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Cancer-related genes, Disease mutation, Dwarfism, Ehlers-Danlos syndrome, FDA approved drug targets, Osteogenesis imperfecta" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "cervix, uterine: 415.7" "Cell line enhanced" "Detected in some" "ASC TERT1: 89.7;BJ: 172.4;fHDF/TERT166: 260.2;HSkMC: 131.8;U-138 MG: 140.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in some" "Cell type enriched" "Detected in single" 5 "naive CD8 T-cell: 1.1" "Lineage enriched" "Detected in single" 5 "T-cells: 1.1" "Low region specificity" "Detected in many" "Low region specificity" "Detected in some" HPA011795 Approved Approved Vesicles,Cytosol "Secreted to extracellular matrix" 58000000 Cytosol Vesicles "HPA011795: AB_1847088" "unprognostic (1.61e-1)" "unprognostic (3.60e-3)" "unprognostic (8.29e-2)" "unprognostic (5.52e-2)" "unprognostic (7.74e-2)" "unprognostic (2.22e-1)" "unprognostic (6.01e-2)" "prognostic unfavourable (4.43e-4)" "unprognostic (1.23e-2)" "unprognostic (2.55e-2)" "unprognostic (8.53e-2)" "unprognostic (9.90e-2)" "prognostic unfavourable (7.19e-12)" "unprognostic (2.74e-2)" "unprognostic (4.73e-2)" "unprognostic (7.26e-2)" "unprognostic (3.87e-3)" 30.2 5.7 0.7 28.2 4.0 0.1 31.7 0.6 0.9 415.7 25.7 1.6 23.9 3.0 121.8 70.9 17.4 33.0 110.3 43.9 0.7 0.1 7.5 4.6 18.8 38.5 0.7 1.2 73.6 10.5 1.0 10.7 89.1 2.2 31.5 4.0 9.2 9.1 21.0 11.0 35.5 10.6 88.0 1.3 13.7 15.0 44.6 0.7 7.7 6.7 15.5 8.7 67.3 49.7 0.2 0.0 0.0 0.0 0.0 1.1 0.0 0.3 0.2 0.9 0.1 36.9 89.7 1.5 172.4 46.8 43.0 27.0 3.4 0.8 0.0 0.4 260.2 0.5 0.4 0.1 7.7 0.2 0.3 0.0 4.3 0.2 70.3 0.0 0.0 131.8 2.5 52.5 0.2 0.0 0.1 0.0 21.6 0.4 0.0 0.0 0.9 0.5 0.3 0.1 0.1 0.2 0.0 0.1 0.4 0.3 0.2 0.0 2.2 0.0 0.0 140.1 30.6 20.9 0.8 0.1 0.3 0.0 10.4 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.7 4.0 0.6 0.9 0.7 0.1 0.7 1.2 2.2 0.7 COL1A2 OI4 ENSG00000164692 "Collagen type I alpha 2 chain" P08123 7 94394561-94431232 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins" "Cancer-related genes, Disease mutation, Dwarfism, Ehlers-Danlos syndrome, Osteogenesis imperfecta" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "cervix, uterine: 244.6" "Cell line enhanced" "Detected in some" "ASC diff: 150.8;ASC TERT1: 181.0;BJ: 148.1;BJ hTERT+: 108.7;fHDF/TERT166: 501.0;HSkMC: 157.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in some" "CAB032650, HPA059738" Approved Supported "Endoplasmic reticulum" "Secreted to extracellular matrix" 21000000 "Endoplasmic reticulum" "CAB032650: AB_2082039, HPA059738: " "unprognostic (1.20e-1)" "unprognostic (6.34e-2)" "unprognostic (1.32e-1)" "unprognostic (3.40e-2)" "unprognostic (2.86e-2)" "unprognostic (2.81e-1)" "unprognostic (5.15e-2)" "unprognostic (7.38e-3)" "unprognostic (2.01e-2)" "unprognostic (1.40e-2)" "unprognostic (5.83e-2)" "unprognostic (2.15e-1)" "prognostic unfavourable (1.51e-9)" "unprognostic (1.35e-2)" "unprognostic (5.25e-2)" "unprognostic (1.15e-1)" "unprognostic (3.31e-3)" 44.7 9.8 1.2 34.9 4.3 0.0 33.4 1.7 2.4 244.6 26.5 2.1 54.1 3.8 166.9 139.1 28.2 36.6 101.4 45.1 1.3 0.8 10.2 4.1 37.1 20.4 1.8 2.8 68.3 10.9 1.8 6.0 70.6 3.8 40.3 10.1 23.0 17.5 28.0 12.1 35.6 15.2 100.7 3.2 16.4 16.1 49.7 1.1 5.6 14.7 42.7 12.6 62.4 55.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 55.8 150.8 181.0 0.0 148.1 108.7 24.4 32.5 0.0 0.1 0.0 0.1 501.0 0.0 0.0 0.0 6.0 0.0 0.0 0.0 0.0 0.0 39.5 0.0 0.0 157.1 0.0 19.2 0.0 0.0 0.0 0.0 20.5 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.5 62.2 0.0 38.5 4.2 0.0 0.0 0.0 15.6 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 4.3 1.7 2.4 1.3 0.8 1.8 2.8 3.8 1.1 COL2A1 "AOM, SEDC, STL1" ENSG00000139219 "Collagen type II alpha 1 chain" P02458 12 47972965-48004554 "Cancer-related genes, Disease related genes, Predicted secreted proteins" "Cancer-related genes, Cataract, Deafness, Disease mutation, Dwarfism, Stickler syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "epididymis: 22.7;pituitary gland: 11.0;retina: 8.1;stomach 1: 11.3" "Cell line enhanced" "Detected in some" "AF22: 54.0;HAP1: 33.8;HEK 293: 12.5" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in some" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "CAB002214, HPA055753" Supported Approved Nucleoplasm "Secreted to extracellular matrix" Nucleoplasm "CAB002214: AB_563666, HPA055753: " "unprognostic (7.25e-2)" "unprognostic (1.20e-1)" "unprognostic (2.58e-1)" "unprognostic (3.44e-1)" "unprognostic (2.88e-2)" "unprognostic (3.08e-2)" "unprognostic (8.63e-2)" "unprognostic (2.77e-1)" "unprognostic (1.22e-1)" "unprognostic (3.12e-2)" "unprognostic (1.31e-4)" "unprognostic (2.64e-1)" "unprognostic (3.44e-3)" "unprognostic (1.89e-1)" "unprognostic (2.93e-1)" "unprognostic (2.07e-1)" "unprognostic (1.02e-1)" 0.0 0.0 0.1 2.2 0.3 0.0 0.7 0.9 0.9 0.0 0.2 0.3 0.0 0.0 0.3 22.7 0.0 0.0 0.0 0.0 0.5 1.3 0.0 0.0 1.4 0.0 0.0 0.7 1.3 0.0 0.0 11.0 0.4 1.9 2.6 0.4 8.1 0.0 0.0 0.0 0.0 0.2 0.0 0.6 0.0 11.3 2.8 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 54.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.2 0.0 0.0 33.8 0.0 0.0 0.0 12.5 0.0 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.7 0.0 0.0 1.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.9 0.9 0.5 1.3 0.0 0.7 1.9 0.0 COL4A2 "DKFZp686I14213, FLJ22259" ENSG00000134871 "Collagen type IV alpha 2 chain" P08572 13 110305812-110513027 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" Angiogenesis "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "placenta: 125.7" "Cell line enhanced" "Detected in many" "EFO-21: 142.4;WM-115: 60.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB010751, HPA029118" Enhanced Supported Vesicles "Secreted to extracellular matrix" 1900000 Vesicles "CAB010751: AB_476828, HPA029118: " "unprognostic (2.43e-1)" "unprognostic (4.13e-3)" "unprognostic (8.04e-2)" "unprognostic (6.03e-3)" "unprognostic (2.20e-1)" "unprognostic (2.64e-2)" "unprognostic (3.45e-2)" "unprognostic (1.15e-2)" "unprognostic (3.50e-2)" "unprognostic (1.78e-1)" "unprognostic (1.49e-1)" "unprognostic (1.65e-1)" "prognostic unfavourable (3.49e-5)" "unprognostic (1.33e-2)" "unprognostic (1.57e-2)" "unprognostic (6.95e-2)" "prognostic unfavourable (9.25e-4)" 87.2 9.5 4.6 26.1 3.3 0.1 50.1 2.0 3.0 37.2 53.1 1.9 30.3 7.6 48.4 25.5 23.0 26.3 52.4 26.6 3.6 1.4 18.4 5.7 35.9 17.5 3.8 1.7 25.7 8.3 7.3 3.8 125.7 5.0 26.9 5.5 12.2 7.6 29.3 26.3 9.2 16.9 84.1 2.8 58.5 23.4 11.0 1.9 4.2 16.0 8.0 5.7 65.3 20.3 0.0 0.0 0.0 0.0 0.0 0.0 0.4 11.4 6.5 29.5 0.0 38.5 16.0 46.5 40.1 14.5 23.9 11.2 0.7 0.0 0.0 142.4 9.3 11.2 0.0 12.0 4.6 1.5 6.1 0.0 11.0 0.3 28.4 0.0 0.1 7.2 0.7 16.7 11.5 24.9 0.0 0.0 3.9 0.2 0.0 1.0 4.6 2.3 0.0 12.2 0.0 26.3 0.2 0.9 4.8 0.0 0.1 12.5 0.0 0.5 42.8 13.1 33.4 0.3 21.7 0.0 0.2 0.5 0.3 0.0 60.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 4.6 3.3 2.0 3.0 3.6 1.4 3.8 1.7 5.0 1.9 COL4A3 ENSG00000169031 "Collagen type IV alpha 3 chain" Q01955 2 227164565-227314792 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Cell adhesion" "Alport syndrome, Cancer-related genes, Deafness, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "kidney: 27.9" "Cell line enhanced" "Detected in some" "HeLa: 16.1;Karpas-707: 9.5;RPTEC TERT1: 10.7;U-266/70: 8.8" "Group enriched" "Detected in some" 6 "lung cancer: 1.7;renal cancer: 3.0;thyroid cancer: 5.0" "Low region specificity" "Detected in many" "Group enriched" "Detected in some" 5 "memory B-cell: 3.8;naive B-cell: 1.6" "Lineage enriched" "Detected in single" 7 "B-cells: 3.8" "Not detected" "Not detected" HPA042064 Approved Approved "Endoplasmic reticulum,Vesicles" "Secreted to extracellular matrix" Vesicles "Endoplasmic reticulum" "HPA042064: AB_10794410" "unprognostic (4.81e-2)" "unprognostic (2.25e-1)" "unprognostic (2.23e-1)" "unprognostic (9.28e-6)" "unprognostic (1.43e-1)" "unprognostic (3.29e-2)" "unprognostic (1.84e-2)" "unprognostic (7.07e-3)" "unprognostic (2.30e-1)" "unprognostic (9.09e-3)" "unprognostic (9.30e-2)" "unprognostic (3.02e-2)" "prognostic favourable (2.51e-7)" "unprognostic (1.78e-1)" "unprognostic (3.10e-2)" "unprognostic (2.49e-2)" "unprognostic (1.26e-1)" 0.7 9.5 0.9 5.4 2.9 0.3 0.9 1.4 2.9 0.7 0.7 1.7 12.0 0.7 1.5 15.3 1.1 1.5 5.3 6.7 1.6 1.2 27.9 0.7 15.0 3.6 2.4 0.0 3.6 4.4 0.2 16.7 0.2 7.5 4.9 1.0 20.9 1.1 11.2 17.8 0.6 5.0 2.9 3.1 6.1 1.5 1.5 3.4 0.0 16.2 9.4 5.8 1.8 1.2 3.8 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.8 0.0 0.0 0.2 1.0 0.0 16.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 9.5 0.0 0.4 0.0 0.1 1.3 0.0 0.0 0.0 2.9 10.7 2.1 0.5 0.0 0.8 0.1 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.1 8.8 3.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.5 3.8 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 2.9 1.4 2.9 1.6 1.2 2.4 0.0 7.5 3.4 COL5A1 ENSG00000130635 "Collagen type V alpha 1 chain" P20908 9 134641774-134844843 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" Heparin-binding "Cancer-related genes, Disease mutation, Ehlers-Danlos syndrome" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "cervix, uterine: 110.7" "Cell line enhanced" "Detected in many" "BJ: 71.5;fHDF/TERT166: 66.4;HeLa: 47.4;HHSteC: 45.1;SiHa: 47.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 7 "MAIT T-cell: 2.3" "Lineage enriched" "Detected in single" 23 "T-cells: 2.3" "Low region specificity" "Detected in many" "Low region specificity" "Detected in single" HPA030769 Approved Approved Vesicles "Secreted to extracellular matrix" 12000000 Vesicles "HPA030769: " "unprognostic (7.77e-2)" "unprognostic (4.55e-3)" "unprognostic (2.22e-2)" "unprognostic (2.33e-1)" "prognostic unfavourable (9.56e-4)" "unprognostic (8.07e-2)" "unprognostic (8.09e-2)" "unprognostic (2.38e-3)" "unprognostic (1.54e-2)" "unprognostic (5.03e-3)" "unprognostic (5.05e-2)" "unprognostic (1.40e-1)" "prognostic unfavourable (2.07e-12)" "unprognostic (2.02e-2)" "unprognostic (4.73e-2)" "unprognostic (1.65e-2)" "unprognostic (2.50e-3)" 11.5 4.2 1.5 13.7 1.4 0.0 9.5 3.0 1.2 110.7 20.9 1.4 11.8 3.6 42.1 24.1 12.3 20.5 31.8 12.2 1.8 0.9 4.3 3.4 13.4 7.8 3.0 1.3 19.5 3.7 3.7 2.6 53.8 2.2 23.3 4.7 9.1 5.1 9.9 5.0 6.9 8.7 26.7 1.5 6.5 12.5 9.5 1.1 2.7 4.1 10.1 4.0 21.8 22.9 0.0 0.0 0.0 0.0 0.0 2.3 0.0 0.1 2.7 2.1 3.4 32.1 34.6 1.3 71.5 14.4 12.2 13.1 0.0 0.0 0.0 15.8 66.4 0.9 0.0 0.0 3.5 0.0 0.1 0.0 47.4 0.0 45.1 0.0 0.4 33.9 0.0 11.8 0.9 14.5 0.0 0.2 6.4 0.6 0.0 0.1 1.2 1.3 2.5 8.3 0.2 0.0 0.0 0.9 0.4 47.1 0.3 0.0 0.1 0.0 24.7 25.7 10.6 31.4 14.9 0.0 0.0 0.0 20.4 0.0 4.3 0.0 0.0 0.0 0.3 0.0 2.3 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 1.4 3.0 1.2 1.8 0.9 3.0 1.3 2.2 1.1 COL5A3 ENSG00000080573 "Collagen type V alpha 3 chain" P25940 19 9959561-10010471 "Cancer-related genes, Predicted secreted proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adipose tissue: 48.9" "Cell line enhanced" "Detected in some" "ASC TERT1: 23.4;BJ: 13.5;BJ hTERT+: 15.1;BJ hTERT+ SV40 Large T+: 8.4;HSkMC: 16.8;WM-115: 15.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 5 "MAIT T-cell: 1.7" "Lineage enriched" "Detected in single" 18 "T-cells: 1.7" "Low region specificity" "Detected in some" "Low region specificity" "Detected in many" HPA048256 Approved "Secreted to extracellular matrix" 210000 "HPA048256: " "unprognostic (1.17e-1)" "unprognostic (1.35e-2)" "unprognostic (4.63e-2)" "unprognostic (3.24e-2)" "unprognostic (6.84e-3)" "unprognostic (3.01e-1)" "unprognostic (7.47e-2)" "unprognostic (1.79e-2)" "unprognostic (2.36e-1)" "unprognostic (2.27e-1)" "unprognostic (4.62e-2)" "unprognostic (2.09e-1)" "prognostic unfavourable (7.17e-8)" "unprognostic (3.25e-2)" "unprognostic (7.31e-3)" "unprognostic (6.00e-2)" "prognostic unfavourable (6.87e-5)" 48.9 2.6 11.6 10.8 15.9 0.4 27.0 3.2 11.9 24.5 7.8 3.2 3.1 3.6 17.5 9.8 11.3 8.1 10.7 9.5 10.1 3.0 1.9 4.1 6.4 9.2 5.2 3.5 3.4 3.8 3.2 0.9 30.2 4.5 6.8 2.2 9.7 5.1 9.1 15.4 19.0 3.9 9.6 2.5 1.3 3.4 5.3 2.6 1.6 4.5 11.5 4.7 7.3 10.2 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.3 0.0 7.4 23.4 0.0 13.5 15.1 8.4 3.4 0.0 0.0 0.0 0.1 2.5 1.3 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 16.8 0.3 3.0 3.2 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 3.7 0.0 0.0 0.0 6.9 3.2 0.2 0.0 0.0 0.0 0.0 0.9 0.0 15.1 0.0 0.0 0.0 0.3 0.0 1.7 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 11.6 15.9 3.2 11.9 10.1 3.0 5.2 3.5 4.5 2.6 COL6A1 ENSG00000142156 "Collagen type VI alpha 1 chain" P12109 21 45981737-46005050 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins" "Cell adhesion" "Cancer-related genes, Congenital muscular dystrophy, Disease mutation, Limb-girdle muscular dystrophy" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "ASC diff: 92.0;ASC TERT1: 187.3;BJ: 70.3;HHSteC: 81.7;HSkMC: 136.9;U-138 MG: 102.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "MAIT T-cell: 1.0;memory CD8 T-cell: 1.7" "Lineage enriched" "Detected in single" 18 "T-cells: 1.7" "Low region specificity" "Detected in all" "HPA019142, HPA029401" Enhanced Approved Cytosol "Secreted to extracellular matrix" 250000000 Cytosol "HPA019142: AB_1847093, HPA029401: AB_10601361" "unprognostic (3.45e-1)" "unprognostic (4.09e-2)" "unprognostic (8.71e-2)" "unprognostic (1.72e-1)" "unprognostic (5.79e-3)" "unprognostic (2.12e-1)" "unprognostic (6.27e-2)" "unprognostic (1.09e-2)" "unprognostic (4.47e-2)" "unprognostic (3.69e-2)" "unprognostic (6.06e-3)" "unprognostic (3.86e-1)" "prognostic unfavourable (1.07e-8)" "unprognostic (5.16e-2)" "unprognostic (7.39e-2)" "unprognostic (3.53e-3)" "prognostic unfavourable (4.54e-4)" 73.4 10.8 6.8 45.5 7.1 0.1 85.4 31.9 9.1 100.7 111.6 5.1 34.7 17.1 98.8 75.0 54.5 64.7 89.7 39.7 6.0 5.6 10.2 9.9 21.6 24.7 4.8 5.4 83.0 13.5 6.2 19.8 65.7 9.2 59.6 9.9 18.6 23.1 36.4 20.0 28.2 33.8 147.8 4.7 15.9 40.9 20.2 5.5 9.4 15.9 23.4 12.8 86.9 49.5 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.2 1.5 2.4 7.7 92.0 187.3 0.3 70.3 45.4 18.1 6.3 1.2 4.8 0.0 5.8 39.5 0.3 1.0 0.1 1.5 0.0 1.0 0.0 0.2 0.3 81.7 0.0 0.1 136.9 0.0 45.0 0.6 0.4 0.0 0.0 4.6 0.1 0.0 0.2 1.7 19.7 0.0 1.4 0.3 0.1 0.8 0.0 3.0 6.5 0.0 1.3 0.3 0.3 0.0 102.6 6.8 28.1 26.8 0.0 0.0 0.0 36.6 0.5 8.9 0.0 0.0 0.0 0.7 0.0 1.0 0.0 0.3 1.7 0.0 0.0 0.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 6.8 7.1 31.9 9.1 6.0 5.6 4.8 5.4 9.2 5.5 COX17 ENSG00000138495 "COX17, cytochrome c oxidase copper chaperone" Q14061 3 119654513-119677454 "Cancer-related genes, Predicted intracellular proteins" Chaperone "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "HPA042226, HPA048158" Supported Supported Mitochondria 1000000 Mitochondria "HPA042226: , HPA048158: " "unprognostic (1.98e-2)" "unprognostic (3.49e-2)" "unprognostic (1.96e-2)" "unprognostic (8.29e-2)" "unprognostic (2.88e-2)" "unprognostic (6.63e-3)" "unprognostic (3.49e-2)" "unprognostic (2.90e-1)" "unprognostic (1.36e-1)" "unprognostic (7.11e-3)" "unprognostic (2.12e-1)" "unprognostic (4.45e-2)" "unprognostic (1.33e-2)" "unprognostic (2.15e-2)" "unprognostic (1.65e-1)" "unprognostic (9.19e-2)" "unprognostic (2.64e-2)" 16.6 42.9 20.0 18.2 19.4 21.2 30.4 21.1 20.4 10.2 16.8 9.2 43.5 22.0 11.9 22.9 11.7 11.0 13.6 53.5 17.2 23.0 27.6 37.0 17.8 20.3 23.2 15.2 7.9 39.9 21.1 45.7 18.2 33.7 17.2 16.2 19.4 25.6 33.3 80.4 8.7 21.0 15.4 20.8 15.3 22.3 13.4 16.7 11.1 16.6 37.1 17.2 13.7 20.1 35.6 53.5 52.8 46.9 19.8 33.9 22.0 27.2 28.5 15.6 3.8 6.0 5.6 5.6 15.2 9.2 14.1 14.7 25.1 19.8 19.7 18.5 7.2 10.3 15.4 15.5 8.5 24.8 18.5 17.1 22.6 19.8 6.9 24.9 32.0 6.4 15.0 8.8 12.1 9.1 13.9 47.5 16.3 44.4 25.0 35.9 17.5 47.6 11.1 10.5 32.6 21.9 16.1 26.0 11.4 18.8 18.1 22.8 22.7 39.7 7.2 12.1 19.0 7.6 20.9 33.8 33.7 41.8 17.2 19.1 20.8 50.1 22.4 52.8 21.8 33.2 23.0 35.6 27.2 24.7 22.9 27.2 21.7 22.6 17.7 19.8 46.9 53.5 33.9 22.0 20.0 19.4 21.1 20.4 17.2 23.0 23.2 15.2 33.7 16.7 CP ENSG00000047457 Ceruloplasmin P00450 3 149162410-149222055 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins" "Copper transport, Ion transport, Transport" Oxidoreductase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 20 "liver: 311.1" "Cell line enriched" "Detected in some" 9 "EFO-21: 80.4" "Cancer enhanced" "Detected in many" "liver cancer: 98.3" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001834, CAB008591" Supported "Secreted to blood" 160000000000 830000000000 "CAB008591: AB_1613734, HPA001834: AB_1078502" "unprognostic (3.58e-1)" "unprognostic (4.24e-1)" "unprognostic (9.61e-2)" "unprognostic (1.80e-2)" "unprognostic (4.14e-2)" "unprognostic (1.02e-2)" "unprognostic (1.06e-1)" "unprognostic (2.97e-2)" "unprognostic (2.07e-1)" "unprognostic (8.75e-2)" "unprognostic (6.03e-2)" "unprognostic (1.70e-1)" "prognostic unfavourable (1.14e-7)" "unprognostic (2.68e-2)" "unprognostic (1.59e-1)" "unprognostic (2.00e-1)" "unprognostic (2.70e-1)" 1.8 0.7 2.6 0.6 5.7 0.4 3.5 2.6 3.5 10.5 2.0 2.5 0.0 1.7 2.3 0.3 1.1 1.5 0.5 6.6 3.6 1.7 1.6 311.1 2.1 2.4 4.2 0.9 0.4 1.2 1.4 5.3 1.9 9.4 2.1 2.7 15.5 6.9 0.4 1.2 2.0 2.6 0.7 4.8 3.5 0.7 0.5 4.4 0.0 2.8 0.4 3.0 3.2 2.9 1.3 0.8 0.6 1.0 0.3 1.3 0.4 0.0 4.7 4.8 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 80.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.4 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.1 1.7 4.0 0.0 0.0 0.1 0.2 0.0 0.0 0.1 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.6 1.0 0.5 0.8 0.6 0.8 0.9 0.4 0.5 0.6 1.3 0.4 1.3 0.4 0.3 0.4 0.8 0.4 0.4 2.6 5.7 2.6 3.5 3.6 1.7 4.2 0.9 9.4 4.4 CRABP1 "CRABP, CRABP-I, CRABPI, RBP5" ENSG00000166426 "Cellular retinoic acid binding protein 1" P29762 15 78340324-78348230 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" Transport "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 40.1;retina: 73.2;thyroid gland: 80.6" "Group enriched" "Detected in some" 8 "AF22: 143.3;NTERA-2: 42.9" "Cancer enhanced" "Detected in many" "ovarian cancer: 117.2" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 13 "myeloid DC: 1.2" "Lineage enriched" "Detected in single" 13 "dendritic cells: 1.2" "Group enriched" "Detected in many" 5 "amygdala: 6.6;basal ganglia: 20.9;hypothalamus: 15.5;olfactory region: 15.7;pons and medulla: 7.8" "Low region specificity" "Detected in some" HPA017203 Enhanced Supported "HPA017203: AB_1846512" "unprognostic (1.23e-1)" "unprognostic (3.76e-3)" "unprognostic (1.46e-1)" "prognostic unfavourable (4.72e-4)" "unprognostic (2.01e-1)" "unprognostic (4.35e-2)" "unprognostic (1.05e-1)" "unprognostic (1.35e-1)" "unprognostic (2.45e-2)" "unprognostic (9.79e-2)" "unprognostic (1.21e-1)" "unprognostic (2.79e-2)" "unprognostic (9.37e-2)" "unprognostic (2.17e-1)" "unprognostic (1.07e-1)" "unprognostic (2.69e-1)" 0.7 1.3 6.3 1.8 25.6 0.6 24.8 2.8 12.4 1.2 1.9 3.3 0.3 0.9 1.5 1.9 0.7 0.5 1.2 0.7 1.1 21.9 4.2 0.5 0.8 0.6 16.9 4.5 0.7 0.7 0.5 6.3 7.0 40.1 1.0 1.3 73.2 0.6 24.8 0.5 12.3 2.3 1.3 7.3 21.1 1.9 0.6 2.4 0.4 80.6 2.4 1.0 0.7 0.4 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 143.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.7 0.1 0.0 0.9 0.0 0.0 1.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 7.6 0.0 42.9 0.1 0.0 0.0 0.0 0.0 0.2 12.0 8.1 0.0 0.0 0.0 0.2 4.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.3 25.6 2.8 12.4 1.1 21.9 16.9 4.5 40.1 2.4 CRADD RAIDD ENSG00000169372 "CASP2 and RIPK1 domain containing adaptor with death domain" P78560 12 93677375-93894840 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" Apoptosis "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB005337 Uncertain Approved Nucleoplasm,Cytosol Cytosol Nucleoplasm "CAB005337: AB_2085481" "unprognostic (1.07e-2)" "prognostic favourable (9.06e-5)" "unprognostic (9.65e-3)" "unprognostic (5.51e-2)" "unprognostic (2.88e-1)" "unprognostic (3.10e-1)" "unprognostic (3.79e-2)" "unprognostic (8.99e-2)" "unprognostic (1.54e-1)" "unprognostic (7.89e-2)" "unprognostic (6.06e-2)" "unprognostic (3.18e-2)" "prognostic favourable (4.04e-9)" "unprognostic (2.57e-2)" "unprognostic (6.86e-2)" "unprognostic (2.08e-1)" "unprognostic (3.02e-2)" 7.8 15.9 11.0 4.4 14.2 7.1 10.4 12.5 10.4 8.8 9.3 11.5 16.7 14.8 10.6 11.9 9.9 8.3 9.6 35.7 12.3 8.9 14.8 31.4 7.5 7.1 9.8 9.7 8.5 9.7 18.7 21.2 6.5 13.3 9.4 7.5 11.3 10.3 8.8 22.1 8.0 15.4 12.2 11.5 8.3 9.5 15.0 13.2 9.7 8.6 15.5 5.5 10.2 8.4 8.6 7.6 25.3 12.2 10.8 15.0 6.8 6.1 13.9 6.9 7.8 10.0 18.1 8.7 7.0 8.7 6.2 7.3 13.0 2.5 10.9 4.4 8.1 6.3 7.4 9.3 8.1 11.5 10.0 5.8 5.9 9.5 10.3 5.3 5.6 16.4 14.2 10.0 7.9 7.5 16.4 5.2 7.3 9.8 7.7 9.5 8.8 10.7 13.1 3.5 15.1 6.0 4.5 10.6 10.2 9.5 9.4 16.8 16.6 10.4 7.9 14.5 7.2 6.9 7.1 12.3 6.7 10.1 6.8 7.9 6.8 24.9 6.9 25.3 14.7 8.3 13.0 8.6 10.3 15.0 5.6 7.2 11.1 8.2 19.4 10.8 12.2 7.6 11.5 6.8 11.0 14.2 12.5 10.4 12.3 8.9 9.8 9.7 13.3 13.2 CREB1 ENSG00000118260 "CAMP responsive element binding protein 1" P16220 2 207529737-207603431 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Differentiation, Host-virus interaction, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003803, HPA019150" Supported Enhanced Nucleoplasm Nucleoplasm "CAB003803: AB_562092, HPA019150: AB_1847220" "unprognostic (1.20e-1)" "unprognostic (3.15e-1)" "unprognostic (3.30e-2)" "unprognostic (2.69e-2)" "unprognostic (3.16e-2)" "unprognostic (1.03e-1)" "prognostic unfavourable (2.77e-5)" "unprognostic (8.41e-2)" "unprognostic (1.04e-2)" "unprognostic (2.53e-1)" "unprognostic (9.58e-2)" "unprognostic (1.74e-2)" "unprognostic (4.82e-3)" "unprognostic (5.53e-3)" "unprognostic (1.06e-1)" "unprognostic (1.77e-1)" "unprognostic (8.45e-2)" 21.2 12.9 19.4 24.8 17.0 22.9 16.7 25.5 18.7 17.6 15.7 14.3 14.7 12.6 19.3 14.9 17.9 15.4 15.5 14.4 15.4 14.5 14.6 13.1 17.7 21.7 15.8 17.7 20.5 12.9 19.8 20.0 19.8 16.1 16.3 16.2 11.2 16.2 14.9 11.6 14.3 15.2 19.5 19.8 19.0 13.3 39.2 18.5 38.4 19.7 13.3 27.7 16.1 23.6 22.1 20.7 34.8 19.1 28.4 22.5 14.5 15.4 13.8 25.7 9.8 15.1 15.5 14.6 9.9 14.9 17.3 18.2 14.0 15.7 10.0 13.4 14.6 13.5 23.2 13.6 25.5 16.0 8.4 18.4 12.4 14.3 12.6 17.3 13.5 11.1 10.1 14.3 21.3 24.3 12.9 14.7 21.3 10.6 26.4 10.3 18.3 8.4 20.6 14.0 13.2 15.4 16.0 17.7 15.4 13.8 10.1 11.9 11.3 19.0 11.6 14.1 15.1 14.8 12.7 13.3 16.8 23.1 17.4 16.0 14.8 16.9 17.0 16.8 17.3 18.0 15.4 22.1 16.6 16.7 20.7 20.2 19.9 13.5 34.8 28.4 19.1 11.3 22.5 14.5 19.4 17.0 25.5 18.7 15.4 14.5 15.8 17.7 16.1 18.5 CREB3L1 OASIS ENSG00000157613 "CAMP responsive element binding protein 3 like 1" Q96BA8 11 46277661-46321422 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors" "Host-virus interaction, Transcription, Transcription regulation, Unfolded protein response" "Activator, Developmental protein, DNA-binding" "Cancer-related genes, Osteogenesis imperfecta" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "pancreas: 60.7" "Cell line enhanced" "Detected in many" "BJ: 30.0;BJ hTERT+: 29.5;BJ hTERT+ SV40 Large T+: 27.6;fHDF/TERT166: 71.4;HHSteC: 26.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in some" "Low region specificity" "Detected in all" "HPA024069, CAB026151" Enhanced "CAB026151: , HPA024069: AB_1854750" "unprognostic (2.46e-2)" "unprognostic (2.80e-1)" "unprognostic (1.34e-1)" "prognostic favourable (3.92e-4)" "unprognostic (1.66e-3)" "unprognostic (2.93e-1)" "unprognostic (5.41e-2)" "unprognostic (2.75e-2)" "unprognostic (3.21e-2)" "unprognostic (3.13e-1)" "unprognostic (1.54e-1)" "unprognostic (1.87e-1)" "prognostic unfavourable (2.97e-4)" "unprognostic (2.62e-1)" "unprognostic (1.93e-1)" "prognostic unfavourable (8.59e-4)" "unprognostic (1.12e-2)" 2.5 3.6 3.7 3.1 2.3 0.0 3.0 1.6 2.9 17.2 13.1 0.9 9.5 8.6 9.7 9.2 2.2 1.7 37.6 4.8 3.3 3.5 1.4 1.5 10.4 0.5 3.4 1.7 9.7 60.7 0.0 3.3 8.2 0.6 17.6 14.1 1.8 28.3 14.3 1.6 2.3 12.9 12.8 1.8 2.2 22.1 3.8 0.2 0.4 1.8 2.2 13.0 15.1 3.4 0.0 0.1 0.0 0.4 0.1 0.0 0.0 0.2 0.1 0.3 5.9 19.1 18.3 0.1 30.0 29.5 27.6 19.2 3.0 0.0 0.0 0.1 71.4 0.0 0.3 0.0 15.4 0.0 0.3 0.4 0.1 0.0 26.6 0.0 0.4 17.5 0.0 15.6 0.5 0.2 2.4 0.0 23.1 0.0 0.0 0.0 3.8 3.1 0.0 4.1 0.0 0.0 0.0 0.0 0.0 0.2 0.7 0.0 0.0 1.0 0.0 14.5 4.3 11.1 18.2 0.0 0.0 0.0 17.3 0.0 0.1 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 3.7 2.3 1.6 2.9 3.3 3.5 3.4 1.7 0.6 0.2 CREB3L2 "BBF2H7, TCAG_1951439" ENSG00000182158 "CAMP responsive element binding protein 3 like 2" Q70SY1 7 137874979-138002067 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors" "Transcription, Transcription regulation, Unfolded protein response" "Activator, Developmental protein, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "placenta: 81.6" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA015068, HPA015534" Uncertain Supported "Nucleoplasm,Endoplasmic reticulum" "Nucleoplasm, Endoplasmic reticulum" "HPA015068: AB_1847224, HPA015534: " "unprognostic (8.50e-2)" "unprognostic (3.70e-2)" "unprognostic (2.77e-1)" "unprognostic (1.50e-3)" "unprognostic (9.88e-2)" "unprognostic (9.09e-2)" "unprognostic (5.17e-2)" "unprognostic (4.50e-1)" "unprognostic (4.77e-1)" "unprognostic (8.93e-2)" "unprognostic (9.48e-2)" "unprognostic (9.65e-2)" "unprognostic (2.42e-1)" "unprognostic (3.08e-3)" "unprognostic (7.65e-2)" "unprognostic (2.59e-2)" "unprognostic (1.32e-2)" 14.9 19.8 4.7 17.1 9.8 10.8 15.7 1.9 6.0 25.4 16.7 11.4 18.7 11.6 28.2 25.5 12.8 16.2 16.2 20.4 5.6 4.3 17.0 11.7 14.6 15.2 11.8 3.7 25.9 16.0 38.4 28.8 81.6 9.8 15.9 9.5 24.9 26.5 23.3 5.0 6.9 17.5 17.7 6.2 12.1 14.1 9.8 9.1 7.0 35.8 10.9 18.1 21.3 15.7 4.6 12.4 7.4 5.6 6.5 11.8 3.2 4.0 6.2 11.8 0.2 20.2 20.1 8.9 20.0 32.5 14.1 14.2 8.5 3.6 0.8 5.4 21.7 2.1 6.9 14.7 27.6 5.8 3.4 25.3 8.5 20.2 13.4 7.6 36.3 8.3 9.4 17.7 20.8 18.5 13.0 11.8 16.4 7.2 2.4 9.4 4.2 4.4 5.3 6.4 6.7 11.0 4.1 3.0 7.1 6.5 16.9 8.9 2.4 5.7 19.7 18.9 2.9 22.7 7.3 14.0 4.8 5.3 22.7 21.5 41.9 7.4 5.6 5.9 8.2 2.9 10.6 4.0 6.0 8.6 5.8 4.6 2.2 3.8 2.1 6.5 1.5 12.4 11.8 3.2 4.7 9.8 1.9 6.0 5.6 4.3 11.8 3.7 9.8 9.1 CREBBP "CBP, KAT3A, RSTS, RTS" ENSG00000005339 "CREB binding protein" Q92793 16 3725054-3880726 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Biological rhythms, Host-virus interaction, Transcription, Transcription regulation" "Activator, Acyltransferase, Transferase" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004212, HPA055861" Supported Enhanced "Nucleoplasm,Nuclear bodies" Nucleoplasm "Nuclear bodies" "CAB004212: AB_626817, HPA055861: " "unprognostic (1.17e-1)" "unprognostic (8.51e-2)" "unprognostic (1.60e-1)" "unprognostic (1.63e-1)" "unprognostic (1.49e-1)" "unprognostic (5.09e-2)" "unprognostic (9.59e-3)" "unprognostic (6.98e-2)" "unprognostic (8.96e-2)" "unprognostic (1.08e-1)" "unprognostic (1.76e-1)" "unprognostic (2.84e-1)" "prognostic favourable (6.24e-5)" "unprognostic (1.47e-1)" "unprognostic (1.74e-1)" "unprognostic (3.97e-2)" "unprognostic (8.23e-2)" 18.5 10.9 17.2 22.8 17.5 37.0 17.4 42.6 18.8 20.1 17.2 16.8 17.1 9.9 25.1 15.2 14.1 18.9 21.3 14.5 17.1 8.7 11.1 12.3 16.9 14.4 20.5 12.0 31.6 23.4 24.3 13.0 13.3 15.8 18.4 11.6 14.6 14.9 16.7 28.2 20.4 16.4 17.0 13.6 17.4 14.7 29.1 20.2 29.6 19.5 13.8 16.1 19.0 29.9 4.7 2.3 10.6 3.8 2.0 2.7 1.1 5.5 14.3 18.6 8.2 11.4 11.3 9.6 8.0 13.5 13.9 13.5 12.9 10.5 15.4 9.6 15.3 10.8 21.4 6.6 15.8 26.0 8.6 12.1 13.2 8.2 12.6 12.1 17.4 10.0 6.7 15.4 18.6 10.4 13.7 21.1 7.5 19.1 8.0 5.8 15.2 5.9 37.8 14.7 11.8 5.4 7.5 15.5 10.2 13.7 13.5 8.1 12.0 11.9 16.1 17.0 16.9 8.7 7.3 9.9 10.6 29.9 3.4 7.3 11.9 2.9 1.7 1.3 2.7 2.2 1.4 4.7 1.3 2.0 1.0 3.3 1.4 1.7 10.6 2.0 3.8 2.3 1.3 1.1 17.2 17.5 42.6 18.8 17.1 8.7 20.5 12.0 15.8 20.2 CRP PTX1 ENSG00000132693 "C-reactive protein" P02741 1 159712289-159714589 "Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Acute phase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 66 "liver: 1139.7" "Cell line enhanced" "Detected in some" "EFO-21: 8.0;HDLM-2: 7.6;U-2 OS: 5.4;U-266/84: 12.8" "Cancer enriched" "Detected in some" 13 "liver cancer: 1010.0" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB005036, HPA027367, HPA027396" Supported Approved "Nucleoplasm,Vesicles,Intermediate filaments" "Secreted to blood" 1832500000 5400000000 "Nucleoplasm, Vesicles" "Intermediate filaments" "CAB005036: AB_562362, HPA027367: AB_1847216, HPA027396: AB_1847217" "unprognostic (3.74e-1)" "unprognostic (5.31e-2)" "unprognostic (2.97e-2)" "unprognostic (1.27e-1)" "unprognostic (3.57e-2)" "unprognostic (1.33e-2)" "unprognostic (3.13e-1)" "prognostic unfavourable (4.17e-10)" "unprognostic (3.39e-2)" "unprognostic (3.48e-1)" "unprognostic (5.60e-2)" "unprognostic (6.61e-2)" 0.4 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.4 0.1 0.1 0.0 17.2 0.1 0.1 0.0 0.1 1139.7 0.1 0.1 0.1 0.1 0.1 7.0 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.3 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.0 0.0 0.3 0.0 0.0 0.0 7.6 0.0 0.3 0.0 0.0 0.0 0.3 0.1 1.0 0.0 0.0 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 2.6 0.0 0.0 0.0 0.0 0.1 0.0 5.4 0.1 0.9 0.0 12.8 2.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 CRTC1 "FLJ14027, KIAA0616, MECT1, TORC1" ENSG00000105662 "CREB regulated transcription coactivator 1" Q6UUV9 19 18683677-18782333 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Biological rhythms, Host-virus interaction, Transcription, Transcription regulation" Activator "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 40.7" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA022035 Enhanced Supported "Nucleoplasm,Nuclear bodies,Plasma membrane,Cytosol" "Nucleoplasm, Nuclear bodies" "Plasma membrane, Cytosol" "HPA022035: AB_1847255" "unprognostic (5.95e-3)" "unprognostic (2.57e-1)" "unprognostic (9.94e-2)" "unprognostic (8.62e-3)" "unprognostic (9.07e-2)" "unprognostic (1.57e-2)" "unprognostic (1.04e-1)" "unprognostic (5.57e-2)" "unprognostic (2.27e-1)" "unprognostic (6.68e-2)" "prognostic favourable (1.80e-5)" "unprognostic (3.37e-2)" "prognostic favourable (3.83e-5)" "unprognostic (6.83e-3)" "unprognostic (1.02e-1)" "unprognostic (2.51e-2)" "unprognostic (2.03e-2)" 8.6 7.7 26.0 7.4 38.8 3.2 3.8 40.7 30.1 5.0 4.4 6.5 4.3 6.5 6.8 5.6 3.1 10.5 5.5 5.6 17.7 7.8 6.6 4.5 5.7 6.3 6.4 18.1 6.7 10.0 8.4 11.3 6.4 6.0 7.0 2.6 5.1 8.8 9.4 12.4 5.5 6.2 4.3 4.8 8.1 8.0 7.5 10.2 1.9 7.4 1.1 3.7 4.6 3.5 4.1 3.8 1.8 3.4 1.1 3.0 1.3 4.3 8.0 5.8 9.3 5.4 4.6 16.5 4.8 3.2 4.6 4.5 5.4 5.7 6.1 10.2 4.6 4.7 1.7 3.0 1.1 2.7 13.9 5.1 7.1 8.8 5.2 7.0 14.5 7.4 2.9 4.0 1.2 2.6 4.0 5.6 2.6 16.0 4.5 8.1 7.5 11.8 7.2 2.5 6.7 2.9 7.8 10.7 9.6 5.4 5.2 5.8 5.8 4.3 4.6 5.3 8.1 9.6 5.5 3.8 3.0 4.0 6.1 7.6 4.0 1.5 3.4 1.8 1.7 1.3 1.8 2.3 2.7 3.0 3.0 4.1 2.3 1.8 1.7 1.1 1.9 3.8 1.8 1.3 26.0 38.8 40.7 30.1 17.7 7.8 6.4 18.1 6.0 10.2 CRTC3 FLJ21868 ENSG00000140577 "CREB regulated transcription coactivator 3" Q6UUV7 15 90529925-90645345 "Cancer-related genes, Predicted intracellular proteins" "Host-virus interaction, Transcription, Transcription regulation" Activator "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HeLa: 39.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "basophil: 16.0" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA043735, HPA063691" Uncertain Enhanced Nucleoplasm,Cytosol Nucleoplasm Cytosol "HPA043735: AB_10794286, HPA063691: " "unprognostic (7.60e-2)" "unprognostic (6.13e-2)" "unprognostic (1.35e-1)" "unprognostic (2.31e-2)" "unprognostic (5.12e-2)" "unprognostic (3.51e-1)" "unprognostic (1.75e-2)" "unprognostic (1.69e-1)" "unprognostic (6.48e-2)" "unprognostic (3.60e-1)" "unprognostic (1.47e-1)" "unprognostic (2.23e-1)" "unprognostic (5.22e-3)" "unprognostic (4.67e-2)" "unprognostic (9.32e-2)" "unprognostic (9.51e-2)" "unprognostic (2.30e-1)" 22.3 14.0 13.7 17.0 20.9 11.4 26.6 15.0 16.2 21.2 22.2 27.5 15.3 8.9 23.9 14.5 15.1 19.4 21.5 17.2 14.0 9.7 10.7 11.7 19.2 21.7 24.1 10.9 45.9 13.9 17.1 9.6 20.2 15.7 18.2 11.7 17.4 19.9 22.0 16.1 15.8 13.7 31.8 20.3 13.1 14.2 15.3 23.6 12.8 22.7 9.2 18.1 24.0 29.6 5.3 2.1 16.0 2.5 3.3 6.6 3.0 4.7 7.9 5.4 8.8 11.7 8.7 24.7 6.1 8.9 9.6 9.1 6.5 4.8 0.1 4.4 12.6 8.0 8.6 5.3 7.6 8.2 10.0 12.1 39.3 3.0 13.3 3.1 20.7 9.7 8.5 7.9 10.7 6.9 6.4 2.8 7.1 5.5 1.3 4.5 1.9 3.7 4.1 8.6 0.2 3.4 10.1 9.9 8.8 17.8 5.9 9.9 5.9 5.9 8.5 10.7 7.9 9.9 7.0 3.7 5.0 3.6 4.4 6.3 5.1 16.0 2.5 1.4 3.7 0.8 4.2 3.1 4.5 4.0 1.6 5.3 6.6 4.1 0.5 3.3 0.3 2.1 4.2 3.0 13.7 20.9 15.0 16.2 14.0 9.7 24.1 10.9 15.7 23.6 CRYAB "CRYA2, HSPB5" ENSG00000109846 "Crystallin alpha B" P02511 11 111908565-111923722 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Chaperone, Eye lens protein" "Cancer-related genes, Cardiomyopathy, Cataract, Disease mutation, Myofibrillar myopathy" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "heart muscle: 743.1;skeletal muscle: 581.1" "Group enriched" "Detected in some" 5 "ASC diff: 230.1;fHDF/TERT166: 75.0" "Group enriched" "Detected in all" 6 "glioma: 426.4;renal cancer: 575.9" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB002053, CAB040560, HPA057100" Enhanced Enhanced "Plasma membrane,Cytosol" 12000 "Plasma membrane, Cytosol" "CAB002053: AB_442024, CAB040560: , HPA057100: " "unprognostic (1.06e-2)" "unprognostic (2.26e-1)" "prognostic unfavourable (4.90e-5)" "unprognostic (2.46e-2)" "unprognostic (3.02e-2)" "unprognostic (8.41e-3)" "unprognostic (9.29e-3)" "unprognostic (7.35e-2)" "unprognostic (8.91e-2)" "unprognostic (1.55e-2)" "unprognostic (6.68e-2)" "unprognostic (7.02e-2)" "unprognostic (3.68e-2)" "unprognostic (7.92e-2)" "unprognostic (8.83e-2)" "unprognostic (1.18e-1)" "prognostic unfavourable (1.70e-5)" 107.4 11.5 47.8 16.7 82.3 2.1 69.5 24.8 153.7 22.4 23.6 132.9 7.2 5.5 14.8 25.9 41.9 13.5 14.0 743.1 65.9 44.0 151.8 3.8 8.4 3.9 139.2 29.7 8.8 6.6 3.3 8.6 16.1 80.7 30.3 12.9 23.3 30.6 75.1 581.1 18.1 6.2 45.2 168.0 5.5 11.6 3.9 101.8 0.0 40.7 94.1 9.2 16.2 53.6 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 4.3 230.1 10.1 1.6 6.4 0.2 0.1 0.2 0.1 0.0 0.0 3.8 75.0 0.1 0.2 0.2 0.1 0.0 0.0 0.0 1.2 0.6 1.9 0.0 0.0 8.1 1.0 0.0 0.5 0.0 0.5 0.2 18.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 2.8 0.0 0.0 0.0 0.4 0.8 3.4 0.5 0.0 0.1 29.8 10.7 0.8 0.3 0.1 0.0 0.0 0.6 0.1 3.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 47.8 82.3 24.8 48.5 65.9 44.0 139.2 29.7 80.7 101.8 CSDE1 "D1S155E, UNR" ENSG00000009307 "Cold shock domain containing E1" O75534 1 114716913-114758676 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" RNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 266.5" "Cell line enhanced" "Detected in all" "MCF7: 222.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA018846, HPA052221" Supported Enhanced "Plasma membrane,Cytosol" 13000 "Plasma membrane, Cytosol" "HPA018846: AB_1847266, HPA052221: " "unprognostic (2.84e-1)" "unprognostic (9.18e-3)" "unprognostic (4.86e-3)" "unprognostic (3.30e-3)" "unprognostic (2.83e-2)" "unprognostic (4.51e-2)" "unprognostic (5.32e-3)" "unprognostic (5.16e-2)" "unprognostic (1.78e-1)" "unprognostic (5.19e-2)" "unprognostic (3.24e-2)" "unprognostic (2.40e-1)" "unprognostic (4.69e-2)" "unprognostic (4.67e-2)" "unprognostic (1.18e-1)" "unprognostic (5.17e-3)" "unprognostic (2.54e-2)" 71.2 31.4 33.5 25.8 33.2 37.9 42.1 29.6 35.4 39.0 64.7 29.6 35.9 29.5 46.4 38.9 58.8 30.3 29.4 64.2 33.2 31.7 37.4 39.5 34.2 31.4 41.6 31.4 43.9 37.2 50.3 38.4 38.8 44.4 52.6 32.9 32.0 43.2 42.0 266.5 33.8 46.5 88.3 42.4 32.2 39.9 41.5 35.1 39.6 55.7 73.9 31.9 75.4 45.5 43.9 59.0 57.9 65.2 48.1 62.3 80.5 60.6 21.4 38.1 38.0 43.5 56.6 53.3 53.6 40.1 36.1 29.4 31.3 18.4 47.8 45.3 51.1 25.8 42.2 41.6 52.7 58.4 28.8 46.9 39.0 27.7 38.5 34.8 28.0 41.0 45.3 43.2 57.1 41.3 47.5 31.4 44.1 222.4 46.7 22.2 72.6 28.9 35.0 118.0 22.5 28.7 47.8 47.1 31.3 52.5 43.8 40.6 22.5 55.7 49.7 42.7 58.9 56.0 58.8 48.0 52.2 53.6 55.2 39.6 130.2 46.4 57.7 57.9 40.9 60.8 55.5 43.9 52.2 49.7 59.0 34.7 62.3 52.3 40.9 48.1 65.2 23.0 56.7 80.5 33.5 33.2 29.6 35.4 33.2 31.7 41.6 31.4 44.4 35.1 CSE1L "CAS, CSE1, XPO2" ENSG00000124207 "Chromosome segregation 1 like" P55060 20 49046246-49096960 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters" "Protein transport, Transport" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002140, HPA038059, HPA038060" Enhanced Enhanced Nucleoplasm,Cytosol 64000 "Nucleoplasm, Cytosol" "CAB002140: AB_563461, HPA038059: AB_2675811, HPA038060: AB_2675812" "unprognostic (4.01e-2)" "unprognostic (3.15e-2)" "unprognostic (5.63e-2)" "prognostic unfavourable (2.91e-5)" "unprognostic (4.86e-1)" "unprognostic (4.91e-2)" "prognostic unfavourable (2.42e-8)" "unprognostic (3.44e-2)" "unprognostic (1.45e-2)" "unprognostic (2.63e-2)" "unprognostic (2.72e-3)" "unprognostic (2.54e-2)" "prognostic unfavourable (1.89e-4)" "unprognostic (2.59e-1)" "unprognostic (4.84e-1)" "unprognostic (5.71e-1)" "prognostic unfavourable (6.91e-4)" 15.7 18.9 19.5 18.7 23.7 13.7 21.2 24.9 31.3 17.5 14.2 13.4 14.0 12.0 19.5 15.5 25.5 17.3 11.8 17.8 20.0 17.7 18.8 18.7 12.8 24.0 27.3 19.4 18.7 17.3 23.2 16.8 23.1 24.2 16.7 18.4 8.4 15.5 17.0 34.3 20.9 12.4 21.7 31.3 12.6 17.1 50.9 21.0 27.0 14.7 28.1 25.3 18.3 17.5 12.8 14.8 9.4 15.9 16.8 18.0 12.8 35.5 24.8 30.3 23.3 11.8 15.2 32.9 28.1 14.9 88.5 37.5 81.0 28.8 36.5 37.7 17.8 41.3 44.5 52.8 84.5 5.9 21.6 25.3 29.1 39.2 7.2 27.8 13.9 8.5 19.8 43.2 25.1 29.2 35.7 14.4 33.1 12.2 33.5 14.4 25.5 37.0 21.4 49.9 28.4 19.4 24.9 26.7 15.5 44.9 48.7 16.0 40.6 18.2 18.8 47.1 39.6 27.7 39.8 8.4 20.4 34.2 28.1 22.5 25.0 9.4 11.8 2.7 11.0 15.2 16.5 12.8 16.8 13.4 14.8 10.4 18.0 15.3 3.3 16.8 15.9 6.6 14.4 12.8 19.5 23.7 24.9 31.3 20.0 17.7 27.3 19.4 24.2 21.0 CSF1 "M-CSF, MCSF, MGC31930" ENSG00000184371 "Colony stimulating factor 1" P09603 1 109910242-109930992 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins" "Immunity, Inflammatory response, Innate immunity" "Cytokine, Growth factor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "ASC diff: 46.6;ASC TERT1: 29.3;BJ hTERT+: 30.7;HHSteC: 70.9;HSkMC: 45.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 11 "basophil: 7.0;eosinophil: 16.5" "Lineage enriched" "Detected in many" 16 "granulocytes: 16.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" HPA076624 Supported "Nuclear bodies,Plasma membrane" "Secreted to blood" 423300 17000000 "Plasma membrane" "Nuclear bodies" "HPA076624: " "unprognostic (2.35e-3)" "unprognostic (2.14e-1)" "unprognostic (7.36e-2)" "unprognostic (4.19e-1)" "unprognostic (3.60e-1)" "unprognostic (1.64e-2)" "prognostic unfavourable (4.25e-5)" "unprognostic (1.04e-1)" "unprognostic (1.75e-2)" "unprognostic (2.18e-1)" "unprognostic (1.72e-1)" "unprognostic (5.10e-2)" "prognostic unfavourable (1.00e-11)" "unprognostic (2.03e-1)" "unprognostic (1.88e-2)" "unprognostic (4.01e-1)" "unprognostic (3.16e-2)" 38.1 21.4 11.5 14.6 16.7 10.1 36.5 4.3 14.6 13.8 12.8 28.2 3.6 8.5 12.0 10.1 11.3 15.7 20.6 16.0 11.4 5.8 10.7 10.3 23.5 16.9 24.3 5.4 16.9 11.3 6.7 5.2 26.0 19.2 16.3 11.0 12.2 12.4 11.6 12.7 10.4 12.7 16.0 21.9 25.8 11.9 7.5 20.3 2.9 12.4 7.8 11.0 20.6 29.2 0.0 0.0 16.5 0.0 0.0 1.0 0.1 1.5 5.7 2.9 1.1 46.6 29.3 1.0 6.7 30.7 5.3 4.9 0.2 0.8 0.0 8.4 16.4 1.2 1.2 2.2 2.0 18.6 0.9 2.0 3.3 1.9 70.9 0.0 2.6 45.3 0.6 11.7 7.1 1.0 0.4 1.1 6.3 0.1 0.0 0.3 1.0 0.5 0.2 1.5 0.1 2.2 1.5 0.1 0.3 1.9 0.5 2.3 0.4 0.2 3.5 5.6 1.9 24.5 3.7 0.5 0.2 0.0 14.1 0.0 20.7 7.0 0.0 16.5 0.2 0.0 0.5 0.0 0.7 0.5 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 1.0 0.1 11.5 16.7 4.3 14.6 11.4 5.8 24.3 5.4 19.2 20.3 CSF1R "C-FMS, CD115, CSFR, FMS" ENSG00000182578 "Colony stimulating factor 1 receptor" P07333 5 150053291-150113372 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins" "Immunity, Inflammatory response, Innate immunity" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 82.5;lymphoid tissue: 82.6" "Group enriched" "Detected in some" 5 "BEWO: 50.6;SK-BR-3: 19.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "intermediate monocyte: 60.7;non-classical monocyte: 82.5" "Lineage enriched" "Detected in many" 4 "monocytes: 82.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB008970, HPA012323" Uncertain Supported "Vesicles,Plasma membrane" "Intracellular and membrane" 1500000000 "Vesicles, Plasma membrane" "CAB008970: , HPA012323: AB_1848977" "unprognostic (3.82e-2)" "unprognostic (1.31e-1)" "unprognostic (1.86e-3)" "unprognostic (9.83e-2)" "unprognostic (1.20e-1)" "unprognostic (7.33e-2)" "unprognostic (1.03e-1)" "unprognostic (1.45e-1)" "unprognostic (9.37e-2)" "unprognostic (1.11e-2)" "unprognostic (2.49e-1)" "unprognostic (1.65e-1)" "prognostic unfavourable (1.08e-4)" "unprognostic (3.67e-2)" "prognostic unfavourable (4.92e-4)" "unprognostic (1.72e-2)" "unprognostic (4.61e-2)" 20.9 12.4 18.2 28.1 18.9 1.8 7.7 2.8 13.5 9.3 8.3 25.4 1.1 9.2 5.9 13.1 8.4 7.9 16.1 8.7 16.4 13.7 7.8 15.1 13.7 25.4 21.3 6.0 5.3 5.2 5.9 6.4 52.1 17.1 8.5 8.4 16.8 8.0 8.7 3.0 5.8 14.5 16.2 25.8 82.6 9.0 4.9 23.0 3.1 4.2 2.9 8.2 16.4 4.7 0.0 19.1 2.9 82.5 0.0 0.1 13.9 1.7 0.0 0.0 0.0 0.8 0.2 50.6 0.1 0.0 0.0 0.0 1.5 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.4 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.7 0.2 0.0 0.0 0.0 0.1 0.0 19.3 0.0 0.0 7.2 0.0 0.3 0.0 0.0 1.3 0.0 0.1 0.0 2.6 0.9 0.0 0.4 18.1 0.5 0.1 60.7 0.0 0.0 0.0 0.0 19.1 0.0 0.0 0.0 2.9 0.0 82.5 1.4 0.0 13.9 18.2 18.9 2.8 13.4 16.4 13.7 21.3 6.0 17.1 23.0 CSF2 "GM-CSF, GMCSF" ENSG00000164400 "Colony stimulating factor 2" P04141 5 132073790-132076170 "Cancer-related genes, Predicted secreted proteins" "Cytokine, Growth factor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "blood: 9.5;lung: 6.8;pancreas: 4.5" "Cell line enriched" "Detected in some" 4 "BJ hTERT+: 44.0" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Cell type enriched" "Detected in single" 11 "NK-cell: 9.5" "Lineage enriched" "Detected in single" 11 "NK-cells: 9.5" "Not detected" "Not detected" "Low region specificity" "Detected in many" "HPA057404, HPA062006" Enhanced Vesicles "Secreted to blood" 36150 Vesicles "HPA057404: , HPA062006: " "unprognostic (7.29e-2)" "unprognostic (2.49e-3)" "unprognostic (8.77e-2)" "unprognostic (2.09e-2)" "unprognostic (1.05e-2)" "unprognostic (1.26e-1)" "unprognostic (2.56e-1)" "unprognostic (1.47e-2)" "unprognostic (2.64e-1)" "unprognostic (3.68e-3)" "unprognostic (1.87e-8)" "unprognostic (4.81e-2)" "unprognostic (1.22e-1)" "unprognostic (9.07e-2)" "unprognostic (2.06e-2)" 0.2 0.1 0.1 3.9 0.1 1.1 0.1 0.1 0.1 0.1 0.2 0.0 0.0 0.0 0.7 0.0 1.5 0.1 1.1 0.2 0.1 0.1 0.3 0.9 6.8 0.3 0.1 0.0 0.1 4.5 0.0 0.1 0.5 0.0 0.2 0.7 0.0 1.9 0.0 0.1 0.4 1.0 0.6 0.1 1.0 0.2 0.2 0.0 0.4 0.2 0.0 1.8 2.3 0.1 0.0 0.0 0.0 0.0 9.5 0.8 0.0 4.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 44.0 0.0 2.5 0.0 3.5 0.0 0.7 0.0 0.1 0.0 3.2 2.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 10.2 6.8 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 1.7 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.4 0.1 1.8 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.8 0.0 0.0 0.0 0.0 0.0 9.5 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 CSF2RA "alphaGMR, CD116, CSF2R" ENSG00000198223 "Colony stimulating factor 2 receptor alpha subunit" P15509 X 1268800-1310381 "Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins" Receptor "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 60.2;placenta: 79.5" "Group enriched" "Detected in some" 7 "BEWO: 59.0;HMC-1: 17.7;SK-MEL-30: 41.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 4 "classical monocyte: 30.0;eosinophil: 36.0;intermediate monocyte: 17.7;myeloid DC: 31.9;neutrophil: 60.2;plasmacytoid DC: 30.5" "Group enriched" "Detected in many" 28 "dendritic cells: 31.9;granulocytes: 60.2;monocytes: 30.0" CAB016148 Uncertain "Secreted to blood" 9400000 "CAB016148: AB_626868" "unprognostic (4.19e-2)" "prognostic favourable (2.38e-5)" "unprognostic (5.47e-2)" "unprognostic (4.33e-2)" "unprognostic (4.88e-2)" "prognostic favourable (2.81e-4)" "unprognostic (8.24e-2)" "unprognostic (2.17e-1)" "unprognostic (5.55e-2)" "unprognostic (8.48e-2)" "unprognostic (8.89e-2)" "unprognostic (3.80e-1)" "unprognostic (2.89e-2)" "unprognostic (8.91e-3)" "prognostic unfavourable (5.53e-4)" "unprognostic (3.60e-1)" "unprognostic (9.44e-2)" 8.7 2.3 11.8 11.1 11.1 8.9 17.7 3.4 9.6 3.1 2.2 0.6 0.6 2.2 4.4 0.6 2.1 2.2 5.7 3.7 15.0 4.7 2.4 1.7 11.2 8.3 18.8 6.5 3.5 1.0 0.2 2.1 79.5 13.2 1.5 3.3 0.6 3.1 1.0 0.6 1.8 3.3 2.9 25.5 12.6 1.7 0.6 16.3 0.6 2.5 0.6 10.4 4.2 1.5 0.3 31.9 60.2 30.0 1.4 0.2 10.1 0.1 3.4 0.2 0.0 0.0 0.0 59.0 0.0 0.1 0.1 0.0 1.2 0.3 0.0 3.8 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 2.4 0.0 0.0 1.3 17.7 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 5.4 0.5 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.1 1.0 0.0 41.3 2.7 4.9 0.0 0.0 1.7 0.3 0.0 0.1 0.1 0.1 0.0 5.3 0.0 2.4 30.0 36.0 0.0 17.7 0.2 0.3 0.0 0.0 31.9 0.1 0.0 0.0 60.2 1.4 8.4 30.5 0.1 10.1 11.8 11.1 3.4 9.6 15.0 4.7 18.8 6.5 13.2 16.3 CSF3R "CD114, GCSFR" ENSG00000119535 "Colony stimulating factor 3 receptor" Q99062 1 36466043-36483278 "Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" Receptor "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "blood: 167.3;bone marrow: 88.9;lymphoid tissue: 71.4;placenta: 152.7" "Group enriched" "Detected in some" 18 "BEWO: 34.1;NB-4: 9.2;THP-1: 22.4;U-937: 21.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in some" 8 "neutrophil: 167.3" "Lineage enriched" "Detected in many" 8 "granulocytes: 167.3" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB017116, HPA048086" Enhanced "Intracellular and membrane" "CAB017116: , HPA048086: " "unprognostic (5.57e-3)" "unprognostic (8.05e-2)" "unprognostic (7.23e-2)" "unprognostic (3.87e-2)" "unprognostic (2.88e-1)" "unprognostic (2.92e-2)" "unprognostic (2.86e-2)" "unprognostic (1.35e-1)" "unprognostic (1.83e-1)" "unprognostic (5.65e-2)" "unprognostic (2.47e-1)" "unprognostic (3.44e-1)" "prognostic unfavourable (5.72e-4)" "unprognostic (6.33e-2)" "prognostic unfavourable (3.79e-4)" "unprognostic (2.03e-1)" "unprognostic (2.31e-2)" 8.5 1.5 2.9 39.5 3.2 88.9 2.4 0.7 2.9 1.1 1.1 4.2 0.4 0.6 0.7 1.1 1.2 6.9 4.3 5.6 2.6 2.0 1.7 4.5 26.9 27.5 7.2 1.1 1.1 1.3 0.3 1.1 152.7 3.8 1.3 0.5 2.1 1.6 0.5 0.6 0.3 1.6 3.1 7.1 71.4 2.2 1.4 3.3 1.1 1.0 0.4 0.9 4.6 3.9 0.0 8.2 167.3 22.1 0.2 0.0 10.3 0.0 0.0 0.0 0.0 0.0 0.0 34.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.8 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 9.2 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 22.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 21.6 0.0 0.0 22.1 0.6 0.0 4.8 0.0 0.0 0.0 0.0 8.2 0.0 0.0 0.0 167.3 0.2 1.8 0.2 0.0 10.3 2.9 3.2 0.7 2.9 2.6 2.0 7.2 1.1 3.8 3.3 CSN1S1 "CASA, CSN1" ENSG00000126545 "Casein alpha s1" P47710 4 69931081-69946574 "Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins" "Milk protein" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 4 "breast: 184.8" "Cell line enhanced" "Detected in some" "ASC diff: 2.4;HL-60: 1.4;U-266/70: 1.4" "Cancer enriched" "Detected in some" 10 "breast cancer: 17.1" "Low region specificity" "Detected in single" "Group enriched" "Detected in some" 6 "NK-cell: 1.6;plasmacytoid DC: 3.2" "Group enriched" "Detected in many" 11 "dendritic cells: 3.2;NK-cells: 1.6" "HPA035659, HPA057031" Enhanced "Secreted in female reproductive system" "HPA035659: AB_10696356, HPA057031: AB_2683315" "unprognostic (1.52e-2)" "unprognostic (1.01e-1)" 44.7 0.0 0.0 0.0 0.1 0.0 184.8 0.0 0.9 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.4 0.0 0.1 1.2 0.0 0.0 0.0 0.5 0.6 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 3.2 0.2 0.1 1.6 0.0 0.2 0.0 0.0 0.0 0.0 2.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 1.4 0.5 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.2 1.6 0.0 3.2 0.0 0.2 0.0 0.1 0.0 0.9 0.1 1.2 0.6 0.0 0.1 0.0 CSNK1E "CKIE, CKIepsilon, HCKIE" ENSG00000213923 "Casein kinase 1 epsilon" P49674 22 38290691-38318084 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Biological rhythms" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "plasmacytoid DC: 15.7" "Low lineage specificity" "Detected in all" "CAB009626, HPA026288" Approved Approved Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "CAB009626: AB_2084517, HPA026288: AB_1847276" "unprognostic (2.32e-1)" "unprognostic (8.41e-2)" "unprognostic (5.14e-2)" "unprognostic (5.01e-3)" "unprognostic (1.95e-2)" "unprognostic (4.50e-3)" "prognostic unfavourable (8.20e-5)" "unprognostic (2.08e-3)" "unprognostic (3.69e-1)" "unprognostic (1.22e-1)" "unprognostic (9.63e-2)" "unprognostic (4.16e-3)" "prognostic unfavourable (4.67e-6)" "unprognostic (1.91e-1)" "unprognostic (1.66e-1)" "unprognostic (2.58e-1)" "unprognostic (3.25e-3)" 28.5 22.9 30.7 18.3 32.5 21.4 28.6 40.1 42.6 26.4 21.5 32.3 15.7 19.0 37.3 27.3 23.4 28.0 22.1 28.8 31.7 22.3 17.3 11.8 28.4 17.3 28.6 30.1 38.1 25.4 56.2 29.2 33.1 28.7 26.2 17.4 30.5 23.9 23.1 26.3 35.3 17.1 24.0 23.2 20.9 21.8 13.0 33.9 13.3 21.4 14.2 17.4 25.5 28.8 3.7 15.7 4.8 1.8 5.9 4.0 1.2 23.3 11.4 31.0 29.7 15.5 23.8 23.3 30.5 39.1 27.8 27.0 14.6 18.3 17.6 13.3 28.8 20.0 23.5 42.2 20.2 28.1 51.1 5.6 37.7 11.2 32.0 12.3 15.0 22.7 35.8 42.3 57.3 29.5 12.4 36.4 26.8 15.6 17.1 15.1 22.7 16.5 32.0 22.2 27.6 25.5 19.6 45.9 18.0 26.0 27.0 30.5 13.8 17.9 33.5 25.2 27.5 14.5 24.3 16.3 23.3 24.8 37.4 13.9 42.2 3.8 1.8 3.4 3.4 0.8 4.0 2.5 3.8 3.4 1.8 3.7 2.1 3.1 4.8 5.9 0.6 15.7 1.7 1.2 30.7 32.5 40.1 38.8 31.7 22.3 28.6 30.1 28.7 33.9 CSNK2B "Ckb1, Ckb2" ENSG00000204435 "Casein kinase 2 beta" P67870 6 31665236-31670343 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Wnt signaling pathway" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004349, HPA005944, CAB013087, CAB016059" Approved "CAB004349: AB_626791, CAB013087: AB_2533571, CAB016059: AB_626792, HPA005944: AB_1847290" "unprognostic (1.61e-1)" "unprognostic (3.21e-2)" "unprognostic (8.88e-2)" "unprognostic (1.55e-3)" "unprognostic (9.51e-2)" "unprognostic (1.38e-1)" "unprognostic (3.03e-3)" "unprognostic (1.60e-1)" "unprognostic (7.52e-2)" "unprognostic (1.62e-3)" "unprognostic (1.19e-1)" "unprognostic (1.19e-1)" "prognostic unfavourable (1.06e-5)" "unprognostic (5.88e-2)" "unprognostic (1.72e-1)" "unprognostic (9.67e-2)" "unprognostic (3.72e-2)" 28.1 30.5 26.6 28.8 28.0 30.3 27.6 26.9 42.9 29.9 32.7 30.8 24.0 13.9 26.2 101.7 51.5 30.1 32.0 43.8 24.4 23.1 41.1 49.8 34.4 33.8 25.4 24.6 32.9 42.1 3.5 26.4 39.6 23.6 34.3 26.0 30.4 30.3 32.5 40.8 58.3 31.6 32.2 26.6 33.3 26.9 66.0 20.8 60.2 38.5 41.8 33.4 28.3 25.9 20.6 24.9 21.3 22.8 16.3 20.2 16.0 0.0 6.5 0.0 10.7 6.5 10.9 8.0 15.0 26.0 30.7 29.0 0.0 9.4 23.1 8.1 11.0 0.0 0.0 26.5 30.1 11.2 26.9 0.0 0.0 0.0 16.6 25.3 0.0 21.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 14.4 0.0 7.7 0.0 11.7 0.0 14.7 14.7 8.7 0.0 18.3 0.1 0.0 11.5 0.1 0.0 7.4 12.8 15.6 14.6 0.0 9.5 14.8 14.7 9.1 0.0 11.6 16.5 22.8 21.3 16.2 22.3 16.0 20.6 16.7 16.7 21.1 16.4 14.4 12.7 18.4 16.3 14.1 24.9 20.2 16.0 26.6 28.0 26.9 42.9 24.4 23.1 25.4 24.6 23.6 20.8 CST3 ENSG00000101439 "Cystatin C" P01034 20 23626706-23638473 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins" "Protease inhibitor, Thiol protease inhibitor" "Age-related macular degeneration, Amyloidosis, Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "ASC diff: 160.1;ASC TERT1: 109.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 7 "classical monocyte: 163.9;intermediate monocyte: 211.0;myeloid DC: 269.6;non-classical monocyte: 135.1;plasmacytoid DC: 153.5" "Group enriched" "Detected in many" 9 "dendritic cells: 269.6;monocytes: 211.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000118, HPA013143" Enhanced Supported "Golgi apparatus,Vesicles" "Secreted to blood" 4100000000 "Golgi apparatus, Vesicles" "CAB000118: , HPA013143: AB_1847417" "unprognostic (3.89e-2)" "unprognostic (1.63e-1)" "unprognostic (1.45e-1)" "prognostic favourable (1.83e-4)" "unprognostic (8.53e-2)" "unprognostic (4.06e-2)" "unprognostic (2.10e-2)" "unprognostic (2.18e-2)" "unprognostic (3.46e-2)" "unprognostic (3.72e-1)" "unprognostic (2.29e-3)" "unprognostic (3.51e-2)" "unprognostic (1.85e-1)" "unprognostic (1.16e-1)" "unprognostic (2.97e-1)" "unprognostic (5.01e-2)" "prognostic favourable (8.77e-4)" 95.8 72.6 229.0 37.9 254.7 22.2 68.6 61.4 196.7 76.6 78.2 75.4 39.5 59.4 47.6 143.6 73.8 64.9 89.4 79.7 157.4 96.2 35.9 67.3 58.0 91.2 148.3 90.6 51.4 142.1 34.5 45.6 25.8 69.9 55.2 66.1 195.0 338.2 74.2 44.2 44.9 77.9 57.3 73.3 85.5 105.5 57.4 68.4 40.7 43.2 40.1 31.9 49.4 50.2 0.6 269.6 27.4 211.0 6.4 2.4 106.7 12.6 28.8 6.7 15.5 160.1 109.6 12.6 22.1 30.8 15.2 12.3 54.7 19.6 0.0 20.8 30.1 43.0 6.2 44.1 4.7 0.0 21.3 13.0 5.7 93.0 57.3 0.6 21.9 84.8 37.2 20.4 21.9 23.7 11.8 0.3 21.1 20.2 0.1 13.8 9.0 63.2 0.4 8.2 17.5 62.4 28.7 7.4 8.5 16.1 4.8 27.4 13.6 47.7 59.8 14.4 10.4 20.1 8.2 13.6 0.4 0.1 12.3 28.6 16.2 1.4 163.9 1.0 2.4 211.0 0.9 0.6 0.6 1.6 269.6 0.5 0.6 1.2 27.4 6.4 135.1 153.5 0.4 106.7 229.0 254.7 61.4 196.7 157.4 96.2 148.3 90.6 69.9 68.4 CST6 ENSG00000175315 "Cystatin E/M" Q15828 11 66011841-66013505 "Cancer-related genes, Plasma proteins, Predicted secreted proteins" "Protease inhibitor, Thiol protease inhibitor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "skin 1: 124.5" "Group enriched" "Detected in some" 6 "A-431: 26.2;CAPAN-2: 73.1" "Cancer enhanced" "Detected in many" "thyroid cancer: 171.0" "Not detected" "Not detected" "Cell type enhanced" "Detected in single" "classical monocyte: 1.6" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB019316, HPA044963" Enhanced Approved "Plasma membrane,Cytosol" "Secreted in other tissues" 110000000 "Plasma membrane" Cytosol "CAB019316: , HPA044963: " "unprognostic (3.01e-2)" "unprognostic (5.10e-2)" "unprognostic (1.14e-1)" "unprognostic (3.59e-2)" "unprognostic (5.00e-2)" "unprognostic (2.60e-1)" "unprognostic (1.65e-1)" "unprognostic (8.38e-2)" "unprognostic (5.02e-1)" "unprognostic (8.89e-3)" "unprognostic (1.29e-3)" "unprognostic (1.46e-1)" "unprognostic (1.74e-3)" "unprognostic (5.89e-3)" "unprognostic (1.83e-1)" "unprognostic (1.64e-2)" "unprognostic (2.59e-2)" 0.6 0.2 0.1 1.5 0.1 0.2 8.7 0.4 0.2 5.5 0.2 0.0 1.4 0.1 0.3 0.8 11.3 4.3 0.7 2.4 0.1 0.2 1.0 0.1 27.2 1.2 0.1 0.0 1.3 0.2 0.5 0.4 26.5 0.2 0.9 0.1 1.1 1.3 26.5 0.7 124.5 0.2 0.2 0.2 0.2 0.2 1.0 0.0 2.8 14.6 13.6 4.4 0.5 3.7 0.4 0.9 0.0 1.6 0.0 0.2 0.7 26.2 0.0 0.0 0.1 0.0 0.0 7.8 0.2 0.0 0.0 0.0 0.1 73.1 0.0 0.4 0.9 0.9 0.0 6.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.0 0.1 0.0 0.0 7.3 0.1 0.1 0.0 0.0 0.0 0.5 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.9 0.4 0.0 0.2 0.0 0.0 0.6 0.0 0.0 0.7 0.1 0.1 0.4 0.1 0.1 0.2 0.1 0.0 0.2 0.0 CSTA "STF1, STFA" ENSG00000121552 "Cystatin A" P01040 3 122325244-122341972 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell adhesion" "Protease inhibitor, Thiol protease inhibitor" "Cancer-related genes, Ichthyosis" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "esophagus: 312.4;tongue: 421.9" "Cell line enhanced" "Detected in some" "HBEC3-KT: 33.1;hTCEpi: 146.6;THP-1: 91.6;U-698: 58.3;U-937: 29.1" "Cancer enhanced" "Detected in all" "head and neck cancer: 405.0" "Low region specificity" "Detected in single" "Group enriched" "Detected in many" 20 "classical monocyte: 74.6;intermediate monocyte: 37.5;myeloid DC: 54.6;neutrophil: 36.0;non-classical monocyte: 21.6" "Group enriched" "Detected in many" 193 "dendritic cells: 54.6;granulocytes: 36.0;monocytes: 74.6" "CAB000469, HPA001031, CAB047315" Enhanced Approved Nucleoplasm,Cytosol 39000000 "Nucleoplasm, Cytosol" "CAB000469: , CAB047315: , HPA001031: AB_1078610" "unprognostic (5.22e-3)" "unprognostic (6.10e-2)" "unprognostic (2.64e-1)" "unprognostic (6.07e-2)" "unprognostic (7.79e-3)" "prognostic favourable (5.86e-4)" "unprognostic (4.46e-1)" "unprognostic (1.63e-1)" "unprognostic (1.78e-1)" "unprognostic (7.99e-2)" "unprognostic (2.56e-2)" "unprognostic (2.15e-1)" "prognostic unfavourable (2.60e-6)" "unprognostic (8.89e-2)" "unprognostic (3.43e-2)" "unprognostic (9.24e-3)" "unprognostic (1.99e-1)" 2.0 0.2 0.3 4.4 0.8 19.8 4.5 0.2 0.5 55.4 0.4 0.2 1.1 0.0 4.7 1.7 312.4 0.2 0.7 1.0 0.3 0.0 0.4 3.4 6.8 4.8 1.1 0.2 1.8 0.2 0.0 0.3 1.3 0.5 1.3 0.1 0.3 57.4 0.7 0.7 28.2 0.3 0.4 0.7 2.0 2.2 0.3 0.6 2.2 0.3 421.9 99.0 1.5 93.5 0.1 54.6 36.0 74.6 0.2 0.2 32.0 1.6 0.1 0.0 0.3 3.8 7.1 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.9 0.6 10.2 0.0 33.1 0.0 0.0 0.0 0.0 0.0 0.7 0.8 13.3 0.2 3.7 146.6 0.3 14.4 0.0 0.0 3.5 0.0 0.0 0.0 12.4 0.0 0.0 0.0 0.1 0.0 0.0 16.4 0.0 0.0 1.6 0.8 1.1 0.1 91.6 0.0 0.2 2.4 0.0 0.1 0.0 0.1 58.3 3.2 29.1 0.0 0.7 74.6 2.2 0.0 37.5 0.2 0.1 0.1 0.1 54.6 0.0 0.0 0.1 36.0 0.2 21.6 1.0 0.1 32.0 0.3 0.8 0.2 0.5 0.3 0.0 1.1 0.2 0.5 0.6 CSTB "CST6, EPM1, PME, STFB" ENSG00000160213 "Cystatin B" P04080 21 43772511-43776445 "Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters" "Protease inhibitor, Thiol protease inhibitor" "Cancer-related genes, Disease mutation, Epilepsy" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "esophagus: 365.3;lymphoid tissue: 130.6;tongue: 138.8" "Cell line enhanced" "Detected in all" "RT4: 90.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA017380, CAB047320, HPA058557" Enhanced Supported Nucleoli,Cytosol 6100000 Cytosol Nucleoli "CAB047320: , HPA017380: AB_1847414, HPA058557: " "unprognostic (1.69e-1)" "unprognostic (3.35e-1)" "unprognostic (2.09e-1)" "unprognostic (3.05e-2)" "unprognostic (3.05e-2)" "unprognostic (5.92e-2)" "prognostic unfavourable (6.66e-5)" "unprognostic (1.90e-1)" "unprognostic (1.32e-1)" "unprognostic (2.14e-1)" "unprognostic (1.27e-2)" "unprognostic (1.79e-1)" "prognostic unfavourable (2.10e-4)" "unprognostic (3.63e-1)" "unprognostic (4.88e-1)" "unprognostic (4.24e-2)" "unprognostic (1.24e-1)" 21.1 7.5 5.6 6.1 5.9 3.2 13.6 3.0 5.3 57.8 8.8 4.4 3.9 5.6 6.1 6.4 365.3 6.0 7.2 6.5 4.6 5.0 9.6 17.3 17.2 11.2 5.3 4.9 7.8 5.0 3.2 7.6 5.2 5.8 7.1 7.2 7.8 65.2 6.2 4.8 9.4 7.5 6.3 5.1 7.4 10.4 4.1 4.1 8.6 11.6 138.8 130.6 14.0 81.5 11.4 43.2 25.4 69.1 7.7 22.3 21.3 57.8 17.5 5.8 7.3 30.9 25.4 14.4 12.5 14.5 7.9 7.9 13.5 32.5 4.7 9.7 19.5 10.4 13.3 14.0 5.0 19.4 15.8 13.1 13.5 15.6 27.6 3.2 10.9 26.9 14.6 21.8 10.8 11.0 9.7 25.8 11.6 14.6 4.1 10.1 14.0 30.2 6.8 3.3 53.1 22.7 90.4 5.5 4.9 16.5 8.8 35.2 8.2 8.1 16.9 13.2 6.9 12.3 7.9 6.4 11.2 8.7 57.4 15.2 9.2 16.8 28.2 16.9 14.5 45.9 13.3 11.4 18.6 15.0 43.2 9.7 13.2 13.0 25.4 7.7 69.1 5.3 22.3 21.3 5.6 5.9 3.0 5.3 4.6 5.0 5.3 4.9 5.8 4.1 CTAG1A "ESO1, LAGE2A" ENSG00000268651 "Cancer/testis antigen 1A" P78358 X 154585143-154586821 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "heart muscle: 3.0;testis: 8.1" "Cell line enriched" "Detected in some" 4 "U-266/70: 120.8" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" CAB013061 Enhanced "CAB013061: " 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 8.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 120.8 28.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 CTAG1B "CT6.1, CTAG, CTAG1, ESO1, LAGE2A, LAGE2B, NY-ESO-1" ENSG00000184033 "Cancer/testis antigen 1B" P78358 X 154617609-154619282 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 56 "testis: 12.0" "Cell line enriched" "Detected in some" 4 "U-266/70: 128.5" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" CAB015453 Enhanced "CAB015453: AB_784921" 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 12.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 128.5 31.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 CTAG2 "CAMEL, CT6.2a, CT6.2b, ESO2, LAGE-1, LAGE-1a, LAGE-1b, LAGE1, MGC138724, MGC3803" ENSG00000126890 "Cancer/testis antigen 2" O75638 X 154651972-154653579 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "heart muscle: 8.5;skeletal muscle: 5.7;testis: 11.9" "Group enriched" "Detected in some" 37 "K-562: 28.2;RPMI-8226: 62.9;SK-BR-3: 41.1;U-266/84: 71.2" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "HPA071467, HPA076586" Enhanced Enhanced "Nucleoplasm,Nuclear bodies,Vesicles" "Nucleoplasm, Vesicles" "Nuclear bodies" "HPA071467: , HPA076586: " "prognostic unfavourable (2.35e-4)" "unprognostic (3.87e-1)" "unprognostic (1.00e-1)" "unprognostic (1.25e-2)" 0.2 1.0 0.4 0.0 0.0 0.2 0.1 0.2 0.5 0.0 0.2 0.0 0.0 0.0 1.0 2.9 0.0 8.5 0.0 0.0 0.1 0.8 0.2 0.0 0.2 0.8 3.6 0.0 0.4 4.4 0.2 0.0 0.1 0.0 5.7 0.2 0.0 0.0 0.0 0.3 0.6 11.9 0.0 0.0 0.0 0.6 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 28.2 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 62.9 0.0 0.0 0.0 0.0 0.0 41.1 0.0 0.0 0.1 0.0 1.3 0.0 0.1 0.0 0.5 71.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 CTCF ENSG00000102974 "CCCTC-binding factor" P49711 16 67562407-67639185 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Chromosome partition, Transcription, Transcription regulation" "Activator, Chromatin regulator, DNA-binding, Repressor" "Cancer-related genes, Disease mutation, Mental retardation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004122, CAB062550, CAB068181, CAB068182" Supported Supported Nucleoplasm Nucleoplasm "CAB062550: , CAB068181: , CAB068182: , HPA004122: " "unprognostic (2.70e-1)" "unprognostic (4.21e-2)" "unprognostic (3.41e-2)" "unprognostic (4.70e-2)" "unprognostic (4.41e-2)" "unprognostic (2.70e-1)" "prognostic unfavourable (4.21e-4)" "unprognostic (1.71e-2)" "unprognostic (1.29e-1)" "unprognostic (1.14e-1)" "unprognostic (1.36e-2)" "unprognostic (1.99e-2)" "prognostic favourable (4.06e-4)" "unprognostic (3.47e-1)" "unprognostic (5.99e-2)" "unprognostic (4.58e-2)" "unprognostic (1.11e-2)" 19.1 17.5 22.3 35.0 24.3 32.2 20.2 31.6 26.6 23.0 19.4 20.5 21.0 16.5 24.2 15.4 23.1 21.7 20.3 17.6 21.8 16.7 19.5 19.5 17.2 27.9 22.3 21.0 24.6 21.2 42.4 21.8 23.5 17.9 19.4 23.2 14.3 19.9 24.9 29.4 25.2 21.4 22.0 20.2 26.1 18.5 14.8 22.9 68.8 20.7 16.2 35.5 22.6 26.7 10.1 7.9 9.6 6.2 4.9 7.2 1.9 10.9 16.9 22.5 8.9 10.3 8.8 18.3 10.5 11.1 15.5 14.9 13.8 11.4 34.4 8.5 9.1 14.2 21.7 11.8 17.6 12.2 14.3 20.8 9.6 15.8 7.0 23.6 20.0 7.1 14.3 11.6 13.0 11.8 18.2 14.4 12.8 21.5 49.5 9.0 19.5 11.3 36.2 18.5 18.9 9.5 15.9 19.3 13.4 19.0 11.1 9.3 13.7 14.7 11.2 13.4 13.9 10.2 11.5 12.6 15.8 50.1 7.7 14.2 14.3 9.4 3.4 4.9 6.7 3.4 6.3 7.9 7.2 5.4 3.1 10.1 5.9 6.7 9.6 4.9 6.2 7.9 5.4 1.9 22.3 24.3 31.6 26.6 21.8 16.7 22.3 21.0 17.9 22.9 CTGF "CCN2, IGFBP8" ENSG00000118523 "Connective tissue growth factor" P29279 6 131948176-131951373 "Cancer-related genes, Plasma proteins, Predicted secreted proteins" "Cell adhesion, DNA synthesis" Heparin-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "EFO-21: 128.3;HUVEC TERT2: 107.9;TIME: 222.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in some" 11 "naive B-cell: 11.6" "Lineage enriched" "Detected in single" 117 "B-cells: 11.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB005123, HPA031074, HPA031075" Approved Approved "Golgi apparatus,Vesicles" "Secreted in other tissues" 5200000 "Golgi apparatus, Vesicles" "CAB005123: AB_638805, HPA031074: AB_10599618, HPA031075: AB_10611248" "unprognostic (2.87e-1)" "unprognostic (1.43e-1)" "unprognostic (4.41e-2)" "unprognostic (5.68e-2)" "unprognostic (9.79e-2)" "unprognostic (1.82e-2)" "unprognostic (3.38e-1)" "unprognostic (4.96e-2)" "unprognostic (1.68e-1)" "unprognostic (3.89e-2)" "unprognostic (2.39e-1)" "unprognostic (2.06e-1)" "unprognostic (1.27e-3)" "prognostic unfavourable (5.04e-4)" "unprognostic (1.62e-1)" "unprognostic (1.77e-2)" "unprognostic (3.84e-3)" 51.9 15.5 3.5 48.2 7.6 0.0 39.2 1.6 7.1 84.0 26.9 7.2 27.5 5.8 84.9 50.1 38.9 56.3 82.5 73.6 8.8 3.6 83.5 18.8 45.8 53.3 4.7 9.4 30.7 26.3 4.7 9.7 44.0 13.8 54.5 19.7 55.0 28.2 45.3 29.4 30.1 28.7 123.4 12.0 169.8 41.6 24.4 2.3 5.9 66.9 46.9 9.8 48.5 23.3 11.6 0.0 0.0 0.0 0.0 0.0 0.3 0.3 0.5 10.0 0.2 22.7 12.9 0.1 29.0 13.9 18.0 9.6 0.0 0.9 0.0 128.3 37.2 0.4 0.3 2.0 17.0 0.1 0.2 0.0 4.1 10.4 8.9 0.0 0.0 18.8 0.4 13.0 3.2 107.9 0.0 0.0 51.0 0.1 0.0 0.0 4.8 1.7 2.4 0.4 0.0 6.5 0.0 0.0 0.0 2.9 4.9 1.3 0.4 0.2 222.6 25.0 19.5 31.4 53.4 0.9 0.1 0.2 3.4 0.0 31.2 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 11.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 3.5 7.6 1.6 7.1 8.8 3.6 4.7 9.4 13.8 2.3 CTNNB1 "armadillo, beta-catenin, CTNNB" ENSG00000168036 "Catenin beta 1" P35222 3 41194741-41260096 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell adhesion, Host-virus interaction, Neurogenesis, Transcription, Transcription regulation, Wnt signaling pathway" Activator "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000108, CAB001950, HPA029159, HPA029160" Supported Enhanced "Plasma membrane" 1000000 "Plasma membrane" "CAB000108: , CAB001950: , HPA029159: AB_10599619, HPA029160: AB_10600996" "unprognostic (2.47e-1)" "unprognostic (3.48e-2)" "prognostic favourable (7.54e-4)" "unprognostic (1.61e-1)" "unprognostic (9.55e-2)" "unprognostic (1.05e-2)" "unprognostic (3.20e-3)" "unprognostic (2.79e-1)" "unprognostic (1.57e-1)" "unprognostic (1.80e-2)" "unprognostic (1.88e-2)" "unprognostic (9.05e-2)" "unprognostic (1.97e-3)" "unprognostic (1.82e-2)" "unprognostic (1.17e-1)" "unprognostic (2.61e-1)" "unprognostic (9.79e-2)" 52.9 54.5 38.8 33.5 45.9 46.3 70.5 78.8 59.3 71.7 49.6 57.3 34.2 48.7 79.2 42.5 46.3 49.8 45.0 42.1 38.6 41.5 46.9 53.2 53.6 31.6 37.0 47.0 84.2 38.6 59.2 44.0 82.6 41.5 50.8 50.1 75.9 53.9 49.7 31.2 44.7 70.4 66.5 39.4 41.0 37.3 29.0 39.3 40.1 62.3 44.5 36.6 46.9 54.2 10.1 13.5 7.5 14.5 11.1 13.5 4.8 22.6 30.2 63.7 35.6 34.4 28.2 48.9 25.6 36.4 42.8 42.5 20.8 32.4 18.6 23.4 45.2 17.0 46.1 73.9 45.9 17.2 31.4 30.0 40.1 74.3 25.7 17.0 14.4 41.0 33.5 51.1 31.1 37.6 21.2 11.6 47.4 23.0 11.9 9.2 58.0 23.5 9.0 41.5 12.4 26.5 70.9 15.2 25.8 42.4 21.6 113.7 35.4 35.4 48.4 32.2 24.7 20.6 37.5 7.2 11.2 19.8 33.0 21.5 53.7 4.3 8.1 6.9 11.2 14.5 13.5 9.6 10.5 12.1 13.5 10.1 10.7 10.8 7.5 11.1 13.7 11.7 12.6 4.8 38.8 45.9 78.8 59.3 38.6 41.5 37.0 47.0 41.5 39.3 CTNNBL1 "C20orf33, FLJ21108, NAP, NYD-SP19, P14, P14L" ENSG00000132792 "Catenin beta like 1" Q8WYA6 20 37693955-37872129 "Cancer-related genes, Predicted intracellular proteins" "Apoptosis, mRNA processing, mRNA splicing" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HMC-1: 74.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004742, HPA027906, HPA027907" Approved Enhanced Nucleoplasm,Centrosome,Cytosol Nucleoplasm "Centrosome, Cytosol" "HPA004742: AB_1847323, HPA027906: , HPA027907: AB_10601362" "unprognostic (2.81e-1)" "unprognostic (3.42e-1)" "unprognostic (8.80e-2)" "unprognostic (1.88e-3)" "unprognostic (1.93e-1)" "unprognostic (2.55e-2)" "unprognostic (1.44e-1)" "unprognostic (5.11e-2)" "unprognostic (1.02e-1)" "unprognostic (3.79e-2)" "unprognostic (2.56e-1)" "unprognostic (1.43e-1)" "unprognostic (2.06e-3)" "unprognostic (1.62e-1)" "unprognostic (1.67e-1)" "unprognostic (2.81e-1)" "unprognostic (5.31e-2)" 21.0 14.7 19.6 25.8 21.4 27.3 18.9 20.9 21.3 20.3 23.5 18.4 31.7 16.1 25.4 25.2 18.9 21.0 17.7 25.6 17.5 15.8 19.3 35.3 19.3 26.9 17.9 14.7 21.7 14.6 14.5 22.6 22.4 17.5 19.4 18.1 16.1 15.5 34.3 27.3 20.1 19.7 23.8 16.6 49.5 25.9 35.5 20.6 31.0 15.9 15.5 29.7 22.2 29.3 24.9 31.4 60.3 29.1 21.7 18.2 18.4 15.3 14.2 13.6 10.6 9.8 8.1 21.5 9.8 10.3 23.6 20.9 52.9 12.4 17.1 14.4 9.9 16.5 18.2 23.2 25.5 8.2 9.1 56.1 7.8 25.8 10.2 17.7 74.6 8.6 13.8 13.3 13.3 14.1 15.1 7.0 12.6 12.7 28.7 23.6 12.2 20.6 20.2 26.3 12.9 10.3 12.9 10.9 13.0 17.0 24.5 17.2 12.0 14.3 10.4 23.7 14.1 15.5 15.9 8.2 10.4 19.9 16.6 11.1 12.5 60.3 22.3 27.9 15.8 29.1 15.0 24.9 15.4 16.2 31.4 23.4 15.5 16.6 4.9 21.7 28.7 24.7 18.2 18.4 19.6 21.4 20.9 21.3 17.5 15.8 17.9 14.7 17.5 20.6 CTNND1 "CTNND, KIAA0384, p120, p120cas, p120ctn" ENSG00000198561 "Catenin delta 1" O60716 11 57753243-57819546 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell adhesion, Transcription, Transcription regulation, Wnt signaling pathway" "Cancer-related genes, Disease mutation, Ectodermal dysplasia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "intermediate monocyte: 12.5;non-classical monocyte: 11.9" "Group enriched" "Detected in many" 8 "dendritic cells: 10.2;monocytes: 12.5" "Low region specificity" "Detected in all" "CAB003837, HPA015954, HPA015955" Enhanced Enhanced "Plasma membrane" 15000 "Plasma membrane" "CAB003837: AB_562066, HPA015954: AB_2669326, HPA015955: AB_1846068" "unprognostic (1.06e-2)" "unprognostic (1.60e-2)" "unprognostic (5.17e-3)" "unprognostic (4.87e-2)" "unprognostic (7.81e-2)" "unprognostic (2.30e-1)" "unprognostic (2.98e-2)" "unprognostic (3.52e-3)" "unprognostic (4.17e-1)" "unprognostic (2.89e-2)" "prognostic unfavourable (3.02e-4)" "unprognostic (2.75e-1)" "prognostic favourable (3.54e-4)" "unprognostic (7.17e-2)" "unprognostic (4.09e-2)" "unprognostic (3.34e-1)" "unprognostic (7.33e-2)" 39.7 19.9 15.1 20.4 17.0 3.2 31.4 15.0 20.5 28.8 41.9 25.7 49.2 37.5 32.7 32.7 76.3 22.9 28.8 18.2 15.6 10.3 30.6 31.2 34.0 11.6 14.4 12.8 23.3 50.4 41.9 34.5 49.8 16.4 29.7 39.8 34.4 46.4 39.1 11.8 48.7 82.0 22.8 17.2 25.9 39.4 27.8 14.7 7.1 38.4 34.9 45.6 32.3 38.9 1.4 10.2 0.4 12.5 0.4 0.5 2.3 37.4 28.1 25.1 16.8 13.6 18.6 35.6 17.2 19.4 15.6 14.9 21.8 41.6 0.7 30.4 21.3 49.2 20.2 26.1 20.0 0.4 6.6 9.3 11.0 24.6 14.1 2.0 14.7 20.5 31.6 19.7 20.2 47.4 14.0 0.4 17.2 12.1 0.7 3.5 17.9 15.1 0.7 21.2 0.8 23.3 40.0 2.3 11.2 24.3 33.3 25.4 35.0 2.5 40.1 15.0 12.9 14.7 9.7 1.3 0.8 1.1 14.0 1.2 26.4 0.0 6.9 0.2 0.2 12.5 0.5 1.0 0.1 0.4 10.2 1.4 0.2 0.3 0.4 0.4 11.9 3.1 0.2 2.3 15.1 17.0 15.0 20.5 15.6 10.3 14.4 12.8 16.4 14.7 CTSB ENSG00000164733 "Cathepsin B" P07858 8 11842524-11869448 "Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins" "Hydrolase, Protease, Thiol protease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "thyroid gland: 297.0" "Cell line enhanced" "Detected in many" "BJ hTERT+: 237.0;fHDF/TERT166: 137.7" "Cancer enhanced" "Detected in all" "thyroid cancer: 1446.9" "Low region specificity" "Detected in all" "Group enriched" "Detected in all" 4 "basophil: 53.1;classical monocyte: 127.4;intermediate monocyte: 97.0;myeloid DC: 68.0;non-classical monocyte: 54.7;plasmacytoid DC: 95.4" "Group enriched" "Detected in all" 5 "dendritic cells: 95.4;granulocytes: 53.1;monocytes: 127.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000457, HPA018156, HPA048998" Enhanced Supported Nucleoli,Vesicles "Secreted to blood" 130000000 Vesicles Nucleoli "CAB000457: , HPA018156: AB_1846069, HPA048998: " "unprognostic (5.74e-2)" "unprognostic (4.32e-2)" "unprognostic (1.38e-2)" "unprognostic (2.17e-2)" "unprognostic (2.98e-3)" "unprognostic (5.96e-2)" "unprognostic (1.36e-2)" "unprognostic (1.07e-1)" "unprognostic (2.82e-2)" "unprognostic (1.06e-1)" "unprognostic (7.61e-2)" "unprognostic (8.30e-2)" "unprognostic (2.85e-1)" "unprognostic (7.39e-2)" "unprognostic (4.12e-2)" "prognostic favourable (5.76e-4)" "prognostic unfavourable (9.02e-4)" 227.9 42.1 19.6 67.2 24.4 14.7 67.6 14.9 31.4 76.7 49.1 30.1 22.7 29.9 53.2 44.8 54.2 52.4 43.6 120.7 18.3 23.7 95.6 167.8 94.3 175.1 29.1 16.5 44.2 31.6 13.8 21.6 68.7 24.8 42.6 27.9 33.8 63.7 33.6 41.3 22.8 51.2 51.1 35.9 116.4 26.7 21.5 20.4 18.1 297.0 25.9 38.4 56.8 62.2 7.9 95.4 53.1 127.4 5.3 17.1 108.5 6.4 29.1 3.7 16.0 65.8 74.1 11.6 121.4 237.0 42.5 50.4 13.9 37.9 0.1 17.6 137.7 35.4 5.1 33.5 26.9 3.1 5.0 9.4 3.4 34.1 67.0 2.1 7.0 81.1 45.7 38.4 34.4 83.1 7.8 21.5 35.3 5.1 0.8 3.4 3.1 9.8 3.3 3.8 16.4 12.9 10.1 1.6 9.5 14.0 7.6 63.3 12.3 6.3 115.1 72.3 24.5 23.1 22.6 21.4 15.5 0.5 82.9 8.1 33.8 53.1 127.4 16.3 5.2 97.0 7.2 7.9 17.1 5.8 68.0 6.1 9.6 4.1 18.5 5.3 54.7 95.4 13.4 108.5 19.6 24.4 14.9 28.0 18.3 23.7 29.1 16.5 24.8 20.4 CTSD "CLN10, CPSD" ENSG00000117984 "Cathepsin D" P07339 11 1752752-1764573 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins" "Aspartyl protease, Hydrolase, Protease" "Alzheimer disease, Cancer-related genes, Disease mutation, Neurodegeneration, Neuronal ceroid lipofuscinosis" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "CAPAN-2: 215.7;SK-BR-3: 206.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "CAB000109, HPA003001" Supported "Secreted to blood" 540000000 "CAB000109: , HPA003001: AB_1078404" "unprognostic (9.95e-2)" "unprognostic (1.62e-1)" "prognostic unfavourable (2.46e-4)" "unprognostic (1.09e-1)" "unprognostic (1.71e-3)" "unprognostic (2.65e-2)" "unprognostic (9.40e-3)" "unprognostic (1.11e-1)" "unprognostic (1.52e-1)" "unprognostic (1.12e-3)" "unprognostic (1.59e-1)" "unprognostic (1.86e-2)" "prognostic favourable (4.93e-5)" "unprognostic (8.98e-2)" "unprognostic (3.39e-2)" "unprognostic (2.13e-2)" "unprognostic (1.60e-1)" 151.9 148.7 21.4 32.8 27.0 83.7 67.7 18.6 47.4 56.3 59.3 41.4 41.9 61.6 25.9 48.2 46.2 34.2 90.0 86.0 25.3 27.6 150.5 163.5 102.6 81.1 49.6 25.7 41.2 62.3 21.3 24.9 56.1 42.8 33.9 33.7 234.4 64.1 42.3 76.2 50.8 90.9 23.3 36.7 87.6 47.0 29.8 29.7 21.1 36.3 42.9 41.4 64.6 43.5 4.9 22.7 51.1 83.8 28.4 26.1 58.7 15.6 42.4 4.9 20.4 62.1 21.2 7.9 11.6 36.2 15.6 18.5 10.5 215.7 3.8 30.1 29.9 84.4 7.1 13.0 4.3 16.1 15.4 5.8 8.0 13.2 65.5 13.3 61.6 34.2 57.0 8.4 15.5 11.4 6.9 23.2 27.6 57.7 3.4 7.5 11.6 17.0 4.9 6.0 14.1 55.0 49.0 6.8 6.7 13.8 206.2 39.1 80.7 18.4 14.3 47.5 7.3 6.5 18.6 32.0 40.1 2.4 69.2 36.1 39.8 29.0 83.8 25.2 26.1 47.6 15.1 4.9 12.2 18.3 22.7 3.2 14.3 18.3 51.1 28.4 38.5 19.2 13.5 58.7 21.4 27.0 18.6 47.4 25.3 27.6 49.6 25.7 42.8 29.7 CTSH "ACC-4, ACC-5, ACC4, ACC5, CPSB" ENSG00000103811 "Cathepsin H" P09668 15 78921058-78949574 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Hydrolase, Protease, Thiol protease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lung: 82.6" "Cell line enhanced" "Detected in many" "CAPAN-2: 42.5;HaCaT: 31.0;RT4: 118.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "classical monocyte: 42.8" "Group enriched" "Detected in all" 5 "B-cells: 20.6;dendritic cells: 41.2;monocytes: 42.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB000458, HPA003524" Enhanced Supported "Vesicles,Cytosol,Cytoplasmic bodies" "Intracellular and membrane" 10000000 "Vesicles, Cytosol, Cytoplasmic bodies" "CAB000458: , HPA003524: AB_1846075" "unprognostic (6.47e-2)" "unprognostic (4.65e-3)" "unprognostic (1.05e-1)" "prognostic favourable (6.90e-4)" "unprognostic (4.37e-2)" "unprognostic (1.93e-1)" "unprognostic (7.18e-2)" "unprognostic (3.30e-3)" "unprognostic (2.22e-1)" "unprognostic (5.96e-2)" "unprognostic (4.10e-2)" "unprognostic (3.89e-2)" "unprognostic (6.63e-3)" "unprognostic (3.83e-1)" "unprognostic (4.42e-2)" "unprognostic (2.70e-3)" "unprognostic (1.79e-3)" 16.7 10.6 9.5 24.2 7.0 5.4 23.9 4.5 9.8 25.1 11.4 17.7 14.7 10.6 10.3 17.1 7.8 13.1 29.2 16.5 14.8 6.7 66.7 18.7 82.6 65.4 12.1 11.6 14.6 25.8 12.3 6.5 7.7 9.4 18.6 6.6 6.7 15.4 15.9 7.0 13.5 16.6 9.8 10.8 20.3 15.6 6.7 15.7 6.6 8.5 4.8 34.8 39.6 13.5 20.6 41.2 1.4 42.8 1.3 7.6 27.3 16.0 1.1 0.4 4.7 1.1 0.0 5.2 1.6 0.6 2.8 1.5 7.0 42.5 5.6 1.7 0.1 31.0 2.0 7.7 2.3 23.6 0.1 0.1 0.2 16.2 1.6 0.0 1.0 0.8 2.2 0.0 0.0 0.2 11.4 0.0 3.8 1.7 3.6 9.8 1.2 0.3 0.0 0.3 0.9 9.8 118.0 0.5 1.1 6.9 3.9 9.6 1.5 5.3 2.2 0.0 1.0 0.0 0.7 0.1 12.2 3.1 0.0 10.3 1.7 0.0 42.8 0.4 1.4 28.3 7.6 20.6 4.1 2.1 41.2 12.0 0.4 0.7 1.4 1.3 17.0 4.2 3.1 27.3 9.5 7.0 4.5 9.8 14.8 6.7 12.1 11.6 9.4 15.7 CTSL "CTSL1, FLJ31037" ENSG00000135047 "Cathepsin L" P07711 9 87725519-87731393 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Hydrolase, Protease, Thiol protease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "placenta: 237.0" "Cell line enhanced" "Detected in many" "ASC TERT1: 198.5;HSkMC: 91.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 9 "intermediate monocyte: 31.0;non-classical monocyte: 44.3" "Lineage enriched" "Detected in many" 10 "monocytes: 44.3" "CAB000459, HPA070413" Enhanced Approved "Golgi apparatus,Vesicles" "Intracellular and membrane" 17000000 "Golgi apparatus" Vesicles "CAB000459: AB_2292484, HPA070413: " "unprognostic (1.05e-1)" "unprognostic (1.01e-1)" "unprognostic (1.24e-2)" "unprognostic (1.53e-1)" "prognostic unfavourable (3.73e-4)" "unprognostic (1.19e-3)" "unprognostic (8.12e-3)" "prognostic unfavourable (5.15e-5)" "unprognostic (2.09e-1)" "unprognostic (3.15e-1)" "unprognostic (6.80e-2)" "unprognostic (3.21e-1)" "prognostic favourable (4.34e-4)" "unprognostic (5.64e-3)" "unprognostic (2.26e-2)" "unprognostic (1.72e-1)" "unprognostic (7.11e-3)" 60.3 21.5 10.4 27.2 24.6 18.4 23.3 6.9 12.3 14.8 23.2 14.1 13.7 9.0 24.1 22.3 11.4 25.7 20.7 37.7 10.7 11.4 65.4 98.0 53.1 80.5 18.9 7.7 25.0 14.3 18.8 18.0 237.0 18.4 19.4 13.0 23.2 22.0 23.5 29.3 9.1 12.0 36.6 16.1 108.1 17.5 14.1 15.7 6.8 19.2 9.4 10.1 41.3 26.5 0.0 1.7 0.1 44.3 0.0 4.3 2.4 6.3 36.8 2.5 4.3 46.3 198.5 15.4 20.5 59.7 17.6 22.1 3.5 5.9 0.0 9.6 26.5 5.4 3.3 6.6 14.5 0.1 3.2 1.1 10.4 8.6 30.0 0.0 4.4 91.8 11.2 28.8 11.2 13.8 11.9 0.0 25.3 10.6 0.0 0.7 4.9 7.0 1.5 1.5 0.0 12.3 3.3 3.7 4.5 4.3 9.6 23.5 1.1 7.3 21.7 15.8 8.6 57.5 8.6 1.6 5.9 0.0 57.8 0.0 5.2 0.1 3.5 0.1 0.0 31.0 0.0 0.0 1.8 0.0 1.7 0.0 4.3 0.3 0.1 0.0 44.3 0.1 0.3 2.4 10.4 24.6 6.9 11.7 10.7 11.4 18.9 7.7 18.4 15.7 CTTN EMS1 ENSG00000085733 Cortactin Q14247 11 70398404-70436584 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" Endocytosis "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "A-431: 128.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "neutrophil: 4.6" "Lineage enriched" "Detected in single" 5 "granulocytes: 4.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB011235, HPA057242" Supported Supported "Golgi apparatus,Vesicles,Plasma membrane,Cytosol" 34000000 "Plasma membrane, Cytosol" "Golgi apparatus, Vesicles" "CAB011235: , HPA057242: " "unprognostic (6.34e-2)" "unprognostic (2.65e-2)" "unprognostic (2.05e-1)" "unprognostic (3.13e-2)" "unprognostic (5.81e-2)" "prognostic unfavourable (2.19e-6)" "prognostic unfavourable (4.45e-4)" "unprognostic (6.10e-2)" "unprognostic (2.39e-1)" "unprognostic (1.10e-1)" "unprognostic (1.25e-3)" "unprognostic (1.20e-1)" "unprognostic (1.50e-2)" "unprognostic (6.97e-2)" "unprognostic (2.79e-1)" "unprognostic (3.72e-3)" "unprognostic (1.94e-1)" 37.5 53.6 33.0 19.7 36.7 5.7 32.0 33.3 41.1 41.3 35.3 42.3 33.7 37.1 48.8 40.2 49.4 35.5 56.2 37.3 28.5 23.5 47.2 24.9 30.5 13.7 45.0 32.0 46.3 40.0 28.9 38.3 32.3 37.2 38.9 32.4 24.4 38.0 38.5 31.5 52.9 39.2 43.1 36.0 21.4 51.3 30.2 38.6 7.7 36.0 44.5 26.7 33.2 38.2 0.1 0.8 4.6 0.2 0.0 0.4 13.9 128.4 28.3 9.6 11.0 16.2 25.3 15.8 27.5 27.5 24.3 19.2 37.4 32.4 5.0 27.3 35.2 28.6 11.4 28.9 17.8 10.1 11.5 0.5 21.1 17.5 35.0 0.1 6.8 35.7 20.4 26.8 15.2 20.3 14.4 0.9 23.9 35.1 0.2 1.8 10.4 17.3 0.0 11.8 4.0 27.1 41.9 7.9 13.5 20.1 27.6 45.7 22.5 0.5 25.3 21.4 13.7 33.2 18.3 2.2 1.4 0.3 42.7 0.1 29.2 1.4 0.2 0.2 0.0 0.1 0.0 0.1 0.2 0.0 0.2 0.0 0.4 0.0 4.6 0.0 0.2 0.8 0.0 13.9 33.0 36.7 33.3 41.1 28.5 23.5 45.0 32.0 37.2 38.6 CUL1 ENSG00000055130 "Cullin 1" Q13616 7 148697914-148801036 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction, Ubl conjugation pathway" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002676, HPA064584" Supported Supported Nucleoplasm,Nucleoli 190000 Nucleoplasm Nucleoli "CAB002676: , HPA064584: " "unprognostic (3.59e-2)" "unprognostic (1.23e-1)" "unprognostic (5.23e-1)" "unprognostic (1.19e-1)" "unprognostic (5.06e-3)" "unprognostic (9.45e-2)" "unprognostic (1.41e-2)" "unprognostic (8.23e-2)" "unprognostic (2.40e-2)" "unprognostic (3.65e-2)" "unprognostic (3.40e-2)" "unprognostic (2.84e-2)" "unprognostic (2.18e-2)" "unprognostic (3.88e-2)" "unprognostic (1.48e-1)" "unprognostic (2.40e-1)" "unprognostic (7.24e-3)" 26.0 20.9 21.2 20.4 22.4 22.3 27.5 27.5 26.2 23.9 25.8 19.5 22.5 16.7 30.2 23.7 22.7 21.2 18.7 25.7 21.1 21.8 16.9 35.2 20.5 26.5 21.7 16.7 25.0 17.9 24.9 30.7 32.0 21.0 23.9 18.8 22.7 19.6 25.0 58.9 20.5 21.2 37.7 26.3 21.9 22.4 65.6 23.7 16.9 24.5 24.6 24.5 26.1 28.8 16.8 24.1 13.4 17.1 22.1 20.8 16.1 30.7 23.9 23.5 36.3 18.5 20.8 29.8 25.4 30.0 25.7 24.5 25.4 21.5 42.2 20.4 25.1 20.8 33.5 23.7 30.3 27.5 28.5 24.9 16.9 24.6 21.7 28.2 23.7 17.0 23.3 18.8 19.1 28.0 38.4 32.6 28.0 29.4 24.5 32.3 44.0 22.9 29.8 20.7 40.6 21.1 22.5 33.8 24.8 29.6 35.3 20.0 11.6 22.4 21.5 18.4 6.4 37.2 29.2 30.6 21.2 41.8 37.4 31.5 27.1 13.4 15.2 12.0 16.1 17.1 18.6 16.8 16.7 18.6 24.1 14.4 20.8 16.7 2.1 22.1 14.5 5.5 15.9 16.1 21.2 22.4 27.5 26.2 21.1 21.8 21.7 16.7 21.0 23.7 CUL2 ENSG00000108094 "Cullin 2" Q13617 10 35008551-35090642 "Cancer-related genes, Predicted intracellular proteins" "Host-virus interaction, Ubl conjugation pathway" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002677, HPA024578" Approved Enhanced Nucleoplasm Nucleoplasm "CAB002677: , HPA024578: AB_1847338" "unprognostic (8.11e-3)" "unprognostic (1.12e-1)" "unprognostic (9.77e-2)" "unprognostic (1.17e-2)" "unprognostic (1.53e-2)" "unprognostic (1.59e-2)" "prognostic unfavourable (8.24e-6)" "unprognostic (2.18e-1)" "unprognostic (1.34e-1)" "unprognostic (1.20e-1)" "unprognostic (4.70e-2)" "unprognostic (6.94e-2)" "prognostic unfavourable (9.32e-5)" "unprognostic (2.26e-2)" "unprognostic (2.31e-1)" "unprognostic (3.70e-1)" "unprognostic (2.29e-1)" 16.2 14.9 17.2 12.6 22.6 14.3 13.6 16.8 20.9 11.6 14.3 9.0 18.1 11.9 13.6 9.5 14.3 12.1 10.1 15.7 15.4 15.1 12.2 17.2 11.9 15.4 14.3 20.8 12.9 17.7 21.4 19.3 21.9 17.3 13.3 13.0 7.0 12.8 14.1 33.7 14.2 12.4 16.1 14.0 15.1 14.5 27.9 15.4 20.3 13.7 14.4 16.6 15.6 12.3 11.4 11.9 10.0 13.7 11.3 17.4 7.7 19.6 11.6 15.4 13.2 17.6 19.4 16.3 23.2 13.0 23.0 23.3 15.5 18.9 15.7 12.9 24.5 18.2 22.3 21.4 26.5 18.4 14.5 20.4 12.6 13.7 19.3 11.1 13.4 18.7 17.9 25.2 8.8 25.6 23.3 14.3 25.2 13.4 18.3 6.2 5.6 47.7 15.5 24.9 9.8 21.2 15.5 7.5 10.0 13.0 16.4 18.3 12.5 12.7 23.4 14.3 15.9 24.3 15.1 6.0 8.1 18.9 27.4 25.1 10.0 9.6 9.3 10.0 12.3 13.7 17.4 10.8 14.0 14.7 11.9 11.4 16.7 15.5 4.4 11.3 13.3 5.4 16.6 7.7 17.2 22.6 16.8 20.9 15.4 15.1 14.3 20.8 17.3 15.4 CUL4B ENSG00000158290 "Cullin 4B" Q13620 X 120524609-120575794 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, DNA damage, DNA repair, Ubl conjugation pathway" "Cancer-related genes, Disease mutation, Dwarfism, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "fHDF/TERT166: 62.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003046, HPA011880, CAB017786, HPA058979" Enhanced Enhanced Nucleoplasm Nucleoplasm "CAB017786: , HPA003046: , HPA011880: AB_1847340, HPA058979: " "unprognostic (2.34e-2)" "unprognostic (2.74e-2)" "unprognostic (2.69e-2)" "unprognostic (7.73e-3)" "unprognostic (9.66e-2)" "unprognostic (3.91e-1)" "unprognostic (3.88e-3)" "unprognostic (8.99e-2)" "unprognostic (8.12e-3)" "unprognostic (3.20e-2)" "unprognostic (1.07e-1)" "unprognostic (1.90e-1)" "unprognostic (2.87e-3)" "unprognostic (3.83e-2)" "unprognostic (1.35e-1)" "unprognostic (6.82e-2)" "unprognostic (2.84e-1)" 20.9 24.0 19.0 19.2 28.1 12.2 25.3 28.9 25.7 32.6 20.5 12.1 25.7 14.0 24.2 47.2 29.3 19.6 18.5 19.4 18.5 20.2 19.1 20.4 23.8 23.5 17.3 20.4 30.1 18.8 34.4 48.3 17.0 18.4 30.8 17.2 15.7 17.3 27.3 10.8 17.7 16.3 36.0 20.5 19.9 17.0 34.0 17.3 29.8 18.8 13.9 24.1 40.4 22.5 7.6 12.5 15.4 4.3 5.5 8.3 4.9 12.0 10.2 8.5 9.0 37.5 19.0 6.9 27.3 32.8 22.6 23.7 9.2 34.2 12.1 9.4 62.8 9.0 17.4 8.0 25.8 7.0 9.0 5.9 14.8 6.5 16.2 6.3 8.4 21.3 6.1 13.0 11.3 40.4 9.1 9.4 21.8 6.4 8.3 6.6 12.9 10.3 7.0 8.4 12.3 7.5 6.0 9.7 8.1 20.2 9.9 10.0 8.4 5.8 53.2 16.3 9.0 21.7 24.4 6.0 10.4 15.1 17.6 8.6 14.6 5.8 4.3 9.0 7.2 3.8 7.7 7.6 7.0 6.6 5.1 5.7 7.9 8.3 15.4 5.5 2.7 12.5 8.2 4.9 19.0 28.1 28.9 25.7 18.5 20.2 17.3 20.4 18.4 17.3 CUL5 VACM-1 ENSG00000166266 "Cullin 5" Q93034 11 108008733-108107776 "Cancer-related genes, Predicted intracellular proteins" "Host-virus interaction, Ubl conjugation pathway" Receptor "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002185, CAB017787" Approved Approved "Golgi apparatus,Cytosol" "Golgi apparatus, Cytosol" "CAB017787: , HPA002185: AB_1078587" "unprognostic (5.66e-2)" "unprognostic (6.58e-2)" "unprognostic (7.16e-3)" "unprognostic (1.30e-1)" "unprognostic (5.54e-2)" "unprognostic (1.62e-1)" "unprognostic (2.32e-2)" "unprognostic (2.80e-1)" "unprognostic (5.97e-3)" "unprognostic (1.78e-1)" "unprognostic (9.17e-2)" "unprognostic (1.77e-2)" "prognostic favourable (1.06e-5)" "unprognostic (3.83e-2)" "unprognostic (1.24e-1)" "unprognostic (1.12e-1)" "unprognostic (1.10e-1)" 11.6 13.2 10.8 9.0 14.8 25.0 13.4 17.1 19.3 13.1 10.8 12.7 11.0 9.0 13.6 10.7 11.2 10.9 8.7 14.8 11.3 10.6 16.7 15.3 9.7 10.2 12.5 12.3 13.2 11.2 17.8 14.6 12.6 19.5 12.9 9.5 11.2 11.4 10.9 41.6 11.5 11.2 11.8 13.1 12.5 10.3 6.5 12.7 23.1 14.6 15.1 10.0 10.8 13.6 6.4 5.9 4.1 6.7 4.0 6.2 3.6 9.7 4.6 13.8 10.6 9.1 14.6 6.9 10.3 11.4 9.5 10.7 14.6 11.5 13.7 19.3 12.9 12.5 12.8 8.6 13.9 8.8 7.8 12.9 4.4 10.8 15.6 14.5 10.5 11.5 11.8 9.9 13.2 13.0 16.5 5.1 14.9 5.4 13.9 12.6 7.2 8.1 10.1 10.3 14.9 12.0 14.8 10.0 14.2 14.0 14.9 8.4 21.7 12.0 13.5 17.6 8.2 12.4 11.0 5.2 4.0 17.9 6.9 16.6 11.1 1.9 6.7 4.1 5.4 5.2 4.9 4.4 5.6 5.3 5.9 6.4 6.1 6.2 1.2 4.0 6.0 5.9 4.0 3.6 10.8 14.8 17.1 19.3 11.3 10.6 12.5 12.3 19.5 12.7 CUX1 "CASP, CDP, CDP/Cut, CDP/Cux, CDP1, Clox, CUT, CUTL1, CUX, Cux/CDP, GOLIM6" ENSG00000257923 "Cut like homeobox 1" "Q13948, P39880" 7 101815904-102283958 "Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors" "Transcription, Transcription regulation, Transport" "Developmental protein, DNA-binding, Repressor" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "non-classical monocyte: 21.0" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003277, HPA003317" Approved Supported "Nucleoplasm,Golgi apparatus" "Nucleoplasm, Golgi apparatus" "HPA003277: AB_10601804, HPA003317: " "unprognostic (5.86e-2)" "unprognostic (5.39e-3)" "unprognostic (9.62e-3)" "unprognostic (1.73e-1)" "prognostic unfavourable (7.51e-4)" "unprognostic (5.85e-2)" "unprognostic (1.54e-1)" "unprognostic (1.04e-1)" "unprognostic (1.50e-1)" "unprognostic (2.89e-3)" "unprognostic (2.20e-1)" "unprognostic (2.50e-1)" "prognostic favourable (5.72e-7)" "unprognostic (1.12e-1)" "unprognostic (8.85e-2)" "unprognostic (1.97e-2)" "unprognostic (2.97e-1)" 19.3 12.7 22.9 19.2 24.4 19.5 12.3 48.6 29.9 31.6 26.4 23.1 17.3 22.2 52.1 17.4 23.9 24.5 23.2 53.8 18.8 18.3 27.4 16.0 22.0 11.8 20.4 11.7 33.0 41.4 34.4 30.2 24.4 16.9 22.8 17.2 26.8 26.3 16.9 31.0 15.9 25.3 27.5 31.6 15.0 23.4 8.3 17.1 44.0 33.5 23.2 24.1 31.8 21.9 2.0 12.1 4.7 21.0 3.0 2.2 4.5 14.3 15.4 10.9 13.4 8.8 18.3 6.8 14.4 15.3 6.1 4.0 9.1 9.2 18.5 23.2 14.2 11.8 6.9 11.6 3.7 8.9 7.7 6.5 11.4 7.6 23.5 8.4 3.6 12.7 23.7 4.7 10.7 7.9 15.1 15.8 5.7 29.5 27.3 10.3 4.4 16.1 18.1 9.0 22.0 10.1 16.4 10.0 29.8 12.6 31.6 12.3 6.2 10.1 11.7 25.9 17.5 19.5 8.2 10.3 4.9 40.1 23.9 7.8 18.0 2.1 8.6 1.5 2.1 8.8 2.2 2.0 1.6 2.2 7.0 1.7 1.6 2.2 4.7 3.0 21.0 12.1 1.5 4.5 22.9 24.4 48.6 29.9 18.8 18.3 20.4 11.7 16.9 17.1 CXCL13 "ANGIE, ANGIE2, BCA-1, BLC, BLR1L, SCYB13" ENSG00000156234 "C-X-C motif chemokine ligand 13" O43927 4 77511753-77611834 "Cancer-related genes, Predicted secreted proteins" "Chemotaxis, Inflammatory response" Cytokine "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "lymphoid tissue: 82.5" "Cell line enhanced" "Detected in some" "HL-60: 1.4;RH-30: 1.2;U-266/70: 5.3" "Low cancer specificity" "Detected in all" "Cell type enhanced" "Detected in single" "memory CD8 T-cell: 1.0" "Lineage enhanced" "Detected in single" "T-cells: 1.0" HPA052613 Uncertain "Secreted to blood" 126167 "HPA052613: " "unprognostic (5.25e-3)" "unprognostic (1.19e-2)" "prognostic favourable (9.12e-4)" "prognostic favourable (5.52e-4)" "unprognostic (1.53e-2)" "unprognostic (1.17e-3)" "unprognostic (1.49e-1)" "unprognostic (6.41e-3)" "unprognostic (9.82e-3)" "prognostic favourable (5.41e-4)" "unprognostic (1.13e-1)" "unprognostic (2.07e-1)" "prognostic unfavourable (1.16e-10)" "unprognostic (2.04e-2)" "unprognostic (1.37e-1)" "unprognostic (1.37e-1)" "unprognostic (6.68e-3)" 0.2 0.1 0.0 15.3 0.2 0.0 1.5 0.3 0.0 0.1 1.1 0.0 0.8 0.0 0.6 0.2 0.2 0.0 0.0 0.0 0.3 4.3 0.2 65.1 0.0 0.2 0.0 0.0 0.8 0.0 3.8 1.8 0.8 0.0 0.0 0.1 15.5 0.0 0.0 82.5 3.7 0.3 0.5 57.5 6.2 0.2 0.0 0.3 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.5 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.5 1.4 0.1 0.3 0.0 0.0 0.0 0.0 0.5 0.5 0.0 0.0 0.0 0.1 0.1 0.0 0.0 1.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.1 0.0 5.3 0.0 0.1 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 CXCL5 "ENA-78, SCYB5" ENSG00000163735 "C-X-C motif chemokine ligand 5" P42830 4 73995642-73998779 "Cancer-related genes, Plasma proteins, Predicted secreted proteins" Cytokine "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lung: 20.0;lymphoid tissue: 28.0;salivary gland: 31.2" "Cell line enhanced" "Detected in some" "A549: 33.7;EFO-21: 28.4;HSkMC: 20.5;hTEC/SVTERT24-B: 14.7;RPTEC TERT1: 108.7" "Cancer enhanced" "Detected in many" "stomach cancer: 74.0" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 4 "neutrophil: 1.1" "Lineage enriched" "Detected in single" 4 "granulocytes: 1.1" HPA065474 Approved "Secreted to blood" 513680 "HPA065474: " "unprognostic (5.56e-3)" "prognostic unfavourable (3.43e-4)" "unprognostic (1.80e-2)" "unprognostic (1.43e-2)" "unprognostic (2.04e-3)" "unprognostic (2.05e-1)" "prognostic unfavourable (1.39e-4)" "unprognostic (1.06e-2)" "unprognostic (3.04e-1)" "unprognostic (1.87e-1)" "prognostic unfavourable (2.23e-4)" "unprognostic (7.99e-2)" "prognostic unfavourable (2.45e-5)" "unprognostic (3.72e-1)" "unprognostic (3.07e-1)" "unprognostic (2.72e-2)" "unprognostic (9.30e-2)" 1.7 0.3 1.6 28.0 6.0 0.7 2.4 0.4 1.4 10.5 0.7 1.5 0.2 0.6 0.3 0.0 0.6 0.4 3.9 1.4 4.3 2.8 0.4 2.1 20.0 13.6 1.2 0.1 0.3 0.8 0.0 0.3 1.5 7.4 1.5 0.2 0.0 31.2 0.5 0.3 0.3 1.8 0.1 2.6 5.2 6.4 5.4 0.2 1.0 0.3 10.8 0.8 10.9 0.3 0.0 0.0 1.1 0.1 0.0 0.2 5.5 0.0 33.7 0.1 0.0 0.0 1.2 0.0 0.6 0.5 0.2 0.5 0.1 0.3 0.0 28.4 0.0 0.0 0.0 0.0 3.2 0.0 0.0 0.0 0.0 0.0 2.8 0.0 0.0 20.5 0.0 14.7 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 108.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.2 5.5 1.6 6.0 0.4 1.0 4.3 2.8 1.2 0.1 7.4 0.2 CXCL8 "3-10C, AMCF-I, b-ENAP, GCP-1, GCP1, IL-8, IL8, K60, LECT, LUCT, LYNAP, MDNCF, MONAP, NAF, NAP-1, NAP1, SCYB8, TSG-1" ENSG00000169429 "C-X-C motif chemokine ligand 8" P10145 4 73740506-73743716 "Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins" "Chemotaxis, Inflammatory response" Cytokine "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "blood: 79.4;bone marrow: 300.7;lung: 106.1" "Cell line enriched" "Detected in many" 7 "BJ hTERT+: 288.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 428 "neutrophil: 79.4" "Lineage enriched" "Detected in single" 794 "granulocytes: 79.4" "Not detected" "Not detected" HPA057179 Supported "Secreted to blood" 6307 "HPA057179: " "unprognostic (3.42e-1)" "prognostic unfavourable (1.18e-5)" "unprognostic (3.91e-3)" "unprognostic (8.49e-2)" "unprognostic (3.29e-2)" "unprognostic (3.03e-3)" "prognostic unfavourable (1.19e-5)" "unprognostic (1.37e-3)" "unprognostic (3.19e-1)" "unprognostic (4.46e-1)" "unprognostic (7.19e-3)" "unprognostic (7.16e-2)" "prognostic unfavourable (3.13e-6)" "unprognostic (4.73e-2)" "unprognostic (8.57e-2)" "unprognostic (1.64e-2)" "unprognostic (6.15e-2)" 13.4 1.6 1.8 21.9 1.9 300.7 1.7 0.4 1.5 6.5 1.4 0.8 0.0 0.5 4.5 0.9 6.7 3.9 18.9 17.7 1.3 1.1 2.4 8.4 106.1 2.3 2.4 0.9 4.4 4.3 0.3 1.1 9.6 7.8 4.3 1.0 1.9 7.4 0.3 2.9 0.5 1.6 1.4 5.5 1.6 2.8 13.5 1.1 1.0 1.1 9.3 7.7 27.9 1.5 0.0 0.0 79.4 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.2 1.4 0.0 1.8 288.7 2.6 8.5 0.0 0.9 0.0 39.6 0.0 3.4 0.0 0.0 41.2 0.1 0.0 0.0 0.0 0.4 0.5 2.6 0.1 0.9 0.1 8.6 0.2 8.9 0.0 0.0 0.0 0.0 0.0 3.8 0.0 1.4 0.0 0.0 0.0 22.9 1.2 0.0 0.0 0.1 0.0 3.9 0.0 0.3 22.2 4.1 0.3 1.1 3.7 0.0 0.0 0.1 18.6 2.1 6.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 79.4 0.0 0.0 0.0 0.0 0.0 1.8 1.9 0.4 1.5 1.3 1.1 2.4 0.9 7.8 1.1 CXCR1 "CD181, CDw128a, CKR-1, CMKAR1, IL8RA" ENSG00000163464 "C-X-C motif chemokine receptor 1" P25024 2 218162845-218166995 "Cancer-related genes, CD markers, G-protein coupled receptors, Predicted membrane proteins" Chemotaxis "G-protein coupled receptor, Receptor, Transducer" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "blood: 144.6" "Cell line enriched" "Detected in single" 26 "HMC-1: 11.3" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in some" "Cell type enriched" "Detected in some" 16 "neutrophil: 144.6" "Lineage enriched" "Detected in many" 59 "granulocytes: 144.6" "Not detected" "Not detected" HPA031991 Uncertain "HPA031991: " "unprognostic (2.80e-1)" "unprognostic (2.91e-2)" "unprognostic (3.53e-2)" "unprognostic (5.74e-2)" "unprognostic (1.19e-1)" "unprognostic (1.68e-1)" "unprognostic (2.14e-2)" "unprognostic (3.36e-2)" "unprognostic (2.32e-1)" "unprognostic (1.57e-1)" "unprognostic (8.27e-2)" "unprognostic (2.15e-2)" "unprognostic (2.88e-1)" "unprognostic (5.47e-2)" "unprognostic (2.97e-1)" "unprognostic (1.30e-1)" "unprognostic (8.85e-2)" 11.5 0.4 0.8 21.1 0.7 7.3 0.6 0.9 2.6 0.6 0.6 0.2 0.0 0.0 0.5 0.1 1.3 2.8 3.6 3.8 0.9 0.6 0.7 2.9 20.3 33.4 5.9 0.0 1.7 1.2 0.0 0.8 2.1 2.3 0.9 0.1 1.4 0.6 0.0 1.0 0.5 0.6 1.4 3.4 33.7 1.0 1.4 0.7 0.1 0.9 0.6 0.4 4.5 4.1 0.0 0.0 144.6 0.2 0.1 2.4 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 11.3 0.0 0.4 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.7 0.2 0.2 2.4 0.0 0.0 0.0 0.2 0.6 0.0 0.0 0.0 0.9 144.6 0.1 0.2 0.0 0.0 0.7 0.8 0.7 0.9 2.6 0.9 0.6 5.9 0.0 2.3 0.7 CXCR2 "CD182, CMKAR2, IL8RB" ENSG00000180871 "C-X-C motif chemokine receptor 2" P25025 2 218125289-218137253 "Cancer-related genes, CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins" Chemotaxis "G-protein coupled receptor, Receptor, Transducer" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "blood: 216.1" "Group enriched" "Detected in some" 11 "BEWO: 12.1;HL-60: 6.7;HMC-1: 14.1;THP-1: 12.8;U-937: 12.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in many" 59 "neutrophil: 216.1" "Lineage enriched" "Detected in many" 109 "granulocytes: 216.1" "Low region specificity" "Detected in single" "CAB016268, HPA031999, HPA032017" Enhanced Supported "Nucleoplasm,Plasma membrane,Microtubules,Mitotic spindle" "Plasma membrane" "Nucleoplasm, Microtubules, Mitotic spindle" "CAB016268: AB_626893, HPA031999: AB_2674105, HPA032017: AB_2674112" "unprognostic (4.89e-2)" "unprognostic (2.01e-1)" "unprognostic (5.63e-2)" "unprognostic (1.10e-2)" "unprognostic (1.58e-1)" "unprognostic (3.13e-1)" "unprognostic (1.33e-1)" "unprognostic (2.13e-1)" "unprognostic (5.96e-2)" "unprognostic (1.22e-2)" "unprognostic (5.67e-2)" "unprognostic (1.41e-1)" "unprognostic (7.54e-2)" "unprognostic (1.04e-1)" "unprognostic (7.23e-2)" "unprognostic (8.18e-2)" "unprognostic (5.48e-2)" 9.3 0.9 1.3 25.6 1.5 4.0 0.6 1.2 1.3 5.2 0.6 0.5 2.5 0.0 0.8 1.1 18.1 3.3 5.2 4.3 1.5 0.6 0.7 4.6 16.7 40.5 6.6 0.0 1.2 1.7 0.0 0.7 4.5 1.7 1.9 0.3 1.8 3.3 2.6 0.6 3.0 0.7 1.4 4.1 30.6 1.0 1.1 0.7 0.6 0.6 4.8 10.1 5.4 6.4 0.0 1.6 216.1 1.9 0.4 1.9 1.0 0.0 0.0 0.1 0.0 0.0 0.0 12.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 6.7 14.1 0.0 0.1 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.3 1.0 0.2 0.0 0.3 0.0 1.0 0.0 0.7 0.0 0.0 0.0 0.1 0.0 0.0 12.8 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 12.6 0.0 3.6 1.9 3.2 1.9 0.5 0.0 0.0 0.0 0.4 0.8 0.0 0.0 0.7 216.1 0.4 0.2 1.6 0.0 1.0 1.3 1.5 1.2 1.3 1.5 0.6 6.6 0.0 1.7 0.7 CYB5R3 DIA1 ENSG00000100243 "Cytochrome b5 reductase 3" P00387 22 42617840-42649568 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Cholesterol biosynthesis, Cholesterol metabolism, Lipid biosynthesis, Lipid metabolism, Steroid biosynthesis, Steroid metabolism, Sterol biosynthesis, Sterol metabolism" Oxidoreductase "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "ASC diff: 115.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA001566 Approved Supported "Endoplasmic reticulum" 67000000 "Endoplasmic reticulum" "HPA001566: AB_1078601" "unprognostic (4.73e-2)" "unprognostic (2.93e-1)" "unprognostic (1.79e-1)" "unprognostic (1.89e-1)" "unprognostic (3.05e-1)" "unprognostic (1.04e-2)" "prognostic unfavourable (2.13e-5)" "unprognostic (2.45e-1)" "unprognostic (8.22e-3)" "unprognostic (3.01e-1)" "unprognostic (2.72e-2)" "unprognostic (6.76e-2)" "unprognostic (3.33e-3)" "unprognostic (1.31e-1)" "unprognostic (1.64e-1)" "unprognostic (1.92e-1)" "unprognostic (5.24e-2)" 79.7 57.1 33.2 22.8 32.6 19.3 86.8 19.5 33.1 52.4 31.9 37.6 51.8 25.9 51.9 35.0 39.1 39.3 38.6 86.4 31.3 24.1 43.3 78.2 43.5 30.3 31.8 25.4 58.8 21.9 15.1 27.2 32.1 33.9 40.6 21.3 37.9 29.3 96.4 34.4 43.1 32.5 55.5 36.3 20.2 33.7 44.0 25.9 14.1 30.1 28.4 23.2 43.4 53.5 28.6 37.6 70.3 39.7 14.2 22.3 19.7 16.2 10.4 17.2 10.5 115.5 91.8 10.1 47.8 44.4 35.7 31.9 13.6 12.8 7.7 21.4 88.4 15.0 11.4 23.7 18.4 8.3 25.6 10.9 18.0 26.2 29.4 15.2 20.4 55.3 18.8 25.7 17.1 29.5 9.4 40.0 48.5 17.9 14.9 14.0 6.8 19.2 11.0 20.9 17.0 27.5 11.9 7.6 9.9 15.8 15.3 17.4 12.2 14.7 45.2 38.8 24.2 26.1 18.0 10.6 11.5 9.4 45.2 8.9 31.9 26.3 25.7 70.3 19.7 32.4 19.9 28.6 19.1 21.6 37.6 26.4 13.6 14.3 13.4 14.2 39.7 34.3 22.3 19.7 33.2 32.6 19.5 33.1 31.3 24.1 31.8 25.4 33.9 25.9 CYLD "CYLD1, KIAA0849, USPL2" ENSG00000083799 "CYLD lysine 63 deubiquitinase" Q9NQC7 16 50742050-50801935 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Cell cycle, Immunity, Innate immunity, Ubl conjugation pathway, Wnt signaling pathway" "Hydrolase, Protease, Thiol protease" "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HDLM-2: 46.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB011713, HPA050095" Approved Supported "Nucleoplasm,Centriolar satellite" "Centriolar satellite" Nucleoplasm "CAB011713: AB_731794, HPA050095: " "unprognostic (9.83e-2)" "unprognostic (1.17e-2)" "unprognostic (5.01e-2)" "unprognostic (2.83e-2)" "unprognostic (3.84e-1)" "unprognostic (5.06e-2)" "unprognostic (3.87e-2)" "unprognostic (3.24e-2)" "unprognostic (9.46e-2)" "unprognostic (1.11e-1)" "unprognostic (1.18e-2)" "unprognostic (2.32e-1)" "unprognostic (1.03e-1)" "unprognostic (1.07e-1)" "unprognostic (3.43e-2)" "unprognostic (6.83e-2)" "unprognostic (8.42e-2)" 9.3 16.2 13.9 22.9 26.4 51.1 9.1 14.2 20.9 9.2 10.3 18.8 12.8 10.2 16.1 8.1 15.3 8.5 13.3 12.7 15.7 17.0 9.4 13.2 15.6 30.7 16.3 14.3 11.5 12.2 20.3 27.8 9.8 20.0 11.0 12.7 13.3 12.6 10.9 31.7 12.4 14.2 12.5 16.3 23.4 12.4 22.6 13.7 16.9 16.2 8.0 29.3 14.1 12.6 9.2 10.2 31.4 9.8 13.6 19.1 10.2 9.1 2.9 3.3 3.7 5.3 7.7 3.0 13.6 19.9 14.2 8.4 2.4 4.3 10.6 4.9 13.2 3.6 3.9 8.2 21.1 46.4 6.0 5.3 5.1 1.9 10.6 5.2 24.9 8.4 6.7 17.1 17.9 5.7 2.2 9.2 19.8 1.3 5.1 7.6 3.5 4.8 4.6 6.8 10.1 4.6 3.2 4.3 3.3 11.5 3.9 3.3 3.9 6.6 6.4 24.3 5.5 8.5 5.5 24.3 23.1 11.8 17.8 5.9 5.1 31.4 8.6 20.8 10.7 9.8 12.9 9.2 15.8 14.4 10.2 6.2 14.7 11.4 19.4 13.6 9.5 6.2 19.1 10.2 13.9 26.4 14.2 20.9 15.7 17.0 16.3 14.3 20.0 13.7 CYP19A1 "ARO, ARO1, aromatase, CPV1, CYAR, CYP19, P-450AROM" ENSG00000137869 "Cytochrome P450 family 19 subfamily A member 1" P11511 15 51208057-51338610 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Monooxygenase, Oxidoreductase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Pseudohermaphroditism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 49 "placenta: 440.1" "Cell line enhanced" "Detected in some" "ASC TERT1: 44.8;HDLM-2: 7.8;HSkMC: 15.0" "Low cancer specificity" "Detected in single" "Region enriched" "Detected in single" 8 "basal ganglia: 5.9" "Cell type enriched" "Detected in single" 17 "neutrophil: 1.7" "Lineage enriched" "Detected in single" 17 "granulocytes: 1.7" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB000355, HPA051194" Enhanced Approved Mitochondria Mitochondria "CAB000355: , HPA051194: " "unprognostic (9.41e-2)" "unprognostic (7.44e-2)" "unprognostic (9.52e-5)" "unprognostic (6.81e-2)" "unprognostic (2.72e-1)" "unprognostic (4.25e-4)" "unprognostic (5.18e-5)" "unprognostic (1.54e-3)" "unprognostic (2.38e-2)" "unprognostic (2.52e-1)" "unprognostic (1.97e-1)" "unprognostic (5.37e-2)" "unprognostic (1.54e-5)" "unprognostic (2.52e-3)" "unprognostic (2.11e-1)" "unprognostic (1.40e-2)" "unprognostic (1.11e-1)" 9.0 4.6 0.2 0.2 5.9 0.1 2.1 0.2 0.3 0.9 0.3 0.3 0.2 0.4 0.2 0.3 0.3 0.2 0.3 1.3 0.2 0.7 0.3 0.2 0.6 0.2 0.2 0.2 4.4 0.6 0.1 0.2 440.1 0.2 0.5 0.1 0.2 0.9 1.4 0.8 2.3 0.2 0.7 0.5 0.5 0.1 3.0 0.2 0.3 3.0 0.2 0.2 1.2 0.5 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 44.8 2.8 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 7.8 0.0 0.3 0.1 3.7 0.2 0.0 0.0 15.0 0.0 0.1 1.8 0.0 0.0 0.3 0.1 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 1.1 0.0 0.0 0.2 0.0 0.1 0.0 0.1 0.0 1.4 0.6 0.0 0.3 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.2 5.9 0.2 0.3 0.2 0.7 0.2 0.2 0.2 0.2 CYP1A2 "CP12, P3-450" ENSG00000140505 "Cytochrome P450 family 1 subfamily A member 2" P05177 15 74748844-74756202 "Cancer-related genes, Enzymes, Predicted membrane proteins" "Fatty acid metabolism, Lipid metabolism, Steroid metabolism, Sterol metabolism" "Lyase, Monooxygenase, Oxidoreductase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 31 "liver: 143.0" "Cell line enhanced" "Detected in many" "SK-BR-3: 6.0" "Group enriched" "Detected in some" 22 "liver cancer: 25.3;urothelial cancer: 6.5" "Not detected" "Not detected" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" CAB016531 Enhanced "CAB016531: AB_629359" "unprognostic (1.54e-4)" "unprognostic (1.29e-1)" "unprognostic (1.98e-1)" "unprognostic (1.74e-1)" "unprognostic (1.59e-2)" "unprognostic (1.76e-1)" "unprognostic (1.17e-2)" "unprognostic (5.48e-2)" "unprognostic (2.33e-2)" "unprognostic (7.41e-2)" "unprognostic (2.53e-1)" 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.1 1.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 143.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 1.7 1.1 4.5 1.2 1.1 0.7 0.3 1.1 1.0 2.7 2.2 0.2 0.0 1.6 0.7 0.0 0.0 0.2 0.6 1.3 2.2 0.5 0.0 1.2 0.1 0.2 0.1 0.6 1.2 2.8 1.6 0.8 0.1 1.9 1.1 0.4 0.3 0.1 0.0 0.2 1.9 4.1 0.0 0.8 2.5 1.3 1.7 0.6 2.6 2.4 0.9 0.0 2.3 2.2 1.1 2.1 6.0 0.4 1.6 1.0 0.4 1.1 1.4 1.1 1.2 1.0 0.7 1.6 1.1 2.4 1.2 3.2 1.2 1.2 0.6 0.6 0.5 0.8 0.7 0.5 0.4 1.7 0.7 0.7 4.5 1.1 0.8 1.1 0.4 0.3 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 CYP2C19 "CPCJ, CYP2C, P450IIC19" ENSG00000165841 "Cytochrome P450 family 2 subfamily C member 19" P33261 10 94762681-94853205 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Fatty acid metabolism, Lipid metabolism" "Monooxygenase, Oxidoreductase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 16 "intestine: 47.7;liver: 76.4" "Cell line enhanced" "Detected in some" "CACO-2: 1.8;RPMI-8226: 1.6" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA015066 Supported "Intracellular and membrane" "HPA015066: AB_1847433" "unprognostic (3.15e-2)" "unprognostic (2.13e-1)" "unprognostic (2.48e-1)" "unprognostic (1.83e-2)" "unprognostic (1.53e-1)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.2 30.0 0.0 0.0 14.7 0.0 0.0 1.0 0.0 3.7 0.0 0.0 0.0 0.0 76.4 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 47.7 0.0 0.0 0.0 0.5 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.5 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 CYP2E1 CYP2E ENSG00000130649 "Cytochrome P450 family 2 subfamily E member 1" P05181 10 133520406-133561220 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Fatty acid metabolism, Lipid metabolism" "Monooxygenase, Oxidoreductase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 87 "liver: 802.4" "Cell line enhanced" "Detected in many" "HaCaT: 9.6;HL-60: 7.4;HMC-1: 7.9;NB-4: 20.2" "Cancer enriched" "Detected in some" 278 "liver cancer: 265.3" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "MAIT T-cell: 3.9;myeloid DC: 9.1" "Group enriched" "Detected in many" 17 "dendritic cells: 9.1;T-cells: 3.9" "Not detected" "Not detected" "Low region specificity" "Detected in all" "HPA009128, HPA029564" Enhanced "Intracellular and membrane" "HPA009128: AB_1078613, HPA029564: AB_10602213" "unprognostic (6.32e-2)" "unprognostic (1.51e-2)" "unprognostic (3.83e-5)" "unprognostic (1.27e-1)" "unprognostic (3.37e-2)" "unprognostic (1.26e-1)" "unprognostic (2.92e-3)" "unprognostic (6.36e-3)" "unprognostic (2.41e-2)" "unprognostic (1.49e-1)" "unprognostic (1.63e-1)" "unprognostic (3.21e-2)" "unprognostic (1.70e-4)" "unprognostic (1.72e-1)" "unprognostic (8.36e-2)" "unprognostic (3.78e-1)" "unprognostic (9.59e-2)" 0.1 0.0 0.1 0.1 0.2 0.0 0.1 0.6 0.3 0.1 0.1 0.2 0.7 0.0 0.1 0.3 0.8 0.2 1.3 0.1 0.1 0.1 0.3 802.4 0.1 0.1 0.1 0.1 0.1 0.4 0.0 0.1 0.1 0.3 0.1 0.0 0.2 0.1 1.1 0.1 0.6 0.1 0.1 0.1 0.4 0.1 0.3 0.1 0.1 0.2 0.2 1.5 0.1 0.1 0.0 9.1 0.0 0.3 0.2 3.9 0.3 0.1 0.0 0.3 0.9 3.2 1.8 0.6 1.4 3.9 0.0 0.3 0.0 2.3 1.2 0.2 0.4 9.6 0.0 0.2 0.3 0.2 1.3 1.5 0.1 1.1 0.5 7.4 7.9 0.9 0.2 0.0 0.6 0.0 0.4 0.3 0.9 0.6 0.5 20.2 5.5 0.3 0.3 5.4 0.0 1.7 0.0 0.0 0.0 3.7 0.0 0.6 0.2 0.8 0.0 1.2 0.4 2.0 0.9 2.0 0.8 2.7 1.3 6.3 0.1 0.0 0.0 0.0 0.1 0.0 3.9 0.0 1.7 1.0 9.1 0.0 0.1 0.0 0.0 0.2 0.3 0.1 0.0 0.3 0.1 0.2 0.6 0.3 0.1 0.1 0.1 0.1 0.3 0.1 CYP3A4 CYP3A3 ENSG00000160868 "Cytochrome P450 family 3 subfamily A member 4" P08684 7 99756960-99784265 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism, Steroid biosynthesis, Steroid metabolism, Sterol metabolism" "Monooxygenase, Oxidoreductase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 45 "intestine: 145.3;liver: 464.6" "Cell line enhanced" "Detected in some" "BEWO: 4.1;NB-4: 4.4;RPMI-8226: 6.6;SCLC-21H: 2.5;SH-SY5Y: 4.9" "Cancer enriched" "Detected in some" 240 "liver cancer: 351.3" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "CAB033671, HPA072245" Enhanced Uncertain Cytosol Cytosol "CAB033671: AB_782375, HPA072245: " "unprognostic (4.55e-2)" "unprognostic (8.95e-2)" "unprognostic (8.08e-2)" "unprognostic (1.63e-1)" "unprognostic (5.89e-2)" "unprognostic (5.37e-2)" "unprognostic (7.07e-3)" "unprognostic (9.09e-2)" "unprognostic (8.27e-3)" "unprognostic (4.92e-2)" "unprognostic (3.78e-2)" "unprognostic (6.42e-2)" "unprognostic (1.89e-8)" "unprognostic (2.59e-1)" "unprognostic (1.75e-2)" "unprognostic (9.79e-2)" "unprognostic (6.82e-2)" 0.1 0.4 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 145.3 0.1 0.1 56.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.2 464.6 0.1 0.1 0.1 0.1 0.1 6.8 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.3 0.2 126.7 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.4 0.2 0.6 0.2 0.6 0.2 0.2 0.0 0.1 0.0 0.0 0.0 0.0 4.1 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 1.3 0.1 0.2 0.0 1.9 0.4 0.0 1.2 0.0 0.4 0.0 0.5 0.0 0.5 0.0 0.1 4.4 0.3 0.0 0.0 2.1 6.6 0.0 0.4 2.5 4.9 0.4 0.0 0.0 0.1 0.0 0.8 0.0 0.0 1.3 0.0 0.7 0.0 0.7 0.1 0.7 0.1 0.3 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.4 0.1 0.2 0.6 0.6 0.0 0.2 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 CYP3A5 "CP35, P450PCN3, PCN3" ENSG00000106258 "Cytochrome P450 family 3 subfamily A member 5" P20815 7 99648194-99680026 "Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins" "Lipid metabolism, Steroid metabolism" "Monooxygenase, Oxidoreductase" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "intestine: 72.9;liver: 73.4;stomach 1: 21.3" "Cell line enhanced" "Detected in some" "A549: 3.1;CACO-2: 12.1;CAPAN-2: 8.1;Hep G2: 8.4" "Cancer enhanced" "Detected in many" "liver cancer: 38.5" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA072245 Uncertain Cytosol Cytosol "HPA072245: " "unprognostic (2.13e-1)" "unprognostic (4.36e-2)" "unprognostic (4.04e-2)" "unprognostic (1.00e-1)" "unprognostic (1.06e-2)" "unprognostic (2.73e-1)" "prognostic favourable (3.72e-5)" "unprognostic (1.37e-3)" "unprognostic (1.21e-2)" "unprognostic (7.29e-3)" "unprognostic (3.85e-1)" "unprognostic (4.05e-2)" "unprognostic (1.46e-1)" "unprognostic (1.00e-1)" "unprognostic (1.93e-1)" "unprognostic (2.39e-4)" "unprognostic (6.58e-3)" 1.0 3.3 0.4 2.0 0.5 0.0 1.3 0.6 0.6 1.9 32.6 0.6 1.0 30.3 0.7 0.5 5.2 0.5 8.2 0.4 0.4 0.0 6.8 73.4 2.4 0.8 0.4 0.4 0.6 12.1 0.0 1.8 0.6 0.8 4.9 5.1 0.4 0.6 1.3 0.4 4.3 72.9 0.6 0.5 0.4 21.3 0.7 0.4 0.5 0.4 2.2 4.0 3.0 2.7 0.0 0.2 0.1 0.6 0.0 0.7 0.2 0.0 3.1 0.0 0.0 0.5 0.8 0.1 0.0 0.0 0.0 0.0 12.1 8.1 0.0 0.5 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 8.4 0.1 0.1 0.2 0.0 2.6 0.0 0.1 0.0 2.6 0.2 0.0 0.1 0.0 0.5 0.2 0.0 0.1 0.0 0.8 0.7 0.6 0.0 0.4 0.0 0.0 0.1 0.0 0.0 0.8 0.0 0.3 1.0 0.0 0.0 0.0 0.0 0.4 0.1 0.0 0.0 0.6 0.0 0.0 0.2 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.2 0.4 0.5 0.6 0.6 0.4 0.0 0.4 0.4 0.8 0.4 DAD1 OST2 ENSG00000129562 "Defender against cell death 1" P61803 14 22564905-22589269 "Cancer-related genes, Predicted membrane proteins" Apoptosis "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA028882 Uncertain Approved Cytosol 14000 Cytosol "HPA028882: AB_10602214" "unprognostic (2.76e-1)" "unprognostic (1.21e-1)" "unprognostic (1.15e-1)" "unprognostic (1.97e-2)" "unprognostic (2.02e-1)" "unprognostic (1.18e-3)" "prognostic unfavourable (7.73e-4)" "unprognostic (9.43e-3)" "unprognostic (3.06e-2)" "unprognostic (6.09e-2)" "unprognostic (1.99e-2)" "unprognostic (9.64e-2)" "unprognostic (6.62e-3)" "unprognostic (1.19e-1)" "unprognostic (3.08e-1)" "unprognostic (1.93e-1)" "unprognostic (1.37e-3)" 48.1 64.7 47.9 36.4 49.4 26.4 61.2 19.3 39.5 59.0 46.7 55.9 93.6 39.7 49.8 118.7 61.2 56.5 54.9 55.2 45.9 43.1 85.1 123.6 48.4 54.6 51.5 25.1 55.4 114.1 35.6 57.0 54.6 51.9 48.3 51.5 43.5 81.9 100.1 39.7 35.6 73.4 49.6 65.3 57.4 48.0 56.7 33.6 84.6 107.0 50.7 52.2 49.3 43.4 80.2 121.1 75.3 65.9 61.5 95.6 122.5 48.8 45.8 37.7 51.2 103.1 74.1 32.6 52.2 63.4 46.4 65.7 28.8 70.3 30.8 33.5 60.0 44.7 39.0 50.1 74.4 41.8 35.7 30.1 26.9 114.7 71.9 42.0 43.7 55.1 67.5 48.5 62.6 67.6 22.7 72.9 68.3 59.9 19.9 51.4 23.2 75.0 28.0 31.9 40.2 68.2 40.4 29.0 36.3 39.7 56.9 57.6 34.3 42.9 51.1 40.5 32.5 49.2 32.8 54.6 63.3 39.8 36.6 29.5 58.4 66.0 65.9 68.1 86.7 56.2 85.1 80.2 90.9 81.7 62.0 71.2 95.6 83.8 75.3 61.5 47.8 121.1 83.5 122.5 47.9 49.4 19.3 39.5 45.9 43.1 51.5 25.1 51.9 33.6 DAPK1 "DAPK, ROCO3" ENSG00000196730 "Death associated protein kinase 1" P53355 9 87497228-87708633 "Cancer-related genes, Enzymes, Predicted membrane proteins" "Apoptosis, Translation regulation" "Calmodulin-binding, Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "placenta: 94.7" "Cell line enhanced" "Detected in many" "HMC-1: 38.7;HUVEC TERT2: 21.9;RPTEC TERT1: 20.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 4 "classical monocyte: 5.3;eosinophil: 6.9;intermediate monocyte: 11.9;myeloid DC: 4.0;non-classical monocyte: 11.7;plasmacytoid DC: 5.3" "Group enriched" "Detected in many" 55 "dendritic cells: 5.3;granulocytes: 6.9;monocytes: 11.9" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB037302, HPA040472, HPA048436" Approved Approved Centrosome Centrosome "CAB037302: AB_1078622, HPA040472: , HPA048436: " "unprognostic (2.55e-1)" "unprognostic (1.47e-1)" "prognostic unfavourable (2.48e-5)" "unprognostic (2.77e-1)" "unprognostic (1.74e-1)" "unprognostic (3.47e-2)" "unprognostic (1.74e-1)" "unprognostic (1.75e-1)" "unprognostic (1.88e-2)" "unprognostic (5.77e-3)" "unprognostic (2.19e-2)" "unprognostic (2.77e-3)" "unprognostic (8.31e-3)" "unprognostic (8.76e-2)" "unprognostic (2.40e-1)" "unprognostic (1.68e-1)" "unprognostic (1.09e-3)" 14.6 4.9 10.4 8.8 25.5 3.8 4.1 2.9 17.6 8.1 16.6 6.5 8.1 7.8 8.7 16.1 4.5 12.2 21.6 4.1 12.4 8.1 14.7 21.3 28.6 8.5 4.6 10.4 32.7 21.2 4.8 16.6 94.7 6.6 5.1 7.5 5.9 9.3 7.3 1.5 3.7 11.0 8.1 4.8 16.4 15.0 6.3 7.3 34.5 7.2 1.5 5.2 13.2 10.5 0.1 5.3 6.9 11.9 0.1 0.1 2.1 0.0 18.2 8.8 6.1 0.2 0.1 14.0 1.2 1.7 7.2 8.1 2.6 0.1 0.1 1.8 0.3 17.0 5.4 0.4 3.1 0.1 4.4 8.8 2.5 8.9 7.8 0.0 38.7 0.5 2.9 1.3 0.5 21.9 6.6 3.7 6.0 0.5 2.6 0.0 9.9 0.0 0.7 7.8 0.0 20.0 18.2 4.0 4.5 0.0 1.8 7.7 0.0 5.8 0.1 0.0 0.1 0.0 0.0 14.6 3.0 0.0 0.1 2.4 1.2 1.3 5.3 6.9 0.0 11.9 0.0 0.1 0.0 0.0 4.0 0.0 0.0 0.1 1.6 0.1 11.7 5.3 0.0 2.1 10.4 25.5 2.9 17.6 12.4 8.1 4.6 10.4 6.6 7.3 DAXX DAP6 ENSG00000204209 "Death domain associated protein" Q9UER7 6 33318558-33323016 "Cancer-related genes, Predicted intracellular proteins" "Apoptosis, Host-virus interaction, Transcription, Transcription regulation" "Chaperone, Chromatin regulator, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002224, HPA008736, HPA008797, CAB025546, HPA065779" Enhanced Enhanced "Nucleoplasm,Nuclear bodies" "Nucleoplasm, Nuclear bodies" "CAB002224: AB_563688, CAB025546: , HPA008736: AB_1078625, HPA008797: , HPA065779: " "prognostic favourable (6.05e-4)" "unprognostic (2.90e-1)" "unprognostic (9.66e-2)" "unprognostic (4.04e-2)" "unprognostic (8.55e-2)" "unprognostic (1.36e-1)" "unprognostic (1.46e-3)" "unprognostic (3.48e-1)" "unprognostic (1.92e-1)" "unprognostic (8.58e-3)" "unprognostic (1.34e-1)" "unprognostic (2.01e-2)" "prognostic unfavourable (6.32e-7)" "unprognostic (2.43e-1)" "unprognostic (5.37e-1)" "unprognostic (1.26e-1)" "unprognostic (1.04e-1)" 10.4 14.3 10.7 13.5 11.9 8.8 10.8 11.3 14.8 11.8 12.2 9.4 7.3 11.2 13.2 43.7 13.5 12.6 12.1 9.1 9.7 7.3 9.2 12.0 10.3 18.3 10.2 8.5 13.8 18.6 24.4 10.4 11.6 11.6 13.0 14.1 7.3 10.7 15.2 14.8 11.6 12.7 15.5 8.1 20.4 10.5 20.2 11.5 25.0 16.1 6.8 30.9 11.5 10.9 17.0 5.9 12.6 11.2 15.3 18.2 21.8 2.2 0.0 7.1 2.9 1.2 2.3 4.7 7.0 23.1 18.0 13.3 0.8 2.4 7.0 2.5 5.4 1.3 0.1 5.7 16.7 8.3 15.7 9.1 12.5 11.2 3.9 9.6 2.6 6.1 8.5 2.0 5.4 0.5 5.0 4.5 5.6 5.3 3.8 21.5 0.4 3.3 5.9 0.1 7.8 1.4 0.7 8.6 2.2 0.0 0.4 3.7 2.2 0.2 5.9 4.5 5.6 0.2 0.1 7.8 16.3 15.1 3.3 4.4 4.7 7.8 7.5 12.6 16.3 8.0 18.2 16.6 15.4 15.8 5.9 17.0 13.9 14.1 7.4 15.3 11.2 5.9 17.1 21.8 10.7 11.9 11.3 14.8 9.7 7.3 10.2 8.5 11.6 11.5 DBI "ACBD1, ACBP" ENSG00000155368 "Diazepam binding inhibitor, acyl-CoA binding protein" P07108 2 119366921-119372560 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" Transport "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HMC-1: 222.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" HPA051428 Approved 7100000 "HPA051428: " "unprognostic (1.24e-1)" "prognostic favourable (5.77e-5)" "unprognostic (4.93e-2)" "unprognostic (1.16e-1)" "unprognostic (1.71e-2)" "unprognostic (1.92e-2)" "unprognostic (7.28e-3)" "unprognostic (1.70e-3)" "unprognostic (1.71e-1)" "unprognostic (2.85e-2)" "unprognostic (1.45e-1)" "unprognostic (3.56e-2)" "prognostic unfavourable (3.73e-5)" "unprognostic (1.03e-1)" "unprognostic (2.27e-1)" "unprognostic (5.75e-2)" "unprognostic (1.45e-1)" 55.3 22.5 87.5 25.0 53.9 17.1 122.9 47.3 55.4 27.9 52.5 55.2 108.2 50.8 11.2 113.8 90.5 14.0 33.0 78.6 79.8 52.4 90.5 157.2 41.0 27.4 74.1 45.5 12.7 25.3 71.8 11.5 19.0 61.9 77.5 50.1 16.7 53.3 113.7 39.8 57.5 39.1 16.3 87.7 18.3 29.6 24.6 68.8 11.9 22.4 101.0 50.9 18.6 41.6 66.2 99.6 129.8 60.0 53.1 74.9 82.8 46.1 24.2 49.7 22.7 122.4 104.4 31.3 24.6 62.6 34.7 67.4 50.3 37.6 64.3 28.1 38.2 24.3 34.9 51.4 31.2 42.5 23.1 55.0 24.7 66.3 30.7 17.4 222.3 59.1 33.6 53.2 20.0 40.9 6.4 60.3 49.3 47.7 36.7 49.9 32.9 37.9 13.4 48.3 55.9 83.9 71.0 23.6 18.9 20.6 48.6 52.5 29.9 82.2 29.0 23.4 29.9 25.7 29.7 19.8 14.0 52.4 33.0 31.5 27.7 116.9 57.6 129.8 63.9 60.0 46.3 55.9 50.5 61.9 94.2 66.2 38.8 58.3 36.7 53.1 47.2 99.6 74.9 82.8 87.5 53.9 47.3 50.6 79.8 52.4 74.1 45.5 61.9 68.8 DCC "IGDCC1, NTN1R1" ENSG00000187323 "DCC netrin 1 receptor" P43146 18 52340172-53535903 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" Apoptosis "Developmental protein, Receptor" "Cancer-related genes, Disease mutation, Mental retardation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "brain: 22.0;testis: 16.5" "Group enriched" "Detected in some" 4 "AF22: 15.1;U-266/70: 46.8;U-266/84: 22.0" "Cancer enhanced" "Detected in single" "glioma: 0.9" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA055376, HPA069552" Enhanced Supported "Golgi apparatus" 25000 "Golgi apparatus" "HPA055376: , HPA069552: " "unprognostic (1.96e-3)" "unprognostic (1.69e-2)" "unprognostic (3.13e-1)" "unprognostic (3.90e-3)" "unprognostic (1.04e-1)" "unprognostic (1.35e-3)" "unprognostic (2.59e-1)" "unprognostic (5.59e-2)" "unprognostic (2.00e-1)" "unprognostic (2.58e-1)" "unprognostic (8.22e-4)" "unprognostic (4.14e-2)" "unprognostic (1.27e-4)" "unprognostic (7.21e-2)" "unprognostic (1.84e-2)" "unprognostic (1.42e-1)" "unprognostic (2.69e-3)" 0.5 1.9 6.3 0.8 22.0 0.4 0.6 0.7 10.1 0.8 0.9 1.3 0.0 0.5 0.4 1.0 0.7 0.7 0.5 0.5 18.4 2.0 0.9 0.5 3.8 0.4 1.5 9.9 0.7 1.2 0.6 1.1 0.4 5.3 1.3 0.8 0.0 0.8 3.5 0.4 0.8 0.7 0.5 2.4 0.8 0.8 16.5 6.5 0.7 0.5 0.0 1.1 0.8 0.7 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.4 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 4.7 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 46.8 22.0 0.0 2.5 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.3 22.0 0.7 10.1 18.4 2.0 1.5 9.9 5.3 6.5 DCN "DSPG2, SLRR1B" ENSG00000011465 Decorin P07585 12 91140484-91183123 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Cancer-related genes, Corneal dystrophy" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in some" "ASC diff: 227.5;ASC TERT1: 175.3;BJ hTERT+: 175.9;HSkMC: 159.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in some" 7 "basophil: 18.7" "Lineage enriched" "Detected in single" 21 "granulocytes: 18.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in some" "HPA003315, CAB017118, HPA064736, CAB068930" Enhanced "Secreted to extracellular matrix" 1300000 "CAB017118: , CAB068930: AB_425394, HPA003315: AB_1078639, HPA064736: AB_2685340" "unprognostic (1.73e-1)" "unprognostic (1.90e-1)" "unprognostic (1.43e-1)" "unprognostic (3.22e-2)" "unprognostic (8.63e-2)" "unprognostic (1.34e-1)" "unprognostic (1.01e-2)" "unprognostic (2.68e-1)" "unprognostic (1.98e-1)" "unprognostic (6.12e-2)" "unprognostic (1.65e-1)" "unprognostic (5.15e-2)" "prognostic unfavourable (1.46e-5)" "unprognostic (3.06e-3)" "unprognostic (5.37e-2)" "unprognostic (1.59e-3)" "unprognostic (7.56e-3)" 152.8 64.6 4.8 52.8 8.3 0.0 137.1 4.5 5.8 177.7 60.6 5.1 105.8 7.8 124.0 266.8 142.9 113.6 94.3 190.2 5.2 4.0 35.4 35.1 107.0 27.5 16.7 9.1 265.5 25.7 1.5 12.7 192.0 12.4 130.7 28.3 40.7 32.7 51.8 77.2 76.0 34.9 222.4 24.9 1.8 47.5 116.5 6.0 3.3 74.2 99.4 29.3 187.8 113.8 0.8 0.6 18.7 0.3 0.5 0.4 0.0 0.0 0.0 0.2 0.0 227.5 175.3 0.3 40.3 175.9 1.9 2.0 0.0 0.0 0.0 0.0 34.3 0.1 0.0 0.1 0.3 0.0 0.0 0.0 1.3 0.0 48.6 0.0 0.0 159.5 0.4 5.1 2.4 0.0 0.0 0.0 3.9 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.1 0.7 0.5 0.0 0.0 0.0 0.0 0.0 9.1 0.0 32.4 0.0 0.1 0.1 0.1 0.5 0.1 0.0 18.7 0.3 0.6 0.4 0.2 0.3 0.4 0.3 0.3 0.1 0.8 0.4 0.4 2.7 0.5 0.2 0.6 0.3 0.0 4.8 8.3 4.5 5.8 5.2 4.0 16.7 9.1 12.4 6.0 DCTN1 ENSG00000204843 "Dynactin subunit 1" Q14203 2 74361154-74392087 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division, Mitosis, Transport" "Amyotrophic lateral sclerosis, Cancer-related genes, Neurodegeneration, Neuropathy, Parkinsonism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009108, HPA034635, HPA071875" Approved Supported "Microtubules,Cytokinetic bridge,Mitotic spindle" 220000 Microtubules "Cytokinetic bridge, Mitotic spindle" "CAB009108: AB_2090601, HPA034635: , HPA071875: " "unprognostic (1.14e-1)" "unprognostic (7.19e-2)" "unprognostic (1.33e-3)" "unprognostic (4.08e-2)" "unprognostic (1.20e-1)" "unprognostic (2.67e-1)" "unprognostic (4.61e-3)" "unprognostic (2.11e-2)" "unprognostic (2.79e-1)" "unprognostic (3.73e-3)" "unprognostic (1.87e-1)" "unprognostic (2.26e-1)" "prognostic favourable (2.34e-7)" "unprognostic (5.41e-2)" "unprognostic (3.11e-1)" "unprognostic (7.86e-3)" "unprognostic (1.12e-3)" 20.7 21.1 36.0 13.7 54.6 11.1 14.0 45.9 70.9 23.5 17.1 37.8 8.9 11.8 18.5 9.8 22.9 19.7 15.1 37.7 39.5 35.8 13.5 10.0 18.9 10.9 37.7 40.3 21.9 15.2 70.2 21.6 17.2 54.6 16.5 14.0 13.2 23.5 21.7 39.5 19.9 13.7 26.5 32.2 12.4 16.0 25.5 26.7 9.4 17.0 9.5 12.8 17.2 18.0 11.6 12.1 12.9 15.8 9.8 16.7 15.5 18.7 22.0 20.7 21.6 38.0 28.3 16.7 30.3 31.6 38.6 27.6 29.2 14.5 25.9 12.4 62.8 18.8 25.2 38.4 29.5 32.1 25.4 26.8 17.7 24.5 29.3 14.6 33.2 34.0 18.8 41.9 25.1 33.0 11.5 18.5 29.1 16.1 26.5 15.1 22.3 23.4 23.8 36.4 18.5 21.4 11.6 25.5 22.6 16.9 20.4 18.2 13.1 10.6 24.9 35.2 25.6 15.1 22.4 11.5 9.1 23.5 32.9 23.8 24.6 7.3 11.4 12.9 16.7 14.2 13.5 11.6 9.5 12.4 12.1 8.6 6.8 7.5 9.8 9.8 15.8 9.6 8.1 15.5 36.0 54.6 45.9 70.9 39.5 35.8 37.7 40.3 54.6 26.7 DDB2 "DDBB, FLJ34321, UV-DDB2, XPE" ENSG00000134574 "Damage specific DNA binding protein 2" Q92466 11 47214465-47239240 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "DNA damage, DNA repair, Ubl conjugation pathway" DNA-binding "Cancer-related genes, Disease mutation, Xeroderma pigmentosum" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB025912, HPA058406" Enhanced Supported "Nucleoplasm,Cell Junctions" "Nucleoplasm, Cell Junctions" "CAB025912: , HPA058406: " "prognostic favourable (7.29e-4)" "prognostic favourable (1.58e-4)" "unprognostic (1.49e-1)" "prognostic favourable (1.20e-4)" "unprognostic (4.29e-2)" "unprognostic (2.04e-2)" "unprognostic (2.96e-2)" "unprognostic (6.18e-2)" "unprognostic (2.25e-1)" "unprognostic (3.58e-3)" "unprognostic (3.53e-1)" "unprognostic (1.94e-1)" "unprognostic (4.57e-3)" "unprognostic (1.21e-2)" "unprognostic (4.25e-2)" "unprognostic (9.82e-3)" "unprognostic (1.07e-1)" 12.2 22.2 5.3 13.3 8.6 8.1 11.3 11.0 8.2 16.8 13.5 7.3 13.4 6.0 18.2 14.1 25.4 14.3 13.0 6.1 4.7 2.9 6.6 20.8 11.3 16.1 15.0 5.0 9.8 15.6 6.1 8.6 5.5 6.3 20.9 12.3 8.1 17.6 14.8 6.3 36.9 11.0 19.0 17.6 15.1 9.1 7.6 7.6 23.3 6.6 16.7 26.0 17.3 15.2 11.4 6.1 11.5 11.0 7.4 27.0 9.0 8.2 22.3 9.3 7.0 6.0 12.2 11.0 9.1 21.3 11.6 13.7 3.6 4.8 19.9 1.9 8.3 14.6 5.3 18.5 5.8 4.9 10.0 4.7 21.3 16.5 5.9 5.4 12.4 16.3 21.0 5.8 13.0 34.0 1.2 9.7 19.0 15.6 20.7 2.6 3.0 8.1 10.4 2.3 10.7 4.9 8.2 4.9 6.1 11.1 3.2 2.9 20.4 1.8 14.6 35.7 16.3 7.8 4.2 10.2 7.7 4.4 13.4 6.9 12.8 5.9 8.1 11.5 12.1 11.0 11.7 11.4 12.7 11.7 6.1 7.4 9.4 10.1 2.2 7.4 9.2 0.1 27.0 9.0 5.3 8.6 11.0 8.2 4.7 2.9 15.0 5.0 6.3 7.6 DDIT3 "CHOP, CHOP10, GADD153" ENSG00000175197 "DNA damage inducible transcript 3" P35638 12 57516588-57521737 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Apoptosis, Cell cycle, Growth arrest, Stress response, Transcription, Transcription regulation, Unfolded protein response, Wnt signaling pathway" "Activator, DNA-binding, Repressor" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HHSteC: 122.9;hTERT-HME1: 61.8;SK-MEL-30: 57.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "neutrophil: 50.8" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA058416, HPA068416" Uncertain Supported Nucleoplasm Nucleoplasm "HPA058416: , HPA068416: " "unprognostic (1.12e-1)" "unprognostic (5.33e-2)" "unprognostic (2.20e-3)" "unprognostic (4.92e-2)" "unprognostic (7.86e-3)" "unprognostic (2.28e-1)" "prognostic unfavourable (6.55e-4)" "unprognostic (8.55e-2)" "unprognostic (1.26e-3)" "unprognostic (9.40e-3)" "unprognostic (4.92e-2)" "unprognostic (4.16e-2)" "unprognostic (3.52e-2)" "unprognostic (3.70e-1)" "unprognostic (1.62e-1)" "unprognostic (2.56e-1)" "unprognostic (6.76e-2)" 19.1 25.5 15.9 8.3 29.9 82.2 21.4 16.7 25.2 14.8 13.5 20.1 15.7 10.6 19.5 55.8 13.0 13.1 16.0 25.8 18.6 19.8 28.8 26.1 17.1 8.8 34.4 15.5 27.3 13.0 13.5 26.8 18.0 32.1 22.8 13.9 27.3 20.7 13.9 18.0 16.3 10.9 15.4 21.8 11.2 14.7 14.3 35.3 2.9 88.9 12.6 9.4 30.2 17.0 13.8 4.6 50.8 5.4 9.2 10.9 5.1 2.5 2.4 1.5 5.2 14.1 9.6 8.2 7.2 15.9 10.7 10.1 8.4 6.8 3.7 7.2 2.1 3.2 5.8 1.1 11.1 3.0 2.3 2.9 2.6 6.1 122.9 4.6 4.5 27.4 23.3 18.1 61.8 2.5 12.4 14.2 4.7 1.5 3.0 6.0 3.0 5.6 1.7 33.7 3.2 3.8 3.3 3.2 2.3 2.1 2.4 57.3 5.2 12.2 1.4 7.3 3.1 6.9 6.2 25.2 8.4 3.9 8.8 4.3 12.9 27.5 5.4 13.5 8.0 4.6 7.0 13.8 5.7 7.3 3.7 13.1 10.9 9.9 50.8 9.2 5.1 4.6 6.5 5.1 15.9 29.9 16.7 25.2 18.6 19.8 34.4 15.5 32.1 35.3 DDR2 "NTRKR3, TKT, TYRO10" ENSG00000162733 "Discoidin domain receptor tyrosine kinase 2" Q16832 1 162631373-162787400 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" Osteogenesis "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, Dwarfism, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "ASC diff: 60.6;ASC TERT1: 59.9;BJ hTERT+: 44.3;fHDF/TERT166: 31.7;HSkMC: 42.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "gdT-cell: 1.1;MAIT T-cell: 1.3" "Lineage enriched" "Detected in single" 5 "T-cells: 1.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA070112 Supported "Plasma membrane,Actin filaments" 850000 "Plasma membrane, Actin filaments" "HPA070112: " "unprognostic (4.12e-2)" "unprognostic (2.73e-1)" "unprognostic (6.97e-3)" "unprognostic (4.52e-2)" "unprognostic (1.17e-1)" "unprognostic (8.16e-2)" "unprognostic (1.81e-1)" "unprognostic (1.19e-1)" "unprognostic (6.62e-2)" "unprognostic (2.24e-2)" "unprognostic (1.00e-1)" "unprognostic (1.15e-1)" "prognostic unfavourable (1.73e-7)" "unprognostic (1.56e-3)" "unprognostic (8.26e-3)" "unprognostic (7.57e-2)" "unprognostic (4.10e-3)" 42.1 43.5 4.7 10.9 6.9 0.2 15.6 7.9 7.1 30.3 30.4 9.0 18.6 3.3 24.2 17.7 25.0 13.4 16.6 15.4 7.9 4.7 4.0 3.3 8.9 5.1 12.9 3.4 26.4 2.2 2.1 4.0 6.6 12.7 21.8 9.1 30.7 6.4 19.3 5.2 6.1 10.1 34.3 19.7 3.4 14.1 8.3 7.5 0.0 8.6 12.8 4.1 29.0 18.3 0.1 0.2 0.0 0.0 0.2 1.3 0.0 0.1 0.0 0.0 16.0 60.6 59.9 0.2 23.6 44.3 10.3 14.9 0.0 0.0 0.0 0.0 31.7 0.0 0.0 0.1 14.1 12.7 0.1 0.0 0.0 0.0 26.3 0.0 0.0 42.5 0.1 18.2 0.4 11.8 0.1 5.0 9.4 0.0 0.0 0.0 0.1 0.1 0.0 6.7 0.1 0.0 0.0 0.0 9.7 0.0 0.0 0.8 0.0 0.0 0.6 16.5 3.6 8.3 3.2 0.7 1.3 0.0 14.9 0.0 16.7 0.0 0.0 0.0 1.1 0.0 1.3 0.0 0.8 0.1 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.2 0.0 0.0 4.7 6.9 7.9 7.1 7.9 4.7 12.9 3.4 12.7 7.5 DDX10 "Dbp4, HRH-J8" ENSG00000178105 "DEAD-box helicase 10" Q13206 11 108665025-108940930 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Helicase, Hydrolase, RNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "U-698: 57.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA004691 Approved Approved Nucleoli Nucleoli "HPA004691: AB_1078629" "unprognostic (9.49e-2)" "unprognostic (9.32e-2)" "unprognostic (1.34e-1)" "unprognostic (2.58e-1)" "unprognostic (7.97e-2)" "unprognostic (1.48e-2)" "prognostic unfavourable (2.52e-5)" "unprognostic (2.86e-2)" "unprognostic (1.23e-2)" "unprognostic (1.06e-1)" "prognostic unfavourable (5.75e-4)" "unprognostic (1.00e-1)" "prognostic favourable (2.14e-5)" "unprognostic (5.20e-2)" "unprognostic (1.98e-1)" "unprognostic (4.64e-1)" "unprognostic (2.43e-3)" 14.0 11.9 17.3 15.0 20.3 10.4 15.5 20.5 18.3 14.3 12.2 8.1 11.7 8.8 18.4 12.8 12.6 16.8 8.8 12.1 13.5 11.5 19.6 12.5 10.6 13.1 12.2 16.3 18.6 18.0 16.7 22.2 12.9 13.1 12.4 13.3 7.9 10.6 14.7 13.6 14.8 9.1 16.8 13.3 15.0 11.3 25.1 12.6 13.8 13.4 8.8 14.2 14.3 18.8 11.6 8.4 1.4 6.7 9.4 11.3 4.3 7.2 7.1 6.8 9.5 6.7 5.5 7.1 7.8 4.2 9.5 9.4 20.3 10.7 24.7 14.8 6.0 8.2 19.4 9.5 13.7 9.4 8.7 16.8 4.2 7.6 12.0 17.1 8.0 4.9 7.5 10.8 13.5 8.6 23.5 2.7 9.3 4.7 14.3 14.4 8.8 10.9 12.2 11.1 23.1 5.8 6.3 12.6 6.7 11.0 9.7 4.1 11.7 6.0 9.1 10.0 10.2 9.5 10.6 4.2 7.3 57.2 3.4 20.6 10.1 1.4 5.0 1.0 8.6 6.7 11.3 10.4 7.5 10.1 8.4 11.6 8.1 7.8 0.7 9.4 6.4 8.2 6.3 4.3 17.3 20.3 20.5 18.3 13.5 11.5 12.2 16.3 13.1 12.6 DDX3X "DBX, DDX14, DDX3, HLP2" ENSG00000215301 "DEAD-box helicase 3, X-linked" O00571 X 41333284-41364472 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Apoptosis, Chromosome partition, Host-virus interaction, Immunity, Innate immunity, Ribosome biogenesis, Transcription, Transcription regulation, Translation regulation" "DNA-binding, Helicase, Hydrolase, RNA-binding" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001648, HPA005631, HPA059585" Supported Supported Approved Nucleoplasm,Cytosol 110000 Cytosol Nucleoplasm "HPA001648: AB_1078635, HPA005631: AB_1078633, HPA059585: " "unprognostic (2.42e-2)" "unprognostic (1.11e-1)" "unprognostic (8.01e-3)" "unprognostic (1.66e-1)" "unprognostic (8.12e-2)" "unprognostic (6.43e-2)" "unprognostic (1.17e-3)" "unprognostic (1.88e-1)" "unprognostic (9.80e-2)" "unprognostic (1.40e-1)" "unprognostic (3.25e-2)" "unprognostic (2.05e-1)" "unprognostic (1.51e-1)" "unprognostic (2.95e-1)" "unprognostic (4.77e-1)" "unprognostic (9.44e-2)" "unprognostic (2.93e-2)" 80.9 49.3 26.1 40.0 34.5 49.3 46.5 31.1 36.2 52.4 43.3 35.1 21.3 29.5 56.4 25.9 53.5 56.3 42.6 47.6 30.8 24.5 55.6 77.9 45.3 40.4 41.4 29.0 60.1 30.9 68.7 60.2 79.9 37.9 30.0 29.2 30.8 37.4 26.5 63.4 42.2 54.0 57.2 53.9 46.1 43.0 27.0 39.0 49.2 45.6 44.0 42.6 55.8 50.2 13.1 20.5 32.0 21.6 17.3 21.5 17.9 45.4 50.5 47.2 25.9 55.6 47.2 28.8 33.1 46.6 34.0 27.4 51.9 30.6 0.5 23.7 37.1 30.7 57.7 46.6 56.7 26.9 45.0 28.9 50.3 31.2 28.9 54.1 52.0 34.1 33.1 57.3 55.4 53.3 53.0 28.6 31.6 34.4 34.1 16.9 45.4 20.4 40.0 50.3 37.0 32.0 61.2 32.3 48.9 75.0 38.5 39.7 34.6 36.8 48.1 35.1 37.6 37.5 39.3 33.4 39.6 44.9 35.4 32.8 33.2 22.5 20.2 17.5 14.8 21.1 21.5 13.1 14.5 16.3 20.5 9.0 16.3 15.1 32.0 17.3 21.6 6.9 14.3 17.9 26.1 34.5 31.1 36.2 30.8 24.5 41.4 29.0 37.9 39.0 DDX5 "G17P1, HLR1, p68" ENSG00000108654 "DEAD-box helicase 5" P17844 17 64499616-64508199 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Biological rhythms, mRNA processing, mRNA splicing, Transcription, Transcription regulation" "Helicase, Hydrolase, RNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB005868, HPA020043" Supported Enhanced Nucleoplasm 150000 Nucleoplasm "CAB005868: AB_446484, HPA020043: AB_1847572" "unprognostic (6.64e-2)" "unprognostic (6.98e-2)" "prognostic favourable (2.12e-4)" "unprognostic (8.94e-2)" "unprognostic (5.08e-2)" "unprognostic (9.85e-2)" "unprognostic (5.80e-2)" "unprognostic (1.61e-2)" "unprognostic (3.17e-2)" "unprognostic (4.71e-2)" "unprognostic (3.03e-3)" "unprognostic (1.44e-1)" "unprognostic (4.00e-1)" "unprognostic (2.08e-1)" "unprognostic (2.37e-1)" "unprognostic (2.17e-1)" "unprognostic (9.28e-3)" 91.6 61.4 46.9 80.0 68.0 108.3 94.7 61.6 58.9 81.6 81.1 53.3 104.2 27.4 106.7 94.5 64.5 96.9 101.4 53.9 48.5 30.6 53.1 68.0 84.8 70.9 62.8 44.1 74.0 49.3 88.9 110.5 56.6 73.1 59.5 55.4 50.9 62.2 103.6 77.6 59.7 54.7 113.1 71.0 67.6 69.0 39.7 57.8 82.1 81.1 77.7 69.3 91.0 63.9 46.9 59.6 66.4 66.2 40.3 60.8 109.8 54.0 20.4 61.8 39.1 57.2 53.9 39.3 53.6 69.2 65.7 65.9 22.1 33.1 79.3 30.7 70.4 32.2 66.5 61.7 74.4 28.1 47.7 51.6 15.5 16.9 41.9 65.6 55.0 60.7 53.3 60.1 46.9 70.2 40.8 67.8 50.6 32.2 137.1 19.1 36.0 63.0 85.9 65.2 55.8 40.3 25.9 43.4 72.9 52.0 50.5 65.3 47.3 36.9 49.3 40.0 44.7 43.1 55.5 37.9 74.6 140.0 42.4 32.3 47.1 66.4 62.5 66.4 53.7 56.9 60.8 46.9 42.9 51.7 59.6 46.8 44.5 43.1 37.8 40.3 66.2 37.0 50.2 109.8 46.9 68.0 61.6 58.9 48.5 30.6 62.8 44.1 73.1 57.8 DDX6 "HLR2, RCK" ENSG00000110367 "DEAD-box helicase 6" P26196 11 118747766-118791149 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Helicase, Hydrolase, RNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004668, HPA024201, HPA026644" Approved Supported "Cytosol,Cytoplasmic bodies" "Cytoplasmic bodies" Cytosol "CAB004668: AB_436960, HPA024201: AB_10603562, HPA026644: AB_1847582" "unprognostic (1.26e-1)" "unprognostic (1.40e-1)" "unprognostic (1.89e-1)" "unprognostic (3.40e-2)" "unprognostic (4.12e-2)" "unprognostic (5.82e-2)" "prognostic unfavourable (6.56e-4)" "unprognostic (3.43e-1)" "unprognostic (1.48e-2)" "unprognostic (1.16e-1)" "unprognostic (1.00e-1)" "unprognostic (7.76e-2)" "unprognostic (1.98e-1)" "unprognostic (4.91e-3)" "unprognostic (1.88e-1)" "unprognostic (9.58e-2)" "unprognostic (4.55e-2)" 29.8 23.0 25.0 24.1 41.0 43.3 25.1 41.9 39.2 26.9 23.2 29.4 14.5 17.1 30.1 22.9 31.8 23.4 17.5 26.8 25.5 25.1 22.8 24.6 23.4 32.2 21.9 27.1 38.2 27.9 30.9 43.2 26.1 29.6 24.9 20.8 25.4 26.8 22.9 43.8 23.9 24.1 27.8 30.4 30.6 21.2 19.9 24.0 46.0 27.9 19.4 42.8 33.0 25.7 12.2 6.5 17.8 10.3 7.2 12.6 5.7 11.7 16.0 25.8 25.4 22.6 23.3 16.9 15.9 20.9 14.8 14.1 23.3 18.1 26.9 16.7 26.0 18.8 30.1 23.2 23.9 20.2 6.0 51.8 10.3 18.9 15.0 37.1 20.0 24.6 17.1 21.9 35.7 23.6 23.8 39.1 20.9 32.0 27.0 17.2 18.3 11.8 29.8 20.8 21.5 17.3 30.4 17.1 23.6 30.0 24.1 9.5 28.2 14.6 26.9 24.6 13.5 14.0 16.0 12.2 15.8 32.1 9.8 17.9 21.0 10.5 4.1 11.6 10.1 5.7 12.6 11.4 9.9 10.4 4.7 12.2 12.4 10.8 17.8 7.2 10.3 6.5 8.9 5.7 25.0 41.0 41.9 39.2 25.5 25.1 21.9 27.1 29.6 24.0 DEFA1 "DEF1, DEFA2, HNP-1, MRS" ENSG00000206047 "Defensin alpha 1" P59665 8 6977649-6980080 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters" "Antiviral defense" "Antibiotic, Antimicrobial, Defensin, Fungicide" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 7 "bone marrow: 825.5" "Cell line enriched" "Detected in single" 17 "NB-4: 6.6" "Not detected" "Not detected" "Cell type enhanced" "Detected in single" "memory CD4 T-cell: 1.3" "Low lineage specificity" "Detected in single" "CAB032548, HPA052517" Enhanced "Intracellular and membrane" "CAB032548: AB_2277258, HPA052517: " 1.3 0.1 0.2 0.1 0.6 825.5 0.6 0.0 0.4 0.1 0.1 0.1 0.4 0.1 0.1 0.1 0.1 2.3 0.2 0.2 0.2 6.0 41.9 0.3 0.3 0.1 0.1 0.1 1.0 0.6 0.1 0.1 0.6 0.1 0.5 1.8 0.1 0.1 0.0 115.5 0.1 0.1 0.6 0.1 0.1 0.0 0.1 0.3 0.5 0.7 0.3 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.3 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.3 0.1 0.0 0.2 0.0 0.3 0.7 0.0 0.3 0.0 DEFA1B ENSG00000240247 "Defensin alpha 1B" P59665 8 6996766-6999195 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters" "Antiviral defense" "Antibiotic, Antimicrobial, Defensin, Fungicide" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 15 "bone marrow: 734.0" "Not detected" "Not detected" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "memory B-cell: 1.8" "Low lineage specificity" "Detected in many" HPA052517 Supported "Intracellular and membrane" "HPA052517: " 0.4 0.0 0.0 0.0 0.0 734.0 0.1 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 2.0 16.0 0.0 0.0 0.0 0.0 0.0 0.3 0.5 0.0 0.0 1.8 0.0 0.0 0.5 0.0 0.0 0.0 49.1 0.0 0.0 0.2 0.0 0.0 0.0 1.8 1.2 0.8 0.1 0.1 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.1 0.0 1.8 0.5 1.1 1.2 0.3 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 DEFA3 "DEF3, HNP-3" ENSG00000239839 "Defensin alpha 3" P59666 8 7015869-7018301 "Cancer-related genes, Predicted intracellular proteins" "Antiviral defense" "Antibiotic, Antimicrobial, Defensin, Fungicide" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 7 "blood: 235.0;bone marrow: 924.7" "Cell line enriched" "Detected in single" 8 "NB-4: 5.7" "Not detected" "Not detected" "Low region specificity" "Detected in some" "Cell type enriched" "Detected in some" 18 "neutrophil: 51.5" "Lineage enriched" "Detected in many" 18 "granulocytes: 51.5" HPA052517 Supported "Intracellular and membrane" "HPA052517: " "unprognostic (8.21e-2)" 0.7 0.0 0.3 0.3 1.0 924.7 0.3 0.3 0.9 0.3 0.3 0.3 0.3 0.0 0.6 0.3 0.3 0.0 0.3 10.1 0.3 0.2 0.3 3.4 25.6 0.3 0.3 0.3 0.3 0.3 0.0 0.8 2.5 2.3 0.3 0.0 0.6 0.7 0.3 0.3 1.2 0.3 0.3 0.3 81.5 0.0 0.3 0.3 2.0 0.7 0.3 0.3 0.3 0.3 0.1 0.0 51.5 1.6 0.0 2.7 235.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 1.6 0.1 2.7 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.4 0.0 51.5 0.0 0.1 0.0 0.0 235.0 0.3 1.0 0.3 0.9 0.3 0.2 0.3 0.3 2.3 0.3 DEK D6S231E ENSG00000124795 "DEK proto-oncogene" P35659 6 18223868-18264823 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Chromatin regulator, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB015226, HPA054505, HPA057799" Supported Enhanced Nucleoplasm Nucleoplasm "CAB015226: , HPA054505: , HPA057799: " "unprognostic (6.35e-2)" "unprognostic (6.11e-2)" "unprognostic (5.04e-3)" "unprognostic (1.40e-2)" "unprognostic (3.66e-1)" "unprognostic (5.02e-3)" "prognostic unfavourable (9.65e-4)" "unprognostic (1.76e-1)" "unprognostic (1.48e-2)" "unprognostic (1.61e-3)" "unprognostic (6.49e-3)" "unprognostic (1.12e-2)" "prognostic unfavourable (3.45e-4)" "unprognostic (1.59e-1)" "unprognostic (1.68e-1)" "unprognostic (2.31e-1)" "unprognostic (3.78e-1)" 30.9 20.0 22.9 41.8 29.5 50.8 28.9 41.5 30.2 31.0 35.8 11.4 24.0 28.2 32.9 19.7 31.0 23.8 19.2 33.5 26.8 14.1 19.3 23.8 29.2 42.7 30.7 17.6 28.3 19.3 20.5 27.8 24.3 27.7 33.9 29.9 11.0 26.8 21.4 40.2 23.2 35.9 51.3 28.1 29.8 24.2 12.6 32.9 58.8 44.9 33.9 38.4 45.1 43.3 40.0 40.2 57.7 49.3 34.0 46.3 35.0 59.7 17.6 46.7 38.9 9.4 16.4 27.1 55.1 30.5 49.8 67.5 28.8 22.5 68.1 58.5 24.8 35.9 34.5 27.3 83.8 45.8 33.0 42.1 31.7 33.6 9.2 64.1 34.3 8.1 13.6 34.3 27.1 23.8 51.1 0.0 31.7 21.5 46.2 28.8 28.6 19.7 61.6 62.0 39.9 24.0 34.6 28.6 26.3 49.7 43.2 30.1 38.9 26.4 24.1 58.4 32.4 32.5 68.6 4.2 10.0 71.8 13.9 32.7 54.0 51.1 49.3 21.9 41.4 39.3 46.3 40.0 42.1 42.5 40.2 33.2 33.5 32.0 57.7 34.0 43.9 31.0 40.6 35.0 22.9 29.5 41.5 30.2 26.8 14.1 30.7 17.6 27.7 32.9 DES "CMD1I, CSM1, CSM2" ENSG00000175084 Desmin P17661 2 219418377-219426739 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Muscle protein" "Cancer-related genes, Cardiomyopathy, Desmin-related myopathy, Disease mutation, Limb-girdle muscular dystrophy, Myofibrillar myopathy" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "heart muscle: 531.0;skeletal muscle: 600.8;smooth muscle: 439.9" "Cell line enhanced" "Detected in some" "HSkMC: 17.6;LHCN-M2: 35.2;RH-30: 81.8" "Cancer enhanced" "Detected in all" "prostate cancer: 562.1" "Not detected" "Not detected" "Group enriched" "Detected in some" 4 "classical monocyte: 2.7;intermediate monocyte: 1.9;non-classical monocyte: 1.4" "Lineage enriched" "Detected in single" 6 "monocytes: 2.7" "Not detected" "Not detected" "Region enhanced" "Detected in many" "midbrain: 45.7" "CAB000034, HPA018803" Enhanced Supported "Intermediate filaments" 1300000 "Intermediate filaments" "CAB000034: , HPA018803: AB_1847616" "unprognostic (1.75e-1)" "unprognostic (1.95e-3)" "unprognostic (3.43e-2)" "unprognostic (8.76e-2)" "unprognostic (7.75e-3)" "unprognostic (6.61e-3)" "unprognostic (1.55e-1)" "unprognostic (2.72e-2)" "unprognostic (4.67e-1)" "unprognostic (3.84e-2)" "unprognostic (2.57e-1)" "unprognostic (7.43e-2)" "prognostic unfavourable (5.08e-4)" "unprognostic (3.49e-2)" "unprognostic (1.34e-1)" "unprognostic (1.22e-1)" "unprognostic (9.25e-3)" 9.1 2.5 0.1 35.1 0.2 0.1 1.9 0.1 0.3 41.3 238.3 0.4 69.1 12.6 95.6 80.2 209.7 33.0 149.8 531.0 0.1 0.1 2.1 0.3 4.8 3.0 0.3 0.8 20.3 0.7 0.0 0.1 2.4 0.8 101.0 11.2 3.8 11.9 104.2 600.8 4.2 43.2 439.9 0.3 0.6 72.6 10.9 0.0 0.0 9.4 161.2 12.5 343.7 34.4 0.0 0.2 0.4 2.7 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.5 1.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 2.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.3 0.0 0.3 17.6 0.0 0.0 0.0 0.0 0.6 0.0 35.2 0.0 0.0 9.2 0.1 0.0 0.0 81.8 0.4 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 2.7 0.0 0.0 1.9 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.4 0.0 1.4 0.0 0.0 0.7 0.1 0.2 0.1 0.3 0.1 0.1 0.3 0.8 0.8 0.0 DHFR ENSG00000228716 "Dihydrofolate reductase" P00374 5 80626228-80654983 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Methotrexate resistance, One-carbon metabolism" "Oxidoreductase, RNA-binding" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "CAB037129, HPA051465" Uncertain Supported Mitochondria Mitochondria "CAB037129: AB_439683, HPA051465: " "unprognostic (1.44e-2)" "unprognostic (1.03e-2)" "unprognostic (2.24e-3)" "unprognostic (2.91e-3)" "unprognostic (3.27e-1)" "unprognostic (1.32e-1)" "unprognostic (2.83e-2)" "unprognostic (2.35e-2)" "unprognostic (2.02e-2)" "unprognostic (4.19e-3)" "unprognostic (1.83e-2)" "unprognostic (2.55e-1)" "unprognostic (1.15e-2)" "unprognostic (1.82e-2)" "unprognostic (2.49e-1)" "unprognostic (1.57e-1)" "unprognostic (1.09e-1)" 17.7 6.1 16.0 11.6 13.9 28.3 10.9 10.2 14.0 7.5 12.6 18.1 11.7 14.5 5.9 9.0 9.8 4.7 6.9 9.7 17.3 14.4 13.1 35.5 8.6 23.2 18.9 9.4 7.5 4.9 9.6 7.2 8.5 13.0 5.9 15.5 8.6 8.0 8.4 10.4 5.9 14.5 7.3 25.3 9.1 7.4 10.5 11.5 13.4 9.2 2.3 22.8 7.9 6.1 2.4 3.3 3.5 2.6 2.1 4.0 2.1 19.6 13.6 34.6 25.6 6.6 6.9 12.7 15.7 12.1 27.4 31.7 12.9 23.7 39.8 6.9 9.1 13.8 44.4 20.3 44.4 17.6 27.4 19.1 22.6 12.0 1.4 22.2 8.5 4.8 2.1 24.5 2.7 13.2 21.4 30.6 27.7 19.7 54.7 9.0 17.4 8.0 35.5 67.9 39.4 15.7 12.5 28.3 19.8 22.2 10.4 11.2 20.5 22.0 7.9 8.7 13.2 24.3 30.0 14.4 28.8 43.1 19.4 45.2 22.3 0.8 1.2 1.1 2.3 2.6 1.1 2.1 2.7 3.2 1.9 2.4 2.1 2.7 3.5 2.1 1.7 3.3 4.0 2.1 16.0 13.9 10.2 14.0 17.3 14.4 18.9 9.4 13.0 11.5 DHX9 "DDX9, LKP, RHA" ENSG00000135829 "DExH-box helicase 9" Q08211 1 182839369-182887751 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Biological rhythms, DNA replication, Host-virus interaction, Immunity, Inflammatory response, Innate immunity, mRNA processing, mRNA splicing, mRNA transport, RNA-mediated gene silencing, Transcription, Transcription regulation, Transcription termination, Translation regulation, Transport" "Activator, DNA-binding, Helicase, Hydrolase, RNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB011819, HPA028050" Supported Supported Nucleoplasm 97000 Nucleoplasm "CAB011819: AB_777725, HPA028050: AB_10603564" "unprognostic (8.14e-2)" "unprognostic (9.32e-2)" "unprognostic (1.84e-2)" "unprognostic (4.80e-2)" "unprognostic (1.58e-1)" "unprognostic (7.40e-2)" "prognostic unfavourable (3.17e-4)" "unprognostic (9.98e-2)" "prognostic unfavourable (6.04e-4)" "unprognostic (2.76e-1)" "unprognostic (2.88e-2)" "unprognostic (5.53e-2)" "unprognostic (7.51e-2)" "unprognostic (1.43e-1)" "unprognostic (1.70e-1)" "unprognostic (3.17e-1)" "unprognostic (1.99e-1)" 30.2 25.9 25.7 28.5 28.6 68.9 32.9 42.5 33.1 31.9 24.5 23.3 25.2 19.8 38.2 24.2 27.7 30.6 19.7 22.9 24.4 22.6 36.2 31.4 27.8 32.0 34.2 23.1 37.5 24.9 51.8 35.8 28.5 28.0 25.7 30.1 21.1 28.2 29.4 27.6 26.6 27.0 31.6 25.3 32.8 26.5 29.4 37.4 68.3 30.1 31.6 41.2 32.4 31.9 16.8 22.9 12.0 17.4 14.7 21.9 15.0 35.1 34.5 49.5 27.2 25.9 20.1 48.9 31.2 28.6 45.4 30.8 38.5 27.2 56.5 30.5 28.0 30.5 75.1 33.8 50.8 22.9 37.3 37.6 28.2 26.0 14.6 54.4 25.8 17.9 17.0 44.5 12.1 35.4 59.0 20.3 36.3 30.9 55.0 13.4 62.7 21.3 50.2 46.2 32.3 29.3 40.9 35.7 41.0 44.2 28.0 18.2 32.7 30.8 27.6 28.2 31.5 28.6 42.2 21.3 34.8 67.1 17.7 29.9 38.2 5.6 16.0 12.0 19.2 17.4 21.9 16.8 16.8 17.6 22.9 14.6 18.4 19.9 6.5 14.7 14.3 11.1 15.4 15.0 25.7 28.6 42.5 33.1 24.4 22.6 34.2 23.1 28.0 37.4 DIAPH1 "DFNA1, hDIA1, LFHL1" ENSG00000131504 "Diaphanous related formin 1" O60610 5 141515016-141619055 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" Hearing Actin-binding "Cancer-related genes, Deafness, Disease mutation, Epilepsy, Non-syndromic deafness" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 79.8" "Cell line enhanced" "Detected in all" "HMC-1: 105.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004916, HPA076913" Approved Approved "Plasma membrane" 10000000 "Plasma membrane" "HPA004916: AB_1847668, HPA076913: " "unprognostic (6.79e-2)" "unprognostic (2.99e-1)" "unprognostic (2.12e-3)" "unprognostic (3.73e-2)" "unprognostic (4.18e-2)" "unprognostic (1.54e-1)" "unprognostic (2.08e-1)" "unprognostic (4.54e-3)" "unprognostic (2.03e-1)" "unprognostic (1.27e-2)" "prognostic unfavourable (7.81e-5)" "unprognostic (2.88e-3)" "prognostic favourable (1.29e-5)" "unprognostic (1.64e-2)" "unprognostic (1.84e-2)" "unprognostic (7.00e-2)" "unprognostic (1.65e-1)" 14.5 10.0 5.2 22.3 10.4 27.9 10.6 8.8 7.8 11.6 17.1 3.9 11.4 14.2 9.9 16.8 26.5 9.1 15.7 21.3 5.1 6.3 30.1 48.7 22.4 21.7 3.8 4.3 9.7 20.2 17.6 22.1 28.2 7.2 7.8 11.0 8.8 18.0 13.8 79.8 19.1 24.1 9.6 3.4 20.2 15.5 12.1 2.9 44.2 14.9 23.8 34.1 12.3 13.3 5.9 8.6 19.2 9.3 8.2 22.7 9.3 25.5 16.6 9.6 12.6 7.7 10.4 13.3 10.5 11.2 12.3 12.9 56.6 24.5 28.6 16.1 15.4 28.5 21.4 35.8 15.6 15.4 11.9 49.3 21.9 18.4 7.3 34.3 105.8 6.6 19.0 17.7 17.9 16.1 17.3 20.2 12.1 24.9 38.1 44.8 9.5 11.0 42.8 15.8 15.8 23.6 28.2 12.8 6.8 26.0 34.7 10.4 14.5 16.6 9.3 17.3 9.2 9.5 21.4 10.1 16.0 19.8 9.4 27.5 10.7 12.7 8.6 19.2 22.7 9.2 15.2 5.9 14.4 17.6 8.6 5.0 10.5 17.3 9.4 8.2 9.3 6.6 11.9 9.3 5.2 10.4 8.8 7.8 5.1 6.3 3.8 4.3 7.2 2.9 DIAPH3 "AN, AUNA1, DRF3, FLJ34705, NSDAN" ENSG00000139734 "Diaphanous related formin 3" Q9NSV4 13 59665583-60163987 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cancer-related genes, Deafness, Neuropathy, Non-syndromic deafness" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 35.2;testis: 19.6" "Cell line enhanced" "Detected in many" "HBF TERT88: 38.9" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 4 "plasmacytoid DC: 2.0" "Lineage enriched" "Detected in single" 4 "dendritic cells: 2.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in some" HPA032151 Supported "Plasma membrane,Microtubules" "Plasma membrane, Microtubules" "HPA032151: " "unprognostic (3.78e-2)" "unprognostic (1.28e-2)" "prognostic favourable (9.04e-4)" "prognostic unfavourable (4.18e-4)" "unprognostic (2.78e-1)" "unprognostic (4.69e-2)" "unprognostic (1.27e-4)" "prognostic unfavourable (3.72e-4)" "unprognostic (1.74e-2)" "unprognostic (2.19e-1)" "unprognostic (5.22e-5)" "unprognostic (3.59e-3)" "unprognostic (5.31e-5)" "unprognostic (4.30e-2)" "unprognostic (2.37e-1)" "unprognostic (4.07e-1)" "unprognostic (2.74e-3)" 1.8 0.4 1.7 11.5 1.8 6.7 1.6 0.1 1.4 0.9 4.7 0.2 0.4 2.0 1.4 1.1 7.1 0.3 2.5 1.1 1.0 1.6 1.7 0.4 4.1 2.9 1.0 0.0 0.4 0.4 0.5 0.2 9.4 0.2 0.4 2.3 0.0 1.6 0.0 0.1 1.8 4.3 2.7 0.3 2.5 3.1 19.6 0.0 35.2 0.2 5.3 5.9 0.8 1.5 0.4 2.0 0.4 0.2 0.0 0.5 0.2 17.9 6.0 6.2 3.5 1.1 2.9 10.6 25.2 11.2 25.5 22.3 15.9 12.2 6.0 2.0 12.9 12.3 10.1 9.9 38.9 6.8 7.0 8.6 15.4 3.6 1.6 11.7 6.9 1.1 0.2 15.5 10.5 11.4 6.6 8.6 24.2 2.6 10.4 5.0 5.8 3.5 7.1 15.4 4.9 8.3 3.7 3.3 5.7 12.8 8.9 3.9 6.5 6.4 11.3 16.2 10.4 5.4 20.8 5.8 6.3 9.4 4.3 5.8 12.2 0.0 0.0 0.0 0.2 0.0 0.0 0.4 0.4 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.2 2.0 0.5 0.2 1.7 1.8 0.1 1.4 1.0 1.6 1.0 0.0 0.2 0.0 DICER1 "Dicer, HERNA, K12H4.8-LIKE, KIAA0928, MNG1" ENSG00000100697 "Dicer 1, ribonuclease III" Q9UPY3 14 95086228-95158010 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "RNA-mediated gene silencing" "Endonuclease, Helicase, Hydrolase, Nuclease, RNA-binding" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA000694, CAB068185" Approved Supported Cytosol Cytosol "CAB068185: , HPA000694: AB_1078661" "unprognostic (2.97e-1)" "unprognostic (2.70e-2)" "unprognostic (1.21e-1)" "unprognostic (1.72e-1)" "unprognostic (6.75e-2)" "unprognostic (9.62e-2)" "unprognostic (1.96e-2)" "unprognostic (7.73e-2)" "unprognostic (1.21e-1)" "unprognostic (8.52e-3)" "unprognostic (5.73e-2)" "unprognostic (9.22e-2)" "unprognostic (4.22e-2)" "unprognostic (9.07e-2)" "unprognostic (2.58e-1)" "unprognostic (6.04e-3)" "unprognostic (3.74e-2)" 23.2 12.5 18.4 22.4 33.3 20.5 23.2 28.5 29.9 19.0 18.1 31.4 22.4 13.0 20.8 20.6 23.4 18.5 16.2 15.3 22.0 14.1 19.5 23.6 22.4 20.3 29.7 19.6 23.8 19.8 26.9 30.9 29.9 23.2 20.3 19.7 14.5 19.5 18.9 28.0 20.7 17.3 19.0 26.8 20.7 17.1 20.6 32.0 17.0 23.8 14.7 20.3 20.7 24.1 2.5 1.8 10.7 7.2 1.2 3.3 1.0 12.8 13.4 25.1 9.3 6.5 9.8 19.9 10.6 6.4 6.8 8.2 17.0 9.9 14.5 11.5 9.8 15.2 19.9 10.0 14.2 22.5 8.9 21.9 7.4 12.2 6.6 13.4 13.5 9.1 8.3 9.1 13.9 10.1 9.2 12.9 11.4 18.0 15.0 8.9 7.1 6.6 12.0 20.5 8.0 9.0 20.5 20.8 11.8 10.7 11.0 12.0 12.4 9.9 10.0 5.2 10.3 10.1 11.9 14.8 21.1 20.6 5.4 10.9 9.3 3.1 3.0 1.2 1.6 3.1 3.3 1.9 1.5 1.2 1.8 2.5 1.5 1.3 10.7 1.2 7.2 1.6 1.6 1.0 18.4 33.3 28.5 29.9 22.0 14.1 29.7 19.6 23.2 32.0 DIS3 "dis3p, EXOSC11, KIAA1008, RRP44" ENSG00000083520 "DIS3 homolog, exosome endoribonuclease and 3'-5' exoribonuclease" Q9Y2L1 13 72752169-72782096 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "rRNA processing" "Endonuclease, Exonuclease, Hydrolase, Nuclease, RNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA039281, HPA058762" Approved Enhanced Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "HPA039281: AB_10795583, HPA058762: " "unprognostic (1.61e-1)" "unprognostic (1.52e-1)" "unprognostic (1.18e-1)" "unprognostic (8.97e-2)" "unprognostic (8.14e-2)" "unprognostic (1.51e-2)" "unprognostic (1.49e-1)" "unprognostic (2.84e-1)" "unprognostic (6.38e-2)" "unprognostic (8.68e-2)" "unprognostic (1.32e-3)" "unprognostic (3.35e-3)" "unprognostic (1.02e-1)" "unprognostic (2.37e-2)" "unprognostic (3.69e-2)" "unprognostic (7.88e-2)" "unprognostic (1.03e-1)" 25.5 14.7 11.7 17.6 24.8 23.8 22.4 23.4 19.4 20.3 18.8 11.6 17.0 11.8 18.0 19.3 23.1 17.8 16.0 21.6 12.4 13.6 20.2 25.6 19.3 22.2 13.9 17.0 23.4 15.3 15.8 22.8 26.3 18.7 18.0 15.6 9.8 17.4 19.3 19.9 17.3 17.9 17.5 12.9 22.8 16.2 27.7 14.6 23.7 21.3 19.1 23.0 26.7 19.3 6.9 6.8 11.1 9.7 10.3 10.0 5.0 15.6 7.3 14.4 12.1 15.4 18.4 9.5 14.0 17.1 14.3 17.6 11.2 13.1 19.1 12.2 14.3 13.1 19.7 16.1 23.2 15.6 14.5 22.4 15.7 10.1 19.2 37.8 13.0 19.1 11.3 16.2 21.4 15.3 14.9 8.0 17.4 5.5 16.0 18.6 13.5 8.6 13.0 11.0 8.6 14.4 12.6 13.1 17.2 11.5 9.6 13.5 9.3 17.3 14.3 8.7 7.0 9.7 14.8 15.5 17.4 15.3 24.2 18.0 12.5 11.1 5.5 7.8 6.5 9.7 9.4 6.9 8.5 7.3 6.8 6.0 8.1 7.6 3.4 10.3 7.6 4.3 10.0 5.0 11.7 24.8 23.4 19.4 12.4 13.6 13.9 17.0 18.7 14.6 DLC1 "ARHGAP7, DLC-1, HP, p122-RhoGAP, STARD12" ENSG00000164741 "DLC1 Rho GTPase activating protein" Q96QB1 8 13083361-13604610 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "GTPase activation" "Cancer-related genes, Tumor suppressor" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "hTEC/SVTERT24-B: 18.7;hTERT-HME1: 13.8;HUVEC TERT2: 18.8;U-2197: 18.6;WM-115: 13.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in some" 5 "basophil: 6.5" "Lineage enriched" "Detected in many" 5 "granulocytes: 6.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA017753 Uncertain Approved "Nucleoplasm,Golgi apparatus,Vesicles" "Nucleoplasm, Golgi apparatus, Vesicles" "HPA017753: AB_10600805" "unprognostic (1.83e-1)" "unprognostic (1.67e-1)" "unprognostic (1.29e-1)" "prognostic favourable (1.11e-4)" "unprognostic (7.47e-2)" "unprognostic (1.39e-1)" "unprognostic (3.11e-2)" "unprognostic (1.23e-1)" "unprognostic (1.11e-1)" "unprognostic (1.12e-1)" "unprognostic (8.46e-3)" "unprognostic (6.49e-2)" "unprognostic (2.02e-2)" "unprognostic (3.56e-3)" "unprognostic (2.79e-2)" "unprognostic (7.33e-2)" "unprognostic (1.67e-1)" 33.9 8.0 8.5 8.8 15.4 4.9 31.9 3.1 11.4 13.6 13.1 16.0 2.0 6.1 12.4 7.4 8.6 10.4 13.1 15.1 10.0 7.3 9.2 24.1 32.4 5.6 18.0 6.8 8.0 6.3 6.3 4.4 22.3 16.2 5.7 4.5 13.6 4.9 4.1 7.6 5.4 8.5 18.7 15.0 16.6 11.1 5.5 16.5 0.0 12.0 6.1 2.9 17.1 17.2 0.0 0.2 6.5 1.3 0.0 0.1 0.0 0.0 0.1 1.6 0.0 12.3 7.0 5.9 0.6 0.1 0.2 0.5 3.9 2.4 0.0 0.2 11.7 2.0 1.0 1.6 1.1 0.0 0.9 0.3 0.0 4.1 6.4 0.0 3.5 5.4 0.1 18.7 13.8 18.8 1.0 0.0 5.6 0.3 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.4 5.9 0.0 0.8 0.0 0.2 6.2 0.0 0.0 1.9 13.5 7.3 18.6 4.4 0.0 0.0 0.0 10.4 0.0 13.7 6.5 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 8.5 15.4 3.1 11.0 10.0 7.3 18.0 6.8 16.2 16.5 DMD "BMD, DXS142, DXS164, DXS206, DXS230, DXS239, DXS268, DXS269, DXS270, DXS272, MRX85" ENSG00000198947 Dystrophin P11532 X 31097677-33339441 "Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters" Actin-binding "Cancer-related genes, Cardiomyopathy, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "AF22: 16.1;Hep G2: 14.7;RH-30: 20.3" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 4 "memory B-cell: 2.6;naive B-cell: 4.9;plasmacytoid DC: 1.6" "Group enriched" "Detected in many" 18 "B-cells: 4.9;dendritic cells: 1.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000119, HPA002725, HPA023885" Enhanced "CAB000119: , HPA002725: AB_1078714, HPA023885: AB_1847931" "unprognostic (3.91e-3)" "unprognostic (2.29e-1)" "unprognostic (1.83e-2)" "unprognostic (1.09e-1)" "unprognostic (2.17e-1)" "unprognostic (7.58e-2)" "unprognostic (3.41e-1)" "unprognostic (2.60e-4)" "unprognostic (6.98e-2)" "unprognostic (1.25e-1)" "unprognostic (5.84e-3)" "unprognostic (2.38e-1)" "unprognostic (1.15e-2)" "unprognostic (8.76e-3)" "unprognostic (1.82e-1)" "unprognostic (9.83e-2)" "unprognostic (1.51e-2)" 19.8 11.8 12.5 11.6 11.1 0.7 11.8 15.6 11.6 18.9 25.6 6.8 30.3 4.5 22.2 10.0 13.1 12.5 22.3 27.5 10.0 7.6 4.4 36.2 5.9 3.7 8.5 9.8 11.7 34.5 4.9 4.1 10.3 7.8 14.5 6.8 10.7 19.7 31.6 57.7 8.5 7.4 48.2 6.1 1.9 11.9 4.6 7.4 0.0 6.2 34.5 4.7 32.6 7.9 4.9 1.6 0.0 0.1 0.0 0.1 0.0 0.0 0.0 16.1 0.0 0.1 0.1 4.8 3.2 0.3 1.7 1.9 8.0 0.0 0.2 0.0 8.8 5.4 6.4 8.2 2.7 4.7 5.1 0.2 7.3 14.7 9.3 0.0 1.5 2.1 6.0 3.0 11.3 4.3 0.6 0.1 4.6 0.3 2.5 0.0 8.1 7.4 0.1 20.3 0.0 0.1 1.3 0.3 4.5 0.0 1.2 2.3 1.1 0.0 0.5 0.1 0.0 0.2 3.3 0.1 6.6 0.3 0.4 0.0 8.8 0.0 0.0 0.0 0.0 0.1 0.0 2.6 0.1 0.0 0.7 4.9 0.0 0.0 0.0 0.0 0.0 1.6 0.1 0.0 12.5 11.1 15.6 11.6 10.0 7.6 8.5 9.8 7.8 7.4 DNAH12 "DHC3, DLP12, DNAH12L, DNAH7L, Dnahc3, DNHD2, FLJ40427, FLJ44290, hdhc3, HL-19" ENSG00000174844 "Dynein axonemal heavy chain 12" Q6ZR08 3 57293699-57544344 "Cancer-related genes, Predicted intracellular proteins" "Ubl conjugation pathway" "Motor protein" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 23.0;fallopian tube: 16.7;lung: 17.5;testis: 17.6" "Cell line enhanced" "Detected in some" "CACO-2: 3.1;LHCN-M2: 2.1" "Cancer enhanced" "Detected in single" "endometrial cancer: 0.6" "Region enriched" "Detected in many" 8 "pons and medulla: 23.0" "Cell type enhanced" "Detected in single" "NK-cell: 1.2" "Low lineage specificity" "Detected in single" "HPA037493, HPA058203, HPA061365" Enhanced "HPA037493: AB_10671758, HPA058203: AB_2683637, HPA061365: " "unprognostic (4.85e-2)" "unprognostic (1.29e-2)" "unprognostic (2.23e-1)" "unprognostic (2.18e-3)" "unprognostic (2.96e-2)" "unprognostic (2.17e-1)" "unprognostic (2.80e-2)" "unprognostic (1.51e-3)" "unprognostic (3.06e-2)" "unprognostic (3.21e-1)" "unprognostic (4.40e-2)" "unprognostic (5.90e-2)" "unprognostic (3.43e-5)" "unprognostic (2.82e-2)" "unprognostic (1.34e-1)" "unprognostic (2.53e-2)" "unprognostic (5.47e-2)" 0.2 0.3 0.6 0.1 3.0 0.1 0.4 0.2 0.5 1.3 0.2 5.3 0.0 0.1 1.4 11.6 0.2 16.7 0.5 0.1 2.9 0.8 0.2 0.3 17.5 0.2 0.4 0.0 7.6 3.1 0.1 8.9 0.1 23.0 0.2 0.2 0.0 0.3 0.2 0.2 0.3 0.2 0.2 0.4 0.2 0.2 17.6 1.0 0.0 0.3 0.0 0.1 0.2 0.2 0.5 0.5 0.0 0.0 1.2 0.9 0.1 0.3 0.7 0.0 0.0 0.9 0.3 0.1 0.0 0.2 0.3 0.0 3.1 0.3 0.1 0.0 0.4 0.4 0.0 0.3 0.2 0.7 0.2 0.0 0.0 0.0 0.3 0.2 0.0 0.2 0.6 0.1 0.4 0.2 0.2 0.1 2.1 0.0 0.0 0.4 0.0 0.5 0.0 0.2 0.0 0.4 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.1 0.3 0.0 0.9 0.1 0.0 0.8 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.3 0.1 0.0 0.0 0.5 0.2 0.0 0.0 1.2 0.0 0.5 0.0 0.1 0.6 3.0 0.2 0.3 2.9 0.8 0.4 0.0 23.0 1.0 DNAJB1 "Hsp40, HSPF1, RSPH16B, Sis1" ENSG00000132002 "DnaJ heat shock protein family (Hsp40) member B1" P25685 19 14514770-14529770 "Cancer-related genes, Predicted intracellular proteins" "Stress response" Chaperone "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "vagina: 291.1" "Cell line enhanced" "Detected in all" "Karpas-707: 109.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB017450, HPA063247" Enhanced Supported Nucleoplasm 9600 Nucleoplasm "CAB017450: AB_10631418, HPA063247: " "unprognostic (3.75e-2)" "unprognostic (2.23e-1)" "unprognostic (1.46e-1)" "unprognostic (2.12e-1)" "unprognostic (1.60e-1)" "unprognostic (1.32e-1)" "unprognostic (1.52e-1)" "unprognostic (1.74e-2)" "unprognostic (3.83e-1)" "unprognostic (1.85e-1)" "unprognostic (7.91e-3)" "unprognostic (2.17e-1)" "prognostic favourable (5.96e-4)" "unprognostic (2.20e-2)" "unprognostic (4.44e-2)" "unprognostic (2.00e-2)" "unprognostic (6.77e-2)" 29.2 76.9 28.5 13.2 30.0 36.2 67.0 41.4 29.4 19.3 15.5 21.5 14.5 10.5 20.4 11.8 72.3 21.7 56.4 23.5 28.2 31.6 23.4 37.7 35.7 10.7 53.4 12.0 32.3 22.6 18.3 25.0 33.5 45.8 29.6 13.1 12.2 18.4 40.8 16.1 25.3 9.5 24.0 40.2 9.4 19.1 37.5 37.9 15.0 28.9 18.0 31.1 19.2 291.1 19.7 15.2 28.2 31.6 23.0 61.6 56.7 36.6 39.0 14.1 15.0 26.0 20.9 8.8 24.4 18.1 38.7 29.3 23.0 20.7 10.1 28.0 20.8 27.9 28.8 17.5 27.4 10.6 14.3 16.1 25.8 48.2 17.7 11.4 15.3 11.6 42.1 14.9 13.1 12.7 23.9 109.8 21.3 23.2 18.3 10.6 15.0 42.0 14.0 19.9 22.8 17.6 12.6 13.0 9.6 22.1 43.8 24.0 12.0 11.1 13.2 31.4 18.9 36.2 51.2 48.9 30.0 13.3 22.4 19.8 28.0 11.5 18.9 22.3 36.6 31.1 38.9 19.4 52.5 45.4 15.2 19.7 61.6 47.6 28.2 23.0 31.6 9.1 51.8 56.7 28.5 30.0 41.4 29.4 28.2 31.6 53.4 12.0 45.8 37.9 DNAJC2 "MPHOSPH11, MPP11, ZRF1, ZUO1, zuotin" ENSG00000105821 "DnaJ heat shock protein family (Hsp40) member C2" Q99543 7 103312474-103344873 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, Chaperone, Chromatin regulator" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA020454 Approved Supported Cytosol Cytosol "HPA020454: AB_1859492" "unprognostic (1.07e-1)" "unprognostic (1.66e-1)" "unprognostic (5.53e-2)" "unprognostic (2.20e-2)" "unprognostic (1.11e-1)" "unprognostic (7.71e-2)" "unprognostic (2.13e-3)" "unprognostic (2.13e-3)" "unprognostic (1.63e-2)" "unprognostic (5.35e-2)" "unprognostic (2.21e-2)" "unprognostic (1.27e-2)" "prognostic unfavourable (1.12e-5)" "unprognostic (1.11e-1)" "unprognostic (2.30e-1)" "unprognostic (3.51e-1)" "unprognostic (3.28e-1)" 12.8 12.5 12.8 21.5 14.2 37.0 13.6 12.9 16.8 13.3 15.0 5.1 10.7 14.3 13.4 12.5 13.6 11.8 11.5 13.6 11.4 11.0 16.2 25.2 10.7 15.5 13.3 12.7 16.4 13.2 12.2 28.5 13.8 16.1 12.0 13.0 5.6 12.6 9.1 29.4 12.7 18.6 13.1 12.2 19.7 12.8 30.6 15.7 17.6 13.0 12.0 13.6 16.6 16.5 9.1 7.1 28.6 9.1 10.0 8.8 3.7 17.3 12.6 7.2 13.8 5.8 8.1 14.8 12.0 8.7 13.4 10.0 18.7 12.8 24.6 19.3 8.2 11.8 19.5 8.7 20.5 13.1 16.1 18.2 11.9 15.8 10.5 32.0 14.5 7.0 7.6 15.6 14.0 8.7 42.1 16.1 10.9 29.1 30.5 33.1 25.8 19.5 19.6 14.9 22.9 7.9 8.3 14.2 13.2 16.2 22.6 12.5 9.6 16.3 10.3 13.3 21.3 28.7 23.4 17.1 22.5 49.3 9.5 33.4 16.6 28.6 6.0 5.5 7.6 6.5 8.4 7.8 7.6 7.9 5.9 9.1 8.8 8.8 2.4 10.0 9.1 7.1 8.1 3.7 12.8 14.2 12.9 16.8 11.4 11.0 13.3 12.7 16.1 15.7 DNER "bet, UNQ26" ENSG00000187957 "Delta/notch like EGF repeat containing" Q8NFT8 2 229357629-229714558 "Cancer-related genes, Predicted membrane proteins" "Notch signaling pathway" "Activator, Receptor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "adrenal gland: 45.6;brain: 85.2;salivary gland: 46.1" "Group enriched" "Detected in some" 5 "hTERT-HME1: 39.4;U-138 MG: 66.4;U-87 MG: 39.3" "Cancer enriched" "Detected in many" 32 "glioma: 73.2" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "plasmacytoid DC: 1.4" "Lineage enhanced" "Detected in single" "dendritic cells: 1.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA017320 Enhanced 2700000 "HPA017320: AB_1847808" "unprognostic (4.39e-2)" "unprognostic (1.83e-1)" "unprognostic (3.25e-1)" "unprognostic (1.00e-3)" "unprognostic (8.73e-2)" "unprognostic (6.23e-2)" "prognostic unfavourable (1.05e-4)" "unprognostic (4.23e-3)" "unprognostic (2.97e-1)" "unprognostic (1.17e-1)" "unprognostic (1.60e-1)" "unprognostic (8.60e-2)" "prognostic unfavourable (3.42e-4)" "unprognostic (2.59e-2)" "unprognostic (7.32e-2)" "unprognostic (5.63e-2)" "unprognostic (5.13e-3)" 1.7 45.6 25.4 2.2 26.8 1.3 3.1 19.5 85.2 2.2 2.3 38.4 0.0 1.6 2.1 5.7 1.5 4.1 1.5 6.8 23.9 36.8 9.7 1.3 2.0 1.5 39.8 15.2 1.6 1.9 1.7 9.6 1.5 30.0 2.8 2.2 2.5 46.1 1.6 1.3 2.5 1.9 2.2 26.4 1.3 8.3 2.0 30.4 0.0 1.4 0.0 2.1 1.4 0.2 0.0 1.4 0.0 0.3 0.0 0.0 0.0 0.1 0.5 1.0 0.0 0.1 0.1 0.0 0.0 0.3 2.2 0.7 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.3 1.1 0.0 0.0 0.0 3.5 0.0 0.3 0.0 0.0 0.7 2.4 1.7 39.4 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.6 3.6 0.0 0.4 0.0 3.7 0.0 7.9 0.6 0.2 0.0 0.2 0.0 0.0 0.0 66.4 0.0 2.2 9.9 0.0 0.0 0.0 39.3 0.0 2.7 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.3 1.4 0.0 0.0 25.4 26.8 19.5 26.6 23.9 36.8 39.8 15.2 30.0 30.4 DNM2 "CMT2M, CMTDI1, CMTDIB, DI-CMTB, DYN2, DYNII" ENSG00000079805 "Dynamin 2" P50570 19 10718079-10833488 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters" "Endocytosis, Phagocytosis" "Hydrolase, Motor protein" "Cancer-related genes, Charcot-Marie-Tooth disease, Disease mutation, Neurodegeneration, Neuropathy" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA054246 Supported Approved "Golgi apparatus,Cytosol" 500000 "Golgi apparatus, Cytosol" "HPA054246: " "unprognostic (2.30e-1)" "unprognostic (5.23e-2)" "unprognostic (4.72e-2)" "unprognostic (1.23e-1)" "unprognostic (1.76e-1)" "prognostic favourable (8.91e-4)" "prognostic unfavourable (3.63e-4)" "unprognostic (1.03e-1)" "unprognostic (3.79e-1)" "unprognostic (1.89e-1)" "unprognostic (4.75e-2)" "unprognostic (5.35e-2)" "unprognostic (5.47e-2)" "unprognostic (5.40e-3)" "unprognostic (2.68e-1)" "unprognostic (1.61e-1)" "unprognostic (1.99e-3)" 23.8 32.6 18.5 29.3 31.2 53.4 20.4 25.7 29.7 20.1 51.4 57.5 46.0 32.1 20.4 16.8 29.9 19.7 27.0 35.0 20.8 18.0 38.5 25.1 39.2 28.2 48.3 18.0 17.9 32.2 19.5 20.0 32.3 32.2 24.0 42.5 24.5 24.7 37.7 46.6 40.6 50.8 18.6 43.1 37.6 48.2 23.3 36.4 39.1 23.5 21.1 41.5 35.7 31.5 3.4 11.1 8.6 9.8 10.1 5.8 4.6 34.9 28.9 21.2 16.9 21.9 21.5 27.2 23.4 22.2 34.7 29.5 28.8 23.1 25.4 42.2 25.2 30.7 28.9 25.4 29.1 31.1 23.0 48.7 25.8 32.2 27.0 26.7 46.3 22.0 19.6 26.5 25.0 33.7 39.1 43.7 21.3 42.3 37.2 25.5 24.1 35.0 37.8 23.0 28.6 22.8 52.7 30.6 20.0 26.7 22.9 16.7 18.4 31.8 30.5 38.1 12.9 53.5 30.9 36.2 36.9 23.4 28.5 40.9 18.8 3.0 4.5 8.6 5.6 8.2 5.1 3.4 4.2 5.8 5.3 3.1 2.4 4.1 8.5 10.1 9.8 11.1 4.8 4.6 18.5 31.2 25.7 29.7 20.8 18.0 48.3 18.0 32.2 36.4 DNMT3A ENSG00000119772 "DNA methyltransferase 3 alpha" Q9Y6K1 2 25227855-25342590 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transcription factors" "Chromatin regulator, DNA-binding, Methyltransferase, Repressor, Transferase" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "NTERA-2: 25.5;REH: 25.1;SH-SY5Y: 31.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009469, HPA026588" Approved Supported Nucleoplasm Nucleoplasm "CAB009469: AB_2093990, HPA026588: AB_1847812" "unprognostic (2.38e-1)" "unprognostic (2.94e-1)" "unprognostic (5.65e-2)" "prognostic unfavourable (1.55e-4)" "unprognostic (8.38e-2)" "unprognostic (7.27e-2)" "prognostic unfavourable (1.58e-4)" "unprognostic (2.24e-1)" "unprognostic (7.25e-2)" "unprognostic (2.72e-1)" "prognostic favourable (1.18e-4)" "unprognostic (2.35e-2)" "prognostic unfavourable (2.49e-4)" "unprognostic (1.43e-1)" "unprognostic (1.87e-1)" "unprognostic (1.14e-1)" "unprognostic (2.70e-2)" 7.8 12.4 13.7 12.7 15.5 10.8 8.6 21.6 20.1 9.0 12.7 14.5 7.6 9.1 13.0 12.2 8.0 9.6 8.9 8.2 12.3 6.7 9.4 6.9 9.5 13.6 15.3 10.1 18.3 12.1 6.3 12.6 20.8 10.7 9.3 9.2 12.0 8.5 9.2 29.1 6.6 11.4 11.3 7.9 17.5 11.6 6.6 15.2 20.8 9.1 10.5 11.8 9.8 8.4 3.0 4.1 4.9 4.1 8.7 8.3 2.3 1.0 3.5 14.7 3.6 1.6 1.2 19.4 1.0 0.9 2.0 1.6 8.7 5.7 0.0 2.2 1.9 0.9 1.6 2.2 1.2 3.6 2.5 6.3 5.3 10.4 3.8 1.3 4.1 3.6 1.1 2.6 0.9 8.2 7.3 1.3 1.5 8.4 13.8 14.9 25.5 1.9 25.1 16.2 2.1 1.2 1.5 8.8 31.0 1.2 8.4 2.6 0.9 6.7 2.8 2.5 3.2 0.6 1.3 3.1 2.2 8.5 0.9 3.8 2.6 4.7 1.8 3.1 5.2 3.0 7.0 2.3 3.4 4.9 2.0 3.0 8.3 6.6 4.9 8.7 4.1 4.1 2.8 2.3 13.7 15.5 21.6 20.1 12.3 6.7 15.3 10.1 10.7 15.2 DOCK2 KIAA0209 ENSG00000134516 "Dedicator of cytokinesis 2" Q92608 5 169637247-170083382 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Guanine-nucleotide releasing factor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 31.0;bone marrow: 29.8;lymphoid tissue: 50.3" "Cell line enhanced" "Detected in some" "Daudi: 31.9;HDLM-2: 40.1;HL-60: 31.8;HMC-1: 37.0;MOLT-4: 24.2;U-698: 28.2;U-937: 22.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA036469 Enhanced "HPA036469: " "unprognostic (3.45e-2)" "unprognostic (1.84e-2)" "unprognostic (3.90e-3)" "unprognostic (2.04e-2)" "unprognostic (1.03e-1)" "unprognostic (5.92e-3)" "unprognostic (3.47e-1)" "unprognostic (1.61e-2)" "unprognostic (1.34e-1)" "unprognostic (2.10e-1)" "unprognostic (1.15e-1)" "unprognostic (1.31e-1)" "unprognostic (2.03e-3)" "unprognostic (1.47e-1)" "unprognostic (2.22e-2)" "unprognostic (6.95e-2)" "unprognostic (7.24e-2)" 7.3 3.1 2.9 30.7 4.8 29.8 4.1 1.0 2.7 2.2 3.5 5.8 1.2 2.6 2.9 2.7 2.4 2.9 4.9 2.7 3.4 2.5 3.1 2.9 12.6 22.6 4.8 1.3 1.9 1.9 0.7 2.2 3.8 4.1 3.3 4.5 2.6 6.6 1.2 1.3 2.0 13.7 3.6 8.5 28.0 3.6 1.8 3.7 50.3 2.8 1.7 31.5 6.2 2.5 6.4 14.0 12.7 31.0 6.6 6.6 9.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 1.6 3.2 0.0 0.0 31.9 0.6 2.5 0.0 0.0 0.0 4.0 40.1 0.0 17.7 0.3 0.0 0.0 31.8 37.0 0.0 0.0 0.7 0.0 0.0 0.3 16.0 0.8 0.0 24.2 8.2 0.0 0.0 15.1 0.5 12.7 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.8 0.1 0.3 1.0 0.4 0.7 5.0 7.8 28.2 0.6 22.1 0.0 6.2 12.7 10.0 6.4 23.0 6.6 6.4 5.9 6.3 14.0 5.3 4.3 5.0 12.7 6.6 31.0 4.8 5.3 9.4 2.9 4.8 1.0 2.7 3.4 2.5 4.8 1.3 4.1 3.7 DST "BP240, BPA, BPAG1, CATX-15, FLJ13425, FLJ21489, FLJ30627, FLJ32235, KIAA0728, MACF2" ENSG00000151914 Dystonin Q03001 6 56457987-56954628 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell adhesion" "Actin-binding, Muscle protein" "Cancer-related genes, Epidermolysis bullosa, Neurodegeneration, Neuropathy" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "hTCEpi: 92.5;hTERT-HME1: 68.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "plasmacytoid DC: 5.3" "Group enriched" "Detected in many" 5 "dendritic cells: 5.3;monocytes: 1.7;NK-cells: 2.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA030200 Uncertain Approved Nucleoplasm,Microtubules,Cytosol "Nucleoplasm, Microtubules" Cytosol "HPA030200: AB_10601901" "unprognostic (4.87e-3)" "unprognostic (1.29e-1)" "unprognostic (3.40e-1)" "unprognostic (1.54e-1)" "unprognostic (1.25e-2)" "unprognostic (3.60e-2)" "unprognostic (5.78e-2)" "unprognostic (2.35e-2)" "unprognostic (1.09e-1)" "unprognostic (2.75e-2)" "unprognostic (1.13e-1)" "unprognostic (3.69e-1)" "unprognostic (4.39e-2)" "unprognostic (5.13e-3)" "unprognostic (1.46e-1)" "unprognostic (2.66e-1)" "unprognostic (7.62e-2)" 26.5 29.2 43.4 11.7 57.1 2.5 59.2 43.6 52.4 53.8 31.5 32.1 11.5 15.1 53.6 21.7 37.1 19.4 16.8 28.1 41.2 36.2 18.0 26.6 29.4 5.4 56.5 28.9 30.3 14.0 32.1 28.2 15.1 53.9 22.6 17.4 8.4 23.6 25.3 57.5 81.8 16.9 53.6 54.9 12.8 14.8 11.7 66.5 6.1 7.6 33.6 7.7 19.7 23.7 0.6 5.3 0.3 1.7 2.1 0.4 0.3 11.9 5.7 7.7 4.4 12.8 20.2 4.4 16.1 15.4 6.7 7.5 3.3 3.2 1.8 6.7 36.4 8.4 6.5 28.4 13.2 11.4 9.7 3.4 10.4 6.1 11.5 3.2 0.0 8.9 92.5 16.2 68.5 12.6 2.7 7.9 17.3 3.3 0.9 1.3 5.9 4.2 0.0 6.0 2.7 20.2 15.4 10.3 7.7 6.9 2.4 11.0 3.7 5.2 33.8 14.8 12.4 7.0 13.3 8.9 6.3 0.9 10.5 1.7 7.0 0.3 1.7 0.0 0.3 1.3 0.1 0.2 0.4 0.0 3.2 0.6 0.1 0.2 0.1 2.1 1.0 5.3 0.0 0.3 43.4 57.1 43.6 52.4 41.2 36.2 56.5 28.9 53.9 66.5 DUSP1 "CL100, HVH1, MKP-1, PTPN10" ENSG00000120129 "Dual specificity phosphatase 1" P28562 5 172768090-172771195 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Cell cycle, Stress response" "Hydrolase, Protein phosphatase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HHSteC: 43.1;hTCEpi: 75.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in many" 5 "neutrophil: 326.0" "Lineage enriched" "Detected in all" 10 "granulocytes: 326.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA069577 Approved Nucleoli,Cytosol Nucleoli Cytosol "HPA069577: " "unprognostic (1.51e-1)" "unprognostic (1.24e-1)" "unprognostic (9.73e-2)" "unprognostic (8.17e-2)" "unprognostic (4.64e-1)" "unprognostic (1.58e-3)" "unprognostic (4.18e-2)" "unprognostic (6.94e-2)" "unprognostic (3.11e-1)" "unprognostic (1.43e-2)" "unprognostic (2.23e-1)" "unprognostic (1.51e-2)" "unprognostic (2.76e-2)" "prognostic unfavourable (3.11e-5)" "unprognostic (2.69e-1)" "unprognostic (2.35e-2)" "unprognostic (1.41e-3)" 158.4 78.0 12.4 68.5 14.0 89.7 91.8 17.4 14.9 81.4 37.1 32.4 48.5 9.4 55.4 71.6 82.7 94.8 138.8 49.2 12.5 11.4 29.8 115.4 135.0 43.5 30.6 9.7 69.4 34.4 26.6 40.8 93.7 29.3 67.1 34.2 61.0 38.1 192.8 54.8 116.1 27.6 65.0 29.5 36.1 53.6 45.9 18.7 10.8 90.4 104.1 46.9 69.0 109.7 2.4 11.5 326.0 31.8 4.5 9.8 14.0 2.1 5.4 1.7 2.3 37.5 22.0 2.9 34.9 10.2 23.5 9.5 5.9 2.5 0.7 10.2 24.5 0.9 1.6 8.6 11.0 19.1 4.6 0.4 11.9 2.5 43.1 0.2 0.8 21.0 75.3 10.6 17.3 7.3 1.7 13.7 15.1 2.5 1.1 1.0 1.5 1.6 40.5 3.2 6.3 16.7 1.1 7.4 3.1 9.4 16.1 1.2 1.3 0.4 19.2 16.7 8.3 16.2 2.6 2.8 1.6 0.6 14.8 0.3 0.6 33.3 24.6 69.8 3.9 25.0 9.8 2.4 3.5 4.0 11.5 2.1 1.7 1.9 326.0 4.5 31.8 0.6 2.8 14.0 12.4 14.0 17.4 14.9 12.5 11.4 30.6 9.7 29.3 18.7 DUSP14 "MKP-L, MKP6" ENSG00000276023 "Dual specificity phosphatase 14" O95147 17 37489831-37513501 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Hydrolase, Protein phosphatase" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "BJ hTERT+ SV40 Large T+: 10.7;BJ hTERT+ SV40 Large T+ RasG12V: 12.5;HBF TERT88: 17.9;WM-115: 10.3" "Low cancer specificity" "Detected in all" "Cell type enhanced" "Detected in single" "neutrophil: 3.2" "Lineage enriched" "Detected in single" 6 "granulocytes: 3.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA019911 Approved Approved Nucleoplasm,Cytosol 44000 "Nucleoplasm, Cytosol" "HPA019911: AB_1847888" "unprognostic (1.32e-1)" "unprognostic (3.06e-1)" "unprognostic (2.19e-2)" "unprognostic (1.57e-1)" "unprognostic (4.60e-1)" "unprognostic (3.22e-2)" "unprognostic (3.43e-3)" "unprognostic (2.02e-3)" "unprognostic (2.18e-1)" "unprognostic (2.59e-1)" "unprognostic (7.02e-3)" "unprognostic (3.81e-1)" "prognostic unfavourable (6.97e-9)" "unprognostic (7.93e-2)" "unprognostic (1.97e-1)" "unprognostic (1.73e-1)" "unprognostic (1.41e-3)" 4.7 3.7 3.3 2.1 6.6 1.1 3.9 1.8 8.0 3.3 1.0 1.5 0.1 0.7 2.7 1.2 7.2 11.7 5.1 2.6 2.3 2.1 6.5 2.4 1.0 1.9 2.5 3.0 2.9 1.7 3.3 11.6 2.6 1.4 1.4 1.6 2.8 1.1 1.7 8.4 0.9 3.5 2.7 1.7 1.0 3.5 0.8 2.3 8.3 6.1 4.3 1.9 1.0 0.5 0.0 3.2 0.0 0.4 0.4 0.5 1.7 0.1 0.4 0.8 0.0 0.5 1.5 8.0 6.1 10.7 12.5 0.9 1.8 0.1 0.7 5.8 1.3 0.1 4.7 17.9 0.1 0.5 0.0 1.0 2.0 0.8 0.4 1.2 4.7 2.9 3.8 2.0 0.2 0.4 0.0 7.9 0.3 0.8 0.2 0.2 0.0 0.7 0.5 0.2 2.6 0.7 1.3 0.1 0.4 0.7 1.1 0.6 1.0 0.7 8.6 2.0 0.1 4.0 0.0 0.2 0.1 0.0 0.0 10.3 0.0 0.0 0.9 0.4 0.0 0.2 0.5 0.1 0.0 0.0 0.2 0.3 0.2 3.2 0.4 0.0 0.0 0.0 0.5 DUSP4 "HVH2, MKP-2, TYP" ENSG00000120875 "Dual specificity phosphatase 4" Q13115 8 29333064-29350668 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Hydrolase, Protein phosphatase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "ductus deferens: 46.7;pancreas: 78.6;seminal vesicle: 63.5" "Cell line enhanced" "Detected in many" "A549: 30.0;SK-MEL-30: 46.2;WM-115: 37.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in some" 8 "T-reg: 9.6" "Lineage enriched" "Detected in single" 18 "T-cells: 9.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA061967 Supported Nucleoplasm Nucleoplasm "HPA061967: " "unprognostic (1.92e-1)" "unprognostic (5.97e-3)" "unprognostic (3.24e-1)" "unprognostic (6.54e-2)" "unprognostic (2.18e-2)" "unprognostic (7.66e-3)" "unprognostic (7.30e-2)" "unprognostic (7.08e-2)" "unprognostic (1.83e-2)" "unprognostic (9.73e-3)" "unprognostic (9.60e-3)" "unprognostic (3.15e-2)" "prognostic unfavourable (4.19e-4)" "unprognostic (6.88e-2)" "unprognostic (1.62e-1)" "unprognostic (1.08e-2)" "unprognostic (6.07e-2)" 10.9 3.4 1.2 3.6 1.1 3.4 17.1 4.8 2.7 4.6 1.7 1.0 46.7 0.8 3.2 0.7 1.6 1.3 13.1 1.5 4.6 0.8 0.7 0.4 3.7 1.8 0.8 0.8 1.2 78.6 0.1 3.7 17.7 0.7 4.3 0.9 17.1 8.9 63.5 2.7 3.5 1.3 1.5 1.1 0.6 20.6 1.7 0.2 3.9 1.2 2.0 4.7 7.4 3.0 0.0 0.5 0.0 0.0 0.2 9.6 0.1 11.1 30.0 17.8 0.8 2.3 0.0 1.5 2.3 12.8 7.0 3.1 0.3 5.7 0.0 6.3 1.0 3.6 0.2 7.7 4.2 0.3 0.6 0.0 1.0 0.2 0.0 0.1 14.6 1.4 5.1 2.2 13.1 5.7 0.1 1.3 14.0 12.6 0.0 2.1 3.1 18.4 0.3 0.6 2.3 16.1 5.9 0.1 9.9 3.2 15.2 46.2 3.2 0.3 16.0 5.2 0.0 0.0 1.6 3.6 0.4 0.0 15.6 2.6 37.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.4 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.5 9.6 0.1 1.2 1.1 4.8 2.7 4.6 0.8 0.8 0.8 0.7 0.2 DVL3 KIAA0208 ENSG00000161202 "Dishevelled segment polarity protein 3" Q92997 3 184155388-184173610 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Wnt signaling pathway" "Developmental protein" "Cancer-related genes, Dwarfism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB046486, HPA058265" Approved Approved "Intermediate filaments,Midbody ring,Centrosome" "Midbody ring, Centrosome" "Intermediate filaments" "CAB046486: AB_10610845, HPA058265: " "unprognostic (2.20e-1)" "unprognostic (1.52e-1)" "prognostic unfavourable (1.90e-4)" "unprognostic (1.88e-2)" "unprognostic (1.64e-2)" "unprognostic (2.23e-1)" "prognostic unfavourable (8.41e-4)" "unprognostic (8.61e-2)" "unprognostic (5.34e-2)" "unprognostic (2.49e-1)" "unprognostic (3.14e-1)" "prognostic unfavourable (4.77e-5)" "prognostic unfavourable (1.53e-8)" "unprognostic (1.87e-1)" "unprognostic (4.10e-1)" "unprognostic (8.41e-2)" "unprognostic (3.95e-1)" 22.8 18.5 18.0 16.8 19.4 15.3 25.1 18.3 23.2 22.6 27.6 24.7 23.9 16.2 32.1 16.4 20.0 22.2 22.2 27.9 19.9 12.3 16.8 13.1 20.6 12.1 21.4 16.0 30.0 22.7 17.2 17.8 56.0 17.4 19.7 15.8 31.1 18.7 26.2 26.3 27.6 19.1 30.3 16.4 17.8 19.4 15.6 20.1 7.3 20.9 13.3 14.6 24.5 26.3 2.5 2.7 4.1 4.0 1.5 3.1 1.2 19.8 6.5 15.8 17.9 16.4 16.4 40.7 11.8 12.1 14.3 11.9 19.1 8.0 13.9 31.7 15.4 17.0 12.9 9.4 10.0 21.9 13.5 15.5 9.8 11.5 24.6 8.6 12.1 16.5 16.9 10.4 11.9 10.4 15.5 19.3 15.0 19.0 12.7 10.2 13.9 9.4 20.3 18.3 12.1 13.3 16.4 17.1 21.7 14.7 17.0 28.8 42.5 11.0 10.2 13.0 12.7 13.6 18.3 20.7 15.3 15.5 12.9 9.2 10.0 0.2 2.4 4.1 2.3 4.0 3.1 2.5 1.5 2.4 2.3 2.0 2.0 1.3 3.6 1.5 2.8 2.7 1.1 1.2 18.0 19.4 18.3 23.2 19.9 12.3 21.4 16.0 17.4 20.1 DYNLL1 "DLC1, DLC8, DNCL1, hdlc1, LC8, PIN" ENSG00000088986 "Dynein light chain LC8-type 1" P63167 12 120469850-120498493 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Apoptosis, Host-virus interaction, Transcription, Transcription regulation, Transport" "Activator, Motor protein" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" HPA039954 Approved "Nucleoplasm,Nuclear bodies,Cytosol" 650000 "Nucleoplasm, Cytosol" "Nuclear bodies" "HPA039954: " "unprognostic (1.94e-1)" "unprognostic (1.08e-1)" "unprognostic (3.43e-2)" "unprognostic (2.88e-2)" "unprognostic (5.63e-2)" "unprognostic (7.09e-2)" "prognostic unfavourable (7.33e-5)" "unprognostic (4.41e-3)" "unprognostic (4.64e-2)" "unprognostic (6.17e-3)" "unprognostic (1.61e-2)" "unprognostic (9.10e-2)" "prognostic unfavourable (7.97e-7)" "unprognostic (4.91e-2)" "unprognostic (2.80e-2)" "unprognostic (7.91e-2)" "unprognostic (1.62e-1)" 45.5 48.5 128.5 34.4 97.8 21.9 54.3 48.4 120.5 50.6 61.8 61.9 31.1 31.6 47.2 64.9 113.7 107.1 46.7 44.2 124.1 105.2 49.7 40.7 40.3 41.2 92.9 90.7 49.0 45.7 30.4 46.4 49.8 67.4 39.9 64.5 24.8 34.0 54.9 15.0 117.3 38.9 75.2 93.6 30.4 45.1 59.4 56.8 35.4 37.1 84.3 65.6 59.0 63.0 55.0 80.6 73.6 55.0 46.7 63.4 50.8 78.4 89.7 89.0 68.2 78.2 83.0 28.6 108.6 50.2 88.7 53.2 84.5 52.9 44.0 58.7 103.7 70.8 105.7 90.8 88.7 58.3 69.2 43.0 64.3 114.3 79.0 44.8 71.5 50.4 97.2 66.5 54.6 92.1 53.9 50.7 117.0 103.9 58.5 97.6 73.0 104.7 59.8 46.1 54.6 126.7 72.7 61.2 45.2 88.5 76.9 98.6 76.2 65.6 70.8 68.3 58.3 60.2 93.5 30.6 58.7 43.7 75.7 70.1 87.4 73.6 49.5 63.6 37.7 51.4 28.7 55.0 39.0 39.0 49.1 36.5 25.2 31.5 9.1 46.7 55.0 80.6 63.4 50.8 128.5 97.8 48.4 120.5 124.1 105.2 92.9 90.7 67.4 56.8 DYRK2 ENSG00000127334 "Dual specificity tyrosine phosphorylation regulated kinase 2" Q92630 12 67648338-67665406 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Apoptosis, Ubl conjugation pathway" "Kinase, Serine/threonine-protein kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA027230, HPA056902" Approved Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "HPA027230: AB_1847925, HPA056902: " "unprognostic (5.86e-3)" "unprognostic (4.18e-1)" "unprognostic (4.08e-3)" "unprognostic (2.56e-3)" "unprognostic (1.18e-2)" "unprognostic (1.69e-1)" "unprognostic (3.37e-3)" "unprognostic (7.83e-2)" "unprognostic (2.83e-2)" "unprognostic (1.22e-1)" "unprognostic (1.04e-1)" "unprognostic (3.47e-1)" "unprognostic (2.12e-2)" "unprognostic (2.03e-2)" "unprognostic (1.38e-1)" "unprognostic (1.57e-1)" "unprognostic (1.35e-1)" 12.2 5.3 4.5 20.1 4.8 8.6 8.1 4.4 6.6 10.1 21.3 4.1 8.3 13.7 14.6 9.6 9.6 9.1 16.9 26.1 4.7 3.2 6.3 4.6 10.1 17.9 4.0 3.3 7.6 8.5 3.6 4.4 13.0 5.0 7.1 15.3 6.6 7.2 6.6 23.7 9.4 26.0 11.2 5.3 10.3 14.0 4.4 3.9 34.3 7.6 12.5 17.2 11.1 12.2 2.7 1.9 5.9 1.3 6.9 6.8 1.6 13.5 7.7 11.5 8.3 5.8 7.9 9.2 13.8 9.0 6.8 3.9 10.1 7.5 25.4 17.1 20.0 15.9 9.2 5.4 7.3 10.9 12.0 4.1 5.1 3.8 2.2 9.2 8.9 6.5 7.8 18.2 14.6 3.8 5.0 13.3 8.6 7.8 7.9 4.5 10.0 12.4 21.1 11.4 11.2 7.9 17.1 15.2 18.0 5.8 7.8 8.0 5.3 7.8 5.6 10.8 10.2 7.4 10.9 6.3 1.0 14.1 10.4 6.3 11.1 3.2 0.5 5.9 5.2 1.3 4.0 2.7 3.9 6.8 1.9 2.7 3.3 6.1 0.7 6.9 1.3 0.8 3.1 1.6 4.5 4.8 4.4 6.6 4.7 3.2 4.0 3.3 5.0 3.9 E2F1 "RBBP3, RBP3" ENSG00000101412 "E2F transcription factor 1" Q01094 20 33675683-33686404 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Apoptosis, Cell cycle, Host-virus interaction, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 32.5;lymphoid tissue: 21.9" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "non-classical monocyte: 3.7" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB000329, HPA008003, CAB019308, HPA029735" Enhanced Enhanced Nucleoplasm,Centrosome "Nucleoplasm, Centrosome" "CAB000329: AB_627476, CAB019308: , HPA008003: AB_1847936, HPA029735: " "unprognostic (7.46e-2)" "prognostic favourable (9.22e-6)" "unprognostic (2.11e-2)" "prognostic unfavourable (4.33e-5)" "unprognostic (1.51e-1)" "unprognostic (1.21e-2)" "prognostic unfavourable (3.83e-5)" "unprognostic (1.25e-2)" "unprognostic (8.23e-2)" "unprognostic (9.66e-2)" "prognostic unfavourable (4.18e-4)" "unprognostic (3.15e-2)" "prognostic unfavourable (8.99e-5)" "unprognostic (1.05e-2)" "unprognostic (7.50e-2)" "prognostic favourable (1.62e-4)" "unprognostic (1.91e-1)" 2.4 5.3 6.8 12.7 9.7 32.5 2.1 1.1 6.4 1.2 4.4 5.1 0.7 3.9 1.4 0.8 5.1 1.5 4.1 2.0 7.1 3.6 0.9 1.7 8.1 9.3 6.2 2.9 3.4 1.2 2.3 0.3 3.3 5.9 1.7 4.8 0.3 1.6 1.4 1.4 5.4 4.9 3.3 6.2 4.8 3.4 12.1 6.0 21.9 1.0 4.9 7.7 1.9 3.1 2.2 0.6 0.7 3.7 1.4 1.2 0.6 15.9 15.5 18.0 14.0 1.8 1.3 13.7 15.3 7.4 19.6 16.5 27.4 16.5 29.4 15.5 6.8 12.0 8.7 8.1 8.8 8.8 12.5 24.0 23.1 15.9 0.1 11.2 15.2 1.0 0.5 10.7 1.9 5.0 6.3 20.8 12.1 14.1 23.8 23.8 5.4 22.3 23.8 49.1 12.1 3.3 9.8 26.9 18.9 18.6 13.0 7.6 16.3 14.2 2.7 22.9 13.4 15.8 21.7 20.3 13.7 24.2 19.0 6.7 13.5 0.0 0.0 0.7 0.1 0.9 0.0 2.2 0.6 0.4 0.2 0.2 0.2 1.2 0.3 1.4 3.7 0.6 0.8 0.6 6.8 9.7 1.1 6.4 7.1 3.6 6.2 2.9 5.9 6.0 E2F3 ENSG00000112242 "E2F transcription factor 3" O00716 6 20401906-20493715 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Cell cycle, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA029779, HPA065012" Supported "Nucleoplasm,Nuclear speckles,Cytosol" "Nucleoplasm, Nuclear speckles" Cytosol "HPA029779: , HPA065012: " "unprognostic (4.10e-2)" "unprognostic (1.15e-1)" "unprognostic (1.06e-1)" "unprognostic (1.80e-3)" "unprognostic (2.96e-1)" "unprognostic (9.14e-2)" "unprognostic (8.99e-3)" "unprognostic (9.13e-2)" "unprognostic (1.10e-1)" "prognostic favourable (1.69e-4)" "unprognostic (1.14e-2)" "unprognostic (5.64e-2)" "prognostic unfavourable (1.63e-8)" "unprognostic (1.23e-1)" "unprognostic (2.16e-1)" "unprognostic (3.50e-1)" "unprognostic (5.99e-3)" 9.5 8.4 7.6 12.2 13.4 22.1 10.8 1.7 10.1 4.8 7.1 2.9 3.2 6.8 6.3 6.9 8.0 4.9 9.9 11.1 8.3 6.8 14.6 6.1 7.8 19.7 5.8 7.3 4.0 3.6 2.9 3.2 7.4 7.9 5.0 8.6 5.1 4.7 4.5 15.1 4.3 8.0 7.9 5.0 16.9 5.0 8.9 3.1 17.7 11.4 10.2 12.0 9.2 4.8 0.7 3.7 10.3 3.1 4.8 3.6 1.5 6.7 5.5 15.9 17.0 5.3 5.9 11.0 9.1 7.9 8.8 9.7 6.8 4.2 15.1 17.7 8.5 7.1 18.1 8.2 14.8 5.9 12.8 27.5 9.1 7.5 5.7 18.0 16.5 4.7 6.1 8.6 10.5 6.0 30.4 9.4 9.9 6.9 20.4 20.1 11.9 5.7 22.2 14.0 17.4 10.5 11.8 11.5 21.0 8.5 11.7 12.0 6.0 10.9 8.0 14.2 8.9 7.0 14.5 5.9 18.7 19.0 3.5 11.2 20.1 6.9 3.1 1.4 2.3 2.3 3.1 0.7 1.5 3.6 3.7 0.7 1.3 2.8 10.3 4.8 1.5 1.6 2.2 1.5 7.6 13.4 1.7 10.1 8.3 6.8 5.8 7.3 7.9 3.1 E2F5 ENSG00000133740 "E2F transcription factor 5" Q15329 8 85177225-85217158 "Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors" "Cilium biogenesis/degradation, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "AF22: 27.0;Daudi: 53.1;U-698: 25.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 7 "memory B-cell: 13.3;naive B-cell: 7.6" "Lineage enriched" "Detected in many" 9 "B-cells: 13.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA055723, HPA065441" Enhanced Nucleoplasm,Nucleoli,Vesicles Nucleoplasm "Nucleoli, Vesicles" "HPA055723: , HPA065441: " "unprognostic (8.73e-2)" "unprognostic (3.45e-1)" "unprognostic (3.15e-2)" "unprognostic (1.02e-3)" "unprognostic (6.73e-3)" "unprognostic (1.62e-1)" "unprognostic (3.36e-5)" "unprognostic (1.23e-1)" "unprognostic (9.53e-2)" "unprognostic (1.28e-1)" "unprognostic (3.18e-1)" "unprognostic (3.87e-2)" "prognostic unfavourable (1.89e-6)" "unprognostic (2.88e-2)" "unprognostic (3.25e-2)" "unprognostic (3.64e-1)" "unprognostic (2.95e-3)" 3.0 9.0 6.4 22.2 8.1 1.5 5.9 2.6 5.3 5.0 5.9 4.0 3.4 4.6 5.4 7.4 4.7 7.2 6.6 3.2 5.6 5.6 9.0 4.5 5.1 22.4 4.6 2.7 8.3 14.6 12.7 10.6 4.3 3.8 5.1 7.2 3.4 5.7 5.9 1.1 1.7 7.3 3.8 4.5 9.9 5.1 10.5 3.2 13.6 10.2 3.0 26.0 6.0 7.6 13.3 1.4 0.0 0.0 1.1 0.6 0.6 4.8 5.2 27.0 10.0 0.5 0.7 8.7 0.9 2.1 0.8 2.3 3.1 5.7 53.1 3.8 1.1 1.0 15.7 1.3 1.0 5.5 7.2 5.3 2.9 7.3 4.3 1.6 0.0 1.0 2.1 1.0 3.8 0.8 11.2 0.4 1.4 3.1 5.4 3.5 8.7 4.6 4.3 1.1 5.7 8.7 3.4 3.3 10.4 0.6 1.8 8.0 11.3 1.7 0.0 1.3 1.0 1.5 3.5 10.0 6.7 25.4 1.5 1.3 2.6 0.0 0.0 0.0 0.1 0.0 0.0 13.3 0.0 0.0 0.1 7.6 0.2 0.4 0.0 1.1 0.0 1.4 0.6 0.6 6.4 8.1 2.6 4.5 5.6 5.6 4.6 2.7 3.8 3.2 EBAG9 "EB9, RCAS1" ENSG00000147654 "Estrogen receptor binding site associated, antigen, 9" O00559 8 109539711-109565996 "Cancer-related genes, Predicted intracellular proteins" Apoptosis "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA021153, HPA021154, CAB072810, CAB072811, CAB072812" Enhanced Enhanced "Golgi apparatus" "Intracellular and membrane" "Golgi apparatus" "CAB072810: , CAB072811: , CAB072812: , HPA021153: AB_1856151, HPA021154: AB_1856152" "unprognostic (3.04e-2)" "unprognostic (9.99e-2)" "unprognostic (2.08e-1)" "unprognostic (1.99e-1)" "unprognostic (5.06e-2)" "unprognostic (8.13e-2)" "unprognostic (2.63e-1)" "unprognostic (3.17e-2)" "unprognostic (1.72e-1)" "unprognostic (4.22e-2)" "unprognostic (1.04e-1)" "unprognostic (3.72e-1)" "unprognostic (9.72e-3)" "unprognostic (6.46e-2)" "unprognostic (5.16e-1)" "unprognostic (3.53e-1)" "unprognostic (3.71e-2)" 17.1 23.7 24.4 19.8 23.4 10.7 24.1 24.2 25.6 28.1 20.3 13.3 24.9 16.9 17.0 34.2 15.6 20.7 16.0 23.9 21.4 21.5 27.1 31.9 22.7 19.2 20.2 21.9 18.2 32.1 24.1 27.4 19.2 18.2 21.2 23.2 15.1 29.0 36.3 34.1 12.9 21.0 16.1 20.8 20.7 19.0 17.4 15.5 17.0 42.4 20.1 18.7 22.5 15.0 21.8 13.0 7.8 10.3 15.4 20.2 7.9 16.2 11.5 11.7 8.0 7.3 11.9 9.1 8.9 6.7 12.6 11.9 11.6 17.4 23.2 15.5 6.2 11.5 11.2 14.2 13.4 25.6 12.3 25.5 7.5 17.6 16.3 8.8 7.5 9.5 28.1 10.8 22.2 11.8 26.2 17.1 11.0 24.8 25.5 14.0 7.3 11.6 13.7 9.3 19.4 14.5 10.7 12.9 10.3 9.7 10.4 12.1 20.6 11.5 7.9 9.8 7.1 8.8 6.5 25.7 16.5 21.8 10.0 23.7 9.0 2.7 7.4 7.8 11.3 10.3 19.8 21.8 15.9 15.6 12.2 20.2 20.2 17.8 1.5 15.4 8.9 13.0 17.1 7.9 24.4 23.4 24.2 25.6 21.4 21.5 20.2 21.9 18.2 15.5 EBF1 "EBF, OLF1" ENSG00000164330 "Early B cell factor 1" Q9UH73 5 158695916-159099761 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in some" "ASC diff: 19.0;HSkMC: 14.8;REH: 39.7" "Low cancer specificity" "Detected in many" "Region enriched" "Detected in all" 5 "cerebellum: 23.6" "Group enriched" "Detected in some" 62 "memory B-cell: 11.8;naive B-cell: 10.4" "Lineage enriched" "Detected in single" 66 "B-cells: 11.8" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA061169 Approved Nucleoplasm,Vesicles Nucleoplasm Vesicles "HPA061169: " "unprognostic (7.86e-2)" "unprognostic (3.08e-2)" "unprognostic (7.29e-2)" "unprognostic (4.70e-2)" "unprognostic (2.63e-1)" "unprognostic (1.39e-2)" "unprognostic (1.78e-1)" "unprognostic (1.60e-1)" "unprognostic (5.75e-2)" "unprognostic (1.60e-1)" "unprognostic (4.58e-2)" "unprognostic (1.02e-1)" "prognostic unfavourable (9.62e-7)" "prognostic unfavourable (7.80e-4)" "unprognostic (5.75e-2)" "unprognostic (5.81e-2)" "unprognostic (4.37e-3)" 33.7 3.3 1.9 9.7 2.5 3.1 25.0 23.6 2.0 15.9 5.8 1.1 9.0 1.2 19.7 13.0 5.0 8.5 9.4 15.5 2.0 2.4 3.3 0.9 5.2 12.7 3.2 1.2 7.4 3.7 1.8 2.6 10.7 4.7 8.5 3.4 10.4 4.7 10.8 15.5 4.8 4.5 25.7 6.6 5.4 3.4 8.4 1.0 0.1 6.8 13.2 9.1 11.7 12.5 11.8 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.2 6.1 0.0 19.0 8.2 0.0 0.0 0.0 0.2 0.5 0.0 0.0 5.4 0.0 2.2 0.0 0.2 0.0 0.1 1.2 0.0 0.0 1.6 0.0 0.3 0.0 0.0 14.8 0.0 5.8 0.2 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.5 0.0 39.7 0.2 0.0 0.0 0.0 3.2 0.8 0.3 0.0 0.0 0.0 0.0 0.0 7.3 0.8 8.3 0.1 0.0 0.0 5.5 4.8 0.4 6.6 0.1 0.0 0.1 0.0 0.0 0.0 11.8 0.0 0.0 0.0 10.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 1.9 2.5 23.6 1.6 2.0 2.4 3.2 1.2 4.7 1.0 EDN1 ET1 ENSG00000078401 "Endothelin 1" P05305 6 12290363-12297194 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins" "Vasoactive, Vasoconstrictor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "EFO-21: 107.5;HUVEC TERT2: 71.2;T-47d: 22.0;TIME: 52.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in some" 6 "non-classical monocyte: 7.9" "Lineage enriched" "Detected in many" 6 "monocytes: 7.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA031976, CAB032500, CAB037291" Approved Approved "Nucleoplasm,Nucleoli,Golgi apparatus" "Secreted to blood" 1085 "Nucleoli, Golgi apparatus" Nucleoplasm "CAB032500: AB_2096241, CAB037291: AB_259277, HPA031976: AB_10602489" "unprognostic (1.51e-2)" "unprognostic (2.38e-1)" "unprognostic (3.95e-2)" "unprognostic (9.72e-2)" "unprognostic (3.40e-1)" "unprognostic (1.91e-1)" "unprognostic (6.24e-2)" "unprognostic (2.94e-3)" "unprognostic (1.42e-1)" "unprognostic (8.92e-2)" "unprognostic (4.19e-2)" "unprognostic (3.17e-1)" "unprognostic (8.02e-3)" "unprognostic (2.09e-1)" "unprognostic (1.71e-1)" "unprognostic (1.34e-1)" "unprognostic (3.47e-1)" 35.7 1.5 8.4 6.2 30.8 3.6 19.2 3.2 22.0 8.2 9.2 4.2 1.1 9.0 7.2 15.3 10.8 8.6 11.9 5.2 19.0 6.2 5.7 2.8 25.1 6.7 10.9 5.5 4.3 8.2 1.6 1.0 16.0 25.1 5.4 12.9 6.9 9.7 8.5 25.6 8.2 6.7 9.7 13.5 10.2 6.8 4.8 5.6 0.2 2.9 3.8 2.1 5.3 4.1 0.2 0.2 1.2 7.9 0.0 0.2 0.0 1.5 9.0 0.1 0.0 0.0 0.0 0.0 2.8 2.5 2.4 2.0 11.6 1.3 0.0 107.5 1.1 0.8 0.0 1.6 1.7 0.1 0.0 0.0 0.3 0.3 0.1 0.0 0.0 0.0 1.0 0.4 0.3 71.2 0.0 0.0 9.0 0.2 0.0 0.0 0.1 0.1 0.0 0.8 0.0 5.6 1.4 0.1 0.0 0.2 8.5 0.0 22.0 0.1 52.7 6.0 4.8 0.1 3.6 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 1.2 0.0 0.3 0.0 0.0 0.0 0.0 0.2 0.2 0.2 0.0 0.0 0.0 7.9 0.1 0.0 0.0 8.4 30.8 3.2 22.0 19.0 6.2 10.9 5.5 25.1 5.6 EEF1A1 "EE1A1, EEF1A, EF1A, LENG7" ENSG00000156508 "Eukaryotic translation elongation factor 1 alpha 1" P68104 6 73515750-73523797 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Protein biosynthesis, Transcription, Transcription regulation" "Elongation factor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA051759, HPA053862, HPA056990" Supported Supported Cytosol Cytosol "HPA051759: , HPA053862: , HPA056990: " "unprognostic (6.47e-2)" "unprognostic (7.86e-3)" "unprognostic (2.53e-2)" "unprognostic (9.64e-2)" "unprognostic (1.39e-2)" "unprognostic (1.08e-1)" "prognostic unfavourable (5.57e-4)" "unprognostic (3.13e-1)" "unprognostic (1.61e-1)" "unprognostic (2.77e-1)" "unprognostic (1.41e-1)" "unprognostic (3.47e-1)" "unprognostic (8.61e-2)" "unprognostic (1.65e-1)" "unprognostic (8.00e-2)" "unprognostic (2.04e-1)" "unprognostic (7.73e-2)" 134.1 124.1 80.2 136.0 75.6 140.9 182.0 103.3 106.2 149.6 133.3 94.9 93.7 81.7 152.0 127.3 136.4 143.1 102.4 88.2 71.5 58.0 130.9 123.1 169.6 135.6 74.3 93.2 240.8 227.6 106.3 111.2 89.1 79.7 115.0 114.7 105.0 133.3 123.6 51.3 139.8 101.6 121.6 108.6 111.3 121.5 129.9 71.6 125.1 132.4 143.1 169.7 151.1 134.8 258.9 209.7 54.6 187.6 184.6 366.8 517.5 111.1 141.0 200.2 273.4 410.7 679.5 159.4 166.6 430.1 213.7 205.1 218.7 153.9 454.1 222.8 281.5 118.0 244.5 318.4 206.0 79.2 153.0 169.5 115.0 243.6 356.6 315.0 185.1 587.0 541.5 157.3 530.9 289.4 313.2 143.7 258.2 148.2 134.8 330.2 214.2 98.0 268.8 337.3 509.0 274.5 235.6 164.3 182.4 83.5 196.4 329.6 133.5 509.2 240.4 91.3 130.0 67.6 189.1 161.4 143.4 106.6 94.8 261.3 143.4 54.6 187.6 20.8 198.7 165.4 366.8 258.9 288.8 250.9 209.7 199.5 323.8 277.8 17.0 184.6 169.0 161.7 202.9 517.5 80.2 75.6 103.3 106.2 71.5 58.0 74.3 93.2 79.7 71.6 EEF2 "EEF-2, EF2" ENSG00000167658 "Eukaryotic translation elongation factor 2" P13639 19 3976056-3985469 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Protein biosynthesis" "Elongation factor" "Cancer-related genes, Disease mutation, Neurodegeneration, Spinocerebellar ataxia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB007795, HPA040534, HPA057351" Enhanced Enhanced "Plasma membrane,Cytosol" 9700000 "Plasma membrane, Cytosol" "CAB007795: AB_598149, HPA040534: AB_2677024, HPA057351: AB_2683417" "unprognostic (5.47e-2)" "unprognostic (9.59e-2)" "unprognostic (3.75e-1)" "prognostic favourable (1.81e-6)" "unprognostic (2.06e-2)" "unprognostic (3.26e-1)" "unprognostic (1.53e-2)" "unprognostic (2.11e-1)" "unprognostic (1.83e-1)" "unprognostic (1.77e-2)" "unprognostic (1.25e-2)" "unprognostic (1.42e-1)" "prognostic favourable (1.25e-5)" "unprognostic (4.46e-2)" "unprognostic (5.60e-2)" "unprognostic (6.82e-2)" "unprognostic (9.86e-2)" 104.2 84.9 64.0 66.7 57.1 92.7 77.5 55.7 96.2 93.4 91.3 55.8 80.8 95.4 100.1 75.1 115.1 83.4 88.6 104.1 51.6 44.4 65.5 161.0 67.7 108.9 51.4 38.3 167.1 395.7 45.1 72.3 63.7 47.5 105.6 41.3 67.7 191.3 64.4 260.8 87.2 100.9 112.3 46.8 85.4 98.5 70.9 32.4 123.4 127.1 112.5 108.3 111.8 94.7 84.9 60.0 10.0 58.4 48.3 76.3 83.7 95.2 68.4 39.8 105.1 106.7 192.3 57.3 74.9 101.4 71.7 70.6 107.8 44.2 199.0 44.6 69.1 72.3 62.8 116.0 38.0 49.6 104.2 50.8 65.7 110.7 156.0 109.1 88.4 248.2 122.7 63.1 97.7 74.2 99.1 146.7 43.6 138.2 97.9 83.7 105.3 69.2 109.1 59.2 126.5 59.0 85.2 109.0 101.3 47.1 94.3 135.0 91.9 132.7 88.9 51.4 53.7 104.4 115.2 157.4 105.6 99.0 76.6 137.2 67.0 10.0 58.4 8.3 38.6 45.8 68.7 84.9 67.7 50.8 60.0 70.7 76.3 59.4 6.1 48.3 43.8 50.5 58.4 83.7 64.0 57.1 55.7 96.2 51.6 44.4 51.4 38.3 47.5 32.4 EFNA1 "ECKLG, EPLG1, LERK1, TNFAIP4" ENSG00000169242 "Ephrin A1" P20827 1 155127460-155134857 "Cancer-related genes, Predicted secreted proteins, RAS pathway related proteins" Angiogenesis "Cancer-related genes, Tumor suppressor" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 123.2" "Cell line enhanced" "Detected in many" "BEWO: 57.1;HaCaT: 19.9;SiHa: 32.9;SK-BR-3: 50.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 8 "naive CD4 T-cell: 12.1;naive CD8 T-cell: 6.0" "Lineage enriched" "Detected in single" 26 "T-cells: 12.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB032498 Uncertain "Secreted to blood" 2100000 "CAB032498: AB_2262137" "unprognostic (5.14e-2)" "unprognostic (3.04e-3)" "unprognostic (5.03e-2)" "unprognostic (2.01e-1)" "unprognostic (1.59e-1)" "unprognostic (2.47e-2)" "unprognostic (1.78e-2)" "unprognostic (5.80e-3)" "unprognostic (1.53e-1)" "unprognostic (4.56e-2)" "unprognostic (2.00e-2)" "unprognostic (2.23e-1)" "unprognostic (4.44e-2)" "unprognostic (3.58e-1)" "unprognostic (1.93e-1)" "unprognostic (2.41e-1)" "unprognostic (1.32e-1)" 16.2 6.1 6.8 2.9 14.5 0.4 29.5 4.4 10.9 7.1 27.6 11.8 10.7 21.7 7.2 11.7 12.6 8.0 8.7 13.3 6.4 4.6 16.1 123.2 27.0 2.7 15.7 4.3 5.7 14.0 4.9 5.3 38.2 13.8 18.6 20.2 5.0 17.7 17.2 10.4 27.5 27.5 5.1 9.6 2.3 13.1 3.3 14.8 3.7 30.2 7.8 4.1 10.7 12.7 0.3 0.0 0.4 0.0 0.3 12.1 2.0 3.1 1.3 0.1 2.4 0.4 0.0 57.1 0.0 0.0 0.0 0.0 3.2 7.0 0.0 5.7 0.0 19.9 1.3 6.9 0.0 1.9 0.4 0.0 4.4 17.2 0.1 0.0 0.3 0.9 17.0 0.0 5.9 10.7 0.5 0.1 0.0 11.4 0.0 0.2 0.4 4.2 1.2 0.3 1.9 13.5 4.9 2.0 3.0 32.9 50.5 1.2 10.6 0.0 1.3 0.0 2.0 0.1 0.3 0.5 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.2 0.0 1.0 0.7 0.0 0.3 12.1 6.0 0.4 0.3 0.0 0.0 0.0 2.0 6.8 14.5 4.4 10.9 6.4 4.6 15.7 4.3 13.8 14.8 EFNA2 "ELF-1, EPLG6, LERK6" ENSG00000099617 "Ephrin A2" O43921 19 1286154-1300237 "Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "gallbladder: 10.0;intestine: 30.3;liver: 14.2" "Cell line enhanced" "Detected in some" "AF22: 4.8;BEWO: 4.9;Hep G2: 9.3;NTERA-2: 5.4;REH: 7.1;SH-SY5Y: 16.8;U-2 OS: 5.6" "Cancer enhanced" "Detected in many" "colorectal cancer: 11.5" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA067567 Approved Mitochondria,Cytosol "Intracellular and membrane" "Mitochondria, Cytosol" "HPA067567: " "unprognostic (1.98e-1)" "unprognostic (3.26e-1)" "unprognostic (2.87e-3)" "unprognostic (1.96e-2)" "unprognostic (4.04e-2)" "unprognostic (3.90e-1)" "unprognostic (7.19e-2)" "unprognostic (2.34e-3)" "unprognostic (3.58e-2)" "unprognostic (6.82e-2)" "unprognostic (8.48e-2)" "unprognostic (1.12e-1)" "unprognostic (1.61e-3)" "unprognostic (1.17e-1)" "unprognostic (1.03e-1)" "unprognostic (2.82e-4)" "unprognostic (1.94e-1)" 0.2 0.1 1.5 3.4 2.2 0.2 0.1 1.5 2.0 0.1 10.7 2.0 0.0 12.0 0.2 0.1 0.4 0.1 10.0 0.1 1.0 1.6 0.3 14.2 0.1 0.1 1.2 0.5 0.1 0.1 0.1 0.3 0.2 1.1 0.1 2.3 1.9 0.1 0.2 0.2 0.1 30.3 0.2 0.9 0.2 0.6 0.6 0.7 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 4.8 1.7 0.0 0.0 4.9 0.2 0.0 0.0 0.0 3.5 0.0 0.0 2.3 0.0 0.0 2.2 0.0 0.0 0.1 2.1 0.0 0.0 9.3 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.1 5.4 0.0 7.1 0.6 0.0 0.0 0.1 0.0 16.8 0.2 0.0 0.1 0.2 0.0 0.0 0.0 5.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 2.2 1.5 2.0 1.0 1.6 1.2 0.5 1.1 0.7 EFNA5 "AF1, EPLG7, LERK7" ENSG00000184349 "Ephrin A5" P52803 5 107376889-107670895 "Cancer-related genes, Predicted membrane proteins, RAS pathway related proteins" "Differentiation, Neurogenesis" "Developmental protein" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "AF22: 19.3;RPTEC TERT1: 29.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "gdT-cell: 3.5;memory CD8 T-cell: 3.0" "Group enriched" "Detected in many" 7 "NK-cells: 2.5;T-cells: 3.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB013282, HPA054047" Approved Approved Vesicles,Cytosol "Vesicles, Cytosol" "CAB013282: AB_2533353, HPA054047: " "unprognostic (1.67e-1)" "unprognostic (4.04e-2)" "unprognostic (7.52e-2)" "unprognostic (2.15e-3)" "unprognostic (3.98e-3)" "unprognostic (2.74e-2)" "unprognostic (8.91e-4)" "unprognostic (9.46e-3)" "unprognostic (4.92e-1)" "unprognostic (2.28e-3)" "unprognostic (1.26e-3)" "unprognostic (1.47e-1)" "prognostic unfavourable (1.92e-7)" "prognostic unfavourable (3.77e-4)" "unprognostic (1.52e-1)" "unprognostic (2.13e-2)" "unprognostic (1.27e-1)" 5.3 1.9 1.9 2.3 6.0 0.0 7.3 10.1 22.2 15.0 4.2 0.9 2.5 1.2 1.6 2.8 9.1 3.9 3.6 8.3 2.5 5.3 5.3 0.6 7.0 3.2 2.1 8.9 5.5 0.7 6.9 18.5 3.1 4.8 6.2 3.6 3.3 11.2 6.8 1.1 13.3 2.3 2.8 3.5 6.3 3.1 1.8 1.1 0.1 2.5 6.0 3.3 4.0 8.1 0.0 0.0 0.4 0.1 2.5 3.5 0.4 6.2 11.1 19.3 0.0 9.3 8.1 1.8 0.2 3.3 2.4 6.0 0.1 7.0 0.0 10.6 1.2 6.5 10.7 9.2 2.3 0.0 6.5 0.0 6.1 0.0 1.8 0.3 0.0 8.6 8.8 0.0 7.8 7.6 0.0 0.0 4.6 6.0 0.0 0.0 2.3 0.9 0.0 8.7 0.2 29.4 8.1 2.9 7.7 3.0 4.5 1.9 1.9 1.2 0.1 14.6 2.6 8.9 3.5 0.5 0.0 4.0 6.4 0.4 15.7 0.2 0.0 0.1 3.5 0.0 0.0 0.0 0.8 3.0 0.0 0.0 0.3 1.4 0.4 2.5 0.1 0.0 0.1 0.4 1.9 6.0 10.1 22.2 2.5 5.3 2.1 8.9 4.8 1.1 EFNB1 "CFNS, Elk-L, EPLG2, LERK2" ENSG00000090776 "Ephrin B1" P98172 X 68828997-68842147 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins" "Differentiation, Neurogenesis" "Developmental protein" "Cancer-related genes, Craniosynostosis, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HBEC3-KT: 35.4;hTCEpi: 27.6;PC-3: 26.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "myeloid DC: 7.1" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB031489, HPA067188" Uncertain Supported "Plasma membrane" 790000 "Plasma membrane" "CAB031489: AB_631414, HPA067188: " "unprognostic (2.00e-1)" "unprognostic (1.33e-2)" "unprognostic (1.77e-2)" "prognostic unfavourable (3.32e-5)" "unprognostic (1.04e-1)" "unprognostic (2.48e-2)" "unprognostic (8.05e-3)" "unprognostic (2.15e-1)" "prognostic unfavourable (8.68e-4)" "unprognostic (3.94e-2)" "prognostic unfavourable (4.29e-4)" "unprognostic (1.29e-1)" "unprognostic (2.17e-3)" "unprognostic (2.76e-2)" "unprognostic (8.03e-2)" "unprognostic (1.72e-3)" "unprognostic (1.86e-2)" 36.5 13.2 5.0 11.5 4.5 1.3 26.5 2.3 4.7 19.5 21.1 4.7 13.1 14.0 15.2 14.9 17.4 15.2 33.7 16.0 3.6 2.7 25.5 15.3 23.0 5.2 4.7 3.5 21.6 4.5 15.0 6.4 34.3 3.9 15.9 10.1 14.9 7.0 13.2 9.1 26.4 24.0 12.3 2.6 15.3 13.3 7.4 4.2 4.8 11.9 22.0 11.2 16.7 14.8 0.5 7.1 0.6 3.4 1.3 1.0 1.0 3.7 1.9 15.6 5.7 8.3 5.1 8.2 3.2 3.5 1.4 1.0 1.7 6.9 0.9 21.2 1.2 19.8 14.7 35.4 0.8 1.5 3.7 0.9 0.8 3.0 7.6 0.7 8.0 9.5 27.6 3.5 16.0 10.8 1.0 0.0 1.2 3.0 1.5 0.7 10.8 26.2 6.6 1.6 5.9 5.9 13.1 5.8 2.8 2.4 0.7 0.9 0.6 1.3 18.1 2.7 3.3 7.2 1.2 0.0 0.8 0.9 1.3 4.0 1.7 0.0 1.3 0.6 1.0 3.4 0.6 0.5 0.9 0.9 7.1 0.4 0.8 0.4 0.3 1.3 2.1 1.0 0.4 1.0 5.0 4.5 2.3 4.7 3.6 2.7 4.7 3.5 3.9 4.2 EFNB2 "EPLG5, Htk-L, HTKL, LERK5, MGC126226, MGC126227, MGC126228" ENSG00000125266 "Ephrin B2" P52799 13 106489731-106535662 "Cancer-related genes, Plasma proteins, Predicted membrane proteins" "Angiogenesis, Differentiation, Host-virus interaction, Neurogenesis" "Developmental protein, Host cell receptor for virus entry, Receptor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "AF22: 49.4;SH-SY5Y: 24.8;U-87 MG: 22.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "NK-cell: 1.5" "Lineage enhanced" "Detected in single" "NK-cells: 1.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008999, CAB009368" Supported Supported Nucleoplasm,Cytosol 760000 Nucleoplasm Cytosol "CAB009368: AB_2095700, HPA008999: AB_1078721" "unprognostic (1.70e-1)" "unprognostic (1.95e-3)" "unprognostic (1.72e-1)" "unprognostic (5.22e-3)" "unprognostic (4.52e-3)" "prognostic unfavourable (3.11e-6)" "unprognostic (2.32e-2)" "prognostic unfavourable (8.43e-4)" "unprognostic (2.09e-1)" "unprognostic (1.11e-1)" "prognostic unfavourable (8.70e-5)" "unprognostic (1.60e-1)" "unprognostic (1.09e-2)" "unprognostic (1.30e-1)" "unprognostic (3.07e-1)" "unprognostic (4.62e-2)" "unprognostic (2.27e-3)" 15.7 4.9 11.2 8.2 11.0 0.8 21.8 8.3 14.0 13.2 23.1 5.8 13.1 13.9 10.8 5.2 11.4 13.6 11.2 11.8 10.4 6.5 9.3 11.8 50.1 7.8 6.2 11.5 8.4 3.7 5.7 6.1 27.7 5.2 11.8 18.4 15.2 12.7 20.6 6.6 14.3 20.6 10.5 5.0 9.3 21.3 7.2 5.9 7.3 11.2 8.8 5.9 7.7 12.4 0.2 0.0 0.4 0.0 1.5 0.0 0.0 11.8 1.1 49.4 0.0 0.1 0.4 0.2 5.4 3.4 5.3 3.1 11.9 18.1 0.0 5.2 1.6 14.1 1.8 6.9 5.8 0.0 10.6 0.0 4.1 0.0 1.0 3.9 0.3 2.3 12.4 0.2 10.6 6.7 0.0 0.0 5.8 2.0 0.1 0.0 2.6 2.4 9.9 2.0 0.0 7.6 1.5 3.5 24.8 2.0 1.0 0.0 0.6 0.1 5.2 10.6 0.0 0.3 12.1 0.1 0.0 0.0 22.2 0.2 2.3 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.3 1.5 0.0 0.0 0.0 0.0 11.2 11.0 8.3 14.0 10.4 6.5 6.2 11.5 5.2 5.9 EFNB3 "EPLG8, LERK-8" ENSG00000108947 "Ephrin B3" Q15768 17 7705202-7711378 "Cancer-related genes, Predicted membrane proteins" "Differentiation, Host-virus interaction, Neurogenesis" "Developmental protein, Host cell receptor for virus entry, Receptor" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 34.6" "Cell line enhanced" "Detected in many" "AF22: 30.7;AN3-CA: 18.2;SH-SY5Y: 16.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" HPA001623 Approved "HPA001623: AB_1848026" "unprognostic (5.17e-2)" "unprognostic (7.15e-2)" "unprognostic (6.08e-2)" "prognostic unfavourable (5.52e-4)" "unprognostic (3.27e-1)" "unprognostic (1.62e-2)" "unprognostic (5.63e-2)" "unprognostic (3.61e-1)" "unprognostic (2.64e-2)" "unprognostic (1.14e-1)" "prognostic favourable (8.21e-4)" "unprognostic (3.71e-1)" "unprognostic (1.02e-1)" "unprognostic (1.56e-2)" "unprognostic (3.00e-1)" "unprognostic (8.56e-2)" "unprognostic (2.20e-2)" 1.7 2.8 10.6 1.1 26.5 0.4 4.3 1.1 34.6 4.8 1.0 4.0 0.0 0.8 12.3 1.0 2.2 6.7 1.8 1.1 10.9 19.0 1.4 2.3 1.5 0.7 3.0 11.8 3.2 1.8 1.1 3.0 1.8 4.3 2.7 1.1 1.4 1.7 1.0 0.8 6.9 1.0 4.7 1.3 0.5 1.3 2.1 2.1 0.0 1.2 0.1 1.4 2.0 1.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.6 30.7 18.2 0.6 0.4 0.2 0.3 4.0 2.7 1.8 1.1 1.9 0.0 0.6 1.1 0.2 7.8 3.8 1.6 0.0 3.8 0.1 0.0 0.0 0.9 0.0 0.0 1.8 0.8 0.8 0.6 0.2 0.0 0.0 0.5 2.9 0.0 0.0 2.7 0.6 0.1 0.1 0.0 4.2 0.4 1.9 16.1 0.0 0.0 0.6 1.6 0.0 0.0 1.8 6.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 2.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 10.6 26.5 1.1 26.3 10.9 19.0 3.0 11.8 4.3 2.1 EGFR "ERBB, ERBB1" ENSG00000146648 "Epidermal growth factor receptor" P00533 7 55019021-55211628 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins" "Host-virus interaction" "Developmental protein, Host cell receptor for virus entry, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "placenta: 102.3" "Cell line enriched" "Detected in many" 12 "A-431: 337.7" "Cancer enhanced" "Detected in all" "glioma: 136.0" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB000035, HPA001200, HPA018530, CAB068186, CAB073534" Enhanced Enhanced "Plasma membrane,Cell Junctions" "Secreted to blood" 93000000 "Plasma membrane, Cell Junctions" "CAB000035: , CAB068186: , CAB073534: , HPA001200: AB_1078723, HPA018530: AB_1848044" "unprognostic (2.62e-2)" "unprognostic (9.56e-3)" "unprognostic (1.59e-1)" "unprognostic (7.51e-2)" "unprognostic (1.08e-1)" "unprognostic (1.27e-2)" "unprognostic (6.11e-2)" "unprognostic (4.88e-2)" "unprognostic (2.85e-2)" "unprognostic (3.30e-3)" "unprognostic (1.78e-3)" "unprognostic (1.04e-1)" "unprognostic (1.93e-3)" "unprognostic (6.98e-3)" "unprognostic (1.72e-1)" "unprognostic (6.62e-2)" "prognostic unfavourable (2.04e-5)" 16.2 8.4 4.9 7.5 6.8 0.1 39.8 5.1 8.5 13.8 7.8 3.3 10.7 3.6 8.2 11.7 15.6 8.8 8.5 4.8 6.8 2.7 7.6 23.5 14.2 2.3 4.1 3.9 10.4 10.1 1.8 2.1 102.3 5.6 10.9 6.7 9.2 15.4 12.9 10.7 32.5 6.3 15.5 3.5 3.3 7.8 5.5 5.9 3.2 12.8 15.5 8.0 10.2 28.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 337.7 4.3 1.1 1.5 6.9 4.3 1.1 3.3 4.5 2.0 1.6 0.8 3.7 0.2 0.8 2.8 13.5 0.0 14.9 2.5 0.1 0.2 0.0 1.8 0.2 1.8 0.0 0.0 2.1 13.7 5.2 27.9 0.2 0.0 0.0 4.4 0.2 0.0 0.0 0.3 2.2 0.0 0.6 0.0 2.5 3.6 0.0 1.3 2.8 3.4 0.6 0.3 0.7 1.0 1.9 0.5 14.6 3.1 0.0 0.3 0.1 2.5 0.1 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.9 6.8 5.1 6.6 6.8 2.7 4.1 3.9 5.6 5.9 EGR1 "AT225, G0S30, KROX-24, NGFI-A, TIS8, ZIF-268, ZNF225" ENSG00000120738 "Early growth response 1" P18146 5 138465490-138469315 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "ASC TERT1: 39.2;hTCEpi: 57.1;U-266/84: 86.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 4 "classical monocyte: 3.5;intermediate monocyte: 5.1;neutrophil: 9.9" "Group enriched" "Detected in many" 8 "granulocytes: 9.9;monocytes: 5.1" "Group enriched" "Detected in all" 6 "amygdala: 88.4;basal ganglia: 148.1;cerebral cortex: 237.4;hippocampal formation: 138.8;olfactory region: 126.1" "Low region specificity" "Detected in all" "CAB019427, HPA029937, HPA029938" Supported Enhanced Nucleoplasm Nucleoplasm "CAB019427: AB_2097038, HPA029937: , HPA029938: " "unprognostic (5.47e-2)" "unprognostic (4.09e-1)" "unprognostic (1.57e-1)" "unprognostic (7.74e-2)" "unprognostic (6.32e-2)" "unprognostic (2.66e-1)" "unprognostic (1.80e-1)" "unprognostic (2.96e-1)" "unprognostic (7.36e-2)" "unprognostic (2.97e-3)" "unprognostic (1.75e-1)" "unprognostic (2.94e-2)" "unprognostic (3.51e-3)" "unprognostic (3.57e-2)" "unprognostic (1.03e-1)" "unprognostic (1.67e-1)" "unprognostic (1.98e-3)" 78.7 47.9 5.5 114.3 23.3 18.3 28.7 23.7 25.0 61.8 40.5 31.6 8.0 6.8 51.7 15.6 47.2 187.3 158.4 42.9 7.0 8.1 22.0 68.8 39.7 18.6 4.9 7.0 130.9 23.0 15.8 43.3 24.3 17.8 45.2 21.7 56.1 18.7 100.5 19.4 54.2 29.8 60.8 4.4 8.8 46.1 14.7 2.8 19.4 76.6 67.5 26.6 43.2 20.3 0.9 0.9 9.9 5.1 0.1 0.2 0.4 4.1 0.1 8.9 13.2 24.2 39.2 1.0 7.1 4.4 9.6 7.8 5.0 3.6 0.2 1.1 15.4 1.9 0.5 14.4 4.4 0.2 0.6 0.5 1.7 1.4 3.1 1.5 11.4 3.0 57.1 8.5 1.9 0.8 20.9 5.1 2.8 20.5 0.6 6.4 0.8 0.0 0.1 1.3 0.7 7.3 2.5 11.2 1.2 8.6 23.9 18.5 0.3 1.2 0.3 3.5 4.5 1.7 2.7 11.9 86.2 1.7 4.0 19.6 1.0 0.0 3.5 0.4 0.2 5.1 0.0 0.9 0.1 0.1 0.9 0.3 0.2 0.2 9.9 0.1 1.4 0.0 0.2 0.4 5.5 23.3 23.7 25.0 7.0 8.1 4.9 7.0 17.8 2.8 EI24 "EPG4, PIG8, TP53I8" ENSG00000149547 "EI24, autophagy associated transmembrane protein" O14681 11 125569216-125584687 "Cancer-related genes, Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Apoptosis, Autophagy" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "parathyroid gland: 164.6" "Cell line enhanced" "Detected in all" "HEL: 117.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA047165, HPA051029" Approved Supported "Endoplasmic reticulum,Golgi apparatus,Cytosol" "Endoplasmic reticulum, Cytosol" "Golgi apparatus" "HPA047165: AB_2679965, HPA051029: AB_2681317" "unprognostic (2.04e-3)" "unprognostic (2.69e-2)" "unprognostic (1.25e-2)" "unprognostic (3.43e-2)" "unprognostic (1.68e-1)" "unprognostic (2.78e-2)" "unprognostic (5.02e-2)" "unprognostic (6.38e-2)" "unprognostic (6.74e-2)" "unprognostic (1.17e-2)" "prognostic unfavourable (9.28e-4)" "unprognostic (3.50e-2)" "unprognostic (1.35e-1)" "unprognostic (4.58e-2)" "unprognostic (8.35e-2)" "unprognostic (2.07e-1)" "unprognostic (3.01e-1)" 13.4 10.2 13.3 8.9 16.2 4.6 16.7 11.2 22.1 12.7 17.0 14.4 13.8 11.3 13.6 12.9 22.7 12.1 15.8 16.4 10.6 10.7 14.6 55.5 12.1 11.2 12.0 11.1 13.1 34.2 164.6 9.2 11.9 11.0 13.7 18.9 13.2 20.9 14.3 26.5 17.2 16.1 15.9 9.2 10.5 17.7 10.4 10.5 9.9 12.0 14.2 13.0 16.2 12.9 8.5 15.5 5.4 7.3 6.5 10.0 4.9 24.5 18.7 21.4 25.8 35.2 26.8 26.8 25.2 19.1 17.4 15.7 28.4 49.6 24.7 42.9 23.7 28.4 32.5 53.0 22.6 6.5 20.6 117.8 13.4 26.6 26.2 26.5 12.8 25.0 48.6 26.1 38.6 36.7 53.4 10.1 24.4 17.3 12.1 13.6 28.2 20.5 17.8 25.3 21.0 29.0 44.0 20.0 19.2 29.5 35.2 9.5 71.9 26.5 30.5 22.4 15.2 15.6 20.3 6.3 12.7 32.2 9.8 40.8 29.8 4.1 7.3 5.4 8.2 7.0 8.1 8.5 6.5 10.0 11.6 7.3 9.4 7.6 0.9 6.5 5.1 15.5 9.0 4.9 13.3 16.2 11.2 22.1 10.6 10.7 12.0 11.1 11.0 10.5 EIF2S2 "EIF2, EIF2beta, PPP1R67" ENSG00000125977 "Eukaryotic translation initiation factor 2 subunit beta" P20042 20 34088298-34112332 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Protein biosynthesis" "Initiation factor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB034415, HPA041262, HPA041332" Approved Supported "Nucleoli,Endoplasmic reticulum" "Endoplasmic reticulum" Nucleoli "CAB034415: AB_2095998, HPA041262: , HPA041332: " "unprognostic (5.76e-3)" "unprognostic (7.12e-2)" "unprognostic (2.66e-2)" "prognostic unfavourable (8.74e-4)" "unprognostic (1.02e-1)" "unprognostic (1.47e-3)" "prognostic unfavourable (3.23e-5)" "unprognostic (9.36e-3)" "unprognostic (2.39e-1)" "unprognostic (6.55e-3)" "unprognostic (3.04e-3)" "unprognostic (1.25e-2)" "prognostic unfavourable (9.64e-10)" "unprognostic (2.52e-2)" "unprognostic (1.82e-1)" "unprognostic (1.04e-1)" "unprognostic (1.12e-2)" 25.9 30.1 32.8 23.3 40.7 21.4 38.1 20.2 37.7 21.1 24.3 10.9 27.1 21.2 21.2 22.4 36.3 17.0 18.3 36.3 30.1 20.4 22.0 40.1 27.2 37.7 40.0 26.2 19.9 45.4 18.7 22.4 29.9 35.8 20.4 24.7 7.4 26.3 25.5 101.8 21.2 20.4 37.0 50.2 23.0 28.1 19.6 35.6 18.2 24.1 32.7 30.1 25.0 30.7 38.8 48.5 28.1 39.3 32.4 42.4 27.3 38.9 26.2 19.9 24.0 19.5 29.7 38.0 35.7 34.3 35.6 36.0 92.0 27.4 35.0 26.3 32.2 36.9 32.3 58.7 43.3 11.2 17.6 69.3 21.6 47.0 50.4 44.3 22.6 30.3 50.1 35.2 52.7 37.2 40.6 33.5 29.2 25.0 41.0 37.0 19.3 47.9 23.7 33.9 32.3 28.1 32.7 20.3 13.8 39.5 24.0 73.2 36.3 52.5 25.0 40.8 25.1 25.5 33.4 31.5 27.7 36.5 38.3 34.5 29.5 21.2 37.0 28.1 26.9 39.3 32.9 38.8 38.2 37.6 34.7 31.8 36.4 36.5 21.9 32.4 35.6 48.5 42.4 27.3 32.8 40.7 20.2 37.7 30.1 20.4 40.0 26.2 35.8 35.6 EIF3E "eIF3-p48, eIF3e, EIF3S6, INT6" ENSG00000104408 "Eukaryotic translation initiation factor 3 subunit E" P60228 8 108201216-108435333 "Cancer-related genes, Predicted intracellular proteins" "Protein biosynthesis" "Initiation factor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA023973 Approved Supported Cytosol Cytosol "HPA023973: AB_1848083" "unprognostic (8.18e-2)" "unprognostic (4.28e-2)" "unprognostic (6.26e-2)" "unprognostic (1.51e-1)" "unprognostic (3.52e-3)" "unprognostic (6.93e-3)" "unprognostic (2.29e-2)" "unprognostic (2.57e-2)" "unprognostic (3.47e-1)" "unprognostic (1.96e-1)" "unprognostic (1.67e-3)" "unprognostic (3.63e-1)" "prognostic unfavourable (3.06e-7)" "unprognostic (2.46e-1)" "unprognostic (1.60e-1)" "unprognostic (1.81e-1)" "unprognostic (2.77e-2)" 88.2 44.0 27.6 49.2 38.2 57.8 75.1 41.5 25.2 101.6 73.6 14.6 47.2 34.4 55.5 47.6 111.2 45.4 41.0 39.5 23.9 22.4 51.8 63.6 60.3 75.3 33.0 19.5 127.6 90.2 29.2 72.5 54.6 28.9 100.1 40.3 22.8 56.9 45.5 100.4 46.7 56.3 73.7 38.4 63.9 49.7 52.7 31.5 100.5 93.8 70.8 50.7 121.7 69.2 49.0 51.7 14.0 39.5 38.7 78.1 59.4 62.0 30.6 41.0 50.7 69.9 147.9 28.0 32.4 50.6 48.2 50.4 38.3 62.5 106.9 42.6 36.4 38.6 54.0 63.6 64.2 42.0 55.0 85.3 32.4 54.6 56.0 50.8 40.0 111.7 94.1 36.4 101.0 73.3 71.8 44.4 54.2 61.3 65.8 96.3 40.9 48.9 61.2 50.8 83.2 63.0 37.4 46.4 42.3 18.2 15.4 72.2 65.5 73.7 46.5 28.2 48.7 29.2 40.7 33.5 25.0 61.2 34.9 88.8 31.4 14.0 39.5 7.4 26.6 36.2 52.0 49.0 52.6 37.7 51.7 40.4 78.1 56.1 3.7 38.7 33.6 27.3 45.2 59.4 27.6 38.2 41.5 25.2 23.9 22.4 33.0 19.5 28.9 31.5 EIF3H "eIF3-gamma, eIF3-p40, eIF3h, EIF3S3" ENSG00000147677 "Eukaryotic translation initiation factor 3 subunit H" O15372 8 116642130-116766925 "Cancer-related genes, Predicted intracellular proteins" "Protein biosynthesis" "Initiation factor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "SK-BR-3: 201.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA023117, HPA023553" Approved Approved Cytosol 3300000 Cytosol "HPA023117: AB_1848076, HPA023553: AB_1848077" "prognostic unfavourable (5.26e-4)" "prognostic unfavourable (8.07e-4)" "unprognostic (1.81e-1)" "unprognostic (1.15e-1)" "unprognostic (6.69e-2)" "unprognostic (1.11e-2)" "prognostic unfavourable (8.34e-4)" "unprognostic (3.63e-2)" "unprognostic (1.37e-1)" "unprognostic (1.96e-1)" "unprognostic (1.12e-3)" "unprognostic (3.08e-1)" "unprognostic (3.77e-2)" "unprognostic (6.36e-2)" "unprognostic (1.48e-1)" "unprognostic (9.19e-2)" "unprognostic (1.11e-1)" 63.1 41.3 39.4 41.3 47.6 65.8 56.8 39.5 39.9 69.2 52.8 35.1 30.8 38.8 53.1 43.6 80.9 49.7 36.4 52.9 33.2 33.0 53.4 55.6 44.2 58.0 38.6 26.7 96.0 65.4 37.6 52.6 52.0 40.1 77.1 47.0 34.9 51.5 38.5 94.6 44.8 56.2 68.3 45.4 56.0 46.3 44.9 31.6 90.0 72.3 59.3 74.7 83.7 57.6 69.1 73.6 21.6 55.3 47.1 88.5 76.7 48.4 28.0 33.8 29.4 44.7 78.5 33.7 32.1 41.5 35.6 34.7 28.9 57.5 77.6 32.6 33.4 31.3 37.1 48.8 44.9 50.2 30.1 68.5 25.1 43.0 56.0 29.5 36.6 72.2 68.0 32.1 74.7 38.5 57.8 41.1 39.9 36.0 82.1 41.5 34.4 44.8 47.6 22.6 55.0 53.4 35.7 38.4 46.5 16.8 201.6 53.5 59.8 59.6 35.3 22.8 42.6 33.7 41.9 66.5 59.9 64.1 31.7 52.3 31.1 21.6 55.3 19.8 36.7 54.8 60.3 69.1 66.5 53.1 73.6 59.1 88.5 71.9 12.0 47.1 53.3 41.1 73.2 76.7 39.4 47.6 39.5 39.9 33.2 33.0 38.6 26.7 40.1 31.6 EIF4A2 "BM-010, DDX2B, EIF4A, EIF4F" ENSG00000156976 "Eukaryotic translation initiation factor 4A2" Q14240 3 186783205-186789900 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction, Protein biosynthesis" "Helicase, Hydrolase, Initiation factor, RNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "EFO-21: 106.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "CAB011690, HPA068286" Uncertain Approved Cytosol 1000000 Cytosol "CAB011690: AB_732123, HPA068286: " "unprognostic (1.49e-1)" "unprognostic (9.62e-2)" "unprognostic (3.78e-2)" "unprognostic (9.50e-3)" "unprognostic (2.82e-2)" "unprognostic (1.10e-2)" "unprognostic (4.46e-2)" "unprognostic (6.27e-2)" "unprognostic (4.32e-3)" "unprognostic (1.00e-1)" "unprognostic (6.39e-2)" "unprognostic (3.99e-2)" "unprognostic (6.36e-2)" "unprognostic (3.22e-1)" "unprognostic (3.03e-1)" "unprognostic (4.67e-2)" "unprognostic (2.62e-2)" 34.6 66.1 61.2 27.7 79.9 1.9 53.5 121.1 111.5 65.1 52.1 26.5 30.1 30.3 73.1 45.5 44.5 73.9 45.1 83.7 58.4 71.9 63.9 43.5 33.7 36.1 48.9 61.7 142.0 59.0 30.9 84.1 47.3 69.6 57.9 40.1 31.8 43.7 62.8 126.7 19.8 35.6 57.1 41.9 32.5 39.0 32.9 39.5 23.9 67.8 36.4 35.4 61.1 51.7 55.1 19.3 39.4 24.8 33.0 63.4 51.3 10.5 5.3 22.3 3.6 85.9 81.0 6.8 19.0 17.2 20.2 26.6 19.6 3.8 23.6 106.5 27.3 17.8 32.7 8.0 35.6 22.0 17.2 38.0 7.1 26.3 33.7 8.0 26.7 54.2 38.5 5.8 48.6 35.8 12.8 39.8 65.6 1.8 12.7 3.9 22.1 25.5 16.3 15.8 14.3 40.0 12.9 43.9 8.8 30.9 21.3 40.4 33.2 29.3 26.1 16.0 8.0 15.4 11.6 31.7 44.8 10.8 11.0 8.4 7.5 39.4 16.0 18.5 28.5 18.2 45.3 55.1 41.9 34.8 19.3 46.1 63.4 50.2 11.0 33.0 24.8 17.4 38.6 51.3 61.2 79.9 121.1 111.5 58.4 71.9 48.9 61.7 69.6 39.5 EIF4E "EIF4E1, EIF4EL1, EIF4F" ENSG00000151247 "Eukaryotic translation initiation factor 4E" P06730 4 98871684-98930637 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction, Protein biosynthesis, Translation regulation" "Initiation factor, RNA-binding" "Autism, Autism spectrum disorder, Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "CAB004077, CAB016316, HPA051311" Supported Enhanced "Cytosol,Cytoplasmic bodies" 580000 "Cytosol, Cytoplasmic bodies" "CAB004077: AB_823488, CAB016316: AB_627502, HPA051311: " "unprognostic (3.07e-3)" "unprognostic (1.43e-1)" "unprognostic (6.53e-3)" "unprognostic (7.52e-2)" "unprognostic (1.41e-1)" "unprognostic (2.43e-3)" "unprognostic (2.03e-5)" "unprognostic (6.55e-3)" "unprognostic (1.09e-2)" "unprognostic (1.33e-1)" "unprognostic (1.28e-1)" "unprognostic (1.63e-1)" "unprognostic (1.10e-3)" "unprognostic (5.40e-2)" "unprognostic (1.43e-1)" "unprognostic (2.31e-2)" "unprognostic (1.28e-1)" 22.3 26.8 25.7 20.1 35.3 25.2 23.1 40.8 38.4 21.4 27.2 23.3 19.1 19.8 21.7 21.4 39.6 19.9 18.8 23.0 26.0 29.9 29.3 26.2 18.8 24.4 27.7 28.4 18.8 16.1 24.7 25.6 21.8 35.3 19.9 33.2 15.4 23.2 21.0 29.8 19.1 19.5 24.8 31.0 19.4 20.6 39.1 23.4 22.4 33.4 27.1 34.2 22.1 24.2 31.3 25.4 36.6 32.0 32.6 32.2 30.0 25.6 22.5 38.4 25.5 21.9 23.0 23.0 48.9 30.7 40.5 30.5 30.2 32.5 52.0 15.8 30.0 13.0 52.8 36.8 49.5 34.3 15.3 35.4 15.7 27.5 18.8 50.8 26.8 16.4 23.5 31.2 24.7 31.1 58.8 24.3 35.8 22.0 47.0 19.7 30.2 21.0 29.7 26.0 23.1 35.7 22.9 32.5 21.4 22.8 48.4 15.8 23.6 20.1 22.8 29.3 31.5 26.3 39.4 18.2 46.1 47.0 26.1 26.1 33.1 23.3 22.3 36.6 26.3 25.9 30.5 31.3 29.2 27.0 25.4 26.9 32.2 31.9 16.2 32.6 32.0 21.4 28.7 30.0 25.7 35.3 40.8 38.4 26.0 29.9 27.7 28.4 35.3 23.4 EIF4EBP1 "4E-BP1, PHAS-I" ENSG00000187840 "Eukaryotic translation initiation factor 4E binding protein 1" Q13541 8 38030341-38060365 "Cancer-related genes, Predicted intracellular proteins" "Translation regulation" "Protein synthesis inhibitor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "pancreas: 94.7;salivary gland: 109.8" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in all" 4 "classical monocyte: 53.5;eosinophil: 31.3;intermediate monocyte: 41.2;memory B-cell: 16.3;myeloid DC: 41.3;naive B-cell: 13.5;non-classical monocyte: 31.4;plasmacytoid DC: 31.3" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB005032, CAB005039, HPA023501" Supported Supported Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "CAB005032: AB_562030, CAB005039: AB_562029, HPA023501: AB_1848095" "unprognostic (1.55e-2)" "unprognostic (2.45e-1)" "unprognostic (1.58e-1)" "prognostic unfavourable (8.86e-4)" "unprognostic (6.94e-2)" "unprognostic (2.69e-1)" "unprognostic (1.94e-2)" "unprognostic (3.27e-2)" "unprognostic (1.61e-1)" "unprognostic (1.16e-2)" "unprognostic (3.18e-3)" "unprognostic (7.21e-2)" "prognostic unfavourable (0.00e+0)" "unprognostic (7.98e-2)" "unprognostic (3.01e-1)" "unprognostic (4.57e-2)" "unprognostic (5.72e-3)" 17.7 3.4 2.5 4.9 3.6 9.2 21.7 1.8 3.2 5.5 15.4 2.0 7.7 6.2 5.3 2.1 22.2 5.0 7.0 9.4 2.2 1.8 6.0 39.6 6.9 7.4 4.3 1.4 9.3 94.7 1.7 2.2 8.7 2.8 7.4 4.6 2.8 109.8 8.0 38.4 4.9 9.0 7.1 4.2 9.3 10.6 3.0 2.7 2.7 3.7 12.6 9.2 11.3 11.1 16.3 41.3 31.3 53.5 4.0 7.6 28.0 20.4 10.6 3.1 18.4 4.0 3.5 13.6 22.7 10.6 12.3 19.7 7.0 5.3 8.0 15.9 11.3 10.9 10.3 18.5 7.3 6.1 33.5 46.8 4.7 9.6 41.8 15.1 7.5 9.8 30.2 13.6 25.5 19.7 25.5 21.4 5.1 12.8 13.2 36.8 22.9 42.7 11.6 13.0 28.2 4.6 2.0 43.2 32.8 4.6 7.5 53.4 10.0 17.8 18.5 7.4 24.3 21.9 17.2 30.8 16.7 9.2 17.3 26.8 16.0 5.1 53.5 31.3 3.9 41.2 3.5 16.3 4.5 4.0 41.3 13.5 3.6 3.6 4.7 4.0 31.4 31.3 7.6 28.0 2.5 3.6 1.8 3.2 2.2 1.8 4.3 1.4 2.8 2.7 EIF4G1 "EIF4F, EIF4G, p220, PARK18" ENSG00000114867 "Eukaryotic translation initiation factor 4 gamma 1" Q04637 3 184314495-184335358 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction, Protein biosynthesis, Translation regulation" "Initiation factor, RNA-binding, Translational shunt" "Cancer-related genes, Disease mutation, Neurodegeneration, Parkinson disease, Parkinsonism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB014774, HPA028487, HPA043866" Approved Enhanced Cytosol 17000 Cytosol "CAB014774: , HPA028487: AB_10602219, HPA043866: " "unprognostic (4.14e-3)" "unprognostic (2.10e-2)" "unprognostic (6.01e-2)" "unprognostic (3.01e-2)" "unprognostic (2.25e-1)" "unprognostic (2.41e-3)" "prognostic unfavourable (7.99e-4)" "unprognostic (4.27e-3)" "unprognostic (2.35e-1)" "unprognostic (1.54e-1)" "unprognostic (1.55e-3)" "unprognostic (7.06e-3)" "unprognostic (2.42e-1)" "unprognostic (7.15e-2)" "unprognostic (2.45e-1)" "unprognostic (1.31e-1)" "unprognostic (2.33e-3)" 30.2 33.1 18.3 26.4 18.9 26.3 30.3 18.0 23.2 24.1 25.2 19.6 33.6 21.9 24.5 30.5 45.2 20.9 31.1 33.0 16.9 16.9 40.6 108.0 26.0 21.0 19.4 15.9 29.3 46.4 47.5 21.9 34.6 18.3 24.0 21.8 19.9 31.4 34.1 103.7 39.0 31.6 26.8 15.7 33.1 27.1 30.8 18.0 25.8 30.0 46.2 34.3 28.6 27.6 8.8 15.9 5.5 17.0 8.1 11.4 9.1 90.2 37.9 31.8 36.1 35.5 35.1 55.1 49.8 35.2 55.4 42.2 80.3 29.5 57.8 66.4 61.8 48.9 54.9 61.1 43.2 61.0 57.7 52.2 38.8 35.5 30.8 52.2 36.6 35.4 35.6 50.4 48.2 48.3 37.9 45.8 36.6 67.1 35.4 18.8 62.6 30.7 36.4 31.3 46.3 29.3 55.1 33.4 29.7 42.5 70.4 33.8 75.0 37.4 60.4 39.4 39.8 51.5 93.3 35.7 43.1 106.8 44.3 45.9 43.0 4.8 13.6 5.5 11.4 13.9 11.0 7.6 7.7 9.2 12.2 8.8 7.1 7.0 5.1 8.1 17.0 15.9 5.4 9.1 18.3 18.9 18.0 23.2 16.9 16.9 19.4 15.9 18.3 18.0 EIF4H "KIAA0038, WBSCR1, WSCR1" ENSG00000106682 "Eukaryotic translation initiation factor 4H" Q15056 7 74174245-74197101 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction, Protein biosynthesis" "Initiation factor, RNA-binding" "Cancer-related genes, Williams-Beuren syndrome" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA030542 Approved Approved "Nucleoplasm,Nuclear bodies,Cytosol" 520000 "Nucleoplasm, Nuclear bodies, Cytosol" "HPA030542: AB_10601368" "unprognostic (2.83e-1)" "unprognostic (9.50e-2)" "unprognostic (2.36e-1)" "unprognostic (1.50e-2)" "prognostic unfavourable (3.89e-4)" "prognostic unfavourable (2.15e-4)" "unprognostic (1.61e-2)" "unprognostic (2.72e-3)" "unprognostic (1.79e-1)" "unprognostic (2.99e-2)" "unprognostic (1.72e-2)" "unprognostic (2.52e-1)" "unprognostic (1.07e-2)" "unprognostic (3.04e-1)" "unprognostic (2.23e-1)" "unprognostic (5.68e-2)" "unprognostic (1.27e-2)" 46.8 42.7 47.6 37.6 52.8 82.3 42.8 56.0 89.5 39.8 44.5 46.6 36.2 43.1 48.1 37.9 58.6 44.4 40.7 47.4 45.6 41.4 34.5 50.7 37.4 42.8 45.4 54.6 54.2 74.3 54.3 30.1 72.2 47.6 44.8 35.1 35.6 60.3 45.4 89.6 53.0 41.5 43.4 59.9 34.6 45.4 52.5 32.1 46.8 43.5 57.9 44.2 43.4 41.4 38.4 57.6 60.2 64.2 46.7 52.0 80.6 86.2 57.5 43.9 53.2 39.1 41.7 49.9 61.7 46.9 51.1 50.3 70.4 66.5 74.1 16.9 56.9 45.8 48.3 82.0 48.4 49.8 56.6 41.3 54.0 56.5 44.8 69.6 41.7 48.7 52.1 56.7 80.8 55.9 72.5 32.2 52.3 73.6 54.9 82.6 58.5 56.9 64.4 58.8 66.9 42.5 55.2 44.6 56.4 57.5 72.7 48.9 82.2 45.1 58.2 73.3 49.8 61.2 77.5 38.3 45.7 126.5 57.3 73.1 75.2 45.7 58.4 60.2 43.5 64.2 44.9 38.4 44.7 43.0 57.6 35.3 52.0 42.4 39.0 46.7 63.6 24.4 47.6 80.6 47.6 52.8 56.0 89.5 45.6 41.4 45.4 54.6 47.6 32.1 EIF5A "EIF-5A, EIF5A1, MGC104255, MGC99547" ENSG00000132507 "Eukaryotic translation initiation factor 5A" P63241 17 7306999-7312463 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters" "mRNA transport, Protein biosynthesis, Protein transport, Translocation, Transport" "Elongation factor, RNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB005042, HPA061298" Approved Supported Nucleoplasm,Cytosol Cytosol Nucleoplasm "CAB005042: AB_562281, HPA061298: " "unprognostic (3.72e-1)" "unprognostic (1.67e-1)" "unprognostic (8.10e-2)" "unprognostic (2.80e-1)" "unprognostic (6.95e-2)" "unprognostic (1.39e-2)" "unprognostic (1.06e-2)" "prognostic unfavourable (9.04e-4)" "unprognostic (4.10e-1)" "unprognostic (4.11e-2)" "unprognostic (1.64e-2)" "unprognostic (8.25e-2)" "prognostic unfavourable (1.63e-5)" "unprognostic (3.53e-1)" "unprognostic (2.79e-1)" "unprognostic (6.01e-2)" "unprognostic (7.65e-2)" 69.0 55.6 37.9 57.0 40.4 83.1 44.5 35.0 59.8 44.6 54.8 37.5 39.8 47.4 47.2 45.5 107.0 38.1 52.9 55.8 35.6 33.6 58.5 192.9 46.6 67.2 34.3 35.9 50.3 126.0 26.0 34.1 73.9 34.0 38.0 57.2 40.7 87.7 40.7 100.6 71.1 49.0 45.4 29.5 65.5 42.9 56.8 24.2 77.9 57.9 105.4 79.0 48.6 50.7 64.7 87.7 44.4 75.7 75.2 79.3 64.3 133.0 166.1 51.2 102.5 39.6 51.0 72.0 100.5 66.3 135.9 95.1 99.3 56.8 129.0 65.1 77.2 91.0 111.3 129.5 123.7 71.7 161.6 77.6 137.6 127.2 70.2 58.9 80.3 54.1 68.0 100.3 136.3 87.2 106.7 36.1 91.9 82.5 69.2 85.2 97.2 82.0 68.5 62.3 118.9 82.0 74.0 59.6 77.5 64.4 78.5 62.2 62.1 45.4 81.7 95.8 69.0 63.6 158.7 30.4 41.5 83.4 90.6 88.7 109.1 44.4 56.0 38.9 65.1 75.7 79.3 64.7 67.1 57.7 85.8 62.6 62.3 62.6 25.1 75.2 68.6 87.7 58.9 64.3 37.9 40.4 35.0 59.8 35.6 33.6 34.3 35.9 34.0 24.2 ELANE "ELA2, HLE, HNE, NE" ENSG00000197561 "Elastase, neutrophil expressed" P08246 19 851014-856247 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins" "Hydrolase, Protease, Serine protease" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 8 "bone marrow: 244.3" "Cell line enriched" "Detected in some" 65 "THP-1: 193.2" "Group enriched" "Detected in some" 7 "pancreatic cancer: 3.5;stomach cancer: 3.7" "Not detected" "Not detected" "Group enriched" "Detected in some" 9 "classical monocyte: 3.2;neutrophil: 6.9" "Group enriched" "Detected in many" 9 "granulocytes: 6.9;monocytes: 3.2" "Not detected" "Not detected" "Low region specificity" "Detected in single" "CAB015409, HPA066836" Enhanced "Secreted to blood" 59000 "CAB015409: AB_831596, HPA066836: " "unprognostic (3.46e-2)" "unprognostic (1.10e-1)" "unprognostic (1.42e-3)" "unprognostic (2.09e-2)" "unprognostic (1.80e-3)" "unprognostic (3.43e-2)" "unprognostic (3.92e-1)" "unprognostic (6.38e-3)" "unprognostic (5.80e-1)" "unprognostic (2.54e-2)" "unprognostic (4.06e-2)" "unprognostic (3.48e-2)" "unprognostic (1.19e-10)" "unprognostic (6.27e-3)" "unprognostic (4.00e-2)" "unprognostic (2.76e-2)" "unprognostic (4.75e-3)" 1.5 0.3 0.1 0.3 0.1 244.3 1.6 0.2 0.6 0.3 0.6 0.7 0.0 0.3 0.3 0.7 0.5 0.6 0.8 31.2 0.0 0.0 0.3 1.5 17.8 1.6 0.0 0.0 0.3 1.8 0.3 0.4 4.7 0.5 1.4 0.3 1.0 0.7 0.3 1.1 2.1 0.5 0.5 0.0 22.5 0.5 0.3 0.0 23.0 2.3 0.9 0.3 1.0 0.2 0.0 0.0 6.9 3.2 0.0 0.5 11.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 193.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.9 0.0 0.0 3.2 0.0 0.5 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.9 0.0 0.0 0.0 0.0 11.2 0.1 0.1 0.2 0.6 0.0 0.0 0.0 0.0 0.5 0.0 ELF3 "EPR-1, ERT, ESE-1, ESX" ENSG00000163435 "E74 like ETS transcription factor 3" P78545 1 202007945-202017188 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Differentiation, Inflammatory response, Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 100.8" "Cell line enhanced" "Detected in some" "A549: 40.4;CAPAN-2: 57.6;RT4: 41.4;SK-BR-3: 79.9" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Cell type enhanced" "Detected in single" "neutrophil: 2.0" "Low lineage specificity" "Detected in single" "Not detected" "Not detected" "Not detected" "Not detected" "HPA003316, HPA003479" Enhanced Enhanced Nucleoplasm Nucleoplasm "HPA003316: AB_1078757, HPA003479: AB_1078756" "unprognostic (9.90e-3)" "unprognostic (1.72e-1)" "unprognostic (7.50e-2)" "unprognostic (1.12e-1)" "unprognostic (2.96e-3)" "unprognostic (3.88e-2)" "unprognostic (1.38e-2)" "unprognostic (1.83e-1)" "unprognostic (1.69e-1)" "unprognostic (5.05e-3)" "unprognostic (7.67e-3)" "unprognostic (7.07e-2)" "unprognostic (9.92e-3)" "unprognostic (4.03e-2)" "unprognostic (1.30e-1)" "unprognostic (1.85e-1)" "unprognostic (3.37e-3)" 0.3 0.1 0.1 16.0 0.2 0.0 34.0 0.2 0.2 13.2 80.7 0.2 12.5 34.4 3.8 8.9 59.3 8.6 67.7 1.1 0.1 0.1 38.1 33.3 24.6 0.1 0.1 0.1 5.8 38.4 1.1 1.7 16.7 0.3 39.9 31.3 0.7 37.9 11.3 0.7 3.5 100.8 9.5 0.3 0.2 29.9 1.9 0.1 0.6 5.7 25.5 43.5 44.7 22.7 0.3 0.8 2.0 0.3 0.2 0.3 0.0 10.5 40.4 0.0 0.0 0.0 0.0 12.6 0.0 1.5 0.0 0.0 9.0 57.6 0.0 4.7 0.0 10.5 0.0 0.0 0.0 1.2 0.0 0.0 7.3 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.6 0.0 0.1 0.6 3.4 0.0 0.0 0.5 15.3 41.4 0.0 0.0 0.4 79.9 0.0 5.6 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.7 0.0 0.0 0.0 0.0 0.8 0.3 0.2 0.2 0.1 0.3 0.1 0.1 0.1 0.8 0.3 0.2 0.1 2.0 0.2 0.3 0.2 0.0 0.0 0.1 0.2 0.2 0.2 0.1 0.1 0.1 0.1 0.3 0.1 ELF4 "ELFR, MEF" ENSG00000102034 "E74 like ETS transcription factor 4" Q99607 X 130064874-130110716 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Not detected" "Not detected" "Low region specificity" "Detected in many" "HPA058595, HPA060277" Enhanced Supported "Nucleoplasm,Nuclear bodies" "Nuclear bodies" Nucleoplasm "HPA058595: , HPA060277: " "unprognostic (1.33e-1)" "unprognostic (8.51e-2)" "unprognostic (3.83e-1)" "unprognostic (2.13e-2)" "unprognostic (1.14e-1)" "unprognostic (1.80e-1)" "unprognostic (4.43e-3)" "unprognostic (7.86e-3)" "unprognostic (3.50e-2)" "unprognostic (1.80e-1)" "unprognostic (1.29e-2)" "unprognostic (3.95e-1)" "prognostic unfavourable (6.49e-6)" "unprognostic (1.43e-1)" "unprognostic (5.46e-2)" "unprognostic (2.51e-1)" "prognostic favourable (1.42e-4)" 16.9 3.6 2.0 18.1 2.5 27.6 16.9 0.5 3.0 7.7 10.8 3.1 7.0 8.4 10.5 8.1 10.5 9.5 11.0 7.3 3.1 1.2 5.9 2.5 21.9 33.3 3.8 0.9 12.7 4.5 3.8 4.2 23.5 3.0 6.6 10.9 3.6 5.4 7.9 5.7 9.1 16.3 6.4 4.2 18.9 12.3 3.5 2.9 18.1 3.9 7.4 11.5 11.7 14.4 3.9 6.1 9.4 10.3 8.4 10.3 5.1 22.5 8.4 1.5 0.1 3.9 8.4 22.0 10.5 13.4 12.8 14.2 11.6 16.1 11.6 21.1 14.2 14.7 8.4 12.4 12.6 12.4 7.0 22.7 11.2 5.4 8.7 19.8 29.1 8.7 13.9 20.5 20.3 12.3 8.7 3.2 6.9 13.1 3.2 11.3 1.0 8.3 7.0 2.7 4.9 7.8 26.1 5.8 2.5 9.4 9.1 2.9 4.5 19.1 11.4 9.0 7.1 16.7 19.4 1.7 0.7 9.3 10.6 18.2 2.0 1.6 5.4 7.8 10.3 10.3 8.3 3.9 6.2 8.8 6.1 3.5 6.2 7.2 9.4 8.4 7.0 3.7 6.3 5.1 2.0 2.5 0.5 3.0 3.1 1.2 3.8 0.9 3.0 2.9 ELK3 "ERP, NET, SAP2" ENSG00000111145 "ELK3, ETS transcription factor" P41970 12 96194382-96269835 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA001600 Approved Supported Nucleoplasm,Mitochondria Nucleoplasm Mitochondria "HPA001600: AB_1078752" "unprognostic (3.11e-1)" "unprognostic (8.81e-3)" "unprognostic (6.38e-2)" "unprognostic (5.77e-2)" "unprognostic (7.18e-3)" "unprognostic (1.12e-1)" "unprognostic (1.15e-1)" "unprognostic (5.10e-3)" "unprognostic (7.39e-2)" "prognostic unfavourable (4.93e-4)" "unprognostic (2.29e-2)" "unprognostic (1.13e-1)" "unprognostic (1.20e-3)" "unprognostic (2.90e-3)" "unprognostic (1.61e-1)" "unprognostic (1.70e-1)" "unprognostic (2.05e-2)" 36.9 9.3 5.0 20.9 6.7 8.3 23.5 12.9 4.5 29.2 12.6 7.3 12.0 4.6 45.2 15.6 25.7 15.0 16.3 15.5 4.8 5.1 13.3 8.2 17.1 20.6 6.1 2.8 13.3 5.8 6.6 6.0 15.9 8.9 18.1 7.5 15.7 14.1 8.6 10.5 8.7 11.1 20.8 13.1 32.7 9.1 8.6 6.3 17.4 19.7 25.1 32.1 15.9 20.9 11.3 9.4 4.1 12.8 10.5 24.1 6.3 12.8 7.7 7.9 4.2 20.2 38.0 2.0 16.4 31.4 13.1 10.1 0.4 9.6 2.0 5.6 18.3 4.6 0.8 26.2 23.1 5.6 3.0 0.6 3.2 2.9 6.1 6.2 1.5 22.3 4.9 26.9 20.4 31.2 1.5 8.6 44.1 1.9 1.2 4.2 9.7 10.3 10.2 13.4 2.3 11.2 3.4 0.4 8.4 5.3 2.4 8.2 1.3 3.4 19.2 36.0 14.1 22.1 14.2 16.6 13.7 0.5 12.7 7.3 24.9 3.3 12.8 0.3 6.2 6.9 24.1 11.3 14.7 8.4 9.4 9.9 8.9 6.5 4.1 10.5 5.9 3.8 23.4 6.3 5.0 6.7 12.9 4.5 4.8 5.1 6.1 2.8 8.9 6.3 ELK4 SAP1 ENSG00000158711 "ELK4, ETS transcription factor" P28324 1 205597556-205631962 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "basophil: 8.7" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA028863 Uncertain Supported Nucleoplasm Nucleoplasm "HPA028863: AB_10602492" "unprognostic (2.08e-1)" "unprognostic (2.71e-2)" "unprognostic (1.98e-1)" "unprognostic (1.59e-1)" "unprognostic (2.15e-1)" "prognostic favourable (4.65e-4)" "unprognostic (2.97e-1)" "unprognostic (1.48e-1)" "unprognostic (1.19e-1)" "unprognostic (3.53e-1)" "unprognostic (1.27e-2)" "unprognostic (2.64e-1)" "prognostic unfavourable (2.94e-6)" "unprognostic (2.21e-2)" "unprognostic (1.26e-1)" "unprognostic (1.08e-1)" "unprognostic (5.58e-3)" 14.1 7.1 10.0 14.7 12.7 12.0 13.8 16.2 10.4 10.1 8.9 10.4 8.6 7.3 11.3 9.2 11.7 9.5 11.4 10.8 10.6 5.0 15.2 15.6 13.8 19.1 10.0 6.9 13.1 12.4 13.6 16.8 9.5 9.5 32.6 8.7 12.2 12.4 8.2 14.7 17.6 13.5 10.5 8.2 18.3 9.4 8.4 11.0 24.4 10.8 8.3 19.6 15.1 13.2 2.2 1.5 8.7 1.1 1.2 3.1 0.6 8.2 7.4 2.9 7.6 7.0 9.1 7.5 5.5 5.8 4.4 5.2 3.2 8.3 17.4 5.2 6.9 10.3 6.2 6.8 7.7 19.8 4.4 7.5 12.1 6.7 9.6 14.1 30.1 7.9 8.4 7.0 14.3 18.4 6.9 14.7 6.1 11.1 11.6 5.3 4.9 4.5 8.6 18.2 14.2 5.9 18.0 3.4 4.1 14.3 7.9 9.4 7.3 4.7 13.3 8.9 10.5 7.9 10.5 11.0 10.0 11.8 7.8 5.8 10.4 8.7 0.8 1.2 1.6 1.1 2.1 1.4 1.8 2.1 1.1 2.2 2.2 3.1 0.4 1.2 0.6 1.5 1.8 0.6 10.0 12.7 16.2 10.4 10.6 5.0 10.0 6.9 9.5 11.0 ELL "C19orf17, ELL1, Men, PPP1R68" ENSG00000105656 "Elongation factor for RNA polymerase II" P55199 19 18442663-18522127 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA046076 Uncertain "HPA046076: " "unprognostic (9.49e-2)" "unprognostic (1.38e-1)" "unprognostic (3.26e-3)" "unprognostic (2.07e-1)" "unprognostic (1.64e-1)" "unprognostic (2.10e-1)" "unprognostic (8.26e-2)" "unprognostic (2.71e-1)" "unprognostic (2.34e-1)" "unprognostic (3.00e-2)" "unprognostic (6.28e-3)" "unprognostic (2.38e-2)" "unprognostic (1.57e-1)" "unprognostic (2.07e-1)" "unprognostic (5.12e-1)" "unprognostic (2.46e-1)" "unprognostic (1.06e-1)" 19.9 7.7 5.1 13.4 9.9 38.4 10.8 17.0 9.7 11.9 13.5 7.7 8.6 10.4 12.6 9.5 9.3 9.1 10.9 9.5 5.8 4.4 9.8 11.6 14.2 10.7 6.2 3.5 12.7 14.6 6.2 10.5 27.0 6.3 10.4 4.4 9.1 10.6 9.0 20.3 13.3 10.9 10.0 5.1 15.9 9.3 31.7 7.7 11.0 7.8 7.2 13.6 18.5 13.2 3.1 8.6 17.2 5.6 2.1 7.9 3.3 8.8 4.3 2.2 4.8 2.5 3.2 16.8 7.0 6.2 5.3 5.2 4.9 7.0 11.1 8.7 4.6 6.2 3.3 7.7 2.7 9.1 7.9 6.7 4.3 4.3 3.8 7.3 8.6 6.4 6.6 6.9 5.5 3.7 9.3 15.4 2.8 7.5 8.5 8.0 7.6 12.4 7.4 3.7 11.7 3.8 6.2 4.1 4.5 5.1 8.9 7.6 4.5 9.1 6.2 6.2 4.8 8.5 6.5 25.1 15.8 8.3 8.2 12.4 8.8 0.3 5.6 3.8 4.7 4.1 7.9 3.1 2.9 4.2 4.7 2.3 1.9 2.9 17.2 2.1 2.1 8.6 3.0 3.3 5.1 9.9 17.0 9.7 5.8 4.4 6.2 3.5 6.3 7.7 EML4 "C2orf2, ELP120, ROPP120" ENSG00000143924 "Echinoderm microtubule associated protein like 4" Q9HC35 2 42169350-42332548 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "Hep G2: 60.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA036687, HPA036688, HPA065337" Enhanced Supported "Intermediate filaments,Microtubules,Cytosol" 41000 Microtubules "Intermediate filaments, Cytosol" "HPA036687: AB_2675251, HPA036688: AB_10671968, HPA065337: AB_2685474" "unprognostic (1.70e-1)" "unprognostic (1.38e-1)" "unprognostic (8.17e-2)" "unprognostic (3.53e-3)" "unprognostic (1.79e-2)" "unprognostic (9.19e-2)" "unprognostic (8.61e-3)" "unprognostic (1.61e-2)" "unprognostic (2.96e-3)" "unprognostic (6.80e-2)" "unprognostic (7.44e-2)" "unprognostic (1.60e-2)" "unprognostic (1.86e-2)" "unprognostic (1.27e-1)" "unprognostic (1.05e-1)" "unprognostic (1.39e-1)" "unprognostic (2.13e-2)" 11.3 17.3 5.8 29.3 6.8 19.2 10.5 4.6 5.2 9.4 21.6 6.7 6.8 20.3 13.6 11.6 10.7 8.7 20.3 6.5 5.1 3.9 11.7 26.4 19.3 27.7 4.6 4.0 12.5 37.8 10.8 11.6 26.9 6.5 8.5 12.8 12.1 17.7 8.9 4.3 17.9 33.5 9.2 5.0 30.9 11.7 14.2 5.3 17.4 13.2 6.9 30.0 14.0 9.0 11.5 4.2 10.0 11.0 9.4 17.5 5.9 14.4 25.1 14.6 11.6 5.3 8.8 16.0 9.0 7.1 10.0 9.7 26.2 18.2 13.2 6.2 8.8 7.5 12.6 8.6 17.5 25.8 10.5 12.1 7.8 60.0 6.8 9.1 12.5 9.6 3.3 13.2 9.0 6.9 12.0 13.4 10.7 8.5 8.6 2.4 14.9 7.2 8.9 23.2 7.8 8.2 21.0 14.5 29.2 8.8 9.2 6.8 4.8 3.7 8.0 10.2 13.7 8.1 8.1 15.1 10.5 11.4 8.9 8.8 7.1 4.4 3.9 7.7 7.8 10.9 16.3 11.5 13.0 12.7 3.3 7.9 11.4 8.3 10.0 9.4 11.0 4.2 17.5 5.9 5.8 6.8 4.6 5.2 5.1 3.9 4.6 4.0 6.5 5.3 ENC1 "ENC-1, KLHL37, NRPB, PIG10, TP53I10" ENSG00000171617 "Ectodermal-neural cortex 1" O14682 5 74627406-74641424 "Cancer-related genes, Predicted intracellular proteins" "Actin-binding, Developmental protein" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 9 "brain: 106.8" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Group enriched" "Detected in all" 7 "amygdala: 39.7;basal ganglia: 42.7;cerebral cortex: 86.4;hippocampal formation: 44.1;olfactory region: 43.9" "Group enriched" "Detected in many" 6 "classical monocyte: 5.4;eosinophil: 3.4;gdT-cell: 2.3;intermediate monocyte: 4.8;memory CD8 T-cell: 3.0;myeloid DC: 2.4;naive CD8 T-cell: 2.5;neutrophil: 1.4;NK-cell: 2.8;non-classical monocyte: 1.3" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA078061 Uncertain "Plasma membrane" "Plasma membrane" "HPA078061: " "prognostic unfavourable (3.88e-4)" "unprognostic (4.90e-2)" "unprognostic (1.13e-1)" "unprognostic (3.00e-3)" "unprognostic (1.05e-1)" "unprognostic (2.22e-3)" "unprognostic (1.36e-1)" "unprognostic (9.74e-2)" "unprognostic (1.24e-1)" "unprognostic (2.59e-1)" "unprognostic (4.98e-2)" "unprognostic (8.08e-2)" "prognostic unfavourable (2.95e-5)" "unprognostic (9.69e-2)" "unprognostic (3.08e-1)" "unprognostic (2.88e-1)" "unprognostic (5.65e-2)" 2.2 1.1 39.7 4.7 42.7 5.4 1.8 1.3 106.8 4.2 5.2 2.4 2.1 6.4 2.9 1.6 2.5 1.3 7.5 3.2 44.1 7.7 2.2 6.4 4.8 2.2 4.6 43.9 6.0 12.3 1.0 2.4 4.2 4.9 4.3 8.1 0.8 5.4 7.4 1.7 1.7 8.1 3.0 2.3 4.0 9.8 4.5 1.5 0.5 1.3 0.3 2.0 6.5 1.3 0.4 2.4 3.4 5.4 2.8 3.0 1.4 11.9 14.8 14.8 7.0 6.4 1.6 31.9 8.0 9.1 9.2 6.8 23.9 20.2 0.0 10.0 6.8 9.7 0.2 15.5 20.1 0.2 1.1 13.2 2.8 10.4 0.6 1.3 0.1 2.5 1.0 24.4 2.4 7.5 2.9 7.7 24.0 2.9 1.2 1.7 15.4 13.3 1.5 9.7 1.2 5.0 9.1 19.9 8.1 1.4 6.6 0.7 3.1 1.6 17.8 15.6 26.1 9.2 25.8 0.1 0.0 0.2 18.0 1.1 23.7 0.0 5.4 3.4 2.3 4.8 0.0 0.1 0.5 3.0 2.4 0.4 0.2 2.5 1.4 2.8 1.3 0.0 0.0 1.4 39.7 42.7 1.3 86.4 44.1 7.7 4.6 43.9 4.9 1.5 ENG "CD105, END, HHT1, ORW, ORW1" ENSG00000106991 Endoglin P17813 9 127815012-127854756 "Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins" "Angiogenesis, Cell adhesion" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HUVEC TERT2: 66.9;TIME: 136.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 4 "classical monocyte: 12.2;intermediate monocyte: 17.7;myeloid DC: 6.4;NK-cell: 4.6;non-classical monocyte: 13.0" "Group enriched" "Detected in many" 4 "dendritic cells: 6.4;monocytes: 17.7;NK-cells: 4.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000096, HPA011862, HPA067440, CAB072873" Enhanced Supported "Nuclear bodies,Plasma membrane" 260000000 "Plasma membrane" "Nuclear bodies" "CAB000096: AB_563482, CAB072873: , HPA011862: AB_1846217, HPA067440: " "unprognostic (2.28e-1)" "unprognostic (1.13e-1)" "unprognostic (3.87e-2)" "unprognostic (2.96e-2)" "unprognostic (1.77e-1)" "prognostic favourable (6.61e-4)" "prognostic favourable (5.62e-6)" "unprognostic (2.15e-1)" "unprognostic (4.06e-1)" "unprognostic (3.87e-2)" "unprognostic (2.20e-2)" "unprognostic (8.98e-2)" "prognostic unfavourable (4.26e-4)" "unprognostic (3.33e-3)" "unprognostic (7.35e-2)" "unprognostic (2.84e-1)" "unprognostic (1.27e-1)" 40.3 19.3 6.4 26.6 10.5 5.5 52.7 3.9 8.6 26.3 14.0 7.6 18.5 11.2 27.0 25.2 17.2 23.2 28.3 105.4 8.0 5.0 40.8 26.8 66.7 44.1 10.6 7.0 66.4 9.6 8.6 12.5 60.2 10.1 23.1 6.4 35.5 9.9 51.7 24.1 10.1 14.5 23.1 8.7 52.4 11.6 37.2 7.7 6.7 35.4 19.3 11.0 20.3 44.8 1.1 6.4 0.3 17.7 4.6 2.3 4.6 0.1 0.1 0.9 0.0 16.8 11.5 29.6 19.5 14.0 10.4 6.1 0.0 0.1 0.1 9.5 35.8 0.3 0.0 3.1 3.4 0.0 0.0 5.5 11.0 0.6 13.1 2.6 0.0 19.7 0.7 13.5 4.9 66.9 0.0 0.1 12.1 0.1 0.0 0.2 0.2 0.5 8.7 1.7 0.1 0.0 0.0 0.1 0.2 10.3 9.0 2.6 1.8 3.9 136.5 34.1 1.8 22.2 0.0 0.7 0.1 0.1 9.2 6.8 11.2 0.0 12.2 0.3 1.3 17.7 0.4 0.4 2.1 2.3 6.4 1.1 1.3 2.0 0.3 4.6 13.0 2.4 0.8 4.6 6.4 10.5 3.9 8.6 8.0 5.0 10.6 7.0 10.1 7.7 ENO1 "ENO1L1, MBP-1, MPB1, PPH" ENSG00000074800 "Enolase 1" P06733 1 8861000-8879250 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Glycolysis, Plasminogen activation, Transcription, Transcription regulation" "DNA-binding, Lyase, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB018614, HPA068284, HPA068721, CAB069394" Supported Enhanced "Plasma membrane,Cytosol" 490000000 "Plasma membrane, Cytosol" "CAB018614: AB_2099061, CAB069394: , HPA068284: , HPA068721: " "unprognostic (6.51e-3)" "unprognostic (9.50e-3)" "unprognostic (3.56e-2)" "unprognostic (1.86e-1)" "prognostic unfavourable (2.71e-4)" "unprognostic (1.82e-2)" "prognostic unfavourable (1.30e-8)" "unprognostic (2.37e-2)" "unprognostic (5.58e-2)" "unprognostic (9.72e-2)" "unprognostic (1.67e-2)" "unprognostic (1.46e-1)" "unprognostic (7.53e-2)" "unprognostic (6.20e-2)" "unprognostic (1.97e-1)" "unprognostic (2.22e-1)" "unprognostic (1.36e-3)" 68.6 57.7 92.7 94.9 109.6 121.8 73.4 46.6 119.4 47.3 63.8 74.6 21.7 71.3 44.9 24.2 138.2 52.2 55.0 45.2 79.1 70.7 180.4 165.4 64.8 80.3 74.9 62.7 58.2 31.6 52.7 35.5 70.5 88.6 38.6 66.4 62.6 106.1 69.1 45.0 74.6 70.3 84.0 56.4 80.0 44.3 31.7 48.8 98.8 55.4 91.0 119.3 73.5 62.9 38.7 114.1 22.1 105.4 55.5 63.7 159.3 180.7 158.0 76.2 65.2 63.8 71.3 69.1 98.3 109.0 211.8 199.1 101.1 105.0 130.3 131.2 118.2 89.2 129.4 262.3 216.0 88.9 136.7 110.0 160.5 125.6 95.9 219.2 67.8 73.6 79.6 167.7 255.0 135.6 120.5 51.0 137.3 89.5 82.6 117.4 83.1 158.6 85.6 113.6 212.8 250.7 43.1 103.1 63.7 115.3 167.9 121.2 84.1 65.7 123.9 146.7 129.9 125.1 167.1 145.5 103.2 197.7 227.8 179.8 123.1 13.9 105.4 20.8 52.3 75.8 59.1 38.7 55.8 53.8 114.1 32.7 45.6 47.8 22.1 55.5 72.4 31.2 63.7 159.3 92.7 109.6 46.6 119.4 79.1 70.7 74.9 62.7 88.6 48.8 ENO2 ENSG00000111674 "Enolase 2" P09104 12 6913745-6923698 "Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins" Glycolysis Lyase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "brain: 119.2" "Cell line enhanced" "Detected in many" "U-87 MG: 81.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 5 "gdT-cell: 8.2;MAIT T-cell: 9.7;memory B-cell: 5.6;memory CD4 T-cell: 10.8;memory CD8 T-cell: 9.6;naive B-cell: 3.3;naive CD4 T-cell: 7.1;naive CD8 T-cell: 7.4;neutrophil: 6.2;T-reg: 5.5" "Group enriched" "Detected in many" 7 "B-cells: 5.6;granulocytes: 6.2;T-cells: 10.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000063, HPA068284, HPA068721, CAB073539, CAB079023" Enhanced Supported Supported "Plasma membrane,Cytosol" 89000000 "Plasma membrane, Cytosol" "CAB000063: AB_2099322, CAB073539: , CAB079023: , HPA068284: , HPA068721: " "unprognostic (8.96e-2)" "unprognostic (8.28e-2)" "prognostic unfavourable (6.96e-4)" "unprognostic (1.28e-1)" "unprognostic (7.95e-3)" "unprognostic (1.39e-2)" "prognostic unfavourable (5.15e-4)" "unprognostic (1.48e-1)" "unprognostic (9.43e-2)" "unprognostic (1.58e-1)" "unprognostic (1.98e-1)" "unprognostic (2.02e-2)" "prognostic unfavourable (7.89e-11)" "unprognostic (7.61e-2)" "unprognostic (3.06e-1)" "unprognostic (8.10e-3)" "unprognostic (1.24e-1)" 4.2 20.7 31.2 8.3 48.0 4.0 4.9 115.2 119.2 7.6 7.9 10.9 2.6 4.9 11.7 6.3 5.9 9.4 8.0 10.3 30.2 39.2 3.5 2.0 10.1 10.5 29.6 47.4 3.7 4.1 19.1 15.5 4.8 47.7 8.0 7.4 28.6 3.1 15.3 2.1 5.8 6.0 15.2 15.7 5.8 6.4 3.2 13.3 1.7 14.2 0.3 10.3 7.1 5.0 5.6 1.0 6.2 0.2 0.4 10.8 4.5 14.0 8.9 3.2 0.1 4.8 5.2 0.2 10.9 7.0 16.2 25.0 1.7 1.1 19.8 1.8 4.7 2.1 33.7 3.0 24.6 39.6 3.1 27.3 9.1 11.8 3.5 1.6 32.9 2.6 0.1 11.9 2.4 3.4 1.8 0.2 10.8 1.9 12.8 1.7 17.1 5.0 14.2 2.7 4.3 7.9 1.9 25.9 18.2 2.8 0.2 18.6 0.9 0.8 4.3 14.2 15.0 19.1 14.1 14.5 14.5 2.9 81.3 0.0 2.9 1.3 0.0 0.1 8.2 0.0 9.7 5.6 10.8 9.6 0.0 3.3 7.1 7.4 6.2 0.4 0.2 1.0 5.5 4.5 31.2 48.0 115.2 91.3 30.2 39.2 29.6 47.4 47.7 13.3 ENPP2 "ATX, PD-IALPHA, PDNP2" ENSG00000136960 "Ectonucleotide pyrophosphatase/phosphodiesterase 2" Q13822 8 119557086-119673453 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Chemotaxis, Lipid degradation, Lipid metabolism" Hydrolase "Cancer-related genes, Obesity" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 103.7;placenta: 79.0" "Cell line enhanced" "Detected in some" "AF22: 24.7;ASC diff: 33.8;ASC TERT1: 72.2;BJ hTERT+: 41.5;fHDF/TERT166: 26.8;HSkMC: 33.1" "Cancer enhanced" "Detected in all" "renal cancer: 46.7" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in some" 5 "basophil: 26.8" "Lineage enriched" "Detected in many" 7 "granulocytes: 26.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA023700, HPA053652" Approved Approved "Nucleoplasm,Golgi apparatus,Actin filaments" "Intracellular and membrane" 1100000000 "Nucleoplasm, Golgi apparatus" "Actin filaments" "HPA023700: AB_1848170, HPA053652: " "unprognostic (1.17e-2)" "unprognostic (6.29e-2)" "unprognostic (3.63e-2)" "unprognostic (3.93e-2)" "unprognostic (1.23e-1)" "unprognostic (1.37e-1)" "unprognostic (9.70e-3)" "unprognostic (7.14e-2)" "unprognostic (1.29e-1)" "unprognostic (1.26e-1)" "prognostic favourable (2.07e-5)" "unprognostic (5.54e-2)" "unprognostic (3.14e-1)" "unprognostic (2.37e-1)" "unprognostic (5.18e-2)" "unprognostic (2.37e-2)" "unprognostic (1.50e-1)" 29.9 15.4 24.0 18.2 42.0 0.7 26.2 4.4 33.3 19.6 8.1 103.7 1.7 20.8 44.8 6.4 2.9 18.7 12.7 3.6 39.8 21.5 24.9 8.9 13.5 31.0 71.5 20.9 5.3 5.2 0.9 4.1 79.0 59.7 8.5 10.6 67.6 3.4 9.2 3.0 5.4 12.1 28.9 102.4 17.3 8.3 9.7 63.9 3.6 3.7 0.8 26.1 13.4 5.7 0.2 3.8 26.8 0.1 0.2 1.8 0.3 0.0 0.0 24.7 0.0 33.8 72.2 0.0 22.7 41.5 9.8 9.4 0.0 0.0 0.0 0.3 26.8 0.0 0.5 0.0 6.9 1.8 0.7 0.0 0.0 0.6 15.1 0.0 0.1 33.1 0.2 20.0 1.0 0.1 0.0 4.0 0.5 0.0 0.0 0.1 0.9 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.4 0.0 0.0 0.0 0.0 0.0 0.0 19.9 0.4 23.9 0.1 0.2 0.0 0.0 16.8 0.1 0.5 26.8 0.1 5.2 0.0 0.0 0.0 0.2 0.2 0.0 0.5 0.0 1.8 0.6 0.3 0.2 0.0 3.8 0.0 0.3 24.0 42.0 4.4 33.3 39.8 21.5 71.5 20.9 59.7 63.9 EP300 "KAT3B, p300" ENSG00000100393 "E1A binding protein p300" Q09472 22 41091786-41180079 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Biological rhythms, Cell cycle, Host-virus interaction, Transcription, Transcription regulation" "Acyltransferase, Transferase" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000146, HPA003128, HPA004112" Supported Enhanced Nucleoplasm Nucleoplasm "CAB000146: AB_2533138, HPA003128: AB_1078745, HPA004112: AB_1078746" "unprognostic (7.67e-2)" "unprognostic (5.56e-2)" "unprognostic (2.29e-1)" "unprognostic (2.52e-1)" "unprognostic (6.10e-3)" "unprognostic (1.66e-1)" "unprognostic (2.21e-2)" "unprognostic (2.13e-1)" "unprognostic (1.54e-1)" "unprognostic (8.97e-2)" "unprognostic (1.74e-2)" "unprognostic (8.54e-2)" "prognostic favourable (7.45e-5)" "unprognostic (7.97e-2)" "unprognostic (1.41e-1)" "unprognostic (1.01e-1)" "unprognostic (8.66e-2)" 16.8 14.8 19.1 13.9 15.5 45.3 14.5 33.0 20.6 14.8 16.8 15.6 18.9 11.1 18.1 11.6 16.8 15.7 16.5 10.7 16.6 8.3 11.5 12.2 14.1 12.9 16.9 12.7 20.2 15.7 26.4 14.5 27.7 13.8 13.2 12.2 12.3 15.3 17.9 19.5 18.2 17.4 13.8 12.7 15.9 14.7 20.6 18.6 29.3 16.9 10.9 14.1 18.7 22.5 4.3 4.4 9.8 3.9 5.7 3.9 2.3 15.5 11.2 19.0 11.8 12.1 13.0 17.0 7.5 10.9 11.3 10.8 14.2 5.7 16.2 6.6 14.8 12.5 27.4 10.3 12.5 15.8 18.2 12.2 12.8 11.1 13.7 28.8 13.8 12.7 10.8 16.3 13.6 12.5 12.8 22.3 8.9 5.7 8.3 9.0 13.7 7.8 17.1 8.9 10.1 10.7 20.7 6.1 6.4 26.6 13.6 13.0 9.6 16.8 16.1 11.3 13.7 8.0 10.6 15.3 7.2 25.3 8.3 8.9 10.7 5.0 3.2 3.0 3.7 3.9 3.2 4.3 3.6 3.9 4.4 2.9 3.1 2.6 9.8 5.7 2.1 3.0 2.6 2.3 19.1 15.5 33.0 20.6 16.6 8.3 16.9 12.7 13.8 18.6 EPAS1 "bHLHe73, HIF2A, HLF, MOP2, PASD2" ENSG00000116016 "Endothelial PAS domain protein 1" Q99814 2 46293667-46386703 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Angiogenesis, Differentiation, Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding" "Cancer-related genes, Congenital erythrocytosis, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lung: 200.8" "Cell line enhanced" "Detected in many" "BEWO: 45.9;HHSteC: 57.5;RT4: 56.9;TIME: 56.7;U-138 MG: 49.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 16 "basophil: 14.9;eosinophil: 7.1" "Lineage enriched" "Detected in single" 21 "granulocytes: 14.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA031200, HPA069697" Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "HPA031200: , HPA069697: " "unprognostic (1.74e-1)" "unprognostic (9.47e-2)" "unprognostic (1.29e-2)" "unprognostic (2.74e-1)" "unprognostic (5.25e-2)" "unprognostic (1.75e-1)" "unprognostic (2.22e-2)" "unprognostic (8.67e-2)" "unprognostic (6.00e-2)" "unprognostic (9.72e-2)" "unprognostic (1.55e-2)" "unprognostic (9.29e-2)" "prognostic favourable (2.63e-4)" "unprognostic (6.66e-3)" "unprognostic (7.75e-2)" "unprognostic (7.56e-2)" "unprognostic (1.36e-1)" 71.2 14.2 12.5 17.1 15.7 0.8 101.7 5.3 13.9 24.9 20.9 8.9 11.3 12.0 28.8 13.0 21.6 24.8 35.2 40.0 12.8 11.0 35.2 31.2 200.8 27.2 14.3 11.1 20.2 15.5 18.1 9.4 119.6 18.4 20.7 11.5 41.2 13.3 18.7 25.2 13.0 15.6 19.2 12.5 20.5 12.8 13.8 8.0 1.1 43.8 15.2 10.3 32.2 39.3 0.0 0.0 14.9 0.1 0.7 0.1 0.1 5.2 5.6 0.3 0.4 27.0 17.4 45.9 16.6 45.2 9.5 10.4 0.9 0.9 0.0 4.1 31.5 2.5 0.1 13.3 7.1 0.1 0.2 0.0 1.8 11.7 57.5 0.0 3.4 25.5 18.3 18.6 13.1 32.7 0.5 0.0 5.8 4.5 0.1 0.1 0.2 3.1 0.1 0.6 1.7 5.9 56.9 0.2 11.8 13.0 29.9 3.6 2.0 2.3 56.7 49.3 1.4 6.5 1.3 0.0 0.0 0.0 36.0 0.9 1.2 14.9 0.1 7.1 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.7 0.0 0.0 0.1 0.1 12.5 15.7 5.3 12.6 12.8 11.0 14.3 11.1 18.4 8.0 EPCAM "17-1A, 323/A3, CD326, CO-17A, EGP-2, EGP34, EGP40, Ep-CAM, ESA, GA733-2, HEA125, KS1/4, KSA, Ly74, M4S1, MH99, MIC18, MK-1, MOC31, TACST-1, TACSTD1, TROP1" ENSG00000119888 "Epithelial cell adhesion molecule" P16422 2 47345158-47387601 "Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Tumor antigen" "Cancer-related genes, Disease mutation, FDA approved drug targets, Hereditary nonpolyposis colorectal cancer" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 303.2" "Cell line enhanced" "Detected in many" "A-431: 58.3;CACO-2: 75.6;CAPAN-2: 106.4;RPTEC TERT1: 45.4;SCLC-21H: 41.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in single" "plasmacytoid DC: 1.9" "Lineage enriched" "Detected in single" 5 "dendritic cells: 1.9" "Not detected" "Not detected" "Low region specificity" "Detected in some" "CAB003809, HPA026761, CAB030012, CAB055098, HPA067463" Enhanced Supported "Plasma membrane" "Plasma membrane" "CAB003809: AB_562285, CAB030012: AB_756075, CAB055098: AB_2335685, HPA026761: AB_1848198, HPA067463: " "unprognostic (6.79e-2)" "unprognostic (2.28e-1)" "unprognostic (1.59e-2)" "unprognostic (1.16e-2)" "unprognostic (1.61e-1)" "unprognostic (3.49e-2)" "unprognostic (2.01e-1)" "unprognostic (3.61e-2)" "unprognostic (3.40e-1)" "prognostic favourable (3.30e-4)" "unprognostic (5.27e-2)" "unprognostic (3.28e-2)" "prognostic favourable (1.04e-6)" "unprognostic (6.38e-3)" "unprognostic (1.28e-1)" "unprognostic (6.45e-3)" "unprognostic (6.08e-2)" 0.4 2.1 1.8 49.8 3.0 0.2 8.9 0.6 1.0 10.8 155.8 0.7 31.5 66.8 4.4 35.2 2.8 10.2 41.6 0.4 1.7 2.7 60.2 1.2 22.6 0.4 1.2 0.4 3.8 54.1 19.8 38.7 2.2 0.9 9.0 70.5 0.7 47.2 25.0 0.5 2.0 303.2 1.7 1.4 0.5 15.3 5.5 0.9 1.7 83.6 4.2 4.1 4.1 2.1 0.2 1.9 0.4 0.2 0.0 0.0 0.6 58.3 0.6 0.0 0.1 0.0 0.0 37.0 0.0 0.0 0.0 0.0 75.6 106.4 0.0 16.4 0.1 27.5 0.5 6.9 0.2 0.0 6.7 0.0 0.3 29.7 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.1 17.4 0.0 0.0 29.8 0.0 2.8 19.1 3.8 0.0 0.0 14.8 45.4 25.8 41.1 0.3 0.4 21.7 0.0 18.3 0.1 0.0 0.0 0.7 0.2 0.1 4.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.2 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.2 1.9 0.0 0.6 1.8 3.0 0.6 1.0 1.7 2.7 1.2 0.4 0.9 0.9 EPHA1 "EPH, EPHT, EPHT1" ENSG00000146904 "EPH receptor A1" P21709 7 143390289-143408892 "Cancer-related genes, Enzymes, Plasma proteins, Predicted membrane proteins" "Angiogenesis, Cell adhesion" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "parathyroid gland: 104.4" "Cell line enhanced" "Detected in some" "CACO-2: 10.3;HaCaT: 9.6;HBEC3-KT: 7.8;MCF7: 8.5;NTERA-2: 32.1" "Low cancer specificity" "Detected in many" "Region enhanced" "Detected in single" "pons and medulla: 1.1" "Group enriched" "Detected in some" 6 "memory CD4 T-cell: 3.4;naive CD4 T-cell: 6.9;naive CD8 T-cell: 5.1" "Lineage enriched" "Detected in single" 9 "T-cells: 6.9" "Not detected" "Not detected" CAB026144 Uncertain 24000000 "CAB026144: " "unprognostic (1.54e-2)" "unprognostic (3.04e-2)" "unprognostic (2.07e-1)" "unprognostic (4.58e-3)" "unprognostic (5.82e-3)" "unprognostic (2.45e-2)" "unprognostic (9.56e-2)" "unprognostic (1.81e-2)" "unprognostic (5.09e-1)" "unprognostic (7.59e-3)" "unprognostic (6.54e-2)" "unprognostic (3.24e-3)" "prognostic favourable (1.14e-6)" "unprognostic (3.73e-2)" "unprognostic (3.28e-2)" "unprognostic (1.91e-1)" "unprognostic (1.21e-1)" 0.4 0.4 0.0 2.0 0.1 0.5 1.2 0.9 0.3 5.7 7.9 0.0 3.3 3.3 0.9 1.4 29.3 1.6 7.9 0.4 0.0 0.0 2.8 10.6 2.9 5.8 0.0 0.0 1.2 2.9 104.4 1.3 5.5 1.1 2.1 0.9 1.3 5.8 3.9 0.3 9.5 12.3 0.4 0.2 0.5 1.8 0.8 0.0 5.1 6.0 16.4 17.2 1.6 11.8 0.0 0.7 0.2 0.1 0.2 6.9 1.6 4.9 0.0 0.0 0.0 0.0 0.0 4.7 0.0 0.0 0.0 0.0 10.3 4.1 0.0 0.0 0.0 9.6 0.0 7.8 0.0 0.0 0.0 1.0 0.0 0.9 0.0 0.4 0.0 0.0 2.6 0.0 0.0 0.0 0.0 0.0 0.0 8.5 0.0 1.0 32.1 0.0 0.0 0.0 0.0 0.6 3.9 0.1 0.0 0.0 4.8 0.0 2.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.0 3.4 0.9 0.4 0.0 6.9 5.1 0.2 0.2 0.0 0.7 0.2 1.6 0.0 0.1 0.9 0.1 0.0 0.0 0.0 0.0 1.1 0.0 EPHA2 ECK ENSG00000142627 "EPH receptor A2" P29317 1 16124337-16156087 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, RAS pathway related proteins" "Angiogenesis, Apoptosis, Cell adhesion, Differentiation, Host-virus interaction" "Host cell receptor for virus entry, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Cataract, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "esophagus: 51.2" "Cell line enhanced" "Detected in many" "CAPAN-2: 41.9;EFO-21: 40.4;PC-3: 48.0;U-251 MG: 49.2;WM-115: 53.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 115 "plasmacytoid DC: 11.4" "Lineage enriched" "Detected in single" 115 "dendritic cells: 11.4" "Low region specificity" "Detected in all" CAB010464 Supported "Nuclear speckles,Golgi apparatus,Plasma membrane,Cell Junctions" "Plasma membrane, Cell Junctions" "Nuclear speckles, Golgi apparatus" "CAB010464: AB_631436" "unprognostic (9.41e-2)" "unprognostic (1.67e-1)" "unprognostic (4.13e-2)" "unprognostic (1.67e-2)" "unprognostic (6.22e-2)" "unprognostic (9.12e-2)" "unprognostic (5.24e-2)" "unprognostic (1.29e-3)" "unprognostic (2.52e-2)" "unprognostic (7.05e-3)" "unprognostic (1.52e-3)" "unprognostic (2.77e-1)" "unprognostic (2.65e-2)" "unprognostic (2.08e-1)" "unprognostic (1.73e-1)" "unprognostic (4.77e-3)" "unprognostic (4.40e-2)" 6.7 3.4 1.3 3.1 2.6 0.0 5.2 0.5 2.1 12.1 4.9 1.6 1.9 4.3 7.8 3.8 51.2 4.6 16.7 6.4 1.1 0.8 5.7 8.2 6.6 4.7 2.7 1.3 4.5 10.2 2.2 2.8 8.9 3.4 5.8 2.6 5.4 31.0 2.8 3.4 12.7 13.1 2.7 3.0 2.8 6.8 2.4 1.2 1.2 5.7 21.8 25.5 15.2 18.5 0.0 11.4 0.0 0.0 0.0 0.0 0.0 15.4 31.3 8.7 4.2 0.6 0.7 5.1 9.3 13.3 17.0 10.8 13.0 41.9 0.0 40.4 5.3 6.3 2.0 21.6 5.9 0.0 1.4 0.0 9.1 8.3 11.1 0.0 0.0 1.0 8.1 9.2 20.5 18.1 0.0 0.0 10.7 4.9 0.0 0.0 4.2 48.0 0.0 7.9 0.0 18.0 8.0 0.0 1.3 18.2 4.4 1.2 0.6 0.1 22.3 6.1 16.3 0.4 49.2 0.0 0.1 0.1 4.7 0.0 53.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 11.4 0.0 0.0 1.3 2.6 0.5 2.1 1.1 0.8 2.7 1.3 3.4 1.2 EPHA3 "ETK, ETK1, HEK, HEK4, TYRO4" ENSG00000044524 "EPH receptor A3" P29320 3 89107524-89482134 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "prostate: 39.0" "Cell line enriched" "Detected in some" 6 "AF22: 65.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB010462, HPA069390" Approved Supported "Nucleoplasm,Nuclear membrane,Plasma membrane,Actin filaments,Cytosol" "Intracellular and membrane" "Nuclear membrane, Plasma membrane, Cytosol" "Nucleoplasm, Actin filaments" "CAB010462: AB_2099218, HPA069390: " "unprognostic (1.48e-3)" "unprognostic (2.30e-2)" "unprognostic (4.95e-2)" "unprognostic (1.90e-1)" "unprognostic (2.96e-2)" "unprognostic (1.47e-2)" "unprognostic (2.03e-1)" "unprognostic (9.10e-3)" "unprognostic (1.24e-3)" "unprognostic (7.43e-2)" "unprognostic (1.83e-1)" "unprognostic (2.23e-1)" "prognostic unfavourable (3.28e-7)" "unprognostic (3.63e-2)" "unprognostic (1.88e-2)" "unprognostic (4.05e-2)" "unprognostic (1.20e-2)" 9.7 1.1 2.3 1.7 4.5 0.2 5.1 1.3 8.7 12.3 5.8 0.6 1.4 2.2 13.9 1.3 6.3 2.6 17.2 10.0 2.2 2.5 1.5 4.4 2.7 3.0 2.5 3.4 4.2 2.8 1.2 3.4 17.5 11.9 39.0 5.9 5.4 3.8 6.8 1.7 1.7 3.5 17.3 2.9 1.2 3.7 1.3 2.0 0.0 16.3 6.0 3.0 11.8 12.2 0.3 0.1 0.5 0.1 0.3 0.2 0.0 0.0 0.0 65.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.1 0.0 0.0 0.0 3.7 0.0 0.2 0.0 0.8 0.0 0.0 4.0 0.0 0.0 0.5 0.0 0.0 0.0 0.2 0.0 0.8 0.0 0.1 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.1 0.0 0.0 11.5 0.0 0.0 0.0 0.5 0.0 0.5 0.2 0.1 0.2 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.3 0.0 0.0 0.5 0.3 0.1 0.1 0.0 0.0 2.3 4.5 1.3 8.7 2.2 2.5 2.5 3.4 11.9 2.0 EPHA4 "Hek8, TYRO1" ENSG00000116106 "EPH receptor A4" P54764 2 221418027-221574202 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion, Neurogenesis" "Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 29.6" "Cell line enhanced" "Detected in many" "AF22: 35.0;ASC diff: 15.5;CACO-2: 25.6;U-2197: 17.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 8 "basophil: 3.0;gdT-cell: 3.4;MAIT T-cell: 3.4;memory B-cell: 2.5;memory CD4 T-cell: 5.0;memory CD8 T-cell: 3.3;naive B-cell: 1.8;naive CD4 T-cell: 1.9;NK-cell: 6.0;T-reg: 2.1" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" CAB028368 Enhanced 8400000 "CAB028368: AB_2099353" "unprognostic (1.28e-1)" "unprognostic (5.87e-2)" "unprognostic (2.28e-1)" "unprognostic (2.46e-2)" "unprognostic (5.99e-2)" "unprognostic (1.33e-1)" "unprognostic (7.05e-4)" "unprognostic (1.80e-2)" "unprognostic (2.40e-1)" "prognostic unfavourable (9.56e-4)" "unprognostic (1.12e-1)" "unprognostic (2.85e-2)" "prognostic favourable (5.67e-4)" "unprognostic (3.12e-2)" "unprognostic (1.96e-1)" "unprognostic (2.36e-1)" "unprognostic (8.66e-2)" 7.1 1.8 8.1 1.9 18.3 3.5 5.2 14.7 29.6 4.9 5.9 3.1 3.2 1.1 6.5 3.1 5.0 6.6 3.3 16.7 19.9 4.4 5.2 0.9 3.7 2.5 2.4 16.4 11.7 1.2 2.0 1.2 1.7 4.9 5.9 4.7 0.8 3.7 6.7 3.1 12.8 4.1 8.2 2.1 3.3 4.0 11.4 2.6 0.5 9.8 3.7 3.2 4.6 4.9 2.5 0.2 3.0 0.0 6.0 5.0 0.7 1.1 1.0 35.0 0.0 15.5 9.6 0.0 8.3 3.6 7.5 2.8 25.6 0.4 0.0 0.0 11.6 3.0 5.4 0.0 3.2 4.1 3.0 0.0 0.3 0.0 0.4 0.0 0.6 3.8 1.9 2.3 0.0 7.1 0.0 0.0 1.9 4.1 0.1 0.0 2.5 0.7 0.0 3.8 0.0 11.7 1.8 6.2 0.0 2.7 0.5 0.6 1.3 0.0 0.0 0.8 1.4 17.1 0.4 0.0 0.0 0.0 3.1 0.0 1.5 3.0 0.0 0.0 3.4 0.0 3.4 2.5 5.0 3.3 0.0 1.8 1.9 0.3 0.2 6.0 0.0 0.2 2.1 0.7 8.1 18.3 14.7 29.6 19.9 4.4 2.4 16.4 4.9 2.6 EPHA7 Hek11 ENSG00000135333 "EPH receptor A7" Q15375 6 93240020-93419547 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Apoptosis, Neurogenesis" "Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "parathyroid gland: 110.4" "Group enriched" "Detected in some" 4 "AF22: 8.7;HEK 293: 25.0;RH-30: 23.8;THP-1: 20.3" "Cancer enhanced" "Detected in many" "renal cancer: 6.4" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB010496 Approved "Intracellular and membrane" 340000 "CAB010496: AB_2099673" "unprognostic (3.34e-1)" "unprognostic (7.82e-2)" "unprognostic (1.41e-1)" "unprognostic (9.32e-2)" "unprognostic (1.19e-1)" "unprognostic (3.56e-2)" "unprognostic (1.62e-2)" "unprognostic (4.07e-1)" "unprognostic (4.16e-2)" "unprognostic (3.19e-2)" "unprognostic (5.69e-2)" "unprognostic (1.69e-1)" "unprognostic (1.74e-2)" "unprognostic (1.35e-1)" "unprognostic (1.56e-2)" "unprognostic (4.82e-2)" 1.3 1.3 6.0 1.7 24.6 1.2 2.2 21.6 8.6 2.4 24.6 0.0 0.1 2.5 2.0 7.5 14.7 1.7 3.1 4.2 13.8 2.9 6.9 1.3 1.5 1.3 2.4 5.8 3.0 1.3 110.4 5.6 1.6 6.7 17.9 3.6 0.4 8.2 1.9 1.3 1.4 6.5 20.2 4.8 4.7 14.9 2.1 4.4 0.0 1.3 0.0 1.3 9.7 5.9 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.5 8.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.8 0.0 0.0 0.0 25.0 0.0 2.4 0.0 0.0 0.0 0.0 0.3 0.0 3.6 0.0 0.0 0.0 0.0 3.9 0.0 0.0 0.0 0.5 0.6 4.4 23.8 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 20.3 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 6.0 24.6 21.6 8.6 13.8 2.9 2.4 5.8 6.7 4.4 EPHA8 "EEK, Hek3" ENSG00000070886 "EPH receptor A8" P29322 1 22563564-22603594 "Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion, Neurogenesis" "Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 4 "adrenal gland: 9.4;brain: 5.3;lymphoid tissue: 10.3;pancreas: 8.3;testis: 3.5" "Cell line enriched" "Detected in some" 12 "SCLC-21H: 36.4" "Low cancer specificity" "Detected in single" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Region enriched" "Detected in many" 5 "cerebellum: 25.0" "CAB009660, HPA031433" Uncertain "Intracellular and membrane" "CAB009660: AB_2099696, HPA031433: AB_10601371" "unprognostic (8.58e-2)" "unprognostic (8.59e-2)" "unprognostic (3.72e-1)" "unprognostic (1.15e-2)" "unprognostic (4.69e-4)" "unprognostic (3.58e-1)" "unprognostic (7.14e-2)" "unprognostic (1.52e-1)" "unprognostic (4.75e-2)" "unprognostic (9.80e-2)" "unprognostic (2.10e-1)" "unprognostic (9.84e-14)" "unprognostic (2.14e-3)" "unprognostic (1.69e-1)" "unprognostic (2.76e-1)" "unprognostic (8.68e-2)" 0.2 9.4 1.6 0.2 3.1 0.2 0.1 1.8 3.9 0.2 0.2 2.2 0.0 1.7 0.1 0.3 0.2 0.1 0.2 0.2 2.0 2.6 0.1 0.1 0.2 0.2 2.1 4.1 0.1 8.3 0.2 1.7 0.1 5.3 0.2 0.2 1.6 0.8 0.2 0.3 0.4 0.2 0.1 1.3 10.3 0.2 3.5 0.6 0.0 0.2 0.0 0.1 0.1 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 2.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.0 0.0 0.0 0.0 0.0 36.4 2.9 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.5 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 1.6 3.1 1.8 3.9 2.0 2.6 2.1 4.1 5.3 0.6 EPHB2 "DRT, EPHT3, ERK, Hek5, Tyro5" ENSG00000133216 "EPH receptor B2" P29323 1 22710839-22921500 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" Neurogenesis "Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 25.0" "Cell line enhanced" "Detected in many" "HBEC3-KT: 22.8;HUVEC TERT2: 31.1;TIME: 30.7;U-251 MG: 26.8" "Cancer enhanced" "Detected in many" "colorectal cancer: 23.7" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "classical monocyte: 2.5;intermediate monocyte: 2.1" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB013647, HPA071200" Approved Supported "Nucleoplasm,Plasma membrane" "Intracellular and membrane" 290000 "Plasma membrane" Nucleoplasm "CAB013647: , HPA071200: " "unprognostic (2.47e-2)" "unprognostic (2.43e-2)" "prognostic favourable (4.98e-4)" "prognostic unfavourable (1.05e-5)" "unprognostic (3.99e-2)" "unprognostic (8.91e-3)" "unprognostic (1.23e-1)" "unprognostic (2.33e-3)" "unprognostic (1.56e-1)" "unprognostic (7.73e-2)" "unprognostic (1.23e-2)" "unprognostic (2.15e-2)" "unprognostic (2.16e-4)" "unprognostic (1.45e-1)" "unprognostic (8.07e-2)" "unprognostic (2.58e-1)" "unprognostic (3.46e-2)" 3.7 2.9 3.4 15.4 5.4 0.9 2.5 1.9 8.2 3.8 23.9 16.2 4.6 21.6 2.5 3.2 1.1 5.4 4.4 5.4 5.6 6.5 3.5 1.1 3.0 5.5 12.7 3.8 17.9 5.4 6.1 5.4 12.0 8.2 3.3 25.0 2.2 6.6 4.0 0.7 1.8 22.6 4.0 12.1 3.3 2.3 2.9 9.3 0.1 8.4 1.0 2.1 5.3 3.3 0.1 0.6 0.3 2.5 0.1 0.1 0.4 16.7 7.1 6.8 10.9 0.6 0.6 0.0 3.9 0.2 11.8 2.5 2.4 6.7 0.2 8.4 1.7 15.8 4.6 22.8 3.1 0.0 1.6 0.0 0.7 0.0 7.1 0.0 1.7 2.3 7.3 21.1 0.1 31.1 0.6 0.0 2.3 2.5 0.3 0.1 1.6 4.6 2.0 7.0 0.3 5.8 1.6 7.4 7.8 6.8 0.2 0.1 0.4 0.2 30.7 4.7 12.4 11.9 26.8 0.0 0.1 0.0 8.8 0.3 0.1 0.3 2.5 0.1 0.1 2.1 0.0 0.0 0.0 0.0 0.6 0.1 0.1 0.1 0.3 0.1 0.1 0.1 0.1 0.4 3.4 5.4 1.9 8.2 5.6 6.5 12.7 3.8 8.2 9.3 EPHB3 "ETK2, Hek2, Tyro6" ENSG00000182580 "EPH receptor B3" P54753 3 184561784-184582409 "Cancer-related genes, Enzymes, Predicted membrane proteins" "Angiogenesis, Neurogenesis" "Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "pancreas: 49.3" "Cell line enhanced" "Detected in many" "BEWO: 17.2;HaCaT: 23.6;SK-BR-3: 18.3;T-47d: 12.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 5 "classical monocyte: 1.1;myeloid DC: 3.1" "Group enriched" "Detected in many" 5 "dendritic cells: 3.1;monocytes: 1.1" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA007698, HPA008184, CAB034350" Enhanced 20000 "CAB034350: AB_2262377, HPA007698: AB_1848205, HPA008184: AB_1848206" "unprognostic (2.94e-2)" "unprognostic (5.88e-2)" "unprognostic (2.17e-2)" "unprognostic (7.80e-2)" "unprognostic (1.52e-1)" "unprognostic (9.19e-2)" "unprognostic (8.35e-2)" "unprognostic (1.94e-1)" "unprognostic (5.51e-2)" "unprognostic (1.76e-1)" "unprognostic (7.42e-2)" "unprognostic (3.31e-1)" "prognostic unfavourable (7.88e-5)" "unprognostic (8.83e-3)" "unprognostic (3.03e-2)" "unprognostic (9.59e-3)" "unprognostic (2.10e-3)" 1.4 0.9 4.5 5.0 2.6 0.5 9.0 9.7 5.7 22.7 8.8 2.3 1.7 5.7 10.0 1.9 19.9 3.0 9.7 1.6 4.7 1.8 1.7 1.0 4.7 1.0 3.3 3.7 9.0 49.3 1.1 1.7 6.3 7.2 7.7 9.7 3.8 27.7 3.5 0.7 32.3 5.6 3.5 1.3 1.2 16.0 1.1 4.0 0.2 1.0 15.7 8.4 4.0 13.6 0.0 3.1 0.3 1.1 0.0 0.4 0.4 3.8 1.3 8.9 0.9 2.7 0.2 17.2 0.6 1.1 1.3 0.7 1.2 0.1 0.0 1.7 3.6 23.6 3.2 1.2 0.3 0.1 0.7 0.0 0.2 0.0 0.2 0.0 0.2 0.7 7.7 1.1 0.1 0.0 0.0 0.0 0.6 10.1 0.0 3.8 0.9 1.5 0.9 5.4 0.0 0.0 3.4 1.1 1.3 0.7 18.3 0.8 12.1 0.1 0.0 2.2 3.2 1.1 1.4 0.0 0.0 0.1 0.2 0.0 8.4 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.3 0.0 3.1 0.0 0.1 0.4 0.3 0.0 0.0 0.0 0.0 0.4 4.5 2.6 9.7 5.7 4.7 1.8 3.3 3.7 7.2 4.0 EPHB4 "HTK, Tyro11" ENSG00000196411 "EPH receptor B4" P54760 7 100802565-100827521 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" Angiogenesis "Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in some" "classical monocyte: 3.6;neutrophil: 7.4" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB013537 Uncertain 1000000 "CAB013537: " "prognostic unfavourable (8.56e-4)" "unprognostic (1.05e-2)" "prognostic unfavourable (4.33e-4)" "unprognostic (1.33e-1)" "unprognostic (5.23e-2)" "unprognostic (3.43e-2)" "unprognostic (1.46e-1)" "unprognostic (1.01e-1)" "unprognostic (2.73e-1)" "unprognostic (1.84e-1)" "unprognostic (8.16e-3)" "unprognostic (1.43e-1)" "unprognostic (9.51e-3)" "unprognostic (6.63e-2)" "unprognostic (3.13e-1)" "unprognostic (2.07e-2)" "prognostic unfavourable (8.84e-4)" 14.0 20.7 1.8 4.2 2.9 2.2 17.1 1.9 3.0 29.1 9.5 2.9 14.6 4.1 28.8 10.3 11.0 13.1 35.0 19.0 3.4 1.1 16.8 29.8 16.5 12.0 2.2 0.9 24.6 11.6 5.6 3.1 35.5 3.2 13.7 5.4 11.6 10.8 14.7 5.1 14.2 7.0 12.4 2.2 50.5 8.6 12.2 2.1 2.3 10.2 13.1 7.0 7.7 21.5 0.0 1.6 7.4 3.6 0.0 0.0 1.2 12.5 11.1 11.1 32.2 7.1 4.6 32.9 4.9 10.7 7.7 10.1 9.1 9.6 1.6 22.4 5.0 13.1 4.8 12.9 4.1 2.0 8.9 0.4 6.4 14.1 4.1 0.2 0.3 5.4 19.5 4.9 11.4 28.7 23.6 0.6 6.2 21.8 0.2 4.9 19.0 16.7 17.0 5.5 2.9 9.8 6.6 0.0 9.6 7.5 3.5 7.3 8.9 2.2 24.1 9.6 15.3 17.7 7.2 0.1 0.2 0.5 1.4 4.1 17.4 0.0 3.6 0.0 0.0 0.9 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 7.4 0.0 0.2 0.3 0.0 1.2 1.8 2.9 1.9 3.0 3.4 1.1 2.2 0.9 3.2 2.1 EPHX1 EPHX ENSG00000143819 "Epoxide hydrolase 1" P07099 1 225810092-225845563 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Aromatic hydrocarbons catabolism, Detoxification" Hydrolase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "adrenal gland: 156.4;liver: 265.0" "Cell line enhanced" "Detected in many" "ASC diff: 153.8;SiHa: 73.1" "Cancer enriched" "Detected in all" 6 "liver cancer: 1047.0" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "classical monocyte: 6.6" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA020593, HPA048847" Enhanced 83000 "HPA020593: AB_10601373, HPA048847: AB_2680538" "unprognostic (2.85e-2)" "unprognostic (2.52e-2)" "unprognostic (2.00e-2)" "unprognostic (2.53e-3)" "unprognostic (2.50e-1)" "unprognostic (6.60e-2)" "unprognostic (3.92e-2)" "prognostic favourable (7.02e-5)" "unprognostic (1.02e-1)" "unprognostic (2.53e-2)" "unprognostic (1.01e-1)" "prognostic favourable (1.32e-4)" "unprognostic (8.10e-2)" "unprognostic (1.80e-1)" "unprognostic (1.65e-1)" "unprognostic (5.15e-2)" "unprognostic (1.88e-2)" 39.5 156.4 16.8 5.7 20.1 3.4 31.3 8.3 25.1 31.3 12.6 28.7 15.3 16.6 21.8 15.7 24.9 26.2 17.8 11.5 16.3 11.2 36.8 265.0 24.1 6.9 17.1 14.5 45.6 85.0 39.5 14.0 5.4 23.6 25.9 8.4 27.3 26.3 21.3 16.4 8.8 9.6 18.6 10.7 8.3 12.1 22.7 12.6 3.6 24.9 15.6 14.9 20.9 32.3 0.5 2.2 0.5 6.6 1.4 1.3 2.3 4.4 42.3 1.6 15.6 153.8 16.0 3.4 5.1 6.4 3.7 5.2 8.7 45.0 0.1 19.3 19.2 4.9 4.6 2.4 1.5 0.9 8.0 3.1 17.9 48.8 16.7 1.9 1.8 15.0 5.6 10.5 1.0 2.7 2.2 3.9 6.6 5.1 1.9 3.6 9.1 11.9 4.1 2.0 12.8 11.1 27.9 14.6 1.9 73.1 26.2 6.7 19.4 5.7 8.1 6.3 5.1 8.5 8.1 1.3 6.7 0.5 9.5 2.1 8.3 0.0 6.6 0.2 0.5 1.9 0.9 0.3 0.9 0.5 1.5 0.5 1.3 1.0 0.5 1.4 0.8 2.2 0.7 2.3 16.8 20.1 8.3 25.1 16.3 11.2 17.1 14.5 23.6 12.6 EPO EP ENSG00000130427 Erythropoietin P01588 7 100720800-100723700 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Predicted secreted proteins" "Erythrocyte maturation" Hormone "Cancer-related genes, Congenital erythrocytosis, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "cervix, uterine: 10.9;endometrium 1: 8.7;liver: 29.3" "Group enriched" "Detected in some" 7 "BEWO: 3.5;Hep G2: 13.0" "Group enriched" "Detected in many" 5 "liver cancer: 2.7;renal cancer: 5.4" "Region enriched" "Detected in single" 9 "cerebral cortex: 4.4" "Cell type enriched" "Detected in single" 13 "non-classical monocyte: 1.2" "Lineage enriched" "Detected in single" 13 "monocytes: 1.2" "Not detected" "Not detected" "Low region specificity" "Detected in single" CAB010336 Supported "Secreted to blood" "CAB010336: AB_2098408" "unprognostic (2.93e-1)" "unprognostic (1.57e-2)" "unprognostic (1.08e-3)" "unprognostic (7.30e-2)" "unprognostic (1.09e-1)" "unprognostic (1.78e-3)" "prognostic unfavourable (5.67e-5)" "unprognostic (3.52e-2)" "unprognostic (5.16e-2)" "unprognostic (9.70e-2)" "unprognostic (2.44e-3)" "unprognostic (3.31e-1)" "prognostic unfavourable (2.18e-6)" "unprognostic (4.80e-2)" "unprognostic (1.87e-1)" "unprognostic (1.59e-2)" "unprognostic (3.34e-1)" 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.1 4.4 10.9 0.0 0.0 0.0 0.0 8.7 0.6 0.4 0.0 0.0 0.1 0.0 0.0 2.8 29.3 0.0 0.0 0.0 0.0 0.1 7.8 0.0 0.0 0.7 0.0 1.6 0.0 0.7 0.9 1.6 0.0 0.7 0.0 0.6 0.0 0.0 0.0 2.4 0.4 0.3 0.0 0.0 0.3 0.0 0.1 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 3.5 0.1 0.0 0.0 0.0 0.8 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.1 1.1 0.1 0.0 0.0 13.0 0.0 0.0 0.1 0.1 0.0 0.1 0.1 0.0 0.2 0.2 0.2 0.0 0.0 0.6 0.4 0.1 0.1 0.0 0.2 0.0 0.0 0.0 0.2 0.0 0.6 0.2 0.0 0.1 0.0 0.1 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.5 0.1 4.4 0.0 0.0 0.0 0.0 0.0 0.4 EPOR ENSG00000187266 "Erythropoietin receptor" P19235 19 11377205-11384342 "Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted membrane proteins" Receptor "Cancer-related genes, Congenital erythrocytosis, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA077654 Supported "Nuclear speckles,Plasma membrane" "Intracellular and membrane" "Plasma membrane" "Nuclear speckles" "HPA077654: " "unprognostic (9.13e-2)" "unprognostic (7.14e-2)" "unprognostic (1.45e-2)" "unprognostic (1.04e-1)" "unprognostic (1.88e-1)" "unprognostic (1.11e-1)" "unprognostic (3.70e-1)" "unprognostic (1.50e-2)" "unprognostic (5.60e-2)" "unprognostic (9.00e-2)" "prognostic favourable (3.17e-5)" "unprognostic (6.37e-3)" "unprognostic (1.59e-2)" "unprognostic (2.08e-1)" "unprognostic (2.00e-1)" "unprognostic (7.48e-2)" "unprognostic (1.01e-3)" 5.5 8.6 2.1 1.1 2.9 14.7 2.6 1.3 1.7 3.9 3.3 2.8 13.3 1.0 3.6 11.6 2.4 3.2 1.8 11.2 1.9 1.4 12.1 8.4 8.5 6.9 1.9 1.6 1.9 9.2 28.1 5.2 12.7 2.3 3.1 1.4 3.3 8.7 18.3 2.0 1.1 1.7 1.5 4.0 8.0 3.7 2.2 1.0 1.6 21.5 1.0 1.5 1.9 2.1 2.6 2.5 12.2 7.7 0.9 4.8 2.9 3.4 1.1 3.5 4.1 5.3 3.4 2.1 2.2 6.8 3.5 4.5 1.2 1.3 2.4 3.9 3.9 0.9 2.7 1.3 4.1 1.9 1.6 13.0 1.1 2.0 3.8 2.7 5.4 2.5 0.5 4.7 3.3 8.2 11.4 11.6 3.9 3.1 2.5 3.2 1.9 9.3 6.7 5.9 5.2 3.3 1.8 1.4 10.9 1.4 2.0 6.0 3.5 4.7 3.4 1.9 2.6 6.5 1.9 5.9 4.3 2.6 10.3 2.6 2.0 8.1 4.2 3.3 2.1 5.1 4.5 2.6 4.2 3.1 2.5 1.6 4.8 2.8 12.2 0.9 7.7 0.1 3.7 2.9 2.1 2.9 1.3 1.7 1.9 1.4 1.9 1.6 2.3 1.0 EPS15 "AF-1P, MLLT5" ENSG00000085832 "Epidermal growth factor receptor pathway substrate 15" P42566 1 51354263-51519328 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Endocytosis, Host-virus interaction, Protein transport, Transport" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008451, CAB010164, HPA061431" Approved Enhanced Vesicles,Cytosol "Intracellular and membrane" 67000 "Vesicles, Cytosol" "CAB010164: AB_631445, HPA008451: AB_1848221, HPA061431: " "unprognostic (1.45e-2)" "prognostic unfavourable (6.44e-4)" "unprognostic (1.05e-2)" "unprognostic (7.72e-3)" "unprognostic (3.99e-1)" "unprognostic (1.42e-1)" "unprognostic (4.96e-3)" "unprognostic (9.26e-2)" "unprognostic (4.13e-2)" "unprognostic (5.80e-2)" "unprognostic (1.17e-1)" "unprognostic (1.41e-1)" "unprognostic (5.36e-2)" "unprognostic (8.73e-3)" "unprognostic (2.13e-1)" "unprognostic (1.21e-1)" "unprognostic (1.24e-1)" 39.0 26.9 35.5 25.3 27.8 13.2 19.3 22.2 41.0 25.7 16.7 35.7 16.2 11.4 21.8 21.3 19.6 14.1 19.3 18.9 40.7 26.0 21.0 19.1 24.4 30.7 36.2 11.2 22.4 10.9 17.0 14.6 22.8 20.3 22.5 15.5 25.7 24.3 16.4 30.9 18.1 19.3 18.2 36.8 33.8 15.2 32.4 33.1 25.0 20.3 23.4 32.1 25.3 17.0 16.1 10.8 14.9 12.2 10.7 18.7 8.0 14.7 4.4 9.6 9.0 22.2 22.2 23.9 10.3 16.4 8.5 12.6 6.0 8.2 30.2 10.7 16.2 14.1 12.4 9.9 12.9 34.1 7.8 26.9 7.6 7.2 20.9 15.2 24.8 18.0 9.2 14.8 20.2 15.8 16.6 13.8 12.9 7.2 12.2 8.3 13.1 7.2 10.0 14.5 6.6 11.2 18.4 6.6 9.2 12.3 21.9 17.9 8.9 10.8 21.8 7.9 8.5 15.8 8.6 16.5 16.7 20.4 11.7 17.3 6.9 14.9 10.1 11.6 10.1 10.7 15.3 16.1 12.2 15.6 10.8 10.0 7.3 10.5 7.8 10.7 12.2 7.1 18.7 8.0 35.5 27.8 22.2 41.0 40.7 26.0 36.2 11.2 20.3 33.1 ERBB2 "CD340, HER-2, HER2, NEU, NGL" ENSG00000141736 "Erb-b2 receptor tyrosine kinase 2" P04626 17 39687914-39730426 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Transcription, Transcription regulation" "Activator, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enriched" "Detected in many" 27 "SK-BR-3: 263.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "gdT-cell: 8.8" "Lineage enriched" "Detected in many" 4 "T-cells: 8.8" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB000043, HPA001060, HPA001338, HPA001383, CAB020416, CAB062555" Enhanced Supported "Plasma membrane,Cytosol" 430000 "Plasma membrane" Cytosol "CAB000043: AB_2335701, CAB020416: AB_442047, CAB062555: , HPA001060: , HPA001338: , HPA001383: AB_1078500" "unprognostic (1.97e-1)" "unprognostic (6.60e-3)" "unprognostic (6.21e-2)" "prognostic unfavourable (8.99e-8)" "unprognostic (2.96e-2)" "unprognostic (1.40e-2)" "unprognostic (1.97e-2)" "unprognostic (9.04e-2)" "unprognostic (1.79e-2)" "unprognostic (1.20e-3)" "prognostic unfavourable (9.17e-4)" "unprognostic (3.92e-1)" "prognostic favourable (2.41e-14)" "unprognostic (9.29e-2)" "unprognostic (1.40e-1)" "unprognostic (3.75e-2)" "unprognostic (1.96e-1)" 5.8 2.4 5.2 10.4 7.0 0.1 20.1 4.2 7.0 19.1 46.5 9.1 55.2 21.6 14.9 18.7 40.9 22.7 26.6 24.8 6.3 3.1 37.5 21.5 17.6 3.7 5.1 5.6 19.3 16.2 27.7 8.1 60.8 7.5 23.6 16.6 15.9 28.7 58.1 8.9 35.3 47.2 10.9 4.5 4.0 17.1 6.5 3.7 2.8 35.7 20.8 22.9 19.7 20.3 1.3 0.3 2.1 0.4 0.9 8.8 2.2 3.1 3.8 4.2 2.7 5.1 3.6 5.7 2.2 3.7 4.9 4.2 2.8 8.6 0.2 4.6 5.1 9.8 0.2 5.1 2.3 0.4 3.2 0.1 3.0 4.5 3.0 0.0 0.0 3.5 4.8 3.0 1.8 2.0 0.4 0.1 3.6 4.8 0.5 0.2 7.6 0.9 0.3 1.7 0.4 5.0 9.8 0.8 0.2 4.2 263.9 1.3 7.4 0.1 0.2 2.5 3.3 3.2 1.4 0.4 0.2 0.2 0.2 0.0 8.2 1.6 0.4 0.8 8.8 0.3 0.7 0.9 0.5 2.5 0.3 1.3 1.0 2.5 2.1 0.9 0.2 0.2 0.4 2.2 5.2 7.0 4.2 7.0 6.3 3.1 5.1 5.6 7.5 3.7 ERBB3 "HER3, LCCS2" ENSG00000065361 "Erb-b2 receptor tyrosine kinase 3" P21860 12 56076799-56103505 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "Hep G2: 31.1;MCF7: 20.3;RT4: 24.3;SK-BR-3: 28.6;SK-MEL-30: 38.1;T-47d: 31.7;WM-115: 40.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "basophil: 5.3" "Lineage enriched" "Detected in many" 4 "granulocytes: 5.3" "Low region specificity" "Detected in many" "CAB025331, HPA045396" Uncertain Approved "Plasma membrane,Actin filaments" "Secreted - unknown location" 420000 "Actin filaments" "Plasma membrane" "CAB025331: , HPA045396: " "unprognostic (2.97e-1)" "unprognostic (2.71e-2)" "unprognostic (1.91e-1)" "unprognostic (8.97e-2)" "unprognostic (1.63e-1)" "unprognostic (1.07e-3)" "unprognostic (2.31e-3)" "unprognostic (2.66e-2)" "unprognostic (9.89e-2)" "unprognostic (4.30e-2)" "unprognostic (4.76e-3)" "unprognostic (5.77e-2)" "unprognostic (1.06e-2)" "unprognostic (4.56e-2)" "unprognostic (1.57e-1)" "unprognostic (6.72e-3)" "unprognostic (2.07e-2)" 1.1 1.4 11.6 12.6 16.5 0.6 26.8 2.0 16.7 6.8 40.5 40.3 12.0 37.7 2.8 7.5 29.4 5.7 22.9 3.4 18.6 9.0 16.5 33.9 13.4 0.5 23.5 9.3 0.9 21.5 11.4 1.0 15.4 14.9 16.8 29.7 5.5 36.8 22.3 1.1 30.7 41.3 3.2 27.4 0.5 32.9 1.2 23.8 0.0 4.5 7.4 8.5 11.8 14.4 0.9 0.7 5.3 0.6 1.2 1.2 0.2 10.1 0.6 0.8 0.3 0.0 0.0 16.5 0.8 1.9 1.1 1.1 5.5 18.3 0.0 0.2 0.2 8.6 1.2 1.9 0.6 0.2 0.8 0.0 0.3 31.1 0.0 0.0 0.1 0.4 2.5 0.2 0.0 0.0 0.7 0.3 0.1 20.3 0.1 0.3 2.8 0.4 0.1 1.9 0.5 2.1 24.3 0.9 0.3 0.7 28.6 38.1 31.7 0.1 0.0 0.1 1.1 0.6 0.1 0.3 0.1 0.1 0.1 0.0 40.5 5.3 0.4 0.8 0.9 0.4 0.4 0.4 0.7 0.3 0.3 0.9 0.6 1.2 3.3 1.2 0.6 0.7 0.8 0.2 11.6 16.5 2.0 16.7 18.6 9.0 23.5 9.3 14.9 23.8 ERBB4 "ALS19, HER4" ENSG00000178568 "Erb-b2 receptor tyrosine kinase 4" Q15303 2 211375717-212538841 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Apoptosis, Lactation, Transcription, Transcription regulation" "Activator, Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Amyotrophic lateral sclerosis, Cancer-related genes, Disease mutation, FDA approved drug targets, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "fallopian tube: 24.5" "Cell line enhanced" "Detected in some" "AF22: 9.4;EFO-21: 7.0;HEK 293: 5.2;RPTEC TERT1: 7.7;SCLC-21H: 4.3;T-47d: 6.9" "Cancer enhanced" "Detected in many" "breast cancer: 4.1" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000276, HPA012016, CAB025522" Enhanced 140000 "CAB000276: , CAB025522: , HPA012016: AB_1846541" "unprognostic (1.48e-1)" "unprognostic (3.28e-1)" "unprognostic (4.31e-3)" "unprognostic (1.76e-3)" "unprognostic (3.59e-1)" "unprognostic (2.75e-1)" "unprognostic (2.88e-1)" "unprognostic (9.56e-2)" "unprognostic (2.07e-1)" "unprognostic (4.67e-3)" "unprognostic (1.07e-1)" "unprognostic (3.61e-1)" "unprognostic (7.14e-3)" "unprognostic (1.49e-3)" "unprognostic (1.41e-1)" "unprognostic (1.14e-1)" "unprognostic (4.11e-2)" 1.6 1.9 15.1 1.2 15.0 1.0 13.4 18.6 14.1 7.8 1.1 7.6 8.8 1.1 1.5 1.2 1.3 24.5 1.2 7.0 14.3 6.5 11.9 1.1 2.9 1.2 7.8 10.7 1.3 2.4 10.8 5.1 1.3 8.8 1.7 1.1 2.0 9.7 18.1 3.8 1.8 1.2 1.1 7.3 1.2 1.5 7.6 12.0 0.0 4.5 1.1 1.2 1.4 0.7 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 9.4 0.2 0.0 0.0 0.0 0.0 0.3 0.5 0.1 0.0 0.0 0.0 7.0 1.0 0.4 0.2 0.0 0.0 0.1 5.2 0.0 1.7 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 7.7 0.4 4.3 0.2 0.0 0.1 0.1 6.9 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.1 15.0 18.6 14.1 14.3 6.5 7.8 10.7 8.8 12.0 ERC1 "CAST2, ELKS, KIAA1081, MGC12974, RAB6IP2" ENSG00000082805 "ELKS/RAB6-interacting/CAST family member 1" Q8IUD2 12 990509-1495933 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Protein transport, Transport" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019513, HPA019523, HPA024130" Approved Supported "Vesicles,Plasma membrane,Cytosol" Cytosol "Vesicles, Plasma membrane" "HPA019513: AB_1856012, HPA019523: AB_1856013, HPA024130: AB_1856014" "unprognostic (2.41e-1)" "unprognostic (4.00e-2)" "unprognostic (2.14e-1)" "unprognostic (5.70e-2)" "unprognostic (2.81e-1)" "unprognostic (1.32e-1)" "unprognostic (5.50e-2)" "unprognostic (8.49e-2)" "unprognostic (2.53e-1)" "unprognostic (3.26e-2)" "unprognostic (1.04e-1)" "unprognostic (6.79e-2)" "unprognostic (3.75e-3)" "unprognostic (4.19e-2)" "unprognostic (3.01e-1)" "unprognostic (7.37e-2)" "prognostic unfavourable (7.01e-4)" 12.6 11.4 10.3 12.5 14.7 7.4 15.1 41.7 10.4 11.2 11.9 8.5 9.2 4.3 17.1 11.0 13.7 9.8 9.9 14.7 10.0 11.2 11.2 8.0 8.8 5.4 9.0 6.4 12.5 8.6 24.3 19.4 13.2 10.7 11.4 7.5 10.1 9.3 14.4 9.2 9.9 6.4 22.1 8.5 7.3 8.6 11.0 9.9 9.8 15.3 7.2 8.6 15.7 15.3 8.6 2.9 2.1 3.8 1.1 3.5 0.5 2.9 7.3 3.9 2.6 10.4 8.8 5.4 9.2 7.4 6.3 5.8 6.4 3.6 4.5 1.3 11.9 5.0 8.3 7.1 8.8 9.5 4.2 11.1 7.3 3.2 7.9 5.7 2.6 7.1 6.2 11.1 20.8 8.1 3.3 9.0 4.7 3.2 1.8 1.2 6.2 3.5 3.6 14.8 1.4 6.2 5.3 2.3 4.6 14.4 3.3 5.2 3.4 2.4 15.0 10.9 11.1 8.0 8.6 2.4 4.5 6.7 7.1 3.4 4.8 1.4 2.8 2.1 1.6 1.0 2.2 8.6 2.4 2.4 2.4 5.6 3.5 2.6 2.1 1.1 3.8 2.9 2.2 0.5 10.3 14.7 41.7 10.4 10.0 11.2 9.0 6.4 10.7 9.9 ERCC1 RAD10 ENSG00000012061 "ERCC excision repair 1, endonuclease non-catalytic subunit" P07992 19 45407333-45478828 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "DNA damage, DNA repair" "DNA-binding, Endonuclease, Hydrolase, Nuclease" "Cancer-related genes, Cataract" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004390, HPA029773, HPA050182, CAB072859, CAB072860" Supported Enhanced Nucleoplasm Nucleoplasm "CAB004390: AB_2278023, CAB072859: , CAB072860: , HPA029773: AB_10602129, HPA050182: " "unprognostic (1.54e-3)" "unprognostic (5.99e-2)" "unprognostic (1.58e-1)" "unprognostic (1.34e-1)" "unprognostic (1.41e-3)" "unprognostic (1.97e-1)" "prognostic unfavourable (9.69e-4)" "unprognostic (2.57e-1)" "unprognostic (5.80e-2)" "unprognostic (7.37e-2)" "unprognostic (1.93e-2)" "unprognostic (2.75e-2)" "prognostic unfavourable (9.00e-5)" "unprognostic (6.19e-2)" "unprognostic (1.96e-1)" "unprognostic (1.60e-1)" "unprognostic (1.43e-1)" 25.0 28.2 25.9 20.2 27.5 20.8 30.6 28.4 34.8 26.4 21.5 35.4 20.6 20.8 27.4 34.6 28.6 30.9 24.0 63.5 24.7 24.4 22.9 24.2 21.3 26.3 28.3 25.0 37.6 42.9 31.6 32.0 20.3 27.4 29.1 17.1 29.1 53.8 24.4 43.3 43.5 20.4 26.1 23.5 24.3 22.4 21.6 26.7 22.6 28.4 25.7 25.1 22.0 26.0 16.6 69.0 5.3 29.7 12.6 14.2 17.9 13.7 23.7 20.1 29.4 13.8 26.3 6.4 20.6 27.6 25.1 33.4 2.6 13.5 8.1 5.8 21.9 10.6 6.4 65.7 15.5 17.7 6.5 12.1 9.0 8.0 28.9 12.2 22.8 19.6 14.1 26.2 23.7 27.2 7.4 16.3 39.3 9.2 11.5 9.8 4.7 9.4 17.4 9.4 10.9 18.4 8.8 8.6 18.2 13.1 11.2 18.0 13.6 23.4 15.6 22.6 21.6 13.8 20.8 12.1 9.7 8.7 26.0 10.6 68.1 4.7 29.2 5.3 14.2 29.7 9.6 16.4 8.7 11.0 29.3 16.6 7.0 11.3 4.0 12.6 21.8 69.0 10.2 17.9 25.9 27.5 28.4 34.8 24.7 24.4 28.3 25.0 27.4 26.7 ERCC2 "EM9, MAG, MGC102762, MGC126218, MGC126219, TFIIH, XPD" ENSG00000104884 "ERCC excision repair 2, TFIIH core complex helicase subunit" P18074 19 45349837-45370918 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Chromosome partition, DNA damage, DNA repair, Host-virus interaction, Transcription, Transcription regulation" "DNA-binding, Helicase, Hydrolase" "Cancer-related genes, Cataract, Cockayne syndrome, Deafness, Disease mutation, Dwarfism, Ichthyosis, Xeroderma pigmentosum" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB005375, HPA038057, HPA069266" Approved Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "CAB005375: AB_2100152, HPA038057: , HPA069266: " "unprognostic (1.10e-1)" "unprognostic (5.48e-1)" "unprognostic (5.08e-2)" "unprognostic (9.92e-3)" "unprognostic (1.35e-1)" "unprognostic (1.23e-2)" "unprognostic (1.67e-3)" "unprognostic (1.46e-1)" "unprognostic (3.41e-1)" "unprognostic (1.06e-1)" "prognostic favourable (3.26e-4)" "unprognostic (3.36e-2)" "unprognostic (2.44e-3)" "unprognostic (1.94e-1)" "unprognostic (5.47e-1)" "unprognostic (8.99e-2)" "unprognostic (3.45e-2)" 7.4 15.6 11.4 10.6 17.7 6.7 7.1 9.5 23.8 9.4 8.1 11.7 7.8 7.9 11.7 6.0 6.7 10.0 10.1 7.9 9.4 9.1 8.7 13.2 6.5 9.9 8.2 10.5 9.5 13.1 12.9 10.9 7.2 14.0 8.2 6.4 12.5 9.5 11.8 15.9 10.7 7.1 11.2 5.3 9.7 8.3 17.2 7.8 10.8 10.2 5.1 8.3 9.3 6.6 7.8 17.2 5.0 13.9 11.3 9.8 8.7 12.3 6.0 12.6 17.7 7.5 8.9 6.7 17.6 12.1 22.8 17.5 14.0 8.5 4.4 10.1 17.1 6.4 8.8 14.8 8.7 10.6 14.5 7.5 11.5 14.7 15.9 11.9 13.3 10.2 2.3 26.0 14.8 13.2 18.2 5.0 15.7 6.0 7.0 7.9 5.8 10.6 13.5 8.9 3.7 6.5 10.9 7.4 8.0 15.6 11.1 6.2 10.5 15.8 17.1 21.8 11.9 9.2 39.1 11.6 6.7 6.4 6.4 7.3 9.6 0.0 13.3 5.0 7.7 13.9 9.8 7.8 7.4 7.4 17.2 5.8 7.1 7.4 0.4 11.3 10.9 8.3 7.4 8.7 11.4 17.7 9.5 23.8 9.4 9.1 8.2 10.5 14.0 7.8 ERCC3 "BTF2, GTF2H, RAD25, TFIIH, XPB" ENSG00000163161 "ERCC excision repair 3, TFIIH core complex helicase subunit" P19447 2 127257290-127294176 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "DNA damage, DNA repair, Host-virus interaction, Transcription, Transcription regulation" "DNA-binding, Helicase, Hydrolase" "Cancer-related genes, Cockayne syndrome, Deafness, Disease mutation, Dwarfism, Ichthyosis, Xeroderma pigmentosum" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB037153, HPA046077" Approved Enhanced Nucleoplasm Nucleoplasm "CAB037153: AB_796181, HPA046077: " "unprognostic (2.31e-1)" "unprognostic (1.15e-1)" "unprognostic (3.03e-2)" "unprognostic (1.07e-3)" "unprognostic (1.05e-1)" "unprognostic (8.85e-2)" "prognostic unfavourable (1.62e-7)" "unprognostic (2.74e-1)" "unprognostic (9.13e-3)" "unprognostic (9.25e-2)" "unprognostic (1.25e-1)" "unprognostic (2.46e-2)" "prognostic unfavourable (4.30e-6)" "unprognostic (3.71e-1)" "unprognostic (8.50e-2)" "unprognostic (5.73e-2)" "unprognostic (3.92e-2)" 17.4 20.0 26.1 23.8 28.9 20.5 21.0 35.9 32.0 22.1 19.4 19.7 17.1 11.5 21.6 15.7 19.1 23.6 20.4 20.4 23.2 18.8 17.5 17.4 19.4 23.1 19.7 25.8 23.3 22.4 32.0 26.4 16.3 21.5 20.1 17.1 18.3 18.0 21.8 30.1 19.7 17.3 26.1 16.0 24.5 17.4 39.5 20.1 24.1 19.3 15.8 25.9 22.4 20.8 11.8 13.9 7.2 9.7 18.8 16.2 11.7 21.8 15.1 18.6 19.7 20.8 14.2 23.1 20.1 26.2 32.6 31.6 22.9 16.0 16.6 16.7 18.3 19.6 28.4 21.2 28.4 25.9 25.4 20.8 18.4 24.2 15.4 18.1 22.7 14.7 19.9 37.7 16.1 20.9 20.2 10.9 20.5 21.6 25.7 19.5 27.1 23.5 21.2 21.4 13.7 18.2 20.4 22.6 24.4 17.2 26.2 26.3 14.1 20.8 16.6 19.6 22.5 17.8 23.9 19.5 38.1 26.0 17.3 8.7 20.9 6.6 9.5 7.2 16.0 9.7 16.2 11.5 11.8 13.5 13.9 11.8 15.8 10.9 3.1 18.8 7.9 11.3 16.1 11.7 26.1 28.9 35.9 32.0 23.2 18.8 19.7 25.8 21.5 20.1 ERCC4 "FANCQ, RAD1, XPF" ENSG00000175595 "ERCC excision repair 4, endonuclease catalytic subunit" Q92889 16 13920157-13952345 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA repair" "DNA-binding, Endonuclease, Hydrolase, Nuclease" "Cancer-related genes, Cockayne syndrome, Disease mutation, Dwarfism, Fanconi anemia, Xeroderma pigmentosum" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000156, HPA045828" Approved Supported "Nucleoplasm,Nuclear bodies,Cell Junctions" "Nucleoplasm, Nuclear bodies" "Cell Junctions" "CAB000156: , HPA045828: " "unprognostic (2.05e-1)" "unprognostic (1.52e-1)" "unprognostic (2.12e-3)" "unprognostic (9.41e-2)" "unprognostic (3.35e-1)" "unprognostic (1.40e-2)" "unprognostic (1.64e-2)" "unprognostic (2.26e-1)" "unprognostic (3.59e-1)" "unprognostic (1.56e-1)" "unprognostic (1.18e-1)" "unprognostic (8.49e-2)" "unprognostic (5.26e-2)" "unprognostic (1.67e-1)" "unprognostic (1.15e-1)" "unprognostic (6.30e-2)" "unprognostic (5.88e-4)" 8.4 12.7 8.6 7.0 11.3 5.3 6.4 8.9 9.7 8.1 6.7 9.9 6.0 4.1 8.5 6.8 6.7 8.5 6.8 7.8 7.2 7.1 6.9 7.2 6.9 6.8 10.5 8.8 9.9 7.6 13.3 13.0 5.9 9.6 8.3 5.4 7.1 6.4 7.0 31.3 6.9 5.7 8.5 10.3 7.7 6.6 14.2 8.9 13.7 9.7 5.6 6.4 9.1 7.8 8.4 7.9 8.3 6.8 8.9 7.4 2.6 5.4 7.0 6.4 9.2 10.7 10.1 5.0 7.2 7.7 6.5 8.3 2.4 5.4 9.1 10.4 6.3 6.9 9.5 4.9 10.1 12.3 5.6 4.5 7.8 6.0 9.8 6.0 5.1 7.6 6.9 8.6 7.3 8.6 7.0 10.7 9.1 4.5 8.0 4.1 4.7 3.7 9.2 13.0 11.2 4.0 3.7 5.3 6.3 8.8 7.2 6.7 9.1 4.6 9.7 9.6 7.1 8.6 6.3 9.5 11.1 6.3 9.2 7.3 9.7 8.3 6.2 5.4 6.8 6.8 7.4 6.2 6.4 5.1 5.5 8.4 6.4 6.9 7.2 8.9 5.7 7.9 5.8 2.6 8.6 11.3 8.9 9.7 7.2 7.1 10.5 8.8 9.6 8.9 ERCC5 "ERCM2, XPGC" ENSG00000134899 "ERCC excision repair 5, endonuclease" P28715 13 102807146-102876001 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA repair" "DNA-binding, Endonuclease, Hydrolase, Nuclease" "Cancer-related genes, Cockayne syndrome, Deafness, Disease mutation, Dwarfism, Xeroderma pigmentosum" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA045845, HPA050126, HPA050374" Supported Enhanced Nucleoplasm Nucleoplasm "HPA045845: , HPA050126: , HPA050374: " "unprognostic (1.28e-3)" "unprognostic (1.32e-3)" "unprognostic (1.86e-2)" "unprognostic (9.28e-3)" "unprognostic (6.19e-2)" "unprognostic (8.73e-2)" "unprognostic (1.23e-1)" "unprognostic (8.72e-2)" "unprognostic (2.52e-1)" "unprognostic (2.55e-1)" "unprognostic (7.77e-3)" "unprognostic (5.76e-3)" "prognostic unfavourable (2.96e-6)" "unprognostic (3.56e-2)" "unprognostic (1.56e-1)" "unprognostic (1.67e-1)" "prognostic favourable (6.82e-4)" 22.3 19.1 15.9 16.1 17.8 23.7 20.1 26.4 20.8 19.7 27.0 17.9 27.0 25.0 22.1 25.7 21.0 15.1 21.1 15.4 14.6 13.1 18.7 28.1 19.9 26.4 17.1 16.2 22.9 22.3 15.7 25.6 17.9 19.0 20.1 23.1 15.9 20.5 24.7 14.6 25.8 31.1 17.0 19.4 30.6 21.9 14.0 17.8 40.8 21.8 16.6 26.0 22.4 19.6 10.1 10.8 23.4 17.4 17.7 17.5 12.0 14.7 5.4 10.8 6.7 21.5 20.2 6.5 14.9 19.9 8.7 11.3 8.2 20.6 9.3 7.5 15.1 15.4 9.5 13.7 9.1 14.0 5.3 13.8 15.6 7.2 10.5 28.0 18.0 19.2 13.2 10.0 15.6 15.1 6.4 8.5 15.2 4.0 15.1 19.5 4.6 7.5 8.2 8.0 9.3 17.9 8.2 7.2 10.7 7.8 13.2 8.0 11.8 26.2 15.2 6.7 3.4 5.6 9.4 12.4 3.7 4.7 26.2 11.4 8.4 23.4 9.8 18.3 16.7 12.3 15.5 9.6 15.5 17.5 10.8 10.1 16.6 16.1 7.2 17.7 17.4 7.7 16.6 12.0 15.9 17.8 26.4 20.8 14.6 13.1 17.1 16.2 19.0 17.8 ERCC6 "ARMD5, CKN2, CSB, RAD26" ENSG00000225830 "ERCC excision repair 6, chromatin remodeling factor" "Q03468, P0DP91, Q8N328" 10 49455368-49539538 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA repair, Neurogenesis, Transcription, Transcription regulation" "DNA-binding, Helicase, Hydrolase" "Age-related macular degeneration, Cancer-related genes, Cataract, Cockayne syndrome, Deafness, Disease mutation, Dwarfism, Mental retardation, Premature ovarian failure, Xeroderma pigmentosum" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "hTERT-HME1: 34.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA071297 Approved "Nucleoplasm,Nuclear bodies" Nucleoplasm "Nuclear bodies" "HPA071297: " "unprognostic (1.92e-2)" "unprognostic (1.85e-1)" "unprognostic (9.79e-3)" "unprognostic (7.26e-2)" "unprognostic (5.45e-2)" "unprognostic (2.95e-2)" "unprognostic (3.03e-2)" "unprognostic (2.99e-2)" "unprognostic (1.71e-2)" "unprognostic (1.13e-1)" "unprognostic (1.80e-1)" "unprognostic (4.57e-2)" "unprognostic (1.04e-1)" "unprognostic (8.61e-2)" "unprognostic (4.75e-2)" "unprognostic (1.73e-1)" "unprognostic (7.05e-2)" 7.9 6.9 11.5 6.0 12.3 13.9 11.1 21.0 13.9 9.8 7.0 8.9 10.6 6.4 9.3 8.6 13.5 8.1 7.7 9.1 12.7 6.5 10.1 10.0 8.0 7.9 9.2 11.4 12.5 13.1 20.3 14.2 9.7 10.1 10.5 8.8 9.2 10.5 13.7 9.6 14.4 9.1 7.9 11.8 9.2 7.6 7.8 12.4 7.8 13.6 8.2 9.6 9.9 11.6 7.9 5.1 10.9 8.1 1.6 5.3 2.1 6.6 3.5 2.6 1.6 4.5 7.6 2.1 11.9 16.5 8.2 5.8 3.6 4.1 2.9 2.2 10.7 6.2 3.7 9.4 8.3 4.6 2.4 2.2 13.1 2.0 2.6 3.0 2.3 2.6 12.9 8.0 34.2 11.9 4.3 0.8 10.6 4.9 2.1 1.7 2.4 6.2 2.0 3.8 1.7 2.8 4.7 3.5 3.6 8.8 3.2 5.3 5.8 1.7 22.8 4.6 3.8 5.5 3.0 3.2 3.0 2.8 5.6 3.3 3.4 10.9 4.1 9.7 5.3 3.7 4.2 7.9 3.1 2.9 5.1 6.3 3.8 1.8 9.8 1.6 8.1 2.8 4.0 2.1 11.5 12.3 21.0 13.9 12.7 6.5 9.2 11.4 10.1 12.4 ERG "erg-3, p55" ENSG00000157554 "ERG, ETS transcription factor" P11308 21 38380027-38661780 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Group enriched" "Detected in some" 5 "HUVEC TERT2: 42.7;MOLT-4: 14.0;REH: 45.3;TIME: 34.6" "Cancer enhanced" "Detected in all" "prostate cancer: 18.6" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 5 "myeloid DC: 1.7;NK-cell: 1.0" "Group enriched" "Detected in many" 5 "dendritic cells: 1.7;NK-cells: 1.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB018377, HPA046598" Approved Approved Nucleoplasm,Cytosol Nucleoplasm Cytosol "CAB018377: AB_675518, HPA046598: " "unprognostic (2.14e-1)" "prognostic unfavourable (6.18e-6)" "unprognostic (6.44e-3)" "unprognostic (8.64e-3)" "unprognostic (5.65e-2)" "unprognostic (1.91e-1)" "unprognostic (9.03e-4)" "unprognostic (4.30e-2)" "unprognostic (2.63e-2)" "unprognostic (1.29e-1)" "unprognostic (3.42e-2)" "unprognostic (2.89e-1)" "prognostic unfavourable (3.94e-4)" "unprognostic (4.31e-3)" "unprognostic (3.88e-2)" "unprognostic (2.64e-2)" "unprognostic (5.63e-3)" 39.1 4.2 5.7 6.5 8.5 6.6 20.5 3.6 7.0 17.9 5.2 2.3 5.6 3.3 16.9 9.0 6.2 9.2 11.6 10.1 6.2 3.6 10.8 6.0 19.9 7.4 8.0 1.8 7.7 4.8 2.3 3.9 23.2 8.0 8.1 3.6 7.8 4.2 5.6 13.5 5.3 6.2 11.8 4.7 32.5 5.0 4.8 5.0 2.4 10.8 9.1 3.6 9.6 15.8 0.0 1.7 0.0 0.2 1.0 0.0 0.4 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.5 0.0 0.0 0.0 7.0 0.0 0.0 0.3 0.0 42.7 0.0 0.0 0.0 0.3 14.0 0.0 0.1 0.0 45.3 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 34.6 0.2 0.7 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.4 5.7 8.5 3.6 7.0 6.2 3.6 8.0 1.8 8.0 5.0 ESR1 "ER-alpha, Era, ESR, NR3A1" ENSG00000091831 "Estrogen receptor 1" P03372 6 151656691-152129619 "Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Receptor" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "cervix, uterine: 64.5;endometrium 1: 68.9" "Group enriched" "Detected in some" 9 "MCF7: 24.3;T-47d: 31.5" "Group enriched" "Detected in many" 9 "breast cancer: 40.2;endometrial cancer: 24.3;ovarian cancer: 8.7" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "naive CD4 T-cell: 2.5" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in single" "Low region specificity" "Detected in many" "CAB000037, HPA000449, HPA000450, CAB055099, CAB072858" Enhanced Approved Nucleoplasm,Vesicles Vesicles Nucleoplasm "CAB000037: AB_563706, CAB055099: AB_2101946, CAB072858: , HPA000449: AB_1078753, HPA000450: AB_1078754" "unprognostic (8.28e-2)" "unprognostic (3.02e-2)" "unprognostic (1.43e-2)" "prognostic favourable (5.47e-7)" "unprognostic (4.79e-1)" "unprognostic (2.43e-3)" "unprognostic (4.10e-5)" "unprognostic (9.92e-2)" "unprognostic (2.20e-1)" "unprognostic (7.17e-2)" "unprognostic (7.35e-2)" "unprognostic (3.45e-1)" "unprognostic (1.20e-2)" "unprognostic (7.91e-3)" "unprognostic (6.45e-2)" "unprognostic (1.25e-1)" "unprognostic (1.52e-1)" 3.0 0.9 0.5 1.6 0.5 0.2 16.2 0.8 0.4 64.5 1.5 0.2 2.2 0.1 68.9 27.7 1.1 26.7 1.9 1.1 0.5 0.8 1.5 6.6 3.6 1.6 0.4 0.1 14.2 0.4 0.0 9.3 0.9 0.6 3.6 0.1 2.6 1.6 4.1 2.0 0.6 0.5 20.8 0.4 1.6 0.3 1.9 0.4 1.9 1.3 2.2 2.5 3.8 23.7 0.6 1.0 0.0 0.8 0.3 2.5 1.0 0.3 0.0 0.1 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.1 0.0 0.0 0.6 0.0 24.3 0.0 0.0 0.0 0.0 0.7 0.0 0.4 0.0 1.8 0.0 0.0 0.0 0.3 0.0 31.5 0.0 0.0 0.1 0.1 0.3 0.0 2.9 0.5 0.0 0.1 0.2 0.0 0.0 0.8 0.0 0.3 0.2 1.0 0.6 1.3 0.4 1.0 0.4 2.5 0.9 0.0 0.3 0.0 0.0 0.3 1.0 0.5 0.5 0.8 0.4 0.5 0.8 0.4 0.1 0.6 0.4 ESR2 "ER-beta, Erb, NR3A2" ENSG00000140009 "Estrogen receptor 2" Q92731 14 64084232-64338112 "Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Receptor" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "ovary: 19.1;testis: 30.2;vagina: 14.3" "Cell line enhanced" "Detected in some" "U-266/70: 10.5;U-698: 17.2" "Not detected" "Not detected" "Low region specificity" "Detected in some" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in some" "Region enriched" "Detected in many" 5 "cerebellum: 17.8" CAB079300 Enhanced "CAB079300: " "unprognostic (7.63e-3)" "unprognostic (2.28e-3)" "unprognostic (8.27e-3)" "unprognostic (5.41e-2)" "unprognostic (2.91e-2)" "unprognostic (1.06e-1)" "unprognostic (1.80e-1)" "unprognostic (4.38e-2)" "unprognostic (1.95e-1)" "unprognostic (8.75e-2)" "unprognostic (2.57e-2)" "unprognostic (1.65e-1)" "unprognostic (3.03e-5)" "unprognostic (1.57e-1)" "unprognostic (1.66e-1)" "unprognostic (4.21e-2)" "unprognostic (5.89e-2)" 2.1 9.4 0.2 2.3 0.8 1.0 3.7 0.8 0.6 1.3 2.9 0.6 0.2 1.4 1.7 0.7 1.7 1.1 0.6 1.0 1.1 0.4 1.4 0.7 1.3 2.8 0.2 0.2 19.1 2.5 0.0 1.6 0.7 1.4 2.2 1.5 0.5 1.5 0.9 1.4 1.2 1.5 0.6 1.0 3.0 1.3 30.2 0.6 5.0 0.6 0.2 2.9 1.8 14.3 2.4 4.0 1.1 0.3 0.4 1.3 0.2 0.7 0.3 0.7 0.6 0.0 0.1 1.3 0.1 0.0 0.1 0.1 0.2 0.8 2.8 0.1 0.0 1.0 0.9 0.0 0.1 0.7 0.3 0.3 0.7 0.1 0.1 0.1 0.2 0.0 0.0 0.1 0.2 0.2 0.6 4.0 0.1 0.7 0.4 0.2 0.7 0.4 0.5 0.3 0.2 0.1 1.3 2.4 0.7 0.5 0.2 1.1 0.8 0.0 0.4 0.5 0.9 0.2 0.1 10.5 3.2 17.2 0.2 0.1 0.7 0.3 0.3 1.0 0.8 0.2 0.6 1.7 0.6 1.1 0.1 2.4 1.3 1.0 1.1 0.4 0.2 4.0 0.5 0.2 0.2 0.8 0.8 0.6 1.1 0.4 0.2 0.2 1.4 0.6 ETNK1 "EKI, EKI1" ENSG00000139163 "Ethanolamine kinase 1" Q9HBU6 12 22625075-22690665 "Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins" "Lipid biosynthesis, Lipid metabolism, Phospholipid biosynthesis, Phospholipid metabolism" "Kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA010712, HPA029407" Approved Supported "Nucleoplasm,Plasma membrane,Cytosol" "Plasma membrane, Cytosol" Nucleoplasm "HPA010712: , HPA029407: " "unprognostic (2.06e-1)" "unprognostic (7.48e-2)" "unprognostic (1.23e-3)" "unprognostic (2.19e-1)" "unprognostic (8.79e-3)" "unprognostic (1.31e-2)" "prognostic unfavourable (5.85e-4)" "unprognostic (3.98e-3)" "unprognostic (8.30e-2)" "unprognostic (7.97e-3)" "unprognostic (2.01e-1)" "unprognostic (1.64e-2)" "unprognostic (4.53e-3)" "unprognostic (2.77e-1)" "unprognostic (2.91e-1)" "unprognostic (3.01e-1)" "prognostic favourable (1.75e-4)" 15.7 17.7 15.2 41.1 19.4 13.7 16.9 19.7 22.2 12.9 33.2 16.4 14.6 27.2 16.6 24.1 14.7 13.1 27.3 10.4 15.6 23.9 22.0 30.2 19.6 18.5 17.2 15.8 17.2 14.9 15.8 30.6 13.4 18.9 13.8 19.5 15.9 16.7 14.7 8.2 17.8 24.5 10.0 17.1 18.3 53.7 22.3 17.5 33.4 17.6 8.2 16.5 14.2 18.6 16.2 10.7 28.1 17.6 14.0 15.7 13.4 6.7 14.0 15.5 14.3 11.2 11.4 11.6 8.0 6.0 8.3 8.5 10.8 17.0 20.0 7.2 5.2 5.1 13.6 3.8 14.9 16.6 11.0 16.5 6.1 9.2 10.7 15.8 15.2 7.4 3.7 11.1 9.5 10.2 19.8 8.5 10.9 4.6 17.2 32.2 30.0 9.1 15.6 13.8 16.1 13.7 9.1 5.0 8.8 8.7 7.5 12.5 11.8 15.3 8.8 6.6 10.6 8.9 12.0 6.2 7.7 21.5 8.4 10.3 11.0 28.1 11.7 12.1 12.9 17.5 12.7 16.2 14.1 11.9 10.7 13.0 15.7 15.5 11.5 14.0 17.6 9.7 15.3 13.4 15.2 19.4 19.7 22.2 15.6 23.9 17.2 15.8 18.9 17.5 ETV1 ER81 ENSG00000006468 "ETS variant 1" P50549 7 13891228-13991425 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 90.0;salivary gland: 45.8" "Cell line enhanced" "Detected in many" "AN3-CA: 22.2;SCLC-21H: 26.3;U-87 MG: 51.9;WM-115: 25.6" "Cancer enhanced" "Detected in all" "glioma: 22.5" "Region enriched" "Detected in all" 8 "cerebellum: 90.0" "Cell type enriched" "Detected in single" 5 "T-reg: 3.1" "Lineage enriched" "Detected in single" 5 "T-cells: 3.1" "Low region specificity" "Detected in all" "Region enhanced" "Detected in all" "cerebellum: 418.9" "HPA068389, HPA077249" Supported Approved Nucleoplasm Nucleoplasm "HPA068389: , HPA077249: " "unprognostic (2.45e-1)" "unprognostic (1.01e-1)" "unprognostic (6.98e-2)" "unprognostic (1.04e-1)" "unprognostic (1.49e-2)" "unprognostic (2.13e-2)" "unprognostic (1.64e-7)" "unprognostic (7.08e-3)" "unprognostic (7.21e-2)" "unprognostic (2.36e-1)" "unprognostic (2.01e-1)" "unprognostic (3.02e-1)" "unprognostic (1.51e-3)" "unprognostic (2.21e-2)" "unprognostic (2.05e-1)" "unprognostic (1.05e-1)" "unprognostic (1.20e-2)" 2.5 12.4 8.1 1.1 11.7 0.2 4.4 90.0 35.2 1.4 2.4 3.1 0.1 1.2 2.4 1.3 1.5 1.1 9.2 18.0 7.0 4.5 2.1 2.0 14.9 0.7 4.5 6.9 1.0 1.6 11.4 7.4 1.9 8.3 3.1 2.4 0.9 45.8 7.1 0.9 1.5 1.9 2.0 3.5 4.5 1.7 4.5 2.9 0.3 6.5 0.9 4.7 1.8 1.3 0.0 0.0 0.0 0.6 0.0 3.1 0.2 0.0 1.6 11.7 22.2 4.1 12.2 0.0 1.0 3.9 0.6 2.6 0.0 5.3 0.0 1.2 1.8 0.1 0.4 1.2 1.4 0.3 0.5 0.6 1.0 0.0 2.4 3.8 1.5 3.6 0.0 7.6 0.6 5.0 3.4 0.1 4.7 0.0 0.0 0.0 17.5 11.8 0.0 7.1 0.9 7.9 0.1 26.3 5.1 0.0 0.4 6.3 0.4 0.1 2.7 2.3 0.7 4.5 4.3 4.0 1.2 0.0 51.9 0.2 25.6 0.0 0.2 0.0 0.1 0.6 0.3 0.0 0.3 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.1 0.2 8.1 11.7 90.0 10.9 7.0 4.5 4.5 6.9 8.3 2.9 ETV4 "E1A-F, E1AF, PEA3" ENSG00000175832 "ETS variant 4" P43268 17 43527844-43579620 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "gallbladder: 38.4" "Cell line enhanced" "Detected in many" "AN3-CA: 45.0;Hep G2: 42.2;SK-MEL-30: 48.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in single" "neutrophil: 1.3" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" HPA005768 Approved Supported Nucleoli Nucleoli "HPA005768: AB_1848294" "unprognostic (2.32e-1)" "unprognostic (7.33e-2)" "unprognostic (2.14e-1)" "unprognostic (2.51e-1)" "unprognostic (1.97e-2)" "unprognostic (3.14e-3)" "prognostic unfavourable (2.48e-4)" "unprognostic (1.58e-2)" "unprognostic (5.34e-2)" "unprognostic (8.13e-2)" "unprognostic (7.05e-2)" "unprognostic (3.01e-1)" "unprognostic (7.79e-2)" "unprognostic (2.03e-1)" "unprognostic (7.08e-2)" "prognostic favourable (7.60e-4)" "unprognostic (1.69e-1)" 0.6 2.4 1.4 0.9 1.4 0.0 6.8 1.6 8.3 3.6 3.3 0.4 1.3 5.7 3.4 2.2 9.9 2.4 38.4 2.6 1.8 1.3 7.8 1.4 2.5 0.4 2.3 1.1 1.2 23.8 19.3 19.7 11.6 2.7 4.7 1.6 1.7 4.9 4.5 1.3 6.7 3.8 1.2 1.8 0.5 3.6 1.3 0.5 0.3 6.6 15.0 12.1 3.1 5.3 0.2 0.0 1.3 0.2 0.0 0.6 0.1 5.9 16.7 20.5 45.0 0.8 5.3 4.5 1.9 5.3 3.8 3.9 9.4 8.5 0.0 1.1 1.0 10.9 0.6 10.0 3.4 0.2 0.1 0.5 2.6 42.2 1.1 11.4 5.3 0.9 0.3 14.5 9.0 8.1 11.7 0.0 7.8 2.3 0.0 20.2 29.6 28.0 24.4 2.4 14.3 8.4 4.3 0.0 18.3 0.5 1.1 48.7 0.2 3.4 3.7 2.7 13.4 4.0 5.4 1.8 11.2 0.0 4.9 2.2 15.8 0.0 0.0 0.0 0.0 0.2 0.5 0.2 0.1 0.0 0.0 0.0 0.2 0.6 1.3 0.0 0.0 0.0 0.0 0.1 1.4 1.4 1.6 3.6 1.8 1.3 2.3 1.1 2.7 0.5 ETV5 ERM ENSG00000244405 "ETS variant 5" P41161 3 186046308-186110318 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "parathyroid gland: 55.3" "Cell line enhanced" "Detected in many" "SK-MEL-30: 55.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "intermediate monocyte: 3.1" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009590, HPA063065" Approved Supported Nucleoplasm Nucleoplasm "CAB009590: AB_2101008, HPA063065: " "unprognostic (3.85e-1)" "unprognostic (5.81e-2)" "unprognostic (1.54e-2)" "unprognostic (3.30e-1)" "unprognostic (9.00e-2)" "unprognostic (2.56e-3)" "prognostic unfavourable (7.85e-9)" "unprognostic (3.52e-3)" "unprognostic (2.97e-1)" "unprognostic (1.22e-2)" "unprognostic (4.18e-2)" "unprognostic (1.48e-1)" "unprognostic (1.57e-3)" "unprognostic (6.80e-2)" "unprognostic (1.57e-1)" "unprognostic (3.58e-2)" "unprognostic (3.84e-3)" 5.8 30.3 13.2 5.5 21.7 1.6 11.3 12.1 35.2 4.7 3.0 15.7 1.3 5.1 6.8 6.2 3.8 4.6 4.8 8.8 13.6 9.4 7.1 6.2 21.9 8.9 9.9 11.0 2.5 25.4 55.3 28.1 24.3 11.5 6.3 3.1 7.4 5.5 5.1 9.8 5.3 2.8 6.1 9.6 10.0 11.9 7.2 6.1 2.0 16.6 1.7 3.6 3.6 3.6 0.6 1.8 0.9 3.1 0.1 0.3 0.5 12.8 8.9 11.4 24.8 7.0 7.3 0.8 11.0 12.4 8.7 9.5 9.7 7.9 0.3 14.8 10.7 2.2 0.2 8.4 13.0 2.8 0.3 3.7 0.3 10.9 11.7 9.3 7.0 6.4 1.3 13.9 17.1 12.8 3.4 4.6 14.9 5.9 1.2 14.3 17.0 10.1 26.2 11.4 8.6 7.2 3.0 0.5 14.7 2.7 0.1 55.7 0.0 5.2 12.3 4.8 7.8 12.1 21.6 3.5 14.4 0.0 14.7 7.5 28.6 0.0 0.3 0.1 0.3 3.1 0.0 0.6 0.0 0.0 1.8 0.1 0.0 0.0 0.9 0.1 1.5 1.6 0.0 0.5 13.2 21.7 12.1 31.7 13.6 9.4 9.9 11.0 11.5 6.1 ETV6 TEL ENSG00000139083 "ETS variant 6" P41212 12 11649854-11895402 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Repressor" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HDLM-2: 38.9;NB-4: 20.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA000264 Enhanced Approved Nucleoli,Cytosol Nucleoli Cytosol "HPA000264: AB_1078763" "unprognostic (4.03e-3)" "unprognostic (3.08e-2)" "unprognostic (7.54e-3)" "unprognostic (2.60e-1)" "unprognostic (2.07e-1)" "unprognostic (1.35e-3)" "unprognostic (2.74e-2)" "unprognostic (4.02e-2)" "unprognostic (3.16e-1)" "unprognostic (9.46e-2)" "prognostic unfavourable (9.38e-5)" "unprognostic (1.15e-1)" "prognostic unfavourable (4.66e-8)" "unprognostic (1.33e-2)" "unprognostic (5.99e-2)" "unprognostic (8.92e-2)" "prognostic favourable (1.54e-5)" 17.2 8.9 5.1 20.0 7.6 32.8 20.4 1.6 9.1 10.5 14.5 6.0 9.8 7.2 10.8 14.2 11.3 8.9 15.3 6.7 5.6 3.8 9.2 9.6 16.0 13.4 6.0 3.1 10.5 10.4 8.4 8.7 7.7 7.4 14.9 11.0 8.0 41.9 12.4 6.9 23.9 14.6 25.0 9.4 17.8 9.7 4.7 5.7 30.6 10.0 10.0 19.9 19.0 15.8 2.9 6.2 11.4 7.1 2.4 2.2 1.3 2.5 3.5 3.2 5.5 2.4 2.3 3.8 1.9 3.2 2.5 3.0 0.2 12.2 2.1 1.9 3.2 3.3 1.4 5.8 3.0 38.9 0.7 13.7 1.9 1.3 3.0 14.4 15.0 4.5 3.6 2.4 5.1 7.5 1.0 7.3 2.2 1.6 8.1 20.7 5.1 0.9 2.3 3.0 5.6 5.7 16.2 0.6 3.2 3.8 3.7 3.5 1.2 9.1 8.5 5.6 4.8 1.8 4.0 3.2 2.4 1.2 3.6 0.1 6.4 5.6 5.7 6.6 1.5 6.6 2.0 2.9 2.2 1.4 4.1 2.3 1.3 0.8 11.4 2.4 7.1 6.2 1.4 1.3 5.1 7.6 1.6 9.1 5.6 3.8 6.0 3.1 7.4 5.7 EWSR1 EWS ENSG00000182944 "EWS RNA binding protein 1" Q01844 22 29268009-29300525 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Transcription, Transcription regulation" "Calmodulin-binding, Repressor, RNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004230, HPA051771, HPA062953" Enhanced Enhanced Nucleoplasm,Nucleoli Nucleoplasm Nucleoli "CAB004230: AB_675526, HPA051771: AB_2681602, HPA062953: AB_2684910" "unprognostic (1.96e-1)" "unprognostic (6.39e-3)" "unprognostic (1.32e-1)" "unprognostic (3.93e-2)" "unprognostic (3.59e-1)" "unprognostic (3.15e-2)" "prognostic unfavourable (1.27e-6)" "unprognostic (1.33e-1)" "unprognostic (1.09e-2)" "unprognostic (2.71e-2)" "unprognostic (7.04e-2)" "unprognostic (9.30e-2)" "prognostic unfavourable (1.21e-5)" "unprognostic (7.33e-3)" "unprognostic (1.79e-1)" "unprognostic (3.67e-2)" "unprognostic (1.50e-3)" 35.3 43.2 45.3 41.3 51.3 67.5 32.1 58.2 48.6 32.4 39.8 43.2 31.3 41.0 45.1 38.5 40.8 37.6 25.9 40.7 40.1 32.8 33.0 48.5 33.4 50.5 32.7 49.9 38.4 32.0 47.2 44.3 34.0 41.7 35.0 39.9 41.5 32.3 38.2 52.8 34.8 36.6 40.5 33.8 44.1 34.5 85.6 32.5 39.9 32.5 30.9 55.4 36.4 34.5 52.0 65.8 50.6 81.1 58.4 67.8 76.1 56.4 44.0 60.5 47.0 30.9 25.6 41.6 34.4 55.0 57.1 49.0 50.1 29.3 77.2 21.8 52.7 44.4 86.2 70.4 58.8 52.5 61.5 58.3 39.0 47.9 46.2 89.6 41.7 39.1 29.7 47.6 77.3 44.1 43.6 34.9 42.2 56.7 90.0 34.4 42.5 33.5 63.2 58.3 46.6 52.5 60.0 49.6 47.4 42.8 50.2 37.1 32.2 48.8 45.0 34.9 38.8 21.9 49.9 45.4 36.4 71.6 33.2 39.9 42.4 48.4 57.9 50.6 60.2 81.1 60.7 50.4 56.6 59.6 65.8 52.0 55.8 53.6 43.3 58.4 78.6 35.3 67.8 76.1 45.3 51.3 58.2 48.6 40.1 32.8 32.7 49.9 41.7 32.5 EXT1 "LGCR, LGS, ttv" ENSG00000182197 "Exostosin glycosyltransferase 1" Q16394 8 117794490-118111853 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Glycosyltransferase, Transferase" "Cancer-related genes, Disease mutation, Hereditary multiple exostoses, Tumor suppressor" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 66.4" "Cell line enhanced" "Detected in many" "BJ hTERT+: 55.1;fHDF/TERT166: 55.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA044394 Uncertain 9600000 "HPA044394: AB_10963838" "unprognostic (1.29e-2)" "prognostic unfavourable (7.04e-4)" "unprognostic (2.73e-2)" "unprognostic (2.02e-3)" "unprognostic (2.19e-1)" "unprognostic (7.55e-2)" "unprognostic (1.99e-1)" "prognostic unfavourable (1.20e-5)" "unprognostic (1.70e-1)" "unprognostic (3.01e-2)" "unprognostic (1.31e-2)" "unprognostic (6.58e-2)" "unprognostic (1.27e-2)" "unprognostic (9.84e-2)" "unprognostic (9.49e-2)" "prognostic unfavourable (4.64e-4)" "unprognostic (1.85e-1)" 13.8 11.9 5.8 20.5 4.6 2.1 16.5 7.3 7.4 13.3 17.1 4.1 8.7 23.2 11.5 12.5 11.2 8.8 19.3 14.4 4.6 3.1 8.8 66.4 19.9 8.3 3.0 6.8 10.4 17.9 7.1 6.4 15.6 4.8 9.8 16.0 13.2 9.8 13.3 4.2 12.3 32.0 16.8 4.3 20.1 11.5 5.0 2.7 8.7 12.0 10.3 7.2 11.0 18.5 0.8 1.7 1.2 4.5 0.7 2.4 1.0 17.2 5.0 7.5 2.9 13.6 11.0 3.4 32.3 55.1 23.8 21.9 5.1 1.7 0.3 14.5 55.7 10.9 3.3 18.9 33.5 6.5 5.6 0.6 4.7 4.1 6.4 0.0 1.2 6.9 5.1 28.9 26.6 14.6 0.4 4.8 11.0 1.4 0.8 0.0 2.4 6.4 0.0 2.8 0.5 9.4 6.3 2.3 2.2 4.9 2.3 4.8 3.2 0.2 19.4 20.1 18.4 18.4 9.5 2.7 2.7 1.6 18.6 0.0 5.3 0.3 4.4 0.2 0.2 4.5 1.3 0.8 0.5 0.6 1.0 0.1 0.5 0.9 1.2 0.7 2.2 1.7 2.4 1.0 5.8 4.6 7.3 7.4 4.6 3.1 3.0 6.8 4.8 2.7 EXT2 SOTV ENSG00000151348 "Exostosin glycosyltransferase 2" Q93063 11 44095549-44245429 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins" "Glycosyltransferase, Transferase" "Cancer-related genes, Disease mutation, Epilepsy, Hereditary multiple exostoses, Mental retardation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA078409 Supported "Golgi apparatus" 20000000 "Golgi apparatus" "HPA078409: " "unprognostic (5.87e-2)" "unprognostic (3.05e-3)" "unprognostic (3.48e-2)" "unprognostic (3.94e-1)" "unprognostic (1.42e-1)" "prognostic unfavourable (2.50e-4)" "unprognostic (1.77e-3)" "unprognostic (2.22e-2)" "unprognostic (1.97e-1)" "unprognostic (2.05e-1)" "unprognostic (1.74e-3)" "unprognostic (3.70e-2)" "prognostic unfavourable (5.36e-6)" "unprognostic (7.07e-3)" "unprognostic (2.97e-1)" "unprognostic (3.85e-1)" "unprognostic (1.36e-2)" 24.5 19.5 11.6 17.2 18.5 6.6 25.8 14.5 23.0 26.8 25.0 15.5 17.5 17.6 37.1 25.5 16.7 26.0 23.4 22.7 11.7 13.0 19.2 36.3 22.3 16.8 11.8 12.3 29.3 21.8 25.7 17.3 58.0 16.2 23.7 20.6 22.9 24.7 22.8 16.9 20.2 34.0 35.0 12.2 18.7 19.3 20.0 11.4 16.2 24.7 16.7 13.0 20.2 23.2 6.7 14.9 13.0 12.0 17.8 17.6 9.8 12.9 17.9 9.7 30.2 44.8 33.0 13.4 40.2 50.3 23.8 32.4 12.7 8.9 8.9 18.3 47.0 20.6 10.4 28.5 28.8 17.9 14.3 8.2 9.4 9.7 17.7 8.2 17.8 25.6 18.9 14.4 22.5 33.8 11.0 16.2 17.3 9.9 5.7 5.0 10.4 12.8 7.2 27.8 4.5 13.7 12.3 7.0 7.8 25.4 10.4 6.7 17.3 8.8 30.5 32.2 21.1 31.5 25.7 7.3 9.5 6.5 21.2 6.4 34.3 9.3 11.9 13.0 15.6 12.0 17.6 6.4 12.5 14.4 14.9 6.7 11.9 11.7 2.6 17.8 8.5 5.1 9.6 9.8 11.6 18.5 14.5 23.0 11.7 13.0 11.8 12.3 16.2 11.4 EZH1 "KIAA0388, KMT6B" ENSG00000108799 "Enhancer of zeste 1 polycomb repressive complex 2 subunit" Q92800 17 42700275-42745049 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Chromatin regulator, Methyltransferase, Repressor, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "ASC diff: 31.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA005478, HPA077684" Supported Supported Nucleoplasm Nucleoplasm "HPA005478: AB_1848340, HPA077684: " "unprognostic (1.01e-1)" "unprognostic (6.02e-2)" "unprognostic (2.19e-2)" "unprognostic (8.57e-2)" "unprognostic (1.89e-1)" "unprognostic (1.84e-3)" "unprognostic (1.76e-2)" "unprognostic (1.18e-2)" "unprognostic (1.25e-1)" "unprognostic (1.55e-3)" "unprognostic (5.22e-3)" "unprognostic (4.11e-3)" "unprognostic (1.48e-2)" "unprognostic (4.60e-2)" "unprognostic (3.29e-1)" "unprognostic (5.39e-2)" "unprognostic (4.74e-2)" 21.7 10.4 15.0 10.1 25.0 9.9 18.7 39.6 26.1 18.4 15.1 21.4 10.0 9.7 29.8 21.2 10.6 18.8 9.7 17.2 19.0 11.2 13.6 5.3 12.6 14.0 13.7 22.0 38.2 8.1 20.0 19.1 9.3 25.6 13.1 12.1 21.5 10.7 19.3 25.4 16.0 14.0 16.4 19.9 16.0 10.6 8.6 16.7 11.9 15.0 7.5 14.9 16.0 15.9 6.2 6.0 18.8 5.4 4.8 8.3 2.3 5.4 5.8 7.9 5.4 31.7 19.2 6.7 8.8 8.1 7.3 7.5 2.7 6.8 8.3 5.5 9.3 12.4 5.1 5.9 10.6 9.2 9.2 2.8 10.7 3.3 10.9 6.2 6.9 10.9 10.7 5.5 13.4 5.9 7.5 11.7 6.4 2.3 10.0 7.9 2.1 3.0 6.6 8.0 8.8 7.6 5.8 5.4 4.3 4.9 2.4 5.8 8.4 4.0 6.1 7.9 3.3 9.2 5.5 12.3 6.2 4.9 5.6 6.4 4.0 10.2 5.2 6.9 5.9 5.4 8.3 5.7 5.2 6.0 1.9 6.2 7.7 5.7 18.8 4.8 3.3 6.0 5.7 2.3 15.0 25.0 39.6 26.1 19.0 11.2 13.7 22.0 25.6 16.7 EZH2 "ENX-1, EZH1, KMT6, KMT6A" ENSG00000106462 "Enhancer of zeste 2 polycomb repressive complex 2 subunit" Q15910 7 148807383-148884321 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Biological rhythms, Transcription, Transcription regulation" "Chromatin regulator, Methyltransferase, Repressor, Transferase" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 25.5;lymphoid tissue: 44.1" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB009589 Enhanced Supported Nucleoplasm Nucleoplasm "CAB009589: " "unprognostic (2.42e-1)" "unprognostic (3.95e-3)" "unprognostic (1.57e-1)" "unprognostic (3.30e-3)" "unprognostic (1.33e-1)" "unprognostic (3.85e-3)" "prognostic unfavourable (2.11e-6)" "unprognostic (2.21e-2)" "prognostic unfavourable (1.96e-4)" "unprognostic (2.32e-3)" "unprognostic (1.58e-3)" "unprognostic (1.69e-3)" "prognostic unfavourable (8.18e-12)" "prognostic favourable (6.97e-4)" "unprognostic (1.83e-1)" "unprognostic (2.12e-1)" "unprognostic (6.67e-2)" 2.0 1.7 1.8 10.6 1.6 25.5 1.4 4.9 2.7 2.6 4.8 1.1 0.1 3.8 1.7 2.8 11.0 0.9 3.0 0.9 0.8 0.6 1.7 3.3 2.3 12.6 1.3 0.3 2.2 3.8 0.6 1.7 3.4 1.4 1.4 5.1 1.8 3.2 1.6 3.7 6.4 4.8 1.5 1.2 5.8 2.7 19.6 1.3 44.1 0.9 5.5 12.4 2.6 3.5 1.5 4.7 1.3 3.9 8.5 10.3 1.7 16.9 7.9 27.1 18.0 0.8 1.4 14.8 13.2 5.3 10.9 11.0 11.9 19.6 29.9 6.4 4.9 10.4 13.9 4.5 13.9 42.8 13.9 12.7 9.8 9.2 2.2 28.4 10.5 1.2 2.6 8.1 4.3 6.4 27.1 19.9 9.7 19.2 55.1 23.7 21.5 10.7 34.1 15.2 18.5 5.0 8.1 25.9 16.5 16.6 12.6 4.3 9.2 12.2 3.9 11.6 5.4 23.1 23.6 17.9 19.4 30.1 10.6 19.4 22.7 0.5 2.2 1.3 1.7 1.5 1.3 1.5 3.4 2.9 4.7 0.8 1.9 1.2 0.2 8.5 3.9 1.0 10.3 1.7 1.8 1.6 4.9 2.7 0.8 0.6 1.3 0.3 1.4 1.3 EZR VIL2 ENSG00000092820 Ezrin P15311 6 158765741-158819412 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Cell shape" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004035, HPA021616, CAB047324, CAB075739" Enhanced Enhanced "Plasma membrane" 75000000 "Plasma membrane" "CAB004035: AB_2100309, CAB047324: , CAB075739: , HPA021616: AB_1848342" "unprognostic (4.79e-3)" "unprognostic (1.48e-1)" "unprognostic (1.97e-2)" "unprognostic (2.50e-1)" "unprognostic (1.07e-1)" "unprognostic (1.31e-3)" "unprognostic (1.76e-2)" "unprognostic (2.41e-1)" "unprognostic (1.32e-1)" "unprognostic (7.53e-2)" "prognostic unfavourable (1.70e-4)" "unprognostic (5.59e-2)" "prognostic favourable (9.56e-8)" "unprognostic (1.16e-1)" "unprognostic (1.32e-1)" "unprognostic (1.34e-2)" "unprognostic (9.00e-2)" 22.8 56.4 30.9 31.2 31.4 24.7 13.3 4.0 21.5 18.0 45.5 28.2 35.2 33.8 9.8 25.8 71.8 25.1 30.2 34.3 37.6 13.9 53.5 16.2 44.3 36.7 14.8 19.0 20.7 33.0 77.1 14.6 125.1 23.5 21.7 22.8 37.0 27.4 32.0 13.6 47.5 87.9 22.8 12.8 26.0 55.4 21.4 22.2 41.6 37.1 34.4 75.6 38.2 25.3 81.7 30.0 24.3 31.2 20.7 61.7 41.1 87.0 47.6 11.8 16.9 1.3 1.4 68.9 27.4 9.0 30.9 26.1 55.7 48.3 87.7 27.2 31.3 66.8 23.2 30.5 35.9 30.6 15.0 1.8 28.9 24.6 31.4 21.7 13.5 2.3 23.7 29.1 28.3 20.2 17.3 43.0 17.9 22.9 30.7 26.2 19.6 15.9 23.1 5.5 19.9 63.5 26.5 21.4 17.5 47.9 69.1 5.2 16.8 28.7 26.1 10.0 32.1 13.7 42.1 29.7 27.0 75.2 6.2 11.2 11.9 24.3 14.0 16.4 34.8 31.2 41.0 81.7 36.7 42.9 30.0 67.5 19.9 26.5 6.1 20.7 30.6 14.0 61.7 41.1 30.9 31.4 4.0 21.5 37.6 13.9 14.8 19.0 23.5 22.2 F13A1 F13A ENSG00000124491 "Coagulation factor XIII A chain" P00488 6 6144085-6321013 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Blood coagulation, Hemostasis" "Acyltransferase, Transferase" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "placenta: 110.1" "Cell line enhanced" "Detected in some" "AF22: 15.3;LHCN-M2: 5.7;RH-30: 28.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 5 "classical monocyte: 27.6;myeloid DC: 33.7" "Group enriched" "Detected in many" 5 "dendritic cells: 33.7;monocytes: 27.6" "Low region specificity" "Detected in all" "Not detected" "Not detected" "HPA001804, CAB002155" Enhanced "Secreted to blood" 1400000000 "CAB002155: AB_564077, HPA001804: AB_1078792" "unprognostic (4.44e-1)" "unprognostic (5.90e-2)" "unprognostic (2.65e-2)" "unprognostic (3.93e-2)" "unprognostic (5.02e-2)" "unprognostic (3.75e-2)" "unprognostic (5.27e-2)" "unprognostic (1.96e-1)" "unprognostic (2.68e-2)" "unprognostic (6.84e-3)" "unprognostic (4.96e-2)" "unprognostic (1.97e-1)" "prognostic unfavourable (6.61e-6)" "unprognostic (2.79e-2)" "unprognostic (1.52e-1)" "unprognostic (1.57e-1)" "unprognostic (2.54e-3)" 56.6 19.4 2.2 11.4 6.5 3.1 57.9 2.2 1.8 13.3 21.8 2.6 2.5 2.2 4.7 35.6 13.4 16.8 12.6 55.4 2.0 2.2 17.5 1.3 14.5 52.7 5.8 1.4 10.2 8.9 5.3 9.3 110.1 7.5 16.4 15.1 11.6 11.5 3.3 18.5 10.4 10.6 20.1 5.0 5.1 11.5 16.7 2.5 2.7 22.4 8.3 6.1 23.7 6.5 0.0 33.7 6.6 27.6 0.0 0.1 63.5 0.0 0.0 15.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 5.7 0.0 0.0 0.1 0.0 0.0 0.0 28.9 0.5 0.0 0.0 0.2 0.2 0.1 0.0 0.0 0.0 2.5 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 5.7 27.6 0.2 0.1 4.9 0.1 0.0 0.0 0.0 33.7 0.0 0.0 0.0 6.6 0.0 0.1 2.4 0.0 63.5 2.2 6.5 2.2 1.8 2.0 2.2 5.8 1.4 7.5 2.5 F13B FXIIIB ENSG00000143278 "Coagulation factor XIII B chain" P05160 1 197039191-197067267 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins" "Blood coagulation, Hemostasis" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 95 "liver: 76.3" "Cell line enhanced" "Detected in some" "A549: 1.8;Hep G2: 2.2" "Cancer enriched" "Detected in single" 816 "liver cancer: 46.3" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "HPA003827, HPA052139" Supported "Secreted to blood" 3400000000 "HPA003827: AB_1078794, HPA052139: " "unprognostic (1.46e-1)" "prognostic favourable (6.78e-5)" "unprognostic (1.21e-2)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 76.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.8 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.3 2.2 0.0 0.5 0.1 0.0 0.1 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.1 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 F2 ENSG00000180210 "Coagulation factor II, thrombin" P00734 11 46719180-46739506 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Acute phase, Blood coagulation, Hemostasis" "Hydrolase, Protease, Serine protease" "Cancer-related genes, Disease mutation, FDA approved drug targets, Thrombophilia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 593 "liver: 324.8" "Cell line enriched" "Detected in some" 21 "Hep G2: 76.5" "Cancer enriched" "Detected in some" 110 "liver cancer: 508.2" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "CAB016780, CAB018650, HPA051476, HPA054698" Enhanced "Secreted to blood" 107500000000 43000000000 "CAB016780: , CAB018650: AB_2246689, HPA051476: , HPA054698: " "unprognostic (1.98e-1)" "unprognostic (2.52e-1)" "unprognostic (2.64e-2)" "unprognostic (1.85e-1)" "unprognostic (2.29e-1)" "unprognostic (2.81e-1)" "unprognostic (2.23e-2)" "unprognostic (3.94e-2)" "unprognostic (5.79e-2)" "unprognostic (8.29e-2)" "unprognostic (4.46e-2)" "prognostic unfavourable (6.75e-12)" "unprognostic (5.65e-3)" "unprognostic (5.80e-2)" "unprognostic (1.54e-3)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 324.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.1 0.5 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.6 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 76.5 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.5 0.0 0.5 0.0 0.1 0.4 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 F3 "CD142, TF" ENSG00000117525 "Coagulation factor III, tissue factor" P13726 1 94529225-94541800 "Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" "Blood coagulation, Hemostasis" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "A-431: 115.2;HaCaT: 54.6;HBEC3-KT: 141.7;U-2197: 53.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "neutrophil: 2.8" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB009438, HPA049292, HPA069132" Uncertain Approved Vesicles "Secreted to blood" 7733431000 Vesicles "CAB009438: AB_668005, HPA049292: , HPA069132: " "unprognostic (3.86e-2)" "unprognostic (1.19e-1)" "unprognostic (8.04e-2)" "unprognostic (1.64e-1)" "unprognostic (2.69e-2)" "unprognostic (1.23e-3)" "unprognostic (4.93e-2)" "unprognostic (8.00e-2)" "unprognostic (5.88e-1)" "unprognostic (1.35e-1)" "prognostic unfavourable (1.07e-4)" "unprognostic (1.25e-1)" "prognostic unfavourable (2.02e-8)" "unprognostic (4.84e-2)" "unprognostic (4.08e-1)" "unprognostic (1.23e-1)" "unprognostic (1.08e-1)" 45.5 9.8 27.0 14.1 42.9 2.1 55.1 3.4 27.9 14.8 18.7 20.9 18.7 18.3 30.5 23.7 21.3 25.4 30.9 18.8 26.9 14.5 6.6 2.8 31.4 5.8 14.1 20.3 41.6 35.0 6.1 28.8 65.4 39.2 29.7 22.2 49.9 29.2 33.0 2.4 17.7 19.2 5.9 46.3 2.9 18.2 16.4 16.0 0.0 21.8 17.3 11.9 24.7 22.3 0.5 0.9 2.8 0.8 0.7 0.4 0.2 115.2 0.2 0.2 0.0 12.6 6.2 6.5 16.4 9.8 17.8 19.4 2.0 24.7 0.0 8.4 20.3 54.6 1.4 141.7 29.3 0.1 0.1 0.0 3.5 0.3 4.2 0.0 0.0 10.7 3.2 8.4 41.1 0.1 0.1 0.1 12.4 0.2 0.1 2.4 1.1 0.2 0.1 1.1 0.0 2.2 0.3 0.1 0.3 13.1 5.4 0.4 0.1 1.5 0.0 10.8 0.3 53.8 4.9 0.1 0.1 0.0 8.2 0.6 0.4 1.7 0.8 0.1 0.3 0.3 0.4 0.2 0.3 0.2 0.2 0.5 0.3 0.3 2.8 0.7 0.2 0.9 0.2 0.2 27.0 42.9 3.4 27.1 26.9 14.5 14.1 20.3 39.2 16.0 FABP1 L-FABP ENSG00000163586 "Fatty acid binding protein 1" P07148 2 88122982-88128116 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" Transport "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 7 "intestine: 453.2;liver: 370.7" "Group enriched" "Detected in some" 7 "CACO-2: 25.6;Hep G2: 81.3" "Group enriched" "Detected in many" 14 "colorectal cancer: 175.1;liver cancer: 437.4" "Not detected" "Not detected" "Cell type enriched" "Detected in single" 23 "neutrophil: 2.3" "Lineage enriched" "Detected in single" 23 "granulocytes: 2.3" "Not detected" "Not detected" "Low region specificity" "Detected in many" "CAB002305, HPA028275" Enhanced Approved Nucleoplasm,Cytosol 32000000 "Nucleoplasm, Cytosol" "CAB002305: AB_563728, HPA028275: AB_10600909" "unprognostic (1.91e-1)" "unprognostic (7.91e-3)" "unprognostic (5.47e-2)" "unprognostic (1.96e-1)" "unprognostic (2.03e-2)" "unprognostic (2.35e-1)" "unprognostic (7.99e-2)" "unprognostic (8.92e-2)" "unprognostic (2.29e-1)" 0.4 0.1 0.4 33.9 0.4 0.0 0.4 0.4 0.5 0.4 153.5 0.4 0.4 137.9 0.4 0.4 0.4 0.5 0.4 0.4 0.4 0.2 57.6 370.7 0.4 0.4 0.4 0.4 0.4 0.4 0.0 0.4 0.4 0.4 0.4 97.7 0.4 0.5 0.4 0.4 0.1 453.2 6.7 0.4 0.4 0.2 0.5 0.4 0.4 0.5 0.5 0.4 0.4 0.4 0.0 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.4 0.0 0.0 0.0 0.0 25.6 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 81.3 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 7.0 0.1 0.0 0.0 1.4 7.5 0.0 0.1 0.8 5.6 0.4 0.0 0.0 0.0 0.0 0.5 0.0 0.0 2.6 0.1 0.0 0.0 0.6 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.4 0.4 0.4 0.5 0.4 0.2 0.4 0.4 0.4 0.4 FABP2 I-FABP ENSG00000145384 "Fatty acid binding protein 2" P12104 4 119317250-119322390 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" Transport "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 47 "intestine: 358.6" "Cell line enhanced" "Detected in some" "BEWO: 2.8;Hep G2: 2.4;NB-4: 3.8;RPMI-8226: 3.2;SH-SY5Y: 2.6" "Group enriched" "Detected in some" 9 "colorectal cancer: 3.2;pancreatic cancer: 1.6;stomach cancer: 2.7" "Not detected" "Not detected" "Group enriched" "Detected in some" 5 "basophil: 2.1;neutrophil: 7.6" "Lineage enriched" "Detected in single" 8 "granulocytes: 7.6" "Not detected" "Not detected" "Low region specificity" "Detected in all" "HPA034607, CAB047325, CAB047326" Enhanced Approved "Plasma membrane,Actin filaments,Cytosol" 46000 "Actin filaments, Cytosol" "Plasma membrane" "CAB047325: , CAB047326: , HPA034607: AB_10601317" "unprognostic (3.94e-2)" "unprognostic (1.10e-1)" "unprognostic (1.05e-1)" "unprognostic (4.58e-1)" "unprognostic (1.51e-2)" "unprognostic (2.61e-2)" "unprognostic (1.69e-4)" "unprognostic (1.93e-1)" "unprognostic (1.02e-1)" 0.1 0.2 0.1 0.8 0.1 0.0 0.1 0.1 0.1 0.1 47.0 0.0 0.0 50.0 0.1 0.0 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.1 5.9 0.1 0.1 0.0 0.1 0.1 358.6 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.5 0.5 7.6 0.7 0.9 0.5 0.0 0.2 0.3 0.2 0.4 0.0 0.0 2.8 0.4 0.0 0.0 0.0 0.4 0.3 0.4 0.1 0.0 0.3 0.0 0.2 0.1 0.1 0.3 0.1 0.4 2.4 0.0 0.5 0.4 0.2 0.0 0.2 0.1 0.0 0.2 0.5 0.0 0.1 0.4 3.8 0.2 0.5 0.3 0.2 3.2 0.0 0.5 1.0 2.6 0.1 0.4 0.0 0.3 0.1 0.9 0.4 0.4 1.4 0.1 0.7 0.2 0.6 0.3 0.2 0.1 2.1 0.7 0.7 0.4 0.3 0.4 0.2 0.4 0.3 0.2 0.5 0.5 0.5 7.6 0.9 0.2 0.5 0.5 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 FABP4 "A-FABP, aP2" ENSG00000170323 "Fatty acid binding protein 4" P15090 8 81478419-81483263 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" Transport "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 9 "adipose tissue: 492.7;breast: 545.8" "Group enriched" "Detected in some" 325 "ASC diff: 275.5;RT4: 136.3" "Group enriched" "Detected in all" 7 "breast cancer: 42.1;cervical cancer: 141.7;head and neck cancer: 133.8;urothelial cancer: 65.5" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "HPA002188, CAB024961" Enhanced 30000000 "CAB024961: , HPA002188: AB_1078822" "unprognostic (4.81e-2)" "unprognostic (2.30e-3)" "unprognostic (1.64e-3)" "unprognostic (2.63e-2)" "unprognostic (2.58e-1)" "unprognostic (8.70e-3)" "unprognostic (1.78e-3)" "unprognostic (1.67e-1)" "unprognostic (2.00e-1)" "unprognostic (2.36e-1)" "unprognostic (9.32e-2)" "unprognostic (1.56e-1)" "unprognostic (8.76e-2)" "unprognostic (1.13e-3)" "unprognostic (4.48e-2)" "unprognostic (2.26e-2)" "unprognostic (1.39e-1)" 492.7 3.5 0.3 16.1 0.3 0.1 545.8 0.2 0.2 0.9 42.2 0.0 1.8 0.2 0.6 2.9 4.8 1.0 7.6 15.6 0.3 0.3 1.2 0.4 9.3 4.7 0.3 0.0 0.7 1.3 2.2 0.3 15.9 0.3 7.7 2.9 0.1 7.6 1.7 13.0 5.5 4.5 3.3 0.3 0.7 2.2 6.1 0.0 0.7 7.4 7.3 0.1 15.4 60.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 275.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.6 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 136.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.3 0.2 0.2 0.3 0.3 0.3 0.0 0.3 0.0 FABP5 "E-FABP, KFABP, PA-FABP" ENSG00000164687 "Fatty acid binding protein 5" Q01469 8 81280363-81284777 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters" Transport "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "esophagus: 237.0;tongue: 204.1;vagina: 141.9" "Cell line enhanced" "Detected in many" "Daudi: 92.9;MOLT-4: 90.8" "Cancer enhanced" "Detected in all" "cervical cancer: 268.3;head and neck cancer: 288.8" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "CAB017831, CAB040577, HPA051895" Enhanced Supported "Plasma membrane,Cytosol" "Intracellular and membrane" 28000000 Cytosol "Plasma membrane" "CAB017831: , CAB040577: , HPA051895: " "unprognostic (8.76e-2)" "unprognostic (7.28e-2)" "unprognostic (1.54e-2)" "unprognostic (9.04e-2)" "unprognostic (1.33e-3)" "unprognostic (1.37e-1)" "unprognostic (1.95e-3)" "unprognostic (4.03e-3)" "unprognostic (2.71e-1)" "unprognostic (3.13e-1)" "unprognostic (6.16e-2)" "unprognostic (3.57e-2)" "prognostic unfavourable (4.69e-10)" "unprognostic (1.99e-1)" "unprognostic (3.72e-1)" "unprognostic (1.61e-1)" "unprognostic (6.60e-2)" 41.4 1.5 8.5 11.8 13.2 8.5 37.3 5.5 8.9 78.7 20.6 7.9 2.2 8.0 5.7 3.1 237.0 2.1 8.5 27.1 8.5 9.8 1.6 2.7 24.8 15.1 7.6 5.0 2.0 8.7 0.7 1.9 30.0 19.1 4.4 18.2 4.2 32.9 1.6 9.4 42.9 9.7 4.5 23.0 14.9 15.6 3.8 10.6 6.6 4.4 204.1 25.7 19.5 141.9 6.8 20.3 2.5 5.9 8.2 5.2 4.3 5.7 16.5 10.1 0.0 48.4 4.5 0.0 11.8 0.6 9.2 11.7 0.1 7.9 92.9 6.8 2.9 5.4 24.6 18.9 7.9 47.2 53.4 33.5 11.8 25.0 4.3 32.0 8.7 3.5 38.9 11.4 23.5 53.0 9.6 10.1 5.5 5.6 90.8 16.4 13.4 64.3 40.5 0.0 9.8 14.8 71.8 42.0 15.9 5.7 1.9 4.4 0.0 16.5 7.5 0.0 26.3 0.1 0.1 12.5 4.9 66.2 4.2 30.7 14.8 2.5 5.0 0.3 2.3 5.9 3.7 6.8 2.7 5.2 20.3 3.3 1.3 4.5 2.0 8.2 2.0 20.1 3.5 4.3 8.5 13.2 5.5 8.9 8.5 9.8 7.6 5.0 19.1 10.6 FADD "GIG3, MORT1" ENSG00000168040 "Fas associated via death domain" Q13158 11 70203163-70207390 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Apoptosis, Host-virus interaction, Immunity, Innate immunity" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "A-431: 81.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA001464, CAB010209" Supported Supported Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "CAB010209: AB_2100622, HPA001464: AB_1848348" "unprognostic (2.08e-1)" "prognostic unfavourable (6.35e-4)" "unprognostic (6.91e-2)" "unprognostic (9.51e-2)" "unprognostic (3.89e-1)" "prognostic unfavourable (8.22e-5)" "unprognostic (7.25e-3)" "prognostic unfavourable (2.21e-5)" "unprognostic (1.16e-1)" "unprognostic (1.06e-1)" "unprognostic (2.45e-3)" "unprognostic (2.78e-3)" "unprognostic (1.29e-1)" "unprognostic (2.04e-2)" "unprognostic (2.07e-1)" "prognostic favourable (3.45e-4)" "unprognostic (7.29e-2)" 16.1 20.2 7.9 13.3 8.9 7.1 13.5 10.9 11.8 13.7 16.2 10.9 20.8 13.5 18.0 18.7 18.8 13.3 19.7 11.4 7.8 8.0 17.9 17.4 11.0 19.2 10.5 6.6 12.9 24.9 9.1 9.3 26.3 7.9 12.5 12.7 10.1 14.4 14.5 10.3 13.7 16.9 10.1 8.3 18.8 14.0 8.7 7.4 33.5 16.9 12.4 19.8 14.6 15.1 18.6 17.6 42.7 19.5 16.6 24.6 16.0 81.8 13.8 6.9 6.2 8.4 6.8 6.2 14.1 11.1 12.3 8.3 11.8 13.4 12.2 13.6 9.3 12.1 6.7 12.5 9.6 11.3 7.4 5.5 7.9 6.0 7.5 6.9 7.4 6.7 8.9 13.3 16.9 11.6 9.0 6.3 10.8 12.0 8.4 12.2 10.9 22.9 6.5 16.7 11.6 12.1 6.0 6.1 5.8 10.4 9.8 28.9 10.6 7.7 12.9 9.6 9.4 14.7 13.4 8.8 6.7 7.1 14.0 7.0 13.5 15.0 17.1 12.7 21.0 17.7 24.1 18.6 22.3 24.6 17.6 16.4 23.2 20.9 42.7 16.6 19.5 16.0 20.7 16.0 7.9 8.9 10.9 11.8 7.8 8.0 10.5 6.6 7.9 7.4 FAF1 "CGI-03, hFAF1, HFAF1s, UBXD12, UBXN3A" ENSG00000185104 "Fas associated factor 1" Q9UNN5 1 50437028-50960263 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" Apoptosis "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA018253, CAB072814" Approved Enhanced Nucleoplasm Nucleoplasm "CAB072814: , HPA018253: AB_1848351" "unprognostic (1.52e-1)" "unprognostic (1.25e-2)" "unprognostic (6.49e-3)" "unprognostic (4.69e-2)" "unprognostic (6.35e-2)" "unprognostic (1.19e-2)" "prognostic unfavourable (1.87e-5)" "unprognostic (2.51e-1)" "unprognostic (1.02e-1)" "unprognostic (1.82e-1)" "unprognostic (9.52e-2)" "unprognostic (1.58e-1)" "unprognostic (1.58e-1)" "unprognostic (1.17e-1)" "unprognostic (9.00e-2)" "unprognostic (2.01e-3)" "unprognostic (6.42e-3)" 16.0 13.6 11.6 18.0 13.4 17.4 16.7 20.0 16.3 14.1 14.6 19.1 14.5 12.2 17.2 12.9 16.9 13.3 12.2 22.3 11.1 10.8 13.2 14.7 13.3 14.9 16.4 13.3 17.0 21.3 22.8 21.5 12.0 13.1 13.9 13.0 12.5 18.0 17.3 58.4 19.0 15.8 17.3 13.1 10.6 14.5 29.7 15.7 29.6 15.6 19.6 17.8 19.4 14.0 5.6 5.4 7.3 5.0 6.1 9.1 2.4 14.3 10.6 9.2 15.6 9.2 8.8 13.6 14.0 12.7 21.8 19.9 11.8 10.3 23.2 10.4 11.9 10.7 14.8 13.0 18.7 15.4 13.3 19.3 14.1 12.2 15.0 20.7 11.5 8.1 11.8 22.9 28.2 11.7 22.4 0.0 11.1 5.7 21.4 16.5 12.2 7.6 20.1 20.4 0.0 21.9 12.9 0.1 11.5 12.7 26.0 21.3 8.1 24.8 7.1 12.3 15.1 15.1 0.1 18.2 19.0 27.0 0.0 30.2 14.1 1.4 3.4 7.3 6.6 4.1 8.7 4.0 5.9 6.4 5.4 5.6 7.0 4.7 1.2 6.1 5.0 4.5 9.1 2.4 11.6 13.4 20.0 16.3 11.1 10.8 16.4 13.3 13.1 15.7 FAM129A "C1orf24, GIG39, NIBAN" ENSG00000135842 "Family with sequence similarity 129 member A" Q9BZQ8 1 184790724-184974550 "Cancer-related genes, Predicted intracellular proteins" "Stress response, Translation regulation" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "smooth muscle: 129.1;urinary bladder: 90.3" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in many" 5 "neutrophil: 32.7" "Lineage enriched" "Detected in many" 6 "granulocytes: 32.7" "Low region specificity" "Detected in some" "Low region specificity" "Detected in all" "HPA028172, HPA028231, HPA028657" Approved Supported "Plasma membrane,Cytosol" 40000 "Plasma membrane, Cytosol" "HPA028172: AB_10599602, HPA028231: AB_10601886, HPA028657: AB_10601680" "unprognostic (4.61e-3)" "unprognostic (3.45e-2)" "unprognostic (1.64e-3)" "unprognostic (9.46e-2)" "unprognostic (2.77e-1)" "unprognostic (3.87e-1)" "unprognostic (3.23e-2)" "unprognostic (1.30e-2)" "unprognostic (1.68e-1)" "unprognostic (6.32e-2)" "unprognostic (4.12e-1)" "unprognostic (1.32e-1)" "unprognostic (2.94e-3)" "unprognostic (9.01e-3)" "unprognostic (4.38e-2)" "unprognostic (3.73e-2)" "prognostic unfavourable (4.52e-4)" 10.1 3.5 1.1 16.9 1.8 2.3 7.8 0.8 1.3 13.0 39.3 1.0 14.9 2.5 14.6 11.0 32.3 10.7 30.4 52.2 1.1 1.1 1.8 1.2 6.1 10.7 3.0 0.5 8.0 27.3 0.8 1.9 2.9 1.7 34.6 5.1 13.8 59.3 14.7 21.4 4.1 8.3 129.1 2.1 6.5 30.0 4.1 1.3 4.9 4.7 14.7 8.7 90.3 20.3 0.5 2.3 32.7 1.5 2.6 5.3 0.8 13.6 0.1 0.0 0.0 9.8 14.9 0.5 7.0 14.4 6.1 7.7 0.0 5.8 0.0 4.6 18.0 15.4 0.8 0.5 9.8 27.2 1.1 5.7 2.9 0.0 22.8 18.5 6.5 13.6 22.3 17.7 21.5 0.0 1.3 28.9 0.1 0.0 0.6 3.2 3.7 1.4 4.3 3.3 0.2 8.4 0.2 0.7 0.7 0.1 0.0 10.0 3.0 5.9 1.1 12.1 0.0 2.1 14.4 24.3 9.6 2.9 23.7 7.7 11.8 7.1 1.5 4.7 2.5 0.9 2.1 0.5 2.2 2.3 2.3 0.1 0.2 0.9 32.7 2.6 0.3 0.2 5.3 0.8 1.1 1.8 0.8 1.3 1.1 1.1 3.0 0.5 1.7 1.3 FAM166A ENSG00000188163 "Family with sequence similarity 166 member A" Q6J272 9 137243584-137247770 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 53 "testis: 54.2" "Cell line enhanced" "Detected in some" "T-47d: 3.2" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA023307 Enhanced "HPA023307: AB_1848930" "unprognostic (2.22e-1)" "unprognostic (8.39e-2)" "unprognostic (1.01e-3)" "unprognostic (1.37e-2)" "unprognostic (1.56e-1)" "unprognostic (1.15e-1)" "unprognostic (9.83e-2)" "unprognostic (2.18e-3)" "unprognostic (1.23e-1)" "unprognostic (2.49e-1)" "unprognostic (2.67e-4)" "unprognostic (7.81e-2)" "unprognostic (1.77e-3)" "unprognostic (1.83e-1)" "unprognostic (2.02e-2)" "unprognostic (2.09e-1)" "unprognostic (4.18e-3)" 0.2 0.1 0.1 0.1 0.1 0.0 0.1 0.2 0.2 0.1 0.1 0.1 0.1 0.3 0.1 1.0 0.1 0.0 0.1 0.1 0.1 0.1 0.4 0.7 0.1 0.1 0.1 0.1 0.1 0.2 0.0 0.4 0.1 0.1 0.1 0.0 0.1 0.3 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.0 54.2 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.0 0.1 0.9 0.0 0.0 0.1 0.0 0.0 1.4 0.5 1.2 0.8 0.0 0.7 0.0 0.5 0.0 0.0 0.5 2.0 0.6 0.1 0.0 1.0 0.0 0.0 0.0 1.1 0.7 0.5 1.2 1.0 0.3 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 2.1 0.2 0.9 0.0 0.3 0.3 0.3 0.3 0.1 0.6 0.1 0.8 0.8 0.8 0.3 1.0 0.8 3.2 0.9 0.7 0.8 1.0 0.3 0.1 0.8 1.2 0.1 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.9 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.1 FAM46C FLJ20202 ENSG00000183508 "Family with sequence similarity 46 member C" Q5VWP2 1 117605934-117628372 "Cancer-related genes, Predicted intracellular proteins" "Host-virus interaction" "Nucleotidyltransferase, RNA-binding, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "pancreas: 114.0" "Cell line enhanced" "Detected in some" "Karpas-707: 73.1;RPMI-8226: 43.6;U-266/70: 20.3;U-266/84: 16.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "basophil: 16.3" "Group enriched" "Detected in many" 17 "B-cells: 9.7;granulocytes: 16.3;T-cells: 9.2" "Not detected" "Not detected" "Not detected" "Not detected" HPA054049 Uncertain Approved Nucleoplasm Nucleoplasm "HPA054049: " "unprognostic (3.76e-2)" "unprognostic (3.85e-3)" "unprognostic (3.24e-3)" "prognostic favourable (3.75e-5)" "unprognostic (1.17e-1)" "unprognostic (1.55e-3)" "unprognostic (3.29e-1)" "unprognostic (2.88e-2)" "unprognostic (5.75e-2)" "unprognostic (1.36e-3)" "unprognostic (9.41e-3)" "unprognostic (3.91e-2)" "prognostic favourable (2.77e-5)" "unprognostic (6.26e-2)" "unprognostic (3.16e-2)" "unprognostic (3.08e-2)" "unprognostic (1.10e-2)" 3.2 1.8 1.2 24.5 1.1 28.9 4.4 1.1 1.1 8.1 16.1 1.8 8.4 5.6 4.8 16.6 6.9 3.3 9.7 6.4 1.2 1.1 5.0 5.5 11.2 16.3 1.2 0.1 8.3 114.0 7.2 5.3 10.6 3.9 6.4 9.5 4.4 37.8 11.9 10.0 1.8 10.6 4.7 1.4 19.1 12.2 34.0 0.2 1.5 10.3 10.9 37.0 9.5 8.6 9.7 0.2 16.3 0.0 0.6 9.2 2.1 0.0 0.0 0.0 0.3 0.0 0.0 0.3 0.1 6.6 0.1 0.0 0.4 0.0 1.1 0.0 0.1 0.0 0.0 0.1 0.0 4.1 0.4 9.0 0.0 0.0 0.0 5.2 11.7 0.0 0.0 0.1 0.0 0.0 1.2 73.1 0.0 0.9 0.0 5.4 0.9 0.5 0.0 0.0 43.6 0.0 0.8 0.5 0.0 0.4 0.5 0.4 0.4 0.0 0.1 0.0 0.5 0.0 0.1 20.3 16.8 0.4 0.4 1.9 0.6 16.3 0.0 10.5 2.5 0.0 2.2 9.7 2.5 3.1 0.0 8.0 0.3 1.4 1.1 0.6 0.0 0.2 9.2 2.1 1.2 1.1 1.1 1.1 1.2 1.1 1.2 0.1 3.9 0.2 FANCA "FA-H, FAA, FACA, FAH, FANCH" ENSG00000187741 "Fanconi anemia complementation group A" O15360 16 89737549-89816657 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "DNA damage, DNA repair" "Cancer-related genes, Disease mutation, Fanconi anemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 20.6;testis: 28.8" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA063236 Supported Nucleoplasm Nucleoplasm "HPA063236: " "unprognostic (5.99e-2)" "unprognostic (5.68e-2)" "unprognostic (2.36e-1)" "unprognostic (5.12e-2)" "unprognostic (1.87e-1)" "unprognostic (7.11e-2)" "unprognostic (1.45e-4)" "unprognostic (9.21e-2)" "unprognostic (1.58e-2)" "unprognostic (2.05e-1)" "unprognostic (4.82e-3)" "unprognostic (8.48e-4)" "unprognostic (7.82e-10)" "unprognostic (3.67e-2)" "unprognostic (2.05e-1)" "unprognostic (2.94e-1)" "unprognostic (1.62e-1)" 2.1 2.0 2.2 16.5 3.7 17.1 1.7 5.7 6.6 1.7 5.1 1.1 0.6 5.0 1.7 3.1 6.6 1.9 1.6 1.7 1.8 1.4 2.1 5.8 3.3 11.1 1.3 2.7 1.6 1.8 2.3 1.9 11.2 2.4 1.7 6.3 1.5 2.2 0.5 0.7 5.0 5.4 2.0 1.6 6.9 3.5 28.8 0.8 20.6 1.7 4.6 17.6 2.9 2.5 7.4 6.5 9.9 9.2 7.5 9.5 4.2 9.2 14.2 17.0 14.9 1.1 2.2 13.0 11.5 6.3 19.5 8.2 12.4 15.4 22.7 5.4 3.9 14.2 11.4 8.6 20.6 5.3 19.2 6.7 18.2 25.4 0.7 6.8 7.4 0.7 0.9 15.8 5.0 6.1 16.1 7.0 10.1 21.4 13.6 29.5 11.0 8.9 24.8 13.7 4.1 4.8 8.7 15.3 8.3 17.2 5.1 2.2 9.3 12.3 4.5 15.7 16.5 8.7 12.0 6.3 7.3 22.6 7.4 15.3 14.8 2.6 7.9 9.9 4.7 8.8 3.3 7.4 2.8 4.1 6.5 5.5 0.7 3.0 9.8 7.5 9.2 0.4 9.5 4.2 2.2 3.7 5.7 6.6 1.8 1.4 1.3 2.7 2.4 0.8 FANCC "FA3, FAC, FACC" ENSG00000158169 "Fanconi anemia complementation group C" Q00597 9 95099054-95426796 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA repair" "Cancer-related genes, Disease mutation, Fanconi anemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 29.7" "Cell line enhanced" "Detected in all" "RH-30: 31.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in many" 6 "basophil: 10.4" "Lineage enriched" "Detected in many" 6 "granulocytes: 10.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB017793, HPA030771" Approved Supported Nucleoplasm Nucleoplasm "CAB017793: , HPA030771: " "unprognostic (1.48e-2)" "unprognostic (4.33e-2)" "unprognostic (1.10e-1)" "unprognostic (2.63e-1)" "unprognostic (2.14e-1)" "unprognostic (1.32e-2)" "unprognostic (3.41e-3)" "unprognostic (1.26e-2)" "unprognostic (7.45e-3)" "unprognostic (1.37e-1)" "unprognostic (8.00e-3)" "unprognostic (3.19e-2)" "prognostic favourable (6.03e-6)" "unprognostic (2.35e-2)" "unprognostic (1.82e-1)" "unprognostic (1.49e-1)" "unprognostic (5.71e-2)" 4.9 2.7 4.3 8.6 7.0 3.6 4.6 29.7 7.7 4.6 6.4 4.9 5.1 7.1 6.3 4.1 4.5 3.6 5.2 3.2 4.0 2.7 10.0 25.7 6.7 3.7 7.3 1.6 3.3 5.4 2.9 12.1 4.3 6.7 4.4 6.1 4.0 4.0 4.2 4.5 7.7 8.1 2.9 6.4 3.4 4.4 19.6 7.3 7.9 4.3 3.2 6.0 3.5 4.0 1.0 1.3 10.4 1.7 0.3 1.5 0.7 13.4 9.1 12.0 10.5 1.2 3.2 7.6 5.9 3.8 9.4 8.7 10.4 5.7 7.7 4.1 4.3 16.5 12.2 5.1 5.1 7.3 5.7 6.0 10.2 5.3 2.0 6.0 6.8 2.7 2.1 7.5 3.3 5.2 9.0 3.4 6.7 9.5 5.6 3.5 5.8 5.2 12.1 31.2 3.6 3.9 3.5 17.5 9.3 11.1 4.0 3.4 4.1 5.1 2.5 8.3 12.0 9.0 8.3 3.5 6.5 4.0 4.4 5.5 9.7 10.4 0.4 0.0 1.3 0.8 1.3 1.0 0.7 1.5 0.4 1.0 1.2 1.0 0.1 0.3 1.7 1.3 1.3 0.7 4.3 7.0 29.7 7.7 4.0 2.7 7.3 1.6 6.7 7.3 FANCD2 "FA-D2, FACD, FAD, FANCD" ENSG00000144554 "Fanconi anemia complementation group D2" Q9BXW9 3 10026414-10101930 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cell cycle, DNA damage, DNA repair" "Cancer-related genes, Disease mutation, Fanconi anemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 24.4;testis: 23.3" "Cell line enhanced" "Detected in many" "BEWO: 45.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB016117, HPA063742" Approved Supported "Nucleoplasm,Nucleoli,Nuclear bodies,Cytosol" Nucleoplasm "Nucleoli, Nuclear bodies, Cytosol" "CAB016117: AB_2278211, HPA063742: " "unprognostic (3.25e-2)" "unprognostic (1.09e-1)" "unprognostic (6.21e-2)" "unprognostic (1.12e-2)" "unprognostic (2.92e-1)" "unprognostic (3.36e-2)" "unprognostic (1.08e-5)" "unprognostic (2.96e-2)" "unprognostic (1.59e-3)" "prognostic unfavourable (5.00e-5)" "unprognostic (1.23e-2)" "unprognostic (9.14e-2)" "unprognostic (4.41e-10)" "unprognostic (9.11e-3)" "unprognostic (3.99e-1)" "unprognostic (7.76e-2)" "unprognostic (2.89e-2)" 2.0 1.3 0.8 10.3 2.6 12.2 2.4 1.6 2.7 1.7 2.9 1.1 1.0 2.2 2.2 1.8 4.7 2.4 2.5 1.1 0.8 0.9 2.3 1.0 2.4 9.5 1.3 1.2 3.5 3.5 0.6 1.1 5.3 1.4 2.2 4.9 1.6 3.3 0.4 3.0 3.3 6.2 1.2 2.0 7.3 2.4 23.3 1.6 24.4 1.6 5.6 14.6 2.2 2.4 6.8 3.7 5.3 2.6 2.1 2.9 1.0 8.5 9.1 17.5 4.9 0.9 1.3 45.3 7.9 3.5 11.4 9.3 6.8 8.5 16.8 3.7 2.6 7.5 18.0 6.1 11.4 8.0 12.2 23.0 14.0 6.5 0.1 17.0 14.4 0.4 1.0 12.8 7.1 6.8 14.0 19.3 8.5 9.9 14.2 6.5 21.1 6.4 15.5 14.2 11.9 3.9 9.7 4.9 9.6 9.7 7.6 3.1 11.6 10.8 3.9 9.4 10.8 5.7 11.4 8.2 16.0 28.5 5.4 17.5 16.1 5.3 1.4 3.7 1.5 1.0 1.3 4.9 2.0 1.2 0.9 6.8 2.5 1.9 3.3 2.1 2.6 3.7 2.9 1.0 0.8 2.6 1.6 2.7 0.8 0.9 1.3 1.2 1.4 1.6 FANCE "FACE, FAE" ENSG00000112039 "Fanconi anemia complementation group E" Q9HB96 6 35452361-35467103 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA repair" "Cancer-related genes, Disease mutation, Fanconi anemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" CAB014893 Enhanced Supported Nucleoplasm Nucleoplasm "CAB014893: " "unprognostic (2.66e-1)" "unprognostic (8.01e-3)" "unprognostic (7.73e-2)" "prognostic unfavourable (6.25e-4)" "unprognostic (1.99e-1)" "unprognostic (2.80e-3)" "prognostic unfavourable (2.08e-9)" "unprognostic (8.90e-2)" "unprognostic (5.70e-3)" "unprognostic (8.41e-2)" "unprognostic (1.52e-1)" "unprognostic (2.91e-2)" "unprognostic (1.28e-1)" "unprognostic (1.70e-1)" "unprognostic (3.05e-1)" "unprognostic (2.44e-2)" "unprognostic (5.14e-2)" 7.2 2.1 2.6 7.0 3.8 7.2 8.5 5.5 3.9 6.7 4.1 4.8 1.5 3.1 6.1 4.7 10.0 4.9 5.4 4.1 2.8 3.2 2.4 1.7 5.5 5.4 2.4 1.8 10.8 6.9 2.7 4.0 21.3 3.9 6.7 4.1 3.7 5.3 4.0 20.8 16.8 4.7 4.1 3.7 4.6 3.8 12.1 3.5 3.0 5.9 10.1 8.5 6.7 15.0 2.4 1.8 1.0 1.0 2.6 3.6 0.9 5.6 2.8 7.7 17.3 5.6 10.0 20.7 6.8 5.8 8.9 7.8 6.6 3.2 19.3 4.5 4.2 4.2 8.6 5.8 8.6 6.5 7.5 13.5 6.7 4.3 3.0 7.9 5.5 6.3 17.5 10.9 16.8 5.2 12.4 7.2 7.4 6.6 3.7 9.9 3.2 4.4 10.9 7.3 7.2 2.0 6.2 7.7 7.2 3.9 5.5 6.1 5.4 25.8 3.2 10.8 9.0 6.9 10.6 4.8 16.6 7.0 2.4 14.6 10.1 0.7 1.0 1.0 2.2 0.6 3.0 0.7 2.8 3.6 0.6 2.4 1.9 1.9 0.6 2.6 0.6 1.8 1.7 0.9 2.6 3.8 5.5 3.9 2.8 3.2 2.4 1.8 3.9 3.5 FANCF FAF ENSG00000183161 "Fanconi anemia complementation group F" Q9NPI8 11 22622519-22626787 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "DNA damage, DNA repair" "Cancer-related genes, Fanconi anemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 15.2" "Cell line enhanced" "Detected in many" "SCLC-21H: 20.9" "Low cancer specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" HPA008899 Supported Nucleoplasm Nucleoplasm "HPA008899: " "unprognostic (1.16e-2)" "unprognostic (4.10e-2)" "unprognostic (2.33e-2)" "unprognostic (1.37e-2)" "unprognostic (4.55e-2)" "unprognostic (8.84e-2)" "prognostic unfavourable (2.27e-4)" "unprognostic (4.29e-2)" "unprognostic (1.11e-1)" "unprognostic (2.74e-3)" "unprognostic (3.95e-1)" "unprognostic (1.67e-1)" "unprognostic (2.29e-1)" "unprognostic (3.73e-2)" "unprognostic (1.81e-1)" "unprognostic (9.14e-2)" "unprognostic (7.64e-3)" 1.2 4.1 2.9 3.1 2.8 1.1 3.2 1.0 2.7 3.1 3.4 5.3 3.0 6.0 3.0 6.1 1.7 1.9 2.9 3.9 3.2 4.2 1.8 4.9 3.3 4.2 9.0 3.4 4.5 1.5 2.9 3.7 3.8 3.1 0.4 3.1 4.9 1.1 3.5 5.4 4.6 4.3 3.6 4.8 2.6 2.0 15.2 9.7 11.5 5.7 10.0 15.1 7.3 1.4 4.3 5.6 6.1 2.9 3.5 2.3 2.8 3.3 3.2 3.5 2.8 2.2 7.2 0.7 2.8 6.2 4.5 4.6 1.6 11.7 2.1 2.7 1.8 4.9 3.4 4.9 2.9 3.4 9.0 1.1 4.9 5.0 6.8 9.4 2.0 4.5 12.5 4.6 6.4 5.4 10.9 2.6 8.0 6.0 5.6 20.9 9.8 1.5 4.9 4.8 9.9 4.5 3.6 3.3 3.5 5.9 4.0 5.4 6.9 2.1 5.4 2.0 7.6 5.7 5.4 11.5 11.5 5.5 13.5 11.8 10.8 10.8 6.4 15.2 15.1 12.4 0.8 10.0 5.7 9.7 7.3 7.3 FANCG "FAG, XRCC9" ENSG00000221829 "Fanconi anemia complementation group G" O15287 9 35073835-35080016 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "DNA damage, DNA repair" "Cancer-related genes, Disease mutation, Fanconi anemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB008105, HPA045335" Approved Supported "Nucleoli,Plasma membrane,Cytosol" "Plasma membrane, Cytosol" Nucleoli "CAB008105: AB_2231542, HPA045335: " "unprognostic (9.41e-2)" "unprognostic (2.62e-2)" "unprognostic (1.82e-1)" "unprognostic (1.05e-1)" "unprognostic (2.09e-1)" "unprognostic (5.83e-3)" "prognostic unfavourable (2.02e-4)" "unprognostic (8.92e-2)" "unprognostic (1.42e-2)" "unprognostic (2.27e-3)" "unprognostic (9.01e-2)" "unprognostic (5.62e-2)" "prognostic unfavourable (2.38e-7)" "unprognostic (1.14e-2)" "unprognostic (1.59e-1)" "unprognostic (1.24e-1)" "unprognostic (2.10e-1)" 5.8 5.0 4.4 7.1 6.5 14.9 7.5 13.9 8.5 6.2 5.9 5.3 8.4 6.7 6.8 3.2 9.2 8.6 4.7 5.9 7.6 4.0 5.2 4.5 5.1 9.9 8.7 4.4 9.2 17.0 6.7 4.8 7.6 6.6 7.0 5.5 3.5 8.7 9.7 2.9 8.9 6.5 6.4 4.2 8.6 5.8 8.9 7.6 25.6 9.3 4.8 9.2 6.8 6.9 6.8 4.8 8.9 2.5 8.8 9.2 3.4 15.7 19.5 14.3 13.2 3.2 5.1 12.0 11.1 8.0 21.8 20.9 9.3 9.9 15.6 7.7 3.5 9.7 11.9 10.2 8.3 18.2 7.2 11.1 20.9 5.7 0.9 11.3 12.9 4.2 2.0 19.0 8.6 11.1 7.3 21.0 10.9 14.0 19.1 15.5 14.9 15.1 19.8 16.9 11.0 5.1 6.7 6.9 12.6 7.3 10.4 4.1 13.5 8.1 6.7 10.3 20.7 13.2 14.9 5.7 10.8 9.4 9.2 8.4 14.1 8.9 0.8 7.7 7.4 2.5 6.5 6.8 6.1 5.7 2.2 6.5 4.8 5.0 1.3 8.8 2.3 4.8 9.2 3.4 4.4 6.5 13.9 8.5 7.6 4.0 8.7 4.4 6.6 7.6 FAP DPPIV ENSG00000078098 "Fibroblast activation protein alpha" Q12884 2 162170684-162245151 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Angiogenesis, Apoptosis, Cell adhesion" "Hydrolase, Protease, Serine protease" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "endometrium 1: 30.0" "Cell line enhanced" "Detected in some" "ASC diff: 47.0;ASC TERT1: 49.9;BJ hTERT+: 39.4;TIME: 19.7;U-138 MG: 40.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA059739 Uncertain "Secreted to blood" 34000000 "HPA059739: " "unprognostic (7.48e-3)" "unprognostic (7.87e-3)" "unprognostic (4.10e-2)" "unprognostic (5.04e-2)" "unprognostic (1.49e-2)" "prognostic unfavourable (4.82e-4)" "unprognostic (2.01e-2)" "unprognostic (1.05e-2)" "unprognostic (3.30e-2)" "unprognostic (4.89e-2)" "unprognostic (4.59e-2)" "unprognostic (3.52e-1)" "unprognostic (7.32e-11)" "unprognostic (1.72e-3)" "unprognostic (9.84e-3)" "unprognostic (7.97e-2)" "unprognostic (4.49e-3)" 19.8 0.7 2.6 3.2 1.2 0.0 7.5 0.6 3.7 17.6 4.5 0.4 4.0 0.1 30.0 13.7 4.1 5.1 14.9 5.2 3.1 0.9 2.0 0.9 4.7 0.8 2.6 1.2 4.1 2.3 0.5 1.0 17.0 1.9 4.1 1.5 2.4 5.3 3.9 8.1 2.9 1.4 17.9 2.2 0.9 1.7 9.8 3.4 0.0 3.5 9.0 0.8 12.4 4.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 47.0 49.9 0.0 19.2 39.4 4.0 6.1 0.0 0.0 0.0 0.1 7.3 0.0 0.0 1.2 1.9 0.0 0.0 0.0 0.2 0.0 4.7 0.0 0.0 16.1 0.3 6.7 1.2 0.0 0.0 0.0 12.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 2.0 0.0 2.0 0.0 0.0 19.7 40.1 0.8 9.7 0.0 0.0 0.0 0.0 9.0 0.0 10.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.6 1.2 0.6 3.7 3.1 0.9 2.6 1.2 1.9 3.4 FAS "APO-1, APT1, CD95, FAS1, TNFRSF6" ENSG00000026103 "Fas cell surface death receptor" P25445 10 88990582-89015785 "Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins" Apoptosis "Calmodulin-binding, Receptor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Karpas-707: 43.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 40.1" "Group enriched" "Detected in all" 5 "granulocytes: 40.1;T-cells: 30.9" "Low region specificity" "Detected in all" HPA027444 Uncertain Supported "Nuclear bodies,Plasma membrane,Cytosol" "Secreted to blood" 450000 "Plasma membrane" "Nuclear bodies, Cytosol" "HPA027444: AB_10601378" "unprognostic (6.84e-2)" "unprognostic (2.88e-3)" "unprognostic (8.38e-3)" "unprognostic (1.94e-1)" "unprognostic (2.35e-2)" "unprognostic (9.56e-2)" "unprognostic (7.00e-2)" "unprognostic (2.05e-1)" "unprognostic (3.01e-1)" "unprognostic (7.70e-2)" "unprognostic (1.26e-2)" "unprognostic (1.98e-1)" "unprognostic (1.52e-3)" "unprognostic (2.10e-1)" "unprognostic (2.32e-2)" "unprognostic (4.95e-3)" "unprognostic (1.65e-1)" 13.5 26.3 6.1 17.3 7.7 12.4 10.6 2.1 7.2 15.6 14.2 6.1 7.0 5.9 15.7 16.6 14.1 14.2 14.5 8.9 8.2 2.7 11.7 21.9 28.6 15.6 6.0 3.9 24.7 4.1 4.5 4.6 9.0 7.5 22.3 21.3 4.4 7.1 8.5 4.3 9.6 16.3 12.5 10.2 15.3 5.0 7.3 5.1 12.5 10.0 15.8 14.4 14.8 21.4 3.0 4.0 40.1 6.8 1.2 30.9 3.9 8.5 3.3 1.7 5.5 14.2 21.0 0.0 18.9 19.1 0.7 3.7 0.0 9.3 1.7 7.3 17.7 1.3 0.3 15.8 1.3 27.5 2.7 0.1 1.8 5.6 13.6 0.9 0.4 26.0 14.2 11.8 25.5 1.6 0.0 43.8 19.2 0.7 2.7 1.4 0.2 0.9 0.1 0.1 1.7 26.5 2.7 0.1 0.1 2.7 0.0 0.3 6.0 0.3 4.1 6.0 3.4 5.6 4.3 17.2 1.7 0.1 5.0 3.4 1.8 11.3 3.2 9.4 3.3 3.9 4.8 3.0 10.4 7.2 4.0 0.7 1.2 3.4 40.1 1.2 6.8 0.0 30.9 3.9 6.1 7.7 2.1 7.2 8.2 2.7 6.0 3.9 7.5 5.1 FASLG "APT1LG1, CD178, FasL, TNFSF6" ENSG00000117560 "Fas ligand" P48023 1 172659018-172666874 "Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins" "Apoptosis, Transcription, Transcription regulation" "Cytokine, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 25.6;lymphoid tissue: 13.4" "Cell line enhanced" "Detected in some" "ASC diff: 1.0;LHCN-M2: 2.4;NB-4: 1.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in single" "Cell type enhanced" "Detected in many" "gdT-cell: 25.6" "Group enriched" "Detected in many" 12 "NK-cells: 16.0;T-cells: 25.6" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA054959 Approved "Secreted to blood" 34930061667 "HPA054959: " "unprognostic (1.09e-3)" "unprognostic (1.41e-2)" "unprognostic (8.69e-2)" "unprognostic (1.54e-7)" "unprognostic (3.29e-1)" "unprognostic (2.23e-3)" "unprognostic (5.44e-2)" "unprognostic (1.84e-2)" "unprognostic (4.67e-2)" "unprognostic (4.76e-2)" "unprognostic (8.88e-2)" "unprognostic (1.07e-1)" "prognostic unfavourable (1.59e-6)" "unprognostic (3.49e-2)" "unprognostic (1.22e-1)" "unprognostic (1.15e-2)" "unprognostic (3.82e-3)" 0.9 1.1 0.5 1.9 0.7 3.6 1.8 0.5 0.8 0.7 2.6 0.6 0.0 3.0 3.9 1.2 1.0 0.8 1.6 1.2 0.5 0.5 1.2 2.2 6.8 7.7 1.4 0.0 1.5 0.6 0.0 0.7 2.4 0.6 4.7 1.2 2.8 1.9 0.3 0.4 0.5 3.8 1.9 1.7 13.4 2.1 0.4 0.0 1.2 1.1 0.0 10.1 1.4 0.9 0.0 0.0 1.6 0.0 16.0 25.6 5.5 0.0 0.0 0.3 0.1 1.0 0.0 0.5 0.2 0.0 0.0 0.1 0.0 0.5 0.5 0.1 0.0 0.8 0.0 0.2 0.0 0.1 0.0 0.0 0.3 0.0 0.0 0.2 0.1 0.0 0.2 0.4 0.7 0.0 0.2 0.6 2.4 0.0 0.0 1.2 0.4 0.0 0.0 0.0 0.1 1.0 0.2 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.1 0.3 0.3 0.7 0.0 0.0 0.0 0.1 0.1 1.6 0.0 0.0 25.6 0.0 15.8 0.0 5.4 13.7 0.0 0.0 1.1 11.7 0.8 16.0 0.0 0.0 0.1 5.5 0.5 0.7 0.5 0.8 0.5 0.5 1.4 0.0 0.6 0.0 FASN "FAS, SDR27X1" ENSG00000169710 "Fatty acid synthase" P49327 17 82078333-82098332 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism" "Hydrolase, Lyase, Multifunctional enzyme, Oxidoreductase, Transferase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "adipose tissue: 147.6" "Cell line enhanced" "Detected in many" "SK-BR-3: 152.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB005192, HPA006461, CAB015417, HPA056108" Enhanced Enhanced "Plasma membrane,Cytosol" 1600000 "Plasma membrane, Cytosol" "CAB005192: AB_2101095, CAB015417: AB_2231427, HPA006461: AB_1848437, HPA056108: AB_2683039" "unprognostic (3.35e-2)" "prognostic unfavourable (1.42e-5)" "unprognostic (9.69e-3)" "unprognostic (4.09e-2)" "unprognostic (3.46e-3)" "unprognostic (1.55e-2)" "unprognostic (3.09e-2)" "unprognostic (4.74e-3)" "unprognostic (3.15e-1)" "unprognostic (3.15e-1)" "unprognostic (2.87e-3)" "unprognostic (1.05e-1)" "prognostic unfavourable (7.16e-5)" "unprognostic (4.50e-2)" "unprognostic (9.62e-2)" "unprognostic (1.35e-2)" "unprognostic (7.03e-3)" 147.6 7.8 8.2 14.2 11.5 11.1 57.5 19.1 23.0 6.6 27.7 17.0 14.1 8.2 4.7 14.2 17.1 4.3 19.4 6.3 7.9 6.7 3.7 30.8 26.8 9.8 7.3 11.5 6.4 10.4 6.7 15.3 8.4 21.7 28.8 3.4 7.6 16.9 10.8 7.5 17.2 6.5 4.6 8.4 5.1 11.9 6.6 8.8 1.9 5.1 10.7 5.4 8.0 6.6 0.5 1.4 0.0 0.8 0.2 1.9 0.8 23.1 24.3 11.3 7.8 18.3 12.4 24.2 4.6 6.0 4.9 9.0 25.4 15.8 7.7 3.8 3.5 19.4 10.9 21.3 0.9 3.6 47.4 16.0 18.2 33.9 5.2 8.6 2.4 11.9 5.6 12.5 2.9 5.5 24.1 6.9 1.7 40.1 9.4 13.7 21.9 14.2 8.3 6.4 15.3 5.5 29.7 28.1 15.6 6.8 152.8 12.4 27.2 16.5 9.6 7.2 14.8 5.9 11.0 9.3 2.0 8.0 4.3 9.4 10.6 0.0 0.8 0.0 1.2 0.5 0.7 0.5 1.9 1.4 1.4 0.2 0.7 0.6 0.0 0.2 0.4 1.1 0.6 0.8 8.2 11.5 19.1 23.0 7.9 6.7 7.3 11.5 21.7 8.8 FAT1 "CDHF7, CDHR8, FAT" ENSG00000083857 "FAT atypical cadherin 1" Q14517 4 186587783-186726722 "Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 76.4" "Cell line enhanced" "Detected in many" "fHDF/TERT166: 63.5;LHCN-M2: 46.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001869, HPA023882" Enhanced "Intracellular and membrane" 120000 "HPA001869: AB_1078818, HPA023882: AB_1848429" "unprognostic (1.98e-1)" "unprognostic (4.91e-2)" "unprognostic (2.50e-2)" "unprognostic (1.86e-1)" "unprognostic (1.53e-2)" "unprognostic (5.82e-3)" "unprognostic (2.31e-1)" "prognostic unfavourable (4.22e-4)" "unprognostic (6.10e-2)" "unprognostic (3.05e-2)" "unprognostic (1.15e-3)" "unprognostic (6.80e-2)" "unprognostic (3.57e-2)" "unprognostic (8.03e-3)" "unprognostic (9.41e-2)" "unprognostic (6.25e-3)" "unprognostic (4.27e-2)" 15.5 1.3 7.9 12.3 9.8 0.4 15.4 11.9 8.4 15.9 40.4 11.8 8.1 17.9 20.6 14.0 9.7 9.6 28.2 21.1 10.0 6.0 29.1 13.3 10.9 1.4 11.4 6.2 9.7 13.8 7.5 10.5 14.6 24.7 15.9 22.9 5.0 13.9 18.2 3.0 13.1 76.4 18.3 12.8 1.7 11.5 7.0 11.2 1.3 10.5 10.2 6.7 17.5 9.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.8 18.6 18.4 0.0 18.5 22.3 4.5 24.8 41.0 12.1 7.7 11.0 11.0 0.0 6.0 63.5 9.0 7.2 30.6 16.5 0.0 2.9 0.0 6.6 11.1 9.2 8.0 6.6 8.0 11.1 22.5 14.7 0.2 0.1 0.0 46.6 5.9 14.3 0.0 4.1 3.1 0.0 5.1 0.3 18.2 17.5 1.9 7.4 4.3 7.3 2.9 0.0 2.9 5.3 34.6 13.4 0.4 15.4 0.1 0.0 0.1 7.9 0.0 11.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.9 9.8 11.9 8.4 10.0 6.0 11.4 6.2 24.7 11.2 FAT4 "CDHF14, CDHR11, FAT-J" ENSG00000196159 "FAT atypical cadherin 4" Q6V0I7 4 125316399-125492932 "Cancer-related genes, Disease related genes, Predicted membrane proteins" "Cell adhesion" "Cancer-related genes, Deafness, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "ASC diff: 12.1;ASC TERT1: 9.0;fHDF/TERT166: 8.8;HSkMC: 10.4;HUVEC TERT2: 10.9;TIME: 17.1" "Low cancer specificity" "Detected in many" "Cell type enriched" "Detected in single" 12 "NK-cell: 1.1" "Lineage enriched" "Detected in single" 12 "NK-cells: 1.1" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA052819 Approved Approved Cytosol 7900000 Cytosol "HPA052819: " "unprognostic (1.18e-1)" "unprognostic (1.77e-1)" "unprognostic (7.99e-2)" "unprognostic (1.09e-1)" "unprognostic (2.31e-1)" "unprognostic (2.81e-4)" "unprognostic (6.17e-3)" "unprognostic (1.28e-1)" "unprognostic (1.77e-2)" "unprognostic (2.78e-2)" "unprognostic (1.63e-1)" "unprognostic (1.39e-1)" "prognostic favourable (1.89e-4)" "unprognostic (2.38e-2)" "unprognostic (1.71e-1)" "unprognostic (1.30e-2)" "unprognostic (2.49e-3)" 3.8 0.5 0.9 0.8 0.7 0.0 3.2 0.0 0.5 4.4 7.1 0.3 2.7 0.6 1.9 2.1 4.1 5.0 1.0 0.4 2.6 2.0 5.3 0.1 0.9 5.3 0.5 6.7 0.4 2.5 3.6 1.9 1.0 2.3 1.1 1.4 2.4 3.3 0.6 2.1 2.4 0.1 3.9 0.2 3.0 2.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.7 5.9 0.6 12.1 9.0 0.0 2.0 2.3 0.9 1.0 0.0 0.3 0.0 2.4 8.8 0.0 2.2 2.5 0.6 0.0 1.0 1.3 2.5 0.0 3.9 0.8 0.0 10.4 1.3 0.5 5.5 10.9 0.0 1.6 5.0 0.1 0.4 0.0 0.4 0.2 0.7 1.2 0.0 0.1 0.0 0.1 1.2 0.3 0.0 0.0 0.0 0.0 17.1 6.0 1.7 2.1 0.9 0.2 0.0 0.0 1.6 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 FBN2 "CCA, DA9" ENSG00000138829 "Fibrillin 2" P35556 5 128257909-128659185 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 22 "placenta: 175.9" "Cell line enhanced" "Detected in many" "HHSteC: 37.3;HSkMC: 26.6;hTERT-HME1: 58.9;HUVEC TERT2: 33.1" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "classical monocyte: 2.5;non-classical monocyte: 5.0" "Lineage enriched" "Detected in many" 5 "monocytes: 5.0" "Region enhanced" "Detected in single" "olfactory region: 2.6" "Low region specificity" "Detected in some" "HPA012853, CAB026401" Enhanced Approved Nucleoplasm,Cytosol "Secreted to extracellular matrix" 4600000 Cytosol Nucleoplasm "CAB026401: , HPA012853: AB_1848588" "unprognostic (2.49e-1)" "unprognostic (1.14e-1)" "unprognostic (7.29e-3)" "unprognostic (1.79e-3)" "unprognostic (6.74e-2)" "unprognostic (2.33e-1)" "unprognostic (4.92e-3)" "unprognostic (9.41e-2)" "unprognostic (1.06e-2)" "unprognostic (4.66e-1)" "unprognostic (1.12e-1)" "unprognostic (8.69e-2)" "unprognostic (8.60e-5)" "unprognostic (1.04e-2)" "unprognostic (3.19e-2)" "unprognostic (1.00e-1)" "prognostic unfavourable (7.41e-5)" 0.3 7.9 0.3 1.0 0.3 1.6 0.1 0.2 0.3 1.5 0.7 0.4 1.0 0.2 2.9 0.6 1.1 0.6 0.2 6.7 0.2 0.5 0.2 0.2 0.2 1.3 0.2 0.4 0.9 0.1 0.0 1.3 175.9 0.4 1.0 0.8 6.2 0.4 0.9 0.2 0.3 0.5 0.8 0.4 0.6 0.5 4.6 0.2 0.3 0.9 0.4 0.7 0.4 1.2 0.0 1.1 0.6 5.0 0.0 0.0 0.4 0.0 4.4 16.1 0.0 2.6 4.6 3.3 17.6 0.0 15.6 11.7 0.0 0.0 0.0 0.0 23.5 2.6 10.4 2.6 14.7 0.0 4.2 0.0 7.4 0.0 37.3 2.3 0.0 26.6 1.4 6.6 58.9 33.1 0.0 0.0 9.6 0.0 0.0 0.8 6.9 5.3 5.1 5.2 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.0 4.9 0.0 6.3 12.0 17.9 0.0 0.0 0.0 0.0 1.8 0.0 6.6 0.0 2.5 0.0 0.0 1.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.6 0.0 5.0 0.0 0.0 0.4 0.3 0.3 0.2 0.3 0.2 0.5 0.2 0.4 0.4 0.2 FBXO11 "FBX11, UBR6" ENSG00000138081 "F-box protein 11" Q86XK2 2 47789316-47905793 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Ubl conjugation pathway" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA002690 Supported Nucleoplasm Nucleoplasm "HPA002690: AB_1848448" "unprognostic (1.18e-1)" "unprognostic (8.65e-3)" "unprognostic (3.93e-2)" "unprognostic (2.05e-2)" "unprognostic (7.92e-2)" "unprognostic (1.42e-1)" "unprognostic (3.85e-2)" "unprognostic (1.02e-1)" "unprognostic (2.55e-2)" "unprognostic (9.82e-2)" "unprognostic (5.77e-2)" "unprognostic (2.33e-2)" "unprognostic (3.21e-2)" "unprognostic (1.55e-1)" "unprognostic (3.71e-1)" "unprognostic (2.19e-1)" "unprognostic (3.20e-2)" 18.0 13.8 18.6 15.7 18.8 17.5 26.1 42.2 31.7 21.3 15.3 12.7 15.1 10.4 28.9 16.8 14.5 16.3 15.0 14.1 16.9 13.6 14.3 17.0 22.3 15.0 17.4 21.7 28.9 12.4 25.2 14.4 14.5 19.7 15.3 13.3 12.0 15.6 16.5 22.9 14.5 13.5 19.9 16.4 14.5 13.3 25.1 16.0 14.6 17.3 9.8 17.2 19.3 21.9 4.7 4.3 8.2 2.7 4.8 6.6 2.0 25.5 13.3 32.0 27.2 22.5 21.2 19.1 17.9 24.7 16.8 16.6 11.2 13.1 16.6 23.5 25.2 12.8 21.8 18.9 24.8 11.0 10.9 15.4 11.0 17.8 21.5 16.0 16.4 20.6 21.4 14.9 25.3 21.5 15.0 17.2 20.5 12.3 15.4 15.7 19.5 13.2 20.1 29.7 12.3 24.0 20.9 22.6 26.7 17.0 15.9 26.2 7.4 13.7 23.1 20.8 19.2 14.0 19.6 14.9 7.7 30.2 14.1 15.1 21.2 8.2 2.3 4.3 3.8 2.7 3.8 4.7 3.4 4.1 3.1 3.6 6.6 4.1 4.1 4.8 2.4 4.3 3.6 2.0 18.6 18.8 42.2 31.7 16.9 13.6 17.4 21.7 19.7 16.0 FBXO6 "FBG2, FBS2, FBX6, Fbx6b" ENSG00000116663 "F-box protein 6" Q9NRD1 1 11664124-11674354 "Cancer-related genes, Predicted intracellular proteins" "DNA damage, DNA repair, Ubl conjugation pathway, Unfolded protein response" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA051175 Approved "HPA051175: " "unprognostic (3.23e-3)" "unprognostic (2.58e-2)" "unprognostic (8.27e-2)" "unprognostic (2.69e-3)" "unprognostic (1.11e-1)" "unprognostic (6.64e-2)" "unprognostic (9.46e-3)" "unprognostic (1.22e-1)" "unprognostic (1.18e-1)" "prognostic favourable (7.12e-4)" "unprognostic (1.47e-2)" "unprognostic (3.40e-1)" "prognostic unfavourable (7.83e-6)" "unprognostic (2.65e-2)" "unprognostic (2.11e-1)" "unprognostic (5.23e-2)" "prognostic favourable (5.90e-4)" 9.1 11.8 10.8 12.2 17.4 19.7 13.2 9.5 11.6 7.6 11.6 4.4 9.8 14.6 5.4 9.1 14.1 15.7 11.1 14.4 9.5 12.6 8.9 17.5 12.2 17.5 9.4 12.2 6.8 25.9 10.4 6.8 5.0 9.1 11.4 7.5 8.9 13.8 9.9 16.8 9.3 9.9 10.6 6.6 14.9 9.8 9.9 8.5 5.8 13.0 13.2 12.1 10.5 6.9 6.0 25.1 23.5 31.0 14.4 18.7 12.2 6.1 4.6 0.5 0.2 1.4 4.5 3.0 2.6 4.1 12.9 6.0 4.7 5.4 0.2 12.1 4.4 0.1 4.3 4.7 0.9 16.3 0.6 0.1 0.6 4.7 10.1 5.7 0.0 5.2 10.1 1.6 4.1 1.7 13.7 12.1 1.1 11.8 2.1 4.9 0.5 6.1 1.4 0.1 0.4 4.4 0.9 1.1 1.3 5.8 7.0 8.7 6.7 6.5 1.3 0.6 0.5 1.8 0.2 6.5 4.5 2.4 0.8 13.4 1.1 5.6 19.1 23.5 18.7 28.0 10.3 6.0 5.0 12.5 25.1 5.2 3.0 10.0 15.6 14.4 31.0 9.9 4.7 12.2 10.8 17.4 9.5 11.6 9.5 12.6 9.4 12.2 9.1 8.5 FBXW7 "AGO, CDC4, FBW7, FBX30, FBXW6, FLJ11071, SEL-10, SEL10" ENSG00000109670 "F-box and WD repeat domain containing 7" Q969H0 4 152320544-152536063 "Cancer-related genes, Predicted intracellular proteins" "Biological rhythms, Host-virus interaction, Ubl conjugation pathway" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 60.1;skin 1: 45.0" "Cell line enhanced" "Detected in all" "U-266/70: 37.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB013793, CAB029987" Supported Supported Nucleoplasm,Vesicles "Nucleoplasm, Vesicles" "CAB013793: AB_2533451, CAB029987: AB_2246842" "unprognostic (3.32e-1)" "unprognostic (9.02e-2)" "unprognostic (1.84e-2)" "unprognostic (3.08e-2)" "unprognostic (3.87e-1)" "unprognostic (1.36e-3)" "unprognostic (4.37e-1)" "unprognostic (1.94e-1)" "unprognostic (8.28e-2)" "unprognostic (3.29e-1)" "unprognostic (5.32e-3)" "unprognostic (3.19e-2)" "prognostic unfavourable (1.52e-4)" "unprognostic (3.38e-2)" "unprognostic (1.41e-1)" "unprognostic (5.49e-3)" "unprognostic (2.17e-3)" 9.2 6.8 27.0 8.9 27.9 11.1 9.8 27.2 60.1 5.5 6.1 3.6 3.8 4.9 6.0 18.3 9.8 10.6 6.3 10.9 21.4 10.1 4.1 7.3 6.9 9.8 9.1 40.5 6.4 8.0 6.4 7.3 6.2 37.2 5.1 6.9 2.8 7.6 5.3 15.8 45.0 6.5 6.1 6.4 10.1 8.0 13.7 5.7 6.5 6.8 10.6 12.3 7.9 6.5 2.9 2.2 16.6 3.4 7.8 5.0 1.3 4.9 3.9 10.2 7.4 7.1 5.1 8.4 7.1 6.5 4.4 4.2 7.9 6.3 12.7 2.0 6.8 2.9 8.7 16.0 6.2 7.2 4.1 5.9 4.8 5.6 7.2 14.4 5.4 8.1 25.3 7.6 12.9 7.7 9.3 13.6 5.5 6.9 16.5 5.7 5.0 3.1 16.6 4.3 2.5 5.4 8.5 6.5 5.6 4.5 6.2 3.9 3.4 6.8 8.1 6.0 6.8 3.1 4.0 37.4 21.3 12.4 4.8 4.7 4.3 16.6 3.1 1.7 5.0 3.4 3.3 2.9 3.7 3.2 1.8 2.4 3.9 3.2 5.5 7.8 2.5 2.2 3.3 1.3 27.0 27.9 27.2 60.1 21.4 10.1 9.1 40.5 37.2 5.7 FCER2 "CD23, CD23A, CLEC4J, FCE2" ENSG00000104921 "Fc fragment of IgE receptor II" P06734 19 7688758-7702146 "Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" "IgE-binding protein, Receptor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 8 "blood: 87.2;lymphoid tissue: 38.4" "Cell line enriched" "Detected in some" 14 "HDLM-2: 97.5" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in some" 23 "memory B-cell: 28.2;naive B-cell: 87.2" "Lineage enriched" "Detected in many" 34 "B-cells: 87.2" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" "CAB002624, HPA008928" Enhanced "Secreted to blood" 59000 "CAB002624: , HPA008928: AB_1846285" "unprognostic (3.20e-4)" "unprognostic (1.87e-3)" "unprognostic (1.95e-2)" "unprognostic (2.44e-2)" "unprognostic (4.77e-2)" "unprognostic (1.77e-3)" "unprognostic (1.64e-1)" "unprognostic (1.89e-3)" "unprognostic (2.71e-1)" "unprognostic (1.88e-1)" "unprognostic (2.04e-2)" "unprognostic (8.55e-2)" "unprognostic (2.46e-4)" "unprognostic (2.99e-1)" "unprognostic (1.80e-1)" "unprognostic (4.89e-2)" "unprognostic (5.17e-2)" 2.4 0.3 0.5 17.1 0.5 2.3 1.2 0.3 1.1 0.3 1.0 0.1 0.4 1.3 0.3 2.3 1.0 0.4 0.5 0.8 0.3 0.3 0.6 0.6 0.8 21.1 0.3 0.0 0.4 0.3 0.0 0.3 0.3 0.1 0.3 0.8 0.0 7.5 0.7 0.4 0.6 7.7 0.4 0.3 38.4 0.8 0.5 0.0 6.3 0.7 0.0 33.8 2.0 0.5 87.2 0.7 0.2 2.5 0.0 0.0 3.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 97.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 7.1 0.0 0.0 0.5 0.0 0.0 2.5 0.0 28.2 0.0 0.0 0.7 87.2 0.0 0.0 0.2 0.0 0.7 0.1 0.0 3.0 0.5 0.5 0.3 0.3 0.3 0.3 0.3 0.0 0.1 0.0 FCGR2B "CD32, CD32B, FCG2, FCGR2" ENSG00000072694 "Fc fragment of IgG receptor IIb" P31994 1 161663147-161678654 "Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins" "Host-virus interaction" "IgG-binding protein, Receptor" "Cancer-related genes, FDA approved drug targets, Proto-oncogene, Systemic lupus erythematosus" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "blood: 53.3;placenta: 83.2" "Cell line enhanced" "Detected in some" "Daudi: 18.2;HMC-1: 23.0;NB-4: 5.1;RPMI-8226: 8.2" "Low cancer specificity" "Detected in many" "Cell type enhanced" "Detected in many" "basophil: 53.3;memory B-cell: 42.2" "Group enriched" "Detected in many" 18 "B-cells: 42.2;dendritic cells: 14.5;granulocytes: 53.3" "CAB007796, HPA014730" Enhanced "CAB007796: AB_562288, HPA014730: " "unprognostic (1.58e-1)" "unprognostic (5.14e-2)" "unprognostic (3.32e-3)" "unprognostic (3.12e-2)" "unprognostic (6.79e-3)" "unprognostic (4.05e-3)" "unprognostic (1.27e-1)" "unprognostic (4.65e-3)" "unprognostic (1.91e-1)" "unprognostic (4.72e-2)" "unprognostic (2.89e-2)" "unprognostic (3.49e-1)" "prognostic unfavourable (8.82e-4)" "unprognostic (3.51e-2)" "unprognostic (6.36e-2)" "unprognostic (4.31e-1)" "unprognostic (3.37e-1)" 11.3 2.4 0.0 2.0 0.2 0.0 4.1 0.0 0.0 1.9 3.4 0.2 0.9 0.2 2.1 2.1 2.3 3.7 0.0 0.2 2.0 9.5 5.6 2.5 0.5 0.8 0.6 0.0 0.3 83.2 0.3 2.0 3.3 0.2 0.5 2.0 4.6 3.1 4.7 6.7 1.5 0.1 1.7 5.6 3.3 1.2 42.2 14.5 53.3 1.9 0.1 0.3 2.4 0.0 0.1 0.0 1.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 18.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 23.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 5.1 0.1 0.0 0.0 0.0 8.2 0.0 0.0 0.1 0.1 0.0 0.0 1.6 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 2.2 0.0 53.3 1.8 5.4 0.3 1.9 0.1 42.2 0.1 0.2 14.5 34.3 0.0 0.3 11.2 0.1 1.7 0.0 0.0 2.4 FCRL4 "CD307d, FCRH4, IGFP2, IRTA1" ENSG00000163518 "Fc receptor like 4" Q96PJ5 1 157573749-157598080 "Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins" "Adaptive immunity, Immunity" Receptor "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 4 "intestine: 5.4;lymphoid tissue: 15.6" "Cell line enriched" "Detected in single" 102 "U-266/70: 10.1" "Not detected" "Not detected" "Not detected" "Not detected" "Cell type enriched" "Detected in single" 12 "memory B-cell: 1.1" "Lineage enriched" "Detected in single" 12 "B-cells: 1.1" "Low region specificity" "Detected in many" HPA054030 Approved "HPA054030: " "unprognostic (6.06e-2)" "unprognostic (3.41e-3)" "unprognostic (2.57e-1)" "unprognostic (5.08e-2)" "unprognostic (4.69e-4)" "unprognostic (2.06e-2)" "unprognostic (6.38e-2)" "unprognostic (1.99e-1)" "unprognostic (2.14e-1)" "unprognostic (3.37e-1)" "unprognostic (6.77e-2)" 0.1 0.1 0.1 15.6 0.1 0.0 0.1 0.1 0.2 0.1 0.3 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 5.1 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.4 0.0 2.5 0.0 0.1 0.1 5.4 0.0 0.1 2.2 0.3 0.1 0.0 1.1 0.1 1.9 14.9 0.4 0.1 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.0 0.0 0.0 FEN1 "FEN-1, MF1, RAD2" ENSG00000168496 "Flap structure-specific endonuclease 1" P39748 11 61792637-61797244 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA repair, DNA replication" "Endonuclease, Exonuclease, Hydrolase, Nuclease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 36.3" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002262, HPA006748" Enhanced Enhanced Nucleoplasm,Nucleoli 38000 Nucleoplasm Nucleoli "CAB002262: AB_563729, HPA006748: AB_1848494" "unprognostic (1.82e-1)" "unprognostic (2.71e-2)" "unprognostic (3.76e-2)" "unprognostic (2.77e-1)" "unprognostic (1.26e-1)" "unprognostic (6.45e-2)" "prognostic unfavourable (3.39e-6)" "unprognostic (1.50e-2)" "unprognostic (9.82e-2)" "prognostic favourable (7.85e-4)" "unprognostic (2.82e-3)" "unprognostic (5.86e-2)" "prognostic unfavourable (5.73e-6)" "prognostic favourable (9.46e-4)" "unprognostic (1.10e-1)" "unprognostic (4.49e-3)" "unprognostic (4.04e-2)" 4.8 9.6 7.9 14.6 8.5 23.9 7.4 16.9 14.9 4.9 11.0 8.5 5.0 8.1 5.0 6.6 13.3 4.2 7.0 4.6 8.6 8.5 4.9 9.3 5.0 22.5 8.3 9.8 3.9 6.3 5.2 7.9 11.2 12.6 4.7 12.0 7.3 9.3 4.6 11.2 6.8 8.2 6.4 7.1 12.3 7.2 16.2 5.9 36.3 3.5 10.6 25.5 6.1 4.2 11.5 18.1 14.5 9.4 13.3 18.0 7.3 31.0 28.6 31.4 16.9 3.1 3.9 20.0 27.5 15.7 33.7 38.4 25.0 23.4 44.9 21.5 11.7 32.9 44.2 24.1 34.6 23.6 24.3 23.7 39.1 25.4 2.4 36.8 24.5 2.7 3.3 31.1 8.3 13.1 35.8 32.5 28.0 39.1 51.2 33.1 34.5 28.1 35.2 36.4 46.3 13.4 29.5 35.8 29.7 18.3 24.1 15.8 34.9 25.9 8.8 30.0 37.9 38.2 27.7 25.7 39.9 46.6 20.9 24.7 25.8 14.5 5.0 10.2 12.4 9.4 13.1 11.5 10.0 11.8 5.8 11.5 11.2 11.3 2.1 13.3 8.8 18.1 18.0 7.3 7.9 8.5 16.9 14.9 8.6 8.5 8.3 9.8 12.6 5.9 FES FPS ENSG00000182511 "FES proto-oncogene, tyrosine kinase" P07332 15 90883695-90895776 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Proto-oncogene, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 60.8;lymphoid tissue: 49.7" "Cell line enhanced" "Detected in many" "HEL: 20.9;HL-60: 18.6;HMC-1: 39.8;NB-4: 24.4;THP-1: 36.6;U-937: 15.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "eosinophil: 60.8" "Group enriched" "Detected in many" 4 "dendritic cells: 32.6;granulocytes: 60.8;monocytes: 30.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" HPA001376 Approved Approved Nucleoplasm,Vesicles,Cytosol "Nucleoplasm, Cytosol" Vesicles "HPA001376: AB_1078847" "unprognostic (1.07e-2)" "unprognostic (2.54e-2)" "prognostic unfavourable (5.78e-4)" "unprognostic (2.31e-2)" "unprognostic (4.05e-3)" "unprognostic (7.33e-2)" "unprognostic (1.74e-1)" "unprognostic (2.22e-1)" "unprognostic (1.58e-3)" "unprognostic (1.35e-1)" "unprognostic (4.66e-2)" "unprognostic (5.15e-3)" "unprognostic (1.78e-3)" "unprognostic (2.53e-3)" "unprognostic (6.08e-2)" "unprognostic (1.18e-1)" "unprognostic (1.40e-1)" 14.9 3.4 4.8 9.7 4.1 38.3 12.7 2.4 5.7 6.8 5.4 3.2 4.7 3.0 7.4 5.6 4.9 7.6 7.3 7.9 4.2 2.2 5.2 11.8 12.7 23.3 3.7 0.9 6.4 3.7 1.8 2.7 8.1 7.2 7.7 2.4 5.3 33.8 6.3 3.4 3.5 5.2 5.4 6.9 49.7 4.3 3.2 4.7 3.1 7.2 4.1 4.5 7.2 9.4 1.1 32.6 60.8 30.5 9.3 0.1 13.8 0.1 0.2 0.3 3.5 1.0 3.1 6.0 0.9 0.0 1.7 1.0 0.8 0.0 2.2 0.1 2.0 0.5 0.6 0.1 0.5 1.1 0.3 20.9 0.0 3.7 2.0 18.6 39.8 3.0 0.0 2.6 0.0 10.5 0.6 0.0 0.0 6.8 0.5 24.4 1.0 0.0 2.7 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.9 0.8 0.0 36.6 8.3 0.0 3.6 0.1 0.0 0.0 2.6 0.8 0.1 15.8 0.8 10.4 30.5 60.8 0.1 17.6 0.0 1.1 0.0 0.0 32.6 0.9 0.0 0.0 20.0 9.3 7.3 12.9 0.0 13.8 4.8 4.1 2.4 5.7 4.2 2.2 3.7 0.9 7.2 4.7 FEV Pet-1 ENSG00000163497 "FEV, ETS transcription factor" Q99581 2 218981087-218985657 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Differentiation, Neurogenesis, Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 6.9;intestine: 7.0;pituitary gland: 5.4;stomach 1: 6.1" "Group enriched" "Detected in some" 6 "HMC-1: 18.7;SH-SY5Y: 23.9" "Group enriched" "Detected in some" 10 "pancreatic cancer: 3.0;prostate cancer: 9.9;stomach cancer: 2.4" "Region enhanced" "Detected in many" "pons and medulla: 6.9" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 13 "midbrain: 2.3;pons and medulla: 0.9" "Group enriched" "Detected in some" 34 "midbrain: 7.3;pons and medulla: 3.9" HPA067679 Supported Supported "Nuclear speckles" "Nuclear speckles" "HPA067679: " "unprognostic (4.58e-1)" "unprognostic (1.60e-1)" "unprognostic (7.21e-2)" "prognostic favourable (4.85e-4)" "unprognostic (2.87e-1)" "unprognostic (3.96e-1)" "unprognostic (1.52e-1)" "unprognostic (2.15e-1)" 0.1 4.1 0.0 1.2 3.5 0.0 0.0 0.0 2.6 0.0 2.0 0.7 0.0 7.0 0.1 0.0 0.0 0.1 0.0 0.0 1.1 0.2 0.0 0.0 0.0 0.0 0.2 0.0 0.0 4.2 0.0 5.4 0.0 6.9 4.0 3.2 0.0 0.0 0.0 0.0 0.0 5.4 0.0 0.1 0.0 6.1 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.8 0.0 0.0 0.0 0.0 18.7 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.7 23.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.5 0.0 2.6 1.1 0.2 0.2 0.0 6.9 1.0 FGA ENSG00000171560 "Fibrinogen alpha chain" P02671 4 154583126-154590766 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins" "Adaptive immunity, Blood coagulation, Hemostasis, Immunity, Innate immunity" "Amyloidosis, Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 740 "liver: 2009.3" "Cell line enriched" "Detected in some" 15 "Hep G2: 94.6" "Cancer enriched" "Detected in many" 43 "liver cancer: 2431.6" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "CAB016776, HPA051370, HPA064755" Supported Approved "Endoplasmic reticulum" "Secreted to blood" 406800000 170000000000 "Endoplasmic reticulum" "CAB016776: , HPA051370: , HPA064755: " "unprognostic (5.95e-2)" "unprognostic (6.25e-2)" "unprognostic (2.02e-1)" "unprognostic (5.68e-2)" "prognostic favourable (7.33e-4)" "unprognostic (1.29e-3)" "unprognostic (1.84e-1)" "prognostic unfavourable (4.23e-6)" "unprognostic (4.20e-1)" "unprognostic (1.41e-1)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.4 0.0 0.0 0.0 2.7 2009.3 0.1 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 1.5 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.3 0.0 0.6 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.7 0.0 94.6 0.0 1.3 0.1 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 1.4 0.0 0.0 0.1 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.2 0.0 0.4 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 FGB ENSG00000171564 "Fibrinogen beta chain" P02675 4 154562956-154571086 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Adaptive immunity, Blood coagulation, Hemostasis, Immunity, Innate immunity" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 189 "liver: 1908.6" "Cell line enriched" "Detected in some" 12 "Hep G2: 75.9" "Cancer enriched" "Detected in many" 42 "liver cancer: 2262.6" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "HPA001900, HPA001901, CAB008624" Enhanced Enhanced "Endoplasmic reticulum" "Secreted to blood" 120000000000 "Endoplasmic reticulum" "CAB008624: AB_1615610, HPA001900: AB_1078865, HPA001901: AB_1078864" "unprognostic (1.16e-1)" "unprognostic (3.89e-2)" "unprognostic (4.65e-2)" "unprognostic (3.44e-1)" "unprognostic (2.20e-3)" "unprognostic (1.42e-2)" "unprognostic (1.79e-1)" "prognostic unfavourable (5.72e-5)" "unprognostic (2.48e-2)" "unprognostic (7.91e-2)" 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 10.1 1908.6 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.4 0.0 0.6 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.7 0.0 75.9 0.0 1.7 0.1 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.5 0.0 0.0 0.1 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.9 0.1 0.0 0.0 0.0 0.4 0.0 0.0 0.2 0.0 0.2 0.0 0.7 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 FGF1 "AFGF, ECGF, ECGF-beta, ECGFA, ECGFB, FGF-alpha, FGFA, GLIO703, HBGF1" ENSG00000113578 "Fibroblast growth factor 1" P05230 5 142592178-142698070 "Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins" "Angiogenesis, Differentiation" "Developmental protein, Growth factor, Heparin-binding, Mitogen" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "brain: 65.0;heart muscle: 35.5;kidney: 41.5" "Cell line enhanced" "Detected in some" "BJ: 19.3;BJ hTERT+: 14.4;BJ hTERT+ SV40 Large T+: 16.0;BJ hTERT+ SV40 Large T+ RasG12V: 20.2;HBF TERT88: 28.8;hTEC/SVTERT24-B: 20.1;LHCN-M2: 13.4;U-2 OS: 14.4" "Cancer enriched" "Detected in many" 12 "glioma: 33.9" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003265, CAB017519" Enhanced Supported Nucleoplasm "Secreted in other tissues" Nucleoplasm "CAB017519: AB_629473, HPA003265: AB_1848522" "unprognostic (1.25e-2)" "unprognostic (2.43e-1)" "unprognostic (1.06e-1)" "unprognostic (3.41e-3)" "unprognostic (2.55e-2)" "unprognostic (3.52e-1)" "unprognostic (2.77e-1)" "unprognostic (2.39e-1)" "unprognostic (3.63e-1)" "unprognostic (1.57e-2)" "unprognostic (1.89e-1)" "unprognostic (1.54e-1)" "prognostic favourable (2.59e-5)" "unprognostic (3.72e-4)" "unprognostic (2.49e-1)" "prognostic favourable (3.45e-5)" "unprognostic (3.01e-4)" 7.3 3.5 44.2 2.0 43.1 1.5 9.7 10.5 59.9 1.8 1.7 65.0 0.0 1.6 3.1 8.7 2.3 2.1 2.7 35.5 47.4 33.0 41.5 2.0 2.9 1.4 62.6 13.8 1.5 1.4 3.4 1.6 2.3 36.3 2.2 1.8 0.8 5.8 2.6 2.3 2.0 1.7 2.6 57.7 5.5 1.1 2.2 48.6 0.0 4.9 0.8 2.2 1.7 0.4 1.2 1.0 1.8 0.6 0.1 2.3 0.2 2.3 0.1 0.1 0.7 0.5 1.5 0.8 19.3 14.4 16.0 20.2 0.1 0.1 0.5 1.4 6.6 0.3 0.0 1.5 28.8 0.1 0.0 0.0 0.3 0.1 0.2 0.0 0.2 0.7 0.5 20.1 1.2 0.0 0.0 0.7 13.4 0.3 0.0 0.4 0.6 0.6 0.1 0.6 0.2 0.6 0.1 0.5 1.0 0.0 0.4 0.2 0.0 0.1 0.4 2.6 14.4 0.3 9.1 0.3 0.1 0.1 3.6 0.1 0.7 0.3 0.3 1.8 2.3 0.1 1.8 0.4 0.8 0.9 0.2 1.2 0.9 1.9 1.7 0.1 0.6 1.0 0.5 0.2 44.2 43.1 10.5 22.6 47.4 33.0 62.6 13.8 36.3 48.6 FGF17 FGF-13 ENSG00000158815 "Fibroblast growth factor 17" O60258 8 22042398-22048809 "Cancer-related genes, Disease related genes, Predicted secreted proteins, RAS pathway related proteins" "Developmental protein, Growth factor" "Cancer-related genes, Disease mutation, Hypogonadotropic hypogonadism, Kallmann syndrome" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 6 "brain: 31.3" "Cell line enhanced" "Detected in some" "HaCaT: 3.2;Hep G2: 2.3;MOLT-4: 2.2;RPMI-8226: 4.4" "Cancer enhanced" "Detected in some" "testis cancer: 3.9" "Region enriched" "Detected in many" 4 "cerebellum: 31.3" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in single" 4 "basal ganglia: 2.2" "Low region specificity" "Detected in some" HPA052600 Uncertain "Secreted in brain" "HPA052600: " "unprognostic (3.45e-2)" "unprognostic (1.64e-2)" "unprognostic (3.03e-2)" "unprognostic (1.34e-1)" "unprognostic (1.33e-2)" "unprognostic (3.51e-2)" "unprognostic (1.09e-1)" "unprognostic (2.78e-2)" "unprognostic (5.65e-2)" "unprognostic (1.34e-1)" "unprognostic (7.92e-5)" "unprognostic (6.85e-2)" "unprognostic (2.58e-4)" "unprognostic (6.55e-3)" "unprognostic (7.18e-2)" "unprognostic (2.41e-1)" "unprognostic (1.95e-3)" 0.4 4.9 2.5 0.4 3.2 0.2 0.4 31.3 7.7 0.5 0.4 0.4 0.4 0.2 2.2 0.6 0.4 0.7 0.6 0.4 2.2 4.7 0.4 0.4 0.5 0.4 1.3 2.9 0.5 2.6 3.6 2.1 0.4 3.3 1.2 0.2 0.4 2.4 0.5 0.4 0.9 0.4 1.0 0.9 3.0 0.8 0.6 0.4 1.6 2.3 0.4 0.4 0.4 0.4 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.1 0.2 0.6 0.6 1.0 0.3 0.0 0.1 0.1 0.0 0.1 0.1 0.0 0.0 0.6 0.0 3.2 0.0 0.0 0.0 0.0 0.9 0.7 0.0 2.3 0.1 0.0 1.5 0.0 0.3 0.0 0.1 0.0 0.1 0.1 0.0 0.7 2.2 0.8 0.0 0.0 0.0 0.0 4.4 0.0 0.0 1.0 1.5 0.0 0.0 0.2 0.0 1.2 0.0 0.0 0.1 0.6 0.0 0.0 0.1 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.5 3.2 31.3 7.7 2.2 4.7 1.3 2.9 3.3 0.4 FGF18 "FGF-18, ZFGF5" ENSG00000156427 "Fibroblast growth factor 18" O76093 5 171419656-171457623 "Cancer-related genes, Predicted secreted proteins, RAS pathway related proteins" "Growth factor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "heart muscle: 23.0" "Cell line enriched" "Detected in some" 57 "EFO-21: 65.1" "Group enriched" "Detected in many" 6 "endometrial cancer: 19.0;ovarian cancer: 21.9" "Low region specificity" "Detected in some" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA018795 Uncertain "Secreted in other tissues" "HPA018795: AB_1848523" "unprognostic (3.01e-1)" "unprognostic (2.38e-2)" "unprognostic (1.23e-1)" "unprognostic (3.66e-3)" "unprognostic (6.62e-3)" "unprognostic (1.50e-1)" "unprognostic (3.20e-2)" "unprognostic (1.72e-2)" "unprognostic (2.98e-3)" "unprognostic (3.65e-2)" "unprognostic (3.18e-2)" "unprognostic (2.29e-1)" "unprognostic (1.37e-8)" "unprognostic (7.33e-2)" "unprognostic (2.58e-1)" "unprognostic (3.19e-1)" "unprognostic (2.76e-2)" 4.4 0.6 0.6 2.8 0.6 0.1 2.0 0.4 1.2 1.3 0.8 0.5 0.0 1.1 1.6 1.5 0.9 2.0 1.4 23.0 0.5 0.4 1.3 0.4 2.9 0.5 0.4 0.0 1.6 0.9 0.1 1.8 0.9 1.6 2.2 0.3 0.3 1.0 0.7 5.4 1.8 2.2 1.2 0.9 1.1 0.7 1.0 0.3 0.2 2.2 2.5 0.8 2.2 0.5 0.9 0.1 0.2 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 1.1 0.1 0.0 65.1 0.0 0.1 0.0 0.0 0.0 1.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.1 0.0 0.0 0.2 0.2 0.0 0.0 0.2 0.1 0.0 0.0 0.1 0.1 0.9 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.6 0.6 0.4 1.2 0.5 0.4 0.4 0.0 1.6 0.3 FGF19 ENSG00000162344 "Fibroblast growth factor 19" O95750 11 69698232-69704642 "Cancer-related genes, Predicted secreted proteins, RAS pathway related proteins" "Growth factor" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 13 "gallbladder: 62.4" "Cell line enriched" "Detected in some" 16 "CAPAN-2: 46.7" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Region enhanced" "Detected in single" "basal ganglia: 0.8" "Region enriched" "Detected in single" 18 "basal ganglia: 0.9" HPA036082 Approved "Secreted to blood" 132900 "HPA036082: AB_10669665" "unprognostic (7.46e-3)" "unprognostic (2.43e-3)" "unprognostic (5.52e-3)" "unprognostic (1.22e-1)" "unprognostic (4.68e-3)" "unprognostic (6.45e-2)" "unprognostic (5.72e-3)" "unprognostic (2.26e-1)" "unprognostic (6.39e-3)" "unprognostic (1.66e-2)" "unprognostic (8.82e-3)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 62.4 0.0 0.0 0.4 0.0 2.8 0.0 0.0 0.0 0.0 0.1 0.4 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.8 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 46.7 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.9 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 FGF2 FGFB ENSG00000138685 "Fibroblast growth factor 2" P09038 4 122826708-122898236 "Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins, Transporters" "Angiogenesis, Differentiation" "Developmental protein, Growth factor, Heparin-binding, Mitogen" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "BJ: 56.5;BJ hTERT+: 33.1;fHDF/TERT166: 61.3;hTERT-HME1: 33.8" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in single" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000125, HPA065502" Enhanced Supported "Nucleoplasm,Nuclear bodies" "Secreted in other tissues" "Nucleoplasm, Nuclear bodies" "CAB000125: , HPA065502: " "unprognostic (1.53e-2)" "unprognostic (3.12e-1)" "unprognostic (1.08e-1)" "unprognostic (7.42e-2)" "unprognostic (2.10e-1)" "unprognostic (3.33e-1)" "unprognostic (6.98e-2)" "unprognostic (1.25e-1)" "unprognostic (2.82e-1)" "unprognostic (1.79e-1)" "prognostic unfavourable (9.85e-4)" "unprognostic (3.37e-1)" "unprognostic (4.61e-3)" "unprognostic (2.36e-1)" "unprognostic (1.81e-1)" "unprognostic (4.45e-2)" "unprognostic (3.45e-3)" 28.1 3.8 19.4 6.9 21.3 0.7 12.1 6.5 15.3 10.2 14.2 10.3 1.9 2.6 17.9 6.3 6.4 10.1 9.4 5.6 17.1 11.0 5.5 2.9 8.3 2.5 9.9 10.7 16.8 2.4 10.1 4.0 8.1 18.6 10.3 5.6 7.5 4.6 11.9 2.0 2.3 4.1 16.2 17.3 1.9 7.6 3.0 12.3 0.0 3.1 3.8 2.7 7.5 14.5 0.8 0.8 0.5 0.5 0.3 1.0 0.0 1.2 3.1 1.7 6.8 4.3 7.2 0.0 56.5 33.1 23.7 13.8 0.0 0.1 0.0 6.6 61.3 0.2 1.8 0.1 23.9 4.4 0.8 0.0 6.4 0.0 12.8 0.3 0.0 3.9 0.3 23.4 33.8 2.6 1.7 1.9 6.1 0.0 0.0 0.0 5.1 1.3 0.0 0.9 0.0 7.5 0.0 1.0 0.9 10.9 0.0 0.4 0.0 0.1 2.3 19.6 3.8 7.2 4.8 3.3 3.6 0.0 5.6 0.0 2.0 0.5 0.5 0.4 0.3 0.4 0.2 0.4 0.5 0.4 0.2 0.8 0.7 1.0 0.4 0.3 0.4 0.8 0.7 0.0 19.4 21.3 6.5 15.3 17.1 11.0 9.9 10.7 18.6 12.3 FGF3 "HBGF-3, INT2" ENSG00000186895 "Fibroblast growth factor 3" P11487 11 69809969-69819024 "Cancer-related genes, Disease related genes, Predicted secreted proteins, RAS pathway related proteins" Differentiation "Developmental protein, Growth factor, Mitogen" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 43 "brain: 16.6" "Cell line enriched" "Detected in single" 48 "CAPAN-2: 4.8" "Low cancer specificity" "Detected in many" "Region enriched" "Detected in single" 38 "cerebellum: 16.6" "Not detected" "Not detected" "Not detected" "Not detected" "Region enhanced" "Detected in some" "basal ganglia: 2.7" "Not detected" "Not detected" HPA012692 Enhanced "Secreted in brain" "HPA012692: AB_1848526" "unprognostic (6.42e-3)" "unprognostic (7.82e-2)" "unprognostic (1.89e-1)" "unprognostic (3.61e-1)" "unprognostic (7.75e-2)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 16.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 16.6 0.0 0.0 0.0 0.0 0.0 0.4 0.0 FGF4 "HBGF-4, HST, HST-1, HSTF1, K-FGF, KFGF" ENSG00000075388 "Fibroblast growth factor 4" P08620 11 69771016-69775403 "Cancer-related genes, Predicted secreted proteins, RAS pathway related proteins" Differentiation "Developmental protein, Growth factor, Heparin-binding, Mitogen" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 2.6;intestine: 1.6;testis: 2.4;tongue: 2.0" "Cell line enriched" "Detected in single" 93 "NTERA-2: 18.6" "Cancer enriched" "Detected in some" 5 "testis cancer: 13.9" "Group enriched" "Detected in some" 19 "midbrain: 2.6;pons and medulla: 1.2" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA011209 Uncertain "Secreted in other tissues" "HPA011209: AB_1848527" "unprognostic (1.47e-2)" "unprognostic (6.22e-2)" "unprognostic (7.77e-2)" "unprognostic (8.56e-2)" 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.1 0.1 2.6 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.1 0.0 0.1 0.0 0.0 0.0 1.4 0.0 1.2 0.8 0.1 2.4 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 18.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.6 0.0 1.2 0.0 FGF7 KGF ENSG00000140285 "Fibroblast growth factor 7" P21781 15 49423096-49488775 "Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins" "Growth factor, Heparin-binding, Mitogen" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in some" "ASC diff: 23.7;ASC TERT1: 21.8;fHDF/TERT166: 9.8;HSkMC: 22.2;RH-30: 17.6;U-138 MG: 12.0" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in single" "Cell type enhanced" "Detected in single" "basophil: 1.6" "Low lineage specificity" "Detected in single" "Region enriched" "Detected in single" 9 "cerebellum: 9.7" HPA043605 Uncertain Approved Nucleoplasm,Nucleoli "Secreted in other tissues" "Nucleoplasm, Nucleoli" "HPA043605: AB_10960215" "unprognostic (4.65e-1)" "unprognostic (7.62e-2)" "unprognostic (2.50e-1)" "unprognostic (6.98e-2)" "unprognostic (1.19e-1)" "unprognostic (1.47e-1)" "unprognostic (1.03e-1)" "unprognostic (3.62e-2)" "unprognostic (5.74e-3)" "unprognostic (2.56e-2)" "unprognostic (7.30e-2)" "unprognostic (5.79e-2)" "unprognostic (1.91e-3)" "unprognostic (1.22e-3)" "unprognostic (7.59e-2)" "unprognostic (1.98e-3)" "unprognostic (1.63e-3)" 39.7 2.7 0.6 9.9 0.6 0.0 16.5 0.6 2.4 73.3 22.2 0.0 10.1 1.1 13.1 16.1 25.2 14.1 25.4 19.1 0.6 0.6 5.9 1.2 44.8 5.5 2.1 0.0 43.7 2.5 2.9 2.8 9.1 0.8 42.5 4.5 2.7 6.4 8.1 25.6 3.6 4.2 38.3 1.4 1.0 6.6 12.7 0.0 0.0 23.2 24.7 2.9 72.2 32.4 0.2 0.1 1.6 0.2 0.3 0.5 0.0 0.1 0.0 0.1 0.1 23.7 21.8 0.0 7.2 4.4 0.0 0.0 0.0 0.1 0.0 0.1 9.8 0.4 0.0 0.1 0.0 0.0 0.1 0.0 0.2 0.0 2.0 0.1 0.0 22.2 0.4 1.9 0.0 0.0 0.0 0.1 1.5 0.0 0.0 0.0 0.1 0.1 0.0 17.6 0.0 0.0 0.0 0.9 0.3 0.2 0.0 0.0 0.1 0.1 0.1 12.0 0.2 0.4 0.0 0.2 0.1 0.0 3.3 0.0 0.2 1.6 0.0 0.0 0.2 0.0 0.0 0.0 0.5 0.3 0.0 0.2 0.5 0.2 0.0 0.3 0.2 0.1 0.4 0.0 0.6 0.6 0.6 0.6 0.6 0.6 2.1 0.0 0.8 0.0 FGF9 ENSG00000102678 "Fibroblast growth factor 9" P31371 13 21671383-21704498 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins" Differentiation "Developmental protein, Growth factor, Heparin-binding, Mitogen" "Cancer-related genes, Deafness, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 17.7;kidney: 21.7" "Cell line enhanced" "Detected in some" "CAPAN-2: 2.4;HEK 293: 2.4;RPMI-8226: 3.6;RPTEC TERT1: 5.5;SCLC-21H: 11.4" "Cancer enhanced" "Detected in some" "endometrial cancer: 3.7" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in some" "Group enriched" "Detected in many" 5 "B-cells: 1.0;T-cells: 1.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA067007 Enhanced "Secreted in other tissues" "HPA067007: " "unprognostic (6.59e-3)" "unprognostic (9.09e-3)" "unprognostic (2.15e-2)" "unprognostic (9.24e-2)" "unprognostic (2.19e-1)" "unprognostic (2.37e-2)" "unprognostic (7.42e-4)" "unprognostic (1.98e-1)" "unprognostic (2.86e-1)" "unprognostic (3.86e-1)" "unprognostic (2.38e-3)" "unprognostic (7.93e-2)" "prognostic favourable (1.70e-6)" "unprognostic (5.38e-2)" "unprognostic (1.27e-1)" "unprognostic (3.49e-1)" "unprognostic (6.92e-2)" 3.1 7.3 2.1 1.0 4.4 0.8 0.7 17.7 7.3 3.8 2.1 0.3 0.5 1.8 3.7 0.9 0.9 1.0 1.2 5.5 3.7 2.6 21.7 0.5 2.6 0.6 2.6 2.5 2.3 1.8 0.5 12.0 0.7 12.6 1.1 3.1 2.4 1.2 1.6 1.4 0.5 4.0 4.0 2.5 0.6 2.2 1.5 0.3 0.0 0.6 0.0 0.5 3.0 1.4 1.0 0.0 0.0 0.2 0.0 1.7 0.2 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 2.4 0.0 1.6 0.9 0.0 0.5 0.0 0.0 0.0 2.4 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.7 1.1 3.6 5.5 0.0 11.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 1.7 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.2 0.6 0.7 1.4 1.7 0.0 1.0 0.9 0.9 0.0 0.0 0.0 0.0 0.0 0.2 2.1 4.4 17.7 7.3 3.7 2.6 2.6 2.5 12.6 0.3 FGFBP1 "FGFBP, HBP17" ENSG00000137440 "Fibroblast growth factor binding protein 1" Q14512 4 15935569-15938740 "Cancer-related genes, Predicted secreted proteins" "Growth factor binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "esophagus: 106.6;lymphoid tissue: 56.8;tongue: 133.1" "Group enriched" "Detected in some" 4 "HaCaT: 77.2;HBEC3-KT: 133.6" "Cancer enhanced" "Detected in many" "head and neck cancer: 246.0" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Not detected" "Not detected" HPA004332 Enhanced "Secreted in other tissues" "HPA004332: AB_1078856" "unprognostic (2.87e-3)" "unprognostic (3.55e-1)" "unprognostic (5.03e-2)" "unprognostic (6.99e-2)" "unprognostic (1.86e-2)" "unprognostic (1.97e-2)" "unprognostic (3.60e-1)" "unprognostic (1.10e-1)" "prognostic unfavourable (5.03e-4)" "unprognostic (1.03e-1)" "unprognostic (1.34e-2)" "unprognostic (2.04e-2)" "unprognostic (1.51e-1)" "unprognostic (2.36e-1)" "unprognostic (3.31e-3)" 0.2 0.0 0.2 0.6 0.2 0.0 4.1 0.2 0.2 27.1 5.1 0.2 0.2 0.4 1.1 0.2 106.6 0.1 0.3 0.2 0.2 0.0 0.3 0.2 1.9 0.2 0.2 0.2 0.3 0.2 0.0 0.2 0.7 0.2 0.3 4.6 0.4 14.1 0.2 0.2 14.6 1.3 0.3 0.2 0.2 0.5 0.2 0.2 0.2 0.3 133.1 56.8 1.8 31.3 0.0 0.0 0.0 0.0 0.0 0.0 0.6 20.2 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 26.2 0.0 1.5 0.0 77.2 0.0 133.6 0.0 0.0 0.1 0.0 0.3 0.0 0.0 0.0 0.0 0.0 19.8 0.0 2.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.4 0.0 0.0 0.0 13.0 0.9 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.2 0.2 0.2 0.2 0.2 0.0 0.2 0.2 0.2 0.2 FGFR1 "BFGFR, CD331, CEK, FLG, FLT2, H2, H3, H4, H5, KAL2, N-SAM" ENSG00000077782 "Fibroblast growth factor receptor 1" P11362 8 38411138-38468834 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters" "Transcription, Transcription regulation" "Heparin-binding, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Craniosynostosis, Disease mutation, Dwarfism, FDA approved drug targets, Holoprosencephaly, Hypogonadotropic hypogonadism, Kallmann syndrome, Mental retardation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "AN3-CA: 109.2;BJ hTERT+: 49.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB033614, HPA056402" Approved 120000000 "CAB033614: AB_783377, HPA056402: " "unprognostic (9.53e-2)" "unprognostic (7.33e-2)" "unprognostic (2.44e-1)" "unprognostic (1.35e-2)" "unprognostic (4.23e-3)" "unprognostic (7.02e-2)" "unprognostic (6.59e-2)" "unprognostic (2.77e-1)" "unprognostic (1.81e-1)" "unprognostic (3.99e-2)" "unprognostic (7.97e-3)" "unprognostic (4.59e-2)" "unprognostic (7.69e-2)" "unprognostic (6.87e-3)" "unprognostic (5.60e-2)" "unprognostic (4.59e-3)" "unprognostic (1.05e-3)" 41.1 8.6 12.5 14.5 12.2 7.2 39.5 45.0 10.5 36.0 31.5 10.1 11.6 5.5 29.3 20.6 22.9 29.4 32.4 31.7 12.8 10.1 11.8 5.4 18.6 9.7 11.4 14.3 42.0 51.2 11.5 22.3 28.4 20.0 28.2 10.8 35.8 14.0 31.6 12.0 12.9 14.4 52.4 15.6 4.5 16.4 16.4 8.5 11.3 12.6 13.0 9.8 39.6 41.2 1.6 0.7 1.8 1.1 0.8 5.7 0.7 2.4 9.3 40.3 109.2 25.1 17.9 26.6 24.8 49.8 17.3 18.0 6.0 1.4 0.3 6.9 23.8 0.0 19.1 1.2 20.0 6.5 4.2 0.0 1.5 5.9 14.1 5.8 0.1 16.2 0.1 14.0 2.8 16.6 2.2 0.1 8.1 2.8 17.0 1.9 28.4 3.9 15.7 4.2 0.0 8.4 0.0 1.6 3.6 4.4 0.2 1.0 2.2 1.1 10.4 11.3 6.2 31.2 5.9 0.4 0.7 0.0 13.4 0.3 5.9 1.4 1.1 0.4 5.7 0.3 3.9 0.7 2.7 3.7 0.1 1.6 1.5 4.1 1.8 0.8 0.5 0.7 2.2 0.7 12.5 12.2 45.0 10.5 12.8 10.1 11.4 14.3 20.0 8.5 FGFR1OP FOP ENSG00000213066 "FGFR1 oncogene partner" O95684 6 166999182-167094789 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cilium biogenesis/degradation" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "testis: 50.3" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA071876 Supported Centrosome Centrosome "HPA071876: " "unprognostic (9.14e-2)" "unprognostic (2.24e-1)" "unprognostic (3.98e-2)" "unprognostic (2.39e-1)" "unprognostic (1.30e-1)" "unprognostic (1.69e-2)" "unprognostic (9.59e-2)" "unprognostic (1.00e-1)" "unprognostic (6.95e-2)" "unprognostic (8.83e-2)" "unprognostic (1.08e-3)" "unprognostic (4.06e-2)" "prognostic unfavourable (7.32e-4)" "unprognostic (1.29e-2)" "unprognostic (2.49e-1)" "unprognostic (3.15e-1)" "unprognostic (2.09e-3)" 6.2 12.2 11.2 12.9 12.5 9.8 10.2 11.9 13.0 10.1 9.5 6.9 11.8 10.8 13.6 14.1 8.8 19.1 7.9 6.4 10.8 9.1 12.2 24.9 6.7 9.4 6.4 11.5 11.8 10.2 8.2 17.2 6.6 9.4 7.4 12.1 8.9 8.1 11.6 5.8 7.9 13.0 7.4 7.4 9.4 7.8 50.3 8.0 14.5 12.5 6.2 11.8 7.0 8.2 6.8 10.0 24.1 4.1 3.5 6.8 3.0 12.0 6.7 17.0 11.6 10.0 7.5 20.7 15.6 10.5 12.8 12.4 24.9 10.3 14.4 8.9 9.5 11.4 14.9 11.0 24.1 9.0 12.9 9.9 12.1 27.0 5.4 17.6 10.5 4.1 8.2 26.2 12.3 8.8 32.3 12.4 16.3 11.1 14.1 25.8 14.5 5.2 16.3 11.6 11.9 13.3 6.5 12.7 12.8 12.7 13.7 5.4 11.2 21.8 5.7 12.8 21.3 15.2 19.5 10.6 14.5 14.6 14.4 16.5 15.6 0.2 4.1 13.5 3.3 3.6 4.9 6.8 3.9 3.1 6.5 5.0 2.3 3.7 24.1 3.5 3.6 10.0 6.8 3.0 11.2 12.5 11.9 13.0 10.8 9.1 6.4 11.5 9.4 8.0 FGFR2 "BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25" ENSG00000066468 "Fibroblast growth factor receptor 2" P21802 10 121478334-121598458 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins" Apoptosis "Heparin-binding, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Craniosynostosis, Disease mutation, Ectodermal dysplasia, FDA approved drug targets, Lacrimo-auriculo-dento-digital syndrome, Mental retardation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 74.8" "Cell line enhanced" "Detected in some" "AN3-CA: 57.8;BEWO: 19.4;CACO-2: 15.1;HaCaT: 17.4;HAP1: 18.7;NTERA-2: 18.5;T-47d: 15.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 15 "basophil: 10.8;eosinophil: 4.6" "Lineage enriched" "Detected in single" 35 "granulocytes: 10.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010886, HPA035305" Uncertain Supported "Nucleoplasm,Vesicles,Cell Junctions" "Secreted - unknown location" 500000 "Cell Junctions" "Nucleoplasm, Vesicles" "CAB010886: AB_259379, HPA035305: AB_10672862" "unprognostic (5.53e-2)" "prognostic favourable (8.79e-4)" "unprognostic (1.08e-1)" "unprognostic (5.23e-2)" "unprognostic (1.73e-1)" "prognostic favourable (9.32e-4)" "unprognostic (1.53e-1)" "unprognostic (4.96e-3)" "unprognostic (1.74e-1)" "unprognostic (1.56e-1)" "unprognostic (1.07e-1)" "unprognostic (3.74e-2)" "unprognostic (1.01e-1)" "unprognostic (6.11e-2)" "unprognostic (2.54e-1)" "unprognostic (6.93e-2)" "unprognostic (2.25e-1)" 2.1 8.8 16.4 3.0 30.3 0.0 9.9 15.8 21.3 6.8 14.1 55.7 5.6 4.2 22.0 6.6 10.2 12.5 12.5 1.4 20.6 11.1 11.4 16.1 13.1 1.0 41.2 13.3 7.4 12.8 25.5 2.5 6.2 30.2 11.7 8.7 16.4 23.8 24.3 0.4 45.4 4.7 18.3 74.8 0.5 9.3 2.9 32.1 0.8 23.4 1.6 3.4 6.9 8.5 0.1 0.1 10.8 0.1 0.1 0.3 0.0 2.2 0.1 9.0 57.8 0.0 0.0 19.4 0.1 0.0 0.0 0.0 15.1 0.3 0.0 4.1 0.9 17.4 18.7 4.0 0.0 0.0 4.0 0.0 0.0 0.3 0.4 0.0 3.8 0.0 8.4 0.0 0.2 0.0 0.0 0.0 0.0 3.5 0.0 0.0 18.5 0.0 0.0 0.0 2.2 5.6 4.9 0.1 0.1 0.1 10.6 0.0 15.5 0.0 0.0 0.1 2.8 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.1 10.8 0.1 4.6 0.1 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.1 0.5 0.1 0.0 0.1 0.0 0.0 16.4 30.3 15.8 21.3 20.6 11.1 41.2 13.3 30.2 32.1 FGFR3 "ACH, CD333, CEK2, JTK4" ENSG00000068078 "Fibroblast growth factor receptor 3" P22607 4 1793293-1808872 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins" Apoptosis "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Craniosynostosis, Deafness, Disease mutation, Dwarfism, Ectodermal dysplasia, FDA approved drug targets, Lacrimo-auriculo-dento-digital syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "skin 1: 131.7" "Cell line enhanced" "Detected in many" "CACO-2: 19.1;HaCaT: 14.9;Hep G2: 32.1;NTERA-2: 15.6;RT4: 19.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004231, HPA067204" Enhanced Supported "Endoplasmic reticulum" "Intracellular and membrane" 670000 "Endoplasmic reticulum" "CAB004231: AB_627596, HPA067204: " "unprognostic (1.34e-1)" "unprognostic (5.29e-3)" "unprognostic (1.49e-1)" "prognostic unfavourable (3.77e-4)" "unprognostic (5.90e-2)" "unprognostic (1.24e-3)" "unprognostic (7.22e-2)" "unprognostic (2.54e-1)" "unprognostic (1.99e-1)" "unprognostic (2.17e-1)" "unprognostic (1.38e-1)" "unprognostic (2.88e-2)" "unprognostic (1.30e-1)" "unprognostic (9.11e-3)" "unprognostic (1.98e-1)" "unprognostic (4.74e-2)" "unprognostic (1.97e-1)" 1.5 1.5 24.7 1.7 30.3 1.6 4.2 10.2 22.0 4.1 4.9 15.8 3.4 9.9 1.8 2.7 26.9 2.0 5.0 2.0 21.6 11.7 9.6 7.4 4.5 1.3 17.6 21.5 1.1 23.0 1.2 3.0 5.6 15.1 3.7 3.8 1.7 3.8 9.0 1.7 131.7 7.4 1.3 9.0 2.1 4.9 8.1 10.6 0.1 1.3 8.5 7.3 8.5 10.1 0.1 0.6 0.1 0.1 0.2 0.3 0.0 0.0 1.5 9.0 2.6 0.0 0.1 9.2 1.0 0.1 0.4 0.2 19.1 0.4 0.0 7.6 0.3 14.9 2.6 0.1 0.1 0.1 9.6 5.9 1.5 32.1 0.0 0.0 0.1 0.0 5.0 0.1 0.0 0.0 6.4 0.0 0.0 9.5 0.3 0.2 15.6 0.0 0.5 0.5 0.1 1.3 19.1 2.6 0.7 0.8 1.6 0.0 8.9 1.1 0.4 0.0 0.9 0.2 0.6 0.0 0.0 0.0 0.1 0.7 0.5 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.2 0.0 0.6 0.1 0.0 24.7 30.3 10.2 22.0 21.6 11.7 17.6 21.5 15.1 10.6 FGFR4 "CD334, JTK2" ENSG00000160867 "Fibroblast growth factor receptor 4" P22455 5 177086886-177098144 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "gallbladder: 33.6;kidney: 37.7;liver: 45.3" "Group enriched" "Detected in many" 4 "CACO-2: 42.0;Hep G2: 42.0;RH-30: 67.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in some" "Cell type enhanced" "Detected in some" "neutrophil: 3.0" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB005196, HPA027273, HPA027369, HPA028251" Approved "Intracellular and membrane" 4300000 "CAB005196: AB_631512, HPA027273: AB_10600212, HPA027369: AB_10599427, HPA028251: AB_10601221" "unprognostic (1.96e-1)" "unprognostic (2.10e-2)" "unprognostic (1.12e-1)" "unprognostic (9.06e-3)" "unprognostic (2.87e-1)" "unprognostic (1.95e-2)" "unprognostic (7.85e-3)" "unprognostic (9.19e-2)" "unprognostic (4.25e-1)" "unprognostic (4.46e-2)" "unprognostic (1.16e-1)" "unprognostic (3.48e-2)" "unprognostic (1.78e-1)" "unprognostic (1.71e-3)" "unprognostic (2.41e-1)" "unprognostic (5.75e-2)" "unprognostic (4.68e-2)" 0.5 5.7 0.7 14.3 0.6 0.1 1.6 2.6 0.5 2.8 10.4 0.9 0.7 13.5 0.9 4.8 1.6 1.7 33.6 0.7 0.8 0.3 37.7 45.3 25.3 2.5 0.7 1.0 13.6 26.0 0.0 0.7 1.3 0.8 4.0 3.7 2.0 1.6 0.3 4.3 0.5 17.3 1.6 0.8 11.2 5.4 2.9 0.4 0.3 0.8 2.3 0.7 1.9 3.6 1.1 0.9 3.0 1.1 0.4 0.4 0.0 0.7 11.8 0.2 2.9 0.0 0.0 5.8 0.0 0.0 0.0 0.0 42.0 1.6 1.2 5.5 0.0 0.6 2.3 0.4 0.0 0.7 2.8 0.1 0.6 42.0 1.3 0.1 1.0 0.2 0.0 2.1 0.0 0.0 3.9 0.1 0.9 9.6 0.0 0.8 7.1 1.0 1.9 67.6 7.1 5.7 0.1 0.4 0.7 0.4 3.0 1.4 2.9 0.6 0.2 0.0 5.7 0.0 0.1 0.4 0.4 0.7 0.0 0.2 0.5 1.5 1.1 0.4 0.4 0.3 0.3 1.1 0.4 0.0 0.1 0.6 0.4 0.4 3.0 0.4 0.3 0.9 0.2 0.0 0.7 0.6 2.6 0.5 0.8 0.3 0.7 1.0 0.8 0.4 FGG ENSG00000171557 "Fibrinogen gamma chain" P02679 4 154604134-154612967 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Blood coagulation, Hemostasis" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 495 "liver: 2225.7" "Cell line enriched" "Detected in some" 55 "Hep G2: 125.7" "Cancer enriched" "Detected in many" 19 "liver cancer: 1503.5" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "HPA027529, CAB033120, HPA074638" Supported Approved "Endoplasmic reticulum" "Secreted to blood" 267000000000 68000000000 "Endoplasmic reticulum" "CAB033120: AB_2103818, HPA027529: AB_10601322, HPA074638: " "unprognostic (1.26e-2)" "unprognostic (4.77e-3)" "unprognostic (6.33e-3)" "unprognostic (3.69e-3)" "unprognostic (2.18e-3)" "unprognostic (9.63e-2)" "unprognostic (7.57e-3)" "prognostic unfavourable (1.00e-6)" "unprognostic (1.75e-3)" "unprognostic (3.21e-1)" "unprognostic (1.14e-1)" 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.9 0.0 0.0 0.0 2.7 2225.7 4.4 0.0 0.0 0.0 0.2 0.7 0.0 0.0 1.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.2 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.6 0.0 125.7 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 1.1 0.0 0.0 0.1 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.2 0.0 0.6 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 FH fumarase ENSG00000091483 "Fumarate hydratase" P07954 1 241497603-241519761 "Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "DNA damage, DNA repair, Tricarboxylic acid cycle" Lyase "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 93.4" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB017785, HPA025770, HPA025948, HPA027341" Enhanced Supported Enhanced Mitochondria 2800000 Mitochondria "CAB017785: , HPA025770: AB_10599603, HPA025948: AB_10602177, HPA027341: AB_10601222" "unprognostic (1.03e-2)" "unprognostic (3.82e-2)" "unprognostic (9.46e-3)" "unprognostic (2.18e-1)" "unprognostic (2.10e-1)" "unprognostic (2.07e-1)" "unprognostic (2.28e-2)" "unprognostic (1.55e-1)" "unprognostic (5.14e-2)" "unprognostic (1.85e-2)" "unprognostic (1.27e-2)" "unprognostic (1.09e-1)" "prognostic favourable (2.76e-7)" "unprognostic (1.05e-1)" "unprognostic (1.05e-1)" "unprognostic (4.41e-2)" "unprognostic (1.24e-2)" 14.3 28.1 15.7 10.4 20.2 9.3 13.3 15.7 24.4 10.5 22.7 9.9 16.7 23.2 13.7 10.7 17.7 10.3 9.5 59.0 22.9 13.9 35.0 93.4 9.9 13.3 15.2 19.4 9.4 13.9 25.2 11.4 14.3 18.4 12.3 24.4 10.2 18.4 20.6 65.1 13.4 21.4 14.7 14.4 11.1 17.5 14.0 11.7 13.8 12.3 45.2 13.4 13.4 11.2 16.0 26.4 4.5 18.8 10.4 13.9 8.9 29.2 24.5 23.3 21.0 22.9 27.0 36.9 36.3 28.5 41.0 25.8 35.1 18.3 18.6 24.1 27.8 41.7 35.6 27.0 35.8 21.2 11.5 17.4 26.0 29.9 20.5 40.7 15.9 19.5 16.8 23.0 26.0 25.2 53.0 24.1 29.8 14.6 35.1 27.2 24.7 52.7 29.0 25.5 83.5 39.5 24.9 30.0 25.9 30.6 36.3 23.2 27.6 27.7 24.7 18.4 23.8 32.5 60.5 21.6 23.1 22.6 20.6 46.8 26.4 4.5 12.8 2.7 9.7 18.8 12.6 16.0 11.4 9.0 26.4 14.1 13.9 12.7 0.7 10.4 15.7 13.2 13.2 8.9 15.7 20.2 15.7 24.4 22.9 13.9 15.2 19.4 18.4 11.7 FHIT "AP3Aase, FRA3B" ENSG00000189283 "Fragile histidine triad" P49789 3 59749310-61251459 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Apoptosis, Transcription, Transcription regulation" Hydrolase "Cancer-related genes, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "RPMI-8226: 11.9;U-266/70: 24.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in many" 5 "naive CD4 T-cell: 38.3" "Lineage enriched" "Detected in all" 14 "T-cells: 38.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002684, HPA018840, HPA018909" Enhanced Approved "Nucleoli fibrillar center,Plasma membrane" "Nucleoli fibrillar center, Plasma membrane" "CAB002684: , HPA018840: AB_1848538, HPA018909: AB_1848537" "unprognostic (2.36e-3)" "unprognostic (6.38e-2)" "unprognostic (1.59e-1)" "unprognostic (4.42e-2)" "unprognostic (1.10e-1)" "unprognostic (1.08e-2)" "unprognostic (1.18e-1)" "unprognostic (3.16e-2)" "unprognostic (2.77e-2)" "unprognostic (8.49e-2)" "unprognostic (2.36e-1)" "unprognostic (6.77e-2)" "prognostic favourable (1.36e-4)" "unprognostic (1.54e-1)" "unprognostic (5.96e-2)" "unprognostic (1.29e-2)" "unprognostic (1.80e-2)" 6.4 24.0 13.7 8.0 17.5 9.0 12.1 4.7 13.3 7.9 8.0 21.0 12.4 8.2 6.2 9.5 5.1 9.2 13.0 14.9 15.3 13.8 30.9 10.7 5.2 9.3 19.5 9.3 8.9 11.8 16.3 15.2 4.1 14.4 5.8 7.8 14.0 11.4 9.9 11.6 7.0 7.6 9.1 17.1 6.0 8.1 10.5 18.2 3.7 15.6 5.7 6.9 7.3 6.1 1.6 2.4 1.8 1.8 2.6 38.3 4.7 0.0 0.0 1.0 0.0 0.6 0.0 1.6 0.1 0.1 0.0 0.0 1.8 3.0 2.6 0.5 0.1 0.0 10.0 2.1 0.0 1.4 3.4 2.2 1.3 4.1 2.6 5.6 0.1 6.8 4.1 0.1 5.1 0.0 1.6 8.3 0.1 2.5 10.1 4.5 0.8 0.6 7.5 0.0 11.9 11.2 1.3 2.1 2.8 1.0 6.9 6.5 0.4 0.1 0.0 1.2 0.4 0.1 1.5 24.4 7.4 0.0 2.7 0.0 1.4 1.8 1.8 0.2 0.9 1.2 0.5 1.6 6.9 0.7 2.2 1.4 38.3 6.7 0.3 2.6 0.4 2.4 7.4 4.7 13.7 17.5 4.7 13.3 15.3 13.8 19.5 9.3 14.4 18.2 FIP1L1 "DKFZp586K0717, FIP1" ENSG00000145216 "Factor interacting with PAPOLA and CPSF1" Q6UN15 4 53377643-53460861 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "mRNA processing" RNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA037475, HPA058202" Supported Enhanced Nucleoplasm Nucleoplasm "HPA037475: AB_10696933, HPA058202: " "unprognostic (3.80e-1)" "unprognostic (5.46e-2)" "unprognostic (5.60e-3)" "unprognostic (1.40e-1)" "unprognostic (7.18e-2)" "unprognostic (4.71e-2)" "prognostic unfavourable (1.51e-4)" "unprognostic (1.87e-1)" "unprognostic (9.00e-3)" "unprognostic (1.14e-2)" "unprognostic (5.48e-2)" "unprognostic (1.42e-1)" "unprognostic (4.07e-1)" "unprognostic (1.10e-1)" "unprognostic (8.66e-3)" "unprognostic (3.10e-2)" "unprognostic (1.39e-1)" 25.7 24.4 20.2 27.6 25.8 35.8 24.0 23.0 25.1 24.5 18.0 19.4 16.1 16.0 27.4 17.7 23.4 22.4 16.2 19.7 17.1 16.6 19.7 19.0 20.3 24.5 20.1 26.0 32.2 16.9 26.6 26.6 28.2 20.9 21.7 21.0 16.2 21.5 18.0 33.9 24.5 20.0 23.5 19.4 24.5 20.4 40.2 22.4 42.4 22.7 17.8 29.2 26.6 22.6 26.5 32.7 36.5 24.0 33.7 32.4 21.3 17.9 11.8 21.7 13.0 16.4 16.8 27.7 22.7 28.7 18.6 14.4 17.2 16.7 33.0 17.7 24.3 11.3 23.5 16.9 24.1 11.4 12.8 26.0 9.8 15.9 26.1 38.6 22.3 19.1 15.4 23.5 24.1 13.6 29.9 15.4 14.6 13.2 34.8 17.8 14.2 11.7 31.2 9.8 14.5 15.1 16.2 16.9 18.3 15.9 18.4 26.1 10.4 14.3 14.4 19.1 16.6 17.7 27.2 19.4 11.2 41.6 16.5 24.2 33.9 25.8 16.9 36.5 25.7 17.8 29.2 26.5 25.8 25.1 22.6 24.2 28.9 25.4 20.7 33.7 24.0 32.7 32.4 21.3 20.2 25.8 23.0 25.1 17.1 16.6 20.1 26.0 20.9 22.4 FKBP5 "FKBP51, FKBP54, P54, PPIase, Ptg-10" ENSG00000096060 "FK506 binding protein 5" Q13451 6 35573585-35728583 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Chaperone, Isomerase, Rotamase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 277.2" "Cell line enhanced" "Detected in many" "ASC diff: 101.4;ASC TERT1: 63.1;HHSteC: 79.4;HSkMC: 95.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009315, HPA031092, HPA031093, HPA031095" Enhanced Enhanced Nucleoplasm Nucleoplasm "CAB009315: AB_2278350, HPA031092: AB_10600195, HPA031093: AB_10601748, HPA031095: " "unprognostic (2.09e-3)" "unprognostic (1.70e-1)" "unprognostic (1.44e-2)" "unprognostic (1.17e-2)" "unprognostic (1.02e-1)" "unprognostic (1.93e-1)" "unprognostic (4.72e-1)" "unprognostic (6.30e-3)" "unprognostic (3.70e-3)" "unprognostic (1.47e-1)" "unprognostic (1.69e-1)" "unprognostic (1.73e-1)" "unprognostic (7.48e-3)" "unprognostic (2.18e-3)" "unprognostic (8.31e-2)" "unprognostic (4.22e-2)" "unprognostic (6.90e-3)" 78.8 20.7 9.5 14.2 15.6 4.9 36.7 2.4 10.9 16.5 29.0 5.1 29.8 2.2 18.6 16.9 29.2 19.4 17.9 26.3 10.6 4.2 44.9 30.7 19.7 55.9 15.7 3.6 27.2 43.7 8.6 33.8 6.0 13.1 18.3 8.2 11.8 30.4 25.1 277.2 20.2 36.7 18.6 18.2 32.3 25.0 14.3 12.4 20.1 24.2 9.8 16.8 22.5 18.4 4.0 30.6 24.9 31.2 11.8 42.3 39.9 4.9 2.1 9.5 14.2 101.4 63.1 0.1 2.7 0.1 1.7 4.1 3.7 0.8 24.5 2.5 0.5 0.0 5.6 11.9 4.2 9.6 5.3 10.5 1.8 5.2 79.4 6.6 1.0 95.9 48.2 3.1 29.1 10.3 11.2 10.0 18.6 3.1 27.3 12.4 2.4 1.6 12.2 2.4 11.9 7.9 3.0 3.6 2.2 2.2 2.5 0.5 14.0 7.8 22.7 2.5 2.2 0.3 3.7 4.5 5.2 31.1 0.8 12.9 0.9 13.7 31.2 19.4 20.0 27.0 23.8 3.0 28.2 20.8 30.6 4.0 42.3 30.2 24.9 11.8 12.0 9.2 10.3 39.9 9.5 15.6 2.4 10.9 10.6 4.2 15.7 3.6 13.1 12.4 FKBP8 "FKBP38, FKBPr38" ENSG00000105701 "FK506 binding protein 8" Q14318 19 18531751-18544077 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Apoptosis, Host-virus interaction" "Isomerase, Rotamase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in all" 5 "eosinophil: 32.5;neutrophil: 31.0" "Lineage enriched" "Detected in all" 5 "granulocytes: 32.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB025346, HPA045177" Supported Supported "Endoplasmic reticulum,Mitochondria,Cytosol" Mitochondria "Endoplasmic reticulum, Cytosol" "CAB025346: , HPA045177: " "unprognostic (1.61e-1)" "unprognostic (1.33e-1)" "prognostic unfavourable (1.24e-4)" "unprognostic (8.93e-2)" "unprognostic (2.73e-1)" "unprognostic (9.22e-2)" "unprognostic (2.54e-2)" "unprognostic (2.26e-1)" "unprognostic (2.10e-2)" "unprognostic (1.49e-1)" "prognostic favourable (7.76e-4)" "unprognostic (8.51e-2)" "unprognostic (1.61e-1)" "unprognostic (2.97e-1)" "unprognostic (6.89e-2)" "unprognostic (1.12e-2)" "unprognostic (2.32e-1)" 44.3 38.1 75.9 27.5 82.1 82.5 26.5 43.4 113.7 35.2 31.9 41.2 34.6 31.1 31.4 27.2 48.7 39.3 34.5 43.4 69.6 62.1 28.9 42.7 34.3 31.1 55.3 54.3 56.1 60.4 28.8 42.2 36.6 51.2 36.5 12.9 31.9 73.1 46.1 56.7 35.1 31.6 34.6 46.3 36.7 31.9 49.5 26.9 32.1 38.8 24.2 30.7 36.3 45.8 4.3 4.3 32.5 6.9 3.1 6.6 9.1 36.6 26.3 20.6 39.1 21.3 33.5 51.7 29.7 31.6 22.7 31.5 24.9 50.0 21.0 48.3 36.4 19.9 12.7 41.3 6.4 25.6 60.3 19.6 34.3 29.9 36.7 19.4 43.2 43.7 39.9 20.4 13.0 23.3 41.1 50.0 19.7 61.0 35.2 58.1 42.1 38.2 37.0 17.1 71.8 30.5 24.0 22.9 41.7 20.8 17.2 37.0 20.2 56.7 27.1 28.4 26.0 55.4 22.5 38.3 21.9 24.4 64.3 31.2 25.2 6.3 5.6 32.5 6.0 5.8 5.5 4.1 6.1 6.6 4.3 4.3 4.7 5.3 31.0 3.1 6.9 4.3 6.0 9.1 75.9 82.1 43.4 113.7 69.6 62.1 55.3 54.3 51.2 26.9 FLCN "BHD, MGC17998, MGC23445" ENSG00000154803 Folliculin Q8NFG4 17 17212212-17237188 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "CAB015158, HPA028760" Supported Supported "Plasma membrane,Cytosol" Cytosol "Plasma membrane" "CAB015158: AB_2231645, HPA028760: AB_10601323" "unprognostic (1.99e-1)" "unprognostic (1.77e-1)" "unprognostic (1.53e-2)" "unprognostic (1.74e-1)" "unprognostic (3.85e-2)" "unprognostic (3.69e-1)" "unprognostic (3.73e-2)" "unprognostic (1.32e-1)" "unprognostic (3.58e-2)" "unprognostic (3.90e-1)" "prognostic favourable (4.49e-4)" "unprognostic (6.45e-3)" "unprognostic (2.55e-3)" "unprognostic (1.92e-1)" "unprognostic (9.71e-2)" "unprognostic (2.62e-2)" "unprognostic (1.65e-1)" 11.9 15.3 23.6 10.8 41.6 15.6 13.9 49.4 26.9 18.0 21.3 18.5 10.4 25.0 22.1 15.8 11.0 14.5 17.6 17.2 17.2 8.6 9.6 15.5 15.6 11.6 24.2 13.5 25.2 13.7 6.1 20.3 13.3 18.1 15.4 10.7 14.8 10.5 14.8 22.7 12.6 20.2 15.4 14.8 16.5 15.3 12.5 29.1 6.6 15.8 3.9 8.0 15.0 14.8 6.0 2.4 10.5 6.8 4.5 5.0 3.1 6.4 15.7 5.8 7.5 18.9 10.8 8.5 5.8 9.7 9.2 12.8 11.9 5.4 3.2 8.1 7.0 7.5 7.0 3.6 4.8 6.1 5.9 6.5 4.6 6.8 17.5 2.4 18.3 15.8 12.4 14.4 10.7 7.5 8.9 8.3 8.8 8.3 4.3 4.1 5.9 3.9 8.6 26.8 3.7 5.5 7.1 7.0 4.5 6.1 3.7 10.1 5.6 4.5 8.8 21.7 9.4 29.9 7.6 4.1 3.9 3.0 13.7 5.5 8.5 3.6 4.7 2.8 2.9 6.8 4.1 5.3 3.5 2.5 2.4 6.0 3.9 3.4 10.5 4.5 2.2 2.4 5.0 3.1 23.6 41.6 49.4 26.9 17.2 8.6 24.2 13.5 18.1 29.1 FLG ENSG00000143631 Filaggrin P20930 1 152302175-152325203 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Developmental protein" "Cancer-related genes, Ichthyosis" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "esophagus: 21.9;skin 1: 109.7;tongue: 38.6" "Cell line enhanced" "Detected in some" "HaCaT: 14.0;NTERA-2: 4.4;TIME: 3.0;U-2 OS: 3.4;U-2197: 3.6" "Cancer enriched" "Detected in some" 7 "melanoma: 11.6" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "CAB002210, HPA027505, HPA030188, HPA030189" Enhanced Enhanced "Cytoplasmic bodies" 500000 "Cytoplasmic bodies" "CAB002210: AB_563731, HPA027505: AB_10600107, HPA030188: AB_10601749, HPA030189: AB_10601999" "unprognostic (3.37e-2)" "unprognostic (3.76e-1)" "unprognostic (8.83e-2)" "unprognostic (2.96e-3)" "unprognostic (9.65e-2)" "unprognostic (1.17e-1)" "unprognostic (2.02e-1)" "unprognostic (4.03e-2)" "unprognostic (1.12e-1)" "unprognostic (9.98e-2)" "unprognostic (1.73e-1)" "unprognostic (2.40e-1)" "unprognostic (2.35e-2)" "unprognostic (1.45e-1)" "unprognostic (4.28e-2)" "unprognostic (4.15e-2)" "unprognostic (7.41e-3)" 0.1 0.0 0.0 0.0 0.0 0.0 4.1 0.0 0.1 2.1 0.0 0.0 0.0 0.0 0.8 0.0 21.9 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.3 0.1 0.0 0.0 0.0 0.5 0.0 0.4 109.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.3 0.0 38.6 7.3 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.1 0.5 0.0 0.0 0.7 14.0 0.0 0.0 0.0 1.5 0.1 1.1 0.1 0.5 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 4.4 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.1 3.0 1.2 3.4 3.6 2.6 0.0 0.0 0.0 0.1 0.0 2.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 FLI1 "EWSR2, SIC-1" ENSG00000151702 "Fli-1 proto-oncogene, ETS transcription factor" Q01543 11 128686535-128813267 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 40.2" "Cell line enhanced" "Detected in many" "HEL: 40.2;HUVEC TERT2: 22.3;REH: 18.8;TIME: 23.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA073099 Supported "Nucleoplasm,Nuclear bodies" "Nucleoplasm, Nuclear bodies" "HPA073099: " "unprognostic (1.38e-2)" "unprognostic (7.46e-2)" "unprognostic (6.16e-2)" "unprognostic (3.74e-2)" "unprognostic (6.22e-2)" "unprognostic (4.26e-3)" "unprognostic (1.33e-1)" "unprognostic (8.32e-3)" "unprognostic (2.97e-1)" "unprognostic (9.91e-2)" "unprognostic (1.60e-2)" "unprognostic (1.42e-1)" "prognostic unfavourable (4.60e-4)" "unprognostic (4.79e-2)" "unprognostic (2.07e-2)" "unprognostic (2.62e-1)" "unprognostic (4.79e-2)" 14.7 2.5 3.5 15.8 4.4 10.6 9.9 1.4 3.2 6.7 5.1 3.8 2.1 3.3 7.8 6.5 4.8 5.3 6.0 7.5 3.8 3.1 4.2 3.6 17.4 24.4 6.2 1.6 4.0 3.2 2.5 2.0 11.4 3.8 4.3 3.1 4.8 4.2 3.3 5.2 3.2 6.9 5.7 6.6 40.2 4.1 2.7 4.6 26.8 5.7 2.8 17.9 6.2 6.7 4.5 13.1 20.1 12.0 7.8 8.8 11.6 0.0 0.0 2.0 0.0 0.2 0.4 0.0 1.2 3.4 1.4 1.2 0.0 0.0 6.8 12.2 4.0 0.0 0.3 5.0 1.6 3.2 0.1 40.2 0.2 0.0 2.4 4.8 5.7 0.3 0.4 2.9 6.8 22.3 0.0 8.8 0.3 0.0 4.8 2.7 0.6 1.2 18.8 0.0 7.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 7.8 23.1 0.2 0.0 0.1 1.2 2.8 5.9 5.9 0.0 11.7 1.8 20.1 9.5 16.1 7.2 10.3 8.8 4.5 6.2 5.8 13.1 3.6 2.6 5.6 7.8 7.8 12.0 2.2 7.4 11.6 3.5 4.4 1.4 3.2 3.8 3.1 6.2 1.6 3.8 4.6 FLT1 "FLT, VEGFR1" ENSG00000102755 "Fms related tyrosine kinase 1" P17948 13 28300344-28495145 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins" "Angiogenesis, Chemotaxis, Differentiation" "Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in all" 8 "placenta: 155.3" "Cell line enhanced" "Detected in some" "BJ: 17.0;BJ hTERT+: 13.5;HMC-1: 84.6;HUVEC TERT2: 15.3;WM-115: 30.3" "Cancer enhanced" "Detected in all" "renal cancer: 28.7" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 4 "memory B-cell: 1.1;naive B-cell: 3.7;neutrophil: 2.1" "Group enriched" "Detected in many" 5 "B-cells: 3.7;granulocytes: 2.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA011740, HPA014290, CAB068189, CAB068190" Enhanced Supported "Plasma membrane,Actin filaments" "Secreted to blood" 875697 54000 "Plasma membrane, Actin filaments" "CAB068189: , CAB068190: , HPA011740: AB_1858737, HPA014290: AB_1858738" "unprognostic (3.33e-2)" "unprognostic (3.52e-3)" "unprognostic (1.13e-3)" "unprognostic (5.02e-2)" "unprognostic (3.65e-1)" "unprognostic (5.03e-2)" "unprognostic (8.25e-2)" "unprognostic (2.27e-3)" "unprognostic (9.91e-2)" "unprognostic (6.61e-2)" "unprognostic (2.33e-1)" "unprognostic (1.57e-1)" "prognostic unfavourable (2.19e-4)" "unprognostic (4.20e-2)" "unprognostic (6.00e-2)" "unprognostic (1.57e-1)" "unprognostic (6.32e-2)" 18.9 4.0 9.9 4.0 14.3 1.2 13.5 8.0 15.9 7.1 4.6 3.5 1.7 3.5 7.2 2.2 3.4 4.0 6.9 18.3 11.4 7.3 10.3 7.6 12.3 2.5 10.3 3.2 5.1 5.4 13.4 3.7 155.3 13.8 5.1 3.1 9.1 3.0 5.0 12.5 2.6 3.4 7.3 9.6 7.2 4.6 6.8 10.2 0.0 19.1 3.8 2.8 7.6 9.2 3.7 0.5 2.1 0.1 0.2 0.4 0.2 0.0 0.0 0.0 0.1 0.1 0.2 0.0 17.0 13.5 6.2 3.6 0.0 0.0 0.0 0.0 2.2 0.0 1.6 0.0 11.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 84.6 0.1 0.0 0.0 0.2 15.3 0.4 0.0 0.0 0.0 1.0 0.8 9.0 0.0 0.6 0.0 0.0 0.0 0.0 1.9 0.1 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.2 0.0 0.0 0.5 0.2 0.0 0.1 0.0 30.3 0.2 0.1 0.1 0.1 0.1 0.0 1.1 0.1 0.1 0.0 3.7 0.4 0.4 2.1 0.2 0.1 0.5 0.2 0.2 9.9 14.3 8.0 15.9 11.4 7.3 10.3 3.2 13.8 10.2 FLT3 "CD135, FLK2, STK1" ENSG00000122025 "Fms related tyrosine kinase 3" P36888 13 28003274-28100592 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, RAS pathway related proteins" "Host-virus interaction" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 29.9;brain: 19.3;lymphoid tissue: 15.0" "Group enriched" "Detected in some" 11 "REH: 27.8;THP-1: 17.1" "Cancer enhanced" "Detected in some" "breast cancer: 1.8" "Region enhanced" "Detected in many" "cerebellum: 19.3" "Group enriched" "Detected in some" 11 "myeloid DC: 29.9;plasmacytoid DC: 12.1" "Lineage enriched" "Detected in many" 16 "dendritic cells: 29.9" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA047539 Approved "Endoplasmic reticulum" 180000 "Endoplasmic reticulum" "HPA047539: " "unprognostic (2.19e-3)" "unprognostic (3.16e-3)" "unprognostic (6.54e-3)" "unprognostic (9.96e-2)" "unprognostic (3.88e-1)" "unprognostic (3.96e-7)" "unprognostic (7.99e-3)" "unprognostic (1.65e-2)" "unprognostic (5.37e-2)" "unprognostic (1.01e-2)" "unprognostic (1.96e-1)" "unprognostic (1.03e-1)" "unprognostic (4.56e-2)" "unprognostic (3.65e-1)" "unprognostic (3.91e-2)" "unprognostic (2.51e-1)" "unprognostic (2.22e-1)" 0.9 0.6 0.6 7.2 1.1 7.5 2.6 19.3 3.5 0.9 1.2 0.1 0.1 0.4 0.8 0.8 1.0 1.2 4.6 0.5 0.9 1.7 2.8 0.7 2.7 15.0 1.8 1.1 0.5 5.7 0.0 0.4 0.0 7.4 0.6 1.4 0.1 2.3 0.6 0.4 1.2 3.0 1.3 4.4 8.8 0.9 1.2 0.0 8.2 0.6 0.0 5.8 2.4 0.7 0.1 29.9 1.4 1.8 0.8 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 2.0 0.5 0.0 27.8 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 17.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 1.8 1.4 0.0 0.3 0.0 0.1 0.0 0.0 29.9 0.0 0.0 0.0 0.0 0.8 0.0 12.1 0.0 1.2 0.6 1.1 19.3 3.5 0.9 1.7 1.8 1.1 7.4 0.0 FLT4 "PCL, VEGFR3" ENSG00000037280 "Fms related tyrosine kinase 4" P35916 5 180601506-180649624 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins" Angiogenesis "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "placenta: 56.3" "Cell line enhanced" "Detected in some" "AN3-CA: 8.3;BEWO: 10.2;HEK 293: 12.6;HL-60: 7.4;HUVEC TERT2: 8.1;T-47d: 12.0;TIME: 12.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in some" 5 "MAIT T-cell: 7.7" "Lineage enriched" "Detected in single" 35 "T-cells: 7.7" "Low region specificity" "Detected in many" "Not detected" "Not detected" "CAB000099, HPA046519, HPA067906" Approved Approved "Nucleoplasm,Plasma membrane,Cell Junctions" "Secreted to blood" 270000000 "Plasma membrane" "Nucleoplasm, Cell Junctions" "CAB000099: , HPA046519: , HPA067906: " "unprognostic (7.35e-2)" "unprognostic (1.63e-1)" "unprognostic (9.45e-3)" "unprognostic (3.81e-1)" "unprognostic (9.26e-2)" "unprognostic (3.20e-3)" "unprognostic (1.13e-2)" "unprognostic (1.80e-2)" "unprognostic (2.19e-1)" "unprognostic (1.70e-1)" "unprognostic (2.13e-2)" "unprognostic (3.69e-1)" "unprognostic (1.88e-2)" "unprognostic (9.41e-3)" "unprognostic (1.83e-1)" "unprognostic (8.26e-2)" "unprognostic (1.32e-1)" 14.8 7.1 1.6 4.9 6.0 0.7 28.5 1.3 2.7 6.3 7.3 1.9 2.1 3.1 7.3 6.2 5.7 9.2 5.3 6.4 1.7 0.9 11.7 10.2 14.1 23.6 2.0 0.8 5.8 2.3 2.3 6.2 56.3 2.1 4.9 1.4 6.7 3.3 4.4 4.8 2.8 4.7 4.7 1.5 14.5 2.4 3.5 2.0 0.3 19.4 4.4 2.3 6.1 14.7 0.0 0.1 0.2 0.0 0.0 7.7 0.2 0.1 2.0 2.7 8.3 0.0 0.0 10.2 0.2 0.1 0.0 0.0 0.3 0.3 0.2 0.8 0.1 0.3 2.8 0.1 0.2 0.1 12.6 1.0 0.4 0.4 0.1 7.4 0.2 0.2 0.0 0.1 0.3 8.1 0.3 0.3 1.7 4.5 0.1 0.4 5.8 0.5 6.5 0.0 0.1 0.1 0.2 0.2 0.9 0.1 0.2 0.0 12.0 0.2 12.7 0.1 5.9 0.2 0.1 0.2 0.1 0.0 0.0 0.2 0.1 0.1 0.0 0.0 0.9 0.0 7.7 0.0 0.4 1.6 0.0 0.0 0.0 0.2 0.2 0.0 0.0 0.1 0.0 0.2 1.6 6.0 1.3 2.7 1.7 0.9 2.0 0.8 2.1 2.0 FMO5 ENSG00000131781 "Flavin containing monooxygenase 5" P49326 1 147175351-147243050 "Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins" "Monooxygenase, Oxidoreductase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "intestine: 61.1;liver: 119.4;stomach 1: 38.6" "Cell line enhanced" "Detected in some" "Hep G2: 28.4;HMC-1: 6.4;THP-1: 7.2" "Cancer enriched" "Detected in many" 7 "liver cancer: 43.0" "Group enriched" "Detected in many" 6 "basal ganglia: 5.5;cerebral cortex: 4.5;midbrain: 17.1;pons and medulla: 5.2;thalamus: 6.0" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA012373 Enhanced Supported "Endoplasmic reticulum,Cytosol" "Endoplasmic reticulum, Cytosol" "HPA012373: AB_1848975" "unprognostic (2.70e-1)" "unprognostic (1.28e-1)" "unprognostic (1.33e-1)" "unprognostic (2.06e-2)" "unprognostic (1.39e-1)" "unprognostic (3.96e-2)" "unprognostic (2.43e-2)" "unprognostic (2.94e-2)" "unprognostic (1.10e-1)" "unprognostic (1.85e-2)" "unprognostic (2.93e-1)" "unprognostic (1.13e-1)" "prognostic favourable (1.34e-6)" "unprognostic (3.77e-1)" "unprognostic (1.38e-1)" "unprognostic (1.85e-1)" "unprognostic (4.11e-2)" 1.1 2.4 1.1 1.9 5.5 0.2 8.6 0.6 4.5 1.3 61.1 1.5 0.8 12.5 1.0 1.3 0.7 1.1 8.5 1.0 1.3 0.5 9.0 119.4 17.0 0.8 17.1 0.5 1.0 11.9 8.8 4.9 0.6 5.2 1.9 8.2 0.5 9.7 0.6 0.4 4.2 53.6 0.9 7.1 1.2 38.6 1.2 6.0 0.2 1.1 1.5 0.5 1.9 0.8 9.2 4.9 6.2 12.1 1.0 2.0 3.6 0.1 0.7 0.5 0.0 1.9 0.5 0.6 0.4 0.3 0.2 0.6 0.4 1.5 0.3 0.5 0.4 0.3 0.0 0.0 0.0 1.0 0.1 1.1 0.0 28.4 0.6 0.9 6.4 0.9 0.1 0.3 0.0 0.4 0.1 0.1 1.1 0.9 0.2 0.5 2.0 0.5 0.3 0.3 0.2 2.4 0.4 0.4 0.2 0.6 1.9 0.9 1.4 7.2 0.7 0.0 0.2 0.6 0.0 0.2 0.0 0.2 0.7 0.3 0.2 6.2 12.1 3.5 2.0 5.6 0.3 3.6 0.5 0.6 4.9 9.2 0.3 1.3 1.2 1.0 1.6 2.4 1.4 3.6 1.1 5.5 0.6 4.5 1.3 0.5 17.1 0.5 5.2 6.0 FN1 "CIG, FINC, GFND2, LETS, MSF" ENSG00000115414 "Fibronectin 1" P02751 2 215360440-215436172 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Acute phase, Angiogenesis, Cell adhesion, Cell shape" Heparin-binding "Cancer-related genes, Disease mutation, Dwarfism, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "ductus deferens: 235.4;placenta: 433.0" "Cell line enhanced" "Detected in many" "ASC TERT1: 837.5;HSkMC: 391.7;hTERT-HME1: 230.4" "Cancer enhanced" "Detected in all" "thyroid cancer: 833.9" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB000126, HPA027066" Enhanced "Secreted to blood" 47000000000 "CAB000126: , HPA027066: AB_10602500" "unprognostic (8.08e-2)" "unprognostic (1.09e-3)" "unprognostic (2.20e-2)" "unprognostic (3.45e-3)" "unprognostic (1.82e-2)" "unprognostic (3.47e-3)" "unprognostic (3.36e-2)" "unprognostic (5.91e-3)" "unprognostic (2.96e-2)" "unprognostic (2.91e-3)" "unprognostic (1.41e-2)" "unprognostic (2.84e-1)" "prognostic unfavourable (3.44e-8)" "prognostic unfavourable (8.82e-5)" "unprognostic (7.88e-2)" "unprognostic (7.74e-2)" "prognostic unfavourable (3.33e-4)" 20.2 4.5 3.1 13.0 5.2 0.2 13.1 2.2 4.3 21.9 57.1 4.4 235.4 3.5 25.1 27.5 37.4 26.5 20.9 57.3 3.9 2.9 5.8 166.3 81.5 7.9 4.6 5.0 16.9 3.3 1.7 3.5 433.0 6.1 17.1 25.1 5.1 10.4 141.2 9.8 7.0 13.5 114.9 4.6 1.9 21.8 9.0 2.7 9.4 5.4 17.4 2.6 64.7 16.9 0.2 0.8 0.0 0.6 0.0 0.3 0.0 0.2 1.9 2.6 0.5 106.3 837.5 0.1 43.2 28.8 43.7 31.2 26.1 1.0 0.0 0.2 143.6 4.4 0.4 98.4 23.6 0.0 0.1 0.0 0.6 81.5 76.9 0.0 0.1 391.7 0.6 103.4 230.4 50.7 0.1 0.1 87.2 0.3 0.0 0.0 1.2 0.3 0.0 0.0 0.1 1.1 0.3 0.1 0.6 5.1 2.7 28.0 0.4 0.0 97.2 63.4 6.7 69.3 8.0 0.1 0.0 0.0 75.3 0.0 16.4 0.0 0.6 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.1 0.3 0.0 0.0 0.0 0.8 0.0 0.0 3.1 5.2 2.2 4.3 3.9 2.9 4.6 5.0 6.1 2.7 FOLH1 "FOLH, GCP2, GCPII, NAALAD1, NAALAdase, PSM, PSMA" ENSG00000086205 "Folate hydrolase 1" Q04609 11 49146635-49208670 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Carboxypeptidase, Dipeptidase, Hydrolase, Metalloprotease, Multifunctional enzyme, Protease" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 37.7;intestine: 111.2;prostate: 33.8" "Cell line enhanced" "Detected in some" "HAP1: 5.3;RPMI-8226: 3.7;SK-BR-3: 4.4;TIME: 2.8;WM-115: 5.3" "Cancer enriched" "Detected in many" 27 "prostate cancer: 142.7" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB001451, HPA010593" Enhanced "CAB001451: AB_563979, HPA010593: AB_1079685" "unprognostic (1.33e-1)" "unprognostic (1.19e-1)" "unprognostic (1.24e-1)" "prognostic favourable (5.24e-5)" "unprognostic (2.55e-1)" "unprognostic (8.31e-2)" "prognostic favourable (4.25e-4)" "unprognostic (1.32e-1)" "unprognostic (2.09e-2)" "unprognostic (2.67e-3)" "unprognostic (2.13e-2)" "unprognostic (2.72e-1)" "prognostic unfavourable (1.30e-6)" "unprognostic (4.81e-2)" "unprognostic (7.27e-2)" "unprognostic (4.74e-3)" "unprognostic (4.04e-1)" 1.2 1.0 10.4 0.9 16.4 0.8 2.5 1.4 12.7 1.4 67.6 37.7 0.0 111.2 1.3 0.8 1.2 2.1 5.0 0.7 16.9 8.7 6.1 15.7 1.1 0.9 19.0 9.1 1.0 0.7 0.7 0.4 0.7 17.7 33.8 0.8 0.6 20.7 0.8 0.6 1.2 61.1 1.0 33.0 1.5 1.0 0.9 16.2 0.0 1.0 0.0 0.8 1.2 0.5 0.9 0.1 0.3 0.8 1.4 1.2 0.0 0.3 0.0 0.1 0.0 0.0 0.0 2.6 0.3 0.0 0.0 0.0 0.0 0.9 0.2 0.6 0.0 0.2 5.3 0.5 0.0 1.2 0.9 0.0 0.5 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 1.1 1.0 0.0 0.3 0.3 3.7 0.0 0.0 0.4 1.6 0.0 4.4 1.0 1.0 0.0 2.8 0.2 2.7 0.4 0.3 0.1 0.5 0.1 0.0 0.9 5.3 0.1 0.8 0.3 0.9 0.6 0.2 0.6 1.2 0.5 0.0 0.9 0.7 0.3 0.2 1.4 0.5 0.1 0.4 0.0 10.4 16.4 1.4 12.7 16.9 8.7 19.0 9.1 17.7 16.2 FOS "AP-1, c-fos" ENSG00000170345 "Fos proto-oncogene, AP-1 transcription factor subunit" P01100 14 75278774-75282230 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" DNA-binding "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enriched" "Detected in many" 5 "hTCEpi: 98.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in many" 6 "neutrophil: 84.5" "Lineage enriched" "Detected in many" 7 "granulocytes: 84.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" HPA018531 Approved Supported Nucleoplasm Nucleoplasm "HPA018531: AB_1846576" "unprognostic (1.18e-2)" "unprognostic (8.70e-2)" "unprognostic (1.61e-1)" "unprognostic (3.80e-1)" "unprognostic (3.08e-2)" "unprognostic (4.82e-2)" "unprognostic (2.09e-1)" "unprognostic (3.30e-1)" "unprognostic (9.55e-3)" "unprognostic (4.20e-3)" "unprognostic (1.04e-1)" "prognostic favourable (7.81e-4)" "unprognostic (3.20e-2)" "unprognostic (1.52e-2)" "unprognostic (3.22e-1)" "unprognostic (1.43e-1)" "unprognostic (2.66e-2)" 104.8 58.4 17.0 143.7 30.0 157.6 40.7 24.0 21.3 132.3 48.7 52.3 22.1 17.4 79.7 50.5 93.6 239.5 271.8 56.8 17.5 21.4 22.7 47.9 70.7 31.0 23.9 10.6 94.5 32.7 40.9 52.9 130.2 44.6 60.6 49.3 64.4 42.8 255.8 37.5 156.2 44.1 98.1 43.7 18.5 60.7 33.2 26.8 10.1 77.5 226.7 28.1 60.8 54.0 0.0 11.6 84.5 12.3 0.7 0.1 3.3 0.4 0.3 1.5 2.2 13.2 4.0 9.1 1.3 0.5 0.9 0.7 0.9 2.6 0.1 0.4 9.2 0.6 0.7 15.9 0.2 0.2 0.2 0.2 3.8 0.3 6.1 0.5 9.3 9.9 98.7 0.8 6.0 0.5 0.4 4.2 0.2 5.4 0.1 2.6 1.6 0.5 0.4 0.3 4.8 4.1 4.3 11.3 0.7 2.0 18.3 7.8 0.3 1.9 1.3 0.1 1.2 0.8 0.4 11.4 11.9 2.0 0.6 1.6 1.2 6.0 12.3 14.6 0.0 3.5 0.0 0.0 0.0 0.1 11.6 0.0 0.0 0.0 84.5 0.7 0.4 0.2 0.0 3.3 17.0 30.0 24.0 21.3 17.5 21.4 23.9 10.6 44.6 26.8 FOSL1 fra-1 ENSG00000175592 "FOS like 1, AP-1 transcription factor subunit" P15407 11 65892049-65900573 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "esophagus: 35.2;tongue: 46.8" "Cell line enhanced" "Detected in many" "PC-3: 92.9;U-2197: 62.3;WM-115: 140.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in some" 4 "myeloid DC: 6.9" "Lineage enriched" "Detected in many" 4 "dendritic cells: 6.9" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB004396, HPA030728" Supported Supported Nucleoplasm Nucleoplasm "CAB004396: AB_627632, HPA030728: " "unprognostic (2.88e-2)" "unprognostic (1.56e-1)" "unprognostic (9.46e-2)" "unprognostic (1.33e-1)" "prognostic unfavourable (1.80e-4)" "prognostic unfavourable (2.05e-4)" "unprognostic (2.70e-1)" "prognostic unfavourable (1.95e-4)" "unprognostic (1.12e-1)" "unprognostic (2.11e-1)" "prognostic unfavourable (9.26e-5)" "unprognostic (7.85e-2)" "prognostic unfavourable (6.40e-6)" "unprognostic (2.23e-1)" "unprognostic (1.53e-1)" "unprognostic (2.28e-1)" "unprognostic (2.82e-2)" 22.4 3.7 1.5 8.2 3.1 17.9 3.6 1.1 2.8 5.4 2.8 1.5 0.2 0.8 2.1 2.0 35.2 4.4 24.4 5.8 2.3 1.3 2.2 4.4 7.7 1.7 2.6 0.5 2.6 9.9 0.4 2.0 3.2 6.5 3.1 1.7 0.6 5.4 1.0 6.6 9.2 2.0 3.6 3.5 1.6 8.7 1.5 2.3 0.3 2.1 46.8 16.5 16.6 4.6 0.0 6.9 1.0 1.6 0.0 0.6 1.1 36.0 5.3 0.6 2.4 5.4 5.4 5.2 33.8 31.0 29.3 16.4 1.6 30.1 0.0 7.4 23.4 6.8 2.2 27.2 25.2 1.1 0.0 2.2 0.5 4.0 6.8 1.4 0.8 2.3 2.7 22.9 34.7 9.4 5.2 0.2 38.4 1.5 0.0 3.0 2.5 92.9 0.1 2.9 0.1 13.6 2.4 0.0 0.0 2.0 0.0 25.4 0.1 1.3 23.3 34.7 7.1 62.3 49.5 0.0 0.1 0.1 48.8 0.6 140.9 0.0 1.6 0.0 0.3 1.1 0.2 0.0 0.6 0.3 6.9 0.0 0.6 0.0 1.0 0.0 0.5 0.8 0.0 1.1 1.5 3.1 1.1 2.7 2.3 1.3 2.6 0.5 6.5 2.3 FOXA1 HNF3A ENSG00000129514 "Forkhead box A1" P55317 14 37589984-37596059 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, Chromatin regulator, Developmental protein, DNA-binding, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 47.0;prostate: 44.4" "Cell line enhanced" "Detected in some" "Hep G2: 16.3;MCF7: 35.4;PC-3: 24.7;RT4: 33.1;SK-BR-3: 33.5;T-47d: 47.5" "Cancer enhanced" "Detected in many" "prostate cancer: 127.0" "Region enriched" "Detected in single" 6 "midbrain: 2.0" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 15 "hypothalamus: 1.0;midbrain: 1.3;thalamus: 1.1" "Region enriched" "Detected in some" 6 "midbrain: 6.1" "CAB011595, HPA050505" Enhanced Supported "Nucleoplasm,Nucleoli fibrillar center" Nucleoplasm "Nucleoli fibrillar center" "CAB011595: AB_2104842, HPA050505: " "unprognostic (1.61e-1)" "unprognostic (8.80e-2)" "unprognostic (1.12e-1)" "unprognostic (4.65e-1)" "unprognostic (2.58e-1)" "unprognostic (1.51e-1)" "unprognostic (1.74e-1)" "unprognostic (1.78e-1)" "unprognostic (1.71e-1)" "unprognostic (3.01e-1)" "unprognostic (1.54e-2)" "unprognostic (6.30e-2)" "unprognostic (0.00e+0)" "unprognostic (3.67e-1)" "unprognostic (2.58e-1)" "unprognostic (1.69e-2)" "prognostic favourable (1.00e-4)" 0.1 0.0 0.1 6.1 0.1 0.0 23.5 0.1 0.3 1.5 9.4 0.1 0.1 4.6 0.1 0.5 7.2 1.3 6.5 0.1 0.1 0.3 0.4 47.0 13.2 0.1 2.0 0.1 0.6 0.2 0.0 1.1 0.1 0.2 44.4 6.0 0.2 9.4 0.7 0.1 0.7 5.1 2.4 0.1 0.1 13.0 0.6 0.1 0.2 0.1 4.4 9.9 12.5 11.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 1.5 0.0 0.9 0.0 0.0 0.2 0.0 0.1 0.0 0.0 7.3 0.9 0.0 0.5 0.0 8.2 4.6 1.1 0.0 0.0 8.1 0.0 1.4 16.3 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.3 0.0 0.0 35.4 0.0 0.1 0.0 24.7 0.0 0.3 0.1 3.4 33.1 4.2 0.0 1.6 33.5 0.0 47.5 0.1 0.0 0.3 0.0 0.1 1.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.3 0.1 0.3 2.0 0.1 0.2 0.1 FOXA2 HNF3B ENSG00000125798 "Forkhead box A2" Q9Y261 20 22581005-22585455 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, Chromatin regulator, Developmental protein, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 44.4;pancreas: 47.9;stomach 1: 20.7" "Cell line enhanced" "Detected in some" "A549: 10.2;HBEC3-KT: 11.7;Hep G2: 16.2;hTERT-HME1: 7.9;PC-3: 15.1;SCLC-21H: 26.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in single" "Not detected" "Not detected" "Not detected" "Not detected" "Region enhanced" "Detected in single" "midbrain: 1.1" "Region enriched" "Detected in single" 7 "midbrain: 4.9" "CAB001388, HPA066846" Enhanced Supported "Nucleoplasm,Cell Junctions" "Nucleoplasm, Cell Junctions" "CAB001388: AB_2262810, HPA066846: " "unprognostic (1.19e-1)" "unprognostic (1.99e-1)" "prognostic favourable (7.57e-6)" "unprognostic (6.82e-2)" "unprognostic (1.50e-6)" "unprognostic (1.38e-1)" "unprognostic (8.17e-2)" "prognostic favourable (6.28e-4)" "prognostic favourable (2.34e-4)" "unprognostic (3.18e-1)" "unprognostic (2.55e-15)" "unprognostic (2.50e-2)" "unprognostic (1.68e-1)" "unprognostic (7.12e-2)" "unprognostic (3.93e-3)" 0.2 0.0 0.2 1.3 0.2 0.0 0.2 0.2 0.3 9.7 4.5 0.2 0.2 2.2 1.8 0.2 0.2 3.8 13.1 0.2 0.2 0.1 0.2 44.4 15.9 0.2 1.4 0.2 3.4 47.9 0.0 0.4 0.3 0.4 0.5 6.0 0.2 0.2 0.2 0.2 0.0 1.8 0.2 0.2 0.2 20.7 0.3 0.2 0.2 2.2 0.2 0.9 0.3 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.9 0.3 0.0 0.1 0.0 0.0 0.0 11.7 0.0 0.0 0.7 0.0 0.0 16.2 0.0 0.0 0.0 0.0 6.3 0.0 7.9 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 15.1 0.0 0.0 0.0 0.5 0.0 26.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 3.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.2 0.3 0.2 0.1 1.4 0.2 0.4 0.2 FOXJ1 "FKHL13, HFH-4, HFH4" ENSG00000129654 "Forkhead box J1" Q92949 17 76136333-76141299 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Cilium biogenesis/degradation, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 19.9;epididymis: 20.4;fallopian tube: 45.9" "Group enriched" "Detected in some" 9 "BEWO: 22.4;CAPAN-2: 18.7" "Cancer enhanced" "Detected in many" "endometrial cancer: 73.7" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in single" "naive CD8 T-cell: 2.6" "Lineage enriched" "Detected in single" 9 "T-cells: 2.6" "Low region specificity" "Detected in many" "Region enhanced" "Detected in many" "midbrain: 55.6" HPA005714 Enhanced "HPA005714: AB_1078902" "prognostic favourable (9.39e-4)" "unprognostic (4.97e-3)" "unprognostic (1.22e-1)" "unprognostic (2.77e-3)" "unprognostic (1.19e-1)" "unprognostic (2.54e-3)" "unprognostic (1.71e-3)" "unprognostic (6.15e-2)" "unprognostic (1.00e-2)" "unprognostic (7.84e-3)" "unprognostic (1.43e-2)" "unprognostic (1.63e-1)" "prognostic unfavourable (2.03e-5)" "unprognostic (7.49e-2)" "unprognostic (1.94e-1)" "unprognostic (2.27e-1)" "unprognostic (1.91e-1)" 0.4 0.4 4.1 0.5 8.9 0.6 0.4 0.1 2.2 5.1 0.9 19.9 0.4 0.6 2.4 20.4 0.4 45.9 0.4 0.4 6.5 6.6 1.5 0.4 17.0 0.4 2.0 1.2 14.7 1.2 0.4 1.2 0.4 19.6 0.6 0.6 0.1 0.4 2.8 0.4 0.8 0.6 0.5 1.8 0.4 0.9 15.2 3.4 0.0 2.9 0.0 0.4 1.1 0.2 0.0 0.0 0.0 0.0 0.2 2.6 0.1 0.0 0.4 1.3 0.0 0.0 0.0 22.4 0.0 0.0 0.0 0.0 2.3 18.7 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 1.2 0.0 0.4 0.0 0.0 0.1 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.7 0.0 0.0 0.6 2.6 0.0 0.2 0.0 0.0 0.0 0.1 4.1 8.9 0.1 2.2 6.5 6.6 2.0 1.2 19.6 3.4 FOXL2 "BPES, BPES1" ENSG00000183770 "Forkhead box L2" P58012 3 138944224-138947140 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Differentiation, Transcription, Transcription regulation" DNA-binding "Cancer-related genes, Disease mutation, Premature ovarian failure" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "cervix, uterine: 13.9;ovary: 55.5;parathyroid gland: 15.3" "Cell line enhanced" "Detected in some" "A-431: 5.4;fHDF/TERT166: 6.3;HEL: 9.0;hTCEpi: 8.3;K-562: 9.2;SiHa: 6.4;THP-1: 6.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in some" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA069613 Enhanced Supported "Nucleoplasm,Cytokinetic bridge" Nucleoplasm "Cytokinetic bridge" "HPA069613: " "unprognostic (1.46e-1)" "unprognostic (3.28e-2)" "unprognostic (4.76e-3)" "unprognostic (2.05e-1)" "unprognostic (5.16e-4)" "unprognostic (3.55e-2)" "unprognostic (2.35e-3)" "unprognostic (5.08e-2)" "unprognostic (3.79e-2)" "unprognostic (2.19e-1)" "unprognostic (9.63e-8)" "unprognostic (2.16e-2)" "unprognostic (4.65e-1)" "unprognostic (2.90e-2)" "unprognostic (1.61e-2)" 0.0 1.5 0.3 0.0 1.2 0.0 0.0 0.3 1.0 13.9 0.0 0.6 0.0 0.0 10.0 0.4 0.1 6.4 0.0 0.1 0.4 0.2 0.0 0.0 0.0 0.0 0.3 0.4 55.5 0.6 15.3 13.1 1.4 0.8 0.2 0.0 1.7 0.0 0.4 0.0 0.2 0.0 0.9 0.3 0.0 0.0 0.8 0.2 0.0 0.2 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.4 2.1 0.3 3.9 0.1 0.0 1.7 0.2 0.0 0.4 0.1 0.0 0.4 0.0 2.6 6.3 1.2 0.0 0.0 0.1 0.0 0.0 9.0 1.1 0.0 0.0 0.1 0.0 0.0 8.3 0.0 0.0 0.0 9.2 0.0 3.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.4 1.8 0.0 0.0 6.4 0.0 0.0 0.0 6.6 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 1.2 0.3 1.0 0.4 0.2 0.3 0.4 0.8 0.2 FOXM1 "FKHL16, HFH-11, HNF-3, INS-1, MPHOSPH2, MPP2, TGT3, trident" ENSG00000111206 "Forkhead box M1" Q08050 12 2857681-2877155 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Cell cycle, DNA damage, DNA repair, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 47.5;testis: 40.1" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in some" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in some" "Low region specificity" "Detected in all" CAB017832 Uncertain Supported Nucleoplasm,Nucleoli,Cytosol "Nucleoplasm, Nucleoli" Cytosol "CAB017832: " "unprognostic (3.18e-2)" "unprognostic (1.69e-1)" "unprognostic (1.22e-2)" "unprognostic (1.09e-2)" "unprognostic (4.30e-2)" "unprognostic (3.75e-2)" "prognostic unfavourable (1.95e-6)" "prognostic unfavourable (2.92e-4)" "unprognostic (1.01e-2)" "unprognostic (3.25e-2)" "prognostic unfavourable (3.03e-5)" "unprognostic (6.09e-2)" "prognostic unfavourable (0.00e+0)" "unprognostic (2.80e-2)" "unprognostic (1.87e-1)" "unprognostic (1.29e-1)" "unprognostic (1.94e-1)" 1.7 1.7 1.0 9.3 0.9 13.8 2.4 0.4 1.2 2.0 6.5 0.4 1.1 6.0 1.2 2.1 13.5 0.4 4.1 1.2 0.8 0.6 1.3 1.6 2.8 6.6 0.8 0.3 0.8 0.6 0.0 0.5 3.9 0.9 0.9 8.2 0.6 2.6 1.1 0.7 3.7 7.1 4.4 1.2 5.0 3.2 40.1 0.4 47.5 0.6 11.4 11.6 2.0 3.7 0.7 0.6 1.0 0.6 0.4 1.9 0.1 28.6 29.1 22.6 20.7 3.4 4.5 28.8 18.7 18.5 38.1 34.5 36.7 25.7 18.5 4.0 26.8 22.3 33.8 17.2 37.3 34.6 18.1 20.9 27.9 15.7 0.5 16.8 17.1 2.3 1.9 35.3 24.9 26.8 11.7 41.7 29.9 26.9 22.8 8.0 49.8 21.7 16.6 34.3 9.7 9.0 18.4 12.7 20.2 24.0 20.1 11.0 19.7 18.8 10.7 30.9 47.0 36.1 65.0 5.5 9.1 26.8 14.3 16.1 32.7 0.4 0.6 0.1 0.4 0.2 0.4 0.7 0.5 0.4 0.2 0.7 0.9 0.3 1.0 0.4 0.1 0.6 1.9 0.1 1.0 0.9 0.4 1.2 0.8 0.6 0.8 0.3 0.9 0.4 FOXO1 "FKH1, FKHR, FOXO1A" ENSG00000150907 "Forkhead box O1" Q12778 13 40469953-40666597 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Apoptosis, Autophagy, Differentiation, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 85.9" "Cell line enhanced" "Detected in many" "ASC diff: 18.9;Daudi: 20.0;HSkMC: 25.2;U-698: 25.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001252, CAB022326" Approved Approved Supported Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "CAB022326: , HPA001252: AB_1078906" "unprognostic (4.72e-2)" "unprognostic (1.81e-1)" "unprognostic (8.54e-2)" "unprognostic (4.35e-1)" "unprognostic (2.42e-1)" "unprognostic (2.52e-1)" "prognostic favourable (3.74e-4)" "unprognostic (6.35e-2)" "unprognostic (1.60e-1)" "unprognostic (8.65e-3)" "unprognostic (1.71e-1)" "unprognostic (1.31e-1)" "prognostic favourable (1.33e-5)" "unprognostic (1.93e-1)" "unprognostic (5.44e-1)" "unprognostic (9.09e-2)" "unprognostic (9.63e-2)" 41.6 6.9 7.0 18.4 11.2 8.0 35.5 2.3 5.0 21.4 13.4 8.4 7.7 3.5 27.4 9.8 9.5 17.2 13.3 9.9 7.8 3.9 8.3 25.6 15.3 22.4 8.3 3.9 46.0 12.2 3.8 6.2 9.5 6.5 7.9 6.8 5.7 7.5 9.3 85.9 12.3 7.6 18.6 9.7 10.8 7.4 12.3 9.0 9.4 13.1 9.0 15.6 14.4 16.2 6.1 0.5 2.8 1.6 1.1 7.1 1.0 0.3 0.6 5.6 0.1 18.9 3.7 5.4 0.8 1.1 0.2 0.1 1.4 1.3 20.0 3.7 0.5 4.8 4.4 2.4 0.3 9.1 4.6 0.0 0.6 4.4 9.0 0.1 0.5 25.2 16.4 0.1 3.1 14.2 0.3 6.4 1.4 0.7 0.0 0.2 8.2 1.4 14.2 6.5 1.5 10.5 2.5 1.2 0.3 0.7 3.8 0.8 0.6 0.5 8.3 0.1 1.1 0.0 0.5 3.6 1.3 25.9 0.5 0.9 2.6 0.9 0.8 0.5 1.5 1.0 2.3 3.2 3.9 2.2 0.5 6.1 7.1 5.3 2.8 1.1 1.6 0.0 5.5 1.0 7.0 11.2 2.3 5.0 7.8 3.9 8.3 3.9 6.5 9.0 FOXO3 "AF6q21, FKHRL1, FOXO2, FOXO3A" ENSG00000118689 "Forkhead box O3" O43524 6 108559835-108684774 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Apoptosis, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Karpas-707: 39.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "neutrophil: 15.7" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004074, HPA063104" Supported Enhanced Nucleoplasm Nucleoplasm "CAB004074: AB_2106672, HPA063104: " "unprognostic (3.42e-2)" "unprognostic (3.76e-2)" "unprognostic (4.28e-2)" "unprognostic (1.96e-2)" "unprognostic (6.68e-2)" "unprognostic (4.63e-2)" "unprognostic (4.08e-3)" "unprognostic (1.73e-1)" "unprognostic (3.81e-2)" "unprognostic (5.18e-2)" "unprognostic (1.98e-2)" "unprognostic (1.75e-1)" "unprognostic (2.54e-2)" "unprognostic (9.09e-2)" "unprognostic (1.13e-1)" "unprognostic (5.81e-2)" "unprognostic (5.68e-2)" 29.6 7.7 11.5 12.2 12.6 36.7 35.4 28.0 18.1 19.9 16.1 12.6 9.8 7.8 17.4 16.1 22.3 16.5 18.0 12.9 9.7 7.7 10.7 14.0 21.1 16.8 12.4 14.0 28.8 52.3 14.3 8.8 13.1 10.3 13.8 11.0 14.3 21.2 10.5 54.7 20.3 11.3 13.9 7.9 14.2 14.8 13.1 13.2 11.6 13.1 12.7 10.2 17.1 20.3 1.8 2.7 15.7 4.6 3.4 4.0 1.0 8.9 3.3 5.9 9.5 18.3 21.9 7.4 7.5 7.9 6.6 9.1 5.8 8.2 5.8 6.4 8.7 6.6 6.1 9.1 9.8 5.2 8.8 14.4 2.9 4.4 21.3 3.4 10.6 24.9 18.4 13.4 18.5 4.9 9.7 39.3 11.9 5.1 4.8 5.3 3.8 4.9 5.5 16.7 19.3 13.0 6.8 10.4 27.1 6.3 5.2 7.4 5.7 11.5 7.9 11.2 6.3 6.8 9.6 0.7 6.7 5.5 6.1 6.9 7.6 6.7 2.9 5.7 3.6 1.5 4.0 1.0 1.9 3.0 1.7 1.8 1.7 2.3 15.7 3.4 4.6 2.7 1.8 1.0 11.5 12.6 28.0 18.1 9.7 7.7 12.4 14.0 10.3 13.2 FOXO4 "AFX1, MLLT7" ENSG00000184481 "Forkhead box O4" P98177 X 71096197-71103535 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, RAS pathway related proteins, Transcription factors" "Cell cycle, Differentiation, Myogenesis, Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "placenta: 98.6" "Cell line enriched" "Detected in many" 5 "BEWO: 60.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA039560, HPA040232" Enhanced Supported "Nuclear speckles,Cytosol" "Nuclear speckles" Cytosol "HPA039560: , HPA040232: " "unprognostic (4.64e-2)" "unprognostic (2.94e-2)" "unprognostic (2.19e-1)" "unprognostic (2.49e-1)" "unprognostic (4.79e-2)" "prognostic favourable (4.61e-4)" "unprognostic (1.09e-1)" "unprognostic (3.20e-2)" "unprognostic (1.58e-1)" "unprognostic (7.18e-2)" "unprognostic (2.13e-2)" "unprognostic (8.16e-2)" "prognostic favourable (3.46e-4)" "unprognostic (2.45e-2)" "unprognostic (2.07e-1)" "unprognostic (1.20e-1)" "unprognostic (1.75e-3)" 8.5 13.2 21.7 3.8 21.5 9.9 5.1 9.1 15.6 4.8 8.4 9.1 11.9 6.3 6.8 10.2 7.3 7.7 5.8 9.7 21.4 14.5 5.2 3.6 5.5 3.6 22.8 8.4 13.4 6.8 8.7 3.0 98.6 9.2 7.0 4.7 4.9 8.5 11.3 33.8 5.5 6.6 9.4 17.3 6.0 5.2 13.9 13.1 4.4 5.9 7.5 4.2 7.5 11.0 0.9 0.2 3.4 0.6 1.0 1.8 0.9 1.7 0.5 1.4 1.8 3.3 2.3 60.0 1.4 1.6 0.7 1.7 1.2 2.4 2.3 1.8 1.8 0.8 3.6 1.6 0.8 2.3 5.5 3.4 11.2 1.9 1.9 1.9 2.7 1.9 3.8 0.6 0.4 1.8 6.9 4.6 0.3 0.3 3.0 3.1 6.5 2.1 2.1 3.5 3.6 1.2 1.0 1.0 2.9 2.9 0.4 3.1 0.7 1.2 1.7 0.4 0.9 3.1 0.3 3.0 1.6 0.4 1.6 5.2 0.5 0.2 0.6 3.2 0.9 0.6 0.3 0.8 0.5 0.9 0.2 0.9 0.4 1.8 3.4 1.0 0.3 0.0 1.3 0.9 21.7 21.5 9.1 15.6 21.4 14.5 22.8 8.4 9.2 13.1 FOXP1 "12CC4, hFKH1B, HSPC215, QRF1" ENSG00000114861 "Forkhead box P1" Q9H334 3 70952817-71583993 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Repressor" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "hTEC/SVTERT24-B: 39.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "HPA003876, CAB011501" Supported Enhanced Nucleoplasm Nucleoplasm "CAB011501: AB_732428, HPA003876: AB_1078907" "unprognostic (2.31e-1)" "unprognostic (4.35e-3)" "unprognostic (2.09e-2)" "unprognostic (3.54e-2)" "unprognostic (2.69e-1)" "unprognostic (2.81e-3)" "unprognostic (1.68e-1)" "unprognostic (1.00e-1)" "unprognostic (1.23e-1)" "unprognostic (2.03e-1)" "unprognostic (4.38e-3)" "unprognostic (3.40e-1)" "unprognostic (6.14e-2)" "unprognostic (1.05e-1)" "unprognostic (8.65e-2)" "unprognostic (1.27e-1)" "unprognostic (6.05e-2)" 24.6 5.1 7.0 30.2 19.2 32.7 21.9 7.2 13.1 16.3 29.3 8.7 10.3 10.1 19.8 9.9 19.6 13.1 19.3 15.5 8.4 5.9 7.6 12.9 26.1 34.0 7.6 10.2 30.3 14.7 7.2 25.7 11.4 7.4 21.6 21.6 11.3 24.6 11.2 12.7 12.2 16.7 34.3 7.9 18.6 20.4 11.7 10.1 38.1 19.8 13.1 27.0 28.5 31.8 29.9 8.4 14.4 9.9 9.2 29.6 11.2 3.7 2.8 7.0 4.7 3.3 9.4 3.3 11.2 12.9 9.8 7.2 20.9 4.4 10.1 1.7 5.0 2.6 12.9 9.6 16.6 3.1 5.3 5.2 7.0 19.7 8.1 9.8 12.8 9.6 4.0 39.5 17.5 14.6 5.2 14.9 4.4 16.5 4.8 3.9 8.6 18.3 14.6 12.0 1.8 8.0 11.9 5.9 10.7 11.7 3.2 0.7 2.3 7.2 18.4 13.6 5.9 19.0 15.5 3.7 2.8 14.3 8.7 12.5 2.9 14.4 5.7 6.0 8.3 5.7 9.3 25.8 18.3 10.3 5.3 29.9 29.6 18.9 8.3 9.2 9.9 8.4 15.9 11.2 7.0 19.2 7.2 13.1 8.4 5.9 7.6 10.2 7.4 10.1 FOXQ1 HFH1 ENSG00000164379 "Forkhead box Q1" Q9C009 6 1312440-1314748 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "stomach 1: 65.5;vagina: 39.9" "Cell line enhanced" "Detected in some" "CACO-2: 16.4;CAPAN-2: 9.9;HaCaT: 19.2;Hep G2: 40.4;RT4: 17.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" HPA059700 Supported Nucleoplasm Nucleoplasm "HPA059700: " "unprognostic (2.04e-3)" "unprognostic (3.44e-1)" "unprognostic (1.10e-1)" "unprognostic (7.18e-2)" "unprognostic (1.50e-3)" "unprognostic (2.15e-1)" "unprognostic (3.26e-2)" "unprognostic (1.15e-3)" "unprognostic (1.04e-2)" "unprognostic (1.06e-1)" "unprognostic (7.65e-3)" "prognostic favourable (6.68e-4)" "unprognostic (1.49e-2)" "unprognostic (3.16e-3)" "unprognostic (2.82e-1)" "unprognostic (3.93e-2)" "unprognostic (1.96e-2)" 0.6 0.5 2.3 0.6 4.0 0.5 1.4 1.6 5.9 7.1 1.9 3.2 0.0 6.9 1.1 0.7 7.2 3.2 31.8 0.5 2.2 1.9 7.1 3.6 5.8 0.5 2.7 1.5 0.5 10.1 0.5 1.8 1.2 3.8 18.2 0.8 7.5 35.8 1.3 0.6 16.8 0.8 6.6 1.9 0.5 65.5 0.6 0.8 0.8 3.1 7.8 11.7 26.3 39.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.6 0.5 0.0 0.0 0.0 0.0 0.0 0.3 6.6 0.0 0.0 16.4 9.9 0.0 0.2 0.0 19.2 0.0 0.8 0.0 0.0 0.5 0.0 3.5 40.4 0.0 0.0 1.0 0.0 7.9 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.0 0.0 0.0 0.2 17.0 0.1 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.9 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.3 4.0 1.6 5.9 2.2 1.9 2.7 1.5 3.8 0.8 FRMD7 "FLJ43346, NYS, NYS1" ENSG00000165694 "FERM domain containing 7" Q6ZUT3 X 132076993-132128020 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" Neurogenesis "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 6 "endometrium 1: 7.4;kidney: 6.6;smooth muscle: 5.5" "Cell line enhanced" "Detected in some" "AF22: 1.1;HSkMC: 1.7;U-87 MG: 5.8" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in single" 29 "olfactory region: 80.8" "Region enriched" "Detected in single" 100 "olfactory region: 45.5" HPA000886 Uncertain "HPA000886: AB_1079269" "unprognostic (3.08e-2)" "unprognostic (1.27e-1)" "unprognostic (1.36e-1)" "unprognostic (3.07e-1)" "unprognostic (4.02e-2)" "unprognostic (1.64e-2)" "unprognostic (2.28e-1)" "unprognostic (2.18e-2)" "unprognostic (3.84e-1)" "unprognostic (3.54e-2)" "unprognostic (3.00e-1)" 0.2 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.3 0.0 0.0 7.4 1.1 0.0 1.1 0.0 0.1 0.0 0.1 6.6 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 1.1 0.0 0.5 0.0 5.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.3 0.0 0.3 0.0 0.0 0.0 1.1 0.0 0.1 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 5.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.3 0.0 0.0 0.0 0.3 0.0 0.0 0.0 FSCN1 "FLJ38511, p55, SNL" ENSG00000075618 "Fascin actin-bundling protein 1" Q16658 7 5592823-5606655 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" Actin-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 56.9" "Cell line enhanced" "Detected in many" "BEWO: 80.6;K-562: 67.5;NB-4: 76.7;PC-3: 67.5;SH-SY5Y: 64.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "myeloid DC: 5.4" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000121, HPA005723, CAB035991, HPA050654" Enhanced Supported "Plasma membrane,Cytosol" 4500000 Cytosol "Plasma membrane" "CAB000121: AB_2278596, CAB035991: , HPA005723: AB_1849159, HPA050654: " "unprognostic (1.91e-1)" "unprognostic (2.03e-2)" "unprognostic (3.12e-2)" "unprognostic (5.00e-3)" "unprognostic (1.18e-1)" "prognostic unfavourable (5.76e-4)" "unprognostic (2.16e-3)" "prognostic unfavourable (2.28e-4)" "unprognostic (6.31e-2)" "unprognostic (1.25e-1)" "unprognostic (3.27e-3)" "unprognostic (1.54e-1)" "prognostic unfavourable (8.15e-7)" "unprognostic (1.21e-2)" "unprognostic (8.57e-2)" "unprognostic (1.05e-2)" "unprognostic (6.93e-3)" 26.3 13.3 23.7 29.6 30.1 6.3 8.1 5.5 56.9 9.9 5.5 35.1 0.0 5.4 11.7 2.3 22.3 5.9 8.9 10.6 27.7 16.8 5.5 7.1 11.3 15.2 26.9 23.6 21.8 5.1 2.3 7.0 29.4 20.1 4.1 3.0 8.1 11.0 3.9 7.8 17.3 6.6 7.0 29.6 39.3 7.6 15.9 28.3 9.3 8.5 15.9 11.4 14.7 12.3 0.2 5.4 1.0 1.9 0.0 0.1 1.4 7.8 18.3 12.2 43.7 4.7 9.1 80.6 18.9 8.4 3.2 3.5 12.7 2.0 0.1 23.2 8.3 30.0 7.0 30.4 0.2 9.0 3.8 0.5 19.4 59.7 2.5 0.0 1.5 5.6 9.0 6.1 5.0 15.9 67.5 0.1 4.2 0.8 0.2 76.7 31.9 67.5 17.8 2.9 0.3 4.7 0.7 9.8 64.8 15.9 0.2 0.6 0.4 4.8 32.3 22.5 39.6 13.0 19.4 0.1 0.1 0.0 14.5 0.0 42.2 0.0 1.9 0.1 0.0 0.5 0.0 0.2 0.1 0.0 5.4 0.0 0.0 0.0 1.0 0.0 0.0 0.1 0.0 1.4 23.7 30.1 5.5 41.3 27.7 16.8 26.9 23.6 20.1 28.3 FSHB ENSG00000131808 "Follicle stimulating hormone beta subunit" P01225 11 30231016-30235261 "Cancer-related genes, Disease related genes, Predicted secreted proteins" Hormone "Cancer-related genes, Disease mutation, Hypogonadotropic hypogonadism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 90 "pituitary gland: 70.7" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "CAB023410, HPA069703" Enhanced "Secreted to blood" 47000 "CAB023410: AB_324983, HPA069703: " "unprognostic (1.04e-1)" 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.3 0.5 0.0 0.5 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 70.7 0.0 0.3 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.3 0.5 0.0 0.0 0.3 0.3 0.0 FST FS ENSG00000134363 Follistatin P19883 5 53480409-53487134 "Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 42.7" "Cell line enhanced" "Detected in many" "BJ hTERT+: 58.2;HaCaT: 49.3;HBEC3-KT: 31.5;HMC-1: 35.4;PC-3: 95.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Group enriched" "Detected in some" 5 "memory CD4 T-cell: 1.0;naive CD4 T-cell: 2.0;non-classical monocyte: 1.0" "Group enriched" "Detected in many" 5 "monocytes: 1.0;T-cells: 2.0" "Low region specificity" "Detected in many" "Low region specificity" "Detected in single" CAB026025 Approved "Secreted to blood" 1800000 "CAB026025: " "unprognostic (1.43e-1)" "unprognostic (6.50e-2)" "unprognostic (1.44e-1)" "unprognostic (7.73e-3)" "unprognostic (2.30e-1)" "unprognostic (1.50e-3)" "unprognostic (8.02e-2)" "unprognostic (2.32e-2)" "unprognostic (3.06e-1)" "unprognostic (1.57e-1)" "unprognostic (1.93e-1)" "unprognostic (1.94e-1)" "prognostic unfavourable (4.44e-5)" "unprognostic (1.21e-3)" "unprognostic (2.48e-1)" "unprognostic (2.07e-2)" "unprognostic (2.18e-1)" 12.4 3.2 2.0 3.1 0.8 0.1 7.1 0.2 0.7 3.5 5.2 0.3 1.1 0.9 2.3 9.5 3.6 4.9 4.1 5.6 1.0 1.0 1.7 42.7 4.3 0.8 0.4 0.6 20.7 19.4 0.0 2.9 13.5 1.0 9.3 1.7 5.7 5.5 6.5 12.6 9.0 4.3 3.7 0.4 0.2 4.8 4.9 0.5 1.2 2.0 6.7 7.1 6.2 13.8 0.1 0.2 0.0 1.0 0.0 2.0 0.1 3.2 0.3 5.8 0.0 6.6 2.3 9.6 12.7 58.2 7.8 7.7 0.0 0.0 0.0 0.1 3.3 49.3 0.0 31.5 5.6 0.1 0.0 0.6 0.2 5.2 3.5 0.0 35.4 5.4 0.0 14.4 9.4 6.6 0.0 0.1 4.9 0.0 0.0 0.2 8.9 95.2 0.6 7.4 0.0 0.0 5.4 0.0 0.0 0.5 0.0 0.3 0.0 0.0 0.0 21.6 6.2 2.2 1.8 0.0 0.0 0.0 2.5 0.6 19.6 0.0 0.0 0.0 0.0 0.1 0.0 0.0 1.0 0.0 0.2 0.1 2.0 0.0 0.0 0.0 1.0 0.0 0.0 0.1 2.0 0.8 0.2 0.7 1.0 1.0 0.4 0.6 1.0 0.5 FSTL3 "FLRG, FSRP" ENSG00000070404 "Follistatin like 3" O95633 19 676365-683399 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins" "Osteogenesis, Transcription, Transcription regulation" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in all" 6 "placenta: 201.0" "Cell line enhanced" "Detected in many" "BEWO: 35.5;hTCEpi: 39.2;SiHa: 72.5;U-2197: 37.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB024899, HPA045378" Approved Approved Nucleoplasm "Secreted in other tissues" 6800000 Nucleoplasm "CAB024899: , HPA045378: " "unprognostic (9.86e-3)" "unprognostic (1.32e-3)" "prognostic unfavourable (3.01e-4)" "prognostic unfavourable (3.03e-4)" "unprognostic (2.19e-3)" "unprognostic (1.51e-3)" "unprognostic (8.64e-3)" "prognostic unfavourable (4.61e-7)" "unprognostic (9.50e-2)" "prognostic unfavourable (1.65e-4)" "unprognostic (3.50e-2)" "unprognostic (5.91e-2)" "unprognostic (1.03e-3)" "unprognostic (7.22e-3)" "unprognostic (3.07e-1)" "unprognostic (3.75e-1)" "unprognostic (5.89e-3)" 19.9 29.1 4.0 10.7 6.2 5.6 24.7 1.3 4.2 13.1 14.9 3.8 8.1 3.8 12.8 15.6 12.7 14.1 13.1 27.0 5.0 2.0 13.7 5.1 26.9 8.7 7.3 4.5 16.8 11.7 1.4 5.3 201.0 6.0 14.3 3.1 12.0 4.5 11.0 4.1 6.2 6.5 20.6 10.4 3.9 9.1 34.5 4.9 0.7 7.2 5.5 1.4 16.7 18.3 0.9 2.2 0.1 4.4 0.6 2.6 2.0 1.9 15.6 1.1 0.8 4.9 12.6 35.5 26.5 3.9 6.6 2.4 5.7 3.0 0.8 10.7 17.8 13.7 0.8 22.6 2.2 1.6 1.8 0.7 21.8 4.6 21.2 1.3 2.6 15.7 39.2 7.3 30.7 1.1 1.6 1.1 10.0 6.8 0.5 0.8 1.3 5.4 1.4 0.7 1.7 9.2 0.3 0.7 1.2 72.5 1.4 0.8 1.3 0.7 15.9 6.7 23.1 37.4 9.7 1.8 0.8 0.4 1.0 4.2 3.0 0.0 4.4 0.0 1.0 4.4 0.2 0.3 1.4 1.1 2.2 0.9 2.6 1.6 0.1 0.6 3.2 0.9 0.2 2.0 4.0 6.2 1.3 4.2 5.0 2.0 7.3 4.5 6.0 4.9 FTH1 "FHC, FTH, FTHL6, PIG15, PLIF" ENSG00000167996 "Ferritin heavy chain 1" P02794 11 61959718-61967660 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Iron storage" Oxidoreductase "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 756.2" "Cell line enhanced" "Detected in all" "ASC diff: 547.1;HHSteC: 570.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "neutrophil: 756.2" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" CAB008623 Approved Approved Microtubules 9000000 Microtubules "CAB008623: " "unprognostic (7.15e-2)" "unprognostic (1.52e-2)" "unprognostic (2.27e-1)" "unprognostic (2.00e-2)" "unprognostic (2.53e-1)" "prognostic unfavourable (7.56e-5)" "prognostic unfavourable (6.18e-4)" "unprognostic (3.08e-2)" "unprognostic (2.48e-2)" "unprognostic (6.65e-2)" "unprognostic (2.44e-2)" "unprognostic (8.13e-2)" "prognostic unfavourable (5.20e-5)" "unprognostic (2.99e-1)" "unprognostic (4.89e-2)" "unprognostic (3.44e-1)" "unprognostic (5.83e-2)" 155.1 118.0 177.6 138.9 92.6 162.0 302.9 38.5 163.7 104.2 142.4 97.8 72.0 72.2 81.6 102.4 88.8 70.6 83.5 236.1 124.7 91.2 113.5 128.2 297.3 394.0 118.5 110.6 81.7 150.8 49.7 46.7 70.1 77.5 60.9 138.5 79.5 180.5 65.1 124.1 42.5 110.0 140.0 182.1 84.4 81.0 67.8 88.2 58.5 100.3 64.1 48.9 106.7 94.0 69.5 163.3 756.2 424.5 30.7 69.2 284.2 64.4 181.0 27.6 73.0 547.1 265.0 152.3 59.1 254.1 60.4 61.0 21.9 89.5 7.5 375.8 170.2 110.4 24.6 48.9 39.2 30.7 12.1 37.5 250.9 142.9 570.0 17.6 59.0 358.9 240.3 120.5 226.6 75.5 55.9 86.0 210.8 87.2 19.7 28.8 47.2 306.1 19.6 34.1 53.6 308.6 175.5 23.5 29.7 203.3 22.4 96.2 39.8 23.7 84.1 188.8 45.2 83.5 37.1 14.9 51.2 23.1 257.4 7.8 44.9 401.9 297.7 247.4 40.8 367.6 40.2 68.6 58.3 40.4 163.3 69.5 49.3 38.2 756.2 30.7 424.5 121.2 69.2 284.2 177.6 92.6 38.5 163.7 124.7 91.2 118.5 110.6 77.5 88.2 FTL "MGC71996, NBIA3" ENSG00000087086 "Ferritin light chain" P02792 19 48965301-48966878 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Iron storage" "Cancer-related genes, Cataract, Disease mutation, FDA approved drug targets, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 1149.4" "Cell line enhanced" "Detected in all" "HHSteC: 570.4;HSkMC: 477.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Group enriched" "Detected in all" 4 "granulocytes: 1149.4;monocytes: 890.5" "CAB020769, HPA041602" Enhanced Approved Cytosol 240000000 Cytosol "CAB020769: , HPA041602: " "unprognostic (2.95e-1)" "unprognostic (2.64e-2)" "unprognostic (1.31e-1)" "unprognostic (1.56e-3)" "unprognostic (7.48e-2)" "unprognostic (5.28e-2)" "unprognostic (2.16e-3)" "unprognostic (6.17e-3)" "unprognostic (1.18e-1)" "unprognostic (1.08e-1)" "unprognostic (2.66e-1)" "unprognostic (2.96e-1)" "prognostic unfavourable (4.40e-5)" "unprognostic (1.32e-1)" "unprognostic (2.43e-2)" "unprognostic (2.30e-2)" "unprognostic (1.87e-2)" 326.0 111.3 147.1 113.6 130.9 179.8 321.8 25.8 101.3 105.7 107.5 134.7 58.2 120.5 54.9 85.4 85.0 71.3 214.6 140.8 111.7 88.2 295.2 526.9 391.6 444.6 139.4 49.6 126.8 108.0 27.0 63.6 166.3 89.0 108.0 92.3 114.4 59.4 75.4 75.6 48.3 159.4 149.2 194.5 317.9 105.2 53.9 74.5 45.1 130.0 57.5 67.5 159.8 172.1 147.8 231.2 1149.4 890.5 41.5 86.1 674.1 18.5 282.8 21.2 32.4 367.1 381.0 38.0 48.2 283.8 69.5 156.5 61.9 75.4 14.1 92.8 287.8 11.1 17.4 28.5 62.8 190.6 11.2 37.5 73.8 404.9 570.4 88.0 126.2 477.2 38.7 118.2 52.1 100.6 69.3 29.6 137.1 4.5 24.3 51.4 38.5 28.9 20.3 14.4 145.7 44.1 11.8 27.2 15.8 126.6 6.9 26.3 4.0 184.1 75.2 76.1 40.0 97.6 65.9 128.1 282.4 13.2 80.7 92.8 133.0 488.0 642.5 675.8 63.9 890.5 72.6 147.8 71.3 68.3 231.2 132.2 86.1 74.8 1149.4 41.5 768.3 97.2 83.8 674.1 147.1 130.9 25.8 101.3 111.7 88.2 139.4 49.6 89.0 74.5 FUBP1 "FBP, FUBP" ENSG00000162613 "Far upstream element binding protein 1" Q96AE4 1 77944055-77979110 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA006149 Supported Enhanced Nucleoplasm 200000 Nucleoplasm "HPA006149: AB_1849172" "unprognostic (4.17e-2)" "unprognostic (2.83e-2)" "unprognostic (3.35e-3)" "unprognostic (3.89e-2)" "unprognostic (3.77e-1)" "unprognostic (5.65e-2)" "prognostic unfavourable (9.83e-9)" "unprognostic (2.32e-2)" "unprognostic (2.16e-1)" "unprognostic (1.69e-1)" "unprognostic (3.31e-3)" "unprognostic (9.80e-3)" "unprognostic (9.02e-3)" "unprognostic (1.37e-1)" "unprognostic (1.67e-1)" "unprognostic (6.24e-2)" "unprognostic (9.46e-2)" 23.9 35.5 21.8 42.4 26.9 56.8 27.0 34.0 31.8 24.3 19.6 18.1 23.0 21.8 29.4 35.0 23.5 25.2 18.4 27.5 22.0 22.3 26.6 16.3 27.2 37.6 17.5 28.8 44.4 31.6 36.0 41.5 27.3 26.3 22.4 28.3 22.0 28.2 35.6 27.4 21.3 24.0 22.7 31.3 28.6 22.6 17.6 19.9 64.9 35.0 26.2 40.3 24.0 29.1 16.1 11.3 10.8 16.1 23.5 22.2 12.8 21.8 19.2 45.6 18.1 7.1 8.9 37.4 22.6 13.5 21.7 15.8 19.5 24.4 39.1 10.6 16.8 21.8 30.5 24.9 29.1 43.0 15.5 25.0 32.0 28.6 15.3 42.8 10.5 11.7 20.6 23.2 18.4 17.3 28.6 17.4 17.1 22.1 34.0 20.7 35.6 13.8 41.7 36.1 15.0 22.5 21.5 24.1 22.7 21.0 19.9 17.8 24.3 15.5 22.2 21.0 30.7 5.9 27.0 16.7 18.0 50.7 9.1 18.9 21.4 3.8 9.6 10.8 18.7 15.7 22.2 16.1 18.3 19.4 8.7 13.1 17.9 20.9 4.0 23.5 16.1 11.3 21.3 12.8 21.8 26.9 34.0 31.8 22.0 22.3 17.5 28.8 26.3 19.9 FUS "ALS6, FUS1, hnRNP-P2, HNRNPP2, TLS" ENSG00000089280 "FUS RNA binding protein" P35637 16 31180110-31194871 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "DNA-binding, RNA-binding" "Amyotrophic lateral sclerosis, Cancer-related genes, Disease mutation, Neurodegeneration, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008784, CAB033036, CAB058691" Supported Enhanced Nucleoplasm 190000 Nucleoplasm "CAB033036: AB_2105208, CAB058691: , HPA008784: AB_1849181" "unprognostic (3.06e-2)" "unprognostic (2.53e-1)" "unprognostic (1.86e-2)" "unprognostic (8.68e-2)" "unprognostic (1.44e-1)" "unprognostic (8.03e-2)" "prognostic unfavourable (4.38e-4)" "unprognostic (2.15e-2)" "unprognostic (1.00e-1)" "unprognostic (5.22e-3)" "unprognostic (1.01e-1)" "unprognostic (1.01e-3)" "unprognostic (1.12e-3)" "unprognostic (1.87e-1)" "unprognostic (5.27e-1)" "unprognostic (1.66e-1)" "unprognostic (1.49e-2)" 44.0 24.2 35.0 47.1 43.3 41.7 29.9 64.1 59.0 39.7 32.4 48.6 22.6 28.0 54.5 44.7 29.6 48.6 35.9 32.0 32.7 34.6 30.3 24.4 27.7 51.3 31.1 39.0 66.7 28.8 41.7 24.8 44.1 39.2 29.1 30.2 39.3 27.6 30.5 43.6 24.3 28.7 46.5 33.7 36.2 27.7 40.7 30.7 66.3 29.1 40.1 49.6 30.3 31.4 16.4 22.3 24.2 29.0 14.2 24.8 9.4 47.8 41.5 54.7 35.5 13.5 11.5 58.2 64.4 23.4 29.5 22.5 56.0 32.2 73.7 46.0 32.5 20.9 54.5 41.7 28.2 43.8 35.4 62.3 31.4 56.4 22.5 66.2 42.9 23.2 11.5 42.5 28.9 28.1 66.0 25.1 36.6 58.6 48.1 58.6 83.3 45.6 79.0 72.8 42.2 32.9 35.1 35.7 64.0 42.3 29.9 31.9 36.0 73.7 34.8 47.2 47.4 31.1 68.1 23.4 44.7 103.8 26.4 45.1 57.0 5.6 17.5 24.2 24.8 29.0 24.0 12.8 17.4 21.8 19.3 16.4 20.3 21.1 14.9 14.2 25.1 22.3 13.9 9.4 35.0 43.3 64.1 59.0 32.7 34.6 31.1 39.0 39.2 30.7 FZD1 DKFZp564G072 ENSG00000157240 "Frizzled class receptor 1" Q9UP38 7 91264364-91271326 "Cancer-related genes, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Transporters" "Wnt signaling pathway" "Developmental protein, G-protein coupled receptor, Receptor, Transducer" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "thyroid gland: 61.2" "Cell line enhanced" "Detected in many" "AF22: 16.3;HSkMC: 21.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "intermediate monocyte: 4.2;non-classical monocyte: 5.4" "Lineage enriched" "Detected in many" 4 "monocytes: 5.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB013008 Approved Supported "Plasma membrane" "Plasma membrane" "CAB013008: " "unprognostic (1.46e-1)" "unprognostic (1.70e-1)" "unprognostic (1.15e-1)" "unprognostic (3.16e-2)" "unprognostic (4.51e-3)" "unprognostic (2.09e-1)" "unprognostic (5.29e-3)" "unprognostic (3.70e-2)" "unprognostic (2.36e-2)" "unprognostic (5.48e-3)" "unprognostic (2.14e-1)" "unprognostic (7.39e-3)" "prognostic favourable (8.87e-7)" "unprognostic (1.05e-2)" "unprognostic (4.16e-2)" "unprognostic (5.53e-2)" "unprognostic (4.13e-2)" 5.8 4.6 2.6 4.9 3.5 0.9 10.7 8.2 2.8 17.6 8.5 4.1 9.3 4.9 10.1 9.9 7.8 6.1 11.0 12.3 6.1 1.8 15.3 3.9 10.5 1.4 2.0 3.2 15.0 7.9 2.5 4.6 10.0 5.7 12.3 3.7 11.1 9.2 17.5 3.1 10.7 8.3 7.2 4.6 3.4 4.5 4.4 3.5 1.4 61.2 6.5 2.9 10.4 13.9 0.1 1.3 0.2 5.4 0.0 0.0 0.4 0.5 1.6 16.3 1.7 13.3 11.5 3.0 5.9 3.8 2.2 1.5 0.7 2.8 0.0 1.4 3.8 3.0 2.5 1.3 1.4 0.0 3.2 0.1 3.1 0.8 0.9 2.6 0.7 21.8 2.3 5.0 1.6 0.5 0.9 2.3 6.3 3.9 0.4 0.7 4.2 2.7 3.2 10.0 0.2 3.5 7.6 2.2 4.3 4.5 3.7 0.9 1.9 2.4 2.4 9.3 7.0 9.8 2.4 2.2 1.5 0.2 10.0 2.2 10.7 0.0 1.4 0.0 0.0 4.2 0.0 0.1 0.0 0.0 1.3 0.0 0.0 0.0 0.2 0.0 5.4 0.1 0.0 0.4 2.6 3.5 8.2 2.8 6.1 1.8 2.0 3.2 5.7 3.5 FZD2 ENSG00000180340 "Frizzled class receptor 2" Q14332 17 44557459-44559570 "Cancer-related genes, G-protein coupled receptors, Predicted membrane proteins" "Wnt signaling pathway" "Developmental protein, G-protein coupled receptor, Receptor, Transducer" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "A549: 25.7;BJ hTERT+ SV40 Large T+: 25.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Group enriched" "Detected in some" 5 "classical monocyte: 3.5;myeloid DC: 5.6;plasmacytoid DC: 2.6" "Group enriched" "Detected in many" 6 "dendritic cells: 5.6;monocytes: 3.5" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA057667 Uncertain Approved "Nucleoplasm,Nuclear bodies,Cell Junctions" "Nucleoplasm, Nuclear bodies" "Cell Junctions" "HPA057667: " "unprognostic (6.94e-2)" "unprognostic (1.12e-2)" "unprognostic (3.04e-2)" "unprognostic (8.83e-3)" "unprognostic (2.04e-1)" "unprognostic (5.29e-3)" "unprognostic (1.44e-2)" "unprognostic (2.29e-1)" "unprognostic (9.45e-2)" "unprognostic (5.61e-2)" "unprognostic (1.15e-2)" "unprognostic (1.86e-1)" "unprognostic (5.10e-3)" "unprognostic (1.19e-2)" "unprognostic (6.35e-2)" "unprognostic (1.05e-1)" "unprognostic (4.17e-3)" 2.3 2.8 2.3 3.9 5.8 0.9 3.2 0.7 3.1 16.1 2.9 2.1 3.0 2.9 10.8 7.6 2.4 6.6 7.7 5.8 3.2 1.5 5.0 0.5 6.9 3.1 2.1 2.9 12.1 2.7 1.6 1.9 8.4 4.9 4.2 0.8 14.3 2.9 7.9 1.8 1.1 3.6 3.3 2.0 3.7 2.1 6.5 1.8 1.1 5.3 2.4 3.1 3.8 4.3 0.2 5.6 0.0 3.5 0.0 0.8 0.6 7.5 25.7 14.7 8.4 3.3 2.9 0.3 21.3 13.0 25.5 18.4 19.8 4.4 0.0 6.7 5.3 3.5 1.7 1.8 6.1 1.9 5.0 0.8 4.2 0.1 4.3 0.1 4.4 5.5 1.4 6.2 4.2 1.0 1.6 0.2 6.4 4.0 3.4 1.9 16.1 4.8 9.8 4.4 1.3 3.3 0.3 1.9 6.4 2.7 0.7 1.6 8.2 3.6 0.4 13.8 12.2 2.6 12.5 0.6 0.4 1.8 2.5 1.4 6.3 0.0 3.5 0.0 0.1 0.2 0.0 0.0 0.0 0.8 5.6 0.2 0.0 0.2 0.0 0.0 0.2 2.6 0.0 0.6 2.3 5.8 0.7 2.1 3.2 1.5 2.1 2.9 4.9 1.8 G6PD G6PD1 ENSG00000160211 "Glucose-6-phosphate dehydrogenase" P11413 X 154531391-154547572 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Carbohydrate metabolism, Glucose metabolism" Oxidoreductase "Cancer-related genes, Disease mutation, Hereditary hemolytic anemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "testis: 83.1" "Cell line enhanced" "Detected in all" "A549: 225.5;MCF7: 85.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "eosinophil: 77.3" "Lineage enriched" "Detected in all" 5 "granulocytes: 77.3" "Low region specificity" "Detected in all" "HPA000247, HPA000834" Enhanced Enhanced "Centriolar satellite,Cytosol" 12000000 Cytosol "Centriolar satellite" "HPA000247: AB_1078978, HPA000834: AB_1078977" "unprognostic (1.73e-2)" "unprognostic (1.53e-3)" "unprognostic (1.13e-2)" "unprognostic (1.02e-1)" "unprognostic (7.78e-2)" "unprognostic (4.34e-2)" "prognostic unfavourable (9.45e-13)" "unprognostic (2.78e-2)" "unprognostic (1.66e-1)" "unprognostic (1.76e-2)" "unprognostic (1.09e-1)" "unprognostic (3.66e-1)" "unprognostic (2.89e-3)" "unprognostic (2.83e-1)" "unprognostic (1.94e-1)" "unprognostic (1.47e-1)" "unprognostic (7.25e-2)" 21.9 29.4 10.4 15.6 10.7 51.4 18.2 8.4 14.7 12.2 7.5 13.6 4.8 7.2 14.0 13.2 29.0 11.0 24.7 10.1 8.8 10.1 15.4 3.7 20.8 31.0 10.3 8.0 19.8 7.9 5.9 20.7 9.2 10.9 11.3 7.3 17.8 13.9 8.6 4.4 11.3 7.3 17.5 11.1 20.3 9.9 83.1 9.5 22.5 24.6 44.8 25.7 24.1 19.0 3.6 7.6 77.3 16.2 12.7 10.3 11.8 15.4 225.5 4.6 17.8 19.5 26.7 4.1 10.8 31.0 11.0 19.1 10.3 5.8 10.0 16.8 24.7 13.8 7.2 18.3 5.7 10.2 5.0 10.6 51.0 23.2 38.2 10.6 36.4 12.9 5.4 21.6 4.6 22.9 6.3 4.4 19.9 85.5 6.8 7.6 3.3 16.7 6.7 2.6 10.9 33.2 19.3 4.7 5.9 10.8 42.1 9.0 6.3 8.9 27.2 7.0 24.7 9.7 16.6 5.3 6.9 17.1 19.4 7.0 14.3 29.3 16.2 77.3 10.3 13.6 6.6 3.4 2.7 7.4 7.6 3.6 3.5 5.9 27.1 12.7 11.1 3.5 3.5 11.8 10.4 10.7 8.4 14.7 8.8 10.1 10.3 8.0 10.9 9.5 GADD45A "DDIT1, GADD45" ENSG00000116717 "Growth arrest and DNA damage inducible alpha" P24522 1 67685061-67688338 "Cancer-related genes, Predicted intracellular proteins" "Cell cycle, DNA damage, Growth arrest" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "kidney: 86.7;skeletal muscle: 102.1" "Cell line enhanced" "Detected in many" "HHSteC: 59.4;hTERT-HME1: 91.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "eosinophil: 24.9" "Group enriched" "Detected in all" 5 "granulocytes: 24.9;T-cells: 9.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in single" HPA053420 Supported "Nuclear speckles" "Nuclear speckles" "HPA053420: " "unprognostic (1.36e-2)" "unprognostic (3.29e-2)" "unprognostic (9.58e-2)" "unprognostic (3.76e-3)" "unprognostic (5.81e-2)" "unprognostic (1.36e-2)" "unprognostic (1.57e-3)" "unprognostic (2.80e-3)" "unprognostic (1.42e-1)" "unprognostic (6.26e-2)" "unprognostic (3.43e-2)" "unprognostic (5.21e-2)" "prognostic favourable (8.06e-6)" "unprognostic (6.11e-2)" "unprognostic (2.89e-1)" "unprognostic (3.43e-3)" "unprognostic (1.93e-1)" 29.6 6.8 10.7 8.2 20.9 46.2 20.9 1.7 15.8 11.7 10.8 5.8 18.8 10.1 23.3 13.8 12.2 8.8 16.7 12.9 18.1 9.8 86.7 66.9 17.1 4.9 11.4 4.1 13.8 8.3 4.1 5.1 10.8 21.2 16.5 9.0 9.4 9.5 15.6 102.1 14.8 20.4 16.1 15.5 7.4 14.1 9.2 7.5 9.2 26.2 10.1 10.9 23.9 11.1 1.1 2.2 24.9 3.2 3.1 9.3 4.8 21.9 1.4 3.7 1.1 6.7 7.0 35.4 39.1 18.2 13.0 14.2 7.7 3.7 9.5 12.0 6.3 13.2 0.4 33.4 24.6 6.9 3.8 11.8 3.5 7.7 59.4 3.4 1.1 11.8 16.9 16.5 91.6 9.3 25.3 16.9 15.3 0.7 1.0 4.2 4.8 15.5 2.5 29.1 9.7 6.7 16.6 16.2 2.8 8.2 2.3 23.4 0.4 3.7 9.6 13.6 18.3 14.4 27.3 43.3 8.4 17.2 6.0 1.6 13.3 7.2 3.2 24.9 3.7 1.5 3.0 1.1 2.5 3.0 1.4 0.7 0.7 1.2 4.1 3.1 1.0 2.2 9.3 4.8 10.7 20.9 1.7 15.8 18.1 9.8 11.4 4.1 21.2 7.5 GADD45G "CR6, DDIT2, GADD45gamma, GRP17" ENSG00000130222 "Growth arrest and DNA damage inducible gamma" O95257 9 89605013-89606555 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Apoptosis, Differentiation" "Developmental protein" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "placenta: 65.6" "Group enriched" "Detected in some" 4 "HDLM-2: 46.7;SCLC-21H: 24.6" "Cancer enhanced" "Detected in all" "prostate cancer: 79.8" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in some" 7 "eosinophil: 8.0" "Lineage enriched" "Detected in single" 22 "granulocytes: 8.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA023606 Approved "HPA023606: AB_1849409" "unprognostic (5.84e-2)" "unprognostic (1.61e-2)" "unprognostic (1.08e-2)" "prognostic favourable (7.06e-4)" "unprognostic (4.45e-2)" "unprognostic (1.85e-1)" "unprognostic (1.77e-3)" "unprognostic (3.75e-2)" "unprognostic (7.65e-3)" "unprognostic (4.16e-3)" "prognostic favourable (3.80e-5)" "unprognostic (1.11e-1)" "unprognostic (1.63e-2)" "unprognostic (4.95e-1)" "unprognostic (3.88e-2)" "unprognostic (3.41e-1)" "unprognostic (1.22e-1)" 7.0 23.6 4.6 4.4 7.7 8.4 6.7 4.8 5.4 23.3 7.4 2.8 12.0 4.2 21.3 6.5 6.1 6.4 5.9 53.4 4.1 3.8 6.7 48.4 4.6 1.5 5.3 3.7 14.1 28.7 4.9 25.4 65.6 7.4 12.7 1.6 3.0 14.7 10.2 58.0 5.5 6.0 5.5 6.7 1.3 6.5 13.0 3.0 0.8 8.4 26.8 2.6 5.1 6.2 0.0 0.2 8.0 0.3 0.0 0.1 0.1 1.2 0.0 6.7 0.0 0.0 0.0 8.8 0.4 0.0 0.0 0.0 1.0 0.1 0.0 1.0 0.0 0.9 2.2 0.0 0.0 46.7 0.4 0.1 0.1 0.0 0.3 0.0 0.1 0.1 0.8 0.0 0.0 0.1 0.1 0.0 0.0 1.9 0.1 0.4 6.1 0.1 0.5 1.9 0.4 0.0 0.3 24.6 5.6 0.4 2.6 0.0 1.0 0.0 0.8 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 8.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 1.2 0.0 0.0 0.2 0.1 0.1 4.6 7.7 4.8 5.4 4.1 3.8 5.3 3.7 7.4 3.0 GAS1 ENSG00000180447 "Growth arrest specific 1" P54826 9 86944363-86947189 "Cancer-related genes, Predicted intracellular proteins" "Cell cycle, Growth arrest" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "endometrium 1: 61.8" "Cell line enhanced" "Detected in many" "AN3-CA: 19.3;ASC diff: 13.3;BJ hTERT+: 26.2;HSkMC: 18.7;RH-30: 39.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Not detected" "Not detected" "CAB024164, HPA036085, HPA066902" Approved Approved "Nuclear speckles" "Nuclear speckles" "CAB024164: AB_2107950, HPA036085: , HPA066902: " "unprognostic (2.78e-1)" "unprognostic (1.63e-1)" "prognostic unfavourable (1.55e-4)" "unprognostic (1.97e-2)" "unprognostic (6.15e-2)" "unprognostic (2.84e-2)" "unprognostic (6.46e-2)" "unprognostic (6.91e-2)" "unprognostic (3.32e-1)" "unprognostic (1.28e-3)" "unprognostic (2.25e-3)" "unprognostic (4.30e-2)" "prognostic unfavourable (1.96e-5)" "prognostic unfavourable (8.26e-4)" "unprognostic (6.73e-2)" "prognostic unfavourable (1.13e-5)" "unprognostic (3.59e-2)" 26.5 2.9 0.9 8.3 1.1 0.0 14.0 1.3 1.3 26.4 9.1 2.1 15.0 0.9 61.8 37.1 10.0 20.9 11.8 9.9 1.0 0.5 4.5 0.8 4.1 5.7 1.8 0.8 31.5 4.3 0.8 3.2 50.1 2.0 18.1 1.0 8.7 4.8 8.9 8.1 10.1 3.4 24.5 0.9 1.2 6.3 18.9 0.5 3.6 6.0 3.8 1.6 11.3 15.6 0.0 0.8 0.0 0.0 0.1 0.6 0.0 0.0 0.0 3.3 19.3 13.3 5.0 0.3 3.6 26.2 1.3 1.1 0.0 0.0 0.0 0.2 6.7 0.2 0.0 0.1 0.5 2.1 7.4 0.0 10.8 0.0 6.7 0.0 0.3 18.7 2.8 0.4 2.3 0.0 0.0 0.0 5.5 0.0 0.0 0.1 4.0 0.0 3.8 39.9 0.0 0.2 0.0 0.4 1.7 5.4 0.0 5.7 0.0 0.1 0.0 5.6 1.6 0.4 1.2 0.0 0.0 0.0 0.2 0.2 1.8 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.8 0.0 0.0 0.9 1.1 1.3 1.2 1.0 0.5 1.8 0.8 2.0 0.5 GAS7 "KIAA0394, MGC1348" ENSG00000007237 "Growth arrest specific 7" O60861 17 9910609-10198551 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Differentiation, Neurogenesis" "Developmental protein" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 86.2" "Cell line enriched" "Detected in some" 9 "WM-115: 107.7" "Cancer enhanced" "Detected in all" "melanoma: 54.6" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "classical monocyte: 17.6" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004838, HPA064678" Enhanced Approved "Plasma membrane,Actin filaments,Focal adhesion sites" "Plasma membrane" "Actin filaments, Focal adhesion sites" "HPA004838: AB_2667263, HPA064678: " "unprognostic (1.68e-2)" "unprognostic (2.84e-3)" "unprognostic (1.80e-1)" "unprognostic (1.28e-3)" "unprognostic (1.15e-1)" "unprognostic (1.01e-2)" "unprognostic (7.32e-2)" "unprognostic (7.16e-2)" "unprognostic (2.88e-1)" "unprognostic (1.50e-2)" "unprognostic (2.48e-1)" "unprognostic (1.79e-1)" "unprognostic (1.94e-3)" "unprognostic (6.48e-2)" "unprognostic (8.78e-2)" "unprognostic (3.08e-2)" "prognostic unfavourable (6.89e-4)" 19.1 6.5 22.1 15.4 40.3 18.7 10.8 86.2 64.7 22.6 9.3 33.4 1.7 5.2 9.7 4.4 17.0 12.6 11.5 23.1 25.8 15.0 1.5 2.1 9.9 5.9 28.1 25.0 5.9 2.8 1.4 1.7 11.0 14.2 3.7 8.7 7.7 4.0 8.2 3.9 21.2 7.4 16.3 33.8 10.0 4.2 11.8 22.2 2.7 2.5 2.7 7.2 11.7 7.8 0.4 3.6 11.0 17.6 2.8 2.1 4.4 0.0 0.1 0.1 0.2 3.4 4.8 0.0 0.1 0.0 0.5 0.2 0.0 0.0 1.3 0.3 1.3 0.0 0.0 0.0 0.3 0.0 0.3 0.0 0.2 0.1 1.1 0.3 9.9 0.9 0.0 1.0 0.0 0.0 0.0 0.1 0.0 0.0 10.4 3.1 0.5 0.0 2.7 0.0 9.6 0.0 0.0 0.0 0.6 0.0 0.0 12.4 0.5 4.9 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.1 7.0 107.7 0.4 17.6 10.8 2.1 4.7 0.7 0.3 0.2 1.0 3.6 0.4 0.2 1.0 11.0 2.8 3.1 0.6 0.0 4.4 22.1 40.3 86.2 38.8 25.8 15.0 28.1 25.0 14.2 22.2 GAST GAS ENSG00000184502 Gastrin P01350 17 41712326-41715969 "Cancer-related genes, Predicted secreted proteins" Hormone "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 61 "stomach 1: 529.2" "Group enriched" "Detected in some" 6 "BEWO: 5.0;HaCaT: 9.5;hTCEpi: 5.9" "Group enriched" "Detected in many" 6 "pancreatic cancer: 38.8;stomach cancer: 23.5" "Region enhanced" "Detected in single" "cerebral cortex: 1.2" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in some" "Low region specificity" "Detected in single" CAB000038 Enhanced "Secreted to digestive system" 43000 "CAB000038: " "unprognostic (1.27e-1)" "unprognostic (4.27e-3)" "unprognostic (1.12e-1)" "unprognostic (1.07e-2)" "unprognostic (2.75e-2)" "unprognostic (5.68e-2)" "unprognostic (2.11e-1)" "unprognostic (2.85e-1)" "unprognostic (3.17e-1)" "unprognostic (9.07e-2)" 0.0 0.0 0.1 0.0 0.4 0.0 0.0 0.0 1.2 0.1 1.7 6.9 0.0 2.4 7.3 0.0 0.0 0.0 2.6 0.0 0.1 0.3 0.2 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.1 5.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.3 529.2 0.1 0.0 8.6 0.0 0.0 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 5.0 0.3 0.0 0.0 0.0 0.6 0.0 0.2 0.7 0.0 9.5 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 1.1 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.4 0.0 1.2 0.1 0.3 0.1 0.0 0.0 0.0 GATA1 "ERYF1, GATA-1, GF1, NF-E1, NFE1" ENSG00000102145 "GATA binding protein 1" P15976 X 48786554-48794311 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 10 "blood: 78.3;bone marrow: 37.0" "Group enriched" "Detected in some" 9 "HEL: 49.6;HMC-1: 51.2;K-562: 52.8" "Not detected" "Not detected" "Not detected" "Not detected" "Cell type enriched" "Detected in some" 6 "eosinophil: 78.3" "Lineage enriched" "Detected in single" 784 "granulocytes: 78.3" "Not detected" "Not detected" "Low region specificity" "Detected in many" "HPA000232, HPA000233, CAB009195" Enhanced Supported Nucleoplasm Nucleoplasm "CAB009195: AB_2232148, HPA000232: AB_1078949, HPA000233: AB_1078951" "unprognostic (1.93e-1)" "unprognostic (7.54e-2)" "unprognostic (8.95e-3)" "unprognostic (3.84e-3)" "unprognostic (2.25e-1)" "unprognostic (3.00e-4)" "unprognostic (4.87e-2)" "unprognostic (3.48e-2)" "unprognostic (4.44e-2)" "unprognostic (1.95e-2)" "unprognostic (6.04e-2)" "unprognostic (7.71e-3)" "unprognostic (4.13e-2)" "unprognostic (2.24e-1)" "unprognostic (2.78e-1)" "unprognostic (9.10e-2)" "unprognostic (2.71e-2)" 0.7 0.2 0.1 2.4 0.7 37.0 0.3 0.0 0.3 0.7 0.3 0.0 0.0 0.6 4.9 2.4 0.4 0.3 0.6 2.3 0.1 0.3 0.4 0.8 5.6 0.2 0.6 0.0 0.1 0.1 0.1 0.5 2.8 0.3 1.4 0.4 1.6 0.3 0.2 0.1 0.6 0.8 2.4 0.3 4.9 0.5 3.1 0.0 1.5 0.6 1.1 0.6 0.9 0.6 0.0 0.0 78.3 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 49.6 0.0 0.0 0.0 0.0 51.2 0.0 0.0 0.0 0.0 0.0 52.8 0.1 0.0 0.0 0.0 5.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 12.2 0.0 78.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.7 0.1 0.7 0.0 0.3 0.1 0.3 0.6 0.0 0.3 0.0 GATA2 NFE1B ENSG00000179348 "GATA binding protein 2" P23769 3 128479427-128493185 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Phagocytosis, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 81.2;ductus deferens: 85.8;seminal vesicle: 209.1" "Cell line enhanced" "Detected in many" "BEWO: 55.8;HEL: 68.8;HMC-1: 37.2;SH-SY5Y: 65.0" "Cancer enhanced" "Detected in all" "prostate cancer: 36.7" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 339 "basophil: 81.2" "Lineage enriched" "Detected in single" 813 "granulocytes: 81.2" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA005633, CAB024847" Enhanced Supported Nucleoplasm Nucleoplasm "CAB024847: , HPA005633: AB_1078954" "unprognostic (1.71e-1)" "unprognostic (8.90e-2)" "unprognostic (1.12e-1)" "unprognostic (8.61e-2)" "unprognostic (8.67e-2)" "unprognostic (4.17e-2)" "unprognostic (5.96e-3)" "unprognostic (7.30e-2)" "unprognostic (3.98e-2)" "unprognostic (4.12e-2)" "unprognostic (3.58e-2)" "unprognostic (3.04e-1)" "prognostic favourable (2.04e-4)" "unprognostic (2.50e-1)" "unprognostic (8.07e-2)" "unprognostic (2.08e-1)" "prognostic favourable (5.22e-5)" 7.0 6.2 2.1 1.5 2.4 2.5 7.9 1.2 1.9 22.4 2.8 1.4 85.8 2.5 20.6 5.4 3.2 23.0 9.7 4.8 1.5 1.0 7.6 0.6 16.1 2.2 1.8 1.1 4.6 5.8 3.4 4.5 51.8 2.4 27.8 1.8 6.1 1.9 209.1 3.5 4.1 3.4 8.4 1.4 5.1 2.9 2.7 1.5 0.4 3.3 2.7 1.5 22.4 12.4 0.0 0.0 81.2 0.0 0.0 0.0 0.4 4.6 1.1 0.2 3.1 0.4 0.1 55.8 10.4 8.9 3.6 1.3 1.9 2.0 0.1 2.9 6.1 4.9 2.9 0.0 1.5 0.0 1.6 68.8 7.6 3.0 0.8 6.9 37.2 0.0 0.0 0.1 0.0 5.6 18.0 0.1 0.0 1.7 0.0 14.1 0.2 0.3 0.0 1.3 0.0 0.1 4.1 4.3 65.0 2.6 13.8 0.4 2.6 2.8 10.0 0.2 0.1 2.5 1.4 0.0 0.0 0.0 0.1 0.4 0.7 81.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 2.1 2.4 1.2 1.9 1.5 1.0 1.8 1.1 2.4 1.5 GATA3 HDR ENSG00000107485 "GATA binding protein 3" P23771 10 8045378-8075203 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Immunity, Innate immunity, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Deafness, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "seminal vesicle: 97.8;skin 1: 61.7" "Cell line enhanced" "Detected in some" "BEWO: 32.6;MCF7: 77.8;RT4: 31.8;SH-SY5Y: 27.3;T-47d: 101.3" "Group enriched" "Detected in many" 24 "breast cancer: 190.0;urothelial cancer: 87.0" "Low region specificity" "Detected in single" "Group enriched" "Detected in many" 42 "gdT-cell: 9.7;MAIT T-cell: 13.3;memory CD4 T-cell: 18.2;memory CD8 T-cell: 14.1;naive CD4 T-cell: 10.0;naive CD8 T-cell: 9.0;NK-cell: 16.6;T-reg: 18.9" "Group enriched" "Detected in many" 54 "NK-cells: 16.6;T-cells: 18.9" "Region enriched" "Detected in single" 6 "midbrain: 7.3" "Group enriched" "Detected in some" 46 "midbrain: 25.5;pons and medulla: 17.5;thalamus: 20.0" "CAB016217, HPA029730" Enhanced Supported Nucleoplasm Nucleoplasm "CAB016217: AB_2108591, HPA029730: AB_10601907" "unprognostic (1.70e-1)" "unprognostic (7.23e-2)" "unprognostic (3.58e-2)" "unprognostic (2.00e-1)" "unprognostic (7.03e-3)" "unprognostic (4.68e-3)" "unprognostic (4.23e-2)" "unprognostic (9.65e-2)" "unprognostic (2.06e-1)" "unprognostic (2.55e-1)" "unprognostic (3.83e-1)" "unprognostic (1.17e-1)" "prognostic unfavourable (3.13e-4)" "unprognostic (1.48e-1)" "unprognostic (5.16e-2)" "unprognostic (6.31e-2)" "unprognostic (1.82e-3)" 2.0 2.0 0.3 3.4 0.3 0.9 17.8 0.3 0.3 1.8 0.5 0.1 44.4 0.1 0.4 13.5 0.8 0.4 0.4 0.9 0.3 0.4 12.9 0.7 1.6 2.7 0.8 0.0 0.3 0.4 55.0 3.8 53.4 1.4 8.1 0.0 1.8 8.9 97.8 0.8 61.7 1.2 3.4 0.4 2.7 0.5 0.8 0.1 42.4 3.3 0.6 3.4 26.9 16.4 0.2 0.0 0.3 0.0 16.6 18.9 3.0 5.4 1.3 0.0 0.0 0.0 0.0 32.6 0.1 0.0 0.0 0.0 2.0 4.9 0.0 0.0 0.0 4.7 0.5 0.1 0.0 15.6 1.6 0.0 0.0 0.0 0.3 0.0 0.0 0.0 1.1 0.0 0.3 2.5 0.0 0.0 0.0 77.8 8.5 0.0 0.5 0.7 0.4 0.4 0.1 0.0 31.8 1.6 27.3 0.0 4.4 0.0 101.3 0.0 0.0 0.4 1.0 0.2 0.6 0.1 0.0 0.0 0.2 0.0 0.2 0.0 0.0 0.0 9.7 0.0 13.3 0.2 18.2 14.1 0.0 0.0 10.0 9.0 0.3 16.6 0.0 0.0 18.9 3.0 0.3 0.3 0.3 0.3 0.3 0.4 0.8 0.0 1.4 0.1 GCLM GLCLR ENSG00000023909 "Glutamate-cysteine ligase modifier subunit" P48507 1 93885205-93909456 "Cancer-related genes, Predicted intracellular proteins" "Glutathione biosynthesis" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009568, HPA023696, CAB040554" Uncertain Approved "Nucleoplasm,Plasma membrane,Cytosol" 1000000 "Nucleoplasm, Cytosol" "Plasma membrane" "CAB009568: AB_2107835, CAB040554: , HPA023696: AB_1849560" "unprognostic (2.31e-1)" "unprognostic (7.92e-2)" "unprognostic (8.85e-3)" "unprognostic (1.56e-2)" "unprognostic (2.83e-2)" "unprognostic (4.64e-2)" "prognostic unfavourable (9.83e-6)" "unprognostic (2.37e-1)" "unprognostic (1.07e-1)" "unprognostic (3.53e-1)" "unprognostic (3.51e-2)" "unprognostic (3.89e-2)" "unprognostic (2.19e-2)" "unprognostic (1.09e-2)" "unprognostic (1.79e-1)" "unprognostic (2.43e-1)" "unprognostic (2.34e-3)" 10.3 17.5 7.0 6.0 7.7 11.3 23.9 5.7 8.9 4.5 22.8 4.2 11.5 16.6 3.5 6.5 8.8 12.8 12.5 7.7 6.8 8.9 17.8 41.7 8.4 10.4 9.2 5.7 4.6 6.9 6.3 5.1 10.3 8.7 5.3 5.2 6.4 6.7 6.4 19.2 3.4 20.0 3.4 7.7 6.9 6.1 3.2 2.8 5.6 15.0 23.0 8.6 8.9 8.0 3.2 1.9 3.3 0.7 4.6 6.7 1.2 14.0 22.2 2.4 4.8 8.3 5.2 9.5 16.8 10.5 12.8 9.6 3.7 8.3 5.3 33.7 10.8 14.2 3.6 6.8 10.3 14.4 4.9 37.1 15.2 16.0 15.6 13.6 5.9 6.4 2.6 26.0 4.2 13.9 14.7 7.9 9.2 2.7 9.8 3.1 8.4 10.6 4.6 7.4 7.8 9.1 16.4 5.8 2.4 15.8 12.5 5.8 2.8 8.5 14.6 13.4 7.9 25.2 25.1 7.1 9.1 5.5 11.1 7.7 4.7 3.3 0.7 1.3 5.3 0.4 3.1 2.6 5.0 6.7 0.6 3.2 3.2 3.2 2.9 4.6 0.5 1.9 1.3 1.2 7.0 7.7 5.7 8.9 6.8 8.9 9.2 5.7 8.7 2.8 GDF15 "MIC-1, MIC1, NAG-1, PDF, PLAB, PTGFB" ENSG00000130513 "Growth differentiation factor 15" Q99988 19 18374731-18389176 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Cytokine, Growth factor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 7 "placenta: 463.0" "Cell line enhanced" "Detected in many" "BEWO: 70.7;Hep G2: 36.4;HHSteC: 98.3;TIME: 35.3" "Low cancer specificity" "Detected in all" "Region enriched" "Detected in single" 10 "pons and medulla: 6.5" "Cell type enhanced" "Detected in some" "neutrophil: 6.3" "Group enriched" "Detected in many" 5 "granulocytes: 6.3;monocytes: 2.3" "Not detected" "Not detected" "Low region specificity" "Detected in all" "HPA011191, CAB062554, HPA070957" Enhanced Enhanced "Golgi apparatus" "Secreted to blood" 1258667 890000 "Golgi apparatus" "CAB062554: , HPA011191: AB_1078962, HPA070957: " "unprognostic (1.04e-1)" "unprognostic (1.89e-2)" "unprognostic (3.45e-2)" "unprognostic (3.36e-2)" "unprognostic (2.04e-2)" "unprognostic (2.39e-2)" "unprognostic (2.03e-2)" "unprognostic (2.30e-2)" "unprognostic (2.80e-1)" "unprognostic (2.89e-1)" "unprognostic (5.09e-2)" "unprognostic (1.46e-1)" "unprognostic (6.55e-3)" "unprognostic (3.81e-2)" "unprognostic (8.45e-2)" "unprognostic (1.25e-1)" "unprognostic (3.04e-3)" 13.4 2.2 0.4 1.0 0.6 0.0 13.1 0.4 0.5 3.9 13.0 1.0 1.9 1.8 5.9 1.9 2.4 1.1 13.1 1.2 0.5 0.0 64.7 24.1 12.6 0.8 0.4 0.5 2.9 21.9 0.3 2.4 463.0 6.5 25.5 11.0 1.6 2.4 5.1 13.6 1.1 1.8 4.8 1.2 1.4 12.0 2.5 0.4 0.4 5.2 0.5 0.8 47.0 2.7 0.2 0.8 6.3 2.3 0.0 0.0 0.3 0.3 15.8 1.5 0.5 3.8 3.2 70.7 5.5 3.0 0.2 3.2 0.7 4.9 0.0 10.0 0.4 0.1 0.0 2.0 0.8 0.0 0.3 0.2 1.5 36.4 98.3 0.0 6.1 8.4 23.8 15.4 10.0 16.7 24.3 0.1 3.8 3.8 0.0 0.1 0.9 8.9 0.0 0.6 0.0 11.7 15.6 0.1 0.1 0.0 0.9 19.8 0.4 0.0 35.3 0.0 1.3 0.3 0.2 0.2 0.6 0.0 8.9 0.0 4.6 0.0 1.8 2.1 0.0 1.4 0.0 0.0 0.0 0.0 0.8 0.2 0.0 0.0 6.3 0.0 2.3 0.0 0.0 0.3 0.4 0.6 0.4 0.5 0.5 0.0 0.4 0.5 6.5 0.4 GDNF "ATF1, ATF2, HFB1-GDNF" ENSG00000168621 "Glial cell derived neurotrophic factor" P39905 5 37812677-37839686 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins" "Growth factor" "Cancer-related genes, Disease mutation, Hirschsprung disease" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 14.1;skeletal muscle: 12.4" "Cell line enhanced" "Detected in some" "hTEC/SVTERT24-B: 24.6;U-87 MG: 7.4;WM-115: 27.0" "Low cancer specificity" "Detected in many" "Region enriched" "Detected in many" 6 "cerebellum: 14.1" "Low cell type specificity" "Detected in single" "Low lineage specificity" "Detected in single" "Region enhanced" "Detected in single" "basal ganglia: 2.5" "Low region specificity" "Detected in many" "CAB005210, HPA070283" Supported Approved Nucleoplasm,Vesicles "Secreted in other tissues" Vesicles Nucleoplasm "CAB005210: AB_2247684, HPA070283: " "unprognostic (1.08e-1)" "unprognostic (6.30e-2)" "unprognostic (3.54e-2)" "unprognostic (8.87e-2)" "unprognostic (1.09e-1)" "unprognostic (1.08e-1)" "unprognostic (5.33e-2)" "unprognostic (1.92e-1)" "unprognostic (3.71e-2)" "unprognostic (2.01e-2)" "unprognostic (2.41e-1)" "unprognostic (2.10e-1)" "unprognostic (1.16e-4)" "unprognostic (2.04e-1)" "unprognostic (8.86e-2)" "unprognostic (1.05e-1)" "unprognostic (4.42e-2)" 1.9 0.3 0.6 1.9 2.3 0.0 0.4 14.1 1.3 0.8 9.4 0.4 0.4 1.6 1.7 3.4 1.0 0.9 0.9 0.9 0.6 0.4 1.0 0.7 0.4 0.4 0.6 1.2 4.5 0.4 0.0 0.4 6.3 1.4 1.6 3.1 1.1 0.4 6.3 12.4 1.4 2.5 2.5 0.5 0.4 1.9 3.9 2.4 0.4 0.4 1.5 0.4 0.6 1.1 0.8 0.4 1.2 0.3 0.9 0.4 0.0 0.0 0.0 0.0 0.0 1.1 0.4 0.0 3.3 2.1 0.6 0.9 0.0 0.0 0.0 0.0 4.4 0.1 0.0 0.0 1.2 0.0 0.1 0.0 0.2 0.3 0.1 0.0 0.0 1.0 0.1 24.6 0.0 0.0 0.0 0.0 1.3 0.1 0.0 0.0 0.2 0.0 0.0 5.3 0.0 0.0 0.1 0.2 0.0 0.1 0.1 1.6 0.0 0.0 0.0 3.3 0.0 0.8 3.8 2.3 0.0 0.0 7.4 0.0 27.0 0.4 0.3 0.2 0.3 0.2 0.3 0.2 0.3 0.3 0.1 0.8 0.2 0.4 1.2 0.9 0.2 0.4 0.1 0.0 0.6 2.3 14.1 1.3 0.6 0.4 0.6 1.2 1.4 2.4 GH1 "GH, GH-N, GHN, hGH-N" ENSG00000259384 "Growth hormone 1" P01241 17 63917200-63918838 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins" Hormone "Cancer-related genes, Disease mutation, Dwarfism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "pituitary gland: 994.5" "Cell line enriched" "Detected in some" 5 "U-698: 7.4" "Not detected" "Not detected" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "naive B-cell: 2.1;T-reg: 2.2" "Group enriched" "Detected in many" 4 "B-cells: 2.1;T-cells: 2.2" HPA043715 Supported "Secreted to blood" 1735000 180000 "HPA043715: " "unprognostic (1.91e-2)" "unprognostic (3.51e-2)" "unprognostic (1.72e-2)" "unprognostic (2.98e-1)" "unprognostic (9.45e-4)" "unprognostic (2.48e-1)" "unprognostic (2.09e-4)" "unprognostic (2.03e-2)" "unprognostic (6.57e-2)" "unprognostic (2.33e-1)" 0.3 0.0 0.0 0.5 0.0 1.1 0.2 0.1 0.1 0.4 0.4 0.0 0.0 3.3 1.0 0.0 0.2 0.5 0.0 0.1 0.0 0.0 0.0 0.2 0.4 0.6 0.0 0.0 0.0 0.0 0.3 994.5 217.7 0.1 0.2 0.5 0.0 0.1 0.2 0.8 0.9 0.4 0.1 0.0 1.6 0.3 0.5 0.0 0.0 0.0 0.0 0.6 0.1 0.0 2.1 0.0 0.0 0.5 0.0 2.2 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.1 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.4 1.5 7.4 0.0 0.0 0.0 0.0 0.2 0.0 0.4 0.0 0.0 0.0 0.6 0.0 0.0 2.1 0.3 0.0 0.0 0.0 0.5 0.0 2.2 0.2 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.0 GH2 "GH-V, GHL, GHV, hGH-V" ENSG00000136487 "Growth hormone 2" P01242 17 63880215-63881935 "Cancer-related genes, Predicted secreted proteins" Hormone "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 309 "pituitary gland: 47.3;placenta: 138.4" "Cell line enriched" "Detected in single" 20 "BEWO: 13.4" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA043715 Supported "Secreted to blood" "HPA043715: " "unprognostic (1.02e-1)" 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 47.3 138.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 13.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 GJA1 "CX43, GJAL, ODD, ODDD, ODOD, SDTY3" ENSG00000152661 "Gap junction protein alpha 1" P17302 6 121435692-121449727 "Cancer-related genes, Disease related genes, Predicted membrane proteins" "Cancer-related genes, Cataract, Disease mutation, Hypotrichosis, Palmoplantar keratoderma" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "BJ hTERT+: 48.8;HUVEC TERT2: 61.6;NTERA-2: 62.7;TIME: 45.3;U-87 MG: 61.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010753, HPA035097, HPA047551, HPA069245" Enhanced Supported Supported "Nucleoplasm,Vesicles,Cell Junctions" "Vesicles, Cell Junctions" Nucleoplasm "CAB010753: AB_476857, HPA035097: , HPA047551: , HPA069245: " "unprognostic (3.37e-2)" "unprognostic (3.41e-3)" "unprognostic (2.95e-1)" "unprognostic (4.18e-2)" "unprognostic (1.48e-2)" "unprognostic (1.67e-2)" "unprognostic (1.27e-1)" "unprognostic (6.78e-2)" "unprognostic (2.89e-2)" "unprognostic (1.56e-1)" "unprognostic (5.47e-2)" "unprognostic (1.00e-1)" "unprognostic (4.88e-2)" "prognostic unfavourable (4.99e-5)" "unprognostic (2.39e-1)" "unprognostic (1.29e-1)" "unprognostic (3.00e-3)" 19.7 65.2 78.6 5.5 69.7 0.4 14.2 32.4 44.4 64.5 4.0 23.8 6.1 4.2 23.5 5.5 17.3 7.8 23.0 36.0 87.3 25.5 3.6 2.5 15.2 4.4 42.9 39.9 10.5 4.5 94.7 5.7 63.8 53.7 20.0 4.8 26.3 7.1 35.7 3.4 86.3 4.4 25.6 38.7 1.1 6.4 8.3 64.3 0.5 38.9 9.9 7.6 14.8 32.2 0.5 0.5 0.4 0.5 0.0 0.4 0.0 0.0 7.2 32.1 0.0 17.5 10.9 0.0 24.0 48.8 8.1 19.8 0.1 0.0 0.0 2.7 9.3 3.1 0.8 14.7 26.4 0.0 8.8 0.3 2.9 0.0 21.9 0.0 0.0 29.0 15.9 29.6 10.7 61.6 0.0 0.7 1.6 1.3 0.0 12.9 62.7 8.0 0.0 0.0 0.6 32.4 3.5 0.0 0.5 0.0 0.0 0.0 2.5 0.0 45.3 25.0 6.9 21.1 15.5 0.0 0.0 0.0 61.0 0.0 3.5 0.4 0.5 0.0 0.2 0.0 0.2 0.0 0.3 0.0 0.2 0.5 0.4 0.4 0.0 0.0 0.1 0.5 0.1 0.0 78.6 69.7 32.4 42.8 87.3 25.5 42.9 39.9 53.7 64.3 GJB5 CX31.1 ENSG00000189280 "Gap junction protein beta 5" O95377 1 34755047-34758512 "Cancer-related genes, Predicted membrane proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "esophagus: 39.0;lymphoid tissue: 26.1;skin 1: 37.7;tongue: 28.0" "Cell line enhanced" "Detected in some" "A-431: 9.7;HaCaT: 31.1;HBEC3-KT: 13.9;hTCEpi: 51.5;RT4: 17.3" "Group enriched" "Detected in many" 5 "cervical cancer: 36.7;head and neck cancer: 57.5;lung cancer: 13.7;urothelial cancer: 21.1" "Low region specificity" "Detected in single" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA038146 Uncertain "HPA038146: AB_10697242" "unprognostic (2.62e-1)" "unprognostic (1.63e-1)" "unprognostic (3.48e-1)" "unprognostic (5.71e-2)" "unprognostic (8.26e-2)" "unprognostic (3.12e-1)" "unprognostic (7.89e-2)" "unprognostic (2.76e-2)" "unprognostic (5.35e-2)" "unprognostic (1.10e-1)" "prognostic unfavourable (1.54e-4)" "unprognostic (4.30e-2)" "unprognostic (1.09e-3)" "unprognostic (2.36e-1)" "unprognostic (2.41e-3)" "unprognostic (5.59e-2)" "unprognostic (5.67e-3)" 0.0 0.1 0.7 0.0 0.5 0.1 2.6 0.6 2.3 7.5 0.1 0.0 0.5 0.0 0.1 2.1 39.0 0.4 3.3 0.1 0.8 0.1 0.1 0.1 0.3 0.0 0.2 0.5 0.1 0.6 0.0 0.4 7.0 0.2 3.0 0.1 0.0 5.6 2.1 0.2 37.7 0.1 0.3 0.1 0.0 0.1 0.8 0.0 0.6 0.6 28.0 26.1 3.4 11.7 0.0 0.0 0.0 0.8 0.0 0.1 0.8 9.7 0.1 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.4 0.0 31.1 0.0 13.9 0.0 0.0 0.0 2.3 0.3 0.0 0.0 0.0 0.0 0.0 51.5 0.0 8.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 17.3 0.0 0.0 1.2 0.5 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.8 0.0 0.0 0.8 0.7 0.5 0.6 2.3 0.8 0.1 0.2 0.5 0.2 0.0 GLO1 GLOD1 ENSG00000124767 "Glyoxalase I" Q04760 6 38675925-38703141 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" Lyase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enriched" "Detected in all" 4 "HMC-1: 244.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB040541, CAB040542, HPA059791" Enhanced Supported "Nucleoplasm,Plasma membrane,Cytosol" 1600000 "Nucleoplasm, Plasma membrane, Cytosol" "CAB040541: , CAB040542: , HPA059791: " "unprognostic (4.33e-2)" "unprognostic (1.09e-1)" "unprognostic (4.37e-2)" "unprognostic (1.08e-2)" "unprognostic (3.96e-3)" "unprognostic (2.51e-1)" "prognostic unfavourable (5.21e-4)" "unprognostic (5.09e-2)" "unprognostic (2.10e-2)" "unprognostic (1.28e-2)" "unprognostic (2.61e-2)" "unprognostic (8.71e-2)" "unprognostic (1.20e-2)" "unprognostic (9.29e-2)" "unprognostic (1.83e-1)" "unprognostic (2.54e-1)" "unprognostic (6.21e-2)" 22.2 30.5 42.1 19.5 42.3 11.4 32.0 25.4 42.3 27.1 42.1 19.7 22.9 48.1 25.3 49.2 28.2 31.5 17.8 39.2 37.8 37.7 37.1 65.3 30.7 31.6 38.9 29.7 37.6 25.9 33.2 12.6 26.7 40.6 74.0 22.7 21.7 21.7 28.2 57.5 31.3 64.3 28.9 37.6 25.6 21.3 12.9 21.4 19.8 32.6 42.5 24.3 28.6 24.7 25.9 28.6 8.5 15.6 10.8 24.4 14.7 18.1 8.4 24.2 24.0 11.5 20.8 21.4 15.8 15.0 22.3 23.2 20.5 7.0 20.2 12.5 12.6 12.0 20.7 20.4 28.3 18.3 32.0 29.9 10.9 19.1 17.3 11.3 244.2 17.7 12.6 21.1 15.1 24.0 23.5 13.4 20.8 15.3 17.7 14.4 17.4 16.5 15.4 29.3 13.2 20.3 13.7 18.9 19.1 11.1 15.5 29.8 18.0 57.1 9.9 17.4 16.0 15.0 25.0 10.6 20.0 55.5 6.3 29.4 27.9 8.5 9.8 6.9 18.0 15.6 24.4 24.7 18.1 18.3 18.3 25.9 17.1 17.9 1.2 10.8 12.1 28.6 15.7 14.7 42.1 42.3 25.4 42.3 37.8 37.7 38.9 29.7 40.6 21.4 GMNN Gem ENSG00000112312 "Geminin, DNA replication inhibitor" O75496 6 24774931-24786099 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cell cycle" "DNA replication inhibitor" "Cancer-related genes, Disease mutation, Dwarfism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "pancreas: 95.0" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB011458, CAB047327, CAB047328, HPA049977, HPA054597" Enhanced Enhanced Nucleoplasm Nucleoplasm "CAB011458: AB_2110946, CAB047327: , CAB047328: , HPA049977: , HPA054597: " "unprognostic (1.37e-1)" "unprognostic (3.43e-3)" "unprognostic (3.91e-3)" "unprognostic (1.52e-2)" "unprognostic (1.28e-1)" "unprognostic (4.37e-2)" "unprognostic (2.90e-3)" "unprognostic (8.29e-2)" "unprognostic (1.23e-3)" "prognostic favourable (4.13e-4)" "prognostic unfavourable (9.77e-4)" "unprognostic (1.33e-2)" "prognostic unfavourable (7.82e-5)" "unprognostic (2.25e-1)" "unprognostic (7.92e-2)" "unprognostic (3.63e-2)" "unprognostic (5.90e-3)" 4.5 3.9 10.7 11.2 19.0 24.1 10.7 15.6 9.4 4.9 17.1 3.2 9.7 7.6 5.3 6.3 8.0 7.3 4.7 3.7 11.0 10.2 10.8 8.4 4.4 12.0 13.6 9.8 7.2 95.0 2.6 7.5 7.9 10.7 18.4 18.9 3.4 4.2 11.6 3.7 17.3 7.4 5.7 7.9 12.6 9.7 19.6 11.9 26.1 13.2 11.0 9.7 15.2 7.4 8.5 9.2 15.8 6.7 5.3 15.2 5.6 24.5 14.6 37.0 15.2 5.2 5.6 24.7 24.1 12.8 29.0 31.9 28.2 8.8 24.7 30.8 7.7 14.4 31.9 17.7 31.3 9.1 33.4 33.8 25.9 46.2 4.9 26.2 12.4 4.5 5.8 17.6 6.9 14.2 42.5 13.1 20.4 19.2 49.2 28.4 20.2 11.5 28.7 28.9 31.7 12.2 21.4 29.7 18.3 10.8 17.8 21.2 18.7 16.1 7.0 17.8 18.0 20.5 40.8 14.6 45.0 46.3 5.4 49.6 25.5 5.3 5.3 15.8 4.6 6.7 5.8 8.5 8.9 7.1 7.4 4.5 6.6 7.3 3.0 5.3 4.7 9.2 15.2 5.6 10.7 19.0 15.6 9.4 11.0 10.2 13.6 9.8 10.7 11.9 GNA11 "FBH, FBH2, FHH2, HHC2" ENSG00000088256 "G protein subunit alpha 11" P29992 19 3094410-3124004 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" Transducer "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "intestine: 103.3" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 9.1" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA048886 Approved "HPA048886: " "unprognostic (4.64e-3)" "unprognostic (2.21e-1)" "unprognostic (3.12e-1)" "unprognostic (2.23e-2)" "unprognostic (1.30e-1)" "unprognostic (1.53e-2)" "prognostic unfavourable (4.86e-4)" "unprognostic (2.56e-2)" "unprognostic (1.40e-1)" "unprognostic (6.26e-2)" "unprognostic (7.85e-3)" "unprognostic (2.43e-1)" "prognostic favourable (1.48e-11)" "unprognostic (1.05e-2)" "unprognostic (1.01e-1)" "unprognostic (2.47e-1)" "unprognostic (3.02e-1)" 19.3 14.2 17.3 13.7 17.1 5.9 14.2 38.5 28.0 16.1 40.8 18.6 18.3 65.9 19.8 14.5 17.2 19.8 19.5 21.9 16.0 12.8 17.8 16.6 15.1 5.0 11.7 12.6 19.4 19.6 14.2 13.8 20.0 14.1 18.2 23.0 27.1 17.5 30.5 27.3 20.0 103.3 17.6 12.2 10.5 17.2 20.1 12.5 3.9 18.0 13.5 7.6 19.2 22.1 2.4 3.9 9.1 2.4 0.7 2.2 0.4 20.3 12.4 11.3 19.6 16.7 11.1 12.5 20.2 20.1 27.4 22.5 15.6 10.5 5.0 11.2 28.2 14.8 14.2 16.2 17.5 11.0 8.4 1.4 13.4 8.9 16.5 1.3 4.6 15.2 14.1 18.5 11.2 21.8 10.2 1.0 18.3 9.4 1.4 6.0 7.8 11.2 8.9 10.0 4.6 13.3 16.0 25.5 16.1 14.5 17.4 10.1 12.5 2.9 18.6 18.1 12.9 32.6 27.0 0.5 1.4 3.3 12.9 1.1 19.6 2.8 2.4 0.5 1.1 1.3 1.4 1.3 0.9 1.1 0.4 2.4 2.2 1.6 9.1 0.7 2.4 3.9 0.3 0.4 17.3 17.1 38.5 28.0 16.0 12.8 11.7 12.6 14.1 12.5 GNA13 "G13, MGC46138" ENSG00000120063 "G protein subunit alpha 13" Q14344 17 65010715-65056839 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" Transducer "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "bone marrow: 75.6" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA010087 Approved Supported Cytosol 4000000 Cytosol "HPA010087: AB_10601478" "unprognostic (2.55e-1)" "unprognostic (2.27e-1)" "unprognostic (1.33e-3)" "unprognostic (1.23e-3)" "unprognostic (8.21e-2)" "unprognostic (7.05e-2)" "unprognostic (4.22e-3)" "unprognostic (1.09e-1)" "unprognostic (7.77e-2)" "unprognostic (4.66e-1)" "unprognostic (1.16e-2)" "unprognostic (1.94e-1)" "unprognostic (1.18e-1)" "unprognostic (1.18e-1)" "unprognostic (1.21e-1)" "unprognostic (1.44e-1)" "unprognostic (1.59e-1)" 28.2 17.4 16.4 25.3 17.5 75.6 15.1 15.1 15.0 14.2 19.1 23.0 13.0 14.0 12.9 12.1 13.2 12.1 17.7 15.4 16.8 13.3 12.4 17.4 27.6 27.5 18.5 9.4 16.3 10.0 12.1 10.0 25.0 14.8 16.8 17.3 10.7 10.5 13.9 35.0 11.4 17.5 15.9 32.1 22.5 13.6 11.3 20.4 34.9 11.9 9.0 27.5 28.3 26.0 5.7 5.5 15.8 13.4 7.8 11.2 4.4 11.6 13.2 12.1 8.2 12.6 11.4 12.5 9.1 10.6 12.5 14.3 7.4 7.8 47.6 6.0 9.8 8.1 12.9 11.1 19.3 12.3 7.5 24.8 8.0 14.5 18.2 18.5 16.5 9.6 17.0 12.0 16.6 18.8 10.0 29.7 14.4 11.0 28.4 6.7 7.5 9.8 16.5 24.3 17.3 12.6 19.1 8.9 18.8 6.6 13.8 15.6 14.2 18.1 13.4 20.8 18.3 8.9 11.9 22.0 26.1 54.0 7.6 12.0 11.0 7.1 6.4 8.5 7.2 13.4 7.3 5.7 8.9 8.5 5.5 4.8 5.2 5.7 15.8 7.8 8.3 2.5 11.2 4.4 16.4 17.5 15.1 15.0 16.8 13.3 18.5 9.4 14.8 20.4 GNAI1 ENSG00000127955 "G protein subunit alpha i1" P63096 7 80133955-80219402 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division, Mitosis, Transport" Transducer "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in some" 5 "NK-cell: 20.0" "Lineage enriched" "Detected in many" 5 "NK-cells: 20.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB022449, HPA042141" Approved Supported Nucleoplasm,Nucleoli,Centrosome 9000000 Centrosome "Nucleoplasm, Nucleoli" "CAB022449: , HPA042141: " "unprognostic (2.29e-1)" "unprognostic (2.83e-2)" "unprognostic (2.64e-2)" "unprognostic (1.54e-1)" "unprognostic (7.05e-2)" "unprognostic (1.18e-1)" "unprognostic (1.92e-2)" "unprognostic (2.08e-2)" "prognostic unfavourable (5.09e-4)" "unprognostic (9.78e-2)" "unprognostic (1.26e-1)" "unprognostic (4.48e-1)" "unprognostic (9.41e-3)" "prognostic unfavourable (6.47e-4)" "unprognostic (1.12e-1)" "unprognostic (1.94e-2)" "unprognostic (1.53e-1)" 33.2 23.4 17.2 5.4 26.2 1.5 14.4 14.4 33.7 9.4 10.5 36.9 3.0 6.9 10.0 3.0 16.6 9.0 8.6 5.7 23.8 18.3 25.9 13.1 10.3 3.4 40.3 21.9 14.3 5.4 2.5 7.3 30.4 26.2 10.1 9.0 2.8 4.9 9.5 4.2 32.4 5.3 12.2 49.7 5.7 8.3 11.1 32.0 0.9 11.1 3.2 4.6 15.5 9.0 0.1 3.7 2.1 1.5 20.0 2.3 0.7 2.9 20.5 18.8 0.1 23.4 15.0 8.6 12.5 15.1 11.1 13.7 0.0 3.2 0.1 4.0 13.4 3.0 10.4 12.8 14.7 0.1 9.6 17.6 18.1 1.2 23.7 2.2 3.8 16.1 32.4 5.9 17.1 7.4 1.4 0.0 20.7 0.5 0.1 0.1 5.4 7.4 8.2 7.2 8.8 33.1 9.9 13.8 9.5 13.4 0.2 10.6 2.5 0.4 13.1 24.8 17.5 5.7 4.7 0.1 0.0 0.1 6.5 1.3 11.0 2.1 0.7 0.7 0.1 0.7 0.0 0.0 0.3 0.2 3.7 0.1 2.3 0.9 0.3 20.0 1.5 0.3 0.2 0.7 17.2 26.2 14.4 25.5 23.8 18.3 40.3 21.9 26.2 32.0 GNAQ "G-ALPHA-q, GAQ" ENSG00000156052 "G protein subunit alpha q" P50148 9 77716087-78031458 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" Transducer "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "basophil: 18.4" "Lineage enriched" "Detected in many" 5 "granulocytes: 18.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010036, HPA048886" Uncertain Approved "Nuclear speckles,Plasma membrane,Cytosol" 28000000 "Nuclear speckles" "Plasma membrane, Cytosol" "CAB010036: AB_631536, HPA048886: " "unprognostic (2.10e-1)" "unprognostic (8.53e-2)" "unprognostic (1.45e-1)" "unprognostic (4.37e-2)" "unprognostic (1.87e-1)" "unprognostic (6.83e-3)" "unprognostic (1.05e-1)" "unprognostic (3.84e-2)" "unprognostic (2.46e-1)" "unprognostic (2.16e-1)" "unprognostic (1.85e-1)" "unprognostic (1.44e-1)" "prognostic favourable (1.11e-7)" "unprognostic (1.90e-1)" "unprognostic (3.13e-1)" "unprognostic (1.05e-1)" "unprognostic (2.01e-1)" 12.7 12.6 24.3 9.9 20.8 21.8 11.6 12.5 29.6 13.1 16.6 17.1 9.1 7.9 13.7 11.2 13.1 10.0 11.6 5.6 24.2 18.3 12.1 12.3 23.1 11.8 19.1 14.6 13.5 8.5 12.7 7.6 12.1 14.3 13.0 16.0 10.4 9.8 15.9 5.9 5.1 9.0 18.2 23.9 5.8 15.5 6.0 14.8 18.6 13.3 4.0 4.8 14.5 13.1 0.8 2.8 18.4 3.5 3.3 2.0 1.2 12.1 13.9 12.3 13.5 15.6 16.0 17.8 16.5 12.5 7.3 8.8 4.2 10.0 0.0 13.4 15.1 20.0 9.1 10.0 9.1 0.4 5.3 33.3 12.1 8.5 14.1 20.3 12.5 10.9 12.3 14.1 14.4 17.8 5.8 0.1 12.8 15.4 23.4 12.9 10.0 2.0 8.7 15.1 0.1 16.5 26.1 13.8 21.1 11.9 10.1 12.4 9.1 7.6 22.3 12.8 0.8 17.4 9.6 0.1 0.0 0.1 8.8 12.0 13.2 18.4 2.2 4.6 0.8 1.9 1.6 0.8 1.8 1.0 2.4 0.8 2.0 1.6 7.7 3.3 3.5 2.8 1.9 1.2 24.3 20.8 12.5 24.0 24.2 18.3 19.1 14.6 14.3 14.8 GNAS "GNAS1, GNASXL, GPSA, NESP, NESP55, SCG6, SgVI" ENSG00000087460 "GNAS complex locus" "O95467, P63092, P84996, Q5JWF2" 20 58839718-58911192 "Cancer-related genes, Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters" Transducer "Cancer-related genes, Cushing syndrome, Disease mutation, Dwarfism, Obesity, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "pituitary gland: 303.3;thyroid gland: 304.5" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010337, HPA018122, HPA027478, HPA028386" Uncertain Approved "Nucleoplasm,Plasma membrane,Cytosol" "Intracellular and membrane" Nucleoplasm "Plasma membrane, Cytosol" "CAB010337: AB_631538, HPA018122: AB_1849236, HPA027478: AB_10599284, HPA028386: AB_10601983" "unprognostic (7.48e-2)" "unprognostic (1.41e-1)" "unprognostic (3.90e-2)" "unprognostic (4.77e-2)" "unprognostic (8.37e-3)" "unprognostic (2.82e-2)" "unprognostic (4.53e-3)" "unprognostic (8.01e-2)" "unprognostic (4.29e-2)" "prognostic favourable (8.76e-4)" "unprognostic (2.07e-2)" "unprognostic (1.58e-1)" "prognostic unfavourable (3.49e-4)" "unprognostic (5.24e-3)" "unprognostic (1.61e-1)" "unprognostic (8.25e-2)" "unprognostic (1.36e-1)" 56.2 79.0 84.2 34.4 44.5 42.1 87.4 86.0 107.4 43.2 42.3 25.4 27.0 33.2 37.2 44.7 41.0 43.6 34.4 106.0 71.0 144.0 39.6 35.3 46.6 44.6 75.8 64.7 43.6 118.1 120.9 303.3 49.8 85.6 36.3 31.5 42.7 171.6 31.1 172.9 26.3 34.9 40.5 61.4 36.9 42.4 18.2 27.4 56.0 304.5 80.6 41.0 37.3 44.6 27.3 41.5 29.9 36.2 25.3 24.2 24.6 9.6 32.5 54.8 25.5 93.1 42.6 49.2 55.8 51.0 63.9 45.8 94.7 50.1 31.7 86.9 72.5 41.8 50.2 74.3 43.3 20.9 30.2 35.2 49.4 62.0 43.1 20.4 22.2 50.7 37.8 31.0 41.7 48.3 30.9 43.3 42.0 132.2 104.3 50.1 17.4 34.4 64.2 48.0 55.9 51.2 38.2 68.0 155.7 77.6 77.0 62.2 58.9 56.1 53.1 84.8 76.2 30.5 52.5 75.9 49.0 66.9 37.2 10.0 43.2 29.9 24.8 29.5 20.7 35.7 22.1 26.7 22.0 22.2 37.8 27.3 21.3 24.2 29.1 25.3 36.2 41.5 23.3 24.6 84.2 44.5 86.0 107.4 71.0 144.0 75.8 64.7 85.6 27.4 GNB1 ENSG00000078369 "G protein subunit beta 1" P62873 1 1785285-1891117 "Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins, Transporters" Transducer "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA040736 Supported Approved "Golgi apparatus,Plasma membrane" 60000000 "Plasma membrane" "Golgi apparatus" "HPA040736: " "unprognostic (9.49e-2)" "unprognostic (4.91e-3)" "unprognostic (1.24e-1)" "unprognostic (1.56e-1)" "unprognostic (3.34e-1)" "unprognostic (9.07e-3)" "prognostic unfavourable (3.61e-6)" "unprognostic (1.99e-2)" "unprognostic (3.60e-1)" "unprognostic (7.27e-2)" "unprognostic (8.47e-3)" "unprognostic (1.95e-1)" "unprognostic (9.76e-2)" "unprognostic (1.08e-1)" "unprognostic (4.62e-2)" "unprognostic (1.14e-1)" "unprognostic (7.90e-2)" 55.2 42.1 84.7 55.1 82.3 41.7 37.8 78.8 112.5 44.0 52.1 46.4 26.0 55.4 44.3 31.2 41.7 38.8 36.6 39.6 74.7 65.7 43.9 38.7 47.1 47.1 68.5 52.1 45.0 33.9 48.9 36.9 45.3 56.6 40.1 41.0 70.7 37.6 41.7 19.7 35.5 65.3 51.2 61.0 51.0 40.8 31.4 39.2 44.5 37.6 19.5 45.6 42.2 54.1 7.7 18.8 18.4 13.2 10.6 9.9 6.0 54.0 51.2 60.8 42.4 34.8 38.3 23.5 76.8 51.3 69.8 54.8 41.7 54.2 56.5 56.6 77.4 28.6 60.9 55.7 63.8 86.6 30.0 54.8 48.5 47.4 43.8 32.9 60.2 33.8 39.3 66.6 62.0 56.6 33.9 51.1 66.5 33.7 72.1 25.9 35.0 41.5 70.4 47.0 44.6 47.8 33.7 74.8 85.3 71.2 46.4 62.3 32.4 45.2 86.2 61.5 41.3 47.8 55.7 34.7 60.4 129.3 52.6 69.5 34.6 7.4 11.1 17.1 8.7 13.2 8.0 7.4 8.7 9.7 10.9 7.7 5.9 6.5 18.4 10.6 13.2 18.8 9.9 6.0 84.7 82.3 78.8 112.5 74.7 65.7 68.5 52.1 56.6 39.2 GNPTAB "GNPTA, KIAA1208, MGC4170" ENSG00000111670 "N-acetylglucosamine-1-phosphate transferase alpha and beta subunits" Q3T906 12 101745497-101830938 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" Transferase "Cancer-related genes, Disease mutation, Mucolipidosis" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA014558, HPA042343" Approved Supported "Golgi apparatus" 47000 "Golgi apparatus" "HPA014558: , HPA042343: " "unprognostic (6.72e-2)" "unprognostic (1.66e-1)" "unprognostic (8.71e-3)" "prognostic favourable (8.48e-4)" "unprognostic (1.39e-1)" "unprognostic (8.37e-2)" "unprognostic (2.73e-1)" "unprognostic (8.57e-2)" "unprognostic (3.73e-2)" "unprognostic (1.09e-2)" "unprognostic (2.28e-2)" "unprognostic (2.00e-1)" "unprognostic (6.86e-2)" "unprognostic (3.44e-1)" "unprognostic (1.02e-1)" "unprognostic (5.44e-2)" "unprognostic (4.98e-2)" 15.2 6.5 21.9 11.9 23.0 15.2 12.2 13.9 25.6 14.0 21.3 10.3 5.9 10.3 9.0 6.5 11.7 7.1 11.0 15.9 17.9 13.7 11.0 7.3 19.6 20.3 14.4 13.0 6.6 11.4 29.9 9.0 10.8 10.9 15.6 22.5 11.3 37.6 10.2 10.8 18.1 14.5 11.7 13.1 15.4 15.2 7.4 10.8 24.5 10.5 8.6 12.6 14.7 14.8 3.9 5.8 5.9 3.4 14.2 16.4 2.7 8.3 8.1 3.0 5.1 25.6 12.2 9.4 11.9 24.6 11.8 15.5 6.2 5.9 17.5 8.6 16.3 10.9 14.0 15.3 18.5 8.2 7.3 7.5 7.5 8.8 4.8 6.8 15.2 9.4 8.5 11.2 6.6 20.7 11.6 5.2 11.0 12.7 20.4 9.6 10.4 5.9 4.8 15.5 23.5 19.0 21.7 6.6 5.4 19.8 14.1 28.0 14.5 4.5 20.3 11.2 6.1 9.3 6.6 14.3 14.6 10.0 12.7 10.1 6.9 5.9 3.1 3.4 16.4 2.9 5.4 2.4 3.6 8.9 5.8 3.9 4.6 7.1 1.2 14.2 3.4 5.8 2.6 2.7 21.9 23.0 13.9 25.6 17.9 13.7 14.4 13.0 10.9 10.8 GOLGA5 "golgin-84, GOLIM5, ret-II, rfg5" ENSG00000066455 "Golgin A5" Q8TBA6 14 92794231-92839963 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA000992, HPA063876" Enhanced Supported Supported "Golgi apparatus" "Golgi apparatus" "HPA000992: AB_1079009, HPA063876: AB_2685140" "unprognostic (2.06e-1)" "unprognostic (1.76e-1)" "unprognostic (1.57e-1)" "unprognostic (2.64e-1)" "unprognostic (1.73e-1)" "unprognostic (2.77e-2)" "unprognostic (1.68e-1)" "unprognostic (3.15e-1)" "unprognostic (1.78e-1)" "unprognostic (5.02e-2)" "unprognostic (1.15e-2)" "unprognostic (2.83e-2)" "unprognostic (7.67e-2)" "unprognostic (6.44e-2)" "unprognostic (1.76e-1)" "unprognostic (1.06e-2)" "unprognostic (2.49e-2)" 20.8 20.3 16.8 15.7 17.3 6.5 24.4 11.6 17.5 24.9 20.4 17.2 25.5 16.5 18.2 41.7 21.2 15.3 17.5 18.3 17.5 15.6 21.5 51.0 16.6 18.2 18.6 14.6 18.9 26.8 23.6 27.2 44.4 16.4 23.4 23.7 12.7 24.3 30.2 20.6 18.9 25.6 18.9 19.4 16.9 23.0 23.5 17.6 13.5 24.8 17.8 16.4 20.7 15.8 9.7 9.7 22.2 12.7 8.1 12.4 6.3 12.6 11.6 10.5 9.6 22.1 30.0 18.1 17.5 32.3 17.1 20.2 8.5 17.4 8.2 14.4 27.8 13.3 9.3 14.3 23.3 10.0 4.4 7.7 5.8 11.4 25.7 9.0 13.0 23.0 26.0 12.0 24.9 16.8 6.8 11.1 18.7 23.4 6.9 7.8 6.5 12.5 5.4 15.5 8.2 17.4 15.4 7.5 10.6 15.9 12.0 17.8 20.6 10.0 13.9 9.8 6.5 12.7 8.7 13.6 10.5 7.2 22.6 7.2 16.4 9.1 9.8 22.2 10.9 12.7 12.3 9.7 11.1 11.1 9.7 9.2 9.9 8.6 8.7 8.1 10.8 9.1 12.4 6.3 16.8 17.3 11.6 17.5 17.5 15.6 18.6 14.6 16.4 17.6 GOPC "CAL, dJ94G16.2, FIG, GOPC1, PIST" ENSG00000047932 "Golgi associated PDZ and coiled-coil motif containing" Q9HD26 6 117560269-117602542 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Protein transport, Transport" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "HPA019477, HPA024018" Approved Enhanced "Golgi apparatus" "Golgi apparatus" "HPA019477: AB_1849890, HPA024018: AB_1849891" "unprognostic (2.48e-2)" "unprognostic (1.63e-3)" "unprognostic (1.71e-1)" "unprognostic (5.56e-2)" "unprognostic (1.84e-2)" "unprognostic (3.17e-2)" "unprognostic (3.12e-2)" "unprognostic (9.21e-2)" "unprognostic (6.22e-2)" "unprognostic (6.77e-2)" "unprognostic (8.23e-2)" "unprognostic (9.46e-2)" "unprognostic (1.40e-2)" "unprognostic (2.67e-2)" "unprognostic (1.38e-1)" "unprognostic (9.55e-2)" "unprognostic (3.01e-2)" 18.4 15.6 17.2 21.1 22.2 6.5 21.5 30.0 27.8 26.9 19.3 17.0 25.7 12.7 25.3 20.1 15.1 20.3 17.3 22.8 18.9 17.8 15.6 19.2 14.1 19.0 18.6 21.8 28.3 16.9 32.6 34.2 21.2 21.2 18.0 21.8 10.7 17.5 24.6 17.6 19.5 17.3 20.7 18.7 18.5 15.5 17.6 18.3 32.1 25.3 13.2 17.4 18.7 26.4 9.9 11.0 9.8 5.5 10.6 11.9 4.9 5.8 6.3 8.3 11.0 18.1 21.5 13.1 24.3 17.9 13.3 13.8 9.6 6.6 17.6 10.6 13.6 13.2 15.9 11.7 18.8 8.8 8.9 16.1 16.5 15.5 19.0 21.4 10.8 25.5 32.7 9.8 28.9 11.3 15.0 7.2 26.8 5.3 8.9 16.7 7.1 6.8 13.7 16.0 12.7 10.1 5.4 11.8 9.2 24.4 8.5 6.5 6.1 20.9 13.4 0.9 12.2 12.3 26.0 13.0 11.6 15.0 16.6 18.2 10.2 9.8 5.0 3.8 8.4 4.5 11.9 9.7 9.1 8.9 6.6 9.9 10.7 10.8 3.7 10.6 5.5 11.0 8.9 4.9 17.2 22.2 30.0 27.8 18.9 17.8 18.6 21.8 21.2 18.3 GOT1 AST1 ENSG00000120053 "Glutamic-oxaloacetic transaminase 1" P17174 10 99396870-99430624 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Amino-acid biosynthesis" "Aminotransferase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "heart muscle: 116.9;liver: 82.9;skeletal muscle: 102.1" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA064532, HPA072629" Enhanced Supported Nucleoplasm,Cytosol 130000000 Nucleoplasm Cytosol "HPA064532: AB_2685279, HPA072629: AB_2686540" "unprognostic (6.40e-2)" "prognostic favourable (6.23e-4)" "unprognostic (5.99e-2)" "unprognostic (2.84e-2)" "unprognostic (2.82e-1)" "unprognostic (2.96e-2)" "unprognostic (5.25e-2)" "unprognostic (1.08e-3)" "unprognostic (6.67e-2)" "unprognostic (1.45e-1)" "unprognostic (1.79e-2)" "unprognostic (1.79e-1)" "prognostic favourable (3.72e-13)" "unprognostic (1.93e-2)" "unprognostic (4.23e-1)" "unprognostic (6.85e-2)" "unprognostic (1.00e-1)" 3.3 14.0 15.7 3.6 32.1 2.0 5.9 22.9 56.4 13.5 12.0 9.7 5.9 14.7 3.4 7.0 10.3 4.6 12.2 116.9 19.4 19.0 34.6 82.9 3.5 3.4 17.8 16.4 3.8 8.2 15.9 4.9 3.7 49.9 5.9 14.7 9.0 12.4 7.2 102.1 4.5 12.7 5.4 7.7 3.6 10.1 9.3 4.7 3.3 11.7 31.3 7.1 4.9 4.0 10.6 21.4 3.9 16.8 11.4 15.6 8.8 16.9 9.4 11.1 28.0 8.6 7.4 31.4 13.9 25.6 24.3 26.5 21.3 13.8 16.6 4.8 11.7 21.3 25.3 18.3 26.8 5.7 10.8 6.3 12.1 27.7 45.6 18.0 10.8 11.6 19.8 20.6 55.9 11.7 16.2 26.0 15.5 15.3 9.6 13.5 7.1 13.1 10.5 10.6 17.3 42.4 9.3 4.8 7.1 10.5 14.9 51.9 28.5 6.2 5.4 6.2 13.8 6.7 15.9 18.6 21.9 16.9 16.3 9.4 8.2 2.4 5.3 3.9 12.4 14.7 11.4 10.6 13.5 12.9 12.9 10.2 10.2 14.5 0.5 11.4 16.8 21.4 15.6 8.8 15.7 32.1 22.9 56.4 19.4 19.0 17.8 16.4 49.9 4.7 GOT2 "KAT4, KATIV, KYAT4, mitAAT" ENSG00000125166 "Glutamic-oxaloacetic transaminase 2" P00505 16 58707131-58734357 "Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Transporters" "Lipid transport, Transport" "Aminotransferase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 167.8" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA018139 Enhanced "Intracellular and membrane" 7000000 "HPA018139: AB_1849903" "unprognostic (1.50e-2)" "unprognostic (4.79e-2)" "unprognostic (2.73e-3)" "unprognostic (2.63e-3)" "unprognostic (3.02e-2)" "prognostic unfavourable (1.61e-4)" "prognostic favourable (5.75e-5)" "unprognostic (1.12e-2)" "unprognostic (3.19e-1)" "unprognostic (3.72e-2)" "unprognostic (2.27e-1)" "unprognostic (3.00e-1)" "prognostic favourable (2.90e-9)" "unprognostic (1.16e-1)" "unprognostic (1.48e-1)" "unprognostic (5.56e-2)" "unprognostic (2.22e-1)" 6.1 21.0 12.7 8.0 19.1 5.5 10.7 19.4 35.7 10.6 15.9 16.0 33.3 10.6 10.4 19.5 17.7 13.5 8.9 78.1 15.8 16.7 24.6 85.5 7.1 11.1 16.2 17.8 8.7 8.8 27.0 13.0 7.3 27.7 17.2 18.8 23.4 13.0 20.5 167.8 10.4 9.4 13.5 12.3 8.0 13.6 10.8 9.9 10.7 12.3 53.9 15.0 15.5 11.2 14.3 17.6 3.5 9.9 14.5 24.5 14.3 27.1 36.9 19.5 23.6 14.1 12.8 25.5 20.9 22.3 41.2 22.6 31.9 24.6 60.8 24.9 23.1 40.2 41.6 40.6 52.6 16.7 38.2 16.4 20.1 35.6 17.9 26.2 15.1 12.3 23.1 25.9 22.7 41.3 32.8 6.3 20.9 24.3 32.6 25.4 26.4 71.7 35.8 29.7 58.3 38.9 40.0 31.1 22.6 40.0 43.1 15.0 21.8 8.6 16.6 15.0 27.5 11.7 26.5 14.6 13.5 49.8 16.1 26.3 15.1 2.3 9.9 3.5 15.2 8.6 23.5 14.3 18.0 18.4 17.6 10.6 16.7 15.3 0.9 14.5 8.5 15.5 24.5 14.3 12.7 19.1 19.4 35.7 15.8 16.7 16.2 17.8 27.7 9.9 GPA33 A33 ENSG00000143167 "Glycoprotein A33" Q99795 1 167052836-167166479 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 6 "intestine: 101.1" "Cell line enhanced" "Detected in some" "HL-60: 1.9;MOLT-4: 2.3;NB-4: 1.1;NTERA-2: 4.0;RPMI-8226: 2.9;THP-1: 1.1" "Cancer enriched" "Detected in many" 6 "colorectal cancer: 84.0" "Not detected" "Not detected" "Cell type enhanced" "Detected in many" "naive CD4 T-cell: 17.8;T-reg: 13.0" "Lineage enriched" "Detected in many" 7 "T-cells: 17.8" "Not detected" "Not detected" "Not detected" "Not detected" "HPA018858, CAB025943" Enhanced "CAB025943: , HPA018858: AB_1849909" "unprognostic (2.41e-2)" "unprognostic (1.71e-3)" "unprognostic (1.08e-2)" "unprognostic (1.16e-1)" "unprognostic (2.06e-1)" "unprognostic (8.39e-4)" "unprognostic (1.55e-1)" "unprognostic (8.34e-2)" "unprognostic (1.00e-2)" "unprognostic (9.63e-2)" "unprognostic (2.10e-2)" "unprognostic (9.44e-2)" "unprognostic (6.75e-2)" "unprognostic (5.22e-3)" "unprognostic (3.13e-1)" "unprognostic (9.68e-3)" "unprognostic (2.96e-3)" 0.2 0.2 0.2 12.1 0.2 0.0 0.2 0.2 0.2 0.2 46.9 0.2 0.1 31.6 0.2 0.1 0.3 0.2 0.3 0.2 0.2 0.2 0.2 0.2 1.2 1.6 0.2 0.1 0.2 0.2 0.0 0.2 0.3 0.2 0.2 43.5 0.2 0.3 0.1 0.2 0.2 101.1 1.4 0.2 0.6 0.2 0.2 0.1 0.6 0.2 0.1 0.6 0.2 0.2 1.7 1.7 0.1 2.5 0.1 17.8 4.6 0.0 0.0 0.2 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.3 1.1 4.0 0.1 0.0 0.0 2.9 0.0 0.0 0.3 0.6 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 2.0 2.5 1.1 0.1 7.6 3.9 1.7 1.7 17.8 2.4 0.1 0.1 1.6 0.0 13.0 4.6 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.1 0.2 0.1 GPC3 "DGSX, OCI-5, SDYS, SGB, SGBS, SGBS1" ENSG00000147257 "Glypican 3" P51654 X 133535745-133985895 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Protease inhibitor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "placenta: 262.7" "Group enriched" "Detected in some" 8 "HAP1: 53.1;Hep G2: 209.8" "Cancer enhanced" "Detected in all" "liver cancer: 269.0" "Low region specificity" "Detected in some" "Group enriched" "Detected in some" 4 "naive CD4 T-cell: 5.0;naive CD8 T-cell: 3.5;NK-cell: 1.7" "Group enriched" "Detected in many" 12 "NK-cells: 1.7;T-cells: 5.0" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA006316 Supported "Plasma membrane" "Intracellular and membrane" "Plasma membrane" "HPA006316: AB_1078994" "unprognostic (2.06e-1)" "unprognostic (2.36e-1)" "unprognostic (9.51e-2)" "unprognostic (4.17e-2)" "unprognostic (1.78e-1)" "unprognostic (1.46e-1)" "unprognostic (6.10e-2)" "unprognostic (1.17e-2)" "unprognostic (2.07e-2)" "unprognostic (3.92e-3)" "unprognostic (6.06e-2)" "unprognostic (1.71e-1)" "unprognostic (3.81e-3)" "prognostic unfavourable (4.83e-4)" "unprognostic (1.43e-1)" "unprognostic (2.21e-1)" "unprognostic (1.60e-1)" 30.1 5.9 0.4 3.6 0.7 0.0 50.2 0.6 0.4 3.3 4.5 0.5 2.2 0.5 2.5 11.7 2.0 3.4 9.2 8.0 0.4 1.1 21.2 1.1 37.0 1.9 1.6 0.4 6.0 4.6 0.3 16.9 262.7 1.6 3.6 1.0 6.3 3.8 2.3 4.1 5.5 1.8 3.3 2.1 0.9 4.0 2.1 0.3 2.3 7.2 11.2 3.0 7.6 8.0 0.0 0.2 0.0 0.0 1.7 5.0 0.6 0.0 0.0 2.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 16.4 0.0 0.0 0.0 0.0 0.0 53.1 0.0 0.0 0.0 2.4 0.0 0.1 209.8 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 16.1 0.0 0.0 0.0 0.0 14.5 0.6 1.7 4.3 0.0 0.0 0.0 0.0 2.6 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.8 0.5 0.2 0.0 5.0 3.5 0.0 1.7 0.0 0.0 0.0 0.6 0.4 0.7 0.6 0.4 0.4 1.1 1.6 0.4 1.6 0.3 GPHN KIAA1385 ENSG00000171723 Gephyrin Q9NQX3 14 66507407-67181803 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Molybdenum cofactor biosynthesis" "Multifunctional enzyme, Transferase" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003116, CAB004419, HPA024694" Enhanced Uncertain "Cytoplasmic bodies" "Cytoplasmic bodies" "CAB004419: AB_627670, HPA003116: AB_1078963, HPA024694: AB_1849616" "unprognostic (8.37e-2)" "unprognostic (2.53e-2)" "unprognostic (2.42e-1)" "unprognostic (1.20e-1)" "unprognostic (5.14e-2)" "unprognostic (4.89e-3)" "unprognostic (8.29e-2)" "unprognostic (1.41e-2)" "unprognostic (1.42e-1)" "unprognostic (2.23e-1)" "unprognostic (2.49e-2)" "unprognostic (8.54e-2)" "prognostic favourable (5.25e-12)" "unprognostic (9.81e-2)" "unprognostic (2.27e-1)" "unprognostic (7.50e-2)" "prognostic unfavourable (4.61e-5)" 13.0 12.4 26.1 10.9 31.1 5.2 17.1 40.9 31.2 11.0 18.2 9.3 15.6 11.1 12.3 20.8 8.6 7.5 8.2 11.9 26.4 22.9 34.5 49.0 14.1 7.3 18.3 11.5 7.2 22.9 17.4 24.5 5.8 13.9 11.1 13.2 7.4 10.8 21.3 23.4 10.7 10.8 11.6 16.4 5.6 13.5 7.8 16.2 3.1 12.2 10.0 6.8 7.4 15.1 3.1 3.0 0.5 2.5 2.3 6.2 1.5 22.3 4.4 7.8 8.6 9.3 7.9 5.0 6.4 3.1 6.5 6.6 1.3 10.1 0.0 1.1 3.1 7.9 7.8 12.4 8.6 6.8 8.5 6.6 6.3 13.6 4.8 3.7 9.9 6.7 7.3 1.8 7.2 7.6 4.5 8.5 3.6 11.9 6.6 14.0 3.3 10.2 0.0 15.1 6.5 10.5 4.4 13.9 5.4 4.3 19.0 7.0 10.2 6.4 2.8 6.6 14.6 6.4 6.5 11.3 4.8 0.1 5.2 0.5 6.3 0.0 1.3 0.5 3.9 2.5 6.2 2.4 4.9 2.9 1.9 3.1 3.5 3.3 0.0 2.3 1.9 3.0 5.3 1.5 26.1 31.1 40.9 27.0 26.4 22.9 18.3 11.5 13.9 16.2 GPI "AMF, NLK" ENSG00000105220 "Glucose-6-phosphate isomerase" P06744 19 34359480-34402413 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" "Gluconeogenesis, Glycolysis" "Cytokine, Growth factor, Isomerase" "Cancer-related genes, Disease mutation, Hereditary hemolytic anemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB018655, HPA024305, CAB040563, HPA052171" Enhanced Supported "Nucleoplasm,Plasma membrane,Cytosol" "Secreted to blood" 140000000 "Plasma membrane, Cytosol" Nucleoplasm "CAB018655: AB_2112653, CAB040563: , HPA024305: AB_1849922, HPA052171: AB_2681748" "unprognostic (1.03e-1)" "unprognostic (8.39e-3)" "unprognostic (2.39e-2)" "unprognostic (1.38e-2)" "unprognostic (4.52e-2)" "unprognostic (6.45e-3)" "unprognostic (1.95e-2)" "unprognostic (8.52e-3)" "unprognostic (3.18e-1)" "unprognostic (1.45e-1)" "unprognostic (4.93e-2)" "unprognostic (2.75e-1)" "unprognostic (3.24e-3)" "unprognostic (2.62e-2)" "unprognostic (2.43e-1)" "unprognostic (2.60e-3)" "unprognostic (2.88e-2)" 62.1 66.6 43.4 27.6 58.2 83.3 34.8 62.6 88.7 20.6 36.6 20.8 23.7 48.2 21.1 20.6 45.3 24.2 33.5 107.2 42.0 45.6 51.3 77.9 19.6 29.6 39.3 64.3 22.5 21.4 66.9 33.7 20.4 50.2 23.7 37.2 36.2 34.6 33.9 144.7 29.4 44.3 34.2 22.8 23.1 26.7 19.7 19.0 23.8 26.1 68.5 32.6 32.5 25.2 16.2 26.3 74.8 40.9 14.5 27.5 24.6 76.1 107.4 9.4 73.5 30.9 23.0 22.5 29.4 23.2 37.1 44.8 60.5 27.0 50.2 43.7 28.8 53.1 56.8 63.9 42.2 55.8 22.9 64.5 51.8 63.6 20.0 83.5 42.0 31.5 26.4 43.9 22.8 34.6 32.8 39.8 26.1 64.6 36.3 29.2 25.4 38.0 34.0 24.9 94.8 46.5 51.3 51.4 29.9 59.3 104.6 21.4 23.7 26.6 29.8 14.0 30.9 39.8 45.3 73.5 41.7 45.5 46.8 63.5 28.4 38.5 22.9 74.8 22.5 35.2 27.5 16.2 20.7 25.5 26.3 13.3 17.5 20.7 1.6 14.5 40.9 8.7 21.6 24.6 43.4 58.2 62.6 88.7 42.0 45.6 39.3 64.3 50.2 19.0 GPS2 ENSG00000132522 "G protein pathway suppressor 2" Q13227 17 7311324-7315564 "Cancer-related genes, Predicted intracellular proteins" "Host-virus interaction, Transcription, Transcription regulation" "Activator, Repressor" "Cancer-related genes, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" HPA067540 Approved Supported Nucleoplasm Nucleoplasm "HPA067540: " "unprognostic (1.53e-2)" "unprognostic (3.43e-1)" "unprognostic (3.33e-2)" "unprognostic (1.71e-3)" "unprognostic (1.55e-1)" "unprognostic (1.53e-4)" "unprognostic (1.37e-2)" "unprognostic (1.33e-1)" "unprognostic (3.18e-2)" "unprognostic (2.84e-1)" "prognostic favourable (7.50e-5)" "unprognostic (1.37e-2)" "prognostic unfavourable (3.42e-5)" "unprognostic (2.09e-1)" "unprognostic (1.44e-1)" "unprognostic (6.87e-2)" "unprognostic (1.28e-3)" 21.8 22.8 21.1 17.6 20.9 27.8 25.0 18.2 25.4 18.5 23.4 19.1 14.4 14.4 20.0 15.5 24.6 19.9 15.5 35.3 19.9 17.1 28.7 30.1 18.5 15.2 19.5 16.9 20.9 23.0 26.6 21.1 21.9 16.5 17.5 20.2 14.3 19.7 21.5 72.4 23.0 25.7 18.2 21.2 20.6 18.0 45.8 22.1 21.2 22.4 21.0 21.1 19.2 25.0 55.2 48.3 58.1 46.4 28.2 57.0 38.8 19.4 37.8 12.1 16.5 24.1 13.6 13.9 14.1 16.7 28.6 24.7 26.2 10.0 22.0 10.7 19.4 26.7 15.3 27.5 22.2 26.8 24.1 20.4 35.9 32.4 17.1 12.2 23.7 12.8 19.1 39.3 10.5 16.7 12.3 5.2 29.6 16.4 23.7 12.9 16.5 15.8 18.2 22.4 22.5 21.2 22.0 16.1 27.0 23.0 14.8 19.3 14.5 11.9 10.0 13.4 13.8 18.5 32.8 17.2 24.4 14.7 20.1 14.4 23.4 44.1 35.3 58.1 40.8 43.0 38.4 55.2 45.5 45.8 29.5 43.3 42.5 38.5 56.4 28.2 46.4 48.3 57.0 38.8 21.1 20.9 18.2 25.4 19.9 17.1 19.5 16.9 16.5 22.1 GPX2 GSHPX-GI ENSG00000176153 "Glutathione peroxidase 2" P18283 14 64939152-64942905 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Oxidoreductase, Peroxidase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "gallbladder: 126.9;liver: 195.2" "Group enriched" "Detected in some" 20 "A549: 120.7;HaCaT: 33.4;Hep G2: 112.0;RT4: 79.8;SCLC-21H: 36.1" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Cell type enhanced" "Detected in single" "NK-cell: 2.4" "Low lineage specificity" "Detected in single" "Region enhanced" "Detected in single" "pons and medulla: 1.3" "Low region specificity" "Detected in single" HPA003545 Enhanced Approved Nucleoplasm,Cytosol Nucleoplasm Cytosol "HPA003545: AB_10962695" "unprognostic (3.54e-1)" "unprognostic (1.08e-2)" "unprognostic (1.51e-1)" "unprognostic (1.90e-3)" "unprognostic (4.75e-3)" "prognostic unfavourable (5.10e-4)" "unprognostic (2.96e-2)" "unprognostic (2.93e-2)" "unprognostic (7.87e-2)" "unprognostic (1.54e-2)" "unprognostic (8.45e-2)" "unprognostic (1.44e-1)" "unprognostic (2.77e-2)" "unprognostic (4.39e-2)" "unprognostic (3.39e-2)" "unprognostic (6.66e-4)" "unprognostic (1.73e-2)" 0.1 0.0 0.1 23.8 0.2 0.0 0.8 0.2 0.1 5.5 50.4 0.5 2.0 14.4 0.3 1.0 53.0 0.6 126.9 0.2 0.1 0.2 29.4 195.2 2.0 0.1 0.1 0.1 0.9 7.0 0.0 0.2 0.1 0.2 16.8 71.6 0.1 59.7 4.1 0.3 3.9 35.4 5.6 0.2 0.1 57.8 0.4 0.1 0.5 0.2 44.0 7.4 56.3 15.0 0.2 0.0 0.5 0.8 2.4 0.1 0.0 0.0 120.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.9 1.0 0.0 0.7 0.0 33.4 0.0 0.5 0.0 0.0 0.0 0.0 0.1 112.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 79.8 36.1 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.8 0.0 0.1 0.1 0.0 0.0 0.2 0.0 0.0 0.5 2.4 0.0 0.0 0.0 0.0 0.1 0.2 0.2 0.1 0.1 0.2 0.1 0.1 0.2 0.1 GRB10 ENSG00000106070 "Growth factor receptor bound protein 10" Q13322 7 50590063-50793462 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "pancreas: 65.8" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 12 "basophil: 11.4;eosinophil: 3.5" "Lineage enriched" "Detected in single" 26 "granulocytes: 11.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB019423, HPA027502, HPA031818" Approved Supported Vesicles Vesicles "CAB019423: AB_2112883, HPA027502: AB_10602325, HPA031818: " "unprognostic (2.82e-2)" "unprognostic (1.69e-3)" "unprognostic (1.25e-2)" "unprognostic (1.45e-2)" "unprognostic (3.68e-2)" "unprognostic (1.60e-1)" "unprognostic (6.83e-2)" "unprognostic (5.91e-3)" "unprognostic (1.67e-2)" "unprognostic (2.31e-3)" "unprognostic (4.44e-1)" "unprognostic (2.07e-1)" "unprognostic (1.23e-3)" "unprognostic (1.73e-3)" "unprognostic (8.16e-3)" "unprognostic (2.63e-2)" "unprognostic (8.50e-2)" 14.3 14.6 14.7 4.9 26.7 6.5 18.8 22.0 20.9 9.7 10.5 14.6 2.0 12.3 8.9 8.0 7.3 9.0 15.6 19.1 13.8 14.8 19.8 15.6 8.3 4.3 19.8 10.7 6.5 65.8 6.0 21.5 10.6 20.9 10.6 5.1 16.5 7.0 11.7 35.7 3.7 8.4 13.0 9.9 15.9 7.2 11.4 16.9 0.4 18.3 4.2 3.2 12.7 17.3 0.0 0.1 11.4 0.2 0.0 0.4 0.1 0.1 10.6 17.4 7.0 8.2 6.3 9.2 4.3 3.7 8.3 10.1 6.4 0.1 0.2 7.6 5.4 1.0 17.9 4.5 4.1 0.1 7.2 18.3 10.8 4.6 17.4 11.4 28.3 16.3 7.1 12.8 12.7 21.2 34.5 0.2 6.3 1.2 2.0 15.4 19.0 18.4 5.3 0.0 0.1 5.5 4.2 7.6 0.0 0.5 2.7 22.7 9.2 23.2 25.9 7.4 10.1 15.0 16.2 0.7 0.2 0.1 23.4 10.4 24.9 11.4 0.1 3.5 0.0 0.2 0.0 0.0 0.4 0.0 0.0 0.0 0.2 0.0 0.6 0.0 0.0 0.1 0.0 0.1 14.7 26.7 22.0 20.9 13.8 14.8 19.8 10.7 20.9 16.9 GRB2 NCKAP2 ENSG00000177885 "Growth factor receptor bound protein 2" P62993 17 75318076-75405709 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins" "Host-virus interaction" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002589, HPA030749, HPA030750" Approved Enhanced Nucleoplasm 1900000 Nucleoplasm "CAB002589: AB_10693935, HPA030749: AB_2673590, HPA030750: AB_2673591" "unprognostic (4.83e-3)" "unprognostic (1.85e-1)" "unprognostic (1.14e-1)" "unprognostic (3.42e-3)" "unprognostic (1.70e-1)" "unprognostic (2.06e-1)" "prognostic unfavourable (6.04e-7)" "unprognostic (1.01e-2)" "unprognostic (2.73e-1)" "unprognostic (1.80e-2)" "unprognostic (1.06e-2)" "unprognostic (1.89e-2)" "unprognostic (1.08e-2)" "unprognostic (8.13e-2)" "unprognostic (3.40e-2)" "unprognostic (1.56e-1)" "unprognostic (1.58e-1)" 29.0 29.2 36.1 48.2 40.3 56.3 23.6 42.2 41.6 18.5 27.8 28.2 19.1 29.2 28.3 19.4 27.0 22.1 22.5 32.2 34.7 33.9 24.9 32.2 33.7 54.8 30.9 29.2 21.8 16.7 21.8 21.8 33.1 26.9 21.4 27.9 21.8 21.2 25.6 27.8 18.6 30.5 30.6 42.6 56.7 22.8 10.8 27.1 45.8 20.4 15.6 53.1 29.8 19.2 24.7 25.0 64.9 42.8 12.0 13.4 20.7 24.8 21.7 14.9 18.0 16.5 15.5 34.0 26.3 21.4 27.7 26.6 18.6 16.7 32.5 15.6 24.0 14.9 21.5 18.9 28.8 16.0 19.7 34.8 14.3 27.1 14.9 40.0 68.0 14.3 19.8 28.9 14.5 33.2 23.5 22.6 20.1 31.0 46.8 38.7 10.3 22.1 28.1 32.0 23.5 21.1 18.6 18.0 26.0 22.2 21.7 27.7 24.0 64.7 21.1 26.6 20.2 21.0 26.7 41.5 31.9 52.2 20.5 31.3 19.0 25.1 32.1 38.5 13.4 38.4 11.7 23.7 12.1 13.2 25.0 24.7 12.7 12.0 64.9 12.0 42.8 16.7 13.2 20.7 36.1 40.3 42.2 41.6 34.7 33.9 30.9 29.2 26.9 27.1 GRB7 ENSG00000141738 "Growth factor receptor bound protein 7" Q14451 17 39737927-39747291 "Cancer-related genes, Predicted intracellular proteins" "Repressor, RNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "esophagus: 53.9" "Cell line enriched" "Detected in some" 9 "SK-BR-3: 89.5" "Low cancer specificity" "Detected in many" "Region enriched" "Detected in some" 4 "cerebellum: 7.4" "Cell type enriched" "Detected in single" 20 "naive B-cell: 2.0" "Lineage enriched" "Detected in single" 20 "B-cells: 2.0" "Region enhanced" "Detected in some" "cerebellum: 9.3" "Low region specificity" "Detected in all" "CAB005226, HPA057084, CAB073538" Approved Supported "Plasma membrane,Cytosol" "Plasma membrane, Cytosol" "CAB005226: AB_2113278, CAB073538: , HPA057084: " "unprognostic (8.46e-2)" "unprognostic (2.06e-2)" "unprognostic (1.45e-1)" "prognostic unfavourable (6.60e-7)" "unprognostic (7.06e-3)" "unprognostic (2.09e-2)" "unprognostic (1.02e-1)" "unprognostic (1.85e-1)" "unprognostic (2.02e-1)" "prognostic unfavourable (3.10e-4)" "prognostic unfavourable (6.90e-4)" "unprognostic (2.59e-2)" "prognostic favourable (8.23e-5)" "unprognostic (1.83e-2)" "unprognostic (4.77e-2)" "unprognostic (5.49e-3)" "unprognostic (4.01e-2)" 2.9 0.1 0.1 2.8 0.6 0.0 16.1 7.4 1.2 6.7 12.7 0.3 25.0 6.7 2.6 8.1 53.9 14.5 16.3 0.8 0.2 0.1 23.4 5.2 12.3 0.1 0.1 0.4 3.1 20.5 5.8 3.7 42.6 1.6 10.2 6.4 0.7 14.0 25.5 0.5 19.1 12.4 2.0 0.1 0.3 7.2 2.3 0.3 0.5 8.5 6.5 17.2 7.2 11.7 2.0 0.0 0.0 0.0 0.0 0.0 0.0 2.8 3.4 0.0 0.0 0.0 0.0 4.4 0.0 0.2 0.0 0.1 10.4 5.9 0.0 0.9 0.1 5.6 0.0 3.9 0.0 0.0 0.5 0.0 1.3 9.0 0.0 0.0 0.0 0.0 3.4 0.0 0.9 0.0 0.0 0.0 0.0 2.7 0.0 0.0 1.2 0.8 0.0 0.0 4.1 4.6 3.3 2.3 0.0 4.5 89.5 0.0 3.3 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.2 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.6 7.4 1.2 0.2 0.1 0.1 0.4 1.6 0.3 GRIN2A "GluN2A, NMDAR2A" ENSG00000183454 "Glutamate ionotropic receptor NMDA type subunit 2A" Q12879 16 9753404-10182754 "Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "Cancer-related genes, Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "brain: 25.2" "Cell line enhanced" "Detected in some" "fHDF/TERT166: 7.7;RPMI-8226: 2.9;U-138 MG: 8.4" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" CAB022725 Enhanced "CAB022725: " "unprognostic (6.43e-2)" "unprognostic (2.47e-1)" "unprognostic (5.97e-2)" "unprognostic (3.21e-2)" "unprognostic (3.13e-2)" "unprognostic (1.59e-2)" "unprognostic (1.62e-1)" "unprognostic (2.10e-1)" "unprognostic (2.08e-1)" "unprognostic (5.39e-2)" "unprognostic (1.47e-1)" "unprognostic (1.69e-1)" "unprognostic (3.75e-3)" "unprognostic (4.79e-3)" "unprognostic (2.05e-1)" "unprognostic (3.92e-3)" "unprognostic (3.33e-2)" 0.9 1.0 5.4 0.5 5.9 0.4 0.6 8.5 25.2 0.6 0.7 1.5 0.0 0.9 0.8 4.5 2.1 4.1 0.5 4.0 8.0 1.9 0.9 0.4 1.0 0.5 1.7 10.3 0.5 0.6 0.4 0.3 0.4 1.4 0.5 0.7 1.4 0.7 1.0 0.5 1.2 0.7 0.9 1.2 0.4 1.1 5.2 0.8 0.0 0.8 0.0 0.7 0.6 0.5 0.6 0.0 0.3 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.1 1.8 0.5 1.4 0.0 0.1 0.0 0.0 7.7 0.1 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 2.9 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 8.4 0.8 0.0 0.1 0.0 0.0 0.0 1.2 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.6 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 5.4 5.9 8.5 17.9 8.0 1.9 1.7 10.3 1.4 0.8 GSK3A ENSG00000105723 "Glycogen synthase kinase 3 alpha" P49840 19 42230186-42242625 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Carbohydrate metabolism, Glycogen metabolism, Neurogenesis, Wnt signaling pathway" "Kinase, Serine/threonine-protein kinase, Signal transduction inhibitor, Transferase" "Alzheimer disease, Cancer-related genes, Diabetes mellitus" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004422, HPA028423" Approved Approved Cytosol Cytosol "CAB004422: AB_627680, HPA028423: AB_10612116" "unprognostic (5.46e-2)" "unprognostic (1.50e-1)" "unprognostic (1.45e-1)" "prognostic unfavourable (4.02e-4)" "unprognostic (1.35e-1)" "unprognostic (3.96e-2)" "prognostic unfavourable (1.13e-4)" "unprognostic (3.80e-3)" "unprognostic (2.27e-1)" "unprognostic (2.87e-1)" "unprognostic (4.99e-2)" "unprognostic (3.36e-1)" "unprognostic (2.69e-1)" "unprognostic (2.77e-2)" "unprognostic (4.49e-2)" "unprognostic (7.22e-2)" "unprognostic (8.22e-3)" 15.3 19.8 31.0 16.8 38.0 14.4 12.0 31.4 62.2 15.9 16.8 24.3 11.4 28.6 16.9 18.0 17.3 16.7 11.8 21.3 31.3 23.6 17.5 13.1 14.2 15.0 21.8 26.3 20.0 19.3 16.1 14.2 14.7 31.7 15.8 16.1 15.5 18.1 20.3 41.0 25.1 27.0 18.5 18.0 14.5 14.7 19.1 17.7 16.6 15.8 11.9 15.8 15.8 15.5 1.6 2.2 4.0 1.9 1.7 2.0 1.0 23.6 42.0 24.1 22.3 14.4 12.9 10.2 16.7 15.9 22.1 20.0 15.7 15.1 17.1 17.2 13.1 10.9 19.8 19.4 15.5 13.8 31.8 17.8 13.5 15.5 19.0 20.2 21.8 12.6 20.6 18.1 20.7 20.0 29.9 25.6 18.9 28.7 26.2 17.9 17.8 17.4 23.9 14.0 13.2 20.4 24.8 28.1 28.4 22.9 30.0 15.2 17.3 26.8 17.7 22.8 17.1 13.2 29.5 26.2 30.0 13.4 26.5 20.4 25.0 2.5 1.5 1.6 2.0 1.9 1.4 1.2 1.2 1.3 1.4 1.6 0.7 1.5 4.0 1.7 1.1 2.2 1.0 1.0 31.0 38.0 31.4 62.2 31.3 23.6 21.8 26.3 31.7 17.7 GSN DKFZp313L0718 ENSG00000148180 Gelsolin P06396 9 121207794-121332843 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Cilium biogenesis/degradation" "Actin capping, Actin-binding" "Amyloidosis, Cancer-related genes, Corneal dystrophy, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "ASC diff: 167.4;HaCaT: 66.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "eosinophil: 133.9" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010823, CAB016728, CAB036009, HPA054026" Supported Supported "Actin filaments" "Secreted to blood" 111500000000 510000000000 "Actin filaments" "CAB010823: , CAB016728: , CAB036009: , HPA054026: " "unprognostic (3.25e-2)" "unprognostic (4.44e-3)" "unprognostic (1.22e-1)" "unprognostic (3.10e-3)" "unprognostic (4.23e-2)" "unprognostic (4.85e-2)" "unprognostic (1.21e-1)" "unprognostic (1.49e-1)" "unprognostic (1.22e-1)" "unprognostic (1.20e-1)" "unprognostic (6.54e-2)" "unprognostic (6.56e-2)" "unprognostic (3.06e-2)" "unprognostic (8.01e-3)" "unprognostic (4.98e-2)" "unprognostic (1.23e-2)" "prognostic unfavourable (1.79e-5)" 187.8 23.1 14.1 23.7 21.4 26.6 186.2 7.3 20.0 81.9 69.6 53.7 48.0 22.3 88.1 64.7 99.6 57.8 59.6 235.1 17.6 11.9 14.8 3.9 30.6 12.9 42.8 16.5 40.8 20.4 7.4 25.7 17.5 33.4 74.0 29.0 83.0 44.8 63.2 48.1 55.6 32.7 154.8 33.4 12.4 45.0 32.5 29.9 5.6 67.7 46.4 20.9 113.5 109.0 2.2 43.3 133.9 15.2 24.4 0.4 11.8 5.8 8.0 5.9 16.9 167.4 55.1 3.8 19.5 43.1 4.7 9.5 8.1 17.5 0.4 5.3 25.7 66.5 0.4 13.4 2.7 1.0 1.0 4.7 7.4 18.4 4.6 1.0 22.9 20.5 12.8 7.8 4.9 17.0 1.4 0.6 21.0 10.5 0.0 34.3 2.0 6.2 1.1 2.0 0.5 22.2 9.0 0.9 1.5 8.8 9.5 25.6 37.7 20.9 30.9 13.7 4.8 1.2 1.9 0.2 0.2 0.4 15.2 2.3 37.7 30.2 15.2 133.9 0.2 10.2 0.1 2.2 0.1 0.1 43.3 0.6 0.0 0.0 37.0 24.4 2.6 28.7 0.4 11.8 14.1 21.4 7.3 20.0 17.6 11.9 42.8 16.5 33.4 29.9 GSR ENSG00000104687 "Glutathione-disulfide reductase" P00390 8 30678061-30727999 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" Oxidoreductase "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001538, CAB008632" Approved Supported "Plasma membrane,Cytosol" 110000000 Cytosol "Plasma membrane" "CAB008632: AB_1616690, HPA001538: AB_1078986" "unprognostic (1.23e-1)" "prognostic favourable (3.37e-4)" "prognostic favourable (4.08e-5)" "unprognostic (2.89e-3)" "unprognostic (1.62e-1)" "unprognostic (3.50e-1)" "prognostic unfavourable (3.26e-5)" "unprognostic (3.61e-2)" "unprognostic (1.01e-1)" "unprognostic (4.15e-2)" "unprognostic (2.83e-2)" "unprognostic (6.92e-3)" "prognostic favourable (1.80e-4)" "unprognostic (2.31e-3)" "unprognostic (2.26e-1)" "unprognostic (1.01e-1)" "unprognostic (1.29e-1)" 8.9 14.4 6.8 10.7 9.1 7.9 6.2 9.1 11.8 18.6 18.7 7.1 18.4 20.4 13.2 12.0 19.4 8.8 17.3 11.9 5.0 5.7 27.9 17.8 10.8 9.7 4.9 6.0 11.8 17.6 22.9 7.2 8.9 6.8 16.4 17.2 10.9 12.0 17.4 14.7 6.5 31.8 9.3 4.5 13.6 17.7 7.9 4.2 17.0 9.2 11.8 12.0 23.9 14.5 2.5 4.7 19.0 5.7 2.6 7.3 2.1 12.0 51.0 8.3 6.4 8.9 10.0 8.0 5.4 11.8 7.7 10.3 15.0 6.4 23.6 26.7 6.9 13.6 12.5 11.7 8.4 6.1 11.6 23.7 17.6 50.1 24.0 7.2 38.3 16.6 7.4 11.5 4.6 10.9 19.6 10.5 17.3 11.0 25.5 8.5 14.7 9.1 9.8 9.5 11.4 15.2 30.6 6.3 8.1 7.4 17.3 12.9 7.5 8.2 14.7 3.2 8.9 7.6 8.0 5.8 6.4 15.1 10.2 10.2 10.5 19.0 4.6 11.5 4.2 4.2 7.3 2.5 3.8 4.6 4.7 2.0 2.4 3.1 6.5 2.6 5.7 2.9 3.2 2.1 6.8 9.1 9.1 11.8 5.0 5.7 4.9 6.0 6.8 4.2 GSTM1 "GST1, H-B, MU" ENSG00000134184 "Glutathione S-transferase mu 1" P09488 1 109687814-109709039 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" Transferase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 163.2;seminal vesicle: 101.4" "Cell line enhanced" "Detected in some" "HEL: 26.6;HeLa: 31.8;HHSteC: 25.4;hTEC/SVTERT24-B: 23.0;HUVEC TERT2: 19.5;MOLT-4: 34.3" "Cancer enhanced" "Detected in all" "urothelial cancer: 63.1" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "CAB022669, CAB047357, HPA048652, HPA055972, HPA055973" Approved Approved Cytosol Cytosol "CAB022669: , CAB047357: , HPA048652: , HPA055972: , HPA055973: " "unprognostic (2.22e-2)" "unprognostic (5.35e-2)" "unprognostic (3.87e-3)" "unprognostic (3.20e-1)" "unprognostic (4.95e-2)" "unprognostic (1.03e-1)" "unprognostic (3.56e-2)" "unprognostic (1.81e-1)" "unprognostic (2.41e-1)" "unprognostic (6.55e-2)" "unprognostic (2.34e-1)" "unprognostic (3.45e-1)" "unprognostic (3.17e-2)" "unprognostic (2.12e-1)" "unprognostic (1.36e-1)" "unprognostic (2.18e-1)" "unprognostic (4.72e-3)" 14.5 25.4 15.2 6.9 15.6 2.9 8.2 5.6 19.2 22.0 7.8 16.9 0.0 7.7 9.8 20.2 22.5 13.8 8.2 6.4 14.4 6.8 14.1 163.2 7.7 1.0 7.8 32.1 29.0 18.2 41.4 5.3 2.9 8.2 38.1 6.6 25.7 11.8 101.4 25.1 18.8 17.7 18.2 6.8 21.7 7.5 15.1 11.2 10.9 7.6 1.6 14.5 30.8 19.5 14.6 34.9 14.1 18.9 13.3 17.3 10.0 0.0 0.1 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.2 2.2 8.2 0.0 12.7 0.4 0.0 0.1 0.2 0.0 0.1 26.6 31.8 0.5 25.4 0.0 0.2 0.0 0.0 23.0 0.1 19.5 0.0 17.8 0.7 0.0 34.3 0.2 17.1 0.0 0.1 0.1 3.3 2.8 0.0 1.6 0.2 0.0 0.1 0.1 0.3 14.0 0.0 11.4 0.6 0.2 0.0 14.3 18.8 1.1 9.8 0.3 0.6 0.7 12.2 14.1 14.8 18.9 15.7 14.6 15.8 13.7 34.9 14.6 16.5 15.6 1.0 13.3 7.4 19.2 17.3 10.0 15.2 15.6 5.6 19.2 14.4 6.8 7.8 32.1 8.2 11.2 GSTM3 GST5 ENSG00000134202 "Glutathione S-transferase mu 3" P21266 1 109733932-109741038 "Cancer-related genes, Enzymes, Predicted intracellular proteins" Transferase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "seminal vesicle: 115.3;testis: 96.0" "Cell line enhanced" "Detected in many" "SK-BR-3: 44.8;T-47d: 94.8;WM-115: 36.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "naive CD4 T-cell: 11.1" "Group enriched" "Detected in many" 7 "granulocytes: 4.1;T-cells: 11.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB017130, HPA035190, CAB040583, HPA055972" Enhanced Supported Cytosol 560000 Cytosol "CAB017130: , CAB040583: , HPA035190: AB_10795023, HPA055972: " "unprognostic (2.13e-2)" "unprognostic (2.76e-2)" "unprognostic (1.95e-1)" "unprognostic (5.87e-2)" "unprognostic (1.25e-1)" "unprognostic (7.28e-2)" "unprognostic (3.28e-3)" "unprognostic (1.98e-1)" "prognostic unfavourable (1.89e-4)" "unprognostic (3.45e-1)" "unprognostic (1.51e-1)" "unprognostic (2.30e-1)" "unprognostic (6.16e-3)" "unprognostic (1.38e-2)" "unprognostic (1.21e-2)" "unprognostic (1.90e-2)" "unprognostic (3.48e-2)" 7.5 11.3 21.4 2.9 27.8 0.9 23.1 8.5 18.4 15.4 11.7 9.9 51.0 12.6 9.0 67.2 11.1 8.8 12.3 27.6 14.0 14.4 54.0 5.3 5.2 2.4 9.6 22.0 32.3 26.5 7.3 9.4 5.8 30.7 13.6 5.6 13.4 4.5 115.3 15.5 15.0 7.5 15.9 13.3 3.3 14.2 96.0 6.4 0.1 15.8 15.6 3.3 17.4 12.0 0.6 0.8 4.1 0.3 1.0 11.1 1.4 0.0 1.3 9.7 0.0 13.2 8.1 1.6 10.5 1.8 11.5 11.2 4.2 0.3 0.0 6.1 5.3 0.5 1.9 4.3 16.0 0.0 2.9 9.8 31.8 6.3 14.1 0.0 22.8 8.1 5.3 17.3 0.0 14.2 0.8 0.1 5.1 5.7 2.6 0.2 1.0 18.2 0.0 6.2 0.4 3.2 22.5 17.1 9.2 21.9 44.8 2.0 94.8 14.3 11.1 0.1 4.2 11.8 6.9 1.5 2.4 0.0 0.1 0.0 36.8 0.8 0.3 4.1 4.2 0.1 1.2 0.6 5.3 3.1 0.1 0.6 11.1 5.5 2.0 1.0 0.2 0.8 2.3 1.4 21.4 27.8 8.5 18.4 14.0 14.4 9.6 22.0 30.7 6.4 GSTP1 "FAEES3, GST3, GSTP" ENSG00000084207 "Glutathione S-transferase pi 1" P09211 11 67583595-67586656 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" Transferase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "hTCEpi: 298.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019779, HPA019869" Enhanced Supported Mitochondria,Cytosol 120000000 "Mitochondria, Cytosol" "HPA019779: AB_1849799, HPA019869: AB_1849801" "unprognostic (9.81e-2)" "unprognostic (6.52e-2)" "unprognostic (7.24e-2)" "unprognostic (2.72e-2)" "unprognostic (1.06e-2)" "unprognostic (1.30e-3)" "unprognostic (3.27e-1)" "unprognostic (4.98e-2)" "unprognostic (1.28e-1)" "unprognostic (5.16e-3)" "unprognostic (2.14e-3)" "unprognostic (9.37e-2)" "unprognostic (5.72e-2)" "unprognostic (7.78e-2)" "unprognostic (2.23e-1)" "unprognostic (6.72e-3)" "unprognostic (1.48e-1)" 24.2 25.3 20.2 23.8 21.7 46.2 39.5 15.5 19.8 51.8 51.9 23.5 125.4 35.2 43.5 41.9 181.6 60.8 51.1 45.3 18.3 23.5 44.2 5.9 61.0 39.4 25.5 19.9 33.4 60.7 44.1 33.8 57.9 46.0 37.0 17.9 59.9 50.2 110.8 33.7 58.5 34.0 30.1 22.8 25.1 48.5 15.4 15.4 29.8 91.6 131.5 75.6 40.8 79.5 25.3 191.4 12.4 168.2 70.1 40.7 167.2 68.1 93.0 45.3 70.5 35.1 39.6 41.9 29.8 40.0 45.6 35.5 170.8 71.7 0.1 68.4 47.1 99.7 122.4 131.2 12.9 47.5 44.5 3.3 67.7 0.0 52.1 22.4 39.9 49.1 298.4 36.3 35.1 68.3 73.9 19.0 35.6 0.2 51.3 62.5 86.7 39.9 47.9 7.6 0.2 72.5 0.2 15.4 44.0 41.8 13.6 135.0 0.2 37.7 36.8 21.0 53.4 44.0 21.6 11.8 73.8 25.0 23.9 37.1 43.6 2.3 168.2 12.4 40.7 125.7 15.0 25.3 18.4 33.3 191.4 24.3 15.3 27.3 7.0 70.1 79.4 76.2 18.3 167.2 20.2 21.7 15.5 19.8 18.3 23.5 25.5 19.9 46.0 15.4 GTF2H1 "BTF2, P62, TFIIH" ENSG00000110768 "General transcription factor IIH subunit 1" P32780 11 18322295-18367044 "Cancer-related genes, Predicted intracellular proteins" "DNA damage, DNA repair, Transcription, Transcription regulation" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004637, HPA046660" Enhanced Enhanced Nucleoplasm Nucleoplasm "CAB004637: AB_425470, HPA046660: " "unprognostic (2.25e-1)" "unprognostic (2.33e-1)" "unprognostic (9.78e-2)" "unprognostic (2.38e-1)" "unprognostic (2.63e-1)" "unprognostic (1.40e-1)" "prognostic unfavourable (5.98e-9)" "unprognostic (7.71e-2)" "unprognostic (4.24e-2)" "unprognostic (2.81e-1)" "unprognostic (1.33e-1)" "unprognostic (2.26e-2)" "unprognostic (7.42e-3)" "unprognostic (8.31e-2)" "unprognostic (1.24e-1)" "unprognostic (7.90e-2)" "unprognostic (2.94e-1)" 27.1 26.4 24.1 18.2 28.8 10.5 33.0 32.6 35.7 21.5 21.6 19.3 24.1 18.0 23.5 23.1 26.2 18.6 22.9 21.4 24.1 20.4 25.9 25.0 19.1 23.7 19.6 22.2 27.2 24.3 27.1 32.4 24.3 27.4 22.5 20.9 21.2 25.8 26.0 20.8 32.4 21.7 20.6 21.1 23.4 20.5 38.5 23.3 22.7 29.3 21.7 25.7 22.9 22.2 12.0 11.8 20.3 12.1 15.9 13.9 8.8 12.2 11.4 9.5 13.6 21.9 17.5 12.0 18.4 19.8 16.3 18.9 11.8 4.8 20.5 7.4 18.9 17.1 15.6 16.8 21.2 9.0 15.5 13.3 11.6 11.9 31.3 25.5 14.5 19.7 20.2 10.1 32.1 14.4 20.4 10.9 23.5 11.4 12.8 20.3 8.4 16.4 13.2 20.3 9.5 13.4 16.9 11.0 11.8 15.2 14.7 22.7 7.7 15.0 10.6 22.1 10.7 39.5 14.9 5.6 13.2 15.1 19.1 20.0 21.0 20.3 10.9 11.3 9.1 11.0 9.8 11.7 11.5 10.1 11.8 12.0 13.9 11.1 7.9 15.9 12.1 6.5 11.0 8.8 24.1 28.8 32.6 35.7 24.1 20.4 19.6 22.2 27.4 23.3 GUSB ENSG00000169919 "Glucuronidase beta" P08236 7 65960684-65982314 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Glycosidase, Hydrolase" "Cancer-related genes, Disease mutation, Mucopolysaccharidosis" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "Karpas-707: 55.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA036322, HPA036323" Approved Supported Vesicles "Intracellular and membrane" 48000 Vesicles "HPA036322: AB_10670796, HPA036323: " "unprognostic (1.54e-2)" "unprognostic (6.49e-2)" "unprognostic (1.18e-2)" "unprognostic (3.50e-1)" "unprognostic (2.58e-2)" "unprognostic (4.46e-2)" "unprognostic (2.89e-1)" "unprognostic (1.56e-3)" "unprognostic (1.32e-1)" "unprognostic (2.32e-1)" "unprognostic (7.00e-3)" "unprognostic (1.91e-1)" "unprognostic (3.34e-2)" "unprognostic (8.83e-3)" "unprognostic (1.98e-1)" "unprognostic (5.06e-1)" "unprognostic (1.45e-1)" 23.5 12.0 3.7 7.9 5.5 20.7 25.4 5.7 4.4 10.4 14.6 7.7 22.0 10.0 10.4 12.2 9.3 7.6 11.1 8.0 3.7 2.9 11.8 50.4 15.3 12.3 6.3 3.1 8.6 17.1 9.0 7.3 30.0 4.5 12.1 11.4 9.9 17.2 11.8 5.9 10.0 16.1 8.3 3.9 17.5 11.0 7.9 5.8 14.7 17.7 5.9 13.0 9.2 7.4 9.7 27.7 22.1 36.0 15.2 11.5 15.8 16.8 6.5 6.4 14.3 21.9 13.1 9.3 5.3 14.9 11.8 10.9 9.3 17.4 7.7 8.4 6.8 6.9 4.1 6.4 7.0 7.2 8.4 10.5 9.8 6.4 10.7 22.4 17.5 9.0 6.9 6.8 8.9 10.2 15.9 55.9 7.6 12.2 8.2 24.1 4.3 5.5 8.5 14.8 43.7 7.4 10.2 9.4 8.3 14.3 33.6 18.7 18.7 22.4 7.2 14.4 13.1 5.4 13.3 31.8 38.1 13.0 10.8 29.9 17.5 7.4 28.1 22.1 11.5 36.0 10.3 9.7 9.0 10.2 27.7 7.8 6.2 7.3 4.5 15.2 30.0 11.3 11.3 15.8 3.7 5.5 5.7 4.4 3.7 2.9 6.3 3.1 4.5 5.8 H3F3A "H3.3A, H3F3" ENSG00000163041 "H3 histone family member 3A" P84243 1 226061851-226072001 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" DNA-binding "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 258.7" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "neutrophil: 258.7" "Lineage enriched" "Detected in all" 5 "granulocytes: 258.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB011481, CAB037178, HPA042570" Supported Supported Nucleoplasm Nucleoplasm "CAB011481: AB_880446, CAB037178: AB_532248, HPA042570: " "unprognostic (1.82e-1)" "unprognostic (1.95e-2)" "unprognostic (1.00e-1)" "unprognostic (2.19e-3)" "unprognostic (2.83e-2)" "unprognostic (3.74e-1)" "unprognostic (9.83e-3)" "unprognostic (4.71e-2)" "unprognostic (1.77e-3)" "unprognostic (3.69e-2)" "unprognostic (1.29e-1)" "unprognostic (1.29e-1)" "prognostic unfavourable (1.21e-6)" "unprognostic (3.66e-2)" "unprognostic (8.03e-3)" "unprognostic (2.21e-3)" "unprognostic (6.03e-2)" 39.0 43.4 37.2 83.4 33.4 126.8 67.9 45.0 42.8 44.6 54.0 31.6 62.9 47.9 43.4 60.6 66.3 42.4 49.6 59.4 36.1 31.2 45.9 59.2 73.2 217.9 37.8 23.2 44.4 79.7 30.8 34.8 59.1 29.2 38.4 59.4 42.7 49.0 49.7 37.0 47.1 50.0 42.0 48.6 71.9 41.4 87.6 31.7 148.9 38.5 71.0 84.1 43.5 47.6 39.2 44.6 258.7 56.9 23.6 34.9 60.5 53.7 30.7 119.8 67.6 33.3 38.8 90.0 25.5 31.0 41.4 32.8 32.0 89.7 51.8 56.8 31.3 51.6 59.2 46.5 40.8 32.0 102.3 64.0 45.5 42.8 33.0 65.7 77.8 35.5 53.9 29.0 38.2 61.3 90.1 88.6 47.1 31.1 136.4 122.3 162.5 60.9 92.4 87.5 133.4 85.8 57.5 117.0 174.0 72.8 92.1 63.1 104.4 154.2 34.5 30.2 42.1 40.7 73.9 39.5 50.5 90.4 28.8 62.8 64.5 40.0 56.9 80.8 23.1 44.9 23.6 39.2 25.0 24.9 44.6 36.0 23.7 25.7 258.7 23.6 50.8 36.6 34.9 60.5 37.2 33.4 45.0 42.8 36.1 31.2 37.8 23.2 29.2 31.7 H3F3B H3.3B ENSG00000132475 "H3 histone family member 3B" P84243 17 75776434-75785893 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" DNA-binding "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 570.8;bone marrow: 441.9" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "neutrophil: 570.8" "Lineage enriched" "Detected in all" 6 "granulocytes: 570.8" "CAB037166, CAB037187, CAB037221, HPA042570" Supported Enhanced Nucleoplasm Nucleoplasm "CAB037166: AB_2115285, CAB037187: AB_477069, CAB037221: AB_477076, HPA042570: " "unprognostic (1.66e-1)" "unprognostic (8.42e-3)" "unprognostic (3.42e-2)" "unprognostic (1.06e-1)" "unprognostic (1.81e-1)" "unprognostic (1.95e-1)" "unprognostic (2.41e-1)" "unprognostic (2.43e-3)" "unprognostic (3.37e-2)" "unprognostic (1.64e-1)" "unprognostic (5.88e-2)" "unprognostic (1.07e-1)" "unprognostic (1.26e-3)" "unprognostic (9.20e-2)" "unprognostic (4.81e-2)" "unprognostic (2.33e-1)" "unprognostic (1.99e-1)" 57.2 41.2 38.1 58.9 48.6 441.9 71.4 60.2 47.0 86.6 44.6 65.9 42.7 37.9 60.5 77.7 93.2 70.2 75.8 35.1 38.5 33.9 42.8 48.1 64.2 62.3 50.4 41.2 141.0 90.9 33.0 41.5 58.5 42.7 60.5 26.6 65.8 58.4 55.4 71.1 114.0 58.0 63.7 51.8 65.9 45.1 66.9 46.2 78.6 58.9 69.1 55.7 78.5 71.9 78.9 88.1 570.8 98.4 80.0 77.2 203.5 118.3 105.1 43.9 43.3 25.1 39.4 60.7 56.1 49.7 68.9 55.3 112.5 84.2 59.3 53.6 32.6 46.6 34.7 77.5 39.3 32.3 78.2 52.9 56.1 95.2 56.7 87.8 68.1 42.9 48.0 70.6 91.1 51.7 74.8 106.6 35.4 174.1 126.0 73.7 35.2 117.5 93.8 80.4 64.6 54.4 70.3 89.1 99.0 56.9 83.5 120.3 65.4 94.8 48.2 123.7 109.4 53.3 148.4 129.0 76.3 71.2 65.4 83.8 67.4 182.8 98.4 259.3 74.4 86.9 70.2 78.9 71.8 70.5 86.7 65.3 77.2 64.5 570.8 80.0 78.9 88.1 76.0 203.5 38.1 48.6 60.2 47.0 38.5 33.9 50.4 41.2 42.7 46.2 H3F3C H3.5 ENSG00000188375 "H3 histone family member 3C" Q6NXT2 12 31791185-31792241 "Cancer-related genes, Predicted intracellular proteins" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 7 "blood: 34.7;testis: 23.5" "Cell line enhanced" "Detected in many" "SH-SY5Y: 5.5" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in single" "Cell type enhanced" "Detected in all" "neutrophil: 34.7" "Lineage enriched" "Detected in all" 5 "granulocytes: 34.7" HPA042570 Approved "HPA042570: " "unprognostic (2.82e-1)" "unprognostic (2.80e-4)" "unprognostic (2.60e-2)" "unprognostic (9.21e-2)" "unprognostic (3.77e-2)" "unprognostic (2.89e-2)" "unprognostic (2.92e-1)" "unprognostic (1.45e-1)" "unprognostic (7.56e-2)" "unprognostic (2.39e-1)" "unprognostic (4.06e-2)" "unprognostic (3.53e-2)" "unprognostic (2.73e-3)" "unprognostic (4.02e-2)" "unprognostic (2.99e-2)" "unprognostic (2.80e-2)" "unprognostic (3.86e-2)" 1.8 0.5 0.5 2.1 0.9 4.2 1.6 0.6 0.6 2.0 0.8 0.6 1.3 0.9 1.8 1.7 1.9 0.8 0.8 0.5 1.1 0.5 0.5 1.1 1.0 0.7 0.6 0.9 3.1 1.0 0.5 0.6 0.7 0.6 1.5 0.3 1.5 1.7 1.4 0.6 1.3 1.2 1.7 0.6 1.9 1.0 23.5 0.9 0.9 1.0 3.3 1.1 1.7 0.8 6.7 6.1 34.7 7.0 6.7 6.1 14.9 3.6 0.7 1.6 0.7 0.4 0.0 1.4 0.5 0.2 0.9 0.4 1.1 1.5 0.5 1.4 0.0 1.2 0.1 0.1 0.2 1.1 0.0 0.1 0.9 0.5 0.0 1.0 1.3 0.2 0.1 0.0 1.2 0.1 0.4 1.6 0.0 0.1 2.7 3.6 0.7 0.2 1.7 0.8 2.4 0.2 0.6 2.9 5.5 0.1 2.1 4.0 1.2 3.5 0.3 2.0 3.5 1.4 4.5 2.7 1.0 1.4 1.7 1.7 1.7 13.8 6.7 18.9 5.1 7.0 4.5 6.7 5.3 5.0 6.1 5.2 5.6 5.3 34.7 6.7 6.1 5.9 6.1 14.9 0.5 0.9 0.6 0.5 1.1 0.5 0.6 0.9 0.6 0.9 HDAC10 DKFZP761B039 ENSG00000100429 "Histone deacetylase 10" Q969S8 22 50245183-50251405 "Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Autophagy, DNA damage, DNA recombination, DNA repair" Hydrolase "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HMC-1: 18.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB045977 Supported "CAB045977: AB_11124034" "unprognostic (1.53e-1)" "prognostic favourable (4.46e-4)" "unprognostic (1.43e-2)" "prognostic favourable (2.45e-5)" "unprognostic (2.71e-2)" "unprognostic (3.70e-2)" "unprognostic (6.15e-3)" "unprognostic (5.48e-2)" "unprognostic (3.28e-1)" "unprognostic (2.56e-2)" "prognostic favourable (9.25e-4)" "unprognostic (4.93e-2)" "prognostic unfavourable (4.74e-11)" "unprognostic (2.21e-2)" "unprognostic (2.52e-2)" "unprognostic (1.43e-2)" "unprognostic (1.38e-3)" 8.9 9.3 10.1 14.7 10.3 16.9 6.8 10.9 8.8 8.6 13.9 4.7 14.6 12.9 7.7 13.5 10.2 7.9 13.1 4.0 8.4 6.1 11.4 15.1 8.2 12.5 4.9 8.8 7.8 15.0 6.4 13.2 7.0 6.1 10.2 3.7 8.8 18.6 12.9 9.2 12.1 14.2 7.1 4.4 17.1 14.2 2.4 4.7 16.1 9.3 7.6 19.2 8.2 7.7 1.1 3.1 5.4 4.2 1.1 1.9 2.5 4.1 2.3 0.6 3.4 3.0 2.3 7.6 2.7 2.4 1.6 0.9 4.3 4.5 2.7 3.9 2.1 6.9 1.4 4.1 0.3 3.4 3.9 5.8 6.1 7.2 5.2 6.8 18.9 4.9 3.0 1.5 0.9 2.9 4.0 4.1 1.4 12.8 3.8 17.0 1.4 5.1 9.1 2.2 16.7 2.5 7.0 1.8 4.5 2.8 1.0 4.8 7.8 11.0 4.7 2.7 3.9 4.6 1.6 5.1 1.7 2.3 4.4 4.3 2.1 0.8 4.0 5.4 1.9 4.2 1.6 1.0 0.9 1.2 3.1 1.1 0.8 1.0 2.0 1.1 2.3 2.7 1.6 2.5 10.1 10.3 10.9 8.8 8.4 6.1 4.9 8.8 6.1 4.7 HDAC2 "RPD3, YAF1" ENSG00000196591 "Histone deacetylase 2" Q92769 6 113933028-114011308 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Biological rhythms, Transcription, Transcription regulation" "Chromatin regulator, Hydrolase, Repressor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB005054, HPA011727" Supported Enhanced Nucleoplasm Nucleoplasm "CAB005054: AB_562295, HPA011727: AB_1850540" "prognostic unfavourable (7.07e-4)" "unprognostic (1.44e-1)" "unprognostic (2.67e-1)" "unprognostic (2.56e-2)" "unprognostic (2.61e-2)" "unprognostic (1.89e-2)" "prognostic unfavourable (5.39e-10)" "unprognostic (2.03e-1)" "unprognostic (2.63e-2)" "unprognostic (9.00e-2)" "unprognostic (2.01e-1)" "unprognostic (3.92e-1)" "unprognostic (1.84e-2)" "unprognostic (1.96e-1)" "unprognostic (2.42e-1)" "unprognostic (9.80e-2)" "unprognostic (3.51e-1)" 25.8 33.8 25.8 30.1 31.3 34.9 58.7 32.8 36.5 32.1 30.7 25.6 32.2 22.0 38.7 36.7 36.3 32.7 23.3 27.6 26.5 26.9 31.6 22.2 29.9 41.5 29.6 26.5 39.2 31.5 31.7 45.1 38.1 27.9 32.1 36.1 17.5 29.3 39.0 33.9 30.8 26.1 36.1 31.1 30.7 29.9 47.4 27.4 64.0 35.1 31.3 32.5 33.1 47.3 27.0 35.7 28.2 32.6 26.3 32.6 24.3 24.2 16.7 78.2 44.9 20.2 23.0 32.8 28.9 23.7 34.2 41.0 44.3 17.9 20.0 24.2 26.0 19.1 53.0 29.3 57.6 28.5 36.6 48.2 21.7 25.6 26.9 48.9 21.8 18.6 19.7 36.4 34.2 39.8 62.0 20.4 56.5 20.3 43.8 44.3 44.2 23.1 29.8 39.0 18.4 35.3 29.3 52.3 44.4 22.9 21.6 24.1 15.7 57.1 32.1 21.8 25.1 22.8 47.9 16.2 21.3 47.9 18.5 47.2 36.9 23.1 27.6 28.2 21.1 26.6 28.1 27.0 25.9 22.7 35.7 22.3 32.6 29.7 16.3 26.3 32.6 30.9 24.5 24.3 25.8 31.3 32.8 36.5 26.5 26.9 29.6 26.5 27.9 27.4 HDAC5 "FLJ90614, KIAA0600, NY-CO-9" ENSG00000108840 "Histone deacetylase 5" Q9UQL6 17 44076746-44123702 "Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Transcription, Transcription regulation" "Chromatin regulator, Hydrolase, Repressor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB019400, HPA030991" Approved Supported "Nuclear speckles,Golgi apparatus,Cytosol" "Nuclear speckles" "Golgi apparatus, Cytosol" "CAB019400: AB_2116626, HPA030991: AB_10795286" "unprognostic (1.30e-2)" "prognostic favourable (6.14e-4)" "unprognostic (6.65e-2)" "unprognostic (8.06e-2)" "unprognostic (3.49e-1)" "unprognostic (3.52e-2)" "prognostic unfavourable (3.12e-5)" "unprognostic (8.80e-3)" "unprognostic (3.80e-2)" "unprognostic (2.37e-2)" "unprognostic (4.91e-3)" "unprognostic (4.30e-1)" "prognostic favourable (3.30e-5)" "unprognostic (1.51e-2)" "unprognostic (3.11e-1)" "unprognostic (6.00e-2)" "unprognostic (1.76e-2)" 15.6 17.6 24.9 7.9 15.8 13.2 18.1 35.9 25.8 16.5 8.8 19.6 9.5 8.4 15.0 11.9 20.1 16.9 11.3 24.4 22.1 24.2 8.6 6.3 13.6 8.8 24.7 22.1 24.5 16.1 28.2 17.5 23.0 19.3 13.6 5.5 11.7 14.2 11.9 42.6 34.0 9.7 12.4 20.5 13.8 9.3 10.3 18.1 7.6 15.0 9.8 8.2 14.9 20.4 7.6 9.4 17.9 13.6 3.5 4.9 5.0 3.5 2.3 6.4 1.5 12.4 9.7 23.1 9.6 24.0 4.8 7.9 5.1 3.8 5.6 3.9 22.8 2.9 7.5 4.1 2.0 8.7 12.2 10.9 7.7 11.7 5.3 3.5 15.4 13.7 7.1 5.5 6.9 3.9 8.1 11.4 27.8 2.7 5.8 10.7 7.0 5.5 22.5 17.9 14.4 0.5 1.6 16.7 8.8 2.8 11.8 13.0 16.8 20.7 2.1 12.1 7.8 2.8 4.8 18.8 15.7 6.7 7.0 4.4 5.7 7.1 7.3 7.7 4.9 11.6 3.5 6.6 3.9 4.9 9.4 7.6 4.1 3.5 17.9 3.5 13.6 8.3 3.5 5.0 24.9 15.8 35.9 25.8 22.1 24.2 24.7 22.1 19.3 18.1 HERPUD1 "HERP, KIAA0025, Mif1, SUP" ENSG00000051108 "Homocysteine inducible ER protein with ubiquitin like domain 1" Q15011 16 56932048-56944863 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Unfolded protein response" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HHSteC: 61.2;RPMI-8226: 76.8;U-266/70: 87.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB037041, CAB037104, HPA040754, HPA041219" Approved Uncertain "Plasma membrane,Cytosol" "Plasma membrane, Cytosol" "CAB037041: AB_1840910, CAB037104: AB_1840912, HPA040754: AB_10794068, HPA041219: AB_10794268" "unprognostic (1.92e-1)" "unprognostic (3.47e-1)" "unprognostic (8.64e-2)" "unprognostic (3.93e-3)" "unprognostic (3.39e-1)" "unprognostic (5.00e-3)" "unprognostic (1.17e-1)" "unprognostic (9.69e-3)" "unprognostic (3.33e-1)" "unprognostic (2.56e-1)" "unprognostic (2.84e-1)" "unprognostic (3.50e-1)" "prognostic favourable (1.41e-9)" "unprognostic (1.06e-1)" "unprognostic (3.93e-2)" "unprognostic (2.19e-2)" "unprognostic (2.27e-3)" 22.7 38.8 16.2 35.6 20.7 21.6 39.4 17.7 20.0 30.1 32.1 20.0 48.8 21.4 21.6 51.6 15.0 20.2 32.5 28.8 15.8 15.5 42.9 57.7 30.4 40.0 25.6 12.5 44.8 148.6 37.6 26.7 26.2 25.6 49.5 32.3 35.3 108.6 76.1 34.6 18.3 24.7 17.6 24.2 38.3 37.2 10.6 20.8 9.6 64.2 20.4 53.8 24.4 25.9 50.8 121.9 29.0 39.5 22.4 33.4 46.5 4.4 4.9 4.8 10.0 11.2 14.6 17.2 10.6 16.9 13.7 10.7 6.8 10.2 18.1 13.6 10.2 7.7 8.2 3.7 13.6 10.4 4.9 1.5 8.2 24.5 61.2 3.2 8.1 17.7 35.8 6.2 19.7 10.4 2.4 25.9 38.2 3.7 6.1 6.7 3.1 11.1 4.2 12.2 76.8 29.4 5.0 5.3 6.1 9.2 45.4 46.9 5.0 12.2 6.3 5.7 5.7 5.0 4.2 87.6 28.5 28.3 8.1 4.5 7.4 23.9 39.5 18.0 16.1 31.0 17.4 50.8 17.5 21.1 30.6 37.8 11.4 17.4 29.0 22.4 21.5 121.9 33.4 46.5 16.2 20.7 17.7 20.0 15.8 15.5 25.6 12.5 25.6 20.8 HEY1 "bHLHb31, CHF-2, CHF2, HERP2, HESR-1, HESR1, HRT-1" ENSG00000164683 "Hes related family bHLH transcription factor with YRPW motif 1" Q9Y5J3 8 79764010-79767863 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Notch signaling pathway, Transcription, Transcription regulation" "Developmental protein, DNA-binding, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 60.6" "Cell line enhanced" "Detected in many" "HEK 293: 48.4;PC-3: 11.0;SK-MEL-30: 33.1;WM-115: 11.3" "Cancer enhanced" "Detected in all" "glioma: 43.1" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in some" 6 "neutrophil: 9.9" "Lineage enriched" "Detected in many" 6 "granulocytes: 9.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA055599, HPA063472" Enhanced Approved "Nucleoplasm,Nuclear membrane,Cytosol" "Nucleoplasm, Cytosol" "Nuclear membrane" "HPA055599: AB_2682858, HPA063472: " "unprognostic (1.15e-1)" "unprognostic (5.06e-2)" "unprognostic (5.13e-3)" "unprognostic (2.12e-1)" "unprognostic (1.86e-3)" "unprognostic (8.47e-2)" "unprognostic (4.21e-3)" "unprognostic (9.56e-2)" "unprognostic (1.72e-1)" "unprognostic (7.22e-2)" "unprognostic (1.25e-2)" "unprognostic (6.71e-3)" "unprognostic (5.92e-3)" "unprognostic (5.77e-2)" "unprognostic (8.53e-2)" "unprognostic (1.74e-2)" "unprognostic (1.00e-1)" 13.3 3.8 13.7 3.6 22.9 1.8 8.8 11.2 60.6 8.9 4.4 10.7 0.0 3.3 3.8 2.4 4.6 3.9 5.7 13.4 11.3 11.6 3.8 2.9 16.4 3.3 11.9 9.3 2.6 4.3 3.0 9.9 20.3 12.5 4.5 3.9 10.3 4.5 3.0 10.3 3.5 3.2 4.4 9.1 2.8 3.6 3.9 10.5 1.3 5.0 3.7 3.7 5.2 2.5 0.0 0.0 9.9 1.7 0.0 0.3 0.1 0.6 0.0 0.4 3.4 0.3 0.2 8.8 0.8 0.8 0.1 0.1 0.1 0.0 1.6 0.8 0.3 2.2 1.8 0.1 0.2 0.1 48.4 0.0 1.5 0.8 0.5 0.0 0.3 0.4 1.4 0.0 6.1 1.6 3.1 1.4 0.5 0.1 0.0 0.2 0.1 11.0 0.0 1.8 1.4 0.1 1.5 2.0 5.6 0.0 1.0 33.1 0.0 0.0 1.1 0.2 0.9 0.0 0.6 1.2 0.2 0.0 1.2 0.0 11.3 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 9.9 0.0 1.7 0.0 0.0 0.1 13.7 22.9 11.2 12.3 11.3 11.6 11.9 9.3 12.5 10.5 HGF "DFNB39, F-TCF, HGFB, HPTA, SF" ENSG00000019991 "Hepatocyte growth factor" P14210 7 81699008-81770438 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins, RAS pathway related proteins" "Growth factor, Serine protease homolog" "Cancer-related genes, Deafness, Non-syndromic deafness" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "placenta: 116.9" "Cell line enhanced" "Detected in some" "ASC TERT1: 44.8;HHSteC: 35.1;HL-60: 19.6;hTEC/SVTERT24-B: 22.0;Karpas-707: 60.7;U-87 MG: 16.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in many" 4 "basophil: 33.5" "Lineage enriched" "Detected in many" 4 "granulocytes: 33.5" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB010333, HPA040360, HPA044088" Approved Approved Centrosome,Cytosol "Secreted to blood" Cytosol Centrosome "CAB010333: AB_647965, HPA040360: , HPA044088: " "unprognostic (5.24e-2)" "unprognostic (6.77e-2)" "unprognostic (1.72e-2)" "unprognostic (5.12e-2)" "unprognostic (1.85e-2)" "unprognostic (7.45e-5)" "unprognostic (1.66e-1)" "unprognostic (9.28e-3)" "unprognostic (3.28e-2)" "unprognostic (2.97e-2)" "unprognostic (2.74e-1)" "unprognostic (5.29e-2)" "prognostic unfavourable (5.59e-4)" "unprognostic (7.90e-3)" "unprognostic (2.92e-2)" "unprognostic (1.14e-2)" "unprognostic (2.06e-2)" 6.2 10.6 1.4 2.9 1.2 4.6 4.8 0.5 4.5 5.1 4.0 0.4 2.9 1.5 5.2 3.1 2.9 4.0 7.1 9.3 3.6 1.3 7.3 27.5 15.8 2.0 1.3 1.4 3.2 1.4 1.6 4.3 116.9 1.9 10.8 1.9 2.0 2.2 3.2 1.4 0.9 1.8 15.1 6.0 6.6 2.3 2.0 0.9 0.5 5.3 1.4 1.4 10.5 21.5 0.0 2.0 33.5 7.6 0.0 0.0 1.5 0.0 0.0 0.0 0.0 5.5 44.8 0.0 0.1 8.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 35.1 19.6 0.1 10.6 0.0 22.0 0.0 0.5 0.0 60.7 0.1 0.0 0.0 13.6 0.0 0.0 0.2 0.0 1.8 0.0 0.0 0.0 2.3 0.0 0.0 0.0 0.0 0.8 0.1 0.5 0.0 0.0 0.0 0.0 0.0 0.0 16.1 4.1 0.0 33.5 6.6 1.6 0.0 7.6 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.0 1.3 0.0 6.7 0.4 0.0 1.5 1.4 1.2 0.5 4.5 3.6 1.3 1.3 1.4 1.9 0.9 HGFAC "HGFA, HGFAP" ENSG00000109758 "HGF activator" Q04756 4 3441887-3449495 "Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins" "Hydrolase, Protease, Serine protease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 141 "liver: 128.0" "Cell line enriched" "Detected in some" 8 "Hep G2: 10.7" "Cancer enriched" "Detected in some" 22 "liver cancer: 26.7" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "HPA058279, HPA059076" Enhanced "Secreted to blood" 7586667 11000000000 "HPA058279: AB_2683665, HPA059076: AB_2683898" "unprognostic (2.70e-2)" "unprognostic (8.20e-2)" "unprognostic (1.57e-1)" "unprognostic (1.86e-1)" "unprognostic (1.36e-1)" "unprognostic (1.39e-2)" "unprognostic (2.85e-3)" "unprognostic (5.37e-3)" "unprognostic (5.90e-2)" "unprognostic (1.81e-1)" "unprognostic (8.54e-3)" "unprognostic (5.52e-2)" "prognostic unfavourable (9.31e-4)" "unprognostic (2.87e-1)" "unprognostic (2.24e-1)" "unprognostic (9.49e-2)" "unprognostic (3.74e-4)" 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.4 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.1 0.0 0.0 0.1 0.0 0.1 128.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.2 0.0 0.1 0.1 0.0 0.0 0.0 0.4 0.5 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 10.7 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.6 0.2 1.2 0.7 0.4 0.1 0.0 0.0 0.6 1.1 0.0 0.0 0.3 0.1 0.0 0.0 0.5 0.7 0.0 0.1 0.3 0.3 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.4 0.1 0.1 0.0 0.0 0.0 0.1 0.0 HIF1A "bHLHe78, HIF-1alpha, HIF1, MOP1, PASD8" ENSG00000100644 "Hypoxia inducible factor 1 alpha subunit" Q16665 14 61695513-61748259 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "LHCN-M2: 117.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "eosinophil: 47.8" "Lineage enriched" "Detected in all" 6 "granulocytes: 47.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA000907, HPA001275, CAB017442" Supported Supported "Nucleoplasm,Nuclear bodies,Plasma membrane" "Nucleoplasm, Nuclear bodies" "Plasma membrane" "CAB017442: AB_10621732, HPA000907: , HPA001275: AB_1079057" "unprognostic (1.07e-2)" "unprognostic (1.13e-3)" "unprognostic (9.41e-2)" "unprognostic (1.07e-1)" "unprognostic (2.51e-2)" "unprognostic (1.90e-1)" "unprognostic (2.94e-3)" "unprognostic (3.40e-1)" "unprognostic (4.05e-1)" "unprognostic (1.39e-1)" "unprognostic (1.77e-2)" "unprognostic (8.39e-2)" "unprognostic (1.24e-1)" "unprognostic (3.23e-2)" "unprognostic (3.58e-1)" "unprognostic (7.35e-2)" "unprognostic (3.88e-2)" 31.9 62.0 15.6 45.2 17.8 125.2 24.9 22.7 18.5 45.7 15.3 12.3 23.5 10.8 17.7 31.3 31.2 21.7 50.0 19.4 17.5 16.5 76.4 42.7 42.8 27.3 18.3 11.0 34.5 12.7 13.7 26.8 24.2 25.1 17.6 13.9 14.0 24.6 36.2 8.0 17.4 16.9 18.7 27.2 57.3 16.0 21.1 12.4 24.7 26.9 18.4 28.8 37.8 21.5 6.6 6.0 47.8 6.8 6.2 7.9 5.1 37.6 15.0 15.1 43.2 24.0 38.7 20.5 31.3 37.8 39.5 35.6 6.5 12.5 9.2 23.6 38.7 8.9 9.7 51.5 49.4 4.0 5.0 5.6 13.8 11.2 53.6 2.3 6.2 67.6 16.3 28.9 31.0 24.8 3.8 0.0 117.8 7.8 7.3 2.9 13.6 19.8 0.5 34.0 2.7 50.9 25.1 12.7 14.1 58.8 8.4 20.7 8.8 4.5 14.7 89.7 20.1 29.7 26.3 4.9 7.2 10.4 47.3 4.7 24.2 11.2 6.8 47.8 3.8 5.5 4.9 6.5 5.0 4.4 6.0 6.6 7.9 5.1 18.2 6.2 5.6 2.9 3.4 5.1 15.6 17.8 22.7 13.2 17.5 16.5 18.3 11.0 25.1 12.4 HIP1 ILWEQ ENSG00000127946 "Huntingtin interacting protein 1" O00291 7 75533300-75738962 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Apoptosis, Differentiation, Endocytosis, Transcription, Transcription regulation" "Actin-binding, Activator" "Cancer-related genes, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "A549: 27.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA013606, CAB015334, CAB016402, HPA017964" Enhanced Enhanced Vesicles Vesicles "CAB015334: AB_2117565, CAB016402: AB_627725, HPA013606: AB_1850717, HPA017964: AB_1850719" "unprognostic (8.23e-2)" "unprognostic (1.22e-1)" "unprognostic (2.20e-2)" "unprognostic (1.64e-1)" "unprognostic (1.04e-1)" "unprognostic (2.59e-1)" "unprognostic (2.73e-3)" "unprognostic (1.03e-2)" "unprognostic (1.11e-2)" "unprognostic (2.02e-2)" "unprognostic (2.70e-2)" "unprognostic (7.98e-2)" "unprognostic (1.73e-3)" "unprognostic (9.67e-2)" "unprognostic (1.75e-1)" "unprognostic (1.00e-2)" "unprognostic (1.09e-1)" 16.5 8.7 14.6 7.2 25.9 5.1 13.5 13.2 20.8 13.2 5.3 34.4 4.9 2.9 13.4 10.1 5.7 13.8 8.7 9.2 17.5 11.9 14.6 9.6 17.7 4.6 27.2 11.8 8.1 4.0 4.9 3.6 20.0 16.1 6.8 4.5 9.9 4.0 12.4 3.9 10.8 4.6 12.6 24.8 10.8 4.6 18.5 29.7 1.6 15.8 5.7 4.6 9.7 8.8 0.5 4.0 8.8 1.1 3.3 1.5 0.3 2.5 27.3 18.6 17.5 7.9 10.7 5.6 4.8 3.1 3.1 2.3 1.5 2.4 1.8 5.6 11.8 3.1 18.8 3.9 4.2 1.5 3.5 1.4 3.2 2.5 7.8 0.4 7.4 8.2 2.4 10.2 2.1 13.0 1.9 1.8 5.0 10.4 1.2 10.6 20.2 3.3 2.1 7.8 0.1 2.4 9.7 0.9 8.2 4.4 2.8 6.3 17.2 6.7 4.6 9.2 7.1 3.1 6.6 2.0 0.2 4.4 9.2 3.9 6.2 8.8 1.1 7.6 1.1 1.1 1.0 0.4 0.2 0.9 1.6 0.5 0.1 0.7 7.7 3.3 0.8 4.0 1.5 0.3 14.6 25.9 13.2 16.9 17.5 11.9 27.2 11.8 16.1 29.7 HIP1R "FLJ14000, HIP12, HIP3, ILWEQ, KIAA0655" ENSG00000130787 "Huntingtin interacting protein 1 related" O75146 12 122834453-122862960 "Cancer-related genes, Predicted intracellular proteins" Endocytosis Actin-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "memory B-cell: 9.5;naive B-cell: 12.3" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB017187, HPA038135, HPA038136" Enhanced Supported "Vesicles,Plasma membrane,Cytosol" "Plasma membrane, Cytosol" Vesicles "CAB017187: , HPA038135: AB_2675851, HPA038136: AB_2675852" "unprognostic (4.52e-1)" "unprognostic (6.39e-2)" "unprognostic (7.07e-2)" "unprognostic (6.55e-3)" "unprognostic (8.67e-2)" "unprognostic (1.00e-2)" "unprognostic (1.02e-2)" "unprognostic (8.11e-2)" "unprognostic (6.37e-2)" "unprognostic (1.76e-1)" "unprognostic (1.39e-2)" "unprognostic (6.72e-2)" "prognostic favourable (6.50e-7)" "unprognostic (2.18e-2)" "unprognostic (2.84e-1)" "unprognostic (2.54e-3)" "prognostic favourable (7.26e-4)" 9.8 14.5 24.6 13.2 26.5 11.6 8.0 11.5 31.6 4.6 11.6 40.5 19.7 29.2 4.0 9.1 7.0 4.0 7.8 10.8 29.5 21.7 16.2 9.0 6.3 15.3 31.4 20.6 3.2 27.7 7.4 15.6 5.2 18.0 8.6 5.4 2.9 52.0 24.1 5.7 26.5 21.3 3.0 27.4 11.1 30.4 4.0 30.6 8.1 8.1 5.9 12.6 7.4 6.5 12.3 0.0 2.7 0.0 0.6 3.2 1.6 17.3 5.0 3.8 15.6 1.1 3.0 18.7 2.7 4.5 2.8 2.2 7.7 5.2 16.5 9.2 2.0 15.0 4.6 10.0 0.2 2.6 6.6 0.3 5.7 8.1 3.5 1.3 11.8 1.8 7.1 3.8 6.4 19.3 4.3 0.9 1.6 24.9 7.8 4.0 3.5 6.0 4.1 4.8 5.7 9.4 21.0 3.8 8.5 3.2 8.5 4.5 17.4 0.7 15.2 1.8 13.4 5.5 2.6 11.9 6.3 9.8 2.9 2.8 1.5 0.0 0.0 2.7 2.9 0.0 1.7 9.5 1.8 2.2 0.0 12.3 3.2 2.0 0.2 0.6 0.0 0.0 0.4 1.6 24.6 26.5 11.5 19.8 29.5 21.7 31.4 20.6 18.0 30.6 HIST1H1E "H1.4, H1e, H1F4, H1s-4" ENSG00000168298 "Histone cluster 1 H1 family member e" P10412 6 26156354-26157107 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" DNA-binding "Cancer-related genes, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in all" 5 "blood: 56.4;bone marrow: 102.3;lymphoid tissue: 123.9" "Cell line enhanced" "Detected in many" "RPMI-8226: 9.7;U-266/70: 11.8;U-266/84: 13.2;U-87 MG: 12.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB011506, HPA055907" Supported Supported "Nuclear speckles" "Nuclear speckles" "CAB011506: AB_470256, HPA055907: " "unprognostic (6.96e-2)" "unprognostic (1.25e-1)" "unprognostic (3.06e-2)" "unprognostic (1.86e-1)" "unprognostic (9.62e-2)" "unprognostic (1.04e-2)" "unprognostic (5.78e-3)" "unprognostic (2.31e-2)" "unprognostic (1.24e-1)" "unprognostic (1.00e-1)" "unprognostic (1.20e-1)" "unprognostic (1.37e-1)" "unprognostic (7.72e-13)" "unprognostic (4.54e-3)" "unprognostic (3.46e-2)" "unprognostic (1.30e-3)" "unprognostic (2.18e-2)" 6.7 3.6 3.1 14.3 3.5 102.3 10.3 8.1 9.0 10.7 7.7 4.7 4.2 4.1 6.8 7.5 13.7 4.0 11.3 7.4 4.0 3.5 6.6 6.7 13.1 18.4 3.4 2.4 19.3 17.1 3.7 9.0 7.3 3.5 10.2 4.4 9.8 10.0 4.0 4.1 14.4 9.0 7.4 6.8 14.6 5.3 5.9 0.7 123.9 4.6 10.0 18.4 14.3 10.7 39.6 14.6 56.4 12.9 19.2 24.4 9.4 2.4 0.3 0.4 5.2 0.1 0.0 6.3 0.0 0.4 1.1 0.8 0.1 1.5 1.2 0.7 0.1 1.1 0.3 0.7 0.5 1.7 1.5 0.8 0.5 0.4 0.1 0.7 1.0 0.1 0.3 0.3 0.5 0.5 3.9 6.7 0.1 0.5 7.7 7.1 1.8 0.8 3.6 1.2 9.7 0.3 0.0 3.8 0.9 3.1 0.8 1.1 1.0 2.5 0.4 2.4 3.6 1.4 2.4 11.8 13.2 5.3 12.1 2.1 1.1 56.4 12.7 30.0 21.1 12.9 24.4 21.4 16.7 19.2 14.3 39.6 12.7 11.6 18.6 19.2 10.9 14.6 16.4 9.4 3.1 3.5 8.1 9.0 4.0 3.5 3.4 2.4 3.5 0.7 HIST1H2AC H2AFL ENSG00000180573 "Histone cluster 1 H2A family member c" Q93077 6 26124145-26139116 "Cancer-related genes, Predicted intracellular proteins" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in all" 4 "blood: 116.1;lymphoid tissue: 202.5" "Cell line enhanced" "Detected in many" "HSkMC: 31.7;SiHa: 27.2;U-2 OS: 27.4;U-266/84: 27.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "neutrophil: 116.1" "Lineage enriched" "Detected in all" 17 "granulocytes: 116.1" "Low region specificity" "Detected in all" HPA041189 Supported "HPA041189: " "unprognostic (4.89e-2)" "unprognostic (1.97e-1)" "unprognostic (7.15e-3)" "unprognostic (1.34e-1)" "unprognostic (4.70e-1)" "unprognostic (1.33e-1)" "unprognostic (3.25e-1)" "unprognostic (1.37e-1)" "unprognostic (8.16e-2)" "unprognostic (2.57e-1)" "unprognostic (1.61e-3)" "unprognostic (1.75e-1)" "unprognostic (1.19e-2)" "unprognostic (2.58e-1)" "unprognostic (1.17e-1)" "unprognostic (1.20e-1)" "unprognostic (5.89e-3)" 13.6 14.5 13.6 22.5 16.4 19.0 29.9 7.3 9.8 35.6 21.0 12.2 17.9 18.1 13.2 32.8 27.5 23.6 13.9 12.6 18.5 12.4 21.4 34.1 29.2 28.5 18.6 8.5 23.8 15.7 3.7 13.4 26.2 8.5 37.2 15.0 21.1 10.4 17.0 17.5 15.4 21.6 14.4 27.0 26.4 26.9 16.3 10.4 202.5 24.5 9.2 34.9 29.6 25.8 6.6 4.5 116.1 3.6 1.9 2.1 48.3 5.6 1.6 1.9 0.6 16.2 8.9 0.8 2.8 1.8 8.6 7.4 2.1 1.4 0.2 14.0 5.6 6.7 1.6 2.9 6.2 5.3 0.9 0.9 0.7 0.3 12.8 0.9 6.5 31.7 5.0 1.8 5.6 0.5 14.0 10.3 3.8 4.6 0.9 1.0 2.3 0.5 0.6 1.0 16.5 8.2 0.6 3.0 1.2 27.2 5.8 8.8 13.2 1.4 1.9 5.3 27.4 2.3 1.2 13.4 27.2 1.5 1.9 14.2 2.2 36.0 2.0 24.4 1.4 1.5 1.2 3.3 1.5 1.0 1.4 6.6 2.1 1.1 116.1 1.9 3.6 4.5 2.0 48.3 13.6 16.4 7.3 9.8 18.5 12.4 18.6 8.5 8.5 10.4 HIST1H3B "H3/l, H3FL" ENSG00000274267 "Histone cluster 1 H3 family member b" P68431 6 26031650-26032060 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" DNA-binding "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 13 "lymphoid tissue: 343.5" "Cell line enhanced" "Detected in many" "U-266/84: 11.9" "Low cancer specificity" "Detected in many" "Cell type enhanced" "Detected in some" "T-reg: 1.4" "Low lineage specificity" "Detected in many" HPA042570 Approved "HPA042570: " "unprognostic (2.82e-1)" "unprognostic (2.64e-2)" "unprognostic (1.09e-1)" "unprognostic (5.59e-2)" "unprognostic (1.37e-1)" "unprognostic (2.34e-2)" "unprognostic (2.31e-2)" "unprognostic (1.17e-1)" "unprognostic (1.13e-1)" "unprognostic (2.03e-2)" "unprognostic (1.08e-2)" "unprognostic (5.34e-2)" "unprognostic (2.31e-7)" "unprognostic (8.52e-2)" "unprognostic (2.78e-1)" "unprognostic (1.90e-3)" 1.7 0.7 0.0 36.1 0.0 18.1 3.6 0.0 0.3 0.8 6.9 0.0 0.0 0.3 0.8 2.5 11.8 0.5 1.9 2.4 0.0 0.6 0.3 3.4 10.4 0.0 0.0 0.3 0.3 0.3 0.0 7.8 0.0 0.3 0.8 0.0 1.0 0.3 0.3 0.3 6.3 0.8 0.0 14.7 0.5 26.9 0.0 343.5 0.8 18.2 27.7 0.3 0.0 0.8 0.1 1.2 0.0 0.0 1.4 3.1 1.8 4.6 1.3 4.0 0.0 0.4 0.0 0.2 0.8 0.7 0.7 1.1 1.0 3.0 2.0 0.3 0.7 1.6 1.2 1.7 2.0 4.4 3.2 5.9 1.3 0.0 2.4 2.1 2.9 0.0 0.6 0.0 1.0 6.5 5.9 1.1 0.9 7.3 7.4 3.1 3.2 4.3 2.9 8.4 0.5 0.0 2.0 1.7 5.1 1.6 0.5 2.8 1.5 1.4 1.3 4.1 0.7 1.7 9.5 11.9 3.9 3.4 4.5 2.7 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.8 0.8 0.1 0.5 0.0 0.2 1.2 0.0 0.0 0.0 1.4 3.1 HIST1H4E "H4/j, H4FJ" ENSG00000276966 "Histone cluster 1 H4 family member e" P62805 6 26204552-26206038 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "lymphoid tissue: 71.9" "Cell line enhanced" "Detected in many" "MOLT-4: 7.4;U-266/70: 14.6" "Low cancer specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" HPA042201 Supported 30000000 "HPA042201: " "unprognostic (8.62e-2)" "unprognostic (4.86e-2)" "unprognostic (5.71e-3)" "unprognostic (1.23e-1)" "unprognostic (1.63e-1)" "unprognostic (1.57e-1)" "unprognostic (5.08e-3)" "unprognostic (7.99e-2)" "unprognostic (1.21e-1)" "unprognostic (6.57e-2)" "unprognostic (2.34e-3)" "unprognostic (4.34e-2)" "prognostic unfavourable (2.00e-6)" "unprognostic (1.28e-2)" "unprognostic (1.88e-1)" "unprognostic (1.40e-1)" "unprognostic (4.92e-2)" 2.2 4.8 2.4 5.4 6.8 13.0 4.6 15.1 17.3 7.3 4.7 5.2 5.1 7.4 4.9 6.6 5.2 6.5 5.0 5.1 2.0 3.0 1.9 2.6 5.1 1.3 5.7 11.2 1.6 2.5 2.6 4.7 2.4 10.5 5.0 6.7 7.5 4.6 1.8 2.2 4.6 6.5 2.0 4.9 4.8 7.7 1.8 71.9 6.5 2.7 7.7 7.8 0.0 10.4 5.1 4.8 8.0 3.7 5.9 2.1 1.3 0.9 1.7 3.9 0.6 0.0 0.9 1.5 0.4 0.7 0.5 0.5 1.4 0.5 2.0 0.4 2.4 0.8 0.1 1.0 1.1 1.0 0.4 1.6 0.8 0.0 0.6 1.6 0.4 0.1 0.6 0.4 0.5 2.8 3.3 0.2 0.5 7.4 3.5 1.6 1.3 3.3 1.8 3.3 0.6 0.5 4.8 1.2 1.1 1.6 0.5 1.5 0.7 0.7 2.0 2.7 0.6 1.2 14.6 5.6 2.1 0.4 1.4 1.4 3.2 3.7 2.9 3.8 3.1 5.3 3.9 5.5 3.6 5.1 10.4 5.9 4.5 4.8 3.7 8.0 4.7 3.3 2.1 HIST1H4I "H4/m, H4FM" ENSG00000276180 "Histone cluster 1 H4 family member i" P62805 6 27138588-27139881 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "blood: 14.5" "Cell line enhanced" "Detected in many" "K-562: 29.3;SiHa: 17.6;U-2 OS: 30.2;U-266/84: 30.4" "Low cancer specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" HPA042201 Approved 30000000 "HPA042201: " "unprognostic (2.49e-2)" "prognostic favourable (9.70e-4)" "unprognostic (1.97e-2)" "unprognostic (2.51e-2)" "unprognostic (2.26e-1)" "unprognostic (2.25e-1)" "unprognostic (1.07e-1)" "unprognostic (2.16e-1)" "unprognostic (2.85e-1)" "unprognostic (1.29e-3)" "unprognostic (1.86e-3)" "unprognostic (1.95e-1)" "prognostic unfavourable (1.32e-5)" "unprognostic (6.28e-2)" "unprognostic (1.49e-1)" "unprognostic (1.80e-1)" "unprognostic (2.02e-2)" 0.1 2.5 2.4 1.7 0.0 0.1 0.0 0.8 2.7 1.1 0.0 1.7 0.0 1.3 0.5 0.0 1.9 0.8 2.6 0.8 2.7 0.0 1.5 2.0 0.0 1.6 0.0 0.0 0.2 2.9 0.0 2.3 3.2 1.8 2.6 0.0 1.9 6.0 5.5 14.5 4.6 2.4 3.4 3.1 1.6 3.4 1.9 1.2 1.3 0.1 2.1 3.3 0.1 0.1 0.1 3.2 2.4 0.5 9.4 0.0 2.6 0.3 0.1 0.0 2.2 5.0 1.1 5.5 0.1 0.2 0.9 6.1 0.4 0.1 0.0 0.1 0.1 29.3 9.0 0.0 5.0 1.4 2.2 0.7 2.1 1.3 1.1 8.2 0.1 0.9 6.3 2.3 17.6 8.1 1.9 15.5 0.7 1.1 2.3 30.2 2.8 0.3 9.1 30.4 5.7 1.3 6.6 2.3 9.2 2.6 14.1 1.5 2.0 1.3 4.6 1.3 1.4 2.5 6.0 1.6 1.7 14.5 2.4 4.6 5.5 3.4 3.1 HK1 ENSG00000156515 "Hexokinase 1" P19367 10 69269984-69401884 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Glycolysis, Immunity, Inflammatory response, Innate immunity" "Allosteric enzyme, Kinase, Transferase" "Cancer-related genes, Charcot-Marie-Tooth disease, Disease mutation, Neurodegeneration, Neuropathy, Retinitis pigmentosa" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA007043, HPA007044, CAB010052, HPA011956" Supported Supported Mitochondria 16000000 Mitochondria "CAB010052: AB_627721, HPA007043: AB_1850652, HPA007044: AB_1079049, HPA011956: AB_1850758" "unprognostic (8.80e-2)" "unprognostic (1.78e-1)" "unprognostic (2.03e-1)" "unprognostic (2.00e-3)" "unprognostic (1.15e-2)" "prognostic unfavourable (3.39e-6)" "unprognostic (1.23e-1)" "unprognostic (1.97e-1)" "unprognostic (4.29e-2)" "unprognostic (1.16e-1)" "unprognostic (3.93e-3)" "unprognostic (1.12e-1)" "unprognostic (1.37e-3)" "unprognostic (7.25e-2)" "unprognostic (1.40e-2)" "unprognostic (2.00e-3)" "unprognostic (3.86e-2)" 17.5 10.5 21.1 19.9 30.4 23.5 15.8 40.0 48.6 16.6 16.9 10.1 7.6 6.3 13.5 9.4 44.8 15.2 12.6 61.6 19.8 23.3 10.8 4.4 17.2 14.3 19.8 31.3 9.0 4.6 12.5 14.7 22.6 31.3 25.5 15.4 21.2 21.5 26.8 62.1 30.7 8.6 25.6 9.7 13.3 20.3 28.9 10.6 18.9 33.6 32.6 23.0 25.8 23.1 11.4 25.5 17.8 39.3 8.9 23.0 29.6 17.4 9.9 13.3 12.7 14.9 11.2 8.5 17.4 45.8 23.3 25.2 2.9 1.9 1.2 13.8 29.1 15.3 12.4 38.9 22.3 11.6 9.7 43.4 10.6 0.2 17.0 0.8 32.9 16.9 22.7 33.3 74.5 24.1 72.3 9.2 31.9 28.9 5.0 2.2 20.4 44.3 7.7 8.1 0.1 16.1 20.6 13.7 16.1 19.9 38.7 11.5 21.1 2.8 24.7 34.8 15.9 19.1 24.2 11.0 7.2 3.0 45.1 22.8 10.0 17.8 27.3 13.4 14.0 39.3 23.0 11.4 16.2 15.8 25.5 6.8 14.5 11.5 6.6 8.9 39.3 2.9 17.8 29.6 21.1 30.4 40.0 48.6 19.8 23.3 19.8 31.3 31.3 10.6 HK2 ENSG00000159399 "Hexokinase 2" P52789 2 74833981-74893359 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" Glycolysis "Allosteric enzyme, Kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "U-87 MG: 53.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "eosinophil: 26.2" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "Low region specificity" "Detected in many" HPA028587 Enhanced "HPA028587: AB_10602605" "unprognostic (1.28e-1)" "unprognostic (1.52e-3)" "unprognostic (3.02e-1)" "unprognostic (3.63e-2)" "unprognostic (1.69e-1)" "unprognostic (7.21e-2)" "prognostic unfavourable (3.65e-4)" "unprognostic (2.85e-2)" "unprognostic (2.57e-1)" "unprognostic (2.17e-1)" "unprognostic (4.43e-3)" "unprognostic (2.24e-2)" "prognostic unfavourable (1.37e-4)" "unprognostic (1.20e-1)" "unprognostic (1.17e-1)" "unprognostic (1.42e-1)" "unprognostic (7.67e-2)" 27.0 2.2 4.4 9.5 5.0 20.4 10.8 0.7 4.5 5.3 23.2 7.3 5.7 1.3 2.6 40.1 13.6 4.8 9.1 8.3 2.8 2.3 2.1 1.4 16.5 5.0 8.5 1.1 14.9 3.5 1.1 1.7 13.2 5.4 4.0 19.2 9.6 10.3 0.5 29.3 9.7 8.9 1.7 10.9 7.4 8.7 24.8 7.4 4.3 7.1 22.3 9.2 29.0 8.3 0.8 6.2 26.2 7.1 0.0 0.8 2.0 16.2 0.1 3.8 13.7 32.3 3.4 14.0 6.3 9.2 7.1 10.3 13.0 2.9 11.8 6.1 2.9 5.6 17.2 13.3 20.8 3.3 3.7 16.0 3.7 17.8 10.2 23.3 26.3 5.6 14.5 13.6 23.8 3.4 13.9 0.0 2.0 11.5 5.6 23.9 13.6 11.3 9.2 7.9 9.2 4.3 22.9 2.7 13.4 4.0 20.4 8.0 1.0 3.7 2.7 22.8 4.0 9.4 11.4 8.1 2.3 5.9 53.2 17.1 5.8 6.6 7.1 26.2 0.1 5.7 0.3 0.6 0.4 0.1 6.2 0.8 0.7 0.7 5.9 0.0 3.7 0.1 0.8 2.0 4.4 5.0 0.7 4.5 2.8 2.3 8.5 1.1 5.4 7.4 HLA-A ENSG00000206503 "Major histocompatibility complex, class I, A" "P16188, P04439, P13746" 6 29941260-29945884 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Host-virus interaction, Immunity, Innate immunity" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "A-431: 154.8;fHDF/TERT166: 41.4;HBEC3-KT: 42.5;RPMI-8226: 40.3;U-266/70: 41.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" CAB078470 Supported "Golgi apparatus,Plasma membrane" "Plasma membrane" "Golgi apparatus" "CAB078470: AB_10985125" "unprognostic (1.56e-2)" "unprognostic (9.14e-2)" "unprognostic (1.34e-2)" "prognostic favourable (9.59e-4)" "unprognostic (3.49e-1)" "unprognostic (1.21e-1)" "unprognostic (1.12e-1)" "unprognostic (7.28e-2)" "unprognostic (3.42e-2)" "prognostic favourable (6.47e-4)" "unprognostic (2.96e-1)" "unprognostic (3.24e-1)" "unprognostic (1.84e-2)" "unprognostic (1.01e-1)" "unprognostic (2.32e-2)" "unprognostic (1.20e-2)" "unprognostic (1.54e-2)" 69.4 57.5 16.0 69.1 18.2 41.2 40.8 9.1 20.7 54.4 92.6 20.4 28.6 105.7 38.4 76.2 48.4 27.8 92.3 59.1 14.6 16.6 80.5 47.6 112.0 90.5 19.5 8.9 57.2 30.0 22.5 33.3 38.7 22.7 64.1 38.5 52.4 28.3 19.2 44.0 110.4 129.4 30.3 22.8 150.0 115.9 26.6 12.3 71.1 62.3 38.5 97.7 86.4 41.0 23.0 10.9 65.8 25.2 25.9 46.7 45.4 154.8 3.9 0.0 0.0 25.0 23.6 0.1 0.1 0.3 0.2 0.2 0.0 0.0 0.4 0.0 41.4 3.8 0.0 42.5 0.0 0.3 1.5 27.0 1.2 0.8 1.4 0.0 1.8 0.2 0.0 0.3 0.1 0.0 0.0 0.1 0.0 0.0 0.1 2.4 0.3 0.4 3.3 0.3 40.3 29.0 31.8 0.0 1.4 3.5 0.0 1.4 0.1 3.6 0.5 2.3 0.1 0.7 0.4 41.3 10.5 8.7 0.0 22.8 0.0 65.8 25.2 35.4 38.3 17.9 28.8 23.0 29.6 34.4 4.1 14.9 21.7 29.7 47.9 25.9 19.8 10.9 46.7 45.4 16.0 18.2 9.1 20.7 14.6 16.6 19.5 8.9 22.7 12.3 HLA-B AS ENSG00000234745 "Major histocompatibility complex, class I, B" "P30486, Q29836, Q31610, Q31612, P01889, P30480" 6 31269491-31357188 "Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Host-virus interaction, Immunity, Innate immunity" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "A-431: 69.9;EFO-21: 63.8;U-266/70: 161.8;U-698: 44.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" CAB015418 Enhanced "CAB015418: AB_831547" "unprognostic (2.87e-2)" "unprognostic (1.49e-1)" "unprognostic (4.90e-2)" "unprognostic (2.65e-2)" "unprognostic (1.86e-1)" "unprognostic (1.81e-1)" "unprognostic (5.16e-3)" "unprognostic (8.51e-2)" "prognostic favourable (2.90e-4)" "unprognostic (2.69e-3)" "unprognostic (3.05e-2)" "unprognostic (1.59e-1)" "unprognostic (9.28e-3)" "unprognostic (3.27e-1)" "unprognostic (7.83e-2)" "unprognostic (8.24e-3)" "unprognostic (3.67e-2)" 83.5 40.1 11.7 91.4 14.2 11.0 52.6 6.7 13.1 41.4 96.5 18.2 15.6 2.0 52.8 51.5 46.1 30.8 100.3 76.8 11.9 13.4 63.3 57.1 194.5 214.9 17.3 10.5 40.2 21.8 16.2 20.2 39.5 19.1 70.4 56.1 45.4 108.9 23.4 37.4 56.4 164.1 20.6 23.8 200.6 43.2 32.1 11.9 54.1 44.5 19.1 136.3 117.6 48.6 45.6 41.4 118.7 56.5 46.5 64.3 81.8 69.9 0.0 0.0 0.0 1.7 12.0 0.4 0.0 0.3 0.1 0.2 0.0 0.5 2.5 63.8 12.4 29.4 14.5 12.8 0.0 0.2 3.4 0.9 0.0 0.0 9.4 0.0 0.6 23.6 0.0 0.0 1.6 0.0 0.1 3.4 0.0 0.0 0.3 18.2 0.2 0.0 2.1 0.4 0.4 19.3 0.0 0.1 0.5 0.6 0.1 0.1 11.1 0.7 15.0 3.8 0.6 0.6 0.2 161.8 36.0 44.3 0.2 0.7 0.1 20.6 56.5 59.1 64.3 42.7 62.2 45.6 54.9 58.5 41.4 35.1 42.1 55.2 118.7 46.5 37.4 33.9 56.2 81.8 11.7 14.2 6.7 13.1 11.9 13.4 17.3 10.5 19.1 11.9 HLA-G ENSG00000204632 "Major histocompatibility complex, class I, G" P17693 6 29826967-29831125 "Cancer-related genes, Predicted membrane proteins, Predicted secreted proteins" Immunity "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 4 "placenta: 66.0" "Cell line enriched" "Detected in single" 5 "CAPAN-2: 2.1" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" CAB016158 Enhanced "Secreted to blood" 32800000 "CAB016158: AB_627938" "unprognostic (1.13e-2)" "unprognostic (9.95e-2)" "unprognostic (1.30e-1)" "unprognostic (3.40e-2)" "unprognostic (8.35e-2)" "unprognostic (1.35e-1)" "unprognostic (1.18e-3)" "unprognostic (2.51e-1)" "prognostic favourable (3.91e-5)" "unprognostic (6.34e-2)" "unprognostic (8.31e-2)" "unprognostic (1.78e-1)" "unprognostic (1.03e-2)" "unprognostic (6.56e-3)" "unprognostic (1.40e-1)" "unprognostic (1.52e-2)" "unprognostic (3.19e-3)" 0.2 0.1 0.0 0.5 0.1 0.2 0.3 0.1 0.1 0.2 0.5 0.1 0.0 1.2 0.2 0.6 0.1 0.1 0.2 0.3 0.2 0.0 0.5 0.2 2.8 0.7 0.1 0.1 0.3 1.9 0.1 15.2 66.0 0.1 0.2 0.2 0.3 0.4 0.6 0.2 0.2 0.8 0.1 0.2 1.2 0.9 2.2 0.2 1.3 0.4 0.2 0.2 0.2 0.3 0.3 0.3 2.2 0.9 0.2 1.2 5.7 0.4 0.0 0.0 0.1 0.2 0.0 0.1 0.0 0.2 0.0 0.2 0.0 2.1 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.2 0.3 0.0 0.1 0.0 0.1 0.0 0.3 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.2 0.6 0.9 1.2 0.7 0.5 1.2 0.3 0.1 0.5 0.3 0.3 0.6 1.2 2.2 0.2 0.6 0.1 0.5 5.7 0.0 0.1 0.1 0.1 0.2 0.0 0.1 0.1 0.1 0.2 HLF MGC33822 ENSG00000108924 "HLF, PAR bZIP transcription factor" Q16534 17 55265012-55325065 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Transcription, Transcription regulation" DNA-binding "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enhanced" "Detected in all" "liver: 78.8" "Cell line enriched" "Detected in some" 6 "Hep G2: 58.6" "Cancer enhanced" "Detected in many" "liver cancer: 13.6" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 7 "memory CD4 T-cell: 2.4;T-reg: 2.1" "Lineage enriched" "Detected in single" 25 "T-cells: 2.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA068156, HPA071210" Enhanced Nucleoplasm Nucleoplasm "HPA068156: , HPA071210: " "unprognostic (1.24e-1)" "unprognostic (1.19e-3)" "unprognostic (1.27e-1)" "unprognostic (1.35e-1)" "unprognostic (3.30e-1)" "prognostic favourable (1.88e-4)" "unprognostic (5.30e-3)" "prognostic favourable (2.71e-7)" "unprognostic (1.42e-1)" "unprognostic (3.44e-2)" "unprognostic (1.24e-3)" "unprognostic (2.19e-1)" "prognostic favourable (3.55e-6)" "unprognostic (8.47e-2)" "unprognostic (1.64e-1)" "unprognostic (6.85e-2)" "unprognostic (1.60e-2)" 9.5 15.2 13.3 2.0 26.2 1.0 10.8 15.2 38.0 10.5 10.6 6.4 2.4 1.7 10.3 8.5 18.1 9.3 6.1 15.9 12.6 6.9 9.2 78.8 9.5 2.1 6.6 24.5 34.6 2.7 2.8 8.0 1.5 12.3 9.9 3.1 23.7 15.9 9.5 5.3 11.6 3.0 14.3 5.5 5.7 4.7 3.4 6.3 0.0 23.4 7.1 5.6 9.2 5.2 0.0 0.0 0.0 0.0 0.0 2.4 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.3 0.2 0.0 0.0 0.1 0.0 0.0 9.7 0.2 0.0 0.0 58.6 0.0 0.3 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.4 0.0 0.0 0.9 0.0 0.1 0.1 4.8 0.0 4.1 0.2 0.0 2.6 0.0 0.1 0.0 0.0 0.3 0.0 0.2 0.1 1.9 1.7 0.0 0.1 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.3 0.0 2.4 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 2.1 0.1 13.3 26.2 15.2 38.0 12.6 6.9 6.6 24.5 12.3 6.3 HMGA1 HMGIY ENSG00000137309 "High mobility group AT-hook 1" P17096 6 34236873-34246231 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 107.3" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "CAB032200, HPA065612, HPA068442" Enhanced Approved Nucleoplasm,Nucleoli 18000 Nucleoplasm Nucleoli "CAB032200: AB_2117771, HPA065612: , HPA068442: " "unprognostic (1.81e-1)" "unprognostic (1.25e-1)" "unprognostic (1.08e-1)" "prognostic unfavourable (7.13e-4)" "unprognostic (1.57e-1)" "unprognostic (1.20e-3)" "prognostic unfavourable (1.29e-6)" "prognostic unfavourable (3.36e-4)" "unprognostic (8.54e-2)" "unprognostic (1.84e-2)" "prognostic unfavourable (8.71e-4)" "unprognostic (1.55e-1)" "unprognostic (8.22e-2)" "unprognostic (4.52e-3)" "unprognostic (1.19e-1)" "unprognostic (4.37e-1)" "unprognostic (2.65e-2)" 15.8 3.5 14.8 35.7 13.5 55.4 13.0 13.8 19.0 26.1 22.0 5.9 7.7 42.3 8.6 7.2 79.4 15.1 17.8 13.0 11.7 12.6 14.6 6.9 16.0 46.1 10.7 8.7 3.9 13.0 4.1 5.1 31.8 12.5 8.7 21.2 9.9 22.0 6.9 33.7 38.3 36.0 3.8 8.4 31.6 24.2 32.6 7.2 107.3 12.5 39.6 72.7 13.0 29.6 26.6 33.4 12.8 10.1 7.3 22.4 11.0 120.4 47.7 24.5 17.1 11.4 84.6 107.0 48.7 55.7 37.8 21.1 31.2 84.5 56.8 24.6 19.9 25.9 28.8 86.9 30.1 12.4 19.3 17.4 16.1 41.7 24.2 62.2 20.1 36.2 9.7 68.4 35.8 114.1 70.1 2.9 52.6 12.2 53.9 76.6 119.2 80.9 80.2 0.5 62.7 25.6 11.1 42.8 18.1 5.1 24.7 45.0 9.9 66.8 98.9 19.7 62.2 28.6 45.6 23.4 36.2 73.4 41.7 26.0 98.3 6.2 10.1 12.8 10.2 10.1 13.3 26.6 18.7 16.0 30.7 16.4 22.4 17.7 2.6 7.3 9.4 33.4 21.0 11.0 14.8 13.5 13.8 19.0 11.7 12.6 10.7 8.7 12.5 7.2 HMGA2 "BABL, HMGIC, LIPO" ENSG00000149948 "High mobility group AT-hook 2" P52926 12 65824131-65966295 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Cell cycle, Cell division, DNA condensation, Growth regulation, Mitosis, Transcription, Transcription regulation" DNA-binding "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "testis: 25.3" "Cell line enhanced" "Detected in many" "AF22: 66.0;NTERA-2: 38.7" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in single" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "CAB017809, HPA039076" Approved Supported Nucleoplasm,Nucleoli "Nucleoplasm, Nucleoli" "CAB017809: , HPA039076: " "unprognostic (2.39e-1)" "unprognostic (6.00e-2)" "unprognostic (2.08e-1)" "unprognostic (3.68e-3)" "unprognostic (5.21e-3)" "prognostic unfavourable (4.79e-4)" "unprognostic (4.05e-3)" "unprognostic (6.17e-3)" "unprognostic (6.71e-2)" "unprognostic (1.16e-1)" "unprognostic (1.54e-6)" "unprognostic (3.33e-2)" "unprognostic (4.55e-5)" "unprognostic (4.22e-2)" "unprognostic (2.53e-1)" "unprognostic (2.53e-2)" "prognostic unfavourable (2.86e-4)" 6.5 0.3 0.5 3.8 0.8 8.1 2.1 0.2 0.6 2.5 7.6 0.4 0.0 2.4 2.7 0.1 1.1 2.4 3.3 0.5 0.3 0.4 1.0 0.4 0.5 0.1 0.3 1.3 2.1 1.7 0.0 1.7 0.3 0.6 0.5 4.6 0.4 0.5 1.8 2.0 0.7 5.1 0.7 1.7 0.8 2.1 25.3 0.0 0.8 1.1 3.0 0.1 0.8 2.8 0.7 0.3 3.8 2.1 1.3 0.7 0.1 9.5 4.2 66.0 9.4 3.1 17.3 0.0 30.5 13.9 5.4 5.4 5.4 4.0 0.0 19.8 1.4 4.2 10.9 26.2 25.7 0.0 11.4 0.0 0.1 33.0 1.7 0.9 0.1 13.1 1.6 11.5 20.8 21.1 0.0 0.1 30.5 0.0 0.1 5.4 38.7 19.0 2.6 3.2 0.0 14.2 0.0 0.0 0.0 0.0 0.0 16.7 0.1 0.1 24.6 19.4 5.8 14.8 9.1 0.0 0.0 0.0 23.4 0.0 4.4 3.8 1.0 0.7 0.5 0.6 0.3 0.3 0.4 0.5 0.2 0.7 0.4 0.7 2.5 1.3 2.1 0.3 0.3 0.1 0.5 0.8 0.2 0.6 0.3 0.4 0.3 1.3 0.6 0.0 HMGXB4 "HMG2L1, THC211630" ENSG00000100281 "HMG-box containing 4" Q9UGU5 22 35257452-35295807 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Wnt signaling pathway" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA000725 Approved "HPA000725: AB_1079073" "unprognostic (2.22e-1)" "unprognostic (1.12e-1)" "prognostic favourable (3.24e-5)" "unprognostic (4.81e-2)" "unprognostic (1.93e-2)" "unprognostic (1.41e-1)" "prognostic unfavourable (4.79e-4)" "unprognostic (2.85e-2)" "unprognostic (8.25e-3)" "unprognostic (6.67e-3)" "prognostic unfavourable (1.16e-4)" "unprognostic (1.62e-1)" "unprognostic (8.71e-3)" "unprognostic (1.13e-1)" "unprognostic (1.98e-1)" "unprognostic (1.20e-1)" "unprognostic (8.54e-2)" 13.6 11.6 11.4 11.4 17.6 28.6 13.6 17.4 15.1 14.4 10.9 17.2 9.5 10.6 17.4 8.4 14.4 14.5 10.8 9.8 10.0 8.6 8.6 8.0 10.2 10.5 14.4 13.8 21.7 10.9 9.4 7.6 20.2 12.4 12.4 12.2 8.7 11.9 12.7 17.2 14.4 13.1 15.0 12.6 10.0 10.3 12.1 16.9 20.0 10.6 10.2 11.6 14.8 13.5 11.8 9.4 22.6 12.5 7.4 13.1 4.7 12.9 2.9 20.2 10.1 4.9 9.7 5.8 13.4 17.7 13.1 12.2 2.2 4.8 15.5 6.0 13.3 8.0 8.7 9.4 15.3 13.6 9.8 14.2 3.8 2.8 6.7 29.8 14.5 8.8 8.2 11.0 8.4 9.0 11.1 12.9 9.7 5.9 18.0 7.2 9.4 8.7 14.5 19.1 5.4 7.4 9.5 12.8 12.6 12.0 8.7 9.6 6.0 9.3 8.3 12.0 26.5 13.9 11.0 13.8 13.5 19.3 10.1 9.1 17.0 22.6 11.1 13.8 12.6 12.5 10.8 8.9 12.1 13.1 8.8 11.8 8.1 9.2 16.8 7.4 11.5 9.4 10.1 4.7 11.4 17.6 17.4 15.1 10.0 8.6 14.4 13.8 12.4 16.9 HMOX1 "bK286B10, HO-1" ENSG00000100292 "Heme oxygenase 1" P09601 22 35380361-35394214 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" Apoptosis Oxidoreductase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 209.8" "Cell line enhanced" "Detected in many" "BEWO: 110.9;U-138 MG: 64.7;U-87 MG: 62.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Group enriched" "Detected in many" 4 "classical monocyte: 17.7;intermediate monocyte: 40.5;non-classical monocyte: 53.4" "Lineage enriched" "Detected in many" 6 "monocytes: 53.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA000635, CAB017444" Enhanced Uncertain "Golgi apparatus,Plasma membrane" 17000 "Golgi apparatus, Plasma membrane" "CAB017444: AB_10617276, HPA000635: AB_1079089" "unprognostic (3.12e-1)" "unprognostic (1.00e-1)" "unprognostic (9.42e-2)" "unprognostic (6.94e-2)" "unprognostic (5.57e-2)" "unprognostic (2.47e-2)" "prognostic unfavourable (1.59e-4)" "unprognostic (7.56e-2)" "unprognostic (1.71e-1)" "unprognostic (4.91e-2)" "unprognostic (1.62e-1)" "unprognostic (2.76e-1)" "unprognostic (1.95e-3)" "unprognostic (1.91e-1)" "unprognostic (4.82e-2)" "unprognostic (2.26e-1)" "unprognostic (7.54e-2)" 28.4 10.3 4.1 12.5 8.7 16.3 13.8 0.8 20.6 5.7 12.0 6.1 0.6 22.0 2.5 8.5 8.8 9.8 9.8 10.2 4.1 3.1 23.0 63.7 54.0 76.3 12.5 1.3 28.6 8.8 0.5 2.7 21.1 7.5 3.6 4.9 3.3 3.5 0.8 21.9 13.8 22.8 6.9 11.2 209.8 4.6 5.9 7.6 3.6 4.2 7.3 8.3 6.7 10.2 4.8 7.9 8.4 53.4 1.1 0.3 10.1 1.4 22.6 0.2 4.6 18.5 5.4 110.9 10.4 6.2 4.9 5.3 10.0 1.4 0.0 2.3 8.5 1.2 1.3 0.2 1.5 37.3 1.1 0.5 6.9 20.4 25.7 1.4 7.0 17.0 0.4 32.3 2.1 14.7 0.0 10.8 15.6 1.1 0.0 0.5 2.2 2.5 0.1 1.9 3.4 3.5 12.1 0.3 0.3 26.9 2.4 1.8 1.0 0.3 5.5 64.7 2.9 10.5 10.1 6.8 8.7 1.0 62.8 0.6 1.0 2.0 17.7 1.2 0.2 40.5 0.0 4.8 0.1 0.3 7.9 0.5 0.0 0.0 8.4 1.1 53.4 0.2 0.2 10.1 4.1 8.7 0.8 4.8 4.1 3.1 12.5 1.3 7.5 7.6 HNF1A "HNF1, LFB1, MODY3, TCF1" ENSG00000135100 "HNF1 homeobox A" 12 120978543-121002512 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "intestine: 24.2;kidney: 17.2;liver: 15.6" "Group enriched" "Detected in some" 7 "A549: 6.2;CACO-2: 20.6;Hep G2: 22.4" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in single" "Not detected" "Not detected" "Low region specificity" "Detected in many" "CAB010430, HPA035231" Enhanced Supported Nucleoplasm Nucleoplasm "CAB010430: AB_2116746, HPA035231: " "unprognostic (5.92e-3)" "unprognostic (8.47e-2)" "unprognostic (4.12e-3)" "unprognostic (6.18e-3)" "unprognostic (3.72e-1)" "unprognostic (1.27e-2)" "unprognostic (9.18e-2)" "unprognostic (9.18e-2)" "unprognostic (2.99e-1)" "unprognostic (2.01e-1)" "unprognostic (9.77e-3)" "unprognostic (5.21e-2)" "unprognostic (6.25e-3)" "unprognostic (5.55e-2)" "unprognostic (2.48e-1)" "unprognostic (6.93e-3)" 0.1 0.0 0.1 0.8 0.1 0.0 0.1 0.1 0.1 0.1 17.3 0.1 0.1 13.7 0.1 1.5 0.1 0.8 5.1 0.1 0.1 0.0 17.2 15.6 0.1 0.1 0.1 0.1 0.2 6.3 0.0 0.1 0.1 0.1 0.1 2.1 0.1 0.1 0.1 0.1 0.0 24.2 0.5 0.1 0.1 3.6 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.5 0.5 1.8 0.3 0.3 0.4 0.2 0.0 6.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 20.6 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 22.4 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.8 0.3 0.2 0.2 0.3 0.2 0.3 0.4 0.4 0.1 0.5 0.4 0.4 1.6 0.3 0.3 0.5 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 HNRNPA2B1 HNRPA2B1 ENSG00000122566 "Heterogeneous nuclear ribonucleoprotein A2/B1" P22626 7 26189927-26201529 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction, mRNA processing, mRNA splicing, mRNA transport, Transport" "Ribonucleoprotein, RNA-binding" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001666, HPA005812, CAB012403, HPA065537" Supported Enhanced Nucleoplasm "Intracellular and membrane" 11000000 Nucleoplasm "CAB012403: , HPA001666: AB_1850836, HPA005812: , HPA065537: " "unprognostic (1.19e-1)" "unprognostic (4.45e-1)" "unprognostic (2.33e-1)" "unprognostic (6.39e-2)" "unprognostic (5.64e-2)" "unprognostic (8.04e-3)" "prognostic unfavourable (1.03e-6)" "unprognostic (1.25e-2)" "unprognostic (9.12e-3)" "unprognostic (4.35e-3)" "unprognostic (1.31e-1)" "prognostic unfavourable (5.12e-4)" "prognostic unfavourable (8.01e-5)" "unprognostic (6.74e-2)" "unprognostic (3.36e-2)" "unprognostic (2.02e-1)" "unprognostic (1.56e-2)" 82.2 97.4 85.1 105.3 106.3 90.9 74.4 123.3 87.4 77.1 85.7 89.4 68.7 87.5 92.6 71.9 90.4 75.1 51.7 87.9 82.4 71.8 113.4 103.7 76.2 127.7 118.6 57.0 121.0 75.7 107.2 121.2 100.7 96.3 75.5 98.6 64.4 71.4 66.5 167.2 58.7 94.8 73.7 139.7 116.5 74.1 73.1 135.4 180.3 81.9 104.4 140.7 74.2 128.8 33.7 46.5 35.1 52.4 32.1 42.5 36.0 122.0 104.2 151.7 113.7 39.0 35.7 70.2 78.3 61.1 86.5 78.4 96.2 88.9 223.1 74.9 72.5 85.2 162.2 102.3 122.0 69.4 98.9 135.2 125.7 115.0 32.8 145.5 92.7 33.7 53.6 82.3 75.1 89.3 159.0 73.0 87.4 98.7 155.7 170.3 134.3 80.3 144.7 123.3 93.5 99.9 106.8 88.6 108.7 94.1 92.7 57.2 103.9 126.8 77.1 48.7 100.8 65.9 133.6 97.0 192.2 212.4 62.7 166.0 91.7 17.4 38.7 35.1 42.5 52.4 38.6 33.7 35.5 36.6 46.5 29.2 35.6 35.6 13.0 32.1 48.4 43.6 36.1 36.0 85.1 106.3 123.3 87.4 82.4 71.8 118.6 57.0 96.3 135.4 HOOK3 HK3 ENSG00000168172 "Hook microtubule tethering protein 3" Q86VS8 8 42896932-43030539 "Cancer-related genes, Predicted intracellular proteins" "Protein transport, Transport" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" HPA024756 Approved Supported "Golgi apparatus,Centriolar satellite,Cytosol" "Centriolar satellite" "Golgi apparatus, Cytosol" "HPA024756: AB_1850913" "unprognostic (1.84e-2)" "unprognostic (1.61e-1)" "unprognostic (2.73e-1)" "unprognostic (8.61e-3)" "unprognostic (6.05e-2)" "unprognostic (1.77e-3)" "unprognostic (2.36e-1)" "unprognostic (2.23e-1)" "unprognostic (1.78e-1)" "unprognostic (3.97e-2)" "unprognostic (1.13e-1)" "unprognostic (4.13e-1)" "prognostic unfavourable (1.32e-4)" "unprognostic (1.63e-1)" "unprognostic (3.78e-1)" "unprognostic (2.55e-1)" "unprognostic (7.12e-2)" 15.5 9.3 11.3 10.1 15.1 13.1 16.3 16.0 19.2 13.5 11.3 10.3 14.1 10.2 13.7 12.0 14.8 11.7 20.0 9.5 11.2 11.3 9.9 10.7 14.6 10.3 14.7 11.7 13.4 13.9 13.4 14.4 12.0 13.1 17.7 10.9 6.8 17.1 15.2 24.1 11.0 11.9 19.3 17.5 11.6 12.8 14.5 14.3 7.4 37.5 8.9 10.1 19.2 17.6 1.8 3.8 10.2 3.2 2.0 2.0 1.8 7.3 7.3 17.8 9.6 13.2 11.7 6.8 9.3 7.8 7.8 7.3 9.6 8.6 9.1 9.6 12.4 4.1 14.7 6.3 12.7 6.2 4.2 17.2 6.0 6.6 7.4 1.8 10.2 9.5 4.6 10.5 9.1 11.2 9.4 10.7 9.4 1.8 13.9 3.4 6.4 2.2 8.2 18.6 2.3 5.8 10.9 4.5 7.2 10.6 4.5 4.9 8.2 6.2 20.0 11.7 9.2 14.1 5.9 10.6 11.5 12.0 9.9 6.6 17.3 10.2 3.2 3.1 2.0 3.2 0.8 1.6 1.9 1.5 3.8 1.8 1.1 1.5 3.8 2.0 3.1 2.4 1.4 1.8 11.3 15.1 16.0 13.1 11.2 11.3 14.7 11.7 13.1 14.3 HOXA11 "HOX1, HOX1I" ENSG00000005073 "Homeobox A11" P31270 7 27181510-27185223 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "cervix, uterine: 35.7;endometrium 1: 60.9;smooth muscle: 27.3" "Cell line enhanced" "Detected in many" "BJ hTERT+: 17.5;HEK 293: 24.6;THP-1: 17.6;U-937: 22.9" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "HPA006770, HPA035623" Enhanced Supported Nucleoplasm Nucleoplasm "HPA006770: , HPA035623: AB_10601576" "unprognostic (5.95e-2)" "unprognostic (9.23e-2)" "unprognostic (3.07e-2)" "unprognostic (2.70e-2)" "unprognostic (6.29e-2)" "unprognostic (9.78e-2)" "unprognostic (2.82e-3)" "unprognostic (4.36e-2)" "unprognostic (1.61e-2)" "unprognostic (3.05e-2)" "unprognostic (2.08e-3)" "unprognostic (1.73e-2)" "prognostic unfavourable (2.57e-5)" "unprognostic (2.17e-2)" "unprognostic (6.90e-2)" "unprognostic (2.03e-2)" "unprognostic (2.56e-1)" 1.5 0.4 0.0 1.7 0.0 0.0 2.0 0.0 0.0 35.7 9.3 0.0 5.7 0.0 60.9 8.8 0.0 0.7 0.0 0.2 0.0 0.0 3.6 0.1 0.0 0.1 0.0 0.0 1.8 0.0 0.0 0.0 9.0 0.0 16.5 2.4 0.0 0.1 6.3 4.9 0.7 0.2 27.3 0.0 0.0 0.1 3.1 0.0 0.0 0.0 0.0 0.0 20.1 6.8 0.0 0.0 0.0 0.2 0.0 0.0 0.0 2.3 0.1 0.0 6.7 8.2 5.8 0.0 14.5 17.5 10.3 7.4 0.1 0.8 0.0 3.3 12.2 1.6 8.6 0.0 7.5 0.8 24.6 3.0 6.0 0.3 0.5 6.1 0.8 3.7 0.3 0.0 0.0 7.4 0.1 0.0 1.1 0.1 0.0 4.7 0.0 7.2 0.3 0.0 0.1 4.9 4.2 3.2 0.0 3.5 0.0 1.0 0.6 17.6 0.0 0.1 7.1 1.6 0.7 0.0 0.0 0.0 0.1 22.9 1.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 HOXA13 "HOX1, HOX1J" ENSG00000106031 "Homeobox A13" P31271 7 27193503-27200106 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "cervix, uterine: 48.5;prostate: 25.1" "Cell line enhanced" "Detected in many" "HAP1: 15.2;HEK 293: 21.1;PC-3: 10.5;RT4: 23.5;THP-1: 10.0;U-937: 11.2" "Cancer enhanced" "Detected in many" "prostate cancer: 10.9" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in single" HPA069061 Supported "Nucleoplasm,Intermediate filaments" Nucleoplasm "Intermediate filaments" "HPA069061: " "unprognostic (7.20e-2)" "unprognostic (1.89e-1)" "unprognostic (1.02e-1)" "unprognostic (8.04e-4)" "unprognostic (1.06e-3)" "unprognostic (2.24e-2)" "unprognostic (1.79e-1)" "unprognostic (1.40e-2)" "unprognostic (9.22e-3)" "unprognostic (7.30e-3)" "unprognostic (8.39e-3)" "unprognostic (1.54e-1)" "unprognostic (1.42e-11)" "unprognostic (2.58e-3)" "unprognostic (1.38e-1)" "unprognostic (1.72e-1)" "unprognostic (1.36e-2)" 0.6 0.2 0.1 0.0 0.1 0.0 0.1 0.1 0.1 48.5 6.9 0.0 7.1 0.0 5.5 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.0 0.1 16.5 0.0 25.1 8.6 0.0 0.1 17.9 1.2 0.4 0.1 15.7 0.1 0.1 0.1 0.2 0.0 0.0 0.1 0.0 0.0 12.1 12.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.9 0.0 1.4 0.1 0.0 0.0 7.4 8.2 2.9 1.9 1.5 0.1 0.0 0.9 3.5 0.0 15.2 0.0 2.5 0.0 21.1 1.0 4.0 0.1 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 4.8 0.0 10.5 1.5 0.3 0.0 0.0 23.5 0.4 0.0 1.8 0.0 0.1 0.0 10.0 0.0 0.2 2.7 0.1 0.1 0.0 0.0 0.0 0.0 11.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 HOXA9 "HOX1, HOX1G" ENSG00000078399 "Homeobox A9" P31269 7 27162435-27175180 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "kidney: 35.1" "Cell line enhanced" "Detected in some" "HEK 293: 42.7;PC-3: 14.9;RPTEC TERT1: 14.7;SCLC-21H: 39.7;U-937: 14.2" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in many" 4 "basophil: 5.4;myeloid DC: 6.0;NK-cell: 11.7" "Group enriched" "Detected in many" 5 "dendritic cells: 6.0;granulocytes: 5.4;NK-cells: 11.7" HPA061982 Uncertain Supported Nucleoplasm Nucleoplasm "HPA061982: " "unprognostic (4.72e-1)" "unprognostic (1.23e-2)" "unprognostic (2.86e-1)" "unprognostic (5.24e-3)" "unprognostic (2.36e-1)" "unprognostic (2.02e-1)" "unprognostic (8.35e-2)" "unprognostic (8.44e-3)" "unprognostic (5.50e-2)" "unprognostic (5.71e-2)" "unprognostic (9.87e-3)" "unprognostic (4.42e-2)" "unprognostic (2.80e-3)" "unprognostic (6.45e-2)" "unprognostic (7.58e-2)" "unprognostic (1.92e-2)" "unprognostic (1.35e-1)" 3.2 3.4 0.2 8.8 0.1 2.4 8.7 0.1 0.2 15.5 12.8 0.2 4.1 0.0 10.4 16.8 1.4 12.2 0.3 0.1 0.1 0.0 35.1 0.1 0.8 0.7 0.1 0.1 2.0 0.1 0.0 0.1 1.4 0.4 16.6 4.5 0.2 0.5 5.6 21.0 13.3 8.2 13.1 0.7 1.0 0.0 2.4 0.1 2.6 0.3 0.3 0.3 16.2 11.4 0.5 6.0 5.4 1.0 11.7 1.5 0.5 12.4 0.0 0.0 6.3 2.1 1.6 0.0 5.0 4.0 0.4 0.4 0.8 0.5 0.1 0.5 2.7 11.7 8.1 0.0 0.4 0.0 42.7 0.1 0.3 0.0 0.2 0.0 0.1 2.1 0.0 0.0 0.0 10.5 0.0 0.0 0.4 0.0 0.0 0.3 0.0 14.9 2.7 0.0 0.0 14.7 0.2 39.7 0.0 5.3 0.0 0.1 0.0 10.5 0.4 0.0 4.0 4.8 0.0 0.0 0.0 0.0 0.0 14.2 0.0 5.4 1.0 0.0 1.5 0.2 0.2 0.2 0.0 0.1 6.0 0.5 0.3 0.1 0.9 11.7 0.4 1.9 0.2 0.5 0.2 0.1 0.1 0.2 0.1 0.0 0.1 0.1 0.4 0.1 HOXC11 HOX3H ENSG00000123388 "Homeobox C11" O43248 12 53973126-53977643 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors" "Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "skeletal muscle: 7.0;skin 1: 9.2" "Cell line enhanced" "Detected in some" "AN3-CA: 23.0;BJ hTERT+: 11.6;HaCaT: 10.1;T-47d: 18.1" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA038291 Uncertain Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "HPA038291: AB_10674552" "unprognostic (1.50e-3)" "unprognostic (1.93e-2)" "unprognostic (1.14e-2)" "unprognostic (1.51e-1)" "unprognostic (1.93e-3)" "unprognostic (1.17e-2)" "unprognostic (6.90e-3)" "unprognostic (1.32e-2)" "unprognostic (7.41e-3)" "unprognostic (4.46e-3)" "unprognostic (2.25e-1)" "unprognostic (3.26e-3)" "unprognostic (3.99e-2)" "unprognostic (1.06e-1)" "unprognostic (1.82e-1)" 4.8 0.0 0.1 0.1 0.1 0.0 1.2 0.1 0.1 2.5 0.1 0.1 0.1 0.8 2.0 1.0 0.1 0.7 0.1 0.1 0.1 0.0 2.0 0.1 0.1 0.7 0.1 0.1 0.5 0.1 0.0 0.1 0.6 0.3 0.5 0.0 0.1 0.1 2.0 7.0 9.2 2.7 0.4 0.1 0.1 0.0 1.6 0.1 0.5 0.1 0.1 0.1 1.2 3.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.9 0.7 0.0 23.0 2.2 3.3 0.0 3.3 11.6 4.9 3.6 0.2 0.9 0.0 0.2 3.1 10.1 4.4 0.0 2.2 0.6 0.1 0.1 7.5 0.0 0.0 0.1 0.1 0.6 0.9 0.0 0.3 0.0 0.9 0.0 3.1 1.4 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.4 0.8 0.0 0.1 2.1 5.2 2.0 18.1 0.0 0.0 0.0 4.0 0.3 0.2 0.0 0.0 0.0 0.0 0.3 2.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.3 0.1 HOXC13 "HOX3, HOX3G" ENSG00000123364 "Homeobox C13" P31276 12 53938765-53946544 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes, Disease mutation, Ectodermal dysplasia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "breast: 4.4;skin 1: 13.5;tongue: 4.1" "Cell line enhanced" "Detected in many" "AN3-CA: 15.4;HaCaT: 32.4;SK-BR-3: 17.9;T-47d: 13.8" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA051634 Enhanced "HPA051634: AB_2616459" "unprognostic (5.16e-3)" "unprognostic (1.46e-1)" "unprognostic (1.29e-1)" "unprognostic (2.27e-3)" "unprognostic (2.78e-2)" "unprognostic (1.20e-1)" "unprognostic (2.20e-1)" "unprognostic (4.04e-2)" "unprognostic (1.53e-1)" "unprognostic (9.77e-2)" "unprognostic (9.74e-9)" "unprognostic (2.41e-1)" "unprognostic (1.41e-1)" "unprognostic (1.68e-1)" 2.6 0.0 0.0 0.0 0.0 0.0 4.4 0.0 0.3 0.4 0.5 0.0 0.0 0.0 0.6 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.9 0.0 0.0 2.5 0.0 0.6 13.5 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 4.1 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.4 5.1 0.0 15.4 0.2 0.0 9.2 0.9 2.1 1.4 0.8 1.3 0.2 0.0 0.2 0.0 32.4 3.9 1.0 0.8 0.0 3.1 0.0 4.2 0.0 0.0 0.0 3.3 0.0 7.6 0.0 3.0 0.0 5.5 0.0 5.6 9.5 0.0 0.0 0.1 1.3 0.0 0.2 0.0 0.0 2.9 0.0 0.0 5.1 17.9 2.3 13.8 0.0 0.0 0.0 6.7 0.1 2.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 HOXD11 "HOX4, HOX4F" ENSG00000128713 "Homeobox D11" P31277 2 176104216-176109754 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "No human protein/transcript evidence" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "endometrium 1: 15.8" "Cell line enhanced" "Detected in some" "HEK 293: 20.3;SCLC-21H: 6.2;U-251 MG: 4.6" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA055155 Supported Nucleoplasm Nucleoplasm "HPA055155: " "unprognostic (1.99e-1)" "unprognostic (1.48e-1)" "unprognostic (2.32e-2)" "unprognostic (9.05e-2)" "unprognostic (1.85e-3)" "unprognostic (2.48e-1)" "unprognostic (1.93e-2)" "unprognostic (2.13e-2)" "unprognostic (6.73e-2)" "unprognostic (5.00e-2)" "unprognostic (2.11e-8)" "unprognostic (2.09e-3)" "unprognostic (2.49e-2)" "unprognostic (2.27e-3)" 0.0 0.0 0.0 0.7 0.3 0.0 0.0 0.0 0.0 5.4 4.2 0.0 0.0 0.0 15.8 0.4 0.3 0.1 0.0 0.0 0.0 0.0 5.5 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 1.6 0.3 5.7 0.9 0.0 0.0 2.9 0.0 0.2 0.0 1.7 0.0 0.0 0.0 0.6 0.0 0.0 0.2 0.0 0.0 1.0 5.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.5 0.0 0.0 0.0 0.0 0.0 0.4 0.0 1.2 0.0 0.0 0.1 0.0 20.3 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.6 0.3 6.2 0.3 2.4 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 4.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 HOXD13 "HOX4I, SPD" ENSG00000128714 "Homeobox D13" P35453 2 176092891-176095938 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "cervix, uterine: 14.0;intestine: 13.1;prostate: 13.8;seminal vesicle: 19.0;vagina: 15.0" "Group enriched" "Detected in some" 4 "HAP1: 9.6;HEK 293: 27.6;HL-60: 30.7;NB-4: 18.3;SCLC-21H: 8.0" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA064064 Approved Nucleoplasm Nucleoplasm "HPA064064: " "unprognostic (2.04e-1)" "unprognostic (1.13e-1)" "prognostic unfavourable (6.95e-5)" "unprognostic (2.52e-3)" "unprognostic (7.25e-2)" "unprognostic (2.08e-2)" "unprognostic (4.62e-2)" "unprognostic (1.77e-1)" "unprognostic (4.66e-1)" "unprognostic (1.01e-2)" "unprognostic (2.82e-4)" "unprognostic (4.95e-2)" "unprognostic (3.70e-2)" "unprognostic (9.98e-3)" 0.4 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.2 14.0 13.1 0.1 0.1 0.0 0.3 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.3 0.1 0.0 0.1 0.1 0.1 13.8 8.8 0.1 0.1 19.0 0.6 0.0 0.1 3.7 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 3.8 15.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.6 0.0 1.1 2.5 0.0 0.0 0.0 0.0 0.0 0.0 9.6 0.0 1.5 0.0 27.6 4.2 0.0 0.0 0.0 30.7 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.0 0.0 0.0 18.3 0.9 1.5 0.0 0.1 0.0 0.0 0.2 8.0 1.9 1.9 0.0 4.4 0.0 0.0 0.0 1.0 0.0 0.4 2.5 0.0 0.0 0.0 1.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.2 0.1 0.0 0.1 0.1 0.1 0.1 HP ENSG00000257017 Haptoglobin P00738 16 72054592-72061055 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins" "Acute phase, Immunity" "Antibiotic, Antimicrobial, Antioxidant, Serine protease homolog" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 37 "liver: 1156.9" "Group enriched" "Detected in some" 5 "Hep G2: 64.7;HSkMC: 37.1" "Cancer enriched" "Detected in many" 81 "liver cancer: 1297.4" "Not detected" "Not detected" "Group enriched" "Detected in some" 4 "classical monocyte: 20.0;eosinophil: 30.9" "Group enriched" "Detected in many" 7 "granulocytes: 30.9;monocytes: 20.0" "CAB003787, HPA047750" Enhanced Approved Vesicles "Secreted to blood" 181000000 140000000000 Vesicles "CAB003787: , HPA047750: " "unprognostic (6.38e-3)" "unprognostic (7.73e-3)" "unprognostic (1.23e-1)" "unprognostic (2.41e-2)" "unprognostic (2.34e-3)" "unprognostic (2.07e-1)" "unprognostic (7.79e-3)" "unprognostic (1.37e-1)" "unprognostic (2.31e-1)" "unprognostic (1.84e-1)" "unprognostic (6.30e-2)" "unprognostic (8.18e-2)" "prognostic unfavourable (6.94e-13)" "unprognostic (4.34e-4)" "unprognostic (1.80e-1)" "unprognostic (6.61e-2)" "unprognostic (2.49e-2)" 9.8 0.0 0.3 0.4 0.3 4.4 0.3 0.3 0.3 1.5 0.4 0.3 0.3 0.0 0.3 0.5 0.3 1.1 0.3 3.0 0.3 0.0 0.4 1156.9 1.4 0.4 0.3 0.3 0.3 0.5 0.0 0.5 0.3 0.3 0.3 0.0 0.3 0.3 0.3 0.3 0.0 0.3 0.3 0.3 1.4 0.0 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.5 0.0 3.5 30.9 20.0 0.0 0.0 5.0 0.0 0.0 0.0 0.0 2.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 2.4 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 3.3 0.0 64.7 0.1 9.2 1.7 37.1 0.0 0.0 0.0 0.0 2.4 0.0 0.0 0.0 0.5 0.1 0.7 0.0 0.3 6.9 0.0 0.0 0.0 0.0 0.0 4.7 0.0 0.0 0.0 2.1 1.4 0.0 0.2 0.0 0.0 1.2 0.0 4.4 0.0 3.6 0.0 2.6 20.0 30.9 0.0 0.8 0.0 0.0 0.0 0.0 3.5 0.0 0.0 0.0 5.8 0.0 0.9 0.0 0.0 5.0 0.3 0.3 0.3 0.3 0.3 0.0 0.3 0.3 0.3 0.3 HPGD SDR36C1 ENSG00000164120 "15-hydroxyprostaglandin dehydrogenase" P15428 4 174490177-174523154 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Fatty acid metabolism, Lipid metabolism, Prostaglandin metabolism" Oxidoreductase "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "placenta: 193.3" "Cell line enhanced" "Detected in some" "A549: 27.3;ASC diff: 16.9;HEL: 59.7;RT4: 92.8" "Cancer enhanced" "Detected in many" "urothelial cancer: 52.4" "Region enriched" "Detected in single" 4 "pons and medulla: 3.8" "Group enriched" "Detected in many" 5 "basophil: 37.7;T-reg: 15.1" "Group enriched" "Detected in many" 71 "granulocytes: 37.7;T-cells: 15.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004919, HPA005679" Enhanced Supported Nucleoplasm,Cytosol Cytosol Nucleoplasm "HPA004919: AB_1079081, HPA005679: AB_1079080" "unprognostic (1.23e-3)" "unprognostic (1.61e-1)" "unprognostic (5.96e-2)" "unprognostic (1.25e-1)" "unprognostic (1.09e-2)" "unprognostic (2.53e-2)" "unprognostic (1.27e-1)" "unprognostic (2.23e-1)" "unprognostic (1.08e-1)" "unprognostic (4.28e-2)" "unprognostic (3.54e-3)" "unprognostic (2.34e-2)" "prognostic favourable (3.20e-4)" "unprognostic (2.44e-1)" "unprognostic (2.59e-1)" "unprognostic (1.37e-4)" "unprognostic (2.33e-2)" 5.1 2.6 0.5 7.9 0.6 0.0 24.6 0.4 0.6 23.0 73.3 0.5 2.5 22.9 13.4 7.5 32.0 4.5 10.7 1.2 0.6 0.7 8.5 63.7 22.9 7.9 0.8 0.5 2.3 0.4 0.0 0.9 193.3 3.8 20.1 8.4 4.6 3.0 1.1 1.6 15.3 64.5 9.3 0.5 2.9 36.3 1.9 0.5 5.5 0.4 5.0 7.9 61.2 31.8 0.1 0.2 37.7 0.1 0.3 15.1 1.0 0.0 27.3 0.0 0.0 16.9 1.0 0.0 0.0 0.0 0.0 0.0 7.9 0.0 0.0 0.0 0.0 2.5 2.5 0.0 0.0 0.0 0.5 59.7 2.0 0.0 0.0 0.3 0.1 0.9 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.2 1.4 2.8 0.0 0.2 5.6 92.8 0.1 0.1 0.0 0.2 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.2 0.0 0.0 0.0 0.0 0.0 37.7 0.1 5.4 3.7 0.0 5.7 0.1 1.9 1.6 0.2 0.0 0.6 1.5 0.4 0.3 0.0 0.0 15.1 1.0 0.5 0.6 0.4 0.6 0.6 0.7 0.8 0.5 3.8 0.5 HPN TMPRSS1 ENSG00000105707 Hepsin P05981 19 35040506-35066571 "Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins" "Hydrolase, Protease, Serine protease" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 9 "kidney: 55.4;liver: 146.5;pancreas: 80.1" "Group enriched" "Detected in some" 9 "EFO-21: 19.4;Hep G2: 27.5;T-47d: 13.4" "Cancer enhanced" "Detected in many" "liver cancer: 127.5" "Low region specificity" "Detected in single" "Cell type enhanced" "Detected in some" "memory CD8 T-cell: 1.2;naive CD8 T-cell: 1.2" "Lineage enriched" "Detected in single" 5 "T-cells: 1.2" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" HPA006804 Approved 1000000 "HPA006804: AB_1079046" "unprognostic (6.74e-3)" "unprognostic (6.00e-2)" "unprognostic (4.10e-2)" "unprognostic (1.16e-1)" "unprognostic (2.72e-1)" "unprognostic (9.96e-2)" "unprognostic (4.22e-3)" "unprognostic (1.27e-1)" "unprognostic (4.13e-3)" "unprognostic (9.54e-2)" "unprognostic (3.54e-1)" "unprognostic (1.16e-1)" "prognostic favourable (5.45e-5)" "unprognostic (1.22e-1)" "unprognostic (1.52e-1)" "unprognostic (1.12e-1)" "unprognostic (7.96e-2)" 0.2 0.0 0.3 0.1 0.5 0.0 3.2 0.4 1.1 0.3 0.3 0.2 8.4 0.2 1.1 10.7 0.1 1.9 3.2 0.7 0.6 0.3 55.4 146.5 4.9 0.1 0.9 0.2 0.4 80.1 2.6 3.2 0.2 0.4 5.3 0.0 0.4 4.1 8.5 8.5 0.0 0.2 0.1 0.9 0.3 6.9 0.8 0.3 0.1 4.3 0.4 0.2 0.3 0.1 0.2 0.2 0.0 0.1 0.0 1.2 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 2.1 0.0 0.1 19.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 27.5 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.1 0.2 0.0 0.0 0.0 2.0 0.1 0.1 0.0 0.1 13.4 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.2 0.0 0.1 0.0 1.0 0.0 0.6 0.2 0.5 1.2 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.2 0.0 0.3 0.3 0.5 0.4 1.1 0.6 0.3 0.9 0.2 0.4 0.3 HRAS HRAS1 ENSG00000174775 "HRas proto-oncogene, GTPase" P01112 11 532242-537287 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002015, HPA049830, HPA070222" Approved Approved Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "CAB002015: , HPA049830: , HPA070222: " "unprognostic (3.06e-2)" "unprognostic (2.98e-2)" "unprognostic (7.01e-2)" "unprognostic (3.08e-3)" "unprognostic (3.49e-3)" "unprognostic (3.87e-1)" "prognostic unfavourable (2.32e-4)" "unprognostic (1.07e-1)" "unprognostic (2.25e-1)" "unprognostic (1.50e-1)" "unprognostic (2.88e-3)" "unprognostic (9.85e-2)" "unprognostic (2.81e-1)" "unprognostic (1.85e-1)" "unprognostic (1.80e-1)" "unprognostic (1.58e-2)" "unprognostic (1.38e-1)" 12.3 11.4 25.2 9.1 34.5 5.0 16.2 16.1 25.3 7.9 9.5 8.1 10.8 8.9 6.2 9.2 22.3 8.3 10.9 28.7 22.2 22.4 8.2 6.5 8.9 8.0 23.2 12.9 7.7 9.7 11.7 10.3 10.1 15.0 10.0 6.2 8.2 10.1 12.7 51.8 32.0 8.2 8.4 17.0 6.5 7.2 6.1 11.0 5.9 8.1 24.5 9.3 9.9 19.8 2.1 1.1 0.7 4.6 0.1 2.0 0.3 21.8 19.4 9.3 8.3 5.8 4.1 12.0 10.9 5.8 17.1 14.6 9.8 8.7 8.4 3.4 14.8 17.4 9.9 26.5 4.8 6.9 22.1 4.3 7.8 8.5 8.8 3.4 3.3 6.2 29.6 9.2 10.0 8.5 8.8 12.3 9.6 17.9 12.7 12.1 9.4 19.3 10.2 11.8 7.5 9.6 5.4 36.3 14.4 10.1 18.1 7.8 14.8 6.7 13.5 15.3 12.1 5.6 14.0 4.6 6.1 6.5 14.4 6.3 14.3 0.0 0.6 0.7 1.4 1.2 1.6 0.8 1.4 1.3 0.7 2.1 2.0 0.6 0.0 0.1 4.6 1.1 2.0 0.3 25.2 34.5 16.1 21.1 22.2 22.4 23.2 12.9 15.0 11.0 HSF1 HSTF1 ENSG00000185122 "Heat shock transcription factor 1" Q00613 8 144291591-144314722 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "DNA damage, DNA repair, Host-virus interaction, mRNA processing, mRNA transport, Stress response, Transcription, Transcription regulation, Transport" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004239, HPA008888" Supported Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "CAB004239: AB_627753, HPA008888: AB_1079088" "unprognostic (7.08e-2)" "unprognostic (1.89e-2)" "unprognostic (6.07e-2)" "prognostic unfavourable (8.93e-4)" "unprognostic (1.55e-1)" "unprognostic (5.63e-2)" "prognostic unfavourable (4.95e-4)" "unprognostic (5.69e-3)" "unprognostic (1.05e-1)" "unprognostic (4.35e-2)" "unprognostic (1.40e-2)" "unprognostic (1.47e-1)" "unprognostic (1.41e-1)" "unprognostic (1.07e-2)" "unprognostic (2.23e-1)" "unprognostic (2.13e-1)" "unprognostic (1.12e-1)" 24.7 22.9 17.4 21.0 20.9 20.8 30.8 24.4 23.6 21.3 26.9 18.3 17.7 18.9 23.3 16.7 25.5 28.5 22.9 42.8 17.0 17.5 21.2 19.5 20.3 23.6 17.4 15.9 32.4 36.8 25.8 21.8 22.8 17.8 26.7 15.2 20.7 26.4 24.6 55.2 20.3 17.8 35.1 14.4 20.3 23.6 42.6 17.8 23.2 29.9 24.2 19.8 30.3 33.9 16.9 20.3 20.3 24.2 12.9 18.4 14.2 14.6 19.9 8.6 7.3 14.5 13.6 14.3 11.0 10.0 10.9 9.5 13.3 12.9 16.9 16.2 15.2 10.7 13.1 15.8 7.0 10.7 15.1 21.2 20.4 18.1 22.9 6.1 16.4 13.2 14.9 15.3 28.3 14.7 14.0 10.2 10.9 29.7 20.6 9.4 11.0 57.4 13.4 7.5 21.4 7.8 14.9 13.0 10.5 16.8 13.5 19.4 15.2 12.6 14.8 11.2 25.4 17.6 18.0 7.1 5.4 14.5 16.0 11.5 10.7 10.6 18.9 20.3 14.5 19.9 15.2 16.9 15.7 18.4 20.3 15.5 15.6 13.9 8.1 12.9 24.2 10.3 18.1 14.2 17.4 20.9 24.4 23.6 17.0 17.5 17.4 15.9 17.8 17.8 HSP90AA1 "FLJ31884, Hsp89, Hsp90, HSP90N, HSPC1, HSPCA" ENSG00000080824 "Heat shock protein 90 alpha family class A member 1" P07900 14 102080738-102139699 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction, Stress response" Chaperone "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "vagina: 519.3" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB002058 Approved Supported Cytosol 94000000 Cytosol "CAB002058: " "prognostic unfavourable (5.59e-4)" "unprognostic (3.77e-2)" "unprognostic (1.78e-2)" "unprognostic (9.25e-2)" "unprognostic (2.53e-1)" "unprognostic (1.05e-3)" "prognostic unfavourable (3.09e-5)" "unprognostic (7.79e-3)" "unprognostic (5.71e-2)" "unprognostic (7.81e-3)" "unprognostic (3.68e-2)" "unprognostic (1.65e-2)" "prognostic favourable (1.18e-5)" "unprognostic (1.04e-1)" "unprognostic (2.54e-1)" "unprognostic (1.43e-1)" "unprognostic (1.12e-1)" 50.8 75.3 96.1 46.7 106.8 64.1 118.6 81.3 113.4 51.0 47.3 50.7 43.0 31.0 40.7 55.5 40.9 94.7 61.0 70.9 99.6 113.3 75.6 62.5 51.7 48.1 134.4 58.6 53.4 40.1 94.9 121.6 67.2 143.6 63.2 53.3 23.4 57.0 57.0 65.2 35.6 38.9 51.0 139.7 35.7 41.3 84.6 132.7 53.5 91.5 34.3 59.5 54.2 519.3 30.7 46.9 31.8 29.9 57.7 63.1 21.9 86.3 118.1 75.4 52.0 45.8 38.8 100.2 96.1 46.2 117.9 66.5 71.7 81.2 106.2 90.5 61.8 95.9 216.5 94.0 215.1 80.3 71.3 82.0 67.5 91.5 22.7 122.0 63.3 36.4 40.0 75.3 27.8 65.0 113.2 54.6 106.6 116.8 130.4 56.1 78.4 111.7 125.8 102.5 45.8 68.4 111.7 99.4 71.7 121.5 91.5 53.6 117.6 48.7 46.0 82.5 53.4 122.6 182.5 51.7 161.1 157.1 78.1 75.4 99.4 31.8 19.9 24.0 47.8 29.9 63.1 29.6 40.5 49.0 23.9 30.7 30.1 43.5 13.5 57.7 27.5 46.9 39.2 21.9 96.1 106.8 81.3 102.7 99.6 113.3 134.4 58.6 143.6 132.7 HSP90AB1 "HSPC2, HSPCB" ENSG00000096384 "Heat shock protein 90 alpha family class B member 1" P08238 6 44246166-44253888 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Stress response" Chaperone "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB005230, HPA055729, HPA072606, HPA074351" Enhanced Supported Cytosol "Intracellular and membrane" 62000000 Cytosol "CAB005230: AB_2121392, HPA055729: AB_2682899, HPA072606: AB_2732203, HPA074351: AB_2732252" "unprognostic (6.12e-3)" "unprognostic (2.96e-3)" "unprognostic (4.72e-2)" "unprognostic (9.24e-2)" "unprognostic (4.20e-1)" "unprognostic (1.15e-3)" "unprognostic (1.76e-3)" "unprognostic (2.74e-1)" "unprognostic (7.97e-2)" "prognostic favourable (4.03e-4)" "unprognostic (1.31e-1)" "unprognostic (1.60e-1)" "prognostic unfavourable (9.94e-4)" "unprognostic (3.02e-1)" "unprognostic (9.53e-2)" "unprognostic (2.63e-1)" "unprognostic (1.06e-1)" 79.9 116.1 88.0 65.9 105.0 74.6 107.8 92.1 118.2 92.3 60.4 61.7 80.9 40.6 113.3 107.6 71.6 138.4 63.8 115.0 89.0 110.5 72.0 70.7 76.2 73.8 109.7 94.4 238.4 113.9 151.6 95.3 83.6 133.7 93.5 76.4 52.7 64.8 100.3 197.1 67.9 49.0 102.1 93.9 57.5 77.3 45.9 100.2 58.3 133.8 89.8 102.5 86.2 223.4 75.9 50.5 7.2 45.7 55.7 82.5 74.9 138.6 89.0 79.1 97.1 54.3 56.9 82.8 62.7 61.5 116.1 81.8 133.0 42.5 177.7 68.0 65.2 80.9 192.3 93.3 143.7 58.8 77.8 138.3 50.4 173.8 39.3 138.0 95.8 52.5 63.2 91.2 78.8 111.1 184.5 66.3 78.9 140.0 114.9 83.3 92.2 68.2 110.9 80.8 97.5 78.5 84.4 115.8 70.8 48.7 70.6 87.9 91.8 69.1 69.6 69.3 116.0 56.6 143.1 76.8 120.4 321.0 75.3 101.5 78.9 7.2 30.2 6.8 49.3 45.7 82.5 75.9 55.2 56.4 50.5 63.2 75.2 71.3 3.7 55.7 43.3 31.4 42.6 74.9 88.0 105.0 92.1 118.2 89.0 110.5 109.7 94.4 133.7 100.2 HSP90B1 "GP96, GRP94, TRA1" ENSG00000166598 "Heat shock protein 90 beta family member 1" P14625 12 103930107-103953645 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" Chaperone "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 325.1;thyroid gland: 338.5" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003901, CAB005224, HPA008424, CAB078151" Enhanced Enhanced "Endoplasmic reticulum" "Intracellular and membrane" 410000000 "Endoplasmic reticulum" "CAB005224: AB_2119181, CAB078151: , HPA003901: AB_1851181, HPA008424: AB_1851184" "unprognostic (1.03e-1)" "unprognostic (3.44e-2)" "unprognostic (1.18e-1)" "unprognostic (5.70e-2)" "unprognostic (1.17e-2)" "unprognostic (7.14e-3)" "unprognostic (3.00e-2)" "unprognostic (7.22e-2)" "unprognostic (8.77e-2)" "unprognostic (8.30e-2)" "unprognostic (2.76e-1)" "unprognostic (1.43e-2)" "prognostic unfavourable (1.03e-10)" "unprognostic (2.95e-1)" "unprognostic (2.39e-1)" "unprognostic (1.24e-1)" "unprognostic (1.28e-2)" 49.0 57.1 26.9 50.0 32.0 45.9 60.3 16.5 25.5 45.7 43.4 17.5 108.5 32.1 42.2 127.2 34.3 42.0 32.4 67.0 27.1 32.0 74.0 325.1 46.6 49.2 31.5 26.0 53.9 95.5 47.1 50.0 123.6 29.4 46.9 46.9 15.8 43.8 136.8 25.4 19.2 54.4 45.0 37.8 89.3 37.0 25.7 27.9 44.5 338.5 24.0 36.9 66.1 106.1 25.6 81.0 22.2 23.8 40.2 53.3 33.9 79.2 43.0 86.8 89.1 88.9 84.0 117.8 133.6 101.0 71.2 95.1 76.6 74.3 23.2 106.3 140.2 55.4 85.4 143.5 96.1 54.8 32.6 62.3 48.5 79.0 137.1 62.8 48.9 49.2 64.0 87.6 125.8 136.9 49.8 88.2 94.0 28.5 37.7 70.3 71.3 51.8 34.4 56.0 96.9 95.2 50.0 25.8 61.8 83.4 86.3 84.3 70.2 93.3 78.7 53.9 46.2 43.8 55.7 90.3 84.5 42.9 107.4 46.5 83.4 22.2 21.2 6.9 45.6 23.8 53.3 25.6 26.7 39.3 28.0 15.9 18.0 31.3 4.9 40.2 19.3 81.0 16.4 33.9 26.9 32.0 16.5 25.5 27.1 32.0 31.5 26.0 29.4 27.9 HSPA1L "HSP70-HOM, hum70t" ENSG00000204390 "Heat shock protein family A (Hsp70) member 1 like" P34931 6 31809619-31815065 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "testis: 29.1;vagina: 17.0" "Cell line enhanced" "Detected in some" "ASC diff: 1.9;EFO-21: 2.1;HEK 293: 6.7;U-266/70: 2.8;U-266/84: 2.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in some" "Lineage enriched" "Detected in single" 4 "T-cells: 1.7" "Low region specificity" "Detected in single" "Low region specificity" "Detected in some" "HPA043285, HPA052504" Enhanced Approved Nucleoplasm,Vesicles 49000000 Vesicles Nucleoplasm "HPA043285: AB_10962482, HPA052504: " "unprognostic (1.80e-1)" "unprognostic (8.70e-2)" "unprognostic (2.52e-3)" "unprognostic (6.97e-4)" "unprognostic (2.69e-2)" "unprognostic (1.17e-2)" "unprognostic (4.24e-2)" "unprognostic (4.33e-2)" "unprognostic (1.71e-1)" "prognostic favourable (1.02e-4)" "unprognostic (5.26e-3)" "unprognostic (9.96e-2)" "prognostic favourable (4.63e-4)" "unprognostic (4.48e-2)" "unprognostic (4.30e-1)" "unprognostic (1.02e-1)" "unprognostic (1.53e-3)" 0.4 0.5 1.8 0.5 2.2 0.5 1.2 1.4 3.1 0.5 0.7 1.5 0.0 0.3 0.8 3.0 0.8 1.5 0.3 0.5 2.0 1.1 0.9 0.7 1.7 0.7 4.5 0.8 1.1 1.5 0.3 0.7 1.0 2.6 1.2 0.6 0.2 0.4 1.5 3.9 0.6 0.8 0.5 4.6 1.1 0.8 29.1 3.2 0.0 2.0 0.0 0.7 0.5 17.0 0.3 0.0 0.4 0.1 0.0 1.7 1.1 0.0 1.7 0.0 0.0 1.9 1.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 2.1 0.5 0.0 0.0 0.9 0.0 0.0 6.7 0.0 0.0 0.2 0.2 1.4 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.0 0.2 0.0 0.2 0.7 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.2 0.0 0.0 0.2 0.3 0.0 2.8 2.4 0.0 1.7 0.0 0.0 0.0 0.1 0.4 0.4 0.0 0.0 0.0 1.0 1.3 0.0 0.3 1.5 1.6 0.3 0.0 0.0 0.0 1.7 1.1 1.8 2.2 1.4 3.1 2.0 1.1 4.5 0.8 2.6 3.2 HSPA2 ENSG00000126803 "Heat shock protein family A (Hsp70) member 2" P54652 14 64535905-64546173 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Differentiation, Spermatogenesis, Stress response" Chaperone "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 87.0;skeletal muscle: 90.5" "Cell line enhanced" "Detected in many" "A549: 24.6;BEWO: 38.4;BJ hTERT+: 32.8;SCLC-21H: 34.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA000798, HPA052504" Enhanced Supported Approved Nucleoplasm,Vesicles 77000000 Vesicles Nucleoplasm "HPA000798: AB_1079090, HPA052504: " "prognostic favourable (1.78e-4)" "unprognostic (1.72e-1)" "unprognostic (2.73e-1)" "unprognostic (1.08e-2)" "unprognostic (3.78e-2)" "unprognostic (2.90e-2)" "unprognostic (7.11e-2)" "prognostic unfavourable (9.11e-4)" "unprognostic (1.31e-1)" "unprognostic (3.14e-2)" "unprognostic (2.09e-1)" "unprognostic (2.60e-1)" "unprognostic (5.31e-2)" "unprognostic (1.14e-1)" "unprognostic (1.90e-1)" "unprognostic (8.36e-2)" "unprognostic (1.25e-1)" 5.2 3.3 21.1 5.2 45.3 1.5 5.2 3.7 37.6 3.3 23.3 87.0 0.1 4.4 13.8 12.8 25.2 7.2 4.2 22.8 33.2 18.7 26.6 2.6 4.5 3.2 71.0 20.6 2.4 3.8 7.5 4.3 37.6 37.7 3.8 6.9 3.5 10.2 4.0 90.5 14.8 7.8 17.9 83.8 8.5 5.7 58.8 65.2 0.0 2.3 8.2 3.9 12.4 4.0 0.7 0.3 2.4 0.6 0.9 3.7 0.5 9.6 24.6 3.8 0.0 2.7 0.2 38.4 13.9 32.8 5.6 9.2 0.9 17.4 2.4 5.6 15.1 11.0 0.0 0.7 3.4 1.3 1.9 0.0 1.4 0.0 2.7 0.0 3.3 1.2 0.5 0.8 0.0 0.3 0.0 2.0 2.7 4.3 0.1 0.1 2.8 3.0 1.9 0.0 0.0 8.6 1.5 34.1 1.9 0.6 1.2 0.0 0.9 1.0 0.5 0.1 0.0 1.2 0.0 2.5 0.0 0.0 3.1 0.0 3.7 0.9 0.2 0.1 1.8 0.4 0.1 0.7 1.7 0.8 0.0 0.5 0.6 0.6 2.4 0.9 0.6 0.3 3.7 0.5 21.1 45.3 3.7 28.3 33.2 18.7 71.0 20.6 37.7 65.2 HSPA4 "HS24/P52, HSPH2" ENSG00000170606 "Heat shock protein family A (Hsp70) member 4" P34932 5 133051962-133106449 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Stress response" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA010023, CAB025529" Uncertain Supported Nucleoplasm,Cytosol 10000000 "Nucleoplasm, Cytosol" "CAB025529: , HPA010023: AB_1851206" "unprognostic (2.54e-2)" "unprognostic (3.59e-1)" "unprognostic (2.91e-2)" "unprognostic (2.62e-1)" "unprognostic (5.30e-2)" "unprognostic (2.52e-3)" "prognostic unfavourable (4.13e-4)" "unprognostic (2.31e-3)" "unprognostic (2.90e-1)" "unprognostic (2.40e-1)" "unprognostic (1.53e-1)" "unprognostic (2.85e-1)" "unprognostic (4.44e-3)" "unprognostic (2.54e-1)" "unprognostic (1.09e-1)" "unprognostic (4.05e-2)" "unprognostic (1.41e-1)" 20.6 35.0 26.6 25.6 27.6 20.5 39.0 25.9 35.6 19.4 20.5 18.7 19.9 17.4 23.3 20.2 42.0 19.2 18.9 32.9 26.4 31.9 30.3 31.1 17.2 28.9 30.9 24.5 23.2 19.5 37.1 32.8 24.5 34.3 18.9 23.9 16.0 20.3 19.2 48.3 19.6 18.5 23.6 25.9 20.0 20.9 39.8 29.5 27.3 26.8 24.8 38.6 24.5 77.1 27.7 17.9 15.5 23.0 14.1 14.9 11.5 34.2 47.2 33.0 53.7 31.4 26.5 59.9 37.6 28.3 36.5 45.3 88.6 36.0 57.0 39.6 36.1 30.6 57.2 62.2 52.9 26.3 32.8 42.0 31.7 48.5 25.1 26.0 36.9 26.3 26.3 47.0 30.9 34.8 43.9 17.7 39.8 30.2 36.6 19.4 45.2 21.9 33.6 40.4 30.3 33.0 45.2 26.3 21.6 35.8 18.8 50.0 27.6 25.6 30.4 33.3 47.9 28.4 44.5 20.3 45.0 43.8 28.5 43.3 33.0 14.8 14.4 15.5 12.6 23.0 14.9 22.6 11.6 13.0 17.9 27.7 12.1 11.2 9.6 14.1 16.4 6.8 11.3 11.5 26.6 27.6 25.9 35.6 26.4 31.9 30.9 24.5 34.3 29.5 HSPA8 "HSC70, HSC71, HSP73, HSPA10" ENSG00000109971 "Heat shock protein family A (Hsp70) member 8" P11142 11 123057489-123063230 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction, mRNA processing, mRNA splicing, Stress response, Transcription, Transcription regulation" "Chaperone, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002056, HPA052504" Uncertain Approved Nucleoplasm,Vesicles 210000000 Nucleoplasm Vesicles "CAB002056: , HPA052504: " "unprognostic (2.28e-3)" "unprognostic (1.19e-3)" "prognostic favourable (6.14e-6)" "unprognostic (1.75e-1)" "unprognostic (1.84e-2)" "unprognostic (5.70e-2)" "prognostic unfavourable (1.93e-4)" "unprognostic (9.65e-3)" "unprognostic (3.82e-1)" "unprognostic (9.64e-2)" "unprognostic (2.93e-1)" "unprognostic (3.22e-1)" "prognostic favourable (3.81e-4)" "unprognostic (2.53e-1)" "unprognostic (1.83e-1)" "unprognostic (2.74e-1)" "unprognostic (7.16e-2)" 70.0 96.8 93.7 78.1 102.8 58.1 73.8 119.5 125.1 52.8 64.1 72.0 77.3 77.7 59.9 98.3 83.4 76.2 76.7 106.4 83.1 102.4 128.6 114.2 68.9 93.3 105.7 72.4 66.7 191.1 97.2 98.3 71.6 169.2 65.3 81.0 53.1 62.4 69.9 224.6 31.2 74.4 75.4 91.8 79.7 92.7 58.3 98.1 92.9 90.9 98.3 124.4 76.1 123.2 77.4 47.5 41.1 84.2 76.1 124.3 200.0 82.8 125.6 83.4 72.0 77.2 82.8 110.5 164.7 91.3 201.5 121.3 188.4 109.0 134.9 104.0 91.6 112.9 238.2 59.7 201.2 116.6 36.2 146.4 59.0 91.8 21.1 142.2 112.5 44.1 96.6 61.9 19.3 107.8 158.4 70.2 161.4 73.8 147.8 105.6 131.9 111.9 133.4 59.5 76.3 104.4 60.6 85.6 64.9 120.0 130.3 45.4 113.6 55.7 105.9 101.2 81.3 87.0 145.9 47.4 116.9 115.8 112.8 203.3 122.1 30.3 41.5 41.1 96.5 82.9 115.9 77.4 113.4 105.2 47.5 53.7 109.6 105.1 14.9 76.1 84.2 34.4 124.3 200.0 93.7 102.8 119.5 125.1 83.1 102.4 105.7 72.4 169.2 98.1 HSPB1 "CMT2F, Hs.76067, Hsp25, HSP27, HSP28" ENSG00000106211 "Heat shock protein family B (small) member 1" P04792 7 76302544-76304295 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction, Stress response" Chaperone "Cancer-related genes, Charcot-Marie-Tooth disease, Disease mutation, Neurodegeneration, Neuropathy" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "vagina: 565.5" "Cell line enhanced" "Detected in many" "hTCEpi: 162.0;MCF7: 227.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA000497, CAB004439, CAB047330, CAB047331, CAB047332" Enhanced Enhanced "Plasma membrane,Cytosol" 57000000 "Plasma membrane, Cytosol" "CAB004439: AB_627755, CAB047330: , CAB047331: , CAB047332: , HPA000497: AB_1851172" "unprognostic (2.55e-1)" "unprognostic (7.25e-3)" "prognostic unfavourable (9.94e-5)" "unprognostic (7.07e-3)" "unprognostic (3.47e-3)" "unprognostic (6.61e-3)" "unprognostic (4.08e-3)" "unprognostic (4.50e-2)" "unprognostic (1.27e-1)" "unprognostic (9.78e-2)" "unprognostic (8.70e-2)" "unprognostic (2.21e-1)" "unprognostic (5.72e-2)" "unprognostic (5.18e-2)" "unprognostic (2.67e-1)" "unprognostic (2.56e-1)" "unprognostic (3.63e-1)" 67.6 41.7 23.0 42.9 22.8 7.3 186.2 10.1 21.3 127.6 84.9 10.8 89.2 27.1 126.5 65.9 410.5 57.7 52.2 164.8 21.4 22.5 85.4 26.3 43.3 25.1 25.7 14.3 63.4 34.7 16.6 15.5 106.9 32.8 99.6 12.0 31.1 50.5 101.3 439.2 164.4 24.6 139.7 27.3 17.8 37.6 22.0 23.4 31.9 72.9 207.3 126.8 146.2 565.5 27.8 17.8 4.1 27.9 23.2 36.8 14.4 72.6 54.0 5.8 43.1 35.1 31.1 0.3 30.9 16.3 16.8 21.1 4.8 42.6 0.6 23.9 40.0 66.7 25.3 18.1 5.4 40.5 8.5 3.3 41.7 22.8 18.8 4.9 30.5 38.6 162.0 25.3 3.7 55.4 26.4 74.3 19.2 227.6 8.3 33.6 29.6 47.3 25.7 11.9 59.0 24.9 27.7 0.4 33.1 21.7 88.6 27.6 104.4 34.8 29.9 50.5 75.3 15.7 77.9 5.2 8.6 0.7 36.9 15.2 36.7 4.1 4.5 2.8 18.6 21.1 9.6 27.5 30.6 20.2 11.1 27.8 36.8 31.5 1.7 23.2 27.9 17.8 19.7 14.4 23.0 22.8 10.1 21.3 21.4 22.5 25.7 14.3 32.8 23.4 HSPD1 "GroEL, HSP60, SPG13" ENSG00000144381 "Heat shock protein family D (Hsp60) member 1" P10809 2 197486581-197516737 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Host-virus interaction" "Chaperone, Isomerase" "Cancer-related genes, Disease mutation, Hereditary spastic paraplegia, Leukodystrophy, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "vagina: 162.6" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "HPA001523, CAB002775, HPA050025, CAB072816" Supported Enhanced Mitochondria 53000000 Mitochondria "CAB002775: , CAB072816: , HPA001523: AB_1079028, HPA050025: AB_2680995" "unprognostic (2.79e-2)" "unprognostic (1.72e-2)" "unprognostic (5.21e-2)" "prognostic unfavourable (1.61e-4)" "unprognostic (2.59e-1)" "unprognostic (3.57e-3)" "prognostic unfavourable (2.25e-4)" "unprognostic (3.51e-2)" "unprognostic (9.91e-2)" "unprognostic (8.63e-3)" "unprognostic (3.47e-2)" "unprognostic (7.83e-3)" "unprognostic (5.64e-3)" "unprognostic (1.73e-2)" "unprognostic (1.52e-1)" "unprognostic (2.61e-2)" "unprognostic (4.10e-2)" 28.5 125.2 28.7 23.4 31.8 21.0 55.9 18.2 24.3 17.4 30.3 17.8 23.3 28.9 17.5 18.5 27.2 25.3 16.3 24.0 24.2 27.8 67.1 147.5 22.4 25.3 35.5 16.1 30.2 50.6 32.5 25.9 27.1 33.6 25.9 37.2 11.9 17.6 21.0 36.4 13.7 32.0 23.6 32.4 22.7 25.2 10.9 35.8 22.7 38.7 29.4 30.3 33.3 162.6 25.6 30.3 6.2 29.3 23.1 33.5 22.2 40.4 49.8 41.8 37.5 28.7 30.0 60.8 42.2 22.3 50.8 37.3 167.0 24.4 123.1 55.1 22.0 41.4 163.6 46.5 72.1 30.2 65.6 87.4 80.6 193.3 27.0 96.8 27.5 33.9 54.0 45.0 79.4 39.8 107.6 48.3 37.3 51.8 60.1 98.0 82.6 104.2 72.3 51.6 88.9 53.4 42.3 54.8 31.0 42.3 45.8 54.1 31.7 57.5 17.7 31.6 43.8 40.6 66.6 27.1 59.6 102.2 37.1 58.5 33.9 4.5 19.7 5.3 15.5 29.3 28.8 25.6 25.0 21.8 30.3 21.0 33.5 29.0 6.2 23.1 25.8 20.2 19.7 22.2 28.7 31.8 18.2 24.3 24.2 27.8 35.5 16.1 33.6 35.8 HSPE1 "CPN10, EPF, GroES, HSP10" ENSG00000115541 "Heat shock protein family E (Hsp10) member 1" P61604 2 197499994-197503457 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Stress response" Chaperone "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "Hep G2: 196.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB017366, HPA038755, HPA048272" Supported 9000000 "CAB017366: AB_10998950, HPA038755: , HPA048272: " "unprognostic (2.75e-2)" "unprognostic (6.89e-2)" "unprognostic (1.86e-1)" "unprognostic (1.43e-2)" "unprognostic (1.98e-1)" "unprognostic (1.85e-2)" "unprognostic (5.83e-3)" "unprognostic (4.14e-2)" "unprognostic (1.26e-2)" "unprognostic (2.94e-3)" "unprognostic (1.39e-2)" "unprognostic (6.21e-3)" "unprognostic (2.63e-1)" "unprognostic (4.51e-2)" "unprognostic (6.30e-2)" "unprognostic (1.94e-1)" "unprognostic (7.08e-3)" 24.9 134.7 38.4 25.0 35.0 17.8 50.6 17.1 41.2 19.1 39.9 16.3 20.3 30.8 15.8 31.7 24.3 21.1 16.7 33.8 33.7 37.3 62.5 120.9 18.6 23.8 51.5 26.8 22.7 35.9 14.9 27.2 26.0 48.3 21.9 39.0 9.1 25.1 27.6 39.1 13.0 27.7 17.9 46.7 18.6 21.7 9.4 45.7 10.4 30.6 31.5 30.8 20.2 116.3 50.8 44.9 3.6 29.0 31.5 48.1 28.0 34.4 45.7 42.3 31.2 29.3 14.7 52.4 37.8 16.9 32.9 30.8 138.0 29.2 64.9 48.7 17.9 29.8 106.4 36.6 38.4 31.2 45.5 69.5 91.6 196.9 12.9 93.7 30.2 20.1 25.0 33.1 16.4 29.2 87.0 21.6 22.1 49.7 70.3 91.5 61.8 84.1 43.0 37.7 76.6 44.9 51.8 33.2 21.4 35.8 42.2 29.8 16.4 49.8 22.6 27.2 38.7 30.0 61.1 25.7 58.5 111.3 30.5 42.5 36.8 3.6 16.7 3.3 30.2 29.0 38.4 50.8 40.3 37.1 27.0 37.1 45.8 48.1 1.8 31.5 22.1 44.9 32.0 28.0 38.4 35.0 17.1 41.2 33.7 37.3 51.5 26.8 48.3 45.7 HSPH1 "HSP105A, HSP105B, KIAA0201, NY-CO-25" ENSG00000120694 "Heat shock protein family H (Hsp110) member 1" Q92598 13 31134974-31162388 "Cancer-related genes, Predicted intracellular proteins" "Stress response" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in all" 5 "vagina: 286.1" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002060, HPA028675, HPA031569" Uncertain Enhanced Nucleoplasm,Cytosol 820000 Cytosol Nucleoplasm "CAB002060: AB_563775, HPA028675: AB_10601581, HPA031569: AB_2673938" "unprognostic (1.10e-2)" "unprognostic (4.94e-2)" "unprognostic (5.44e-2)" "unprognostic (1.36e-1)" "unprognostic (1.05e-1)" "prognostic unfavourable (4.90e-4)" "prognostic unfavourable (1.41e-5)" "unprognostic (5.03e-2)" "unprognostic (1.38e-1)" "unprognostic (1.74e-1)" "unprognostic (1.53e-1)" "unprognostic (3.13e-1)" "unprognostic (7.45e-3)" "unprognostic (9.61e-2)" "unprognostic (2.58e-1)" "unprognostic (2.04e-1)" "unprognostic (7.89e-2)" 13.7 19.8 36.6 12.2 57.1 9.8 33.7 11.7 44.0 14.7 10.6 9.8 13.0 6.1 13.3 21.7 13.9 31.0 18.1 14.2 34.8 40.3 16.6 14.8 15.9 17.4 36.5 16.3 13.4 10.1 15.1 24.1 19.8 32.7 14.5 14.5 3.6 7.0 17.3 10.5 11.0 6.4 15.7 34.8 9.0 12.2 35.0 34.6 12.1 22.5 7.8 23.8 17.0 286.1 9.0 6.8 2.1 14.6 13.7 12.8 5.5 14.5 27.8 23.0 2.2 22.1 12.6 15.3 25.2 22.4 39.2 18.3 32.7 22.6 37.7 15.8 17.5 28.2 88.5 22.4 50.6 29.5 11.1 32.7 15.4 28.8 7.3 22.6 26.1 7.9 51.8 26.1 15.0 22.6 27.3 6.0 27.4 19.8 32.4 25.9 32.7 20.8 25.6 18.8 12.5 29.5 17.7 23.8 19.8 22.9 22.6 11.6 7.5 22.0 13.7 13.5 17.2 19.4 27.8 4.7 15.4 32.3 11.2 27.5 22.5 1.0 3.9 2.1 6.6 9.6 8.1 9.0 8.4 10.0 6.8 7.8 12.8 11.9 0.4 13.7 14.6 5.3 5.3 5.5 36.6 57.1 11.7 44.0 34.8 40.3 36.5 16.3 32.7 34.6 HUWE1 "Ib772, KIAA0312, UREB1" ENSG00000086758 "HECT, UBA and WWE domain containing 1, E3 ubiquitin protein ligase" Q7Z6Z7 X 53532096-53686729 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Biological rhythms, Differentiation, DNA damage, DNA repair, Ubl conjugation pathway" "DNA-binding, Transferase" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002548, CAB022718" Approved Enhanced Nucleoplasm,Cytosol 3400 "Nucleoplasm, Cytosol" "CAB022718: , HPA002548: AB_1080489" "unprognostic (4.73e-2)" "unprognostic (9.06e-2)" "unprognostic (1.31e-1)" "unprognostic (1.59e-2)" "unprognostic (6.64e-2)" "unprognostic (3.16e-2)" "unprognostic (1.33e-2)" "unprognostic (2.21e-1)" "unprognostic (3.56e-1)" "unprognostic (5.51e-2)" "unprognostic (1.33e-1)" "unprognostic (8.89e-2)" "unprognostic (8.10e-3)" "unprognostic (2.17e-1)" "unprognostic (1.32e-1)" "unprognostic (3.67e-2)" "unprognostic (2.45e-1)" 24.6 28.2 27.7 23.8 43.3 22.4 28.0 37.0 41.1 31.8 25.9 34.3 26.6 17.1 31.9 52.4 27.4 26.5 23.1 27.1 28.0 31.8 30.3 26.2 20.3 23.1 30.0 30.2 43.3 27.8 59.8 34.2 27.2 34.6 27.3 22.7 25.6 26.4 29.6 59.1 50.1 22.1 33.9 23.9 26.6 25.7 28.4 27.7 32.4 27.6 20.7 28.6 27.0 22.9 5.1 7.2 8.2 7.0 6.9 8.9 3.5 50.1 30.9 20.1 14.2 35.3 21.1 24.8 15.1 19.5 15.9 16.7 23.5 16.2 26.3 10.3 27.4 24.1 45.4 25.3 21.8 37.9 20.1 20.9 27.7 18.3 32.5 31.3 12.9 20.1 19.0 38.2 43.9 27.5 20.8 17.1 20.6 30.9 16.9 17.5 27.5 22.3 15.7 27.8 15.9 26.4 34.8 16.8 12.1 42.6 19.0 13.6 27.2 15.2 35.0 14.7 21.1 20.9 19.2 15.0 14.7 23.0 15.7 30.7 21.1 4.0 4.7 8.2 7.2 3.8 8.9 5.1 6.9 7.6 6.7 5.1 4.9 4.9 4.2 6.9 7.0 7.2 5.7 3.5 27.7 43.3 37.0 41.1 28.0 31.8 30.0 30.2 34.6 27.7 ICAM1 "BB2, CD54" ENSG00000090339 "Intercellular adhesion molecule 1" P05362 19 10270835-10286615 "Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion, Host-virus interaction" "Host cell receptor for virus entry, Receptor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 68.3;lung: 91.3" "Cell line enhanced" "Detected in many" "HHSteC: 31.1;Karpas-707: 88.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "HPA002126, CAB002142, HPA004877" Enhanced Uncertain "Plasma membrane,Cytosol" 3100000000 "Plasma membrane, Cytosol" "CAB002142: AB_563596, HPA002126: AB_1078470, HPA004877: AB_1846317" "prognostic favourable (7.09e-4)" "unprognostic (1.88e-1)" "unprognostic (1.94e-1)" "unprognostic (2.63e-2)" "unprognostic (3.25e-3)" "unprognostic (3.05e-1)" "unprognostic (1.45e-2)" "unprognostic (3.48e-1)" "unprognostic (3.18e-2)" "unprognostic (1.09e-2)" "unprognostic (1.49e-2)" "unprognostic (1.79e-1)" "prognostic unfavourable (1.32e-6)" "unprognostic (2.77e-1)" "unprognostic (2.16e-2)" "unprognostic (2.25e-1)" "unprognostic (3.70e-3)" 26.1 8.6 4.0 41.0 4.1 36.5 15.0 1.0 4.5 5.6 10.0 2.7 1.6 6.1 8.5 7.7 7.9 10.7 19.8 16.3 2.6 2.1 10.9 68.3 91.3 32.8 5.4 1.7 12.4 7.2 2.5 4.0 9.3 6.8 10.4 6.6 10.6 7.2 3.6 13.9 6.9 7.9 8.0 7.8 42.2 7.3 6.5 3.6 8.3 11.6 13.7 13.4 14.8 17.1 2.2 13.3 22.2 14.2 7.9 5.6 8.9 8.2 0.1 1.5 0.0 0.4 0.9 2.1 1.7 18.5 4.1 12.5 2.7 9.3 7.6 25.8 0.7 1.7 0.3 0.0 8.7 22.7 0.0 0.7 0.2 11.3 31.1 0.2 4.5 10.9 0.7 2.6 4.0 2.1 2.8 88.5 0.3 0.6 0.1 6.4 0.5 4.7 0.2 0.0 28.1 7.0 0.0 0.0 0.2 11.4 0.6 18.1 1.4 0.5 6.4 4.2 0.4 2.3 0.1 27.0 27.8 4.7 6.8 4.9 6.2 2.2 13.9 2.6 3.0 14.2 5.6 2.2 2.4 3.6 13.3 0.9 1.0 2.2 22.2 7.9 7.9 7.5 3.4 8.9 4.0 4.1 1.0 4.5 2.6 2.1 5.4 1.7 6.8 3.6 ID1 "bHLHb24, dJ857M17.1.2" ENSG00000125968 "Inhibitor of DNA binding 1, HLH protein" P41134 20 31605283-31606515 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Transcription, Transcription regulation" "Developmental protein, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "seminal vesicle: 163.1" "Cell line enhanced" "Detected in many" "EFO-21: 75.1;HaCaT: 71.6;Hep G2: 59.5;PC-3: 74.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 4 "neutrophil: 3.9" "Lineage enriched" "Detected in single" 5 "granulocytes: 3.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB025915, HPA051456, HPA058518" Approved Enhanced Nucleoplasm "Intracellular and membrane" Nucleoplasm "CAB025915: , HPA051456: , HPA058518: " "unprognostic (3.89e-2)" "unprognostic (3.45e-2)" "unprognostic (2.62e-2)" "unprognostic (3.19e-2)" "unprognostic (1.27e-2)" "unprognostic (1.74e-1)" "unprognostic (2.35e-1)" "prognostic unfavourable (4.85e-4)" "unprognostic (2.29e-1)" "unprognostic (1.58e-1)" "unprognostic (2.14e-2)" "unprognostic (7.83e-2)" "unprognostic (1.67e-2)" "unprognostic (1.71e-3)" "unprognostic (2.97e-1)" "unprognostic (6.17e-3)" "unprognostic (3.41e-3)" 28.6 12.3 8.2 15.2 9.1 4.4 33.2 5.6 13.8 36.3 33.3 15.4 38.5 36.4 25.9 11.6 78.0 25.1 19.0 33.5 8.7 8.4 22.3 23.4 57.4 17.9 10.0 7.9 12.3 5.8 4.0 25.7 22.1 14.3 56.4 13.1 34.9 10.5 163.1 23.0 16.5 40.6 16.9 8.1 15.3 48.6 7.8 4.0 2.4 78.8 36.2 21.0 80.0 26.4 0.4 0.7 3.9 0.7 0.3 0.5 0.5 10.5 35.1 0.4 7.1 4.6 2.1 27.4 45.0 1.8 8.3 0.9 18.5 16.0 0.0 75.1 12.0 71.6 5.8 2.5 1.3 0.8 3.7 5.8 30.4 59.5 6.3 0.1 0.3 8.6 10.2 0.0 0.6 5.0 12.9 0.3 15.9 13.8 1.5 0.2 25.2 74.9 0.1 29.3 0.5 1.6 29.4 13.7 12.8 37.4 13.4 0.3 8.2 1.0 26.8 22.3 43.5 7.1 30.2 0.8 0.8 0.6 26.0 5.6 3.0 0.0 0.6 0.9 0.1 0.2 0.0 0.1 0.1 0.0 0.7 0.4 0.0 0.5 3.9 0.3 0.7 0.0 0.0 0.5 8.2 9.1 5.6 13.8 8.7 8.4 10.0 7.9 14.3 4.0 ID2 "bHLHb26, GIG8" ENSG00000115738 "Inhibitor of DNA binding 2" Q02363 2 8678845-8684453 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Transcription, Transcription regulation" "Developmental protein, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "parathyroid gland: 274.1" "Cell line enhanced" "Detected in many" "HDLM-2: 107.5;HEK 293: 69.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "eosinophil: 110.4" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA027612 Approved "Nucleoplasm,Nuclear bodies,Centrosome" "Nucleoplasm, Nuclear bodies" Centrosome "HPA027612: AB_10599729" "unprognostic (2.53e-1)" "unprognostic (8.16e-3)" "unprognostic (8.51e-2)" "unprognostic (6.66e-2)" "unprognostic (2.24e-1)" "prognostic favourable (9.95e-4)" "unprognostic (4.39e-2)" "unprognostic (6.31e-2)" "unprognostic (1.95e-1)" "unprognostic (2.07e-1)" "unprognostic (1.11e-1)" "unprognostic (2.81e-1)" "unprognostic (5.98e-2)" "unprognostic (2.42e-2)" "unprognostic (1.74e-1)" "unprognostic (1.38e-3)" "unprognostic (1.92e-3)" 34.2 37.4 24.9 19.1 20.6 69.8 31.5 11.3 57.3 21.9 34.0 22.9 13.2 20.7 18.6 11.6 12.1 28.1 33.5 46.1 20.0 14.6 31.2 117.5 25.4 22.4 19.0 35.3 59.7 15.0 274.1 17.2 14.8 20.0 27.2 26.4 13.3 24.5 72.7 8.8 16.6 20.4 19.2 15.8 21.3 16.2 7.1 14.2 19.0 46.8 15.1 10.2 31.8 38.0 0.3 25.0 110.4 26.0 90.9 42.4 18.0 0.2 19.9 8.2 10.1 13.2 2.1 31.4 22.7 2.7 10.2 4.3 39.8 1.0 0.5 27.0 38.8 17.1 5.3 0.1 3.0 107.5 69.6 14.3 12.2 48.6 3.9 10.6 40.3 3.6 0.4 4.6 0.2 0.2 0.8 17.0 15.7 6.7 1.1 1.2 14.9 15.7 1.4 5.7 10.7 10.2 8.9 15.5 22.0 1.2 17.3 1.7 2.8 6.3 4.1 12.6 2.2 18.6 1.3 1.3 1.0 12.4 15.9 32.8 6.8 9.0 8.2 110.4 42.4 24.2 25.3 0.3 13.1 29.5 25.0 0.2 16.4 31.4 11.2 90.9 26.0 1.1 1.0 18.0 24.9 20.6 11.3 57.3 20.0 14.6 19.0 35.3 20.0 14.2 ID3 "bHLHb25, HEIR-1" ENSG00000117318 "Inhibitor of DNA binding 3, HLH protein" Q02535 1 23557918-23559794 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Myogenesis, Transcription, Transcription regulation" Repressor "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "seminal vesicle: 117.9" "Cell line enhanced" "Detected in many" "U-698: 82.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "memory B-cell: 47.4;naive B-cell: 42.9" "Group enriched" "Detected in many" 37 "B-cells: 47.4;T-cells: 24.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB021353, HPA024677" Approved Supported Nucleoplasm Nucleoplasm "CAB021353: , HPA024677: " "unprognostic (6.73e-2)" "unprognostic (2.48e-1)" "unprognostic (5.19e-2)" "prognostic favourable (1.27e-5)" "unprognostic (5.58e-3)" "unprognostic (1.46e-1)" "unprognostic (8.98e-2)" "unprognostic (7.76e-2)" "unprognostic (3.89e-2)" "unprognostic (6.47e-3)" "unprognostic (2.42e-1)" "unprognostic (1.50e-1)" "unprognostic (2.52e-2)" "unprognostic (1.36e-1)" "unprognostic (2.01e-1)" "unprognostic (4.37e-3)" "unprognostic (8.36e-2)" 33.5 12.2 13.3 18.9 15.5 6.0 41.6 2.4 14.4 22.0 25.9 16.6 31.4 18.9 21.7 17.8 20.6 33.8 22.9 42.2 21.1 12.4 21.3 11.1 25.8 15.3 16.6 9.1 27.2 10.2 4.2 31.1 31.3 17.7 38.9 13.0 42.6 9.1 117.9 17.0 14.2 17.0 13.3 16.9 12.4 21.6 6.9 20.7 20.5 82.8 19.3 10.7 35.0 72.1 47.4 0.9 0.5 0.2 0.0 24.9 6.1 3.2 20.0 6.9 24.0 3.1 0.4 8.0 24.1 2.1 13.5 1.7 1.2 0.1 21.4 24.9 9.0 27.6 8.5 3.2 1.3 0.1 8.8 0.3 26.1 10.7 9.7 0.0 0.0 10.1 16.9 0.3 0.2 12.0 0.1 0.2 12.2 7.9 2.8 0.0 6.0 5.0 26.7 12.7 0.7 0.1 7.6 10.1 7.9 23.0 17.1 1.7 4.4 0.5 24.7 19.1 10.2 9.5 12.5 6.7 6.0 82.5 4.2 0.2 11.1 0.0 0.2 0.0 0.6 0.2 0.2 47.4 10.9 2.1 0.7 42.9 18.2 7.2 0.5 0.0 0.2 0.9 24.9 6.1 13.3 15.5 2.4 14.4 21.1 12.4 16.6 9.1 17.7 20.7 IDH1 ENSG00000138413 "Isocitrate dehydrogenase (NADP(+)) 1, cytosolic" O75874 2 208236227-208266074 "Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Glyoxylate bypass, Tricarboxylic acid cycle" Oxidoreductase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "Hep G2: 108.5;RT4: 75.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB033218, HPA035248, HPA057936, CAB062556" Enhanced Approved "Nuclear bodies,Cytosol" 16000000 "Nuclear bodies, Cytosol" "CAB033218: AB_2123166, CAB062556: , HPA035248: AB_10600714, HPA057936: " "unprognostic (2.79e-1)" "unprognostic (1.00e-1)" "unprognostic (1.02e-1)" "unprognostic (2.47e-3)" "unprognostic (1.93e-1)" "unprognostic (2.39e-2)" "prognostic unfavourable (6.93e-5)" "unprognostic (3.32e-1)" "unprognostic (2.20e-3)" "unprognostic (8.03e-2)" "unprognostic (5.54e-2)" "unprognostic (4.18e-3)" "prognostic unfavourable (2.45e-5)" "unprognostic (2.09e-1)" "unprognostic (1.77e-1)" "unprognostic (1.13e-1)" "unprognostic (2.69e-2)" 41.3 82.3 6.2 8.8 7.0 1.3 20.9 6.5 8.3 12.6 35.2 8.7 38.0 30.6 8.0 29.9 30.3 8.8 18.7 10.8 6.3 6.2 20.5 91.0 19.8 14.3 8.1 4.7 19.4 21.5 4.8 6.2 24.1 8.7 38.5 23.1 15.4 18.7 39.0 4.7 7.4 54.1 10.1 9.3 21.3 20.4 15.6 8.4 3.5 7.9 11.0 11.9 43.4 12.1 4.9 22.8 6.4 31.6 7.4 6.6 12.0 9.6 16.2 23.2 9.4 42.2 30.1 13.2 4.0 18.4 6.8 16.6 25.6 23.6 1.9 25.6 12.5 14.9 16.7 19.4 6.6 1.3 6.3 8.3 13.4 108.5 56.2 5.4 8.3 25.9 41.3 15.5 11.3 18.7 8.3 6.7 10.4 6.1 3.8 9.3 42.4 6.7 3.7 8.4 5.4 30.6 75.8 4.0 6.9 15.3 14.8 50.1 5.7 15.8 12.3 6.9 7.0 9.8 4.3 3.2 5.0 2.5 22.4 32.8 5.5 5.7 31.6 4.8 4.5 14.5 5.1 4.9 4.0 5.3 22.8 4.9 3.3 3.9 6.4 7.4 6.5 8.4 6.6 12.0 6.2 7.0 6.5 8.3 6.3 6.2 8.1 4.7 8.7 8.4 IDH2 ENSG00000182054 "Isocitrate dehydrogenase (NADP(+)) 2, mitochondrial" P48735 15 90083045-90102504 "Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Glyoxylate bypass, Tricarboxylic acid cycle" Oxidoreductase "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "heart muscle: 126.2;skeletal muscle: 190.7" "Cell line enhanced" "Detected in all" "MOLT-4: 68.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA007831 Enhanced Supported Mitochondria 53000000 Mitochondria "HPA007831: AB_1851397" "unprognostic (2.45e-2)" "prognostic favourable (5.15e-5)" "unprognostic (2.92e-1)" "unprognostic (1.53e-1)" "unprognostic (3.53e-1)" "unprognostic (8.46e-2)" "unprognostic (3.83e-2)" "unprognostic (2.55e-3)" "unprognostic (1.86e-2)" "unprognostic (1.89e-2)" "unprognostic (2.76e-1)" "unprognostic (4.90e-2)" "unprognostic (2.19e-3)" "unprognostic (3.92e-3)" "unprognostic (4.46e-1)" "unprognostic (1.30e-2)" "unprognostic (2.58e-2)" 5.4 2.0 14.9 10.1 16.6 22.6 8.8 4.9 19.1 6.4 16.2 13.8 12.4 16.1 5.9 15.3 23.7 6.0 9.4 126.2 10.2 9.3 25.0 93.2 6.9 15.8 14.4 12.0 3.0 25.1 8.4 3.3 15.1 11.9 13.3 14.5 6.0 28.0 21.9 190.7 11.0 13.9 15.8 11.0 7.5 27.9 1.2 7.6 28.2 3.4 69.0 13.6 11.0 8.6 16.8 32.8 17.2 56.3 22.2 29.5 31.2 10.2 5.8 30.2 30.0 4.2 5.2 25.7 12.8 19.5 12.1 13.0 2.7 8.9 12.2 3.6 10.6 3.5 4.4 3.9 5.8 23.9 2.9 20.8 2.2 20.3 5.1 14.2 21.1 10.8 2.2 2.9 2.3 24.8 3.1 10.5 9.3 29.8 68.3 22.1 9.0 2.4 57.9 21.7 36.3 18.7 12.3 43.6 22.1 15.9 63.6 5.1 51.3 43.9 5.9 21.7 3.1 2.8 5.9 17.3 3.2 1.4 6.9 30.0 12.5 9.0 26.4 17.2 26.1 48.0 12.4 16.8 18.7 29.5 32.8 9.8 10.2 18.2 5.1 22.2 56.3 17.8 15.9 31.2 14.9 16.6 4.9 19.1 10.2 9.3 14.4 12.0 11.9 7.6 IDO1 "IDO, INDO" ENSG00000131203 "Indoleamine 2,3-dioxygenase 1" P14902 8 39902275-39928444 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Immunity, Tryptophan catabolism" "Dioxygenase, Oxidoreductase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 77.7;placenta: 33.2" "Cell line enriched" "Detected in some" 7 "EFO-21: 35.7" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Cell type enriched" "Detected in some" 17 "eosinophil: 77.7" "Lineage enriched" "Detected in many" 17 "granulocytes: 77.7" "Region enriched" "Detected in single" 13 "basal ganglia: 30.5" "Low region specificity" "Detected in all" "HPA023072, HPA023149, HPA027772, CAB072820" Enhanced Supported Nucleoplasm,Vesicles,Mitochondria,Cytosol Cytosol "Nucleoplasm, Vesicles, Mitochondria" "CAB072820: , HPA023072: AB_1846220, HPA023149: AB_1846221, HPA027772: AB_1846222" "unprognostic (1.68e-2)" "unprognostic (1.71e-2)" "unprognostic (4.08e-3)" "unprognostic (7.21e-3)" "unprognostic (1.90e-1)" "unprognostic (1.09e-2)" "unprognostic (1.86e-1)" "unprognostic (3.06e-2)" "prognostic favourable (5.27e-4)" "prognostic favourable (3.32e-4)" "unprognostic (3.59e-2)" "unprognostic (2.74e-1)" "prognostic unfavourable (1.12e-7)" "unprognostic (4.18e-2)" "unprognostic (4.42e-2)" "unprognostic (1.16e-1)" "unprognostic (1.97e-2)" 8.7 0.2 0.9 11.2 0.9 0.0 1.4 0.9 0.9 4.0 1.5 0.9 0.9 2.6 2.6 0.9 1.2 0.6 1.3 1.0 0.9 0.0 0.9 0.9 16.8 14.1 0.9 0.9 0.9 0.9 0.0 0.9 33.2 0.9 1.6 2.1 1.9 0.9 0.9 2.5 0.3 5.9 0.9 2.0 6.2 2.2 0.9 0.9 0.9 7.2 0.9 8.9 2.3 0.9 0.0 4.6 77.7 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 4.4 2.5 0.1 0.3 0.0 35.7 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 4.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 5.0 0.0 0.1 0.0 0.1 0.0 4.5 0.1 77.7 0.0 0.2 0.0 0.0 0.0 0.0 4.6 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.1 0.9 0.9 0.9 0.9 0.9 0.0 0.9 0.9 0.9 0.9 IFNA1 "IFL, IFN, IFN-ALPHA, IFN-alphaD, IFNA@, IFNA13" ENSG00000197919 "Interferon alpha 1" P01562 9 21440454-21441316 "Cancer-related genes, Plasma proteins, Predicted secreted proteins" "Antiviral defense" Cytokine "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "brain: 2.3;urinary bladder: 2.1" "Cell line enhanced" "Detected in some" "A549: 1.7;BJ: 1.0;HeLa: 6.6;NB-4: 1.5" "Not detected" "Not detected" "Region enriched" "Detected in single" 13 "cerebellum: 2.3" "Not detected" "Not detected" "Not detected" "Not detected" HPA047557 Uncertain "Secreted to blood" 10000 "HPA047557: " "unprognostic (3.14e-1)" "unprognostic (1.55e-1)" "unprognostic (9.75e-2)" "unprognostic (5.88e-2)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.3 0.1 0.1 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.4 0.0 0.0 0.0 0.0 0.0 2.1 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 IFNA13 ENSG00000233816 "Interferon alpha 13" P01562 9 21367424-21368962 "Cancer-related genes, Plasma proteins, Predicted secreted proteins" "Antiviral defense" Cytokine "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 4 "brain: 2.1;epididymis: 3.7" "Cell line enhanced" "Detected in some" "A549: 2.7;HeLa: 1.6;NB-4: 3.5;TIME: 1.4" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA047557 Uncertain "Secreted to blood" "HPA047557: " 0.0 0.0 1.1 0.0 2.1 0.0 0.0 0.4 0.6 0.0 0.0 0.0 0.1 3.7 0.0 0.1 0.0 0.0 1.5 0.6 0.4 0.0 0.2 0.2 0.8 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.4 0.7 0.0 0.3 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.3 2.7 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 IFNAR1 "IFNAR, IFRC" ENSG00000142166 "Interferon alpha and beta receptor subunit 1" P17181 21 33324477-33359862 "Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" Receptor "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA018015, HPA029226" Uncertain 100000 "HPA018015: AB_1851433, HPA029226: " "unprognostic (2.42e-3)" "unprognostic (2.95e-1)" "unprognostic (3.01e-1)" "unprognostic (1.15e-1)" "unprognostic (4.93e-2)" "unprognostic (2.22e-1)" "unprognostic (1.01e-1)" "unprognostic (3.02e-1)" "unprognostic (4.69e-2)" "unprognostic (1.28e-1)" "unprognostic (2.31e-2)" "unprognostic (2.38e-1)" "unprognostic (9.38e-3)" "unprognostic (5.93e-2)" "unprognostic (2.01e-1)" "unprognostic (8.45e-2)" "unprognostic (3.06e-2)" 27.2 16.4 18.5 16.8 18.7 14.8 15.9 18.1 22.9 14.2 16.8 15.1 10.0 12.3 15.7 10.9 15.8 13.5 16.2 14.5 16.9 15.8 17.5 56.4 16.6 15.0 19.7 13.8 16.6 18.3 30.6 17.9 23.2 18.3 14.7 12.2 12.1 17.6 12.6 17.3 10.6 15.8 13.7 22.2 29.8 18.8 10.3 16.7 26.9 21.4 9.1 13.1 18.7 18.1 20.5 17.8 64.5 23.1 7.3 12.1 10.7 13.1 12.0 5.1 5.8 16.9 17.3 5.9 14.2 15.2 6.5 6.7 12.9 15.1 10.2 11.5 9.7 7.9 4.8 8.3 7.0 11.5 9.6 15.1 11.6 7.6 7.2 11.1 10.8 14.3 7.4 10.8 6.5 12.5 17.3 49.9 10.7 10.9 8.2 4.5 5.5 7.7 8.1 18.0 17.3 7.2 17.3 6.1 5.5 14.2 10.2 9.0 15.6 8.2 19.8 13.2 7.2 17.3 7.9 33.4 45.8 11.7 17.7 15.7 14.1 18.9 16.8 9.7 8.0 19.7 7.5 18.5 10.6 9.0 11.3 20.5 12.1 9.4 64.5 7.3 23.1 17.8 12.0 10.7 18.5 18.7 18.1 22.9 16.9 15.8 19.7 13.8 18.3 16.7 IFNB1 "IFB, IFF, IFNB" ENSG00000171855 "Interferon beta 1" P01574 9 21077105-21077963 "Cancer-related genes, Predicted secreted proteins" "Antiviral defense" Cytokine "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 6 "blood: 1.8;bone marrow: 3.7;breast: 5.9" "Cell line enhanced" "Detected in some" "BJ hTERT+ SV40 Large T+: 2.2;BJ hTERT+ SV40 Large T+ RasG12V: 4.8;NB-4: 1.1" "Not detected" "Not detected" "Not detected" "Not detected" "Cell type enhanced" "Detected in single" "naive CD8 T-cell: 1.8" "Lineage enriched" "Detected in single" 8 "T-cells: 1.8" "Low region specificity" "Detected in some" CAB009386 Uncertain "Secreted to blood" 3750 "CAB009386: AB_2248817" "unprognostic (2.38e-1)" "unprognostic (2.60e-4)" 0.1 0.3 0.0 0.0 0.0 3.7 5.9 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.3 0.1 0.1 0.0 0.3 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.3 0.0 0.1 0.0 0.1 0.6 0.0 0.2 0.0 0.0 0.3 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.2 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.2 4.8 0.0 0.0 0.1 0.3 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.8 0.0 0.0 0.5 0.0 0.0 0.2 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.2 0.0 0.5 0.0 0.4 0.0 0.0 0.5 0.0 0.0 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 IFNG ENSG00000111537 "Interferon gamma" P01579 12 68154768-68159747 "Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins" "Antiviral defense, Growth regulation" Cytokine "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 14.4;lung: 14.5" "Cell line enhanced" "Detected in some" "Karpas-707: 2.2;U-266/70: 2.2;U-698: 1.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in some" "Group enriched" "Detected in some" 5 "gdT-cell: 7.3;memory CD4 T-cell: 3.3;memory CD8 T-cell: 8.6;naive CD8 T-cell: 5.2" "Lineage enriched" "Detected in many" 7 "T-cells: 8.6" "Low region specificity" "Detected in single" CAB010344 Approved "Secreted to blood" 400 "CAB010344: AB_2123447" "unprognostic (2.16e-4)" "unprognostic (1.93e-3)" "unprognostic (9.21e-2)" "unprognostic (1.04e-4)" "unprognostic (5.14e-1)" "unprognostic (3.96e-3)" "unprognostic (1.33e-1)" "unprognostic (3.17e-4)" "unprognostic (7.79e-2)" "unprognostic (7.97e-3)" "unprognostic (1.63e-2)" "unprognostic (5.36e-2)" "unprognostic (7.62e-9)" "unprognostic (3.54e-2)" "unprognostic (5.36e-1)" "unprognostic (6.32e-2)" "unprognostic (7.38e-3)" 2.4 0.9 0.3 4.5 0.3 14.4 0.5 0.1 1.0 1.4 0.9 0.5 0.0 0.2 0.6 1.4 1.3 0.2 0.6 1.0 0.3 0.3 0.7 4.1 14.5 8.5 1.5 0.4 0.4 0.2 0.0 0.5 0.8 0.6 1.2 0.4 1.1 1.4 0.2 1.7 0.3 0.7 0.7 1.3 4.1 0.8 0.2 0.0 0.8 1.3 3.1 4.7 2.2 0.6 0.5 0.0 0.2 0.0 1.2 8.6 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.2 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 7.3 0.0 0.0 0.0 3.3 8.6 0.0 0.5 0.8 5.2 0.2 1.2 0.0 0.0 0.2 1.1 0.3 0.3 0.1 1.0 0.3 0.3 1.5 0.4 0.6 0.0 IGF1R "CD221, IGFIR, IGFR, JTK13, MGC18216" ENSG00000140443 "Insulin like growth factor 1 receptor" P08069 15 98648971-98964530 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 7.7" "Group enriched" "Detected in many" 5 "granulocytes: 7.7;T-cells: 2.9" "Low region specificity" "Detected in all" "CAB010268, HPA045563" Approved Approved Vesicles 36000 Vesicles "CAB010268: AB_671792, HPA045563: " "unprognostic (1.30e-3)" "unprognostic (5.81e-3)" "unprognostic (1.53e-1)" "unprognostic (3.34e-2)" "unprognostic (2.65e-1)" "unprognostic (2.05e-2)" "unprognostic (1.29e-2)" "unprognostic (6.87e-2)" "unprognostic (2.64e-2)" "unprognostic (2.87e-2)" "unprognostic (8.56e-2)" "unprognostic (1.62e-1)" "prognostic favourable (3.75e-7)" "unprognostic (1.57e-1)" "unprognostic (3.59e-1)" "unprognostic (1.41e-1)" "unprognostic (1.06e-1)" 8.4 12.7 11.5 5.9 13.5 16.3 18.5 23.0 15.7 15.3 13.4 10.4 22.7 4.2 15.3 16.3 9.2 18.9 7.7 11.6 11.7 7.3 17.0 2.0 11.0 4.9 8.0 11.8 23.2 22.5 4.7 13.8 17.5 9.5 21.7 7.2 16.7 12.5 23.2 9.1 13.0 7.5 18.1 8.0 7.3 10.7 12.0 11.5 10.7 16.1 7.0 5.6 12.8 21.6 1.0 0.4 7.7 0.6 1.0 2.9 0.7 3.3 16.5 11.6 0.2 5.8 4.2 7.7 3.7 7.4 1.2 1.1 7.1 8.8 0.8 10.7 7.2 15.8 5.1 15.0 1.0 0.0 5.2 12.5 18.5 14.2 5.1 6.6 1.3 6.6 7.1 2.1 10.2 4.1 0.6 2.9 5.7 23.4 2.5 4.4 10.8 0.9 4.0 9.0 3.0 3.5 20.3 3.9 17.3 26.7 1.5 14.4 8.1 3.1 11.3 1.1 15.0 3.0 5.8 1.0 4.4 2.7 2.2 4.9 2.8 4.0 0.6 1.8 0.9 0.6 0.6 0.4 0.8 0.3 0.4 1.0 2.9 1.0 7.7 1.0 0.5 0.3 0.0 0.7 11.5 13.5 23.0 15.7 11.7 7.3 8.0 11.8 9.5 11.5 IGF2 "C11orf43, FLJ44734, IGF-II" ENSG00000167244 "Insulin like growth factor 2" P01344 11 2129112-2149603 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins" "Carbohydrate metabolism, Glucose metabolism, Osteogenesis" "Growth factor, Hormone, Mitogen" "Cancer-related genes, Dwarfism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 8 "placenta: 330.5" "Cell line enhanced" "Detected in some" "CACO-2: 112.8;Hep G2: 77.4;LHCN-M2: 44.5;RH-30: 55.3;SH-SY5Y: 67.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "HPA007556, HPA007993" Enhanced Approved Nucleoplasm,Vesicles,Cytosol "Secreted to blood" 609000000 1700000000 Vesicles "Nucleoplasm, Cytosol" "HPA007556: , HPA007993: AB_1851474" "unprognostic (1.54e-1)" "unprognostic (1.65e-2)" "unprognostic (1.31e-1)" "unprognostic (7.08e-2)" "unprognostic (2.30e-3)" "unprognostic (2.59e-1)" "prognostic favourable (7.12e-4)" "unprognostic (7.92e-2)" "unprognostic (2.59e-2)" "unprognostic (1.68e-2)" "unprognostic (3.69e-2)" "unprognostic (1.85e-1)" "unprognostic (1.79e-3)" "unprognostic (2.00e-2)" "unprognostic (8.98e-2)" "unprognostic (8.93e-3)" "unprognostic (5.78e-2)" 16.6 8.0 1.3 4.5 2.0 0.5 23.3 2.3 1.9 23.4 5.0 3.4 4.7 1.0 9.9 32.0 5.2 17.2 4.5 20.5 1.5 1.6 8.1 39.7 1.9 1.1 3.5 1.6 20.4 5.5 0.7 5.0 330.5 7.6 10.4 1.0 33.2 2.6 6.7 21.9 1.7 2.3 7.5 17.0 2.0 3.2 12.4 0.2 1.8 2.6 14.5 1.8 15.2 14.1 0.0 0.1 0.5 0.2 0.2 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.2 14.9 0.1 0.4 0.0 112.8 0.0 0.0 1.1 0.0 0.0 0.1 0.9 1.0 0.0 0.0 0.0 0.0 77.4 19.8 0.0 0.0 24.1 0.0 0.1 0.0 0.1 0.0 0.0 44.5 0.2 0.0 0.1 0.1 0.2 0.0 55.3 0.1 0.0 0.1 4.4 67.3 0.0 0.0 0.0 0.5 0.0 0.0 0.0 2.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.2 0.1 0.0 0.0 1.3 2.0 2.3 1.4 1.5 1.6 3.5 1.6 7.6 0.2 IGF2R "CD222, CI-M6PR, CI-MPR, CIMPR, M6P-R, MPR1, MPR300, MPRI" ENSG00000197081 "Insulin like growth factor 2 receptor" P11717 6 159969099-160113507 "Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" Transport Receptor "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HBEC3-KT: 59.6;hTERT-HME1: 60.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 13.3" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009661, HPA011332" Supported Enhanced "Golgi apparatus,Vesicles" 150000000 "Golgi apparatus, Vesicles" "CAB009661: AB_2122795, HPA011332: AB_1846276" "prognostic unfavourable (3.01e-4)" "prognostic unfavourable (2.92e-5)" "unprognostic (5.83e-2)" "unprognostic (1.72e-1)" "unprognostic (4.15e-1)" "unprognostic (3.25e-1)" "unprognostic (7.32e-3)" "unprognostic (2.32e-1)" "unprognostic (1.62e-1)" "unprognostic (1.07e-2)" "unprognostic (2.37e-1)" "unprognostic (1.45e-1)" "unprognostic (5.74e-3)" "unprognostic (1.16e-1)" "unprognostic (1.46e-1)" "unprognostic (1.85e-1)" "prognostic unfavourable (6.08e-4)" 28.0 22.2 6.8 13.5 8.1 16.7 39.4 6.4 8.2 14.9 17.3 9.5 13.0 9.4 19.6 16.0 16.7 13.1 17.9 27.9 6.7 6.2 20.6 26.6 32.6 44.7 12.3 3.6 18.0 19.6 23.5 13.6 15.5 10.0 14.1 13.3 13.9 18.2 13.5 62.0 15.9 15.4 16.5 7.6 30.2 14.4 13.8 9.0 37.9 18.5 17.3 14.1 16.3 26.9 0.4 2.9 13.3 2.0 1.0 3.6 0.9 7.7 7.0 12.4 17.4 45.3 25.0 16.8 12.2 26.4 10.1 17.4 10.6 12.2 3.2 13.7 13.4 10.4 9.3 59.6 17.0 16.8 6.6 1.4 12.2 19.1 26.8 7.4 12.1 19.9 19.1 21.0 60.7 6.5 13.9 17.4 15.9 5.7 3.4 7.4 5.5 7.5 8.0 8.5 16.3 14.3 7.8 4.1 9.1 16.5 14.8 16.5 6.2 21.0 9.8 9.8 10.3 21.1 22.3 10.3 14.4 3.3 18.9 10.2 15.1 0.1 2.0 1.1 3.6 0.8 1.4 0.3 1.2 1.7 0.3 0.4 1.0 2.4 13.3 1.0 1.4 2.9 0.7 0.9 6.8 8.1 6.4 8.2 6.7 6.2 12.3 3.6 10.0 9.0 IGFBP2 IBP2 ENSG00000115457 "Insulin like growth factor binding protein 2" P18065 2 216632828-216664436 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Growth regulation" "Growth factor binding" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 165.3;pancreas: 228.7" "Cell line enhanced" "Detected in many" "ASC diff: 138.4;HMC-1: 322.9;NB-4: 66.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in single" "NK-cell: 2.0" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" HPA077723 Approved "Endoplasmic reticulum" "Secreted to blood" 539805000 1000000000 "Endoplasmic reticulum" "HPA077723: " "unprognostic (2.58e-1)" "unprognostic (5.95e-2)" "unprognostic (1.94e-1)" "unprognostic (3.32e-3)" "unprognostic (9.50e-3)" "unprognostic (2.36e-2)" "unprognostic (2.06e-1)" "unprognostic (9.11e-3)" "prognostic unfavourable (2.43e-4)" "unprognostic (2.34e-1)" "unprognostic (1.63e-3)" "unprognostic (1.82e-1)" "prognostic unfavourable (2.22e-5)" "unprognostic (5.04e-2)" "unprognostic (1.07e-1)" "unprognostic (5.83e-2)" "unprognostic (1.22e-1)" 21.7 6.4 0.9 13.7 2.8 2.6 17.5 1.0 10.4 11.9 12.6 4.5 20.6 11.4 28.7 37.7 26.4 19.4 11.8 29.6 1.5 0.9 21.3 165.3 8.7 3.8 1.4 3.4 35.7 228.7 0.8 8.2 32.0 7.6 25.7 5.2 8.0 9.1 32.6 5.3 3.1 7.8 7.5 1.8 46.7 50.2 13.7 1.0 12.1 8.4 29.3 12.9 23.4 11.4 0.0 0.3 0.0 0.4 2.0 0.8 1.3 0.0 3.2 25.3 24.6 138.4 42.3 0.5 7.7 3.8 0.3 0.0 0.0 0.0 0.0 10.8 0.0 0.7 9.0 9.6 0.0 0.0 5.2 5.5 0.0 1.5 3.4 2.3 322.9 14.1 1.0 0.1 0.4 0.0 0.2 0.7 0.1 6.2 9.6 66.6 27.3 0.3 8.3 0.5 0.1 0.1 7.1 5.3 27.9 0.0 0.2 0.1 20.7 4.1 0.0 0.1 0.1 0.1 0.3 0.3 0.0 0.5 0.3 10.6 29.5 0.0 0.4 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 2.0 0.0 0.3 0.0 1.3 0.9 2.8 1.0 10.4 1.5 0.9 1.4 3.4 7.6 1.0 IGFBP3 "BP-53, IBP3" ENSG00000146674 "Insulin like growth factor binding protein 3" P17936 7 45912245-45921874 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" Apoptosis "Growth factor binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "placenta: 320.7" "Cell line enhanced" "Detected in many" "fHDF/TERT166: 412.2;U-2197: 171.0;U-87 MG: 88.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in many" 5 "plasmacytoid DC: 28.9" "Lineage enriched" "Detected in many" 5 "dendritic cells: 28.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" CAB010360 Approved Nucleoplasm,Vesicles,Cytosol "Secreted to blood" 3247666667 5600000000 Vesicles "Nucleoplasm, Cytosol" "CAB010360: AB_2233528" "unprognostic (4.46e-3)" "unprognostic (4.84e-2)" "prognostic unfavourable (1.08e-4)" "unprognostic (2.30e-1)" "unprognostic (1.15e-1)" "unprognostic (6.54e-2)" "prognostic unfavourable (1.64e-4)" "unprognostic (8.14e-3)" "unprognostic (3.31e-2)" "unprognostic (2.03e-1)" "unprognostic (9.67e-3)" "unprognostic (2.80e-1)" "prognostic unfavourable (5.07e-7)" "unprognostic (2.36e-2)" "unprognostic (4.14e-2)" "unprognostic (2.37e-3)" "unprognostic (2.63e-1)" 47.4 1.6 4.4 10.6 2.7 0.0 52.1 2.7 4.1 44.3 21.3 1.7 3.2 6.9 58.4 8.1 11.7 14.9 5.4 41.6 4.4 2.6 11.1 80.4 11.7 12.7 3.7 1.9 49.2 2.2 0.6 19.2 320.7 4.1 22.5 6.1 9.1 6.4 9.3 13.9 23.9 10.2 22.9 3.8 18.7 8.3 12.1 3.1 2.2 5.6 8.6 8.3 32.0 26.3 0.0 28.9 0.0 0.0 0.0 6.0 1.7 9.3 2.8 5.5 0.0 4.2 1.7 0.0 41.2 7.5 3.5 1.9 0.0 7.6 0.0 13.1 412.2 22.6 0.0 0.1 1.4 0.0 0.0 0.0 1.0 0.0 1.1 0.0 0.0 14.4 0.6 0.7 2.6 0.0 0.0 0.1 1.3 0.0 0.0 0.0 0.3 0.5 0.0 0.0 3.8 2.6 20.4 0.6 1.6 14.2 0.5 0.7 0.0 0.0 0.0 40.7 0.0 171.0 2.3 0.5 0.0 0.0 88.5 0.0 13.7 0.0 0.0 0.0 5.2 0.0 4.3 0.0 6.0 5.6 0.0 0.0 2.8 4.7 0.0 0.0 0.0 28.9 0.3 1.7 4.4 2.7 2.7 4.1 4.4 2.6 3.7 1.9 4.1 3.1 IKBKB "IKK-beta, IKK2, IKKB, NFKBIKB" ENSG00000104365 "Inhibitor of nuclear factor kappa B kinase subunit beta" O14920 8 42271302-42332653 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins" "Host-virus interaction" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, FDA approved drug targets, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001249, CAB004447" Enhanced Approved Cytosol Cytosol "CAB004447: AB_627785, HPA001249: AB_1079126" "unprognostic (1.04e-1)" "unprognostic (2.30e-2)" "unprognostic (1.31e-1)" "unprognostic (1.73e-3)" "unprognostic (1.26e-1)" "unprognostic (1.27e-3)" "unprognostic (1.95e-1)" "unprognostic (1.25e-3)" "unprognostic (1.75e-1)" "unprognostic (1.55e-1)" "unprognostic (3.27e-1)" "unprognostic (1.73e-1)" "unprognostic (1.20e-2)" "unprognostic (1.89e-2)" "unprognostic (9.20e-2)" "unprognostic (3.02e-1)" "prognostic favourable (1.46e-6)" 9.1 10.8 10.9 17.0 16.7 9.3 10.0 26.1 16.9 10.3 10.3 12.4 11.4 4.7 15.3 13.2 17.9 16.4 14.9 7.9 13.1 6.9 12.4 9.9 14.9 12.2 20.3 7.9 9.6 13.3 18.0 13.6 11.2 11.9 14.0 10.9 10.5 11.4 9.7 17.6 22.2 9.8 16.4 10.5 18.7 10.8 8.3 18.6 12.9 14.3 8.4 17.1 18.1 12.8 12.6 14.8 14.1 9.6 11.9 11.2 5.8 3.6 13.1 3.7 6.4 14.5 12.6 4.8 3.2 11.5 9.7 8.5 3.0 6.8 7.2 5.6 8.9 4.2 5.1 13.0 12.5 7.0 5.8 10.1 6.1 2.3 11.1 1.9 10.6 8.4 9.9 9.3 14.4 14.3 8.5 3.5 21.2 4.2 7.0 3.2 3.6 4.1 7.2 6.4 4.2 10.9 3.3 1.1 2.1 2.1 3.6 5.3 4.8 8.5 7.4 6.8 3.6 5.3 2.3 2.1 2.2 5.1 8.1 4.8 7.7 14.1 9.6 10.4 10.1 7.6 10.3 9.4 10.5 11.2 8.9 12.6 10.2 10.4 11.4 11.9 9.0 14.8 9.9 5.8 10.9 16.7 26.1 16.9 13.1 6.9 20.3 7.9 11.9 18.6 IKZF1 "hIk-1, Hs.54452, IKAROS, LyF-1, PPP1R92, ZNFN1A1" ENSG00000185811 "IKAROS family zinc finger 1" Q13422 7 50304068-50405101 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors" "Cell cycle, Transcription, Transcription regulation" "Activator, Chromatin regulator, Developmental protein, DNA-binding, Repressor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 28.7;bone marrow: 55.2;lymphoid tissue: 86.7" "Cell line enhanced" "Detected in some" "Daudi: 26.6;HDLM-2: 45.2;HMC-1: 42.4;MOLT-4: 33.1;REH: 35.8;U-698: 68.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB009247, HPA035221, HPA035222" Enhanced "CAB009247: AB_2124699, HPA035221: AB_2674524, HPA035222: AB_2674525" "prognostic favourable (4.28e-4)" "prognostic favourable (2.02e-4)" "unprognostic (2.49e-3)" "unprognostic (2.41e-3)" "unprognostic (5.59e-1)" "prognostic favourable (8.63e-4)" "unprognostic (1.45e-2)" "unprognostic (1.37e-2)" "unprognostic (1.15e-2)" "unprognostic (2.43e-1)" "unprognostic (6.63e-2)" "unprognostic (2.95e-1)" "unprognostic (1.69e-3)" "unprognostic (1.71e-1)" "unprognostic (2.84e-2)" "unprognostic (6.77e-2)" "unprognostic (4.67e-2)" 3.5 1.5 2.9 25.5 3.8 55.2 2.3 0.7 1.8 1.6 3.6 2.8 0.8 2.4 1.6 2.1 2.2 2.4 2.9 1.6 3.4 1.8 2.5 2.3 8.3 44.4 5.9 1.1 1.1 1.3 0.2 1.2 1.2 3.4 2.2 2.5 1.5 5.2 0.7 0.9 1.9 14.5 1.4 5.1 31.0 3.7 1.1 4.1 86.7 2.4 1.2 26.3 4.5 2.9 24.0 12.6 12.8 23.6 12.8 28.7 12.7 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 26.6 0.0 0.0 0.0 0.0 0.0 0.0 45.2 0.0 9.1 0.0 0.0 0.0 16.1 42.4 0.0 0.0 0.0 0.0 0.0 11.7 3.1 0.0 0.0 33.1 16.0 0.4 0.0 35.8 0.0 7.5 0.0 0.0 0.3 0.3 0.1 0.2 0.1 0.0 22.2 0.0 0.0 0.3 0.0 0.0 14.5 7.4 68.0 0.1 17.5 0.1 10.2 7.7 12.8 20.4 23.6 17.0 24.0 21.2 19.9 8.2 21.3 28.7 20.7 11.2 12.8 22.3 12.6 17.1 12.7 2.9 3.8 0.7 1.8 3.4 1.8 5.9 1.1 3.4 4.1 IL10 "CSIF, IL-10, IL10A, TGIF" ENSG00000136634 "Interleukin 10" P22301 1 206767602-206772494 "Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" Cytokine "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 28.3" "Group enriched" "Detected in some" 8 "HMC-1: 18.2;U-266/70: 9.3" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in some" "classical monocyte: 5.4;intermediate monocyte: 4.0" "Lineage enriched" "Detected in many" 5 "monocytes: 5.4" "Not detected" "Not detected" "Low region specificity" "Detected in many" "CAB013120, HPA071391" Approved "Secreted to blood" 4757 "CAB013120: , HPA071391: " "unprognostic (3.65e-2)" "unprognostic (1.14e-1)" "unprognostic (1.03e-2)" "unprognostic (8.71e-2)" "unprognostic (2.20e-1)" "unprognostic (2.63e-3)" "unprognostic (2.58e-1)" "unprognostic (1.54e-1)" "unprognostic (9.59e-2)" "unprognostic (4.26e-1)" "unprognostic (8.01e-2)" "unprognostic (4.00e-1)" "unprognostic (4.66e-4)" "unprognostic (7.11e-2)" "unprognostic (1.93e-2)" "unprognostic (2.73e-1)" "unprognostic (1.96e-2)" 10.9 3.1 1.1 10.7 1.2 4.1 2.1 0.3 1.3 1.6 1.8 2.1 0.5 0.8 1.0 1.9 1.7 4.0 5.2 3.9 0.8 0.9 1.3 3.1 4.3 9.2 1.8 0.9 1.5 1.2 0.4 2.3 3.6 2.3 1.7 1.8 2.1 1.6 0.8 0.9 0.7 2.1 4.6 2.2 28.3 2.0 1.6 1.4 2.2 2.4 0.9 3.5 4.1 1.0 0.2 0.5 0.5 5.4 0.1 1.0 1.0 0.0 0.0 0.1 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 18.2 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.4 0.1 0.0 0.0 0.0 1.8 0.0 0.0 0.2 0.2 0.0 0.0 0.3 0.0 0.0 0.1 0.1 0.1 0.1 0.0 9.3 0.3 0.3 0.0 0.1 0.0 0.5 5.4 0.1 0.2 4.0 0.0 0.1 0.2 1.0 0.5 0.2 0.1 0.1 0.3 0.1 1.4 0.1 0.9 1.0 1.1 1.2 0.3 1.3 0.8 0.9 1.8 0.9 2.3 1.4 IL12A "CLMF, IL-12A, NFSK, NKSF1, p35" ENSG00000168811 "Interleukin 12A" P29459 3 159988750-159996019 "Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins" "Host-virus interaction" "Cytokine, Growth factor" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "esophagus: 10.1" "Cell line enhanced" "Detected in many" "BJ hTERT+ SV40 Large T+ RasG12V: 7.4;HDLM-2: 11.2;SK-BR-3: 16.8" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "naive B-cell: 5.1" "Group enriched" "Detected in many" 7 "B-cells: 5.1;granulocytes: 1.3;T-cells: 1.6" "Region enhanced" "Detected in single" "cerebral cortex: 2.7" "Low region specificity" "Detected in some" HPA001886 Uncertain "Secreted to blood" "HPA001886: AB_1079132" "unprognostic (6.23e-2)" "unprognostic (7.82e-5)" "unprognostic (1.25e-1)" "unprognostic (3.10e-2)" "unprognostic (4.22e-1)" "unprognostic (7.18e-2)" "unprognostic (4.18e-5)" "unprognostic (2.22e-1)" "unprognostic (1.91e-1)" "unprognostic (1.07e-2)" "unprognostic (1.28e-1)" "unprognostic (2.31e-2)" "unprognostic (9.57e-10)" "unprognostic (1.62e-1)" "unprognostic (1.42e-1)" "unprognostic (1.16e-1)" "unprognostic (9.61e-2)" 0.7 1.4 3.4 1.6 6.2 3.3 2.0 2.6 5.6 0.5 1.6 1.0 0.0 1.5 1.2 0.8 10.1 5.7 0.6 1.4 3.1 2.2 1.2 0.6 5.2 2.9 3.2 1.7 1.6 1.1 0.1 1.0 0.4 5.4 0.9 1.3 0.2 2.1 1.1 0.4 0.2 1.5 0.8 2.7 2.8 1.2 0.9 4.1 0.0 0.5 0.5 2.1 0.9 1.1 5.1 0.1 1.3 0.3 0.0 1.6 0.3 2.7 0.3 0.4 2.3 0.0 0.1 0.2 3.1 1.9 3.5 7.4 1.2 0.1 0.0 0.2 0.5 0.3 0.8 0.5 3.3 11.2 3.9 0.1 0.1 0.8 2.5 0.6 5.2 0.6 0.9 6.3 2.4 1.1 0.0 1.9 2.2 0.0 0.1 0.0 0.3 1.6 2.2 0.0 0.4 0.4 0.2 0.1 1.1 0.0 16.8 0.4 0.8 1.2 0.8 0.9 0.8 2.1 5.7 1.2 0.0 0.0 1.4 5.1 0.7 0.0 0.1 1.3 0.9 0.3 1.4 1.3 0.4 1.6 0.1 5.1 0.0 0.5 0.0 0.0 0.0 0.0 1.4 0.3 3.4 6.2 2.6 5.6 3.1 2.2 3.2 1.7 5.4 4.1 IL13 "ALRH, BHR1, IL-13, MGC116786, MGC116788, MGC116789, P600" ENSG00000169194 "Interleukin 13" P35225 5 132656263-132661110 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins" Cytokine "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "testis: 20.7" "Cell line enriched" "Detected in single" 177 "HDLM-2: 29.5" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA042421 Approved "Plasma membrane,Cytosol" "Secreted to blood" 33773 "Plasma membrane, Cytosol" "HPA042421: AB_10795504" "unprognostic (2.17e-1)" "unprognostic (2.29e-2)" "unprognostic (7.48e-2)" "unprognostic (2.18e-2)" "unprognostic (1.92e-1)" "unprognostic (5.21e-3)" "unprognostic (1.79e-1)" "unprognostic (2.69e-1)" "unprognostic (5.20e-1)" "unprognostic (7.10e-2)" "unprognostic (3.61e-3)" "unprognostic (3.34e-1)" "unprognostic (5.97e-4)" "unprognostic (4.70e-2)" "unprognostic (2.05e-1)" "unprognostic (7.39e-2)" "unprognostic (1.38e-1)" 0.3 0.0 0.1 0.8 0.1 0.3 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.6 0.1 3.0 0.0 0.0 0.1 0.0 0.0 1.8 3.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 3.1 0.2 0.2 0.6 0.0 0.0 0.0 0.0 20.7 0.0 2.9 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 29.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 IL13RA2 "CD213a2, CT19, IL-13R, IL13BP" ENSG00000123496 "Interleukin 13 receptor subunit alpha 2" Q14627 X 115003975-115019977 "Cancer-related genes, CD markers, Predicted membrane proteins" Receptor "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "pituitary gland: 16.1;testis: 31.5" "Group enriched" "Detected in some" 9 "PC-3: 26.4;U-2197: 84.9;U-251 MG: 57.0;U-87 MG: 33.8" "Cancer enhanced" "Detected in many" "glioma: 17.2" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Region enhanced" "Detected in some" "olfactory region: 8.7" "Low region specificity" "Detected in many" "HPA045831, HPA067363" Approved "Nucleoplasm,Vesicles,Plasma membrane,Cell Junctions" "Plasma membrane, Cell Junctions" "Nucleoplasm, Vesicles" "HPA045831: , HPA067363: " "unprognostic (1.97e-1)" "unprognostic (2.83e-1)" "unprognostic (6.62e-4)" "unprognostic (7.39e-2)" "unprognostic (8.45e-2)" "unprognostic (1.80e-1)" "prognostic favourable (3.55e-4)" "unprognostic (3.54e-1)" "unprognostic (2.85e-1)" "unprognostic (1.92e-2)" "unprognostic (2.20e-3)" "unprognostic (2.19e-2)" "unprognostic (1.53e-5)" "unprognostic (1.58e-1)" "unprognostic (1.63e-1)" "unprognostic (9.70e-3)" "unprognostic (1.20e-1)" 0.5 4.8 3.7 3.9 11.3 0.0 0.8 0.3 3.1 1.2 0.4 2.1 5.7 0.3 0.9 4.4 0.5 0.1 0.8 0.6 5.1 11.2 3.5 9.6 1.0 0.1 1.2 2.6 0.1 0.1 0.5 16.1 2.1 3.9 4.3 0.7 1.6 0.8 3.7 0.0 0.1 0.3 0.4 0.6 0.2 0.1 31.5 1.4 0.0 1.3 0.2 0.2 1.9 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.1 0.7 0.0 5.8 5.5 0.0 0.0 0.0 0.0 0.0 0.1 2.9 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 1.0 0.1 0.9 5.4 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 26.4 0.0 0.0 0.0 0.4 0.0 0.0 1.3 0.4 0.0 0.1 0.0 0.0 0.0 3.0 0.0 84.9 57.0 0.0 0.0 0.0 33.8 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.7 11.3 0.3 3.1 5.1 11.2 1.2 2.6 3.9 1.4 IL15 "IL-15, MGC9721" ENSG00000164136 "Interleukin 15" P40933 4 141636599-141733987 "Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins" Cytokine "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "HDLM-2: 15.5;Karpas-707: 15.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "CAB004457, HPA037738" Approved Supported "Nucleoplasm,Nuclear speckles" "Secreted to blood" 20753 "Nucleoplasm, Nuclear speckles" "CAB004457: AB_2124575, HPA037738: " "unprognostic (1.10e-2)" "unprognostic (1.53e-1)" "unprognostic (1.04e-2)" "unprognostic (8.57e-2)" "unprognostic (8.77e-3)" "unprognostic (1.69e-1)" "unprognostic (1.17e-1)" "unprognostic (2.90e-1)" "unprognostic (1.80e-1)" "unprognostic (1.48e-1)" "unprognostic (5.20e-2)" "unprognostic (1.74e-2)" "unprognostic (3.75e-2)" "unprognostic (1.09e-1)" "unprognostic (4.03e-2)" "unprognostic (3.29e-2)" "unprognostic (1.54e-1)" 7.7 3.7 1.1 21.3 1.5 2.9 9.2 1.8 2.2 6.0 8.8 0.8 2.2 6.3 11.3 7.4 5.6 4.6 9.9 9.3 1.1 1.5 6.9 3.7 14.4 18.8 2.3 1.6 3.2 3.1 0.5 4.5 9.9 2.1 7.7 5.7 5.9 6.9 3.6 9.1 3.2 14.2 7.1 2.6 17.0 5.3 2.6 2.0 9.8 18.1 5.9 11.0 9.8 16.9 3.7 4.6 8.1 14.0 2.6 4.5 4.4 2.4 5.2 0.2 0.5 0.8 4.7 1.3 5.6 5.3 5.8 4.7 2.8 6.8 2.3 7.3 4.8 3.6 0.1 3.0 3.2 15.5 1.4 0.4 13.7 0.4 3.9 1.6 1.1 1.7 1.2 3.8 0.4 3.7 3.8 15.2 3.7 0.8 3.4 0.3 2.6 1.6 0.9 13.4 0.3 7.6 0.6 0.5 1.3 2.4 3.7 2.7 0.9 0.2 5.5 5.9 3.8 1.7 3.4 10.7 1.3 0.7 6.3 0.6 2.1 8.1 14.0 0.8 2.5 12.4 4.5 3.7 2.9 2.2 4.6 3.4 1.2 1.3 1.0 2.6 12.5 0.1 1.5 4.4 1.1 1.5 1.8 2.2 1.1 1.5 2.3 1.6 2.1 2.0 IL16 "FLJ16806, FLJ42735, HsT19289, IL-16, LCF, prIL-16" ENSG00000172349 "Interleukin 16" Q14005 15 81159575-81314058 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Chemotaxis, Host-virus interaction, Transcription, Transcription regulation" Cytokine "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 75.7;lymphoid tissue: 97.9" "Cell line enhanced" "Detected in some" "Daudi: 12.2;HEL: 12.9;HMC-1: 23.3;RPMI-8226: 22.1;U-266/70: 27.7;U-698: 11.4;U-937: 15.5" "Low cancer specificity" "Detected in all" "Region enriched" "Detected in all" 6 "cerebellum: 40.1" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Group enriched" "Detected in some" 13 "cerebellum: 61.1;hippocampal formation: 29.7" "Region enriched" "Detected in single" 38 "cerebellum: 96.7" "CAB005247, HPA018467, HPA048861" Enhanced Supported "Nuclear speckles,Plasma membrane,Midbody ring,Cytosol" "Secreted to blood" 125370 14000 "Nuclear speckles" "Plasma membrane, Midbody ring, Cytosol" "CAB005247: AB_2124730, HPA018467: AB_1851642, HPA048861: " "unprognostic (8.23e-3)" "unprognostic (2.70e-3)" "unprognostic (1.97e-2)" "unprognostic (9.61e-4)" "unprognostic (2.01e-1)" "unprognostic (5.26e-4)" "unprognostic (2.63e-2)" "unprognostic (6.72e-3)" "unprognostic (2.25e-1)" "unprognostic (3.91e-1)" "unprognostic (1.47e-1)" "unprognostic (6.21e-2)" "unprognostic (3.16e-3)" "unprognostic (1.21e-1)" "unprognostic (3.23e-2)" "unprognostic (5.26e-2)" "unprognostic (1.29e-1)" 8.8 2.4 4.1 48.0 5.8 19.5 7.8 40.1 4.3 4.7 4.8 4.6 0.9 3.8 5.4 2.9 3.4 9.7 5.6 5.1 4.9 2.1 2.5 3.9 14.7 58.0 5.8 2.3 3.7 1.7 0.7 1.4 3.0 6.7 3.5 5.9 3.4 13.5 1.5 1.8 6.1 19.2 3.3 7.8 38.2 5.0 2.2 5.5 97.9 3.7 2.4 54.8 8.7 5.4 43.3 37.1 75.7 35.0 49.3 60.5 66.5 0.0 0.0 0.0 0.0 8.2 3.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 12.2 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 12.9 0.0 0.0 0.4 9.1 23.3 0.4 0.0 0.0 0.2 0.1 1.3 4.9 0.0 0.0 0.7 9.7 0.0 0.0 0.0 0.0 22.1 0.0 0.0 0.0 0.0 0.0 0.0 4.4 0.0 2.0 0.1 0.1 0.1 0.4 0.0 27.7 2.3 11.4 0.8 15.5 0.7 52.7 27.4 75.7 43.1 35.0 48.6 43.3 45.1 47.1 37.1 39.9 60.5 48.6 69.1 49.3 33.7 28.0 47.0 66.5 4.1 5.8 40.1 4.3 4.9 2.1 5.8 2.3 6.7 5.5 IL17A "CTLA8, IL-17, IL-17A, IL17" ENSG00000112115 "Interleukin 17A" Q16552 6 52186387-52190638 "Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins" Cytokine "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 6 "lymphoid tissue: 7.6;tongue: 12.2;urinary bladder: 4.4" "Group enriched" "Detected in some" 37 "Karpas-707: 7.2;U-266/84: 4.4" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA052258 Uncertain "Secreted to blood" 9915 "HPA052258: " "unprognostic (5.55e-1)" "unprognostic (2.18e-4)" "unprognostic (3.05e-4)" "unprognostic (1.41e-2)" "unprognostic (2.22e-2)" 0.2 0.0 0.0 3.2 0.0 0.0 0.0 0.0 0.0 0.4 0.3 0.0 0.0 0.4 0.0 0.0 1.3 0.5 0.6 0.0 0.1 0.0 0.1 0.1 0.5 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.4 0.0 0.1 0.0 0.1 0.1 1.0 0.1 0.0 0.1 0.3 0.1 0.0 0.0 0.0 12.2 7.6 4.4 0.5 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 4.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 IL17B "IL-17B, IL-20, MGC138900, MGC138901, NIRF, ZCYTO7" ENSG00000127743 "Interleukin 17B" Q9UHF5 5 149371324-149404202 "Cancer-related genes, Predicted secreted proteins" Cytokine "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in some" "HEL: 4.4;Hep G2: 2.0;K-562: 1.6;Karpas-707: 3.6;NB-4: 2.5" "Low cancer specificity" "Detected in some" "Region enriched" "Detected in some" 6 "midbrain: 8.9" "Cell type enriched" "Detected in single" 14 "basophil: 4.3" "Lineage enriched" "Detected in single" 14 "granulocytes: 4.3" "Low region specificity" "Detected in some" "Low region specificity" "Detected in all" HPA042441 Uncertain "Secreted to blood" 75000 "HPA042441: AB_10797014" "unprognostic (2.83e-4)" "unprognostic (2.71e-2)" "unprognostic (4.90e-3)" "unprognostic (9.22e-2)" "unprognostic (7.43e-2)" "unprognostic (5.03e-2)" "unprognostic (9.62e-3)" "unprognostic (3.00e-1)" "unprognostic (1.80e-1)" "unprognostic (6.54e-2)" "unprognostic (9.30e-3)" "unprognostic (3.22e-1)" "unprognostic (6.98e-8)" "unprognostic (2.66e-1)" "unprognostic (1.53e-1)" "unprognostic (6.47e-2)" "unprognostic (1.10e-1)" 2.1 3.3 0.1 2.2 0.1 0.6 7.5 0.1 0.8 4.7 4.2 0.1 2.8 0.7 6.8 3.6 4.1 1.6 1.1 5.1 0.1 0.0 0.8 0.1 0.9 0.1 8.9 1.2 0.7 0.1 0.0 0.1 0.4 1.4 3.6 0.4 2.4 7.1 5.6 1.5 1.3 1.7 5.3 5.4 1.1 1.3 5.9 0.4 0.4 0.6 1.6 0.3 1.8 1.3 0.0 0.2 4.3 0.0 0.0 0.3 0.0 0.0 0.0 0.5 0.3 0.0 0.0 0.0 0.8 0.0 0.3 0.0 0.0 0.0 0.9 0.3 0.8 0.0 0.0 0.0 0.0 0.5 0.0 4.4 0.0 2.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 3.6 0.0 0.0 0.0 2.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.2 0.0 0.0 0.0 0.0 1.0 0.0 0.0 1.1 0.4 0.0 0.5 0.2 0.1 0.0 0.0 0.9 4.3 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.8 0.1 0.0 8.9 1.2 1.4 0.4 IL18 "IGIF, IL-18, IL-1g, IL1F4" ENSG00000150782 "Interleukin 18" Q14116 11 112143251-112164117 "Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Inflammatory response" Cytokine "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "esophagus: 53.9;skin 1: 57.2" "Cell line enhanced" "Detected in many" "A-431: 26.0;CAPAN-2: 41.2;HaCaT: 37.8;HBEC3-KT: 28.4;hTCEpi: 43.5;PC-3: 25.2;U-2 OS: 49.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "myeloid DC: 17.1" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "HPA003980, CAB007772" Enhanced Approved "Nucleoplasm,Golgi apparatus,Cytosol" "Secreted to blood" 136427 "Nucleoplasm, Golgi apparatus" Cytosol "CAB007772: AB_562304, HPA003980: AB_1851670" "unprognostic (2.31e-3)" "unprognostic (3.25e-1)" "prognostic favourable (2.78e-4)" "unprognostic (3.41e-2)" "unprognostic (1.25e-1)" "unprognostic (1.62e-1)" "unprognostic (1.65e-1)" "unprognostic (8.15e-2)" "unprognostic (3.23e-1)" "unprognostic (2.78e-1)" "unprognostic (1.96e-3)" "unprognostic (4.13e-1)" "unprognostic (3.58e-2)" "unprognostic (1.51e-1)" "unprognostic (3.19e-2)" "unprognostic (3.15e-2)" "unprognostic (9.01e-2)" 9.4 2.6 5.3 12.5 7.9 10.8 5.2 1.3 5.3 18.5 13.1 6.4 2.5 8.6 2.1 3.7 53.9 3.3 11.9 2.1 5.7 3.1 17.5 3.6 15.2 22.6 7.4 1.4 1.4 7.0 0.3 3.3 2.6 8.2 5.5 11.6 2.2 8.3 1.4 3.8 57.2 9.1 4.0 24.7 26.6 5.1 1.7 7.5 3.9 1.8 21.2 26.5 9.1 35.4 0.5 17.1 10.4 6.9 13.8 0.3 1.6 26.0 9.1 0.0 0.0 0.0 0.0 0.1 0.4 0.0 0.0 0.0 5.0 41.2 0.0 6.0 0.0 37.8 0.0 28.4 0.0 0.0 0.2 3.9 9.3 2.1 0.9 2.0 7.6 0.0 43.5 0.0 10.1 0.0 0.1 0.0 0.3 0.0 0.0 0.2 0.0 25.2 0.0 0.0 0.0 18.6 5.6 0.0 0.0 17.9 11.9 0.1 7.1 5.7 0.0 0.1 49.0 0.3 8.0 0.1 0.0 0.1 0.0 15.1 0.0 3.5 6.0 10.4 0.1 6.9 0.0 0.4 0.0 0.0 17.1 0.5 0.0 0.3 6.7 13.8 3.7 3.8 0.0 1.6 5.3 7.9 1.3 5.3 5.7 3.1 7.4 1.4 8.2 7.5 IL1R1 "CD121A, D2S1473, IL1R, IL1RA" ENSG00000115594 "Interleukin 1 receptor type 1" P14778 2 102064544-102179874 "Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters" "Inflammatory response" Receptor "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "ASC diff: 93.4;ASC TERT1: 41.7;HHSteC: 29.3;HSkMC: 115.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "neutrophil: 4.0" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA001237, HPA005823, CAB007779, HPA029560" Approved Approved "Nucleoplasm,Vesicles,Plasma membrane,Cytosol" "Secreted to blood" 1000000 "Nucleoplasm, Vesicles" "Plasma membrane, Cytosol" "CAB007779: AB_562073, HPA001237: , HPA005823: , HPA029560: " "unprognostic (6.16e-3)" "unprognostic (3.55e-2)" "unprognostic (3.33e-1)" "unprognostic (1.22e-1)" "unprognostic (4.26e-2)" "unprognostic (7.10e-2)" "unprognostic (2.01e-1)" "unprognostic (3.36e-2)" "unprognostic (1.44e-1)" "unprognostic (3.16e-1)" "unprognostic (4.26e-2)" "unprognostic (7.77e-2)" "prognostic unfavourable (6.92e-6)" "unprognostic (2.48e-2)" "unprognostic (6.95e-2)" "unprognostic (4.83e-2)" "unprognostic (7.73e-2)" 48.6 25.2 2.6 18.2 5.2 4.0 92.4 2.4 3.9 47.8 21.0 2.5 34.3 5.2 15.2 30.2 18.2 17.1 25.8 27.0 4.2 2.5 23.7 74.8 40.5 28.0 5.6 1.1 25.1 17.1 16.9 7.3 66.2 10.9 26.0 8.4 8.6 12.7 36.4 15.5 13.5 13.0 15.1 10.0 19.2 15.6 13.4 2.8 3.5 33.6 9.0 9.6 32.0 36.4 0.1 0.1 4.0 0.5 0.8 1.8 0.2 0.2 1.8 0.0 1.5 93.4 41.7 0.6 3.9 17.7 2.8 4.2 0.8 0.4 0.0 2.9 7.8 0.7 0.0 0.3 2.3 7.7 0.0 0.1 0.4 4.3 29.3 0.0 0.0 115.0 0.3 3.1 0.7 1.2 0.4 0.1 4.0 0.7 0.0 0.1 0.1 0.1 0.0 0.2 0.0 2.6 1.9 0.0 0.0 1.7 1.1 0.0 1.6 0.1 0.0 8.0 0.5 13.4 0.3 0.0 0.0 0.0 3.1 0.0 0.5 0.6 0.5 0.1 0.0 0.0 0.7 0.1 1.1 0.0 0.1 0.1 0.0 0.1 4.0 0.8 0.0 0.1 1.8 0.2 2.6 5.2 2.4 3.9 4.2 2.5 5.6 1.1 10.9 2.8 IL1R2 "CD121b, IL1RB" ENSG00000115590 "Interleukin 1 receptor type 2" P27930 2 101991844-102028544 "Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins" Receptor "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 73.2;lymphoid tissue: 74.1" "Cell line enriched" "Detected in some" 19 "HDLM-2: 100.0" "Low cancer specificity" "Detected in many" "Region enriched" "Detected in many" 4 "midbrain: 9.2" "Cell type enriched" "Detected in some" 25 "neutrophil: 73.2" "Lineage enriched" "Detected in many" 25 "granulocytes: 73.2" "Low region specificity" "Detected in many" "Not detected" "Not detected" "HPA027597, HPA027598" Uncertain "Secreted to blood" 7132500 21000000 "HPA027597: AB_10600768, HPA027598: AB_10601229" "unprognostic (3.54e-2)" "unprognostic (1.87e-1)" "unprognostic (1.21e-1)" "unprognostic (3.83e-2)" "unprognostic (6.59e-2)" "unprognostic (1.42e-1)" "unprognostic (6.36e-2)" "unprognostic (4.82e-3)" "unprognostic (1.62e-2)" "unprognostic (7.15e-2)" "unprognostic (8.20e-3)" "unprognostic (1.07e-1)" "prognostic unfavourable (5.58e-12)" "unprognostic (1.92e-1)" "unprognostic (7.51e-2)" "unprognostic (1.77e-1)" "unprognostic (6.62e-2)" 9.1 3.2 1.2 16.4 1.9 22.3 1.6 1.2 1.9 6.4 13.4 0.4 0.1 0.1 1.3 1.3 20.4 9.7 3.4 15.1 1.2 0.5 5.8 8.2 25.5 74.1 9.2 0.2 2.5 1.4 0.0 2.4 24.9 2.2 1.1 20.0 1.8 4.3 0.8 2.8 14.1 2.2 1.3 4.4 47.5 14.6 1.6 1.1 1.6 1.8 8.5 25.1 3.2 9.1 0.0 2.8 73.2 0.8 0.0 1.1 0.2 1.5 0.1 0.0 0.0 0.2 0.2 0.1 0.0 0.0 0.0 0.0 1.6 0.0 0.0 3.3 0.0 0.6 0.0 0.1 0.0 100.0 0.1 0.0 0.0 0.8 0.5 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.2 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 1.6 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.8 0.0 0.0 0.4 0.0 0.0 0.1 0.0 2.8 0.0 0.0 0.0 73.2 0.0 0.0 0.0 1.1 0.2 1.2 1.9 1.2 1.9 1.2 0.5 9.2 0.2 2.2 1.1 IL1RN "ICIL-1RA, IL-1RN, IL1F3, IL1RA, IRAP, MGC10430" ENSG00000136689 "Interleukin 1 receptor antagonist" P18510 2 113107214-113134016 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "esophagus: 217.8;lymphoid tissue: 194.7;tongue: 123.7" "Cell line enhanced" "Detected in some" "A-431: 20.6;HaCaT: 40.8;RT4: 39.8;THP-1: 11.5" "Cancer enhanced" "Detected in all" "head and neck cancer: 92.7" "Not detected" "Not detected" "Group enriched" "Detected in some" 4 "classical monocyte: 17.1;myeloid DC: 17.1;neutrophil: 65.2" "Group enriched" "Detected in many" 332 "dendritic cells: 17.1;granulocytes: 65.2;monocytes: 17.1" "Not detected" "Not detected" "HPA001482, CAB009633" Enhanced Approved Nucleoplasm,Centrosome,Cytosol "Secreted to blood" 421933 Nucleoplasm "Centrosome, Cytosol" "CAB009633: AB_2125576, HPA001482: AB_1078437" "unprognostic (3.85e-3)" "unprognostic (3.96e-2)" "unprognostic (1.00e-1)" "prognostic unfavourable (3.00e-4)" "unprognostic (2.21e-1)" "unprognostic (3.63e-2)" "unprognostic (3.15e-2)" "unprognostic (2.55e-1)" "unprognostic (4.46e-2)" "unprognostic (9.54e-2)" "prognostic unfavourable (6.85e-4)" "unprognostic (5.59e-3)" "prognostic unfavourable (2.66e-6)" "unprognostic (2.05e-1)" "prognostic unfavourable (8.23e-4)" "unprognostic (4.25e-2)" "unprognostic (1.03e-1)" 17.3 0.2 0.2 7.2 0.3 32.9 1.1 0.2 0.5 27.2 3.8 0.6 1.4 1.1 1.5 0.7 217.8 0.2 4.1 0.5 0.2 0.0 0.5 23.5 2.9 1.9 0.3 0.2 0.4 0.4 0.1 0.3 3.1 0.6 1.6 0.3 0.4 30.9 1.3 0.5 14.4 3.7 0.7 0.2 3.6 5.7 1.4 0.2 1.0 0.7 123.7 194.7 3.3 42.2 0.0 17.1 65.2 17.1 0.0 0.0 4.9 20.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.8 0.0 0.1 0.0 0.2 0.1 0.1 0.0 40.8 0.0 1.1 0.0 0.0 0.0 0.1 0.0 6.9 0.0 0.1 7.7 0.0 5.3 0.2 0.0 0.0 0.1 0.1 0.0 0.1 0.0 5.4 0.0 0.0 0.0 0.0 0.0 0.0 39.8 0.0 0.0 0.0 0.3 0.0 0.0 11.5 0.1 0.5 0.0 0.3 0.0 0.3 0.0 0.0 3.9 4.6 0.1 0.0 17.1 0.3 0.0 7.6 0.0 0.0 0.0 0.0 17.1 0.0 0.0 0.0 65.2 0.0 3.4 0.1 0.0 4.9 0.2 0.3 0.2 0.5 0.2 0.0 0.3 0.2 0.6 0.2 IL2 "IL-2, TCGF" ENSG00000109471 "Interleukin 2" P60568 4 122451470-122456725 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins" "Adaptive immunity, Immunity" "Cytokine, Growth factor" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "blood: 1.9;intestine: 2.4;lymphoid tissue: 1.9" "Cell line enriched" "Detected in single" 23 "MOLT-4: 2.3" "Not detected" "Not detected" "Cell type enhanced" "Detected in single" "memory CD4 T-cell: 1.9" "Lineage enriched" "Detected in single" 19 "T-cells: 1.9" "Not detected" "Not detected" "Low region specificity" "Detected in all" CAB010310 Uncertain "Secreted to blood" 20467 "CAB010310: AB_649346" "unprognostic (8.87e-5)" "unprognostic (6.13e-3)" "unprognostic (1.38e-3)" "unprognostic (9.79e-3)" "unprognostic (2.56e-2)" "unprognostic (7.32e-2)" "unprognostic (2.06e-5)" "unprognostic (5.21e-3)" "unprognostic (8.01e-2)" 0.6 0.0 0.0 0.6 0.0 0.4 0.5 0.0 0.0 0.9 0.3 0.5 0.1 0.0 0.8 0.6 0.5 0.0 0.0 0.0 0.2 0.3 0.7 1.1 0.0 0.1 0.0 0.0 0.0 0.0 0.4 1.9 0.1 0.0 0.0 0.4 2.4 0.0 0.2 0.8 0.3 0.0 0.4 1.9 0.8 0.4 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 IL21R CD360 ENSG00000103522 "Interleukin 21 receptor" Q9HBE5 16 27402162-27452042 "Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins" Receptor "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "blood: 17.9;lymphoid tissue: 47.8" "Cell line enhanced" "Detected in some" "Daudi: 10.1;HDLM-2: 42.9;Karpas-707: 19.9;RH-30: 15.1;RPMI-8226: 24.0;U-266/70: 10.0" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA042296 Uncertain Uncertain "Plasma membrane,Cytosol" "Plasma membrane, Cytosol" "HPA042296: AB_10806236" "unprognostic (2.91e-2)" "unprognostic (2.65e-3)" "unprognostic (6.64e-4)" "unprognostic (1.58e-3)" "unprognostic (2.14e-1)" "prognostic favourable (7.29e-4)" "unprognostic (8.33e-2)" "unprognostic (2.06e-1)" "unprognostic (8.50e-6)" "unprognostic (2.26e-2)" "unprognostic (1.13e-2)" "unprognostic (8.71e-2)" "unprognostic (2.34e-10)" "unprognostic (8.79e-2)" "unprognostic (4.42e-2)" "unprognostic (1.50e-1)" "unprognostic (9.58e-2)" 0.8 0.6 0.6 33.6 3.7 5.7 0.6 0.5 1.6 0.5 0.9 0.3 0.0 0.5 0.5 1.3 1.0 0.8 1.1 1.8 0.6 2.3 1.6 1.3 5.6 20.9 1.3 0.0 0.5 0.5 0.0 0.9 0.9 1.9 0.9 0.9 1.8 3.7 0.3 0.7 0.7 4.0 0.6 1.7 11.2 1.3 1.0 1.4 47.8 1.3 0.8 31.7 2.7 0.8 11.5 1.6 0.7 17.9 6.3 10.3 4.2 0.0 0.0 0.1 0.1 0.0 0.5 0.3 0.3 0.0 0.0 0.9 0.0 0.0 10.1 0.1 0.8 0.0 0.0 0.0 0.0 42.9 0.0 2.1 0.0 0.2 1.4 0.0 0.6 1.5 0.0 2.7 0.0 0.0 0.1 19.9 1.5 0.0 0.0 0.2 0.3 0.0 0.1 15.1 24.0 0.0 0.0 0.1 0.0 0.0 0.0 1.1 0.0 0.5 1.1 0.8 0.2 0.2 0.0 10.0 3.5 2.3 2.1 0.5 0.0 0.2 0.3 0.0 9.8 5.8 3.6 1.0 6.3 10.3 1.6 11.5 6.9 6.7 0.7 6.3 17.9 0.7 7.6 4.2 0.6 3.7 0.5 1.6 0.6 2.3 1.3 0.0 1.9 1.4 IL24 "C49A, FISP, IL-24, IL10B, mda-7, Mob-5, ST16" ENSG00000162892 "Interleukin 24" Q13007 1 206897443-206904139 "Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins" Apoptosis Cytokine "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 18.7;lymphoid tissue: 22.5" "Cell line enriched" "Detected in some" 9 "BJ hTERT+: 62.3" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in single" "Low cell type specificity" "Detected in many" "Group enriched" "Detected in many" 5 "B-cells: 18.7;T-cells: 12.0" "Not detected" "Not detected" "Region enhanced" "Detected in single" "cerebral cortex: 0.9" CAB025972 Uncertain "Secreted to blood" 140000 "CAB025972: " "prognostic favourable (5.09e-4)" "unprognostic (3.79e-1)" "unprognostic (2.89e-2)" "unprognostic (4.09e-3)" "unprognostic (3.98e-1)" "unprognostic (2.68e-1)" "unprognostic (2.85e-2)" "unprognostic (2.20e-2)" "unprognostic (3.98e-1)" "unprognostic (3.35e-2)" "unprognostic (8.04e-2)" "unprognostic (7.63e-2)" "unprognostic (3.43e-4)" "unprognostic (5.41e-2)" "unprognostic (1.29e-1)" "unprognostic (7.91e-2)" "unprognostic (3.33e-2)" 5.3 0.0 0.2 9.2 0.2 1.6 0.2 0.2 0.4 0.2 1.3 0.2 0.2 0.3 0.9 0.7 0.9 1.4 1.7 0.8 0.2 0.0 0.6 2.4 2.5 22.5 0.2 0.2 0.9 0.2 0.0 0.2 1.1 1.3 1.3 0.0 0.2 0.2 0.2 3.9 0.2 1.3 0.2 0.2 19.6 0.9 0.5 0.2 0.4 0.2 0.9 2.7 3.3 0.3 18.7 0.4 0.7 0.0 3.4 12.0 3.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 62.3 0.0 0.1 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.1 1.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.6 0.0 0.1 0.9 7.0 0.0 0.0 0.8 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 3.3 0.0 0.0 0.0 0.0 0.6 0.1 5.0 0.0 0.0 0.0 0.8 0.4 2.7 0.1 3.3 0.2 0.5 0.5 0.0 0.1 0.4 0.0 0.0 4.3 0.0 6.2 18.7 6.8 6.4 0.0 18.6 11.8 6.5 0.7 3.4 0.0 0.4 12.0 3.6 0.2 0.2 0.2 0.4 0.2 0.0 0.2 0.2 1.3 0.2 IL2RA "CD25, IDDM10, IL2R" ENSG00000134460 "Interleukin 2 receptor subunit alpha" P01589 10 6010689-6062370 "Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" Immunity Receptor "Cancer-related genes, Diabetes mellitus, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "adipose tissue: 16.5;blood: 55.4;lymphoid tissue: 56.7" "Cell line enriched" "Detected in some" 59 "HDLM-2: 153.9" "Low cancer specificity" "Detected in many" "Region enhanced" "Detected in single" "pons and medulla: 2.4" "Group enriched" "Detected in many" 6 "basophil: 30.3;T-reg: 55.4" "Group enriched" "Detected in many" 12 "granulocytes: 30.3;T-cells: 55.4" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB002419, HPA054622" Enhanced 110000 "CAB002419: AB_563538, HPA054622: " "unprognostic (2.82e-1)" "unprognostic (8.10e-3)" "unprognostic (1.75e-2)" "unprognostic (5.86e-2)" "unprognostic (1.50e-1)" "unprognostic (1.45e-3)" "unprognostic (2.78e-2)" "unprognostic (2.73e-1)" "unprognostic (5.03e-2)" "unprognostic (6.32e-2)" "unprognostic (7.21e-2)" "unprognostic (2.07e-1)" "prognostic unfavourable (2.08e-9)" "unprognostic (2.10e-2)" "unprognostic (4.66e-2)" "unprognostic (2.22e-1)" "unprognostic (5.10e-2)" 16.5 2.5 0.3 10.9 0.6 0.1 1.4 0.3 0.3 0.6 3.1 0.1 0.0 1.3 0.8 4.9 1.9 0.8 2.2 1.9 0.4 0.5 2.6 1.3 4.0 50.4 0.5 0.0 0.6 1.0 0.0 1.8 1.8 2.4 1.1 1.6 3.4 2.2 0.5 0.8 0.6 10.3 3.5 2.2 56.7 1.4 0.4 0.0 4.5 4.2 2.0 16.8 5.0 0.6 3.6 0.0 30.3 0.0 2.9 55.4 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 153.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 2.6 0.0 0.0 0.0 30.3 0.0 4.5 0.1 0.0 0.5 3.6 6.8 0.7 0.0 1.5 0.5 0.0 0.2 2.9 0.0 0.0 55.4 0.7 0.3 0.6 0.3 0.3 0.4 0.5 0.5 0.0 2.4 0.0 IL2RB "CD122, IL15RB" ENSG00000100385 "Interleukin 2 receptor subunit beta" P14784 22 37125838-37175054 "Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Host-virus interaction" Receptor "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 51.6;lymphoid tissue: 35.0;placenta: 58.5" "Cell line enriched" "Detected in some" 8 "HDLM-2: 104.1" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Group enriched" "Detected in many" 4 "gdT-cell: 14.7;NK-cell: 51.6" "Group enriched" "Detected in many" 32 "NK-cells: 51.6;T-cells: 14.7" "Region enriched" "Detected in single" 7 "basal ganglia: 1.6" "Low region specificity" "Detected in all" HPA062657 Enhanced "HPA062657: " "unprognostic (3.38e-3)" "unprognostic (1.21e-2)" "prognostic favourable (6.76e-4)" "prognostic favourable (3.18e-5)" "unprognostic (2.44e-2)" "unprognostic (9.69e-3)" "unprognostic (2.60e-1)" "unprognostic (5.22e-2)" "unprognostic (1.03e-3)" "unprognostic (5.37e-2)" "unprognostic (1.09e-1)" "unprognostic (2.74e-1)" "prognostic unfavourable (3.50e-7)" "unprognostic (4.63e-2)" "unprognostic (7.96e-2)" "unprognostic (3.94e-3)" "unprognostic (2.46e-2)" 2.2 1.0 0.8 20.5 0.8 12.3 1.6 0.6 0.7 1.3 5.5 0.6 1.4 1.8 4.3 2.8 2.6 1.8 5.8 3.7 0.7 0.8 1.9 6.0 7.4 20.8 0.8 0.2 1.5 1.0 0.0 1.1 58.5 0.7 3.5 1.8 2.9 3.7 2.1 0.9 4.0 7.3 0.6 1.1 35.0 2.3 1.1 0.2 21.0 2.1 1.8 28.7 4.0 1.5 0.3 0.0 1.0 0.1 51.6 14.7 7.9 0.0 0.0 0.2 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.6 0.0 0.0 0.0 0.0 0.0 104.1 0.1 0.2 0.0 0.0 0.0 0.0 5.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.8 0.6 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 2.8 0.0 0.1 7.5 12.8 0.0 0.1 0.0 0.1 1.0 0.0 0.1 14.7 0.1 8.1 0.1 3.3 8.2 0.0 0.3 1.1 4.3 0.3 51.6 0.1 0.0 6.8 7.9 0.8 0.8 0.6 0.7 0.7 0.8 0.8 0.2 0.7 0.2 IL2RG "CD132, CIDX, IMD4, SCIDX1" ENSG00000147168 "Interleukin 2 receptor subunit gamma" P31785 X 71107404-71112108 "Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Host-virus interaction" Receptor "Cancer-related genes, Disease mutation, FDA approved drug targets, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "blood: 115.3;lymphoid tissue: 169.3" "Cell line enriched" "Detected in some" 6 "Karpas-707: 220.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "HPA046641, HPA049691" Enhanced Approved Vesicles Vesicles "HPA046641: AB_2679733, HPA049691: " "unprognostic (2.97e-3)" "unprognostic (4.24e-2)" "unprognostic (1.23e-1)" "prognostic favourable (1.73e-4)" "unprognostic (8.25e-2)" "unprognostic (1.93e-3)" "unprognostic (1.37e-1)" "unprognostic (1.53e-1)" "unprognostic (1.91e-3)" "unprognostic (1.23e-2)" "unprognostic (4.36e-1)" "unprognostic (1.45e-1)" "prognostic unfavourable (2.28e-7)" "unprognostic (1.73e-1)" "unprognostic (4.69e-2)" "unprognostic (4.89e-2)" "unprognostic (9.54e-2)" 5.8 1.3 1.4 39.5 1.4 12.8 3.6 0.8 0.9 2.9 16.6 0.9 0.9 8.2 3.0 2.1 5.3 3.1 5.3 2.6 1.4 1.5 3.7 4.7 13.6 70.4 1.8 0.6 2.9 1.5 0.0 1.2 5.3 1.5 3.2 20.8 2.9 10.4 1.8 1.6 2.7 28.6 1.5 2.9 58.7 6.0 2.0 0.9 169.3 3.3 4.2 61.4 7.6 3.1 51.9 30.6 65.6 19.7 94.6 115.3 99.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.8 17.2 1.2 0.0 0.1 0.0 0.0 0.0 14.4 0.0 2.2 0.0 0.0 0.0 8.9 0.4 0.0 0.0 0.0 0.0 0.0 3.8 220.5 0.0 0.0 31.9 17.4 0.0 0.0 7.3 0.0 1.8 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 12.6 22.2 11.1 0.2 37.0 0.0 35.2 8.5 13.4 107.2 19.7 105.6 51.9 97.7 110.4 20.3 51.6 68.0 84.9 65.6 94.6 13.5 30.6 115.3 99.0 1.4 1.4 0.8 0.9 1.4 1.5 1.8 0.6 1.5 0.9 IL4 "BCGF-1, BCGF1, BSF1, IL-4, MGC79402" ENSG00000113520 "Interleukin 4" P05112 5 132673986-132682676 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins" "B-cell activation" "Cytokine, Growth factor" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 16 "blood: 73.8" "Cell line enriched" "Detected in some" 5 "MOLT-4: 20.9" "Not detected" "Not detected" "Not detected" "Not detected" "Cell type enriched" "Detected in single" 679 "basophil: 73.8" "Lineage enriched" "Detected in single" 679 "granulocytes: 73.8" "Low region specificity" "Detected in many" HPA072995 Approved "Secreted to blood" 7157 "HPA072995: " "unprognostic (3.40e-2)" "unprognostic (9.19e-2)" "unprognostic (1.41e-1)" "unprognostic (2.49e-1)" "unprognostic (2.02e-1)" "unprognostic (1.96e-1)" "unprognostic (1.69e-1)" "unprognostic (7.33e-2)" "unprognostic (2.26e-2)" "unprognostic (1.96e-1)" "unprognostic (1.47e-10)" "unprognostic (9.21e-3)" "unprognostic (2.88e-1)" "unprognostic (4.93e-2)" "unprognostic (1.24e-2)" 0.4 1.2 0.3 1.1 0.3 0.9 0.3 0.4 0.3 0.3 0.3 0.3 0.3 0.0 1.1 0.3 0.7 0.8 0.8 0.3 0.3 0.1 0.5 0.3 4.6 1.1 0.3 0.3 0.3 0.3 3.7 1.4 0.3 0.3 0.4 0.0 0.3 0.4 0.3 0.3 1.6 1.0 0.3 0.3 0.7 0.2 1.0 0.3 1.3 0.8 0.3 0.3 0.3 0.3 0.0 0.0 73.8 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 4.0 0.0 0.0 0.1 0.0 0.0 0.0 0.7 0.0 0.0 20.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.3 0.3 0.0 0.0 73.8 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.3 0.4 0.3 0.3 0.1 0.3 0.3 0.3 0.3 IL4R CD124 ENSG00000077238 "Interleukin 4 receptor" P24394 16 27313668-27364778 "Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" Immunity Receptor "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Daudi: 35.8;HBEC3-KT: 34.4;U-698: 33.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "naive B-cell: 34.4" "Group enriched" "Detected in all" 6 "B-cells: 34.4;granulocytes: 11.9" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB004451, HPA050124, HPA070380" Enhanced Supported "Nucleoplasm,Plasma membrane,Centriolar satellite" "Secreted to blood" 49000 "Plasma membrane" "Nucleoplasm, Centriolar satellite" "CAB004451: AB_626889, HPA050124: , HPA070380: " "unprognostic (6.80e-2)" "unprognostic (6.35e-2)" "unprognostic (2.84e-1)" "prognostic favourable (6.43e-4)" "unprognostic (1.12e-1)" "unprognostic (1.14e-1)" "unprognostic (2.33e-2)" "unprognostic (1.95e-3)" "unprognostic (1.34e-1)" "unprognostic (1.54e-1)" "unprognostic (2.41e-1)" "unprognostic (1.97e-1)" "prognostic unfavourable (1.23e-5)" "unprognostic (1.49e-2)" "unprognostic (1.73e-1)" "unprognostic (1.36e-1)" "unprognostic (9.58e-2)" 20.7 14.8 8.7 31.6 10.6 36.9 12.0 4.4 7.7 20.8 30.3 5.9 11.5 10.9 18.0 12.8 24.7 13.6 25.1 12.3 6.7 4.4 13.3 39.1 40.9 44.8 10.8 1.7 14.7 11.3 3.8 5.5 16.1 10.1 18.8 15.1 12.3 7.7 11.5 7.2 9.9 18.6 39.6 13.6 31.8 21.1 10.4 9.8 9.1 8.6 13.7 38.4 31.6 15.4 34.4 1.6 11.9 2.6 3.3 4.0 1.8 11.3 3.0 1.9 3.9 0.9 4.5 4.1 7.2 8.3 2.9 2.3 6.1 31.4 35.8 9.0 11.3 12.1 2.1 34.4 2.5 31.0 1.0 6.7 1.8 9.3 13.0 1.8 19.1 6.9 13.9 13.2 7.9 15.4 2.9 3.0 4.6 5.0 0.1 5.4 2.4 2.6 0.1 14.9 2.9 13.3 13.0 0.6 0.3 1.0 6.9 1.5 2.6 6.9 23.0 6.5 2.9 5.8 5.0 1.8 0.5 33.3 0.7 6.0 0.0 0.5 2.6 4.7 1.7 1.1 1.3 7.7 2.6 1.7 1.6 34.4 4.0 1.9 11.9 3.3 0.6 1.6 1.8 1.8 8.7 10.6 4.4 7.7 6.7 4.4 10.8 1.7 10.1 9.8 IL5 "EDF, IL-5, TRF" ENSG00000113525 "Interleukin 5" P05113 5 132541444-132556838 "Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins" "Cytokine, Growth factor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "blood: 3.8;testis: 10.6" "Group enriched" "Detected in some" 4 "CACO-2: 2.5;HEK 293: 2.1;Hep G2: 7.1;TIME: 3.3" "Not detected" "Not detected" "Low region specificity" "Detected in some" "Cell type enriched" "Detected in single" 6 "memory B-cell: 3.8" "Lineage enriched" "Detected in single" 6 "B-cells: 3.8" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" CAB010304 Approved "Secreted to blood" 3543 "CAB010304: AB_2296159" "unprognostic (1.66e-1)" "unprognostic (4.76e-2)" "unprognostic (5.30e-3)" "unprognostic (2.35e-1)" "unprognostic (9.07e-2)" "unprognostic (7.98e-2)" "unprognostic (2.03e-2)" "unprognostic (3.51e-2)" "unprognostic (1.97e-1)" "unprognostic (1.44e-2)" "unprognostic (1.53e-1)" "unprognostic (2.09e-1)" "unprognostic (5.27e-2)" "unprognostic (5.84e-3)" "unprognostic (1.91e-1)" 0.1 0.1 0.3 0.3 1.0 0.0 0.1 0.3 1.3 0.2 0.1 0.0 0.0 1.0 0.5 0.0 0.1 0.7 1.1 0.4 1.0 0.3 0.1 0.3 0.1 0.0 0.3 0.0 0.2 0.1 0.0 2.0 0.0 0.9 0.1 0.3 0.0 0.1 0.0 0.1 0.1 1.8 0.1 0.3 0.1 0.3 10.6 0.0 0.4 0.7 0.0 0.2 0.2 0.2 3.8 0.6 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.5 0.7 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.1 2.1 0.0 0.2 7.1 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.6 0.8 0.0 0.0 0.0 0.0 0.2 0.0 0.5 0.1 0.0 0.0 0.0 0.6 0.1 0.0 0.0 0.0 0.0 0.0 3.3 0.0 0.3 0.0 0.3 0.9 0.4 0.8 0.0 0.2 0.8 0.0 0.0 0.0 0.5 0.0 0.0 3.8 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.3 1.0 0.3 1.3 1.0 0.3 0.3 0.0 0.9 0.0 IL6 "BSF2, HGF, HSF, IFNB2, IL-6" ENSG00000136244 "Interleukin 6" P05231 7 22725884-22732002 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Acute phase" "Cytokine, Growth factor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adipose tissue: 60.1;lymphoid tissue: 48.0" "Cell line enriched" "Detected in some" 5 "BJ hTERT+: 221.9" "Low cancer specificity" "Detected in many" "Group enriched" "Detected in many" 4 "basal ganglia: 10.0;cerebral cortex: 4.4;hippocampal formation: 3.9;pons and medulla: 12.8" "Group enriched" "Detected in some" 70 "memory B-cell: 6.1;naive B-cell: 7.7" "Lineage enriched" "Detected in single" 77 "B-cells: 7.7" "Not detected" "Not detected" "CAB023406, CAB072821" Supported Approved Vesicles "Secreted to blood" 6103 Vesicles "CAB023406: AB_617317, CAB072821: " "unprognostic (1.13e-1)" "unprognostic (1.55e-2)" "unprognostic (1.47e-1)" "unprognostic (1.35e-1)" "unprognostic (3.59e-2)" "unprognostic (9.88e-3)" "unprognostic (1.35e-1)" "unprognostic (3.07e-3)" "unprognostic (3.25e-1)" "unprognostic (2.17e-1)" "unprognostic (2.48e-2)" "unprognostic (8.57e-2)" "prognostic unfavourable (1.10e-11)" "unprognostic (2.45e-3)" "unprognostic (2.10e-1)" "unprognostic (4.31e-2)" "unprognostic (7.80e-2)" 60.1 5.6 1.4 48.0 10.0 15.3 11.5 0.7 4.4 2.9 8.1 1.2 0.4 0.7 2.1 4.6 14.3 7.8 16.1 21.6 3.9 1.5 1.3 5.2 34.9 3.0 1.8 0.2 5.3 8.3 5.7 14.2 4.5 12.8 6.5 7.5 3.3 3.1 0.8 6.9 2.8 4.5 8.2 7.0 3.5 6.5 3.2 1.2 0.1 4.5 12.7 3.5 34.9 8.4 7.7 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.2 0.7 0.8 221.9 4.2 14.2 0.0 0.0 0.0 7.3 1.4 0.1 0.0 0.0 5.6 8.7 0.0 0.0 0.3 0.0 4.7 0.0 0.0 0.5 0.0 42.4 6.1 1.5 0.9 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 11.0 0.0 0.0 0.0 14.4 0.0 0.0 0.0 0.0 1.3 1.4 0.1 2.6 0.4 0.0 2.5 0.0 10.4 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 6.1 0.0 0.0 0.0 7.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 1.4 10.0 0.7 4.4 3.9 1.5 1.8 0.2 12.8 1.2 IL6ST "CD130, GP130" ENSG00000134352 "Interleukin 6 signal transducer" P40189 5 55935095-55994993 "Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins" "Host-virus interaction" Receptor "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "ASC TERT1: 57.0;BJ hTERT+: 58.0;HHSteC: 64.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "naive CD4 T-cell: 21.0" "Lineage enriched" "Detected in many" 5 "T-cells: 21.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA010558, CAB025784" Approved Supported "Golgi apparatus,Plasma membrane" "Secreted to blood" 100000000 "Plasma membrane" "Golgi apparatus" "CAB025784: , HPA010558: AB_1078439" "unprognostic (1.81e-2)" "unprognostic (1.25e-1)" "unprognostic (7.61e-2)" "unprognostic (3.95e-2)" "unprognostic (8.93e-2)" "unprognostic (3.99e-2)" "unprognostic (5.18e-2)" "unprognostic (9.53e-3)" "unprognostic (1.89e-2)" "unprognostic (2.29e-1)" "unprognostic (4.78e-2)" "unprognostic (1.59e-1)" "prognostic unfavourable (5.05e-4)" "unprognostic (3.69e-2)" "unprognostic (1.06e-1)" "unprognostic (1.80e-1)" "unprognostic (1.25e-1)" 44.8 34.2 24.7 25.5 23.4 8.8 76.9 15.9 22.9 38.1 23.9 15.0 29.0 8.7 26.1 24.9 22.7 23.1 31.1 31.9 21.9 19.7 37.2 71.2 36.3 70.0 25.8 14.7 42.1 16.4 35.8 36.2 97.0 22.5 31.9 17.1 20.0 26.3 33.0 27.1 12.5 20.6 36.6 33.8 35.5 19.7 13.7 20.3 19.4 37.6 12.5 18.7 33.7 51.1 0.7 2.1 0.9 3.8 0.8 21.0 4.0 9.4 11.8 3.8 9.1 27.3 57.0 15.8 28.2 58.0 15.2 22.7 16.5 9.0 0.3 21.1 17.4 4.1 3.0 8.4 31.2 0.8 3.0 2.2 9.7 13.6 64.9 0.2 4.5 49.9 4.6 33.0 16.1 34.7 1.6 39.8 17.5 1.6 0.4 0.4 0.6 3.9 0.5 10.7 5.4 8.3 5.6 2.0 3.4 11.4 3.8 11.6 19.0 1.5 55.7 5.9 6.7 23.8 14.8 9.8 4.2 0.3 15.8 0.4 15.3 0.2 3.8 0.1 0.8 3.5 0.4 0.7 4.9 0.8 2.1 0.6 21.0 5.9 0.9 0.8 0.6 1.8 3.4 4.0 24.7 23.4 15.9 22.9 21.9 19.7 25.8 14.7 22.5 20.3 IL7 IL-7 ENSG00000104432 "Interleukin 7" P13232 8 78675743-78805523 "Cancer-related genes, Plasma proteins, Predicted secreted proteins" "Cytokine, Growth factor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 20.5;lymphoid tissue: 26.3" "Cell line enhanced" "Detected in some" "CAPAN-2: 5.8;HDLM-2: 12.9;HEL: 13.7;HMC-1: 20.3" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "memory B-cell: 10.9" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in single" "Low region specificity" "Detected in single" HPA019590 Approved "Secreted to blood" 65993 "HPA019590: AB_10794621" "unprognostic (3.19e-3)" "unprognostic (1.44e-1)" "unprognostic (9.57e-3)" "unprognostic (5.45e-2)" "unprognostic (9.37e-3)" "unprognostic (3.36e-1)" "unprognostic (1.71e-1)" "unprognostic (1.65e-2)" "unprognostic (2.28e-1)" "unprognostic (2.47e-1)" "unprognostic (3.02e-2)" "unprognostic (2.28e-1)" "prognostic unfavourable (2.69e-4)" "unprognostic (1.38e-1)" "unprognostic (1.33e-1)" "unprognostic (6.55e-2)" "unprognostic (2.11e-4)" 6.8 1.9 1.3 13.4 1.8 1.8 2.2 1.7 1.7 2.6 9.5 0.4 1.3 7.0 1.9 5.0 5.0 5.2 8.2 1.5 1.0 0.9 5.6 8.9 6.5 26.3 0.8 0.1 2.4 2.6 0.0 1.3 1.0 1.0 5.0 4.8 1.1 7.9 2.0 0.9 9.6 20.5 2.4 1.2 8.6 4.4 3.0 0.9 2.0 4.1 4.4 10.4 3.9 3.3 10.9 2.4 5.4 0.8 0.5 7.5 0.6 0.2 0.0 0.1 0.0 0.3 0.3 0.0 1.1 1.1 1.0 1.5 0.0 5.8 0.1 0.0 3.3 3.3 0.1 0.0 0.0 12.9 0.0 13.7 0.3 1.7 0.0 0.1 20.3 1.0 0.0 0.1 0.5 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 1.1 0.0 0.9 0.0 4.2 2.3 0.0 1.9 2.0 0.2 0.1 0.1 0.0 0.2 0.7 0.8 0.0 1.5 0.2 0.0 0.0 2.7 0.0 1.5 5.4 0.3 0.0 0.4 0.2 0.0 10.9 1.1 1.1 2.4 8.2 0.3 0.3 0.0 0.5 0.8 0.3 7.5 0.6 1.3 1.8 1.7 1.7 1.0 0.9 0.8 0.1 1.0 0.9 IL7R CD127 ENSG00000168685 "Interleukin 7 receptor" P16871 5 35852695-35879603 "Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" Receptor "Cancer-related genes, Disease mutation, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "blood: 70.3;intestine: 34.0;lung: 52.6;lymphoid tissue: 133.1" "Cell line enhanced" "Detected in many" "BJ: 21.7;fHDF/TERT166: 40.7;HBF TERT88: 37.4;REH: 84.6" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Group enriched" "Detected in many" 5 "gdT-cell: 19.2;MAIT T-cell: 70.3;memory CD4 T-cell: 39.9;memory CD8 T-cell: 28.0;naive CD4 T-cell: 34.5;naive CD8 T-cell: 22.5;NK-cell: 19.1" "Group enriched" "Detected in many" 33 "NK-cells: 19.1;T-cells: 70.3" "Low region specificity" "Detected in single" "Low region specificity" "Detected in single" CAB010215 Supported "Plasma membrane,Centriolar satellite" "Intracellular and membrane" 180000 "Plasma membrane, Centriolar satellite" "CAB010215: AB_673727" "unprognostic (2.93e-3)" "unprognostic (3.38e-2)" "unprognostic (3.82e-3)" "unprognostic (5.58e-3)" "unprognostic (3.06e-2)" "unprognostic (1.74e-1)" "unprognostic (2.51e-3)" "unprognostic (5.53e-2)" "unprognostic (1.12e-1)" "unprognostic (9.29e-3)" "unprognostic (1.43e-1)" "unprognostic (2.69e-1)" "unprognostic (1.76e-2)" "unprognostic (5.64e-2)" "unprognostic (3.27e-3)" "unprognostic (2.22e-1)" "unprognostic (1.78e-1)" 6.7 3.6 0.7 34.0 0.7 3.1 4.8 0.5 0.6 4.8 20.6 0.3 0.9 3.5 1.8 2.9 6.6 3.7 8.5 1.9 0.7 0.7 7.0 2.7 52.6 133.1 0.8 0.1 2.5 1.7 0.0 1.5 1.2 0.8 3.3 5.4 1.7 13.2 1.8 0.9 1.8 34.0 1.2 1.5 32.3 7.8 3.0 0.4 130.9 5.1 5.3 42.9 12.6 4.6 0.4 0.3 1.3 0.2 19.1 70.3 12.7 0.1 0.0 0.1 0.1 0.1 0.1 0.2 21.7 11.0 19.6 11.6 0.1 0.1 2.1 0.0 40.7 3.5 0.0 1.3 37.4 1.8 0.2 0.6 2.3 0.0 0.3 0.1 1.5 0.3 0.0 4.2 0.9 0.5 0.1 0.3 15.4 0.0 0.5 0.2 0.1 1.0 84.6 1.1 0.1 0.0 1.2 0.0 0.0 3.6 0.3 0.0 0.1 0.0 1.5 7.7 13.1 3.3 2.8 0.1 0.0 2.4 3.9 2.0 5.9 0.5 0.2 0.1 19.2 0.2 70.3 0.2 39.9 28.0 0.1 0.4 34.5 22.5 1.3 19.1 0.2 0.3 6.7 12.7 0.7 0.7 0.5 0.6 0.7 0.7 0.8 0.1 0.8 0.4 ILF3 "DRBP76, MPHOSPH4, MPP4, NF90, NFAR-1" ENSG00000129351 "Interleukin enhancer binding factor 3" Q12906 19 10654261-10692417 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Antiviral defense, Transcription, Transcription regulation" "DNA-binding, RNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA001897 Supported Supported Nucleoplasm,Nucleoli,Mitochondria 1100000 "Nucleoplasm, Nucleoli, Mitochondria" "HPA001897: AB_1078703" "unprognostic (2.39e-1)" "unprognostic (9.44e-2)" "unprognostic (1.51e-1)" "unprognostic (1.25e-1)" "unprognostic (7.53e-2)" "unprognostic (5.55e-3)" "unprognostic (1.11e-3)" "unprognostic (2.96e-1)" "prognostic unfavourable (1.57e-4)" "unprognostic (3.45e-2)" "unprognostic (1.04e-1)" "unprognostic (4.38e-2)" "prognostic unfavourable (9.65e-4)" "unprognostic (7.57e-3)" "unprognostic (7.61e-2)" "unprognostic (1.03e-1)" "unprognostic (6.20e-2)" 31.0 39.0 29.6 45.5 26.8 88.2 34.5 48.3 35.2 34.2 30.2 30.8 35.2 30.3 45.4 31.7 40.5 41.9 32.5 34.0 25.5 20.0 28.1 25.6 34.1 44.9 24.7 27.8 52.8 36.8 34.9 34.9 31.8 32.3 34.9 27.3 35.5 35.1 46.2 50.1 37.7 37.2 33.2 33.3 44.5 32.6 54.3 28.0 58.6 43.4 32.4 41.1 38.5 32.1 18.7 18.7 11.5 14.3 15.4 19.4 8.0 45.4 37.0 60.0 54.9 13.0 17.9 34.9 29.1 24.7 48.9 38.3 42.4 26.4 56.8 29.0 26.1 40.8 64.8 39.3 44.1 36.3 57.7 73.7 32.7 39.5 18.7 53.0 36.8 16.9 17.6 38.8 43.5 41.7 62.9 44.7 28.4 37.4 87.9 85.3 72.0 40.7 64.8 57.2 39.3 19.4 48.3 66.3 48.2 37.5 29.8 21.6 25.2 34.1 33.4 40.1 38.2 41.5 57.4 38.4 52.4 69.0 22.4 56.7 43.2 11.5 13.4 7.1 19.4 10.4 16.1 14.7 15.9 17.3 16.8 18.7 15.7 16.0 2.1 15.4 14.3 18.7 15.0 8.0 29.6 26.8 48.3 35.2 25.5 20.0 24.7 27.8 32.3 28.0 ILK ENSG00000166333 "Integrin linked kinase" Q13418 11 6603708-6610874 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004041, HPA048437" Enhanced Supported "Nucleoplasm,Cell Junctions,Focal adhesion sites" 130000000 "Cell Junctions, Focal adhesion sites" Nucleoplasm "CAB004041: AB_2127050, HPA048437: " "unprognostic (1.78e-1)" "unprognostic (2.26e-2)" "unprognostic (5.26e-2)" "unprognostic (2.12e-2)" "unprognostic (7.57e-2)" "unprognostic (1.01e-1)" "unprognostic (6.19e-3)" "unprognostic (5.25e-3)" "unprognostic (1.49e-2)" "unprognostic (9.65e-2)" "unprognostic (2.64e-1)" "unprognostic (8.12e-2)" "prognostic favourable (2.44e-4)" "unprognostic (4.01e-3)" "unprognostic (9.27e-2)" "unprognostic (2.42e-1)" "unprognostic (6.36e-3)" 20.9 17.6 11.0 22.3 11.9 7.5 37.0 9.4 14.6 40.2 75.1 14.7 41.9 13.5 75.4 25.2 35.7 33.2 41.1 35.1 11.1 9.2 21.6 15.1 21.9 18.9 11.5 14.0 24.2 22.3 20.4 10.9 22.2 11.5 39.9 24.6 19.3 19.4 89.9 18.5 12.4 22.2 103.5 10.6 20.2 33.2 14.2 11.0 8.2 17.5 14.1 13.6 60.8 25.9 19.5 45.9 76.5 49.4 45.3 25.8 63.7 23.8 18.4 29.1 10.0 44.9 31.9 13.2 35.1 69.4 41.6 50.8 19.2 28.1 9.0 9.3 57.4 19.2 16.2 29.7 41.8 15.7 14.8 12.9 17.6 14.9 30.1 10.3 14.8 30.6 14.0 28.1 21.5 39.6 11.8 10.7 54.2 17.9 9.1 17.7 18.3 21.6 9.6 15.2 9.5 30.5 19.1 5.0 11.4 16.6 23.0 19.3 16.0 11.8 45.8 52.2 23.6 21.6 17.0 7.8 4.8 12.6 38.7 15.6 24.3 48.3 49.4 76.5 25.8 47.9 25.1 19.5 23.3 24.4 45.9 17.1 14.7 18.5 31.7 45.3 44.4 18.5 25.7 63.7 11.0 11.9 9.4 14.6 11.1 9.2 11.5 14.0 11.5 11.0 ING1 "p24ING1c, p33, p33ING1, p33ING1b, p47, p47ING1a" ENSG00000153487 "Inhibitor of growth family member 1" Q9UK53 13 110712736-110723339 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cell cycle" "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB016136, CAB017773, HPA052591" Approved Approved Nucleoplasm,Cytosol Nucleoplasm Cytosol "CAB016136: AB_628077, CAB017773: , HPA052591: " "unprognostic (1.14e-2)" "unprognostic (3.25e-2)" "unprognostic (3.51e-2)" "prognostic favourable (5.81e-4)" "unprognostic (4.62e-2)" "unprognostic (3.47e-2)" "unprognostic (3.36e-1)" "unprognostic (1.87e-1)" "unprognostic (9.43e-2)" "unprognostic (2.27e-1)" "unprognostic (1.81e-1)" "unprognostic (1.22e-1)" "unprognostic (1.36e-3)" "unprognostic (1.35e-1)" "unprognostic (7.05e-3)" "unprognostic (6.78e-2)" "unprognostic (2.40e-3)" 11.8 11.1 8.9 11.7 10.2 24.9 19.8 12.8 12.1 15.7 14.9 6.9 9.5 13.9 16.3 8.3 10.7 13.7 20.0 9.5 9.4 9.0 9.3 16.7 14.1 20.5 11.6 8.0 25.8 11.8 3.8 9.5 13.3 11.7 13.3 6.6 9.5 13.6 10.9 12.2 8.5 13.6 11.1 10.2 17.6 10.0 26.0 12.0 22.0 11.5 8.3 10.6 18.3 14.8 15.5 3.0 21.4 3.7 12.3 11.6 6.1 17.4 6.9 12.5 12.0 5.9 4.1 12.5 9.0 7.6 5.9 7.1 13.2 12.4 11.2 14.7 3.5 11.0 5.0 4.4 4.9 21.1 9.6 9.9 9.5 9.8 3.3 13.0 9.6 3.7 4.7 5.1 3.1 4.1 9.1 9.5 3.8 10.0 22.5 15.1 12.3 5.8 16.4 6.4 6.3 5.1 9.0 12.3 13.3 8.9 17.9 12.3 6.0 15.5 6.1 7.2 8.9 7.5 10.0 11.5 11.5 14.3 12.1 10.8 11.8 21.4 2.9 11.1 10.8 3.6 11.1 14.8 9.1 9.7 2.8 15.5 9.4 7.8 4.0 12.3 3.7 3.0 11.6 6.1 8.9 10.2 12.8 12.1 9.4 9.0 11.6 8.0 11.7 12.0 INPPL1 SHIP2 ENSG00000165458 "Inositol polyphosphate phosphatase like 1" O15357 11 72223701-72239105 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Cell adhesion, Immunity" "Actin-binding, Hydrolase" "Cancer-related genes, Diabetes mellitus, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA037601 Approved Supported "Golgi apparatus,Cytosol" "Golgi apparatus, Cytosol" "HPA037601: AB_10672281" "unprognostic (2.68e-1)" "unprognostic (2.69e-2)" "unprognostic (1.12e-1)" "unprognostic (1.12e-1)" "unprognostic (3.68e-3)" "unprognostic (1.58e-1)" "prognostic unfavourable (7.37e-4)" "unprognostic (2.49e-2)" "unprognostic (3.54e-2)" "unprognostic (1.51e-2)" "unprognostic (1.64e-1)" "unprognostic (4.34e-2)" "unprognostic (3.66e-2)" "unprognostic (2.33e-1)" "unprognostic (2.88e-1)" "unprognostic (1.99e-3)" "unprognostic (2.07e-1)" 20.9 23.7 22.2 20.4 19.5 25.1 18.6 11.1 18.9 25.2 32.0 22.7 28.8 19.8 24.7 18.4 17.4 24.3 29.6 29.5 24.1 10.3 23.9 17.1 24.9 19.0 27.6 10.4 30.1 22.7 21.6 26.9 31.9 20.4 28.7 13.5 30.7 27.5 24.2 60.0 17.7 23.0 34.7 27.5 28.3 24.5 11.8 24.3 16.0 29.1 19.3 18.3 25.0 18.1 2.6 5.2 7.0 7.6 4.2 4.5 3.3 6.4 13.8 16.6 11.3 8.2 9.8 29.6 29.8 13.9 18.7 11.9 18.9 16.3 18.4 30.5 22.8 24.6 13.6 8.4 6.4 23.8 14.2 19.1 70.0 6.9 16.1 12.6 42.8 13.9 8.9 18.1 7.2 10.0 13.4 7.9 10.2 17.4 9.3 51.0 16.9 21.6 43.9 37.7 4.1 21.7 10.8 8.1 11.8 32.0 19.3 41.6 20.4 23.9 16.9 20.1 23.5 30.7 9.7 22.9 3.8 17.9 5.7 12.0 10.8 5.2 7.6 7.0 4.5 4.4 3.7 2.2 3.7 3.0 5.2 2.6 2.7 3.7 5.2 4.2 7.0 3.9 3.3 3.3 22.2 19.5 11.1 18.9 24.1 10.3 27.6 10.4 20.4 24.3 INS "IDDM1, IDDM2" ENSG00000254647 Insulin P01308 11 2159779-2161341 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins" "Carbohydrate metabolism, Glucose metabolism" Hormone "Cancer-related genes, Diabetes mellitus, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 193 "pancreas: 514.0" "Group enriched" "Detected in some" 9 "EFO-21: 52.5;U-2 OS: 68.8;U-698: 21.7" "Cancer enriched" "Detected in single" 7166 "pancreatic cancer: 1751.3" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in single" 13 "midbrain: 1.7" "CAB000048, HPA004932, CAB012098, CAB053843" Enhanced "Secreted to blood" 437220 "CAB000048: , CAB012098: AB_300968, CAB053843: AB_620123, HPA004932: AB_1851816" "unprognostic (7.61e-2)" 0.4 0.1 0.1 0.1 0.1 1.1 0.1 0.1 0.7 0.1 0.3 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.0 1.4 0.1 0.1 0.1 0.1 0.1 0.1 514.0 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 2.6 0.1 0.1 0.1 0.1 1.1 0.4 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 52.5 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 68.8 0.0 5.2 0.0 2.4 21.7 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 INTS12 "INT12, PHF22, SBBI22" ENSG00000138785 "Integrator complex subunit 12" Q96CB8 4 105682627-105895986 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA035772, HPA041814" Approved Approved "Nucleoplasm,Nuclear bodies,Plasma membrane,Cytosol" "Nucleoplasm, Cytosol" "Nuclear bodies, Plasma membrane" "HPA035772: AB_10671109, HPA041814: " "unprognostic (5.30e-2)" "unprognostic (4.54e-2)" "unprognostic (1.84e-3)" "unprognostic (1.78e-1)" "unprognostic (3.68e-2)" "unprognostic (2.58e-3)" "prognostic unfavourable (2.67e-4)" "unprognostic (3.95e-2)" "unprognostic (1.13e-1)" "unprognostic (1.53e-3)" "unprognostic (3.00e-2)" "unprognostic (3.48e-2)" "unprognostic (5.93e-3)" "unprognostic (3.62e-1)" "unprognostic (1.37e-1)" "unprognostic (2.16e-2)" "unprognostic (2.06e-1)" 16.7 13.5 18.7 12.5 20.7 25.3 20.0 17.3 18.1 14.5 17.0 13.4 11.6 17.0 16.1 17.9 13.6 14.4 12.3 19.3 18.3 15.3 18.2 21.4 15.4 12.1 16.5 11.5 15.0 16.0 17.3 20.7 11.2 17.4 18.1 15.4 10.4 14.8 13.7 28.2 14.1 21.0 16.6 19.3 15.9 14.9 12.6 13.8 22.1 31.1 15.9 15.4 13.8 12.6 20.6 27.6 33.3 17.0 27.1 21.9 14.0 12.5 6.7 15.4 15.9 15.2 18.2 11.2 14.9 15.5 18.8 19.6 9.4 14.3 18.1 8.3 16.7 7.3 16.8 21.5 23.4 18.9 10.2 13.6 10.9 13.2 24.5 23.9 12.4 17.1 28.0 18.6 28.1 17.2 20.2 14.3 20.2 13.2 28.0 14.9 6.6 10.3 14.4 16.7 13.8 17.5 8.5 16.6 13.3 10.5 17.4 16.3 14.1 14.1 11.2 12.4 12.7 13.3 15.9 22.1 20.4 27.0 13.7 16.4 24.4 33.3 15.9 24.1 17.9 16.8 20.0 20.6 20.6 20.2 18.0 19.3 21.6 20.2 12.1 27.1 17.0 27.6 21.9 14.0 18.7 20.7 17.3 18.1 18.3 15.3 16.5 11.5 17.4 13.8 IPO7 "Imp7, RANBP7" ENSG00000205339 "Importin 7" O95373 11 9384622-9448126 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters" "Host-virus interaction, Protein transport, Transport" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019002, HPA056590" Approved Approved Supported Nucleoplasm,Cytosol 26000 "Nucleoplasm, Cytosol" "HPA019002: AB_1856059, HPA056590: " "unprognostic (1.92e-1)" "prognostic unfavourable (4.98e-4)" "unprognostic (9.50e-2)" "unprognostic (1.27e-1)" "unprognostic (3.68e-1)" "unprognostic (1.60e-2)" "prognostic unfavourable (6.57e-4)" "unprognostic (1.19e-2)" "unprognostic (7.60e-2)" "unprognostic (2.12e-1)" "prognostic unfavourable (8.38e-6)" "unprognostic (3.06e-1)" "unprognostic (1.55e-1)" "unprognostic (1.13e-1)" "unprognostic (8.08e-2)" "unprognostic (2.17e-1)" "unprognostic (3.90e-3)" 23.9 20.6 21.8 18.6 24.4 12.3 36.0 24.1 30.6 24.3 27.4 14.4 19.3 17.0 25.7 19.3 29.0 20.3 20.3 37.7 22.8 23.4 26.5 24.7 22.0 23.2 23.3 17.4 23.4 25.9 33.1 19.1 26.5 24.8 24.4 22.1 12.0 21.4 22.4 88.2 17.1 16.1 53.4 25.7 16.6 21.5 9.7 16.8 20.8 34.3 28.5 20.9 43.7 33.9 3.8 5.8 1.3 6.3 6.9 5.4 1.6 37.3 29.2 34.4 27.3 34.9 45.1 27.6 45.5 29.3 33.7 36.5 25.3 34.4 35.1 16.6 35.0 29.4 48.8 35.3 56.3 16.7 40.3 29.0 33.2 25.3 21.8 44.3 22.1 28.8 38.3 22.1 52.2 39.7 43.4 21.1 43.8 15.2 26.7 21.7 33.9 34.0 28.1 54.2 15.8 27.8 35.3 13.7 26.9 20.3 40.3 32.8 18.5 22.3 31.1 41.5 28.6 42.7 48.6 6.1 23.4 24.2 27.2 23.9 22.5 0.1 2.5 0.6 2.7 4.8 5.4 3.8 3.1 3.9 5.8 3.1 3.9 3.2 1.3 6.9 6.3 2.7 2.8 1.6 21.8 24.4 24.1 30.6 22.8 23.4 23.3 17.4 24.8 16.8 IRF1 MAR ENSG00000125347 "Interferon regulatory factor 1" P10914 5 132481609-132490798 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Antiviral defense, Immunity, Innate immunity, Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 103.0" "Cell line enhanced" "Detected in many" "HHSteC: 46.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB011662, HPA063131" Supported Supported Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "CAB011662: AB_775784, HPA063131: " "unprognostic (1.30e-3)" "unprognostic (2.00e-2)" "unprognostic (2.47e-3)" "unprognostic (1.21e-1)" "unprognostic (2.27e-1)" "unprognostic (4.48e-2)" "unprognostic (3.67e-1)" "unprognostic (1.64e-1)" "unprognostic (1.52e-2)" "unprognostic (2.24e-2)" "unprognostic (6.93e-2)" "unprognostic (1.06e-1)" "prognostic unfavourable (1.09e-7)" "unprognostic (1.93e-2)" "unprognostic (1.50e-1)" "unprognostic (1.21e-1)" "unprognostic (9.53e-3)" 19.7 8.5 4.1 64.2 9.9 43.8 21.0 3.9 4.6 10.6 27.3 4.0 4.4 31.1 11.4 9.9 12.4 11.8 18.1 11.8 4.2 3.5 14.2 20.9 49.3 41.0 6.8 1.4 11.5 14.5 2.8 8.8 24.7 10.3 18.9 13.6 10.3 13.2 10.3 14.0 8.4 52.1 11.3 8.0 51.7 17.5 5.7 4.9 36.6 26.5 14.7 33.0 14.7 26.7 12.1 16.2 103.0 42.1 21.3 28.5 21.3 8.9 7.2 0.6 2.5 7.1 6.2 14.7 4.3 18.3 13.7 17.2 3.7 26.7 8.9 5.8 6.4 12.5 2.2 10.4 4.6 18.8 2.4 11.9 3.4 2.7 46.9 5.8 10.2 11.6 2.6 10.1 9.7 6.4 2.1 34.3 3.8 4.9 31.6 9.7 0.8 5.1 36.7 7.7 10.8 7.0 10.1 1.3 1.1 4.5 10.2 4.4 1.7 8.0 4.0 7.8 2.8 4.5 6.3 27.2 6.8 6.3 9.0 9.3 5.6 23.1 26.2 40.2 28.5 40.0 19.4 12.1 18.7 22.9 16.2 11.5 11.5 16.0 103.0 21.3 42.1 8.2 20.2 21.3 4.1 9.9 3.9 4.6 4.2 3.5 6.8 1.4 10.3 4.9 IRF4 "LSIRF, MUM1" ENSG00000137265 "Interferon regulatory factor 4" Q15306 6 391739-411447 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 48.7" "Cell line enhanced" "Detected in some" "HDLM-2: 49.1;Karpas-707: 45.6;RPMI-8226: 44.1;U-266/70: 41.3;U-266/84: 30.7;WM-115: 25.0" "Cancer enriched" "Detected in many" 9 "melanoma: 27.0" "Not detected" "Not detected" "Group enriched" "Detected in many" 5 "memory B-cell: 9.5;myeloid DC: 9.0;naive B-cell: 9.7;plasmacytoid DC: 10.4;T-reg: 4.8" "Group enriched" "Detected in many" 5 "B-cells: 9.7;dendritic cells: 10.4;T-cells: 4.8" "Not detected" "Not detected" "Low region specificity" "Detected in all" "HPA002038, HPA002698, CAB013508" Enhanced Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "CAB013508: , HPA002038: AB_1079148, HPA002698: AB_1851893" "prognostic favourable (6.44e-4)" "unprognostic (1.88e-3)" "unprognostic (1.00e-3)" "unprognostic (1.72e-4)" "unprognostic (2.74e-1)" "prognostic favourable (1.64e-6)" "unprognostic (4.72e-2)" "unprognostic (1.05e-1)" "unprognostic (1.89e-2)" "unprognostic (5.74e-4)" "unprognostic (8.51e-2)" "unprognostic (1.12e-1)" "unprognostic (9.18e-7)" "unprognostic (2.38e-1)" "unprognostic (6.24e-2)" "unprognostic (2.90e-1)" "unprognostic (3.65e-2)" 7.1 0.5 0.4 36.6 0.4 18.4 4.0 0.4 0.4 17.4 13.9 0.1 0.4 5.0 2.2 0.7 6.4 1.2 4.1 1.6 0.4 0.5 1.4 5.6 4.2 31.5 0.5 0.0 1.9 0.7 0.0 0.7 0.5 0.1 1.5 4.8 15.8 21.3 1.9 0.7 4.5 11.1 0.3 0.6 33.8 4.6 1.7 0.1 15.2 1.3 2.4 48.7 8.4 4.2 9.7 10.4 0.0 1.6 0.2 4.8 1.3 0.0 0.0 0.0 0.0 5.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 49.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 45.6 0.0 0.0 0.0 0.0 0.2 0.0 5.8 0.0 44.1 0.0 0.0 0.1 0.0 0.0 0.0 7.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 41.3 30.7 13.4 0.0 0.0 25.0 0.0 1.6 0.0 0.6 1.2 0.0 9.5 0.9 0.9 9.0 9.7 1.6 0.7 0.0 0.2 1.2 10.4 4.8 1.3 0.4 0.4 0.4 0.4 0.4 0.5 0.5 0.0 0.1 0.1 IRF6 "LPS, OFC6, VWS, VWS1" ENSG00000117595 "Interferon regulatory factor 6" O14896 1 209785623-209806175 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Differentiation, Transcription, Transcription regulation" DNA-binding "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in some" "A-431: 16.0;HaCaT: 58.3;HBEC3-KT: 21.3;hTCEpi: 47.0;hTERT-HME1: 23.5;RT4: 20.8" "Low cancer specificity" "Detected in many" "Group enriched" "Detected in many" 6 "cerebellum: 8.6;pons and medulla: 4.4" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "Low region specificity" "Detected in all" "HPA063121, HPA076162" Enhanced Supported Nucleoplasm,Cytosol Cytosol Nucleoplasm "HPA063121: AB_2684942, HPA076162: AB_2686780" "unprognostic (2.59e-1)" "unprognostic (1.79e-3)" "unprognostic (1.74e-1)" "unprognostic (7.80e-2)" "unprognostic (1.33e-2)" "unprognostic (4.94e-3)" "unprognostic (1.46e-1)" "unprognostic (1.36e-1)" "unprognostic (7.82e-2)" "unprognostic (1.46e-1)" "unprognostic (1.74e-3)" "unprognostic (2.03e-1)" "prognostic favourable (0.00e+0)" "unprognostic (2.70e-1)" "unprognostic (2.66e-2)" "unprognostic (2.14e-1)" "unprognostic (4.42e-2)" 1.0 6.3 1.1 4.1 1.0 0.3 13.3 8.6 0.9 11.7 12.9 1.0 38.6 9.2 3.9 31.4 63.7 7.6 17.5 10.3 1.1 0.8 12.9 18.4 8.8 0.3 0.9 0.7 3.9 13.9 10.3 6.8 26.7 4.4 21.8 11.3 1.5 24.8 34.6 0.6 45.6 20.3 3.1 1.1 1.2 9.5 4.3 0.3 13.0 22.1 32.3 33.8 15.0 19.1 0.9 0.5 2.0 1.0 0.6 2.8 0.7 16.0 0.0 0.0 0.0 0.1 0.0 6.0 0.0 0.1 0.0 0.0 3.4 5.7 0.0 0.0 0.0 58.3 0.0 21.3 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 47.0 0.0 23.5 0.9 0.0 0.0 0.0 2.1 0.0 0.0 0.3 0.0 0.0 0.0 0.0 2.1 20.8 5.2 1.7 0.4 9.3 0.5 6.7 0.1 0.0 0.0 0.0 0.0 0.0 0.2 4.1 0.0 0.0 0.0 0.0 0.2 0.1 2.0 2.8 1.0 1.9 0.6 0.6 0.9 0.5 0.9 2.1 1.1 0.1 0.6 0.1 0.2 0.0 0.7 1.1 1.0 8.6 0.9 1.1 0.8 0.9 0.7 4.4 0.3 IRS2 ENSG00000185950 "Insulin receptor substrate 2" Q9Y4H2 13 109752698-109786568 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" Transducer "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "bone marrow: 70.1" "Cell line enhanced" "Detected in many" "hTERT-HME1: 18.0;SH-SY5Y: 18.9;THP-1: 28.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "neutrophil: 6.9" "Lineage enriched" "Detected in many" 5 "granulocytes: 6.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB016944, HPA054664" Approved Supported Aggresome,Cytosol Cytosol Aggresome "CAB016944: , HPA054664: " "unprognostic (2.87e-3)" "unprognostic (5.73e-3)" "unprognostic (4.39e-2)" "unprognostic (1.09e-3)" "unprognostic (1.08e-1)" "unprognostic (5.49e-3)" "unprognostic (2.10e-1)" "unprognostic (9.28e-2)" "unprognostic (9.70e-2)" "unprognostic (2.34e-3)" "unprognostic (1.17e-1)" "unprognostic (2.09e-2)" "unprognostic (6.21e-3)" "unprognostic (1.50e-1)" "unprognostic (2.82e-1)" "unprognostic (3.17e-2)" "unprognostic (1.24e-1)" 38.9 24.3 27.6 10.9 25.2 70.1 33.5 19.6 30.6 13.5 10.9 13.0 6.7 8.7 14.4 12.2 7.1 7.7 8.4 13.5 23.6 14.6 7.7 24.6 11.6 5.3 24.2 22.1 27.1 7.9 6.1 23.0 13.6 19.5 20.0 7.5 9.3 11.5 12.2 20.9 15.3 9.7 9.7 25.1 9.0 8.3 6.3 21.3 2.0 10.7 4.7 5.3 8.4 17.8 0.5 0.1 6.9 1.4 0.2 0.5 0.2 2.6 3.0 1.9 0.0 16.5 3.3 1.0 2.9 3.4 1.7 1.5 0.2 3.2 0.0 1.8 2.0 1.2 1.0 2.6 2.2 1.0 13.6 1.2 4.3 0.0 16.7 4.7 1.5 6.9 13.9 0.5 18.0 0.6 0.8 0.0 17.0 1.3 0.0 13.9 2.1 0.6 5.9 1.8 1.2 4.9 0.7 2.9 18.9 1.5 0.0 11.6 0.3 28.3 0.0 3.7 0.0 0.2 3.8 0.0 1.3 0.9 2.7 4.6 6.3 2.7 1.4 1.9 0.2 0.3 0.3 0.1 0.4 0.1 0.1 0.5 0.5 0.4 6.9 0.2 0.4 0.1 0.5 0.2 27.6 25.2 19.6 30.6 23.6 14.6 24.2 22.1 19.5 21.3 IRS4 "IRS-4, PY160" ENSG00000133124 "Insulin receptor substrate 4" O14654 X 108732482-108736409 "Cancer-related genes, Predicted intracellular proteins" Transducer "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 6 "pituitary gland: 56.0" "Cell line enhanced" "Detected in some" "HEK 293: 13.6;NTERA-2: 1.7;RT4: 4.0;WM-115: 3.0" "Low cancer specificity" "Detected in some" "Region enriched" "Detected in single" 7 "hypothalamus: 4.6" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 5 "basal ganglia: 12.8;hypothalamus: 52.4" "Group enriched" "Detected in some" 6 "basal ganglia: 21.5;hypothalamus: 55.3" HPA017372 Uncertain "HPA017372: " "unprognostic (3.74e-3)" "unprognostic (3.27e-2)" "unprognostic (1.32e-2)" "unprognostic (2.52e-1)" "unprognostic (1.89e-1)" "unprognostic (2.12e-1)" "unprognostic (1.65e-1)" "unprognostic (1.05e-2)" "unprognostic (1.77e-1)" "unprognostic (9.28e-4)" "unprognostic (8.71e-2)" 0.0 0.0 0.2 0.0 0.3 0.0 0.1 0.0 0.6 1.9 0.0 0.1 0.3 0.1 2.6 0.3 0.3 0.5 0.0 0.0 0.3 4.6 0.0 0.0 0.1 0.0 0.5 0.1 9.5 0.0 0.0 56.0 0.1 0.6 0.2 0.0 2.7 0.0 0.5 0.0 0.6 0.0 1.0 0.2 0.1 0.5 0.1 0.5 5.1 3.3 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 13.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 4.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.3 0.0 0.3 0.3 4.6 0.5 0.1 0.6 0.5 ITGA1 "CD49a, VLA1" ENSG00000213949 "Integrin subunit alpha 1" P56199 5 52787896-52959210 "Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins, Transporters" "Cell adhesion" "Integrin, Receptor" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "fHDF/TERT166: 21.0;HHSteC: 25.8;WM-115: 19.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "memory CD8 T-cell: 1.8" "Group enriched" "Detected in many" 5 "granulocytes: 1.2;T-cells: 1.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA042555 Uncertain 2300000 "HPA042555: AB_10794281" "unprognostic (1.48e-1)" "unprognostic (1.07e-2)" "unprognostic (2.44e-1)" "unprognostic (1.33e-1)" "unprognostic (1.38e-1)" "unprognostic (9.89e-3)" "unprognostic (2.74e-1)" "unprognostic (1.72e-1)" "unprognostic (1.79e-3)" "unprognostic (1.50e-2)" "unprognostic (2.62e-1)" "unprognostic (9.86e-2)" "prognostic unfavourable (2.24e-4)" "unprognostic (3.13e-3)" "unprognostic (2.06e-2)" "unprognostic (1.07e-2)" "unprognostic (1.62e-2)" 22.6 20.2 2.3 12.7 2.7 0.0 12.4 1.2 2.9 10.9 28.2 1.5 13.6 5.3 15.9 12.5 22.3 9.2 13.9 11.1 2.5 2.2 17.9 40.4 28.8 10.2 3.1 1.4 9.6 3.3 11.5 3.0 24.8 3.3 26.1 8.2 5.9 2.9 18.2 9.7 2.4 13.5 52.8 2.7 66.0 16.8 4.1 1.6 0.6 10.7 3.5 2.2 42.7 17.8 0.0 0.1 1.2 0.3 0.0 1.8 0.1 0.0 0.0 2.0 0.0 5.8 1.7 1.2 2.7 7.2 1.6 4.8 3.7 0.3 0.0 0.9 21.0 1.4 0.4 2.3 1.5 0.0 1.5 0.0 3.4 2.7 25.8 0.0 0.0 3.9 0.2 1.9 0.7 0.3 0.0 0.0 2.4 0.0 0.8 0.0 1.1 0.7 0.0 1.9 0.0 3.1 0.0 0.1 9.1 2.7 0.6 0.6 0.0 0.0 2.1 4.4 0.4 0.1 1.4 0.0 0.0 0.0 2.8 0.0 19.1 0.0 0.3 1.1 0.1 0.0 0.0 0.0 0.6 1.8 0.1 0.0 0.2 0.0 1.2 0.0 0.0 0.0 0.1 0.1 2.3 2.7 1.2 2.9 2.5 2.2 3.1 1.4 3.3 1.6 ITGA2 CD49b ENSG00000164171 "Integrin subunit alpha 2" P17301 5 52989326-53094779 "Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins" "Cell adhesion, Host-virus interaction" "Host cell receptor for virus entry, Integrin, Receptor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "BJ hTERT+: 30.1;HaCaT: 30.4;HUVEC TERT2: 28.0;TIME: 23.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "Low region specificity" "Detected in many" "CAB017690, HPA060991, HPA063556" Enhanced Approved Nucleoplasm,Cytosol 46000000 Nucleoplasm Cytosol "CAB017690: AB_1124939, HPA060991: AB_2684405, HPA063556: AB_2685040" "unprognostic (8.35e-2)" "unprognostic (1.33e-1)" "unprognostic (3.85e-3)" "unprognostic (1.07e-1)" "unprognostic (1.22e-1)" "unprognostic (3.70e-2)" "unprognostic (2.67e-3)" "unprognostic (2.38e-2)" "unprognostic (1.87e-1)" "unprognostic (1.69e-2)" "prognostic unfavourable (1.02e-5)" "unprognostic (4.27e-1)" "unprognostic (3.88e-2)" "unprognostic (2.87e-2)" "unprognostic (1.84e-1)" "unprognostic (1.30e-1)" "unprognostic (1.11e-1)" 1.9 14.0 2.9 4.7 13.4 0.4 7.9 1.8 6.8 7.1 6.5 22.5 12.1 7.6 5.1 10.4 16.7 2.8 9.3 2.5 5.4 3.6 15.1 1.8 17.2 1.4 18.3 4.5 1.8 2.7 16.1 2.5 4.8 10.7 8.5 6.0 0.8 15.8 16.8 1.2 16.9 17.0 2.5 8.4 9.1 7.4 1.3 13.0 1.5 2.5 7.4 10.0 7.5 11.1 0.5 1.5 1.7 0.6 0.2 0.6 0.3 19.5 5.0 0.4 0.2 1.3 2.4 1.5 19.8 30.1 0.7 1.2 9.4 13.8 0.0 3.4 8.4 30.4 1.6 22.2 2.9 0.0 1.5 1.4 1.3 5.6 4.6 0.2 0.4 1.0 3.9 19.9 3.5 28.0 0.0 0.0 0.5 3.6 0.2 0.0 1.2 10.1 0.0 0.1 0.0 6.3 10.4 0.2 1.1 1.0 1.3 2.0 3.2 0.0 23.9 3.6 2.1 0.5 3.9 0.0 0.0 0.0 21.8 0.0 15.9 1.7 0.6 0.2 0.6 0.2 0.4 0.4 0.5 0.5 0.1 0.5 0.5 0.6 0.8 0.2 0.1 1.5 0.4 0.3 2.9 13.4 1.8 6.8 5.4 3.6 18.3 4.5 10.7 13.0 ITGA2B "CD41, CD41B, GP2B, PPP1R93" ENSG00000005961 "Integrin subunit alpha 2b" P08514 17 44372180-44389505 "Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Integrin, Receptor" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 28.5;epididymis: 25.2;lymphoid tissue: 22.8" "Group enriched" "Detected in some" 13 "HEL: 69.4;HMC-1: 118.6" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in some" 10 "basophil: 28.5" "Lineage enriched" "Detected in single" 54 "granulocytes: 28.5" "Low region specificity" "Detected in single" "CAB018611, HPA031168, HPA031169, HPA031170, HPA031171" Enhanced Approved "Plasma membrane" 1100000000 "Plasma membrane" "CAB018611: AB_2265153, HPA031168: AB_10670151, HPA031169: AB_10669671, HPA031170: AB_10696214, HPA031171: AB_10669773" "unprognostic (6.11e-2)" "unprognostic (3.23e-2)" "unprognostic (1.23e-1)" "unprognostic (4.85e-2)" "unprognostic (1.59e-2)" "unprognostic (3.98e-3)" "unprognostic (4.23e-5)" "unprognostic (1.25e-1)" "unprognostic (1.33e-2)" "unprognostic (7.22e-2)" "unprognostic (2.97e-3)" "unprognostic (1.30e-1)" "unprognostic (8.83e-9)" "unprognostic (7.82e-2)" "unprognostic (1.85e-1)" "unprognostic (1.95e-1)" "unprognostic (2.25e-1)" 0.7 0.2 1.4 0.4 1.0 15.2 0.6 3.8 2.4 1.2 0.9 0.4 0.4 0.1 1.1 25.2 0.7 1.9 1.4 10.6 0.9 1.6 1.0 0.4 6.5 0.5 0.7 0.8 2.1 2.5 0.1 2.5 1.9 1.1 0.6 0.3 0.6 0.4 1.6 0.8 0.1 0.6 0.4 0.8 22.8 0.2 3.0 0.4 0.4 5.2 1.0 0.6 0.7 1.9 0.0 0.5 28.5 0.2 0.0 0.2 11.1 0.0 0.1 0.7 0.0 0.0 0.0 2.8 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.4 69.4 0.0 0.6 0.0 0.0 118.6 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 7.2 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.6 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 28.5 0.2 2.1 0.1 0.0 0.2 0.0 0.0 0.0 0.3 0.0 0.0 0.0 2.8 0.0 0.0 0.5 0.0 11.1 1.4 1.0 3.8 2.4 0.9 1.6 0.7 0.8 1.1 0.4 ITGA3 "CD49c, GAP-B3, MSK18, VCA-2, VLA3a" ENSG00000005884 "Integrin subunit alpha 3" P26006 17 50055968-50090481 "Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Integrin, Receptor" "Cancer-related genes, Disease mutation, Epidermolysis bullosa" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "HBEC3-KT: 74.7;hTERT-HME1: 64.9;RPTEC TERT1: 65.8;U-138 MG: 65.1;U-87 MG: 112.1;WM-115: 67.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "T-reg: 1.1" "Lineage enriched" "Detected in single" 4 "T-cells: 1.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008572, CAB018594" Enhanced Supported "Plasma membrane" 180000 "Plasma membrane" "CAB018594: AB_668044, HPA008572: AB_2668094" "unprognostic (3.24e-3)" "prognostic unfavourable (6.75e-4)" "unprognostic (9.51e-2)" "unprognostic (3.46e-3)" "unprognostic (3.45e-3)" "prognostic unfavourable (1.36e-4)" "unprognostic (8.28e-3)" "unprognostic (2.76e-3)" "unprognostic (1.26e-3)" "unprognostic (1.82e-2)" "prognostic unfavourable (5.95e-5)" "unprognostic (7.05e-2)" "unprognostic (1.14e-1)" "unprognostic (1.93e-1)" "unprognostic (1.30e-1)" "unprognostic (1.28e-2)" "unprognostic (2.35e-2)" 15.7 15.8 4.1 8.6 5.1 0.1 8.7 7.7 6.5 10.9 20.9 2.3 8.9 17.1 11.6 11.6 12.8 14.5 32.6 8.4 4.2 5.4 36.0 1.7 37.6 3.2 3.2 6.7 10.7 8.0 13.0 11.2 26.4 4.3 12.0 8.9 11.6 10.0 9.7 6.6 17.3 37.3 11.6 3.3 6.5 13.7 3.9 1.5 3.3 36.1 13.3 8.3 19.0 8.1 0.2 0.0 0.0 0.0 0.0 1.1 0.2 20.5 27.2 0.1 0.8 0.5 2.1 4.4 9.6 20.8 14.6 11.1 0.6 32.1 0.0 60.9 7.0 14.6 0.2 74.7 8.9 2.5 0.4 0.0 6.9 0.1 12.9 0.0 0.6 2.6 36.9 14.6 64.9 10.7 0.0 0.3 27.4 5.9 0.0 0.0 0.6 16.5 0.0 1.4 1.5 65.8 35.8 1.1 0.4 10.5 1.4 24.1 2.4 0.2 23.1 65.1 20.5 0.6 37.5 0.9 1.5 0.6 112.1 0.2 67.6 0.0 0.0 0.0 0.8 0.0 1.0 0.2 0.1 0.1 0.0 0.2 0.2 0.6 0.0 0.0 0.0 0.0 1.1 0.2 4.1 5.1 7.7 6.5 4.2 5.4 3.2 6.7 4.3 1.5 ITGA4 CD49d ENSG00000115232 "Integrin subunit alpha 4" P13612 2 181457202-181536187 "Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Integrin, Receptor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 38.4;lymphoid tissue: 101.6" "Cell line enhanced" "Detected in many" "fHDF/TERT166: 38.7;HEL: 61.5;MOLT-4: 71.7" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Region enriched" "Detected in many" 7 "cerebellum: 26.0" HPA074961 Approved "Plasma membrane" "Intracellular and membrane" 100000 "Plasma membrane" "HPA074961: " "unprognostic (5.31e-2)" "unprognostic (1.54e-1)" "unprognostic (1.99e-2)" "unprognostic (3.94e-2)" "unprognostic (3.76e-1)" "prognostic favourable (8.29e-4)" "unprognostic (1.27e-1)" "unprognostic (1.11e-2)" "unprognostic (1.76e-1)" "unprognostic (2.67e-2)" "unprognostic (1.85e-1)" "unprognostic (1.94e-1)" "prognostic unfavourable (3.08e-5)" "unprognostic (2.26e-2)" "unprognostic (8.64e-3)" "unprognostic (2.49e-1)" "unprognostic (2.57e-2)" 3.8 1.7 1.3 39.7 1.1 19.2 3.2 2.4 1.9 6.7 4.8 0.5 1.1 3.8 3.0 3.1 2.9 2.1 6.9 1.7 2.9 1.3 3.0 2.5 13.6 33.7 1.2 0.5 1.8 1.6 0.0 1.3 7.1 0.9 3.8 4.9 2.9 7.5 2.0 1.0 1.5 11.6 2.4 1.6 36.0 4.4 1.2 0.2 101.6 2.6 1.5 14.3 6.0 4.1 11.0 19.1 38.4 38.3 8.8 15.9 16.2 0.0 0.2 1.0 0.0 9.1 13.8 0.0 8.9 11.2 4.8 10.1 0.0 0.0 7.1 0.0 38.7 5.3 3.1 0.1 5.8 0.0 0.7 61.5 0.2 0.0 0.9 27.2 1.5 9.8 0.0 0.3 0.0 0.4 0.0 10.4 3.0 0.0 71.7 19.1 0.8 0.0 15.7 4.5 1.0 0.0 0.0 1.6 0.6 0.0 0.0 0.3 0.0 18.0 4.8 1.5 0.9 0.1 1.8 20.4 15.1 4.0 0.8 13.5 20.6 6.7 16.2 38.4 12.9 38.3 9.7 11.0 14.6 15.9 19.1 10.0 8.5 10.4 2.1 8.8 37.5 5.0 3.7 16.2 1.3 1.1 2.4 1.9 2.9 1.3 1.2 0.5 0.9 0.2 ITGA5 "CD49e, FNRA" ENSG00000161638 "Integrin subunit alpha 5" P08648 12 54395261-54419460 "Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins" "Cell adhesion, Host-virus interaction" "Host cell receptor for virus entry, Integrin, Receptor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "smooth muscle: 137.7" "Cell line enhanced" "Detected in many" "HUVEC TERT2: 140.8;TIME: 134.1;U-87 MG: 66.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "neutrophil: 31.5" "Low lineage specificity" "Detected in many" "Region enriched" "Detected in single" 7 "basal ganglia: 9.3" "Low region specificity" "Detected in some" "HPA002642, CAB009008" Enhanced 23000000 "CAB009008: AB_647474, HPA002642: AB_1078469" "unprognostic (7.51e-3)" "prognostic unfavourable (4.07e-6)" "prognostic unfavourable (8.43e-4)" "unprognostic (1.58e-1)" "unprognostic (8.51e-3)" "prognostic unfavourable (2.91e-4)" "prognostic unfavourable (2.23e-5)" "prognostic unfavourable (2.44e-4)" "unprognostic (2.76e-2)" "unprognostic (6.19e-2)" "unprognostic (8.99e-2)" "unprognostic (8.28e-2)" "prognostic unfavourable (1.32e-8)" "unprognostic (2.11e-3)" "unprognostic (3.35e-2)" "prognostic unfavourable (8.89e-4)" "unprognostic (2.18e-3)" 23.3 7.9 2.1 32.2 2.8 9.2 30.5 1.2 2.2 16.0 66.9 2.2 19.0 3.4 19.3 13.8 18.2 12.0 12.4 20.3 2.9 0.8 4.6 15.2 20.4 9.2 3.2 1.2 13.6 5.3 3.7 1.8 57.7 3.3 26.6 10.2 4.9 4.4 28.9 10.0 8.8 14.9 137.7 3.5 3.1 19.7 6.6 2.5 3.0 7.3 5.8 4.5 82.1 20.6 0.1 22.2 31.5 22.9 9.1 5.6 12.4 6.6 2.4 4.6 0.0 14.3 30.5 12.0 30.0 31.2 30.9 22.8 1.6 1.5 0.0 21.9 31.3 1.0 1.2 8.3 21.4 0.0 1.2 2.9 3.3 0.1 19.8 9.0 4.6 22.0 4.1 36.2 27.9 140.8 2.4 0.0 17.5 0.6 1.3 10.1 1.8 1.9 1.4 3.1 0.6 4.9 0.1 0.0 0.0 6.0 0.4 0.2 0.7 8.1 134.1 37.6 6.7 9.2 12.4 0.0 0.3 0.0 66.9 8.6 12.2 5.6 22.9 0.1 5.6 10.0 4.4 0.0 4.2 4.2 22.2 0.1 3.1 2.6 31.5 9.1 7.6 1.2 1.7 12.4 2.1 2.8 1.2 2.2 2.9 0.8 3.2 1.2 3.3 2.5 ITGA6 CD49f ENSG00000091409 "Integrin subunit alpha 6" P23229 2 172427354-172506282 "Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Cell adhesion" "Integrin, Receptor" "Cancer-related genes, Epidermolysis bullosa" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "BJ: 50.1;HaCaT: 55.2;HBEC3-KT: 108.5;hTCEpi: 47.3;hTERT-HME1: 48.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "eosinophil: 16.2" "Group enriched" "Detected in many" 34 "granulocytes: 16.2;NK-cells: 5.5;T-cells: 10.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009009, HPA012696, HPA027582" Enhanced 45000000 "CAB009009: AB_2128038, HPA012696: AB_1851822, HPA027582: AB_10602606" "unprognostic (1.02e-1)" "unprognostic (3.33e-1)" "unprognostic (2.59e-2)" "unprognostic (5.96e-2)" "unprognostic (4.93e-2)" "prognostic unfavourable (1.03e-4)" "unprognostic (1.19e-1)" "unprognostic (1.61e-3)" "unprognostic (9.34e-2)" "unprognostic (6.01e-2)" "unprognostic (1.85e-3)" "unprognostic (1.84e-1)" "prognostic favourable (2.35e-11)" "unprognostic (3.35e-2)" "unprognostic (3.32e-1)" "unprognostic (2.98e-2)" "unprognostic (1.21e-3)" 28.0 3.1 9.8 19.1 10.5 1.6 30.1 3.0 8.4 27.0 34.9 9.4 42.3 28.5 28.2 11.3 17.0 11.1 23.8 21.7 9.7 8.2 22.0 4.9 29.0 14.9 9.8 5.1 7.6 31.3 7.4 4.9 38.7 12.6 14.3 25.2 17.6 37.1 32.4 13.5 17.5 44.2 15.2 9.6 14.9 25.0 12.4 6.9 15.1 11.5 35.2 13.2 24.1 17.3 0.3 0.1 16.2 0.2 5.5 10.0 3.3 11.4 9.8 4.3 7.7 0.2 0.1 23.6 50.1 5.4 5.1 3.2 5.5 22.0 0.1 14.1 13.3 55.2 2.8 108.5 9.3 0.1 2.6 0.2 10.5 9.1 0.7 3.1 0.3 1.0 47.3 0.3 48.1 32.8 0.0 0.8 6.4 0.5 0.8 2.7 7.8 8.4 0.1 12.8 0.2 7.8 16.1 0.1 0.5 9.2 0.0 10.7 2.0 0.2 14.7 7.2 6.5 13.2 8.6 0.7 0.5 0.3 0.2 1.1 28.9 2.6 0.2 16.2 4.2 0.0 8.5 0.2 5.4 5.0 0.1 0.3 10.0 4.6 0.5 5.5 0.0 0.0 5.7 3.3 9.8 10.5 3.0 8.4 9.7 8.2 9.8 5.1 12.6 6.9 ITGAM "CD11b, CR3A, MAC-1" ENSG00000169896 "Integrin subunit alpha M" P11215 16 31259990-31332892 "Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion, Immunity, Innate immunity" "Integrin, Receptor" "Cancer-related genes, Systemic lupus erythematosus" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 93.7" "Group enriched" "Detected in some" 4 "HMC-1: 32.7;NB-4: 11.6;U-937: 14.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 5 "basophil: 29.4;classical monocyte: 19.1;eosinophil: 23.8;gdT-cell: 12.2;intermediate monocyte: 7.6;neutrophil: 21.0;NK-cell: 18.8" "Low lineage specificity" "Detected in all" "HPA002274, CAB025091, CAB072870" Enhanced 900000 "CAB025091: , CAB072870: , HPA002274: AB_1078435" "unprognostic (1.82e-2)" "unprognostic (1.70e-2)" "unprognostic (8.78e-2)" "unprognostic (2.54e-2)" "unprognostic (2.40e-2)" "unprognostic (4.20e-2)" "prognostic unfavourable (3.43e-4)" "unprognostic (1.86e-1)" "unprognostic (1.73e-1)" "unprognostic (3.29e-3)" "unprognostic (1.27e-1)" "unprognostic (1.80e-1)" "prognostic unfavourable (6.93e-5)" "unprognostic (9.89e-2)" "prognostic unfavourable (6.93e-4)" "unprognostic (3.99e-2)" "unprognostic (5.03e-2)" 19.7 5.0 6.0 14.0 7.2 93.7 6.0 2.0 4.5 2.9 3.2 9.4 0.5 1.8 2.5 3.5 2.2 4.8 4.0 6.5 4.3 3.9 3.0 3.3 14.6 22.8 10.5 1.6 2.5 2.9 1.6 1.8 4.9 5.3 3.6 2.7 3.3 3.2 2.0 1.6 1.5 4.4 6.9 8.6 29.9 2.8 1.5 7.4 2.3 2.1 1.7 6.6 4.9 4.5 1.9 3.4 29.4 19.1 18.8 12.2 8.0 0.5 1.1 0.0 0.0 0.0 0.0 0.9 0.1 0.0 0.0 0.0 0.3 0.4 0.8 0.5 0.0 0.1 0.0 0.2 0.0 4.7 0.0 0.6 0.0 0.0 0.0 1.1 32.7 0.0 0.1 0.0 0.0 0.0 1.1 0.1 0.0 0.0 0.0 11.6 0.0 0.0 0.1 0.0 0.6 0.0 1.3 0.0 0.0 0.0 0.3 0.2 0.1 2.7 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 14.0 0.0 29.4 19.1 23.8 12.2 7.6 0.7 1.9 1.3 3.6 3.4 0.3 0.3 3.0 21.0 18.8 1.1 0.2 0.5 8.0 6.0 7.2 2.0 4.5 4.3 3.9 10.5 1.6 5.3 7.4 ITGAV "CD51, MSK8, VNRA, VTNR" ENSG00000138448 "Integrin subunit alpha V" P06756 2 186590065-186680901 "Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Cell adhesion, Host-virus interaction" "Host cell receptor for virus entry, Integrin, Receptor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "RT4: 75.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "basophil: 7.7" "Group enriched" "Detected in many" 4 "granulocytes: 7.7;monocytes: 2.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002499, HPA004856" Supported Approved "Focal adhesion sites,Cytosol" 750000 "Focal adhesion sites, Cytosol" "CAB002499: AB_563594, HPA004856: AB_1846316" "unprognostic (4.03e-2)" "unprognostic (5.17e-3)" "unprognostic (1.22e-2)" "unprognostic (5.22e-2)" "unprognostic (1.33e-1)" "unprognostic (1.18e-1)" "prognostic unfavourable (2.08e-4)" "unprognostic (1.48e-2)" "unprognostic (6.95e-2)" "unprognostic (2.89e-1)" "prognostic unfavourable (5.07e-4)" "unprognostic (5.84e-2)" "unprognostic (2.67e-2)" "prognostic unfavourable (1.05e-6)" "unprognostic (2.61e-1)" "unprognostic (9.11e-2)" "unprognostic (8.07e-2)" 23.2 22.1 17.9 18.3 21.8 3.1 25.8 16.7 23.1 22.9 13.6 23.4 11.6 8.4 26.0 11.4 14.2 14.5 25.2 40.7 16.8 12.3 51.5 9.5 20.6 7.6 24.2 11.6 35.4 18.7 65.0 11.0 29.6 22.1 16.5 11.9 83.4 17.9 15.9 13.1 21.5 10.1 29.6 33.0 12.1 17.3 11.2 17.0 7.8 33.1 10.9 11.1 17.6 17.9 0.3 0.9 7.7 2.3 0.4 1.1 0.5 9.7 11.7 7.8 24.9 28.7 19.4 29.7 19.2 15.5 6.8 6.8 10.2 33.8 0.0 37.9 21.6 12.3 3.9 18.1 9.8 1.9 3.5 2.3 15.4 14.0 11.3 1.6 1.4 14.1 8.6 15.2 12.9 16.2 2.2 4.9 18.1 3.8 0.9 1.3 5.9 5.9 0.0 15.9 1.3 17.6 75.3 1.6 4.8 22.2 6.9 8.1 5.4 4.5 49.1 42.2 13.2 8.6 16.2 1.2 2.0 1.1 17.0 0.6 20.8 7.7 1.1 1.6 1.0 2.3 0.7 0.3 0.5 0.8 0.9 0.1 0.5 0.5 0.5 0.4 1.2 0.4 1.1 0.5 17.9 21.8 16.7 17.3 16.8 12.3 24.2 11.6 22.1 17.0 ITGB1 "CD29, FNRB, GPIIA, MDF2, MSK12" ENSG00000150093 "Integrin subunit beta 1" P05556 10 32900319-33005792 "Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Cell adhesion, Host-virus interaction" "Host cell receptor for virus entry, Integrin, Receptor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003434, HPA059297, HPA069003" Enhanced Supported "Endoplasmic reticulum,Plasma membrane,Focal adhesion sites" 540000000 "Plasma membrane, Focal adhesion sites" "Endoplasmic reticulum" "CAB003434: AB_303570, HPA059297: , HPA069003: " "unprognostic (3.07e-2)" "prognostic unfavourable (5.01e-4)" "unprognostic (8.67e-2)" "unprognostic (4.36e-1)" "unprognostic (1.20e-2)" "unprognostic (3.87e-2)" "unprognostic (1.60e-2)" "prognostic unfavourable (3.36e-6)" "unprognostic (3.22e-1)" "unprognostic (2.36e-3)" "unprognostic (3.68e-3)" "unprognostic (2.42e-1)" "unprognostic (1.02e-3)" "unprognostic (1.25e-2)" "unprognostic (2.23e-1)" "unprognostic (2.48e-1)" "unprognostic (3.08e-2)" 95.2 30.6 13.7 32.1 19.7 9.7 107.7 6.5 14.8 55.1 61.3 17.0 80.2 20.2 84.2 56.2 59.9 45.0 49.8 68.7 15.0 14.4 47.3 85.8 55.4 34.5 23.0 11.1 47.4 37.4 17.6 35.2 83.3 19.5 53.1 32.2 18.6 30.3 76.2 58.0 19.5 42.3 109.3 30.1 59.8 45.4 26.9 18.8 12.7 36.8 27.6 19.4 92.7 47.4 31.3 9.1 4.3 27.1 21.9 68.4 26.2 47.4 69.7 37.6 41.7 90.9 78.3 32.8 159.7 92.6 76.1 69.6 15.6 111.2 12.8 28.9 133.9 33.2 11.3 90.9 84.9 12.6 9.2 15.4 33.2 18.2 64.0 3.4 15.3 79.3 49.7 80.0 32.6 93.4 10.6 5.7 125.4 7.8 5.9 3.5 8.4 35.4 3.9 27.9 2.3 108.5 13.8 8.9 22.3 49.8 8.5 35.8 11.4 12.4 104.5 98.0 56.9 69.6 53.2 5.2 1.1 7.2 72.2 14.6 38.4 1.6 9.8 4.3 25.5 17.8 6.0 31.3 54.6 37.5 9.1 8.6 7.1 19.1 2.3 21.9 27.1 3.7 68.4 26.2 13.7 19.7 6.5 14.8 15.0 14.4 23.0 11.1 19.5 18.8 ITGB3 "CD61, GP3A, GPIIIa" ENSG00000259207 "Integrin subunit beta 3" P05106 17 47253846-47311816 "Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion, Host-virus interaction" "Host cell receptor for virus entry, Integrin, Receptor" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "thyroid gland: 36.6" "Cell line enhanced" "Detected in some" "EFO-21: 45.5;HEL: 40.3;RPTEC TERT1: 26.2;U-87 MG: 20.6;WM-115: 65.7" "Group enriched" "Detected in many" 6 "melanoma: 7.5;renal cancer: 3.6;thyroid cancer: 11.5" "Low region specificity" "Detected in many" "Group enriched" "Detected in some" 19 "basophil: 2.8;neutrophil: 2.8" "Lineage enriched" "Detected in single" 19 "granulocytes: 2.8" HPA027852 Approved Supported "Nucleoplasm,Plasma membrane" "Intracellular and membrane" 710000000 "Plasma membrane" Nucleoplasm "HPA027852: AB_10601760" "unprognostic (1.13e-2)" "unprognostic (1.97e-3)" "unprognostic (2.47e-1)" "unprognostic (3.00e-2)" "unprognostic (1.91e-2)" "unprognostic (6.04e-3)" "unprognostic (3.70e-1)" "unprognostic (3.00e-1)" "unprognostic (1.44e-1)" "unprognostic (3.85e-1)" "unprognostic (6.35e-2)" "unprognostic (7.22e-2)" "unprognostic (1.36e-1)" "unprognostic (1.03e-2)" "unprognostic (2.72e-2)" "unprognostic (1.48e-1)" "unprognostic (1.17e-3)" 10.0 0.6 1.0 6.2 2.5 2.7 7.0 0.4 1.6 4.6 13.6 0.9 2.4 2.2 9.7 5.7 6.4 6.4 2.8 8.5 0.7 0.6 16.0 3.7 5.2 1.2 2.3 0.1 4.6 0.6 0.7 1.6 23.5 1.6 6.4 4.8 1.8 2.5 11.5 4.9 2.4 5.0 17.0 1.8 9.5 3.6 2.6 0.6 0.2 36.6 1.9 0.9 11.0 7.8 0.1 0.0 2.8 0.1 0.0 0.0 9.5 0.0 0.4 0.1 0.0 2.3 1.0 0.0 1.2 6.0 2.6 2.4 0.0 0.0 0.1 45.5 0.3 0.0 0.0 0.0 3.4 0.8 0.0 40.3 0.1 0.0 1.9 0.0 0.0 0.9 0.0 15.2 0.3 11.3 0.1 0.0 0.5 0.0 0.2 0.0 0.0 0.1 0.0 1.0 0.0 26.2 0.0 0.0 0.1 1.5 0.0 8.2 0.0 0.0 12.3 0.5 0.6 0.3 2.8 0.0 0.0 0.2 20.6 0.0 65.7 2.8 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 2.8 0.0 0.0 0.0 0.0 9.5 1.0 2.5 0.4 1.6 0.7 0.6 2.3 0.1 1.6 0.6 ITGB4 CD104 ENSG00000132470 "Integrin subunit beta 4" P16144 17 75721328-75757818 "Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Integrin, Receptor" "Cancer-related genes, Disease mutation, Epidermolysis bullosa" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in some" "CAPAN-2: 117.5;HaCaT: 45.0;HBEC3-KT: 100.3;hTCEpi: 34.3;RT4: 33.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "plasmacytoid DC: 8.2" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB002422, CAB005258, HPA036348, HPA036349" Enhanced Supported "Plasma membrane,Cell Junctions" 79000 "Plasma membrane, Cell Junctions" "CAB002422: AB_563480, CAB005258: AB_2129021, HPA036348: AB_2675077, HPA036349: AB_2675078" "unprognostic (3.17e-3)" "unprognostic (3.52e-1)" "unprognostic (4.19e-1)" "unprognostic (2.27e-1)" "unprognostic (5.75e-2)" "unprognostic (6.11e-3)" "unprognostic (1.28e-1)" "prognostic unfavourable (7.18e-4)" "unprognostic (1.05e-1)" "unprognostic (4.14e-2)" "prognostic unfavourable (6.39e-4)" "unprognostic (1.02e-1)" "unprognostic (2.23e-2)" "unprognostic (1.65e-2)" "unprognostic (1.05e-1)" "unprognostic (1.07e-1)" "unprognostic (1.43e-1)" 6.3 3.4 9.7 10.9 9.7 1.4 13.7 4.7 7.7 14.3 32.1 15.6 10.0 35.3 9.7 8.8 24.0 13.7 47.8 4.3 9.4 7.9 4.8 1.5 7.4 3.7 10.1 9.1 4.7 6.7 3.1 5.7 50.0 17.2 19.7 10.4 9.8 52.3 13.2 2.4 47.0 58.5 7.4 10.7 17.0 41.0 3.9 9.8 1.8 3.2 22.1 15.9 17.2 20.5 2.4 8.2 1.3 0.7 0.0 2.2 0.8 21.8 19.3 0.0 0.2 0.0 0.1 26.6 0.1 0.0 0.0 0.1 2.0 117.5 0.0 4.2 0.0 45.0 0.1 100.3 0.0 0.1 0.0 0.1 4.9 2.1 0.1 0.0 0.2 0.1 34.3 0.0 21.4 0.7 0.0 2.0 0.0 12.2 0.2 0.2 0.1 16.8 0.3 0.5 0.2 26.8 33.0 0.0 0.2 0.6 2.0 0.3 8.4 0.2 2.2 0.6 1.0 0.0 0.2 0.7 0.2 0.0 0.2 0.1 0.3 0.0 0.4 0.0 0.7 0.7 2.2 1.4 0.3 1.0 0.1 2.4 0.9 0.6 1.3 0.0 0.0 8.2 1.4 0.8 9.7 9.7 4.7 7.7 9.4 7.9 10.1 9.1 17.2 9.8 ITGB5 ENSG00000082781 "Integrin subunit beta 5" P18084 3 124761948-124901418 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion, Host-virus interaction" "Host cell receptor for virus entry, Integrin, Receptor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "A549: 74.0;WM-115: 77.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "gdT-cell: 2.1" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001820, CAB022050" Approved Approved "Plasma membrane,Mitochondria" 95000 "Plasma membrane, Mitochondria" "CAB022050: , HPA001820: AB_1079142" "unprognostic (2.63e-1)" "unprognostic (1.04e-1)" "unprognostic (3.57e-1)" "unprognostic (4.44e-2)" "unprognostic (1.37e-2)" "unprognostic (6.07e-2)" "unprognostic (3.49e-3)" "unprognostic (3.16e-3)" "unprognostic (1.68e-1)" "unprognostic (1.53e-2)" "prognostic unfavourable (1.40e-4)" "unprognostic (1.16e-1)" "unprognostic (2.16e-3)" "unprognostic (2.49e-3)" "unprognostic (1.12e-1)" "unprognostic (1.01e-1)" "unprognostic (4.38e-3)" 72.5 13.8 9.7 9.7 10.0 0.8 50.1 5.7 8.2 34.2 18.8 14.8 28.0 12.9 31.7 17.2 25.6 13.9 29.1 32.9 9.4 5.1 19.6 22.1 20.4 3.5 12.0 6.2 17.4 12.1 8.9 8.4 36.4 13.0 23.0 10.1 27.1 18.6 23.1 15.9 33.3 16.1 25.1 9.0 18.7 12.4 17.0 8.7 2.8 18.8 16.2 10.9 24.4 27.1 0.1 1.1 0.4 0.6 0.9 2.1 5.8 29.6 74.0 5.3 13.4 50.2 14.6 27.5 31.8 19.7 5.9 9.6 14.7 38.8 0.1 15.5 54.0 23.8 4.8 16.5 5.2 0.3 3.2 10.5 11.4 15.5 8.8 0.0 19.3 8.7 3.8 14.9 7.8 19.8 9.3 15.9 20.3 30.2 0.1 0.1 23.8 8.2 0.0 8.5 11.2 16.8 6.5 0.1 11.1 23.6 35.1 26.8 19.8 0.6 51.0 22.4 33.8 19.4 16.4 2.7 2.8 0.2 23.4 0.1 77.2 0.4 0.6 0.2 2.1 0.2 0.0 0.0 0.2 0.0 1.1 0.1 0.3 0.4 0.4 0.9 0.4 0.1 0.0 5.8 9.7 10.0 5.7 8.2 9.4 5.1 12.0 6.2 13.0 8.7 ITGB6 ENSG00000115221 "Integrin subunit beta 6" P18564 2 160099666-160200313 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins" "Cell adhesion, Host-virus interaction" "Host cell receptor for virus entry, Integrin, Receptor" "Amelogenesis imperfecta, Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "kidney: 62.1" "Group enriched" "Detected in some" 5 "CAPAN-2: 36.6;RPTEC TERT1: 73.2" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in some" "HPA023626, CAB073536" Approved Approved "Nucleoplasm,Cell Junctions,Centrosome" "Nucleoplasm, Cell Junctions" Centrosome "CAB073536: , HPA023626: " "unprognostic (1.27e-1)" "unprognostic (1.57e-2)" "unprognostic (6.90e-2)" "unprognostic (8.22e-3)" "unprognostic (3.61e-3)" "unprognostic (1.50e-2)" "unprognostic (1.72e-3)" "unprognostic (2.04e-2)" "unprognostic (1.72e-1)" "unprognostic (7.06e-2)" "prognostic unfavourable (5.03e-6)" "unprognostic (1.04e-1)" "unprognostic (2.73e-1)" "unprognostic (4.97e-2)" "unprognostic (1.23e-1)" "unprognostic (2.16e-1)" "unprognostic (1.00e-1)" 0.3 0.3 0.3 3.1 0.3 0.0 8.7 0.3 0.3 4.1 8.3 0.1 4.5 3.5 2.1 2.5 18.7 1.2 12.0 0.7 0.3 0.3 62.1 0.3 28.8 0.1 0.3 0.1 1.5 3.8 7.0 2.2 18.7 0.2 7.5 3.0 0.1 3.8 4.8 31.5 1.9 11.7 2.0 0.3 0.3 7.9 0.6 0.1 0.1 4.9 6.8 5.9 12.8 8.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.8 0.0 0.0 0.0 0.0 0.0 4.0 0.0 0.0 0.0 0.0 0.0 36.6 0.0 0.2 0.0 7.5 0.0 11.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 8.4 0.0 0.0 0.0 0.0 0.0 1.0 1.1 0.0 0.0 0.0 0.0 0.0 2.9 0.0 73.2 12.1 0.0 0.0 0.0 11.6 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.1 0.2 0.1 ITGB7 ENSG00000139626 "Integrin subunit beta 7" P26010 12 53191318-53207307 "Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Host cell receptor for virus entry, Integrin, Receptor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 31.3;lymphoid tissue: 37.6" "Group enriched" "Detected in some" 99 "Karpas-707: 288.3;RPMI-8226: 225.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in single" "Low region specificity" "Detected in many" HPA042277 Uncertain "Plasma membrane,Cytosol" 42000 "Plasma membrane, Cytosol" "HPA042277: AB_10793877" "unprognostic (5.34e-2)" "unprognostic (4.47e-2)" "unprognostic (2.80e-3)" "unprognostic (1.40e-2)" "unprognostic (6.57e-4)" "unprognostic (3.51e-5)" "unprognostic (3.11e-3)" "unprognostic (1.37e-2)" "unprognostic (3.58e-1)" "unprognostic (2.18e-1)" "unprognostic (9.63e-3)" "unprognostic (3.36e-1)" "unprognostic (1.02e-2)" "unprognostic (2.16e-1)" "unprognostic (6.95e-2)" "unprognostic (9.34e-2)" "unprognostic (2.47e-4)" 1.8 1.4 1.4 29.1 1.8 7.5 1.5 0.6 1.2 1.8 8.7 2.9 0.8 6.7 2.3 2.8 6.6 2.0 5.6 1.4 1.5 1.0 5.4 5.1 4.9 26.4 1.9 1.0 1.1 1.3 0.7 1.7 1.8 2.4 2.7 5.6 2.1 10.7 2.2 1.0 6.4 15.1 1.5 2.0 26.7 4.3 0.9 2.0 7.8 3.6 4.4 37.6 4.6 3.0 10.1 15.4 31.3 1.9 7.5 23.0 5.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 2.5 0.0 0.0 0.5 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.1 0.0 0.0 0.0 0.0 288.3 0.0 0.0 0.0 0.4 0.0 0.0 0.1 0.0 225.1 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.5 0.9 0.2 0.2 0.1 0.0 22.6 1.9 31.3 19.3 0.5 14.3 10.1 19.4 23.0 15.4 8.3 16.3 17.1 0.5 7.5 0.1 4.2 22.7 5.2 1.4 1.8 0.6 1.2 1.5 1.0 1.9 1.0 2.4 2.0 ITGB8 ENSG00000105855 "Integrin subunit beta 8" P26012 7 20330702-20415754 "Cancer-related genes, Predicted membrane proteins" "Cell adhesion" "Integrin, Receptor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "AF22: 16.3;EFO-21: 21.0;RPTEC TERT1: 32.6;WM-115: 46.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 105 "basophil: 13.8" "Lineage enriched" "Detected in single" 105 "granulocytes: 13.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA027796, HPA027797" Enhanced Approved "Plasma membrane,Cytosol" "Plasma membrane, Cytosol" "HPA027796: AB_10600299, HPA027797: AB_10600879" "unprognostic (8.32e-3)" "unprognostic (1.42e-1)" "unprognostic (1.03e-1)" "unprognostic (3.37e-3)" "unprognostic (5.63e-2)" "unprognostic (3.53e-1)" "unprognostic (1.75e-1)" "unprognostic (1.46e-1)" "unprognostic (4.36e-2)" "unprognostic (1.75e-2)" "unprognostic (2.49e-3)" "unprognostic (8.47e-2)" "prognostic favourable (1.77e-4)" "unprognostic (2.90e-1)" "unprognostic (1.56e-1)" "unprognostic (4.63e-2)" "unprognostic (6.92e-3)" 4.7 4.1 18.0 5.8 20.0 1.2 12.7 7.8 24.3 22.1 4.6 19.4 9.0 4.6 10.5 19.0 8.8 10.4 11.7 3.9 19.4 12.5 28.1 1.7 3.7 1.3 29.3 14.5 7.1 17.5 8.1 7.7 10.7 22.8 9.6 4.4 37.5 16.6 13.1 0.9 8.5 6.0 7.0 23.1 0.8 6.2 8.7 24.0 0.0 3.4 1.3 9.0 6.8 9.9 0.0 0.0 13.8 0.1 0.0 0.1 0.0 10.0 0.4 16.3 2.0 1.4 5.7 0.0 0.0 0.1 0.1 0.5 0.1 2.5 0.0 21.0 0.7 11.2 0.7 1.6 0.2 0.0 0.2 0.0 7.8 0.0 0.7 0.0 0.0 0.6 4.6 0.2 0.8 0.8 0.0 3.0 0.3 0.0 0.0 0.0 1.2 1.8 0.0 1.4 0.0 32.6 0.8 0.2 0.7 3.1 0.0 8.1 0.2 0.0 1.1 4.3 2.8 1.2 2.1 3.8 0.0 0.0 1.0 0.0 46.6 13.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.0 18.0 20.0 7.8 14.2 19.4 12.5 29.3 14.5 22.8 24.0 ITIH4 "H4P, IHRP, ITIHL1" ENSG00000055955 "Inter-alpha-trypsin inhibitor heavy chain family member 4" Q14624 3 52812975-52831479 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Acute phase" "Protease inhibitor, Serine protease inhibitor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 20 "liver: 461.4" "Cell line enhanced" "Detected in some" "HDLM-2: 5.4;U-266/70: 6.6" "Cancer enriched" "Detected in single" 27 "liver cancer: 7.4" "Not detected" "Not detected" "Cell type enhanced" "Detected in single" "NK-cell: 2.6" "Low lineage specificity" "Detected in single" "Not detected" "Not detected" "Low region specificity" "Detected in many" "HPA001835, HPA003948, CAB072872" Enhanced Approved Vesicles "Secreted to blood" 3056667 53000000000 Vesicles "CAB072872: , HPA001835: AB_1079432, HPA003948: AB_1079433" "unprognostic (6.08e-2)" "unprognostic (4.45e-2)" "unprognostic (1.67e-1)" "unprognostic (2.69e-1)" "unprognostic (2.64e-1)" "unprognostic (1.96e-1)" "unprognostic (5.86e-2)" "unprognostic (1.98e-2)" "unprognostic (5.64e-2)" "unprognostic (1.02e-1)" "unprognostic (2.47e-2)" "unprognostic (1.52e-1)" "unprognostic (1.10e-14)" "unprognostic (1.71e-3)" "unprognostic (2.96e-2)" "unprognostic (1.52e-1)" "unprognostic (4.21e-5)" 0.5 1.8 0.1 0.1 0.1 1.0 0.1 0.1 0.2 0.4 0.2 0.1 0.1 0.1 0.1 1.3 0.2 0.1 0.1 0.6 0.1 0.0 0.2 461.4 0.2 0.1 0.1 0.2 0.2 22.8 0.0 0.1 0.1 0.2 0.2 0.1 0.1 0.2 0.2 4.1 0.1 0.1 0.2 0.1 0.5 0.1 0.3 0.1 0.1 0.2 0.1 0.2 0.2 0.2 0.3 0.3 0.6 0.6 2.6 0.8 0.0 0.0 0.4 1.0 2.1 1.1 0.0 0.4 0.1 0.0 0.0 0.2 0.3 0.2 1.3 0.0 0.5 1.1 0.0 0.0 0.5 5.4 0.2 2.2 0.0 2.9 0.9 2.5 0.2 0.3 0.4 0.0 0.1 0.0 0.6 1.8 0.0 0.2 0.5 0.7 1.0 0.0 1.8 1.0 0.0 0.8 0.7 0.1 1.0 0.7 0.0 0.4 1.1 0.7 0.2 0.0 0.9 1.0 0.0 6.6 3.1 0.5 0.1 0.7 1.2 0.0 0.6 0.0 0.1 0.1 0.1 0.3 0.7 0.0 0.0 0.2 0.0 0.8 0.6 2.6 0.1 0.3 0.4 0.0 0.1 0.1 0.1 0.2 0.1 0.0 0.1 0.2 0.2 0.1 ITPKB "IP3-3KB, IP3KB" ENSG00000143772 "Inositol-trisphosphate 3-kinase B" P27987 1 226631690-226739323 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Calmodulin-binding, Kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 63.1" "Cell line enhanced" "Detected in many" "SK-MEL-30: 28.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA030273, HPA072923" Enhanced Approved Nucleoplasm Nucleoplasm "HPA030273: AB_10601127, HPA072923: " "unprognostic (4.54e-2)" "unprognostic (3.85e-2)" "unprognostic (8.41e-3)" "unprognostic (9.37e-3)" "unprognostic (1.53e-1)" "prognostic favourable (1.72e-5)" "unprognostic (1.24e-1)" "prognostic favourable (6.65e-4)" "unprognostic (2.29e-1)" "unprognostic (9.57e-2)" "unprognostic (1.41e-2)" "unprognostic (1.75e-2)" "unprognostic (3.23e-3)" "unprognostic (2.90e-2)" "unprognostic (7.46e-2)" "unprognostic (6.54e-3)" "unprognostic (7.87e-2)" 23.8 4.2 34.7 13.0 35.1 14.8 15.2 11.1 33.6 14.3 19.7 32.4 8.5 6.0 27.1 15.6 12.6 15.3 8.9 7.8 27.9 24.8 9.7 3.2 13.4 22.7 50.4 16.3 8.8 4.8 10.1 4.2 13.5 40.0 13.1 6.3 20.8 24.9 21.3 9.8 10.5 12.5 32.6 63.1 19.0 12.4 3.2 34.0 20.0 5.9 4.3 17.1 19.6 8.5 3.1 0.9 7.7 3.5 3.0 7.9 2.6 2.8 3.0 4.9 5.6 3.8 2.5 1.3 0.7 3.3 1.5 3.6 0.5 3.5 12.8 4.6 0.7 4.1 6.2 2.5 0.7 1.7 4.2 5.7 3.3 0.0 1.5 5.3 10.2 2.8 3.6 1.7 1.6 10.5 0.0 1.8 0.2 2.6 9.7 7.1 10.6 4.9 3.8 8.8 2.8 11.3 4.5 2.9 3.7 2.3 1.7 28.1 7.2 6.0 7.3 2.0 1.5 1.8 4.5 0.1 4.6 15.7 0.5 4.8 7.4 1.2 1.4 7.7 4.4 2.1 3.9 1.9 5.3 4.5 0.9 3.1 7.9 5.7 5.4 3.0 3.5 0.8 3.0 2.6 34.7 35.1 11.1 27.9 27.9 24.8 50.4 16.3 40.0 34.0 JAK1 "JAK1A, JAK1B, JTK3" ENSG00000162434 "Janus kinase 1" P23458 1 64833229-64966504 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "ASC diff: 69.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB013088 Approved "CAB013088: " "prognostic favourable (9.63e-4)" "unprognostic (1.24e-1)" "prognostic favourable (2.81e-4)" "unprognostic (5.10e-2)" "unprognostic (1.16e-1)" "unprognostic (4.21e-2)" "unprognostic (1.53e-1)" "unprognostic (7.00e-3)" "unprognostic (8.40e-2)" "unprognostic (7.88e-3)" "unprognostic (1.66e-2)" "unprognostic (8.84e-2)" "prognostic favourable (2.67e-4)" "unprognostic (2.35e-1)" "unprognostic (2.04e-1)" "unprognostic (7.30e-2)" "unprognostic (3.51e-1)" 46.7 20.4 15.5 31.1 16.5 21.2 56.6 24.3 20.4 27.3 27.1 16.3 16.5 13.8 28.2 22.0 27.0 20.7 27.7 27.3 15.3 16.5 31.4 38.3 36.5 61.4 15.6 14.1 33.3 29.1 28.3 39.8 22.9 25.1 26.0 22.2 18.1 19.8 21.3 45.1 29.7 29.3 30.7 16.3 52.7 20.9 17.3 15.0 62.7 29.0 17.9 42.5 37.2 29.3 20.2 15.4 34.9 17.1 68.1 27.5 25.8 10.9 14.4 6.0 0.6 69.4 39.3 7.8 17.2 25.4 14.3 16.9 4.7 6.1 16.7 13.4 30.5 6.2 4.0 13.3 20.4 22.1 6.4 22.7 7.5 10.2 25.6 8.7 15.8 34.5 18.5 21.6 22.6 44.6 8.2 17.9 15.8 6.3 4.7 5.8 4.1 8.6 6.8 17.3 6.1 36.9 19.4 4.2 12.7 23.6 11.1 10.1 23.5 5.4 40.4 17.2 7.7 38.9 9.1 11.2 5.1 13.3 16.0 11.5 7.7 31.2 10.9 31.5 22.8 15.2 27.5 20.2 22.0 25.7 15.4 16.1 24.3 20.7 34.9 68.1 17.1 10.5 26.5 25.8 15.5 16.5 24.3 20.4 15.3 16.5 15.6 14.1 25.1 15.0 JAK2 JTK10 ENSG00000096968 "Janus kinase 2" O60674 9 4984390-5128183 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Adaptive immunity, Immunity, Innate immunity" "Chromatin regulator, Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Group enriched" "Detected in many" 5 "ASC diff: 18.9;HDLM-2: 26.7;HEL: 54.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "basophil: 40.8" "Lineage enriched" "Detected in all" 4 "granulocytes: 40.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB013089, HPA040820, HPA043870" Approved Supported "Nucleoplasm,Plasma membrane,Focal adhesion sites" Nucleoplasm "Plasma membrane, Focal adhesion sites" "CAB013089: AB_2533647, HPA040820: , HPA043870: " "unprognostic (2.24e-3)" "unprognostic (2.76e-2)" "unprognostic (1.50e-2)" "unprognostic (7.67e-2)" "unprognostic (5.50e-2)" "unprognostic (3.09e-2)" "unprognostic (1.48e-1)" "unprognostic (7.36e-2)" "unprognostic (1.09e-1)" "unprognostic (5.49e-3)" "unprognostic (1.58e-1)" "unprognostic (1.72e-2)" "unprognostic (3.85e-1)" "unprognostic (4.53e-2)" "unprognostic (3.43e-2)" "unprognostic (1.96e-1)" "unprognostic (7.37e-3)" 19.8 8.8 11.5 19.0 10.5 19.0 17.7 14.7 14.4 17.8 10.6 7.0 10.3 7.2 14.8 13.6 12.4 13.4 14.6 27.6 10.3 6.7 7.7 5.6 16.1 19.4 7.0 10.5 15.9 6.7 10.1 7.5 12.0 10.0 12.0 7.4 9.4 7.2 7.4 14.4 19.0 12.3 10.4 11.7 21.5 14.1 10.1 9.0 13.6 8.6 6.5 13.5 13.9 15.6 2.1 9.6 40.8 7.5 3.4 2.1 2.5 2.5 1.4 1.4 2.5 18.9 4.9 0.4 3.4 2.9 2.6 1.7 0.1 0.8 0.1 0.8 2.0 0.8 1.5 2.1 1.9 26.7 0.5 54.8 2.9 0.7 3.9 3.7 2.8 4.0 0.9 1.1 1.8 2.4 3.9 6.4 4.7 0.9 0.9 5.2 1.3 1.7 1.9 2.7 0.7 2.0 1.3 1.6 0.9 1.0 1.5 1.0 0.7 6.5 5.0 4.0 1.3 4.1 2.4 1.2 2.2 0.5 5.2 1.8 2.0 40.8 7.5 13.4 2.1 7.3 1.7 2.1 1.6 1.2 9.6 1.9 0.9 1.1 7.1 3.4 5.8 3.6 1.6 2.5 11.5 10.5 14.7 14.4 10.3 6.7 7.0 10.5 10.0 9.0 JAK3 "JAK-3, JAK3_HUMAN, JAKL, L-JAK, LJAK" ENSG00000105639 "Janus kinase 3" P52333 19 17824780-17848071 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Adaptive immunity, Immunity, Innate immunity" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "lymphoid tissue: 68.3" "Cell line enhanced" "Detected in some" "HDLM-2: 20.1;HEL: 9.0;HMC-1: 9.2;Karpas-707: 23.5;U-266/70: 9.1;U-266/84: 13.5;U-937: 13.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA070314 Enhanced Approved "Plasma membrane,Cytosol" "Plasma membrane, Cytosol" "HPA070314: " "unprognostic (5.59e-3)" "prognostic favourable (6.42e-5)" "unprognostic (5.71e-2)" "unprognostic (2.34e-1)" "unprognostic (6.13e-3)" "unprognostic (1.11e-3)" "unprognostic (4.21e-2)" "unprognostic (2.60e-1)" "unprognostic (2.38e-2)" "unprognostic (2.36e-1)" "unprognostic (3.58e-2)" "unprognostic (1.94e-1)" "prognostic unfavourable (2.89e-14)" "unprognostic (2.28e-1)" "unprognostic (2.21e-2)" "unprognostic (4.43e-2)" "unprognostic (7.61e-2)" 6.8 1.7 4.0 24.5 8.5 12.0 2.7 2.4 3.1 1.9 2.3 1.0 0.0 2.2 1.7 2.0 2.5 3.5 3.6 4.3 2.7 2.8 3.8 2.0 8.4 68.3 7.5 0.0 11.0 2.0 0.4 2.3 4.1 5.3 3.0 2.4 1.6 6.1 1.5 0.7 1.3 9.5 2.5 8.4 36.1 3.2 1.8 5.8 20.9 3.4 1.7 28.8 5.3 2.4 7.4 4.5 16.9 9.6 8.4 15.0 6.8 0.1 0.3 0.3 1.0 0.4 1.4 0.2 0.5 0.0 0.0 0.1 0.0 0.9 0.4 1.9 0.4 0.1 0.0 0.2 0.0 20.1 0.0 9.0 0.0 0.8 0.7 0.0 9.2 5.0 0.2 0.0 0.0 0.2 0.0 23.5 0.0 0.4 3.6 0.0 0.1 0.7 4.6 0.0 0.4 0.5 0.0 0.0 0.3 0.1 0.2 0.0 2.0 1.3 0.4 0.0 0.4 0.0 0.0 9.1 13.5 2.5 0.1 13.7 0.2 1.2 4.9 0.2 12.6 9.6 14.5 6.5 15.0 13.1 4.5 7.4 14.9 13.0 16.9 8.4 8.8 3.7 11.8 6.8 4.0 8.5 2.4 3.1 2.7 2.8 7.5 0.0 5.3 5.8 JKAMP "C14orf100, CDA06, HSPC213, HSPC327, JAMP" ENSG00000050130 "JNK1/MAPK8 associated membrane protein" Q9P055 14 59484443-59505410 "Cancer-related genes, Predicted membrane proteins" "Unfolded protein response" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA031172, HPA071650" Supported Approved Nucleoplasm,Vesicles Vesicles Nucleoplasm "HPA031172: AB_10670563, HPA071650: " "unprognostic (1.48e-1)" "unprognostic (2.19e-2)" "unprognostic (4.95e-2)" "unprognostic (5.88e-2)" "unprognostic (2.54e-1)" "unprognostic (1.49e-3)" "prognostic unfavourable (3.09e-6)" "unprognostic (2.68e-1)" "unprognostic (3.52e-1)" "unprognostic (1.16e-1)" "unprognostic (3.09e-1)" "unprognostic (3.14e-1)" "prognostic favourable (1.36e-4)" "unprognostic (1.76e-1)" "unprognostic (2.27e-1)" "unprognostic (1.36e-1)" "unprognostic (1.73e-1)" 19.0 29.5 19.3 13.0 25.5 15.7 24.2 16.7 28.4 17.5 21.3 25.0 18.1 13.8 22.8 19.6 18.6 23.2 21.7 18.3 18.8 29.4 38.9 26.1 22.2 16.2 29.5 19.5 19.7 18.7 42.3 44.5 24.1 36.9 22.9 22.5 22.8 24.9 20.3 15.9 17.5 25.0 20.7 30.3 22.1 18.7 24.6 27.0 18.6 24.6 18.0 14.7 21.0 16.7 14.9 29.0 37.0 31.7 18.0 18.3 21.5 19.7 23.3 20.1 16.4 15.0 19.9 15.3 31.0 26.5 18.3 21.8 7.3 36.2 9.8 27.8 28.6 14.4 14.7 19.1 24.7 29.3 8.4 9.8 15.0 14.5 20.0 16.5 19.4 21.7 21.7 17.1 11.8 18.6 8.9 19.7 34.4 17.8 9.0 12.7 11.0 20.6 10.6 24.4 9.0 31.5 19.6 8.6 15.0 28.1 22.5 16.4 22.7 12.7 24.4 19.3 25.3 17.6 20.3 9.2 16.3 11.4 27.3 11.2 24.2 28.2 25.2 32.5 15.1 29.8 14.6 14.9 16.5 15.9 21.2 13.6 17.7 16.6 37.0 18.0 31.7 29.0 18.3 21.5 19.3 25.5 16.7 28.4 18.8 29.4 29.5 19.5 36.9 27.0 JTB "hJT, PAR" ENSG00000143543 "Jumping translocation breakpoint" O76095 1 153974269-153977688 "Cancer-related genes, Plasma proteins, Predicted membrane proteins" "Apoptosis, Cell cycle, Cell division, Mitosis" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA006514 Approved Approved "Vesicles,Actin filaments" Vesicles "Actin filaments" "HPA006514: AB_1079164" "unprognostic (1.33e-1)" "unprognostic (1.77e-1)" "unprognostic (8.01e-2)" "unprognostic (1.66e-1)" "unprognostic (1.08e-1)" "unprognostic (3.40e-1)" "unprognostic (5.66e-3)" "unprognostic (8.62e-3)" "unprognostic (5.60e-2)" "prognostic favourable (7.87e-4)" "unprognostic (1.00e-3)" "unprognostic (8.16e-2)" "prognostic unfavourable (6.65e-9)" "unprognostic (1.36e-1)" "unprognostic (4.25e-1)" "unprognostic (5.48e-2)" "unprognostic (2.58e-3)" 23.9 30.2 28.5 23.0 32.7 43.2 32.6 30.7 32.3 31.8 36.0 23.6 51.3 35.9 25.1 41.0 30.4 26.1 37.1 36.2 25.4 23.9 34.2 81.1 27.7 34.7 27.7 19.8 26.9 106.8 24.8 49.8 30.0 24.4 33.4 36.0 24.9 100.6 45.9 42.1 23.4 45.6 21.6 20.5 35.9 42.4 15.3 25.2 30.5 58.5 32.0 34.0 25.2 33.0 47.4 54.1 60.7 43.0 30.4 46.4 30.2 39.5 27.4 11.8 21.6 38.8 24.1 33.3 28.9 28.2 19.3 19.5 26.3 32.9 37.8 41.0 33.4 36.2 29.8 22.2 15.8 35.6 59.6 21.9 32.6 26.6 40.7 42.2 33.8 22.9 42.0 20.3 24.1 22.8 32.5 27.8 13.5 68.8 30.4 54.2 25.3 48.3 32.2 16.1 75.9 24.4 21.7 32.4 32.8 22.9 66.5 38.7 41.8 61.4 17.8 9.6 16.5 28.9 36.8 41.5 46.3 41.0 23.6 40.6 20.6 32.6 43.0 60.7 29.4 30.3 35.5 47.4 41.1 46.4 33.4 45.2 42.4 33.7 39.9 30.4 33.4 54.1 33.6 30.2 28.5 32.7 30.7 32.3 25.4 23.9 27.7 19.8 24.4 25.2 JUN "AP-1, c-Jun" ENSG00000177606 "Jun proto-oncogene, AP-1 transcription factor subunit" P05412 1 58780788-58784327 "Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "RH-30: 71.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003801, CAB007780, HPA059474" Enhanced Enhanced Nucleoplasm Nucleoplasm "CAB003801: AB_365485, CAB007780: AB_562268, HPA059474: " "unprognostic (2.06e-2)" "unprognostic (1.76e-2)" "unprognostic (1.34e-1)" "unprognostic (7.85e-2)" "unprognostic (1.60e-1)" "unprognostic (1.70e-1)" "unprognostic (4.11e-2)" "unprognostic (5.21e-2)" "unprognostic (1.24e-1)" "unprognostic (5.00e-2)" "unprognostic (2.14e-1)" "unprognostic (2.82e-1)" "unprognostic (5.15e-2)" "unprognostic (1.45e-1)" "unprognostic (2.83e-1)" "unprognostic (2.37e-1)" "unprognostic (2.81e-3)" 64.5 29.4 26.7 33.7 17.2 68.4 61.7 19.5 20.6 60.0 32.7 30.8 28.4 13.3 40.5 21.8 34.1 72.6 48.5 31.3 20.2 12.4 21.2 39.3 55.1 14.3 15.3 12.0 49.8 48.7 15.0 16.7 21.6 24.1 48.6 16.7 40.5 59.4 39.3 32.2 51.3 28.6 40.7 17.6 22.9 47.0 18.2 18.1 9.0 61.0 35.2 23.3 41.5 33.1 7.4 1.3 4.0 5.1 3.2 2.5 1.2 16.0 2.3 5.2 1.0 8.3 9.4 0.1 20.5 7.5 14.5 8.8 4.2 1.2 0.6 9.9 12.7 5.6 0.4 6.6 9.2 12.7 37.3 0.2 0.9 4.7 6.8 1.1 3.7 10.1 17.1 18.7 7.8 10.8 5.6 9.3 5.6 3.0 1.0 9.0 4.1 14.6 0.4 71.1 3.2 13.6 1.5 14.4 4.2 14.2 14.9 6.0 5.3 0.6 19.0 33.1 15.0 12.0 25.6 20.7 3.3 1.2 34.5 2.1 9.4 1.2 5.1 2.0 2.4 1.1 1.3 4.1 1.2 2.5 1.3 7.4 0.3 1.7 4.0 3.2 0.4 0.2 0.9 1.2 26.7 17.2 19.5 20.6 20.2 12.4 15.3 12.0 24.1 18.1 JUND AP-1 ENSG00000130522 "JunD proto-oncogene, AP-1 transcription factor subunit" P17535 19 18279760-18281622 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "bone marrow: 204.7" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB005268, HPA063029" Supported Supported Nucleoplasm Nucleoplasm "CAB005268: AB_2130177, HPA063029: " "prognostic favourable (6.15e-5)" "unprognostic (4.18e-3)" "unprognostic (8.89e-2)" "unprognostic (2.52e-1)" "unprognostic (3.70e-1)" "unprognostic (6.39e-2)" "unprognostic (1.63e-2)" "unprognostic (6.35e-2)" "unprognostic (3.48e-2)" "unprognostic (2.00e-1)" "unprognostic (3.37e-3)" "unprognostic (4.09e-2)" "unprognostic (3.35e-2)" "unprognostic (1.22e-1)" "unprognostic (3.99e-1)" "unprognostic (5.37e-2)" "unprognostic (1.49e-1)" 75.7 52.7 35.4 38.9 32.4 204.7 51.5 34.7 56.5 42.4 49.5 42.6 21.1 35.7 43.4 31.0 31.7 55.7 43.5 35.9 31.5 32.1 26.9 66.5 55.7 17.2 21.6 22.6 78.1 64.3 21.7 47.8 80.3 27.0 45.5 21.0 35.2 39.0 33.3 29.2 44.5 61.8 34.4 31.5 39.3 46.2 34.9 19.2 32.0 27.2 33.7 23.1 41.7 30.8 8.6 10.7 19.0 7.8 4.5 6.3 1.7 22.0 9.3 9.3 10.5 7.4 8.3 41.2 9.2 11.1 5.2 7.1 10.1 19.9 11.4 10.9 9.4 12.0 2.2 2.1 2.7 22.6 20.2 16.8 7.6 21.8 16.5 7.8 22.0 8.0 9.4 5.6 7.3 4.2 22.9 33.3 1.4 29.3 23.1 24.5 19.3 13.4 8.5 5.8 23.9 7.6 3.4 50.7 20.8 11.4 12.6 30.0 10.5 11.8 14.4 3.2 15.2 20.3 5.6 46.6 18.5 9.2 11.3 11.9 7.4 8.0 6.4 5.8 4.9 7.8 3.8 7.4 6.3 4.4 4.6 8.6 4.7 4.9 19.0 4.5 7.4 10.7 5.1 1.7 35.4 32.4 34.7 56.5 31.5 32.1 21.6 22.6 27.0 19.2 JUP "CTNNG, DP3, DPIII, PDGB, PKGB" ENSG00000173801 "Junction plakoglobin" P14923 17 41754604-41786931 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell adhesion" "Cancer-related genes, Cardiomyopathy, Disease mutation, Palmoplantar keratoderma" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "esophagus: 146.3;skin 1: 126.1;tongue: 122.8" "Cell line enhanced" "Detected in many" "HaCaT: 126.0;hTCEpi: 63.6;RT4: 77.4;SK-BR-3: 76.5;T-47d: 63.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 4 "classical monocyte: 7.6;eosinophil: 14.8;intermediate monocyte: 12.8;memory B-cell: 7.9;myeloid DC: 7.8;naive B-cell: 7.4;non-classical monocyte: 20.6" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB002139, HPA032047" Supported Supported "Vesicles,Plasma membrane,Cell Junctions" 61000000 "Plasma membrane, Cell Junctions" Vesicles "CAB002139: AB_563468, HPA032047: " "unprognostic (3.96e-3)" "unprognostic (3.40e-1)" "unprognostic (2.32e-1)" "unprognostic (4.71e-3)" "unprognostic (2.49e-2)" "unprognostic (1.12e-1)" "unprognostic (2.02e-1)" "unprognostic (8.11e-3)" "unprognostic (1.41e-2)" "unprognostic (9.85e-3)" "unprognostic (2.29e-3)" "unprognostic (9.60e-2)" "prognostic favourable (2.06e-10)" "unprognostic (2.50e-1)" "unprognostic (9.49e-2)" "unprognostic (9.05e-2)" "unprognostic (1.51e-2)" 12.5 2.6 2.8 9.5 4.5 3.3 13.0 6.5 3.7 34.5 17.9 8.7 12.3 15.6 12.2 9.6 146.3 13.0 19.0 34.5 3.3 1.6 31.6 11.7 13.2 4.0 5.3 2.2 12.5 12.8 3.6 5.8 42.4 4.0 14.0 8.8 8.3 34.3 14.3 17.6 126.1 36.1 4.3 3.2 4.5 15.4 3.6 4.6 10.8 27.9 122.8 84.8 12.5 55.4 7.9 7.8 14.8 20.6 0.3 0.1 2.9 30.2 25.1 2.5 2.1 0.0 0.0 39.3 1.7 10.4 0.7 0.6 37.9 33.5 0.6 18.7 1.1 126.0 3.6 28.0 0.1 0.0 8.9 1.3 20.0 8.3 4.2 0.8 13.4 0.0 63.6 0.1 5.2 11.2 11.1 11.0 0.0 38.8 0.2 10.9 4.9 4.2 35.4 0.0 22.7 19.4 77.4 6.2 4.6 3.9 76.5 0.2 63.8 0.9 17.6 0.0 1.8 0.8 0.5 0.9 3.4 0.6 0.1 1.4 0.3 1.7 7.6 14.8 0.0 12.8 0.0 7.9 0.0 0.1 7.8 7.4 0.1 0.1 0.3 0.3 20.6 2.5 0.0 2.9 2.8 4.5 6.5 3.7 3.3 1.6 5.3 2.2 4.0 4.6 KALRN "ARHGEF24, DUET, duo, HAPIP, Hs.8004, Kalirin, TRAD" ENSG00000160145 "Kalirin RhoGEF kinase" O60229 3 124080023-124726325 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Guanine-nucleotide releasing factor, Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 35.2;retina: 31.2" "Cell line enhanced" "Detected in many" "CACO-2: 32.1;HEL: 19.6;SH-SY5Y: 9.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "T-reg: 4.3" "Lineage enriched" "Detected in single" 5 "T-cells: 4.3" "Low region specificity" "Detected in many" "HPA011913, CAB026456" Approved Approved Nucleoplasm,Cytosol 110000 "Nucleoplasm, Cytosol" "CAB026456: , HPA011913: AB_1850494" "unprognostic (2.54e-2)" "unprognostic (3.43e-1)" "unprognostic (2.08e-1)" "unprognostic (3.12e-4)" "unprognostic (2.54e-1)" "unprognostic (1.74e-1)" "unprognostic (1.52e-1)" "unprognostic (1.53e-1)" "unprognostic (3.41e-2)" "unprognostic (8.58e-2)" "unprognostic (1.65e-1)" "unprognostic (1.04e-1)" "unprognostic (2.26e-3)" "unprognostic (5.58e-2)" "unprognostic (2.67e-1)" "unprognostic (3.70e-2)" "unprognostic (2.81e-3)" 5.5 4.3 12.7 2.4 14.1 0.6 4.2 1.8 35.2 4.0 3.8 3.7 0.5 2.7 5.6 2.3 9.6 4.2 3.1 12.1 17.6 3.9 2.6 7.3 2.9 1.1 4.1 15.8 2.3 11.9 2.5 14.4 6.8 9.4 3.1 2.1 31.2 2.2 5.4 23.5 1.5 7.2 6.4 3.6 8.0 11.5 2.2 2.4 0.0 5.3 6.7 3.1 2.9 4.1 0.1 0.0 0.9 0.0 0.1 4.3 1.2 0.3 0.6 3.6 0.7 0.5 0.1 4.6 1.4 0.8 1.4 0.6 32.1 2.5 0.1 0.4 3.6 0.2 0.8 0.0 1.1 0.0 0.3 19.6 0.3 4.9 0.0 0.0 0.0 0.2 0.0 0.3 0.0 1.6 4.5 0.1 0.4 2.3 0.0 0.0 2.0 3.1 1.0 1.6 0.0 0.1 0.3 1.2 9.2 0.4 0.3 0.3 0.7 0.1 8.1 4.1 1.6 0.6 0.6 0.0 0.3 0.0 0.5 0.0 1.8 0.1 0.0 0.0 0.1 0.0 0.0 0.1 1.8 0.3 0.0 0.0 2.4 0.7 0.9 0.1 0.0 0.0 4.3 1.2 12.7 14.1 1.8 35.2 17.6 3.9 4.1 15.8 9.4 2.4 KAT2B "GCN5, GCN5L, P/CAF, PCAF" ENSG00000114166 "Lysine acetyltransferase 2B" Q92831 3 20040023-20154404 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Biological rhythms, Cell cycle, Host-virus interaction, Transcription, Transcription regulation" "Activator, Acyltransferase, Transferase" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002470, CAB004526" Supported Supported Nucleoplasm,Centrosome Nucleoplasm Centrosome "CAB004526: AB_2128417, HPA002470: " "unprognostic (2.91e-2)" "unprognostic (6.85e-3)" "unprognostic (9.05e-2)" "unprognostic (2.25e-1)" "unprognostic (2.66e-2)" "unprognostic (3.01e-3)" "unprognostic (2.44e-1)" "unprognostic (3.83e-3)" "unprognostic (2.44e-2)" "unprognostic (1.03e-1)" "unprognostic (5.23e-3)" "unprognostic (7.13e-2)" "unprognostic (7.03e-2)" "unprognostic (2.26e-2)" "unprognostic (1.59e-1)" "unprognostic (5.16e-2)" "unprognostic (4.63e-2)" 10.6 6.6 30.1 9.4 27.5 24.9 6.8 22.0 20.1 10.2 9.4 27.6 7.9 10.9 7.8 5.4 17.3 7.7 8.0 21.9 24.7 18.0 10.8 24.0 10.1 12.7 26.8 15.9 18.2 11.6 38.1 8.7 8.5 24.2 9.5 8.1 10.7 20.9 9.2 33.4 8.9 13.0 8.7 21.4 11.7 9.0 1.8 31.1 8.7 10.0 7.4 12.0 8.7 11.0 2.1 2.7 5.5 1.5 1.1 4.8 0.8 1.5 3.9 2.2 3.6 9.0 8.4 5.1 5.0 7.4 5.3 7.8 1.1 2.6 13.4 2.1 9.4 1.1 5.4 1.6 4.5 12.2 5.1 11.8 6.2 0.4 4.2 1.8 15.3 3.6 2.9 4.6 3.0 5.0 7.5 19.0 7.5 1.8 3.8 3.5 0.9 3.9 5.1 4.1 2.8 7.2 8.0 1.1 2.4 2.8 4.5 17.0 4.7 8.0 4.8 9.0 3.6 3.3 5.7 7.3 15.1 3.2 8.2 7.8 18.9 1.3 1.1 2.8 3.6 1.5 3.4 1.0 3.1 2.5 0.9 2.1 1.1 2.1 5.5 1.1 1.1 2.7 4.8 0.8 30.1 27.5 22.0 20.1 24.7 18.0 26.8 15.9 24.2 31.1 KAT6A "MOZ, MYST3, RUNXBP2, ZC2HC6A, ZNF220" ENSG00000083168 "Lysine acetyltransferase 6A" Q92794 8 41929479-42051990 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, Acyltransferase, Chromatin regulator, Repressor, Transferase" "Cancer-related genes, Mental retardation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB017023, HPA063266, HPA065052" Supported Approved "Nucleoli,Nuclear speckles,Cytosol" "Nuclear speckles" "Nucleoli, Cytosol" "CAB017023: , HPA063266: , HPA065052: " "unprognostic (3.51e-2)" "unprognostic (1.14e-1)" "unprognostic (2.04e-1)" "unprognostic (3.23e-2)" "unprognostic (2.28e-1)" "unprognostic (9.27e-3)" "unprognostic (3.61e-1)" "unprognostic (2.29e-1)" "unprognostic (2.95e-1)" "unprognostic (2.45e-2)" "unprognostic (1.50e-1)" "unprognostic (4.45e-2)" "unprognostic (4.20e-3)" "unprognostic (1.18e-1)" "unprognostic (2.24e-1)" "unprognostic (8.58e-2)" "unprognostic (2.95e-2)" 20.8 10.9 15.3 19.8 20.3 36.8 22.6 29.9 18.7 19.7 14.6 19.4 14.4 10.7 20.6 12.1 16.9 16.5 14.3 13.0 15.5 11.5 12.3 13.6 26.9 28.2 23.2 10.3 27.2 13.1 26.8 22.3 20.9 15.7 14.1 12.0 12.8 15.1 17.0 21.0 25.5 18.0 25.0 22.9 20.4 14.0 14.1 21.7 30.4 17.9 14.3 20.1 16.9 24.2 4.7 1.8 10.9 1.6 3.1 3.9 1.4 12.9 10.6 17.5 11.1 9.8 11.2 5.9 8.7 11.3 10.8 8.4 6.7 6.2 19.2 8.7 8.5 8.3 13.6 8.2 12.7 9.9 7.9 27.6 6.6 5.0 7.4 14.5 12.7 9.3 9.4 10.0 12.4 10.3 23.1 12.2 9.8 5.7 29.5 4.6 6.7 4.2 23.6 19.6 6.1 5.3 14.9 10.9 9.4 10.1 6.8 7.0 15.6 6.4 12.0 13.3 9.4 11.8 9.3 10.0 16.1 20.8 7.1 6.6 11.5 3.5 1.6 2.8 3.5 1.2 3.9 2.4 2.6 3.3 1.0 4.7 3.6 2.9 10.9 3.1 1.2 1.8 3.5 1.4 15.3 20.3 29.9 18.7 15.5 11.5 23.2 10.3 15.7 21.7 KAT6B "Morf, MOZ2, MYST4, qkf, querkopf, ZC2HC6B" ENSG00000156650 "Lysine acetyltransferase 6B" Q8WYB5 10 74825582-75032622 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, Acyltransferase, Chromatin regulator, Repressor, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "PC-3: 22.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA006104 Supported Approved "Nucleoplasm,Nuclear bodies" "Nucleoplasm, Nuclear bodies" "HPA006104: AB_1079445" "unprognostic (4.17e-1)" "unprognostic (1.98e-1)" "unprognostic (1.82e-1)" "unprognostic (2.32e-2)" "unprognostic (7.83e-2)" "unprognostic (2.85e-2)" "unprognostic (3.56e-1)" "unprognostic (2.62e-1)" "unprognostic (2.54e-1)" "unprognostic (1.09e-1)" "unprognostic (9.47e-2)" "unprognostic (8.78e-2)" "prognostic favourable (4.82e-4)" "unprognostic (2.52e-1)" "unprognostic (3.70e-1)" "unprognostic (2.59e-2)" "unprognostic (3.15e-1)" 11.6 9.5 11.1 13.2 11.9 15.1 12.4 19.0 11.6 16.7 12.2 13.3 15.3 7.2 25.1 13.0 12.0 13.2 12.0 10.0 10.6 9.5 9.0 7.3 9.2 9.0 9.0 9.9 24.6 13.3 24.8 31.1 9.4 8.9 13.5 9.6 10.1 17.9 12.0 15.3 10.6 11.3 16.2 9.3 10.4 13.0 12.8 12.1 26.6 13.0 8.9 12.5 14.3 12.7 3.2 1.9 1.6 1.1 5.3 3.7 1.5 3.9 4.1 7.4 6.2 5.8 8.6 3.6 3.5 6.9 3.0 3.3 2.7 4.6 8.4 1.9 6.4 3.1 3.9 3.0 4.9 3.5 5.7 3.1 3.3 3.8 4.4 7.3 2.1 5.6 5.0 4.1 6.6 3.4 3.3 7.3 3.8 4.2 7.0 3.4 4.1 22.7 11.0 3.8 1.8 2.2 2.0 3.7 6.1 3.6 6.5 3.2 3.7 2.9 4.2 4.2 5.0 2.8 3.3 5.4 6.2 5.6 4.6 7.8 0.9 0.7 1.1 1.6 3.2 0.9 3.4 2.4 2.4 2.7 1.2 3.2 3.7 3.4 0.9 5.3 0.8 1.9 2.4 1.5 11.1 11.9 19.0 11.6 10.6 9.5 9.0 9.9 8.9 12.1 KCNJ5 "CIR, GIRK4, KATP1, Kir3.4, LQT13" ENSG00000120457 "Potassium voltage-gated channel subfamily J member 5" P48544 11 128891356-128921035 "Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Voltage-gated channel" "Cancer-related genes, Disease mutation, Long QT syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adrenal gland: 40.7;ductus deferens: 54.6;pituitary gland: 23.4" "Cell line enriched" "Detected in some" 13 "HBEC3-KT: 17.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in some" "neutrophil: 2.9" "Low lineage specificity" "Detected in single" "Group enriched" "Detected in many" 6 "basal ganglia: 3.1;hypothalamus: 8.0;midbrain: 2.2;thalamus: 4.0" "Low region specificity" "Detected in all" "HPA014722, HPA017353, CAB022569" Enhanced "CAB022569: , HPA014722: AB_1852133, HPA017353: AB_1852135" "unprognostic (2.01e-1)" "unprognostic (2.43e-3)" "unprognostic (2.56e-3)" "unprognostic (5.81e-2)" "unprognostic (4.24e-2)" "unprognostic (3.60e-2)" "unprognostic (2.90e-1)" "unprognostic (3.54e-2)" "unprognostic (6.83e-2)" "unprognostic (1.96e-1)" "unprognostic (3.17e-1)" "unprognostic (9.29e-2)" "unprognostic (1.81e-2)" "unprognostic (6.82e-2)" "unprognostic (9.49e-2)" "unprognostic (1.88e-2)" "unprognostic (2.23e-2)" 1.8 40.7 0.8 0.3 1.9 0.2 0.9 0.3 1.2 0.8 0.8 1.9 54.6 0.4 0.3 1.1 0.6 0.6 1.3 8.7 1.6 2.5 2.0 0.3 3.4 0.8 3.7 0.8 0.8 16.6 0.7 23.4 4.3 3.4 0.8 0.4 3.3 0.9 21.7 0.3 0.4 0.5 0.7 4.5 7.7 1.5 0.7 0.9 2.3 0.7 0.4 0.3 1.1 0.5 0.9 0.4 2.9 0.7 0.6 0.4 0.4 0.0 0.0 0.2 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.2 0.3 0.1 0.1 0.0 0.1 0.4 17.1 0.0 0.1 0.1 0.1 0.6 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.4 0.3 0.0 0.2 0.0 0.3 0.2 0.0 0.0 0.9 0.0 0.1 0.0 0.1 0.1 0.2 0.1 0.0 0.0 0.1 0.0 0.2 0.2 0.1 0.0 0.5 0.2 0.1 0.1 1.3 0.0 2.2 0.7 0.6 0.4 0.3 0.3 0.3 0.2 0.3 0.3 0.9 0.3 0.4 2.9 0.6 0.4 0.4 0.2 0.4 0.8 1.9 0.3 1.2 1.6 2.5 3.7 0.8 3.4 0.9 KDM5A "JARID1A, RBBP2" ENSG00000073614 "Lysine demethylase 5A" P29375 12 280129-389454 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Transcription, Transcription regulation" "Activator, Chromatin regulator, Developmental protein, Dioxygenase, Oxidoreductase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA006201 Supported "Nuclear bodies,Cytosol" "Nuclear bodies" Cytosol "HPA006201: AB_1079160" "unprognostic (2.75e-1)" "unprognostic (1.68e-1)" "unprognostic (1.83e-1)" "unprognostic (1.12e-1)" "unprognostic (4.46e-2)" "unprognostic (1.60e-1)" "unprognostic (3.53e-3)" "unprognostic (1.81e-2)" "unprognostic (5.81e-2)" "unprognostic (3.19e-1)" "unprognostic (1.77e-3)" "unprognostic (6.11e-2)" "unprognostic (1.79e-2)" "unprognostic (1.10e-1)" "unprognostic (1.52e-1)" "unprognostic (2.60e-2)" "unprognostic (7.69e-2)" 13.6 14.4 10.6 13.7 13.0 41.6 13.1 21.8 13.2 11.8 10.3 14.8 11.3 7.8 14.2 8.1 13.6 11.2 10.0 10.1 11.5 5.7 9.0 10.7 13.1 14.9 15.1 9.1 15.2 11.5 16.8 13.8 12.4 11.3 10.6 10.9 10.6 12.9 8.6 9.7 20.3 13.0 10.4 10.1 15.5 10.6 21.2 14.8 28.8 11.4 7.1 16.1 13.1 18.8 17.2 16.8 33.7 14.1 18.6 18.1 10.1 7.6 13.7 10.1 7.8 9.1 8.7 11.2 6.8 9.0 10.2 11.1 8.1 9.3 12.8 2.1 11.3 7.2 10.5 7.7 12.3 20.1 8.7 15.6 14.4 4.8 7.4 20.3 12.3 9.4 7.3 12.5 16.8 10.3 9.3 18.0 8.6 5.1 14.5 5.8 15.7 4.3 13.6 26.4 6.0 4.9 17.6 3.9 11.4 13.3 6.0 7.2 6.5 12.8 14.1 6.7 9.7 7.5 11.3 6.4 7.0 29.4 8.7 8.9 9.9 30.2 11.3 22.2 17.7 13.1 18.1 14.1 13.8 14.2 11.8 17.2 15.1 12.9 33.7 18.6 14.1 16.8 10.5 10.1 10.6 13.0 21.8 13.2 11.5 5.7 15.1 9.1 11.3 14.8 KDM5C "DXS1272E, JARID1C, MRX13, SMCX, XE169" ENSG00000126012 "Lysine demethylase 5C" P41229 X 53191321-53225422 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Transcription, Transcription regulation" "Chromatin regulator, Dioxygenase, Oxidoreductase, Repressor" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA038244, HPA046147" Enhanced Nucleoplasm,Cytosol Nucleoplasm Cytosol "HPA038244: , HPA046147: " "unprognostic (1.19e-1)" "unprognostic (1.13e-1)" "unprognostic (1.56e-2)" "unprognostic (7.10e-2)" "unprognostic (9.75e-2)" "unprognostic (2.19e-1)" "prognostic unfavourable (2.11e-4)" "unprognostic (2.08e-2)" "unprognostic (2.11e-1)" "unprognostic (1.24e-1)" "unprognostic (5.45e-2)" "unprognostic (1.58e-2)" "unprognostic (5.05e-3)" "unprognostic (1.96e-2)" "unprognostic (6.91e-2)" "unprognostic (1.30e-1)" "unprognostic (1.00e-1)" 19.5 22.9 22.4 22.6 24.7 26.3 17.9 43.0 31.7 25.9 19.5 23.4 16.7 22.2 29.2 13.3 26.9 24.8 15.2 17.6 21.6 15.3 17.0 18.8 20.6 25.8 24.6 21.8 33.1 22.5 37.7 31.8 34.0 22.8 18.7 13.5 17.0 25.6 17.1 36.6 28.4 22.2 23.6 16.0 25.0 19.4 10.6 26.2 29.0 22.2 11.3 24.5 21.5 26.4 4.5 4.3 4.8 4.0 2.8 6.1 3.8 17.3 23.8 25.5 19.5 17.7 16.2 18.1 10.9 12.8 14.8 13.8 16.0 11.4 16.2 14.2 14.3 15.6 28.8 23.3 11.3 12.1 42.6 15.7 25.3 11.3 21.8 18.6 31.4 12.7 17.2 28.9 35.6 21.8 30.6 10.8 10.8 22.3 13.6 20.9 21.6 22.3 15.4 15.2 17.6 9.4 16.7 19.2 24.8 33.1 30.7 12.4 21.5 16.4 14.9 16.5 14.3 14.8 10.5 15.7 12.8 12.4 21.4 22.1 12.2 3.0 3.8 2.7 6.1 3.6 5.1 4.5 3.7 5.7 3.1 3.2 4.5 2.9 4.8 2.8 4.0 4.3 4.3 3.8 22.4 24.7 43.0 31.7 21.6 15.3 24.6 21.8 22.8 26.2 KDM6A UTX ENSG00000147050 "Lysine demethylase 6A" O15550 X 44873177-45112602 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Chromatin regulator, Dioxygenase, Oxidoreductase" "Cancer-related genes, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA000568, HPA001165, HPA002111" Enhanced Approved Nucleoplasm,Nucleoli "Intracellular and membrane" Nucleoplasm Nucleoli "HPA000568: AB_1858705, HPA001165: AB_1080541, HPA002111: AB_1858704" "unprognostic (1.73e-3)" "unprognostic (6.86e-3)" "unprognostic (1.45e-2)" "unprognostic (1.36e-1)" "unprognostic (1.72e-1)" "unprognostic (2.65e-2)" "unprognostic (2.58e-3)" "unprognostic (8.22e-3)" "unprognostic (3.23e-1)" "unprognostic (2.44e-1)" "unprognostic (2.56e-1)" "unprognostic (1.07e-1)" "unprognostic (2.73e-1)" "unprognostic (2.24e-2)" "unprognostic (5.18e-2)" "unprognostic (1.26e-1)" "unprognostic (3.16e-2)" 12.3 12.1 16.5 17.6 24.5 47.9 21.4 26.1 22.0 16.9 11.8 16.7 12.0 13.1 22.6 11.3 15.4 16.9 15.2 9.1 18.2 6.5 11.6 13.5 19.7 15.1 28.8 11.3 23.8 14.9 21.3 20.2 13.3 18.3 10.3 11.3 10.3 16.1 12.6 15.1 21.3 17.6 13.5 14.9 18.1 15.0 17.7 26.1 19.1 14.5 6.9 13.6 14.9 22.8 5.5 7.1 15.7 7.5 6.2 7.9 3.5 8.9 7.8 11.6 11.7 8.3 8.6 24.9 7.0 5.0 8.4 8.8 18.4 7.7 5.9 3.8 6.5 19.3 14.8 12.3 7.8 8.5 15.9 7.3 9.9 6.8 5.9 3.9 20.7 4.6 10.2 13.8 14.5 6.5 10.1 14.6 5.2 5.8 8.1 11.5 9.7 9.0 9.0 11.1 1.0 4.8 16.8 10.0 5.4 22.3 11.2 9.5 10.8 0.1 5.5 8.0 6.2 8.0 3.6 9.2 11.1 8.9 5.6 4.1 4.6 15.7 3.8 3.5 5.3 7.5 6.0 5.5 7.2 7.9 7.1 3.8 7.0 6.3 7.3 6.2 7.2 3.8 5.6 3.5 16.5 24.5 26.1 22.0 18.2 6.5 28.8 11.3 18.3 26.1 KDR "CD309, FLK1, VEGFR, VEGFR2" ENSG00000128052 "Kinase insert domain receptor" P35968 4 55078259-55125595 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins" "Angiogenesis, Differentiation, Host-virus interaction" "Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Group enriched" "Detected in some" 9 "HUVEC TERT2: 31.8;TIME: 35.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" CAB004028 Enhanced Supported "Plasma membrane" "Intracellular and membrane" 7400000 "Plasma membrane" "CAB004028: AB_2212507" "unprognostic (1.61e-1)" "unprognostic (2.03e-1)" "unprognostic (9.65e-2)" "unprognostic (1.97e-1)" "unprognostic (9.63e-2)" "unprognostic (1.22e-2)" "unprognostic (1.78e-3)" "unprognostic (2.59e-2)" "unprognostic (1.19e-2)" "unprognostic (1.10e-1)" "unprognostic (8.79e-3)" "unprognostic (1.34e-1)" "prognostic unfavourable (7.26e-4)" "unprognostic (4.00e-2)" "unprognostic (2.30e-1)" "unprognostic (3.22e-1)" "unprognostic (1.86e-1)" 19.7 6.2 1.8 4.4 3.1 0.4 20.5 1.1 2.2 11.4 6.0 1.8 11.5 2.3 28.8 10.2 5.2 9.5 6.2 12.1 2.3 1.7 7.8 10.4 13.2 14.1 3.1 2.9 6.0 8.1 8.0 6.8 34.5 3.9 9.5 1.4 27.6 7.1 10.3 5.3 3.0 3.8 7.7 2.6 4.4 4.2 5.3 1.2 0.5 20.0 5.3 3.0 4.4 12.0 0.1 0.1 0.7 0.0 0.2 0.2 0.1 0.0 0.0 1.7 0.0 0.2 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.9 0.0 0.0 3.7 0.0 0.0 0.3 0.0 0.0 0.2 31.8 0.0 0.0 0.2 0.0 0.0 0.0 0.8 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 35.9 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.4 0.0 0.1 0.1 0.0 0.7 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.1 0.0 0.2 0.0 0.1 0.0 0.1 1.8 3.1 1.1 2.2 2.3 1.7 3.1 2.9 3.9 1.2 KDSR "DHSR, FVT1, SDR35C1" ENSG00000119537 "3-ketodihydrosphingosine reductase" Q06136 18 63327726-63367510 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Lipid metabolism, Sphingolipid metabolism" Oxidoreductase "Cancer-related genes, Disease mutation, Palmoplantar keratoderma, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "U-266/70: 37.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003673, HPA044884" Approved "CAB003673: AB_425440, HPA044884: " "unprognostic (4.44e-2)" "unprognostic (8.57e-2)" "unprognostic (2.52e-2)" "unprognostic (4.56e-2)" "unprognostic (5.88e-3)" "unprognostic (7.50e-3)" "unprognostic (1.80e-2)" "unprognostic (2.66e-1)" "unprognostic (2.97e-1)" "unprognostic (1.97e-1)" "unprognostic (2.70e-2)" "unprognostic (6.81e-2)" "prognostic favourable (9.53e-6)" "unprognostic (3.32e-2)" "unprognostic (5.77e-2)" "unprognostic (2.22e-1)" "unprognostic (2.16e-3)" 21.1 19.4 19.0 11.1 22.4 6.4 29.7 12.5 17.2 18.2 17.3 23.9 14.2 10.0 19.4 30.0 17.8 14.3 17.7 15.8 19.7 16.9 21.3 52.6 15.3 11.5 32.1 14.6 29.1 14.3 19.6 10.5 24.9 19.5 18.0 11.0 15.9 16.1 17.4 12.4 28.8 13.1 18.9 39.0 9.1 11.8 10.4 23.3 8.8 21.2 12.3 9.9 19.9 22.8 4.0 5.6 0.9 5.6 9.8 19.5 3.7 5.9 2.6 2.8 3.1 22.0 16.5 5.4 19.5 12.0 4.3 5.8 1.1 4.0 6.0 8.4 7.6 26.1 3.5 11.0 5.3 11.2 5.8 4.6 3.5 1.3 16.9 8.4 3.2 15.7 20.9 6.9 19.8 4.2 3.7 8.6 11.4 2.4 9.3 3.9 3.3 9.8 6.3 8.1 8.5 11.9 3.8 3.5 6.8 9.4 4.6 8.4 2.5 4.8 10.0 18.4 4.4 6.1 8.5 37.6 17.1 3.4 13.8 5.2 5.4 0.0 3.7 0.3 4.8 5.6 19.5 4.0 10.2 7.6 5.6 3.6 7.3 4.6 0.9 9.8 2.6 2.8 12.9 3.7 19.0 22.4 12.5 15.9 19.7 16.9 32.1 14.6 19.5 23.3 KEAP1 "INrf2, KIAA0132, KLHL19, MGC10630, MGC1114, MGC20887, MGC4407, MGC9454" ENSG00000079999 "Kelch like ECH associated protein 1" Q14145 19 10486120-10503741 "Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins" "Host-virus interaction, Ubl conjugation pathway" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA005558, CAB025337" Approved Supported "Nucleoplasm,Centriolar satellite,Cytosol" "Nucleoplasm, Centriolar satellite" Cytosol "CAB025337: , HPA005558: AB_1079175" "unprognostic (1.98e-1)" "prognostic favourable (3.28e-4)" "unprognostic (1.61e-1)" "unprognostic (1.02e-1)" "unprognostic (1.42e-1)" "unprognostic (1.63e-2)" "unprognostic (2.64e-2)" "unprognostic (1.46e-1)" "unprognostic (1.48e-1)" "unprognostic (5.22e-3)" "unprognostic (2.04e-1)" "unprognostic (9.99e-2)" "unprognostic (1.29e-1)" "unprognostic (7.71e-3)" "unprognostic (5.06e-1)" "unprognostic (8.18e-2)" "unprognostic (1.60e-2)" 16.0 13.7 13.5 10.4 14.3 9.1 12.4 13.2 15.1 13.1 15.7 15.4 13.8 13.6 11.0 12.7 26.3 15.1 12.7 19.7 13.9 13.7 13.2 22.0 10.8 15.5 16.7 7.4 11.8 14.3 11.1 10.2 11.5 14.3 13.9 8.8 11.8 11.3 13.9 63.9 16.8 13.8 11.6 16.5 11.3 10.6 12.2 13.8 13.1 14.5 29.1 16.1 14.5 11.2 14.6 23.7 21.3 19.8 21.0 30.8 19.6 17.2 31.7 8.8 11.7 18.1 15.5 9.4 14.7 11.0 15.1 13.6 22.5 17.4 24.6 38.8 16.3 15.5 17.4 11.5 7.5 23.8 19.1 37.2 9.4 26.6 17.5 19.4 20.2 16.0 15.6 17.0 7.9 14.3 22.7 45.6 13.1 23.9 14.1 53.4 25.6 26.7 25.6 11.0 28.7 9.8 20.7 24.2 12.6 20.5 13.8 12.7 11.9 26.0 17.6 24.4 13.1 27.3 17.8 26.6 33.3 24.1 18.8 23.2 17.9 16.1 19.8 21.3 30.8 17.0 29.3 14.6 21.5 28.3 23.7 5.7 13.5 19.1 10.9 21.0 16.6 16.3 25.4 19.6 13.5 14.3 13.2 12.8 13.9 13.7 16.7 7.4 14.3 13.8 KEL "CD238, ECE3" ENSG00000197993 "Kell blood group, metallo-endopeptidase" P23276 7 142941114-142962681 "Blood group antigen proteins, Cancer-related genes, CD markers, Enzymes, Predicted intracellular proteins, Predicted membrane proteins" "Blood group antigen, Hydrolase, Metalloprotease, Protease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 6 "bone marrow: 21.1;testis: 36.4" "Group enriched" "Detected in some" 12 "HEL: 14.9;K-562: 12.1" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in some" "Cell type enriched" "Detected in single" 7 "intermediate monocyte: 1.4" "Lineage enriched" "Detected in single" 14 "monocytes: 1.4" "Not detected" "Not detected" "Low region specificity" "Detected in single" HPA064442 Supported "Nucleoplasm,Plasma membrane,Cytosol" "Plasma membrane" "Nucleoplasm, Cytosol" "HPA064442: " "unprognostic (5.78e-3)" "unprognostic (1.08e-5)" "unprognostic (5.29e-3)" "unprognostic (4.85e-3)" "unprognostic (9.68e-2)" "unprognostic (1.96e-2)" "unprognostic (1.03e-1)" "unprognostic (1.54e-2)" "unprognostic (5.18e-2)" "unprognostic (1.08e-2)" "unprognostic (3.71e-2)" "unprognostic (3.57e-2)" "unprognostic (2.29e-3)" "unprognostic (9.24e-2)" "unprognostic (7.05e-2)" "unprognostic (3.32e-2)" "unprognostic (3.25e-3)" 0.2 0.0 0.9 2.5 1.1 21.1 0.2 0.2 0.4 0.4 0.2 0.3 0.2 0.0 0.2 0.2 0.6 0.1 0.2 0.2 1.4 0.7 0.4 0.2 1.4 5.0 2.0 0.2 0.2 0.2 0.0 0.2 1.1 0.3 0.2 0.0 0.3 2.5 0.2 0.2 0.0 0.5 0.2 4.4 3.8 0.0 36.4 0.3 0.4 0.2 0.2 3.7 0.2 0.2 0.0 0.0 0.0 1.4 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 14.9 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 12.1 0.1 0.0 0.0 0.5 0.2 0.3 0.0 0.1 0.0 0.1 0.0 1.1 0.0 0.1 0.1 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.9 1.1 0.2 0.4 1.4 0.7 2.0 0.2 0.3 0.3 KIAA1109 "FLJ21404, FSA, KIAA1371, Tweek" ENSG00000138688 KIAA1109 Q2LD37 4 122152333-122362758 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA038076 Approved Approved Nucleoplasm,Centrosome "Nucleoplasm, Centrosome" "HPA038076: AB_10670652" "unprognostic (2.53e-1)" "unprognostic (2.04e-2)" "unprognostic (3.52e-2)" "unprognostic (1.09e-1)" "unprognostic (1.63e-1)" "unprognostic (2.63e-3)" "unprognostic (1.04e-1)" "unprognostic (6.62e-2)" "unprognostic (7.61e-2)" "unprognostic (3.65e-2)" "unprognostic (2.38e-1)" "unprognostic (7.97e-2)" "prognostic favourable (4.33e-8)" "unprognostic (2.04e-1)" "unprognostic (3.55e-1)" "unprognostic (2.28e-2)" "unprognostic (2.29e-2)" 18.4 17.1 25.6 18.0 34.1 42.9 26.1 33.4 34.2 22.9 18.7 24.1 17.9 15.6 20.9 25.4 12.3 16.8 16.4 15.3 25.5 22.0 24.0 17.4 19.5 14.8 26.4 26.2 34.3 16.6 68.2 33.1 14.3 33.6 19.1 18.8 22.6 16.6 21.5 40.1 23.1 20.8 18.6 29.3 20.0 15.2 20.4 24.2 15.3 25.4 12.6 13.6 18.0 18.5 3.1 2.3 7.7 3.6 1.7 3.5 0.7 16.7 5.5 12.8 8.4 21.4 27.9 6.7 7.6 14.3 7.9 8.7 4.0 8.9 8.8 4.4 18.0 6.3 7.9 9.4 12.8 6.6 5.0 9.7 10.0 7.6 11.1 9.1 5.4 16.0 11.3 9.4 13.0 16.7 6.3 10.7 16.1 5.6 7.8 7.1 4.2 6.1 4.5 17.8 2.2 13.8 12.7 7.5 6.7 4.8 5.5 10.7 6.0 7.5 22.3 9.8 9.7 8.0 7.7 10.4 6.7 6.4 10.4 8.0 7.1 3.3 1.4 7.7 3.3 3.6 3.5 2.5 2.3 2.3 1.4 3.1 2.0 2.3 6.6 1.7 1.7 2.3 2.9 0.7 25.6 34.1 33.4 34.2 25.5 22.0 26.4 26.2 33.6 24.2 KIF2A "HK2, KIF2" ENSG00000068796 "Kinesin family member 2A" O00139 5 62306162-62537249 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division, Differentiation, Mitosis, Neurogenesis" "Developmental protein, Motor protein" "Cancer-related genes, Disease mutation, Lissencephaly" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004715, HPA004716" Approved Enhanced Nucleoplasm,Nucleoli,Centrosome 2100000 "Nucleoplasm, Nucleoli, Centrosome" "HPA004715: , HPA004716: AB_1079211" "unprognostic (2.40e-2)" "unprognostic (3.43e-1)" "prognostic favourable (1.70e-4)" "unprognostic (2.74e-2)" "unprognostic (1.43e-1)" "prognostic favourable (5.45e-4)" "prognostic unfavourable (3.17e-6)" "unprognostic (8.77e-3)" "unprognostic (4.69e-2)" "unprognostic (9.10e-2)" "unprognostic (1.85e-1)" "unprognostic (1.34e-1)" "prognostic unfavourable (3.81e-5)" "unprognostic (3.53e-2)" "unprognostic (2.95e-2)" "unprognostic (1.65e-1)" "unprognostic (1.58e-1)" 11.3 9.3 25.4 21.9 26.4 12.4 15.5 15.4 40.1 19.7 13.5 19.4 8.0 10.3 12.9 7.6 14.3 17.5 13.7 7.2 26.2 24.1 8.2 5.8 10.6 29.4 24.9 24.6 13.0 12.3 15.2 14.3 27.8 37.0 10.2 14.5 6.8 10.7 11.9 7.4 7.9 15.8 13.5 34.3 17.4 9.6 39.2 26.4 28.7 13.0 5.6 26.7 17.4 14.8 9.0 8.4 7.1 3.0 15.8 25.4 9.7 17.2 17.3 28.9 25.6 10.9 15.4 23.6 18.5 15.3 20.2 25.6 18.6 18.9 42.8 20.4 16.3 11.0 21.9 14.9 27.0 42.9 15.3 43.0 16.2 10.1 12.9 23.4 16.4 12.7 9.8 19.6 17.8 18.4 30.4 26.1 16.8 13.0 39.1 11.6 16.8 10.9 28.9 22.9 23.6 9.0 21.0 25.9 21.5 25.1 10.6 13.0 13.8 13.2 15.9 12.0 19.9 13.9 18.4 24.7 35.6 45.2 13.9 28.2 14.7 7.1 3.0 3.4 20.2 2.6 22.8 9.0 20.3 20.6 4.0 7.8 17.9 18.4 5.3 15.8 1.8 8.4 25.4 9.7 25.4 26.4 15.4 31.2 26.2 24.1 24.9 24.6 37.0 26.4 KIF2C "CT139, KNSL6, MCAK" ENSG00000142945 "Kinesin family member 2C" Q99661 1 44739818-44767767 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division, Chromosome partition, Mitosis" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 39.9;testis: 61.4" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Cell type enhanced" "Detected in many" "T-reg: 5.8" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" HPA006219 Supported Nucleoplasm,Midbody,Centrosome "Nucleoplasm, Centrosome" Midbody "HPA006219: " "unprognostic (3.29e-2)" "unprognostic (1.35e-2)" "unprognostic (1.03e-2)" "unprognostic (1.71e-3)" "unprognostic (2.77e-1)" "unprognostic (5.17e-2)" "prognostic unfavourable (3.07e-7)" "unprognostic (7.49e-3)" "unprognostic (3.33e-3)" "unprognostic (3.66e-1)" "prognostic unfavourable (6.86e-4)" "unprognostic (4.27e-2)" "prognostic unfavourable (0.00e+0)" "unprognostic (2.33e-3)" "unprognostic (1.49e-1)" "unprognostic (1.86e-2)" "unprognostic (2.41e-1)" 1.1 0.7 0.4 8.7 0.4 12.7 0.8 0.5 0.5 1.2 2.4 0.4 0.2 2.1 1.3 1.4 4.6 0.6 0.7 0.9 0.6 0.5 0.7 0.6 1.6 6.7 0.4 0.2 0.7 0.4 0.3 0.6 2.2 0.6 0.6 3.2 0.4 1.1 0.2 0.4 2.3 2.2 1.1 0.4 3.3 1.4 61.4 0.2 39.9 0.8 4.7 12.0 0.9 1.7 1.3 1.5 0.0 0.2 3.9 5.8 1.0 28.7 11.2 25.0 20.0 1.3 2.9 16.8 21.6 15.4 44.2 38.6 18.9 20.8 33.1 10.4 10.6 13.7 25.4 14.5 40.5 21.4 10.9 39.2 19.8 15.7 0.1 28.9 18.2 0.7 1.4 31.5 15.4 14.2 30.9 28.4 27.9 11.2 30.4 17.5 24.4 14.1 24.4 37.8 20.8 7.4 10.4 17.2 12.3 28.7 20.5 18.1 11.8 22.0 8.4 16.1 31.9 17.4 37.8 15.1 15.3 47.8 10.3 28.2 30.9 0.0 0.0 0.0 1.9 0.0 0.1 1.3 3.4 2.6 0.3 0.2 0.7 0.5 0.0 3.9 0.2 1.5 5.8 1.0 0.4 0.4 0.5 0.5 0.6 0.5 0.4 0.2 0.6 0.2 KIF5B "KNS, KNS1" ENSG00000170759 "Kinesin family member 5B" P33176 10 32009010-32056431 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Motor protein" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009846, HPA037589, HPA037590" Approved Enhanced "Centriolar satellite,Cytosol" 260000 "Centriolar satellite, Cytosol" "CAB009846: AB_2280915, HPA037589: AB_2675563, HPA037590: AB_2675564" "unprognostic (4.94e-3)" "unprognostic (1.70e-1)" "unprognostic (1.06e-1)" "unprognostic (1.84e-1)" "unprognostic (4.00e-2)" "unprognostic (6.21e-2)" "unprognostic (1.06e-2)" "unprognostic (1.84e-1)" "unprognostic (2.70e-1)" "unprognostic (6.37e-3)" "unprognostic (2.03e-1)" "unprognostic (2.60e-1)" "unprognostic (1.81e-1)" "unprognostic (2.43e-2)" "unprognostic (2.39e-1)" "unprognostic (8.06e-2)" "unprognostic (1.76e-1)" 26.3 19.9 55.7 20.2 55.5 34.1 23.0 22.2 42.4 23.8 34.2 21.7 20.9 23.5 25.7 17.8 28.0 20.3 28.0 48.4 51.5 39.3 21.1 15.3 23.8 16.5 62.9 26.1 18.2 18.9 56.8 22.4 27.7 38.3 31.8 30.0 8.9 20.1 25.6 34.3 17.6 28.6 37.2 80.4 21.1 23.1 27.7 43.7 25.0 23.5 21.5 16.1 33.8 28.1 13.8 27.6 30.0 18.9 13.4 16.5 9.2 29.4 25.1 34.0 23.8 24.4 26.9 14.5 40.7 19.3 31.5 26.9 27.5 32.6 20.2 17.7 48.3 24.5 31.0 26.0 42.3 17.4 16.9 25.7 23.5 26.8 28.1 17.8 28.3 21.8 37.0 36.3 25.4 40.2 30.9 21.3 43.5 17.7 18.6 10.1 5.5 11.5 24.4 63.4 8.3 24.3 20.7 33.1 24.2 31.5 12.6 30.3 15.2 25.6 33.5 32.1 30.1 37.1 30.1 6.4 7.4 23.9 30.6 36.9 30.1 20.8 15.2 24.2 11.8 18.9 11.4 13.6 14.9 12.5 14.2 13.8 13.3 13.0 30.0 13.4 18.9 27.6 16.5 9.2 55.7 55.5 22.2 42.4 51.5 39.3 62.9 26.1 38.3 43.7 KIFC3 ENSG00000140859 "Kinesin family member C3" Q9BVG8 16 57758217-57863053 "Cancer-related genes, Predicted intracellular proteins" "Motor protein" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "A549: 55.9;HMC-1: 54.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA021240 Uncertain "HPA021240: AB_1852509" "unprognostic (1.53e-1)" "unprognostic (3.10e-3)" "unprognostic (8.56e-3)" "unprognostic (1.11e-1)" "unprognostic (2.95e-3)" "unprognostic (2.29e-1)" "unprognostic (3.71e-2)" "unprognostic (1.10e-1)" "unprognostic (2.18e-1)" "unprognostic (7.66e-3)" "unprognostic (1.59e-2)" "unprognostic (2.18e-2)" "unprognostic (3.42e-2)" "unprognostic (2.14e-1)" "unprognostic (1.01e-2)" "unprognostic (1.40e-1)" "unprognostic (4.33e-2)" 11.0 10.3 10.0 12.9 14.5 7.7 13.0 5.3 16.2 7.3 16.6 18.4 4.6 15.2 8.6 18.8 11.5 5.8 10.9 21.6 10.0 11.5 36.3 36.3 16.8 6.5 19.3 10.3 9.7 29.0 20.2 12.6 20.5 18.7 10.1 6.8 30.3 8.1 11.9 6.3 40.2 31.0 9.9 13.7 8.4 8.4 24.7 18.7 0.9 26.6 7.4 6.1 10.5 13.4 2.3 0.5 2.3 1.6 0.3 4.6 1.5 10.5 55.9 4.3 8.9 1.9 2.8 7.4 13.3 17.2 20.3 9.7 15.1 16.6 1.6 17.2 8.5 11.4 0.4 12.2 7.1 0.6 2.7 8.8 17.5 19.3 7.9 1.4 54.9 4.0 4.4 10.7 10.9 5.3 15.5 2.3 7.5 7.8 1.9 15.5 2.7 12.0 1.2 6.1 8.4 13.0 5.7 1.4 3.1 22.6 16.2 14.1 4.9 6.7 10.5 26.4 18.7 12.2 18.3 1.9 1.0 1.3 13.4 1.0 24.8 0.6 0.7 0.6 4.6 0.0 0.7 2.3 2.0 4.2 0.5 2.0 1.0 1.3 2.3 0.3 1.6 0.5 0.2 1.5 10.0 14.5 5.3 16.2 10.0 11.5 19.3 10.3 18.7 18.7 KISS1 ENSG00000170498 "KiSS-1 metastasis suppressor" Q15726 1 204190341-204196486 "Cancer-related genes, Disease related genes, Predicted secreted proteins" "Cancer-related genes, Disease mutation, Hypogonadotropic hypogonadism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 24 "placenta: 267.2" "Group enriched" "Detected in some" 22 "BJ: 54.6;U-2 OS: 22.2" "Cancer enhanced" "Detected in many" "urothelial cancer: 9.2" "Group enriched" "Detected in some" 8 "basal ganglia: 11.3;hypothalamus: 4.2" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB017775, HPA035542" Enhanced Approved Vesicles "Secreted in female reproductive system" Vesicles "CAB017775: , HPA035542: " "unprognostic (9.64e-2)" "unprognostic (1.78e-2)" "unprognostic (1.86e-2)" "unprognostic (1.18e-2)" "unprognostic (3.89e-1)" "unprognostic (6.87e-2)" "unprognostic (1.87e-1)" "unprognostic (3.28e-2)" "unprognostic (1.28e-2)" "unprognostic (4.51e-2)" "unprognostic (1.63e-1)" "unprognostic (8.98e-12)" "unprognostic (2.25e-1)" "unprognostic (2.91e-2)" "unprognostic (1.76e-1)" "prognostic favourable (6.29e-6)" 0.2 0.0 0.2 0.2 11.3 0.0 0.2 1.0 0.2 0.2 0.2 0.2 0.2 0.4 0.2 0.2 0.2 0.0 0.2 0.2 0.2 4.2 1.1 2.7 0.5 0.2 0.2 0.2 0.2 0.4 0.1 2.5 267.2 0.2 0.2 0.0 0.2 0.2 0.2 0.2 0.0 0.5 0.2 0.2 0.7 1.4 3.6 0.2 0.2 0.2 0.2 0.2 0.5 0.2 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.9 54.6 0.7 0.9 0.2 0.0 0.2 0.0 0.5 0.0 0.0 0.0 0.0 1.7 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.2 0.0 0.1 0.1 0.0 0.0 22.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 11.3 1.0 0.2 0.2 4.2 0.2 0.2 0.2 0.2 KIT "C-Kit, CD117, PBT, SCFR" ENSG00000157404 "KIT proto-oncogene receptor tyrosine kinase" P10721 4 54657918-54740715 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "breast: 65.5" "Group enriched" "Detected in some" 13 "HEL: 47.7;HMC-1: 100.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 6 "basophil: 12.7;eosinophil: 10.0;NK-cell: 9.7" "Group enriched" "Detected in many" 6 "granulocytes: 12.7;NK-cells: 9.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003288, HPA004471, CAB068253, CAB072867, HPA073252" Enhanced Supported Supported "Plasma membrane" 48000000 "Plasma membrane" "CAB003288: AB_2335702, CAB068253: , CAB072867: , HPA004471: AB_1078431, HPA073252: " "unprognostic (1.55e-2)" "unprognostic (1.91e-1)" "unprognostic (4.04e-2)" "unprognostic (8.19e-2)" "unprognostic (3.96e-2)" "unprognostic (2.18e-2)" "unprognostic (2.33e-2)" "unprognostic (1.97e-2)" "unprognostic (3.60e-2)" "unprognostic (1.64e-1)" "unprognostic (2.20e-1)" "unprognostic (1.92e-2)" "prognostic favourable (5.63e-4)" "unprognostic (1.34e-3)" "unprognostic (1.87e-1)" "unprognostic (1.29e-2)" "unprognostic (2.30e-1)" 8.1 1.6 9.5 6.6 11.8 3.7 65.5 18.3 12.0 12.1 10.3 6.5 10.2 5.8 8.9 4.2 9.9 2.5 15.5 2.4 36.0 4.4 9.4 1.1 13.8 3.8 3.6 6.0 28.5 2.1 1.3 2.3 6.2 5.7 9.6 10.4 20.7 12.9 6.9 1.3 14.6 8.9 10.2 3.9 3.2 12.8 4.0 4.5 0.4 28.9 4.3 4.9 9.8 12.5 0.0 1.8 12.7 0.9 9.7 1.9 0.1 0.0 0.0 0.7 0.0 0.1 0.0 0.0 0.6 0.9 2.5 3.2 0.0 0.0 0.0 0.0 1.4 0.0 0.5 0.0 2.1 0.0 1.1 47.7 0.0 0.0 0.0 0.0 100.2 0.0 0.0 0.0 0.0 5.6 0.6 0.1 0.0 0.0 0.2 0.4 1.3 0.0 0.1 0.0 0.0 0.0 4.7 1.2 0.4 0.0 0.0 0.0 0.0 0.5 0.0 0.1 0.0 1.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 12.7 0.0 10.0 0.1 0.0 1.9 0.0 0.3 0.7 1.8 0.0 0.0 0.0 0.8 9.7 0.9 0.0 0.0 0.1 9.5 11.8 18.3 12.0 36.0 4.4 3.6 6.0 5.7 4.5 KITLG "DFNA69, FPH2, Kitl, KL-1, MGF, SCF, SF, SLF" ENSG00000049130 "KIT ligand" P21583 12 88492793-88580851 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins" "Cell adhesion" "Growth factor" "Cancer-related genes, Deafness, Disease mutation, Non-syndromic deafness" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "CACO-2: 81.7;SK-BR-3: 28.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA070395 Approved Approved Vesicles "Intracellular and membrane" 150000 Vesicles "HPA070395: " "unprognostic (7.13e-2)" "unprognostic (1.90e-1)" "unprognostic (5.00e-2)" "unprognostic (2.05e-1)" "unprognostic (2.70e-1)" "unprognostic (1.93e-2)" "prognostic unfavourable (4.01e-4)" "unprognostic (2.22e-3)" "unprognostic (5.61e-3)" "unprognostic (7.89e-2)" "unprognostic (5.47e-3)" "unprognostic (5.03e-2)" "prognostic favourable (5.81e-7)" "unprognostic (7.15e-2)" "unprognostic (1.23e-1)" "unprognostic (1.15e-1)" "unprognostic (1.54e-2)" 10.1 3.8 7.8 8.0 6.4 0.0 11.2 4.8 11.5 9.6 16.1 2.9 8.5 6.2 11.7 8.7 16.7 4.7 13.9 5.6 8.4 3.9 21.9 2.8 22.9 6.1 3.3 7.7 4.4 5.0 1.9 3.2 10.1 4.0 17.9 15.9 7.8 11.8 14.8 4.8 5.3 9.5 21.0 3.7 2.6 13.0 5.8 2.9 0.7 6.5 5.8 6.6 17.5 17.8 0.0 0.2 0.0 0.5 0.0 0.0 0.0 3.4 1.9 1.8 0.2 7.1 15.3 0.0 21.0 15.0 3.6 1.6 81.7 3.3 0.0 0.6 17.6 12.7 2.7 4.7 3.4 0.0 2.4 0.0 2.9 0.6 1.1 0.4 0.0 13.2 5.0 11.4 6.8 4.3 0.0 0.0 1.6 0.6 0.0 0.0 1.2 4.7 0.0 3.3 0.0 6.0 1.7 0.5 1.2 5.1 28.5 0.5 14.6 1.0 2.9 16.5 2.3 19.2 1.6 0.0 0.0 0.0 2.1 0.0 1.3 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.8 6.4 4.8 11.5 8.4 3.9 3.3 7.7 4.0 2.9 KLF4 "EZF, GKLF" ENSG00000136826 "Kruppel like factor 4" O43474 9 107484852-107490482 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skin 1: 92.1" "Cell line enhanced" "Detected in many" "ASC TERT1: 15.3;hTCEpi: 32.4;hTERT-HME1: 20.1;U-2197: 49.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 10 "classical monocyte: 5.2;intermediate monocyte: 7.4;myeloid DC: 4.4;non-classical monocyte: 2.9" "Group enriched" "Detected in many" 12 "dendritic cells: 4.4;monocytes: 7.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" HPA002926 Enhanced Supported Nucleoplasm Nucleoplasm "HPA002926: AB_1852541" "unprognostic (2.06e-1)" "unprognostic (1.42e-2)" "unprognostic (1.14e-2)" "unprognostic (2.45e-1)" "unprognostic (1.55e-1)" "unprognostic (6.58e-3)" "unprognostic (3.44e-2)" "unprognostic (6.49e-2)" "unprognostic (3.45e-1)" "unprognostic (1.29e-2)" "unprognostic (1.18e-2)" "unprognostic (1.08e-1)" "prognostic favourable (3.93e-5)" "unprognostic (2.55e-1)" "unprognostic (1.67e-1)" "unprognostic (8.13e-2)" "unprognostic (8.32e-2)" 29.2 8.5 2.7 23.8 3.9 14.4 23.7 1.8 3.5 39.1 28.9 5.6 5.5 10.2 17.8 18.6 34.9 22.0 32.4 18.6 2.4 2.2 4.8 5.1 35.6 4.4 2.7 2.2 18.6 2.3 2.7 2.8 41.0 6.2 11.3 29.6 11.7 11.9 6.5 13.6 92.1 39.4 16.0 3.3 21.8 22.2 11.2 2.0 1.9 7.8 81.1 30.7 16.8 24.1 0.0 4.4 0.4 7.4 0.1 0.0 1.3 5.6 2.3 0.2 0.0 6.0 15.3 2.2 2.0 10.5 2.7 3.1 0.8 7.2 0.0 0.3 2.6 4.2 2.6 1.4 1.0 0.0 1.1 0.0 4.0 0.1 8.9 0.0 0.0 2.0 32.4 5.4 20.1 0.2 0.2 0.0 1.4 3.7 0.0 0.6 1.7 11.4 0.1 0.6 0.1 0.8 1.6 0.1 0.1 1.5 4.8 6.0 0.7 2.5 1.2 1.6 0.0 49.3 0.8 0.0 0.0 0.0 1.5 1.0 2.7 0.0 5.2 0.0 0.0 7.4 0.0 0.0 0.0 0.0 4.4 0.0 0.0 0.0 0.4 0.1 2.9 0.4 0.0 1.3 2.7 3.9 1.8 3.5 2.4 2.2 2.7 2.2 6.2 2.0 KLF5 "BTEB2, CKLF, IKLF" ENSG00000102554 "Kruppel like factor 5" Q13887 13 73054976-73077542 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "esophagus: 88.4;intestine: 88.1" "Cell line enhanced" "Detected in many" "CAPAN-2: 29.8;HaCaT: 34.2;HBEC3-KT: 29.8;hTCEpi: 42.6;RT4: 36.0;SiHa: 30.4" "Low cancer specificity" "Detected in all" "Region enriched" "Detected in many" 5 "basal ganglia: 22.2" "Cell type enriched" "Detected in single" 18 "basophil: 16.3" "Lineage enriched" "Detected in single" 106 "granulocytes: 16.3" "Group enriched" "Detected in many" 4 "amygdala: 5.6;basal ganglia: 9.3;cerebral cortex: 6.9;hippocampal formation: 8.8;hypothalamus: 4.3" "Low region specificity" "Detected in many" HPA040398 Approved Supported "Nucleoplasm,Golgi apparatus,Vesicles" Nucleoplasm "Golgi apparatus, Vesicles" "HPA040398: AB_10673267" "unprognostic (7.90e-3)" "unprognostic (5.11e-2)" "unprognostic (2.03e-2)" "unprognostic (1.56e-1)" "unprognostic (4.69e-2)" "unprognostic (2.75e-1)" "unprognostic (1.18e-1)" "unprognostic (3.97e-2)" "unprognostic (5.82e-1)" "unprognostic (1.47e-2)" "prognostic unfavourable (2.55e-4)" "unprognostic (4.43e-2)" "unprognostic (1.42e-3)" "unprognostic (3.56e-3)" "unprognostic (3.98e-1)" "unprognostic (5.09e-2)" "unprognostic (1.54e-2)" 2.3 1.5 4.1 24.3 22.2 12.9 8.1 0.7 1.2 19.6 74.4 0.4 4.3 28.7 4.8 3.7 88.4 8.3 48.4 1.3 1.4 1.2 3.9 1.2 12.8 0.1 0.9 1.1 5.0 3.5 0.0 7.3 22.8 4.3 17.6 32.9 1.8 26.4 5.4 10.0 59.4 88.1 4.1 2.4 0.8 17.9 12.2 1.4 3.0 20.7 64.4 61.8 23.4 34.1 0.0 0.0 16.3 0.0 0.0 0.1 0.0 5.7 8.1 0.0 0.1 0.3 0.4 9.2 3.4 7.9 1.5 1.9 7.4 29.8 0.1 18.1 3.0 34.2 10.4 29.8 2.4 0.2 2.7 0.1 17.0 0.7 2.1 2.7 0.5 2.2 42.6 0.4 16.7 0.0 0.4 0.6 6.8 2.0 0.5 0.2 0.3 11.5 0.5 7.6 0.6 23.6 36.0 0.7 0.3 30.4 4.9 2.1 0.6 0.6 0.0 2.1 6.2 0.0 1.4 0.9 0.4 1.0 2.9 0.5 2.5 16.3 0.0 0.9 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.5 0.0 0.0 0.0 0.1 0.0 4.1 22.2 0.7 1.2 1.4 1.2 0.9 1.1 4.3 1.4 KLF6 "BCD1, COPEB, CPBP, GBF, PAC1, ST12, Zf9" ENSG00000067082 "Kruppel like factor 6" Q99612 10 3775996-3785281 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB013529, HPA069585" Supported Approved "Nucleoplasm,Nucleoli fibrillar center,Vesicles,Cytosol" "Nucleoplasm, Nucleoli fibrillar center" "Vesicles, Cytosol" "CAB013529: AB_2533431, HPA069585: " "unprognostic (1.23e-1)" "unprognostic (1.53e-2)" "unprognostic (1.47e-3)" "unprognostic (4.53e-2)" "unprognostic (1.47e-1)" "unprognostic (7.55e-2)" "unprognostic (2.00e-1)" "unprognostic (1.08e-3)" "unprognostic (1.61e-1)" "unprognostic (2.83e-2)" "unprognostic (1.36e-2)" "unprognostic (2.35e-2)" "prognostic favourable (2.28e-4)" "unprognostic (8.07e-3)" "unprognostic (4.85e-2)" "unprognostic (6.87e-2)" "unprognostic (1.37e-2)" 69.8 10.0 8.4 26.3 10.6 80.6 101.1 7.4 10.1 28.6 31.7 10.3 9.7 11.0 24.9 28.8 38.6 28.0 38.6 18.6 7.8 5.1 32.2 32.5 46.0 35.8 13.8 4.2 20.2 23.8 7.5 4.7 26.1 11.2 20.1 21.0 13.2 26.9 16.5 57.8 60.2 44.8 42.8 17.0 20.3 26.7 14.3 10.0 12.5 41.0 28.8 21.5 44.7 30.7 15.6 29.8 77.8 18.7 13.0 30.8 23.2 13.0 3.5 6.8 2.2 39.6 39.8 4.3 22.5 11.5 24.1 16.4 9.1 17.6 3.7 5.2 24.3 7.9 4.2 20.7 20.1 18.3 2.5 0.5 4.1 8.6 17.0 2.4 12.9 13.1 39.6 17.1 32.7 24.5 4.1 29.2 30.5 0.9 4.5 3.8 2.5 6.4 3.0 7.0 13.1 23.6 13.0 3.0 2.9 5.5 16.0 33.7 7.9 2.0 31.9 32.5 4.5 19.2 10.3 5.6 18.2 6.9 8.7 3.3 10.0 50.9 17.0 43.7 27.1 14.2 23.9 15.6 30.8 26.8 13.1 12.5 9.6 14.8 77.8 13.0 18.7 29.8 22.2 23.2 8.4 10.6 7.4 10.1 7.8 5.1 13.8 4.2 11.2 10.0 KLHL8 KIAA1378 ENSG00000145332 "Kelch like family member 8" Q9P2G9 4 87160103-87240314 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Ubl conjugation pathway" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "epididymis: 56.2" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA013856, HPA017762" Approved Enhanced Nucleoplasm Nucleoplasm "HPA013856: AB_1852594, HPA017762: " "unprognostic (2.93e-2)" "unprognostic (4.91e-3)" "unprognostic (3.44e-2)" "unprognostic (4.66e-2)" "unprognostic (1.18e-1)" "unprognostic (3.27e-2)" "unprognostic (2.12e-1)" "unprognostic (4.46e-3)" "unprognostic (3.27e-2)" "unprognostic (2.06e-2)" "unprognostic (1.13e-1)" "unprognostic (3.46e-1)" "prognostic favourable (1.53e-5)" "unprognostic (4.24e-3)" "unprognostic (3.05e-1)" "unprognostic (3.57e-3)" "unprognostic (1.57e-3)" 6.8 7.3 6.9 5.6 8.1 3.0 12.0 10.0 10.7 9.2 7.5 5.3 3.8 7.3 8.3 56.2 5.3 5.4 5.0 7.4 7.7 7.2 11.4 10.3 9.0 8.1 6.3 5.6 6.1 6.3 7.1 14.2 6.6 7.3 5.7 8.5 4.6 6.5 7.7 23.4 4.8 8.2 6.6 8.0 6.9 5.5 4.2 6.5 7.0 17.3 2.9 4.7 6.8 10.9 3.8 10.3 8.6 12.1 8.7 4.9 5.0 6.5 5.7 10.4 4.6 9.5 7.0 5.6 8.4 4.5 5.6 6.6 9.2 5.0 9.5 6.8 6.1 2.8 11.0 8.3 12.2 9.0 6.9 11.5 4.3 5.4 8.1 18.9 7.3 8.7 6.0 8.6 8.6 6.6 14.9 8.7 5.8 7.2 22.6 9.6 2.6 2.3 8.5 8.9 5.8 9.5 6.8 21.9 7.6 5.5 13.5 6.2 4.6 14.0 6.2 7.1 8.8 7.5 6.9 13.0 8.5 16.9 5.4 9.0 7.8 1.9 12.1 7.3 3.0 9.2 4.9 3.3 2.4 2.5 10.3 3.8 4.4 4.3 8.6 8.7 9.0 2.7 0.9 5.0 6.9 8.1 10.0 10.7 7.7 7.2 6.3 5.6 7.3 6.5 KLK11 "PRSS20, TLSP" ENSG00000167757 "Kallikrein related peptidase 11" Q9UBX7 19 51022216-51028039 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Hydrolase, Protease, Serine protease" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "esophagus: 103.4;lymphoid tissue: 88.5;salivary gland: 96.5" "Group enriched" "Detected in some" 4 "EFO-21: 9.4;HaCaT: 29.3" "Low cancer specificity" "Detected in many" "Region enriched" "Detected in single" 11 "pons and medulla: 10.7" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" CAB026340 Approved "Secreted in other tissues" 320000 "CAB026340: " "unprognostic (4.23e-2)" "unprognostic (1.50e-2)" "unprognostic (1.27e-1)" "prognostic favourable (3.78e-4)" "unprognostic (2.08e-2)" "unprognostic (4.67e-1)" "unprognostic (5.32e-2)" "unprognostic (3.72e-1)" "unprognostic (3.02e-1)" "prognostic unfavourable (4.17e-4)" "unprognostic (2.92e-2)" "unprognostic (4.16e-6)" "unprognostic (3.90e-2)" "unprognostic (2.73e-1)" "unprognostic (4.40e-2)" "unprognostic (2.53e-1)" 5.5 0.0 0.2 1.1 0.2 0.0 4.9 0.2 0.6 24.5 1.7 2.0 0.4 0.0 5.1 2.7 103.4 9.7 61.8 0.4 0.9 0.0 0.2 0.6 12.3 0.2 0.2 0.2 2.3 25.0 0.0 2.1 0.4 10.7 18.8 0.0 5.1 96.5 1.6 0.3 49.8 0.6 0.3 0.2 0.2 18.7 7.7 0.2 0.9 0.2 65.2 88.5 0.7 33.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 4.5 0.0 9.4 0.0 29.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.2 0.6 0.9 0.0 0.2 0.2 10.7 0.2 KLK13 KLK-L4 ENSG00000167759 "Kallikrein related peptidase 13" Q9UKR3 19 51056206-51065114 "Cancer-related genes, Enzymes, Predicted secreted proteins" "Hydrolase, Protease, Serine protease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "esophagus: 100.5" "Cell line enriched" "Detected in some" 11 "HaCaT: 20.3" "Cancer enhanced" "Detected in many" "head and neck cancer: 42.3" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA062136 Enhanced "Secreted in other tissues" "HPA062136: " "unprognostic (1.99e-3)" "unprognostic (1.89e-1)" "unprognostic (1.25e-1)" "unprognostic (3.66e-2)" "unprognostic (3.43e-1)" "unprognostic (2.99e-2)" "unprognostic (1.69e-1)" "unprognostic (6.76e-2)" "unprognostic (2.18e-2)" "unprognostic (8.30e-2)" "unprognostic (7.07e-6)" "unprognostic (7.33e-2)" "unprognostic (2.53e-1)" "unprognostic (6.38e-2)" "unprognostic (7.06e-2)" 0.1 0.1 0.1 0.1 0.1 0.0 0.3 0.1 0.2 15.7 0.4 0.2 0.1 0.2 0.3 0.1 100.5 0.2 0.9 0.1 0.1 0.0 0.1 0.1 0.2 0.1 0.1 0.1 0.4 1.7 0.0 0.5 0.1 0.2 0.1 0.0 0.3 12.4 0.1 1.2 2.1 0.4 0.1 0.1 0.1 0.2 6.1 0.1 0.1 0.1 17.9 12.8 0.1 19.4 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.8 0.0 20.3 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.3 0.0 0.0 0.0 0.0 1.9 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.4 1.1 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.2 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.2 0.1 0.0 0.1 0.1 0.2 0.1 KLK14 KLK-L6 ENSG00000129437 "Kallikrein related peptidase 14" Q9P0G3 19 51077495-51084245 "Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins" "Hydrolase, Protease, Serine protease" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "skin 1: 14.2" "Cell line enhanced" "Detected in some" "HaCaT: 13.7;HEK 293: 3.9;U-266/84: 7.1" "Cancer enhanced" "Detected in many" "head and neck cancer: 26.8" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" CAB026228 Uncertain "Secreted in other tissues" "CAB026228: " "unprognostic (2.08e-1)" "unprognostic (1.22e-1)" "unprognostic (2.44e-2)" "unprognostic (2.60e-2)" "unprognostic (1.23e-1)" "unprognostic (6.12e-2)" "unprognostic (4.91e-2)" "unprognostic (5.79e-2)" "unprognostic (7.84e-2)" "unprognostic (1.38e-1)" "unprognostic (7.60e-2)" "unprognostic (8.87e-2)" "unprognostic (2.04e-8)" "unprognostic (1.93e-1)" "unprognostic (3.74e-3)" "unprognostic (1.94e-2)" "unprognostic (8.08e-2)" 0.2 0.0 0.4 0.2 1.2 0.1 2.7 2.1 0.9 3.8 0.6 1.8 0.4 0.9 1.2 0.8 0.3 1.1 0.6 0.5 0.1 0.1 0.5 0.4 0.3 0.9 0.4 0.0 0.3 0.0 0.7 0.4 1.1 0.7 0.3 14.2 1.0 0.0 0.3 0.4 0.8 0.7 0.1 0.6 0.2 3.9 0.0 0.0 0.3 0.1 0.0 0.0 0.0 1.7 0.7 0.1 0.9 0.6 0.6 0.7 0.2 0.0 0.0 0.2 1.7 2.1 0.8 0.6 0.3 13.7 0.2 0.3 0.0 0.5 3.9 0.3 1.0 0.0 0.2 0.3 0.3 0.4 0.4 0.5 0.6 0.2 0.3 0.5 0.0 1.2 0.2 0.8 0.8 1.5 0.2 0.1 0.8 0.0 0.7 0.1 0.0 0.3 1.2 0.4 0.6 0.0 0.0 0.2 0.6 0.9 0.2 3.6 7.1 0.5 0.1 0.3 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 KLK15 "ACO, HSRNASPH, prostinogen" ENSG00000174562 "Kallikrein related peptidase 15" Q9H2R5 19 50825289-50837213 "Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins" "Hydrolase, Protease, Serine protease" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "intestine: 5.7;salivary gland: 9.7" "Cell line enriched" "Detected in some" 5 "RPMI-8226: 7.2" "Cancer enhanced" "Detected in some" "prostate cancer: 3.5" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA019802 Uncertain "Secreted to blood" "HPA019802: AB_1852601" "unprognostic (6.06e-2)" "unprognostic (2.85e-1)" "unprognostic (8.13e-2)" "unprognostic (2.90e-1)" "unprognostic (2.29e-2)" "unprognostic (1.16e-1)" "unprognostic (1.17e-1)" "unprognostic (1.55e-1)" "unprognostic (2.52e-1)" "unprognostic (2.72e-2)" 0.0 2.4 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 5.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 1.4 2.1 9.7 0.0 0.0 0.3 0.2 0.0 0.0 0.0 0.0 2.1 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 7.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 KLK2 ENSG00000167751 "Kallikrein related peptidase 2" P20151 19 50861568-50880567 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Hydrolase, Protease, Serine protease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 29 "prostate: 163.5" "Cell line enhanced" "Detected in many" "NB-4: 9.9" "Cancer enriched" "Detected in some" 1666 "prostate cancer: 989.9" "Not detected" "Not detected" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" HPA000764 Supported "Secreted in male reproductive system" "HPA000764: AB_1079700" "unprognostic (3.05e-2)" "unprognostic (2.40e-1)" "unprognostic (1.69e-1)" "unprognostic (8.53e-2)" "unprognostic (1.15e-1)" "unprognostic (8.97e-2)" "unprognostic (3.22e-1)" "unprognostic (6.44e-2)" "unprognostic (8.06e-2)" "unprognostic (3.61e-1)" "unprognostic (2.11e-3)" "unprognostic (7.56e-2)" "unprognostic (8.10e-2)" "unprognostic (1.68e-1)" "unprognostic (2.04e-1)" 0.0 0.1 0.0 0.1 0.0 1.1 0.2 0.0 0.6 0.0 0.0 0.0 0.6 0.1 0.1 0.5 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 163.5 0.0 0.1 2.3 0.0 0.2 0.0 0.1 0.2 0.0 0.0 0.0 0.6 0.0 0.0 1.1 0.0 0.0 0.2 0.0 2.2 1.9 5.7 2.2 1.6 1.3 0.5 1.7 1.1 0.6 1.6 0.0 0.8 4.9 0.5 0.3 0.2 0.2 0.6 0.7 1.8 0.2 0.0 2.0 0.2 0.0 0.3 1.7 1.1 0.0 1.3 0.4 0.0 0.3 3.1 0.4 0.3 0.3 0.4 0.0 1.4 1.9 0.3 1.8 1.2 9.9 1.1 0.0 0.9 0.0 2.8 0.0 1.6 0.9 1.5 0.3 1.3 1.3 1.2 0.4 0.8 1.3 1.9 4.8 1.6 1.8 3.2 0.8 1.9 1.7 1.4 0.9 2.2 1.6 1.2 1.0 1.0 1.0 0.8 1.0 0.5 2.2 0.8 1.3 5.7 1.6 0.8 1.9 0.4 0.5 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 KLK3 "APS, PSA" ENSG00000142515 "Kallikrein related peptidase 3" P07288 19 50854915-50860764 "Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins" "Hydrolase, Protease, Serine protease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 115 "prostate: 447.4" "Group enriched" "Detected in some" 135 "BEWO: 21.9;NB-4: 18.5;RPMI-8226: 12.2;SH-SY5Y: 7.3;U-2197: 7.5" "Cancer enriched" "Detected in some" 3905 "prostate cancer: 4241.6" "Region enriched" "Detected in single" 8 "cerebral cortex: 1.0" "Not detected" "Not detected" "Not detected" "Not detected" "CAB000070, HPA000764" Enhanced "Secreted in male reproductive system" "CAB000070: , HPA000764: AB_1079700" "unprognostic (5.06e-3)" "unprognostic (5.60e-2)" "unprognostic (9.93e-2)" "unprognostic (3.90e-2)" "unprognostic (1.09e-2)" "unprognostic (1.26e-2)" "unprognostic (1.88e-2)" "unprognostic (1.54e-1)" "unprognostic (5.13e-3)" "unprognostic (1.94e-1)" "unprognostic (4.64e-1)" "unprognostic (3.15e-1)" 0.1 0.3 0.0 0.1 0.0 0.0 0.7 0.0 1.0 0.1 0.1 0.0 0.2 0.1 0.1 0.5 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 447.4 0.0 0.1 3.8 1.3 0.0 0.0 0.1 0.3 0.0 0.0 0.0 1.0 0.0 0.1 0.0 0.0 0.1 0.3 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 21.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 18.5 0.0 0.0 0.0 0.0 12.2 0.0 0.0 0.0 7.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.1 0.0 KLK4 "EMSP, EMSP1, KLK-L1, PRSS17, PSTS" ENSG00000167749 "Kallikrein related peptidase 4" Q9Y5K2 19 50906352-50910738 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins" Biomineralization "Hydrolase, Protease, Serine protease" "Amelogenesis imperfecta, Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 9 "prostate: 79.3" "Cell line enhanced" "Detected in many" "CAPAN-2: 8.2;HaCaT: 10.1;SK-BR-3: 6.5" "Cancer enriched" "Detected in many" 55 "prostate cancer: 463.7" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" HPA051839 Enhanced "Secreted in male reproductive system" "HPA051839: " "unprognostic (3.58e-2)" "unprognostic (2.26e-1)" "unprognostic (1.23e-3)" "unprognostic (1.66e-3)" "unprognostic (3.11e-2)" "unprognostic (4.35e-1)" "unprognostic (3.18e-1)" "unprognostic (6.66e-2)" "unprognostic (9.69e-2)" "unprognostic (8.23e-3)" "unprognostic (1.26e-1)" "unprognostic (1.07e-1)" "unprognostic (4.20e-3)" "unprognostic (3.27e-3)" "unprognostic (2.21e-2)" "unprognostic (1.64e-2)" "unprognostic (1.34e-1)" 0.2 0.8 0.1 0.3 0.1 0.1 0.7 0.2 0.5 2.0 1.2 0.0 3.8 1.8 1.5 7.7 0.4 0.2 0.1 0.1 0.3 0.2 0.2 0.1 0.2 0.0 0.2 0.0 0.1 0.1 0.0 0.1 0.1 0.5 79.3 0.8 0.2 3.2 2.1 0.7 2.4 1.2 0.6 0.1 0.1 0.3 0.6 0.1 0.0 8.7 0.0 0.0 0.2 0.2 0.1 0.4 0.6 0.1 0.0 0.3 0.0 5.0 2.1 0.2 0.3 0.0 0.0 4.5 0.1 0.0 0.0 0.0 4.6 8.2 0.5 0.4 0.1 10.1 0.0 5.4 0.0 1.3 1.4 1.6 3.7 1.7 0.0 1.7 2.3 0.0 2.6 0.0 0.0 0.0 0.9 4.2 0.0 1.2 0.1 2.5 0.1 0.4 0.3 0.5 1.1 0.0 3.3 0.0 0.6 0.3 6.5 0.0 5.2 0.4 1.1 0.3 0.3 1.3 0.3 2.6 1.0 0.5 0.1 0.3 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.4 0.0 0.0 0.1 0.1 0.2 0.5 0.3 0.2 0.2 0.0 0.5 0.1 KLK5 "KLK-L2, SCTE" ENSG00000167754 "Kallikrein related peptidase 5" Q9Y337 19 50943303-50953093 "Cancer-related genes, Enzymes, Predicted secreted proteins" "Hydrolase, Protease, Serine protease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 6 "skin 1: 69.2;tongue: 67.3" "Group enriched" "Detected in some" 40 "A-431: 85.3;HaCaT: 83.0" "Cancer enhanced" "Detected in many" "ovarian cancer: 112.2" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "HPA014343, CAB025503, CAB026341" Enhanced "Secreted in other tissues" "CAB025503: , CAB026341: , HPA014343: AB_1852603" "unprognostic (3.19e-2)" "unprognostic (1.06e-1)" "prognostic unfavourable (2.33e-4)" "unprognostic (4.30e-4)" "unprognostic (3.01e-1)" "prognostic unfavourable (9.79e-4)" "unprognostic (3.04e-1)" "unprognostic (3.05e-1)" "unprognostic (1.70e-3)" "unprognostic (2.21e-1)" "unprognostic (2.76e-1)" "unprognostic (2.53e-1)" "unprognostic (9.16e-3)" "prognostic unfavourable (3.85e-6)" 1.1 0.0 0.7 0.4 0.2 0.0 12.1 0.2 0.5 3.8 0.3 0.2 0.2 0.1 1.4 0.9 6.5 0.2 0.3 0.2 0.2 0.1 0.6 0.2 2.5 0.2 0.2 0.2 0.2 0.2 0.0 0.2 0.2 0.4 0.2 0.0 0.3 7.0 0.2 0.4 69.2 0.2 0.2 0.2 0.2 0.0 3.3 0.2 0.4 0.3 67.3 4.4 0.2 3.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 85.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.1 0.0 0.0 0.0 83.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.0 0.0 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.2 0.2 0.5 0.2 0.1 0.2 0.2 0.4 0.2 KLK6 "Bssp, Klk7, neurosin, PRSS18, PRSS9" ENSG00000167755 "Kallikrein related peptidase 6" Q92876 19 50958631-50969673 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Hydrolase, Protease, Serine protease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 97.6;esophagus: 48.9" "Group enriched" "Detected in some" 14 "A-431: 68.4;CAPAN-2: 163.7" "Cancer enhanced" "Detected in many" "ovarian cancer: 131.3" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Region enhanced" "Detected in many" "pons and medulla: 175.6" "Group enriched" "Detected in many" 8 "midbrain: 106.3;pons and medulla: 164.1;thalamus: 62.4" HPA051837 Supported "Nucleoplasm,Nuclear membrane,Cytokinetic bridge" "Secreted in other tissues" 6800000 Nucleoplasm "Nuclear membrane, Cytokinetic bridge" "HPA051837: " "unprognostic (7.30e-2)" "unprognostic (3.32e-1)" "unprognostic (6.58e-2)" "prognostic unfavourable (1.38e-5)" "unprognostic (1.10e-1)" "unprognostic (2.31e-1)" "prognostic unfavourable (8.85e-4)" "unprognostic (3.02e-1)" "unprognostic (2.46e-1)" "prognostic unfavourable (7.82e-4)" "unprognostic (4.45e-1)" "unprognostic (2.72e-2)" "unprognostic (1.31e-1)" "unprognostic (2.46e-1)" "unprognostic (9.07e-2)" "prognostic unfavourable (1.27e-4)" 0.9 0.9 9.7 0.9 23.5 0.9 6.5 3.3 42.2 10.0 1.0 82.0 0.0 1.1 2.0 1.2 48.9 24.6 3.8 0.9 20.1 11.8 9.0 0.9 0.9 0.9 46.1 14.9 0.9 0.9 0.9 0.2 0.9 44.3 1.0 0.9 0.0 5.9 2.8 0.9 2.9 0.9 1.0 97.6 5.1 1.0 1.5 32.6 0.0 0.9 15.7 28.1 0.9 5.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 68.4 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 8.1 163.7 0.0 1.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.2 0.0 0.0 0.0 1.9 0.0 0.0 0.0 0.0 0.0 0.6 0.1 0.2 0.0 0.1 5.9 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 9.7 23.5 3.3 23.1 20.1 11.8 46.1 14.9 44.3 32.6 KLK7 "PRSS6, SCCE" ENSG00000169035 "Kallikrein related peptidase 7" P49862 19 50976482-50984099 "Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins" "Hydrolase, Protease, Serine protease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "esophagus: 29.1;skin 1: 77.5;tongue: 90.2" "Group enriched" "Detected in some" 6 "CAPAN-2: 6.6;HaCaT: 25.9" "Cancer enhanced" "Detected in many" "ovarian cancer: 139.8" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "HPA018994, CAB026342, HPA062126" Enhanced Supported "Nuclear membrane,Plasma membrane" "Secreted in other tissues" 960000 "Plasma membrane" "Nuclear membrane" "CAB026342: , HPA018994: AB_1852607, HPA062126: AB_2684691" "unprognostic (1.88e-2)" "unprognostic (6.41e-2)" "unprognostic (8.57e-2)" "prognostic unfavourable (8.06e-5)" "unprognostic (4.33e-3)" "unprognostic (2.28e-1)" "unprognostic (4.44e-3)" "unprognostic (2.99e-1)" "unprognostic (1.31e-1)" "prognostic unfavourable (1.16e-4)" "unprognostic (2.10e-1)" "unprognostic (2.82e-3)" "unprognostic (3.25e-1)" "unprognostic (4.47e-2)" "unprognostic (1.12e-2)" "unprognostic (5.60e-3)" 2.1 0.3 5.4 0.3 4.3 0.4 5.6 0.5 11.3 5.4 0.3 0.0 0.0 0.5 0.7 0.3 29.1 7.8 3.3 0.2 4.8 0.5 2.6 0.2 1.6 0.3 0.3 3.5 1.0 0.2 0.2 0.1 0.5 4.2 0.3 0.2 0.0 7.4 0.3 0.6 77.5 0.3 0.4 0.3 0.5 0.4 0.3 0.0 0.0 0.4 90.2 15.3 0.2 9.0 1.1 0.4 1.3 0.8 2.1 1.0 0.6 2.6 0.0 0.0 0.2 0.0 0.0 1.3 0.0 0.0 0.0 0.0 1.5 6.6 0.0 1.0 0.0 25.9 0.0 0.8 0.0 0.0 0.3 0.1 0.0 0.0 0.0 0.0 0.2 0.0 2.1 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.1 0.1 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.1 0.1 1.3 0.8 0.4 0.4 0.4 0.7 0.6 0.6 0.4 0.4 1.1 1.0 0.9 0.9 2.1 0.4 0.4 0.7 0.6 5.4 4.3 0.5 11.3 4.8 0.5 0.3 3.5 4.2 0.0 KLK8 "HNP, neuropsin, ovasin, PRSS19, TADG14" ENSG00000129455 "Kallikrein related peptidase 8" O60259 19 50996007-51002711 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Hydrolase, Protease, Serine protease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "esophagus: 43.6;skin 1: 40.4;tongue: 46.9" "Group enriched" "Detected in some" 7 "A-431: 31.5;CAPAN-2: 41.3;HaCaT: 30.5" "Cancer enhanced" "Detected in many" "head and neck cancer: 29.9;ovarian cancer: 30.7" "Low region specificity" "Detected in single" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in many" 5 "hippocampal formation: 39.6" "CAB019393, HPA035761" Enhanced Approved Vesicles "Secreted in other tissues" 950000 Vesicles "CAB019393: , HPA035761: " "unprognostic (4.27e-3)" "unprognostic (2.59e-1)" "unprognostic (2.54e-1)" "prognostic unfavourable (2.31e-4)" "unprognostic (5.46e-2)" "prognostic unfavourable (5.72e-4)" "unprognostic (2.95e-1)" "unprognostic (9.02e-2)" "prognostic unfavourable (1.10e-4)" "unprognostic (4.29e-2)" "unprognostic (4.66e-2)" "unprognostic (1.54e-1)" "prognostic unfavourable (6.17e-4)" 1.6 0.0 0.1 0.4 0.1 0.0 4.5 1.0 0.3 8.1 0.7 0.1 0.1 0.0 1.1 0.7 43.6 6.7 0.3 0.1 0.1 0.0 0.2 0.1 0.1 0.1 0.1 0.1 1.1 0.1 0.0 0.1 0.4 0.6 0.3 0.0 0.3 6.0 0.1 0.3 40.4 0.1 0.1 0.6 0.3 0.0 0.7 0.1 0.5 0.3 46.9 11.1 0.3 13.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 31.5 0.0 0.0 0.2 0.0 0.0 4.6 0.0 0.0 0.0 0.0 0.6 41.3 0.0 0.8 0.0 30.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 1.0 0.3 0.1 0.0 0.1 0.1 0.6 0.1 KLK9 KLK-L3 ENSG00000213022 "Kallikrein related peptidase 9" Q9UKQ9 19 51003111-51009634 "Cancer-related genes, Enzymes, Predicted secreted proteins" "Hydrolase, Protease, Serine protease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "tongue: 37.6" "Group enriched" "Detected in some" 27 "HaCaT: 1.2;HBEC3-KT: 4.1" "Cancer enriched" "Detected in single" 6 "head and neck cancer: 0.7" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" CAB025049 Enhanced "Secreted to digestive system" "CAB025049: " "unprognostic (3.22e-2)" 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 4.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 8.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 37.6 3.8 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 4.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 KLRK1 "CD314, D12S2489E, KLR, NKG2-D, NKG2D" ENSG00000213809 "Killer cell lectin like receptor K1" P26718 12 10372353-10391874 "Cancer-related genes, CD markers, Predicted membrane proteins, Transporters" "Adaptive immunity, Differentiation, Immunity, Innate immunity" Receptor "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 50.8;lymphoid tissue: 30.7" "Cell line enriched" "Detected in some" 8 "U-698: 36.0" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Group enriched" "Detected in many" 39 "gdT-cell: 49.4;MAIT T-cell: 18.5;memory CD8 T-cell: 44.0;naive CD8 T-cell: 44.3;NK-cell: 50.8" "Group enriched" "Detected in many" 47 "NK-cells: 50.8;T-cells: 49.4" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB021896, HPA068877" Enhanced Supported "Plasma membrane" 33000 "Plasma membrane" "CAB021896: , HPA068877: " "unprognostic (3.34e-4)" "unprognostic (2.65e-4)" "unprognostic (3.25e-1)" "unprognostic (2.59e-2)" "unprognostic (1.53e-1)" "unprognostic (1.01e-5)" "unprognostic (5.61e-4)" "unprognostic (1.00e-3)" "unprognostic (1.33e-1)" "unprognostic (9.22e-2)" "unprognostic (1.28e-2)" "unprognostic (2.10e-2)" "unprognostic (6.56e-10)" "unprognostic (1.24e-2)" "unprognostic (6.32e-2)" "unprognostic (7.59e-2)" "unprognostic (7.08e-10)" 4.1 0.9 1.3 18.3 1.1 10.6 2.1 0.4 0.8 2.8 4.5 1.2 0.6 2.0 2.4 2.7 3.1 2.0 7.7 1.3 1.3 1.1 2.4 3.6 13.6 22.2 2.1 0.1 1.5 3.3 0.0 1.2 1.6 1.2 2.2 2.1 2.4 7.0 0.6 0.5 1.1 13.1 1.3 2.1 30.7 3.3 1.9 0.6 6.0 2.9 2.8 11.4 11.3 2.5 1.0 0.2 0.8 0.1 50.8 49.4 16.7 0.2 0.0 0.4 1.8 0.1 4.6 0.4 0.0 0.0 0.0 0.0 0.2 0.0 0.3 0.0 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.2 1.6 0.0 0.0 0.1 0.0 0.7 0.0 0.2 0.0 0.2 0.1 0.3 0.0 0.3 0.0 0.0 0.0 0.0 0.5 0.2 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.5 0.0 0.0 0.0 0.0 36.0 0.1 0.0 0.2 0.0 0.0 0.0 49.4 0.1 18.5 0.8 0.3 44.0 0.1 1.0 0.4 44.3 0.8 50.8 0.1 0.2 0.1 16.7 1.3 1.1 0.4 0.8 1.3 1.1 2.1 0.1 1.2 0.6 KMT2A "ALL-1, CXXC7, HRX, HTRX1, MLL, MLL1A, TRX1" ENSG00000118058 "Lysine methyltransferase 2A" Q03164 11 118436490-118526832 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transcription factors" "Apoptosis, Biological rhythms, Transcription, Transcription regulation" "Chromatin regulator, DNA-binding, Methyltransferase, Transferase" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB017794, CAB024270, HPA044910" Enhanced Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "CAB017794: , CAB024270: , HPA044910: " "unprognostic (6.80e-2)" "unprognostic (8.93e-2)" "unprognostic (1.83e-1)" "unprognostic (4.56e-1)" "unprognostic (4.96e-2)" "unprognostic (1.72e-3)" "unprognostic (4.52e-3)" "unprognostic (6.07e-2)" "unprognostic (1.61e-1)" "unprognostic (8.46e-2)" "unprognostic (3.21e-1)" "unprognostic (1.16e-1)" "unprognostic (5.91e-3)" "unprognostic (7.90e-2)" "unprognostic (3.73e-1)" "unprognostic (1.67e-1)" "unprognostic (1.02e-1)" 14.4 11.3 17.7 17.0 19.2 28.6 16.8 43.8 21.2 17.3 14.6 19.8 18.1 8.5 21.8 17.1 10.6 15.7 14.1 10.2 17.3 13.4 13.1 9.3 15.3 19.6 16.6 18.7 35.6 16.8 28.9 21.8 10.2 15.4 15.6 12.4 14.4 14.2 19.2 11.1 16.8 14.2 15.2 12.1 15.7 12.3 7.9 23.4 16.6 16.6 7.8 19.4 18.8 24.6 6.7 3.5 8.3 2.0 6.5 5.3 0.8 11.9 5.5 14.9 11.2 9.1 10.9 4.4 5.4 7.8 5.7 6.6 11.1 8.7 14.7 11.1 7.9 10.4 15.8 5.9 11.3 16.2 6.1 28.8 5.1 6.0 5.1 17.2 5.6 5.2 6.1 12.4 16.7 8.8 18.7 12.6 7.1 9.3 11.4 10.1 9.0 8.2 8.7 14.3 4.9 8.4 9.0 12.3 8.0 13.5 4.4 2.8 7.6 5.8 13.0 9.8 8.8 7.1 9.6 3.7 2.8 9.9 3.7 12.7 5.8 8.3 2.0 4.6 5.3 1.3 4.3 6.2 4.8 4.6 0.8 6.7 4.9 4.8 1.3 6.5 1.4 3.5 3.9 0.8 17.7 19.2 43.8 21.2 17.3 13.4 16.6 18.7 15.4 23.4 KMT2B "CXXC10, HRX2, KIAA0304, MLL1B, MLL2, MLL4, TRX2, WBP7" ENSG00000272333 "Lysine methyltransferase 2B" Q9UMN6 19 35718019-35738878 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Chromatin regulator, DNA-binding, Methyltransferase, Transferase" "Cancer-related genes, Disease mutation, Dystonia" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "neutrophil: 3.2" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" HPA006487 Approved Nucleoplasm,Cytosol Nucleoplasm Cytosol "HPA006487: AB_1080587" "unprognostic (1.09e-2)" "unprognostic (3.53e-2)" "unprognostic (3.41e-2)" "unprognostic (7.95e-2)" "unprognostic (9.92e-2)" "unprognostic (3.53e-3)" "unprognostic (2.33e-2)" "unprognostic (4.57e-2)" "unprognostic (7.28e-2)" "unprognostic (2.07e-2)" "unprognostic (3.13e-3)" "unprognostic (2.63e-3)" "unprognostic (9.47e-3)" "unprognostic (2.10e-1)" "unprognostic (2.37e-1)" "unprognostic (3.77e-2)" "unprognostic (2.24e-2)" 10.2 9.3 11.4 14.2 13.1 18.4 10.4 23.9 11.4 10.0 12.0 14.2 12.9 13.8 13.0 7.1 11.4 11.6 12.6 7.5 11.0 5.3 9.9 8.9 10.6 14.7 14.7 6.8 15.3 19.6 10.8 13.3 9.3 11.2 12.1 5.6 13.8 14.7 10.0 13.3 19.9 12.3 12.2 12.4 15.8 12.1 21.5 14.9 14.1 14.9 7.0 14.2 12.4 14.2 0.4 0.7 3.2 0.7 2.1 0.7 0.2 11.3 19.2 8.9 9.7 4.6 4.5 9.3 5.5 4.0 5.6 4.3 12.8 5.8 10.1 8.7 4.6 7.5 8.0 4.7 2.5 15.0 8.9 18.2 9.0 6.4 4.5 11.1 20.9 6.1 6.4 5.7 6.3 5.5 15.2 12.7 3.6 11.6 9.4 9.6 8.2 6.8 14.8 5.8 5.5 3.1 10.1 10.1 8.1 8.4 13.6 5.8 8.3 11.8 7.6 11.3 12.2 7.5 11.7 17.5 10.7 8.1 6.1 10.3 7.8 1.0 0.7 0.6 0.7 0.4 0.4 0.3 0.2 0.3 0.2 0.4 0.3 0.4 3.2 2.1 0.3 0.7 0.2 0.2 11.4 13.1 23.9 11.4 11.0 5.3 14.7 6.8 11.2 14.9 KMT2C "HALR, KIAA1506, MLL3" ENSG00000055609 "Lysine methyltransferase 2C" Q8NEZ4 7 152134922-152436005 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Transcription, Transcription regulation" "Activator, Acyltransferase, Chromatin regulator, DNA-binding, Methyltransferase, Transferase" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA074736 Approved Nucleoplasm Nucleoplasm "HPA074736: " "unprognostic (7.75e-2)" "unprognostic (3.10e-1)" "unprognostic (2.83e-1)" "unprognostic (1.33e-2)" "unprognostic (1.31e-1)" "unprognostic (5.23e-3)" "unprognostic (1.09e-1)" "unprognostic (1.59e-2)" "unprognostic (1.01e-1)" "unprognostic (1.17e-1)" "unprognostic (3.45e-1)" "unprognostic (1.06e-1)" "prognostic favourable (8.01e-6)" "unprognostic (1.78e-1)" "unprognostic (3.83e-1)" "unprognostic (3.04e-2)" "unprognostic (2.64e-1)" 13.9 12.6 11.7 16.7 18.6 29.7 14.5 24.8 14.1 18.4 12.6 15.5 21.4 9.7 20.2 20.6 14.4 12.8 12.7 10.8 13.4 9.5 10.3 11.4 13.0 12.1 17.7 9.4 18.8 18.4 18.8 18.9 38.0 12.6 14.0 11.8 12.6 15.8 22.9 30.3 25.2 13.1 13.6 16.0 14.6 14.9 13.6 19.6 22.6 16.9 9.3 16.8 17.8 31.6 5.6 3.5 16.1 3.9 5.5 2.9 0.6 9.5 4.8 9.0 9.5 16.2 9.8 10.5 5.0 3.8 4.0 4.9 9.1 5.8 15.2 7.3 9.1 5.5 9.6 7.3 6.7 9.6 4.9 9.0 7.2 6.3 7.9 15.3 11.1 8.2 10.1 5.7 7.6 5.7 14.5 13.2 8.7 13.3 11.0 13.9 5.4 4.8 7.4 8.1 7.9 6.9 9.9 13.1 10.3 8.2 14.7 5.4 4.8 12.5 7.2 6.7 3.5 7.1 7.1 13.8 6.7 16.4 8.7 12.5 6.8 8.8 3.5 4.3 2.1 2.2 2.9 5.6 1.7 1.7 1.7 3.8 2.7 1.8 16.1 5.5 3.9 3.5 1.3 0.6 11.7 18.6 24.8 14.1 13.4 9.5 17.7 9.4 12.6 19.6 KMT2D "ALR, CAGL114, MLL2, MLL4, TNRC21" ENSG00000167548 "Lysine methyltransferase 2D" O14686 12 49018975-49059774 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Transcription, Transcription regulation" "Chromatin regulator, Methyltransferase, Transferase" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "neutrophil: 5.9" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" HPA035977 Approved Approved "Nucleoplasm,Plasma membrane,Cytosol" "Plasma membrane, Cytosol" Nucleoplasm "HPA035977: AB_10670673" "unprognostic (8.33e-2)" "unprognostic (1.49e-1)" "unprognostic (9.14e-2)" "unprognostic (2.52e-1)" "unprognostic (8.07e-2)" "unprognostic (6.91e-3)" "unprognostic (7.35e-2)" "unprognostic (2.29e-1)" "unprognostic (3.57e-1)" "unprognostic (5.14e-2)" "unprognostic (7.23e-2)" "unprognostic (3.07e-1)" "unprognostic (1.68e-2)" "unprognostic (7.10e-2)" "unprognostic (1.87e-1)" "unprognostic (3.20e-2)" "unprognostic (7.60e-2)" 12.1 7.6 4.9 6.7 10.8 26.1 6.8 11.7 10.5 9.5 6.5 5.8 13.0 5.5 15.7 7.4 8.8 8.9 5.8 9.1 6.1 3.5 6.2 6.5 22.9 9.6 6.7 3.3 9.7 11.6 13.3 9.2 12.9 13.7 6.7 6.6 9.8 7.6 8.0 16.1 13.6 9.4 7.1 9.1 13.6 8.3 7.3 5.7 6.2 11.0 6.1 7.6 7.0 6.3 2.0 2.2 5.9 0.5 1.5 0.8 0.6 17.0 16.2 16.4 13.2 17.0 11.4 17.6 9.0 9.4 11.7 6.3 28.4 7.2 17.7 11.7 12.6 11.6 21.6 10.0 9.8 10.3 17.3 22.5 16.9 15.2 11.7 26.7 22.6 9.7 14.3 16.4 17.0 17.4 28.2 9.8 13.2 18.7 13.2 24.9 15.5 14.0 19.9 10.1 6.4 9.8 18.9 13.7 11.6 13.9 13.7 9.5 13.6 23.4 23.1 9.2 16.5 8.1 15.1 14.0 9.0 17.2 10.6 13.8 6.9 0.6 0.5 3.0 0.8 0.2 0.4 0.3 0.3 0.5 0.3 2.0 0.3 0.8 5.9 1.5 0.1 2.2 0.0 0.6 4.9 10.8 11.7 10.5 6.1 3.5 6.7 3.3 13.7 5.7 KNL1 "AF15Q14, CASC5, CT29, D40, hKNL-1, hSpc105, KIAA1570, MCPH4, PPP1R55, Spc7" ENSG00000137812 "Kinetochore scaffold 1" Q8NG31 15 40594020-40664342 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division, Chromosome partition, Mitosis" "Cancer-related genes, Disease mutation, Mental retardation, Primary microcephaly" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 8 "lymphoid tissue: 54.7;testis: 35.6" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "HPA026624, HPA049647" Enhanced Enhanced "Nucleoplasm,Nuclear bodies" Nucleoplasm "Nuclear bodies" "HPA026624: AB_10601696, HPA049647: " "unprognostic (5.35e-2)" "unprognostic (1.01e-1)" "unprognostic (5.59e-3)" "unprognostic (4.22e-2)" "unprognostic (1.59e-2)" "unprognostic (5.66e-2)" "unprognostic (1.41e-1)" "prognostic unfavourable (2.11e-4)" "unprognostic (2.06e-2)" "unprognostic (1.43e-1)" "unprognostic (3.20e-4)" "unprognostic (2.22e-2)" "unprognostic (1.93e-12)" "unprognostic (3.07e-2)" "unprognostic (3.08e-1)" "unprognostic (8.45e-2)" "unprognostic (7.36e-2)" 0.7 0.5 0.3 7.1 0.4 5.4 0.7 0.3 0.3 0.6 4.0 0.1 0.0 1.5 0.4 0.8 3.9 0.4 0.9 0.5 0.4 0.4 0.9 1.0 1.3 4.7 0.3 0.0 0.5 0.5 0.0 0.4 2.8 0.1 0.5 1.5 0.0 0.8 0.0 0.4 0.8 3.9 0.5 0.4 3.3 0.8 35.6 0.0 54.7 0.5 4.1 3.7 0.7 0.9 2.9 1.2 0.7 0.5 0.7 2.5 0.0 10.8 5.6 11.4 8.2 0.3 1.7 5.1 12.7 5.1 10.0 8.4 6.8 4.4 7.2 4.0 5.5 13.6 10.8 5.9 10.6 12.5 2.9 21.2 9.6 2.0 0.0 16.2 10.7 0.3 0.2 6.7 4.2 8.5 13.5 12.1 11.6 3.7 13.8 3.2 5.6 5.9 12.6 16.3 3.6 1.5 9.6 9.9 4.6 11.0 6.2 1.3 6.7 4.9 7.8 11.6 10.3 13.3 7.0 4.6 15.8 14.1 4.7 11.0 11.0 0.4 0.2 0.1 0.1 0.1 0.0 2.9 1.1 0.1 1.2 2.2 0.0 0.7 0.7 0.7 0.5 0.1 2.5 0.0 0.3 0.4 0.3 0.3 0.4 0.4 0.3 0.0 0.1 0.0 KRAS "KRAS1, KRAS2" ENSG00000133703 "KRAS proto-oncogene, GTPase" P01116 12 25204789-25250936 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, RAS pathway related proteins" "Cancer-related genes, Cardiomyopathy, Deafness, Disease mutation, Ectodermal dysplasia, Mental retardation, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA049830 Approved 5800000 "HPA049830: " "unprognostic (2.24e-2)" "unprognostic (2.16e-2)" "unprognostic (4.86e-3)" "unprognostic (1.08e-2)" "unprognostic (7.39e-2)" "unprognostic (1.51e-1)" "unprognostic (1.47e-2)" "unprognostic (3.74e-2)" "unprognostic (1.79e-1)" "unprognostic (2.39e-1)" "prognostic unfavourable (3.59e-4)" "unprognostic (6.42e-2)" "prognostic favourable (2.75e-5)" "unprognostic (1.95e-2)" "unprognostic (2.37e-1)" "unprognostic (2.81e-2)" "unprognostic (9.97e-2)" 11.7 9.9 14.4 15.5 19.5 24.1 10.6 21.1 25.6 10.3 26.2 7.3 7.9 16.1 11.3 7.7 25.1 10.1 13.9 9.3 13.6 16.6 14.0 17.9 14.9 15.1 11.6 15.8 13.1 13.6 12.7 9.8 15.7 21.1 12.1 28.1 9.8 16.2 9.8 10.0 14.0 23.7 17.2 11.3 15.7 23.6 7.8 9.5 18.5 11.1 10.6 16.3 16.8 14.3 10.0 7.1 20.8 18.9 9.4 13.8 5.0 7.2 7.4 16.6 9.4 6.2 8.4 33.3 7.4 9.4 7.8 9.3 25.7 16.8 16.8 4.5 12.9 8.0 19.4 8.1 14.8 11.4 6.7 15.8 7.9 6.3 6.5 14.8 12.1 7.8 11.1 9.4 8.4 11.3 11.2 8.0 11.5 6.2 20.4 22.5 36.4 3.0 17.6 17.6 24.1 11.5 12.9 5.1 14.2 8.9 11.7 8.9 13.0 10.7 13.0 8.8 11.6 16.4 9.2 7.0 11.8 18.2 6.7 8.7 6.3 20.8 7.8 12.4 11.9 14.4 7.5 10.0 10.4 13.0 7.1 8.6 13.8 12.1 19.0 9.4 18.9 7.1 6.7 5.0 14.4 19.5 21.1 25.6 13.6 16.6 11.6 15.8 21.1 9.5 KRT13 "CK13, K13, MGC161462, MGC3781" ENSG00000171401 "Keratin 13" P13646 17 41500981-41505705 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "esophagus: 1075.6;lymphoid tissue: 404.8;tongue: 499.8" "Group enriched" "Detected in some" 100 "A-431: 211.8;HaCaT: 141.5" "Group enriched" "Detected in many" 5 "cervical cancer: 899.2;head and neck cancer: 758.7;urothelial cancer: 504.9" "Not detected" "Not detected" "Cell type enriched" "Detected in single" 12 "neutrophil: 1.1" "Lineage enriched" "Detected in single" 12 "granulocytes: 1.1" "Not detected" "Not detected" "Not detected" "Not detected" "CAB000133, HPA030877, HPA069771" Enhanced Enhanced "Intermediate filaments" 1100000000 "Intermediate filaments" "CAB000133: , HPA030877: , HPA069771: AB_2732141" "unprognostic (1.45e-1)" "unprognostic (6.23e-2)" "unprognostic (1.37e-1)" "unprognostic (2.19e-2)" "unprognostic (9.30e-5)" "unprognostic (7.30e-3)" "unprognostic (1.95e-1)" "unprognostic (1.77e-1)" "unprognostic (5.81e-3)" "prognostic unfavourable (1.02e-4)" "unprognostic (3.16e-1)" "prognostic unfavourable (1.45e-6)" "unprognostic (1.80e-1)" "unprognostic (2.76e-1)" "unprognostic (3.04e-2)" "unprognostic (4.33e-1)" 0.3 0.3 0.0 0.3 0.0 0.5 0.3 0.0 0.3 250.9 0.3 0.0 0.0 0.3 13.7 0.3 1075.6 0.3 0.6 0.5 0.0 0.0 0.3 0.3 0.3 0.3 0.0 0.0 0.3 0.3 0.3 0.0 0.3 0.0 2.4 0.3 0.1 134.9 0.4 0.4 0.3 0.3 1.7 0.0 0.3 0.3 0.4 0.0 0.6 0.3 499.8 404.8 14.9 222.2 0.0 0.0 1.1 0.0 0.0 0.0 0.0 211.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 141.5 0.0 0.0 0.0 0.1 0.0 0.3 1.7 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.4 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.9 0.0 0.0 0.1 0.1 0.7 0.2 0.5 0.4 0.0 0.0 0.0 0.6 0.0 0.5 0.4 0.1 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 KRT14 "EBS3, EBS4" ENSG00000186847 "Keratin 14" P02533 17 41582279-41586921 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cancer-related genes, Disease mutation, Ectodermal dysplasia, Epidermolysis bullosa, Palmoplantar keratoderma" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 6 "skin 1: 439.2;tongue: 363.5" "Cell line enhanced" "Detected in some" "HaCaT: 259.8;HBEC3-KT: 128.1;hTCEpi: 160.3;hTERT-HME1: 52.4;U-2197: 45.2" "Group enriched" "Detected in many" 6 "cervical cancer: 1263.1;head and neck cancer: 5910.5;melanoma: 1277.8" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in some" "CAB000134, HPA000452, HPA000539, HPA023040" Enhanced Enhanced "Intermediate filaments" 2200000000 "Intermediate filaments" "CAB000134: , HPA000452: AB_1079177, HPA000539: , HPA023040: AB_1852201" "prognostic favourable (2.66e-4)" "unprognostic (1.64e-1)" "unprognostic (1.01e-2)" "unprognostic (1.42e-2)" "unprognostic (1.66e-1)" "unprognostic (1.02e-2)" "unprognostic (2.03e-2)" "unprognostic (2.74e-1)" "unprognostic (1.35e-1)" "unprognostic (1.00e-2)" "unprognostic (5.74e-3)" "unprognostic (1.49e-8)" "unprognostic (8.91e-2)" "unprognostic (2.00e-1)" "unprognostic (8.80e-3)" "unprognostic (1.22e-2)" 0.2 0.1 0.2 0.2 0.2 0.2 23.1 0.2 0.2 27.0 0.2 0.2 0.2 0.1 0.3 0.2 69.3 0.1 0.2 0.2 0.2 0.0 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.1 0.2 7.6 0.2 2.1 0.1 0.2 30.8 0.3 1.0 439.2 0.2 0.2 0.2 0.2 0.1 0.2 0.2 4.6 0.2 363.5 47.6 0.2 37.1 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 259.8 0.0 128.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 160.3 0.1 52.4 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.1 45.2 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.2 0.2 0.2 0.0 0.2 0.2 0.2 0.2 KRT15 "CK15, K15, K1CO" ENSG00000171346 "Keratin 15" P19012 17 41513743-41522529 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "breast: 37.4;esophagus: 115.3;skin 1: 119.3;vagina: 38.6" "Group enriched" "Detected in some" 10 "HaCaT: 120.2;hTCEpi: 92.9" "Cancer enhanced" "Detected in many" "cervical cancer: 178.9" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "HPA023910, HPA024554" Enhanced Supported "Nucleoplasm,Intermediate filaments" 580000000 "Intermediate filaments" Nucleoplasm "HPA023910: AB_1852205, HPA024554: AB_1852207" "prognostic favourable (4.50e-4)" "unprognostic (9.14e-2)" "unprognostic (3.28e-2)" "unprognostic (1.19e-3)" "unprognostic (3.57e-2)" "unprognostic (8.84e-2)" "unprognostic (6.12e-3)" "unprognostic (1.70e-1)" "unprognostic (2.13e-1)" "unprognostic (8.65e-3)" "unprognostic (9.91e-3)" "unprognostic (2.09e-1)" "unprognostic (2.24e-11)" "unprognostic (6.91e-3)" "unprognostic (2.62e-1)" "unprognostic (1.33e-5)" "unprognostic (5.35e-2)" 0.6 0.0 1.4 0.6 1.5 0.0 37.4 0.6 1.1 14.6 1.1 0.6 0.6 0.0 0.6 0.6 115.3 2.7 10.6 0.6 1.3 0.0 1.1 0.6 2.1 0.6 0.6 0.6 0.6 0.6 0.0 0.6 3.0 1.1 16.4 0.0 1.4 15.1 0.6 0.6 119.3 3.5 0.6 0.6 0.6 0.0 0.6 0.6 0.6 0.6 1.9 6.2 0.8 38.6 0.0 0.0 0.0 0.4 0.0 0.0 0.0 5.9 0.8 0.0 0.0 0.0 0.0 0.0 0.5 0.1 0.0 0.0 0.6 2.1 0.0 0.2 0.0 120.2 0.0 4.1 0.0 0.0 0.0 0.0 0.6 0.2 0.0 0.0 0.4 0.0 92.9 0.2 0.7 0.3 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.6 0.0 0.0 10.2 0.3 0.7 0.2 0.0 0.1 1.7 0.1 2.3 0.0 2.0 0.0 0.2 0.0 0.2 0.0 0.0 0.0 0.8 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 1.4 1.5 0.6 1.1 1.3 0.0 0.6 0.6 1.1 0.6 KRT17 PCHC1 ENSG00000128422 "Keratin 17" Q04695 17 41619437-41624842 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cancer-related genes, Disease mutation, Ectodermal dysplasia, Palmoplantar keratoderma" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "skin 1: 109.0;tongue: 144.0" "Group enriched" "Detected in some" 7 "hTCEpi: 638.7;SiHa: 265.9" "Cancer enhanced" "Detected in all" "head and neck cancer: 3317.2" "Low region specificity" "Detected in single" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "CAB000029, HPA000452, HPA000453, HPA000539, HPA045062" Enhanced Enhanced "Intermediate filaments" 750000000 "Intermediate filaments" "CAB000029: AB_2133155, HPA000452: AB_1079177, HPA000453: AB_1079176, HPA000539: , HPA045062: " "prognostic favourable (4.44e-4)" "unprognostic (1.43e-1)" "unprognostic (1.15e-1)" "unprognostic (3.65e-3)" "unprognostic (4.46e-2)" "unprognostic (4.34e-1)" "unprognostic (4.36e-3)" "unprognostic (1.32e-2)" "unprognostic (2.27e-1)" "unprognostic (1.29e-1)" "unprognostic (7.86e-3)" "unprognostic (1.53e-1)" "prognostic unfavourable (5.74e-4)" "unprognostic (1.82e-1)" "unprognostic (1.77e-1)" "unprognostic (2.20e-1)" "unprognostic (3.89e-1)" 0.7 0.0 0.7 0.7 0.7 0.1 52.3 0.7 0.8 12.6 0.8 0.7 1.2 0.0 1.0 3.1 38.6 0.9 0.9 0.7 0.7 0.0 0.8 0.7 3.7 0.7 0.7 1.0 0.8 0.7 0.0 0.9 4.1 0.8 15.0 0.0 0.7 26.8 33.4 0.7 109.0 0.7 1.2 0.7 0.7 0.0 0.8 0.7 5.1 0.8 144.0 19.7 55.6 25.2 0.0 0.0 0.0 0.0 0.0 0.2 0.1 6.4 0.0 0.0 0.0 0.0 0.0 1.5 0.1 0.0 0.0 0.0 0.5 0.0 0.0 0.4 0.0 64.6 0.0 66.0 0.0 0.0 0.0 0.0 28.9 0.0 0.0 0.0 0.0 0.0 638.7 0.0 49.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 24.2 0.0 0.0 265.9 0.1 0.0 0.0 0.0 0.0 0.0 13.1 0.0 0.0 0.0 0.0 0.1 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.7 0.7 0.7 0.8 0.7 0.0 0.7 1.0 0.8 0.7 KRT18 ENSG00000111057 "Keratin 18" P05783 12 52948871-52952901 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cell cycle, Host-virus interaction" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "placenta: 268.7" "Cell line enhanced" "Detected in many" "A549: 225.8;BEWO: 142.5;CACO-2: 248.3;CAPAN-2: 180.4;MCF7: 330.6;SK-BR-3: 182.8" "Low cancer specificity" "Detected in all" "Region enhanced" "Detected in many" "pons and medulla: 10.0" "Cell type enriched" "Detected in many" 5 "basophil: 28.6" "Lineage enriched" "Detected in many" 5 "granulocytes: 28.6" "Not detected" "Not detected" "Low region specificity" "Detected in many" "CAB000008, CAB000030, HPA001605" Enhanced Supported Cytosol 140000000 Cytosol "CAB000008: , CAB000030: , HPA001605: " "unprognostic (1.98e-1)" "unprognostic (1.03e-1)" "unprognostic (3.31e-1)" "unprognostic (1.63e-2)" "unprognostic (1.25e-1)" "unprognostic (7.26e-3)" "unprognostic (4.09e-3)" "prognostic unfavourable (5.06e-4)" "unprognostic (8.81e-2)" "unprognostic (4.17e-1)" "prognostic unfavourable (1.78e-4)" "unprognostic (3.05e-1)" "unprognostic (1.04e-1)" "unprognostic (1.27e-1)" "unprognostic (2.19e-1)" "unprognostic (1.11e-2)" "unprognostic (1.13e-2)" 23.3 4.8 1.0 31.0 1.1 0.0 24.1 2.9 1.2 28.6 45.4 1.3 66.3 35.0 6.6 55.3 22.4 21.7 147.4 6.8 1.1 2.5 61.9 181.0 39.6 2.8 1.2 1.0 13.7 162.9 8.2 39.8 268.7 10.0 29.3 57.0 14.1 121.1 49.9 1.3 6.5 83.6 3.9 1.4 4.4 36.0 9.5 0.8 4.2 83.4 10.8 20.9 21.5 10.8 4.1 1.0 28.6 0.1 1.0 5.9 1.6 75.7 225.8 0.0 0.3 0.0 0.0 142.5 11.5 14.0 14.9 4.2 248.3 180.4 0.0 32.1 12.5 18.5 3.1 87.6 9.0 0.0 5.3 0.7 36.9 68.3 38.6 0.0 0.0 0.5 8.2 13.0 18.0 15.9 18.2 0.0 0.0 330.6 0.1 1.3 18.4 17.1 0.1 0.0 8.6 72.7 45.7 2.6 0.1 18.7 182.8 0.7 96.5 0.2 5.0 0.2 17.4 0.2 2.5 0.0 0.2 0.1 0.0 0.0 1.4 28.6 0.1 1.1 0.2 0.1 1.1 2.1 2.3 0.6 1.0 4.1 5.9 2.1 1.5 1.0 0.0 0.0 0.2 1.6 1.0 1.1 2.9 1.2 1.1 2.5 1.2 1.0 10.0 0.8 KRT19 "CK19, K19, K1CS, MGC15366" ENSG00000171345 "Keratin 19" P08727 17 41523617-41528308 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "gallbladder: 205.3;intestine: 184.9;placenta: 179.4" "Cell line enhanced" "Detected in many" "CAPAN-2: 100.7;HBEC3-KT: 151.7;MCF7: 111.9;RT4: 161.1;SK-BR-3: 284.6;T-47d: 191.7" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in some" "Cell type enriched" "Detected in single" 4 "NK-cell: 2.7" "Lineage enriched" "Detected in single" 4 "NK-cells: 2.7" "Not detected" "Not detected" "CAB000031, HPA002465" Enhanced Supported "Intermediate filaments" 330000000 "Intermediate filaments" "CAB000031: AB_2234418, HPA002465: AB_1079179" "unprognostic (1.09e-1)" "unprognostic (1.83e-1)" "unprognostic (3.86e-2)" "unprognostic (1.59e-2)" "unprognostic (2.24e-2)" "unprognostic (1.13e-1)" "unprognostic (2.29e-1)" "unprognostic (2.80e-2)" "unprognostic (3.14e-1)" "unprognostic (4.86e-2)" "prognostic unfavourable (6.82e-5)" "unprognostic (1.90e-2)" "prognostic unfavourable (2.98e-5)" "unprognostic (3.52e-2)" "unprognostic (2.14e-1)" "unprognostic (3.08e-2)" "unprognostic (2.35e-2)" 9.8 1.6 0.7 22.8 0.9 0.0 50.1 2.9 0.8 37.4 126.7 1.0 38.0 37.8 9.9 53.0 102.1 19.5 205.3 2.3 0.8 0.2 35.0 2.1 50.6 0.7 0.8 0.8 16.7 7.5 1.2 2.6 179.4 1.3 39.2 40.1 1.8 103.0 46.3 0.7 15.8 184.9 11.7 0.6 0.6 69.1 6.4 0.7 33.3 4.9 21.2 89.2 77.0 35.4 0.0 0.0 0.0 0.0 2.7 0.6 0.2 0.1 17.6 0.0 0.3 0.0 0.0 61.6 21.2 0.0 0.6 0.1 50.6 100.7 0.0 20.8 10.1 53.9 0.0 151.7 0.1 0.0 0.5 0.0 11.4 34.6 1.6 0.0 4.3 0.0 27.6 0.4 0.0 1.3 7.3 0.1 0.0 111.9 0.2 0.1 0.9 25.6 0.1 0.0 0.3 69.5 161.1 2.1 0.0 0.1 284.6 0.0 191.7 0.0 0.0 0.1 0.3 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.6 0.0 0.0 0.0 0.0 0.0 2.7 0.0 0.0 0.0 0.2 0.7 0.9 2.9 0.8 0.8 0.2 0.8 0.8 1.3 0.7 KRT4 "CK4, CYK4, K4" ENSG00000170477 "Keratin 4" P19013 12 52806549-52814551 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 8 "esophagus: 637.8;lymphoid tissue: 403.6;tongue: 174.6" "Group enriched" "Detected in some" 30 "HaCaT: 94.2;SK-BR-3: 38.2" "Group enriched" "Detected in many" 5 "cervical cancer: 94.3;head and neck cancer: 151.8;stomach cancer: 73.1;urothelial cancer: 38.5" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB002154, HPA034881" Enhanced Supported "Intermediate filaments" 540000000 "Intermediate filaments" "CAB002154: AB_563803, HPA034881: " "unprognostic (4.04e-1)" "unprognostic (3.22e-3)" "unprognostic (5.16e-3)" "unprognostic (8.52e-3)" "unprognostic (1.20e-1)" "unprognostic (2.64e-1)" "unprognostic (1.84e-1)" "prognostic unfavourable (3.26e-4)" "unprognostic (2.85e-3)" "unprognostic (2.84e-2)" "unprognostic (2.58e-11)" "unprognostic (1.64e-1)" "unprognostic (6.97e-2)" "unprognostic (1.16e-1)" "prognostic unfavourable (6.26e-4)" 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.0 0.1 25.5 0.1 0.0 0.0 0.1 2.5 0.1 637.8 0.3 0.1 0.2 0.0 0.0 0.1 0.1 0.6 0.1 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.0 48.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.1 174.6 403.6 0.2 20.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 94.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 38.2 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 KRT8 "CARD2, CK8, CYK8, K2C8, K8, KO" ENSG00000170421 "Keratin 8" P05787 12 52897187-52949954 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 102.9" "Cell line enhanced" "Detected in many" "A549: 224.1;BEWO: 150.2;CACO-2: 278.9;CAPAN-2: 176.2;MCF7: 376.4;SK-BR-3: 191.3;T-47d: 160.9" "Low cancer specificity" "Detected in many" "Region enriched" "Detected in many" 5 "pons and medulla: 13.7" "Cell type enhanced" "Detected in some" "plasmacytoid DC: 4.9" "Group enriched" "Detected in many" 4 "dendritic cells: 4.9;granulocytes: 3.2;NK-cells: 1.6" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB000131, CAB001696, HPA049866" Enhanced Supported "Intermediate filaments" 920000000 "Intermediate filaments" "CAB000131: AB_2281144, CAB001696: , HPA049866: " "unprognostic (5.72e-2)" "unprognostic (2.29e-1)" "unprognostic (2.49e-2)" "unprognostic (1.52e-1)" "unprognostic (2.76e-2)" "unprognostic (4.86e-3)" "unprognostic (3.10e-2)" "unprognostic (2.52e-2)" "unprognostic (1.92e-1)" "unprognostic (4.58e-1)" "prognostic unfavourable (1.51e-4)" "unprognostic (8.99e-2)" "unprognostic (2.08e-2)" "unprognostic (2.83e-2)" "unprognostic (3.18e-1)" "unprognostic (3.68e-1)" "unprognostic (1.19e-2)" 13.4 4.8 2.0 11.0 1.5 0.0 13.9 2.7 1.3 15.1 90.2 2.1 29.8 87.2 11.1 18.3 19.3 10.4 20.3 17.6 1.1 0.2 28.8 55.8 20.1 18.4 1.4 1.2 10.6 75.9 4.0 31.8 28.9 13.7 25.2 45.0 12.1 36.9 46.0 3.7 5.0 102.9 5.2 3.3 14.3 61.8 5.1 1.2 2.9 27.6 9.2 11.6 27.1 10.5 0.7 4.9 3.2 0.7 1.6 0.6 0.5 99.5 224.1 0.0 0.2 0.0 0.1 150.2 0.4 1.7 0.2 0.2 278.9 176.2 0.0 42.6 0.5 34.8 0.6 27.6 0.2 0.1 4.8 0.1 46.7 79.7 8.1 0.0 0.0 0.3 0.4 0.5 1.9 0.6 17.1 0.0 0.0 376.4 0.2 0.3 15.6 4.9 0.1 0.0 0.5 44.4 49.4 4.8 0.1 39.0 191.3 0.3 160.9 0.3 0.6 0.2 16.9 0.3 0.3 0.0 0.2 0.2 0.1 0.0 0.4 3.2 0.5 0.6 0.6 0.7 0.4 0.3 0.4 0.3 2.1 0.7 0.4 0.5 1.4 1.6 0.3 4.9 0.5 0.5 2.0 1.5 2.7 1.3 1.1 0.2 1.4 1.2 13.7 1.2 KTN1 "CG1, KIAA0004, KNT" ENSG00000126777 "Kinectin 1" Q86UP2 14 55559072-55701526 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003178, CAB015331, HPA017876" Enhanced Enhanced "Endoplasmic reticulum" "Endoplasmic reticulum" "CAB015331: , HPA003178: AB_1079218, HPA017876: AB_1852652" "unprognostic (7.00e-3)" "unprognostic (2.99e-2)" "unprognostic (8.60e-2)" "unprognostic (5.50e-2)" "unprognostic (2.49e-1)" "prognostic unfavourable (6.83e-5)" "prognostic unfavourable (3.76e-4)" "unprognostic (1.75e-1)" "unprognostic (1.21e-2)" "unprognostic (1.01e-1)" "unprognostic (9.08e-2)" "unprognostic (8.72e-2)" "prognostic favourable (1.01e-6)" "unprognostic (1.27e-1)" "unprognostic (2.75e-1)" "unprognostic (1.30e-1)" "unprognostic (1.04e-1)" 26.5 27.5 30.8 18.9 37.3 9.5 44.2 30.8 35.2 22.7 28.8 15.8 23.4 13.0 18.8 30.8 26.1 16.8 18.1 36.1 32.2 25.3 33.1 31.8 21.2 16.9 39.3 24.5 23.1 22.8 48.3 54.7 21.3 49.5 26.9 28.7 13.1 21.4 24.0 101.9 41.4 20.1 40.5 51.9 22.1 18.9 40.9 42.0 14.5 33.3 37.9 17.9 32.7 39.7 35.6 58.3 27.0 15.5 19.6 24.0 4.8 40.2 27.9 20.9 22.7 28.8 27.6 30.3 32.9 26.5 20.7 18.4 18.6 50.2 31.1 47.1 33.8 75.5 25.5 28.7 35.0 52.2 14.0 22.0 46.2 35.2 27.3 32.2 17.8 25.7 26.3 25.5 44.3 33.9 21.4 18.2 39.7 31.5 27.6 19.1 16.1 41.6 22.0 54.9 14.8 51.9 63.4 25.7 21.5 52.2 24.0 28.9 24.9 20.6 47.8 42.3 54.3 21.7 30.9 8.3 11.1 23.2 49.5 18.9 23.4 27.0 14.8 14.6 19.6 13.1 18.7 28.3 23.2 22.1 14.2 35.6 24.0 20.6 9.4 19.6 15.5 58.3 14.8 4.8 30.8 37.3 30.8 35.2 32.2 25.3 39.3 24.5 49.5 42.0 LALBA LYZL7 ENSG00000167531 "Lactalbumin alpha" P00709 12 48567684-48570066 "Cancer-related genes, Predicted secreted proteins" "Lactose biosynthesis" "Milk protein" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 194 "breast: 217.7" "Cell line enhanced" "Detected in some" "HDLM-2: 1.5;MCF7: 1.3" "Cancer enriched" "Detected in single" 599 "breast cancer: 29.9" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in some" "Not detected" "Not detected" "CAB026343, HPA029855, HPA029856" Enhanced "Secreted in female reproductive system" "CAB026343: , HPA029855: AB_2673222, HPA029856: AB_10671362" "unprognostic (7.85e-2)" 0.0 0.0 0.0 0.0 0.0 0.0 217.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 LAMB1 CLM ENSG00000091136 "Laminin subunit beta 1" P07942 7 107923799-108003255 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Cell adhesion" "Cancer-related genes, Lissencephaly" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "ASC diff: 81.0;ASC TERT1: 106.9;HSkMC: 104.6;TIME: 77.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004056, HPA004132, CAB004256" Enhanced "Secreted to extracellular matrix" 140000000 "CAB004256: AB_627867, HPA004056: AB_1079226, HPA004132: AB_1079225" "unprognostic (2.39e-1)" "unprognostic (6.45e-3)" "unprognostic (2.01e-1)" "unprognostic (6.75e-2)" "unprognostic (3.45e-3)" "unprognostic (8.26e-2)" "prognostic unfavourable (2.07e-4)" "unprognostic (3.77e-2)" "unprognostic (1.04e-2)" "unprognostic (2.04e-2)" "unprognostic (3.44e-1)" "unprognostic (5.01e-2)" "unprognostic (2.87e-2)" "unprognostic (4.50e-3)" "unprognostic (1.75e-1)" "unprognostic (4.45e-2)" "unprognostic (1.46e-1)" 47.3 9.9 5.4 11.8 9.9 0.0 36.4 7.0 5.7 20.3 29.4 1.9 9.3 13.2 31.8 16.8 20.5 18.5 21.2 36.2 2.5 1.4 36.9 6.8 39.4 18.2 3.1 3.9 16.5 20.1 3.3 10.9 57.5 6.9 25.1 17.8 20.4 10.4 13.4 15.8 13.8 24.2 27.0 4.6 28.5 20.3 13.3 2.6 6.7 31.8 7.8 5.5 28.2 20.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 12.3 17.7 10.7 0.5 81.0 106.9 42.2 14.8 22.4 8.3 9.0 37.2 21.7 0.0 21.4 24.2 5.4 3.0 17.9 6.6 0.0 3.2 0.7 7.3 15.6 54.6 0.0 0.8 104.6 6.8 21.3 24.6 56.4 2.2 0.0 17.7 4.4 0.0 0.0 6.3 12.8 0.1 7.5 0.0 44.2 12.6 3.8 21.6 10.4 14.7 10.0 4.9 0.1 77.4 23.9 6.9 8.1 17.6 0.0 0.0 0.0 12.2 0.0 44.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.4 9.9 7.0 5.7 2.5 1.4 3.1 3.9 6.9 2.6 LAMC1 LAMB2 ENSG00000135862 "Laminin subunit gamma 1" P11047 1 183023460-183145592 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Cell adhesion" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "ASC diff: 167.8;ASC TERT1: 92.4;HSkMC: 104.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 13 "memory B-cell: 1.1;naive B-cell: 3.2;plasmacytoid DC: 1.3" "Group enriched" "Detected in many" 15 "B-cells: 3.2;dendritic cells: 1.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001908, HPA001909, CAB004486, CAB078163" Enhanced Approved "Endoplasmic reticulum,Plasma membrane" "Secreted to extracellular matrix" 90000000 "Endoplasmic reticulum, Plasma membrane" "CAB004486: AB_627870, CAB078163: , HPA001908: AB_1079229, HPA001909: AB_1079230" "unprognostic (1.46e-1)" "unprognostic (1.05e-2)" "unprognostic (8.30e-2)" "unprognostic (8.84e-3)" "unprognostic (3.75e-2)" "unprognostic (1.02e-1)" "unprognostic (1.55e-2)" "unprognostic (1.54e-2)" "unprognostic (1.38e-2)" "unprognostic (2.71e-2)" "unprognostic (1.10e-1)" "unprognostic (1.80e-1)" "unprognostic (1.88e-3)" "unprognostic (1.10e-3)" "unprognostic (1.53e-1)" "unprognostic (1.54e-1)" "prognostic unfavourable (8.85e-5)" 49.0 6.8 2.9 11.3 4.0 0.2 51.5 5.9 3.4 30.4 27.7 2.8 12.8 4.9 30.5 28.7 31.5 21.5 25.9 39.5 3.4 2.0 10.0 6.8 22.5 10.6 3.9 2.7 22.7 9.8 7.4 4.1 73.1 3.5 23.9 11.4 11.7 11.6 17.3 32.2 15.6 17.6 41.3 3.0 4.7 22.3 16.1 2.7 3.5 21.7 16.4 7.3 40.2 37.6 3.2 1.3 0.0 0.1 0.0 0.0 0.2 5.1 8.4 27.7 7.8 167.8 92.4 42.0 38.0 38.2 15.3 9.1 24.9 5.9 1.8 17.6 18.2 12.9 5.2 10.0 11.8 0.0 5.3 0.0 7.6 9.0 26.4 1.6 0.9 104.0 5.4 18.3 14.5 26.7 0.0 5.7 18.6 2.2 0.0 1.7 11.2 1.6 1.3 23.4 0.9 24.8 13.7 1.8 5.2 10.0 0.0 9.7 2.1 4.3 49.2 18.8 7.4 17.3 9.5 2.2 0.0 1.2 15.5 1.2 18.1 0.0 0.1 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 3.2 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.2 2.9 4.0 5.9 3.4 3.4 2.0 3.9 2.7 3.5 2.7 LASP1 "Lasp-1, MLN50" ENSG00000002834 "LIM and SH3 protein 1" Q14847 17 38869859-38921770 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Ion transport, Transport" Actin-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "intestine: 124.5" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA012072, CAB022049" Enhanced Supported "Plasma membrane,Focal adhesion sites,Cytosol" 26000000 "Plasma membrane, Cytosol" "Focal adhesion sites" "CAB022049: , HPA012072: AB_1852714" "unprognostic (1.23e-1)" "unprognostic (2.09e-2)" "unprognostic (1.77e-1)" "prognostic unfavourable (4.57e-4)" "unprognostic (1.47e-1)" "unprognostic (3.03e-2)" "prognostic unfavourable (2.41e-4)" "unprognostic (1.06e-3)" "unprognostic (2.24e-1)" "unprognostic (9.60e-2)" "unprognostic (9.87e-3)" "unprognostic (1.01e-1)" "unprognostic (9.65e-3)" "unprognostic (1.29e-3)" "unprognostic (3.95e-2)" "unprognostic (1.60e-3)" "unprognostic (4.53e-2)" 51.2 20.0 23.8 40.3 22.4 45.4 35.5 15.5 25.7 23.6 57.4 16.3 18.7 54.4 23.4 24.1 22.4 20.8 48.3 15.2 18.4 23.3 33.1 47.5 33.3 44.2 20.0 14.3 28.4 30.1 10.1 17.6 40.0 16.1 18.9 38.6 24.2 22.4 24.1 10.7 18.3 124.5 21.3 12.2 43.1 39.5 13.9 12.9 40.5 18.3 18.7 33.7 22.0 28.3 6.4 13.9 34.0 19.9 17.3 16.5 13.1 34.8 72.7 21.3 18.8 31.3 34.0 36.7 43.9 42.9 46.3 34.0 21.7 38.0 15.9 36.7 67.8 55.6 9.6 33.4 40.5 11.6 5.2 7.6 21.0 37.7 29.7 17.5 23.1 30.1 11.7 39.2 11.1 31.0 12.9 5.3 64.3 11.5 20.8 27.0 10.6 18.2 11.8 11.3 20.1 56.8 30.7 3.2 7.8 26.1 27.4 22.7 43.3 21.4 54.1 27.8 40.5 32.4 26.6 13.7 18.1 12.3 29.3 15.8 33.4 9.9 14.8 16.8 16.5 17.1 11.3 6.4 8.4 11.0 13.9 6.3 7.2 10.9 34.0 17.3 19.9 10.7 10.7 13.1 23.8 22.4 15.5 25.7 18.4 23.3 20.0 14.3 16.1 12.9 LCK ENSG00000182866 "LCK proto-oncogene, Src family tyrosine kinase" P06239 1 32251239-32286165 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Host-virus interaction" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 8 "blood: 112.2;lymphoid tissue: 153.0" "Group enriched" "Detected in some" 6 "MOLT-4: 98.9;U-698: 57.0" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in many" 14 "gdT-cell: 83.4;MAIT T-cell: 77.5;memory CD4 T-cell: 86.1;memory CD8 T-cell: 90.2;naive CD4 T-cell: 97.0;naive CD8 T-cell: 91.3;NK-cell: 42.8;T-reg: 112.2" "Group enriched" "Detected in many" 13 "NK-cells: 42.8;T-cells: 112.2" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA003494, CAB003816" Enhanced Approved "Golgi apparatus" "Golgi apparatus" "CAB003816: AB_562158, HPA003494: AB_1852751" "unprognostic (6.38e-3)" "unprognostic (5.45e-3)" "unprognostic (8.39e-2)" "prognostic favourable (2.96e-6)" "unprognostic (2.20e-2)" "prognostic favourable (2.91e-4)" "unprognostic (4.78e-3)" "unprognostic (1.33e-2)" "prognostic favourable (5.65e-5)" "unprognostic (3.07e-2)" "unprognostic (3.80e-2)" "unprognostic (2.83e-1)" "prognostic unfavourable (2.60e-5)" "unprognostic (8.15e-2)" "unprognostic (4.05e-2)" "unprognostic (7.39e-2)" "unprognostic (1.17e-2)" 2.6 0.7 0.4 28.2 0.5 3.8 1.3 0.3 0.5 1.7 3.9 0.5 0.9 2.2 1.1 4.5 2.3 1.6 3.8 1.0 0.4 0.4 3.0 2.3 6.6 34.9 0.9 0.5 1.2 0.8 0.0 0.8 0.7 0.6 2.2 1.9 1.3 8.4 1.3 0.9 1.0 16.5 0.7 1.0 28.9 3.5 0.7 0.5 153.0 2.9 1.5 27.1 5.8 2.1 6.1 0.5 2.5 0.3 42.8 112.2 109.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 12.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 98.9 0.0 1.1 0.0 3.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 57.0 0.0 0.0 0.0 0.6 0.3 0.4 83.4 0.3 77.5 4.0 86.1 90.2 0.3 6.1 97.0 91.3 2.5 42.8 0.3 0.5 112.2 109.3 0.4 0.5 0.3 0.5 0.4 0.4 0.9 0.5 0.6 0.5 LCP1 "CP64, L-PLASTIN, LC64P, PLS2" ENSG00000136167 "Lymphocyte cytosolic protein 1" P13796 13 46125920-46211871 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" Actin-binding "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 188.6;lymphoid tissue: 118.2" "Cell line enhanced" "Detected in many" "Daudi: 82.6;HDLM-2: 75.5;HL-60: 80.2;HMC-1: 85.1;THP-1: 74.8;U-698: 106.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019493, CAB020673" Enhanced Approved "Plasma membrane,Actin filaments,Cytosol" 2200000000 "Plasma membrane, Cytosol" "Actin filaments" "CAB020673: , HPA019493: AB_1855457" "unprognostic (2.79e-2)" "unprognostic (8.20e-3)" "unprognostic (1.19e-2)" "unprognostic (3.95e-3)" "unprognostic (1.19e-1)" "unprognostic (2.84e-2)" "unprognostic (2.70e-1)" "unprognostic (4.99e-2)" "unprognostic (6.70e-3)" "unprognostic (2.54e-1)" "unprognostic (5.47e-2)" "unprognostic (3.63e-1)" "unprognostic (3.32e-3)" "unprognostic (2.51e-1)" "unprognostic (1.02e-1)" "unprognostic (7.50e-2)" "unprognostic (2.92e-1)" 57.1 10.0 5.6 44.3 9.4 71.2 8.7 3.9 4.6 3.6 6.2 4.5 5.0 4.5 5.3 43.1 6.2 8.3 8.9 5.5 4.3 3.8 7.2 12.2 33.7 59.1 12.0 1.0 5.7 3.9 0.1 2.8 24.7 7.7 21.5 8.1 5.5 9.5 2.5 3.5 6.8 21.7 6.5 11.9 112.9 6.1 8.2 9.2 118.2 4.5 4.1 68.7 14.0 7.1 25.4 79.3 133.5 127.6 43.2 67.2 188.6 3.3 0.0 0.1 0.0 0.0 0.0 40.1 0.0 0.1 0.3 0.2 22.1 0.1 82.6 17.6 0.0 0.1 0.0 0.0 0.3 75.5 19.6 17.8 0.0 0.0 0.0 80.2 85.1 0.2 0.0 0.1 0.1 0.0 9.3 55.0 0.0 0.1 56.8 55.5 0.0 0.8 42.3 0.1 59.0 0.0 22.8 0.1 0.7 0.1 8.8 0.6 0.4 74.8 0.2 2.1 1.3 0.1 2.4 13.1 27.3 106.3 1.6 48.9 0.3 57.1 96.6 54.3 67.2 127.6 60.8 25.4 40.4 55.5 79.3 18.3 25.2 42.3 133.5 43.2 118.1 20.8 40.5 188.6 5.6 9.4 3.9 4.6 4.3 3.8 12.0 1.0 7.7 9.2 LCTL "FLJ33279, KLG, KLPH" ENSG00000188501 "Lactase like" Q6UWM7 15 66547179-66565979 "Cancer-related genes, Predicted membrane proteins" "Sensory transduction, Vision" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 10.4" "Cell line enhanced" "Detected in some" "EFO-21: 6.4;NTERA-2: 5.9;U-2 OS: 16.6;U-251 MG: 7.0" "Group enriched" "Detected in some" 5 "glioma: 1.5;melanoma: 0.6" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in some" "neutrophil: 3.9" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" HPA071640 Approved "Endoplasmic reticulum,Plasma membrane" "Plasma membrane" "Endoplasmic reticulum" "HPA071640: " "unprognostic (4.60e-2)" "unprognostic (5.46e-2)" "unprognostic (8.70e-2)" "unprognostic (1.56e-2)" "unprognostic (3.22e-3)" "unprognostic (3.53e-2)" "unprognostic (6.67e-2)" "unprognostic (1.06e-2)" "unprognostic (2.59e-2)" "unprognostic (1.04e-1)" "unprognostic (3.47e-1)" "unprognostic (4.51e-3)" "unprognostic (4.44e-16)" "unprognostic (6.06e-2)" "unprognostic (3.39e-1)" "unprognostic (5.48e-2)" "unprognostic (1.39e-1)" 0.4 0.7 6.0 0.9 4.3 3.1 0.4 0.7 3.1 0.4 0.5 3.1 0.0 1.4 0.8 0.9 0.7 0.3 1.0 0.4 3.3 1.2 0.4 0.4 0.4 1.0 5.3 3.1 0.6 0.7 0.2 0.4 0.3 4.9 0.4 0.3 1.1 0.6 0.3 3.0 2.6 0.7 0.4 10.4 0.8 0.7 1.5 2.3 0.0 0.5 0.0 0.2 0.3 0.3 0.9 0.6 3.9 0.7 1.0 0.5 0.2 0.3 0.3 3.2 0.3 0.1 0.1 0.8 0.8 0.0 0.1 0.4 0.4 0.4 0.5 6.4 0.2 0.7 0.0 0.0 0.2 0.2 0.2 0.7 1.0 1.6 0.0 0.2 0.4 0.4 0.0 0.3 0.0 0.0 0.4 0.4 0.2 0.1 0.3 0.4 5.9 0.1 0.2 3.5 0.3 0.0 0.4 0.4 0.3 0.1 0.3 1.8 0.4 0.5 0.4 1.7 16.6 0.6 7.0 0.2 0.2 0.2 2.2 0.7 3.0 1.6 0.7 0.5 0.5 0.4 0.3 0.4 0.5 0.3 0.2 0.9 0.5 0.4 3.9 1.0 0.4 0.6 0.5 0.2 6.0 4.3 0.7 2.7 3.3 1.2 5.3 3.1 4.9 2.3 LDHA ENSG00000134333 "Lactate dehydrogenase A" P00338 11 18394388-18408425 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" Oxidoreductase "Cancer-related genes, Disease mutation, FDA approved drug targets, Glycogen storage disease" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 249.1" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB015336, CAB069404" Uncertain Supported Vesicles,Cytosol 300000000 Cytosol Vesicles "CAB015336: AB_2134947, CAB069404: " "unprognostic (8.83e-2)" "prognostic unfavourable (2.78e-5)" "unprognostic (3.81e-2)" "unprognostic (1.73e-1)" "unprognostic (3.43e-3)" "unprognostic (4.66e-3)" "prognostic unfavourable (3.26e-8)" "prognostic unfavourable (2.27e-6)" "unprognostic (1.08e-1)" "unprognostic (1.88e-2)" "prognostic unfavourable (8.09e-6)" "unprognostic (1.76e-2)" "prognostic unfavourable (9.69e-9)" "unprognostic (4.15e-2)" "unprognostic (1.89e-1)" "unprognostic (3.07e-1)" "unprognostic (1.05e-2)" 84.2 56.4 24.5 52.6 32.5 64.0 56.0 22.3 40.2 38.1 53.5 13.5 9.1 60.5 24.9 36.2 77.7 29.0 31.6 59.4 24.4 33.0 100.1 249.1 37.1 59.4 29.7 25.7 49.7 34.1 10.5 16.4 49.7 44.3 33.3 51.2 45.9 46.3 37.0 199.6 70.2 128.3 50.7 35.5 45.0 31.2 25.9 23.9 45.0 56.4 90.6 60.1 81.9 44.8 27.6 76.5 29.1 61.2 32.8 52.2 72.1 131.7 82.0 3.1 46.2 72.2 49.3 44.0 127.5 135.5 112.0 166.7 36.6 21.7 99.7 41.9 128.8 106.6 82.0 195.4 242.9 34.0 48.5 34.5 74.9 62.8 17.8 85.1 25.9 49.2 90.1 44.0 44.1 66.1 48.6 48.0 131.1 34.9 70.0 53.9 19.8 102.6 45.4 32.7 83.5 178.0 30.6 24.6 30.4 69.1 57.0 23.6 26.8 20.3 59.5 140.3 50.9 122.1 1.5 38.2 55.9 95.9 200.8 44.1 47.2 28.9 53.1 29.1 38.1 61.2 42.6 27.6 50.2 40.1 76.5 19.2 32.8 33.3 18.1 32.8 59.5 25.8 52.2 72.1 24.5 32.5 22.3 40.2 24.4 33.0 29.7 25.7 44.3 23.9 LEF1 "TCF10, TCF1ALPHA, TCF7L3" ENSG00000138795 "Lymphoid enhancer binding factor 1" Q9UJU2 4 108047545-108168956 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation, Wnt signaling pathway" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "lymphoid tissue: 231.5" "Group enriched" "Detected in some" 5 "MOLT-4: 103.2;REH: 79.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "naive CD4 T-cell: 42.2" "Lineage enriched" "Detected in many" 5 "T-cells: 42.2" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA002087, CAB019405" Enhanced Approved Nucleoplasm Nucleoplasm "CAB019405: AB_823558, HPA002087: AB_1079245" "unprognostic (1.03e-3)" "unprognostic (7.36e-3)" "unprognostic (2.97e-2)" "prognostic favourable (1.37e-5)" "unprognostic (9.08e-2)" "unprognostic (5.24e-2)" "unprognostic (3.81e-2)" "unprognostic (1.10e-2)" "unprognostic (1.77e-1)" "unprognostic (5.21e-2)" "unprognostic (9.99e-2)" "unprognostic (1.37e-1)" "prognostic unfavourable (2.47e-6)" "unprognostic (1.12e-1)" "unprognostic (5.22e-2)" "unprognostic (7.88e-2)" "unprognostic (8.91e-2)" 0.9 13.5 3.5 9.3 5.4 7.6 2.0 1.6 3.4 3.6 1.0 2.9 0.8 0.4 6.0 3.5 3.4 5.0 2.8 0.5 4.7 5.2 2.7 0.3 2.4 25.3 4.9 1.9 1.8 0.8 0.0 1.1 7.8 3.1 2.8 1.0 1.6 3.1 0.7 0.5 2.4 3.9 2.9 4.4 7.0 0.9 8.2 2.3 231.5 2.7 1.3 20.6 4.8 3.2 0.3 0.1 0.5 0.0 8.9 42.2 9.5 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 1.3 0.3 0.8 4.5 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.6 0.0 3.2 1.2 0.0 0.0 0.0 4.0 0.6 0.0 0.1 0.0 0.1 0.0 2.3 0.0 0.5 0.1 103.2 0.0 0.3 0.2 79.7 1.5 0.0 0.4 0.2 0.5 0.9 0.0 0.0 15.2 0.4 0.0 0.0 2.2 1.8 0.0 2.6 6.7 2.8 18.3 1.3 0.0 8.8 0.0 0.0 0.0 2.6 0.0 0.5 0.1 19.7 8.8 0.0 0.3 42.2 29.2 0.5 8.9 0.0 0.1 25.7 9.5 3.5 5.4 1.6 3.4 4.7 5.2 4.9 1.9 3.1 2.3 LEP "OB, OBS" ENSG00000174697 Leptin P41159 7 128241284-128257628 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins" "Cancer-related genes, Diabetes mellitus, Disease mutation, Obesity" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 15 "adipose tissue: 85.2;breast: 63.7;placenta: 24.3" "Group enriched" "Detected in some" 9 "BEWO: 6.8;HSkMC: 2.8" "Cancer enhanced" "Detected in some" "breast cancer: 1.6" "Not detected" "Not detected" "Cell type enriched" "Detected in single" 4 "neutrophil: 3.8" "Lineage enriched" "Detected in single" 7 "granulocytes: 3.8" "Not detected" "Not detected" "Low region specificity" "Detected in many" CAB010490 Approved "Secreted to blood" 26000000 "CAB010490: AB_2296951" "unprognostic (8.19e-3)" "unprognostic (5.33e-1)" "unprognostic (1.60e-4)" "unprognostic (1.19e-1)" "unprognostic (7.99e-3)" "unprognostic (1.83e-1)" "unprognostic (6.56e-3)" "unprognostic (1.98e-2)" "unprognostic (1.42e-2)" "unprognostic (2.45e-2)" "unprognostic (2.63e-1)" "unprognostic (1.02e-3)" "unprognostic (2.83e-1)" "unprognostic (1.92e-1)" "unprognostic (2.23e-2)" "unprognostic (6.84e-2)" 85.2 0.3 0.0 1.5 0.0 0.0 63.7 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.5 0.7 0.0 0.0 0.1 0.0 0.4 2.0 0.0 0.0 0.1 0.7 0.0 0.0 24.3 0.0 0.0 0.1 0.0 0.4 0.0 0.6 1.1 0.4 0.2 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.1 0.0 1.5 2.1 0.4 0.4 3.8 0.5 0.5 0.3 0.2 0.0 0.2 0.2 0.4 0.3 0.0 6.8 0.1 0.0 0.0 0.0 0.0 0.2 0.4 0.2 0.0 0.3 0.0 0.0 0.0 0.2 0.0 0.2 0.1 0.0 0.0 0.1 0.3 2.8 0.0 0.0 0.0 0.0 0.1 0.3 0.0 0.4 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.0 0.3 0.2 0.3 0.2 0.4 0.1 0.3 0.1 0.0 0.2 0.3 0.5 0.2 0.2 0.1 0.3 0.4 0.2 0.4 0.9 0.5 0.3 0.3 0.3 0.2 0.2 0.2 0.2 0.1 0.4 0.2 0.3 3.8 0.5 0.4 0.4 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 LEPR "CD295, OBR" ENSG00000116678 "Leptin receptor" P48357 1 65420652-65641559 "Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins" Receptor "Cancer-related genes, FDA approved drug targets, Obesity" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 82.8" "Cell line enhanced" "Detected in many" "K-562: 46.1;RPTEC TERT1: 22.3" "Cancer enriched" "Detected in many" 7 "liver cancer: 13.1" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "basophil: 6.9" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in some" HPA030899 Approved Supported "Secreted to blood" 8235000 8300000 "HPA030899: AB_10610003" "unprognostic (1.59e-2)" "unprognostic (1.09e-3)" "unprognostic (3.09e-1)" "unprognostic (8.95e-2)" "unprognostic (2.32e-1)" "unprognostic (2.64e-1)" "unprognostic (2.58e-1)" "unprognostic (2.30e-1)" "unprognostic (1.78e-1)" "unprognostic (6.59e-3)" "unprognostic (1.79e-1)" "unprognostic (2.41e-1)" "unprognostic (7.53e-2)" "unprognostic (1.11e-1)" "unprognostic (2.27e-1)" "unprognostic (3.49e-2)" "unprognostic (1.73e-1)" 15.9 5.5 3.8 3.7 4.3 3.3 23.5 2.5 3.9 15.0 9.2 5.6 5.4 3.2 20.6 7.3 10.9 11.7 10.1 9.2 4.3 4.9 14.6 82.8 20.3 9.0 4.9 3.3 18.4 16.7 3.9 13.1 12.8 8.2 10.8 4.1 18.1 12.0 5.7 5.6 10.2 7.3 12.9 7.0 6.4 11.9 6.6 3.1 1.9 13.1 11.2 6.9 13.6 8.6 0.6 1.8 6.9 1.9 1.1 2.3 1.8 1.3 0.8 1.1 1.2 5.0 4.6 3.8 5.9 3.4 2.0 1.9 0.6 3.2 0.5 4.4 7.4 1.1 0.9 5.1 5.5 6.9 1.5 7.7 3.5 0.1 3.0 0.5 0.6 13.0 3.0 1.2 4.6 5.8 46.1 0.9 9.5 0.3 0.6 0.1 1.8 0.1 0.1 0.9 0.3 22.3 0.6 0.7 11.3 1.4 0.6 1.6 2.1 2.0 2.2 2.1 4.3 0.4 3.2 1.3 0.8 0.2 4.4 2.2 2.0 6.9 1.9 2.8 1.3 1.5 1.3 0.6 1.1 1.1 1.8 0.3 0.9 1.5 1.1 1.1 1.7 1.2 2.3 1.8 3.8 4.3 2.5 3.9 4.3 4.9 4.9 3.3 8.2 3.1 LGALS3 "GALIG, LGALS2, MAC-2" ENSG00000131981 "Galectin 3" P17931 14 55124110-55145413 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Differentiation, Immunity, Innate immunity, mRNA processing, mRNA splicing" "IgE-binding protein" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "ASC TERT1: 93.8;CAPAN-2: 74.5;SK-MEL-30: 175.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 4 "classical monocyte: 67.4;intermediate monocyte: 55.4;myeloid DC: 41.7;non-classical monocyte: 44.2;T-reg: 25.9" "Group enriched" "Detected in all" 12 "dendritic cells: 41.7;monocytes: 67.4;T-cells: 25.9" "Low region specificity" "Detected in many" "Low region specificity" "Detected in single" "HPA003162, CAB005191" Enhanced Supported "Nucleoplasm,Plasma membrane,Cytosol" "Secreted to blood" 2300000 "Nucleoplasm, Cytosol" "Plasma membrane" "CAB005191: AB_2136784, HPA003162: AB_1078937" "unprognostic (1.42e-1)" "unprognostic (9.79e-2)" "unprognostic (1.14e-1)" "unprognostic (3.15e-1)" "unprognostic (2.46e-2)" "unprognostic (3.34e-2)" "unprognostic (1.73e-3)" "unprognostic (1.00e-1)" "unprognostic (2.13e-2)" "unprognostic (1.28e-1)" "unprognostic (1.08e-3)" "unprognostic (5.97e-2)" "unprognostic (8.52e-2)" "unprognostic (1.44e-1)" "unprognostic (2.96e-2)" "unprognostic (2.65e-3)" "unprognostic (7.60e-3)" 95.7 11.0 10.4 50.9 13.6 29.8 53.2 6.5 11.7 54.1 127.1 6.1 42.4 75.7 50.3 30.7 76.1 26.1 83.9 42.3 8.4 5.7 19.9 3.9 65.5 16.6 8.5 9.4 58.9 24.2 0.5 11.0 78.7 5.5 51.7 93.7 25.7 78.3 51.7 31.3 76.1 182.4 48.2 8.7 11.1 36.9 20.4 5.7 5.5 18.0 65.7 41.7 41.1 44.4 1.3 41.7 3.6 67.4 2.5 25.9 37.2 22.4 7.2 0.2 0.1 46.8 93.8 27.4 18.0 37.9 5.0 8.9 15.5 74.5 0.0 9.5 20.9 22.5 0.4 18.8 2.8 26.6 0.3 0.0 8.0 7.1 35.5 0.0 0.0 29.3 28.7 5.7 12.1 7.8 0.1 21.7 11.3 15.1 0.0 5.4 0.4 20.2 0.0 0.9 1.6 46.8 30.0 0.6 1.7 42.1 0.0 175.1 18.5 2.4 14.2 23.7 3.3 8.8 0.3 12.1 38.3 0.1 34.1 1.4 2.5 1.7 67.4 3.4 1.8 55.4 11.4 1.3 6.8 5.1 41.7 0.4 0.3 1.0 3.6 2.5 44.2 1.1 25.9 37.2 10.4 13.6 6.5 11.7 8.4 5.7 8.5 9.4 5.5 5.7 LGALS3BP "90K, BTBD17B, CyCAP, gp90, M2BP, MAC-2-BP, TANGO10B" ENSG00000108679 "Galectin 3 binding protein" Q08380 17 78971238-78980109 "Cancer-related genes, Plasma proteins, Predicted secreted proteins" "Cell adhesion" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "CAPAN-2: 75.9;SK-BR-3: 172.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "naive CD4 T-cell: 30.2" "Group enriched" "Detected in all" 6 "monocytes: 10.6;T-cells: 30.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA000410, HPA000554" Uncertain "Secreted to blood" 11000000000 "HPA000410: , HPA000554: AB_1079246" "unprognostic (1.23e-2)" "unprognostic (1.40e-2)" "unprognostic (1.03e-1)" "unprognostic (2.22e-2)" "unprognostic (9.63e-3)" "unprognostic (1.62e-2)" "unprognostic (1.68e-2)" "unprognostic (1.48e-1)" "unprognostic (3.12e-2)" "unprognostic (1.57e-2)" "unprognostic (4.55e-1)" "unprognostic (1.40e-1)" "prognostic unfavourable (1.07e-6)" "unprognostic (1.58e-1)" "unprognostic (1.65e-2)" "unprognostic (2.53e-1)" "unprognostic (5.43e-2)" 34.8 60.8 10.0 18.7 16.2 9.0 28.4 3.7 21.4 36.4 40.9 49.8 32.9 61.9 31.9 43.8 34.2 32.2 85.0 73.4 12.9 16.5 27.9 23.6 33.7 11.2 28.7 10.1 45.9 17.2 18.6 36.7 43.1 31.6 39.9 16.2 35.0 100.6 39.8 5.0 9.3 56.5 20.0 43.6 17.3 62.1 29.7 20.8 25.3 37.1 21.3 21.3 30.4 30.8 2.0 3.1 2.0 10.6 3.3 30.2 10.0 41.7 26.2 0.6 0.9 13.1 15.5 12.8 5.7 3.8 30.5 60.4 10.6 75.9 0.2 36.4 2.7 17.7 4.4 16.4 0.8 0.1 31.4 3.2 22.7 42.6 31.5 0.0 2.7 26.0 9.3 16.1 1.1 0.8 0.3 0.1 6.7 6.0 11.8 0.5 1.2 16.7 8.4 18.3 0.4 11.4 36.3 21.2 24.2 5.1 172.9 67.9 5.0 1.4 1.5 23.5 16.1 0.5 19.2 0.0 0.2 0.2 29.9 8.3 22.4 0.3 7.5 2.0 5.2 10.6 10.8 2.0 18.6 7.6 3.1 1.1 30.2 14.0 0.6 3.3 4.9 0.2 10.0 10.0 10.0 16.2 3.7 21.4 12.9 16.5 28.7 10.1 31.6 20.8 LGALS4 GAL4 ENSG00000171747 "Galectin 4" P56470 19 38801671-38813364 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 9 "gallbladder: 157.1;intestine: 326.8;lymphoid tissue: 83.5" "Cell line enhanced" "Detected in some" "CACO-2: 3.0;NB-4: 2.6;RT4: 6.9;SH-SY5Y: 2.5" "Group enriched" "Detected in many" 21 "colorectal cancer: 450.7;liver cancer: 133.6;pancreatic cancer: 213.7;stomach cancer: 190.0" "Not detected" "Not detected" "Cell type enriched" "Detected in single" 8 "basophil: 1.7" "Lineage enriched" "Detected in single" 8 "granulocytes: 1.7" "Low region specificity" "Detected in many" "Low region specificity" "Detected in single" "CAB025653, HPA031184, HPA031185, HPA031186" Enhanced Uncertain "Plasma membrane" 92000 "Plasma membrane" "CAB025653: , HPA031184: AB_2673776, HPA031185: AB_2673777, HPA031186: AB_2673778" "unprognostic (1.11e-1)" "unprognostic (1.12e-1)" "unprognostic (2.57e-3)" "unprognostic (7.88e-2)" "unprognostic (1.12e-1)" "unprognostic (1.61e-2)" "unprognostic (5.01e-2)" "unprognostic (5.34e-2)" "unprognostic (1.54e-1)" "unprognostic (7.58e-2)" "unprognostic (3.80e-2)" "unprognostic (1.48e-2)" "prognostic unfavourable (2.28e-4)" "unprognostic (1.69e-1)" "unprognostic (3.38e-1)" "unprognostic (9.71e-2)" "prognostic favourable (3.21e-4)" 0.3 0.2 0.2 83.5 0.2 0.0 0.3 0.3 0.2 0.3 190.6 0.3 0.3 65.5 0.3 0.5 0.6 0.5 157.1 0.2 0.2 0.2 0.4 20.3 1.5 0.2 0.2 0.2 0.3 8.3 0.0 0.2 0.2 0.2 0.8 75.8 0.3 0.3 0.4 0.3 0.3 326.8 4.9 0.2 0.6 10.5 0.2 0.2 0.3 0.4 0.3 0.2 2.7 0.3 0.0 0.0 1.7 0.0 0.0 0.2 0.0 0.1 0.6 0.2 0.0 0.7 0.1 2.1 0.0 0.0 0.1 0.1 3.0 0.5 0.5 0.4 0.2 0.0 0.0 0.0 0.0 0.7 0.1 0.5 0.3 0.0 0.3 0.0 0.3 0.0 2.1 0.0 0.0 0.1 0.1 0.2 0.0 0.6 0.3 2.6 0.0 0.0 0.3 0.2 2.1 0.2 6.9 0.3 2.5 0.2 0.2 0.1 0.4 2.3 0.0 0.0 0.6 1.7 0.1 0.7 0.4 0.2 0.0 0.2 0.3 1.7 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.3 0.2 0.2 0.2 0.2 0.2 0.2 0.2 LGMN "LGMN1, PRSC1" ENSG00000100600 Legumain Q99538 14 92703807-92748702 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Hydrolase, Protease, Thiol protease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Group enriched" "Detected in many" 4 "RPMI-8226: 127.6;U-266/70: 70.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in many" 11 "plasmacytoid DC: 54.2" "Lineage enriched" "Detected in many" 11 "dendritic cells: 54.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA001426 Enhanced Approved Nucleoplasm,Vesicles "Intracellular and membrane" 1200000 Vesicles Nucleoplasm "HPA001426: AB_1079247" "unprognostic (1.19e-1)" "unprognostic (1.16e-1)" "unprognostic (2.37e-1)" "unprognostic (1.52e-1)" "unprognostic (1.99e-1)" "unprognostic (3.29e-2)" "unprognostic (4.52e-2)" "unprognostic (1.31e-1)" "unprognostic (5.03e-2)" "unprognostic (3.50e-2)" "unprognostic (4.70e-2)" "unprognostic (2.47e-1)" "prognostic favourable (4.70e-4)" "unprognostic (8.06e-2)" "unprognostic (3.64e-2)" "unprognostic (7.18e-3)" "unprognostic (7.24e-2)" 42.9 16.3 8.6 17.4 10.7 3.5 19.9 5.8 17.9 13.3 22.3 11.7 13.9 24.2 12.1 48.1 17.4 14.1 32.7 38.8 10.3 10.1 87.6 44.6 31.5 42.4 8.3 10.1 20.5 14.6 54.4 9.7 113.6 9.9 22.0 24.5 23.2 22.6 8.4 17.3 11.9 37.1 23.3 11.5 58.3 23.7 14.0 7.9 17.2 36.8 19.2 17.3 31.4 18.2 4.7 54.2 0.7 0.8 1.0 4.3 1.7 4.8 7.0 4.7 8.6 14.6 11.8 16.4 10.5 10.0 10.9 12.9 5.4 8.7 2.7 15.5 17.1 12.1 0.0 9.0 5.2 0.2 5.4 0.1 3.9 6.2 4.3 0.1 0.4 8.3 4.4 10.5 6.0 12.9 1.0 22.6 0.7 6.5 1.2 0.2 2.3 4.8 1.2 4.1 127.6 11.8 19.0 5.1 3.5 14.5 8.9 7.5 6.6 0.0 7.0 5.4 6.9 9.7 3.1 70.2 8.2 3.6 3.0 0.1 10.3 0.7 0.4 0.1 0.2 0.8 0.4 4.7 1.4 0.4 5.0 3.4 4.3 2.5 0.5 1.0 0.2 54.2 2.6 1.7 8.6 10.7 5.8 17.9 10.3 10.1 8.3 10.1 9.9 7.9 LHB "CGB4, hLHB, LSH-B" ENSG00000104826 "Luteinizing hormone beta polypeptide" P01229 19 49015980-49017081 "Cancer-related genes, Disease related genes, Predicted secreted proteins" Hormone "Cancer-related genes, Disease mutation, Hypogonadotropic hypogonadism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 13 "pituitary gland: 301.4" "Cell line enhanced" "Detected in many" "A549: 6.5;U-266/84: 7.0" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "memory CD4 T-cell: 1.8;T-reg: 1.3" "Lineage enriched" "Detected in single" 12 "T-cells: 1.8" "CAB022241, CAB022707, HPA038925" Enhanced Approved Cytosol "Secreted to blood" Cytosol "CAB022241: , CAB022707: , HPA038925: " "unprognostic (8.12e-2)" "unprognostic (3.59e-1)" "unprognostic (2.34e-3)" "unprognostic (1.41e-2)" "unprognostic (8.89e-2)" "unprognostic (6.25e-2)" "unprognostic (3.90e-3)" "unprognostic (5.69e-2)" "unprognostic (7.04e-2)" "unprognostic (6.06e-2)" "prognostic unfavourable (6.78e-4)" "unprognostic (2.47e-2)" "unprognostic (1.68e-3)" "unprognostic (1.38e-1)" "unprognostic (4.46e-1)" "unprognostic (9.52e-2)" "unprognostic (4.86e-2)" 0.1 0.5 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 3.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.4 0.1 23.1 0.0 301.4 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.5 0.5 0.1 0.1 0.1 0.5 1.4 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.0 1.8 0.1 1.3 6.5 0.2 1.3 0.0 0.0 1.8 0.5 0.0 1.0 0.5 5.3 1.9 1.7 0.1 0.0 0.5 0.0 0.4 0.0 1.7 5.1 0.3 1.7 2.5 0.3 0.4 1.7 0.0 0.0 0.3 0.0 0.3 4.7 2.8 0.3 0.3 0.1 0.6 0.7 0.5 2.8 1.1 1.3 0.0 1.3 3.0 1.2 1.9 0.4 2.2 2.0 0.0 0.0 2.6 2.7 0.3 3.3 2.4 7.0 1.8 1.3 3.0 1.1 0.0 0.0 0.0 0.7 0.0 0.0 0.1 1.8 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 1.3 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.4 0.1 0.1 LHX1 "LIM-1, LIM1" ENSG00000273706 "LIM homeobox 1" P48742 17 36936785-36944612 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Differentiation, Neurogenesis, Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "brain: 15.0;kidney: 5.7;seminal vesicle: 7.1" "Cell line enhanced" "Detected in some" "HAP1: 6.2;HMC-1: 2.6;WM-115: 11.4" "Cancer enhanced" "Detected in some" "ovarian cancer: 8.1" "Cell type enhanced" "Detected in single" "memory CD8 T-cell: 1.1" "Lineage enhanced" "Detected in single" "T-cells: 1.1" "Region enhanced" "Detected in many" "cerebellum: 21.5" "Region enriched" "Detected in many" 4 "cerebellum: 20.4" "HPA044307, HPA073521, HPA074382" Enhanced Approved "Nucleoplasm,Nuclear membrane,Golgi apparatus" Nucleoplasm "Nuclear membrane, Golgi apparatus" "HPA044307: , HPA073521: , HPA074382: " "unprognostic (3.86e-5)" "unprognostic (1.64e-1)" "prognostic unfavourable (3.63e-5)" "unprognostic (3.85e-2)" "unprognostic (1.06e-4)" "unprognostic (2.67e-2)" "unprognostic (2.72e-1)" "unprognostic (1.52e-1)" "unprognostic (4.20e-3)" "unprognostic (1.74e-5)" "unprognostic (1.33e-1)" "unprognostic (8.62e-2)" "unprognostic (3.05e-2)" 0.1 0.0 0.0 0.1 0.0 0.0 0.0 15.0 0.0 0.2 0.0 0.0 1.8 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.1 5.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 7.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.0 0.0 1.1 0.1 1.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.7 0.0 0.0 6.2 0.0 0.0 0.0 0.2 0.0 0.0 0.2 0.0 0.0 2.6 0.0 0.1 0.0 1.9 0.0 0.0 0.0 0.0 1.6 0.0 0.1 0.2 1.3 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.1 0.4 0.0 0.0 1.9 0.0 1.5 0.0 0.0 0.0 0.1 0.0 11.4 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 1.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.4 0.1 LIF "CDF, DIA, HILDA" ENSG00000128342 "LIF, interleukin 6 family cytokine" P15018 22 30240447-30246851 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Cytokine, Growth factor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "gallbladder: 28.7" "Cell line enhanced" "Detected in many" "hTEC/SVTERT24-B: 35.5;U-138 MG: 39.6;U-251 MG: 28.6;U-87 MG: 31.3" "Low cancer specificity" "Detected in all" "Region enhanced" "Detected in many" "pons and medulla: 11.7" "Cell type enriched" "Detected in single" 5 "NK-cell: 1.2" "Lineage enriched" "Detected in single" 5 "NK-cells: 1.2" "Low region specificity" "Detected in some" "Not detected" "Not detected" "HPA018844, CAB025985" Uncertain Supported Cytosol "Secreted in other tissues" Cytosol "CAB025985: , HPA018844: AB_1852814" "unprognostic (1.28e-2)" "prognostic unfavourable (9.01e-4)" "unprognostic (8.79e-2)" "unprognostic (4.61e-2)" "unprognostic (7.36e-3)" "unprognostic (4.18e-3)" "unprognostic (1.17e-2)" "unprognostic (1.41e-2)" "unprognostic (3.18e-3)" "unprognostic (1.22e-1)" "unprognostic (8.10e-2)" "unprognostic (9.65e-2)" "prognostic unfavourable (6.78e-8)" "unprognostic (2.02e-1)" "unprognostic (6.40e-2)" "unprognostic (8.99e-2)" "unprognostic (4.71e-3)" 20.3 1.7 1.4 21.6 3.3 0.6 5.2 0.9 4.3 4.4 3.9 1.8 1.6 3.7 6.9 2.6 2.0 7.3 28.7 14.2 1.2 0.6 5.7 3.4 17.4 3.8 2.2 0.5 7.9 7.5 0.2 7.3 1.3 11.7 8.6 4.7 3.5 3.2 1.2 1.9 6.0 5.2 4.6 4.3 1.6 4.1 2.0 1.8 0.9 3.4 2.2 5.4 20.8 1.7 0.0 0.0 0.0 0.0 1.2 0.2 0.1 8.7 14.7 0.4 3.3 0.0 1.2 5.4 1.2 5.3 1.6 3.8 2.3 14.3 0.0 3.2 0.0 2.2 0.3 4.0 2.1 2.0 0.6 1.1 5.0 3.2 1.4 0.0 11.5 1.4 0.7 35.5 1.0 0.0 0.2 0.0 6.9 6.5 0.1 0.0 0.5 9.1 0.2 5.0 0.0 12.7 3.4 0.0 0.1 1.4 0.1 2.6 0.3 0.1 0.1 39.6 14.6 14.9 28.6 0.0 0.0 0.0 31.3 0.0 18.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.1 1.4 3.3 0.9 4.3 1.2 0.6 2.2 0.5 11.7 1.8 LIFR CD118 ENSG00000113594 "LIF receptor alpha" P42702 5 38474963-38608354 "Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" Receptor "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "AF22: 39.8;HHSteC: 17.0;SCLC-21H: 26.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004478, CAB010252" Approved "Nuclear speckles,Golgi apparatus" "Intracellular and membrane" 74000 "Nuclear speckles" "Golgi apparatus" "CAB010252: AB_2128043, HPA004478: " "unprognostic (6.00e-3)" "unprognostic (2.53e-1)" "unprognostic (1.05e-1)" "unprognostic (2.81e-3)" "unprognostic (8.80e-2)" "unprognostic (7.13e-2)" "unprognostic (1.11e-1)" "prognostic favourable (1.92e-4)" "unprognostic (1.78e-1)" "unprognostic (9.80e-2)" "unprognostic (2.73e-3)" "unprognostic (1.06e-1)" "prognostic favourable (1.40e-7)" "unprognostic (3.69e-2)" "unprognostic (1.15e-1)" "unprognostic (2.03e-2)" "unprognostic (1.65e-1)" 35.3 14.7 15.8 8.2 19.2 0.5 33.9 10.1 21.3 27.7 10.4 25.3 22.8 4.9 34.8 14.8 10.4 26.0 10.2 16.3 19.1 11.0 20.3 23.9 21.7 20.2 24.3 11.8 17.9 17.8 13.5 12.5 41.5 23.4 23.6 7.5 17.1 24.9 24.7 24.0 10.5 11.7 26.9 21.4 22.5 18.8 9.3 25.3 4.7 31.4 7.3 8.1 13.6 15.8 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.6 2.2 39.8 3.0 11.2 12.4 0.3 3.3 1.9 2.7 1.6 0.4 2.1 0.0 0.5 4.7 0.3 2.6 0.9 4.6 0.0 3.6 0.0 4.2 1.5 17.0 0.0 0.2 10.4 0.7 6.5 0.7 3.7 1.0 6.4 3.3 0.5 0.0 0.1 1.0 7.1 0.0 8.4 0.0 2.6 1.0 26.1 3.2 13.7 0.6 0.0 0.9 0.0 0.7 4.3 8.5 10.1 2.0 0.0 0.0 0.0 7.0 0.0 2.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.8 19.2 10.1 21.3 19.1 11.0 24.3 11.8 23.4 25.3 LIG4 ENSG00000174405 "DNA ligase 4" P49917 13 108207439-108218368 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Cell cycle, Cell division, DNA damage, DNA recombination, DNA repair, DNA replication" Ligase "Cancer-related genes, Disease mutation, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001334, HPA057325" Supported Supported "Nucleoplasm,Cytoplasmic bodies" Nucleoplasm "Cytoplasmic bodies" "HPA001334: AB_1078689, HPA057325: " "unprognostic (9.93e-2)" "unprognostic (1.56e-1)" "unprognostic (2.35e-1)" "unprognostic (2.00e-2)" "unprognostic (1.40e-1)" "unprognostic (1.97e-1)" "unprognostic (1.56e-1)" "unprognostic (7.97e-2)" "unprognostic (2.43e-1)" "unprognostic (4.87e-1)" "unprognostic (1.96e-2)" "unprognostic (4.21e-3)" "unprognostic (1.94e-2)" "unprognostic (3.04e-1)" "unprognostic (1.82e-1)" "unprognostic (1.50e-2)" "unprognostic (9.03e-3)" 8.8 12.4 11.6 10.4 15.9 4.3 9.1 14.2 20.6 5.4 7.1 10.2 7.8 8.9 5.8 11.4 8.1 5.9 8.7 8.8 15.6 14.4 11.2 16.7 8.7 12.7 15.5 10.6 7.9 8.3 17.0 20.3 8.3 19.6 7.5 8.7 3.8 6.7 7.1 9.5 6.6 8.6 8.4 14.4 12.6 9.7 11.7 13.6 18.6 10.0 5.4 10.2 8.1 5.3 3.3 2.1 6.8 10.7 2.7 2.7 1.5 9.4 3.6 9.8 6.5 8.2 8.8 3.5 9.4 7.1 7.2 8.7 4.3 4.3 16.2 7.7 6.1 3.9 6.5 6.3 12.5 9.4 6.2 7.6 8.3 2.2 9.8 10.2 8.1 8.0 10.5 7.0 6.3 8.6 2.7 3.0 11.1 5.1 16.8 7.4 2.5 2.3 15.5 3.9 2.6 9.4 6.1 6.2 6.4 2.1 5.8 7.1 4.9 15.7 12.7 4.3 4.7 4.8 8.4 8.0 5.2 26.3 16.6 5.9 9.7 0.8 2.3 6.8 1.8 3.8 2.5 2.6 2.0 1.9 2.1 3.3 2.0 2.7 3.2 2.7 10.7 1.4 2.7 1.5 11.6 15.9 14.2 20.6 15.6 14.4 15.5 10.6 19.6 13.6 LIMK1 LIMK ENSG00000106683 "LIM domain kinase 1" P53667 7 74082933-74122525 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Williams-Beuren syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 45.2" "Cell line enhanced" "Detected in all" "U-87 MG: 51.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA028064, HPA028516" Approved Supported "Nuclear speckles,Cytosol" "Nuclear speckles, Cytosol" "HPA028064: AB_10600111, HPA028516: AB_10601751" "unprognostic (1.45e-2)" "unprognostic (2.75e-1)" "prognostic unfavourable (4.95e-5)" "unprognostic (2.77e-2)" "unprognostic (1.40e-3)" "unprognostic (3.35e-2)" "prognostic unfavourable (7.79e-6)" "unprognostic (1.90e-2)" "unprognostic (2.16e-1)" "unprognostic (1.18e-1)" "unprognostic (3.32e-2)" "unprognostic (3.16e-2)" "prognostic unfavourable (6.63e-8)" "unprognostic (4.14e-2)" "unprognostic (7.00e-2)" "unprognostic (3.84e-2)" "unprognostic (5.79e-2)" 8.8 8.6 31.6 18.2 18.6 6.3 7.4 14.3 44.1 11.5 6.6 7.1 6.6 6.9 7.3 5.3 6.4 6.0 10.8 6.3 26.8 32.9 5.2 2.6 12.5 22.0 33.4 22.2 12.1 8.1 4.0 7.2 8.0 45.2 6.1 4.7 4.8 18.1 9.6 10.9 6.8 7.2 7.6 10.8 18.4 7.8 10.4 6.5 4.3 7.5 3.7 18.1 14.1 7.2 4.6 8.6 3.8 7.7 6.9 2.4 3.1 17.2 13.5 10.3 17.1 13.6 18.5 7.5 10.7 10.3 8.7 9.7 7.8 17.0 10.7 4.8 13.1 10.4 3.8 6.6 3.3 18.5 6.7 7.9 4.6 8.9 15.6 6.0 29.0 18.2 5.9 7.0 3.7 12.9 5.3 3.4 10.8 15.1 5.1 10.8 19.5 8.4 7.5 16.0 6.7 9.6 3.7 4.1 9.4 6.9 16.5 8.6 5.2 5.4 15.3 13.9 12.9 35.7 17.1 3.9 4.3 19.5 51.4 4.4 9.4 0.1 6.5 3.8 2.4 7.7 1.8 4.6 0.6 1.5 8.6 2.4 0.2 0.7 0.7 6.9 4.7 0.8 0.4 3.1 31.6 18.6 14.3 44.1 26.8 32.9 33.4 22.2 45.2 6.5 LMNA "CMD1A, HGPS, LGMD1B, LMN1, LMNL1, MADA, PRO1" ENSG00000160789 "Lamin A/C" P02545 1 156082573-156140089 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cancer-related genes, Cardiomyopathy, Charcot-Marie-Tooth disease, Congenital muscular dystrophy, Disease mutation, Emery-Dreifuss muscular dystrophy, Limb-girdle muscular dystrophy, Neurodegeneration, Neuropathy" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 6 "basophil: 10.4;memory CD4 T-cell: 8.9;myeloid DC: 34.8;T-reg: 35.4" "Group enriched" "Detected in all" 8 "dendritic cells: 34.8;granulocytes: 10.4;T-cells: 35.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004022, HPA006660, HPA012078" Supported Enhanced "Nucleoplasm,Nuclear bodies,Cytosol" 3200000 Nucleoplasm "Nuclear bodies, Cytosol" "CAB004022: AB_2136278, HPA006660: AB_1079231, HPA012078: " "unprognostic (2.22e-2)" "unprognostic (1.89e-1)" "unprognostic (1.04e-2)" "unprognostic (5.75e-2)" "unprognostic (7.43e-3)" "unprognostic (1.47e-1)" "unprognostic (5.23e-3)" "unprognostic (3.27e-2)" "unprognostic (8.33e-2)" "unprognostic (5.90e-2)" "unprognostic (5.10e-2)" "unprognostic (6.34e-2)" "unprognostic (1.41e-2)" "unprognostic (1.24e-1)" "unprognostic (2.89e-1)" "unprognostic (3.08e-2)" "unprognostic (1.44e-2)" 64.0 37.3 7.4 51.4 11.8 21.3 88.6 9.0 10.8 62.8 32.6 21.9 27.2 28.6 69.1 52.3 62.2 40.1 77.7 62.5 8.8 7.5 25.9 26.6 51.8 39.6 15.7 11.2 60.3 30.9 15.2 17.4 73.3 18.1 34.0 15.2 32.7 37.5 26.4 36.3 68.7 29.9 63.0 10.3 22.4 36.7 30.2 12.9 9.4 31.5 140.0 35.6 46.4 51.2 1.1 34.8 10.4 3.5 1.7 35.4 6.4 58.6 58.2 6.4 17.3 32.6 56.6 19.9 63.4 80.9 47.9 33.2 14.7 58.1 0.5 37.7 97.5 68.7 9.4 49.2 12.4 19.9 5.5 18.5 46.9 34.0 29.5 3.2 54.7 33.9 21.4 38.9 26.8 42.7 9.9 4.5 52.4 46.3 0.1 10.2 4.8 74.2 0.2 22.6 17.2 47.4 28.2 6.6 13.2 42.8 46.5 58.9 39.3 15.3 76.1 45.7 29.1 56.4 51.2 4.4 1.1 1.2 74.7 3.0 136.2 10.4 3.5 0.1 1.2 0.8 1.0 1.1 8.9 3.4 34.8 0.0 0.1 0.3 0.8 1.7 0.1 0.3 35.4 6.4 7.4 11.8 9.0 10.8 8.8 7.5 15.7 11.2 18.1 12.9 LMO2 "RBTN2, RBTNL1, RHOM2, TTG2" ENSG00000135363 "LIM domain only 2" P25791 11 33858576-33892289 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in some" "HEL: 22.8;HL-60: 22.7;K-562: 23.0;THP-1: 30.1;U-937: 10.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 5 "basophil: 1.5;classical monocyte: 1.1;eosinophil: 3.0;intermediate monocyte: 3.1;myeloid DC: 4.3;neutrophil: 1.6;non-classical monocyte: 3.6" "Group enriched" "Detected in many" 7 "dendritic cells: 4.3;granulocytes: 3.0;monocytes: 3.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB016258, HPA029285, HPA070901, HPA070910" Approved Enhanced Nucleoplasm Nucleoplasm "CAB016258: AB_2136572, HPA029285: , HPA070901: , HPA070910: " "unprognostic (1.60e-1)" "unprognostic (1.47e-2)" "unprognostic (6.03e-2)" "unprognostic (1.71e-3)" "unprognostic (1.89e-1)" "unprognostic (1.14e-3)" "prognostic favourable (3.12e-4)" "unprognostic (1.73e-3)" "unprognostic (8.95e-2)" "unprognostic (5.76e-2)" "unprognostic (7.86e-3)" "unprognostic (3.69e-1)" "unprognostic (7.10e-2)" "unprognostic (9.65e-2)" "unprognostic (3.90e-1)" "unprognostic (1.45e-1)" "unprognostic (4.46e-2)" 18.2 6.1 13.8 13.6 15.6 28.8 14.5 5.2 18.4 9.4 5.5 10.3 6.4 6.2 9.7 9.9 6.9 8.6 9.1 6.4 15.8 12.2 12.9 5.5 15.9 22.2 14.2 7.2 5.1 3.9 4.2 8.3 8.5 11.9 8.3 2.7 14.6 4.5 4.0 25.0 4.2 5.5 6.6 13.9 22.0 4.4 3.6 11.1 1.0 10.7 8.1 13.3 11.1 14.8 0.5 4.3 3.0 3.6 0.0 0.1 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.1 0.0 0.0 0.9 0.5 5.6 0.0 0.0 0.0 0.1 0.0 0.0 0.1 22.8 0.0 0.0 0.1 22.7 7.9 0.0 0.0 0.0 0.0 4.4 23.0 0.0 0.0 0.1 2.1 9.7 0.4 0.0 6.4 0.3 0.0 0.0 0.3 1.9 0.0 0.1 0.2 0.0 0.0 30.1 0.3 0.0 0.1 0.7 0.0 0.0 0.1 0.2 2.1 10.6 0.1 1.5 1.1 3.0 0.0 3.1 0.1 0.5 0.0 0.0 4.3 0.0 0.0 0.0 1.6 0.0 3.6 0.3 0.0 0.5 13.8 15.6 5.2 9.5 15.8 12.2 14.2 7.2 11.9 11.1 LPP ENSG00000145012 "LIM domain containing preferred translocation partner in lipoma" Q93052 3 188153284-188890671 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell adhesion" Activator "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "smooth muscle: 127.8;urinary bladder: 105.1" "Cell line enhanced" "Detected in many" "Daudi: 28.8;EFO-21: 35.8;U-698: 59.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 18.0" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA011133, HPA017342" Enhanced Enhanced "Focal adhesion sites,Cytosol" 520000 "Focal adhesion sites, Cytosol" "HPA011133: AB_1853247, HPA017342: AB_1853249" "unprognostic (1.50e-1)" "unprognostic (4.97e-3)" "unprognostic (1.41e-1)" "unprognostic (2.18e-1)" "unprognostic (1.86e-1)" "unprognostic (4.05e-1)" "unprognostic (2.43e-3)" "unprognostic (7.97e-2)" "unprognostic (2.17e-1)" "unprognostic (5.56e-2)" "unprognostic (3.44e-3)" "unprognostic (2.10e-1)" "unprognostic (2.57e-3)" "unprognostic (2.25e-2)" "unprognostic (6.86e-2)" "unprognostic (2.82e-3)" "unprognostic (1.48e-1)" 19.6 4.2 2.7 29.5 2.8 3.1 12.5 3.0 2.7 42.2 29.9 2.1 19.6 5.0 68.6 14.9 59.7 10.0 37.9 9.3 2.6 2.8 10.9 5.3 11.4 6.0 2.8 1.6 26.1 4.4 4.7 3.2 5.2 3.0 37.7 12.8 8.5 7.0 28.4 11.6 5.9 17.2 127.8 3.2 9.5 12.1 30.7 1.5 5.1 5.4 4.2 7.8 105.1 38.3 5.9 4.9 18.0 4.5 4.3 5.0 1.4 7.5 7.0 5.1 3.4 11.1 11.4 5.5 4.9 6.3 3.6 2.4 12.6 3.6 28.8 35.8 11.2 3.2 1.5 3.3 9.1 3.1 1.7 1.4 5.4 3.3 4.7 0.6 1.7 8.1 4.7 8.1 7.0 6.1 0.0 0.6 6.3 2.4 1.4 0.6 2.0 2.3 1.8 3.8 0.1 4.0 8.0 0.3 0.0 10.6 3.5 6.0 2.7 2.4 13.1 8.4 6.5 6.0 12.2 0.0 1.1 59.7 4.2 1.3 7.6 0.8 4.5 1.9 5.0 4.2 3.2 2.9 4.3 3.6 2.4 5.9 2.3 2.9 18.0 4.3 4.0 4.9 1.6 1.4 2.7 2.8 3.0 2.7 2.6 2.8 2.8 1.6 3.0 1.5 LRIG3 "FLJ90440, KIAA3016" ENSG00000139263 "Leucine rich repeats and immunoglobulin like domains 3" Q6UXM1 12 58872149-58920522 "Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins" "Developmental protein" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "hTCEpi: 27.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA010773 Approved Approved Cytosol Cytosol "HPA010773: AB_1853275" "unprognostic (1.79e-1)" "unprognostic (2.71e-1)" "unprognostic (1.01e-2)" "unprognostic (3.88e-2)" "unprognostic (2.53e-1)" "unprognostic (3.46e-2)" "unprognostic (1.83e-2)" "unprognostic (1.34e-3)" "unprognostic (1.21e-1)" "unprognostic (1.92e-1)" "unprognostic (3.04e-2)" "unprognostic (4.25e-2)" "unprognostic (2.74e-3)" "unprognostic (2.47e-2)" "unprognostic (1.10e-1)" "unprognostic (1.28e-2)" "unprognostic (1.46e-2)" 15.8 1.7 3.6 11.8 4.1 0.0 16.4 1.0 3.7 18.7 14.8 7.8 12.1 8.4 14.2 13.8 17.1 9.9 17.8 4.7 4.6 1.8 6.5 6.1 9.6 5.0 3.6 2.6 14.7 15.3 4.8 10.3 6.8 5.8 15.5 16.0 13.5 24.9 11.6 5.0 25.9 10.0 21.6 3.0 7.2 13.5 6.4 6.6 5.4 37.6 15.0 12.8 15.7 20.7 0.0 0.0 0.0 0.0 0.0 0.4 0.1 2.0 1.9 7.3 0.5 13.4 15.6 1.7 4.9 14.1 4.7 5.0 5.7 2.6 1.9 9.9 5.4 9.4 2.7 12.4 3.4 14.4 9.5 0.5 3.3 2.8 2.6 0.7 0.2 15.5 27.0 5.0 10.8 12.9 0.1 2.4 3.1 0.9 2.3 0.0 7.8 2.9 0.0 6.2 4.7 3.6 10.4 7.4 0.0 4.3 2.7 4.4 5.0 0.1 5.5 6.5 4.4 3.8 6.3 1.0 0.0 0.0 1.3 0.0 3.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 3.6 4.1 1.0 3.7 4.6 1.8 3.6 2.6 5.8 6.6 LRP1B "LRP-DIT, LRPDIT" ENSG00000168702 "LDL receptor related protein 1B" Q9NZR2 2 140231423-142131701 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" Endocytosis Receptor "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 25.7;thyroid gland: 14.9" "Cell line enhanced" "Detected in some" "ASC diff: 4.2;HEK 293: 4.4;HeLa: 2.3;HSkMC: 2.1;U-138 MG: 4.9;U-87 MG: 2.5" "Cancer enhanced" "Detected in some" "glioma: 1.3" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 13 "myeloid DC: 1.4;plasmacytoid DC: 1.2" "Lineage enriched" "Detected in single" 14 "dendritic cells: 1.4" "Low region specificity" "Detected in all" "HPA069094, HPA074788" Approved Approved Vesicles 63000 Vesicles "HPA069094: , HPA074788: " "unprognostic (5.31e-4)" "unprognostic (3.68e-2)" "unprognostic (2.61e-1)" "unprognostic (7.36e-4)" "unprognostic (5.19e-2)" "unprognostic (1.26e-1)" "unprognostic (2.00e-2)" "unprognostic (3.49e-1)" "unprognostic (3.75e-1)" "unprognostic (7.02e-3)" "unprognostic (1.64e-3)" "unprognostic (1.05e-1)" "unprognostic (2.94e-3)" "unprognostic (4.85e-3)" "unprognostic (1.52e-1)" "unprognostic (1.66e-2)" "unprognostic (1.36e-1)" 4.8 4.5 17.6 1.3 14.1 1.2 2.6 23.2 25.7 1.4 1.3 6.5 0.0 1.2 1.3 6.8 1.3 1.9 1.4 1.6 18.3 9.3 2.2 1.6 1.4 1.2 10.8 16.7 3.0 1.2 1.1 12.7 1.2 12.8 3.5 1.3 0.1 2.5 3.8 10.5 1.7 1.3 1.3 8.2 1.2 1.5 1.9 10.6 0.0 14.9 0.0 1.3 1.2 1.4 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 4.2 0.0 0.0 0.2 0.9 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.1 0.9 0.2 0.2 0.6 4.4 0.0 2.3 0.0 0.0 0.0 0.0 2.1 0.0 0.0 0.4 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 1.8 0.2 0.0 0.0 0.0 0.0 0.0 4.9 0.1 0.0 0.0 0.0 0.0 0.0 2.5 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 17.6 14.1 23.2 21.3 18.3 9.3 10.8 16.7 12.8 10.6 LRP6 ADCAD2 ENSG00000070018 "LDL receptor related protein 6" O75581 12 12116025-12267012 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Endocytosis, Wnt signaling pathway" "Developmental protein, Receptor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "naive CD4 T-cell: 1.7" "Lineage enhanced" "Detected in single" "T-cells: 1.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004490, HPA029925" Enhanced 270000 "CAB004490: AB_627894, HPA029925: AB_10601768" "unprognostic (1.80e-1)" "unprognostic (3.72e-1)" "unprognostic (2.76e-1)" "unprognostic (1.91e-1)" "unprognostic (6.11e-2)" "unprognostic (1.07e-1)" "unprognostic (4.56e-2)" "unprognostic (1.37e-2)" "unprognostic (3.35e-2)" "unprognostic (6.98e-2)" "unprognostic (1.82e-1)" "unprognostic (5.00e-2)" "unprognostic (1.55e-1)" "unprognostic (2.44e-2)" "unprognostic (3.16e-1)" "unprognostic (1.23e-2)" "unprognostic (2.47e-1)" 7.6 5.3 7.3 5.6 10.1 1.2 9.9 11.6 8.2 16.7 8.7 7.4 5.8 6.8 14.2 8.2 5.0 8.7 9.3 7.3 8.1 4.7 11.7 17.9 10.9 2.4 5.5 8.7 13.1 10.1 21.5 11.2 18.4 7.8 8.8 6.9 9.9 13.3 11.9 10.8 6.9 5.9 9.6 5.5 2.7 8.5 7.9 8.2 4.2 10.3 7.3 3.6 7.5 14.1 0.4 0.0 0.0 0.0 0.0 1.7 0.0 4.2 11.9 9.3 4.7 5.9 3.9 8.3 7.4 4.8 4.1 4.9 5.8 3.3 0.0 3.6 4.7 3.7 13.0 3.3 7.8 0.0 4.9 4.1 4.6 3.1 2.1 5.7 3.1 3.0 2.1 6.2 4.8 4.3 5.5 0.0 2.7 2.7 4.0 1.0 15.6 2.2 5.1 9.1 1.0 6.3 6.6 2.0 6.3 7.1 2.3 6.0 1.8 3.3 7.7 3.3 14.0 2.6 5.3 0.0 0.0 2.0 3.2 0.0 5.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.4 1.7 0.9 0.0 0.0 0.0 0.0 0.0 0.0 7.3 10.1 11.6 8.2 8.1 4.7 5.5 8.7 7.8 8.2 LRRK2 "DKFZp434H2111, FLJ45829, PARK8, RIPK7, ROCO2" ENSG00000188906 "Leucine rich repeat kinase 2" Q5S007 12 40196744-40369285 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Autophagy, Differentiation" "GTPase activation, Hydrolase, Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, Neurodegeneration, Parkinson disease, Parkinsonism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in all" 4 "blood: 40.4;lung: 50.4" "Cell line enhanced" "Detected in some" "A549: 9.7;ASC TERT1: 10.0;BJ hTERT+: 5.6;RPTEC TERT1: 10.7" "Group enriched" "Detected in many" 7 "lung cancer: 5.3;renal cancer: 17.1;thyroid cancer: 22.7" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in many" 7 "neutrophil: 40.4" "Lineage enriched" "Detected in many" 7 "granulocytes: 40.4" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA014293, CAB037160" Approved Approved Nucleoplasm,Vesicles "Nucleoplasm, Vesicles" "CAB037160: AB_1840989, HPA014293: AB_1853353" "unprognostic (2.67e-1)" "unprognostic (1.75e-1)" "unprognostic (6.45e-3)" "unprognostic (1.06e-1)" "unprognostic (3.00e-2)" "unprognostic (6.10e-3)" "unprognostic (2.71e-1)" "unprognostic (3.14e-1)" "unprognostic (2.25e-1)" "unprognostic (9.07e-2)" "unprognostic (2.76e-1)" "unprognostic (1.23e-1)" "prognostic favourable (3.02e-6)" "unprognostic (2.55e-2)" "unprognostic (3.43e-2)" "unprognostic (2.01e-3)" "unprognostic (5.21e-3)" 3.7 3.4 2.3 7.0 3.9 8.6 3.0 1.7 5.0 5.1 4.5 1.7 2.6 0.7 5.3 2.9 5.3 3.8 4.5 4.0 1.8 1.4 10.6 4.5 50.4 6.8 2.2 3.6 5.8 3.3 10.9 2.5 1.0 1.9 3.6 1.6 3.3 4.2 2.0 5.6 2.6 3.4 6.7 4.9 8.6 2.7 1.2 2.4 0.5 3.9 2.7 4.9 4.6 6.8 0.9 1.5 40.4 5.8 0.0 0.0 0.8 0.0 9.7 0.1 0.0 3.9 10.0 0.1 2.1 5.6 0.4 0.3 0.0 0.0 0.0 0.0 1.9 0.0 0.3 0.0 0.4 0.0 0.7 0.3 0.2 0.0 0.7 0.5 0.1 2.5 0.7 0.0 0.2 0.6 0.0 0.0 0.7 0.0 0.0 1.2 0.2 0.1 0.0 0.0 0.0 10.7 0.0 0.1 0.6 0.0 0.2 2.7 2.8 2.2 1.4 1.1 1.1 1.2 0.7 0.0 0.0 0.0 2.3 0.0 0.5 0.0 5.8 1.2 0.0 3.1 0.0 0.9 0.0 0.0 1.5 0.9 0.0 0.0 40.4 0.0 3.0 0.2 0.0 0.8 2.3 3.9 1.7 5.0 1.8 1.4 2.2 3.6 1.9 2.4 LTA "LT, TNFB, TNFSF1" ENSG00000226979 "Lymphotoxin alpha" P01374 6 31572054-31574324 "Cancer-related genes, Disease related genes, Predicted secreted proteins" Cytokine "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 4 "lymphoid tissue: 25.3" "Cell line enhanced" "Detected in some" "MOLT-4: 3.9;U-266/84: 1.7" "Low cancer specificity" "Detected in many" "Region enhanced" "Detected in single" "cerebellum: 1.3" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in single" "Not detected" "Not detected" HPA007729 Uncertain "Secreted to blood" 13100 "HPA007729: AB_1852906" "unprognostic (3.76e-2)" "unprognostic (1.48e-2)" "unprognostic (1.36e-3)" "unprognostic (8.99e-5)" "unprognostic (3.22e-1)" "unprognostic (5.13e-3)" "unprognostic (2.07e-1)" "unprognostic (4.71e-2)" "unprognostic (3.10e-2)" "unprognostic (3.39e-4)" "unprognostic (2.68e-2)" "unprognostic (6.77e-2)" "unprognostic (8.72e-12)" "unprognostic (2.59e-1)" "unprognostic (5.49e-2)" "unprognostic (4.30e-2)" "unprognostic (3.03e-1)" 0.4 0.1 0.2 25.3 0.6 1.1 0.1 1.3 0.2 0.2 0.5 0.1 0.0 0.1 0.1 0.1 0.9 0.2 0.1 0.1 0.2 0.1 0.3 0.4 2.0 7.2 0.1 0.0 0.3 0.1 0.1 0.1 0.3 0.0 0.6 0.4 0.2 2.4 0.5 0.3 0.2 2.8 0.2 0.3 10.0 0.4 6.0 0.0 11.2 0.2 0.5 17.5 0.7 0.1 0.2 0.0 0.5 0.6 0.1 0.6 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 3.9 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.8 1.7 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.2 0.1 0.1 0.0 0.0 0.1 0.6 0.5 0.1 0.6 0.0 0.1 0.0 0.2 0.6 1.3 0.2 0.2 0.1 0.1 0.0 0.0 0.0 LTA4H ENSG00000111144 "Leukotriene A4 hydrolase" P09960 12 96000828-96043520 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Leukotriene biosynthesis" "Hydrolase, Metalloprotease, Protease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008399, CAB015221, HPA017017" Supported Approved Nucleoplasm,Cytosol 85000000 "Nucleoplasm, Cytosol" "CAB015221: , HPA008399: AB_1852816, HPA017017: AB_1852818" "prognostic favourable (9.79e-4)" "unprognostic (6.62e-2)" "unprognostic (6.04e-2)" "unprognostic (1.87e-1)" "unprognostic (1.38e-2)" "unprognostic (2.59e-2)" "unprognostic (4.25e-3)" "prognostic favourable (8.96e-4)" "unprognostic (1.72e-1)" "unprognostic (1.75e-2)" "unprognostic (3.38e-2)" "unprognostic (1.34e-1)" "unprognostic (1.73e-1)" "unprognostic (1.74e-1)" "unprognostic (1.04e-1)" "unprognostic (3.50e-2)" "unprognostic (1.34e-1)" 27.9 33.2 11.2 21.5 16.7 55.7 19.0 24.1 15.6 27.2 29.1 13.1 16.7 27.6 27.6 14.1 53.4 22.7 14.5 19.2 10.6 12.2 27.2 19.4 68.0 33.4 12.3 11.3 49.9 28.2 21.2 31.8 11.3 13.3 29.6 17.8 20.7 21.1 16.1 20.6 23.6 41.2 21.5 13.3 44.3 22.1 13.7 11.5 29.2 38.8 22.3 43.1 30.1 25.2 20.6 35.3 6.1 84.2 14.2 9.0 54.6 23.5 25.4 35.7 21.3 31.0 34.7 15.6 9.9 29.3 19.6 22.8 18.6 20.5 52.9 12.4 14.7 31.1 29.2 40.3 26.8 18.1 28.3 19.4 16.3 22.5 18.3 10.2 11.8 33.0 34.0 27.0 33.1 38.7 11.8 9.3 28.2 16.2 26.8 31.5 41.6 34.5 25.2 26.6 30.5 35.9 30.1 18.5 21.9 20.0 23.4 21.4 29.0 12.5 13.8 8.3 14.0 11.8 10.7 12.6 21.8 24.5 5.9 18.6 6.5 0.4 76.0 2.2 4.5 84.2 8.4 15.1 6.3 5.8 35.3 20.6 9.0 6.7 6.1 14.2 73.2 8.7 6.3 54.6 11.2 16.7 24.1 15.6 10.6 12.2 12.3 11.3 13.3 11.5 LTB "p33, TNFC, TNFSF3" ENSG00000227507 "Lymphotoxin beta" Q06643 6 31580525-31582522 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" Cytokine "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 44.1;lymphoid tissue: 81.5" "Cell line enhanced" "Detected in some" "CAPAN-2: 6.0;Daudi: 19.4;HDLM-2: 10.9;NB-4: 12.6;REH: 11.9;U-698: 14.3" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA048884 Approved Approved Centrosome Centrosome "HPA048884: " "unprognostic (1.43e-2)" "unprognostic (3.89e-2)" "unprognostic (7.29e-2)" "prognostic favourable (2.36e-6)" "unprognostic (2.91e-3)" "prognostic favourable (1.74e-4)" "unprognostic (1.45e-1)" "unprognostic (9.49e-3)" "unprognostic (1.42e-3)" "unprognostic (4.26e-2)" "unprognostic (4.52e-2)" "unprognostic (1.49e-1)" "prognostic unfavourable (3.31e-7)" "unprognostic (8.91e-2)" "unprognostic (4.92e-2)" "unprognostic (6.56e-3)" "unprognostic (1.99e-1)" 1.0 0.2 0.2 35.9 0.2 3.4 0.5 0.1 0.1 0.2 1.5 0.0 0.0 1.3 0.2 0.3 2.7 0.4 0.7 1.9 0.2 0.1 4.2 1.3 4.2 27.8 0.2 0.0 0.5 0.8 0.0 0.2 0.3 0.1 0.7 0.6 0.5 6.1 0.3 0.1 0.6 18.0 0.3 0.3 69.7 2.0 0.2 0.0 81.5 1.1 0.8 41.6 1.6 0.5 44.1 15.6 17.8 3.6 5.2 39.3 10.7 2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.0 19.4 0.2 0.0 0.0 0.0 0.0 0.0 10.9 0.0 0.1 0.0 0.0 0.0 0.0 5.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.2 12.6 0.0 0.0 11.9 0.0 2.7 4.6 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 14.3 0.0 0.0 0.0 2.5 0.4 17.8 3.7 2.0 26.8 42.5 39.3 17.3 0.6 44.1 33.5 14.2 14.5 5.2 3.6 15.6 22.2 10.7 0.2 0.2 0.1 0.1 0.2 0.1 0.2 0.0 0.1 0.0 LTBR "D12S370, TNF-R-III, TNFCR, TNFR-RP, TNFR2-RP, TNFRSF3" ENSG00000111321 "Lymphotoxin beta receptor" P36941 12 6375045-6391571 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Apoptosis, Host-virus interaction" Receptor "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HHSteC: 75.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 5 "classical monocyte: 24.6;intermediate monocyte: 22.9;myeloid DC: 17.6;neutrophil: 15.8;non-classical monocyte: 16.4" "Group enriched" "Detected in many" 32 "dendritic cells: 17.6;granulocytes: 15.8;monocytes: 24.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB026202, HPA061617" Uncertain Supported "Golgi apparatus" "Golgi apparatus" "CAB026202: , HPA061617: " "unprognostic (2.60e-2)" "unprognostic (1.24e-2)" "unprognostic (7.75e-3)" "unprognostic (2.23e-2)" "unprognostic (3.01e-2)" "unprognostic (3.24e-3)" "prognostic unfavourable (5.13e-4)" "unprognostic (2.08e-2)" "unprognostic (2.24e-2)" "unprognostic (1.43e-1)" "unprognostic (2.45e-3)" "unprognostic (1.91e-1)" "prognostic unfavourable (5.92e-4)" "unprognostic (3.66e-2)" "unprognostic (9.84e-3)" "unprognostic (6.91e-2)" "unprognostic (2.86e-1)" 32.7 24.8 6.0 13.6 8.1 3.6 77.6 2.7 4.8 25.0 25.1 4.9 31.3 18.9 26.7 19.5 34.9 18.1 29.8 15.2 9.5 3.3 39.4 85.2 38.7 21.7 8.1 2.6 28.3 79.8 18.1 10.6 27.0 8.4 31.3 13.7 16.9 31.3 27.0 19.1 25.2 43.6 28.2 12.5 23.3 24.5 14.3 5.7 4.2 45.8 33.6 19.1 27.0 23.0 0.0 17.6 15.8 24.6 0.6 0.1 8.0 17.4 23.6 0.0 7.6 46.9 35.3 16.3 12.1 28.2 18.5 19.1 10.8 27.2 0.0 7.4 26.4 20.2 0.0 25.6 7.3 0.0 0.0 10.3 9.7 6.1 75.2 0.7 17.4 51.7 47.5 13.1 37.1 16.8 9.8 0.1 21.1 16.2 0.0 4.9 0.2 13.0 0.0 1.2 0.0 27.5 20.1 0.1 0.1 11.4 22.7 25.5 3.8 18.9 10.4 6.5 7.4 23.9 12.9 0.0 0.0 0.0 2.7 6.4 23.8 1.4 24.6 0.1 0.0 22.9 0.0 0.0 0.0 0.0 17.6 0.0 0.1 0.1 15.8 0.6 16.4 4.2 0.0 8.0 6.0 8.1 2.7 4.8 9.5 3.3 8.1 2.6 8.4 5.7 LTF HLF2 ENSG00000012223 Lactotransferrin P02788 3 46435645-46485234 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Immunity, Ion transport, Iron transport, Osteogenesis, Transcription, Transcription regulation, Transport" "Antibiotic, Antimicrobial, DNA-binding, Heparin-binding, Hydrolase, Protease, Serine protease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 277.8;salivary gland: 181.9;seminal vesicle: 177.1" "Group enriched" "Detected in some" 10 "RPMI-8226: 29.1;TIME: 10.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in single" "Group enriched" "Detected in some" 27 "neutrophil: 4.0;non-classical monocyte: 13.5" "Group enriched" "Detected in many" 27 "granulocytes: 4.0;monocytes: 13.5" "Not detected" "Not detected" "Low region specificity" "Detected in many" "CAB008646, CAB016201, HPA057177, HPA059976" Enhanced "Secreted in other tissues" 600000000 "CAB008646: AB_1618695, CAB016201: AB_629860, HPA057177: , HPA059976: " "unprognostic (7.24e-3)" "unprognostic (2.43e-1)" "unprognostic (5.94e-2)" "unprognostic (3.41e-2)" "unprognostic (7.14e-3)" "unprognostic (3.45e-2)" "unprognostic (6.43e-3)" "unprognostic (2.52e-1)" "unprognostic (1.92e-1)" "unprognostic (4.21e-2)" "unprognostic (3.43e-1)" "unprognostic (1.04e-1)" "prognostic favourable (6.30e-5)" "unprognostic (1.66e-2)" "unprognostic (3.53e-1)" "unprognostic (2.05e-1)" "unprognostic (9.09e-3)" 1.0 0.3 0.4 8.8 0.5 277.8 23.0 0.3 0.3 53.1 0.3 3.2 108.0 0.0 0.7 39.3 3.8 0.9 2.2 2.5 0.6 0.6 20.8 0.6 10.8 1.3 0.6 0.0 0.3 2.7 0.0 1.2 0.8 1.5 13.0 0.0 0.2 181.9 177.1 0.4 1.2 0.9 0.1 0.7 9.1 22.6 2.8 0.1 4.0 1.6 13.4 30.7 2.3 1.0 0.0 0.3 4.0 13.5 0.0 0.0 14.7 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.5 0.1 0.0 0.0 1.4 0.3 0.0 0.2 0.0 0.2 0.0 0.0 0.5 0.1 0.0 0.0 0.5 29.1 0.1 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 10.1 0.0 0.2 0.8 0.1 0.4 0.0 0.1 0.1 1.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.0 0.0 13.5 0.3 0.0 14.7 0.4 0.5 0.3 0.3 0.6 0.6 0.6 0.0 1.5 0.1 LUM "LDC, SLRR2D" ENSG00000139329 Lumican P51884 12 91102629-91111831 "Cancer-related genes, Plasma proteins, Predicted secreted proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "placenta: 344.8" "Cell line enriched" "Detected in some" 5 "BJ hTERT+: 182.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in single" "Cell type enriched" "Detected in single" 103 "basophil: 10.2" "Lineage enriched" "Detected in single" 103 "granulocytes: 10.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "HPA001522, CAB025783" Supported "Secreted to extracellular matrix" 59000000000 "CAB025783: , HPA001522: AB_1079285" "unprognostic (5.54e-2)" "unprognostic (2.27e-1)" "unprognostic (3.32e-1)" "unprognostic (2.75e-1)" "unprognostic (1.65e-1)" "unprognostic (8.38e-2)" "unprognostic (1.09e-1)" "unprognostic (2.87e-1)" "unprognostic (4.08e-2)" "unprognostic (1.19e-1)" "unprognostic (1.65e-2)" "unprognostic (2.20e-2)" "prognostic unfavourable (1.75e-6)" "unprognostic (5.25e-3)" "unprognostic (2.27e-2)" "unprognostic (2.38e-2)" "unprognostic (2.06e-2)" 44.8 25.3 0.8 15.1 0.7 0.0 19.7 0.7 0.7 56.7 26.9 0.7 28.1 5.1 64.8 77.8 28.1 12.2 76.6 48.8 0.8 0.7 26.9 6.4 77.1 32.0 0.9 0.6 73.0 9.1 0.7 2.7 344.8 2.8 77.4 13.3 1.4 5.6 9.9 9.1 8.3 24.0 48.7 4.0 1.3 8.2 30.9 0.3 1.7 18.1 32.3 11.5 65.3 20.0 0.0 0.0 10.2 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 22.5 11.1 0.0 36.9 182.3 1.5 2.3 0.0 0.0 0.0 0.0 30.8 0.0 0.0 0.0 0.5 0.0 0.0 0.0 2.3 0.0 17.6 0.0 0.0 15.2 0.0 3.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.9 0.0 0.0 0.0 1.5 0.4 1.3 0.0 0.0 0.0 0.0 0.8 0.0 0.0 10.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.7 0.7 0.7 0.8 0.7 0.9 0.6 2.8 0.3 LYL1 bHLHa18 ENSG00000104903 "LYL1, basic helix-loop-helix family member" P12980 19 13099033-13103161 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 37.4;lymphoid tissue: 25.4" "Cell line enhanced" "Detected in some" "HEL: 32.3;HL-60: 22.6;HMC-1: 54.5;K-562: 25.3;NB-4: 33.1;REH: 24.3;THP-1: 21.9;U-937: 21.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "eosinophil: 8.8" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA075004 Approved "Golgi apparatus" "Golgi apparatus" "HPA075004: " "unprognostic (8.62e-2)" "unprognostic (1.58e-1)" "unprognostic (1.27e-2)" "unprognostic (3.29e-3)" "unprognostic (2.76e-1)" "unprognostic (3.64e-3)" "unprognostic (2.46e-1)" "unprognostic (1.05e-2)" "unprognostic (1.90e-2)" "unprognostic (5.87e-2)" "unprognostic (1.78e-3)" "unprognostic (1.36e-1)" "prognostic unfavourable (3.89e-4)" "unprognostic (1.18e-1)" "unprognostic (6.54e-2)" "unprognostic (1.33e-1)" "unprognostic (4.28e-1)" 6.3 3.0 3.4 19.9 5.8 37.4 8.0 1.1 3.8 4.0 3.7 5.5 1.3 3.0 5.3 3.9 5.9 3.8 3.5 4.9 4.5 2.9 3.9 2.0 8.1 24.0 7.1 1.6 3.2 1.6 0.8 1.7 8.0 5.1 6.2 1.4 4.4 6.4 2.4 3.5 2.0 8.8 3.3 6.0 25.4 4.2 11.9 4.1 3.6 3.5 1.4 18.9 3.3 7.0 4.6 1.4 8.8 3.6 0.0 0.5 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.0 0.1 0.0 6.3 2.2 0.0 0.0 0.1 0.0 0.0 3.7 0.0 32.3 0.0 0.3 0.3 22.6 54.5 0.1 0.0 0.0 0.0 8.3 25.3 1.1 0.0 0.0 0.1 33.1 0.0 0.8 24.3 0.0 2.7 0.0 0.0 0.0 2.4 0.7 0.0 1.5 0.0 21.9 13.3 0.0 0.0 0.9 0.0 0.0 0.0 5.1 0.0 21.8 0.0 2.5 2.3 8.8 0.1 2.9 0.2 2.8 0.3 0.2 1.4 4.6 0.2 0.2 3.6 0.0 3.6 0.4 0.5 0.6 3.4 5.8 1.1 3.7 4.5 2.9 7.1 1.6 5.1 4.1 LYN JTK8 ENSG00000254087 "LYN proto-oncogene, Src family tyrosine kinase" P07948 8 55879813-56014168 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Adaptive immunity, Host-virus interaction, Immunity, Inflammatory response, Innate immunity" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 70.9" "Cell line enhanced" "Detected in many" "HEL: 56.8;HMC-1: 57.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 36.8" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001231, CAB004492" Enhanced Supported "Golgi apparatus,Vesicles,Plasma membrane" 11000000 "Golgi apparatus, Plasma membrane" Vesicles "CAB004492: AB_627897, HPA001231: AB_1079286" "unprognostic (7.87e-2)" "unprognostic (4.89e-2)" "unprognostic (9.04e-2)" "unprognostic (3.74e-1)" "unprognostic (8.12e-2)" "unprognostic (2.17e-1)" "unprognostic (5.70e-2)" "unprognostic (1.11e-1)" "unprognostic (2.79e-1)" "unprognostic (8.80e-2)" "unprognostic (3.68e-2)" "unprognostic (7.15e-2)" "prognostic unfavourable (3.43e-4)" "unprognostic (2.13e-1)" "unprognostic (2.72e-3)" "unprognostic (1.21e-1)" "unprognostic (7.39e-2)" 8.8 6.8 4.5 34.0 6.3 33.6 11.1 9.5 4.1 5.3 10.5 5.8 7.2 15.6 3.4 7.8 7.2 6.7 13.7 8.9 4.8 3.6 6.1 13.8 34.6 70.9 7.7 2.1 5.3 9.8 3.1 4.9 19.1 5.6 5.7 6.6 6.3 14.9 8.5 2.7 3.4 16.2 6.6 8.5 69.4 7.4 3.6 5.1 3.8 9.4 5.3 25.8 10.7 7.5 8.4 9.2 36.8 26.5 1.9 0.9 2.7 12.6 7.5 1.7 0.3 0.1 0.0 13.7 9.7 14.2 6.1 4.3 5.2 4.4 12.2 4.3 3.8 5.9 7.1 7.2 5.2 19.8 7.1 56.8 2.3 1.8 1.9 5.7 57.7 0.3 2.5 0.1 4.4 8.2 30.0 26.5 0.9 0.7 0.0 6.0 10.9 0.8 0.9 2.8 1.5 3.9 6.0 1.1 22.0 4.8 0.0 2.0 1.1 13.4 9.6 0.0 2.8 0.0 4.4 8.9 3.2 27.6 0.6 11.3 0.4 2.1 7.2 12.3 0.9 16.8 0.7 8.2 0.2 0.3 6.4 8.4 0.1 0.4 36.8 1.9 26.5 9.2 0.0 2.7 4.5 6.3 9.5 4.1 4.8 3.6 7.7 2.1 5.6 5.1 LZTR1 "BTBD29, LZTR-1" ENSG00000099949 "Leucine zipper like transcription regulator 1" Q8N653 22 20982013-20999038 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Ubl conjugation pathway" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA067852, HPA068772, HPA071248" Approved Approved Nucleoplasm,Centrosome,Cytosol Nucleoplasm "Centrosome, Cytosol" "HPA067852: , HPA068772: , HPA071248: " "unprognostic (1.88e-2)" "unprognostic (1.01e-1)" "unprognostic (1.90e-1)" "unprognostic (1.08e-1)" "unprognostic (1.06e-1)" "unprognostic (2.44e-2)" "prognostic unfavourable (5.15e-4)" "unprognostic (9.81e-2)" "unprognostic (3.55e-1)" "unprognostic (3.78e-2)" "unprognostic (1.01e-2)" "unprognostic (2.64e-1)" "unprognostic (1.16e-3)" "unprognostic (4.29e-2)" "unprognostic (1.65e-1)" "unprognostic (6.25e-2)" "unprognostic (1.25e-2)" 21.2 16.9 17.3 15.6 17.4 10.3 17.9 20.7 24.7 18.5 18.3 25.3 20.6 18.9 24.9 14.0 16.5 18.3 21.2 15.8 15.4 10.9 17.2 13.1 16.2 12.8 19.6 16.5 21.7 16.2 24.9 26.0 18.8 19.0 16.9 12.9 18.9 17.5 18.0 17.2 15.0 15.7 21.9 14.0 19.3 14.5 10.8 19.2 10.8 19.6 12.6 12.5 18.5 16.4 1.6 2.2 0.2 3.4 1.8 3.0 1.5 6.2 5.1 7.6 9.2 17.6 12.2 6.2 12.8 9.0 7.3 10.0 3.0 2.6 6.6 4.8 14.2 8.4 5.7 10.5 2.9 12.3 13.3 7.1 6.7 4.4 9.4 3.8 9.4 11.2 5.3 9.2 6.7 14.1 29.4 11.5 8.2 3.8 6.8 3.6 2.4 5.6 8.0 11.1 2.6 5.7 8.4 7.5 11.2 6.9 12.1 7.5 5.6 7.1 12.6 17.0 8.7 7.7 6.9 5.0 4.4 2.0 7.7 3.7 8.2 0.0 2.5 0.2 3.0 3.1 1.6 1.6 1.5 2.8 2.2 1.0 2.1 1.5 0.1 1.8 3.4 1.2 0.5 1.5 17.3 17.4 20.7 24.7 15.4 10.9 19.6 16.5 19.0 19.2 MAD2L1 "HSMAD2, MAD2" ENSG00000164109 "Mitotic arrest deficient 2 like 1" Q13257 4 120055608-120067074 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division, Mitosis" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 27.3" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA003348 Uncertain Approved Nucleoplasm Nucleoplasm "HPA003348: AB_10603014" "unprognostic (4.08e-3)" "unprognostic (7.31e-2)" "unprognostic (5.17e-3)" "unprognostic (1.10e-2)" "unprognostic (1.27e-1)" "unprognostic (5.54e-2)" "prognostic unfavourable (5.15e-5)" "prognostic unfavourable (2.17e-4)" "unprognostic (6.74e-3)" "unprognostic (1.47e-1)" "unprognostic (3.20e-3)" "unprognostic (3.87e-3)" "prognostic unfavourable (3.07e-11)" "unprognostic (3.06e-2)" "unprognostic (4.05e-1)" "unprognostic (1.03e-1)" "unprognostic (9.70e-2)" 1.4 1.8 2.4 4.2 5.7 10.3 2.4 4.4 4.1 1.9 4.4 1.2 0.3 3.8 1.7 1.4 6.5 2.9 1.1 1.7 2.7 2.7 1.2 1.2 1.5 7.6 2.3 3.6 1.7 1.2 0.7 1.0 3.5 2.4 1.6 5.5 0.7 2.4 1.2 1.2 2.3 4.2 1.8 2.8 3.8 1.9 13.7 1.2 27.3 1.2 8.2 7.3 2.1 2.4 1.8 2.2 2.0 0.8 2.5 3.9 1.7 14.4 6.4 15.0 9.7 1.6 2.0 6.4 11.5 6.5 12.1 9.3 8.5 8.9 21.3 3.8 4.2 3.9 14.9 8.8 16.9 10.1 10.4 11.8 6.2 8.0 0.5 19.2 6.8 1.1 1.3 8.2 5.1 6.9 14.1 12.3 6.3 6.4 18.4 8.4 10.2 7.2 9.5 20.1 8.8 4.9 5.6 15.9 11.3 5.7 7.1 3.5 4.7 7.1 4.3 8.1 9.2 8.2 14.5 11.5 12.2 14.0 7.5 10.0 10.6 2.0 0.5 0.4 1.6 0.5 2.1 1.8 3.8 3.0 0.4 1.4 3.5 3.5 1.3 2.5 0.8 2.2 3.9 1.7 2.4 5.7 4.4 4.1 2.7 2.7 2.3 3.6 2.4 1.2 MAD2L2 "FANCV, MAD2B, POLZ2, REV7" ENSG00000116670 "Mitotic arrest deficient 2 like 2" Q9UI95 1 11674480-11691650 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cell cycle, Cell division, DNA damage, DNA repair, Mitosis, Transcription, Transcription regulation" "Cancer-related genes, Disease mutation, Fanconi anemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB008110, HPA024176, HPA024612" Approved Approved Nucleoli,Cytosol Cytosol Nucleoli "CAB008110: AB_217976, HPA024176: , HPA024612: " "unprognostic (1.26e-2)" "unprognostic (2.55e-1)" "unprognostic (2.43e-1)" "unprognostic (3.27e-1)" "unprognostic (2.41e-1)" "unprognostic (6.84e-2)" "unprognostic (3.04e-3)" "unprognostic (1.48e-1)" "unprognostic (1.80e-1)" "unprognostic (1.34e-1)" "unprognostic (4.60e-2)" "unprognostic (1.24e-1)" "unprognostic (9.09e-3)" "unprognostic (1.54e-1)" "unprognostic (9.27e-2)" "unprognostic (8.43e-2)" "unprognostic (2.36e-1)" 12.4 10.1 15.4 15.7 15.6 37.9 13.7 15.5 13.5 10.0 10.5 14.5 11.9 8.6 10.4 11.8 9.8 9.9 10.3 17.3 13.2 11.2 13.2 34.4 12.9 18.3 19.6 9.7 14.6 23.0 5.8 11.1 8.2 12.4 11.8 6.1 8.4 21.0 9.2 23.0 12.0 7.4 11.5 15.0 11.9 12.4 37.0 15.8 42.1 12.0 10.4 19.0 11.9 13.4 19.5 46.9 13.8 31.7 13.2 29.8 27.7 11.5 10.6 17.9 20.1 5.5 10.8 7.2 10.8 12.1 21.2 18.9 13.7 11.2 16.3 13.2 11.3 5.1 22.2 11.1 12.3 24.6 24.6 7.3 16.4 16.9 9.7 14.7 12.1 7.0 11.4 15.5 13.4 9.6 30.0 26.2 10.4 17.1 67.9 69.8 46.0 17.3 46.2 19.7 20.0 7.6 2.5 33.2 23.3 17.9 6.9 31.1 10.1 32.0 5.0 17.6 22.3 16.3 15.2 21.0 14.7 42.4 13.0 51.9 13.4 11.9 29.4 13.8 29.8 31.7 23.9 19.5 20.1 23.1 34.0 15.9 13.7 20.3 12.5 13.2 27.2 46.9 22.9 27.7 15.4 15.6 15.5 13.4 13.2 11.2 19.6 9.7 12.4 15.8 MAF c-MAF ENSG00000178573 "MAF bZIP transcription factor" O75444 16 79585843-79600714 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Cancer-related genes, Cataract, Disease mutation, Dwarfism, Mental retardation, Proto-oncogene, Tumor suppressor" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Group enriched" "Detected in some" 12 "Karpas-707: 49.1;RPMI-8226: 80.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 4 "basophil: 20.7;MAIT T-cell: 6.3" "Group enriched" "Detected in many" 16 "granulocytes: 20.7;T-cells: 6.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB010296, HPA028289" Approved "CAB010296: AB_638562, HPA028289: AB_10602024" "unprognostic (6.76e-2)" "unprognostic (1.74e-2)" "unprognostic (6.45e-2)" "unprognostic (7.65e-2)" "unprognostic (7.89e-3)" "unprognostic (1.07e-2)" "unprognostic (1.63e-2)" "unprognostic (2.33e-1)" "unprognostic (8.76e-2)" "unprognostic (3.16e-2)" "unprognostic (9.46e-2)" "unprognostic (1.28e-1)" "prognostic unfavourable (3.74e-4)" "unprognostic (4.54e-2)" "unprognostic (7.83e-2)" "unprognostic (1.09e-2)" "unprognostic (4.56e-3)" 19.0 10.2 15.4 17.3 13.5 2.5 28.5 9.3 11.2 25.6 31.8 10.7 9.1 41.7 18.8 15.6 16.7 15.1 12.4 19.0 14.3 5.8 28.7 18.0 16.8 38.1 20.5 9.9 31.4 3.1 59.1 4.8 21.7 13.9 15.8 7.2 14.1 9.7 10.4 26.3 37.2 57.7 15.8 18.7 19.8 9.5 12.4 14.0 10.2 18.4 16.7 14.3 14.6 23.4 0.0 0.0 20.7 0.8 0.6 6.3 0.4 0.0 0.0 5.2 0.0 0.2 0.0 0.1 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.1 0.1 0.0 1.6 1.9 0.0 0.0 0.0 0.2 0.0 3.4 0.0 1.5 0.0 0.0 0.0 0.5 49.1 0.3 0.0 0.0 0.0 3.2 0.0 0.0 1.4 80.0 0.0 0.4 0.1 0.0 0.2 0.0 0.1 0.0 0.0 1.0 0.0 1.7 0.1 0.2 0.0 0.0 0.0 0.2 0.0 0.3 20.7 0.2 0.0 0.8 0.8 6.3 0.0 2.4 1.9 0.0 0.0 0.2 0.3 0.0 0.6 0.2 0.0 3.1 0.4 15.4 13.5 9.3 11.2 14.3 5.8 20.5 9.9 13.9 14.0 MAFB KRML ENSG00000204103 "MAF bZIP transcription factor B" Q9Y5Q3 20 40685848-40689240 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Cancer-related genes, Disease mutation, Proto-oncogene, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 87.6;parathyroid gland: 154.1" "Cell line enhanced" "Detected in some" "HSkMC: 15.8;hTCEpi: 33.3;SCLC-21H: 9.1;SiHa: 8.2;U-138 MG: 9.0;U-2197: 13.1;U-87 MG: 8.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 4 "intermediate monocyte: 27.4;non-classical monocyte: 36.7" "Lineage enriched" "Detected in many" 14 "monocytes: 36.7" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA005653 Approved Approved "Nucleoplasm,Nucleoli,Golgi apparatus,Cytosol" Nucleoplasm "Nucleoli, Golgi apparatus, Cytosol" "HPA005653: AB_1079293" "unprognostic (1.55e-1)" "unprognostic (1.17e-2)" "unprognostic (1.16e-3)" "prognostic unfavourable (5.64e-4)" "unprognostic (9.16e-2)" "unprognostic (3.92e-2)" "unprognostic (1.10e-1)" "unprognostic (2.10e-1)" "unprognostic (2.57e-2)" "unprognostic (6.09e-2)" "unprognostic (5.45e-3)" "unprognostic (9.92e-2)" "unprognostic (3.95e-2)" "unprognostic (1.05e-1)" "unprognostic (3.21e-3)" "unprognostic (3.49e-2)" "unprognostic (2.30e-2)" 38.3 7.9 3.2 13.0 4.0 17.0 19.5 1.0 9.7 10.6 6.9 3.0 1.2 3.3 5.6 8.9 16.8 7.0 9.2 12.4 3.6 2.3 10.9 14.0 21.9 28.9 4.7 3.4 7.0 6.1 154.1 2.3 9.4 5.0 7.6 3.3 5.6 10.4 2.7 11.0 41.6 7.6 5.5 7.7 87.6 4.7 7.5 3.8 6.9 18.2 20.5 11.4 8.2 10.9 0.0 2.5 0.7 36.7 0.0 0.0 2.5 0.0 0.0 0.0 1.4 0.8 0.1 0.2 0.2 0.0 0.1 0.0 0.2 0.1 0.0 1.0 0.2 2.0 0.0 0.0 0.0 0.0 0.7 0.0 0.6 0.1 0.5 0.0 0.1 15.8 33.3 0.1 1.1 0.2 0.0 0.0 0.0 0.5 0.1 3.8 1.4 0.0 0.0 0.0 0.0 0.3 0.2 9.1 0.7 8.2 0.8 2.0 0.8 0.1 0.2 9.0 0.1 13.1 0.0 0.0 0.0 0.0 8.7 0.3 0.0 0.1 7.3 0.0 0.0 27.4 0.0 0.0 0.0 0.0 2.5 0.0 0.0 0.0 0.7 0.0 36.7 0.0 0.0 2.5 3.2 4.0 1.0 9.7 3.6 2.3 4.7 3.4 5.0 3.8 MAGEA4 "CT1.4, MAGE-41, MAGE-X2, MAGE4, MAGE4A, MAGE4B, MGC21336" ENSG00000147381 "MAGE family member A4" P43358 X 151912509-151925170 "Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins" "Tumor antigen" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 32 "placenta: 12.1;testis: 23.5" "Cell line enhanced" "Detected in some" "A-431: 61.4;AN3-CA: 38.3;HMC-1: 73.1;U-266/84: 113.8" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "HPA021942, CAB040535" Enhanced Approved "Nuclear speckles,Cytosol" "Nuclear speckles" Cytosol "CAB040535: , HPA021942: AB_1853490" "unprognostic (7.90e-3)" "unprognostic (6.66e-3)" "unprognostic (5.39e-1)" "unprognostic (1.36e-1)" "unprognostic (5.81e-2)" "unprognostic (2.94e-2)" "unprognostic (4.10e-1)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 12.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 23.5 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 61.4 0.0 0.0 38.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 73.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.5 0.0 0.0 19.6 0.0 0.3 15.6 113.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 MAGEB5 "CT3.3, MAGE-B5" ENSG00000188408 "MAGE family member B5" Q9BZ81 X 26216169-26218270 "Cancer-related genes, Predicted intracellular proteins" "Tumor antigen" "Cancer-related genes" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enriched" "Detected in single" 10 "testis: 3.3" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA052627 Uncertain "HPA052627: " 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 MAGEB6 "CT3.4, FLJ40242, MAGE-B6, MAGEB6A" ENSG00000176746 "MAGE family member B6" Q8N7X4 X 26192440-26195646 "Cancer-related genes, Predicted intracellular proteins" "Tumor antigen" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 87 "testis: 8.6" "Cell line enriched" "Detected in single" 10 "K-562: 9.8" "Cancer enhanced" "Detected in single" "testis cancer: 0.5" "Not detected" "Not detected" "Not detected" "Not detected" "HPA041853, HPA076711" Enhanced "HPA041853: AB_10796785, HPA076711: " "unprognostic (2.05e-1)" "unprognostic (1.31e-2)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 9.8 0.6 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.9 0.0 0.0 0.0 0.1 0.0 0.1 0.6 0.1 0.0 0.0 0.0 0.2 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 MAGEC1 "CT7, CT7.1, MAGE-C1, MGC39366" ENSG00000155495 "MAGE family member C1" O60732 X 141903894-141909388 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Tumor antigen" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 11 "testis: 23.5" "Cell line enhanced" "Detected in some" "K-562: 22.3;Karpas-707: 22.4;U-2 OS: 15.1;U-2197: 28.5;U-266/70: 20.4;U-266/84: 18.0" "Cancer enhanced" "Detected in many" "melanoma: 4.6" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "HPA004622, CAB015452" Enhanced Approved Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "CAB015452: AB_784404, HPA004622: AB_1853495" "unprognostic (5.63e-2)" "unprognostic (1.59e-1)" "unprognostic (1.68e-1)" "unprognostic (4.52e-2)" "unprognostic (9.96e-2)" "unprognostic (3.47e-1)" "unprognostic (8.56e-2)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.0 0.0 23.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 22.3 22.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.0 1.6 0.0 0.0 0.0 0.0 15.1 28.5 0.0 20.4 18.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 MAGEC2 "CT10, HCA587, MAGE-C2, MAGEE1" ENSG00000046774 "MAGE family member C2" Q9UBF1 X 142202345-142205290 "Cancer-related genes, Predicted intracellular proteins" "Ubl conjugation pathway" "Tumor antigen" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 319 "testis: 31.8" "Group enriched" "Detected in some" 8 "K-562: 34.9;U-266/84: 39.4" "Cancer enhanced" "Detected in many" "melanoma: 19.0" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA062230 Enhanced Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "HPA062230: " "unprognostic (1.25e-1)" "unprognostic (5.68e-2)" "unprognostic (3.99e-1)" "unprognostic (2.82e-1)" "unprognostic (1.04e-1)" "unprognostic (4.00e-1)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 31.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 4.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 34.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.4 1.5 0.0 0.0 0.1 2.4 0.4 4.8 0.0 0.0 39.4 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 MAGEC3 "CT7.2, HCA2, MAGE-C3" ENSG00000165509 "MAGE family member C3" Q8TD91 X 141838316-141897832 "Cancer-related genes, Predicted intracellular proteins" "Tumor antigen" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 4.9;epididymis: 3.0;testis: 3.1" "Group enriched" "Detected in some" 4 "U-2197: 1.9;U-266/70: 2.9;U-266/84: 6.3" "Cancer enriched" "Detected in single" 7 "testis cancer: 0.7" "Not detected" "Not detected" "Not detected" "Not detected" HPA052067 Approved "HPA052067: " "unprognostic (3.45e-1)" "unprognostic (2.39e-1)" "unprognostic (4.01e-1)" "unprognostic (2.95e-1)" "unprognostic (2.10e-2)" "unprognostic (3.45e-2)" "unprognostic (2.35e-11)" "unprognostic (3.21e-2)" "unprognostic (4.29e-2)" 0.1 0.1 1.6 0.0 2.5 0.1 0.5 0.5 2.5 0.2 0.0 0.0 0.2 3.0 0.1 0.4 0.2 0.0 3.3 2.0 0.1 0.1 0.2 0.0 2.8 0.4 0.0 0.0 0.7 0.0 0.3 0.0 0.5 0.3 0.0 0.1 0.2 0.3 4.9 1.1 0.1 3.1 0.5 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.1 0.0 0.0 0.9 0.0 0.3 0.1 0.0 0.0 0.0 0.3 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.2 0.1 1.9 0.3 2.9 6.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 MAGED1 "DLXIN-1, NRAGE" ENSG00000179222 "MAGE family member D1" Q9Y5V3 X 51803007-51902357 "Cancer-related genes, Predicted intracellular proteins" "Biological rhythms, Ubl conjugation pathway" "Tumor antigen" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "fHDF/TERT166: 82.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA043645 Approved Cytosol Cytosol "HPA043645: " "unprognostic (5.70e-2)" "unprognostic (1.16e-1)" "unprognostic (7.29e-2)" "unprognostic (1.39e-2)" "unprognostic (3.92e-2)" "unprognostic (1.37e-1)" "unprognostic (4.04e-3)" "unprognostic (2.04e-2)" "unprognostic (3.92e-1)" "unprognostic (1.77e-1)" "unprognostic (3.15e-3)" "unprognostic (1.42e-1)" "unprognostic (6.10e-3)" "unprognostic (2.14e-3)" "unprognostic (2.22e-1)" "prognostic unfavourable (3.25e-4)" "unprognostic (1.71e-3)" 15.4 57.6 35.3 16.8 52.9 6.9 18.6 34.6 61.8 50.9 18.8 25.9 38.9 15.2 27.6 67.4 13.1 31.6 28.1 32.4 42.2 58.4 22.5 48.6 17.5 13.6 32.2 38.0 30.7 37.2 42.9 69.6 53.5 39.4 35.1 19.3 34.7 38.1 45.5 19.6 12.7 13.4 36.3 25.7 15.9 25.8 33.8 16.1 24.6 35.4 12.5 17.9 23.9 15.8 10.1 28.8 1.5 3.2 7.7 11.6 6.9 3.2 11.8 37.9 32.6 30.0 54.2 20.4 43.8 56.3 24.3 38.6 24.2 11.1 4.6 8.6 82.7 2.4 33.8 15.6 18.3 4.8 13.1 3.1 0.0 31.3 23.0 11.5 5.7 50.9 5.6 20.5 4.7 29.1 4.7 9.1 48.8 29.6 13.1 3.8 29.8 24.4 13.4 24.6 0.6 25.0 5.8 9.8 54.5 0.0 12.8 6.4 23.0 2.8 28.9 10.6 27.3 37.3 4.8 6.0 8.8 9.4 41.5 1.0 27.5 0.7 2.2 1.5 11.6 3.2 10.3 9.3 7.6 10.0 6.8 10.1 9.6 11.3 0.7 7.7 2.8 28.8 10.5 6.9 35.3 52.9 34.6 61.8 42.2 58.4 32.2 38.0 39.4 16.1 MAGED2 "11B6, BCG1, HCA10, JCL-1, MAGE-D2, MAGED, MGC8386" ENSG00000102316 "MAGE family member D2" Q9UNF1 X 54807599-54816012 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Tumor antigen" "Bartter syndrome, Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA031572, HPA031573" Supported Enhanced Nucleoplasm,Nucleoli,Cytosol "Nucleoplasm, Nucleoli, Cytosol" "HPA031572: AB_10599819, HPA031573: AB_10602181" "unprognostic (1.33e-1)" "unprognostic (8.60e-2)" "unprognostic (3.32e-1)" "unprognostic (1.69e-3)" "unprognostic (4.79e-2)" "unprognostic (3.52e-1)" "unprognostic (2.41e-3)" "unprognostic (1.39e-1)" "unprognostic (2.97e-1)" "prognostic favourable (2.88e-4)" "prognostic favourable (2.82e-4)" "unprognostic (6.34e-2)" "unprognostic (3.55e-3)" "prognostic unfavourable (9.43e-4)" "unprognostic (1.58e-1)" "unprognostic (9.77e-2)" "unprognostic (3.58e-1)" 22.1 38.4 26.9 14.8 26.5 8.2 50.2 24.4 43.0 55.7 27.3 27.8 21.4 16.2 41.1 31.8 21.9 45.9 28.5 40.7 23.8 38.2 42.7 17.3 24.0 13.5 30.3 36.0 79.7 23.5 34.5 57.6 58.6 57.1 63.9 16.4 43.1 32.0 53.7 25.6 16.5 17.6 41.6 24.7 17.5 22.5 21.8 18.3 23.4 45.1 17.3 22.0 31.9 29.2 17.1 11.7 43.1 37.0 28.5 35.5 32.5 5.5 10.3 61.7 18.8 29.4 40.0 11.4 23.1 41.2 18.3 32.6 10.2 14.2 7.7 60.6 46.4 7.6 17.5 17.4 13.2 13.8 14.5 16.1 12.2 20.0 25.2 4.1 12.4 52.4 7.3 18.6 9.4 34.8 3.9 9.5 35.0 15.4 9.1 6.9 22.8 12.3 6.1 22.1 11.0 25.1 4.2 9.7 25.1 9.2 10.7 53.4 44.0 7.0 29.9 15.6 24.4 23.3 6.5 6.1 5.1 5.6 22.8 10.8 79.7 43.1 9.1 35.5 35.5 22.4 27.3 16.3 29.4 33.1 11.7 17.1 29.7 34.1 3.4 28.5 37.0 7.2 29.2 32.5 26.9 26.5 24.4 43.0 23.8 38.2 30.3 36.0 57.1 18.3 MAGI1 "AIP3, BAIAP1, BAP1, MAGI-1, TNRC19, WWP3" ENSG00000151276 "Membrane associated guanylate kinase, WW and PDZ domain containing 1" Q96QZ7 3 65353525-66038834 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "HEL: 24.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA031851, HPA031852, HPA031853, HPA077002" Supported Supported "Nucleoplasm,Cell Junctions" "Cell Junctions" Nucleoplasm "HPA031851: AB_10599289, HPA031852: , HPA031853: AB_10602095, HPA077002: " "unprognostic (5.00e-2)" "unprognostic (9.84e-2)" "unprognostic (6.00e-3)" "unprognostic (1.73e-3)" "unprognostic (1.64e-1)" "unprognostic (2.17e-2)" "unprognostic (1.46e-3)" "unprognostic (9.46e-3)" "unprognostic (8.59e-2)" "unprognostic (2.19e-1)" "unprognostic (6.58e-2)" "unprognostic (2.05e-3)" "prognostic favourable (4.55e-8)" "unprognostic (3.51e-2)" "unprognostic (1.34e-1)" "unprognostic (1.68e-2)" "unprognostic (8.03e-2)" 18.0 6.0 10.1 6.4 9.8 1.0 16.5 38.6 16.8 6.9 11.2 10.1 25.7 10.7 11.6 7.6 9.4 12.6 19.7 11.1 9.4 11.8 14.3 17.6 13.3 2.9 8.8 10.4 4.3 16.7 18.7 13.1 11.1 9.6 9.2 9.5 7.7 17.4 37.9 7.7 13.0 11.6 7.9 8.3 13.9 19.8 10.7 7.7 0.6 23.2 5.8 4.4 6.9 13.0 0.1 0.0 0.0 0.8 0.0 0.0 0.0 2.8 1.5 8.7 0.9 1.7 1.3 3.9 4.8 4.1 1.8 2.8 10.3 2.4 0.0 0.7 5.7 0.8 2.4 1.6 2.9 0.0 1.3 24.5 3.0 6.9 1.1 0.0 0.8 1.9 1.4 6.3 1.3 4.2 10.3 0.0 1.9 2.1 0.0 0.0 11.6 1.5 0.0 2.4 0.6 2.2 9.3 2.8 7.6 1.9 2.3 0.0 4.5 0.0 1.1 5.9 4.3 1.5 1.9 0.0 0.0 0.0 3.4 0.0 0.7 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.1 9.8 38.6 15.5 9.4 11.8 8.8 10.4 9.6 7.7 MALT1 "MLT, PCASP1" ENSG00000172175 "MALT1 paracaspase" Q9UDY8 18 58671386-58754477 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Ubl conjugation pathway" "Hydrolase, Protease" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "RPTEC TERT1: 50.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB004494, HPA048432" Enhanced Approved "Nucleoli fibrillar center,Cytosol" "Nucleoli fibrillar center" Cytosol "CAB004494: AB_627909, HPA048432: " "unprognostic (3.25e-1)" "unprognostic (2.31e-1)" "unprognostic (3.64e-2)" "unprognostic (3.25e-2)" "unprognostic (1.65e-3)" "unprognostic (4.67e-2)" "unprognostic (6.46e-2)" "unprognostic (4.50e-2)" "unprognostic (3.33e-2)" "unprognostic (4.16e-3)" "unprognostic (3.74e-1)" "unprognostic (2.07e-1)" "unprognostic (2.53e-2)" "unprognostic (2.34e-1)" "unprognostic (2.97e-1)" "unprognostic (1.03e-1)" "unprognostic (6.00e-2)" 11.2 3.9 4.1 21.7 5.6 10.2 10.6 9.1 6.8 11.0 10.7 3.9 10.9 5.5 8.1 10.5 16.4 6.6 8.1 8.7 4.0 4.3 14.9 10.5 14.3 29.0 4.1 1.8 8.1 6.2 10.0 9.3 8.8 4.9 18.1 7.9 7.5 10.7 8.4 10.7 12.6 12.2 6.6 6.2 19.9 6.2 11.8 4.8 22.4 7.9 12.4 24.0 9.6 12.3 6.3 3.6 1.2 1.7 1.6 4.8 1.1 7.4 10.6 13.0 3.2 2.6 5.8 5.8 13.3 9.4 11.6 9.9 8.6 9.6 11.8 6.0 16.5 7.3 5.6 5.5 14.3 7.9 3.1 4.2 7.6 13.8 4.2 8.5 5.7 3.6 11.7 9.1 9.2 2.5 6.8 20.6 6.3 2.4 1.8 3.6 3.2 3.6 6.4 7.7 8.3 50.8 3.1 1.4 3.0 7.3 3.8 5.0 3.7 4.9 3.4 15.0 6.6 4.4 12.2 18.4 21.8 10.3 6.0 6.4 5.9 0.8 1.5 1.0 2.7 1.7 2.1 3.6 4.8 2.9 2.2 6.3 4.3 2.8 1.2 1.6 1.6 3.6 2.9 1.1 4.1 5.6 9.1 6.8 4.0 4.3 4.1 1.8 4.9 4.8 MAML2 "KIAA1819, MAM3" ENSG00000184384 "Mastermind like transcriptional coactivator 2" Q8IZL2 11 95976598-96343180 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Notch signaling pathway, Transcription, Transcription regulation" Activator "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HDLM-2: 27.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" HPA035223 Approved Supported "Nucleoplasm,Nuclear bodies,Cytosol" "Nuclear bodies" "Nucleoplasm, Cytosol" "HPA035223: AB_10671101" "unprognostic (8.11e-2)" "unprognostic (2.51e-1)" "unprognostic (7.08e-2)" "unprognostic (9.07e-2)" "unprognostic (3.57e-3)" "unprognostic (3.32e-2)" "unprognostic (3.66e-2)" "unprognostic (2.33e-1)" "unprognostic (3.99e-2)" "unprognostic (8.05e-2)" "prognostic unfavourable (3.89e-4)" "unprognostic (9.11e-2)" "prognostic favourable (1.90e-4)" "unprognostic (9.76e-2)" "unprognostic (1.73e-2)" "unprognostic (1.99e-1)" "unprognostic (7.19e-2)" 26.3 5.5 10.2 16.1 8.1 4.2 19.7 27.8 13.4 15.8 9.2 10.4 8.4 4.3 11.2 8.5 9.3 11.7 10.8 8.9 10.5 6.9 13.8 3.5 15.0 10.9 6.9 3.4 11.7 8.2 13.3 15.2 18.8 9.3 12.3 8.9 10.8 16.6 12.3 4.4 14.2 8.9 10.2 14.4 16.8 6.5 4.3 10.6 21.2 11.8 4.8 13.6 16.0 15.3 2.1 1.2 4.7 1.1 4.2 6.4 2.0 5.5 1.1 9.6 2.5 10.0 11.6 2.1 6.4 9.6 4.2 4.4 0.6 11.8 1.2 15.2 14.8 5.1 1.9 6.2 5.9 27.4 0.7 0.7 2.0 2.1 5.8 0.0 0.0 16.9 0.6 7.5 4.5 2.4 3.1 1.7 7.5 0.4 0.1 1.5 1.0 1.8 1.9 1.8 6.4 6.3 7.8 0.1 0.8 2.4 1.0 2.7 0.9 0.2 10.4 7.5 1.8 2.5 4.0 1.2 0.2 1.8 3.6 1.1 13.7 0.1 1.1 0.0 1.5 0.6 2.6 1.9 3.2 4.1 1.2 2.1 6.4 4.3 4.7 4.2 0.7 0.9 1.2 2.0 10.2 8.1 27.8 7.0 10.5 6.9 6.9 3.4 9.3 10.6 MAP2K1 "MAPKK1, MEK1, PRKMK1" ENSG00000169032 "Mitogen-activated protein kinase kinase 1" Q02750 15 66386817-66492312 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins" "Kinase, Serine/threonine-protein kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Cardiomyopathy, Disease mutation, Ectodermal dysplasia, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003834, HPA026430" Approved Enhanced "Plasma membrane,Cytosol" 62000 "Plasma membrane, Cytosol" "CAB003834: AB_562310, HPA026430: AB_1853742" "unprognostic (4.05e-2)" "unprognostic (1.23e-2)" "unprognostic (2.07e-1)" "unprognostic (4.92e-2)" "prognostic unfavourable (1.95e-4)" "unprognostic (1.81e-3)" "unprognostic (5.78e-2)" "unprognostic (9.91e-3)" "unprognostic (1.11e-1)" "unprognostic (1.77e-1)" "unprognostic (1.45e-1)" "unprognostic (7.62e-3)" "unprognostic (1.20e-1)" "unprognostic (2.71e-1)" "unprognostic (1.96e-1)" "unprognostic (1.15e-1)" "unprognostic (9.40e-3)" 28.6 16.9 33.9 19.1 54.1 29.0 23.6 32.5 48.4 12.5 12.1 8.4 10.2 10.0 11.8 16.5 22.0 10.6 14.4 19.1 49.2 26.4 15.3 53.1 16.4 23.3 17.6 31.2 13.5 11.7 23.4 12.0 15.4 17.2 14.4 12.9 9.1 13.2 12.4 39.5 12.3 10.9 16.9 17.4 14.5 10.8 7.8 12.6 12.6 12.3 9.7 27.9 13.6 18.7 4.6 16.2 5.5 8.2 8.4 7.9 2.7 33.1 15.6 31.5 13.1 19.0 14.3 18.2 24.1 20.6 26.2 23.4 23.5 27.3 30.5 29.9 19.8 29.6 29.4 35.2 30.8 24.5 17.5 9.8 16.4 12.7 15.4 12.9 14.6 11.0 21.8 18.9 28.1 20.4 17.3 39.0 38.1 12.8 10.3 16.8 16.1 13.7 11.7 19.5 27.1 25.4 14.3 19.4 10.8 19.5 15.3 20.2 13.8 11.0 28.1 34.1 20.9 24.0 35.7 24.2 43.0 19.4 36.0 22.8 15.9 3.2 8.2 5.5 7.4 8.2 6.7 3.0 6.6 6.9 8.3 4.6 7.9 4.9 3.9 8.4 7.3 16.2 4.9 2.7 33.9 54.1 32.5 46.9 49.2 26.4 17.6 31.2 17.2 12.6 MAP2K2 "MEK2, PRKMK2" ENSG00000126934 "Mitogen-activated protein kinase kinase 2" P36507 19 4090321-4124129 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins" "Kinase, Serine/threonine-protein kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Cardiomyopathy, Disease mutation, Ectodermal dysplasia, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "CAB003835, HPA051993" Supported Supported Cytosol Cytosol "CAB003835: AB_562312, HPA051993: " "unprognostic (4.39e-1)" "prognostic favourable (3.72e-4)" "unprognostic (4.24e-1)" "unprognostic (1.26e-3)" "unprognostic (2.58e-1)" "prognostic favourable (7.98e-4)" "unprognostic (2.08e-3)" "unprognostic (2.11e-1)" "unprognostic (2.65e-1)" "unprognostic (1.06e-1)" "unprognostic (7.45e-3)" "unprognostic (4.95e-2)" "unprognostic (1.32e-1)" "prognostic favourable (5.43e-5)" "unprognostic (2.91e-2)" "unprognostic (2.25e-1)" "unprognostic (4.90e-2)" 23.9 33.0 35.6 27.6 36.1 46.7 30.2 31.2 43.4 22.6 38.8 24.6 27.0 70.9 21.8 23.2 32.8 21.7 27.9 41.4 33.1 31.0 22.7 42.0 24.1 44.5 34.4 29.2 30.8 46.0 18.9 29.7 21.3 26.1 25.7 24.3 21.7 41.5 24.0 134.9 27.4 56.7 19.0 25.2 25.9 28.3 42.0 20.9 44.1 26.2 42.2 29.1 20.0 26.9 11.4 10.7 28.3 10.6 11.3 12.1 4.5 36.2 40.0 21.9 30.7 30.3 36.6 21.9 23.9 32.0 32.7 29.7 34.6 19.7 31.0 22.6 27.2 26.2 17.1 25.5 25.4 26.3 20.8 11.3 21.8 38.2 46.5 20.8 23.9 40.4 24.9 22.9 30.6 28.9 21.6 61.3 27.5 45.4 41.1 29.2 25.1 29.1 31.5 14.4 35.4 28.5 23.3 29.7 29.6 21.9 30.4 74.5 23.4 35.7 25.5 26.9 23.3 68.6 36.8 61.7 37.3 21.7 41.7 37.5 45.9 15.2 9.1 28.3 11.9 10.6 9.7 8.9 9.7 12.1 10.7 11.4 8.9 11.6 14.4 11.3 8.7 6.0 9.2 4.5 35.6 36.1 31.2 43.4 33.1 31.0 34.4 29.2 26.1 20.9 MAP2K4 "JNKK1, MEK4, MKK4, PRKMK4, SERK1" ENSG00000065559 "Mitogen-activated protein kinase kinase 4" P45985 17 12020824-12143830 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Apoptosis, Stress response" "Kinase, Serine/threonine-protein kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 13.2" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB007751, HPA060074" Enhanced Approved "Nucleoplasm,Cell Junctions" Nucleoplasm "Cell Junctions" "CAB007751: , HPA060074: " "unprognostic (1.55e-1)" "unprognostic (1.85e-1)" "unprognostic (4.47e-2)" "unprognostic (1.02e-2)" "unprognostic (1.04e-1)" "unprognostic (2.70e-1)" "unprognostic (2.89e-1)" "unprognostic (2.16e-1)" "unprognostic (1.93e-3)" "unprognostic (2.53e-1)" "unprognostic (2.76e-3)" "unprognostic (4.82e-2)" "unprognostic (5.32e-3)" "unprognostic (3.13e-1)" "unprognostic (2.30e-1)" "unprognostic (7.00e-2)" "unprognostic (1.79e-1)" 10.7 13.2 23.7 9.4 21.0 3.1 14.4 25.0 42.7 12.5 11.5 7.9 8.5 9.6 12.1 17.8 18.5 11.5 10.7 14.9 31.7 29.3 15.8 20.6 11.4 14.6 24.5 27.1 13.0 11.1 19.6 16.7 15.1 23.4 14.5 13.1 6.5 9.8 13.2 20.6 14.4 9.9 13.5 16.3 10.7 10.7 10.3 9.8 10.3 16.5 11.6 13.4 11.1 11.2 2.8 1.8 13.2 4.3 3.5 3.3 2.3 17.9 15.5 20.4 10.5 11.3 14.7 13.0 12.3 16.2 14.0 13.4 9.2 6.2 7.5 10.0 19.1 12.1 17.7 17.1 21.1 13.2 20.8 8.3 9.1 17.3 13.3 7.9 12.6 12.1 17.0 16.4 17.2 12.7 8.8 4.4 17.6 6.7 9.6 7.4 11.9 7.6 11.8 22.9 5.1 19.2 11.6 4.1 12.1 14.2 7.6 11.8 9.6 5.8 11.6 6.9 10.7 9.5 14.5 8.7 9.7 5.9 13.0 6.3 10.0 0.6 2.7 2.0 3.0 1.5 2.7 2.8 2.4 2.4 1.8 2.7 2.0 3.3 13.2 3.5 4.3 1.8 2.6 2.3 23.7 21.0 25.0 42.7 31.7 29.3 24.5 27.1 23.4 9.8 MAP3K1 "MAPKKK1, MEKK, MEKK1" ENSG00000095015 "Mitogen-activated protein kinase kinase kinase 1" Q13233 5 56815574-56896152 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "SH-SY5Y: 27.0;THP-1: 25.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Region enriched" "Detected in many" 6 "olfactory region: 22.5" "Low region specificity" "Detected in all" "CAB004500, HPA046509" Approved Approved Cytosol Cytosol "CAB004500: AB_627926, HPA046509: " "unprognostic (1.77e-1)" "unprognostic (1.71e-2)" "unprognostic (4.09e-1)" "unprognostic (2.18e-1)" "unprognostic (3.48e-2)" "unprognostic (5.39e-3)" "unprognostic (5.20e-3)" "unprognostic (2.52e-2)" "unprognostic (1.35e-1)" "unprognostic (1.41e-1)" "unprognostic (1.05e-2)" "unprognostic (6.73e-2)" "unprognostic (1.97e-3)" "unprognostic (2.18e-2)" "unprognostic (1.58e-1)" "unprognostic (9.92e-3)" "unprognostic (1.11e-1)" 6.7 4.9 5.4 14.6 4.8 15.2 14.9 8.0 4.5 7.6 6.7 5.4 7.3 4.3 7.1 9.4 12.7 7.2 5.9 4.3 3.7 3.2 9.5 4.4 8.8 21.4 6.4 3.1 8.4 9.2 6.3 7.9 8.1 4.5 8.3 4.5 12.6 15.4 9.7 3.5 21.8 11.2 4.0 3.8 21.3 5.5 8.5 5.1 11.7 19.2 6.6 18.2 6.0 11.7 6.6 2.8 6.7 7.2 2.7 5.8 2.3 6.4 3.9 6.2 4.1 1.0 0.8 10.4 1.2 1.7 3.9 5.5 18.4 4.9 5.8 0.4 1.5 3.4 5.1 2.3 5.4 2.0 2.2 3.2 1.7 8.6 2.5 5.1 9.0 1.0 2.5 1.2 1.9 1.7 2.8 10.5 1.0 2.8 3.5 6.9 2.8 0.5 5.6 4.4 19.9 6.8 6.8 2.6 27.0 3.8 4.8 11.0 13.2 25.2 4.9 0.3 3.3 1.4 2.3 7.7 3.9 11.1 0.6 3.0 6.6 6.7 4.5 1.0 1.2 6.8 1.2 6.6 3.8 1.8 2.8 5.1 2.5 0.9 2.6 2.7 7.2 1.5 5.8 2.3 5.4 4.8 8.0 4.5 3.7 3.2 6.4 3.1 4.5 5.1 MAP3K13 "LZK, MEKK13" ENSG00000073803 "Mitogen-activated protein kinase kinase kinase 13" O43283 3 185282941-185489097 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA016497, HPA036691, HPA036692" Uncertain Approved "Nucleoplasm,Centriolar satellite,Cytosol" "Centriolar satellite" "Nucleoplasm, Cytosol" "HPA016497: AB_10670027, HPA036691: AB_10673661, HPA036692: AB_10670845" "unprognostic (8.95e-2)" "unprognostic (6.72e-3)" "unprognostic (9.46e-2)" "prognostic unfavourable (1.28e-5)" "unprognostic (5.16e-2)" "unprognostic (2.81e-1)" "unprognostic (2.61e-1)" "unprognostic (1.23e-2)" "unprognostic (9.04e-2)" "prognostic favourable (1.11e-4)" "prognostic unfavourable (7.27e-5)" "unprognostic (2.70e-3)" "unprognostic (1.54e-2)" "unprognostic (2.94e-2)" "unprognostic (2.82e-1)" "unprognostic (6.64e-2)" "unprognostic (9.31e-3)" 9.8 24.8 21.7 8.7 22.2 9.5 15.1 16.4 26.1 12.9 16.9 18.4 10.5 16.8 12.9 42.1 15.2 14.6 13.1 8.1 19.2 18.6 21.9 20.7 15.2 7.4 23.2 17.1 16.5 24.9 20.9 24.5 9.1 21.8 14.5 18.9 18.6 26.2 11.4 3.3 9.8 23.4 12.1 26.4 8.7 16.4 12.9 15.8 4.4 18.6 8.3 10.3 12.5 11.5 23.7 21.5 21.1 13.2 11.5 17.4 7.8 29.1 5.8 11.3 0.3 10.3 12.7 6.6 6.7 4.6 10.9 13.2 11.2 11.0 0.2 23.0 12.2 16.7 0.3 15.5 19.4 32.4 15.0 0.1 7.9 9.2 11.2 15.3 8.4 11.5 13.6 9.3 11.7 12.1 0.3 23.7 9.7 9.1 1.8 7.2 13.0 13.7 0.2 13.5 16.0 19.2 7.6 18.6 12.4 11.3 17.1 23.2 25.8 8.6 8.0 9.0 11.7 16.2 14.5 12.1 15.6 9.6 13.2 7.8 14.7 6.4 13.2 5.1 10.3 12.2 15.8 23.7 12.4 12.8 21.5 19.0 17.4 16.8 21.1 11.5 8.6 9.4 4.8 7.8 21.7 22.2 16.4 26.1 19.2 18.6 23.2 17.1 21.8 15.8 MAP3K3 "MAPKKK3, MEKK3" ENSG00000198909 "Mitogen-activated protein kinase kinase kinase 3" Q99759 17 63622415-63696303 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB007764, HPA035410, HPA035411" Uncertain Approved Nucleoplasm Nucleoplasm "CAB007764: AB_562314, HPA035410: , HPA035411: " "unprognostic (9.65e-3)" "unprognostic (1.33e-1)" "unprognostic (5.14e-2)" "prognostic unfavourable (1.13e-4)" "unprognostic (1.16e-1)" "unprognostic (4.12e-2)" "unprognostic (1.03e-2)" "unprognostic (1.33e-1)" "unprognostic (1.36e-1)" "unprognostic (9.37e-2)" "unprognostic (1.46e-3)" "unprognostic (5.51e-2)" "unprognostic (2.35e-1)" "unprognostic (2.79e-2)" "unprognostic (4.68e-2)" "unprognostic (1.09e-1)" "unprognostic (3.08e-2)" 23.9 11.8 10.5 20.5 15.0 24.8 19.1 26.8 14.9 22.2 21.8 15.0 14.0 8.0 24.5 13.2 16.6 18.3 20.6 37.4 11.3 8.4 17.1 12.4 23.1 21.4 14.4 9.6 21.6 11.4 16.9 12.3 21.0 11.9 18.4 8.3 21.7 12.8 18.5 19.6 15.4 14.7 20.4 13.2 30.4 16.4 26.5 12.3 12.9 15.5 12.8 15.4 19.0 26.8 1.9 3.5 18.3 8.5 1.1 2.6 2.3 10.1 7.6 9.7 9.4 18.6 15.0 4.4 10.0 11.0 12.5 10.1 3.5 2.1 10.9 7.1 19.6 3.8 6.3 7.1 7.9 9.5 13.9 8.9 10.3 4.9 9.7 6.8 9.5 10.7 4.9 15.5 8.2 30.3 5.4 14.5 9.9 7.1 12.2 7.1 6.0 8.1 6.5 24.8 7.1 4.5 4.6 5.0 11.9 6.8 8.2 8.3 8.2 6.8 27.2 32.0 8.5 17.3 12.1 14.4 14.6 4.0 6.9 5.5 8.3 8.8 8.5 10.4 2.2 8.3 2.3 1.5 2.6 2.1 3.5 1.9 2.5 2.5 18.3 1.1 8.2 1.3 1.9 2.3 10.5 15.0 26.8 14.9 11.3 8.4 14.4 9.6 11.9 12.3 MAP3K4 "KIAA0213, MAPKKK4, MEKK4, MTK1" ENSG00000085511 "Mitogen-activated protein kinase kinase kinase 4" Q9Y6R4 6 160991727-161117385 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA007625 Uncertain Approved Cytosol Cytosol "HPA007625: AB_1853770" "unprognostic (3.05e-3)" "unprognostic (2.19e-2)" "unprognostic (1.36e-1)" "unprognostic (1.44e-1)" "unprognostic (2.06e-1)" "unprognostic (7.65e-2)" "unprognostic (1.35e-3)" "unprognostic (6.38e-2)" "unprognostic (2.09e-1)" "unprognostic (3.81e-3)" "unprognostic (2.09e-2)" "unprognostic (2.61e-1)" "unprognostic (1.16e-2)" "unprognostic (5.86e-2)" "unprognostic (3.45e-1)" "unprognostic (1.93e-1)" "unprognostic (6.84e-2)" 12.0 8.0 13.1 17.7 12.6 9.1 14.6 23.1 14.0 16.4 13.9 9.3 12.2 9.5 22.2 11.9 21.4 14.1 11.4 12.4 11.9 7.8 9.4 8.2 15.9 14.4 12.8 8.9 17.4 12.1 15.8 16.2 12.4 9.2 14.2 9.8 9.4 15.0 15.4 24.4 15.1 13.3 13.9 7.7 10.6 11.1 13.5 12.4 16.2 10.6 13.0 16.8 15.8 23.9 8.8 5.4 17.5 3.8 3.5 8.9 2.2 4.6 5.3 10.1 8.6 6.3 7.4 6.5 5.3 4.7 6.1 6.5 7.5 3.4 9.6 3.8 13.5 11.7 10.3 10.6 7.5 7.0 8.4 12.5 4.9 7.4 4.8 13.0 6.1 4.6 12.3 6.4 5.8 7.9 31.6 11.1 6.5 4.8 8.7 6.6 6.1 8.2 9.6 9.3 7.6 5.6 3.4 5.8 5.2 9.9 10.6 0.9 4.3 15.9 7.4 7.5 9.6 6.9 25.0 6.5 5.2 8.8 8.8 13.4 7.8 17.5 3.8 2.3 5.0 3.0 8.9 6.2 7.1 4.5 4.3 8.8 5.0 4.9 0.2 3.5 1.7 5.4 4.8 2.2 13.1 12.6 23.1 14.0 11.9 7.8 12.8 8.9 9.2 12.4 MAP4K3 "GLK, MAPKKKK3, RAB8IPL1" ENSG00000011566 "Mitogen-activated protein kinase kinase kinase kinase 3" Q8IVH8 2 39249266-39437312 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "AF22: 40.8;RT4: 37.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA030380 Approved Approved "Nucleoplasm,Centriolar satellite" "Centriolar satellite" Nucleoplasm "HPA030380: AB_10601132" "unprognostic (4.82e-2)" "unprognostic (7.22e-2)" "unprognostic (5.87e-3)" "unprognostic (7.34e-3)" "unprognostic (6.77e-2)" "unprognostic (2.57e-1)" "unprognostic (1.05e-2)" "unprognostic (6.73e-2)" "unprognostic (1.66e-1)" "unprognostic (6.73e-2)" "unprognostic (4.33e-3)" "unprognostic (4.26e-2)" "unprognostic (2.12e-1)" "unprognostic (3.08e-2)" "unprognostic (3.30e-1)" "unprognostic (2.43e-1)" "unprognostic (5.08e-2)" 19.7 18.9 17.6 15.4 17.6 9.6 17.8 37.1 19.6 19.2 16.9 14.6 9.8 13.7 23.5 14.8 11.1 15.3 18.7 19.5 15.4 12.5 26.2 15.4 15.6 5.8 15.4 13.4 24.6 14.0 25.7 24.6 30.8 14.4 18.6 14.1 17.9 13.3 15.7 33.0 17.8 17.2 18.6 15.3 11.5 26.1 21.0 16.5 9.4 25.9 11.3 7.5 18.8 32.6 0.7 0.5 2.5 1.9 1.0 1.3 0.4 9.7 6.1 40.8 6.4 6.6 13.4 11.2 8.7 11.1 8.6 7.4 5.1 4.9 2.1 9.8 5.9 5.3 15.3 7.7 13.2 2.4 6.3 3.5 4.3 11.9 17.3 1.5 5.8 11.9 7.7 11.2 12.1 7.4 4.5 4.0 11.5 5.3 3.4 2.3 12.3 9.3 3.7 13.3 1.6 11.4 37.8 7.3 8.3 5.1 8.2 22.6 5.5 2.2 6.0 6.7 8.0 6.0 4.7 6.1 3.4 0.7 8.3 2.5 7.8 2.5 0.7 0.0 1.2 1.1 0.1 0.1 1.2 0.9 0.1 0.7 1.1 1.3 0.0 1.0 1.9 0.5 0.6 0.4 17.6 17.6 37.1 19.6 15.4 12.5 15.4 13.4 14.4 16.5 MAPK1 "ERK, ERK2, MAPK2, p41mapk, PRKM1, PRKM2" ENSG00000100030 "Mitogen-activated protein kinase 1" P28482 22 21754500-21867680 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins" "Apoptosis, Cell cycle, Host-virus interaction, Transcription, Transcription regulation" "DNA-binding, Kinase, Repressor, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 80.3" "Cell line enhanced" "Detected in all" "K-562: 79.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003995, CAB004229, HPA005700, HPA030069" Approved 250000 "CAB004229: AB_627547, HPA003995: AB_1078751, HPA005700: AB_1078750, HPA030069: AB_10602035" "unprognostic (9.41e-3)" "unprognostic (2.68e-1)" "unprognostic (2.50e-3)" "unprognostic (4.17e-1)" "unprognostic (4.44e-3)" "unprognostic (1.72e-1)" "prognostic unfavourable (4.95e-4)" "unprognostic (2.29e-1)" "unprognostic (1.67e-1)" "unprognostic (1.58e-1)" "unprognostic (8.43e-3)" "unprognostic (1.04e-1)" "unprognostic (1.35e-2)" "unprognostic (2.08e-1)" "unprognostic (1.94e-1)" "unprognostic (1.41e-1)" "unprognostic (6.49e-2)" 16.1 21.1 32.9 18.3 80.3 20.2 13.6 31.0 54.5 18.6 18.5 23.2 9.6 13.7 17.4 10.6 25.7 16.9 14.9 22.8 32.4 23.4 21.7 16.4 19.9 16.6 18.4 23.6 16.0 19.8 27.4 10.9 17.2 27.6 16.4 19.9 14.2 15.8 17.8 28.2 17.5 15.1 22.8 20.4 19.8 17.2 24.2 21.5 19.5 23.0 11.1 21.4 17.7 15.3 2.5 3.2 13.5 4.9 7.0 13.7 2.5 19.3 12.2 15.7 9.0 18.7 18.9 6.0 21.4 20.0 19.2 18.6 9.7 10.3 10.7 10.6 28.6 18.4 18.5 17.1 25.1 43.1 17.3 19.4 11.5 11.4 15.4 27.3 20.1 14.0 13.7 23.2 21.5 26.2 79.5 12.2 23.4 7.9 17.6 6.0 5.9 12.1 19.4 39.0 2.9 11.0 15.9 12.9 7.1 23.1 14.0 12.5 10.5 9.2 22.9 16.1 21.0 18.4 13.6 11.7 14.3 16.7 15.2 13.3 17.4 1.0 4.0 5.8 13.7 4.6 3.9 2.0 2.9 4.9 3.2 2.5 2.8 5.1 13.5 7.0 4.9 3.2 2.7 2.5 32.9 80.3 31.0 54.5 32.4 23.4 18.4 23.6 27.6 21.5 MAPK14 "CSBP1, CSBP2, CSPB1, Mxi2, p38, PRKM14, PRKM15" ENSG00000112062 "Mitogen-activated protein kinase 14" Q16539 6 36027677-36111236 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Apoptosis, Stress response, Transcription, Transcription regulation" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in all" 5 "basophil: 32.1;neutrophil: 12.3" "Lineage enriched" "Detected in all" 7 "granulocytes: 32.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010285, CAB040578, HPA051825" Approved Supported "Nuclear speckles,Cytosol" 7100000 "Nuclear speckles" Cytosol "CAB010285: AB_632140, CAB040578: , HPA051825: " "unprognostic (6.76e-3)" "unprognostic (6.28e-2)" "unprognostic (6.30e-3)" "unprognostic (3.30e-3)" "unprognostic (6.98e-2)" "unprognostic (4.04e-2)" "unprognostic (8.10e-2)" "unprognostic (1.93e-1)" "unprognostic (2.20e-3)" "unprognostic (8.39e-2)" "unprognostic (6.27e-2)" "unprognostic (1.10e-1)" "unprognostic (1.47e-2)" "unprognostic (3.66e-3)" "unprognostic (6.66e-2)" "unprognostic (3.25e-1)" "unprognostic (1.58e-1)" 21.5 20.6 11.7 18.4 15.5 49.9 20.7 26.5 18.1 22.0 20.5 12.5 11.9 16.9 38.8 12.1 24.0 18.9 16.0 16.4 9.3 9.5 16.0 29.8 21.5 29.0 12.0 11.3 17.7 18.5 15.0 27.2 27.3 10.2 23.4 18.3 17.0 16.7 16.5 21.2 25.6 22.5 26.0 10.6 35.5 18.2 11.1 10.3 34.1 20.9 17.6 20.8 25.0 30.0 2.3 4.0 32.1 4.9 3.0 2.8 2.1 18.3 10.1 10.9 17.5 24.8 24.8 24.0 19.2 25.0 22.8 23.8 24.7 9.5 14.9 19.1 21.1 13.2 18.0 16.6 23.9 16.8 14.3 34.4 14.4 20.6 13.7 21.6 20.8 17.4 16.2 16.4 16.3 25.8 19.0 18.7 15.5 8.7 22.2 26.0 6.7 10.1 26.4 17.7 13.8 16.1 25.3 8.2 7.0 17.3 13.0 20.1 15.3 40.4 18.1 20.5 11.9 12.9 17.6 9.2 21.0 14.9 9.3 42.8 16.8 32.1 4.9 3.0 2.4 3.5 2.8 1.5 2.2 2.6 4.0 2.3 2.5 2.4 12.3 3.0 4.7 1.9 2.6 2.1 11.7 15.5 26.5 18.1 9.3 9.5 12.0 11.3 10.2 10.3 MAPK3 "ERK1, p44erk1, p44mapk, PRKM3" ENSG00000102882 "Mitogen-activated protein kinase 3" P27361 16 30114105-30123506 "Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins" "Apoptosis, Cell cycle, Host-virus interaction" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 6 "eosinophil: 25.1;neutrophil: 11.3" "Lineage enriched" "Detected in many" 8 "granulocytes: 25.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002683, HPA003995, HPA005700, HPA030069" Approved Approved Nucleoplasm Nucleoplasm "CAB002683: , HPA003995: AB_1078751, HPA005700: AB_1078750, HPA030069: AB_10602035" "unprognostic (5.03e-2)" "unprognostic (4.62e-2)" "unprognostic (3.46e-2)" "unprognostic (1.60e-1)" "unprognostic (4.70e-3)" "unprognostic (2.75e-1)" "prognostic unfavourable (1.11e-4)" "unprognostic (2.09e-2)" "unprognostic (3.59e-2)" "unprognostic (1.12e-1)" "unprognostic (1.55e-1)" "unprognostic (3.51e-2)" "unprognostic (8.78e-2)" "unprognostic (1.45e-1)" "unprognostic (3.01e-2)" "unprognostic (2.38e-1)" "unprognostic (1.19e-2)" 24.9 18.5 63.3 15.3 43.2 15.6 21.1 24.8 52.0 21.3 45.1 30.4 6.3 39.7 24.2 11.4 44.1 28.7 25.6 21.2 37.1 34.0 13.4 8.8 23.3 13.1 33.8 27.4 32.7 13.0 26.1 15.2 27.6 27.6 20.1 36.7 26.2 17.1 18.3 13.9 18.7 49.2 24.0 27.8 15.9 33.7 11.6 19.5 8.4 20.5 18.7 26.0 18.2 22.2 1.4 1.5 25.1 2.7 0.8 3.1 1.4 13.7 7.5 16.1 9.1 40.5 53.8 9.0 10.3 25.6 16.4 19.6 9.0 27.8 13.9 10.2 28.8 5.1 13.5 12.1 16.0 26.3 15.7 4.3 8.3 15.0 40.7 3.1 11.9 33.1 7.0 18.7 8.4 41.6 5.8 17.9 21.6 36.3 14.3 5.0 4.3 6.6 17.0 9.6 31.2 14.9 8.7 14.2 10.1 5.9 20.8 6.0 13.6 7.6 29.4 10.8 9.3 12.3 3.5 20.3 9.3 7.1 21.6 6.7 7.6 2.4 2.7 25.1 0.9 1.9 1.4 1.3 2.1 1.6 1.4 1.4 1.5 1.6 11.3 0.8 1.0 1.5 3.1 1.4 63.3 43.2 24.8 52.0 37.1 34.0 33.8 27.4 27.6 19.5 MAPK7 "BMK1, ERK5, PRKM7" ENSG00000166484 "Mitogen-activated protein kinase 7" Q13164 17 19377721-19383544 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Differentiation" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "ASC diff: 27.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB018561, HPA031031" Uncertain Enhanced Nucleoplasm,Cytosol Nucleoplasm Cytosol "CAB018561: AB_2140544, HPA031031: " "unprognostic (1.63e-1)" "unprognostic (2.75e-2)" "unprognostic (1.72e-1)" "unprognostic (2.90e-2)" "unprognostic (4.38e-2)" "unprognostic (1.20e-3)" "prognostic unfavourable (1.86e-4)" "unprognostic (5.67e-3)" "unprognostic (1.62e-2)" "unprognostic (1.16e-1)" "unprognostic (1.83e-2)" "unprognostic (4.75e-2)" "unprognostic (1.23e-2)" "unprognostic (1.90e-1)" "unprognostic (5.71e-1)" "unprognostic (1.55e-1)" "unprognostic (3.78e-2)" 11.5 15.0 6.4 7.3 7.6 9.2 11.8 12.5 7.9 13.4 15.3 7.2 6.0 9.2 13.1 14.1 17.3 9.4 11.8 8.2 5.9 4.7 10.8 4.8 9.9 9.2 8.2 5.2 25.4 5.7 7.3 7.5 12.5 6.7 14.0 6.9 10.5 7.8 12.3 7.5 13.1 11.2 13.8 7.1 13.2 8.0 13.3 7.5 4.5 8.6 11.3 10.6 12.7 15.9 2.2 2.6 11.5 7.4 5.5 4.7 3.0 4.1 6.5 5.4 4.2 27.1 11.3 6.3 5.6 5.2 7.8 7.2 7.5 0.7 2.5 4.6 9.7 4.6 6.3 5.1 4.9 4.3 4.8 1.2 4.7 3.3 11.7 1.1 4.2 11.9 3.6 11.8 4.2 5.7 2.2 0.9 7.7 2.7 8.3 4.4 6.2 4.3 4.5 7.9 1.7 2.6 2.3 2.4 7.2 5.7 0.5 2.9 3.5 1.4 3.2 8.4 6.2 9.2 3.8 1.6 2.4 0.6 9.7 1.0 5.0 1.0 3.6 11.5 4.7 7.4 2.5 2.2 2.2 4.1 2.6 1.4 2.1 2.6 1.3 5.5 6.5 1.7 1.0 3.0 6.4 7.6 12.5 7.9 5.9 4.7 8.2 5.2 6.7 7.5 MAPK8 "JNK, JNK1, PRKM8, SAPK1" ENSG00000107643 "Mitogen-activated protein kinase 8" P45983 10 48306639-48439360 "Cancer-related genes, Enzymes, Predicted intracellular proteins, RAS pathway related proteins" "Biological rhythms" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004463, CAB069396" Approved "CAB004463: AB_675868, CAB069396: AB_1619977" "unprognostic (7.49e-2)" "unprognostic (1.47e-1)" "unprognostic (2.74e-2)" "unprognostic (1.46e-1)" "unprognostic (3.07e-2)" "unprognostic (1.60e-2)" "prognostic unfavourable (8.66e-4)" "unprognostic (4.23e-2)" "unprognostic (5.98e-2)" "unprognostic (4.31e-3)" "unprognostic (2.33e-1)" "unprognostic (6.06e-2)" "prognostic favourable (8.66e-4)" "unprognostic (1.58e-1)" "unprognostic (9.95e-2)" "unprognostic (1.85e-2)" "unprognostic (1.01e-3)" 13.4 11.7 15.3 11.5 18.5 13.3 22.1 33.6 35.2 15.2 13.9 12.9 19.5 16.7 17.1 10.8 16.1 12.4 15.1 11.2 20.0 18.0 20.1 23.6 11.7 12.0 15.9 16.7 18.9 15.3 12.7 23.7 12.2 23.6 13.0 14.3 12.4 17.2 15.9 18.9 10.8 17.7 14.6 13.7 9.6 12.2 23.4 12.2 20.5 22.3 9.0 13.8 11.8 13.0 4.5 4.3 5.2 4.3 4.7 5.7 3.5 15.7 4.3 14.3 8.1 5.5 6.5 11.1 23.8 16.3 14.3 11.7 4.9 16.4 5.7 6.5 13.3 9.7 5.0 9.2 18.7 34.1 8.2 8.2 5.0 6.7 9.1 14.0 9.6 5.5 10.6 10.6 21.1 13.1 13.1 10.6 9.3 4.6 17.1 7.4 8.9 3.1 11.2 14.7 5.7 8.7 6.1 24.1 19.1 9.3 7.8 10.7 8.5 6.7 11.2 10.7 25.6 8.1 17.9 3.3 8.1 11.6 7.4 14.9 6.1 0.0 3.3 3.0 4.1 2.8 4.7 4.5 5.7 5.0 3.3 2.9 5.6 3.9 5.2 4.7 4.3 4.3 2.9 3.5 15.3 18.5 33.6 35.2 20.0 18.0 15.9 16.7 23.6 12.2 MAPK8IP1 "IB1, JIP-1, JIP1, PRKM8IP" ENSG00000121653 "Mitogen-activated protein kinase 8 interacting protein 1" Q9UQF2 11 45885651-45906465 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cancer-related genes, Diabetes mellitus, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 73.5" "Cell line enhanced" "Detected in many" "SCLC-21H: 38.6" "Cancer enhanced" "Detected in all" "glioma: 51.2" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "NK-cell: 2.6" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA058921, HPA070332" Enhanced "Plasma membrane" "Plasma membrane" "HPA058921: , HPA070332: " "unprognostic (3.96e-2)" "unprognostic (8.73e-2)" "unprognostic (1.08e-1)" "unprognostic (6.88e-2)" "unprognostic (5.59e-2)" "unprognostic (2.82e-1)" "unprognostic (8.25e-3)" "unprognostic (3.42e-3)" "unprognostic (1.27e-2)" "unprognostic (9.54e-2)" "unprognostic (3.22e-3)" "unprognostic (2.20e-2)" "prognostic favourable (1.23e-11)" "unprognostic (7.19e-2)" "unprognostic (4.01e-2)" "unprognostic (4.46e-2)" "unprognostic (1.80e-3)" 3.0 12.8 33.3 2.1 29.6 1.4 2.7 24.9 73.5 3.1 1.9 4.6 0.1 1.6 4.9 3.1 2.1 6.6 3.0 2.9 38.1 22.3 5.1 2.7 2.6 1.0 28.0 18.9 4.4 26.4 14.7 24.8 1.6 23.5 4.9 1.5 4.5 4.8 5.0 1.7 1.7 2.0 4.4 44.4 1.7 3.8 10.8 4.8 0.0 3.9 0.5 0.9 2.0 0.4 0.4 0.4 2.1 0.9 2.6 0.2 0.0 0.0 3.5 4.7 13.1 1.8 0.9 0.1 2.5 2.2 5.0 3.6 3.0 0.5 0.2 1.2 2.9 2.8 5.0 2.3 2.2 1.9 6.5 0.0 4.4 2.0 1.6 0.2 2.2 1.2 0.5 3.2 0.6 1.1 5.4 0.8 1.4 1.8 0.1 0.3 12.5 5.2 0.3 7.7 0.1 2.3 0.0 38.6 14.4 4.1 3.4 4.7 5.5 0.2 1.0 6.4 9.8 9.5 4.5 0.5 0.6 0.2 4.0 0.1 1.9 2.1 0.9 0.0 0.2 0.2 0.1 0.2 0.0 0.1 0.0 0.4 0.1 0.2 1.8 2.6 0.0 0.4 0.1 0.0 33.3 29.6 24.9 41.7 38.1 22.3 28.0 18.9 23.5 4.8 MAPKAPK2 ENSG00000162889 "Mitogen-activated protein kinase-activated protein kinase 2" P49137 1 206684944-206734283 "Cancer-related genes, Enzymes, Predicted membrane proteins" "DNA damage" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in many" 6 "plasmacytoid DC: 18.7" "Lineage enriched" "Detected in all" 6 "dendritic cells: 18.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010297, HPA045556, HPA063708, HPA064435" Approved Supported Nucleoplasm,Centrosome Nucleoplasm Centrosome "CAB010297: AB_2250405, HPA045556: , HPA063708: , HPA064435: " "unprognostic (7.93e-2)" "unprognostic (1.83e-1)" "unprognostic (5.27e-2)" "unprognostic (5.12e-2)" "unprognostic (1.80e-1)" "unprognostic (1.32e-2)" "prognostic unfavourable (1.93e-4)" "unprognostic (9.85e-2)" "unprognostic (1.68e-1)" "unprognostic (2.00e-1)" "unprognostic (1.01e-2)" "unprognostic (1.35e-1)" "prognostic unfavourable (4.58e-6)" "unprognostic (2.12e-1)" "unprognostic (1.37e-1)" "unprognostic (6.96e-2)" "unprognostic (3.29e-2)" 23.0 25.3 11.6 21.2 15.7 58.6 23.9 11.1 14.5 19.3 25.6 17.2 14.5 25.7 20.0 18.5 23.5 17.3 26.0 89.2 12.3 8.7 33.7 26.7 26.7 21.5 16.7 6.5 23.3 19.1 16.9 22.8 13.6 15.7 20.2 14.4 17.8 19.8 14.4 62.9 18.3 32.9 18.3 14.6 37.7 23.1 21.3 14.6 26.9 24.3 25.2 28.2 22.9 46.1 1.1 18.7 3.2 1.1 2.3 1.6 0.5 20.9 8.3 11.5 12.9 34.0 20.0 14.3 14.6 33.1 22.3 21.1 15.8 10.2 10.1 10.2 29.4 15.9 8.6 15.5 16.1 11.7 6.5 16.9 10.3 10.2 26.3 24.9 56.6 27.5 19.9 21.4 23.7 18.2 19.4 45.9 18.0 26.0 10.0 18.0 13.3 11.6 25.8 24.1 3.2 16.8 12.8 9.2 11.9 17.2 29.1 20.2 14.1 24.2 17.3 20.1 17.0 23.3 19.8 59.8 53.1 8.2 22.8 15.2 6.6 1.1 0.7 1.4 1.6 1.1 1.5 1.0 1.2 1.5 0.6 1.1 0.6 1.1 3.2 2.3 1.0 18.7 1.4 0.5 11.6 15.7 11.1 14.5 12.3 8.7 16.7 6.5 15.7 14.6 MAST2 "KIAA0807, MAST205" ENSG00000086015 "Microtubule associated serine/threonine kinase 2" Q6P0Q8 1 45786987-46036124 "Cancer-related genes, Enzymes, Predicted membrane proteins" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 83.3" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "non-classical monocyte: 4.3" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA039722, HPA040155" Approved Approved Cytosol Cytosol "HPA039722: AB_10795294, HPA040155: AB_10793957" "unprognostic (7.80e-2)" "unprognostic (3.02e-2)" "unprognostic (5.77e-2)" "unprognostic (1.52e-1)" "unprognostic (3.82e-1)" "unprognostic (3.17e-2)" "prognostic unfavourable (4.31e-8)" "unprognostic (8.86e-2)" "unprognostic (2.34e-2)" "unprognostic (1.98e-1)" "unprognostic (1.60e-1)" "unprognostic (1.75e-1)" "prognostic unfavourable (6.85e-13)" "unprognostic (4.82e-3)" "unprognostic (2.43e-1)" "unprognostic (9.73e-2)" "unprognostic (4.90e-1)" 8.9 4.3 7.0 9.9 8.1 3.7 7.1 7.1 11.8 13.6 15.2 8.4 6.6 11.2 16.7 7.7 8.8 9.5 9.9 25.5 5.0 7.6 4.8 6.1 5.9 4.4 8.9 7.3 19.8 3.6 9.1 10.5 5.5 10.1 13.9 13.9 7.2 8.3 8.6 83.3 5.5 21.3 14.9 5.8 2.5 9.0 24.8 4.8 3.5 5.7 27.4 7.5 16.3 10.6 0.5 1.9 1.4 4.3 1.4 1.4 0.5 15.2 12.4 12.5 9.6 16.4 23.6 13.9 16.3 11.8 15.1 16.9 14.2 5.0 23.9 7.7 19.9 7.6 15.1 9.3 16.0 11.5 8.1 10.8 14.0 13.0 14.3 5.8 13.9 18.1 12.1 25.3 20.3 14.1 8.3 7.3 18.0 10.4 8.4 6.0 10.3 14.2 12.4 21.0 4.5 7.8 8.3 17.5 10.4 19.2 25.1 8.2 11.4 5.7 13.7 29.3 18.9 15.3 16.1 10.0 8.9 8.7 19.6 7.9 12.1 0.0 1.1 1.4 1.4 0.6 1.4 0.2 0.7 1.4 1.9 0.5 0.5 1.0 0.0 1.4 4.3 0.1 0.0 0.5 7.0 8.1 7.1 11.8 5.0 7.6 8.9 7.3 10.1 4.8 MATK "CHK, CTK, DKFZp434N1212, HHYLTK, HYL, HYLTK, Lsk, MGC1708, MGC2101" ENSG00000007264 "Megakaryocyte-associated tyrosine kinase" P42679 19 3777970-3802129 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 29.3;bone marrow: 19.1;brain: 27.4" "Cell line enhanced" "Detected in some" "HL-60: 40.7;HMC-1: 12.5;K-562: 18.1;MCF7: 13.2;NB-4: 28.4;SCLC-21H: 12.4;THP-1: 10.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "gdT-cell: 19.4;NK-cell: 29.3" "Group enriched" "Detected in many" 54 "NK-cells: 29.3;T-cells: 19.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004847, HPA066547" Approved Approved "Microtubules,Cytokinetic bridge,Mitotic spindle,Centriolar satellite,Cytosol" Microtubules "Cytokinetic bridge, Mitotic spindle, Centriolar satellite, Cytosol" "HPA004847: AB_1079316, HPA066547: " "prognostic favourable (5.27e-4)" "unprognostic (1.28e-2)" "unprognostic (1.84e-1)" "unprognostic (3.54e-2)" "unprognostic (3.36e-1)" "unprognostic (3.39e-2)" "unprognostic (9.50e-2)" "unprognostic (1.23e-1)" "unprognostic (7.91e-2)" "unprognostic (3.19e-3)" "unprognostic (2.07e-2)" "unprognostic (4.51e-2)" "unprognostic (1.16e-2)" "unprognostic (7.59e-2)" "unprognostic (1.66e-1)" "unprognostic (2.26e-1)" "unprognostic (2.33e-2)" 11.2 1.6 22.1 6.8 18.1 19.1 2.2 1.5 27.4 1.5 2.3 1.7 0.0 7.0 1.2 0.4 1.1 4.7 5.1 1.7 25.1 10.0 1.1 2.8 7.3 9.6 7.0 11.0 1.0 1.6 0.1 1.4 1.4 6.1 1.2 1.4 0.6 3.8 1.0 0.8 1.6 6.7 1.1 2.8 14.8 4.1 2.1 1.3 3.5 0.9 0.0 4.5 2.4 0.7 0.4 0.3 0.4 0.0 29.3 19.4 2.7 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.6 0.0 4.1 5.4 0.1 0.0 0.0 7.0 4.5 0.5 1.1 0.0 40.7 12.5 0.0 0.0 0.0 0.0 0.0 18.1 0.0 0.0 13.2 0.1 28.4 3.3 0.1 0.0 0.0 0.0 0.0 0.0 12.4 0.0 0.0 0.0 0.0 0.0 10.7 1.3 0.0 0.2 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 19.4 0.0 13.2 0.0 2.5 12.2 0.3 0.4 1.2 7.1 0.4 29.3 0.0 0.1 0.1 2.7 22.1 18.1 1.5 27.4 25.1 10.0 7.0 11.0 6.1 1.3 MAX "bHLHd4, bHLHd5, bHLHd6, bHLHd7, bHLHd8" ENSG00000125952 "MYC associated factor X" P61244 14 65006174-65102695 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HMC-1: 92.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000328, HPA003474" Supported Supported "Nucleoplasm,Golgi apparatus,Vesicles" Nucleoplasm "Golgi apparatus, Vesicles" "CAB000328: AB_2281783, HPA003474: AB_1079317" "unprognostic (4.50e-3)" "unprognostic (1.51e-3)" "unprognostic (4.08e-2)" "unprognostic (2.87e-1)" "unprognostic (8.37e-2)" "unprognostic (2.42e-2)" "unprognostic (1.13e-3)" "unprognostic (1.30e-3)" "unprognostic (1.53e-2)" "unprognostic (7.36e-3)" "unprognostic (7.19e-2)" "unprognostic (1.66e-2)" "prognostic unfavourable (5.57e-4)" "unprognostic (2.99e-1)" "unprognostic (4.68e-2)" "prognostic favourable (2.12e-4)" "unprognostic (6.03e-2)" 33.4 25.5 31.3 31.5 38.6 68.7 25.8 59.0 38.2 34.6 29.4 37.2 26.3 31.5 34.3 24.0 47.6 38.2 27.9 30.1 29.9 28.4 26.3 21.8 31.4 43.4 37.1 21.6 39.7 20.0 17.4 23.7 30.2 32.7 31.9 25.0 26.8 33.6 37.7 27.8 32.1 40.2 30.7 34.8 42.9 24.8 15.7 40.9 41.3 30.2 22.5 40.7 35.1 40.7 18.7 19.1 87.5 23.6 19.2 30.0 44.8 28.3 11.1 6.8 11.0 18.0 14.1 8.9 10.0 15.3 12.5 15.4 7.1 19.9 23.6 8.4 12.0 14.1 17.1 13.9 9.4 23.8 10.4 36.7 7.3 7.8 21.1 13.8 92.4 16.8 9.9 11.5 12.7 13.8 17.2 9.6 12.6 15.7 31.9 47.6 9.1 18.2 18.1 10.8 10.6 11.5 9.5 14.7 9.6 13.1 14.0 12.8 13.7 17.7 17.2 11.5 13.9 10.6 8.0 11.8 10.0 14.9 14.3 13.3 11.4 87.5 23.6 80.6 21.7 20.1 23.7 18.7 25.4 22.1 19.1 17.6 26.6 22.3 49.5 19.2 17.4 18.3 30.0 44.8 31.3 38.6 59.0 38.2 29.9 28.4 37.1 21.6 32.7 40.9 MBD1 "CXXC3, PCM1" ENSG00000141644 "Methyl-CpG binding domain protein 1" Q9UIS9 18 50266882-50281774 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009017, CAB036003, HPA068850" Approved Enhanced Nucleoplasm,Vesicles "Nucleoplasm, Vesicles" "CAB009017: AB_2095559, CAB036003: , HPA068850: " "unprognostic (2.12e-2)" "unprognostic (5.05e-2)" "unprognostic (6.88e-2)" "unprognostic (5.01e-3)" "unprognostic (9.20e-2)" "unprognostic (6.85e-2)" "prognostic unfavourable (5.08e-6)" "unprognostic (5.91e-2)" "unprognostic (2.61e-2)" "unprognostic (4.65e-2)" "unprognostic (1.96e-3)" "prognostic unfavourable (1.70e-6)" "unprognostic (7.06e-3)" "unprognostic (7.70e-2)" "unprognostic (7.05e-2)" "unprognostic (4.61e-2)" "unprognostic (1.31e-1)" 14.7 21.7 18.0 18.8 20.8 29.4 15.7 27.1 29.4 15.3 17.2 18.8 16.2 18.7 18.4 16.6 21.1 16.4 16.8 19.7 19.2 14.0 17.4 18.9 16.0 20.9 21.8 23.1 20.7 19.7 28.2 24.2 19.4 18.2 18.0 13.9 15.0 19.6 19.5 25.9 24.2 18.3 18.3 15.2 22.6 18.0 72.3 21.5 19.1 19.9 20.0 18.2 19.1 20.0 13.1 11.7 22.2 11.6 14.3 17.4 12.1 10.2 9.7 11.0 12.4 11.8 9.7 11.8 12.4 14.3 17.2 13.3 7.3 8.2 16.3 9.0 12.0 18.6 12.5 21.7 10.0 18.2 8.0 10.3 13.8 7.7 22.9 24.8 21.8 11.3 35.1 19.6 45.0 14.1 12.9 25.6 13.2 9.5 20.8 13.0 10.3 7.8 19.3 8.1 17.7 8.5 4.7 14.5 13.8 9.2 8.8 11.3 11.2 22.8 15.2 18.7 8.6 6.0 12.5 47.6 20.1 17.2 12.1 19.1 16.9 15.2 11.6 22.2 17.4 10.1 16.4 13.0 15.2 14.4 11.7 13.1 15.9 12.8 15.6 14.3 7.9 10.7 13.9 12.1 18.0 20.8 27.1 29.4 19.2 14.0 21.8 23.1 18.2 21.5 MBD2 ENSG00000134046 "Methyl-CpG binding domain protein 2" Q9UBB5 18 54151601-54224788 "Cancer-related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "non-classical monocyte: 8.2" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB037282, HPA067582, HPA067615" Approved Enhanced Nucleoplasm Nucleoplasm "CAB037282: AB_477234, HPA067582: , HPA067615: " "unprognostic (4.86e-2)" "unprognostic (7.21e-2)" "prognostic favourable (6.49e-4)" "unprognostic (1.19e-1)" "unprognostic (3.36e-2)" "unprognostic (2.47e-1)" "unprognostic (2.38e-3)" "unprognostic (2.35e-2)" "unprognostic (2.71e-2)" "unprognostic (2.36e-3)" "unprognostic (8.04e-3)" "unprognostic (1.10e-2)" "unprognostic (1.08e-1)" "unprognostic (8.70e-2)" "unprognostic (1.67e-1)" "unprognostic (2.51e-3)" "unprognostic (5.19e-2)" 29.8 11.9 8.5 27.9 9.8 15.3 24.0 9.9 9.0 17.5 22.5 7.4 20.1 10.5 12.5 14.8 33.1 11.3 18.7 17.9 7.9 8.1 23.3 23.2 21.3 33.7 10.0 5.3 15.3 19.3 13.1 12.5 38.1 8.6 18.3 15.0 12.1 23.3 17.3 13.9 24.1 26.7 15.7 11.7 36.9 12.5 26.1 9.4 31.0 31.0 25.4 32.2 22.8 27.1 2.0 1.5 2.2 8.2 0.4 2.6 0.8 12.6 5.7 10.7 5.2 12.6 10.7 10.4 11.9 15.0 13.8 12.1 3.7 7.0 29.8 6.1 18.4 20.2 9.0 16.1 15.2 22.2 4.9 4.4 9.0 7.9 13.0 13.9 8.1 9.3 18.1 10.5 15.5 15.9 3.4 27.7 12.4 6.0 14.0 7.8 11.1 7.6 9.5 6.2 12.0 19.8 13.1 11.6 4.9 9.2 9.4 6.2 4.8 7.1 13.7 14.2 6.5 4.9 10.5 30.1 16.3 23.0 12.4 11.9 8.4 0.1 2.6 1.2 1.2 4.6 1.6 1.4 1.3 1.9 1.5 2.0 0.7 1.2 2.2 0.4 8.2 1.2 2.6 0.8 8.5 9.8 9.9 9.0 7.9 8.1 10.0 5.3 8.6 9.4 MBD4 MED1 ENSG00000129071 "Methyl-CpG binding domain 4, DNA glycosylase" O95243 3 129430944-129440179 "Cancer-related genes, Predicted intracellular proteins" "DNA damage, DNA repair" "DNA-binding, Hydrolase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA002031 Supported Supported "Nuclear speckles" "Nuclear speckles" "HPA002031: AB_1079319" "unprognostic (2.70e-2)" "unprognostic (3.48e-3)" "unprognostic (1.18e-2)" "unprognostic (6.37e-2)" "unprognostic (4.31e-2)" "unprognostic (7.11e-2)" "unprognostic (4.70e-2)" "unprognostic (3.25e-2)" "unprognostic (2.02e-2)" "unprognostic (5.73e-2)" "prognostic unfavourable (2.18e-4)" "prognostic unfavourable (4.75e-4)" "prognostic unfavourable (2.73e-6)" "unprognostic (9.27e-2)" "unprognostic (1.59e-2)" "unprognostic (8.58e-2)" "unprognostic (3.35e-2)" 18.1 14.5 14.9 41.9 19.0 26.2 22.8 22.1 16.3 24.0 17.2 14.2 11.2 16.0 16.6 17.8 14.1 15.3 17.4 22.0 15.3 12.8 24.1 30.1 19.0 41.6 17.6 13.7 26.5 18.9 14.8 23.8 17.4 13.6 14.7 16.2 8.4 16.2 16.2 18.2 16.0 21.9 14.7 15.9 34.2 18.7 11.3 15.4 30.4 16.0 14.7 47.8 18.3 18.0 40.3 8.7 19.6 9.5 9.3 15.1 8.7 19.3 11.8 14.3 16.0 16.5 14.8 16.6 16.8 16.0 16.1 19.3 14.4 13.1 27.4 13.7 10.4 17.6 10.9 10.4 19.7 15.4 7.2 16.4 13.5 10.3 26.4 29.8 21.8 17.6 14.9 13.7 12.2 15.2 18.2 20.7 11.9 18.0 17.2 21.0 12.6 10.1 16.2 8.5 18.8 17.9 9.7 16.1 9.0 21.2 11.1 17.6 14.1 26.5 10.0 15.4 11.8 16.4 11.1 14.1 8.5 48.0 13.1 17.0 12.6 19.6 8.7 11.6 11.5 7.8 8.7 40.3 12.3 11.3 7.3 36.0 15.1 12.6 15.4 9.3 9.5 8.7 10.5 8.7 14.9 19.0 22.1 16.3 15.3 12.8 17.6 13.7 13.6 15.4 MCL1 "BCL2L3, Mcl-1" ENSG00000143384 "MCL1, BCL2 family apoptosis regulator" Q07820 1 150574551-150579738 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Apoptosis, Differentiation" "Developmental protein" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enriched" "Detected in all" 12 "U-698: 328.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "neutrophil: 42.1" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002781, HPA008455, HPA031125, CAB068195" Approved Enhanced Mitochondria Mitochondria "CAB002781: , CAB068195: , HPA008455: AB_1079334, HPA031125: AB_10602026" "unprognostic (3.82e-2)" "unprognostic (8.79e-2)" "unprognostic (9.15e-2)" "unprognostic (2.05e-2)" "unprognostic (1.34e-1)" "unprognostic (3.91e-2)" "unprognostic (3.16e-2)" "unprognostic (2.43e-2)" "unprognostic (1.29e-1)" "unprognostic (8.60e-2)" "unprognostic (1.57e-2)" "unprognostic (1.65e-2)" "prognostic unfavourable (7.16e-4)" "unprognostic (3.22e-2)" "unprognostic (1.94e-1)" "unprognostic (4.87e-2)" "unprognostic (4.46e-2)" 67.7 37.1 19.0 59.3 21.6 134.5 46.3 15.3 18.9 35.9 38.5 19.0 23.9 21.2 36.1 27.6 56.5 57.2 73.3 32.5 20.4 14.9 30.5 76.7 61.8 52.4 28.2 11.4 32.1 41.9 20.3 27.7 59.4 26.7 34.0 30.7 31.0 36.0 24.5 39.8 45.7 50.2 38.9 26.4 51.1 44.3 19.8 23.0 32.3 45.4 53.3 57.4 40.6 59.4 5.0 6.2 42.1 8.0 3.8 11.1 3.9 9.8 5.0 9.4 5.6 19.1 20.2 12.9 12.1 12.4 12.7 10.3 6.3 8.1 12.5 7.1 8.6 13.2 7.1 14.4 12.8 10.3 4.9 5.1 8.1 7.2 15.1 8.6 11.6 11.0 16.6 12.4 24.2 13.9 11.4 18.2 16.6 10.8 4.2 6.6 17.4 8.9 6.5 7.6 6.5 14.0 7.1 7.3 9.9 8.6 11.7 15.5 7.4 13.3 17.1 8.1 8.5 5.1 15.1 23.3 27.3 328.0 13.9 6.8 10.6 7.6 8.0 18.8 6.1 6.5 7.2 5.0 8.0 6.7 6.2 4.6 9.6 7.2 42.1 3.8 5.8 3.7 11.1 3.9 19.0 21.6 15.3 18.9 20.4 14.9 28.2 11.4 26.7 23.0 MCM2 "BM28, CCNL1, cdc19, CDCL1, D3S3194, DFNA70, KIAA0030" ENSG00000073111 "Minichromosome maintenance complex component 2" P49736 3 127598223-127622436 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Cell cycle, DNA replication" "DNA-binding, Helicase, Hydrolase" "Cancer-related genes, Deafness, Disease mutation, Non-syndromic deafness" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 69.9" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Not detected" "Not detected" "CAB000303, HPA031495, HPA031496" Enhanced Enhanced Nucleoplasm 8600 Nucleoplasm "CAB000303: AB_322519, HPA031495: AB_2673904, HPA031496: " "unprognostic (2.43e-1)" "prognostic favourable (4.66e-4)" "unprognostic (4.44e-2)" "unprognostic (3.12e-3)" "unprognostic (1.68e-1)" "unprognostic (2.25e-2)" "prognostic unfavourable (1.51e-7)" "unprognostic (8.43e-3)" "unprognostic (1.92e-2)" "unprognostic (1.79e-1)" "unprognostic (1.41e-3)" "unprognostic (1.21e-2)" "unprognostic (1.16e-2)" "unprognostic (8.16e-3)" "unprognostic (1.56e-1)" "unprognostic (3.29e-2)" "unprognostic (2.82e-1)" 2.9 3.7 2.1 24.3 4.0 32.5 3.5 6.7 3.2 4.7 7.1 3.3 2.2 4.7 4.7 5.9 11.2 4.8 5.4 3.6 2.0 2.3 3.9 3.4 3.4 14.6 2.2 3.5 5.1 3.0 2.4 2.4 26.4 3.0 3.2 6.0 2.5 4.7 1.9 7.0 6.0 7.1 2.9 2.9 13.3 3.8 20.3 3.9 69.9 4.1 16.6 20.7 3.4 5.1 10.4 3.6 0.9 1.4 5.8 10.6 3.4 24.8 21.2 23.2 20.3 1.4 3.0 22.7 13.1 8.4 26.3 28.7 35.1 16.5 26.8 12.8 6.4 20.0 41.5 15.0 16.4 22.1 25.9 44.3 28.4 25.5 0.9 41.4 19.4 1.6 1.7 17.8 2.7 8.2 22.1 24.6 9.6 33.0 38.3 30.4 34.0 18.7 43.1 33.3 38.4 5.4 19.3 28.9 21.9 33.5 10.0 3.4 21.4 32.5 4.2 20.5 17.5 25.2 17.6 25.5 28.9 66.6 14.2 31.4 7.8 0.0 0.6 0.2 4.7 1.4 5.9 10.4 4.1 5.5 2.8 9.2 3.9 5.0 0.9 5.8 0.3 3.6 10.6 3.4 2.1 4.0 6.7 3.2 2.0 2.3 2.2 3.5 3.0 3.9 MCM3 ENSG00000112118 "Minichromosome maintenance complex component 3" P25205 6 52264009-52284881 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, DNA replication" "DNA-binding, Helicase, Hydrolase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 82.5" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002162, HPA004789, HPA004790" Supported Enhanced Nucleoplasm 29000 Nucleoplasm "CAB002162: AB_564115, HPA004789: AB_1079336, HPA004790: AB_1079335" "unprognostic (9.14e-2)" "prognostic favourable (1.89e-4)" "unprognostic (2.37e-1)" "unprognostic (1.53e-2)" "unprognostic (2.14e-1)" "unprognostic (5.48e-3)" "prognostic unfavourable (1.40e-4)" "unprognostic (1.36e-1)" "prognostic unfavourable (4.40e-5)" "unprognostic (1.01e-3)" "unprognostic (2.96e-2)" "unprognostic (1.15e-1)" "unprognostic (8.35e-2)" "unprognostic (1.16e-2)" "unprognostic (1.00e-1)" "prognostic favourable (3.13e-5)" "unprognostic (1.34e-2)" 17.3 10.9 8.5 29.7 10.5 22.3 15.3 10.7 9.7 15.9 17.2 9.5 20.2 9.0 21.2 13.0 21.7 15.5 15.8 15.4 7.4 6.6 16.1 12.6 13.7 30.1 8.9 5.8 20.0 13.8 16.0 7.4 24.7 10.0 15.9 19.2 12.7 12.6 23.4 12.1 15.0 17.8 17.7 9.5 23.2 15.3 16.1 10.5 82.5 12.9 20.1 35.7 19.1 15.3 21.1 12.9 11.4 13.3 22.2 29.4 18.6 30.2 20.1 35.1 33.1 7.6 6.9 23.1 22.5 17.3 38.4 39.5 41.2 16.5 33.1 22.6 13.1 24.1 46.3 27.5 38.9 37.2 43.8 62.5 40.5 58.0 2.0 61.3 25.6 4.1 6.4 28.2 7.9 19.6 50.8 76.3 19.8 20.0 61.7 47.4 29.1 14.2 54.8 53.8 44.2 17.0 32.2 35.7 27.3 23.6 13.6 20.4 26.8 43.5 10.0 26.3 28.3 27.1 33.6 22.6 25.8 58.9 22.6 53.2 30.7 11.1 8.0 11.4 22.9 13.3 19.7 21.1 23.3 23.0 12.9 19.2 22.6 24.0 1.1 22.2 7.4 8.3 29.4 18.6 8.5 10.5 10.7 9.7 7.4 6.6 8.9 5.8 10.0 10.5 MCM5 CDC46 ENSG00000100297 "Minichromosome maintenance complex component 5" P33992 22 35400063-35425430 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Cell cycle, DNA replication" "DNA-binding, Helicase, Hydrolase" "Cancer-related genes, Disease mutation, Dwarfism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "bone marrow: 57.0;lymphoid tissue: 60.6" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000101, HPA000845, HPA052880" Enhanced Enhanced Nucleoplasm Nucleoplasm "CAB000101: AB_2235163, HPA000845: AB_1079338, HPA052880: " "unprognostic (6.71e-2)" "prognostic favourable (2.81e-6)" "unprognostic (5.29e-3)" "unprognostic (7.94e-2)" "unprognostic (1.83e-2)" "unprognostic (1.46e-2)" "prognostic unfavourable (1.78e-4)" "prognostic unfavourable (3.95e-4)" "unprognostic (1.29e-1)" "unprognostic (3.34e-2)" "unprognostic (1.37e-1)" "unprognostic (8.07e-2)" "prognostic unfavourable (3.58e-5)" "unprognostic (3.26e-2)" "unprognostic (1.01e-1)" "unprognostic (1.77e-3)" "unprognostic (1.53e-1)" 12.1 4.9 6.1 27.5 9.0 57.0 9.1 6.7 5.7 10.4 11.5 12.3 5.0 9.5 10.8 10.8 15.8 8.7 9.4 5.2 4.4 3.4 6.8 8.0 9.3 31.1 8.8 3.7 17.9 10.8 6.2 3.6 19.3 5.8 7.2 8.3 6.5 8.9 5.1 8.8 10.3 16.7 6.0 7.8 31.2 8.4 16.4 8.8 60.6 9.0 17.7 33.0 8.7 9.6 46.8 30.9 19.0 26.0 21.3 32.9 24.0 38.9 28.3 22.4 22.8 2.1 4.4 19.6 26.0 13.8 38.9 37.0 18.8 19.4 25.8 15.1 13.2 19.4 22.3 20.6 12.5 20.8 41.0 36.8 28.4 37.5 0.7 75.9 33.3 2.4 1.9 23.2 6.3 17.2 22.7 38.6 14.7 32.1 61.8 25.3 29.7 16.8 70.0 31.7 32.5 7.7 22.6 17.3 18.4 35.8 14.4 8.0 15.0 29.0 10.1 39.3 29.9 24.4 26.8 21.5 26.4 48.5 25.4 28.7 30.0 19.0 20.7 14.5 18.4 24.1 13.1 46.8 16.1 19.4 27.1 37.0 13.1 14.8 9.9 21.3 26.0 30.9 32.9 24.0 6.1 9.0 6.7 5.7 4.4 3.4 8.8 3.7 5.8 8.8 MCM7 "CDC47, MCM2, PPP1R104" ENSG00000166508 "Minichromosome maintenance complex component 7" P33993 7 100092728-100101940 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, DNA replication" "DNA-binding, Helicase, Hydrolase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002163, HPA003898, CAB016312" Enhanced Enhanced Nucleoplasm Nucleoplasm "CAB002163: AB_564113, CAB016312: AB_627235, HPA003898: AB_1853632" "unprognostic (1.87e-1)" "prognostic favourable (1.28e-4)" "unprognostic (1.36e-1)" "unprognostic (5.20e-2)" "unprognostic (1.94e-1)" "unprognostic (7.03e-2)" "prognostic unfavourable (2.18e-4)" "unprognostic (2.08e-2)" "unprognostic (5.79e-3)" "unprognostic (2.16e-2)" "unprognostic (2.42e-1)" "unprognostic (9.34e-3)" "unprognostic (3.83e-2)" "unprognostic (5.41e-2)" "unprognostic (1.76e-1)" "unprognostic (1.32e-2)" "unprognostic (2.38e-1)" 8.6 5.2 17.5 13.6 21.7 37.3 11.2 20.0 20.6 8.2 14.2 19.2 15.0 10.4 16.0 6.3 10.7 8.6 9.9 5.1 18.1 12.4 5.5 8.5 7.4 22.4 23.7 9.5 12.6 13.1 7.5 10.3 10.7 15.5 10.0 15.7 7.2 9.2 9.2 11.5 10.1 10.3 11.7 23.5 10.7 7.8 14.9 22.3 7.5 9.4 4.1 28.2 10.3 10.0 7.3 5.7 1.9 5.7 7.6 9.0 6.0 24.5 28.4 31.3 23.6 3.0 4.0 16.0 14.9 18.1 41.7 44.5 21.6 25.9 41.6 14.3 10.6 19.4 45.9 21.7 35.3 21.3 39.3 26.5 15.9 14.9 1.6 44.9 17.2 2.8 4.1 30.6 18.4 15.8 50.6 34.1 21.1 52.4 76.3 18.4 27.4 20.5 41.1 45.9 50.7 8.1 14.9 20.5 31.2 23.6 21.9 7.4 10.1 18.8 6.7 15.8 28.6 30.8 29.6 14.3 24.3 74.8 10.9 36.1 28.1 1.8 2.5 1.9 8.1 4.1 6.2 5.3 5.7 7.9 5.5 7.3 5.9 5.7 1.6 7.6 5.7 5.7 9.0 6.0 17.5 21.7 20.0 20.6 18.1 12.4 23.7 9.5 15.5 22.3 MDC1 "Em:AB023051.5, KIAA0170, NFBD1" ENSG00000137337 "Mediator of DNA damage checkpoint 1" Q14676 6 30699807-30717889 "Cancer-related genes, Predicted intracellular proteins" "Cell cycle, DNA damage, DNA repair" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "A-431: 15.4;AN3-CA: 12.1;HEK 293: 29.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "NK-cell: 3.8" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" HPA006915 Enhanced Supported "Nucleoplasm,Nuclear bodies" "Nuclear bodies" Nucleoplasm "HPA006915: AB_1853669" "unprognostic (8.52e-2)" "unprognostic (4.32e-1)" "unprognostic (4.11e-2)" "unprognostic (2.66e-2)" "unprognostic (1.60e-1)" "unprognostic (1.61e-1)" "unprognostic (5.40e-3)" "unprognostic (1.13e-1)" "unprognostic (1.09e-2)" "unprognostic (9.44e-2)" "unprognostic (2.74e-3)" "unprognostic (1.31e-1)" "unprognostic (1.62e-2)" "unprognostic (3.86e-2)" "unprognostic (2.99e-1)" "unprognostic (4.39e-3)" "unprognostic (3.23e-1)" 10.8 3.6 5.7 9.5 5.9 4.9 5.5 10.2 8.0 6.9 6.3 8.5 3.8 3.8 9.9 5.1 3.7 8.3 5.0 5.0 5.2 2.4 5.1 6.2 5.1 5.4 4.9 3.7 11.3 5.7 3.1 12.5 3.1 6.0 6.4 2.9 9.4 5.5 3.5 11.1 11.7 6.4 6.1 5.5 7.1 7.7 26.7 5.3 11.4 11.9 2.4 13.0 5.2 5.4 2.0 1.8 0.4 0.2 3.8 1.2 0.3 15.4 1.0 1.2 12.1 3.9 3.8 1.0 1.3 0.7 2.7 1.0 1.0 1.7 2.6 6.6 7.7 1.6 2.4 4.4 2.5 2.1 29.3 1.9 2.9 0.6 0.4 1.1 1.4 0.9 0.9 4.1 1.9 0.4 3.8 2.9 0.4 1.4 0.7 0.2 0.8 0.8 2.2 1.3 2.9 4.5 3.3 2.6 1.3 0.6 3.1 0.5 2.8 2.2 0.9 1.0 1.5 2.0 1.4 1.9 7.2 6.7 0.3 4.3 2.1 0.4 0.1 0.3 1.1 0.2 0.9 0.8 0.9 1.2 0.2 2.0 1.0 0.8 0.1 3.8 0.1 1.8 0.0 0.3 5.7 5.9 10.2 8.0 5.2 2.4 4.9 3.7 6.0 5.3 MDH1 ENSG00000014641 "Malate dehydrogenase 1" P40925 2 63588609-63607197 "Cancer-related genes, Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins" "Tricarboxylic acid cycle" Oxidoreductase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "heart muscle: 155.8" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA027296, CAB047333, HPA054276" Uncertain Supported Centrosome,Cytosol 63000000 "Centrosome, Cytosol" "CAB047333: , HPA027296: AB_10611118, HPA054276: " "unprognostic (1.01e-1)" "unprognostic (6.52e-3)" "unprognostic (1.61e-2)" "prognostic unfavourable (7.13e-4)" "unprognostic (1.83e-1)" "unprognostic (8.84e-3)" "unprognostic (5.81e-2)" "unprognostic (2.79e-2)" "unprognostic (9.52e-2)" "unprognostic (2.05e-1)" "unprognostic (3.26e-1)" "unprognostic (8.80e-2)" "prognostic favourable (9.95e-4)" "unprognostic (6.37e-2)" "unprognostic (1.75e-1)" "unprognostic (5.97e-2)" "unprognostic (3.05e-1)" 32.0 28.6 28.0 10.5 58.1 9.2 18.4 38.0 69.5 12.4 21.4 12.5 9.0 19.3 13.4 22.6 16.7 14.7 11.5 155.8 33.6 37.5 47.6 33.2 11.2 14.7 33.4 40.1 10.9 8.9 26.0 18.3 11.4 65.9 16.1 24.9 13.8 15.4 19.9 91.1 11.1 17.1 21.5 18.6 9.4 22.4 8.6 12.2 14.1 15.6 47.1 20.2 15.6 10.2 61.7 57.1 50.7 61.5 46.7 74.5 67.8 44.0 36.1 48.8 31.9 69.4 51.4 50.6 34.7 51.3 52.9 53.7 42.7 39.1 55.5 20.6 45.4 38.8 54.9 64.3 75.9 33.6 42.4 52.1 33.8 67.8 38.1 59.9 41.3 50.9 43.9 49.5 29.3 40.3 28.8 40.4 69.5 26.5 52.4 60.5 28.6 45.0 41.9 57.5 54.4 87.5 41.8 45.3 27.0 29.1 46.9 66.5 34.2 62.5 23.4 40.6 39.8 33.7 43.6 50.4 44.2 67.9 50.1 54.2 33.5 50.7 45.8 45.8 52.7 61.5 55.0 61.7 61.3 57.6 57.1 56.4 60.5 57.5 7.0 46.7 55.7 43.3 74.5 67.8 28.0 58.1 38.0 69.5 33.6 37.5 33.4 40.1 65.9 12.2 MDK "FLJ27379, MK, NEGF2" ENSG00000110492 Midkine P21741 11 46380756-46383837 "Cancer-related genes, Predicted secreted proteins" Differentiation "Developmental protein, Growth factor, Heparin-binding, Mitogen" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "ovary: 115.9" "Cell line enhanced" "Detected in many" "AF22: 75.8;NTERA-2: 88.8;REH: 129.2;SH-SY5Y: 110.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "memory B-cell: 3.6;neutrophil: 4.9" "Group enriched" "Detected in many" 5 "B-cells: 3.6;granulocytes: 4.9;T-cells: 2.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010055, HPA057126" Uncertain Approved Vesicles "Secreted to blood" 158000 1200000 Vesicles "CAB010055: AB_627949, HPA057126: " "unprognostic (8.87e-3)" "unprognostic (6.65e-2)" "unprognostic (4.02e-2)" "unprognostic (7.24e-2)" "prognostic unfavourable (5.48e-4)" "unprognostic (1.90e-1)" "unprognostic (5.67e-3)" "unprognostic (1.02e-1)" "unprognostic (3.66e-2)" "unprognostic (1.11e-2)" "unprognostic (4.01e-2)" "unprognostic (4.15e-1)" "prognostic unfavourable (3.06e-6)" "unprognostic (8.78e-2)" "unprognostic (1.31e-1)" "unprognostic (3.48e-1)" "unprognostic (1.12e-2)" 8.0 16.2 4.7 11.9 5.6 1.7 13.5 5.3 5.9 62.5 36.3 5.3 13.9 50.6 41.0 33.9 6.5 34.6 35.0 6.4 4.0 5.9 6.1 2.0 8.0 3.6 4.9 4.4 115.9 13.1 8.9 64.8 11.5 5.5 47.7 7.4 59.0 22.2 24.5 4.7 4.1 58.4 16.6 4.0 13.9 21.0 9.3 2.1 22.5 5.2 5.5 12.4 15.3 23.0 3.6 0.2 4.9 0.6 0.2 2.0 1.5 4.8 6.5 75.8 0.2 0.5 6.4 1.8 3.8 7.6 14.6 13.0 49.2 21.6 0.3 53.4 5.6 42.2 42.7 0.0 1.3 15.0 9.0 2.1 0.6 67.3 34.6 0.1 0.3 10.2 1.3 8.9 0.0 21.3 36.4 0.3 8.2 33.5 1.8 0.9 88.8 38.5 129.2 2.8 0.4 0.1 0.1 42.1 110.3 12.6 1.1 1.0 34.6 34.0 5.8 22.5 53.9 0.3 2.6 0.2 1.0 0.4 0.6 1.3 19.5 0.0 0.1 0.0 0.3 0.5 0.0 3.6 0.2 0.5 0.1 1.1 0.2 0.0 4.9 0.2 0.6 0.2 2.0 1.5 4.7 5.6 5.3 5.9 4.0 5.9 4.9 4.4 5.5 2.1 MDM2 "HDM2, MGC5370" ENSG00000135679 "MDM2 proto-oncogene" Q00987 12 68808176-68850686 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Host-virus interaction, Ubl conjugation pathway" Transferase "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HBEC3-KT: 93.7;U-698: 90.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000086, CAB016303" Supported Supported Nucleoplasm Nucleoplasm "CAB000086: AB_563872, CAB016303: AB_627920" "unprognostic (1.16e-1)" "prognostic favourable (3.23e-4)" "unprognostic (6.16e-2)" "prognostic favourable (4.51e-7)" "unprognostic (7.25e-2)" "unprognostic (6.91e-2)" "unprognostic (3.77e-2)" "unprognostic (1.72e-1)" "unprognostic (2.45e-2)" "unprognostic (3.23e-1)" "unprognostic (1.80e-3)" "unprognostic (2.36e-1)" "unprognostic (4.22e-2)" "unprognostic (4.59e-2)" "unprognostic (1.81e-1)" "unprognostic (2.68e-1)" "unprognostic (8.95e-2)" 16.6 15.3 11.1 12.5 10.8 23.1 12.5 12.0 11.3 13.1 16.6 13.6 11.9 5.2 8.8 9.4 14.2 12.6 12.3 9.0 8.8 8.6 11.2 25.7 15.9 13.3 14.2 7.1 11.0 21.4 11.4 10.4 24.5 11.9 12.6 21.5 7.8 10.5 11.1 19.5 9.8 7.2 10.8 10.8 15.3 9.8 6.5 11.5 29.5 13.6 10.8 14.1 13.5 12.6 4.9 4.0 19.3 6.4 3.6 4.4 3.0 3.1 7.3 7.7 3.9 10.0 9.3 39.4 8.7 8.7 4.6 7.4 4.4 1.4 32.6 2.4 5.7 1.8 5.2 93.7 7.5 8.6 3.7 6.0 6.2 19.8 9.8 5.3 5.5 14.3 8.0 18.4 12.5 12.9 6.1 7.9 8.8 5.0 7.0 1.7 6.5 1.4 24.8 5.3 2.7 2.8 26.1 5.9 3.4 5.5 4.3 1.9 10.1 3.5 13.8 3.5 6.7 2.9 3.1 12.1 7.6 90.1 5.4 2.1 14.4 5.3 5.4 4.8 4.4 4.0 3.9 4.7 3.7 4.1 2.8 4.9 4.0 3.7 19.3 3.6 6.4 4.0 3.8 3.0 11.1 10.8 12.0 11.3 8.8 8.6 14.2 7.1 11.9 11.5 MDM4 "HDMX, MDMX" ENSG00000198625 "MDM4, p53 regulator" O15151 1 204516379-204558120 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "BEWO: 33.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA018919, HPA048821" Approved Supported Nucleoplasm Nucleoplasm "HPA018919: AB_1853694, HPA048821: " "unprognostic (4.63e-2)" "unprognostic (3.73e-1)" "unprognostic (6.38e-2)" "unprognostic (1.50e-1)" "unprognostic (3.84e-2)" "unprognostic (1.68e-3)" "unprognostic (2.33e-1)" "unprognostic (1.29e-1)" "unprognostic (1.51e-2)" "unprognostic (2.34e-2)" "unprognostic (1.17e-2)" "prognostic unfavourable (9.87e-4)" "prognostic unfavourable (7.06e-6)" "unprognostic (1.20e-1)" "unprognostic (1.73e-1)" "unprognostic (2.49e-2)" "prognostic favourable (2.49e-4)" 12.7 8.8 14.4 21.1 18.0 59.1 14.6 19.7 16.4 12.2 10.6 20.4 15.8 7.6 12.5 23.6 10.4 12.3 10.3 11.3 13.7 8.0 11.1 12.3 15.4 21.0 20.5 9.5 19.0 16.7 11.1 19.0 12.4 13.4 13.1 12.4 14.2 11.3 15.4 12.0 23.7 15.2 18.5 13.5 19.9 11.9 19.6 19.4 55.8 15.1 9.5 21.0 13.9 12.7 15.1 9.0 8.1 4.8 4.9 7.8 2.4 3.5 7.0 7.1 9.7 5.0 5.5 33.5 2.6 2.7 3.4 5.1 3.6 4.9 12.2 2.6 3.7 3.8 4.7 4.0 4.7 3.7 3.3 9.7 15.6 4.2 3.8 7.5 9.6 5.6 2.6 5.6 10.0 3.3 5.5 17.8 3.0 11.8 4.6 6.7 9.7 2.9 5.5 5.8 4.0 3.4 17.2 3.2 7.1 2.7 5.3 5.0 10.0 4.4 3.4 3.9 7.0 2.5 4.3 9.0 3.2 10.1 2.7 3.3 5.6 8.1 4.7 6.2 7.2 4.8 6.0 9.0 5.4 5.0 4.1 15.1 7.8 6.5 7.8 4.9 4.3 9.0 3.0 2.4 14.4 18.0 19.7 16.4 13.7 8.0 20.5 9.5 13.4 19.4 MECOM "EVI1, KMT8E, MDS1, MDS1-EVI1, PRDM3" ENSG00000085276 "MDS1 and EVI1 complex locus" Q03112 3 169083499-169663618 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Apoptosis, Differentiation, Transcription, Transcription regulation" "Developmental protein, DNA-binding, Methyltransferase, Transferase" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "HUVEC TERT2: 21.5;RPTEC TERT1: 27.6;RT4: 43.5;TIME: 20.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "NK-cell: 1.8" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" HPA046537 Supported Supported "Nuclear speckles" "Nuclear speckles" "HPA046537: " "unprognostic (4.09e-2)" "unprognostic (1.96e-1)" "unprognostic (3.24e-3)" "unprognostic (7.29e-2)" "unprognostic (2.87e-2)" "unprognostic (2.53e-1)" "unprognostic (1.83e-2)" "unprognostic (4.77e-3)" "unprognostic (1.53e-2)" "unprognostic (3.27e-3)" "prognostic unfavourable (2.59e-4)" "unprognostic (1.87e-1)" "unprognostic (2.60e-3)" "unprognostic (6.54e-2)" "unprognostic (1.03e-1)" "unprognostic (2.81e-2)" "unprognostic (3.37e-3)" 25.9 0.7 3.3 5.7 5.6 0.3 9.1 3.4 5.3 13.5 13.9 1.6 22.1 11.2 15.4 5.7 10.4 14.3 8.1 8.2 3.3 2.9 32.2 2.6 30.0 1.5 4.6 1.4 6.2 27.8 1.1 5.3 10.0 4.7 9.3 17.5 4.2 5.9 25.3 16.0 2.3 5.9 5.6 5.8 6.4 39.4 2.7 3.5 0.2 4.7 3.3 3.5 18.1 18.5 0.3 0.0 0.6 1.5 1.8 1.0 0.0 9.6 0.1 0.2 0.0 1.3 1.0 0.1 1.3 1.5 0.5 0.8 3.8 9.9 0.0 15.2 0.2 5.1 4.0 5.9 1.1 0.5 6.3 6.1 1.6 0.1 0.1 0.0 1.9 2.1 0.8 0.3 4.5 21.5 4.6 0.7 3.8 1.0 0.0 0.0 0.2 2.5 3.6 4.9 0.2 27.6 43.5 0.3 1.1 0.4 2.5 0.1 2.9 0.0 20.4 3.8 2.5 1.0 6.4 0.5 0.1 0.3 1.9 0.0 0.5 0.3 0.0 0.6 0.4 0.2 1.0 0.1 0.1 0.0 0.0 0.3 0.2 0.0 0.3 1.8 1.5 0.0 0.1 0.0 3.3 5.6 3.4 5.3 3.3 2.9 4.6 1.4 4.7 3.5 MECP2 "MRX16, MRX79, RTT" ENSG00000169057 "Methyl-CpG binding protein 2" P51608 X 154021573-154137103 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "DNA-binding, Repressor" "Autism, Autism spectrum disorder, Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA000593, HPA001341, CAB037264" Enhanced Approved Nucleoplasm Nucleoplasm "CAB037264: AB_477252, HPA000593: AB_1079348, HPA001341: AB_1079347" "unprognostic (1.27e-3)" "unprognostic (2.60e-3)" "unprognostic (2.16e-3)" "prognostic unfavourable (8.35e-5)" "unprognostic (2.35e-1)" "unprognostic (3.66e-1)" "unprognostic (6.12e-2)" "unprognostic (1.18e-2)" "unprognostic (8.81e-2)" "unprognostic (1.53e-1)" "unprognostic (1.84e-3)" "unprognostic (4.22e-1)" "prognostic favourable (7.32e-9)" "unprognostic (7.63e-2)" "unprognostic (1.00e-1)" "unprognostic (9.08e-2)" "unprognostic (6.05e-2)" 18.6 21.4 29.2 17.0 27.1 33.8 17.6 39.1 33.5 20.2 19.2 17.6 15.9 13.9 20.0 15.1 18.8 21.1 19.5 23.1 22.5 14.0 17.1 16.4 22.8 19.7 22.5 26.7 29.0 21.2 24.3 22.9 13.9 25.4 23.0 8.0 20.8 18.7 23.7 31.6 14.1 15.3 16.2 21.1 23.3 15.0 9.7 24.4 13.8 19.1 8.7 14.3 18.7 28.6 5.6 4.2 22.4 4.9 2.9 6.8 1.8 19.2 11.5 9.7 12.1 8.4 6.0 8.2 9.7 10.9 11.9 19.4 8.9 9.4 23.2 23.0 8.5 9.2 14.5 11.3 6.0 17.6 17.6 8.9 10.5 5.6 10.2 11.2 18.8 6.1 6.5 11.1 13.1 9.2 9.6 19.8 7.1 11.5 13.5 12.8 7.6 12.9 11.7 10.6 7.6 8.4 8.8 13.7 7.9 7.6 8.8 18.5 5.7 14.6 9.6 9.1 17.9 18.3 19.5 23.8 17.7 26.4 13.1 22.1 15.5 22.4 3.5 13.3 6.8 3.2 4.8 5.6 4.8 5.5 2.4 4.9 4.6 4.4 16.9 2.9 4.9 4.2 5.0 1.8 29.2 27.1 39.1 33.5 22.5 14.0 22.5 26.7 25.4 24.4 MED1 "CRSP1, CRSP200, DRIP230, PBP, PPARBP, PPARGBP, RB18A, TRAP220, TRIP2" ENSG00000125686 "Mediator complex subunit 1" Q15648 17 39404285-39451286 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "SK-BR-3: 85.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB017696, HPA052818" Approved Supported Nucleoplasm 170000 Nucleoplasm "CAB017696: AB_1128703, HPA052818: " "unprognostic (1.77e-1)" "unprognostic (1.63e-1)" "unprognostic (9.26e-2)" "unprognostic (1.21e-1)" "unprognostic (2.18e-2)" "unprognostic (1.67e-1)" "unprognostic (1.21e-2)" "unprognostic (4.50e-1)" "unprognostic (7.86e-2)" "unprognostic (1.95e-3)" "unprognostic (4.09e-2)" "unprognostic (1.04e-1)" "unprognostic (1.78e-2)" "unprognostic (2.00e-1)" "unprognostic (5.94e-2)" "unprognostic (9.40e-2)" "unprognostic (5.79e-2)" 16.4 13.8 11.8 14.8 13.7 15.5 15.1 19.8 16.5 16.9 14.6 18.8 9.3 10.3 17.9 9.7 15.0 14.3 10.9 12.8 11.6 10.5 13.0 13.3 12.3 17.7 12.0 10.3 22.2 16.2 34.5 21.1 16.5 14.5 12.5 14.2 16.5 13.4 11.6 19.5 16.1 14.1 17.1 14.0 20.4 13.0 15.1 12.1 34.1 13.2 12.1 22.5 16.6 13.4 6.6 4.9 4.4 4.0 5.0 6.1 2.7 8.0 10.7 13.5 9.2 9.9 10.1 10.9 9.8 10.6 13.5 13.2 10.3 8.0 21.5 11.2 12.2 15.9 16.1 9.7 21.5 20.7 13.5 13.5 10.2 10.2 10.7 24.1 14.3 9.5 9.8 16.6 24.2 11.4 17.3 11.7 10.9 4.5 22.4 9.1 8.7 6.4 16.9 18.2 9.2 7.9 9.3 8.6 9.8 13.0 85.6 11.2 15.8 13.8 10.1 10.5 13.1 11.6 17.2 10.7 14.3 22.2 10.3 11.9 12.8 3.2 4.0 4.4 5.2 3.9 5.8 6.6 5.5 5.8 4.0 6.4 5.4 6.1 3.3 5.0 2.6 4.9 3.3 2.7 11.8 13.7 19.8 16.5 11.6 10.5 12.0 10.3 14.5 12.1 MED12 "CAGH45, FGS1, HOPA, KIAA0192, OKS, OPA1, TNRC11, TRAP230" ENSG00000184634 "Mediator complex subunit 12" Q93074 X 71118556-71142454 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Activator, Repressor" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003184, HPA003185" Enhanced Approved Nucleoplasm Nucleoplasm "HPA003184: AB_1079349, HPA003185: AB_1079350" "unprognostic (1.39e-1)" "unprognostic (2.23e-1)" "unprognostic (5.42e-2)" "unprognostic (2.07e-1)" "unprognostic (6.89e-3)" "unprognostic (7.14e-2)" "unprognostic (1.68e-2)" "unprognostic (1.15e-2)" "unprognostic (2.10e-1)" "unprognostic (1.53e-1)" "unprognostic (2.45e-1)" "unprognostic (2.50e-1)" "unprognostic (1.22e-3)" "unprognostic (1.28e-1)" "unprognostic (1.02e-1)" "unprognostic (3.67e-1)" "unprognostic (5.16e-2)" 18.2 31.3 12.3 15.3 14.7 16.6 18.1 18.0 15.1 16.8 12.8 19.8 21.3 10.2 21.7 16.5 13.1 17.7 14.2 12.9 12.9 8.5 13.3 9.8 14.0 15.3 15.7 10.7 28.8 14.2 20.1 17.9 23.0 11.6 16.5 11.8 18.6 14.6 20.3 14.9 17.6 14.8 16.4 11.2 27.3 14.2 15.3 12.9 33.1 17.8 12.6 15.9 15.4 16.4 4.0 5.1 9.7 3.7 5.0 7.4 3.6 8.6 10.2 16.1 9.6 11.8 10.6 23.8 6.1 8.8 9.8 7.0 12.2 8.2 11.4 8.2 10.6 8.6 18.8 7.7 7.8 11.9 14.6 18.8 23.0 16.5 9.3 17.3 16.7 12.3 8.4 12.8 14.9 15.0 17.5 19.9 9.6 14.5 18.1 9.9 9.2 13.4 17.1 18.0 8.6 7.4 17.2 9.0 10.8 14.1 7.2 8.0 8.7 8.6 13.1 10.7 12.7 9.8 4.3 9.8 5.5 8.3 6.3 9.7 7.1 9.7 3.7 7.2 5.9 3.6 5.0 4.0 4.1 5.4 3.9 4.0 4.6 3.9 7.7 5.0 2.4 5.1 7.4 3.6 12.3 14.7 18.0 15.1 12.9 8.5 15.7 10.7 11.6 12.9 MED13 "KIAA0593, THRAP1, TRAP240" ENSG00000108510 "Mediator complex subunit 13" Q9UHV7 17 61942605-62065282 "Cancer-related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Activator, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA067939 Supported Nucleoplasm Nucleoplasm "HPA067939: " "unprognostic (7.26e-2)" "unprognostic (4.50e-2)" "prognostic favourable (1.43e-4)" "unprognostic (8.79e-2)" "unprognostic (1.69e-2)" "unprognostic (3.56e-1)" "unprognostic (1.33e-1)" "unprognostic (5.69e-2)" "unprognostic (1.18e-1)" "unprognostic (1.97e-1)" "unprognostic (1.88e-1)" "unprognostic (3.92e-2)" "unprognostic (2.63e-2)" "unprognostic (2.53e-1)" "unprognostic (1.21e-1)" "unprognostic (4.51e-3)" "unprognostic (2.30e-1)" 10.4 7.6 6.3 6.6 9.1 19.3 8.8 8.8 7.5 8.7 9.0 13.8 6.8 7.1 13.6 9.0 9.7 6.8 8.2 8.4 12.6 5.3 9.0 14.3 12.7 7.3 8.2 3.5 9.9 8.6 15.3 5.9 9.6 15.6 7.1 8.3 6.4 21.6 5.9 31.8 10.0 8.1 12.0 13.8 6.7 7.4 11.9 8.3 15.1 10.4 12.4 8.9 10.7 8.4 3.2 5.6 7.9 5.0 2.7 3.5 0.7 12.9 15.4 11.9 9.7 11.0 12.0 9.1 7.1 10.4 14.5 14.0 11.7 7.1 13.8 6.8 11.2 8.0 15.2 9.3 20.3 8.9 8.9 22.5 11.2 7.4 11.5 19.7 10.5 9.2 10.8 15.8 18.0 10.9 18.4 23.8 9.9 21.9 17.7 5.9 6.3 8.0 14.6 30.6 8.4 10.2 15.3 9.4 17.9 14.9 4.3 9.3 15.6 14.0 13.6 16.7 24.5 8.6 13.4 11.6 13.1 19.0 8.8 8.8 9.4 1.6 2.1 2.5 2.8 1.0 3.5 2.0 2.7 2.9 2.1 3.2 1.9 3.5 7.9 2.7 5.0 5.6 3.0 0.7 6.3 9.1 8.8 7.5 12.6 5.3 8.2 3.5 15.6 8.3 MED17 "CRSP6, CRSP77, DRIP80, SRB4, TRAP80" ENSG00000042429 "Mediator complex subunit 17" Q9NVC6 11 93784227-93814963 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Transcription, Transcription regulation" Activator "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" HPA046619 Approved "Nuclear speckles,Cytosol" "Nuclear speckles" Cytosol "HPA046619: " "prognostic unfavourable (4.94e-4)" "unprognostic (2.92e-1)" "unprognostic (2.72e-3)" "unprognostic (1.38e-1)" "unprognostic (6.71e-2)" "unprognostic (1.42e-1)" "prognostic unfavourable (4.04e-6)" "unprognostic (1.50e-1)" "unprognostic (4.48e-3)" "unprognostic (7.73e-2)" "unprognostic (1.41e-1)" "unprognostic (4.59e-2)" "unprognostic (1.02e-2)" "unprognostic (1.77e-1)" "unprognostic (2.22e-1)" "unprognostic (5.56e-3)" "unprognostic (1.48e-1)" 9.0 7.4 5.8 9.9 8.0 9.5 9.2 13.9 10.7 10.7 10.2 9.0 9.4 4.3 12.1 7.5 7.9 10.4 7.3 11.5 6.3 5.4 6.4 4.6 8.2 8.1 9.5 7.3 13.8 9.9 5.4 13.1 9.5 6.1 8.2 4.9 8.0 9.4 6.6 9.3 10.2 14.0 7.7 7.7 13.9 12.1 7.9 8.8 20.7 7.8 5.5 9.8 11.2 11.6 10.5 6.8 10.8 5.7 10.2 8.5 5.1 3.0 1.0 2.6 5.6 3.2 0.4 5.1 6.7 2.3 4.5 2.8 5.3 6.3 5.0 11.3 0.6 9.4 2.4 1.4 1.2 6.0 2.7 5.6 3.4 1.5 1.7 9.4 9.5 1.3 3.3 3.3 2.2 1.8 5.0 3.0 2.7 0.9 11.2 2.7 4.9 0.8 8.6 7.6 4.1 2.7 2.1 9.2 11.7 5.6 4.7 2.8 7.0 2.3 6.1 7.0 5.6 9.3 5.8 4.7 9.1 3.6 1.8 6.7 8.0 4.9 4.6 10.8 6.4 5.7 7.6 10.5 8.2 8.0 6.0 9.0 8.5 4.8 4.7 10.2 3.3 6.8 8.1 5.1 5.8 8.0 13.9 7.9 6.3 5.4 9.5 7.3 6.1 8.8 MED23 "CRSP130, CRSP3, DRIP130, Sur2" ENSG00000112282 "Mediator complex subunit 23" Q9ULK4 6 131573966-131628229 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Transcription, Transcription regulation" Activator "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA070341 Approved Nucleoplasm,Vesicles "Nucleoplasm, Vesicles" "HPA070341: " "unprognostic (1.11e-2)" "unprognostic (4.66e-2)" "unprognostic (5.51e-3)" "unprognostic (1.80e-1)" "unprognostic (3.06e-2)" "unprognostic (1.14e-2)" "unprognostic (6.62e-3)" "unprognostic (4.47e-1)" "unprognostic (1.64e-1)" "unprognostic (6.81e-3)" "unprognostic (1.44e-2)" "unprognostic (3.59e-1)" "unprognostic (1.64e-1)" "unprognostic (1.82e-2)" "unprognostic (2.21e-1)" "unprognostic (2.44e-2)" "unprognostic (2.53e-2)" 14.0 17.1 12.1 19.7 12.7 21.8 16.3 23.0 17.6 14.7 12.3 12.1 17.8 12.7 21.6 13.3 14.9 14.6 10.2 10.2 11.7 8.3 12.2 9.6 13.1 15.4 15.9 12.3 20.5 18.7 23.9 16.1 12.3 11.3 13.9 14.4 12.3 19.8 16.8 14.8 15.0 15.4 14.3 11.0 13.7 14.9 13.1 13.3 22.7 18.0 7.4 16.7 16.2 20.7 6.0 6.8 8.8 5.7 15.0 10.9 4.6 5.1 5.8 13.8 17.4 17.2 13.2 12.7 13.1 14.9 12.1 17.7 6.0 7.3 11.6 9.6 13.4 9.4 7.4 8.5 18.9 13.1 10.3 12.1 10.6 10.2 12.5 20.0 20.7 11.5 10.2 13.4 13.7 15.0 15.5 12.2 12.8 8.0 15.1 12.6 6.6 5.8 13.7 8.6 6.9 9.4 7.7 10.4 9.4 9.3 13.1 8.5 3.6 14.1 15.1 9.0 10.3 14.4 11.9 13.0 8.7 16.7 11.1 9.2 12.1 4.5 5.3 8.8 7.3 5.7 10.9 6.0 7.2 8.0 6.8 5.2 7.4 6.7 4.5 15.0 3.9 3.6 7.8 4.6 12.1 12.7 23.0 17.6 11.7 8.3 15.9 12.3 11.3 13.3 MEF2A "RSRFC4, RSRFC9" ENSG00000068305 "Myocyte enhancer factor 2A" Q02078 15 99565417-99716466 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Apoptosis, Differentiation, Neurogenesis, Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004499, HPA046597" Approved Supported Nucleoplasm Nucleoplasm "CAB004499: AB_627921, HPA046597: " "unprognostic (1.89e-1)" "unprognostic (8.82e-2)" "unprognostic (5.91e-2)" "unprognostic (8.04e-2)" "unprognostic (8.68e-2)" "unprognostic (2.05e-1)" "unprognostic (2.25e-1)" "unprognostic (6.26e-2)" "unprognostic (1.93e-2)" "unprognostic (1.91e-2)" "unprognostic (7.08e-3)" "unprognostic (1.46e-1)" "prognostic favourable (6.93e-4)" "prognostic unfavourable (7.96e-4)" "unprognostic (4.69e-2)" "unprognostic (1.32e-1)" "unprognostic (1.69e-3)" 28.9 17.4 17.4 19.1 24.3 12.0 20.1 22.9 31.6 21.9 19.7 20.1 18.2 9.5 30.5 24.7 16.6 20.5 16.6 62.0 14.9 12.7 18.8 17.5 26.0 16.7 14.0 21.9 23.0 11.7 32.0 10.2 18.8 16.1 19.9 11.4 14.5 15.5 18.4 46.1 38.4 16.3 31.2 23.6 22.2 16.3 10.7 15.8 17.6 15.2 19.6 17.3 25.2 15.9 12.8 10.7 11.3 14.2 5.6 4.5 4.3 8.7 5.0 8.4 4.2 10.7 13.8 4.2 8.9 20.5 7.3 10.0 5.1 12.2 11.0 12.6 19.0 9.6 8.5 7.0 9.6 7.4 12.5 22.1 11.1 4.6 18.4 8.7 10.9 9.2 11.8 9.8 20.4 13.3 7.8 21.1 13.6 3.6 14.3 13.0 4.6 7.3 21.0 18.4 8.9 15.1 12.4 5.4 7.6 13.5 5.9 25.0 5.5 8.0 21.7 20.5 11.2 10.1 10.7 11.5 13.1 24.0 14.3 9.7 19.4 6.2 10.3 11.3 3.4 12.8 2.9 12.8 3.2 3.0 10.7 10.4 4.5 3.4 10.2 5.6 14.2 6.6 2.1 4.3 17.4 24.3 22.9 31.6 14.9 12.7 14.0 21.9 16.1 15.8 MEN1 ENSG00000133895 "Menin 1" O00255 11 64803510-64811294 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Chromatin regulator, DNA-binding, Repressor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA030342 Uncertain Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "HPA030342: AB_10610138" "unprognostic (2.06e-1)" "unprognostic (1.76e-1)" "unprognostic (3.78e-2)" "unprognostic (2.31e-2)" "unprognostic (1.05e-1)" "unprognostic (8.41e-2)" "prognostic unfavourable (1.08e-4)" "unprognostic (2.66e-1)" "unprognostic (2.59e-1)" "unprognostic (1.42e-2)" "unprognostic (4.96e-2)" "unprognostic (1.36e-1)" "unprognostic (7.39e-2)" "prognostic favourable (6.31e-5)" "unprognostic (1.40e-1)" "unprognostic (3.03e-1)" "unprognostic (3.76e-1)" 12.1 20.6 13.2 15.6 17.7 11.8 12.5 25.8 26.9 15.5 14.9 16.4 22.2 16.9 14.8 18.4 18.9 17.6 14.7 9.0 12.4 11.5 15.9 23.0 12.8 22.1 12.5 15.6 19.7 25.9 16.8 18.0 16.1 16.0 15.9 11.6 16.6 23.3 19.9 8.4 21.6 15.8 11.0 9.8 20.6 15.3 21.2 12.3 33.2 23.9 6.2 20.3 13.7 15.5 5.2 2.9 3.4 1.5 1.8 4.8 1.0 16.4 22.1 14.1 22.2 15.8 10.3 16.6 11.8 11.8 18.5 12.4 12.7 16.2 23.4 19.4 9.1 23.5 19.1 16.4 11.1 19.9 28.3 19.4 17.7 17.0 14.0 12.4 13.2 11.8 12.3 15.5 12.9 17.1 28.1 8.9 10.2 30.7 31.4 25.2 18.5 33.2 24.4 16.1 22.4 11.9 15.2 20.0 17.6 14.0 19.8 14.4 29.5 13.9 10.8 17.5 16.8 20.9 10.0 14.1 16.3 11.8 13.8 9.7 11.1 0.9 1.3 3.4 3.7 1.5 4.8 3.7 2.6 4.6 1.3 5.2 4.5 2.6 0.2 1.8 0.5 2.9 1.9 1.0 13.2 17.7 25.8 26.9 12.4 11.5 12.5 15.6 16.0 12.3 MET "DFNB97, HGFR, RCCP2" ENSG00000105976 "MET proto-oncogene, receptor tyrosine kinase" P08581 7 116672390-116798386 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Deafness, Disease mutation, FDA approved drug targets, Non-syndromic deafness, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "A-431: 45.4;CAPAN-2: 49.6;EFO-21: 43.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in single" "Group enriched" "Detected in many" 5 "amygdala: 3.5;basal ganglia: 9.9;cerebral cortex: 7.6;hippocampal formation: 8.0;olfactory region: 9.1" "Low region specificity" "Detected in many" "CAB005282, CAB018577, HPA055607" Approved Supported "Plasma membrane,Cytosol" "Secreted to blood" 178550000 70000000 "Plasma membrane, Cytosol" "CAB005282: AB_631940, CAB018577: AB_649068, HPA055607: " "unprognostic (1.60e-2)" "unprognostic (7.71e-2)" "unprognostic (2.53e-2)" "unprognostic (1.58e-1)" "unprognostic (3.57e-3)" "prognostic unfavourable (6.75e-4)" "unprognostic (1.68e-1)" "unprognostic (3.22e-2)" "unprognostic (3.81e-2)" "unprognostic (2.52e-2)" "prognostic unfavourable (1.21e-7)" "unprognostic (1.86e-1)" "unprognostic (1.25e-1)" "unprognostic (5.53e-2)" "unprognostic (8.88e-2)" "unprognostic (2.01e-2)" "unprognostic (2.20e-1)" 16.2 1.1 1.8 4.5 2.3 4.3 11.2 0.9 15.2 9.9 6.5 2.4 2.4 4.4 7.5 5.2 5.1 4.6 12.3 5.4 5.7 1.8 20.1 30.2 15.6 1.4 3.6 2.1 2.0 9.3 0.7 8.1 24.4 2.6 8.0 6.6 34.1 12.2 8.4 12.8 7.2 8.6 4.0 2.3 5.7 10.6 2.7 2.4 0.5 21.4 7.0 2.1 10.1 15.0 0.2 0.3 1.2 0.2 0.3 0.4 0.0 45.4 26.1 0.0 0.1 2.0 2.0 1.8 26.0 10.6 14.0 11.8 5.4 49.6 2.0 43.3 16.3 12.0 4.5 24.7 28.7 0.1 5.6 0.0 27.1 4.7 0.3 0.0 0.0 2.6 9.8 9.1 30.1 9.6 0.9 0.2 25.9 1.0 0.0 0.0 3.9 26.7 0.0 22.0 0.0 24.6 5.2 3.8 0.0 10.7 3.4 10.1 0.0 0.2 17.7 20.9 7.4 11.0 20.1 0.5 4.0 0.2 23.0 0.0 2.9 1.1 0.2 0.4 0.4 0.1 0.2 0.2 0.2 0.2 0.1 0.2 0.2 0.2 1.2 0.3 0.1 0.3 0.1 0.0 1.8 2.3 0.9 15.2 5.7 1.8 3.6 2.1 2.6 2.4 METTL14 KIAA1627 ENSG00000145388 "Methyltransferase like 14" Q9HCE5 4 118685368-118715433 "Cancer-related genes, Predicted intracellular proteins" "Differentiation, Spermatogenesis" RNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA038002 Supported Supported Nucleoplasm Nucleoplasm "HPA038002: AB_10672401" "unprognostic (4.48e-1)" "unprognostic (5.13e-2)" "unprognostic (5.98e-3)" "unprognostic (3.44e-2)" "unprognostic (1.33e-1)" "unprognostic (1.83e-1)" "unprognostic (3.75e-2)" "unprognostic (4.40e-1)" "unprognostic (9.97e-2)" "unprognostic (2.40e-2)" "unprognostic (3.64e-2)" "unprognostic (3.33e-3)" "prognostic favourable (1.46e-5)" "unprognostic (1.05e-1)" "unprognostic (1.32e-1)" "unprognostic (1.76e-3)" "unprognostic (7.76e-3)" 17.3 16.4 15.5 12.4 19.2 25.8 18.0 25.9 19.4 21.8 16.1 12.8 11.7 13.4 19.1 17.2 16.4 15.9 12.0 12.3 13.3 11.3 17.4 22.0 13.9 15.9 16.4 16.0 22.6 14.6 17.1 34.5 13.6 16.0 20.0 13.0 12.3 13.7 14.9 13.5 16.4 15.4 14.5 17.3 17.3 14.2 26.6 18.4 24.1 18.7 10.6 16.2 23.0 16.1 18.9 12.3 24.1 17.5 17.1 18.4 10.7 14.4 6.7 14.6 13.7 9.2 11.7 10.7 12.9 9.9 9.8 11.3 9.6 17.3 16.4 7.7 9.0 7.1 12.4 10.6 12.6 12.9 7.5 13.7 8.4 10.6 10.5 22.1 16.4 10.3 12.3 11.3 7.5 8.8 14.6 14.0 13.3 9.7 21.6 18.6 12.5 5.8 12.4 18.3 8.3 10.6 9.6 12.0 13.5 9.1 16.9 12.3 7.7 21.1 11.9 14.2 13.0 12.6 10.2 11.8 12.2 18.7 10.1 12.4 11.5 24.1 10.6 22.3 14.7 15.6 16.6 18.9 15.4 15.1 12.3 18.1 18.4 16.6 8.5 17.1 17.5 9.8 16.2 10.7 15.5 19.2 25.9 19.4 13.3 11.3 16.4 16.0 16.0 18.4 MFGE8 "BA46, EDIL1, hP47, HsT19888, MFG-E8, OAcGD3S, SED1, SPAG10" ENSG00000140545 "Milk fat globule-EGF factor 8 protein" Q08431 15 88898683-88913411 "Cancer-related genes, Predicted secreted proteins" "Angiogenesis, Cell adhesion, Fertilization" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "ASC diff: 177.8;ASC TERT1: 92.3;fHDF/TERT166: 62.5;HSkMC: 93.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "T-reg: 13.3" "Group enriched" "Detected in many" 6 "granulocytes: 3.6;NK-cells: 6.3;T-cells: 13.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002753, HPA002807" Supported Approved Cytosol "Secreted to blood" 2831507 1100000 Cytosol "CAB002753: , HPA002807: AB_1078072" "unprognostic (1.28e-1)" "unprognostic (1.23e-1)" "unprognostic (1.63e-2)" "unprognostic (7.68e-2)" "unprognostic (2.75e-1)" "unprognostic (1.12e-1)" "unprognostic (2.32e-1)" "unprognostic (1.42e-1)" "unprognostic (8.11e-3)" "unprognostic (6.27e-2)" "unprognostic (8.49e-2)" "unprognostic (3.99e-1)" "prognostic unfavourable (6.06e-9)" "prognostic unfavourable (3.08e-4)" "unprognostic (4.85e-2)" "unprognostic (7.36e-3)" "unprognostic (2.41e-3)" 34.2 23.2 5.4 14.5 11.2 0.9 73.4 5.7 14.8 43.4 15.8 9.6 11.3 5.2 73.2 38.6 32.8 56.2 30.2 115.4 5.6 4.1 12.4 3.9 20.8 14.9 6.0 8.3 49.8 6.6 2.9 8.1 23.1 10.8 29.5 7.3 59.5 15.6 50.7 57.8 18.3 15.4 39.6 8.8 6.5 22.2 23.6 4.4 8.5 21.7 21.1 12.6 32.8 68.3 1.2 0.0 3.6 0.2 6.3 13.3 2.0 1.8 7.0 7.6 9.3 177.8 92.3 0.6 45.8 13.7 9.1 10.9 6.1 2.2 0.0 14.1 62.5 0.9 2.6 9.1 3.1 7.3 4.6 13.3 0.4 0.6 46.9 0.0 4.7 93.6 24.5 7.2 12.1 3.5 2.1 4.0 17.8 0.1 2.0 0.3 39.0 2.4 2.0 7.3 2.4 3.2 0.6 0.8 4.0 2.5 0.2 20.8 0.2 0.9 3.8 22.9 12.3 5.8 3.3 14.0 2.7 1.4 3.0 1.1 8.8 3.6 0.2 0.4 1.2 0.0 4.2 1.2 4.2 3.0 0.0 0.8 4.4 3.1 0.0 6.3 0.1 0.0 13.3 2.0 5.4 11.2 5.7 14.8 5.6 4.1 6.0 8.3 10.8 4.4 MGA "FLJ12634, KIAA0518, MAD5, MXD5" ENSG00000174197 "MGA, MAX dimerization protein" Q8IWI9 15 41621224-41773081 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA042278, HPA058183" Approved Supported Nucleoplasm,Cytosol "Intracellular and membrane" Nucleoplasm Cytosol "HPA042278: AB_10794647, HPA058183: " "unprognostic (5.78e-2)" "unprognostic (7.97e-2)" "unprognostic (2.97e-1)" "unprognostic (7.20e-2)" "unprognostic (6.26e-3)" "unprognostic (5.82e-3)" "unprognostic (8.61e-3)" "unprognostic (1.70e-1)" "unprognostic (1.90e-2)" "unprognostic (3.96e-3)" "unprognostic (3.71e-1)" "unprognostic (3.80e-2)" "unprognostic (1.43e-2)" "unprognostic (1.57e-1)" "unprognostic (3.93e-1)" "unprognostic (2.50e-1)" "unprognostic (3.89e-1)" 9.3 11.3 13.8 13.6 15.3 14.3 13.0 28.2 16.9 14.5 10.1 13.3 12.2 6.8 14.2 11.5 9.8 11.3 7.8 10.1 11.2 7.7 10.1 8.5 8.5 12.7 18.7 10.5 22.7 12.0 18.0 27.6 12.4 13.7 11.0 9.7 7.2 10.3 10.8 11.8 11.2 10.6 11.8 16.1 12.5 9.8 16.4 14.7 22.4 13.9 5.3 13.4 11.6 11.5 5.0 4.1 4.9 4.9 9.8 5.0 1.5 1.4 8.4 10.6 6.9 8.3 6.6 8.5 4.2 4.2 5.0 5.0 8.9 4.9 9.9 7.6 4.8 5.8 16.3 3.6 6.9 4.7 5.3 21.0 13.8 7.8 7.4 19.2 10.5 5.0 4.6 6.9 6.9 6.4 24.4 4.5 4.4 4.1 11.6 7.5 6.5 4.3 13.2 10.8 5.1 2.6 6.0 10.0 9.8 14.9 5.2 2.7 4.2 12.3 6.8 6.1 8.6 6.2 4.9 6.2 9.2 9.7 3.8 7.4 3.0 4.9 2.3 2.5 4.7 1.8 4.6 4.8 3.7 5.0 2.4 5.0 3.9 4.3 1.2 9.8 4.9 4.1 1.8 1.5 13.8 15.3 28.2 16.9 11.2 7.7 18.7 10.5 13.7 14.7 MGMT ENSG00000170430 "O-6-methylguanine-DNA methyltransferase" P16455 10 129467184-129768007 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "DNA damage, DNA repair" "DNA-binding, Methyltransferase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB002786, HPA032135, HPA032136, HPA069497, CAB069881" Supported Enhanced Nucleoplasm Nucleoplasm "CAB002786: , CAB069881: AB_10002128, HPA032135: , HPA032136: , HPA069497: " "unprognostic (1.10e-1)" "prognostic favourable (9.42e-4)" "unprognostic (1.48e-1)" "unprognostic (5.81e-2)" "unprognostic (7.84e-3)" "unprognostic (1.67e-1)" "prognostic favourable (1.54e-4)" "unprognostic (6.54e-3)" "unprognostic (4.71e-2)" "unprognostic (2.03e-1)" "unprognostic (1.26e-1)" "unprognostic (6.32e-1)" "unprognostic (4.89e-1)" "unprognostic (2.75e-1)" "unprognostic (1.95e-1)" "unprognostic (1.66e-1)" "unprognostic (1.08e-1)" 11.7 11.3 7.4 15.5 7.6 7.1 11.3 3.5 9.1 8.3 12.2 10.0 19.6 10.8 15.3 17.1 9.9 15.2 14.1 10.5 7.1 7.1 12.6 45.6 7.5 11.6 8.6 6.6 12.3 16.5 5.7 5.8 4.5 9.2 11.2 3.4 11.8 14.9 24.5 14.4 9.2 9.6 10.9 8.1 8.6 9.9 11.7 3.9 16.0 10.2 14.9 14.7 12.6 13.0 20.3 17.7 6.5 15.3 18.2 21.2 16.6 0.0 2.6 2.8 13.3 5.8 12.1 10.4 5.9 6.6 4.3 4.2 16.2 17.3 12.1 9.5 7.6 7.9 1.7 6.3 1.9 0.0 1.0 2.4 5.9 10.3 9.0 0.2 6.9 7.7 0.0 2.5 0.0 0.0 0.0 8.5 5.3 21.8 9.5 12.4 0.6 10.4 11.0 0.0 4.7 7.9 5.9 2.8 7.0 7.1 2.9 0.0 11.4 9.4 0.0 5.7 2.9 0.0 0.0 0.0 0.0 6.1 0.0 3.9 0.0 2.6 15.3 6.5 19.1 14.8 18.6 20.3 17.5 17.8 15.8 19.9 17.6 18.9 1.8 18.2 13.7 17.7 21.2 16.6 7.4 7.6 3.5 9.1 7.1 7.1 8.6 6.6 9.2 3.9 MIA CD-RAP ENSG00000261857 "Melanoma inhibitory activity" Q16674 19 40771648-40777490 "Cancer-related genes, Predicted secreted proteins" "Growth factor" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "brain: 16.1;breast: 28.7;pituitary gland: 33.5;salivary gland: 22.7;stomach 1: 28.9" "Group enriched" "Detected in some" 35 "AN3-CA: 21.3;CAPAN-2: 17.8;SK-MEL-30: 62.1;WM-115: 58.8" "Cancer enriched" "Detected in many" 5 "melanoma: 58.6" "Region enriched" "Detected in some" 8 "midbrain: 16.1" "Cell type enhanced" "Detected in some" "basophil: 1.6;neutrophil: 3.0" "Lineage enriched" "Detected in single" 4 "granulocytes: 3.0" HPA042369 Approved "Secreted to blood" 8273333 "HPA042369: AB_10794420" "prognostic favourable (2.08e-4)" "unprognostic (1.30e-1)" "unprognostic (3.15e-1)" "unprognostic (9.02e-3)" "unprognostic (2.27e-1)" "unprognostic (1.11e-1)" "unprognostic (6.37e-3)" "unprognostic (3.67e-2)" "unprognostic (1.61e-1)" "unprognostic (9.37e-2)" "unprognostic (1.17e-1)" "unprognostic (3.19e-1)" "unprognostic (3.29e-8)" "unprognostic (5.88e-2)" "unprognostic (2.44e-1)" "unprognostic (2.20e-1)" "unprognostic (2.56e-1)" 0.7 1.5 0.6 3.5 0.6 1.4 28.7 0.9 0.4 3.7 6.1 0.5 2.2 0.8 2.8 3.2 4.0 1.0 3.2 4.1 0.4 0.4 0.9 0.8 1.4 0.7 16.1 0.4 2.6 0.4 0.0 33.5 0.9 2.1 2.2 1.9 6.0 22.7 1.7 0.8 4.5 2.2 3.4 3.1 2.4 28.9 1.0 0.4 0.5 1.1 5.9 4.4 2.0 1.5 0.7 0.0 3.0 0.1 0.0 0.3 0.1 0.0 0.1 0.2 21.3 0.2 0.2 0.2 0.0 0.0 0.0 0.1 0.1 17.8 0.0 0.0 0.0 0.0 0.1 1.1 0.0 0.7 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.9 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 62.1 0.1 0.2 0.0 0.0 0.8 0.0 0.2 0.0 0.0 0.2 0.0 0.1 58.8 1.6 0.0 0.7 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.3 3.0 0.0 0.1 0.0 0.0 0.1 0.6 0.6 0.9 0.4 0.4 0.4 16.1 0.4 2.1 0.4 MIF "GIF, GLIF" ENSG00000240972 "Macrophage migration inhibitory factor" P14174 22 23894004-23895227 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Immunity, Inflammatory response, Innate immunity" "Cytokine, Isomerase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HEK 293: 127.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003868, CAB005284" Approved Approved Nucleoplasm,Cytosol "Secreted to blood" 13800000 14000000 Cytosol Nucleoplasm "CAB005284: AB_648587, HPA003868: AB_1079290" "unprognostic (1.68e-1)" "unprognostic (7.79e-3)" "unprognostic (2.49e-1)" "unprognostic (1.46e-1)" "unprognostic (1.33e-1)" "unprognostic (1.36e-2)" "unprognostic (9.48e-2)" "unprognostic (1.22e-3)" "unprognostic (2.17e-2)" "unprognostic (1.78e-2)" "unprognostic (1.52e-1)" "unprognostic (2.28e-2)" "unprognostic (2.19e-2)" "unprognostic (1.20e-1)" "unprognostic (1.55e-1)" "unprognostic (2.56e-1)" "unprognostic (1.02e-1)" 30.6 49.8 43.9 42.0 39.9 46.0 71.6 19.0 66.1 23.0 42.7 10.4 55.6 39.9 22.5 113.3 51.9 23.3 42.5 60.7 42.8 40.3 71.8 58.8 46.2 113.9 33.5 43.7 24.5 80.2 16.2 41.1 30.5 45.2 54.8 11.6 15.0 57.3 101.2 36.0 63.3 50.6 26.7 78.3 42.5 56.2 24.9 19.2 19.0 28.9 43.7 16.7 21.4 44.6 56.8 42.5 17.6 23.8 38.3 52.7 66.0 48.9 10.9 2.4 11.0 0.9 2.2 18.4 18.5 3.1 5.9 7.7 8.1 8.1 23.3 14.7 1.3 21.8 2.5 11.2 0.7 19.6 127.1 8.8 9.9 16.9 4.8 34.0 20.7 4.7 6.7 3.5 1.7 4.7 13.6 11.8 2.0 24.6 23.1 63.0 14.0 59.3 29.7 4.1 65.3 4.6 3.4 31.9 37.2 11.8 12.5 30.5 16.1 10.2 13.5 5.2 35.0 3.1 0.4 51.4 18.1 24.0 21.1 12.7 10.6 16.3 23.8 17.6 37.4 22.3 52.7 56.8 51.8 40.4 31.6 49.1 46.1 38.0 7.1 38.3 14.6 42.5 48.3 66.0 43.9 39.9 19.0 66.1 42.8 40.3 33.5 43.7 45.2 19.2 MITF "bHLHe32, MI, WS2, WS2A" ENSG00000187098 "Melanogenesis associated transcription factor" O75030 3 69739435-69968337 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding" "Albinism, Cancer-related genes, Deafness, Disease mutation, Microphthalmia, Osteopetrosis, Waardenburg syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "HMC-1: 26.5;SK-MEL-30: 71.3" "Group enriched" "Detected in all" 8 "melanoma: 39.2;renal cancer: 9.1" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 4 "basophil: 4.5;classical monocyte: 10.9;intermediate monocyte: 3.6;myeloid DC: 6.8;non-classical monocyte: 5.7" "Group enriched" "Detected in many" 5 "dendritic cells: 6.8;granulocytes: 4.5;monocytes: 10.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002578, HPA003259" Enhanced "CAB002578: AB_564111, HPA003259: AB_1079381" "unprognostic (3.29e-1)" "unprognostic (4.26e-2)" "unprognostic (2.98e-2)" "unprognostic (6.04e-2)" "unprognostic (1.03e-1)" "unprognostic (3.25e-1)" "unprognostic (1.04e-2)" "unprognostic (1.09e-1)" "unprognostic (2.75e-1)" "unprognostic (5.31e-3)" "unprognostic (3.87e-3)" "unprognostic (1.94e-1)" "prognostic favourable (8.35e-10)" "unprognostic (6.37e-2)" "unprognostic (1.08e-1)" "unprognostic (2.04e-1)" "unprognostic (1.73e-1)" 12.8 3.8 2.6 2.6 3.9 0.8 17.8 1.7 3.0 30.6 10.1 5.9 6.4 1.5 37.9 6.2 8.3 6.4 9.9 23.4 3.1 2.4 12.8 1.8 7.1 1.7 4.2 1.1 11.1 2.4 9.7 6.2 1.8 4.0 9.0 2.5 40.1 4.0 8.2 39.1 5.8 4.1 26.2 5.0 1.8 5.1 4.7 5.1 0.1 4.4 8.1 1.0 12.1 10.3 0.0 6.8 4.5 10.9 1.4 0.1 3.4 4.8 3.3 0.3 1.5 5.6 0.1 0.6 4.9 2.8 2.2 1.4 1.7 0.2 0.0 1.1 0.0 2.6 1.0 2.7 2.5 0.0 0.6 10.7 7.1 0.1 1.4 0.2 26.5 4.6 1.1 0.6 2.5 0.7 3.5 1.5 1.6 0.2 0.1 0.3 0.2 2.4 0.0 0.5 2.3 13.4 2.5 0.2 0.5 2.5 0.9 71.3 0.2 0.6 0.0 1.1 4.0 1.6 1.0 0.1 0.2 0.0 2.3 0.7 2.8 4.5 10.9 0.0 0.0 3.6 0.0 0.0 0.0 0.1 6.8 0.0 0.0 0.0 0.7 1.4 5.7 0.5 0.0 3.4 2.6 3.9 1.7 3.0 3.1 2.4 4.2 1.1 4.0 5.1 MKI67 "MIB-, PPP1R105" ENSG00000148773 "Marker of proliferation Ki-67" P46013 10 128096659-128126385 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 25.2;lymphoid tissue: 81.5" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "naive CD4 T-cell: 1.4;T-reg: 1.3" "Group enriched" "Detected in many" 13 "NK-cells: 1.1;T-cells: 1.4" "CAB000058, HPA000451, HPA001164, CAB068198" Enhanced Enhanced Nucleoplasm,Nucleoli "Nucleoplasm, Nucleoli" "CAB000058: AB_2142367, CAB068198: , HPA000451: AB_1079186, HPA001164: AB_1079187" "unprognostic (2.54e-1)" "unprognostic (1.29e-1)" "unprognostic (3.37e-1)" "unprognostic (9.92e-3)" "unprognostic (3.17e-1)" "unprognostic (1.10e-1)" "prognostic unfavourable (3.61e-6)" "unprognostic (7.16e-3)" "unprognostic (1.45e-2)" "unprognostic (3.73e-1)" "prognostic unfavourable (9.47e-5)" "unprognostic (2.45e-2)" "prognostic unfavourable (0.00e+0)" "unprognostic (1.42e-2)" "unprognostic (2.10e-1)" "unprognostic (2.50e-1)" "unprognostic (4.61e-1)" 1.8 1.2 0.2 9.9 0.5 25.2 1.8 0.3 0.5 1.5 5.0 0.6 0.2 3.6 0.7 1.4 13.4 0.3 1.2 1.3 0.2 0.2 1.2 1.0 1.9 8.8 0.2 0.2 0.5 0.4 0.0 0.4 2.9 0.5 0.7 5.8 0.5 2.2 0.6 0.5 3.9 6.2 1.3 0.8 6.5 3.5 2.5 0.2 81.5 0.4 5.2 10.0 1.3 3.5 0.0 0.0 0.0 0.0 1.1 1.4 0.4 47.3 24.1 25.1 17.8 1.0 2.1 7.8 18.0 13.3 17.1 15.3 19.7 19.7 35.7 5.2 12.3 28.9 26.3 13.5 25.8 37.6 12.7 30.6 17.8 12.3 0.0 43.0 16.6 0.5 0.6 17.6 18.0 16.7 14.0 34.4 16.9 18.8 25.6 13.1 10.0 11.0 19.1 32.9 4.7 6.2 13.3 8.7 9.5 25.5 9.2 4.4 7.5 9.2 15.4 9.1 18.2 12.8 48.6 15.7 12.4 43.3 7.5 19.7 7.8 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.4 0.1 0.0 0.0 1.4 1.0 0.0 1.1 0.0 0.0 1.3 0.4 0.2 0.5 0.3 0.5 0.2 0.2 0.2 0.2 0.5 0.2 MKL1 "BSAC, KIAA1438, MAL, MKL, MRTF-A" ENSG00000196588 "Megakaryoblastic leukemia (translocation) 1" Q969V6 22 40410281-40636702 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" Actin-binding "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "eosinophil: 50.9" "Group enriched" "Detected in all" 5 "dendritic cells: 26.4;granulocytes: 50.9;monocytes: 15.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA030782 Approved Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "HPA030782: AB_10600930" "unprognostic (7.90e-3)" "unprognostic (4.51e-2)" "unprognostic (2.99e-1)" "unprognostic (1.29e-1)" "unprognostic (9.04e-2)" "unprognostic (9.37e-2)" "unprognostic (4.38e-3)" "unprognostic (1.02e-3)" "unprognostic (1.30e-1)" "unprognostic (1.35e-2)" "unprognostic (1.51e-1)" "unprognostic (3.74e-2)" "prognostic unfavourable (1.58e-7)" "unprognostic (9.05e-2)" "unprognostic (8.15e-2)" "unprognostic (1.30e-2)" "unprognostic (3.98e-1)" 18.1 11.1 15.4 25.4 19.1 69.2 15.8 16.2 26.1 17.6 14.2 13.5 10.1 11.3 27.6 12.9 12.3 17.5 13.2 16.3 14.2 11.1 11.3 8.9 17.4 25.6 11.8 16.6 16.9 14.5 10.2 10.5 18.9 12.6 14.2 9.4 13.3 16.9 15.7 14.3 18.0 13.6 15.7 11.0 23.9 14.3 25.4 10.8 28.2 17.3 9.0 25.5 15.5 14.6 4.9 26.4 50.9 15.0 3.8 5.6 7.5 10.7 14.6 6.3 7.5 8.0 6.1 12.4 10.5 6.8 9.7 9.4 6.8 3.3 11.5 4.3 11.0 14.2 5.3 12.9 6.3 12.7 9.3 19.0 16.3 10.1 7.9 22.0 37.5 6.6 15.6 9.4 6.5 7.1 5.3 5.2 4.6 10.5 8.6 24.7 5.0 5.1 14.0 7.1 5.8 7.7 8.1 3.5 3.8 17.2 8.7 6.3 5.8 24.9 11.6 6.6 17.7 8.7 9.0 7.0 6.2 16.5 5.4 11.1 12.7 12.0 15.0 50.9 4.4 11.6 4.1 3.2 4.0 3.4 17.8 4.9 5.6 4.7 14.5 3.8 15.0 26.4 5.2 7.5 15.4 19.1 16.2 26.1 14.2 11.1 11.8 16.6 12.6 10.8 MLF1 ENSG00000178053 "Myeloid leukemia factor 1" P58340 3 158571163-158607252 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cell cycle, Differentiation" "Developmental protein, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "heart muscle: 41.4;skeletal muscle: 53.6;testis: 101.1" "Cell line enhanced" "Detected in many" "A-431: 34.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "T-reg: 10.4" "Lineage enriched" "Detected in single" 12 "T-cells: 10.4" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA069479 Approved Nucleoplasm,Cytosol Nucleoplasm Cytosol "HPA069479: " "unprognostic (6.49e-2)" "unprognostic (1.98e-3)" "unprognostic (1.98e-1)" "prognostic unfavourable (2.15e-5)" "unprognostic (1.72e-2)" "unprognostic (2.65e-2)" "unprognostic (8.55e-2)" "unprognostic (4.11e-2)" "unprognostic (2.01e-1)" "unprognostic (2.07e-1)" "unprognostic (7.21e-2)" "unprognostic (1.07e-1)" "unprognostic (7.82e-2)" "prognostic unfavourable (5.54e-4)" "unprognostic (9.34e-3)" "unprognostic (2.47e-3)" "unprognostic (3.36e-2)" 3.5 2.6 6.0 1.8 11.9 0.9 5.3 3.4 7.1 3.1 2.7 6.5 0.5 0.8 4.9 5.6 3.5 18.3 4.9 41.4 6.3 6.3 5.7 1.2 5.2 1.0 4.9 6.3 6.2 3.1 5.2 10.4 1.0 20.1 2.0 1.7 2.8 2.2 1.6 53.6 1.8 1.3 4.5 4.7 1.2 1.9 101.1 5.7 0.0 5.3 18.9 1.4 4.2 1.5 0.6 0.3 0.4 0.3 0.8 10.4 2.3 34.1 4.5 11.5 0.0 6.1 7.2 3.4 3.5 3.4 13.0 11.8 0.0 19.5 0.0 13.5 6.1 6.6 0.1 6.0 17.3 0.0 7.5 2.0 3.3 0.3 4.2 0.0 2.6 4.4 8.8 6.2 3.4 3.0 2.5 0.0 8.5 5.0 0.0 0.1 2.7 10.0 0.0 6.4 0.4 9.9 2.4 14.9 8.8 16.1 5.7 16.9 16.4 3.4 1.1 12.1 12.4 14.3 13.7 6.1 3.8 0.0 8.7 0.0 8.7 0.0 0.0 0.0 3.6 0.0 1.6 0.6 8.3 8.7 0.3 0.3 2.1 4.4 0.4 0.8 0.3 0.2 10.4 2.3 6.0 11.9 3.4 7.1 6.3 6.3 4.9 6.3 20.1 5.7 MLH1 "COCA2, FCC2, HNPCC, HNPCC2" ENSG00000076242 "MutL homolog 1" P40692 3 36993332-37050918 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, DNA damage, DNA repair" "Cancer-related genes, Disease mutation, Hereditary nonpolyposis colorectal cancer, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB013294, HPA052707, HPA060714, CAB070868" Supported Enhanced Nucleoplasm Nucleoplasm "CAB013294: AB_2533406, CAB070868: , HPA052707: , HPA060714: " "unprognostic (1.26e-2)" "unprognostic (3.88e-3)" "unprognostic (2.36e-2)" "unprognostic (1.82e-1)" "unprognostic (3.33e-2)" "unprognostic (1.05e-1)" "prognostic unfavourable (8.24e-5)" "unprognostic (3.36e-2)" "unprognostic (2.18e-1)" "unprognostic (1.32e-1)" "unprognostic (8.54e-2)" "unprognostic (8.63e-3)" "unprognostic (2.10e-3)" "unprognostic (4.37e-2)" "unprognostic (1.38e-1)" "unprognostic (1.02e-2)" "unprognostic (8.86e-2)" 16.3 20.7 18.2 19.4 21.4 24.4 18.7 19.7 19.6 15.3 17.3 28.8 19.6 12.4 18.7 23.6 15.1 16.2 14.4 32.0 17.3 17.7 18.8 20.5 17.8 22.8 19.9 16.0 17.6 18.1 26.0 29.4 17.3 19.2 18.5 17.7 16.7 15.6 18.1 46.4 14.2 14.1 21.1 21.6 20.7 16.5 27.6 21.5 29.0 22.2 19.5 24.5 16.9 21.4 12.0 12.9 13.2 23.2 6.7 13.4 9.0 14.0 22.2 27.8 0.0 12.4 15.5 12.4 21.0 16.8 24.5 26.1 16.7 15.7 34.9 10.4 17.0 9.7 23.8 17.7 26.2 15.8 12.3 24.4 20.5 23.4 13.7 29.9 17.0 11.5 12.6 22.8 28.4 15.1 31.2 16.7 24.8 11.3 31.1 12.3 20.3 12.2 3.1 33.9 14.7 15.5 15.2 5.9 14.0 21.3 22.6 14.0 32.7 21.3 11.9 19.2 20.8 18.9 24.6 13.2 36.1 32.6 14.9 28.3 17.2 10.9 11.7 13.2 13.4 19.5 9.7 12.0 8.4 10.7 12.9 10.3 9.6 9.7 3.4 6.7 23.2 6.1 12.5 9.0 18.2 21.4 19.7 19.6 17.3 17.7 19.9 16.0 19.2 21.5 MLLT1 "ENL, LTG19, YEATS1" ENSG00000130382 "MLLT1, super elongation complex subunit" Q03111 19 6210379-6279948 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" Activator "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA031166 Approved Supported Nucleoplasm Nucleoplasm "HPA031166: AB_10601874" "unprognostic (3.21e-1)" "unprognostic (2.75e-3)" "unprognostic (4.84e-2)" "unprognostic (3.36e-2)" "unprognostic (2.47e-1)" "prognostic favourable (6.03e-5)" "unprognostic (1.30e-3)" "unprognostic (1.44e-2)" "unprognostic (1.56e-1)" "unprognostic (1.98e-1)" "unprognostic (3.93e-3)" "unprognostic (4.76e-2)" "unprognostic (3.65e-3)" "unprognostic (1.14e-2)" "unprognostic (2.01e-1)" "unprognostic (1.66e-2)" "unprognostic (7.99e-3)" 20.1 13.7 21.8 17.1 23.4 8.8 12.9 32.7 28.6 17.7 16.8 16.8 17.7 13.4 22.1 15.5 13.1 25.5 19.3 18.2 16.9 14.3 10.7 12.8 16.7 10.9 13.0 18.5 29.8 22.4 26.2 10.7 45.2 14.6 17.2 6.8 18.7 21.7 18.8 23.5 18.8 13.1 15.0 10.6 13.9 15.1 10.7 13.7 10.8 18.9 12.1 10.2 20.6 23.6 1.5 5.2 4.9 3.5 1.9 2.5 1.6 24.4 12.0 14.9 17.5 11.7 10.1 17.3 15.2 9.9 12.8 13.2 19.8 8.3 17.8 19.9 19.9 15.3 11.8 14.9 7.7 14.9 18.4 22.1 32.6 14.9 22.5 14.3 20.3 16.3 13.1 12.2 10.0 14.5 21.3 20.8 8.4 13.5 24.4 13.7 18.1 25.4 21.0 11.1 14.2 6.9 15.2 25.9 23.5 15.7 17.4 18.8 15.7 17.0 15.1 18.0 14.0 27.8 20.9 25.6 19.8 14.0 20.8 24.7 25.5 0.2 1.9 0.4 1.8 3.0 2.5 1.5 1.3 1.7 1.4 1.4 1.1 1.5 4.9 1.9 3.5 5.2 0.5 1.6 21.8 23.4 32.7 28.6 16.9 14.3 13.0 18.5 14.6 13.7 MLLT10 AF10 ENSG00000078403 "MLLT10, histone lysine methyltransferase DOT1L cofactor" P55197 10 21524675-21743630 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "testis: 71.2" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA005747 Enhanced Supported Nucleoplasm Nucleoplasm "HPA005747: AB_1079393" "unprognostic (6.58e-2)" "unprognostic (1.57e-1)" "unprognostic (7.32e-2)" "unprognostic (1.47e-2)" "unprognostic (1.31e-2)" "prognostic favourable (8.75e-4)" "unprognostic (1.03e-3)" "unprognostic (9.56e-3)" "unprognostic (9.29e-2)" "unprognostic (1.78e-1)" "unprognostic (2.69e-2)" "unprognostic (7.85e-2)" "unprognostic (6.57e-2)" "unprognostic (1.26e-1)" "unprognostic (1.50e-1)" "unprognostic (1.07e-1)" "unprognostic (1.67e-1)" 16.3 12.1 11.7 18.4 14.3 21.9 12.8 25.4 13.6 19.0 17.0 12.0 13.6 8.5 26.3 12.8 14.7 14.5 13.7 15.8 10.2 8.5 12.3 13.5 12.3 11.6 10.5 9.9 21.4 12.3 16.6 23.2 20.3 11.8 12.6 11.3 14.6 13.2 16.3 13.4 18.7 12.1 18.7 11.2 10.6 11.4 71.2 14.3 14.6 18.1 9.7 15.2 18.5 19.6 5.5 6.9 12.0 6.8 5.3 7.2 2.8 14.3 12.2 18.9 13.1 12.0 15.1 20.7 9.1 5.8 11.4 11.2 13.0 15.4 17.2 5.1 10.1 13.5 20.8 12.2 11.5 11.9 12.0 26.6 10.6 18.7 14.8 0.6 17.2 11.2 14.6 9.5 11.0 15.1 28.4 13.4 9.0 11.1 20.7 12.5 7.7 3.9 18.0 10.1 14.4 11.0 6.8 6.6 18.4 12.1 14.5 20.4 6.8 18.5 13.6 7.2 12.6 14.3 9.0 11.7 13.4 19.2 8.3 10.3 5.5 10.6 6.8 12.0 5.3 4.6 5.2 5.0 6.2 5.7 5.6 5.5 7.2 6.7 5.8 5.3 5.2 6.9 4.6 2.8 11.7 14.3 25.4 13.6 10.2 8.5 10.5 9.9 11.8 14.3 MLLT11 AF1Q ENSG00000213190 "MLLT11, transcription factor 7 cofactor" Q13015 1 151057758-151068497 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 42.1" "Cell line enhanced" "Detected in many" "AF22: 38.4;EFO-21: 29.2;SH-SY5Y: 42.1;U-698: 35.8" "Cancer enhanced" "Detected in all" "glioma: 29.9" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA000540 Uncertain Supported Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "HPA000540: " "unprognostic (2.96e-2)" "unprognostic (1.98e-2)" "unprognostic (1.08e-2)" "prognostic unfavourable (4.26e-5)" "unprognostic (1.69e-1)" "unprognostic (1.96e-2)" "unprognostic (5.80e-2)" "unprognostic (1.17e-1)" "unprognostic (1.01e-2)" "unprognostic (2.49e-2)" "unprognostic (1.44e-1)" "unprognostic (1.01e-1)" "prognostic unfavourable (4.25e-12)" "unprognostic (5.66e-3)" "unprognostic (1.42e-1)" "unprognostic (1.29e-1)" "unprognostic (3.94e-3)" 1.9 7.5 13.6 3.4 9.1 1.1 1.2 16.3 42.1 1.9 2.1 5.1 1.2 0.8 3.7 1.2 1.3 0.8 11.1 11.8 11.3 16.4 1.2 1.2 5.3 2.3 10.3 1.2 4.2 1.3 8.4 1.8 1.2 3.2 1.3 1.1 1.2 1.5 1.2 2.6 1.0 2.0 4.2 5.8 2.1 0.9 1.2 1.2 2.0 1.2 1.2 2.6 3.2 1.2 2.4 1.0 6.5 1.0 4.2 9.2 2.8 1.2 5.2 38.4 6.0 0.6 1.0 0.6 2.4 2.6 2.3 4.2 0.5 2.5 1.9 29.2 1.8 1.5 9.2 2.2 1.3 11.2 2.5 5.0 3.8 0.1 1.2 0.3 0.8 1.7 0.3 12.7 0.5 16.9 5.3 0.9 7.4 0.4 17.6 3.3 16.7 0.8 16.8 5.1 0.1 4.3 1.1 23.1 42.1 0.2 0.4 1.2 1.4 0.6 11.8 5.0 5.5 1.8 4.3 0.9 0.8 35.8 12.4 0.3 9.3 1.6 0.6 1.6 5.9 0.7 2.7 2.4 3.9 6.0 0.8 2.1 5.3 9.2 6.5 4.2 1.0 1.0 3.6 2.8 13.6 9.1 16.3 21.0 11.3 16.4 10.3 1.2 3.2 1.2 MLLT3 "AF-9, AF9, YEATS3" ENSG00000171843 "MLLT3, super elongation complex subunit" P42568 9 20341665-20622543 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" Activator "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HEL: 72.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "naive CD4 T-cell: 14.4" "Group enriched" "Detected in many" 5 "NK-cells: 3.8;T-cells: 14.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA001824 Approved Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "HPA001824: AB_1079394" "unprognostic (3.31e-1)" "unprognostic (2.22e-1)" "unprognostic (1.23e-3)" "unprognostic (1.27e-2)" "unprognostic (1.99e-1)" "unprognostic (7.57e-2)" "unprognostic (3.83e-2)" "unprognostic (1.01e-3)" "unprognostic (2.12e-1)" "unprognostic (3.92e-3)" "unprognostic (1.05e-1)" "unprognostic (2.03e-2)" "prognostic favourable (1.84e-4)" "unprognostic (1.85e-1)" "unprognostic (4.81e-2)" "unprognostic (1.40e-2)" "unprognostic (1.68e-1)" 8.6 17.3 18.0 10.4 25.8 19.7 11.4 34.6 20.3 12.3 20.9 7.2 10.6 7.2 13.6 7.9 10.2 11.5 12.7 8.6 18.0 12.8 10.1 2.1 10.7 9.1 14.8 13.8 10.5 4.6 18.3 24.7 10.3 13.2 11.7 22.8 7.4 21.3 12.1 9.1 7.9 12.3 13.5 12.0 5.9 15.3 3.6 21.4 22.1 22.5 6.1 6.5 12.9 10.4 1.4 0.7 1.6 0.3 3.8 14.4 2.8 2.5 7.1 2.5 2.9 5.9 3.7 1.6 6.7 11.3 3.0 3.4 6.9 2.4 9.8 3.6 3.1 1.3 2.4 11.6 2.7 20.2 6.2 72.2 21.9 3.2 4.3 1.3 6.1 2.7 4.5 1.0 7.3 3.0 0.0 12.7 6.3 1.9 7.0 4.2 1.6 2.1 0.0 4.6 2.6 13.9 3.8 8.2 2.9 5.4 2.7 2.9 2.8 1.9 1.9 0.0 1.7 1.7 2.3 5.7 5.2 4.0 0.0 3.1 1.4 1.6 0.3 0.5 3.9 0.2 3.6 0.5 7.0 5.3 0.7 1.4 14.4 8.3 0.1 3.8 0.3 0.4 7.3 2.8 18.0 25.8 34.6 20.3 18.0 12.8 14.8 13.8 13.2 21.4 MLLT6 "AF17, FLJ23480" ENSG00000275023 "MLLT6, PHD finger containing" 17 38705542-38729803 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at transcript level" "Evidence at transcript level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA004021 Approved Approved Nucleoplasm Nucleoplasm "HPA004021: AB_1853995" "prognostic favourable (4.18e-4)" "unprognostic (1.50e-1)" "unprognostic (2.53e-1)" "unprognostic (1.44e-2)" "unprognostic (1.29e-1)" "prognostic favourable (3.98e-4)" "unprognostic (4.98e-2)" "unprognostic (1.79e-2)" "unprognostic (1.77e-1)" "unprognostic (7.12e-3)" "prognostic favourable (7.41e-4)" "unprognostic (1.78e-1)" "unprognostic (1.84e-2)" "unprognostic (9.12e-2)" "unprognostic (1.12e-1)" "unprognostic (2.05e-1)" "unprognostic (2.46e-3)" 6.5 7.6 10.0 10.3 10.6 7.3 6.3 14.1 16.9 6.2 6.8 7.2 11.1 7.2 9.2 8.6 5.5 10.3 9.2 7.5 9.7 5.8 1.2 8.5 11.8 8.5 9.6 13.0 9.0 12.8 10.1 4.8 7.2 7.3 5.7 10.0 10.3 12.5 22.3 8.5 8.9 8.2 8.1 11.7 6.7 4.1 9.2 6.3 7.2 4.8 10.1 5.5 11.5 1.4 0.9 2.0 0.8 2.8 6.0 1.7 5.7 6.4 6.5 14.2 7.2 6.5 3.4 3.6 6.6 4.4 5.3 2.3 11.3 16.4 5.2 4.2 15.0 4.2 7.4 3.9 17.5 11.4 6.0 10.7 10.5 3.5 9.2 8.2 6.6 7.6 3.9 8.8 7.2 10.0 13.9 3.8 4.8 18.0 8.9 0.8 3.3 10.6 8.9 15.1 5.1 13.3 14.6 16.1 3.8 12.4 10.6 12.3 6.8 9.5 5.2 7.7 7.2 6.5 23.6 7.7 11.0 7.6 8.5 5.5 1.7 0.8 0.4 6.0 0.5 4.6 1.4 3.2 4.2 0.4 1.4 3.1 4.1 2.0 2.8 0.3 0.9 1.7 1.7 MME "CALLA, CD10, NEP" ENSG00000196549 "Membrane metalloendopeptidase" P08473 3 155024124-155183729 "Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Hydrolase, Metalloprotease, Protease" "Cancer-related genes, Charcot-Marie-Tooth disease, Disease mutation, FDA approved drug targets, Neurodegeneration, Neuropathy, Spinocerebellar ataxia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 61.1;intestine: 136.0;kidney: 64.9" "Cell line enhanced" "Detected in many" "ASC TERT1: 95.0;BJ hTERT+: 142.9;HSkMC: 92.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 129 "neutrophil: 61.1" "Lineage enriched" "Detected in single" 129 "granulocytes: 61.1" "Low region specificity" "Detected in many" "Region enhanced" "Detected in many" "basal ganglia: 26.8" "CAB000013, HPA052583, HPA056072" Enhanced 99000 "CAB000013: AB_563478, HPA052583: AB_2681872, HPA056072: AB_2683027" "unprognostic (1.36e-1)" "unprognostic (1.02e-3)" "unprognostic (8.52e-2)" "unprognostic (2.95e-1)" "unprognostic (2.78e-2)" "unprognostic (6.52e-3)" "unprognostic (1.20e-1)" "unprognostic (1.67e-2)" "unprognostic (8.67e-2)" "unprognostic (1.96e-1)" "unprognostic (7.30e-3)" "unprognostic (1.31e-1)" "unprognostic (2.71e-3)" "unprognostic (1.50e-1)" "unprognostic (7.29e-2)" "unprognostic (1.06e-2)" "unprognostic (1.37e-2)" 26.5 0.4 0.4 3.4 7.4 1.9 14.7 0.4 0.7 4.8 65.6 0.1 18.4 74.0 2.8 8.1 0.7 0.9 8.5 1.8 0.3 0.4 64.9 11.5 13.7 3.0 2.1 0.2 0.9 0.6 0.0 0.6 35.0 8.6 18.3 0.4 1.3 3.7 11.3 11.7 1.4 136.0 0.6 0.9 2.7 0.7 1.0 1.2 13.2 1.0 5.3 2.3 3.4 4.9 0.1 0.4 61.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 38.6 95.0 0.2 21.2 142.9 10.8 28.1 0.0 0.0 23.4 0.0 18.8 0.0 0.7 0.8 26.1 0.0 0.1 0.0 0.0 0.0 30.9 0.0 0.0 92.1 0.1 5.8 41.6 8.2 0.0 0.0 17.3 0.1 0.0 0.1 0.9 0.1 38.8 18.2 0.1 0.6 0.2 0.0 0.2 0.0 0.0 4.1 0.0 0.0 23.3 46.7 0.1 15.9 3.7 0.0 0.0 30.8 5.6 0.0 1.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 61.1 0.0 0.0 0.4 0.0 0.0 0.4 7.4 0.4 0.7 0.3 0.4 2.1 0.2 8.6 1.2 MMP1 CLG ENSG00000196611 "Matrix metallopeptidase 1" P03956 11 102789920-102798160 "Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins" "Collagen degradation, Host-virus interaction" "Hydrolase, Metalloprotease, Protease" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "gallbladder: 62.4;stomach 1: 27.2" "Cell line enhanced" "Detected in some" "BJ hTERT+: 88.1;HBF TERT88: 87.3;HUVEC TERT2: 229.4;WM-115: 113.0" "Cancer enhanced" "Detected in many" "head and neck cancer: 344.2" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA004920 Approved Vesicles "Secreted to extracellular matrix" 430000 Vesicles "HPA004920: " "unprognostic (4.11e-3)" "prognostic unfavourable (4.66e-4)" "unprognostic (4.20e-3)" "unprognostic (1.19e-3)" "unprognostic (6.46e-2)" "unprognostic (6.50e-2)" "prognostic unfavourable (4.22e-6)" "unprognostic (7.83e-3)" "unprognostic (2.94e-2)" "unprognostic (5.44e-2)" "unprognostic (1.11e-3)" "unprognostic (1.75e-1)" "prognostic unfavourable (9.86e-10)" "unprognostic (1.67e-2)" "unprognostic (1.49e-1)" "unprognostic (1.26e-2)" "unprognostic (5.11e-2)" 0.2 0.1 0.3 12.3 0.3 0.0 0.9 0.3 0.3 0.3 2.7 0.3 0.2 3.2 4.8 0.2 3.3 0.1 62.4 0.4 0.2 0.1 0.7 1.3 4.7 0.2 0.2 0.2 0.2 1.6 0.0 0.2 8.6 0.5 0.7 3.0 0.3 2.0 0.2 0.2 0.3 8.8 0.2 0.4 1.8 27.2 2.2 0.2 0.4 0.3 1.3 0.9 11.0 0.2 0.0 0.0 0.6 0.0 0.0 0.0 1.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 39.9 88.1 36.0 9.4 0.7 0.0 0.0 0.4 21.1 0.3 0.0 12.3 87.3 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 37.0 3.1 229.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.3 0.0 0.1 0.0 0.0 11.9 29.9 0.0 1.3 0.1 0.0 0.0 0.0 0.7 0.0 113.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 1.9 0.3 0.3 0.3 0.3 0.2 0.1 0.2 0.2 0.5 0.2 MMP10 STMY2 ENSG00000166670 "Matrix metallopeptidase 10" P09238 11 102770503-102780628 "Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins" "Collagen degradation" "Hydrolase, Metalloprotease, Protease" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 4 "endometrium 1: 89.4" "Cell line enhanced" "Detected in some" "BJ: 12.3;HUVEC TERT2: 15.8;SCLC-21H: 5.0" "Cancer enhanced" "Detected in many" "head and neck cancer: 102.2" "Region enriched" "Detected in single" 9 "pons and medulla: 2.8" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" CAB002159 Uncertain Approved "Plasma membrane,Cytosol" "Secreted to extracellular matrix" Cytosol "Plasma membrane" "CAB002159: AB_564103" "unprognostic (8.76e-2)" "unprognostic (3.38e-1)" "unprognostic (1.98e-3)" "unprognostic (2.72e-3)" "unprognostic (7.17e-3)" "unprognostic (1.52e-2)" "unprognostic (5.67e-8)" "unprognostic (2.08e-3)" "unprognostic (2.20e-1)" "unprognostic (1.75e-1)" "unprognostic (1.67e-2)" "unprognostic (2.67e-1)" "unprognostic (6.99e-5)" "unprognostic (2.66e-2)" "unprognostic (7.98e-2)" "unprognostic (5.46e-2)" "prognostic favourable (7.12e-4)" 0.1 0.1 0.0 2.6 0.2 0.1 0.1 0.0 0.3 1.7 0.5 0.0 0.0 0.4 89.4 0.1 0.2 0.1 0.5 0.1 0.0 0.1 0.1 3.6 11.0 0.1 0.0 0.0 0.5 0.3 0.1 0.9 19.8 2.8 3.2 0.2 0.0 2.9 0.1 0.1 0.1 0.7 0.1 0.0 0.2 3.3 0.5 0.0 1.2 0.1 0.0 1.9 0.6 5.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.8 0.2 0.0 0.0 0.2 12.3 0.7 0.1 0.1 0.3 0.0 0.0 3.6 1.9 2.8 0.0 1.4 0.0 0.0 0.2 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.4 0.6 15.8 0.7 0.0 0.0 0.0 0.0 0.3 2.9 1.7 0.0 0.0 0.0 0.0 0.7 5.0 0.0 2.5 0.0 0.0 0.0 0.0 2.0 3.8 1.2 0.4 0.5 0.0 0.0 0.0 0.6 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.3 0.0 0.1 0.0 0.0 2.8 0.0 MMP11 STMY3 ENSG00000099953 "Matrix metallopeptidase 11" P24347 22 23768226-23784316 "Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins" "Collagen degradation" "Hydrolase, Metalloprotease, Protease" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "endometrium 1: 44.1;placenta: 119.6" "Cell line enhanced" "Detected in some" "AN3-CA: 18.9;BJ hTERT+: 5.1;REH: 7.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in single" "Cell type enhanced" "Detected in some" "plasmacytoid DC: 7.8" "Group enriched" "Detected in many" 5 "B-cells: 2.4;dendritic cells: 7.8" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB002593, HPA068864" Approved "Secreted to extracellular matrix" "CAB002593: , HPA068864: " "unprognostic (1.06e-1)" "unprognostic (3.08e-1)" "unprognostic (1.83e-1)" "unprognostic (1.84e-3)" "unprognostic (2.77e-2)" "unprognostic (6.73e-2)" "unprognostic (2.14e-2)" "unprognostic (5.15e-1)" "unprognostic (2.73e-2)" "unprognostic (2.20e-1)" "unprognostic (1.89e-3)" "unprognostic (7.04e-2)" "prognostic unfavourable (2.62e-4)" "unprognostic (8.05e-2)" "unprognostic (6.78e-2)" "unprognostic (1.10e-1)" "unprognostic (1.68e-2)" 1.7 0.6 0.2 1.0 0.6 0.1 1.6 1.0 0.5 13.4 1.8 0.4 0.4 1.9 44.1 1.1 0.8 2.2 2.0 3.1 0.5 0.0 1.7 0.5 0.7 1.8 0.4 0.2 7.7 1.1 0.2 0.3 119.6 0.5 1.4 1.0 0.8 2.5 0.4 0.5 2.0 4.0 2.7 0.3 0.9 0.7 3.4 0.2 2.6 0.5 0.6 0.9 1.6 2.1 2.4 7.8 0.0 0.0 0.0 1.0 0.1 0.1 0.0 2.3 18.9 2.9 4.2 0.0 0.2 5.1 0.6 0.4 0.0 0.6 0.6 3.5 1.3 0.1 1.0 0.0 0.2 0.0 0.3 0.0 0.0 1.0 2.1 0.0 0.0 2.7 0.4 0.5 0.0 3.0 0.3 0.0 0.7 0.1 0.0 0.0 0.7 0.1 7.9 0.0 0.2 0.3 0.0 3.0 5.1 1.9 0.3 0.0 1.8 0.0 1.3 0.3 0.0 0.8 0.0 0.1 0.1 2.5 0.1 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 2.4 1.0 0.3 0.0 0.0 0.0 7.8 0.0 0.1 0.2 0.6 1.0 0.5 0.5 0.0 0.4 0.2 0.5 0.2 MMP13 CLG3 ENSG00000137745 "Matrix metallopeptidase 13" P45452 11 102942995-102955734 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins" "Collagen degradation" "Hydrolase, Metalloprotease, Protease" "Cancer-related genes, Disease mutation, Dwarfism, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "lung: 12.6;vagina: 10.8" "Group enriched" "Detected in some" 5 "HaCaT: 19.1;PC-3: 7.2" "Cancer enhanced" "Detected in many" "head and neck cancer: 70.9" "Not detected" "Not detected" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" CAB002742 Supported "Secreted to extracellular matrix" "CAB002742: " "unprognostic (8.98e-3)" "unprognostic (1.54e-1)" "unprognostic (4.75e-2)" "unprognostic (4.57e-2)" "unprognostic (3.05e-2)" "unprognostic (1.59e-3)" "unprognostic (1.32e-1)" "unprognostic (6.35e-3)" "unprognostic (1.69e-1)" "unprognostic (7.55e-3)" "unprognostic (2.24e-1)" "unprognostic (1.73e-8)" "unprognostic (2.12e-2)" "unprognostic (3.14e-1)" "unprognostic (4.14e-2)" "unprognostic (4.33e-2)" 0.5 0.1 0.0 0.8 0.0 1.3 0.4 0.0 0.2 1.3 0.1 0.0 0.0 0.6 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.2 0.1 12.6 0.1 0.0 0.0 0.1 0.0 0.0 3.1 0.1 0.1 1.2 0.0 0.0 0.6 0.0 0.0 1.0 0.5 0.0 0.0 0.1 0.1 1.9 0.0 1.4 0.0 0.0 0.1 4.6 10.8 1.0 0.7 2.7 0.5 1.9 1.3 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.4 0.0 0.0 0.0 0.3 0.0 0.0 0.0 19.1 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.1 0.0 0.5 0.1 0.0 0.0 7.2 0.0 0.0 0.1 0.0 1.9 0.0 0.1 0.1 2.2 0.0 0.0 0.0 0.0 2.7 1.4 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 2.7 0.5 0.6 1.3 0.4 1.0 0.5 0.7 0.8 0.3 1.0 0.6 1.1 1.9 1.9 0.3 0.7 0.4 0.5 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.1 0.0 MMP14 MT1-MMP ENSG00000157227 "Matrix metallopeptidase 14" P50281 14 22836557-22849027 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Hydrolase, Metalloprotease, Protease" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "ASC diff: 98.0;HHSteC: 92.7;HSkMC: 94.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009918, HPA051432" Approved Approved "Intermediate filaments,Cytosol" 570000 Cytosol "Intermediate filaments" "CAB009918: AB_2250767, HPA051432: " "unprognostic (1.34e-1)" "unprognostic (1.37e-1)" "unprognostic (1.11e-2)" "unprognostic (2.81e-1)" "unprognostic (4.28e-2)" "unprognostic (1.12e-2)" "unprognostic (3.05e-3)" "unprognostic (5.91e-3)" "unprognostic (1.95e-1)" "prognostic unfavourable (9.48e-4)" "unprognostic (3.82e-3)" "unprognostic (7.31e-2)" "prognostic unfavourable (1.34e-4)" "unprognostic (5.02e-2)" "unprognostic (6.69e-2)" "unprognostic (1.00e-2)" "unprognostic (3.41e-3)" 60.9 10.5 2.4 16.6 4.7 0.2 64.2 2.2 3.2 56.3 35.0 8.2 12.7 12.0 53.1 24.1 47.0 21.9 39.6 17.5 3.4 1.8 16.8 9.0 29.8 16.9 5.8 2.9 39.3 11.2 34.4 4.7 73.5 16.4 39.1 11.3 27.1 24.4 16.7 20.4 37.0 22.9 28.5 20.7 22.5 18.2 26.3 4.6 5.4 22.3 14.6 16.7 52.5 53.9 0.1 0.7 0.0 0.7 0.0 0.0 0.1 7.9 0.1 2.4 0.1 98.0 62.3 45.0 25.1 50.6 7.6 13.6 2.3 29.9 0.1 14.0 26.4 20.3 0.0 26.1 9.8 0.1 0.1 3.7 0.1 0.5 92.7 0.0 0.1 94.2 15.8 31.7 27.2 46.0 0.1 0.2 17.9 0.1 0.0 9.0 1.5 4.3 0.3 8.6 0.0 6.9 13.7 0.0 0.0 16.4 0.0 54.4 0.1 8.1 40.7 61.9 5.3 18.0 28.6 0.1 0.1 0.1 37.7 0.0 35.8 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 2.4 4.7 2.2 3.2 3.4 1.8 5.8 2.9 16.4 4.6 MMP15 "MT2-MMP, MTMMP2, SMCP-2" ENSG00000102996 "Matrix metallopeptidase 15" P51511 16 58025566-58046901 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Hydrolase, Metalloprotease, Protease" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 43.2" "Cell line enhanced" "Detected in many" "BEWO: 36.8;Hep G2: 19.1;SK-BR-3: 18.5;WM-115: 30.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 30 "plasmacytoid DC: 2.9" "Lineage enriched" "Detected in single" 30 "dendritic cells: 2.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002611, HPA040390" Uncertain Approved "Nucleoplasm,Plasma membrane,Cytosol" "Plasma membrane, Cytosol" Nucleoplasm "CAB002611: , HPA040390: " "unprognostic (1.76e-2)" "unprognostic (7.32e-2)" "unprognostic (2.69e-1)" "unprognostic (6.85e-2)" "unprognostic (3.09e-1)" "unprognostic (1.68e-1)" "unprognostic (6.88e-3)" "unprognostic (1.40e-1)" "unprognostic (3.02e-2)" "unprognostic (1.24e-2)" "unprognostic (4.81e-2)" "unprognostic (1.81e-1)" "prognostic favourable (8.54e-8)" "unprognostic (3.63e-2)" "unprognostic (1.36e-1)" "unprognostic (1.28e-1)" "prognostic favourable (3.08e-4)" 5.9 2.3 2.0 5.5 3.0 0.1 7.7 3.7 7.2 3.3 19.5 4.2 16.3 22.6 2.9 1.7 2.5 3.6 15.9 17.6 2.3 3.7 8.4 26.4 6.1 2.0 2.5 2.2 2.1 10.3 7.3 5.2 28.5 10.4 3.6 8.2 9.5 4.7 14.7 3.4 2.3 43.2 3.4 3.4 5.2 14.7 28.0 2.1 1.1 26.8 2.5 2.2 3.3 4.2 0.0 2.9 0.0 0.0 0.0 0.0 0.0 5.7 4.3 2.3 11.8 2.4 0.1 36.8 0.5 0.3 2.1 0.4 3.4 14.8 0.0 7.0 0.6 8.1 1.9 1.7 0.6 0.0 3.9 0.0 1.9 19.1 3.1 0.1 7.7 1.2 3.0 0.3 0.9 1.4 4.7 0.0 0.7 2.8 0.2 0.9 6.7 1.2 2.8 0.3 3.1 6.5 2.1 0.6 4.1 7.7 18.5 3.5 2.0 3.1 1.3 0.1 3.7 1.4 0.5 0.0 0.0 0.1 0.7 0.9 30.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.9 0.0 0.0 2.0 3.0 3.7 7.2 2.3 3.7 2.5 2.2 10.4 2.1 MMP16 "C8orf57, DKFZp761D112, MT3-MMP" ENSG00000156103 "Matrix metallopeptidase 16" P51512 8 88032009-88328025 "Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" "Collagen degradation" "Hydrolase, Metalloprotease, Protease" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 15.9" "Cell line enhanced" "Detected in many" "AN3-CA: 20.0;HUVEC TERT2: 8.7;SH-SY5Y: 11.1;U-138 MG: 9.5;WM-115: 19.5" "Cancer enhanced" "Detected in many" "glioma: 4.8" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA023693 Uncertain Approved Vesicles,Cytosol "Secreted to extracellular matrix" Cytosol Vesicles "HPA023693: AB_1854025" "unprognostic (2.58e-1)" "unprognostic (2.42e-2)" "unprognostic (1.38e-1)" "unprognostic (1.87e-1)" "unprognostic (7.09e-2)" "unprognostic (3.31e-2)" "unprognostic (2.39e-3)" "unprognostic (1.45e-3)" "unprognostic (2.46e-1)" "unprognostic (2.61e-1)" "unprognostic (9.42e-2)" "unprognostic (2.92e-1)" "unprognostic (2.09e-8)" "unprognostic (6.90e-3)" "unprognostic (1.16e-1)" "unprognostic (3.62e-1)" "unprognostic (2.19e-3)" 2.4 1.3 11.0 1.4 6.8 0.5 4.9 8.3 15.9 5.3 2.2 2.9 0.7 0.8 4.9 2.1 1.7 2.1 7.3 2.7 8.7 6.9 0.8 0.9 1.0 1.0 5.5 9.1 3.3 2.1 1.5 1.7 3.0 6.3 3.2 1.7 0.6 1.2 2.4 0.7 1.1 1.3 4.0 4.6 1.5 1.4 1.5 5.5 0.0 3.2 0.7 1.0 2.6 3.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 5.4 20.0 0.7 1.4 0.0 7.3 1.0 2.1 1.2 0.0 0.0 0.0 0.0 3.3 0.0 3.9 0.0 2.5 0.0 2.3 0.0 0.0 0.0 1.7 0.0 0.3 1.0 0.0 3.0 0.9 8.7 0.0 0.7 1.1 0.0 0.0 0.0 1.1 2.0 0.2 0.4 0.0 0.4 0.0 0.1 11.1 0.0 0.0 0.1 0.8 0.0 4.8 9.5 5.4 0.1 2.7 0.0 0.0 0.0 3.8 0.0 19.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 11.0 6.8 8.3 14.1 8.7 6.9 5.5 9.1 6.3 5.5 MMP2 "CLG4, CLG4A, TBE-1" ENSG00000087245 "Matrix metallopeptidase 2" P08253 16 55389700-55506691 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Angiogenesis, Collagen degradation" "Hydrolase, Metalloprotease, Protease" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "ASC diff: 335.4;ASC TERT1: 97.7;HSkMC: 83.3;U-138 MG: 91.2;U-87 MG: 106.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA001939, CAB002788" Approved Approved Vesicles "Secreted to extracellular matrix" 160000000 Vesicles "CAB002788: , HPA001939: AB_1079395" "unprognostic (7.26e-2)" "unprognostic (1.36e-3)" "unprognostic (1.66e-1)" "unprognostic (2.14e-3)" "unprognostic (5.03e-2)" "unprognostic (1.20e-1)" "unprognostic (1.74e-1)" "unprognostic (9.36e-3)" "unprognostic (4.81e-3)" "unprognostic (3.79e-2)" "unprognostic (4.59e-3)" "unprognostic (6.12e-2)" "unprognostic (1.28e-3)" "unprognostic (1.59e-2)" "unprognostic (8.00e-2)" "unprognostic (8.98e-2)" "unprognostic (4.63e-2)" 197.5 9.0 1.2 13.2 1.6 0.0 136.4 0.8 1.4 74.3 74.4 2.4 36.9 5.6 85.0 123.0 52.3 25.7 115.4 54.0 0.9 0.5 9.4 3.5 38.9 3.9 1.5 1.1 71.0 6.5 0.7 2.2 58.9 2.2 66.8 18.7 36.4 18.6 20.4 68.6 68.2 22.6 57.1 1.8 12.4 20.5 57.0 1.1 1.3 20.6 31.8 9.1 84.1 105.3 0.0 0.0 0.9 0.7 0.0 0.0 0.0 0.3 0.2 11.1 0.1 335.4 97.7 18.2 28.7 65.9 5.8 4.6 0.0 0.1 0.0 23.1 50.5 3.1 0.0 0.2 3.3 0.0 0.0 0.0 0.7 0.1 31.7 0.0 0.8 83.3 0.0 29.8 0.2 37.4 0.0 0.1 19.3 0.0 0.0 0.4 8.8 0.0 0.0 2.6 0.0 0.9 0.4 0.1 20.2 5.3 0.0 0.1 0.0 2.0 52.7 91.2 8.7 17.5 3.7 0.0 0.0 0.1 106.8 1.5 16.6 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.2 0.0 0.0 0.0 1.2 1.6 0.8 1.4 0.9 0.5 1.5 1.1 2.2 1.1 MMP3 "STMY, STMY1" ENSG00000149968 "Matrix metallopeptidase 3" P08254 11 102835801-102843803 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Collagen degradation" "Hydrolase, Metalloprotease, Protease" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "epididymis: 177.5;salivary gland: 73.4" "Group enriched" "Detected in some" 17 "BJ: 98.9;BJ hTERT+: 269.1;fHDF/TERT166: 116.5" "Cancer enhanced" "Detected in many" "head and neck cancer: 59.9" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" HPA007875 Uncertain Supported Vesicles "Secreted to extracellular matrix" 170000 Vesicles "HPA007875: AB_1079396" "unprognostic (2.27e-1)" "prognostic unfavourable (9.73e-4)" "unprognostic (1.63e-3)" "unprognostic (5.11e-3)" "unprognostic (3.78e-1)" "unprognostic (5.11e-2)" "unprognostic (5.26e-6)" "unprognostic (3.46e-2)" "unprognostic (7.14e-2)" "unprognostic (2.87e-1)" "prognostic unfavourable (4.09e-4)" "unprognostic (3.26e-2)" "unprognostic (1.22e-15)" "unprognostic (3.17e-1)" "unprognostic (1.55e-1)" "unprognostic (3.43e-2)" "unprognostic (2.34e-1)" 19.1 0.0 0.2 14.4 0.3 0.0 6.9 0.2 0.5 0.2 1.5 0.3 0.2 1.8 28.3 177.5 0.2 0.0 1.4 0.2 0.2 0.0 0.3 0.5 0.4 0.2 0.2 0.2 0.3 0.2 0.0 0.2 0.2 0.2 1.2 1.7 0.2 73.4 1.5 7.3 12.6 0.7 5.9 0.2 0.2 2.8 1.4 0.2 0.2 0.6 1.5 0.9 7.5 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 98.9 269.1 1.7 0.5 0.0 0.0 0.0 0.0 116.5 0.0 0.0 0.0 2.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 7.9 0.3 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 9.2 0.8 0.1 0.0 0.0 0.0 0.0 3.8 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.3 0.2 0.5 0.2 0.0 0.2 0.2 0.2 0.2 MMP7 "MPSL1, PUMP-1" ENSG00000137673 "Matrix metallopeptidase 7" P09237 11 102520508-102530753 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins" "Collagen degradation" "Hydrolase, Metalloprotease, Protease" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "gallbladder: 93.0;kidney: 129.5;salivary gland: 79.3" "Cell line enhanced" "Detected in some" "A549: 22.6;CAPAN-2: 126.5;EFO-21: 30.0;RPTEC TERT1: 54.7" "Cancer enhanced" "Detected in all" "pancreatic cancer: 352.1" "Region enriched" "Detected in single" 5 "pons and medulla: 1.3" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB025869, HPA051358" Supported Approved Nucleoplasm,Vesicles "Secreted to extracellular matrix" "Nucleoplasm, Vesicles" "CAB025869: , HPA051358: " "unprognostic (1.06e-3)" "unprognostic (9.51e-2)" "unprognostic (4.15e-2)" "unprognostic (1.38e-1)" "unprognostic (7.70e-3)" "unprognostic (7.28e-2)" "prognostic unfavourable (2.53e-4)" "prognostic unfavourable (3.38e-4)" "unprognostic (3.96e-2)" "unprognostic (5.63e-2)" "unprognostic (6.59e-3)" "unprognostic (1.51e-1)" "unprognostic (6.36e-3)" "unprognostic (1.42e-2)" "unprognostic (5.54e-2)" "unprognostic (1.48e-1)" "unprognostic (1.46e-1)" 6.8 0.2 0.2 1.2 0.2 0.0 28.8 0.2 0.2 5.2 0.2 0.2 2.1 0.0 17.2 12.3 3.3 16.4 93.0 0.2 0.2 0.2 129.5 1.4 5.0 0.9 0.2 0.2 3.9 23.5 0.0 0.7 2.7 1.3 42.0 0.0 0.2 79.3 6.7 0.2 7.8 0.3 0.5 0.2 0.2 0.9 9.4 0.2 1.2 0.3 1.4 4.5 19.9 0.8 0.8 0.0 0.0 0.0 0.0 0.0 0.1 0.0 22.6 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.2 126.5 0.0 30.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 54.7 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.4 0.0 0.2 0.0 0.0 0.0 0.1 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 1.3 0.2 MMP8 CLG1 ENSG00000118113 "Matrix metallopeptidase 8" P22894 11 102711795-102727050 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Collagen degradation" "Hydrolase, Metalloprotease, Protease" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 6 "bone marrow: 119.3" "Cell line enriched" "Detected in some" 8 "WM-115: 39.2" "Cancer enriched" "Detected in single" 17 "melanoma: 5.7" "Region enhanced" "Detected in single" "cerebral cortex: 1.7" "Group enriched" "Detected in some" 32 "neutrophil: 1.4;non-classical monocyte: 4.9" "Group enriched" "Detected in many" 32 "granulocytes: 1.4;monocytes: 4.9" "Not detected" "Not detected" "Not detected" "Not detected" "HPA021221, HPA022935" Enhanced "Secreted to extracellular matrix" 83000 "HPA021221: AB_1854043, HPA022935: AB_1854044" "unprognostic (3.03e-1)" "unprognostic (8.49e-5)" "unprognostic (1.08e-2)" "unprognostic (3.95e-3)" "unprognostic (1.80e-1)" "unprognostic (1.01e-2)" "unprognostic (7.68e-3)" "unprognostic (1.27e-1)" "unprognostic (4.92e-2)" "unprognostic (6.64e-3)" "unprognostic (2.45e-6)" "unprognostic (2.33e-4)" "unprognostic (1.33e-1)" "unprognostic (4.97e-1)" "unprognostic (2.30e-2)" 1.9 0.1 0.2 0.2 0.4 119.3 0.3 0.1 1.7 0.1 0.2 0.0 0.0 0.1 0.6 0.1 0.1 0.1 0.1 9.0 0.2 0.3 0.4 0.8 12.6 2.6 0.3 0.0 0.9 0.9 0.1 0.6 1.4 0.2 0.1 0.1 0.1 0.3 0.1 0.6 0.3 0.1 0.2 0.3 18.7 0.2 0.1 0.1 5.2 1.9 0.0 0.1 0.2 7.6 0.0 0.0 1.4 4.9 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.9 0.0 0.0 0.0 2.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 39.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 4.9 0.0 0.0 1.7 0.2 0.4 0.1 1.7 0.2 0.3 0.3 0.0 0.2 0.1 MMP9 CLG4B ENSG00000100985 "Matrix metallopeptidase 9" P14780 20 46008908-46016561 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins" "Collagen degradation" "Hydrolase, Metalloprotease, Protease" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "adipose tissue: 64.0;blood: 63.2;bone marrow: 89.4;lymphoid tissue: 80.1" "Cell line enriched" "Detected in some" 12 "NB-4: 87.3" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Cell type enriched" "Detected in single" 141 "neutrophil: 63.2" "Lineage enriched" "Detected in single" 339 "granulocytes: 63.2" "Not detected" "Not detected" "Not detected" "Not detected" "CAB000348, HPA001238, HPA063909, CAB068199, CAB068200, CAB068201" Enhanced Approved Cytosol "Secreted to blood" 57000000 Cytosol "CAB000348: , CAB068199: , CAB068200: , CAB068201: , HPA001238: AB_1079398, HPA063909: AB_2685150" "unprognostic (4.62e-2)" "unprognostic (1.64e-1)" "unprognostic (2.85e-2)" "prognostic favourable (2.55e-4)" "unprognostic (6.65e-3)" "unprognostic (2.82e-1)" "prognostic unfavourable (7.19e-4)" "unprognostic (1.54e-1)" "unprognostic (8.57e-2)" "unprognostic (3.21e-2)" "unprognostic (4.15e-2)" "unprognostic (1.96e-1)" "prognostic unfavourable (4.05e-5)" "unprognostic (4.65e-1)" "unprognostic (9.85e-3)" "unprognostic (2.48e-2)" "unprognostic (2.17e-3)" 64.0 0.5 0.6 38.6 0.7 89.4 4.3 0.4 0.6 0.8 1.2 0.1 0.0 2.8 0.6 0.2 0.9 1.5 0.6 4.0 0.5 0.6 1.4 2.0 13.3 80.1 0.6 0.0 2.7 1.4 0.0 0.8 2.6 0.5 0.6 0.8 0.5 12.5 0.0 1.3 1.3 4.2 0.3 0.5 53.7 2.5 2.7 0.0 23.6 1.3 2.3 44.5 4.5 2.9 0.0 0.0 63.2 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.8 0.0 7.3 0.0 0.1 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.9 0.0 87.3 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.3 0.0 2.6 2.7 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 63.2 0.0 0.0 0.0 0.0 0.0 0.6 0.7 0.4 0.6 0.5 0.6 0.6 0.0 0.5 0.0 MN1 "MGCR, MGCR1, MGCR1-PEN" ENSG00000169184 "MN1 proto-oncogene, transcriptional regulator" Q10571 22 27748277-27801498 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Activator, Developmental protein" "Cancer-related genes, Tumor suppressor" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 62.7" "Cell line enhanced" "Detected in some" "AF22: 22.0;HeLa: 8.9;RH-30: 8.9;TIME: 14.0;U-2 OS: 12.0;U-2197: 12.7" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 6 "non-classical monocyte: 1.7" "Lineage enriched" "Detected in single" 8 "monocytes: 1.7" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA003072 Approved Approved Nucleoplasm Nucleoplasm "HPA003072: AB_1079399" "unprognostic (5.64e-2)" "unprognostic (2.48e-2)" "unprognostic (1.09e-2)" "unprognostic (1.26e-1)" "unprognostic (2.88e-2)" "unprognostic (2.52e-2)" "unprognostic (7.01e-2)" "unprognostic (3.03e-2)" "unprognostic (4.17e-2)" "unprognostic (1.64e-1)" "unprognostic (4.00e-2)" "unprognostic (7.33e-2)" "unprognostic (5.13e-7)" "unprognostic (3.84e-2)" "unprognostic (2.00e-1)" "unprognostic (5.28e-3)" "unprognostic (2.21e-4)" 3.7 2.0 3.4 4.2 17.3 2.4 1.9 1.3 5.6 5.9 4.2 2.6 2.5 2.1 3.0 9.0 7.0 3.4 11.1 5.1 2.5 2.7 1.6 1.4 4.3 1.3 3.3 3.5 12.4 1.5 1.3 2.3 2.6 4.5 3.1 2.2 10.8 2.1 2.7 62.7 2.9 2.1 5.8 1.0 1.5 3.5 2.0 5.4 0.0 1.8 14.8 2.1 5.0 4.7 0.0 0.2 0.0 1.7 0.0 0.1 0.0 0.0 1.0 22.0 0.6 0.4 0.9 0.0 0.5 0.8 0.0 0.0 0.0 0.0 0.0 2.2 3.9 1.8 1.1 1.3 0.0 0.0 0.6 0.0 8.9 0.0 0.5 0.0 0.2 0.0 2.5 0.5 2.2 0.2 0.0 0.1 0.7 0.0 0.0 0.2 2.9 2.0 3.6 8.9 0.0 0.3 0.0 0.0 0.3 1.9 0.0 0.0 0.2 0.0 14.0 0.7 12.0 12.7 0.2 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.0 0.1 0.2 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.2 0.0 0.0 3.4 17.3 1.3 4.2 2.5 2.7 3.3 3.5 4.5 5.4 MORC4 "FLJ11565, ZCW4, ZCWCC2" ENSG00000133131 "MORC family CW-type zinc finger 4" Q8TE76 X 106813871-107000244 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in all" 5 "placenta: 94.5" "Cell line enhanced" "Detected in all" "A549: 46.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in some" "Low region specificity" "Detected in all" "HPA000395, HPA015547, HPA050250" Enhanced Enhanced Nucleoplasm Nucleoplasm "HPA000395: AB_1079405, HPA015547: AB_2669216, HPA050250: " "prognostic unfavourable (3.56e-5)" "unprognostic (3.30e-3)" "unprognostic (1.09e-1)" "unprognostic (1.13e-1)" "unprognostic (1.40e-1)" "unprognostic (6.29e-3)" "unprognostic (1.39e-1)" "unprognostic (1.43e-1)" "unprognostic (1.47e-1)" "unprognostic (2.30e-2)" "unprognostic (5.56e-2)" "unprognostic (8.59e-2)" "unprognostic (1.60e-1)" "unprognostic (1.60e-2)" "unprognostic (6.57e-2)" "unprognostic (4.89e-2)" "unprognostic (8.69e-2)" 8.7 20.0 3.2 6.0 4.8 5.1 6.2 4.9 3.6 8.0 5.3 4.6 12.7 4.6 8.8 8.5 6.8 7.3 6.7 5.3 4.3 2.8 4.9 9.7 6.0 2.2 4.9 2.2 12.3 9.1 6.0 4.9 94.5 5.8 7.7 4.9 4.2 8.7 8.8 9.4 8.6 4.9 7.4 5.4 2.6 5.6 12.5 5.0 2.3 7.6 7.5 5.2 6.3 15.1 6.0 4.6 10.5 3.8 2.8 4.0 0.7 11.5 46.3 4.6 10.6 14.1 16.3 24.2 11.3 12.0 5.7 7.3 24.5 5.3 1.8 5.9 11.6 9.1 15.4 9.9 6.9 2.7 8.9 2.8 15.7 10.3 10.4 2.0 5.9 8.6 9.6 7.8 11.4 5.1 1.6 17.6 12.7 10.2 4.2 2.8 4.1 17.6 2.0 9.3 2.0 18.5 9.2 4.0 5.1 13.7 13.4 8.9 8.0 2.0 5.3 9.2 9.3 18.2 6.2 5.0 6.5 4.6 9.8 1.8 6.6 10.5 3.8 3.1 3.7 3.0 3.2 3.3 3.6 2.8 1.6 6.0 4.0 3.4 8.2 2.8 3.6 4.6 2.6 0.7 3.2 4.8 4.9 3.6 4.3 2.8 4.9 2.2 5.8 5.0 MPL "CD110, TPOR" ENSG00000117400 "MPL proto-oncogene, thrombopoietin receptor" P40238 1 43337849-43352772 "Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" Receptor "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 8.6" "Cell line enriched" "Detected in single" 78 "HEL: 40.7" "Not detected" "Not detected" "Low region specificity" "Detected in single" "Cell type enriched" "Detected in single" 5 "neutrophil: 1.6" "Lineage enriched" "Detected in single" 5 "granulocytes: 1.6" "Region enhanced" "Detected in single" "cerebral cortex: 1.4" "Low region specificity" "Detected in all" HPA007619 Supported "Nuclear membrane,Plasma membrane" "Plasma membrane" "Nuclear membrane" "HPA007619: AB_1854080" "unprognostic (2.74e-1)" "unprognostic (6.56e-2)" "unprognostic (2.95e-1)" "unprognostic (8.71e-2)" "unprognostic (1.37e-2)" "unprognostic (1.06e-3)" "unprognostic (1.19e-1)" "unprognostic (1.22e-2)" "unprognostic (5.83e-2)" "unprognostic (1.03e-1)" "unprognostic (5.94e-4)" "unprognostic (1.51e-1)" "unprognostic (1.19e-4)" "unprognostic (2.39e-1)" "unprognostic (3.26e-1)" "unprognostic (1.03e-4)" "unprognostic (1.42e-1)" 1.1 0.3 0.9 0.5 0.8 2.0 0.9 0.5 2.2 0.6 0.6 0.5 0.5 0.3 0.9 1.7 0.9 2.1 0.5 3.9 0.8 0.6 0.5 0.5 2.0 0.5 0.9 0.5 6.6 1.1 0.6 0.6 2.2 0.5 1.5 0.7 0.5 0.5 0.7 0.6 0.4 1.2 2.1 2.5 8.6 0.5 2.1 0.5 0.5 2.2 2.4 0.5 0.9 0.5 0.0 0.0 1.6 0.3 0.0 0.0 4.0 0.1 0.5 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.5 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.2 0.0 40.7 0.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.3 0.1 0.0 0.0 0.1 0.4 0.2 0.2 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 4.0 0.9 0.8 0.5 2.2 0.8 0.6 0.9 0.5 0.5 0.5 MPO ENSG00000005381 Myeloperoxidase P05164 17 58269856-58280935 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Hydrogen peroxide" "Oxidoreductase, Peroxidase" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 15 "bone marrow: 315.2" "Group enriched" "Detected in some" 93 "HL-60: 212.9;NB-4: 279.1" "Cancer enhanced" "Detected in single" "stomach cancer: 1.1" "Low region specificity" "Detected in single" "Group enriched" "Detected in some" 5 "classical monocyte: 7.6;intermediate monocyte: 3.8;myeloid DC: 3.2;neutrophil: 2.0" "Group enriched" "Detected in many" 30 "dendritic cells: 3.2;granulocytes: 2.0;monocytes: 7.6" "Not detected" "Not detected" "Not detected" "Not detected" "CAB000059, HPA021147, HPA061464" Enhanced Supported Nucleoplasm,Vesicles "Intracellular and membrane" 15000000 Vesicles Nucleoplasm "CAB000059: AB_2335676, HPA021147: AB_1854083, HPA061464: AB_2684531" "unprognostic (1.91e-1)" "unprognostic (9.08e-2)" "unprognostic (4.62e-2)" "unprognostic (2.90e-2)" "unprognostic (2.13e-3)" "unprognostic (2.78e-1)" "unprognostic (3.23e-1)" "unprognostic (2.91e-1)" "unprognostic (2.56e-1)" "unprognostic (1.68e-1)" "unprognostic (6.92e-2)" "unprognostic (8.34e-3)" "unprognostic (4.91e-2)" "unprognostic (3.07e-3)" "unprognostic (2.83e-1)" "unprognostic (1.14e-2)" "unprognostic (8.05e-2)" 0.2 0.1 0.5 0.1 0.8 315.2 0.1 0.4 1.0 0.1 0.1 1.4 0.0 0.1 0.2 0.2 0.1 0.1 0.1 21.5 0.6 0.8 0.1 1.4 6.9 0.8 0.6 0.0 0.6 0.1 0.1 1.0 2.9 0.4 0.2 0.1 0.2 6.3 0.1 0.7 0.5 0.1 0.1 0.4 17.8 0.1 0.4 0.2 19.7 0.6 0.0 0.5 0.1 0.0 0.0 3.2 2.0 7.6 0.0 0.1 7.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 212.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 279.1 0.0 0.0 0.3 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 7.6 0.0 0.0 3.8 0.0 0.0 0.0 0.1 3.2 0.0 0.0 0.0 2.0 0.0 0.8 0.0 0.1 7.2 0.5 0.8 0.4 1.0 0.6 0.8 0.6 0.0 0.4 0.2 MRE11 "ATLD, MRE11A" ENSG00000020922 "MRE11 homolog, double strand break repair nuclease" P49959 11 94415578-94493908 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA repair, Host-virus interaction, Meiosis" "Endonuclease, Exonuclease, Hydrolase, Nuclease" "Cancer-related genes, Ciliopathy, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002691, CAB004081" Supported Enhanced Nucleoplasm Nucleoplasm "CAB004081: AB_2145100, HPA002691: AB_1079409" "unprognostic (5.59e-3)" "unprognostic (4.35e-2)" "unprognostic (8.55e-2)" "unprognostic (2.76e-2)" "unprognostic (9.82e-2)" "unprognostic (5.17e-2)" "prognostic unfavourable (7.14e-4)" "unprognostic (2.85e-1)" "unprognostic (1.03e-2)" "unprognostic (1.34e-1)" "unprognostic (8.66e-3)" "unprognostic (6.96e-3)" "unprognostic (1.57e-3)" "unprognostic (1.39e-1)" "unprognostic (1.77e-1)" "unprognostic (1.22e-1)" "unprognostic (8.06e-3)" 14.7 11.0 10.7 15.2 12.5 24.0 16.6 21.2 12.0 17.5 11.0 10.8 13.9 8.0 17.4 11.2 13.9 13.2 8.9 9.4 8.7 6.5 8.8 8.9 11.4 13.8 13.3 7.9 16.7 15.5 8.2 12.8 14.2 9.8 12.7 14.1 10.4 14.1 10.8 9.3 18.3 12.8 12.8 13.5 17.2 11.8 9.9 13.0 25.3 12.7 7.4 18.4 14.3 13.3 8.7 14.8 7.9 13.1 10.3 11.8 7.9 10.0 10.3 19.3 2.4 6.5 9.2 11.0 14.1 9.2 12.8 15.2 18.6 20.7 26.3 23.0 7.3 19.3 16.3 10.6 16.9 17.4 9.7 22.9 14.7 10.7 3.0 15.0 16.6 6.4 6.6 16.5 10.4 11.1 16.0 17.1 10.1 7.2 15.2 14.3 6.2 11.3 13.6 17.3 13.2 8.3 14.1 6.8 9.7 19.5 12.3 3.8 21.1 9.1 8.1 19.2 14.0 16.5 10.1 4.3 15.2 25.8 5.1 24.0 15.2 5.4 11.1 7.9 11.2 13.1 11.0 8.5 8.4 11.8 14.8 8.7 7.1 11.5 4.8 10.3 9.8 10.5 10.9 7.9 10.7 12.5 21.2 12.0 8.7 6.5 13.3 7.9 9.8 13.0 MSH2 "COCA1, HNPCC, HNPCC1" ENSG00000095002 "MutS homolog 2" P43246 2 47402969-47663146 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA repair" DNA-binding "Cancer-related genes, Disease mutation, Hereditary nonpolyposis colorectal cancer, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009572, HPA066845, CAB070867" Approved Supported Nucleoplasm,Vesicles Nucleoplasm Vesicles "CAB009572: AB_2144828, CAB070867: , HPA066845: " "unprognostic (2.35e-1)" "unprognostic (1.54e-2)" "unprognostic (2.89e-3)" "prognostic unfavourable (4.44e-4)" "unprognostic (2.23e-1)" "unprognostic (6.31e-3)" "prognostic unfavourable (1.72e-9)" "unprognostic (1.77e-1)" "unprognostic (7.09e-3)" "unprognostic (8.57e-2)" "prognostic unfavourable (4.63e-4)" "unprognostic (5.38e-2)" "unprognostic (3.29e-3)" "unprognostic (1.20e-3)" "unprognostic (5.74e-1)" "unprognostic (8.46e-2)" "unprognostic (1.48e-1)" 7.3 9.8 14.2 12.2 25.5 11.4 14.1 22.6 18.1 9.4 11.6 7.6 5.6 6.5 10.5 13.3 10.8 11.1 4.9 8.4 13.0 14.0 7.3 5.5 7.1 19.7 12.5 17.0 7.9 8.4 15.3 9.1 9.9 18.5 7.9 13.8 12.3 9.4 7.3 6.7 10.3 8.0 7.8 13.8 9.4 6.7 13.4 13.5 37.0 13.9 6.6 21.4 8.5 7.6 7.4 2.9 3.9 4.2 12.2 12.6 6.2 28.0 9.6 26.3 14.1 1.9 5.5 15.9 16.7 8.3 20.8 20.1 18.0 12.1 34.5 22.6 5.9 11.9 19.6 9.5 31.4 17.8 14.6 24.9 11.1 16.3 2.0 24.3 8.8 3.1 2.8 17.7 4.8 11.4 41.4 8.0 15.8 11.2 28.1 18.3 49.4 11.4 37.7 46.9 20.2 9.0 14.9 21.8 23.6 14.8 11.5 11.8 11.5 9.5 4.6 13.8 18.1 14.2 18.6 5.1 18.3 48.4 8.4 18.0 8.5 2.8 1.0 3.9 7.9 4.2 8.6 6.3 7.4 9.5 2.3 7.4 12.6 11.9 0.7 12.2 3.2 2.9 10.1 6.2 14.2 25.5 22.6 18.1 13.0 14.0 12.5 17.0 18.5 13.5 MSH6 GTBP ENSG00000116062 "MutS homolog 6" P52701 2 47695530-47810101 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA repair, Host-virus interaction" DNA-binding "Cancer-related genes, Disease mutation, Hereditary nonpolyposis colorectal cancer" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009091, HPA028376, HPA028446, CAB070870" Enhanced Supported "Nucleoplasm,Golgi apparatus,Vesicles" Nucleoplasm "Golgi apparatus, Vesicles" "CAB009091: AB_670083, CAB070870: AB_2144959, HPA028376: AB_10598909, HPA028446: AB_10602182" "unprognostic (5.10e-2)" "unprognostic (5.87e-3)" "unprognostic (3.29e-2)" "prognostic unfavourable (1.34e-4)" "unprognostic (1.98e-1)" "unprognostic (3.09e-2)" "prognostic unfavourable (7.86e-4)" "unprognostic (1.79e-1)" "unprognostic (2.35e-3)" "unprognostic (1.01e-1)" "unprognostic (1.74e-3)" "unprognostic (8.99e-2)" "prognostic unfavourable (1.06e-7)" "unprognostic (1.22e-1)" "unprognostic (2.31e-1)" "unprognostic (9.68e-2)" "unprognostic (3.48e-2)" 13.0 20.5 9.7 13.1 18.8 13.6 13.0 20.5 13.1 17.9 13.3 17.6 10.7 6.1 28.2 11.0 12.4 18.3 8.4 8.6 11.4 8.8 9.5 14.6 11.0 21.7 23.9 9.6 43.2 27.6 16.2 17.3 14.9 15.0 14.6 10.3 8.7 12.0 13.2 10.4 10.3 10.5 22.1 14.9 11.6 11.1 25.1 22.0 40.4 13.4 10.4 25.8 14.2 16.4 8.4 8.4 7.6 9.8 9.7 15.1 5.7 27.2 20.3 37.9 9.0 11.4 12.1 17.1 15.2 13.4 15.7 16.6 14.9 9.5 45.0 22.7 16.4 11.5 34.1 19.3 20.5 19.6 17.0 28.8 16.2 15.1 7.0 28.9 10.6 9.8 6.2 16.0 10.7 9.8 25.0 16.6 15.3 19.6 30.7 13.7 33.3 9.4 73.0 49.7 20.3 9.6 17.8 21.2 23.0 21.1 10.1 9.2 12.0 10.2 6.0 18.3 22.4 13.8 19.6 15.6 21.0 75.4 15.5 18.5 11.2 7.6 5.8 4.9 8.4 9.8 10.4 8.4 9.5 8.3 8.4 8.1 15.1 7.6 3.9 9.7 9.3 4.2 9.5 5.7 9.7 18.8 20.5 13.1 11.4 8.8 23.9 9.6 15.0 22.0 MSI2 ENSG00000153944 "Musashi RNA binding protein 2" Q96DH6 17 57255851-57684685 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" RNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "REH: 48.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB022300 Approved Supported Cytosol Cytosol "CAB022300: " "unprognostic (4.73e-2)" "unprognostic (2.28e-1)" "unprognostic (3.42e-2)" "unprognostic (1.26e-1)" "unprognostic (1.12e-1)" "unprognostic (1.08e-1)" "unprognostic (4.20e-2)" "unprognostic (2.20e-2)" "unprognostic (4.89e-2)" "unprognostic (2.96e-1)" "unprognostic (4.17e-2)" "unprognostic (1.18e-1)" "prognostic favourable (9.22e-8)" "prognostic favourable (2.00e-4)" "unprognostic (4.87e-2)" "unprognostic (1.57e-1)" "unprognostic (2.72e-3)" 3.4 34.7 20.0 22.4 21.5 8.4 8.8 18.0 25.3 9.7 14.4 7.7 14.2 5.0 6.7 36.3 4.6 11.1 23.5 28.5 13.9 16.9 18.0 3.6 6.9 9.6 21.0 6.4 22.8 6.1 41.4 23.1 10.7 19.7 10.5 7.4 14.6 9.8 48.5 25.6 3.6 5.4 4.6 14.8 8.7 7.7 7.5 9.5 23.7 12.4 8.4 8.6 11.6 5.0 1.9 3.0 4.8 1.5 1.9 4.1 0.5 3.4 5.8 20.1 7.7 2.3 2.2 15.8 3.8 4.4 5.0 3.0 6.9 5.8 15.8 13.5 2.3 3.4 12.8 5.1 9.3 22.0 8.9 6.9 12.9 15.8 5.0 7.6 7.0 2.8 6.7 0.6 8.2 5.1 15.0 11.9 17.5 7.9 34.2 2.1 7.2 9.4 48.0 30.1 12.5 12.2 22.2 22.3 41.5 6.2 5.9 17.7 10.6 5.9 6.5 3.2 8.3 2.8 6.5 16.5 14.0 19.2 8.4 4.6 19.3 4.4 0.4 4.8 2.0 0.3 1.5 1.9 1.9 1.8 0.6 1.1 1.8 1.7 0.4 1.9 1.5 3.0 4.1 0.5 20.0 21.5 18.0 25.3 13.9 16.9 21.0 6.4 19.7 9.5 MSLN "CAK1, MPF" ENSG00000102854 Mesothelin Q13421 16 760762-768865 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "fallopian tube: 85.5;lung: 88.5" "Cell line enhanced" "Detected in some" "CAPAN-2: 102.3;EFO-21: 15.8;HeLa: 31.2;hTCEpi: 22.7" "Cancer enhanced" "Detected in many" "ovarian cancer: 343.4" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "myeloid DC: 9.0" "Group enriched" "Detected in many" 59 "dendritic cells: 9.0;monocytes: 2.6" "Low region specificity" "Detected in many" "CAB002216, HPA017172" Enhanced Supported Nucleoplasm,Vesicles "Intracellular and membrane" 14000000 Vesicles Nucleoplasm "CAB002216: AB_563874, HPA017172: AB_1853819" "unprognostic (1.73e-1)" "unprognostic (1.77e-1)" "unprognostic (2.06e-2)" "unprognostic (1.33e-1)" "unprognostic (3.43e-2)" "unprognostic (3.95e-2)" "unprognostic (2.46e-1)" "unprognostic (9.47e-2)" "unprognostic (8.57e-2)" "unprognostic (4.69e-2)" "prognostic unfavourable (6.66e-4)" "unprognostic (2.63e-1)" "prognostic favourable (5.91e-4)" "unprognostic (2.00e-2)" "unprognostic (1.60e-1)" "unprognostic (2.14e-2)" "unprognostic (3.35e-2)" 36.5 0.0 0.4 6.7 0.5 0.7 0.3 0.1 0.4 5.4 5.4 0.8 26.8 2.1 4.8 18.9 3.1 85.5 9.6 4.3 0.4 0.3 2.6 0.2 88.5 0.4 0.6 0.0 22.3 0.4 0.0 0.6 13.7 0.9 1.9 1.2 0.2 14.4 33.1 0.0 0.5 0.7 1.0 0.8 0.1 3.7 2.1 0.0 0.1 0.1 0.6 7.8 1.4 1.3 0.0 9.0 0.0 2.6 0.0 0.0 0.4 0.0 0.4 0.0 0.2 0.0 0.0 0.4 0.0 1.5 1.8 0.4 1.4 102.3 0.0 15.8 0.1 0.2 0.0 0.1 0.1 0.0 0.0 0.0 31.2 1.1 0.9 0.0 0.0 0.0 22.7 0.0 0.4 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.5 0.0 0.0 0.0 5.9 0.0 0.0 0.1 0.0 0.0 0.0 2.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 1.4 0.0 0.0 0.0 0.0 9.0 0.0 0.0 0.0 0.0 0.0 2.6 0.2 0.0 0.4 0.4 0.5 0.1 0.4 0.4 0.3 0.6 0.0 0.9 0.0 MSMB "IGBF, MSP, MSPB, PN44, PRPS, PSP, PSP-94, PSP57, PSP94" ENSG00000263639 "Microseminoprotein beta" P08118 10 46033307-46046269 "Cancer-related genes, Disease related genes, Predicted secreted proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 15 "prostate: 437.8" "Cell line enhanced" "Detected in some" "BEWO: 20.0;NB-4: 16.1;RPMI-8226: 8.4;SH-SY5Y: 4.6;SK-BR-3: 4.7;U-2197: 9.5" "Cancer enriched" "Detected in many" 42 "prostate cancer: 3435.3" "Cell type enriched" "Detected in single" 5 "eosinophil: 1.9" "Lineage enriched" "Detected in single" 5 "granulocytes: 1.9" "CAB026357, HPA051257" Enhanced "Secreted in male reproductive system" 3700000 "CAB026357: , HPA051257: " "unprognostic (6.47e-2)" "unprognostic (7.21e-3)" "unprognostic (1.37e-2)" "unprognostic (8.18e-3)" "unprognostic (4.28e-3)" "unprognostic (9.24e-3)" "unprognostic (1.66e-1)" "unprognostic (8.66e-2)" "unprognostic (2.01e-1)" "unprognostic (4.55e-2)" "unprognostic (2.01e-1)" "unprognostic (7.04e-2)" "unprognostic (1.39e-1)" "prognostic favourable (7.19e-4)" 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.4 1.0 0.8 0.0 0.1 0.1 0.0 1.8 0.1 0.0 7.2 0.0 0.0 0.0 0.0 29.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 437.8 0.0 0.0 14.8 0.1 0.0 0.0 0.0 0.2 0.0 0.0 26.8 0.6 0.0 0.0 0.0 0.1 0.7 0.7 0.0 0.0 0.0 1.9 0.0 0.0 0.4 0.0 0.0 0.2 0.0 0.0 0.0 0.0 20.0 0.1 0.0 0.0 0.0 0.5 0.0 0.0 0.5 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.6 0.0 0.0 0.2 0.0 1.2 0.0 0.0 0.0 0.0 0.1 0.0 1.2 0.2 16.1 0.2 0.0 0.0 0.0 8.4 0.0 1.2 0.9 4.6 0.0 4.7 0.0 0.3 0.0 0.0 0.0 0.0 9.5 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 1.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 MSN ENSG00000147065 Moesin P26038 X 65588377-65741931 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA000263, CAB010898, HPA011135, HPA011227, CAB047336, CAB047337, CAB047338" Enhanced Enhanced "Plasma membrane" 340000000 "Plasma membrane" "CAB010898: AB_260635, CAB047336: , CAB047337: , CAB047338: , HPA000263: AB_1856043, HPA011135: AB_1854053, HPA011227: AB_1854054" "unprognostic (1.03e-1)" "unprognostic (7.89e-2)" "unprognostic (7.64e-2)" "unprognostic (5.38e-2)" "unprognostic (4.08e-3)" "unprognostic (3.51e-2)" "unprognostic (1.11e-2)" "unprognostic (1.44e-2)" "unprognostic (3.35e-2)" "unprognostic (1.70e-2)" "unprognostic (9.04e-3)" "unprognostic (1.32e-1)" "prognostic unfavourable (1.60e-5)" "unprognostic (5.68e-3)" "unprognostic (7.75e-2)" "unprognostic (7.21e-2)" "unprognostic (6.81e-2)" 36.3 17.6 10.2 40.7 14.4 38.5 98.2 8.6 18.6 25.1 21.3 19.2 7.6 6.5 33.4 14.2 15.7 21.8 20.2 53.8 11.5 10.4 25.6 29.5 102.8 85.0 17.5 5.4 28.8 19.4 5.7 10.2 24.2 30.0 23.1 13.0 16.6 16.3 21.9 13.6 19.5 18.3 41.4 21.8 31.6 17.3 9.0 12.9 18.7 26.2 17.6 38.1 22.7 28.9 16.0 36.4 54.1 69.0 28.0 37.1 81.8 27.8 21.4 21.0 17.3 25.2 33.3 0.1 70.7 45.8 39.2 30.4 0.0 4.9 23.4 63.2 62.5 19.2 22.1 50.4 51.2 43.3 6.1 64.9 37.1 0.0 23.8 78.8 105.1 24.9 10.9 72.1 63.8 86.5 31.4 73.0 62.0 0.0 46.5 59.1 26.0 40.7 24.4 37.7 17.8 41.9 0.0 0.1 0.0 56.8 0.4 22.5 0.2 42.9 137.0 44.7 28.4 60.1 46.8 26.5 40.1 25.4 32.7 100.1 49.7 30.8 44.4 30.0 37.1 58.9 27.9 16.0 20.4 29.1 36.4 13.9 14.0 21.3 54.1 28.0 69.0 5.2 15.5 81.8 10.2 14.4 8.6 18.6 11.5 10.4 17.5 5.4 30.0 12.9 MSR1 "CD204, SCARA1, SR-A, SR-AI, SR-AII, SR-AIII" ENSG00000038945 "Macrophage scavenger receptor 1" P21757 8 16107878-16567490 "Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" Endocytosis Receptor "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in all" 5 "adipose tissue: 88.1;lung: 70.4" "Group enriched" "Detected in many" 7 "BJ hTERT+: 47.1;REH: 17.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "intermediate monocyte: 16.0" "Lineage enriched" "Detected in many" 5 "monocytes: 16.0" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" "HPA000272, CAB032491" Enhanced 25000 "CAB032491: AB_672722, HPA000272: AB_1846269" "unprognostic (8.19e-3)" "unprognostic (4.87e-2)" "unprognostic (1.93e-2)" "unprognostic (2.10e-1)" "unprognostic (9.24e-2)" "unprognostic (1.32e-2)" "unprognostic (5.85e-3)" "unprognostic (2.89e-1)" "unprognostic (9.70e-2)" "unprognostic (1.62e-2)" "unprognostic (7.19e-2)" "unprognostic (8.82e-2)" "unprognostic (2.76e-2)" "unprognostic (9.16e-2)" "unprognostic (7.39e-2)" "unprognostic (6.85e-2)" "unprognostic (4.69e-2)" 88.1 9.0 2.2 6.1 4.5 3.7 6.9 10.4 3.3 4.5 3.1 1.8 1.0 2.1 3.1 6.2 2.4 4.5 11.4 8.0 3.8 3.1 9.5 13.6 70.4 6.9 4.3 0.8 6.7 3.8 1.2 2.6 10.4 7.7 3.2 3.9 4.5 6.2 2.3 3.2 1.6 4.0 6.5 11.9 10.9 2.5 4.9 3.1 1.5 2.2 1.7 0.7 10.8 1.8 1.5 1.0 3.0 16.0 0.3 1.3 0.5 0.6 0.9 1.3 0.6 0.6 0.6 0.6 0.3 47.1 0.1 0.2 1.6 0.1 1.5 2.4 0.4 0.3 0.3 0.4 0.9 0.2 1.9 1.9 1.8 1.8 0.4 1.0 1.1 0.3 0.3 0.3 0.7 0.0 0.7 1.4 0.9 1.8 0.6 0.6 0.2 0.6 17.8 1.0 0.4 0.9 2.7 1.0 0.5 0.4 1.2 0.1 0.1 0.5 1.1 1.2 0.5 4.9 1.2 4.8 3.7 3.2 0.5 0.6 1.0 1.1 3.1 0.5 0.9 16.0 0.4 0.9 0.7 0.7 1.0 1.5 1.3 0.9 3.0 0.3 7.8 0.5 0.6 0.5 2.2 4.5 10.4 2.7 3.8 3.1 4.3 0.8 7.7 3.1 MST1 "D3F15S2, DNF15S2, HGFL, MSP, NF15S2" ENSG00000173531 "Macrophage stimulating 1" 3 49683947-49689501 "Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins" "Cancer-related genes" "Evidence at transcript level" "Evidence at transcript level" "Tissue enriched" "Detected in many" 8 "liver: 117.0" "Cell line enhanced" "Detected in many" "Hep G2: 41.5;NB-4: 8.4;U-266/70: 11.3" "Cancer enriched" "Detected in many" 7 "liver cancer: 42.6" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "gdT-cell: 1.1;memory B-cell: 1.2" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA024036 Approved "Secreted to blood" "HPA024036: AB_1854147" "unprognostic (5.13e-3)" "unprognostic (1.45e-1)" "unprognostic (1.58e-1)" "unprognostic (1.04e-1)" "unprognostic (1.83e-1)" "unprognostic (2.00e-2)" "unprognostic (1.16e-2)" "unprognostic (9.42e-3)" "unprognostic (8.24e-2)" "unprognostic (2.97e-1)" "prognostic favourable (7.14e-4)" "unprognostic (3.07e-2)" "unprognostic (1.57e-2)" "unprognostic (1.11e-1)" "unprognostic (2.48e-1)" "unprognostic (8.03e-2)" "unprognostic (1.68e-3)" 3.7 3.5 4.0 0.3 4.8 1.4 1.0 4.9 5.4 0.9 1.4 2.5 1.9 14.4 1.2 3.3 0.8 1.7 1.9 0.5 6.5 1.1 8.8 117.0 1.6 0.7 2.0 2.9 1.7 1.9 3.8 4.8 1.5 4.8 1.5 0.5 1.6 3.4 3.7 2.8 4.0 8.2 1.3 4.2 1.7 0.8 9.9 2.3 0.9 5.0 0.3 1.1 0.8 0.7 1.2 0.9 0.0 0.2 0.0 1.1 0.2 0.1 0.2 0.6 1.0 1.9 4.0 1.9 0.5 0.7 0.3 0.4 1.9 0.6 0.1 1.3 0.6 0.4 0.3 0.8 0.3 0.6 0.3 0.3 0.9 41.5 3.0 0.0 0.8 5.4 1.3 0.3 1.1 0.7 0.3 5.0 0.9 0.3 0.2 8.4 0.1 0.5 0.2 0.2 1.1 2.2 0.3 0.1 1.4 0.0 0.9 0.2 0.7 2.8 0.4 1.0 0.3 0.0 0.1 11.3 1.4 0.2 1.1 1.5 0.7 0.0 0.0 0.0 1.1 0.0 0.0 1.2 0.0 0.0 0.3 0.4 0.0 0.0 0.0 0.0 0.2 0.9 0.0 0.2 4.0 4.8 4.9 5.4 6.5 1.1 2.0 2.9 4.8 2.3 MT1A "MT1, MT1S" ENSG00000205362 "Metallothionein 1A" P04731 16 56638666-56640087 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adipose tissue: 108.5;liver: 146.5;skeletal muscle: 111.3" "Cell line enhanced" "Detected in some" "ASC TERT1: 13.7;HHSteC: 9.5;HMC-1: 14.1;hTEC/SVTERT24-B: 38.1;NTERA-2: 18.9" "Cancer enhanced" "Detected in all" "liver cancer: 33.3" "Group enriched" "Detected in many" 7 "basal ganglia: 35.4;cerebral cortex: 14.5;hippocampal formation: 15.3;pons and medulla: 37.2" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in single" "CAB002161, CAB013056" Approved "CAB002161: AB_563878, CAB013056: " "unprognostic (1.36e-1)" "unprognostic (4.91e-3)" "unprognostic (1.22e-1)" "unprognostic (3.30e-1)" "unprognostic (1.26e-3)" "unprognostic (9.33e-2)" "unprognostic (1.38e-1)" "unprognostic (1.16e-2)" "unprognostic (1.28e-1)" "unprognostic (1.42e-1)" "unprognostic (1.74e-1)" "unprognostic (3.47e-2)" "unprognostic (6.67e-3)" "unprognostic (3.10e-2)" "unprognostic (1.86e-1)" "unprognostic (9.43e-2)" "unprognostic (1.35e-2)" 108.5 14.2 2.7 8.0 35.4 1.0 35.2 0.6 14.5 11.3 10.2 0.7 0.2 4.8 1.8 4.1 17.4 11.0 16.1 16.2 15.3 1.8 20.7 146.5 16.1 14.2 3.6 0.0 7.1 46.1 1.2 11.0 1.4 37.2 4.4 7.8 3.8 3.0 2.6 111.3 4.4 12.4 9.2 16.9 4.6 6.1 2.0 2.1 0.0 18.6 4.1 1.7 10.7 7.1 0.4 0.6 0.0 0.1 0.3 1.1 0.2 0.0 2.9 0.0 0.0 8.9 13.7 0.1 0.9 3.7 0.6 0.7 1.0 2.2 0.0 1.1 0.5 0.2 0.0 0.1 1.4 0.0 0.0 0.0 1.3 4.5 9.5 0.1 14.1 4.0 0.0 38.1 0.0 3.6 0.3 0.0 2.6 0.0 0.0 0.0 18.9 0.0 0.0 0.0 1.7 0.2 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.1 2.9 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 1.0 0.0 0.1 0.0 0.6 0.0 0.6 0.4 0.8 1.1 0.6 0.0 0.5 0.9 0.0 0.3 0.0 0.3 1.0 0.2 2.7 35.4 0.6 14.5 15.3 1.8 3.6 0.0 37.2 2.1 MTA1 ENSG00000182979 "Metastasis associated 1" Q13330 14 105419820-105470729 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004508, HPA005544" Supported Enhanced Nucleoplasm,Cytosol Nucleoplasm Cytosol "CAB004508: AB_627969, HPA005544: AB_1079420" "unprognostic (6.79e-3)" "unprognostic (4.22e-2)" "unprognostic (1.06e-1)" "unprognostic (6.36e-2)" "unprognostic (2.91e-2)" "unprognostic (7.74e-2)" "prognostic unfavourable (4.62e-4)" "unprognostic (6.59e-2)" "unprognostic (1.47e-1)" "unprognostic (6.72e-3)" "prognostic favourable (9.48e-5)" "unprognostic (4.57e-3)" "unprognostic (1.39e-2)" "unprognostic (2.88e-2)" "unprognostic (1.48e-1)" "unprognostic (1.75e-1)" "unprognostic (1.18e-1)" 23.4 20.1 22.4 24.7 24.3 22.0 22.9 33.8 23.4 17.9 18.9 21.9 22.5 22.3 22.1 21.3 14.9 22.5 20.0 27.7 22.1 17.3 14.8 15.1 20.1 22.3 22.8 18.4 31.4 31.1 15.7 26.5 16.1 19.4 21.9 10.6 22.2 28.7 24.8 29.1 20.0 19.8 27.1 15.0 23.6 18.9 31.4 24.1 27.3 21.1 16.1 16.3 19.3 20.5 1.8 3.7 2.8 0.9 1.8 1.8 0.6 13.1 10.5 19.6 19.5 7.5 12.9 17.4 10.5 8.0 10.4 10.1 13.6 17.8 25.8 11.0 7.6 18.2 14.2 10.0 7.1 16.9 23.9 13.4 9.5 13.9 16.6 16.8 10.4 14.4 12.7 7.4 17.0 14.8 15.2 11.3 5.4 23.6 30.3 33.4 28.3 22.3 28.7 11.9 8.4 8.3 10.3 31.7 33.0 14.1 16.5 15.0 14.8 16.1 10.6 8.5 9.0 13.9 10.9 23.0 11.1 16.4 10.5 11.4 14.7 0.5 0.9 2.8 1.4 0.9 1.2 1.5 1.2 1.1 1.1 1.8 1.5 1.8 0.2 1.8 0.5 3.7 0.9 0.6 22.4 24.3 33.8 23.4 22.1 17.3 22.8 18.4 19.4 24.1 MTCP1 "P13MTCP1, p8MTCP1" ENSG00000214827 "Mature T cell proliferation 1" P56278 X 155061622-155147937 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HeLa: 14.0" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA032040 Approved "Nucleoplasm,Plasma membrane" Nucleoplasm "Plasma membrane" "HPA032040: " "unprognostic (2.42e-2)" "unprognostic (2.07e-2)" "unprognostic (1.14e-1)" "unprognostic (6.29e-3)" "unprognostic (8.30e-2)" "unprognostic (4.10e-1)" "unprognostic (2.40e-5)" "unprognostic (9.30e-2)" "unprognostic (1.17e-1)" "unprognostic (4.94e-2)" "unprognostic (5.72e-2)" "unprognostic (1.15e-2)" "prognostic unfavourable (4.52e-8)" "unprognostic (1.55e-3)" "unprognostic (1.06e-2)" "unprognostic (1.39e-2)" "unprognostic (1.75e-2)" 6.4 7.1 4.1 5.3 5.3 7.2 15.8 4.4 4.8 6.0 6.2 3.4 7.7 5.7 6.0 8.2 7.0 6.1 4.4 30.1 4.7 2.9 6.7 12.8 8.5 15.5 4.5 2.7 9.1 20.7 3.9 6.5 3.5 6.4 5.8 6.1 3.9 7.3 7.0 11.4 12.0 6.7 8.7 7.2 6.7 6.2 16.1 3.8 2.5 8.2 5.4 7.2 6.9 4.0 0.2 0.0 0.8 0.7 0.5 2.0 0.1 1.4 4.9 2.4 3.8 1.6 1.3 2.6 3.0 1.5 1.9 4.7 4.2 7.4 2.6 3.0 0.6 4.7 3.1 3.5 2.3 1.8 3.1 1.2 14.0 2.3 1.3 2.8 3.2 2.4 1.6 3.1 3.0 1.7 1.1 4.8 1.3 2.0 3.7 6.0 1.1 0.8 3.9 2.5 6.0 2.4 2.0 1.2 1.8 2.1 1.2 2.1 2.1 1.3 1.8 2.2 3.8 2.1 2.2 10.5 4.5 5.1 4.2 3.4 3.1 0.0 0.6 0.8 1.1 0.0 2.0 0.2 1.2 0.4 0.0 0.1 0.2 1.4 0.0 0.5 0.7 0.0 0.0 0.1 4.1 5.3 4.4 4.8 4.7 2.9 4.5 2.7 6.4 3.8 MTOR "FLJ44809, FRAP, FRAP1, FRAP2, RAFT1, RAPT1" ENSG00000198793 "Mechanistic target of rapamycin kinase" P42345 1 11106535-11262507 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Biological rhythms" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, Epilepsy, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB069425, HPA071227" Approved Approved Vesicles,Cytosol "Vesicles, Cytosol" "CAB069425: , HPA071227: " "unprognostic (3.18e-1)" "unprognostic (1.50e-1)" "unprognostic (1.20e-1)" "unprognostic (2.45e-3)" "unprognostic (5.50e-2)" "unprognostic (2.55e-2)" "unprognostic (1.39e-1)" "unprognostic (1.68e-1)" "unprognostic (1.18e-1)" "unprognostic (8.24e-3)" "unprognostic (3.48e-2)" "unprognostic (1.88e-1)" "prognostic favourable (1.49e-5)" "unprognostic (1.27e-1)" "unprognostic (2.45e-1)" "unprognostic (6.60e-2)" "unprognostic (7.55e-2)" 11.3 13.9 18.7 13.0 22.5 12.3 14.9 25.2 25.2 11.3 14.5 18.2 10.4 11.2 13.8 23.6 13.1 10.5 15.7 14.2 14.5 13.6 15.8 19.4 10.8 14.3 14.0 14.4 10.7 16.6 26.5 16.0 12.5 15.5 15.2 17.1 14.4 14.2 15.2 24.6 16.5 13.6 15.2 10.4 15.4 13.1 38.6 13.1 16.6 13.2 9.9 15.7 11.7 10.2 3.9 4.0 3.0 6.4 2.6 5.6 2.3 15.2 13.8 18.7 14.1 22.6 10.8 9.3 12.9 12.4 17.2 17.0 14.2 14.1 16.9 11.1 15.2 18.2 25.2 19.7 22.3 13.5 18.4 22.5 28.6 17.9 14.2 21.9 16.8 13.8 15.0 24.6 25.0 21.8 25.1 14.6 12.0 17.4 15.1 16.7 14.1 13.1 15.2 22.0 11.3 15.2 13.8 18.9 13.8 27.6 14.9 16.9 12.1 13.0 23.2 15.1 13.7 11.5 17.2 14.4 13.4 33.3 10.9 23.7 15.8 0.7 2.9 3.0 5.2 6.4 4.3 3.9 3.0 2.7 4.0 3.4 3.6 3.1 2.0 2.6 3.3 3.1 5.6 2.3 18.7 22.5 25.2 25.2 14.5 13.6 14.0 14.4 15.5 13.1 MUC1 "ADMCKD, ADMCKD1, CD227, MCD, MCKD, MCKD1, PEM, PUM" ENSG00000185499 "Mucin 1, cell surface associated" P15941 1 155185824-155192916 "Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" "Cancer-related genes, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "gallbladder: 168.1;kidney: 158.5;lung: 143.5" "Group enriched" "Detected in many" 7 "CAPAN-2: 139.8;RPTEC TERT1: 107.3;T-47d: 47.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in some" "Cell type enhanced" "Detected in some" "T-reg: 4.0" "Group enriched" "Detected in many" 10 "granulocytes: 1.3;T-cells: 4.0" "CAB000036, CAB001986, HPA004179, HPA007235, HPA008855" Enhanced Supported "Plasma membrane" "Secreted in other tissues" 4900000 "Plasma membrane" "CAB000036: AB_2148557, CAB001986: , HPA004179: AB_1846282, HPA007235: AB_1846281, HPA008855: AB_1846283" "unprognostic (4.74e-2)" "unprognostic (2.84e-2)" "unprognostic (2.19e-1)" "unprognostic (8.01e-2)" "unprognostic (1.32e-2)" "unprognostic (1.70e-1)" "unprognostic (2.61e-3)" "unprognostic (6.34e-2)" "unprognostic (1.43e-1)" "unprognostic (3.23e-1)" "prognostic unfavourable (4.60e-4)" "unprognostic (4.75e-1)" "unprognostic (2.05e-2)" "unprognostic (1.13e-1)" "unprognostic (8.12e-2)" "unprognostic (1.42e-1)" "unprognostic (1.21e-1)" 1.5 0.7 0.8 12.6 1.2 0.9 12.6 0.4 0.7 31.6 15.9 1.2 2.4 2.9 10.5 9.8 51.8 18.7 168.1 0.8 0.5 0.3 158.5 2.0 143.5 0.3 0.5 0.3 14.9 74.2 0.0 4.7 15.5 2.1 6.1 16.1 0.8 17.0 5.9 0.8 1.8 3.6 2.8 0.7 0.6 105.0 4.3 0.5 0.7 15.7 10.5 47.8 12.3 5.2 0.0 0.2 1.3 0.1 0.0 4.0 0.2 1.8 0.9 0.6 0.5 0.4 0.5 0.2 0.6 1.5 0.7 1.9 0.0 139.8 0.0 10.2 1.1 2.8 0.1 0.0 0.2 1.2 0.1 0.2 11.8 0.0 0.3 0.0 4.4 1.2 0.2 0.3 0.2 0.2 1.0 1.9 0.5 14.2 0.1 0.1 0.4 0.2 0.2 0.0 3.4 107.3 0.1 0.6 0.2 3.4 5.9 0.1 47.1 0.6 0.2 0.4 0.8 1.3 0.1 2.2 1.1 0.0 0.7 0.1 0.1 1.3 0.1 0.0 0.0 0.0 0.8 0.0 2.3 0.4 0.2 0.0 0.3 0.7 0.0 0.0 0.0 0.0 4.0 0.2 0.8 1.2 0.4 0.7 0.5 0.3 0.5 0.3 2.1 0.5 MUC17 ENSG00000169876 "Mucin 17, cell surface associated" Q685J3 7 101020072-101058745 "Cancer-related genes, Predicted membrane proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 299 "intestine: 125.2" "Cell line enhanced" "Detected in single" "BEWO: 1.3" "Group enriched" "Detected in some" 29 "colorectal cancer: 6.1;pancreatic cancer: 4.9;stomach cancer: 22.8" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA031634 Enhanced "Intracellular and membrane" "HPA031634: AB_10603021" "unprognostic (2.37e-2)" "unprognostic (2.41e-1)" "unprognostic (8.17e-3)" "unprognostic (5.57e-3)" "unprognostic (6.07e-2)" "unprognostic (8.79e-8)" "unprognostic (1.28e-1)" "unprognostic (2.47e-2)" 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 64.7 0.0 0.0 15.8 0.0 0.0 0.1 0.0 0.4 0.1 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.1 2.5 0.0 0.1 0.0 0.1 0.1 125.2 0.1 0.0 0.0 0.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 MUTYH MYH ENSG00000132781 "MutY DNA glycosylase" Q9UIF7 1 45329163-45340470 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "DNA damage, DNA repair" "Glycosidase, Hydrolase" "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA008732 Uncertain Supported Nucleoplasm Nucleoplasm "HPA008732: AB_1854219" "unprognostic (6.30e-3)" "unprognostic (7.12e-2)" "unprognostic (6.29e-2)" "unprognostic (8.80e-2)" "unprognostic (3.43e-1)" "unprognostic (5.16e-3)" "prognostic unfavourable (4.76e-8)" "unprognostic (2.80e-2)" "unprognostic (7.12e-3)" "unprognostic (3.05e-2)" "unprognostic (7.80e-2)" "unprognostic (1.14e-1)" "prognostic unfavourable (7.25e-5)" "unprognostic (3.50e-3)" "unprognostic (1.62e-1)" "unprognostic (5.57e-2)" "unprognostic (5.49e-3)" 7.7 8.4 10.3 12.7 14.8 11.1 8.3 31.6 12.4 10.5 10.1 15.1 11.0 11.1 11.5 9.8 8.3 11.0 10.0 6.1 10.9 7.3 9.7 9.0 7.2 14.0 13.6 10.1 12.9 8.4 7.5 12.5 12.5 11.6 9.1 11.0 12.6 9.5 11.7 8.5 11.1 9.8 7.5 12.6 12.8 11.8 4.9 16.6 14.1 11.9 7.4 12.0 9.3 9.2 7.2 6.5 1.9 8.9 6.6 15.4 6.3 4.9 4.4 10.3 7.0 7.4 5.5 17.9 3.5 4.8 7.5 6.2 9.3 7.1 14.1 6.2 2.4 7.8 5.4 6.4 3.5 11.6 4.1 6.9 7.0 6.6 6.8 5.9 5.0 3.6 6.6 10.1 16.9 5.4 10.7 5.5 3.2 8.1 16.2 5.6 25.9 5.4 22.0 7.9 7.6 3.9 9.5 9.3 7.4 7.6 5.9 11.7 4.7 6.8 3.4 6.6 4.1 5.0 5.5 8.4 9.6 8.6 5.7 9.0 5.0 1.5 5.6 1.9 9.8 8.9 15.4 7.2 10.2 9.9 6.5 7.2 11.3 11.0 0.9 6.6 6.8 5.5 10.3 6.3 10.3 14.8 31.6 12.4 10.9 7.3 13.6 10.1 11.6 16.6 MVP "LRP, VAULT1" ENSG00000013364 "Major vault protein" Q14764 16 29820394-29848039 "Cancer-related genes, Predicted intracellular proteins, Transporters" "mRNA transport, Protein transport, Translocation, Transport" Ribonucleoprotein "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "TIME: 68.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002321, CAB002752, CAB022717, HPA064740" Enhanced Supported Cytosol 38000 Cytosol "CAB002752: , CAB022717: , HPA002321: AB_1079277, HPA064740: " "prognostic favourable (4.51e-4)" "unprognostic (1.06e-1)" "unprognostic (2.77e-1)" "unprognostic (1.80e-1)" "unprognostic (8.17e-2)" "unprognostic (3.03e-2)" "unprognostic (1.11e-2)" "unprognostic (2.22e-2)" "unprognostic (6.03e-3)" "unprognostic (2.19e-1)" "unprognostic (6.85e-3)" "unprognostic (2.86e-1)" "prognostic favourable (5.49e-5)" "unprognostic (2.22e-1)" "unprognostic (5.19e-2)" "unprognostic (5.69e-3)" "unprognostic (2.65e-2)" 32.4 55.4 6.8 37.8 17.9 13.9 20.7 5.4 11.4 20.5 49.5 12.0 11.7 48.7 29.5 29.0 28.6 21.0 46.6 27.8 6.6 6.0 58.9 43.6 57.9 59.4 20.4 4.9 42.7 37.2 8.9 14.6 22.8 13.2 18.3 32.6 14.5 23.3 14.8 16.9 17.6 81.5 24.4 14.6 38.8 34.2 27.4 13.5 17.4 27.1 23.5 23.3 25.4 21.6 10.1 28.7 41.1 53.1 17.6 22.4 33.3 10.4 31.0 0.9 1.0 36.9 48.4 4.5 26.6 43.8 16.2 21.0 4.7 35.5 1.9 21.7 38.9 13.5 1.5 23.3 7.8 25.3 1.6 0.6 13.4 13.9 33.3 1.0 11.4 63.2 18.3 36.0 10.6 47.1 0.7 15.1 28.6 5.2 0.5 2.7 1.0 3.8 2.4 1.6 6.6 39.1 17.9 3.7 2.0 7.6 9.8 5.5 2.3 3.7 68.7 21.1 10.5 20.3 10.6 11.9 8.4 1.1 49.3 1.9 4.4 9.7 33.8 13.4 19.3 53.1 15.1 10.1 21.8 19.8 28.7 7.1 16.8 14.9 41.1 17.6 47.5 17.5 22.4 33.3 6.8 17.9 5.4 11.4 6.6 6.0 20.4 4.9 13.2 13.5 MXI1 "bHLHc11, MAD2, MXD2, MXI" ENSG00000119950 "MAX interactor 1, dimerization protein" P50539 10 110207605-110287365 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Repressor" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "hTCEpi: 29.5;SK-MEL-30: 53.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA035319, HPA035320, HPA056762" Approved Supported Nucleoplasm,Nucleoli,Cytosol Nucleoplasm "Nucleoli, Cytosol" "HPA035319: AB_10670588, HPA035320: , HPA056762: " "unprognostic (1.77e-2)" "unprognostic (2.02e-1)" "unprognostic (3.34e-1)" "unprognostic (3.03e-2)" "unprognostic (1.11e-1)" "unprognostic (1.71e-2)" "unprognostic (1.08e-2)" "unprognostic (1.03e-1)" "unprognostic (1.37e-2)" "unprognostic (1.59e-1)" "unprognostic (9.26e-3)" "prognostic unfavourable (9.17e-4)" "prognostic unfavourable (1.02e-5)" "unprognostic (3.05e-2)" "unprognostic (1.36e-2)" "unprognostic (2.29e-1)" "unprognostic (2.96e-1)" 16.9 19.4 37.2 7.5 34.9 32.7 26.5 56.4 36.9 20.3 26.4 33.9 20.1 12.0 26.0 23.8 39.5 19.1 17.4 36.0 35.1 26.6 23.9 30.5 16.5 7.1 37.0 25.9 46.4 23.1 25.6 12.1 14.4 26.2 24.5 22.1 15.8 41.2 32.7 22.8 25.4 22.5 18.2 44.7 7.8 14.7 13.5 38.1 7.0 29.2 13.4 9.8 32.8 33.9 4.5 2.2 11.0 4.7 1.4 8.6 2.3 5.5 2.2 5.7 11.4 9.0 6.8 2.5 3.2 11.0 2.1 6.8 1.0 10.0 7.3 5.2 5.6 7.2 6.8 7.7 5.7 3.7 9.2 1.9 4.5 4.1 5.9 3.9 4.4 7.2 29.5 3.7 15.0 2.1 7.3 15.9 3.5 3.6 2.6 7.9 2.4 6.8 1.6 7.5 11.6 7.5 0.5 9.7 15.9 3.2 2.4 53.2 2.7 12.7 2.1 3.8 6.5 4.0 1.7 13.2 6.9 2.6 10.1 14.5 4.0 2.2 3.1 11.0 3.1 2.5 5.8 3.9 6.7 3.6 1.7 4.5 8.6 2.2 7.8 1.4 4.7 2.2 5.0 2.3 37.2 34.9 56.4 36.9 35.1 26.6 37.0 25.9 26.2 38.1 MXRA5 DKFZp564I1922 ENSG00000101825 "Matrix remodeling associated 5" Q9NR99 X 3308565-3346641 "Cancer-related genes, Disease related genes, Predicted secreted proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "cervix, uterine: 49.4;pancreas: 46.6" "Cell line enhanced" "Detected in some" "ASC TERT1: 12.5;BJ hTERT+: 47.9;fHDF/TERT166: 22.4;HaCaT: 19.9;HSkMC: 9.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in single" "Not detected" "Not detected" "Not detected" "Not detected" HPA000508 Uncertain "Secreted - unknown location" 1700000 "HPA000508: AB_2147995" "unprognostic (7.51e-2)" "unprognostic (6.45e-2)" "unprognostic (8.00e-2)" "unprognostic (2.51e-2)" "prognostic unfavourable (1.81e-4)" "unprognostic (7.05e-2)" "unprognostic (7.25e-2)" "unprognostic (1.35e-2)" "unprognostic (1.13e-1)" "unprognostic (2.53e-2)" "unprognostic (6.32e-3)" "unprognostic (1.38e-1)" "unprognostic (1.65e-2)" "unprognostic (1.58e-1)" "unprognostic (1.90e-2)" "unprognostic (1.50e-1)" "prognostic unfavourable (8.94e-4)" 6.5 12.1 0.5 10.4 1.2 0.0 7.5 0.4 0.8 49.4 4.4 0.6 18.8 2.1 11.4 6.0 8.7 4.2 5.8 9.2 0.6 0.5 8.0 4.5 5.9 0.9 0.6 0.7 7.9 46.6 0.5 1.4 7.9 0.8 11.0 5.9 10.2 11.5 29.5 1.1 16.6 7.8 8.8 0.5 7.7 5.1 4.0 0.3 5.7 15.0 11.7 6.2 12.7 9.6 0.0 0.0 0.3 0.0 0.0 0.2 0.0 0.0 0.0 0.3 0.0 0.1 12.5 0.0 7.4 47.9 0.0 0.0 0.0 0.2 0.0 0.6 22.4 19.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 9.7 2.3 1.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.8 0.0 0.0 4.3 0.0 0.0 0.0 0.0 0.0 0.7 0.6 0.0 0.0 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.3 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 1.2 0.4 0.8 0.6 0.5 0.6 0.7 0.8 0.3 MYB c-myb ENSG00000118513 "MYB proto-oncogene, transcription factor" P10242 6 135181315-135219173 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "lymphoid tissue: 104.9" "Cell line enhanced" "Detected in many" "HL-60: 38.9;MOLT-4: 70.8;NB-4: 36.9;REH: 43.7;THP-1: 61.8;U-937: 33.7" "Cancer enhanced" "Detected in many" "breast cancer: 17.7" "Region enhanced" "Detected in some" "basal ganglia: 4.7" "Group enriched" "Detected in some" 4 "basophil: 5.6;eosinophil: 10.0" "Lineage enriched" "Detected in many" 6 "granulocytes: 10.0" "Low region specificity" "Detected in some" "Low region specificity" "Detected in some" "CAB017704, HPA071605" Approved Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "CAB017704: , HPA071605: " "unprognostic (1.69e-1)" "unprognostic (5.82e-2)" "unprognostic (1.82e-3)" "unprognostic (1.37e-2)" "unprognostic (4.06e-1)" "unprognostic (8.35e-3)" "unprognostic (1.13e-3)" "unprognostic (2.48e-2)" "unprognostic (6.44e-2)" "unprognostic (1.00e-1)" "unprognostic (3.71e-2)" "prognostic favourable (9.65e-4)" "unprognostic (2.41e-11)" "prognostic favourable (9.87e-4)" "unprognostic (8.35e-2)" "unprognostic (3.04e-2)" "unprognostic (9.40e-2)" 0.5 0.7 1.3 9.1 4.7 18.9 13.2 0.3 0.6 1.4 15.4 0.5 0.3 6.5 0.9 1.0 3.7 5.0 1.7 0.6 0.7 0.7 0.4 0.5 1.8 3.3 0.3 0.5 1.0 0.3 0.4 0.3 0.6 0.5 1.6 16.7 0.5 0.8 1.5 1.0 3.5 5.9 0.7 0.4 1.4 0.9 2.0 0.6 104.9 0.4 2.0 4.7 0.7 1.5 0.1 1.7 10.0 0.8 0.0 0.5 0.1 0.3 0.0 0.3 0.5 0.0 0.0 0.0 0.1 0.0 0.2 0.1 0.0 0.2 1.8 0.0 0.0 0.1 1.0 0.0 0.1 3.1 0.4 24.8 0.1 0.0 0.0 38.9 19.6 0.0 0.0 0.1 0.0 0.0 20.1 3.7 0.2 2.0 70.8 36.9 0.2 0.3 43.7 1.0 6.0 0.0 0.2 1.9 1.2 0.0 1.9 0.0 1.4 61.8 0.0 0.0 0.3 1.4 0.4 4.7 1.2 12.0 0.0 33.7 0.4 5.6 0.8 10.0 0.0 0.1 0.2 0.0 0.0 0.0 0.2 0.1 0.1 0.2 0.0 0.0 0.0 1.7 0.5 0.1 1.3 4.7 0.3 0.6 0.7 0.7 0.3 0.5 0.5 0.6 MYBL2 "B-MYB, BMYB" ENSG00000101057 "MYB proto-oncogene like 2" P10244 20 43667019-43716496 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 35.9;bone marrow: 33.0;lymphoid tissue: 49.2" "Cell line enhanced" "Detected in many" "MCF7: 101.9" "Cancer enriched" "Detected in all" 5 "testis cancer: 295.8" "Not detected" "Not detected" "Cell type enriched" "Detected in some" 30 "plasmacytoid DC: 35.9" "Lineage enriched" "Detected in many" 30 "dendritic cells: 35.9" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB017114, HPA030530, HPA055416" Uncertain Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "CAB017114: , HPA030530: , HPA055416: " "unprognostic (9.75e-3)" "unprognostic (1.29e-2)" "unprognostic (3.20e-1)" "prognostic unfavourable (9.73e-4)" "unprognostic (2.35e-1)" "unprognostic (1.67e-1)" "prognostic unfavourable (2.11e-7)" "unprognostic (2.66e-3)" "unprognostic (9.23e-3)" "unprognostic (1.78e-1)" "unprognostic (2.38e-3)" "unprognostic (1.32e-2)" "prognostic unfavourable (0.00e+0)" "unprognostic (1.42e-1)" "unprognostic (2.27e-1)" "unprognostic (1.19e-1)" "unprognostic (1.84e-1)" 1.7 0.7 0.2 48.3 0.2 33.0 1.0 0.2 0.2 1.0 4.4 0.2 0.1 2.7 1.1 1.1 8.4 0.3 1.7 0.9 0.2 0.2 1.0 1.2 1.8 22.3 0.3 0.1 0.8 9.4 0.0 0.4 4.0 0.2 0.7 2.7 0.3 2.9 0.1 0.3 1.8 6.4 0.6 0.3 43.9 2.9 12.6 0.1 49.2 0.6 6.4 33.8 1.9 2.1 1.1 35.9 0.0 0.0 0.0 0.4 0.3 25.8 16.5 14.6 15.1 0.1 0.5 19.0 11.7 4.0 37.1 27.4 80.9 16.3 52.3 6.8 5.1 15.8 26.4 8.1 13.9 9.8 16.9 24.5 16.5 21.8 0.0 22.3 17.0 0.3 0.7 14.1 3.2 9.9 24.4 65.1 3.2 101.9 45.3 31.4 16.8 14.5 31.6 30.1 30.0 6.8 5.3 13.5 19.6 34.8 35.0 3.5 23.1 24.5 4.6 2.3 37.4 16.4 20.1 22.6 46.5 82.3 4.8 19.1 14.2 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.1 0.0 0.4 0.0 0.0 0.0 0.0 0.0 35.9 0.4 0.3 0.2 0.2 0.2 0.2 0.2 0.2 0.3 0.1 0.2 0.1 MYC "bHLHe39, c-Myc, MYCC" ENSG00000136997 "MYC proto-oncogene, bHLH transcription factor" P01106 8 127735434-127741434 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "RPMI-8226: 129.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB000084, CAB010307, HPA055893, HPA066556" Approved Enhanced Nucleoplasm Nucleoplasm "CAB000084: , CAB010307: AB_631274, HPA055893: , HPA066556: " "unprognostic (1.45e-2)" "unprognostic (4.00e-3)" "unprognostic (3.94e-3)" "unprognostic (2.41e-3)" "unprognostic (8.14e-2)" "unprognostic (3.36e-3)" "unprognostic (5.80e-2)" "unprognostic (4.94e-3)" "unprognostic (1.59e-1)" "prognostic unfavourable (7.52e-4)" "unprognostic (5.19e-3)" "unprognostic (9.86e-3)" "prognostic unfavourable (5.49e-8)" "unprognostic (7.85e-2)" "unprognostic (4.66e-2)" "unprognostic (2.48e-1)" "prognostic unfavourable (4.96e-5)" 67.4 20.8 3.2 46.6 7.1 16.3 36.0 1.2 5.0 23.9 23.3 3.8 11.8 11.1 23.8 14.4 47.6 59.5 32.4 23.7 5.8 2.2 11.2 36.6 16.0 40.5 5.8 1.2 38.7 64.6 2.1 7.4 14.9 9.8 20.6 11.3 6.1 14.4 21.8 69.6 78.5 17.2 21.3 12.0 38.3 24.7 16.3 3.8 40.2 9.0 48.4 27.1 28.9 37.3 25.5 8.8 1.0 10.3 20.9 55.2 22.0 7.1 13.8 1.2 12.3 20.0 23.7 3.6 8.6 3.7 10.7 9.0 18.8 18.7 72.9 12.0 5.1 15.5 63.9 27.8 7.1 17.2 22.3 43.9 23.4 24.5 18.4 30.7 7.0 16.5 61.5 7.2 57.0 12.3 64.8 38.6 5.3 20.5 50.1 66.8 3.4 27.6 27.9 5.2 129.7 9.0 7.4 84.9 8.0 4.0 33.5 22.2 13.6 20.2 14.9 8.1 9.6 6.2 10.7 0.7 1.2 35.2 7.1 34.3 4.0 0.7 10.3 0.1 8.6 9.1 43.4 25.5 31.1 18.6 8.8 20.6 55.2 34.8 1.0 20.9 6.1 0.3 24.8 22.0 3.2 7.1 1.2 3.6 5.8 2.2 5.8 1.2 9.8 3.8 MYCL "bHLHe38, LMYC, MYCL1" ENSG00000116990 "MYCL proto-oncogene, bHLH transcription factor" P12524 1 39895426-39902256 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "pancreas: 46.4;skin 1: 26.0" "Group enriched" "Detected in some" 7 "U-266/70: 94.1;U-266/84: 69.1" "Cancer enhanced" "Detected in all" "urothelial cancer: 28.9" "Low region specificity" "Detected in many" "Group enriched" "Detected in some" 5 "classical monocyte: 11.5;intermediate monocyte: 5.5;myeloid DC: 12.9;plasmacytoid DC: 15.4" "Group enriched" "Detected in many" 75 "dendritic cells: 15.4;monocytes: 11.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "HPA063132, HPA074515" Enhanced Nucleoplasm Nucleoplasm "HPA063132: , HPA074515: " "unprognostic (7.45e-2)" "unprognostic (6.91e-2)" "unprognostic (7.36e-2)" "unprognostic (1.83e-3)" "unprognostic (1.61e-2)" "unprognostic (2.92e-3)" "unprognostic (6.72e-3)" "prognostic favourable (4.49e-4)" "unprognostic (1.24e-1)" "unprognostic (1.77e-2)" "unprognostic (5.44e-2)" "unprognostic (1.12e-1)" "unprognostic (5.01e-3)" "unprognostic (2.75e-2)" "unprognostic (5.21e-2)" "unprognostic (1.53e-2)" "unprognostic (5.80e-2)" 0.3 0.3 1.2 4.4 2.1 0.1 1.7 0.8 1.7 3.6 7.5 1.8 8.5 2.6 1.0 4.0 17.8 1.6 2.3 0.7 1.1 0.9 0.8 6.4 1.9 2.9 0.6 1.4 0.5 46.4 0.0 2.1 11.2 1.8 5.3 3.6 1.8 4.6 16.6 0.6 26.0 7.3 1.2 1.1 4.0 3.3 1.5 0.6 6.4 4.2 3.1 6.0 18.4 7.3 0.0 15.4 0.1 11.5 0.0 0.1 3.8 0.2 0.0 2.9 0.7 0.0 0.0 7.0 0.1 0.0 0.2 0.1 0.1 0.1 0.4 0.3 0.0 0.7 2.0 0.5 0.1 0.4 1.0 0.1 0.0 0.1 0.0 0.0 1.7 0.2 2.3 0.0 0.2 0.2 0.7 0.0 0.1 0.2 0.0 0.0 2.7 0.1 0.2 3.3 0.6 0.2 11.3 0.5 0.7 0.2 0.4 0.1 0.7 3.6 0.0 0.0 1.1 1.3 0.1 94.1 69.1 0.1 0.0 0.4 0.0 0.0 11.5 0.0 0.0 5.5 0.0 0.0 0.0 0.1 12.9 0.0 0.0 0.0 0.1 0.0 2.3 15.4 0.0 3.8 1.2 2.1 0.8 1.7 1.1 0.9 0.6 1.4 1.8 0.6 MYCN "bHLHe37, MYCNOT, N-myc, NMYC" ENSG00000134323 "MYCN proto-oncogene, bHLH transcription factor" P04198 2 15940564-15947007 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "placenta: 16.8" "Cell line enhanced" "Detected in some" "AF22: 12.7;BEWO: 68.9;HMC-1: 16.6;NTERA-2: 26.1;RH-30: 18.2" "Cancer enhanced" "Detected in many" "testis cancer: 45.5" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA057420 Approved Nucleoplasm,Nucleoli Nucleoli Nucleoplasm "HPA057420: " "unprognostic (8.04e-2)" "unprognostic (1.96e-1)" "unprognostic (1.29e-1)" "unprognostic (2.07e-2)" "unprognostic (4.11e-1)" "unprognostic (2.46e-2)" "unprognostic (1.23e-2)" "unprognostic (3.03e-2)" "unprognostic (1.81e-1)" "unprognostic (3.35e-3)" "unprognostic (3.09e-2)" "unprognostic (2.09e-1)" "unprognostic (1.12e-3)" "unprognostic (8.89e-2)" "unprognostic (2.47e-1)" "unprognostic (4.90e-2)" "unprognostic (1.23e-1)" 0.9 1.9 5.1 1.8 5.5 1.6 1.2 1.4 8.4 3.1 1.2 12.1 0.0 3.0 1.9 0.8 1.3 1.4 2.6 2.3 7.0 4.7 6.0 1.5 1.6 2.9 6.0 2.2 10.3 0.7 0.4 0.7 16.8 6.8 0.6 1.3 1.1 6.6 0.7 1.0 2.4 1.7 0.9 8.9 0.9 8.5 6.5 4.0 5.7 5.1 2.3 3.5 2.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 12.7 0.0 0.0 0.0 68.9 0.0 0.0 0.0 0.0 1.0 0.0 0.0 1.2 0.0 0.0 0.5 0.0 0.0 0.0 0.0 4.6 0.0 0.0 0.0 0.0 16.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 26.1 0.0 0.0 18.2 3.5 0.0 0.8 0.2 4.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.1 5.5 1.4 7.0 7.0 4.7 6.0 2.2 6.8 4.0 MYD88 ENSG00000172936 "Myeloid differentiation primary response 88" Q99836 3 38138478-38143022 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Immunity, Inflammatory response, Innate immunity" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 68.0" "Cell line enhanced" "Detected in many" "SK-BR-3: 54.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB009104 Approved Supported Vesicles,Mitochondria,Cytosol Cytosol "Vesicles, Mitochondria" "CAB009104: AB_2146724" "prognostic favourable (8.45e-4)" "unprognostic (1.19e-1)" "unprognostic (4.31e-2)" "unprognostic (2.51e-2)" "unprognostic (4.77e-2)" "unprognostic (4.38e-3)" "unprognostic (4.37e-2)" "unprognostic (3.63e-1)" "unprognostic (1.67e-1)" "unprognostic (7.28e-2)" "unprognostic (1.01e-2)" "unprognostic (7.30e-2)" "unprognostic (2.11e-2)" "unprognostic (4.41e-1)" "unprognostic (4.17e-2)" "unprognostic (1.65e-1)" "unprognostic (2.08e-2)" 25.0 11.3 5.9 19.5 6.9 18.1 14.7 5.2 4.6 10.0 13.4 5.8 5.0 15.1 9.5 12.3 25.5 9.8 12.4 10.4 5.3 3.2 15.1 47.9 25.6 40.1 6.2 3.5 13.3 10.3 5.4 10.4 17.8 6.7 11.3 14.3 8.8 13.9 5.4 3.9 12.5 30.4 10.7 7.0 39.0 12.5 5.8 5.1 28.5 10.4 17.5 30.8 13.9 13.7 7.8 34.7 49.0 68.0 8.3 14.3 34.6 8.1 12.0 1.8 10.7 8.5 11.1 3.7 8.0 13.1 22.6 24.0 7.5 9.9 17.4 4.8 14.3 10.2 14.2 8.0 7.6 13.5 2.9 9.4 6.1 11.4 7.0 11.9 24.6 12.7 8.5 12.8 4.8 12.8 4.1 7.1 11.8 8.2 19.6 3.8 7.6 12.0 8.5 2.3 7.5 11.6 19.0 0.8 3.9 11.3 54.5 7.1 8.5 13.5 11.9 4.4 2.7 20.4 7.6 10.5 11.7 12.9 8.6 20.9 9.6 38.3 37.6 48.1 12.2 56.5 10.4 7.8 11.0 12.2 34.7 6.7 7.7 10.9 49.0 8.3 68.0 16.6 14.3 34.6 5.9 6.9 5.2 4.6 5.3 3.2 6.2 3.5 6.7 5.1 MYH11 "SMHC, SMMHC" ENSG00000133392 "Myosin heavy chain 11" P35749 16 15703172-15857033 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Actin-binding, Calmodulin-binding, Motor protein, Muscle protein, Myosin" "Aortic aneurysm, Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "smooth muscle: 507.4;urinary bladder: 394.5" "Cell line enhanced" "Detected in some" "BEWO: 3.5;NB-4: 3.8;U-698: 9.7" "Cancer enhanced" "Detected in many" "prostate cancer: 173.2" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Region enhanced" "Detected in many" "midbrain: 54.5" "CAB002302, HPA014539, HPA015310" Enhanced Supported "Plasma membrane,Cytosol" 130000000 "Plasma membrane, Cytosol" "CAB002302: AB_563902, HPA014539: AB_1854260, HPA015310: AB_1854261" "unprognostic (7.99e-2)" "unprognostic (3.07e-2)" "unprognostic (4.18e-2)" "unprognostic (9.21e-3)" "unprognostic (6.70e-2)" "unprognostic (2.75e-2)" "prognostic favourable (1.10e-5)" "unprognostic (1.41e-2)" "unprognostic (1.87e-1)" "unprognostic (3.44e-2)" "unprognostic (1.28e-1)" "unprognostic (1.14e-1)" "unprognostic (1.19e-3)" "unprognostic (4.06e-2)" "unprognostic (9.53e-2)" "unprognostic (5.00e-2)" "unprognostic (5.45e-3)" 13.2 3.0 0.6 31.5 1.2 0.0 5.9 0.5 1.7 90.3 227.5 1.3 100.0 11.6 102.0 38.4 233.0 43.8 94.3 6.2 0.6 0.7 4.7 0.7 8.5 1.5 1.4 2.6 45.5 1.3 0.0 1.0 5.3 3.6 164.7 22.2 37.0 8.8 127.2 6.4 5.0 50.6 507.4 1.4 3.7 77.7 22.3 0.2 0.1 3.7 6.2 3.0 394.5 57.5 1.5 0.9 6.0 0.9 1.1 1.5 0.4 0.1 0.4 0.2 0.1 0.0 0.0 3.5 0.1 0.0 0.0 0.0 0.0 0.3 0.1 0.2 0.0 0.6 0.0 0.0 0.0 0.4 0.4 0.2 0.1 0.0 0.0 0.1 1.0 0.0 0.0 0.0 0.0 0.0 0.1 1.5 0.0 0.3 0.3 3.8 0.4 0.1 0.4 0.1 1.9 0.0 0.2 0.7 1.4 0.2 0.5 1.2 0.4 0.0 0.3 0.1 0.3 2.0 0.1 0.4 0.4 9.7 0.4 0.4 0.4 3.1 0.9 2.7 1.2 0.6 1.2 1.5 1.5 1.4 0.5 1.2 1.4 1.4 6.0 1.1 0.6 0.9 1.4 0.4 0.6 1.2 0.5 1.7 0.6 0.7 1.4 2.6 3.6 0.2 MYH9 "DFNA17, EPSTS, FTNS, MHA, NMHC-II-A, NMMHCA" ENSG00000100345 "Myosin heavy chain 9" P35579 22 36281277-36388067 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell adhesion, Cell shape" "Actin-binding, Calmodulin-binding, Motor protein, Myosin" "Alport syndrome, Cancer-related genes, Cataract, Deafness, Disease mutation, Non-syndromic deafness" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001644, CAB015386, HPA064783" Enhanced Supported "Plasma membrane,Actin filaments,Cytosol" 3100000000 "Plasma membrane, Actin filaments" Cytosol "CAB015386: AB_784698, HPA001644: AB_1079439, HPA064783: AB_2732721" "unprognostic (1.38e-1)" "unprognostic (9.12e-2)" "unprognostic (4.21e-2)" "unprognostic (6.34e-2)" "unprognostic (1.49e-1)" "unprognostic (3.90e-2)" "unprognostic (9.56e-2)" "unprognostic (8.28e-2)" "unprognostic (5.50e-2)" "unprognostic (6.38e-2)" "unprognostic (1.93e-2)" "unprognostic (1.61e-1)" "unprognostic (7.98e-2)" "unprognostic (9.48e-2)" "unprognostic (1.64e-1)" "unprognostic (1.62e-1)" "unprognostic (2.59e-2)" 115.5 26.1 11.9 43.7 12.9 55.6 59.0 9.3 16.8 67.1 44.6 18.0 26.4 26.9 120.8 39.7 48.3 45.6 66.9 39.2 11.0 8.1 45.0 42.8 74.4 57.7 15.1 9.2 56.4 43.9 19.0 15.4 65.7 17.9 47.6 23.6 32.4 66.2 27.2 36.9 40.3 49.8 46.7 13.5 91.5 37.1 25.8 11.9 76.0 42.5 38.4 65.0 56.0 53.7 6.9 8.2 28.5 11.5 4.2 16.6 19.3 60.6 28.2 9.0 7.6 16.8 21.1 45.7 40.7 52.7 58.2 43.7 30.4 17.5 15.7 24.2 68.1 42.1 13.1 79.7 60.0 35.4 12.4 30.3 30.3 25.9 51.5 34.4 48.6 24.9 24.6 78.6 66.8 47.9 6.6 21.3 46.5 16.1 12.2 20.3 5.3 17.4 23.3 27.9 14.6 32.9 59.1 13.5 5.5 57.2 22.5 26.2 16.8 17.8 137.0 129.1 39.2 24.7 73.5 14.1 11.1 13.3 48.9 17.4 37.4 26.8 10.4 28.5 16.6 9.6 14.7 6.9 12.0 13.2 8.2 6.4 9.6 10.1 19.7 4.2 11.5 3.8 12.6 19.3 11.9 12.9 9.3 16.8 11.0 8.1 15.1 9.2 17.9 11.9 MYO5A "GS1, MYH12, MYO5, MYR12" ENSG00000197535 "Myosin VA" Q9Y4I1 15 52307283-52529050 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Protein transport, Transport" "Actin-binding, Calmodulin-binding, Motor protein, Myosin" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 34.5;parathyroid gland: 47.6" "Cell line enhanced" "Detected in many" "Karpas-707: 58.9;RPMI-8226: 39.9" "Cancer enhanced" "Detected in all" "melanoma: 25.2" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA001356 Enhanced Approved "Focal adhesion sites,Centriolar satellite" "Focal adhesion sites, Centriolar satellite" "HPA001356: AB_1079441" "unprognostic (1.54e-1)" "unprognostic (1.78e-1)" "unprognostic (6.95e-2)" "unprognostic (2.29e-2)" "unprognostic (1.97e-2)" "unprognostic (3.91e-2)" "unprognostic (2.30e-2)" "unprognostic (6.65e-2)" "unprognostic (7.89e-2)" "unprognostic (4.74e-2)" "unprognostic (9.36e-3)" "unprognostic (1.71e-1)" "unprognostic (5.63e-3)" "unprognostic (3.79e-3)" "unprognostic (1.24e-1)" "unprognostic (7.16e-2)" "prognostic unfavourable (4.22e-4)" 8.4 7.1 16.6 9.5 27.5 15.7 5.5 27.4 34.5 6.2 4.4 7.8 0.4 3.3 4.2 3.2 5.0 3.6 7.3 4.6 15.9 15.4 4.6 2.7 7.3 11.2 15.6 17.6 5.4 4.3 47.6 10.5 5.2 29.3 4.5 5.2 9.9 4.0 3.4 4.1 10.4 3.9 7.7 10.1 7.3 4.1 4.6 7.1 3.1 6.8 2.7 10.3 7.3 4.2 2.3 5.2 6.3 4.4 0.7 4.5 1.9 5.4 9.6 5.1 6.1 5.2 6.4 5.5 9.9 9.0 5.3 4.2 0.9 2.2 5.2 2.6 11.8 4.5 11.7 10.2 6.6 29.4 2.7 4.8 2.5 1.1 2.7 2.5 4.7 4.2 6.4 7.8 15.5 30.8 0.1 58.9 10.2 9.6 2.2 0.3 2.3 7.7 4.1 8.2 39.9 4.4 3.9 3.8 2.2 9.2 7.6 18.0 4.0 2.8 14.7 10.7 4.6 5.0 9.6 6.1 13.5 6.3 11.7 7.3 15.4 0.9 4.4 5.4 2.9 3.6 4.5 2.3 2.9 1.9 5.2 1.6 0.5 1.0 6.3 0.7 2.6 3.1 4.1 1.9 16.6 27.5 27.4 34.5 15.9 15.4 15.6 17.6 29.3 7.1 MYOCD MYCD ENSG00000141052 Myocardin Q8IZQ8 17 12665890-12768949 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Transcription, Transcription regulation" Activator "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "smooth muscle: 63.4" "Cell line enhanced" "Detected in some" "BJ: 6.8;BJ hTERT+: 6.8;HBF TERT88: 11.3;hTEC/SVTERT24-B: 12.5;REH: 8.6" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in single" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in single" "Region enhanced" "Detected in some" "cerebellum: 6.4" "CAB046485, HPA071528, HPA072582" Approved Approved Nucleoplasm Nucleoplasm "CAB046485: AB_10600720, HPA071528: , HPA072582: " "unprognostic (2.82e-1)" "unprognostic (1.69e-1)" "unprognostic (2.36e-2)" "unprognostic (1.90e-1)" "unprognostic (3.79e-2)" "unprognostic (5.33e-2)" "unprognostic (2.15e-4)" "unprognostic (2.71e-2)" "unprognostic (1.61e-2)" "unprognostic (2.31e-1)" "unprognostic (1.76e-1)" "unprognostic (4.83e-2)" "unprognostic (1.01e-4)" "unprognostic (2.88e-2)" "unprognostic (1.07e-1)" "unprognostic (5.45e-2)" "unprognostic (1.91e-2)" 3.1 0.8 0.6 5.1 1.0 0.0 1.9 0.3 0.5 19.6 19.9 0.2 17.6 2.1 16.6 10.9 14.4 7.4 12.2 18.6 0.4 0.4 0.9 0.4 2.5 0.0 0.5 0.8 10.6 0.4 0.0 0.5 2.6 0.6 17.2 4.2 5.1 0.4 18.7 1.2 1.5 6.6 63.4 0.6 0.5 6.7 3.7 0.1 0.0 1.0 1.2 0.0 33.4 9.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 6.8 6.8 2.6 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 11.3 0.0 0.0 0.0 3.0 0.0 0.0 0.0 0.0 0.3 0.0 12.5 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 8.6 1.7 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 1.0 0.3 0.5 0.4 0.4 0.5 0.8 0.6 0.1 MYOD1 "bHLHc1, MYF3, MYOD, PUM" ENSG00000129152 "Myogenic differentiation 1" P15172 11 17719568-17722131 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Differentiation, Myogenesis, Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 7 "skeletal muscle: 31.8" "Cell line enriched" "Detected in some" 15 "RH-30: 101.2" "Cancer enhanced" "Detected in single" "ovarian cancer: 0.7" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in single" 6 "hippocampal formation: 0.5" "HPA055436, HPA078647" Enhanced Nucleoplasm Nucleoplasm "HPA055436: , HPA078647: " "unprognostic (1.07e-3)" "unprognostic (2.10e-1)" "unprognostic (1.01e-1)" 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.0 0.0 0.0 0.7 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.6 0.0 0.0 0.5 0.0 31.8 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.2 4.6 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 6.7 0.0 0.0 0.0 0.0 0.0 0.0 101.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.7 0.0 0.0 0.0 0.0 0.0 MYOG "bHLHc3, MYF4" ENSG00000122180 Myogenin P15173 1 203083132-203086036 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Cell cycle, Differentiation, Myogenesis, Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "skeletal muscle: 60.0" "Group enriched" "Detected in some" 200 "HSkMC: 17.6;RH-30: 33.6" "Group enriched" "Detected in some" 6 "head and neck cancer: 3.9;testis cancer: 1.7" "Not detected" "Not detected" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "Low region specificity" "Detected in many" HPA028336 Supported Nucleoplasm Nucleoplasm "HPA028336: " "unprognostic (1.71e-1)" "unprognostic (1.64e-1)" "unprognostic (1.05e-3)" "unprognostic (2.22e-1)" "unprognostic (2.79e-9)" "unprognostic (3.96e-1)" "unprognostic (2.56e-1)" 1.9 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.8 1.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 1.3 0.0 0.0 2.4 0.0 60.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.1 1.7 13.3 1.7 0.0 0.0 0.8 0.8 2.3 1.3 1.8 1.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 17.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 33.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 2.3 0.4 0.8 0.4 0.7 1.0 0.8 0.5 0.6 0.3 0.6 0.9 1.0 1.4 1.8 1.3 0.8 0.8 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 NAB2 MADER ENSG00000166886 "NGFI-A binding protein 2" Q15742 12 57088894-57095476 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Transcription, Transcription regulation" Repressor "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004510, HPA027464" Approved Approved Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "CAB004510: AB_627982, HPA027464: AB_10601138" "prognostic favourable (7.41e-4)" "unprognostic (4.04e-2)" "unprognostic (2.20e-3)" "unprognostic (2.43e-2)" "unprognostic (4.74e-2)" "unprognostic (2.10e-1)" "unprognostic (1.88e-3)" "unprognostic (1.80e-1)" "unprognostic (5.85e-2)" "unprognostic (1.19e-1)" "unprognostic (2.13e-1)" "unprognostic (6.98e-2)" "prognostic unfavourable (9.38e-6)" "unprognostic (1.95e-1)" "unprognostic (9.76e-2)" "unprognostic (5.67e-3)" "unprognostic (6.19e-3)" 9.5 12.6 11.7 9.9 14.2 4.8 7.9 33.3 20.4 18.7 13.7 5.3 9.6 8.2 22.8 18.9 10.5 15.6 14.5 9.6 8.6 6.8 8.4 18.7 12.8 9.1 4.4 14.6 29.2 8.5 14.5 17.0 13.4 6.8 15.0 4.4 8.5 5.6 14.5 7.1 18.6 7.1 14.5 4.1 8.0 8.2 11.8 7.0 12.4 9.8 7.7 8.6 14.5 26.5 4.2 1.2 0.9 5.4 0.9 2.5 1.2 5.5 3.5 18.7 17.1 16.8 22.0 2.0 16.6 15.0 10.5 8.8 5.7 3.2 3.5 6.8 16.3 10.0 6.4 12.2 5.6 1.4 1.7 4.1 2.7 5.8 12.8 3.3 10.0 24.5 13.5 12.5 4.3 2.8 9.4 3.6 12.2 25.7 5.0 16.1 3.8 6.2 3.7 24.6 1.8 4.5 2.1 2.1 4.9 8.0 4.7 34.9 10.5 7.3 3.1 15.5 13.0 11.0 4.8 8.6 2.1 1.8 15.1 2.2 9.3 0.0 2.3 0.3 1.2 5.3 1.4 2.1 2.0 1.5 1.2 4.2 2.5 2.5 0.9 0.9 5.4 0.0 1.9 1.2 11.7 14.2 33.3 20.4 8.6 6.8 4.4 14.6 6.8 7.0 NAGA D22S674 ENSG00000198951 Alpha-N-acetylgalactosaminidase P17050 22 42058354-42070842 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Glycosidase, Hydrolase" "Cancer-related genes, Disease mutation, Epilepsy" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HMC-1: 65.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in all" 8 "classical monocyte: 38.5;intermediate monocyte: 47.6;myeloid DC: 37.9;non-classical monocyte: 46.1;plasmacytoid DC: 23.2" "Group enriched" "Detected in all" 9 "dendritic cells: 37.9;monocytes: 47.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA000649 Enhanced "Intracellular and membrane" 2300000 "HPA000649: AB_1079448" "unprognostic (3.74e-2)" "unprognostic (1.19e-2)" "unprognostic (1.24e-1)" "unprognostic (1.45e-3)" "unprognostic (1.55e-1)" "unprognostic (1.28e-1)" "unprognostic (3.02e-2)" "unprognostic (4.27e-1)" "unprognostic (1.32e-2)" "unprognostic (1.50e-1)" "unprognostic (2.53e-2)" "unprognostic (1.93e-1)" "unprognostic (3.64e-2)" "unprognostic (3.68e-2)" "unprognostic (1.92e-3)" "unprognostic (8.95e-2)" "unprognostic (2.53e-1)" 23.7 13.5 12.1 20.3 14.5 11.3 12.5 11.8 10.3 16.3 18.3 15.0 10.7 13.2 18.9 16.1 14.5 17.3 16.5 15.8 10.1 8.6 17.9 28.2 19.9 32.6 12.6 7.3 18.1 9.5 27.8 13.1 45.3 11.5 15.2 18.0 19.8 16.6 14.5 9.2 9.9 25.6 18.7 11.4 22.0 14.1 9.3 13.2 12.0 15.0 11.4 17.9 17.3 14.5 2.1 37.9 4.9 47.6 3.4 3.4 19.2 9.0 4.6 7.4 13.1 12.9 14.8 5.4 7.5 15.4 12.9 13.5 10.3 13.4 4.4 4.6 16.2 6.4 5.6 9.1 7.7 10.1 7.1 10.9 7.1 6.9 7.5 9.0 65.2 10.1 8.0 11.6 4.9 21.3 4.0 18.9 10.2 10.5 3.3 3.7 1.9 6.2 7.5 3.7 7.8 10.0 10.8 2.3 2.6 9.9 9.1 9.8 13.6 16.7 11.4 9.1 11.1 5.8 6.7 10.5 10.5 3.5 9.7 17.3 11.2 4.9 38.5 4.6 2.8 47.6 2.8 2.1 2.9 2.6 37.9 1.5 1.9 1.8 1.9 3.4 46.1 23.2 3.4 19.2 12.1 14.5 11.8 10.3 10.1 8.6 12.6 7.3 11.5 13.2 NAIP "BIRC1, NLRB1" ENSG00000249437 "NLR family apoptosis inhibitory protein" Q13075 5 70968483-71025114 "Cancer-related genes, Predicted intracellular proteins" "Apoptosis, Immunity, Inflammatory response, Innate immunity" "Protease inhibitor, Thiol protease inhibitor" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 8.1;lymphoid tissue: 17.5" "Cell line enhanced" "Detected in some" "MOLT-4: 7.8;SiHa: 4.5;T-47d: 4.9" "Not detected" "Not detected" "Region enhanced" "Detected in some" "pons and medulla: 6.4" "Group enriched" "Detected in some" 10 "classical monocyte: 8.1;intermediate monocyte: 2.9;myeloid DC: 6.9;neutrophil: 5.9" "Group enriched" "Detected in many" 14 "dendritic cells: 6.9;granulocytes: 5.9;monocytes: 8.1" HPA042438 Approved "HPA042438: AB_10796578" "unprognostic (9.03e-2)" "unprognostic (6.03e-2)" "unprognostic (1.31e-1)" "unprognostic (7.50e-2)" "unprognostic (3.33e-1)" "unprognostic (1.12e-3)" "unprognostic (1.12e-1)" "unprognostic (2.23e-2)" "unprognostic (4.36e-2)" "unprognostic (1.86e-1)" "unprognostic (2.54e-2)" "unprognostic (5.13e-1)" "unprognostic (1.69e-3)" "unprognostic (1.17e-1)" "unprognostic (1.18e-2)" "unprognostic (1.38e-1)" "unprognostic (9.96e-2)" 2.4 1.0 0.8 4.7 0.8 2.4 0.8 0.8 2.6 0.8 0.8 0.8 0.8 0.1 0.9 1.2 0.8 1.6 1.6 0.8 0.8 0.6 0.8 0.8 3.9 3.4 1.2 0.8 0.8 0.8 0.2 0.8 0.8 6.4 0.8 0.7 0.8 0.8 0.8 1.0 0.4 2.3 1.1 2.3 17.5 3.0 0.8 0.8 0.8 0.9 0.8 0.8 3.6 0.8 0.3 6.9 5.9 8.1 0.4 0.2 2.0 0.0 0.0 1.1 0.4 0.4 0.0 0.3 0.0 0.0 0.3 0.0 0.8 0.8 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.7 0.8 0.7 1.6 0.2 1.5 0.5 0.0 0.0 0.0 0.2 0.0 0.3 0.6 0.2 0.0 7.8 0.0 0.1 0.0 0.1 0.0 1.7 0.3 0.1 0.3 0.0 4.5 0.0 0.3 4.9 0.0 0.0 1.2 0.3 0.2 0.0 0.9 0.0 0.6 0.1 0.1 0.8 0.2 8.1 0.0 0.2 2.9 0.1 0.1 0.0 0.1 6.9 0.3 0.2 0.1 5.9 0.4 0.5 0.3 0.1 2.0 0.8 0.8 0.8 2.6 0.8 0.6 1.2 0.8 6.4 0.8 NAMPT "PBEF, PBEF1" ENSG00000105835 "Nicotinamide phosphoribosyltransferase" P43490 7 106248285-106286326 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Biological rhythms, Pyridine nucleotide biosynthesis" "Cytokine, Glycosyltransferase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "U-87 MG: 108.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in many" 18 "neutrophil: 143.5" "Lineage enriched" "Detected in many" 20 "granulocytes: 143.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB034349, HPA047776, HPA057722" Approved Approved "Nuclear speckles,Cell Junctions" "Secreted to blood" 2140000 410000 "Nuclear speckles" "Cell Junctions" "CAB034349: AB_2251220, HPA047776: , HPA057722: " "unprognostic (2.87e-1)" "prognostic unfavourable (4.78e-4)" "unprognostic (5.90e-3)" "unprognostic (1.63e-2)" "unprognostic (1.50e-2)" "prognostic unfavourable (8.81e-4)" "unprognostic (2.15e-1)" "unprognostic (2.74e-2)" "unprognostic (2.74e-1)" "unprognostic (3.30e-1)" "prognostic unfavourable (1.51e-4)" "unprognostic (3.02e-1)" "prognostic unfavourable (2.49e-6)" "unprognostic (6.83e-2)" "unprognostic (6.96e-2)" "unprognostic (7.76e-2)" "unprognostic (6.44e-3)" 67.3 22.2 8.1 113.6 18.1 110.4 52.6 7.8 12.9 11.6 18.2 2.9 9.5 9.3 9.9 13.5 53.4 27.8 28.1 84.4 13.4 6.3 13.5 92.9 48.9 117.5 10.3 5.2 27.3 18.3 5.5 10.0 23.9 29.2 17.4 10.5 8.2 32.9 14.3 41.0 12.9 14.1 44.9 59.1 41.1 26.4 11.9 7.1 6.2 13.5 40.7 13.2 48.8 26.4 0.8 2.0 143.5 7.3 1.0 1.5 1.3 18.9 12.6 4.6 7.6 19.4 22.6 7.5 6.0 34.0 12.2 21.6 7.4 11.5 15.9 14.4 6.7 15.0 8.4 18.1 26.8 9.4 9.1 6.4 5.4 5.8 72.5 12.4 11.9 21.6 20.7 21.8 25.5 38.8 13.4 60.9 14.5 9.9 12.3 5.2 8.8 10.2 5.9 6.5 34.9 11.6 17.8 9.3 5.1 8.4 18.5 21.4 5.9 3.6 33.0 18.2 14.1 26.1 11.0 42.0 23.8 22.8 108.1 14.1 26.9 8.1 2.3 3.5 0.4 5.6 0.7 0.8 0.5 0.6 2.0 0.7 0.8 0.4 143.5 1.0 7.3 0.8 1.5 1.3 8.1 18.1 7.8 12.9 13.4 6.3 10.3 5.2 29.2 7.1 NAT2 AAC2 ENSG00000156006 "N-acetyltransferase 2" P11245 8 18391245-18401218 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Acyltransferase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 22 "intestine: 28.4;liver: 75.5" "Cell line enhanced" "Detected in some" "RPTEC TERT1: 2.8;RT4: 4.1;SCLC-21H: 5.7;SK-BR-3: 3.6" "Cancer enhanced" "Detected in some" "colorectal cancer: 4.0;liver cancer: 4.9" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA043704 Uncertain "HPA043704: " "unprognostic (2.74e-3)" "unprognostic (4.03e-1)" "prognostic favourable (4.61e-5)" "unprognostic (1.43e-2)" "unprognostic (1.07e-1)" "unprognostic (1.83e-1)" "unprognostic (2.52e-2)" "unprognostic (2.67e-2)" "unprognostic (1.27e-1)" "unprognostic (1.33e-2)" "unprognostic (4.07e-1)" "unprognostic (6.05e-3)" "unprognostic (1.02e-1)" "unprognostic (3.40e-1)" "unprognostic (1.83e-1)" "unprognostic (1.64e-1)" 0.2 0.1 0.2 2.3 0.3 0.0 0.3 0.1 0.2 0.3 14.0 0.1 0.1 13.0 0.4 0.4 0.1 0.2 0.3 0.4 0.1 0.1 0.6 75.5 0.2 0.1 0.2 0.2 0.2 0.1 0.0 0.2 0.2 0.3 0.3 5.1 0.1 0.1 0.1 0.1 0.1 28.4 0.4 0.2 0.6 0.1 0.3 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.5 0.1 0.0 0.2 0.0 0.0 0.3 0.0 1.7 0.0 0.1 0.0 1.4 0.0 0.0 0.2 0.3 0.1 0.5 0.1 0.5 0.1 0.0 0.0 0.0 0.6 0.0 0.3 0.0 0.1 0.0 0.1 0.1 0.0 0.6 0.0 0.0 0.0 1.0 0.0 0.0 1.0 0.0 0.0 0.1 1.0 0.0 0.0 0.9 0.0 2.8 4.1 5.7 0.1 0.1 3.6 0.0 1.0 0.5 1.5 1.0 0.5 0.3 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.2 0.3 0.1 0.2 0.1 0.1 0.2 0.2 0.3 0.1 NAV3 "KIAA0938, POMFIL1" ENSG00000067798 "Neuron navigator 3" Q8IVL0 12 77324641-78213008 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 25.2;ovary: 29.6" "Cell line enhanced" "Detected in many" "hTEC/SVTERT24-B: 23.4;THP-1: 20.5;U-138 MG: 15.7;WM-115: 19.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 9 "basophil: 1.9;neutrophil: 3.8" "Lineage enriched" "Detected in single" 12 "granulocytes: 3.8" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA032111, HPA061392" Approved Approved "Nuclear membrane,Cytosol" "Nuclear membrane" Cytosol "HPA032111: AB_10603881, HPA061392: " "unprognostic (3.51e-1)" "unprognostic (6.72e-2)" "unprognostic (1.09e-2)" "unprognostic (1.79e-1)" "unprognostic (8.98e-2)" "unprognostic (2.14e-1)" "unprognostic (2.78e-1)" "unprognostic (3.25e-2)" "unprognostic (3.03e-2)" "unprognostic (2.06e-2)" "unprognostic (2.99e-1)" "unprognostic (1.90e-1)" "unprognostic (5.68e-7)" "unprognostic (6.86e-3)" "unprognostic (1.23e-1)" "unprognostic (1.58e-2)" "unprognostic (2.29e-3)" 6.2 8.5 17.8 2.4 14.2 1.5 7.1 14.7 25.2 2.8 2.1 9.7 2.6 1.2 4.1 5.8 3.8 3.6 8.6 3.7 14.2 7.5 1.4 2.3 3.8 1.6 7.8 13.0 29.6 1.4 2.2 9.3 4.3 7.1 4.5 2.0 12.3 2.2 5.1 2.6 4.1 1.3 4.6 10.6 12.7 1.6 5.0 8.3 0.0 1.7 0.0 1.4 3.9 2.3 0.3 0.1 3.8 0.2 0.1 0.0 0.0 1.8 4.3 0.3 0.1 4.5 9.3 0.1 13.1 10.3 5.4 2.8 1.2 0.3 0.1 1.0 10.5 1.4 3.8 2.0 9.6 0.0 0.0 0.0 1.8 0.1 3.5 0.0 0.1 3.4 0.0 23.4 5.9 8.0 0.0 0.0 13.2 0.1 0.0 5.9 1.5 1.2 0.6 1.1 0.0 0.9 0.0 0.3 0.0 0.9 0.1 1.8 0.0 20.5 6.9 15.7 4.4 6.7 9.0 0.7 0.0 0.4 4.7 0.2 19.4 1.9 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.0 3.8 0.1 0.2 0.1 0.0 0.0 17.8 14.2 14.7 20.5 14.2 7.5 7.8 13.0 7.1 8.3 NBN "AT-V1, AT-V2, ATV, NBS, NBS1" ENSG00000104320 Nibrin O60934 8 89933336-90003228 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cell cycle, DNA damage, DNA repair, Host-virus interaction, Meiosis" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "SK-BR-3: 76.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001429, CAB003836" Supported Approved "Nucleoplasm,Golgi apparatus" "Golgi apparatus" Nucleoplasm "CAB003836: AB_562172, HPA001429: AB_1854460" "unprognostic (1.52e-1)" "unprognostic (1.72e-1)" "unprognostic (2.32e-3)" "unprognostic (7.46e-2)" "unprognostic (2.49e-2)" "unprognostic (1.28e-1)" "unprognostic (1.05e-2)" "prognostic unfavourable (5.46e-5)" "unprognostic (5.05e-2)" "unprognostic (4.61e-2)" "prognostic unfavourable (4.20e-4)" "unprognostic (1.15e-1)" "unprognostic (6.68e-2)" "unprognostic (3.14e-2)" "unprognostic (3.28e-1)" "unprognostic (2.84e-2)" "unprognostic (1.03e-1)" 19.2 16.1 17.9 23.6 29.5 41.3 23.0 17.4 21.0 19.3 22.6 12.2 16.9 13.3 33.2 16.6 19.7 17.5 20.2 14.2 19.4 16.7 25.9 19.3 17.9 26.7 16.9 18.1 19.3 17.1 21.0 29.4 13.2 18.4 17.6 20.9 7.1 18.4 17.6 15.7 11.2 18.0 22.2 18.1 26.5 14.7 13.9 18.9 23.4 20.8 14.7 22.8 17.5 16.0 10.1 12.0 21.8 18.5 9.7 8.6 7.6 15.1 8.5 8.6 4.5 4.7 11.8 5.5 10.8 14.4 13.8 15.0 4.9 11.5 22.9 12.6 9.8 5.1 10.4 10.1 17.7 10.7 6.0 19.4 5.3 6.9 9.2 11.6 10.3 8.8 5.4 7.7 17.1 11.1 14.2 13.4 15.6 13.5 17.7 7.3 2.5 9.3 11.9 7.5 13.6 17.8 20.9 2.5 7.9 6.8 76.8 6.4 14.4 8.6 8.3 12.0 8.5 7.2 10.6 6.2 7.1 12.8 12.1 10.9 11.0 14.1 11.1 20.3 8.1 12.5 8.6 10.1 5.9 5.9 12.0 6.1 5.7 6.2 21.8 9.7 18.5 6.6 3.7 7.6 17.9 29.5 17.4 21.0 19.4 16.7 16.9 18.1 18.4 18.9 NBPF1 "FLJ20719, KIAA1693" ENSG00000219481 "NBPF member 1" 1 16562319-16613562 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "HPA038748, HPA042595, HPA043105, HPA043692, HPA044023, HPA046971, HPA058050" Approved Approved "Nucleoplasm,Nuclear bodies" "Nuclear bodies" Nucleoplasm "HPA038748: , HPA042595: , HPA043105: , HPA043692: , HPA044023: , HPA046971: , HPA058050: " "unprognostic (8.16e-3)" "unprognostic (6.96e-2)" "unprognostic (1.33e-2)" "unprognostic (6.09e-2)" "unprognostic (3.49e-1)" "unprognostic (4.76e-2)" "unprognostic (1.15e-5)" "unprognostic (2.16e-2)" "unprognostic (5.40e-2)" "unprognostic (2.99e-1)" "unprognostic (4.90e-2)" "unprognostic (2.14e-2)" "prognostic favourable (1.06e-4)" "unprognostic (1.57e-1)" "unprognostic (1.05e-1)" "unprognostic (5.18e-2)" "unprognostic (1.68e-1)" 6.8 23.3 14.2 6.4 18.3 4.5 7.4 32.7 13.1 11.7 11.6 21.5 6.0 7.5 9.5 6.2 6.6 13.9 7.9 5.2 13.4 9.3 8.1 7.7 7.3 3.2 32.8 4.2 18.6 5.5 22.3 12.3 9.7 18.4 9.0 11.3 9.3 6.5 9.6 4.5 5.9 16.6 12.2 21.3 6.7 7.3 22.3 21.5 3.7 9.5 3.3 4.3 10.4 8.5 2.0 0.9 4.3 1.0 0.4 1.7 0.5 5.4 7.8 7.9 4.8 2.2 2.6 1.5 3.8 4.9 7.2 6.5 2.8 2.3 4.3 1.1 10.6 5.1 3.8 2.3 8.5 2.7 4.2 1.4 2.6 2.7 3.5 2.1 3.4 2.8 2.9 10.4 3.0 3.2 4.6 2.4 2.8 4.3 9.2 1.6 1.5 15.4 7.9 4.3 0.4 2.0 1.1 9.8 9.6 9.7 4.0 5.4 6.1 1.5 3.8 6.4 3.5 8.6 3.3 1.3 5.9 2.4 1.5 3.2 2.6 0.4 0.7 4.3 1.2 0.8 1.4 1.1 1.1 1.5 0.5 2.0 1.3 1.7 0.2 0.4 1.0 0.9 0.0 0.5 14.2 18.3 32.7 13.1 13.4 9.3 32.8 4.2 18.4 21.5 NBPF10 AG1 ENSG00000271425 "NBPF member 10" 1 146064699-146144804 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Not detected" "Not detected" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "HPA038748, HPA042595, HPA043105, HPA043692, HPA044023, HPA046971, HPA058050" Approved Approved "Nucleoplasm,Nuclear bodies" "Nuclear bodies" Nucleoplasm "HPA038748: , HPA042595: , HPA043105: , HPA043692: , HPA044023: , HPA046971: , HPA058050: " "unprognostic (2.05e-1)" "unprognostic (8.84e-2)" "unprognostic (5.84e-2)" "unprognostic (5.61e-3)" "unprognostic (1.06e-1)" "unprognostic (5.16e-3)" "unprognostic (3.26e-1)" "unprognostic (2.17e-1)" "unprognostic (9.49e-2)" "unprognostic (6.64e-5)" "unprognostic (1.60e-1)" "unprognostic (6.01e-2)" "unprognostic (1.11e-3)" "unprognostic (2.19e-1)" "unprognostic (1.61e-1)" "unprognostic (9.61e-2)" "unprognostic (6.68e-2)" 1.5 0.0 0.9 3.3 2.3 0.0 3.0 0.9 0.0 1.6 1.9 1.0 1.3 0.5 0.0 0.4 1.2 1.3 0.6 3.2 1.1 1.5 0.7 1.1 1.1 0.3 1.3 0.0 4.2 0.0 1.5 2.0 0.1 1.2 0.7 0.6 0.2 1.3 2.4 3.7 1.5 0.4 0.4 0.2 5.4 1.4 3.2 2.3 11.3 13.5 2.8 3.1 4.2 3.1 3.2 1.4 2.5 2.5 0.6 6.1 2.7 3.8 4.2 6.4 2.8 2.4 5.4 3.8 0.7 4.5 2.5 1.7 12.3 4.0 8.3 8.5 3.8 1.7 7.7 6.7 6.7 1.0 2.2 1.5 4.4 1.3 2.0 3.3 2.4 3.7 0.3 0.4 4.7 4.7 1.6 3.8 3.1 11.4 3.1 2.7 2.9 3.8 4.7 1.9 3.0 2.8 2.7 2.4 0.8 1.5 1.8 0.4 1.1 0.2 1.1 0.2 0.3 0.7 1.3 0.4 0.3 3.7 0.4 1.2 2.4 0.3 0.2 NCAM1 "CD56, NCAM" ENSG00000149294 "Neural cell adhesion molecule 1" P13591 11 112961247-113278436 "Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion, Host-virus interaction" "Host cell receptor for virus entry, Receptor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 110.6;heart muscle: 67.7" "Cell line enhanced" "Detected in some" "HEL: 19.1;RH-30: 43.1;SCLC-21H: 35.1;SH-SY5Y: 17.2;U-138 MG: 24.0;WM-115: 25.4" "Cancer enriched" "Detected in many" 8 "glioma: 31.0" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in some" 14 "NK-cell: 27.2" "Lineage enriched" "Detected in many" 14 "NK-cells: 27.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000142, CAB018071, HPA039835" Enhanced Enhanced "Plasma membrane,Cytosol" "Intracellular and membrane" 2800000000 "Plasma membrane" Cytosol "CAB000142: , CAB018071: AB_627129, HPA039835: " "unprognostic (7.04e-2)" "unprognostic (1.16e-1)" "unprognostic (2.77e-2)" "unprognostic (2.18e-2)" "unprognostic (2.91e-1)" "unprognostic (1.74e-3)" "unprognostic (2.82e-1)" "unprognostic (4.42e-3)" "unprognostic (2.13e-1)" "unprognostic (1.63e-2)" "prognostic favourable (9.11e-6)" "unprognostic (8.13e-2)" "prognostic unfavourable (8.20e-4)" "unprognostic (2.97e-2)" "unprognostic (2.24e-1)" "unprognostic (3.75e-2)" "unprognostic (5.82e-5)" 3.5 36.4 22.7 3.0 35.7 1.8 2.1 20.2 110.6 13.3 9.0 55.8 0.3 3.4 24.7 3.0 4.8 8.3 3.6 67.7 22.5 19.2 2.3 2.6 2.0 1.7 45.0 27.1 21.9 2.3 1.1 9.1 1.4 38.8 8.4 4.6 5.5 2.5 10.9 14.6 1.8 5.3 25.6 27.6 3.4 6.7 2.9 39.2 0.0 16.9 0.7 1.7 7.0 6.5 0.0 0.0 0.4 0.1 27.2 2.0 0.9 0.0 0.0 6.7 0.1 0.0 0.1 0.1 0.3 0.0 0.2 0.4 0.1 0.1 0.9 6.0 6.3 0.1 0.0 0.0 0.0 0.1 3.8 19.1 0.0 0.0 0.7 0.0 3.1 4.1 0.0 0.0 6.1 0.0 0.0 0.3 6.7 0.0 0.0 1.6 0.5 0.1 0.0 43.1 3.1 0.0 0.0 35.1 17.2 0.0 0.1 0.0 0.0 0.2 0.0 24.0 11.2 0.1 10.0 0.0 0.1 0.0 2.7 9.0 25.4 0.0 0.1 0.0 2.0 0.0 0.6 0.0 0.1 0.2 0.0 0.0 0.0 0.8 0.4 27.2 0.0 0.0 0.1 0.9 22.7 35.7 20.2 41.6 22.5 19.2 45.0 27.1 38.8 39.2 NCOA1 "bHLHe74, F-SRC-1, KAT13A, NCoA-1, RIP160, SRC1" ENSG00000084676 "Nuclear receptor coactivator 1" Q15788 2 24491914-24770702 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, Acyltransferase, Transferase" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "RH-30: 40.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB019402, HPA070213, HPA070520" Supported Enhanced "Nucleoplasm,Plasma membrane,Cytosol" Nucleoplasm "Plasma membrane, Cytosol" "CAB019402: AB_2196189, HPA070213: , HPA070520: " "unprognostic (2.73e-1)" "unprognostic (5.82e-2)" "unprognostic (2.46e-2)" "unprognostic (9.89e-3)" "unprognostic (7.60e-2)" "unprognostic (2.36e-2)" "unprognostic (7.06e-3)" "unprognostic (1.45e-1)" "unprognostic (1.43e-1)" "unprognostic (1.72e-1)" "unprognostic (2.93e-3)" "unprognostic (1.16e-1)" "unprognostic (2.10e-2)" "unprognostic (7.15e-2)" "unprognostic (3.08e-1)" "unprognostic (1.29e-1)" "unprognostic (2.92e-2)" 9.8 10.0 15.3 7.3 18.0 8.9 10.5 15.9 17.1 13.7 8.9 13.5 4.9 12.5 13.0 11.5 10.8 10.0 8.3 8.8 20.8 12.2 11.9 8.8 9.4 8.2 10.8 9.9 17.2 10.3 23.9 16.0 10.1 14.2 9.6 10.1 19.9 10.6 13.0 42.5 9.3 10.9 11.6 9.7 9.6 7.6 11.4 10.7 8.5 7.0 12.2 9.3 9.7 10.8 2.5 5.5 14.2 3.5 3.4 4.1 1.8 6.6 4.9 8.7 4.5 9.6 8.8 13.3 3.5 7.1 4.5 4.0 4.6 2.8 4.8 1.5 6.4 1.6 5.2 3.0 4.9 22.8 7.5 17.2 2.0 1.9 6.0 7.9 14.4 14.0 4.6 4.3 3.5 4.5 10.4 8.0 6.8 4.4 7.0 2.8 4.1 3.3 5.5 40.1 2.4 4.9 9.0 8.0 6.3 8.2 5.0 3.6 6.0 4.0 4.9 7.5 5.9 5.1 3.5 9.3 8.0 8.4 4.3 5.0 3.7 11.0 3.5 6.9 3.8 2.7 4.1 1.8 3.4 4.1 2.6 2.5 3.3 4.0 14.2 3.4 2.8 5.5 3.7 1.8 15.3 18.0 15.9 17.1 20.8 12.2 10.8 9.9 14.2 10.7 NCOA2 "bHLHe75, GRIP1, KAT13C, NCoA-2, TIF2" ENSG00000140396 "Nuclear receptor coactivator 2" Q15596 8 70109762-70403805 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Transcription, Transcription regulation" Activator "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA060243 Supported "Nucleoplasm,Nuclear bodies" "Nucleoplasm, Nuclear bodies" "HPA060243: " "unprognostic (9.79e-3)" "unprognostic (1.40e-1)" "unprognostic (2.72e-1)" "unprognostic (4.94e-3)" "unprognostic (1.91e-2)" "unprognostic (2.18e-3)" "unprognostic (1.30e-1)" "unprognostic (6.77e-2)" "unprognostic (2.06e-1)" "unprognostic (7.00e-2)" "unprognostic (2.20e-2)" "unprognostic (2.63e-2)" "prognostic favourable (5.08e-4)" "unprognostic (2.52e-1)" "unprognostic (3.35e-1)" "unprognostic (1.07e-1)" "unprognostic (1.76e-1)" 13.6 13.2 16.9 13.1 14.0 22.5 14.9 19.2 14.0 13.9 17.3 10.1 49.7 12.4 16.6 33.6 20.0 12.5 12.6 15.8 13.9 13.0 16.4 25.5 15.5 16.9 10.8 11.4 18.5 9.7 23.4 17.1 16.2 10.0 14.8 11.8 15.3 14.8 21.7 13.2 14.9 28.8 19.2 9.6 14.5 11.7 15.5 12.9 15.3 13.4 10.3 13.8 18.9 17.2 3.8 2.5 9.4 7.8 2.1 3.8 1.6 8.6 10.8 11.9 6.7 10.8 11.2 12.2 5.0 5.0 3.8 3.7 5.5 10.0 10.2 2.0 9.1 5.1 14.6 6.9 4.3 24.2 11.6 17.9 5.5 8.7 5.7 3.6 4.8 9.7 7.7 5.2 7.5 2.6 5.6 15.7 4.4 8.6 8.9 3.6 6.2 5.1 8.8 5.0 6.4 6.1 14.4 9.1 6.7 8.6 4.6 7.1 10.9 6.6 3.4 5.6 7.1 7.0 2.6 20.7 10.5 10.0 5.7 4.8 8.1 4.5 2.5 3.5 3.8 3.9 2.8 2.2 2.3 3.3 2.5 3.8 2.8 2.7 9.4 2.1 7.8 1.1 3.2 1.6 16.9 14.0 19.2 13.5 13.9 13.0 10.8 11.4 10.0 12.9 NCOA3 "ACTR, AIB1, bHLHe42, CAGH16, KAT13B, p/CIP, RAC3, SRC-3, SRC3, TNRC16, TRAM-1" ENSG00000124151 "Nuclear receptor coactivator 3" Q9Y6Q9 20 47501902-47656877 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, Acyltransferase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "MCF7: 62.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009800, HPA024210" Supported Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "CAB009800: AB_2251314, HPA024210: AB_10602011" "unprognostic (7.26e-3)" "unprognostic (1.00e-1)" "unprognostic (2.69e-1)" "unprognostic (3.23e-2)" "unprognostic (5.78e-2)" "unprognostic (4.33e-2)" "prognostic unfavourable (8.09e-4)" "unprognostic (2.83e-2)" "unprognostic (1.47e-1)" "unprognostic (5.22e-3)" "unprognostic (2.09e-2)" "unprognostic (2.10e-1)" "unprognostic (2.05e-1)" "unprognostic (1.95e-1)" "unprognostic (2.04e-2)" "unprognostic (4.18e-1)" "unprognostic (1.63e-1)" 20.1 8.9 6.6 34.0 7.4 11.1 15.7 11.9 9.9 12.3 10.1 8.1 9.0 6.7 15.5 8.8 16.7 12.0 8.6 11.5 6.7 4.8 9.1 9.3 17.4 25.8 7.9 4.7 13.3 10.7 13.5 13.5 54.7 7.9 9.7 9.0 10.8 13.5 10.0 32.5 15.0 17.1 11.3 9.5 30.8 11.4 9.2 7.2 17.6 13.5 10.5 33.3 15.1 17.7 13.0 6.7 6.0 7.3 2.7 4.0 3.5 5.7 18.8 5.3 7.2 12.5 14.7 37.3 5.6 8.4 9.6 5.1 9.0 6.4 20.1 3.7 9.6 14.2 4.1 6.9 7.3 10.6 2.2 2.7 5.3 12.5 7.4 2.1 15.0 6.7 19.8 9.1 10.6 6.8 6.2 4.7 5.3 62.6 3.2 3.7 1.8 7.2 6.0 3.7 8.6 5.3 13.6 1.0 1.9 14.1 17.6 6.0 8.1 5.5 11.8 5.7 5.0 6.9 2.4 12.9 11.8 20.7 6.6 2.2 3.8 3.4 5.2 4.0 3.5 7.3 3.2 13.0 3.2 3.1 6.7 10.0 3.7 4.0 6.0 2.7 7.0 5.5 4.0 3.5 6.6 7.4 11.9 9.9 6.7 4.8 7.9 4.7 7.9 7.2 NCOA4 "ARA70, DKFZp762E1112, ELE1, PTC3, RFG" ENSG00000266412 "Nuclear receptor coactivator 4" Q13772 10 46005088-46030714 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" Activator "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 100.1" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Group enriched" "Detected in all" 4 "dendritic cells: 30.2;granulocytes: 100.1;monocytes: 40.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA051260, HPA065208" Uncertain Approved "Nucleoli,Golgi apparatus,Cytosol" Nucleoli "Golgi apparatus, Cytosol" "HPA051260: , HPA065208: " "unprognostic (4.23e-2)" "unprognostic (1.50e-1)" "unprognostic (2.44e-2)" "unprognostic (1.82e-1)" "prognostic favourable (3.26e-4)" "unprognostic (1.34e-1)" "unprognostic (1.80e-1)" "unprognostic (9.34e-2)" "unprognostic (4.67e-2)" "unprognostic (5.22e-2)" "unprognostic (9.16e-2)" "unprognostic (2.04e-2)" "prognostic favourable (8.04e-6)" "unprognostic (1.35e-1)" "unprognostic (4.71e-3)" "unprognostic (1.14e-1)" "unprognostic (2.78e-1)" 18.5 6.9 5.5 9.5 10.0 17.4 10.0 5.5 11.3 10.8 22.5 13.6 5.9 27.0 9.9 9.4 17.0 6.3 9.0 16.6 5.7 20.8 40.9 11.6 11.6 8.7 7.1 11.0 9.1 9.3 9.6 28.4 13.5 14.7 12.4 9.9 12.6 8.5 15.5 6.8 36.4 11.2 9.7 23.8 8.9 6.4 8.1 26.8 13.2 13.9 16.3 13.0 6.4 7.3 30.2 100.1 40.4 13.4 10.9 53.9 31.3 13.3 15.6 16.0 41.4 37.6 39.1 28.8 46.7 28.5 27.9 20.4 23.2 35.4 34.7 47.1 32.0 16.3 31.7 31.7 25.0 16.8 23.9 18.3 58.5 29.1 60.8 53.4 36.5 31.8 24.2 40.7 41.8 26.0 21.4 38.7 14.0 29.5 22.8 9.4 7.8 17.5 22.7 21.2 34.1 26.7 15.7 10.6 29.1 33.3 28.8 24.0 29.9 38.5 17.6 21.2 18.6 19.4 15.9 17.0 35.2 22.0 51.2 9.3 69.1 40.4 70.7 10.0 26.8 10.9 7.3 9.4 9.5 30.2 6.6 10.2 8.6 100.1 13.4 30.4 9.3 10.8 53.9 NCOR1 "hCIT529I10, hN-CoR, KIAA1047, MGC104216, N-CoR, PPP1R109, TRAC1" ENSG00000141027 "Nuclear receptor corepressor 1" O75376 17 16029157-16218185 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Transcription, Transcription regulation" "Chromatin regulator, DNA-binding, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA043246, HPA050288, HPA051168, CAB072830" Supported Enhanced Nucleoplasm,Cytosol Nucleoplasm Cytosol "CAB072830: , HPA043246: , HPA050288: , HPA051168: " "unprognostic (1.83e-1)" "unprognostic (3.05e-1)" "unprognostic (9.17e-2)" "unprognostic (1.10e-1)" "unprognostic (7.38e-2)" "unprognostic (3.59e-2)" "unprognostic (2.55e-2)" "unprognostic (4.27e-2)" "unprognostic (4.87e-2)" "unprognostic (4.06e-2)" "unprognostic (7.07e-2)" "unprognostic (1.52e-2)" "prognostic favourable (7.92e-5)" "unprognostic (4.40e-2)" "unprognostic (2.52e-1)" "unprognostic (1.33e-1)" "unprognostic (5.42e-2)" 19.6 21.2 25.4 24.0 30.8 27.0 25.0 41.8 31.5 24.0 30.6 19.6 18.6 33.2 29.0 19.5 25.0 20.5 21.9 17.8 22.4 17.8 25.6 33.8 20.1 19.5 25.1 19.1 25.9 24.3 39.9 39.8 19.8 21.6 20.8 29.7 17.1 20.9 29.1 43.0 23.8 36.9 29.7 26.4 23.7 29.8 22.1 26.4 38.8 25.3 15.7 23.8 29.6 27.0 43.4 29.9 78.2 24.8 30.4 35.5 19.7 23.8 39.9 28.5 23.7 23.5 17.9 14.2 17.6 19.9 19.4 17.6 21.3 10.9 25.1 12.4 30.7 18.3 35.0 21.3 28.8 33.4 25.9 25.0 34.5 25.0 23.0 15.6 29.8 18.3 22.4 30.0 35.2 26.9 21.8 10.4 19.0 15.5 27.5 10.1 14.1 10.9 27.5 28.9 11.7 20.1 27.1 9.7 16.2 29.1 12.7 13.8 12.2 17.9 23.4 20.0 11.8 14.6 24.2 7.2 8.3 14.7 19.0 18.6 17.1 78.2 24.8 52.2 31.3 19.5 25.9 40.7 35.5 34.1 17.5 43.4 34.7 34.8 48.5 30.4 24.0 29.9 31.7 19.7 25.4 30.8 41.8 31.5 22.4 17.8 25.1 19.1 21.6 26.4 NCOR2 "CTG26, SMRT, SMRTE, TNRC14, TRAC-1" ENSG00000196498 "Nuclear receptor corepressor 2" Q9Y618 12 124324415-124567589 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "basophil: 8.1" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA001928 Approved Supported Nucleoplasm Nucleoplasm "HPA001928: AB_1079454" "unprognostic (9.51e-3)" "unprognostic (7.37e-3)" "unprognostic (4.66e-2)" "unprognostic (2.55e-3)" "unprognostic (2.14e-1)" "unprognostic (7.37e-2)" "unprognostic (3.19e-2)" "unprognostic (8.86e-2)" "unprognostic (2.21e-2)" "unprognostic (2.90e-3)" "unprognostic (6.42e-3)" "unprognostic (1.96e-1)" "unprognostic (9.86e-2)" "unprognostic (6.26e-2)" "unprognostic (1.59e-1)" "unprognostic (7.56e-2)" "unprognostic (8.90e-2)" 24.0 22.0 21.3 21.3 19.0 16.8 18.3 33.8 33.5 24.5 17.2 24.3 17.7 16.4 21.3 19.0 15.7 16.3 21.5 18.2 22.0 14.8 16.0 11.2 23.4 11.9 19.0 15.6 28.6 30.0 13.8 39.5 13.2 28.3 21.3 7.6 32.7 29.2 24.5 62.4 22.8 22.2 17.4 12.2 17.4 24.0 10.8 22.0 9.3 16.7 25.0 7.6 16.3 14.7 0.6 1.7 8.1 4.0 0.2 1.9 0.4 19.4 36.7 10.5 10.0 6.1 8.3 31.4 20.2 10.1 11.8 5.3 19.5 14.4 19.8 15.0 16.4 18.5 4.1 21.5 4.8 20.8 8.1 15.9 34.6 11.8 12.3 11.9 20.2 13.3 8.1 14.7 8.8 11.2 20.4 5.9 10.5 16.8 42.9 13.8 14.6 35.8 13.9 17.5 10.0 5.6 22.8 27.7 20.2 24.8 21.0 12.7 17.1 15.1 53.9 27.5 47.6 27.1 42.9 11.3 11.4 12.1 15.6 8.9 25.7 8.1 0.7 1.6 1.9 0.4 0.5 0.6 0.5 1.5 0.3 0.4 0.6 0.5 1.6 0.2 4.0 1.7 0.0 0.4 21.3 19.0 33.8 28.4 22.0 14.8 19.0 15.6 28.3 22.0 NDRG1 "CAP43, DRG1, NDR1, RTP, TDD5" ENSG00000104419 "N-myc downstream regulated 1" Q92597 8 133237171-133302022 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cancer-related genes, Charcot-Marie-Tooth disease, Neurodegeneration, Neuropathy" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "hTCEpi: 69.0;hTERT-HME1: 139.1;U-87 MG: 93.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA006881 Approved Supported Microtubules,Cytosol Cytosol Microtubules "HPA006881: AB_1078392" "unprognostic (6.96e-3)" "unprognostic (3.31e-3)" "unprognostic (8.53e-2)" "unprognostic (1.41e-3)" "unprognostic (1.54e-3)" "unprognostic (2.60e-2)" "prognostic unfavourable (1.47e-4)" "unprognostic (3.04e-3)" "unprognostic (5.33e-2)" "unprognostic (4.29e-2)" "unprognostic (9.09e-2)" "unprognostic (2.46e-1)" "prognostic unfavourable (4.13e-4)" "unprognostic (7.27e-2)" "unprognostic (1.91e-1)" "unprognostic (2.47e-3)" "unprognostic (4.28e-2)" 43.9 23.6 42.0 17.0 80.9 18.0 29.8 6.4 36.2 33.1 47.7 73.2 24.2 74.2 20.9 20.6 83.0 24.7 26.8 22.2 48.7 32.9 62.6 12.1 31.0 11.4 96.3 19.8 37.5 16.7 17.8 18.6 32.5 50.0 115.0 22.4 16.2 29.0 26.4 13.2 56.9 78.2 19.2 102.0 11.5 45.7 15.0 74.3 10.3 21.4 40.0 34.9 58.7 64.9 1.9 12.2 8.9 4.1 1.3 9.3 2.9 21.5 2.7 0.1 0.1 13.7 9.6 2.9 1.5 11.8 1.1 6.1 1.3 3.0 0.1 15.5 6.4 7.0 0.2 34.0 2.4 1.3 25.5 0.2 5.5 1.6 5.2 0.7 0.5 8.9 69.0 5.8 139.1 5.1 0.2 15.1 1.9 1.2 2.0 2.1 0.3 17.9 0.2 2.4 10.0 3.5 3.2 1.6 1.6 3.3 35.7 8.6 0.1 2.3 6.6 9.7 5.0 4.2 1.2 11.3 29.6 0.1 93.6 8.1 19.0 8.9 4.1 0.0 6.3 3.7 9.3 1.7 5.9 7.5 6.1 1.9 4.6 3.1 4.2 1.3 4.0 12.2 8.0 2.9 42.0 80.9 6.4 36.2 48.7 32.9 96.3 19.8 50.0 74.3 NEB "NEB177D, NEM2" ENSG00000183091 Nebulin P20929 2 151485336-151734487 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Actin-binding, Muscle protein" "Cancer-related genes, Nemaline myopathy" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 8 "skeletal muscle: 505.8" "Cell line enhanced" "Detected in some" "Karpas-707: 6.7;RH-30: 26.6;U-266/70: 10.0" "Cancer enhanced" "Detected in many" "head and neck cancer: 3.8" "Not detected" "Not detected" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Group enriched" "Detected in some" 7 "cerebellum: 7.4;olfactory region: 4.9" "Region enriched" "Detected in some" 7 "cerebellum: 25.3" HPA016601 Enhanced "HPA016601: AB_1854361" "unprognostic (2.40e-2)" "unprognostic (6.71e-2)" "unprognostic (2.13e-2)" "unprognostic (2.52e-2)" "unprognostic (1.20e-1)" "unprognostic (1.85e-3)" "unprognostic (2.54e-2)" "unprognostic (1.45e-1)" "unprognostic (4.41e-2)" "unprognostic (1.73e-1)" "unprognostic (1.40e-1)" "unprognostic (1.07e-1)" "unprognostic (4.45e-13)" "unprognostic (6.80e-2)" "unprognostic (2.22e-2)" "unprognostic (4.07e-3)" "unprognostic (4.06e-2)" 9.6 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.0 5.2 4.0 0.0 0.8 1.5 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0 1.3 0.0 0.0 3.8 0.0 505.8 0.3 0.0 0.0 0.1 0.1 0.0 0.3 0.0 0.0 3.0 65.9 2.6 0.1 0.0 1.3 0.5 1.7 0.6 0.8 0.9 0.3 0.3 0.3 0.6 0.5 0.1 0.1 1.7 0.3 0.0 0.0 0.0 4.6 0.5 1.2 0.9 0.1 0.9 0.1 0.0 0.0 0.6 0.7 0.4 0.6 1.5 0.0 0.8 1.1 4.0 0.2 0.0 0.0 0.6 0.9 6.7 0.4 0.5 0.4 0.7 1.1 0.8 1.1 26.6 0.1 0.0 0.9 1.5 0.2 0.2 0.3 0.1 0.7 0.8 0.6 0.7 0.9 0.1 0.9 10.0 1.4 0.3 0.1 0.6 1.1 1.2 0.6 1.7 0.9 0.0 0.9 1.2 0.8 0.5 0.0 1.3 0.3 0.4 1.1 0.8 0.0 0.5 0.4 0.3 0.1 0.1 0.1 0.0 0.1 0.2 0.1 0.0 0.0 0.0 NEDD4L "KIAA0439, NEDD4-2, RSP5" ENSG00000049759 "Neural precursor cell expressed, developmentally down-regulated 4-like, E3 ubiquitin protein ligase" Q96PU5 18 58044367-58401540 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Differentiation, Host-virus interaction, Ubl conjugation pathway" Transferase "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Hep G2: 50.1;SK-MEL-30: 39.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "T-reg: 8.1" "Group enriched" "Detected in many" 4 "granulocytes: 4.7;T-cells: 8.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA024618 Approved "HPA024618: AB_1854362" "unprognostic (2.56e-1)" "unprognostic (2.41e-2)" "unprognostic (1.58e-2)" "unprognostic (3.14e-1)" "unprognostic (3.90e-2)" "unprognostic (1.50e-1)" "unprognostic (2.11e-3)" "unprognostic (2.26e-2)" "unprognostic (9.24e-3)" "unprognostic (4.39e-2)" "unprognostic (1.24e-1)" "unprognostic (1.27e-1)" "prognostic favourable (6.55e-15)" "unprognostic (2.42e-1)" "unprognostic (8.26e-2)" "unprognostic (8.49e-3)" "unprognostic (4.75e-2)" 5.9 6.8 9.1 5.4 38.8 13.2 15.8 21.4 24.7 5.0 22.6 3.2 18.2 11.1 3.6 6.1 7.0 6.0 7.6 12.7 9.8 7.1 29.9 10.1 26.9 2.5 7.2 14.9 3.0 33.2 9.2 16.5 13.0 4.1 30.6 25.2 12.2 16.5 23.2 38.3 5.9 26.8 8.2 3.2 3.1 26.0 4.6 8.8 0.8 9.1 5.5 5.1 14.9 9.3 1.4 0.4 4.7 0.7 0.9 8.1 0.5 18.4 6.6 3.9 5.8 1.4 0.5 13.6 5.2 23.7 13.4 20.5 7.7 10.0 3.9 16.1 2.0 13.4 5.2 23.1 27.7 9.2 4.6 2.8 4.1 50.1 0.7 0.1 1.7 3.5 15.1 18.1 22.0 1.0 4.8 1.7 5.5 4.5 0.2 0.2 3.4 10.2 3.8 5.3 4.5 13.3 24.1 4.9 1.3 4.3 1.3 39.1 7.9 1.6 7.9 36.2 10.9 2.0 22.3 2.3 3.9 2.4 7.4 2.8 2.9 4.7 0.6 1.7 0.4 0.7 1.0 1.4 1.3 0.3 0.3 0.6 0.8 0.6 0.3 0.9 0.1 0.4 8.1 0.5 9.1 38.8 21.4 24.7 9.8 7.1 7.2 14.9 4.1 8.8 NEDD8 Nedd-8 ENSG00000129559 "Neural precursor cell expressed, developmentally down-regulated 8" Q15843 14 24216852-24232454 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Ubl conjugation pathway" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004082, HPA027583, HPA060254" Uncertain Enhanced Nucleoplasm,Cytosol 5700000 Nucleoplasm Cytosol "CAB004082: AB_10695300, HPA027583: , HPA060254: " "unprognostic (1.26e-2)" "unprognostic (2.55e-1)" "unprognostic (1.14e-1)" "unprognostic (1.08e-1)" "unprognostic (1.69e-1)" "unprognostic (3.34e-3)" "unprognostic (1.83e-3)" "unprognostic (9.19e-2)" "unprognostic (4.66e-1)" "unprognostic (1.35e-2)" "unprognostic (2.66e-2)" "unprognostic (1.41e-1)" "unprognostic (1.78e-3)" "unprognostic (2.76e-2)" "unprognostic (1.31e-1)" "unprognostic (2.79e-2)" "unprognostic (5.25e-3)" 38.2 48.1 55.5 30.7 58.1 34.6 42.2 34.1 62.4 41.0 36.3 26.8 32.6 25.0 32.2 59.9 40.3 34.3 31.3 50.7 47.1 49.5 46.5 48.4 30.5 31.5 49.4 54.6 34.3 33.4 101.1 31.3 39.7 45.5 31.6 40.0 27.4 37.2 40.7 70.7 36.5 28.4 43.0 36.0 34.9 29.9 25.7 34.3 26.9 37.5 44.7 46.8 30.7 32.0 60.2 76.1 90.2 60.1 43.2 64.1 89.9 25.5 44.8 36.5 25.7 41.4 36.2 26.5 35.0 37.1 41.2 38.1 30.9 31.3 22.1 20.5 49.2 27.0 36.3 54.6 58.0 31.2 22.0 23.6 41.3 105.3 36.0 39.0 24.7 38.4 36.3 34.7 27.3 49.2 21.0 25.9 63.5 56.9 31.0 37.0 26.9 52.5 22.1 28.9 22.5 47.5 48.7 15.4 35.9 30.2 30.8 25.1 18.6 31.0 36.8 23.5 23.6 30.0 30.9 30.8 46.4 32.0 16.8 22.5 22.2 73.5 57.9 90.2 46.8 60.1 50.7 60.2 54.4 51.9 56.9 51.1 51.2 52.0 62.2 43.2 59.0 76.1 64.1 89.9 55.5 58.1 34.1 62.4 47.1 49.5 49.4 54.6 45.5 34.3 NEO1 "HsT17534, IGDCC2, NGN, NTN1R2" ENSG00000067141 "Neogenin 1" Q92859 15 73051710-73305206 "Cancer-related genes, Plasma proteins, Predicted membrane proteins" "Cell adhesion" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "MAIT T-cell: 3.1" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009320, HPA027804, HPA027805, HPA027806" Uncertain Approved "Nucleoplasm,Golgi apparatus,Plasma membrane" 280000000 "Nucleoplasm, Plasma membrane" "Golgi apparatus" "CAB009320: AB_2150998, HPA027804: AB_10600771, HPA027805: AB_10601755, HPA027806: AB_10601006" "unprognostic (1.90e-1)" "unprognostic (2.38e-2)" "unprognostic (7.60e-3)" "unprognostic (3.76e-2)" "unprognostic (5.44e-1)" "unprognostic (3.83e-2)" "unprognostic (8.30e-2)" "unprognostic (2.31e-1)" "unprognostic (3.22e-1)" "unprognostic (3.30e-2)" "unprognostic (5.51e-2)" "unprognostic (8.05e-2)" "prognostic favourable (4.39e-4)" "unprognostic (1.51e-1)" "unprognostic (1.41e-1)" "unprognostic (1.33e-2)" "unprognostic (3.75e-1)" 7.3 5.8 19.2 6.2 22.4 1.2 11.4 12.7 23.9 13.4 30.0 44.5 14.8 17.9 14.2 7.2 8.0 15.4 13.4 6.8 20.1 14.1 16.2 5.9 10.7 2.7 27.1 15.7 17.5 11.5 44.4 6.9 1.5 19.3 23.1 36.9 16.0 11.5 25.5 17.9 24.6 19.0 16.0 22.3 3.6 15.1 9.0 22.5 2.1 12.5 3.8 4.7 10.1 9.5 0.0 0.3 1.4 0.3 0.8 3.1 0.3 3.7 18.2 21.8 14.4 13.2 3.9 5.4 1.4 1.7 3.6 0.7 2.7 18.4 1.0 2.1 4.0 0.8 15.2 8.3 1.5 6.6 11.2 12.2 0.2 2.5 3.8 0.3 0.4 9.5 15.5 0.7 7.1 0.0 0.0 23.4 0.8 11.2 4.3 0.2 20.8 1.5 10.0 11.7 2.4 6.9 10.0 9.9 14.0 17.1 7.6 9.0 8.0 2.2 0.0 16.8 9.0 5.4 3.9 10.0 18.5 2.6 3.6 3.5 4.7 0.0 0.3 0.4 1.8 0.0 3.1 0.0 1.1 1.4 0.0 0.0 0.6 0.5 1.4 0.8 0.0 0.3 0.0 0.3 19.2 22.4 12.7 23.9 20.1 14.1 27.1 15.7 19.3 22.5 NF1 ENSG00000196712 "Neurofibromin 1" P21359 17 31094927-31382116 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins" "GTPase activation" "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Group enriched" "Detected in many" 6 "B-cells: 2.3;granulocytes: 6.5;T-cells: 8.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA045502 Uncertain Approved Mitochondria Mitochondria "HPA045502: " "unprognostic (6.69e-2)" "unprognostic (8.73e-2)" "unprognostic (8.26e-2)" "unprognostic (1.76e-2)" "unprognostic (2.06e-2)" "unprognostic (2.79e-2)" "unprognostic (1.38e-1)" "unprognostic (1.07e-1)" "unprognostic (1.11e-1)" "unprognostic (1.30e-2)" "unprognostic (3.14e-2)" "unprognostic (3.88e-2)" "unprognostic (1.00e-2)" "unprognostic (2.19e-1)" "unprognostic (1.53e-1)" "unprognostic (1.40e-1)" "unprognostic (3.70e-1)" 12.9 15.9 22.6 13.3 25.9 5.5 18.5 30.2 26.0 17.6 13.6 19.8 12.2 11.0 16.9 17.0 10.5 15.2 13.1 17.3 21.6 19.6 20.0 15.1 12.7 11.5 19.4 25.6 22.9 16.5 34.1 19.0 19.4 20.9 16.1 14.7 12.1 14.4 20.5 14.8 12.0 12.1 14.5 21.4 11.9 13.0 15.4 21.5 11.6 31.1 7.6 12.4 15.3 19.5 2.3 0.7 6.5 0.4 0.9 8.4 1.0 9.7 12.7 15.5 8.3 13.2 17.2 7.8 8.4 15.3 12.5 14.2 11.4 6.6 9.4 2.4 15.8 17.1 14.0 11.9 21.3 4.5 8.8 8.3 12.0 5.8 9.4 14.8 6.9 13.6 7.6 13.3 16.3 6.0 11.9 9.4 11.9 7.7 12.3 5.4 4.5 4.2 9.7 23.7 7.5 9.5 14.0 6.4 9.6 15.7 5.3 8.7 16.0 9.5 8.8 10.0 14.0 11.8 3.2 8.5 4.1 10.4 8.2 6.3 10.4 6.5 0.4 0.9 2.3 0.2 1.6 2.3 4.4 3.9 0.5 2.1 3.3 3.2 1.0 0.9 0.4 0.7 8.4 1.0 22.6 25.9 30.2 23.5 21.6 19.6 19.4 25.6 20.9 21.5 NF2 "ACN, BANF, merlin, SCH" ENSG00000186575 "Neurofibromin 2" P35240 22 29603556-29698598 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cancer-related genes, Deafness, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003097, CAB005385" Supported Enhanced "Nucleoplasm,Plasma membrane,Cytosol" "Plasma membrane" "Nucleoplasm, Cytosol" "CAB005385: AB_2298548, HPA003097: AB_1079473" "unprognostic (3.27e-1)" "unprognostic (1.34e-2)" "unprognostic (1.34e-1)" "unprognostic (1.76e-2)" "unprognostic (3.14e-1)" "unprognostic (1.62e-1)" "unprognostic (5.76e-3)" "unprognostic (1.61e-1)" "unprognostic (3.67e-2)" "unprognostic (2.16e-2)" "unprognostic (2.01e-3)" "unprognostic (4.66e-1)" "prognostic favourable (2.89e-5)" "unprognostic (7.73e-3)" "unprognostic (1.31e-1)" "unprognostic (2.24e-1)" "unprognostic (9.62e-2)" 11.8 12.4 23.6 11.1 20.1 10.0 15.4 20.8 28.1 10.8 9.7 9.0 11.8 7.8 10.5 11.3 14.2 11.3 8.0 19.7 26.6 16.4 13.5 11.1 11.9 24.1 18.0 13.5 11.0 12.9 46.8 8.6 6.9 11.4 10.2 8.7 9.5 9.3 15.4 25.7 12.1 8.5 11.9 10.7 10.4 8.8 21.6 10.1 14.9 15.6 11.5 9.9 10.6 10.2 8.5 13.6 6.6 17.3 11.6 15.0 9.8 26.3 10.6 3.7 24.3 7.3 7.3 3.6 21.4 12.1 23.5 20.3 10.5 6.5 7.0 17.8 22.0 9.3 7.7 12.4 21.1 10.2 6.1 8.3 7.9 7.5 7.8 11.9 9.9 6.7 5.7 16.6 20.3 16.5 4.0 6.5 22.8 11.0 7.2 4.7 2.8 10.1 7.5 20.0 6.7 23.8 12.3 5.8 4.0 12.3 8.3 4.8 5.3 4.8 30.6 35.0 39.9 15.2 36.1 10.2 8.1 8.4 9.3 4.7 22.3 6.6 9.5 3.6 15.0 13.5 12.8 8.2 11.3 10.1 13.6 8.5 9.8 9.2 2.3 11.6 17.3 9.3 9.4 9.8 23.6 20.1 20.8 28.1 26.6 16.4 18.0 13.5 11.4 10.1 NFATC2 "NF-ATP, NFAT1, NFATp" ENSG00000101096 "Nuclear factor of activated T cells 2" Q13469 20 51386957-51562831 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 44.6" "Cell line enhanced" "Detected in many" "HDLM-2: 14.2;HMC-1: 16.3;WM-115: 24.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "HPA008789, CAB018567, HPA024369" Enhanced Supported Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "CAB018567: AB_628012, HPA008789: AB_1079474, HPA024369: AB_1854413" "unprognostic (2.69e-3)" "unprognostic (2.92e-2)" "unprognostic (2.31e-1)" "unprognostic (1.58e-2)" "unprognostic (1.15e-1)" "unprognostic (1.26e-2)" "unprognostic (3.94e-2)" "unprognostic (4.05e-2)" "unprognostic (9.26e-2)" "unprognostic (3.74e-3)" "unprognostic (2.17e-2)" "unprognostic (4.86e-2)" "prognostic unfavourable (1.57e-4)" "unprognostic (9.25e-2)" "unprognostic (1.02e-1)" "unprognostic (1.05e-2)" "unprognostic (6.59e-2)" 8.6 2.4 4.1 44.6 8.2 4.4 9.8 1.1 5.1 8.4 7.8 6.8 3.9 8.4 7.0 7.6 4.0 5.6 19.4 8.5 4.1 3.3 3.4 6.7 6.1 25.2 8.4 0.7 5.0 8.7 3.9 3.7 8.1 10.4 5.4 4.1 6.2 7.9 7.2 5.4 7.0 11.7 5.9 6.5 16.0 11.0 4.5 6.5 8.6 7.0 13.2 18.7 4.5 4.9 1.6 1.7 3.8 0.7 7.6 7.7 1.6 1.5 1.7 0.0 2.1 0.0 0.0 4.5 0.2 1.1 0.7 0.3 8.2 1.5 10.9 1.3 0.5 0.0 0.5 0.0 0.6 14.2 0.2 4.6 1.2 2.1 0.0 1.3 16.3 0.0 0.0 0.6 0.0 5.0 4.5 7.3 0.0 1.8 1.9 7.7 0.1 3.9 0.8 0.0 4.8 0.2 0.0 0.1 0.0 5.1 1.2 11.9 2.0 3.1 0.5 1.0 1.9 2.5 0.1 6.2 4.0 11.2 1.0 5.1 24.5 0.3 0.0 3.8 7.7 0.7 3.2 1.6 4.3 6.1 1.7 1.6 2.4 4.4 0.2 7.6 0.2 0.6 2.3 1.6 4.1 8.2 1.1 5.1 4.1 3.3 8.4 0.7 10.4 6.5 NFE2L2 NRF2 ENSG00000116044 "Nuclear factor, erythroid 2 like 2" Q16236 2 177227595-177392697 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Host-virus interaction, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002990, CAB020317, HPA043438" Supported Approved "Nucleoplasm,Plasma membrane,Cytosol" "Nucleoplasm, Plasma membrane" Cytosol "CAB020317: , HPA002990: AB_1079476, HPA043438: " "unprognostic (2.11e-1)" "unprognostic (3.12e-2)" "unprognostic (5.22e-2)" "unprognostic (1.41e-1)" "unprognostic (5.95e-2)" "unprognostic (3.90e-1)" "unprognostic (5.27e-2)" "unprognostic (9.58e-2)" "unprognostic (3.48e-2)" "unprognostic (9.86e-2)" "unprognostic (4.86e-2)" "unprognostic (1.83e-1)" "prognostic favourable (2.26e-4)" "unprognostic (1.97e-2)" "unprognostic (1.61e-1)" "unprognostic (1.26e-1)" "unprognostic (9.77e-3)" 30.9 24.4 25.4 19.3 34.7 15.0 24.6 36.4 29.7 31.7 28.3 25.8 22.2 28.1 27.7 30.9 82.5 27.0 28.9 32.3 28.0 16.9 44.8 49.3 29.0 19.7 49.0 18.7 53.1 16.3 21.7 52.5 29.4 33.5 39.0 25.4 21.7 34.7 28.1 25.9 48.1 29.2 42.1 42.7 26.8 45.9 21.9 41.6 21.1 49.5 35.8 25.5 43.7 47.1 23.5 41.1 42.4 35.6 25.8 43.2 22.6 10.9 12.7 11.5 12.4 39.0 42.1 13.2 18.7 26.1 17.1 19.4 16.8 21.0 10.8 20.4 21.2 20.4 13.5 28.6 24.0 8.4 8.2 13.9 22.3 32.6 49.9 8.2 13.2 28.9 67.3 24.3 36.2 16.9 14.5 21.3 23.5 10.9 8.4 21.8 12.6 11.9 6.9 10.1 10.9 26.1 41.4 15.1 9.8 42.5 13.7 44.4 10.6 22.3 25.5 17.8 11.8 19.7 11.5 15.0 9.0 9.1 17.8 9.2 34.0 42.4 35.6 21.4 23.0 34.1 26.6 23.5 26.9 23.6 41.1 19.9 43.2 28.2 39.9 25.8 31.9 15.5 25.0 22.6 25.4 34.7 36.4 29.7 28.0 16.9 49.0 18.7 33.5 41.6 NFIB "NFI-RED, NFIB2, NFIB3" ENSG00000147862 "Nuclear factor I B" O00712 9 14081843-14398983 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "DNA replication, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "AN3-CA: 53.9;HBEC3-KT: 21.8;HUVEC TERT2: 21.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "neutrophil: 2.4" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA003956 Supported Supported "Nucleoplasm,Nucleoli fibrillar center" "Nucleoplasm, Nucleoli fibrillar center" "HPA003956: AB_1854424" "unprognostic (1.93e-1)" "unprognostic (3.18e-2)" "unprognostic (4.00e-1)" "unprognostic (2.16e-3)" "unprognostic (1.12e-1)" "unprognostic (2.55e-2)" "unprognostic (1.32e-1)" "unprognostic (4.72e-3)" "unprognostic (7.46e-2)" "unprognostic (9.35e-2)" "unprognostic (3.68e-1)" "unprognostic (1.12e-1)" "prognostic favourable (3.53e-4)" "unprognostic (4.69e-1)" "unprognostic (2.39e-1)" "unprognostic (1.87e-2)" "unprognostic (1.62e-1)" 29.3 9.5 22.6 9.2 12.9 1.0 39.7 30.0 22.9 14.8 17.0 13.6 34.1 11.3 16.8 22.3 11.5 17.0 18.0 24.1 22.0 9.3 18.8 22.3 16.3 9.8 10.8 15.5 18.7 17.5 8.2 6.0 14.7 13.7 21.3 10.4 9.2 40.0 41.3 20.8 23.6 16.8 24.2 14.9 10.4 14.2 7.6 15.6 2.7 18.8 13.9 7.7 27.4 23.4 0.3 0.3 2.4 0.4 0.5 1.0 1.3 6.3 4.5 2.8 53.9 13.6 7.9 0.1 0.1 0.0 1.3 4.7 0.0 2.6 0.1 4.2 0.4 1.4 2.6 21.8 2.3 0.9 2.6 19.4 10.1 0.6 4.5 0.5 0.1 6.8 3.0 4.9 18.1 21.8 0.6 0.1 1.8 2.9 0.0 0.1 1.0 5.3 0.0 2.5 0.0 4.0 2.3 4.5 16.8 4.6 5.7 1.8 11.5 0.0 21.2 4.2 6.3 3.2 4.0 0.5 0.4 1.5 3.7 0.0 5.3 1.3 0.1 0.2 0.3 0.2 1.0 0.2 0.2 0.2 0.1 0.3 0.2 0.1 2.4 0.5 0.4 0.3 0.5 1.3 22.6 12.9 30.0 18.8 22.0 9.3 10.8 15.5 13.7 15.6 NFKB1 "KBF1, NF-kappaB, NF-kB1, NFkappaB, NFKB-p50, p105, p50" ENSG00000109320 "Nuclear factor kappa B subunit 1" P19838 4 102501329-102617302 "Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins, Transcription factors" "Apoptosis, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004031, HPA027305" Enhanced Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "CAB004031: AB_330564, HPA027305: AB_1854429" "unprognostic (1.06e-1)" "unprognostic (1.61e-2)" "unprognostic (4.37e-2)" "unprognostic (2.38e-2)" "unprognostic (1.60e-1)" "unprognostic (1.20e-1)" "unprognostic (2.04e-2)" "unprognostic (8.98e-2)" "unprognostic (1.96e-1)" "unprognostic (9.03e-3)" "unprognostic (2.28e-1)" "unprognostic (2.71e-1)" "prognostic favourable (1.76e-4)" "unprognostic (1.84e-2)" "unprognostic (6.75e-3)" "unprognostic (1.74e-1)" "unprognostic (6.92e-3)" 19.8 14.7 8.2 37.7 12.0 44.5 26.6 12.4 10.3 18.2 17.1 10.4 10.4 10.7 17.5 11.2 20.5 16.4 20.3 14.5 7.5 5.1 13.2 15.8 26.9 46.0 11.4 4.8 17.5 14.3 10.2 8.7 13.7 10.0 18.8 14.6 10.8 17.7 13.5 17.1 19.6 16.7 16.0 10.1 30.0 14.6 9.3 12.5 37.5 14.7 16.3 26.7 18.4 22.7 5.8 10.4 5.5 7.1 14.3 10.6 3.5 16.9 9.5 5.1 7.8 16.0 14.4 6.3 9.7 28.8 12.1 12.4 10.5 24.3 27.7 8.8 15.3 13.5 10.2 17.0 16.7 25.0 6.0 11.8 7.7 11.3 15.0 21.0 25.1 11.9 12.0 11.8 16.4 15.2 11.4 20.4 8.7 11.9 1.8 11.5 3.1 8.8 14.8 12.2 12.5 11.3 23.9 3.5 5.8 17.9 25.0 9.8 5.1 15.7 19.4 16.5 8.6 8.9 13.6 9.0 6.2 26.9 10.5 10.8 23.3 5.2 5.4 4.9 3.4 7.1 6.0 5.6 8.4 5.6 10.4 5.8 10.6 8.9 5.5 14.3 5.9 7.4 4.5 3.5 8.2 12.0 12.4 10.3 7.5 5.1 11.4 4.8 10.0 12.5 NFKB2 "LYT-10, NF-kB2, p105, p49/p100, p52" ENSG00000077150 "Nuclear factor kappa B subunit 2" Q00653 10 102394110-102402529 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HDLM-2: 49.5;Karpas-707: 54.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008422, CAB022098, HPA023900" Enhanced Approved Nucleoplasm,Cytosol Cytosol Nucleoplasm "CAB022098: , HPA008422: AB_1854434, HPA023900: AB_1854435" "unprognostic (1.10e-2)" "unprognostic (1.43e-1)" "prognostic unfavourable (3.86e-4)" "unprognostic (1.53e-2)" "unprognostic (8.08e-3)" "unprognostic (2.15e-1)" "unprognostic (2.38e-3)" "unprognostic (3.98e-2)" "prognostic favourable (8.45e-5)" "unprognostic (4.04e-1)" "unprognostic (8.34e-2)" "unprognostic (4.14e-2)" "prognostic unfavourable (6.69e-12)" "unprognostic (2.37e-3)" "unprognostic (1.63e-1)" "unprognostic (4.90e-2)" "unprognostic (1.56e-1)" 14.9 10.8 5.6 43.6 7.1 40.6 18.7 2.0 4.9 12.5 20.1 4.2 9.4 11.3 18.8 11.0 12.9 10.8 20.4 10.9 4.6 2.5 15.5 14.5 20.6 34.2 6.6 2.5 15.1 17.4 5.2 6.3 12.8 7.9 19.6 5.2 7.3 16.7 15.1 13.6 10.4 14.1 24.0 7.7 28.0 13.1 6.6 5.8 19.5 11.5 14.8 39.2 21.9 24.4 5.2 1.4 7.5 3.4 1.3 2.0 0.9 21.0 13.1 2.6 10.5 3.3 5.0 6.2 6.0 19.2 6.1 8.9 7.8 17.3 9.7 15.0 3.6 12.8 6.0 8.2 2.4 49.5 3.5 2.4 3.2 4.5 9.2 1.6 14.1 6.9 4.0 10.2 10.1 2.1 2.3 54.1 2.3 7.2 2.4 6.6 3.3 4.7 5.3 7.3 7.7 10.3 6.2 0.5 2.9 4.9 11.9 8.4 9.2 4.7 6.3 6.3 9.3 8.9 15.9 35.8 33.1 10.2 10.3 4.2 3.3 0.3 2.4 0.1 1.4 1.5 1.4 5.2 1.7 1.5 1.4 4.5 1.8 1.5 7.5 1.3 3.4 0.9 2.0 0.9 5.6 7.1 2.0 4.9 4.6 2.5 6.6 2.5 7.9 5.8 NFKBIA "IkappaBalpha, IKBA, MAD-3, NFKBI" ENSG00000100906 "NFKB inhibitor alpha" P25963 14 35401511-35404749 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Host-virus interaction" "Cancer-related genes, Disease mutation, Ectodermal dysplasia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "bone marrow: 209.1" "Cell line enhanced" "Detected in all" "RT4: 83.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003815, HPA029207" Approved Enhanced Cytosol Cytosol "CAB003815: AB_344886, HPA029207: AB_10603122" "prognostic favourable (1.33e-5)" "unprognostic (3.39e-1)" "unprognostic (7.29e-2)" "unprognostic (7.24e-2)" "unprognostic (8.88e-2)" "unprognostic (1.62e-1)" "unprognostic (3.51e-1)" "unprognostic (2.46e-1)" "unprognostic (2.39e-1)" "unprognostic (2.46e-1)" "unprognostic (2.46e-1)" "unprognostic (7.19e-2)" "unprognostic (2.32e-2)" "unprognostic (3.69e-1)" "unprognostic (4.44e-2)" "unprognostic (9.74e-2)" "unprognostic (3.80e-2)" 49.0 38.5 14.9 63.7 25.7 209.1 60.8 16.1 27.8 33.8 32.8 10.3 36.7 13.5 21.3 15.6 50.4 30.5 34.3 30.9 18.8 10.5 30.6 45.1 73.0 47.7 29.7 7.8 57.4 22.1 6.5 25.3 25.5 21.8 28.7 18.6 19.5 44.2 64.6 33.1 48.2 42.3 24.9 23.0 47.4 26.1 19.6 23.9 35.0 27.8 46.2 38.1 41.8 45.2 45.3 55.0 118.2 58.3 33.2 37.3 51.7 12.9 11.5 4.3 3.9 25.7 17.1 15.6 5.4 52.0 11.7 10.5 3.6 7.8 7.8 14.5 8.5 17.1 8.2 22.4 16.9 47.8 3.2 3.9 8.3 21.2 15.4 6.1 3.2 18.6 22.7 7.9 20.4 10.5 3.2 12.7 8.3 15.2 8.0 14.8 4.0 7.1 18.3 5.0 6.5 20.1 83.5 3.9 6.8 14.4 25.3 6.0 14.3 13.1 19.6 16.1 5.8 4.6 8.6 15.5 15.7 13.4 13.4 4.6 3.3 35.8 58.3 36.6 24.2 33.4 37.3 34.0 29.3 25.4 55.0 45.3 25.6 21.7 118.2 33.2 22.1 29.7 19.5 51.7 14.9 25.7 16.1 27.8 18.8 10.5 29.7 7.8 21.8 23.9 NFKBIE IKBE ENSG00000146232 "NFKB inhibitor epsilon" O00221 6 44258166-44265788 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA002692, HPA005941, CAB010272" Supported Supported "Nucleoplasm,Nucleoli fibrillar center,Cytosol" "Nucleoli fibrillar center" "Nucleoplasm, Cytosol" "CAB010272: AB_2235977, HPA002692: AB_1079479, HPA005941: AB_1079478" "prognostic favourable (1.72e-5)" "unprognostic (1.43e-1)" "unprognostic (1.39e-2)" "unprognostic (2.37e-2)" "unprognostic (6.32e-3)" "unprognostic (1.28e-1)" "prognostic unfavourable (3.50e-4)" "unprognostic (4.88e-2)" "unprognostic (1.09e-1)" "unprognostic (3.43e-2)" "unprognostic (3.36e-1)" "unprognostic (2.60e-1)" "prognostic unfavourable (1.37e-6)" "unprognostic (2.61e-2)" "unprognostic (8.83e-2)" "unprognostic (1.37e-2)" "prognostic favourable (8.07e-4)" 5.8 5.2 7.6 24.6 5.4 24.0 5.2 9.4 7.8 3.7 8.0 4.2 3.2 6.7 4.7 5.5 6.9 3.0 9.8 4.6 7.9 5.5 11.5 8.7 15.9 17.1 6.0 4.1 6.1 7.1 3.5 4.1 6.0 4.8 7.1 5.9 3.6 7.7 4.1 3.7 7.4 9.5 3.6 5.0 29.6 6.3 7.9 3.7 14.5 5.5 4.6 22.7 6.7 6.7 8.1 8.2 7.1 10.2 0.8 3.5 1.6 14.4 3.7 5.1 8.0 2.0 1.5 2.7 2.5 12.6 8.0 8.4 7.8 6.8 7.8 9.2 2.6 3.1 5.4 8.1 9.0 13.4 3.0 4.0 1.5 8.7 6.2 13.2 12.2 3.9 3.6 7.4 4.6 5.4 3.7 20.9 2.0 7.4 2.5 27.0 2.7 2.0 4.9 4.5 7.2 18.4 15.8 3.3 4.1 1.8 6.7 10.5 4.6 15.5 9.5 4.5 5.3 2.8 8.0 13.3 5.6 14.4 4.0 14.7 8.5 7.1 8.1 3.8 1.8 9.4 3.5 8.1 2.4 1.6 6.8 7.3 1.1 1.7 3.2 0.8 10.2 8.2 3.0 1.6 7.6 5.4 9.4 7.8 7.9 5.5 6.0 4.1 4.8 3.7 NGFR "CD271, p75NTR, TNFRSF16" ENSG00000064300 "Nerve growth factor receptor" P08138 17 49495293-49515017 "Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins" "Apoptosis, Biological rhythms, Differentiation, Neurogenesis" "Developmental protein, Receptor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Group enriched" "Detected in some" 7 "RH-30: 54.7;WM-115: 60.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 7 "plasmacytoid DC: 4.2" "Lineage enriched" "Detected in single" 7 "dendritic cells: 4.2" "Low region specificity" "Detected in many" "Group enriched" "Detected in some" 5 "basal ganglia: 13.1;hypothalamus: 8.2;pons and medulla: 3.7" "CAB000143, CAB001995, HPA004765" Enhanced Approved "Nucleoplasm,Plasma membrane" 100000 Nucleoplasm "Plasma membrane" "CAB000143: , CAB001995: , HPA004765: AB_1079233" "unprognostic (6.25e-3)" "unprognostic (1.06e-3)" "unprognostic (3.39e-3)" "unprognostic (6.67e-2)" "unprognostic (1.46e-2)" "unprognostic (2.26e-1)" "unprognostic (8.22e-2)" "unprognostic (4.94e-2)" "unprognostic (1.08e-2)" "unprognostic (4.10e-3)" "unprognostic (1.85e-2)" "unprognostic (1.25e-1)" "unprognostic (3.37e-2)" "unprognostic (4.01e-2)" "unprognostic (3.06e-2)" "unprognostic (2.77e-3)" "prognostic unfavourable (3.40e-4)" 30.9 24.0 1.2 9.2 7.4 1.0 11.7 6.1 4.5 7.6 9.4 10.4 7.9 3.2 6.8 15.0 11.3 12.6 10.8 22.2 2.4 2.9 4.8 29.1 1.4 11.6 13.8 1.3 7.6 6.2 2.8 6.7 16.7 15.9 17.7 3.4 20.2 17.2 9.7 4.8 8.4 5.0 10.7 22.4 18.9 4.9 12.2 4.4 0.4 25.8 7.4 7.0 13.1 6.8 0.0 4.2 0.0 0.4 0.0 0.5 0.2 0.0 0.0 1.7 2.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 1.3 0.4 1.2 0.0 0.1 0.2 0.1 0.0 1.0 0.1 0.0 0.1 5.8 0.0 0.1 0.4 0.0 0.0 0.0 7.9 0.1 0.0 0.0 1.0 0.0 1.0 54.7 0.0 0.0 0.0 0.5 0.3 0.0 0.0 3.6 0.1 0.0 0.0 0.0 0.9 0.1 2.7 0.0 0.0 0.0 0.0 0.5 60.7 0.0 0.0 0.0 0.5 0.2 0.1 0.0 0.3 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.4 4.2 0.0 0.2 1.2 7.4 6.1 4.0 2.4 2.9 13.8 1.3 15.9 4.4 NIN ENSG00000100503 Ninein Q8N4C6 14 50719763-50831121 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cancer-related genes, Disease mutation, Dwarfism, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA005939, HPA070691" Approved Enhanced Nucleoplasm,Nucleoli,Centrosome Centrosome "Nucleoplasm, Nucleoli" "HPA005939: , HPA070691: " "unprognostic (1.98e-1)" "unprognostic (1.06e-1)" "unprognostic (3.54e-2)" "unprognostic (3.96e-1)" "unprognostic (1.52e-1)" "unprognostic (1.43e-2)" "unprognostic (3.41e-2)" "unprognostic (3.31e-1)" "unprognostic (5.81e-3)" "unprognostic (1.78e-2)" "unprognostic (2.07e-1)" "unprognostic (4.06e-1)" "unprognostic (2.46e-2)" "unprognostic (2.67e-1)" "unprognostic (1.28e-1)" "unprognostic (2.58e-2)" "unprognostic (7.66e-3)" 13.0 6.1 15.1 24.9 10.3 34.8 9.7 12.6 14.0 8.0 9.2 7.6 4.5 5.0 11.8 6.1 11.8 8.2 7.6 16.4 11.7 4.9 6.7 5.2 10.7 30.2 7.6 10.0 11.0 5.4 9.1 12.3 20.2 7.1 6.5 7.7 6.2 8.2 5.1 16.9 10.9 8.3 12.0 7.1 18.2 9.3 4.6 9.0 16.4 7.8 5.1 25.8 11.7 10.3 6.8 6.3 18.4 2.3 1.5 6.0 1.3 12.2 8.7 18.1 15.4 7.0 11.2 7.6 10.5 9.1 8.9 7.5 5.6 6.5 28.8 7.2 14.1 12.9 14.5 6.6 18.7 13.9 4.5 10.6 5.3 5.3 4.1 18.4 30.6 7.7 5.3 15.5 6.4 14.1 2.6 11.8 13.4 13.4 13.9 7.4 2.5 9.6 15.8 33.5 2.0 8.0 13.9 8.4 9.5 13.2 4.0 11.3 7.5 16.4 20.5 22.6 31.4 8.6 11.6 9.5 4.8 19.9 5.9 15.0 12.2 12.6 2.3 18.4 3.3 1.7 3.5 6.8 2.2 6.0 1.5 5.5 4.4 3.8 8.3 1.5 1.5 6.3 1.9 1.3 15.1 10.3 12.6 14.0 11.7 4.9 7.6 10.0 7.1 9.0 NKX2-1 "BCH, NKX2A, TITF1, TTF-1, TTF1" ENSG00000136352 "NK2 homeobox 1" P43699 14 36516392-36521149 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Cancer-related genes, Congenital hypothyroidism, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 18 "lung: 51.5;thyroid gland: 122.8" "Cell line enriched" "Detected in some" 28 "SCLC-21H: 47.6" "Group enriched" "Detected in some" 39 "lung cancer: 30.9;thyroid cancer: 103.2" "Group enriched" "Detected in some" 6 "basal ganglia: 2.4;hypothalamus: 2.5" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 5 "basal ganglia: 3.4;hypothalamus: 12.0" "Group enriched" "Detected in some" 13 "basal ganglia: 6.4;hypothalamus: 16.1" "CAB000078, CAB053633, HPA074316" Enhanced Uncertain "Golgi apparatus,Vesicles" "Golgi apparatus, Vesicles" "CAB000078: , CAB053633: AB_442138, HPA074316: " "unprognostic (3.79e-1)" "unprognostic (4.25e-3)" "unprognostic (1.12e-1)" "unprognostic (1.79e-2)" "unprognostic (1.26e-2)" "unprognostic (2.23e-1)" "unprognostic (1.18e-1)" "unprognostic (1.29e-1)" "unprognostic (1.83e-2)" "unprognostic (4.18e-1)" 0.1 0.1 0.0 0.0 2.4 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 2.5 0.0 0.0 51.5 0.1 0.0 0.1 0.0 0.0 0.0 4.9 0.0 0.1 0.0 0.0 0.0 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.4 0.1 0.4 0.0 122.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.6 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 47.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 2.4 0.0 0.1 0.2 2.5 0.0 0.1 0.1 0.4 NKX3-1 "BAPX2, NKX3.1, NKX3A" ENSG00000167034 "NK3 homeobox 1" Q99801 8 23678693-23682927 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Repressor" "Cancer-related genes, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "prostate: 95.3" "Cell line enhanced" "Detected in many" "SiHa: 17.5;U-138 MG: 17.8;U-251 MG: 15.2" "Cancer enriched" "Detected in many" 65 "prostate cancer: 392.7" "Low region specificity" "Detected in single" "Group enriched" "Detected in some" 7 "eosinophil: 23.5;neutrophil: 23.4" "Lineage enriched" "Detected in many" 19 "granulocytes: 23.5" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA025693, HPA078571" Enhanced Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "HPA025693: AB_1854522, HPA078571: " "unprognostic (1.47e-2)" "unprognostic (4.03e-2)" "unprognostic (2.67e-1)" "unprognostic (5.87e-2)" "unprognostic (2.56e-6)" "unprognostic (6.90e-3)" "unprognostic (1.13e-1)" "unprognostic (4.11e-3)" "unprognostic (9.42e-2)" "unprognostic (1.41e-1)" "unprognostic (3.00e-2)" "unprognostic (1.87e-1)" "unprognostic (4.37e-2)" "unprognostic (4.60e-2)" "unprognostic (3.88e-2)" "unprognostic (3.09e-2)" "unprognostic (1.69e-1)" 0.6 1.3 0.3 0.6 0.9 0.6 1.5 0.1 0.8 1.1 0.6 0.2 0.5 0.5 0.7 0.5 1.2 0.7 0.8 2.4 0.8 0.3 0.4 1.6 0.8 0.7 0.6 0.2 1.6 0.6 0.5 0.4 0.3 1.2 95.3 0.2 0.5 17.9 0.7 2.0 0.2 0.4 0.7 0.6 0.3 0.5 12.3 0.7 0.0 0.6 3.2 20.5 0.7 2.5 1.0 0.0 23.5 0.0 0.2 1.2 0.1 3.2 2.4 0.0 5.9 2.2 0.5 4.9 4.4 2.8 9.5 11.2 1.4 3.7 0.0 0.6 3.3 0.8 2.3 5.1 7.5 0.0 1.2 2.2 1.8 3.5 4.2 0.0 0.8 0.8 1.3 9.6 0.5 0.5 0.1 0.0 3.7 1.0 7.6 0.6 1.4 1.7 0.0 3.8 0.3 0.5 3.8 1.1 0.3 17.5 3.3 0.3 2.3 0.3 0.6 17.8 6.3 1.3 15.2 0.0 0.0 0.0 8.7 1.7 2.1 3.4 0.0 23.5 0.5 0.0 0.1 1.0 0.2 0.5 0.0 0.9 0.7 1.2 23.4 0.2 0.0 0.0 0.0 0.1 0.3 0.9 0.1 0.8 0.8 0.3 0.6 0.2 1.2 0.7 NLRP3 "AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1, FCAS, FCU, MWS, NALP3, PYPAF1" ENSG00000162711 "NLR family pyrin domain containing 3" Q96P20 1 247416156-247449108 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Immunity, Inflammatory response, Innate immunity, Transcription, Transcription regulation" Activator "Amyloidosis, Cancer-related genes, Deafness, Disease mutation, Non-syndromic deafness" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "blood: 40.3;bone marrow: 38.2" "Cell line enhanced" "Detected in some" "NB-4: 7.1;THP-1: 40.7;U-937: 10.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "basophil: 40.3" "Group enriched" "Detected in many" 20 "dendritic cells: 13.4;granulocytes: 40.3;monocytes: 12.5" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA012878 Uncertain "Intracellular and membrane" "HPA012878: AB_1846752" "unprognostic (3.56e-2)" "unprognostic (1.33e-1)" "unprognostic (6.23e-2)" "unprognostic (3.96e-2)" "unprognostic (1.43e-1)" "unprognostic (2.69e-1)" "unprognostic (7.86e-2)" "unprognostic (4.46e-2)" "unprognostic (3.84e-1)" "unprognostic (7.39e-2)" "unprognostic (1.04e-1)" "unprognostic (1.11e-1)" "unprognostic (1.52e-2)" "unprognostic (4.88e-3)" "unprognostic (2.17e-4)" "unprognostic (1.10e-1)" "unprognostic (6.10e-2)" 7.4 1.4 2.8 8.3 3.3 38.2 3.2 0.7 3.7 1.8 1.5 6.9 1.5 0.8 4.5 0.9 2.4 3.0 8.9 2.0 3.0 3.1 1.3 1.8 8.2 8.9 3.3 0.8 1.3 1.4 1.1 1.2 3.0 5.2 1.0 1.7 2.4 1.5 0.7 0.9 0.8 2.5 4.1 4.9 8.5 1.6 0.6 3.3 1.0 1.0 3.2 2.8 3.3 0.9 0.0 13.4 40.3 12.5 0.0 1.1 3.9 3.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.1 0.2 0.0 0.2 0.0 0.1 0.0 0.0 0.0 1.2 1.5 0.2 0.0 0.7 0.0 0.0 0.0 2.7 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 7.1 0.0 0.2 0.2 0.0 0.1 0.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 40.7 0.0 1.7 1.3 0.0 0.1 0.0 0.0 0.0 3.9 10.1 1.2 40.3 12.5 0.1 0.2 7.7 0.6 0.0 1.1 0.4 13.4 0.0 0.4 0.2 3.0 0.0 3.6 0.6 0.0 3.9 2.8 3.3 0.7 3.7 3.0 3.1 3.3 0.8 5.2 3.3 NME1 "NDPKA, NM23, NM23-H1" ENSG00000239672 "NME/NM23 nucleoside diphosphate kinase 1" P15531 17 51153536-51162428 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Differentiation, Endocytosis, Neurogenesis, Nucleotide metabolism" "Kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008467, CAB040571, HPA041113" Supported Supported "Nucleoplasm,Plasma membrane,Cytosol" "Intracellular and membrane" 28000000 Cytosol "Nucleoplasm, Plasma membrane" "CAB040571: , HPA008467: AB_1079492, HPA041113: " "unprognostic (2.24e-1)" "unprognostic (2.01e-1)" "unprognostic (3.48e-3)" "unprognostic (5.96e-2)" "unprognostic (9.71e-2)" "unprognostic (2.33e-3)" "prognostic unfavourable (2.60e-5)" "unprognostic (4.54e-2)" "unprognostic (3.35e-1)" "unprognostic (2.33e-3)" "unprognostic (2.90e-2)" "unprognostic (1.01e-1)" "prognostic unfavourable (2.07e-9)" "unprognostic (9.01e-2)" "unprognostic (1.51e-1)" "unprognostic (1.83e-1)" "unprognostic (9.46e-2)" 25.0 29.5 38.0 28.1 30.1 27.9 29.0 19.6 41.9 16.4 25.4 13.1 10.1 15.1 17.3 22.5 30.1 22.2 13.4 14.1 41.7 39.4 19.6 56.0 14.2 28.5 34.2 34.2 15.6 43.6 13.7 17.3 16.9 38.9 14.5 36.8 14.9 34.3 14.7 14.8 22.4 12.4 29.6 20.5 22.4 13.4 11.6 11.3 19.0 18.8 32.7 41.4 22.8 15.2 24.9 36.2 0.6 19.5 17.2 20.3 18.4 47.6 95.2 32.9 45.9 13.8 22.1 55.3 37.2 25.8 77.1 58.5 74.9 28.9 83.9 38.8 34.4 25.6 62.8 63.2 66.0 40.7 84.6 55.0 73.9 103.9 28.0 60.2 25.2 21.0 39.8 58.0 54.3 46.4 81.1 27.9 45.6 80.7 71.5 69.3 39.4 86.8 43.9 64.9 77.2 59.2 33.3 45.7 52.6 19.5 53.4 34.6 55.6 40.8 29.2 49.8 45.2 30.9 76.3 36.0 83.0 98.8 30.1 51.1 37.8 0.2 15.2 0.6 13.4 19.5 20.3 24.9 14.4 14.6 36.2 17.3 16.4 17.8 0.4 17.2 11.5 20.7 12.1 18.4 38.0 30.1 19.6 41.9 41.7 39.4 34.2 34.2 38.9 11.3 NME2 "NDPKB, NM23-H2" ENSG00000243678 "NME/NM23 nucleoside diphosphate kinase 2" P22392 17 51165435-51171747 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Nucleotide metabolism, Transcription, Transcription regulation" "Activator, DNA-binding, Kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "CAB036213, CAB036214, CAB036215, HPA041113" Approved Supported Nucleoplasm,Cytosol Cytosol Nucleoplasm "CAB036213: , CAB036214: , CAB036215: , HPA041113: " "unprognostic (7.21e-3)" "prognostic unfavourable (4.74e-4)" "unprognostic (4.85e-2)" "unprognostic (1.15e-2)" "unprognostic (8.86e-2)" "unprognostic (1.42e-2)" "prognostic unfavourable (7.09e-4)" "unprognostic (6.62e-3)" "unprognostic (5.68e-2)" "unprognostic (2.31e-1)" "unprognostic (1.38e-1)" "unprognostic (6.41e-2)" "prognostic unfavourable (1.55e-6)" "unprognostic (2.82e-1)" "unprognostic (9.09e-2)" "unprognostic (8.87e-2)" "unprognostic (3.19e-2)" 62.1 54.6 42.3 58.2 44.1 44.2 188.9 20.1 43.7 58.9 74.0 16.3 67.7 52.5 65.0 52.0 104.3 56.8 65.3 115.1 38.2 32.1 77.3 115.7 59.0 174.7 45.0 23.7 90.7 234.3 17.5 30.4 37.9 34.0 64.0 62.7 29.9 109.4 65.8 105.3 63.3 45.1 88.3 34.6 69.4 50.2 32.3 24.4 42.5 66.9 102.0 56.6 81.3 140.8 49.3 71.3 8.3 43.7 32.6 34.5 38.2 91.8 135.0 32.3 56.4 72.3 105.5 89.2 63.7 66.3 97.5 74.3 108.9 48.9 77.3 103.2 65.2 58.8 67.8 86.9 80.3 93.1 200.5 65.0 94.2 157.6 79.0 102.5 45.5 95.5 101.5 62.9 110.7 58.0 88.9 52.1 70.2 163.4 51.3 128.2 48.2 207.4 49.2 107.1 123.4 105.6 116.1 73.7 45.7 39.2 98.5 95.6 67.9 78.7 58.8 94.0 68.0 66.8 101.2 91.1 118.3 88.5 50.8 52.2 47.1 8.3 35.1 2.0 24.7 43.7 34.5 49.3 33.0 26.9 61.5 36.2 23.8 25.6 2.1 32.6 38.0 71.3 29.9 38.2 42.3 44.1 20.1 43.7 38.2 32.1 45.0 23.7 34.0 24.4 NONO "NMT55, NRB54, P54, P54NRB, PPP1R114" ENSG00000147140 "Non-POU domain containing octamer binding" Q15233 X 71283192-71301168 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Biological rhythms, DNA damage, DNA recombination, DNA repair, Immunity, Innate immunity, mRNA processing, mRNA splicing, Transcription, Transcription regulation" "Activator, DNA-binding, Repressor, RNA-binding" "Cancer-related genes, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB022069, HPA054094, HPA054559" Enhanced Enhanced "Nucleoplasm,Nucleoli fibrillar center,Nuclear speckles" 150000 Nucleoplasm "Nucleoli fibrillar center, Nuclear speckles" "CAB022069: , HPA054094: AB_2682376, HPA054559: AB_2682522" "unprognostic (2.39e-3)" "unprognostic (2.22e-2)" "unprognostic (2.64e-1)" "prognostic unfavourable (9.29e-4)" "unprognostic (8.87e-2)" "unprognostic (5.54e-2)" "unprognostic (1.02e-3)" "unprognostic (9.34e-2)" "unprognostic (2.32e-2)" "unprognostic (1.41e-2)" "unprognostic (3.12e-1)" "unprognostic (2.07e-1)" "unprognostic (7.29e-3)" "unprognostic (6.79e-2)" "unprognostic (5.73e-3)" "unprognostic (2.76e-2)" "unprognostic (3.04e-2)" 37.2 55.9 30.2 37.7 30.8 51.2 37.2 54.8 38.6 45.4 33.4 36.0 38.4 29.9 52.4 40.5 41.0 40.5 37.2 30.5 27.5 29.0 40.1 43.3 37.3 45.7 28.8 31.7 69.2 61.0 39.4 48.2 42.4 27.5 40.8 37.5 42.5 39.8 41.4 37.2 38.4 35.2 40.5 38.3 45.9 40.3 34.4 29.0 98.4 51.0 39.1 57.4 43.6 36.8 44.1 47.3 35.3 51.8 45.4 51.8 58.9 58.5 64.8 89.7 49.2 36.6 37.8 49.1 48.0 44.7 65.0 57.4 51.4 43.5 66.6 53.5 44.2 43.8 133.8 41.7 71.6 50.7 89.4 54.6 68.0 51.1 31.0 76.6 48.0 40.0 29.8 65.7 44.1 53.3 69.6 69.9 59.9 52.0 99.0 69.8 111.6 52.6 89.1 94.0 57.1 49.8 51.8 62.3 77.3 62.2 40.6 55.1 38.2 49.6 48.9 42.1 63.2 58.8 55.5 40.3 76.3 75.8 31.4 89.1 60.1 35.3 44.8 34.9 45.8 47.6 51.8 43.7 46.6 44.9 47.3 44.1 50.8 50.2 20.8 45.4 51.8 41.2 50.1 58.9 30.2 30.8 54.8 38.6 27.5 29.0 28.8 31.7 27.5 29.0 NOS1 "nNOS, NOS" ENSG00000089250 "Nitric oxide synthase 1" P29475 12 117208142-117452170 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Calmodulin-binding, Oxidoreductase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 6 "brain: 13.4;skeletal muscle: 36.3" "Cell line enhanced" "Detected in some" "HaCaT: 6.2;RH-30: 12.8;RPTEC TERT1: 8.0;U-2 OS: 2.5" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002167, HPA058312, HPA069509" Enhanced Supported "Nucleoplasm,Plasma membrane" "Plasma membrane" Nucleoplasm "CAB002167: AB_564073, HPA058312: , HPA069509: " "unprognostic (1.63e-1)" "unprognostic (3.14e-2)" "unprognostic (2.18e-2)" "unprognostic (6.64e-3)" "unprognostic (4.91e-2)" "unprognostic (2.74e-1)" "unprognostic (2.54e-1)" "unprognostic (9.12e-3)" "unprognostic (2.51e-1)" "unprognostic (1.10e-1)" "unprognostic (1.07e-1)" "unprognostic (7.56e-2)" "unprognostic (1.01e-1)" "unprognostic (3.73e-2)" "unprognostic (1.34e-1)" "unprognostic (5.97e-4)" "unprognostic (1.87e-1)" 0.5 0.6 3.8 3.5 13.4 0.7 0.6 4.4 4.8 0.7 2.0 1.1 0.0 0.5 0.6 0.7 1.3 0.8 0.5 0.5 2.8 4.4 1.9 0.5 1.4 0.6 2.4 1.6 0.5 1.9 0.4 0.8 0.4 5.9 1.6 0.9 0.6 3.8 0.6 36.3 2.2 0.6 0.8 1.2 0.5 0.5 0.9 3.0 0.0 0.6 0.0 0.5 0.9 0.6 0.9 0.6 2.1 0.5 0.8 0.5 0.0 0.0 0.4 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.3 0.0 6.2 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.2 1.4 0.0 12.8 0.1 8.0 0.0 0.3 1.3 0.0 0.0 0.0 0.1 0.0 0.1 0.1 2.5 0.0 0.0 0.1 0.0 0.1 0.3 0.1 0.0 2.1 0.5 0.5 0.5 0.4 0.4 0.7 0.4 0.3 0.2 0.9 0.5 0.5 1.9 0.8 0.5 0.6 0.3 0.0 3.8 13.4 4.4 4.8 2.8 4.4 2.4 1.6 5.9 3.0 NOS2 "HEP-NOS, iNOS, NOS, NOS2A" ENSG00000007171 "Nitric oxide synthase 2" P35228 17 27756766-27800499 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Calmodulin-binding, Oxidoreductase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 20.8;lymphoid tissue: 15.6" "Group enriched" "Detected in some" 8 "CACO-2: 16.6;SCLC-21H: 13.6" "Cancer enhanced" "Detected in many" "colorectal cancer: 16.0" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" CAB002014 Enhanced "CAB002014: " "unprognostic (1.95e-3)" "unprognostic (3.08e-3)" "unprognostic (4.75e-3)" "unprognostic (4.42e-3)" "unprognostic (3.49e-1)" "unprognostic (2.13e-2)" "unprognostic (5.61e-2)" "unprognostic (5.09e-2)" "unprognostic (9.91e-3)" "unprognostic (1.93e-1)" "unprognostic (2.39e-2)" "unprognostic (1.34e-1)" "unprognostic (6.04e-2)" "unprognostic (8.02e-2)" "unprognostic (3.68e-1)" "unprognostic (8.69e-2)" "unprognostic (4.03e-2)" 1.0 0.7 1.6 15.6 1.6 0.0 0.5 1.5 7.3 0.4 6.8 0.0 0.0 11.8 0.4 0.0 1.0 0.5 0.4 0.7 1.3 1.1 1.7 0.2 3.8 1.8 1.0 2.2 1.0 0.3 0.1 2.1 3.4 0.4 0.9 9.0 1.2 0.2 0.2 0.7 0.4 20.8 1.7 0.8 0.2 0.3 0.4 0.2 0.2 0.5 5.3 1.7 5.4 0.3 0.4 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.1 0.1 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 16.6 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 13.6 0.9 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.6 0.0 0.0 0.4 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 1.6 1.5 7.3 1.3 1.1 1.0 2.2 0.4 0.2 NOS3 "ECNOS, eNOS" ENSG00000164867 "Nitric oxide synthase 3" P29474 7 150990995-151014588 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Calmodulin-binding, Oxidoreductase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 70.6" "Cell line enhanced" "Detected in some" "BEWO: 11.2;HUVEC TERT2: 21.5;K-562: 7.6;TIME: 39.2" "Low cancer specificity" "Detected in all" "Group enriched" "Detected in all" 5 "basal ganglia: 32.4;cerebral cortex: 12.4;hippocampal formation: 18.8;pons and medulla: 35.3" "Low cell type specificity" "Detected in many" "Lineage enriched" "Detected in many" 5 "T-cells: 5.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB002168 Enhanced "CAB002168: AB_564072" "unprognostic (6.53e-2)" "unprognostic (3.36e-1)" "unprognostic (1.63e-2)" "unprognostic (8.46e-2)" "unprognostic (2.96e-2)" "unprognostic (1.47e-1)" "unprognostic (1.35e-1)" "unprognostic (1.36e-1)" "unprognostic (6.97e-2)" "unprognostic (2.56e-1)" "unprognostic (9.40e-2)" "unprognostic (2.36e-1)" "prognostic unfavourable (3.63e-4)" "unprognostic (1.25e-2)" "unprognostic (6.63e-2)" "unprognostic (1.05e-1)" "unprognostic (1.01e-1)" 11.4 4.5 3.1 7.5 32.4 1.9 25.6 1.8 12.4 4.6 3.2 1.7 1.0 4.0 8.3 2.5 4.7 5.0 6.6 35.2 18.8 3.4 5.5 5.4 14.0 10.3 4.7 1.7 4.5 4.1 2.7 4.8 11.5 35.3 5.2 2.5 5.2 3.0 3.2 6.0 4.9 4.0 5.4 25.9 70.6 3.6 4.5 1.6 0.0 5.9 2.1 2.4 5.1 7.3 1.1 0.5 0.7 0.4 0.5 5.3 1.2 0.2 0.0 0.6 1.9 0.0 0.0 11.2 0.0 0.0 0.0 0.0 0.1 1.0 0.2 1.0 0.0 0.3 0.0 0.0 0.0 0.0 0.2 1.0 0.1 2.9 0.3 0.2 5.0 0.0 0.1 0.0 0.0 21.5 7.6 1.8 0.0 0.0 0.1 0.2 0.8 0.0 1.4 0.0 0.8 0.0 0.1 0.2 0.2 0.1 0.7 0.0 0.1 0.6 39.2 0.1 0.4 0.1 0.0 1.2 4.0 1.0 0.0 3.5 0.0 0.3 0.3 0.2 2.5 0.4 1.5 0.8 3.9 2.2 0.5 1.1 5.3 2.1 0.7 0.5 0.4 0.5 4.4 1.2 3.1 32.4 1.8 12.4 18.8 3.4 4.7 1.7 35.3 1.6 NOTCH1 TAN1 ENSG00000148400 "Notch 1" P46531 9 136494433-136545786 "Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters" "Angiogenesis, Differentiation, Notch signaling pathway, Transcription, Transcription regulation" "Activator, Developmental protein, Receptor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HaCaT: 24.5;HMC-1: 21.3;hTCEpi: 23.6;MOLT-4: 37.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 8.8" "Group enriched" "Detected in many" 4 "granulocytes: 8.8;NK-cells: 2.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB008112, CAB022466, HPA067168" Supported Approved Nucleoplasm 8100000 Nucleoplasm "CAB008112: AB_2153490, CAB022466: , HPA067168: " "unprognostic (1.77e-1)" "unprognostic (2.65e-2)" "unprognostic (2.16e-1)" "unprognostic (8.38e-3)" "unprognostic (3.04e-1)" "unprognostic (1.13e-1)" "unprognostic (7.56e-2)" "unprognostic (1.02e-1)" "unprognostic (5.74e-3)" "unprognostic (5.50e-3)" "unprognostic (8.78e-2)" "unprognostic (8.50e-2)" "prognostic unfavourable (5.45e-4)" "unprognostic (2.14e-2)" "unprognostic (1.92e-1)" "unprognostic (5.65e-2)" "unprognostic (8.84e-2)" 20.0 4.0 10.0 14.5 10.4 14.6 12.8 3.8 18.8 12.8 14.2 19.9 8.2 9.8 11.2 5.1 13.3 9.6 13.1 9.6 10.7 5.8 9.4 7.2 17.4 13.7 11.6 7.5 9.2 17.8 3.7 5.6 8.5 9.3 12.1 5.7 10.4 14.2 11.8 8.2 32.3 10.8 7.7 6.6 20.7 8.6 4.1 9.9 34.8 9.4 10.2 10.9 12.3 22.2 0.6 1.1 8.8 1.0 2.7 1.3 0.9 4.4 7.3 6.1 3.0 0.2 0.5 7.6 2.2 0.6 1.3 0.4 1.0 0.5 5.9 4.6 1.7 24.5 2.0 10.0 0.2 13.5 1.1 3.3 3.0 0.4 3.4 3.5 21.3 0.3 23.6 1.7 3.7 7.8 1.4 1.1 0.8 7.9 37.4 5.7 5.1 3.4 7.7 4.9 11.0 0.9 3.7 0.0 0.4 3.2 3.4 1.4 2.1 5.6 11.5 3.2 4.7 3.1 2.4 1.2 1.0 2.4 2.2 2.5 16.5 0.7 1.0 2.8 1.3 0.4 0.8 0.4 0.6 1.0 0.6 0.6 0.4 1.1 8.8 2.7 0.4 1.1 0.4 0.9 10.0 10.4 3.8 11.7 10.7 5.8 11.6 7.5 9.3 9.9 NOTCH2 ENSG00000134250 "Notch 2" Q04721 1 119911553-120069626 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Differentiation, Notch signaling pathway, Transcription, Transcription regulation" "Activator, Developmental protein, Receptor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA048743 Approved Supported "Nucleoplasm,Plasma membrane" 67000000 "Nucleoplasm, Plasma membrane" "HPA048743: " "unprognostic (1.33e-1)" "unprognostic (1.43e-2)" "unprognostic (2.66e-1)" "unprognostic (1.40e-3)" "unprognostic (7.98e-2)" "unprognostic (4.01e-2)" "unprognostic (1.22e-1)" "unprognostic (7.32e-2)" "unprognostic (1.18e-2)" "prognostic unfavourable (5.24e-4)" "prognostic unfavourable (9.48e-4)" "unprognostic (3.86e-2)" "unprognostic (6.12e-3)" "unprognostic (1.55e-2)" "unprognostic (2.65e-2)" "unprognostic (1.12e-2)" "unprognostic (7.35e-3)" 12.0 7.3 6.0 9.4 6.8 4.4 10.6 3.0 5.6 14.5 7.6 4.4 11.3 1.6 12.3 11.8 13.4 11.4 12.8 7.9 6.8 2.3 5.5 11.4 10.6 5.7 5.3 7.6 15.5 27.6 6.1 3.3 10.3 6.5 9.9 5.2 9.4 17.7 10.0 9.3 17.2 6.1 12.4 6.2 11.5 5.8 15.7 4.4 8.0 11.4 8.6 6.6 9.6 13.0 4.2 5.2 7.7 9.6 1.5 1.7 2.0 14.9 5.0 7.8 6.0 32.7 28.0 7.8 11.4 15.7 15.2 16.5 4.6 4.0 0.3 9.6 21.5 5.7 12.4 10.1 24.3 17.9 7.9 8.6 13.6 0.4 12.2 9.0 2.3 22.4 6.6 45.6 30.4 7.7 0.1 19.0 18.3 16.7 3.8 2.5 10.1 5.6 2.5 27.6 9.6 8.0 9.5 0.3 3.9 15.4 14.5 8.2 8.0 3.1 27.1 19.9 13.7 29.8 17.8 7.9 3.9 4.4 29.2 8.3 18.9 5.6 6.4 6.4 1.5 6.6 1.7 4.2 1.3 1.1 5.2 3.9 1.0 1.7 7.7 1.5 9.6 4.2 0.8 2.0 6.0 6.8 3.0 5.6 6.8 2.3 5.3 7.6 6.5 4.4 NOTCH3 "CADASIL, CASIL" ENSG00000074181 "Notch 3" Q9UM47 19 15159038-15200981 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Differentiation, Notch signaling pathway, Transcription, Transcription regulation" "Activator, Developmental protein, Receptor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "AF22: 27.9;MCF7: 27.4;U-87 MG: 19.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "plasmacytoid DC: 2.4" "Group enriched" "Detected in many" 10 "dendritic cells: 2.4;granulocytes: 1.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB005393, HPA044392" Approved Supported "Nucleoplasm,Actin filaments,Cytosol" 18000000 "Nucleoplasm, Cytosol" "Actin filaments" "CAB005393: AB_2151246, HPA044392: " "unprognostic (4.97e-2)" "unprognostic (3.89e-2)" "unprognostic (7.06e-3)" "prognostic unfavourable (5.92e-4)" "unprognostic (9.20e-2)" "unprognostic (1.73e-2)" "unprognostic (2.72e-1)" "unprognostic (9.04e-2)" "unprognostic (3.90e-3)" "unprognostic (1.23e-1)" "unprognostic (1.19e-1)" "unprognostic (3.13e-1)" "prognostic unfavourable (2.53e-7)" "unprognostic (3.35e-2)" "unprognostic (8.34e-3)" "unprognostic (4.40e-2)" "unprognostic (2.00e-3)" 35.9 3.7 4.7 6.4 6.4 0.5 53.7 2.7 7.5 25.9 7.3 6.2 9.2 3.7 22.9 23.1 33.8 14.6 22.7 25.0 4.6 3.6 9.2 1.6 16.2 11.7 5.0 6.4 14.1 6.9 10.1 4.9 37.3 6.4 13.4 3.0 8.3 11.4 11.4 16.6 48.3 6.2 11.0 2.8 11.8 5.5 10.1 3.9 44.4 14.9 36.7 10.3 14.9 24.6 0.1 2.4 1.0 0.1 0.1 0.1 0.0 5.2 3.3 27.9 12.7 3.9 3.2 12.6 4.2 0.2 0.2 0.1 6.3 5.5 0.1 3.3 7.7 6.2 5.0 0.1 0.2 0.0 1.3 0.1 5.2 1.4 1.9 0.0 0.5 3.6 3.1 6.5 0.7 0.3 0.2 0.2 0.5 27.4 6.3 0.0 16.3 0.0 0.0 1.6 0.1 0.0 16.9 0.8 9.0 0.0 15.9 0.0 16.9 0.0 0.0 0.8 9.1 0.1 0.1 0.0 0.3 0.0 19.5 0.1 0.4 1.0 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.6 0.1 0.0 2.4 0.0 0.0 4.7 6.4 2.7 7.5 4.6 3.6 5.0 6.4 6.4 3.9 NPM1 "B23, NPM" ENSG00000181163 "Nucleophosmin 1" P06748 5 171387116-171411137 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Host-virus interaction" "Chaperone, RNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA011384, CAB012983" Supported Enhanced Nucleoplasm,Nucleoli 810000 Nucleoli Nucleoplasm "CAB012983: AB_2533084, HPA011384: AB_1854692" "unprognostic (1.84e-3)" "unprognostic (2.59e-1)" "unprognostic (2.23e-2)" "unprognostic (3.30e-2)" "unprognostic (2.65e-1)" "prognostic unfavourable (7.48e-4)" "prognostic unfavourable (4.82e-6)" "unprognostic (1.86e-2)" "unprognostic (5.25e-3)" "unprognostic (1.39e-1)" "unprognostic (2.26e-3)" "unprognostic (1.27e-1)" "prognostic unfavourable (2.89e-6)" "unprognostic (2.19e-1)" "unprognostic (1.17e-1)" "unprognostic (1.52e-1)" "unprognostic (1.24e-2)" 56.8 44.7 29.9 61.1 33.6 76.0 67.0 37.7 34.6 113.5 57.8 24.8 39.3 36.7 78.2 50.5 81.6 65.0 44.0 48.5 28.8 31.6 64.9 78.8 59.5 128.1 36.1 27.9 177.4 102.0 27.1 57.9 65.2 36.1 87.2 49.3 29.5 47.3 48.2 67.9 42.7 52.8 92.4 43.2 85.9 54.0 56.7 31.3 111.3 112.6 66.5 82.1 116.8 65.7 85.3 54.1 12.3 29.1 59.0 126.6 91.4 118.4 80.2 97.5 138.1 59.6 108.9 145.4 107.8 98.5 146.1 131.6 191.5 83.7 317.2 85.7 62.3 69.5 135.3 245.1 190.4 98.7 107.3 111.9 78.7 141.0 88.4 225.3 92.8 96.0 86.4 99.1 195.6 109.0 136.0 73.0 106.0 147.1 147.0 160.3 122.0 98.6 132.0 107.6 162.6 124.6 83.6 76.9 61.8 64.4 105.4 195.1 129.3 100.0 68.0 48.9 107.8 56.2 181.5 58.5 106.3 190.8 73.9 183.5 97.4 12.3 26.9 8.4 45.7 29.1 84.6 85.3 85.1 66.2 54.1 62.8 126.6 99.0 4.0 59.0 23.1 48.7 73.2 91.4 29.9 33.6 37.7 34.6 28.8 31.6 36.1 27.9 36.1 31.3 NQO1 "DHQU, DIA4, DTD, NMOR1, QR1" ENSG00000181019 "NAD(P)H quinone dehydrogenase 1" P15559 16 69706996-69726951 "Cancer-related genes, Enzymes, Predicted intracellular proteins" Oxidoreductase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "stomach 1: 142.1" "Cell line enhanced" "Detected in many" "A549: 162.9;Hep G2: 143.8;SiHa: 185.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA007308, CAB012421" Enhanced Enhanced Cytosol 310000 Cytosol "CAB012421: , HPA007308: AB_1079501" "unprognostic (1.04e-2)" "unprognostic (1.95e-3)" "unprognostic (3.14e-1)" "unprognostic (3.76e-3)" "unprognostic (9.03e-2)" "prognostic unfavourable (1.45e-4)" "unprognostic (1.05e-3)" "unprognostic (1.97e-1)" "unprognostic (5.07e-2)" "unprognostic (1.24e-2)" "unprognostic (1.49e-2)" "unprognostic (2.25e-1)" "unprognostic (2.41e-2)" "unprognostic (6.36e-2)" "unprognostic (1.45e-1)" "unprognostic (1.98e-1)" "unprognostic (3.27e-1)" 31.3 24.2 12.8 6.4 20.7 0.6 77.1 2.7 9.1 7.6 23.2 7.8 5.7 29.5 3.9 8.6 36.3 8.2 77.2 9.3 9.9 7.5 44.7 1.2 17.2 6.9 11.3 6.0 3.7 2.5 7.0 3.7 3.5 25.5 9.8 20.8 20.2 10.5 7.6 7.6 2.3 17.7 22.7 10.4 6.0 142.1 3.8 4.9 0.1 25.7 69.7 16.2 21.2 18.9 5.2 3.2 0.9 3.2 15.1 12.3 4.4 14.3 162.9 13.7 61.0 34.1 49.4 5.1 24.3 43.7 25.1 38.8 19.8 93.0 0.4 28.9 125.7 15.0 5.3 27.4 12.9 5.8 0.2 0.7 40.4 143.8 45.2 3.4 11.7 11.6 17.4 43.5 5.0 62.2 5.9 1.0 134.1 46.5 0.6 6.3 7.2 15.9 1.1 2.9 6.6 50.0 52.2 4.9 1.1 185.1 26.3 108.3 42.5 11.4 42.1 25.3 10.5 9.4 19.1 0.8 3.2 0.6 32.4 1.8 125.1 0.6 3.2 0.2 5.7 0.3 2.9 5.2 6.6 7.2 3.2 2.1 2.1 4.7 0.9 15.1 0.3 1.2 12.3 4.4 12.8 20.7 2.7 9.1 9.9 7.5 11.3 6.0 25.5 4.9 NR0B1 "AHC, AHCH, DAX1, DSS" ENSG00000169297 "Nuclear receptor subfamily 0 group B member 1" P51843 X 30304206-30309598 "Cancer-related genes, Disease related genes, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Receptor, Repressor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 8 "adrenal gland: 23.9;testis: 36.0" "Group enriched" "Detected in some" 4 "A549: 34.3;RT4: 10.8" "Cancer enhanced" "Detected in many" "lung cancer: 4.1" "Low region specificity" "Detected in some" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in some" "HPA061948, HPA067207" Supported "Nuclear speckles,Vesicles,Centriolar satellite" "Nuclear speckles" "Vesicles, Centriolar satellite" "HPA061948: , HPA067207: " "unprognostic (1.50e-2)" "unprognostic (9.68e-2)" "unprognostic (9.47e-3)" "unprognostic (1.23e-1)" "unprognostic (2.81e-1)" "unprognostic (7.45e-3)" "unprognostic (4.83e-2)" "unprognostic (9.00e-2)" "unprognostic (1.33e-3)" 0.4 23.9 1.0 0.0 0.8 0.0 0.2 0.4 1.1 1.3 0.1 1.7 0.0 0.0 0.4 0.9 0.1 0.0 0.0 0.0 0.9 0.9 0.0 0.0 0.1 0.0 0.5 0.6 3.5 2.1 0.0 1.6 0.0 0.6 0.2 0.1 0.0 0.0 0.0 0.0 0.2 0.1 0.7 0.6 0.1 0.7 36.0 0.7 0.1 0.0 0.0 0.1 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 34.3 0.0 0.0 1.3 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 3.9 0.0 1.3 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 10.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 5.0 0.0 2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.8 0.4 1.1 0.9 0.9 0.5 0.6 0.6 0.7 NR1H2 "LXR-b, NER, NER-I, RIP15, UNR" ENSG00000131408 "Nuclear receptor subfamily 1 group H member 2" P55055 19 50329653-50382982 "Cancer-related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Receptor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA005446, HPA056838, HPA070212" Uncertain Enhanced Nucleoplasm,Vesicles Nucleoplasm Vesicles "HPA005446: , HPA056838: , HPA070212: " "unprognostic (1.31e-1)" "unprognostic (5.35e-2)" "prognostic unfavourable (9.86e-4)" "unprognostic (1.34e-3)" "unprognostic (1.68e-1)" "unprognostic (5.24e-3)" "unprognostic (2.26e-2)" "unprognostic (9.69e-2)" "unprognostic (6.45e-2)" "unprognostic (5.23e-2)" "unprognostic (2.40e-1)" "unprognostic (1.88e-1)" "unprognostic (2.69e-2)" "unprognostic (1.86e-1)" "unprognostic (1.35e-1)" "unprognostic (5.12e-2)" "unprognostic (1.69e-3)" 30.1 27.5 24.5 24.7 27.5 98.0 24.4 20.6 33.5 25.1 30.9 23.1 25.2 30.9 31.2 23.1 27.9 26.9 28.7 36.8 23.8 19.4 27.1 31.4 28.3 23.3 31.7 25.9 26.5 37.6 22.0 18.6 30.5 28.1 27.9 10.5 23.2 33.8 33.8 76.2 25.3 30.3 29.9 22.9 29.9 26.7 21.2 29.1 20.4 27.1 24.4 21.7 33.2 27.6 34.1 34.2 63.0 37.7 22.3 28.6 32.5 16.0 42.2 4.1 10.3 12.1 12.8 13.2 22.2 18.9 13.2 15.1 8.7 15.6 10.3 19.9 13.3 15.0 2.6 12.1 3.2 25.7 22.7 9.9 14.2 9.0 23.3 16.3 27.1 13.4 16.6 13.5 9.2 12.0 16.1 21.5 7.4 17.8 11.6 13.4 8.3 36.3 7.0 10.7 17.9 11.3 18.0 4.6 16.1 14.4 17.9 13.9 12.3 13.6 15.1 17.7 14.4 18.0 19.7 26.9 22.2 7.5 35.3 10.8 17.7 39.1 35.9 63.0 27.7 35.0 27.0 34.1 27.4 25.9 34.2 34.1 28.6 24.9 55.4 22.3 37.7 29.5 24.4 32.5 24.5 27.5 20.6 33.5 23.8 19.4 31.7 25.9 28.1 29.1 NR4A2 "HZF-3, NOT, NURR1, RNR1, TINUR" ENSG00000153234 "Nuclear receptor subfamily 4 group A member 2" P43354 2 156324432-156342348 "Cancer-related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "seminal vesicle: 102.1" "Cell line enhanced" "Detected in many" "HeLa: 14.2;HMC-1: 10.5;U-266/70: 14.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 10.1" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA000543, CAB010481" Uncertain Supported "Nuclear speckles" "Nuclear speckles" "CAB010481: AB_2298676, HPA000543: AB_1854631" "unprognostic (4.26e-2)" "unprognostic (2.14e-1)" "unprognostic (3.42e-2)" "unprognostic (4.10e-2)" "unprognostic (3.04e-2)" "unprognostic (5.26e-2)" "unprognostic (2.30e-1)" "unprognostic (6.14e-2)" "unprognostic (8.63e-2)" "unprognostic (3.88e-2)" "unprognostic (1.60e-2)" "unprognostic (2.89e-1)" "unprognostic (2.39e-2)" "unprognostic (3.58e-2)" "unprognostic (3.43e-1)" "unprognostic (9.29e-3)" "unprognostic (1.11e-1)" 15.0 58.5 3.1 10.2 5.7 49.1 7.5 15.2 14.4 9.1 4.2 7.3 11.0 1.4 6.4 7.5 5.7 13.6 21.3 15.8 5.2 2.6 5.9 7.6 12.5 2.8 4.8 4.2 60.0 4.2 8.7 23.7 2.3 5.1 11.7 8.5 5.3 18.0 102.1 6.1 5.3 6.0 8.4 5.9 2.1 8.3 3.8 3.7 2.1 6.8 8.0 5.3 17.8 7.5 0.7 2.8 10.1 2.3 0.0 1.6 0.6 0.8 1.2 0.5 1.7 3.1 0.6 0.8 1.0 5.2 0.4 1.3 0.0 3.6 0.0 1.2 0.4 1.5 2.5 0.7 0.4 1.2 1.3 0.9 14.2 0.0 0.6 0.8 10.5 0.6 1.1 0.4 0.4 0.3 1.4 1.0 1.0 1.7 0.0 0.8 2.2 0.9 0.2 0.7 3.0 0.6 0.8 2.6 0.1 2.5 3.9 6.9 0.2 0.9 0.7 2.8 0.8 0.7 0.4 14.2 1.5 0.0 5.2 0.9 6.6 3.0 2.3 3.4 1.6 0.5 0.9 0.7 0.5 0.8 2.8 0.5 0.9 0.4 10.1 0.0 0.9 0.0 0.5 0.6 3.1 5.7 15.2 14.4 5.2 2.6 4.8 4.2 5.1 3.7 NR4A3 "CHN, CSMF, MINOR, NOR1" ENSG00000119508 "Nuclear receptor subfamily 4 group A member 3" Q92570 9 99821855-99866891 "Cancer-related genes, Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "seminal vesicle: 80.6" "Group enriched" "Detected in some" 5 "BJ hTERT+: 21.0;HeLa: 7.3;SK-MEL-30: 14.5;U-266/70: 8.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "eosinophil: 1.3;NK-cell: 1.3" "Group enriched" "Detected in many" 6 "granulocytes: 1.3;NK-cells: 1.3" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA043360 Uncertain "HPA043360: AB_10961186" "prognostic favourable (5.97e-4)" "unprognostic (6.92e-3)" "unprognostic (5.34e-2)" "unprognostic (2.78e-3)" "unprognostic (1.40e-1)" "unprognostic (9.46e-2)" "unprognostic (2.89e-2)" "unprognostic (3.30e-2)" "unprognostic (2.65e-3)" "unprognostic (1.40e-2)" "unprognostic (2.28e-1)" "unprognostic (3.30e-1)" "unprognostic (2.25e-1)" "unprognostic (1.29e-3)" "unprognostic (6.11e-2)" "unprognostic (2.80e-2)" "unprognostic (1.69e-1)" 19.9 46.5 3.5 10.2 4.5 22.1 5.9 1.6 5.0 9.7 4.8 9.5 6.3 0.8 10.7 6.1 3.1 15.7 16.6 37.3 4.1 2.5 3.8 7.1 12.4 1.2 1.6 3.1 37.2 4.0 4.0 12.2 4.7 5.0 12.0 3.2 7.0 1.6 80.6 28.5 1.5 4.2 23.0 5.1 2.6 9.0 1.3 3.4 7.6 4.2 15.5 1.9 23.5 7.5 0.0 0.2 1.3 0.0 1.3 0.0 0.0 0.1 0.1 0.6 0.1 1.2 0.4 1.0 1.3 21.0 0.2 0.2 0.2 0.1 0.1 0.3 0.5 0.1 0.4 0.0 0.1 1.8 0.3 0.1 7.3 0.0 0.1 0.1 2.0 0.3 0.0 0.5 0.1 0.0 0.0 0.5 0.1 0.6 0.0 0.2 0.0 0.6 0.0 0.9 0.0 0.0 0.1 0.4 0.4 2.3 1.7 14.5 0.0 0.0 0.1 1.4 0.4 1.7 0.1 8.6 0.1 0.0 0.9 0.0 0.8 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.8 1.3 0.0 0.0 0.0 0.0 3.5 4.5 1.6 5.0 4.1 2.5 1.6 3.1 5.0 3.4 NRAS N-ras ENSG00000213281 "NRAS proto-oncogene, GTPase" P01111 1 114704469-114716894 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, RAS pathway related proteins" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010157, HPA049830" Uncertain 4800000 "CAB010157: AB_632073, HPA049830: " "unprognostic (4.75e-2)" "unprognostic (2.81e-1)" "unprognostic (1.09e-3)" "unprognostic (2.11e-2)" "unprognostic (8.59e-3)" "unprognostic (1.14e-1)" "prognostic unfavourable (3.03e-7)" "unprognostic (7.76e-3)" "unprognostic (1.57e-2)" "unprognostic (1.01e-3)" "prognostic unfavourable (1.36e-4)" "unprognostic (6.60e-3)" "prognostic unfavourable (7.87e-4)" "unprognostic (2.68e-1)" "unprognostic (1.30e-1)" "unprognostic (1.16e-1)" "unprognostic (3.33e-2)" 18.0 9.7 13.1 16.5 14.4 33.5 12.4 9.7 16.6 10.0 18.4 15.8 3.8 14.4 9.8 6.2 19.7 8.7 11.8 7.1 11.7 13.8 24.0 23.9 13.4 18.7 15.3 9.6 10.3 14.2 8.3 7.6 27.4 19.0 9.2 18.5 8.4 12.4 5.2 7.9 16.1 23.4 9.6 20.9 19.5 14.4 9.8 9.7 45.0 11.1 14.0 19.6 13.2 10.5 11.0 9.9 23.7 15.0 12.1 11.1 10.1 24.4 6.6 17.9 6.7 7.4 15.9 12.8 11.7 13.1 21.9 24.7 13.3 9.1 18.6 15.6 15.7 7.0 23.9 18.9 31.5 25.3 9.3 12.6 10.1 15.8 14.7 31.2 19.6 14.3 15.4 25.1 18.4 27.8 20.0 21.4 19.3 65.4 21.5 12.1 30.3 4.8 16.5 31.8 11.5 19.4 13.2 10.8 16.3 12.0 9.9 28.1 8.7 25.4 21.2 12.0 22.9 22.3 23.9 37.9 26.1 21.8 24.0 17.1 43.0 23.7 10.0 9.6 9.8 15.0 8.9 11.0 8.0 9.7 9.9 8.8 8.7 11.1 2.7 12.1 12.7 7.7 10.4 10.1 13.1 14.4 9.7 16.6 11.7 13.8 15.3 9.6 19.0 9.7 NRG1 "GGF, HGL, HRG, NDF, NRG1-IT2" ENSG00000157168 "Neuregulin 1" Q02297 8 31639386-32767959 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" "Growth factor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 28.3" "Cell line enhanced" "Detected in many" "A549: 38.9;BJ: 26.6;fHDF/TERT166: 29.8;HBF TERT88: 26.2;hTEC/SVTERT24-B: 27.9;hTERT-HME1: 29.3" "Cancer enhanced" "Detected in many" "head and neck cancer: 4.4" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in some" 5 "classical monocyte: 22.8" "Lineage enriched" "Detected in many" 5 "monocytes: 22.8" "Low region specificity" "Detected in all" HPA010964 Uncertain Approved Nucleoplasm "Secreted to blood" Nucleoplasm "HPA010964: AB_1854641" "unprognostic (5.76e-3)" "unprognostic (8.60e-2)" "unprognostic (1.96e-4)" "unprognostic (2.67e-1)" "unprognostic (1.94e-4)" "unprognostic (4.99e-2)" "unprognostic (6.69e-2)" "unprognostic (7.72e-2)" "unprognostic (2.98e-1)" "unprognostic (5.65e-2)" "unprognostic (7.99e-2)" "unprognostic (8.49e-2)" "unprognostic (4.47e-2)" "unprognostic (1.31e-1)" "unprognostic (2.88e-1)" "unprognostic (5.40e-2)" "unprognostic (7.83e-2)" 0.7 2.1 4.6 5.0 3.3 1.2 8.8 14.8 8.1 10.6 4.2 0.3 2.1 3.5 2.5 1.1 3.7 2.0 4.8 2.2 4.7 15.4 11.5 23.6 5.7 0.6 6.2 3.5 2.9 0.9 0.8 23.9 0.2 28.3 3.2 5.4 3.6 2.5 1.6 0.2 4.3 5.7 1.1 2.5 1.7 3.1 6.4 0.8 0.2 13.8 7.2 2.2 7.2 3.5 0.0 4.9 0.8 22.8 0.0 0.0 4.6 0.1 38.9 0.7 0.0 0.3 0.8 0.0 26.6 18.9 22.1 16.9 0.0 0.8 0.0 4.9 29.8 21.0 0.2 10.6 26.2 0.0 0.2 0.5 0.5 0.5 0.1 0.0 0.0 0.3 1.1 27.9 29.3 12.7 0.0 0.1 7.9 0.0 0.0 0.0 0.9 0.0 0.0 0.2 0.0 16.3 1.1 1.1 1.3 2.0 0.0 0.0 0.0 0.0 9.2 15.4 4.7 24.5 14.8 0.0 0.0 0.2 7.9 0.0 1.8 0.0 22.8 0.2 0.0 2.1 0.0 0.0 0.0 0.0 4.9 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 4.6 4.6 3.3 14.8 8.1 4.7 15.4 6.2 3.5 28.3 0.8 NRG2 "Don-1, HRG2, NTAK" ENSG00000158458 "Neuregulin 2" O14511 5 139846779-140043299 "Cancer-related genes, Predicted membrane proteins, Predicted secreted proteins" "Growth factor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 27.3" "Cell line enhanced" "Detected in some" "AN3-CA: 8.3;Karpas-707: 5.5;PC-3: 14.5;RPTEC TERT1: 7.4;SCLC-21H: 5.5" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "gdT-cell: 2.1" "Lineage enriched" "Detected in single" 4 "T-cells: 2.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA038935, HPA047973" Approved Supported Nucleoplasm,Nucleoli "Secreted to blood" Nucleoplasm Nucleoli "HPA038935: AB_10672833, HPA047973: " "unprognostic (8.66e-4)" "unprognostic (2.17e-1)" "unprognostic (1.21e-1)" "unprognostic (6.04e-2)" "unprognostic (3.22e-1)" "unprognostic (2.96e-2)" "unprognostic (8.66e-3)" "unprognostic (1.11e-1)" "unprognostic (3.99e-1)" "unprognostic (1.88e-1)" "unprognostic (4.26e-3)" "unprognostic (4.00e-2)" "unprognostic (7.79e-3)" "unprognostic (3.64e-3)" "unprognostic (9.54e-2)" "unprognostic (2.23e-2)" "unprognostic (2.07e-2)" 4.5 4.5 4.0 1.4 7.0 0.6 4.4 27.3 5.1 13.1 2.3 3.8 2.6 1.0 3.0 2.9 3.7 7.6 7.6 1.5 4.2 3.5 1.3 0.6 1.2 2.1 5.2 3.4 15.9 3.2 15.8 7.7 1.1 4.1 4.5 0.9 2.9 13.6 4.7 6.0 5.0 1.0 5.1 3.6 3.3 1.1 2.7 4.9 0.0 0.8 1.0 1.5 4.8 3.7 0.4 0.1 0.0 0.1 0.0 2.1 0.1 0.0 1.9 0.2 8.3 0.0 0.0 0.0 0.0 0.3 0.3 0.1 0.0 0.1 0.0 0.4 0.0 2.4 0.4 0.2 0.1 4.7 3.6 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.3 0.5 0.2 0.0 5.5 0.0 0.4 0.0 0.0 0.1 14.5 0.1 0.0 0.0 7.4 1.7 5.5 3.3 0.0 3.2 3.3 0.0 0.0 0.2 2.5 0.4 0.0 1.6 1.1 0.0 0.0 3.6 0.0 0.7 0.0 0.0 0.0 2.1 0.1 0.5 0.1 0.2 0.4 0.0 0.4 0.4 1.2 0.0 0.0 0.0 0.1 0.0 0.1 4.0 7.0 27.3 5.1 4.2 3.5 5.2 3.4 4.1 4.9 NRG3 ENSG00000185737 "Neuregulin 3" P56975 10 81875314-82987179 "Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins" "Growth factor" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 30.6" "Cell line enhanced" "Detected in some" "AF22: 1.5;HEK 293: 3.3;HUVEC TERT2: 1.6;SK-MEL-30: 7.2;U-2 OS: 6.3" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA075789 Uncertain Vesicles "Secreted in brain" Vesicles "HPA075789: " "unprognostic (6.15e-3)" "unprognostic (2.43e-2)" "unprognostic (1.65e-5)" "unprognostic (1.89e-1)" "unprognostic (7.03e-4)" "unprognostic (1.85e-2)" "unprognostic (1.06e-1)" "unprognostic (7.05e-2)" "unprognostic (9.33e-2)" "unprognostic (1.82e-1)" "unprognostic (1.21e-1)" "unprognostic (3.75e-2)" "unprognostic (3.31e-4)" "unprognostic (1.04e-1)" "unprognostic (7.68e-3)" "unprognostic (7.27e-4)" 0.9 1.5 15.6 1.2 8.2 0.6 2.8 1.9 30.6 0.8 0.9 4.8 0.0 0.8 0.7 0.7 0.9 8.0 5.3 0.9 14.5 6.2 1.2 1.5 1.6 0.8 4.9 8.0 0.7 0.9 0.7 1.6 1.2 6.5 0.9 0.9 3.1 5.0 1.1 0.7 0.8 0.9 0.9 5.6 0.8 0.8 3.3 6.0 0.0 0.9 0.0 0.8 1.1 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.2 0.0 0.4 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.4 0.0 1.0 0.0 0.0 7.2 0.0 0.0 0.0 0.0 6.3 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.6 8.2 1.9 12.8 14.5 6.2 4.9 8.0 6.5 6.0 NRP1 "CD304, NRP, VEGF165R" ENSG00000099250 "Neuropilin 1" O14786 10 33177492-33336262 "Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" "Angiogenesis, Differentiation, Neurogenesis" "Developmental protein, Heparin-binding, Receptor" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "fHDF/TERT166: 69.8;TIME: 58.0;U-87 MG: 69.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in some" 14 "plasmacytoid DC: 24.0" "Lineage enriched" "Detected in many" 14 "dendritic cells: 24.0" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB004511, HPA030278" Approved "Secreted in other tissues" 720000000 "CAB004511: AB_2282634, HPA030278: AB_10601976" "unprognostic (3.19e-1)" "prognostic unfavourable (7.10e-5)" "unprognostic (1.50e-2)" "unprognostic (3.80e-2)" "prognostic unfavourable (5.79e-4)" "unprognostic (6.17e-2)" "unprognostic (1.46e-2)" "unprognostic (1.08e-1)" "unprognostic (6.66e-2)" "unprognostic (2.52e-1)" "unprognostic (1.82e-1)" "unprognostic (4.78e-2)" "prognostic unfavourable (3.87e-4)" "prognostic unfavourable (1.22e-5)" "unprognostic (3.83e-2)" "unprognostic (5.48e-2)" "unprognostic (7.79e-2)" 69.9 15.0 4.9 13.6 4.9 0.7 53.8 1.3 5.6 25.1 17.6 2.4 16.4 6.7 29.8 21.9 14.7 17.0 23.3 50.5 17.2 5.9 47.1 27.4 47.1 30.1 3.5 3.2 27.1 14.1 11.7 6.4 44.3 3.6 25.2 7.8 24.3 11.8 31.6 22.3 9.1 14.6 19.1 5.5 38.7 9.8 15.6 2.8 5.9 30.4 24.6 7.9 22.3 23.8 0.4 24.0 0.3 1.7 0.6 0.4 0.4 8.7 34.0 1.7 0.1 33.2 37.2 0.2 35.2 34.3 17.8 19.1 4.3 20.9 0.1 4.2 69.8 2.4 2.1 10.2 14.5 0.1 1.7 0.0 3.9 7.3 11.7 3.1 0.2 44.4 1.7 42.2 19.1 48.2 0.1 0.2 34.6 14.7 0.2 0.5 0.8 32.3 1.4 3.8 0.1 16.7 0.1 0.8 0.4 3.6 2.7 0.1 0.1 0.4 58.0 25.4 6.0 30.5 23.7 0.1 0.1 0.1 69.5 4.0 22.9 0.2 1.7 0.3 0.3 0.3 0.4 0.4 0.3 0.3 1.4 0.3 0.4 0.3 0.3 0.6 0.1 24.0 0.3 0.4 4.9 4.9 1.3 5.6 17.2 5.9 3.5 3.2 3.6 2.8 NRP2 VEGF165R2 ENSG00000118257 "Neuropilin 2" O60462 2 205681990-205798133 "Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins" "Differentiation, Host-virus interaction, Neurogenesis" "Developmental protein, Heparin-binding, Receptor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "CAPAN-2: 34.2;HUVEC TERT2: 30.0;TIME: 28.6;U-251 MG: 58.5;U-87 MG: 27.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "classical monocyte: 1.8;naive B-cell: 1.4" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA039980, HPA054974" Enhanced Supported "Vesicles,Plasma membrane" "Secreted in other tissues" 15000000 "Vesicles, Plasma membrane" "HPA039980: AB_10795517, HPA054974: " "unprognostic (4.28e-2)" "unprognostic (1.17e-1)" "unprognostic (8.12e-3)" "unprognostic (3.38e-1)" "unprognostic (1.62e-1)" "unprognostic (1.57e-2)" "unprognostic (9.36e-2)" "unprognostic (3.70e-1)" "unprognostic (2.15e-3)" "unprognostic (2.90e-2)" "unprognostic (2.56e-3)" "unprognostic (4.17e-1)" "prognostic unfavourable (7.68e-7)" "unprognostic (2.22e-3)" "unprognostic (5.45e-2)" "unprognostic (6.41e-3)" "prognostic unfavourable (7.80e-5)" 24.3 14.5 8.7 11.4 7.4 2.6 7.8 1.2 7.0 34.4 35.4 3.9 8.4 3.5 33.7 4.6 24.8 13.1 25.8 4.4 11.5 8.3 3.4 6.2 15.8 4.9 8.9 3.9 33.0 1.4 2.5 6.6 29.9 9.0 18.6 7.0 27.7 2.6 21.0 2.5 3.3 8.2 44.7 8.6 4.7 17.1 3.4 5.2 2.6 7.3 6.0 3.0 39.3 24.6 1.4 0.5 0.0 1.8 0.0 0.0 0.5 0.6 14.1 9.0 0.0 8.2 2.6 2.6 2.2 4.3 2.8 2.7 13.3 34.2 0.0 3.4 7.1 5.4 0.4 4.3 4.6 0.0 1.9 0.1 0.6 0.1 22.2 0.0 0.5 19.5 3.3 3.9 3.5 30.0 0.0 0.0 1.9 0.0 0.0 0.0 11.3 2.5 0.0 0.5 3.1 5.7 0.0 8.1 0.3 0.3 0.0 20.2 0.0 0.1 28.6 12.4 0.1 3.2 58.5 0.0 0.0 0.8 27.6 0.0 25.9 0.0 1.8 0.0 0.0 0.4 0.0 0.2 0.0 0.0 0.5 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 8.7 7.4 1.2 3.8 11.5 8.3 8.9 3.9 9.0 5.2 NSD1 "ARA267, FLJ22263, KMT3B, STO" ENSG00000165671 "Nuclear receptor binding SET domain protein 1" Q96L73 5 177133025-177300215 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Transcription, Transcription regulation" "Activator, Chromatin regulator, Methyltransferase, Repressor, Transferase" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA048431, HPA070333, HPA073705" Supported Supported "Nucleoplasm,Plasma membrane" "Nucleoplasm, Plasma membrane" "HPA048431: , HPA070333: , HPA073705: " "unprognostic (3.48e-2)" "unprognostic (7.46e-2)" "unprognostic (7.14e-3)" "unprognostic (2.64e-3)" "unprognostic (1.38e-1)" "unprognostic (9.67e-2)" "unprognostic (2.29e-2)" "unprognostic (7.08e-2)" "unprognostic (1.68e-3)" "unprognostic (8.04e-2)" "unprognostic (1.48e-1)" "unprognostic (2.09e-1)" "unprognostic (7.77e-3)" "unprognostic (3.53e-2)" "unprognostic (1.01e-1)" "unprognostic (7.51e-2)" "unprognostic (7.32e-2)" 11.8 13.2 11.9 25.4 15.7 23.9 14.0 28.9 16.7 15.6 14.2 18.5 17.0 10.6 19.0 13.9 17.8 13.6 15.8 11.7 12.8 11.5 14.4 10.5 12.3 19.4 12.9 11.7 16.6 27.1 24.6 19.3 16.0 13.4 14.2 14.3 13.8 13.5 18.7 20.6 16.1 14.5 15.6 13.2 16.1 13.1 28.1 16.1 27.3 20.1 10.6 22.7 13.4 20.2 10.2 8.9 18.7 10.8 10.9 7.8 2.9 9.7 12.6 13.1 11.3 6.4 8.3 0.4 8.8 8.9 12.4 11.6 2.8 8.2 20.1 10.0 12.1 8.4 20.8 19.6 15.1 34.0 12.6 8.9 14.2 0.1 10.7 19.2 10.6 7.8 11.9 14.7 13.8 18.0 12.1 7.1 12.5 20.4 13.3 6.2 14.2 11.1 14.8 1.7 6.2 8.0 11.8 15.9 11.0 22.9 10.0 6.9 10.0 16.0 13.3 8.7 12.6 5.5 10.9 8.3 7.2 14.4 5.0 9.4 9.3 10.7 9.1 9.4 7.5 6.1 6.3 8.5 6.3 5.0 6.7 10.2 7.8 6.3 18.7 10.9 10.8 8.9 5.7 2.9 11.9 15.7 28.9 16.7 12.8 11.5 12.9 11.7 13.4 16.1 NSD2 "KMT3G, MMSET, WHSC1" ENSG00000109685 "Nuclear receptor binding SET domain protein 2" O96028 4 1871424-1982207 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Chromatin regulator, DNA-binding, Methyltransferase, Transferase" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA015801, CAB068246, CAB068247" Enhanced Supported Nucleoplasm Nucleoplasm "CAB068246: , CAB068247: , HPA015801: AB_1858830" "unprognostic (3.70e-1)" "unprognostic (9.80e-2)" "unprognostic (3.33e-2)" "unprognostic (1.77e-1)" "unprognostic (4.01e-1)" "unprognostic (1.31e-2)" "prognostic unfavourable (2.61e-4)" "unprognostic (3.24e-2)" "unprognostic (6.22e-2)" "unprognostic (7.66e-2)" "unprognostic (2.09e-1)" "unprognostic (9.25e-3)" "prognostic unfavourable (7.19e-4)" "unprognostic (3.89e-2)" "unprognostic (2.95e-1)" "unprognostic (1.31e-1)" "unprognostic (6.15e-2)" 8.7 7.6 17.6 11.5 16.2 35.1 8.5 20.6 18.2 7.0 14.8 12.4 6.3 14.0 9.5 7.4 12.7 6.8 6.9 11.9 15.1 10.9 8.4 7.5 11.1 18.8 14.7 16.1 7.0 11.7 10.7 11.8 9.8 14.6 8.7 17.7 9.4 10.2 7.4 11.8 12.1 14.6 10.5 15.3 13.5 11.0 26.3 13.4 46.7 13.8 5.5 17.7 8.6 9.4 4.9 3.9 4.1 1.8 2.7 4.3 0.6 27.4 13.9 41.9 18.3 4.5 6.7 12.2 22.2 19.7 27.2 30.5 12.2 32.6 29.6 7.6 18.3 12.0 27.0 18.3 46.8 14.2 11.1 35.2 19.2 7.2 5.7 21.5 18.5 2.6 4.6 23.9 23.0 21.4 19.0 31.1 22.3 10.8 57.5 22.6 17.6 16.0 32.9 27.3 10.2 11.2 13.0 26.0 20.8 18.2 6.8 8.3 16.1 14.5 16.5 27.2 20.3 17.2 44.6 14.6 15.4 26.8 16.3 21.4 25.2 2.1 1.7 1.7 2.9 1.8 3.2 1.8 3.2 3.2 1.5 4.9 2.8 2.3 4.1 2.7 1.4 3.9 4.3 0.6 17.6 16.2 20.6 18.2 15.1 10.9 14.7 16.1 14.6 13.4 NSD3 "FLJ20353, KMT3F, WHISTLE, WHSC1L1" ENSG00000147548 "Nuclear receptor binding SET domain protein 3" Q9BZ95 8 38269697-38382272 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Transcription, Transcription regulation" "Chromatin regulator, Methyltransferase, Transferase" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA005659, CAB013721, HPA018893" Uncertain Approved Nucleoplasm,Mitochondria Mitochondria Nucleoplasm "CAB013721: , HPA005659: AB_1080596, HPA018893: AB_1858833" "unprognostic (6.21e-2)" "unprognostic (3.73e-2)" "unprognostic (2.18e-2)" "unprognostic (4.12e-1)" "unprognostic (2.25e-1)" "unprognostic (1.53e-2)" "unprognostic (4.35e-2)" "unprognostic (1.97e-2)" "unprognostic (2.49e-1)" "unprognostic (5.72e-2)" "prognostic unfavourable (7.48e-4)" "unprognostic (5.06e-2)" "unprognostic (5.60e-3)" "unprognostic (6.69e-2)" "unprognostic (4.04e-1)" "unprognostic (1.05e-2)" "unprognostic (1.60e-2)" 19.2 11.3 31.1 15.8 31.4 36.3 20.1 51.5 37.7 18.5 15.5 16.7 14.0 16.2 16.0 12.5 17.0 16.8 17.0 12.7 24.4 16.6 14.2 11.2 17.9 22.3 25.0 26.8 26.5 16.3 21.0 24.2 22.5 21.9 16.4 18.7 12.3 18.3 17.9 12.3 16.2 17.7 16.0 15.3 17.2 19.7 9.3 25.6 16.7 19.2 6.9 20.4 19.6 23.3 26.7 5.6 26.2 5.1 8.6 18.0 2.9 23.9 13.8 23.7 16.0 16.6 19.2 17.6 20.1 22.3 17.4 20.3 7.3 13.3 28.6 18.5 13.7 14.4 18.7 16.1 24.9 11.3 11.0 36.4 11.1 8.6 17.1 16.0 13.2 10.3 16.4 15.7 32.1 20.0 25.8 19.0 16.5 8.6 46.7 13.6 16.1 6.5 21.4 25.9 9.0 12.4 18.6 13.4 18.1 16.3 14.3 14.0 18.1 12.2 19.0 18.2 18.9 27.0 11.8 17.0 20.2 27.6 15.3 16.2 13.1 13.9 5.1 9.1 8.0 2.4 5.3 16.5 12.0 7.1 4.1 26.7 15.0 6.3 26.2 8.6 1.5 5.6 18.0 2.9 31.1 31.4 51.5 37.7 24.4 16.6 25.0 26.8 21.9 25.6 NT5C2 "cN-II, GMP, NT5B, PNT5, SPG65" ENSG00000076685 "5'-nucleotidase, cytosolic II" P49902 10 103088017-103193306 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Nucleotide metabolism" "Allosteric enzyme, Hydrolase" "Cancer-related genes, Disease mutation, Hereditary spastic paraplegia, Neurodegeneration" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA003751 Approved "HPA003751: AB_1854664" "unprognostic (8.18e-2)" "unprognostic (1.98e-1)" "unprognostic (2.55e-2)" "unprognostic (2.46e-1)" "unprognostic (5.54e-2)" "unprognostic (4.87e-3)" "unprognostic (2.24e-2)" "unprognostic (1.72e-1)" "unprognostic (6.41e-2)" "unprognostic (9.59e-2)" "unprognostic (2.93e-3)" "unprognostic (6.20e-2)" "unprognostic (3.26e-2)" "unprognostic (3.70e-2)" "unprognostic (6.40e-2)" "unprognostic (3.43e-1)" "unprognostic (1.50e-1)" 15.0 17.0 17.6 18.2 21.2 31.6 19.7 22.5 19.6 17.5 20.7 25.4 24.5 10.9 24.6 19.6 38.6 14.8 17.0 16.5 16.7 20.7 19.6 15.5 18.8 16.8 21.8 17.3 24.8 19.4 18.7 29.5 16.9 29.1 22.9 17.0 26.2 67.2 21.6 41.6 11.7 13.9 20.4 19.1 20.5 15.9 21.7 14.5 29.7 39.2 16.3 31.5 21.1 31.1 6.7 9.7 23.8 14.5 10.5 8.7 7.1 50.1 20.4 14.2 31.9 12.5 14.0 8.1 25.2 24.5 12.3 12.7 14.8 40.2 24.0 19.6 17.4 25.7 9.4 12.9 14.4 14.5 8.8 17.3 8.7 14.4 22.4 25.0 8.6 21.4 14.4 10.7 17.3 11.2 11.2 16.8 21.2 29.6 22.3 32.4 13.5 25.3 36.5 12.3 6.9 17.6 28.7 4.3 10.7 13.2 10.4 19.7 15.9 19.4 11.4 9.8 9.8 14.0 18.3 14.7 24.4 32.2 9.9 28.9 2.8 19.8 11.7 23.8 8.1 11.9 8.7 6.7 7.0 6.5 9.7 4.2 6.0 6.2 21.4 10.5 14.5 7.3 6.5 7.1 17.6 21.2 22.5 18.0 16.7 20.7 21.8 17.3 29.1 14.5 NTF3 NGF2 ENSG00000185652 "Neurotrophin 3" P20783 12 5432112-5521536 "Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins" "Growth factor" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 29.2" "Cell line enhanced" "Detected in some" "BJ hTERT+: 9.0;BJ hTERT+ SV40 Large T+: 11.9;BJ hTERT+ SV40 Large T+ RasG12V: 15.8;HBF TERT88: 14.7;RT4: 6.7" "Low cancer specificity" "Detected in some" "Region enriched" "Detected in some" 16 "cerebellum: 29.2" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in many" 5 "amygdala: 4.1;basal ganglia: 7.4;cerebellum: 12.3;hippocampal formation: 12.3" "Low region specificity" "Detected in all" HPA032001 Uncertain Approved Vesicles "Secreted in other tissues" Vesicles "HPA032001: " "unprognostic (3.04e-2)" "unprognostic (7.46e-2)" "unprognostic (7.33e-3)" "unprognostic (4.66e-3)" "unprognostic (8.89e-2)" "unprognostic (1.08e-2)" "unprognostic (1.36e-3)" "unprognostic (7.68e-2)" "unprognostic (1.35e-1)" "unprognostic (2.14e-1)" "unprognostic (1.86e-1)" "unprognostic (2.20e-1)" "unprognostic (7.77e-4)" "unprognostic (4.02e-3)" "unprognostic (1.92e-1)" "unprognostic (8.06e-3)" "unprognostic (4.51e-3)" 4.9 2.7 0.5 2.4 0.5 0.0 5.4 29.2 0.6 12.9 4.7 0.3 5.6 2.7 9.2 6.8 5.0 2.2 5.3 4.1 1.7 0.2 4.3 10.4 2.5 1.0 0.7 0.2 16.8 0.4 0.1 1.3 2.7 1.2 8.9 1.5 8.9 4.6 3.7 3.6 3.7 6.6 11.5 0.4 8.5 3.0 3.5 0.0 0.2 1.2 3.9 2.0 10.4 9.1 0.4 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 5.4 0.0 0.0 0.0 0.0 3.4 9.0 11.9 15.8 0.1 0.2 0.0 5.4 5.6 1.9 0.0 0.0 14.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 2.7 0.0 0.0 0.0 1.5 0.0 0.0 0.0 3.5 3.7 6.7 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 2.5 0.1 0.0 0.1 0.0 0.6 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.5 29.2 0.6 1.7 0.2 0.7 0.2 1.2 0.0 NTF4 "GLC1O, NT-4/5, NTF5" ENSG00000225950 "Neurotrophin 4" P34130 19 49061066-49065054 "Cancer-related genes, Disease related genes, Predicted secreted proteins, RAS pathway related proteins" "Growth factor" "Cancer-related genes, Glaucoma" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "skin 1: 24.3" "Cell line enhanced" "Detected in some" "CAPAN-2: 8.1;HaCaT: 18.3;HBEC3-KT: 6.8;hTCEpi: 30.3" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in single" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA049376 Approved "Golgi apparatus" "Secreted in other tissues" "Golgi apparatus" "HPA049376: " "unprognostic (4.15e-2)" "unprognostic (1.07e-1)" "unprognostic (9.27e-4)" "unprognostic (1.76e-4)" "unprognostic (2.36e-1)" "unprognostic (1.02e-2)" "unprognostic (1.60e-1)" "unprognostic (2.73e-2)" "unprognostic (4.87e-3)" "unprognostic (3.90e-4)" "unprognostic (2.97e-1)" "unprognostic (1.40e-3)" "unprognostic (3.71e-2)" "unprognostic (2.49e-1)" "unprognostic (1.89e-2)" "unprognostic (2.46e-3)" 0.3 0.0 0.3 0.3 0.3 0.0 3.6 0.3 1.0 2.8 0.3 0.3 5.7 0.0 0.3 8.0 7.1 1.7 0.3 0.3 0.3 0.0 0.3 0.3 3.3 0.3 0.3 0.3 0.3 0.3 0.0 2.3 3.0 0.3 11.9 0.0 0.3 5.7 6.1 11.9 24.3 0.3 1.4 0.3 0.3 0.0 1.3 0.3 1.4 0.9 2.3 2.2 6.2 5.6 0.0 0.4 0.0 0.0 0.0 0.0 0.0 2.2 0.1 0.1 1.3 0.0 0.0 5.5 0.0 0.0 0.0 0.0 2.0 8.1 0.0 2.1 0.0 18.3 0.0 6.8 0.0 0.0 0.3 0.0 0.2 0.0 0.0 0.0 0.0 0.0 30.3 0.0 0.9 0.0 0.0 0.1 0.2 0.6 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 5.1 0.0 0.0 0.4 0.1 0.0 4.8 0.0 0.1 1.1 2.2 0.1 5.4 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.3 0.3 1.0 0.3 0.0 0.3 0.3 0.3 0.3 NTHL1 "NTH1, OCTS3" ENSG00000065057 "Nth like DNA glycosylase 1" P78549 16 2039815-2047866 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "DNA damage, DNA repair" "Glycosidase, Hydrolase, Lyase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB025152 Supported "CAB025152: " "unprognostic (1.06e-1)" "unprognostic (9.71e-2)" "unprognostic (1.23e-1)" "unprognostic (2.54e-1)" "unprognostic (7.89e-2)" "unprognostic (1.77e-1)" "unprognostic (2.86e-1)" "unprognostic (2.46e-2)" "unprognostic (4.98e-2)" "unprognostic (1.11e-1)" "unprognostic (2.77e-2)" "unprognostic (6.78e-2)" "unprognostic (6.53e-2)" "unprognostic (2.27e-1)" "unprognostic (1.34e-1)" "unprognostic (5.08e-2)" "unprognostic (1.62e-2)" 10.5 8.2 13.4 10.5 19.9 6.0 7.8 15.6 17.9 14.8 12.3 9.0 15.1 9.7 11.8 6.9 9.4 20.5 14.7 10.6 12.5 12.1 7.4 17.5 11.1 10.4 13.6 15.7 18.8 24.6 5.8 8.7 8.3 13.3 9.8 8.2 9.1 22.2 18.2 12.4 6.3 11.2 7.8 10.4 15.2 11.1 6.4 11.6 9.6 9.5 6.6 8.4 7.8 9.3 21.4 14.7 2.4 14.2 9.7 18.8 8.5 10.7 26.4 7.7 11.6 3.1 6.0 8.5 4.5 4.8 8.6 5.4 18.8 10.5 22.9 9.5 3.7 9.6 9.5 10.6 1.5 10.6 23.3 7.1 16.7 20.8 4.3 8.1 8.4 5.0 5.5 4.5 4.9 11.9 7.7 8.3 3.3 12.0 12.1 30.4 17.1 17.3 29.0 8.1 36.7 6.2 3.9 16.3 16.3 4.9 15.1 8.7 10.8 8.0 4.6 7.3 8.1 6.5 8.3 11.3 13.2 9.3 3.3 11.4 9.1 2.4 8.7 2.0 8.8 14.2 9.8 21.4 10.5 9.8 14.7 17.1 7.8 9.5 0.3 9.7 12.1 14.6 18.8 8.5 13.4 19.9 15.6 17.9 12.5 12.1 13.6 15.7 13.3 11.6 NTN1 NTN1L ENSG00000065320 "Netrin 1" O95631 17 9021542-9244000 "Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins" Apoptosis "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in some" "BEWO: 19.9;T-47d: 11.8;U-2 OS: 10.5;U-251 MG: 15.4;WM-115: 9.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA056419 Approved "Secreted to extracellular matrix" 150000 "HPA056419: " "unprognostic (2.72e-1)" "unprognostic (2.59e-2)" "unprognostic (7.12e-2)" "unprognostic (5.25e-2)" "unprognostic (2.51e-1)" "unprognostic (9.33e-3)" "unprognostic (9.42e-2)" "unprognostic (2.20e-1)" "unprognostic (1.63e-1)" "unprognostic (1.33e-2)" "unprognostic (1.89e-1)" "unprognostic (1.15e-1)" "unprognostic (2.49e-2)" "unprognostic (2.20e-2)" "unprognostic (2.60e-1)" "unprognostic (6.07e-3)" "unprognostic (8.31e-3)" 3.9 1.1 1.2 3.6 1.6 0.0 4.3 1.3 5.7 6.3 10.4 2.7 0.8 5.0 5.6 3.2 21.2 8.1 16.7 20.8 1.5 1.6 1.8 5.3 3.8 0.1 2.8 0.3 1.9 1.4 0.0 1.8 0.5 6.9 3.2 3.0 15.6 7.0 1.5 1.6 2.7 9.4 6.8 4.4 1.0 6.4 1.6 1.5 0.0 1.5 6.0 8.0 7.1 4.1 0.2 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 1.0 3.3 3.1 0.1 19.9 0.2 0.3 0.2 0.3 0.0 4.0 0.0 4.5 0.0 0.1 0.9 0.6 0.0 4.4 7.4 1.0 0.0 0.0 0.1 0.4 0.1 0.1 1.5 0.5 0.0 0.0 0.0 0.0 0.0 3.9 0.0 0.4 1.3 0.0 2.3 3.5 0.0 0.0 0.2 0.0 0.0 0.1 3.3 0.7 11.8 0.2 0.0 4.9 10.5 0.0 15.4 0.0 0.0 0.0 0.0 0.0 9.1 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 1.6 1.3 1.6 1.5 1.6 2.8 0.3 6.9 1.5 NTN4 ENSG00000074527 "Netrin 4" Q9HB63 12 95657807-95791152 "Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 76.9" "Cell line enhanced" "Detected in many" "BJ hTERT+: 92.6;hTERT-HME1: 38.3;PC-3: 35.0;TIME: 52.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 11 "MAIT T-cell: 4.9" "Lineage enriched" "Detected in single" 49 "T-cells: 4.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA049832 Approved "Secreted to extracellular matrix" "HPA049832: " "unprognostic (3.08e-1)" "unprognostic (2.17e-1)" "unprognostic (2.33e-1)" "unprognostic (4.15e-2)" "unprognostic (2.11e-2)" "unprognostic (1.42e-1)" "unprognostic (1.67e-1)" "unprognostic (3.03e-2)" "unprognostic (8.71e-2)" "unprognostic (2.58e-1)" "prognostic unfavourable (9.50e-4)" "unprognostic (2.85e-1)" "prognostic favourable (8.12e-9)" "unprognostic (3.52e-2)" "unprognostic (7.08e-2)" "unprognostic (1.93e-1)" "prognostic favourable (6.67e-5)" 11.1 8.5 4.0 4.4 6.3 0.0 22.8 1.2 9.0 9.9 8.9 2.5 7.3 3.4 8.2 11.9 10.7 10.7 13.0 27.2 3.9 2.4 35.8 13.6 21.7 0.7 4.1 6.1 28.5 18.2 6.6 4.5 7.7 2.8 24.1 5.4 8.4 14.7 19.6 7.2 3.8 8.7 7.2 2.2 76.9 14.5 6.5 2.2 1.5 6.7 9.7 4.2 14.1 11.9 0.0 0.0 0.0 0.0 0.0 4.9 0.0 4.7 13.0 0.3 0.0 5.3 8.5 0.5 9.1 92.6 12.3 14.8 10.2 9.0 0.0 0.6 19.1 7.6 0.1 2.7 6.3 0.0 0.8 0.4 2.4 1.9 0.3 0.0 0.0 0.2 7.9 14.2 38.3 24.2 0.0 0.0 4.6 3.5 0.0 0.0 0.2 35.0 0.0 0.1 0.0 12.0 24.4 0.0 0.1 11.0 14.1 0.2 4.1 0.0 52.6 4.8 1.8 18.8 0.9 0.0 0.0 0.0 1.1 0.0 1.0 0.0 0.0 0.0 0.1 0.0 4.9 0.0 0.4 0.3 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 4.0 6.3 1.2 9.0 3.9 2.4 4.1 6.1 2.8 2.2 NTRK1 "MTC, TRK, TRKA" ENSG00000198400 "Neurotrophic receptor tyrosine kinase 1" P04629 1 156815640-156881850 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, RAS pathway related proteins" "Differentiation, Neurogenesis" "Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 8 "adrenal gland: 15.8;blood: 32.3;brain: 28.3" "Cell line enriched" "Detected in some" 4 "HMC-1: 41.1" "Cancer enhanced" "Detected in some" "glioma: 1.3" "Region enriched" "Detected in many" 5 "pons and medulla: 28.3" "Cell type enriched" "Detected in single" 127 "basophil: 32.3" "Lineage enriched" "Detected in single" 323 "granulocytes: 32.3" "Region enhanced" "Detected in some" "basal ganglia: 8.2" "Low region specificity" "Detected in all" "CAB004606, HPA035799, HPA076570" Approved Approved Vesicles,Cytosol 140000 "Vesicles, Cytosol" "CAB004606: AB_628397, HPA035799: , HPA076570: " "unprognostic (5.89e-3)" "unprognostic (7.56e-2)" "unprognostic (2.74e-2)" "unprognostic (5.99e-3)" "unprognostic (7.26e-2)" "unprognostic (1.43e-3)" "unprognostic (1.56e-1)" "unprognostic (7.42e-3)" "unprognostic (7.63e-2)" "unprognostic (1.35e-1)" "unprognostic (6.73e-2)" "unprognostic (2.29e-2)" "unprognostic (3.18e-11)" "unprognostic (2.18e-3)" "unprognostic (3.79e-2)" "unprognostic (1.07e-1)" "unprognostic (4.89e-1)" 1.0 15.8 0.5 0.8 6.0 0.9 0.4 0.0 0.7 0.9 1.1 0.1 0.0 0.8 1.6 2.0 0.7 0.6 2.1 1.5 0.0 1.2 2.9 0.2 1.9 0.3 2.1 0.6 0.3 0.3 0.3 1.1 0.5 28.3 2.2 0.2 3.1 1.2 0.5 0.7 0.2 0.4 1.1 1.2 0.2 1.0 2.4 1.5 0.4 0.3 0.0 0.4 0.7 0.8 0.0 0.0 32.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 5.6 0.0 6.6 0.0 0.0 0.0 0.0 41.1 0.0 0.0 0.0 0.0 0.0 2.1 0.7 0.0 0.0 0.0 1.1 0.0 0.6 1.2 0.0 0.1 0.0 0.0 0.7 9.4 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.6 0.0 0.0 1.6 0.2 0.0 0.0 0.0 0.0 32.3 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 6.0 0.0 0.6 0.0 1.2 2.1 0.6 28.3 1.5 NTRK2 TRKB ENSG00000148053 "Neurotrophic receptor tyrosine kinase 2" Q16620 9 84668551-85027070 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, RAS pathway related proteins" "Differentiation, Neurogenesis" "Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, Epilepsy, Obesity" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 133.8;thyroid gland: 63.4" "Cell line enhanced" "Detected in some" "AF22: 10.4;HaCaT: 3.7;RPTEC TERT1: 11.6;SH-SY5Y: 13.3" "Group enriched" "Detected in many" 5 "glioma: 31.6;head and neck cancer: 8.0;lung cancer: 9.8;thyroid cancer: 26.4" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "T-reg: 1.4" "Lineage enriched" "Detected in single" 14 "T-cells: 1.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA007637, CAB010346" Enhanced Approved Cytosol 13000000 Cytosol "CAB010346: AB_2155274, HPA007637: AB_1080385" "unprognostic (2.75e-3)" "unprognostic (3.48e-2)" "unprognostic (1.82e-2)" "unprognostic (3.26e-1)" "unprognostic (9.26e-2)" "unprognostic (2.56e-2)" "unprognostic (1.29e-2)" "unprognostic (9.16e-2)" "unprognostic (6.13e-2)" "unprognostic (1.05e-1)" "unprognostic (4.25e-2)" "unprognostic (2.18e-2)" "unprognostic (2.66e-2)" "unprognostic (1.20e-2)" "unprognostic (1.21e-2)" "unprognostic (1.31e-1)" "unprognostic (1.39e-3)" 19.8 2.7 66.1 2.0 56.7 1.2 33.2 15.1 133.8 6.4 4.4 27.4 0.0 1.4 3.0 3.3 5.6 3.7 18.7 5.8 61.0 30.7 12.5 2.1 6.3 2.7 32.4 41.4 6.6 18.9 1.6 3.0 2.1 34.1 3.8 3.1 2.0 8.6 11.9 2.0 7.2 1.6 3.0 22.1 6.5 1.4 2.4 34.1 0.0 63.4 2.6 3.4 3.5 3.8 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 10.4 0.0 0.0 0.0 0.0 0.8 0.1 0.0 0.0 0.0 1.6 0.0 0.2 0.0 3.7 0.0 0.0 0.0 0.2 0.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 11.6 0.8 0.9 13.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.5 0.0 0.1 0.0 0.4 0.0 3.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.6 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 66.1 56.7 15.1 45.6 61.0 30.7 32.4 41.4 34.1 34.1 NTRK3 TRKC ENSG00000140538 "Neurotrophic receptor tyrosine kinase 3" Q16288 15 87859751-88256768 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Differentiation, Neurogenesis" "Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 41.8" "Cell line enriched" "Detected in some" 8 "U-138 MG: 47.4" "Cancer enhanced" "Detected in some" "glioma: 2.5" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009233, HPA027484, HPA048065" Approved Supported "Nuclear membrane,Nucleoli" 11000000 Nucleoli "Nuclear membrane" "CAB009233: AB_632555, HPA027484: , HPA048065: " "unprognostic (1.27e-3)" "unprognostic (1.24e-2)" "unprognostic (1.98e-2)" "unprognostic (2.04e-2)" "unprognostic (1.65e-1)" "unprognostic (3.34e-1)" "unprognostic (3.18e-2)" "unprognostic (2.23e-2)" "unprognostic (2.34e-1)" "unprognostic (3.91e-1)" "unprognostic (2.88e-1)" "unprognostic (1.09e-1)" "unprognostic (5.78e-3)" "unprognostic (6.45e-3)" "unprognostic (1.06e-2)" "unprognostic (1.26e-2)" "unprognostic (2.49e-3)" 20.8 7.4 22.0 2.5 28.1 1.5 6.2 30.4 41.8 7.0 4.0 8.4 1.3 2.0 12.4 6.7 3.4 9.5 3.9 5.5 22.0 11.1 5.1 2.0 5.7 3.1 11.2 18.7 5.1 2.9 1.6 7.9 2.8 14.7 6.8 4.7 8.0 11.5 8.7 1.9 2.9 2.5 7.7 13.7 4.1 3.0 13.8 13.7 0.0 2.5 0.7 4.3 7.1 4.8 0.7 0.4 1.3 0.5 0.5 0.8 0.0 0.0 5.9 1.2 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.5 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 1.1 0.0 0.0 1.2 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 47.4 0.9 0.0 0.5 0.0 0.0 0.0 1.4 0.0 0.1 1.2 0.5 0.4 0.3 0.1 0.2 0.4 0.3 0.3 0.1 0.7 0.4 0.4 1.3 0.5 0.1 0.4 0.8 0.0 22.0 28.1 30.4 28.9 22.0 11.1 11.2 18.7 14.7 13.7 NUDT1 MTH1 ENSG00000106268 "Nudix hydrolase 1" P36639 7 2242222-2251146 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Hydrolase, RNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 59.5" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA012636 Approved Supported Cytosol Cytosol "HPA012636: AB_1854696" "unprognostic (1.31e-1)" "unprognostic (1.19e-2)" "unprognostic (2.13e-2)" "unprognostic (2.37e-1)" "unprognostic (3.01e-3)" "unprognostic (3.37e-1)" "prognostic unfavourable (4.44e-4)" "unprognostic (2.15e-2)" "unprognostic (4.77e-1)" "unprognostic (3.81e-2)" "unprognostic (3.81e-2)" "unprognostic (1.53e-1)" "prognostic unfavourable (1.30e-7)" "unprognostic (1.29e-1)" "unprognostic (6.71e-2)" "unprognostic (3.49e-2)" "unprognostic (1.70e-1)" 8.8 3.9 7.4 12.6 13.4 37.1 10.8 5.0 10.8 5.9 9.0 8.7 2.2 9.1 8.2 9.2 13.1 6.0 8.1 11.3 8.7 4.7 4.1 2.9 7.2 18.9 8.2 7.0 4.8 4.0 0.7 1.8 5.8 7.2 7.2 6.3 4.0 5.5 4.2 12.0 18.8 9.3 10.5 11.9 11.1 5.5 26.7 5.3 30.7 4.1 14.4 17.2 6.8 8.1 18.3 59.5 11.9 21.3 10.1 20.4 13.0 21.5 34.8 19.1 25.3 7.0 9.7 14.0 9.5 8.3 13.1 15.3 18.7 16.3 22.8 7.8 10.4 26.4 14.5 14.5 7.7 10.1 24.7 17.8 29.3 15.8 1.7 13.8 18.0 6.4 3.8 18.9 6.7 7.0 14.0 25.5 14.5 55.0 25.7 53.8 41.0 21.5 35.9 28.4 19.1 7.1 12.2 19.2 26.6 9.8 28.9 4.4 19.1 36.7 6.5 12.6 48.1 29.0 22.6 19.7 14.9 23.6 12.7 34.4 45.2 9.0 17.5 11.9 12.9 21.3 10.2 18.3 15.1 13.6 26.6 18.0 15.1 13.1 4.6 10.1 17.4 59.5 20.4 13.0 7.4 13.4 5.0 10.8 8.7 4.7 8.2 7.0 7.2 5.3 NUMA1 ENSG00000137497 "Nuclear mitotic apparatus protein 1" Q14980 11 72002864-72080693 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division, Chromosome partition, Mitosis" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019841, HPA019859, HPA029912" Enhanced Enhanced Nucleoplasm Nucleoplasm "HPA019841: AB_1854708, HPA019859: AB_1854709, HPA029912: AB_10602811" "unprognostic (1.60e-2)" "unprognostic (3.31e-1)" "unprognostic (2.06e-2)" "unprognostic (2.84e-1)" "unprognostic (1.14e-1)" "unprognostic (6.47e-2)" "unprognostic (5.75e-2)" "unprognostic (8.74e-3)" "unprognostic (5.91e-2)" "unprognostic (9.45e-2)" "unprognostic (1.60e-2)" "unprognostic (2.51e-2)" "prognostic favourable (7.92e-4)" "unprognostic (1.28e-1)" "unprognostic (1.37e-1)" "unprognostic (1.49e-1)" "unprognostic (1.39e-1)" 29.7 33.5 23.6 20.6 28.1 26.8 33.1 38.4 31.8 51.9 37.7 55.6 40.1 25.5 58.3 30.9 34.1 37.8 31.2 21.2 21.6 19.4 23.0 13.1 28.3 23.3 37.6 24.8 51.4 30.0 70.7 29.5 26.0 28.3 50.3 24.2 41.2 35.3 40.1 43.7 41.9 30.2 45.3 29.5 23.0 31.2 25.9 39.5 39.4 32.6 22.5 31.8 50.5 37.2 10.3 12.9 4.9 5.7 7.0 9.7 6.6 18.5 23.6 29.6 19.9 26.3 27.5 15.1 25.1 29.1 26.2 22.9 24.5 34.4 25.3 22.0 30.7 39.9 27.0 25.4 24.0 26.0 12.7 31.0 37.1 18.6 21.2 23.4 22.6 29.0 16.8 25.6 25.9 22.1 18.2 30.6 17.8 35.8 30.2 13.1 18.4 17.0 37.1 51.6 19.5 19.6 29.1 35.8 50.8 40.0 37.1 37.3 49.9 13.7 30.4 27.8 21.7 39.2 16.6 19.8 19.6 35.6 18.6 11.1 15.8 4.9 5.6 2.5 9.7 3.5 7.4 5.2 6.0 7.5 4.9 10.3 7.5 5.2 4.6 7.0 5.7 12.9 7.2 6.6 23.6 28.1 38.4 31.8 21.6 19.4 37.6 24.8 28.3 39.5 NUMB C14orf41 ENSG00000133961 "NUMB, endocytic adaptor protein" P49757 14 73275107-73458617 "Cancer-related genes, Predicted intracellular proteins" Neurogenesis "Developmental protein" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "neutrophil: 64.9" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002874, CAB011478" Approved Enhanced "Cell Junctions" "Cell Junctions" "CAB011478: AB_443023, HPA002874: " "unprognostic (5.28e-2)" "unprognostic (7.23e-2)" "unprognostic (1.32e-1)" "unprognostic (1.32e-3)" "unprognostic (2.02e-1)" "unprognostic (2.01e-1)" "unprognostic (2.43e-1)" "unprognostic (9.49e-2)" "unprognostic (1.33e-2)" "unprognostic (4.08e-3)" "unprognostic (2.65e-3)" "unprognostic (4.14e-2)" "prognostic favourable (2.32e-6)" "unprognostic (9.12e-2)" "unprognostic (1.63e-1)" "unprognostic (3.92e-2)" "unprognostic (2.87e-1)" 27.3 21.5 26.2 24.5 23.5 21.3 26.4 37.1 27.0 24.2 35.9 17.3 26.1 31.3 30.8 23.9 30.1 28.8 28.8 23.3 23.3 14.1 30.3 35.5 40.5 23.0 18.9 20.7 29.2 26.8 31.8 28.3 29.9 23.4 23.7 29.4 22.3 34.2 23.9 16.4 24.6 45.3 38.0 26.1 32.9 25.1 19.0 19.8 20.1 27.7 17.0 26.2 30.5 26.9 5.2 15.2 64.9 20.9 2.7 3.8 11.6 20.9 14.4 10.4 9.4 21.1 32.2 14.2 19.9 27.0 16.1 17.2 17.4 26.5 9.6 12.5 24.6 13.9 12.3 20.5 24.5 14.7 6.9 7.7 9.5 11.2 22.4 7.0 18.1 17.9 22.1 39.6 23.7 34.7 13.9 11.6 20.3 18.9 12.8 9.8 4.8 15.5 8.3 14.5 6.4 22.3 32.2 4.3 11.2 24.9 16.9 10.1 25.3 10.4 33.2 24.2 13.6 15.5 8.5 9.7 11.2 8.8 48.6 8.3 10.6 16.3 19.8 20.8 3.0 17.1 3.1 5.2 3.0 3.3 15.2 5.1 3.1 2.8 64.9 2.7 20.9 2.8 3.8 11.6 26.2 23.5 37.1 27.0 23.3 14.1 18.9 20.7 23.4 19.8 NUP210L ENSG00000143552 "Nucleoporin 210 like" Q5VU65 1 153992685-154155116 "Cancer-related genes, Predicted membrane proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 12 "testis: 42.7" "Cell line enriched" "Detected in single" 43 "MCF7: 18.3" "Not detected" "Not detected" "Not detected" "Not detected" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in single" "Not detected" "Not detected" "Low region specificity" "Detected in single" "HPA047195, HPA064245, HPA066707" Enhanced Approved "Nuclear bodies" "Nuclear bodies" "HPA047195: , HPA064245: , HPA066707: " "unprognostic (2.11e-1)" "unprognostic (1.78e-1)" "unprognostic (3.01e-1)" "unprognostic (1.80e-2)" "unprognostic (1.63e-2)" "unprognostic (1.72e-3)" "unprognostic (6.90e-2)" "unprognostic (1.79e-3)" "unprognostic (3.45e-2)" "unprognostic (5.57e-2)" "unprognostic (4.51e-4)" "unprognostic (1.15e-1)" "unprognostic (9.35e-10)" "unprognostic (4.20e-2)" "unprognostic (3.78e-2)" "unprognostic (7.45e-2)" "unprognostic (4.09e-2)" 0.2 0.1 0.1 0.1 0.3 0.2 0.1 0.1 0.9 0.1 0.1 1.5 0.0 0.0 1.1 0.1 0.0 0.1 0.1 0.1 0.1 0.2 0.2 0.2 0.2 0.1 0.1 0.0 0.1 0.2 0.0 0.4 0.4 0.6 0.1 0.0 0.8 0.9 0.4 0.1 0.1 0.1 3.4 0.2 0.1 0.1 42.7 0.0 0.3 0.3 0.0 0.1 1.2 0.1 0.6 0.6 1.8 0.2 0.9 0.8 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 18.3 0.0 0.3 0.1 0.0 0.0 0.3 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 1.4 0.3 0.1 0.2 0.6 0.4 0.5 0.0 0.5 0.8 0.3 1.8 0.9 0.0 0.6 0.7 0.0 0.1 0.3 0.1 0.9 0.1 0.2 0.1 0.0 0.6 0.0 NUP214 "CAIN, CAN, D9S46E, N214" ENSG00000126883 "Nucleoporin 214" P35658 9 131125561-131234670 "Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters" "Host-virus interaction, mRNA transport, Protein transport, Translocation, Transport" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 131.5" "Cell line enhanced" "Detected in all" "K-562: 71.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 5 "classical monocyte: 43.7;neutrophil: 131.5" "Group enriched" "Detected in many" 5 "granulocytes: 131.5;monocytes: 43.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA048789 Approved "Nucleoplasm,Vesicles,Focal adhesion sites" 100000 Nucleoplasm "Vesicles, Focal adhesion sites" "HPA048789: " "unprognostic (1.30e-1)" "unprognostic (9.51e-3)" "unprognostic (9.92e-3)" "unprognostic (1.15e-1)" "unprognostic (7.42e-2)" "unprognostic (8.31e-2)" "unprognostic (1.07e-3)" "unprognostic (2.10e-2)" "unprognostic (3.35e-1)" "unprognostic (4.95e-1)" "unprognostic (6.60e-3)" "unprognostic (1.08e-1)" "prognostic favourable (2.39e-5)" "unprognostic (5.49e-2)" "unprognostic (6.84e-2)" "unprognostic (1.82e-1)" "unprognostic (1.53e-1)" 16.9 10.3 11.5 13.8 13.9 29.4 12.9 13.0 14.4 10.2 11.4 19.8 10.4 9.0 15.0 13.7 16.1 12.1 10.2 9.7 9.5 8.1 19.0 15.1 11.7 13.3 13.2 8.8 14.2 17.0 16.7 16.9 13.0 11.3 11.1 10.8 15.3 13.0 11.1 15.5 17.5 11.7 11.1 14.3 35.8 12.3 63.7 13.3 27.4 11.8 7.6 16.8 10.7 11.2 1.2 16.8 131.5 43.7 1.2 0.8 17.9 6.7 9.6 8.2 4.9 6.6 6.4 8.6 6.0 6.2 7.8 6.3 7.8 4.9 10.9 4.8 8.2 15.4 11.0 7.8 7.6 7.9 5.4 6.8 13.7 15.2 5.8 10.6 7.3 7.0 7.2 10.0 8.1 8.0 71.4 6.3 8.0 12.5 13.9 16.0 8.9 8.5 4.8 10.3 10.9 9.0 6.2 7.0 7.2 10.0 9.2 5.2 12.1 26.4 6.8 13.8 7.8 9.0 9.6 5.5 10.7 10.5 6.7 6.4 8.3 3.5 43.7 17.3 0.7 18.4 0.8 1.2 0.7 0.6 16.8 1.1 0.7 0.7 131.5 1.2 15.0 1.5 0.4 17.9 11.5 13.9 13.0 14.4 9.5 8.1 13.2 8.8 11.3 13.3 NUP93 KIAA0095 ENSG00000102900 "Nucleoporin 93" Q8N1F7 16 56730105-56850286 "Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "mRNA transport, Protein transport, Translocation, Transport" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA017937 Uncertain "HPA017937: AB_1854726" "unprognostic (6.31e-2)" "unprognostic (3.22e-2)" "unprognostic (1.41e-1)" "unprognostic (8.85e-2)" "unprognostic (3.99e-3)" "unprognostic (2.78e-3)" "prognostic unfavourable (1.72e-6)" "unprognostic (9.18e-2)" "unprognostic (9.35e-3)" "unprognostic (5.22e-2)" "unprognostic (4.55e-2)" "unprognostic (1.97e-1)" "unprognostic (2.66e-2)" "unprognostic (3.71e-1)" "unprognostic (1.85e-1)" "unprognostic (9.68e-2)" "unprognostic (3.74e-2)" 14.2 12.2 14.8 15.6 29.7 33.7 12.6 16.8 29.1 12.7 12.4 14.4 4.4 7.2 15.0 9.8 16.8 12.0 8.6 11.5 26.1 11.2 9.9 6.9 12.6 19.1 13.1 16.7 13.4 9.8 16.5 9.6 14.1 23.8 13.9 14.5 23.0 10.4 10.2 15.5 16.3 11.2 14.5 20.7 17.8 11.1 29.3 13.9 28.0 27.4 10.4 22.5 11.5 13.2 12.0 16.9 54.1 21.3 15.1 14.6 11.9 19.1 23.8 21.6 23.5 8.3 9.1 23.9 16.8 13.7 41.8 28.7 32.7 19.2 30.1 16.9 15.8 34.4 40.9 23.9 41.3 9.2 22.3 20.1 17.2 26.7 10.2 26.6 24.1 9.1 10.5 28.3 17.9 24.0 24.3 6.0 20.6 13.7 35.7 22.9 27.4 26.7 43.4 36.4 30.4 16.2 12.8 19.1 12.6 43.8 15.4 13.8 11.7 16.6 16.0 19.9 22.3 16.6 19.0 10.4 14.2 50.2 14.0 25.2 19.4 5.1 14.3 54.1 11.9 21.3 14.6 12.0 9.1 12.9 16.9 11.6 9.5 13.2 3.6 15.1 20.9 8.8 11.0 11.9 14.8 29.7 16.8 29.1 26.1 11.2 13.1 16.7 23.8 13.9 NUP98 NUP96 ENSG00000110713 "Nucleoporin 98" P52948 11 3671083-3797792 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction, mRNA transport, Protein transport, Translocation, Transport" "Hydrolase, Protease, Serine protease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA074810 Supported Nucleoplasm,Vesicles Nucleoplasm Vesicles "HPA074810: " "unprognostic (1.11e-1)" "unprognostic (1.49e-1)" "unprognostic (7.41e-2)" "unprognostic (2.13e-1)" "unprognostic (7.71e-3)" "unprognostic (3.40e-1)" "unprognostic (4.08e-3)" "unprognostic (6.47e-2)" "unprognostic (1.04e-2)" "unprognostic (1.83e-2)" "unprognostic (7.76e-3)" "unprognostic (1.02e-1)" "unprognostic (1.23e-1)" "unprognostic (5.09e-1)" "unprognostic (1.91e-1)" "unprognostic (2.46e-1)" "unprognostic (1.21e-1)" 20.2 13.5 8.7 23.5 11.7 40.8 23.5 14.2 13.2 18.0 15.3 14.6 17.8 11.2 19.2 17.5 18.6 17.3 17.1 18.2 7.8 8.0 12.8 20.1 20.7 17.4 11.4 8.7 25.5 19.0 25.7 23.6 20.7 12.7 18.6 15.2 17.8 17.4 25.0 35.2 18.5 15.7 20.8 10.4 18.3 16.0 57.0 10.6 27.5 20.9 15.0 26.6 22.6 19.3 8.9 9.9 24.9 10.0 6.1 13.2 8.7 29.8 23.4 19.3 21.3 21.4 17.6 17.0 21.3 24.9 29.3 26.4 25.7 37.1 29.2 10.1 25.5 32.2 33.9 21.0 40.0 20.7 24.5 31.3 19.2 17.6 18.0 39.9 26.4 20.0 14.5 16.1 29.4 22.7 38.9 23.5 31.1 12.2 40.1 13.0 24.4 18.0 24.5 23.5 14.0 16.7 23.6 17.8 11.9 30.9 25.1 14.2 15.4 15.7 16.6 23.5 20.4 25.6 19.4 14.2 24.2 31.0 15.9 17.2 24.7 19.1 7.9 15.5 11.0 10.0 11.0 8.9 10.7 9.7 9.9 7.8 12.2 10.5 24.9 6.1 6.3 2.7 13.2 8.7 8.7 11.7 14.2 13.2 7.8 8.0 11.4 8.7 12.7 10.6 NUTM1 "C15orf55, DKFZp434O192, FAM22H, NUT" ENSG00000184507 "NUT midline carcinoma family member 1" Q86Y26 15 34343315-34357737 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 127 "testis: 48.9" "Cell line enhanced" "Detected in some" "BEWO: 1.0;NTERA-2: 2.2" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" HPA040421 Enhanced "HPA040421: AB_10793965" "unprognostic (4.14e-2)" "unprognostic (3.61e-1)" "unprognostic (2.11e-1)" "unprognostic (7.38e-2)" "unprognostic (1.99e-1)" "unprognostic (8.37e-2)" "unprognostic (8.66e-2)" "unprognostic (2.76e-1)" "unprognostic (1.34e-1)" "unprognostic (5.55e-2)" "unprognostic (1.34e-2)" "unprognostic (5.97e-3)" "unprognostic (1.61e-1)" "unprognostic (2.77e-1)" "unprognostic (4.27e-2)" "unprognostic (4.79e-2)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.2 0.0 0.0 0.0 0.1 48.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.3 0.2 0.0 0.1 0.4 0.4 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.6 0.1 0.1 0.1 0.0 0.5 0.3 0.0 0.0 0.4 0.5 0.1 0.2 0.1 0.0 0.1 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.3 0.1 2.2 0.3 0.2 0.2 0.0 0.0 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.2 0.6 0.2 0.0 0.7 0.2 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 NUTM2A FAM22A ENSG00000184923 "NUT family member 2A" Q8IVF1 10 87225448-87236908 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in some" "HMC-1: 14.2" "Not detected" "Not detected" "Cell type enhanced" "Detected in single" "eosinophil: 1.3" "Low lineage specificity" "Detected in single" HPA064635 Approved "Nuclear bodies" "Nuclear bodies" "HPA064635: " "unprognostic (1.75e-2)" "unprognostic (1.33e-2)" "unprognostic (1.03e-1)" "unprognostic (8.29e-2)" "unprognostic (5.67e-2)" "unprognostic (8.08e-2)" "unprognostic (1.75e-2)" "unprognostic (6.84e-2)" "unprognostic (2.46e-3)" "unprognostic (1.75e-2)" "unprognostic (7.24e-2)" "unprognostic (1.40e-1)" "unprognostic (4.24e-3)" "unprognostic (1.35e-1)" "unprognostic (1.11e-1)" "unprognostic (1.96e-2)" "unprognostic (2.65e-1)" 3.5 1.8 2.8 0.4 2.5 1.7 1.1 1.5 2.9 1.1 1.8 1.3 1.7 2.1 0.9 1.9 0.8 3.0 3.4 2.2 1.5 1.3 1.6 0.9 2.9 3.0 2.4 2.9 2.0 1.3 2.5 1.0 5.9 0.8 2.3 4.4 2.0 0.7 3.6 1.7 1.8 2.4 2.6 0.2 1.4 1.2 0.4 0.0 1.3 0.2 0.0 0.2 0.2 1.4 0.2 0.7 0.0 1.8 0.9 0.9 0.6 1.8 0.8 0.5 0.2 0.7 1.4 0.1 0.0 1.4 0.0 0.9 0.1 0.3 1.5 1.7 0.4 0.2 0.7 0.6 14.2 0.5 4.1 0.9 1.1 0.0 1.8 0.4 0.2 0.7 1.1 2.4 3.2 0.5 1.7 0.2 0.0 0.5 0.1 1.8 2.7 0.7 0.6 0.6 0.3 0.9 1.4 0.0 0.2 0.8 0.1 0.0 0.1 0.7 0.8 1.4 0.0 0.0 0.2 1.3 0.1 0.2 0.0 0.4 0.0 0.1 0.0 0.0 0.1 0.2 0.4 0.0 0.2 0.0 0.0 0.2 NUTM2B "bA119F19.1, FAM22B" ENSG00000188199 "NUT family member 2B" A6NNL0 10 79703227-79714681 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "No human protein/transcript evidence" "No human protein/transcript evidence" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "HMC-1: 6.2" "Not detected" "Not detected" "Cell type enhanced" "Detected in single" "eosinophil: 1.0" "Low lineage specificity" "Detected in single" HPA064635 Approved "Nuclear bodies" "Nuclear bodies" "HPA064635: " "unprognostic (9.51e-2)" "unprognostic (6.09e-2)" "unprognostic (1.21e-2)" "unprognostic (1.10e-1)" "unprognostic (3.63e-1)" "unprognostic (6.60e-2)" "unprognostic (2.47e-2)" "unprognostic (7.66e-2)" "unprognostic (1.33e-2)" "unprognostic (1.95e-1)" "unprognostic (7.79e-3)" "unprognostic (1.15e-1)" "unprognostic (9.70e-2)" "unprognostic (9.97e-2)" "unprognostic (5.72e-2)" "unprognostic (5.37e-2)" "unprognostic (2.32e-2)" 0.9 1.8 2.8 1.6 2.6 3.6 0.6 2.2 3.0 1.1 1.0 0.6 0.9 1.6 0.4 2.3 0.3 2.1 2.8 1.9 1.6 1.1 1.9 1.6 1.7 2.0 2.1 2.2 2.7 0.7 1.6 0.4 3.0 0.7 2.3 2.2 1.2 0.2 1.9 2.0 0.9 4.6 1.1 1.6 0.4 0.7 0.5 0.4 1.0 0.8 0.1 0.1 0.1 1.4 1.4 2.9 2.3 1.0 0.9 1.5 0.6 1.1 0.9 0.9 0.2 3.3 3.3 0.5 0.5 1.4 0.2 1.5 0.5 2.0 1.2 2.3 0.5 0.8 1.3 1.8 6.2 2.0 1.0 0.4 0.7 0.0 3.4 1.8 0.6 2.8 0.4 4.8 3.4 1.8 0.7 0.5 0.4 1.2 0.4 1.7 4.0 2.1 2.6 3.7 0.6 3.1 1.7 0.3 0.6 0.5 1.0 0.7 0.2 0.8 0.0 0.3 0.0 0.0 0.0 1.0 0.1 0.1 0.0 0.2 0.0 0.0 0.0 0.5 0.1 0.0 0.4 0.1 0.8 0.4 0.0 0.1 ODAM "APin, FLJ20513" ENSG00000109205 "Odontogenic, ameloblast associated" A1E959 4 70196496-70204576 "Cancer-related genes, Predicted intracellular proteins" Biomineralization "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 15 "salivary gland: 157.7" "Cell line enriched" "Detected in some" 17 "Hep G2: 25.9" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in some" "HPA036279, HPA036543, HPA070297" Supported Nucleoplasm,Cytosol "Intracellular and membrane" Nucleoplasm Cytosol "HPA036279: , HPA036543: AB_10669797, HPA070297: " "unprognostic (2.34e-2)" "unprognostic (2.43e-1)" "unprognostic (1.26e-1)" "unprognostic (1.75e-1)" "unprognostic (3.34e-3)" "unprognostic (1.06e-1)" "unprognostic (1.88e-2)" "unprognostic (3.47e-1)" "unprognostic (3.08e-1)" "unprognostic (3.03e-1)" "unprognostic (2.72e-1)" "unprognostic (1.86e-2)" "unprognostic (2.50e-2)" 0.0 0.2 0.0 0.7 0.0 0.0 0.2 0.0 0.0 0.2 0.8 0.0 2.5 0.2 0.1 1.9 0.1 0.1 0.1 0.0 0.0 0.2 0.5 0.0 1.4 0.0 0.0 0.0 0.0 0.2 0.5 0.2 0.2 0.0 0.4 0.1 0.0 157.7 2.6 0.0 0.0 0.3 1.9 0.1 0.0 2.5 0.0 0.0 0.0 5.1 10.6 0.5 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 25.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.3 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 OGG1 "HMMH, HOGG1, MUTM, OGH1" ENSG00000114026 "8-oxoguanine DNA glycosylase" O15527 3 9749944-9788219 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "DNA damage, DNA repair" "Glycosidase, Hydrolase, Lyase, Multifunctional enzyme" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA027514, CAB047301" Approved Enhanced Nucleoplasm Nucleoplasm "CAB047301: , HPA027514: AB_10602189" "unprognostic (6.95e-2)" "unprognostic (7.82e-3)" "unprognostic (7.19e-2)" "unprognostic (1.24e-3)" "unprognostic (9.69e-2)" "unprognostic (1.97e-2)" "prognostic unfavourable (5.77e-5)" "unprognostic (7.83e-2)" "unprognostic (2.45e-2)" "unprognostic (3.43e-3)" "unprognostic (9.66e-3)" "unprognostic (4.23e-2)" "prognostic favourable (2.65e-4)" "unprognostic (2.06e-2)" "unprognostic (2.24e-1)" "unprognostic (1.65e-1)" "unprognostic (1.59e-1)" 10.4 12.9 15.4 28.5 16.2 12.7 11.5 22.0 17.7 16.7 18.8 16.2 10.5 22.0 16.2 13.1 10.0 14.7 12.1 10.7 14.7 10.8 30.1 17.8 9.9 28.5 12.3 14.1 22.5 12.0 5.8 10.2 10.3 15.3 14.4 10.2 14.6 14.3 13.2 7.4 11.5 28.2 12.1 13.6 14.1 10.8 7.3 15.6 19.8 12.2 6.3 25.5 12.2 13.3 12.2 11.9 15.4 8.5 19.4 15.4 8.3 5.7 10.7 10.9 6.8 10.7 12.3 20.1 7.5 7.7 11.5 13.8 10.3 5.7 35.0 5.0 9.5 5.6 6.4 8.2 4.9 12.4 9.2 17.4 17.3 14.7 11.3 6.7 11.2 12.2 10.5 19.9 8.5 14.2 5.5 5.7 10.9 10.7 5.4 6.7 5.7 15.4 4.0 7.3 11.4 6.4 2.9 4.9 8.6 9.6 7.8 5.8 12.4 11.5 9.2 11.7 12.4 9.1 12.2 5.7 8.1 18.0 9.4 19.5 7.2 11.3 8.5 15.4 15.1 6.6 14.6 10.4 13.0 12.3 7.6 12.2 10.2 9.6 2.1 19.4 5.3 11.9 15.4 8.3 15.4 16.2 22.0 17.7 14.7 10.8 12.3 14.1 15.3 15.6 OLIG2 "BHLHB1, bHLHe19, OLIGO2, PRKCBP2, RACK17" ENSG00000205927 "Oligodendrocyte transcription factor 2" Q13516 21 33025845-33029196 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "brain: 66.2" "Cell line enhanced" "Detected in some" "HMC-1: 29.3;NB-4: 21.2;THP-1: 18.4;WM-115: 6.0" "Cancer enriched" "Detected in some" 52 "glioma: 46.9" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in some" 8 "eosinophil: 15.4" "Lineage enriched" "Detected in single" 154 "granulocytes: 15.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003254, CAB019381" Enhanced Uncertain "Nucleoplasm,Plasma membrane" Nucleoplasm "Plasma membrane" "CAB019381: , HPA003254: AB_1854795" "unprognostic (5.14e-1)" "unprognostic (4.56e-1)" "unprognostic (1.44e-2)" "unprognostic (8.27e-2)" "unprognostic (3.24e-2)" "unprognostic (4.34e-2)" "unprognostic (4.81e-2)" "unprognostic (5.41e-2)" "unprognostic (1.39e-1)" "unprognostic (5.78e-5)" "unprognostic (2.76e-1)" 1.3 1.3 24.1 1.4 19.1 1.4 1.3 4.2 66.2 1.3 1.3 41.4 0.0 1.7 1.3 1.3 1.3 1.3 1.3 1.3 23.6 15.6 1.3 1.3 1.3 1.3 20.9 15.5 1.3 1.3 1.3 0.0 1.3 17.1 1.3 1.3 0.0 1.3 1.3 1.3 1.3 1.5 1.3 16.8 1.3 1.4 1.3 16.6 0.0 1.3 0.0 1.3 1.4 0.0 0.0 0.0 15.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.4 0.0 0.0 0.0 0.6 4.2 0.0 0.0 0.0 0.8 29.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 21.2 1.9 0.0 0.0 1.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 18.4 0.0 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.7 0.0 6.0 1.8 0.0 15.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 24.1 19.1 4.2 27.6 23.6 15.6 20.9 15.5 17.1 16.6 OMA1 "FLJ33782, MPRP-1, YKR087C, ZMPOMA1" ENSG00000162600 "OMA1 zinc metallopeptidase" Q96E52 1 58415384-58546802 "Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins" "Hydrolase, Metalloprotease, Protease" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA055120 Approved Approved Nucleoplasm,Mitochondria "Nucleoplasm, Mitochondria" "HPA055120: " "prognostic favourable (1.63e-4)" "unprognostic (2.67e-2)" "prognostic favourable (7.70e-4)" "unprognostic (1.60e-3)" "unprognostic (1.61e-1)" "unprognostic (9.57e-2)" "unprognostic (3.94e-3)" "prognostic favourable (8.52e-4)" "unprognostic (8.22e-3)" "unprognostic (6.91e-2)" "unprognostic (4.10e-2)" "unprognostic (1.40e-1)" "unprognostic (9.54e-3)" "unprognostic (2.52e-2)" "unprognostic (3.93e-2)" "unprognostic (1.74e-2)" "unprognostic (5.24e-3)" 10.2 22.4 13.8 21.5 18.1 9.2 15.8 10.6 14.6 14.5 16.4 14.1 20.1 12.1 15.4 15.1 17.1 15.9 12.1 15.8 12.6 10.0 23.0 23.8 19.1 17.9 16.7 9.6 15.0 18.2 15.7 20.9 8.9 13.0 17.8 16.1 11.3 20.6 22.7 20.9 10.2 16.1 24.2 18.2 17.2 13.9 6.9 19.4 18.4 18.3 14.5 16.4 17.0 20.6 22.5 9.5 18.6 19.5 18.6 22.8 10.2 13.5 5.7 3.8 3.5 19.2 18.0 10.9 5.6 6.1 4.9 6.2 1.6 8.2 30.7 11.9 5.8 13.9 13.4 13.7 5.9 23.5 7.5 9.6 4.4 6.6 9.6 23.3 6.7 17.0 15.3 4.8 10.0 4.3 18.0 9.2 13.4 8.3 7.9 8.3 5.6 12.4 9.9 12.5 12.8 10.7 9.1 4.0 1.9 11.4 18.9 15.8 8.5 9.0 2.5 2.5 5.1 12.6 5.8 7.5 9.8 20.2 7.8 18.3 6.2 10.8 9.2 18.6 12.8 14.5 16.5 22.5 15.7 15.0 9.5 21.4 22.8 20.8 10.6 18.6 19.5 5.0 13.9 10.2 13.8 18.1 10.6 14.6 12.6 10.0 16.7 9.6 13.0 19.4 OR52N1 ENSG00000181001 "Olfactory receptor family 52 subfamily N member 1" Q8NH53 11 5786471-5791265 "Cancer-related genes, G-protein coupled receptors, Predicted membrane proteins" "Olfaction, Sensory transduction" "G-protein coupled receptor, Receptor, Transducer" "Cancer-related genes" "Evidence at transcript level" "Evidence at transcript level" "No human protein/transcript evidence" "No human protein/transcript evidence" "Tissue enhanced" "Detected in some" "adipose tissue: 1.8;bone marrow: 1.4" "Cell line enhanced" "Detected in single" "Karpas-707: 1.7" "Not detected" "Not detected" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" HPA054028 Uncertain "HPA054028: " 1.8 0.0 0.0 0.3 0.0 1.4 0.3 0.0 0.2 0.0 0.1 0.0 0.4 0.1 0.1 0.2 0.9 0.2 0.0 0.0 0.1 0.1 0.2 0.2 0.1 0.1 0.1 0.0 0.1 0.1 0.3 0.0 0.1 0.0 0.3 0.1 0.6 0.0 0.0 0.2 0.1 0.4 0.0 0.0 0.1 0.0 0.5 0.7 1.2 0.6 1.0 0.7 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.5 0.2 0.0 0.0 0.0 0.4 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.7 0.2 0.0 0.2 0.1 0.0 0.0 0.0 0.3 0.0 0.2 1.7 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.6 0.3 0.0 0.1 0.7 0.5 0.0 0.2 0.3 0.0 0.1 0.0 0.7 0.8 0.7 0.2 0.1 0.2 0.0 0.1 0.4 0.6 1.2 0.6 0.2 0.5 0.4 0.6 0.5 0.7 0.6 0.0 0.5 0.7 0.7 0.5 1.0 0.5 0.7 0.1 0.0 ORM1 ENSG00000229314 "Orosomucoid 1" P02763 9 114323056-114326475 "Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins" "Acute phase, Transport" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 16 "liver: 834.6" "Cell line enriched" "Detected in some" 11 "Hep G2: 157.9" "Cancer enriched" "Detected in many" 16 "liver cancer: 2506.9" "Cell type enriched" "Detected in some" 45 "neutrophil: 53.4" "Lineage enriched" "Detected in many" 45 "granulocytes: 53.4" "CAB006265, HPA046438, HPA047725, HPA057726" Approved Approved "Golgi apparatus,Vesicles" "Secreted to blood" 945333333333 120000000000 Vesicles "Golgi apparatus" "CAB006265: AB_425575, HPA046438: , HPA047725: , HPA057726: " "unprognostic (3.85e-1)" "unprognostic (2.12e-1)" "unprognostic (1.09e-2)" "unprognostic (2.16e-2)" "unprognostic (3.22e-2)" "unprognostic (1.47e-1)" "unprognostic (2.29e-1)" "unprognostic (2.26e-1)" "unprognostic (1.16e-1)" "unprognostic (4.85e-2)" "unprognostic (1.74e-1)" "prognostic unfavourable (2.35e-4)" "unprognostic (2.10e-1)" "unprognostic (4.38e-2)" "unprognostic (9.32e-3)" "unprognostic (4.51e-2)" 0.1 0.0 0.0 0.2 0.0 6.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 834.6 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 53.4 1.1 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 157.9 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 1.0 0.0 0.0 0.0 0.0 0.0 0.7 0.7 0.0 0.0 13.9 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.5 0.0 0.6 0.0 0.0 1.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 53.4 0.0 0.2 0.0 0.0 0.3 OTUD7A "C15orf16, CEZANNE2, OTUD7" ENSG00000169918 "OTU deubiquitinase 7A" Q8TE49 15 31475398-31870789 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Ubl conjugation pathway" "Hydrolase, Protease, Thiol protease" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 20.4" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in single" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "plasmacytoid DC: 3.2" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA044554 Uncertain Approved Nucleoli,Cytosol "Nucleoli, Cytosol" "HPA044554: AB_10794895" "unprognostic (3.61e-2)" "unprognostic (1.35e-3)" "unprognostic (1.39e-1)" "unprognostic (1.25e-3)" "unprognostic (1.29e-1)" "unprognostic (1.03e-4)" "unprognostic (1.50e-1)" "unprognostic (1.21e-1)" "unprognostic (1.38e-1)" "unprognostic (1.67e-1)" "unprognostic (3.24e-3)" "unprognostic (1.34e-1)" "unprognostic (1.79e-11)" "unprognostic (6.78e-2)" "unprognostic (2.76e-1)" "unprognostic (8.27e-2)" "unprognostic (1.79e-1)" 2.6 2.0 12.4 1.7 13.9 5.9 1.5 13.2 17.0 1.8 3.4 16.0 0.0 1.5 1.9 1.9 1.9 2.0 2.3 2.1 10.0 4.6 2.3 1.0 1.5 3.5 20.4 7.1 2.0 2.5 4.6 1.7 0.9 10.5 1.2 3.1 0.7 1.6 2.0 1.8 3.2 2.1 2.9 9.1 2.2 2.3 8.2 17.4 0.0 2.3 0.0 2.4 1.9 1.3 0.1 3.2 0.3 1.4 0.1 0.7 0.4 3.6 4.1 4.5 6.0 0.4 1.3 3.2 2.5 1.3 3.9 1.9 2.5 3.2 2.9 2.2 0.9 4.6 4.8 2.0 3.2 5.9 6.6 3.7 8.3 2.0 0.3 4.0 5.7 0.0 0.2 3.8 4.3 3.5 6.0 5.4 1.8 2.9 3.1 3.9 2.0 2.0 5.6 3.0 1.4 1.6 3.9 10.9 6.0 3.4 3.0 1.0 2.5 4.3 2.3 5.3 5.2 3.0 6.2 3.3 2.4 3.0 2.9 5.8 4.5 0.0 0.4 0.3 0.6 0.5 0.3 0.0 0.3 0.7 0.2 0.1 0.2 0.2 0.0 0.1 1.4 3.2 0.0 0.4 12.4 13.9 13.2 13.8 10.0 4.6 20.4 7.1 10.5 17.4 P2RY8 P2Y8 ENSG00000182162 "P2Y receptor family member 8" Q86VZ1 X 1462572-1537107 "Cancer-related genes, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 26.7;lymphoid tissue: 19.0" "Cell line enhanced" "Detected in some" "Daudi: 33.2;RPMI-8226: 20.4;THP-1: 20.4;U-266/70: 27.9;U-698: 54.3;U-937: 16.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" HPA003631 Enhanced "HPA003631: AB_1079543" "unprognostic (4.32e-2)" "unprognostic (3.22e-5)" "unprognostic (6.31e-2)" "unprognostic (2.51e-2)" "unprognostic (1.17e-1)" "prognostic favourable (7.80e-5)" "prognostic favourable (1.73e-4)" "unprognostic (5.27e-3)" "unprognostic (5.76e-3)" "unprognostic (5.52e-3)" "prognostic favourable (6.54e-4)" "unprognostic (4.29e-2)" "unprognostic (8.45e-3)" "unprognostic (2.90e-1)" "unprognostic (4.00e-2)" "unprognostic (3.55e-1)" "unprognostic (2.80e-1)" 2.9 4.8 0.5 8.9 2.2 13.9 8.2 0.9 1.8 4.7 1.6 0.5 0.5 1.3 7.1 0.5 0.8 0.8 1.6 11.8 0.9 0.2 13.5 0.8 2.1 19.0 3.6 1.7 5.8 1.1 1.0 6.9 3.4 2.7 1.6 1.3 0.5 1.6 0.5 1.1 0.4 7.8 0.5 3.9 16.6 2.0 0.5 2.0 0.5 8.1 0.5 16.7 2.7 2.8 18.5 5.8 17.8 7.3 15.6 26.7 18.3 0.1 0.1 0.1 0.4 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.1 0.2 33.2 0.1 0.0 0.1 0.0 0.0 0.0 1.2 0.1 0.3 0.3 1.6 0.0 14.5 3.5 0.0 0.0 0.0 0.0 0.0 0.3 14.0 0.0 0.0 16.4 16.4 0.2 0.3 14.8 0.1 20.4 0.0 0.2 0.0 0.2 0.1 0.3 0.1 0.1 20.4 0.0 0.3 0.3 0.1 0.0 27.9 5.2 54.3 0.0 16.9 0.0 17.8 7.3 12.4 26.7 5.5 24.6 15.4 20.2 25.1 5.8 18.5 16.1 16.5 4.7 15.6 2.2 1.5 15.9 18.3 0.5 2.2 0.9 1.8 0.9 0.2 3.6 1.7 2.7 2.0 PABPC1 "PAB1, PABP1, PABPC2, PABPL1" ENSG00000070756 "Poly(A) binding protein cytoplasmic 1" P11940 8 100685816-100722809 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "mRNA processing, mRNA splicing, Nonsense-mediated mRNA decay" RNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB011536, HPA045423, HPA067156" Supported Supported Cytosol 2700000 Cytosol "CAB011536: AB_777008, HPA045423: , HPA067156: " "unprognostic (5.00e-2)" "unprognostic (2.64e-2)" "unprognostic (3.18e-1)" "unprognostic (4.50e-1)" "prognostic favourable (2.51e-4)" "unprognostic (1.93e-2)" "prognostic unfavourable (5.80e-4)" "unprognostic (2.51e-3)" "unprognostic (5.70e-2)" "unprognostic (1.50e-2)" "unprognostic (3.21e-3)" "unprognostic (7.24e-2)" "prognostic unfavourable (5.70e-12)" "unprognostic (6.22e-2)" "unprognostic (2.55e-1)" "unprognostic (6.98e-3)" "unprognostic (1.40e-2)" 85.6 49.6 33.6 66.1 38.8 94.2 80.5 35.8 32.5 84.2 80.7 41.9 57.2 64.1 85.3 48.8 195.5 54.6 56.4 35.1 32.3 19.3 43.6 83.2 72.8 156.2 40.6 24.3 111.1 106.9 31.8 34.1 50.6 36.8 88.2 71.5 43.4 192.9 79.0 35.1 95.4 104.0 89.9 65.2 135.3 73.4 98.7 37.6 137.2 65.4 63.0 157.9 120.9 116.4 70.8 98.4 32.3 106.7 65.9 106.0 90.6 180.2 45.1 35.3 64.1 66.2 131.6 61.0 44.1 63.9 47.5 51.8 53.9 84.9 228.8 172.1 77.6 70.0 55.3 86.3 81.3 69.9 36.5 118.0 34.0 69.3 82.1 50.5 83.5 122.2 136.7 44.2 217.6 74.2 99.1 88.1 70.4 52.5 251.4 105.3 79.1 64.1 83.0 42.9 82.6 57.4 117.4 49.3 54.9 29.4 46.0 103.0 82.8 83.8 69.1 42.8 79.9 62.8 74.2 86.4 59.8 128.2 50.4 113.5 43.0 27.6 83.3 28.8 39.7 99.9 84.2 70.8 78.3 64.4 98.4 62.6 106.0 85.1 32.3 65.9 106.7 65.5 67.4 90.6 33.6 38.8 35.8 32.5 32.3 19.3 40.6 24.3 36.8 37.6 PAFAH1B2 ENSG00000168092 "Platelet activating factor acetylhydrolase 1b catalytic subunit 2" P68402 11 117144267-117176894 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Lipid degradation, Lipid metabolism" Hydrolase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA051836 Approved Supported "Nucleoli,Plasma membrane,Cytosol" 1600000 Cytosol "Nucleoli, Plasma membrane" "HPA051836: " "unprognostic (1.08e-2)" "unprognostic (3.14e-2)" "unprognostic (2.07e-2)" "unprognostic (3.88e-2)" "unprognostic (9.94e-2)" "unprognostic (1.21e-3)" "prognostic unfavourable (9.44e-4)" "prognostic unfavourable (3.07e-4)" "unprognostic (1.01e-1)" "prognostic favourable (4.25e-4)" "prognostic unfavourable (7.79e-5)" "unprognostic (8.18e-2)" "unprognostic (1.11e-2)" "unprognostic (9.97e-2)" "unprognostic (3.25e-1)" "unprognostic (2.46e-1)" "unprognostic (1.34e-1)" 21.5 34.1 30.6 19.2 29.7 33.5 32.3 43.5 41.3 21.6 20.2 33.3 12.7 21.1 23.4 22.8 23.3 20.8 19.3 26.2 31.9 36.8 24.6 22.5 20.5 17.7 39.3 31.6 23.6 23.0 23.1 24.2 26.9 39.6 22.2 19.6 17.3 19.3 17.4 14.1 20.8 18.0 19.9 51.6 18.3 21.4 29.9 26.3 15.1 30.9 10.8 20.4 25.9 20.3 26.8 21.6 36.8 35.7 18.9 31.4 26.9 14.8 17.0 19.7 28.3 22.0 15.4 15.3 25.0 21.9 13.9 12.7 31.0 32.8 16.1 35.9 29.9 23.9 28.5 32.3 18.4 14.3 11.0 41.3 15.6 19.9 19.7 14.2 15.8 17.0 25.6 27.8 35.1 22.8 21.9 12.3 21.3 9.5 13.7 21.0 18.0 13.4 15.4 22.3 17.6 21.3 23.3 21.9 29.1 28.8 21.8 9.5 24.3 12.3 36.4 25.5 16.9 12.4 17.7 3.9 5.9 21.6 10.3 27.4 21.4 32.1 30.8 26.7 24.2 33.3 28.2 26.8 28.0 25.3 21.6 25.4 29.3 31.4 36.8 18.9 35.7 15.8 19.5 26.9 30.6 29.7 43.5 37.8 31.9 36.8 39.3 31.6 39.6 26.3 PAGE4 "CT16.7, GAGEC1, PAGE-4" ENSG00000101951 "PAGE family member 4" O60829 X 49829260-49833973 "Cancer-related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 13 "epididymis: 129.2;placenta: 199.4;prostate: 58.4" "Cell line enhanced" "Detected in some" "CACO-2: 6.8;U-266/70: 8.4;U-266/84: 30.7" "Group enriched" "Detected in some" 17 "liver cancer: 14.8;prostate cancer: 7.4" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA023880 Enhanced Approved "Golgi apparatus,Vesicles" Vesicles "Golgi apparatus" "HPA023880: AB_1854930" "unprognostic (8.56e-2)" "unprognostic (1.47e-1)" "unprognostic (1.04e-1)" "unprognostic (4.82e-3)" "unprognostic (5.37e-2)" 0.2 0.7 0.5 0.1 0.1 0.0 0.1 0.2 0.2 0.6 0.1 0.2 5.7 0.0 6.6 129.2 0.1 6.8 0.1 0.1 0.4 0.5 0.8 0.1 0.2 0.1 0.1 0.2 0.9 0.1 0.0 0.6 199.4 0.2 58.4 0.0 0.1 0.1 9.8 0.8 0.1 0.1 2.4 0.2 0.1 0.1 2.1 0.1 0.1 0.1 0.1 0.1 0.2 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 6.8 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.6 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 8.4 30.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.5 0.1 0.2 0.2 0.4 0.5 0.1 0.2 0.2 0.1 PALB2 "FANCN, FLJ21816" ENSG00000083093 "Partner and localizer of BRCA2" Q86YC2 16 23603160-23641310 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "DNA damage, DNA recombination, DNA repair" DNA-binding "Cancer-related genes, Fanconi anemia, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" "CAB014895, HPA057000" Approved Supported Nucleoplasm Nucleoplasm "CAB014895: , HPA057000: " "unprognostic (1.11e-1)" "unprognostic (5.67e-3)" "prognostic favourable (2.83e-5)" "unprognostic (1.43e-2)" "unprognostic (6.22e-2)" "unprognostic (1.61e-2)" "unprognostic (2.00e-3)" "unprognostic (5.18e-2)" "unprognostic (2.46e-2)" "unprognostic (2.00e-2)" "prognostic unfavourable (2.35e-5)" "unprognostic (2.05e-2)" "unprognostic (1.04e-2)" "unprognostic (2.72e-1)" "unprognostic (1.25e-1)" "unprognostic (7.20e-2)" "unprognostic (3.21e-1)" 12.4 9.9 10.7 19.6 11.9 6.8 15.2 16.5 14.1 12.4 14.0 10.8 9.1 14.8 10.9 13.5 17.6 9.6 7.8 10.5 10.0 10.6 13.7 16.1 9.2 13.4 9.7 12.5 15.3 10.6 13.7 16.1 9.1 14.9 10.9 12.7 8.6 11.0 14.7 10.3 17.0 14.1 12.8 10.8 14.1 11.0 16.9 10.5 12.9 12.1 12.0 15.3 13.6 13.3 3.7 3.9 7.2 7.7 3.9 5.5 2.0 11.8 9.2 11.1 7.7 9.2 7.3 9.9 8.6 13.1 14.1 17.1 7.8 12.4 12.5 6.3 6.0 10.6 9.8 14.4 16.9 7.3 5.7 7.6 12.6 21.9 8.6 14.0 12.4 8.2 14.7 13.3 15.2 7.5 15.7 6.7 12.4 11.7 14.4 14.6 24.6 5.3 16.7 13.6 17.1 10.7 10.6 8.2 8.1 8.8 10.0 11.2 9.2 9.6 5.4 16.9 6.5 8.3 9.2 7.9 12.8 12.8 11.1 10.3 10.1 7.2 3.3 3.0 4.4 4.2 5.3 3.7 4.9 5.3 3.9 3.1 5.5 4.3 0.2 3.9 7.7 2.8 3.1 2.0 10.7 11.9 16.5 14.1 10.0 10.6 9.7 12.5 14.9 10.5 PAPD5 TRF4-2 ENSG00000121274 "Poly(A) RNA polymerase D5, non-canonical" Q8NDF8 16 50152918-50235310 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division, Mitosis, mRNA processing, rRNA processing" "DNA-binding, DNA-directed DNA polymerase, Nucleotidyltransferase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA042968, HPA048225" Uncertain "HPA042968: , HPA048225: " "unprognostic (1.05e-2)" "unprognostic (4.09e-2)" "unprognostic (1.77e-2)" "unprognostic (1.63e-1)" "unprognostic (3.27e-1)" "unprognostic (2.91e-2)" "unprognostic (4.33e-2)" "unprognostic (2.46e-1)" "unprognostic (7.83e-2)" "unprognostic (1.30e-1)" "unprognostic (1.30e-1)" "unprognostic (3.30e-2)" "prognostic favourable (1.85e-4)" "unprognostic (4.24e-2)" "unprognostic (1.06e-1)" "unprognostic (1.83e-1)" "unprognostic (7.00e-2)" 9.4 9.9 5.9 8.8 8.6 19.2 12.6 14.9 10.8 15.9 10.0 4.5 8.8 11.1 13.1 6.3 7.4 10.8 6.3 8.0 7.7 6.9 10.0 11.9 8.5 11.2 6.4 8.0 10.5 7.9 18.5 13.4 9.2 7.5 10.0 6.4 6.7 7.6 9.8 9.9 8.1 9.4 9.7 6.1 6.0 8.0 12.3 8.0 6.8 7.5 6.0 6.6 13.1 30.8 3.5 4.9 4.6 2.9 7.2 5.6 1.2 11.3 8.7 7.1 12.7 11.2 9.5 9.1 10.2 10.4 12.3 5.7 12.0 8.1 13.7 12.2 12.4 8.6 13.3 7.6 16.2 8.0 8.7 8.2 4.7 15.5 12.6 6.8 12.7 5.7 9.4 10.1 12.8 8.5 8.4 4.8 11.3 4.9 9.5 10.2 9.2 9.4 12.8 14.2 17.9 3.5 4.2 9.1 5.4 10.3 13.3 7.0 4.4 5.0 7.3 11.4 10.0 9.9 5.8 9.6 7.4 18.1 6.8 6.3 8.1 4.6 2.6 1.3 4.0 2.9 3.5 2.9 4.3 4.8 2.0 3.5 4.8 5.6 4.0 7.2 2.1 4.9 3.7 1.2 5.9 8.6 14.9 10.8 7.7 6.9 6.4 8.0 7.5 8.0 PAPPA "ASBABP2, DIPLA1, IGFBP-4ase, PAPA, PAPP-A, PAPPA1" ENSG00000182752 "Pappalysin 1" Q13219 9 116153804-116402322 "Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins" "Hydrolase, Metalloprotease, Protease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 86 "placenta: 484.6" "Cell line enhanced" "Detected in some" "ASC diff: 19.0;ASC TERT1: 14.5;HSkMC: 52.2;U-138 MG: 13.6" "Low cancer specificity" "Detected in some" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in some" "Group enriched" "Detected in many" 5 "midbrain: 10.4;olfactory region: 4.1;pons and medulla: 8.3;thalamus: 4.8" "HPA001667, CAB016724" Enhanced "Secreted in female reproductive system" 41000 "CAB016724: , HPA001667: AB_1854960" "unprognostic (3.25e-1)" "unprognostic (6.18e-6)" "unprognostic (2.47e-1)" "unprognostic (6.49e-2)" "unprognostic (2.01e-2)" "unprognostic (1.14e-1)" "unprognostic (1.13e-1)" "unprognostic (5.42e-3)" "unprognostic (5.44e-2)" "unprognostic (3.87e-2)" "unprognostic (6.87e-3)" "unprognostic (8.25e-2)" "unprognostic (8.00e-3)" "unprognostic (2.37e-3)" "unprognostic (2.48e-1)" "unprognostic (4.01e-1)" "unprognostic (1.02e-3)" 4.8 2.3 0.5 1.0 0.5 0.0 0.8 0.4 0.6 3.6 2.4 0.6 1.0 0.1 3.5 1.0 3.6 2.0 1.1 3.7 0.4 0.0 4.3 0.5 2.4 0.7 0.4 0.4 1.4 0.7 5.6 0.7 484.6 0.7 1.4 0.9 0.9 0.5 1.2 0.5 1.1 0.9 2.4 0.6 0.6 1.0 0.8 0.5 0.4 1.3 1.0 1.0 2.3 3.4 0.2 0.0 0.2 0.0 0.0 0.1 0.0 0.0 5.4 8.3 0.0 19.0 14.5 0.0 4.4 7.8 1.2 2.1 0.0 0.0 0.0 0.0 3.1 0.6 0.0 0.0 5.9 0.0 0.0 0.9 4.5 0.0 9.2 0.0 0.0 52.2 0.0 6.1 0.7 0.0 0.2 0.0 1.4 0.0 0.0 0.0 2.4 0.0 0.0 0.2 0.0 0.2 0.0 0.0 0.4 0.6 0.0 0.0 0.0 0.0 10.5 13.6 0.7 0.3 0.5 0.0 0.0 0.0 9.7 0.0 4.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.5 0.5 0.4 0.6 0.4 0.0 0.4 0.4 0.7 0.5 PARP1 "ADPRT, PARP, PPOL" ENSG00000143799 "Poly(ADP-ribose) polymerase 1" P09874 1 226360691-226408079 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA repair, Transcription, Transcription regulation" "DNA-binding, Glycosyltransferase, Transferase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000147, CAB003839, CAB003840, HPA045168, CAB075726, CAB075727" Supported Supported Enhanced Nucleoplasm 39000 Nucleoplasm "CAB000147: AB_430876, CAB003839: AB_365493, CAB003840: AB_562187, CAB075726: , CAB075727: , HPA045168: " "unprognostic (2.02e-1)" "unprognostic (9.40e-2)" "unprognostic (7.44e-3)" "unprognostic (1.32e-1)" "unprognostic (4.29e-1)" "unprognostic (9.22e-2)" "prognostic unfavourable (3.40e-4)" "unprognostic (2.20e-1)" "unprognostic (3.62e-2)" "unprognostic (1.39e-1)" "unprognostic (2.13e-1)" "unprognostic (1.66e-1)" "prognostic unfavourable (1.35e-5)" "unprognostic (2.38e-2)" "unprognostic (1.82e-1)" "unprognostic (3.14e-2)" "unprognostic (2.64e-1)" 17.3 16.6 31.2 35.7 31.2 14.3 15.3 21.1 29.2 14.3 21.8 37.4 10.3 15.0 18.2 13.0 18.1 15.0 10.8 24.2 27.8 21.9 13.4 24.8 14.1 56.3 40.7 21.8 14.6 28.1 62.6 22.9 28.7 30.4 22.0 19.2 16.3 17.0 24.7 47.3 11.7 19.6 25.5 49.1 32.7 15.9 22.5 34.8 29.5 14.5 16.5 70.2 19.9 13.7 53.0 16.5 9.0 17.5 11.1 21.8 11.5 28.5 15.3 42.6 30.1 11.2 9.2 24.3 18.9 16.9 25.8 21.2 24.3 14.0 83.2 28.3 11.5 21.5 58.5 18.6 22.7 34.9 81.7 32.2 20.4 15.9 6.7 53.4 15.6 9.1 7.4 20.7 14.7 20.0 51.2 42.5 13.3 13.6 17.1 19.3 78.4 30.4 51.8 73.0 76.9 12.1 20.4 42.9 37.6 24.6 27.6 15.5 23.2 33.5 15.2 13.7 22.7 18.5 35.4 17.3 29.0 71.5 11.4 18.1 30.7 9.0 6.7 6.9 18.3 11.3 21.6 46.8 19.4 18.0 14.3 53.0 15.2 16.4 1.0 11.1 17.5 16.5 21.8 11.5 31.2 31.2 21.1 28.4 27.8 21.9 40.7 21.8 30.4 34.8 PARVB CGI-56 ENSG00000188677 "Parvin beta" Q9HBI1 22 43999211-44172949 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" Actin-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 82.1" "Cell line enhanced" "Detected in many" "HUVEC TERT2: 43.7;RPMI-8226: 42.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA062601, HPA072217" Enhanced Approved Cytosol 90000000 Cytosol "HPA062601: , HPA072217: " "unprognostic (2.41e-1)" "unprognostic (5.52e-3)" "unprognostic (1.66e-1)" "unprognostic (3.83e-2)" "unprognostic (2.10e-3)" "unprognostic (7.65e-3)" "unprognostic (1.28e-1)" "unprognostic (1.73e-2)" "unprognostic (2.28e-1)" "unprognostic (6.46e-2)" "unprognostic (1.03e-2)" "unprognostic (6.45e-2)" "unprognostic (1.28e-2)" "unprognostic (4.87e-3)" "unprognostic (3.19e-2)" "unprognostic (4.19e-2)" "unprognostic (7.05e-3)" 15.9 10.7 6.4 9.7 7.3 16.8 17.4 3.1 8.3 8.0 7.2 3.5 6.3 3.7 8.6 8.7 7.3 6.8 5.3 28.5 5.6 8.8 7.3 7.3 12.6 19.7 8.0 6.3 13.4 4.8 8.6 9.3 10.2 5.8 7.8 4.4 9.3 5.3 7.2 82.1 5.1 6.3 11.9 8.3 15.2 5.4 5.7 4.5 2.3 4.9 22.4 7.9 11.7 26.0 6.3 14.1 4.8 6.4 0.7 2.2 8.3 6.3 7.5 0.1 5.3 8.0 10.2 0.0 8.9 5.5 5.8 4.4 7.8 3.8 0.0 4.9 23.8 0.2 12.7 0.5 3.2 8.9 7.9 27.1 13.2 0.0 13.4 20.4 24.4 15.9 6.7 4.2 0.0 43.7 9.7 18.6 6.3 4.2 0.1 13.4 2.7 5.2 0.0 0.2 42.7 0.1 0.1 6.9 4.8 2.3 0.4 22.4 4.4 8.3 27.2 5.3 5.7 8.2 0.9 4.6 4.0 0.2 23.4 6.0 29.3 4.5 6.1 1.4 1.0 6.4 1.6 6.0 1.7 1.4 6.8 6.3 0.4 0.9 4.8 0.7 2.6 14.1 2.2 8.3 6.4 7.3 3.1 8.3 5.6 8.8 8.0 6.3 5.8 4.5 PATZ1 "dJ400N23, MAZR, PATZ, RIAZ, ZBTB19, ZNF278, ZSG" ENSG00000100105 "POZ/BTB and AT hook containing zinc finger 1" Q9HBE1 22 31325804-31346232 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Repressor" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA047893, HPA048315" Approved Supported Nucleoplasm Nucleoplasm "HPA047893: , HPA048315: " "unprognostic (3.25e-1)" "unprognostic (8.72e-2)" "unprognostic (1.77e-1)" "unprognostic (2.88e-3)" "prognostic favourable (1.06e-4)" "unprognostic (1.77e-1)" "unprognostic (8.34e-3)" "prognostic favourable (8.71e-5)" "unprognostic (1.14e-1)" "unprognostic (1.41e-2)" "unprognostic (1.99e-3)" "unprognostic (1.76e-1)" "prognostic favourable (8.54e-8)" "unprognostic (9.22e-2)" "unprognostic (2.15e-1)" "unprognostic (1.51e-1)" "prognostic favourable (7.79e-6)" 9.6 11.2 13.0 12.7 12.9 12.9 12.1 16.8 16.0 14.2 13.0 21.7 21.8 9.4 19.6 14.4 7.3 22.2 14.1 10.4 14.0 11.8 11.4 11.0 17.4 30.3 15.3 13.4 27.7 16.6 25.4 11.0 8.9 13.6 14.0 6.8 17.5 17.5 17.8 9.1 7.5 11.9 15.6 12.5 14.3 10.5 13.0 15.5 38.5 18.9 8.2 13.8 17.4 14.2 4.7 7.1 4.8 1.8 3.5 5.7 2.0 8.3 10.5 21.5 12.6 5.7 5.3 11.3 2.5 6.5 10.4 9.6 7.3 8.1 17.8 9.3 4.7 6.5 14.5 7.8 5.4 10.4 13.3 7.5 7.3 14.9 9.3 25.1 10.1 8.2 9.4 6.6 7.4 8.2 3.1 7.2 6.6 25.4 16.0 17.3 14.4 12.4 27.2 9.1 5.9 7.0 17.7 28.1 22.5 6.4 7.8 14.0 15.5 16.1 5.8 7.0 13.3 4.3 8.6 9.3 6.1 16.2 2.9 3.3 11.9 0.0 1.8 4.8 3.4 1.1 3.5 4.7 2.6 4.4 2.5 3.8 5.7 4.1 0.8 3.5 0.6 7.1 3.7 2.0 13.0 12.9 16.8 16.0 14.0 11.8 15.3 13.4 13.6 15.5 PAX3 "HUP2, WS1" ENSG00000135903 "Paired box 3" P23760 2 222199888-222298996 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Myogenesis, Neurogenesis, Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes, Deafness, Disease mutation, Proto-oncogene, Waardenburg syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 19.1;retina: 39.6" "Cell line enhanced" "Detected in some" "BJ hTERT+ SV40 Large T+: 7.5;BJ hTERT+ SV40 Large T+ RasG12V: 8.9;HBF TERT88: 6.6;RH-30: 12.9;SK-MEL-30: 22.7" "Cancer enriched" "Detected in some" 24 "melanoma: 20.3" "Group enriched" "Detected in some" 6 "cerebellum: 19.1;pons and medulla: 7.8" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 7 "cerebellum: 3.9;midbrain: 1.6;pons and medulla: 1.4" "Group enriched" "Detected in many" 5 "cerebellum: 10.0;midbrain: 11.7;pons and medulla: 3.5" "HPA063659, HPA069000" Uncertain Enhanced Nucleoplasm Nucleoplasm "HPA063659: , HPA069000: " "unprognostic (2.57e-2)" "unprognostic (1.48e-2)" "unprognostic (1.27e-2)" "unprognostic (1.65e-1)" "unprognostic (2.61e-2)" "unprognostic (3.70e-1)" "unprognostic (6.18e-2)" "unprognostic (1.41e-1)" "unprognostic (2.26e-1)" "unprognostic (9.70e-2)" 0.8 0.1 0.0 0.1 0.8 0.1 2.9 19.1 0.2 0.3 0.1 0.1 0.3 0.1 0.2 0.1 0.1 0.1 0.1 0.3 0.0 0.2 0.1 0.1 0.1 0.2 2.2 0.0 0.1 0.2 0.1 0.0 0.1 7.8 0.4 0.1 39.6 7.9 0.2 8.6 7.9 0.1 0.1 4.2 0.1 0.2 2.9 0.8 0.0 0.1 3.9 0.5 0.1 0.2 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 3.9 0.0 0.0 0.0 0.0 5.1 5.1 7.5 8.9 0.0 0.5 0.0 0.0 3.4 0.0 0.0 0.0 6.6 0.0 5.8 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.1 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 5.3 0.1 0.0 0.0 12.9 0.0 0.0 0.0 1.3 0.0 0.0 0.0 22.7 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 2.8 0.0 6.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.8 19.1 0.1 0.0 0.2 2.2 0.0 7.8 0.8 PAX5 BSAP ENSG00000196092 "Paired box 5" Q02548 9 36833275-37034185 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Differentiation, Neurogenesis, Spermatogenesis, Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "blood: 21.6;lymphoid tissue: 33.4" "Group enriched" "Detected in some" 8 "Daudi: 21.0;REH: 61.0;U-698: 27.6" "Low cancer specificity" "Detected in some" "Region enriched" "Detected in single" 5 "midbrain: 1.6" "Group enriched" "Detected in some" 209 "memory B-cell: 20.1;naive B-cell: 21.6" "Lineage enriched" "Detected in single" 216 "B-cells: 21.6" "Region enriched" "Detected in single" 11 "midbrain: 4.7" "Group enriched" "Detected in some" 6 "hippocampal formation: 3.8;midbrain: 10.8;pons and medulla: 3.2" "CAB026269, CAB026869, HPA056394, HPA068498" Enhanced Supported Approved Nucleoplasm,Vesicles,Cytosol Nucleoplasm "Vesicles, Cytosol" "CAB026269: , CAB026869: , HPA056394: , HPA068498: " "unprognostic (4.69e-4)" "unprognostic (3.83e-1)" "unprognostic (9.13e-2)" "unprognostic (1.42e-1)" "unprognostic (2.65e-2)" "unprognostic (1.15e-1)" "unprognostic (2.09e-2)" "unprognostic (2.95e-2)" "unprognostic (2.48e-1)" "unprognostic (2.00e-2)" "unprognostic (1.03e-1)" "unprognostic (2.46e-2)" "unprognostic (1.11e-3)" "unprognostic (3.15e-1)" "unprognostic (8.96e-2)" "unprognostic (6.03e-2)" "unprognostic (1.01e-1)" 0.4 0.2 0.2 33.4 0.2 5.5 0.2 0.2 0.2 0.2 0.7 0.1 0.0 0.0 0.2 0.0 0.7 0.2 0.4 0.2 0.2 0.3 0.5 0.3 0.3 23.2 1.6 0.0 0.2 0.2 0.0 0.5 0.1 0.2 0.3 0.3 0.4 2.5 0.0 0.6 0.2 8.7 0.0 0.3 16.5 0.7 0.9 0.0 2.3 0.4 0.2 30.1 1.3 0.2 21.6 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.1 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 21.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.4 0.0 0.0 0.6 0.1 61.0 0.1 0.1 0.0 0.0 4.3 1.0 0.0 0.2 0.0 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 27.6 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 20.1 0.0 0.0 0.0 21.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.2 0.2 0.2 0.2 0.2 0.3 1.6 0.0 0.2 0.0 PAX8 ENSG00000125618 "Paired box 8" Q06710 2 113215997-113278950 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Differentiation, Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes, Congenital hypothyroidism, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "kidney: 69.3;thyroid gland: 120.5" "Group enriched" "Detected in some" 10 "EFO-21: 26.7;RPTEC TERT1: 63.0" "Group enriched" "Detected in many" 12 "endometrial cancer: 60.6;ovarian cancer: 63.5;renal cancer: 33.2;thyroid cancer: 122.2" "Low region specificity" "Detected in some" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Region enriched" "Detected in some" 4 "pons and medulla: 5.8" "HPA030062, CAB055097, CAB061888, HPA064554" Enhanced Enhanced Nucleoplasm Nucleoplasm "CAB055097: AB_2236705, CAB061888: AB_10895719, HPA030062: AB_10603982, HPA064554: " "unprognostic (2.63e-3)" "unprognostic (3.80e-1)" "unprognostic (1.17e-1)" "prognostic unfavourable (1.75e-5)" "unprognostic (7.24e-2)" "unprognostic (5.16e-5)" "unprognostic (1.56e-2)" "unprognostic (3.29e-2)" "unprognostic (1.03e-1)" "unprognostic (2.16e-1)" "unprognostic (4.13e-2)" "unprognostic (4.00e-2)" "unprognostic (3.37e-2)" "unprognostic (3.27e-1)" "unprognostic (2.37e-1)" "unprognostic (8.93e-3)" "unprognostic (1.02e-1)" 0.9 1.4 1.1 0.5 0.4 0.0 0.6 0.2 0.8 3.8 0.4 0.2 11.7 0.1 2.2 15.2 0.6 9.6 0.8 0.6 0.5 0.5 69.3 0.4 0.5 0.7 0.4 0.3 3.8 0.6 0.1 0.7 0.8 1.5 1.1 0.1 0.5 0.5 10.0 0.3 0.5 0.6 0.4 0.8 0.3 0.4 1.9 0.2 0.4 120.5 0.0 0.2 0.8 1.9 4.4 2.8 1.5 3.4 1.9 2.5 1.1 2.9 0.2 0.1 0.0 0.1 0.0 1.0 0.8 2.6 0.2 0.4 1.8 0.5 0.5 26.7 0.2 0.0 0.5 0.8 0.2 1.2 0.0 0.4 0.2 1.0 0.3 0.0 0.0 0.7 0.1 0.2 0.6 0.0 0.4 2.0 0.8 0.6 0.3 1.2 0.1 1.8 0.0 0.2 0.6 63.0 4.6 0.5 0.0 3.3 0.0 1.8 0.0 1.1 0.9 4.6 0.1 0.8 2.3 0.4 1.3 0.1 4.0 0.6 0.0 1.5 3.4 0.0 0.6 1.8 1.5 4.4 1.5 1.1 2.8 1.9 2.5 1.5 0.5 1.9 1.3 1.1 0.8 1.1 1.1 0.4 0.2 0.8 0.5 0.5 0.4 0.3 1.5 0.2 PBRM1 "BAF180, PB1" ENSG00000163939 "Polybromo 1" Q86U86 3 52545352-52685917 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Chromatin regulator, DNA-binding" "Cancer-related genes, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA015629, HPA059373" Uncertain Enhanced Nucleoplasm Nucleoplasm "HPA015629: AB_1855012, HPA059373: " "unprognostic (1.87e-1)" "unprognostic (1.73e-1)" "unprognostic (1.91e-2)" "unprognostic (2.00e-1)" "unprognostic (6.15e-2)" "unprognostic (1.34e-2)" "unprognostic (1.02e-2)" "unprognostic (9.54e-2)" "unprognostic (1.87e-2)" "unprognostic (1.43e-1)" "unprognostic (1.99e-2)" "unprognostic (4.32e-2)" "unprognostic (2.89e-3)" "unprognostic (3.06e-1)" "unprognostic (1.96e-1)" "unprognostic (1.53e-2)" "unprognostic (1.06e-1)" 24.3 14.8 13.8 20.6 15.9 17.2 24.4 19.1 13.8 18.9 18.5 14.0 22.9 12.2 25.9 13.9 19.9 18.9 13.7 15.9 11.1 10.0 11.7 14.5 14.9 16.5 16.5 8.2 25.1 15.4 14.4 30.6 28.0 14.7 16.1 15.3 12.7 17.5 16.2 21.8 17.2 14.3 21.1 15.6 19.1 14.8 13.1 13.7 51.0 22.0 10.5 17.1 22.4 23.0 6.6 10.7 11.1 8.7 4.6 7.4 1.9 12.3 8.0 28.6 14.0 14.1 14.4 20.0 17.0 11.8 19.7 17.3 8.9 8.4 30.0 2.4 20.0 8.5 24.8 12.9 24.0 32.0 13.3 28.4 15.0 6.9 20.2 23.6 21.6 13.4 14.9 22.0 14.2 19.0 16.2 16.5 19.8 4.1 39.0 7.1 17.3 13.1 20.4 17.9 15.2 8.2 24.2 19.4 21.5 20.5 4.9 16.2 9.2 13.7 21.9 18.5 14.0 15.9 20.8 11.9 18.8 28.5 11.4 19.2 18.4 10.1 5.0 11.1 4.8 3.2 4.9 3.6 4.8 5.3 4.8 6.6 7.4 4.7 2.7 4.6 8.7 10.7 4.5 1.9 13.8 15.9 19.1 13.8 11.1 10.0 16.5 8.2 14.7 13.7 PBX1 ENSG00000185630 "PBX homeobox 1" P40424 1 164555584-164899296 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Differentiation, Sexual differentiation, Steroidogenesis, Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding, Repressor" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HEL: 30.5;NTERA-2: 29.9;SK-BR-3: 61.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "basophil: 2.9" "Lineage enriched" "Detected in single" 9 "granulocytes: 2.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003505, HPA003881, CAB018768" Supported Enhanced "Nucleoplasm,Nuclear bodies,Cytosol" Nucleoplasm "Nuclear bodies, Cytosol" "CAB018768: AB_675783, HPA003505: AB_1855019, HPA003881: AB_1855020" "unprognostic (2.26e-2)" "unprognostic (1.95e-1)" "unprognostic (9.09e-2)" "unprognostic (2.14e-2)" "unprognostic (5.21e-3)" "unprognostic (6.94e-3)" "unprognostic (5.95e-2)" "unprognostic (2.49e-1)" "unprognostic (1.65e-1)" "unprognostic (2.24e-3)" "unprognostic (2.30e-1)" "unprognostic (8.81e-2)" "unprognostic (1.34e-2)" "unprognostic (2.13e-1)" "unprognostic (5.07e-2)" "unprognostic (1.11e-1)" "unprognostic (1.25e-1)" 13.2 17.3 14.9 8.3 15.0 1.4 16.4 14.1 17.4 73.4 26.3 11.2 15.9 13.6 67.2 15.3 20.8 35.1 25.8 12.6 10.9 9.7 15.4 4.2 10.4 2.3 11.6 14.6 35.2 29.4 21.3 12.4 9.6 8.1 27.6 9.3 10.2 19.6 25.1 16.8 6.0 14.6 56.8 8.0 5.1 13.9 9.7 8.7 2.7 17.4 8.5 6.6 32.2 24.7 0.0 0.1 2.9 0.0 0.3 0.2 2.5 1.1 22.3 22.1 5.9 14.9 7.2 1.3 9.3 6.1 2.5 1.8 4.3 4.0 0.0 1.9 12.7 7.8 8.6 2.4 1.0 1.1 9.3 30.5 17.9 0.0 9.8 0.0 7.8 7.1 0.0 1.6 0.7 0.1 0.0 0.0 0.6 14.7 0.0 0.1 29.9 1.1 0.0 7.3 8.9 1.8 13.3 0.8 13.1 10.8 61.6 0.0 23.4 0.0 0.1 1.3 3.1 8.7 2.7 2.8 21.1 0.0 0.1 0.0 0.1 2.9 0.0 0.5 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.7 0.3 0.0 0.1 0.0 2.5 14.9 15.0 14.1 17.4 10.9 9.7 11.6 14.6 8.1 8.7 PCBP1 "hnRNP-E1, hnRNP-X, HNRPE1, HNRPX" ENSG00000169564 "Poly(rC) binding protein 1" Q15365 2 70087454-70089203 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Viral RNA replication" "DNA-binding, Ribonucleoprotein, RNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB037113, HPA043803, HPA068497" Supported Enhanced "Nuclear speckles,Cytoplasmic bodies" 12000000 "Nuclear speckles" "Cytoplasmic bodies" "CAB037113: AB_1840915, HPA043803: , HPA068497: " "unprognostic (1.63e-1)" "unprognostic (2.69e-2)" "unprognostic (1.01e-1)" "unprognostic (7.08e-2)" "unprognostic (5.37e-1)" "unprognostic (1.63e-2)" "unprognostic (8.33e-2)" "unprognostic (9.94e-3)" "unprognostic (2.01e-1)" "unprognostic (2.70e-1)" "unprognostic (6.65e-2)" "unprognostic (2.77e-1)" "prognostic favourable (1.71e-5)" "unprognostic (3.85e-2)" "unprognostic (9.25e-2)" "unprognostic (1.22e-1)" "unprognostic (5.90e-2)" 52.7 57.6 34.4 49.7 36.7 79.5 149.6 33.3 39.9 38.8 47.2 32.4 45.7 41.1 54.1 39.3 55.6 39.3 45.4 55.1 34.0 31.2 41.6 69.5 46.3 77.8 43.5 29.8 42.3 88.3 42.8 30.5 52.7 37.5 36.3 31.2 29.6 47.9 42.0 149.0 41.5 39.6 59.7 39.1 52.0 43.2 31.6 42.1 91.0 43.8 59.9 48.4 49.6 148.0 15.1 29.2 49.6 32.1 31.6 30.3 28.9 61.4 63.5 54.9 42.8 59.3 45.4 88.5 46.1 42.7 45.8 38.6 73.5 41.4 84.6 23.8 52.3 55.1 64.4 67.2 47.0 60.3 49.7 67.6 38.9 112.2 66.9 55.9 65.1 39.5 43.9 37.7 52.7 58.1 69.1 62.7 57.4 76.4 72.0 84.1 55.4 42.0 58.3 60.1 84.8 62.2 63.7 52.2 42.0 37.9 77.8 54.5 46.2 50.9 53.3 43.1 54.1 36.4 58.1 83.6 85.8 85.9 45.6 77.7 52.9 12.6 30.8 45.5 30.3 32.1 27.8 15.1 23.7 26.0 29.2 14.4 24.2 26.9 49.6 31.6 26.7 21.0 27.7 28.9 34.4 36.7 33.3 39.9 34.0 31.2 43.5 29.8 37.5 42.1 PCM1 PTC4 ENSG00000078674 "Pericentriolar material 1" Q15154 8 17922840-18029944 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cilium biogenesis/degradation" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA023370, HPA023374, CAB058695" Enhanced Enhanced "Nuclear membrane,Centrosome,Cytosol" Centrosome "Nuclear membrane, Cytosol" "CAB058695: , HPA023370: AB_1855072, HPA023374: AB_1855073" "unprognostic (1.52e-2)" "unprognostic (1.77e-2)" "unprognostic (6.54e-3)" "unprognostic (3.35e-2)" "unprognostic (9.52e-2)" "unprognostic (1.62e-2)" "unprognostic (1.40e-1)" "unprognostic (7.74e-3)" "unprognostic (1.09e-1)" "unprognostic (2.26e-1)" "unprognostic (2.84e-1)" "unprognostic (2.83e-1)" "unprognostic (1.76e-2)" "unprognostic (2.16e-1)" "unprognostic (4.60e-1)" "unprognostic (1.34e-1)" "unprognostic (2.45e-1)" 19.6 19.0 26.2 26.7 40.4 25.1 25.1 29.2 29.0 25.0 21.1 21.6 22.8 12.4 23.3 27.3 16.4 26.4 17.8 23.0 22.9 18.4 18.8 22.0 19.1 21.1 24.5 24.9 29.1 27.0 42.0 35.8 19.8 26.4 20.2 16.3 16.2 19.4 25.3 63.1 17.6 18.3 26.7 27.2 20.8 17.9 80.0 28.0 40.2 28.2 19.1 20.4 27.0 22.6 11.5 14.9 19.9 7.5 11.2 13.0 4.3 20.3 21.7 33.4 44.2 18.9 19.7 17.3 17.2 21.2 18.4 20.8 14.7 12.2 26.7 11.9 17.1 14.8 21.3 15.8 31.4 8.8 8.2 45.8 15.4 29.8 21.1 20.0 11.8 17.1 16.9 21.3 23.7 21.1 30.9 20.8 22.4 10.2 42.9 33.2 27.5 6.3 25.9 29.9 9.5 15.2 28.3 25.6 19.3 18.4 10.1 26.4 15.9 29.3 18.8 16.8 13.7 20.5 14.5 8.9 19.6 23.9 14.2 22.1 17.1 19.9 6.0 14.4 11.5 3.8 12.0 11.1 10.4 13.0 5.9 11.5 11.6 11.6 6.4 11.2 7.5 14.9 10.3 4.3 26.2 40.4 29.2 29.0 22.9 18.4 24.5 24.9 26.4 28.0 PCNA ENSG00000132646 "Proliferating cell nuclear antigen" P12004 20 5114953-5126626 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA repair, DNA replication, Host-virus interaction" DNA-binding "Cancer-related genes, Deafness, Disease mutation, Dwarfism, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 115.8" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "CAB000148, HPA030521, HPA030522, HPA030523" Enhanced Enhanced Nucleoplasm Nucleoplasm "CAB000148: AB_628110, HPA030521: AB_10600218, HPA030522: AB_10602096, HPA030523: AB_10602199" "unprognostic (5.21e-2)" "prognostic favourable (1.86e-5)" "unprognostic (2.96e-2)" "unprognostic (2.43e-1)" "unprognostic (3.17e-1)" "unprognostic (5.60e-3)" "prognostic unfavourable (2.61e-4)" "unprognostic (1.47e-2)" "unprognostic (2.22e-1)" "unprognostic (3.89e-2)" "unprognostic (1.01e-2)" "unprognostic (9.78e-2)" "prognostic unfavourable (3.03e-6)" "unprognostic (2.12e-2)" "unprognostic (2.29e-1)" "unprognostic (7.11e-3)" "unprognostic (7.46e-2)" 13.9 21.4 11.1 31.8 15.8 87.2 13.7 17.2 14.6 13.7 23.1 15.6 13.7 18.9 15.7 13.7 36.0 12.7 17.5 13.6 11.6 9.8 21.7 14.9 17.8 41.6 18.8 10.8 14.4 14.3 14.0 13.9 24.0 14.3 10.8 26.1 18.7 17.7 15.6 11.0 16.5 20.5 12.8 16.1 24.5 15.7 40.5 17.4 115.8 18.1 40.7 38.7 17.3 17.2 16.9 16.0 8.7 11.6 19.6 24.4 16.9 73.2 57.7 58.6 25.2 13.9 13.0 41.1 48.3 28.5 45.5 64.7 45.0 58.6 74.5 15.7 17.2 55.1 34.6 58.2 41.7 22.1 38.2 52.3 22.2 104.8 5.9 71.6 23.5 9.4 13.8 38.7 9.2 25.9 46.5 63.0 44.3 26.5 136.8 79.2 43.8 32.0 75.6 51.5 60.1 20.6 42.8 50.3 34.2 33.8 52.3 33.1 36.9 36.5 17.3 32.9 37.8 46.2 55.1 32.0 91.3 126.2 14.8 68.2 42.1 2.4 11.6 8.7 19.2 10.9 23.8 16.9 24.4 19.3 16.0 13.6 22.4 20.1 3.8 19.6 11.4 14.7 23.3 16.9 11.1 15.8 17.2 14.6 11.6 9.8 18.8 10.8 14.3 17.4 PDAP1 "HASPP28, PAP, PAP1" ENSG00000106244 "PDGFA associated protein 1" Q13442 7 99392048-99408829 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB021103, HPA050294, HPA060836" Approved Enhanced "Plasma membrane,Cytosol" 40000 Cytosol "Plasma membrane" "CAB021103: AB_10057973, HPA050294: , HPA060836: " "unprognostic (2.27e-1)" "unprognostic (1.45e-1)" "unprognostic (3.87e-2)" "unprognostic (1.49e-1)" "unprognostic (1.41e-2)" "unprognostic (4.01e-3)" "prognostic unfavourable (6.67e-4)" "unprognostic (5.77e-2)" "unprognostic (3.50e-1)" "unprognostic (2.65e-2)" "unprognostic (2.63e-1)" "unprognostic (3.35e-2)" "unprognostic (1.45e-2)" "unprognostic (3.51e-2)" "unprognostic (1.79e-1)" "unprognostic (3.49e-1)" "unprognostic (2.97e-2)" 26.7 25.7 25.5 25.0 23.9 23.0 22.4 23.4 28.5 22.8 25.9 18.3 21.6 21.1 25.8 21.6 32.2 20.5 23.4 30.2 23.4 20.4 25.2 31.8 20.5 20.2 23.2 23.5 23.4 28.2 23.3 18.0 28.8 24.2 23.0 22.0 19.0 27.8 26.4 103.5 24.8 19.6 26.9 22.2 20.5 22.6 19.7 24.3 20.1 22.4 37.2 25.2 24.1 28.2 11.3 15.8 24.2 11.9 20.4 14.2 4.6 30.7 26.9 18.2 23.2 14.1 14.7 11.8 25.6 14.8 20.7 17.5 27.2 15.4 13.6 22.7 24.1 16.7 21.9 25.6 20.2 19.3 24.3 13.7 26.0 23.6 20.7 25.7 13.6 15.4 19.3 22.7 37.3 20.6 32.3 24.8 20.2 64.2 35.7 35.1 23.3 29.2 16.5 18.2 23.5 20.9 23.7 18.7 37.4 19.1 30.5 13.0 13.4 13.5 18.6 27.9 30.9 33.0 39.9 23.9 27.3 30.1 22.4 23.1 29.1 7.6 9.4 8.6 12.4 11.9 11.1 11.3 11.5 8.9 7.4 11.1 8.3 10.3 24.2 20.4 10.6 15.8 14.2 4.6 25.5 23.9 23.4 28.5 23.4 20.4 23.2 23.5 24.2 24.3 PDCD1LG2 "B7-DC, bA574F11.2, Btdc, CD273, PD-L2, PDL2" ENSG00000197646 "Programmed cell death 1 ligand 2" Q9BQ51 9 5510570-5571254 "Cancer-related genes, CD markers, Predicted membrane proteins, Predicted secreted proteins" "Adaptive immunity, Immunity" Receptor "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "BJ: 25.4;BJ hTERT+: 39.9;HDLM-2: 30.5;TIME: 17.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA013411 Approved Approved Cytosol "Secreted - unknown location" 34000000 Cytosol "HPA013411: AB_1855102" "unprognostic (3.93e-2)" "unprognostic (1.90e-1)" "unprognostic (3.51e-3)" "unprognostic (6.68e-3)" "unprognostic (7.66e-2)" "unprognostic (6.77e-2)" "unprognostic (5.72e-2)" "unprognostic (2.91e-1)" "unprognostic (1.68e-1)" "unprognostic (4.37e-3)" "unprognostic (5.79e-2)" "unprognostic (5.29e-2)" "prognostic unfavourable (1.15e-4)" "unprognostic (5.00e-2)" "unprognostic (4.66e-2)" "unprognostic (2.01e-1)" "unprognostic (7.51e-3)" 15.2 1.8 1.2 7.7 1.4 0.2 9.5 0.7 1.2 7.0 1.9 2.3 0.0 0.8 2.9 7.2 3.9 3.8 4.0 5.8 1.2 1.3 2.5 6.4 13.3 10.8 1.6 0.5 4.1 1.8 0.5 1.1 12.9 1.9 5.0 2.5 2.4 2.9 1.7 5.5 3.6 2.5 4.6 3.7 19.5 1.9 4.2 1.2 8.1 3.5 3.5 8.1 6.0 5.4 0.5 0.9 4.1 3.6 0.0 3.0 0.7 2.0 0.0 0.0 0.0 1.7 2.0 0.0 25.4 39.9 12.3 14.9 0.0 0.1 0.0 0.0 10.3 0.2 0.0 3.4 12.2 30.5 0.0 0.0 0.0 0.0 9.9 0.0 0.0 1.8 0.0 5.7 6.7 8.0 0.0 3.0 14.7 0.0 0.0 0.0 0.0 0.0 0.0 15.2 0.2 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 17.6 8.8 0.5 4.2 7.0 0.4 0.0 0.0 5.0 0.0 1.0 4.1 0.9 0.0 1.4 3.6 1.9 0.5 2.2 0.9 0.9 0.3 0.0 1.0 2.0 0.0 0.5 0.0 3.0 0.7 1.2 1.4 0.7 1.2 1.2 1.3 1.6 0.5 1.9 1.2 PDCD2L MGC13096 ENSG00000126249 "Programmed cell death 2 like" Q9BRP1 19 34404384-34426168 "Cancer-related genes, Predicted intracellular proteins" "Cell cycle" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" HPA052181 Approved Approved Mitochondria Mitochondria "HPA052181: " "unprognostic (5.39e-2)" "unprognostic (3.48e-1)" "unprognostic (1.51e-1)" "unprognostic (6.99e-2)" "unprognostic (1.07e-1)" "unprognostic (3.22e-1)" "prognostic unfavourable (5.81e-4)" "unprognostic (1.82e-1)" "unprognostic (1.49e-1)" "unprognostic (8.78e-2)" "unprognostic (1.30e-2)" "unprognostic (2.39e-1)" "prognostic unfavourable (1.23e-5)" "unprognostic (1.75e-1)" "unprognostic (1.72e-1)" "unprognostic (3.00e-2)" "unprognostic (5.98e-2)" 6.2 6.6 7.7 7.3 8.9 4.5 6.1 8.8 15.6 5.4 5.8 6.8 6.3 4.6 5.8 6.1 5.8 6.9 6.3 9.3 7.1 7.8 4.5 9.7 4.0 7.1 5.8 6.2 6.9 16.0 4.0 6.8 4.4 5.7 5.7 6.1 5.5 8.9 8.1 26.7 7.4 4.2 5.4 5.8 5.8 7.3 22.9 4.3 6.2 6.1 12.2 7.7 5.3 4.2 9.9 17.4 0.5 3.8 8.5 10.5 4.1 10.7 18.6 2.4 4.5 1.1 2.3 7.4 3.5 2.6 5.9 6.0 17.3 8.0 9.0 15.5 2.0 3.7 9.4 7.9 6.0 13.3 19.5 8.9 2.9 13.5 7.8 17.1 5.0 2.8 7.0 3.4 11.7 6.0 17.7 4.8 5.3 13.8 6.4 6.4 9.1 18.5 9.8 4.2 13.3 7.6 6.3 13.8 4.8 0.3 11.4 6.2 4.9 7.2 3.1 3.9 4.8 4.7 11.7 10.7 16.3 16.4 4.9 15.2 3.2 0.0 2.5 0.0 7.3 3.8 10.0 9.9 7.2 7.0 5.1 7.5 10.5 8.0 0.5 8.5 2.3 17.4 8.1 4.1 7.7 8.9 8.8 15.6 7.1 7.8 5.8 6.2 5.7 4.3 PDE4DIP "CMYA2, KIAA0454, KIAA0477, MMGL" ENSG00000178104 "Phosphodiesterase 4D interacting protein" Q5VU43 1 148808181-149048286 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in all" 10 "heart muscle: 106.0;skeletal muscle: 276.2" "Cell line enhanced" "Detected in many" "ASC diff: 62.3;ASC TERT1: 50.7;K-562: 50.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" HPA012678 Supported "Golgi apparatus" "Golgi apparatus" "HPA012678: AB_1855123" "unprognostic (2.14e-1)" "unprognostic (3.27e-1)" "unprognostic (5.31e-2)" "unprognostic (6.73e-2)" "unprognostic (7.82e-2)" "unprognostic (1.16e-2)" "unprognostic (2.17e-1)" "unprognostic (9.72e-2)" "unprognostic (7.65e-2)" "unprognostic (1.67e-1)" "unprognostic (2.23e-2)" "unprognostic (5.08e-2)" "unprognostic (1.70e-3)" "unprognostic (1.82e-1)" "unprognostic (4.14e-2)" "unprognostic (9.13e-2)" "unprognostic (2.28e-1)" 4.8 2.9 9.2 4.3 8.3 2.3 9.0 12.1 15.1 4.8 6.2 8.3 5.6 3.8 3.1 11.8 6.1 3.3 5.0 106.0 9.7 7.8 6.6 9.3 5.5 3.8 15.6 8.1 2.3 3.4 13.6 7.7 10.2 9.3 4.6 4.1 7.2 5.4 4.5 276.2 4.1 7.7 3.1 18.5 2.9 4.4 1.7 11.2 1.5 3.1 18.1 3.8 3.6 6.1 12.0 6.7 7.4 5.9 4.7 13.2 4.3 7.8 1.5 2.2 2.4 62.3 50.7 13.0 9.2 8.7 9.0 11.8 7.2 5.0 4.0 2.8 13.2 4.0 5.3 6.5 15.3 2.9 7.6 2.0 3.2 2.8 16.5 1.7 2.1 36.0 13.0 38.2 20.8 3.5 50.9 9.4 15.9 13.3 1.3 1.0 7.8 3.3 2.9 5.6 1.5 5.4 8.1 10.7 0.9 9.0 26.3 7.2 7.8 2.3 4.6 10.4 2.3 26.1 20.4 4.1 5.8 5.9 42.6 1.6 6.4 7.4 5.3 4.1 5.4 5.9 5.5 12.0 10.9 7.2 6.7 11.7 8.4 4.6 1.2 4.7 1.9 2.9 13.2 4.3 9.2 8.3 12.1 10.2 9.7 7.8 15.6 8.1 9.3 11.2 PDGFA "PDGF-A, PDGF1" ENSG00000197461 "Platelet derived growth factor subunit A" P04085 7 497258-520296 "Cancer-related genes, Candidate cardiovascular disease genes, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins" "Developmental protein, Growth factor, Mitogen" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 63.1" "Cell line enriched" "Detected in many" 4 "WM-115: 80.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB005579 Approved Approved "Vesicles,Centriolar satellite" "Secreted to blood" 300000 "Vesicles, Centriolar satellite" "CAB005579: AB_2161916" "unprognostic (2.22e-1)" "unprognostic (2.83e-1)" "unprognostic (1.17e-1)" "unprognostic (1.26e-1)" "prognostic unfavourable (1.75e-4)" "prognostic unfavourable (1.78e-4)" "unprognostic (2.63e-3)" "unprognostic (4.37e-2)" "unprognostic (3.02e-1)" "unprognostic (1.96e-1)" "unprognostic (1.85e-1)" "unprognostic (8.26e-2)" "unprognostic (1.07e-2)" "unprognostic (5.87e-2)" "unprognostic (8.35e-2)" "unprognostic (1.02e-1)" "prognostic unfavourable (8.67e-4)" 9.5 6.1 13.1 6.6 20.4 2.1 16.5 9.0 16.6 11.1 14.8 33.4 5.8 16.3 15.5 11.2 8.5 12.1 10.0 14.0 14.9 14.2 10.4 5.4 16.5 8.1 29.8 12.5 6.6 54.7 5.7 6.1 21.5 21.1 14.4 12.7 7.4 16.6 10.2 63.1 10.6 20.3 10.7 26.4 11.8 20.9 4.5 22.7 1.6 6.0 8.6 2.7 11.0 12.7 3.0 3.3 11.6 4.6 5.3 3.6 2.9 5.7 3.9 0.4 5.6 1.1 0.2 13.3 1.3 0.7 1.7 1.1 6.0 6.5 0.1 2.3 1.1 14.6 0.4 17.7 0.9 3.2 0.6 0.1 3.2 2.1 7.2 0.6 0.7 0.8 7.0 0.8 5.6 3.2 0.5 0.8 4.1 7.2 0.8 1.3 10.4 0.8 2.9 0.4 0.6 2.3 1.3 0.6 0.4 19.7 1.1 3.3 2.8 0.6 9.5 3.6 10.0 2.1 7.8 0.2 0.3 0.2 3.3 1.8 80.7 11.6 2.6 3.5 2.7 2.9 3.6 3.0 2.7 2.5 2.3 3.0 3.3 3.3 7.6 5.3 4.6 3.3 2.8 2.9 13.1 20.4 9.0 14.5 14.9 14.2 29.8 12.5 21.1 22.7 PDGFB "SIS, SSV" ENSG00000100311 "Platelet derived growth factor subunit B" P01127 22 39223359-39244751 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins" "Developmental protein, Growth factor, Mitogen" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "EFO-21: 29.1;HUVEC TERT2: 22.4;SK-BR-3: 22.2;TIME: 27.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "MAIT T-cell: 10.8" "Lineage enriched" "Detected in single" 12 "T-cells: 10.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB011604, HPA011972, CAB018341" Supported Approved Vesicles "Secreted to blood" 324500 98000 Vesicles "CAB011604: AB_2162180, CAB018341: AB_2162187, HPA011972: AB_1855134" "unprognostic (4.96e-2)" "unprognostic (8.94e-3)" "unprognostic (8.41e-2)" "unprognostic (2.66e-1)" "unprognostic (9.84e-2)" "unprognostic (4.46e-3)" "unprognostic (4.34e-1)" "prognostic unfavourable (3.67e-5)" "unprognostic (3.22e-2)" "unprognostic (2.07e-1)" "unprognostic (1.05e-1)" "unprognostic (8.68e-2)" "unprognostic (1.84e-3)" "unprognostic (5.12e-3)" "unprognostic (7.47e-2)" "unprognostic (6.50e-2)" "unprognostic (1.03e-1)" 23.5 6.4 10.4 6.4 9.3 0.6 22.5 5.7 13.0 8.3 14.3 12.4 4.2 4.7 10.8 6.5 6.5 5.6 10.8 13.8 9.7 6.1 10.9 3.8 20.8 6.1 14.7 7.3 4.0 8.3 9.2 3.5 37.3 9.6 5.8 3.7 12.1 7.9 8.6 15.2 7.5 6.7 8.9 11.4 5.6 6.2 5.2 10.3 0.8 12.6 8.6 2.3 6.9 5.0 0.0 0.9 0.1 0.4 0.0 10.8 2.3 13.3 1.0 3.5 0.0 0.0 0.0 4.1 0.0 0.1 0.0 0.0 5.3 4.2 0.0 29.1 0.0 5.0 0.2 1.2 0.0 0.0 0.1 0.3 0.4 1.9 1.9 0.0 7.5 0.0 0.1 0.0 0.2 22.4 0.5 2.5 0.8 5.5 0.0 0.0 1.3 1.4 0.0 0.1 9.0 12.1 0.0 0.1 0.0 0.2 22.2 0.1 10.1 0.0 27.8 0.0 2.7 0.0 3.0 0.0 0.1 0.1 0.0 0.6 12.9 0.0 0.0 0.0 8.1 0.1 10.8 0.0 4.7 6.1 0.0 0.0 4.1 2.2 0.1 0.0 0.4 0.9 2.4 2.3 10.4 9.3 5.7 13.0 9.7 6.1 14.7 7.3 9.6 10.3 PDGFRA "CD140a, GAS9, PDGFR2" ENSG00000134853 "Platelet derived growth factor receptor alpha" P16234 4 54229097-54298247 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins" "Chemotaxis, Host-virus interaction" "Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "ovary: 81.5" "Cell line enhanced" "Detected in some" "ASC diff: 81.0;ASC TERT1: 37.9;BJ hTERT+: 47.0;fHDF/TERT166: 32.7;HHSteC: 27.4;HSkMC: 68.9" "Cancer enhanced" "Detected in all" "glioma: 30.8" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004947, CAB018143" Supported Approved "Nucleoplasm,Plasma membrane,Cell Junctions" "Intracellular and membrane" 150000 "Nucleoplasm, Plasma membrane, Cell Junctions" "CAB018143: AB_2162351, HPA004947: " "unprognostic (1.67e-1)" "unprognostic (9.35e-2)" "unprognostic (4.59e-3)" "unprognostic (1.60e-1)" "unprognostic (8.92e-2)" "prognostic favourable (9.33e-4)" "unprognostic (1.24e-1)" "unprognostic (2.00e-2)" "unprognostic (1.46e-1)" "unprognostic (2.18e-2)" "unprognostic (2.18e-1)" "unprognostic (7.01e-2)" "prognostic unfavourable (9.79e-6)" "unprognostic (9.58e-3)" "unprognostic (9.87e-2)" "unprognostic (2.16e-2)" "unprognostic (1.72e-3)" 35.0 12.4 12.6 16.1 7.6 0.9 17.2 2.4 20.1 33.2 19.1 9.2 6.4 9.6 27.6 14.6 21.9 22.5 16.2 15.3 8.9 7.4 22.8 8.4 24.1 26.9 9.2 4.0 81.5 6.8 1.6 2.1 25.1 7.2 18.6 15.2 19.2 8.5 8.3 11.9 7.0 17.4 19.7 8.8 51.6 13.6 19.0 9.3 0.5 11.3 12.8 4.3 35.9 24.6 0.9 0.4 2.5 0.4 0.3 0.8 0.3 0.0 0.0 0.2 0.1 81.0 37.9 0.1 4.2 47.0 0.0 0.1 11.2 0.0 0.1 0.1 32.7 0.1 3.2 0.0 0.0 0.4 0.1 0.1 0.1 0.2 27.4 0.0 0.0 68.9 0.0 5.3 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.2 0.6 0.1 0.1 0.0 0.0 0.0 0.3 0.1 6.6 0.0 0.1 0.0 0.1 0.0 0.1 14.8 0.5 16.2 0.0 0.0 0.0 0.1 0.4 0.0 0.3 2.5 0.4 0.2 0.5 0.2 0.2 0.6 0.8 0.4 0.0 0.9 0.7 0.4 2.3 0.3 0.3 0.4 0.2 0.3 12.6 7.6 2.4 7.3 8.9 7.4 9.2 4.0 7.2 9.3 PDGFRB "CD140b, JTK12, PDGFR, PDGFR1" ENSG00000113721 "Platelet derived growth factor receptor beta" P09619 5 150113837-150155872 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins" Chemotaxis "Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Group enriched" "Detected in some" 4 "ASC diff: 169.0;ASC TERT1: 58.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "gdT-cell: 2.9;non-classical monocyte: 4.1" "Group enriched" "Detected in many" 8 "monocytes: 4.1;T-cells: 2.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003842, CAB018144, HPA028499" Enhanced Supported "Golgi apparatus,Vesicles" 35000000 Vesicles "Golgi apparatus" "CAB003842: AB_562328, CAB018144: AB_2162497, HPA028499: AB_10602018" "unprognostic (4.75e-2)" "unprognostic (2.48e-1)" "unprognostic (5.21e-2)" "unprognostic (3.60e-2)" "unprognostic (3.27e-1)" "unprognostic (5.61e-2)" "unprognostic (1.02e-1)" "unprognostic (3.36e-2)" "unprognostic (2.12e-2)" "unprognostic (2.57e-3)" "unprognostic (6.72e-2)" "unprognostic (1.25e-1)" "prognostic unfavourable (5.87e-8)" "unprognostic (3.13e-3)" "unprognostic (1.25e-2)" "unprognostic (5.47e-2)" "prognostic unfavourable (8.11e-4)" 61.8 10.4 8.3 11.0 9.1 0.5 66.1 4.6 10.4 73.1 15.7 6.7 6.9 5.1 44.3 17.3 21.7 26.1 51.7 24.2 8.2 3.9 17.0 4.6 28.9 21.5 7.9 8.1 46.5 7.5 10.4 7.7 46.4 7.7 24.2 6.3 22.9 11.2 19.3 29.8 20.3 11.2 29.8 5.0 19.6 9.2 21.5 6.7 1.4 21.4 16.0 7.3 23.6 35.1 0.4 0.1 0.0 4.1 0.0 2.9 0.6 0.0 0.0 1.0 0.0 169.0 58.5 0.3 5.9 24.5 4.1 7.0 0.6 0.0 0.0 0.7 16.9 0.0 0.0 0.0 1.9 0.0 0.0 0.0 0.3 0.4 24.0 0.0 0.0 26.3 0.0 5.7 0.0 0.0 0.0 0.6 0.6 0.0 0.0 0.0 1.1 0.0 0.4 0.3 0.0 0.0 0.0 0.0 3.1 0.0 0.0 0.0 0.0 0.0 0.0 6.7 2.2 2.8 0.3 0.0 0.0 0.0 4.1 0.0 0.1 0.0 0.0 0.0 2.9 0.6 0.0 0.4 0.1 0.8 0.1 0.1 0.0 1.3 0.0 0.0 4.1 0.0 0.0 0.6 8.3 9.1 4.6 10.4 8.2 3.9 7.9 8.1 7.7 6.7 PDSS2 "bA59I9.3, C6orf210" ENSG00000164494 "Decaprenyl diphosphate synthase subunit 2" Q86YH6 6 107152557-107459564 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Isoprene biosynthesis, Ubiquinone biosynthesis" Transferase "Cancer-related genes, Disease mutation, Primary mitochondrial disease" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA029685, HPA029686" Approved Enhanced Cytosol Cytosol "HPA029685: AB_10600219, HPA029686: AB_10602309" "prognostic unfavourable (1.34e-5)" "unprognostic (1.44e-1)" "prognostic favourable (5.74e-5)" "unprognostic (5.76e-2)" "unprognostic (1.42e-1)" "unprognostic (3.30e-2)" "unprognostic (3.26e-2)" "unprognostic (1.42e-1)" "unprognostic (1.15e-1)" "unprognostic (1.18e-1)" "unprognostic (9.38e-2)" "unprognostic (2.19e-1)" "prognostic favourable (3.75e-7)" "unprognostic (2.25e-1)" "unprognostic (2.86e-1)" "unprognostic (1.29e-1)" "unprognostic (2.11e-2)" 10.6 27.3 7.2 17.0 8.3 8.3 19.6 9.0 10.3 10.4 12.7 9.0 13.7 9.6 13.1 11.4 11.5 9.2 11.2 16.0 7.0 6.8 22.1 27.4 18.2 18.3 9.2 5.3 10.8 14.0 11.4 19.4 7.0 9.6 15.6 13.9 12.0 19.9 19.9 13.1 9.0 10.1 11.0 8.1 9.1 10.5 12.8 10.1 11.3 14.1 11.1 10.6 10.9 12.9 8.5 9.4 4.1 12.1 4.6 8.3 4.3 5.6 7.6 6.5 10.1 11.3 14.5 15.0 10.0 12.7 9.6 9.3 7.5 8.2 10.8 9.2 11.1 7.8 15.7 12.5 13.2 6.9 7.7 10.7 9.0 12.5 12.0 13.8 8.7 10.7 14.9 15.2 12.1 10.1 15.2 14.7 9.4 7.0 4.0 14.6 4.1 9.9 7.2 5.8 8.7 11.9 7.8 6.4 5.6 6.8 12.0 14.3 9.8 16.7 6.3 6.9 4.1 9.6 8.5 4.1 5.0 8.4 12.8 20.6 12.6 4.1 6.6 3.5 5.3 7.6 8.3 6.6 5.6 6.8 9.4 8.5 7.3 6.9 0.9 4.6 12.1 4.5 7.1 4.3 7.2 8.3 9.0 10.3 7.0 6.8 9.2 5.3 9.6 10.1 PDZD4 "FLJ34125, KIAA1444, LNX5, LU1, PDZK4, PDZRN4L" ENSG00000067840 "PDZ domain containing 4" Q76G19 X 153802166-153830565 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 7 "brain: 71.6" "Cell line enhanced" "Detected in some" "AF22: 15.8;NTERA-2: 8.0;RH-30: 11.3;SCLC-21H: 19.2;SH-SY5Y: 18.7;U-2 OS: 9.4" "Cancer enhanced" "Detected in many" "glioma: 20.1" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "gdT-cell: 3.5" "Group enriched" "Detected in many" 25 "NK-cells: 1.5;T-cells: 3.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA003878 Enhanced "HPA003878: AB_2162807" "unprognostic (9.18e-3)" "unprognostic (1.25e-1)" "unprognostic (1.11e-4)" "unprognostic (1.07e-1)" "unprognostic (6.79e-2)" "unprognostic (1.85e-2)" "unprognostic (1.92e-3)" "unprognostic (2.17e-1)" "unprognostic (2.32e-3)" "unprognostic (5.90e-2)" "prognostic favourable (2.96e-5)" "unprognostic (2.27e-1)" "unprognostic (2.54e-4)" "unprognostic (2.27e-2)" "unprognostic (1.48e-1)" "unprognostic (2.83e-2)" "unprognostic (2.87e-2)" 3.3 5.8 42.8 2.6 36.7 2.5 2.0 40.1 71.6 2.3 3.5 5.1 0.4 2.5 4.4 2.2 3.3 7.9 2.8 3.3 40.8 14.8 1.6 1.7 3.0 2.6 9.9 24.9 1.7 2.6 1.5 7.4 1.2 9.0 4.5 2.3 1.8 4.3 10.5 3.6 4.8 3.3 5.0 7.0 7.0 2.3 3.4 6.4 0.0 1.6 0.0 1.6 2.4 1.4 0.0 0.0 0.0 0.0 1.5 3.5 0.6 0.0 1.0 15.8 4.1 0.0 0.1 0.0 0.4 0.0 0.5 0.5 0.4 0.0 0.0 0.2 0.0 0.1 2.8 0.0 0.1 0.0 0.5 0.0 1.0 0.0 0.0 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 3.1 0.1 0.5 8.0 0.2 0.0 11.3 0.0 0.0 0.0 19.2 18.7 0.8 0.0 5.6 1.8 0.1 0.0 0.0 9.4 0.2 1.1 0.0 0.0 0.0 0.1 0.0 5.0 0.0 0.0 0.0 3.5 0.0 0.8 0.0 1.5 2.0 0.0 0.0 0.1 0.9 0.0 1.5 0.0 0.0 0.0 0.6 42.8 36.7 40.1 49.2 40.8 14.8 9.9 24.9 9.0 6.4 PER1 "PER, RIGUI" ENSG00000179094 "Period circadian regulator 1" O15534 17 8140472-8156506 "Cancer-related genes, Predicted intracellular proteins" "Biological rhythms, Transcription, Transcription regulation" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HBEC3-KT: 23.2;hTCEpi: 27.1;hTERT-HME1: 26.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA047947, HPA067064" Supported Nucleoplasm,Cytosol Cytosol Nucleoplasm "HPA047947: , HPA067064: " "unprognostic (7.64e-2)" "prognostic favourable (3.89e-4)" "unprognostic (5.54e-2)" "unprognostic (1.20e-1)" "unprognostic (2.59e-1)" "unprognostic (9.44e-2)" "prognostic favourable (2.56e-4)" "unprognostic (5.28e-2)" "unprognostic (6.67e-2)" "unprognostic (6.21e-3)" "unprognostic (6.87e-2)" "unprognostic (4.68e-2)" "unprognostic (7.09e-3)" "prognostic unfavourable (1.94e-4)" "unprognostic (2.08e-1)" "unprognostic (1.37e-1)" "unprognostic (3.34e-2)" 39.4 33.4 13.2 21.6 15.0 27.3 31.3 19.5 23.9 27.8 24.6 20.9 27.8 6.9 19.5 17.2 31.6 25.2 36.9 24.0 13.3 6.3 14.2 18.6 25.8 10.8 15.6 11.3 50.1 61.8 19.3 29.8 12.7 20.1 23.1 8.1 36.6 23.3 43.5 70.3 47.9 16.9 29.3 17.5 16.7 23.6 13.8 17.1 4.6 28.5 33.1 12.1 30.2 25.0 1.6 4.9 3.3 3.6 0.5 2.1 1.2 1.0 3.8 4.4 6.3 14.5 10.7 2.5 1.5 2.7 1.9 2.3 3.8 2.5 7.1 1.2 2.2 3.1 4.4 23.2 1.3 2.2 5.5 3.7 8.3 1.1 20.0 1.5 5.7 16.0 27.1 3.3 26.5 4.2 4.7 9.9 3.5 3.5 4.3 2.9 3.8 2.5 6.0 2.5 3.7 4.6 0.8 1.9 4.7 3.2 3.7 3.0 2.7 1.1 7.2 2.2 4.3 0.8 1.3 5.8 2.2 2.5 3.0 1.8 1.6 0.0 3.6 1.7 1.9 2.5 2.1 1.0 1.7 1.2 4.9 1.6 1.6 1.1 3.3 0.5 1.2 0.7 1.1 1.2 13.2 15.0 19.5 23.9 13.3 6.3 15.6 11.3 20.1 17.1 PF4 "CXCL4, SCYB4" ENSG00000163737 "Platelet factor 4" P02776 4 73981077-73982124 "Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins" Chemotaxis "Cytokine, Heparin-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "blood: 50.5;bone marrow: 46.8;heart muscle: 46.0;lymphoid tissue: 42.6" "Cell line enriched" "Detected in some" 10 "HEL: 29.7" "Cancer enhanced" "Detected in some" "colorectal cancer: 4.4" "Low region specificity" "Detected in some" "Group enriched" "Detected in some" 9 "basophil: 18.3;neutrophil: 16.5" "Lineage enriched" "Detected in many" 9 "granulocytes: 18.3" "CAB026008, HPA052485" Enhanced "Secreted to blood" 7700000 "CAB026008: , HPA052485: " "unprognostic (4.14e-4)" "unprognostic (1.00e-2)" "unprognostic (2.49e-1)" "unprognostic (1.96e-4)" "unprognostic (7.58e-2)" "unprognostic (1.42e-1)" "unprognostic (7.55e-2)" "unprognostic (2.04e-1)" "unprognostic (9.02e-3)" "unprognostic (1.84e-2)" "unprognostic (3.03e-2)" "unprognostic (9.54e-5)" "unprognostic (2.55e-1)" "unprognostic (8.77e-2)" "unprognostic (9.69e-2)" "unprognostic (4.81e-2)" 0.7 0.4 0.2 0.7 0.9 46.8 0.8 0.2 0.3 0.3 1.1 0.0 0.0 0.1 0.2 0.4 0.2 0.5 0.8 46.0 0.8 0.3 0.5 1.7 9.1 3.3 2.6 0.3 3.0 0.4 0.1 0.4 4.8 1.9 0.2 0.9 1.0 0.4 0.2 1.0 0.2 0.3 0.2 0.9 42.6 0.9 0.6 0.0 0.0 1.8 0.9 0.1 1.0 3.0 0.3 1.9 18.3 1.4 0.0 0.3 50.5 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.2 29.7 0.0 0.0 1.5 0.0 0.0 3.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 18.3 1.4 0.4 0.3 0.3 0.3 0.0 0.0 0.0 0.5 0.3 0.2 0.1 16.5 0.0 1.1 1.9 0.2 50.5 0.2 0.9 0.2 0.3 0.8 0.3 2.6 0.3 1.9 0.0 PGC ENSG00000096088 Progastricsin P20142 6 41736711-41754109 "Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins, Transporters" Digestion "Aspartyl protease, Hydrolase, Protease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "ductus deferens: 249.6;pancreas: 798.6;stomach 1: 963.7" "Cell line enriched" "Detected in some" 13 "Hep G2: 73.2" "Cancer enhanced" "Detected in many" "stomach cancer: 1050.3" "Not detected" "Not detected" "Cell type enriched" "Detected in single" 7 "intermediate monocyte: 1.9" "Lineage enriched" "Detected in single" 7 "monocytes: 1.9" "Not detected" "Not detected" "Not detected" "Not detected" "HPA031717, HPA031718" Enhanced Approved Nucleoplasm "Secreted to digestive system" Nucleoplasm "HPA031717: AB_10670130, HPA031718: AB_10610148" "unprognostic (9.18e-2)" "unprognostic (1.87e-1)" "unprognostic (9.83e-2)" "unprognostic (2.27e-1)" "unprognostic (7.18e-2)" "unprognostic (2.74e-1)" "unprognostic (1.47e-1)" "unprognostic (8.50e-2)" "unprognostic (1.86e-1)" "unprognostic (9.23e-2)" "unprognostic (1.09e-1)" "unprognostic (1.33e-2)" "unprognostic (2.92e-1)" "unprognostic (1.65e-1)" "unprognostic (8.74e-2)" 0.1 0.2 0.1 0.0 0.1 0.0 0.2 0.1 0.1 0.3 0.1 3.0 249.6 41.7 0.1 0.0 3.3 0.3 16.8 0.1 0.1 0.1 0.1 0.3 139.4 0.0 0.1 0.0 0.1 798.6 0.0 0.1 0.0 0.1 2.3 0.0 0.0 0.1 35.9 0.1 0.1 0.1 0.0 0.1 0.1 963.7 0.1 0.0 0.0 0.1 0.0 0.0 0.4 0.2 0.0 0.0 0.0 1.9 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.7 0.0 0.0 0.0 0.0 5.4 0.0 0.0 0.1 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 73.2 0.0 0.1 1.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.2 1.7 0.0 0.8 0.0 1.7 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.8 0.0 0.0 1.1 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 1.9 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.0 PGF "D12S1900, PGFL, PIGF, PLGF, PlGF-2, SHGC-10760" ENSG00000119630 "Placental growth factor" P49763 14 74941834-74955784 "Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins" "Angiogenesis, Differentiation" "Developmental protein, Growth factor, Heparin-binding, Mitogen" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 7 "placenta: 177.3" "Group enriched" "Detected in some" 6 "BEWO: 91.3;HUVEC TERT2: 43.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" HPA041624 Approved Nucleoplasm,Mitochondria,Cytosol "Secreted to blood" 12380 Nucleoplasm "Mitochondria, Cytosol" "HPA041624: AB_10794522" "unprognostic (1.67e-2)" "unprognostic (4.62e-2)" "unprognostic (9.25e-3)" "unprognostic (1.34e-3)" "unprognostic (8.67e-3)" "unprognostic (2.41e-1)" "prognostic unfavourable (1.40e-4)" "unprognostic (7.26e-2)" "unprognostic (1.48e-1)" "unprognostic (4.45e-1)" "unprognostic (1.45e-2)" "unprognostic (3.51e-3)" "prognostic unfavourable (1.33e-6)" "unprognostic (2.52e-3)" "unprognostic (1.20e-1)" "unprognostic (3.49e-2)" "unprognostic (1.14e-1)" 4.3 2.7 1.9 4.4 2.4 0.0 4.3 1.6 3.5 13.1 2.3 2.3 4.0 1.3 2.9 6.3 3.9 9.2 3.4 5.1 2.4 4.1 3.1 2.6 3.6 4.9 2.9 2.0 3.8 1.9 5.4 2.0 177.3 4.6 7.5 1.1 3.5 3.8 6.7 3.3 6.0 4.3 4.6 1.7 1.2 1.7 3.3 2.0 1.4 24.2 4.4 2.9 5.1 5.9 0.7 0.7 1.1 1.0 0.0 2.4 0.2 0.3 0.3 0.3 0.2 0.4 0.0 91.3 0.8 0.8 0.4 0.5 2.1 0.1 0.0 2.0 0.6 0.1 0.4 4.1 0.3 0.0 0.5 0.0 0.0 2.2 0.3 0.0 2.4 1.0 1.0 1.6 0.4 43.0 0.0 0.0 12.1 0.1 0.0 0.1 0.4 0.7 0.0 11.3 0.0 0.1 0.2 6.9 3.7 0.0 0.1 1.6 0.0 0.1 8.7 0.0 2.3 0.0 3.6 0.0 0.0 0.1 1.4 0.1 0.1 0.0 0.2 1.1 2.4 1.0 0.0 0.7 0.3 0.7 0.3 0.3 0.6 1.0 0.0 0.0 0.8 0.7 0.5 0.2 1.9 2.4 1.6 2.2 2.4 4.1 2.9 2.0 4.6 2.0 PGR "NR3C3, PR" ENSG00000082175 "Progesterone receptor" P06401 11 101029624-101130524 "Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "cervix, uterine: 50.7;endometrium 1: 116.4;smooth muscle: 31.2" "Cell line enriched" "Detected in single" 349 "T-47d: 60.8" "Group enriched" "Detected in some" 13 "breast cancer: 10.1;endometrial cancer: 11.1" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB000068, HPA004751, HPA008428, HPA017176, CAB055100" Enhanced "CAB000068: AB_442124, CAB055100: AB_2532076, HPA004751: AB_1079681, HPA008428: AB_1079680, HPA017176: AB_1855728" "unprognostic (2.59e-2)" "unprognostic (9.80e-3)" "unprognostic (5.23e-3)" "prognostic favourable (5.76e-8)" "unprognostic (2.81e-2)" "unprognostic (1.56e-1)" "unprognostic (4.11e-1)" "unprognostic (1.64e-1)" "unprognostic (2.08e-1)" "unprognostic (2.50e-1)" "unprognostic (3.29e-2)" "unprognostic (1.77e-1)" "unprognostic (7.71e-3)" "unprognostic (1.90e-2)" "unprognostic (2.35e-2)" "unprognostic (1.15e-1)" "unprognostic (5.44e-3)" 0.8 0.7 0.2 0.3 0.6 0.0 5.0 0.2 0.7 50.7 1.3 0.2 0.4 0.0 116.4 6.1 0.5 13.2 0.4 2.0 0.5 0.6 0.4 0.1 1.2 0.3 0.4 0.1 10.6 0.8 0.0 2.8 1.8 0.8 3.8 0.1 0.7 3.5 5.5 0.3 0.3 1.2 31.2 0.9 0.5 0.4 1.5 0.3 0.1 0.3 0.8 0.2 1.1 6.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 60.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.6 0.2 0.7 0.5 0.6 0.4 0.1 0.8 0.3 PHF20 "C20orf104, dJ1121G12.1, TDRD20A" ENSG00000025293 "PHD finger protein 20" Q9BVI0 20 35771974-35950381 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Transcription, Transcription regulation" "Chromatin regulator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA029619, HPA029620, HPA029621" Approved Supported "Nucleoplasm,Nuclear membrane,Cytosol" Nucleoplasm "Nuclear membrane, Cytosol" "HPA029619: AB_10600090, HPA029620: AB_10601110, HPA029621: AB_10602201" "unprognostic (1.21e-3)" "unprognostic (7.30e-2)" "unprognostic (3.20e-2)" "unprognostic (2.35e-3)" "unprognostic (1.36e-1)" "unprognostic (1.95e-1)" "prognostic unfavourable (2.49e-4)" "unprognostic (2.76e-1)" "unprognostic (2.17e-1)" "unprognostic (2.64e-2)" "unprognostic (4.59e-2)" "unprognostic (1.09e-1)" "unprognostic (1.92e-2)" "unprognostic (1.17e-1)" "unprognostic (1.07e-1)" "unprognostic (7.23e-2)" "unprognostic (1.01e-2)" 19.1 11.6 14.0 16.8 19.0 14.1 17.2 25.1 19.2 15.9 15.9 16.1 8.1 8.1 19.1 11.6 16.5 14.2 14.8 15.2 14.1 13.8 11.2 11.1 16.5 17.3 14.9 13.0 18.9 9.4 17.9 20.0 15.6 15.0 14.7 11.7 14.7 15.3 15.7 46.6 12.9 12.3 17.2 18.9 20.8 12.7 17.4 15.2 19.4 14.2 14.5 20.8 18.7 21.8 12.0 8.2 23.6 11.9 13.0 12.4 6.5 9.6 7.7 13.5 19.9 9.8 11.3 12.6 11.0 10.5 11.1 9.7 22.4 7.3 16.1 10.0 14.6 6.0 12.4 15.3 13.6 7.2 5.3 30.0 14.7 8.3 9.9 14.3 11.7 8.8 21.6 11.7 18.1 12.1 12.2 10.4 12.7 5.7 14.5 8.4 6.7 9.6 10.6 20.0 9.5 8.8 6.7 12.3 10.0 19.6 22.8 10.1 18.0 10.7 16.9 24.6 5.6 12.7 11.2 9.6 11.4 11.8 18.2 10.5 12.6 11.9 8.6 23.6 10.6 9.0 11.3 12.0 10.5 11.9 8.2 9.8 12.0 12.4 20.5 13.0 11.9 7.7 5.5 6.5 14.0 19.0 25.1 19.0 14.1 13.8 14.9 13.0 15.0 15.2 PHF6 "BFLS, BORJ, CENP-31, KIAA1823, MGC14797" ENSG00000156531 "PHD finger protein 6" Q8IWS0 X 134373253-134428791 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes, Disease mutation, Epilepsy, Hypotrichosis, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA001023 Enhanced Supported Nucleoplasm,Nucleoli "Nucleoplasm, Nucleoli" "HPA001023: AB_1079606" "unprognostic (2.38e-3)" "unprognostic (8.21e-2)" "unprognostic (1.99e-1)" "unprognostic (3.04e-3)" "unprognostic (6.03e-3)" "unprognostic (5.20e-3)" "prognostic unfavourable (3.38e-4)" "unprognostic (1.81e-1)" "unprognostic (4.85e-2)" "unprognostic (1.08e-1)" "prognostic unfavourable (9.96e-4)" "unprognostic (1.09e-1)" "unprognostic (5.96e-2)" "unprognostic (4.84e-2)" "unprognostic (7.45e-2)" "unprognostic (1.28e-1)" "unprognostic (1.29e-2)" 7.4 19.3 10.2 14.1 12.2 6.5 9.7 18.2 13.5 8.7 8.0 11.6 20.3 7.8 9.0 30.1 11.5 7.3 6.1 7.2 11.0 11.1 9.9 7.5 8.4 20.4 12.5 9.3 30.7 10.4 24.1 18.1 8.2 13.3 8.6 9.5 5.4 11.3 16.8 6.2 7.4 10.2 8.1 17.1 17.8 8.1 8.3 14.4 30.2 11.8 6.0 25.0 8.9 9.8 18.4 11.0 5.3 7.4 9.6 9.9 5.0 11.3 9.4 41.3 16.9 7.7 9.9 7.8 11.4 9.1 12.2 15.2 5.6 11.8 18.2 26.2 6.9 10.2 28.8 12.9 20.6 14.8 13.4 17.6 16.1 6.4 8.3 17.5 9.8 6.5 9.8 13.3 16.6 17.0 12.9 9.0 14.9 7.4 28.2 8.7 12.6 12.7 27.9 15.1 13.8 13.0 13.7 14.3 16.9 8.7 8.1 11.9 7.5 9.7 12.9 11.4 8.2 14.3 17.4 4.6 10.7 24.6 7.5 20.9 14.2 5.3 6.1 3.7 7.9 6.0 8.5 18.4 8.2 7.1 8.8 12.8 9.9 8.2 2.5 9.6 7.4 11.0 8.3 5.0 10.2 12.2 18.2 13.5 11.0 11.1 12.5 9.3 13.3 14.4 PHLDA1 "DT1P1B11, PHRIP, TDAG51" ENSG00000139289 "Pleckstrin homology like domain family A member 1" Q8WV24 12 76025447-76033932 "Cancer-related genes, Predicted intracellular proteins" Apoptosis "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in all" 4 "salivary gland: 142.4" "Cell line enhanced" "Detected in many" "hTERT-HME1: 43.3;RPTEC TERT1: 54.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 5 "gdT-cell: 2.4;MAIT T-cell: 3.9;memory CD4 T-cell: 2.5;memory CD8 T-cell: 2.5;non-classical monocyte: 2.5;T-reg: 4.1" "Group enriched" "Detected in many" 7 "monocytes: 2.5;T-cells: 4.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB016160, HPA019000, HPA063520" Enhanced Supported Nucleoplasm,Nucleoli Nucleoli Nucleoplasm "CAB016160: AB_628117, HPA019000: AB_1855309, HPA063520: " "unprognostic (9.09e-2)" "unprognostic (2.27e-2)" "unprognostic (2.03e-1)" "unprognostic (4.51e-3)" "unprognostic (2.33e-1)" "unprognostic (2.60e-3)" "unprognostic (1.40e-1)" "unprognostic (4.18e-2)" "unprognostic (2.21e-1)" "unprognostic (1.16e-1)" "unprognostic (5.21e-3)" "unprognostic (5.03e-2)" "unprognostic (1.21e-1)" "unprognostic (3.34e-2)" "unprognostic (2.32e-1)" "unprognostic (1.29e-1)" "unprognostic (4.55e-3)" 13.2 15.9 9.4 8.4 12.1 9.0 13.5 6.4 15.7 11.5 4.5 11.1 4.8 3.4 7.1 3.1 33.3 5.1 20.0 9.6 8.2 7.9 13.8 33.2 14.2 3.0 8.4 5.6 10.8 8.8 2.6 6.0 7.1 10.0 4.8 5.5 24.9 142.4 6.5 3.3 6.3 7.0 7.6 9.7 14.6 10.8 2.3 10.1 2.5 18.0 13.2 19.9 17.0 17.8 0.3 0.1 0.4 2.5 0.3 4.1 0.6 13.5 16.3 12.8 7.0 6.0 12.4 0.9 11.5 31.1 5.2 7.3 9.0 16.6 0.0 3.5 4.8 7.0 0.3 19.3 11.3 2.0 0.2 0.3 0.8 15.2 8.7 0.3 3.5 3.8 14.2 21.8 43.3 12.5 1.1 0.4 26.8 1.7 0.0 1.7 4.6 25.2 0.0 3.3 0.4 54.9 30.8 0.9 2.4 2.0 0.1 37.4 8.2 0.1 11.6 17.9 1.7 20.8 11.3 0.2 0.0 0.0 30.2 0.2 22.3 0.3 0.1 0.2 2.4 0.2 3.9 0.3 2.5 2.5 0.0 0.2 0.5 0.6 0.4 0.3 2.5 0.1 4.1 0.6 9.4 12.1 6.4 7.7 8.2 7.9 8.4 5.6 10.0 10.1 PHOX2B "NBPhox, Phox2b, PMX2B" ENSG00000109132 "Paired like homeobox 2b" Q99453 4 41744082-41748970 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "adrenal gland: 14.5;brain: 24.8" "Cell line enriched" "Detected in single" 91 "SH-SY5Y: 52.3" "Not detected" "Not detected" "Region enriched" "Detected in single" 99 "pons and medulla: 24.8" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in single" 17 "pons and medulla: 5.9" "Region enriched" "Detected in single" 38 "pons and medulla: 2.0" "HPA074325, HPA074941" Enhanced Enhanced Nucleoplasm Nucleoplasm "HPA074325: , HPA074941: " "unprognostic (1.01e-1)" "unprognostic (2.47e-1)" "unprognostic (5.27e-2)" 0.0 14.5 0.0 2.1 0.0 0.0 0.0 0.0 0.0 0.0 5.6 0.2 0.0 0.8 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 1.4 0.0 0.0 0.0 24.8 0.2 1.4 0.8 0.0 0.0 0.0 0.0 3.2 0.5 0.4 0.0 0.9 0.1 0.0 0.1 0.0 0.0 0.0 0.6 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 52.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 24.8 0.0 PICALM "CALM, CLTH" ENSG00000073921 "Phosphatidylinositol binding clathrin assembly protein" Q13492 11 85957684-86069882 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" Endocytosis "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "neutrophil: 25.8" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019053, HPA019061" Enhanced Enhanced Vesicles 28000 Vesicles "HPA019053: AB_1855361, HPA019061: AB_1855362" "unprognostic (9.27e-3)" "unprognostic (7.29e-2)" "unprognostic (3.51e-1)" "unprognostic (6.83e-2)" "unprognostic (5.13e-2)" "unprognostic (1.93e-1)" "unprognostic (5.36e-3)" "unprognostic (9.02e-3)" "unprognostic (9.80e-2)" "unprognostic (6.27e-3)" "prognostic unfavourable (6.61e-4)" "unprognostic (4.31e-1)" "prognostic favourable (2.02e-6)" "unprognostic (1.26e-2)" "unprognostic (5.21e-3)" "unprognostic (2.52e-1)" "unprognostic (1.02e-1)" 72.9 24.2 35.6 43.1 51.4 37.1 51.3 30.2 39.7 38.7 35.9 60.0 27.7 39.6 41.6 26.0 41.3 31.5 48.1 41.4 43.7 34.2 63.9 53.8 45.1 35.2 52.0 33.5 38.2 29.7 70.6 23.8 76.7 50.7 29.9 32.0 26.7 31.8 37.0 35.5 35.0 45.3 49.9 70.7 49.5 30.7 22.9 55.1 31.0 30.8 28.5 34.8 44.0 49.2 2.1 7.1 25.8 8.5 3.9 5.3 3.1 28.9 13.8 21.9 15.3 33.6 35.3 41.4 37.3 48.5 29.5 26.1 54.4 39.5 22.6 38.5 59.8 24.0 22.9 27.2 42.7 6.7 8.2 64.2 18.8 17.3 34.3 15.0 28.9 30.6 29.5 55.3 46.1 32.0 41.1 18.7 55.5 17.0 17.6 13.8 12.0 7.9 12.2 33.2 16.0 57.3 24.5 13.3 10.8 45.8 15.5 12.3 21.0 12.2 34.6 54.6 19.0 64.4 29.7 6.7 17.5 20.7 12.9 11.9 36.8 3.6 8.5 4.2 3.9 7.2 3.3 2.1 2.9 5.3 7.1 1.4 3.0 2.7 25.8 3.9 7.2 2.5 3.8 3.1 35.6 51.4 30.2 39.7 43.7 34.2 52.0 33.5 50.7 55.1 PIGR ENSG00000162896 "Polymeric immunoglobulin receptor" P01833 1 206928518-206946466 "Cancer-related genes, Plasma proteins, Predicted membrane proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "gallbladder: 139.0;intestine: 320.1;salivary gland: 398.1" "Cell line enriched" "Detected in some" 5 "EFO-21: 28.0" "Cancer enhanced" "Detected in many" "colorectal cancer: 731.7" "Not detected" "Not detected" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "Low region specificity" "Detected in all" "HPA006154, CAB009454, HPA012012" Enhanced "Intracellular and membrane" 1900000000 "CAB009454: AB_2164819, HPA006154: AB_1855370, HPA012012: AB_1855371" "prognostic favourable (1.22e-5)" "unprognostic (7.42e-2)" "unprognostic (4.78e-3)" "prognostic favourable (2.57e-4)" "unprognostic (2.31e-2)" "unprognostic (6.71e-2)" "unprognostic (1.13e-1)" "unprognostic (3.07e-2)" "unprognostic (6.45e-2)" "unprognostic (1.19e-1)" "unprognostic (5.23e-2)" "unprognostic (2.13e-1)" "prognostic favourable (5.08e-5)" "unprognostic (1.83e-1)" "unprognostic (1.41e-1)" "unprognostic (6.92e-3)" "unprognostic (3.39e-2)" 0.3 0.3 0.3 74.2 0.3 0.0 6.9 0.3 0.3 35.1 232.8 0.6 0.4 158.9 2.6 0.5 2.6 0.7 139.0 0.3 0.3 0.3 52.5 5.0 25.1 0.3 0.3 0.3 0.6 4.2 0.0 0.9 0.4 0.3 3.0 75.6 0.4 398.1 0.6 0.4 0.4 320.1 2.0 0.3 0.4 25.3 0.6 0.3 0.4 0.4 23.9 22.5 4.9 0.6 3.4 1.1 1.4 0.5 0.5 0.5 0.2 0.2 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.1 0.1 28.0 0.0 0.2 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.2 1.4 0.2 0.0 0.2 0.0 4.9 0.1 1.3 0.6 2.0 0.0 5.3 0.0 0.0 0.0 0.0 0.0 1.0 0.2 0.4 0.2 0.3 1.0 0.0 0.1 0.0 1.4 0.5 0.3 0.4 0.2 0.5 3.4 0.3 0.3 1.1 3.4 0.5 0.5 1.4 0.5 0.3 0.9 0.2 0.2 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 PIK3CA PI3K ENSG00000121879 "Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha" P42336 3 179148114-179240093 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins" "Angiogenesis, Phagocytosis" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA009985, CAB017804" Approved Approved Cytosol Cytosol "CAB017804: , HPA009985: AB_1079610" "unprognostic (1.81e-1)" "unprognostic (2.77e-1)" "unprognostic (2.18e-1)" "unprognostic (2.69e-3)" "unprognostic (6.49e-3)" "unprognostic (1.43e-1)" "unprognostic (2.65e-2)" "unprognostic (1.00e-2)" "unprognostic (1.03e-1)" "unprognostic (2.37e-1)" "unprognostic (2.57e-3)" "unprognostic (5.21e-2)" "unprognostic (4.50e-2)" "unprognostic (1.16e-2)" "unprognostic (2.48e-1)" "unprognostic (9.74e-2)" "unprognostic (3.82e-2)" 20.1 12.3 13.7 11.5 13.4 25.7 22.4 17.1 24.5 12.9 14.0 5.2 5.7 6.5 15.3 7.9 11.6 11.1 13.2 14.2 18.4 9.7 11.7 10.8 13.2 13.8 9.8 15.7 15.4 9.2 24.7 11.6 16.5 16.3 10.7 8.9 7.2 10.9 10.9 15.2 12.0 10.5 12.8 14.4 16.2 10.6 9.3 9.8 29.6 11.0 7.3 13.9 15.1 15.7 6.2 2.6 7.8 3.8 2.4 5.0 1.1 14.4 4.9 7.9 7.3 18.7 21.8 5.7 9.2 12.5 9.1 14.4 4.2 10.7 13.2 15.8 11.0 5.9 6.4 8.0 13.2 22.0 5.7 18.1 5.3 3.7 8.9 10.1 10.3 13.7 8.5 10.0 11.5 13.0 9.0 14.7 13.0 5.7 7.7 9.1 6.2 6.7 11.8 8.0 15.8 7.2 8.8 4.4 7.6 10.0 8.9 12.0 14.9 8.7 13.8 8.6 5.6 13.5 9.2 7.1 10.1 23.7 7.7 7.6 5.0 2.1 3.8 1.6 5.0 2.9 3.9 5.8 4.2 2.8 2.2 6.2 4.6 3.8 7.8 2.4 3.0 2.6 4.1 1.1 13.7 13.4 17.1 24.5 18.4 9.7 9.8 15.7 16.3 9.8 PIK3CB PIK3C1 ENSG00000051382 "Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta" P42338 3 138652699-138834938 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins" "Autophagy, Cell adhesion, Endocytosis" "Kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HEL: 41.2;HMC-1: 65.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB031938, HPA042288, HPA064207" Approved Supported Nucleoplasm,Nucleoli,Vesicles,Midbody Nucleoplasm "Nucleoli, Vesicles, Midbody" "CAB031938: AB_2165408, HPA042288: , HPA064207: " "unprognostic (4.89e-2)" "unprognostic (1.42e-2)" "unprognostic (5.97e-2)" "unprognostic (7.85e-2)" "unprognostic (4.89e-2)" "unprognostic (6.01e-2)" "prognostic unfavourable (6.42e-4)" "unprognostic (3.98e-2)" "unprognostic (1.35e-1)" "unprognostic (2.28e-1)" "prognostic unfavourable (3.99e-5)" "unprognostic (2.15e-1)" "unprognostic (6.18e-3)" "unprognostic (9.33e-2)" "unprognostic (7.82e-2)" "unprognostic (2.79e-1)" "unprognostic (4.59e-2)" 12.5 9.9 10.6 9.7 20.6 17.4 11.5 29.9 25.0 12.4 14.6 11.9 11.7 13.7 9.6 6.9 15.2 10.9 8.7 12.7 12.2 14.2 22.6 9.3 9.5 9.1 11.9 15.2 8.8 20.3 20.2 10.9 18.1 24.1 13.4 15.7 12.2 14.9 15.9 33.4 19.6 16.4 8.3 12.5 9.9 11.0 6.4 10.7 14.4 37.4 7.1 11.9 13.4 11.0 4.6 9.1 11.3 7.8 1.3 6.5 2.6 22.6 9.8 4.2 3.5 3.9 5.2 28.7 5.3 5.1 5.4 5.8 10.5 8.6 9.1 14.5 5.2 9.7 5.5 8.4 9.7 11.6 6.2 41.2 6.7 6.3 4.0 10.0 65.3 4.4 6.5 3.8 7.7 8.1 15.7 6.8 6.7 10.3 5.8 7.0 6.0 9.2 4.2 4.4 6.5 8.3 12.5 3.7 2.7 14.7 6.4 18.9 16.0 23.9 8.5 3.5 4.4 7.5 7.4 11.5 7.5 8.3 8.5 9.7 4.8 7.0 7.8 11.3 4.0 4.5 2.7 4.6 5.2 3.0 9.1 4.1 6.5 4.4 10.0 1.3 4.3 1.4 2.2 2.6 10.6 20.6 29.9 25.0 12.2 14.2 11.9 15.2 24.1 10.7 PIK3CG ENSG00000105851 "Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma" P48736 7 106865278-106907145 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Angiogenesis, Chemotaxis, Endocytosis, Immunity, Inflammatory response" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "blood: 24.5;bone marrow: 27.8;lymphoid tissue: 40.8" "Cell line enhanced" "Detected in some" "Daudi: 12.2;HMC-1: 15.2;Karpas-707: 12.6;MOLT-4: 23.0;U-266/70: 30.9;U-937: 21.8" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA069976 Enhanced Supported "Plasma membrane,Cytosol" "Plasma membrane" Cytosol "HPA069976: " "unprognostic (8.34e-2)" "unprognostic (2.01e-2)" "unprognostic (1.44e-2)" "unprognostic (1.71e-2)" "unprognostic (3.20e-2)" "unprognostic (3.82e-3)" "unprognostic (3.02e-1)" "unprognostic (6.77e-2)" "unprognostic (1.16e-1)" "unprognostic (7.06e-3)" "unprognostic (1.15e-1)" "unprognostic (1.97e-1)" "unprognostic (1.77e-2)" "unprognostic (9.08e-2)" "unprognostic (1.23e-1)" "unprognostic (5.38e-1)" "unprognostic (5.24e-2)" 5.0 1.8 2.2 16.0 3.1 27.8 2.3 0.8 1.7 1.7 4.1 2.7 0.0 2.8 1.7 2.0 2.0 1.8 3.5 1.7 1.7 1.5 1.9 1.5 4.3 13.1 3.0 1.0 1.7 1.5 0.6 1.4 2.0 2.5 2.2 2.6 1.9 3.1 0.5 1.1 1.3 6.1 1.9 6.4 17.4 2.5 7.6 3.0 40.8 2.3 0.9 21.2 4.1 1.5 6.2 5.6 14.2 24.5 5.3 5.6 3.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 12.2 1.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 7.5 0.0 0.0 0.0 11.9 15.2 0.0 0.0 0.0 0.0 4.7 8.5 12.6 0.0 0.0 23.0 4.6 0.0 0.0 6.1 0.0 8.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.1 1.2 0.0 0.1 0.0 0.0 30.9 0.0 11.5 0.0 21.8 2.9 4.6 3.4 14.2 5.6 10.6 5.1 4.7 2.6 4.2 5.6 6.2 2.8 3.8 13.9 5.3 24.5 4.9 2.6 3.6 2.2 3.1 0.8 1.7 1.7 1.5 3.0 1.0 2.5 3.0 PIK3R1 "GRB1, p85, p85-ALPHA" ENSG00000145675 "Phosphoinositide-3-kinase regulatory subunit 1" P27986 5 68215720-68301821 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins" "Host-virus interaction, Protein transport, Stress response, Transport" "Cancer-related genes, Disease mutation, Dwarfism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "ASC diff: 71.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001216, CAB004268" Approved Approved Cytosol Cytosol "CAB004268: AB_628126, HPA001216: AB_1079612" "unprognostic (5.74e-2)" "unprognostic (6.58e-2)" "unprognostic (2.01e-1)" "unprognostic (1.31e-2)" "unprognostic (1.18e-1)" "unprognostic (1.33e-2)" "prognostic favourable (8.09e-4)" "unprognostic (3.78e-3)" "unprognostic (1.78e-1)" "unprognostic (2.71e-1)" "unprognostic (6.10e-2)" "unprognostic (1.32e-1)" "unprognostic (4.59e-3)" "unprognostic (5.66e-3)" "unprognostic (1.27e-1)" "unprognostic (5.92e-2)" "unprognostic (1.54e-1)" 26.2 13.4 26.0 13.0 24.3 51.6 42.3 15.3 50.3 27.1 20.3 12.8 12.8 8.1 41.3 22.1 20.8 33.0 18.1 33.9 24.0 13.4 17.9 46.5 16.3 12.0 22.0 40.8 25.8 6.8 22.3 9.4 15.0 18.2 15.2 10.8 8.7 54.6 16.2 48.9 19.1 16.1 36.3 17.6 18.8 13.1 7.6 23.6 16.2 12.8 8.5 10.8 25.2 24.4 2.2 2.1 10.6 4.1 8.2 14.8 4.0 1.0 2.1 6.3 18.7 71.7 21.0 2.7 6.0 2.8 2.3 2.5 5.2 1.9 5.5 10.3 8.2 2.6 1.7 12.1 2.9 23.0 2.3 6.6 1.7 4.2 24.1 6.7 5.3 22.1 27.6 4.2 22.5 3.0 1.0 4.2 2.1 2.8 16.4 2.6 1.8 1.1 15.4 3.0 4.3 3.0 12.3 1.2 5.7 0.9 1.6 3.9 9.0 4.8 3.6 2.7 2.8 4.5 3.7 4.7 7.0 6.4 2.9 8.5 2.0 10.6 1.2 5.9 9.2 1.7 12.7 1.2 11.5 8.4 2.1 2.2 14.8 10.8 1.5 8.2 4.1 0.9 8.5 4.0 26.0 24.3 15.3 50.3 24.0 13.4 22.0 40.8 18.2 23.6 PIK3R2 "p85, P85B" ENSG00000105647 "Phosphoinositide-3-kinase regulatory subunit 2" O00459 19 18153118-18170540 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins" "Protein transport, Stress response, Transport" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" HPA069291 Approved Approved "Golgi apparatus" "Golgi apparatus" "HPA069291: " "unprognostic (2.50e-1)" "unprognostic (1.90e-3)" "unprognostic (1.68e-2)" "unprognostic (1.87e-1)" "unprognostic (2.00e-2)" "unprognostic (9.65e-3)" "unprognostic (1.69e-3)" "unprognostic (2.36e-3)" "unprognostic (9.24e-2)" "unprognostic (4.28e-2)" "unprognostic (1.17e-1)" "unprognostic (3.36e-1)" "unprognostic (1.69e-2)" "unprognostic (2.02e-1)" "unprognostic (6.35e-3)" "unprognostic (8.63e-2)" "unprognostic (2.00e-2)" 6.4 20.9 27.5 7.2 30.1 10.1 7.2 14.4 36.6 14.5 13.5 11.4 6.7 21.7 13.9 12.0 19.0 17.8 17.2 12.5 33.2 11.5 10.3 10.3 8.4 6.3 10.1 18.1 20.2 13.0 24.3 16.7 10.2 7.9 11.6 10.1 11.4 14.5 11.9 10.9 26.2 16.5 11.1 7.4 7.1 15.9 9.8 11.0 11.3 9.0 9.4 10.4 13.9 11.6 2.5 1.9 3.1 1.8 1.9 3.2 0.8 18.8 9.7 13.3 17.7 17.7 17.9 20.1 15.1 19.0 11.4 8.4 9.9 9.2 14.9 23.9 21.0 14.2 8.0 16.5 6.3 12.2 29.1 5.7 13.1 23.6 14.2 12.9 7.0 22.3 16.3 7.6 11.7 2.8 16.2 5.4 14.0 29.4 8.8 11.0 15.5 21.7 9.3 18.5 11.4 16.3 14.0 29.9 33.9 14.3 13.8 13.1 8.8 7.1 5.7 20.3 10.5 25.1 13.4 10.2 13.0 6.7 16.2 18.9 12.8 0.7 1.7 3.1 3.2 1.8 2.0 2.5 1.7 1.5 1.9 2.3 1.6 1.8 1.0 1.9 1.0 1.4 0.3 0.8 27.5 30.1 14.4 36.6 33.2 11.5 10.1 18.1 7.9 11.0 PIK3R3 p55 ENSG00000117461 "Phosphoinositide-3-kinase regulatory subunit 3" Q92569 1 46040140-46133036 "Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "RT4: 33.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "eosinophil: 8.6" "Group enriched" "Detected in many" 8 "granulocytes: 8.6;monocytes: 3.1;T-cells: 3.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA005751, HPA071988" Approved Approved Nucleoplasm,Vesicles Vesicles Nucleoplasm "HPA005751: AB_1855350, HPA071988: " "unprognostic (1.98e-1)" "unprognostic (3.75e-3)" "unprognostic (8.04e-2)" "prognostic favourable (1.93e-4)" "unprognostic (6.32e-2)" "prognostic favourable (3.62e-4)" "unprognostic (4.88e-2)" "unprognostic (3.33e-3)" "unprognostic (4.16e-2)" "unprognostic (4.63e-2)" "unprognostic (1.05e-2)" "unprognostic (1.45e-1)" "unprognostic (9.99e-3)" "unprognostic (2.87e-2)" "unprognostic (9.74e-2)" "unprognostic (6.71e-2)" "unprognostic (8.22e-3)" 33.7 10.9 7.4 7.0 8.2 0.8 24.7 36.4 11.0 16.9 6.3 3.5 9.1 3.3 15.8 11.0 8.4 7.6 10.9 28.7 6.8 8.5 10.4 4.1 20.0 6.0 8.7 3.1 4.6 4.0 18.7 10.2 13.4 10.4 9.0 5.3 13.6 9.4 8.0 14.8 4.6 6.0 12.3 7.1 10.9 7.4 24.0 4.5 5.9 12.7 6.2 5.3 12.3 8.7 0.5 0.6 8.6 3.1 0.1 3.5 0.9 4.6 1.6 21.4 10.8 2.1 0.9 6.8 2.8 2.0 3.7 4.6 0.9 1.4 6.1 8.5 1.0 2.8 7.4 2.5 2.4 4.8 6.7 3.8 19.2 0.7 0.7 3.5 5.3 2.6 1.5 3.9 1.4 7.6 1.4 4.4 5.2 7.1 14.0 2.1 7.5 4.3 18.0 5.7 7.3 9.2 33.3 15.5 11.2 9.0 23.9 2.5 6.6 3.1 14.2 3.9 3.7 0.6 2.7 6.3 6.5 3.7 3.1 4.7 2.0 0.0 0.3 8.6 3.3 0.5 3.0 0.5 0.8 2.9 0.0 0.0 0.3 1.9 0.1 0.1 3.1 0.6 3.5 0.9 7.4 8.2 36.4 8.9 6.8 8.5 8.7 3.1 10.4 4.5 PIM1 PIM ENSG00000137193 "Pim-1 proto-oncogene, serine/threonine kinase" P11309 6 37170203-37175426 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Apoptosis, Cell cycle" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HEL: 34.8;HMC-1: 64.9;U-698: 116.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "basophil: 64.6" "Group enriched" "Detected in all" 5 "granulocytes: 64.6;T-cells: 19.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003941, CAB017040" Uncertain Supported Nucleoli,Cytosol Cytosol Nucleoli "CAB017040: , HPA003941: AB_1079618" "unprognostic (1.25e-2)" "unprognostic (4.77e-1)" "unprognostic (3.61e-2)" "prognostic unfavourable (9.73e-4)" "unprognostic (1.91e-2)" "unprognostic (1.06e-1)" "unprognostic (3.75e-1)" "unprognostic (4.64e-2)" "unprognostic (2.36e-1)" "unprognostic (1.10e-1)" "unprognostic (2.65e-2)" "unprognostic (7.32e-2)" "unprognostic (2.14e-3)" "unprognostic (8.16e-3)" "unprognostic (1.04e-1)" "unprognostic (5.26e-3)" "unprognostic (2.90e-1)" 39.3 5.4 7.4 18.5 8.9 80.9 20.1 8.1 9.9 23.0 17.9 4.7 4.2 17.9 15.4 9.8 56.3 21.6 24.7 20.8 8.2 3.7 7.5 24.5 14.5 35.7 7.4 2.2 20.0 9.6 2.0 5.6 28.7 12.7 15.6 8.8 6.9 12.8 4.5 26.5 31.3 26.1 31.6 10.7 21.4 12.1 6.8 7.6 15.0 7.2 20.1 28.8 32.6 31.2 1.7 1.4 64.6 1.7 8.4 19.0 8.5 3.0 1.2 2.0 1.1 4.6 2.4 23.5 1.0 3.3 2.2 3.6 4.5 4.2 6.0 1.7 1.2 3.5 2.0 3.2 2.0 27.5 1.3 34.8 1.3 5.8 4.7 0.6 64.9 8.3 4.0 2.0 1.3 0.6 29.9 9.8 0.3 0.7 1.9 3.1 3.7 1.9 4.6 3.6 7.1 0.6 18.4 9.7 1.9 2.3 0.2 0.6 0.5 1.0 1.1 1.3 3.9 5.8 1.3 4.6 2.4 116.6 0.5 8.8 1.3 64.6 1.7 24.4 14.7 1.6 19.0 1.7 13.1 12.9 1.4 1.3 11.9 9.0 14.1 8.4 0.9 0.4 9.4 8.5 7.4 8.9 8.1 9.9 8.2 3.7 7.4 2.2 12.7 7.6 PIM2 ENSG00000102096 "Pim-2 proto-oncogene, serine/threonine kinase" Q9P1W9 X 48913182-48919024 "Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins" "Apoptosis, Cell cycle" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 63.4;lymphoid tissue: 71.2" "Group enriched" "Detected in many" 5 "HDLM-2: 58.9;Karpas-707: 73.0;RPMI-8226: 71.9;U-266/70: 133.0;U-266/84: 117.5" "Cancer enriched" "Detected in all" 6 "testis cancer: 171.3" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA000285 Approved Cytosol Cytosol "HPA000285: AB_1079619" "unprognostic (2.34e-3)" "prognostic favourable (4.05e-5)" "unprognostic (8.04e-2)" "unprognostic (7.30e-2)" "unprognostic (6.41e-3)" "unprognostic (2.74e-3)" "unprognostic (2.84e-1)" "unprognostic (5.23e-2)" "unprognostic (2.47e-2)" "unprognostic (4.01e-2)" "unprognostic (1.33e-3)" "unprognostic (2.73e-1)" "prognostic unfavourable (1.17e-11)" "unprognostic (3.36e-2)" "unprognostic (1.96e-2)" "unprognostic (1.27e-1)" "unprognostic (4.38e-2)" 3.6 3.4 4.3 37.2 7.2 30.4 3.4 7.1 7.9 4.5 13.4 2.1 2.2 29.5 2.8 4.3 10.0 5.6 8.3 3.1 5.6 6.7 5.2 5.4 10.6 59.7 3.8 4.6 5.4 3.0 1.0 4.9 2.4 6.7 3.6 17.7 6.1 16.9 4.9 1.5 3.0 19.2 2.2 3.1 71.2 14.7 5.7 1.3 39.4 4.8 3.6 47.9 24.6 3.3 26.0 2.9 46.9 3.0 17.0 63.4 13.2 1.8 1.5 0.8 1.6 0.3 0.2 1.2 1.1 1.4 1.6 1.4 1.4 1.3 7.8 0.5 0.5 1.1 2.6 1.0 1.5 58.9 2.1 9.4 1.6 1.4 0.7 2.2 6.4 0.6 0.9 1.6 1.0 0.5 10.0 73.0 0.9 1.3 0.8 4.7 17.8 2.4 1.0 0.5 71.9 1.6 0.2 0.5 0.8 1.2 0.8 0.8 2.0 3.1 0.3 0.3 0.2 0.3 1.1 133.0 117.5 15.0 1.5 2.0 0.3 46.9 1.5 14.3 12.5 1.9 21.2 26.0 34.4 17.6 2.5 15.9 36.9 23.0 38.3 17.0 3.0 2.9 63.4 13.2 4.3 7.2 7.1 7.9 5.6 6.7 3.8 4.6 6.7 1.3 PIM3 ENSG00000198355 "Pim-3 proto-oncogene, serine/threonine kinase" Q86V86 22 49960513-49964080 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Apoptosis, Cell cycle" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "Karpas-707: 45.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 16.9" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA068758 Supported Cytosol Cytosol "HPA068758: " "unprognostic (3.67e-2)" "unprognostic (7.69e-3)" "unprognostic (1.07e-1)" "unprognostic (1.11e-1)" "unprognostic (3.67e-2)" "unprognostic (5.83e-2)" "unprognostic (1.48e-2)" "unprognostic (1.13e-2)" "unprognostic (2.71e-2)" "prognostic unfavourable (9.68e-4)" "unprognostic (2.00e-2)" "unprognostic (1.00e-1)" "prognostic favourable (8.09e-4)" "unprognostic (5.59e-3)" "unprognostic (1.71e-1)" "unprognostic (3.92e-3)" "unprognostic (7.27e-3)" 32.5 15.5 6.8 19.9 16.7 62.4 50.5 7.6 11.9 16.4 22.6 11.3 20.9 15.9 14.4 17.6 25.0 15.9 37.8 23.6 7.5 7.9 29.1 25.7 38.3 29.4 21.1 4.9 13.9 36.4 4.8 14.9 31.4 15.1 28.4 7.6 9.7 27.6 22.7 39.9 31.3 20.9 12.2 10.1 25.4 33.6 13.0 13.5 9.7 19.1 19.9 19.0 25.6 18.3 6.1 5.7 16.9 4.0 1.2 4.5 1.9 7.2 4.8 3.2 6.1 2.5 1.9 18.5 4.6 7.4 5.4 3.9 8.0 6.2 12.9 5.8 1.2 6.2 6.2 3.4 1.9 9.7 25.7 5.3 11.5 9.6 12.0 11.5 10.3 3.6 11.5 3.3 5.7 17.6 7.3 45.7 1.6 16.2 5.8 20.6 6.8 7.7 27.2 5.4 15.3 2.9 5.5 11.6 8.1 8.9 40.6 28.4 5.3 15.3 4.6 3.4 14.8 5.6 7.4 23.5 14.9 11.0 8.6 6.5 9.2 0.0 3.1 0.1 1.9 3.2 2.3 3.4 4.4 3.8 2.5 6.1 4.1 1.7 16.9 1.2 4.0 5.7 4.5 1.9 6.8 16.7 7.6 11.9 7.5 7.9 21.1 4.9 15.1 13.5 PIN1 dod ENSG00000127445 "Peptidylprolyl cis/trans isomerase, NIMA-interacting 1" Q13526 19 9835257-9849682 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Cell cycle" "Isomerase, Rotamase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 88.2" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "CAB004528, CAB009326, HPA068650, HPA070887" Approved Enhanced Nucleoplasm,Cytosol 30000 Nucleoplasm Cytosol "CAB004528: AB_628132, CAB009326: AB_2237080, HPA068650: , HPA070887: " "unprognostic (2.54e-1)" "unprognostic (6.14e-3)" "unprognostic (6.50e-2)" "unprognostic (4.36e-2)" "unprognostic (1.71e-2)" "unprognostic (6.50e-3)" "unprognostic (1.90e-1)" "unprognostic (2.86e-2)" "unprognostic (2.67e-1)" "unprognostic (7.23e-3)" "prognostic favourable (3.25e-4)" "unprognostic (9.43e-2)" "prognostic favourable (7.80e-5)" "unprognostic (2.20e-2)" "unprognostic (2.56e-1)" "unprognostic (3.13e-2)" "unprognostic (1.21e-2)" 24.5 36.3 40.0 18.7 38.8 25.6 9.3 27.4 66.0 9.2 15.8 18.1 8.5 22.9 14.0 8.3 11.3 16.4 10.1 25.9 38.0 35.2 17.4 14.5 13.2 14.8 38.7 37.2 13.9 21.1 9.5 13.6 13.3 57.3 23.2 6.5 14.1 21.3 15.7 50.2 10.2 21.7 11.1 19.6 15.4 19.6 24.8 15.0 19.7 9.9 8.1 9.3 11.1 9.7 36.4 72.8 88.2 44.9 40.7 53.8 46.2 25.9 23.8 17.8 16.5 6.2 5.6 10.5 19.4 8.4 14.5 14.0 22.1 8.3 16.1 31.0 7.2 13.3 12.2 11.7 4.6 34.3 52.0 41.8 29.3 19.0 10.1 19.5 24.6 7.6 7.9 9.4 4.4 11.8 18.9 24.5 8.7 18.2 29.5 76.2 17.0 36.6 27.0 18.5 27.0 10.4 12.8 22.4 26.4 18.7 9.4 21.7 12.0 23.4 19.9 20.1 16.1 31.1 31.1 31.6 29.7 21.7 21.5 25.0 24.7 52.2 43.4 88.2 42.0 44.9 39.2 35.6 41.5 42.1 39.7 36.4 33.1 37.2 26.8 40.7 41.7 72.8 53.8 46.2 40.0 38.8 27.4 66.0 38.0 35.2 38.7 37.2 57.3 15.0 PIP4K2B "PIP5K2B, PIP5KIIB, PIP5KIIbeta" ENSG00000276293 "Phosphatidylinositol-5-phosphate 4-kinase type 2 beta" P78356 17 38765689-38800126 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 23.6" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA047875, HPA062220" Approved Supported Nucleoplasm Nucleoplasm "HPA047875: , HPA062220: " "unprognostic (7.77e-2)" "unprognostic (8.37e-2)" "unprognostic (3.74e-2)" "unprognostic (1.13e-1)" "unprognostic (2.67e-1)" "unprognostic (1.91e-1)" "prognostic unfavourable (4.54e-4)" "unprognostic (2.64e-1)" "unprognostic (2.33e-1)" "unprognostic (1.50e-2)" "unprognostic (6.10e-3)" "unprognostic (3.79e-1)" "unprognostic (4.82e-3)" "unprognostic (3.38e-2)" "unprognostic (3.22e-1)" "prognostic favourable (1.36e-4)" "unprognostic (2.48e-1)" 5.1 6.5 12.4 3.3 12.9 1.1 5.0 8.8 17.4 6.8 2.7 7.0 4.2 2.2 7.2 5.9 3.5 7.4 3.6 7.1 9.6 4.1 2.2 5.0 4.2 5.4 13.3 13.3 3.0 5.1 2.7 5.4 7.5 5.1 3.2 4.1 3.8 6.5 23.6 5.8 2.3 7.3 4.7 5.1 2.5 2.8 6.5 2.0 4.7 2.2 4.5 3.7 5.9 3.3 3.1 2.4 2.4 3.4 5.0 3.7 5.9 13.1 21.8 22.7 19.1 15.2 4.5 11.1 12.4 14.1 11.5 8.8 5.9 15.2 7.0 19.0 12.8 14.4 9.2 13.6 10.5 9.3 13.2 8.5 13.0 8.7 15.1 8.1 13.3 11.3 11.0 8.1 11.6 11.5 7.2 15.1 4.5 13.8 11.0 12.2 6.1 15.0 21.6 8.3 10.3 7.4 12.2 17.7 11.2 4.6 11.3 14.4 14.3 12.3 11.9 7.9 10.2 9.6 9.5 11.9 6.9 14.1 11.9 10.7 1.6 2.4 0.8 4.8 2.2 5.0 3.1 4.1 4.6 3.1 3.3 4.7 4.2 2.4 3.4 1.8 3.0 3.9 3.7 PIP5K1A ENSG00000143398 "Phosphatidylinositol-4-phosphate 5-kinase type 1 alpha" Q99755 1 151197949-151249536 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA029366 Approved Supported "Nucleoplasm,Plasma membrane,Cytosol" "Plasma membrane, Cytosol" Nucleoplasm "HPA029366: AB_10602116" "unprognostic (1.05e-1)" "unprognostic (2.36e-2)" "unprognostic (8.64e-2)" "unprognostic (7.94e-3)" "unprognostic (1.17e-1)" "unprognostic (3.28e-2)" "unprognostic (1.26e-2)" "unprognostic (3.01e-1)" "unprognostic (8.79e-2)" "unprognostic (1.15e-1)" "unprognostic (1.37e-1)" "unprognostic (1.04e-1)" "prognostic unfavourable (4.16e-7)" "unprognostic (1.44e-1)" "unprognostic (8.14e-2)" "unprognostic (2.93e-1)" "unprognostic (1.59e-1)" 18.1 19.5 15.7 15.4 21.0 9.6 20.2 22.6 27.6 19.8 18.0 20.3 14.7 16.4 24.8 22.6 20.7 19.4 20.7 18.9 17.3 13.4 17.8 18.3 21.7 17.1 12.7 17.5 20.4 16.6 21.8 25.3 44.6 14.6 17.3 15.6 29.5 17.8 15.2 26.1 20.4 20.4 27.2 16.1 20.1 16.8 42.1 14.0 19.3 20.1 13.9 22.3 16.2 17.7 9.1 8.7 11.7 6.2 4.7 5.9 6.3 17.7 13.8 21.4 24.6 14.1 14.9 21.0 23.4 33.0 43.8 39.3 25.1 17.2 16.1 25.0 24.9 15.1 27.7 16.1 38.4 24.3 19.8 12.8 18.2 11.9 26.7 22.9 16.2 19.9 14.9 27.2 34.5 17.8 12.5 13.8 22.0 24.8 22.8 11.4 31.7 21.4 22.1 18.7 12.0 22.5 10.3 14.3 19.0 31.6 24.4 20.6 25.5 21.7 17.0 17.4 24.4 16.0 28.1 19.3 32.1 36.4 16.9 6.7 20.8 0.1 5.5 7.3 5.3 6.2 4.1 9.1 5.0 5.9 8.4 4.6 5.4 4.2 11.7 4.7 4.8 8.7 3.9 6.3 15.7 21.0 22.6 27.6 17.3 13.4 12.7 17.5 14.6 14.0 PKM "OIP3, PK3, PKM2, THBP1" ENSG00000067225 "Pyruvate kinase M1/2" P14618 15 72199029-72231822 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" Glycolysis "Allosteric enzyme, Kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in all" 5 "skeletal muscle: 541.2" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB019421, HPA029501" Uncertain Enhanced Cytosol 540000000 Cytosol "CAB019421: AB_2252325, HPA029501: AB_10602118" "unprognostic (8.73e-3)" "unprognostic (4.63e-3)" "unprognostic (1.68e-2)" "unprognostic (3.09e-1)" "unprognostic (6.51e-2)" "prognostic unfavourable (1.30e-4)" "prognostic unfavourable (2.74e-6)" "prognostic unfavourable (2.85e-4)" "unprognostic (9.51e-2)" "unprognostic (1.17e-2)" "prognostic unfavourable (5.17e-5)" "unprognostic (3.16e-1)" "unprognostic (3.22e-1)" "unprognostic (7.85e-2)" "unprognostic (3.17e-2)" "unprognostic (1.44e-1)" "unprognostic (1.25e-2)" 23.2 76.8 53.8 49.8 70.4 57.5 41.6 56.6 85.9 65.7 31.2 32.1 31.5 26.4 24.7 41.8 76.4 37.9 32.9 94.8 50.1 57.1 60.9 6.1 33.3 39.4 62.5 63.6 26.2 15.6 33.3 28.3 27.1 80.5 34.8 31.9 54.4 47.1 47.5 541.2 51.8 25.1 44.7 34.9 30.7 26.7 29.0 29.4 23.5 23.8 114.4 60.6 53.1 40.9 25.1 79.6 14.9 90.6 11.6 37.4 114.9 81.5 209.8 42.3 50.0 50.9 57.2 35.0 88.5 206.7 142.1 143.9 59.0 100.5 62.1 89.6 165.6 118.9 133.7 180.0 111.4 109.0 63.2 38.0 105.5 48.8 35.5 49.3 82.0 51.9 83.9 109.5 45.0 83.6 9.5 49.8 224.1 50.7 18.4 21.2 52.3 80.1 54.7 135.4 118.3 188.7 105.0 44.0 48.0 115.4 71.2 90.5 49.9 35.9 65.1 161.9 88.6 158.2 160.5 64.0 90.4 54.7 199.3 81.6 158.6 12.6 90.6 14.9 23.5 52.6 22.8 25.1 31.3 23.2 79.6 16.1 27.3 20.2 11.8 11.6 40.2 16.2 37.4 114.9 53.8 70.4 56.6 85.9 50.1 57.1 62.5 63.6 80.5 29.4 PLAG1 ZNF912 ENSG00000181690 "PLAG1 zinc finger" Q6DJT9 8 56160904-56211324 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "ASC diff: 13.0;ASC TERT1: 17.2;HSkMC: 12.2;hTERT-HME1: 12.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" HPA072290 Supported "Nucleoplasm,Nuclear speckles,Centrosome,Cytosol" "Nucleoplasm, Nuclear speckles" "Centrosome, Cytosol" "HPA072290: " "unprognostic (1.89e-2)" "unprognostic (1.93e-2)" "unprognostic (1.22e-3)" "unprognostic (1.63e-4)" "unprognostic (6.81e-2)" "unprognostic (1.07e-1)" "unprognostic (5.63e-3)" "unprognostic (8.56e-2)" "unprognostic (1.18e-1)" "unprognostic (7.99e-2)" "unprognostic (3.42e-2)" "unprognostic (1.97e-1)" "unprognostic (1.32e-3)" "unprognostic (2.83e-2)" "unprognostic (3.94e-1)" "unprognostic (1.21e-2)" "unprognostic (6.14e-2)" 1.9 3.6 2.4 3.5 2.9 2.1 2.5 11.0 2.7 7.6 3.8 4.1 9.0 3.4 3.4 9.8 2.0 7.5 2.1 6.8 1.9 1.8 3.7 1.2 4.6 6.7 4.8 2.1 11.6 2.2 2.1 17.8 8.0 4.6 5.1 1.6 7.9 7.5 9.2 1.4 3.4 5.5 2.5 6.3 6.2 3.0 5.2 4.5 11.7 3.5 1.5 5.2 4.8 7.0 3.5 0.2 1.1 0.5 0.7 4.6 1.0 1.5 0.0 9.5 0.1 13.0 17.2 3.0 4.2 5.5 2.0 0.9 0.6 4.9 0.2 4.1 2.3 0.3 2.6 5.6 2.0 0.1 5.8 6.0 0.5 1.4 2.7 1.9 1.8 12.2 3.1 1.1 12.6 3.7 2.5 0.1 4.2 0.0 0.5 3.6 2.7 1.4 4.7 0.7 3.7 2.6 0.5 0.1 0.0 0.1 0.0 0.3 0.1 1.8 5.6 2.9 3.8 4.7 1.0 1.5 1.1 2.2 3.3 0.7 0.8 1.1 0.1 1.1 0.3 0.1 0.2 3.5 1.0 0.6 0.1 2.0 4.6 4.3 1.0 0.7 0.5 0.2 0.2 1.0 2.4 2.9 11.0 2.7 1.9 1.8 4.8 2.1 4.6 4.5 PLAT ENSG00000104368 "Plasminogen activator, tissue type" P00750 8 42175233-42207724 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins" "Plasminogen activation" "Hydrolase, Protease, Serine protease" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "parathyroid gland: 132.2" "Cell line enhanced" "Detected in many" "CAPAN-2: 85.8;HMC-1: 55.1;LHCN-M2: 55.6;U-2197: 58.0;WM-115: 115.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "memory CD4 T-cell: 2.1;T-reg: 2.3" "Group enriched" "Detected in many" 7 "granulocytes: 1.6;T-cells: 2.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003412, CAB009335" Supported Approved "Actin filaments" "Secreted to blood" 9900000 12000 "Actin filaments" "CAB009335: AB_2237146, HPA003412: AB_1858205" "prognostic favourable (7.57e-4)" "unprognostic (2.23e-1)" "unprognostic (4.08e-1)" "unprognostic (3.39e-1)" "unprognostic (4.88e-3)" "unprognostic (9.39e-2)" "unprognostic (4.65e-3)" "unprognostic (5.78e-2)" "unprognostic (1.55e-1)" "unprognostic (1.75e-1)" "unprognostic (2.98e-3)" "unprognostic (2.46e-1)" "prognostic unfavourable (4.95e-4)" "unprognostic (8.72e-3)" "unprognostic (1.37e-2)" "unprognostic (2.63e-2)" "unprognostic (6.09e-2)" 19.3 14.9 5.2 12.9 6.8 0.4 13.3 2.2 6.2 24.5 17.1 9.1 19.0 11.2 35.5 28.1 18.1 19.1 18.5 7.3 6.0 5.9 67.6 2.8 15.9 1.9 8.2 3.6 18.4 5.8 132.2 5.1 15.5 9.4 27.4 12.2 39.4 6.1 12.7 5.8 2.0 31.7 23.0 7.0 1.0 14.6 12.2 3.8 0.6 11.2 14.7 7.4 47.9 13.7 0.3 0.1 1.6 0.0 0.0 2.3 0.3 0.5 0.2 4.2 1.0 7.7 10.5 0.1 18.0 32.0 7.7 6.6 0.2 85.8 0.0 0.6 2.3 1.4 0.0 4.0 15.9 7.8 1.4 0.1 0.1 0.1 37.9 0.0 55.1 10.5 0.0 18.8 0.7 14.4 0.5 0.1 55.6 0.0 0.0 0.0 5.6 7.6 0.0 15.6 0.0 2.5 0.0 0.0 0.9 0.0 0.1 24.5 0.1 0.0 27.5 1.5 5.7 58.0 1.8 0.0 0.1 0.0 1.2 0.0 115.3 1.6 0.0 0.0 0.3 0.0 1.0 0.3 2.1 0.5 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.1 2.3 0.3 5.2 6.8 2.2 6.2 6.0 5.9 8.2 3.6 9.4 3.8 PLAU "UPA, URK" ENSG00000122861 "Plasminogen activator, urokinase" P00749 10 73909177-73917497 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Blood coagulation, Fibrinolysis, Hemostasis, Plasminogen activation" "Hydrolase, Protease, Serine protease" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "placenta: 48.4" "Cell line enhanced" "Detected in many" "CAPAN-2: 68.9;LHCN-M2: 66.5;RPTEC TERT1: 252.9;U-251 MG: 67.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 9 "myeloid DC: 2.4;neutrophil: 4.5;plasmacytoid DC: 4.5" "Group enriched" "Detected in many" 11 "dendritic cells: 4.5;granulocytes: 4.5" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA008719 Approved "Secreted to blood" 647333 58000 "HPA008719: AB_1858635" "unprognostic (1.96e-2)" "unprognostic (2.99e-2)" "unprognostic (7.40e-2)" "prognostic favourable (3.38e-4)" "unprognostic (4.73e-2)" "prognostic unfavourable (2.70e-4)" "unprognostic (1.39e-2)" "prognostic unfavourable (4.04e-4)" "unprognostic (2.26e-1)" "unprognostic (6.58e-2)" "prognostic unfavourable (1.32e-4)" "unprognostic (1.61e-1)" "prognostic unfavourable (3.51e-4)" "unprognostic (2.83e-1)" "unprognostic (3.37e-2)" "unprognostic (1.51e-2)" "unprognostic (1.77e-2)" 26.7 2.4 1.0 15.5 2.1 11.3 9.7 1.6 1.5 6.9 5.8 2.9 4.9 3.8 10.7 21.2 9.1 6.5 10.7 14.3 1.3 1.0 23.3 2.3 23.4 5.5 1.6 1.5 6.8 3.7 3.6 1.8 48.4 3.1 7.5 6.7 4.5 10.6 5.0 12.2 9.0 8.1 8.4 2.5 23.8 7.8 5.8 1.3 4.8 10.9 11.6 8.2 16.3 9.3 0.1 4.5 4.5 0.4 0.0 0.0 0.3 13.0 7.0 3.0 0.1 0.2 5.0 0.1 7.9 37.2 3.2 5.1 0.1 68.9 0.0 14.7 1.1 9.0 0.0 13.3 3.7 0.7 0.0 0.0 0.3 0.1 6.1 1.1 2.6 13.3 1.6 22.2 8.6 9.2 0.0 0.0 66.5 0.0 0.0 1.7 0.8 18.3 0.0 9.0 0.0 252.9 10.3 0.0 0.0 0.0 0.3 0.2 0.0 1.8 23.3 0.2 1.6 1.7 67.9 0.0 0.1 0.1 17.9 1.9 0.0 0.0 0.4 0.0 0.0 0.1 0.0 0.1 0.0 0.0 2.4 0.0 0.0 0.0 4.5 0.0 0.0 4.5 0.0 0.3 1.0 2.1 1.6 1.5 1.3 1.0 1.6 1.5 3.1 1.3 PLAUR "CD87, UPAR, URKR" ENSG00000011422 "Plasminogen activator, urokinase receptor" Q03405 19 43646095-43670547 "Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" Receptor "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 118.0;bone marrow: 165.0" "Cell line enhanced" "Detected in many" "hTEC/SVTERT24-B: 49.4;U-251 MG: 70.2;U-87 MG: 61.3;WM-115: 59.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 118.0" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in some" "Low region specificity" "Detected in all" "HPA050843, CAB073533" Uncertain Supported "Plasma membrane" "Intracellular and membrane" 760000 "Plasma membrane" "CAB073533: , HPA050843: " "unprognostic (9.28e-2)" "unprognostic (9.65e-3)" "unprognostic (1.39e-1)" "unprognostic (1.29e-3)" "unprognostic (3.59e-3)" "unprognostic (1.50e-2)" "unprognostic (2.18e-3)" "prognostic unfavourable (2.33e-5)" "unprognostic (8.08e-3)" "unprognostic (4.30e-2)" "unprognostic (2.29e-3)" "unprognostic (5.30e-2)" "prognostic unfavourable (7.83e-9)" "unprognostic (4.99e-2)" "unprognostic (1.66e-1)" "unprognostic (5.45e-2)" "unprognostic (9.33e-2)" 25.2 3.6 3.0 23.6 4.8 165.0 6.3 2.2 6.1 10.7 7.5 4.4 1.8 3.3 9.5 6.0 8.6 10.6 23.0 11.5 4.5 3.2 5.1 6.1 39.4 8.1 6.0 1.1 11.9 4.3 2.5 4.4 12.2 6.9 6.1 6.0 4.6 11.0 3.7 7.9 3.5 7.3 7.2 7.1 12.6 12.0 6.3 6.3 2.5 4.4 7.7 7.0 22.7 14.9 0.2 21.3 118.0 50.5 0.6 0.9 21.0 14.0 4.9 4.5 0.3 4.0 14.4 2.7 29.6 30.1 18.7 23.5 0.4 16.6 0.5 7.5 18.3 6.0 1.2 7.3 20.9 0.9 0.9 2.6 7.4 0.6 5.1 3.1 34.3 14.8 1.4 49.4 7.4 20.6 2.7 0.6 17.9 1.0 3.4 8.4 1.4 10.6 3.9 3.0 1.0 5.8 0.7 0.2 3.9 13.2 3.0 3.9 0.6 9.8 21.1 41.3 21.2 18.9 70.2 0.6 1.4 0.1 61.3 5.8 59.7 7.2 48.9 72.4 0.7 41.5 0.8 0.2 0.9 0.6 21.3 0.1 0.3 0.4 118.0 0.6 50.5 6.8 0.3 21.0 3.0 4.8 2.2 6.1 4.5 3.2 6.0 1.1 6.9 6.3 PLCG1 "NCKAP3, PLC-II, PLC1, PLC148, PLCgamma1" ENSG00000124181 "Phospholipase C gamma 1" P19174 20 41136960-41196801 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins" "Host-virus interaction, Lipid degradation, Lipid metabolism" "Hydrolase, Transducer" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 7 "gdT-cell: 5.9;MAIT T-cell: 8.0;memory CD4 T-cell: 5.2;memory CD8 T-cell: 4.9;naive CD4 T-cell: 5.7;naive CD8 T-cell: 5.4;NK-cell: 4.0;T-reg: 4.4" "Group enriched" "Detected in many" 8 "NK-cells: 4.0;T-cells: 8.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004277, HPA036681, HPA036682" Approved Enhanced Cytosol Cytosol "CAB004277: AB_628119, HPA036681: , HPA036682: " "unprognostic (2.77e-1)" "unprognostic (1.35e-1)" "unprognostic (1.65e-1)" "unprognostic (4.31e-2)" "unprognostic (5.82e-2)" "unprognostic (2.09e-2)" "unprognostic (4.45e-3)" "unprognostic (1.25e-2)" "unprognostic (2.29e-2)" "unprognostic (1.16e-1)" "prognostic favourable (4.72e-4)" "unprognostic (3.32e-1)" "unprognostic (2.73e-3)" "unprognostic (1.82e-1)" "unprognostic (2.65e-1)" "unprognostic (9.27e-2)" "unprognostic (2.79e-2)" 20.2 15.1 25.1 20.9 22.1 8.3 34.9 52.6 26.8 19.9 13.9 23.4 12.5 16.5 27.6 13.9 13.5 17.0 18.7 20.9 25.4 13.6 15.3 6.8 19.3 30.7 18.5 20.5 28.7 9.1 16.9 14.2 22.2 18.7 18.4 13.2 20.0 13.2 20.6 13.4 22.3 17.1 22.2 15.4 20.1 12.4 19.9 23.9 48.1 28.5 11.9 21.9 17.1 21.1 0.7 0.0 0.0 0.0 4.0 8.0 3.3 5.3 6.8 32.9 24.1 13.2 9.3 10.5 8.8 11.4 17.8 15.2 16.4 1.8 12.0 10.9 9.6 10.0 14.3 15.8 10.4 3.4 7.6 0.8 11.4 19.3 10.0 4.7 3.3 11.8 8.9 13.1 10.3 19.9 8.9 7.9 16.1 40.1 28.9 3.7 12.2 12.6 23.1 24.0 5.9 9.8 9.9 11.7 22.4 15.8 7.4 15.9 8.6 5.5 21.4 42.7 13.9 13.6 10.7 8.9 3.9 10.0 10.2 5.1 17.7 0.0 0.0 0.0 5.9 0.0 8.0 0.3 5.2 4.9 0.0 0.7 5.7 5.4 0.0 4.0 0.0 0.0 4.4 3.3 25.1 22.1 52.6 26.8 25.4 13.6 18.5 20.5 18.7 23.9 PLCG2 ENSG00000197943 "Phospholipase C gamma 2" P16885 16 81739097-81962693 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins" "Lipid degradation, Lipid metabolism" "Hydrolase, Transducer" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 55.8" "Cell line enhanced" "Detected in some" "Daudi: 39.6;HMC-1: 19.0;U-698: 87.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB004280, HPA020099, HPA020100" Enhanced Approved Vesicles 21000 Vesicles "CAB004280: AB_628120, HPA020099: AB_1855324, HPA020100: AB_1855325" "unprognostic (2.86e-2)" "unprognostic (1.34e-1)" "unprognostic (1.09e-3)" "unprognostic (1.10e-1)" "unprognostic (1.58e-1)" "prognostic favourable (6.71e-4)" "unprognostic (6.23e-2)" "unprognostic (5.01e-2)" "unprognostic (2.22e-1)" "unprognostic (4.58e-2)" "unprognostic (4.66e-2)" "unprognostic (1.71e-2)" "prognostic favourable (4.88e-4)" "unprognostic (1.52e-2)" "unprognostic (1.21e-1)" "unprognostic (2.89e-1)" "unprognostic (3.40e-3)" 8.4 3.8 3.3 55.8 4.9 14.1 10.7 1.0 2.4 5.6 10.3 5.3 3.1 8.7 11.2 12.2 6.0 4.7 10.1 4.4 3.3 2.8 20.6 8.8 10.7 35.5 5.2 1.8 2.0 3.6 1.0 1.8 4.1 4.5 4.3 3.6 4.6 8.8 2.8 2.0 4.1 17.6 4.6 8.6 33.6 4.2 2.3 4.2 6.3 5.3 2.6 44.6 7.5 7.7 18.8 3.9 26.8 12.2 14.0 1.1 2.3 0.3 0.7 0.1 0.6 0.0 0.0 0.9 0.0 0.0 0.5 0.2 0.2 1.7 39.6 6.8 0.0 0.9 0.8 0.1 0.3 0.3 0.4 4.7 0.0 0.0 0.2 4.7 19.0 0.0 0.4 0.3 0.2 0.9 0.5 3.3 0.0 1.2 0.5 11.9 0.7 0.2 16.1 0.0 5.0 0.1 0.8 0.3 0.0 1.1 0.3 0.3 0.7 14.6 0.2 0.0 0.7 0.1 0.1 7.9 12.9 87.9 0.0 6.5 0.3 2.8 4.4 26.8 0.7 5.7 0.3 18.8 0.2 1.1 3.9 17.3 0.3 0.8 24.8 14.0 12.2 2.6 0.1 2.3 3.3 4.9 1.0 2.4 3.3 2.8 5.2 1.8 4.5 4.2 PLEC "EBS1, PCN, PLEC1, PLTN" ENSG00000178209 Plectin Q15149 8 143915147-143976734 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" Actin-binding "Cancer-related genes, Disease mutation, Epidermolysis bullosa, Limb-girdle muscular dystrophy" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 144.9" "Cell line enhanced" "Detected in many" "PC-3: 72.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003847, HPA025967, HPA029906" Enhanced Enhanced "Intermediate filaments,Focal adhesion sites,Cytosol" 7100000 "Intermediate filaments, Cytosol" "Focal adhesion sites" "CAB003847: AB_562198, HPA025967: AB_10601671, HPA029906: AB_10602279" "unprognostic (1.02e-1)" "unprognostic (1.37e-3)" "prognostic unfavourable (4.29e-4)" "unprognostic (2.09e-2)" "unprognostic (1.04e-1)" "unprognostic (1.05e-2)" "unprognostic (1.76e-3)" "prognostic unfavourable (5.33e-4)" "unprognostic (1.72e-3)" "unprognostic (1.13e-2)" "unprognostic (2.85e-3)" "unprognostic (5.48e-2)" "prognostic unfavourable (7.98e-6)" "unprognostic (2.30e-1)" "unprognostic (4.04e-2)" "unprognostic (6.58e-2)" "unprognostic (5.58e-3)" 20.9 11.0 15.9 16.5 13.3 27.9 13.1 15.0 20.7 20.7 17.7 14.6 16.7 13.1 20.2 16.8 25.1 18.2 29.0 23.4 18.9 10.7 11.2 10.9 16.6 15.0 9.9 13.0 18.0 14.0 8.8 12.0 24.2 13.2 17.5 9.8 13.0 17.8 14.8 144.9 36.4 24.1 24.7 11.0 16.9 21.4 6.7 12.7 16.3 9.2 44.2 24.5 20.2 19.2 1.5 3.4 0.8 4.1 0.7 2.9 3.2 16.3 51.2 3.3 4.1 6.0 13.4 11.7 24.0 10.7 6.4 3.6 7.1 17.1 1.6 18.7 35.1 19.4 2.2 33.6 2.5 12.2 1.8 6.2 52.0 5.8 9.5 2.0 5.2 15.4 6.6 17.2 33.6 7.4 3.0 5.3 7.4 28.7 1.2 3.4 2.2 72.1 0.3 9.4 4.4 10.7 30.3 3.4 3.4 40.9 8.7 3.9 10.7 2.4 23.8 24.8 44.9 21.8 28.4 0.8 0.6 1.2 23.6 2.6 35.2 0.0 4.1 0.2 1.4 3.8 2.8 1.4 2.7 2.0 3.4 1.5 2.0 1.1 0.8 0.7 2.7 2.8 2.9 3.2 15.9 13.3 15.0 17.3 18.9 10.7 9.9 13.0 13.2 12.7 PLG ENSG00000122194 Plasminogen P00747 6 160702238-160753315 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins" "Blood coagulation, Fibrinolysis, Hemostasis, Tissue remodeling" "Hydrolase, Protease, Serine protease" "Cancer-related genes, Disease mutation, FDA approved drug targets, Thrombophilia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 11 "liver: 269.9" "Cell line enhanced" "Detected in some" "HL-60: 3.5;RH-30: 3.9;U-698: 2.0;U-937: 1.6" "Cancer enriched" "Detected in some" 84 "liver cancer: 180.7" "Not detected" "Not detected" "Not detected" "Not detected" "CAB000668, CAB016678, HPA021602, HPA048823" Supported "Secreted to blood" 140000000000 41000000000 "CAB000668: , CAB016678: AB_1621208, HPA021602: AB_1855453, HPA048823: " "unprognostic (1.70e-1)" "unprognostic (2.16e-3)" "unprognostic (2.44e-1)" "unprognostic (8.54e-3)" "unprognostic (1.41e-1)" "unprognostic (1.76e-3)" "unprognostic (6.28e-2)" "unprognostic (7.25e-2)" "prognostic favourable (4.22e-4)" "unprognostic (3.97e-3)" "unprognostic (5.21e-2)" "unprognostic (2.33e-2)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 24.0 269.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.5 0.0 3.5 0.6 0.0 0.0 0.0 0.0 0.0 0.9 0.4 0.0 0.0 0.3 0.2 0.8 0.0 0.4 3.9 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.5 0.0 0.1 0.0 0.0 1.0 0.0 2.0 0.0 1.6 0.0 0.5 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 PLK1 PLK ENSG00000166851 "Polo like kinase 1" P53350 16 23677656-23690367 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Cell cycle, Cell division, Mitosis" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 83.9;testis: 32.4" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in some" 5 "T-reg: 9.0" "Lineage enriched" "Detected in many" 5 "T-cells: 9.0" "Low region specificity" "Detected in single" "Low region specificity" "Detected in many" "HPA051638, HPA053229" Approved "HPA051638: , HPA053229: " "unprognostic (7.21e-3)" "unprognostic (1.77e-1)" "unprognostic (1.98e-3)" "unprognostic (4.97e-3)" "unprognostic (9.56e-2)" "unprognostic (5.12e-2)" "prognostic unfavourable (2.70e-7)" "prognostic unfavourable (2.28e-5)" "unprognostic (2.55e-2)" "unprognostic (1.89e-1)" "prognostic unfavourable (4.12e-4)" "unprognostic (1.24e-2)" "prognostic unfavourable (0.00e+0)" "unprognostic (1.33e-1)" "unprognostic (8.10e-2)" "unprognostic (1.19e-1)" "unprognostic (1.26e-2)" 2.9 1.1 1.1 14.2 1.5 15.9 1.7 2.1 1.1 1.5 7.1 0.7 0.5 6.0 1.1 0.9 10.4 0.7 1.5 1.0 1.0 0.8 1.3 1.2 2.6 15.2 0.8 0.6 1.2 0.7 0.0 0.8 6.8 0.7 0.9 5.9 0.5 1.7 0.8 0.8 2.9 5.9 2.0 0.7 8.3 3.6 32.4 0.5 83.9 0.6 6.6 20.4 2.1 2.6 1.9 0.5 0.7 0.1 1.3 9.0 2.3 43.1 45.0 37.2 20.2 1.1 2.6 20.9 24.7 16.3 38.7 28.9 39.3 28.5 21.6 12.9 16.6 24.8 50.7 20.3 46.6 30.7 28.6 27.4 35.5 53.7 0.3 31.6 30.1 1.0 1.1 27.4 28.3 28.3 42.6 29.8 29.8 39.4 29.7 31.6 42.5 22.9 46.5 25.3 34.3 11.0 9.4 21.0 14.6 28.2 19.8 12.8 25.2 19.5 14.3 18.4 23.6 18.0 42.1 21.2 33.0 37.4 15.6 27.5 30.1 0.0 0.1 0.0 0.0 0.0 0.0 1.9 1.4 0.5 0.5 0.0 0.0 0.0 0.7 1.3 0.0 0.0 9.0 2.3 1.1 1.5 2.1 1.1 1.0 0.8 0.8 0.6 0.7 0.5 PLP1 "GPM6C, PLP, SPG2" ENSG00000123560 "Proteolipid protein 1" P60201 X 103773718-103792619 "Cancer-related genes, Disease related genes, Predicted membrane proteins" "Cancer-related genes, Disease mutation, Hereditary spastic paraplegia, Leukodystrophy, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 26 "brain: 463.6" "Group enriched" "Detected in some" 5 "SK-MEL-30: 66.3;WM-115: 39.6" "Group enriched" "Detected in many" 22 "glioma: 160.5;melanoma: 75.4" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 9 "plasmacytoid DC: 2.3" "Lineage enriched" "Detected in single" 9 "dendritic cells: 2.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA004128 Enhanced "HPA004128: AB_1079635" "unprognostic (5.72e-2)" "unprognostic (1.77e-2)" "unprognostic (2.27e-2)" "unprognostic (4.09e-3)" "unprognostic (1.32e-1)" "unprognostic (3.95e-2)" "unprognostic (2.57e-2)" "unprognostic (1.02e-1)" "unprognostic (5.92e-2)" "unprognostic (2.28e-2)" "unprognostic (1.21e-1)" "unprognostic (1.62e-5)" "unprognostic (4.91e-2)" "unprognostic (1.86e-1)" "unprognostic (3.46e-2)" "unprognostic (1.16e-2)" 3.6 5.6 90.6 2.8 109.9 1.9 3.1 8.9 463.6 3.9 5.7 208.1 0.0 3.3 3.6 3.5 4.2 2.5 4.0 5.0 143.8 73.8 2.1 2.1 2.1 2.0 174.8 42.2 3.0 2.2 17.9 0.3 1.9 124.4 3.6 5.4 0.0 3.4 9.3 2.2 7.3 5.1 7.0 453.8 2.0 2.8 9.2 145.2 0.0 2.0 0.0 2.0 2.7 0.8 0.0 2.3 0.0 0.0 0.0 0.2 0.0 0.0 0.0 5.9 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.2 0.5 0.0 0.0 0.0 0.2 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 1.1 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 10.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 66.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 1.1 0.0 39.6 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 2.3 0.0 0.0 90.6 109.9 8.9 68.1 143.8 73.8 174.8 42.2 124.4 145.2 PMEPA1 "STAG1, TMEPAI" ENSG00000124225 "Prostate transmembrane protein, androgen induced 1" Q969W9 20 57648392-57711536 "Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins" "Ubl conjugation pathway" "Signal transduction inhibitor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "cervix, uterine: 60.4;prostate: 67.3" "Cell line enhanced" "Detected in many" "SiHa: 39.5;U-2 OS: 25.8;U-251 MG: 90.8;WM-115: 45.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 5 "naive B-cell: 5.2;plasmacytoid DC: 18.4" "Group enriched" "Detected in many" 7 "B-cells: 5.2;dendritic cells: 18.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA072291 Supported Vesicles "Intracellular and membrane" Vesicles "HPA072291: " "unprognostic (2.72e-3)" "prognostic unfavourable (2.45e-4)" "unprognostic (5.77e-2)" "unprognostic (1.73e-1)" "unprognostic (6.61e-2)" "unprognostic (2.11e-3)" "unprognostic (3.13e-2)" "prognostic unfavourable (4.73e-5)" "unprognostic (5.53e-1)" "unprognostic (1.32e-3)" "unprognostic (7.83e-3)" "unprognostic (2.02e-1)" "prognostic unfavourable (2.87e-7)" "unprognostic (1.16e-1)" "unprognostic (2.35e-1)" "unprognostic (9.87e-3)" "prognostic unfavourable (7.60e-4)" 27.0 7.8 7.5 10.6 34.8 1.3 9.5 2.6 12.6 60.4 10.8 11.0 4.2 4.4 22.1 6.7 7.1 7.7 21.8 10.7 7.5 8.6 5.3 1.7 8.5 4.5 10.2 5.9 6.2 18.6 2.6 5.6 3.0 12.1 67.3 5.7 21.3 11.6 13.3 17.4 6.8 7.6 17.6 8.1 4.0 5.3 3.2 9.1 1.3 5.4 6.0 6.2 8.4 13.0 5.2 18.4 0.1 0.3 0.0 1.6 0.4 5.9 14.5 0.4 0.7 0.4 0.0 0.1 0.9 0.0 0.3 0.1 0.2 18.8 0.0 3.5 1.4 23.0 0.3 19.4 0.2 0.1 0.7 0.0 4.0 0.0 0.3 0.0 0.1 0.2 10.9 0.8 2.4 2.5 0.1 0.2 1.2 12.3 0.7 0.1 1.8 1.8 0.0 7.0 2.1 4.7 0.0 3.4 2.7 39.5 23.5 2.7 3.6 0.7 6.3 3.5 25.8 0.3 90.8 1.1 0.1 0.0 1.6 0.2 45.8 0.0 0.3 0.0 0.0 0.0 0.0 2.2 0.6 0.2 0.0 5.2 1.6 0.9 0.1 0.0 0.0 18.4 0.4 0.4 7.5 34.8 2.6 12.6 7.5 8.6 10.2 5.9 12.1 9.1 PML "MYL, RNF71, TRIM19" ENSG00000140464 "Promyelocytic leukemia" P29590 15 73994673-74047812 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Antiviral defense, Apoptosis, Biological rhythms, Host-virus interaction, Immunity, Innate immunity, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Proto-oncogene, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008312, CAB010194, CAB016304" Supported Enhanced "Nuclear bodies" "Nuclear bodies" "CAB010194: AB_2166848, CAB016304: AB_628162, HPA008312: AB_1079643" "prognostic favourable (3.24e-4)" "unprognostic (4.83e-2)" "unprognostic (5.76e-2)" "unprognostic (1.58e-3)" "unprognostic (7.53e-3)" "unprognostic (1.58e-1)" "unprognostic (2.35e-2)" "unprognostic (5.30e-3)" "unprognostic (4.54e-3)" "unprognostic (1.15e-1)" "prognostic unfavourable (3.29e-4)" "unprognostic (2.67e-2)" "prognostic unfavourable (6.27e-8)" "unprognostic (1.58e-2)" "unprognostic (4.17e-2)" "unprognostic (1.02e-1)" "unprognostic (8.99e-2)" 46.2 15.4 13.5 29.9 13.0 30.0 50.0 11.4 17.2 24.7 21.9 8.3 22.1 16.9 29.4 22.1 19.3 23.0 25.6 17.6 10.7 7.5 20.5 12.9 37.2 27.3 11.9 12.4 21.2 11.0 9.6 15.0 22.4 16.1 21.2 8.7 14.6 38.0 27.7 18.7 24.2 19.6 20.1 14.3 25.9 21.4 8.7 13.1 25.3 25.9 23.3 23.0 20.7 35.6 11.8 12.9 19.1 18.2 12.7 13.2 7.8 13.8 5.2 4.6 4.4 13.2 18.7 15.9 7.2 12.8 22.3 25.8 5.5 25.0 6.2 25.4 12.9 25.5 6.3 14.4 3.2 21.7 9.7 13.4 8.2 6.0 15.3 12.7 12.3 35.1 10.4 15.1 7.9 15.5 11.3 11.1 13.1 6.5 10.4 19.9 5.0 9.6 8.1 5.5 11.6 24.9 23.1 4.0 4.4 11.5 6.3 17.1 4.9 10.7 25.8 22.6 6.2 11.2 14.3 11.6 7.3 3.0 15.6 16.2 7.2 5.4 12.7 19.1 12.4 18.0 9.6 11.8 9.9 13.2 12.9 9.8 8.1 8.2 11.0 12.7 18.2 8.3 12.9 7.8 13.5 13.0 11.4 17.2 10.7 7.5 11.9 12.4 16.1 13.1 PMS2 "H_DJ0042M02.9, HNPCC4, MLH4, PMSL2" ENSG00000122512 "PMS1 homolog 2, mismatch repair system component" P54278 7 5973239-6009125 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "DNA damage, DNA repair" "Endonuclease, Hydrolase, Nuclease" "Cancer-related genes, Disease mutation, Hereditary nonpolyposis colorectal cancer, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010235, HPA066490, HPA070310" Approved Enhanced Nucleoplasm Nucleoplasm "CAB010235: AB_2167281, HPA066490: , HPA070310: " "unprognostic (5.13e-2)" "unprognostic (6.55e-3)" "unprognostic (1.54e-1)" "unprognostic (1.43e-3)" "unprognostic (5.14e-2)" "unprognostic (1.29e-1)" "unprognostic (7.36e-2)" "unprognostic (1.02e-1)" "unprognostic (7.43e-2)" "unprognostic (2.35e-1)" "unprognostic (1.86e-1)" "unprognostic (7.38e-2)" "prognostic favourable (1.23e-5)" "unprognostic (5.31e-2)" "unprognostic (2.01e-2)" "unprognostic (3.67e-2)" "unprognostic (2.81e-2)" 6.3 7.4 8.7 6.0 19.8 3.6 8.1 15.5 21.2 6.2 6.0 11.5 6.9 6.4 6.4 6.3 7.5 7.5 5.0 5.3 9.0 10.3 14.2 5.8 5.5 9.1 8.4 9.5 7.5 7.1 16.6 7.1 5.9 16.2 7.0 6.2 8.0 7.1 7.8 5.7 14.8 6.8 7.1 7.5 6.9 6.1 4.8 5.8 7.5 12.4 5.7 10.7 7.7 6.5 6.2 5.8 7.2 7.9 4.0 9.3 6.3 9.5 10.5 8.4 20.9 6.6 9.8 7.2 5.2 3.9 5.0 4.1 9.1 6.9 18.1 6.2 7.4 13.2 12.6 3.3 5.5 7.1 5.1 7.9 8.5 6.5 11.3 9.7 5.4 10.3 9.6 4.0 15.0 9.2 14.7 8.8 8.3 8.8 2.9 6.9 8.5 6.4 9.9 10.1 9.2 10.6 7.2 7.7 16.6 10.1 14.7 11.0 18.2 6.8 7.8 6.4 14.3 9.4 9.3 11.8 19.7 18.2 4.5 9.5 14.6 7.2 5.4 3.1 8.4 7.9 9.3 6.2 6.6 7.2 5.8 5.6 8.8 6.2 2.4 4.0 3.2 5.3 6.4 6.3 8.7 19.8 15.5 21.2 9.0 10.3 8.4 9.5 16.2 5.8 PNMT PENT ENSG00000141744 "Phenylethanolamine N-methyltransferase" P11086 17 39667981-39670475 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Catecholamine biosynthesis" "Methyltransferase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "adrenal gland: 94.6;ductus deferens: 53.7;seminal vesicle: 40.7" "Cell line enhanced" "Detected in some" "HEL: 4.7;K-562: 10.2;NB-4: 20.2;NTERA-2: 3.9;SCLC-21H: 5.5;SH-SY5Y: 5.0" "Cancer enhanced" "Detected in many" "cervical cancer: 27.0" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in some" "gdT-cell: 2.5" "Group enriched" "Detected in many" 5 "B-cells: 1.0;T-cells: 2.5" "Region enhanced" "Detected in some" "basal ganglia: 1.3" "Low region specificity" "Detected in single" "CAB017029, HPA043412, HPA051005" Enhanced "CAB017029: , HPA043412: AB_2630373, HPA051005: AB_2681306" "unprognostic (1.50e-1)" "unprognostic (3.74e-2)" "unprognostic (1.08e-1)" "prognostic unfavourable (3.95e-5)" "unprognostic (4.27e-2)" "unprognostic (3.02e-1)" "unprognostic (2.98e-2)" "unprognostic (5.75e-2)" "unprognostic (5.29e-2)" "unprognostic (1.30e-1)" "unprognostic (1.51e-1)" "unprognostic (1.33e-1)" "unprognostic (1.52e-4)" "unprognostic (1.58e-1)" "unprognostic (1.97e-1)" "unprognostic (4.72e-2)" "unprognostic (1.87e-2)" 2.3 94.6 3.9 0.8 13.8 1.6 5.4 0.9 3.0 1.3 1.9 1.5 53.7 0.9 1.0 2.7 0.9 1.9 0.8 4.9 1.7 5.4 1.0 0.7 1.6 0.8 9.1 1.5 0.9 0.7 2.4 12.9 2.4 3.6 4.3 0.7 0.9 0.7 40.7 10.5 0.8 1.0 0.8 0.7 0.9 0.9 1.3 2.7 0.0 0.7 0.8 0.7 1.3 1.7 1.0 0.0 0.3 0.3 0.0 2.5 0.3 0.0 0.0 0.5 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.2 0.5 0.2 0.0 0.1 0.1 0.0 0.0 0.0 1.4 4.7 0.1 0.4 1.9 0.0 0.0 0.1 0.0 0.0 0.0 0.0 10.2 0.0 0.0 0.0 0.0 20.2 3.9 0.0 0.1 0.0 0.3 0.0 0.0 5.5 5.0 0.0 2.1 0.1 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 2.5 0.0 0.4 1.0 0.4 1.5 0.0 0.4 0.0 0.7 0.3 0.0 0.3 0.0 0.0 0.3 3.9 13.8 0.9 3.0 1.7 5.4 9.1 1.5 3.6 2.7 POLD1 "CDC2, POLD" ENSG00000062822 "DNA polymerase delta 1, catalytic subunit" P28340 19 50384204-50418016 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "DNA damage, DNA excision, DNA repair, DNA replication" "DNA-binding, DNA-directed DNA polymerase, Exonuclease, Hydrolase, Nuclease, Nucleotidyltransferase, Transferase" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004375, HPA046524" Supported Supported Nucleoplasm Nucleoplasm "CAB004375: AB_675487, HPA046524: " "unprognostic (2.45e-1)" "unprognostic (7.02e-3)" "unprognostic (1.59e-1)" "unprognostic (4.35e-2)" "unprognostic (2.55e-1)" "unprognostic (1.85e-2)" "prognostic unfavourable (2.87e-6)" "unprognostic (4.12e-2)" "unprognostic (1.16e-2)" "unprognostic (2.83e-1)" "unprognostic (5.08e-1)" "unprognostic (3.92e-3)" "unprognostic (4.01e-3)" "unprognostic (1.28e-2)" "unprognostic (1.61e-1)" "unprognostic (2.89e-1)" "unprognostic (3.70e-2)" 7.9 5.7 5.4 18.3 9.9 31.6 6.6 9.4 5.4 8.2 10.0 6.1 5.9 6.8 9.5 7.2 11.3 6.9 5.2 5.5 4.4 3.2 7.6 9.3 10.9 15.7 7.0 3.6 8.2 8.4 5.2 5.1 10.9 6.7 6.3 5.2 4.9 8.1 5.4 7.2 13.1 9.9 6.2 7.7 14.1 6.5 13.2 6.5 27.4 12.1 8.1 14.2 5.9 7.8 9.3 10.5 2.1 8.5 5.4 7.3 5.6 18.1 25.0 13.7 7.9 1.7 1.5 14.1 11.3 5.0 13.9 17.8 13.6 14.4 26.0 6.4 3.4 14.9 16.2 12.3 4.8 21.9 43.5 22.6 24.2 17.9 1.6 21.5 20.0 2.9 3.8 12.6 3.8 7.1 24.3 20.2 5.8 12.2 33.3 33.7 16.1 18.2 33.1 23.0 22.8 4.4 17.3 14.3 12.9 11.2 13.8 2.6 7.6 20.4 5.6 7.1 23.0 7.6 19.8 19.1 31.4 27.8 7.7 24.3 6.9 1.6 6.2 2.1 7.3 7.8 6.2 7.8 6.5 5.9 5.7 9.3 6.5 5.9 1.1 5.4 8.5 10.5 4.5 5.6 5.4 9.9 9.4 5.4 4.4 3.2 7.0 3.6 6.7 6.5 POLE POLE1 ENSG00000177084 "DNA polymerase epsilon, catalytic subunit" Q07864 12 132623753-132687365 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA repair, DNA replication" "DNA-binding, DNA-directed DNA polymerase, Hydrolase, Nucleotidyltransferase, Transferase" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Region enhanced" "Detected in all" "cerebellum: 34.8" "Cell type enhanced" "Detected in some" "NK-cell: 4.8" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Not detected" "Not detected" "HPA058210, HPA067385" Supported "Nucleoplasm,Plasma membrane" Nucleoplasm "Plasma membrane" "HPA058210: , HPA067385: " "unprognostic (1.60e-1)" "unprognostic (1.77e-3)" "unprognostic (2.00e-1)" "unprognostic (9.17e-2)" "unprognostic (1.68e-1)" "unprognostic (2.01e-2)" "unprognostic (3.96e-3)" "unprognostic (2.23e-1)" "prognostic unfavourable (1.44e-4)" "unprognostic (7.12e-2)" "unprognostic (2.21e-1)" "unprognostic (1.67e-1)" "prognostic unfavourable (3.19e-8)" "unprognostic (8.60e-2)" "unprognostic (3.18e-1)" "unprognostic (1.28e-1)" "unprognostic (9.95e-2)" 6.1 3.4 6.7 10.2 4.4 29.3 6.2 34.8 14.4 7.0 6.6 2.0 7.6 7.3 6.1 4.4 7.5 6.2 6.5 4.7 5.6 1.6 3.8 8.6 5.4 8.2 3.3 4.3 8.7 6.8 3.6 3.1 6.5 5.1 6.8 7.7 4.3 8.7 7.4 8.9 17.9 8.5 6.8 3.7 16.7 7.8 25.6 4.4 29.8 5.1 6.0 10.3 6.7 8.7 0.5 1.7 0.8 0.8 4.8 0.7 0.5 11.1 14.9 22.1 10.6 4.7 3.6 19.7 11.4 5.2 13.7 10.0 18.0 6.6 12.8 4.8 6.2 15.5 15.4 7.7 8.4 5.9 19.5 20.2 19.2 8.8 0.9 15.8 11.6 2.8 3.0 14.2 4.7 4.8 22.6 7.2 6.7 18.1 25.9 28.9 17.2 8.9 21.5 12.5 5.8 4.3 18.3 18.5 10.6 13.3 10.9 2.5 16.1 9.8 4.3 12.5 12.8 9.4 11.5 9.6 6.5 20.1 6.8 21.9 8.8 0.0 0.3 0.8 0.5 0.1 0.7 0.5 0.3 0.4 0.7 0.3 0.5 0.3 0.1 4.8 0.8 1.7 0.6 0.5 6.7 4.4 34.8 14.4 5.6 1.6 3.3 4.3 5.1 4.4 POLQ POLH ENSG00000051341 "DNA polymerase theta" O75417 3 121431427-121546641 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "DNA damage, DNA repair" "DNA-directed DNA polymerase, Nucleotidyltransferase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 9.5;lymphoid tissue: 21.4" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "basophil: 1.6" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "Region enhanced" "Detected in many" "cerebellum: 5.2" "HPA048931, HPA053359" Uncertain "Nucleoplasm,Golgi apparatus,Cytosol" "Nucleoplasm, Golgi apparatus, Cytosol" "HPA048931: , HPA053359: " "unprognostic (1.59e-1)" "unprognostic (4.18e-2)" "unprognostic (2.66e-2)" "prognostic unfavourable (5.46e-5)" "unprognostic (2.70e-1)" "unprognostic (6.23e-3)" "unprognostic (3.09e-5)" "unprognostic (8.55e-3)" "unprognostic (1.09e-4)" "unprognostic (2.86e-1)" "unprognostic (5.59e-5)" "unprognostic (2.06e-3)" "unprognostic (0.00e+0)" "prognostic favourable (1.04e-4)" "unprognostic (1.76e-1)" "unprognostic (6.01e-2)" "unprognostic (5.76e-2)" 0.5 0.8 0.2 8.2 0.7 9.5 0.6 0.6 0.4 0.9 3.5 0.2 0.8 2.0 0.9 0.6 6.0 0.3 0.4 0.8 0.3 0.2 0.4 0.6 0.9 4.7 0.3 0.0 0.4 0.4 0.0 0.2 2.8 0.3 0.4 3.7 0.1 1.1 0.8 1.2 2.4 3.9 0.5 0.4 2.6 1.1 5.8 0.6 21.4 0.3 5.6 7.5 0.6 1.7 0.5 1.1 1.6 0.4 0.0 0.4 0.0 13.3 9.1 7.8 5.5 0.7 0.9 7.1 6.3 2.4 7.5 10.1 7.2 5.0 15.9 2.9 3.4 10.6 9.2 4.1 12.8 4.6 5.0 10.2 5.6 4.5 0.0 11.0 9.3 0.1 0.3 6.8 4.2 3.7 6.7 12.1 7.8 5.2 9.9 6.4 7.4 4.4 8.4 9.4 5.6 2.4 7.7 4.3 3.8 7.3 4.0 2.6 3.7 10.9 2.8 6.6 8.7 2.6 8.2 6.1 4.9 16.5 3.2 8.2 4.9 1.6 0.2 0.0 0.3 0.2 0.0 0.3 0.4 0.3 0.4 0.5 0.0 0.2 0.0 0.0 0.4 1.1 0.1 0.0 0.2 0.7 0.6 0.4 0.3 0.2 0.3 0.0 0.3 0.6 POMC "ACTH, CLIP, LPH, MSH, NPP, POC" ENSG00000115138 Proopiomelanocortin P01189 2 25160853-25168903 "Cancer-related genes, Disease related genes, Predicted secreted proteins" "Endorphin, Hormone" "Cancer-related genes, Obesity" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 36 "pituitary gland: 811.1" "Cell line enhanced" "Detected in some" "CACO-2: 2.6;HMC-1: 4.1;THP-1: 5.4" "Cancer enriched" "Detected in many" 6 "testis cancer: 18.5" "Region enriched" "Detected in single" 5 "hypothalamus: 1.8" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Not detected" "Not detected" "Region enriched" "Detected in single" 4 "hypothalamus: 77.9" "CAB002762, HPA046135, HPA063644" Enhanced "Secreted to blood" "CAB002762: , HPA046135: AB_2679552, HPA063644: AB_2685071" "unprognostic (8.02e-2)" "unprognostic (1.47e-2)" "unprognostic (4.78e-2)" "unprognostic (1.96e-3)" "unprognostic (3.15e-1)" "unprognostic (1.15e-1)" "unprognostic (1.09e-1)" "unprognostic (4.30e-2)" "unprognostic (8.74e-3)" "unprognostic (1.38e-1)" "prognostic favourable (5.70e-4)" "unprognostic (8.02e-2)" "unprognostic (4.29e-2)" "unprognostic (2.94e-3)" "unprognostic (1.42e-1)" "unprognostic (1.37e-3)" "unprognostic (3.84e-2)" 1.0 3.2 0.3 0.8 0.3 0.5 0.3 0.3 0.7 0.3 0.3 0.3 0.3 0.1 0.3 0.5 0.3 0.0 0.3 0.3 0.3 1.8 0.5 0.3 0.3 0.6 0.3 0.3 0.3 22.2 0.0 811.1 0.9 0.3 0.3 0.0 0.3 0.4 0.3 3.6 0.9 0.3 0.3 0.3 1.3 0.4 2.9 0.3 0.3 0.3 0.4 0.3 0.3 0.3 13.7 22.2 6.6 10.1 12.6 10.5 7.6 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.4 0.0 0.0 0.0 2.6 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 1.1 0.0 4.1 1.1 0.2 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.3 0.0 0.0 0.6 0.2 0.0 0.0 0.0 0.0 5.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.2 9.9 6.6 9.8 10.1 7.7 12.8 7.5 9.3 12.5 13.7 9.9 10.5 3.1 12.6 5.9 22.2 7.9 7.6 0.3 0.3 0.3 0.3 0.3 1.8 0.3 0.3 0.3 0.3 PON1 "ESA, PON" ENSG00000005421 "Paraoxonase 1" P27169 7 95297676-95324707 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins, Transporters" Hydrolase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 23 "liver: 144.1" "Cell line enhanced" "Detected in some" "A549: 1.4;RH-30: 1.0" "Cancer enriched" "Detected in some" 78 "liver cancer: 97.8" "Not detected" "Not detected" "Cell type enhanced" "Detected in single" "NK-cell: 1.0" "Low lineage specificity" "Detected in single" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA001610 Approved "Secreted to blood" 96000000000 24000000000 "HPA001610: AB_1079656" "unprognostic (2.02e-2)" "unprognostic (2.41e-2)" "unprognostic (3.04e-1)" "unprognostic (3.54e-2)" "unprognostic (2.70e-1)" "prognostic favourable (7.24e-7)" "unprognostic (2.24e-1)" "unprognostic (1.95e-1)" "unprognostic (9.02e-3)" "unprognostic (1.76e-3)" "unprognostic (3.97e-2)" "unprognostic (6.74e-9)" "unprognostic (1.09e-3)" "unprognostic (2.29e-2)" "unprognostic (2.07e-1)" "unprognostic (5.54e-3)" 0.0 1.7 0.2 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.1 0.0 144.1 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.3 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 6.1 0.0 0.0 0.0 0.0 0.0 0.1 0.5 0.6 0.0 1.0 0.1 0.0 0.0 1.4 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.6 0.3 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.9 0.6 0.0 0.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.1 0.4 0.4 0.2 0.0 1.0 0.0 0.0 0.3 0.6 0.1 0.0 0.3 0.0 0.4 0.0 0.5 0.0 0.1 0.0 0.2 0.9 0.3 0.0 0.0 0.2 0.2 0.6 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.3 1.0 0.0 0.5 0.0 0.0 0.2 0.1 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 POSTN "OSF-2, periostin, PN" ENSG00000133110 Periostin Q15063 13 37562583-37598844 "Cancer-related genes, Plasma proteins, Predicted secreted proteins" "Cell adhesion" Heparin-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Group enriched" "Detected in some" 6 "hTEC/SVTERT24-B: 77.4;U-138 MG: 98.9;U-2197: 67.3" "Cancer enhanced" "Detected in all" "breast cancer: 231.9" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA012306 Enhanced Approved "Nucleoplasm,Golgi apparatus" "Secreted to extracellular matrix" 740000000 "Golgi apparatus" Nucleoplasm "HPA012306: AB_1854827" "unprognostic (7.73e-2)" "unprognostic (1.44e-3)" "unprognostic (2.19e-2)" "unprognostic (2.57e-2)" "unprognostic (4.73e-2)" "unprognostic (2.22e-2)" "unprognostic (4.19e-3)" "prognostic unfavourable (2.93e-4)" "unprognostic (3.05e-3)" "unprognostic (7.10e-2)" "unprognostic (1.32e-2)" "unprognostic (5.93e-2)" "prognostic unfavourable (1.83e-7)" "prognostic unfavourable (4.86e-4)" "unprognostic (1.15e-1)" "unprognostic (1.20e-1)" "unprognostic (8.32e-3)" 60.9 2.0 5.3 12.7 4.0 0.0 26.9 0.5 2.7 17.6 14.1 0.6 11.7 0.6 29.0 20.0 16.5 20.3 14.5 34.1 6.2 0.5 47.5 3.0 28.4 19.5 0.5 1.1 21.0 3.1 8.2 1.7 17.3 2.5 12.4 19.7 0.8 10.8 10.2 14.2 46.1 9.6 14.5 1.7 0.7 37.3 21.5 0.1 3.1 8.0 5.5 1.7 23.5 12.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 11.1 0.2 13.7 8.3 0.0 3.5 0.0 0.8 0.1 0.0 0.2 0.0 0.0 2.8 0.0 0.1 0.0 0.4 0.0 0.0 0.0 0.0 0.0 2.3 0.0 0.0 14.6 0.0 77.4 0.3 0.1 0.0 0.0 1.8 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 98.9 0.0 67.3 0.5 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.3 4.0 0.5 2.7 6.2 0.5 0.5 1.1 2.5 0.1 POT1 "DKFZp586D211, hPot1" ENSG00000128513 "Protection of telomeres 1" Q9NUX5 7 124822386-124929983 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" DNA-binding "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" HPA068538 Supported Nucleoplasm Nucleoplasm "HPA068538: " "unprognostic (1.39e-3)" "unprognostic (1.34e-1)" "unprognostic (2.04e-1)" "unprognostic (5.71e-2)" "unprognostic (1.69e-1)" "unprognostic (1.49e-1)" "unprognostic (1.38e-3)" "unprognostic (7.88e-2)" "unprognostic (2.26e-2)" "unprognostic (1.51e-1)" "unprognostic (2.48e-2)" "unprognostic (9.89e-2)" "unprognostic (1.42e-1)" "unprognostic (2.92e-1)" "unprognostic (1.75e-2)" "unprognostic (4.77e-3)" "unprognostic (7.42e-2)" 12.0 13.2 11.1 8.3 14.3 6.2 15.8 13.0 16.6 13.4 10.1 16.0 12.0 7.8 17.0 13.4 10.1 12.6 11.3 11.2 15.5 11.3 16.6 14.7 9.9 14.0 15.0 12.4 15.7 9.4 15.5 29.6 11.1 16.4 12.0 9.7 12.2 8.7 10.1 9.5 8.0 8.8 13.1 16.4 13.6 9.5 15.8 14.8 17.9 21.5 9.3 12.9 13.6 9.8 4.8 3.6 2.7 3.3 5.2 7.4 2.7 12.7 5.5 8.1 6.2 5.4 10.2 5.7 7.2 8.5 8.2 12.4 4.4 12.9 11.5 5.8 5.4 5.1 8.8 7.3 12.9 14.9 12.9 11.2 5.4 4.7 12.2 10.8 6.7 7.2 8.7 7.5 11.9 10.4 19.9 27.6 9.2 2.5 14.4 11.4 9.1 9.0 8.5 8.5 16.4 7.0 7.1 8.6 11.5 7.3 9.8 10.1 4.3 10.4 3.4 9.9 4.4 11.9 9.5 15.3 15.7 16.4 10.0 12.4 12.2 0.9 3.1 2.7 4.3 3.3 6.3 4.8 4.5 5.0 3.1 3.4 7.4 5.5 0.7 5.2 3.0 3.6 4.4 2.7 11.1 14.3 13.0 16.6 15.5 11.3 15.0 12.4 16.4 14.8 POTEF "A26C1B, POTE2alpha, POTEACTIN" ENSG00000196604 "POTE ankyrin domain family member F" A5A3E0 2 130074030-130129222 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "testis: 5.7" "Cell line enhanced" "Detected in some" "AN3-CA: 4.3;BEWO: 3.5;CACO-2: 4.0;MCF7: 2.9;U-2 OS: 9.6;U-266/70: 4.6" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "HPA041264, HPA041271, HPA043260" Uncertain "HPA041264: , HPA041271: , HPA043260: " "unprognostic (1.36e-1)" "unprognostic (1.23e-1)" "unprognostic (1.04e-1)" "unprognostic (2.98e-1)" "unprognostic (1.01e-1)" "unprognostic (1.18e-2)" "unprognostic (8.13e-3)" "unprognostic (1.44e-2)" "unprognostic (2.90e-2)" "unprognostic (1.16e-1)" "unprognostic (3.38e-1)" "unprognostic (2.23e-1)" "unprognostic (3.50e-1)" "unprognostic (1.02e-1)" "unprognostic (4.48e-1)" "unprognostic (1.05e-2)" "unprognostic (9.35e-2)" 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.1 0.0 0.0 0.1 0.2 0.0 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.7 0.5 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.1 5.7 0.0 0.0 0.0 0.0 0.1 0.7 0.7 0.7 0.2 0.5 1.1 0.2 0.2 0.0 4.3 0.0 0.0 3.5 0.0 0.0 0.0 0.0 4.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 1.7 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 2.9 0.0 0.1 0.0 0.0 0.0 0.0 0.6 0.0 0.1 0.3 0.0 0.0 1.3 0.1 0.0 0.0 0.0 0.0 9.6 0.1 0.2 4.6 1.3 0.0 0.0 0.0 0.0 0.5 0.6 0.7 0.4 0.7 0.1 0.1 0.2 0.3 0.7 0.1 0.1 0.3 0.6 0.2 0.7 0.1 0.5 1.1 POU2AF1 "BOB1, OBF1" ENSG00000110777 "POU class 2 associating factor 1" Q16633 11 111352252-111455630 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Transcription, Transcription regulation" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 21.2;lymphoid tissue: 84.0" "Cell line enhanced" "Detected in some" "Daudi: 45.4;Karpas-707: 52.0;U-266/70: 50.7;U-266/84: 22.8;U-698: 93.3" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in some" "Group enriched" "Detected in some" 11 "memory B-cell: 19.9;naive B-cell: 14.2" "Lineage enriched" "Detected in many" 13 "B-cells: 19.9" "Not detected" "Not detected" "Not detected" "Not detected" CAB011193 Enhanced "CAB011193: AB_532299" "prognostic favourable (1.68e-4)" "prognostic favourable (1.63e-4)" "unprognostic (1.04e-2)" "unprognostic (5.50e-3)" "unprognostic (1.88e-1)" "prognostic favourable (3.59e-4)" "unprognostic (2.09e-1)" "unprognostic (3.63e-3)" "unprognostic (7.15e-2)" "unprognostic (2.52e-2)" "unprognostic (1.34e-1)" "unprognostic (4.81e-2)" "unprognostic (8.51e-8)" "unprognostic (2.35e-1)" "unprognostic (3.90e-1)" "unprognostic (7.14e-3)" "unprognostic (1.23e-1)" 0.9 0.5 0.6 62.7 0.7 2.0 1.4 0.4 0.6 1.9 7.8 1.8 0.0 6.7 0.7 0.3 8.7 1.1 1.4 0.5 0.8 0.7 2.1 1.0 2.6 42.6 1.0 0.5 1.2 0.5 0.0 0.4 0.5 1.2 1.3 4.1 1.2 8.4 0.9 0.4 0.4 21.2 0.0 1.4 74.2 12.2 1.0 0.9 5.0 1.7 1.4 84.0 5.0 1.4 19.9 0.1 1.5 0.2 0.3 0.7 0.6 0.1 0.1 0.0 0.0 0.8 0.8 0.1 0.0 0.0 0.0 0.0 0.1 0.0 45.4 0.1 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 1.7 52.0 0.0 0.1 0.2 0.2 0.0 0.0 9.7 0.1 12.2 0.0 0.1 0.0 0.9 0.1 0.0 0.0 0.2 0.1 0.4 0.0 0.4 0.0 0.0 50.7 22.8 93.3 0.0 0.1 0.0 1.5 0.1 0.3 0.1 0.1 0.1 19.9 0.2 0.1 0.0 14.2 0.2 0.1 0.9 0.3 0.2 0.1 0.7 0.6 0.6 0.7 0.4 0.6 0.8 0.7 1.0 0.5 1.2 0.9 POU2F2 "OCT2, OTF2" ENSG00000028277 "POU class 2 homeobox 2" P09086 19 42086110-42196585 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "blood: 33.1;brain: 12.0;intestine: 10.8;lymphoid tissue: 43.1" "Cell line enhanced" "Detected in many" "BJ hTERT+: 18.1;Daudi: 38.2;hTEC/SVTERT24-B: 15.0;U-266/70: 26.6;U-266/84: 25.7;U-698: 30.3;U-87 MG: 14.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "non-classical monocyte: 33.1" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002513, HPA049056, HPA062096, HPA064404" Enhanced Enhanced Nucleoplasm,Vesicles "Nucleoplasm, Vesicles" "CAB002513: AB_442118, HPA049056: , HPA062096: , HPA064404: " "unprognostic (2.07e-2)" "unprognostic (1.14e-1)" "unprognostic (1.16e-2)" "unprognostic (8.89e-2)" "unprognostic (6.77e-2)" "unprognostic (1.44e-2)" "unprognostic (1.62e-2)" "unprognostic (3.34e-1)" "unprognostic (8.39e-2)" "unprognostic (2.09e-1)" "unprognostic (1.52e-1)" "unprognostic (8.56e-2)" "prognostic unfavourable (7.57e-11)" "unprognostic (2.31e-1)" "unprognostic (1.76e-1)" "unprognostic (2.61e-2)" "unprognostic (1.54e-1)" 1.9 2.0 5.6 43.1 7.4 4.8 1.2 12.0 5.7 0.9 3.2 2.5 0.0 2.1 0.9 1.7 1.4 1.5 2.3 4.8 5.7 5.9 1.6 1.4 3.1 31.4 6.8 1.5 0.7 1.6 0.4 2.1 2.5 6.6 2.5 2.1 1.4 2.1 2.3 0.7 1.2 10.8 1.9 6.5 22.7 3.1 6.0 6.2 1.9 1.3 0.6 30.0 4.3 1.0 13.9 8.0 1.7 33.1 0.6 2.7 4.5 0.3 0.5 0.6 0.0 0.0 1.0 0.1 2.8 18.1 1.8 3.5 0.1 0.5 38.2 1.0 1.0 0.3 0.2 2.9 8.2 0.1 0.1 0.9 0.1 0.0 0.2 0.3 0.7 0.8 0.5 15.0 1.0 1.1 0.4 8.8 0.4 0.2 0.1 2.0 0.1 0.2 0.4 0.0 0.1 0.0 0.2 0.6 0.3 0.1 0.2 0.2 0.0 4.8 1.4 7.8 0.8 0.0 0.3 26.6 25.7 30.3 14.6 0.9 1.0 1.0 10.7 0.1 1.2 19.3 1.1 11.0 1.8 1.6 8.0 13.9 0.9 1.3 1.7 0.6 33.1 1.3 2.7 4.5 5.6 7.4 12.0 5.7 5.7 5.9 6.8 1.5 6.6 6.2 POU5F1 "MGC22487, OCT3, Oct4, OTF3" ENSG00000204531 "POU class 5 homeobox 1" Q01860 6 31164337-31180731 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Group enriched" "Detected in some" 12 "HAP1: 52.5;NTERA-2: 139.7" "Cancer enriched" "Detected in many" 34 "testis cancer: 355.9" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "CAB025600, CAB026380, HPA058267, CAB079773" Approved Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "CAB025600: , CAB026380: , CAB079773: AB_2687916, HPA058267: " "unprognostic (3.25e-2)" "unprognostic (3.12e-1)" "unprognostic (2.87e-1)" "unprognostic (1.06e-2)" "unprognostic (3.02e-2)" "unprognostic (2.11e-2)" "unprognostic (2.62e-2)" "unprognostic (2.27e-1)" "unprognostic (2.59e-1)" "unprognostic (9.27e-2)" "unprognostic (2.27e-2)" "unprognostic (4.79e-2)" "unprognostic (1.19e-3)" "unprognostic (1.38e-1)" "unprognostic (1.35e-1)" "unprognostic (3.86e-2)" "prognostic favourable (2.04e-5)" 1.2 0.0 1.2 1.2 1.2 1.2 1.2 1.2 1.2 2.3 2.3 1.2 1.2 4.9 3.1 5.7 1.2 5.2 4.3 1.2 1.2 0.0 11.1 5.0 2.0 1.2 1.2 1.2 1.2 8.8 0.0 1.2 1.2 1.2 4.7 1.0 1.2 1.2 3.0 1.2 1.8 5.9 1.2 1.2 1.2 6.3 2.2 1.2 1.2 1.2 1.2 1.2 11.2 1.2 3.0 1.8 1.8 1.0 1.1 0.9 0.3 0.6 0.2 8.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.3 0.0 1.2 0.0 0.7 52.5 0.6 0.0 0.0 0.2 0.0 0.4 0.6 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.2 139.7 0.0 0.1 0.1 0.1 1.0 1.1 0.1 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.2 0.0 0.2 0.1 0.1 0.0 0.1 0.1 1.4 1.0 0.5 0.8 0.7 0.5 1.0 0.4 0.4 0.2 3.0 0.9 0.6 1.8 1.1 0.5 1.8 0.3 0.3 1.2 1.2 1.2 1.2 1.2 0.0 1.2 1.2 1.2 1.2 PPA2 FLJ20459 ENSG00000138777 "Pyrophosphatase (inorganic) 2" Q9H2U2 4 105369077-105474081 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" Hydrolase "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA030888, HPA031671, HPA031672" Supported Approved Nucleoplasm,Mitochondria 8300 Mitochondria Nucleoplasm "HPA030888: , HPA031671: AB_10603986, HPA031672: AB_2673988" "prognostic unfavourable (2.98e-4)" "unprognostic (5.64e-2)" "prognostic favourable (6.60e-4)" "unprognostic (9.26e-3)" "unprognostic (2.93e-2)" "unprognostic (5.10e-2)" "unprognostic (1.15e-1)" "unprognostic (2.44e-1)" "unprognostic (1.50e-1)" "unprognostic (1.20e-1)" "unprognostic (7.05e-2)" "unprognostic (9.54e-2)" "prognostic favourable (1.27e-11)" "unprognostic (3.69e-1)" "unprognostic (1.94e-1)" "unprognostic (2.00e-1)" "unprognostic (1.10e-1)" 9.2 18.0 18.4 17.2 15.4 24.0 20.6 12.3 17.6 10.2 19.8 9.3 20.3 18.1 13.3 20.7 14.8 10.7 18.7 42.5 15.6 15.3 23.7 21.2 23.1 34.8 17.2 12.1 9.5 25.0 10.4 15.0 9.3 15.4 16.1 16.7 12.6 21.4 26.8 29.6 15.0 16.8 22.8 12.4 12.1 15.0 9.7 10.7 9.4 14.3 28.2 10.6 12.2 9.5 20.0 35.3 14.7 20.8 22.0 17.0 14.6 11.5 5.5 10.7 18.1 6.8 5.5 7.8 6.5 8.6 8.0 5.7 12.1 17.0 9.5 8.7 5.3 5.8 21.4 10.3 9.5 13.4 7.6 8.5 8.9 11.0 5.4 20.1 8.2 5.3 10.7 5.5 4.3 7.7 14.1 13.1 7.3 14.6 17.1 14.5 7.8 18.7 15.2 6.6 9.3 26.5 8.9 11.0 6.6 4.5 26.7 9.4 14.0 16.4 4.1 5.8 11.3 6.2 11.3 11.6 14.6 9.9 10.1 10.9 7.8 14.7 15.0 9.7 15.3 20.8 13.3 20.0 16.0 16.2 35.3 16.6 15.5 17.0 6.4 22.0 16.2 17.7 15.9 14.6 18.4 15.4 12.3 17.6 15.6 15.3 17.2 12.1 15.4 10.7 PPARG "NR1C3, PPARG1, PPARG2, PPARgamma" ENSG00000132170 "Peroxisome proliferator activated receptor gamma" P37231 3 12287368-12434356 "Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Transcription, Transcription regulation" "Activator, DNA-binding, Receptor" "Cancer-related genes, Diabetes mellitus, Disease mutation, FDA approved drug targets, Obesity" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adipose tissue: 97.6;breast: 102.1" "Cell line enhanced" "Detected in many" "ASC diff: 47.4;ASC TERT1: 27.0;BEWO: 55.9;CAPAN-2: 25.0;HSkMC: 27.8;PC-3: 24.9;RT4: 34.1" "Cancer enhanced" "Detected in all" "urothelial cancer: 33.5" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in some" "classical monocyte: 1.8;intermediate monocyte: 2.3" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in many" "Not detected" "Not detected" "CAB004282, HPA051239, HPA063663" Approved Enhanced Nucleoplasm,Vesicles "Nucleoplasm, Vesicles" "CAB004282: AB_628115, HPA051239: , HPA063663: " "unprognostic (7.35e-3)" "unprognostic (3.27e-2)" "unprognostic (4.05e-2)" "unprognostic (8.37e-2)" "unprognostic (2.41e-2)" "unprognostic (5.27e-3)" "prognostic unfavourable (3.41e-5)" "unprognostic (9.13e-2)" "unprognostic (2.32e-2)" "unprognostic (1.38e-1)" "unprognostic (1.02e-2)" "unprognostic (2.77e-1)" "prognostic favourable (1.59e-8)" "unprognostic (1.51e-2)" "unprognostic (1.46e-1)" "unprognostic (9.68e-3)" "prognostic favourable (5.52e-5)" 97.6 1.6 1.9 17.1 1.2 0.7 102.1 1.5 1.3 3.1 24.9 0.8 2.1 7.5 3.5 2.2 2.8 2.4 8.7 12.5 1.4 0.9 6.7 5.9 24.8 11.4 1.1 0.9 6.7 1.2 2.8 0.3 26.8 0.9 10.4 13.9 1.1 5.8 1.5 5.0 2.7 9.6 7.4 1.2 7.0 11.9 3.5 0.6 0.9 6.2 4.3 2.1 30.2 14.1 0.0 0.4 0.0 2.3 0.0 0.7 0.3 9.6 8.6 0.0 0.0 47.4 27.0 55.9 0.9 10.4 1.3 0.5 1.8 25.0 0.0 0.0 0.9 3.9 3.4 0.1 0.2 23.2 4.8 0.0 1.9 2.3 12.6 0.0 0.0 27.8 2.3 2.3 9.0 0.1 0.0 0.0 2.0 2.4 0.0 0.1 0.1 24.9 0.0 0.0 0.0 7.1 34.1 0.0 0.2 4.0 1.5 0.5 0.0 7.7 7.8 1.8 2.6 1.0 0.0 0.0 0.0 0.0 0.8 0.1 0.2 0.0 1.8 0.0 0.0 2.3 0.0 0.0 0.7 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.4 0.3 1.9 1.2 1.5 1.3 1.4 0.9 1.1 0.9 0.9 0.6 PPARGC1A "PGC-1alpha, PGC1, PGC1A, PPARGC1" ENSG00000109819 "PPARG coactivator 1 alpha" Q9UBK2 4 23755041-23904089 "Cancer-related genes, Predicted intracellular proteins" "Biological rhythms, Transcription, Transcription regulation" "Activator, RNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "kidney: 49.5;liver: 49.7;skeletal muscle: 55.6" "Cell line enriched" "Detected in some" 7 "A-431: 42.9" "Cancer enhanced" "Detected in many" "renal cancer: 7.7" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA063136 Supported Nucleoplasm Nucleoplasm "HPA063136: " "unprognostic (1.08e-1)" "unprognostic (7.47e-2)" "unprognostic (6.85e-3)" "unprognostic (2.28e-6)" "unprognostic (5.00e-2)" "unprognostic (1.15e-1)" "prognostic favourable (3.35e-6)" "unprognostic (3.04e-1)" "unprognostic (1.79e-1)" "unprognostic (1.69e-1)" "unprognostic (6.77e-2)" "unprognostic (4.58e-2)" "prognostic favourable (1.49e-14)" "unprognostic (3.62e-2)" "unprognostic (2.31e-1)" "prognostic unfavourable (5.80e-4)" "unprognostic (3.07e-3)" 5.7 2.4 3.1 2.4 4.2 0.3 1.3 4.7 5.5 2.6 9.4 4.2 1.8 5.7 0.9 4.8 3.0 1.2 2.2 24.6 3.3 3.1 49.5 49.7 2.5 0.4 3.1 1.8 1.3 2.8 14.6 7.6 0.3 7.8 2.6 6.6 14.0 30.4 3.0 55.6 5.5 14.2 1.6 3.2 0.8 3.1 3.4 3.4 0.3 17.4 18.2 1.5 1.7 1.0 0.0 0.0 0.2 0.6 0.0 0.0 0.3 42.9 0.0 0.8 0.0 1.2 0.0 0.0 0.0 0.8 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.3 0.0 2.1 4.9 0.0 0.0 0.0 3.9 0.0 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.3 0.0 6.2 0.0 2.0 0.1 1.4 0.0 1.7 0.2 0.7 0.0 0.4 0.3 0.0 0.8 3.8 0.0 0.0 0.8 0.7 0.1 0.2 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 3.1 4.2 4.7 5.5 3.3 3.1 3.1 1.8 7.8 3.4 PPFIBP1 "hSGT2, hSgt2p, L2, SGT2" ENSG00000110841 "PPFIA binding protein 1" Q86W92 12 27523431-27695564 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "naive B-cell: 7.0" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" HPA001924 Uncertain Approved "Plasma membrane,Cytosol" "Plasma membrane, Cytosol" "HPA001924: AB_1079665" "unprognostic (5.27e-2)" "unprognostic (5.71e-2)" "unprognostic (3.10e-2)" "prognostic unfavourable (6.29e-4)" "unprognostic (4.73e-2)" "unprognostic (6.94e-2)" "unprognostic (1.47e-1)" "prognostic unfavourable (5.11e-4)" "unprognostic (7.33e-2)" "unprognostic (3.84e-2)" "prognostic unfavourable (2.56e-4)" "unprognostic (1.92e-2)" "prognostic favourable (5.11e-7)" "unprognostic (8.54e-2)" "unprognostic (7.54e-2)" "unprognostic (2.64e-1)" "unprognostic (4.09e-2)" 21.3 17.1 15.5 8.0 16.8 2.2 22.6 4.9 25.0 18.3 15.4 13.3 13.0 7.1 28.1 9.3 17.1 16.5 12.2 43.3 17.1 9.0 23.8 15.7 25.0 7.8 13.1 16.4 53.1 13.7 12.7 22.2 34.5 15.3 15.3 11.1 8.1 14.2 18.4 13.7 17.8 10.0 20.5 11.2 16.6 15.1 7.1 13.3 6.2 23.9 14.9 6.2 17.2 18.4 7.0 2.0 1.5 0.6 0.3 1.8 0.6 4.5 9.2 7.5 6.4 12.5 34.9 13.4 16.6 18.7 9.8 14.2 24.2 13.9 3.4 19.4 33.6 11.4 4.0 15.2 17.7 7.8 2.2 7.6 7.0 3.5 5.4 2.3 4.3 27.1 10.6 28.5 29.3 33.5 4.0 3.5 34.8 3.5 2.1 0.6 13.4 7.1 3.5 18.7 1.3 14.5 10.1 0.6 3.1 8.3 4.4 23.1 5.7 3.5 32.5 27.7 9.3 15.1 16.9 0.0 0.0 0.2 30.7 3.3 43.6 1.5 0.6 0.3 0.7 0.2 1.4 0.7 1.3 0.7 0.6 7.0 1.3 1.3 1.5 0.3 0.2 2.0 1.8 0.6 15.5 16.8 4.9 25.0 17.1 9.0 13.1 16.4 15.3 13.3 PPM1D "PP2C-DELTA, Wip1" ENSG00000170836 "Protein phosphatase, Mg2+/Mn2+ dependent 1D" O15297 17 60600183-60666280 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Cell cycle" "Hydrolase, Protein phosphatase" "Autism spectrum disorder, Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "MCF7: 26.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA022277 Approved Approved "Endoplasmic reticulum" "Endoplasmic reticulum" "HPA022277: AB_1858839" "unprognostic (1.48e-1)" "unprognostic (1.36e-2)" "prognostic favourable (3.52e-4)" "unprognostic (1.76e-1)" "unprognostic (1.02e-1)" "unprognostic (5.12e-2)" "prognostic unfavourable (4.27e-4)" "unprognostic (5.50e-2)" "unprognostic (1.70e-2)" "unprognostic (6.07e-2)" "unprognostic (2.52e-3)" "unprognostic (3.46e-2)" "unprognostic (1.95e-3)" "unprognostic (7.33e-2)" "unprognostic (1.58e-1)" "unprognostic (1.71e-2)" "unprognostic (1.98e-1)" 12.2 7.0 6.1 5.7 9.2 13.6 11.9 30.8 6.6 11.1 10.0 10.6 7.8 7.6 12.0 8.3 8.6 11.1 8.3 5.8 7.7 4.4 7.4 7.4 9.2 7.9 10.3 4.6 17.3 12.3 8.1 8.9 18.5 8.8 9.3 9.4 8.2 8.1 6.8 9.7 8.1 8.1 8.2 7.3 9.2 7.3 16.2 12.5 15.5 8.7 6.9 7.0 7.8 11.3 7.3 13.1 20.5 13.2 6.8 8.3 6.8 2.7 5.4 6.1 5.2 4.1 2.5 7.9 4.3 2.8 2.8 4.0 5.5 1.6 7.8 3.5 2.9 2.9 3.9 1.8 3.8 1.4 8.7 5.6 5.4 6.4 3.4 2.2 4.3 2.2 2.9 4.1 2.4 6.3 4.1 3.3 3.0 26.5 6.1 3.4 2.6 4.2 7.4 7.8 4.7 2.5 3.4 8.4 6.1 5.7 1.9 1.3 2.3 3.0 4.6 3.6 10.0 2.8 2.3 5.3 5.6 5.9 1.4 2.3 2.8 8.2 13.2 14.1 6.7 10.2 5.9 7.3 5.6 6.1 13.1 5.9 6.1 6.2 20.5 6.8 6.1 5.8 8.3 6.8 6.1 9.2 30.8 6.6 7.7 4.4 10.3 4.6 8.8 12.5 PPP1R15A GADD34 ENSG00000087074 "Protein phosphatase 1 regulatory subunit 15A" O75807 19 48872392-48876057 "Cancer-related genes, Predicted intracellular proteins" "Apoptosis, Stress response, Translation regulation" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "bone marrow: 156.9" "Cell line enhanced" "Detected in all" "HHSteC: 54.6;hTERT-HME1: 94.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "neutrophil: 69.8" "Group enriched" "Detected in all" 5 "dendritic cells: 23.8;granulocytes: 69.8" "Low region specificity" "Detected in all" "CAB018395, HPA020240" Approved Uncertain Vesicles Vesicles "CAB018395: AB_2237473, HPA020240: AB_1849404" "unprognostic (2.43e-3)" "unprognostic (3.21e-1)" "unprognostic (7.75e-2)" "unprognostic (1.17e-3)" "unprognostic (2.22e-2)" "unprognostic (6.17e-2)" "prognostic unfavourable (1.95e-4)" "unprognostic (5.46e-2)" "unprognostic (2.66e-2)" "unprognostic (7.16e-3)" "unprognostic (5.40e-2)" "unprognostic (1.52e-1)" "unprognostic (2.22e-1)" "unprognostic (6.43e-3)" "unprognostic (1.49e-1)" "unprognostic (1.29e-2)" "unprognostic (6.94e-2)" 39.8 29.1 16.2 33.6 12.9 156.9 56.3 12.1 12.8 26.3 19.7 13.6 12.0 12.0 37.8 19.5 28.2 34.0 32.3 42.0 14.6 13.9 18.6 18.6 56.5 10.6 29.5 6.3 24.5 10.9 9.8 16.2 44.7 31.5 28.2 15.6 12.4 9.2 23.6 35.2 40.0 16.0 36.2 17.7 13.3 19.8 14.5 17.8 3.4 18.6 46.7 19.0 41.1 114.7 8.1 23.8 69.8 10.3 2.5 6.1 6.6 9.9 4.3 4.7 3.8 13.7 7.8 7.4 17.5 27.5 20.1 18.2 6.6 5.1 3.4 4.7 12.6 7.2 1.7 9.1 15.2 1.9 2.6 15.6 2.5 3.2 54.6 3.6 22.5 10.6 25.5 27.7 94.1 10.4 20.9 29.1 12.9 1.1 1.9 5.0 1.1 7.9 2.2 4.3 1.1 4.1 11.7 2.6 4.6 9.0 6.2 39.6 2.2 6.5 11.1 24.0 6.0 16.8 10.7 15.7 12.4 3.3 8.8 2.5 28.7 27.4 10.3 17.7 4.9 6.3 4.3 8.1 4.8 4.0 7.3 5.5 2.7 2.4 69.8 2.5 7.1 23.8 6.1 6.6 16.2 12.9 12.1 12.8 14.6 13.9 29.5 6.3 31.5 17.8 PPP2R1A "PP2A-Aalpha, PP2AA, PR65A" ENSG00000105568 "Protein phosphatase 2 scaffold subunit Aalpha" P30153 19 52190039-52229533 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Chromosome partition" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB018599 Approved Cytosol 3400000 Cytosol "CAB018599: AB_628178" "unprognostic (1.78e-1)" "unprognostic (2.31e-2)" "unprognostic (4.52e-2)" "unprognostic (2.87e-1)" "unprognostic (6.67e-2)" "unprognostic (7.82e-2)" "prognostic unfavourable (1.76e-4)" "prognostic unfavourable (2.50e-4)" "unprognostic (4.30e-2)" "unprognostic (3.06e-1)" "unprognostic (6.48e-3)" "unprognostic (8.28e-2)" "prognostic favourable (1.20e-4)" "unprognostic (1.97e-1)" "unprognostic (3.57e-2)" "unprognostic (1.70e-2)" "unprognostic (9.19e-2)" 25.3 57.3 60.7 20.5 71.0 18.0 21.4 47.5 82.1 29.6 31.2 26.6 21.5 33.4 26.4 37.9 37.7 47.0 39.9 74.7 70.2 44.8 31.0 29.3 20.0 27.5 44.0 50.9 45.8 24.3 37.8 29.5 24.6 51.0 31.0 29.8 31.0 24.3 35.6 50.6 33.5 25.3 34.5 25.2 20.5 19.8 21.7 18.1 29.0 28.9 35.9 30.6 27.3 23.1 52.8 62.8 51.9 67.2 69.8 56.3 67.8 30.4 51.7 41.3 36.7 33.6 35.2 21.7 25.7 33.7 34.4 30.0 26.0 24.1 26.7 18.5 40.8 22.0 44.2 38.7 20.0 19.7 119.9 19.6 28.5 29.2 30.7 21.1 18.7 47.2 32.1 32.1 29.6 32.6 22.7 18.8 38.0 35.2 29.5 40.3 40.9 45.7 29.0 24.0 29.8 55.2 50.2 31.2 33.4 31.4 31.4 19.1 28.4 37.3 30.9 27.3 24.6 13.3 29.3 19.5 28.5 31.3 29.3 21.4 34.3 45.0 55.3 51.9 50.4 67.2 45.8 48.4 45.1 47.1 62.8 52.8 37.7 43.0 33.7 69.8 59.8 39.0 56.3 67.8 60.7 71.0 47.5 82.1 70.2 44.8 44.0 50.9 51.0 18.1 PPP6C PP6 ENSG00000119414 "Protein phosphatase 6 catalytic subunit" O00743 9 125146573-125189939 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Cell cycle, Immunity, Innate immunity" "Hydrolase, Protein phosphatase" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" HPA050940 Uncertain "HPA050940: " "unprognostic (6.45e-2)" "unprognostic (4.01e-3)" "unprognostic (7.12e-2)" "unprognostic (5.36e-2)" "unprognostic (2.78e-2)" "unprognostic (2.92e-2)" "unprognostic (2.57e-3)" "unprognostic (1.53e-1)" "unprognostic (2.14e-1)" "unprognostic (2.44e-1)" "unprognostic (1.71e-2)" "unprognostic (2.28e-2)" "prognostic favourable (4.50e-6)" "unprognostic (1.54e-2)" "unprognostic (3.51e-1)" "unprognostic (1.12e-2)" "unprognostic (1.12e-1)" 21.7 20.1 20.1 15.7 24.5 24.8 21.2 20.8 26.2 17.0 19.1 25.9 15.1 13.9 15.6 17.2 21.2 14.0 12.9 15.3 19.8 16.6 22.8 17.8 16.3 21.5 20.1 16.1 17.5 27.7 21.3 17.3 17.6 17.8 14.5 21.8 16.8 26.9 14.6 50.5 19.3 17.3 16.3 22.6 19.4 16.5 22.8 23.7 34.1 22.2 20.5 24.0 13.8 15.6 17.3 14.8 32.2 19.5 13.9 23.3 13.8 14.3 10.5 19.2 18.1 20.6 17.3 19.4 15.3 16.6 22.6 18.9 16.8 15.3 20.7 11.9 20.5 29.4 25.9 16.6 26.3 18.5 12.5 17.0 16.5 14.9 16.9 29.6 23.6 14.2 22.8 18.5 17.8 21.0 19.9 24.1 24.3 21.4 27.9 18.7 17.8 19.6 22.8 29.0 27.7 19.2 14.5 19.9 19.7 27.3 22.0 17.7 34.0 18.7 20.4 13.9 13.3 27.0 20.2 26.6 48.0 27.5 18.7 19.4 22.6 27.2 13.2 21.4 14.7 17.4 18.0 17.3 18.9 16.6 14.8 13.3 18.9 17.5 32.2 13.9 19.5 10.7 23.3 13.8 20.1 24.5 20.8 26.2 19.8 16.6 20.1 16.1 17.8 23.7 PPY PNP ENSG00000108849 "Pancreatic polypeptide" P01298 17 43940804-43942468 "Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins" Hormone "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 37 "pancreas: 275.8" "Group enriched" "Detected in some" 4 "BEWO: 7.0;EFO-21: 6.5;U-2 OS: 7.2" "Cancer enriched" "Detected in some" 132 "pancreatic cancer: 630.6" "Not detected" "Not detected" "Cell type enriched" "Detected in single" 7 "myeloid DC: 4.1" "Lineage enriched" "Detected in single" 42 "dendritic cells: 4.1" "Not detected" "Not detected" "Not detected" "Not detected" "CAB016735, HPA032122" Enhanced "Secreted to blood" 62720 "CAB016735: , HPA032122: " "unprognostic (5.12e-3)" "unprognostic (1.10e-1)" "unprognostic (3.27e-2)" "unprognostic (1.65e-2)" "unprognostic (7.56e-3)" "unprognostic (8.13e-2)" "unprognostic (1.33e-1)" "unprognostic (7.78e-3)" "unprognostic (1.42e-1)" 0.1 0.1 0.1 0.1 0.1 0.5 0.1 0.1 0.1 0.1 0.6 0.1 0.1 0.1 0.1 1.3 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 275.8 7.5 0.1 0.1 0.1 0.1 2.5 0.1 0.1 0.1 0.1 2.2 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.5 0.1 0.1 0.1 0.1 0.0 4.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.0 0.0 0.0 0.0 0.3 1.4 0.0 0.0 6.5 0.0 0.0 0.0 0.6 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.3 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.6 1.0 0.0 7.2 0.8 0.9 0.0 0.5 1.4 0.2 0.6 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.1 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 PRCC RCCP1 ENSG00000143294 "Papillary renal cell carcinoma (translocation-associated)" Q92733 1 156750610-156800817 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB017151, HPA019463, HPA019481" Supported Enhanced "Nuclear speckles" "Nuclear speckles" "CAB017151: , HPA019463: AB_1855672, HPA019481: AB_1855673" "unprognostic (6.12e-2)" "unprognostic (2.68e-1)" "unprognostic (2.68e-3)" "prognostic unfavourable (5.55e-4)" "unprognostic (3.19e-1)" "unprognostic (1.72e-1)" "prognostic unfavourable (8.63e-4)" "unprognostic (3.03e-1)" "unprognostic (9.16e-2)" "unprognostic (3.27e-3)" "unprognostic (1.14e-1)" "unprognostic (6.80e-2)" "prognostic unfavourable (8.99e-15)" "unprognostic (1.72e-1)" "unprognostic (2.74e-1)" "prognostic unfavourable (3.72e-4)" "unprognostic (1.02e-2)" 31.3 24.9 28.5 25.8 29.7 33.7 23.7 33.2 43.5 29.8 30.0 35.9 21.8 24.6 35.1 22.8 30.3 25.6 28.7 23.8 28.0 24.5 26.1 33.1 22.0 30.1 22.1 25.2 30.1 23.7 31.0 22.7 38.8 22.6 25.6 21.5 25.6 37.2 24.0 47.4 33.6 30.1 25.7 20.4 29.7 24.1 26.2 19.2 51.9 27.5 29.8 30.7 25.4 23.8 21.4 27.1 36.9 23.1 19.3 22.1 16.9 19.8 17.2 13.6 15.5 11.4 9.1 23.7 13.9 13.6 15.5 13.4 27.0 16.8 20.4 24.1 10.9 20.8 19.3 14.6 12.1 25.5 25.3 14.9 12.7 17.4 14.1 20.5 17.6 12.9 17.0 13.5 12.4 14.2 24.6 19.0 10.9 35.4 23.4 24.1 32.9 21.4 20.6 12.0 27.4 16.3 19.1 24.2 43.2 14.7 37.1 23.0 26.7 33.1 13.0 15.8 16.6 17.3 22.8 49.1 73.4 31.6 15.6 13.3 14.6 26.9 20.0 36.9 20.5 20.6 19.6 18.0 18.5 22.1 22.4 21.4 18.4 18.9 19.3 19.3 23.1 27.1 18.5 16.9 28.5 29.7 33.2 43.5 28.0 24.5 22.1 25.2 22.6 19.2 PRDM1 "BLIMP1, PRDI-BF1" ENSG00000057657 "PR/SET domain 1" O75626 6 106086320-106109939 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Adaptive immunity, Immunity, Innate immunity, Transcription, Transcription regulation" "DNA-binding, Methyltransferase, Repressor, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 49.9" "Cell line enhanced" "Detected in some" "Karpas-707: 66.9;RPMI-8226: 12.5;U-266/70: 25.1;U-266/84: 16.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Group enriched" "Detected in many" 4 "eosinophil: 5.6;gdT-cell: 12.6;MAIT T-cell: 19.3;memory CD4 T-cell: 12.0;memory CD8 T-cell: 11.6;naive CD8 T-cell: 6.8;neutrophil: 6.8;T-reg: 15.4" "Group enriched" "Detected in many" 5 "granulocytes: 6.8;T-cells: 19.3" "Region enriched" "Detected in single" 6 "olfactory region: 4.4" "Low region specificity" "Detected in all" HPA030033 Approved Approved Nucleoplasm,Nucleoli Nucleoli Nucleoplasm "HPA030033: AB_10601050" "unprognostic (9.60e-2)" "unprognostic (3.28e-2)" "unprognostic (1.71e-1)" "unprognostic (1.98e-2)" "unprognostic (4.03e-1)" "unprognostic (3.77e-2)" "unprognostic (1.04e-1)" "unprognostic (1.49e-1)" "unprognostic (2.42e-1)" "unprognostic (1.81e-1)" "unprognostic (3.50e-2)" "unprognostic (7.56e-2)" "prognostic unfavourable (9.81e-5)" "unprognostic (1.52e-1)" "unprognostic (3.51e-1)" "unprognostic (2.45e-3)" "unprognostic (7.90e-2)" 11.6 1.5 1.6 26.3 3.2 10.4 7.0 5.3 1.6 14.0 16.5 1.9 1.4 5.4 11.6 2.2 33.4 3.8 8.1 2.3 1.9 2.0 3.1 2.4 18.8 33.3 2.1 0.5 4.2 1.8 1.2 2.1 9.0 4.9 3.6 11.0 4.3 10.6 3.0 2.0 8.9 18.2 3.4 7.4 24.2 8.6 3.0 1.5 3.1 7.7 35.7 49.9 12.8 18.0 1.5 0.2 6.8 0.6 2.5 19.3 1.3 0.4 0.1 0.3 0.0 0.5 0.6 0.0 2.3 7.0 0.7 1.3 0.4 2.7 0.5 0.1 4.5 0.1 0.0 1.0 0.8 6.3 0.0 0.1 1.4 0.0 1.1 0.2 0.5 0.7 3.5 1.0 3.0 0.8 0.4 66.9 0.1 0.0 0.0 0.1 0.2 0.0 0.1 0.0 12.5 0.6 0.1 0.0 0.0 0.3 0.2 0.0 0.3 0.7 0.4 1.1 0.6 0.6 2.1 25.1 16.2 1.4 1.5 0.4 0.6 1.2 0.4 5.6 12.6 0.6 19.3 1.5 12.0 11.6 0.2 0.5 1.1 6.8 6.8 2.5 0.1 0.2 15.4 1.3 1.6 3.2 5.3 1.6 1.9 2.0 2.1 0.5 4.9 1.5 PRDM13 ENSG00000112238 "PR/SET domain 13" Q9H4Q3 6 99606730-99615578 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Methyltransferase, Transferase" "Cancer-related genes" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enhanced" "Detected in single" "blood: 1.1" "Not detected" "Not detected" "Not detected" "Not detected" "Cell type enriched" "Detected in single" 5 "MAIT T-cell: 1.1" "Lineage enriched" "Detected in single" 12 "T-cells: 1.1" "Not detected" "Not detected" "Not detected" "Not detected" HPA070592 Uncertain "HPA070592: " "unprognostic (4.09e-1)" "unprognostic (1.68e-2)" "unprognostic (4.30e-1)" "unprognostic (3.65e-1)" "unprognostic (1.55e-1)" "unprognostic (3.16e-2)" "unprognostic (1.24e-2)" "unprognostic (2.93e-1)" "unprognostic (1.86e-2)" "unprognostic (7.54e-2)" "unprognostic (1.29e-1)" 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 PRDM16 "KIAA1675, KMT8F, MEL1, MGC166915, PFM13" ENSG00000142611 "PR/SET domain 16" Q9HAZ2 1 3069168-3438621 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Differentiation, Transcription, Transcription regulation" "Activator, DNA-binding, Methyltransferase, Repressor, Transferase" "Cancer-related genes, Cardiomyopathy, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in some" "AN3-CA: 3.6;CACO-2: 3.4;HAP1: 3.2;HEK 293: 4.2;HHSteC: 4.9;MCF7: 3.7" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 13 "NK-cell: 5.4" "Lineage enriched" "Detected in single" 13 "NK-cells: 5.4" "Region enriched" "Detected in many" 5 "basal ganglia: 16.1" "Low region specificity" "Detected in many" "HPA050343, HPA060467" Supported Nucleoplasm Nucleoplasm "HPA050343: , HPA060467: " "unprognostic (2.44e-1)" "unprognostic (1.44e-1)" "unprognostic (5.31e-4)" "unprognostic (1.27e-1)" "unprognostic (1.14e-1)" "unprognostic (3.95e-2)" "unprognostic (9.15e-3)" "unprognostic (5.68e-4)" "unprognostic (2.58e-1)" "unprognostic (2.07e-2)" "unprognostic (5.21e-2)" "unprognostic (1.71e-1)" "unprognostic (7.80e-6)" "unprognostic (2.14e-1)" "unprognostic (1.73e-1)" "prognostic unfavourable (4.70e-5)" "unprognostic (4.06e-2)" 2.7 0.7 5.3 1.4 5.6 0.5 1.6 0.5 4.7 2.1 6.2 3.3 12.8 14.1 1.5 4.5 1.1 2.0 11.7 5.1 5.2 1.9 7.0 0.6 4.2 1.4 2.9 3.1 3.6 12.7 1.2 1.1 0.6 3.3 1.1 0.9 16.1 1.3 15.0 1.2 0.9 8.0 1.5 2.5 4.2 14.8 1.4 4.8 0.0 10.7 0.0 0.9 1.1 1.5 0.3 0.1 0.0 0.0 5.4 0.4 0.0 0.0 0.0 1.3 3.6 0.0 0.0 0.0 0.0 0.0 0.0 0.5 3.4 0.7 0.0 0.6 0.0 0.0 3.2 0.0 0.0 0.4 4.2 0.0 0.0 0.7 4.9 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.7 0.4 0.0 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.8 0.0 1.4 0.0 0.1 0.0 0.0 0.0 0.2 0.9 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.0 0.4 0.0 5.4 0.0 0.0 0.0 0.0 5.3 5.6 0.5 4.7 5.2 1.9 2.9 3.1 3.3 4.8 PRDX2 "MGC4104, NKEFB, PRP, PRX2, PRXII, TDPX1, TSA" ENSG00000167815 "Peroxiredoxin 2" P32119 19 12796820-12801859 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Antioxidant, Oxidoreductase, Peroxidase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" CAB008713 Approved 1100000000 "CAB008713: AB_1620974" "unprognostic (1.12e-1)" "unprognostic (1.98e-3)" "unprognostic (8.58e-2)" "unprognostic (4.40e-2)" "unprognostic (4.56e-2)" "unprognostic (1.92e-2)" "unprognostic (2.44e-1)" "unprognostic (2.59e-2)" "unprognostic (1.01e-1)" "unprognostic (1.47e-1)" "unprognostic (3.26e-2)" "unprognostic (9.18e-2)" "prognostic favourable (5.66e-11)" "unprognostic (7.01e-3)" "unprognostic (2.15e-1)" "unprognostic (3.51e-2)" "unprognostic (1.41e-1)" 39.8 95.1 54.7 17.9 55.6 119.1 27.7 52.1 80.8 22.5 39.9 27.8 42.2 53.6 28.1 33.8 49.9 31.5 36.4 142.0 49.2 54.4 44.5 79.4 15.9 22.7 62.2 41.6 40.0 43.0 32.8 49.4 20.9 70.9 30.6 30.8 35.9 42.3 41.5 136.8 44.3 44.9 27.6 27.5 18.1 31.5 13.7 23.5 38.9 36.8 69.9 29.5 31.5 24.6 42.1 24.6 9.5 20.6 23.3 76.8 72.3 44.8 0.1 62.0 80.2 9.0 6.2 45.7 20.8 20.7 28.4 16.1 47.2 11.3 13.2 48.7 20.0 42.9 39.1 33.7 8.2 56.5 61.8 23.9 63.6 70.4 24.3 0.0 0.1 26.6 15.5 21.3 10.4 26.2 51.0 20.8 10.8 81.4 52.8 20.3 45.7 86.9 52.3 0.0 63.6 37.7 48.7 76.8 60.7 49.3 50.6 16.4 45.3 34.4 11.5 21.3 17.9 59.1 45.0 25.5 24.9 60.6 20.2 8.0 4.8 2.8 20.6 9.5 53.6 14.3 56.2 42.1 73.5 54.8 24.6 29.2 74.9 58.5 2.7 23.3 15.4 14.4 76.8 72.3 54.7 55.6 52.1 80.8 49.2 54.4 62.2 41.6 70.9 23.5 PRDX4 AOE37-2 ENSG00000123131 "Peroxiredoxin 4" Q13162 X 23664262-23686399 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Antioxidant, Oxidoreductase, Peroxidase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in all" 6 "liver: 127.6;pancreas: 320.8" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB008659, CAB027389, CAB047362" Enhanced Supported "Endoplasmic reticulum,Cytosol" "Intracellular and membrane" 11000000 "Endoplasmic reticulum, Cytosol" "CAB008659: AB_1620984, CAB027389: , CAB047362: " "unprognostic (3.82e-2)" "unprognostic (6.05e-2)" "unprognostic (1.09e-1)" "unprognostic (6.06e-3)" "unprognostic (1.64e-1)" "unprognostic (1.65e-2)" "unprognostic (1.29e-3)" "unprognostic (1.08e-1)" "unprognostic (8.32e-2)" "unprognostic (3.75e-2)" "unprognostic (2.97e-1)" "unprognostic (1.79e-1)" "prognostic unfavourable (1.33e-6)" "unprognostic (7.44e-2)" "unprognostic (1.29e-1)" "unprognostic (3.56e-1)" "unprognostic (4.10e-2)" 11.6 14.8 3.8 7.0 6.4 3.9 11.2 3.3 5.4 13.2 10.7 6.5 17.4 8.9 11.5 10.5 13.1 9.6 12.9 17.6 3.8 4.0 11.8 127.6 8.9 16.9 7.2 4.0 14.6 320.8 6.1 15.8 21.9 7.4 9.3 11.4 8.0 25.4 14.1 7.8 7.2 10.6 8.8 8.1 12.6 12.8 25.2 6.1 4.7 12.0 10.0 15.0 10.8 8.7 27.9 31.4 2.0 39.3 24.1 22.7 21.3 24.2 33.5 14.2 27.4 77.4 39.6 20.0 32.7 35.7 29.7 43.4 35.1 30.6 20.9 15.4 42.4 29.4 40.8 20.3 28.5 12.7 78.5 14.8 29.6 44.3 32.3 19.0 14.1 41.9 26.3 28.9 29.0 37.2 28.5 77.1 27.4 36.1 9.7 29.8 49.0 49.2 13.5 35.5 117.8 26.5 8.5 20.8 17.7 30.1 35.8 24.1 37.8 24.3 24.5 21.2 14.0 54.7 24.5 25.3 30.6 22.3 38.0 24.7 30.2 1.7 20.6 2.0 17.8 32.2 21.8 27.9 22.7 18.6 31.4 16.2 16.4 16.7 1.5 24.1 39.3 22.0 22.1 21.3 3.8 6.4 3.3 5.4 3.8 4.0 7.2 4.0 7.4 6.1 PREX2 "DEP.2, DEPDC2, FLJ12987, P-REX2, PPP1R129" ENSG00000046889 "Phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 2" Q70Z35 8 67952118-68237030 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Guanine-nucleotide releasing factor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in some" "AF22: 12.7;HUVEC TERT2: 17.3;NTERA-2: 11.0;RH-30: 5.0" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in single" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA015234, HPA075956" Enhanced Approved "Endoplasmic reticulum" "Endoplasmic reticulum" "HPA015234: AB_1847604, HPA075956: " "unprognostic (2.25e-1)" "unprognostic (3.32e-2)" "unprognostic (1.30e-2)" "unprognostic (3.39e-2)" "unprognostic (1.79e-1)" "unprognostic (2.37e-2)" "unprognostic (4.19e-1)" "unprognostic (8.27e-2)" "unprognostic (2.00e-1)" "unprognostic (1.98e-2)" "unprognostic (2.53e-2)" "unprognostic (8.77e-2)" "prognostic unfavourable (1.61e-7)" "unprognostic (8.30e-3)" "unprognostic (2.79e-1)" "unprognostic (3.67e-2)" "unprognostic (6.64e-2)" 18.8 3.0 14.1 3.3 17.9 1.0 8.5 11.4 16.4 10.8 4.4 13.1 3.0 4.3 6.2 4.5 4.4 12.4 7.6 7.6 15.5 8.1 4.1 3.2 9.1 2.4 12.4 10.0 5.2 3.1 3.7 4.4 17.5 17.2 6.3 4.4 2.6 3.0 5.7 4.9 4.4 4.0 6.1 12.7 3.5 4.1 2.7 16.2 0.0 12.1 3.9 2.9 5.9 15.8 1.1 0.3 0.8 0.1 0.2 0.4 0.0 0.0 0.0 12.7 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 3.3 0.0 0.0 3.6 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 17.3 0.0 0.0 0.0 0.0 2.6 0.0 11.0 0.0 0.0 5.0 0.0 0.6 0.0 3.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.1 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.8 0.1 0.1 0.4 0.1 0.2 0.5 0.2 0.2 0.0 1.1 0.2 0.3 0.5 0.2 0.1 0.3 0.0 0.0 14.1 17.9 11.4 13.6 15.5 8.1 12.4 10.0 17.2 16.2 PRF1 "HPLH2, P1, PFP" ENSG00000180644 "Perforin 1" P14222 10 70597348-70602775 "Cancer-related genes, Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters" Cytolysis "Cancer-related genes, Disease mutation, Familial hemophagocytic lymphohistiocytosis" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 100.3;lymphoid tissue: 38.7" "Cell line enriched" "Detected in some" 11 "HDLM-2: 71.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in some" "Group enriched" "Detected in many" 4 "gdT-cell: 100.3;MAIT T-cell: 70.9;memory CD8 T-cell: 54.9;naive CD8 T-cell: 36.1;NK-cell: 65.1" "Group enriched" "Detected in many" 48 "NK-cells: 65.1;T-cells: 100.3" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB002436, HPA037940" Approved Approved Cytosol "Intracellular and membrane" 960000 Cytosol "CAB002436: AB_563955, HPA037940: " "unprognostic (6.11e-3)" "unprognostic (1.26e-2)" "unprognostic (1.71e-1)" "prognostic favourable (2.09e-4)" "unprognostic (1.87e-2)" "prognostic favourable (3.54e-4)" "unprognostic (6.98e-3)" "unprognostic (2.62e-1)" "unprognostic (1.44e-3)" "unprognostic (1.69e-2)" "unprognostic (5.22e-2)" "unprognostic (1.45e-1)" "prognostic unfavourable (1.08e-5)" "unprognostic (7.38e-2)" "unprognostic (2.70e-1)" "unprognostic (7.97e-3)" "unprognostic (5.22e-3)" 8.8 1.3 0.9 5.5 1.1 15.3 2.4 0.5 0.7 1.7 3.8 0.4 0.2 1.4 4.4 2.9 2.7 1.7 5.3 4.1 0.8 0.9 1.8 6.5 19.6 11.3 2.5 0.3 2.1 1.6 0.0 1.1 3.1 1.2 3.3 0.8 3.9 2.5 3.3 2.6 0.9 5.1 1.2 1.4 38.7 3.1 1.6 0.2 12.7 2.8 1.0 10.3 3.2 1.7 0.4 0.3 1.7 0.2 65.1 100.3 46.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 71.0 0.0 0.4 0.0 2.1 0.0 0.0 3.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.6 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.4 0.2 0.0 100.3 0.1 70.9 0.4 14.6 54.9 0.2 0.2 6.2 36.1 1.7 65.1 0.2 0.3 11.1 46.7 0.9 1.1 0.5 0.7 0.8 0.9 2.5 0.3 1.2 0.2 PRKACA PKACa ENSG00000072062 "Protein kinase cAMP-activated catalytic subunit alpha" P17612 19 14091688-14118084 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Cushing syndrome, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010361, HPA071185" Approved Approved Cytosol 1300000 Cytosol "CAB010361: AB_2268772, HPA071185: " "unprognostic (1.08e-1)" "prognostic favourable (6.28e-6)" "unprognostic (2.09e-2)" "prognostic unfavourable (6.26e-5)" "unprognostic (1.38e-2)" "unprognostic (2.95e-1)" "unprognostic (1.64e-1)" "unprognostic (9.36e-3)" "unprognostic (7.01e-2)" "unprognostic (3.41e-1)" "prognostic favourable (6.47e-4)" "unprognostic (2.86e-1)" "unprognostic (1.17e-1)" "unprognostic (4.68e-2)" "unprognostic (1.87e-1)" "unprognostic (3.66e-2)" "unprognostic (6.14e-3)" 25.6 43.4 19.6 17.8 22.7 9.1 34.1 29.1 39.6 20.6 17.5 16.0 16.2 13.4 19.8 15.6 20.9 18.8 16.4 91.6 20.7 29.4 14.7 34.5 16.5 28.2 21.6 27.5 47.0 15.6 20.8 24.6 15.4 26.9 16.6 16.2 18.4 15.5 24.9 92.4 13.4 14.4 29.0 16.2 28.1 13.9 24.4 11.1 15.2 15.7 26.2 14.8 21.1 17.3 1.7 2.4 8.6 5.3 0.7 1.7 1.2 25.7 15.0 34.0 40.5 30.1 32.0 6.1 27.4 25.4 39.0 35.8 18.2 9.2 11.1 22.2 43.4 16.9 23.9 26.0 37.1 20.3 12.0 20.5 28.3 17.6 25.8 12.6 21.7 30.4 12.5 31.0 10.8 32.8 19.2 29.2 39.8 38.2 28.4 9.5 12.2 33.4 25.7 31.4 25.7 19.0 16.3 26.8 17.1 24.8 15.2 11.3 21.7 12.2 25.4 46.1 12.9 61.6 25.6 20.2 20.7 16.4 30.9 19.2 17.2 0.3 3.4 0.4 1.7 5.3 0.8 1.7 0.9 1.1 2.4 1.3 1.2 1.7 8.6 0.7 4.6 1.6 0.8 1.2 19.6 22.7 29.1 39.6 20.7 29.4 21.6 27.5 26.9 11.1 PRKAR1A "CNC1, PRKAR1, TSE1" ENSG00000108946 "Protein kinase cAMP-dependent type I regulatory subunit alpha" P10644 17 68511780-68551319 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cancer-related genes, Cushing syndrome, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB019378, HPA049979" Approved Approved Cytosol 11000000 Cytosol "CAB019378: , HPA049979: " "unprognostic (8.69e-2)" "unprognostic (6.97e-2)" "unprognostic (5.34e-2)" "unprognostic (2.04e-1)" "unprognostic (1.68e-1)" "unprognostic (4.39e-2)" "unprognostic (2.61e-1)" "unprognostic (6.42e-2)" "unprognostic (2.27e-1)" "unprognostic (2.30e-1)" "unprognostic (1.19e-2)" "unprognostic (5.55e-2)" "unprognostic (8.56e-3)" "unprognostic (6.26e-2)" "unprognostic (6.92e-2)" "unprognostic (3.29e-2)" "unprognostic (1.11e-1)" 47.1 48.0 41.7 34.5 54.8 14.6 38.7 40.4 57.4 48.2 23.8 44.9 31.4 15.1 43.6 37.7 29.6 43.2 37.4 122.7 42.5 52.3 49.2 43.4 47.3 29.5 50.1 43.6 62.5 19.1 107.8 41.9 47.3 57.7 35.6 24.2 32.2 47.5 43.6 99.8 22.8 19.3 39.4 52.8 35.3 25.1 36.9 40.1 28.2 51.8 23.6 29.2 33.8 33.4 11.3 26.9 52.6 28.7 18.5 13.0 22.9 16.4 31.6 40.6 24.3 54.2 61.6 6.1 22.2 45.8 34.7 30.7 12.3 22.2 16.7 15.3 48.4 13.6 30.0 36.0 49.9 11.3 10.7 25.8 27.5 40.2 39.3 19.7 29.0 44.0 37.4 40.0 33.8 57.6 11.6 26.3 42.0 31.1 21.7 10.6 15.0 21.6 15.2 67.3 18.4 52.6 35.8 14.8 20.0 20.3 37.2 85.5 29.0 27.9 40.8 49.0 23.4 22.1 20.6 21.9 15.5 24.9 29.6 18.8 30.5 31.1 26.1 46.3 13.0 25.5 13.0 11.3 9.8 11.6 26.9 8.5 8.9 9.8 52.6 18.5 28.7 8.8 12.3 22.9 41.7 54.8 40.4 57.4 42.5 52.3 50.1 43.6 57.7 40.1 PRKCA PKCA ENSG00000154229 "Protein kinase C alpha" P17252 17 66302636-66810743 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins" "Angiogenesis, Apoptosis, Cell adhesion" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "U-87 MG: 53.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Group enriched" "Detected in many" 17 "dendritic cells: 1.4;monocytes: 2.7;T-cells: 4.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003844, HPA006563, HPA006564, CAB016290" Enhanced Approved Enhanced "Plasma membrane,Cytosol" 1900000 Cytosol "Plasma membrane" "CAB003844: AB_562331, CAB016290: AB_628141, HPA006563: AB_1079626, HPA006564: AB_1079625" "unprognostic (3.06e-1)" "unprognostic (3.56e-2)" "unprognostic (1.38e-2)" "unprognostic (1.01e-1)" "unprognostic (1.53e-1)" "unprognostic (7.41e-3)" "unprognostic (7.43e-2)" "unprognostic (6.86e-3)" "unprognostic (4.93e-2)" "unprognostic (1.50e-1)" "unprognostic (2.09e-1)" "unprognostic (2.24e-2)" "unprognostic (5.50e-2)" "unprognostic (2.46e-1)" "unprognostic (1.83e-1)" "unprognostic (1.35e-3)" "unprognostic (8.77e-2)" 4.0 19.6 26.5 9.0 22.8 2.5 3.0 10.8 33.9 7.0 13.8 19.0 3.5 14.6 14.8 6.7 4.7 6.1 10.8 5.8 31.6 15.6 16.7 6.5 6.0 8.4 18.7 15.6 20.4 5.5 1.7 6.0 6.5 17.6 17.2 11.2 7.0 3.1 22.3 6.6 3.8 12.7 13.7 15.0 7.9 7.9 3.7 14.4 0.4 4.5 1.3 5.9 9.5 9.5 0.0 1.4 0.1 2.7 0.1 4.0 1.0 2.3 12.3 2.5 2.6 6.2 15.9 0.3 13.3 8.7 9.6 8.2 1.4 1.5 3.1 3.6 21.4 0.3 1.3 1.5 20.9 5.1 3.0 0.0 7.3 6.4 8.5 3.8 20.9 6.9 0.6 12.0 10.3 8.2 8.0 0.0 14.8 0.7 7.7 2.3 1.0 6.6 1.4 18.8 0.0 3.4 2.0 1.5 8.5 4.4 2.5 0.1 0.3 5.4 24.5 16.7 9.7 10.4 8.3 0.0 0.0 0.3 53.0 0.0 8.2 0.1 0.6 0.0 0.5 0.8 1.5 0.0 2.5 1.2 1.1 0.0 4.0 2.3 0.0 0.1 2.7 1.4 0.5 1.0 26.5 22.8 10.8 28.2 31.6 15.6 18.7 15.6 17.6 14.4 PRKCB "PKCB, PRKCB1, PRKCB2" ENSG00000166501 "Protein kinase C beta" P05771 16 23835946-24220611 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins" "Adaptive immunity, Apoptosis, Immunity, Transcription, Transcription regulation" "Chromatin regulator, Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 57.2;lymphoid tissue: 31.2" "Cell line enhanced" "Detected in some" "HEL: 40.8;HMC-1: 40.9;K-562: 58.1;THP-1: 18.4;U-937: 16.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003843, HPA048321, HPA054203" Approved Supported Nucleoplasm,Cytosol 3400000 Nucleoplasm Cytosol "CAB003843: AB_562197, HPA048321: , HPA054203: " "unprognostic (1.53e-3)" "unprognostic (4.53e-4)" "unprognostic (2.52e-3)" "unprognostic (3.07e-2)" "unprognostic (1.72e-1)" "unprognostic (7.13e-3)" "unprognostic (2.06e-1)" "unprognostic (1.67e-3)" "unprognostic (3.19e-2)" "unprognostic (1.79e-1)" "unprognostic (7.38e-2)" "unprognostic (1.06e-1)" "unprognostic (3.17e-3)" "unprognostic (2.08e-1)" "unprognostic (2.12e-2)" "unprognostic (3.28e-1)" "unprognostic (4.95e-2)" 4.0 1.9 13.9 20.8 55.6 20.4 1.8 14.1 57.2 4.1 4.7 4.4 0.6 4.9 3.5 1.2 3.2 2.6 3.9 1.5 23.4 7.8 1.8 3.7 5.4 31.0 11.0 20.4 1.2 1.4 0.9 1.4 2.5 8.3 6.2 4.4 3.5 1.9 8.4 1.2 4.6 9.1 5.8 7.3 31.2 3.8 6.4 6.4 24.1 3.9 0.0 27.7 7.6 1.7 23.6 18.5 21.8 14.6 20.1 19.0 7.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.7 0.2 0.0 0.1 0.1 0.0 0.0 0.0 0.8 40.8 1.9 0.0 0.0 5.9 40.9 0.0 0.1 0.0 0.0 0.0 58.1 0.1 0.0 0.0 12.9 12.9 0.3 0.0 12.3 0.1 2.3 0.1 3.6 7.1 0.0 0.0 0.0 0.6 0.0 18.4 0.2 0.0 0.0 0.0 0.0 1.0 0.0 0.3 0.0 16.4 0.0 17.5 7.6 14.4 14.5 10.7 6.7 23.6 9.5 17.2 6.2 22.1 7.8 19.0 21.8 20.1 14.6 18.5 6.7 7.5 13.9 55.6 14.1 57.2 23.4 7.8 11.0 20.4 8.3 6.4 PRKCD ENSG00000163932 "Protein kinase C delta" Q05655 3 53156009-53192717 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Apoptosis, Cell cycle" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "SK-BR-3: 63.3;THP-1: 45.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 6 "basophil: 17.7;classical monocyte: 22.9;eosinophil: 17.0;intermediate monocyte: 22.2;myeloid DC: 17.6;neutrophil: 20.7;non-classical monocyte: 15.3;plasmacytoid DC: 8.5" "Group enriched" "Detected in all" 7 "dendritic cells: 17.6;granulocytes: 20.7;monocytes: 22.9" "Group enriched" "Detected in many" 5 "basal ganglia: 124.2;thalamus: 366.1" "Low region specificity" "Detected in all" "HPA001863, HPA001890, CAB010469, CAB013225" Enhanced Enhanced "Endoplasmic reticulum,Golgi apparatus,Cytosol" 300000 Cytosol "Endoplasmic reticulum, Golgi apparatus" "CAB010469: AB_632229, CAB013225: , HPA001863: AB_1079627, HPA001890: AB_1079628" "unprognostic (3.59e-1)" "unprognostic (4.85e-2)" "unprognostic (2.66e-2)" "unprognostic (1.90e-1)" "unprognostic (1.17e-1)" "unprognostic (6.97e-2)" "prognostic unfavourable (2.24e-4)" "prognostic favourable (9.01e-4)" "unprognostic (1.95e-2)" "unprognostic (1.42e-1)" "unprognostic (1.79e-1)" "unprognostic (2.89e-1)" "unprognostic (2.05e-1)" "unprognostic (1.73e-1)" "unprognostic (2.48e-2)" "unprognostic (2.06e-3)" "unprognostic (2.95e-3)" 27.8 33.4 9.4 29.7 11.5 30.3 17.6 5.7 10.7 10.3 27.8 10.1 43.7 21.4 5.5 21.3 18.3 16.1 33.7 11.9 8.3 3.7 16.5 4.5 29.2 24.5 10.2 5.6 8.1 13.4 6.1 5.1 7.5 7.1 17.9 16.1 10.3 14.1 40.7 3.9 17.1 42.9 17.4 10.2 32.1 24.8 9.6 8.0 10.5 26.9 13.4 26.3 22.9 12.7 3.1 17.6 20.7 22.9 2.4 1.5 6.4 7.7 3.0 1.2 2.0 9.0 5.2 11.2 4.7 5.9 5.8 5.7 7.3 7.6 20.0 2.1 10.2 3.5 7.9 11.5 4.7 17.4 6.0 11.1 4.1 7.8 5.7 14.6 25.1 4.1 8.4 5.9 5.5 5.0 2.2 2.9 8.3 19.1 1.6 24.9 3.1 5.5 1.7 3.0 4.7 6.3 16.7 2.0 1.4 3.6 63.3 9.7 5.3 45.2 7.2 2.8 3.6 3.7 4.4 4.4 6.8 10.2 6.7 25.2 5.4 17.7 22.9 17.0 1.5 22.2 1.0 3.1 1.1 1.2 17.6 2.9 0.8 0.7 20.7 2.4 15.3 8.5 1.1 6.4 9.4 11.5 5.7 10.7 8.3 3.7 10.2 5.6 7.1 8.0 PRKCE ENSG00000171132 "Protein kinase C epsilon" Q02156 2 45651345-46187990 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Cell adhesion, Cell cycle, Cell division, Immunity" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 36.5" "Cell line enhanced" "Detected in many" "REH: 19.1;TIME: 19.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "naive B-cell: 5.5" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB001948, HPA044496, HPA054252" Enhanced Supported Approved Vesicles Vesicles "CAB001948: , HPA044496: , HPA054252: " "unprognostic (1.10e-1)" "unprognostic (1.78e-1)" "unprognostic (2.27e-1)" "prognostic unfavourable (2.42e-4)" "unprognostic (9.61e-2)" "unprognostic (5.70e-2)" "unprognostic (1.51e-1)" "prognostic favourable (9.62e-4)" "unprognostic (3.05e-1)" "unprognostic (6.72e-2)" "unprognostic (7.49e-3)" "unprognostic (9.99e-2)" "prognostic favourable (2.63e-7)" "unprognostic (1.21e-1)" "unprognostic (7.11e-2)" "unprognostic (6.43e-3)" "unprognostic (2.23e-2)" 5.5 7.4 15.3 7.2 14.2 9.3 8.1 28.8 36.5 6.6 5.5 3.8 5.9 3.6 5.6 4.6 4.7 7.6 4.7 7.7 22.5 10.0 12.8 15.5 17.5 6.9 6.0 15.0 4.1 4.2 16.3 6.0 10.4 9.1 3.6 4.7 3.7 3.6 8.6 7.2 3.0 3.7 6.2 4.4 4.9 4.4 7.2 3.7 1.5 6.5 1.2 5.4 5.0 6.5 5.5 2.2 1.7 1.4 0.9 1.3 0.6 5.3 2.0 2.8 2.8 4.3 5.1 2.3 3.8 6.8 3.2 3.4 0.5 5.3 8.1 3.6 3.9 1.3 1.8 2.0 4.5 4.8 3.4 0.0 1.4 1.1 4.9 0.6 2.9 4.5 2.2 4.7 3.4 11.6 1.1 1.9 3.6 2.7 2.6 0.3 1.0 1.0 19.1 13.5 8.6 2.9 3.7 2.0 4.3 1.7 5.7 12.3 4.6 1.9 19.2 6.2 6.5 4.5 3.7 0.0 0.0 6.8 5.1 4.5 6.2 0.0 1.2 1.7 1.0 0.4 1.1 3.6 0.7 0.7 2.2 5.5 1.3 0.4 0.4 0.9 1.4 0.9 0.0 0.6 15.3 14.2 28.8 33.2 22.5 10.0 6.0 15.0 9.1 3.7 PRKCH "PKC-L, PKCL, PRKCL" ENSG00000027075 "Protein kinase C eta" P24723 14 61187559-61550976 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" Differentiation "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "BEWO: 29.9;HUVEC TERT2: 39.2;MOLT-4: 26.0;RT4: 16.5;TIME: 25.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 12 "gdT-cell: 30.0;MAIT T-cell: 23.9;memory CD4 T-cell: 23.0;memory CD8 T-cell: 35.3;naive CD4 T-cell: 28.5;naive CD8 T-cell: 27.6;NK-cell: 27.3;T-reg: 18.6" "Group enriched" "Detected in many" 14 "NK-cells: 27.3;T-cells: 35.3" "Group enriched" "Detected in many" 6 "basal ganglia: 25.0;thalamus: 19.5" "Low region specificity" "Detected in many" "HPA026294, HPA053709" Approved Approved "Plasma membrane,Cytosol" Cytosol "Plasma membrane" "HPA026294: AB_10603988, HPA053709: " "unprognostic (1.42e-1)" "unprognostic (3.89e-3)" "unprognostic (1.78e-1)" "unprognostic (1.96e-3)" "unprognostic (1.04e-1)" "prognostic favourable (8.55e-6)" "unprognostic (1.14e-2)" "unprognostic (2.97e-2)" "unprognostic (4.14e-1)" "unprognostic (1.94e-1)" "unprognostic (7.96e-2)" "unprognostic (1.60e-1)" "unprognostic (1.52e-3)" "unprognostic (1.13e-1)" "unprognostic (4.14e-2)" "unprognostic (6.98e-2)" "unprognostic (4.73e-3)" 17.5 5.4 5.0 21.6 22.0 11.2 14.7 2.8 6.1 13.6 10.3 6.2 6.9 5.1 19.1 7.0 20.1 8.6 12.7 10.1 6.8 4.4 8.1 5.5 24.1 27.6 5.9 2.5 7.1 5.9 8.8 15.5 22.7 7.2 9.8 5.0 9.1 24.7 10.8 9.1 15.9 16.0 10.5 5.7 25.9 6.0 4.3 6.4 54.6 15.1 10.6 34.6 13.2 14.4 0.4 2.2 1.5 0.7 27.3 35.3 17.9 6.2 2.2 0.3 1.7 1.0 0.2 29.9 0.1 0.5 0.3 0.3 0.6 3.7 0.1 4.5 0.0 4.4 0.2 4.8 0.5 0.7 2.8 0.0 0.7 0.2 0.4 0.0 0.9 0.8 5.0 0.2 3.4 39.2 0.0 0.1 2.2 11.5 26.0 0.2 0.5 3.0 2.2 1.1 0.0 0.0 16.5 1.1 1.9 0.7 5.8 3.6 5.7 0.5 25.7 0.7 5.2 0.7 0.3 0.5 0.1 0.2 1.1 0.3 1.2 0.1 0.7 0.5 30.0 0.4 23.9 0.4 23.0 35.3 2.2 0.3 28.5 27.6 1.5 27.3 0.2 0.7 18.6 17.9 5.0 22.0 2.8 6.1 6.8 4.4 5.9 2.5 7.2 6.4 PRKCI "DXS1179E, PKCI" ENSG00000163558 "Protein kinase C iota" P41743 3 170222365-170305981 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Proto-oncogene, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA026574, HPA038635" Approved Supported "Microtubules,Cytokinetic bridge,Cytosol" Cytosol "Microtubules, Cytokinetic bridge" "HPA026574: AB_1855428, HPA038635: " "unprognostic (2.26e-1)" "unprognostic (6.75e-2)" "unprognostic (4.57e-2)" "prognostic unfavourable (3.93e-6)" "unprognostic (1.59e-1)" "unprognostic (1.84e-2)" "prognostic unfavourable (3.02e-4)" "unprognostic (2.52e-1)" "unprognostic (7.10e-2)" "unprognostic (1.73e-2)" "prognostic unfavourable (1.22e-4)" "unprognostic (5.32e-3)" "prognostic favourable (3.10e-4)" "unprognostic (1.16e-1)" "unprognostic (2.65e-1)" "unprognostic (1.06e-1)" "unprognostic (9.73e-2)" 10.3 7.5 11.4 5.9 15.5 2.1 9.5 14.8 16.6 12.5 11.1 7.0 6.0 10.4 13.1 8.4 20.6 15.1 10.5 10.1 9.5 7.7 13.0 6.7 14.8 3.9 5.6 9.4 15.2 7.7 12.4 14.7 9.8 11.0 16.3 12.2 7.3 25.8 12.6 12.7 11.0 11.6 12.5 6.8 6.1 30.2 15.0 5.3 12.6 23.1 8.4 9.9 16.3 13.0 1.9 1.8 1.0 1.3 5.8 4.8 1.4 35.9 9.1 9.2 9.8 8.2 11.4 14.9 9.2 13.7 12.3 13.3 13.3 17.6 11.0 30.5 13.0 16.9 17.3 18.1 21.1 8.0 10.7 10.2 11.6 7.4 13.0 9.2 4.6 10.2 12.7 10.4 16.5 9.5 11.2 9.1 12.3 12.4 13.3 3.6 19.3 10.2 9.6 14.2 18.2 19.3 11.0 14.6 11.9 20.0 26.3 9.0 28.9 6.3 10.1 12.8 9.9 11.9 15.2 15.7 15.1 15.7 9.2 7.2 5.0 0.1 1.3 1.0 2.6 1.2 4.0 1.8 3.6 4.8 1.8 1.9 3.9 2.2 0.7 5.8 1.1 1.8 2.3 1.4 11.4 15.5 14.8 16.6 9.5 7.7 5.6 9.4 11.0 5.3 PRKCQ ENSG00000065675 "Protein kinase C theta" Q04759 10 6427143-6580301 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Immunity, Inflammatory response" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "blood: 19.7;lymphoid tissue: 32.1;skeletal muscle: 63.4" "Cell line enhanced" "Detected in some" "HEL: 30.9;MOLT-4: 23.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Group enriched" "Detected in many" 10 "gdT-cell: 12.7;MAIT T-cell: 9.8;memory CD4 T-cell: 13.5;memory CD8 T-cell: 13.2;naive CD4 T-cell: 10.7;naive CD8 T-cell: 10.0;NK-cell: 6.5;T-reg: 19.7" "Group enriched" "Detected in many" 11 "NK-cells: 6.5;T-cells: 19.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA065279, HPA073098" Enhanced "Centriolar satellite" 200000 "Centriolar satellite" "HPA065279: , HPA073098: " "unprognostic (6.61e-3)" "unprognostic (2.12e-1)" "unprognostic (1.87e-1)" "unprognostic (1.48e-1)" "unprognostic (1.50e-1)" "unprognostic (2.24e-1)" "unprognostic (2.69e-3)" "unprognostic (2.46e-1)" "unprognostic (8.40e-2)" "unprognostic (2.66e-1)" "unprognostic (1.17e-1)" "unprognostic (3.22e-1)" "unprognostic (5.26e-2)" "unprognostic (7.74e-2)" "unprognostic (2.79e-1)" "prognostic unfavourable (5.27e-4)" "unprognostic (3.51e-2)" 0.9 0.7 3.6 9.4 4.3 3.1 0.8 0.9 5.2 1.3 1.1 7.4 0.1 1.2 1.8 5.4 1.6 2.6 1.3 0.5 4.4 4.0 4.6 0.9 3.3 6.6 4.0 2.2 1.1 7.7 0.3 1.0 0.4 2.7 1.4 1.3 5.4 2.8 1.0 63.4 0.6 2.5 0.8 3.6 3.4 1.4 0.9 4.5 32.1 9.1 7.5 6.8 1.9 0.8 0.0 0.1 1.1 0.2 6.5 19.7 5.2 0.0 2.9 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.1 0.1 0.2 1.8 0.2 0.0 0.0 0.0 1.8 3.3 0.0 0.0 2.1 30.9 0.0 0.2 0.4 1.5 0.3 0.1 2.0 0.1 0.1 0.3 6.7 0.0 0.0 0.0 23.2 4.3 3.2 0.0 4.5 0.7 0.0 6.5 1.6 0.2 1.2 0.0 0.0 0.0 0.0 3.1 0.0 0.0 3.2 0.0 0.0 0.0 0.0 0.0 0.0 3.8 0.0 1.1 0.1 0.1 12.7 0.2 9.8 0.0 13.5 13.2 0.1 0.0 10.7 10.0 0.8 6.5 0.0 0.0 19.7 5.2 3.6 4.3 0.9 5.2 4.4 4.0 4.0 2.2 2.7 4.5 PRKDC "DNA-PKcs, DNAPK, DNPK1, HYRC, HYRC1, p350, XRCC7" ENSG00000253729 "Protein kinase, DNA-activated, catalytic polypeptide" P78527 8 47773108-47960183 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Biological rhythms, DNA damage, DNA recombination, DNA repair, Immunity, Innate immunity" "DNA-binding, Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB005167, HPA035174" Supported Enhanced Nucleoplasm 1100000 Nucleoplasm "CAB005167: AB_2172845, HPA035174: " "unprognostic (3.14e-2)" "unprognostic (3.02e-3)" "unprognostic (1.56e-2)" "prognostic unfavourable (1.03e-4)" "unprognostic (8.95e-2)" "unprognostic (1.34e-1)" "unprognostic (7.70e-3)" "unprognostic (5.74e-2)" "unprognostic (1.12e-2)" "unprognostic (1.60e-2)" "unprognostic (7.76e-3)" "unprognostic (7.77e-2)" "unprognostic (2.84e-2)" "unprognostic (2.32e-1)" "unprognostic (2.20e-1)" "unprognostic (6.76e-3)" "unprognostic (2.15e-2)" 21.3 20.5 16.0 22.3 22.0 27.4 30.2 16.5 23.1 19.6 20.6 17.3 18.1 12.0 26.2 14.5 27.4 24.4 13.0 21.1 20.8 15.2 16.7 18.4 17.0 33.6 16.6 18.2 24.6 23.8 33.4 29.4 20.5 17.3 17.9 20.3 17.8 17.9 17.8 34.0 23.9 18.4 27.0 20.3 24.4 19.1 20.5 15.9 44.4 20.8 15.9 27.9 21.3 19.1 17.0 13.9 7.1 11.5 11.5 11.3 2.3 32.4 27.8 27.1 25.7 16.9 17.9 11.5 13.8 13.6 19.5 19.2 18.1 10.7 31.0 12.0 16.9 18.5 35.8 18.9 30.6 6.8 22.2 60.9 25.0 22.2 7.3 23.1 12.7 12.9 6.2 30.7 32.2 20.0 40.5 13.1 21.4 15.2 32.6 19.1 29.8 8.4 16.0 21.3 10.9 9.8 28.0 13.6 17.3 42.6 13.9 13.4 19.9 16.0 23.2 25.5 21.7 20.1 27.7 11.5 14.6 44.6 14.4 26.3 20.6 6.7 8.1 3.5 8.7 6.3 10.9 12.6 10.8 8.8 5.9 17.0 11.3 10.3 7.1 11.5 11.5 13.9 7.4 2.3 16.0 22.0 16.5 23.1 20.8 15.2 16.6 18.2 17.3 15.9 PRL ENSG00000172179 Prolactin P01236 6 22287244-22297501 "Cancer-related genes, Plasma proteins, Predicted secreted proteins" Lactation Hormone "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 81 "pituitary gland: 1739.5" "Cell line enhanced" "Detected in some" "Daudi: 17.6;SCLC-21H: 6.6;U-937: 3.1" "Not detected" "Not detected" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "naive CD8 T-cell: 1.2;non-classical monocyte: 1.0" "Group enriched" "Detected in many" 12 "monocytes: 1.0;T-cells: 1.2" "Not detected" "Not detected" "CAB023353, HPA042416, HPA062017" Enhanced "Secreted to blood" 75460000 3300000 "CAB023353: AB_617369, HPA042416: AB_2677987, HPA062017: AB_2684660" "unprognostic (1.66e-1)" "unprognostic (4.08e-3)" "unprognostic (5.89e-3)" "unprognostic (4.83e-3)" "unprognostic (2.87e-1)" "unprognostic (1.11e-4)" "unprognostic (4.54e-1)" "unprognostic (1.57e-1)" "unprognostic (3.79e-2)" "unprognostic (4.29e-5)" "unprognostic (2.20e-1)" 0.2 0.0 0.0 0.9 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 7.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1739.5 21.5 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 1.6 0.0 0.0 0.0 1.3 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 1.0 0.0 1.2 0.6 0.0 0.0 0.1 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 17.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.6 0.0 0.3 0.0 0.2 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 3.1 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 1.2 0.0 0.0 1.0 0.0 0.0 0.6 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.6 0.0 PROC ENSG00000115718 "Protein C, inactivator of coagulation factors Va and VIIIa" P04070 2 127418427-127429246 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Blood coagulation, Hemostasis" "Hydrolase, Protease, Serine protease" "Cancer-related genes, Disease mutation, FDA approved drug targets, Thrombophilia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "liver: 137.5" "Cell line enriched" "Detected in some" 16 "Hep G2: 57.5" "Cancer enriched" "Detected in many" 22 "liver cancer: 118.3" "Not detected" "Not detected" "Cell type enriched" "Detected in some" 9 "plasmacytoid DC: 29.2" "Lineage enriched" "Detected in many" 9 "dendritic cells: 29.2" "Not detected" "Not detected" "Not detected" "Not detected" "HPA005550, CAB016721, CAB016792" Supported "Secreted to blood" 6400000000 "CAB016721: , CAB016792: , HPA005550: AB_1079687" "unprognostic (2.46e-2)" "unprognostic (1.08e-1)" "unprognostic (1.38e-1)" "unprognostic (1.58e-1)" "unprognostic (6.64e-2)" "unprognostic (3.13e-2)" "unprognostic (4.90e-3)" "unprognostic (2.63e-1)" "unprognostic (1.67e-1)" "unprognostic (3.29e-1)" "unprognostic (3.74e-3)" "unprognostic (2.56e-2)" "unprognostic (8.12e-3)" "unprognostic (2.01e-2)" "unprognostic (1.71e-1)" "unprognostic (4.60e-3)" "unprognostic (8.06e-2)" 0.0 0.0 0.4 0.1 0.1 0.2 0.0 0.1 0.2 0.1 0.2 0.0 0.1 0.2 0.0 0.1 0.0 0.0 0.6 0.0 0.4 0.2 4.2 137.5 0.2 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.4 0.1 0.1 0.0 0.0 0.1 0.0 0.1 0.5 0.0 0.1 0.0 0.6 0.0 0.0 0.7 0.0 0.0 0.1 0.1 0.0 0.4 29.2 3.1 0.0 0.0 0.0 0.1 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 1.5 0.0 0.3 0.0 3.6 0.0 0.1 0.0 0.0 0.0 0.0 2.7 57.5 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.6 0.1 0.2 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.1 0.0 0.0 0.0 3.1 0.0 0.0 29.2 0.0 0.1 0.4 0.1 0.1 0.2 0.4 0.2 0.1 0.1 0.4 0.0 PRPF8 "hPrp8, Prp8, PRPC8, RP13, SNRNP220" ENSG00000174231 "Pre-mRNA processing factor 8" Q6P2Q9 17 1650629-1684882 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "mRNA processing, mRNA splicing" "Ribonucleoprotein, RNA-binding" "Cancer-related genes, Disease mutation, Retinitis pigmentosa" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009941, CAB015457" Supported Enhanced Nucleoplasm 240000 Nucleoplasm "CAB009941: AB_2171185, CAB015457: AB_831685" "unprognostic (1.23e-1)" "unprognostic (1.49e-1)" "unprognostic (2.76e-2)" "unprognostic (3.13e-2)" "unprognostic (1.56e-1)" "unprognostic (4.94e-2)" "unprognostic (6.58e-2)" "unprognostic (1.56e-1)" "unprognostic (4.19e-2)" "unprognostic (1.77e-1)" "unprognostic (2.69e-2)" "unprognostic (1.04e-1)" "unprognostic (2.45e-3)" "unprognostic (2.00e-1)" "unprognostic (2.66e-1)" "unprognostic (1.16e-1)" "unprognostic (1.23e-1)" 30.0 37.4 23.1 25.7 40.3 39.0 26.2 43.1 57.2 31.2 28.0 36.5 29.5 19.4 35.6 28.4 29.4 35.4 28.1 34.0 22.2 24.3 23.3 35.5 27.9 30.7 21.3 23.9 47.7 25.9 66.5 45.4 31.1 32.5 30.7 27.2 45.1 30.5 33.1 46.3 30.7 27.5 36.3 17.9 34.1 26.4 45.9 19.6 63.4 30.9 22.2 41.2 32.2 27.9 14.5 20.1 10.0 12.3 10.1 17.1 5.4 18.4 40.2 24.2 19.6 21.0 16.4 19.5 13.8 17.7 27.1 21.9 37.3 9.1 27.1 14.7 24.8 25.7 59.1 23.7 31.3 17.1 37.9 21.5 34.9 31.8 12.3 25.4 23.9 15.6 15.2 34.9 24.4 23.8 21.2 21.6 19.4 20.1 18.3 31.8 16.7 14.9 36.0 13.8 13.0 10.4 20.5 12.4 18.7 27.8 10.1 13.6 14.9 17.0 21.9 16.5 14.2 25.2 31.5 7.9 8.1 19.1 13.7 18.4 20.4 10.0 6.5 6.7 15.7 8.9 17.1 13.3 14.7 15.7 9.7 14.5 13.0 16.4 7.1 10.1 12.3 20.1 14.8 5.4 23.1 40.3 43.1 57.2 22.2 24.3 21.3 23.9 32.5 19.6 PRRX1 "PHOX1, PMX1" ENSG00000116132 "Paired related homeobox 1" P54821 1 170662728-170739419 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Developmental protein, DNA-binding" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in some" "ASC diff: 72.3;ASC TERT1: 57.7;BJ hTERT+: 40.4;HSkMC: 29.4;U-138 MG: 28.3;U-2197: 27.0" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "HPA051084, HPA063566" Uncertain Supported Nucleoplasm Nucleoplasm "HPA051084: , HPA063566: " "unprognostic (2.03e-1)" "unprognostic (2.00e-1)" "unprognostic (1.09e-1)" "unprognostic (7.00e-2)" "unprognostic (1.24e-1)" "unprognostic (4.97e-2)" "unprognostic (2.52e-2)" "unprognostic (1.88e-2)" "unprognostic (2.94e-3)" "unprognostic (1.13e-1)" "unprognostic (1.98e-2)" "unprognostic (3.29e-1)" "prognostic unfavourable (6.60e-10)" "unprognostic (4.23e-3)" "unprognostic (4.48e-2)" "unprognostic (2.68e-3)" "unprognostic (1.69e-3)" 44.8 4.4 5.2 7.2 6.3 0.0 21.0 4.0 9.2 58.5 4.1 6.7 10.6 0.4 31.4 19.4 10.8 17.9 14.5 19.5 6.8 4.5 1.8 0.7 10.4 13.0 6.1 5.3 27.6 1.9 3.4 3.1 2.7 7.7 17.3 2.5 17.4 18.4 34.1 58.6 11.9 2.2 23.0 6.6 1.0 2.3 17.6 6.8 5.0 21.7 28.7 14.9 19.4 31.2 0.0 0.6 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.4 0.0 72.3 57.7 0.0 20.5 40.4 2.9 2.9 0.0 0.0 0.0 0.0 16.8 0.0 3.5 0.0 0.9 0.0 0.0 0.0 0.3 0.0 0.2 0.0 0.0 29.4 0.0 14.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 28.3 0.5 27.0 3.1 0.0 0.0 0.0 14.9 0.0 5.7 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 5.2 6.3 4.0 3.9 6.8 4.5 6.1 5.3 7.7 6.8 PRSS1 TRY1 ENSG00000204983 "Serine protease 1" P07477 7 142749468-142753076 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" Digestion "Hydrolase, Protease, Serine protease" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 1708 "pancreas: 3057.4" "Cell line enhanced" "Detected in some" "EFO-21: 3.5;HDLM-2: 1.7;RPMI-8226: 6.9;U-2 OS: 4.1;U-251 MG: 1.5;U-266/84: 2.5" "Cancer enriched" "Detected in many" 224 "pancreatic cancer: 1920.3" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "basophil: 1.7" "Low lineage specificity" "Detected in many" "CAB025487, CAB025538, HPA062452, HPA063471" Enhanced Approved "Endoplasmic reticulum,Vesicles" "Secreted to digestive system" 26000000000 Vesicles "Endoplasmic reticulum" "CAB025487: , CAB025538: , HPA062452: , HPA063471: " "unprognostic (6.55e-5)" "unprognostic (5.28e-1)" "unprognostic (7.58e-2)" "prognostic unfavourable (6.41e-6)" "unprognostic (8.26e-2)" "prognostic favourable (7.05e-4)" "unprognostic (1.35e-1)" "unprognostic (3.93e-2)" "unprognostic (1.96e-1)" "prognostic favourable (4.91e-4)" "unprognostic (3.12e-1)" 0.4 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.2 0.1 0.1 0.2 0.2 0.2 0.2 0.1 0.1 0.0 0.1 0.4 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 1.6 3057.4 0.0 0.1 0.1 0.1 0.2 0.0 0.1 0.4 0.2 0.1 0.0 0.4 0.1 0.1 0.1 0.5 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 1.0 0.0 1.7 0.0 0.0 0.9 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 3.5 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 6.9 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.1 0.0 1.5 0.0 2.5 0.6 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 1.0 0.9 0.0 0.0 0.8 0.3 0.0 0.0 0.0 0.0 0.0 0.6 0.1 0.1 0.1 0.1 0.2 0.1 0.0 0.1 0.1 0.1 0.1 PSCA ENSG00000167653 "Prostate stem cell antigen" O43653 8 142670308-142682724 "Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "esophagus: 72.6;stomach 1: 230.2;urinary bladder: 112.0" "Cell line enhanced" "Detected in some" "CAPAN-2: 11.5;HeLa: 22.2;RT4: 31.8;SK-BR-3: 8.1" "Cancer enriched" "Detected in many" 6 "urothelial cancer: 785.0" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "HPA030783, HPA056418" Approved Supported "Plasma membrane" "Plasma membrane" "HPA030783: , HPA056418: " "unprognostic (1.21e-3)" "unprognostic (1.76e-3)" "unprognostic (3.20e-1)" "unprognostic (2.24e-1)" "unprognostic (1.77e-2)" "unprognostic (7.57e-2)" "unprognostic (1.93e-2)" "unprognostic (7.81e-3)" "unprognostic (8.25e-3)" "unprognostic (2.13e-1)" "prognostic unfavourable (5.60e-5)" "unprognostic (6.82e-2)" "unprognostic (2.38e-3)" "unprognostic (4.93e-2)" "unprognostic (2.68e-1)" "unprognostic (3.07e-1)" "unprognostic (1.06e-3)" 0.4 0.2 0.0 0.2 0.0 0.2 0.3 0.0 0.2 7.0 2.4 0.7 0.1 0.6 0.3 0.2 72.6 1.1 21.2 0.1 0.0 0.0 2.6 0.1 3.0 0.2 0.0 0.0 0.1 0.3 0.1 0.5 17.2 0.0 30.1 0.7 0.1 11.7 0.6 0.1 0.8 1.5 18.9 0.0 0.2 230.2 0.2 0.0 0.0 0.1 9.3 35.1 112.0 54.5 0.0 0.8 0.0 0.3 0.0 0.0 0.0 5.3 0.3 0.0 0.0 1.1 3.7 5.5 2.5 0.5 1.1 0.9 0.0 11.5 0.0 0.2 0.2 1.1 0.0 0.2 0.6 0.3 0.0 0.0 22.2 0.0 0.0 0.0 0.7 3.2 4.1 2.4 0.0 0.0 0.0 0.0 0.8 2.9 0.8 0.3 0.6 0.6 0.3 0.0 0.4 0.5 31.8 0.1 0.2 2.6 8.1 1.7 0.1 0.1 0.5 0.8 0.9 1.5 0.0 1.0 0.0 0.0 1.5 0.4 0.4 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 PSEN1 "AD3, FAD, PS1, S182" ENSG00000080815 "Presenilin 1" P49768 14 73136418-73223691 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Apoptosis, Cell adhesion, Notch signaling pathway" "Hydrolase, Protease" "Alzheimer disease, Amyloidosis, Cancer-related genes, Cardiomyopathy, Disease mutation, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB006844, HPA030760, HPA067496" Approved Approved "Nucleoplasm,Golgi apparatus,Cell Junctions" "Golgi apparatus" "Nucleoplasm, Cell Junctions" "CAB006844: , HPA030760: AB_10696211, HPA067496: " "unprognostic (1.67e-1)" "unprognostic (4.79e-2)" "unprognostic (7.39e-2)" "unprognostic (8.68e-3)" "unprognostic (3.84e-1)" "unprognostic (5.48e-3)" "prognostic unfavourable (1.99e-5)" "unprognostic (1.65e-1)" "unprognostic (8.99e-2)" "unprognostic (8.45e-2)" "unprognostic (1.76e-3)" "unprognostic (2.74e-1)" "prognostic favourable (1.52e-8)" "unprognostic (2.29e-1)" "unprognostic (2.32e-1)" "unprognostic (7.12e-3)" "unprognostic (1.85e-1)" 16.3 15.3 21.0 13.4 34.9 19.2 15.7 15.5 24.7 16.5 26.2 66.1 9.5 26.6 14.2 15.4 19.0 12.6 17.1 9.9 28.6 18.2 19.7 16.9 16.9 10.8 42.1 20.7 13.5 15.0 21.8 9.2 22.7 31.8 13.6 25.6 15.0 16.8 13.4 13.0 24.7 27.9 14.6 61.9 14.6 16.3 16.8 39.7 15.4 19.7 8.7 15.9 17.2 13.5 9.0 24.4 38.1 34.0 11.7 10.5 17.1 14.2 21.9 20.5 8.1 28.7 20.5 18.7 21.0 24.1 21.5 27.2 27.2 35.7 9.3 13.9 19.9 38.0 17.2 15.9 23.6 21.2 10.7 10.6 14.9 13.2 26.5 10.7 20.8 21.0 28.9 17.8 22.0 17.2 11.8 19.0 20.1 28.3 8.1 13.9 8.9 16.3 10.3 17.4 11.8 30.0 30.3 11.4 15.2 22.9 21.5 18.7 26.6 23.9 18.2 21.9 18.1 17.9 9.9 12.4 18.2 9.4 18.4 13.0 13.3 29.2 27.1 27.1 7.2 30.8 7.0 7.2 7.0 5.9 24.4 9.0 6.6 6.4 38.1 11.7 34.0 12.8 10.5 17.1 21.0 34.9 15.5 24.7 28.6 18.2 42.1 20.7 31.8 39.7 PSIP1 "DFS70, LEDGF, p52, p75, PSIP2" ENSG00000164985 "PC4 and SFRS1 interacting protein 1" O75475 9 15464066-15511019 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction, Transcription, Transcription regulation" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HEL: 130.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB013718, HPA019697" Enhanced Enhanced Nucleoplasm Nucleoplasm "CAB013718: , HPA019697: AB_1852779" "unprognostic (8.54e-2)" "unprognostic (3.70e-2)" "unprognostic (1.31e-1)" "unprognostic (3.29e-2)" "unprognostic (1.22e-1)" "unprognostic (2.23e-1)" "unprognostic (2.89e-3)" "unprognostic (5.10e-2)" "unprognostic (5.93e-2)" "unprognostic (2.53e-2)" "unprognostic (6.49e-3)" "unprognostic (5.49e-2)" "unprognostic (6.98e-2)" "unprognostic (2.04e-1)" "unprognostic (2.99e-1)" "unprognostic (7.14e-2)" "unprognostic (1.39e-1)" 15.1 20.3 42.7 20.8 48.8 24.9 12.2 65.3 49.4 22.6 16.1 19.0 11.5 10.8 27.9 18.2 12.9 20.0 14.9 16.0 38.7 42.7 16.1 10.5 15.6 35.4 34.1 30.2 43.6 8.1 18.8 24.9 18.7 32.4 18.3 15.3 12.3 9.0 21.1 16.3 12.3 14.2 21.3 37.7 24.6 12.5 37.2 29.3 70.4 18.1 6.5 31.9 17.0 16.1 11.4 2.6 8.5 4.3 8.0 16.4 1.9 17.6 11.7 40.0 29.2 8.6 10.5 8.9 21.3 15.2 19.2 22.8 4.9 9.2 37.6 4.9 11.2 4.9 24.8 11.5 27.8 24.7 15.0 130.0 30.7 9.1 10.5 15.1 14.4 8.8 3.4 16.0 11.8 16.7 21.4 20.9 12.4 6.4 31.3 37.7 62.0 18.2 29.3 21.8 7.6 10.7 6.2 25.4 28.0 19.0 8.4 9.9 8.5 20.4 11.8 14.0 14.1 10.4 20.1 9.0 12.6 33.9 11.1 15.3 8.0 8.5 2.1 4.2 5.5 1.6 6.7 8.4 11.0 7.6 2.4 11.4 16.4 10.1 7.2 8.0 4.3 2.6 9.8 1.9 42.7 48.8 65.3 46.6 38.7 42.7 34.1 30.2 32.4 29.3 PSMD4 "AF, AF-1, Rpn10, S5A" ENSG00000159352 "Proteasome 26S subunit, non-ATPase 4" P55036 1 151254703-151267479 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA038807, HPA039252, CAB047300" Enhanced Enhanced Nucleoplasm,Cytosol Nucleoplasm Cytosol "CAB047300: , HPA038807: AB_2676217, HPA039252: AB_10673418" "unprognostic (3.83e-2)" "unprognostic (7.89e-2)" "unprognostic (6.86e-3)" "unprognostic (1.70e-1)" "unprognostic (2.63e-1)" "unprognostic (2.89e-2)" "unprognostic (1.79e-3)" "unprognostic (2.16e-1)" "unprognostic (2.81e-1)" "unprognostic (2.61e-2)" "unprognostic (7.57e-2)" "unprognostic (2.11e-1)" "prognostic unfavourable (6.66e-10)" "unprognostic (9.80e-2)" "unprognostic (6.60e-2)" "unprognostic (2.03e-2)" "unprognostic (3.91e-1)" 27.5 28.0 44.3 24.4 46.4 25.5 29.9 25.7 50.4 21.9 28.6 28.3 16.5 22.7 25.1 41.5 26.7 31.4 21.8 38.7 37.5 36.8 25.3 44.7 20.2 28.2 47.5 44.8 26.7 27.7 27.4 19.3 30.0 43.2 23.0 28.1 24.3 25.6 31.2 86.7 28.0 20.5 39.3 29.6 26.3 25.8 35.9 29.1 23.1 23.7 25.7 36.2 28.0 19.8 62.7 65.1 111.6 76.0 54.2 74.2 88.2 41.8 50.5 37.3 30.5 40.7 30.2 40.7 28.5 34.9 45.5 36.3 66.0 48.0 34.1 69.9 40.1 43.9 47.9 43.0 38.9 55.5 41.8 33.2 43.0 68.0 45.0 39.0 38.8 32.7 35.8 51.9 48.0 39.6 51.7 43.3 38.1 123.6 35.9 47.5 70.9 51.1 30.5 36.3 61.5 44.6 36.0 29.3 50.0 31.6 46.4 37.6 48.5 77.2 34.8 22.7 35.7 27.8 48.5 51.9 64.5 72.7 37.6 36.8 41.3 59.6 71.5 111.6 43.0 76.0 48.4 62.7 50.5 47.3 65.1 61.1 46.4 46.0 95.8 54.2 75.5 39.2 74.2 88.2 44.3 46.4 25.7 50.4 37.5 36.8 47.5 44.8 43.2 29.1 PTCH1 "BCNS, NBCCS, PTCH" ENSG00000185920 "Patched 1" Q13635 9 95442980-95517057 "Cancer-related genes, Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" Receptor "Cancer-related genes, Disease mutation, Holoprosencephaly, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "NTERA-2: 15.5;WM-115: 37.0" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "gdT-cell: 8.9" "Lineage enriched" "Detected in many" 8 "T-cells: 8.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB013717, HPA075072" Uncertain Approved "Golgi apparatus" "Golgi apparatus" "CAB013717: , HPA075072: " "unprognostic (1.46e-1)" "unprognostic (1.06e-1)" "unprognostic (3.16e-1)" "unprognostic (1.79e-2)" "unprognostic (3.22e-2)" "unprognostic (9.01e-2)" "unprognostic (2.13e-1)" "unprognostic (3.54e-3)" "unprognostic (2.63e-1)" "unprognostic (8.66e-3)" "unprognostic (1.52e-2)" "unprognostic (2.82e-1)" "unprognostic (1.13e-6)" "unprognostic (8.63e-2)" "unprognostic (4.40e-2)" "unprognostic (2.76e-1)" "unprognostic (2.82e-1)" 4.1 3.8 6.7 6.0 9.5 0.7 7.9 21.0 6.4 28.5 12.5 6.1 8.0 7.8 16.2 4.2 3.0 7.4 13.2 2.8 7.0 6.6 4.9 2.2 7.1 4.5 9.5 3.2 5.2 10.8 3.4 4.0 3.7 6.9 6.9 12.3 11.2 6.9 9.5 2.7 4.3 10.9 8.5 5.1 3.8 12.1 14.3 7.9 1.0 6.3 1.9 3.2 11.3 6.9 1.0 0.0 0.0 0.0 0.3 8.9 1.8 5.0 2.4 10.7 6.7 1.6 2.7 6.1 1.0 0.9 1.2 0.7 2.5 2.5 4.1 1.7 1.9 11.6 6.1 0.8 0.7 4.0 4.0 0.0 2.5 1.1 1.4 0.1 2.2 2.5 1.2 1.1 0.7 2.2 3.6 4.7 0.5 1.0 0.0 1.5 15.5 0.9 0.0 8.2 2.1 0.8 0.7 7.3 3.7 3.6 3.6 1.6 0.9 1.0 0.5 1.4 7.0 7.1 0.7 9.5 8.2 2.7 2.0 2.0 37.0 0.0 0.0 0.0 8.9 0.0 5.3 1.0 1.7 3.8 0.0 0.3 2.8 3.2 0.0 0.3 0.0 0.0 1.4 1.8 6.7 9.5 21.0 6.4 7.0 6.6 9.5 3.2 6.9 7.9 PTEN "BZS, MHAM, MMAC1, PTEN1, TEP1" ENSG00000171862 "Phosphatase and tensin homolog" P60484 10 87863113-87971930 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins" "Apoptosis, Lipid metabolism, Neurogenesis" "Hydrolase, Protein phosphatase" "Autism spectrum disorder, Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "neutrophil: 29.6" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004076, HPA031335" Approved Supported Nucleoplasm,Cytosol "Secreted - unknown location" Nucleoplasm Cytosol "CAB004076: AB_390810, HPA031335: " "unprognostic (8.72e-2)" "unprognostic (2.45e-1)" "unprognostic (5.43e-1)" "unprognostic (1.50e-2)" "unprognostic (3.71e-2)" "unprognostic (1.30e-1)" "unprognostic (2.18e-1)" "unprognostic (2.08e-1)" "unprognostic (2.07e-1)" "unprognostic (6.87e-2)" "unprognostic (9.77e-2)" "unprognostic (2.71e-1)" "prognostic unfavourable (7.35e-4)" "unprognostic (1.57e-1)" "unprognostic (2.73e-1)" "unprognostic (6.54e-3)" "unprognostic (2.41e-1)" 42.4 24.1 17.7 20.9 17.7 13.5 32.8 39.9 19.7 43.1 26.7 9.9 19.0 15.1 29.8 22.8 26.8 30.3 21.0 19.1 16.0 17.4 19.6 32.4 27.2 30.4 15.7 19.5 29.1 21.3 16.4 23.6 36.4 14.2 35.3 17.7 21.6 16.8 20.8 16.8 20.4 25.4 26.0 11.7 40.9 17.8 18.7 12.5 49.7 25.2 13.3 18.6 29.6 30.9 4.3 5.1 29.6 11.0 4.3 4.7 2.0 10.4 4.9 5.7 5.1 13.1 9.0 5.1 5.6 12.5 6.6 9.3 5.0 12.9 12.3 3.8 9.2 6.3 7.5 6.4 10.5 6.2 2.1 4.1 12.8 6.1 14.0 13.8 7.1 6.1 17.9 8.3 10.8 9.3 3.1 33.6 6.0 8.0 7.7 25.1 2.1 0.0 12.0 3.0 9.1 10.3 6.0 2.0 9.2 7.5 3.5 9.4 9.9 20.0 8.1 21.9 5.1 8.5 4.5 11.1 14.3 14.1 6.8 13.1 1.3 8.3 7.9 12.2 3.6 11.0 3.9 4.3 4.0 3.5 5.1 3.7 4.7 4.5 29.6 4.3 7.2 4.2 3.5 2.0 17.7 17.7 39.9 19.7 16.0 17.4 15.7 19.5 14.2 12.5 PTGS1 "COX1, PGHS-1, PTGHS" ENSG00000095303 "Prostaglandin-endoperoxide synthase 1" P23219 9 122370530-122395703 "Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism, Prostaglandin biosynthesis, Prostaglandin metabolism" "Dioxygenase, Oxidoreductase, Peroxidase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "smooth muscle: 211.4;urinary bladder: 163.9" "Cell line enhanced" "Detected in some" "ASC diff: 28.1;ASC TERT1: 22.3;BJ: 27.3;BJ hTERT+: 37.3;HEL: 17.1;HMC-1: 72.7" "Cancer enhanced" "Detected in all" "ovarian cancer: 53.4" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Group enriched" "Detected in many" 5 "dendritic cells: 13.0;granulocytes: 14.4;monocytes: 8.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002834, CAB020315" Enhanced Supported "Golgi apparatus,Vesicles" "Intracellular and membrane" 25000000 "Golgi apparatus" Vesicles "CAB020315: , HPA002834: AB_1079711" "unprognostic (4.20e-1)" "unprognostic (6.23e-2)" "unprognostic (1.08e-2)" "unprognostic (2.27e-2)" "unprognostic (5.88e-2)" "unprognostic (2.00e-2)" "unprognostic (1.22e-3)" "unprognostic (3.32e-1)" "unprognostic (2.24e-1)" "unprognostic (3.16e-2)" "unprognostic (1.23e-1)" "unprognostic (1.46e-1)" "prognostic unfavourable (8.68e-4)" "unprognostic (4.03e-2)" "unprognostic (1.78e-2)" "unprognostic (2.08e-1)" "prognostic unfavourable (9.35e-4)" 4.5 1.1 1.8 9.1 3.1 2.6 2.5 0.5 2.7 2.6 35.3 4.6 3.0 3.9 2.5 1.6 25.7 16.7 9.4 4.9 1.9 1.6 3.9 1.8 4.0 1.4 3.5 0.7 3.6 1.0 0.7 2.4 0.8 2.5 60.9 9.3 1.5 1.9 2.3 0.7 55.9 6.5 211.4 4.9 3.6 7.8 1.0 3.1 0.4 1.5 5.3 4.2 163.9 19.5 2.5 13.0 14.4 8.5 1.9 0.1 13.7 0.0 0.1 0.1 0.0 28.1 22.3 0.0 27.3 37.3 0.2 0.2 0.0 0.0 0.9 1.3 4.6 1.7 0.0 2.5 0.2 0.0 0.0 17.1 0.1 0.0 8.1 1.1 72.7 11.4 0.2 1.4 0.0 10.1 0.0 0.0 0.5 0.0 0.0 1.5 0.3 0.1 0.0 0.3 2.0 3.5 0.0 0.1 0.1 0.1 2.3 0.0 0.0 1.9 0.2 0.1 0.1 0.4 0.0 0.0 0.0 0.0 0.1 7.4 0.0 12.0 7.6 14.4 0.0 8.5 0.0 1.7 0.0 0.0 13.0 2.5 0.0 0.0 3.5 1.9 6.1 0.9 0.1 13.7 1.8 3.1 0.5 2.7 1.9 1.6 3.5 0.7 2.5 3.1 PTGS2 COX2 ENSG00000073756 "Prostaglandin-endoperoxide synthase 2" P35354 1 186671791-186680427 "Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism, Prostaglandin biosynthesis, Prostaglandin metabolism" "Dioxygenase, Oxidoreductase, Peroxidase, Transferase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 11 "ductus deferens: 324.6;seminal vesicle: 377.9" "Cell line enriched" "Detected in some" 4 "BJ hTERT+: 93.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 16 "neutrophil: 12.8" "Lineage enriched" "Detected in single" 16 "granulocytes: 12.8" "Region enhanced" "Detected in many" "hippocampal formation: 16.5" "Low region specificity" "Detected in many" "CAB000113, HPA001335" Approved Supported "Endoplasmic reticulum" "Intracellular and membrane" "Endoplasmic reticulum" "CAB000113: , HPA001335: AB_1079712" "unprognostic (1.36e-3)" "unprognostic (9.97e-3)" "unprognostic (3.97e-2)" "unprognostic (3.31e-2)" "unprognostic (1.55e-1)" "unprognostic (1.11e-1)" "unprognostic (5.96e-2)" "unprognostic (9.50e-2)" "unprognostic (9.03e-3)" "unprognostic (2.81e-1)" "unprognostic (3.24e-2)" "unprognostic (3.07e-2)" "prognostic unfavourable (9.79e-4)" "unprognostic (8.04e-3)" "unprognostic (4.38e-2)" "unprognostic (8.89e-2)" "unprognostic (3.74e-2)" 5.7 2.1 1.2 3.7 1.1 32.6 1.5 0.8 1.9 21.1 11.4 1.1 324.6 0.4 2.3 1.8 1.7 4.0 9.5 9.1 1.1 1.0 3.3 2.7 22.1 2.3 1.3 0.8 1.6 0.4 3.1 2.2 2.5 1.9 9.2 2.7 3.9 0.9 377.9 1.0 1.1 2.4 7.7 4.7 0.9 11.4 1.0 0.9 0.6 1.5 3.4 1.3 17.3 1.9 0.0 0.5 12.8 0.8 0.0 0.0 0.0 0.0 4.9 0.0 0.0 0.5 0.5 0.0 21.3 93.1 0.1 0.8 3.3 3.9 0.0 0.0 0.1 2.8 0.0 1.7 0.3 0.0 0.0 0.1 0.5 0.0 3.1 0.0 0.1 0.2 0.6 2.6 6.7 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.3 0.0 0.2 0.0 0.2 0.0 0.1 0.3 4.5 0.1 3.1 0.1 0.0 0.0 0.0 6.5 0.1 0.5 0.0 0.4 0.3 0.0 0.8 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 12.8 0.0 0.4 0.0 0.0 0.0 1.2 1.1 0.8 1.9 1.1 1.0 1.3 0.8 1.9 0.9 PTH PTH1 ENSG00000152266 "Parathyroid hormone" P01270 11 13492055-13496181 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins" Hormone "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 7 "parathyroid gland: 963.9" "Cell line enhanced" "Detected in single" "U-2197: 1.0" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "CAB000072, CAB023409, CAB026363, HPA048540" Enhanced "Secreted to blood" 27980 "CAB000072: , CAB023409: AB_619175, CAB026363: , HPA048540: " 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 963.9 0.0 0.0 0.0 0.0 0.0 0.0 3.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 129.7 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 PTHLH "HHM, PLP, PTHR, PTHRP" ENSG00000087494 "Parathyroid hormone like hormone" P12272 12 27958084-27972705 "Cancer-related genes, Disease related genes, Predicted secreted proteins" Hormone "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "gallbladder: 45.6" "Group enriched" "Detected in some" 4 "HaCaT: 63.2;HBEC3-KT: 78.1" "Cancer enhanced" "Detected in many" "head and neck cancer: 64.0" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 7 "T-reg: 3.0" "Lineage enriched" "Detected in single" 30 "T-cells: 3.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA035982 Approved Approved Supported "Nucleoplasm,Golgi apparatus,Cytosol" "Secreted in other tissues" "Nucleoplasm, Cytosol" "Golgi apparatus" "HPA035982: AB_10794631" "unprognostic (1.67e-1)" "unprognostic (5.26e-3)" "unprognostic (1.31e-1)" "unprognostic (4.41e-2)" "unprognostic (2.11e-1)" "unprognostic (1.13e-1)" "prognostic unfavourable (3.37e-4)" "unprognostic (1.60e-2)" "unprognostic (1.18e-1)" "unprognostic (5.16e-2)" "unprognostic (4.09e-3)" "unprognostic (3.84e-1)" "prognostic unfavourable (1.82e-9)" "unprognostic (2.01e-2)" "unprognostic (1.34e-1)" "unprognostic (5.23e-3)" "unprognostic (7.87e-3)" 2.9 1.0 6.5 3.5 5.3 0.0 20.2 1.4 8.7 11.0 2.3 1.4 2.1 2.4 11.2 2.0 17.0 1.2 45.6 4.0 4.3 3.5 0.4 0.2 1.3 1.1 1.4 4.3 2.6 1.7 0.7 2.3 3.6 3.1 5.5 1.8 2.4 5.3 2.6 0.7 1.5 1.6 13.4 0.8 3.6 1.9 1.3 1.0 0.1 1.4 15.8 3.4 8.0 12.3 0.0 0.0 0.0 0.0 0.0 3.0 0.1 0.3 2.1 0.0 0.0 0.6 0.6 0.0 0.0 0.2 0.1 0.2 0.0 1.7 0.0 0.1 0.5 63.2 0.2 78.1 0.0 1.5 0.3 0.1 0.4 0.0 0.1 0.0 0.1 0.0 4.3 2.0 7.7 2.4 0.0 0.0 0.0 0.0 0.0 0.0 0.3 3.6 0.0 0.3 0.1 7.6 0.0 0.0 0.0 3.5 0.0 0.4 0.1 0.0 1.2 0.3 1.9 1.1 16.6 1.0 0.0 2.5 1.6 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.0 0.1 6.5 5.3 1.4 6.2 4.3 3.5 1.4 4.3 3.1 1.0 PTK2 "FADK, FAK, FAK1, PPP1R71" ENSG00000169398 "Protein tyrosine kinase 2" Q05397 8 140657900-141002216 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" Angiogenesis "Developmental protein, Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001842, CAB004036, HPA029671" Approved Supported "Vesicles,Focal adhesion sites,Cytosol" 32000 "Focal adhesion sites" "Vesicles, Cytosol" "CAB004036: AB_2269034, HPA001842: AB_1855891, HPA029671: AB_10610288" "prognostic unfavourable (3.21e-4)" "unprognostic (3.86e-2)" "unprognostic (1.95e-1)" "prognostic unfavourable (9.11e-4)" "unprognostic (1.93e-1)" "unprognostic (2.28e-1)" "unprognostic (3.02e-2)" "unprognostic (1.27e-1)" "unprognostic (1.97e-1)" "unprognostic (2.96e-2)" "unprognostic (1.06e-2)" "unprognostic (2.38e-1)" "unprognostic (2.80e-2)" "unprognostic (2.94e-2)" "unprognostic (1.11e-1)" "unprognostic (1.53e-1)" "unprognostic (2.90e-2)" 22.6 20.4 36.0 14.4 42.3 3.1 19.3 20.5 40.8 24.9 17.9 55.7 23.5 14.5 20.2 29.9 14.6 18.7 18.4 20.0 43.5 23.9 22.3 17.0 21.5 13.0 41.4 31.4 19.4 18.2 33.1 13.0 42.1 30.0 19.2 20.7 11.0 21.9 25.5 17.9 13.5 16.3 21.9 38.0 12.2 17.5 21.2 46.1 2.8 22.5 10.2 14.0 22.2 17.8 8.6 7.2 1.8 3.9 5.2 5.7 4.1 14.6 23.4 32.5 11.7 13.7 14.7 21.0 14.5 20.2 13.6 13.4 10.2 12.2 8.9 33.0 18.6 17.4 19.1 33.3 20.6 0.1 8.9 19.7 12.9 14.0 18.7 0.0 9.4 10.0 16.4 17.0 24.0 40.1 19.8 0.2 18.2 25.5 0.2 0.2 12.6 26.2 13.1 17.8 0.4 28.7 33.5 12.9 16.1 22.7 7.3 14.7 17.2 0.3 24.2 13.4 25.3 15.8 16.3 0.0 0.1 0.9 17.4 0.1 18.1 1.8 3.9 0.0 0.3 1.6 0.0 6.8 0.8 0.1 5.3 8.6 5.7 2.0 1.7 5.2 0.9 7.2 0.2 4.1 36.0 42.3 20.5 40.8 43.5 23.9 41.4 31.4 30.0 46.1 PTK6 BRK ENSG00000101213 "Protein tyrosine kinase 6" Q13882 20 63528001-63537370 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "esophagus: 44.0;intestine: 24.2;skin 1: 24.2" "Cell line enhanced" "Detected in some" "A-431: 11.3;CAPAN-2: 21.8;HaCaT: 17.7;hTCEpi: 24.0;RT4: 13.8;T-47d: 13.3" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB032952, HPA036070, HPA036071" Approved Supported "Nucleoplasm,Nuclear bodies,Plasma membrane,Cytosol" "Nucleoplasm, Plasma membrane, Cytosol" "Nuclear bodies" "CAB032952: AB_634461, HPA036070: AB_10602292, HPA036071: AB_10669982" "unprognostic (2.32e-2)" "unprognostic (1.36e-1)" "unprognostic (1.05e-1)" "unprognostic (2.42e-2)" "unprognostic (1.41e-1)" "unprognostic (1.35e-1)" "unprognostic (1.04e-1)" "unprognostic (2.29e-1)" "unprognostic (3.03e-1)" "unprognostic (3.72e-2)" "prognostic unfavourable (1.96e-4)" "unprognostic (1.28e-1)" "prognostic unfavourable (1.26e-9)" "unprognostic (4.19e-2)" "unprognostic (1.74e-1)" "unprognostic (1.73e-1)" "unprognostic (4.24e-2)" 0.7 0.0 0.4 5.3 0.4 0.0 1.7 0.4 0.4 7.6 18.1 0.5 0.8 13.6 0.6 0.5 44.0 0.0 11.7 0.4 0.4 0.0 0.8 1.7 1.1 0.4 0.4 0.4 0.4 1.4 0.0 0.4 0.6 0.4 2.2 7.4 0.4 7.6 0.4 0.4 24.2 24.2 0.9 0.4 0.4 12.5 0.4 0.4 0.4 0.4 18.9 17.2 6.5 15.0 1.3 4.5 1.2 2.4 0.3 1.9 0.9 11.3 1.3 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 21.8 0.0 3.9 0.0 17.7 0.0 0.0 0.0 2.8 0.2 0.0 4.5 0.0 0.0 0.0 3.6 0.0 24.0 0.0 0.1 0.0 0.1 1.3 0.1 6.3 0.0 0.1 0.1 8.2 0.0 0.6 0.2 0.0 13.8 0.2 1.2 1.3 4.3 0.0 13.3 0.8 0.1 0.2 0.2 0.4 0.1 0.2 0.1 0.0 0.2 0.2 0.6 1.2 2.4 0.4 0.5 1.7 1.9 1.2 0.4 0.1 4.5 1.3 0.4 0.6 1.2 0.3 1.3 0.3 0.5 0.9 0.4 0.4 0.4 0.4 0.4 0.0 0.4 0.4 0.4 0.4 PTN "HBGF8, HBNF, NEGF1" ENSG00000105894 Pleiotrophin P21246 7 137227341-137343865 "Cancer-related genes, Predicted secreted proteins" "Growth factor, Heparin-binding, Mitogen" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "parathyroid gland: 160.7" "Cell line enriched" "Detected in some" 12 "AF22: 186.3" "Cancer enriched" "Detected in all" 11 "glioma: 514.1" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB017685, HPA073913" Enhanced Supported "Endoplasmic reticulum" "Secreted to blood" 166965 1800000 "Endoplasmic reticulum" "CAB017685: AB_1128556, HPA073913: " "unprognostic (1.51e-2)" "unprognostic (7.87e-2)" "unprognostic (5.44e-2)" "unprognostic (4.23e-2)" "unprognostic (1.92e-1)" "unprognostic (7.19e-2)" "unprognostic (2.81e-2)" "unprognostic (7.29e-2)" "unprognostic (1.30e-1)" "unprognostic (1.09e-2)" "unprognostic (3.86e-1)" "unprognostic (1.22e-2)" "prognostic favourable (1.35e-4)" "unprognostic (2.34e-1)" "unprognostic (1.18e-1)" "unprognostic (1.03e-1)" "unprognostic (1.16e-2)" 7.8 6.6 55.5 2.0 43.3 0.9 27.7 38.6 58.5 30.7 7.2 26.9 9.9 2.5 25.2 18.7 25.0 7.2 18.2 29.4 42.3 29.7 12.7 3.4 6.5 2.6 31.6 27.0 7.2 3.4 160.7 52.5 11.8 31.4 38.5 7.7 19.0 12.0 18.1 1.5 3.6 4.0 17.7 23.4 12.4 5.4 16.8 23.3 1.3 5.1 8.7 5.3 7.7 18.4 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.1 0.0 186.3 2.2 0.0 0.1 15.2 4.8 14.3 2.7 3.7 0.0 0.0 0.0 0.0 6.3 0.1 0.0 0.0 2.0 0.0 0.1 0.0 0.0 0.0 0.8 0.0 0.0 0.2 0.0 1.8 0.0 0.0 0.0 0.8 0.7 0.0 0.0 0.0 14.4 0.1 0.0 0.3 0.0 0.0 0.0 0.8 12.7 0.0 0.0 0.0 0.0 0.0 0.0 4.1 3.6 0.1 10.3 0.0 0.0 0.0 13.1 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 55.5 43.3 38.6 42.0 42.3 29.7 31.6 27.0 31.4 23.3 PTPN11 "BPTP3, NS1, PTP2C, SH-PTP2, SHP-2, SHP2" ENSG00000179295 "Protein tyrosine phosphatase, non-receptor type 11" Q06124 12 112418351-112509913 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins" "Hydrolase, Protein phosphatase" "Cancer-related genes, Deafness, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB005377 Approved Supported "Nucleoplasm,Nucleoli,Actin filaments,Cytosol" 160000 Nucleoli "Nucleoplasm, Actin filaments, Cytosol" "CAB005377: AB_632401" "unprognostic (2.18e-3)" "unprognostic (1.73e-3)" "unprognostic (5.62e-2)" "unprognostic (1.19e-1)" "unprognostic (1.63e-2)" "unprognostic (2.27e-1)" "unprognostic (6.05e-2)" "unprognostic (4.25e-2)" "unprognostic (3.55e-2)" "unprognostic (1.88e-1)" "unprognostic (2.22e-2)" "unprognostic (8.85e-2)" "unprognostic (3.75e-3)" "unprognostic (1.66e-1)" "unprognostic (2.46e-1)" "unprognostic (3.62e-2)" "unprognostic (1.80e-2)" 25.4 16.8 38.6 14.4 39.0 17.7 30.8 17.5 39.5 18.3 14.7 26.9 9.9 11.9 19.1 13.3 17.6 11.1 13.1 30.1 38.0 32.2 18.0 23.1 15.1 14.5 45.3 22.5 13.1 14.0 29.3 12.9 16.6 26.2 16.2 13.9 9.4 12.0 20.0 34.0 14.1 11.1 28.0 45.7 10.9 12.8 7.6 32.1 10.9 21.2 8.2 13.7 17.4 15.4 17.3 17.1 22.0 11.8 11.3 15.4 6.3 34.8 33.3 24.3 23.0 35.4 34.6 28.8 42.4 46.3 33.4 25.2 33.1 13.5 36.9 22.1 39.2 20.9 31.2 37.6 55.7 28.0 25.7 53.7 31.0 18.1 35.4 43.0 34.3 28.0 37.9 35.9 51.1 27.6 40.7 13.0 32.2 25.2 30.2 20.9 29.4 21.8 31.1 35.9 21.2 30.8 39.2 16.9 20.8 40.8 31.3 26.0 36.0 29.9 33.6 39.4 35.3 23.4 37.1 25.2 41.5 36.9 32.7 30.2 36.8 22.0 11.0 15.0 14.8 9.5 14.1 15.5 13.4 12.1 12.6 17.3 15.4 11.8 10.3 11.3 11.8 17.1 9.8 6.3 38.6 39.0 17.5 39.5 38.0 32.2 45.3 22.5 26.2 32.1 PTPN13 "PTP-BAS, PTP-BL, PTP1E, PTPL1" ENSG00000163629 "Protein tyrosine phosphatase, non-receptor type 13" Q12923 4 86594315-86815171 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Hydrolase, Protein phosphatase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "AF22: 44.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 6 "intermediate monocyte: 3.0;MAIT T-cell: 2.3;memory CD4 T-cell: 2.2;non-classical monocyte: 4.9" "Group enriched" "Detected in many" 7 "monocytes: 4.9;T-cells: 2.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002213, HPA063119" Approved Supported "Nucleoplasm,Nucleoli fibrillar center,Cytosol" Nucleoplasm "Nucleoli fibrillar center, Cytosol" "CAB002213: AB_564089, HPA063119: " "unprognostic (5.36e-2)" "unprognostic (4.46e-1)" "unprognostic (1.11e-1)" "unprognostic (2.54e-3)" "unprognostic (4.02e-1)" "unprognostic (9.03e-3)" "unprognostic (4.43e-2)" "unprognostic (4.38e-2)" "unprognostic (2.46e-1)" "unprognostic (7.05e-2)" "unprognostic (3.69e-2)" "unprognostic (1.46e-1)" "unprognostic (1.28e-3)" "unprognostic (3.95e-3)" "unprognostic (2.26e-1)" "unprognostic (2.66e-1)" "unprognostic (2.85e-2)" 10.3 5.9 10.8 2.7 16.9 0.7 9.9 5.7 11.6 15.9 4.1 13.0 7.6 1.2 10.8 21.2 18.7 11.4 6.5 5.3 10.4 5.7 22.1 1.6 18.0 4.3 16.9 7.9 24.1 4.3 26.6 38.3 3.0 14.2 12.0 2.4 39.0 5.9 9.4 1.0 43.0 2.3 8.7 10.3 3.5 3.6 12.2 17.6 1.9 16.9 12.4 11.8 15.7 17.6 0.0 0.5 0.1 4.9 0.1 2.3 0.1 5.0 2.5 44.4 4.3 18.8 16.4 0.0 9.3 19.1 3.5 4.5 0.0 2.5 0.0 2.0 10.3 16.7 7.7 14.1 6.9 0.1 5.7 4.2 5.5 0.0 2.3 7.4 0.0 10.5 4.5 2.6 8.6 0.0 0.0 7.2 0.0 2.2 0.6 2.7 10.1 1.9 1.5 0.0 0.0 13.5 21.2 2.6 3.7 2.8 6.2 5.1 3.6 0.2 0.0 3.4 2.7 0.0 1.2 7.6 0.0 0.0 3.6 0.0 1.5 0.0 0.2 0.0 0.2 3.0 2.3 0.0 2.2 0.3 0.5 0.0 0.0 0.0 0.1 0.1 4.9 0.0 0.1 0.1 10.8 16.9 5.7 11.6 10.4 5.7 16.9 7.9 14.2 17.6 PTPRB PTPB ENSG00000127329 "Protein tyrosine phosphatase, receptor type B" P23467 12 70515866-70637440 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" Angiogenesis "Hydrolase, Protein phosphatase" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in some" "EFO-21: 11.1;HUVEC TERT2: 27.5;TIME: 40.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 7 "memory B-cell: 3.5" "Lineage enriched" "Detected in single" 7 "B-cells: 3.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004782, HPA067868" Uncertain Approved "Vesicles,Plasma membrane,Cell Junctions" 6700000 "Plasma membrane" "Vesicles, Cell Junctions" "CAB004782: , HPA067868: " "unprognostic (3.18e-1)" "unprognostic (2.99e-6)" "unprognostic (1.56e-1)" "unprognostic (1.80e-1)" "unprognostic (3.55e-2)" "unprognostic (1.77e-2)" "prognostic favourable (6.05e-4)" "unprognostic (4.59e-1)" "unprognostic (2.22e-2)" "unprognostic (1.85e-1)" "unprognostic (2.28e-2)" "unprognostic (1.40e-1)" "prognostic favourable (1.02e-4)" "unprognostic (2.91e-2)" "unprognostic (7.18e-2)" "unprognostic (1.31e-1)" "unprognostic (1.38e-1)" 23.5 7.0 4.5 5.5 7.0 0.1 22.9 3.6 6.1 11.3 8.0 4.3 7.1 5.3 17.1 8.5 5.8 8.2 11.4 17.6 6.2 5.1 18.7 12.0 39.9 3.3 6.9 4.6 5.5 4.4 4.9 5.7 23.3 7.8 6.1 8.2 16.0 3.6 7.1 11.8 4.7 7.4 13.3 7.3 22.9 5.2 3.7 4.3 0.7 14.0 12.2 2.6 6.5 14.7 3.5 0.1 0.2 0.0 0.4 0.3 0.2 1.9 0.1 0.8 0.1 0.0 0.0 0.4 0.4 1.9 1.0 2.4 0.0 1.5 0.7 11.1 0.3 6.8 0.1 0.3 3.5 0.5 0.3 0.1 0.7 0.4 0.1 0.3 0.0 0.0 0.3 2.7 0.0 27.5 1.5 0.4 0.6 0.0 0.0 0.0 1.0 0.4 0.0 0.7 0.3 5.1 0.7 0.0 0.4 0.7 0.0 1.6 0.0 0.6 40.2 0.4 0.4 0.1 2.3 0.5 0.3 0.3 0.2 0.4 0.0 0.2 0.0 0.0 0.2 0.0 0.0 3.5 0.0 0.3 0.0 0.3 0.1 0.0 0.1 0.4 0.0 0.1 0.0 0.2 4.5 7.0 3.6 6.1 6.2 5.1 6.9 4.6 7.8 4.3 PTPRC "CD45, GP180, LCA, T200" ENSG00000081237 "Protein tyrosine phosphatase, receptor type C" 1 198638457-198757476 "Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "blood: 116.9;lymphoid tissue: 172.5" "Cell line enhanced" "Detected in some" "Daudi: 51.0;HEL: 28.8;HL-60: 26.0;MOLT-4: 38.5;THP-1: 21.4;U-266/70: 23.9;U-266/84: 21.6;U-698: 30.6;U-937: 23.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB000052, HPA000440, CAB002800, CAB056154, CAB068221" Enhanced Uncertain Nucleoplasm,Vesicles "Intracellular and membrane" "Nucleoplasm, Vesicles" "CAB000052: AB_2314143, CAB002800: AB_2237910, CAB056154: , CAB068221: , HPA000440: AB_1078468" "unprognostic (1.51e-2)" "unprognostic (1.24e-2)" "unprognostic (5.10e-3)" "unprognostic (2.33e-3)" "unprognostic (1.30e-1)" "unprognostic (2.40e-3)" "unprognostic (1.62e-1)" "unprognostic (3.17e-2)" "unprognostic (1.25e-1)" "unprognostic (3.18e-2)" "unprognostic (8.08e-2)" "unprognostic (3.95e-1)" "prognostic unfavourable (2.42e-4)" "unprognostic (2.31e-1)" "unprognostic (3.43e-2)" "unprognostic (6.41e-2)" "unprognostic (7.06e-2)" 9.8 2.9 3.4 48.0 6.2 36.1 4.3 1.3 3.5 3.1 5.6 2.8 0.5 4.9 2.9 3.9 4.8 5.6 8.8 4.9 3.9 4.5 4.4 5.2 27.5 93.2 7.9 1.3 2.9 2.1 0.3 2.5 4.5 5.3 4.2 5.8 3.3 10.7 1.0 1.7 2.5 22.2 4.5 13.2 89.3 6.5 2.3 5.3 172.5 4.6 3.9 53.2 13.1 3.7 28.5 42.8 94.7 103.8 53.7 76.1 116.9 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 51.0 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.0 28.8 0.0 0.0 0.0 26.0 0.1 0.0 0.0 0.0 0.0 0.1 0.6 0.8 0.0 0.0 38.5 15.7 0.1 0.1 1.1 0.1 0.1 0.0 0.0 0.3 0.4 0.0 0.1 0.1 0.0 21.4 0.3 0.0 0.2 0.1 0.1 23.9 21.6 30.6 0.0 23.3 0.1 20.8 52.0 56.3 76.1 99.7 64.5 28.5 52.9 72.7 42.8 26.8 60.2 60.3 94.7 53.7 103.8 6.4 54.6 116.9 3.4 6.2 1.3 3.5 3.9 4.5 7.9 1.3 5.3 5.3 PTPRK R-PTP-kappa ENSG00000152894 "Protein tyrosine phosphatase, receptor type K" Q15262 6 127968779-128520674 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Hydrolase, Protein phosphatase, Receptor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 6 "memory B-cell: 2.3;naive B-cell: 4.8;naive CD8 T-cell: 1.6" "Group enriched" "Detected in many" 7 "B-cells: 4.8;T-cells: 1.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA054056, HPA054822" Uncertain Supported "Vesicles,Plasma membrane,Cell Junctions" 13000000 "Cell Junctions" "Vesicles, Plasma membrane" "HPA054056: , HPA054822: " "unprognostic (3.15e-2)" "unprognostic (1.07e-2)" "unprognostic (5.79e-3)" "unprognostic (4.95e-3)" "unprognostic (1.89e-2)" "unprognostic (7.26e-2)" "unprognostic (3.27e-1)" "unprognostic (6.06e-2)" "unprognostic (2.04e-1)" "unprognostic (1.08e-1)" "prognostic unfavourable (1.99e-4)" "unprognostic (1.46e-1)" "prognostic favourable (9.33e-5)" "unprognostic (2.10e-1)" "unprognostic (1.55e-1)" "unprognostic (2.59e-1)" "unprognostic (9.32e-2)" 12.0 5.2 18.6 10.7 20.3 1.2 20.9 4.7 24.4 12.2 21.9 25.6 11.2 25.7 12.1 10.3 9.1 13.2 29.6 11.4 17.2 12.6 13.3 23.6 17.4 5.7 20.5 19.3 15.6 25.7 11.4 12.2 17.4 14.9 16.3 23.4 3.9 18.3 17.5 9.1 13.5 27.4 14.6 17.1 6.4 24.6 2.7 23.7 15.3 10.1 6.5 7.6 18.4 15.1 4.8 0.0 0.0 0.0 0.4 1.6 0.2 4.4 4.8 2.9 0.2 6.1 8.2 2.9 12.1 23.5 5.0 4.6 8.0 3.7 0.0 3.7 11.1 12.7 3.0 9.6 7.1 13.4 4.9 0.1 7.4 11.1 7.5 0.0 0.4 6.0 8.9 10.5 14.4 13.7 0.0 0.2 12.3 9.0 6.8 0.0 3.0 6.2 24.5 6.2 0.8 12.4 9.2 15.3 0.0 12.5 14.0 0.7 3.8 0.3 23.1 7.9 5.5 15.3 10.9 0.1 1.6 0.0 10.1 0.0 8.3 0.0 0.0 0.0 0.0 0.0 0.0 2.3 0.1 0.1 0.0 4.8 0.4 1.6 0.0 0.4 0.0 0.0 0.1 0.2 18.6 20.3 4.7 24.4 17.2 12.6 20.5 19.3 14.9 23.7 PTPRO "GLEPP1, NPHS6, PTP-oc, PTP-U2, PTPU2" ENSG00000151490 "Protein tyrosine phosphatase, receptor type O" Q16827 12 15322397-15597399 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Hydrolase, Protein phosphatase, Receptor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 26.1;intestine: 28.5;kidney: 21.6" "Cell line enhanced" "Detected in some" "NTERA-2: 9.3;SCLC-21H: 5.7;SH-SY5Y: 11.2;THP-1: 4.6" "Cancer enhanced" "Detected in many" "colorectal cancer: 8.7" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 4 "classical monocyte: 5.2;intermediate monocyte: 10.5;memory B-cell: 8.3;myeloid DC: 7.4;naive B-cell: 7.0;naive CD4 T-cell: 2.9;non-classical monocyte: 10.5;plasmacytoid DC: 9.5" "Low lineage specificity" "Detected in many" "Region enhanced" "Detected in many" "olfactory region: 215.3" "Low region specificity" "Detected in many" HPA034525 Enhanced "Intracellular and membrane" "HPA034525: AB_10669785" "unprognostic (3.68e-2)" "unprognostic (3.49e-1)" "unprognostic (9.64e-2)" "unprognostic (1.25e-2)" "unprognostic (7.87e-2)" "unprognostic (2.08e-1)" "unprognostic (5.93e-3)" "unprognostic (5.37e-2)" "unprognostic (2.03e-1)" "unprognostic (3.72e-2)" "unprognostic (2.00e-1)" "unprognostic (5.43e-2)" "unprognostic (4.89e-2)" "unprognostic (2.12e-1)" "unprognostic (1.99e-2)" "unprognostic (1.24e-1)" "unprognostic (1.44e-1)" 3.3 1.2 16.2 3.1 26.1 0.6 1.1 1.0 15.3 1.7 10.4 1.5 0.0 2.0 4.5 2.1 0.8 1.2 1.6 0.7 11.3 10.6 21.6 1.6 6.7 3.2 4.8 8.8 0.7 0.6 0.6 3.8 4.4 4.0 0.7 28.5 1.1 0.8 1.1 0.5 0.7 1.9 7.1 2.6 3.6 1.0 0.9 3.5 0.0 0.5 0.0 3.5 1.7 0.5 8.3 9.5 0.0 10.5 0.1 2.9 2.7 0.0 0.1 0.5 0.4 0.6 0.1 0.2 0.0 0.0 0.9 2.2 0.0 0.0 0.3 0.1 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.8 0.0 0.3 0.1 0.2 0.9 0.0 0.0 0.7 0.0 0.0 0.0 0.3 0.0 0.0 0.7 9.3 0.1 0.0 0.0 0.1 0.2 0.3 5.7 11.2 1.3 0.0 0.1 0.1 4.6 0.0 0.1 0.4 0.0 0.4 1.4 0.1 0.4 0.1 0.3 1.7 0.0 5.2 0.0 0.0 10.5 0.0 8.3 1.7 0.4 7.4 7.0 2.9 1.3 0.0 0.1 10.5 9.5 1.3 2.7 16.2 26.1 1.0 15.3 11.3 10.6 4.8 8.8 4.0 3.5 PTPRT "KIAA0283, RPTPrho" ENSG00000196090 "Protein tyrosine phosphatase, receptor type T" O14522 20 42072752-43189970 "Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins" "Hydrolase, Protein phosphatase, Receptor" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "brain: 23.5;fallopian tube: 17.0" "Cell line enhanced" "Detected in some" "BEWO: 4.5;RPMI-8226: 1.2;SCLC-21H: 2.9;U-266/70: 1.0" "Cancer enhanced" "Detected in many" "breast cancer: 5.1" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA017336, CAB069423" Approved "CAB069423: AB_1622602, HPA017336: AB_1855943" "unprognostic (7.17e-3)" "unprognostic (1.02e-1)" "unprognostic (5.61e-3)" "unprognostic (1.08e-2)" "unprognostic (5.95e-2)" "unprognostic (3.71e-2)" "unprognostic (1.97e-1)" "unprognostic (1.31e-2)" "unprognostic (6.93e-2)" "unprognostic (2.00e-1)" "unprognostic (1.37e-6)" "unprognostic (3.16e-1)" "unprognostic (1.13e-2)" "unprognostic (1.81e-1)" "unprognostic (3.17e-1)" "unprognostic (1.10e-1)" "unprognostic (1.17e-1)" 0.6 0.8 5.0 0.6 11.1 0.5 4.6 1.6 23.5 1.6 0.7 0.9 0.0 1.2 0.5 1.8 0.5 17.0 0.7 0.8 4.7 6.5 0.6 0.9 2.1 1.0 2.2 12.6 0.5 0.9 0.5 4.1 4.6 5.1 0.8 0.6 0.5 2.0 4.6 0.5 0.8 1.0 0.5 1.4 0.7 1.8 2.8 0.9 4.9 0.5 0.0 1.1 0.5 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.5 0.0 0.4 0.0 0.0 0.3 0.0 0.0 0.0 1.2 0.0 0.0 2.9 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.0 11.1 1.6 22.6 4.7 6.5 2.2 12.6 5.1 0.9 PTTG1 "EAP1, HPTTG, PTTG, securin, TUTR1" ENSG00000164611 "Pituitary tumor-transforming 1" O95997 5 160421822-160428744 "Cancer-related genes, Predicted intracellular proteins" "Cell cycle, Cell division, Chromosome partition, DNA damage, DNA repair, Mitosis" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 54.5;testis: 100.1" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "T-reg: 54.5" "Lineage enriched" "Detected in all" 7 "T-cells: 54.5" "CAB008373, HPA008890, HPA045034" Enhanced Supported Nucleoli,Cytosol Cytosol Nucleoli "CAB008373: AB_592493, HPA008890: AB_1079717, HPA045034: " "unprognostic (6.48e-2)" "unprognostic (1.03e-2)" "unprognostic (1.40e-3)" "unprognostic (4.46e-3)" "unprognostic (5.81e-2)" "unprognostic (1.29e-1)" "prognostic unfavourable (1.62e-6)" "unprognostic (7.50e-3)" "unprognostic (5.24e-2)" "unprognostic (3.47e-2)" "unprognostic (2.13e-3)" "unprognostic (6.70e-2)" "prognostic unfavourable (0.00e+0)" "unprognostic (7.17e-2)" "unprognostic (1.72e-1)" "unprognostic (4.23e-2)" "unprognostic (3.35e-2)" 1.5 1.7 2.1 16.2 5.5 34.1 2.9 1.4 4.6 3.8 8.2 1.0 0.7 5.8 1.3 2.6 24.1 1.0 1.9 2.3 5.1 2.7 1.7 1.4 3.8 19.2 1.5 2.2 1.1 1.2 0.2 2.0 5.0 2.2 1.6 11.3 1.5 4.5 1.1 1.2 8.7 5.8 4.5 1.4 7.5 3.4 100.1 1.0 29.8 23.9 23.2 35.1 3.3 7.2 8.1 6.1 2.4 2.1 3.3 54.5 4.7 45.5 23.7 53.6 38.4 9.1 8.9 16.7 24.2 55.5 64.3 70.5 45.8 40.1 49.8 21.6 27.5 23.9 33.2 67.3 92.3 56.9 30.2 26.2 32.1 27.5 1.8 23.8 23.1 4.2 11.3 43.6 26.5 45.3 21.0 38.8 66.0 21.4 28.4 58.5 27.0 34.5 26.5 63.0 42.7 32.8 9.3 33.4 21.2 34.9 21.3 71.9 43.5 26.1 19.3 29.1 38.9 22.7 70.6 33.4 29.8 56.9 31.3 41.2 51.5 1.9 0.7 2.4 7.0 2.1 2.5 8.1 14.4 16.2 6.1 5.5 3.6 8.9 0.8 3.3 1.4 5.8 54.5 4.7 2.1 5.5 1.4 4.6 5.1 2.7 1.5 2.2 2.2 1.0 PZP CPAMD6 ENSG00000126838 "PZP, alpha-2-macroglobulin like" P20742 12 9148840-9208370 "Cancer-related genes, Plasma proteins, Predicted secreted proteins" "Protease inhibitor, Serine protease inhibitor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 16 "liver: 56.9" "Group enriched" "Detected in some" 8 "HeLa: 9.7;SiHa: 5.0" "Cancer enhanced" "Detected in some" "endometrial cancer: 1.0" "Low region specificity" "Detected in some" "Cell type enhanced" "Detected in some" "gdT-cell: 3.5;MAIT T-cell: 3.5" "Lineage enriched" "Detected in single" 12 "T-cells: 3.5" "HPA041403, HPA041471" Supported "Secreted to blood" 13000000000 "HPA041403: AB_10804003, HPA041471: AB_10795636" "unprognostic (8.48e-3)" "unprognostic (1.12e-2)" "unprognostic (2.28e-1)" "unprognostic (8.54e-4)" "unprognostic (4.79e-1)" "unprognostic (3.50e-2)" "unprognostic (2.04e-4)" "unprognostic (4.57e-2)" "unprognostic (2.18e-1)" "unprognostic (2.55e-2)" "unprognostic (9.71e-2)" "unprognostic (4.95e-2)" "unprognostic (1.08e-5)" "unprognostic (5.49e-2)" "unprognostic (1.01e-1)" "unprognostic (1.65e-2)" "unprognostic (9.81e-3)" 0.0 0.0 0.2 0.0 1.4 0.0 0.0 0.0 0.0 0.1 0.0 1.3 0.0 0.0 0.8 0.1 0.0 0.7 0.0 0.0 0.9 0.6 0.0 56.9 0.7 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 1.4 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.2 0.1 0.1 0.0 1.0 0.6 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 3.5 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 9.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.5 0.0 3.5 0.0 0.7 0.9 0.0 0.0 0.2 0.8 0.0 0.0 0.0 0.2 0.0 0.0 0.2 1.4 0.0 0.0 0.9 0.6 0.0 0.0 1.4 0.6 QKI QK3 ENSG00000112531 "QKI, KH domain containing RNA binding" Q96PU8 6 163414000-163578596 "Cancer-related genes, Predicted intracellular proteins" "Differentiation, mRNA processing, mRNA splicing, mRNA transport, Translation regulation, Transport" "Developmental protein, RNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 100.3" "Cell line enhanced" "Detected in all" "AF22: 64.0" "Cancer enriched" "Detected in all" 6 "glioma: 42.0" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019123, CAB022602" Enhanced Supported Supported Nucleoplasm Nucleoplasm "CAB022602: , HPA019123: AB_1855980" "unprognostic (2.42e-1)" "unprognostic (5.81e-2)" "unprognostic (1.31e-1)" "unprognostic (1.06e-2)" "unprognostic (8.57e-2)" "unprognostic (1.65e-1)" "prognostic unfavourable (1.27e-4)" "unprognostic (1.34e-1)" "unprognostic (7.06e-2)" "unprognostic (1.76e-3)" "unprognostic (1.08e-1)" "unprognostic (5.15e-2)" "prognostic unfavourable (2.31e-5)" "prognostic unfavourable (3.69e-4)" "unprognostic (1.16e-1)" "unprognostic (3.86e-1)" "unprognostic (4.09e-2)" 32.4 12.4 37.5 16.2 63.5 27.1 14.6 15.1 100.3 14.9 12.2 83.9 3.7 4.0 14.7 4.9 16.0 12.3 15.7 64.0 43.7 18.1 11.1 18.4 24.9 11.4 72.5 31.9 18.4 7.6 7.8 4.7 23.4 46.5 7.9 8.4 7.1 10.2 11.1 59.9 12.4 7.1 21.1 68.8 16.9 8.9 20.5 74.3 5.0 10.4 10.8 11.4 15.8 17.7 1.7 7.3 10.8 8.4 7.4 3.8 1.3 4.2 18.0 64.0 21.3 19.4 21.6 14.9 11.6 27.5 19.1 23.1 12.2 3.9 5.2 9.7 29.1 6.4 33.9 12.1 31.0 10.4 10.9 20.4 9.9 13.6 23.7 10.8 6.3 25.2 5.0 20.4 32.5 26.3 29.8 12.3 12.3 8.1 7.2 2.3 8.2 9.1 11.1 39.9 10.3 10.5 13.5 1.2 7.4 12.4 6.8 5.1 2.6 17.7 26.7 13.2 11.2 14.2 21.3 7.8 9.5 6.3 11.4 9.6 31.0 3.4 8.4 3.8 2.3 5.4 3.8 1.4 1.6 2.0 4.3 1.7 1.5 2.5 10.8 7.4 5.5 7.3 1.1 1.3 37.5 63.5 15.1 41.4 43.7 18.1 72.5 31.9 46.5 74.3 RAB11FIP3 "eferin, KIAA0665, Rab11-FIP3" ENSG00000090565 "RAB11 family interacting protein 3" O75154 16 425619-523011 "Cancer-related genes, Predicted intracellular proteins" "Cell cycle, Cell division, Transport" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "kidney: 70.5" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA028088, HPA028631, HPA030086" Approved Supported "Vesicles,Cytokinetic bridge,Centriolar satellite" "Vesicles, Cytokinetic bridge, Centriolar satellite" "HPA028088: AB_10601672, HPA028631: AB_10601853, HPA030086: AB_10669596" "unprognostic (6.65e-2)" "unprognostic (1.84e-2)" "unprognostic (1.51e-1)" "prognostic favourable (1.22e-4)" "unprognostic (2.87e-2)" "unprognostic (1.85e-1)" "prognostic unfavourable (9.87e-5)" "unprognostic (6.71e-2)" "unprognostic (4.74e-1)" "unprognostic (9.66e-2)" "prognostic favourable (3.16e-5)" "unprognostic (1.12e-1)" "prognostic favourable (7.99e-4)" "unprognostic (1.39e-1)" "unprognostic (1.77e-1)" "unprognostic (1.58e-1)" "unprognostic (1.44e-1)" 10.2 13.4 19.3 7.5 16.9 8.7 7.3 29.7 27.4 11.5 10.6 12.2 9.0 13.4 11.9 11.0 8.2 9.5 11.3 14.0 18.7 12.1 70.5 12.2 10.5 8.1 12.0 18.0 13.4 22.2 22.4 14.6 10.0 10.6 11.5 5.4 9.9 13.2 12.6 23.5 12.2 14.6 10.8 8.9 10.2 7.6 13.5 11.9 5.7 8.6 7.4 5.3 9.7 16.6 1.1 0.8 0.1 0.1 0.1 1.5 0.6 4.4 10.1 9.7 8.5 14.3 9.4 8.4 8.4 7.9 7.7 5.6 7.4 2.1 12.2 9.9 12.3 4.6 6.0 8.9 2.7 9.0 8.6 5.5 9.4 21.5 15.3 5.4 6.8 9.0 6.1 7.9 6.9 11.7 2.8 4.8 9.7 13.6 8.8 10.8 8.1 4.1 18.3 7.8 3.2 7.8 2.7 10.1 9.4 8.6 10.5 5.3 5.9 10.1 19.0 11.3 7.5 10.5 5.5 6.7 5.3 14.4 4.3 3.9 8.3 0.0 0.1 0.0 1.5 0.0 1.3 0.8 0.9 0.7 0.5 1.1 0.6 0.3 0.1 0.1 0.0 0.8 0.0 0.6 19.3 16.9 29.7 27.4 18.7 12.1 12.0 18.0 10.6 11.9 RAB18 ENSG00000099246 "RAB18, member RAS oncogene family" Q9NP72 10 27504174-27542237 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Protein transport, Transport" "Developmental protein" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA025928 Uncertain 210000 "HPA025928: AB_1855997" "unprognostic (9.45e-3)" "unprognostic (7.71e-2)" "unprognostic (2.95e-1)" "unprognostic (6.71e-2)" "unprognostic (3.37e-2)" "unprognostic (1.28e-2)" "unprognostic (8.59e-3)" "unprognostic (1.17e-1)" "unprognostic (3.64e-1)" "unprognostic (1.27e-2)" "unprognostic (8.97e-2)" "unprognostic (3.22e-1)" "unprognostic (1.71e-3)" "unprognostic (9.55e-2)" "unprognostic (1.01e-1)" "unprognostic (1.39e-1)" "unprognostic (8.48e-2)" 29.3 45.2 36.4 20.8 45.1 58.3 38.3 34.0 42.9 26.8 25.3 24.5 26.6 25.0 25.7 32.8 40.6 20.0 20.6 40.3 40.9 42.5 36.6 38.9 22.4 17.8 35.9 42.2 24.6 23.8 27.0 33.3 34.8 43.5 32.5 27.4 21.8 26.2 27.9 49.1 33.8 27.2 28.1 38.2 21.6 27.4 25.0 26.8 24.2 32.8 28.7 24.0 25.7 28.5 6.4 10.3 49.6 14.2 11.3 24.8 11.1 21.8 15.6 19.0 13.7 32.3 18.5 12.7 33.8 15.6 29.6 28.3 15.0 14.7 8.9 14.5 29.0 14.7 12.4 21.6 24.4 13.6 11.3 12.6 15.2 19.1 23.4 5.4 15.3 24.2 41.2 18.4 10.7 22.7 7.1 18.5 24.8 14.2 11.9 3.7 8.2 7.3 8.8 31.5 10.8 28.0 12.3 10.3 12.5 16.7 19.1 21.4 38.4 11.4 22.5 13.6 16.9 25.7 19.5 8.1 14.8 11.3 23.3 31.9 7.5 44.9 13.8 33.5 11.3 12.6 24.8 6.4 9.9 12.2 10.3 6.3 8.4 9.9 49.6 11.3 14.2 6.7 10.5 11.1 36.4 45.1 34.0 42.9 40.9 42.5 35.9 42.2 43.5 26.8 RAB25 CATX-8 ENSG00000132698 "RAB25, member RAS oncogene family" P57735 1 156061160-156070514 "Cancer-related genes, Predicted intracellular proteins" "Protein transport, Transport" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "esophagus: 98.3" "Cell line enhanced" "Detected in some" "BEWO: 26.9;CAPAN-2: 26.2;HaCaT: 23.8;hTCEpi: 23.5;MCF7: 36.3;RT4: 33.0;SK-BR-3: 53.7;T-47d: 50.2" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "MAIT T-cell: 3.3;naive CD4 T-cell: 3.4" "Lineage enriched" "Detected in single" 24 "T-cells: 3.4" "Not detected" "Not detected" "Low region specificity" "Detected in all" "HPA010872, CAB033645" Enhanced Uncertain "Cell Junctions,Cytosol" "Cell Junctions, Cytosol" "CAB033645: AB_1128883, HPA010872: AB_1079729" "unprognostic (2.43e-1)" "unprognostic (4.57e-1)" "unprognostic (2.24e-1)" "unprognostic (1.71e-1)" "unprognostic (2.64e-1)" "unprognostic (1.97e-1)" "unprognostic (4.27e-2)" "unprognostic (4.63e-2)" "unprognostic (2.82e-1)" "unprognostic (2.03e-2)" "unprognostic (1.22e-2)" "unprognostic (1.39e-1)" "prognostic favourable (1.38e-6)" "unprognostic (2.31e-2)" "unprognostic (3.24e-2)" "unprognostic (3.14e-2)" "unprognostic (4.94e-2)" 0.4 0.3 0.3 10.9 0.3 0.0 10.8 0.5 0.4 23.6 28.4 0.3 28.1 14.8 4.0 15.9 98.3 9.7 33.3 0.3 0.3 0.3 18.2 1.0 19.1 0.6 0.3 0.2 2.3 27.4 8.6 9.5 19.1 0.3 13.3 16.2 0.4 44.1 26.8 0.4 48.0 43.0 2.1 0.4 0.3 16.2 1.1 0.2 3.7 36.1 74.6 60.9 13.0 31.8 0.1 0.0 0.0 0.0 0.0 3.4 0.8 19.7 0.0 0.0 0.0 0.0 0.0 26.9 0.0 0.0 0.0 0.0 19.3 26.2 0.0 0.0 0.0 23.8 0.0 11.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 23.5 0.0 0.0 0.0 0.0 0.0 0.0 36.3 0.0 0.1 1.0 0.0 0.0 0.0 0.0 0.0 33.0 2.9 0.0 0.0 53.7 0.0 50.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.3 0.1 2.8 0.8 0.0 0.0 3.4 2.9 0.0 0.0 0.0 0.0 0.9 0.8 0.3 0.3 0.5 0.4 0.3 0.3 0.3 0.2 0.3 0.2 RAB40A "Rar-2, RAR2A" ENSG00000172476 "RAB40A, member RAS oncogene family" Q8WXH6 X 103499130-103519489 "Cancer-related genes, Predicted intracellular proteins" "Ubl conjugation pathway" "Cancer-related genes" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enhanced" "Detected in many" "epididymis: 34.0" "Cell line enhanced" "Detected in many" "AF22: 6.4;NTERA-2: 7.1" "Low cancer specificity" "Detected in single" "Region enriched" "Detected in single" 5 "basal ganglia: 4.2" "Cell type enriched" "Detected in single" 5 "memory B-cell: 1.2" "Lineage enriched" "Detected in single" 5 "B-cells: 1.2" HPA076172 Uncertain Vesicles Vesicles "HPA076172: " "unprognostic (3.49e-1)" "unprognostic (6.01e-2)" "unprognostic (4.33e-2)" "unprognostic (4.49e-3)" "unprognostic (8.73e-2)" "unprognostic (1.08e-1)" "unprognostic (8.21e-2)" "unprognostic (1.72e-1)" "unprognostic (1.24e-1)" "unprognostic (4.05e-1)" "unprognostic (3.82e-2)" "unprognostic (4.43e-1)" "unprognostic (7.36e-4)" "unprognostic (7.85e-3)" "unprognostic (9.39e-5)" "unprognostic (1.43e-1)" "unprognostic (1.11e-3)" 2.0 1.4 0.6 0.6 4.2 0.0 0.8 0.6 1.1 2.8 0.8 0.6 11.9 0.5 5.5 34.0 10.6 2.6 2.9 0.6 0.6 0.9 1.3 0.6 2.0 1.7 0.6 0.6 5.4 0.6 0.6 2.4 0.8 0.8 5.5 0.4 0.6 0.6 6.2 0.6 0.7 0.9 1.3 0.6 0.8 0.5 7.8 0.6 0.6 0.6 0.6 0.6 1.5 2.0 1.2 0.2 0.0 0.0 0.0 0.1 0.0 0.4 1.7 6.4 0.2 1.4 1.9 3.1 1.9 0.4 0.3 0.5 1.3 0.9 1.6 2.4 0.3 0.1 0.4 0.1 0.3 0.0 3.7 0.5 2.9 0.3 0.6 0.1 0.2 1.5 0.3 0.6 0.4 0.3 2.3 1.0 0.6 0.4 0.4 0.2 7.1 1.0 0.0 0.5 0.1 0.1 0.6 2.7 3.3 0.6 0.1 1.3 0.0 0.2 3.2 2.6 1.5 4.0 1.8 1.1 0.7 1.2 2.9 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.2 0.1 0.0 0.6 4.2 0.6 0.6 0.6 0.9 0.6 0.6 0.8 0.6 RABEP1 "neurocrescin, RAB5EP, rabaptin-5, RABPT5" ENSG00000029725 "Rabaptin, RAB GTPase binding effector protein 1" Q15276 17 5282265-5385812 "Cancer-related genes, Predicted intracellular proteins" "Apoptosis, Endocytosis, Protein transport, Transport" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004549, HPA019669, HPA024235, HPA024691" Supported Supported Vesicles Vesicles "CAB004549: AB_628192, HPA019669: AB_1856019, HPA024235: AB_1856020, HPA024691: AB_1856021" "unprognostic (3.22e-1)" "unprognostic (2.90e-2)" "unprognostic (2.45e-1)" "unprognostic (8.75e-3)" "unprognostic (1.64e-1)" "unprognostic (8.25e-2)" "unprognostic (3.71e-2)" "unprognostic (1.20e-1)" "unprognostic (1.60e-2)" "unprognostic (7.73e-2)" "prognostic favourable (6.43e-4)" "unprognostic (1.14e-1)" "unprognostic (6.09e-3)" "unprognostic (7.67e-2)" "unprognostic (2.60e-1)" "unprognostic (1.00e-1)" "unprognostic (9.00e-3)" 19.2 16.7 29.6 18.8 31.1 10.3 31.8 24.1 32.7 16.3 14.2 19.0 12.5 10.9 18.1 18.3 12.7 12.9 15.0 27.4 29.7 25.9 16.6 21.8 13.1 21.1 36.2 24.4 15.5 12.1 38.4 16.3 20.2 31.3 22.2 14.2 10.0 14.8 16.0 41.2 11.6 13.4 20.8 35.6 17.7 15.7 11.8 29.0 21.4 17.6 13.5 25.5 14.5 13.0 37.6 14.2 12.6 19.3 9.1 11.2 6.4 17.9 22.2 23.3 13.0 24.5 24.6 12.8 23.4 17.4 24.5 23.4 19.6 7.5 37.8 19.5 23.5 14.1 34.1 19.3 34.6 24.9 31.2 23.2 27.4 14.9 23.2 15.1 15.3 19.0 13.3 23.5 30.6 21.1 19.7 18.7 21.2 12.4 25.0 12.4 10.7 10.7 23.7 28.0 12.6 12.3 16.4 10.1 15.8 20.6 20.6 19.6 37.4 7.0 18.6 21.0 9.8 21.1 27.2 11.0 12.0 20.3 16.3 24.8 14.3 4.9 9.0 8.7 11.2 9.2 9.8 30.2 8.7 10.6 9.2 37.6 11.1 9.7 12.6 9.1 19.3 14.2 8.0 6.4 29.6 31.1 24.1 32.5 29.7 25.9 36.2 24.4 31.3 29.0 RAC1 "p21-Rac1, Rac-1, TC-25" ENSG00000136238 "Rac family small GTPase 1" P63000 7 6374523-6403977 "Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins" Hydrolase "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB035994, HPA047820" Approved Approved Nucleoplasm,Nucleoli,Cytosol 44000000 "Nucleoplasm, Cytosol" Nucleoli "CAB035994: , HPA047820: " "unprognostic (8.66e-3)" "unprognostic (2.47e-1)" "unprognostic (4.00e-1)" "unprognostic (2.40e-2)" "unprognostic (1.88e-3)" "unprognostic (4.06e-2)" "prognostic unfavourable (1.74e-5)" "prognostic unfavourable (4.59e-4)" "unprognostic (1.59e-1)" "unprognostic (2.04e-1)" "prognostic unfavourable (4.57e-5)" "unprognostic (3.63e-1)" "prognostic unfavourable (2.11e-4)" "unprognostic (1.95e-1)" "unprognostic (2.11e-2)" "unprognostic (4.13e-2)" "unprognostic (8.72e-3)" 45.2 35.0 71.0 28.4 64.0 24.4 46.5 42.1 93.0 48.7 58.9 75.5 22.5 51.6 48.7 49.5 93.4 47.2 40.0 48.4 73.8 59.8 47.8 42.9 45.6 38.3 76.7 60.9 45.1 29.2 51.0 25.2 55.8 54.9 40.5 64.0 37.2 43.3 48.9 57.4 58.6 49.8 57.3 88.2 35.0 49.7 28.1 47.1 41.3 40.9 42.8 50.7 52.2 54.0 11.0 32.0 49.1 31.9 7.3 11.8 10.7 73.9 33.6 34.7 37.7 41.2 52.7 20.7 41.7 51.3 55.7 56.8 32.9 70.0 20.9 27.1 58.2 52.8 37.0 50.6 71.4 9.7 30.7 21.0 27.2 23.8 49.6 18.9 17.2 35.1 45.3 40.1 45.0 49.0 37.4 16.5 60.0 53.9 10.4 44.4 62.2 40.3 18.4 35.3 30.6 71.6 46.9 26.3 44.3 29.4 107.9 33.5 60.8 56.9 51.4 36.6 55.1 44.8 48.1 12.6 13.8 19.6 33.7 36.1 69.3 7.6 31.9 16.4 7.2 22.2 4.5 11.0 8.1 9.2 32.0 11.0 9.8 6.5 49.1 7.3 22.1 18.2 11.8 10.7 71.0 64.0 42.1 93.0 73.8 59.8 76.7 60.9 54.9 47.1 RAD21 "hHR21, KIAA0078, SCC1" ENSG00000164754 "RAD21 cohesin complex component" O60216 8 116845935-116874866 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Apoptosis, Cell cycle, Cell division, Chromosome partition, DNA damage, DNA repair, Mitosis, Transcription, Transcription regulation" "Activator, Developmental protein, Repressor" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA020044, CAB022065" Supported Enhanced Nucleoplasm Nucleoplasm "CAB022065: , HPA020044: AB_1856035" "unprognostic (7.85e-2)" "unprognostic (4.92e-1)" "unprognostic (3.05e-1)" "unprognostic (5.43e-3)" "unprognostic (9.56e-2)" "unprognostic (3.50e-1)" "prognostic unfavourable (1.71e-4)" "unprognostic (1.86e-3)" "unprognostic (8.99e-2)" "unprognostic (8.80e-2)" "unprognostic (5.58e-3)" "unprognostic (3.56e-2)" "unprognostic (4.40e-2)" "unprognostic (2.00e-1)" "unprognostic (1.82e-1)" "unprognostic (1.39e-1)" "unprognostic (1.95e-1)" 31.6 40.9 48.2 30.5 52.2 78.5 37.7 58.8 55.3 24.2 36.3 37.5 21.5 24.8 30.5 25.3 32.1 23.1 22.0 37.8 45.6 44.1 30.5 27.9 29.6 49.2 54.3 35.4 33.5 18.2 29.1 30.0 38.9 45.5 26.5 37.3 19.0 25.3 31.0 37.8 24.0 26.0 33.4 49.7 31.2 31.5 37.6 56.2 58.3 41.9 20.9 50.4 37.1 36.0 8.7 5.4 17.9 7.1 8.0 25.4 6.2 42.6 21.0 41.1 23.1 20.7 17.9 18.4 29.7 28.2 33.0 30.5 17.2 40.3 63.1 16.4 21.1 23.8 35.0 19.1 38.7 83.7 22.5 64.3 25.8 21.9 13.0 20.6 37.9 15.2 15.7 19.3 23.4 25.8 25.8 88.4 28.4 25.7 94.3 12.1 24.1 26.5 34.6 29.9 31.7 19.6 25.1 52.0 26.8 31.1 84.0 20.0 35.2 25.5 18.8 23.3 34.2 24.4 31.1 46.8 53.8 56.8 19.9 29.7 27.9 17.2 4.5 15.5 11.0 5.3 11.2 8.7 12.9 13.0 5.4 8.3 13.5 13.0 17.9 8.0 7.1 4.5 25.4 6.2 48.2 52.2 58.8 55.3 45.6 44.1 54.3 35.4 45.5 56.2 RAD23A "HHR23A, MGC111083" ENSG00000179262 "RAD23 homolog A, nucleotide excision repair protein" P54725 19 12945855-12953642 "Cancer-related genes, Predicted intracellular proteins" "DNA damage, DNA repair, Host-virus interaction" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in all" 6 "skeletal muscle: 225.3" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA026418, HPA053901, HPA057003, HPA065599" Approved Enhanced Nucleoplasm,Cytosol 3100000 Nucleoplasm Cytosol "HPA026418: , HPA053901: , HPA057003: , HPA065599: " "unprognostic (2.09e-1)" "unprognostic (1.58e-3)" "unprognostic (1.23e-3)" "unprognostic (7.90e-3)" "unprognostic (1.45e-1)" "unprognostic (1.48e-1)" "unprognostic (3.78e-3)" "unprognostic (3.57e-3)" "unprognostic (3.13e-1)" "unprognostic (3.12e-3)" "unprognostic (1.09e-1)" "unprognostic (4.08e-2)" "unprognostic (2.09e-3)" "unprognostic (2.32e-3)" "unprognostic (9.99e-2)" "unprognostic (8.56e-2)" "unprognostic (6.59e-3)" 19.6 15.2 19.1 13.4 17.7 19.9 16.0 15.1 25.3 12.9 18.0 14.6 10.7 13.6 15.3 14.3 19.9 17.7 13.6 34.3 16.6 16.0 13.2 24.5 14.2 14.1 15.4 15.6 17.1 21.1 14.0 12.3 17.3 15.5 15.1 10.7 12.6 18.6 15.8 225.3 19.8 11.9 16.5 15.4 15.7 14.9 19.1 12.5 14.6 17.2 37.7 13.8 20.7 17.0 29.5 30.0 22.7 35.6 26.5 32.1 22.5 31.4 11.6 13.5 13.9 22.5 25.8 22.6 15.4 31.0 36.6 33.3 13.0 22.7 26.8 35.5 23.1 24.4 18.4 32.0 13.9 37.8 23.4 10.8 15.0 12.5 43.8 23.3 31.7 26.3 48.0 26.4 50.6 25.1 27.7 24.7 32.9 30.7 29.0 28.9 18.5 28.8 15.3 14.0 43.5 28.5 12.6 25.0 19.7 17.0 31.1 34.0 24.2 40.5 19.7 52.7 14.0 62.5 47.0 35.8 29.9 19.5 43.4 44.1 43.2 10.4 27.9 22.7 29.7 35.6 32.1 29.2 25.3 25.1 23.4 29.5 24.6 27.8 3.9 26.5 34.9 30.0 27.0 22.5 19.1 17.7 15.1 25.3 16.6 16.0 15.4 15.6 15.5 12.5 RAD23B "HHR23B, HR23B, P58" ENSG00000119318 "RAD23 homolog B, nucleotide excision repair protein" P54727 9 107283137-107332194 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA repair, Ubl conjugation pathway" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA029718, HPA029720, CAB033868" Enhanced Supported Nucleoplasm,Cytosol 8200000 "Nucleoplasm, Cytosol" "CAB033868: AB_1128418, HPA029718: AB_10600116, HPA029720: AB_10601008" "unprognostic (3.95e-3)" "unprognostic (1.01e-2)" "unprognostic (2.28e-2)" "unprognostic (8.14e-2)" "unprognostic (4.71e-2)" "prognostic unfavourable (2.58e-4)" "unprognostic (2.94e-1)" "prognostic unfavourable (6.71e-4)" "unprognostic (1.34e-1)" "unprognostic (3.72e-1)" "unprognostic (3.31e-2)" "unprognostic (1.20e-1)" "unprognostic (2.94e-3)" "unprognostic (2.69e-2)" "unprognostic (2.43e-1)" "unprognostic (7.49e-3)" "unprognostic (1.04e-1)" 41.0 30.1 21.9 23.5 24.5 37.0 28.9 33.3 28.1 28.9 31.4 18.4 28.2 21.8 27.0 38.0 45.3 22.6 24.1 45.5 22.2 23.0 29.7 82.0 27.7 20.7 20.8 23.3 31.6 45.9 21.0 24.8 66.1 25.6 31.1 25.9 17.3 28.7 25.8 98.2 38.2 29.1 29.4 22.6 29.8 23.0 38.5 18.6 32.8 30.4 34.0 27.1 42.1 32.6 5.2 2.5 7.1 2.7 5.0 4.9 1.2 33.3 29.7 42.1 27.0 29.0 46.0 47.5 51.8 42.7 46.2 31.8 49.2 36.6 46.9 21.0 56.6 47.0 58.0 46.1 46.7 31.8 19.0 24.4 31.3 37.5 38.6 43.6 21.0 38.5 43.1 44.1 66.6 32.1 39.3 35.3 41.6 54.5 42.4 22.2 44.8 34.7 31.7 55.3 22.2 39.7 31.6 38.5 26.1 35.8 50.7 31.9 51.7 17.9 29.4 34.5 33.9 42.5 38.7 24.3 44.4 25.3 36.8 26.0 36.1 1.7 2.7 2.3 4.4 2.7 4.9 4.0 2.6 3.7 2.2 5.2 4.4 3.5 7.1 5.0 1.7 2.5 4.6 1.2 21.9 24.5 33.3 27.4 22.2 23.0 20.8 23.3 25.6 18.6 RAD51 "BRCC5, FANCR, HsRad51, HsT16930, RAD51A, RECA" ENSG00000051180 "RAD51 recombinase" Q06609 15 40694774-40732339 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "DNA damage, DNA recombination, DNA repair" DNA-binding "Cancer-related genes, Disease mutation, Fanconi anemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 27.9;testis: 24.0" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "CAB010381, HPA039310" Enhanced Supported Nucleoli,Cytosol Nucleoli Cytosol "CAB010381: AB_2253533, HPA039310: " "prognostic unfavourable (7.94e-4)" "unprognostic (7.20e-3)" "unprognostic (1.22e-1)" "unprognostic (2.72e-2)" "unprognostic (8.23e-2)" "unprognostic (1.37e-1)" "prognostic unfavourable (9.33e-4)" "unprognostic (3.40e-3)" "unprognostic (2.53e-2)" "unprognostic (1.76e-1)" "unprognostic (1.41e-3)" "unprognostic (2.53e-3)" "unprognostic (0.00e+0)" "unprognostic (2.26e-2)" "unprognostic (2.34e-1)" "unprognostic (9.59e-2)" "unprognostic (1.94e-2)" 1.0 0.9 0.4 6.6 0.9 5.3 1.0 0.7 0.9 1.1 5.7 0.4 0.3 1.7 0.8 2.0 4.9 0.5 1.7 1.8 0.5 0.5 1.0 1.0 1.9 7.4 0.5 0.3 0.9 0.7 0.0 0.4 6.2 0.7 0.8 7.6 0.4 1.4 0.3 1.3 2.1 2.6 1.2 1.1 5.0 1.5 24.0 0.5 27.9 0.6 3.7 9.7 1.0 1.9 3.1 1.7 2.7 2.2 2.2 8.8 1.7 12.5 5.6 13.4 5.0 1.4 3.6 12.1 22.3 6.1 19.8 19.9 13.1 8.6 7.1 11.0 7.9 26.7 25.2 10.4 19.3 14.8 8.6 17.8 10.9 10.0 0.1 14.4 12.2 0.5 1.8 13.3 5.9 10.7 23.3 20.0 17.1 11.0 20.5 13.3 15.3 7.0 23.5 18.9 11.9 7.2 17.0 6.0 11.2 9.8 17.3 3.5 10.5 12.0 4.5 14.3 9.1 20.0 11.4 5.0 24.9 23.7 6.2 30.1 12.5 2.0 0.9 2.7 4.1 2.0 0.8 3.1 4.3 5.5 1.7 1.6 1.2 2.1 1.3 2.2 2.2 1.2 8.8 1.7 0.4 0.9 0.7 0.9 0.5 0.5 0.5 0.3 0.7 0.5 RAD51B "hREC2, R51H2, RAD51L1, REC2" ENSG00000182185 "RAD51 paralog B" O15315 14 67819779-68730218 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "DNA damage, DNA recombination, DNA repair" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB016191, HPA051869" Enhanced Approved "Nucleoplasm,Nuclear bodies" "Nuclear bodies" Nucleoplasm "CAB016191: AB_2238209, HPA051869: " "unprognostic (9.10e-3)" "unprognostic (5.45e-2)" "unprognostic (4.92e-1)" "unprognostic (6.65e-2)" "unprognostic (2.38e-2)" "unprognostic (4.85e-2)" "unprognostic (6.42e-3)" "unprognostic (2.54e-2)" "unprognostic (1.06e-1)" "unprognostic (3.08e-1)" "unprognostic (6.80e-3)" "unprognostic (1.47e-1)" "unprognostic (6.25e-2)" "unprognostic (1.77e-1)" "unprognostic (2.49e-2)" "unprognostic (6.79e-2)" "unprognostic (8.13e-3)" 5.1 4.9 4.2 4.6 10.1 9.2 8.2 2.0 5.6 8.2 4.3 11.6 11.2 1.7 10.8 13.8 7.0 6.0 6.4 3.4 5.6 3.2 4.3 3.2 5.0 6.6 9.2 4.0 10.0 5.7 8.0 10.0 8.0 7.5 7.0 4.0 9.4 18.7 3.8 2.4 7.1 5.8 6.7 7.3 6.9 3.7 3.4 7.3 12.6 4.9 4.6 12.1 7.7 8.3 13.6 6.6 14.0 5.9 7.8 10.1 4.8 12.2 4.8 5.4 3.3 5.1 8.7 3.4 6.2 4.8 6.9 8.9 3.4 16.7 15.1 4.1 3.8 11.1 3.4 9.9 9.5 6.7 3.5 7.2 4.4 2.7 2.7 6.0 7.3 4.4 7.7 7.9 8.4 6.2 5.8 7.0 5.6 9.5 11.8 2.1 3.2 4.9 13.3 6.5 5.5 5.4 3.5 3.7 2.4 5.0 1.8 10.7 8.4 5.5 1.6 8.5 8.2 6.6 5.1 3.4 3.4 12.0 4.6 10.7 4.7 14.0 5.9 5.4 8.6 4.7 7.1 13.6 8.2 9.2 6.5 11.5 10.1 9.7 0.7 7.8 4.5 6.6 9.1 4.8 4.2 10.1 2.0 5.6 5.6 3.2 9.2 4.0 7.5 7.3 RAD52 ENSG00000002016 "RAD52 homolog, DNA repair protein" P43351 12 912077-990053 "Cancer-related genes, Predicted intracellular proteins" "DNA damage, DNA recombination, DNA repair" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA028957 Approved "Nuclear speckles,Plasma membrane" "Nuclear speckles" "Plasma membrane" "HPA028957: " "unprognostic (4.53e-1)" "unprognostic (8.08e-3)" "unprognostic (4.68e-2)" "unprognostic (5.27e-2)" "unprognostic (7.37e-2)" "unprognostic (1.42e-2)" "unprognostic (1.82e-3)" "unprognostic (1.88e-1)" "unprognostic (2.80e-2)" "unprognostic (8.43e-2)" "unprognostic (1.03e-2)" "unprognostic (3.27e-1)" "prognostic unfavourable (2.22e-6)" "unprognostic (1.54e-1)" "unprognostic (1.61e-1)" "unprognostic (1.68e-1)" "unprognostic (3.74e-2)" 7.4 8.5 12.4 8.1 15.1 5.0 10.0 18.8 15.9 12.6 11.7 14.5 13.6 9.4 12.5 14.2 8.2 11.0 9.0 7.8 14.3 7.3 9.9 10.5 6.9 8.9 15.0 9.6 17.6 11.4 9.6 15.6 8.5 15.0 10.5 11.7 9.5 8.4 11.0 16.5 14.9 10.4 12.8 17.0 10.3 8.8 6.8 20.9 9.4 14.6 4.3 9.7 9.7 13.3 7.0 9.6 7.4 3.8 4.0 6.0 1.4 3.1 12.2 9.6 10.7 10.5 7.9 10.3 6.4 5.9 7.0 7.0 11.7 11.2 10.0 2.0 6.3 9.4 7.3 4.3 6.3 13.5 6.5 11.2 11.8 8.1 5.9 12.0 3.4 4.6 7.5 7.4 22.8 5.9 7.4 5.8 6.8 6.7 8.1 11.9 12.4 8.0 8.3 9.4 3.7 7.3 5.8 3.4 3.9 8.2 8.9 4.5 8.2 5.9 5.8 9.9 11.9 7.7 6.6 2.2 3.5 10.5 5.1 5.1 3.6 7.4 3.4 2.0 4.6 2.9 6.0 4.8 4.9 4.0 4.4 7.0 5.7 5.2 2.8 4.0 3.8 9.6 4.4 1.4 12.4 15.1 18.8 15.9 14.3 7.3 15.0 9.6 15.0 20.9 RAD54B RDH54 ENSG00000197275 "RAD54 homolog B (S. cerevisiae)" Q9Y620 8 94371960-94475109 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA repair" "DNA-binding, Helicase, Hydrolase" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 21.2" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 9 "gdT-cell: 1.4;MAIT T-cell: 4.4;memory B-cell: 1.7;memory CD4 T-cell: 2.4;memory CD8 T-cell: 1.3;naive B-cell: 2.6;naive CD4 T-cell: 1.8;naive CD8 T-cell: 2.6;T-reg: 1.4" "Group enriched" "Detected in many" 14 "B-cells: 2.6;T-cells: 4.4" HPA007087 Uncertain "HPA007087: AB_1856040" "unprognostic (1.68e-3)" "unprognostic (2.51e-1)" "unprognostic (2.31e-2)" "unprognostic (8.84e-3)" "unprognostic (4.15e-2)" "unprognostic (1.44e-1)" "unprognostic (5.56e-8)" "unprognostic (1.96e-2)" "unprognostic (1.77e-2)" "unprognostic (5.39e-2)" "unprognostic (2.30e-2)" "unprognostic (2.64e-1)" "unprognostic (2.04e-12)" "unprognostic (5.86e-2)" "unprognostic (5.23e-1)" "unprognostic (9.08e-2)" "unprognostic (6.68e-5)" 2.7 3.9 3.9 7.7 8.6 4.6 4.7 11.8 9.1 6.1 4.7 3.8 4.4 3.8 4.0 4.7 5.4 7.7 2.3 3.5 7.7 3.5 3.5 4.3 2.6 6.3 5.4 4.2 5.2 4.1 5.0 6.6 3.7 7.2 5.2 4.8 3.1 3.7 5.7 1.9 4.2 3.4 3.1 9.4 3.2 4.2 10.5 6.7 21.2 3.6 5.0 6.7 6.7 3.8 2.6 0.2 0.0 0.2 0.2 4.4 0.9 14.1 9.8 13.9 7.5 1.1 1.5 7.6 10.7 5.7 15.1 14.4 5.0 9.7 10.2 16.2 3.0 7.7 12.3 5.3 16.5 11.7 7.3 15.5 5.6 4.0 1.3 5.8 5.5 1.3 0.7 7.6 9.3 5.5 11.5 6.7 15.3 6.6 19.7 3.8 9.6 8.7 4.7 15.2 5.8 6.3 6.8 8.9 6.2 7.6 1.8 5.7 9.6 3.3 4.3 10.3 5.5 11.4 11.7 3.5 7.5 5.3 5.5 10.4 10.3 0.0 0.0 0.0 1.4 0.0 4.4 1.7 2.4 1.3 0.2 2.6 1.8 2.6 0.0 0.2 0.2 0.1 1.4 0.9 3.9 8.6 11.8 9.1 7.7 3.5 5.4 4.2 7.2 6.7 RAF1 "c-Raf, CRAF, Raf-1" ENSG00000132155 "Raf-1 proto-oncogene, serine/threonine kinase" P04049 3 12583601-12664226 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Cardiomyopathy, Deafness, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "neutrophil: 53.9" "Lineage enriched" "Detected in all" 5 "granulocytes: 53.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002640, CAB019291" Approved Approved "Nuclear speckles" "Nuclear speckles" "CAB019291: , HPA002640: AB_1856047" "unprognostic (6.33e-2)" "unprognostic (1.29e-1)" "unprognostic (5.92e-2)" "unprognostic (2.17e-3)" "unprognostic (6.51e-3)" "unprognostic (7.66e-3)" "unprognostic (2.66e-3)" "unprognostic (1.53e-2)" "unprognostic (2.72e-1)" "unprognostic (7.66e-2)" "unprognostic (2.92e-2)" "unprognostic (1.29e-2)" "unprognostic (2.79e-2)" "unprognostic (1.79e-1)" "unprognostic (1.27e-1)" "unprognostic (2.64e-2)" "unprognostic (2.36e-2)" 19.5 15.6 15.1 14.7 17.1 32.2 17.5 35.2 18.9 19.9 20.3 21.1 19.6 18.4 24.9 15.7 24.6 18.6 20.2 39.3 15.3 11.0 21.7 36.2 19.7 15.7 16.0 13.4 24.9 31.3 30.7 16.9 24.8 14.3 18.8 19.2 25.0 18.3 18.4 79.7 23.9 29.6 23.7 13.8 22.1 23.7 16.7 17.8 27.7 26.9 27.9 26.1 20.5 20.4 6.6 9.3 53.9 9.9 8.5 8.6 7.7 15.1 17.4 26.6 20.5 23.1 18.7 53.5 23.1 39.2 30.6 34.8 13.6 12.5 15.9 11.1 35.8 9.7 28.0 20.5 31.9 27.7 21.9 21.4 21.0 12.6 23.4 20.8 20.3 17.2 20.7 31.5 25.6 21.9 15.5 41.8 29.5 25.9 26.7 15.3 27.0 23.7 21.6 23.4 20.0 18.3 22.9 8.3 17.5 18.9 18.3 12.3 30.4 27.5 15.7 21.1 20.1 17.6 25.7 32.6 51.8 34.2 18.2 24.3 22.4 11.3 9.7 18.4 7.4 9.9 7.5 6.6 7.3 7.2 9.3 6.3 7.5 7.6 53.9 8.5 9.6 4.2 8.6 7.7 15.1 17.1 35.2 18.9 15.3 11.0 16.0 13.4 14.3 17.8 RANBP2 "ADANE, ANE1, NUP358" ENSG00000153201 "RAN binding protein 2" P49792 2 108719481-108785811 "Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters" "mRNA transport, Protein transport, Translocation, Transport, Ubl conjugation pathway" "RNA-binding, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "HPA018437, HPA023960, CAB034063, HPA049497, HPA051675, HPA067564" Supported Enhanced "Nuclear membrane,Vesicles" "Nuclear membrane, Vesicles" "CAB034063: AB_2176784, HPA018437: AB_2620151, HPA023960: , HPA049497: , HPA051675: , HPA067564: " "unprognostic (2.51e-1)" "unprognostic (3.99e-2)" "unprognostic (1.22e-1)" "unprognostic (4.37e-2)" "unprognostic (1.28e-2)" "unprognostic (9.30e-2)" "unprognostic (5.47e-2)" "unprognostic (2.91e-1)" "unprognostic (4.02e-2)" "unprognostic (2.54e-1)" "unprognostic (4.23e-1)" "unprognostic (5.23e-2)" "unprognostic (1.62e-2)" "unprognostic (8.74e-2)" "unprognostic (3.08e-1)" "unprognostic (3.40e-2)" "unprognostic (2.53e-1)" 20.5 24.3 14.4 17.0 18.6 35.5 24.4 23.1 22.2 19.8 17.1 12.8 25.5 13.3 19.9 21.5 17.0 19.1 14.8 20.2 12.9 12.5 18.9 19.5 17.7 19.2 15.1 17.0 32.4 24.1 48.5 37.5 18.8 16.5 21.8 15.8 14.3 20.0 31.6 37.5 17.3 17.4 23.2 17.8 16.3 20.9 20.6 15.9 26.6 28.7 18.0 17.5 20.5 19.7 5.6 5.1 8.3 6.3 4.2 8.7 2.3 18.2 11.2 16.1 14.6 18.8 16.9 15.6 16.5 13.1 13.6 12.0 27.8 8.8 28.8 12.8 17.1 15.4 27.5 17.1 19.9 17.5 13.3 30.0 13.9 19.6 11.0 35.0 10.1 14.1 13.1 21.3 16.6 20.8 32.1 16.0 18.0 10.1 15.5 14.3 20.3 13.4 14.6 24.8 13.9 12.1 22.9 23.5 10.8 14.6 12.6 16.0 8.0 16.1 24.8 14.3 18.9 10.0 18.4 13.3 19.6 26.2 11.1 15.8 11.0 8.3 5.3 5.1 7.6 3.4 8.7 5.5 6.3 6.9 4.2 5.6 6.2 6.7 8.3 4.2 6.3 5.1 5.1 2.3 14.4 18.6 23.1 22.2 12.9 12.5 15.1 17.0 16.5 15.9 RANBP3 ENSG00000031823 "RAN binding protein 3" Q9H6Z4 19 5916139-5978142 "Cancer-related genes, Predicted intracellular proteins" "Protein transport, Transport" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA043375, HPA043389" Enhanced Enhanced Nucleoplasm Nucleoplasm "HPA043375: AB_10959889, HPA043389: AB_10963696" "unprognostic (1.81e-1)" "unprognostic (1.18e-3)" "unprognostic (3.61e-1)" "prognostic favourable (1.22e-5)" "unprognostic (4.24e-2)" "unprognostic (1.42e-3)" "unprognostic (5.44e-2)" "unprognostic (3.90e-2)" "unprognostic (3.58e-1)" "unprognostic (1.08e-1)" "prognostic favourable (4.14e-4)" "unprognostic (2.27e-1)" "unprognostic (3.80e-2)" "unprognostic (2.91e-1)" "unprognostic (5.15e-2)" "prognostic favourable (8.14e-4)" "unprognostic (1.06e-2)" 19.5 30.2 24.8 25.2 31.5 20.9 18.6 38.2 40.9 21.2 29.8 31.6 18.3 24.7 28.2 16.5 23.4 23.9 20.3 30.8 25.0 26.5 19.3 24.6 21.9 26.7 24.3 21.2 29.2 33.1 22.4 26.1 22.3 28.8 25.6 14.2 30.1 27.9 28.0 33.9 21.2 25.1 27.9 25.0 24.9 24.9 36.7 28.0 33.5 21.9 14.7 27.7 28.0 20.9 20.7 21.3 25.0 21.4 14.9 28.7 20.1 30.3 21.4 18.2 20.3 13.7 14.0 13.0 19.4 18.4 22.8 24.7 26.9 10.8 28.7 21.9 15.0 18.9 16.2 18.9 14.0 29.3 26.4 15.4 16.7 32.0 14.9 22.4 22.6 13.6 13.1 14.2 16.3 16.6 27.8 27.2 12.8 12.7 37.3 10.9 33.3 27.1 27.7 17.5 26.1 14.8 23.5 20.1 22.6 17.3 18.3 17.1 14.0 17.1 17.1 19.3 14.1 33.6 28.5 28.2 28.4 24.7 24.4 28.3 23.6 13.2 20.8 25.0 22.7 21.4 23.3 17.0 22.0 22.7 21.3 20.7 19.6 25.1 24.0 14.9 20.6 20.2 28.7 20.1 24.8 31.5 38.2 40.9 25.0 26.5 24.3 21.2 28.8 28.0 RAP1GDS1 SmgGDS ENSG00000138698 "Rap1 GTPase-GDP dissociation stimulator 1" P52306 4 98261384-98443861 "Cancer-related genes, Predicted intracellular proteins" "GTPase activation" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA019060 Approved Supported Cytosol 120000 Cytosol "HPA019060: AB_1856068" "unprognostic (8.12e-2)" "unprognostic (1.50e-1)" "unprognostic (2.69e-3)" "unprognostic (1.66e-1)" "unprognostic (9.11e-2)" "unprognostic (1.35e-2)" "unprognostic (1.57e-3)" "unprognostic (3.44e-1)" "unprognostic (6.31e-2)" "unprognostic (1.27e-1)" "unprognostic (3.15e-1)" "unprognostic (4.60e-1)" "prognostic favourable (2.00e-4)" "unprognostic (7.11e-2)" "unprognostic (3.09e-1)" "unprognostic (1.47e-1)" "unprognostic (2.76e-1)" 11.3 9.7 25.8 12.9 28.2 9.0 13.1 28.0 43.6 9.3 12.0 20.0 9.0 7.3 8.9 8.7 13.7 6.1 8.6 6.8 29.7 28.0 12.3 15.2 10.1 15.3 36.9 20.5 7.9 13.8 8.4 15.3 9.6 30.1 8.0 14.0 8.0 8.6 11.9 3.6 10.5 9.0 16.3 37.0 12.5 8.2 15.5 26.2 16.2 13.0 4.8 17.0 12.5 7.6 13.9 31.9 16.0 14.7 19.5 22.7 8.4 17.7 10.3 13.2 11.3 17.1 20.5 5.3 30.2 16.8 18.0 14.2 7.7 23.0 21.1 9.8 22.5 10.1 16.3 27.6 24.4 21.5 6.7 13.0 13.3 10.0 33.9 21.6 9.1 23.8 16.9 15.9 24.7 23.6 8.6 18.1 44.6 9.3 35.7 10.7 4.8 7.5 14.9 7.9 7.1 18.3 13.9 19.6 11.9 12.6 28.4 16.7 6.4 14.1 23.2 18.7 13.5 8.6 17.9 6.2 10.8 17.7 15.5 16.2 24.3 16.0 10.6 5.7 14.2 14.6 14.3 13.9 14.5 13.6 16.7 11.0 7.8 11.9 1.6 19.5 14.7 31.9 22.7 8.4 25.8 28.2 28.0 30.5 29.7 28.0 36.9 20.5 30.1 26.2 RARA "NR1B1, RAR" ENSG00000131759 "Retinoic acid receptor alpha" P10276 17 40309192-40357643 "Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "MCF7: 63.1;SK-BR-3: 40.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 26.6" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA058282 Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "HPA058282: " "unprognostic (8.05e-3)" "unprognostic (1.89e-1)" "unprognostic (9.48e-3)" "prognostic favourable (2.60e-4)" "unprognostic (8.67e-3)" "unprognostic (4.87e-3)" "unprognostic (2.77e-1)" "unprognostic (5.73e-2)" "unprognostic (1.45e-1)" "unprognostic (3.54e-2)" "unprognostic (1.19e-1)" "unprognostic (1.79e-1)" "unprognostic (2.29e-3)" "unprognostic (1.59e-2)" "unprognostic (5.60e-2)" "unprognostic (1.60e-1)" "unprognostic (1.09e-2)" 27.6 13.5 5.0 18.6 7.6 32.3 23.7 11.5 15.2 30.2 29.6 5.0 16.8 18.0 23.8 23.9 17.3 23.3 30.2 24.3 5.9 6.1 14.6 24.0 32.0 23.4 4.6 7.8 50.0 9.3 7.4 18.1 16.6 6.5 22.9 8.5 26.8 12.1 32.7 43.1 14.3 31.6 18.6 3.7 31.1 14.3 21.8 2.9 9.7 16.3 15.4 20.2 31.5 20.3 1.0 6.1 26.6 9.3 2.5 2.6 1.9 5.0 11.9 3.6 6.0 7.0 10.8 3.6 4.2 6.3 6.2 4.0 8.2 4.4 2.7 6.6 9.4 14.9 4.1 9.9 3.5 20.2 6.1 7.7 6.0 8.0 11.3 2.7 24.4 15.1 2.9 6.5 8.3 9.1 4.8 5.9 6.9 63.1 1.7 9.4 3.1 3.8 3.6 21.1 10.2 3.6 4.0 1.5 12.2 8.9 40.1 12.2 37.8 11.1 10.6 7.7 13.2 13.5 4.5 14.2 4.7 2.3 12.9 5.5 22.8 8.7 4.2 15.7 1.6 6.9 2.6 1.0 1.7 1.7 6.1 0.9 0.8 1.3 26.6 2.5 9.3 1.8 1.4 1.9 5.0 7.6 11.5 15.2 5.9 6.1 4.6 7.8 6.5 2.9 RARB "HAP, NR1B2, RRB2" ENSG00000077092 "Retinoic acid receptor beta" P10826 3 25174332-25597932 "Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes, Disease mutation, FDA approved drug targets, Microphthalmia, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "retina: 39.1" "Cell line enhanced" "Detected in some" "ASC diff: 9.9;HEK 293: 11.2;HUVEC TERT2: 9.3;WM-115: 25.6" "Low cancer specificity" "Detected in all" "Region enhanced" "Detected in all" "basal ganglia: 22.6" "Low cell type specificity" "Detected in single" "Low lineage specificity" "Detected in single" "Region enriched" "Detected in many" 9 "basal ganglia: 97.9" "Low region specificity" "Detected in all" "CAB002617, HPA004174" Enhanced Enhanced Nucleoplasm Nucleoplasm "CAB002617: , HPA004174: AB_1079744" "unprognostic (2.04e-2)" "unprognostic (3.53e-2)" "unprognostic (1.93e-1)" "unprognostic (1.09e-1)" "unprognostic (1.56e-1)" "unprognostic (6.72e-2)" "unprognostic (1.30e-2)" "unprognostic (2.70e-2)" "unprognostic (2.43e-1)" "unprognostic (4.71e-2)" "unprognostic (1.62e-1)" "unprognostic (2.86e-1)" "prognostic favourable (3.43e-5)" "unprognostic (9.24e-3)" "unprognostic (2.28e-1)" "unprognostic (9.99e-2)" "unprognostic (6.56e-3)" 3.9 7.1 2.4 2.3 22.6 0.0 6.8 1.5 9.1 13.4 6.0 2.2 6.8 1.7 14.4 7.5 8.1 6.2 5.3 13.6 2.6 2.2 17.5 6.2 5.6 5.6 2.0 3.7 12.2 1.5 12.8 18.9 13.9 3.2 13.0 2.3 39.1 13.7 11.8 2.5 1.4 2.4 14.7 4.6 7.7 4.8 1.7 4.8 0.0 10.0 2.9 4.6 12.1 10.2 1.0 0.4 0.1 0.6 0.1 0.8 0.0 0.0 1.3 0.8 4.5 9.9 2.6 0.0 1.1 0.5 0.0 0.4 0.2 0.0 0.1 0.1 1.7 0.2 0.0 0.1 0.0 0.0 11.2 0.1 0.1 0.7 0.2 0.1 0.1 5.2 0.0 0.0 0.0 9.3 0.1 3.9 0.1 0.0 0.0 0.1 0.2 0.0 0.2 0.0 0.0 0.0 0.1 0.4 5.9 0.0 0.1 0.1 0.0 0.0 0.0 0.8 0.1 1.5 4.8 0.1 0.0 0.0 4.0 0.1 25.6 0.0 0.6 0.0 0.8 0.1 0.3 0.3 0.5 0.5 0.4 1.0 0.6 0.8 0.1 0.1 0.1 0.4 0.0 0.0 2.4 22.6 1.5 9.1 2.6 2.2 2.0 3.7 3.2 4.8 RARG "NR1B3, RARC" ENSG00000172819 "Retinoic acid receptor gamma" P13631 12 53210567-53232980 "Cancer-related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "esophagus: 49.4;skin 1: 52.1" "Cell line enhanced" "Detected in many" "CAPAN-2: 33.2;MCF7: 35.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "MAIT T-cell: 17.0" "Group enriched" "Detected in all" 4 "dendritic cells: 5.6;T-cells: 17.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" HPA053883 Supported Supported Nucleoplasm Nucleoplasm "HPA053883: AB_2682292" "unprognostic (7.29e-2)" "unprognostic (1.95e-2)" "unprognostic (6.11e-2)" "prognostic unfavourable (3.68e-6)" "unprognostic (2.53e-1)" "unprognostic (5.43e-2)" "unprognostic (2.28e-1)" "unprognostic (1.08e-2)" "unprognostic (3.54e-3)" "unprognostic (7.21e-3)" "unprognostic (3.78e-3)" "unprognostic (4.44e-2)" "prognostic unfavourable (3.08e-6)" "unprognostic (5.41e-3)" "unprognostic (1.98e-2)" "unprognostic (5.94e-3)" "unprognostic (7.41e-2)" 4.8 5.0 2.7 7.0 3.6 1.3 10.8 6.3 3.8 26.8 6.3 1.8 7.3 1.0 14.6 6.0 49.4 10.6 8.6 6.9 3.0 1.4 3.7 1.9 7.4 6.7 2.4 2.3 12.6 2.7 4.2 2.8 4.4 1.6 11.3 3.4 10.3 9.5 10.6 2.6 52.1 3.0 9.7 1.5 4.7 6.0 3.9 1.7 2.3 7.3 30.6 26.8 10.9 19.8 1.8 5.6 1.5 2.5 1.7 17.0 2.9 7.2 8.0 1.8 16.9 18.8 16.2 0.5 7.6 16.6 10.0 7.8 2.7 33.2 0.1 4.1 30.5 24.4 6.1 14.6 2.5 1.9 3.1 1.0 6.1 2.3 7.9 0.0 3.0 11.9 21.4 9.5 2.1 4.2 0.2 3.2 3.9 35.0 0.4 0.3 5.4 14.1 2.3 0.6 5.8 2.9 12.0 1.5 7.6 15.4 16.7 10.1 14.5 0.4 4.5 12.0 5.6 7.9 0.4 1.5 0.8 0.5 14.7 1.2 16.9 1.5 2.5 0.7 6.6 0.8 17.0 1.8 5.7 4.8 5.6 0.6 4.8 4.1 0.0 1.7 0.0 0.4 1.5 2.9 2.7 3.6 6.3 3.8 3.0 1.4 2.4 2.3 1.6 1.7 RASA1 "CM-AVM, GAP, p120, p120GAP, p120RASGAP, RASA" ENSG00000145715 "RAS p21 protein activator 1" P20936 5 87267888-87391931 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins" "GTPase activation" "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in all" 13 "placenta: 260.6" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB007789, HPA036393, HPA064556" Enhanced 7900 "CAB007789: AB_598183, HPA036393: , HPA064556: " "unprognostic (1.57e-1)" "unprognostic (7.63e-2)" "unprognostic (1.88e-3)" "unprognostic (2.14e-1)" "unprognostic (1.23e-1)" "unprognostic (1.38e-2)" "unprognostic (6.88e-2)" "unprognostic (8.38e-3)" "unprognostic (2.23e-1)" "unprognostic (1.07e-2)" "unprognostic (4.12e-3)" "unprognostic (1.03e-1)" "unprognostic (3.98e-2)" "unprognostic (1.59e-2)" "unprognostic (5.39e-2)" "unprognostic (1.65e-1)" "unprognostic (1.30e-3)" 12.4 8.8 12.3 8.9 12.8 6.4 11.4 17.3 16.3 11.3 8.1 8.6 9.3 6.9 12.4 11.4 10.2 9.5 9.3 7.2 12.0 10.9 8.7 6.5 8.4 9.2 10.1 13.8 15.9 8.2 20.3 12.2 260.6 9.3 8.0 9.8 9.6 10.6 9.6 6.9 9.7 10.0 9.0 9.4 13.7 7.4 14.4 10.0 10.7 14.4 5.7 9.6 11.3 9.8 2.0 1.3 3.1 2.6 8.1 3.5 1.1 11.5 6.5 11.3 7.3 9.6 14.2 8.8 18.5 12.0 11.4 18.9 4.3 30.6 7.5 4.5 20.2 5.4 5.2 15.0 34.7 7.3 4.2 5.6 5.6 4.7 9.7 4.1 6.7 8.0 9.6 32.1 18.2 15.9 3.1 16.2 39.3 7.0 5.0 6.1 5.9 12.1 6.2 25.7 11.1 9.9 10.0 6.9 7.5 6.8 8.8 9.7 7.9 6.4 23.5 14.6 6.4 7.5 23.0 5.7 5.9 7.6 21.3 8.5 10.4 3.1 1.3 1.4 2.0 2.6 3.5 1.4 2.4 1.9 1.1 2.0 2.1 1.9 1.7 8.1 2.4 1.3 3.0 1.1 12.3 12.8 17.3 16.3 12.0 10.9 10.1 13.8 9.3 10.0 RB1 "OSRC, PPP1R130, RB" ENSG00000139687 "RB transcriptional corepressor 1" P06400 13 48303726-48599436 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Host-virus interaction, Transcription, Transcription regulation" "Chromatin regulator, DNA-binding, Repressor" "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "MOLT-4: 57.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000095, CAB016687, HPA050082" Supported Enhanced Nucleoplasm Nucleoplasm "CAB000095: , CAB016687: AB_1622010, HPA050082: " "unprognostic (4.24e-3)" "unprognostic (1.00e-1)" "unprognostic (3.62e-2)" "unprognostic (4.67e-2)" "unprognostic (2.04e-2)" "unprognostic (3.86e-1)" "unprognostic (4.69e-2)" "unprognostic (7.08e-2)" "unprognostic (1.59e-1)" "prognostic unfavourable (6.92e-4)" "unprognostic (4.06e-2)" "unprognostic (9.40e-2)" "unprognostic (4.67e-2)" "unprognostic (1.79e-1)" "unprognostic (9.99e-2)" "unprognostic (2.31e-1)" "unprognostic (1.70e-1)" 19.6 21.5 14.9 23.2 18.4 14.7 28.1 25.6 19.4 18.0 13.2 11.5 19.0 12.3 16.8 19.5 27.9 12.7 15.3 19.5 15.4 15.3 18.1 12.1 25.4 30.1 17.0 11.8 15.2 11.6 12.8 17.2 21.5 16.0 15.5 15.3 11.6 20.0 17.4 27.9 20.3 14.3 16.8 23.6 29.4 13.7 14.4 15.3 39.1 19.9 15.8 25.3 17.4 23.6 20.5 10.3 13.2 12.2 3.6 4.6 4.0 9.0 4.9 13.4 14.4 6.6 7.7 6.1 17.9 14.9 18.9 16.1 4.2 16.1 11.7 4.1 11.9 12.6 17.4 14.4 28.9 16.4 6.6 21.6 10.1 7.1 7.1 18.5 20.5 4.3 8.9 12.2 15.7 13.0 7.1 9.7 21.6 4.3 57.9 9.3 6.5 5.4 24.9 13.4 13.5 19.6 8.8 0.6 13.7 17.7 8.9 14.6 9.7 24.2 10.1 11.7 7.7 14.3 16.1 4.3 1.2 0.1 6.2 11.6 15.8 11.0 9.7 5.0 4.6 12.2 3.7 17.4 3.8 4.6 9.3 20.5 3.2 3.8 13.2 3.6 12.1 10.3 4.5 4.0 14.9 18.4 25.6 19.4 15.4 15.3 17.0 11.8 16.0 15.3 RBBP4 "lin-53, NURF55, RbAp48" ENSG00000162521 "RB binding protein 4, chromatin remodeling factor" Q09028 1 32651142-32686211 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, DNA replication, Transcription, Transcription regulation" "Chromatin regulator, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB006264, HPA060710, HPA060724" Supported Enhanced Nucleoplasm 27000 Nucleoplasm "CAB006264: AB_425651, HPA060710: , HPA060724: " "unprognostic (1.18e-3)" "unprognostic (1.79e-3)" "unprognostic (2.96e-3)" "unprognostic (1.82e-2)" "prognostic favourable (9.23e-4)" "unprognostic (1.62e-2)" "prognostic unfavourable (1.89e-6)" "unprognostic (1.24e-2)" "prognostic unfavourable (6.45e-4)" "unprognostic (1.57e-2)" "unprognostic (1.30e-1)" "unprognostic (2.69e-1)" "unprognostic (1.36e-3)" "unprognostic (3.05e-2)" "unprognostic (1.51e-1)" "unprognostic (2.29e-1)" "unprognostic (1.88e-2)" 23.8 33.6 28.2 34.3 27.8 23.4 29.1 30.5 35.1 32.2 24.1 32.0 42.3 20.5 36.0 29.2 26.0 35.4 21.3 24.0 27.9 24.8 25.2 25.4 23.0 43.9 30.6 29.0 37.6 31.3 27.0 32.9 26.2 26.9 24.2 35.5 31.2 30.1 43.1 31.8 24.9 26.8 32.6 26.9 27.6 28.8 53.4 31.4 73.3 35.8 20.5 65.2 32.5 26.6 33.7 45.4 26.7 39.4 33.1 32.4 48.4 15.4 13.6 38.9 28.3 12.0 11.4 15.7 11.8 10.3 24.1 23.5 19.4 31.9 47.0 13.1 13.9 10.0 42.5 12.3 26.1 18.3 20.4 43.8 27.4 25.4 17.4 41.3 19.0 12.5 15.7 18.2 11.8 17.8 30.8 33.7 20.6 10.8 53.0 13.0 43.2 15.9 51.5 40.9 40.8 16.9 33.2 37.2 22.1 28.0 10.0 19.1 17.1 19.2 14.8 14.7 15.0 18.5 15.8 26.8 28.1 52.8 17.5 33.4 22.5 26.4 38.8 26.7 31.1 39.4 32.4 33.7 29.7 31.4 45.4 26.6 26.7 28.8 10.2 33.1 35.3 38.3 30.3 48.4 28.2 27.8 30.5 35.1 27.9 24.8 30.6 29.0 26.9 31.4 RBL1 "cp107, p107, PRB1" ENSG00000080839 "RB transcriptional corepressor like 1" P28749 20 36996349-37095995 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell cycle, Host-virus interaction, Transcription, Transcription regulation" "Chromatin regulator, Repressor" "Cancer-related genes, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in some" "Low region specificity" "Detected in all" "HPA054962, HPA056525" Enhanced Enhanced Nucleoplasm Nucleoplasm "HPA054962: AB_2682652, HPA056525: AB_2683165" "unprognostic (1.97e-1)" "unprognostic (2.47e-2)" "unprognostic (1.30e-2)" "unprognostic (3.70e-3)" "unprognostic (2.13e-1)" "unprognostic (1.51e-1)" "unprognostic (6.25e-5)" "unprognostic (6.91e-2)" "unprognostic (7.19e-3)" "unprognostic (1.20e-1)" "unprognostic (4.49e-3)" "unprognostic (3.23e-2)" "prognostic unfavourable (2.52e-6)" "unprognostic (3.15e-2)" "unprognostic (2.75e-1)" "unprognostic (1.47e-2)" "unprognostic (1.26e-1)" 5.0 4.3 4.9 12.3 7.1 20.4 4.8 16.6 7.8 5.1 5.6 5.5 5.9 4.0 8.1 3.0 7.7 4.4 3.6 4.0 4.0 3.6 3.3 3.0 4.5 11.1 6.5 2.2 7.8 6.0 5.9 5.9 8.3 5.7 4.4 6.1 5.3 4.8 2.7 10.2 5.3 5.9 5.9 7.1 6.9 4.6 8.2 5.5 19.6 5.3 6.1 11.4 4.7 7.1 5.0 5.1 2.2 1.9 3.6 7.4 1.6 12.0 7.9 9.9 6.6 2.5 3.3 6.3 14.1 6.3 12.2 12.7 8.3 6.8 13.5 4.1 5.8 11.9 8.8 9.1 20.5 4.7 4.7 13.3 9.3 7.0 1.5 17.1 9.3 1.6 1.2 16.1 5.7 6.8 9.7 13.1 6.9 5.1 15.9 5.7 2.9 7.7 10.4 29.4 10.2 2.8 6.0 2.3 5.9 15.4 8.9 4.1 5.7 12.4 4.5 21.7 8.3 19.8 12.2 4.4 7.7 13.7 15.5 12.1 10.6 1.4 1.2 2.2 5.0 1.4 4.2 5.0 5.6 4.5 2.2 3.9 6.0 4.8 0.6 3.6 1.9 5.1 7.4 1.6 4.9 7.1 16.6 7.8 4.0 3.6 6.5 2.2 5.7 5.5 RBL2 "p130, Rb2" ENSG00000103479 "RB transcriptional corepressor like 2" Q08999 16 53433977-53491649 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Transcription, Transcription regulation" "Chromatin regulator, DNA-binding, Repressor" "Cancer-related genes, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB016547, HPA019703" Supported Supported Nucleoplasm,Nucleoli,Cytosol "Nucleoplasm, Nucleoli" Cytosol "CAB016547: AB_785011, HPA019703: AB_1856106" "unprognostic (1.51e-1)" "unprognostic (4.38e-2)" "unprognostic (4.00e-2)" "unprognostic (1.26e-1)" "unprognostic (6.88e-2)" "unprognostic (6.43e-2)" "unprognostic (5.03e-2)" "unprognostic (2.46e-2)" "unprognostic (1.04e-1)" "unprognostic (2.11e-1)" "unprognostic (4.70e-1)" "unprognostic (8.12e-2)" "prognostic favourable (3.57e-5)" "unprognostic (9.57e-3)" "unprognostic (1.02e-1)" "unprognostic (8.70e-2)" "unprognostic (7.51e-2)" 27.8 20.6 15.7 22.2 20.0 11.1 25.5 24.1 18.7 26.3 23.7 24.7 25.6 15.4 30.0 20.2 21.5 25.1 19.5 19.9 15.5 11.7 23.8 34.2 24.0 31.6 25.8 13.7 29.3 30.7 55.3 22.6 12.4 15.8 28.2 18.9 20.2 26.2 30.5 28.3 20.8 24.6 26.1 17.9 27.2 24.9 28.6 22.8 54.4 31.0 10.3 31.6 36.5 26.8 9.1 8.0 20.2 9.8 26.2 35.1 24.5 12.6 8.6 11.5 10.6 30.2 29.2 5.4 9.3 13.3 11.6 4.0 5.6 15.9 18.5 14.1 15.7 15.9 8.6 14.4 18.5 6.6 11.9 8.3 8.7 10.4 13.0 11.5 26.1 18.5 17.7 7.9 11.3 17.9 6.7 11.6 12.9 3.7 22.9 15.5 4.7 7.8 16.7 21.0 21.2 11.4 12.9 9.4 7.8 21.1 9.3 9.1 12.0 15.2 14.8 14.4 7.7 11.9 6.9 17.9 10.5 21.7 18.0 14.4 9.9 16.4 8.2 20.2 21.2 5.9 23.7 8.7 23.8 24.3 8.0 9.1 35.1 29.6 15.7 26.2 9.8 4.9 17.5 24.5 15.7 20.0 24.1 18.7 15.5 11.7 25.8 13.7 15.8 22.8 RBM10 "DXS8237E, GPATC9, GPATCH9, KIAA0122, ZRANB5" ENSG00000182872 "RNA binding motif protein 10" P98175 X 47144869-47186813 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "mRNA processing, mRNA splicing" RNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA034972, HPA057372" Approved Enhanced "Nuclear speckles" "Nuclear speckles" "HPA034972: AB_10602919, HPA057372: " "unprognostic (9.07e-2)" "prognostic favourable (6.71e-4)" "unprognostic (7.83e-2)" "unprognostic (1.61e-2)" "unprognostic (1.86e-1)" "unprognostic (3.04e-2)" "unprognostic (4.47e-3)" "unprognostic (8.11e-2)" "unprognostic (9.86e-3)" "unprognostic (1.76e-1)" "prognostic favourable (2.86e-6)" "unprognostic (1.18e-1)" "unprognostic (6.23e-3)" "unprognostic (3.33e-2)" "unprognostic (1.09e-1)" "unprognostic (4.40e-2)" "unprognostic (1.20e-3)" 18.1 22.2 19.8 38.0 21.9 34.0 17.1 41.2 22.9 19.9 20.5 25.7 22.7 21.8 22.1 17.3 23.7 26.2 29.1 21.7 19.8 18.3 18.4 21.6 17.1 27.2 20.1 19.2 36.4 27.4 20.1 28.3 24.9 17.9 23.5 14.2 18.5 25.1 28.8 20.6 23.8 23.7 18.9 17.2 24.7 20.5 8.7 21.4 32.9 26.8 18.0 22.7 17.6 20.9 15.9 14.6 14.4 19.2 12.3 18.3 11.5 20.7 22.5 21.6 25.5 11.6 9.5 25.1 15.8 9.3 16.4 16.0 19.6 17.1 25.4 9.7 10.9 20.3 28.1 19.9 9.0 25.7 25.5 19.0 27.4 20.5 16.9 19.1 22.9 12.5 9.6 27.0 22.0 17.5 15.8 20.4 9.9 31.7 35.0 32.4 35.6 25.3 31.0 18.0 26.2 12.1 18.4 25.6 19.5 23.9 17.9 15.2 22.0 19.1 15.3 19.3 24.5 20.8 16.6 21.5 17.4 20.9 17.1 13.8 26.9 14.0 10.8 14.4 18.3 14.5 17.0 15.9 14.7 15.3 12.3 15.6 14.8 14.1 10.1 12.3 19.2 14.6 16.6 11.5 19.8 21.9 41.2 21.9 19.8 18.3 20.1 19.2 17.9 21.4 RBM15 "OTT, OTT1" ENSG00000162775 "RNA binding motif protein 15" Q96T37 1 110338506-110346681 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction" RNA-binding "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "bone marrow: 48.7" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB015201, HPA019824, HPA049642" Supported Enhanced Nucleoplasm Nucleoplasm "CAB015201: , HPA019824: AB_1856113, HPA049642: " "unprognostic (1.70e-1)" "unprognostic (1.63e-1)" "unprognostic (9.39e-2)" "unprognostic (7.57e-3)" "unprognostic (2.43e-1)" "unprognostic (2.11e-2)" "prognostic unfavourable (7.61e-4)" "unprognostic (1.13e-1)" "unprognostic (1.84e-2)" "unprognostic (4.91e-2)" "unprognostic (9.67e-2)" "unprognostic (2.76e-2)" "prognostic unfavourable (1.37e-4)" "prognostic favourable (7.97e-4)" "unprognostic (2.88e-1)" "unprognostic (2.46e-2)" "unprognostic (2.12e-1)" 8.5 7.6 6.3 12.2 7.6 48.7 7.9 18.6 8.3 6.6 8.8 7.6 8.3 7.3 8.5 7.2 8.0 7.3 6.6 8.8 5.2 4.3 6.3 11.0 10.5 13.7 8.3 6.0 8.6 7.5 7.1 8.1 7.1 5.9 5.7 5.7 8.1 7.4 6.4 17.2 7.2 11.3 5.5 5.0 12.5 8.3 14.0 7.9 21.8 7.0 5.3 13.4 6.5 8.6 10.5 4.8 9.8 6.9 5.0 9.9 5.5 7.0 7.7 6.9 7.1 4.4 4.6 10.9 3.7 4.9 5.9 7.8 9.4 6.5 13.3 6.0 4.2 10.0 10.8 9.4 8.8 13.8 10.0 10.8 11.7 6.8 6.2 11.7 11.5 4.2 6.6 8.2 7.7 6.3 15.2 23.4 5.9 7.2 10.5 9.2 14.8 4.3 12.5 10.5 9.1 4.8 7.1 8.4 4.2 8.2 10.3 7.9 7.2 14.1 4.3 5.7 10.2 6.1 6.8 18.0 9.1 28.9 8.5 11.8 7.0 8.2 6.9 9.4 7.0 6.0 9.9 10.5 7.7 6.0 4.8 10.0 6.8 8.2 9.8 5.0 6.4 4.7 7.5 5.5 6.3 7.6 18.6 8.3 5.2 4.3 8.3 6.0 5.9 7.9 RBM6 "3G2, DEF-3, DEF3, g16, NY-LU-12" ENSG00000004534 "RNA binding motif protein 6" P78332 3 49940007-50100045 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" RNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA026272, HPA027164" Enhanced Approved "Nuclear speckles,Cytoplasmic bodies" "Nuclear speckles" "Cytoplasmic bodies" "HPA026272: AB_1847592, HPA027164: AB_1847593" "unprognostic (3.81e-3)" "unprognostic (2.13e-1)" "unprognostic (3.52e-2)" "unprognostic (2.40e-2)" "unprognostic (4.53e-2)" "unprognostic (2.88e-2)" "unprognostic (1.40e-2)" "unprognostic (7.97e-3)" "unprognostic (8.84e-3)" "unprognostic (5.09e-2)" "prognostic favourable (1.41e-4)" "unprognostic (4.31e-2)" "prognostic unfavourable (8.83e-4)" "unprognostic (7.82e-2)" "unprognostic (1.47e-1)" "unprognostic (1.45e-1)" "prognostic favourable (5.13e-5)" 24.4 30.2 30.2 51.3 37.1 30.0 25.1 49.4 41.1 31.2 31.0 28.9 38.5 30.3 51.4 34.3 21.8 28.8 32.6 25.3 32.1 19.8 29.2 30.6 26.8 39.8 38.1 26.0 42.6 35.9 41.9 36.9 21.9 30.5 40.1 29.8 25.6 28.1 38.3 25.3 35.9 32.4 36.7 40.9 42.6 28.0 29.7 38.0 24.9 32.6 21.9 35.9 25.1 36.6 12.8 9.9 14.7 8.6 7.3 15.6 5.9 9.6 6.1 25.1 16.7 25.7 14.1 8.9 16.3 14.2 14.4 15.2 10.6 10.9 49.5 9.6 16.2 8.0 21.4 14.4 18.3 19.8 8.0 22.9 14.1 13.7 14.6 24.1 23.8 13.1 17.8 16.3 18.4 18.1 18.8 12.5 13.7 9.1 22.6 35.8 20.1 11.2 8.7 10.8 12.6 14.3 18.8 9.9 17.9 14.9 10.8 10.2 8.4 19.0 16.8 14.4 17.2 11.7 16.5 17.2 40.7 29.8 8.3 20.2 14.1 14.7 8.6 5.0 15.6 4.7 12.1 12.8 10.2 8.5 8.8 11.9 10.5 11.5 6.1 7.3 7.7 9.9 6.7 5.9 30.2 37.1 49.4 41.1 32.1 19.8 38.1 26.0 30.5 38.0 RBMX "hnRNP-G, HNRNPG, RNMX" ENSG00000147274 "RNA binding motif protein, X-linked" P38159 X 136848004-136880764 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "mRNA processing, mRNA splicing, Transcription" "Activator, Repressor, Ribonucleoprotein, RNA-binding" "Cancer-related genes, Mental retardation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA057707 Supported Approved Nucleoplasm Nucleoplasm "HPA057707: " "unprognostic (1.53e-1)" "unprognostic (1.52e-3)" "unprognostic (2.12e-3)" "unprognostic (1.14e-2)" "unprognostic (2.62e-2)" "unprognostic (8.13e-2)" "prognostic unfavourable (5.16e-6)" "unprognostic (5.59e-2)" "unprognostic (1.05e-2)" "unprognostic (1.68e-2)" "unprognostic (4.87e-2)" "unprognostic (2.32e-2)" "unprognostic (2.94e-2)" "unprognostic (1.57e-1)" "unprognostic (7.65e-2)" "unprognostic (6.27e-2)" "unprognostic (4.64e-3)" 31.0 25.0 30.6 57.1 41.1 48.0 40.6 28.7 33.0 44.2 28.3 32.5 32.7 24.6 45.9 31.7 26.7 38.9 22.1 31.4 26.5 18.0 25.6 20.9 34.4 64.6 34.0 29.3 81.9 39.1 30.1 30.1 25.3 30.5 28.4 33.4 27.5 29.9 29.4 50.0 27.6 27.3 43.0 44.2 27.4 30.1 23.6 29.2 70.1 31.5 34.4 44.8 36.1 33.4 47.1 41.9 25.0 44.9 39.4 60.7 62.9 39.9 43.7 80.1 35.6 20.0 34.0 46.8 39.9 43.5 55.3 58.7 46.6 40.2 72.8 41.3 28.5 26.8 85.0 41.7 64.1 31.4 40.0 55.7 43.0 49.6 17.6 60.7 51.3 27.8 20.2 43.0 60.3 44.5 49.9 37.4 44.9 50.9 88.6 41.0 50.8 36.6 73.7 53.6 44.9 41.0 47.9 46.8 50.6 31.8 28.8 36.9 33.1 41.0 28.2 31.4 34.1 21.7 50.7 26.8 35.7 77.1 22.4 44.4 42.7 25.0 37.5 20.8 36.4 44.9 50.3 47.1 47.4 43.1 41.9 45.0 60.7 49.6 6.0 39.4 39.2 25.4 46.8 62.9 30.6 41.1 28.7 33.0 26.5 18.0 34.0 29.3 30.5 29.2 RBP4 ENSG00000138207 "Retinol binding protein 4" P02753 10 93591687-93601744 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Sensory transduction, Transport, Vision" "Cancer-related genes, Disease mutation, Microphthalmia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 23 "liver: 897.1" "Cell line enriched" "Detected in some" 4 "Hep G2: 151.8" "Cancer enriched" "Detected in all" 27 "liver cancer: 3135.4" "Low region specificity" "Detected in many" "Group enriched" "Detected in some" 14 "classical monocyte: 1.2;myeloid DC: 1.5" "Group enriched" "Detected in many" 14 "dendritic cells: 1.5;monocytes: 1.2" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA001641, CAB004555" Supported "Secreted to blood" 46066666667 420000000000 "CAB004555: AB_670938, HPA001641: AB_1079795" "unprognostic (9.42e-3)" "unprognostic (3.40e-2)" "unprognostic (1.90e-1)" "prognostic unfavourable (1.50e-4)" "unprognostic (2.60e-2)" "unprognostic (6.69e-4)" "prognostic favourable (1.74e-8)" "unprognostic (2.39e-1)" "unprognostic (5.76e-2)" "unprognostic (3.26e-2)" "unprognostic (3.26e-1)" "unprognostic (3.44e-1)" "unprognostic (7.14e-3)" "unprognostic (9.88e-3)" "unprognostic (2.31e-1)" "unprognostic (1.03e-1)" "unprognostic (8.60e-2)" 39.0 2.0 1.4 2.4 3.1 0.3 27.0 0.0 2.1 0.3 1.8 0.0 0.1 0.5 0.4 0.4 0.3 0.4 2.1 1.2 1.4 2.2 7.9 897.1 1.5 1.0 0.2 1.1 0.5 4.7 0.3 28.3 1.8 0.4 0.9 0.6 5.6 1.8 0.5 0.4 0.4 0.6 0.3 0.1 0.3 0.7 0.4 0.0 0.0 0.3 0.5 0.2 0.6 1.6 0.0 1.5 0.0 1.2 0.0 0.0 0.4 0.0 2.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.3 0.0 36.6 0.0 0.2 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.3 0.1 151.8 0.0 1.2 0.0 2.7 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.0 1.0 0.2 17.1 0.0 1.0 0.0 0.0 0.0 0.1 0.0 1.3 0.0 0.0 0.0 0.1 0.0 0.0 1.1 0.0 0.0 0.1 0.0 0.5 0.0 0.4 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 1.4 3.1 0.0 2.1 1.4 2.2 0.2 1.1 0.4 0.0 RECQL4 RecQ4 ENSG00000160957 "RecQ like helicase 4" 8 144511288-144517845 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 21.0;lymphoid tissue: 18.9" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Group enriched" "Detected in many" 14 "B-cells: 1.9;monocytes: 1.0;T-cells: 1.6" "Low region specificity" "Detected in some" "Low region specificity" "Detected in all" "CAB017800, HPA025821" Supported Enhanced Nucleoplasm Nucleoplasm "CAB017800: , HPA025821: AB_1856168" "unprognostic (5.92e-2)" "unprognostic (1.86e-1)" "unprognostic (2.05e-1)" "unprognostic (1.18e-1)" "unprognostic (9.17e-2)" "unprognostic (3.17e-2)" "prognostic unfavourable (1.91e-4)" "unprognostic (1.12e-2)" "unprognostic (4.12e-2)" "unprognostic (7.53e-2)" "unprognostic (2.65e-2)" "unprognostic (4.26e-2)" "unprognostic (1.12e-3)" "unprognostic (8.82e-3)" "unprognostic (1.74e-1)" "unprognostic (2.24e-1)" "unprognostic (1.34e-1)" 2.0 1.6 2.6 12.3 5.6 21.0 2.8 11.5 3.7 1.8 4.3 1.5 1.6 5.6 2.5 4.9 9.4 1.5 1.9 1.9 2.3 1.7 1.6 1.9 1.6 5.9 1.5 2.2 1.9 3.5 0.3 2.4 2.7 2.2 7.7 1.5 1.4 5.4 0.9 2.1 9.4 4.8 1.1 1.7 4.7 3.0 18.1 1.8 18.9 2.5 5.3 8.0 1.6 1.8 1.9 0.1 0.0 1.0 0.0 1.6 0.2 10.3 18.5 8.7 18.2 0.5 0.8 15.2 10.5 1.9 7.8 6.6 18.2 15.3 7.1 7.0 1.7 12.6 5.7 4.5 2.1 12.4 21.8 25.5 31.7 13.5 0.1 6.4 21.2 1.1 0.6 8.7 1.7 2.1 25.3 9.2 2.6 32.0 23.5 17.5 6.0 22.2 24.6 6.8 11.8 2.1 11.2 17.1 10.3 14.2 11.9 3.7 14.5 14.2 2.9 12.6 38.3 15.1 19.3 5.1 5.4 11.9 7.3 20.0 12.6 0.0 0.1 0.0 1.1 1.0 0.0 1.9 0.5 1.1 0.1 0.0 0.9 1.6 0.0 0.0 0.0 0.1 0.0 0.2 2.6 5.6 11.5 3.7 2.3 1.7 1.5 2.2 2.2 1.8 REL "c-Rel, I-Rel" ENSG00000162924 "REL proto-oncogene, NF-kB subunit" Q04864 2 60881521-60931610 "Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Daudi: 26.6;U-698: 51.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB004404 Uncertain "CAB004404: AB_670194" "unprognostic (2.77e-1)" "unprognostic (2.05e-2)" "unprognostic (8.26e-2)" "unprognostic (1.20e-1)" "unprognostic (2.23e-1)" "unprognostic (4.41e-2)" "unprognostic (1.11e-1)" "unprognostic (7.15e-2)" "unprognostic (2.15e-1)" "unprognostic (5.87e-2)" "unprognostic (4.38e-2)" "unprognostic (4.37e-1)" "unprognostic (2.82e-2)" "unprognostic (2.91e-2)" "unprognostic (3.53e-1)" "unprognostic (3.85e-1)" "unprognostic (3.66e-2)" 11.2 4.7 3.5 25.9 5.4 35.1 7.7 9.8 5.0 9.7 8.4 4.3 6.2 4.8 8.7 6.6 11.9 6.9 10.1 5.7 3.2 3.1 4.5 8.0 20.5 15.3 5.5 1.8 13.3 7.1 10.8 9.1 6.3 4.7 10.8 5.3 6.0 7.9 6.9 5.0 14.2 9.3 7.7 10.6 22.5 6.0 5.0 5.2 15.3 7.2 6.4 23.8 21.3 14.1 20.8 9.5 11.2 12.9 6.5 7.2 5.5 3.0 1.8 1.4 1.8 1.1 1.1 3.1 1.0 1.6 1.0 1.2 1.3 2.6 26.6 2.6 0.9 3.6 2.4 1.7 2.1 7.2 2.4 2.7 2.8 1.4 0.6 5.3 3.2 1.0 4.6 2.1 3.3 2.4 3.5 1.7 0.7 1.6 3.8 2.1 1.7 0.7 5.4 3.9 1.1 1.1 12.0 1.3 1.5 3.0 3.3 0.9 1.9 2.3 2.6 2.2 2.5 1.5 1.5 2.3 1.0 51.6 1.3 4.6 1.1 6.5 9.6 6.0 7.2 10.9 5.0 14.4 3.8 5.5 9.5 20.8 2.4 5.4 11.2 6.5 12.9 6.7 4.6 5.5 3.5 5.4 9.8 5.0 3.2 3.1 5.5 1.8 4.7 5.2 RELA "NFKB3, p65" ENSG00000173039 "RELA proto-oncogene, NF-kB subunit" Q04206 11 65653596-65663094 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, RAS pathway related proteins, Transcription factors" "Host-virus interaction, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004264, CAB005030, HPA063461" Supported Enhanced Cytosol Cytosol "CAB004264: AB_628017, CAB005030: AB_562171, HPA063461: " "unprognostic (9.17e-2)" "unprognostic (1.79e-1)" "unprognostic (2.04e-1)" "unprognostic (3.22e-1)" "unprognostic (7.67e-2)" "unprognostic (5.39e-2)" "prognostic unfavourable (9.18e-4)" "unprognostic (1.30e-3)" "unprognostic (1.69e-2)" "unprognostic (1.33e-1)" "unprognostic (6.03e-2)" "unprognostic (2.37e-1)" "prognostic unfavourable (5.66e-4)" "unprognostic (2.78e-1)" "unprognostic (1.46e-1)" "unprognostic (9.81e-2)" "unprognostic (2.53e-1)" 36.2 23.1 21.4 27.6 32.0 50.2 37.8 21.5 28.2 35.6 32.3 22.9 23.6 23.6 36.9 26.8 36.4 32.8 33.6 28.9 21.1 12.9 28.4 38.5 37.7 30.8 35.6 13.3 51.9 29.0 27.3 19.3 27.1 22.6 31.1 19.7 23.9 32.8 39.2 46.5 35.2 26.7 33.5 29.5 38.1 31.8 20.6 30.1 34.3 26.3 30.6 36.4 54.7 38.8 15.2 13.2 18.3 14.4 21.3 23.3 12.4 26.1 26.9 12.0 16.7 19.2 18.7 12.2 20.1 24.4 23.2 18.8 12.2 26.6 19.8 33.8 28.2 23.4 13.8 24.4 16.4 23.3 19.9 21.8 20.1 17.7 21.2 16.1 30.9 21.5 24.1 25.8 30.6 28.1 21.8 23.1 18.6 34.9 29.2 13.6 7.8 23.7 24.4 11.8 29.6 19.4 23.7 9.9 22.8 17.2 27.0 26.8 31.4 10.6 38.3 25.1 21.5 38.3 19.1 35.0 32.2 21.1 28.4 11.1 23.9 10.5 11.3 15.1 20.5 14.4 23.3 15.2 18.2 20.4 13.2 13.7 17.3 18.2 18.3 21.3 12.5 13.1 17.8 12.4 21.4 32.0 21.5 28.2 21.1 12.9 35.6 13.3 22.6 30.1 RELB REL-B ENSG00000104856 "RELB proto-oncogene, NF-kB subunit" Q01201 19 45001430-45038198 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Daudi: 25.0;HDLM-2: 31.8;U-698: 26.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "neutrophil: 14.5" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB007753, HPA040506" Approved Approved Nucleoplasm,Cytosol Nucleoplasm Cytosol "CAB007753: AB_562340, HPA040506: " "prognostic favourable (1.55e-4)" "unprognostic (1.20e-1)" "unprognostic (7.13e-2)" "unprognostic (5.52e-2)" "unprognostic (1.12e-2)" "unprognostic (3.41e-2)" "unprognostic (1.71e-2)" "unprognostic (4.30e-2)" "unprognostic (5.81e-3)" "unprognostic (1.02e-3)" "unprognostic (6.01e-2)" "unprognostic (6.48e-2)" "prognostic unfavourable (2.99e-6)" "unprognostic (2.68e-2)" "unprognostic (4.69e-2)" "unprognostic (2.09e-1)" "unprognostic (2.20e-2)" 8.0 6.8 2.2 27.6 3.6 27.8 6.8 1.2 3.1 4.9 12.2 2.1 1.6 8.8 8.5 4.7 6.4 5.2 10.9 11.9 1.8 1.6 10.1 7.4 12.8 18.2 3.6 0.9 7.8 12.3 1.9 2.1 4.7 2.8 9.9 3.4 3.6 7.3 4.8 8.1 8.3 13.0 8.4 3.9 17.2 8.3 3.7 1.7 17.7 5.6 7.2 24.8 8.8 6.1 8.2 3.9 14.5 5.0 2.1 2.2 1.7 8.7 5.3 0.5 2.3 1.1 3.9 1.8 1.6 11.4 2.5 4.0 1.8 9.7 25.0 4.6 2.6 4.0 0.2 3.6 2.1 31.8 0.8 0.9 0.3 1.0 10.2 1.9 14.9 6.4 1.5 5.1 6.0 1.6 0.2 16.3 0.9 2.1 0.4 5.9 0.8 0.9 1.9 1.3 3.0 4.1 13.6 0.0 0.8 1.6 4.7 4.5 1.6 4.8 5.1 6.0 3.0 2.2 5.8 20.6 12.1 26.8 6.6 0.7 3.3 0.0 5.0 2.1 1.4 3.2 2.1 8.2 2.2 2.0 3.6 7.9 1.8 0.9 14.5 2.1 2.6 3.9 1.1 1.7 2.2 3.6 1.2 3.1 1.8 1.6 3.6 0.9 2.8 1.7 RET "CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1, PTC, RET51" ENSG00000165731 "Ret proto-oncogene" P07949 10 43077027-43130351 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Hirschsprung disease, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "parathyroid gland: 63.9" "Cell line enhanced" "Detected in some" "MCF7: 17.6;NB-4: 11.6;SH-SY5Y: 89.7;THP-1: 26.8" "Cancer enhanced" "Detected in many" "breast cancer: 11.0" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in some" "non-classical monocyte: 6.7" "Group enriched" "Detected in many" 13 "dendritic cells: 2.1;monocytes: 6.7" "Low region specificity" "Detected in many" "Region enriched" "Detected in many" 6 "midbrain: 95.5" "CAB002581, HPA008356, HPA008495" Approved Supported Approved "Golgi apparatus,Plasma membrane,Cytosol" 260000 "Golgi apparatus, Cytosol" "Plasma membrane" "CAB002581: AB_563673, HPA008356: AB_1847232, HPA008495: " "unprognostic (7.94e-2)" "unprognostic (3.68e-2)" "unprognostic (4.49e-1)" "prognostic unfavourable (5.02e-4)" "unprognostic (1.15e-1)" "unprognostic (9.13e-4)" "unprognostic (1.27e-2)" "unprognostic (3.62e-2)" "unprognostic (2.86e-1)" "unprognostic (2.01e-1)" "unprognostic (1.54e-3)" "unprognostic (4.43e-1)" "unprognostic (9.35e-5)" "unprognostic (1.64e-3)" "unprognostic (8.28e-2)" "unprognostic (3.67e-3)" "unprognostic (2.02e-2)" 1.8 15.2 1.1 1.8 1.3 0.7 1.2 4.1 9.0 1.9 3.1 0.9 1.1 1.5 0.9 0.6 1.2 0.7 1.0 1.2 1.5 5.8 1.0 11.7 0.7 0.8 17.5 1.2 0.8 1.3 63.9 6.3 0.8 16.8 2.2 1.5 2.8 13.6 2.0 4.5 1.1 2.6 1.1 2.8 0.6 2.1 2.0 0.0 0.1 0.8 5.1 0.6 1.9 1.4 0.2 2.1 0.0 6.7 0.0 0.3 0.4 0.0 0.1 0.0 0.5 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 17.6 0.0 11.6 2.1 0.0 0.0 0.0 0.0 0.0 0.0 1.3 89.7 0.0 0.0 0.0 1.2 26.8 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 1.8 0.0 0.2 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 6.7 2.1 0.3 0.4 1.1 1.3 4.1 9.0 1.5 5.8 17.5 1.2 16.8 0.0 RHEB RHEB2 ENSG00000106615 "Ras homolog, mTORC1 binding" Q15382 7 151466012-151520120 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" CAB019436 Uncertain 24000 "CAB019436: AB_2178777" "unprognostic (2.22e-2)" "unprognostic (2.29e-2)" "unprognostic (2.25e-2)" "unprognostic (9.47e-2)" "unprognostic (2.65e-2)" "unprognostic (3.08e-3)" "prognostic unfavourable (9.08e-5)" "unprognostic (9.37e-2)" "unprognostic (4.76e-3)" "unprognostic (9.76e-3)" "unprognostic (1.85e-3)" "unprognostic (3.67e-2)" "unprognostic (2.36e-3)" "unprognostic (3.04e-1)" "unprognostic (1.29e-1)" "unprognostic (1.91e-1)" "unprognostic (3.15e-1)" 21.8 37.2 30.9 15.1 32.4 23.8 28.0 21.1 34.6 16.5 22.3 14.6 26.7 13.3 24.2 44.4 18.3 15.4 14.9 26.2 31.4 29.3 25.0 27.4 19.8 9.8 28.9 18.2 18.7 20.4 19.0 48.6 37.0 27.3 21.0 16.1 24.8 20.4 27.1 34.2 11.5 13.4 30.0 29.7 15.2 17.1 15.8 25.4 10.8 40.6 12.8 11.6 19.6 14.1 16.5 32.2 30.9 24.3 23.5 30.1 26.0 57.1 17.5 31.0 29.4 38.7 31.8 23.4 42.3 37.4 35.6 43.5 25.1 62.4 14.8 66.7 37.4 19.5 22.2 20.4 46.3 15.6 17.1 12.6 21.4 18.7 60.5 23.3 20.7 24.3 32.8 28.3 38.2 27.4 39.0 68.9 49.0 37.0 32.9 33.4 50.8 25.5 16.0 27.3 29.8 41.3 20.6 29.8 37.5 43.0 41.8 47.8 15.6 29.3 29.9 28.2 11.7 48.6 68.0 25.9 35.3 21.3 68.2 43.8 76.2 22.7 24.3 30.9 18.5 20.6 30.1 16.5 25.7 23.1 18.4 15.1 18.8 23.2 23.9 23.5 22.3 32.2 24.9 26.0 30.9 32.4 21.1 34.2 31.4 29.3 28.9 18.2 27.3 25.4 RHOA "ARH12, ARHA, Rho12, RhoA, RHOH12" ENSG00000067560 "Ras homolog family member A" P61586 3 49359145-49412998 "Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins" "Cell cycle, Cell division, Host-virus interaction" Hydrolase "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB005052 Approved Supported "Plasma membrane,Cytosol" 65000000 "Plasma membrane, Cytosol" "CAB005052: AB_562216" "unprognostic (1.50e-1)" "unprognostic (3.38e-1)" "prognostic favourable (3.08e-4)" "unprognostic (8.75e-2)" "unprognostic (1.63e-1)" "unprognostic (1.24e-1)" "prognostic unfavourable (9.15e-4)" "unprognostic (1.39e-1)" "unprognostic (8.83e-2)" "unprognostic (9.44e-3)" "unprognostic (2.21e-2)" "unprognostic (4.29e-2)" "prognostic favourable (3.21e-6)" "unprognostic (5.14e-2)" "unprognostic (7.50e-2)" "unprognostic (1.57e-1)" "unprognostic (4.52e-2)" 141.1 89.5 63.0 79.8 60.6 91.4 93.1 34.3 77.3 80.3 79.1 100.4 48.9 63.6 84.4 66.4 116.7 67.8 74.2 72.5 57.6 54.8 104.0 80.7 104.6 102.4 74.0 43.8 102.7 64.9 45.8 48.2 105.3 68.8 76.0 80.3 81.6 66.5 72.0 86.0 73.9 90.8 88.9 97.3 116.0 73.4 57.3 60.3 127.1 108.1 80.1 99.8 103.4 75.7 42.6 78.4 124.2 125.7 38.3 50.5 151.5 54.9 42.4 53.2 57.0 61.1 92.6 41.6 119.6 76.7 83.6 77.2 35.9 57.6 80.6 34.4 143.6 31.3 58.4 65.2 85.9 62.1 34.8 77.0 57.0 42.1 65.5 75.8 57.7 72.3 46.4 68.4 55.1 107.0 41.0 50.7 99.1 26.2 82.6 74.0 50.8 54.0 38.2 53.5 63.4 72.3 62.8 19.5 44.4 71.8 52.0 53.8 33.7 85.5 115.5 67.1 60.8 88.6 86.0 50.4 102.2 92.6 65.5 74.7 76.7 52.5 99.7 106.8 49.1 125.7 41.6 42.6 41.4 47.6 78.4 37.5 32.2 40.1 124.2 38.3 120.4 58.7 50.5 151.5 63.0 60.6 34.3 77.3 57.6 54.8 74.0 43.8 68.8 60.3 RHOC "ARH9, ARHC, RhoC" ENSG00000155366 "Ras homolog family member C" P08134 1 112701106-112707434 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "WM-115: 203.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "non-classical monocyte: 129.9" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA051461 Uncertain 54000000 "HPA051461: " "unprognostic (2.31e-2)" "unprognostic (1.23e-1)" "unprognostic (1.04e-1)" "unprognostic (1.93e-1)" "unprognostic (8.34e-2)" "unprognostic (1.74e-1)" "prognostic unfavourable (2.68e-4)" "unprognostic (2.08e-2)" "unprognostic (9.90e-2)" "unprognostic (1.40e-2)" "unprognostic (6.79e-3)" "unprognostic (3.95e-2)" "prognostic unfavourable (3.65e-5)" "unprognostic (1.26e-1)" "unprognostic (1.76e-1)" "unprognostic (3.08e-2)" "unprognostic (2.51e-3)" 56.5 36.0 31.3 23.2 28.6 2.8 46.2 11.1 18.2 48.5 71.0 19.2 46.7 53.6 47.4 110.1 51.3 32.4 58.1 79.2 21.7 23.8 88.3 45.0 63.3 21.8 30.1 14.6 57.6 24.2 89.6 21.2 67.4 24.9 47.8 49.9 37.9 27.0 58.3 29.9 28.4 122.4 48.6 21.6 54.6 28.0 41.5 17.7 15.8 43.1 28.0 17.6 59.6 43.0 6.4 24.6 1.8 129.9 32.5 23.1 25.5 60.2 24.9 14.8 16.6 27.9 49.3 16.8 55.2 68.3 40.3 34.1 19.8 18.4 0.8 23.0 80.4 17.3 10.9 50.3 39.3 14.4 6.0 7.0 16.6 15.9 46.7 1.2 32.4 57.7 35.4 64.5 44.7 103.7 14.0 12.8 72.9 32.2 3.0 4.8 4.0 41.5 5.1 17.7 2.7 46.4 17.2 0.7 6.3 27.5 18.2 34.9 38.3 5.1 87.6 54.6 37.5 73.4 40.1 8.4 7.0 2.6 61.5 4.8 203.5 0.1 7.0 0.1 23.1 77.2 15.4 4.8 4.6 9.4 24.6 6.4 1.1 7.2 1.8 32.5 129.9 18.4 4.9 25.5 31.3 28.6 11.1 18.2 21.7 23.8 30.1 14.6 24.9 17.7 RHOH "ARHH, RhoH, TTF" ENSG00000168421 "Ras homolog family member H" Q15669 4 40191053-40246967 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 54.8;lymphoid tissue: 94.7" "Cell line enhanced" "Detected in some" "Daudi: 35.6;HMC-1: 27.4;MOLT-4: 49.6;U-266/70: 19.2;U-266/84: 15.4;U-698: 32.9" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in single" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA030345, HPA061314" Uncertain Approved "Golgi apparatus,Vesicles" "Golgi apparatus, Vesicles" "HPA030345: AB_10601607, HPA061314: " "unprognostic (4.00e-2)" "unprognostic (1.83e-4)" "unprognostic (1.24e-2)" "unprognostic (2.22e-5)" "unprognostic (1.35e-1)" "unprognostic (1.32e-3)" "unprognostic (1.16e-1)" "unprognostic (2.73e-2)" "unprognostic (2.30e-2)" "unprognostic (4.30e-2)" "unprognostic (9.07e-2)" "unprognostic (1.38e-1)" "unprognostic (3.31e-6)" "unprognostic (2.96e-1)" "unprognostic (3.91e-2)" "unprognostic (4.46e-2)" "unprognostic (2.44e-2)" 1.8 0.6 0.6 33.8 1.1 21.7 5.2 0.4 0.4 1.3 2.4 0.5 0.4 1.6 2.0 0.9 2.5 1.5 4.1 1.1 0.6 0.7 1.6 1.7 4.8 43.2 0.8 0.2 0.7 0.8 0.0 0.9 0.3 0.8 2.1 2.0 1.0 7.8 0.6 0.5 1.2 15.1 0.7 1.2 33.1 2.7 0.7 0.6 94.7 1.6 1.9 41.0 5.1 1.5 41.2 4.7 32.2 0.2 12.3 54.8 21.1 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 35.6 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 5.3 0.0 0.0 0.0 5.8 27.4 0.4 0.0 0.0 0.0 0.0 0.4 0.3 0.0 0.0 49.6 3.7 0.6 0.1 5.3 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.2 0.0 1.6 0.1 0.1 0.0 0.1 0.0 0.0 19.2 15.4 32.9 0.0 1.2 0.0 32.2 0.2 29.6 21.6 0.1 19.4 30.5 34.6 29.1 0.3 41.2 54.8 43.3 1.6 12.3 0.2 4.7 47.0 21.1 0.6 1.1 0.4 0.4 0.6 0.7 0.8 0.2 0.8 0.6 RIT1 "MGC125864, MGC125865, RIBB, RIT, ROC1" ENSG00000143622 "Ras like without CAAX 1" Q92963 1 155897808-155911404 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA053249 Approved "HPA053249: " "unprognostic (1.84e-1)" "unprognostic (1.07e-1)" "unprognostic (7.27e-2)" "unprognostic (3.66e-2)" "unprognostic (1.35e-2)" "unprognostic (3.11e-2)" "prognostic unfavourable (8.64e-6)" "unprognostic (3.80e-2)" "unprognostic (4.99e-2)" "unprognostic (1.12e-1)" "unprognostic (6.45e-2)" "unprognostic (2.19e-2)" "unprognostic (9.22e-3)" "unprognostic (4.82e-2)" "unprognostic (3.74e-1)" "unprognostic (1.51e-1)" "unprognostic (2.33e-3)" 16.4 12.3 11.0 15.0 13.8 47.7 17.0 5.7 8.7 15.5 12.1 9.8 10.1 9.1 12.9 11.7 31.1 8.9 12.0 14.4 10.8 9.5 21.0 10.0 20.9 26.7 13.8 9.0 10.1 8.9 9.4 14.4 15.7 11.5 12.3 9.7 13.8 12.8 14.5 10.1 9.4 11.7 14.8 10.8 19.5 14.2 11.6 11.0 17.3 11.2 11.5 17.7 17.6 17.6 6.9 11.4 40.1 15.4 9.9 8.4 9.7 9.8 9.9 20.6 10.2 10.2 12.7 5.8 18.2 17.2 16.3 16.9 10.7 19.7 4.5 23.7 20.0 12.3 14.8 8.8 14.4 5.9 7.2 9.7 11.2 7.0 27.0 9.8 19.1 16.3 10.9 19.4 13.2 22.2 8.9 13.3 26.2 12.9 13.0 7.3 11.3 6.3 11.0 15.5 9.2 14.5 19.5 9.4 14.2 12.6 25.3 16.1 17.7 13.9 29.9 15.1 10.9 13.5 14.2 15.4 13.8 17.3 15.8 10.8 20.4 8.1 15.4 16.3 7.7 9.5 6.4 6.3 6.9 7.3 11.4 6.9 8.1 7.5 40.1 9.9 9.9 4.9 8.4 9.7 11.0 13.8 5.7 8.7 10.8 9.5 13.8 9.0 11.5 11.0 RMC1 "C18orf8, HsT2591, MIC1, WDR98" ENSG00000141452 "Regulator of MON1-CCZ1" Q96DM3 18 23503470-23531807 "Cancer-related genes, Predicted intracellular proteins" Autophagy "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA043589 Uncertain Uncertain Nucleoplasm Nucleoplasm "HPA043589: " "unprognostic (6.45e-2)" "unprognostic (6.43e-3)" "unprognostic (2.38e-2)" "unprognostic (1.78e-1)" "unprognostic (5.51e-3)" "unprognostic (8.16e-2)" "prognostic unfavourable (3.94e-4)" "unprognostic (4.26e-2)" "unprognostic (3.77e-1)" "unprognostic (1.73e-2)" "unprognostic (2.37e-1)" "unprognostic (1.27e-1)" "unprognostic (3.03e-1)" "unprognostic (3.76e-1)" "unprognostic (1.25e-1)" "unprognostic (3.04e-2)" "unprognostic (4.13e-2)" 16.6 14.3 11.6 13.9 13.2 30.1 25.2 15.8 20.5 13.2 17.1 13.1 11.8 20.3 16.4 12.4 15.0 14.4 13.3 12.7 16.6 10.7 20.9 23.8 19.5 24.1 15.4 12.0 14.1 17.3 14.6 23.5 17.5 13.4 13.2 14.1 16.2 16.3 14.2 17.2 16.3 23.1 13.6 14.0 21.9 18.9 26.2 11.6 19.7 13.3 11.0 22.9 16.3 14.8 20.0 27.1 24.1 25.4 19.7 18.0 10.2 8.5 8.9 6.6 11.5 15.1 10.9 8.8 13.5 14.4 18.2 21.7 8.0 5.2 12.9 11.4 11.6 16.9 17.2 7.6 16.1 13.3 9.8 6.5 6.3 8.0 19.8 17.1 23.3 9.8 11.9 22.5 12.9 10.7 10.1 13.9 12.0 11.0 14.3 7.8 3.6 13.6 11.5 9.9 12.7 9.5 8.4 9.0 12.1 17.4 8.8 11.1 6.8 10.7 10.3 15.5 4.1 6.2 11.6 22.2 16.8 14.9 16.1 11.7 11.7 24.1 9.9 21.5 15.5 18.4 16.0 19.9 13.8 14.9 12.1 20.0 9.4 11.4 9.6 19.7 25.4 27.1 18.0 10.2 11.6 13.2 15.8 20.5 16.6 10.7 15.4 12.0 13.4 11.6 RMI2 "BLAP18, C16orf75, MGC24665" ENSG00000175643 "RecQ mediated genome instability 2" Q96E14 16 11249619-11351762 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "DNA replication" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 31.7;testis: 29.6" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in some" "memory B-cell: 6.5" "Group enriched" "Detected in many" 5 "B-cells: 6.5;T-cells: 3.0" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" HPA040995 Uncertain Supported "Nuclear speckles,Cytosol" "Nuclear speckles" Cytosol "HPA040995: AB_10795531" "unprognostic (2.76e-1)" "prognostic favourable (5.69e-5)" "unprognostic (1.17e-1)" "unprognostic (3.09e-3)" "unprognostic (1.69e-2)" "unprognostic (1.80e-3)" "prognostic unfavourable (2.77e-5)" "unprognostic (3.98e-1)" "unprognostic (1.16e-1)" "unprognostic (1.83e-1)" "unprognostic (3.44e-3)" "unprognostic (3.89e-1)" "unprognostic (2.18e-1)" "unprognostic (5.50e-2)" "unprognostic (3.68e-2)" "unprognostic (3.60e-3)" "unprognostic (1.03e-1)" 1.0 1.8 4.2 18.0 5.1 4.8 2.8 0.7 4.1 2.8 7.3 1.0 0.4 4.3 2.5 3.2 11.8 1.0 2.6 1.9 2.5 1.5 3.1 2.3 2.9 17.9 1.6 5.6 3.6 1.6 0.7 1.1 13.2 1.2 2.6 9.0 0.8 2.9 1.7 1.1 8.7 5.6 1.1 1.4 4.2 4.0 29.6 1.2 31.7 1.4 2.8 20.4 3.6 4.5 6.5 0.6 0.9 0.0 0.3 3.0 0.3 19.0 12.8 25.1 10.7 1.1 5.5 10.5 11.1 8.8 10.5 17.6 4.9 22.7 26.5 9.6 5.2 11.2 10.7 10.6 17.1 5.2 10.0 14.5 7.6 32.4 0.4 5.6 6.5 1.2 2.0 4.5 4.4 5.7 20.0 21.1 5.5 22.0 19.2 26.0 21.1 5.1 23.3 27.1 28.3 6.2 12.4 14.5 11.5 9.4 15.8 8.2 26.7 8.4 1.8 8.5 7.9 16.2 1.6 5.8 9.5 31.4 7.9 18.4 15.5 0.0 0.0 0.9 0.6 0.0 0.0 6.5 0.2 0.0 0.4 2.5 1.8 0.7 0.2 0.3 0.0 0.6 3.0 0.3 4.2 5.1 0.7 4.1 2.5 1.5 1.6 5.6 1.2 1.2 RNF213 "C17orf27, KIAA1554, KIAA1618, MYMY2, NET57" ENSG00000173821 "Ring finger protein 213" Q63HN8 17 80260866-80398786 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Angiogenesis, Ubl conjugation pathway" "Hydrolase, Transferase" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HDLM-2: 36.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003347, HPA026790" Approved Supported Cytosol Cytosol "HPA003347: AB_1079204, HPA026790: AB_10602296" "unprognostic (8.98e-2)" "unprognostic (1.60e-1)" "unprognostic (8.97e-3)" "prognostic unfavourable (4.65e-5)" "unprognostic (7.39e-2)" "unprognostic (3.99e-2)" "unprognostic (2.23e-2)" "unprognostic (1.52e-1)" "unprognostic (4.57e-2)" "unprognostic (3.85e-1)" "unprognostic (1.96e-2)" "unprognostic (1.12e-1)" "unprognostic (1.52e-3)" "unprognostic (8.92e-2)" "unprognostic (1.13e-2)" "unprognostic (1.40e-1)" "unprognostic (4.56e-2)" 17.0 15.1 7.4 16.9 10.3 22.4 10.2 4.7 7.5 11.0 12.2 15.6 14.9 8.5 16.6 13.0 13.2 9.7 12.1 8.5 7.8 7.8 17.1 11.6 15.4 17.9 10.9 5.6 11.5 9.0 41.1 11.4 15.1 10.0 11.2 8.0 12.3 11.7 12.5 9.0 8.7 14.8 13.6 14.3 17.0 10.6 5.9 8.7 24.5 15.9 7.5 18.2 13.6 15.4 7.2 13.9 37.9 9.6 11.4 12.1 1.8 16.1 28.7 2.9 2.0 10.5 16.1 2.2 4.1 8.9 18.5 15.8 3.0 7.5 1.0 3.5 8.5 9.4 3.9 5.3 6.3 36.5 1.7 2.5 11.6 5.3 4.5 2.6 2.6 8.8 3.6 10.4 4.5 14.2 4.6 6.0 6.9 3.9 10.5 1.1 2.1 6.6 7.2 6.7 1.2 5.1 14.0 2.8 3.9 9.9 21.1 7.5 4.8 3.3 18.3 10.3 8.2 6.0 4.2 2.6 2.4 2.9 7.7 3.1 3.7 6.9 9.6 4.2 12.1 8.0 8.1 6.2 8.6 9.7 2.3 7.2 6.9 8.5 37.9 11.4 6.9 13.9 6.4 1.8 7.4 10.3 4.7 7.5 7.8 7.8 10.9 5.6 10.0 8.7 RNF43 "DKFZp781H0392, FLJ20315, URCC" ENSG00000108375 "Ring finger protein 43" Q68DV7 17 58352500-58417595 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins" "Ubl conjugation pathway, Wnt signaling pathway" "Developmental protein, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "CACO-2: 14.9;Hep G2: 29.2" "Cancer enhanced" "Detected in many" "colorectal cancer: 41.7" "Region enriched" "Detected in many" 7 "cerebellum: 30.6" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Not detected" "Not detected" HPA008079 Uncertain "HPA008079: AB_1856371" "unprognostic (2.53e-1)" "unprognostic (1.09e-1)" "unprognostic (7.46e-2)" "unprognostic (2.56e-1)" "unprognostic (1.10e-1)" "unprognostic (4.33e-2)" "unprognostic (1.39e-1)" "unprognostic (3.62e-1)" "unprognostic (2.93e-1)" "unprognostic (1.05e-1)" "unprognostic (5.69e-2)" "unprognostic (3.79e-1)" "prognostic favourable (6.04e-9)" "unprognostic (3.61e-3)" "unprognostic (2.56e-1)" "unprognostic (3.58e-1)" "unprognostic (1.04e-2)" 0.4 9.4 2.2 6.2 3.5 1.9 4.5 30.6 4.3 3.4 26.4 0.9 21.3 18.5 1.7 9.1 10.0 3.9 8.1 3.3 1.9 1.3 8.0 7.0 6.1 2.7 0.8 1.1 1.6 13.2 3.0 13.3 8.7 4.1 8.0 16.3 3.8 13.7 19.0 0.5 8.9 29.0 0.9 0.8 0.9 4.9 3.1 0.7 3.0 1.8 5.7 6.6 4.0 4.4 0.9 1.1 1.7 1.8 5.6 3.6 1.2 0.7 10.4 1.9 0.0 0.0 0.0 5.8 0.0 0.0 0.0 0.0 14.9 5.0 4.2 5.3 0.0 2.9 0.4 4.0 0.0 8.8 7.3 3.4 0.5 29.2 0.0 4.2 3.0 0.0 8.2 0.0 1.3 0.0 0.3 3.6 0.0 0.1 2.2 3.9 0.3 0.7 6.9 0.0 2.2 3.7 5.6 1.2 0.3 0.9 0.4 0.3 1.3 1.2 0.0 0.1 1.2 0.0 0.0 3.8 1.7 3.3 0.4 0.4 2.4 1.7 0.2 1.6 3.1 0.8 3.2 0.9 2.5 3.6 0.4 0.9 2.3 3.0 0.8 5.6 1.8 1.1 1.2 1.2 2.2 3.5 30.6 4.3 1.9 1.3 0.8 1.1 4.1 0.7 ROS1 "c-ros-1, MCF3, ROS" ENSG00000047936 "ROS proto-oncogene 1, receptor tyrosine kinase" P08922 6 117288300-117425855 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "epididymis: 38.6;lung: 20.2" "Group enriched" "Detected in some" 5 "HSkMC: 9.3;hTCEpi: 19.3;LHCN-M2: 13.4" "Cancer enriched" "Detected in some" 13 "lung cancer: 6.9" "Group enriched" "Detected in some" 10 "cerebral cortex: 7.4;olfactory region: 2.5" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "HPA049098, HPA072424" Uncertain Approved Vesicles Vesicles "HPA049098: , HPA072424: " "unprognostic (8.18e-2)" "unprognostic (4.64e-3)" "unprognostic (1.60e-1)" "unprognostic (2.37e-2)" "unprognostic (7.57e-2)" "unprognostic (2.05e-2)" "unprognostic (1.57e-1)" "unprognostic (1.79e-1)" "unprognostic (2.79e-2)" "unprognostic (1.00e-2)" "unprognostic (2.42e-1)" "unprognostic (5.20e-2)" "unprognostic (1.56e-12)" "unprognostic (1.09e-2)" "unprognostic (2.81e-1)" "unprognostic (1.91e-1)" "unprognostic (2.12e-1)" 0.3 0.2 0.2 0.0 0.4 0.0 0.2 0.2 7.4 0.2 0.4 0.0 7.9 0.0 0.2 38.6 0.2 0.2 0.0 0.2 0.2 0.2 0.4 0.2 20.2 0.0 0.2 2.5 0.2 0.2 0.0 0.3 0.7 0.0 0.2 0.3 0.0 0.2 2.3 0.2 0.7 0.3 0.0 0.2 0.2 0.3 0.7 0.0 0.0 0.2 0.0 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0 1.9 0.0 0.0 0.0 0.0 9.3 19.3 0.2 1.7 0.0 0.0 0.0 13.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.5 0.0 0.0 0.0 1.8 0.0 2.3 1.5 0.1 1.8 0.0 0.0 0.0 1.7 3.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.4 0.2 7.4 0.2 0.2 0.2 2.5 0.0 0.0 RPA2 ENSG00000117748 "Replication protein A2" P15927 1 27891524-27914746 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA recombination, DNA repair, DNA replication" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB016538, HPA026306, HPA026309" Supported Enhanced "Nucleoplasm,Nuclear bodies" "Nucleoplasm, Nuclear bodies" "CAB016538: AB_670974, HPA026306: AB_10598913, HPA026309: AB_10601572" "unprognostic (2.59e-1)" "prognostic favourable (4.33e-4)" "unprognostic (8.98e-2)" "unprognostic (6.89e-2)" "unprognostic (1.04e-1)" "prognostic favourable (8.12e-4)" "unprognostic (4.29e-3)" "unprognostic (2.03e-2)" "unprognostic (8.62e-3)" "unprognostic (1.68e-1)" "unprognostic (1.58e-2)" "unprognostic (2.31e-1)" "unprognostic (3.59e-2)" "unprognostic (9.13e-2)" "unprognostic (2.30e-1)" "unprognostic (2.18e-3)" "unprognostic (2.82e-2)" 18.6 17.1 33.6 24.3 38.8 20.5 26.6 23.6 30.5 20.0 15.4 17.2 17.6 9.9 19.5 26.3 18.7 28.8 19.2 22.5 31.4 22.1 19.5 18.4 19.3 37.1 22.0 26.7 32.6 15.3 16.4 27.0 17.2 25.4 17.2 19.0 18.0 16.2 19.8 45.0 22.6 16.8 18.6 22.1 28.4 15.3 34.6 27.7 25.4 30.7 17.2 37.9 20.3 17.1 46.2 31.5 48.4 18.1 49.3 55.9 65.9 13.0 12.5 21.0 15.7 14.3 13.2 12.7 24.3 16.5 31.1 27.1 17.7 16.2 33.3 15.6 9.6 12.2 29.6 13.7 30.4 24.6 27.5 38.7 16.9 15.2 7.2 51.3 27.3 5.7 7.7 30.0 15.5 13.4 40.4 29.0 18.0 13.3 36.5 22.5 41.1 26.7 24.4 31.1 15.5 11.1 14.2 17.9 17.3 26.8 10.8 21.2 11.2 15.2 8.5 7.7 16.7 41.5 15.9 23.6 52.5 28.9 19.0 45.5 13.9 42.8 18.1 48.4 51.6 14.0 55.9 46.2 48.8 47.3 20.4 39.0 55.8 53.9 18.1 49.3 18.1 31.5 42.5 65.9 33.6 38.8 23.6 30.5 31.4 22.1 22.0 26.7 25.4 27.7 RPGR "COD1, CORDX1, CRD, RP15, RP3" ENSG00000156313 "Retinitis pigmentosa GTPase regulator" Q92834 X 38269163-38327564 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Cilium biogenesis/degradation, Sensory transduction, Vision" "Guanine-nucleotide releasing factor" "Cancer-related genes, Ciliopathy, Cone-rod dystrophy, Deafness, Disease mutation, Retinitis pigmentosa" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "pituitary gland: 55.4" "Cell line enhanced" "Detected in many" "HL-60: 22.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "neutrophil: 15.3" "Lineage enriched" "Detected in all" 5 "granulocytes: 15.3" "HPA001593, HPA073455" Approved Supported "Golgi apparatus" "Golgi apparatus" "HPA001593: AB_1079835, HPA073455: " "unprognostic (3.22e-2)" "unprognostic (1.16e-2)" "unprognostic (5.04e-2)" "unprognostic (1.08e-1)" "unprognostic (3.20e-1)" "unprognostic (9.94e-2)" "unprognostic (3.46e-2)" "unprognostic (6.32e-2)" "unprognostic (2.04e-1)" "unprognostic (1.37e-1)" "unprognostic (1.96e-3)" "unprognostic (1.42e-1)" "unprognostic (1.03e-6)" "unprognostic (1.93e-1)" "unprognostic (7.59e-2)" "unprognostic (8.96e-3)" "unprognostic (1.61e-3)" 16.4 5.9 6.1 7.1 9.0 17.4 13.8 7.2 7.0 8.3 8.4 7.1 2.5 5.1 8.8 9.4 5.4 20.8 9.4 6.3 7.2 9.4 4.9 4.9 10.7 7.8 8.9 4.2 7.9 7.2 3.8 55.4 6.3 14.6 5.9 6.4 6.3 3.7 4.8 13.3 4.3 6.2 8.3 9.9 5.1 4.9 11.6 5.7 5.8 8.3 3.6 5.4 7.7 10.9 1.9 2.6 15.3 2.6 1.6 3.1 1.7 3.3 4.4 2.5 2.3 2.9 4.1 1.9 4.2 4.9 3.1 3.6 1.9 1.7 4.9 1.4 2.7 3.2 3.0 1.3 4.3 5.2 5.5 1.8 2.1 3.9 2.6 22.5 4.3 5.9 1.8 6.2 7.0 14.1 2.3 0.0 4.2 1.3 6.6 12.6 6.5 5.6 4.9 8.6 4.6 2.7 2.2 1.9 3.7 4.6 1.9 5.0 1.2 3.9 16.4 3.4 6.0 8.0 5.0 1.4 2.7 4.3 8.0 4.4 4.6 1.4 2.6 5.7 1.4 2.3 3.1 1.9 1.7 1.8 2.6 1.8 2.5 2.0 15.3 1.6 1.8 1.8 1.9 1.7 6.1 9.0 7.2 7.0 7.2 9.4 8.9 4.2 14.6 5.7 RPL10 "DXS648, DXS648E, FLJ23544, L10, NOV, QM" ENSG00000147403 "Ribosomal protein L10" P27635 X 154389955-154409168 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins" "Translation regulation" "Developmental protein, Ribonucleoprotein, Ribosomal protein" "Autism, Autism spectrum disorder, Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "CAB010339, HPA011311" Enhanced Enhanced "Endoplasmic reticulum,Cytosol" 130000 "Endoplasmic reticulum, Cytosol" "CAB010339: AB_2181277, HPA011311: AB_1856431" "unprognostic (2.46e-3)" "unprognostic (3.57e-2)" "unprognostic (1.72e-1)" "unprognostic (2.14e-2)" "unprognostic (1.25e-2)" "unprognostic (2.06e-1)" "unprognostic (6.11e-2)" "unprognostic (9.01e-3)" "unprognostic (1.91e-1)" "unprognostic (2.21e-1)" "unprognostic (5.39e-2)" "unprognostic (3.37e-1)" "prognostic unfavourable (7.67e-6)" "unprognostic (6.84e-2)" "unprognostic (1.86e-1)" "unprognostic (1.65e-2)" "unprognostic (5.68e-2)" 103.6 65.3 41.4 108.0 48.5 103.7 152.6 82.4 70.7 118.2 80.6 44.6 107.8 51.3 100.4 75.5 105.2 122.3 52.6 82.5 38.2 31.9 112.1 155.0 97.6 190.2 48.2 37.4 223.5 242.3 35.0 51.9 87.4 53.1 83.6 77.1 66.7 109.9 101.5 125.9 121.8 108.9 78.7 51.4 93.9 90.5 33.9 47.2 158.9 198.9 137.9 134.4 86.9 119.3 252.9 168.6 64.4 124.1 149.1 304.9 445.3 187.8 87.1 87.3 66.8 198.2 375.4 77.2 72.2 167.6 139.1 177.0 77.2 84.5 372.4 175.0 120.5 73.0 170.8 173.0 119.6 81.8 135.4 50.2 62.4 84.6 233.1 107.9 74.4 283.3 274.0 83.6 261.3 218.2 70.7 119.0 135.8 94.3 117.5 105.0 68.7 150.6 140.9 82.7 206.9 151.8 67.1 70.0 117.0 17.4 153.8 213.5 56.0 150.9 105.0 48.7 92.6 109.6 159.9 283.6 204.8 370.4 74.0 155.8 60.8 64.4 124.1 18.1 149.9 107.7 256.2 252.9 251.6 186.2 151.2 243.2 304.9 231.1 13.0 149.1 94.9 168.6 178.0 445.3 41.4 48.5 82.4 70.7 38.2 31.9 48.2 37.4 53.1 47.2 RPL22 "EAP, L22" ENSG00000116251 "Ribosomal protein L22" P35268 1 6181269-6209389 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins" "Heparin-binding, Ribonucleoprotein, Ribosomal protein, RNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA068294 Approved Nucleoplasm,Nucleoli 320000 Nucleoli Nucleoplasm "HPA068294: " "unprognostic (3.16e-3)" "unprognostic (1.28e-1)" "unprognostic (3.13e-1)" "unprognostic (3.62e-2)" "unprognostic (2.27e-2)" "unprognostic (1.09e-1)" "unprognostic (1.29e-3)" "unprognostic (4.40e-2)" "unprognostic (7.06e-2)" "unprognostic (3.26e-1)" "unprognostic (1.48e-1)" "unprognostic (4.24e-2)" "unprognostic (1.46e-3)" "unprognostic (3.83e-1)" "unprognostic (3.88e-2)" "unprognostic (2.46e-1)" "unprognostic (1.98e-1)" 75.5 71.5 54.3 79.7 42.8 124.7 75.0 46.7 39.5 95.8 73.9 39.2 53.9 66.5 133.6 63.9 103.9 59.1 61.8 50.8 47.4 38.6 58.8 90.2 55.3 142.6 50.6 39.7 163.1 154.8 30.4 57.0 49.8 37.4 90.8 46.4 57.0 140.3 66.8 114.0 79.7 62.6 106.6 58.3 79.1 62.0 38.2 35.0 95.3 91.0 112.8 81.1 101.5 91.9 75.6 62.3 11.0 38.9 42.2 98.8 73.9 88.0 25.1 53.5 54.6 37.7 59.3 42.3 76.9 30.9 28.3 24.2 49.8 76.6 136.7 63.3 28.5 50.9 40.2 40.0 37.3 66.9 65.4 132.8 57.2 61.7 37.4 175.7 53.3 52.3 33.1 25.2 52.2 35.3 109.4 82.8 32.5 38.8 76.8 143.4 33.3 55.7 74.1 111.0 105.8 41.4 30.6 74.0 67.9 62.6 181.4 140.8 58.4 139.3 86.3 40.4 44.5 53.3 72.2 66.7 91.4 206.8 26.7 181.7 25.0 11.0 38.9 8.8 38.0 34.3 66.9 75.6 71.1 52.3 59.8 72.4 98.8 78.1 2.9 42.2 27.8 62.3 54.0 73.9 54.3 42.8 46.7 39.5 47.4 38.6 50.6 39.7 37.4 35.0 RPL27 L27 ENSG00000131469 "Ribosomal protein L27" P61353 17 42998273-43002959 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Ribosomal proteins" "Ribonucleoprotein, Ribosomal protein" "Cancer-related genes, Diamond-Blackfan anemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA002649 Approved 30000 "HPA002649: AB_1079840" "unprognostic (8.53e-3)" "unprognostic (7.15e-2)" "unprognostic (3.97e-2)" "unprognostic (2.81e-2)" "unprognostic (4.99e-2)" "unprognostic (4.31e-2)" "unprognostic (1.91e-3)" "unprognostic (7.32e-2)" "unprognostic (9.17e-2)" "unprognostic (1.19e-1)" "unprognostic (5.12e-2)" "unprognostic (3.86e-1)" "prognostic unfavourable (7.80e-8)" "unprognostic (1.10e-1)" "unprognostic (2.70e-1)" "unprognostic (2.70e-1)" "unprognostic (1.14e-1)" 78.4 66.9 61.7 82.2 45.7 150.0 148.7 63.1 82.7 75.1 76.8 27.2 65.4 48.8 74.8 80.1 91.9 64.9 80.8 120.6 46.2 38.5 76.2 121.7 109.5 222.2 49.2 49.0 123.7 185.0 17.2 44.1 81.0 48.3 65.3 55.0 43.8 119.1 78.5 127.5 113.8 61.9 82.4 43.6 84.4 69.7 40.3 28.8 72.6 70.5 153.8 78.5 86.1 80.9 178.5 152.7 44.2 99.0 111.4 184.7 216.0 112.4 142.6 87.4 126.5 154.8 229.6 141.1 131.0 107.7 140.9 101.1 201.9 88.6 213.2 111.5 103.0 98.7 100.1 167.3 135.6 98.7 238.1 83.8 119.6 213.4 191.0 240.5 88.1 216.3 143.3 95.0 122.0 116.8 155.7 132.0 130.0 110.0 200.1 203.8 132.3 91.3 140.5 246.1 240.9 119.0 152.0 98.3 108.5 51.4 101.4 208.6 170.6 254.1 131.7 105.0 104.0 128.2 192.7 115.3 185.7 208.7 94.4 149.4 106.9 44.2 99.0 29.5 106.6 87.9 150.2 178.5 159.0 124.5 118.6 168.3 184.7 159.1 20.4 111.4 67.3 152.7 112.5 216.0 61.7 45.7 63.1 82.7 46.2 38.5 49.2 49.0 48.3 28.8 RPL5 "L5, PPP1R135" ENSG00000122406 "Ribosomal protein L5" P46777 1 92831983-92841924 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins" "Ribonucleoprotein, Ribosomal protein, RNA-binding, rRNA-binding" "Cancer-related genes, Diamond-Blackfan anemia, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "HPA043717, HPA054444" Approved Supported "Nucleoli,Endoplasmic reticulum,Cytosol" 130000 "Endoplasmic reticulum, Cytosol" Nucleoli "HPA043717: AB_10964719, HPA054444: " "unprognostic (5.81e-3)" "unprognostic (3.96e-1)" "unprognostic (1.04e-1)" "unprognostic (1.52e-1)" "unprognostic (9.44e-3)" "unprognostic (1.96e-1)" "unprognostic (1.03e-3)" "unprognostic (9.95e-2)" "unprognostic (8.68e-2)" "unprognostic (1.23e-1)" "unprognostic (3.98e-2)" "unprognostic (3.48e-1)" "prognostic unfavourable (6.81e-5)" "unprognostic (2.26e-2)" "unprognostic (3.12e-2)" "unprognostic (1.09e-1)" "unprognostic (3.97e-1)" 119.4 80.3 50.0 70.0 50.1 113.8 140.5 46.9 46.8 158.6 111.4 45.0 75.1 61.7 135.2 114.6 159.4 100.5 73.1 73.0 43.5 43.1 99.7 114.9 89.9 148.2 54.5 36.2 296.8 306.5 40.8 90.3 90.2 44.3 175.4 78.8 64.3 121.5 73.2 109.1 97.8 95.3 153.4 61.9 130.1 90.0 68.8 45.7 156.6 210.0 97.7 118.9 191.2 146.6 104.5 85.2 12.8 45.9 72.4 143.0 142.1 116.8 50.2 89.5 75.5 116.4 235.3 143.6 69.9 93.6 87.1 62.4 133.0 51.1 220.5 112.3 78.5 74.7 102.6 131.0 111.3 69.8 140.4 114.4 83.6 122.4 139.7 175.1 48.2 192.4 206.7 77.3 170.2 120.2 141.6 116.3 99.7 66.3 139.4 198.6 138.2 94.9 128.1 173.4 142.4 105.6 97.3 76.3 91.3 45.5 127.1 203.3 70.0 240.9 73.0 44.0 80.4 83.1 126.0 72.0 68.3 149.2 29.8 151.0 29.8 12.8 45.9 7.2 60.9 44.8 122.1 104.5 111.5 91.6 85.2 88.4 143.0 123.9 4.4 72.4 38.3 71.1 83.2 142.1 50.0 50.1 46.9 46.8 43.5 43.1 54.5 36.2 44.3 45.7 RPN1 OST1 ENSG00000163902 "Ribophorin I" P04843 3 128619970-128681075 "Cancer-related genes, Plasma proteins, Predicted membrane proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009748, HPA026828, HPA051520" Enhanced Enhanced "Endoplasmic reticulum" 8200000 "Endoplasmic reticulum" "CAB009748: AB_2182230, HPA026828: AB_10610418, HPA051520: AB_2681521" "unprognostic (4.83e-2)" "unprognostic (5.92e-2)" "unprognostic (1.10e-1)" "unprognostic (7.67e-2)" "unprognostic (2.36e-1)" "unprognostic (2.12e-2)" "prognostic unfavourable (4.80e-4)" "unprognostic (2.71e-1)" "unprognostic (2.43e-1)" "unprognostic (2.28e-2)" "unprognostic (4.58e-3)" "unprognostic (2.87e-1)" "unprognostic (7.68e-2)" "unprognostic (7.86e-2)" "unprognostic (1.52e-2)" "unprognostic (1.44e-1)" "unprognostic (9.74e-2)" 52.3 37.5 22.2 26.6 23.8 24.4 48.2 20.9 31.4 45.8 40.8 31.9 58.8 28.5 38.3 110.2 32.2 38.3 38.8 47.1 23.0 28.0 55.4 174.0 47.4 50.6 26.4 18.3 37.8 62.9 43.5 36.9 58.3 24.3 31.4 41.1 28.6 54.1 55.5 34.4 24.0 37.0 33.5 31.8 48.0 33.7 26.9 23.3 34.3 69.1 27.3 36.5 32.7 39.7 26.7 53.1 64.4 43.5 23.4 45.1 53.3 60.8 33.2 27.7 51.0 75.1 50.3 62.8 52.5 69.0 69.8 81.3 68.7 57.3 38.1 49.5 75.7 61.3 44.7 46.7 68.3 27.3 28.7 67.2 24.7 56.4 82.8 54.4 35.4 41.7 54.7 45.9 67.9 54.4 27.6 51.1 45.7 55.6 30.2 59.8 35.1 30.4 33.0 37.3 91.6 48.3 36.6 42.7 24.6 43.1 44.7 53.1 47.8 56.4 35.4 36.1 28.2 52.7 38.9 55.2 43.4 40.7 59.2 40.6 52.0 38.8 43.5 35.7 37.3 40.0 45.1 26.7 30.7 33.8 43.5 18.3 19.1 29.2 64.4 23.4 40.2 53.1 30.5 53.3 22.2 23.8 20.9 31.4 23.0 28.0 26.4 18.3 24.3 23.3 RPS15 "MGC111130, RIG, S15" ENSG00000115268 "Ribosomal protein S15" P62841 19 1438358-1440494 "Cancer-related genes, Predicted intracellular proteins, Ribosomal proteins" "Ribonucleoprotein, Ribosomal protein" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA054510, HPA057793" Enhanced Approved "Endoplasmic reticulum,Cytosol" 170000 "Endoplasmic reticulum, Cytosol" "HPA054510: AB_2682510, HPA057793: AB_2683528" "unprognostic (4.47e-3)" "unprognostic (1.30e-1)" "unprognostic (6.58e-2)" "unprognostic (1.08e-3)" "unprognostic (5.98e-2)" "unprognostic (2.05e-1)" "unprognostic (4.33e-3)" "unprognostic (4.42e-2)" "unprognostic (2.58e-1)" "unprognostic (2.73e-2)" "unprognostic (3.28e-2)" "unprognostic (5.00e-2)" "unprognostic (1.44e-3)" "unprognostic (5.21e-2)" "unprognostic (5.21e-3)" "unprognostic (1.46e-1)" "unprognostic (2.61e-2)" 61.7 61.2 63.0 67.5 51.4 123.6 74.2 46.0 87.5 56.2 66.4 46.1 41.2 69.0 73.6 52.3 80.9 61.2 73.7 72.1 50.4 40.5 64.8 103.7 43.0 95.3 52.1 52.6 144.8 136.0 21.6 59.3 60.9 45.2 66.9 37.1 61.2 123.7 53.2 154.9 102.4 67.6 51.8 51.0 76.2 63.5 60.8 24.9 70.7 74.2 127.6 82.9 47.6 70.9 237.3 149.5 48.6 106.7 103.8 218.1 269.2 103.1 110.2 48.5 65.9 45.5 66.3 83.6 54.1 43.2 64.9 50.9 176.9 36.5 128.1 48.7 34.7 65.8 47.2 67.0 25.5 106.5 246.9 41.9 101.0 167.0 48.2 106.6 80.0 81.4 81.0 43.9 43.1 57.1 85.0 184.5 40.5 181.6 88.0 143.3 109.7 141.8 91.7 57.9 167.3 58.9 113.7 78.1 92.7 45.6 78.7 155.1 60.2 143.7 57.6 55.0 63.0 109.6 119.3 160.3 158.6 124.5 54.6 97.4 62.8 48.6 106.7 44.5 116.2 89.5 160.8 237.3 179.3 146.1 149.5 222.5 218.1 177.4 21.6 103.8 68.2 124.2 162.9 269.2 63.0 51.4 46.0 87.5 50.4 40.5 52.1 52.6 45.2 24.9 RPS2 "LLREP3, S2" ENSG00000140988 "Ribosomal protein S2" P15880 16 1962052-1964860 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins" "Ribonucleoprotein, Ribosomal protein" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "pancreas: 284.3" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" HPA055133 Approved Approved "Endoplasmic reticulum,Cytosol" 140000 "Endoplasmic reticulum, Cytosol" "HPA055133: " "unprognostic (2.98e-2)" "unprognostic (2.44e-1)" "unprognostic (8.43e-2)" "unprognostic (3.49e-2)" "unprognostic (4.15e-2)" "unprognostic (4.39e-2)" "prognostic unfavourable (7.70e-4)" "unprognostic (7.43e-2)" "unprognostic (3.17e-1)" "unprognostic (7.23e-2)" "unprognostic (2.00e-2)" "unprognostic (3.33e-1)" "prognostic unfavourable (3.04e-7)" "unprognostic (1.61e-1)" "unprognostic (1.75e-1)" "unprognostic (1.15e-1)" "unprognostic (1.47e-1)" 46.1 41.0 28.0 101.8 40.4 97.6 65.9 34.7 30.7 48.2 47.0 22.2 28.8 39.9 45.7 27.1 100.7 61.7 55.7 38.2 19.5 16.0 34.2 107.4 71.1 104.2 36.6 18.6 112.6 284.3 9.6 32.2 45.4 30.1 43.6 32.5 18.3 53.6 28.9 67.3 78.3 47.5 25.8 22.4 131.9 47.8 18.9 28.1 115.2 50.3 114.5 78.3 51.6 77.6 137.5 69.0 18.2 44.9 53.6 125.4 54.7 81.0 117.7 68.2 219.3 99.1 244.6 120.8 55.7 133.9 146.3 103.9 209.6 56.8 155.5 89.2 96.2 101.9 98.5 186.8 55.0 98.1 194.8 52.4 131.3 187.7 242.1 123.0 86.5 326.4 267.9 122.2 203.4 141.8 107.1 88.4 100.8 376.2 154.3 215.6 216.7 106.4 189.2 110.5 185.9 133.5 77.2 122.3 111.1 54.5 171.3 132.0 115.5 216.0 64.7 78.9 104.0 18.9 116.4 34.4 56.6 197.9 42.5 106.6 99.0 4.9 37.6 18.2 50.7 44.9 84.6 137.5 99.9 78.4 68.7 117.9 125.4 93.8 7.6 53.6 36.0 69.0 68.1 54.7 28.0 40.4 34.7 30.7 19.5 16.0 36.6 18.6 30.1 28.1 RPS3 "FLJ26283, FLJ27450, MGC87870, S3" ENSG00000149273 "Ribosomal protein S3" P23396 11 75399486-75422280 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins" "Apoptosis, Cell cycle, Cell division, DNA damage, DNA repair, Mitosis, Transcription, Transcription regulation, Translation regulation" "DNA-binding, Lyase, Ribonucleoprotein, Ribosomal protein, RNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA063339 Uncertain Supported "Endoplasmic reticulum,Cytosol" 430000 "Endoplasmic reticulum, Cytosol" "HPA063339: " "unprognostic (3.62e-2)" "unprognostic (6.94e-3)" "unprognostic (2.64e-1)" "unprognostic (1.44e-2)" "unprognostic (5.55e-2)" "unprognostic (1.08e-2)" "unprognostic (1.22e-2)" "unprognostic (1.35e-1)" "unprognostic (2.69e-1)" "unprognostic (5.75e-2)" "unprognostic (3.27e-3)" "unprognostic (1.96e-1)" "prognostic unfavourable (6.92e-6)" "unprognostic (3.22e-1)" "unprognostic (2.94e-1)" "unprognostic (1.89e-2)" "unprognostic (2.19e-1)" 72.2 52.7 36.6 108.4 41.2 122.2 136.6 32.1 33.8 105.1 102.0 32.5 65.2 65.8 102.4 84.7 136.5 92.2 107.7 58.5 29.7 26.5 52.9 78.1 71.0 218.6 47.6 30.6 224.7 288.7 13.8 51.3 75.9 35.0 105.7 65.7 47.6 151.0 61.8 86.9 117.6 78.0 110.6 42.1 121.4 75.4 54.1 36.5 126.5 119.4 134.7 130.1 110.3 118.9 104.5 69.7 22.6 44.5 64.6 144.2 213.9 85.5 53.1 75.5 83.1 95.5 170.4 97.7 82.1 105.8 109.0 71.1 153.1 102.5 299.4 100.6 73.7 124.1 97.4 152.7 100.5 79.2 76.1 122.6 53.0 67.6 142.6 197.9 80.4 199.9 208.7 74.5 207.1 142.9 122.1 85.3 97.9 94.0 118.7 95.2 94.8 63.0 112.8 264.9 218.1 107.0 71.6 65.0 92.2 60.5 143.9 83.5 146.9 151.7 114.4 52.7 87.8 71.8 74.1 78.3 96.5 331.7 31.6 111.1 53.2 22.6 44.5 14.7 94.2 31.6 129.1 104.5 123.0 99.4 69.7 95.6 144.2 111.8 11.2 64.6 30.1 60.8 78.2 213.9 36.6 41.2 32.1 33.8 29.7 26.5 47.6 30.6 35.0 36.5 RPS6KA1 "HU-1, p90Rsk, RSK, RSK1" ENSG00000117676 "Ribosomal protein S6 kinase A1" Q15418 1 26529761-26575030 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Stress response" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "intestine: 45.2" "Cell line enhanced" "Detected in many" "HMC-1: 29.6;U-937: 31.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Region enriched" "Detected in all" 5 "cerebellum: 60.4" "Low region specificity" "Detected in all" "CAB003852, HPA007981" Enhanced Supported Nucleoplasm,Cytosol Cytosol Nucleoplasm "CAB003852: AB_289590, HPA007981: AB_1079850" "unprognostic (1.04e-3)" "unprognostic (1.23e-1)" "unprognostic (1.61e-3)" "prognostic favourable (7.20e-7)" "unprognostic (7.35e-2)" "unprognostic (3.69e-1)" "unprognostic (6.93e-3)" "unprognostic (1.12e-2)" "unprognostic (1.09e-1)" "unprognostic (7.51e-3)" "unprognostic (2.37e-2)" "unprognostic (9.64e-2)" "prognostic favourable (1.84e-4)" "prognostic favourable (4.58e-4)" "unprognostic (4.77e-2)" "unprognostic (7.61e-2)" "prognostic favourable (8.33e-4)" 11.0 8.2 6.3 24.2 9.7 15.8 5.0 14.4 6.3 4.9 23.2 11.1 4.4 24.5 2.1 3.6 8.9 6.0 8.0 3.4 5.3 5.1 13.6 5.4 26.1 32.7 10.3 3.5 2.1 10.1 10.0 7.4 3.3 8.6 8.6 15.8 3.6 19.0 5.5 1.1 9.0 45.2 2.8 7.9 27.0 9.7 2.7 9.0 15.9 13.9 4.9 17.3 6.2 4.5 5.0 22.0 40.1 18.0 7.9 8.3 17.1 9.7 3.4 2.8 3.7 0.1 0.0 3.7 0.8 1.5 4.2 4.0 4.0 8.1 18.3 4.5 0.5 11.5 6.3 22.7 3.0 15.1 4.1 20.1 8.5 7.0 1.3 23.7 29.6 0.7 8.3 3.8 6.9 1.8 3.4 6.7 0.2 5.4 0.8 23.3 7.2 11.0 12.6 3.6 8.0 12.0 2.7 4.1 1.6 6.9 6.6 3.2 4.2 20.3 1.2 0.2 5.3 0.7 3.3 4.1 4.9 10.0 2.5 31.8 4.0 9.6 18.0 40.1 8.3 16.4 6.9 4.9 6.1 7.3 22.0 5.0 3.9 5.5 34.5 7.9 17.3 8.6 6.0 17.1 6.3 9.7 14.4 6.3 5.3 5.1 10.3 3.5 8.6 9.0 RPS6KA3 "CLS, HU-3, MRX19, RSK, RSK2" ENSG00000177189 "Ribosomal protein S6 kinase A3" P51812 X 20149911-20267519 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Cell cycle, Stress response" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Hep G2: 67.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003221, CAB003853, CAB013520" Approved Approved Nucleoplasm,Nucleoli,Cytosol Nucleoplasm "Nucleoli, Cytosol" "CAB003853: AB_562343, CAB013520: AB_2533378, HPA003221: AB_1853553" "unprognostic (1.87e-2)" "unprognostic (1.03e-1)" "unprognostic (1.80e-2)" "unprognostic (4.26e-2)" "unprognostic (3.53e-1)" "unprognostic (1.11e-1)" "unprognostic (1.15e-2)" "unprognostic (1.61e-3)" "unprognostic (1.02e-1)" "unprognostic (1.57e-1)" "unprognostic (5.04e-1)" "unprognostic (1.07e-1)" "unprognostic (1.04e-1)" "unprognostic (4.49e-3)" "unprognostic (3.91e-1)" "unprognostic (1.09e-1)" "unprognostic (2.22e-1)" 19.7 12.5 9.9 23.0 12.5 8.2 16.5 15.2 12.1 11.4 23.2 4.4 22.1 13.7 12.4 10.1 13.6 12.7 15.7 21.3 9.7 8.8 14.1 25.8 21.6 34.0 9.9 10.0 12.7 14.0 36.6 9.8 11.0 10.2 14.5 18.8 7.7 14.3 11.3 45.2 11.7 23.7 16.1 11.7 25.8 11.8 4.8 9.7 29.4 13.5 15.0 18.2 20.3 19.0 4.2 8.6 12.5 6.9 8.3 11.3 2.7 12.6 22.2 8.4 4.3 8.2 14.5 2.5 11.0 16.8 8.2 11.3 25.1 16.4 8.3 3.8 11.5 9.0 9.6 9.3 15.3 7.0 7.6 9.8 14.0 67.5 8.4 19.0 10.2 9.2 7.5 12.9 16.3 29.8 6.4 23.9 8.6 6.0 12.3 5.8 6.0 13.4 6.6 17.8 9.6 7.1 10.6 3.9 3.8 14.8 4.5 16.0 0.0 5.7 16.6 9.0 6.3 28.5 6.2 19.1 11.6 9.3 17.0 9.5 21.2 12.5 4.7 9.5 6.3 6.9 11.3 2.9 7.3 6.9 7.0 4.2 5.0 6.0 7.5 8.3 6.9 8.6 3.5 2.7 9.9 12.5 15.2 12.1 9.7 8.8 9.9 10.0 10.2 9.7 RSBN1L "FLJ42526, FLJ45813, MGC71764" ENSG00000187257 "Round spermatid basic protein 1 like" Q6PCB5 7 77696443-77783022 "Cancer-related genes, Predicted intracellular proteins" "Dioxygenase, Oxidoreductase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "neutrophil: 31.5" "Lineage enriched" "Detected in all" 4 "granulocytes: 31.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA020406, HPA020413" Approved Supported "Nuclear speckles,Plasma membrane" "Nuclear speckles" "Plasma membrane" "HPA020406: AB_1856488, HPA020413: AB_2253910" "unprognostic (2.02e-1)" "unprognostic (2.61e-2)" "unprognostic (2.41e-1)" "unprognostic (1.72e-1)" "unprognostic (1.34e-1)" "unprognostic (3.62e-2)" "unprognostic (2.43e-2)" "prognostic favourable (3.74e-4)" "unprognostic (1.27e-2)" "unprognostic (3.78e-2)" "unprognostic (1.25e-1)" "unprognostic (9.02e-2)" "unprognostic (7.30e-3)" "unprognostic (1.93e-1)" "unprognostic (1.46e-1)" "unprognostic (2.25e-3)" "unprognostic (1.53e-3)" 12.9 10.6 15.0 22.1 14.6 9.5 15.5 28.7 17.0 22.8 23.5 8.9 12.1 11.1 17.2 13.6 15.0 14.2 13.4 10.6 12.4 10.3 12.0 14.9 15.7 18.2 11.1 11.0 19.2 14.9 19.5 16.2 12.2 11.8 18.8 15.1 13.9 14.0 15.4 13.6 11.7 14.9 18.0 11.0 20.7 14.3 29.8 13.8 34.5 21.1 6.7 18.0 23.6 28.2 7.2 7.0 31.5 4.0 3.0 5.2 1.2 8.8 6.8 11.4 20.0 8.0 10.3 5.6 6.6 7.1 9.4 10.8 8.4 15.9 18.2 2.6 6.8 7.7 15.5 8.5 13.5 9.8 8.3 14.5 10.8 8.3 6.8 17.8 13.7 7.3 6.2 8.6 9.5 7.7 19.6 19.2 9.7 10.2 15.2 17.9 8.1 6.1 15.9 11.4 19.1 5.9 11.7 13.5 14.1 10.0 18.2 7.2 11.1 9.5 7.4 14.1 13.0 8.4 10.0 8.6 9.1 29.3 6.7 16.5 9.2 9.1 4.0 6.4 5.2 2.9 3.9 5.4 4.5 3.8 2.2 7.2 4.3 4.7 31.5 3.0 3.2 7.0 4.5 1.2 15.0 14.6 28.7 17.0 12.4 10.3 11.1 11.0 11.8 13.8 RSPO2 MGC35555 ENSG00000147655 "R-spondin 2" Q6UXX9 8 107899316-108083648 "Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins" "Sensory transduction, Wnt signaling pathway" "Developmental protein, Heparin-binding" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 27.0;placenta: 20.1" "Cell line enhanced" "Detected in some" "HEK 293: 3.5;HEL: 3.3;NTERA-2: 2.0;U-138 MG: 3.5;U-266/70: 10.4" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 5 "intermediate monocyte: 1.6" "Lineage enriched" "Detected in single" 17 "monocytes: 1.6" "Group enriched" "Detected in some" 7 "amygdala: 8.2;cerebral cortex: 18.2;hippocampal formation: 23.2" "Group enriched" "Detected in many" 5 "amygdala: 23.3;cerebral cortex: 18.0;hippocampal formation: 24.1;midbrain: 33.2" "HPA024764, CAB025900, HPA053068" Uncertain "Secreted in other tissues" "CAB025900: , HPA024764: AB_10603236, HPA053068: " "unprognostic (1.10e-2)" "unprognostic (2.18e-1)" "unprognostic (3.97e-2)" "unprognostic (1.52e-1)" "unprognostic (2.04e-1)" "unprognostic (1.19e-1)" "unprognostic (8.33e-3)" "unprognostic (1.82e-1)" "unprognostic (9.48e-2)" "unprognostic (1.31e-1)" "unprognostic (1.40e-1)" "unprognostic (8.45e-2)" "unprognostic (1.95e-2)" "unprognostic (1.17e-2)" 0.4 0.5 3.9 1.4 6.3 0.5 0.2 1.9 27.0 3.6 12.0 4.2 3.6 5.1 0.3 3.6 8.9 0.2 4.8 0.5 5.8 10.5 0.2 1.1 9.3 0.2 15.7 5.4 1.1 0.2 0.2 2.8 20.1 2.0 11.6 10.1 15.5 0.2 3.4 0.3 0.3 5.8 0.7 1.3 0.2 8.3 2.0 1.7 0.0 0.2 0.0 0.2 2.2 1.2 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.5 3.3 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.2 0.3 0.0 0.0 0.6 0.0 0.0 0.0 0.0 2.0 0.1 0.0 0.0 1.0 0.0 0.0 0.3 0.1 0.0 0.0 0.0 0.0 0.2 0.0 3.5 0.2 0.1 0.0 10.4 0.0 0.0 1.0 0.4 0.0 0.0 0.3 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.9 6.3 1.9 27.0 5.8 10.5 15.7 5.4 2.0 1.7 RSPO3 "FLJ14440, THSD2" ENSG00000146374 "R-spondin 3" Q9BXY4 6 127118604-127197765 "Cancer-related genes, Predicted secreted proteins" "Sensory transduction, Wnt signaling pathway" Heparin-binding "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enriched" "Detected in some" 4 "A549: 23.4" "Low cancer specificity" "Detected in many" "Group enriched" "Detected in many" 5 "cerebellum: 5.7;hippocampal formation: 20.5" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Region enhanced" "Detected in many" "hippocampal formation: 32.5" HPA029957 Uncertain "Secreted to blood" "HPA029957: AB_10602087" "unprognostic (4.77e-2)" "unprognostic (3.95e-2)" "unprognostic (1.27e-2)" "unprognostic (2.27e-2)" "unprognostic (1.10e-1)" "unprognostic (2.99e-1)" "unprognostic (9.71e-2)" "unprognostic (1.49e-2)" "unprognostic (3.77e-2)" "unprognostic (3.21e-1)" "unprognostic (1.37e-1)" "unprognostic (3.37e-1)" "unprognostic (1.07e-3)" "unprognostic (7.94e-2)" "unprognostic (2.76e-1)" "unprognostic (1.64e-2)" "unprognostic (7.89e-3)" 18.5 10.5 2.8 12.1 0.8 0.0 40.7 5.7 2.3 12.9 8.5 0.0 23.8 1.2 50.3 32.5 23.7 14.9 7.6 4.2 20.5 1.7 3.3 4.2 3.8 10.2 0.8 2.4 13.2 1.5 0.0 2.6 24.1 0.8 10.2 4.7 8.6 3.9 15.3 19.7 2.2 6.7 34.1 0.6 1.4 10.8 12.4 0.0 0.2 2.9 2.1 0.9 9.3 39.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 23.4 0.0 0.0 1.3 0.0 0.0 0.0 4.0 0.2 0.5 0.0 0.0 0.0 0.5 0.2 0.0 0.6 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.2 0.0 0.0 0.5 0.0 0.0 0.0 2.6 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 1.2 0.0 0.0 0.0 0.0 0.0 5.2 2.0 0.7 0.0 0.0 0.0 0.0 5.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.8 0.8 5.7 2.2 20.5 1.7 0.8 2.4 0.8 0.0 RUNX1 "AML1, AMLCR1, CBFA2, PEBP2A2" ENSG00000159216 "Runt related transcription factor 1" Q01196 21 34787801-36004667 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "breast: 54.3;lymphoid tissue: 58.6" "Cell line enhanced" "Detected in many" "HEL: 65.0;HMC-1: 39.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "basophil: 17.0" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in single" "Low region specificity" "Detected in many" "HPA004176, HPA037912" Enhanced Enhanced Nucleoplasm,Vesicles Nucleoplasm Vesicles "HPA004176: AB_1078412, HPA037912: " "unprognostic (4.06e-3)" "unprognostic (2.35e-2)" "unprognostic (1.42e-2)" "unprognostic (1.52e-1)" "unprognostic (5.15e-3)" "unprognostic (2.62e-1)" "unprognostic (5.87e-2)" "unprognostic (1.15e-1)" "unprognostic (1.13e-1)" "unprognostic (1.12e-3)" "unprognostic (2.33e-2)" "unprognostic (3.47e-2)" "prognostic unfavourable (3.44e-15)" "unprognostic (1.48e-1)" "unprognostic (1.50e-1)" "unprognostic (6.17e-2)" "unprognostic (5.47e-2)" 11.5 3.2 5.2 14.8 7.3 29.8 54.3 1.0 4.3 12.5 4.7 3.8 4.0 3.8 2.9 7.4 6.5 4.6 12.4 7.6 6.1 2.0 4.2 6.7 17.9 13.9 8.5 1.1 6.5 5.8 1.6 5.5 6.4 6.0 9.9 5.1 3.5 29.8 8.8 14.4 8.3 5.1 6.8 12.3 10.6 12.7 2.9 6.6 58.6 4.6 5.7 14.2 11.0 9.1 3.2 3.4 17.0 3.9 1.3 4.8 2.0 13.0 1.0 0.0 0.1 3.4 4.4 8.6 7.4 7.5 4.1 3.1 0.6 10.0 6.4 0.5 6.5 11.8 0.8 8.8 6.0 9.9 1.0 65.0 2.6 3.0 6.3 7.5 39.2 8.5 5.3 12.5 12.4 2.3 4.4 3.8 8.7 2.8 30.3 11.9 0.6 3.8 30.7 22.8 3.9 5.5 5.2 0.3 0.0 7.6 1.9 2.7 3.9 17.6 9.7 6.8 8.8 10.1 11.1 12.5 5.1 6.1 8.5 16.5 9.9 17.0 3.2 6.3 3.4 1.4 3.3 3.2 3.1 3.2 0.9 3.1 4.8 3.8 3.5 1.3 3.9 3.4 4.0 2.0 5.2 7.3 1.0 4.3 6.1 2.0 8.5 1.1 6.0 6.6 RUNX1T1 "AML1T1, CBFA2T1, CDR, ETO, MTG8, ZMYND2" ENSG00000079102 "RUNX1 translocation partner 1" Q06455 8 91954967-92103286 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "DNA-binding, Repressor" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "brain: 57.8" "Cell line enhanced" "Detected in many" "Daudi: 12.9;fHDF/TERT166: 11.0;HEL: 23.7;HSkMC: 9.5" "Low cancer specificity" "Detected in some" "Region enriched" "Detected in all" 4 "cerebellum: 57.8" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA049852, HPA070951" Approved Supported Nucleoplasm Nucleoplasm "HPA049852: , HPA070951: " "unprognostic (2.37e-1)" "unprognostic (1.90e-1)" "unprognostic (1.90e-1)" "unprognostic (2.35e-1)" "unprognostic (1.62e-1)" "unprognostic (3.37e-4)" "unprognostic (2.29e-4)" "unprognostic (5.56e-3)" "unprognostic (1.24e-2)" "unprognostic (1.62e-2)" "unprognostic (2.11e-2)" "unprognostic (2.37e-1)" "unprognostic (5.70e-4)" "unprognostic (8.98e-3)" "unprognostic (6.78e-2)" "unprognostic (1.51e-1)" "unprognostic (7.80e-3)" 9.6 4.6 7.7 4.5 11.5 0.4 6.9 57.8 13.0 14.0 7.8 1.1 2.0 2.0 11.8 5.9 4.1 7.7 7.8 12.3 5.8 4.0 2.5 1.3 6.0 2.0 3.6 9.6 7.7 1.8 1.7 8.6 8.7 4.2 4.2 4.0 5.3 4.7 4.1 5.5 3.6 3.6 10.3 3.0 2.9 4.2 5.6 3.7 0.0 5.2 3.3 1.8 5.7 5.9 0.0 0.1 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.3 1.3 3.5 5.1 0.0 5.1 7.8 3.4 5.3 0.0 0.0 12.9 0.0 11.0 0.0 2.7 0.3 2.3 0.0 2.1 23.7 0.0 0.0 1.4 0.0 0.0 9.5 0.0 5.7 0.2 7.3 0.1 0.0 0.8 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 7.7 4.1 0.0 0.0 0.0 0.0 0.0 0.8 0.3 0.0 0.6 0.0 2.6 0.0 4.1 0.5 0.0 1.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 7.7 11.5 57.8 13.0 5.8 4.0 3.6 9.6 4.2 3.7 RXRA NR2B1 ENSG00000186350 "Retinoid X receptor alpha" P19793 9 134317098-134440585 "Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Host-virus interaction, Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HaCaT: 27.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 14.9;non-classical monocyte: 12.3" "Group enriched" "Detected in many" 8 "granulocytes: 14.9;monocytes: 12.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004565, CAB005352" Supported Supported "Nucleoplasm,Golgi apparatus" Nucleoplasm "Golgi apparatus" "CAB004565: AB_2184877, CAB005352: AB_2184874" "unprognostic (2.68e-1)" "unprognostic (7.94e-2)" "unprognostic (3.67e-2)" "unprognostic (7.22e-2)" "unprognostic (2.07e-2)" "unprognostic (6.69e-2)" "unprognostic (1.52e-1)" "unprognostic (2.15e-1)" "unprognostic (3.45e-2)" "unprognostic (1.65e-3)" "prognostic favourable (7.02e-4)" "unprognostic (7.72e-2)" "prognostic unfavourable (5.58e-4)" "unprognostic (1.25e-2)" "unprognostic (2.58e-1)" "unprognostic (1.49e-2)" "unprognostic (2.59e-1)" 18.5 10.1 9.9 10.4 6.7 19.6 36.8 4.6 9.8 11.0 9.3 4.9 8.1 14.0 10.1 6.1 24.2 9.3 12.9 14.2 9.0 3.7 11.7 49.3 12.8 10.4 6.0 7.0 11.7 20.6 8.0 10.7 9.6 9.4 9.7 2.0 9.5 9.3 9.7 45.8 19.0 15.2 10.6 9.5 11.5 8.8 5.9 8.1 1.5 13.6 18.3 5.9 16.0 23.7 0.1 1.7 14.9 12.3 1.3 1.1 1.8 5.5 15.6 2.0 5.0 3.5 3.3 24.0 3.0 3.5 4.3 2.5 8.6 8.7 0.0 8.2 4.3 27.0 0.7 10.6 0.2 7.9 2.0 0.0 19.0 13.1 4.5 6.5 2.4 5.3 4.5 5.4 2.5 3.7 10.7 0.5 1.0 14.9 0.5 1.4 3.8 5.4 2.8 7.4 10.8 0.2 24.1 4.4 2.0 9.5 9.1 2.4 12.6 8.9 4.8 5.3 6.4 5.7 2.6 0.7 0.0 0.1 4.0 6.6 3.4 1.1 5.2 2.8 1.1 9.3 0.0 0.1 0.7 0.7 1.7 0.0 0.2 0.9 14.9 1.3 12.3 0.1 0.9 1.8 9.9 6.7 4.6 9.8 9.0 3.7 6.0 7.0 9.4 8.1 RXRB "H-2RIIBP, NR2B2, RCoR-1" ENSG00000204231 "Retinoid X receptor beta" P28702 6 33193588-33200688 "Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in some" "CACO-2: 7.0;RH-30: 8.7;RT4: 8.2;T-47d: 8.5;U-698: 8.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002003, HPA063653" Supported Supported Nucleoplasm Nucleoplasm "CAB002003: , HPA063653: " "unprognostic (3.51e-1)" "unprognostic (8.46e-2)" "unprognostic (1.94e-1)" "unprognostic (2.22e-2)" "unprognostic (2.00e-2)" "unprognostic (4.71e-3)" "unprognostic (4.18e-2)" "unprognostic (2.21e-2)" "unprognostic (1.86e-1)" "unprognostic (2.03e-1)" "unprognostic (1.67e-3)" "unprognostic (8.13e-3)" "unprognostic (9.53e-3)" "unprognostic (8.30e-2)" "unprognostic (1.55e-1)" "unprognostic (6.38e-2)" "unprognostic (8.53e-3)" 24.9 18.9 13.0 14.0 16.1 9.8 16.0 24.7 23.2 22.8 17.1 17.7 17.3 19.0 17.4 56.6 13.7 18.5 17.1 27.7 13.5 12.3 14.1 17.4 16.5 9.8 16.4 15.6 19.1 16.2 3.6 17.5 19.2 15.5 20.1 8.4 16.0 16.2 22.0 19.7 25.5 14.1 28.4 10.4 19.8 13.9 10.4 18.2 18.5 22.0 10.9 24.5 14.0 14.5 1.9 1.4 5.2 1.2 1.9 2.5 0.7 0.0 0.0 0.0 0.0 0.0 0.0 4.4 0.0 0.0 0.0 0.0 7.0 0.0 5.3 4.0 0.0 3.5 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 5.1 0.0 5.8 0.0 0.0 0.0 0.0 0.0 5.2 0.0 5.2 0.0 0.0 0.2 3.1 0.0 0.0 8.7 0.0 5.3 8.2 0.0 4.7 0.0 0.0 0.0 8.5 0.0 0.0 0.0 3.8 0.0 0.0 6.8 5.8 8.4 0.0 0.0 0.0 5.2 0.8 2.9 2.5 0.9 1.8 1.9 2.5 2.4 1.3 0.8 2.4 1.5 1.9 1.9 1.2 1.4 2.5 0.7 13.0 16.1 24.7 23.2 13.5 12.3 16.4 15.6 15.5 18.2 RXRG NR2B3 ENSG00000143171 "Retinoid X receptor gamma" P48443 1 165400917-165445355 "Cancer-related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "brain: 14.9;pituitary gland: 29.8;retina: 13.5;skeletal muscle: 44.8" "Cell line enriched" "Detected in some" 7 "SK-MEL-30: 28.3" "Group enriched" "Detected in many" 13 "melanoma: 25.7;thyroid cancer: 34.8" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in many" 5 "basal ganglia: 89.8" "Low region specificity" "Detected in all" "CAB002615, HPA012933" Uncertain Approved "Nucleoplasm,Nuclear bodies" "Nucleoplasm, Nuclear bodies" "CAB002615: , HPA012933: " "unprognostic (2.29e-1)" "unprognostic (1.08e-2)" "unprognostic (1.51e-1)" "unprognostic (1.66e-1)" "unprognostic (4.29e-2)" "unprognostic (6.19e-2)" "unprognostic (1.35e-1)" "unprognostic (1.05e-2)" "unprognostic (9.13e-2)" "unprognostic (6.86e-2)" "unprognostic (2.95e-2)" "unprognostic (5.41e-3)" "unprognostic (2.52e-2)" "unprognostic (6.12e-3)" "unprognostic (1.18e-1)" "prognostic favourable (9.40e-5)" "unprognostic (5.03e-2)" 1.9 3.9 5.4 1.0 14.9 0.6 1.0 0.3 5.9 4.0 2.5 5.3 0.6 1.3 1.8 1.3 1.7 3.6 1.2 5.8 7.5 8.9 0.7 0.8 3.4 0.8 4.1 4.3 1.7 2.7 0.8 29.8 1.3 14.1 1.1 2.7 13.5 1.9 2.1 44.8 2.9 2.0 1.8 8.9 1.0 1.1 1.5 5.4 0.0 1.1 2.5 0.6 1.2 1.2 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.4 0.0 0.0 0.0 1.3 0.0 0.0 0.0 28.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.4 14.9 0.3 5.9 7.5 8.9 4.1 4.3 14.1 5.4 S100A1 "S100-alpha, S100A" ENSG00000160678 "S100 calcium binding protein A1" P23297 1 153627926-153632039 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "heart muscle: 465.5;skeletal muscle: 423.5" "Group enriched" "Detected in some" 5 "Hep G2: 42.7;SK-MEL-30: 146.4" "Group enriched" "Detected in all" 5 "melanoma: 210.5;ovarian cancer: 110.1;thyroid cancer: 123.9" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "basophil: 2.1" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002599, HPA006462" Enhanced 240000 "CAB002599: AB_2315307, HPA006462: AB_1079857" "unprognostic (6.13e-2)" "unprognostic (7.60e-2)" "unprognostic (5.96e-5)" "prognostic unfavourable (1.12e-4)" "unprognostic (1.19e-1)" "unprognostic (3.24e-2)" "unprognostic (2.36e-1)" "unprognostic (2.34e-3)" "unprognostic (6.83e-3)" "unprognostic (5.22e-1)" "unprognostic (5.04e-3)" "unprognostic (9.62e-2)" "prognostic unfavourable (3.08e-4)" "unprognostic (1.68e-1)" "unprognostic (4.56e-2)" "unprognostic (2.70e-3)" "unprognostic (9.74e-4)" 27.7 3.2 70.0 2.8 67.3 2.2 14.3 4.1 42.5 2.0 2.4 47.3 0.0 3.5 2.6 8.5 14.1 8.8 2.6 465.5 44.9 42.9 20.0 2.6 2.4 2.5 85.0 30.7 2.2 4.5 2.0 4.3 4.5 31.4 6.3 2.1 4.3 99.3 3.7 423.5 4.0 2.9 2.1 87.7 2.4 3.3 2.8 31.8 0.0 29.0 57.6 4.7 2.9 0.1 0.6 0.6 2.1 1.0 0.3 0.5 0.5 0.7 0.3 0.5 4.5 0.0 0.0 0.3 0.8 0.0 0.0 0.0 0.9 0.4 0.5 19.1 0.0 1.1 0.0 0.0 0.0 0.4 0.4 1.0 0.6 42.7 0.0 0.2 0.3 0.1 0.0 0.0 0.0 0.0 3.4 0.5 0.0 1.2 0.1 0.5 0.2 0.3 3.0 0.4 1.0 0.8 1.6 0.7 0.2 0.3 1.3 146.4 4.4 2.2 0.3 0.4 0.3 0.3 0.4 0.7 0.7 0.7 0.3 0.7 0.2 2.1 0.3 0.0 0.1 0.3 0.1 0.0 0.2 0.5 0.0 0.6 0.3 0.0 0.0 0.3 1.0 0.6 0.0 0.5 70.0 67.3 4.1 42.5 44.9 42.9 85.0 30.7 31.4 31.8 S100A2 "CAN19, S100L" ENSG00000196754 "S100 calcium binding protein A2" P29034 1 153561108-153567890 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "esophagus: 224.8;tongue: 246.5" "Group enriched" "Detected in some" 5 "HBEC3-KT: 656.0;RT4: 256.5" "Cancer enhanced" "Detected in all" "head and neck cancer: 1229.1" "Not detected" "Not detected" "Cell type enhanced" "Detected in many" "basophil: 11.9" "Lineage enriched" "Detected in many" 4 "granulocytes: 11.9" "Not detected" "Not detected" "CAB002600, CAB047340, HPA062451" Enhanced Approved "Nucleoplasm,Nucleoli,Plasma membrane,Cytosol" 130000 "Nucleoplasm, Cytosol" "Nucleoli, Plasma membrane" "CAB002600: , CAB047340: , HPA062451: " "unprognostic (8.47e-3)" "unprognostic (5.54e-2)" "unprognostic (1.57e-2)" "unprognostic (1.42e-3)" "unprognostic (1.98e-1)" "unprognostic (3.20e-1)" "unprognostic (4.21e-4)" "unprognostic (9.00e-2)" "unprognostic (1.64e-1)" "unprognostic (1.23e-2)" "prognostic unfavourable (2.04e-4)" "unprognostic (3.52e-2)" "unprognostic (8.91e-2)" "unprognostic (1.35e-1)" "unprognostic (2.70e-1)" "unprognostic (1.39e-1)" "unprognostic (2.68e-1)" 0.4 0.0 0.4 0.5 0.4 0.0 2.1 0.4 0.5 16.9 0.4 0.4 0.9 0.0 1.8 1.9 224.8 0.5 0.4 0.4 0.4 0.0 16.6 0.4 1.6 0.4 0.4 0.4 0.4 0.4 0.0 0.5 0.6 0.6 3.3 0.0 0.4 23.3 2.1 0.7 27.5 0.4 1.5 0.5 0.4 0.0 0.5 0.4 0.7 1.0 246.5 48.4 36.2 43.8 0.5 2.6 11.9 0.6 0.0 2.9 0.7 24.8 0.2 0.0 0.0 0.3 0.1 0.0 0.3 0.3 0.2 0.2 0.0 0.8 0.0 13.2 0.5 61.7 0.0 656.0 0.3 0.1 0.1 0.1 1.7 0.1 0.1 0.0 0.0 0.2 87.4 0.7 99.7 0.4 0.0 0.0 1.4 0.1 0.0 0.0 0.0 4.8 0.0 15.6 0.0 15.5 256.5 0.5 0.0 1.0 0.1 0.2 0.1 0.1 0.1 0.3 21.7 2.9 8.4 0.0 0.0 0.1 0.8 0.0 0.7 11.9 0.5 0.0 2.9 0.0 1.8 0.5 2.0 1.6 0.4 0.0 0.6 0.5 5.0 0.0 0.6 2.6 1.8 0.7 0.4 0.4 0.4 0.5 0.4 0.0 0.4 0.4 0.6 0.4 S100A4 "18A2, 42A, CAPL, FSP1, MTS1, P9KA, PEL98" ENSG00000196154 "S100 calcium binding protein A4" P26447 1 153543613-153550136 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 419.2" "Cell line enhanced" "Detected in many" "A549: 112.8;ASC diff: 146.4;BJ hTERT+: 281.6;fHDF/TERT166: 201.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Not detected" "Not detected" "CAB002618, HPA007973, CAB027387, CAB058698, CAB068227, CAB068228" Enhanced Enhanced "Plasma membrane" 13000000 "Plasma membrane" "CAB002618: , CAB027387: , CAB058698: , CAB068227: , CAB068228: , HPA007973: AB_1079858" "unprognostic (1.56e-1)" "unprognostic (6.10e-2)" "unprognostic (2.84e-2)" "unprognostic (8.20e-2)" "unprognostic (6.21e-2)" "prognostic favourable (4.03e-5)" "unprognostic (8.35e-2)" "unprognostic (4.81e-2)" "unprognostic (1.50e-1)" "unprognostic (2.20e-1)" "unprognostic (2.78e-2)" "unprognostic (3.39e-2)" "prognostic unfavourable (2.90e-4)" "unprognostic (1.05e-1)" "unprognostic (3.05e-1)" "unprognostic (2.76e-2)" "unprognostic (3.16e-2)" 125.9 10.1 2.6 29.2 8.3 75.2 171.6 2.2 4.6 52.1 33.9 2.7 25.8 7.3 26.8 52.2 58.6 27.9 34.7 59.9 3.0 1.7 27.8 6.1 80.7 53.2 10.8 3.1 12.7 6.7 0.0 3.0 46.9 6.6 49.5 28.0 19.3 29.8 13.4 25.4 44.5 25.5 38.5 8.9 55.9 17.2 18.2 6.2 8.5 23.7 57.5 26.4 34.9 58.2 18.6 213.1 281.6 293.3 17.3 162.7 419.2 0.5 112.8 0.5 3.3 146.4 100.9 0.1 71.5 281.6 1.4 6.3 0.8 7.9 0.0 13.1 201.4 2.8 0.4 1.0 1.1 16.1 0.0 48.2 25.1 2.5 0.1 4.2 81.6 15.7 1.1 2.8 0.6 0.1 0.4 0.1 102.5 0.4 0.1 50.0 0.3 43.3 2.5 0.1 106.3 4.4 3.0 4.3 0.5 1.2 54.5 0.4 3.3 60.4 0.1 0.3 0.6 96.1 0.4 3.5 24.0 0.5 0.2 53.7 5.5 49.5 293.3 30.8 141.2 201.4 147.2 18.6 127.2 112.3 213.1 6.2 22.4 66.5 281.6 17.3 253.9 37.4 162.7 419.2 2.6 8.3 2.2 4.6 3.0 1.7 10.8 3.1 6.6 6.2 S100A6 "2A9, CABP, CACY, PRA" ENSG00000197956 "S100 calcium binding protein A6" P06703 1 153534599-153536244 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "RPTEC TERT1: 375.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB002601, HPA007575, CAB040549, CAB047354" Enhanced Enhanced "Plasma membrane,Cytosol" 5100000 "Plasma membrane, Cytosol" "CAB002601: , CAB040549: , CAB047354: , HPA007575: AB_1079859" "unprognostic (8.80e-3)" "unprognostic (6.96e-2)" "unprognostic (2.31e-1)" "unprognostic (2.47e-2)" "unprognostic (1.19e-1)" "unprognostic (1.19e-1)" "unprognostic (1.23e-3)" "unprognostic (1.36e-1)" "unprognostic (1.27e-1)" "unprognostic (3.51e-1)" "unprognostic (6.86e-3)" "unprognostic (1.66e-1)" "unprognostic (3.59e-1)" "unprognostic (1.10e-1)" "unprognostic (2.88e-1)" "unprognostic (1.46e-2)" "prognostic favourable (7.56e-4)" 126.4 32.6 14.8 104.9 29.9 73.8 223.6 13.3 14.6 95.4 176.8 10.1 51.2 70.2 65.0 135.5 126.5 42.2 264.5 112.3 13.0 22.5 103.4 6.0 151.9 61.5 45.6 7.9 38.1 13.5 0.5 17.7 100.1 27.3 85.1 85.5 28.5 58.7 55.2 59.1 45.1 98.1 88.9 35.5 27.5 69.9 29.6 17.8 4.9 76.9 183.0 36.2 150.9 145.0 30.7 130.1 303.7 180.7 9.1 69.2 201.7 77.6 86.9 0.0 7.2 146.3 189.8 0.2 95.2 237.8 48.3 63.4 6.0 162.4 0.1 30.2 141.3 33.7 1.5 136.7 22.8 31.9 0.0 16.2 58.1 5.3 55.4 0.7 11.2 88.5 113.7 51.7 89.5 107.1 0.0 0.1 120.3 11.7 0.2 6.6 0.1 143.0 0.0 10.8 28.1 375.0 72.1 22.4 3.9 129.5 131.9 97.9 18.1 25.2 156.4 46.7 12.2 95.3 154.5 0.2 0.2 0.2 181.3 17.4 99.6 139.8 180.7 74.1 62.0 96.8 67.3 30.7 58.5 60.3 130.1 17.2 37.3 49.5 303.7 9.1 86.9 68.3 69.2 201.7 14.8 29.9 13.3 14.6 13.0 22.5 45.6 7.9 27.3 17.8 S100A7 "PSOR1, S100A7c" ENSG00000143556 "S100 calcium binding protein A7" P31151 1 153457744-153460701 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "esophagus: 116.2;lymphoid tissue: 156.7;tongue: 409.9" "Group enriched" "Detected in some" 5 "HaCaT: 7.3;SK-BR-3: 16.9" "Group enriched" "Detected in many" 5 "cervical cancer: 458.9;head and neck cancer: 1201.5;melanoma: 638.4;urothelial cancer: 281.3" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "CAB001453, HPA006997, CAB033766" Enhanced Uncertain Cytosol "Secreted in other tissues" 17000000 Cytosol "CAB001453: AB_564004, CAB033766: AB_2269963, HPA006997: AB_1079860" "unprognostic (3.28e-1)" "unprognostic (9.85e-2)" "unprognostic (1.32e-2)" "unprognostic (2.16e-2)" "unprognostic (3.17e-1)" "unprognostic (2.94e-2)" "unprognostic (1.03e-2)" "unprognostic (4.00e-1)" "unprognostic (1.25e-1)" "unprognostic (1.27e-1)" "unprognostic (2.99e-1)" "unprognostic (5.41e-2)" "unprognostic (1.21e-2)" 0.1 0.0 0.1 0.1 0.1 0.1 2.2 0.1 0.1 45.2 0.1 0.1 0.1 0.0 3.7 3.9 116.2 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.3 0.1 0.1 0.0 0.1 6.2 0.1 0.1 45.7 0.1 0.2 0.1 0.1 0.0 0.3 0.1 1.2 0.1 409.9 156.7 0.2 85.3 0.0 0.4 0.7 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 2.6 0.0 0.0 7.3 0.0 2.2 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.4 0.0 0.0 1.9 0.0 0.0 0.0 1.8 0.0 0.0 0.5 0.0 0.2 0.0 0.0 0.0 0.7 0.1 0.4 0.0 0.0 0.0 0.8 16.9 0.0 0.3 0.0 0.6 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.4 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 S100A8 "60B8AG, CAGA, CFAG, CGLA, MRP8, P8" ENSG00000143546 "S100 calcium binding protein A8" P05109 1 153390032-153391188 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Apoptosis, Autophagy, Chemotaxis, Immunity, Inflammatory response, Innate immunity" Antimicrobial "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 720.9;bone marrow: 718.8;esophagus: 532.3;tongue: 597.1" "Group enriched" "Detected in some" 28 "hTCEpi: 27.5;SK-BR-3: 100.9;THP-1: 53.6" "Cancer enhanced" "Detected in all" "cervical cancer: 2290.9;head and neck cancer: 2382.0" "Low region specificity" "Detected in many" "Group enriched" "Detected in many" 8 "classical monocyte: 320.7;neutrophil: 720.9" "Group enriched" "Detected in many" 8 "granulocytes: 720.9;monocytes: 320.7" "Low region specificity" "Detected in some" "Not detected" "Not detected" "CAB002791, HPA024372" Enhanced Supported "Intermediate filaments,Cytosol" "Secreted to blood" 10876880 530000000 "Intermediate filaments" Cytosol "CAB002791: , HPA024372: AB_1856536" "unprognostic (1.98e-1)" "unprognostic (1.13e-1)" "unprognostic (3.79e-2)" "unprognostic (1.58e-2)" "unprognostic (8.60e-3)" "unprognostic (9.26e-3)" "unprognostic (4.92e-2)" "unprognostic (1.32e-1)" "unprognostic (1.83e-1)" "unprognostic (6.13e-2)" "unprognostic (3.77e-2)" "unprognostic (2.24e-2)" "prognostic unfavourable (8.94e-7)" "unprognostic (1.17e-1)" "unprognostic (8.90e-2)" "unprognostic (8.27e-2)" "unprognostic (8.94e-3)" 14.0 0.8 0.8 30.5 2.6 718.8 1.1 0.5 1.6 123.0 2.8 0.7 0.4 0.4 12.0 1.2 532.3 5.5 2.1 36.7 1.5 0.5 1.4 4.3 26.2 37.3 3.3 0.4 2.1 2.7 0.1 0.9 4.7 3.3 1.4 0.4 1.3 92.4 0.3 2.5 6.2 1.0 9.0 1.8 72.4 2.0 1.9 0.9 2.6 4.6 597.1 257.6 5.0 224.1 0.6 63.7 720.9 320.7 0.3 0.6 244.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.1 0.0 1.6 0.0 2.2 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.7 0.0 0.0 27.5 0.0 0.9 0.0 1.2 0.1 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.7 0.1 0.0 0.0 0.0 0.0 0.4 100.9 0.0 0.6 53.6 1.4 0.0 0.0 0.1 0.0 0.0 0.1 0.3 0.0 1.6 0.0 8.2 320.7 38.9 0.4 26.5 0.6 0.6 0.3 0.2 63.7 0.3 0.3 0.3 720.9 0.3 6.4 2.5 0.4 244.7 0.8 2.6 0.5 1.6 1.5 0.5 3.3 0.4 3.3 0.9 S100A9 "60B8AG, CAGB, CFAG, CGLB, LIAG, MAC387, MIF, MRP14, NIF, P14" ENSG00000163220 "S100 calcium binding protein A9" P06702 1 153357854-153361027 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Apoptosis, Autophagy, Chemotaxis, Immunity, Inflammatory response, Innate immunity" "Antimicrobial, Antioxidant" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 638.3;bone marrow: 820.1;esophagus: 642.6;tongue: 477.6" "Cell line enriched" "Detected in some" 6 "SK-BR-3: 227.6" "Cancer enhanced" "Detected in all" "cervical cancer: 5468.0;head and neck cancer: 6692.8" "Low region specificity" "Detected in many" "Group enriched" "Detected in many" 6 "classical monocyte: 381.5;neutrophil: 638.3" "Group enriched" "Detected in many" 6 "granulocytes: 638.3;monocytes: 381.5" "Low region specificity" "Detected in some" "Not detected" "Not detected" "HPA004193, CAB009441" Enhanced Supported "Nucleoplasm,Cell Junctions,Cytosol" "Secreted to blood" 10597950 1400000000 "Nucleoplasm, Cell Junctions, Cytosol" "CAB009441: AB_2184420, HPA004193: AB_1856537" "unprognostic (1.72e-1)" "unprognostic (3.33e-2)" "unprognostic (2.40e-1)" "unprognostic (3.94e-3)" "unprognostic (1.36e-2)" "unprognostic (5.45e-3)" "prognostic unfavourable (1.13e-6)" "unprognostic (1.10e-2)" "unprognostic (4.31e-1)" "unprognostic (3.06e-1)" "unprognostic (1.35e-2)" "unprognostic (5.59e-2)" "prognostic unfavourable (8.10e-4)" "unprognostic (1.48e-1)" "unprognostic (7.52e-2)" "unprognostic (5.39e-2)" "unprognostic (1.75e-2)" 19.5 2.1 1.3 41.9 4.2 820.1 4.1 0.9 2.1 143.6 4.4 0.7 0.4 0.7 4.9 4.0 642.6 9.9 4.4 51.2 2.5 0.4 2.8 4.8 29.2 169.0 5.3 0.6 3.4 4.4 0.1 0.9 10.4 5.2 2.2 0.7 2.0 109.6 0.5 3.4 7.5 1.4 13.1 2.1 103.2 3.5 2.9 1.4 3.8 6.7 477.6 228.0 24.3 237.0 0.5 87.5 638.3 381.5 0.3 1.0 323.2 2.2 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.8 35.7 0.0 2.1 0.0 14.6 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.7 0.0 0.0 12.4 0.0 0.8 0.0 0.6 0.3 0.0 2.8 0.0 0.3 0.0 0.0 0.0 0.4 7.5 0.0 9.2 0.1 0.0 0.3 227.6 0.1 3.6 28.9 0.6 0.0 0.3 0.0 0.0 0.0 0.1 0.2 0.0 6.5 0.0 5.3 381.5 46.4 0.5 31.6 1.0 0.4 0.4 0.3 87.5 0.5 0.3 0.3 638.3 0.3 15.0 2.9 0.5 323.2 1.3 4.2 0.9 2.1 2.5 0.4 5.3 0.6 5.2 1.4 S100B S100beta ENSG00000160307 "S100 calcium binding protein B" P04271 21 46598962-46605208 "Cancer-related genes, Candidate cardiovascular disease genes, Predicted intracellular proteins, Transporters" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in all" 4 "brain: 342.0" "Group enriched" "Detected in some" 7 "SK-MEL-30: 81.0;WM-115: 159.2" "Group enriched" "Detected in all" 58 "glioma: 463.5;melanoma: 495.2" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "gdT-cell: 78.0" "Lineage enriched" "Detected in many" 7 "T-cells: 78.0" "Low region specificity" "Detected in all" "CAB000073, HPA015768, CAB078196" Enhanced Supported Supported Nucleoplasm,Vesicles,Cytosol 120000 "Nucleoplasm, Cytosol" Vesicles "CAB000073: AB_10013383, CAB078196: , HPA015768: AB_1856538" "unprognostic (5.67e-3)" "unprognostic (6.39e-3)" "unprognostic (2.08e-3)" "unprognostic (2.08e-2)" "unprognostic (4.54e-3)" "unprognostic (1.10e-2)" "unprognostic (1.01e-1)" "unprognostic (6.68e-3)" "unprognostic (2.03e-1)" "unprognostic (1.37e-1)" "unprognostic (8.57e-3)" "unprognostic (6.70e-2)" "unprognostic (4.41e-7)" "unprognostic (3.55e-2)" "unprognostic (7.56e-2)" "unprognostic (1.07e-1)" "unprognostic (1.74e-1)" 67.7 14.0 60.9 5.6 51.0 2.0 13.2 39.4 151.2 5.2 9.1 101.0 3.0 4.7 1.5 7.6 8.6 2.1 8.3 6.6 74.6 65.4 1.5 1.6 2.9 9.8 152.0 36.5 2.4 3.0 1.1 3.1 1.4 90.3 3.0 8.3 7.4 10.1 15.3 1.3 5.7 7.5 4.3 342.0 5.7 4.3 1.5 46.4 0.0 1.3 1.8 10.8 8.2 1.6 0.1 3.4 0.7 1.9 11.0 78.0 10.6 0.1 0.0 17.6 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 2.6 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 81.0 0.0 0.0 0.0 0.1 0.1 0.0 0.5 0.0 0.0 0.0 0.2 1.0 159.2 0.0 0.1 0.0 78.0 1.8 22.4 0.0 0.2 14.5 3.4 0.1 0.6 33.3 0.7 11.0 1.9 0.8 0.0 10.6 60.9 51.0 39.4 37.6 74.6 65.4 152.0 36.5 90.3 46.4 S1PR1 "CD363, D1S3362, edg-1, EDG1" ENSG00000170989 "Sphingosine-1-phosphate receptor 1" P21453 1 101236888-101241518 "Cancer-related genes, CD markers, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "Angiogenesis, Chemotaxis" "G-protein coupled receptor, Receptor, Transducer" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 88.9" "Cell line enhanced" "Detected in many" "BJ: 19.0;HUVEC TERT2: 53.7;TIME: 29.9;U-251 MG: 36.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010104, HPA075568" Supported Supported Vesicles Vesicles "CAB010104: AB_2238920, HPA075568: " "unprognostic (1.41e-1)" "unprognostic (9.35e-2)" "unprognostic (2.46e-2)" "unprognostic (2.61e-1)" "unprognostic (9.78e-2)" "unprognostic (4.49e-3)" "unprognostic (1.34e-3)" "unprognostic (1.99e-1)" "unprognostic (1.36e-1)" "unprognostic (9.12e-2)" "unprognostic (2.34e-2)" "unprognostic (2.23e-1)" "unprognostic (5.82e-3)" "unprognostic (2.54e-2)" "unprognostic (1.04e-1)" "unprognostic (3.64e-1)" "prognostic unfavourable (8.78e-4)" 72.3 8.4 24.7 16.6 26.2 9.7 46.3 21.6 21.8 13.3 10.5 9.5 2.5 5.7 12.1 5.0 14.7 11.5 17.6 43.5 22.9 15.4 8.9 20.5 35.7 24.5 23.2 14.0 7.9 11.0 13.4 4.7 29.6 21.2 8.9 7.0 9.3 7.5 5.6 21.7 8.2 9.8 19.0 11.0 35.2 8.0 5.8 13.9 4.4 17.0 8.7 15.7 15.2 18.5 27.4 0.2 88.9 0.2 33.4 49.8 30.8 3.5 0.0 3.8 0.0 0.4 9.1 0.0 19.0 3.4 11.5 4.1 0.0 0.1 0.0 4.7 6.6 0.0 0.5 0.2 7.7 1.3 0.3 1.3 0.1 0.0 1.8 0.0 0.8 12.2 0.0 0.0 0.9 53.7 0.0 3.9 3.6 0.0 4.5 0.0 1.0 1.2 0.0 3.7 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 29.9 1.9 0.7 0.4 36.8 0.3 0.0 0.2 0.1 0.0 0.1 88.9 0.1 4.9 49.8 0.1 40.2 25.1 45.3 44.1 0.2 27.4 35.7 36.2 1.4 33.4 0.2 0.2 26.8 30.8 24.7 26.2 21.6 16.8 22.9 15.4 23.2 14.0 21.2 13.9 SACS "ARSACS, DKFZp686B15167, DNAJC29, KIAA0730, PPP1R138, SPAX6" ENSG00000151835 "Sacsin molecular chaperone" Q9NZJ4 13 23328826-23433740 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" Chaperone "Cancer-related genes, Disease mutation, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "parathyroid gland: 38.5" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" CAB017714 Uncertain "CAB017714: " "unprognostic (1.22e-1)" "unprognostic (2.18e-1)" "unprognostic (2.02e-3)" "prognostic unfavourable (9.04e-4)" "unprognostic (1.26e-2)" "unprognostic (1.66e-1)" "unprognostic (2.05e-3)" "unprognostic (2.59e-2)" "unprognostic (2.49e-1)" "unprognostic (4.14e-2)" "unprognostic (5.05e-1)" "unprognostic (2.04e-1)" "prognostic unfavourable (6.21e-6)" "unprognostic (2.84e-1)" "unprognostic (4.06e-2)" "unprognostic (3.67e-2)" "unprognostic (7.65e-4)" 6.3 6.0 15.9 7.9 20.3 9.6 7.1 7.7 20.2 5.6 6.4 7.8 2.6 2.8 8.8 6.3 5.5 5.1 5.2 7.4 13.5 10.2 2.8 2.8 4.0 8.1 12.5 11.5 8.6 4.6 38.5 7.5 3.4 21.4 8.0 4.0 2.4 6.0 5.4 13.6 4.8 4.3 13.5 11.6 8.3 4.7 7.8 15.2 6.6 3.2 8.7 7.4 6.9 6.7 2.5 2.0 1.0 0.9 1.3 2.8 0.5 3.8 5.1 10.6 3.2 3.3 12.6 1.6 8.9 11.5 3.5 2.9 2.4 2.1 2.7 3.8 19.0 0.8 15.3 5.3 11.5 6.2 6.2 10.0 3.9 3.6 2.5 18.2 4.0 4.0 1.2 22.2 10.8 11.3 5.7 1.3 15.7 1.8 6.5 7.0 8.7 4.1 7.7 19.5 8.0 6.0 0.4 7.7 7.4 4.9 1.8 3.9 0.9 4.9 24.5 10.7 8.8 5.7 16.8 2.5 2.7 6.6 5.0 6.5 9.3 0.0 0.8 1.0 1.1 0.9 2.0 1.1 1.7 0.8 2.0 2.5 1.2 1.4 0.0 1.3 0.3 1.7 2.8 0.5 15.9 20.3 7.7 20.2 13.5 10.2 12.5 11.5 21.4 15.2 SALL4 "dJ1112F19.1, ZNF797" ENSG00000101115 "Spalt like transcription factor 4" Q9UJQ4 20 51782331-51802520 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes, Disease mutation, Oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "parathyroid gland: 8.8;testis: 11.7;thyroid gland: 8.6" "Cell line enhanced" "Detected in some" "AF22: 13.6;AN3-CA: 9.5;BEWO: 18.2;NTERA-2: 32.7;SiHa: 8.3" "Cancer enriched" "Detected in many" 11 "testis cancer: 22.7" "Not detected" "Not detected" "Cell type enriched" "Detected in single" 9 "NK-cell: 6.3" "Lineage enriched" "Detected in single" 9 "NK-cells: 6.3" "Not detected" "Not detected" "Low region specificity" "Detected in all" "HPA015291, HPA015791" Enhanced Enhanced Nucleoplasm Nucleoplasm "HPA015291: AB_1856548, HPA015791: AB_1856547" "unprognostic (1.30e-1)" "unprognostic (2.35e-2)" "unprognostic (1.11e-1)" "unprognostic (1.09e-3)" "unprognostic (3.55e-2)" "unprognostic (7.43e-2)" "unprognostic (3.63e-2)" "unprognostic (1.47e-1)" "unprognostic (1.20e-1)" "unprognostic (9.23e-2)" "unprognostic (2.50e-2)" "unprognostic (2.39e-2)" "unprognostic (2.42e-8)" "unprognostic (5.90e-3)" "unprognostic (1.82e-1)" "unprognostic (5.00e-5)" "unprognostic (7.41e-2)" 0.3 0.4 0.3 0.3 0.9 1.2 0.3 0.8 0.9 0.4 0.7 0.3 2.2 0.1 0.3 0.8 0.3 0.2 0.3 0.3 0.3 0.1 0.5 1.9 0.3 0.3 0.3 0.3 0.3 4.6 8.8 0.6 0.3 0.9 3.1 0.2 4.5 2.2 0.4 0.3 0.3 0.7 0.3 0.3 0.8 0.3 11.7 0.3 0.3 8.6 0.3 0.3 0.9 0.3 0.1 0.1 0.6 0.1 6.3 0.2 0.0 0.0 0.9 13.6 9.5 0.0 0.1 18.2 0.0 0.1 0.0 0.1 4.7 0.1 0.0 0.1 0.1 2.3 0.1 0.0 0.2 0.2 0.0 0.0 3.2 0.2 0.1 0.0 1.0 0.4 0.3 0.0 0.0 0.2 0.0 0.0 0.0 0.9 0.0 0.0 32.7 0.2 1.2 0.0 0.0 0.0 0.3 3.1 1.7 8.3 0.0 0.8 0.0 0.5 0.0 0.5 1.8 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.2 0.0 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.6 6.3 0.1 0.1 0.0 0.0 0.3 0.9 0.8 0.9 0.3 0.1 0.3 0.3 0.9 0.3 SART1 "Ara1, HAF, SNRNP110, Snu66" ENSG00000175467 "SART1, U4/U6.U5 tri-snRNP-associated protein 1" O43290 11 65961689-65979828 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "mRNA processing, mRNA splicing" "Allergen, Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA031188, HPA031189, HPA031190" Supported Enhanced "Nuclear speckles,Golgi apparatus" "Nuclear speckles" "Golgi apparatus" "HPA031188: AB_10600092, HPA031189: AB_10601854, HPA031190: AB_10602289" "unprognostic (2.93e-2)" "unprognostic (1.13e-2)" "unprognostic (1.09e-2)" "unprognostic (1.76e-1)" "unprognostic (1.45e-1)" "unprognostic (6.99e-2)" "unprognostic (2.52e-3)" "unprognostic (8.15e-2)" "unprognostic (8.97e-2)" "unprognostic (2.10e-1)" "unprognostic (2.11e-2)" "unprognostic (3.05e-1)" "unprognostic (1.39e-1)" "unprognostic (1.04e-1)" "unprognostic (1.58e-1)" "unprognostic (1.62e-1)" "unprognostic (4.24e-2)" 22.3 17.5 26.4 25.0 27.8 50.7 21.7 28.5 27.2 21.4 19.6 17.7 20.9 22.7 26.3 17.4 19.0 20.3 20.7 19.5 23.8 16.8 15.8 18.2 19.0 26.2 23.0 25.7 26.8 28.4 22.5 19.2 22.4 25.2 18.1 12.0 15.9 27.1 27.2 34.6 26.2 19.9 27.9 29.2 29.2 20.3 20.4 25.6 24.0 20.5 19.1 19.0 20.6 41.3 5.9 5.8 12.1 5.3 4.1 8.1 2.7 22.5 27.3 12.5 16.8 12.3 9.8 19.2 17.5 12.4 20.3 13.3 19.7 15.7 25.7 20.2 15.2 22.2 15.7 16.0 10.3 20.6 15.6 29.7 19.4 18.2 18.5 25.6 25.0 12.3 12.3 18.8 16.9 12.6 18.7 18.3 11.6 40.7 32.9 36.9 21.3 26.1 36.2 18.2 27.0 8.4 15.1 14.2 20.1 16.6 17.1 20.3 19.1 20.9 18.7 25.4 25.1 24.9 24.5 28.0 21.8 22.5 21.1 13.0 21.5 2.0 4.5 12.1 7.1 5.3 6.0 5.9 8.0 7.4 5.8 5.4 5.9 6.6 6.3 4.1 3.1 4.9 8.1 2.7 26.4 27.8 28.5 27.2 23.8 16.8 23.0 25.7 25.2 25.6 SBDS "CGI-97, FLJ10917, SDS, SWDS" ENSG00000126524 "SBDS, ribosome maturation factor" Q9Y3A5 7 66987677-66995601 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Ribosome biogenesis" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA028891 Approved Supported Nucleoplasm,Cytosol 55000 "Nucleoplasm, Cytosol" "HPA028891: AB_10601500" "prognostic unfavourable (1.49e-4)" "unprognostic (1.87e-2)" "unprognostic (5.73e-2)" "unprognostic (1.71e-3)" "unprognostic (8.06e-3)" "prognostic unfavourable (3.65e-4)" "unprognostic (1.07e-1)" "unprognostic (2.22e-2)" "unprognostic (1.44e-1)" "unprognostic (6.99e-2)" "unprognostic (7.84e-3)" "unprognostic (4.59e-1)" "unprognostic (1.04e-2)" "unprognostic (9.38e-3)" "unprognostic (1.83e-1)" "unprognostic (2.30e-1)" "unprognostic (5.06e-3)" 40.9 34.5 37.7 18.7 44.0 41.7 44.5 23.6 43.2 30.7 37.5 35.3 20.2 39.1 35.6 27.3 40.8 27.7 34.0 70.0 39.2 40.9 36.9 38.4 32.1 16.7 50.6 36.6 31.9 27.5 50.4 26.9 38.6 44.6 35.1 35.7 20.1 23.5 40.5 130.7 26.1 34.4 52.0 63.2 16.7 32.8 15.9 48.2 7.2 33.9 38.7 15.6 54.0 38.0 21.6 15.5 20.8 12.6 16.6 39.1 19.4 31.0 13.2 11.7 10.6 42.7 31.9 13.1 52.9 43.6 40.5 31.2 27.1 16.0 11.5 40.2 48.3 15.1 19.7 31.4 43.6 11.0 26.0 5.7 24.6 16.2 38.0 14.4 7.9 28.8 42.3 30.8 53.6 24.9 41.7 12.6 62.9 18.6 7.6 21.0 13.0 31.4 5.8 25.2 24.2 42.7 13.9 18.0 12.4 26.5 45.9 35.1 34.2 12.2 33.1 54.8 18.7 27.7 38.5 7.8 9.2 26.4 18.8 23.7 30.3 20.8 11.1 20.2 23.4 12.6 29.6 21.6 30.6 27.2 11.3 18.7 39.1 31.5 4.7 16.6 11.2 15.5 25.9 19.4 37.7 44.0 23.6 43.2 39.2 40.9 50.6 36.6 44.6 48.2 SCGB1A1 "CC10, CC16, CCSP, UGB" ENSG00000149021 "Secretoglobin family 1A member 1" P11684 11 62405103-62423195 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Phospholipase A2 inhibitor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 18 "lung: 508.4" "Cell line enriched" "Detected in some" 69 "HaCaT: 207.4" "Cancer enriched" "Detected in many" 8 "lung cancer: 215.5" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "CAB025686, HPA031828" Enhanced "Secreted in other tissues" 17000000 "CAB025686: , HPA031828: " "unprognostic (2.40e-3)" "unprognostic (1.55e-2)" "unprognostic (5.46e-2)" "unprognostic (2.70e-2)" "unprognostic (4.69e-3)" "unprognostic (2.12e-2)" "unprognostic (1.23e-2)" "unprognostic (2.31e-2)" "unprognostic (2.63e-2)" "unprognostic (1.63e-1)" "unprognostic (2.40e-2)" 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 1.1 28.7 0.0 0.1 0.0 0.1 0.0 0.0 508.4 0.0 0.1 0.0 9.4 0.2 0.0 7.4 0.0 0.1 7.6 0.0 0.0 0.2 1.3 0.0 0.0 0.0 0.0 0.0 0.5 0.3 0.0 0.0 0.2 0.0 0.3 4.8 0.1 0.1 0.0 0.8 0.0 0.7 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 207.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.6 0.0 0.1 0.0 0.0 0.0 0.4 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.0 SCGB1D2 "LIPB, LPHB" ENSG00000124935 "Secretoglobin family 1D member 2" O95969 11 62242210-62244808 "Cancer-related genes, Predicted secreted proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "breast: 101.5;cervix, uterine: 315.2" "Cell line enriched" "Detected in some" 6 "SCLC-21H: 14.4" "Group enriched" "Detected in many" 6 "breast cancer: 625.1;endometrial cancer: 226.0" "Region enriched" "Detected in some" 6 "pons and medulla: 7.3" "Not detected" "Not detected" "Not detected" "Not detected" HPA035318 Approved "Secreted in other tissues" "HPA035318: AB_10610421" "unprognostic (8.76e-2)" "unprognostic (2.14e-1)" "prognostic favourable (3.46e-6)" "unprognostic (2.39e-2)" "unprognostic (5.89e-2)" "unprognostic (4.72e-2)" "unprognostic (1.99e-1)" "unprognostic (6.43e-2)" "prognostic favourable (8.03e-6)" "unprognostic (1.55e-1)" "unprognostic (1.15e-2)" 1.8 0.4 0.8 0.2 0.6 0.0 101.5 0.9 0.5 315.2 0.2 0.9 6.2 0.0 18.4 43.8 0.8 8.5 0.4 1.0 1.2 0.4 1.1 0.2 0.2 0.2 1.0 0.5 1.1 2.9 0.0 1.0 0.6 7.3 1.1 0.0 1.2 9.5 0.5 2.4 59.6 0.2 0.2 0.4 0.2 0.0 1.6 0.5 0.2 0.3 2.1 1.2 0.2 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 2.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.2 0.0 0.0 14.4 0.2 0.0 2.5 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.6 0.9 0.5 1.2 0.4 1.0 0.5 7.3 0.5 SCGB2A1 "LPHC, MGB2, MGC71973, UGB3" ENSG00000124939 "Secretoglobin family 2A member 1" O75556 11 62208668-62213939 "Cancer-related genes, Predicted secreted proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "cervix, uterine: 191.8;epididymis: 135.9" "Cell line enriched" "Detected in some" 4 "EFO-21: 13.7" "Group enriched" "Detected in many" 10 "endometrial cancer: 971.9;ovarian cancer: 208.0" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA034584 Enhanced Approved Vesicles "Secreted in other tissues" Vesicles "HPA034584: AB_10602221" "unprognostic (7.73e-2)" "unprognostic (3.77e-1)" "prognostic favourable (1.22e-4)" "prognostic favourable (1.54e-8)" "unprognostic (2.98e-2)" "unprognostic (1.86e-2)" "unprognostic (3.39e-1)" "unprognostic (1.95e-1)" "unprognostic (2.69e-1)" "unprognostic (6.87e-3)" "prognostic favourable (6.36e-4)" "unprognostic (5.67e-2)" "unprognostic (1.19e-1)" "unprognostic (1.18e-3)" "unprognostic (3.35e-1)" 0.2 0.0 0.2 0.5 0.2 0.0 6.8 0.2 0.3 191.8 1.0 0.3 20.8 0.0 40.8 135.9 1.0 28.7 2.5 0.4 0.2 0.3 1.2 0.4 0.9 0.2 0.2 0.3 5.6 2.2 0.0 1.5 0.7 0.5 1.2 1.3 0.2 18.8 1.4 0.2 2.3 0.3 0.2 0.2 0.2 4.3 4.5 0.2 0.3 0.8 1.1 3.1 0.5 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 13.7 0.0 0.3 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.1 0.0 0.0 0.1 0.0 1.0 0.2 0.0 2.5 0.6 0.0 0.6 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.2 0.3 0.2 0.3 0.2 0.3 0.5 0.2 SCGB2A2 "MGB1, MGC71974, UGB2" ENSG00000110484 "Secretoglobin family 2A member 2" Q13296 11 62270155-62273156 "Cancer-related genes, Predicted secreted proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 4 "breast: 300.8" "Cell line enriched" "Detected in single" 118 "SK-BR-3: 19.8" "Cancer enriched" "Detected in many" 23 "breast cancer: 823.4" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" CAB026270 Enhanced "Secreted in female reproductive system" "CAB026270: AB_912980" "unprognostic (2.38e-1)" "unprognostic (7.28e-2)" "prognostic favourable (9.57e-8)" "unprognostic (4.17e-1)" "unprognostic (3.75e-1)" 2.9 0.0 0.2 0.2 0.2 0.0 300.8 0.2 0.2 34.4 0.2 0.2 0.2 0.0 0.6 0.2 7.2 0.0 0.2 0.5 0.2 0.0 0.3 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.0 0.2 0.2 0.2 0.2 0.0 0.2 13.9 0.2 0.2 75.0 0.2 0.2 0.2 0.2 0.0 0.2 0.2 0.4 0.2 0.6 5.9 0.2 0.9 0.1 0.0 0.1 0.2 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 19.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.2 0.2 0.2 0.2 0.2 0.0 0.2 0.2 0.2 0.2 SDC1 "CD138, SDC, SYND1, syndecan" ENSG00000115884 "Syndecan 1" P18827 2 20200797-20225433 "Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 113.2;placenta: 228.8" "Cell line enhanced" "Detected in many" "HBEC3-KT: 60.9;hTCEpi: 56.3;U-251 MG: 58.0;U-266/70: 60.1;U-266/84: 126.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in single" "Cell type enriched" "Detected in single" 17 "memory B-cell: 3.9" "Lineage enriched" "Detected in single" 40 "B-cells: 3.9" "Group enriched" "Detected in some" 4 "cerebellum: 10.7;olfactory region: 5.9" "Not detected" "Not detected" "CAB002424, HPA006185, HPA067477" Enhanced Supported "Focal adhesion sites" "Secreted to blood" 63100000 1600000 "Focal adhesion sites" "CAB002424: AB_442050, HPA006185: AB_1857705, HPA067477: " "prognostic unfavourable (2.22e-4)" "unprognostic (6.80e-3)" "unprognostic (6.80e-2)" "unprognostic (7.84e-2)" "prognostic unfavourable (5.02e-4)" "unprognostic (1.15e-1)" "unprognostic (4.02e-2)" "unprognostic (6.32e-2)" "unprognostic (1.70e-1)" "unprognostic (3.66e-1)" "unprognostic (2.27e-3)" "unprognostic (1.79e-1)" "unprognostic (1.63e-1)" "unprognostic (1.94e-2)" "unprognostic (4.27e-1)" "unprognostic (1.62e-2)" "unprognostic (1.52e-1)" 0.8 3.4 0.5 5.4 0.6 0.0 4.5 0.8 0.7 21.4 18.3 0.5 3.5 14.3 2.3 8.7 103.7 1.6 55.3 0.3 0.4 0.5 68.5 113.2 15.8 6.3 1.9 0.4 1.6 7.0 0.6 0.6 228.8 0.7 13.3 6.2 1.5 16.0 5.2 0.5 69.5 21.9 4.3 0.4 3.7 16.3 2.6 0.4 1.5 3.5 62.3 48.4 30.0 37.7 3.9 0.0 0.0 0.0 0.0 0.0 0.5 30.8 17.3 5.5 13.8 1.5 0.2 17.3 8.6 8.3 8.1 6.8 3.6 18.8 0.0 3.2 6.1 30.4 2.4 60.9 5.4 0.1 1.6 0.0 1.6 18.5 1.3 1.3 0.1 0.8 56.3 7.2 17.3 0.8 0.7 12.1 4.3 18.4 0.0 0.3 4.9 33.5 0.6 2.0 23.3 10.3 46.3 1.6 12.8 6.5 43.9 1.9 4.3 0.3 1.3 32.1 10.3 1.1 58.0 60.1 126.7 0.1 9.6 0.0 3.5 0.0 0.0 0.0 0.0 0.0 0.0 3.9 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.5 0.6 0.8 0.7 0.4 0.5 1.9 0.4 0.7 0.4 SDC4 "amphiglycan, ryudocan, SYND4" ENSG00000124145 "Syndecan 4" P31431 20 45325288-45348424 "Cancer-related genes, Predicted membrane proteins, Predicted secreted proteins, Transporters" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 141.1" "Cell line enhanced" "Detected in many" "HBEC3-KT: 73.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA005716, CAB013240" Enhanced Approved "Golgi apparatus,Plasma membrane" "Secreted to blood" "Golgi apparatus" "Plasma membrane" "CAB013240: AB_2533250, HPA005716: AB_1080160" "unprognostic (1.34e-2)" "unprognostic (1.80e-1)" "unprognostic (1.71e-2)" "unprognostic (2.16e-1)" "unprognostic (5.39e-2)" "unprognostic (6.59e-3)" "unprognostic (1.16e-1)" "unprognostic (5.93e-2)" "unprognostic (2.68e-1)" "unprognostic (2.95e-2)" "prognostic unfavourable (4.20e-4)" "unprognostic (1.97e-1)" "prognostic favourable (2.44e-7)" "unprognostic (3.00e-1)" "unprognostic (2.18e-1)" "prognostic favourable (2.67e-4)" "unprognostic (7.42e-2)" 15.9 26.2 19.9 15.7 24.3 3.5 40.5 6.9 20.1 20.4 24.8 19.2 9.0 13.3 17.6 14.7 42.4 27.4 26.2 19.5 19.8 12.1 56.6 141.1 56.7 4.8 23.5 20.5 14.7 36.6 6.2 12.5 23.0 30.9 19.5 22.3 21.8 47.6 17.5 25.5 45.5 13.8 38.7 23.0 9.0 46.9 33.7 15.7 2.0 26.5 25.2 23.5 34.4 16.4 0.7 2.8 2.0 3.1 1.4 8.1 1.2 22.6 2.9 1.6 0.1 40.4 24.9 69.8 29.0 39.6 32.8 23.6 34.5 57.9 0.0 13.0 36.4 29.4 1.1 73.7 40.0 6.5 1.0 0.7 2.4 13.4 44.1 0.1 1.2 33.5 49.4 13.5 33.1 4.3 1.1 0.0 18.9 22.5 0.0 2.0 2.9 9.1 0.0 14.6 0.0 54.0 30.2 0.6 2.3 39.8 24.7 7.1 17.9 1.3 8.1 25.1 20.9 2.5 18.6 1.2 0.9 0.1 39.5 2.3 14.9 2.0 3.1 0.7 1.3 1.1 4.1 0.6 4.1 1.6 2.8 0.7 0.9 1.1 1.6 1.4 1.1 2.5 8.1 1.2 19.9 24.3 6.9 20.1 19.8 12.1 23.5 20.5 30.9 15.7 SDHA "FP, SDH2, SDHF" ENSG00000073578 "Succinate dehydrogenase complex flavoprotein subunit A" P31040 5 218241-256700 "Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Electron transport, Transport, Tricarboxylic acid cycle" Oxidoreductase "Cancer-related genes, Cardiomyopathy, Disease mutation, FDA approved drug targets, Leigh syndrome, Primary mitochondrial disease, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "heart muscle: 100.1;skeletal muscle: 114.0" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB034929, HPA041981, HPA064582" Enhanced Supported Nucleoli,Mitochondria 780000 Mitochondria Nucleoli "CAB034929: AB_2183443, HPA041981: AB_2677779, HPA064582: AB_2685293" "prognostic unfavourable (6.00e-4)" "unprognostic (1.93e-1)" "unprognostic (5.97e-2)" "unprognostic (1.36e-1)" "unprognostic (1.89e-1)" "unprognostic (1.62e-1)" "unprognostic (2.80e-1)" "unprognostic (3.14e-2)" "unprognostic (2.88e-1)" "unprognostic (1.67e-2)" "unprognostic (1.97e-1)" "unprognostic (1.24e-1)" "prognostic favourable (9.53e-8)" "unprognostic (1.11e-2)" "unprognostic (2.62e-1)" "unprognostic (3.57e-1)" "unprognostic (1.79e-1)" 17.6 31.4 15.3 11.5 20.3 10.6 12.8 18.8 29.0 10.2 29.4 17.3 10.0 44.3 11.3 12.1 15.3 12.6 14.8 100.1 15.8 14.5 36.5 55.4 10.7 11.7 19.6 19.3 14.5 14.7 23.2 9.5 9.2 29.7 10.7 24.6 14.5 17.3 12.0 114.0 11.5 39.9 16.5 13.2 13.9 21.2 14.6 14.8 15.7 12.5 39.6 12.5 13.2 11.1 28.3 31.9 29.1 29.2 27.1 48.9 32.4 18.4 29.9 12.3 20.1 21.2 15.9 33.4 14.2 18.1 24.5 25.0 32.4 25.1 22.8 45.0 16.2 23.9 21.7 29.0 14.5 48.6 19.9 11.6 82.6 42.0 13.1 14.4 15.1 15.8 18.7 18.3 9.7 26.5 18.6 19.0 11.5 28.2 19.1 39.0 4.2 37.9 24.7 17.9 44.2 52.2 24.5 13.6 7.8 67.0 43.3 17.6 26.3 18.3 19.2 18.2 17.9 10.8 11.7 20.2 8.6 16.8 17.6 20.9 11.5 17.8 24.4 29.1 36.4 29.2 32.1 28.3 34.8 35.1 31.9 24.5 34.5 31.7 5.9 27.1 24.1 20.5 48.9 32.4 15.3 20.3 18.8 29.0 15.8 14.5 19.6 19.3 29.7 14.8 SDHAF2 "C11orf79, FLJ20487, PGL2, SDH5" ENSG00000167985 "Succinate dehydrogenase complex assembly factor 2" Q9NX18 11 61430042-61447529 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" Chaperone "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA039464, HPA039732" Supported Approved Nucleoli,Mitochondria,Cytosol "Mitochondria, Cytosol" Nucleoli "HPA039464: AB_10962146, HPA039732: AB_10962868" "unprognostic (5.31e-2)" "unprognostic (1.12e-2)" "unprognostic (3.13e-1)" "unprognostic (1.30e-2)" "unprognostic (1.40e-1)" "unprognostic (6.71e-2)" "unprognostic (1.98e-3)" "unprognostic (9.06e-2)" "unprognostic (2.17e-1)" "unprognostic (2.09e-3)" "unprognostic (4.21e-3)" "unprognostic (1.50e-1)" "unprognostic (1.81e-2)" "unprognostic (3.61e-1)" "unprognostic (1.78e-1)" "unprognostic (1.45e-1)" "unprognostic (4.48e-2)" 23.7 33.0 22.2 22.4 27.2 34.1 24.8 19.9 33.8 20.5 22.1 23.4 21.0 22.3 23.3 33.5 25.3 25.8 21.1 32.5 20.8 26.9 26.8 39.1 19.9 36.7 24.3 25.0 25.7 22.7 23.3 38.4 26.7 25.2 26.1 24.9 32.0 28.1 21.5 31.4 22.9 27.9 26.6 20.8 32.2 24.3 19.2 21.1 36.1 27.0 20.2 30.9 24.0 19.2 31.3 23.2 44.6 25.4 32.7 43.7 26.7 15.3 22.0 13.1 9.1 19.0 15.5 10.2 11.9 17.2 16.1 12.4 20.6 16.5 15.4 21.8 17.1 16.6 17.0 16.9 17.3 22.8 16.1 13.3 18.1 29.6 19.8 15.6 18.5 19.2 20.7 17.5 17.1 25.9 15.2 19.9 19.4 33.8 15.9 35.5 20.2 32.4 17.2 16.9 28.5 22.9 22.7 14.0 17.5 16.3 19.1 33.0 29.7 18.7 16.1 16.4 13.3 19.4 14.1 12.3 19.0 19.6 15.9 13.9 17.1 41.9 25.4 44.6 32.4 22.8 38.4 31.3 35.9 34.7 20.3 29.9 39.5 38.4 37.0 32.7 17.9 23.2 43.7 26.7 22.2 27.2 19.9 33.8 20.8 26.9 24.3 25.0 25.2 21.1 SDHB "SDH, SDH1" ENSG00000117118 "Succinate dehydrogenase complex iron sulfur subunit B" P21912 1 17018722-17054170 "Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Electron transport, Transport, Tricarboxylic acid cycle" Oxidoreductase "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002868, CAB009822, CAB068233, CAB068234, CAB068235" Enhanced Supported "Nucleoplasm,Plasma membrane,Mitochondria" "Intracellular and membrane" Mitochondria "Nucleoplasm, Plasma membrane" "CAB009822: AB_2183458, CAB068233: , CAB068234: , CAB068235: , HPA002868: AB_1079889" "unprognostic (1.06e-1)" "unprognostic (2.86e-2)" "unprognostic (2.19e-2)" "unprognostic (2.93e-2)" "unprognostic (1.88e-1)" "unprognostic (2.79e-3)" "unprognostic (1.58e-1)" "unprognostic (3.02e-1)" "unprognostic (1.19e-1)" "unprognostic (8.45e-2)" "unprognostic (5.51e-2)" "unprognostic (3.93e-2)" "prognostic favourable (2.93e-7)" "unprognostic (1.46e-1)" "unprognostic (2.75e-1)" "unprognostic (7.82e-2)" "unprognostic (3.82e-2)" 17.8 25.6 19.8 16.6 21.7 17.0 26.4 18.0 29.1 13.9 30.8 12.3 15.1 34.0 14.2 15.7 19.8 13.6 15.1 86.9 18.2 16.4 51.0 75.1 16.8 24.6 20.1 18.9 10.5 30.7 20.0 11.3 15.6 16.7 13.0 31.5 11.7 15.9 19.5 96.2 13.2 31.4 21.3 16.5 17.2 21.7 18.7 15.7 14.2 15.5 52.2 18.0 15.4 17.1 22.2 45.9 48.5 48.7 18.9 26.7 25.0 25.5 25.4 14.5 18.5 28.2 28.1 16.5 22.4 28.8 51.4 46.5 35.7 30.8 35.1 28.0 30.2 30.2 57.7 44.7 58.0 20.6 47.3 31.6 26.4 27.4 34.6 49.4 23.6 28.8 29.5 44.4 75.3 36.3 26.4 40.7 35.7 21.1 32.8 28.2 12.0 51.1 23.6 27.9 43.5 47.3 14.5 27.3 15.0 30.4 38.1 63.9 22.3 27.9 18.0 19.8 22.3 36.3 29.5 17.0 20.9 35.9 30.3 75.3 21.8 16.6 38.4 37.4 18.3 48.7 18.3 22.2 21.2 19.5 45.9 18.3 19.3 19.5 48.5 18.9 42.2 21.5 26.7 25.0 19.8 21.7 18.0 29.1 18.2 16.4 20.1 18.9 16.7 15.7 SDHD "cybS, PGL, PGL1" ENSG00000204370 "Succinate dehydrogenase complex subunit D" O14521 11 112086773-112120013 "Cancer-related genes, Citric acid cycle related proteins, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Electron transport, Transport, Tricarboxylic acid cycle" "Cancer-related genes, Disease mutation, FDA approved drug targets, Primary mitochondrial disease" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" HPA045727 Approved "Intracellular and membrane" "HPA045727: AB_10963114" "unprognostic (9.13e-2)" "unprognostic (3.51e-2)" "unprognostic (4.47e-3)" "unprognostic (4.21e-2)" "unprognostic (1.93e-1)" "unprognostic (4.98e-2)" "unprognostic (5.69e-2)" "unprognostic (2.50e-1)" "unprognostic (1.83e-3)" "unprognostic (7.10e-2)" "unprognostic (3.03e-2)" "unprognostic (1.80e-1)" "prognostic favourable (1.99e-10)" "unprognostic (5.14e-2)" "unprognostic (1.58e-2)" "unprognostic (1.56e-2)" "unprognostic (7.51e-2)" 20.9 23.1 17.1 21.7 19.4 10.9 19.6 14.1 18.4 18.1 33.6 14.2 23.9 36.0 22.7 17.5 35.2 17.3 17.9 42.5 15.1 13.7 66.6 75.4 19.1 23.3 17.1 15.1 18.6 23.2 22.5 16.1 20.1 18.0 23.7 33.9 15.7 32.6 21.7 65.4 15.5 61.2 24.0 15.3 22.8 22.2 8.8 14.8 21.7 46.2 33.9 24.6 23.5 20.3 55.5 74.7 62.1 91.7 46.1 53.7 68.9 16.8 17.3 11.8 17.9 44.2 35.5 19.8 20.6 29.3 21.6 27.1 59.9 44.3 30.7 63.7 27.7 42.4 36.8 29.1 26.5 27.2 18.5 29.2 12.9 31.8 34.4 45.9 22.2 39.1 32.3 25.7 41.2 30.4 30.1 42.4 26.7 21.2 27.5 41.5 16.0 43.0 25.5 31.4 57.2 44.2 41.3 17.1 11.3 28.9 39.0 20.5 40.1 33.1 23.7 21.1 27.7 23.4 18.9 12.6 16.1 56.2 12.0 60.2 20.1 46.1 73.0 48.7 41.4 91.7 44.1 55.5 44.5 43.1 74.7 45.6 53.7 49.8 62.1 46.1 70.7 36.8 44.2 68.9 17.1 19.4 14.1 18.4 15.1 13.7 17.1 15.1 18.0 14.8 SELE "CD62E, ELAM, ELAM1, ESEL" ENSG00000007908 "Selectin E" P16581 1 169722641-169764705 "Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "tongue: 50.0" "Cell line enriched" "Detected in single" 5 "HUVEC TERT2: 5.2" "Low cancer specificity" "Detected in many" "Region enriched" "Detected in many" 4 "pons and medulla: 5.4" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" CAB002143 Enhanced 640000000 "CAB002143: AB_563608" "unprognostic (2.39e-1)" "unprognostic (2.16e-2)" "unprognostic (1.37e-2)" "unprognostic (2.09e-2)" "unprognostic (1.61e-1)" "unprognostic (1.40e-2)" "unprognostic (1.59e-1)" "unprognostic (2.94e-1)" "unprognostic (3.63e-1)" "unprognostic (3.88e-1)" "unprognostic (9.74e-2)" "unprognostic (4.32e-2)" "unprognostic (1.56e-2)" "unprognostic (8.13e-3)" "unprognostic (4.69e-2)" "unprognostic (4.63e-2)" "unprognostic (2.55e-1)" 14.9 2.7 0.9 30.4 1.2 0.2 8.3 0.3 1.0 13.7 2.7 1.9 4.4 0.4 18.1 3.2 6.7 20.1 7.4 4.4 0.9 0.9 2.5 4.9 10.6 2.0 1.2 0.0 9.8 1.4 21.0 3.1 0.9 5.4 21.2 1.9 4.3 2.0 4.6 2.2 3.7 2.4 13.1 4.8 0.2 3.4 5.6 0.5 0.9 9.0 50.0 15.5 16.4 4.0 0.0 0.0 0.0 0.0 0.2 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.2 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.9 0.0 0.9 1.2 0.3 1.0 0.9 0.9 1.2 0.0 5.4 0.5 SELL "CD62L, hLHRc, LAM-1, LAM1, Leu-8, LNHR, LSEL, Lyam-1, LYAM1, PLNHR" ENSG00000188404 "Selectin L" P14151 1 169690667-169711698 "Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins" "Cell adhesion" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "blood: 227.5;lymphoid tissue: 77.8" "Cell line enhanced" "Detected in some" "Daudi: 7.3;EFO-21: 7.1;MOLT-4: 13.4;U-266/70: 25.2;U-698: 11.7;U-937: 7.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB002144, HPA051972" Enhanced Uncertain Cytosol 8100000000 Cytosol "CAB002144: AB_563862, HPA051972: " "prognostic favourable (3.76e-4)" "prognostic favourable (2.25e-4)" "unprognostic (1.52e-2)" "unprognostic (2.89e-2)" "unprognostic (7.87e-3)" "prognostic favourable (6.43e-4)" "unprognostic (1.39e-3)" "unprognostic (3.43e-1)" "unprognostic (2.70e-3)" "prognostic favourable (3.14e-4)" "unprognostic (1.42e-1)" "unprognostic (4.21e-2)" "prognostic unfavourable (4.96e-5)" "unprognostic (4.76e-2)" "unprognostic (8.71e-3)" "unprognostic (9.57e-2)" "unprognostic (1.01e-1)" 6.9 0.9 2.0 25.1 4.6 30.3 1.5 1.1 2.5 0.9 1.4 1.1 0.0 0.4 1.0 1.1 4.2 3.2 5.4 4.1 2.5 2.2 2.3 2.5 11.4 77.8 5.2 0.2 0.8 1.0 10.7 7.9 3.4 2.7 1.2 1.3 3.8 12.1 0.1 0.9 0.8 8.8 2.9 5.2 67.7 1.7 1.0 2.3 43.8 1.9 1.3 64.0 8.1 6.1 40.4 40.7 227.5 49.7 130.8 69.5 90.1 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.5 0.0 0.2 7.3 7.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 5.0 0.9 0.3 0.0 0.0 0.0 1.2 0.0 1.0 0.0 0.8 13.4 0.1 0.0 0.2 5.1 0.1 0.3 4.1 0.2 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.0 25.2 0.0 11.7 1.3 7.3 0.1 170.8 49.7 88.6 16.5 11.2 4.5 33.8 30.7 17.0 40.7 40.4 69.5 39.6 227.5 130.8 4.5 32.8 52.7 90.1 2.0 4.6 1.1 2.5 2.5 2.2 5.2 0.2 2.7 2.3 SELP "CD62, CD62P, GMP140, GRMP, PADGEM, PSEL" ENSG00000174175 "Selectin P" P16109 1 169588849-169630193 "Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Group enriched" "Detected in some" 37 "EFO-21: 24.7;HEL: 22.3" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in single" "Group enriched" "Detected in some" 6 "basophil: 6.0;neutrophil: 2.4;T-reg: 8.9" "Group enriched" "Detected in many" 8 "granulocytes: 6.0;T-cells: 8.9" "Not detected" "Not detected" "Low region specificity" "Detected in many" "CAB002145, HPA002655, HPA005990" Enhanced 830000000 "CAB002145: AB_563984, HPA002655: AB_1078480, HPA005990: AB_1078479" "unprognostic (3.37e-2)" "unprognostic (2.98e-4)" "unprognostic (4.11e-1)" "unprognostic (1.46e-1)" "unprognostic (9.26e-2)" "prognostic favourable (3.12e-4)" "unprognostic (5.30e-4)" "unprognostic (4.14e-2)" "unprognostic (3.59e-1)" "unprognostic (1.74e-1)" "unprognostic (1.93e-2)" "unprognostic (6.61e-2)" "unprognostic (1.19e-1)" "unprognostic (8.24e-3)" "unprognostic (1.74e-2)" "unprognostic (7.85e-3)" "unprognostic (1.66e-1)" 14.2 2.1 0.4 8.4 0.4 1.0 10.9 0.4 0.4 14.8 3.7 0.6 7.5 3.3 10.6 6.2 5.6 7.7 7.0 9.6 0.4 0.4 7.5 4.6 11.3 12.9 0.4 0.4 5.0 1.5 3.8 2.8 7.4 1.3 14.8 2.9 24.7 3.4 4.3 3.7 2.3 5.2 10.5 1.0 1.9 3.5 3.1 0.3 1.4 4.9 7.7 13.0 11.5 27.2 0.9 0.1 6.0 0.5 0.4 8.9 8.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 24.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 22.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 6.0 0.5 0.7 0.0 0.2 0.0 0.9 0.6 0.3 0.0 0.2 0.2 0.1 2.4 0.4 0.0 0.1 8.9 8.8 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 1.3 0.3 SEMA3B "LUCA-1, SemA, sema5, SEMAA, semaV" ENSG00000012171 "Semaphorin 3B" Q13214 3 50267558-50277546 "Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 7 "placenta: 147.6" "Cell line enhanced" "Detected in many" "HeLa: 22.5;Hep G2: 34.0;SK-BR-3: 17.7;WM-115: 55.3" "Low cancer specificity" "Detected in all" "Cell type enriched" "Detected in single" 7 "eosinophil: 3.3" "Lineage enriched" "Detected in single" 7 "granulocytes: 3.3" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA030651 Approved "Secreted in other tissues" 29000 "HPA030651: AB_10602224" "prognostic favourable (1.27e-4)" "unprognostic (6.48e-2)" "unprognostic (5.40e-2)" "unprognostic (1.07e-1)" "unprognostic (1.68e-1)" "unprognostic (4.15e-1)" "unprognostic (1.89e-1)" "unprognostic (2.83e-2)" "unprognostic (2.21e-2)" "unprognostic (2.28e-1)" "unprognostic (1.85e-2)" "unprognostic (4.27e-1)" "unprognostic (7.99e-2)" "unprognostic (7.78e-2)" "unprognostic (3.89e-1)" "unprognostic (8.87e-3)" "unprognostic (1.69e-2)" 3.3 18.8 2.5 2.0 7.4 0.0 1.0 0.3 9.2 9.2 6.0 18.6 2.3 13.3 4.4 3.5 2.5 3.4 5.6 3.4 3.6 7.7 0.0 8.1 0.0 12.9 4.9 2.6 5.6 3.5 0.0 147.6 8.2 2.8 2.8 8.5 1.2 6.8 1.5 0.5 19.7 3.9 5.9 0.3 11.9 0.5 9.5 0.0 1.6 0.6 0.0 1.9 0.6 0.0 0.4 3.3 0.0 0.0 0.0 0.0 3.9 2.6 0.2 2.5 0.2 0.3 0.6 5.2 7.1 1.5 2.5 1.9 9.9 0.0 4.8 5.0 0.6 0.1 8.3 0.6 0.0 0.2 0.0 22.5 34.0 5.6 0.0 0.2 1.7 0.1 1.7 1.3 0.0 0.0 0.6 0.2 7.0 0.0 0.2 0.3 1.4 0.1 0.4 0.1 2.4 0.4 0.3 1.2 1.3 17.7 2.6 1.2 0.0 0.1 0.4 5.2 1.4 1.6 1.4 0.0 0.0 2.6 0.0 55.3 0.0 0.0 3.3 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 SEPT12 FLJ25410 ENSG00000140623 "Septin 12" Q8IYM1 16 4777669-4788521 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cell cycle, Cell division, Differentiation, Spermatogenesis" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 69 "testis: 99.8" "Group enriched" "Detected in some" 8 "BEWO: 2.5;SCLC-21H: 1.3;SK-BR-3: 2.0" "Cancer enhanced" "Detected in single" "testis cancer: 0.5" "Region enriched" "Detected in single" 8 "cerebellum: 1.4" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA041128 Uncertain Microtubules Microtubules "HPA041128: AB_10796568" "unprognostic (2.11e-2)" "unprognostic (1.11e-1)" "unprognostic (1.56e-2)" "unprognostic (2.29e-2)" "unprognostic (2.71e-1)" "unprognostic (5.45e-2)" "unprognostic (7.40e-2)" "unprognostic (1.39e-1)" "unprognostic (3.80e-2)" "unprognostic (1.61e-1)" "unprognostic (1.49e-8)" "unprognostic (7.41e-2)" "unprognostic (9.87e-2)" "unprognostic (8.36e-3)" 0.0 0.0 0.0 0.0 0.1 0.1 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 99.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.5 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 1.3 0.0 0.0 2.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 1.4 0.0 0.1 0.1 0.1 0.0 0.0 0.0 SEPT2 "DIFF6, hNedd5, KIAA0158, NEDD5, Pnutl3" ENSG00000168385 "Septin 2" Q15019 2 241315100-241354027 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division, Differentiation, Mitosis, Spermatogenesis" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "CAB017190, HPA018481" Supported Enhanced "Nucleoplasm,Plasma membrane,Actin filaments,Cytokinetic bridge" 8800000 "Actin filaments" "Nucleoplasm, Plasma membrane, Cytokinetic bridge" "CAB017190: , HPA018481: AB_1856684" "unprognostic (6.31e-2)" "unprognostic (5.27e-2)" "unprognostic (2.95e-2)" "unprognostic (4.03e-2)" "prognostic favourable (8.21e-4)" "unprognostic (3.32e-1)" "prognostic unfavourable (3.66e-4)" "unprognostic (1.96e-3)" "unprognostic (1.83e-2)" "unprognostic (5.69e-2)" "unprognostic (1.11e-3)" "unprognostic (3.16e-1)" "unprognostic (9.58e-3)" "unprognostic (8.11e-2)" "unprognostic (9.53e-2)" "unprognostic (1.40e-1)" "unprognostic (2.17e-2)" 64.2 46.4 76.5 42.9 69.9 29.1 58.7 34.9 61.8 69.3 48.4 85.2 57.4 37.8 59.5 59.8 46.8 48.2 54.0 56.2 65.8 55.4 64.6 31.4 51.2 51.3 76.5 52.7 63.4 73.0 56.6 56.3 58.9 60.7 53.7 53.3 48.8 43.6 64.7 39.5 32.0 42.2 81.8 100.8 51.5 45.6 67.7 57.2 36.2 64.2 39.0 47.5 56.5 42.6 25.5 51.2 38.5 50.5 51.3 36.9 59.4 31.9 28.8 78.5 51.3 73.1 79.8 40.6 70.8 69.8 45.5 58.0 16.1 34.8 13.0 16.9 80.9 28.5 51.2 47.9 74.9 32.8 36.4 52.2 28.8 59.4 44.8 49.7 31.9 71.0 31.4 37.9 36.6 79.2 46.5 19.1 66.9 23.0 29.4 30.4 57.1 21.1 29.1 98.7 27.5 67.5 48.9 56.3 37.9 49.0 33.9 46.7 20.3 44.9 74.8 55.8 23.7 53.8 41.8 37.7 32.8 45.8 48.0 30.4 77.0 38.5 46.0 26.3 30.3 50.5 36.9 25.5 29.6 31.2 51.2 21.6 26.2 27.4 16.3 51.3 37.2 38.6 29.5 59.4 76.5 69.9 34.9 52.3 65.8 55.4 76.5 52.7 60.7 57.2 SERPINA1 "A1A, A1AT, AAT, alpha-1-antitrypsin, alpha1AT, PI, PI1" ENSG00000197249 "Serpin family A member 1" P01009 14 94376747-94390693 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Acute phase, Blood coagulation, Hemostasis" "Protease inhibitor, Serine protease inhibitor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 16 "liver: 3314.2" "Cell line enriched" "Detected in some" 8 "Hep G2: 318.5" "Cancer enriched" "Detected in all" 10 "liver cancer: 3850.6" "Low region specificity" "Detected in some" "Group enriched" "Detected in many" 5 "classical monocyte: 110.2;intermediate monocyte: 165.9;neutrophil: 139.3;non-classical monocyte: 203.0" "Group enriched" "Detected in many" 5 "granulocytes: 139.3;monocytes: 203.0" "Region enriched" "Detected in many" 6 "cerebellum: 334.2" "HPA000927, HPA001292, CAB013211, CAB016648, CAB073396" Enhanced Enhanced Vesicles "Secreted to blood" 1663100000000 210000000000 Vesicles "CAB013211: , CAB016648: AB_1611888, CAB073396: , HPA000927: AB_1844761, HPA001292: AB_1844762" "prognostic favourable (1.61e-5)" "unprognostic (3.37e-1)" "prognostic favourable (5.86e-4)" "unprognostic (1.38e-2)" "unprognostic (1.98e-2)" "unprognostic (5.50e-3)" "unprognostic (3.81e-2)" "unprognostic (6.78e-2)" "unprognostic (2.54e-2)" "unprognostic (7.96e-2)" "unprognostic (1.08e-1)" "unprognostic (4.54e-1)" "unprognostic (1.23e-2)" "unprognostic (1.89e-1)" "unprognostic (1.30e-2)" "unprognostic (1.17e-2)" "unprognostic (1.96e-1)" 0.9 0.4 0.7 4.9 1.4 3.0 2.4 0.2 0.7 2.6 7.5 0.5 3.1 6.3 0.8 8.6 0.4 0.7 14.2 1.0 0.4 0.5 74.1 3314.2 13.6 5.3 1.0 0.2 0.6 7.4 0.0 0.4 0.8 0.8 0.6 4.1 0.6 0.9 3.6 0.2 0.3 36.2 1.4 1.3 8.9 7.0 0.8 0.8 0.5 0.8 0.2 0.9 0.5 0.6 0.3 33.5 139.3 203.0 0.2 0.3 100.0 2.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 12.6 40.1 0.1 1.1 0.0 0.1 0.0 0.8 0.0 4.9 0.0 0.2 0.1 318.5 0.0 1.1 0.1 0.2 0.4 0.0 1.4 0.0 0.2 0.0 0.0 0.0 0.0 0.7 0.1 0.5 0.1 1.1 0.1 21.5 0.2 0.0 0.0 0.4 0.1 0.1 18.9 0.1 0.1 0.1 5.0 0.1 0.6 0.2 0.1 0.4 0.3 2.8 0.0 0.4 110.2 29.1 0.2 165.9 0.3 0.3 0.1 0.2 33.5 0.1 0.2 0.1 139.3 0.2 203.0 0.7 0.2 100.0 0.7 1.4 0.2 0.7 0.4 0.5 1.0 0.2 0.8 0.8 SERPINA3 "AACT, ACT" ENSG00000196136 "Serpin family A member 3" P01011 14 94612377-94624055 "Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Acute phase" "Protease inhibitor, Serine protease inhibitor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 7 "liver: 1244.8" "Cell line enriched" "Detected in some" 7 "Hep G2: 96.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "HPA000893, HPA002560, CAB016647" Enhanced "Secreted to blood" 95000000000 "CAB016647: AB_1611882, HPA000893: AB_10794315, HPA002560: AB_1856717" "prognostic favourable (8.92e-4)" "unprognostic (3.33e-3)" "unprognostic (9.21e-2)" "unprognostic (1.53e-2)" "unprognostic (1.05e-1)" "unprognostic (1.72e-1)" "unprognostic (2.00e-2)" "unprognostic (1.00e-2)" "unprognostic (2.23e-1)" "unprognostic (9.60e-2)" "unprognostic (1.20e-2)" "unprognostic (9.92e-2)" "unprognostic (3.74e-12)" "unprognostic (6.47e-2)" "unprognostic (1.33e-2)" "unprognostic (2.02e-2)" 11.1 2.1 5.4 5.7 17.6 1.2 26.0 1.9 16.1 43.8 2.3 10.0 1.4 2.3 2.2 2.4 3.3 4.3 18.1 10.7 13.4 6.5 61.9 1244.8 4.9 53.0 16.3 0.8 8.3 182.4 1.0 14.0 2.7 34.2 18.3 2.6 10.2 62.1 7.9 6.8 1.5 2.3 10.2 47.2 8.2 9.7 9.5 7.4 0.0 3.5 0.5 1.7 7.6 11.1 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.2 1.0 0.1 1.0 0.0 0.2 0.0 0.9 0.0 0.5 0.0 0.2 0.0 96.2 13.1 0.4 0.1 11.9 14.3 0.0 0.5 0.0 0.0 0.0 0.0 3.6 0.1 0.1 0.1 0.0 0.1 0.5 0.0 0.8 0.0 0.0 0.0 0.4 0.5 14.0 0.5 0.0 0.1 0.0 1.8 0.0 4.1 0.2 0.3 0.4 0.1 0.1 1.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 5.4 17.6 1.9 9.6 13.4 6.5 16.3 0.8 34.2 7.4 SERPINA5 "PAI3, PCI, PLANH3, PROCI" ENSG00000188488 "Serpin family A member 5" P05154 14 94561442-94593120 "Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins" "Fertilization, Lipid transport, Transport" "Heparin-binding, Protease inhibitor, Serine protease inhibitor" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adrenal gland: 100.4;ductus deferens: 126.6;liver: 112.4;seminal vesicle: 106.7;testis: 146.5" "Cell line enriched" "Detected in some" 14 "Hep G2: 74.3" "Cancer enhanced" "Detected in many" "liver cancer: 121.1" "Low region specificity" "Detected in some" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA056919 Approved Mitochondria "Secreted to blood" 2300000000 Mitochondria "HPA056919: " "unprognostic (5.94e-3)" "unprognostic (2.64e-4)" "unprognostic (1.13e-1)" "prognostic favourable (7.72e-4)" "unprognostic (3.34e-3)" "unprognostic (6.10e-3)" "unprognostic (3.94e-2)" "unprognostic (1.39e-3)" "unprognostic (5.36e-1)" "unprognostic (1.50e-1)" "unprognostic (6.16e-2)" "unprognostic (1.87e-2)" "unprognostic (8.39e-3)" "unprognostic (3.38e-3)" "unprognostic (9.92e-2)" "unprognostic (8.08e-2)" "unprognostic (3.23e-1)" 1.1 100.4 0.4 1.8 1.8 0.0 7.7 0.2 0.5 4.0 1.0 1.6 126.6 0.6 4.8 5.0 0.5 3.6 34.3 5.6 0.6 0.4 33.6 112.4 0.3 1.9 3.1 0.3 6.4 33.8 0.0 0.8 0.2 1.9 1.9 0.0 0.9 10.9 106.7 6.6 0.7 0.7 0.4 1.5 36.1 2.0 146.5 0.6 0.1 0.9 1.5 0.6 1.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.4 3.9 0.0 2.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 74.3 0.1 0.1 0.0 0.5 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.1 0.0 1.2 0.0 0.1 5.1 0.0 0.0 2.4 0.0 0.0 0.1 0.0 0.1 0.1 0.4 0.0 0.0 0.1 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 1.8 0.2 0.5 0.6 0.4 3.1 0.3 1.9 0.6 SERPINB13 "headpin, HUR7, hurpin, PI13" ENSG00000197641 "Serpin family B member 13" Q9UIV8 18 63586989-63604639 "Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins" "Protease inhibitor, Serine protease inhibitor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 6 "cervix, uterine: 37.7;esophagus: 70.8;lymphoid tissue: 54.2;tongue: 107.2;vagina: 34.1" "Group enriched" "Detected in some" 132 "HaCaT: 64.1;hTCEpi: 24.4" "Cancer enhanced" "Detected in many" "cervical cancer: 45.9" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "HPA052630, HPA057129" Enhanced Approved "Nuclear speckles,Cytosol" 59000 "Nuclear speckles, Cytosol" "HPA052630: , HPA057129: " "unprognostic (3.49e-2)" "unprognostic (3.73e-1)" "unprognostic (1.11e-1)" "unprognostic (7.27e-2)" "unprognostic (2.28e-1)" "unprognostic (4.29e-2)" "unprognostic (2.81e-1)" "unprognostic (6.04e-3)" 0.1 0.1 0.0 0.1 0.0 0.1 1.0 0.0 0.1 37.7 0.1 0.0 0.0 0.1 3.1 0.1 70.8 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.4 0.1 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.0 10.9 0.1 0.2 5.7 0.1 0.1 0.0 0.1 0.1 0.1 0.0 1.0 0.1 107.2 54.2 1.5 34.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 64.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 24.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 SERPINB2 "HsT1201, PAI2, PLANH2" ENSG00000197632 "Serpin family B member 2" P05120 18 63871692-63903890 "Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Plasminogen activation" "Protease inhibitor, Serine protease inhibitor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "esophagus: 70.6;placenta: 222.1" "Group enriched" "Detected in some" 5 "HaCaT: 79.8;U-138 MG: 95.5;U-2197: 145.1" "Cancer enhanced" "Detected in many" "head and neck cancer: 26.5" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "basophil: 16.3;eosinophil: 7.6" "Lineage enriched" "Detected in many" 4 "granulocytes: 16.3" "Region enriched" "Detected in single" 14 "cerebellum: 2.9" "Low region specificity" "Detected in all" HPA015480 Supported "Intracellular and membrane" 110000 "HPA015480: AB_1855456" "unprognostic (2.11e-1)" "unprognostic (1.74e-1)" "unprognostic (5.46e-2)" "unprognostic (1.36e-4)" "unprognostic (1.17e-1)" "unprognostic (1.65e-2)" "unprognostic (1.37e-1)" "unprognostic (1.92e-1)" "unprognostic (9.69e-2)" "unprognostic (3.76e-3)" "unprognostic (1.90e-1)" "unprognostic (4.33e-6)" "unprognostic (3.89e-2)" "unprognostic (3.94e-1)" "unprognostic (3.29e-1)" "prognostic unfavourable (1.55e-5)" 6.0 0.0 0.1 2.9 0.2 8.7 2.6 0.2 0.1 6.4 0.8 0.1 0.1 0.0 0.7 0.4 70.6 3.1 0.1 0.4 0.1 0.0 0.1 0.1 0.9 0.1 0.1 0.1 0.6 0.3 0.0 0.1 222.1 0.2 0.3 0.0 0.1 11.3 0.2 0.3 25.7 0.2 0.3 0.1 0.3 0.1 0.2 0.1 0.9 0.2 49.0 37.7 1.1 13.8 0.0 0.2 16.3 3.9 0.0 0.0 1.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 19.4 20.6 0.7 1.5 0.1 0.0 0.0 0.0 0.6 79.8 0.0 16.4 14.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 1.6 9.5 4.3 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 1.7 1.5 95.5 0.0 145.1 0.0 0.0 0.0 0.0 2.5 0.2 11.1 16.3 3.9 7.6 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 1.0 0.1 0.2 0.2 0.1 0.1 0.0 0.1 0.1 0.2 0.1 SERPINB3 "HsT1196, SCC, SCCA1, T4-A" ENSG00000057149 "Serpin family B member 3" P29508 18 63655197-63661963 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Protease inhibitor, Serine protease inhibitor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 4 "cervix, uterine: 50.7;esophagus: 140.0;vagina: 80.0" "Cell line enhanced" "Detected in some" "CAPAN-2: 2.5;HaCaT: 8.9;SiHa: 5.5;U-2197: 11.3" "Cancer enhanced" "Detected in many" "cervical cancer: 186.5" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "CAB018772, CAB036006, CAB036007, HPA048341, HPA049988, HPA055992" Enhanced Approved "Plasma membrane,Cytosol" 11000000 Cytosol "Plasma membrane" "CAB018772: AB_2285759, CAB036006: , CAB036007: , HPA048341: , HPA049988: , HPA055992: " "unprognostic (2.95e-3)" "unprognostic (1.66e-1)" "unprognostic (2.03e-1)" "unprognostic (2.91e-2)" "unprognostic (2.11e-1)" "prognostic unfavourable (3.19e-4)" "unprognostic (6.68e-2)" "unprognostic (2.58e-1)" "unprognostic (4.19e-3)" 0.2 0.0 0.2 0.2 0.2 0.0 0.2 0.2 0.2 50.7 0.2 0.2 0.2 0.0 3.8 0.2 140.0 0.0 0.2 0.2 0.2 0.0 0.2 0.2 5.4 0.2 0.2 0.2 0.2 0.2 0.0 2.4 0.2 0.2 1.1 0.0 0.2 13.0 0.2 0.2 7.1 0.2 0.2 0.2 0.2 0.0 0.2 0.2 1.4 0.2 21.3 3.1 13.1 80.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 2.5 0.1 0.0 0.1 8.9 0.0 2.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 1.9 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 5.5 0.0 0.0 0.0 0.0 0.3 0.0 0.0 11.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.2 0.2 0.2 0.0 0.2 0.2 0.2 0.2 SERPINB4 "LEUPIN, PI11, SCCA-2, SCCA1, SCCA2" ENSG00000206073 "Serpin family B member 4" P48594 18 63637259-63644298 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Protease inhibitor, Serine protease inhibitor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 4 "cervix, uterine: 32.5;esophagus: 48.4;tongue: 18.4;vagina: 41.4" "Cell line enhanced" "Detected in some" "HaCaT: 4.0;HSkMC: 2.0;SiHa: 3.1;U-2197: 10.9" "Cancer enhanced" "Detected in many" "cervical cancer: 104.1" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "HPA048341, HPA049988, HPA055992" Supported 5700000 "HPA048341: , HPA049988: , HPA055992: " "unprognostic (8.81e-3)" "unprognostic (9.43e-2)" "unprognostic (8.96e-3)" "unprognostic (4.38e-1)" "unprognostic (1.63e-2)" "prognostic unfavourable (5.48e-4)" "unprognostic (2.46e-1)" "unprognostic (4.37e-2)" "unprognostic (1.27e-2)" 0.1 0.0 0.1 1.4 0.1 0.0 0.1 0.1 0.1 32.5 0.1 0.1 0.1 0.0 1.8 0.1 48.4 0.0 0.1 0.1 0.1 0.0 0.1 0.1 1.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.6 0.0 0.1 7.0 0.1 0.3 4.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 2.0 0.1 18.4 2.3 8.7 41.4 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.4 0.0 0.1 1.0 0.1 0.0 0.0 1.1 0.0 0.1 0.0 4.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.3 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 3.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 10.9 0.0 0.0 0.0 0.1 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 SERPINE1 "PAI, PAI1, PLANH1" ENSG00000106366 "Serpin family E member 1" P05121 7 101127089-101139266 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins" "Protease inhibitor, Serine protease inhibitor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "placenta: 253.6" "Cell line enhanced" "Detected in many" "BJ: 140.2;HUVEC TERT2: 162.7;LHCN-M2: 157.1;TIME: 402.3;U-138 MG: 191.5;U-251 MG: 168.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 20 "NK-cell: 10.8" "Lineage enriched" "Detected in single" 20 "NK-cells: 10.8" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA050039, CAB068501" Uncertain Approved Cytosol "Secreted to blood" 14000000 Cytosol "CAB068501: AB_1642775, HPA050039: " "unprognostic (5.02e-2)" "prognostic unfavourable (5.01e-4)" "prognostic unfavourable (2.82e-4)" "unprognostic (2.10e-2)" "unprognostic (9.04e-3)" "prognostic unfavourable (2.84e-5)" "unprognostic (6.80e-3)" "prognostic unfavourable (4.41e-6)" "unprognostic (2.33e-1)" "unprognostic (1.45e-1)" "unprognostic (2.88e-3)" "unprognostic (1.58e-1)" "prognostic unfavourable (5.88e-8)" "prognostic unfavourable (3.27e-6)" "unprognostic (1.05e-1)" "unprognostic (4.33e-2)" "prognostic unfavourable (5.51e-4)" 45.5 14.0 1.1 16.7 1.8 0.1 11.4 0.5 1.5 13.3 7.0 3.4 3.3 1.2 6.6 14.4 6.8 9.3 69.6 29.2 1.5 0.6 7.8 65.3 56.3 3.3 4.1 1.8 19.7 24.7 1.4 2.6 253.6 5.9 7.6 0.9 2.3 2.4 6.2 12.4 4.1 2.3 13.5 4.1 5.8 6.6 8.6 2.2 0.6 11.3 3.7 2.8 71.7 18.1 0.2 0.4 0.5 0.2 10.8 0.3 1.0 3.0 2.5 0.0 0.2 32.1 64.0 3.6 140.2 26.5 70.7 61.8 0.3 0.2 0.1 33.6 44.6 0.7 0.0 10.8 73.1 0.1 0.0 0.0 0.2 2.4 64.6 0.0 0.1 25.0 4.3 108.5 57.1 162.7 0.2 0.1 157.1 0.0 0.0 0.0 0.7 1.6 0.0 0.2 0.1 0.2 1.2 0.0 0.0 11.5 3.1 0.3 0.1 0.3 402.3 191.5 8.4 65.2 168.3 0.0 0.1 0.1 47.8 0.0 1.8 0.5 0.2 0.0 0.1 0.1 0.0 0.1 0.0 0.3 0.3 0.2 0.0 0.1 0.2 10.8 0.0 0.4 0.0 1.0 1.1 1.8 0.5 1.5 1.5 0.6 4.1 1.8 5.9 2.2 SERPINF1 "EPC-1, PEDF, PIG35" ENSG00000132386 "Serpin family F member 1" P36955 17 1761959-1777574 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Cancer-related genes, Dwarfism, Osteogenesis imperfecta" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "retina: 360.1" "Cell line enhanced" "Detected in some" "ASC diff: 121.4;ASC TERT1: 94.8;Hep G2: 55.4;HHSteC: 40.6;HSkMC: 128.9" "Low cancer specificity" "Detected in all" "Region enriched" "Detected in many" 8 "pons and medulla: 105.5" "Cell type enriched" "Detected in some" 18 "plasmacytoid DC: 143.3" "Lineage enriched" "Detected in many" 119 "dendritic cells: 143.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA005825 Uncertain "Secreted to blood" 9293333333 85000000000 "HPA005825: AB_1079921" "unprognostic (3.85e-1)" "prognostic favourable (5.49e-4)" "unprognostic (9.44e-2)" "unprognostic (2.32e-2)" "unprognostic (2.96e-2)" "unprognostic (2.09e-1)" "unprognostic (3.32e-3)" "unprognostic (2.33e-1)" "unprognostic (7.88e-2)" "unprognostic (5.92e-2)" "unprognostic (1.69e-1)" "unprognostic (4.18e-2)" "prognostic unfavourable (1.40e-8)" "unprognostic (2.11e-3)" "unprognostic (2.82e-1)" "unprognostic (4.53e-3)" "unprognostic (1.25e-3)" 70.0 7.5 2.3 15.1 4.5 1.1 61.6 0.7 13.9 84.1 16.4 20.8 14.8 5.0 48.9 71.9 24.3 75.3 66.8 50.3 11.6 1.9 6.9 190.1 20.1 30.6 1.9 5.9 68.1 54.7 0.6 11.0 38.6 105.5 53.2 6.5 360.1 17.8 14.2 51.4 21.5 15.7 27.6 2.4 21.2 17.8 86.3 1.4 6.0 27.4 38.5 14.6 32.1 37.9 0.8 143.3 0.1 1.2 0.1 0.5 1.3 0.0 0.4 0.2 0.2 121.4 94.8 2.0 5.6 4.7 0.0 0.0 0.9 0.0 0.2 0.2 6.7 0.3 8.0 0.4 0.0 0.0 4.3 0.1 0.0 55.4 40.6 0.1 0.1 128.9 0.7 0.1 0.1 0.0 11.4 0.0 5.9 0.0 0.7 0.6 3.2 0.1 0.3 22.3 0.1 0.0 0.6 0.1 4.1 0.0 0.0 5.7 0.7 17.1 0.2 0.0 1.8 1.4 0.1 0.0 0.2 2.9 0.1 0.0 0.0 0.0 1.2 0.1 0.0 0.4 0.0 0.8 0.0 0.1 7.9 0.4 0.2 0.5 0.1 0.1 0.0 143.3 0.0 1.3 2.3 4.5 0.7 13.9 11.6 1.9 1.9 5.9 105.5 1.4 SET "2PP2A, IPP2A2, PHAPII" ENSG00000119335 "SET nuclear proto-oncogene" Q01105 9 128683424-128696400 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction" "Chaperone, DNA-binding" "Cancer-related genes, Disease mutation, Mental retardation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "CAB005232, HPA063683" Supported Enhanced "Nucleoplasm,Lipid droplets" 880000 Nucleoplasm "Lipid droplets" "CAB005232: AB_2185634, HPA063683: " "unprognostic (1.92e-1)" "unprognostic (2.22e-1)" "unprognostic (2.31e-1)" "unprognostic (3.77e-1)" "unprognostic (7.15e-2)" "unprognostic (4.37e-3)" "prognostic unfavourable (9.41e-7)" "unprognostic (2.00e-2)" "unprognostic (1.88e-2)" "unprognostic (3.62e-1)" "unprognostic (3.78e-2)" "unprognostic (3.27e-2)" "unprognostic (1.29e-1)" "unprognostic (7.57e-2)" "unprognostic (1.91e-1)" "unprognostic (2.09e-1)" "unprognostic (1.54e-2)" 47.2 49.7 66.5 59.3 65.8 71.8 56.5 64.2 61.2 54.4 51.3 55.3 45.6 40.1 64.8 33.1 71.6 51.6 48.9 81.6 63.6 57.3 51.7 57.8 51.2 91.1 65.4 56.1 76.5 61.3 55.0 38.7 65.4 47.3 59.2 56.4 36.3 52.1 46.9 76.3 53.6 45.7 59.0 73.5 62.8 46.8 34.8 58.6 152.9 69.1 46.2 92.7 74.4 84.1 72.2 66.4 43.2 56.5 78.8 77.9 69.7 50.4 57.6 82.9 65.6 24.8 38.9 76.5 41.7 46.2 60.3 41.6 79.2 62.0 130.6 35.3 42.9 94.7 122.5 62.7 69.0 59.5 52.2 75.1 89.7 64.4 55.4 137.0 49.2 32.3 49.1 51.3 103.0 56.3 145.7 53.0 49.3 85.2 114.7 50.6 138.4 61.4 105.0 103.1 105.7 46.5 57.0 84.5 53.1 91.8 61.7 49.8 76.9 42.7 53.9 71.3 53.5 43.9 68.9 41.7 119.8 155.4 33.9 73.0 67.9 34.5 53.9 43.2 58.9 56.5 72.1 72.2 67.9 62.8 52.7 66.3 65.8 77.9 35.4 78.8 45.6 66.4 52.3 69.7 66.5 65.8 64.2 61.2 63.6 57.3 65.4 56.1 47.3 58.6 SETBP1 "KIAA0437, SEB" ENSG00000152217 "SET binding protein 1" Q9Y6X0 18 44680173-45068510 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" DNA-binding "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Group enriched" "Detected in many" 4 "AF22: 9.3;Karpas-707: 37.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "memory B-cell: 4.9;naive B-cell: 7.5" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA049022, HPA057259" Uncertain Supported "Nucleoplasm,Nuclear bodies,Cytosol" Nucleoplasm "Nuclear bodies, Cytosol" "HPA049022: , HPA057259: " "unprognostic (1.25e-1)" "unprognostic (1.57e-1)" "unprognostic (1.11e-1)" "unprognostic (1.97e-2)" "unprognostic (4.63e-2)" "unprognostic (1.80e-1)" "unprognostic (1.91e-1)" "unprognostic (3.57e-2)" "unprognostic (3.49e-1)" "unprognostic (2.01e-2)" "unprognostic (2.71e-3)" "unprognostic (6.52e-2)" "prognostic favourable (6.34e-8)" "unprognostic (2.18e-2)" "unprognostic (2.29e-1)" "unprognostic (6.06e-2)" "unprognostic (7.81e-5)" 10.6 2.9 3.8 13.2 8.7 2.1 9.8 16.0 12.6 16.9 14.6 4.2 19.9 2.5 14.0 17.5 6.6 11.0 7.9 6.8 3.6 3.5 15.0 7.2 9.8 7.0 2.9 7.4 12.8 8.2 9.1 5.1 10.2 3.2 12.2 5.3 14.0 6.9 21.3 14.5 6.6 6.9 19.9 3.7 5.9 9.1 5.5 1.2 3.4 8.4 8.7 8.8 11.9 13.3 7.5 4.3 0.2 1.6 0.0 0.6 0.2 0.0 1.6 9.3 0.0 2.7 0.7 0.6 0.7 1.7 0.9 0.7 0.1 0.0 0.5 0.3 1.0 2.7 1.0 2.9 0.6 0.8 0.4 0.0 1.0 0.6 0.0 0.0 0.0 2.2 1.1 0.0 1.8 0.3 0.0 37.1 0.2 0.5 0.0 0.0 1.3 0.6 3.0 0.0 3.2 3.1 2.1 4.7 2.5 0.0 0.0 0.5 1.3 0.0 0.0 5.5 2.1 0.0 4.3 4.9 0.3 0.0 3.3 0.1 3.1 0.2 0.0 0.0 0.6 1.1 0.0 4.9 0.1 0.5 0.1 7.5 0.0 0.2 0.0 0.0 1.6 4.3 0.0 0.2 3.8 8.7 16.0 12.6 3.6 3.5 2.9 7.4 3.2 1.2 SETD2 "FLJ23184, HIF-1, HYPB, KIAA1732, KMT3A" ENSG00000181555 "SET domain containing 2" Q9BYW2 3 47016429-47163967 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Antiviral defense, Differentiation, DNA damage, DNA repair, Host-virus interaction, Immunity, Innate immunity, Transcription, Transcription regulation" "Activator, Chromatin regulator, Developmental protein, Methyltransferase, Transferase" "Autism spectrum disorder, Cancer-related genes, Disease mutation, Mental retardation, Tumor suppressor" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA042451 Approved Approved "Nuclear speckles,Cytosol" "Nuclear speckles" Cytosol "HPA042451: AB_10806239" "unprognostic (2.78e-1)" "unprognostic (1.01e-1)" "unprognostic (6.08e-2)" "unprognostic (1.01e-1)" "unprognostic (3.37e-2)" "unprognostic (1.37e-2)" "unprognostic (1.40e-2)" "unprognostic (1.01e-2)" "prognostic unfavourable (8.19e-4)" "unprognostic (6.19e-2)" "unprognostic (2.45e-1)" "unprognostic (7.84e-2)" "prognostic favourable (7.99e-6)" "unprognostic (1.03e-1)" "unprognostic (1.91e-1)" "unprognostic (8.79e-2)" "unprognostic (5.43e-2)" 13.2 10.5 12.2 15.2 15.4 20.0 11.7 22.4 16.4 13.4 14.0 9.1 12.9 9.5 15.8 7.5 10.8 11.4 8.7 8.8 10.6 6.8 11.4 10.3 10.4 11.8 11.7 9.5 16.0 13.4 21.4 16.3 10.7 11.3 12.4 10.9 7.7 12.7 14.8 27.6 12.5 11.5 11.9 9.8 13.8 10.4 12.8 12.8 23.2 15.8 5.5 12.8 16.1 15.5 4.8 2.6 6.0 2.3 7.1 3.9 1.0 11.4 9.0 15.2 7.8 9.1 10.6 6.4 10.6 10.3 12.4 11.3 9.5 7.5 25.3 6.6 14.5 7.0 16.4 10.1 16.8 14.5 6.5 25.9 15.1 7.3 6.8 19.4 15.0 9.1 9.7 12.2 15.2 11.4 16.6 9.6 10.1 6.0 14.2 2.6 11.5 7.5 9.4 14.7 13.1 6.2 15.1 6.6 10.5 17.8 7.0 6.6 7.4 14.4 14.6 13.6 10.2 11.6 16.8 12.2 13.6 25.5 7.9 11.1 7.9 2.4 2.2 5.2 3.9 2.3 2.4 3.7 2.4 3.0 2.5 4.8 3.5 3.0 6.0 7.1 1.9 2.6 1.0 1.0 12.2 15.4 22.4 16.4 10.6 6.8 11.7 9.5 11.3 12.8 SETDB1 "ESET, KG1T, KIAA0067, KMT1E, TDRD21" ENSG00000143379 "SET domain bifurcated 1" Q15047 1 150926263-150964744 "Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins" "Transcription, Transcription regulation" "Chromatin regulator, Methyltransferase, Repressor, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enriched" "Detected in all" 5 "U-698: 88.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA018142, HPA058484" Uncertain Supported Nucleoplasm,Vesicles Nucleoplasm Vesicles "HPA018142: AB_1856757, HPA058484: " "unprognostic (1.07e-1)" "unprognostic (4.08e-1)" "unprognostic (8.02e-2)" "unprognostic (2.24e-3)" "unprognostic (1.65e-2)" "unprognostic (9.57e-2)" "prognostic unfavourable (8.88e-4)" "unprognostic (6.03e-2)" "unprognostic (9.94e-3)" "unprognostic (7.13e-2)" "unprognostic (1.21e-1)" "unprognostic (6.65e-2)" "prognostic unfavourable (4.25e-4)" "unprognostic (1.59e-1)" "unprognostic (3.93e-2)" "unprognostic (3.14e-2)" "unprognostic (1.14e-1)" 16.9 15.4 9.5 21.2 15.9 16.9 17.7 21.6 18.2 18.6 15.4 25.2 18.6 13.0 22.8 18.9 15.6 16.8 14.0 10.9 9.6 8.5 13.3 12.7 15.6 20.7 15.3 13.2 23.9 17.6 21.0 15.4 18.4 13.7 14.9 16.8 20.6 16.1 18.5 20.0 18.0 17.1 17.9 13.7 21.9 15.0 33.5 14.2 24.5 18.6 12.0 20.7 18.6 16.3 11.2 12.8 6.9 14.9 7.6 9.1 5.3 5.7 6.7 9.8 6.4 4.7 6.3 16.3 4.8 5.5 6.9 5.9 4.5 8.0 11.4 6.6 5.3 7.3 9.1 5.1 5.5 5.5 11.3 6.4 6.9 5.2 6.7 11.3 6.1 8.2 5.8 5.7 9.2 8.1 10.8 9.3 4.9 11.1 7.8 6.6 13.4 5.4 9.1 6.3 8.4 5.3 6.6 7.1 13.0 7.3 8.6 5.8 9.3 15.4 5.4 4.0 4.2 4.4 6.7 9.7 10.4 88.6 4.2 4.0 3.9 6.8 10.7 6.9 8.3 14.9 8.7 8.7 7.4 9.1 12.8 11.2 8.3 8.3 6.5 7.6 10.6 8.6 4.7 5.3 9.5 15.9 21.6 18.2 9.6 8.5 15.3 13.2 13.7 14.2 SF3B1 "Hsh155, Prp10, PRPF10, SAP155, SF3b155" ENSG00000115524 "Splicing factor 3b subunit 1" O75533 2 197389784-197435091 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "mRNA processing, mRNA splicing" RNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA050275 Approved Enhanced "Nuclear speckles" 840000 "Nuclear speckles" "HPA050275: " "unprognostic (6.86e-2)" "unprognostic (2.78e-1)" "unprognostic (2.14e-1)" "unprognostic (3.51e-1)" "unprognostic (4.42e-2)" "unprognostic (1.25e-3)" "unprognostic (2.44e-3)" "unprognostic (3.31e-3)" "unprognostic (1.25e-2)" "unprognostic (2.20e-1)" "unprognostic (6.79e-2)" "unprognostic (1.78e-2)" "unprognostic (2.57e-2)" "unprognostic (9.15e-2)" "unprognostic (1.16e-1)" "unprognostic (1.79e-1)" "unprognostic (3.41e-2)" 53.9 49.9 36.5 54.5 44.9 88.0 57.9 60.8 47.3 72.3 54.2 44.3 45.6 36.8 64.6 72.0 50.5 53.3 43.1 39.6 34.7 26.0 49.7 50.7 53.1 65.3 56.5 27.7 73.6 60.5 66.2 81.4 64.6 46.7 50.0 51.0 37.0 54.4 45.4 49.3 48.5 67.8 41.2 50.2 88.1 48.8 33.3 53.5 113.0 53.3 38.0 65.7 62.4 56.0 32.7 41.9 41.1 37.8 39.6 45.9 29.4 30.7 28.2 63.6 34.7 49.3 50.4 53.4 43.0 44.0 37.6 46.1 53.8 33.2 58.7 29.0 43.7 29.8 63.5 34.9 58.8 44.9 39.5 62.1 69.0 63.2 37.2 65.9 45.3 52.6 34.1 39.1 48.2 43.7 44.4 40.5 41.6 27.0 60.6 63.5 50.0 44.6 53.4 54.4 39.0 52.2 78.2 35.7 44.3 41.1 25.2 29.4 24.9 50.5 44.0 29.5 25.4 29.8 30.5 37.0 60.1 84.3 28.3 39.9 32.6 27.7 33.1 39.1 37.5 37.8 40.6 32.7 32.5 35.3 41.9 30.8 33.9 33.9 41.1 39.6 36.1 23.8 45.9 29.4 36.5 44.9 60.8 47.3 34.7 26.0 56.5 27.7 46.7 53.5 SFN YWHAS ENSG00000175793 Stratifin P31947 1 26863138-26864457 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "esophagus: 256.2;lymphoid tissue: 107.4;skin 1: 123.8;tongue: 256.0" "Cell line enhanced" "Detected in many" "A-431: 68.6;HaCaT: 108.3;HBEC3-KT: 166.7;hTCEpi: 111.9" "Cancer enhanced" "Detected in all" "head and neck cancer: 2526.8" "Not detected" "Not detected" "Cell type enriched" "Detected in single" 12 "basophil: 7.1" "Lineage enriched" "Detected in single" 12 "granulocytes: 7.1" "Low region specificity" "Detected in some" "CAB006268, HPA011105, CAB040552, HPA061603" Enhanced Supported Nucleoli,Cytosol "Secreted in other tissues" 54000000 Cytosol Nucleoli "CAB006268: AB_425459, CAB040552: , HPA011105: AB_1844339, HPA061603: " "unprognostic (5.70e-2)" "unprognostic (1.26e-1)" "unprognostic (8.37e-2)" "prognostic favourable (1.92e-4)" "unprognostic (1.26e-2)" "unprognostic (1.85e-1)" "prognostic unfavourable (5.68e-5)" "unprognostic (1.71e-2)" "unprognostic (2.99e-1)" "unprognostic (3.96e-1)" "prognostic unfavourable (6.01e-4)" "unprognostic (3.83e-1)" "prognostic unfavourable (7.45e-6)" "unprognostic (7.90e-3)" "unprognostic (3.25e-1)" "unprognostic (8.12e-2)" "unprognostic (2.06e-2)" 0.4 0.0 0.5 3.1 0.5 0.0 3.8 0.4 0.7 37.5 10.7 0.5 0.5 5.9 3.3 0.7 256.2 0.0 6.0 0.3 0.6 0.1 1.2 0.5 8.2 0.3 0.4 0.3 0.3 0.3 0.0 0.3 3.4 0.8 5.9 4.0 0.3 25.5 0.4 0.4 123.8 13.2 0.5 0.7 0.3 6.6 0.4 0.4 3.1 0.4 256.0 107.4 9.1 47.7 0.0 0.0 7.1 0.0 0.0 0.6 0.0 68.6 11.6 0.0 0.1 0.0 0.0 3.4 0.0 0.0 0.0 0.0 4.2 36.2 0.6 3.0 0.0 108.3 0.0 166.7 0.0 16.4 0.5 0.0 11.6 12.2 0.0 0.0 0.1 0.0 111.9 0.0 29.3 0.0 0.1 0.4 0.0 14.6 0.0 0.0 0.2 19.3 0.0 0.0 3.8 25.9 15.8 0.0 0.0 16.6 2.9 0.1 7.7 0.1 0.0 0.0 31.7 0.0 0.4 0.1 0.5 0.3 0.1 0.0 0.0 7.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.6 0.0 0.5 0.5 0.4 0.7 0.6 0.1 0.4 0.3 0.8 0.4 SFPQ "PPP1R140, PSF" ENSG00000116560 "Splicing factor proline and glutamine rich" P23246 1 35176378-35193148 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Biological rhythms, DNA damage, DNA recombination, DNA repair, Immunity, Innate immunity, mRNA processing, mRNA splicing, Transcription, Transcription regulation" "Activator, DNA-binding, Repressor, RNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009886, HPA047513, HPA054689" Enhanced Enhanced Nucleoplasm 280000 Nucleoplasm "CAB009886: AB_2186937, HPA047513: AB_2680073, HPA054689: AB_2682574" "prognostic favourable (9.56e-5)" "unprognostic (1.01e-1)" "unprognostic (1.02e-3)" "unprognostic (1.99e-1)" "unprognostic (5.53e-2)" "unprognostic (1.86e-2)" "prognostic unfavourable (7.91e-13)" "unprognostic (3.10e-1)" "unprognostic (4.00e-3)" "unprognostic (3.85e-2)" "unprognostic (2.20e-2)" "unprognostic (8.03e-3)" "unprognostic (1.25e-3)" "unprognostic (1.16e-2)" "unprognostic (3.97e-3)" "unprognostic (3.07e-1)" "unprognostic (3.77e-3)" 40.5 35.7 31.5 39.4 31.4 122.5 48.3 53.0 38.5 39.0 31.4 37.8 32.9 30.0 45.3 36.5 45.5 43.0 28.1 34.0 29.1 24.6 36.4 34.2 47.6 48.8 26.3 32.6 59.9 40.2 45.8 46.3 35.5 31.9 35.5 38.0 35.7 39.6 38.0 44.9 42.9 34.1 36.5 32.8 42.4 35.5 37.5 32.9 95.2 35.3 24.1 60.6 35.9 38.6 6.9 11.2 4.4 8.8 4.9 8.9 3.3 36.1 30.2 52.8 29.8 13.0 19.6 49.6 19.8 20.2 33.9 24.8 32.9 26.2 66.1 27.6 22.9 33.1 57.4 38.8 46.3 35.2 38.1 49.7 32.6 39.0 17.6 51.6 29.6 15.6 15.1 29.4 14.3 29.5 56.1 31.6 32.9 31.5 60.4 44.3 62.9 29.3 61.4 35.9 43.0 32.7 44.0 38.1 42.4 28.6 22.3 28.7 26.1 36.8 31.3 27.2 40.0 17.8 42.4 36.2 30.7 67.3 19.4 34.2 38.6 2.6 6.5 4.4 7.7 8.8 8.9 6.2 7.6 6.1 5.8 6.9 7.2 7.9 3.4 4.9 6.4 11.2 8.2 3.3 31.5 31.4 53.0 38.5 29.1 24.6 26.3 32.6 31.9 32.9 SFRP4 "FRP-4, frpHE, FRZB-2" ENSG00000106483 "Secreted frizzled related protein 4" Q6FHJ7 7 37905932-38025695 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins" "Differentiation, Wnt signaling pathway" "Developmental protein" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "cervix, uterine: 144.9;endometrium 1: 100.7;retina: 123.0" "Cell line enhanced" "Detected in some" "ASC diff: 13.8;HSkMC: 5.4;U-937: 5.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in single" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in single" "HPA009712, HPA050585" Enhanced "Secreted in female reproductive system" 1500000 "HPA009712: AB_1856778, HPA050585: AB_2681183" "unprognostic (5.93e-2)" "unprognostic (5.84e-3)" "unprognostic (2.75e-2)" "unprognostic (1.58e-3)" "unprognostic (2.61e-1)" "unprognostic (2.35e-2)" "unprognostic (4.02e-2)" "unprognostic (2.60e-1)" "unprognostic (1.21e-1)" "unprognostic (3.76e-2)" "unprognostic (2.12e-1)" "unprognostic (1.18e-1)" "prognostic unfavourable (1.36e-5)" "unprognostic (7.37e-3)" "unprognostic (1.61e-1)" "unprognostic (4.35e-3)" "unprognostic (1.89e-3)" 4.6 2.3 0.5 0.9 0.9 0.0 12.5 0.3 0.4 144.9 0.8 1.7 5.4 0.0 100.7 11.5 3.2 35.1 2.5 5.5 0.4 0.4 1.2 0.2 3.9 0.8 0.8 0.7 42.7 1.4 0.1 4.0 0.4 1.3 4.9 0.2 123.0 2.3 7.1 1.4 0.3 0.5 14.5 3.3 4.1 0.5 5.8 0.3 0.4 3.3 2.5 0.5 8.8 14.8 0.4 0.8 0.4 0.6 0.1 0.1 0.0 0.0 2.5 2.8 0.0 13.8 0.6 0.1 0.0 0.1 0.0 0.0 0.4 0.0 0.1 0.1 2.9 0.1 0.0 0.3 0.3 0.0 0.0 0.2 0.2 2.0 0.1 0.4 0.0 5.4 0.7 0.6 0.0 0.2 0.0 0.3 0.2 0.4 0.0 1.6 0.1 0.0 0.2 1.7 0.0 0.1 0.2 0.1 0.3 0.0 0.0 0.3 0.0 0.0 0.9 0.0 1.2 1.6 0.2 0.5 0.1 0.2 0.3 5.2 0.9 0.0 0.1 0.0 0.0 0.6 0.0 0.4 0.0 0.0 0.1 0.1 0.1 0.0 0.4 0.1 0.0 0.8 0.0 0.0 0.5 0.9 0.3 0.4 0.4 0.4 0.8 0.7 1.3 0.3 SGK1 SGK ENSG00000118515 "Serum/glucocorticoid regulated kinase 1" O00141 6 134169246-134318112 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Apoptosis, Stress response" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "parathyroid gland: 141.3" "Cell line enhanced" "Detected in many" "HHSteC: 50.1;RPTEC TERT1: 76.9;SK-MEL-30: 49.8;TIME: 59.8;U-266/84: 54.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 4 "classical monocyte: 11.7;eosinophil: 45.9;neutrophil: 26.2" "Group enriched" "Detected in many" 7 "granulocytes: 45.9;monocytes: 11.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB022085, CAB025148, HPA051251" Approved Enhanced "Nuclear speckles" "Nuclear speckles" "CAB022085: , CAB025148: , HPA051251: " "unprognostic (2.05e-2)" "prognostic favourable (5.26e-4)" "unprognostic (1.12e-1)" "unprognostic (5.09e-3)" "unprognostic (2.76e-1)" "unprognostic (4.20e-2)" "unprognostic (4.53e-2)" "unprognostic (5.62e-2)" "unprognostic (4.03e-1)" "unprognostic (7.94e-2)" "unprognostic (1.78e-1)" "unprognostic (2.55e-1)" "unprognostic (5.82e-3)" "unprognostic (9.10e-2)" "unprognostic (3.81e-2)" "unprognostic (1.79e-1)" "unprognostic (6.59e-2)" 45.6 35.5 16.8 12.8 43.2 15.8 22.9 10.6 25.0 18.4 62.3 51.7 10.8 14.2 14.9 11.2 30.0 16.1 47.8 12.5 22.9 9.6 37.5 51.1 31.2 8.4 48.8 16.6 47.2 47.8 141.3 4.7 19.2 28.3 18.3 11.3 45.8 26.2 18.4 12.4 25.8 131.8 13.6 40.3 7.6 31.1 12.2 50.1 6.2 22.3 24.8 20.4 26.1 31.7 0.6 4.0 45.9 11.7 0.9 0.7 3.1 0.6 1.1 0.7 0.0 8.6 2.1 0.9 12.3 25.7 16.1 13.2 1.9 1.7 2.0 1.8 12.7 0.4 1.1 1.9 11.9 0.0 0.5 0.1 30.7 1.4 50.1 0.1 1.1 12.9 12.4 15.8 20.6 27.0 3.9 31.4 5.7 0.1 0.1 0.4 0.7 1.3 0.3 1.4 0.2 76.9 0.2 0.3 3.0 38.7 0.1 49.8 0.0 0.3 59.8 4.7 2.0 28.9 2.7 5.9 54.8 6.3 4.4 1.9 6.3 0.6 11.7 45.9 0.2 6.8 0.5 0.6 0.4 0.2 4.0 0.4 0.5 0.6 26.2 0.9 3.7 0.2 0.7 3.1 16.8 43.2 10.6 25.0 22.9 9.6 48.8 16.6 28.3 50.1 SH2B3 "IDDM20, LNK" ENSG00000111252 "SH2B adaptor protein 3" Q9UQQ2 12 111405948-111451623 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Diabetes mellitus" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HMC-1: 31.8;hTEC/SVTERT24-B: 36.4;U-87 MG: 55.3;WM-115: 42.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA005483 Approved Approved Nucleoplasm Nucleoplasm "HPA005483: AB_1079260" "unprognostic (2.77e-1)" "unprognostic (1.74e-1)" "unprognostic (1.20e-1)" "unprognostic (1.12e-1)" "unprognostic (1.18e-1)" "unprognostic (9.09e-2)" "unprognostic (1.23e-1)" "unprognostic (2.42e-1)" "unprognostic (1.18e-1)" "unprognostic (4.65e-2)" "unprognostic (8.17e-3)" "unprognostic (9.08e-2)" "prognostic unfavourable (6.20e-4)" "unprognostic (2.86e-1)" "unprognostic (3.89e-3)" "unprognostic (1.11e-1)" "unprognostic (2.24e-2)" 17.6 9.0 7.9 13.7 7.9 34.4 19.8 3.8 9.3 8.9 7.5 7.2 3.1 5.3 8.0 7.1 5.6 7.5 12.7 15.3 5.8 5.5 9.2 12.5 17.6 27.8 6.6 4.0 8.2 11.0 4.7 7.6 16.1 5.2 8.4 9.3 8.7 5.0 4.2 10.2 3.6 10.3 9.1 7.8 31.7 5.5 13.3 6.8 9.5 10.2 3.2 11.8 10.0 5.8 1.8 6.1 3.8 10.3 2.3 1.7 1.9 2.2 1.3 1.8 1.8 6.3 9.5 1.2 7.4 20.3 5.7 6.1 2.1 1.3 3.9 5.3 11.2 0.4 1.4 4.2 9.2 3.2 0.6 13.2 0.6 1.5 6.2 5.8 31.8 5.6 0.9 36.4 3.3 30.4 9.5 1.5 20.6 0.8 2.3 11.6 2.8 5.4 2.3 4.1 2.5 2.7 0.9 1.2 1.2 1.3 0.1 10.6 0.9 8.3 23.5 5.2 2.9 4.5 12.0 3.6 3.7 4.4 55.3 4.2 42.2 1.1 4.3 1.5 1.6 10.3 1.4 1.8 1.4 1.7 5.9 0.7 1.0 1.3 3.8 2.3 7.6 6.1 0.5 1.9 7.9 7.9 3.8 9.3 5.8 5.5 6.6 4.0 5.2 6.8 SH3GL1 "CNSA1, EEN, MGC111371, SH3D2B, SH3P8" ENSG00000141985 "SH3 domain containing GRB2 like 1, endophilin A2" Q99961 19 4360370-4400547 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" Endocytosis "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA021485 Approved Enhanced Cytosol Cytosol "HPA021485: AB_1856816" "unprognostic (1.32e-1)" "prognostic favourable (1.50e-4)" "unprognostic (6.85e-2)" "prognostic favourable (1.86e-4)" "unprognostic (1.84e-1)" "unprognostic (1.02e-1)" "prognostic unfavourable (1.10e-4)" "unprognostic (1.92e-2)" "unprognostic (1.21e-1)" "unprognostic (1.42e-2)" "unprognostic (1.32e-1)" "unprognostic (1.54e-1)" "prognostic unfavourable (9.36e-8)" "unprognostic (5.48e-3)" "unprognostic (2.45e-1)" "unprognostic (1.02e-3)" "unprognostic (4.10e-2)" 20.5 22.4 12.8 17.7 14.5 28.9 17.5 19.1 25.9 21.6 18.7 13.3 11.9 25.4 16.9 12.1 66.0 15.0 16.1 13.2 13.0 8.0 13.8 19.7 14.8 13.0 11.4 13.0 23.5 20.5 5.6 17.3 33.9 9.4 17.1 6.2 14.9 22.1 16.8 8.6 40.4 29.8 18.8 9.0 19.5 16.4 13.7 11.3 10.1 14.2 19.1 33.0 22.2 30.0 6.1 6.5 9.7 5.1 3.8 7.4 3.4 31.7 14.4 15.0 19.8 17.6 27.5 27.7 27.7 23.9 24.7 24.6 22.4 16.8 7.2 11.7 27.4 26.3 10.6 30.4 6.6 9.5 17.7 8.6 19.8 29.3 25.4 7.7 9.8 23.0 21.2 20.8 12.8 29.0 22.3 16.4 19.8 26.6 7.5 8.1 37.6 16.1 5.9 20.9 12.5 19.5 28.1 14.8 22.8 24.4 24.4 17.3 16.8 12.3 43.7 23.8 17.4 49.8 28.0 10.5 6.4 7.6 34.3 20.1 32.6 1.0 3.8 4.8 5.0 1.9 4.8 6.1 7.4 6.9 5.0 4.5 4.2 4.5 9.7 3.8 5.1 6.5 6.6 3.4 12.8 14.5 19.1 25.9 13.0 8.0 11.4 13.0 9.4 11.3 SIN3A "DKFZP434K2235, KIAA0700" ENSG00000169375 "SIN3 transcription regulator family member A" Q96ST3 15 75369379-75455842 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Biological rhythms, Transcription, Transcription regulation" Repressor "Cancer-related genes, Disease mutation, Dwarfism, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004506, HPA047213, HPA062123" Enhanced Enhanced Nucleoplasm Nucleoplasm "CAB004506: AB_2187766, HPA047213: AB_2679984, HPA062123: AB_2684689" "unprognostic (1.94e-1)" "unprognostic (1.38e-1)" "unprognostic (1.48e-1)" "unprognostic (1.27e-1)" "unprognostic (1.99e-1)" "unprognostic (2.90e-1)" "unprognostic (4.74e-2)" "unprognostic (1.91e-1)" "unprognostic (2.26e-1)" "unprognostic (2.15e-1)" "unprognostic (8.52e-2)" "unprognostic (1.37e-1)" "unprognostic (1.17e-3)" "unprognostic (7.33e-2)" "unprognostic (2.19e-1)" "unprognostic (1.33e-1)" "unprognostic (3.52e-1)" 21.0 15.4 14.0 19.4 18.5 31.6 20.4 26.3 15.5 26.3 20.2 19.9 15.3 11.8 26.6 16.8 17.7 22.1 15.9 13.4 14.2 11.8 13.6 13.9 17.4 20.7 13.0 14.2 27.6 19.8 23.4 16.8 17.2 13.0 22.9 14.3 23.0 17.6 20.5 18.2 23.5 17.9 24.5 12.8 20.3 16.8 28.5 15.1 48.7 24.0 12.8 26.9 26.0 19.0 9.8 6.5 9.3 8.3 9.7 12.7 6.3 12.7 26.4 23.6 15.5 11.8 12.5 13.7 9.6 14.9 14.1 15.2 14.6 17.3 27.8 10.0 14.1 22.8 34.2 14.4 15.5 22.4 17.7 26.2 20.1 11.4 8.9 24.8 22.4 15.1 11.1 16.4 17.2 12.6 20.6 31.0 11.4 14.8 24.3 15.9 23.0 11.1 24.6 31.3 17.1 10.1 23.4 18.7 18.7 23.6 10.6 13.2 16.1 19.7 11.0 17.5 23.7 11.5 14.1 21.3 33.4 29.5 10.4 25.4 9.7 3.3 4.8 6.9 8.5 4.8 12.7 9.3 10.8 10.7 6.5 9.8 11.1 9.5 9.3 9.7 8.3 4.4 9.5 6.3 14.0 18.5 26.3 15.5 14.2 11.8 13.0 14.2 13.0 15.1 SIRT2 SIR2L ENSG00000068903 "Sirtuin 2" Q8IXJ6 19 38878555-38899862 "Cancer-related genes, Predicted intracellular proteins" "Autophagy, Cell cycle, Cell division, Differentiation, Immunity, Innate immunity, Meiosis, Mitosis, Neurogenesis, Transcription, Transcription regulation" Transferase "Cancer-related genes, Neurodegeneration" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 86.6;skeletal muscle: 108.7" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004573, HPA011165" Approved Approved Nucleoplasm,Nucleoli,Cytosol Nucleoli "Nucleoplasm, Cytosol" "CAB004573: AB_2188600, HPA011165: AB_1856900" "unprognostic (2.15e-2)" "unprognostic (2.24e-2)" "unprognostic (2.88e-1)" "prognostic unfavourable (7.20e-7)" "unprognostic (3.75e-3)" "unprognostic (1.28e-2)" "unprognostic (2.85e-2)" "unprognostic (2.44e-3)" "unprognostic (2.73e-1)" "unprognostic (4.83e-2)" "unprognostic (2.97e-3)" "unprognostic (1.02e-1)" "unprognostic (1.90e-1)" "unprognostic (3.60e-2)" "unprognostic (1.19e-1)" "unprognostic (8.73e-2)" "unprognostic (1.70e-1)" 14.1 11.0 30.2 8.1 36.0 10.7 9.1 14.3 38.8 11.0 8.4 78.1 4.0 9.3 9.7 7.8 17.1 12.9 10.7 20.3 36.9 23.5 9.0 12.0 10.8 8.8 52.3 20.5 17.3 9.5 10.1 6.2 7.7 40.8 9.8 7.6 5.8 14.9 11.2 108.7 13.7 9.3 12.8 86.6 9.9 9.0 7.9 46.3 3.2 10.1 23.4 8.9 10.6 7.1 13.2 21.5 28.0 33.0 16.6 23.5 22.1 8.1 5.1 4.4 11.0 25.3 17.4 3.0 6.0 10.7 9.4 12.2 9.2 5.2 2.8 13.1 11.2 4.4 8.0 12.9 5.7 13.0 8.3 5.5 5.8 5.5 17.8 3.8 12.2 18.1 15.6 7.7 9.2 16.4 5.2 22.6 14.3 4.6 7.7 3.0 0.7 7.2 10.2 12.4 7.8 7.5 7.3 11.1 5.0 7.0 9.4 6.6 4.2 9.9 15.6 12.7 2.8 19.6 8.9 9.3 4.5 6.5 10.2 9.6 11.7 19.5 27.3 28.0 23.5 33.0 14.6 12.2 11.4 16.1 21.1 13.2 7.5 12.5 20.7 16.6 25.8 21.5 15.5 22.1 30.2 36.0 14.3 38.8 36.9 23.5 52.3 20.5 40.8 46.3 SIRT4 SIR2L4 ENSG00000089163 "Sirtuin 4" Q9Y6E7 12 120302316-120313249 "Cancer-related genes, Predicted intracellular proteins" "DNA damage" Transferase "Cancer-related genes, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "ASC diff: 10.3" "Low cancer specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA029691, HPA029692" Enhanced "HPA029691: AB_10600118, HPA029692: AB_10611520" "unprognostic (2.62e-2)" "unprognostic (7.08e-2)" "unprognostic (4.46e-3)" "unprognostic (1.09e-1)" "unprognostic (1.51e-1)" "unprognostic (2.35e-2)" "unprognostic (2.37e-2)" "unprognostic (4.53e-2)" "unprognostic (1.25e-1)" "unprognostic (4.49e-2)" "unprognostic (1.56e-3)" "unprognostic (1.54e-1)" "prognostic favourable (1.75e-4)" "unprognostic (4.97e-2)" "unprognostic (2.11e-1)" "unprognostic (9.74e-3)" "unprognostic (2.31e-1)" 0.4 4.4 1.8 0.7 1.6 0.0 0.9 5.1 3.2 1.1 2.6 3.8 1.9 0.6 1.3 1.4 1.0 4.4 1.7 1.7 3.6 3.7 1.5 1.0 1.2 2.8 1.9 2.4 0.6 0.6 1.1 0.8 3.0 1.4 10.2 3.3 1.2 1.8 0.7 1.2 1.9 5.8 1.9 0.8 1.2 1.0 5.1 4.8 8.5 1.8 2.9 7.4 1.8 1.0 2.3 3.2 1.6 10.3 3.5 1.6 2.3 2.7 1.9 5.1 2.5 1.6 1.7 2.8 1.3 0.6 3.2 1.1 3.4 3.3 4.3 0.0 0.5 1.9 2.6 1.8 0.9 3.1 2.8 1.0 0.7 2.6 3.2 0.2 2.9 1.3 3.1 2.7 1.8 2.0 3.8 6.0 1.7 2.7 0.2 3.3 2.8 1.7 0.2 1.4 3.9 0.7 0.4 1.6 2.7 1.4 0.5 4.1 3.5 0.4 1.6 1.1 2.5 8.5 1.8 0.2 5.2 0.7 7.4 3.3 3.4 4.1 1.0 5.1 5.9 5.2 0.0 2.9 0.1 4.8 0.3 1.8 SIX1 DFNA23 ENSG00000126778 "SIX homeobox 1" Q15475 14 60643415-60658259 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Apoptosis, Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding, Repressor" "Cancer-related genes, Deafness, Disease mutation, Non-syndromic deafness" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "pituitary gland: 39.1;salivary gland: 55.1;skeletal muscle: 59.0" "Cell line enhanced" "Detected in many" "LHCN-M2: 52.7;RH-30: 28.8" "Low cancer specificity" "Detected in many" "Group enriched" "Detected in some" 5 "olfactory region: 1.2;pons and medulla: 4.5" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "HPA001893, CAB058690" Enhanced Supported Nucleoplasm,Nucleoli Nucleoplasm Nucleoli "CAB058690: , HPA001893: AB_1079991" "unprognostic (3.62e-1)" "unprognostic (5.44e-2)" "unprognostic (5.09e-2)" "prognostic unfavourable (8.92e-6)" "unprognostic (1.33e-2)" "unprognostic (1.44e-2)" "unprognostic (2.04e-3)" "prognostic favourable (3.94e-4)" "unprognostic (1.40e-1)" "unprognostic (9.15e-2)" "unprognostic (6.45e-2)" "unprognostic (1.89e-1)" "unprognostic (3.06e-8)" "unprognostic (8.61e-2)" "unprognostic (2.13e-1)" "unprognostic (1.94e-1)" "unprognostic (3.86e-1)" 7.1 0.4 0.3 0.1 0.5 0.1 4.7 0.3 0.6 7.4 0.2 0.2 0.0 0.1 0.2 2.1 1.3 0.5 0.4 0.4 0.3 0.3 0.3 0.2 1.8 0.3 0.4 1.2 0.3 0.3 16.8 39.1 0.1 4.5 8.7 0.1 2.0 55.1 0.2 59.0 0.4 0.2 0.7 0.5 0.2 0.5 1.6 0.0 6.5 2.4 22.5 3.0 1.4 9.7 0.6 0.0 0.0 0.0 0.0 0.0 0.0 8.2 1.9 0.2 11.7 6.8 8.0 0.1 2.0 4.5 2.3 2.0 0.0 3.7 0.0 1.1 0.4 2.7 3.9 3.6 0.8 0.0 9.4 0.9 0.8 2.7 0.0 0.0 0.1 6.0 1.7 1.6 0.3 0.1 2.6 0.0 52.7 1.3 0.0 0.2 0.0 4.7 0.0 28.8 0.0 2.2 6.4 1.1 0.1 2.3 0.1 2.4 1.3 0.2 6.7 3.1 3.2 3.6 2.9 0.2 0.0 0.0 0.8 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.5 0.3 0.5 0.3 0.3 0.4 1.2 4.5 0.0 SKP2 "FBL1, FBXL1, p45" ENSG00000145604 "S-phase kinase associated protein 2" Q13309 5 36151989-36184319 "Cancer-related genes, Predicted intracellular proteins" "Antiviral defense, Host-virus interaction, Immunity, Innate immunity, Ubl conjugation pathway" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "placenta: 49.1" "Cell line enhanced" "Detected in all" "BEWO: 73.6;RH-30: 92.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB013491, CAB013533, HPA051196, HPA054633" Approved Supported Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "CAB013491: AB_2533074, CAB013533: , HPA051196: AB_2681383, HPA054633: AB_2682550" "unprognostic (2.32e-2)" "unprognostic (2.87e-1)" "unprognostic (1.26e-1)" "unprognostic (5.74e-2)" "unprognostic (9.56e-2)" "unprognostic (1.52e-2)" "unprognostic (1.21e-3)" "unprognostic (2.22e-1)" "prognostic unfavourable (3.72e-7)" "prognostic favourable (8.57e-4)" "unprognostic (5.06e-2)" "unprognostic (2.71e-1)" "prognostic unfavourable (4.77e-15)" "unprognostic (2.50e-2)" "unprognostic (3.73e-1)" "unprognostic (1.63e-1)" "unprognostic (2.19e-1)" 6.5 6.9 7.8 8.0 7.5 12.9 6.5 11.5 9.0 7.5 7.7 10.3 3.7 10.2 9.9 6.3 13.5 8.1 4.9 4.1 7.3 5.1 4.2 14.0 5.8 9.4 8.8 7.4 7.7 6.1 3.9 12.5 49.1 6.5 7.2 9.5 6.1 6.3 5.4 3.4 7.6 7.7 6.4 7.4 9.4 5.3 3.9 7.4 19.5 5.0 7.5 11.7 7.9 8.4 6.5 16.0 14.7 7.9 7.7 8.5 5.0 7.4 3.7 15.8 17.6 3.9 6.2 73.6 9.7 7.3 24.8 18.8 20.6 5.9 10.8 2.6 7.8 7.8 17.7 12.3 26.7 4.8 10.1 6.3 13.8 9.7 1.9 13.9 2.9 5.7 3.2 4.5 3.1 6.8 10.8 2.5 8.9 3.6 16.1 8.0 14.4 5.7 16.0 92.3 6.9 1.8 7.9 13.6 16.3 30.4 6.6 4.3 6.7 7.9 3.1 9.3 10.8 3.5 6.7 3.1 3.0 13.4 4.2 17.1 6.7 10.3 7.9 14.7 5.4 7.2 8.5 5.6 5.7 5.8 16.0 6.5 7.9 6.0 1.5 7.7 4.1 4.3 5.3 5.0 7.8 7.5 11.5 9.0 7.3 5.1 8.8 7.4 6.5 7.4 SLC19A1 "FOLT, RFC1" ENSG00000173638 "Solute carrier family 19 member 1" P41440 21 45493572-45544411 "Cancer-related genes, Predicted membrane proteins, Transporters" "Antiport, Transport" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 37.6" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in many" 4 "neutrophil: 37.6" "Lineage enriched" "Detected in many" 6 "granulocytes: 37.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA024802 Approved Approved "Plasma membrane" "Plasma membrane" "HPA024802: AB_10602892" "unprognostic (4.31e-3)" "prognostic unfavourable (4.15e-4)" "unprognostic (5.23e-2)" "unprognostic (2.02e-1)" "unprognostic (3.11e-1)" "unprognostic (3.04e-2)" "unprognostic (7.34e-2)" "unprognostic (2.87e-3)" "unprognostic (4.04e-2)" "unprognostic (4.09e-2)" "unprognostic (2.85e-1)" "unprognostic (2.39e-1)" "prognostic unfavourable (1.07e-10)" "unprognostic (1.44e-1)" "unprognostic (2.31e-1)" "unprognostic (7.97e-5)" "unprognostic (3.10e-1)" 9.0 7.8 7.1 8.2 13.5 10.5 12.5 9.6 8.9 5.0 9.7 6.0 9.4 31.2 4.3 4.6 2.3 4.6 3.5 3.2 7.1 6.1 4.7 14.1 13.9 14.1 8.7 4.4 8.1 5.4 1.8 3.5 32.9 11.5 4.7 2.0 17.8 6.0 3.5 3.5 6.1 16.5 2.3 5.9 11.7 5.7 3.4 3.4 11.8 9.6 2.8 4.1 3.1 3.1 0.9 4.9 37.6 6.4 0.4 1.1 2.4 10.4 9.5 1.9 7.8 0.6 0.8 15.6 4.9 0.8 4.5 2.9 22.0 9.7 9.7 9.8 1.2 5.4 3.9 3.6 1.1 8.9 19.0 20.5 5.2 15.3 2.7 13.3 3.2 1.0 2.7 4.9 1.6 3.7 24.4 4.3 1.6 11.7 18.1 12.4 11.2 11.2 24.6 2.2 28.3 2.0 6.3 11.7 10.3 5.5 9.1 4.2 6.9 15.8 4.5 5.9 7.4 1.6 8.0 1.8 6.5 8.8 2.6 21.8 4.7 0.6 6.4 8.5 0.3 6.0 1.1 0.9 0.5 0.7 4.9 0.3 0.8 0.5 37.6 0.4 3.7 1.5 1.0 2.4 7.1 13.5 9.6 8.9 7.1 6.1 8.7 4.4 11.5 3.4 SLC1A3 "EA6, EAAT1, GLAST" ENSG00000079215 "Solute carrier family 1 member 3" P43003 5 36606355-36688334 "Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters" "Amino-acid transport, Symport, Transport" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 11 "brain: 188.6" "Cell line enhanced" "Detected in many" "AF22: 21.2;CACO-2: 34.1;HaCaT: 25.8" "Cancer enriched" "Detected in all" 21 "glioma: 168.1" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 12 "classical monocyte: 4.3;intermediate monocyte: 2.1;myeloid DC: 3.4" "Group enriched" "Detected in many" 39 "dendritic cells: 3.4;monocytes: 4.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002573, HPA037467, HPA037468" Enhanced Supported Approved Nucleoli,Mitochondria Mitochondria Nucleoli "CAB002573: AB_564088, HPA037467: AB_10795027, HPA037468: AB_10671371" "unprognostic (1.23e-1)" "unprognostic (2.15e-2)" "unprognostic (2.58e-3)" "unprognostic (1.74e-2)" "unprognostic (1.02e-1)" "unprognostic (7.70e-2)" "unprognostic (3.89e-3)" "unprognostic (2.36e-1)" "unprognostic (1.24e-1)" "unprognostic (2.84e-2)" "unprognostic (4.17e-3)" "unprognostic (3.28e-1)" "unprognostic (2.46e-1)" "unprognostic (1.06e-1)" "unprognostic (4.17e-2)" "unprognostic (1.03e-1)" "unprognostic (1.31e-2)" 17.3 10.3 76.1 5.9 70.6 3.1 6.3 45.8 188.6 6.9 3.2 26.3 0.0 2.1 2.8 2.3 7.2 5.4 5.9 12.0 57.9 27.3 3.1 3.6 4.7 8.6 32.7 39.6 8.6 4.0 2.6 3.7 12.7 28.5 3.3 2.6 1.9 3.0 4.4 7.6 5.5 2.3 4.1 29.4 5.8 2.9 2.7 33.6 0.0 2.6 0.7 4.5 4.8 1.2 0.0 3.4 0.0 4.3 0.0 0.0 0.8 0.4 0.1 21.2 1.8 2.1 5.9 13.5 0.0 0.0 0.8 1.8 34.1 1.7 0.0 10.3 0.3 25.8 6.2 2.8 0.9 0.3 12.7 0.0 0.1 0.0 0.4 0.4 0.1 10.9 12.8 5.2 2.1 0.0 0.0 0.1 3.6 0.0 0.0 0.0 2.5 2.1 0.0 0.1 0.0 0.0 1.3 1.8 0.0 2.1 6.2 0.3 0.0 1.0 0.0 1.9 3.1 0.0 7.5 0.0 0.0 0.0 8.6 14.3 4.8 0.0 4.3 0.0 0.0 2.1 0.0 0.0 0.0 0.0 3.4 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.8 76.1 70.6 45.8 57.8 57.9 27.3 32.7 39.6 28.5 33.6 SLC26A3 "CLD, DRA" ENSG00000091138 "Solute carrier family 26 member 3" P40879 7 107765467-107803225 "Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters" "Antiport, Transport" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "gallbladder: 53.5;intestine: 110.1;lymphoid tissue: 42.8" "Cell line enhanced" "Detected in some" "BEWO: 2.2;CACO-2: 1.8;NB-4: 1.5;RPMI-8226: 7.5" "Cancer enriched" "Detected in many" 14 "colorectal cancer: 52.5" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in single" "Low region specificity" "Detected in many" HPA036055 Approved "HPA036055: AB_10602401" "unprognostic (1.26e-2)" "unprognostic (1.28e-1)" "unprognostic (1.12e-2)" "unprognostic (2.69e-1)" "unprognostic (4.02e-1)" "unprognostic (4.09e-2)" "unprognostic (3.05e-3)" "unprognostic (6.31e-2)" "unprognostic (1.68e-2)" "unprognostic (1.20e-1)" "unprognostic (1.14e-1)" "unprognostic (2.05e-2)" "unprognostic (8.85e-2)" "unprognostic (8.01e-2)" "unprognostic (5.52e-2)" "unprognostic (2.54e-2)" "unprognostic (3.58e-3)" 0.3 0.3 0.3 42.8 0.3 0.0 6.1 0.3 0.3 0.4 110.1 0.2 0.3 58.4 0.3 1.2 0.3 0.6 53.5 0.3 0.3 0.3 0.3 0.4 0.3 0.2 0.3 0.2 0.3 0.3 0.0 0.3 0.2 0.2 0.5 92.7 0.2 0.3 14.4 0.3 0.3 106.5 1.2 0.3 0.3 0.4 0.3 0.2 0.2 0.3 0.2 0.2 0.4 0.3 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.0 1.8 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.1 0.0 0.0 0.0 7.5 0.0 0.0 0.7 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.3 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.2 0.2 0.2 SLC2A1 "CSE, DYT18, DYT9, GLUT, GLUT1, HTLVR" ENSG00000117394 "Solute carrier family 2 member 1" P11166 1 42925375-42959176 "Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Sugar transport, Transport" "Cancer-related genes, Cataract, Disease mutation, Dystonia, Epilepsy, Hereditary hemolytic anemia, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in all" 4 "placenta: 194.0" "Cell line enhanced" "Detected in many" "BEWO: 44.2;CACO-2: 71.8;Hep G2: 49.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB002759, HPA031345, HPA058494" Enhanced Supported Enhanced "Plasma membrane" 36000000 "Plasma membrane" "CAB002759: , HPA031345: , HPA058494: " "unprognostic (3.60e-2)" "unprognostic (5.85e-3)" "unprognostic (7.59e-2)" "unprognostic (1.31e-2)" "unprognostic (4.10e-3)" "unprognostic (3.22e-2)" "prognostic unfavourable (3.65e-8)" "prognostic unfavourable (1.09e-4)" "unprognostic (1.10e-1)" "unprognostic (4.84e-2)" "prognostic unfavourable (4.39e-5)" "unprognostic (1.87e-1)" "prognostic unfavourable (4.55e-9)" "unprognostic (1.11e-1)" "unprognostic (9.49e-2)" "unprognostic (1.17e-1)" "prognostic unfavourable (4.05e-4)" 4.2 3.7 12.4 3.9 16.9 45.2 4.1 6.7 15.5 15.2 4.8 15.1 4.3 2.4 7.6 3.4 28.8 8.5 8.6 5.0 15.4 13.7 7.6 2.1 2.4 5.3 18.2 5.0 3.4 3.7 7.3 2.9 194.0 15.5 5.2 3.3 44.2 8.4 7.9 1.8 42.1 2.9 2.5 17.8 3.4 5.5 2.5 12.5 1.8 4.0 11.5 12.0 22.2 24.5 8.4 14.7 1.3 0.2 3.0 7.5 2.7 10.6 15.3 12.7 3.2 1.5 0.5 44.2 7.0 15.2 8.6 12.8 71.8 29.7 4.0 21.0 2.1 9.9 2.8 16.3 3.8 2.4 2.6 6.6 8.9 49.0 4.4 3.6 1.9 1.8 12.6 5.4 5.9 1.4 14.8 0.9 3.9 18.9 1.6 2.5 8.1 3.9 1.6 4.1 5.6 7.9 5.2 6.7 4.7 8.2 26.0 3.0 1.1 4.6 3.2 7.9 5.7 1.4 15.8 0.7 1.5 2.4 15.6 2.5 6.4 0.3 0.2 1.3 7.5 0.2 6.9 8.4 4.1 5.1 2.9 7.3 3.2 4.7 1.0 3.0 0.1 14.7 4.7 2.7 12.4 16.9 6.7 15.5 15.4 13.7 18.2 5.0 15.5 12.5 SLC34A2 NAPI-3B ENSG00000157765 "Solute carrier family 34 member 2" O95436 4 25648011-25678748 "Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters" "Ion transport, Sodium transport, Symport, Transport" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "lung: 259.9;seminal vesicle: 69.1" "Group enriched" "Detected in some" 81 "BEWO: 12.3;EFO-21: 46.6;RPTEC TERT1: 33.6" "Cancer enhanced" "Detected in many" "thyroid cancer: 585.2" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "basophil: 1.9" "Low lineage specificity" "Detected in single" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA037989 Enhanced Supported "Nucleoplasm,Golgi apparatus,Plasma membrane,Cytosol" "Plasma membrane, Cytosol" "Nucleoplasm, Golgi apparatus" "HPA037989: AB_10670536" "unprognostic (1.60e-2)" "unprognostic (1.12e-1)" "unprognostic (1.38e-1)" "unprognostic (4.25e-2)" "unprognostic (7.33e-2)" "unprognostic (9.83e-2)" "unprognostic (2.37e-2)" "unprognostic (6.60e-3)" "unprognostic (6.27e-2)" "unprognostic (1.89e-2)" "unprognostic (5.77e-2)" "unprognostic (2.24e-1)" "unprognostic (7.08e-3)" "unprognostic (3.25e-1)" "unprognostic (6.75e-2)" "unprognostic (2.57e-2)" "unprognostic (1.93e-1)" 0.1 0.1 0.1 0.0 0.1 0.0 3.2 0.2 0.1 13.0 0.1 0.0 24.7 2.9 6.9 2.1 0.5 13.0 3.4 0.1 0.1 0.1 10.8 0.5 259.9 0.0 0.1 0.0 2.9 4.4 0.0 0.6 2.6 0.8 0.3 0.0 1.6 27.4 69.1 0.1 0.7 2.1 0.0 0.1 0.1 0.4 0.5 0.0 0.4 27.9 0.1 1.9 0.0 0.1 0.4 0.2 1.9 0.5 0.4 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 12.3 0.0 0.0 0.0 0.0 0.1 0.0 0.1 46.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.1 0.0 0.0 0.0 0.0 33.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.3 0.0 0.2 0.1 0.1 0.0 0.0 0.0 1.9 0.5 0.2 0.3 0.3 0.1 0.2 0.1 0.1 0.0 0.4 0.3 0.2 1.5 0.4 0.1 0.2 0.0 0.0 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.0 0.8 0.0 SLC3A2 "4F2, 4F2HC, 4T2HC, CD98, CD98HC, MDU1, NACAE" ENSG00000168003 "Solute carrier family 3 member 2" P08195 11 62856102-62888875 "Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Amino-acid transport, Transport" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "hTCEpi: 129.8;SiHa: 132.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010455, HPA017980" Enhanced Supported "Nucleoplasm,Plasma membrane,Cytosol" 210000000 "Nucleoplasm, Plasma membrane, Cytosol" "CAB010455: AB_638288, HPA017980: " "unprognostic (1.79e-1)" "unprognostic (9.61e-3)" "unprognostic (3.59e-1)" "unprognostic (7.87e-3)" "unprognostic (2.06e-1)" "unprognostic (2.41e-3)" "prognostic unfavourable (8.17e-4)" "unprognostic (2.09e-3)" "unprognostic (2.62e-1)" "unprognostic (4.16e-2)" "unprognostic (2.29e-2)" "unprognostic (3.71e-1)" "prognostic favourable (8.22e-4)" "unprognostic (2.92e-2)" "unprognostic (5.52e-3)" "unprognostic (3.49e-3)" "prognostic unfavourable (1.48e-4)" 28.5 30.8 34.6 23.0 36.8 62.4 30.8 18.7 34.8 26.0 26.8 25.3 30.4 34.3 29.2 41.2 31.2 23.8 19.9 14.7 31.3 27.1 71.4 31.8 33.5 17.8 37.8 24.1 29.9 39.2 138.6 19.3 75.5 32.9 28.3 13.9 52.5 39.0 27.5 32.5 32.1 33.8 19.6 38.0 21.9 28.2 33.4 30.8 13.6 33.7 33.4 22.2 20.6 56.6 16.6 73.9 11.6 36.2 20.3 39.8 37.3 16.1 68.1 6.9 21.6 8.4 6.8 64.4 28.1 10.8 14.8 13.0 65.1 30.6 17.8 31.2 16.5 56.0 12.7 55.1 7.9 32.3 12.0 12.7 49.6 28.7 78.4 14.9 18.6 14.8 129.8 18.0 55.0 8.6 24.6 39.4 9.0 77.8 15.3 19.0 11.6 23.0 15.9 10.5 34.7 10.3 9.0 11.9 5.7 132.3 49.6 95.4 17.8 19.6 15.7 15.0 22.4 22.0 19.8 49.0 54.3 56.4 14.7 23.5 42.8 8.5 36.2 11.6 30.1 34.8 39.8 14.4 27.7 30.8 22.1 16.6 23.5 25.2 7.5 20.3 27.6 73.9 26.2 37.3 34.6 36.8 18.7 34.7 31.3 27.1 37.8 24.1 32.9 30.8 SLC44A3 "CTL3, MGC45474" ENSG00000143036 "Solute carrier family 44 member 3" Q8N4M1 1 94820342-94895246 "Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "RPTEC TERT1: 43.0;RT4: 28.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in some" 4 "MAIT T-cell: 5.2" "Lineage enriched" "Detected in single" 52 "T-cells: 5.2" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA047433 Enhanced "HPA047433: " "unprognostic (8.06e-2)" "unprognostic (7.65e-2)" "unprognostic (4.63e-3)" "unprognostic (3.57e-2)" "unprognostic (1.53e-2)" "unprognostic (2.37e-1)" "unprognostic (1.14e-1)" "unprognostic (4.03e-2)" "unprognostic (1.94e-1)" "unprognostic (1.46e-1)" "unprognostic (5.78e-2)" "unprognostic (2.44e-2)" "prognostic favourable (7.63e-5)" "unprognostic (9.09e-2)" "unprognostic (8.28e-2)" "unprognostic (5.95e-2)" "unprognostic (3.31e-3)" 1.8 7.3 9.1 6.1 8.3 0.0 5.3 6.6 5.6 5.9 19.8 3.9 4.5 16.5 4.8 5.1 6.6 5.1 16.3 4.5 6.3 5.0 21.4 3.9 6.7 0.4 6.1 3.6 2.7 22.2 5.3 22.2 3.9 5.8 7.2 22.9 9.5 16.0 8.5 1.6 3.7 17.2 2.9 5.4 0.5 17.9 1.6 4.2 2.6 5.4 0.9 4.1 11.0 6.3 0.0 0.0 0.0 0.0 0.0 5.2 0.1 9.4 1.3 0.3 0.0 1.1 1.4 6.7 0.1 1.4 0.3 1.6 8.8 2.4 0.0 6.5 0.1 3.2 1.4 2.3 0.6 0.0 1.7 0.0 0.5 0.7 0.4 0.0 0.0 4.3 2.1 0.6 0.0 0.1 0.0 0.0 0.6 1.4 0.0 0.1 0.4 0.3 0.7 0.3 0.5 43.0 28.7 4.4 7.3 0.4 4.5 3.2 2.6 0.3 0.0 0.2 1.5 0.6 0.1 0.0 0.0 0.0 1.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 5.2 0.0 0.8 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 9.1 8.3 6.6 5.6 6.3 5.0 6.1 3.6 5.8 4.2 SLC45A3 "IPCA-2, IPCA-6, IPCA-8, PCANAP2, PCANAP6, PCANAP8, prostein" ENSG00000158715 "Solute carrier family 45 member 3" Q96JT2 1 205657851-205680459 "Cancer-related genes, Predicted membrane proteins, Transporters" Transport "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "prostate: 115.0" "Cell line enriched" "Detected in some" 30 "HMC-1: 138.2" "Cancer enriched" "Detected in all" 49 "prostate cancer: 539.9" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 226 "basophil: 22.6" "Lineage enriched" "Detected in single" 226 "granulocytes: 22.6" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA019073, HPA019075" Enhanced Approved Nucleoplasm,Vesicles Vesicles Nucleoplasm "HPA019073: AB_1857177, HPA019075: AB_1857179" "unprognostic (1.80e-1)" "unprognostic (1.08e-3)" "unprognostic (3.13e-2)" "prognostic unfavourable (4.04e-5)" "unprognostic (6.93e-2)" "unprognostic (2.36e-2)" "unprognostic (1.15e-1)" "unprognostic (1.50e-1)" "unprognostic (1.84e-1)" "unprognostic (1.10e-1)" "unprognostic (2.90e-2)" "unprognostic (1.18e-1)" "unprognostic (3.03e-2)" "unprognostic (3.16e-1)" "unprognostic (1.55e-1)" "unprognostic (1.96e-1)" "prognostic favourable (7.33e-5)" 0.8 1.5 2.5 1.5 6.2 0.7 0.8 0.4 5.8 1.9 2.1 19.0 0.0 2.1 0.9 0.6 0.9 1.1 1.8 0.7 4.2 2.0 1.1 4.0 1.7 1.6 13.2 1.6 1.0 0.7 0.5 1.9 0.6 7.2 115.0 1.6 0.2 0.9 0.7 2.2 0.9 2.1 0.8 12.4 5.0 6.4 1.4 11.1 0.0 0.5 0.7 0.7 1.5 0.4 0.0 0.0 22.6 0.0 0.0 0.0 0.2 1.5 0.4 0.4 0.4 0.0 0.0 0.3 0.2 0.0 0.5 0.4 1.1 2.9 0.4 0.7 0.0 0.5 0.2 0.5 0.0 0.6 0.4 4.6 0.1 0.3 0.3 0.7 138.2 0.0 0.1 0.3 0.0 1.5 0.7 0.2 0.2 0.3 0.1 1.3 2.0 1.7 0.1 0.6 0.2 0.6 2.1 0.2 0.4 0.2 3.4 0.6 0.7 0.2 1.5 0.2 1.5 0.5 1.1 0.0 0.1 0.0 0.3 0.2 1.1 22.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 2.5 6.2 0.4 5.8 4.2 2.0 13.2 1.6 7.2 11.1 SLC4A5 NBC4 ENSG00000188687 "Solute carrier family 4 member 5" Q9BY07 2 74216242-74343414 "Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins" "Anion exchange, Ion transport, Sodium transport, Transport" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "retina: 109.1" "Cell line enhanced" "Detected in many" "U-266/70: 14.2" "Cancer enriched" "Detected in single" 11 "thyroid cancer: 3.3" "Group enriched" "Detected in many" 5 "cerebellum: 3.4;pons and medulla: 9.0" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in some" "Low region specificity" "Detected in many" HPA036621 Uncertain "HPA036621: AB_10696779" "unprognostic (1.30e-1)" "unprognostic (3.78e-2)" "unprognostic (2.75e-2)" "unprognostic (1.83e-4)" "unprognostic (3.38e-1)" "unprognostic (2.36e-2)" "unprognostic (2.56e-3)" "unprognostic (5.37e-4)" "unprognostic (1.39e-1)" "unprognostic (2.55e-1)" "unprognostic (1.55e-3)" "unprognostic (3.24e-2)" "unprognostic (1.72e-5)" "unprognostic (1.57e-1)" "unprognostic (1.06e-2)" "unprognostic (8.47e-2)" "unprognostic (9.27e-4)" 1.2 0.4 1.0 0.8 0.8 1.6 1.1 3.4 1.2 0.7 0.8 2.5 0.6 0.3 0.9 1.7 0.6 1.4 0.8 0.7 1.2 1.0 0.7 3.2 1.7 1.0 1.0 0.6 1.3 0.9 1.5 2.3 0.6 9.0 0.9 0.3 109.1 1.3 0.8 1.1 3.7 0.7 0.9 1.6 0.7 0.5 16.1 0.7 1.0 21.4 0.6 0.7 0.9 0.9 2.5 5.8 6.1 0.9 1.7 2.5 0.6 0.4 0.8 1.4 1.4 1.5 2.5 1.8 0.4 1.3 0.8 1.2 0.4 1.0 2.1 0.4 0.0 0.1 1.5 0.2 0.3 1.8 0.9 3.2 1.4 0.8 0.2 1.1 2.3 0.7 1.9 0.1 0.3 0.5 0.7 2.3 0.3 5.1 0.5 2.2 1.1 0.3 1.1 1.3 0.0 0.3 1.0 1.0 2.0 0.5 1.7 2.3 1.6 2.2 0.0 1.5 2.4 1.5 0.5 14.2 2.0 1.6 0.9 1.2 0.3 6.1 0.9 0.9 1.5 0.8 1.0 1.8 2.3 2.0 0.6 2.5 2.1 2.5 4.2 1.7 0.3 5.8 2.4 0.6 1.0 0.8 3.4 1.2 1.2 1.0 1.0 0.6 9.0 0.7 SLPI "ALK1, ALP, BLPI, HUSI, HUSI-I, WAP4, WFDC4" ENSG00000124107 "Secretory leukocyte peptidase inhibitor" P03973 20 45252239-45254564 "Cancer-related genes, Plasma proteins, Predicted secreted proteins" "Immunity, Innate immunity" "Antibiotic, Antimicrobial, Protease inhibitor, Serine protease inhibitor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "cervix, uterine: 934.9;ductus deferens: 268.3;salivary gland: 480.2;seminal vesicle: 548.7" "Cell line enhanced" "Detected in some" "EFO-21: 155.4;hTCEpi: 182.5;SiHa: 54.7;THP-1: 46.2" "Low cancer specificity" "Detected in all" "Region enriched" "Detected in single" 11 "pons and medulla: 4.7" "Cell type enriched" "Detected in single" 90 "neutrophil: 68.8" "Lineage enriched" "Detected in single" 90 "granulocytes: 68.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB002303, HPA027774" Enhanced Approved "Golgi apparatus" "Secreted to blood" 26402233 2600000 "Golgi apparatus" "CAB002303: AB_564008, HPA027774: AB_10602405" "unprognostic (2.31e-2)" "unprognostic (3.07e-1)" "unprognostic (3.10e-2)" "unprognostic (2.06e-1)" "unprognostic (1.63e-1)" "unprognostic (3.16e-2)" "unprognostic (9.98e-2)" "unprognostic (2.90e-1)" "unprognostic (3.23e-1)" "unprognostic (1.83e-3)" "unprognostic (4.01e-2)" "unprognostic (2.33e-2)" "prognostic unfavourable (6.91e-5)" "unprognostic (1.53e-1)" "unprognostic (2.15e-1)" "unprognostic (8.81e-2)" "unprognostic (8.31e-2)" 9.2 0.4 0.0 2.4 0.0 10.0 10.0 0.1 0.2 934.9 3.4 0.1 268.3 0.2 11.9 5.5 51.3 23.3 19.6 3.5 0.0 0.0 17.3 20.1 81.5 1.3 0.3 0.4 5.5 5.4 0.1 25.9 1.4 4.7 13.4 3.6 2.0 480.2 548.7 41.3 9.6 0.7 3.9 0.9 0.7 5.2 7.1 0.0 2.3 2.0 86.2 53.0 17.7 24.0 0.0 0.1 68.8 0.7 0.0 0.0 1.1 0.4 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 28.1 0.0 155.4 0.0 11.6 0.0 5.6 0.0 0.7 0.0 0.0 20.8 0.0 30.0 0.0 0.0 0.8 182.5 0.0 12.1 0.0 0.0 0.0 0.0 0.0 0.0 2.0 0.0 10.6 0.0 0.0 0.0 31.6 1.2 0.0 0.0 54.7 11.7 0.1 0.2 46.2 0.0 0.0 0.7 0.1 0.0 0.1 0.7 0.4 0.0 2.8 0.0 0.5 0.2 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 68.8 0.0 0.7 0.0 0.0 1.1 0.0 0.0 0.1 0.2 0.0 0.0 0.3 0.4 4.7 0.0 SMAD1 "JV4-1, MADH1, MADR1" ENSG00000170365 "SMAD family member 1" Q15797 4 145481194-145558079 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HUVEC TERT2: 45.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "basophil: 22.2;non-classical monocyte: 11.9" "Group enriched" "Detected in many" 4 "granulocytes: 22.2;monocytes: 11.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB005389 Approved Supported "Nucleoplasm,Plasma membrane,Cytosol" "Nucleoplasm, Cytosol" "Plasma membrane" "CAB005389: AB_656608" "unprognostic (8.20e-2)" "unprognostic (1.63e-1)" "unprognostic (2.76e-2)" "unprognostic (1.11e-1)" "unprognostic (3.74e-1)" "unprognostic (6.85e-2)" "unprognostic (1.70e-1)" "unprognostic (6.02e-2)" "unprognostic (2.30e-1)" "unprognostic (8.24e-2)" "unprognostic (5.31e-2)" "unprognostic (4.68e-2)" "unprognostic (1.73e-3)" "unprognostic (1.48e-1)" "unprognostic (5.88e-2)" "unprognostic (1.14e-3)" "unprognostic (3.15e-2)" 20.4 7.8 19.9 7.9 21.3 3.8 21.1 17.9 17.8 18.5 15.5 14.3 13.6 11.9 33.2 22.7 16.2 20.3 13.7 10.3 13.5 10.3 12.7 37.4 11.0 11.9 9.3 10.0 12.3 13.1 33.7 14.7 8.7 12.2 13.6 16.9 7.8 17.5 16.0 22.6 20.2 15.3 24.6 12.6 10.1 11.4 10.5 14.3 15.3 15.2 14.9 10.3 16.5 21.9 0.0 4.0 22.2 11.9 1.2 0.7 0.8 3.8 5.0 9.5 11.4 3.7 5.4 4.7 5.5 13.3 9.0 6.9 2.4 14.2 3.3 3.3 12.6 5.6 10.7 12.3 5.4 0.0 5.4 0.0 4.2 5.0 9.9 6.4 1.0 7.4 14.6 4.8 9.5 45.6 4.3 0.1 11.4 3.7 9.6 0.1 8.8 6.2 18.5 8.8 11.5 9.8 6.8 14.8 7.1 7.8 17.1 3.4 5.8 0.0 13.7 4.4 6.1 4.5 3.4 12.6 0.0 22.3 7.0 0.1 4.5 22.2 2.1 0.8 0.0 5.3 0.0 0.0 0.4 0.0 4.0 0.0 0.2 0.0 0.0 1.2 11.9 0.0 0.7 0.8 19.9 21.3 17.9 14.9 13.5 10.3 9.3 10.0 12.2 14.3 SMAD2 "JV18-1, MADH2, MADR2" ENSG00000175387 "SMAD family member 2" Q15796 18 47808957-47931146 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB025507, HPA067203, CAB073546" Approved Supported Nucleoplasm,Nucleoli,Cytosol "Nucleoplasm, Nucleoli, Cytosol" "CAB025507: , CAB073546: , HPA067203: " "unprognostic (1.55e-1)" "unprognostic (2.49e-1)" "unprognostic (1.43e-2)" "unprognostic (9.82e-3)" "unprognostic (9.88e-2)" "unprognostic (1.06e-1)" "prognostic unfavourable (9.44e-5)" "unprognostic (1.91e-2)" "unprognostic (7.59e-2)" "unprognostic (1.41e-3)" "unprognostic (6.46e-2)" "unprognostic (4.91e-2)" "unprognostic (9.20e-3)" "unprognostic (2.68e-1)" "unprognostic (6.13e-2)" "unprognostic (3.20e-2)" "unprognostic (6.28e-2)" 38.5 39.2 29.0 26.2 25.9 19.6 31.4 19.5 28.9 28.8 34.2 29.4 28.9 21.5 26.6 26.3 33.5 28.8 25.7 31.1 26.1 27.1 26.4 20.9 28.3 23.8 30.9 24.3 36.6 28.1 25.7 24.4 34.8 28.6 27.8 29.8 31.7 29.7 28.7 33.9 28.0 26.4 34.6 35.4 34.1 26.3 29.2 26.2 60.7 46.1 23.6 31.5 35.1 35.7 12.0 21.8 28.9 24.7 24.5 25.9 19.7 22.4 32.2 19.7 19.0 31.5 38.5 22.5 24.5 29.4 25.6 29.9 12.3 21.5 34.9 17.6 31.0 24.8 22.1 27.3 34.3 37.9 11.3 29.6 48.7 19.9 36.7 41.1 30.3 28.4 35.3 21.9 50.7 28.2 13.7 29.3 31.4 14.6 28.2 19.8 9.6 7.7 20.6 28.7 23.8 57.4 38.7 18.2 21.4 29.5 20.2 24.0 15.3 27.4 31.5 38.0 21.9 10.3 17.8 28.7 27.5 30.4 26.3 28.1 27.7 28.9 22.6 25.0 16.9 24.7 21.2 12.0 23.1 20.9 21.8 9.4 25.8 19.8 22.7 24.5 20.8 15.5 25.9 19.7 29.0 25.9 19.5 28.9 26.1 27.1 30.9 24.3 28.6 26.2 SMAD3 "HsT17436, JV15-2, MADH3" ENSG00000166949 "SMAD family member 3" P84022 15 67063763-67195195 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Aortic aneurysm, Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB008094, HPA046386, HPA067203, CAB069409" Approved Enhanced Nucleoplasm,Cytosol Nucleoplasm Cytosol "CAB008094: AB_2302271, CAB069409: AB_1622941, HPA046386: , HPA067203: " "unprognostic (1.04e-1)" "unprognostic (1.83e-1)" "unprognostic (1.06e-1)" "unprognostic (1.99e-2)" "unprognostic (1.61e-1)" "unprognostic (1.98e-2)" "unprognostic (8.40e-3)" "unprognostic (1.80e-2)" "unprognostic (7.62e-2)" "unprognostic (6.82e-2)" "prognostic unfavourable (2.48e-4)" "unprognostic (2.93e-1)" "unprognostic (2.14e-2)" "unprognostic (3.10e-1)" "unprognostic (1.79e-1)" "unprognostic (1.15e-1)" "unprognostic (5.97e-2)" 25.3 4.6 12.2 18.5 12.4 12.4 21.6 5.0 12.7 20.9 17.9 7.6 9.5 12.7 19.9 16.6 35.3 14.3 27.7 19.7 7.5 4.8 15.6 13.6 13.9 14.0 6.0 7.5 23.0 12.6 7.0 10.8 11.5 8.2 20.5 9.2 30.8 12.5 10.8 37.3 19.6 19.0 23.2 5.5 11.2 15.8 7.0 7.7 10.5 21.8 23.4 29.7 31.4 24.6 4.8 2.5 3.2 1.9 0.4 6.3 1.8 12.5 42.1 7.9 3.8 13.9 32.1 6.2 7.3 30.0 10.1 8.2 8.7 33.7 4.2 9.8 20.7 29.8 8.2 30.7 10.1 3.3 3.1 0.4 11.9 6.5 10.5 1.6 0.7 29.0 7.2 8.9 7.6 34.1 10.1 11.7 12.6 6.5 0.3 6.3 4.7 13.2 0.4 2.3 1.5 6.8 40.4 0.2 2.7 9.6 5.3 8.3 1.4 7.8 28.7 13.7 12.8 9.8 8.2 4.5 1.2 5.2 12.4 1.8 12.2 0.0 1.9 3.2 5.5 1.5 5.7 2.1 6.2 6.3 1.8 4.8 2.8 2.4 0.1 0.4 1.5 2.5 3.1 1.8 12.2 12.4 5.0 12.7 7.5 4.8 6.0 7.5 8.2 7.7 SMAD4 "DPC4, MADH4" ENSG00000141646 "SMAD family member 4" Q13485 18 51028394-51085045 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA019154 Approved Supported Nucleoplasm,Centrosome,Cytosol "Nucleoplasm, Cytosol" Centrosome "HPA019154: AB_1853480" "unprognostic (1.58e-1)" "unprognostic (1.75e-1)" "unprognostic (1.25e-2)" "unprognostic (4.83e-2)" "unprognostic (1.17e-2)" "unprognostic (4.05e-1)" "unprognostic (7.29e-3)" "unprognostic (9.00e-2)" "unprognostic (4.01e-2)" "unprognostic (2.51e-2)" "unprognostic (1.03e-3)" "unprognostic (4.40e-2)" "prognostic favourable (1.92e-5)" "unprognostic (2.62e-2)" "unprognostic (4.23e-1)" "unprognostic (1.36e-1)" "unprognostic (1.44e-1)" 25.6 17.5 16.0 14.0 16.7 11.4 24.9 29.7 16.0 27.9 22.6 17.9 21.3 15.1 28.2 18.8 21.7 20.5 17.5 19.6 15.3 11.5 21.0 22.0 20.1 16.0 17.2 13.3 30.5 25.0 30.0 28.9 30.6 14.2 27.8 17.4 18.4 23.1 22.8 39.7 18.2 23.4 27.6 13.9 21.7 19.3 17.6 18.4 38.8 35.0 13.9 18.1 29.0 24.1 3.6 3.6 3.4 1.8 2.9 4.7 1.3 8.5 11.3 30.7 8.8 12.7 19.6 17.3 15.0 16.5 20.2 25.4 6.9 2.0 14.2 4.5 13.0 14.1 17.2 6.7 21.5 12.3 9.7 9.8 11.3 7.9 12.6 17.1 7.7 8.9 11.4 9.9 14.6 14.6 11.0 13.1 11.9 4.5 10.1 4.9 16.0 7.1 13.2 15.6 13.9 9.7 3.7 19.0 11.3 14.0 2.6 9.3 7.0 10.0 11.0 17.1 7.9 4.3 9.9 19.7 13.7 12.3 11.1 6.7 11.3 0.8 1.8 1.8 3.2 1.1 3.7 2.2 3.3 2.6 3.6 3.6 4.0 4.7 3.4 2.9 1.3 2.9 4.3 1.3 16.0 16.7 29.7 16.0 15.3 11.5 17.2 13.3 14.2 18.4 SMARCA4 "BAF190, BRG1, FLJ39786, hSNF2b, SNF2, SNF2-BETA, SNF2L4, SNF2LB, SWI2" ENSG00000127616 "SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4" P51532 19 10960825-11079426 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Neurogenesis, Transcription, Transcription regulation" "Activator, Chromatin regulator, Helicase, Hydrolase, Repressor, RNA-binding" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB004208 Supported Supported Nucleoplasm 260000 Nucleoplasm "CAB004208: AB_626762" "unprognostic (2.68e-1)" "unprognostic (4.85e-2)" "unprognostic (1.71e-1)" "unprognostic (3.43e-3)" "unprognostic (1.40e-1)" "unprognostic (6.33e-3)" "prognostic unfavourable (1.11e-4)" "unprognostic (7.19e-2)" "unprognostic (7.29e-2)" "unprognostic (1.73e-2)" "unprognostic (1.97e-1)" "unprognostic (1.15e-2)" "unprognostic (6.80e-3)" "unprognostic (6.83e-3)" "unprognostic (5.44e-2)" "unprognostic (1.01e-1)" "unprognostic (1.29e-1)" 10.3 12.4 15.5 18.0 21.3 20.5 10.9 29.1 28.0 13.2 12.8 16.6 9.7 14.3 16.6 9.4 24.7 15.7 12.8 11.6 14.4 17.7 13.0 9.9 13.0 18.1 17.1 16.8 13.6 13.4 18.1 11.5 14.6 16.1 13.3 9.4 17.3 18.2 12.5 21.9 20.4 12.0 10.6 16.1 13.2 14.5 22.2 12.4 58.2 15.5 10.1 21.5 15.2 12.6 9.8 11.2 8.6 13.5 11.4 13.7 5.9 20.5 1.1 36.7 34.7 7.2 6.1 16.1 14.3 8.6 17.5 13.0 28.7 0.9 48.3 22.2 12.5 15.1 28.6 17.7 9.7 19.8 21.5 38.5 18.2 33.3 10.9 27.9 19.2 10.3 8.6 14.7 15.2 15.6 34.4 18.2 13.7 42.0 46.2 23.9 37.3 31.1 49.3 23.2 25.0 11.2 26.1 41.8 37.9 15.2 19.6 16.3 16.6 20.9 20.7 26.1 13.6 23.8 23.6 37.7 41.8 48.0 14.8 26.8 22.2 8.1 8.3 8.6 13.7 9.5 12.2 7.4 10.4 11.6 8.5 9.8 11.4 11.2 5.2 11.4 13.5 11.2 8.8 5.9 15.5 21.3 29.1 28.0 14.4 17.7 17.1 16.8 16.1 12.4 SMARCB1 "BAF47, hSNFS, Ini1, PPP1R144, RDT, Sfh1p, SNF5L1, Snr1" ENSG00000099956 "SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1" Q12824 22 23786931-23838008 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Host-virus interaction, Neurogenesis, Transcription, Transcription regulation" "Activator, Chromatin regulator, DNA-binding" "Cancer-related genes, Disease mutation, Hypotrichosis, Mental retardation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "AF22: 19.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009196, HPA018248, HPA019127" Supported Supported "Nucleoplasm,Nucleoli fibrillar center" Nucleoplasm "Nucleoli fibrillar center" "CAB009196: AB_2191983, HPA018248: AB_1851162, HPA019127: AB_1851165" "unprognostic (2.15e-1)" "unprognostic (5.62e-2)" "unprognostic (6.60e-3)" "unprognostic (1.63e-2)" "unprognostic (4.01e-3)" "unprognostic (2.14e-1)" "prognostic unfavourable (6.52e-4)" "unprognostic (4.10e-1)" "unprognostic (1.86e-1)" "unprognostic (1.03e-2)" "unprognostic (2.10e-2)" "unprognostic (4.43e-3)" "prognostic favourable (1.14e-6)" "unprognostic (1.24e-1)" "unprognostic (4.58e-2)" "unprognostic (4.57e-2)" "unprognostic (7.04e-2)" 11.0 15.2 14.6 33.2 15.4 16.9 12.1 30.4 21.9 13.4 25.1 16.4 11.4 41.1 17.2 11.0 15.6 12.3 15.0 12.6 13.2 14.2 14.6 11.7 14.0 32.8 13.0 13.8 21.3 16.1 7.9 15.7 20.8 12.8 11.0 9.4 16.7 40.9 13.1 28.1 14.7 27.4 10.6 12.8 19.8 24.1 37.7 12.9 29.4 15.7 12.0 16.0 21.1 12.2 19.5 9.9 4.8 11.6 7.0 7.5 5.9 1.5 1.0 19.0 1.7 1.8 0.5 3.8 6.0 1.8 1.8 2.9 2.2 1.8 15.5 5.2 0.8 2.9 4.5 2.9 3.0 2.5 6.6 12.9 1.7 1.3 2.0 13.6 3.8 1.1 2.2 2.1 4.7 0.9 3.5 8.6 1.1 3.8 11.1 3.1 5.7 3.8 7.0 15.3 7.0 1.5 3.0 9.0 6.8 1.4 0.4 10.2 1.4 2.1 1.6 1.6 6.6 2.6 1.7 9.5 8.7 10.3 1.3 7.5 4.6 4.0 10.0 4.8 3.8 10.2 5.2 19.5 4.6 4.6 9.3 6.4 3.8 2.5 0.8 7.0 11.6 9.9 7.5 5.9 14.6 15.4 30.4 21.9 13.2 14.2 13.0 13.8 12.8 12.9 SMARCD1 "BAF60A, CRACD1, Rsc6p" ENSG00000066117 "SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 1" Q96GM5 12 50084972-50100712 "Cancer-related genes, Predicted intracellular proteins" Neurogenesis "Chromatin regulator" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA004101 Supported Supported Nucleoplasm,Vesicles Nucleoplasm Vesicles "HPA004101: AB_1080026" "unprognostic (1.88e-1)" "unprognostic (1.89e-1)" "unprognostic (1.51e-1)" "unprognostic (2.11e-2)" "unprognostic (1.02e-1)" "unprognostic (2.76e-1)" "prognostic unfavourable (2.53e-8)" "unprognostic (3.62e-2)" "unprognostic (1.44e-1)" "unprognostic (4.23e-2)" "unprognostic (1.16e-2)" "unprognostic (2.10e-2)" "unprognostic (1.20e-3)" "unprognostic (2.18e-1)" "unprognostic (3.45e-1)" "unprognostic (1.38e-1)" "unprognostic (5.04e-2)" 21.3 24.5 16.4 22.6 22.7 29.9 21.3 27.8 28.2 19.8 19.9 29.5 17.6 18.8 23.6 23.4 23.3 19.9 18.2 15.6 16.3 13.8 25.1 18.3 19.4 26.1 15.7 20.4 24.7 19.6 44.3 17.8 24.7 18.8 20.4 22.4 20.3 21.4 25.9 16.6 19.7 24.0 23.8 18.5 28.1 17.4 34.4 14.9 64.3 24.3 17.9 36.7 19.3 18.2 6.0 6.7 4.4 3.4 3.1 6.9 2.3 8.0 13.6 40.3 23.3 12.6 11.9 20.0 10.1 17.9 29.7 17.4 37.4 12.7 31.6 15.2 19.2 10.4 34.0 26.4 25.7 24.4 25.1 31.1 13.8 21.6 15.0 27.5 12.5 12.0 17.8 17.5 31.8 34.9 26.3 19.6 15.0 19.0 39.9 14.8 50.4 22.4 47.9 10.5 27.6 16.8 19.0 21.8 36.3 21.2 10.8 42.1 24.3 23.1 20.9 15.3 17.1 9.6 20.5 27.7 24.3 28.1 12.4 11.2 17.3 4.4 2.3 4.1 6.1 2.1 5.8 6.0 3.3 3.9 3.6 5.6 2.1 6.9 1.1 3.1 3.4 6.7 5.0 2.3 16.4 22.7 27.8 28.2 16.3 13.8 15.7 20.4 18.8 14.9 SMARCE1 BAF57 ENSG00000073584 "SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, member 1" Q969G3 17 40624962-40648864 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" Neurogenesis "Chromatin regulator, DNA-binding" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003916, CAB037318" Supported Supported Nucleoplasm Nucleoplasm "CAB037318: AB_476780, HPA003916: AB_1857279" "unprognostic (7.91e-2)" "unprognostic (2.68e-2)" "unprognostic (2.09e-2)" "unprognostic (8.06e-3)" "unprognostic (1.87e-1)" "unprognostic (2.55e-2)" "unprognostic (4.48e-1)" "unprognostic (1.25e-2)" "unprognostic (2.20e-2)" "unprognostic (1.05e-1)" "unprognostic (2.53e-2)" "unprognostic (2.04e-1)" "unprognostic (9.80e-2)" "unprognostic (5.93e-2)" "unprognostic (7.63e-2)" "unprognostic (1.09e-1)" "unprognostic (1.27e-2)" 25.1 20.2 14.4 17.2 18.8 18.4 20.2 17.0 16.7 37.6 25.1 18.0 12.6 18.4 42.8 19.5 31.0 21.1 20.6 19.6 13.3 12.0 23.0 22.6 20.1 22.3 16.5 14.3 39.5 16.9 13.3 20.4 34.8 15.2 32.4 19.2 17.9 20.6 21.9 32.0 21.3 22.6 33.4 15.8 30.3 19.1 22.0 17.5 53.9 23.8 18.9 25.1 31.2 21.0 40.3 32.0 34.0 30.3 47.2 44.0 39.2 20.5 34.3 42.1 31.3 22.3 32.1 20.7 25.9 35.8 30.5 23.0 22.4 17.9 32.7 37.5 35.0 28.1 26.0 27.4 36.7 30.6 33.8 23.4 18.5 39.4 22.5 42.6 23.8 27.8 21.7 24.3 35.5 32.8 34.0 13.0 29.1 23.1 78.0 8.8 23.5 17.0 43.8 47.4 24.8 36.8 35.3 33.7 32.6 23.0 66.9 21.5 40.1 26.8 26.8 24.8 27.4 22.4 31.9 24.4 28.4 48.9 25.3 19.6 38.2 31.8 26.0 34.0 39.1 26.8 40.5 38.4 35.8 40.9 31.3 40.3 30.2 34.9 11.0 47.2 30.3 32.0 44.0 39.2 14.4 18.8 17.0 16.7 13.3 12.0 16.5 14.3 15.2 17.5 SMC1A "DXS423E, KIAA0178, SB1.8, SMC1L1, Smcb" ENSG00000072501 "Structural maintenance of chromosomes 1A" Q14683 X 53374149-53422728 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division, DNA damage, DNA repair, Meiosis, Mitosis" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA005499, CAB025404" Supported Enhanced Nucleoplasm Nucleoplasm "CAB025404: , HPA005499: AB_1080028" "unprognostic (2.00e-1)" "unprognostic (1.52e-1)" "unprognostic (4.00e-2)" "unprognostic (5.76e-2)" "unprognostic (1.04e-1)" "unprognostic (9.89e-2)" "unprognostic (1.29e-3)" "unprognostic (1.89e-1)" "unprognostic (9.80e-3)" "unprognostic (9.49e-2)" "unprognostic (4.48e-2)" "unprognostic (6.55e-2)" "unprognostic (2.58e-1)" "unprognostic (4.18e-3)" "unprognostic (6.28e-2)" "unprognostic (2.89e-1)" "unprognostic (9.39e-2)" 20.6 14.1 14.6 24.2 28.2 24.6 16.2 33.6 21.7 19.9 18.2 22.0 10.5 16.2 27.5 10.0 22.4 21.7 12.5 16.2 16.8 10.8 19.2 23.5 15.4 30.2 25.2 13.0 21.8 17.2 31.0 18.4 19.5 18.0 13.4 17.3 12.5 16.8 12.9 24.3 16.2 19.7 21.7 21.3 20.1 17.5 10.4 25.8 38.3 16.8 11.1 25.7 22.0 21.3 14.3 15.5 13.7 18.7 15.6 17.8 10.6 28.2 31.7 25.2 21.5 9.3 10.3 14.1 17.1 11.3 21.7 17.6 18.8 16.5 27.6 14.7 11.4 21.6 44.9 24.7 24.3 23.6 52.3 24.1 36.8 13.1 3.8 34.0 34.6 5.8 6.4 24.3 14.8 18.7 35.4 17.8 16.9 17.1 30.6 10.3 37.4 16.9 32.9 43.5 25.5 9.2 18.6 26.8 22.6 44.7 22.1 9.4 23.7 13.9 10.5 18.5 19.6 18.3 16.6 11.7 19.7 25.6 10.6 38.7 18.1 6.1 13.8 13.7 17.8 18.7 17.0 12.2 12.0 15.6 15.5 14.3 14.2 10.9 9.4 15.6 17.4 12.9 8.8 10.6 14.6 28.2 33.6 21.7 16.8 10.8 25.2 13.0 18.0 25.8 SMC3 "BAM, bamacan, CSPG6, HCAP, SMC3L1" ENSG00000108055 "Structural maintenance of chromosomes 3" Q9UQE7 10 110567691-110604636 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division, DNA damage, DNA repair, Meiosis, Mitosis" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA037411, HPA043206" Uncertain Supported Nucleoplasm 10000000 Nucleoplasm "HPA037411: AB_10671753, HPA043206: " "unprognostic (3.40e-1)" "unprognostic (1.73e-2)" "unprognostic (9.05e-2)" "unprognostic (3.00e-2)" "unprognostic (3.73e-2)" "unprognostic (8.89e-3)" "unprognostic (9.74e-3)" "unprognostic (8.06e-2)" "unprognostic (5.31e-2)" "unprognostic (6.32e-2)" "unprognostic (3.53e-2)" "unprognostic (1.17e-2)" "unprognostic (8.73e-3)" "unprognostic (7.22e-2)" "unprognostic (5.18e-2)" "unprognostic (7.95e-2)" "unprognostic (1.32e-1)" 17.1 13.4 16.8 15.4 22.9 32.7 21.3 37.8 18.0 19.2 15.1 9.9 10.7 13.3 20.1 14.3 19.7 15.6 9.9 11.9 16.7 11.2 16.6 17.2 12.6 23.7 18.6 15.4 26.5 18.4 22.2 36.6 22.9 17.7 14.6 15.1 8.8 15.3 14.3 18.4 18.4 18.8 19.6 22.2 18.1 13.5 32.0 23.2 47.4 19.4 11.4 20.8 20.7 19.7 13.2 11.0 19.1 10.5 15.1 17.7 7.4 26.8 16.8 36.6 26.0 12.2 10.5 15.8 21.8 21.8 20.2 19.9 21.2 22.7 35.1 9.6 14.6 21.5 26.2 13.2 30.9 28.6 22.5 28.3 21.2 19.0 12.2 40.2 21.9 8.3 10.8 22.3 35.2 14.8 22.5 27.2 17.4 14.1 30.9 21.4 25.2 13.5 26.3 66.3 19.0 12.5 12.0 20.9 23.9 23.5 6.8 17.9 10.9 19.7 15.2 16.3 25.8 18.3 31.4 15.8 14.1 38.0 14.5 38.8 13.3 19.1 7.7 18.6 13.0 10.5 16.1 13.2 15.1 14.0 8.4 13.1 15.5 15.1 8.4 15.1 8.9 11.0 17.7 7.4 16.8 22.9 37.8 18.0 16.7 11.2 18.6 15.4 17.7 23.2 SMO "FZD11, SMOH" ENSG00000128602 "Smoothened, frizzled class receptor" Q99835 7 129188872-129213545 "Cancer-related genes, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Transporters" "Developmental protein, G-protein coupled receptor, Receptor, Transducer" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "AF22: 20.0;AN3-CA: 37.1;NTERA-2: 28.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB011446 Approved "CAB011446: " "unprognostic (2.48e-2)" "unprognostic (2.69e-2)" "unprognostic (7.09e-2)" "unprognostic (1.10e-1)" "unprognostic (8.16e-2)" "unprognostic (2.02e-1)" "unprognostic (3.63e-1)" "unprognostic (5.89e-2)" "unprognostic (5.38e-3)" "unprognostic (1.59e-1)" "unprognostic (1.17e-2)" "unprognostic (8.74e-3)" "unprognostic (1.62e-1)" "unprognostic (5.15e-3)" "unprognostic (2.09e-1)" "unprognostic (2.25e-1)" "unprognostic (2.61e-2)" 4.0 4.1 4.2 3.8 4.8 0.5 7.4 5.3 4.6 18.2 5.8 5.1 9.2 2.5 20.9 18.7 10.3 11.4 10.0 5.2 8.4 3.7 10.6 13.7 2.4 2.0 4.3 4.5 23.0 7.1 14.4 13.5 2.6 9.0 18.4 2.2 17.2 9.4 12.8 3.5 16.6 3.5 9.8 7.0 2.0 4.2 7.9 3.4 5.3 9.2 6.8 4.6 6.3 17.6 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.6 7.8 20.0 37.1 0.5 0.1 6.3 2.2 2.9 4.4 2.6 6.0 0.1 0.0 6.1 4.4 12.2 12.0 0.6 1.7 0.0 9.8 3.9 0.0 9.6 2.5 0.1 0.0 7.3 4.9 1.4 0.0 2.5 0.6 0.0 1.3 0.0 10.2 0.0 28.4 2.2 14.8 8.5 0.0 2.3 0.0 0.6 13.4 0.0 0.0 5.2 4.9 2.5 0.0 0.3 6.4 7.7 4.2 0.4 0.0 0.0 0.0 0.0 7.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.2 4.8 5.3 4.6 8.4 3.7 4.3 4.5 9.0 3.4 SMYD3 "KMT3E, ZMYND1, ZNFN3A1" ENSG00000185420 "SET and MYND domain containing 3" Q9H7B4 1 245749342-246507312 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Chromatin regulator, Methyltransferase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HMC-1: 92.9;K-562: 35.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB012229, HPA045821, HPA054352" Approved Approved Nucleoplasm,Cytosol Nucleoplasm Cytosol "CAB012229: , HPA045821: , HPA054352: " "unprognostic (7.00e-3)" "unprognostic (7.45e-2)" "unprognostic (1.52e-1)" "unprognostic (6.18e-3)" "unprognostic (3.32e-2)" "unprognostic (5.08e-3)" "unprognostic (3.25e-3)" "unprognostic (1.72e-3)" "unprognostic (4.53e-2)" "unprognostic (1.57e-1)" "unprognostic (1.71e-1)" "unprognostic (2.10e-1)" "unprognostic (3.78e-5)" "unprognostic (9.03e-3)" "unprognostic (2.14e-1)" "unprognostic (1.08e-2)" "unprognostic (1.58e-1)" 6.0 12.0 9.9 9.7 16.2 7.6 10.6 25.9 14.7 8.9 6.5 6.4 3.7 4.5 8.7 21.8 6.1 10.0 7.7 5.8 10.3 12.0 8.9 5.5 9.2 6.3 12.0 10.2 8.0 7.2 6.7 11.9 4.6 15.3 6.8 8.3 9.5 5.3 5.9 9.5 6.7 5.2 7.6 6.8 5.3 6.1 10.5 8.1 7.5 18.8 3.6 9.3 8.3 6.6 11.3 5.9 8.3 3.4 19.4 12.9 8.7 4.6 2.8 4.1 3.5 4.7 6.4 4.1 6.5 4.9 7.7 17.3 3.7 5.4 7.6 5.3 6.0 3.0 3.7 7.3 25.9 4.0 3.8 4.4 4.2 4.4 8.8 4.4 92.9 17.3 1.7 10.2 6.6 5.2 35.1 2.6 7.5 1.6 8.5 8.6 3.7 4.5 7.9 5.0 10.9 5.6 6.8 9.8 4.7 3.1 0.4 5.9 3.8 7.6 4.0 3.7 2.6 2.6 7.7 13.3 3.6 3.9 7.1 6.1 4.3 8.1 3.4 8.3 10.5 3.0 10.8 11.3 11.1 12.8 5.9 11.1 12.3 12.9 2.4 19.4 3.3 3.8 11.8 8.7 9.9 16.2 25.9 14.7 10.3 12.0 12.0 10.2 15.3 8.1 SND1 "p100, TDRD11" ENSG00000197157 "Staphylococcal nuclease and tudor domain containing 1" Q7KZF4 7 127652180-128092609 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction, Transcription, Transcription regulation" "Endonuclease, Hydrolase, Nuclease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002529, HPA002632, CAB019323" Enhanced Enhanced Cytosol 1200000 Cytosol "CAB019323: , HPA002529: AB_1857317, HPA002632: AB_1857316" "unprognostic (2.06e-1)" "unprognostic (8.27e-3)" "unprognostic (2.21e-1)" "prognostic favourable (1.95e-4)" "unprognostic (5.10e-3)" "unprognostic (6.83e-2)" "unprognostic (1.17e-2)" "unprognostic (2.91e-2)" "unprognostic (4.22e-2)" "unprognostic (3.81e-2)" "unprognostic (1.56e-1)" "unprognostic (2.30e-1)" "unprognostic (1.36e-2)" "unprognostic (9.96e-2)" "unprognostic (1.99e-1)" "unprognostic (3.42e-2)" "unprognostic (2.26e-3)" 21.5 29.8 25.3 25.3 19.8 22.5 45.4 28.1 28.1 33.3 20.0 13.0 57.7 21.3 36.1 38.4 24.8 26.7 25.3 28.3 20.9 16.6 17.3 39.6 38.8 64.2 20.2 19.0 39.7 130.3 22.2 30.3 33.7 27.6 24.5 20.2 13.9 37.5 66.7 20.5 21.5 19.2 41.0 40.1 24.9 30.8 37.0 18.0 22.3 26.6 13.5 24.9 26.5 24.2 28.1 34.9 16.1 30.0 21.0 30.9 28.5 27.9 25.4 19.5 35.3 29.5 30.9 26.7 33.0 39.0 30.2 34.0 32.8 24.3 37.2 16.7 40.4 23.5 27.4 35.8 29.6 20.3 23.2 20.5 30.4 31.4 53.8 31.7 20.2 45.5 39.9 25.8 43.3 37.5 22.7 37.4 30.1 20.9 34.5 23.8 21.8 31.7 24.1 17.4 83.2 23.7 19.8 24.5 26.5 23.9 111.1 38.2 13.9 22.6 37.2 24.6 16.1 44.6 25.6 46.1 17.3 39.1 49.4 27.4 44.5 16.1 30.0 5.9 26.1 28.1 30.9 28.1 19.8 21.0 32.3 16.2 14.3 15.8 2.2 21.0 22.8 34.9 15.8 28.5 25.3 19.8 28.1 28.1 20.9 16.6 20.2 19.0 27.6 18.0 SNX25 SBBI31 ENSG00000109762 "Sorting nexin 25" Q9H3E2 4 185204237-185370185 "Cancer-related genes, Predicted intracellular proteins" "Protein transport, Transport" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "HDLM-2: 27.8" "Low cancer specificity" "Detected in all" "Cell type enhanced" "Detected in some" "naive B-cell: 3.6" "Group enriched" "Detected in many" 4 "B-cells: 3.6;T-cells: 1.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA036928 Supported Vesicles Vesicles "HPA036928: AB_10669720" "unprognostic (9.20e-2)" "unprognostic (1.31e-1)" "unprognostic (2.26e-1)" "unprognostic (4.29e-3)" "unprognostic (8.89e-2)" "unprognostic (5.63e-2)" "unprognostic (1.43e-2)" "unprognostic (6.41e-2)" "unprognostic (5.35e-2)" "unprognostic (2.99e-2)" "unprognostic (4.03e-3)" "unprognostic (1.87e-1)" "unprognostic (3.33e-1)" "unprognostic (1.13e-1)" "unprognostic (1.57e-1)" "unprognostic (1.32e-2)" "unprognostic (8.55e-3)" 3.0 3.7 2.6 2.9 5.3 0.1 4.6 11.9 4.2 2.7 5.6 1.1 3.3 2.8 3.1 4.7 3.9 4.4 3.3 5.6 5.6 4.1 15.1 4.9 4.6 3.4 4.6 7.2 5.7 5.6 7.9 3.0 2.8 4.3 4.8 2.5 3.5 3.1 2.1 4.2 2.6 5.9 8.5 6.0 3.8 2.2 3.6 0.2 0.0 0.2 0.6 1.5 0.2 5.8 3.1 3.9 5.6 10.6 7.9 5.9 18.0 8.6 9.1 7.6 2.6 4.1 16.8 2.0 12.8 2.3 4.5 3.9 10.3 27.8 7.5 2.8 3.8 6.1 6.2 1.9 4.1 5.4 4.3 7.9 4.4 7.9 5.9 16.9 12.0 1.7 0.7 3.3 3.2 3.0 2.4 4.5 4.2 22.1 2.2 8.5 6.2 3.7 1.0 14.7 2.1 2.4 15.2 5.2 3.4 5.0 7.8 15.3 6.2 3.6 8.6 1.4 6.5 0.0 0.0 0.0 0.6 0.2 1.0 2.5 1.3 1.5 0.0 3.6 0.4 0.9 0.0 0.6 0.0 0.2 0.8 0.2 SOCS1 "Cish1, JAB, SOCS-1, SSI-1, TIP3" ENSG00000185338 "Suppressor of cytokine signaling 1" O15524 16 11254405-11256200 "Cancer-related genes, Predicted intracellular proteins" "Growth regulation, Ubl conjugation pathway" "Signal transduction inhibitor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 42.3;lymphoid tissue: 58.3" "Cell line enriched" "Detected in some" 5 "HDLM-2: 47.2" "Low cancer specificity" "Detected in all" "Region enriched" "Detected in many" 6 "cerebellum: 15.2" "Cell type enhanced" "Detected in many" "basophil: 12.9" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "Low region specificity" "Detected in many" "CAB010355, HPA074108" Approved Supported "Nucleoplasm,Cytoplasmic bodies" Nucleoplasm "Cytoplasmic bodies" "CAB010355: AB_2193144, HPA074108: " "unprognostic (4.50e-3)" "unprognostic (3.30e-2)" "unprognostic (1.24e-1)" "unprognostic (1.66e-2)" "unprognostic (1.25e-2)" "prognostic favourable (1.10e-4)" "unprognostic (1.71e-2)" "unprognostic (4.09e-3)" "unprognostic (5.31e-3)" "unprognostic (4.82e-2)" "unprognostic (1.17e-1)" "unprognostic (5.39e-2)" "prognostic unfavourable (1.08e-6)" "unprognostic (1.56e-1)" "unprognostic (5.68e-2)" "unprognostic (6.08e-2)" "unprognostic (1.67e-1)" 10.9 2.8 0.7 19.2 1.5 13.9 37.9 15.2 1.1 15.8 6.3 0.3 2.2 3.3 4.9 7.6 5.6 4.2 11.0 3.6 0.6 1.0 11.1 42.3 9.6 25.8 0.8 0.0 9.3 3.8 0.7 16.8 9.3 2.4 5.3 1.8 3.2 3.7 3.9 2.3 6.0 11.0 6.5 1.1 14.7 6.6 7.1 0.4 58.3 5.1 4.8 14.7 5.4 8.3 4.4 1.3 12.9 0.1 5.5 2.7 0.4 1.2 0.2 0.5 0.1 1.6 0.2 1.8 1.0 7.3 0.4 0.6 0.3 0.2 2.8 2.2 0.4 0.5 0.2 0.1 0.1 47.2 0.3 0.7 0.0 3.8 0.6 0.0 8.7 0.6 0.1 1.0 0.0 0.1 6.3 0.8 0.0 1.1 3.1 1.8 5.3 0.8 0.3 0.3 0.3 0.5 0.2 0.7 0.1 0.2 1.7 0.5 0.0 0.4 0.0 0.6 3.1 0.4 0.6 0.2 0.2 4.4 1.2 0.3 0.6 12.9 0.1 8.8 2.2 0.0 2.0 1.4 2.5 2.7 0.0 4.4 2.7 2.5 0.3 5.5 0.0 1.3 2.6 0.4 0.7 1.5 15.2 0.6 0.6 1.0 0.8 0.0 2.4 0.4 SOD1 "ALS, ALS1, IPOA" ENSG00000142168 "Superoxide dismutase 1" P00441 21 31659622-31668931 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Antioxidant, Oxidoreductase" "Amyotrophic lateral sclerosis, Cancer-related genes, Disease mutation, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 282.6" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001401, CAB008670" Enhanced Supported "Nucleoplasm,Plasma membrane,Cytosol" 91000000 "Nucleoplasm, Plasma membrane, Cytosol" "CAB008670: AB_1623312, HPA001401: AB_1080132" "unprognostic (1.73e-1)" "unprognostic (1.18e-2)" "unprognostic (4.43e-1)" "unprognostic (6.19e-2)" "unprognostic (1.39e-1)" "unprognostic (9.59e-3)" "unprognostic (8.34e-2)" "unprognostic (2.30e-1)" "unprognostic (3.47e-1)" "unprognostic (5.28e-2)" "unprognostic (9.33e-2)" "unprognostic (1.96e-1)" "unprognostic (1.03e-2)" "unprognostic (1.66e-1)" "unprognostic (1.74e-2)" "unprognostic (1.57e-1)" "unprognostic (3.26e-2)" 39.2 86.5 71.1 29.1 74.3 24.6 108.6 35.6 74.9 26.8 37.7 19.1 35.4 62.5 24.6 42.2 25.8 36.0 46.8 96.5 77.8 73.1 84.0 282.6 23.0 26.8 80.2 67.0 53.9 27.2 27.1 30.4 29.7 96.1 35.1 32.6 19.3 19.7 39.3 83.9 20.5 45.5 45.2 88.2 19.2 25.8 22.2 43.8 12.3 30.1 34.7 25.6 25.4 124.0 57.6 32.3 24.9 57.2 29.6 95.6 55.6 55.6 48.7 34.2 34.2 45.8 31.9 28.4 47.0 28.1 32.0 24.2 63.1 35.4 66.7 49.5 43.3 20.2 49.0 34.6 26.4 49.2 60.9 107.6 63.9 90.2 30.3 47.5 40.3 33.1 26.4 44.8 24.9 35.9 74.2 85.3 38.5 90.4 51.0 47.9 51.4 52.0 43.9 69.0 103.7 62.5 34.2 37.4 31.4 87.1 46.1 45.2 53.0 42.0 42.0 24.9 55.1 33.6 34.6 65.2 141.0 79.0 50.8 69.3 33.0 22.1 21.9 24.9 45.0 30.2 51.6 57.6 73.1 56.9 28.6 40.9 76.2 59.3 5.1 29.6 57.2 32.3 95.6 55.6 71.1 74.3 35.6 74.9 77.8 73.1 80.2 67.0 96.1 43.8 SOS1 "GF1, GINGF, HGF" ENSG00000115904 "SOS Ras/Rac guanine nucleotide exchange factor 1" Q07889 2 38981396-39124345 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins" "Guanine-nucleotide releasing factor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HMC-1: 55.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB005396 Uncertain Approved Cytosol Cytosol "CAB005396: AB_2270724" "unprognostic (6.68e-2)" "unprognostic (2.12e-2)" "unprognostic (1.01e-1)" "unprognostic (4.14e-3)" "unprognostic (4.02e-2)" "unprognostic (5.14e-2)" "unprognostic (1.74e-3)" "unprognostic (4.55e-2)" "unprognostic (1.10e-1)" "unprognostic (4.13e-2)" "unprognostic (1.24e-2)" "unprognostic (3.18e-2)" "unprognostic (1.38e-2)" "unprognostic (8.96e-3)" "unprognostic (7.61e-2)" "unprognostic (5.59e-2)" "unprognostic (1.33e-2)" 25.9 13.2 19.2 18.8 18.1 12.0 26.1 33.3 18.6 18.6 21.9 12.1 15.3 18.3 19.1 14.6 17.4 17.0 18.1 16.4 17.9 14.1 14.6 15.2 19.9 19.9 18.2 14.0 28.1 13.0 33.5 21.7 21.5 17.8 18.4 16.8 14.6 15.9 18.1 26.2 15.0 23.1 22.3 14.6 16.2 20.1 12.7 20.1 23.1 19.4 12.9 21.8 25.1 22.0 3.2 1.4 3.2 2.0 6.2 4.6 0.9 9.7 6.0 9.4 6.7 12.7 15.2 9.8 6.2 7.6 4.9 4.7 6.5 5.9 14.2 4.2 8.0 5.8 11.0 5.6 9.2 14.2 4.9 22.0 5.2 8.9 5.2 7.0 55.8 9.3 9.0 6.7 6.5 7.7 9.3 6.7 6.3 5.3 7.5 6.5 5.8 4.3 8.4 8.5 4.1 5.2 7.9 9.1 9.1 7.3 13.2 7.6 4.2 3.7 8.6 8.2 6.7 6.4 6.1 7.9 8.0 7.5 6.6 6.9 4.9 0.0 1.2 3.2 3.2 1.8 4.6 3.2 3.3 3.3 1.0 2.4 3.7 3.4 1.4 6.2 2.0 1.4 1.9 0.9 19.2 18.1 33.3 18.6 17.9 14.1 18.2 14.0 17.8 20.1 SOX17 ENSG00000164736 "SRY-box 17" Q9H6I2 8 54457935-54460888 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation, Wnt signaling pathway" "Activator, DNA-binding" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enriched" "Detected in some" 7 "EFO-21: 49.1" "Group enriched" "Detected in many" 12 "endometrial cancer: 122.8;ovarian cancer: 96.2;testis cancer: 25.3" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB025594, HPA068399" Enhanced Approved Nucleoplasm Nucleoplasm "CAB025594: , HPA068399: " "unprognostic (1.87e-1)" "unprognostic (1.13e-1)" "unprognostic (1.76e-3)" "prognostic favourable (2.76e-4)" "unprognostic (1.01e-1)" "unprognostic (3.85e-2)" "unprognostic (3.34e-2)" "unprognostic (1.28e-1)" "unprognostic (1.39e-2)" "unprognostic (7.90e-2)" "unprognostic (3.62e-2)" "unprognostic (1.18e-1)" "unprognostic (4.98e-2)" "unprognostic (7.28e-3)" "unprognostic (1.12e-1)" "unprognostic (3.76e-1)" "unprognostic (1.88e-1)" 26.7 2.0 1.2 9.1 1.8 0.6 31.3 0.6 2.9 25.7 7.9 1.5 1.0 1.4 23.9 7.1 11.6 23.1 20.2 20.6 1.5 1.3 3.0 2.2 8.7 1.5 2.0 1.0 13.0 1.5 1.7 1.5 9.9 2.3 7.6 1.6 3.6 2.4 3.0 13.3 3.1 3.3 5.9 1.8 15.7 3.7 5.8 0.4 0.8 3.6 6.2 1.3 12.3 5.8 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 49.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.3 0.0 0.0 0.0 0.0 0.8 0.1 6.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.5 0.0 1.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 1.8 0.6 2.9 1.5 1.3 2.0 1.0 2.3 0.4 SOX2 ENSG00000181449 "SRY-box 2" P48431 3 181711924-181714436 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding" "Cancer-related genes, Disease mutation, Microphthalmia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "brain: 80.1" "Cell line enhanced" "Detected in some" "AF22: 67.5;HAP1: 28.7;NTERA-2: 55.0;U-251 MG: 12.6" "Cancer enhanced" "Detected in many" "glioma: 136.5" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA045725, HPA062851, HPA071379, CAB079745" Enhanced Supported Enhanced Nucleoplasm Nucleoplasm "CAB079745: , HPA045725: , HPA062851: , HPA071379: " "unprognostic (1.80e-2)" "unprognostic (3.18e-3)" "unprognostic (5.69e-2)" "unprognostic (6.96e-2)" "unprognostic (2.74e-3)" "unprognostic (1.60e-1)" "unprognostic (1.79e-2)" "unprognostic (4.48e-3)" "unprognostic (1.71e-1)" "unprognostic (4.38e-3)" "unprognostic (1.83e-1)" "unprognostic (7.68e-2)" "unprognostic (3.81e-9)" "unprognostic (1.12e-1)" "unprognostic (2.12e-1)" "unprognostic (1.26e-1)" "unprognostic (1.12e-2)" 1.8 2.5 30.3 2.0 25.8 1.5 1.6 13.9 80.1 1.8 2.3 24.3 0.0 2.0 1.5 1.8 15.9 5.0 1.8 1.7 36.0 19.2 1.5 1.5 3.4 1.5 19.4 18.5 1.7 1.6 1.5 5.8 1.5 18.6 3.9 2.0 1.0 6.3 1.9 1.6 1.8 2.3 1.7 18.4 1.6 9.7 3.0 22.4 0.0 1.5 2.1 6.9 2.3 1.7 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 2.1 67.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.6 0.0 0.0 0.0 0.0 0.1 28.7 0.7 0.0 0.0 4.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 55.0 0.1 0.0 0.1 0.0 7.4 0.1 0.1 0.3 0.0 0.0 0.0 0.4 0.0 0.0 0.0 1.0 0.0 12.6 0.0 0.0 0.0 0.0 0.0 8.5 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 30.3 25.8 13.9 20.0 36.0 19.2 19.4 18.5 18.6 22.4 SOX9 "CMD1, CMPD1, SRA1" ENSG00000125398 "SRY-box 9" P48436 17 72121020-72126420 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "salivary gland: 63.4" "Cell line enhanced" "Detected in many" "AN3-CA: 29.5;Hep G2: 35.3;U-251 MG: 24.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001758, CAB022456, CAB068240" Enhanced Enhanced Nucleoplasm Nucleoplasm "CAB022456: , CAB068240: , HPA001758: AB_1080067" "unprognostic (6.92e-2)" "unprognostic (1.73e-2)" "unprognostic (4.47e-3)" "unprognostic (4.43e-2)" "unprognostic (2.55e-2)" "unprognostic (7.96e-3)" "unprognostic (4.32e-3)" "prognostic unfavourable (2.07e-4)" "unprognostic (4.87e-2)" "unprognostic (3.31e-1)" "unprognostic (8.92e-3)" "unprognostic (1.21e-1)" "unprognostic (3.26e-3)" "unprognostic (2.77e-3)" "unprognostic (1.15e-1)" "unprognostic (8.88e-2)" "unprognostic (1.21e-2)" 3.1 2.6 32.2 4.3 31.6 1.1 23.4 20.3 32.4 7.4 14.6 28.4 8.1 16.6 3.5 1.9 7.7 7.4 11.7 9.5 35.5 15.7 11.7 3.9 3.4 1.9 14.6 13.7 1.2 31.9 1.2 7.0 1.4 21.3 21.7 15.7 12.9 63.4 14.4 3.0 13.1 12.9 2.1 15.6 1.3 35.2 25.2 20.2 0.0 17.8 5.3 5.0 1.9 3.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 11.2 7.1 14.8 29.5 1.5 0.4 0.0 1.8 1.5 3.1 1.7 9.9 15.3 0.0 1.1 0.4 11.6 0.0 6.9 2.9 0.0 0.9 0.0 1.5 35.3 0.1 0.0 0.0 0.2 0.6 3.6 3.4 0.0 0.0 0.0 4.4 0.1 0.0 0.0 0.5 11.0 0.0 11.9 0.1 13.3 0.7 0.7 0.7 1.5 1.7 0.0 6.3 0.1 0.0 6.1 16.5 3.2 24.3 0.0 0.0 0.0 4.3 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 32.2 31.6 20.3 26.7 35.5 15.7 14.6 13.7 21.3 20.2 SP1 ENSG00000185591 "Sp1 transcription factor" P08047 12 53380176-53416446 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Host-virus interaction, Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000330, HPA001853, HPA012292" Supported Enhanced Nucleoplasm Nucleoplasm "CAB000330: AB_2171049, HPA001853: AB_1080069, HPA012292: AB_1857394" "unprognostic (1.12e-1)" "unprognostic (8.52e-3)" "unprognostic (6.11e-2)" "unprognostic (1.24e-1)" "unprognostic (2.03e-1)" "unprognostic (4.64e-3)" "unprognostic (1.08e-2)" "unprognostic (2.53e-1)" "unprognostic (1.01e-1)" "unprognostic (2.66e-2)" "prognostic unfavourable (1.43e-4)" "unprognostic (6.38e-2)" "unprognostic (5.14e-2)" "unprognostic (4.05e-2)" "unprognostic (1.37e-1)" "unprognostic (4.77e-2)" "unprognostic (2.12e-2)" 20.7 18.1 8.8 13.9 14.2 17.0 20.1 30.0 14.7 20.9 21.9 17.5 19.3 19.6 25.4 21.2 35.0 20.4 18.7 12.1 14.1 6.8 31.3 14.1 17.6 14.2 18.3 9.7 22.5 17.9 19.0 11.3 19.5 14.4 16.2 20.1 21.5 25.8 19.5 22.0 25.8 30.0 18.4 21.0 19.0 18.8 22.4 15.2 25.8 16.6 17.3 26.6 25.1 21.6 2.7 3.0 11.2 4.2 1.7 2.8 1.4 17.7 19.5 22.3 16.3 18.0 20.8 17.8 12.8 16.6 15.8 14.6 16.2 35.6 24.1 17.0 14.7 25.7 25.6 17.4 17.7 18.4 14.9 21.2 24.7 8.8 12.6 19.3 17.9 21.9 18.1 16.2 31.5 16.2 20.3 34.9 11.6 25.4 28.8 14.8 12.3 14.7 20.5 21.5 14.2 12.4 32.1 11.8 15.7 26.0 21.9 13.2 27.5 20.7 15.6 18.6 17.4 13.8 13.6 12.0 13.8 24.1 14.2 16.1 14.8 4.5 4.2 2.5 2.2 2.7 2.8 2.3 2.2 2.1 2.4 2.7 2.4 2.6 11.2 1.7 3.1 3.0 1.6 1.4 8.8 14.2 30.0 14.7 14.1 6.8 18.3 9.7 14.4 15.2 SPARC ON ENSG00000113140 "Secreted protein acidic and cysteine rich" P09486 5 151661096-151687165 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Cancer-related genes, Disease mutation, Osteogenesis imperfecta" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "ASC diff: 230.6;BJ: 188.2;fHDF/TERT166: 297.7;WM-115: 218.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "neutrophil: 9.3" "Group enriched" "Detected in many" 7 "granulocytes: 9.3;monocytes: 3.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002306, HPA002989, HPA003020" Supported Approved Vesicles "Secreted to blood" 190000000 Vesicles "CAB002306: AB_563919, HPA002989: AB_1079532, HPA003020: AB_1079531" "unprognostic (3.34e-2)" "unprognostic (8.57e-2)" "unprognostic (1.31e-1)" "unprognostic (3.97e-1)" "unprognostic (7.01e-2)" "unprognostic (1.49e-1)" "unprognostic (2.05e-1)" "unprognostic (8.36e-3)" "unprognostic (5.27e-2)" "unprognostic (1.22e-1)" "unprognostic (4.09e-2)" "unprognostic (1.78e-1)" "prognostic unfavourable (3.53e-5)" "unprognostic (2.59e-3)" "unprognostic (1.17e-2)" "unprognostic (3.53e-1)" "unprognostic (4.93e-3)" 178.3 58.3 50.2 47.4 93.3 3.4 68.6 33.8 131.3 115.6 42.8 92.3 22.9 13.2 89.0 65.9 36.9 38.5 177.8 65.5 68.3 100.3 46.3 25.0 66.8 25.4 124.7 18.0 55.1 14.1 36.7 16.8 249.1 153.5 46.3 22.4 47.5 15.8 45.3 31.2 40.2 20.6 144.0 202.0 43.8 20.4 75.2 68.8 7.4 38.6 39.4 14.8 104.6 35.9 0.0 0.8 9.3 3.0 0.0 0.3 40.6 0.2 0.2 55.7 2.6 230.6 78.2 5.2 188.2 62.0 78.0 80.4 0.2 0.1 0.0 44.7 297.7 2.5 7.0 14.3 26.9 0.2 2.6 2.5 0.0 5.1 69.0 0.1 0.2 122.1 20.6 57.4 8.0 107.0 2.3 2.0 44.3 0.0 0.2 1.6 25.7 0.2 0.1 55.3 0.1 0.0 0.0 2.1 4.2 0.1 0.0 25.0 0.2 6.1 126.4 36.4 56.3 16.4 59.1 0.1 0.2 0.2 31.8 0.1 218.8 2.2 3.0 0.9 0.3 0.1 0.0 0.0 0.0 0.0 0.8 0.0 0.1 0.0 9.3 0.0 0.0 0.7 0.0 40.6 50.2 93.3 33.8 24.6 68.3 100.3 124.7 18.0 153.5 68.8 SPARCL1 MAST9 ENSG00000152583 "SPARC like 1" Q14515 4 87473335-87531061 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Group enriched" "Detected in some" 4 "AF22: 22.1;U-266/70: 8.7" "Cancer enhanced" "Detected in all" "glioma: 528.6" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB026225 Enhanced "Secreted in other tissues" 660000000 "CAB026225: " "unprognostic (1.02e-2)" "unprognostic (2.81e-2)" "prognostic unfavourable (4.06e-4)" "unprognostic (1.19e-1)" "unprognostic (1.79e-2)" "unprognostic (4.93e-2)" "unprognostic (1.63e-3)" "unprognostic (1.73e-2)" "unprognostic (3.88e-2)" "unprognostic (6.04e-2)" "unprognostic (1.28e-1)" "unprognostic (1.17e-1)" "unprognostic (2.45e-3)" "unprognostic (1.76e-2)" "unprognostic (5.72e-2)" "unprognostic (2.88e-3)" "prognostic unfavourable (3.33e-4)" 102.2 21.9 110.3 18.8 139.9 0.9 52.1 42.9 212.1 123.2 58.0 17.9 23.8 19.7 148.7 74.6 56.4 92.8 74.7 80.9 98.8 40.9 13.2 4.5 58.7 14.6 67.5 106.4 45.2 13.0 15.8 38.3 48.8 69.7 97.0 30.4 7.9 31.5 166.0 35.2 13.1 27.4 185.6 82.5 23.9 40.8 29.2 53.9 1.2 38.8 24.4 15.6 103.9 50.3 0.0 0.3 0.1 0.1 0.0 0.8 0.0 0.6 0.0 22.1 0.3 0.2 0.1 2.2 0.1 0.1 0.0 0.0 0.0 0.1 0.4 1.8 0.0 1.3 2.4 0.0 0.0 1.8 0.0 0.3 1.1 0.4 1.0 0.3 1.3 3.5 0.0 0.0 0.0 0.0 0.4 3.2 0.0 0.5 0.1 3.3 0.6 0.0 0.3 0.3 1.0 0.0 0.1 0.7 1.8 0.2 0.2 0.1 0.3 0.4 0.0 0.2 0.3 1.3 0.1 8.7 1.2 0.5 3.4 0.4 2.5 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.8 0.1 0.0 0.1 0.3 0.0 0.0 110.3 139.9 42.9 136.4 98.8 40.9 67.5 106.4 69.7 53.9 SPATA6 "FLJ10007, SRF-1, SRF1" ENSG00000132122 "Spermatogenesis associated 6" Q9NWH7 1 48295372-48472208 "Cancer-related genes, Predicted intracellular proteins" "Differentiation, Spermatogenesis" "Developmental protein" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "testis: 61.8" "Cell line enhanced" "Detected in many" "AN3-CA: 10.4;ASC TERT1: 17.6;HSkMC: 12.5" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "non-classical monocyte: 8.2" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA028234 Approved "Nucleoplasm,Golgi apparatus,Vesicles" "Intracellular and membrane" "Golgi apparatus, Vesicles" Nucleoplasm "HPA028234: " "unprognostic (1.36e-2)" "unprognostic (2.96e-2)" "unprognostic (3.38e-2)" "unprognostic (2.87e-2)" "unprognostic (3.22e-1)" "unprognostic (1.68e-1)" "unprognostic (1.77e-2)" "unprognostic (4.69e-3)" "unprognostic (2.40e-2)" "unprognostic (2.61e-2)" "unprognostic (8.41e-2)" "unprognostic (6.50e-2)" "unprognostic (3.41e-3)" "unprognostic (1.15e-1)" "unprognostic (1.01e-1)" "unprognostic (7.89e-2)" "unprognostic (5.71e-3)" 5.8 8.9 6.2 3.0 12.9 1.5 8.4 2.4 8.9 7.5 5.0 12.9 10.1 3.3 6.9 7.9 4.1 16.2 5.9 4.7 7.8 5.6 6.9 2.4 7.5 7.0 14.9 3.9 9.0 5.2 12.8 21.5 5.3 8.5 6.4 4.6 6.6 6.9 12.2 3.8 5.0 3.7 8.3 10.0 4.1 7.3 61.8 13.4 1.1 10.3 2.4 2.2 6.5 12.2 0.2 1.7 5.2 8.2 0.3 0.6 0.7 0.1 0.9 9.4 10.4 8.8 17.6 1.3 1.0 3.9 0.8 0.7 0.1 0.7 0.0 0.6 1.7 0.2 0.8 2.3 0.7 0.7 1.3 0.1 0.4 0.4 1.8 0.0 0.7 12.5 1.8 1.5 0.5 3.7 0.1 0.0 3.9 0.3 0.1 0.1 4.0 1.0 2.9 0.0 0.9 5.8 1.6 2.3 5.2 3.8 0.4 9.0 2.3 0.5 1.1 1.4 1.4 2.2 1.5 0.0 0.0 0.0 5.8 0.1 6.2 0.0 1.8 5.2 0.1 4.3 0.0 0.2 0.4 0.0 1.7 0.1 0.6 0.5 0.3 0.3 8.2 0.8 0.0 0.7 6.2 12.9 2.4 8.9 7.8 5.6 14.9 3.9 8.5 13.4 SPEN "KIAA0929, MINT, RBM15C, SHARP" ENSG00000065526 "Spen family transcriptional repressor" Q96T58 1 15847864-15940460 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction, Notch signaling pathway, Transcription, Transcription regulation" "Activator, DNA-binding, Repressor, RNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA015825, HPA050257" Supported Enhanced Nucleoplasm Nucleoplasm "HPA015825: AB_1856823, HPA050257: " "unprognostic (3.91e-1)" "unprognostic (1.74e-1)" "unprognostic (3.76e-1)" "unprognostic (2.04e-1)" "unprognostic (1.48e-1)" "unprognostic (3.06e-2)" "unprognostic (6.93e-3)" "unprognostic (2.26e-1)" "unprognostic (4.26e-2)" "unprognostic (4.88e-3)" "unprognostic (1.71e-1)" "unprognostic (5.98e-2)" "unprognostic (1.06e-3)" "unprognostic (1.49e-1)" "unprognostic (1.66e-1)" "unprognostic (2.26e-1)" "unprognostic (1.83e-1)" 18.2 11.2 18.2 18.2 22.2 27.2 17.3 38.2 25.9 18.5 13.4 20.7 17.7 11.9 19.0 12.7 16.7 19.4 11.8 13.5 17.6 11.5 14.4 13.2 17.8 16.6 23.4 17.5 31.2 23.9 35.1 17.5 16.2 19.0 14.9 13.3 11.6 16.2 16.2 24.0 22.8 16.0 15.1 22.0 16.5 13.7 13.6 23.3 18.3 20.1 8.7 18.0 17.1 41.9 5.0 2.7 7.7 2.4 1.3 1.7 0.6 12.5 10.7 13.4 10.0 13.4 8.2 7.2 6.5 8.6 7.1 6.0 9.6 9.8 17.8 7.8 12.8 18.2 12.5 11.6 11.5 15.9 34.7 22.3 9.4 6.1 6.1 18.3 10.7 6.0 8.4 10.6 15.4 8.0 23.1 18.3 5.7 7.0 15.1 7.2 6.0 8.2 14.6 13.0 11.0 4.0 11.3 10.3 10.4 18.3 9.0 7.8 3.2 9.0 14.5 6.5 8.1 12.6 9.3 11.1 7.2 20.3 6.4 14.7 9.1 7.7 1.5 0.9 1.6 2.4 1.3 1.8 1.7 1.4 0.7 5.0 0.9 1.3 4.2 1.3 1.2 2.7 1.1 0.6 18.2 22.2 38.2 25.9 17.6 11.5 23.4 17.5 19.0 23.3 SPINK1 "PCTT, PSTI, Spink3, TATI" ENSG00000164266 "Serine peptidase inhibitor, Kazal type 1" P00995 5 147824568-147831786 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins" "Protease inhibitor, Serine protease inhibitor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 68 "pancreas: 1767.1" "Group enriched" "Detected in some" 8 "CACO-2: 43.1;RT4: 118.4" "Cancer enhanced" "Detected in many" "pancreatic cancer: 513.8" "Not detected" "Not detected" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in single" "Not detected" "Not detected" "Not detected" "Not detected" "CAB026366, HPA027498" Enhanced "Secreted to digestive system" 7900000 "CAB026366: , HPA027498: AB_10603115" "unprognostic (1.05e-1)" "unprognostic (1.00e-1)" "unprognostic (9.96e-3)" "unprognostic (3.55e-1)" "unprognostic (6.12e-3)" "unprognostic (1.79e-4)" "unprognostic (8.34e-3)" "unprognostic (2.43e-1)" "unprognostic (2.66e-1)" "unprognostic (1.88e-1)" "unprognostic (3.82e-2)" "unprognostic (8.13e-2)" "prognostic unfavourable (5.44e-7)" "unprognostic (7.98e-2)" "unprognostic (2.07e-1)" "prognostic favourable (2.15e-5)" 0.3 0.0 0.3 1.6 0.3 0.0 0.3 0.3 0.3 0.3 6.0 0.3 0.3 6.3 0.3 0.3 0.3 0.0 1.5 0.3 0.3 0.0 2.0 13.3 0.4 0.3 0.3 0.3 0.3 1767.1 0.0 0.3 0.3 0.3 1.4 6.4 0.3 0.3 0.3 0.3 0.0 6.9 1.0 0.3 0.3 25.8 0.4 0.3 0.3 0.3 0.3 0.3 13.1 2.2 0.7 0.5 1.9 0.5 0.3 0.6 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 43.1 0.0 0.0 0.8 0.0 0.1 0.2 0.0 0.0 0.4 0.0 0.0 0.0 10.7 0.0 0.0 0.5 0.0 0.2 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.0 0.0 0.0 0.2 0.0 118.4 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.1 0.4 0.3 0.5 0.2 2.1 0.0 0.0 1.9 0.4 0.2 0.4 0.5 0.2 0.4 0.4 0.3 0.1 0.7 0.5 0.6 1.8 0.3 0.4 0.5 0.1 0.1 0.3 0.3 0.3 0.3 0.3 0.0 0.3 0.3 0.3 0.3 SPINT1 "HAI, MANSC2" ENSG00000166145 "Serine peptidase inhibitor, Kunitz type 1" O43278 15 40844018-40858207 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" "Protease inhibitor, Serine protease inhibitor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 121.0" "Cell line enhanced" "Detected in many" "BEWO: 51.3;HaCaT: 58.6;hTCEpi: 41.7;RT4: 47.5;SK-BR-3: 88.0;T-47d: 42.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in some" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in single" "Not detected" "Not detected" "HPA006903, HPA031178" Uncertain Supported "Nucleoplasm,Plasma membrane,Cytosol" "Secreted to blood" 3400000 "Plasma membrane, Cytosol" Nucleoplasm "HPA006903: AB_1079038, HPA031178: " "prognostic unfavourable (6.97e-4)" "unprognostic (1.00e-3)" "unprognostic (3.00e-3)" "unprognostic (5.03e-2)" "unprognostic (6.06e-2)" "unprognostic (3.19e-1)" "unprognostic (5.94e-2)" "unprognostic (6.04e-2)" "unprognostic (8.24e-3)" "unprognostic (1.46e-2)" "unprognostic (1.09e-3)" "unprognostic (1.01e-1)" "prognostic favourable (1.37e-7)" "unprognostic (5.37e-2)" "unprognostic (2.22e-1)" "unprognostic (6.45e-3)" "unprognostic (2.17e-2)" 2.2 0.5 0.9 11.6 1.2 0.0 12.6 2.9 0.8 12.9 64.4 1.2 38.6 31.9 3.6 25.5 71.1 6.4 30.7 0.8 0.8 0.7 27.9 1.5 18.5 3.7 0.9 0.6 3.4 25.0 28.8 9.7 85.5 1.3 17.5 17.9 3.2 50.8 24.0 0.6 39.1 121.0 2.3 1.0 3.1 17.6 1.9 0.7 4.8 15.4 26.9 44.3 12.8 21.5 5.1 19.0 15.3 10.9 3.6 1.8 3.8 18.8 0.1 0.0 0.1 0.0 0.0 51.3 0.3 0.4 0.6 0.3 30.0 31.5 0.0 22.5 0.0 58.6 4.8 28.2 0.4 0.1 1.6 0.8 0.5 1.6 0.3 3.3 14.9 0.0 41.7 0.6 2.6 2.3 0.4 0.1 0.0 14.6 0.1 2.5 5.8 2.7 1.9 0.0 3.7 28.4 47.5 12.6 0.6 1.4 88.0 2.3 42.0 2.4 0.0 0.0 0.3 0.1 0.0 0.1 3.5 0.1 0.1 2.4 0.1 0.0 10.9 7.9 0.3 9.3 0.5 5.1 1.8 0.8 19.0 3.9 0.7 0.2 15.3 3.6 9.6 2.3 0.2 3.8 0.9 1.2 2.9 0.8 0.8 0.7 0.9 0.6 1.3 0.7 SPINT2 "HAI-2, Kop" ENSG00000167642 "Serine peptidase inhibitor, Kunitz type 2" O43291 19 38244035-38292614 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Protease inhibitor, Serine protease inhibitor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "A-431: 81.3;CAPAN-2: 120.0;hTCEpi: 66.8;RPTEC TERT1: 89.5;RT4: 69.4;SK-BR-3: 78.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA011101, CAB018969" Approved Uncertain "Plasma membrane,Intermediate filaments,Cytosol" "Plasma membrane, Intermediate filaments, Cytosol" "CAB018969: , HPA011101: AB_1079039" "unprognostic (5.13e-2)" "unprognostic (1.06e-3)" "unprognostic (1.40e-1)" "unprognostic (6.25e-2)" "unprognostic (1.13e-1)" "unprognostic (1.91e-2)" "unprognostic (2.23e-1)" "unprognostic (2.03e-2)" "unprognostic (3.51e-1)" "unprognostic (1.67e-2)" "unprognostic (2.89e-2)" "unprognostic (2.04e-1)" "prognostic favourable (3.41e-4)" "unprognostic (3.59e-1)" "unprognostic (1.32e-1)" "unprognostic (6.94e-2)" "unprognostic (2.68e-2)" 1.5 7.2 11.9 15.1 14.0 10.7 29.2 14.3 20.8 24.0 46.3 4.7 63.2 38.3 7.1 44.9 60.6 30.4 51.8 3.3 10.4 22.9 47.5 2.8 25.6 10.3 9.3 14.6 15.3 78.7 30.2 82.7 77.3 11.0 29.6 40.3 15.3 143.1 61.6 0.7 41.7 82.3 13.1 5.6 9.4 34.1 87.0 2.8 15.0 95.6 32.0 37.5 27.1 25.0 23.1 73.9 70.7 17.9 2.6 13.2 17.6 81.3 59.1 0.3 0.3 0.0 0.0 38.7 1.5 0.1 0.1 0.2 41.8 120.0 0.6 6.6 0.4 27.0 4.2 57.9 0.1 0.7 4.9 15.3 1.5 0.0 0.1 0.1 0.0 0.0 66.8 0.0 28.3 0.2 0.3 0.0 0.1 63.0 2.4 0.2 5.9 16.6 8.3 0.0 36.6 89.5 69.4 22.3 0.3 24.2 78.7 0.2 35.1 10.1 0.0 0.1 0.4 0.3 0.3 5.5 7.0 4.5 0.1 1.0 0.1 57.2 17.9 70.7 0.5 12.5 1.1 20.0 6.5 3.2 41.7 23.1 13.2 11.9 7.8 2.6 8.4 73.9 2.5 17.6 11.9 14.0 14.3 20.8 10.4 22.9 9.3 14.6 11.0 2.8 SPP1 "BNSP, BSPI, ETA-1, OPN" ENSG00000118785 "Secreted phosphoprotein 1" P10451 4 87975650-87983426 "Cancer-related genes, Plasma proteins, Predicted secreted proteins" "Biomineralization, Cell adhesion" Cytokine "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "gallbladder: 303.9;kidney: 700.7;placenta: 331.0" "Cell line enhanced" "Detected in some" "EFO-21: 213.7;Hep G2: 105.2;RPTEC TERT1: 466.7" "Cancer enhanced" "Detected in all" "glioma: 1690.9" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in some" 11 "neutrophil: 19.2" "Lineage enriched" "Detected in single" 192 "granulocytes: 19.2" "Region enhanced" "Detected in all" "pons and medulla: 331.4" "Low region specificity" "Detected in all" "CAB002212, HPA027540, HPA027541" Enhanced Enhanced "Golgi apparatus" "Secreted to blood" 180200000 54000000 "Golgi apparatus" "CAB002212: AB_564074, HPA027540: AB_10600222, HPA027541: AB_10601446" "unprognostic (4.74e-2)" "prognostic unfavourable (9.52e-4)" "unprognostic (1.13e-3)" "unprognostic (2.04e-1)" "unprognostic (2.31e-2)" "unprognostic (6.96e-3)" "prognostic unfavourable (2.84e-6)" "unprognostic (2.46e-3)" "unprognostic (7.86e-2)" "unprognostic (1.90e-2)" "prognostic unfavourable (5.89e-4)" "unprognostic (4.31e-2)" "unprognostic (2.55e-1)" "unprognostic (7.19e-2)" "unprognostic (1.57e-1)" "unprognostic (3.48e-1)" "unprognostic (2.63e-2)" 20.7 4.1 25.5 8.3 42.7 1.1 8.7 4.3 61.0 4.7 2.7 27.3 0.0 2.1 17.3 2.3 1.5 4.2 303.9 2.6 37.2 26.4 700.7 3.9 3.2 2.0 97.0 9.1 3.1 23.6 1.3 1.5 331.0 52.3 2.4 1.9 3.9 7.3 3.9 2.5 1.1 2.1 5.6 147.9 2.1 2.0 2.4 58.9 0.0 1.7 0.0 1.6 5.3 0.3 0.0 0.0 19.2 0.0 0.0 0.0 0.0 0.0 6.1 0.8 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.4 0.0 0.0 0.0 213.7 0.1 0.0 0.0 0.0 0.1 0.4 0.0 0.0 0.0 105.2 0.0 0.2 0.2 0.0 0.0 1.5 0.0 0.1 0.0 0.4 0.0 0.0 0.0 0.9 9.9 0.0 0.1 0.0 50.1 466.7 0.0 0.0 0.0 0.0 0.0 14.0 0.0 0.2 0.0 0.5 1.1 0.0 1.1 0.0 0.3 0.4 19.5 0.0 19.9 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 19.2 0.0 0.0 0.0 0.0 0.0 25.5 42.7 4.3 28.8 37.2 26.4 97.0 9.1 52.3 58.9 SPRR3 ENSG00000163209 "Small proline rich protein 3" Q9UBC9 1 153001747-153003856 "Cancer-related genes, Predicted intracellular proteins" Keratinization "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "esophagus: 855.8;lymphoid tissue: 537.4;tongue: 389.6" "Cell line enhanced" "Detected in some" "CAPAN-2: 6.7;hTCEpi: 10.9;RT4: 13.9;TIME: 3.9" "Cancer enhanced" "Detected in many" "head and neck cancer: 423.4" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA044467 Enhanced 15000 "HPA044467: " "unprognostic (2.78e-2)" "unprognostic (3.54e-1)" "unprognostic (8.77e-2)" "unprognostic (7.50e-3)" "unprognostic (9.67e-3)" "unprognostic (2.36e-1)" "prognostic unfavourable (6.27e-5)" "unprognostic (9.70e-2)" "unprognostic (4.66e-2)" "unprognostic (1.58e-2)" 0.2 0.2 0.0 0.2 0.0 0.2 0.2 0.0 0.2 157.6 0.2 0.0 0.0 0.2 11.5 0.2 855.8 0.2 1.8 0.5 0.0 0.0 0.2 0.3 0.2 0.2 0.0 0.0 0.2 0.2 0.2 0.0 1.2 0.0 0.2 0.2 0.0 93.4 0.2 0.4 0.2 0.2 0.3 0.0 0.2 0.2 0.2 0.0 0.0 0.2 389.6 537.4 0.6 163.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.6 6.7 3.5 0.0 0.0 0.2 0.0 0.5 0.0 0.0 0.0 1.1 0.0 0.0 0.0 1.2 0.0 0.0 10.9 0.0 0.0 0.0 2.8 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 13.9 0.0 0.0 0.4 3.2 0.0 0.0 0.0 3.9 0.0 0.0 0.0 0.0 0.0 1.4 1.2 0.0 2.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 SPRY1 hSPRY1 ENSG00000164056 "Sprouty RTK signaling antagonist 1" O43609 4 123396795-123403760 "Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins" "Developmental protein" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "adipose tissue: 139.1" "Cell line enhanced" "Detected in many" "AF22: 29.6;AN3-CA: 59.8;ASC diff: 24.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "naive B-cell: 29.9" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB013538, HPA051369, HPA070554" Approved Approved "Nucleoplasm,Golgi apparatus,Cytosol" "Golgi apparatus, Cytosol" Nucleoplasm "CAB013538: AB_2533452, HPA051369: , HPA070554: " "unprognostic (1.27e-1)" "unprognostic (9.08e-2)" "unprognostic (2.06e-1)" "unprognostic (7.15e-2)" "unprognostic (5.33e-2)" "unprognostic (2.19e-2)" "unprognostic (1.36e-1)" "unprognostic (9.43e-2)" "unprognostic (6.99e-2)" "unprognostic (4.32e-1)" "unprognostic (4.06e-1)" "unprognostic (3.11e-2)" "unprognostic (8.77e-3)" "unprognostic (1.21e-3)" "unprognostic (4.48e-2)" "unprognostic (1.54e-2)" "unprognostic (1.27e-1)" 139.1 12.6 3.3 14.7 4.3 5.8 69.0 4.9 3.5 28.5 24.8 1.9 18.0 4.5 18.6 28.0 38.1 19.1 27.1 34.1 2.6 1.7 10.2 6.4 23.1 9.1 3.3 2.8 32.2 9.8 17.0 9.5 15.6 2.9 25.0 8.8 11.8 14.6 16.5 48.1 25.5 8.1 20.7 2.8 7.1 11.6 28.4 1.5 13.0 29.6 16.3 8.6 60.8 39.9 29.9 0.7 2.8 0.1 6.1 15.5 0.9 1.8 0.5 29.6 59.8 24.3 16.5 1.9 0.1 1.5 0.1 0.6 1.8 3.1 0.0 13.3 0.8 0.3 0.7 1.4 0.2 0.0 3.0 0.6 0.0 9.2 6.9 4.1 0.0 6.7 0.7 0.2 0.6 2.5 0.5 0.5 1.4 0.2 4.8 10.3 7.1 9.8 2.1 3.2 0.0 4.0 4.3 4.5 3.8 0.0 6.0 5.7 0.6 0.0 6.1 0.3 0.0 0.1 0.8 0.3 0.0 0.0 0.4 0.8 0.9 0.0 0.1 2.8 0.5 0.0 15.5 9.6 1.8 4.2 0.0 29.9 2.7 2.9 0.1 6.1 0.0 0.7 0.0 0.9 3.3 4.3 4.9 3.5 2.6 1.7 3.3 2.8 2.9 1.5 SRC "ASV, c-src, SRC1" ENSG00000197122 "SRC proto-oncogene, non-receptor tyrosine kinase" P12931 20 37344685-37406050 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters" "Cell adhesion, Cell cycle, Host-virus interaction, Immunity" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "A549: 35.5;HBEC3-KT: 33.0;PC-3: 32.1;RT4: 34.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "intermediate monocyte: 5.3;non-classical monocyte: 4.4" "Group enriched" "Detected in many" 6 "dendritic cells: 3.0;monocytes: 5.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004023, HPA030875" Approved Supported "Plasma membrane,Cell Junctions,Cytosol" 20000000 "Plasma membrane, Cell Junctions" Cytosol "CAB004023: AB_2106059, HPA030875: " "unprognostic (5.58e-2)" "unprognostic (9.83e-2)" "unprognostic (3.56e-1)" "unprognostic (4.54e-3)" "unprognostic (1.52e-1)" "unprognostic (1.54e-2)" "prognostic unfavourable (4.90e-5)" "unprognostic (3.89e-2)" "unprognostic (7.04e-2)" "unprognostic (8.13e-2)" "unprognostic (1.54e-2)" "prognostic unfavourable (1.63e-4)" "prognostic unfavourable (1.22e-4)" "unprognostic (2.33e-2)" "unprognostic (4.72e-2)" "unprognostic (3.65e-2)" "prognostic favourable (5.22e-5)" 6.9 17.5 12.8 11.1 12.0 5.4 9.9 6.4 16.0 16.0 16.4 3.5 15.1 29.5 20.3 9.7 16.2 14.2 42.1 5.8 11.3 6.6 13.4 2.9 10.4 7.0 3.3 9.9 15.8 19.1 6.6 11.3 6.3 5.1 19.9 13.1 13.1 7.5 22.5 3.4 7.7 28.1 27.2 3.6 12.2 29.8 27.3 4.8 4.0 6.6 10.5 10.4 26.4 20.0 0.3 3.0 0.1 5.3 0.6 0.1 1.6 7.6 35.5 8.1 7.3 3.1 4.9 17.0 7.1 6.1 8.6 5.5 13.3 6.9 0.2 4.4 12.8 14.0 4.9 33.0 3.4 0.0 4.4 1.9 1.2 20.7 7.4 0.1 3.0 5.3 11.2 5.6 7.5 7.8 0.2 0.0 1.4 5.2 1.8 0.2 3.8 32.1 8.3 2.1 0.2 3.6 34.0 7.6 27.5 8.0 11.3 8.8 10.1 2.8 11.5 10.4 7.0 3.8 6.3 0.1 0.2 0.1 7.3 0.0 7.7 0.0 2.6 0.0 0.0 5.3 0.0 0.3 0.0 0.1 1.1 0.3 0.0 0.0 0.1 0.6 4.4 3.0 0.1 1.6 12.8 12.0 6.4 16.0 11.3 6.6 3.3 9.9 5.1 4.8 SRD5A1 ENSG00000145545 "Steroid 5 alpha-reductase 1" P18405 5 6633343-6674386 "Cancer-related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins" "Differentiation, Sexual differentiation" Oxidoreductase "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 42.4" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" HPA051402 Approved "HPA051402: " "unprognostic (1.40e-2)" "unprognostic (1.33e-2)" "unprognostic (2.30e-3)" "prognostic unfavourable (8.73e-6)" "unprognostic (9.38e-3)" "unprognostic (8.90e-2)" "unprognostic (3.78e-2)" "unprognostic (5.90e-2)" "unprognostic (3.83e-1)" "unprognostic (1.42e-1)" "unprognostic (7.70e-3)" "unprognostic (1.54e-1)" "unprognostic (1.56e-3)" "unprognostic (3.01e-1)" "unprognostic (2.24e-1)" "unprognostic (1.59e-1)" "unprognostic (5.47e-2)" 2.4 3.3 7.7 2.9 8.2 3.2 14.8 9.2 11.8 5.6 5.2 5.3 0.7 5.7 3.1 4.6 24.2 2.9 4.0 1.9 9.3 7.5 6.4 42.4 3.0 3.5 6.2 5.5 4.1 4.3 3.0 1.9 2.1 13.4 2.6 3.6 2.4 5.0 2.1 2.2 17.5 10.4 2.6 3.1 2.9 3.9 2.7 2.9 3.3 2.4 15.3 12.1 2.6 10.1 1.9 3.7 7.0 3.3 1.3 1.3 1.3 5.5 5.5 7.3 6.2 7.0 6.9 3.4 5.4 4.1 5.3 3.3 5.5 4.9 6.7 8.9 7.8 9.0 5.9 3.6 5.7 4.1 2.5 2.1 13.7 3.3 3.2 3.0 1.8 5.0 10.2 3.8 3.0 2.6 3.6 6.2 6.8 6.5 1.4 3.4 4.6 4.4 4.6 5.6 2.0 7.1 5.2 13.8 6.3 16.4 7.3 5.0 3.0 0.8 5.4 8.1 4.0 13.1 6.7 3.3 4.4 2.4 6.7 3.5 7.4 7.0 3.3 1.4 1.0 2.4 0.7 1.7 1.0 1.3 3.7 1.9 0.9 1.0 2.0 1.3 2.6 1.8 1.1 1.3 7.7 8.2 9.2 11.8 9.3 7.5 6.2 5.5 13.4 2.9 SRSF2 "PR264, SC-35, SC35, SFRS2, SFRS2A" ENSG00000161547 "Serine and arginine rich splicing factor 2" Q01130 17 76734115-76737374 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "mRNA processing, mRNA splicing" RNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA049905 Supported Approved Nucleoplasm,Cytosol 140000 Nucleoplasm Cytosol "HPA049905: " "unprognostic (2.50e-1)" "unprognostic (2.16e-3)" "unprognostic (2.73e-3)" "prognostic unfavourable (8.73e-4)" "unprognostic (1.75e-2)" "unprognostic (4.19e-2)" "prognostic unfavourable (3.53e-8)" "unprognostic (1.19e-1)" "unprognostic (7.79e-3)" "unprognostic (7.03e-3)" "unprognostic (1.92e-1)" "unprognostic (1.07e-3)" "prognostic unfavourable (1.05e-7)" "unprognostic (3.85e-2)" "unprognostic (8.05e-2)" "unprognostic (1.95e-1)" "prognostic favourable (9.87e-4)" 35.4 40.2 20.6 56.6 30.3 73.1 35.3 33.3 36.2 42.1 37.7 34.0 19.5 41.8 37.0 33.6 51.1 35.1 34.8 32.4 19.9 22.6 36.9 66.7 37.3 64.3 21.6 24.0 47.1 34.2 29.1 33.8 51.2 29.5 31.3 36.5 35.5 35.6 40.5 44.9 41.1 46.6 25.5 23.9 52.5 35.6 29.2 18.9 105.3 41.1 41.3 64.5 30.6 35.7 11.1 30.2 4.2 23.5 15.6 12.7 12.2 47.7 38.5 45.7 31.9 11.2 9.5 47.5 30.9 22.9 35.9 33.3 40.4 33.5 73.6 22.6 29.0 43.3 45.3 35.7 36.1 30.8 79.0 55.2 37.3 46.9 12.7 61.0 33.1 10.5 8.1 29.7 8.6 28.0 56.1 32.5 28.0 38.2 66.9 66.6 53.5 55.0 67.8 49.2 54.3 24.0 34.4 39.0 55.7 35.2 30.3 16.6 37.1 44.6 29.2 33.1 42.7 22.0 49.9 42.8 32.2 85.2 29.8 48.5 27.3 1.0 17.5 4.2 12.3 23.5 12.6 11.1 8.5 12.7 30.2 9.8 9.8 9.0 2.1 15.6 14.7 22.4 10.6 12.2 20.6 30.3 33.3 36.2 19.9 22.6 21.6 24.0 29.5 18.9 SRSF3 "SFRS3, SRp20" ENSG00000112081 "Serine and arginine rich splicing factor 3" P84103 6 36594353-36605600 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "mRNA processing, mRNA splicing, mRNA transport, Transport" RNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB012986, HPA056981" Supported Supported Nucleoplasm 1600000 Nucleoplasm "CAB012986: AB_2533150, HPA056981: " "unprognostic (3.25e-1)" "unprognostic (1.08e-3)" "prognostic favourable (2.56e-4)" "unprognostic (8.19e-2)" "unprognostic (2.06e-2)" "unprognostic (2.77e-2)" "prognostic unfavourable (6.22e-5)" "unprognostic (2.92e-2)" "prognostic unfavourable (1.95e-4)" "prognostic favourable (1.37e-4)" "unprognostic (9.61e-2)" "unprognostic (1.21e-1)" "prognostic unfavourable (2.02e-4)" "unprognostic (9.88e-2)" "unprognostic (3.33e-2)" "unprognostic (8.33e-2)" "unprognostic (1.06e-2)" 45.3 27.4 37.4 42.1 38.3 69.5 43.5 42.6 39.1 36.4 41.7 32.9 34.0 25.5 37.2 31.8 42.9 40.8 27.4 37.5 33.0 28.1 34.3 36.9 32.3 51.8 35.8 27.0 53.9 31.3 22.4 47.2 37.4 38.1 40.1 46.6 30.1 30.2 33.0 29.2 36.2 35.8 43.1 31.9 36.4 35.2 27.2 36.7 67.5 35.9 46.7 67.0 49.6 38.6 28.0 73.9 12.9 38.0 37.6 37.6 53.9 51.7 34.6 61.1 46.6 23.6 18.5 37.7 37.1 31.1 62.5 48.2 40.6 37.2 87.1 26.7 40.5 41.1 80.1 59.0 66.8 40.6 49.3 52.2 27.5 45.7 28.9 70.1 44.2 16.4 20.1 40.7 45.5 47.4 62.9 36.9 45.3 40.4 86.1 66.4 64.3 36.4 76.8 58.5 52.1 44.2 43.1 47.2 44.7 41.2 40.4 56.0 41.0 75.4 30.9 32.0 46.7 32.0 55.6 36.5 53.9 119.3 27.4 65.2 44.3 12.9 38.0 11.5 32.9 36.2 37.1 28.0 31.1 34.5 73.9 24.0 31.4 32.3 3.7 37.6 24.4 43.7 37.6 53.9 37.4 38.3 42.6 39.1 33.0 28.1 35.8 27.0 38.1 36.7 SS18 "SSXT, SYT" ENSG00000141380 "SS18, nBAF chromatin remodeling complex subunit" Q15532 18 26016253-26091217 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" Activator "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA055741, HPA059539" Supported Approved Nucleoplasm,Cytosol Nucleoplasm Cytosol "HPA055741: , HPA059539: " "unprognostic (2.03e-2)" "unprognostic (1.76e-1)" "unprognostic (1.48e-2)" "unprognostic (1.95e-2)" "unprognostic (3.39e-1)" "unprognostic (8.74e-2)" "unprognostic (4.59e-2)" "unprognostic (1.53e-2)" "unprognostic (1.63e-2)" "unprognostic (1.45e-2)" "unprognostic (1.04e-1)" "unprognostic (2.47e-1)" "prognostic favourable (4.86e-4)" "unprognostic (1.03e-1)" "unprognostic (3.50e-2)" "unprognostic (1.40e-2)" "unprognostic (1.30e-1)" 26.1 40.5 18.7 30.4 26.4 15.5 26.6 17.6 20.2 24.8 21.4 31.8 32.1 14.0 31.7 32.7 29.8 27.2 23.4 22.4 21.6 16.1 30.0 30.9 21.9 25.8 32.6 16.3 39.4 20.6 39.4 41.8 43.2 25.3 28.6 18.7 26.1 26.0 33.5 10.3 31.3 22.6 31.0 23.7 24.7 22.5 28.3 32.6 27.8 35.6 24.7 35.2 25.5 25.9 15.9 13.1 19.9 17.1 20.7 17.6 13.1 19.0 13.8 33.9 16.6 27.0 24.5 17.1 23.4 21.3 20.7 19.8 9.0 15.8 33.2 18.7 27.4 24.9 18.4 22.7 25.6 21.2 8.8 16.4 20.3 14.6 21.4 25.2 25.5 31.4 26.8 26.0 28.5 15.5 12.0 17.1 28.6 19.1 10.3 14.6 6.4 13.4 12.0 26.4 15.9 21.9 22.5 14.5 21.9 35.8 16.6 10.1 16.9 14.9 17.7 43.6 8.7 10.0 22.9 30.8 20.6 24.0 20.4 17.5 23.1 19.9 11.7 16.5 15.1 17.1 17.6 15.9 14.6 15.7 13.1 13.0 15.5 17.4 5.6 20.7 16.7 7.4 15.7 13.1 18.7 26.4 17.6 20.2 21.6 16.1 32.6 16.3 25.3 32.6 SS18L1 "CREST, KIAA0693" ENSG00000184402 "SS18L1, nBAF chromatin remodeling complex subunit" O75177 20 62143795-62182484 "Cancer-related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Activator, Chromatin regulator" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB011827, HPA059046" Approved Supported Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "CAB011827: AB_778216, HPA059046: " "unprognostic (4.12e-2)" "unprognostic (5.82e-2)" "unprognostic (1.54e-1)" "unprognostic (3.03e-2)" "unprognostic (6.57e-2)" "prognostic favourable (8.00e-5)" "unprognostic (1.39e-1)" "prognostic favourable (3.74e-4)" "unprognostic (1.01e-1)" "unprognostic (1.87e-1)" "unprognostic (2.47e-3)" "unprognostic (6.43e-2)" "unprognostic (2.42e-1)" "unprognostic (1.06e-1)" "unprognostic (2.66e-1)" "unprognostic (1.01e-1)" "unprognostic (9.94e-3)" 6.6 8.9 11.9 7.7 12.7 7.7 8.6 35.9 15.8 7.0 7.0 9.9 12.2 9.5 9.7 10.9 9.3 6.9 7.2 6.4 11.5 10.9 11.5 33.3 8.2 7.4 11.2 14.5 10.0 10.4 8.4 10.7 8.8 13.1 8.7 7.8 7.4 8.6 11.8 19.2 23.7 9.0 7.7 9.9 9.2 8.8 10.7 10.9 6.0 8.3 6.7 7.1 6.8 8.6 3.6 1.3 2.5 2.7 1.6 2.8 0.5 6.4 7.7 10.7 9.7 4.8 5.6 7.8 6.1 2.4 10.2 5.1 26.3 6.0 3.9 8.1 3.4 16.7 6.6 5.8 9.3 2.7 4.3 17.5 16.1 13.6 3.6 6.3 15.6 3.4 12.8 5.2 4.4 4.6 11.7 7.6 5.7 7.6 9.6 9.9 4.3 8.8 10.7 13.9 4.4 7.6 8.2 20.4 11.3 10.9 13.3 9.1 12.5 10.2 5.4 19.5 11.8 7.2 8.5 8.5 7.6 3.5 9.7 6.3 6.4 0.3 1.6 0.6 1.7 1.1 1.1 0.7 0.9 1.4 1.3 3.6 2.8 0.9 2.5 1.6 2.7 0.8 0.8 0.5 11.9 12.7 35.9 15.8 11.5 10.9 11.2 14.5 13.1 10.9 SST SMST ENSG00000157005 Somatostatin P61278 3 187668906-187670399 "Cancer-related genes, Plasma proteins, Predicted secreted proteins" Hormone "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "brain: 102.8;intestine: 105.2;pancreas: 105.6;stomach 1: 90.4" "Cell line enhanced" "Detected in some" "EFO-21: 15.2;U-2 OS: 28.3;U-251 MG: 4.7;U-698: 5.9" "Group enriched" "Detected in many" 7 "ovarian cancer: 249.9;pancreatic cancer: 1039.3" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB000075, HPA019472, CAB034105" Enhanced Supported "Secreted to blood" "CAB000075: AB_2688022, CAB034105: AB_2271061, HPA019472: AB_1857360" "unprognostic (2.44e-1)" "unprognostic (2.05e-1)" "prognostic unfavourable (1.93e-5)" "unprognostic (5.12e-3)" "unprognostic (1.54e-2)" "unprognostic (4.69e-1)" "unprognostic (3.31e-2)" "unprognostic (8.16e-3)" "unprognostic (1.63e-1)" "unprognostic (1.07e-3)" "unprognostic (8.47e-2)" "unprognostic (4.19e-1)" "unprognostic (3.27e-1)" "unprognostic (1.45e-1)" 2.0 13.0 28.6 1.9 53.8 1.7 0.7 0.1 47.9 0.7 45.1 1.8 21.9 105.2 0.9 0.7 1.1 0.7 1.0 0.9 17.5 102.8 2.5 0.7 0.7 1.0 6.2 15.4 0.8 105.6 0.7 1.5 0.7 16.1 1.5 7.4 0.4 0.7 7.5 0.7 3.1 36.1 1.4 18.4 0.7 90.4 0.7 8.6 0.0 0.9 0.0 0.7 4.6 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.2 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.2 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 28.3 0.3 4.7 0.0 1.6 5.9 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 28.6 53.8 0.1 47.9 17.5 102.8 6.2 15.4 16.1 8.6 SSX1 CT5.1 ENSG00000126752 "SSX family member 1" Q16384 X 48255317-48267444 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 14 "testis: 12.6" "Cell line enhanced" "Detected in some" "Daudi: 28.1;Karpas-707: 40.8;U-2197: 9.5" "Cancer enhanced" "Detected in many" "liver cancer: 7.9" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA045683 Supported Approved Nucleoplasm,Nucleoli "Nucleoplasm, Nucleoli" "HPA045683: " "unprognostic (2.25e-1)" "unprognostic (3.51e-3)" "unprognostic (2.36e-1)" "unprognostic (4.32e-3)" "unprognostic (3.38e-1)" "unprognostic (5.41e-2)" "unprognostic (6.94e-2)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 12.6 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.1 0.2 0.9 0.4 0.5 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 28.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 40.8 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 9.5 0.0 0.0 2.0 0.0 2.3 0.0 0.0 0.9 0.4 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.3 0.5 0.5 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 SSX2 "CT5.2a, HD21, HOM-MEL-40, MGC119055, MGC15364, MGC3884, SSX" ENSG00000241476 "SSX family member 2" Q16385 X 52696896-52707189 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 57 "testis: 24.1" "Cell line enhanced" "Detected in some" "PC-3: 3.1;U-2197: 1.9" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "HPA045683, CAB046020" Enhanced Approved Nucleoplasm,Nucleoli "Nucleoplasm, Nucleoli" "CAB046020: AB_2194010, HPA045683: " 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 24.1 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.5 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.3 0.3 0.0 0.0 0.0 0.2 3.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.9 0.0 0.6 0.1 0.6 1.9 0.0 0.0 0.3 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 SSX2B CT5.2b ENSG00000268447 "SSX family member 2B" Q16385 X 52751132-52790305 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 24 "testis: 13.5" "Cell line enhanced" "Detected in some" "CAPAN-2: 1.8;HMC-1: 5.3;PC-3: 5.1;T-47d: 2.2;U-2197: 3.2" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA045683 Supported Approved Nucleoplasm,Nucleoli "Nucleoplasm, Nucleoli" "HPA045683: " 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 13.5 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.3 0.0 0.1 0.0 0.0 0.9 0.0 0.8 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 1.8 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.7 0.0 0.0 0.0 5.3 0.0 0.0 0.0 0.0 0.0 0.7 0.5 0.5 0.1 0.0 0.0 0.2 5.1 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.7 0.0 2.2 0.0 1.0 0.0 0.5 3.2 0.0 0.1 0.5 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.3 0.1 0.0 0.0 SSX4 CT5.4 ENSG00000268009 "SSX family member 4" O60224 X 48383516-48393347 "Cancer-related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Tissue enriched" "Detected in single" 14 "testis: 6.8" "Group enriched" "Detected in some" 10 "BEWO: 3.5;Karpas-707: 8.6;U-266/70: 5.1;U-266/84: 9.3" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA045683 Approved Approved Nucleoplasm,Nucleoli "Nucleoplasm, Nucleoli" "HPA045683: " 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.4 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 6.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 3.5 0.0 0.0 0.0 0.0 0.1 0.6 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.5 8.6 0.0 0.0 0.0 0.0 0.3 0.3 0.6 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.1 0.0 0.0 0.0 5.1 9.3 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 ST14 "HAI, MT-SP1, PRSS14, SNC19, TMPRSS14" ENSG00000149418 "Suppression of tumorigenicity 14" Q9Y5Y6 11 130159562-130210376 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins" "Hydrolase, Protease, Serine protease" "Cancer-related genes, Disease mutation, Hypotrichosis, Ichthyosis" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 94.1" "Cell line enhanced" "Detected in some" "CACO-2: 35.7;CAPAN-2: 72.1;HaCaT: 50.5;RPMI-8226: 47.3;SK-BR-3: 33.4;T-47d: 50.5;U-698: 34.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in many" 4 "plasmacytoid DC: 18.2" "Lineage enriched" "Detected in many" 5 "dendritic cells: 18.2" "Not detected" "Not detected" "Low region specificity" "Detected in many" HPA047014 Approved Nucleoplasm,Vesicles 220000 "Nucleoplasm, Vesicles" "HPA047014: " "unprognostic (1.17e-1)" "unprognostic (1.15e-1)" "unprognostic (9.62e-2)" "unprognostic (1.32e-1)" "unprognostic (2.17e-2)" "unprognostic (7.94e-2)" "unprognostic (1.20e-1)" "unprognostic (3.97e-2)" "unprognostic (5.29e-1)" "unprognostic (3.21e-1)" "unprognostic (1.03e-3)" "unprognostic (2.25e-1)" "prognostic favourable (5.03e-11)" "unprognostic (1.92e-2)" "unprognostic (2.71e-1)" "unprognostic (1.28e-2)" "unprognostic (5.60e-2)" 10.1 1.8 0.7 21.9 1.8 0.5 5.5 0.8 1.4 8.9 48.6 0.5 23.8 33.8 2.8 16.9 38.9 9.7 32.4 1.1 0.5 0.5 30.5 3.2 9.5 7.5 1.8 0.6 3.6 34.3 8.4 9.5 12.7 1.5 12.1 15.4 0.7 25.1 15.8 0.7 17.8 94.1 1.2 1.8 4.0 16.7 2.1 1.5 5.2 24.0 20.1 28.4 8.3 14.9 3.8 18.2 2.3 2.7 0.0 0.1 0.8 26.2 0.0 0.0 0.1 0.0 0.0 14.3 0.0 0.0 0.0 0.0 35.7 72.1 26.0 2.7 0.0 50.5 0.0 16.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 3.4 0.1 0.0 8.1 0.0 0.0 0.0 0.0 0.0 0.0 20.3 0.0 0.1 0.2 0.1 0.0 0.0 47.3 4.7 21.5 2.9 0.0 0.2 33.4 0.0 50.5 5.1 0.0 0.0 0.4 0.1 0.1 0.0 0.0 34.4 0.0 8.0 0.0 0.0 2.7 2.3 0.0 1.5 0.1 3.8 0.0 0.0 4.5 2.3 0.0 0.0 0.3 0.0 0.2 18.2 0.0 0.8 0.7 1.8 0.8 1.4 0.5 0.5 1.8 0.6 1.5 1.5 STAG2 "SA-2, SA2, SCC3B" ENSG00000101972 "Stromal antigen 2" Q8N3U4 X 123960212-124422664 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division, Chromosome partition, Meiosis, Mitosis" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA002857 Supported "HPA002857: AB_1079861" "unprognostic (1.62e-1)" "unprognostic (1.01e-2)" "unprognostic (6.75e-2)" "unprognostic (2.16e-2)" "unprognostic (1.37e-2)" "unprognostic (2.70e-2)" "unprognostic (3.77e-2)" "unprognostic (9.67e-3)" "unprognostic (4.68e-2)" "unprognostic (1.86e-1)" "unprognostic (1.24e-1)" "unprognostic (3.38e-1)" "unprognostic (1.59e-3)" "unprognostic (2.81e-1)" "unprognostic (2.77e-2)" "unprognostic (1.63e-1)" "unprognostic (3.97e-1)" 24.0 18.8 21.5 23.9 23.7 39.7 30.1 35.4 23.5 28.1 25.1 16.4 25.2 14.9 24.3 21.0 24.3 20.0 16.3 15.7 21.4 17.9 22.2 18.1 23.4 26.2 24.9 17.5 31.1 19.7 46.1 27.6 25.5 20.6 25.9 18.3 14.2 20.7 27.8 27.6 18.9 21.9 25.9 30.6 26.7 17.6 9.3 26.4 69.3 32.0 19.7 27.1 37.7 37.8 12.8 12.5 30.3 14.4 12.1 15.5 6.7 17.2 16.3 24.5 15.4 10.5 15.9 15.8 16.4 17.7 17.0 21.5 15.1 18.5 31.9 23.2 14.7 15.8 50.1 13.9 24.2 22.6 21.4 29.5 32.6 9.9 10.9 38.5 23.2 12.5 13.8 20.1 32.6 14.2 28.7 34.0 12.5 18.8 49.2 17.4 12.8 24.2 34.9 32.4 26.6 13.2 33.0 22.1 17.7 37.0 13.8 19.4 8.2 17.7 17.3 0.1 9.1 20.0 18.6 14.7 22.1 40.1 10.7 23.7 17.1 16.8 10.2 18.1 10.8 13.1 12.6 10.0 11.2 10.1 12.5 12.8 15.5 12.4 30.3 12.1 14.4 11.2 8.7 6.7 21.5 23.7 35.4 23.5 21.4 17.9 24.9 17.5 20.6 26.4 STARD3 "es64, MLN64" ENSG00000131748 "StAR related lipid transfer domain containing 3" Q14849 17 39637065-39663484 "Cancer-related genes, Predicted membrane proteins, Transporters" "Lipid transport, Transport" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enriched" "Detected in all" 6 "SK-BR-3: 87.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB017021, HPA024307, HPA073948" Uncertain Approved "Nucleoplasm,Endoplasmic reticulum,Vesicles" "Nucleoplasm, Vesicles" "Endoplasmic reticulum" "CAB017021: , HPA024307: , HPA073948: " "unprognostic (1.11e-1)" "unprognostic (2.14e-2)" "unprognostic (6.35e-2)" "unprognostic (8.92e-3)" "unprognostic (2.09e-2)" "unprognostic (2.94e-1)" "prognostic unfavourable (3.60e-5)" "unprognostic (2.26e-1)" "unprognostic (1.77e-1)" "unprognostic (1.48e-1)" "unprognostic (6.25e-3)" "unprognostic (5.88e-2)" "prognostic unfavourable (7.70e-4)" "unprognostic (1.33e-1)" "unprognostic (5.22e-2)" "unprognostic (8.51e-3)" "unprognostic (3.00e-2)" 22.2 34.8 23.3 27.5 28.0 33.5 22.8 27.7 30.1 17.1 23.7 38.1 21.7 26.6 20.6 20.7 22.4 25.6 27.7 17.8 21.0 16.8 18.2 24.0 27.0 31.5 28.5 25.7 21.5 32.7 21.9 23.7 26.9 25.7 19.0 9.7 17.9 21.4 26.7 20.8 24.5 34.2 15.8 27.8 32.3 25.3 26.7 26.1 33.0 21.1 15.1 24.8 28.8 18.7 15.3 23.2 35.3 21.2 21.4 25.3 17.4 7.8 12.3 5.5 9.9 6.7 8.2 8.3 6.4 8.3 8.3 7.6 7.3 12.8 6.9 13.9 5.8 14.9 3.4 7.5 1.9 9.4 12.6 4.7 5.4 8.4 9.5 9.5 10.5 8.9 6.2 9.4 4.5 8.0 10.9 9.0 7.6 6.9 8.9 9.0 6.1 6.8 7.1 9.6 10.3 5.7 8.8 7.0 7.6 4.8 87.9 15.8 10.3 11.4 7.6 11.7 8.1 12.8 11.9 8.6 10.6 5.5 10.4 10.3 12.0 12.5 21.2 29.3 25.3 19.6 18.5 11.9 18.3 19.0 23.2 15.3 18.4 16.9 35.3 21.4 15.6 10.8 20.4 17.4 23.3 28.0 27.7 30.1 21.0 16.8 28.5 25.7 25.7 26.1 STAT3 APRF ENSG00000168610 "Signal transducer and activator of transcription 3" P40763 17 42313324-42388568 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Host-virus interaction, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Diabetes mellitus, Disease mutation, Dwarfism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001671, CAB003859, HPA058603, CAB068241, CAB068242" Supported Supported Nucleoplasm,Cytosol 220000 "Nucleoplasm, Cytosol" "CAB003859: AB_347629, CAB068241: , CAB068242: , HPA001671: AB_1080102, HPA058603: " "unprognostic (1.83e-2)" "unprognostic (2.42e-1)" "unprognostic (9.23e-3)" "unprognostic (2.91e-1)" "unprognostic (5.59e-3)" "unprognostic (1.78e-2)" "unprognostic (8.26e-2)" "unprognostic (1.51e-1)" "unprognostic (1.32e-1)" "unprognostic (1.77e-1)" "unprognostic (2.21e-1)" "unprognostic (1.26e-1)" "unprognostic (6.47e-3)" "unprognostic (7.75e-3)" "unprognostic (2.21e-2)" "unprognostic (7.63e-2)" "unprognostic (1.61e-1)" 44.6 30.7 23.2 34.4 27.5 35.3 49.3 15.7 23.5 25.1 31.5 18.4 21.7 20.5 33.2 27.4 36.4 32.7 34.0 82.9 20.1 14.7 34.5 90.0 45.7 45.5 26.0 11.1 40.6 32.1 18.6 27.9 24.6 27.6 28.9 21.8 24.3 29.3 22.9 53.4 28.4 28.6 49.7 25.1 41.4 29.4 15.4 25.7 16.8 38.0 31.2 28.8 40.4 53.1 10.8 13.7 69.7 20.2 13.9 21.7 26.7 16.6 31.7 14.0 13.8 30.0 28.6 10.2 19.6 24.9 17.0 16.6 8.3 16.2 5.2 19.4 19.4 25.5 12.7 20.0 13.9 43.0 8.7 36.2 19.3 17.1 22.2 8.8 23.6 44.6 19.7 13.5 19.6 23.0 22.2 16.6 11.2 11.8 32.6 8.8 8.1 0.0 7.2 37.4 7.7 26.9 21.7 12.9 8.4 22.6 53.6 8.1 28.1 13.3 19.4 26.3 13.5 15.6 16.0 25.7 20.0 4.4 16.3 9.4 11.6 26.2 19.4 24.9 21.7 20.2 17.3 10.8 16.0 16.8 13.7 10.4 16.6 15.8 69.7 13.9 18.7 7.5 12.0 26.7 23.2 27.5 15.7 23.5 20.1 14.7 26.0 11.1 27.6 25.7 STAT4 ENSG00000138378 "Signal transducer and activator of transcription 4" Q14765 2 191029576-191151596 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Systemic lupus erythematosus" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 29.4;testis: 25.5" "Cell line enhanced" "Detected in some" "Karpas-707: 30.2;U-266/70: 17.0;U-266/84: 5.9" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Group enriched" "Detected in many" 10 "NK-cells: 16.9;T-cells: 29.4" "Low region specificity" "Detected in some" "Low region specificity" "Detected in many" "HPA001860, CAB013108" Enhanced "CAB013108: , HPA001860: AB_1080104" "unprognostic (3.90e-5)" "unprognostic (1.30e-1)" "unprognostic (4.16e-2)" "unprognostic (6.45e-4)" "unprognostic (3.77e-2)" "unprognostic (4.79e-2)" "unprognostic (3.49e-2)" "unprognostic (1.47e-1)" "unprognostic (1.57e-1)" "unprognostic (1.49e-3)" "prognostic favourable (5.88e-4)" "unprognostic (2.43e-1)" "prognostic unfavourable (1.07e-8)" "unprognostic (2.65e-1)" "unprognostic (6.02e-2)" "unprognostic (2.15e-1)" "unprognostic (2.88e-1)" 4.2 3.6 2.1 9.6 12.7 11.2 2.9 1.1 15.5 1.7 3.7 0.0 0.3 4.1 1.7 2.4 1.5 1.7 4.2 20.3 3.3 6.5 2.7 7.6 8.4 14.1 3.3 8.3 1.5 2.2 0.7 19.6 2.4 8.5 1.9 3.2 2.3 4.5 1.5 1.1 1.3 6.6 1.3 2.5 13.8 3.6 25.5 0.5 4.2 2.4 1.0 12.8 3.3 1.9 0.4 2.0 2.3 0.2 16.9 29.4 10.7 0.0 0.9 0.6 0.0 0.0 1.8 0.2 0.2 1.1 0.3 1.3 0.2 0.4 0.0 0.1 1.4 0.5 0.0 2.6 0.7 0.0 0.5 0.7 0.0 0.0 0.3 0.0 0.0 0.8 1.1 0.6 0.3 0.0 0.0 30.2 0.1 0.0 1.7 0.0 0.1 0.5 0.0 0.0 2.1 0.1 0.0 0.1 0.7 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.8 0.0 17.0 5.9 0.0 0.7 0.0 0.0 2.3 0.1 0.0 29.4 0.2 26.5 0.4 17.5 23.8 0.1 0.2 16.7 23.8 0.6 16.9 0.1 2.0 6.1 10.7 2.1 12.7 1.1 15.5 3.3 6.5 3.3 8.3 8.5 0.5 STAT5A "MGF, STAT5" ENSG00000126561 "Signal transducer and activator of transcription 5A" P42229 17 42287547-42311943 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Lactation, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HDLM-2: 25.3;HEL: 38.3;HMC-1: 22.3;K-562: 63.7;MOLT-4: 46.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" "CAB003860, HPA027873, HPA042128, HPA049883, HPA051156" Approved Enhanced Nucleoplasm,Cytosol 140000 "Nucleoplasm, Cytosol" "CAB003860: AB_562347, HPA027873: AB_10603893, HPA042128: , HPA049883: , HPA051156: " "prognostic favourable (5.87e-4)" "unprognostic (3.09e-3)" "unprognostic (2.31e-2)" "unprognostic (1.76e-1)" "unprognostic (1.43e-1)" "unprognostic (3.41e-3)" "unprognostic (2.15e-1)" "unprognostic (6.22e-2)" "unprognostic (3.33e-1)" "unprognostic (6.82e-3)" "unprognostic (2.76e-1)" "unprognostic (2.11e-1)" "unprognostic (3.85e-2)" "unprognostic (5.74e-2)" "unprognostic (1.90e-2)" "unprognostic (1.98e-1)" "unprognostic (5.49e-3)" 44.0 21.5 3.6 16.5 8.1 30.0 24.1 3.4 4.0 12.6 12.8 6.3 10.5 5.1 11.0 11.4 11.6 9.6 15.3 9.8 3.9 4.7 8.9 5.5 12.8 26.7 9.1 3.2 15.6 8.3 1.9 7.0 11.3 6.1 13.9 5.8 11.9 11.9 11.7 18.3 9.7 11.6 13.6 7.4 17.3 7.9 8.5 6.1 21.9 8.6 9.1 17.0 19.9 20.2 7.2 15.0 15.2 18.5 14.3 16.2 8.8 1.0 1.2 0.1 0.0 9.1 4.4 0.0 0.5 2.0 1.0 0.6 0.1 1.0 0.0 2.3 2.0 0.0 0.2 0.0 0.2 25.3 0.0 38.3 2.9 0.3 3.7 3.2 22.3 10.2 0.7 0.3 0.5 3.0 63.7 0.0 0.5 0.1 46.2 18.2 0.3 0.0 1.1 0.3 3.3 0.3 0.7 0.1 0.0 2.3 1.1 4.2 0.7 4.1 1.7 2.3 0.6 1.1 0.0 0.0 0.0 0.0 0.2 6.2 0.5 6.8 11.8 5.9 9.1 15.1 12.8 7.2 15.8 13.2 15.0 6.7 16.2 13.0 15.2 14.3 18.5 5.7 11.2 8.8 3.6 8.1 3.4 4.0 3.9 4.7 9.1 3.2 6.1 6.1 STAT5B ENSG00000173757 "Signal transducer and activator of transcription 5B" P51692 17 42199168-42276707 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Disease mutation, Dwarfism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HDLM-2: 43.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004298, HPA042128, HPA049883, HPA051156" Approved 170000 "CAB004298: AB_2197067, HPA042128: , HPA049883: , HPA051156: " "unprognostic (1.49e-1)" "unprognostic (3.60e-2)" "unprognostic (4.06e-2)" "prognostic favourable (9.37e-4)" "unprognostic (2.68e-1)" "unprognostic (4.29e-1)" "unprognostic (2.23e-1)" "unprognostic (1.03e-1)" "unprognostic (3.06e-2)" "unprognostic (7.98e-2)" "prognostic favourable (1.63e-4)" "unprognostic (1.36e-1)" "prognostic favourable (2.39e-5)" "unprognostic (9.19e-2)" "unprognostic (2.95e-1)" "unprognostic (1.54e-1)" "unprognostic (2.13e-1)" 25.7 24.0 13.5 19.5 16.3 21.8 26.2 32.1 15.9 21.6 21.0 13.7 16.3 8.6 31.9 12.0 11.6 24.5 18.1 12.8 11.9 20.1 12.4 13.5 15.8 24.6 16.0 13.9 34.4 12.1 12.0 22.6 55.4 17.2 20.8 10.3 16.4 12.9 21.7 38.3 12.2 14.8 33.1 10.6 22.1 14.4 13.2 15.7 21.7 15.4 9.6 19.8 21.5 33.1 2.5 2.4 18.8 2.8 3.5 8.3 3.8 5.2 8.2 12.3 3.3 15.4 7.8 5.9 5.4 9.7 7.8 6.8 3.6 4.5 17.1 8.1 6.2 6.8 7.2 4.7 6.2 43.1 8.4 16.7 15.5 5.5 8.5 7.3 27.0 9.5 7.2 5.8 7.4 12.2 30.1 3.7 3.2 5.1 34.5 19.3 3.0 0.0 14.9 7.7 5.9 4.9 8.4 9.1 5.3 9.9 12.6 7.6 8.9 8.7 9.4 10.9 3.8 5.6 7.5 7.4 3.4 8.5 4.3 7.8 5.6 8.8 2.8 4.6 5.9 2.5 6.4 2.5 8.3 6.7 2.4 2.5 5.9 5.0 18.8 3.5 2.8 1.8 6.9 3.8 13.5 16.3 32.1 15.9 11.9 20.1 16.0 13.9 17.2 15.7 STAT6 "D12S1644, IL-4-STAT" ENSG00000166888 "Signal transducer and activator of transcription 6" P42226 12 57095408-57132139 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA001861 Approved Supported Nucleoplasm,Cytosol Cytosol Nucleoplasm "HPA001861: AB_1080106" "unprognostic (3.43e-3)" "unprognostic (1.87e-1)" "unprognostic (1.37e-1)" "prognostic favourable (1.69e-4)" "unprognostic (4.14e-2)" "unprognostic (2.51e-1)" "unprognostic (2.22e-1)" "unprognostic (6.70e-2)" "unprognostic (1.88e-2)" "unprognostic (3.65e-1)" "unprognostic (5.39e-2)" "unprognostic (1.00e-2)" "unprognostic (2.81e-2)" "unprognostic (1.67e-1)" "unprognostic (1.55e-1)" "prognostic favourable (7.76e-4)" "prognostic favourable (1.14e-4)" 33.6 34.9 10.4 35.9 12.8 12.8 27.9 4.6 11.6 37.8 47.3 6.2 28.4 23.9 44.5 26.6 40.8 31.8 33.8 20.9 10.2 3.9 35.0 31.0 34.9 25.2 13.3 12.0 41.9 21.2 18.1 9.2 22.0 9.8 42.3 26.2 23.3 30.1 26.5 11.4 39.1 59.4 43.8 12.2 48.4 32.1 13.3 7.9 29.3 31.1 24.4 42.8 43.1 34.0 6.2 9.6 27.6 13.0 4.7 5.9 14.0 16.8 16.8 4.1 6.8 41.0 39.8 11.9 13.4 29.5 14.9 10.9 7.6 22.9 40.4 21.0 29.7 23.5 5.1 26.0 11.0 18.1 1.9 9.3 17.9 9.4 24.5 10.7 30.5 55.4 21.5 18.1 16.1 26.3 6.5 5.7 19.2 5.7 11.7 12.0 6.3 3.4 13.6 0.3 13.7 25.8 28.1 0.1 0.4 12.5 10.5 12.6 15.6 24.7 21.8 0.3 8.8 15.5 0.2 0.1 0.4 10.1 13.5 10.5 17.9 9.8 12.5 6.8 5.9 13.0 5.2 6.2 4.8 4.8 9.6 6.2 4.7 4.3 27.6 4.7 11.0 4.6 4.9 14.0 10.4 12.8 4.6 11.6 10.2 3.9 13.3 12.0 9.8 7.9 STEAP1 "PRSS24, STEAP" ENSG00000164647 "STEAP family member 1" Q9UHE8 7 90154375-90164829 "Cancer-related genes, Predicted membrane proteins, Transporters" "Electron transport, Ion transport, Iron transport, Transport" Oxidoreductase "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "prostate: 44.7" "Cell line enhanced" "Detected in many" "ASC diff: 29.1;CAPAN-2: 34.8;U-138 MG: 44.3" "Cancer enriched" "Detected in all" 6 "prostate cancer: 94.0" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in single" "myeloid DC: 1.7" "Low lineage specificity" "Detected in single" HPA030985 Uncertain "HPA030985: " "unprognostic (2.88e-3)" "unprognostic (2.29e-1)" "unprognostic (1.19e-1)" "unprognostic (3.21e-3)" "unprognostic (9.20e-3)" "unprognostic (2.03e-1)" "unprognostic (1.33e-2)" "unprognostic (6.74e-3)" "unprognostic (6.36e-2)" "unprognostic (6.45e-3)" "unprognostic (8.31e-3)" "unprognostic (3.79e-1)" "unprognostic (2.60e-2)" "unprognostic (4.39e-2)" "unprognostic (2.42e-1)" "unprognostic (6.09e-2)" "unprognostic (1.38e-1)" 19.8 1.5 2.9 16.5 1.4 0.0 26.0 0.9 6.3 5.5 10.0 0.1 0.7 2.7 3.0 4.4 10.0 7.3 8.4 7.1 1.4 0.5 5.3 21.2 9.3 2.9 0.5 2.7 12.4 6.5 0.2 5.8 0.5 1.4 44.7 7.3 1.2 9.8 5.3 3.9 3.3 7.4 13.7 1.4 2.8 7.4 2.1 0.7 0.0 4.6 6.5 3.7 12.5 16.1 0.8 1.7 0.0 0.0 0.0 0.0 0.2 6.7 13.6 0.8 2.5 29.1 24.2 0.2 4.6 5.7 0.6 0.8 10.2 34.8 0.0 0.2 7.5 1.4 5.9 6.4 1.2 0.0 2.2 0.0 0.1 3.4 1.1 0.0 0.0 17.0 0.9 19.2 10.2 25.0 0.3 19.4 7.9 0.1 0.0 0.1 4.1 6.5 0.0 0.0 0.0 5.5 1.4 0.0 0.3 1.7 0.0 3.1 7.7 0.1 12.8 44.3 2.2 22.2 5.6 3.6 0.1 0.0 21.7 0.0 4.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 1.7 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 2.9 1.4 0.9 6.3 1.4 0.5 0.5 2.7 1.4 0.7 STIL "MCPH7, SIL" ENSG00000123473 "STIL, centriolar assembly protein" Q15468 1 47250139-47314147 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Developmental protein" "Cancer-related genes, Disease mutation, Mental retardation, Primary microcephaly, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 36.0;testis: 23.8" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in some" "Low region specificity" "Detected in all" HPA046543 Approved "Plasma membrane,Cytosol" "Plasma membrane, Cytosol" "HPA046543: " "unprognostic (2.07e-1)" "unprognostic (6.29e-2)" "unprognostic (5.54e-3)" "unprognostic (2.67e-3)" "unprognostic (1.76e-1)" "unprognostic (1.56e-2)" "unprognostic (2.90e-5)" "unprognostic (7.35e-3)" "unprognostic (4.04e-3)" "unprognostic (1.41e-1)" "prognostic unfavourable (1.33e-4)" "unprognostic (5.81e-2)" "unprognostic (3.36e-14)" "unprognostic (5.76e-3)" "unprognostic (2.58e-1)" "unprognostic (1.64e-1)" "unprognostic (2.28e-1)" 1.2 1.4 1.3 10.8 2.4 11.0 2.9 1.4 2.2 1.2 4.1 0.9 2.5 3.6 1.5 2.2 5.8 0.9 1.7 2.0 1.4 1.2 1.5 1.6 1.7 5.0 1.3 1.5 1.2 1.5 0.9 0.9 5.5 1.1 1.7 6.4 0.8 3.6 0.5 0.8 4.2 4.0 1.3 1.2 3.4 2.2 23.8 1.0 36.0 1.1 3.5 7.1 1.3 2.1 1.9 1.6 5.4 0.7 3.3 1.2 0.5 16.9 9.1 13.1 11.7 0.9 2.3 8.3 15.0 7.2 16.8 17.7 9.8 8.4 20.0 7.1 7.4 11.3 15.3 7.8 18.1 14.9 6.9 22.5 11.3 8.6 0.5 18.1 11.5 0.8 1.3 14.4 9.4 11.1 15.9 19.0 12.6 7.7 17.6 5.7 15.8 7.5 11.5 21.3 9.6 4.7 10.2 11.7 7.0 16.1 11.9 7.7 7.7 10.4 6.5 15.8 16.1 11.4 20.2 6.3 13.0 19.6 7.4 13.9 14.7 4.3 0.7 1.1 1.1 0.4 0.5 1.7 1.2 1.0 0.5 1.9 0.8 0.8 5.4 3.3 0.3 1.6 1.1 0.5 1.3 2.4 1.4 2.2 1.4 1.2 1.3 1.5 1.1 1.0 STK11 "LKB1, PJS" ENSG00000118046 "Serine/threonine kinase 11" Q15831 19 1177558-1228435 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Apoptosis, Autophagy, Cell cycle, Differentiation, DNA damage, Spermatogenesis" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 11.7" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB016231, HPA017254, CAB022105, HPA067481" Approved Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "CAB016231: AB_627890, CAB022105: , HPA017254: AB_1852924, HPA067481: " "unprognostic (8.60e-2)" "unprognostic (1.68e-1)" "unprognostic (5.00e-2)" "prognostic favourable (3.69e-5)" "unprognostic (2.04e-2)" "prognostic favourable (1.96e-4)" "unprognostic (9.11e-3)" "unprognostic (3.19e-1)" "unprognostic (9.08e-2)" "unprognostic (1.26e-1)" "unprognostic (1.95e-3)" "unprognostic (7.70e-3)" "unprognostic (3.54e-2)" "unprognostic (3.16e-2)" "unprognostic (1.60e-1)" "unprognostic (3.31e-1)" "unprognostic (3.12e-3)" 13.4 13.7 13.5 11.8 12.4 19.3 16.7 17.8 16.0 12.2 16.1 8.3 19.8 18.1 10.8 8.7 15.1 10.0 11.8 15.3 12.6 9.8 10.7 22.1 9.4 12.5 9.7 10.4 11.0 16.8 10.7 11.6 12.2 9.9 12.2 5.3 11.9 16.0 12.2 49.2 16.8 18.0 7.7 7.6 16.9 15.5 59.8 7.5 11.8 12.4 14.5 19.0 11.4 9.8 2.7 1.9 11.7 6.3 1.9 1.8 0.5 21.1 10.2 7.8 14.7 7.4 6.7 16.5 10.3 10.8 9.7 10.4 8.3 14.8 13.9 11.5 10.8 13.7 7.6 15.9 3.0 25.9 18.7 14.2 0.6 10.5 15.9 14.2 23.8 12.2 11.6 7.5 11.1 9.7 26.5 19.1 5.5 15.8 13.7 14.4 14.9 12.6 21.7 8.3 15.5 8.8 15.5 18.1 13.0 0.0 7.7 11.1 12.1 23.4 13.1 10.1 11.4 19.7 16.4 37.6 15.8 10.4 10.0 19.0 10.3 2.0 4.2 4.5 0.6 6.0 0.4 2.7 1.0 1.8 1.9 1.0 1.0 0.9 11.7 1.9 6.3 1.0 0.7 0.5 13.5 12.4 17.8 16.0 12.6 9.8 9.7 10.4 9.9 7.5 STK19 "D6S60, G11, RP1" ENSG00000204344 "Serine/threonine kinase 19" P49842 6 31971091-31982821 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HDLM-2: 4.8;REH: 4.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA031510, HPA031511, HPA068559" Uncertain Supported "Nuclear speckles" "Nuclear speckles" "HPA031510: AB_10603119, HPA031511: AB_2673915, HPA068559: " "unprognostic (1.65e-1)" "unprognostic (2.30e-1)" "unprognostic (3.31e-1)" "unprognostic (1.86e-1)" "unprognostic (2.63e-1)" "unprognostic (1.67e-1)" "unprognostic (1.15e-2)" "unprognostic (4.26e-2)" "prognostic unfavourable (1.18e-4)" "unprognostic (3.95e-2)" "unprognostic (2.76e-3)" "unprognostic (2.25e-2)" "unprognostic (1.08e-2)" "unprognostic (1.02e-1)" "unprognostic (1.60e-1)" "unprognostic (2.40e-1)" "unprognostic (4.10e-1)" 6.4 8.2 3.8 4.3 6.5 2.9 4.0 9.9 6.3 5.7 6.6 5.5 4.2 2.2 6.0 5.5 5.3 3.5 5.3 3.6 5.0 3.5 3.9 6.6 4.1 2.5 4.3 7.5 5.7 12.4 4.7 4.6 6.3 4.0 6.2 2.7 5.6 2.9 6.7 6.1 6.8 2.6 5.9 3.7 7.0 6.3 7.9 4.2 2.6 4.7 4.1 3.8 4.4 4.2 2.1 2.7 0.4 3.8 0.9 1.1 0.5 0.0 0.3 0.0 1.1 2.9 1.7 0.0 2.3 0.3 0.5 1.1 0.0 1.9 1.5 0.6 1.2 2.0 0.0 0.6 0.9 4.8 0.9 3.6 0.9 0.2 1.4 3.7 0.0 1.5 0.1 0.8 0.3 0.0 0.0 0.6 0.2 0.0 0.0 0.0 0.6 0.0 4.4 2.4 1.1 0.0 0.0 1.0 0.9 0.3 0.6 0.2 1.7 0.0 0.0 0.0 1.1 1.1 0.0 0.1 2.3 0.1 1.9 0.6 0.1 0.0 3.8 0.1 0.6 1.4 0.7 2.1 0.9 0.1 2.7 1.0 1.1 0.5 0.4 0.9 1.4 1.5 0.1 0.5 3.8 6.5 9.9 6.3 5.0 3.5 4.3 7.5 4.0 4.2 STMN1 "C1orf215, FLJ32206, Lag, LAP18, OP18, PP17, PP19, PR22, SMN" ENSG00000117632 "Stathmin 1" P16949 1 25884181-25906991 "Cancer-related genes, Predicted intracellular proteins" "Differentiation, Neurogenesis" "Developmental protein" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 143.4;lymphoid tissue: 117.1" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "plasmacytoid DC: 79.3" "Group enriched" "Detected in all" 5 "dendritic cells: 79.3;T-cells: 26.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB010107 Enhanced Supported Cytosol 210000 Cytosol "CAB010107: AB_628297" "unprognostic (6.30e-2)" "unprognostic (2.40e-3)" "unprognostic (5.31e-2)" "unprognostic (7.94e-2)" "unprognostic (1.89e-1)" "unprognostic (5.02e-2)" "prognostic unfavourable (9.90e-7)" "unprognostic (9.45e-2)" "unprognostic (1.39e-2)" "unprognostic (1.61e-2)" "unprognostic (1.78e-1)" "unprognostic (3.33e-3)" "unprognostic (1.02e-2)" "unprognostic (1.68e-1)" "unprognostic (4.46e-2)" "unprognostic (1.05e-1)" "unprognostic (3.00e-2)" 7.3 13.2 91.7 17.5 47.4 40.7 10.9 54.1 124.8 6.2 16.7 47.0 2.5 12.7 24.7 7.8 13.0 7.3 9.4 9.5 67.9 88.4 13.2 6.4 11.0 42.8 86.5 58.0 33.6 3.5 4.6 12.1 21.7 43.4 5.2 20.7 7.7 5.3 6.3 3.8 9.5 15.9 18.8 143.4 10.9 9.7 58.2 27.1 117.1 6.1 7.2 43.1 13.0 8.1 8.6 79.3 4.0 1.5 10.1 26.2 9.3 67.5 15.2 151.7 60.6 9.1 8.8 15.4 52.7 41.9 75.3 72.9 10.4 69.5 83.1 29.6 38.4 20.7 42.0 30.5 113.3 25.1 20.8 51.5 26.9 36.3 3.6 64.8 36.8 5.4 4.5 30.3 34.6 56.6 69.5 82.9 97.5 17.6 213.2 95.3 93.0 20.5 126.2 118.3 49.3 36.4 6.1 102.8 89.2 47.9 24.0 42.0 34.4 82.6 27.2 50.6 60.1 43.8 43.9 48.9 77.6 103.2 24.9 126.8 54.5 2.0 0.7 4.0 10.4 1.5 6.3 6.4 9.3 13.1 4.2 8.6 15.3 13.7 0.3 10.1 0.7 79.3 26.2 9.3 91.7 47.4 54.1 124.8 67.9 88.4 86.5 58.0 43.4 27.1 STRAP "MAWD, pt-wd, UNRIP" ENSG00000023734 "Serine/threonine kinase receptor associated protein" Q9Y3F4 12 15882391-15903478 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "mRNA processing, mRNA splicing" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA027320, HPA055557, HPA073876" Approved Enhanced Cytosol 290000 Cytosol "HPA027320: AB_1857614, HPA055557: AB_2682849, HPA073876: AB_2686639" "unprognostic (4.64e-3)" "unprognostic (2.25e-2)" "unprognostic (9.88e-2)" "unprognostic (1.42e-2)" "unprognostic (2.88e-1)" "unprognostic (4.05e-3)" "prognostic unfavourable (6.83e-6)" "unprognostic (1.69e-2)" "unprognostic (3.71e-1)" "unprognostic (2.15e-2)" "unprognostic (1.53e-1)" "unprognostic (1.02e-1)" "unprognostic (3.60e-3)" "unprognostic (5.93e-2)" "unprognostic (2.54e-1)" "prognostic unfavourable (9.07e-4)" "prognostic unfavourable (5.10e-4)" 36.7 39.8 43.5 28.1 43.2 24.1 46.4 38.1 55.3 30.5 29.4 19.3 29.2 24.7 31.8 29.1 33.7 24.7 25.8 54.0 55.7 44.9 46.4 42.9 27.7 30.4 35.8 48.3 25.5 38.7 40.4 36.7 34.4 47.1 27.8 29.5 20.5 26.0 32.2 109.2 25.3 23.6 37.4 51.5 20.7 28.9 32.9 27.5 27.9 42.6 36.6 29.4 28.6 29.8 36.9 44.6 30.8 41.8 29.2 43.4 38.5 32.6 38.5 36.8 31.3 32.6 32.6 49.1 39.2 27.3 35.4 33.1 55.0 28.8 36.4 19.5 39.8 23.8 43.9 43.0 52.3 48.6 35.6 36.8 30.6 24.1 53.5 42.6 17.9 31.3 36.7 39.0 44.0 41.1 28.2 11.1 46.0 22.8 35.4 20.4 129.7 25.2 27.3 50.6 21.0 41.0 33.7 23.7 40.4 31.6 21.9 42.7 40.8 22.9 34.4 26.5 31.5 28.0 48.0 12.8 17.3 59.8 32.6 23.7 33.4 26.8 36.7 30.8 34.6 41.8 38.9 36.9 36.0 33.3 44.6 30.8 35.4 37.3 17.0 29.2 35.9 27.4 43.4 38.5 43.5 43.2 38.1 55.3 55.7 44.9 35.8 48.3 47.1 27.5 STRN "PPP2R6A, STRN1" ENSG00000115808 Striatin O43815 2 36843640-36966472 "Cancer-related genes, Predicted intracellular proteins" Calmodulin-binding "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA017286 Approved Approved Nucleoplasm,Cytosol 11000 Cytosol Nucleoplasm "HPA017286: AB_1857618" "unprognostic (1.65e-1)" "unprognostic (1.65e-1)" "unprognostic (3.57e-3)" "unprognostic (2.23e-2)" "unprognostic (3.25e-1)" "unprognostic (1.53e-1)" "unprognostic (1.63e-3)" "unprognostic (7.37e-2)" "unprognostic (1.25e-1)" "unprognostic (2.42e-1)" "unprognostic (1.77e-3)" "unprognostic (1.33e-1)" "prognostic favourable (2.27e-4)" "unprognostic (1.13e-1)" "unprognostic (6.43e-2)" "unprognostic (2.11e-1)" "unprognostic (3.43e-2)" 11.8 8.1 11.4 11.0 22.1 17.4 13.3 16.4 14.2 11.2 14.0 10.9 8.9 10.1 8.6 7.1 25.9 6.8 8.4 25.7 16.2 10.2 11.6 10.2 10.3 9.6 16.9 9.4 9.9 7.1 11.3 6.3 12.6 10.5 8.1 13.7 5.6 16.2 6.9 16.0 16.1 13.2 11.1 34.3 10.9 11.4 9.8 14.8 18.6 8.1 15.5 16.7 11.3 14.4 1.5 0.8 3.7 1.5 0.5 2.1 0.4 23.0 11.7 15.6 6.6 8.6 12.0 15.7 9.3 8.8 9.1 8.4 11.9 7.5 15.3 7.5 11.8 11.0 13.1 10.3 11.3 17.3 10.1 24.8 10.3 6.1 8.2 14.9 13.9 7.2 9.0 14.5 11.5 11.6 18.5 12.2 11.2 6.6 14.7 6.5 12.5 5.9 9.6 24.7 6.7 7.5 19.1 2.9 9.5 14.0 10.8 8.8 7.7 5.8 15.4 16.4 16.5 10.1 12.2 12.3 18.6 13.5 8.3 14.9 11.3 3.4 0.8 1.4 2.1 1.5 0.7 1.5 1.5 1.3 0.4 0.9 0.8 0.9 3.7 0.5 1.4 0.8 0.3 0.4 11.4 22.1 16.4 13.0 16.2 10.2 16.9 9.4 10.5 14.8 STT3A "ITM1, MGC9042, STT3-A, TMC" ENSG00000134910 "STT3A, catalytic subunit of the oligosaccharyltransferase complex" P46977 11 125591712-125625215 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins" "Glycosyltransferase, Transferase" "Cancer-related genes, Congenital disorder of glycosylation, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "parathyroid gland: 202.3" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA030735 Approved Uncertain Nucleoplasm,Vesicles,Cytosol "Nucleoplasm, Cytosol" Vesicles "HPA030735: AB_10603342" "unprognostic (8.25e-3)" "unprognostic (5.45e-2)" "unprognostic (3.02e-2)" "prognostic favourable (1.32e-4)" "unprognostic (5.10e-2)" "unprognostic (1.72e-2)" "prognostic unfavourable (3.57e-4)" "unprognostic (8.40e-2)" "unprognostic (4.80e-2)" "unprognostic (1.16e-2)" "unprognostic (8.96e-3)" "unprognostic (1.31e-1)" "prognostic unfavourable (4.96e-4)" "unprognostic (2.60e-2)" "unprognostic (6.38e-2)" "unprognostic (1.28e-1)" "unprognostic (1.82e-2)" 20.6 20.5 8.3 13.1 11.7 8.3 16.9 10.7 13.9 27.8 19.3 17.7 39.6 12.0 30.5 41.4 19.6 20.8 15.1 19.5 8.3 9.1 26.2 67.1 18.7 14.9 9.3 7.7 30.1 59.0 202.3 27.5 35.9 11.6 22.2 17.4 20.8 50.7 41.4 9.5 12.9 19.8 17.1 12.3 21.8 17.7 17.1 6.7 19.2 38.6 13.6 20.8 19.5 18.0 15.0 53.2 27.0 15.5 17.2 27.5 13.4 20.7 18.9 24.2 33.2 45.6 35.4 26.0 38.0 45.4 31.0 38.8 57.5 56.2 27.1 46.2 55.9 38.4 33.5 33.3 41.2 21.1 17.8 63.8 13.1 39.7 50.5 38.1 29.9 27.3 24.2 42.8 83.7 34.5 26.8 40.6 39.0 15.3 15.3 12.2 15.5 20.6 18.2 20.6 40.7 33.8 32.3 15.1 13.0 26.9 44.0 13.5 51.5 27.5 30.8 44.6 16.1 18.8 29.8 12.8 14.9 20.9 17.2 38.6 35.4 27.0 15.5 11.6 19.7 14.8 27.5 15.0 19.1 18.2 21.6 11.6 13.8 16.0 5.4 17.2 13.0 53.2 14.1 13.4 8.3 11.7 10.7 13.9 8.3 9.1 9.3 7.7 11.6 6.7 STX2 "EPIM, EPM, STX2A, STX2B, STX2C" ENSG00000111450 "Syntaxin 2" P32856 12 130789600-130839266 "Cancer-related genes, Predicted membrane proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA038189, HPA069176, CAB079007" Uncertain Supported Approved Nucleoplasm,Cytosol Nucleoplasm Cytosol "CAB079007: , HPA038189: , HPA069176: " "unprognostic (1.56e-2)" "unprognostic (3.43e-2)" "unprognostic (8.29e-2)" "unprognostic (2.22e-1)" "unprognostic (3.38e-2)" "unprognostic (9.85e-2)" "unprognostic (2.11e-2)" "unprognostic (4.16e-2)" "unprognostic (2.83e-1)" "unprognostic (7.62e-2)" "unprognostic (1.30e-2)" "unprognostic (5.69e-2)" "prognostic unfavourable (5.15e-5)" "unprognostic (3.81e-2)" "unprognostic (2.19e-1)" "unprognostic (1.63e-2)" "unprognostic (3.41e-3)" 15.9 14.5 16.0 15.4 13.4 8.8 27.0 12.5 18.7 13.1 18.8 15.3 8.8 6.1 18.1 15.4 9.6 19.4 14.5 16.4 15.5 11.4 12.2 12.0 18.3 11.9 12.7 12.4 16.0 10.7 11.9 16.3 18.0 17.9 10.2 10.2 9.8 5.2 15.7 6.3 6.1 10.7 23.5 24.8 12.3 11.7 23.2 12.3 9.7 12.6 6.9 9.4 13.5 22.2 2.6 1.6 4.6 2.4 1.4 3.1 0.9 4.7 9.5 13.8 10.7 12.8 29.1 1.4 20.1 16.2 24.9 16.5 2.6 3.3 6.1 3.2 22.0 1.3 12.6 3.3 25.9 9.2 4.3 3.2 8.3 7.4 13.8 4.7 8.0 10.8 4.1 12.1 9.7 12.2 12.7 5.7 21.2 2.8 6.6 4.8 9.2 13.1 7.0 9.0 3.2 13.7 1.0 13.2 12.9 10.2 0.9 8.5 3.2 3.0 16.4 14.3 10.1 15.7 8.8 4.2 3.3 4.0 16.5 5.2 11.2 4.6 2.2 2.8 2.4 2.4 2.4 2.6 2.7 2.7 1.5 1.7 2.9 3.1 3.0 1.4 1.2 1.6 1.9 0.9 16.0 13.4 12.5 18.7 15.5 11.4 12.7 12.4 17.9 12.3 SUFU "PRO1280, SUFUH, SUFUXL" ENSG00000107882 "SUFU negative regulator of hedgehog signaling" Q9UMX1 10 102503987-102633535 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Developmental protein" "Cancer-related genes, Ciliopathy, Disease mutation, Joubert syndrome, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA008700 Supported Supported Nucleoplasm Nucleoplasm "HPA008700: AB_1080125" "unprognostic (1.55e-1)" "unprognostic (4.00e-2)" "unprognostic (5.14e-2)" "unprognostic (1.33e-1)" "unprognostic (4.69e-2)" "unprognostic (5.68e-2)" "unprognostic (3.69e-2)" "unprognostic (5.99e-2)" "unprognostic (1.64e-1)" "unprognostic (3.15e-3)" "unprognostic (9.60e-2)" "unprognostic (2.13e-1)" "unprognostic (3.72e-3)" "unprognostic (1.82e-1)" "unprognostic (1.44e-1)" "unprognostic (5.10e-2)" "unprognostic (3.82e-3)" 10.7 12.8 15.0 15.2 12.8 3.9 18.3 23.0 15.3 13.4 10.4 11.3 12.1 7.7 14.4 13.3 14.7 14.2 16.2 11.0 11.8 7.8 10.8 10.0 21.4 20.5 11.9 11.0 18.0 8.9 20.0 7.8 13.9 10.0 15.4 8.8 11.9 12.6 16.7 14.1 23.1 9.4 14.3 10.7 13.1 7.9 21.1 13.1 19.9 6.2 12.7 15.0 15.2 15.0 2.3 4.5 6.2 5.5 2.8 3.1 2.8 6.4 6.8 11.1 15.9 11.5 9.7 5.4 6.7 13.0 9.7 8.8 6.3 4.8 6.6 19.1 7.4 4.6 13.6 7.4 6.4 4.0 10.5 15.7 3.9 5.9 5.5 5.7 11.3 11.0 5.9 7.2 5.9 12.5 3.5 6.1 5.9 5.4 10.8 8.6 3.2 5.1 11.7 12.0 3.4 6.4 9.7 3.8 6.0 5.3 5.0 6.0 10.9 3.8 13.7 4.3 6.2 4.6 7.3 5.0 3.2 4.8 5.4 11.2 2.9 4.2 4.5 6.2 2.5 5.5 2.0 2.3 3.1 2.8 4.5 2.1 2.2 2.5 1.1 2.8 5.5 2.5 1.9 2.8 15.0 12.8 23.0 15.3 11.8 7.8 11.9 11.0 10.0 13.1 SULT1E1 "EST, STE" ENSG00000109193 "Sulfotransferase family 1E member 1" P49888 4 69841212-69860152 "Cancer-related genes, Enzymes, Predicted intracellular proteins" Transferase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 37.8;liver: 26.2;vagina: 15.8" "Group enriched" "Detected in some" 19 "HHSteC: 37.1;HSkMC: 16.8;hTCEpi: 14.0;HUVEC TERT2: 10.2" "Low cancer specificity" "Detected in many" "Region enriched" "Detected in single" 8 "pons and medulla: 3.3" "Cell type enhanced" "Detected in single" "neutrophil: 1.7" "Low lineage specificity" "Detected in single" "HPA028213, HPA028728, CAB047344" Enhanced Uncertain "Nuclear membrane,Cytosol" "Nuclear membrane, Cytosol" "CAB047344: , HPA028213: AB_10599848, HPA028728: AB_10601894" "unprognostic (5.60e-2)" "prognostic favourable (4.06e-4)" "unprognostic (2.48e-1)" "unprognostic (1.07e-3)" "unprognostic (2.42e-1)" "unprognostic (1.95e-1)" "unprognostic (1.70e-1)" "unprognostic (1.72e-1)" "unprognostic (1.41e-1)" "unprognostic (2.89e-1)" "unprognostic (3.22e-3)" "unprognostic (8.62e-2)" "unprognostic (6.48e-5)" "unprognostic (2.48e-1)" "unprognostic (4.11e-2)" "unprognostic (5.55e-2)" 0.1 9.8 0.1 0.1 0.3 0.1 1.1 0.1 0.4 13.1 8.9 0.5 0.1 19.8 0.4 3.7 0.4 0.1 1.2 0.1 0.1 0.0 1.5 26.2 2.0 0.1 0.3 0.3 0.2 0.1 0.0 0.4 0.1 3.3 1.0 0.1 0.3 4.7 0.3 0.1 10.9 37.8 0.5 0.3 0.1 1.3 0.4 0.1 0.6 0.2 0.1 1.0 0.4 15.8 0.6 0.2 1.7 0.3 0.3 0.2 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 37.1 0.0 0.0 16.8 14.0 0.0 0.4 10.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.3 0.0 0.1 0.1 0.1 0.3 0.2 0.2 0.1 0.6 0.2 0.1 1.7 0.3 0.3 0.2 0.0 0.0 0.1 0.3 0.1 0.4 0.1 0.0 0.3 0.3 3.3 0.1 SUZ12 "CHET9, JJAZ1, KIAA0160" ENSG00000178691 "SUZ12 polycomb repressive complex 2 subunit" Q15022 17 31937018-32001045 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Transcription, Transcription regulation" "Chromatin regulator, Repressor" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA057436 Approved Supported "Nucleoplasm,Nucleoli,Nuclear bodies" "Nucleoplasm, Nucleoli, Nuclear bodies" "HPA057436: " "unprognostic (1.23e-1)" "unprognostic (1.11e-1)" "unprognostic (3.65e-3)" "unprognostic (1.23e-1)" "unprognostic (2.49e-1)" "unprognostic (7.31e-2)" "unprognostic (2.66e-3)" "unprognostic (8.05e-2)" "unprognostic (7.27e-2)" "unprognostic (3.06e-2)" "unprognostic (6.29e-2)" "unprognostic (8.70e-2)" "unprognostic (3.28e-2)" "unprognostic (2.25e-1)" "unprognostic (1.28e-1)" "unprognostic (5.91e-2)" "unprognostic (1.31e-1)" 10.1 10.8 13.4 15.4 10.4 25.5 33.5 16.0 13.8 11.2 11.4 7.5 13.6 10.1 12.5 8.1 12.3 9.8 7.7 9.7 9.1 7.6 10.9 11.5 10.6 19.9 9.3 9.9 10.0 10.1 15.5 10.4 15.3 9.5 10.7 10.9 6.9 10.1 9.6 8.7 9.9 12.2 9.6 7.7 15.2 10.7 17.1 12.5 31.8 12.0 6.5 18.9 10.8 19.5 5.5 4.6 4.1 2.6 4.4 5.5 1.2 14.0 12.5 11.8 13.5 6.8 8.8 12.1 13.7 12.1 16.9 20.5 9.4 7.9 30.8 10.6 8.5 12.5 17.5 7.9 27.5 10.8 17.0 21.3 10.6 6.8 8.0 33.5 21.9 6.1 8.9 16.8 12.9 10.3 20.5 42.8 14.5 4.9 39.8 19.5 6.7 7.6 23.8 30.2 24.9 9.9 13.8 15.1 11.8 22.1 7.2 13.2 20.8 28.0 7.6 13.4 12.2 16.1 21.1 23.4 29.1 38.1 9.8 20.7 12.1 1.4 1.9 3.8 3.8 2.6 3.0 5.5 4.1 4.0 1.4 4.4 3.9 5.5 4.1 4.4 1.8 4.6 4.2 1.2 13.4 10.4 16.0 13.8 9.1 7.6 9.3 9.9 9.5 12.5 SYK ENSG00000165025 "Spleen associated tyrosine kinase" P43405 9 90801787-90898549 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Adaptive immunity, Angiogenesis, Host-virus interaction, Immunity, Innate immunity" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 38.5" "Cell line enhanced" "Detected in many" "Daudi: 38.7;HEL: 22.3;HL-60: 30.8;HMC-1: 20.5;REH: 25.8;THP-1: 23.7;U-698: 18.3;U-937: 21.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 15 "classical monocyte: 21.4;eosinophil: 23.3;intermediate monocyte: 19.0;memory B-cell: 23.1;myeloid DC: 24.9;naive B-cell: 17.5;neutrophil: 32.8;NK-cell: 8.7;non-classical monocyte: 16.4;plasmacytoid DC: 18.5" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA001384, CAB007773" Enhanced Approved "Vesicles,Plasma membrane,Cytosol" 1000000 "Plasma membrane, Cytosol" Vesicles "CAB007773: AB_562232, HPA001384: AB_1080144" "unprognostic (1.01e-1)" "unprognostic (5.45e-2)" "unprognostic (2.10e-1)" "unprognostic (2.69e-2)" "unprognostic (2.31e-1)" "unprognostic (7.92e-2)" "unprognostic (1.06e-1)" "unprognostic (1.34e-1)" "unprognostic (6.41e-2)" "unprognostic (1.78e-2)" "unprognostic (7.20e-2)" "unprognostic (9.93e-2)" "unprognostic (2.55e-3)" "unprognostic (8.77e-2)" "unprognostic (5.36e-3)" "unprognostic (3.41e-2)" "unprognostic (1.06e-2)" 7.2 3.3 6.0 38.1 9.6 18.2 6.7 1.1 4.5 3.7 10.3 6.7 1.5 12.3 2.3 6.7 16.2 6.9 6.6 5.5 7.2 3.2 8.6 2.5 13.7 36.4 9.1 2.5 2.1 8.9 25.9 3.1 5.0 6.1 4.1 8.3 2.8 8.9 1.8 1.4 8.3 22.2 3.5 11.3 38.5 7.4 5.5 7.9 30.5 18.1 7.8 32.2 8.6 7.5 23.1 24.9 32.8 21.4 8.7 0.1 10.2 6.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.5 38.7 1.1 0.0 6.0 0.8 3.2 0.0 0.0 5.3 22.3 0.0 0.0 0.0 30.8 20.5 0.0 4.4 0.0 0.4 0.0 0.6 3.1 0.0 4.7 0.0 13.5 0.2 0.0 25.8 0.0 10.6 0.8 5.8 2.0 1.8 0.0 2.7 0.0 2.5 23.7 0.0 0.0 0.1 0.0 0.0 0.0 0.0 18.3 0.0 21.7 0.0 1.4 21.4 23.3 0.1 19.0 0.1 23.1 0.0 0.0 24.9 17.5 0.0 0.0 32.8 8.7 16.4 18.5 0.0 10.2 6.0 9.6 1.1 4.5 7.2 3.2 9.1 2.5 6.1 7.9 SYNE1 "8B, ARCA1, C6orf98, CPG2, dJ45H2.2, enaptin, KIAA0796, MYNE1, Nesp1, Nesprin-1, SCAR8, SYNE-1B" ENSG00000131018 "Spectrin repeat containing nuclear envelope protein 1" Q8NF91 6 152121684-152637801 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Differentiation, Spermatogenesis" Actin-binding "Cancer-related genes, Disease mutation, Emery-Dreifuss muscular dystrophy, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "U-266/70: 18.9" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in many" 5 "eosinophil: 33.8" "Lineage enriched" "Detected in many" 5 "granulocytes: 33.8" HPA019113 Approved Supported "Nucleoplasm,Nuclear membrane" "Nucleoplasm, Nuclear membrane" "HPA019113: AB_1857707" "unprognostic (9.99e-2)" "unprognostic (1.91e-1)" "unprognostic (2.22e-2)" "unprognostic (1.75e-1)" "unprognostic (2.28e-1)" "unprognostic (9.58e-3)" "unprognostic (1.11e-1)" "unprognostic (3.55e-3)" "unprognostic (1.58e-1)" "unprognostic (9.85e-2)" "unprognostic (8.87e-3)" "unprognostic (2.70e-1)" "unprognostic (4.14e-3)" "unprognostic (5.83e-2)" "unprognostic (1.82e-1)" "unprognostic (1.42e-1)" "unprognostic (2.78e-1)" 12.7 11.5 18.2 9.1 30.2 41.7 9.0 62.0 25.0 16.8 7.3 9.8 12.4 2.7 15.2 18.4 6.2 12.9 7.9 22.7 21.0 17.5 18.4 11.2 16.1 13.7 13.2 15.1 27.7 10.6 37.3 37.0 4.7 19.7 10.1 6.3 10.5 3.6 12.5 22.0 16.9 5.3 19.1 9.7 15.5 9.0 8.3 11.6 9.0 20.6 9.5 12.1 10.0 12.3 3.2 0.8 33.8 1.5 4.7 6.4 1.4 0.1 3.9 2.8 3.2 3.9 8.6 1.0 8.8 4.6 2.3 4.2 0.8 0.1 8.3 0.5 4.8 0.2 1.0 2.3 2.4 10.0 2.7 3.5 2.6 2.7 9.0 0.6 1.6 5.5 0.5 5.0 10.3 4.4 0.0 9.5 6.2 0.4 1.4 0.1 0.6 1.5 1.9 5.5 2.3 8.9 0.1 1.7 2.6 1.4 0.5 6.1 0.5 0.3 5.9 10.7 14.5 3.7 4.8 18.9 8.0 13.3 5.9 1.9 3.1 3.0 1.1 33.8 6.4 0.7 4.1 2.9 4.2 6.1 0.8 3.2 4.0 5.1 1.1 4.7 1.5 0.7 5.1 1.4 18.2 30.2 62.0 25.0 21.0 17.5 13.2 15.1 19.7 11.6 TAF1 "BA2R, CCG1, CCGS, DYT3, DYT3/TAF1, KAT4, NSCL2, TAF2A, TAFII250" ENSG00000147133 "TATA-box binding protein associated factor 1" P21675 X 71366239-71532374 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors" "Cell cycle, Host-virus interaction, Transcription, Transcription regulation" "Acyltransferase, DNA-binding, Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, Dystonia, Mental retardation, Parkinsonism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "HPA001075, CAB016283" Supported Enhanced Nucleoplasm Nucleoplasm "CAB016283: AB_671202, HPA001075: AB_1080179" "unprognostic (2.95e-2)" "unprognostic (1.77e-1)" "unprognostic (6.45e-3)" "unprognostic (1.91e-2)" "unprognostic (1.88e-2)" "unprognostic (1.23e-1)" "unprognostic (1.44e-1)" "prognostic favourable (6.54e-4)" "unprognostic (2.68e-2)" "unprognostic (3.43e-2)" "unprognostic (2.03e-1)" "unprognostic (5.59e-2)" "prognostic unfavourable (6.03e-4)" "unprognostic (1.14e-2)" "unprognostic (1.41e-1)" "unprognostic (1.82e-2)" "unprognostic (2.56e-2)" 20.1 16.2 15.0 17.1 19.8 16.3 17.7 20.7 18.0 20.7 15.5 23.8 17.1 10.0 25.4 17.1 14.4 19.1 16.1 12.9 15.4 12.0 11.9 12.9 13.8 17.8 18.5 16.5 23.9 17.5 25.5 19.3 15.4 17.3 16.9 15.4 20.8 14.5 16.1 19.6 16.8 17.1 18.3 17.2 21.3 15.8 12.2 21.3 19.4 20.1 12.0 18.7 18.4 15.8 5.0 4.7 5.2 4.8 4.2 4.9 1.8 11.2 9.8 11.2 7.5 9.0 15.6 7.0 8.4 7.8 8.9 7.4 7.3 6.8 10.5 7.2 9.4 10.7 15.6 6.7 11.4 6.9 13.7 12.5 12.9 7.2 6.5 23.7 12.1 9.1 6.8 9.5 18.0 9.2 17.0 25.5 9.0 7.9 13.1 10.5 12.9 12.9 12.1 22.8 12.8 6.0 14.6 5.9 9.2 23.4 8.2 10.4 6.0 12.6 11.6 10.5 8.8 8.4 5.8 10.9 10.1 13.6 5.8 19.1 7.8 4.4 4.1 1.1 4.4 2.8 3.8 3.0 4.6 4.5 4.7 5.0 4.4 4.9 5.2 4.2 4.8 3.5 3.1 1.8 15.0 19.8 20.7 18.0 15.4 12.0 18.5 16.5 17.3 21.3 TAF15 "hTAFII68, Npl3, RBP56, TAF2N" ENSG00000270647 "TATA-box binding protein associated factor 15" Q92804 17 35713791-35864615 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "DNA-binding, RNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA052059, HPA063647" Supported Enhanced Nucleoplasm Nucleoplasm "HPA052059: , HPA063647: " "unprognostic (1.26e-1)" "unprognostic (2.66e-3)" "unprognostic (1.10e-1)" "unprognostic (1.63e-2)" "unprognostic (1.82e-1)" "unprognostic (1.27e-1)" "unprognostic (8.48e-3)" "unprognostic (4.75e-2)" "unprognostic (8.06e-3)" "unprognostic (2.08e-2)" "unprognostic (2.33e-1)" "unprognostic (1.44e-2)" "unprognostic (1.79e-2)" "unprognostic (1.39e-2)" "unprognostic (5.41e-2)" "unprognostic (3.35e-2)" "unprognostic (2.99e-1)" 14.0 12.9 12.7 15.3 16.2 13.9 11.0 13.7 14.1 10.5 11.7 15.0 13.2 12.7 10.2 11.0 12.6 8.0 11.5 13.1 11.8 9.8 15.0 8.9 19.4 14.7 8.3 10.7 11.3 14.6 18.1 11.1 11.1 11.4 10.1 9.2 9.8 15.3 26.9 14.7 13.4 17.5 15.9 12.7 11.0 11.3 15.5 21.1 9.4 12.8 15.8 12.0 9.8 3.7 3.2 3.8 3.6 4.7 7.2 2.2 28.7 47.3 25.3 24.5 20.3 11.5 16.6 32.9 11.2 15.0 14.7 31.6 20.8 57.2 23.7 21.3 30.6 33.6 33.1 21.7 16.1 43.9 32.9 34.4 33.1 20.0 53.1 22.1 18.3 17.4 22.7 35.7 20.2 30.8 23.7 16.9 34.3 57.9 12.9 15.6 13.6 34.6 37.6 21.4 19.0 51.7 19.2 18.9 41.0 12.4 13.0 29.0 18.3 27.3 11.6 25.3 16.7 39.5 22.4 27.3 41.7 22.9 26.2 19.0 3.8 3.5 3.5 4.9 3.4 7.2 3.0 3.5 3.8 2.5 3.7 3.3 3.7 2.0 4.7 3.6 3.2 3.9 2.2 TAGLN "DKFZp686P11128, SM22, SMCC, TAGLN1, WS3-10" ENSG00000149591 Transgelin Q01995 11 117199321-117204782 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Actin-binding, Muscle protein" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "BJ: 136.3;BJ hTERT+ SV40 Large T+: 129.6;CACO-2: 122.3;EFO-21: 162.6;fHDF/TERT166: 138.9;LHCN-M2: 95.9;U-138 MG: 126.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 9 "intermediate monocyte: 19.0;non-classical monocyte: 26.6" "Lineage enriched" "Detected in many" 10 "monocytes: 26.6" "Low region specificity" "Detected in all" "Region enhanced" "Detected in many" "midbrain: 176.0" "CAB001447, HPA019467" Enhanced Approved Microtubules,Mitochondria,Cytosol 8000000 "Microtubules, Mitochondria" Cytosol "CAB001447: AB_564012, HPA019467: AB_1857245" "unprognostic (1.36e-2)" "unprognostic (1.06e-1)" "unprognostic (3.57e-3)" "unprognostic (1.91e-1)" "unprognostic (6.58e-2)" "unprognostic (1.02e-2)" "unprognostic (2.39e-2)" "unprognostic (7.16e-2)" "unprognostic (2.35e-2)" "unprognostic (1.24e-1)" "unprognostic (4.43e-2)" "unprognostic (1.76e-1)" "prognostic unfavourable (2.12e-7)" "unprognostic (9.58e-3)" "unprognostic (3.03e-1)" "unprognostic (1.10e-1)" "unprognostic (2.52e-3)" 73.3 22.6 2.3 67.6 5.9 0.2 60.8 2.1 7.7 278.3 328.7 6.1 156.2 22.3 399.7 156.8 337.9 133.3 227.5 48.7 3.1 3.0 49.5 12.9 44.1 38.6 7.1 11.8 159.2 9.3 1.5 8.0 36.2 14.9 237.5 51.6 39.1 24.1 347.5 36.6 17.9 81.0 481.9 9.1 26.0 114.7 65.1 2.1 1.1 47.3 30.0 11.2 473.0 78.1 2.6 1.4 0.8 26.6 0.0 0.3 0.9 1.2 0.3 21.4 0.5 10.0 9.0 18.0 136.3 59.1 129.6 48.5 122.3 1.9 0.2 162.6 138.9 3.2 0.3 1.1 36.9 0.4 0.2 0.3 4.5 8.3 55.7 0.1 0.3 23.7 4.6 18.9 2.4 0.2 0.2 0.4 95.9 0.2 0.1 1.0 6.5 0.1 0.1 1.6 0.6 0.2 1.7 0.1 0.5 2.1 0.7 0.1 0.6 0.3 14.6 126.3 21.3 0.9 5.8 0.6 0.4 1.0 0.7 0.4 0.3 0.8 1.1 0.0 0.1 19.0 0.2 1.6 0.0 0.0 1.4 2.6 0.1 0.0 0.1 0.0 26.6 0.7 0.3 0.9 2.3 5.9 2.1 7.7 3.1 3.0 7.1 11.8 14.9 2.1 TAL1 "bHLHa17, SCL, TCL5" ENSG00000162367 "TAL bHLH transcription factor 1, erythroid differentiation factor" P17542 1 47216290-47232220 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Differentiation, Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "bone marrow: 33.1" "Cell line enhanced" "Detected in some" "HEL: 52.8;HMC-1: 25.4;HUVEC TERT2: 11.0;K-562: 16.5;MOLT-4: 8.8;TIME: 12.0" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 5 "basophil: 3.2;neutrophil: 1.2" "Lineage enriched" "Detected in single" 7 "granulocytes: 3.2" "Region enriched" "Detected in some" 5 "midbrain: 17.1" "Low region specificity" "Detected in many" "CAB017805, HPA047866, HPA073983" Approved Enhanced Nucleoplasm Nucleoplasm "CAB017805: , HPA047866: , HPA073983: " "unprognostic (2.63e-1)" "unprognostic (2.62e-2)" "unprognostic (1.22e-1)" "unprognostic (2.40e-2)" "unprognostic (1.59e-1)" "unprognostic (8.80e-3)" "unprognostic (3.95e-3)" "unprognostic (1.33e-1)" "unprognostic (4.15e-2)" "unprognostic (1.99e-2)" "unprognostic (5.42e-3)" "unprognostic (3.68e-1)" "unprognostic (1.02e-2)" "unprognostic (2.76e-2)" "unprognostic (2.19e-1)" "unprognostic (1.51e-1)" "unprognostic (1.18e-2)" 9.1 2.7 7.0 1.8 5.7 33.1 7.1 1.6 6.9 3.3 2.4 12.0 2.3 1.6 3.7 3.3 2.5 4.1 4.2 3.9 8.8 3.5 4.5 2.4 14.6 2.2 11.1 4.4 1.5 1.3 2.2 2.1 9.8 7.3 2.4 2.4 2.1 1.4 3.0 3.1 2.0 3.3 4.4 9.4 8.5 2.1 1.8 9.2 0.0 6.7 4.1 1.5 2.5 5.5 0.3 0.1 3.2 0.3 0.4 0.4 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 3.7 0.0 0.0 0.0 0.0 52.8 0.0 0.0 0.0 0.0 25.4 0.0 0.0 0.0 0.0 11.0 16.5 0.0 0.0 0.0 8.8 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 12.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.2 0.1 0.2 0.1 0.3 0.1 0.1 0.1 0.1 0.0 0.3 0.4 0.1 1.2 0.4 0.1 0.1 0.1 2.2 7.0 5.7 1.6 6.9 8.8 3.5 11.1 4.4 7.3 9.2 TAL2 bHLHa19 ENSG00000186051 "TAL bHLH transcription factor 2" Q16559 9 105662457-105663112 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 11 "blood: 8.8;kidney: 4.6;skeletal muscle: 17.3" "Cell line enhanced" "Detected in some" "HAP1: 4.8;K-562: 12.6" "Cancer enhanced" "Detected in some" "renal cancer: 1.6" "Group enriched" "Detected in some" 21 "memory B-cell: 8.8;naive B-cell: 7.9;plasmacytoid DC: 2.2" "Group enriched" "Detected in many" 18 "B-cells: 8.8;dendritic cells: 2.2" "Low region specificity" "Detected in single" "Not detected" "Not detected" HPA030886 Uncertain Approved Cytosol Cytosol "HPA030886: AB_10601596" "unprognostic (3.89e-2)" "unprognostic (1.45e-1)" "unprognostic (8.51e-2)" "unprognostic (5.54e-2)" "unprognostic (2.24e-1)" "unprognostic (9.06e-2)" "unprognostic (4.98e-2)" "unprognostic (1.03e-1)" "unprognostic (2.70e-3)" "unprognostic (2.63e-1)" "unprognostic (7.00e-4)" "unprognostic (2.84e-2)" "prognostic favourable (2.69e-4)" "unprognostic (2.70e-2)" "unprognostic (1.24e-1)" "unprognostic (1.29e-1)" "unprognostic (7.39e-2)" 0.1 0.3 0.5 0.1 0.7 0.0 0.0 0.3 0.6 0.2 0.0 0.0 0.2 0.9 0.1 0.2 0.0 0.3 0.4 0.5 4.6 0.3 0.0 0.2 0.7 0.3 0.1 0.0 0.8 0.1 0.1 0.1 0.0 0.2 17.3 0.1 0.1 0.0 0.8 0.3 0.0 0.6 0.1 0.4 0.1 0.0 8.8 2.2 0.0 0.0 0.3 0.0 0.1 0.0 0.6 2.5 0.7 0.3 0.0 0.3 0.1 0.3 0.1 0.4 3.3 0.2 0.1 0.2 0.0 0.1 4.8 0.0 0.1 0.6 0.5 1.1 0.0 0.0 0.2 0.5 1.8 0.2 0.5 0.1 0.2 0.0 12.6 0.3 0.4 0.3 0.8 0.7 0.2 0.2 0.1 0.1 0.0 0.0 0.0 2.8 1.1 0.2 0.2 0.2 0.2 2.0 0.5 0.3 0.8 0.7 1.0 0.9 1.9 0.1 0.2 2.3 0.8 0.0 0.0 0.0 0.0 0.0 0.0 8.8 0.0 0.0 0.0 7.9 0.0 0.0 0.0 0.3 0.0 2.2 0.0 0.1 TAP1 "ABCB2, D6S114E, PSF1, RING4" ENSG00000168394 "Transporter 1, ATP binding cassette subfamily B member" Q03518 6 32845209-32853978 "Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Adaptive immunity, Host-virus interaction, Immunity, Peptide transport, Protein transport, Transport" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 45.3" "Cell line enhanced" "Detected in many" "BEWO: 16.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB009516, HPA072354" Approved Supported "Endoplasmic reticulum,Centriolar satellite" 110000 "Endoplasmic reticulum, Centriolar satellite" "CAB009516: AB_2303048, HPA072354: " "unprognostic (3.59e-2)" "unprognostic (1.06e-1)" "prognostic favourable (9.01e-4)" "unprognostic (1.33e-1)" "unprognostic (1.84e-1)" "unprognostic (3.22e-2)" "unprognostic (4.92e-2)" "unprognostic (6.16e-3)" "unprognostic (2.56e-2)" "prognostic favourable (4.07e-4)" "unprognostic (3.02e-3)" "unprognostic (2.37e-1)" "prognostic unfavourable (6.58e-5)" "unprognostic (2.07e-2)" "unprognostic (4.69e-2)" "unprognostic (2.42e-2)" "unprognostic (2.21e-2)" 10.7 7.9 3.8 20.4 5.2 6.1 8.7 3.1 4.9 6.5 12.6 4.5 1.9 9.1 8.2 3.9 10.5 6.4 9.6 6.5 3.5 3.3 6.5 6.4 17.6 26.9 6.4 3.6 5.0 4.4 3.0 3.6 8.7 6.0 9.0 5.4 6.6 9.4 4.4 7.5 15.3 19.5 5.7 5.2 24.2 12.6 5.8 4.9 20.8 13.1 8.9 20.3 6.6 7.6 22.7 8.8 45.3 10.9 14.4 25.3 21.0 2.8 1.8 0.0 1.7 0.9 1.2 16.6 1.5 3.4 6.9 9.4 0.1 3.0 5.9 3.9 1.1 5.5 1.1 2.4 0.4 10.1 1.5 6.6 1.3 2.3 4.3 0.0 2.4 1.3 2.1 1.9 1.2 1.7 0.4 5.6 0.8 1.7 1.1 13.1 0.0 1.9 5.9 1.2 3.9 8.9 0.5 0.0 0.3 1.6 4.2 5.7 3.8 11.8 0.9 2.6 1.0 6.3 0.0 7.5 10.4 1.7 1.7 4.0 1.8 27.7 10.6 44.2 15.5 10.9 16.3 22.7 17.5 16.4 8.8 20.9 25.3 19.4 45.3 14.4 10.5 7.2 21.7 21.0 3.8 5.2 3.1 4.9 3.5 3.3 6.4 3.6 6.0 4.9 TBC1D12 KIAA0608 ENSG00000108239 "TBC1 domain family member 12" O60347 10 94402504-94535930 "Cancer-related genes, Predicted intracellular proteins" "GTPase activation" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 41.6" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "myeloid DC: 2.2" "Group enriched" "Detected in many" 13 "B-cells: 1.4;dendritic cells: 2.2;monocytes: 1.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA038277, HPA038645" Uncertain Approved "Nucleoplasm,Nuclear speckles" "Nucleoplasm, Nuclear speckles" "HPA038277: AB_10672584, HPA038645: AB_10672650" "unprognostic (7.23e-3)" "unprognostic (1.58e-2)" "prognostic favourable (1.79e-5)" "unprognostic (7.83e-2)" "unprognostic (1.76e-1)" "unprognostic (4.91e-2)" "unprognostic (1.21e-2)" "unprognostic (7.34e-2)" "unprognostic (6.56e-2)" "unprognostic (9.43e-2)" "unprognostic (1.81e-1)" "unprognostic (1.59e-1)" "unprognostic (2.27e-2)" "unprognostic (9.43e-2)" "unprognostic (3.71e-1)" "unprognostic (1.29e-1)" "unprognostic (1.12e-1)" 6.9 4.9 8.9 4.0 18.1 1.2 8.1 7.5 14.8 5.3 8.4 39.2 7.1 6.2 5.6 4.0 4.7 4.3 5.1 4.4 12.4 8.5 5.8 4.1 5.2 3.0 25.5 8.7 5.8 7.1 16.8 3.2 7.8 23.1 6.0 9.7 5.9 3.6 6.5 4.3 5.7 6.9 6.0 41.6 5.6 4.2 10.9 21.3 0.2 4.3 1.5 3.5 5.7 4.9 1.4 2.2 0.0 1.1 0.0 0.1 0.2 7.6 3.4 4.5 6.7 6.3 7.7 5.9 5.0 10.3 5.6 5.3 13.6 3.4 0.0 3.0 7.3 4.3 5.4 3.7 7.2 0.0 6.1 2.4 3.1 4.3 4.8 0.0 1.9 5.2 4.7 5.9 7.6 6.0 3.5 8.0 9.0 4.2 0.0 0.0 1.4 3.6 0.0 5.8 4.0 5.0 3.4 1.9 4.5 5.0 4.3 4.0 9.4 4.6 5.9 3.9 5.4 6.3 3.9 5.7 5.4 0.0 3.9 0.0 2.1 0.0 1.1 0.0 0.0 0.7 0.0 0.5 0.0 0.0 2.2 1.4 0.1 0.0 0.0 0.0 0.4 0.0 0.0 0.2 8.9 18.1 7.5 13.4 12.4 8.5 25.5 8.7 23.1 21.3 TBL1XR1 "C21, DC42, FLJ12894, IRA1, TBLR1" ENSG00000177565 "Transducin beta like 1 X-linked receptor 1" Q9BZK7 3 177019340-177228000 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Transcription, Transcription regulation, Ubl conjugation pathway" "Activator, Chromatin regulator, Repressor" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "U-698: 69.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA019182 Supported Approved Nucleoplasm Nucleoplasm "HPA019182: AB_1857800" "unprognostic (4.11e-2)" "unprognostic (3.00e-1)" "unprognostic (1.33e-2)" "unprognostic (1.27e-3)" "prognostic favourable (5.16e-5)" "unprognostic (4.44e-2)" "prognostic unfavourable (1.08e-7)" "unprognostic (3.75e-1)" "unprognostic (4.84e-2)" "unprognostic (3.04e-1)" "unprognostic (3.13e-3)" "unprognostic (2.50e-1)" "prognostic unfavourable (4.25e-5)" "unprognostic (5.83e-2)" "unprognostic (1.69e-1)" "unprognostic (1.50e-1)" "unprognostic (1.17e-1)" 20.7 26.0 27.4 24.3 26.8 27.3 20.3 27.5 28.1 28.9 29.9 22.6 15.4 24.0 23.9 20.5 23.8 21.9 22.7 30.3 26.2 20.7 19.9 21.8 30.8 27.8 21.4 25.9 26.5 19.9 30.6 11.3 24.0 19.7 24.4 23.2 24.7 21.3 17.7 21.1 17.8 24.3 21.9 19.6 24.7 21.3 17.4 22.3 28.4 45.6 14.9 32.1 29.1 25.5 7.4 13.3 12.9 4.6 6.8 8.3 4.1 23.4 12.0 15.6 8.8 13.3 14.5 9.3 7.4 11.5 6.4 8.9 13.8 19.4 24.0 35.1 10.6 14.5 11.7 15.5 13.0 25.2 3.7 13.5 20.6 8.2 11.4 21.4 8.0 21.3 8.0 9.5 23.6 10.0 10.1 42.6 8.3 8.4 20.0 2.9 9.9 8.2 11.5 19.9 25.6 5.8 33.2 5.6 9.0 10.0 7.9 9.3 28.6 16.4 15.3 10.6 8.9 5.9 16.0 23.3 29.8 69.5 7.1 16.0 12.0 11.4 3.0 3.8 5.8 4.6 5.1 7.3 5.7 6.6 4.0 7.4 5.0 6.4 12.9 6.8 3.9 13.3 8.3 4.1 27.4 26.8 27.5 28.1 26.2 20.7 21.4 25.9 19.7 22.3 TBX3 "TBX3-ISO, UMS, XHL" ENSG00000135111 "T-box 3" O15119 12 114670254-114684164 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Developmental protein, DNA-binding, Repressor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "seminal vesicle: 117.7" "Cell line enhanced" "Detected in many" "BJ: 33.8;BJ hTERT+: 32.2;RT4: 42.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in single" "Low region specificity" "Detected in many" "HPA005799, HPA075876" Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "HPA005799: AB_1857817, HPA075876: " "unprognostic (3.27e-1)" "unprognostic (2.64e-1)" "unprognostic (2.84e-1)" "unprognostic (1.11e-1)" "unprognostic (3.40e-2)" "unprognostic (5.97e-3)" "unprognostic (1.56e-1)" "unprognostic (2.99e-2)" "unprognostic (9.43e-2)" "unprognostic (1.15e-1)" "unprognostic (3.35e-1)" "unprognostic (3.06e-1)" "unprognostic (3.64e-3)" "unprognostic (1.09e-3)" "unprognostic (1.43e-1)" "unprognostic (1.01e-1)" "prognostic favourable (3.28e-4)" 4.3 60.5 0.9 3.3 1.9 0.0 19.9 0.7 2.3 18.2 12.2 1.7 69.6 14.2 13.1 18.7 1.9 7.5 5.0 6.2 1.2 1.5 4.1 15.1 12.6 0.8 1.2 0.5 15.6 1.1 0.3 5.3 67.8 1.6 32.3 1.5 2.6 7.3 117.7 4.2 4.8 19.4 9.7 1.4 2.6 2.2 3.5 1.2 0.5 36.3 7.3 3.5 24.6 25.2 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.7 5.9 0.0 0.0 8.9 12.3 13.4 33.8 32.2 13.1 13.0 5.3 1.4 0.0 0.5 5.8 1.5 2.8 1.2 16.2 0.0 4.0 0.0 1.5 15.4 2.9 0.0 0.0 5.4 0.8 4.4 9.1 0.1 1.2 0.0 1.1 0.5 0.0 0.1 0.0 1.8 0.0 0.0 0.8 0.0 42.2 2.2 6.5 4.8 2.2 1.1 1.6 0.0 0.0 4.0 2.6 2.2 10.9 0.0 0.0 0.0 8.4 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 1.9 0.7 2.3 1.2 1.5 1.2 0.5 1.6 1.2 TCEA1 "GTF2S, SII, TCEA, TF2S, TFIIS" ENSG00000187735 "Transcription elongation factor A1" P23193 8 53966552-54022529 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA043786 Approved Supported Nucleoplasm,Nucleoli Nucleoplasm Nucleoli "HPA043786: AB_10959468" "unprognostic (5.35e-2)" "unprognostic (9.90e-2)" "unprognostic (2.39e-1)" "unprognostic (2.11e-3)" "unprognostic (3.34e-2)" "unprognostic (1.17e-1)" "unprognostic (3.72e-2)" "unprognostic (1.77e-1)" "unprognostic (4.14e-2)" "unprognostic (1.00e-2)" "unprognostic (1.56e-2)" "unprognostic (1.25e-1)" "prognostic unfavourable (3.75e-5)" "unprognostic (3.80e-3)" "unprognostic (1.10e-1)" "unprognostic (1.13e-1)" "unprognostic (3.05e-2)" 26.7 25.3 30.7 40.5 31.5 29.6 31.1 26.1 27.4 26.0 28.3 21.9 26.6 20.3 27.3 20.9 27.5 23.6 24.7 21.4 27.8 24.2 26.5 56.8 22.3 39.2 29.7 17.6 28.5 38.4 32.2 28.7 21.1 27.1 31.3 22.5 20.6 25.4 25.4 21.8 22.8 22.4 38.9 36.8 30.0 26.1 17.3 31.3 39.9 54.6 18.6 46.9 39.6 37.3 60.0 31.9 20.5 17.8 25.2 40.1 17.8 26.8 27.2 24.3 25.0 17.3 21.5 17.4 21.3 25.0 25.2 28.2 15.5 22.5 65.9 24.3 24.4 20.7 30.7 19.5 36.8 37.7 15.4 49.8 13.3 22.9 54.3 19.5 21.5 15.4 52.8 23.7 104.8 21.5 31.6 57.3 22.9 12.7 40.4 13.7 39.6 8.1 31.3 8.5 11.8 34.8 18.3 22.8 16.6 17.6 15.5 57.2 22.4 21.9 19.0 18.6 17.1 20.8 19.1 35.4 22.1 44.7 32.7 22.4 26.1 18.1 17.8 20.5 30.1 16.8 28.6 60.0 31.4 27.7 22.1 44.4 28.0 29.1 6.4 25.2 15.6 31.9 40.1 17.8 30.7 31.5 26.1 27.4 27.8 24.2 29.7 17.6 27.1 31.3 TCF12 "bHLHb20, HEB, HsT17266, HTF4" ENSG00000140262 "Transcription factor 12" Q99081 15 56918623-57299281 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Differentiation, Neurogenesis, Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes, Craniosynostosis, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 89.4" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004432, HPA065827" Approved Supported "Nucleoplasm,Nuclear speckles" "Nucleoplasm, Nuclear speckles" "CAB004432: AB_671267, HPA065827: " "unprognostic (1.19e-1)" "unprognostic (1.11e-1)" "unprognostic (8.26e-2)" "unprognostic (1.65e-1)" "unprognostic (2.07e-3)" "unprognostic (1.11e-1)" "unprognostic (6.63e-2)" "unprognostic (1.85e-1)" "prognostic unfavourable (8.89e-4)" "unprognostic (7.83e-2)" "unprognostic (7.26e-3)" "unprognostic (5.57e-3)" "prognostic unfavourable (5.24e-5)" "unprognostic (2.03e-1)" "unprognostic (2.93e-1)" "unprognostic (3.15e-2)" "unprognostic (1.41e-1)" 20.9 14.3 24.9 12.6 37.5 10.9 18.4 32.7 41.8 48.2 16.5 33.6 14.0 16.0 28.1 15.0 14.8 28.2 21.4 15.7 28.4 16.4 17.0 14.4 17.3 13.7 33.9 15.3 26.2 12.5 29.2 15.7 19.1 27.9 26.3 17.9 14.7 20.1 17.5 18.1 16.0 15.8 25.8 25.3 13.6 17.3 14.7 41.3 89.4 17.0 9.6 15.8 23.3 21.2 11.8 15.9 16.0 19.3 12.2 17.6 10.2 6.5 12.3 54.2 17.5 24.7 21.7 9.5 13.5 23.8 12.0 16.0 8.0 5.3 9.0 11.1 20.4 7.9 21.2 9.7 15.4 11.8 7.9 18.1 13.4 9.5 17.1 11.3 9.5 19.1 17.6 11.0 29.2 21.4 20.2 11.4 16.3 2.2 26.7 6.3 14.6 5.3 36.6 63.0 8.4 16.5 12.2 11.1 32.1 14.6 5.3 13.1 8.2 22.3 16.5 19.4 14.8 8.2 19.7 6.5 11.6 15.0 10.8 22.1 23.1 16.0 11.2 8.7 15.0 14.3 12.4 10.8 12.2 13.6 15.9 11.8 14.1 12.7 1.3 12.2 19.3 6.6 17.6 10.2 24.9 37.5 32.7 26.9 28.4 16.4 33.9 15.3 27.9 41.3 TCF3 "bHLHb21, E2A, E47, ITF1, MGC129647, MGC129648, VDIR" ENSG00000071564 "Transcription factor 3" P15923 19 1609290-1652605 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Differentiation, Neurogenesis, Transcription, Transcription regulation" DNA-binding "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "U-698: 95.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB018351, HPA049808, HPA062476" Approved Enhanced Nucleoplasm Nucleoplasm "CAB018351: AB_675504, HPA049808: , HPA062476: " "unprognostic (8.82e-2)" "unprognostic (4.74e-2)" "unprognostic (1.26e-2)" "unprognostic (1.25e-1)" "unprognostic (1.91e-2)" "unprognostic (8.25e-3)" "prognostic unfavourable (2.46e-4)" "unprognostic (2.07e-2)" "unprognostic (7.99e-2)" "unprognostic (2.35e-1)" "unprognostic (2.42e-1)" "unprognostic (9.29e-3)" "prognostic unfavourable (1.53e-4)" "unprognostic (4.87e-3)" "unprognostic (1.88e-1)" "unprognostic (3.07e-1)" "unprognostic (8.05e-2)" 13.0 8.8 12.8 31.6 9.8 33.2 17.4 8.3 11.9 15.5 16.2 11.9 9.4 18.1 16.6 11.3 16.7 12.1 19.0 9.4 11.2 6.2 11.9 8.9 13.2 42.0 10.7 6.0 18.2 13.5 6.3 13.9 10.8 11.0 17.1 9.7 12.4 13.6 6.9 11.2 16.7 23.0 8.8 10.4 33.1 14.9 36.0 11.2 63.2 15.9 11.6 38.0 15.2 13.9 11.3 12.1 2.9 2.8 2.3 4.2 1.6 15.7 8.1 22.3 19.9 3.2 8.5 9.9 9.8 7.7 11.2 10.0 15.9 12.4 75.4 11.1 8.0 16.3 13.6 10.6 6.6 45.6 9.0 7.1 10.2 17.4 7.3 17.3 10.0 5.4 12.3 8.8 6.8 13.5 29.1 26.1 7.1 27.7 47.8 16.9 30.9 8.5 75.0 10.2 17.0 7.5 13.8 21.2 29.8 9.2 9.2 11.3 11.6 30.9 16.2 14.8 17.5 18.2 16.6 63.8 31.1 95.0 9.6 22.1 13.2 2.9 1.3 0.9 3.5 1.4 3.7 10.8 2.2 3.2 2.7 11.3 3.2 4.2 0.4 2.3 2.8 12.1 2.1 1.6 12.8 9.8 8.3 11.9 11.2 6.2 10.7 6.0 11.0 11.2 TCF7 TCF-1 ENSG00000081059 "Transcription factor 7" P36402 5 134114711-134151865 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation, Wnt signaling pathway" "Activator, DNA-binding, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 9 "lymphoid tissue: 326.1" "Cell line enriched" "Detected in many" 15 "MOLT-4: 166.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Group enriched" "Detected in many" 4 "MAIT T-cell: 10.3;memory CD4 T-cell: 17.8;memory CD8 T-cell: 10.4;naive CD4 T-cell: 35.8;naive CD8 T-cell: 21.8;NK-cell: 14.2" "Group enriched" "Detected in many" 19 "NK-cells: 14.2;T-cells: 35.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB019403, HPA058863, HPA070505" Enhanced Enhanced Nucleoplasm Nucleoplasm "CAB019403: AB_2199302, HPA058863: , HPA070505: " "unprognostic (3.63e-3)" "unprognostic (1.98e-3)" "unprognostic (1.03e-1)" "unprognostic (5.08e-3)" "unprognostic (1.70e-1)" "unprognostic (6.74e-2)" "unprognostic (1.12e-1)" "unprognostic (6.38e-2)" "unprognostic (2.31e-1)" "unprognostic (1.65e-1)" "unprognostic (5.35e-2)" "unprognostic (2.32e-1)" "unprognostic (3.04e-1)" "unprognostic (1.50e-2)" "unprognostic (2.33e-2)" "unprognostic (1.90e-1)" "unprognostic (4.10e-2)" 1.8 3.6 1.3 21.8 1.5 5.2 3.1 0.9 1.2 2.1 3.3 2.5 2.2 5.6 1.4 16.3 2.7 16.1 2.6 1.6 1.5 1.2 2.7 3.7 4.0 41.8 1.3 1.0 2.5 7.2 0.2 6.1 1.4 4.7 2.9 2.3 3.6 7.9 1.8 0.9 2.9 15.1 0.9 3.3 14.4 3.7 2.4 1.1 326.1 4.4 2.2 32.5 3.3 1.5 1.2 0.1 1.0 0.1 14.2 35.8 6.9 0.0 1.0 1.1 3.8 0.5 2.1 1.5 0.3 0.5 0.1 0.1 7.9 2.5 0.0 1.9 1.7 0.1 1.7 0.4 0.0 0.3 1.6 0.0 1.0 5.9 0.0 0.0 0.2 0.1 0.0 1.6 0.0 0.2 1.0 0.0 0.1 0.0 166.9 0.1 1.2 1.4 0.2 0.0 0.1 0.4 0.1 0.4 3.3 0.8 0.2 0.2 0.2 0.9 0.2 10.8 0.0 4.9 0.3 0.1 0.0 0.0 5.7 0.0 0.5 0.7 0.1 1.0 4.4 0.0 10.3 1.2 17.8 10.4 0.0 0.4 35.8 21.8 0.7 14.2 0.0 0.1 2.1 6.9 1.3 1.5 0.9 1.2 1.5 1.2 1.3 1.0 4.7 1.1 TCF7L2 "TCF-4, TCF4" ENSG00000148737 "Transcription factor 7 like 2" Q9NQB0 10 112950250-113167678 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation, Wnt signaling pathway" "Activator, DNA-binding, Repressor" "Cancer-related genes, Diabetes mellitus" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 9 "intermediate monocyte: 12.1;non-classical monocyte: 33.1" "Lineage enriched" "Detected in many" 13 "monocytes: 33.1" "Group enriched" "Detected in many" 8 "midbrain: 84.5;thalamus: 98.3" "Group enriched" "Detected in all" 5 "midbrain: 190.1;pons and medulla: 104.8;thalamus: 169.1" "CAB013535, HPA038800" Supported Approved "Nucleoplasm,Nuclear bodies,Cytosol" Nucleoplasm "Nuclear bodies, Cytosol" "CAB013535: AB_2533167, HPA038800: " "unprognostic (1.79e-2)" "unprognostic (3.36e-1)" "unprognostic (1.11e-1)" "unprognostic (2.31e-2)" "unprognostic (4.59e-3)" "unprognostic (1.72e-1)" "unprognostic (2.09e-1)" "unprognostic (9.84e-2)" "unprognostic (5.09e-1)" "unprognostic (7.10e-2)" "unprognostic (6.10e-3)" "unprognostic (3.46e-2)" "unprognostic (7.25e-3)" "unprognostic (1.60e-1)" "unprognostic (1.55e-1)" "unprognostic (3.64e-1)" "unprognostic (7.36e-3)" 27.4 10.3 8.7 18.7 10.0 7.3 46.4 5.4 10.3 27.4 34.2 15.4 28.1 21.0 26.6 14.9 12.6 18.2 15.3 13.5 8.1 17.9 10.2 22.9 26.9 13.9 8.5 9.0 25.6 13.9 16.5 17.9 24.0 10.2 14.4 23.7 13.9 14.9 52.8 13.7 17.6 40.4 18.0 13.9 27.3 24.0 10.6 10.1 6.6 14.3 9.3 7.0 21.5 16.3 0.0 1.7 2.5 33.1 0.0 0.6 1.1 7.0 18.5 20.3 19.6 10.6 7.1 24.2 5.0 9.8 3.5 4.3 12.2 21.5 0.0 5.7 9.4 5.0 6.9 8.7 4.5 0.8 6.4 5.0 12.3 11.3 11.3 1.9 1.8 12.5 3.2 5.5 9.3 5.9 5.1 0.3 4.1 13.8 3.1 1.2 14.6 10.7 8.9 14.9 3.2 7.6 9.9 0.4 6.2 7.6 7.6 8.1 4.9 1.0 13.6 3.3 9.6 8.4 10.3 1.3 0.1 0.1 3.3 4.2 7.4 0.1 1.8 0.1 0.6 12.1 0.4 0.0 0.1 0.5 1.7 0.0 0.1 0.3 2.5 0.0 33.1 0.0 0.0 1.1 8.7 10.0 5.4 10.3 8.1 17.9 8.5 9.0 10.2 10.1 TCL1A TCL1 ENSG00000100721 "T cell leukemia/lymphoma 1A" P56279 14 95709967-95714196 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 12 "blood: 179.4;lymphoid tissue: 63.7" "Group enriched" "Detected in some" 157 "Daudi: 69.4;REH: 90.3;U-698: 92.2" "Cancer enriched" "Detected in many" 18 "testis cancer: 64.4" "Not detected" "Not detected" "Group enriched" "Detected in some" 381 "memory B-cell: 45.6;naive B-cell: 179.4;plasmacytoid DC: 79.8" "Group enriched" "Detected in many" 487 "B-cells: 179.4;dendritic cells: 79.8" "Not detected" "Not detected" "CAB004045, HPA016604" Enhanced Enhanced "Nucleoplasm,Endoplasmic reticulum,Cytosol" "Endoplasmic reticulum, Cytosol" Nucleoplasm "CAB004045: AB_2179419, HPA016604: AB_1857859" "unprognostic (1.27e-3)" "unprognostic (3.12e-4)" "unprognostic (2.61e-4)" "unprognostic (2.01e-2)" "unprognostic (1.27e-1)" "unprognostic (4.75e-4)" "unprognostic (7.70e-2)" "unprognostic (9.67e-3)" "unprognostic (1.03e-1)" "unprognostic (3.35e-1)" "unprognostic (1.14e-1)" "unprognostic (2.14e-2)" "unprognostic (2.64e-2)" "unprognostic (1.87e-1)" "unprognostic (3.94e-1)" "unprognostic (2.06e-1)" "unprognostic (4.55e-1)" 0.4 0.2 0.2 53.4 0.2 4.8 0.3 0.2 0.2 0.2 0.9 0.0 0.2 0.0 0.3 0.0 0.8 0.3 0.6 0.3 0.2 0.2 1.1 0.4 3.2 63.7 0.2 0.0 0.3 0.2 0.0 0.2 0.6 0.0 0.4 0.2 0.1 2.9 0.0 0.2 0.2 10.4 0.1 0.2 33.5 0.5 5.3 0.0 4.7 0.8 1.2 53.6 3.6 0.3 179.4 79.8 0.2 0.1 0.0 0.1 6.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 69.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 90.3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.4 0.0 0.0 0.0 0.5 92.2 0.0 0.0 0.0 0.2 0.1 0.1 0.0 0.0 0.1 45.6 0.0 0.0 0.1 179.4 0.1 0.0 0.2 0.0 0.1 79.8 0.0 6.0 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.0 0.0 0.0 TCP11L2 MGC40368 ENSG00000166046 "T-complex 11 like 2" Q8N4U5 12 106301929-106347015 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 32.1" "Lineage enriched" "Detected in many" 5 "granulocytes: 32.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA039483, HPA042188" Uncertain Supported "Nuclear speckles" "Nuclear speckles" "HPA039483: AB_10795291, HPA042188: AB_10794415" "unprognostic (1.41e-1)" "unprognostic (3.17e-1)" "unprognostic (1.24e-1)" "unprognostic (8.15e-2)" "unprognostic (1.97e-1)" "prognostic favourable (9.52e-4)" "unprognostic (3.87e-3)" "unprognostic (2.43e-1)" "unprognostic (2.11e-1)" "unprognostic (9.05e-3)" "unprognostic (5.44e-2)" "unprognostic (1.33e-1)" "unprognostic (1.22e-2)" "unprognostic (1.24e-1)" "unprognostic (1.28e-1)" "unprognostic (5.02e-2)" "unprognostic (3.67e-1)" 9.1 12.0 8.1 6.2 18.2 22.3 9.0 10.4 13.0 9.7 8.6 31.5 3.3 6.2 10.3 7.1 20.1 11.6 8.1 18.9 8.3 5.8 6.1 5.6 14.4 12.9 22.2 9.4 9.7 8.6 11.1 7.2 12.3 16.2 7.5 7.9 9.5 15.9 5.9 18.0 14.0 10.3 10.2 14.6 10.2 10.2 8.7 18.4 16.4 12.2 6.3 14.0 11.3 11.8 6.2 0.8 32.1 3.2 1.9 6.3 1.7 2.6 6.6 1.0 1.9 9.2 10.7 4.2 1.7 8.6 1.1 2.8 1.0 3.6 0.9 2.7 6.7 12.6 0.8 3.7 2.0 1.4 2.8 0.5 2.5 4.0 9.0 0.3 1.8 13.4 8.7 1.3 6.5 6.2 1.6 1.3 1.5 1.9 1.6 1.4 1.2 4.2 0.8 0.2 3.0 8.7 12.5 4.2 3.1 4.5 1.4 5.2 3.9 0.3 4.7 1.6 1.4 2.4 0.4 8.4 0.6 3.2 4.6 0.2 0.8 10.8 3.2 4.9 2.4 1.4 1.8 6.2 4.9 2.7 0.8 5.7 6.3 4.1 32.1 1.9 2.2 0.6 5.6 1.7 8.1 18.2 10.4 13.0 8.3 5.8 22.2 9.4 16.2 18.4 TDRD10 DKFZp434M202 ENSG00000163239 "Tudor domain containing 10" Q5VZ19 1 154502219-154548147 "Cancer-related genes, Predicted intracellular proteins" RNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 10 "testis: 48.4" "Group enriched" "Detected in some" 10 "EFO-21: 2.2;HUVEC TERT2: 7.5;RPMI-8226: 2.1;TIME: 4.0" "Cancer enhanced" "Detected in many" "testis cancer: 5.9" "Low region specificity" "Detected in some" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA054327 Approved Vesicles Vesicles "HPA054327: " "unprognostic (1.30e-1)" "unprognostic (6.33e-2)" "unprognostic (1.78e-1)" "unprognostic (5.33e-3)" "unprognostic (9.69e-3)" "unprognostic (5.80e-3)" "unprognostic (2.99e-1)" "unprognostic (5.97e-3)" "unprognostic (2.44e-2)" "unprognostic (2.06e-1)" "unprognostic (1.00e-3)" "unprognostic (1.61e-1)" "unprognostic (1.34e-3)" "unprognostic (1.15e-2)" "unprognostic (1.13e-1)" "prognostic favourable (8.04e-5)" "unprognostic (1.62e-1)" 4.1 1.4 0.7 1.1 0.9 0.0 2.6 0.7 1.4 1.3 0.8 0.9 1.4 0.5 2.1 2.0 1.0 2.1 1.2 2.3 0.7 0.0 1.0 1.5 3.3 1.6 0.9 1.2 4.6 0.7 0.8 0.8 1.4 1.2 1.1 1.1 0.7 0.7 1.0 1.1 0.7 1.0 1.4 1.2 3.5 0.5 48.4 0.8 0.7 4.9 1.5 1.0 1.0 2.9 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.5 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 2.1 0.0 0.0 0.0 0.1 0.3 0.0 0.0 0.0 0.1 4.0 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.7 0.9 0.7 1.4 0.7 0.0 0.9 1.2 1.2 0.8 TDRD6 "bA446F17.4, CT41.2, NY-CO-45, SPATA36" ENSG00000180113 "Tudor domain containing 6" O60522 6 46687875-46704319 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Differentiation, Spermatogenesis" "Developmental protein" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "testis: 37.9" "Cell line enhanced" "Detected in some" "HEK 293: 1.6;HeLa: 3.9;hTCEpi: 2.2;PC-3: 3.3;SCLC-21H: 1.6" "Cancer enhanced" "Detected in some" "prostate cancer: 2.1" "Region enriched" "Detected in many" 6 "cerebellum: 8.2" "Cell type enhanced" "Detected in some" "classical monocyte: 2.4;intermediate monocyte: 1.4" "Lineage enhanced" "Detected in single" "monocytes: 2.4" "Low region specificity" "Detected in single" "Not detected" "Not detected" HPA075923 Enhanced "HPA075923: " "unprognostic (2.01e-1)" "unprognostic (7.41e-3)" "unprognostic (7.25e-3)" "unprognostic (3.88e-2)" "unprognostic (3.54e-1)" "unprognostic (4.10e-2)" "unprognostic (1.03e-1)" "unprognostic (4.32e-2)" "unprognostic (7.97e-2)" "unprognostic (2.50e-1)" "unprognostic (2.20e-3)" "unprognostic (2.20e-1)" "unprognostic (2.79e-1)" "unprognostic (2.86e-1)" "unprognostic (2.00e-1)" "unprognostic (2.16e-2)" "unprognostic (4.38e-3)" 0.7 1.4 0.7 2.6 1.3 0.0 0.7 8.2 1.3 0.7 0.7 0.7 0.7 0.3 0.7 2.9 0.7 0.3 1.7 0.7 1.0 0.8 0.7 1.3 0.7 3.0 1.1 0.7 0.7 0.7 0.4 1.8 1.1 0.7 1.6 0.0 0.9 0.9 0.7 1.5 2.9 0.7 0.7 0.9 1.9 0.3 37.9 0.7 0.7 5.2 0.7 0.7 1.6 0.7 0.0 0.7 0.1 2.4 0.0 0.0 0.4 0.0 0.0 0.2 1.5 0.2 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 1.0 0.4 0.0 0.0 0.0 1.6 0.0 3.9 0.0 0.0 0.0 0.0 0.2 2.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 3.3 0.0 0.0 0.0 0.9 0.6 1.6 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.3 0.6 0.1 0.0 1.1 0.0 0.4 0.0 0.0 0.7 0.0 2.4 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.4 0.7 1.3 8.2 0.9 1.0 0.8 1.1 0.7 0.7 0.7 TEK "CD202b, TIE-2, TIE2, VMCM, VMCM1" ENSG00000120156 "TEK receptor tyrosine kinase" Q02763 9 27109141-27230175 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins" Angiogenesis "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Glaucoma" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Group enriched" "Detected in some" 9 "HUVEC TERT2: 35.8;NTERA-2: 17.8;TIME: 38.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "neutrophil: 2.2" "Lineage enhanced" "Detected in single" "granulocytes: 2.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010359, HPA073265" Approved Supported "Plasma membrane,Centriolar satellite" "Secreted to blood" 7750000 8300000 "Plasma membrane" "Centriolar satellite" "CAB010359: AB_2203226, HPA073265: " "unprognostic (2.24e-1)" "unprognostic (1.74e-1)" "unprognostic (5.55e-2)" "unprognostic (1.83e-2)" "unprognostic (1.68e-1)" "unprognostic (1.26e-3)" "prognostic favourable (2.31e-5)" "unprognostic (7.48e-2)" "unprognostic (1.72e-2)" "unprognostic (1.41e-1)" "unprognostic (5.58e-2)" "unprognostic (2.72e-1)" "prognostic favourable (7.81e-4)" "unprognostic (7.50e-3)" "unprognostic (6.87e-3)" "unprognostic (1.83e-1)" "unprognostic (5.24e-3)" 28.6 7.8 8.1 4.6 5.9 0.4 17.9 3.4 5.4 10.8 4.7 4.6 3.4 3.2 14.5 5.3 6.7 5.9 9.1 13.0 7.1 6.1 25.4 8.7 27.8 2.9 6.9 3.4 6.1 4.5 3.5 4.0 36.3 6.9 5.4 4.7 12.4 3.4 5.5 7.8 3.0 5.3 10.6 5.3 23.4 4.0 3.7 3.5 0.3 9.7 8.4 2.4 6.4 12.4 0.0 0.1 2.2 0.6 0.0 0.0 0.0 0.1 0.0 1.4 0.0 0.2 2.3 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 2.3 1.0 0.0 0.6 0.0 0.0 0.7 0.0 0.8 0.3 35.8 0.0 0.0 0.3 0.0 0.0 0.0 17.8 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 38.8 0.0 0.2 3.6 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 8.1 5.9 3.4 5.4 7.1 6.1 6.9 3.4 6.9 3.5 TERT "EST2, hEST2, TCS1, TP2, TRT" ENSG00000164362 "Telomerase reverse transcriptase" O14746 5 1253147-1295069 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins" "DNA-binding, Nucleotidyltransferase, Ribonucleoprotein, RNA-directed DNA polymerase, Transferase" "Cancer-related genes, Disease mutation, Dyskeratosis congenita" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 6 "bone marrow: 3.4;lymphoid tissue: 12.0;testis: 5.0" "Cell line enhanced" "Detected in some" "ASC TERT1: 61.2;fHDF/TERT166: 58.1;HBEC3-KT: 118.1;hTEC/SVTERT24-B: 74.6;LHCN-M2: 33.7;TIME: 96.1" "Low cancer specificity" "Detected in some" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in single" "Low region specificity" "Detected in many" "HPA054641, HPA065897" Supported Supported "Nucleoplasm,Nuclear speckles,Cytosol" Nucleoplasm "Nuclear speckles, Cytosol" "HPA054641: , HPA065897: " "unprognostic (1.21e-2)" "unprognostic (2.88e-2)" "unprognostic (1.24e-3)" "unprognostic (1.53e-1)" "unprognostic (1.43e-3)" "unprognostic (6.42e-3)" "unprognostic (1.85e-2)" "unprognostic (2.21e-1)" "unprognostic (6.91e-2)" "unprognostic (1.89e-1)" "unprognostic (3.59e-1)" "unprognostic (9.16e-4)" "unprognostic (8.84e-11)" "unprognostic (1.92e-1)" "unprognostic (2.15e-1)" "unprognostic (3.35e-1)" 0.0 0.0 0.0 7.1 0.9 3.4 0.0 0.0 0.2 0.1 1.1 0.0 0.0 1.0 0.1 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 1.0 2.4 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.9 0.0 0.0 1.0 0.4 5.0 0.0 12.0 0.0 0.0 2.8 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 30.6 61.2 0.5 0.0 23.3 4.2 7.9 0.1 0.1 0.7 0.0 58.1 0.0 0.2 118.1 5.0 0.0 0.3 0.0 0.0 0.1 0.0 0.3 0.2 0.0 3.0 74.6 0.8 0.2 0.6 0.1 33.7 0.0 0.2 1.6 0.4 0.2 0.8 0.0 0.8 3.4 0.2 0.0 0.3 0.0 0.0 0.0 0.0 0.2 96.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.2 0.0 0.0 0.7 0.0 0.0 0.0 TET1 "bA119F7.1, CXXC6, KIAA1676, LCX" ENSG00000138336 "Tet methylcytosine dioxygenase 1" Q8NFU7 10 68560656-68694482 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, Chromatin regulator, Dioxygenase, DNA-binding, Oxidoreductase, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "BEWO: 15.1;HAP1: 17.2;K-562: 9.6;NTERA-2: 10.1" "Cancer enriched" "Detected in some" 15 "testis cancer: 10.4" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019032, HPA057273" Supported "Nucleoplasm,Nuclear membrane" Nucleoplasm "Nuclear membrane" "HPA019032: AB_1847363, HPA057273: " "unprognostic (1.60e-1)" "unprognostic (8.30e-2)" "unprognostic (9.85e-2)" "unprognostic (1.67e-2)" "unprognostic (1.27e-1)" "unprognostic (8.15e-2)" "unprognostic (3.60e-3)" "unprognostic (1.12e-1)" "unprognostic (2.00e-1)" "unprognostic (7.90e-3)" "unprognostic (1.83e-1)" "unprognostic (1.71e-1)" "unprognostic (1.18e-3)" "unprognostic (2.88e-4)" "unprognostic (4.02e-2)" "unprognostic (2.54e-1)" "unprognostic (9.52e-3)" 4.4 1.6 3.3 4.3 2.6 1.6 3.1 4.4 4.3 5.1 2.4 5.8 3.2 1.2 6.0 3.4 2.4 2.9 3.5 2.4 3.5 2.3 1.8 1.5 1.6 1.7 2.5 2.6 6.1 1.6 7.4 2.2 5.8 2.9 3.2 2.0 8.1 15.9 4.8 4.0 2.2 1.8 6.5 3.6 1.7 2.2 1.4 5.9 1.2 3.2 3.2 1.8 5.1 5.4 1.3 1.1 1.0 0.0 0.9 2.3 0.2 0.6 0.7 6.8 7.7 0.7 0.6 15.1 0.3 0.8 0.6 1.1 4.6 0.2 0.0 0.2 0.7 0.0 17.2 0.0 0.7 0.2 2.7 1.8 0.0 4.0 1.0 1.5 0.9 0.9 0.1 0.4 0.0 0.1 9.6 1.2 0.6 0.5 2.7 1.2 10.1 0.9 2.6 2.2 0.2 0.3 0.7 1.9 3.0 0.3 0.4 1.4 0.9 1.2 0.2 0.6 1.4 0.0 0.5 0.5 0.5 2.7 0.1 0.0 0.1 0.0 0.0 1.0 1.5 0.0 2.0 1.3 0.8 1.3 0.2 0.5 1.4 1.1 0.0 0.9 0.0 1.1 2.3 0.2 3.3 2.6 4.4 2.6 3.5 2.3 2.5 2.6 2.9 5.9 TET2 "FLJ20032, KIAA1546" ENSG00000168769 "Tet methylcytosine dioxygenase 2" Q6N021 4 105145875-105279816 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Cell cycle" "Chromatin regulator, Dioxygenase, DNA-binding, Oxidoreductase" "Cancer-related genes, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 29.0" "Lineage enriched" "Detected in all" 4 "granulocytes: 29.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA043135 Supported Approved Nucleoplasm Nucleoplasm "HPA043135: AB_10794177" "unprognostic (6.83e-2)" "unprognostic (3.52e-2)" "unprognostic (1.69e-2)" "unprognostic (9.42e-2)" "unprognostic (4.15e-2)" "unprognostic (5.88e-2)" "unprognostic (6.12e-2)" "unprognostic (1.19e-3)" "unprognostic (1.15e-2)" "unprognostic (1.57e-2)" "unprognostic (5.77e-2)" "unprognostic (7.29e-2)" "unprognostic (2.70e-3)" "unprognostic (6.10e-2)" "unprognostic (1.89e-1)" "unprognostic (9.15e-2)" "unprognostic (7.84e-2)" 9.9 6.1 8.7 11.9 11.4 26.3 8.0 4.1 10.0 9.6 7.4 10.1 5.8 8.2 10.1 7.4 16.2 9.2 6.6 6.8 9.0 4.2 6.7 5.5 9.9 9.8 13.7 5.7 8.5 7.0 7.4 29.0 12.4 9.1 6.5 8.0 4.7 13.5 8.2 9.8 16.0 10.2 7.8 15.5 12.9 6.8 3.2 14.6 9.3 7.2 6.9 8.7 9.8 12.3 2.8 5.1 29.0 7.0 2.6 2.1 1.4 4.7 3.1 10.4 10.6 1.9 4.3 4.3 3.4 4.6 4.9 4.8 3.1 6.4 0.5 3.9 4.3 4.6 10.1 6.0 5.6 6.2 2.7 6.6 5.9 1.1 5.3 15.1 11.1 3.6 8.1 4.7 6.1 6.5 7.1 12.5 4.2 3.6 2.5 4.1 2.3 1.9 7.8 5.2 0.9 4.5 10.0 7.4 6.1 3.8 9.8 0.6 4.4 10.9 8.4 7.5 6.8 2.1 5.8 8.4 6.0 6.3 4.6 3.7 7.3 10.8 7.0 7.2 2.1 5.5 0.8 2.6 1.2 1.2 5.1 2.8 1.0 1.6 29.0 2.6 6.4 4.5 1.5 1.4 8.7 11.4 4.1 10.0 9.0 4.2 13.7 5.7 9.1 14.6 TF "PRO1557, PRO2086" ENSG00000091513 Transferrin P02787 3 133745956-133796640 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Ion transport, Iron transport, Transport" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 12 "liver: 711.5" "Cell line enriched" "Detected in some" 48 "Hep G2: 129.1" "Cancer enriched" "Detected in many" 42 "liver cancer: 783.0" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA001527, HPA005692, CAB009538" Enhanced "Secreted to blood" 2500000000000 120000000000 "CAB009538: AB_793365, HPA001527: AB_1080357, HPA005692: AB_1080354" "prognostic favourable (4.05e-4)" "unprognostic (2.45e-2)" "unprognostic (1.78e-1)" "unprognostic (1.50e-1)" "unprognostic (8.99e-2)" "unprognostic (5.18e-2)" "unprognostic (6.63e-2)" "unprognostic (8.46e-2)" "unprognostic (2.82e-1)" "unprognostic (3.08e-1)" "unprognostic (1.37e-1)" "unprognostic (7.60e-2)" "prognostic unfavourable (2.35e-13)" "unprognostic (2.17e-3)" "unprognostic (5.49e-2)" "unprognostic (3.47e-3)" "unprognostic (9.70e-2)" 7.8 1.3 6.7 1.2 26.7 1.3 1.9 3.7 20.4 1.4 1.3 57.2 0.0 1.2 1.3 1.3 1.8 1.3 1.3 2.4 11.3 7.4 1.5 711.5 1.3 1.3 50.8 12.3 1.4 1.6 1.4 0.8 1.3 40.2 1.5 1.3 14.0 4.0 1.3 1.3 1.3 1.2 1.3 46.9 1.3 1.3 2.4 39.9 0.0 1.4 0.0 1.4 1.3 0.6 1.1 1.0 2.6 1.1 0.9 0.8 0.4 0.3 0.2 0.3 0.2 0.9 0.6 0.1 0.3 0.3 0.1 0.1 0.5 0.2 0.2 0.2 0.3 0.3 0.2 0.3 0.2 0.1 0.1 2.7 0.4 129.1 0.2 0.7 0.4 0.4 0.6 0.1 0.2 0.3 1.0 0.3 0.4 0.2 0.1 0.2 0.2 0.3 0.2 0.5 0.1 0.1 0.5 0.3 0.2 0.3 0.4 1.0 0.3 0.2 0.4 0.4 0.2 0.2 0.1 0.3 0.4 0.2 0.3 0.2 0.2 2.6 1.1 0.7 0.6 0.7 0.6 0.6 0.6 0.6 0.6 1.1 0.8 0.8 2.4 0.9 0.7 1.0 0.4 0.4 6.7 26.7 3.7 19.6 11.3 7.4 50.8 12.3 40.2 39.9 TFAP2B AP2-B ENSG00000008196 "Transcription factor AP-2 beta" Q92481 6 50818723-50847613 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "epididymis: 65.5" "Group enriched" "Detected in some" 4 "AF22: 31.7;SH-SY5Y: 59.0" "Cancer enriched" "Detected in some" 8 "breast cancer: 12.1" "Group enriched" "Detected in some" 41 "cerebellum: 4.7;pons and medulla: 6.3" "Not detected" "Not detected" "Not detected" "Not detected" "Region enhanced" "Detected in some" "cerebellum: 11.2" "Low region specificity" "Detected in many" "HPA034683, HPA062942" Enhanced Approved Nucleoplasm Nucleoplasm "HPA034683: AB_10670966, HPA062942: " "unprognostic (2.02e-1)" "unprognostic (2.29e-2)" "unprognostic (4.27e-2)" "unprognostic (5.88e-4)" "unprognostic (9.76e-2)" "unprognostic (2.10e-1)" "unprognostic (1.00e-1)" "unprognostic (4.57e-1)" "unprognostic (6.58e-6)" "unprognostic (1.13e-2)" "unprognostic (1.88e-1)" "unprognostic (7.17e-3)" 0.2 3.0 0.0 0.0 0.0 0.0 9.4 4.7 0.0 0.2 0.2 0.0 8.8 0.0 0.0 65.5 5.8 0.0 0.0 0.1 0.0 0.1 6.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.7 0.2 6.3 0.1 0.0 12.2 7.0 0.6 0.0 6.3 0.0 0.0 1.1 0.0 0.0 1.5 0.0 0.0 0.0 0.3 0.0 0.1 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 31.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 11.2 0.0 0.0 59.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.7 0.0 0.0 0.1 0.1 0.0 6.3 0.0 TFDP1 "DILC, Dp-1, DP1, DRTF1" ENSG00000198176 "Transcription factor Dp-1" Q14186 13 113584721-113641470 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Cell cycle, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "basophil: 20.4" "Low lineage specificity" "Detected in all" "CAB033605, HPA044754, HPA068909" Enhanced Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "CAB033605: AB_783105, HPA044754: , HPA068909: " "unprognostic (4.28e-2)" "unprognostic (9.50e-3)" "unprognostic (1.77e-2)" "unprognostic (1.09e-1)" "unprognostic (7.01e-2)" "unprognostic (2.10e-2)" "prognostic unfavourable (1.03e-4)" "unprognostic (5.50e-3)" "unprognostic (1.68e-2)" "unprognostic (3.96e-1)" "unprognostic (2.04e-2)" "unprognostic (2.43e-2)" "prognostic favourable (7.57e-4)" "prognostic favourable (6.17e-4)" "unprognostic (2.30e-1)" "unprognostic (1.34e-1)" "unprognostic (9.32e-2)" 16.0 13.3 20.1 28.0 21.1 71.6 16.4 24.4 22.4 19.3 19.6 16.3 28.6 16.0 16.8 20.5 36.2 18.0 27.0 26.3 19.0 16.8 17.9 20.9 16.5 32.5 18.0 12.7 14.4 26.7 9.9 16.3 21.8 15.2 16.0 23.0 20.2 18.9 24.2 26.9 22.3 21.3 18.4 23.5 25.6 16.4 37.5 10.3 38.8 21.7 32.7 34.4 18.5 20.8 3.6 4.7 20.4 4.0 1.6 5.4 2.0 62.0 15.3 19.8 16.8 26.9 24.0 22.5 35.0 31.8 45.5 42.1 31.8 29.2 57.9 11.7 33.5 29.9 34.3 31.1 44.7 39.4 39.9 33.6 25.0 19.9 16.9 84.3 29.7 19.8 28.0 28.8 16.8 30.5 27.6 15.6 40.4 21.3 37.0 32.8 18.2 19.7 25.3 17.6 33.1 17.3 23.8 51.2 15.1 15.7 43.2 10.5 29.7 68.0 21.2 14.8 23.6 31.3 38.5 13.3 16.3 59.7 33.0 52.3 25.0 20.4 2.3 3.6 2.6 3.0 2.9 3.6 3.5 3.1 4.7 2.6 5.4 2.7 3.1 1.6 4.0 2.4 4.2 2.0 20.1 21.1 24.4 22.4 19.0 16.8 18.0 12.7 15.2 10.3 TFDP2 Dp-2 ENSG00000114126 "Transcription factor Dp-2" Q14188 3 141944428-142149544 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Cell cycle, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 140.3" "Cell line enhanced" "Detected in all" "MOLT-4: 80.4;REH: 42.8;U-698: 70.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB018396, HPA070399" Supported Supported "Nucleoplasm,Vesicles,Mitotic spindle" Nucleoplasm "Vesicles, Mitotic spindle" "CAB018396: AB_2287284, HPA070399: " "unprognostic (1.35e-2)" "prognostic favourable (6.32e-4)" "unprognostic (8.08e-3)" "unprognostic (2.90e-2)" "unprognostic (4.69e-2)" "unprognostic (1.18e-1)" "unprognostic (1.14e-3)" "unprognostic (2.60e-3)" "unprognostic (5.42e-2)" "unprognostic (1.46e-1)" "unprognostic (5.04e-2)" "unprognostic (2.04e-1)" "prognostic favourable (9.84e-4)" "unprognostic (6.04e-2)" "unprognostic (3.91e-2)" "unprognostic (2.45e-1)" "unprognostic (1.08e-1)" 8.4 8.4 6.1 6.3 8.7 20.7 9.3 9.9 8.6 8.9 11.1 6.5 6.5 10.4 9.9 8.6 8.3 7.2 11.6 12.0 7.5 4.9 14.3 9.5 6.8 5.3 6.0 5.0 11.6 8.8 10.4 19.4 13.5 8.0 9.9 6.6 8.8 7.9 6.9 14.5 8.0 14.6 11.8 8.5 5.3 8.6 51.9 5.4 140.3 10.6 4.8 6.4 9.7 8.0 9.3 16.5 24.6 4.5 18.0 14.7 5.7 6.3 2.9 12.3 9.8 4.1 4.5 27.1 3.2 3.7 5.1 8.3 3.7 6.3 22.5 15.0 3.6 3.8 3.1 6.1 7.2 9.0 5.6 27.1 4.4 4.9 4.0 8.1 9.6 4.2 4.3 5.6 5.4 3.5 10.1 1.2 8.8 4.8 80.4 3.1 9.9 4.0 42.8 8.5 5.2 5.9 3.3 5.4 5.0 10.8 4.0 5.5 9.3 4.2 2.3 4.9 4.5 3.9 4.0 4.2 3.8 70.5 3.9 2.2 2.3 24.6 2.1 22.3 14.7 3.4 5.7 6.6 6.7 7.6 4.8 9.3 10.1 11.8 2.4 18.0 4.5 16.5 6.1 5.7 6.1 8.7 9.9 8.6 7.5 4.9 6.0 5.0 8.0 5.4 TFE3 "bHLHe33, TFEA" ENSG00000068323 "Transcription factor binding to IGHM enhancer 3" P19532 X 49028726-49043486 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Adaptive immunity, Immunity, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 10.5" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA023881 Approved Supported Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "HPA023881: AB_1857931" "unprognostic (2.68e-2)" "unprognostic (2.89e-3)" "unprognostic (2.40e-2)" "unprognostic (5.36e-2)" "unprognostic (2.71e-2)" "unprognostic (1.81e-1)" "prognostic unfavourable (6.03e-5)" "unprognostic (2.40e-1)" "unprognostic (1.26e-1)" "unprognostic (4.32e-2)" "unprognostic (5.41e-2)" "unprognostic (1.16e-1)" "prognostic unfavourable (2.19e-8)" "unprognostic (1.93e-1)" "unprognostic (8.77e-2)" "unprognostic (4.19e-2)" "unprognostic (6.25e-1)" 31.3 20.9 12.6 18.2 14.4 22.6 53.1 16.5 18.1 22.6 17.7 16.6 30.0 9.9 22.8 21.9 20.5 18.8 16.4 15.1 11.3 11.8 21.6 14.1 22.8 10.3 13.2 9.4 24.4 15.9 16.5 16.3 22.0 15.9 21.2 10.4 15.7 12.6 30.6 13.6 14.1 13.5 21.2 14.8 23.0 14.7 10.4 15.2 4.2 21.7 10.8 10.5 28.6 20.5 1.2 1.9 10.5 4.4 0.4 1.4 1.6 11.9 15.3 5.1 14.8 16.7 15.1 5.1 15.7 18.2 16.1 13.8 9.4 9.5 4.5 6.7 23.1 9.8 9.7 14.2 13.0 9.8 5.2 4.1 11.4 8.7 22.5 4.3 10.2 13.1 9.2 26.3 18.9 7.7 7.9 19.7 13.7 7.0 2.8 4.0 13.9 13.8 4.3 8.9 10.2 10.2 5.5 4.9 4.9 16.8 7.2 5.5 10.3 3.9 16.3 17.6 18.9 17.6 8.6 12.1 11.4 3.7 21.0 5.3 12.0 0.0 3.5 1.6 0.5 4.3 0.9 0.6 0.9 0.5 1.9 1.2 0.6 0.4 10.5 0.4 4.4 0.4 1.4 1.6 12.6 14.4 16.5 14.9 11.3 11.8 13.2 9.4 15.9 15.2 TFEB "bHLHe35, TCFEB" ENSG00000112561 "Transcription factor EB" P19484 6 41683978-41736259 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Adaptive immunity, Autophagy, Immunity, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "BEWO: 30.9;Daudi: 19.6;HDLM-2: 17.9;U-698: 28.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 29.0" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA049532 Supported Nucleoplasm Nucleoplasm "HPA049532: " "unprognostic (3.63e-3)" "unprognostic (1.51e-3)" "unprognostic (1.75e-2)" "unprognostic (4.48e-3)" "unprognostic (1.95e-1)" "unprognostic (1.05e-1)" "unprognostic (1.64e-1)" "unprognostic (4.22e-3)" "unprognostic (1.39e-2)" "unprognostic (4.13e-2)" "prognostic favourable (4.77e-4)" "unprognostic (2.12e-2)" "prognostic favourable (1.06e-5)" "unprognostic (1.44e-1)" "unprognostic (3.51e-2)" "unprognostic (2.46e-1)" "unprognostic (1.31e-2)" 8.6 6.4 10.2 16.8 20.7 8.9 6.8 8.6 15.0 6.4 10.5 34.4 8.2 6.8 7.1 4.3 9.3 7.2 9.1 19.3 14.6 8.2 12.2 5.0 8.3 24.1 30.0 6.8 6.7 11.4 26.1 14.9 18.5 16.2 10.7 5.3 6.9 18.0 8.6 45.2 7.9 15.5 8.4 27.4 27.3 7.9 2.5 24.0 2.8 11.1 10.9 18.3 10.8 11.1 22.2 8.5 29.0 9.6 0.8 2.6 4.4 1.7 1.8 0.4 7.2 2.4 1.4 30.9 2.8 5.6 2.5 1.9 4.1 2.1 19.6 3.8 2.9 5.0 1.1 2.8 0.6 17.9 2.0 0.0 7.1 7.5 4.8 0.5 2.6 0.5 5.5 2.9 1.9 1.9 2.3 4.8 0.9 1.3 1.1 1.5 0.1 0.9 12.9 0.2 2.7 4.4 1.4 8.1 2.3 2.4 5.0 0.6 1.4 9.8 3.8 0.9 2.0 0.1 2.0 12.6 2.0 28.9 1.5 8.3 1.0 0.1 9.6 8.8 2.6 9.3 0.4 22.2 0.7 1.0 8.5 15.1 0.2 0.9 29.0 0.8 6.5 1.7 0.4 4.4 10.2 20.7 8.6 15.0 14.6 8.2 30.0 6.8 16.2 24.0 TFF1 "BCEI, D21S21, HP1.A, HPS2, pNR-2, pS2" ENSG00000160182 "Trefoil factor 1" P04155 21 42362282-42366594 "Cancer-related genes, Plasma proteins, Predicted secreted proteins" "Growth factor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 34 "gallbladder: 247.7;stomach 1: 375.3" "Cell line enriched" "Detected in some" 58 "MCF7: 484.6" "Group enriched" "Detected in many" 10 "breast cancer: 402.1;colorectal cancer: 268.3;pancreatic cancer: 805.7;stomach cancer: 744.5" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "CAB002170, HPA003425" Enhanced "Secreted to digestive system" 990000 "CAB002170: AB_563985, HPA003425: AB_1848260" "prognostic favourable (5.00e-4)" "unprognostic (8.81e-3)" "unprognostic (9.82e-2)" "prognostic favourable (5.67e-4)" "unprognostic (2.42e-1)" "unprognostic (1.72e-3)" "unprognostic (8.14e-2)" "unprognostic (2.45e-1)" "unprognostic (1.52e-1)" "unprognostic (6.62e-2)" "unprognostic (1.01e-1)" "unprognostic (1.19e-1)" "unprognostic (7.72e-3)" "unprognostic (1.07e-1)" 0.1 0.0 0.1 1.0 0.2 0.0 3.5 0.1 0.1 0.5 4.9 1.4 0.1 1.4 0.1 0.1 1.1 0.1 247.7 0.1 0.1 0.0 0.1 0.3 0.5 0.1 0.1 0.1 0.1 0.9 0.0 0.1 0.1 0.1 1.9 4.7 0.1 5.0 0.2 0.1 0.0 5.6 0.1 0.1 0.1 375.3 0.1 0.1 0.1 0.2 1.1 9.2 1.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.6 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 484.6 0.1 0.0 0.2 8.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 TFF2 SML1 ENSG00000160181 "Trefoil factor 2" Q03403 21 42346357-42351128 "Cancer-related genes, Predicted secreted proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 6 "gallbladder: 361.8;stomach 1: 332.4" "Group enriched" "Detected in some" 15 "CAPAN-2: 14.8;PC-3: 53.3" "Group enriched" "Detected in many" 11 "pancreatic cancer: 320.9;stomach cancer: 244.9" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "CAB025834, HPA036705" Enhanced "Secreted to digestive system" 670000 "CAB025834: , HPA036705: " "unprognostic (3.95e-2)" "unprognostic (9.87e-2)" "unprognostic (1.82e-1)" "unprognostic (1.30e-1)" "prognostic unfavourable (1.99e-4)" "unprognostic (1.68e-1)" "unprognostic (1.33e-1)" "unprognostic (4.89e-2)" "unprognostic (5.55e-2)" "unprognostic (1.27e-9)" "unprognostic (1.99e-1)" "unprognostic (2.07e-1)" "unprognostic (1.28e-1)" "unprognostic (5.26e-3)" 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.5 0.1 62.9 0.1 0.1 0.5 0.0 361.8 0.2 0.1 0.0 0.1 0.5 0.1 0.1 0.1 0.1 0.1 3.2 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.3 0.1 0.1 0.0 0.1 0.1 0.1 0.1 332.4 0.1 0.1 0.1 0.3 0.1 0.5 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 14.8 0.0 0.1 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.8 0.0 0.7 53.3 0.2 0.0 2.0 0.0 0.4 0.0 0.2 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.6 0.0 0.0 0.8 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 TFG "FLJ36137, SPG57, TF6" ENSG00000114354 "TRK-fused gene" Q92734 3 100709331-100748966 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "ER-Golgi transport, Transport" "Cancer-related genes, Disease mutation, Hereditary spastic paraplegia, Neurodegeneration, Neuropathy, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019473, HPA052206" Approved Supported Vesicles,Cytosol Vesicles Cytosol "HPA019473: AB_1857936, HPA052206: " "unprognostic (1.14e-1)" "unprognostic (3.58e-2)" "unprognostic (1.46e-1)" "unprognostic (2.94e-2)" "unprognostic (1.46e-1)" "unprognostic (4.14e-2)" "prognostic unfavourable (5.48e-4)" "unprognostic (3.31e-3)" "unprognostic (1.42e-1)" "unprognostic (3.73e-2)" "prognostic unfavourable (1.50e-4)" "unprognostic (4.58e-3)" "unprognostic (3.72e-2)" "unprognostic (2.82e-1)" "unprognostic (8.55e-2)" "unprognostic (3.33e-1)" "unprognostic (8.45e-2)" 36.4 40.3 27.2 21.9 33.8 29.7 31.0 28.1 40.5 31.2 34.7 33.3 44.2 52.5 31.2 45.8 46.7 29.0 40.8 46.2 28.1 30.7 44.6 68.6 29.9 25.4 28.2 21.5 33.5 49.2 52.3 45.1 63.3 33.7 27.5 40.7 31.9 39.6 45.8 38.6 31.0 67.1 37.5 31.7 28.3 28.9 33.5 23.0 27.6 43.6 42.9 41.2 29.5 30.1 25.8 27.8 43.2 28.4 27.7 26.8 21.8 48.4 26.4 32.9 20.9 41.6 47.2 40.7 35.1 47.3 45.9 54.8 33.3 24.2 6.5 25.8 43.6 36.4 35.4 40.1 54.7 29.8 20.8 24.4 20.3 30.9 46.5 18.0 14.6 38.6 54.1 27.5 48.5 40.6 17.5 18.1 47.4 33.9 15.8 14.3 31.3 39.8 14.0 19.3 21.1 55.7 32.7 26.0 23.8 23.1 30.1 40.9 35.4 24.4 27.1 27.8 33.6 12.8 25.4 15.4 15.5 23.3 44.4 19.7 32.6 43.2 28.3 27.0 21.8 28.4 26.4 25.8 22.6 24.4 27.8 22.9 21.6 21.6 18.7 27.7 26.4 19.4 26.8 21.8 27.2 33.8 28.1 40.5 28.1 30.7 28.2 21.5 33.7 23.0 TFRC "CD71, p90, TFR1" ENSG00000072274 "Transferrin receptor" P02786 3 196027183-196082189 "Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters" "Endocytosis, Host-virus interaction" "Host cell receptor for virus entry, Receptor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "placenta: 110.0" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000153, HPA028598" Enhanced Supported Endosomes,Lysosomes "Secreted to blood" 1310000000 14000000 "Endosomes, Lysosomes" "CAB000153: AB_2533029, HPA028598: AB_10601599" "unprognostic (2.95e-2)" "prognostic unfavourable (3.67e-4)" "unprognostic (2.55e-1)" "unprognostic (1.48e-2)" "unprognostic (6.75e-2)" "unprognostic (7.88e-3)" "prognostic unfavourable (1.15e-4)" "unprognostic (6.92e-2)" "unprognostic (3.30e-3)" "unprognostic (4.35e-2)" "unprognostic (1.34e-2)" "unprognostic (1.14e-2)" "unprognostic (3.63e-3)" "unprognostic (3.65e-2)" "unprognostic (1.19e-2)" "prognostic unfavourable (2.96e-4)" "unprognostic (2.62e-2)" 24.3 11.9 11.9 20.6 11.3 73.8 7.6 9.6 17.8 11.8 25.0 9.5 3.8 11.9 12.1 7.5 18.5 11.7 11.4 18.7 9.5 8.3 15.3 13.6 28.1 8.1 7.4 9.5 50.0 7.8 18.0 6.9 110.0 26.5 7.2 19.4 8.5 8.3 5.0 25.6 9.9 37.4 10.9 13.2 7.9 10.0 8.3 6.1 14.3 7.0 10.5 12.9 11.2 8.0 5.7 7.5 2.2 12.4 1.8 6.5 2.1 21.9 20.0 9.2 18.6 20.4 11.8 57.5 31.4 23.9 22.1 36.7 48.7 20.2 22.5 59.6 11.6 33.9 31.5 10.4 27.1 107.6 10.7 85.3 17.0 22.6 16.1 69.9 17.3 13.3 10.3 19.0 17.2 7.3 35.5 21.6 17.2 20.3 22.9 14.8 28.0 41.0 12.2 13.7 27.0 19.8 55.6 21.0 8.7 30.3 79.7 7.1 77.4 14.6 9.4 26.3 21.4 23.0 47.0 6.1 47.5 35.2 30.8 19.0 15.9 0.0 1.6 2.2 2.5 7.9 1.7 5.7 2.7 1.7 3.7 3.2 2.5 1.9 0.3 1.8 12.4 7.5 6.5 2.1 11.9 11.3 9.6 17.8 9.5 8.3 7.4 9.5 26.5 6.1 TG "AITD3, TGN" ENSG00000042832 Thyroglobulin P01266 8 132866958-133134903 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Thyroid hormones biosynthesis" "Hormone, Thyroid hormone" "Cancer-related genes, Congenital hypothyroidism, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 247 "thyroid gland: 994.3" "Cell line enhanced" "Detected in some" "HDLM-2: 3.5;HSkMC: 4.2;Karpas-707: 9.7;PC-3: 4.8;U-266/70: 3.5" "Cancer enriched" "Detected in some" 1672 "thyroid cancer: 3072.8" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "neutrophil: 4.0" "Low lineage specificity" "Detected in many" "Region enriched" "Detected in single" 5 "cerebellum: 1.3" "Low region specificity" "Detected in many" "CAB000077, HPA002740, CAB056155" Enhanced "Secreted in other tissues" 1000000 "CAB000077: , CAB056155: , HPA002740: AB_1080277" "unprognostic (1.18e-1)" "unprognostic (6.86e-2)" "unprognostic (7.40e-4)" "unprognostic (1.20e-2)" "unprognostic (2.55e-1)" "unprognostic (1.02e-1)" "unprognostic (2.77e-2)" "unprognostic (7.38e-2)" "unprognostic (4.96e-2)" "unprognostic (1.19e-1)" "unprognostic (3.08e-2)" "unprognostic (3.68e-2)" "unprognostic (1.08e-1)" "unprognostic (1.63e-2)" "unprognostic (1.82e-1)" "unprognostic (5.11e-2)" "unprognostic (3.64e-2)" 0.1 0.1 0.1 0.1 0.1 0.3 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.4 0.6 0.1 0.0 0.1 0.1 0.1 0.4 0.1 0.1 0.1 0.3 0.3 0.1 0.1 0.1 0.1 0.0 0.1 3.5 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 994.3 0.1 0.1 0.1 0.1 0.3 1.2 4.0 0.6 0.0 0.9 0.5 0.0 0.0 0.0 0.0 0.9 1.4 0.6 0.0 1.7 0.0 0.1 0.9 0.0 0.0 0.2 0.4 0.5 0.0 0.0 0.0 3.5 0.0 0.0 0.0 0.0 0.6 0.0 0.0 4.2 2.9 1.1 0.0 0.0 0.0 9.7 0.2 0.0 0.1 0.0 0.0 4.8 0.1 0.0 0.3 0.2 2.8 0.3 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.3 0.2 0.6 0.0 3.5 2.9 0.0 0.2 1.2 0.0 0.0 0.6 0.7 0.2 0.0 0.9 0.0 0.4 0.0 0.0 0.3 0.3 0.2 4.0 0.0 0.3 1.2 0.4 0.5 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 TGFA ENSG00000163235 "Transforming growth factor alpha" P01135 2 70447280-70554193 "Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins" "Growth factor, Mitogen" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in some" "A-431: 23.9;CAPAN-2: 29.5;EFO-21: 15.2;HBEC3-KT: 25.7;RPTEC TERT1: 25.9;U-87 MG: 24.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 4 "basophil: 6.3;eosinophil: 14.0;neutrophil: 14.7" "Lineage enriched" "Detected in many" 5 "granulocytes: 14.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA042297 Approved Approved Vesicles "Secreted to blood" 57867 Vesicles "HPA042297: AB_10793878" "unprognostic (1.23e-1)" "unprognostic (1.06e-3)" "unprognostic (3.57e-3)" "unprognostic (6.39e-2)" "unprognostic (1.41e-1)" "unprognostic (8.49e-3)" "unprognostic (1.52e-1)" "unprognostic (3.00e-3)" "unprognostic (6.69e-2)" "unprognostic (9.21e-2)" "prognostic unfavourable (1.20e-5)" "unprognostic (7.74e-2)" "unprognostic (3.70e-2)" "unprognostic (1.60e-1)" "unprognostic (9.21e-2)" "prognostic favourable (1.52e-4)" "unprognostic (9.19e-2)" 2.0 0.5 8.4 4.3 10.7 1.2 6.2 3.5 7.9 5.7 9.4 21.4 0.3 7.4 1.2 2.8 23.8 5.7 14.6 0.8 10.7 6.9 12.4 4.0 3.5 4.2 10.9 5.2 0.5 12.0 1.0 0.8 1.7 9.4 2.2 7.3 9.7 6.3 1.2 0.4 10.8 13.7 1.3 22.5 5.1 7.6 2.3 12.8 0.2 7.4 17.4 12.1 5.4 10.8 0.0 0.6 14.7 0.4 0.2 2.7 0.4 23.9 3.8 0.0 0.0 0.0 0.0 0.0 3.9 0.0 0.1 0.0 0.0 29.5 0.0 15.2 0.1 12.8 0.2 25.7 0.0 0.0 0.5 0.0 0.6 2.0 0.0 0.3 0.0 0.0 10.3 0.0 10.1 0.0 0.0 0.1 0.0 0.9 0.0 0.5 0.4 7.3 0.0 0.1 6.3 25.9 9.3 0.2 0.0 1.9 0.0 0.0 3.3 0.2 0.2 0.1 1.7 0.0 5.2 0.1 0.1 0.0 24.5 0.8 8.8 6.3 0.4 14.0 1.0 0.1 2.7 0.0 0.6 0.6 0.6 0.0 0.3 0.2 14.7 0.2 0.0 0.0 0.0 0.4 8.4 10.7 3.5 7.9 10.7 6.9 10.9 5.2 9.4 12.8 TGFB1 "CED, DPD1, TGFB, TGFbeta" ENSG00000105329 "Transforming growth factor beta 1" P01137 19 41301587-41353911 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Growth factor, Mitogen" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "eosinophil: 7.5" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000361, HPA073356" Approved Approved "Golgi apparatus,Cytosol" "Secreted to blood" 1288167 38000000 "Golgi apparatus" Cytosol "CAB000361: AB_2201910, HPA073356: " "unprognostic (1.49e-2)" "unprognostic (5.43e-3)" "unprognostic (3.29e-2)" "unprognostic (4.90e-2)" "unprognostic (3.75e-3)" "prognostic unfavourable (3.38e-4)" "unprognostic (8.51e-3)" "unprognostic (5.63e-3)" "unprognostic (2.47e-2)" "unprognostic (5.80e-2)" "unprognostic (1.48e-1)" "unprognostic (1.88e-1)" "prognostic unfavourable (1.19e-8)" "unprognostic (1.65e-3)" "unprognostic (2.79e-2)" "unprognostic (6.39e-2)" "unprognostic (4.86e-3)" 24.3 14.4 7.7 29.8 11.9 53.1 19.0 2.2 8.2 27.8 15.3 14.3 11.5 11.4 24.1 12.8 24.5 13.0 15.6 17.6 8.8 6.5 19.2 10.4 32.4 33.3 12.0 4.1 15.3 8.2 6.9 9.7 54.7 11.7 17.2 5.8 10.3 10.9 15.9 8.7 14.0 17.6 14.6 12.8 55.8 12.8 9.5 12.3 30.6 10.3 9.1 30.6 28.7 24.6 0.7 1.4 7.5 2.2 0.5 1.7 1.3 14.5 22.9 1.2 0.1 10.6 9.4 2.9 21.1 19.0 6.8 4.6 9.7 9.0 14.4 22.7 28.6 7.9 4.1 13.5 2.4 19.1 4.5 48.5 5.5 12.3 13.7 13.3 33.1 12.2 4.3 13.1 8.4 34.1 26.0 36.3 6.2 10.7 11.4 19.5 2.5 13.7 12.3 3.2 21.6 12.1 6.3 0.2 1.6 5.8 0.3 4.1 0.5 11.9 43.1 26.7 20.9 5.6 22.9 20.1 7.8 9.4 26.1 26.7 4.7 1.5 1.9 7.5 1.7 2.2 1.3 0.4 0.9 0.9 1.4 0.7 0.7 0.9 4.7 0.5 2.0 1.4 0.5 1.3 7.7 11.9 2.2 7.6 8.8 6.5 12.0 4.1 11.7 12.3 TGFB3 "ARVD, ARVD1" ENSG00000119699 "Transforming growth factor beta 3" P10600 14 75958099-75982991 "Cancer-related genes, Disease related genes, Predicted secreted proteins" "Growth factor, Mitogen" "Cancer-related genes, Cardiomyopathy, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Group enriched" "Detected in many" 5 "SK-BR-3: 49.2;T-47d: 34.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "naive CD4 T-cell: 1.8" "Lineage enhanced" "Detected in single" "T-cells: 1.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" HPA063582 Approved Vesicles "Secreted to blood" Vesicles "HPA063582: " "unprognostic (7.84e-2)" "unprognostic (1.89e-1)" "unprognostic (4.32e-3)" "unprognostic (1.29e-1)" "unprognostic (3.27e-2)" "unprognostic (1.58e-1)" "unprognostic (1.24e-1)" "unprognostic (9.79e-2)" "unprognostic (2.83e-2)" "unprognostic (1.51e-2)" "unprognostic (5.63e-2)" "unprognostic (4.10e-1)" "prognostic unfavourable (4.01e-7)" "unprognostic (6.38e-3)" "unprognostic (1.10e-1)" "unprognostic (1.22e-2)" "unprognostic (3.27e-3)" 6.9 4.7 10.6 8.4 14.0 0.4 7.8 3.2 8.6 29.2 4.1 6.7 13.1 2.3 10.4 21.4 4.4 4.9 21.5 17.9 11.9 6.6 4.8 12.2 8.6 4.2 16.8 7.0 3.1 11.1 6.8 4.6 31.0 8.4 25.8 3.2 10.0 5.0 12.0 13.3 1.5 2.9 20.7 13.0 2.2 4.5 3.8 8.8 4.2 4.4 5.7 8.2 11.6 6.4 0.4 0.1 0.0 0.0 0.0 1.8 0.2 0.3 0.1 0.4 5.4 0.9 1.3 0.1 0.2 0.4 0.2 0.2 0.3 1.3 0.0 0.4 1.0 0.3 1.1 0.1 0.1 0.3 0.5 0.0 1.1 0.6 1.3 0.2 0.3 4.5 0.1 0.4 0.1 1.3 0.5 2.4 0.3 2.4 0.2 0.2 0.1 1.8 1.1 1.6 0.2 0.5 0.2 8.9 2.1 1.6 49.2 0.3 34.5 0.0 0.3 0.8 1.8 0.8 2.2 0.2 0.2 0.1 1.3 0.3 1.3 0.0 0.0 0.0 0.5 0.0 0.6 0.0 0.1 0.6 0.0 0.4 1.8 0.5 0.0 0.0 0.0 0.1 0.3 0.2 10.6 14.0 3.2 8.6 11.9 6.6 16.8 7.0 8.4 8.8 TGFBR2 "MFS2, TBR-ii, TBRII" ENSG00000163513 "Transforming growth factor beta receptor 2" P37173 3 30606502-30694142 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins" "Apoptosis, Differentiation, Growth regulation" "Kinase, Receptor, Serine/threonine-protein kinase, Transferase" "Aortic aneurysm, Cancer-related genes, Disease mutation, Hereditary nonpolyposis colorectal cancer" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "ASC diff: 53.4;ASC TERT1: 80.5;HSkMC: 69.5;LHCN-M2: 65.8;TIME: 60.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB073537 Supported "Plasma membrane" 560000 "Plasma membrane" "CAB073537: " "unprognostic (1.74e-1)" "unprognostic (1.84e-2)" "unprognostic (3.70e-1)" "unprognostic (3.02e-2)" "unprognostic (1.92e-1)" "unprognostic (2.26e-1)" "unprognostic (1.96e-1)" "unprognostic (1.62e-1)" "unprognostic (1.40e-1)" "unprognostic (2.24e-2)" "unprognostic (7.36e-2)" "unprognostic (1.12e-1)" "unprognostic (1.65e-2)" "unprognostic (4.72e-2)" "unprognostic (1.81e-2)" "unprognostic (8.81e-2)" "unprognostic (8.02e-2)" 91.8 24.6 6.7 24.6 10.3 7.3 88.3 3.6 7.3 36.5 42.6 9.8 18.6 13.2 42.6 23.3 36.2 28.4 42.6 73.5 6.9 5.2 32.6 21.9 52.6 75.7 12.6 3.7 22.2 26.0 17.4 10.3 24.2 9.9 35.2 17.5 27.9 22.5 19.5 34.9 17.0 31.3 37.2 12.0 68.7 26.8 15.4 8.2 19.3 40.9 16.8 26.9 48.0 82.0 5.3 6.8 20.0 6.6 1.4 19.7 3.9 2.4 14.4 0.9 0.0 53.4 80.5 2.4 12.5 17.6 4.3 4.3 3.2 13.3 0.3 45.3 16.8 5.0 0.6 18.3 7.2 1.0 1.3 1.4 1.6 16.2 22.8 2.2 11.8 69.5 16.3 18.6 18.0 46.7 0.2 0.0 65.8 0.2 2.3 1.6 0.4 5.8 2.0 5.8 0.3 23.2 5.8 0.0 0.9 3.7 1.0 3.5 0.0 2.4 60.3 21.2 5.2 9.6 4.7 0.4 0.0 2.0 12.7 2.5 8.5 6.9 2.9 20.0 3.5 3.0 3.2 4.0 5.4 4.2 2.6 5.3 19.7 9.1 12.6 1.4 6.6 6.8 1.2 3.9 6.7 10.3 3.6 7.3 6.9 5.2 12.6 3.7 9.9 8.2 TGFBR3 "betaglycan, BGCAN" ENSG00000069702 "Transforming growth factor beta receptor 3" Q03167 1 91680343-91906335 "Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins" Receptor "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "ASC diff: 65.7;ASC TERT1: 32.0;U-2197: 22.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 5 "gdT-cell: 21.3;MAIT T-cell: 11.6;memory CD4 T-cell: 5.4;memory CD8 T-cell: 11.4;naive CD8 T-cell: 8.0;NK-cell: 9.0" "Group enriched" "Detected in many" 22 "NK-cells: 9.0;T-cells: 21.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008257, CAB018971" Supported Approved Cytosol "Secreted to blood" 29000000 Cytosol "CAB018971: , HPA008257: AB_1080258" "unprognostic (7.57e-2)" "unprognostic (3.67e-1)" "unprognostic (4.86e-2)" "prognostic unfavourable (3.36e-4)" "unprognostic (9.39e-3)" "prognostic favourable (4.84e-4)" "unprognostic (2.07e-2)" "unprognostic (1.05e-1)" "unprognostic (1.09e-1)" "unprognostic (1.79e-1)" "unprognostic (9.32e-2)" "unprognostic (1.07e-1)" "prognostic favourable (4.99e-4)" "unprognostic (2.46e-1)" "unprognostic (2.43e-1)" "prognostic unfavourable (3.14e-4)" "unprognostic (1.08e-2)" 40.1 15.9 3.2 6.8 3.1 1.6 63.5 1.8 4.4 30.1 15.2 3.5 30.0 3.4 17.6 21.0 22.2 17.6 23.3 16.3 3.9 1.9 12.5 11.9 18.4 18.1 2.6 2.0 62.4 8.9 4.4 4.4 25.1 4.5 21.7 5.6 8.8 14.7 46.5 19.2 13.4 9.8 34.4 4.1 27.1 11.1 14.0 3.0 1.1 7.5 6.5 3.1 39.2 42.1 0.0 0.6 0.6 0.6 9.0 21.3 3.9 2.7 2.6 4.0 0.6 65.7 32.0 12.7 2.0 10.0 2.3 2.8 1.2 0.4 0.0 0.5 3.6 0.4 1.0 0.2 1.8 9.3 2.1 0.0 3.3 11.1 1.4 0.1 0.0 7.7 1.3 5.1 1.1 1.1 6.4 0.2 0.6 0.0 0.0 0.0 1.6 0.9 0.1 1.3 0.5 0.9 16.0 0.1 0.0 0.9 0.0 5.5 0.3 1.0 3.6 3.9 1.0 22.3 0.4 9.9 0.9 0.0 0.8 0.5 0.4 0.6 0.0 0.0 21.3 0.1 11.6 0.0 5.4 11.4 0.0 0.0 1.7 8.0 0.3 9.0 0.6 0.6 2.4 3.9 3.2 3.1 1.8 4.4 3.9 1.9 2.6 2.0 4.5 3.0 TGIF1 "HPE4, TGIF" ENSG00000177426 "TGFB induced factor homeobox 1" Q15583 18 3411608-3459978 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Repressor" "Cancer-related genes, Disease mutation, Holoprosencephaly" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA062160 Supported Nucleoplasm Nucleoplasm "HPA062160: " "unprognostic (1.11e-2)" "unprognostic (5.20e-2)" "unprognostic (2.40e-1)" "unprognostic (1.97e-1)" "unprognostic (3.57e-3)" "unprognostic (3.10e-2)" "unprognostic (2.75e-1)" "unprognostic (4.34e-2)" "unprognostic (1.94e-2)" "unprognostic (1.96e-3)" "prognostic unfavourable (6.47e-4)" "unprognostic (9.60e-2)" "unprognostic (1.12e-2)" "unprognostic (9.81e-2)" "unprognostic (4.60e-1)" "unprognostic (7.07e-2)" "unprognostic (2.48e-3)" 31.9 16.6 6.9 17.2 9.3 11.2 22.0 2.7 6.2 26.8 23.8 15.5 48.4 9.6 32.7 47.3 27.1 24.8 31.4 12.9 6.5 7.2 24.7 33.6 27.9 10.6 8.1 5.9 23.0 20.2 5.3 10.2 49.6 9.9 33.2 22.4 15.3 25.1 29.8 21.2 22.9 16.6 18.5 8.6 23.1 19.8 23.1 9.2 18.1 60.2 11.2 21.0 40.5 29.0 18.2 14.0 20.4 17.3 7.4 27.5 12.7 6.1 28.3 18.6 5.9 19.0 25.7 45.5 11.9 45.7 9.8 12.5 11.2 28.4 0.3 4.0 9.7 6.4 7.1 13.4 12.9 2.5 2.9 0.8 13.5 21.1 35.7 8.9 7.4 17.8 57.5 17.7 47.2 20.8 6.4 0.1 19.1 12.1 5.8 11.0 47.4 6.2 6.1 8.3 2.0 40.1 30.5 5.2 5.2 31.5 24.7 17.4 5.7 8.0 8.9 15.3 13.3 18.0 7.4 1.0 0.1 2.8 15.7 3.4 19.2 20.4 17.3 2.9 25.9 6.5 27.5 18.2 21.6 25.2 14.0 12.8 15.5 18.0 7.8 7.4 6.1 1.4 11.4 12.7 6.9 9.3 2.7 6.2 6.5 7.2 8.1 5.9 9.9 9.2 TGM4 TGP ENSG00000163810 "Transglutaminase 4" P49221 3 44874608-44914990 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Acyltransferase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 4 "prostate: 107.8" "Cell line enhanced" "Detected in some" "BEWO: 9.5;hTERT-HME1: 2.6;NB-4: 5.1;RPMI-8226: 3.6;SH-SY5Y: 2.8" "Cancer enriched" "Detected in single" 312 "prostate cancer: 75.4" "Region enriched" "Detected in single" 254 "cerebral cortex: 25.4" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "HPA032072, CAB033571" Enhanced "CAB033571: AB_2287329, HPA032072: AB_10603350" "unprognostic (4.40e-2)" "unprognostic (4.68e-2)" "unprognostic (1.92e-1)" "unprognostic (2.17e-3)" "unprognostic (2.84e-1)" "unprognostic (2.19e-2)" "unprognostic (1.37e-1)" "unprognostic (1.92e-1)" "unprognostic (2.41e-2)" "unprognostic (1.65e-1)" "unprognostic (8.56e-3)" "unprognostic (5.08e-2)" "unprognostic (1.44e-8)" "unprognostic (1.10e-1)" "unprognostic (1.98e-2)" "unprognostic (3.68e-1)" "unprognostic (6.41e-2)" 0.0 0.2 0.0 0.0 0.0 0.1 0.1 0.0 25.4 0.0 0.0 0.0 0.4 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 107.8 0.0 0.0 2.3 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.3 0.2 0.0 0.6 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 9.5 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.4 0.1 2.6 0.3 0.0 0.0 0.1 0.0 0.0 5.1 0.0 0.2 0.0 0.0 3.6 0.0 0.0 0.0 2.8 0.0 0.0 0.0 0.0 1.4 0.5 0.0 0.7 0.7 0.1 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.3 0.2 0.0 0.2 0.6 0.0 0.3 0.0 0.0 0.0 0.0 0.0 25.4 0.0 0.0 0.0 0.0 0.0 0.0 THBS1 "THBS, THBS-1, TSP, TSP-1, TSP1" ENSG00000137801 "Thrombospondin 1" P07996 15 39581079-39599466 "Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins" "Cell adhesion, Unfolded protein response" Heparin-binding "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "fHDF/TERT166: 162.1;HUVEC TERT2: 157.6;LHCN-M2: 117.7;TIME: 229.8" "Low cancer specificity" "Detected in all" "Group enriched" "Detected in many" 5 "basal ganglia: 3.4;pons and medulla: 8.1" "Cell type enhanced" "Detected in some" "eosinophil: 14.1" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in single" "CAB033678, HPA059756" Approved Approved "Plasma membrane" "Secreted to extracellular matrix" 1600000000 "Plasma membrane" "CAB033678: AB_793044, HPA059756: " "unprognostic (1.72e-2)" "unprognostic (9.55e-3)" "unprognostic (7.49e-2)" "unprognostic (3.31e-1)" "unprognostic (4.34e-2)" "unprognostic (1.03e-3)" "unprognostic (3.60e-1)" "unprognostic (1.53e-2)" "unprognostic (1.22e-1)" "unprognostic (2.07e-1)" "unprognostic (6.40e-2)" "unprognostic (9.16e-2)" "prognostic unfavourable (8.47e-5)" "prognostic unfavourable (8.50e-4)" "unprognostic (1.00e-1)" "unprognostic (9.25e-3)" "unprognostic (1.48e-3)" 79.6 15.2 0.9 81.4 3.4 19.3 41.0 0.7 1.3 25.7 42.7 2.5 6.6 5.0 72.8 30.5 22.7 40.8 57.7 49.0 1.0 1.0 23.4 27.2 118.4 38.8 1.1 0.8 60.9 14.0 1.3 7.7 38.1 8.1 31.9 18.3 8.4 38.0 13.2 22.6 9.2 23.0 63.5 4.5 58.0 46.5 27.5 0.2 0.6 14.0 21.4 18.4 111.8 78.9 0.0 0.5 14.1 7.4 7.5 2.6 8.6 11.5 3.9 3.1 1.1 13.1 15.4 0.0 67.0 54.8 18.4 12.1 11.4 8.7 0.0 25.3 162.1 41.2 0.1 32.7 9.3 3.0 0.0 2.9 2.3 2.9 2.9 0.0 0.8 34.5 2.4 15.3 34.5 157.6 0.0 0.1 117.7 0.8 0.0 0.2 0.5 1.4 0.0 8.1 0.0 27.6 29.4 0.0 0.0 19.0 1.0 1.1 11.7 0.2 229.8 64.5 15.3 75.9 76.9 0.1 0.1 0.1 2.1 0.0 68.9 0.2 7.4 14.1 0.8 0.8 2.6 0.0 0.4 0.5 0.5 0.0 0.1 0.1 1.4 7.5 0.1 0.3 0.0 8.6 0.9 3.4 0.7 1.0 1.0 1.0 1.1 0.8 8.1 0.2 THBS2 TSP2 ENSG00000186340 "Thrombospondin 2" P35442 6 169215780-169254044 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins" "Cell adhesion" Heparin-binding "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "breast: 84.6;urinary bladder: 67.4" "Cell line enhanced" "Detected in some" "ASC diff: 81.9;ASC TERT1: 56.2;BJ hTERT+ SV40 Large T+ RasG12V: 27.2;HSkMC: 30.3;hTEC/SVTERT24-B: 29.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB017716, HPA044304" Approved Approved "Nuclear speckles,Plasma membrane,Cytosol" "Secreted to extracellular matrix" 22000000 "Plasma membrane" "Nuclear speckles, Cytosol" "CAB017716: , HPA044304: " "unprognostic (2.85e-2)" "unprognostic (1.41e-1)" "unprognostic (5.87e-2)" "unprognostic (8.90e-2)" "unprognostic (3.64e-2)" "unprognostic (8.73e-2)" "unprognostic (2.93e-1)" "unprognostic (5.10e-3)" "unprognostic (1.39e-1)" "unprognostic (4.71e-2)" "unprognostic (4.00e-2)" "unprognostic (2.56e-1)" "prognostic unfavourable (3.77e-6)" "unprognostic (2.19e-3)" "unprognostic (4.38e-2)" "unprognostic (4.16e-2)" "unprognostic (2.48e-3)" 43.5 4.0 4.3 10.1 7.8 0.4 84.6 1.1 9.0 24.3 17.0 6.3 3.3 1.9 26.1 16.1 9.8 14.8 43.0 21.9 5.5 3.6 4.6 5.9 8.4 3.8 8.1 1.4 26.2 5.9 1.5 4.4 2.0 14.8 10.5 3.4 0.7 3.9 2.8 14.6 22.7 3.8 22.0 16.0 2.8 2.6 12.5 5.2 0.0 13.2 10.6 4.8 67.4 29.4 0.4 0.7 0.2 0.8 0.1 0.3 0.0 0.0 0.0 0.5 0.3 81.9 56.2 0.0 15.6 21.4 21.6 27.2 0.1 0.0 0.0 0.0 18.6 0.0 0.6 0.8 12.4 0.0 0.0 0.0 0.0 0.0 22.9 0.0 0.0 30.3 0.0 29.2 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.8 3.3 0.1 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 9.9 0.1 22.0 1.8 0.0 0.3 0.0 6.1 0.1 0.5 0.0 0.8 0.2 0.2 0.5 0.0 0.4 0.1 0.0 0.2 0.3 0.1 0.3 0.0 0.1 0.5 0.7 0.2 0.0 4.3 7.8 1.1 3.1 5.5 3.6 8.1 1.4 14.8 5.2 THBS4 ENSG00000113296 "Thrombospondin 4" P35443 5 79991311-80083287 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Cell adhesion, Tissue remodeling, Unfolded protein response" "Growth factor, Mitogen" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adipose tissue: 69.8;heart muscle: 59.0;skeletal muscle: 61.7;smooth muscle: 94.0" "Cell line enhanced" "Detected in some" "AF22: 5.0;THP-1: 10.7;U-2 OS: 4.6;U-266/70: 4.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 51 "eosinophil: 8.0" "Lineage enriched" "Detected in single" 51 "granulocytes: 8.0" "Low region specificity" "Detected in some" "Not detected" "Not detected" "CAB004597, HPA042426" Approved Approved Vesicles "Secreted to extracellular matrix" 420000000 Vesicles "CAB004597: AB_628352, HPA042426: " "unprognostic (1.41e-1)" "unprognostic (5.33e-2)" "unprognostic (4.26e-3)" "unprognostic (3.64e-2)" "unprognostic (9.94e-2)" "unprognostic (8.10e-2)" "unprognostic (5.64e-2)" "unprognostic (7.12e-2)" "unprognostic (1.66e-1)" "unprognostic (2.25e-1)" "unprognostic (2.06e-1)" "unprognostic (2.14e-1)" "unprognostic (1.96e-3)" "unprognostic (2.74e-2)" "unprognostic (3.98e-2)" "unprognostic (1.76e-3)" "prognostic unfavourable (3.33e-4)" 69.8 1.0 7.6 2.1 8.3 3.7 9.7 0.8 4.6 1.1 21.4 2.6 1.2 1.3 12.2 13.6 6.5 1.4 4.1 59.0 6.4 6.4 0.8 0.6 1.0 0.9 8.5 1.9 2.1 23.0 5.5 7.8 0.6 10.7 3.7 3.7 4.9 19.8 2.6 61.7 1.5 1.4 94.0 11.5 0.6 4.0 5.5 2.6 2.0 9.9 39.3 4.1 3.4 2.7 0.1 0.0 8.0 0.0 0.0 0.1 0.0 0.2 0.0 5.0 0.3 0.4 2.2 0.5 0.1 0.2 1.5 0.5 0.1 0.6 0.2 0.2 0.4 0.2 0.2 0.6 1.3 0.2 0.7 0.5 0.0 0.3 2.7 0.0 0.1 1.5 0.3 0.1 0.3 0.0 0.0 0.3 0.3 0.7 0.1 0.0 3.9 0.1 0.0 1.5 0.0 0.3 0.1 4.0 1.2 0.1 0.0 0.4 0.0 10.7 0.0 0.1 4.6 0.3 0.3 4.1 0.1 0.7 1.8 3.4 0.9 0.0 0.0 8.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 7.6 8.3 0.8 4.6 6.4 6.4 8.5 1.9 10.7 2.6 THRA "AR7, EAR-7.1/EAR-7.2, ERBA, ERBA1, NR1A1, THRA1, THRA2, THRA3" ENSG00000126351 "Thyroid hormone receptor, alpha" P10827 17 40058290-40093867 "Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes, Congenital hypothyroidism, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 90.7" "Cell line enhanced" "Detected in many" "ASC diff: 37.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA009654, CAB023349" Approved Supported Cytosol Cytosol "CAB023349: AB_619577, HPA009654: AB_1854603" "unprognostic (2.75e-2)" "unprognostic (2.20e-1)" "unprognostic (6.64e-2)" "unprognostic (4.22e-2)" "unprognostic (8.78e-2)" "unprognostic (1.64e-1)" "unprognostic (3.41e-3)" "prognostic favourable (1.84e-4)" "unprognostic (1.47e-1)" "unprognostic (5.47e-2)" "unprognostic (7.85e-2)" "unprognostic (2.65e-2)" "prognostic favourable (6.05e-8)" "unprognostic (3.05e-1)" "unprognostic (1.35e-1)" "unprognostic (4.21e-1)" "unprognostic (1.88e-3)" 17.1 20.7 58.6 5.7 90.7 9.9 12.9 37.4 73.1 19.8 12.6 24.1 8.2 15.1 19.3 11.5 9.7 29.3 12.7 30.1 43.8 38.1 12.1 2.7 11.6 4.5 34.3 45.5 46.5 12.3 13.0 10.7 8.5 29.6 12.4 9.6 10.4 13.7 18.8 38.5 10.0 16.7 17.4 29.4 6.1 11.9 7.8 43.6 1.8 12.5 7.9 3.3 10.0 18.6 1.0 1.5 3.7 0.7 5.1 4.7 1.4 2.1 17.2 5.4 13.4 37.1 13.6 1.9 8.8 10.6 9.2 8.6 14.3 12.5 2.5 14.7 17.2 5.2 10.5 5.4 5.0 0.9 9.9 4.6 20.5 6.1 12.5 7.5 5.2 21.6 4.4 8.6 3.3 12.3 9.3 2.4 7.6 3.2 10.0 12.4 4.9 5.4 14.4 10.6 12.4 3.1 1.5 9.1 8.3 6.8 10.9 15.4 12.7 8.9 8.5 9.2 9.2 8.2 2.6 5.6 3.9 1.5 5.7 8.7 4.9 0.3 0.6 3.7 4.7 0.3 2.0 0.6 1.9 2.8 0.8 1.0 3.4 4.1 2.5 5.1 0.7 1.5 2.2 1.4 58.6 90.7 37.4 41.8 43.8 38.1 34.3 45.5 29.6 43.6 THRB "ERBA-BETA, ERBA2, GRTH, NR1A2, PRTH, THR1, THRB1, THRB2" ENSG00000151090 "Thyroid hormone receptor beta" P10828 3 24117153-24495756 "Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes, Deafness, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "K-562: 26.0;RT4: 19.3" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "basophil: 7.2;naive B-cell: 4.3" "Group enriched" "Detected in many" 11 "B-cells: 4.3;granulocytes: 7.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002008, CAB002009, HPA061035" Approved Supported "Nuclear bodies" "Nuclear bodies" "CAB002008: , CAB002009: , HPA061035: " "unprognostic (1.82e-1)" "unprognostic (4.22e-1)" "unprognostic (2.83e-1)" "unprognostic (2.20e-6)" "unprognostic (3.37e-1)" "unprognostic (2.66e-2)" "unprognostic (1.93e-2)" "unprognostic (1.73e-1)" "unprognostic (5.78e-3)" "unprognostic (2.95e-2)" "unprognostic (4.43e-1)" "unprognostic (2.01e-2)" "prognostic favourable (9.46e-8)" "unprognostic (1.32e-3)" "unprognostic (6.75e-2)" "unprognostic (2.73e-2)" "unprognostic (3.34e-2)" 10.7 5.5 12.5 3.2 14.8 1.1 12.0 2.6 27.0 3.6 11.2 1.9 5.5 2.7 7.5 2.2 7.0 4.3 2.5 7.9 9.2 5.7 12.9 20.8 5.4 1.6 4.3 20.1 2.9 9.6 6.8 20.3 4.7 3.5 8.2 9.0 3.2 6.1 10.4 21.9 7.1 4.0 11.1 3.0 5.7 8.1 1.0 4.0 0.0 4.9 4.7 1.6 9.8 14.6 4.3 0.5 7.2 0.1 0.0 0.0 3.5 5.9 1.8 0.4 0.0 10.7 5.6 4.0 0.2 1.3 1.0 1.9 3.9 5.9 0.0 1.5 4.2 9.0 6.4 2.5 0.7 0.0 3.9 0.0 1.6 5.1 0.3 0.0 0.0 9.9 4.4 0.1 0.7 0.0 26.0 0.0 0.9 0.3 0.0 0.0 3.9 2.2 0.0 0.0 0.0 6.1 19.3 1.1 0.4 9.8 5.3 0.1 5.8 0.0 0.5 2.4 1.9 0.0 1.1 0.1 0.3 0.0 1.7 0.0 0.2 7.2 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.5 4.3 0.0 0.0 1.6 0.0 0.0 0.0 0.0 3.5 12.5 14.8 2.6 27.0 9.2 5.7 4.3 20.1 3.5 4.0 TIMM17A "TIM17, TIM17A" ENSG00000134375 "Translocase of inner mitochondrial membrane 17A" Q99595 1 201955491-201970661 "Cancer-related genes, Predicted membrane proteins" "Protein transport, Translocation, Transport" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" HPA010083 Approved Supported Nucleoplasm,Mitochondria "Nucleoplasm, Mitochondria" "HPA010083: AB_10602899" "prognostic unfavourable (1.98e-5)" "unprognostic (3.28e-1)" "unprognostic (1.32e-1)" "unprognostic (1.09e-1)" "unprognostic (1.14e-1)" "unprognostic (1.80e-3)" "unprognostic (7.58e-2)" "unprognostic (4.15e-2)" "unprognostic (7.45e-2)" "unprognostic (1.64e-2)" "unprognostic (8.54e-3)" "unprognostic (2.02e-2)" "unprognostic (2.01e-1)" "unprognostic (6.45e-3)" "unprognostic (1.21e-1)" "unprognostic (1.44e-2)" "unprognostic (2.81e-1)" 16.6 27.6 22.7 18.7 23.2 16.9 16.8 16.3 29.3 16.5 19.3 9.9 19.2 17.2 15.0 24.1 17.9 11.8 10.7 39.0 32.3 19.6 25.1 53.7 13.5 15.3 20.6 27.0 11.2 18.7 21.5 14.8 17.4 25.0 14.5 21.8 11.7 24.8 17.1 42.1 11.5 13.0 19.6 13.4 14.4 16.3 13.7 14.2 11.3 21.6 30.4 18.9 15.9 12.7 17.6 28.9 16.0 24.9 15.9 20.6 17.8 25.9 26.5 24.1 28.8 20.3 21.4 40.7 41.6 29.8 34.1 30.7 31.1 27.1 36.1 15.3 35.5 20.8 44.1 24.8 36.9 26.4 27.6 19.9 35.3 29.3 21.0 42.3 21.4 24.6 27.7 34.9 29.2 35.6 50.1 20.3 40.0 16.6 22.7 22.9 30.5 14.3 22.4 28.0 45.1 41.9 24.8 36.4 25.7 25.4 65.2 38.4 36.0 28.8 28.5 22.8 24.2 26.5 43.1 30.7 33.1 30.3 24.3 32.3 25.4 8.9 19.0 16.0 13.6 24.9 17.5 17.6 14.9 17.2 28.9 12.7 14.2 16.7 4.4 15.9 24.7 19.3 20.6 17.8 22.7 23.2 16.3 29.3 32.3 19.6 20.6 27.0 25.0 14.2 TIMP1 "CLGI, EPO, TIMP" ENSG00000102265 "TIMP metallopeptidase inhibitor 1" P01033 X 47582313-47586789 "Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Growth factor, Metalloenzyme inhibitor, Metalloprotease inhibitor, Protease inhibitor" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 293.3" "Cell line enhanced" "Detected in many" "ASC diff: 161.3;ASC TERT1: 216.0;HSkMC: 148.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" "CAB022360, HPA053417" Approved Approved "Golgi apparatus" "Secreted to blood" 116666667 750000000 "Golgi apparatus" "CAB022360: , HPA053417: " "unprognostic (5.86e-3)" "unprognostic (1.30e-1)" "prognostic unfavourable (2.09e-4)" "unprognostic (4.68e-2)" "unprognostic (1.81e-2)" "unprognostic (1.07e-3)" "unprognostic (4.99e-2)" "unprognostic (8.24e-3)" "unprognostic (9.12e-3)" "unprognostic (9.69e-2)" "unprognostic (9.10e-2)" "unprognostic (2.17e-1)" "prognostic unfavourable (2.90e-11)" "unprognostic (1.88e-2)" "unprognostic (1.61e-1)" "unprognostic (1.92e-2)" "unprognostic (2.66e-1)" 80.2 82.3 6.3 154.0 12.8 9.2 31.8 3.3 8.4 63.5 29.1 6.5 27.2 6.1 48.9 109.6 34.9 53.5 110.9 105.7 9.2 5.5 71.2 115.9 144.8 293.3 8.4 4.8 149.3 22.2 41.8 48.7 125.5 29.5 62.9 19.0 33.4 45.9 42.0 26.1 11.6 13.2 64.5 14.6 69.3 19.3 71.9 4.6 8.8 98.6 14.6 34.8 121.0 46.8 2.3 56.8 57.1 91.5 9.4 26.4 39.7 9.4 15.8 7.7 91.3 161.3 216.0 1.9 102.5 84.8 32.0 25.9 6.2 17.8 0.1 13.5 131.9 9.4 4.2 43.5 20.7 19.1 10.0 9.7 11.5 9.6 107.4 6.5 124.3 148.0 11.1 97.4 20.7 14.3 15.0 7.2 52.9 18.4 0.1 25.0 8.6 33.2 0.1 15.9 8.4 51.5 6.6 0.1 0.4 60.8 0.4 12.9 0.8 12.6 13.8 47.9 50.5 56.5 10.0 3.0 6.4 0.3 139.3 15.7 31.1 29.5 54.6 0.8 16.2 91.5 16.0 2.3 26.4 14.3 56.8 1.2 8.6 7.7 57.1 9.4 83.6 1.6 10.7 39.7 6.3 12.8 3.3 5.3 9.2 5.5 8.4 4.8 29.5 4.6 TIMP2 CSC-21K ENSG00000035862 "TIMP metallopeptidase inhibitor 2" P16035 17 78852977-78925387 "Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Metalloenzyme inhibitor, Metalloprotease inhibitor, Protease inhibitor" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "placenta: 269.8" "Cell line enhanced" "Detected in many" "ASC diff: 124.8;ASC TERT1: 153.5;BJ hTERT+: 87.2;fHDF/TERT166: 95.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 13.3" "Group enriched" "Detected in many" 4 "granulocytes: 13.3;monocytes: 5.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB010203 Approved "Secreted to extracellular matrix" 83000000 "CAB010203: AB_2204966" "unprognostic (1.03e-1)" "unprognostic (1.71e-2)" "unprognostic (9.81e-2)" "unprognostic (1.76e-3)" "unprognostic (3.24e-2)" "unprognostic (3.05e-1)" "unprognostic (4.31e-1)" "unprognostic (1.63e-2)" "unprognostic (1.39e-1)" "unprognostic (4.73e-2)" "unprognostic (3.97e-2)" "unprognostic (1.13e-1)" "unprognostic (1.08e-1)" "unprognostic (1.38e-3)" "unprognostic (4.62e-2)" "unprognostic (2.05e-1)" "unprognostic (2.77e-3)" 75.2 35.1 30.9 17.7 18.9 3.4 45.6 4.6 25.8 95.8 40.5 36.8 28.2 12.9 87.9 41.5 37.4 39.8 72.3 38.5 23.2 29.6 21.1 12.2 38.4 15.4 25.3 23.2 182.4 14.4 15.8 17.2 269.8 34.0 44.6 20.3 49.7 16.9 51.6 24.5 38.4 22.0 70.7 32.6 37.9 24.2 51.7 26.1 28.4 25.3 24.0 11.3 60.2 58.1 0.2 2.1 13.3 5.0 0.2 0.3 0.8 14.8 7.5 8.5 16.2 124.8 153.5 4.6 52.6 87.2 25.8 20.5 2.7 26.0 0.0 18.6 95.6 2.9 2.6 2.2 27.1 0.3 1.5 0.0 15.2 4.2 37.0 0.2 0.1 60.3 1.1 25.4 4.1 34.1 0.0 0.0 26.5 1.7 15.3 2.6 1.5 11.1 10.3 19.5 6.3 16.4 0.2 4.3 26.8 32.9 15.6 67.1 7.9 3.7 40.4 69.2 13.3 40.1 9.0 7.7 6.4 0.1 15.8 2.8 33.3 0.0 5.0 6.8 0.0 3.3 0.0 0.1 0.1 0.0 2.1 0.2 0.3 0.3 13.3 0.2 3.8 1.4 0.1 0.8 30.9 18.9 4.6 25.8 23.2 29.6 25.3 23.2 34.0 26.1 TJP2 "DFNA51, X104, ZO-2, ZO2" ENSG00000119139 "Tight junction protein 2" Q9UDY2 9 69121264-69255208 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cancer-related genes, Disease mutation, Intrahepatic cholestasis" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "A-431: 53.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "non-classical monocyte: 4.0" "Lineage enriched" "Detected in single" 8 "monocytes: 4.0" "HPA001813, CAB009228, HPA070714" Supported Enhanced "Nucleoplasm,Plasma membrane,Cell Junctions" 790000 "Plasma membrane, Cell Junctions" Nucleoplasm "CAB009228: AB_2203583, HPA001813: AB_1080764, HPA070714: " "unprognostic (1.30e-1)" "unprognostic (7.69e-2)" "unprognostic (1.23e-3)" "unprognostic (7.68e-2)" "unprognostic (2.01e-1)" "unprognostic (8.83e-3)" "unprognostic (1.94e-2)" "unprognostic (1.86e-1)" "unprognostic (4.82e-2)" "unprognostic (3.30e-2)" "unprognostic (2.93e-3)" "unprognostic (3.60e-1)" "prognostic favourable (1.78e-14)" "unprognostic (3.29e-2)" "unprognostic (6.42e-2)" "unprognostic (8.15e-3)" "unprognostic (5.85e-2)" 25.2 9.5 23.7 8.0 29.7 5.7 20.7 35.6 24.9 9.0 20.0 50.3 20.6 27.2 11.9 7.3 28.9 12.6 13.2 19.8 35.1 12.7 23.3 34.5 23.9 5.8 39.7 20.5 20.9 13.2 43.2 3.6 18.0 32.0 13.5 16.7 19.1 18.0 23.1 8.3 18.6 25.7 15.3 39.7 3.5 30.4 17.8 41.1 11.1 22.5 9.0 10.8 26.5 26.6 0.0 0.2 0.4 4.0 0.0 0.5 0.5 53.2 1.7 4.2 4.7 20.1 19.7 23.2 8.1 5.9 12.9 7.0 6.4 19.4 7.6 8.1 4.5 32.7 6.9 17.0 14.7 27.2 5.0 7.4 4.6 32.8 5.6 3.0 14.0 15.3 12.3 10.1 6.0 27.1 4.4 5.2 6.7 7.4 1.1 0.4 10.4 11.6 3.9 6.1 0.8 33.3 35.5 1.9 3.3 2.9 20.7 0.6 6.7 1.6 38.8 9.7 10.5 7.5 8.2 5.3 1.1 0.1 11.1 4.3 3.5 0.0 0.7 0.0 0.0 1.5 0.4 0.0 0.2 0.0 0.2 0.0 0.0 0.1 0.4 0.0 4.0 0.1 0.5 0.5 23.7 29.7 35.6 17.5 35.1 12.7 39.7 20.5 32.0 41.1 TK1 ENSG00000167900 "Thymidine kinase 1" P04183 17 78174075-78187233 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "DNA synthesis" "Kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 32.8;lymphoid tissue: 41.8;tongue: 33.0" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "T-reg: 21.2" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in single" "Low region specificity" "Detected in many" CAB004683 Enhanced "CAB004683: AB_437067" "unprognostic (7.09e-2)" "unprognostic (1.17e-3)" "unprognostic (1.82e-1)" "unprognostic (2.14e-3)" "unprognostic (3.22e-1)" "unprognostic (1.94e-1)" "prognostic unfavourable (6.87e-4)" "prognostic unfavourable (3.03e-5)" "unprognostic (4.05e-2)" "unprognostic (3.18e-3)" "unprognostic (6.64e-3)" "unprognostic (2.76e-2)" "prognostic unfavourable (6.50e-11)" "unprognostic (5.55e-3)" "unprognostic (1.92e-1)" "unprognostic (1.42e-1)" "unprognostic (4.94e-2)" 5.3 2.0 2.1 21.4 4.5 32.8 4.8 1.1 1.9 3.7 11.4 2.2 1.9 8.5 2.4 4.8 18.9 2.2 7.0 4.3 1.6 0.7 7.9 6.2 9.3 15.7 3.1 1.6 2.1 3.6 0.1 1.3 8.6 2.1 2.3 7.9 0.5 4.6 2.0 2.0 6.2 8.5 4.4 1.7 9.0 9.4 3.6 1.6 41.8 1.3 33.0 20.5 3.1 5.8 4.0 2.1 1.1 1.2 6.2 21.2 3.5 65.1 54.2 10.8 13.6 1.0 4.3 7.1 32.4 17.0 48.2 66.9 47.8 27.5 21.2 11.4 19.4 29.7 9.8 28.9 25.0 7.3 36.2 37.4 19.4 31.3 0.3 15.8 24.2 2.1 0.9 25.1 3.4 19.6 23.0 47.0 18.5 48.7 7.9 8.9 5.6 37.8 21.4 43.8 47.3 12.8 21.2 4.9 14.3 24.8 68.2 9.1 46.0 21.3 9.0 47.4 46.6 33.8 41.6 19.8 10.3 27.3 23.3 10.7 21.3 0.0 0.7 0.0 1.1 1.2 0.5 4.0 5.3 2.7 2.1 1.2 0.3 1.4 1.1 6.2 1.0 0.7 21.2 3.5 2.1 4.5 1.1 1.9 1.6 0.7 3.1 1.6 2.1 1.6 TLX1 "HOX11, TCL3" ENSG00000107807 "T cell leukemia homeobox 1" P31314 10 101130505-101137789 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Developmental protein, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 8 "lymphoid tissue: 59.5;salivary gland: 19.5" "Cell line enhanced" "Detected in some" "HAP1: 5.3;HEK 293: 3.0;K-562: 15.0;SCLC-21H: 2.5;SH-SY5Y: 3.7;SiHa: 2.5" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in single" 13 "pons and medulla: 0.5" "Region enriched" "Detected in single" 20 "pons and medulla: 0.5" HPA053185 Supported Nucleoplasm Nucleoplasm "HPA053185: " "unprognostic (8.67e-2)" "unprognostic (2.23e-1)" "prognostic unfavourable (7.32e-4)" "unprognostic (1.06e-5)" "unprognostic (1.06e-1)" "unprognostic (1.60e-1)" "unprognostic (5.07e-1)" "unprognostic (1.57e-2)" "unprognostic (2.12e-2)" "unprognostic (2.69e-2)" "unprognostic (2.52e-3)" "unprognostic (1.81e-1)" "unprognostic (2.63e-1)" "unprognostic (3.26e-1)" "unprognostic (3.06e-1)" "unprognostic (7.35e-2)" 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.1 0.1 0.0 0.8 0.0 0.0 0.1 0.0 0.0 0.2 0.4 0.0 0.0 0.5 0.1 0.0 0.0 0.0 0.0 0.1 0.5 0.0 0.1 0.1 0.2 0.0 0.0 19.5 0.0 0.1 0.0 0.6 0.0 0.0 59.5 0.0 0.1 0.1 0.0 0.0 4.8 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 1.8 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 5.3 0.0 0.0 0.0 3.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 2.5 3.7 2.5 0.0 0.0 0.1 0.4 0.2 0.0 1.5 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.4 0.0 0.0 0.0 0.1 0.1 TLX3 "HOX11L2, RNX" ENSG00000164438 "T cell leukemia homeobox 3" O43711 5 171309284-171312134 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Developmental protein, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 59 "brain: 46.6" "Cell line enriched" "Detected in some" 5 "SH-SY5Y: 24.0" "Cancer enhanced" "Detected in some" "cervical cancer: 1.7" "Region enriched" "Detected in some" 22 "cerebellum: 46.6" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in single" 7 "cerebellum: 2.5" "Region enriched" "Detected in some" 11 "cerebellum: 48.1" "HPA030504, HPA060957, HPA069359" Enhanced Enhanced Nucleoplasm Nucleoplasm "HPA030504: , HPA060957: , HPA069359: " "unprognostic (3.52e-2)" "unprognostic (2.43e-2)" "unprognostic (2.09e-1)" "unprognostic (3.11e-1)" "unprognostic (9.80e-2)" "unprognostic (2.76e-2)" "unprognostic (4.48e-2)" 0.4 0.5 0.0 0.0 0.0 0.0 0.0 46.6 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.4 2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 1.6 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.4 0.0 0.0 0.2 0.0 0.0 0.0 1.3 0.0 4.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.9 0.0 0.2 0.0 0.0 24.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 46.6 0.0 0.0 0.0 0.0 0.0 2.0 0.0 TMF1 "ARA160, TMF" ENSG00000144747 "TATA element modulatory factor 1" P82094 3 69019827-69052339 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Transcription, Transcription regulation" "DNA-binding, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA008729 Approved Supported "Golgi apparatus" "Golgi apparatus" "HPA008729: AB_1080310" "unprognostic (2.71e-1)" "unprognostic (2.11e-2)" "unprognostic (8.02e-3)" "unprognostic (7.19e-2)" "unprognostic (2.74e-1)" "unprognostic (6.75e-3)" "unprognostic (6.73e-3)" "unprognostic (1.79e-1)" "unprognostic (4.62e-2)" "unprognostic (2.37e-2)" "unprognostic (1.08e-2)" "unprognostic (2.83e-2)" "unprognostic (1.50e-1)" "unprognostic (1.03e-2)" "unprognostic (1.80e-1)" "unprognostic (3.51e-2)" "unprognostic (1.01e-1)" 17.4 14.2 12.8 15.2 14.2 26.2 20.8 20.8 15.6 18.8 21.1 9.5 26.6 14.8 18.3 24.2 14.9 17.7 16.8 16.7 11.9 12.1 17.5 17.2 19.0 16.8 13.5 11.1 20.2 23.0 22.3 36.1 28.9 17.2 19.0 16.9 9.5 24.3 28.9 21.3 13.3 22.9 13.8 13.6 16.3 15.9 20.9 16.0 20.3 24.7 11.1 16.4 23.2 18.6 6.6 4.6 10.0 5.9 5.0 6.4 3.1 12.5 5.5 5.3 5.3 14.3 18.5 11.9 16.3 15.8 11.0 13.3 7.8 9.4 4.8 2.6 16.5 7.0 6.8 7.2 18.1 9.2 5.2 9.4 7.3 9.2 13.0 10.5 13.4 10.8 11.6 14.5 13.2 11.7 5.6 7.9 14.2 7.2 6.0 9.1 4.6 2.9 5.0 6.7 6.9 14.2 10.2 3.7 5.6 13.4 9.5 10.1 7.2 12.7 15.2 10.8 4.6 18.9 9.7 8.9 8.5 4.7 16.5 10.9 8.5 7.6 4.5 9.1 6.4 3.7 4.3 5.2 5.7 5.4 4.0 6.6 5.9 5.4 10.0 5.0 5.9 4.6 5.8 3.1 12.8 14.2 20.8 15.6 11.9 12.1 13.5 11.1 17.2 16.0 TMPRSS2 PRSS10 ENSG00000184012 "Transmembrane serine protease 2" O15393 21 41464551-41531116 "Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins" "Hydrolase, Protease, Serine protease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 75.6;pancreas: 64.5;prostate: 68.2" "Cell line enhanced" "Detected in some" "CACO-2: 14.6;MCF7: 6.3;RT4: 35.2;SK-BR-3: 7.2;T-47d: 5.4" "Cancer enriched" "Detected in many" 7 "prostate cancer: 250.6" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "HPA034493, HPA035787" Enhanced Supported "Nucleoplasm,Cell Junctions" "Intracellular and membrane" "Cell Junctions" Nucleoplasm "HPA034493: , HPA035787: AB_2674782" "unprognostic (4.80e-3)" "unprognostic (3.49e-1)" "unprognostic (2.16e-1)" "prognostic favourable (2.56e-4)" "unprognostic (1.72e-1)" "unprognostic (1.05e-2)" "unprognostic (4.28e-2)" "unprognostic (1.51e-3)" "unprognostic (9.43e-2)" "unprognostic (9.02e-3)" "unprognostic (6.24e-2)" "unprognostic (6.43e-2)" "prognostic favourable (7.86e-6)" "unprognostic (2.00e-2)" "unprognostic (1.68e-1)" "unprognostic (1.41e-1)" "unprognostic (2.15e-2)" 0.2 0.1 0.2 15.5 0.4 0.0 6.1 0.2 0.5 1.3 38.7 0.4 24.4 17.5 0.5 0.9 10.7 2.2 17.3 0.2 0.3 0.1 19.4 18.4 20.7 0.2 0.2 0.2 0.7 64.5 0.0 1.3 1.0 0.4 68.2 18.5 0.3 52.3 35.7 0.2 2.1 75.6 0.9 0.2 0.3 36.7 0.8 0.3 0.5 19.9 3.9 10.2 5.9 4.3 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 14.6 1.9 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.3 0.1 0.5 1.3 0.0 0.0 0.0 1.4 0.6 35.2 0.0 0.4 0.0 7.2 0.1 5.4 0.0 0.0 0.0 0.3 0.3 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.2 0.4 0.2 0.5 0.3 0.1 0.2 0.2 0.4 0.3 TNC "DFNA56, HXB, MGC167029, TN" ENSG00000041982 "Tenascin C" P24821 9 115019578-115118257 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Cell adhesion" "Cancer-related genes, Deafness, Disease mutation, Non-syndromic deafness" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "smooth muscle: 111.4" "Cell line enhanced" "Detected in many" "BJ hTERT+: 83.7;hTEC/SVTERT24-B: 68.4;U-138 MG: 57.6;U-87 MG: 76.7;WM-115: 131.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 5 "neutrophil: 1.9" "Lineage enriched" "Detected in single" 5 "granulocytes: 1.9" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB004592, HPA004823" Approved "Secreted to extracellular matrix" 760000000 "CAB004592: AB_628342, HPA004823: AB_1080243" "unprognostic (5.46e-2)" "unprognostic (3.76e-2)" "unprognostic (7.57e-2)" "unprognostic (1.69e-1)" "unprognostic (9.20e-2)" "unprognostic (1.39e-1)" "unprognostic (2.07e-1)" "unprognostic (9.68e-2)" "unprognostic (7.86e-3)" "unprognostic (2.68e-3)" "unprognostic (1.59e-2)" "unprognostic (1.82e-1)" "unprognostic (4.87e-3)" "unprognostic (1.79e-2)" "unprognostic (1.92e-2)" "unprognostic (7.60e-2)" "unprognostic (1.97e-3)" 20.6 2.5 1.4 50.9 11.4 0.5 12.6 0.4 6.4 19.4 63.6 18.6 24.1 5.3 42.4 23.9 18.5 12.0 16.9 13.6 3.4 2.8 16.4 2.6 21.0 66.3 4.3 3.3 10.6 1.8 0.6 3.3 3.2 14.7 13.0 9.3 0.0 8.5 10.8 10.8 10.3 21.2 111.4 5.7 26.9 31.3 5.4 6.8 4.7 5.5 15.4 16.1 20.4 6.6 0.3 0.3 1.9 0.3 0.2 0.3 0.1 2.5 0.6 0.7 0.1 4.1 1.1 0.0 21.5 83.7 45.6 22.5 0.5 5.8 0.0 3.4 30.4 9.0 0.0 1.2 27.4 0.0 0.2 0.0 0.5 0.0 0.0 0.0 0.4 0.6 0.1 68.4 31.9 0.0 0.0 0.5 1.2 0.0 0.0 0.0 7.1 9.2 0.0 48.4 0.0 41.5 0.0 0.0 0.6 9.0 0.0 2.1 0.0 0.1 0.0 57.6 9.5 9.9 50.5 1.5 0.0 0.0 76.7 0.0 131.3 0.1 0.3 0.1 0.3 0.1 0.1 0.2 0.2 0.1 0.3 0.3 0.1 0.2 1.9 0.2 0.0 0.2 0.0 0.1 1.4 11.4 0.4 3.9 3.4 2.8 4.3 3.3 14.7 6.8 TNFAIP2 "B94, EXOC3L3" ENSG00000185215 "TNF alpha induced protein 2" Q03169 14 103123442-103137439 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters" "Angiogenesis, Differentiation" "Developmental protein" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enriched" "Detected in many" 5 "RT4: 126.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 25.9" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB004598, HPA030624" Enhanced Approved "Nucleoplasm,Nuclear membrane,Golgi apparatus,Cytosol" "Golgi apparatus, Cytosol" "Nucleoplasm, Nuclear membrane" "CAB004598: AB_628370, HPA030624: " "unprognostic (5.01e-3)" "unprognostic (4.93e-2)" "unprognostic (1.56e-3)" "unprognostic (8.02e-3)" "unprognostic (3.39e-2)" "unprognostic (2.98e-2)" "unprognostic (5.52e-3)" "unprognostic (5.97e-2)" "unprognostic (1.94e-1)" "unprognostic (7.02e-2)" "unprognostic (1.22e-1)" "unprognostic (1.37e-1)" "prognostic unfavourable (4.10e-4)" "prognostic favourable (2.79e-5)" "unprognostic (1.75e-2)" "unprognostic (3.83e-2)" "prognostic favourable (7.17e-5)" 27.3 17.0 3.8 58.2 5.7 20.1 19.3 2.5 3.6 23.5 12.9 2.8 4.7 8.1 16.7 18.7 35.5 14.3 30.9 12.7 2.9 3.6 18.8 13.6 32.0 17.9 4.6 3.0 9.7 9.0 17.4 3.5 33.0 6.1 21.7 6.1 16.3 25.1 7.1 12.5 13.2 11.3 28.0 3.8 35.9 8.3 13.0 2.9 11.0 8.5 31.4 48.6 39.8 16.3 0.1 5.0 25.9 9.8 0.1 0.1 1.9 5.4 26.9 0.1 0.1 1.7 7.7 9.0 1.6 6.9 4.3 1.5 0.2 24.4 0.0 20.1 7.8 17.4 1.9 0.0 2.1 0.9 0.1 2.4 18.8 0.1 3.3 1.2 3.4 2.9 0.2 1.4 0.0 2.2 2.4 5.9 0.6 0.5 0.0 1.9 1.6 2.2 1.0 3.1 3.9 13.8 126.5 0.2 0.3 24.7 8.6 0.3 13.9 8.0 4.6 0.9 2.3 5.0 5.0 5.3 0.3 0.1 6.5 5.5 2.6 2.5 8.8 4.6 0.0 9.8 0.0 0.0 0.0 0.0 5.0 0.1 0.0 0.1 25.9 0.1 6.9 0.2 0.0 1.9 3.8 5.7 2.5 3.6 2.9 3.6 4.6 3.0 6.1 2.9 TNFAIP3 "A20, OTUD7C" ENSG00000118503 "TNF alpha induced protein 3" P21580 6 137867188-137883312 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Apoptosis, Inflammatory response, Ubl conjugation pathway" "DNA-binding, Hydrolase, Multifunctional enzyme, Protease, Thiol protease, Transferase" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "bone marrow: 112.4" "Cell line enhanced" "Detected in many" "Karpas-707: 48.4;REH: 42.0;U-266/84: 36.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Not detected" "Not detected" "Low region specificity" "Detected in many" "HPA002116, HPA067479" Approved Supported Vesicles Vesicles "HPA002116: AB_1858162, HPA067479: " "unprognostic (5.50e-3)" "unprognostic (9.98e-3)" "unprognostic (3.06e-2)" "unprognostic (1.01e-2)" "unprognostic (4.01e-2)" "unprognostic (9.47e-2)" "unprognostic (5.01e-3)" "unprognostic (4.40e-2)" "unprognostic (2.92e-2)" "unprognostic (2.58e-1)" "unprognostic (1.72e-1)" "unprognostic (2.06e-1)" "prognostic unfavourable (6.05e-4)" "unprognostic (6.06e-2)" "unprognostic (3.55e-3)" "unprognostic (1.27e-1)" "unprognostic (6.29e-2)" 27.4 6.0 1.5 58.6 1.8 112.4 17.2 0.4 1.5 7.7 15.7 3.2 2.6 5.1 9.7 7.3 12.7 12.1 17.0 11.7 2.1 1.3 6.8 8.1 45.1 38.8 2.1 2.6 37.5 7.2 2.1 3.7 14.5 4.6 13.8 6.3 7.2 8.2 3.5 10.7 20.5 17.2 8.2 3.8 25.9 8.0 9.3 2.1 38.6 5.7 9.2 31.4 23.3 9.5 7.1 18.6 10.0 9.7 7.5 20.5 9.0 8.9 1.5 0.5 0.8 3.0 5.1 2.1 5.1 20.0 1.4 1.8 9.9 3.0 2.0 13.2 5.9 6.8 0.3 14.8 2.6 14.6 0.5 2.0 5.2 5.8 3.3 2.7 3.7 4.7 2.1 16.9 16.1 0.8 4.1 48.4 2.4 0.5 14.7 11.5 0.3 0.4 42.0 10.4 1.4 4.4 4.3 0.2 0.0 1.0 1.5 4.4 1.0 3.4 4.0 14.5 1.7 12.9 2.9 15.6 36.1 4.1 5.3 3.5 1.8 5.6 9.7 5.5 14.8 7.1 20.5 6.2 15.1 13.3 10.3 7.1 10.0 7.4 10.0 7.5 3.7 18.6 14.7 9.0 1.5 1.8 0.4 1.5 2.1 1.3 2.1 2.6 4.6 2.1 TNFRSF10A "Apo2, CD261, DR4, TRAILR-1, TRAILR1" ENSG00000104689 "TNF receptor superfamily member 10a" O00220 8 23190452-23225126 "Cancer-related genes, CD markers, Predicted membrane proteins" Apoptosis Receptor "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "HPA050958, HPA054475" Approved Supported Nucleoplasm Nucleoplasm "HPA050958: , HPA054475: " "unprognostic (3.66e-1)" "unprognostic (1.02e-1)" "unprognostic (2.19e-2)" "unprognostic (4.89e-2)" "unprognostic (9.44e-2)" "unprognostic (8.39e-2)" "unprognostic (5.32e-2)" "unprognostic (2.18e-2)" "unprognostic (2.72e-1)" "unprognostic (4.48e-2)" "prognostic unfavourable (1.00e-4)" "unprognostic (1.49e-1)" "unprognostic (1.99e-3)" "unprognostic (1.91e-2)" "unprognostic (1.61e-2)" "unprognostic (2.35e-1)" "unprognostic (2.87e-1)" 11.9 4.0 2.1 13.0 3.4 8.4 9.7 2.0 2.8 6.0 10.9 1.4 4.5 5.9 5.3 5.6 13.6 4.1 12.7 6.3 2.2 2.0 10.9 10.6 11.0 12.4 3.0 0.7 2.7 12.9 3.6 1.8 6.9 4.0 5.1 7.2 2.1 8.2 4.3 3.8 7.1 10.2 3.8 2.9 13.2 6.1 2.6 3.0 9.5 5.8 14.9 25.4 6.7 8.7 13.2 4.5 3.8 4.3 3.9 13.9 4.2 7.9 14.4 0.7 0.0 0.5 2.9 0.0 1.6 1.0 0.8 2.3 11.0 14.0 18.4 18.8 1.0 15.2 12.9 20.6 1.4 4.5 0.1 9.7 8.7 6.2 7.4 5.2 9.3 5.0 17.0 18.3 15.8 9.7 15.0 6.6 3.9 6.2 0.2 3.3 10.0 8.8 0.1 0.0 13.2 11.0 17.2 0.4 0.5 4.0 10.2 0.0 5.4 4.0 13.6 0.0 0.1 0.8 0.0 7.8 11.0 14.3 0.1 1.7 0.2 2.0 4.3 3.8 3.8 1.9 10.3 10.4 12.3 7.7 4.5 13.2 12.1 7.0 0.5 3.9 1.7 0.0 13.9 4.2 2.1 3.4 2.0 2.8 2.2 2.0 3.0 0.7 4.0 3.0 TNFRSF10B "CD262, DR5, KILLER, TRAIL-R2, TRAILR2, TRICK2A, TRICKB" ENSG00000120889 "TNF receptor superfamily member 10b" O14763 8 23020133-23069179 "Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins" Apoptosis Receptor "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" HPA023625 Approved "HPA023625: AB_1847860" "unprognostic (8.43e-3)" "unprognostic (7.43e-3)" "unprognostic (3.04e-2)" "unprognostic (4.94e-3)" "unprognostic (1.13e-1)" "unprognostic (7.74e-2)" "unprognostic (2.15e-1)" "unprognostic (9.51e-3)" "unprognostic (2.70e-1)" "unprognostic (2.82e-2)" "unprognostic (2.30e-3)" "unprognostic (1.96e-2)" "prognostic unfavourable (1.76e-4)" "unprognostic (4.01e-2)" "unprognostic (1.03e-1)" "unprognostic (1.86e-1)" "unprognostic (5.52e-2)" 29.6 18.5 5.2 16.4 7.3 7.6 19.6 2.3 5.8 11.5 23.1 7.5 13.3 14.1 10.4 13.9 12.1 11.4 22.1 13.2 6.4 3.2 14.3 36.1 21.3 11.6 7.9 2.6 16.2 20.0 14.8 6.1 8.5 8.2 15.1 14.3 7.9 11.5 14.5 15.5 6.1 31.2 10.5 8.6 17.4 11.2 7.8 6.4 4.1 17.7 13.0 15.2 17.9 9.9 3.1 12.1 2.8 12.9 0.8 4.0 5.2 8.5 22.7 33.3 10.1 15.6 20.4 32.6 20.6 26.5 11.2 17.5 9.4 8.6 5.1 14.0 11.2 8.3 8.7 39.0 20.0 5.1 7.3 0.0 8.9 17.6 52.3 1.9 8.6 30.3 35.0 24.9 26.6 35.5 3.6 0.0 22.0 2.8 0.2 2.8 8.3 8.2 4.6 12.1 3.2 21.7 13.5 0.0 5.6 10.3 2.9 10.9 5.0 2.4 31.4 16.4 8.5 5.2 14.8 6.6 1.1 2.4 16.7 3.7 23.4 2.8 12.9 0.4 1.6 9.3 2.7 3.1 1.9 1.6 12.1 1.6 4.0 1.6 2.6 0.8 11.9 0.0 1.3 5.2 5.2 7.3 2.3 5.8 6.4 3.2 7.9 2.6 8.2 6.4 TNFRSF10C "CD263, DcR1, LIT, TRAILR3, TRID" ENSG00000173535 "TNF receptor superfamily member 10c" O14798 8 23102590-23117437 "Cancer-related genes, CD markers, Predicted membrane proteins" Apoptosis Receptor "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "blood: 173.4" "Group enriched" "Detected in some" 5 "BEWO: 37.1;HUVEC TERT2: 30.9" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in some" 7 "neutrophil: 173.4" "Lineage enriched" "Detected in many" 113 "granulocytes: 173.4" CAB025635 Enhanced "CAB025635: " "unprognostic (2.63e-1)" "unprognostic (4.49e-3)" "unprognostic (7.21e-3)" "unprognostic (2.07e-2)" "unprognostic (3.55e-2)" "unprognostic (1.46e-1)" "unprognostic (1.81e-2)" "unprognostic (2.11e-3)" "unprognostic (5.56e-2)" "unprognostic (4.37e-2)" "unprognostic (8.98e-2)" "unprognostic (1.94e-3)" "unprognostic (2.74e-3)" "unprognostic (4.83e-1)" "unprognostic (1.84e-1)" "unprognostic (1.34e-3)" "unprognostic (6.54e-2)" 5.5 1.5 1.9 14.0 3.6 12.6 2.0 1.4 3.9 2.9 1.5 0.7 0.1 1.2 1.5 1.2 1.4 3.7 13.5 5.6 1.9 1.1 2.8 3.2 13.7 28.4 9.2 0.0 2.4 2.1 2.5 4.5 12.8 3.1 2.7 1.8 1.7 1.7 0.8 2.3 0.8 2.2 1.9 4.4 26.4 1.8 1.4 2.3 0.8 4.4 0.5 0.9 5.2 1.9 0.0 0.3 173.4 1.5 0.0 0.0 0.4 0.4 1.4 0.5 2.4 0.0 0.3 37.1 1.5 0.0 0.1 0.1 0.0 1.4 0.1 0.7 1.4 0.2 0.1 0.1 0.1 2.5 0.5 0.1 0.3 1.1 3.6 0.2 1.0 4.1 0.3 0.7 0.3 30.9 0.0 0.0 0.2 1.0 0.0 0.9 1.6 0.0 0.1 0.1 0.0 5.9 0.1 0.0 0.0 0.1 0.2 0.7 5.1 0.2 6.5 0.6 1.2 1.4 0.1 1.5 0.8 0.0 2.2 0.3 0.9 2.7 1.5 25.4 0.0 0.8 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 173.4 0.0 1.1 0.0 0.0 0.4 1.9 3.6 1.4 3.9 1.9 1.1 9.2 0.0 3.1 2.3 TNFRSF10D "CD264, DcR2, TRAILR4, TRUNDD" ENSG00000173530 "TNF receptor superfamily member 10d" Q9UBN6 8 23135588-23164030 "Cancer-related genes, CD markers, Predicted membrane proteins" Apoptosis Receptor "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HUVEC TERT2: 24.1;LHCN-M2: 60.9;WM-115: 57.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "naive CD4 T-cell: 9.0" "Low lineage specificity" "Detected in many" HPA070971 Approved "Plasma membrane,Actin filaments" "Plasma membrane, Actin filaments" "HPA070971: " "unprognostic (1.49e-1)" "prognostic unfavourable (1.70e-4)" "unprognostic (1.41e-1)" "unprognostic (8.78e-2)" "unprognostic (8.13e-2)" "unprognostic (7.49e-2)" "unprognostic (2.69e-1)" "unprognostic (7.06e-2)" "unprognostic (3.56e-2)" "unprognostic (1.66e-1)" "unprognostic (1.61e-2)" "unprognostic (1.32e-1)" "unprognostic (2.12e-2)" "unprognostic (2.70e-1)" "unprognostic (1.35e-2)" "unprognostic (6.32e-2)" "unprognostic (1.72e-1)" 16.0 3.1 4.9 7.3 10.0 10.5 10.2 3.4 10.3 5.9 8.5 2.6 5.5 6.2 8.9 5.7 4.1 8.0 11.5 6.5 7.0 3.4 12.1 31.5 12.5 5.1 9.0 0.9 9.8 5.2 2.5 4.3 4.1 9.0 9.0 10.9 3.9 3.9 4.4 3.9 3.1 11.2 10.9 6.3 6.9 7.2 4.3 9.2 2.9 6.0 6.8 6.6 7.3 26.0 2.1 4.5 2.4 3.3 0.3 9.0 2.4 3.5 3.0 4.0 2.2 3.0 12.1 0.0 18.8 7.1 1.4 1.9 5.8 2.9 0.0 4.0 11.2 1.2 3.3 16.5 12.5 0.0 2.9 1.0 1.8 5.0 13.3 0.6 1.3 15.1 18.4 5.0 3.5 24.1 0.0 0.0 60.9 0.0 0.0 1.9 3.2 0.0 0.7 0.0 0.9 4.7 1.6 0.0 0.0 2.0 0.0 0.0 0.0 2.3 14.2 0.0 0.0 1.1 0.0 0.0 0.0 0.0 15.7 0.9 57.8 2.4 3.3 1.5 0.0 1.4 0.1 2.1 3.2 1.1 4.5 0.8 9.0 3.5 2.2 0.3 1.9 0.0 1.0 2.4 4.9 10.0 3.4 10.3 7.0 3.4 9.0 0.9 9.0 9.2 TNFRSF11B "OCIF, OPG, TR1" ENSG00000164761 "TNF receptor superfamily member 11b" O00300 8 118923557-118952200 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins" Apoptosis Receptor "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "kidney: 18.6;thyroid gland: 52.8" "Group enriched" "Detected in some" 4 "BJ: 49.7;BJ hTERT+: 184.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 66 "plasmacytoid DC: 6.5" "Lineage enriched" "Detected in single" 66 "dendritic cells: 6.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB034939 Approved "Secreted in other tissues" "CAB034939: " "unprognostic (1.39e-2)" "prognostic unfavourable (6.22e-4)" "unprognostic (5.27e-2)" "unprognostic (2.33e-2)" "unprognostic (4.27e-3)" "unprognostic (1.10e-3)" "unprognostic (1.21e-3)" "unprognostic (5.50e-2)" "unprognostic (9.94e-2)" "unprognostic (6.32e-2)" "unprognostic (3.53e-2)" "unprognostic (2.43e-1)" "prognostic favourable (6.79e-4)" "unprognostic (1.32e-2)" "unprognostic (4.52e-2)" "unprognostic (1.61e-3)" "prognostic unfavourable (3.88e-4)" 3.0 3.0 2.2 2.8 2.8 0.2 4.4 2.9 5.2 1.2 1.5 0.7 0.5 0.9 5.5 4.1 1.0 1.7 3.2 7.3 2.8 1.4 18.6 7.6 8.1 5.3 1.7 0.8 0.5 2.8 0.3 1.9 4.0 12.0 1.1 2.0 1.8 1.4 0.8 0.6 0.7 1.4 1.5 7.9 1.5 0.8 0.3 2.7 0.9 52.8 0.8 1.7 1.7 1.1 0.0 6.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 2.6 0.5 0.0 49.7 184.9 2.4 0.6 0.5 0.1 0.0 13.4 27.5 0.5 0.0 0.0 1.2 0.0 0.0 0.0 2.3 0.0 0.3 0.0 0.0 0.2 0.0 2.4 0.0 0.0 0.0 0.0 6.9 1.1 0.0 0.0 0.0 0.3 0.0 0.0 0.0 2.2 0.0 0.1 0.0 0.4 0.0 0.0 0.0 0.0 0.1 1.5 0.8 0.9 0.1 0.0 0.0 0.0 0.2 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.5 0.0 0.0 2.2 2.8 2.9 5.2 2.8 1.4 1.7 0.8 12.0 2.7 TNFRSF12A "CD266, FN14, TweakR" ENSG00000006327 "TNF receptor superfamily member 12A" Q9NP84 16 3018445-3022383 "Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Angiogenesis, Apoptosis, Cell adhesion, Differentiation" "Developmental protein, Receptor" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "placenta: 81.3" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Region enriched" "Detected in many" 5 "pons and medulla: 25.0" "Group enriched" "Detected in many" 8 "eosinophil: 38.1;neutrophil: 29.9" "Lineage enriched" "Detected in many" 9 "granulocytes: 38.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in single" HPA007853 Approved Approved "Plasma membrane,Cytosol" 170000 "Plasma membrane, Cytosol" "HPA007853: AB_1858463" "unprognostic (1.44e-1)" "unprognostic (2.46e-3)" "unprognostic (8.90e-2)" "unprognostic (2.60e-1)" "unprognostic (4.06e-3)" "prognostic unfavourable (5.50e-4)" "unprognostic (7.04e-3)" "unprognostic (1.98e-3)" "unprognostic (4.17e-3)" "unprognostic (2.85e-1)" "unprognostic (5.02e-3)" "unprognostic (3.88e-1)" "prognostic unfavourable (8.78e-4)" "unprognostic (2.98e-2)" "unprognostic (6.00e-2)" "unprognostic (2.80e-3)" "unprognostic (2.17e-2)" 10.8 14.2 2.4 11.3 5.1 2.7 21.2 0.9 3.0 8.0 18.9 3.2 4.1 14.5 11.6 10.2 10.7 6.4 28.1 27.0 5.0 2.6 50.4 36.2 23.0 2.6 4.8 0.5 6.4 47.0 51.1 20.0 81.3 25.0 11.1 1.9 2.8 17.3 6.9 23.3 5.0 31.0 16.8 4.3 3.9 13.2 5.3 3.3 1.2 11.5 11.5 4.7 14.8 5.2 0.0 4.1 38.1 3.5 2.0 2.4 1.1 24.3 19.8 2.2 4.1 4.0 9.2 13.1 51.3 37.2 44.0 28.3 8.5 43.5 0.1 68.0 34.1 27.0 0.5 37.5 16.9 0.9 1.3 0.1 6.6 7.2 27.8 0.4 1.8 8.5 26.0 46.2 55.4 12.7 2.7 0.3 46.3 46.0 0.0 3.2 10.7 43.4 0.2 24.7 1.0 44.5 4.8 2.5 0.8 36.6 17.0 30.3 8.9 0.7 22.3 79.3 36.6 52.4 84.2 0.8 0.3 0.3 24.7 2.2 62.3 3.5 3.5 38.1 1.8 2.0 2.4 0.0 0.8 1.5 4.1 0.0 0.4 0.8 29.9 2.0 1.3 0.1 1.0 1.1 2.4 5.1 0.9 3.0 5.0 2.6 4.8 0.5 25.0 3.3 TNFRSF14 "ATAR, CD270, HVEA, HVEM, LIGHTR, TR2" ENSG00000157873 "TNF receptor superfamily member 14" Q92956 1 2555639-2565382 "Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Host-virus interaction, Immunity, Innate immunity" "Host cell receptor for virus entry, Receptor" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "CAPAN-2: 14.3;HDLM-2: 14.4;HHSteC: 16.9;Karpas-707: 13.3;SK-MEL-30: 27.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "HPA006404, CAB026150, CAB030007" Approved Approved "Cytosol,Rods & Rings" Cytosol "Rods & Rings" "CAB026150: , CAB030007: AB_2303380, HPA006404: AB_1851348" "prognostic favourable (4.39e-5)" "unprognostic (3.48e-2)" "unprognostic (1.53e-2)" "prognostic favourable (8.01e-6)" "unprognostic (1.11e-2)" "unprognostic (6.83e-3)" "unprognostic (9.62e-3)" "unprognostic (2.32e-1)" "unprognostic (3.25e-1)" "unprognostic (1.62e-1)" "unprognostic (2.31e-1)" "unprognostic (1.64e-1)" "unprognostic (1.86e-2)" "unprognostic (1.16e-2)" "unprognostic (2.72e-2)" "unprognostic (1.58e-1)" "prognostic favourable (7.79e-6)" 15.9 24.9 4.9 38.9 2.8 11.0 21.9 2.0 4.5 16.8 36.3 3.2 18.5 36.3 15.2 20.5 13.7 12.3 36.7 12.7 4.9 2.5 19.3 20.5 30.3 33.2 3.6 5.7 12.8 7.3 3.5 9.3 8.3 3.9 21.5 8.2 44.1 20.9 22.6 5.2 8.4 41.9 14.6 4.1 36.7 16.7 5.9 2.7 23.5 10.8 10.6 25.0 15.4 17.2 18.2 9.7 30.2 25.8 8.1 25.1 14.2 1.3 0.1 0.1 2.3 5.0 2.7 0.7 0.7 2.3 1.3 1.9 0.2 14.3 0.8 0.1 2.1 1.3 0.0 0.8 0.2 14.4 0.0 8.4 0.4 2.6 16.9 1.1 10.4 2.6 1.4 0.7 0.1 3.7 1.1 13.3 1.2 0.0 4.6 1.3 0.0 1.2 3.8 0.0 4.1 0.2 2.0 0.4 0.0 0.5 0.1 27.9 0.4 0.3 9.4 0.2 0.6 0.2 0.1 10.8 2.6 0.4 2.3 1.2 1.0 3.0 15.1 8.2 17.2 25.8 14.9 16.6 18.0 14.8 9.7 18.2 17.3 14.9 30.2 8.1 24.1 8.7 25.1 14.2 4.9 2.8 2.0 4.5 4.9 2.5 3.6 5.7 3.9 2.7 TNFRSF1A "CD120a, TNF-R, TNF-R-I, TNF-R55, TNFAR, TNFR1, TNFR60" ENSG00000067182 "TNF receptor superfamily member 1A" P19438 12 6328757-6342114 "Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins" "Apoptosis, Host-virus interaction" Receptor "Amyloidosis, Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 86.5" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004102, CAB010309" Approved "Secreted to blood" 170000 "CAB010309: AB_2206639, HPA004102: AB_1846232" "unprognostic (2.19e-2)" "unprognostic (3.76e-2)" "unprognostic (8.14e-2)" "prognostic favourable (8.22e-4)" "unprognostic (3.07e-2)" "prognostic unfavourable (3.68e-4)" "unprognostic (1.50e-1)" "unprognostic (1.41e-3)" "unprognostic (1.00e-1)" "unprognostic (8.05e-2)" "unprognostic (4.78e-2)" "unprognostic (1.54e-2)" "prognostic unfavourable (2.70e-7)" "unprognostic (1.43e-2)" "unprognostic (2.92e-2)" "unprognostic (5.14e-3)" "unprognostic (1.74e-1)" 55.1 43.9 16.8 28.9 16.8 13.7 40.6 7.2 15.6 40.3 41.5 14.1 22.6 39.2 38.2 27.5 39.4 34.2 37.1 26.8 14.0 7.5 49.3 61.6 40.9 37.2 19.2 6.4 59.5 21.4 20.3 19.9 45.3 18.3 37.0 23.0 31.1 25.7 22.2 34.2 30.9 81.7 38.8 25.1 43.6 28.2 21.8 15.7 31.6 42.7 25.4 22.3 49.1 58.5 0.0 20.8 86.5 27.1 1.8 11.6 15.9 7.4 57.8 8.1 11.5 56.0 57.3 15.3 15.9 27.5 21.3 18.6 6.9 29.7 0.6 5.5 34.3 20.8 2.5 18.6 14.8 0.1 4.8 4.1 16.0 15.3 49.7 19.3 13.0 59.0 18.7 17.7 26.1 26.0 6.2 5.7 24.5 10.6 6.1 18.2 19.7 16.9 5.3 12.9 5.7 16.5 13.5 0.0 0.4 22.5 11.8 11.8 3.2 21.1 28.3 16.8 14.4 12.6 14.7 0.0 1.8 2.4 20.1 18.0 20.8 2.2 27.1 15.0 11.6 21.8 11.1 0.0 4.9 9.5 20.8 0.0 4.5 6.6 86.5 1.8 17.5 6.0 4.8 15.9 16.8 16.8 7.2 15.6 14.0 7.5 19.2 6.4 18.3 15.7 TNFRSF1B "CD120b, p75, TNF-R-II, TNF-R75, TNFBR, TNFR2, TNFR80" ENSG00000028137 "TNF receptor superfamily member 1B" P20333 1 12167003-12209228 "Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins" Apoptosis Receptor "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 70.1" "Cell line enhanced" "Detected in many" "CAPAN-2: 17.1;K-562: 20.9;THP-1: 24.5;U-87 MG: 16.8;U-937: 17.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "non-classical monocyte: 70.1" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA004796 Approved "Secreted to blood" 3226667 2500000 "HPA004796: AB_1078436" "unprognostic (4.45e-2)" "unprognostic (2.27e-3)" "unprognostic (7.62e-2)" "unprognostic (3.82e-3)" "unprognostic (6.30e-2)" "unprognostic (4.47e-3)" "unprognostic (5.28e-3)" "unprognostic (2.79e-1)" "unprognostic (1.69e-2)" "unprognostic (1.73e-2)" "unprognostic (7.26e-2)" "unprognostic (2.48e-1)" "prognostic unfavourable (8.35e-5)" "unprognostic (2.02e-1)" "prognostic unfavourable (8.68e-4)" "unprognostic (3.26e-2)" "unprognostic (1.10e-1)" 43.4 4.7 4.6 44.3 13.8 29.2 42.3 2.1 6.1 13.3 13.1 6.6 1.9 11.9 9.7 10.2 6.5 11.3 11.6 21.8 8.5 6.2 6.2 22.2 24.5 60.6 9.1 2.2 9.4 4.2 2.3 4.4 24.9 15.0 7.3 8.2 8.3 5.7 3.7 11.5 6.2 17.3 11.5 22.6 48.3 10.5 6.0 6.1 10.9 6.2 5.6 16.2 18.3 8.4 2.7 13.2 25.7 70.1 2.5 12.7 19.9 0.0 0.1 2.0 0.0 5.5 7.5 4.3 0.5 1.0 2.0 2.2 0.8 17.1 0.1 0.3 1.8 0.0 0.4 0.0 1.1 6.8 0.0 0.0 0.1 0.0 12.9 0.1 1.8 7.4 0.0 6.8 0.0 10.4 20.9 3.1 0.9 0.0 0.0 3.9 0.1 0.6 0.5 0.2 12.0 0.0 0.4 0.0 0.0 0.3 0.1 0.6 0.0 24.5 3.6 3.0 0.1 13.0 0.0 0.9 0.0 0.0 16.8 17.7 0.7 0.0 20.7 3.0 9.4 49.3 5.4 2.7 6.6 7.7 13.2 1.7 2.0 3.0 25.7 2.5 70.1 2.8 12.7 19.9 4.6 13.8 2.1 6.1 8.5 6.2 9.1 2.2 15.0 6.1 TNFRSF4 "ACT35, CD134, OX40, TXGP1L" ENSG00000186827 "TNF receptor superfamily member 4" P43489 1 1211326-1214138 "Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins" "Host-virus interaction" "Host cell receptor for virus entry, Receptor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adipose tissue: 12.5;blood: 18.4;lymphoid tissue: 13.6" "Group enriched" "Detected in some" 9 "MOLT-4: 7.8;NB-4: 15.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in single" "Cell type enhanced" "Detected in many" "memory CD4 T-cell: 15.9;T-reg: 18.4" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Not detected" "Not detected" CAB016128 Enhanced "CAB016128: AB_626897" "unprognostic (2.24e-1)" "unprognostic (8.69e-3)" "unprognostic (1.36e-1)" "unprognostic (8.55e-3)" "unprognostic (1.02e-1)" "prognostic favourable (3.50e-6)" "prognostic unfavourable (6.03e-4)" "unprognostic (3.30e-1)" "unprognostic (1.48e-2)" "unprognostic (7.04e-3)" "unprognostic (1.04e-2)" "unprognostic (1.47e-1)" "prognostic unfavourable (4.52e-6)" "unprognostic (1.61e-1)" "unprognostic (5.46e-2)" "unprognostic (2.42e-1)" "unprognostic (5.91e-2)" 12.5 0.2 0.6 8.8 0.4 0.7 7.3 0.3 1.2 1.1 3.1 0.3 0.3 2.6 0.8 0.7 1.7 0.9 0.8 6.7 0.8 0.1 2.2 0.4 5.3 8.4 0.3 0.6 0.5 0.9 0.0 1.3 5.9 0.6 3.2 0.3 0.6 2.2 1.1 4.4 0.8 4.3 0.3 0.3 13.5 3.5 2.0 0.3 13.6 4.1 0.8 10.9 1.4 0.7 0.0 0.6 4.1 0.0 8.1 18.4 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.8 15.1 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.1 0.0 0.1 0.2 0.0 1.8 0.0 15.9 1.7 0.0 0.0 1.5 0.0 0.2 8.1 0.0 0.6 18.4 1.5 0.6 0.4 0.3 1.2 0.8 0.1 0.3 0.6 0.6 0.3 TNFRSF8 "CD30, D1S166E, KI-1" ENSG00000120949 "TNF receptor superfamily member 8" P28908 1 12063377-12144207 "Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" Receptor "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 33.3" "Cell line enriched" "Detected in some" 21 "HDLM-2: 109.9" "Cancer enriched" "Detected in some" 12 "testis cancer: 9.3" "Region enriched" "Detected in single" 14 "basal ganglia: 13.1" "Cell type enhanced" "Detected in some" "intermediate monocyte: 21.7;non-classical monocyte: 33.3" "Lineage enriched" "Detected in many" 5 "monocytes: 33.3" "Low region specificity" "Detected in many" "CAB000016, HPA014823, HPA032081, HPA032082" Approved Supported "Plasma membrane" "Plasma membrane" "CAB000016: AB_563546, HPA014823: , HPA032081: , HPA032082: " "unprognostic (1.07e-2)" "unprognostic (2.06e-2)" "unprognostic (2.52e-2)" "unprognostic (5.98e-2)" "unprognostic (2.50e-1)" "unprognostic (1.46e-3)" "unprognostic (2.19e-1)" "unprognostic (3.93e-2)" "unprognostic (1.18e-1)" "unprognostic (9.18e-3)" "unprognostic (1.86e-1)" "unprognostic (2.06e-1)" "unprognostic (3.17e-8)" "unprognostic (3.31e-1)" "unprognostic (8.56e-2)" "unprognostic (2.07e-1)" "unprognostic (2.31e-2)" 10.7 0.2 0.1 7.2 13.1 1.4 5.8 0.2 0.4 1.1 0.8 0.0 1.5 0.2 1.7 1.3 0.9 2.1 1.4 3.8 0.1 0.2 0.9 0.2 3.9 2.9 0.5 0.5 1.2 0.4 0.0 0.1 6.2 0.5 1.0 0.5 0.0 0.7 0.3 3.1 1.6 1.3 1.3 1.4 2.9 6.4 2.5 0.9 3.0 0.7 2.7 5.3 2.6 3.8 0.0 3.2 6.8 33.3 0.0 0.3 2.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 2.4 0.0 0.0 0.0 0.0 0.0 109.9 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.3 0.0 0.0 5.1 0.3 0.0 0.0 0.2 0.0 4.4 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.5 0.3 0.0 21.7 0.1 0.0 0.0 0.0 3.2 0.0 0.0 0.0 6.8 0.0 33.3 0.8 0.3 2.7 0.1 13.1 0.2 0.4 0.1 0.2 0.5 0.5 0.5 0.9 TNFRSF9 "4-1BB, CD137, ILA" ENSG00000049249 "TNF receptor superfamily member 9" Q07011 1 7915894-7943165 "Cancer-related genes, CD markers, Predicted membrane proteins" Receptor "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 7 "blood: 13.5;lymphoid tissue: 18.3" "Cell line enriched" "Detected in some" 8 "HDLM-2: 45.9" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in single" "Group enriched" "Detected in many" 5 "memory CD8 T-cell: 8.0;neutrophil: 6.6;NK-cell: 4.1;T-reg: 13.5" "Group enriched" "Detected in many" 5 "granulocytes: 6.6;NK-cells: 4.1;T-cells: 13.5" "Low region specificity" "Detected in some" "Low region specificity" "Detected in all" HPA071425 Approved "Nucleoli,Plasma membrane" "Plasma membrane" Nucleoli "HPA071425: " "unprognostic (7.23e-2)" "unprognostic (1.72e-2)" "unprognostic (8.26e-3)" "unprognostic (1.32e-3)" "unprognostic (1.10e-1)" "unprognostic (1.98e-2)" "unprognostic (2.52e-1)" "unprognostic (1.04e-1)" "unprognostic (1.19e-4)" "unprognostic (9.47e-3)" "unprognostic (2.17e-2)" "unprognostic (2.02e-1)" "prognostic unfavourable (2.69e-8)" "unprognostic (1.64e-2)" "unprognostic (2.25e-2)" "unprognostic (1.19e-1)" "unprognostic (9.55e-2)" 0.8 1.0 0.3 11.0 0.3 1.9 0.5 0.2 0.3 0.4 0.5 0.1 0.1 0.6 0.3 0.1 0.6 0.8 1.6 1.8 0.3 1.0 0.7 0.7 2.1 10.8 0.3 0.1 0.3 0.6 0.0 0.5 0.2 0.5 0.4 0.7 0.3 2.1 0.1 0.3 0.5 2.3 0.1 0.3 7.9 0.7 0.5 0.1 18.3 0.7 0.9 17.5 1.4 0.4 0.5 1.1 6.6 1.5 4.1 13.5 1.1 1.2 0.4 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.9 0.3 0.1 0.4 0.0 0.1 0.0 0.2 0.4 45.9 0.1 0.2 0.2 0.0 0.9 0.0 0.5 0.1 0.3 0.1 0.1 0.0 0.2 0.1 0.0 0.1 0.0 0.2 0.1 0.0 0.0 0.2 0.1 0.2 0.1 0.1 0.1 0.2 0.1 0.0 0.0 0.2 0.2 0.2 1.5 0.1 0.2 0.1 0.1 0.1 5.7 0.2 0.0 1.1 1.5 0.2 1.5 0.4 0.2 0.2 1.0 8.0 1.1 0.5 0.3 1.6 6.6 4.1 0.1 0.3 13.5 1.1 0.3 0.3 0.2 0.3 0.3 1.0 0.3 0.1 0.5 0.1 TNFSF10 "Apo-2L, CD253, TL2, TRAIL" ENSG00000121858 "TNF superfamily member 10" P50591 3 172505508-172523507 "Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" Apoptosis Cytokine "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "kidney: 115.1" "Cell line enhanced" "Detected in many" "BEWO: 20.5;CAPAN-2: 14.6;HMC-1: 67.6;RPTEC TERT1: 34.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 4 "basophil: 42.4;classical monocyte: 25.6;intermediate monocyte: 39.5;neutrophil: 50.3;non-classical monocyte: 38.3" "Group enriched" "Detected in all" 5 "granulocytes: 50.3;monocytes: 39.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA054938 Uncertain Approved Microtubules "Secreted to blood" 67430 Microtubules "HPA054938: " "unprognostic (9.16e-2)" "unprognostic (2.79e-2)" "unprognostic (1.08e-1)" "unprognostic (4.69e-3)" "unprognostic (2.52e-1)" "unprognostic (2.67e-1)" "unprognostic (1.55e-1)" "unprognostic (2.01e-1)" "unprognostic (1.99e-1)" "unprognostic (1.71e-2)" "prognostic unfavourable (9.43e-4)" "unprognostic (1.04e-1)" "unprognostic (1.04e-1)" "unprognostic (1.29e-1)" "unprognostic (3.68e-2)" "unprognostic (1.32e-1)" "unprognostic (6.27e-2)" 30.9 22.1 3.4 14.6 4.7 2.0 23.3 3.0 5.4 31.4 25.8 4.4 17.1 20.6 13.0 10.3 33.3 9.6 10.7 9.9 3.8 3.2 115.1 44.4 91.5 23.5 5.5 3.4 13.5 11.6 10.9 6.7 100.8 6.7 37.6 19.5 12.0 50.6 12.9 13.9 13.0 54.0 7.9 5.6 35.8 9.5 6.0 4.6 8.3 28.2 17.7 16.1 22.4 24.0 3.4 9.5 50.3 39.5 9.3 7.0 11.9 3.3 0.1 0.0 0.0 2.4 1.8 20.5 0.0 0.1 1.0 1.6 0.0 14.6 2.1 9.8 0.0 14.4 0.0 1.8 0.2 5.2 0.0 0.0 0.4 0.3 0.1 3.8 67.6 2.4 2.3 0.4 0.0 7.4 0.0 2.4 0.0 0.0 0.4 5.1 0.0 0.1 0.7 0.0 0.9 34.1 1.3 0.0 0.1 7.5 0.3 0.1 4.1 2.2 0.3 0.0 0.0 0.0 0.2 2.6 0.3 2.6 0.2 2.2 0.0 42.4 25.6 2.7 2.3 39.5 3.1 3.2 6.4 3.5 9.5 3.4 4.7 1.8 50.3 9.3 38.3 0.6 7.0 11.9 3.4 4.7 3.0 5.4 3.8 3.2 5.5 3.4 6.7 4.6 TNFSF11 "CD254, ODF, OPGL, RANKL, TRANCE" ENSG00000120659 "TNF superfamily member 11" O14788 13 42562736-42608013 "Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" Differentiation "Cytokine, Developmental protein, Receptor" "Cancer-related genes, Disease mutation, FDA approved drug targets, Osteopetrosis" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "blood: 14.3;lymphoid tissue: 19.8" "Cell line enhanced" "Detected in some" "Daudi: 1.7;HSkMC: 5.2;NTERA-2: 7.4" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Cell type enriched" "Detected in some" 8 "NK-cell: 14.3" "Lineage enriched" "Detected in many" 8 "NK-cells: 14.3" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB009193, HPA045142" Enhanced "Secreted to blood" 17195 "CAB009193: , HPA045142: " "unprognostic (3.97e-4)" "unprognostic (1.40e-1)" "unprognostic (9.01e-3)" "unprognostic (3.81e-3)" "unprognostic (1.12e-1)" "unprognostic (1.09e-1)" "unprognostic (7.09e-2)" "unprognostic (7.70e-2)" "unprognostic (2.29e-1)" "unprognostic (1.25e-3)" "unprognostic (1.00e-1)" "unprognostic (1.50e-1)" "unprognostic (3.94e-5)" "unprognostic (1.87e-1)" "unprognostic (9.67e-2)" "unprognostic (5.46e-2)" "unprognostic (7.74e-2)" 0.5 0.2 0.2 19.5 0.2 0.0 4.6 0.1 0.2 0.8 0.8 0.1 2.4 0.2 0.2 0.1 3.7 0.2 1.3 0.3 0.1 0.7 0.6 5.3 0.4 19.8 0.1 0.1 0.1 0.6 0.0 0.3 0.3 0.4 0.5 2.2 0.1 1.6 1.0 0.2 0.5 6.0 0.1 0.1 0.8 0.3 3.3 0.1 2.8 0.4 0.1 5.2 2.3 0.7 0.0 0.1 1.8 0.0 14.3 0.1 0.1 0.0 0.3 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.4 1.7 0.0 0.0 0.2 0.0 0.2 0.0 0.1 0.0 0.1 0.5 0.0 0.6 0.0 0.1 5.2 0.5 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.2 7.4 0.1 0.0 0.2 0.0 0.0 0.1 0.1 0.2 0.0 0.0 0.0 0.0 0.7 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 14.3 0.0 0.0 0.0 0.1 0.2 0.2 0.1 0.2 0.1 0.7 0.1 0.1 0.4 0.1 TNFSF13 "APRIL, CD256" ENSG00000161955 "TNF superfamily member 13" O75888 17 7558292-7561608 "Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" Immunity Cytokine "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "salivary gland: 102.8" "Cell line enhanced" "Detected in many" "EFO-21: 18.4;RPTEC TERT1: 46.5;U-937: 17.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 5 "classical monocyte: 63.5;eosinophil: 22.8;intermediate monocyte: 62.7;myeloid DC: 43.0;non-classical monocyte: 37.3;plasmacytoid DC: 19.8" "Group enriched" "Detected in many" 10 "dendritic cells: 43.0;granulocytes: 22.8;monocytes: 63.5" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA004863 Uncertain "Secreted to blood" 6766927 29000 "HPA004863: AB_1078187" "unprognostic (2.46e-2)" "unprognostic (2.20e-1)" "unprognostic (3.42e-1)" "unprognostic (6.53e-2)" "prognostic unfavourable (9.73e-4)" "unprognostic (3.57e-1)" "unprognostic (3.32e-2)" "unprognostic (3.70e-2)" "unprognostic (3.75e-1)" "unprognostic (1.15e-1)" "unprognostic (6.95e-2)" "unprognostic (2.65e-1)" "prognostic favourable (1.30e-9)" "unprognostic (4.69e-2)" "unprognostic (1.42e-2)" "unprognostic (3.46e-1)" "unprognostic (3.38e-2)" 12.1 14.4 18.7 15.4 24.2 18.3 12.9 5.7 15.3 15.7 20.4 8.7 27.4 32.0 7.7 12.8 6.1 14.4 29.1 9.5 11.1 10.7 34.1 11.9 43.0 39.0 14.3 9.4 14.0 20.7 5.7 10.8 6.4 31.6 13.7 18.7 22.0 102.8 69.4 3.0 5.3 18.5 10.9 13.1 16.2 23.4 5.0 9.0 3.3 14.1 8.2 11.5 10.4 8.4 4.1 43.0 22.8 63.5 1.3 0.4 30.6 8.3 3.4 1.1 2.3 1.3 0.7 1.4 1.5 1.0 0.6 0.5 1.8 5.2 3.7 18.4 1.5 5.3 0.0 1.5 0.6 6.5 2.9 2.3 7.5 3.9 2.8 2.0 2.4 1.5 1.4 0.4 2.4 1.9 1.8 1.4 0.5 1.2 0.9 6.6 1.1 2.5 6.6 1.4 15.8 46.5 5.5 2.1 2.0 2.9 7.8 1.0 10.4 5.0 1.0 2.0 2.4 0.9 3.2 0.3 1.1 0.9 0.8 17.8 3.9 9.0 63.5 22.8 0.1 62.7 0.1 2.0 0.0 0.1 43.0 4.1 0.4 0.2 8.6 1.3 37.3 19.8 0.1 30.6 18.7 24.2 5.7 15.3 11.1 10.7 14.3 9.4 31.6 9.0 TNFSF13B "BAFF, BLYS, CD257, TALL-1, TALL1, THANK, TNFSF20" ENSG00000102524 "TNF superfamily member 13b" Q9Y275 13 108251240-108308484 "Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" Immunity Cytokine "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "blood: 76.5;lymphoid tissue: 39.6" "Cell line enriched" "Detected in some" 7 "U-937: 59.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 76.5" "Group enriched" "Detected in many" 10 "dendritic cells: 31.0;granulocytes: 76.5;monocytes: 53.7" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" CAB009188 Enhanced "Secreted to blood" 393384 530000 "CAB009188: " "unprognostic (6.48e-2)" "unprognostic (3.05e-3)" "unprognostic (1.38e-1)" "unprognostic (1.90e-1)" "unprognostic (2.61e-2)" "unprognostic (7.99e-2)" "unprognostic (8.19e-2)" "unprognostic (1.37e-1)" "unprognostic (1.63e-1)" "unprognostic (1.02e-2)" "unprognostic (2.64e-2)" "unprognostic (1.21e-1)" "prognostic unfavourable (2.53e-11)" "unprognostic (1.23e-1)" "unprognostic (4.14e-2)" "unprognostic (1.88e-1)" "unprognostic (1.25e-1)" 7.2 8.2 3.0 18.5 8.2 13.2 3.4 1.4 5.2 1.6 4.2 2.1 1.0 7.8 1.2 6.5 3.5 2.9 9.4 9.4 5.7 2.9 3.1 5.0 13.2 39.6 7.2 2.6 2.9 2.7 0.5 2.1 6.4 5.7 3.7 6.4 2.6 5.4 1.8 1.6 1.6 6.8 3.5 11.6 23.5 3.4 1.0 4.9 7.2 5.1 1.7 12.7 8.5 3.8 1.0 31.0 76.5 53.7 0.6 5.3 20.8 0.0 0.1 0.0 0.0 0.2 0.3 0.0 0.1 0.3 0.2 0.7 0.0 0.6 0.1 0.0 0.0 0.0 0.0 0.0 0.0 4.1 0.0 0.3 0.1 0.0 0.1 3.5 0.1 0.7 0.1 0.0 0.0 0.0 0.0 0.2 0.4 0.0 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.4 0.1 0.0 0.0 0.1 0.0 7.9 0.0 0.1 0.0 0.0 0.1 3.7 0.1 0.0 3.8 59.5 0.6 1.2 53.7 14.4 0.8 39.8 5.3 0.6 3.5 0.7 31.0 1.0 1.7 0.5 76.5 0.6 31.7 11.5 2.8 20.8 3.0 8.2 1.4 5.2 5.7 2.9 7.2 2.6 5.7 4.9 TNFSF4 "CD252, gp34, OX-40L, TXGP1" ENSG00000117586 "TNF superfamily member 4" P23510 1 173183734-173207313 "Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins" Cytokine "Cancer-related genes, Systemic lupus erythematosus" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 11.5;testis: 14.4" "Cell line enhanced" "Detected in some" "fHDF/TERT166: 18.3;HHSteC: 7.9;HUVEC TERT2: 35.9;LHCN-M2: 29.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" HPA059579 Approved Approved Nucleoplasm,Vesicles "Nucleoplasm, Vesicles" "HPA059579: " "unprognostic (1.88e-2)" "unprognostic (1.20e-1)" "unprognostic (4.58e-2)" "unprognostic (2.74e-1)" "unprognostic (1.73e-2)" "unprognostic (1.74e-1)" "unprognostic (1.13e-3)" "unprognostic (2.13e-1)" "unprognostic (8.65e-2)" "unprognostic (5.17e-2)" "unprognostic (1.26e-2)" "unprognostic (1.18e-1)" "unprognostic (1.11e-7)" "unprognostic (3.73e-3)" "unprognostic (2.66e-1)" "unprognostic (9.49e-2)" "unprognostic (2.98e-2)" 2.1 4.0 1.7 8.2 2.3 0.9 3.7 4.5 3.4 1.7 1.8 1.0 0.8 0.3 1.5 1.5 1.6 1.4 2.1 2.1 3.0 2.0 1.5 1.6 2.5 11.5 1.9 0.8 2.7 2.1 1.0 3.3 1.2 1.2 2.8 2.5 1.0 0.8 1.0 0.8 0.3 2.5 1.6 1.9 9.7 1.4 14.4 1.2 9.3 0.8 0.8 3.7 1.6 1.6 1.3 2.6 1.7 0.2 3.4 1.2 6.5 0.0 0.0 0.2 0.5 1.2 6.5 0.0 1.8 0.4 0.1 0.1 0.0 0.0 0.0 0.3 18.3 0.0 0.0 0.0 0.1 0.3 0.0 0.0 0.2 0.7 7.9 0.1 0.0 2.8 0.1 0.9 0.1 35.9 0.0 0.2 29.9 0.0 0.3 0.1 0.1 0.3 0.8 0.0 0.2 0.3 0.0 0.0 0.3 0.1 0.1 0.3 0.0 0.3 0.3 0.0 0.0 0.1 0.1 0.4 0.5 0.1 0.1 3.3 1.9 0.0 0.2 0.3 1.1 0.1 0.8 1.1 0.7 0.9 0.8 1.3 1.2 1.1 1.7 3.4 0.1 2.6 0.9 6.5 1.7 2.3 4.5 3.4 3.0 2.0 1.9 0.8 1.2 1.2 TNK2 "ACK, ACK1, p21cdc42Hs" ENSG00000061938 "Tyrosine kinase non receptor 2" Q07912 3 195863364-195911945 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" Endocytosis "Kinase, Serine/threonine-protein kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA041954 Approved Approved Cytosol Cytosol "HPA041954: AB_10794164" "unprognostic (1.97e-2)" "unprognostic (1.05e-1)" "unprognostic (1.15e-3)" "prognostic unfavourable (8.96e-4)" "unprognostic (1.34e-1)" "unprognostic (8.92e-2)" "unprognostic (1.45e-1)" "unprognostic (1.30e-1)" "unprognostic (8.89e-3)" "unprognostic (1.13e-1)" "unprognostic (8.92e-3)" "unprognostic (4.49e-2)" "prognostic unfavourable (1.30e-4)" "unprognostic (6.82e-2)" "unprognostic (9.76e-2)" "unprognostic (1.44e-1)" "prognostic favourable (1.00e-4)" 9.2 7.6 36.3 16.2 27.6 38.9 8.5 20.7 43.7 6.0 6.3 17.6 3.8 6.6 8.0 6.6 13.0 10.7 6.5 10.6 28.4 21.8 4.1 7.2 9.3 18.1 21.6 31.8 8.6 7.8 5.1 19.3 8.4 20.0 10.8 3.9 5.3 16.8 8.2 30.5 37.1 6.9 7.6 10.3 17.0 12.1 7.7 21.8 3.4 4.6 9.8 12.8 7.7 12.3 6.1 3.1 6.3 3.2 0.9 1.9 1.2 31.3 3.0 5.1 5.4 7.1 4.5 30.5 6.0 5.8 3.6 3.3 4.8 24.3 9.1 21.2 8.2 11.2 4.4 7.5 1.1 21.4 5.6 8.2 10.2 3.5 3.2 4.2 4.1 3.3 11.9 5.0 6.0 4.6 3.3 12.7 3.4 23.1 1.8 15.4 4.8 11.3 5.3 6.1 9.2 3.2 15.2 6.2 6.3 3.9 15.9 7.8 26.0 5.3 7.5 8.4 4.9 4.4 16.8 27.6 3.0 5.6 7.5 13.8 6.2 2.0 2.4 0.9 1.9 3.2 1.1 2.7 1.8 1.0 1.1 6.1 1.4 1.3 6.3 0.9 2.8 3.1 0.2 1.2 36.3 27.6 20.7 33.3 28.4 21.8 21.6 31.8 20.0 21.8 TOM1 ENSG00000100284 "Target of myb1 membrane trafficking protein" O60784 22 35299275-35347994 "Cancer-related genes, Predicted intracellular proteins" "Protein transport, Transport" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 83.8" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA000818, HPA001749" Approved Approved "Plasma membrane,Centriolar satellite,Cytosol" 14000 Cytosol "Plasma membrane, Centriolar satellite" "HPA000818: , HPA001749: AB_1080323" "unprognostic (3.75e-1)" "unprognostic (8.07e-2)" "unprognostic (5.18e-2)" "prognostic favourable (2.20e-5)" "unprognostic (1.11e-2)" "unprognostic (7.55e-2)" "unprognostic (4.07e-3)" "unprognostic (2.24e-1)" "unprognostic (9.92e-2)" "unprognostic (2.32e-1)" "unprognostic (3.71e-1)" "unprognostic (8.16e-2)" "prognostic favourable (3.72e-5)" "unprognostic (1.22e-1)" "unprognostic (1.30e-1)" "unprognostic (7.54e-3)" "unprognostic (3.31e-2)" 17.0 21.2 9.5 10.2 13.8 31.1 13.7 10.2 24.6 16.0 14.6 12.0 7.5 17.4 14.1 15.5 31.6 11.7 15.4 19.1 8.8 15.2 16.1 27.4 17.5 8.2 11.6 11.3 12.1 11.8 21.8 16.8 39.0 23.2 10.2 6.4 17.5 37.0 10.1 83.8 29.1 18.6 7.1 8.4 10.6 8.4 13.6 8.7 10.0 14.8 25.9 19.9 12.1 17.6 4.6 15.2 40.9 31.2 4.6 14.7 17.0 6.6 6.7 3.9 6.3 27.9 16.6 18.4 6.5 19.7 12.7 14.3 9.3 6.2 2.6 12.1 20.3 3.1 4.0 6.8 4.6 7.5 9.1 2.2 7.6 19.3 26.3 4.2 10.1 22.4 8.6 17.9 6.1 8.8 4.3 6.6 6.2 6.4 3.4 9.9 3.0 3.9 6.2 5.6 5.6 5.0 5.0 6.7 5.2 14.8 15.4 14.5 7.8 7.0 9.2 15.1 13.1 11.5 3.2 7.7 4.8 6.8 20.3 4.4 4.9 5.9 31.2 13.1 6.4 18.9 5.3 4.6 9.8 6.1 15.2 4.0 7.9 5.3 40.9 4.6 19.4 8.1 14.7 17.0 9.5 13.8 10.2 24.6 8.8 15.2 11.6 11.3 23.2 8.7 TOP1 ENSG00000198900 "DNA topoisomerase I" P11387 20 41028818-41124487 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Biological rhythms, Host-virus interaction" "DNA-binding, Isomerase, Topoisomerase" "Cancer-related genes, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009058, HPA019039" Supported Supported "Nucleoplasm,Nucleoli fibrillar center" "Nucleoplasm, Nucleoli fibrillar center" "CAB009058: AB_2303554, HPA019039: AB_1858187" "unprognostic (1.46e-1)" "unprognostic (8.65e-2)" "unprognostic (1.33e-2)" "unprognostic (1.92e-3)" "unprognostic (5.05e-2)" "unprognostic (1.49e-3)" "prognostic unfavourable (6.42e-4)" "unprognostic (5.86e-2)" "unprognostic (1.51e-1)" "unprognostic (4.60e-2)" "unprognostic (3.74e-3)" "unprognostic (6.51e-2)" "unprognostic (8.65e-2)" "unprognostic (4.70e-2)" "unprognostic (5.14e-1)" "unprognostic (3.64e-1)" "unprognostic (1.29e-1)" 26.6 31.0 24.6 46.3 25.3 55.3 37.4 39.6 31.1 21.3 30.0 11.1 26.7 29.7 22.9 22.5 36.0 20.5 29.2 21.0 23.0 18.3 31.8 32.7 37.9 38.6 21.9 20.9 25.5 22.5 22.2 39.9 43.9 25.2 23.3 27.2 13.6 25.3 34.3 26.2 24.6 48.4 23.1 27.4 36.9 26.7 14.2 24.2 54.2 31.5 25.1 40.6 25.2 41.7 9.0 17.2 18.4 11.1 5.8 8.2 4.6 21.5 15.1 28.3 23.1 11.5 13.7 28.0 19.5 17.2 22.7 20.7 39.6 27.2 61.5 20.9 10.1 21.0 33.9 31.2 33.3 13.3 17.3 78.4 12.1 28.1 29.9 33.8 27.0 15.5 16.7 22.1 36.4 23.7 34.0 21.4 25.6 47.9 47.7 21.4 22.8 28.1 40.8 26.6 32.7 24.2 20.1 23.5 16.3 30.6 19.0 19.8 21.1 30.3 23.2 18.4 15.6 17.0 20.9 13.6 15.2 71.7 24.7 19.0 17.4 9.1 9.2 14.3 6.5 9.2 8.2 9.0 7.2 6.8 8.6 8.7 7.7 6.9 18.4 5.8 11.1 17.2 7.9 4.6 24.6 25.3 39.6 31.1 23.0 18.3 21.9 20.9 25.2 24.2 TOP2A TOP2 ENSG00000131747 "DNA topoisomerase II alpha" P11388 17 40388516-40417950 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Biological rhythms" "DNA-binding, Isomerase, Topoisomerase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "lymphoid tissue: 146.3;testis: 36.8" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "T-reg: 5.7" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" "CAB002448, HPA006458, HPA026773" Enhanced Approved Supported Nucleoplasm,Nucleoli Nucleoplasm Nucleoli "CAB002448: AB_564035, HPA006458: AB_1858189, HPA026773: AB_1858190" "unprognostic (2.09e-1)" "unprognostic (1.24e-1)" "unprognostic (2.28e-3)" "unprognostic (9.42e-3)" "unprognostic (1.80e-1)" "unprognostic (1.52e-1)" "prognostic unfavourable (5.92e-6)" "prognostic unfavourable (4.99e-4)" "unprognostic (6.21e-3)" "unprognostic (2.09e-1)" "prognostic unfavourable (3.83e-5)" "unprognostic (5.03e-2)" "prognostic unfavourable (0.00e+0)" "unprognostic (7.46e-2)" "unprognostic (1.07e-1)" "unprognostic (2.18e-1)" "unprognostic (2.29e-1)" 2.7 2.0 0.4 20.0 0.5 14.6 4.1 0.4 0.5 3.0 6.9 0.5 0.5 7.0 2.0 3.4 18.2 0.7 2.4 2.3 0.6 0.5 1.4 1.9 5.5 15.4 0.6 0.4 1.2 1.1 0.0 0.4 10.7 0.6 1.2 8.0 0.6 3.2 0.3 0.6 5.9 9.2 2.6 1.8 7.3 4.5 36.8 0.3 146.3 0.9 11.8 16.7 3.2 5.7 1.3 0.3 0.3 0.3 3.2 5.7 1.1 33.7 44.9 57.2 26.1 2.8 5.8 12.7 46.4 25.0 42.7 37.9 21.0 25.9 54.5 23.6 15.7 53.8 43.9 18.5 57.4 29.1 29.3 36.0 28.7 35.1 0.2 50.4 38.3 1.2 1.5 30.0 30.6 22.4 38.9 37.4 46.1 11.7 58.4 33.9 23.7 17.9 49.6 88.8 22.6 10.3 21.6 33.8 24.3 37.4 46.7 14.7 39.2 23.2 14.7 28.2 39.7 32.5 44.5 21.5 24.3 47.6 15.9 34.8 46.9 0.3 0.0 0.0 0.6 0.0 0.0 1.3 0.9 0.9 0.3 0.4 0.2 0.1 0.3 3.2 0.3 0.0 5.7 1.1 0.4 0.5 0.4 0.5 0.6 0.5 0.6 0.4 0.6 0.3 TOP3A "TOP3, ZGRF7" ENSG00000177302 "DNA topoisomerase III alpha" Q13472 17 18271428-18315007 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "DNA-binding, Isomerase, Topoisomerase" "Cancer-related genes, Disease mutation, Dwarfism, Primary mitochondrial disease, Progressive external ophthalmoplegia" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB002449 Approved "CAB002449: AB_564037" "unprognostic (5.49e-2)" "unprognostic (9.04e-2)" "unprognostic (8.99e-2)" "unprognostic (7.24e-3)" "unprognostic (4.01e-2)" "unprognostic (1.95e-2)" "unprognostic (2.33e-3)" "unprognostic (6.54e-2)" "unprognostic (2.34e-1)" "unprognostic (2.74e-1)" "prognostic favourable (1.39e-4)" "prognostic unfavourable (4.59e-4)" "unprognostic (5.58e-2)" "unprognostic (8.80e-2)" "unprognostic (3.53e-2)" "unprognostic (5.05e-2)" "unprognostic (6.05e-2)" 12.5 11.6 10.9 12.5 14.0 23.8 12.0 21.4 17.9 11.0 11.2 13.8 9.1 10.3 13.3 10.4 12.1 11.8 9.5 8.4 9.3 10.5 9.3 15.6 10.8 15.5 9.4 9.0 11.4 16.1 15.0 15.1 10.7 11.1 11.0 13.1 12.8 11.6 9.0 13.0 19.1 10.8 14.1 9.0 16.6 10.5 17.9 11.8 25.9 10.3 7.4 16.2 11.6 10.7 2.1 2.7 10.4 5.9 4.1 4.0 3.3 8.1 13.7 11.2 13.6 5.7 5.8 10.2 8.6 6.2 15.2 15.0 24.9 3.6 14.1 5.6 7.8 11.5 16.8 7.3 16.1 10.4 13.5 12.9 14.2 8.5 5.7 6.4 11.5 3.7 4.7 16.1 9.4 7.0 11.1 5.8 8.8 8.4 14.3 8.1 8.7 7.6 16.3 26.7 13.3 4.5 8.4 8.0 15.0 13.2 8.3 8.5 16.6 6.8 6.7 10.9 8.7 20.7 14.8 6.4 11.5 9.9 6.8 8.9 10.4 1.4 5.9 6.5 4.0 5.8 2.6 1.7 3.0 3.1 2.6 2.1 2.6 2.7 10.4 4.1 2.9 2.7 2.2 3.3 10.9 14.0 21.4 17.9 9.3 10.5 9.4 9.0 11.1 11.8 TP53 "LFS1, p53" ENSG00000141510 "Tumor protein p53" P04637 17 7661779-7687550 "Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transcription factors, Transporters" "Apoptosis, Biological rhythms, Cell cycle, Host-virus interaction, Necrosis, Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Cancer-related genes, Disease mutation, Li-Fraumeni syndrome, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 102.6" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002973, CAB039238, CAB039239, HPA051244, HPA063532, CAB072876" Enhanced Enhanced Nucleoplasm Nucleoplasm "CAB002973: AB_2206626, CAB039238: , CAB039239: , CAB072876: , HPA051244: , HPA063532: " "unprognostic (2.29e-2)" "unprognostic (8.83e-3)" "unprognostic (1.26e-2)" "prognostic favourable (1.35e-4)" "unprognostic (9.95e-2)" "unprognostic (4.00e-2)" "unprognostic (2.79e-3)" "unprognostic (4.99e-2)" "unprognostic (2.75e-2)" "unprognostic (2.55e-1)" "unprognostic (1.30e-1)" "prognostic unfavourable (5.01e-4)" "unprognostic (1.86e-3)" "unprognostic (7.89e-3)" "unprognostic (8.05e-2)" "unprognostic (2.74e-1)" "unprognostic (1.08e-1)" 18.5 11.1 6.0 28.6 6.8 9.0 17.5 2.5 7.3 18.5 14.6 6.8 8.3 9.7 20.3 15.0 25.3 16.7 22.6 8.1 5.0 3.8 10.6 20.8 11.2 26.0 6.6 3.1 33.8 13.8 4.9 6.0 22.8 6.9 16.5 14.5 9.9 15.3 16.1 12.5 24.6 14.0 12.8 6.2 24.2 12.0 14.1 6.9 102.6 13.2 23.5 31.2 16.9 15.0 15.2 19.6 2.2 14.1 11.0 11.3 8.2 19.2 35.6 19.4 14.0 9.1 10.8 20.6 6.9 15.6 19.2 24.3 1.0 9.9 45.3 31.5 13.6 42.5 28.2 19.1 18.0 10.1 18.9 18.3 20.0 16.9 27.4 0.4 9.5 13.7 22.2 9.3 25.7 18.8 0.9 1.7 9.8 34.2 30.7 22.4 19.6 0.7 59.7 13.7 15.7 14.3 21.3 11.6 20.0 22.8 15.4 5.9 26.7 1.7 24.3 23.0 7.6 0.3 11.6 11.9 8.7 19.5 6.0 2.3 19.4 0.8 13.3 2.2 9.1 14.1 11.1 15.2 9.4 10.2 19.6 14.5 9.9 10.8 1.7 11.0 11.9 17.9 11.3 8.2 6.0 6.8 2.5 6.4 5.0 3.8 6.6 3.1 6.9 6.9 TP53BP1 "53BP1, p202, TDRD30" ENSG00000067369 "Tumor protein p53 binding protein 1" Q12888 15 43403061-43510728 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "DNA damage, DNA repair, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004083, HPA008788, HPA022133" Supported Enhanced "Nuclear bodies" "Nuclear bodies" "CAB004083: AB_10694558, HPA008788: AB_1078070, HPA022133: AB_1844382" "unprognostic (2.12e-1)" "unprognostic (7.96e-2)" "unprognostic (1.11e-1)" "unprognostic (1.85e-2)" "unprognostic (4.42e-3)" "unprognostic (2.32e-1)" "unprognostic (2.03e-2)" "unprognostic (3.96e-1)" "unprognostic (2.17e-1)" "unprognostic (2.81e-2)" "unprognostic (3.34e-2)" "unprognostic (4.07e-1)" "unprognostic (8.06e-2)" "unprognostic (9.11e-2)" "unprognostic (1.52e-1)" "unprognostic (6.99e-2)" "unprognostic (3.38e-2)" 7.2 12.9 13.4 9.0 20.7 8.9 9.6 21.9 22.9 17.2 10.0 12.5 10.1 5.7 14.6 15.1 7.0 13.8 9.8 10.7 13.9 12.9 8.6 4.1 8.0 7.2 7.1 14.8 15.9 7.4 30.0 34.8 10.7 17.9 11.4 9.5 7.9 9.8 12.3 7.9 8.2 7.2 15.0 7.9 7.2 7.7 18.3 9.3 15.2 16.2 4.9 10.8 11.5 11.1 5.4 3.5 3.7 1.9 2.1 4.8 1.8 6.2 10.7 31.3 19.5 13.0 16.2 7.6 10.8 16.4 15.4 19.6 9.2 7.6 6.7 9.6 18.4 15.6 22.5 13.2 18.4 18.3 7.7 12.8 18.7 5.5 8.5 14.1 18.5 12.5 9.4 20.7 15.5 18.2 12.5 6.0 17.8 4.4 11.0 6.6 20.1 6.6 11.8 11.7 4.4 11.4 14.8 28.4 13.2 15.6 7.0 4.2 14.4 8.0 12.9 16.5 11.2 13.0 9.6 4.8 10.4 15.8 13.7 7.0 8.4 3.7 1.2 2.5 4.1 1.9 3.5 5.4 4.4 4.1 2.9 4.9 4.8 4.4 1.4 2.1 1.2 3.5 3.4 1.8 13.4 20.7 21.9 22.9 13.9 12.9 7.1 14.8 17.9 9.3 TP53BP2 "53BP2, ASPP2, PPP1R13A" ENSG00000143514 "Tumor protein p53 binding protein 2" Q13625 1 223779899-223845972 "Cancer-related genes, Predicted intracellular proteins" "Apoptosis, Cell cycle" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA021603, HPA050429" Supported Enhanced "Cell Junctions,Cytosol" "Cell Junctions, Cytosol" "HPA021603: AB_1844384, HPA050429: " "unprognostic (1.29e-1)" "unprognostic (5.11e-2)" "unprognostic (3.24e-1)" "unprognostic (1.38e-3)" "unprognostic (1.24e-1)" "unprognostic (1.03e-1)" "unprognostic (7.65e-2)" "unprognostic (1.93e-1)" "unprognostic (1.66e-1)" "unprognostic (1.48e-2)" "unprognostic (7.37e-2)" "unprognostic (2.67e-1)" "unprognostic (7.99e-2)" "unprognostic (5.08e-2)" "unprognostic (1.24e-1)" "unprognostic (2.81e-2)" "unprognostic (1.83e-1)" 10.0 8.3 26.5 17.2 28.7 38.8 20.8 9.3 17.9 10.9 12.0 12.6 8.1 7.9 11.9 9.8 15.9 9.4 17.4 10.9 17.3 14.7 10.1 13.9 21.4 18.6 18.7 8.6 15.5 13.0 16.4 8.3 8.2 12.9 9.6 9.5 17.7 10.2 8.1 12.0 9.9 9.5 12.2 13.0 10.6 9.7 10.2 14.9 17.3 22.1 7.4 11.7 11.8 14.8 2.2 2.9 6.7 2.7 7.2 4.0 2.0 15.3 7.7 21.0 13.2 7.5 7.3 13.4 9.9 14.1 14.5 12.5 15.9 9.3 0.0 8.7 8.2 10.5 16.3 5.9 19.5 29.6 16.1 20.3 7.5 5.4 15.2 16.7 14.3 8.7 6.5 13.3 13.7 8.5 25.7 15.4 12.0 4.4 12.7 10.3 18.1 7.5 16.9 21.9 1.7 13.0 9.7 18.2 23.5 10.9 13.6 14.3 7.7 23.0 9.9 14.9 10.5 16.0 18.5 7.6 7.9 12.7 9.0 11.3 16.9 6.7 2.7 1.6 2.3 2.6 2.8 2.2 2.6 4.0 2.9 1.9 2.7 1.9 3.2 7.2 2.0 1.7 1.6 2.0 26.5 28.7 9.3 17.9 17.3 14.7 18.7 8.6 12.9 14.9 TP63 "EEC3, KET, NBP, OFC8, p51, p53CP, p63, p73H, p73L, SHFM4, TP53CP, TP53L, TP73L" ENSG00000073282 "Tumor protein p63" Q9H3D4 3 189631416-189897279 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Apoptosis, Notch signaling pathway, Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding" "Cancer-related genes, Disease mutation, Ectodermal dysplasia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "skeletal muscle: 83.2;skin 1: 54.2" "Group enriched" "Detected in some" 5 "HaCaT: 23.3;HBEC3-KT: 44.6;hTCEpi: 33.8;hTERT-HME1: 32.3;RT4: 49.0" "Group enriched" "Detected in many" 11 "cervical cancer: 37.9;head and neck cancer: 73.3;lung cancer: 37.3;urothelial cancer: 21.2" "Not detected" "Not detected" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Not detected" "Not detected" "CAB000083, HPA006288, HPA006289, HPA007009, HPA007010" Enhanced Enhanced Nucleoplasm Nucleoplasm "CAB000083: AB_2207187, HPA006288: AB_1080334, HPA006289: , HPA007009: , HPA007010: AB_1080336" "prognostic favourable (1.07e-4)" "unprognostic (1.30e-1)" "unprognostic (1.44e-1)" "unprognostic (3.02e-1)" "unprognostic (4.38e-2)" "unprognostic (3.50e-1)" "unprognostic (1.29e-1)" "unprognostic (5.17e-2)" "unprognostic (2.78e-1)" "unprognostic (5.37e-2)" "unprognostic (2.09e-3)" "unprognostic (1.54e-1)" "unprognostic (1.87e-5)" "unprognostic (1.86e-1)" "unprognostic (1.05e-1)" "unprognostic (1.62e-1)" "unprognostic (2.74e-3)" 2.9 0.1 0.2 0.7 0.1 0.0 7.2 0.1 0.2 9.5 0.1 0.1 5.7 0.0 0.3 8.0 33.7 0.3 0.0 0.2 0.1 0.1 0.4 0.1 1.2 0.2 0.1 0.2 0.1 0.1 0.0 0.3 7.8 0.8 9.6 0.0 0.3 9.0 7.8 83.2 54.2 0.1 2.7 0.6 0.1 0.1 1.2 0.0 9.0 0.4 36.7 26.1 9.6 19.2 3.7 1.3 3.0 0.9 1.2 1.2 0.2 0.6 1.2 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 4.3 0.1 0.0 23.3 0.0 44.6 0.0 0.3 0.0 0.5 0.3 0.1 0.0 0.0 0.1 0.0 33.8 0.0 32.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 49.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 6.8 0.1 0.3 0.1 0.0 0.2 2.0 0.4 1.1 0.9 0.5 0.7 3.7 1.2 1.0 0.4 1.7 0.8 0.7 3.0 1.2 0.9 1.3 0.8 0.2 0.2 0.1 0.1 0.2 0.1 0.1 0.1 0.2 0.8 0.0 TPD52 "D52, hD52, N8L" ENSG00000076554 "Tumor protein D52" P55327 8 80034745-80231232 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Karpas-707: 46.3;SK-BR-3: 105.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "memory B-cell: 24.3" "Group enriched" "Detected in many" 6 "B-cells: 24.3;NK-cells: 6.8;T-cells: 11.1" "HPA028427, HPA062167" Enhanced Approved "Golgi apparatus,Cytosol" 42000 Cytosol "Golgi apparatus" "HPA028427: AB_10610561, HPA062167: AB_2684704" "prognostic unfavourable (1.11e-5)" "unprognostic (1.35e-1)" "unprognostic (1.37e-2)" "unprognostic (3.77e-3)" "unprognostic (8.24e-2)" "unprognostic (3.75e-1)" "unprognostic (7.99e-3)" "unprognostic (6.47e-2)" "unprognostic (2.66e-1)" "unprognostic (1.64e-1)" "unprognostic (1.94e-1)" "unprognostic (2.49e-1)" "prognostic unfavourable (4.77e-6)" "unprognostic (2.06e-1)" "unprognostic (1.81e-1)" "unprognostic (1.47e-1)" "unprognostic (1.70e-2)" 3.2 3.9 33.9 20.2 23.2 3.2 30.9 37.5 43.3 8.3 45.2 19.7 7.3 38.1 4.1 23.2 18.1 6.3 13.2 4.5 35.4 26.9 18.4 15.1 7.8 15.8 27.4 24.0 1.5 26.0 19.1 19.1 13.6 20.3 42.5 51.3 17.4 33.5 8.0 3.1 18.2 40.3 4.4 31.4 9.8 32.7 2.1 19.8 3.5 25.8 7.3 22.2 9.5 10.0 24.3 2.4 2.5 0.0 6.8 11.1 4.1 23.1 6.2 0.2 4.2 0.0 0.0 9.5 1.5 2.3 6.4 3.2 3.2 6.8 33.8 8.4 0.1 9.5 9.6 6.5 4.6 4.1 8.0 4.7 8.9 5.2 0.0 1.5 0.1 0.0 4.6 0.0 2.2 0.3 0.0 46.3 0.0 7.6 7.4 6.9 2.1 15.7 0.0 0.1 21.4 11.1 5.6 12.0 8.2 7.2 105.2 19.4 10.2 6.0 0.3 0.0 6.6 0.1 5.4 17.4 15.0 27.7 4.2 0.0 0.4 0.2 0.0 2.5 6.4 0.0 11.1 24.3 6.4 5.5 1.1 22.4 4.2 4.8 0.2 6.8 0.0 2.4 4.1 4.1 33.9 23.2 37.5 43.3 35.4 26.9 27.4 24.0 20.3 19.8 TPI1 ENSG00000111669 "Triosephosphate isomerase 1" P60174 12 6867119-6870948 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Gluconeogenesis, Glycolysis" "Isomerase, Lyase" "Cancer-related genes, Disease mutation, Hereditary hemolytic anemia" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 234.8;skeletal muscle: 211.0" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA050924, HPA053568" Uncertain Approved Nucleoplasm,Vesicles 270000000 Nucleoplasm Vesicles "HPA050924: AB_2681276, HPA053568: AB_2682193" "unprognostic (2.85e-1)" "unprognostic (5.58e-3)" "unprognostic (1.65e-1)" "unprognostic (1.62e-2)" "unprognostic (6.94e-2)" "unprognostic (2.31e-2)" "prognostic unfavourable (1.04e-5)" "unprognostic (4.14e-3)" "unprognostic (7.49e-2)" "unprognostic (2.13e-2)" "unprognostic (2.11e-2)" "unprognostic (1.63e-1)" "prognostic unfavourable (6.54e-4)" "unprognostic (7.04e-2)" "unprognostic (1.82e-1)" "unprognostic (1.53e-1)" "unprognostic (1.11e-2)" 20.2 41.2 41.2 24.3 46.9 27.4 83.4 93.2 196.1 27.1 39.1 12.8 18.6 40.1 17.2 22.6 51.0 22.1 33.3 94.9 36.7 33.1 43.1 40.8 48.8 140.2 34.0 34.6 19.9 87.0 32.1 16.8 27.1 70.7 19.0 43.5 21.1 26.0 28.7 211.0 25.8 37.8 29.4 20.8 20.1 21.6 15.7 19.4 14.2 20.2 38.4 38.0 23.0 28.0 55.4 170.3 145.5 148.2 81.2 67.1 234.8 119.2 106.9 56.6 87.6 55.5 58.6 100.1 86.3 95.3 163.1 197.9 110.3 65.6 70.0 17.4 85.1 59.4 134.6 144.2 181.0 92.3 100.3 90.7 78.3 72.7 41.4 103.2 74.5 63.6 60.2 125.8 108.4 99.1 46.9 26.9 125.2 87.8 54.2 87.2 139.7 68.1 31.9 93.2 71.8 102.1 85.1 40.3 67.1 75.3 78.4 41.8 17.9 77.6 61.2 87.5 75.0 56.6 126.5 52.6 21.6 104.6 175.6 64.2 62.7 87.7 146.1 145.5 56.1 148.2 57.0 55.4 56.5 54.5 170.3 44.3 39.9 49.3 61.1 81.2 127.8 30.7 67.1 234.8 41.2 46.9 93.2 196.1 36.7 33.1 34.0 34.6 70.7 19.4 TPM1 "C15orf13, CMH3" ENSG00000140416 "Tropomyosin 1" P09493 15 63042632-63071915 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Actin-binding, Muscle protein" "Cancer-related genes, Cardiomyopathy, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "heart muscle: 544.2;skeletal muscle: 589.5" "Cell line enhanced" "Detected in many" "BJ: 123.0;fHDF/TERT166: 122.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "basophil: 23.8" "Group enriched" "Detected in all" 4 "dendritic cells: 8.4;granulocytes: 23.8;monocytes: 11.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA000261, HPA009066, CAB017698, HPA047089, HPA053624" Supported Approved "Actin filaments,Cytosol" 280000000 "Actin filaments" Cytosol "CAB017698: AB_2272017, HPA000261: AB_1080339, HPA009066: AB_1080342, HPA047089: , HPA053624: " "unprognostic (1.07e-1)" "unprognostic (4.20e-2)" "unprognostic (1.00e-2)" "unprognostic (6.20e-2)" "unprognostic (1.28e-1)" "unprognostic (1.45e-2)" "unprognostic (1.18e-1)" "unprognostic (1.08e-1)" "unprognostic (1.35e-2)" "unprognostic (3.27e-1)" "unprognostic (1.27e-2)" "unprognostic (1.20e-1)" "unprognostic (1.66e-3)" "unprognostic (3.38e-2)" "unprognostic (1.78e-1)" "unprognostic (5.53e-2)" "prognostic unfavourable (7.30e-4)" 17.9 5.7 5.5 32.4 5.2 1.2 15.2 5.6 5.1 48.1 119.7 2.4 84.2 14.6 72.4 38.3 121.6 36.2 75.3 544.2 4.1 2.6 14.5 4.4 10.5 3.3 3.3 7.0 27.0 29.3 1.9 3.2 17.7 4.1 72.5 28.0 19.1 12.9 81.3 589.5 6.5 39.5 245.2 2.7 6.5 51.7 9.6 2.3 0.4 7.7 121.7 5.9 193.8 38.7 2.7 8.4 23.8 11.6 1.2 3.4 9.9 43.6 28.8 34.8 1.7 12.2 7.7 114.6 123.0 45.3 75.7 56.3 20.2 8.7 0.1 56.5 122.9 24.2 29.5 19.7 50.4 1.1 4.1 6.4 31.0 9.8 34.2 0.2 1.4 10.7 11.4 62.2 16.6 19.8 0.6 1.5 57.8 22.5 1.9 0.5 41.5 5.0 0.7 12.3 1.2 108.1 24.1 8.3 5.7 14.7 23.3 5.2 17.0 1.2 91.2 100.1 49.2 14.9 87.2 0.4 0.3 0.5 28.3 1.7 69.3 23.8 6.1 2.9 2.5 11.6 2.0 2.7 2.4 2.7 8.4 2.6 2.6 2.3 6.7 1.2 7.9 1.7 3.4 9.9 5.5 5.2 5.6 5.1 4.1 2.6 3.3 7.0 4.1 2.3 TPM2 "AMCD1, DA1, NEM4" ENSG00000198467 "Tropomyosin 2" P07951 9 35681992-35690121 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Actin-binding, Muscle protein" "Cancer-related genes, Disease mutation, Nemaline myopathy" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "skeletal muscle: 1091.5;tongue: 332.2" "Cell line enhanced" "Detected in many" "BJ: 197.7;fHDF/TERT166: 107.9;HSkMC: 94.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 727 "plasmacytoid DC: 76.4" "Lineage enriched" "Detected in single" 727 "dendritic cells: 76.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA047089, HPA053624" Approved 290000000 "HPA047089: , HPA053624: " "unprognostic (5.56e-2)" "unprognostic (5.37e-2)" "prognostic unfavourable (2.64e-4)" "unprognostic (3.34e-2)" "unprognostic (2.70e-1)" "unprognostic (1.75e-2)" "unprognostic (1.18e-3)" "unprognostic (6.56e-3)" "unprognostic (2.58e-2)" "unprognostic (1.97e-1)" "unprognostic (1.23e-1)" "unprognostic (8.67e-2)" "prognostic unfavourable (8.51e-10)" "unprognostic (1.43e-2)" "unprognostic (8.33e-2)" "unprognostic (5.52e-2)" "unprognostic (1.41e-2)" 14.5 8.2 1.8 24.5 1.6 0.7 9.1 3.7 1.7 47.5 101.0 1.4 76.0 8.4 86.6 51.1 166.5 26.8 100.3 34.6 1.9 1.4 9.5 1.1 10.0 5.3 1.5 3.1 29.2 2.2 1.1 2.6 8.6 3.4 72.2 9.6 15.0 21.0 81.0 1091.5 4.2 27.4 231.7 1.6 4.7 48.7 13.4 0.6 0.2 9.3 332.2 22.0 190.7 38.6 0.0 76.4 0.1 0.0 0.0 0.0 0.4 29.9 22.9 16.1 2.6 30.4 81.4 9.9 197.7 80.6 83.7 56.9 0.9 1.9 0.0 17.7 107.9 0.6 0.2 24.4 38.8 55.2 0.7 0.7 81.8 0.9 48.5 0.1 8.1 94.9 3.8 62.7 0.0 19.6 0.3 0.0 84.2 1.1 0.1 2.0 20.4 1.3 1.3 29.8 0.2 2.6 0.5 0.2 1.0 37.6 0.6 1.3 0.5 2.1 2.3 1.2 45.7 0.9 56.3 0.0 0.1 0.2 2.8 0.4 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 76.4 0.0 0.4 1.8 1.6 3.7 1.7 1.9 1.4 1.5 3.1 3.4 0.6 TPM3 "NEM1, TRK" ENSG00000143549 "Tropomyosin 3" P06753 1 154155304-154194648 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Actin-binding, Muscle protein" "Cancer-related genes, Disease mutation, Nemaline myopathy, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 738.4;tongue: 203.6" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA000261, HPA009066, HPA047089, HPA053624" Approved Approved "Actin filaments,Cytosol" 410000000 "Actin filaments" Cytosol "HPA000261: AB_1080339, HPA009066: AB_1080342, HPA047089: , HPA053624: " "unprognostic (1.64e-1)" "unprognostic (2.11e-2)" "unprognostic (3.01e-3)" "unprognostic (1.07e-1)" "unprognostic (2.39e-1)" "unprognostic (2.69e-3)" "prognostic unfavourable (6.73e-6)" "prognostic unfavourable (4.01e-4)" "unprognostic (2.80e-1)" "prognostic favourable (2.39e-5)" "prognostic unfavourable (3.65e-4)" "unprognostic (3.31e-2)" "prognostic unfavourable (3.12e-5)" "unprognostic (3.52e-2)" "unprognostic (1.67e-1)" "unprognostic (1.98e-2)" "unprognostic (1.00e-2)" 10.1 7.3 10.8 10.8 10.5 26.5 6.2 6.4 11.2 4.6 9.6 3.9 3.2 7.9 4.1 27.9 18.3 4.4 6.7 29.7 7.7 8.1 7.2 6.8 9.6 12.9 8.9 5.8 4.8 23.2 3.6 3.2 6.7 5.0 5.7 10.7 4.4 20.5 2.5 738.4 5.9 8.2 5.2 7.7 11.7 6.9 5.4 4.4 6.7 9.3 203.6 28.6 6.8 4.9 38.9 72.6 154.8 95.9 35.4 54.4 146.1 67.5 33.7 43.2 28.3 36.6 47.8 43.5 58.1 53.7 77.1 58.2 62.8 63.4 50.9 47.3 65.5 62.6 42.8 61.1 82.2 35.2 23.3 62.6 32.9 42.2 29.1 91.6 83.2 36.0 33.5 67.9 52.3 118.6 47.0 54.7 95.1 40.5 71.3 94.6 97.2 73.3 61.1 30.0 72.1 55.6 51.6 30.3 56.9 44.1 58.8 57.6 82.0 109.5 88.6 67.5 48.9 64.7 91.0 46.6 76.5 68.0 61.0 69.0 106.6 70.8 64.7 154.8 54.4 87.8 48.6 38.9 48.5 51.1 72.6 30.1 36.6 47.3 74.9 35.4 95.9 36.0 52.1 146.1 10.8 10.5 6.4 11.2 7.7 8.1 8.9 5.8 5.0 4.4 TPM4 ENSG00000167460 "Tropomyosin 4" P67936 19 16067021-16103005 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Actin-binding, Muscle protein" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "U-2197: 225.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004685, HPA047089, HPA053624" Approved Approved "Actin filaments,Cytosol" 950000000 "Actin filaments" Cytosol "CAB004685: AB_425723, HPA047089: , HPA053624: " "unprognostic (1.27e-1)" "unprognostic (1.53e-2)" "unprognostic (3.62e-3)" "unprognostic (7.38e-3)" "unprognostic (3.80e-1)" "unprognostic (2.40e-2)" "unprognostic (3.11e-2)" "unprognostic (2.75e-3)" "unprognostic (1.38e-2)" "unprognostic (3.61e-1)" "prognostic unfavourable (3.07e-4)" "unprognostic (1.03e-1)" "prognostic unfavourable (1.26e-10)" "unprognostic (3.85e-2)" "unprognostic (2.25e-1)" "unprognostic (1.48e-1)" "unprognostic (1.78e-1)" 66.2 17.9 13.3 60.0 13.7 10.8 47.4 46.2 11.5 90.2 40.5 14.6 56.4 17.4 87.1 63.3 149.3 49.4 108.4 39.2 14.5 12.4 32.4 12.2 69.7 27.1 16.0 10.5 102.4 15.4 8.4 16.2 65.0 19.7 84.1 31.8 18.6 47.6 64.6 29.9 39.0 25.2 127.2 22.5 99.7 37.5 30.6 11.7 11.5 20.0 92.2 60.1 177.3 70.5 22.2 35.0 40.7 32.7 24.7 52.5 48.6 58.7 23.3 45.1 27.5 104.9 156.3 56.6 82.3 99.9 69.8 72.0 24.2 61.4 2.7 64.3 102.7 31.7 18.8 47.2 91.3 38.7 10.8 29.6 33.5 19.4 57.7 5.3 70.8 96.7 15.3 57.0 65.6 79.7 3.4 37.3 96.3 20.0 15.9 18.6 23.6 28.4 21.8 38.8 12.7 16.1 50.4 8.2 25.8 55.3 24.8 29.2 0.5 8.2 93.4 121.6 15.4 225.9 76.1 6.5 15.3 13.1 84.3 15.6 41.1 40.7 30.1 2.2 34.8 32.7 26.3 22.2 26.9 31.2 35.0 18.8 7.8 18.3 35.2 24.7 16.2 27.4 52.5 48.6 13.3 13.7 46.2 11.5 14.5 12.4 16.0 10.5 19.7 11.7 TPR ENSG00000047410 "Translocated promoter region, nuclear basket protein" P12270 1 186311652-186375693 "Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters" "Cell cycle, Cell division, Mitosis, mRNA transport, Protein transport, Translocation, Transport" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019661, HPA019663, HPA024336" Enhanced Enhanced "Nuclear membrane" "Nuclear membrane" "HPA019661: AB_1858215, HPA019663: AB_1858216, HPA024336: AB_1858217" "unprognostic (4.51e-2)" "unprognostic (9.87e-3)" "unprognostic (2.48e-1)" "unprognostic (7.56e-2)" "unprognostic (9.88e-3)" "prognostic favourable (4.71e-4)" "prognostic unfavourable (1.06e-4)" "unprognostic (1.71e-1)" "unprognostic (3.71e-2)" "unprognostic (1.14e-1)" "unprognostic (1.45e-2)" "unprognostic (3.63e-2)" "unprognostic (1.31e-3)" "unprognostic (3.75e-1)" "unprognostic (4.19e-2)" "unprognostic (5.06e-2)" "unprognostic (1.98e-2)" 21.5 17.3 14.3 26.7 21.3 21.6 19.0 24.4 17.1 21.7 24.2 7.3 27.1 12.9 20.8 23.5 18.5 16.9 16.8 28.3 13.8 10.5 18.7 20.6 17.9 20.4 14.1 16.6 24.7 17.8 44.2 29.1 29.7 15.1 22.2 17.7 9.1 20.2 30.1 33.1 20.5 21.1 21.2 16.4 26.1 18.8 35.0 17.8 39.5 21.7 19.7 21.4 25.1 19.1 19.1 19.8 50.3 15.2 10.7 16.9 5.2 22.0 19.1 28.7 16.6 23.0 20.6 30.2 25.4 17.0 18.0 16.8 28.7 18.9 25.9 19.7 17.2 29.0 21.6 17.4 22.2 19.4 23.6 34.5 30.9 20.1 12.4 36.8 22.6 15.7 10.6 27.1 21.1 21.2 41.5 23.4 19.1 19.1 18.2 9.8 31.6 6.7 21.7 22.5 22.4 14.7 26.6 15.6 24.8 29.6 19.7 15.9 21.9 23.5 29.7 18.0 17.1 19.8 30.7 25.7 30.0 23.7 11.5 18.8 16.1 29.5 12.0 21.9 15.8 10.0 13.3 15.2 13.8 12.7 6.8 19.1 16.9 11.7 50.3 10.7 15.2 19.8 15.3 5.2 14.3 21.3 24.4 17.1 13.8 10.5 14.1 16.6 15.1 17.8 TPX2 "C20orf1, C20orf2, DIL-2, p100" ENSG00000088325 "TPX2, microtubule nucleation factor" Q9ULW0 20 31739271-31801805 "Cancer-related genes, Predicted intracellular proteins" "Apoptosis, Cell cycle, Cell division, Mitosis" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "lymphoid tissue: 92.7" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "T-reg: 10.4" "Group enriched" "Detected in many" 5 "granulocytes: 4.0;NK-cells: 4.8;T-cells: 10.4" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA005487 Enhanced Supported "Nucleoplasm,Cytokinetic bridge,Mitotic spindle" Nucleoplasm "Cytokinetic bridge, Mitotic spindle" "HPA005487: AB_1858223" "unprognostic (2.18e-2)" "unprognostic (1.77e-1)" "unprognostic (1.97e-2)" "prognostic unfavourable (2.43e-6)" "unprognostic (2.99e-1)" "unprognostic (7.56e-2)" "prognostic unfavourable (8.07e-7)" "prognostic unfavourable (6.46e-4)" "unprognostic (3.70e-2)" "unprognostic (1.19e-1)" "prognostic unfavourable (2.68e-5)" "unprognostic (5.99e-2)" "prognostic unfavourable (0.00e+0)" "unprognostic (4.56e-2)" "unprognostic (2.30e-1)" "unprognostic (1.76e-2)" "unprognostic (1.39e-1)" 1.8 1.7 1.0 13.4 2.0 21.7 1.2 2.2 1.7 2.2 5.7 0.5 0.3 4.6 1.2 2.3 13.3 0.5 1.9 1.5 0.8 0.7 1.2 2.7 2.6 12.9 0.7 1.1 0.8 0.5 0.0 0.7 6.6 0.9 0.7 7.4 0.5 2.3 0.5 2.2 5.9 4.7 3.2 0.9 5.9 3.2 22.0 0.6 92.7 0.7 11.0 16.2 2.2 3.8 1.0 1.4 4.0 0.1 4.8 10.4 1.3 69.6 23.4 28.3 22.1 2.2 4.2 27.3 29.3 16.6 42.6 32.2 49.6 30.1 32.8 17.3 16.3 36.8 32.3 26.6 48.6 14.1 12.5 64.3 22.4 33.8 0.7 24.6 16.6 1.4 1.4 26.7 19.5 22.9 47.5 30.0 33.3 28.6 41.2 19.2 31.5 25.3 23.4 76.4 19.8 11.4 11.4 20.6 13.8 44.8 17.0 13.2 29.5 15.0 15.4 47.8 29.4 21.9 44.9 12.0 20.7 29.4 14.9 87.9 31.0 4.0 0.0 0.5 0.6 0.0 0.3 1.0 1.9 2.3 0.6 0.4 0.4 0.7 0.4 4.8 0.1 1.4 10.4 1.3 1.0 2.0 2.2 1.7 0.8 0.7 0.7 1.1 0.9 0.6 TRAF1 EBI6 ENSG00000056558 "TNF receptor associated factor 1" Q13077 9 120902393-120929173 "Cancer-related genes, Predicted intracellular proteins" Apoptosis "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Group enriched" "Detected in many" 6 "HDLM-2: 35.1;WM-115: 44.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Group enriched" "Detected in many" 5 "dendritic cells: 2.8;T-cells: 11.1" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA001852, CAB009593" Enhanced Approved Nucleoplasm Nucleoplasm "CAB009593: , HPA001852: AB_1080344" "unprognostic (1.45e-3)" "unprognostic (4.51e-2)" "unprognostic (1.21e-2)" "unprognostic (3.17e-3)" "unprognostic (2.32e-2)" "unprognostic (1.48e-3)" "unprognostic (1.03e-1)" "unprognostic (1.94e-1)" "unprognostic (1.02e-2)" "unprognostic (1.39e-1)" "prognostic favourable (2.19e-5)" "unprognostic (3.23e-1)" "prognostic unfavourable (4.42e-5)" "unprognostic (1.85e-3)" "unprognostic (5.70e-3)" "unprognostic (2.64e-1)" "unprognostic (9.87e-3)" 5.4 8.6 9.5 21.6 20.5 8.7 5.7 4.7 13.7 5.3 6.5 17.5 9.2 4.3 6.6 7.4 5.2 6.7 8.6 7.5 11.4 5.5 7.8 4.9 7.4 33.1 14.8 11.2 10.9 3.9 5.3 11.0 3.6 12.5 10.0 5.0 9.4 10.3 7.2 2.4 8.2 8.9 7.8 7.6 15.5 6.6 3.1 19.1 3.5 7.9 2.2 24.0 9.0 10.0 0.2 2.8 0.0 0.4 1.4 11.1 2.0 1.2 0.8 0.1 0.0 1.4 3.6 0.0 0.3 1.9 0.5 1.0 0.1 0.6 2.4 0.4 0.4 0.5 0.2 0.1 0.7 35.1 0.0 0.2 0.8 0.1 1.0 0.1 2.8 1.7 1.9 2.3 1.7 0.3 0.0 4.8 0.3 0.1 0.0 1.0 0.4 0.1 0.5 0.6 4.8 0.2 0.1 0.4 0.0 0.3 0.1 0.1 0.3 0.4 0.3 0.4 0.3 1.9 6.2 3.7 1.3 1.2 1.2 0.2 44.4 0.0 0.3 0.0 3.6 0.4 6.4 0.2 8.8 7.4 0.4 0.2 2.7 4.0 0.0 1.4 0.3 2.8 11.1 2.0 9.5 20.5 4.7 13.7 11.4 5.5 14.8 11.2 12.5 19.1 TRAF2 "RNF117, TRAP3" ENSG00000127191 "TNF receptor associated factor 2" Q12933 9 136881912-136926607 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Apoptosis, Ubl conjugation pathway" Transferase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004603, HPA009972, HPA010634" Uncertain Enhanced Cytosol Cytosol "CAB004603: AB_628389, HPA009972: AB_1080350, HPA010634: AB_1080347" "unprognostic (7.77e-2)" "unprognostic (4.54e-3)" "prognostic unfavourable (9.32e-4)" "unprognostic (1.15e-1)" "unprognostic (1.11e-2)" "unprognostic (1.45e-1)" "prognostic unfavourable (3.06e-4)" "unprognostic (4.91e-2)" "unprognostic (7.23e-2)" "unprognostic (4.28e-2)" "unprognostic (7.39e-2)" "unprognostic (2.82e-2)" "prognostic unfavourable (2.09e-4)" "unprognostic (1.80e-3)" "unprognostic (5.52e-2)" "unprognostic (1.60e-1)" "unprognostic (1.53e-2)" 7.3 6.6 8.7 20.3 10.4 15.9 8.6 16.0 10.0 7.3 8.7 7.4 7.3 11.1 12.3 6.9 12.3 9.0 8.3 8.3 7.5 6.5 8.5 12.3 11.5 19.7 11.2 8.3 6.8 13.9 5.9 8.8 12.1 8.1 10.2 6.2 7.5 13.0 10.1 6.4 13.0 10.4 10.6 8.2 13.8 10.7 13.7 6.4 16.4 14.7 5.2 15.9 8.4 37.5 12.6 11.5 6.7 8.3 10.1 17.4 6.2 10.6 32.9 8.9 7.9 2.5 4.0 17.4 8.8 4.9 12.9 8.8 20.3 19.3 13.3 11.5 5.5 28.1 12.2 14.4 5.3 20.2 9.9 10.0 29.7 12.6 3.7 9.8 10.4 3.0 4.4 10.5 6.0 6.0 16.8 15.2 5.7 15.5 15.9 14.1 14.5 14.8 15.1 13.7 18.1 7.9 8.4 14.6 6.8 11.0 25.8 10.0 18.5 11.6 6.8 16.9 10.9 11.0 14.7 6.3 10.3 13.2 6.0 8.1 12.4 1.3 3.7 6.7 10.4 4.2 14.6 12.6 11.1 13.0 4.9 10.0 9.1 10.9 3.3 10.1 8.3 11.5 17.4 6.2 8.7 10.4 16.0 10.0 7.5 6.5 11.2 8.3 8.1 6.4 TRAF3 "CAP-1, CD40bp, CRAF1, LAP1, RNF118" ENSG00000131323 "TNF receptor associated factor 3" Q13114 14 102777476-102911500 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Apoptosis, Immunity, Ubl conjugation pathway" Transferase "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA002933 Uncertain "HPA002933: AB_1080352" "unprognostic (4.06e-2)" "unprognostic (1.75e-2)" "unprognostic (2.08e-2)" "unprognostic (4.49e-3)" "unprognostic (5.25e-2)" "unprognostic (4.17e-2)" "prognostic unfavourable (1.02e-5)" "unprognostic (1.31e-1)" "unprognostic (7.24e-2)" "unprognostic (1.16e-1)" "prognostic favourable (2.42e-5)" "unprognostic (1.29e-1)" "unprognostic (2.29e-2)" "unprognostic (1.28e-1)" "unprognostic (1.71e-1)" "unprognostic (3.13e-2)" "unprognostic (2.12e-1)" 7.6 5.3 13.6 23.3 9.1 18.8 7.7 12.5 16.0 4.2 8.9 8.8 5.8 8.4 7.5 3.9 7.5 8.9 7.1 7.3 16.6 12.7 6.7 7.0 8.1 26.0 11.5 8.0 4.8 5.1 10.0 10.3 6.8 8.5 6.1 8.0 7.9 5.7 8.0 5.5 7.9 11.8 7.8 9.8 14.2 7.1 12.2 6.6 10.5 7.5 4.1 25.4 11.1 9.3 12.0 6.7 4.3 5.7 2.4 5.1 4.9 11.9 13.6 7.6 4.7 4.4 6.3 11.5 9.4 10.3 10.1 8.5 6.6 17.8 9.5 11.7 10.0 7.3 10.8 10.3 10.4 23.7 7.0 8.9 6.0 4.9 7.2 10.1 26.7 6.3 7.8 7.0 10.1 7.3 9.1 28.4 6.4 12.1 21.6 5.9 4.0 10.3 11.9 10.5 4.8 9.0 14.7 20.2 7.2 10.2 7.1 6.6 6.8 11.5 15.5 9.6 7.4 24.9 13.3 20.6 23.5 17.4 10.4 5.2 11.3 2.6 5.7 1.7 3.7 4.6 3.0 12.0 5.1 3.3 4.1 11.5 3.7 2.6 4.3 2.4 2.8 6.7 4.4 4.9 13.6 9.1 12.5 16.0 16.6 12.7 11.5 8.0 8.5 6.6 TRAF4 "CART1, MLN62, RNF83" ENSG00000076604 "TNF receptor associated factor 4" Q9BUZ4 17 28743984-28750958 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" Apoptosis "Developmental protein" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in all" "SK-BR-3: 53.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in many" 5 "plasmacytoid DC: 27.7" "Lineage enriched" "Detected in many" 5 "dendritic cells: 27.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA052377 Enhanced "HPA052377: " "unprognostic (1.77e-1)" "unprognostic (9.05e-2)" "unprognostic (1.31e-2)" "unprognostic (2.51e-3)" "unprognostic (1.76e-1)" "unprognostic (7.38e-3)" "unprognostic (1.09e-2)" "unprognostic (1.24e-1)" "unprognostic (1.09e-2)" "unprognostic (2.33e-1)" "unprognostic (7.13e-2)" "unprognostic (7.55e-2)" "unprognostic (1.74e-3)" "unprognostic (6.98e-2)" "unprognostic (9.26e-2)" "unprognostic (2.77e-2)" "unprognostic (5.58e-3)" 5.0 8.1 13.8 13.1 14.5 19.9 15.9 6.3 12.4 7.9 22.2 24.7 14.0 32.8 6.8 5.7 15.4 9.5 17.1 2.8 12.7 7.6 20.7 30.1 13.5 12.5 17.9 7.7 7.2 33.8 3.1 8.1 11.8 12.4 16.7 16.0 6.0 32.2 10.4 0.9 7.5 31.4 5.1 10.9 10.2 21.7 7.4 16.4 5.9 16.4 7.1 16.5 15.9 6.0 5.3 27.7 2.7 0.6 0.8 1.4 0.9 11.3 18.2 25.1 12.2 3.6 4.2 39.0 7.7 6.7 8.4 11.1 14.4 14.6 17.8 11.4 8.6 17.3 11.4 17.7 3.4 5.6 16.0 6.3 30.1 16.4 14.0 3.0 7.1 8.0 17.5 9.9 11.8 6.5 16.6 1.6 7.6 19.1 9.6 6.4 19.4 4.2 14.2 11.4 8.7 23.8 33.5 15.8 18.2 12.2 53.7 23.2 20.4 4.9 4.3 5.3 11.1 6.0 10.8 2.4 5.7 22.2 4.2 5.1 24.0 2.7 0.2 0.9 0.6 0.6 1.4 5.3 1.0 1.0 1.5 5.3 0.7 0.7 0.1 0.8 0.4 27.7 0.5 0.9 13.8 14.5 6.3 12.4 12.7 7.6 17.9 7.7 12.4 16.4 TRAF7 "DKFZp586I021, MGC7807, RFWD1, RNF119" ENSG00000131653 "TNF receptor associated factor 7" Q6Q0C0 16 2155698-2178129 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Apoptosis, Transcription, Transcription regulation, Ubl conjugation pathway" Transferase "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA041229 Approved Supported "Vesicles,Plasma membrane" Vesicles "Plasma membrane" "HPA041229: AB_10794194" "unprognostic (1.94e-1)" "unprognostic (5.97e-2)" "unprognostic (1.13e-1)" "unprognostic (4.23e-2)" "unprognostic (1.09e-1)" "unprognostic (1.03e-1)" "unprognostic (1.65e-2)" "unprognostic (2.77e-3)" "unprognostic (7.08e-2)" "unprognostic (3.52e-2)" "unprognostic (1.52e-2)" "unprognostic (1.08e-1)" "unprognostic (9.23e-2)" "unprognostic (6.07e-2)" "unprognostic (2.99e-2)" "unprognostic (2.43e-1)" "unprognostic (8.48e-2)" 16.0 18.2 18.3 22.3 20.6 28.5 39.1 28.7 25.6 22.1 29.4 9.1 21.1 37.3 20.4 18.3 32.9 21.9 36.9 21.0 18.3 14.8 21.3 47.3 18.3 40.9 13.4 14.7 19.3 41.6 17.7 20.3 19.5 12.8 16.2 16.9 13.0 24.4 23.1 25.5 32.2 37.8 28.8 14.1 21.4 25.1 13.2 10.6 26.1 20.3 30.9 21.9 21.9 28.9 6.7 12.3 7.7 13.9 3.0 7.1 5.2 20.8 26.7 15.3 27.3 15.8 30.0 18.0 16.1 20.3 19.0 17.1 32.4 27.0 13.4 19.1 20.5 24.5 14.3 28.6 7.2 21.1 18.3 19.1 35.6 24.8 21.0 20.3 27.7 29.6 23.9 18.3 24.0 36.7 20.3 18.1 18.0 47.7 20.8 23.6 30.0 13.1 38.9 25.4 26.8 15.3 11.2 30.8 25.6 13.5 25.9 17.6 29.4 25.0 27.6 23.1 32.5 21.5 17.5 26.2 19.4 17.7 13.2 13.2 17.9 3.7 10.0 7.7 5.4 13.9 5.0 6.7 5.3 5.7 12.3 4.9 3.8 4.5 6.9 3.0 9.4 6.0 7.1 5.2 18.3 20.6 28.7 25.6 18.3 14.8 13.4 14.7 12.8 10.6 TRIM23 "ARD1, ARFD1, RNF46" ENSG00000113595 "Tripartite motif containing 23" P36406 5 65589680-65625975 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Host-virus interaction, Immunity, Innate immunity, Ubl conjugation pathway" Transferase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA039605 Approved "HPA039605: AB_10673146" "unprognostic (4.06e-1)" "unprognostic (1.07e-1)" "unprognostic (5.11e-2)" "unprognostic (3.63e-1)" "unprognostic (7.96e-2)" "unprognostic (1.59e-1)" "unprognostic (1.02e-1)" "unprognostic (5.00e-3)" "unprognostic (6.51e-2)" "unprognostic (1.89e-2)" "unprognostic (1.73e-2)" "unprognostic (3.19e-1)" "unprognostic (3.19e-2)" "unprognostic (1.06e-2)" "unprognostic (2.62e-1)" "unprognostic (6.55e-3)" "unprognostic (2.70e-1)" 8.6 12.7 15.0 6.6 17.9 7.6 9.4 25.8 34.3 11.5 7.8 9.5 7.3 4.5 10.6 7.0 9.0 8.6 6.3 12.3 16.3 15.2 10.2 11.8 6.6 7.7 14.4 18.8 16.2 6.5 11.1 11.6 7.9 22.1 12.9 5.3 4.1 5.7 9.4 14.8 6.6 5.2 9.3 14.2 8.2 5.6 10.9 14.0 7.5 12.4 4.4 7.6 7.5 7.6 6.0 3.8 14.5 4.5 5.6 9.9 4.5 6.3 8.7 9.3 14.0 14.5 14.6 7.0 12.1 11.6 10.4 12.8 8.0 6.1 4.9 14.6 8.5 5.1 9.1 7.1 16.1 5.1 9.6 3.9 11.9 5.0 13.5 2.4 5.5 11.4 6.0 11.6 10.5 5.0 4.5 7.0 12.2 5.9 5.0 2.7 5.1 3.6 4.7 16.9 7.0 5.4 6.5 5.5 7.7 11.6 3.5 9.6 7.6 3.3 8.5 8.1 8.7 10.1 8.9 8.7 8.0 6.0 9.5 4.7 8.1 14.5 4.0 9.5 5.6 3.0 6.9 4.7 6.1 4.9 3.6 6.0 9.9 7.5 10.1 5.6 4.5 3.8 6.9 4.5 15.0 17.9 25.8 31.1 16.3 15.2 14.4 18.8 22.1 14.0 TRIM24 "hTIF1, RNF82, TIF1, Tif1a" ENSG00000122779 "Tripartite motif containing 24" O15164 7 138460334-138589993 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Transcription, Transcription regulation, Ubl conjugation pathway" "DNA-binding, Repressor, Transferase" "Cancer-related genes, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "AF22: 42.7;HMC-1: 57.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA043495, HPA061717" Approved Enhanced Nucleoplasm "Intracellular and membrane" Nucleoplasm "HPA043495: AB_10962915, HPA061717: AB_2684592" "unprognostic (2.40e-1)" "unprognostic (9.52e-3)" "unprognostic (2.23e-1)" "unprognostic (3.96e-2)" "unprognostic (1.20e-1)" "unprognostic (1.15e-1)" "prognostic unfavourable (9.94e-4)" "prognostic favourable (6.57e-4)" "unprognostic (4.01e-2)" "unprognostic (8.93e-2)" "unprognostic (2.53e-1)" "unprognostic (2.02e-1)" "unprognostic (4.62e-2)" "unprognostic (1.62e-1)" "unprognostic (2.25e-2)" "unprognostic (5.54e-2)" "unprognostic (6.34e-2)" 10.3 31.4 10.4 11.2 10.6 8.8 8.8 8.5 10.7 9.4 9.2 14.6 5.7 9.4 9.0 8.5 11.3 7.0 10.3 9.7 8.4 8.5 9.6 21.5 10.7 8.5 10.5 8.0 29.9 11.6 20.7 7.3 13.5 8.4 13.6 9.1 7.5 10.1 7.1 16.0 9.8 14.1 9.4 8.0 8.5 10.8 24.1 11.3 34.8 8.8 9.2 8.9 11.3 11.2 1.3 1.9 3.7 2.5 2.2 2.7 0.8 4.1 5.1 42.7 12.3 2.9 2.6 3.3 3.9 4.1 3.0 3.0 8.1 3.9 8.0 3.9 3.7 2.2 20.7 3.2 4.5 6.1 5.1 17.7 3.8 24.9 3.9 13.7 57.8 2.3 3.4 2.5 4.1 7.2 20.0 4.9 3.6 8.1 23.4 12.5 16.3 4.6 18.6 5.0 6.8 6.8 12.5 8.9 20.2 7.3 6.5 2.1 4.5 9.1 3.0 3.5 2.9 6.2 5.3 4.6 4.9 13.7 5.9 9.1 5.2 1.1 2.3 3.6 2.2 2.5 0.4 0.9 1.9 1.2 1.9 1.3 1.8 2.0 3.7 2.2 1.1 1.4 2.7 0.8 10.4 10.6 8.5 9.7 8.4 8.5 10.5 8.0 8.4 11.3 TRIM25 "EFP, RNF147, ZNF147" ENSG00000121060 "Tripartite motif containing 25" Q14258 17 56887909-56914038 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Antiviral defense, Host-virus interaction, Immunity, Innate immunity, Ubl conjugation pathway" "Ligase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in many" 7 "neutrophil: 20.0" "Lineage enriched" "Detected in many" 8 "granulocytes: 20.0" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA005909 Approved Approved "Nucleoplasm,Nuclear bodies,Cytosol" 35000 "Nucleoplasm, Cytosol" "Nuclear bodies" "HPA005909: AB_1078722" "unprognostic (8.73e-3)" "unprognostic (1.57e-2)" "unprognostic (2.06e-2)" "unprognostic (6.06e-2)" "unprognostic (2.69e-1)" "unprognostic (3.78e-2)" "prognostic unfavourable (9.37e-4)" "unprognostic (1.53e-1)" "unprognostic (4.23e-1)" "unprognostic (1.15e-1)" "prognostic favourable (3.36e-4)" "unprognostic (3.23e-1)" "unprognostic (3.11e-2)" "prognostic favourable (9.35e-4)" "unprognostic (5.21e-2)" "unprognostic (5.13e-2)" "unprognostic (7.39e-2)" 20.0 19.7 7.5 23.6 8.9 32.6 19.3 11.6 7.8 15.3 22.5 5.0 8.0 15.3 13.4 12.6 17.7 15.3 18.4 8.3 5.8 6.3 10.1 27.0 20.8 15.9 6.7 5.5 13.3 15.3 13.6 11.5 55.0 7.4 12.2 14.3 12.5 14.5 11.5 11.7 23.1 20.7 10.1 5.2 35.8 14.1 12.8 6.5 26.2 11.8 15.1 18.5 10.6 35.9 1.7 2.4 20.0 2.3 0.8 1.5 0.7 28.8 14.3 3.5 11.9 26.7 22.6 0.0 11.4 23.1 27.3 23.6 13.9 15.9 28.2 23.7 10.9 17.2 17.2 15.3 15.3 24.0 13.6 18.2 11.1 15.4 23.0 21.7 13.1 10.1 25.8 14.2 30.3 18.1 4.4 17.3 13.8 19.3 24.2 15.7 2.2 27.8 17.4 11.9 17.7 15.9 22.8 6.9 6.4 9.0 14.5 26.5 19.6 17.7 12.0 12.8 9.2 19.6 11.8 9.8 18.7 4.7 12.4 15.0 5.0 3.0 2.3 0.9 0.9 1.9 1.1 1.7 0.8 0.8 2.4 1.4 0.6 0.8 20.0 0.8 1.4 1.7 1.5 0.7 7.5 8.9 11.6 7.8 5.8 6.3 6.7 5.5 7.4 6.5 TRIM27 "RFP, RNF76" ENSG00000204713 "Tripartite motif containing 27" P14373 6 28903002-28923989 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Transcription, Transcription regulation, Transport, Ubl conjugation pathway" "DNA-binding, Repressor, Transferase" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA048684, HPA053408" Approved Approved Nucleoplasm,Nucleoli Nucleoli Nucleoplasm "HPA048684: , HPA053408: " "unprognostic (1.57e-1)" "unprognostic (1.48e-2)" "unprognostic (2.36e-1)" "unprognostic (1.14e-2)" "unprognostic (1.70e-2)" "unprognostic (2.56e-1)" "unprognostic (2.00e-3)" "unprognostic (1.17e-2)" "unprognostic (1.01e-2)" "unprognostic (1.12e-3)" "unprognostic (4.76e-3)" "unprognostic (1.16e-2)" "prognostic unfavourable (3.50e-6)" "unprognostic (1.27e-1)" "unprognostic (1.41e-1)" "unprognostic (1.47e-1)" "prognostic favourable (2.71e-4)" 11.5 10.6 8.8 25.5 9.7 7.9 9.3 10.1 12.2 11.2 10.2 8.7 20.2 23.8 12.1 13.2 7.8 12.1 11.4 8.1 8.2 9.6 10.1 22.5 10.4 17.4 12.6 8.3 14.7 31.0 7.4 13.9 13.7 10.6 13.7 4.6 7.7 17.0 25.2 12.2 9.7 19.4 9.2 8.4 18.6 18.5 9.2 9.2 16.7 12.5 7.9 12.1 9.9 11.8 12.5 12.5 13.8 13.9 11.2 15.9 13.8 3.3 2.3 0.9 6.0 0.8 1.7 0.6 4.6 1.1 1.4 1.7 1.7 1.4 7.7 7.9 1.3 7.4 1.1 2.7 0.1 3.0 12.9 10.8 0.5 2.3 1.3 4.5 1.7 1.3 1.6 1.2 0.5 1.2 10.5 3.3 0.4 1.3 6.3 2.4 0.0 7.3 9.0 6.9 14.2 1.1 1.1 3.2 12.9 5.5 3.4 7.3 3.3 3.5 3.9 3.4 7.1 6.2 2.7 12.0 14.4 12.0 1.8 11.5 5.2 12.6 13.8 8.8 12.7 13.9 15.9 12.5 12.6 14.4 12.5 10.5 11.8 12.1 13.8 11.2 12.1 9.8 10.4 13.8 8.8 9.7 10.1 12.2 8.2 9.6 12.6 8.3 10.6 9.2 TRIM33 "FLJ11429, KIAA1113, PTC7, RFG7, TF1G, TIF1G, TIF1GAMMA, TIFGAMMA" ENSG00000197323 "Tripartite motif containing 33" Q9UPN9 1 114392777-114511160 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Transcription, Transcription regulation, Ubl conjugation pathway" "DNA-binding, Repressor, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "MCF7: 48.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA004345 Supported Approved Nucleoplasm,Vesicles Vesicles Nucleoplasm "HPA004345: AB_1858287" "unprognostic (8.90e-2)" "unprognostic (5.86e-2)" "prognostic favourable (6.20e-4)" "unprognostic (1.09e-2)" "unprognostic (8.42e-3)" "prognostic favourable (8.93e-4)" "unprognostic (1.34e-2)" "unprognostic (1.83e-1)" "unprognostic (6.75e-2)" "unprognostic (4.58e-2)" "unprognostic (2.14e-1)" "unprognostic (1.08e-1)" "unprognostic (2.27e-2)" "unprognostic (4.84e-2)" "unprognostic (1.99e-1)" "unprognostic (1.40e-1)" "unprognostic (1.68e-1)" 15.2 12.8 16.9 18.4 19.9 27.1 17.1 38.3 21.8 16.9 14.3 11.0 21.9 10.9 19.8 38.3 16.4 15.0 15.6 10.8 18.1 12.5 17.3 15.0 14.3 15.2 12.1 18.0 19.8 15.7 21.8 22.4 27.2 15.2 16.5 13.0 10.7 16.4 19.1 14.3 19.5 14.8 20.2 12.9 14.9 14.1 29.0 16.3 20.5 17.9 9.8 16.6 17.9 28.7 3.4 4.0 12.2 2.8 4.7 4.4 1.0 12.9 7.0 13.2 9.9 5.6 5.9 22.5 6.6 7.0 9.2 9.8 7.9 5.5 13.8 6.8 7.7 7.5 12.0 7.7 12.7 10.4 7.1 13.3 9.2 9.1 6.2 16.8 11.1 5.6 5.7 10.9 11.2 7.7 16.6 9.8 8.8 48.5 16.9 7.1 17.8 7.1 14.6 20.2 4.5 6.6 20.4 9.2 9.7 12.5 15.1 11.9 6.9 9.2 8.6 6.4 10.5 14.8 9.2 6.9 6.4 14.5 9.1 9.8 18.2 12.2 1.6 7.4 3.5 1.8 3.1 3.4 3.7 3.7 2.0 2.2 2.9 4.4 4.8 4.7 2.8 4.0 2.0 1.0 16.9 19.9 38.3 21.8 18.1 12.5 12.1 18.0 15.2 16.3 TRIM7 "GNIP, RNF90" ENSG00000146054 "Tripartite motif containing 7" Q9C029 5 181193924-181205293 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Ubl conjugation pathway" Transferase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "skeletal muscle: 81.8;tongue: 34.0" "Cell line enhanced" "Detected in many" "HaCaT: 11.2;HDLM-2: 23.8;PC-3: 13.2;TIME: 10.8" "Low cancer specificity" "Detected in many" "Region enriched" "Detected in some" 16 "cerebellum: 21.7" "Low cell type specificity" "Detected in many" "Group enriched" "Detected in many" 4 "monocytes: 4.9;T-cells: 2.2" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA039213 Approved Approved Nucleoplasm,Vesicles,Cytosol Vesicles "Nucleoplasm, Cytosol" "HPA039213: AB_10795173" "unprognostic (6.58e-2)" "unprognostic (1.17e-1)" "unprognostic (5.20e-2)" "unprognostic (1.10e-2)" "unprognostic (6.85e-2)" "unprognostic (1.80e-2)" "unprognostic (3.89e-4)" "unprognostic (3.45e-2)" "unprognostic (3.72e-1)" "unprognostic (1.64e-1)" "unprognostic (3.48e-2)" "unprognostic (1.97e-1)" "unprognostic (7.16e-3)" "unprognostic (1.26e-1)" "unprognostic (3.90e-2)" "unprognostic (6.17e-2)" "unprognostic (1.15e-2)" 1.3 0.9 0.1 0.9 0.5 0.5 3.4 21.7 1.3 2.5 0.8 0.3 1.1 0.5 1.0 6.4 13.0 0.6 1.7 2.2 0.1 0.8 2.2 0.5 0.9 0.6 0.2 0.2 0.6 4.2 1.6 1.9 0.5 0.5 2.0 0.6 0.6 5.9 1.1 81.8 9.5 0.6 0.9 0.3 0.8 1.4 0.9 0.2 0.1 3.3 34.0 13.5 1.6 2.9 0.7 0.8 0.1 4.9 0.5 2.2 1.1 6.1 2.9 0.0 0.3 0.5 0.5 0.1 1.4 0.0 0.5 1.2 0.2 8.0 0.4 4.3 1.7 11.2 3.2 9.2 0.1 23.8 1.3 0.5 7.8 0.1 1.6 0.0 1.3 0.1 7.1 0.2 4.6 2.6 0.3 1.3 0.2 0.8 0.3 0.2 0.0 13.2 0.3 4.2 0.9 3.3 0.0 0.3 0.7 2.9 0.1 4.0 0.7 0.2 10.8 0.1 2.4 0.4 4.2 1.9 0.2 0.7 0.3 0.4 1.0 0.0 4.9 0.1 1.4 1.9 2.2 0.4 1.2 1.4 0.8 0.7 2.2 1.8 0.1 0.5 1.4 0.6 2.2 1.1 0.1 0.5 21.7 1.3 0.1 0.8 0.2 0.2 0.5 0.2 TRIO ARHGEF23 ENSG00000038382 "Trio Rho guanine nucleotide exchange factor" O75962 5 14143702-14532128 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Guanine-nucleotide releasing factor, Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "U-87 MG: 62.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008157, HPA064664" Supported Approved Vesicles,Cytosol Cytosol Vesicles "HPA008157: AB_1858327, HPA064664: " "unprognostic (6.65e-2)" "unprognostic (4.21e-3)" "unprognostic (1.65e-1)" "prognostic unfavourable (1.90e-4)" "unprognostic (9.39e-2)" "unprognostic (4.13e-1)" "unprognostic (2.18e-3)" "unprognostic (2.55e-1)" "unprognostic (7.52e-2)" "unprognostic (1.63e-1)" "unprognostic (2.02e-1)" "unprognostic (1.82e-1)" "prognostic unfavourable (3.11e-5)" "unprognostic (1.78e-2)" "unprognostic (1.96e-1)" "unprognostic (4.58e-3)" "unprognostic (2.23e-1)" 29.7 13.7 27.6 15.8 18.9 5.8 30.3 32.6 29.7 13.7 18.5 11.3 9.2 8.3 23.1 19.3 10.4 12.2 25.2 15.1 18.9 15.0 11.7 12.6 15.8 10.9 11.0 17.7 28.9 11.5 17.2 19.6 13.7 12.3 16.3 16.5 23.3 10.5 14.0 19.8 16.0 15.6 22.7 11.6 24.2 13.7 11.3 11.5 7.4 10.0 11.9 12.3 15.6 16.9 3.8 2.7 0.3 1.9 4.3 0.6 0.4 12.2 4.4 10.6 5.0 22.7 29.8 12.1 11.3 13.5 9.1 10.5 2.8 4.8 2.8 8.5 15.4 3.7 1.7 5.3 18.9 7.8 2.5 1.5 11.8 3.5 11.8 3.7 4.2 13.9 5.6 32.2 10.3 8.0 0.3 1.9 22.0 2.3 0.0 2.6 2.6 4.0 2.8 6.4 9.4 8.9 5.5 4.8 19.5 9.6 2.5 5.0 1.5 0.5 18.6 17.6 11.2 12.7 13.3 0.0 0.6 3.6 62.5 2.4 4.1 0.3 1.5 0.0 0.1 1.9 0.3 2.0 0.0 0.0 1.4 3.8 0.0 0.0 0.0 4.3 1.4 2.7 0.6 0.4 27.6 18.9 32.6 29.7 18.9 15.0 11.0 17.7 12.3 11.5 TRIP11 "CEV14, GMAP-210, GMAP210, Trip230" ENSG00000100815 "Thyroid hormone receptor interactor 11" Q15643 14 91965991-92040896 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cancer-related genes, Disease mutation, Dwarfism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002570, HPA070684" Supported Enhanced "Nucleoplasm,Golgi apparatus" "Golgi apparatus" Nucleoplasm "HPA002570: AB_1078995, HPA070684: " "unprognostic (1.65e-1)" "unprognostic (2.81e-2)" "unprognostic (7.14e-2)" "unprognostic (1.12e-1)" "unprognostic (6.89e-2)" "unprognostic (1.39e-1)" "unprognostic (3.49e-3)" "unprognostic (1.60e-1)" "unprognostic (1.46e-1)" "unprognostic (7.33e-3)" "unprognostic (2.04e-1)" "unprognostic (1.21e-1)" "prognostic favourable (1.78e-6)" "unprognostic (1.78e-1)" "unprognostic (5.08e-1)" "unprognostic (7.74e-2)" "unprognostic (5.55e-2)" 13.0 15.0 10.5 10.8 12.5 7.7 12.1 18.5 14.1 17.4 13.0 8.8 15.2 11.1 13.3 12.7 14.7 11.4 11.2 12.9 9.2 6.7 15.5 16.1 10.6 9.4 12.2 11.1 16.0 27.1 27.1 34.9 24.4 15.2 14.5 11.0 9.4 15.1 15.3 24.0 12.4 15.9 11.2 10.7 15.2 16.2 14.0 13.5 16.4 18.4 11.1 11.9 15.8 12.5 20.0 12.7 17.0 13.0 12.1 14.1 3.9 12.4 12.6 8.2 8.6 14.5 22.5 12.5 19.8 15.2 9.8 11.3 7.6 20.3 8.7 14.6 17.4 16.4 10.8 9.6 21.5 13.2 3.3 9.8 11.4 7.2 11.1 11.5 9.8 8.6 11.8 17.3 14.9 15.6 6.4 10.1 15.3 17.4 6.5 2.8 3.7 9.0 8.1 15.7 4.3 8.8 20.4 6.0 5.4 16.0 9.4 6.1 20.5 5.8 20.6 11.4 8.1 11.9 8.9 9.0 13.8 7.8 13.4 6.5 14.3 8.2 8.8 17.0 13.3 8.0 12.8 11.8 14.1 12.1 6.9 20.0 13.5 14.1 8.7 12.1 13.0 12.7 12.2 3.9 10.5 12.5 18.5 14.1 9.2 6.7 12.2 11.1 15.2 13.5 TRIP4 "HsT17391, ZC2HC5" ENSG00000103671 "Thyroid hormone receptor interactor 4" Q15650 15 64387748-64455303 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Cancer-related genes, Congenital muscular dystrophy, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA016605, HPA050666" Approved Supported "Nucleoplasm,Nuclear bodies" "Nucleoplasm, Nuclear bodies" "HPA016605: AB_1858339, HPA050666: " "unprognostic (1.56e-1)" "unprognostic (1.14e-1)" "unprognostic (2.62e-1)" "unprognostic (4.50e-2)" "unprognostic (5.79e-2)" "unprognostic (1.08e-1)" "unprognostic (7.16e-2)" "unprognostic (3.01e-2)" "unprognostic (4.98e-2)" "unprognostic (2.83e-1)" "unprognostic (1.25e-1)" "unprognostic (2.37e-2)" "prognostic favourable (6.34e-6)" "unprognostic (2.41e-1)" "unprognostic (2.96e-1)" "unprognostic (2.61e-2)" "unprognostic (1.25e-1)" 17.1 14.7 14.2 18.8 15.1 13.7 18.3 15.9 19.6 14.3 20.8 16.6 23.5 17.5 17.1 14.6 22.6 15.3 15.6 15.5 12.4 11.2 28.5 15.8 15.3 15.0 17.1 14.6 15.9 19.9 22.9 19.6 19.3 15.3 15.7 20.4 12.7 16.5 13.6 14.6 20.6 26.2 17.3 15.7 20.0 17.4 15.0 14.4 28.0 27.1 17.4 18.6 16.8 17.5 8.6 10.4 30.9 19.7 9.7 11.5 8.3 10.8 16.2 14.3 10.1 11.8 15.6 13.4 11.6 15.0 20.1 19.6 13.5 24.5 7.8 3.9 17.6 15.5 23.1 13.2 19.2 15.8 6.5 11.4 11.6 14.1 21.1 12.3 21.7 19.4 17.4 15.9 16.7 17.5 13.1 9.9 18.4 12.5 7.7 12.8 8.3 8.7 11.9 10.8 13.0 19.7 20.9 7.7 12.2 10.4 12.6 20.9 15.9 18.5 15.4 14.4 9.8 9.5 16.3 8.3 14.8 7.8 11.9 12.7 17.9 30.9 11.4 26.6 11.3 14.6 9.6 8.4 10.8 11.4 10.4 8.6 9.2 9.7 16.1 9.7 19.7 8.2 11.5 8.3 14.2 15.1 15.9 19.6 12.4 11.2 17.1 14.6 15.3 14.4 TRO "KIAA1114, MAGE-D3, MAGED3" ENSG00000067445 Trophinin Q12816 X 54920462-54931431 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Cell adhesion" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "skeletal muscle: 32.1" "Cell line enhanced" "Detected in many" "AF22: 20.9;HEK 293: 12.9;HSkMC: 13.1;SCLC-21H: 14.0;SH-SY5Y: 18.8" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "NK-cell: 5.2" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" HPA053358 Approved "Nucleoplasm,Nucleoli fibrillar center" "Nucleoplasm, Nucleoli fibrillar center" "HPA053358: " "unprognostic (6.18e-2)" "unprognostic (1.01e-1)" "unprognostic (2.24e-2)" "prognostic unfavourable (4.41e-5)" "unprognostic (9.09e-3)" "unprognostic (2.72e-1)" "unprognostic (5.66e-2)" "unprognostic (1.46e-1)" "unprognostic (4.67e-2)" "unprognostic (3.18e-1)" "prognostic favourable (1.93e-4)" "unprognostic (1.17e-1)" "unprognostic (3.19e-2)" "unprognostic (1.67e-4)" "unprognostic (6.33e-2)" "unprognostic (3.27e-2)" "unprognostic (6.86e-2)" 4.5 4.2 21.7 2.1 15.5 1.6 3.7 11.3 23.8 8.0 2.5 7.9 1.4 1.7 16.3 8.6 2.4 7.1 5.6 2.9 17.9 15.6 5.3 13.2 2.5 2.3 10.5 13.2 21.7 5.7 7.6 20.2 5.5 22.3 7.4 3.2 5.0 1.5 6.9 32.1 1.5 1.8 10.9 8.9 1.4 2.0 3.6 14.2 4.2 9.2 0.1 2.4 3.6 5.0 0.7 2.6 0.0 0.2 5.2 1.2 0.4 0.0 0.2 20.9 0.0 4.1 5.7 0.0 1.1 7.2 1.1 0.4 0.0 0.0 0.0 3.0 7.5 0.1 0.1 0.3 0.6 0.0 12.9 9.6 0.0 0.8 1.5 0.0 0.1 13.1 0.0 6.7 0.0 0.5 0.0 0.1 7.7 0.0 0.1 0.0 10.7 0.0 6.1 9.1 0.1 2.0 0.1 14.0 18.8 0.0 0.3 1.8 0.0 1.2 0.0 8.8 9.2 0.1 1.1 3.3 0.4 0.0 1.3 0.0 7.6 0.0 0.0 0.0 1.2 0.0 0.7 0.7 0.1 0.4 0.0 0.5 0.3 0.7 0.0 5.2 0.2 2.6 0.0 0.4 21.7 15.5 11.3 23.8 17.9 15.6 10.5 13.2 22.3 14.2 TRRAP "PAF400, TR-AP, Tra1" ENSG00000196367 "Transformation/transcription domain associated protein" Q9Y4A5 7 98877933-99050831 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Transcription, Transcription regulation" "Activator, Chromatin regulator" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA054376 Supported "Nucleoplasm,Golgi apparatus" Nucleoplasm "Golgi apparatus" "HPA054376: " "unprognostic (2.10e-1)" "unprognostic (7.79e-2)" "unprognostic (2.21e-1)" "unprognostic (4.35e-2)" "unprognostic (2.02e-1)" "unprognostic (2.02e-1)" "prognostic unfavourable (8.77e-4)" "unprognostic (1.40e-2)" "unprognostic (2.39e-2)" "unprognostic (3.99e-2)" "unprognostic (9.45e-2)" "unprognostic (7.02e-2)" "unprognostic (2.21e-3)" "unprognostic (1.59e-1)" "unprognostic (1.98e-1)" "unprognostic (1.04e-1)" "unprognostic (2.96e-1)" 9.6 14.2 10.7 18.4 13.4 18.8 14.9 22.8 14.4 14.1 11.3 15.4 10.0 10.6 15.1 10.1 11.3 17.1 11.4 11.4 10.7 9.5 10.8 11.0 13.1 17.1 12.4 9.4 22.4 16.2 26.7 29.9 12.2 9.6 11.8 10.2 13.7 11.8 16.7 11.7 16.9 13.3 16.9 14.2 14.5 11.5 19.3 12.1 37.1 16.6 7.7 19.3 12.8 11.5 2.7 3.1 5.7 0.9 1.3 2.7 0.3 12.1 14.3 14.8 12.5 7.3 7.6 7.4 5.4 7.2 8.5 8.2 11.1 5.4 17.0 8.6 10.0 6.4 15.3 7.4 9.4 9.8 15.0 10.4 10.4 6.4 5.4 18.6 7.7 7.0 4.4 13.9 11.9 10.9 17.7 32.3 7.9 23.5 22.7 7.4 11.3 8.8 16.8 8.5 13.0 4.4 13.6 11.7 14.6 13.7 9.0 4.6 4.5 8.4 11.4 11.4 16.7 15.1 12.5 13.3 15.1 25.2 8.1 9.6 11.3 5.7 0.9 0.6 1.5 0.6 2.7 2.0 2.7 1.3 0.9 2.7 1.9 1.8 2.9 1.3 0.9 3.1 2.0 0.3 10.7 13.4 22.8 14.4 10.7 9.5 12.4 9.4 9.6 12.1 TSC1 "hamartin, KIAA0243, LAM, TSC" ENSG00000165699 "TSC complex subunit 1" Q92574 9 132891348-132946874 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" Chaperone "Cancer-related genes, Disease mutation, Epilepsy, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB011568, CAB012481, HPA074132" Supported Enhanced Cytosol Cytosol "CAB011568: AB_732752, CAB012481: , HPA074132: " "unprognostic (1.88e-1)" "unprognostic (1.51e-1)" "unprognostic (1.40e-2)" "unprognostic (2.56e-1)" "unprognostic (6.67e-2)" "unprognostic (4.23e-3)" "prognostic unfavourable (6.03e-6)" "unprognostic (1.96e-2)" "unprognostic (3.48e-2)" "unprognostic (1.24e-1)" "prognostic favourable (8.01e-4)" "unprognostic (1.84e-2)" "prognostic favourable (7.91e-4)" "unprognostic (9.49e-2)" "unprognostic (1.46e-1)" "unprognostic (2.35e-1)" "unprognostic (1.16e-1)" 10.4 13.6 15.8 8.8 26.8 13.6 11.4 32.1 28.3 12.7 10.8 22.6 7.9 9.1 14.6 12.3 10.9 12.4 9.7 17.6 13.0 12.1 13.1 9.4 11.6 10.2 12.5 15.1 21.2 12.1 15.9 19.5 15.8 21.1 11.8 12.6 13.1 11.6 10.4 20.0 13.8 11.2 14.2 12.4 13.7 10.6 36.2 14.9 10.5 16.2 8.6 14.2 10.9 11.1 2.8 3.1 4.8 7.0 4.9 7.1 2.6 6.1 7.3 10.0 8.2 10.3 9.8 18.8 8.3 13.4 8.7 8.6 12.4 7.2 14.4 3.6 15.8 16.0 11.7 8.4 8.9 6.9 6.2 4.6 14.5 10.1 12.3 6.7 6.2 10.5 6.4 11.1 13.6 10.0 8.0 7.9 9.9 11.4 6.0 5.8 13.7 6.1 7.3 18.9 8.1 3.9 8.1 5.0 7.7 9.7 6.1 4.8 11.0 4.0 10.3 14.3 8.6 8.5 5.6 4.4 9.8 14.0 8.1 4.0 6.3 4.1 4.4 4.8 6.5 7.0 7.1 1.9 3.6 5.7 3.1 2.8 5.9 5.3 1.7 4.9 3.2 1.8 5.7 2.6 15.8 26.8 32.1 28.3 13.0 12.1 12.5 15.1 21.1 14.9 TSC2 "LAM, PPP1R160, TSC4, tuberin" ENSG00000103197 "TSC complex subunit 2" P49815 16 2047465-2089487 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Host-virus interaction" "GTPase activation" "Cancer-related genes, Disease mutation, Epilepsy, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002225, HPA030409, HPA049679" Approved Enhanced Cytosol Cytosol "CAB002225: AB_564043, HPA030409: AB_10602483, HPA049679: " "unprognostic (2.80e-1)" "unprognostic (1.01e-1)" "unprognostic (1.60e-2)" "unprognostic (2.24e-1)" "unprognostic (1.02e-1)" "unprognostic (1.03e-3)" "unprognostic (2.04e-2)" "unprognostic (6.05e-3)" "unprognostic (3.43e-1)" "unprognostic (8.94e-2)" "prognostic favourable (5.06e-4)" "unprognostic (4.32e-2)" "unprognostic (3.91e-2)" "unprognostic (2.14e-2)" "unprognostic (2.54e-1)" "unprognostic (1.51e-2)" "unprognostic (8.96e-2)" 13.9 11.9 16.9 12.4 20.0 10.9 13.2 35.1 26.9 20.5 17.0 19.4 17.9 14.0 20.1 12.2 13.0 18.6 15.0 14.0 13.3 8.8 11.8 9.8 12.7 10.1 13.8 14.7 21.1 16.1 20.0 18.1 10.6 14.6 13.8 10.8 16.7 22.9 19.6 31.7 14.5 13.2 13.5 11.4 12.9 16.6 21.4 12.9 14.1 20.1 11.3 10.9 18.0 14.0 4.7 5.6 7.7 4.9 3.6 7.0 3.7 7.2 11.6 16.1 18.2 19.2 16.2 13.6 17.4 11.9 13.1 11.2 13.9 13.8 10.9 15.5 14.3 12.0 9.6 12.6 9.8 8.3 15.8 10.3 22.5 5.7 13.2 12.8 12.5 19.1 8.0 10.6 7.9 12.3 10.0 9.8 11.6 14.4 15.2 3.8 16.7 11.4 24.2 17.6 13.9 5.3 6.5 12.2 23.1 24.8 16.4 8.8 15.0 9.5 19.4 13.8 9.4 12.3 8.8 21.9 21.8 21.8 5.7 5.2 16.3 6.2 4.9 5.4 7.0 4.7 6.7 4.4 4.4 4.1 5.6 4.7 3.1 4.8 7.7 3.6 3.7 1.5 3.2 3.7 16.9 20.0 35.1 26.9 13.3 8.8 13.8 14.7 14.6 12.9 TSG101 "TSG10, VPS23" ENSG00000074319 "Tumor susceptibility 101" Q99816 11 18468336-18527232 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division, Growth regulation, Host-virus interaction, Protein transport, Transport" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004283, HPA006161" Approved Supported "Nucleoli,Plasma membrane,Cytosol" 14000 Cytosol "Nucleoli, Plasma membrane" "CAB004283: AB_671392, HPA006161: AB_1080408" "unprognostic (1.42e-1)" "unprognostic (7.91e-2)" "unprognostic (2.11e-1)" "unprognostic (6.77e-2)" "unprognostic (1.82e-1)" "unprognostic (2.72e-3)" "prognostic unfavourable (3.74e-6)" "unprognostic (5.67e-2)" "unprognostic (2.08e-1)" "unprognostic (2.00e-2)" "unprognostic (4.15e-3)" "unprognostic (4.27e-2)" "prognostic favourable (5.52e-6)" "unprognostic (1.92e-2)" "unprognostic (1.02e-1)" "unprognostic (4.02e-3)" "unprognostic (1.06e-1)" 24.7 30.5 18.4 14.2 25.5 23.5 27.6 22.7 25.9 22.5 23.1 23.7 21.6 20.5 25.8 27.7 34.3 23.9 18.4 31.8 17.7 20.6 33.4 29.0 20.1 23.4 21.6 21.4 23.2 39.5 33.2 23.5 38.5 24.6 21.9 28.4 19.4 25.4 22.4 44.5 27.3 25.7 23.1 21.7 20.5 23.0 33.7 20.2 27.5 32.3 37.1 25.5 24.2 25.5 20.5 18.2 42.3 29.2 14.3 22.0 22.2 14.3 23.7 21.0 14.6 24.9 26.0 19.5 22.3 30.1 27.3 27.0 16.2 7.6 19.4 13.7 24.8 22.0 20.9 20.2 30.4 27.2 25.5 12.0 12.5 23.8 32.0 18.0 20.8 22.4 41.1 14.2 38.8 22.4 19.5 16.5 33.0 25.9 11.4 19.6 12.9 24.0 10.3 21.2 16.1 18.3 20.5 15.0 26.9 21.4 18.0 28.5 17.9 18.1 12.0 18.3 11.2 38.2 16.5 10.6 20.4 15.4 18.9 10.0 23.4 42.3 19.5 40.7 14.9 21.7 15.0 20.5 14.4 15.9 18.2 18.0 15.4 16.4 34.5 14.3 29.2 15.4 22.0 22.2 18.4 25.5 22.7 25.9 17.7 20.6 21.6 21.4 24.6 20.2 TSHR LGR3 ENSG00000165409 "Thyroid stimulating hormone receptor" P16473 14 80954989-81146302 "Cancer-related genes, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "Cancer-related genes, Congenital hypothyroidism, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 6 "thyroid gland: 158.0" "Group enriched" "Detected in some" 17 "MOLT-4: 18.1;SCLC-21H: 18.7;U-266/70: 9.2;U-266/84: 4.7" "Cancer enriched" "Detected in some" 116 "thyroid cancer: 100.4" "Not detected" "Not detected" "Cell type enriched" "Detected in some" 5 "T-reg: 9.9" "Lineage enriched" "Detected in many" 5 "T-cells: 9.9" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" CAB000473 Approved "Intracellular and membrane" "CAB000473: AB_2303782" "unprognostic (3.36e-3)" "unprognostic (1.31e-3)" "unprognostic (1.02e-2)" "unprognostic (4.17e-6)" "unprognostic (3.01e-3)" "unprognostic (1.85e-3)" "unprognostic (1.83e-1)" "unprognostic (2.66e-2)" "unprognostic (3.39e-2)" "unprognostic (2.60e-2)" "unprognostic (1.70e-1)" "unprognostic (7.11e-3)" "unprognostic (5.08e-7)" "unprognostic (1.32e-1)" "unprognostic (7.40e-2)" "unprognostic (1.19e-1)" "unprognostic (1.66e-1)" 0.1 0.2 0.1 0.2 0.4 0.3 0.2 0.1 0.3 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.3 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.4 0.1 0.0 0.1 0.1 0.1 0.3 0.3 0.5 0.1 0.0 0.8 0.2 0.0 0.1 0.3 0.1 0.0 0.2 0.2 0.1 0.1 0.1 27.3 158.0 0.2 0.4 0.1 0.1 1.8 0.8 1.3 0.3 0.1 9.9 0.1 0.3 0.2 0.6 0.4 0.1 0.1 0.3 0.1 0.1 0.0 0.1 0.3 0.4 0.6 0.2 0.1 0.2 0.7 0.0 0.1 0.2 0.1 0.3 0.6 0.3 0.0 0.2 0.3 0.3 0.1 0.1 0.2 0.1 0.3 0.6 0.1 0.4 18.1 0.4 0.4 0.2 0.6 0.2 0.7 0.0 0.4 18.7 0.3 0.1 0.2 0.2 0.3 0.0 0.2 0.5 0.4 0.5 0.2 9.2 4.7 0.4 0.2 0.2 0.3 0.6 0.2 0.2 0.2 0.1 0.2 1.0 0.8 0.5 0.1 1.8 0.3 0.2 1.3 0.1 0.3 0.8 9.9 0.1 0.1 0.4 0.1 0.1 0.1 0.1 0.1 0.0 0.5 0.1 TSPAN8 "CO-029, TM4SF3" ENSG00000127324 "Tetraspanin 8" P19075 12 71125085-71441898 "Cancer-related genes, Predicted membrane proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "intestine: 235.3" "Cell line enhanced" "Detected in some" "CACO-2: 14.9;HeLa: 18.0;PC-3: 57.3;RPTEC TERT1: 11.0;RT4: 13.2" "Cancer enhanced" "Detected in many" "colorectal cancer: 283.9" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "CAB026009, HPA044337" Enhanced Approved Nucleoplasm Nucleoplasm "CAB026009: , HPA044337: " "unprognostic (1.64e-1)" "unprognostic (2.18e-2)" "unprognostic (1.64e-1)" "unprognostic (6.40e-2)" "unprognostic (6.81e-2)" "unprognostic (7.29e-3)" "unprognostic (1.90e-1)" "unprognostic (1.15e-1)" "unprognostic (5.62e-2)" "unprognostic (1.06e-1)" "unprognostic (4.01e-3)" "unprognostic (2.93e-1)" "prognostic unfavourable (9.66e-5)" "unprognostic (1.88e-2)" "unprognostic (1.00e-1)" "unprognostic (2.97e-2)" "prognostic favourable (7.36e-5)" 1.9 0.8 0.7 24.1 2.3 0.0 1.1 0.6 1.3 2.0 139.5 2.8 1.5 83.2 1.2 1.5 1.1 1.3 30.8 1.0 0.7 0.7 7.6 3.7 5.1 1.0 4.7 1.0 6.9 9.9 0.0 0.8 0.7 3.5 14.2 79.5 2.6 11.7 1.0 12.5 2.4 235.3 3.4 9.7 0.6 55.5 1.6 2.7 0.6 1.8 3.1 5.0 3.1 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 1.7 0.2 0.9 0.0 0.0 0.0 0.0 14.9 1.0 0.0 0.0 0.0 2.1 0.0 0.0 0.0 0.0 0.0 0.0 18.0 1.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 4.0 0.0 0.0 0.1 0.0 0.0 1.0 0.1 57.3 0.0 0.0 1.5 11.0 13.2 1.3 2.7 3.4 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.2 0.1 0.4 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 2.3 0.6 1.3 0.7 0.7 4.7 1.0 3.5 2.7 TSPO "BZRP, DBI, IBP, MBR, mDRC, PBR, pk18, PKBS" ENSG00000100300 "Translocator protein" "B1AH88, P30536" 22 43151514-43163242 "Cancer-related genes, FDA approved drug targets, Predicted membrane proteins" "Lipid transport, Transport" Receptor "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 139.5" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB011232, HPA046260" Uncertain Approved Vesicles,Mitochondria,Cytosol "Mitochondria, Cytosol" Vesicles "CAB011232: , HPA046260: " "unprognostic (5.29e-3)" "unprognostic (1.41e-1)" "unprognostic (3.31e-1)" "unprognostic (4.02e-3)" "unprognostic (3.95e-1)" "unprognostic (1.46e-2)" "prognostic unfavourable (1.61e-4)" "unprognostic (2.16e-1)" "unprognostic (1.17e-1)" "unprognostic (3.75e-2)" "unprognostic (1.07e-2)" "unprognostic (1.33e-1)" "unprognostic (1.69e-1)" "unprognostic (1.53e-2)" "unprognostic (3.03e-1)" "unprognostic (1.04e-1)" "unprognostic (2.34e-3)" 33.9 21.2 9.8 17.8 11.0 117.3 48.7 2.7 8.1 24.9 23.9 12.3 10.3 20.5 12.3 13.6 83.2 14.3 36.8 32.1 8.0 5.4 18.0 22.0 39.8 40.0 15.4 5.2 13.3 13.2 4.0 6.7 15.5 9.7 23.1 9.7 16.4 34.6 9.2 13.2 46.6 23.0 12.7 11.4 27.2 39.0 10.5 10.0 9.4 17.9 44.3 50.0 19.1 41.3 22.9 99.9 91.4 139.5 28.5 43.8 104.8 47.1 23.4 1.6 22.2 8.9 29.6 1.7 35.3 17.3 17.8 18.9 4.5 36.1 0.0 24.4 27.3 39.1 4.4 27.3 2.3 7.9 18.4 4.8 25.7 1.6 32.4 10.7 24.2 22.9 45.1 10.5 9.4 42.0 3.9 8.9 18.2 39.4 0.1 29.9 1.9 58.4 10.6 0.0 80.5 22.6 28.5 2.3 10.9 16.7 33.4 41.1 12.5 41.5 43.3 22.0 16.5 22.5 14.8 3.6 0.6 0.4 28.6 34.8 28.2 43.8 139.5 75.3 28.4 86.3 22.2 16.3 39.5 27.8 99.9 22.9 30.4 24.5 91.4 28.5 57.1 17.7 43.8 104.8 9.8 11.0 2.7 8.1 8.0 5.4 15.4 5.2 9.7 10.0 TTLL9 "C20orf125, dJ310O13.1" ENSG00000131044 "Tubulin tyrosine ligase like 9" Q3SXZ7 20 31870702-31944963 "Cancer-related genes, Predicted intracellular proteins" Ligase "Cancer-related genes" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enhanced" "Detected in many" "brain: 16.0;epididymis: 8.9;fallopian tube: 9.2;testis: 11.0" "Cell line enhanced" "Detected in some" "Karpas-707: 1.0;REH: 2.0" "Cancer enhanced" "Detected in some" "glioma: 1.2" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA041772, HPA055676" Uncertain Uncertain Nucleoplasm,Microtubules "Nucleoplasm, Microtubules" "HPA041772: AB_10959904, HPA055676: " "unprognostic (8.77e-2)" "unprognostic (8.19e-3)" "unprognostic (1.18e-1)" "unprognostic (1.48e-1)" "unprognostic (4.63e-1)" "unprognostic (1.53e-3)" "unprognostic (1.80e-1)" "unprognostic (1.44e-1)" "unprognostic (1.06e-1)" "unprognostic (4.59e-1)" "unprognostic (9.05e-3)" "unprognostic (6.17e-2)" "unprognostic (8.35e-3)" "unprognostic (1.84e-1)" "unprognostic (1.70e-1)" "unprognostic (1.25e-3)" "unprognostic (2.23e-2)" 0.4 0.6 3.4 0.5 8.9 0.4 1.3 1.0 2.8 0.6 0.5 10.9 1.8 0.6 1.1 8.9 0.6 9.2 0.8 0.5 4.8 3.7 0.8 0.5 1.7 0.7 5.2 0.6 1.8 0.4 2.8 2.8 0.7 16.0 0.6 0.5 0.0 0.5 1.8 0.4 0.6 0.4 0.6 4.5 0.5 0.6 11.0 4.0 0.0 2.1 0.0 0.6 0.5 0.2 0.0 0.0 0.0 0.3 0.0 0.5 0.1 0.1 0.0 0.0 0.5 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.8 0.0 0.1 0.0 0.3 0.2 0.0 0.0 0.3 0.3 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 1.0 0.0 0.9 0.0 0.4 0.0 0.0 2.0 0.0 0.0 0.3 0.0 0.4 0.8 0.0 0.0 0.0 0.3 0.3 0.0 0.3 0.6 0.3 0.0 0.1 0.5 0.0 0.0 0.9 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.1 3.4 8.9 1.0 2.7 4.8 3.7 5.2 0.6 16.0 4.0 TTR "CTS, CTS1, HsT2651, PALB" ENSG00000118271 Transthyretin P02766 18 31591726-31599021 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins" Transport "Hormone, Thyroid hormone" "Amyloidosis, Cancer-related genes, Disease mutation, Neuropathy" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 11 "brain: 1008.0;liver: 680.8;retina: 332.4" "Cell line enhanced" "Detected in some" "CACO-2: 30.7;EFO-21: 10.8;Hep G2: 47.1;U-2 OS: 14.2" "Group enriched" "Detected in many" 28 "liver cancer: 928.2;pancreatic cancer: 666.0" "Region enriched" "Detected in many" 9 "pons and medulla: 1008.0" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in many" 5 "basal ganglia: 1513.1;hippocampal formation: 5269.0;pons and medulla: 5831.5;thalamus: 3501.9" "Region enhanced" "Detected in many" "pons and medulla: 1006.9" "CAB002517, HPA002550, CAB062567, CAB073406" Supported Approved "Golgi apparatus" "Secreted to blood" 345350000000 180000000000 "Golgi apparatus" "CAB002517: AB_563965, CAB062567: , CAB073406: , HPA002550: AB_1080419" "unprognostic (6.79e-3)" "unprognostic (3.38e-2)" "unprognostic (4.10e-1)" "unprognostic (1.74e-1)" "unprognostic (1.84e-2)" "unprognostic (8.15e-2)" "unprognostic (3.74e-2)" "unprognostic (9.66e-3)" "unprognostic (8.72e-2)" "unprognostic (1.23e-2)" "unprognostic (8.35e-3)" "unprognostic (5.26e-1)" "unprognostic (3.52e-2)" 0.5 0.4 3.6 0.4 3.0 0.6 0.4 5.8 60.8 0.4 0.6 361.3 0.0 0.9 0.4 0.4 0.4 0.4 3.3 0.4 115.6 4.4 1.0 680.8 0.4 0.4 7.1 0.0 0.4 62.3 1.6 0.5 0.4 1008.0 0.4 0.5 332.4 0.4 0.4 0.4 1.0 0.6 0.4 4.9 0.5 2.0 0.4 0.6 0.0 0.4 0.0 0.4 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 30.7 0.0 0.6 10.8 0.0 0.0 0.0 0.0 0.0 0.5 0.0 1.1 0.0 47.1 0.0 2.6 0.1 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.3 0.0 14.2 0.0 1.0 0.0 0.6 4.4 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.6 3.0 5.8 60.8 115.6 4.4 7.1 0.0 1008.0 0.6 TUBA1A "B-ALPHA-1, FLJ25113, TUBA3" ENSG00000167552 "Tubulin alpha 1a" Q71U36 12 49184796-49189324 "Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted intracellular proteins" "Cancer-related genes, Disease mutation, FDA approved drug targets, Lissencephaly" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 270.7;smooth muscle: 166.4" "Cell line enhanced" "Detected in many" "AF22: 222.1;SCLC-21H: 149.7" "Cancer enriched" "Detected in all" 9 "glioma: 942.8" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "neutrophil: 151.2" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB008686, HPA039247, HPA043684, HPA063394" Enhanced Enhanced Microtubules Microtubules "CAB008686: AB_1624202, HPA039247: , HPA043684: , HPA063394: " "unprognostic (3.11e-1)" "unprognostic (1.61e-1)" "unprognostic (3.77e-1)" "unprognostic (1.14e-1)" "unprognostic (4.73e-1)" "unprognostic (1.15e-2)" "unprognostic (2.56e-2)" "unprognostic (2.12e-1)" "unprognostic (3.49e-2)" "unprognostic (3.80e-1)" "unprognostic (1.11e-3)" "unprognostic (9.79e-2)" "prognostic unfavourable (2.90e-4)" "unprognostic (1.07e-2)" "unprognostic (4.27e-2)" "unprognostic (1.12e-2)" "unprognostic (1.27e-3)" 27.8 25.5 82.1 29.4 81.3 24.7 35.4 63.2 163.0 40.6 48.8 210.9 6.9 9.9 71.7 34.8 27.7 65.3 37.9 26.3 99.3 118.3 10.3 4.2 39.8 13.4 131.0 50.2 35.7 9.9 16.0 20.6 23.1 165.2 35.1 26.7 16.7 13.6 53.4 5.9 20.0 14.5 166.4 270.7 11.6 18.3 15.7 50.4 19.4 7.4 7.3 10.6 35.1 14.5 14.8 28.9 151.2 69.2 7.5 15.7 38.4 0.2 10.0 222.1 31.6 20.2 48.9 0.8 18.7 24.0 12.3 28.7 0.6 4.0 7.9 23.3 60.5 0.4 26.3 6.8 9.6 6.6 9.0 2.6 2.0 2.2 3.9 4.7 0.2 27.5 2.6 24.2 2.5 72.9 3.1 9.0 65.9 4.4 20.1 3.8 23.4 7.4 16.2 15.9 1.0 55.0 0.9 149.7 81.9 5.2 0.3 7.1 15.7 6.4 62.0 13.2 8.3 1.5 5.4 3.1 8.7 15.9 7.2 7.7 13.1 38.8 23.0 73.1 15.7 48.9 11.5 14.8 13.9 14.3 28.9 14.6 13.6 12.5 151.2 7.5 69.2 9.3 15.2 38.4 82.1 81.3 63.2 126.2 99.3 118.3 131.0 50.2 165.2 50.4 TUSC2 "C3orf11, FUS1, PAP, PDAP2" ENSG00000114383 "Tumor suppressor candidate 2" O75896 3 50320027-50328251 "Cancer-related genes, Predicted intracellular proteins" "Cell cycle" "Cancer-related genes, Tumor suppressor" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" HPA030116 Approved Vesicles,Cytosol Cytosol Vesicles "HPA030116: AB_10602253" "unprognostic (1.58e-2)" "unprognostic (1.55e-1)" "unprognostic (1.73e-1)" "unprognostic (8.46e-2)" "unprognostic (2.73e-1)" "unprognostic (2.81e-1)" "prognostic unfavourable (2.84e-4)" "unprognostic (2.53e-3)" "unprognostic (2.87e-1)" "unprognostic (1.20e-2)" "unprognostic (3.47e-2)" "unprognostic (1.99e-2)" "prognostic favourable (8.70e-7)" "unprognostic (9.22e-3)" "unprognostic (1.98e-1)" "unprognostic (3.15e-1)" "unprognostic (6.34e-3)" 13.4 16.3 28.5 12.2 27.2 9.2 15.1 18.9 38.1 11.9 15.9 11.1 13.9 11.1 10.3 26.2 10.8 18.6 15.5 22.0 26.4 25.8 18.9 18.0 13.5 13.2 26.2 17.0 12.0 15.3 21.3 12.3 15.3 27.3 13.2 15.0 12.2 13.5 17.0 29.9 8.8 12.1 12.3 13.2 14.2 13.9 15.2 8.1 12.0 21.1 15.0 17.2 9.9 8.5 19.5 20.4 26.3 17.3 17.1 22.0 22.9 12.0 10.0 14.1 15.3 15.6 8.1 15.5 9.9 13.3 18.7 15.9 17.6 11.1 20.6 10.8 9.1 7.8 17.1 12.8 16.4 12.1 15.8 10.1 9.4 18.9 13.7 17.8 17.8 8.8 20.8 18.7 9.3 19.2 12.2 9.9 10.7 9.2 18.6 22.9 19.2 14.5 6.5 6.8 16.8 18.7 13.1 7.5 15.6 7.2 12.9 14.2 12.3 21.8 15.1 5.6 13.7 12.7 19.8 24.5 38.0 14.4 12.5 11.9 8.8 10.2 17.3 26.3 20.4 15.3 20.4 19.4 18.1 21.2 11.3 19.5 20.9 22.0 24.5 17.1 13.9 20.4 19.5 22.9 28.5 27.2 18.9 38.1 26.4 25.8 26.2 17.0 27.3 8.1 TXLNA DKFZp451J0118 ENSG00000084652 "Taxilin alpha" P40222 1 32179686-32198285 "Cancer-related genes, Predicted intracellular proteins" Exocytosis "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA045383, HPA072477" Supported Approved Nucleoplasm,Centrosome,Cytosol Cytosol "Nucleoplasm, Centrosome" "HPA045383: AB_10967649, HPA072477: " "prognostic favourable (6.24e-4)" "unprognostic (1.19e-2)" "unprognostic (3.01e-1)" "unprognostic (1.99e-1)" "unprognostic (5.04e-2)" "prognostic favourable (5.53e-4)" "prognostic unfavourable (1.57e-6)" "unprognostic (3.67e-3)" "unprognostic (2.75e-1)" "unprognostic (5.25e-3)" "prognostic favourable (8.69e-5)" "unprognostic (5.06e-2)" "prognostic unfavourable (7.21e-7)" "unprognostic (3.94e-3)" "unprognostic (3.28e-1)" "unprognostic (7.24e-2)" "unprognostic (1.03e-1)" 22.5 29.4 20.2 19.4 27.5 14.0 17.9 23.2 26.4 20.3 23.7 17.0 23.4 16.6 30.4 24.7 24.2 25.0 24.6 16.4 18.5 13.9 20.9 44.8 19.0 19.9 25.6 13.4 26.5 23.6 31.5 35.9 19.3 21.8 24.6 18.5 20.8 23.9 23.3 16.5 31.0 18.9 28.3 19.9 23.5 21.2 38.4 22.9 17.0 22.8 18.8 26.0 19.3 23.5 8.0 14.3 8.4 12.2 14.2 13.9 9.0 19.7 16.9 17.7 19.8 22.9 30.3 14.3 28.3 22.5 27.4 26.3 18.8 21.5 22.6 11.5 27.4 22.4 24.0 18.6 25.0 25.8 18.6 35.7 24.6 24.6 24.4 25.9 28.4 30.3 25.0 28.9 13.7 21.6 14.5 23.4 22.3 10.9 18.9 16.7 25.7 15.6 22.3 26.8 19.9 18.7 25.2 18.5 19.1 29.3 18.6 30.0 17.2 15.8 22.4 29.0 25.1 38.2 36.0 35.0 27.0 20.5 30.0 35.4 26.7 8.4 9.0 4.5 13.9 9.7 11.9 7.3 9.6 10.3 6.9 8.0 8.4 9.1 1.3 14.2 12.2 14.3 7.0 9.0 20.2 27.5 23.2 26.4 18.5 13.9 25.6 13.4 21.8 22.9 TXNIP "ARRDC6, EST01027, HHCPA78, THIF, VDUP1" ENSG00000265972 "Thioredoxin interacting protein" Q9H3M7 1 145992435-145996600 "Cancer-related genes, Predicted intracellular proteins" "Cell cycle, Transcription, Transcription regulation" "Cancer-related genes, Tumor suppressor" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "ASC TERT1: 110.2;HSkMC: 146.6;hTCEpi: 74.7" "Low cancer specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA031085, HPA053694" Approved Approved "Plasma membrane,Cytosol" "Plasma membrane" Cytosol "HPA031085: AB_10601706, HPA053694: AB_2682232" "unprognostic (1.45e-1)" "unprognostic (1.57e-2)" "unprognostic (1.67e-2)" "unprognostic (4.16e-2)" "unprognostic (1.92e-2)" "unprognostic (3.93e-2)" "unprognostic (1.55e-2)" "unprognostic (2.51e-1)" "unprognostic (9.23e-2)" "unprognostic (1.20e-1)" "unprognostic (3.65e-2)" "unprognostic (1.19e-1)" "unprognostic (8.49e-3)" "unprognostic (1.35e-2)" "unprognostic (1.31e-1)" "unprognostic (8.19e-2)" "unprognostic (2.22e-3)" 127.7 10.6 4.1 17.0 4.6 10.5 73.6 2.5 6.0 45.9 49.8 16.1 25.0 6.3 39.3 22.8 41.0 20.3 20.4 55.3 4.8 34.8 11.7 52.3 82.6 6.5 4.2 34.1 25.8 9.3 20.2 19.1 8.3 47.4 16.1 18.8 18.5 19.5 97.0 15.3 27.7 34.6 9.2 39.0 13.6 23.1 6.0 29.0 85.3 16.0 41.5 52.5 32.3 64.9 35.5 134.9 58.3 65.3 90.0 132.5 6.0 0.0 1.4 0.1 33.5 110.2 3.3 7.2 14.5 6.5 9.0 3.8 8.2 1.7 42.9 1.9 1.6 1.4 13.7 17.6 7.9 0.7 4.9 2.2 3.5 1.5 20.1 10.3 146.6 74.7 13.3 23.5 2.5 19.5 13.5 3.3 8.2 3.3 19.3 4.0 5.4 3.0 12.1 52.3 17.1 13.4 6.9 11.2 31.1 9.0 24.6 3.2 28.8 6.1 18.2 1.1 34.0 11.8 19.0 18.1 1.5 4.4 9.3 9.5 94.7 53.3 123.0 90.0 58.3 83.1 58.8 76.5 79.9 35.5 64.9 76.0 80.3 134.9 65.3 49.9 16.7 70.6 132.5 TXNRD1 "GRIM-12, Trxr1, TXNR" ENSG00000198431 "Thioredoxin reductase 1" Q16881 12 104215779-104350305 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Electron transport, Transport" Oxidoreductase "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "fHDF/TERT166: 143.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001395, CAB004607, CAB015834, HPA043871" Approved Supported Nucleoplasm 5900000 Nucleoplasm "CAB004607: AB_628405, CAB015834: , HPA001395: AB_1858377, HPA043871: " "unprognostic (2.52e-2)" "unprognostic (1.16e-1)" "unprognostic (5.48e-2)" "unprognostic (1.01e-1)" "unprognostic (3.15e-1)" "unprognostic (1.94e-2)" "prognostic unfavourable (1.12e-5)" "unprognostic (5.55e-2)" "unprognostic (1.18e-1)" "unprognostic (1.08e-1)" "unprognostic (6.42e-2)" "unprognostic (2.21e-1)" "prognostic unfavourable (1.20e-5)" "unprognostic (2.13e-1)" "unprognostic (1.27e-1)" "unprognostic (1.18e-2)" "unprognostic (8.80e-2)" 19.1 79.2 14.1 15.6 16.9 22.6 18.5 11.1 13.7 13.0 21.8 9.7 19.7 23.5 23.5 14.7 16.7 19.0 23.2 32.4 11.0 11.7 25.3 19.6 29.3 18.1 12.0 10.9 16.4 7.9 10.5 16.2 30.8 16.4 25.3 19.1 18.1 10.6 26.5 30.0 5.7 17.0 99.6 10.9 14.9 24.2 14.8 8.9 15.6 16.5 16.9 13.2 73.2 72.0 8.1 14.2 37.6 16.2 8.3 10.2 8.7 22.0 102.6 11.9 11.2 57.5 32.2 41.6 41.0 26.0 18.5 19.2 10.8 32.9 16.5 19.1 143.4 7.7 23.5 15.7 22.0 8.0 10.2 13.9 80.6 45.6 92.3 21.7 15.2 18.3 16.2 40.9 13.1 63.4 19.1 7.8 27.7 10.6 22.2 9.9 11.5 105.8 22.0 8.3 14.3 21.5 12.1 18.6 11.2 33.1 52.4 32.7 12.4 12.8 84.7 9.1 18.9 20.3 33.5 8.6 16.8 24.8 19.1 12.0 53.9 33.0 10.6 24.7 9.1 14.0 10.2 8.1 8.4 9.0 14.2 5.2 7.6 6.6 37.6 8.3 16.2 9.2 7.1 8.7 14.1 16.9 11.1 11.2 11.0 11.7 12.0 10.9 16.4 8.9 TYMP "ECGF1, MNGIE" ENSG00000025708 "Thymidine phosphorylase" P19971 22 50525752-50530056 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Angiogenesis, Chemotaxis, Differentiation" "Developmental protein, Glycosyltransferase, Growth factor, Transferase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Primary mitochondrial disease, Progressive external ophthalmoplegia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 57.8" "Cell line enhanced" "Detected in many" "CAPAN-2: 15.9;HHSteC: 39.3;Karpas-707: 38.0;U-266/70: 18.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Group enriched" "Detected in many" 6 "classical monocyte: 23.0;eosinophil: 18.2;intermediate monocyte: 22.4;myeloid DC: 12.2;neutrophil: 6.7;non-classical monocyte: 15.9" "Group enriched" "Detected in many" 18 "dendritic cells: 12.2;granulocytes: 18.2;monocytes: 23.0" "Low region specificity" "Detected in some" "HPA000530, HPA001072, CAB002518" Enhanced Approved "Nuclear bodies,Golgi apparatus" 16000000 "Nuclear bodies" "Golgi apparatus" "CAB002518: AB_563953, HPA000530: , HPA001072: AB_1080274" "unprognostic (7.02e-3)" "unprognostic (1.00e-1)" "unprognostic (3.61e-1)" "prognostic favourable (4.34e-5)" "unprognostic (7.60e-2)" "unprognostic (1.16e-2)" "unprognostic (2.40e-1)" "unprognostic (7.17e-2)" "unprognostic (4.64e-2)" "unprognostic (1.33e-1)" "unprognostic (3.31e-2)" "unprognostic (2.17e-1)" "prognostic unfavourable (3.50e-8)" "unprognostic (1.32e-1)" "unprognostic (4.02e-2)" "unprognostic (1.52e-2)" "unprognostic (4.60e-2)" 25.2 7.9 2.8 41.6 8.4 12.1 19.0 1.5 4.4 10.7 10.7 3.8 2.3 10.4 4.4 15.7 22.0 13.7 9.6 15.0 7.0 2.6 18.6 38.1 28.8 57.8 6.5 0.4 7.5 5.8 1.7 3.9 11.5 9.1 7.9 4.9 5.4 16.5 3.8 10.0 8.8 13.9 7.3 15.2 43.9 12.4 3.0 5.0 13.3 12.5 25.5 28.8 12.4 9.4 0.9 12.2 18.2 23.0 0.8 0.9 2.6 6.5 0.7 0.0 0.1 0.9 1.2 0.6 1.1 0.1 2.4 5.3 0.0 15.9 0.5 0.8 2.7 5.8 0.2 0.2 0.0 2.8 1.4 0.3 1.1 0.4 39.3 0.1 7.6 2.4 2.4 3.2 0.0 0.0 0.2 38.0 0.2 0.1 0.0 1.0 0.0 2.1 0.2 0.0 7.6 0.0 0.0 0.0 1.4 6.1 8.3 0.5 0.6 4.8 1.5 0.0 0.6 0.1 0.2 18.2 3.7 0.4 0.2 0.1 0.2 2.5 23.0 18.2 0.3 22.4 0.2 0.8 0.3 0.2 12.2 0.9 0.2 0.1 6.7 0.8 15.9 1.1 0.9 2.6 2.8 8.4 1.5 4.4 7.0 2.6 6.5 0.4 9.1 5.0 TYMS "HsT422, TMS, TS, Tsase" ENSG00000176890 "Thymidylate synthetase" P04818 18 657604-673578 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Nucleotide biosynthesis" "Methyltransferase, Transferase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 34.9;lymphoid tissue: 75.5" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "T-reg: 13.8" "Group enriched" "Detected in many" 6 "NK-cells: 6.8;T-cells: 13.8" "Low region specificity" "Detected in single" "Group enriched" "Detected in some" 5 "cerebellum: 6.7;olfactory region: 8.8" CAB002784 Enhanced "CAB002784: " "unprognostic (7.58e-2)" "unprognostic (2.06e-3)" "unprognostic (9.31e-2)" "unprognostic (2.34e-2)" "unprognostic (7.35e-2)" "unprognostic (1.05e-1)" "prognostic unfavourable (5.10e-6)" "unprognostic (1.62e-3)" "unprognostic (1.68e-2)" "unprognostic (9.82e-2)" "unprognostic (1.07e-3)" "unprognostic (3.28e-2)" "unprognostic (1.23e-2)" "unprognostic (6.34e-2)" "unprognostic (1.66e-1)" "unprognostic (5.65e-3)" "unprognostic (2.47e-1)" 3.0 2.6 4.6 15.5 5.8 34.9 2.8 1.2 6.3 3.4 10.1 10.2 1.5 4.8 2.5 3.6 12.3 2.4 4.6 2.0 5.8 2.9 4.8 5.1 4.2 15.4 3.4 4.5 2.0 3.1 1.1 1.3 14.3 3.4 3.0 12.9 1.1 3.4 0.8 0.7 3.6 6.9 5.5 4.6 8.9 4.2 21.5 5.3 75.5 1.7 10.9 19.3 4.8 4.3 1.2 1.8 1.0 0.1 6.8 13.8 2.5 13.7 21.2 44.3 21.4 4.9 8.2 22.5 32.5 19.4 35.1 42.1 17.9 11.0 21.4 12.7 17.5 6.2 30.9 12.2 30.4 20.1 34.3 36.3 19.9 30.7 1.1 74.5 39.8 7.3 2.9 22.1 6.9 29.3 29.1 34.4 44.1 15.8 89.7 41.3 15.9 15.9 59.4 39.9 25.8 13.2 12.2 15.1 24.5 27.4 12.7 8.2 8.7 34.0 11.6 40.6 80.2 37.1 63.3 42.7 52.5 48.9 10.7 32.3 46.4 0.0 0.0 1.0 1.1 0.1 0.0 1.2 2.9 2.2 1.8 0.0 0.0 0.7 0.6 6.8 0.1 0.3 13.8 2.5 4.6 5.8 1.2 6.3 5.8 2.9 3.4 4.5 3.4 5.3 TYRO3 "Brt, Dtk, Etk-2, Rek, RSE, Sky, Tif" ENSG00000092445 "TYRO3 protein tyrosine kinase" Q06418 15 41557675-41583586 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion, Host-virus interaction" "Host cell receptor for virus entry, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 39.2;ovary: 48.2" "Cell line enhanced" "Detected in many" "BEWO: 33.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "neutrophil: 5.0" "Lineage enriched" "Detected in many" 4 "granulocytes: 5.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA071245 Approved 6400000 "HPA071245: " "unprognostic (1.26e-1)" "unprognostic (6.34e-2)" "unprognostic (1.47e-1)" "unprognostic (2.68e-1)" "unprognostic (3.29e-1)" "unprognostic (6.77e-2)" "unprognostic (1.56e-3)" "unprognostic (5.41e-2)" "unprognostic (3.72e-1)" "unprognostic (3.21e-1)" "unprognostic (2.69e-1)" "unprognostic (1.37e-1)" "unprognostic (1.92e-10)" "unprognostic (7.59e-2)" "unprognostic (5.22e-1)" "unprognostic (4.04e-3)" "unprognostic (1.84e-2)" 18.3 4.1 18.7 2.1 16.6 1.5 7.7 27.3 39.2 2.3 1.8 25.6 1.2 2.3 5.0 4.2 12.7 11.7 3.1 2.5 15.1 7.8 6.4 1.6 3.2 1.9 19.6 18.2 48.2 9.5 1.3 0.8 5.9 14.0 3.3 1.7 1.7 2.4 6.7 1.4 13.0 2.9 4.8 23.1 5.4 3.6 17.9 16.6 0.0 1.8 2.2 4.1 2.9 2.8 1.2 1.0 5.0 0.9 1.0 0.8 0.2 4.7 3.1 9.9 10.8 9.3 6.4 33.5 6.9 4.4 6.9 6.4 17.6 1.6 0.1 8.9 5.6 11.2 11.1 1.7 3.2 2.7 7.4 1.4 10.0 8.3 6.6 2.4 0.2 2.0 3.5 5.2 1.8 5.1 8.7 2.0 3.7 4.5 1.1 0.4 22.9 3.2 14.7 9.0 1.7 0.6 9.2 11.9 3.4 6.5 10.3 7.7 8.5 2.8 3.9 13.7 6.0 10.1 10.4 0.8 1.6 1.4 8.3 15.8 8.2 2.6 0.9 0.8 0.6 0.5 0.6 0.7 0.6 0.8 0.3 1.2 0.7 0.7 5.0 1.0 0.5 1.0 0.5 0.2 18.7 16.6 27.3 32.7 15.1 7.8 19.6 18.2 14.0 16.6 U2AF1 "RN, RNU2AF1, U2AF35, U2AFBP" ENSG00000160201 "U2 small nuclear RNA auxiliary factor 1" Q01081 21 43092956-43107587 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "mRNA processing, mRNA splicing" RNA-binding "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "HPA044833, HPA052083" Supported Enhanced Nucleoplasm Nucleoplasm "HPA044833: AB_10960990, HPA052083: " "unprognostic (1.10e-1)" "unprognostic (1.28e-1)" "unprognostic (5.98e-2)" "unprognostic (2.87e-2)" "unprognostic (1.36e-1)" "unprognostic (8.06e-2)" "unprognostic (2.76e-2)" "unprognostic (4.29e-4)" "unprognostic (4.81e-4)" "unprognostic (3.42e-2)" "unprognostic (2.31e-3)" "unprognostic (8.85e-2)" "unprognostic (2.14e-6)" "unprognostic (1.08e-1)" "unprognostic (1.40e-2)" "unprognostic (1.72e-1)" "unprognostic (1.26e-2)" 20.0 15.1 20.8 19.2 21.1 48.5 61.0 25.6 20.8 16.1 21.5 9.7 12.3 17.6 28.8 26.5 19.3 27.6 17.1 19.5 19.7 15.8 14.6 17.1 35.2 33.5 25.7 2.9 22.1 48.3 15.3 27.8 21.2 20.8 23.9 13.7 9.6 44.5 19.8 33.0 16.6 20.4 38.7 23.9 21.0 17.5 33.9 22.7 20.6 27.3 26.5 20.0 22.9 31.7 58.4 82.8 81.2 54.1 33.1 55.5 53.8 25.0 27.5 15.0 11.3 8.8 6.3 35.1 21.8 15.1 17.8 15.9 63.9 9.2 42.9 11.9 14.1 12.3 31.3 23.1 9.2 33.6 70.7 69.4 14.1 24.0 21.5 29.8 17.1 8.7 14.3 28.8 18.4 14.7 38.0 19.4 12.4 47.1 24.7 33.1 31.8 31.7 40.8 14.4 21.6 11.8 10.6 22.8 17.4 23.4 14.1 11.5 17.2 17.4 18.3 14.8 20.2 13.4 22.7 26.0 30.6 35.5 14.2 55.0 22.8 48.4 52.6 50.9 42.2 52.5 41.4 55.9 46.4 42.1 54.1 58.4 46.4 44.8 81.2 33.1 54.1 82.8 55.5 53.8 20.8 21.1 25.6 20.8 19.7 15.8 25.7 2.9 20.8 22.7 UBA1 "A1S9T, CFAP124, GXP1, POC20, UBE1, UBE1X" ENSG00000130985 "Ubiquitin like modifier activating enzyme 1" P22314 X 47190861-47215128 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Ubl conjugation pathway" Ligase "Cancer-related genes, Disease mutation, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA000289, HPA001506, CAB019435, CAB073410" Approved Enhanced Nucleoplasm 16000000 Nucleoplasm "CAB019435: AB_2211440, CAB073410: , HPA000289: AB_1080443, HPA001506: AB_2756305" "unprognostic (7.18e-3)" "unprognostic (1.52e-1)" "unprognostic (7.54e-2)" "unprognostic (2.40e-1)" "unprognostic (9.29e-2)" "unprognostic (1.02e-1)" "prognostic unfavourable (6.10e-5)" "unprognostic (7.22e-2)" "unprognostic (2.42e-3)" "unprognostic (3.43e-2)" "unprognostic (8.50e-3)" "unprognostic (2.17e-3)" "unprognostic (1.85e-3)" "unprognostic (1.13e-1)" "unprognostic (5.38e-2)" "prognostic favourable (1.78e-4)" "unprognostic (1.21e-2)" 45.6 63.0 56.0 47.2 50.6 42.0 38.3 58.1 75.7 48.0 39.3 55.9 44.9 36.3 52.9 34.1 59.4 56.0 39.9 48.7 49.5 39.9 51.1 60.0 42.0 48.2 47.7 62.3 57.6 34.9 78.8 55.5 39.1 47.6 40.2 35.5 41.0 47.5 45.7 77.7 56.1 37.9 59.4 35.5 53.4 38.7 36.0 48.6 52.7 65.0 43.9 54.0 39.2 52.7 28.9 30.6 32.6 36.0 25.6 29.0 24.1 45.8 47.6 54.5 82.8 37.3 34.0 24.1 30.5 32.5 43.9 35.8 37.8 35.0 34.2 20.3 61.0 44.3 68.3 64.9 32.3 28.3 69.4 21.4 52.8 30.3 26.3 36.0 46.2 31.9 34.0 63.8 49.8 57.5 23.2 30.8 43.5 58.1 33.9 31.9 58.0 74.4 39.5 38.0 58.2 35.1 49.4 35.3 26.5 90.9 44.2 20.2 61.5 22.5 42.0 33.0 38.3 47.5 28.4 21.1 21.9 48.8 33.9 25.8 39.4 17.4 27.0 27.4 29.0 36.0 25.4 28.9 24.0 25.9 30.6 22.0 19.1 23.4 32.6 25.6 32.8 20.8 28.2 24.1 56.0 50.6 58.1 75.7 49.5 39.9 47.7 62.3 47.6 48.6 UBE2C UBCH10 ENSG00000175063 "Ubiquitin conjugating enzyme E2 C" O00762 20 45812576-45816957 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Cell cycle, Cell division, Mitosis, Ubl conjugation pathway" Transferase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "lymphoid tissue: 130.8" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Cell type enhanced" "Detected in many" "T-reg: 10.0" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in single" "Low region specificity" "Detected in some" "CAB011464, HPA034569, CAB035990, HPA054975" Approved Supported "Plasma membrane,Cytosol" "Plasma membrane, Cytosol" "CAB011464: AB_442965, CAB035990: , HPA034569: , HPA054975: " "unprognostic (1.45e-2)" "unprognostic (2.19e-1)" "unprognostic (1.06e-1)" "unprognostic (2.11e-3)" "unprognostic (2.54e-1)" "unprognostic (1.35e-1)" "prognostic unfavourable (6.24e-6)" "unprognostic (2.27e-3)" "unprognostic (2.59e-2)" "unprognostic (1.04e-1)" "prognostic unfavourable (6.91e-4)" "unprognostic (3.76e-2)" "prognostic unfavourable (0.00e+0)" "unprognostic (3.09e-1)" "unprognostic (3.61e-1)" "unprognostic (4.65e-2)" "unprognostic (2.68e-1)" 3.1 2.3 0.4 24.0 0.9 25.1 4.3 0.4 0.7 3.8 9.5 0.4 0.8 7.8 2.0 2.6 25.6 0.6 3.2 2.8 0.5 0.4 2.1 2.1 4.6 15.6 0.6 0.5 1.2 1.3 0.0 0.6 12.6 0.9 1.3 11.7 0.7 3.7 0.6 1.0 8.3 10.0 3.5 1.2 11.6 7.0 15.3 0.5 130.8 0.8 17.6 26.3 2.8 7.8 1.2 0.9 2.7 0.6 2.4 10.0 4.2 39.2 28.8 52.0 24.9 1.4 3.2 29.9 31.2 15.8 51.4 36.9 94.6 45.4 41.6 30.6 14.8 38.8 0.2 33.4 52.5 17.7 27.4 12.8 22.1 24.8 0.4 18.3 32.2 1.0 3.6 34.8 34.1 25.0 0.2 35.4 42.3 64.6 30.2 5.2 31.2 69.0 32.1 47.1 0.2 17.3 13.6 30.0 25.0 49.1 36.0 19.7 36.3 27.0 9.1 46.1 40.3 31.3 60.3 11.2 0.3 46.4 28.0 13.1 43.7 0.0 0.1 0.0 0.2 0.0 0.0 1.2 1.2 2.3 0.9 0.2 0.2 0.1 2.7 2.4 0.6 0.5 10.0 4.2 0.4 0.9 0.4 0.7 0.5 0.4 0.6 0.5 0.9 0.5 UBE2I UBC9 ENSG00000103275 "Ubiquitin conjugating enzyme E2 I" P63279 16 1308880-1327018 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters" "Cell cycle, Cell division, Chromosome partition, Host-virus interaction, Mitosis, Ubl conjugation pathway" Transferase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003909, CAB009021" Approved 120000 "CAB009021: AB_2210610, HPA003909: AB_1858529" "unprognostic (2.12e-1)" "unprognostic (1.01e-2)" "unprognostic (1.55e-2)" "unprognostic (3.51e-1)" "unprognostic (1.21e-1)" "unprognostic (1.52e-1)" "prognostic unfavourable (7.50e-4)" "unprognostic (2.88e-3)" "unprognostic (1.20e-1)" "unprognostic (1.89e-2)" "unprognostic (7.60e-3)" "unprognostic (3.56e-1)" "unprognostic (7.28e-2)" "unprognostic (9.30e-2)" "unprognostic (1.57e-1)" "prognostic favourable (5.68e-4)" "unprognostic (1.15e-3)" 34.3 43.1 28.8 36.3 36.9 48.4 45.2 45.6 48.5 38.1 32.0 28.6 28.1 28.9 55.4 32.9 43.4 35.6 30.3 41.8 27.4 28.4 29.4 26.6 29.1 44.2 22.7 32.9 62.5 35.5 33.4 36.2 47.2 21.4 40.7 31.0 34.1 37.8 32.2 31.6 35.8 32.2 40.0 23.2 43.7 29.4 43.6 21.6 78.0 42.5 31.8 53.9 38.7 38.8 82.2 58.0 85.4 67.4 50.9 57.8 60.0 24.9 34.5 58.2 34.3 25.0 30.3 25.2 36.0 26.0 33.5 33.5 40.8 41.1 43.5 30.0 31.1 30.5 41.6 33.8 43.3 31.3 29.4 27.2 31.9 39.4 39.6 40.3 32.5 28.0 22.0 32.8 39.3 36.2 38.9 27.4 31.6 53.3 71.2 40.6 47.4 25.5 90.4 36.9 49.5 31.2 23.0 33.0 34.8 31.6 35.9 35.9 36.5 48.9 29.8 33.3 38.2 29.2 32.5 29.0 34.3 88.8 18.7 30.0 35.2 63.9 59.3 85.4 48.0 67.4 57.8 82.2 49.0 48.7 58.0 61.8 44.1 44.2 41.3 50.9 62.3 50.1 50.9 60.0 28.8 36.9 45.6 48.5 27.4 28.4 22.7 32.9 21.4 21.6 UBE2N "MGC8489, UBC13, UbcH-ben" ENSG00000177889 "Ubiquitin conjugating enzyme E2 N" P61088 12 93405673-93442262 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA repair, Ubl conjugation pathway" Transferase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" HPA044976 Enhanced Supported "Nucleoplasm,Nucleoli fibrillar center" 4600000 Nucleoplasm "Nucleoli fibrillar center" "HPA044976: " "unprognostic (1.74e-2)" "unprognostic (5.53e-1)" "unprognostic (1.26e-2)" "unprognostic (2.30e-1)" "unprognostic (1.07e-1)" "unprognostic (8.09e-2)" "prognostic unfavourable (2.41e-4)" "unprognostic (8.49e-3)" "unprognostic (2.72e-1)" "unprognostic (4.28e-3)" "unprognostic (1.07e-1)" "unprognostic (9.28e-2)" "unprognostic (1.03e-1)" "unprognostic (3.31e-2)" "unprognostic (1.29e-1)" "unprognostic (1.48e-1)" "unprognostic (1.30e-3)" 24.7 25.0 29.0 28.7 39.1 29.0 21.2 29.2 44.3 18.4 26.6 15.6 15.1 20.7 23.2 20.0 30.4 19.7 17.0 27.7 31.0 33.7 25.4 22.3 19.3 36.1 27.6 34.5 17.4 17.6 13.9 18.2 24.2 34.9 23.4 22.6 13.7 18.0 18.5 35.7 19.1 20.4 21.3 24.6 21.5 19.3 83.7 17.4 32.2 15.5 16.8 35.1 22.7 18.8 53.8 35.5 29.9 39.2 29.5 57.3 51.9 35.8 26.0 43.9 28.1 17.0 16.9 30.6 50.2 26.8 40.3 33.8 46.2 15.6 73.0 11.4 29.3 28.6 48.4 36.8 38.4 60.7 25.1 49.1 14.3 40.7 21.7 58.6 32.8 17.7 15.2 24.0 30.0 31.0 54.5 11.4 41.8 29.5 57.8 54.5 57.1 36.4 45.0 35.6 35.7 33.5 54.3 42.9 39.1 26.5 31.2 24.5 40.8 36.1 32.0 27.3 22.8 24.6 36.1 19.7 53.3 62.0 10.7 31.3 33.3 29.9 27.1 28.9 31.7 35.4 36.9 53.8 40.2 39.2 35.5 38.6 36.0 34.4 8.2 29.5 39.2 26.7 57.3 51.9 29.0 39.1 29.2 44.3 31.0 33.7 27.6 34.5 34.9 17.4 UBR5 "DD5, EDD, EDD1, HYD, KIAA0896" ENSG00000104517 "Ubiquitin protein ligase E3 component n-recognin 5" O95071 8 102253012-102412841 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "DNA damage, DNA repair, Host-virus interaction, Ubl conjugation pathway" Transferase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA053688 Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "HPA053688: " "unprognostic (3.79e-3)" "unprognostic (7.44e-3)" "unprognostic (1.25e-1)" "unprognostic (2.10e-2)" "unprognostic (2.44e-2)" "unprognostic (1.41e-1)" "prognostic unfavourable (1.26e-4)" "unprognostic (2.50e-1)" "unprognostic (1.75e-2)" "unprognostic (7.54e-3)" "unprognostic (8.29e-3)" "unprognostic (3.84e-2)" "unprognostic (6.64e-2)" "unprognostic (3.16e-1)" "unprognostic (1.94e-1)" "unprognostic (1.69e-2)" "unprognostic (2.45e-1)" 27.0 16.7 27.1 29.5 31.7 30.3 29.2 40.8 32.8 24.9 25.0 19.1 21.1 14.4 26.8 24.0 23.8 22.0 17.6 22.7 25.5 15.3 17.9 17.0 24.2 29.6 21.9 20.6 29.7 22.2 32.4 25.5 25.0 23.6 20.2 17.1 19.7 22.9 21.8 39.9 29.7 22.4 29.3 17.5 21.9 21.1 39.7 28.3 37.9 20.3 15.9 27.0 27.5 28.6 5.0 4.0 6.3 5.5 2.4 7.1 2.1 23.2 10.4 20.2 10.3 19.9 20.3 18.6 17.6 15.6 13.8 12.1 10.4 15.7 46.4 15.2 16.5 14.2 17.2 15.3 19.4 20.0 8.4 38.7 14.2 18.7 17.7 12.0 21.4 23.2 15.3 14.2 24.8 16.5 18.6 26.4 13.5 21.0 30.5 14.4 15.2 11.8 17.8 11.9 22.0 12.6 22.9 14.9 12.4 12.3 12.0 12.2 19.2 12.8 16.5 14.7 17.2 13.2 12.2 14.1 13.6 47.7 14.6 18.8 11.9 3.1 3.4 5.0 5.6 3.4 5.6 5.0 6.0 5.9 4.0 3.9 4.8 7.1 6.3 2.4 5.5 3.6 7.1 2.1 27.1 31.7 40.8 32.8 25.5 15.3 21.9 20.6 23.6 28.3 UHRF1BP1L KIAA0701 ENSG00000111647 "UHRF1 binding protein 1 like" A0JNW5 12 100028455-100142848 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA039671, HPA075150" Uncertain Approved Nucleoplasm,Vesicles,Cytosol Nucleoplasm "Vesicles, Cytosol" "HPA039671: AB_10794201, HPA075150: " "unprognostic (4.80e-2)" "unprognostic (3.17e-1)" "unprognostic (2.34e-2)" "unprognostic (1.14e-1)" "unprognostic (8.96e-2)" "unprognostic (7.36e-2)" "unprognostic (8.10e-2)" "unprognostic (5.75e-3)" "unprognostic (2.06e-1)" "unprognostic (5.43e-2)" "unprognostic (1.88e-2)" "unprognostic (2.53e-1)" "unprognostic (2.94e-3)" "unprognostic (6.84e-2)" "unprognostic (1.25e-1)" "unprognostic (3.81e-2)" "unprognostic (1.28e-2)" 14.9 13.9 15.9 11.4 19.9 31.9 10.8 16.9 26.0 9.5 10.0 8.7 5.3 9.9 9.3 8.8 10.2 8.0 10.6 10.4 18.0 13.7 14.7 28.0 10.6 9.7 14.8 12.0 11.1 4.7 21.5 15.3 13.7 22.6 11.1 9.6 6.9 8.7 11.2 26.2 8.4 11.1 11.2 13.7 11.8 9.0 15.2 9.8 10.0 13.0 8.1 8.1 16.7 8.4 3.8 8.4 22.9 8.4 3.7 3.7 3.4 11.3 12.4 6.9 7.1 10.7 15.2 13.8 17.7 17.9 14.4 10.5 9.1 3.9 9.8 4.6 18.1 4.4 12.9 6.0 14.0 26.1 6.3 6.6 9.9 10.6 9.9 12.3 10.8 8.6 5.1 17.2 12.0 10.0 5.2 10.3 14.0 6.3 7.9 10.7 11.9 11.3 9.0 12.3 9.7 7.3 20.1 11.8 7.3 13.5 15.5 5.2 13.9 14.2 7.9 15.9 8.5 13.7 12.4 12.2 20.8 13.8 8.0 9.4 9.6 12.5 7.6 4.9 2.6 8.4 3.7 3.8 2.9 2.9 8.4 3.4 2.5 3.0 22.9 3.7 6.8 5.1 3.2 3.4 15.9 19.9 16.9 26.0 18.0 13.7 14.8 12.0 22.6 9.8 USH1C "AIE-75, DFNB18, harmonin, NY-CO-37, NY-CO-38, PDZ-73, PDZ73, PDZD7C" ENSG00000006611 "USH1 protein network component harmonin" Q9Y6N9 11 17493895-17544416 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Differentiation, Hearing" "Cancer-related genes, Deafness, Non-syndromic deafness, Retinitis pigmentosa, Usher syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "gallbladder: 26.0;intestine: 57.0;kidney: 22.1" "Group enriched" "Detected in some" 5 "CACO-2: 35.2;HeLa: 12.5" "Group enriched" "Detected in many" 7 "colorectal cancer: 34.5;pancreatic cancer: 18.8;renal cancer: 29.4;stomach cancer: 15.3" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Region enhanced" "Detected in single" "olfactory region: 2.2" "CAB013690, HPA027398, HPA027492, HPA028033" Enhanced Enhanced Cytosol Cytosol "CAB013690: , HPA027398: AB_10601775, HPA027492: AB_10601898, HPA028033: AB_10601782" "unprognostic (3.60e-2)" "unprognostic (6.19e-2)" "unprognostic (2.36e-1)" "unprognostic (3.83e-2)" "unprognostic (1.98e-1)" "unprognostic (2.10e-1)" "prognostic unfavourable (2.20e-4)" "unprognostic (2.22e-1)" "unprognostic (2.78e-1)" "unprognostic (1.51e-2)" "unprognostic (9.65e-2)" "prognostic favourable (9.41e-4)" "unprognostic (1.29e-2)" "unprognostic (1.88e-1)" "unprognostic (1.62e-1)" "unprognostic (2.61e-1)" 0.1 0.1 1.6 4.3 7.1 0.0 0.0 0.8 3.3 0.1 23.8 6.2 0.0 40.5 0.0 6.3 0.0 1.3 26.0 0.3 5.0 2.3 22.1 0.4 0.0 0.0 4.8 1.9 0.3 2.1 0.0 5.2 0.0 3.5 0.1 20.7 1.8 0.0 0.1 0.0 0.0 57.0 0.9 10.2 0.0 11.5 0.2 3.6 0.0 0.5 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 35.2 4.9 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 12.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 1.6 7.1 0.8 2.3 5.0 2.3 4.8 1.9 3.5 3.6 USP6 "HRP1, Tre-2, TRE17, Tre2, TRESMCR" ENSG00000129204 "Ubiquitin specific peptidase 6" P35125 17 5116438-5175034 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Ubl conjugation pathway" "Calmodulin-binding, Hydrolase, Protease, Thiol protease" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 9 "skeletal muscle: 18.2;testis: 29.0" "Low cell line specificity" "Detected in many" "Cancer enriched" "Detected in single" 14 "testis cancer: 2.8" "Not detected" "Not detected" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" HPA046969 Uncertain Vesicles Vesicles "HPA046969: " "unprognostic (3.89e-2)" "unprognostic (3.79e-3)" "unprognostic (2.50e-1)" "unprognostic (1.85e-1)" "unprognostic (9.32e-2)" "unprognostic (3.50e-3)" "unprognostic (1.29e-1)" "unprognostic (1.67e-2)" "unprognostic (3.45e-2)" "unprognostic (2.46e-2)" "unprognostic (7.91e-4)" "unprognostic (6.28e-3)" "unprognostic (3.24e-4)" "unprognostic (3.75e-2)" "unprognostic (3.13e-1)" "unprognostic (2.71e-1)" "unprognostic (7.09e-4)" 0.3 0.3 0.3 0.3 0.6 0.2 0.4 0.5 0.5 0.3 0.5 0.3 1.2 0.0 0.6 0.6 0.3 0.5 0.4 0.3 0.3 0.1 0.3 0.3 0.3 0.3 0.3 0.3 2.6 0.3 0.0 0.4 0.4 0.3 0.4 0.1 0.3 0.3 0.3 18.2 0.6 0.7 0.9 0.3 0.3 0.0 29.0 0.3 0.3 0.4 0.3 0.3 0.3 0.3 0.9 1.2 1.9 1.0 0.2 0.4 0.1 2.2 1.0 2.2 1.7 0.4 0.2 2.3 1.9 0.1 0.6 0.4 0.8 1.1 2.2 1.7 1.3 1.0 0.7 0.8 0.5 1.6 1.3 1.7 1.3 0.9 1.2 0.5 2.9 1.1 0.5 0.1 0.2 0.3 0.5 0.3 0.5 2.5 1.9 0.7 1.6 0.1 1.4 2.0 0.2 0.5 0.7 0.9 2.2 1.0 0.1 3.3 2.2 2.2 1.2 1.0 3.3 2.1 1.4 2.0 1.7 1.5 0.0 0.1 2.7 0.1 0.4 0.9 0.4 0.3 0.2 0.6 0.3 0.3 0.3 0.9 0.3 0.4 1.9 0.2 1.0 1.2 0.1 0.1 0.3 0.6 0.5 0.3 0.3 0.1 0.3 0.3 0.3 0.3 USP8 "HumORF8, KIAA0055, SPG59, UBPY" ENSG00000138592 "Ubiquitin specific peptidase 8" P40818 15 50424380-50514419 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Cell cycle, Ubl conjugation pathway" "Hydrolase, Protease, Thiol protease" "Cancer-related genes, Cushing syndrome, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA050215 Approved Supported "Golgi apparatus,Cytosol" "Golgi apparatus" Cytosol "HPA050215: " "unprognostic (5.81e-2)" "unprognostic (1.34e-1)" "unprognostic (1.46e-1)" "unprognostic (9.58e-2)" "unprognostic (2.35e-2)" "unprognostic (2.91e-1)" "unprognostic (1.42e-1)" "unprognostic (3.96e-1)" "unprognostic (1.68e-2)" "unprognostic (5.08e-2)" "unprognostic (2.94e-1)" "unprognostic (3.99e-2)" "prognostic favourable (1.29e-5)" "unprognostic (4.89e-2)" "unprognostic (1.13e-1)" "unprognostic (3.79e-1)" "unprognostic (1.58e-1)" 19.4 21.9 21.0 20.6 20.6 21.6 18.1 27.3 21.6 21.4 23.9 13.8 19.5 20.2 22.1 17.4 22.3 17.4 15.5 17.4 19.7 18.2 28.2 26.4 17.0 25.4 21.8 15.2 21.9 16.7 42.6 43.2 29.1 29.7 16.7 18.9 10.7 19.9 17.9 24.3 17.8 32.1 19.2 29.3 30.3 17.7 27.5 26.1 28.9 24.1 12.7 20.9 22.3 18.4 16.7 10.6 38.1 15.1 9.5 11.9 6.9 11.0 15.9 8.9 15.7 16.3 18.3 12.4 15.9 18.9 15.5 18.4 10.6 7.3 11.7 12.3 18.2 21.5 12.2 11.9 18.4 10.2 8.1 21.6 14.8 10.9 16.8 14.4 14.6 14.2 14.3 13.7 23.3 15.0 12.3 14.2 14.5 22.7 9.2 5.7 10.2 7.3 8.4 16.6 17.5 14.7 26.1 11.4 10.4 16.8 25.1 20.8 13.7 17.7 17.0 16.1 9.1 49.6 21.0 11.1 23.1 12.9 12.9 29.2 15.5 38.1 13.3 22.4 11.1 12.4 10.7 16.5 11.4 11.1 10.6 16.7 11.9 10.7 22.7 9.5 15.1 9.9 8.5 6.9 21.0 20.6 27.3 21.6 19.7 18.2 21.8 15.2 29.7 26.1 VCAM1 CD106 ENSG00000162692 "Vascular cell adhesion molecule 1" P19320 1 100719742-100739045 "Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins" "Cell adhesion" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in all" 5 "kidney: 69.6;lymphoid tissue: 129.2" "Group enriched" "Detected in some" 5 "HHSteC: 56.9;HSkMC: 38.0" "Cancer enriched" "Detected in all" 8 "renal cancer: 89.5" "Low region specificity" "Detected in many" "Group enriched" "Detected in some" 10 "gdT-cell: 1.3;memory CD8 T-cell: 2.9;naive CD8 T-cell: 1.1" "Lineage enriched" "Detected in single" 17 "T-cells: 2.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000154, HPA034796, HPA069867" Enhanced Approved "Cell Junctions" 960000000 "Cell Junctions" "CAB000154: , HPA034796: , HPA069867: " "unprognostic (2.96e-1)" "prognostic favourable (3.82e-4)" "unprognostic (1.31e-1)" "unprognostic (7.49e-3)" "unprognostic (1.04e-1)" "prognostic favourable (7.19e-5)" "unprognostic (1.60e-2)" "unprognostic (2.48e-1)" "unprognostic (1.18e-1)" "unprognostic (1.20e-1)" "unprognostic (3.95e-2)" "unprognostic (8.23e-2)" "unprognostic (1.80e-1)" "unprognostic (5.47e-2)" "unprognostic (1.68e-2)" "unprognostic (3.12e-2)" "unprognostic (2.55e-2)" 10.9 18.1 1.5 20.2 3.2 1.3 5.2 0.9 1.1 3.7 5.0 3.3 1.4 3.3 4.9 4.5 5.3 4.9 6.8 7.2 1.7 2.3 69.6 11.8 9.8 26.8 2.8 1.7 11.1 6.6 10.6 3.5 10.9 4.2 8.3 5.5 15.3 4.9 1.1 4.7 1.8 6.3 4.2 3.7 129.2 3.0 2.5 1.6 13.3 3.5 2.8 20.9 8.2 2.8 0.0 0.1 0.0 0.0 0.0 2.9 0.1 0.0 0.0 0.2 0.1 0.2 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 8.2 0.0 0.0 0.0 0.0 56.9 0.0 0.0 38.0 0.0 10.0 0.0 0.6 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.5 0.0 0.0 0.0 0.1 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.1 2.9 0.1 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.1 1.5 3.2 0.9 1.1 1.7 2.3 2.8 1.7 4.2 1.6 VEGFA "VEGF, VEGF-A, VPF" ENSG00000112715 "Vascular endothelial growth factor A" P15692 6 43770184-43786487 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins" "Angiogenesis, Differentiation" "Developmental protein, Growth factor, Heparin-binding, Mitogen" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "hTEC/SVTERT24-B: 49.7;hTERT-HME1: 49.5;U-87 MG: 108.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "classical monocyte: 1.2;eosinophil: 1.9" "Group enriched" "Detected in many" 9 "granulocytes: 1.9;monocytes: 1.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB005429, CAB039240, HPA069116, CAB069907" Supported "Secreted to blood" 214485 "CAB005429: AB_2212984, CAB039240: , CAB069907: AB_10001947, HPA069116: " "unprognostic (1.12e-1)" "prognostic unfavourable (4.50e-4)" "unprognostic (2.42e-2)" "prognostic unfavourable (2.10e-4)" "unprognostic (4.35e-2)" "unprognostic (1.49e-1)" "prognostic unfavourable (2.34e-5)" "unprognostic (5.10e-2)" "unprognostic (5.27e-3)" "unprognostic (2.30e-2)" "unprognostic (1.40e-1)" "unprognostic (1.00e-2)" "prognostic unfavourable (1.76e-5)" "unprognostic (2.20e-1)" "unprognostic (1.80e-1)" "unprognostic (1.43e-1)" "prognostic favourable (2.73e-4)" 35.0 17.5 16.6 11.4 20.1 12.8 39.5 6.5 32.3 11.8 25.9 8.7 15.0 16.0 54.1 9.4 19.4 10.4 27.5 57.0 13.4 5.4 25.8 58.6 30.0 2.9 15.8 3.7 16.4 25.1 20.6 7.3 16.7 19.8 40.5 7.2 24.4 15.1 23.8 52.9 11.9 26.3 19.2 35.1 19.0 20.5 4.5 15.4 0.3 87.9 19.6 13.6 47.5 15.7 0.0 0.1 1.9 1.2 0.0 0.0 0.0 12.4 2.2 2.1 12.2 3.6 5.8 14.4 7.6 13.7 5.1 10.1 7.1 1.6 4.1 6.1 4.6 5.1 5.7 15.4 9.0 4.5 1.8 3.1 2.9 4.8 38.7 3.3 6.9 10.1 30.7 49.7 49.5 1.3 5.7 20.7 18.5 5.1 0.3 4.6 1.3 3.5 0.3 2.0 9.8 19.7 10.4 3.8 8.0 11.0 7.5 26.4 2.9 12.5 1.7 21.2 5.7 30.6 12.5 11.8 6.9 8.0 108.8 7.9 7.3 0.0 1.2 1.9 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 16.6 20.1 6.5 32.3 13.4 5.4 15.8 3.7 19.8 15.4 VEGFD "FIGF, VEGF-D" ENSG00000165197 "Vascular endothelial growth factor D" O43915 X 15345591-15384376 "Cancer-related genes, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins" "Angiogenesis, Differentiation" "Developmental protein, Growth factor, Mitogen" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lung: 39.0" "Cell line enhanced" "Detected in some" "ASC diff: 7.1;ASC TERT1: 5.9;EFO-21: 2.6;HSkMC: 5.9" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in some" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in some" "Low region specificity" "Detected in many" HPA027342 Uncertain "Secreted to blood" 592125 340000 "HPA027342: AB_1848597" "unprognostic (5.90e-2)" "unprognostic (9.79e-3)" "unprognostic (1.02e-1)" "unprognostic (1.06e-1)" "unprognostic (2.85e-2)" "unprognostic (2.07e-1)" "unprognostic (6.06e-3)" "unprognostic (5.57e-2)" "unprognostic (2.24e-3)" "unprognostic (2.65e-2)" "unprognostic (1.59e-5)" "unprognostic (3.08e-2)" "unprognostic (2.03e-3)" "unprognostic (1.56e-1)" "unprognostic (1.70e-1)" "unprognostic (3.85e-1)" "unprognostic (1.75e-2)" 9.5 7.4 0.6 1.8 1.0 0.1 19.5 1.1 0.7 10.5 7.6 0.2 4.1 1.1 10.1 12.9 15.4 2.7 3.5 27.8 0.6 1.1 1.0 1.3 39.0 0.7 0.8 0.2 7.3 2.6 0.2 4.4 0.2 0.8 22.2 1.9 0.2 1.5 1.8 12.0 0.5 4.3 9.8 0.6 2.3 3.4 14.9 0.1 0.0 2.0 17.5 1.2 12.3 8.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 1.1 1.8 7.1 5.9 0.0 0.0 0.2 0.0 0.0 0.0 0.2 0.3 2.6 0.0 0.5 0.5 0.0 0.0 0.0 0.1 0.0 1.5 0.6 0.4 0.0 0.8 5.9 0.7 0.0 0.0 0.6 0.0 0.4 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.2 0.0 0.5 0.5 0.4 0.3 0.1 0.6 0.0 0.7 0.3 0.0 0.1 0.3 0.3 0.4 1.1 0.0 0.1 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 1.0 1.1 0.7 0.6 1.1 0.8 0.2 0.8 0.1 VHL VHL1 ENSG00000134086 "Von Hippel-Lindau tumor suppressor" P40337 3 10141008-10152220 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Ubl conjugation pathway" "Cancer-related genes, Congenital erythrocytosis, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "BEWO: 53.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "CAB005430, HPA031631, HPA031632" Uncertain Enhanced Nucleoplasm,Cytosol Nucleoplasm Cytosol "CAB005430: AB_2241850, HPA031631: , HPA031632: " "prognostic unfavourable (9.02e-5)" "unprognostic (1.10e-1)" "unprognostic (4.46e-3)" "unprognostic (1.52e-1)" "unprognostic (1.10e-1)" "unprognostic (1.33e-1)" "prognostic unfavourable (1.32e-5)" "unprognostic (3.55e-1)" "unprognostic (3.03e-2)" "unprognostic (4.36e-2)" "unprognostic (5.82e-3)" "unprognostic (1.81e-2)" "unprognostic (2.51e-1)" "prognostic favourable (7.84e-4)" "unprognostic (1.46e-1)" "unprognostic (2.92e-2)" "unprognostic (1.28e-3)" 13.8 17.4 18.1 29.2 18.4 24.3 15.4 25.8 21.4 13.3 19.8 19.3 14.5 15.9 15.1 13.6 16.4 14.3 18.9 10.5 17.1 18.5 13.7 16.3 14.6 27.9 13.5 12.3 15.2 22.5 13.8 14.6 18.8 12.8 15.1 16.6 12.5 21.8 13.7 14.8 14.0 22.3 13.4 17.0 22.6 16.2 17.9 11.2 39.2 16.9 11.5 29.3 15.4 19.1 5.4 3.9 8.0 4.1 4.4 4.3 1.7 6.7 6.5 14.3 8.8 13.3 10.3 53.6 5.9 8.5 7.6 9.0 7.6 8.4 23.8 8.1 8.0 5.8 13.2 8.3 9.4 11.4 12.0 18.5 10.5 10.5 12.6 16.3 14.8 10.3 9.5 10.1 12.8 8.7 16.4 18.1 7.5 12.2 15.5 12.0 9.6 8.3 19.7 12.6 11.9 9.3 17.4 5.4 17.9 12.5 6.7 7.2 13.2 20.7 7.5 7.6 10.1 7.0 9.3 12.9 26.4 38.0 8.4 19.5 6.9 2.6 4.1 3.3 3.8 2.5 3.6 4.1 2.9 4.3 3.9 5.4 2.5 2.7 8.0 4.4 3.2 2.4 3.1 1.7 18.1 18.4 25.8 21.4 17.1 18.5 13.5 12.3 12.8 11.2 VIL1 "D2S1471, VIL" ENSG00000127831 "Villin 1" P09327 2 218419092-218453295 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" Apoptosis "Actin capping, Actin-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 6 "intestine: 129.3" "Group enriched" "Detected in some" 106 "CACO-2: 122.1;Hep G2: 57.3" "Cancer enhanced" "Detected in many" "colorectal cancer: 56.4" "Not detected" "Not detected" "Cell type enriched" "Detected in single" 6 "neutrophil: 2.5" "Lineage enriched" "Detected in single" 6 "granulocytes: 2.5" "Low region specificity" "Detected in single" "Low region specificity" "Detected in many" "CAB002452, HPA006884, HPA006885" Enhanced Enhanced "Plasma membrane" 41000000 "Plasma membrane" "CAB002452: AB_564052, HPA006884: AB_1080566, HPA006885: AB_1080564" "unprognostic (1.28e-1)" "unprognostic (1.91e-2)" "unprognostic (1.61e-2)" "unprognostic (1.09e-1)" "unprognostic (1.83e-1)" "unprognostic (3.36e-1)" "unprognostic (3.03e-1)" "unprognostic (5.90e-2)" "unprognostic (2.44e-2)" "unprognostic (7.06e-2)" "unprognostic (4.14e-1)" "unprognostic (1.03e-1)" "unprognostic (2.25e-3)" "unprognostic (3.90e-1)" "unprognostic (2.58e-1)" "unprognostic (4.79e-2)" "unprognostic (4.65e-2)" 0.3 0.2 0.6 5.7 0.8 0.0 0.3 0.7 0.4 0.3 36.6 0.3 0.3 68.9 0.3 1.2 0.3 0.2 22.6 0.3 0.5 0.5 4.6 6.1 0.3 0.3 0.5 0.3 0.3 7.2 0.0 0.4 0.3 0.3 0.3 32.6 0.3 0.5 0.3 0.3 0.3 129.3 1.2 0.5 0.4 0.9 0.6 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.1 0.4 2.5 0.1 0.1 0.1 7.8 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 122.1 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 57.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 2.5 0.1 0.0 0.4 0.0 7.8 0.6 0.8 0.7 0.4 0.5 0.5 0.5 0.3 0.3 0.3 VIP ENSG00000146469 "Vasoactive intestinal peptide" P01282 6 152750798-152759765 "Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins" Hormone "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 32.5;lymphoid tissue: 64.7" "Group enriched" "Detected in some" 4 "HeLa: 2.1;SH-SY5Y: 6.8;TIME: 4.8;U-2 OS: 2.0" "Group enriched" "Detected in some" 6 "colorectal cancer: 3.7;pancreatic cancer: 4.3;stomach cancer: 2.6" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA017324, CAB018649, HPA072701, CAB079780" Supported Supported Approved "Endoplasmic reticulum" "Secreted to blood" 121550 "Endoplasmic reticulum" "CAB018649: AB_2304501, CAB079780: , HPA017324: AB_1858754, HPA072701: " "unprognostic (9.58e-2)" "unprognostic (2.29e-2)" "unprognostic (2.60e-2)" "unprognostic (1.13e-1)" "unprognostic (3.34e-2)" "unprognostic (3.33e-2)" "unprognostic (2.48e-2)" "unprognostic (7.21e-2)" "unprognostic (2.22e-2)" "unprognostic (2.89e-2)" "unprognostic (2.36e-1)" "unprognostic (3.62e-1)" "unprognostic (2.92e-3)" "unprognostic (7.47e-2)" "unprognostic (1.94e-1)" "unprognostic (1.30e-1)" "unprognostic (5.90e-2)" 1.2 5.7 9.7 64.7 8.3 0.3 0.9 1.5 20.1 0.6 31.5 0.5 0.3 7.5 0.7 0.4 13.1 0.5 4.2 1.1 12.4 7.7 0.9 0.6 1.7 0.4 2.7 8.3 0.4 3.8 0.5 0.4 0.5 1.6 6.3 28.3 3.2 0.4 6.9 0.8 0.4 32.5 18.0 0.4 5.2 13.2 0.5 0.1 0.0 1.3 0.5 0.4 9.1 4.3 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.1 0.0 0.0 0.0 0.0 0.1 0.9 0.1 0.4 0.8 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.1 6.8 0.0 0.0 0.0 0.0 0.0 4.8 0.0 2.0 0.2 0.1 0.5 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 9.7 8.3 1.5 20.1 12.4 7.7 2.7 8.3 1.6 0.1 VTN VN ENSG00000109072 Vitronectin P04004 17 28367276-28373091 "Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins" "Cell adhesion" Heparin-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 42 "liver: 321.7" "Cell line enriched" "Detected in some" 11 "CACO-2: 164.9" "Cancer enriched" "Detected in many" 85 "liver cancer: 2216.6" "Cell type enhanced" "Detected in some" "naive CD8 T-cell: 2.1" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB016695, CAB016765, HPA060933" Supported Supported "Endoplasmic reticulum,Vesicles" "Secreted to blood" 224300000000 32000000000 "Endoplasmic reticulum, Vesicles" "CAB016695: AB_1624536, CAB016765: , HPA060933: " "unprognostic (1.19e-1)" "unprognostic (2.12e-1)" "unprognostic (2.29e-2)" "unprognostic (6.13e-2)" "unprognostic (9.74e-2)" "unprognostic (8.42e-2)" "prognostic favourable (3.74e-4)" "unprognostic (6.20e-2)" "unprognostic (3.97e-1)" "unprognostic (8.95e-2)" "unprognostic (3.24e-3)" "unprognostic (1.01e-2)" "prognostic unfavourable (4.10e-11)" "unprognostic (8.82e-3)" "unprognostic (2.27e-1)" "unprognostic (4.86e-3)" "unprognostic (7.09e-2)" 0.2 7.6 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.6 2.2 0.0 0.0 0.0 321.7 0.0 0.0 0.0 0.0 0.6 0.0 0.0 2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.4 0.0 0.0 0.0 0.0 0.3 0.2 0.6 0.2 0.7 2.1 0.1 0.0 2.9 0.0 0.0 0.0 0.0 0.7 0.2 0.1 0.1 0.0 164.9 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 8.5 0.2 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.1 0.1 15.1 0.9 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.2 0.0 1.0 0.0 0.9 0.0 0.9 0.9 0.1 0.3 0.6 2.1 0.6 0.7 0.0 0.2 0.0 0.1 VWF F8VWF ENSG00000110799 "Von Willebrand factor" P04275 12 5948874-6124770 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins" "Blood coagulation, Cell adhesion, Hemostasis" "Cancer-related genes, Disease mutation, FDA approved drug targets, von Willebrand disease" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adipose tissue: 91.7" "Cell line enriched" "Detected in some" 57 "HUVEC TERT2: 111.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "neutrophil: 1.3" "Lineage enhanced" "Detected in single" "granulocytes: 1.3" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB001694, HPA001815, HPA002082, CAB072874, CAB072875" Supported "Secreted to blood" 351500000 6400000000 "CAB001694: , CAB072874: , CAB072875: , HPA001815: AB_1080574, HPA002082: AB_1080575" "unprognostic (3.66e-1)" "unprognostic (1.11e-1)" "unprognostic (1.46e-2)" "unprognostic (2.27e-1)" "unprognostic (1.43e-1)" "unprognostic (2.91e-3)" "unprognostic (7.09e-2)" "unprognostic (4.63e-1)" "unprognostic (5.63e-2)" "unprognostic (3.92e-2)" "unprognostic (4.69e-1)" "unprognostic (1.12e-1)" "unprognostic (2.98e-2)" "prognostic unfavourable (2.31e-4)" "unprognostic (1.55e-1)" "unprognostic (3.12e-1)" "unprognostic (2.73e-3)" 91.7 3.1 6.1 9.7 8.1 0.8 41.5 3.7 8.6 19.7 13.9 7.3 6.8 6.6 21.5 16.7 14.4 15.1 15.3 38.7 7.4 5.0 4.6 1.5 41.2 9.9 9.4 7.1 13.6 5.8 17.7 2.6 36.4 10.2 18.7 5.1 26.3 7.2 10.5 28.9 8.1 11.8 22.1 7.4 19.0 9.6 12.7 5.9 1.8 18.6 13.2 6.5 18.9 35.0 0.0 0.0 1.3 0.3 0.0 0.0 1.8 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 111.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 1.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 1.8 6.1 8.1 3.7 8.6 7.4 5.0 9.4 7.1 10.2 5.9 WAS "IMD2, THC, WASP, WASPA" ENSG00000015285 "Wiskott-Aldrich syndrome" P42768 X 48676596-48691427 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 30.7;lymphoid tissue: 55.9" "Cell line enhanced" "Detected in some" "Daudi: 21.3;HMC-1: 45.7;MOLT-4: 19.4;NB-4: 21.1;RPMI-8226: 26.0;U-266/70: 24.2;U-937: 24.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "eosinophil: 20.3" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA002022, CAB004290" Enhanced Approved "Plasma membrane,Cytosol" 320000 "Plasma membrane" Cytosol "CAB004290: AB_628445, HPA002022: AB_1080581" "unprognostic (1.43e-3)" "unprognostic (2.09e-3)" "unprognostic (2.36e-2)" "prognostic favourable (4.95e-4)" "unprognostic (9.89e-2)" "prognostic favourable (3.78e-4)" "unprognostic (5.12e-3)" "unprognostic (7.60e-2)" "unprognostic (1.54e-2)" "unprognostic (2.86e-1)" "unprognostic (7.40e-2)" "unprognostic (3.60e-1)" "prognostic unfavourable (5.58e-6)" "unprognostic (2.24e-1)" "unprognostic (2.37e-2)" "unprognostic (3.55e-2)" "unprognostic (1.71e-1)" 7.6 4.0 4.9 28.9 7.8 30.7 3.3 2.0 5.1 2.7 4.4 5.9 0.5 4.8 2.4 5.6 3.7 4.5 4.4 3.0 4.6 4.1 4.1 5.0 12.6 29.9 7.6 1.3 2.6 2.2 0.7 2.6 5.4 6.0 3.2 3.2 3.5 5.4 1.9 1.4 2.2 14.3 3.7 12.8 55.9 4.1 1.7 7.3 53.2 2.8 1.4 33.2 5.8 2.5 2.1 3.5 20.3 5.3 2.1 3.2 2.0 0.2 0.0 0.1 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.3 21.3 0.0 0.0 0.7 0.0 0.0 0.0 12.2 0.1 18.8 0.2 0.0 0.2 9.6 45.7 0.0 0.0 0.0 0.0 0.0 0.2 13.1 0.0 2.1 19.4 21.1 0.1 0.1 16.9 0.0 26.0 0.0 0.0 0.1 0.2 0.3 0.2 0.2 0.1 19.2 0.1 0.0 0.1 0.3 0.0 24.2 11.8 14.9 0.1 24.4 0.0 1.8 4.6 20.3 3.0 5.0 2.2 1.8 2.3 2.5 3.5 2.1 2.1 2.3 18.1 2.1 5.3 1.8 3.2 2.0 4.9 7.8 2.0 5.1 4.6 4.1 7.6 1.3 6.0 7.3 WASF3 "KIAA0900, SCAR3, WAVE3" ENSG00000132970 "WAS protein family member 3" Q9UPY6 13 26557703-26688948 "Cancer-related genes, Predicted intracellular proteins" Actin-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 55.1" "Cell line enhanced" "Detected in many" "ASC diff: 38.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 5 "neutrophil: 1.3" "Lineage enriched" "Detected in single" 5 "granulocytes: 1.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB037086, HPA066228" Enhanced "CAB037086: AB_1080585, HPA066228: " "unprognostic (1.42e-1)" "unprognostic (3.65e-2)" "unprognostic (2.25e-1)" "unprognostic (7.57e-2)" "unprognostic (8.23e-2)" "unprognostic (3.34e-1)" "unprognostic (6.19e-2)" "unprognostic (8.37e-2)" "unprognostic (8.98e-2)" "unprognostic (2.99e-1)" "prognostic favourable (2.21e-4)" "unprognostic (8.86e-3)" "unprognostic (2.93e-3)" "unprognostic (6.35e-2)" "unprognostic (2.12e-2)" "unprognostic (2.69e-3)" "unprognostic (9.18e-2)" 18.7 17.3 27.3 3.4 33.2 1.1 11.8 30.9 55.1 7.1 3.4 18.6 2.0 1.9 8.7 6.0 4.8 7.1 4.6 7.3 22.7 19.7 8.0 7.6 7.9 3.0 22.1 22.5 22.4 6.0 6.8 4.5 1.3 18.4 10.1 4.1 8.9 6.6 10.8 7.4 3.7 2.5 8.4 17.1 5.5 5.3 12.9 14.1 0.0 17.7 0.7 2.4 4.3 5.0 0.2 0.0 1.3 0.0 0.0 0.0 0.8 0.0 0.1 17.5 0.0 38.6 7.5 1.6 6.7 10.2 10.0 5.2 0.0 1.6 6.6 0.9 15.4 1.5 4.9 5.0 8.7 0.0 4.1 0.3 0.0 6.6 5.8 2.2 5.0 15.8 4.9 2.5 7.9 15.5 0.1 0.0 3.7 1.4 0.0 0.0 4.8 1.6 0.0 9.8 0.0 1.3 2.8 4.1 8.2 3.4 3.2 5.1 0.0 0.2 7.8 7.9 3.2 3.8 3.6 0.0 0.0 6.4 4.0 0.0 7.3 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.8 27.3 33.2 30.9 30.7 22.7 19.7 22.1 22.5 18.4 14.1 WDCP "C2orf44, FLJ21945" ENSG00000163026 "WD repeat and coiled coil containing" Q9H6R7 2 24029340-24049575 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA041054 Approved Approved Nucleoli,Cytosol Nucleoli Cytosol "HPA041054: AB_10796566" "unprognostic (1.07e-1)" "unprognostic (3.19e-2)" "unprognostic (3.36e-1)" "prognostic unfavourable (6.53e-4)" "unprognostic (1.32e-1)" "unprognostic (1.35e-1)" "prognostic unfavourable (5.14e-8)" "unprognostic (7.69e-2)" "unprognostic (9.01e-3)" "unprognostic (2.05e-1)" "unprognostic (1.07e-1)" "unprognostic (5.19e-2)" "unprognostic (2.76e-3)" "unprognostic (1.85e-1)" "unprognostic (1.97e-1)" "unprognostic (7.76e-2)" "unprognostic (3.00e-1)" 11.7 9.6 8.3 7.6 9.4 2.4 9.2 14.6 9.8 9.6 9.3 11.5 8.4 5.3 10.7 8.0 7.4 7.2 5.6 6.8 7.1 6.9 7.5 8.9 5.4 12.4 8.3 4.8 11.6 7.7 11.2 9.4 8.5 8.7 8.7 6.2 7.8 7.1 12.9 13.8 5.9 7.5 7.4 8.0 9.4 7.0 12.5 9.2 17.9 8.9 5.5 13.7 9.4 6.4 4.9 4.3 1.5 3.8 5.0 7.8 4.2 7.2 11.1 12.3 8.5 8.5 6.8 4.4 8.8 4.7 9.2 8.8 10.1 3.3 19.0 3.8 4.5 5.3 17.4 6.0 9.6 11.4 10.0 11.5 5.5 10.5 5.8 10.5 8.0 4.0 4.7 9.4 4.7 8.7 16.0 5.3 9.6 3.3 13.7 6.3 14.8 8.7 15.1 20.8 7.6 4.3 3.6 9.5 13.1 4.3 4.2 5.4 3.3 4.7 8.2 7.4 8.2 4.4 8.0 8.7 10.9 26.8 4.8 11.3 5.7 0.0 2.4 1.5 7.5 3.8 7.8 4.9 5.0 5.5 4.3 4.7 6.8 7.5 0.7 5.0 2.6 1.6 7.1 4.2 8.3 9.4 14.6 9.8 7.1 6.9 8.3 4.8 8.7 9.2 WEE1 WEE1A ENSG00000166483 "WEE1 G2 checkpoint kinase" P30291 11 9573681-9593457 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division, Mitosis" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB004619, HPA068845" Approved Approved Nucleoli Nucleoli "CAB004619: AB_628447, HPA068845: " "unprognostic (6.04e-2)" "unprognostic (1.90e-3)" "unprognostic (1.09e-2)" "unprognostic (9.29e-2)" "unprognostic (1.26e-1)" "unprognostic (1.39e-2)" "unprognostic (3.79e-3)" "unprognostic (2.48e-2)" "unprognostic (1.22e-1)" "unprognostic (1.79e-2)" "unprognostic (3.21e-3)" "unprognostic (3.73e-1)" "prognostic unfavourable (5.19e-4)" "unprognostic (1.07e-1)" "unprognostic (3.06e-1)" "unprognostic (2.08e-1)" "unprognostic (3.80e-1)" 6.9 3.5 2.0 26.1 2.1 6.6 27.4 5.3 1.6 12.8 18.0 2.5 15.4 3.7 21.9 14.3 22.1 12.4 20.2 23.0 2.0 2.2 6.8 19.3 10.2 10.9 1.8 1.2 11.1 4.4 4.9 6.1 42.7 4.7 17.0 4.7 5.9 12.8 17.8 12.0 33.3 10.4 22.9 2.4 8.0 12.5 28.3 2.0 35.9 12.0 26.8 26.4 19.8 14.7 8.5 0.1 6.4 0.0 2.1 7.8 0.6 14.2 5.5 21.2 11.7 18.6 9.3 42.0 17.6 13.6 9.9 9.8 10.1 17.5 33.4 6.6 7.7 17.3 14.5 6.8 12.7 11.9 11.9 13.1 8.9 6.7 2.0 19.8 13.1 3.1 7.4 4.6 16.4 6.1 21.3 23.3 17.2 3.4 20.2 10.7 31.9 6.3 19.5 16.6 7.2 7.8 30.1 7.9 10.5 11.9 14.1 8.6 8.9 9.5 7.0 17.8 12.5 7.2 14.1 5.5 16.3 44.2 7.6 10.9 12.5 0.0 0.0 6.4 2.0 0.0 0.2 8.5 2.0 3.3 0.1 3.6 0.1 1.6 0.1 2.1 0.0 0.1 7.8 0.6 2.0 2.1 5.3 1.6 2.0 2.2 1.8 1.2 4.7 2.0 WFDC2 "dJ461P17.6, EDDM4, HE4, WAP5" ENSG00000101443 "WAP four-disulfide core domain 2" Q14508 20 45469706-45481532 "Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins" "Aspartic protease inhibitor, Protease inhibitor, Serine protease inhibitor, Thiol protease inhibitor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "cervix, uterine: 352.3;ductus deferens: 143.4;epididymis: 385.4;kidney: 135.1;salivary gland: 343.7" "Group enriched" "Detected in some" 9 "A-431: 26.2;CAPAN-2: 49.1;EFO-21: 41.0;HaCaT: 35.8;RPTEC TERT1: 38.1" "Cancer enhanced" "Detected in all" "endometrial cancer: 1815.6" "Region enriched" "Detected in single" 5 "basal ganglia: 3.0" "Cell type enriched" "Detected in single" 12 "plasmacytoid DC: 1.2" "Lineage enriched" "Detected in single" 12 "dendritic cells: 1.2" "Group enriched" "Detected in many" 13 "basal ganglia: 10.7;hypothalamus: 32.7;midbrain: 14.3;pons and medulla: 12.8;thalamus: 8.5" HPA042302 Enhanced "Secreted in other tissues" 1300000 "HPA042302: " "unprognostic (5.75e-2)" "unprognostic (2.23e-1)" "unprognostic (4.37e-2)" "unprognostic (2.99e-2)" "prognostic unfavourable (3.04e-5)" "unprognostic (7.19e-3)" "unprognostic (1.94e-1)" "unprognostic (5.49e-3)" "unprognostic (3.71e-1)" "unprognostic (2.01e-1)" "unprognostic (1.42e-1)" "unprognostic (1.40e-1)" "prognostic favourable (4.44e-5)" "unprognostic (1.82e-1)" "unprognostic (1.09e-1)" "unprognostic (2.00e-1)" "unprognostic (3.20e-2)" 1.2 0.1 0.3 1.5 3.0 0.0 10.6 0.2 0.6 352.3 11.0 0.4 143.4 0.7 19.4 385.4 4.5 44.6 10.4 0.4 0.3 0.3 135.1 9.9 31.6 0.2 0.3 0.3 20.4 5.0 5.0 14.9 1.3 0.5 27.2 14.7 2.2 343.7 60.9 0.2 2.8 5.0 10.9 0.2 0.1 3.8 15.6 0.5 0.7 45.5 15.3 29.1 21.9 6.9 0.0 1.2 0.0 0.0 0.0 0.0 0.1 26.2 0.0 0.1 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 1.1 49.1 0.0 41.0 0.0 35.8 0.0 0.0 0.0 0.2 0.4 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.1 0.0 0.0 0.1 0.0 1.4 0.0 0.6 4.3 0.0 0.0 0.0 0.0 38.1 0.3 1.2 0.2 2.4 0.0 0.2 0.7 0.1 0.0 0.0 0.6 0.1 0.1 0.1 0.1 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.1 0.3 3.0 0.2 0.6 0.3 0.3 0.3 0.3 0.5 0.5 WISP1 "CCN4, WISP-1, WISP1-OT1, WISP1-UT1" ENSG00000104415 "WNT1 inducible signaling pathway protein 1" O95388 8 133191039-133231690 "Cancer-related genes, Predicted secreted proteins" "Cell adhesion, Wnt signaling pathway" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in some" "HHSteC: 7.9;HSkMC: 44.5;hTEC/SVTERT24-B: 25.4;U-2197: 24.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in some" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in single" 6 "olfactory region: 11.9" "Not detected" "Not detected" "HPA007121, CAB012205" Uncertain Approved Cytosol "Secreted to extracellular matrix" Cytosol "CAB012205: , HPA007121: AB_1858844" "unprognostic (7.77e-2)" "unprognostic (2.05e-1)" "unprognostic (3.30e-2)" "unprognostic (3.20e-1)" "unprognostic (7.72e-2)" "unprognostic (6.63e-2)" "unprognostic (8.61e-3)" "unprognostic (3.26e-2)" "unprognostic (2.07e-3)" "unprognostic (1.41e-3)" "unprognostic (3.01e-2)" "unprognostic (2.67e-1)" "prognostic unfavourable (1.91e-5)" "unprognostic (7.52e-3)" "unprognostic (2.55e-3)" "unprognostic (6.03e-2)" "unprognostic (5.67e-3)" 4.2 11.0 0.6 7.7 1.6 0.0 2.3 0.6 2.9 14.7 3.9 1.0 0.0 1.2 18.5 6.4 2.2 6.5 8.5 4.0 0.7 0.3 18.0 2.9 8.9 13.4 0.8 0.4 13.0 1.0 0.2 2.7 3.5 1.2 3.4 0.9 4.5 1.3 4.2 2.0 1.6 3.9 14.4 6.2 14.6 3.8 3.7 0.4 0.3 1.3 2.7 4.2 14.4 4.1 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 3.0 1.7 0.0 0.0 3.2 0.0 0.0 0.0 0.0 0.0 0.0 2.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.9 0.0 0.0 44.5 0.0 25.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 5.9 0.3 24.3 0.0 0.0 0.0 0.0 4.9 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.6 1.6 0.6 2.9 0.7 0.3 0.8 0.4 1.2 0.4 WNT2 "INT1L1, IRP" ENSG00000105989 "Wnt family member 2" P09544 7 117276631-117323289 "Cancer-related genes, Predicted secreted proteins" "Wnt signaling pathway" "Developmental protein" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "endometrium 1: 10.4;lung: 10.9;placenta: 40.9" "Cell line enriched" "Detected in some" 5 "U-2197: 21.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in some" "Not detected" "Not detected" "Not detected" "Not detected" "Region enhanced" "Detected in many" "basal ganglia: 12.6" "Low region specificity" "Detected in all" HPA020920 Approved Vesicles "Secreted to extracellular matrix" Vesicles "HPA020920: AB_1858850" "unprognostic (1.90e-1)" "unprognostic (6.97e-2)" "unprognostic (2.88e-2)" "unprognostic (4.11e-3)" "unprognostic (9.14e-2)" "unprognostic (2.47e-1)" "unprognostic (2.54e-2)" "unprognostic (2.75e-1)" "unprognostic (2.74e-1)" "unprognostic (5.70e-2)" "unprognostic (1.36e-2)" "unprognostic (1.41e-1)" "unprognostic (3.43e-1)" "unprognostic (4.05e-2)" "unprognostic (2.50e-2)" "unprognostic (1.05e-1)" "unprognostic (2.10e-1)" 1.8 0.0 0.2 0.1 1.1 0.0 1.4 0.3 2.3 3.0 0.2 0.4 0.4 0.0 10.4 2.7 0.4 1.0 0.2 0.7 0.9 0.9 0.3 0.8 10.9 0.0 0.1 0.5 0.8 0.1 0.0 0.2 40.9 0.5 7.6 0.0 0.9 0.1 0.5 0.0 1.1 0.2 1.2 0.2 1.5 0.1 0.7 0.0 0.0 0.2 0.0 0.1 1.8 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.7 0.0 1.4 2.1 0.0 0.0 0.0 0.0 3.9 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.1 0.0 0.0 2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 21.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 1.1 0.3 2.3 0.9 0.9 0.1 0.5 0.5 0.0 WRN "RECQ3, RECQL2" ENSG00000165392 "Werner syndrome RecQ like helicase" Q14191 8 31033801-31173769 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "DNA damage, DNA repair" "DNA-binding, Exonuclease, Helicase, Hydrolase, Multifunctional enzyme, Nuclease" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA028661 Approved Supported "Nuclear speckles" "Nuclear speckles" "HPA028661: AB_10602255" "unprognostic (8.73e-2)" "unprognostic (9.33e-2)" "unprognostic (1.51e-3)" "unprognostic (3.85e-2)" "unprognostic (1.41e-1)" "unprognostic (1.85e-2)" "unprognostic (2.21e-3)" "unprognostic (1.25e-1)" "unprognostic (1.07e-1)" "unprognostic (1.16e-2)" "unprognostic (1.27e-2)" "unprognostic (6.63e-2)" "unprognostic (1.53e-2)" "unprognostic (6.51e-2)" "unprognostic (2.49e-1)" "unprognostic (1.00e-2)" "unprognostic (2.66e-1)" 10.1 9.2 5.6 8.5 6.6 15.6 11.1 10.7 7.3 14.2 8.0 7.7 7.7 5.5 24.4 8.8 7.6 9.7 6.9 7.0 5.9 4.0 5.1 7.7 7.2 6.7 8.2 5.3 12.0 9.9 7.8 28.1 8.5 7.0 8.6 7.8 8.3 10.8 7.8 7.7 10.2 7.0 12.1 14.9 8.9 8.3 10.4 7.3 11.8 7.9 6.3 9.3 10.8 8.7 3.9 2.7 1.3 1.9 2.9 6.2 1.6 6.4 6.3 13.1 8.3 7.8 12.5 8.3 7.3 7.1 8.9 9.3 4.0 3.9 15.1 6.7 7.3 3.3 8.1 5.2 13.4 4.2 6.9 15.4 6.0 3.3 9.8 9.1 5.7 9.1 5.8 8.5 10.2 8.6 24.3 9.6 8.2 4.1 18.9 4.4 11.2 4.6 10.9 9.9 6.0 3.7 7.0 2.8 7.5 8.8 5.0 6.9 3.5 4.5 13.7 9.7 6.0 5.0 6.1 2.5 2.7 19.0 7.2 7.2 6.6 1.2 1.9 1.3 3.3 1.9 6.2 3.9 3.8 3.3 2.7 3.5 2.5 3.2 0.5 2.9 0.8 2.0 2.8 1.6 5.6 6.6 10.7 7.3 5.9 4.0 8.2 5.3 7.0 7.3 WT1 "AWT1, GUD, NPHS4, WAGR, WIT-2" ENSG00000184937 "Wilms tumor 1" P19544 11 32387775-32435630 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, RNA-binding" "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "endometrium 1: 69.0;fallopian tube: 34.5;ovary: 53.4" "Cell line enhanced" "Detected in some" "HEL: 13.2;HMC-1: 17.0;K-562: 11.9;NB-4: 31.9;THP-1: 15.3" "Cancer enriched" "Detected in many" 14 "ovarian cancer: 55.2" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Region enhanced" "Detected in single" "pons and medulla: 0.5" "Low region specificity" "Detected in single" "CAB000327, HPA035717, HPA053848" Enhanced Enhanced Nucleoplasm Nucleoplasm "CAB000327: AB_2304486, HPA035717: , HPA053848: " "unprognostic (3.09e-3)" "unprognostic (9.97e-4)" "unprognostic (3.32e-1)" "unprognostic (8.24e-3)" "unprognostic (5.20e-2)" "unprognostic (1.98e-3)" "unprognostic (2.94e-2)" "unprognostic (1.59e-2)" "unprognostic (1.23e-2)" "unprognostic (4.15e-2)" "unprognostic (1.86e-2)" "unprognostic (1.36e-1)" "unprognostic (1.31e-10)" "unprognostic (2.65e-3)" "unprognostic (1.87e-1)" "unprognostic (1.96e-3)" "unprognostic (1.30e-2)" 10.3 0.0 0.2 1.8 0.6 0.0 0.2 0.2 0.5 20.3 1.5 0.2 3.7 0.0 69.0 9.3 0.4 34.5 0.8 2.1 0.9 0.0 5.3 0.2 0.8 0.5 0.2 0.2 53.4 0.2 0.0 0.2 6.9 0.3 0.9 0.0 0.2 0.2 4.2 0.2 0.0 0.4 23.7 0.2 14.6 0.0 24.5 0.2 0.2 0.3 0.2 0.2 1.3 4.1 0.1 0.0 0.0 0.4 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.3 0.0 0.1 0.1 0.0 0.0 6.1 0.0 0.0 0.0 4.6 13.2 0.0 1.1 3.7 8.8 17.0 0.0 0.0 2.7 0.0 0.0 11.9 0.1 2.7 0.0 7.7 31.9 0.7 3.7 1.1 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.8 15.3 0.1 0.0 2.3 0.0 0.3 0.0 0.0 0.0 0.1 2.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.2 0.6 0.2 0.5 0.9 0.0 0.2 0.2 0.3 0.2 WWTR1 "DKFZp586I1419, TAZ" ENSG00000018408 "WW domain containing transcription regulator 1" Q9GZV5 3 149517235-149736714 "Cancer-related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" Activator "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "EFO-21: 59.8;SK-MEL-30: 41.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "gdT-cell: 2.6;memory CD8 T-cell: 2.8" "Lineage enriched" "Detected in single" 4 "T-cells: 2.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA007415, CAB017483, CAB068248" Enhanced Supported "Nucleoplasm,Nuclear bodies,Cytosol" "Nucleoplasm, Nuclear bodies" Cytosol "CAB017483: AB_2216639, CAB068248: , HPA007415: AB_1080602" "unprognostic (1.85e-2)" "unprognostic (2.24e-2)" "unprognostic (3.41e-3)" "unprognostic (1.33e-2)" "unprognostic (7.94e-2)" "unprognostic (1.37e-1)" "unprognostic (2.41e-2)" "unprognostic (2.22e-1)" "unprognostic (1.74e-2)" "unprognostic (2.34e-1)" "unprognostic (1.63e-2)" "unprognostic (3.32e-1)" "unprognostic (1.17e-3)" "unprognostic (2.76e-2)" "unprognostic (2.53e-1)" "unprognostic (3.98e-2)" "unprognostic (1.01e-3)" 25.1 9.9 9.3 16.0 18.6 0.2 20.4 7.7 10.5 27.2 38.5 18.4 15.0 5.6 27.2 17.6 41.2 16.4 25.8 20.6 14.7 9.0 31.0 13.1 29.8 6.2 15.2 5.6 30.9 21.7 10.4 8.5 29.0 20.7 34.6 9.1 29.4 15.8 22.4 12.1 13.4 11.7 81.5 25.8 13.8 20.8 12.0 16.4 0.7 18.2 13.2 7.1 68.4 31.0 0.2 0.1 0.6 0.1 0.1 2.8 0.4 16.5 19.7 10.5 13.9 12.5 22.4 11.0 9.6 14.1 4.4 4.6 11.0 14.0 0.0 59.8 10.8 9.8 6.8 7.0 4.3 4.6 5.2 0.0 5.1 9.1 7.1 0.0 0.0 11.8 1.8 15.2 6.6 33.9 0.0 0.0 15.1 2.2 0.0 0.0 2.4 24.9 0.0 14.0 0.1 37.2 2.4 0.0 0.1 6.3 4.5 41.3 7.6 0.3 27.6 8.6 4.1 6.9 18.8 0.1 0.1 0.2 18.4 0.0 21.8 0.4 0.1 0.1 2.6 0.0 0.0 0.0 0.3 2.8 0.0 0.2 0.1 1.3 0.6 0.1 0.0 0.1 1.9 0.4 9.3 18.6 7.7 10.5 14.7 9.0 15.2 5.6 20.7 16.4 XIAP "API3, BIRC4, hILP" ENSG00000101966 "X-linked inhibitor of apoptosis" P98170 X 123859724-123913979 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Apoptosis, Ubl conjugation pathway, Wnt signaling pathway" "Protease inhibitor, Thiol protease inhibitor, Transferase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "CAB009203, HPA042428" Approved Supported "Nucleoplasm,Plasma membrane,Cytosol" "Nucleoplasm, Cytosol" "Plasma membrane" "CAB009203: AB_2257167, HPA042428: " "prognostic unfavourable (9.21e-4)" "unprognostic (8.43e-2)" "unprognostic (1.50e-2)" "unprognostic (2.14e-1)" "unprognostic (1.40e-1)" "unprognostic (9.41e-2)" "unprognostic (1.95e-2)" "unprognostic (8.51e-2)" "unprognostic (9.17e-2)" "unprognostic (3.90e-2)" "unprognostic (7.50e-2)" "unprognostic (4.41e-2)" "unprognostic (3.15e-3)" "unprognostic (8.21e-3)" "unprognostic (2.26e-1)" "unprognostic (4.99e-2)" "unprognostic (4.65e-2)" 17.4 14.4 20.0 18.1 20.2 12.0 15.9 21.3 18.9 17.2 19.4 14.5 22.9 16.1 17.4 17.0 18.9 12.6 14.7 15.7 18.9 22.1 19.8 19.4 16.5 15.5 18.8 14.6 13.9 19.7 36.6 26.1 18.2 15.9 15.6 16.8 16.9 14.6 22.9 21.5 14.2 23.4 17.0 19.0 15.8 16.2 7.0 12.3 13.9 24.3 11.4 14.0 15.4 20.5 5.7 4.3 11.1 3.9 3.3 5.5 1.9 11.5 9.9 7.8 6.7 9.2 11.9 10.2 12.6 9.4 6.9 5.9 4.4 13.6 10.8 18.7 10.7 4.3 11.5 7.9 12.7 11.2 6.3 7.3 8.3 6.7 11.7 13.2 15.2 8.2 12.3 11.4 14.7 9.5 11.5 12.5 13.3 12.0 7.3 6.4 6.4 7.8 7.9 9.1 11.4 10.4 16.8 5.3 7.7 17.2 10.0 10.1 6.1 6.5 11.7 0.3 4.7 20.6 14.0 10.5 10.5 12.0 14.2 9.4 8.7 11.1 2.6 3.5 5.0 2.3 4.7 4.6 3.8 5.5 1.4 5.7 4.4 3.0 8.2 3.3 3.9 4.3 2.5 1.9 20.0 20.2 21.3 18.9 18.9 22.1 18.8 14.6 15.9 12.3 XIRP2 CMYA3 ENSG00000163092 "Xin actin binding repeat containing 2" A4UGR9 2 166888487-167259753 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" Actin-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 6 "skeletal muscle: 292.8" "Cell line enhanced" "Detected in some" "AN3-CA: 3.2;HEL: 1.5;HUVEC TERT2: 8.5;U-2197: 6.0" "Cancer enriched" "Detected in some" 5 "head and neck cancer: 3.4" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "HPA034813, HPA074599" Enhanced Approved "Nucleoplasm,Plasma membrane" "Plasma membrane" Nucleoplasm "HPA034813: AB_10602588, HPA074599: " "unprognostic (5.27e-4)" "unprognostic (5.96e-3)" "unprognostic (7.42e-2)" "unprognostic (2.42e-1)" "unprognostic (1.74e-1)" "unprognostic (2.56e-1)" 7.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.6 3.3 0.0 0.0 24.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 4.3 0.0 292.8 0.0 0.0 0.0 0.0 0.1 0.0 0.6 0.0 0.0 2.3 51.0 2.9 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 3.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 1.5 0.0 0.2 0.2 0.0 0.0 0.9 0.0 0.2 0.7 8.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 6.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 XPA "XP1, XPAC" ENSG00000136936 "XPA, DNA damage recognition and repair factor" P23025 9 97674909-97697357 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "DNA damage, DNA repair" DNA-binding "Cancer-related genes, Disease mutation, Xeroderma pigmentosum" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000155, HPA056856" Supported Approved "Nucleoplasm,Cytokinetic bridge" Nucleoplasm "Cytokinetic bridge" "CAB000155: , HPA056856: " "unprognostic (8.76e-2)" "unprognostic (1.05e-3)" "unprognostic (1.60e-1)" "unprognostic (2.30e-2)" "unprognostic (4.17e-1)" "unprognostic (1.84e-1)" "unprognostic (5.26e-2)" "unprognostic (2.38e-1)" "unprognostic (3.90e-2)" "unprognostic (1.28e-1)" "unprognostic (1.97e-3)" "unprognostic (9.55e-3)" "prognostic favourable (4.28e-5)" "unprognostic (2.19e-2)" "unprognostic (1.56e-1)" "unprognostic (3.03e-2)" "unprognostic (1.17e-1)" 18.7 17.5 20.1 17.1 21.0 10.6 17.4 26.8 20.8 20.3 25.2 17.2 11.7 20.6 25.5 15.4 18.9 15.0 19.5 12.9 17.2 15.3 24.9 24.2 14.8 16.7 18.6 17.5 17.2 14.5 23.0 23.1 12.8 17.7 20.3 13.6 16.4 16.1 21.7 43.3 16.3 22.2 27.5 17.1 16.2 25.1 6.4 15.8 15.7 31.5 11.9 21.6 22.0 16.4 22.2 23.4 12.7 15.8 19.7 21.6 11.3 23.4 5.5 8.2 10.1 10.1 9.8 5.7 6.4 10.1 11.7 7.9 14.3 19.7 13.2 6.2 7.0 11.8 6.5 7.7 9.9 9.0 13.1 10.4 12.0 7.9 11.0 12.2 12.6 8.5 8.4 5.4 5.6 13.0 14.3 10.4 6.4 7.3 15.9 14.8 5.6 9.2 16.3 17.6 11.2 18.6 9.2 11.6 11.6 9.1 7.1 8.3 10.2 7.5 8.1 4.1 10.2 16.2 13.8 18.4 14.7 8.3 10.2 8.8 8.0 6.0 13.3 12.7 16.2 13.1 18.7 19.5 17.7 15.6 13.5 22.2 21.6 18.6 1.5 19.7 15.8 23.4 18.3 11.3 20.1 21.0 26.8 20.8 17.2 15.3 18.6 17.5 17.7 15.8 XPC "RAD4, XPCC" ENSG00000154767 "XPC complex subunit, DNA damage recognition and repair factor" Q01831 3 14145147-14178783 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA repair, Transcription, Transcription regulation" DNA-binding "Cancer-related genes, Disease mutation, Xeroderma pigmentosum" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009932, HPA035707, HPA069673" Supported Enhanced "Nucleoplasm,Plasma membrane" Nucleoplasm "Plasma membrane" "CAB009932: AB_2241587, HPA035707: , HPA069673: " "unprognostic (7.46e-2)" "unprognostic (2.52e-2)" "unprognostic (4.50e-2)" "unprognostic (3.01e-1)" "unprognostic (6.63e-2)" "unprognostic (2.54e-2)" "unprognostic (1.97e-1)" "unprognostic (5.65e-2)" "unprognostic (1.50e-1)" "unprognostic (7.13e-3)" "unprognostic (4.39e-2)" "unprognostic (2.07e-1)" "prognostic favourable (4.14e-7)" "unprognostic (1.59e-1)" "unprognostic (7.88e-2)" "unprognostic (7.62e-2)" "prognostic favourable (2.46e-4)" 20.2 17.1 14.2 24.0 30.2 8.4 21.4 16.1 19.3 22.3 18.9 20.8 27.5 18.0 24.6 18.3 16.9 24.9 25.1 12.4 16.2 14.4 24.6 23.4 19.9 21.1 33.4 15.2 35.0 20.9 35.4 26.7 28.0 22.1 20.9 15.9 16.7 17.6 30.3 22.4 30.5 23.6 17.7 22.6 23.3 15.9 12.9 30.6 18.5 25.7 12.4 20.8 22.4 22.3 10.9 7.0 34.6 8.8 8.8 12.2 6.1 4.4 11.5 13.0 8.3 19.5 13.5 44.0 11.1 32.0 10.8 8.4 4.2 5.4 15.0 4.9 13.5 5.6 8.5 17.8 8.9 6.0 7.3 7.9 12.2 7.7 17.3 5.9 15.1 19.1 21.1 14.3 28.8 12.8 10.9 8.1 12.0 9.4 4.9 5.7 7.7 7.8 6.2 5.9 12.0 13.6 13.4 2.8 10.1 12.1 10.1 8.0 10.6 4.8 20.0 4.2 11.4 6.3 5.1 18.7 13.6 8.9 10.0 7.0 15.1 12.0 8.2 9.4 9.8 6.3 9.6 10.7 11.2 9.6 7.0 10.9 12.2 8.7 34.6 8.8 8.8 6.7 9.2 6.1 14.2 30.2 16.1 19.3 16.2 14.4 33.4 15.2 22.1 30.6 XPO1 "CRM1, emb" ENSG00000082898 "Exportin 1" O14980 2 61477849-61538626 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters" "Host-virus interaction, mRNA transport, Protein transport, Transport" RNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010184, HPA042933" Supported Enhanced "Nucleoplasm,Nuclear membrane,Vesicles,Cytosol" 170000 "Nucleoplasm, Nuclear membrane" "Vesicles, Cytosol" "CAB010184: AB_2215817, HPA042933: " "unprognostic (7.34e-2)" "unprognostic (7.04e-2)" "unprognostic (6.37e-2)" "unprognostic (1.67e-2)" "unprognostic (5.61e-2)" "unprognostic (1.28e-1)" "prognostic unfavourable (1.84e-5)" "unprognostic (1.84e-1)" "unprognostic (1.99e-3)" "unprognostic (4.43e-1)" "unprognostic (3.53e-3)" "unprognostic (4.90e-2)" "prognostic unfavourable (3.74e-4)" "unprognostic (5.69e-2)" "unprognostic (2.08e-1)" "unprognostic (2.43e-1)" "unprognostic (5.55e-2)" 20.7 27.9 36.1 28.1 39.6 21.6 35.1 41.5 36.3 28.2 23.2 19.5 26.0 16.5 35.7 35.3 26.1 36.0 20.3 20.1 33.0 19.2 19.5 22.2 22.0 34.5 42.0 19.5 45.0 34.6 33.4 27.6 30.8 33.6 25.8 24.5 18.0 20.2 29.9 34.9 29.8 25.0 28.4 32.1 24.5 21.9 32.1 39.3 51.1 28.2 16.4 35.7 26.0 57.8 6.1 5.4 12.6 5.1 6.2 5.1 2.5 38.8 34.7 47.1 35.3 21.4 28.7 34.7 43.0 27.7 45.2 38.8 46.1 29.2 57.0 30.1 29.4 33.0 71.8 29.8 66.7 34.8 26.4 56.1 35.8 28.8 15.5 56.5 38.4 16.2 22.3 35.7 39.0 36.9 64.7 33.3 41.6 20.4 47.0 24.8 54.8 26.6 42.1 53.8 34.6 20.6 29.5 37.7 20.0 41.8 35.4 20.9 28.9 27.9 24.6 42.5 48.3 34.6 42.2 27.0 44.6 82.7 26.4 48.5 38.3 12.6 5.1 5.8 5.1 5.0 4.7 4.3 3.6 4.5 3.9 6.1 4.3 3.7 12.4 6.2 3.2 5.4 3.2 2.5 36.1 39.6 41.5 36.3 33.0 19.2 42.0 19.5 33.6 39.3 XRCC1 RCC ENSG00000073050 "X-ray repair cross complementing 1" P18887 19 43543040-43580473 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "DNA damage, DNA repair" "Cancer-related genes, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB005427, HPA006717" Supported Enhanced Nucleoplasm Nucleoplasm "CAB005427: AB_2215661, HPA006717: AB_1858896" "unprognostic (1.10e-2)" "unprognostic (3.51e-3)" "unprognostic (4.59e-1)" "unprognostic (2.81e-2)" "unprognostic (4.08e-1)" "unprognostic (2.68e-2)" "prognostic unfavourable (7.33e-5)" "unprognostic (5.07e-2)" "unprognostic (3.12e-1)" "unprognostic (7.51e-2)" "unprognostic (3.00e-2)" "unprognostic (9.54e-2)" "unprognostic (1.07e-1)" "unprognostic (2.28e-1)" "unprognostic (9.34e-3)" "unprognostic (2.20e-2)" "unprognostic (5.69e-2)" 16.6 17.5 20.8 18.7 22.4 22.4 16.9 23.6 22.7 20.3 17.4 19.2 18.0 13.6 23.8 18.9 20.2 24.9 16.9 15.7 16.5 16.3 16.3 10.4 16.3 22.8 15.8 21.1 34.2 22.1 19.4 32.0 19.7 15.7 16.7 12.6 21.8 16.4 19.2 18.8 20.4 14.2 18.8 15.3 19.5 17.2 25.0 17.9 38.9 21.5 12.0 21.6 18.1 17.2 14.2 13.6 20.3 14.2 10.6 17.7 12.9 25.2 20.8 24.7 22.0 12.1 11.3 13.1 14.2 16.1 18.8 20.5 13.0 18.5 19.1 18.1 12.6 13.1 14.7 16.3 11.2 21.0 15.1 24.4 20.3 15.1 12.2 13.7 21.2 13.1 11.2 23.7 11.9 16.8 15.3 19.4 16.5 20.9 28.3 24.7 7.7 9.2 23.8 15.4 10.9 16.0 20.2 20.4 13.0 17.6 17.3 8.5 16.3 33.7 9.4 24.9 19.4 7.4 17.6 21.4 20.6 14.0 20.1 12.4 27.0 20.3 14.2 16.8 12.9 13.4 14.6 14.2 16.1 17.7 13.6 12.6 14.0 12.8 16.3 10.6 8.3 10.5 16.2 12.9 20.8 22.4 23.6 22.7 16.5 16.3 15.8 21.1 15.7 17.9 XRCC2 FANCU ENSG00000196584 "X-ray repair cross complementing 2" O43543 7 152644779-152676165 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "DNA damage, DNA recombination, DNA repair" DNA-binding "Cancer-related genes, Fanconi anemia" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 12.7;testis: 11.7" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA065153 Approved Nucleoplasm,Vesicles "Nucleoplasm, Vesicles" "HPA065153: " "unprognostic (9.31e-3)" "unprognostic (8.25e-2)" "unprognostic (1.62e-1)" "unprognostic (5.53e-3)" "unprognostic (9.10e-2)" "unprognostic (2.52e-2)" "unprognostic (3.36e-5)" "unprognostic (9.98e-3)" "unprognostic (5.82e-3)" "unprognostic (4.04e-3)" "unprognostic (1.06e-3)" "unprognostic (2.43e-2)" "unprognostic (1.55e-15)" "unprognostic (4.52e-3)" "unprognostic (3.01e-1)" "unprognostic (5.14e-1)" "unprognostic (1.73e-2)" 1.3 1.3 3.4 4.5 2.0 5.4 2.4 4.4 2.6 1.6 1.5 2.5 0.6 1.1 1.9 2.2 2.6 1.3 0.6 2.5 3.3 1.1 1.1 1.3 1.4 3.0 1.9 1.9 2.0 1.2 0.4 1.3 7.2 2.7 1.5 2.9 0.6 1.5 1.3 1.1 1.6 1.9 1.3 1.8 1.8 1.5 11.7 2.2 12.7 1.2 1.1 3.6 1.3 1.6 1.8 1.0 3.1 1.1 1.1 1.6 0.6 7.4 4.5 6.6 7.1 0.8 0.7 7.6 5.4 1.9 4.7 4.6 5.6 6.5 10.6 4.2 2.1 5.4 5.3 4.4 8.5 5.0 5.5 7.6 6.0 3.1 0.3 11.3 3.7 0.5 0.4 7.6 2.0 1.6 15.7 9.1 2.7 5.2 10.4 2.7 8.7 4.0 8.4 8.8 5.9 1.4 4.9 6.3 6.0 6.0 2.6 1.1 2.2 2.4 3.1 6.2 2.8 5.8 9.9 3.3 6.4 9.3 3.3 6.1 8.1 2.0 0.9 1.5 1.6 0.6 1.1 1.3 1.3 1.1 0.3 1.8 1.6 0.8 3.1 1.1 1.1 1.0 1.5 0.6 3.4 2.0 4.4 2.6 3.3 1.1 1.9 1.9 2.7 2.2 XRCC3 ENSG00000126215 "X-ray repair cross complementing 3" O43542 14 103697609-103715504 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "DNA damage, DNA recombination, DNA repair" DNA-binding "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skin 1: 30.3" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA062422, HPA068953" Enhanced Nucleoplasm Nucleoplasm "HPA062422: , HPA068953: " "unprognostic (2.52e-2)" "unprognostic (1.81e-3)" "unprognostic (6.75e-2)" "unprognostic (4.01e-2)" "unprognostic (4.29e-1)" "unprognostic (1.83e-1)" "unprognostic (2.53e-4)" "unprognostic (2.93e-2)" "unprognostic (4.67e-2)" "unprognostic (1.58e-2)" "unprognostic (4.46e-2)" "unprognostic (2.53e-2)" "unprognostic (3.52e-7)" "unprognostic (1.27e-1)" "unprognostic (1.57e-1)" "unprognostic (8.84e-2)" "unprognostic (3.72e-2)" 5.4 3.3 8.1 15.1 7.3 22.0 5.4 11.3 8.0 5.5 5.8 6.5 4.6 5.4 6.4 5.1 8.5 6.1 5.3 4.4 6.9 2.6 4.1 3.8 6.0 11.1 7.3 5.4 7.0 7.8 2.1 4.4 5.6 6.8 7.7 6.2 5.3 11.1 2.9 8.9 30.3 7.0 2.3 5.3 13.5 6.8 10.1 5.0 17.6 5.6 6.7 14.2 5.3 9.0 4.5 2.0 3.0 3.3 2.5 3.9 3.6 12.6 23.1 12.7 15.8 1.1 3.3 23.1 14.0 4.6 19.8 21.4 12.8 20.3 20.1 12.1 2.9 20.2 13.9 20.8 12.2 12.4 14.4 19.6 11.3 11.8 2.0 17.6 12.8 2.5 2.1 17.4 11.1 8.1 12.1 12.4 10.2 27.6 30.4 13.9 11.0 16.5 24.8 18.4 7.9 4.4 17.4 12.6 10.4 16.5 8.9 5.7 14.1 13.7 6.9 10.3 12.1 32.7 15.3 10.6 9.6 25.0 6.4 14.6 15.8 2.6 1.6 3.0 3.8 3.3 3.9 4.5 3.3 3.2 2.0 4.0 3.3 2.2 1.2 2.5 2.5 1.4 2.5 3.6 8.1 7.3 11.3 8.0 6.9 2.6 7.3 5.4 6.8 5.0 XRCC4 ENSG00000152422 "X-ray repair cross complementing 4" Q13426 5 83077498-83353787 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "DNA damage, DNA recombination, DNA repair" "Cancer-related genes, Disease mutation, Dwarfism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "RH-30: 36.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA006801, HPA051538" Supported Enhanced Nucleoplasm Nucleoplasm "HPA006801: AB_1858899, HPA051538: " "prognostic unfavourable (1.80e-5)" "unprognostic (3.05e-2)" "unprognostic (5.12e-2)" "unprognostic (3.91e-3)" "unprognostic (1.55e-1)" "unprognostic (1.69e-1)" "unprognostic (1.44e-3)" "unprognostic (2.23e-2)" "unprognostic (2.19e-2)" "unprognostic (5.77e-2)" "unprognostic (2.38e-2)" "unprognostic (8.24e-2)" "unprognostic (4.46e-2)" "unprognostic (1.79e-1)" "unprognostic (1.97e-1)" "unprognostic (2.34e-1)" "unprognostic (6.91e-2)" 8.8 9.4 8.1 12.9 10.1 5.9 9.4 4.8 10.2 5.3 9.1 7.2 5.4 11.4 8.3 7.7 10.1 6.2 8.1 13.0 8.5 6.6 12.2 8.1 7.6 11.7 8.7 5.8 5.8 4.9 4.0 9.5 11.3 11.5 6.3 8.8 3.7 7.2 7.1 5.3 5.7 15.4 5.9 9.5 14.6 6.4 12.5 8.8 20.6 7.4 9.7 12.9 8.7 5.8 7.4 10.3 12.3 19.1 11.5 7.0 6.8 8.5 6.7 8.3 7.3 4.7 6.9 7.8 8.1 6.7 9.0 10.7 5.7 12.7 12.2 6.1 6.5 7.5 5.5 18.4 14.9 5.6 6.8 6.2 5.1 7.2 3.2 7.0 10.2 4.7 8.4 11.7 6.5 7.2 4.5 5.7 10.3 6.8 12.8 9.0 4.6 10.0 10.7 36.4 12.2 8.3 3.9 5.4 7.0 5.1 3.8 10.3 7.7 11.4 4.5 4.9 10.5 5.2 10.8 4.6 6.8 15.0 8.8 12.6 7.9 12.1 13.5 9.2 4.7 19.1 4.9 7.4 5.2 5.2 10.3 6.3 7.0 5.6 12.3 11.5 17.8 7.6 5.6 6.8 8.1 10.1 4.8 10.2 8.5 6.6 8.7 5.8 11.5 8.8 XRCC5 "KARP-1, KU80, Ku86, KUB2" ENSG00000079246 "X-ray repair cross complementing 5" P13010 2 216107464-216206303 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA recombination, DNA repair, Host-virus interaction, Immunity, Innate immunity, Transcription, Transcription regulation" "Activator, DNA-binding, Helicase, Hydrolase" "Cancer-related genes, Systemic lupus erythematosus" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004468, HPA025813, HPA064685" Supported Enhanced Nucleoplasm 140000 Nucleoplasm "CAB004468: AB_672929, HPA025813: AB_1858901, HPA064685: " "unprognostic (4.23e-2)" "unprognostic (1.75e-1)" "unprognostic (9.07e-3)" "unprognostic (3.44e-3)" "unprognostic (2.44e-2)" "unprognostic (7.00e-2)" "prognostic unfavourable (2.10e-7)" "unprognostic (4.42e-3)" "unprognostic (1.38e-1)" "unprognostic (1.06e-1)" "unprognostic (3.38e-3)" "unprognostic (1.96e-1)" "unprognostic (1.08e-1)" "unprognostic (2.30e-1)" "unprognostic (2.88e-2)" "unprognostic (3.58e-2)" "unprognostic (6.01e-2)" 53.7 47.6 35.2 47.0 56.8 47.0 56.6 47.0 59.7 51.2 44.3 45.2 39.5 39.5 62.9 43.8 61.1 51.7 41.2 43.7 38.6 36.4 62.4 67.1 43.8 56.2 41.8 45.2 58.7 46.7 63.0 56.1 54.3 58.3 46.0 53.5 36.1 49.4 47.9 65.0 54.7 46.5 49.7 44.2 60.5 47.9 36.9 38.0 112.4 64.2 55.6 65.5 56.5 47.7 38.6 51.5 60.9 61.3 50.4 54.0 82.3 38.4 32.7 73.5 39.3 32.7 37.5 44.4 45.9 47.5 53.1 57.3 70.2 38.4 37.3 37.5 40.1 34.5 72.2 55.6 81.9 35.5 49.7 80.9 51.7 65.6 40.5 72.0 39.6 34.1 29.7 62.3 27.3 62.5 51.0 34.1 69.1 37.1 80.4 36.3 85.3 29.2 70.8 65.0 30.8 57.1 43.9 64.4 54.4 36.9 27.4 33.1 33.6 54.1 45.0 50.0 42.1 32.6 51.9 41.3 50.1 83.3 38.9 56.6 49.0 60.9 51.5 51.8 50.2 54.0 54.0 38.6 49.1 50.9 51.5 37.5 49.9 49.8 59.4 50.4 61.3 31.4 49.3 82.3 35.2 56.8 47.0 59.7 38.6 36.4 41.8 45.2 58.3 38.0 XRCC6 "D22S671, D22S731, G22P1, KU70, ML8" ENSG00000196419 "X-ray repair cross complementing 6" P12956 22 41621119-41664048 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA recombination, DNA repair, Host-virus interaction, Immunity, Innate immunity, Transcription, Transcription regulation" "Activator, DNA-binding, Helicase, Hydrolase, Lyase, Multifunctional enzyme" "Cancer-related genes, Systemic lupus erythematosus" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004254, HPA047549, HPA062226" Enhanced Enhanced Nucleoplasm 24000 Nucleoplasm "CAB004254: AB_628453, HPA047549: AB_2680085, HPA062226: AB_2684716" "unprognostic (5.55e-2)" "unprognostic (2.39e-2)" "unprognostic (1.82e-3)" "unprognostic (2.39e-1)" "unprognostic (2.47e-2)" "unprognostic (9.17e-2)" "unprognostic (1.16e-3)" "unprognostic (2.32e-2)" "unprognostic (2.21e-1)" "unprognostic (2.11e-1)" "unprognostic (1.89e-2)" "unprognostic (1.33e-1)" "unprognostic (2.06e-3)" "unprognostic (1.22e-1)" "unprognostic (2.28e-1)" "unprognostic (4.77e-2)" "unprognostic (7.95e-2)" 49.2 67.9 44.4 47.8 54.3 62.3 49.7 44.5 57.5 51.2 51.3 39.5 44.1 44.7 59.9 41.0 68.6 52.4 35.2 63.0 59.3 39.2 50.1 61.6 48.1 66.9 37.2 50.6 61.5 44.0 48.4 53.1 63.5 51.5 46.1 56.4 39.7 59.2 52.1 100.9 58.6 46.9 58.2 68.4 54.4 50.8 113.6 34.2 83.8 49.5 59.2 70.9 51.4 50.1 51.9 63.7 42.7 57.0 46.6 62.6 96.7 64.2 46.4 64.6 56.2 39.4 35.1 50.9 46.9 56.4 98.6 81.3 68.1 40.8 103.7 39.4 56.8 48.4 89.2 58.7 99.5 57.6 112.0 55.6 56.8 67.5 35.7 131.2 64.4 31.8 40.5 61.5 34.0 61.2 54.2 44.0 63.4 70.7 68.2 49.0 59.3 55.0 78.1 68.0 82.3 55.7 48.2 30.1 21.5 76.2 40.7 54.1 46.7 53.1 43.2 49.3 68.6 43.3 61.5 43.7 76.3 105.7 46.2 52.1 58.2 24.5 50.1 42.7 51.1 57.0 53.5 51.9 56.8 55.8 63.7 48.2 62.6 55.8 13.5 46.6 55.5 37.7 61.8 96.7 44.4 54.3 44.5 57.5 59.3 39.2 37.2 50.6 51.5 34.2 YBX1 "BP-8, CSDA2, CSDB, DBPB, MDR-NF1, NSEP-1, NSEP1, YB-1, YB1" ENSG00000065978 "Y-box binding protein 1" P67809 1 42682427-42702349 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "mRNA processing, mRNA splicing, Transcription, Transcription regulation" "Activator, DNA-binding, Mitogen, Repressor, RNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in all" 4 "skeletal muscle: 128.1;testis: 426.5" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB005875, HPA040304, HPA057159" Approved Enhanced Vesicles,Cytosol "Intracellular and membrane" 870000 Cytosol Vesicles "CAB005875: AB_2219278, HPA040304: AB_10795364, HPA057159: " "unprognostic (8.59e-2)" "unprognostic (5.16e-2)" "unprognostic (9.27e-3)" "unprognostic (2.68e-3)" "unprognostic (7.76e-2)" "unprognostic (8.03e-3)" "prognostic unfavourable (9.87e-10)" "unprognostic (2.80e-2)" "unprognostic (2.31e-2)" "unprognostic (2.79e-3)" "unprognostic (7.51e-2)" "unprognostic (5.52e-2)" "prognostic unfavourable (3.59e-7)" "unprognostic (3.66e-2)" "unprognostic (2.44e-1)" "unprognostic (1.94e-2)" "unprognostic (3.25e-1)" 47.5 20.6 15.6 36.4 18.4 57.6 35.2 13.7 14.4 27.9 44.5 21.2 20.1 25.6 35.1 36.4 40.0 25.6 32.5 57.8 15.2 12.3 33.1 38.1 35.3 49.8 17.6 13.2 30.2 36.7 9.4 12.2 26.1 15.5 32.0 33.1 31.1 26.6 23.0 128.1 22.5 27.1 50.0 21.0 47.9 33.2 426.5 15.9 53.2 31.4 64.1 37.2 39.4 41.0 23.5 26.9 21.8 40.5 11.6 23.0 10.6 91.5 54.0 86.5 86.7 84.3 76.3 77.1 67.6 63.0 94.0 73.8 74.0 85.6 116.2 70.9 67.8 55.5 97.4 102.6 93.4 62.0 90.3 118.6 107.3 94.9 68.0 159.2 88.9 70.2 88.4 93.8 116.2 77.7 123.3 50.7 87.5 57.7 179.8 155.0 195.0 73.0 108.8 155.5 125.6 93.1 67.8 119.7 84.4 66.3 89.8 126.2 29.9 317.1 60.6 66.8 114.0 90.5 137.5 74.3 93.1 132.3 63.2 119.4 70.8 4.3 18.1 21.8 16.3 37.8 19.9 23.5 19.5 15.8 26.9 20.1 16.8 17.2 3.3 11.6 40.5 20.9 23.0 10.6 15.6 18.4 13.7 14.4 15.2 12.3 17.6 13.2 15.5 15.9 YWHAB YWHAA ENSG00000166913 "Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein beta" P31946 20 44885676-44908532 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003759, HPA007925, HPA011212, HPA061603" Enhanced Supported Nucleoplasm,Nucleoli,Cytosol 210000000 Cytosol "Nucleoplasm, Nucleoli" "CAB003759: AB_289588, HPA007925: AB_1844340, HPA011212: AB_1844334, HPA061603: " "prognostic unfavourable (9.18e-4)" "unprognostic (1.48e-1)" "unprognostic (9.06e-2)" "prognostic unfavourable (5.46e-4)" "unprognostic (3.80e-1)" "prognostic unfavourable (6.14e-4)" "prognostic unfavourable (1.91e-6)" "prognostic unfavourable (6.01e-4)" "unprognostic (8.92e-2)" "unprognostic (2.01e-1)" "unprognostic (1.53e-2)" "unprognostic (2.35e-1)" "prognostic favourable (2.52e-5)" "unprognostic (6.72e-2)" "unprognostic (2.40e-1)" "unprognostic (6.60e-3)" "unprognostic (8.59e-2)" 39.3 38.6 65.5 39.4 79.2 28.6 33.0 60.1 87.9 34.0 47.5 27.7 28.7 37.9 35.2 26.4 48.1 30.2 29.6 40.3 68.7 63.4 47.3 36.5 37.4 46.8 49.8 76.2 25.8 18.9 41.1 18.4 36.7 50.1 31.4 53.4 22.9 30.7 43.2 28.3 38.4 39.3 43.3 38.4 53.7 36.7 16.8 33.6 48.2 36.1 31.8 60.2 41.2 34.9 30.9 41.9 37.3 58.4 26.8 43.5 26.6 51.8 39.3 31.7 30.4 52.8 46.7 43.0 47.2 46.0 58.2 51.1 81.8 58.8 55.4 49.5 62.3 55.2 44.7 87.8 69.6 21.2 27.3 41.2 34.6 48.5 35.0 66.7 39.9 36.5 65.7 45.6 58.9 58.2 44.4 26.8 59.7 61.3 52.0 55.0 29.9 61.2 40.9 46.0 43.0 62.3 58.0 33.9 36.1 80.0 85.6 55.1 62.3 64.2 66.0 90.5 46.5 51.0 48.0 17.9 32.6 50.8 66.1 44.7 46.0 34.8 40.1 34.4 29.7 52.2 30.2 30.9 37.7 36.3 41.9 28.6 30.8 36.6 37.3 26.8 58.4 26.5 43.5 26.6 65.5 79.2 60.1 87.9 68.7 63.4 49.8 76.2 50.1 33.6 YWHAE FLJ45465 ENSG00000108953 "Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon" P62258 17 1344272-1400378 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008445, CAB016200, CAB021109, CAB047350, HPA061603" Approved Supported Nucleoplasm,Nucleoli,Cytosol 160000000 Cytosol "Nucleoplasm, Nucleoli" "CAB016200: AB_626619, CAB021109: AB_10060396, CAB047350: , HPA008445: AB_1844336, HPA061603: " "unprognostic (1.29e-1)" "unprognostic (1.50e-1)" "unprognostic (3.99e-2)" "prognostic favourable (6.48e-6)" "unprognostic (1.59e-1)" "unprognostic (2.91e-2)" "unprognostic (2.73e-2)" "unprognostic (4.77e-3)" "unprognostic (4.53e-2)" "unprognostic (5.14e-2)" "unprognostic (1.59e-1)" "unprognostic (2.73e-1)" "unprognostic (1.92e-3)" "unprognostic (8.33e-2)" "unprognostic (2.57e-1)" "unprognostic (3.24e-2)" "unprognostic (8.94e-2)" 55.2 54.3 107.5 35.3 87.1 32.7 37.3 71.5 118.4 28.4 40.2 60.9 23.8 40.2 35.9 54.1 43.1 44.2 23.4 57.7 92.3 81.9 64.5 50.9 32.8 25.4 94.1 77.9 40.2 40.2 41.0 37.9 45.1 73.7 35.0 42.5 27.9 42.4 27.7 135.9 36.8 36.2 32.2 101.1 26.2 38.5 46.0 53.6 30.9 47.5 36.5 37.2 31.6 32.1 19.2 41.5 17.2 36.2 15.0 23.3 31.5 77.8 58.2 70.5 59.3 31.2 36.1 67.8 50.4 29.7 45.0 34.9 104.0 32.0 52.9 59.2 41.7 54.1 59.7 50.9 63.8 36.5 111.3 36.9 48.6 44.5 37.3 35.3 37.8 32.7 37.6 45.0 69.0 54.1 42.3 38.2 57.8 37.9 46.7 28.2 64.6 37.8 56.8 33.3 37.5 45.8 45.1 39.3 59.7 60.6 24.9 39.4 47.2 32.7 51.1 43.7 37.1 55.1 88.9 24.0 44.3 44.4 52.4 42.3 63.1 17.2 31.8 8.6 12.4 36.2 15.6 19.2 18.7 13.9 41.5 16.1 17.0 14.3 10.8 15.0 30.9 28.8 23.3 31.5 107.5 87.1 71.5 90.2 92.3 81.9 94.1 77.9 73.7 53.6 YWHAH YWHA1 ENSG00000128245 "Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein eta" Q04917 22 31944461-31957603 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in all" 6 "brain: 154.3" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB025918, HPA061603" Uncertain Approved Nucleoli,Cytosol 130000000 Cytosol Nucleoli "CAB025918: , HPA061603: " "unprognostic (3.77e-1)" "unprognostic (6.13e-2)" "unprognostic (1.67e-2)" "unprognostic (1.86e-2)" "unprognostic (1.13e-2)" "unprognostic (1.73e-1)" "prognostic unfavourable (1.59e-5)" "unprognostic (8.62e-2)" "unprognostic (1.63e-1)" "unprognostic (4.51e-2)" "unprognostic (3.92e-2)" "unprognostic (1.14e-1)" "unprognostic (1.40e-1)" "unprognostic (1.59e-1)" "unprognostic (5.60e-2)" "unprognostic (7.00e-2)" "unprognostic (6.81e-2)" 21.5 18.6 87.9 20.6 47.4 16.3 19.3 41.9 154.3 13.7 24.4 10.0 4.3 17.2 13.1 14.1 14.0 16.4 18.6 15.2 78.8 59.1 11.7 11.5 25.0 13.5 35.5 101.6 10.0 16.7 5.2 10.4 22.4 49.5 12.3 20.1 6.8 9.9 15.6 13.9 9.9 17.4 25.9 19.4 12.8 26.9 3.7 9.1 6.3 10.5 5.5 15.1 18.5 10.6 8.1 16.6 14.9 14.4 17.7 12.8 9.6 67.9 27.2 30.4 17.7 18.5 17.1 19.3 66.1 32.7 38.1 43.6 28.8 23.7 40.1 16.1 60.6 32.9 36.4 36.3 36.0 35.5 31.7 23.7 21.4 25.7 18.7 76.3 26.5 15.5 19.4 32.1 22.9 31.1 32.7 29.4 29.0 27.4 23.1 35.1 36.2 29.8 33.2 41.9 21.3 24.0 29.4 65.4 21.5 37.6 26.3 23.5 15.0 18.9 49.7 38.5 38.5 28.2 41.9 16.4 25.3 50.2 27.9 30.8 33.8 7.8 14.4 14.9 5.7 11.8 8.1 8.1 7.0 8.1 16.6 7.6 2.8 3.6 8.7 17.7 12.2 4.5 12.8 9.6 87.9 47.4 41.9 126.3 78.8 59.1 35.5 101.6 49.5 9.1 ZBTB16 "PLZF, ZNF145" ENSG00000109906 "Zinc finger and BTB domain containing 16" Q05516 11 114059593-114250676 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation, Ubl conjugation pathway" "DNA-binding, Repressor" "Cancer-related genes, Disease mutation, Mental retardation, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in some" "ASC diff: 29.9;ASC TERT1: 17.3;HEL: 17.8;HHSteC: 12.9;HSkMC: 13.8;hTCEpi: 12.8;hTERT-HME1: 11.2" "Cancer enhanced" "Detected in many" "prostate cancer: 5.2" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "gdT-cell: 13.7;MAIT T-cell: 23.5" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001499, CAB004540" Uncertain "CAB004540: AB_2218941, HPA001499: AB_1079640" "unprognostic (2.21e-1)" "unprognostic (2.17e-1)" "unprognostic (7.30e-2)" "unprognostic (1.18e-1)" "unprognostic (2.53e-1)" "unprognostic (3.05e-1)" "unprognostic (1.25e-2)" "unprognostic (1.40e-1)" "unprognostic (1.09e-1)" "unprognostic (8.79e-4)" "unprognostic (1.68e-1)" "unprognostic (1.18e-1)" "prognostic favourable (2.21e-4)" "unprognostic (2.57e-3)" "unprognostic (2.67e-1)" "unprognostic (1.00e-1)" "unprognostic (5.90e-2)" 38.0 16.0 10.0 6.3 14.6 6.3 20.5 18.0 22.8 18.7 14.9 6.7 15.7 1.8 19.6 8.5 24.0 17.3 11.8 25.5 11.8 4.5 8.3 9.3 17.3 6.2 16.1 8.9 41.6 51.5 14.5 9.5 8.3 12.6 10.0 3.0 7.8 10.4 15.1 58.8 17.5 10.4 15.1 10.8 11.1 12.8 4.6 14.2 0.0 24.1 10.9 2.5 21.9 27.5 6.9 0.0 0.6 2.4 5.5 23.5 2.7 0.0 0.0 6.1 0.0 29.9 17.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.2 17.8 0.0 0.0 12.9 0.3 0.2 13.8 12.8 0.0 11.2 2.1 0.0 0.0 0.1 0.0 1.0 3.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 4.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 2.4 0.6 13.7 0.6 23.5 0.1 0.6 2.0 0.0 6.9 0.8 0.4 0.2 5.5 0.5 0.0 0.2 2.7 10.0 14.6 18.0 22.8 11.8 4.5 16.1 8.9 12.6 14.2 ZFHX3 "ATBF1, ZNF927" ENSG00000140836 "Zinc finger homeobox 3" Q15911 16 72782885-73891871 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Myogenesis, Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "NK-cell: 2.5" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA059353 Uncertain "HPA059353: " "prognostic unfavourable (1.55e-4)" "unprognostic (3.57e-2)" "unprognostic (1.68e-1)" "unprognostic (2.03e-2)" "unprognostic (2.81e-2)" "unprognostic (3.12e-1)" "unprognostic (4.24e-2)" "unprognostic (6.36e-2)" "unprognostic (9.94e-3)" "unprognostic (2.85e-1)" "unprognostic (1.06e-1)" "unprognostic (4.16e-2)" "prognostic favourable (1.37e-5)" "unprognostic (6.76e-2)" "unprognostic (1.10e-1)" "unprognostic (2.11e-1)" "unprognostic (2.15e-2)" 7.9 6.0 2.5 2.3 4.6 1.1 11.3 1.5 4.1 7.5 7.7 5.4 14.5 2.0 7.4 7.3 4.5 4.9 18.2 4.9 4.3 4.8 4.4 6.5 6.1 1.4 4.0 2.6 4.4 5.7 23.8 6.3 8.1 5.5 12.0 3.5 10.5 5.0 19.5 16.9 3.6 3.6 15.5 9.7 3.9 5.0 2.3 5.2 0.5 10.8 4.0 1.0 16.7 14.7 0.8 1.0 0.2 1.6 2.5 0.1 0.2 4.4 7.8 12.7 10.5 4.7 6.0 13.1 3.4 3.7 2.1 2.4 8.8 2.5 1.9 5.9 6.3 3.1 8.0 4.0 3.0 7.7 1.9 0.3 10.6 12.6 4.4 1.3 3.2 2.2 2.4 6.3 5.7 4.0 0.9 0.5 5.4 9.1 0.4 2.6 2.2 1.3 5.8 3.4 0.6 3.5 7.4 9.5 3.4 5.9 1.8 4.2 2.6 0.6 8.7 5.3 6.3 5.6 4.4 4.9 1.6 1.3 2.5 1.2 4.0 0.2 1.6 0.2 0.1 0.9 0.1 0.5 0.0 0.0 0.7 0.8 0.0 0.1 0.2 2.5 1.1 1.0 0.1 0.2 2.5 4.6 1.5 4.1 4.3 4.8 4.0 2.6 5.5 5.2 ZFP36L1 "Berg36, BRF1, cMG1, ERF1, RNF162B, TIS11B" ENSG00000185650 "ZFP36 ring finger protein like 1" Q07352 14 68787660-68796253 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "mRNA processing, mRNA transport, Transport" "Developmental protein, DNA-binding, Ribonucleoprotein, RNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in many" 6 "neutrophil: 212.7" "Lineage enriched" "Detected in all" 6 "granulocytes: 212.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA001301 Uncertain "HPA001301: AB_1080644" "unprognostic (1.18e-2)" "unprognostic (2.64e-1)" "unprognostic (1.28e-1)" "unprognostic (1.58e-1)" "unprognostic (7.00e-2)" "unprognostic (1.27e-1)" "unprognostic (1.64e-2)" "unprognostic (1.11e-1)" "unprognostic (2.17e-2)" "unprognostic (3.81e-3)" "unprognostic (1.13e-3)" "unprognostic (1.30e-1)" "unprognostic (1.11e-2)" "unprognostic (6.45e-3)" "unprognostic (5.77e-2)" "unprognostic (2.97e-1)" "unprognostic (5.68e-2)" 59.0 22.4 40.2 42.4 35.0 14.2 89.9 16.3 31.0 91.5 60.2 49.6 24.8 26.0 90.6 37.5 66.8 59.9 36.5 36.2 45.1 15.3 34.6 46.0 45.6 39.0 32.7 16.7 121.7 47.1 63.4 14.8 62.7 44.9 65.3 21.9 29.9 60.3 43.7 31.6 90.2 28.5 91.2 47.3 33.9 42.2 26.9 39.4 22.1 43.3 22.7 57.1 81.2 93.2 37.0 8.7 212.7 17.7 10.4 16.1 14.4 38.8 37.3 15.5 22.4 39.3 31.6 34.3 16.5 27.4 9.6 12.1 16.3 25.8 9.4 10.0 28.4 18.0 1.4 51.0 11.8 4.4 2.2 3.4 18.7 11.5 22.4 0.5 4.3 26.6 65.5 11.7 76.7 19.3 9.6 18.5 51.1 9.2 1.4 1.7 12.9 5.4 24.9 20.8 2.8 35.3 28.0 0.1 0.4 18.6 26.8 13.8 24.6 0.4 44.1 28.6 21.0 22.6 15.7 10.4 5.2 6.5 35.5 0.2 10.8 14.2 17.7 0.2 16.1 17.2 15.0 19.7 12.9 11.2 8.7 37.0 14.1 12.4 212.7 10.4 11.4 1.1 12.0 14.4 40.2 35.0 16.3 31.0 45.1 15.3 32.7 16.7 44.9 39.4 ZFP36L2 "BRF2, ERF2, RNF162C, TIS11D" ENSG00000152518 "ZFP36 ring finger protein like 2" P47974 2 43222402-43226609 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Developmental protein, DNA-binding, Ribonucleoprotein, RNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA047428 Approved "HPA047428: AB_10963428" "unprognostic (2.07e-2)" "unprognostic (1.81e-2)" "unprognostic (9.77e-2)" "unprognostic (6.10e-2)" "unprognostic (9.66e-2)" "unprognostic (2.36e-1)" "unprognostic (1.41e-1)" "unprognostic (7.62e-3)" "unprognostic (2.04e-1)" "unprognostic (4.50e-2)" "unprognostic (9.67e-3)" "unprognostic (1.65e-1)" "unprognostic (1.96e-2)" "unprognostic (2.50e-1)" "unprognostic (4.52e-2)" "unprognostic (1.23e-1)" "unprognostic (2.98e-2)" 57.9 32.6 10.1 65.3 30.1 47.3 104.4 3.6 16.8 43.9 41.2 20.8 24.8 31.4 35.4 32.5 35.4 40.6 78.8 36.3 18.1 9.1 23.1 26.1 74.0 112.5 15.4 11.0 63.7 29.5 6.6 13.7 8.6 70.6 39.2 38.4 27.9 31.7 49.0 33.3 64.9 52.2 40.7 74.2 44.2 34.4 14.8 12.8 76.5 73.3 32.6 39.8 50.1 43.9 11.2 22.0 32.5 17.7 22.4 28.6 10.1 7.6 3.7 3.7 2.0 47.3 48.5 1.5 11.2 20.4 4.8 3.7 13.1 3.6 5.5 8.5 12.9 14.5 3.9 19.5 4.1 9.9 8.3 8.9 1.4 13.8 14.1 19.4 7.8 34.0 32.0 4.9 32.1 8.5 8.9 22.1 4.7 40.7 22.9 40.5 5.7 6.6 17.2 2.8 31.9 8.2 11.1 3.3 8.4 2.1 13.0 6.7 2.2 32.2 4.0 13.1 5.7 11.0 6.8 18.7 5.1 8.3 4.4 48.8 6.0 7.2 17.7 32.5 21.6 14.7 21.2 8.1 21.3 28.6 22.0 11.2 16.2 15.5 27.5 22.4 11.5 9.5 7.8 10.1 10.1 30.1 3.6 16.8 18.1 9.1 15.4 11.0 70.6 12.8 ZMYM2 "FIM, MYM, RAMP, ZNF198" ENSG00000121741 "Zinc finger MYM-type containing 2" Q9UBW7 13 19958670-20091829 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA031765 Approved Approved "Nucleoplasm,Endoplasmic reticulum" "Nucleoplasm, Endoplasmic reticulum" "HPA031765: AB_10601927" "unprognostic (2.96e-1)" "unprognostic (3.42e-3)" "unprognostic (1.85e-1)" "unprognostic (1.69e-1)" "unprognostic (7.71e-2)" "unprognostic (2.33e-1)" "unprognostic (2.66e-3)" "unprognostic (1.16e-1)" "unprognostic (6.78e-2)" "unprognostic (5.88e-2)" "unprognostic (4.60e-2)" "unprognostic (2.80e-2)" "unprognostic (6.65e-3)" "unprognostic (2.05e-1)" "unprognostic (8.74e-2)" "unprognostic (1.06e-1)" "prognostic favourable (6.07e-4)" 15.0 17.3 15.9 18.1 23.3 22.2 16.1 23.9 26.8 18.3 16.8 14.0 13.7 13.3 20.0 14.0 18.5 16.1 15.7 17.1 14.4 12.0 17.3 13.7 15.4 14.2 12.9 20.2 21.7 16.2 17.1 32.1 14.0 23.2 19.4 13.8 13.8 18.2 17.6 19.7 18.3 14.5 15.3 16.2 16.3 16.0 44.5 16.5 38.0 24.3 10.4 19.7 19.5 17.2 5.5 6.3 7.4 5.9 5.4 7.9 3.5 6.3 5.7 22.0 9.5 9.7 10.5 10.5 6.6 10.6 8.6 10.3 8.8 13.1 15.2 6.1 9.3 10.2 16.2 7.1 11.7 6.1 4.6 26.9 8.6 4.4 9.8 22.7 8.2 10.3 13.3 6.8 7.1 14.6 10.2 10.8 11.8 9.0 21.9 6.4 20.4 3.6 24.5 24.0 7.1 6.7 9.3 25.8 25.7 12.8 9.2 12.0 12.2 16.2 8.5 4.3 6.8 5.2 3.5 8.6 6.7 15.7 3.6 5.3 10.2 0.2 5.2 4.0 5.5 5.9 6.7 5.5 7.5 5.6 6.1 4.5 7.9 6.9 7.4 5.4 4.9 6.3 5.4 3.5 15.9 23.3 23.9 26.8 14.4 12.0 12.9 20.2 23.2 16.5 ZNF132 pHZ-12 ENSG00000131849 "Zinc finger protein 132" P52740 19 58432814-58440222 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" HPA008726 Uncertain Approved "Vesicles,Intermediate filaments" Vesicles "Intermediate filaments" "HPA008726: AB_1080664" "unprognostic (4.86e-2)" "unprognostic (2.03e-1)" "unprognostic (6.79e-3)" "unprognostic (3.06e-2)" "unprognostic (8.16e-2)" "unprognostic (4.78e-2)" "unprognostic (4.02e-2)" "unprognostic (2.32e-3)" "unprognostic (5.00e-2)" "unprognostic (1.29e-1)" "prognostic favourable (1.92e-4)" "unprognostic (4.51e-1)" "prognostic favourable (7.26e-13)" "unprognostic (2.70e-1)" "unprognostic (7.65e-2)" "unprognostic (6.09e-2)" "unprognostic (3.72e-1)" 2.9 4.7 4.0 2.5 5.9 0.8 5.1 11.8 8.5 5.9 4.1 6.6 4.5 2.5 4.2 7.2 3.5 7.9 4.7 5.9 6.0 4.5 6.2 2.1 3.6 3.3 4.4 5.5 7.6 4.3 15.3 12.1 3.7 5.9 6.1 2.4 5.4 5.8 6.7 3.7 4.7 2.6 5.9 4.2 4.5 3.6 7.2 6.0 3.1 10.8 2.8 4.3 5.7 6.3 3.9 2.9 2.0 2.6 2.6 5.7 2.1 1.7 2.1 4.8 1.7 5.6 4.6 0.2 3.6 4.5 3.0 2.7 0.1 1.4 4.5 0.3 4.4 1.8 0.0 5.4 2.1 0.7 8.2 0.8 1.4 1.0 5.0 1.7 3.0 5.1 1.9 5.1 3.2 2.6 0.7 0.5 5.6 0.6 1.0 0.1 4.9 1.7 0.6 1.1 1.3 1.8 2.0 4.3 4.4 1.4 1.3 1.5 0.3 4.4 3.3 3.1 0.4 0.8 0.7 5.9 1.1 0.0 1.5 0.1 1.9 0.0 1.9 2.0 2.2 2.2 5.7 2.9 2.9 1.2 2.9 3.9 4.6 3.7 0.2 2.6 2.6 2.4 2.5 2.1 4.0 5.9 11.8 8.5 6.0 4.5 4.4 5.5 5.9 6.0 ZNF180 HHZ168 ENSG00000167384 "Zinc finger protein 180" Q9UJW8 19 44474428-44500524 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA028979, HPA028980" Uncertain Approved Nucleoplasm Nucleoplasm "HPA028979: AB_10600328, HPA028980: AB_10611524" "unprognostic (2.25e-1)" "unprognostic (5.53e-2)" "unprognostic (8.34e-3)" "unprognostic (1.37e-2)" "unprognostic (1.82e-1)" "unprognostic (7.13e-3)" "unprognostic (1.73e-1)" "unprognostic (2.16e-2)" "unprognostic (4.09e-3)" "unprognostic (1.33e-1)" "unprognostic (1.65e-2)" "unprognostic (1.71e-1)" "unprognostic (2.37e-2)" "unprognostic (6.49e-2)" "unprognostic (2.21e-1)" "unprognostic (2.02e-2)" "unprognostic (3.38e-3)" 8.2 8.6 7.3 10.0 9.1 6.7 10.5 13.4 8.7 10.3 7.7 7.1 10.4 8.8 11.1 6.3 7.5 9.7 8.0 5.9 6.8 5.6 9.4 9.5 7.0 10.7 6.9 5.1 11.9 8.0 16.4 13.7 7.5 8.7 12.3 8.7 6.7 7.4 11.6 6.0 8.8 10.7 7.7 6.6 12.8 7.7 8.1 8.3 17.7 11.2 7.2 8.6 8.2 8.7 6.0 3.8 6.5 3.4 3.6 9.6 3.0 8.1 2.3 10.1 7.0 2.1 4.1 6.8 4.2 4.3 6.7 8.1 4.4 1.6 1.0 5.2 5.7 2.1 5.8 9.9 8.4 8.4 4.3 10.0 2.7 2.9 2.2 12.4 6.0 4.4 3.9 4.6 5.6 4.9 4.9 6.9 5.3 1.6 6.3 4.1 6.1 4.6 4.4 5.2 5.4 6.7 14.7 8.5 6.7 7.9 7.2 4.4 4.3 10.3 3.9 12.2 5.3 1.4 6.7 1.9 5.6 3.8 4.0 5.4 6.0 5.8 3.4 6.5 3.5 2.4 4.6 5.4 4.5 5.5 3.8 6.0 5.8 5.4 2.9 3.6 2.7 1.8 9.6 3.0 7.3 9.1 13.4 8.7 6.8 5.6 6.9 5.1 8.7 8.3 ZNF300 ENSG00000145908 "Zinc finger protein 300" Q96RE9 5 150894392-150904983 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "AF22: 17.2;HeLa: 18.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "naive B-cell: 3.8" "Low lineage specificity" "Detected in all" "HPA028975, HPA051777" Uncertain Supported "Nucleoplasm,Nucleoli,Nuclear bodies" "Nucleoplasm, Nucleoli" "Nuclear bodies" "HPA028975: , HPA051777: " "unprognostic (5.06e-2)" "unprognostic (1.05e-2)" "unprognostic (8.41e-2)" "unprognostic (2.31e-1)" "unprognostic (7.61e-2)" "unprognostic (1.13e-2)" "unprognostic (1.15e-1)" "unprognostic (6.23e-3)" "unprognostic (4.21e-2)" "unprognostic (3.23e-1)" "unprognostic (8.62e-2)" "unprognostic (6.85e-3)" "prognostic unfavourable (3.21e-6)" "unprognostic (3.62e-3)" "unprognostic (2.99e-1)" "unprognostic (3.46e-1)" "unprognostic (1.50e-2)" 4.5 1.3 4.8 4.0 12.0 3.6 7.2 12.5 6.4 7.4 4.3 5.4 4.1 4.1 11.7 5.3 7.5 5.4 5.4 4.0 7.5 3.2 7.3 1.5 3.0 4.4 8.2 2.4 16.6 7.3 1.0 7.3 2.4 7.4 7.0 4.4 3.6 3.8 3.9 1.5 6.9 5.8 6.4 9.2 5.1 7.1 14.9 9.1 1.5 9.3 2.7 4.4 5.5 6.2 3.8 1.2 1.1 1.5 1.7 1.0 0.8 1.2 2.8 17.2 0.0 1.5 3.6 0.0 4.2 3.3 3.7 5.4 1.4 2.1 0.0 3.7 3.5 2.5 0.0 9.6 5.8 0.0 5.6 0.0 18.9 2.2 3.1 0.1 0.0 5.5 3.0 7.7 9.1 6.3 0.0 9.1 3.6 0.0 0.0 0.8 16.5 0.0 0.0 2.5 4.9 2.7 3.1 9.7 16.1 9.9 8.6 5.7 5.7 0.0 2.7 5.0 2.1 3.6 7.6 0.3 0.1 0.0 0.5 0.1 10.3 0.0 0.6 1.1 0.7 1.5 0.1 0.9 1.0 0.0 1.2 3.8 0.7 0.4 0.2 1.7 0.1 0.1 0.0 0.8 4.8 12.0 12.5 6.4 7.5 3.2 8.2 2.4 7.4 9.1 ZNF331 "RITA, ZNF361, ZNF463" ENSG00000130844 "Zinc finger protein 331" Q9NQX6 19 53520981-53580269 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "adrenal gland: 66.4;ovary: 86.4" "Cell line enhanced" "Detected in many" "HEK 293: 36.6;RT4: 28.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" HPA063157 Approved Nucleoplasm Nucleoplasm "HPA063157: " "unprognostic (2.19e-1)" "unprognostic (1.79e-1)" "unprognostic (5.18e-2)" "unprognostic (1.55e-2)" "unprognostic (4.24e-1)" "unprognostic (8.16e-2)" "unprognostic (7.62e-3)" "unprognostic (3.25e-2)" "unprognostic (1.84e-2)" "unprognostic (4.40e-2)" "unprognostic (5.68e-3)" "unprognostic (2.69e-1)" "unprognostic (4.73e-2)" "prognostic unfavourable (4.79e-4)" "unprognostic (2.08e-1)" "prognostic unfavourable (7.43e-4)" "unprognostic (6.74e-2)" 19.1 66.4 6.8 9.0 8.2 18.6 10.5 11.4 9.5 9.4 5.3 8.4 8.9 2.1 9.5 11.6 4.9 19.5 23.8 15.5 5.1 7.7 6.6 6.1 15.6 4.0 6.8 5.5 86.4 9.9 11.3 29.0 23.3 7.2 10.2 4.2 9.9 4.7 31.5 6.3 5.2 4.8 8.5 9.1 4.5 6.3 8.1 6.0 3.8 7.8 4.4 4.8 25.7 9.2 8.1 4.1 6.5 7.4 4.6 14.7 5.2 0.1 5.1 10.3 11.9 8.0 6.0 17.3 7.4 6.5 5.6 10.3 5.5 2.6 4.1 1.9 4.3 3.0 7.5 5.5 10.1 0.0 36.6 5.2 8.7 3.4 5.9 3.2 7.2 6.0 3.6 6.2 3.0 2.5 0.2 1.6 5.5 3.6 7.3 6.8 4.6 7.7 9.0 6.5 4.2 3.4 28.0 7.4 7.5 3.5 9.7 2.4 1.7 2.9 2.6 7.9 7.0 4.6 4.8 20.4 13.3 7.8 0.1 0.4 6.2 0.5 4.9 6.5 8.7 3.8 13.4 8.1 9.4 8.8 3.6 8.1 14.7 9.7 0.7 4.6 7.4 4.1 9.4 5.2 6.8 8.2 11.4 9.5 5.1 7.7 6.8 5.5 7.2 6.0 ZNF384 "CAGH1A, CIZ, NMP4, NP, TNRC1" ENSG00000126746 "Zinc finger protein 384" Q8TF68 12 6666477-6689572 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA004051 Supported Approved Nucleoplasm Nucleoplasm "HPA004051: AB_1859228" "unprognostic (1.90e-1)" "unprognostic (5.11e-3)" "unprognostic (1.76e-1)" "unprognostic (6.16e-2)" "unprognostic (1.79e-1)" "unprognostic (3.04e-2)" "unprognostic (1.87e-2)" "unprognostic (9.94e-2)" "unprognostic (1.35e-2)" "unprognostic (2.57e-2)" "unprognostic (3.51e-2)" "unprognostic (4.25e-1)" "unprognostic (1.24e-2)" "unprognostic (1.01e-1)" "unprognostic (2.22e-1)" "unprognostic (2.06e-1)" "unprognostic (8.13e-2)" 20.5 22.8 18.9 30.9 19.9 33.4 22.1 36.1 23.0 23.2 23.3 19.5 16.8 22.1 29.8 17.6 21.1 24.2 25.3 16.1 16.0 10.8 20.7 19.9 19.7 21.9 19.7 17.7 31.3 25.8 25.8 20.5 23.9 14.8 22.7 21.4 18.6 22.4 20.6 22.7 24.1 29.4 24.8 14.2 33.6 21.3 20.5 18.7 39.7 27.0 17.5 29.7 25.2 28.9 10.2 11.1 14.2 13.3 15.6 17.3 7.3 10.6 20.5 25.3 16.9 17.9 12.7 34.0 15.5 14.5 15.0 16.1 22.5 22.9 25.3 5.9 17.4 14.5 18.6 14.2 17.2 45.6 16.9 28.9 27.2 11.7 12.6 27.4 21.4 13.9 13.8 18.5 28.9 13.0 15.0 8.7 16.4 16.6 24.6 17.6 48.9 9.0 24.5 27.1 9.7 13.3 28.8 7.9 25.6 16.0 21.5 13.8 5.6 22.7 16.0 16.5 23.2 12.9 18.2 12.2 11.6 46.1 16.3 9.9 18.7 3.3 8.0 14.2 17.3 9.7 13.8 10.2 11.0 13.6 11.1 8.8 10.8 12.1 14.2 15.6 13.3 7.4 13.2 7.3 18.9 19.9 36.1 23.0 16.0 10.8 19.7 17.7 14.8 18.7 ZNF471 "KIAA1396, Z1971" ENSG00000196263 "Zinc finger protein 471" Q9BX82 19 56507843-56530221 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HSkMC: 10.9;U-138 MG: 9.7" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" HPA066695 Uncertain Supported Nucleoplasm Nucleoplasm "HPA066695: " "unprognostic (2.89e-2)" "unprognostic (2.79e-4)" "unprognostic (1.58e-1)" "unprognostic (2.90e-2)" "unprognostic (2.22e-1)" "unprognostic (2.42e-3)" "unprognostic (1.45e-1)" "unprognostic (8.44e-2)" "unprognostic (1.01e-2)" "unprognostic (4.14e-2)" "unprognostic (4.47e-4)" "unprognostic (9.36e-2)" "prognostic favourable (2.37e-4)" "unprognostic (3.84e-3)" "unprognostic (1.08e-1)" "unprognostic (7.89e-2)" "unprognostic (3.44e-3)" 5.8 7.2 18.5 4.1 18.5 3.0 7.8 23.1 19.3 7.8 8.2 11.2 5.9 2.1 14.2 17.8 5.4 9.8 7.4 5.8 17.4 7.5 5.5 2.6 6.2 3.2 12.2 13.3 24.7 3.9 16.3 10.9 6.6 15.1 9.3 5.1 4.6 6.5 8.5 4.9 10.1 3.2 10.4 11.5 4.6 4.5 8.7 21.3 1.6 10.6 3.1 2.2 6.7 9.9 3.1 1.6 5.4 1.3 3.0 2.1 0.3 0.6 0.6 6.2 0.9 5.2 5.8 0.7 5.6 2.0 2.6 2.3 0.9 0.9 0.9 3.8 6.0 0.5 0.8 0.5 2.6 1.3 2.3 4.4 1.5 0.7 5.1 1.3 4.0 10.9 2.0 3.3 0.3 0.2 1.4 2.0 2.9 0.7 0.5 0.8 1.6 2.4 0.7 4.0 0.6 4.5 4.7 1.0 3.7 0.6 0.3 0.3 0.8 0.9 0.9 9.7 4.2 1.0 4.2 1.5 1.3 0.6 0.8 0.7 0.7 3.9 1.3 0.9 1.9 1.0 1.5 1.2 1.7 1.2 0.7 3.1 1.7 2.1 5.4 3.0 1.0 1.6 1.0 0.3 18.5 18.5 23.1 19.3 17.4 7.5 12.2 13.3 15.1 21.3 ZNF483 "KIAA1962, ZKSCAN16, ZSCAN48" ENSG00000173258 "Zinc finger protein 483" Q8TF39 9 111525159-111577844 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 36.3;pituitary gland: 40.4" "Cell line enhanced" "Detected in many" "NTERA-2: 11.5;SCLC-21H: 6.7" "Cancer enhanced" "Detected in some" "testis cancer: 1.4" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA055041 Approved Nucleoli Nucleoli "HPA055041: " "unprognostic (4.33e-2)" "unprognostic (1.83e-1)" "unprognostic (1.17e-2)" "unprognostic (1.11e-1)" "unprognostic (2.34e-1)" "unprognostic (4.11e-2)" "unprognostic (5.95e-3)" "unprognostic (9.18e-5)" "unprognostic (2.02e-1)" "unprognostic (9.50e-2)" "unprognostic (4.44e-3)" "unprognostic (5.49e-2)" "unprognostic (5.19e-4)" "unprognostic (7.19e-3)" "unprognostic (1.74e-1)" "unprognostic (4.30e-2)" "unprognostic (6.17e-2)" 3.2 10.1 13.9 2.1 30.5 7.7 5.6 35.9 36.3 6.1 4.0 8.6 2.9 2.0 10.0 11.9 2.4 7.0 4.9 4.7 18.1 7.3 5.1 2.5 3.9 3.4 9.5 23.0 12.6 4.3 13.6 40.4 1.8 24.4 7.2 2.4 5.9 3.2 7.7 2.3 3.5 2.9 5.5 9.8 4.8 3.9 11.8 10.3 0.0 12.5 0.0 3.1 4.7 4.8 2.5 1.0 4.6 1.0 2.1 6.5 1.5 0.3 3.2 3.1 4.7 0.4 0.6 1.0 0.4 1.5 3.1 2.9 0.3 1.5 0.5 0.5 1.3 0.9 1.5 1.6 1.9 0.2 1.8 1.6 4.4 2.5 0.9 0.6 0.4 1.2 0.6 1.7 0.9 2.9 1.3 0.8 0.7 3.0 0.2 0.8 11.5 1.1 0.3 4.8 0.4 1.2 1.3 6.7 3.2 1.2 0.6 0.8 1.9 0.4 0.5 0.9 1.6 1.4 2.2 0.7 1.9 0.4 1.0 0.5 0.7 4.6 1.0 0.6 4.8 0.5 2.7 1.5 3.3 2.3 0.3 2.5 5.9 6.5 3.4 2.1 0.7 1.0 1.6 1.5 13.9 30.5 35.9 36.3 18.1 7.3 9.5 23.0 24.4 10.3 ZNF521 "EHZF, Evi3" ENSG00000198795 "Zinc finger protein 521" Q96K83 18 25061926-25352190 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Differentiation, Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding, Repressor" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 69.1" "Cell line enhanced" "Detected in many" "AF22: 31.4;fHDF/TERT166: 14.7;HUVEC TERT2: 21.5;THP-1: 17.5" "Low cancer specificity" "Detected in many" "Region enriched" "Detected in all" 6 "cerebellum: 69.1" "Group enriched" "Detected in some" 5 "basophil: 8.8;plasmacytoid DC: 9.8" "Group enriched" "Detected in many" 5 "dendritic cells: 9.8;granulocytes: 8.8" "Low region specificity" "Detected in all" "Region enriched" "Detected in all" 6 "cerebellum: 105.4" "HPA023056, HPA023849" Enhanced Approved Nucleoplasm Nucleoplasm "HPA023056: AB_1859315, HPA023849: AB_1859316" "unprognostic (8.80e-3)" "unprognostic (9.68e-2)" "unprognostic (2.05e-1)" "unprognostic (3.40e-2)" "unprognostic (5.43e-2)" "unprognostic (3.73e-3)" "unprognostic (1.52e-3)" "unprognostic (6.17e-2)" "unprognostic (1.72e-1)" "unprognostic (1.57e-1)" "unprognostic (8.18e-2)" "unprognostic (1.83e-1)" "unprognostic (1.19e-3)" "unprognostic (1.16e-3)" "unprognostic (2.43e-1)" "unprognostic (2.52e-3)" "unprognostic (7.82e-4)" 9.2 11.3 5.2 2.8 7.0 1.9 9.1 69.1 11.5 11.0 3.4 9.1 4.7 1.7 19.8 5.9 3.8 9.0 10.0 7.0 5.8 5.1 3.1 1.2 6.4 4.0 8.4 2.8 20.5 1.4 1.4 16.8 8.0 12.2 4.4 3.5 6.7 8.7 3.0 3.8 4.6 3.2 13.3 12.2 18.5 2.4 3.4 8.9 0.5 5.3 6.9 2.6 7.4 5.4 0.0 9.8 8.8 0.1 1.7 0.0 0.1 0.0 0.0 31.4 0.0 5.0 8.8 0.1 4.5 6.6 1.6 1.0 0.0 0.0 0.0 0.0 14.7 0.1 0.0 0.0 1.3 0.0 1.8 6.2 0.3 0.2 0.9 0.0 9.4 10.9 0.0 0.1 0.0 21.5 0.1 0.0 2.8 0.0 4.0 0.0 2.1 0.0 0.0 7.1 0.5 0.0 0.0 4.1 2.6 0.4 0.0 0.0 0.0 17.5 12.2 12.5 1.0 3.6 0.6 0.0 0.0 0.1 4.7 0.0 10.2 8.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.1 9.8 0.0 0.1 5.2 7.0 69.1 4.3 5.8 5.1 8.4 2.8 12.2 8.9 ZNF620 MGC50836 ENSG00000177842 "Zinc finger protein 620" Q6ZNG0 3 40505992-40518736 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "basophil: 14.2" "Low lineage specificity" "Detected in all" "HPA031452, HPA059383" Uncertain Approved Centrosome Centrosome "HPA031452: AB_10603939, HPA059383: " "unprognostic (1.42e-2)" "unprognostic (4.23e-2)" "unprognostic (1.14e-3)" "unprognostic (1.48e-2)" "unprognostic (5.62e-2)" "unprognostic (1.86e-1)" "unprognostic (3.04e-3)" "unprognostic (2.15e-2)" "unprognostic (7.73e-2)" "unprognostic (3.78e-2)" "unprognostic (1.71e-2)" "unprognostic (4.09e-2)" "unprognostic (1.21e-5)" "unprognostic (1.28e-1)" "unprognostic (4.78e-1)" "unprognostic (2.61e-2)" "unprognostic (9.19e-4)" 5.8 5.7 5.2 3.0 8.2 8.0 6.1 15.6 8.5 3.7 5.0 8.9 4.8 4.4 4.0 6.3 3.1 5.3 3.2 4.4 5.6 5.7 6.2 4.5 6.2 3.4 10.3 5.8 4.5 8.1 8.7 15.2 6.3 6.4 5.2 5.9 6.1 3.5 5.7 6.3 2.4 4.7 4.3 5.3 5.2 7.3 3.0 7.4 3.7 9.5 3.7 3.1 4.8 4.5 2.0 1.3 14.2 1.0 3.1 3.9 1.2 2.3 3.5 8.4 3.1 0.9 0.9 4.4 0.6 0.9 4.0 5.8 8.2 5.2 0.0 2.6 0.4 0.6 12.4 1.1 2.9 7.1 9.7 6.0 8.7 4.5 1.5 2.1 1.2 0.5 0.8 2.5 1.1 2.7 3.1 1.0 0.5 4.0 0.4 1.8 9.7 1.9 3.2 3.5 1.1 3.7 8.4 9.9 7.5 0.6 5.8 3.8 7.6 2.3 1.8 0.4 5.7 0.8 2.6 1.3 2.1 0.1 1.3 1.2 1.5 14.2 0.6 1.2 2.6 1.0 3.2 0.8 1.0 2.7 0.6 2.0 2.1 2.7 0.9 3.1 0.3 1.3 3.9 1.2 5.2 8.2 15.6 8.5 5.6 5.7 10.3 5.8 6.4 7.4 ZNF750 "FLJ13841, Zfp750" ENSG00000141579 "Zinc finger protein 750" Q32MQ0 17 82829435-82840578 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Differentiation, Transcription, Transcription regulation" Activator "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "esophagus: 59.3;lymphoid tissue: 54.2;skeletal muscle: 84.2" "Cell line enhanced" "Detected in some" "BEWO: 17.0;hTCEpi: 6.3;MCF7: 4.5;SK-BR-3: 12.7" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Cell type enriched" "Detected in single" 5 "naive CD8 T-cell: 1.0" "Lineage enriched" "Detected in single" 5 "T-cells: 1.0" "Not detected" "Not detected" "Not detected" "Not detected" "HPA021573, HPA023012" Enhanced "HPA021573: AB_1859438, HPA023012: AB_1859439" "unprognostic (3.46e-3)" "unprognostic (1.94e-2)" "unprognostic (7.51e-2)" "unprognostic (2.63e-1)" "unprognostic (1.45e-1)" "unprognostic (9.73e-2)" "unprognostic (4.48e-2)" "unprognostic (6.55e-3)" "unprognostic (1.34e-1)" "unprognostic (4.33e-2)" "unprognostic (6.30e-3)" "unprognostic (1.23e-2)" "unprognostic (5.30e-3)" "unprognostic (3.04e-2)" "unprognostic (5.94e-2)" "unprognostic (2.04e-1)" "unprognostic (4.25e-2)" 0.4 0.1 0.1 0.1 0.1 0.1 3.0 0.1 0.1 14.0 0.1 0.0 9.0 0.2 0.9 3.8 59.3 0.4 0.2 0.2 0.1 0.1 0.2 0.1 2.3 0.1 0.1 0.0 0.1 0.1 0.6 2.2 19.5 0.0 3.2 0.1 0.0 38.3 13.2 84.2 46.2 0.1 0.4 0.1 0.1 0.1 0.2 0.0 3.4 6.7 44.1 54.2 3.2 16.8 0.2 0.1 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 17.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.3 0.0 0.0 0.2 0.0 0.0 0.0 4.5 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 2.9 1.1 1.0 0.0 12.7 0.0 2.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 1.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 ZNF814 ENSG00000204514 "Zinc finger protein 814" B7Z6K7 19 57848731-57889074 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "NTERA-2: 21.8;U-266/84: 20.0" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "HPA043800, HPA053762, HPA072145" Approved Uncertain Nucleoplasm Nucleoplasm "HPA043800: , HPA053762: , HPA072145: " "unprognostic (3.74e-2)" "unprognostic (1.24e-1)" "unprognostic (4.53e-2)" "unprognostic (3.29e-2)" "unprognostic (6.01e-2)" "unprognostic (2.12e-2)" "unprognostic (1.03e-1)" "unprognostic (4.69e-2)" "unprognostic (6.78e-4)" "unprognostic (5.05e-3)" "unprognostic (2.41e-4)" "unprognostic (1.56e-2)" "unprognostic (4.99e-4)" "unprognostic (3.94e-1)" "unprognostic (2.33e-1)" "unprognostic (1.08e-1)" "unprognostic (1.54e-5)" 5.6 13.3 11.6 9.0 11.0 12.6 12.2 19.2 10.8 6.4 10.0 4.4 15.7 9.7 5.6 10.5 5.2 12.5 9.8 9.5 11.5 10.3 15.0 11.7 5.9 11.1 9.1 8.4 7.8 6.7 10.9 16.2 9.7 7.7 11.4 7.3 16.1 9.0 18.4 18.6 13.3 12.7 9.0 7.3 13.8 5.5 14.0 5.6 18.7 23.0 4.0 11.5 6.6 5.0 21.2 15.3 5.0 5.0 12.8 13.6 4.5 0.9 2.4 7.4 11.0 0.8 0.7 1.9 2.7 1.9 3.1 0.4 1.3 1.0 5.5 1.8 2.5 0.8 0.5 6.0 3.8 0.8 5.0 4.2 3.3 1.3 3.3 4.7 5.2 5.0 5.3 1.2 1.1 0.9 1.0 2.1 4.7 0.9 15.6 2.1 21.8 3.1 1.8 0.8 9.8 2.4 3.9 2.8 7.9 0.9 1.8 3.7 5.4 1.4 1.4 6.9 2.3 1.5 1.2 6.5 20.0 14.0 1.5 2.5 8.2 2.2 4.5 5.0 3.2 5.0 8.2 19.4 8.4 6.9 6.6 21.2 13.6 11.0 2.7 12.8 2.9 15.3 2.1 4.5 11.6 11.0 19.2 10.8 11.5 10.3 9.1 8.4 7.7 5.6 ZNF844 FLJ14959 ENSG00000223547 "Zinc finger protein 844" Q08AG5 19 12064699-12081565 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "RH-30: 11.3;U-266/84: 16.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" HPA046982 Uncertain "HPA046982: AB_10964399" "unprognostic (2.07e-1)" "unprognostic (1.50e-2)" "unprognostic (1.75e-1)" "unprognostic (8.95e-2)" "unprognostic (2.92e-3)" "unprognostic (9.68e-3)" "unprognostic (1.93e-1)" "unprognostic (1.87e-2)" "unprognostic (1.86e-2)" "unprognostic (5.86e-2)" "unprognostic (2.47e-2)" "unprognostic (6.74e-2)" "prognostic favourable (0.00e+0)" "unprognostic (1.99e-1)" "unprognostic (1.65e-2)" "unprognostic (1.35e-1)" "unprognostic (3.63e-2)" 9.5 5.2 7.2 6.0 10.8 9.7 12.0 26.9 7.8 10.3 8.6 7.8 11.4 4.3 13.2 7.2 9.4 11.9 4.0 10.3 8.5 5.1 17.2 6.5 6.3 8.1 10.1 7.2 21.2 8.1 14.3 21.3 6.6 9.5 13.4 8.6 10.5 9.3 10.9 12.7 7.9 6.2 14.9 12.5 6.3 6.7 8.8 12.2 3.6 18.7 3.9 5.1 12.8 12.5 2.8 1.9 6.3 3.6 3.1 3.6 1.4 0.1 0.1 3.2 5.4 4.4 4.3 2.4 3.9 1.3 4.0 3.5 4.9 0.9 4.1 4.2 3.1 1.3 0.0 0.7 3.8 0.1 0.2 7.3 0.3 1.2 3.4 0.4 5.5 3.8 0.5 2.3 0.1 0.1 0.1 0.4 2.5 0.1 3.4 1.2 4.2 0.4 0.3 11.3 1.0 1.4 0.2 2.5 2.0 0.0 1.9 1.2 5.8 0.4 0.2 1.2 3.0 5.0 4.1 7.4 16.0 0.6 0.1 0.5 0.8 6.3 2.0 5.3 1.7 3.6 0.9 2.8 1.2 1.6 1.9 2.1 3.6 1.9 5.8 3.1 2.0 0.6 0.4 1.4 7.2 10.8 26.9 7.6 8.5 5.1 10.1 7.2 9.5 12.2 ZRANB3 DKFZP434B1727 ENSG00000121988 "Zinc finger RANBP2-type containing 3" Q5FWF4 2 135136916-135531236 "Cancer-related genes, Predicted intracellular proteins" "DNA damage, DNA repair" "Endonuclease, Helicase, Hydrolase, Multifunctional enzyme, Nuclease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA035234 Supported Nucleoplasm Nucleoplasm "HPA035234: " "unprognostic (6.98e-2)" "unprognostic (2.04e-1)" "unprognostic (1.01e-1)" "unprognostic (2.52e-3)" "unprognostic (4.09e-1)" "unprognostic (1.33e-1)" "unprognostic (1.09e-1)" "unprognostic (1.06e-1)" "unprognostic (3.53e-3)" "unprognostic (1.74e-1)" "unprognostic (3.58e-2)" "unprognostic (4.68e-2)" "unprognostic (2.77e-4)" "unprognostic (1.57e-1)" "unprognostic (1.29e-1)" "unprognostic (2.00e-2)" "unprognostic (9.88e-2)" 3.5 6.3 5.5 4.9 7.0 5.2 5.4 7.7 7.9 5.4 3.3 4.1 3.9 2.6 5.4 6.0 3.3 5.4 3.9 4.0 4.7 5.2 4.4 6.3 2.9 4.3 6.0 5.4 7.2 6.1 7.3 15.6 4.3 5.7 5.4 4.7 5.6 3.1 4.0 7.6 3.0 3.0 7.2 4.9 4.0 3.1 12.6 6.6 10.7 6.7 3.0 4.8 4.2 3.6 3.0 1.9 1.4 0.8 1.7 3.5 0.9 3.3 3.2 5.2 3.9 2.8 5.7 4.9 4.3 3.9 4.3 4.7 6.2 3.1 7.3 5.8 3.9 3.6 8.3 4.3 6.1 10.3 4.7 8.2 2.1 11.9 2.7 7.1 2.9 4.9 4.6 3.9 11.3 5.0 9.6 3.2 3.8 4.9 6.9 4.8 3.2 4.8 6.7 4.3 3.0 6.1 1.9 6.4 8.3 4.2 1.7 3.3 4.2 3.1 3.3 3.5 2.8 1.9 3.9 2.4 4.5 8.2 4.2 5.2 3.8 0.6 0.8 1.4 1.6 0.8 3.5 3.0 1.5 1.3 1.9 1.5 1.4 1.5 0.9 1.7 0.3 0.8 0.4 0.9 5.5 7.0 7.7 7.9 4.7 5.2 6.0 5.4 5.7 6.6